data_3zpd_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 3zpd _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.601 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.43 -1.472 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 15.7 t -152.15 158.31 42.75 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 -176.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.489 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -143.38 161.54 38.11 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 121.178 0.513 . . . . 0.0 111.208 -174.271 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.504 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 74.9 p -100.38 175.98 5.52 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.383 0.611 . . . . 0.0 110.653 179.203 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -76.41 -19.52 58.02 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.776 178.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.504 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 6.2 p30 -83.52 -34.0 25.38 Favored 'General case' 0 CA--C 1.514 -0.433 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.732 -179.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 130.32 27.31 0.76 Allowed Glycine 0 N--CA 1.441 -1.022 0 C-N-CA 119.907 -1.139 . . . . 0.0 112.348 177.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.2 m -99.82 99.37 10.16 Favored 'General case' 0 N--CA 1.423 -1.816 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 177.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.5 122.57 35.06 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 176.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.601 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 65.3 mt -97.63 117.59 65.14 Favored Pre-proline 0 C--N 1.294 -1.817 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 178.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -75.33 171.36 18.41 Favored 'Trans proline' 0 C--O 1.245 0.845 0 C-N-CA 122.62 2.213 . . . . 0.0 111.673 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 69.6 mt -67.17 127.57 28.95 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.568 179.285 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 138.37 0.66 2.35 Favored Glycine 0 C--N 1.303 -1.3 0 C-N-CA 120.852 -0.69 . . . . 0.0 111.957 -177.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.49 168.87 43.72 Favored Glycine 0 N--CA 1.427 -1.921 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -178.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 155.49 -165.3 32.4 Favored Glycine 0 C--N 1.288 -2.135 0 C-N-CA 120.06 -1.067 . . . . 0.0 110.879 178.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.455 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 58.1 p -150.28 147.06 27.19 Favored 'General case' 0 N--CA 1.422 -1.868 0 CA-C-N 116.844 0.322 . . . . 0.0 110.373 -177.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -132.43 163.52 28.58 Favored 'General case' 0 N--CA 1.428 -1.556 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 178.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -116.71 107.52 14.78 Favored 'General case' 0 C--N 1.292 -1.929 0 N-CA-C 106.997 -1.482 . . . . 0.0 106.997 178.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 1.4 m -91.44 150.07 3.89 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.35 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -179.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 62.5 m-85 -131.92 112.16 12.18 Favored 'General case' 0 CA--C 1.485 -1.537 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -177.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.475 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 4.5 p -117.1 132.4 66.97 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.293 0 CA-C-O 121.815 0.817 . . . . 0.0 111.535 -173.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . 0.405 ' HB3' ' HB3' ' A' ' 151' ' ' ASN . 2.1 p30 -98.12 123.57 42.23 Favored 'General case' 0 C--N 1.286 -2.176 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.171 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -106.83 160.55 15.42 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 114.408 -1.269 . . . . 0.0 108.051 -178.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -54.92 121.46 35.31 Favored Pre-proline 0 C--N 1.308 -1.233 0 O-C-N 124.381 1.051 . . . . 0.0 109.284 175.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.44 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 63.8 Cg_endo -74.79 1.47 7.57 Favored 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 122.926 2.417 . . . . 0.0 113.035 -177.274 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.419 HG11 ' HG3' ' A' ' 157' ' ' PRO . 86.0 t -128.82 110.11 20.33 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 178.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.498 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 4.5 t -145.96 111.65 1.06 Allowed 'Isoleucine or valine' 0 C--O 1.185 -2.293 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 -179.352 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.587 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -100.57 152.52 20.32 Favored 'General case' 0 C--N 1.267 -2.998 0 C-N-CA 122.707 0.403 . . . . 0.0 111.381 -178.236 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.449 HG11 ' O ' ' A' ' 112' ' ' VAL . 38.9 t -46.37 113.85 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.612 0 C-N-CA 123.314 0.646 . . . . 0.0 111.596 176.633 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 105.29 3.73 41.19 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 114.929 -1.032 . . . . 0.0 112.855 -179.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.587 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -76.29 -177.35 4.01 Favored 'General case' 0 C--N 1.311 -1.069 0 C-N-CA 123.911 0.884 . . . . 0.0 110.067 175.641 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -133.54 91.59 2.87 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 177.11 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.655 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 28.4 tp -91.58 144.41 25.57 Favored 'General case' 0 C--N 1.292 -1.934 0 C-N-CA 119.964 -0.694 . . . . 0.0 109.781 -179.035 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 60.0 t -136.16 125.0 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -177.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.582 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 60.8 t -91.19 88.82 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.523 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 175.246 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -77.84 114.62 16.87 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -178.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 75.6 mt -98.0 -1.4 42.73 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-O 121.577 0.703 . . . . 0.0 110.983 -178.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.522 ' OG ' ' HA ' ' A' ' 104' ' ' PRO . 22.6 m -80.61 0.66 33.12 Favored 'General case' 0 C--N 1.29 -1.982 0 CA-C-O 122.321 1.058 . . . . 0.0 110.166 -178.322 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.2 p -121.59 4.07 10.13 Favored 'General case' 0 N--CA 1.417 -2.123 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.646 176.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.475 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 44.4 mm-40 -125.32 -21.87 4.48 Favored 'General case' 0 C--O 1.239 0.528 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.128 -174.317 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 30.8 mt -135.24 138.22 48.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -175.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.489 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 38.9 m-85 -143.43 130.38 20.55 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -176.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 73.3 m -109.48 151.11 27.15 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 120.976 0.417 . . . . 0.0 110.263 -178.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 7.6 p80 -138.06 129.98 28.49 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.72 0.771 . . . . 0.0 112.034 -175.141 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 46.7 t30 -99.43 99.85 10.81 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.195 -1.002 . . . . 0.0 109.98 176.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -72.37 -12.3 61.06 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 113.771 -1.559 . . . . 0.0 111.231 -176.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 1.622 ' HD1' ' CD2' ' A' ' 48' ' ' TYR . 91.4 m-85 -127.6 71.17 77.39 Favored Pre-proline 0 C--N 1.32 -0.689 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.05 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -70.27 -13.14 33.06 Favored 'Trans proline' 0 C--N 1.332 -0.302 0 C-N-CA 122.491 2.127 . . . . 0.0 113.836 -172.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -110.77 -16.89 13.48 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.354 0.597 . . . . 0.0 110.167 -177.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.449 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.6 OUTLIER -102.4 -30.94 10.73 Favored 'General case' 0 N--CA 1.404 -2.747 0 CA-C-O 121.648 0.737 . . . . 0.0 109.194 -171.476 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.614 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.5 mp -127.93 135.76 62.08 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 CA-C-N 114.97 -1.014 . . . . 0.0 109.071 -176.401 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.9 t -77.73 142.14 38.89 Favored 'General case' 0 C--O 1.248 1.014 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 175.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -82.44 107.29 14.98 Favored 'General case' 0 C--N 1.286 -2.187 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 -175.349 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 1.656 ' HD1' ' CD2' ' A' ' 55' ' ' TYR . 31.8 t80 -144.88 137.04 26.0 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-O 120.761 0.315 . . . . 0.0 110.476 -176.027 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.9 p -150.02 150.56 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-N 116.308 -0.406 . . . . 0.0 109.951 179.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.29 136.21 18.48 Favored 'General case' 0 C--N 1.311 -1.073 0 C-N-CA 123.298 0.639 . . . . 0.0 109.401 176.616 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.517 HD13 ' O ' ' A' ' 130' ' ' ILE . 43.5 tp -73.85 115.5 13.36 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 171.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.592 ' NE2' ' HD3' ' A' ' 132' ' ' ARG . 3.4 tp-100 -59.56 -51.32 70.33 Favored 'General case' 0 C--N 1.312 -1.064 0 C-N-CA 124.764 1.226 . . . . 0.0 111.588 178.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 9.4 ptp180 -171.51 160.42 5.92 Favored 'General case' 0 CA--C 1.5 -0.969 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 -174.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -139.27 146.78 18.54 Favored Glycine 0 N--CA 1.404 -3.454 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 64.4 m -131.48 150.66 52.07 Favored 'General case' 0 C--N 1.285 -2.231 0 C-N-CA 123.455 0.702 . . . . 0.0 109.568 -177.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.536 ' HB3' ' CE2' ' A' ' 84' ' ' PHE . . . -117.3 154.51 31.11 Favored 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -178.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.486 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . 90.9 m-85 -154.4 -179.5 8.0 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 123.71 0.804 . . . . 0.0 109.487 -178.33 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 63.84 -130.97 39.9 Favored Glycine 0 CA--C 1.507 -0.421 0 CA-C-N 116.305 -0.407 . . . . 0.0 113.287 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -90.07 -6.28 69.46 Favored Glycine 0 C--O 1.199 -2.065 0 C-N-CA 120.523 -0.846 . . . . 0.0 111.187 176.14 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.479 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 76.5 t -70.81 -41.63 77.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 122.867 0.467 . . . . 0.0 111.309 -176.442 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.509 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -82.13 -24.67 34.95 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 121.452 0.644 . . . . 0.0 112.367 -179.999 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 28.5 m -101.29 -50.82 3.66 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 114.269 1.211 . . . . 0.0 114.269 -173.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.427 ' O ' HG23 ' A' ' 112' ' ' VAL . 67.4 m-20 -89.87 -23.76 21.56 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 -176.141 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 0.533 ' CB ' ' HB3' ' A' ' 109' ' ' LEU . 86.1 m-85 -112.35 162.17 15.85 Favored 'General case' 0 N--CA 1.427 -1.601 0 CA-C-O 121.75 0.786 . . . . 0.0 111.42 179.686 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.456 ' HB2' HG11 ' A' ' 112' ' ' VAL . 5.5 m -165.94 140.24 4.52 Favored 'General case' 0 N--CA 1.4 -2.969 0 C-N-CA 125.906 1.683 . . . . 0.0 109.177 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.448 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -172.73 -100.35 0.13 Allowed Glycine 0 C--N 1.279 -2.629 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 174.14 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.41 HG21 ' O ' ' A' ' 73' ' ' GLY . 1.1 p -169.94 179.41 3.62 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 125.655 1.582 . . . . 0.0 109.365 -179.468 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.5 p -127.96 144.93 36.11 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.788 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 177.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.616 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.9 tttt -124.91 143.9 50.62 Favored 'General case' 0 N--CA 1.416 -2.13 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.456 -176.013 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 1.631 ' HD2' ' CD1' ' A' ' 77' ' ' TYR . 51.8 t80 -146.69 110.23 4.86 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 114.94 -1.027 . . . . 0.0 108.453 -178.467 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 32.7 t 54.76 39.47 31.39 Favored 'General case' 0 CA--C 1.556 1.202 0 CA-C-O 122.341 1.067 . . . . 0.0 110.86 177.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.5 16.93 69.79 Favored Glycine 0 N--CA 1.438 -1.196 0 CA-C-N 115.416 -0.811 . . . . 0.0 113.191 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.616 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 10.8 t -84.99 -179.74 7.12 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.118 -1.068 . . . . 0.0 108.118 175.445 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.0 t -160.25 97.57 1.25 Allowed 'General case' 0 C--N 1.29 -2.008 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 -178.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 0.443 ' HH ' HD21 ' A' ' 58' ' ' LEU . 3.2 p90 -138.75 159.17 68.38 Favored Pre-proline 0 C--N 1.296 -1.732 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 -174.116 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -68.47 147.27 70.65 Favored 'Trans proline' 0 C--N 1.352 0.729 0 C-N-CA 122.406 2.07 . . . . 0.0 112.799 -174.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.596 ' CD2' HD22 ' A' ' 109' ' ' LEU . 63.0 t80 -121.63 130.93 24.56 Favored Pre-proline 0 C--N 1.305 -1.339 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.17 -179.793 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.482 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 73.4 Cg_endo -73.79 147.63 90.04 Favored 'Cis proline' 0 C--O 1.25 1.087 0 C-N-CA 123.117 -1.618 . . . . 0.0 110.093 -2.331 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.6 t -68.16 -177.06 0.8 Allowed 'General case' 0 CA--C 1.548 0.877 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.259 -174.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 18.9 p -123.42 -12.44 7.76 Favored 'General case' 0 N--CA 1.435 -1.185 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.279 -173.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.8 t -152.05 -124.33 0.04 OUTLIER 'General case' 0 N--CA 1.393 -3.282 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -126.9 -169.15 1.98 Allowed 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 112.249 0.463 . . . . 0.0 112.249 -173.041 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.517 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 45.3 p -100.42 170.67 6.36 Favored Pre-proline 0 C--N 1.313 -0.983 0 C-N-CA 123.302 0.641 . . . . 0.0 112.685 179.058 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . 0.413 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 19.6 Cg_endo -59.53 166.09 8.47 Favored 'Trans proline' 0 C--O 1.246 0.904 0 C-N-CA 122.976 2.451 . . . . 0.0 111.779 170.46 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.1 tmm_? -80.58 117.99 21.77 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 -178.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 69.2 t -127.58 128.51 69.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 CA-C-O 121.353 0.597 . . . . 0.0 111.41 -175.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 81.4 t -106.18 138.31 32.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.554 179.536 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . 1.664 ' HD1' ' CD2' ' A' ' 95' ' ' TYR . 3.1 m-85 -87.59 116.66 25.86 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 175.054 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -97.72 45.25 1.03 Allowed 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 57.7 m -151.77 125.29 8.9 Favored 'General case' 0 N--CA 1.433 -1.298 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.733 -176.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 10.6 ptp180 -102.22 64.02 0.91 Allowed 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 122.044 0.926 . . . . 0.0 111.159 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.8 t -171.22 172.87 5.14 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 -178.438 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -65.12 100.78 0.46 Allowed 'General case' 0 C--N 1.324 -0.508 0 O-C-N 123.71 0.631 . . . . 0.0 110.049 -179.485 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -111.76 138.54 21.61 Favored Pre-proline 0 C--N 1.293 -1.863 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 178.151 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -56.08 148.39 59.17 Favored 'Trans proline' 0 C--O 1.246 0.897 0 C-N-CA 123.27 2.647 . . . . 0.0 112.633 179.09 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . 0.447 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.4 t90 -88.9 112.34 50.12 Favored Pre-proline 0 C--N 1.293 -1.849 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 -179.357 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . 0.522 ' HA ' ' OG ' ' A' ' 39' ' ' SER . 68.0 Cg_endo -75.58 87.57 1.36 Allowed 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 121.816 1.677 . . . . 0.0 112.426 -173.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 67.0 t -144.61 143.48 22.88 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.435 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 -179.396 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.582 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.14 135.72 17.09 Favored 'General case' 0 N--CA 1.415 -2.214 0 O-C-N 123.705 0.628 . . . . 0.0 110.285 177.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.428 HD11 ' CZ ' ' A' ' 84' ' ' PHE . 15.4 mt -100.83 104.71 15.95 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 178.066 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 1.625 ' HE2' ' CE1' ' A' ' 108' ' ' TYR . 12.4 m-85 -81.03 91.92 6.15 Favored 'General case' 0 C--N 1.285 -2.231 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 177.203 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.655 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.9 mm? -118.87 120.51 37.53 Favored 'General case' 0 C--N 1.292 -1.932 0 CA-C-O 120.742 0.306 . . . . 0.0 110.179 178.128 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.406 ' O ' ' HA ' ' A' ' 71' ' ' PHE . 0.3 OUTLIER -123.35 145.78 47.59 Favored Pre-proline 0 N--CA 1.413 -2.306 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.997 -175.085 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.425 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 25.7 Cg_endo -61.7 119.57 6.77 Favored 'Trans proline' 0 C--O 1.247 0.972 0 C-N-CA 123.202 2.601 . . . . 0.0 112.21 -177.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.456 HG11 ' HB2' ' A' ' 72' ' ' SER . 3.6 m -67.74 -117.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.188 -2.173 0 CA-C-N 114.09 -1.414 . . . . 0.0 113.081 175.57 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 41.3 t -112.67 -39.54 4.29 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 178.164 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 66.6 m -78.73 30.35 0.2 Allowed 'General case' 0 N--CA 1.392 -3.356 0 CA-C-N 113.596 -1.638 . . . . 0.0 112.952 -177.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -111.06 140.09 45.89 Favored 'General case' 0 N--CA 1.411 -2.399 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 177.29 128.27 1.13 Allowed Glycine 0 N--CA 1.438 -1.173 0 N-CA-C 111.385 -0.686 . . . . 0.0 111.385 -178.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 65.83 -149.13 51.46 Favored Glycine 0 N--CA 1.443 -0.874 0 CA-C-O 119.02 -0.878 . . . . 0.0 111.408 -176.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -54.51 105.8 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 CA-C-O 122.645 1.212 . . . . 0.0 112.741 -177.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.55 -31.44 9.44 Favored 'General case' 0 C--N 1.295 -1.789 0 CA-C-N 114.735 -1.12 . . . . 0.0 110.936 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.403 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 54.9 mt -128.18 140.07 50.18 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -179.871 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.421 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.7 mmpt? -115.12 133.9 55.63 Favored 'General case' 0 C--N 1.313 -1.009 0 C-N-CA 122.959 0.504 . . . . 0.0 111.584 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.18 133.34 48.71 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.651 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 86.06 0.35 87.21 Favored Glycine 0 C--O 1.242 0.624 0 C-N-CA 121.282 -0.485 . . . . 0.0 112.203 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 19.9 t -101.93 151.06 22.56 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 -178.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -77.92 123.69 27.09 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 -178.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.459 ' HB ' HG23 ' A' ' 67' ' ' VAL . 35.1 pt -110.08 -25.83 3.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 N-CA-C 112.578 0.585 . . . . 0.0 112.578 -178.729 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . 0.405 ' HB1' ' HB ' ' A' ' 148' ' ' ILE . . . -162.02 168.97 21.87 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -178.236 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 70.3 t -143.5 115.82 2.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.41 HD12 HD22 ' A' ' 107' ' ' LEU . 68.7 mt -117.79 146.9 43.49 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 178.141 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.517 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.6 mp -125.28 128.35 72.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 C-N-CA 119.727 -0.789 . . . . 0.0 110.42 177.475 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.431 HD22 ' HG2' ' A' ' 133' ' ' GLN . 0.0 OUTLIER -102.28 136.42 42.14 Favored 'General case' 0 C--N 1.29 -2.0 0 C-N-CA 123.664 0.786 . . . . 0.0 111.998 -177.352 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . 0.592 ' HD3' ' NE2' ' A' ' 59' ' ' GLN . 30.2 mmm180 -95.93 119.36 34.28 Favored 'General case' 0 C--N 1.294 -1.838 0 C-N-CA 124.365 1.066 . . . . 0.0 110.643 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.431 ' HG2' HD22 ' A' ' 131' ' ' LEU . 15.7 mm-40 -102.63 113.87 27.61 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 172.455 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 33.2 m -140.17 144.32 36.57 Favored 'General case' 0 C--N 1.289 -2.057 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -177.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.614 ' CB ' HG21 ' A' ' 52' ' ' ILE . 11.6 p30 . . . . . 0 N--CA 1.435 -1.18 0 C-N-CA 120.059 -0.656 . . . . 0.0 111.161 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 . . . . . 0 N--CA 1.423 -1.784 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 12.9 pt20 -125.71 146.78 49.6 Favored 'General case' 0 N--CA 1.418 -2.065 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.487 -179.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 12.3 m-30 -112.51 133.01 54.8 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 108.577 -0.898 . . . . 0.0 108.577 -176.447 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . 0.455 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 59.5 t -89.87 133.74 30.98 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 178.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . 0.431 ' NE1' ' HB3' ' A' ' 131' ' ' LEU . 70.3 m95 -121.84 97.04 5.31 Favored 'General case' 0 C--N 1.284 -2.281 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 -179.112 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 45.0 m-80 -79.17 114.99 18.55 Favored 'General case' 0 C--N 1.288 -2.08 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . 0.405 ' HB ' ' HB1' ' A' ' 127' ' ' ALA . 24.7 mm -88.36 120.62 37.55 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 -177.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -116.77 154.54 30.48 Favored 'General case' 0 CA--C 1.49 -1.328 0 C-N-CA 123.278 0.631 . . . . 0.0 110.012 178.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.44 129.38 34.62 Favored 'General case' 0 N--CA 1.417 -2.123 0 CA-C-N 115.221 -0.899 . . . . 0.0 109.075 176.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . 0.405 ' HB3' ' HB3' ' A' ' 23' ' ' ASN . 13.3 t-20 -87.75 -17.19 32.21 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 -178.282 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -153.47 144.04 22.54 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 113.708 -1.587 . . . . 0.0 109.507 -173.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -80.87 144.97 31.59 Favored 'General case' 0 C--N 1.317 -0.836 0 O-C-N 124.059 0.85 . . . . 0.0 109.838 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.44 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 74.4 t -121.92 139.26 49.51 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 C-N-CA 122.741 0.416 . . . . 0.0 111.391 -176.156 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.9 t -118.66 141.04 40.17 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.498 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 73.2 t -104.05 100.97 23.07 Favored Pre-proline 0 C--N 1.296 -1.719 0 C-N-CA 123.51 0.724 . . . . 0.0 110.116 178.025 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.419 ' HG3' HG11 ' A' ' 27' ' ' VAL . 33.3 Cg_endo -69.23 -23.99 32.62 Favored 'Trans proline' 0 C--O 1.236 0.402 0 C-N-CA 122.35 2.033 . . . . 0.0 111.84 178.68 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.4 t . . . . . 0 C--O 1.239 0.536 0 C-N-CA 125.077 1.351 . . . . 0.0 113.772 177.502 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.504 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.433 -1.299 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.408 ' HB3' ' CZ2' ' A' ' 146' ' ' TRP . 13.7 t -152.06 159.06 43.78 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.391 -0.924 . . . . 0.0 109.848 -176.156 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.447 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -147.0 155.48 42.28 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 121.29 0.567 . . . . 0.0 110.549 -176.352 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 41.2 p -92.43 174.51 7.25 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.222 178.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.99 -19.53 47.61 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.053 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -85.08 -33.81 22.36 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 114.784 -1.098 . . . . 0.0 111.856 -176.468 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 136.36 5.71 2.0 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 119.649 -1.262 . . . . 0.0 113.733 173.259 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.9 m -89.33 105.5 17.84 Favored 'General case' 0 N--CA 1.423 -1.782 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -103.47 115.71 31.05 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.026 179.635 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.504 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 55.6 mt -90.69 127.83 50.82 Favored Pre-proline 0 C--N 1.295 -1.763 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -86.01 179.62 3.64 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 122.83 2.353 . . . . 0.0 111.546 177.054 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 58.6 mt -69.42 133.79 31.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 177.071 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 127.6 9.24 4.05 Favored Glycine 0 C--N 1.306 -1.13 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.873 -179.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.22 170.19 44.57 Favored Glycine 0 N--CA 1.437 -1.267 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 -177.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.71 -173.85 35.72 Favored Glycine 0 CA--C 1.48 -2.147 0 C-N-CA 119.911 -1.138 . . . . 0.0 111.414 177.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 52.5 p -142.29 144.62 33.35 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -133.21 167.09 21.0 Favored 'General case' 0 N--CA 1.423 -1.793 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 178.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -120.05 104.69 10.34 Favored 'General case' 0 C--N 1.266 -3.025 0 CA-C-N 114.258 -1.337 . . . . 0.0 108.402 178.522 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 1.2 m -89.72 146.78 5.76 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -178.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 1.645 ' HD1' ' CD2' ' A' ' 21' ' ' TYR . 51.6 m-85 -128.17 115.72 18.82 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 120.859 0.361 . . . . 0.0 111.18 -177.56 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.46 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.6 p -123.35 129.67 74.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 CA-C-O 121.663 0.744 . . . . 0.0 111.201 -176.013 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.3 p30 -86.85 123.42 31.97 Favored 'General case' 0 C--N 1.293 -1.855 0 CA-C-N 115.007 -0.997 . . . . 0.0 108.851 177.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 19.5 mt -108.2 160.38 15.88 Favored 'General case' 0 C--N 1.275 -2.656 0 CA-C-N 114.661 -1.154 . . . . 0.0 108.162 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -59.3 118.7 32.75 Favored Pre-proline 0 C--N 1.305 -1.366 0 O-C-N 124.004 0.815 . . . . 0.0 109.869 179.228 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.489 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 56.3 Cg_endo -70.06 -5.22 15.89 Favored 'Trans proline' 0 CA--C 1.54 0.822 0 C-N-CA 122.819 2.346 . . . . 0.0 113.752 -175.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 86.2 t -128.16 111.76 25.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 179.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.464 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 10.6 t -146.49 110.58 0.87 Allowed 'Isoleucine or valine' 0 C--O 1.191 -2.014 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -178.059 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.756 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -96.53 155.73 16.64 Favored 'General case' 0 C--N 1.278 -2.51 0 C-N-CA 124.009 0.924 . . . . 0.0 111.404 -178.678 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.655 HG23 ' O ' ' A' ' 112' ' ' VAL . 89.2 t -46.41 122.88 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 123.121 0.568 . . . . 0.0 111.358 176.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.11 4.8 61.13 Favored Glycine 0 C--N 1.31 -0.911 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.498 178.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.756 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -77.35 -176.26 4.08 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 124.345 1.058 . . . . 0.0 109.648 177.673 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -132.48 92.11 3.03 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.558 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 21.9 tp -93.67 142.7 27.06 Favored 'General case' 0 C--N 1.299 -1.63 0 C-N-CA 120.04 -0.664 . . . . 0.0 109.408 178.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 52.7 t -134.97 118.47 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.967 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 -175.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.604 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 48.7 t -90.6 88.1 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.876 0 N-CA-C 105.586 -2.005 . . . . 0.0 105.586 174.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -85.4 112.41 20.83 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-O 120.973 0.416 . . . . 0.0 110.598 -177.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 83.6 mt -96.11 -3.13 45.16 Favored 'General case' 0 C--N 1.299 -1.627 0 CA-C-N 115.006 -0.997 . . . . 0.0 110.419 -177.639 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.585 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 1.9 m -73.42 1.1 10.42 Favored 'General case' 0 CA--C 1.55 0.955 0 CA-C-O 121.903 0.859 . . . . 0.0 109.47 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.3 p -130.58 6.76 4.8 Favored 'General case' 0 N--CA 1.424 -1.738 0 C-N-CA 124.286 1.034 . . . . 0.0 109.993 178.195 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.46 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 48.4 mm-40 -123.99 -19.87 5.53 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-O 121.085 0.469 . . . . 0.0 110.585 -175.179 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 36.8 mt -134.85 135.07 53.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -176.021 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.633 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 47.7 m-85 -139.11 121.58 16.15 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 120.928 0.394 . . . . 0.0 110.302 -175.475 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.4 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 71.1 m -104.54 140.05 38.54 Favored 'General case' 0 C--N 1.286 -2.175 0 CA-C-O 121.097 0.475 . . . . 0.0 110.256 -177.378 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . 0.444 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 25.2 p-80 -131.12 151.85 51.02 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 121.781 0.801 . . . . 0.0 112.589 -172.269 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.453 ' HB3' ' OD2' ' A' ' 54' ' ' ASP . 19.0 p30 -103.59 127.7 50.97 Favored 'General case' 0 N--CA 1.405 -2.692 0 CA-C-O 122.607 1.194 . . . . 0.0 110.6 174.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -94.14 -28.43 15.69 Favored 'General case' 0 C--N 1.268 -2.961 0 CA-C-N 113.429 -1.714 . . . . 0.0 108.945 -179.249 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -135.58 71.45 65.37 Favored Pre-proline 0 C--N 1.311 -1.084 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.343 178.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -69.97 3.56 2.8 Favored 'Trans proline' 0 N--CA 1.493 1.454 0 C-N-CA 123.425 2.75 . . . . 0.0 113.648 -174.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -120.12 -18.81 7.98 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 121.198 0.523 . . . . 0.0 110.093 -179.455 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.439 ' HB ' HD13 ' A' ' 52' ' ' ILE . 1.1 m -103.08 -30.06 10.97 Favored 'General case' 0 N--CA 1.422 -1.831 0 CA-C-O 122.016 0.913 . . . . 0.0 109.148 -173.335 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.578 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.6 mp -124.38 131.55 72.63 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 CA-C-N 114.811 -1.086 . . . . 0.0 108.173 -178.484 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.0 t -77.25 140.46 40.09 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 106.668 -1.605 . . . . 0.0 106.668 176.599 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.459 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 8.0 m-20 -82.75 107.45 15.39 Favored 'General case' 0 C--N 1.283 -2.322 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 -178.203 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 1.666 ' HD1' ' CD2' ' A' ' 55' ' ' TYR . 29.4 t80 -137.95 128.25 26.16 Favored 'General case' 0 C--N 1.272 -2.771 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -179.765 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.9 p -147.43 149.5 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.327 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -177.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -148.21 133.92 18.89 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 175.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.516 HD22 ' O ' ' A' ' 130' ' ' ILE . 0.7 OUTLIER -68.87 113.0 5.9 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 103.717 -2.697 . . . . 0.0 103.717 171.404 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.41 ' O ' ' HA ' ' A' ' 89' ' ' GLU . 3.4 tp-100 -57.76 -64.29 0.95 Allowed 'General case' 0 C--O 1.198 -1.628 0 C-N-CA 125.893 1.677 . . . . 0.0 109.822 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -165.08 154.15 12.52 Favored 'General case' 0 N--CA 1.424 -1.75 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 -175.725 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -120.82 164.28 14.18 Favored Glycine 0 N--CA 1.43 -1.728 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 -178.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 66.2 m -145.56 144.14 30.33 Favored 'General case' 0 C--N 1.286 -2.165 0 N-CA-C 108.455 -0.942 . . . . 0.0 108.455 178.064 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.557 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -113.15 156.83 22.52 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 1.665 ' HE1' ' CE2' ' A' ' 64' ' ' TYR . 98.5 m-85 -155.2 -179.43 8.07 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 123.849 0.86 . . . . 0.0 110.002 -176.331 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.41 -140.58 42.76 Favored Glycine 0 N--CA 1.461 0.353 0 O-C-N 123.753 0.658 . . . . 0.0 113.126 178.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.78 -10.28 86.33 Favored Glycine 0 C--O 1.209 -1.444 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.525 177.106 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.522 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 91.6 t -68.43 -38.48 79.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 C-N-CA 123.82 0.848 . . . . 0.0 111.697 -176.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.557 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.25 -18.18 32.76 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.422 -0.911 . . . . 0.0 112.198 178.388 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 16.1 t -100.55 -59.41 1.71 Allowed 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.887 -173.086 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.496 ' O ' HG23 ' A' ' 112' ' ' VAL . 37.1 m-20 -90.36 -26.51 19.89 Favored 'General case' 0 CA--C 1.493 -1.222 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.167 -172.339 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 0.551 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 90.1 m-85 -103.98 150.64 24.04 Favored 'General case' 0 N--CA 1.42 -1.951 0 C-N-CA 119.726 -0.789 . . . . 0.0 108.888 176.734 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.3 t -160.88 119.88 2.58 Favored 'General case' 0 N--CA 1.421 -1.881 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 177.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.538 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -152.68 -107.0 0.31 Allowed Glycine 0 N--CA 1.424 -2.139 0 N-CA-C 111.386 -0.685 . . . . 0.0 111.386 177.045 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -164.18 -179.5 6.19 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 124.689 1.195 . . . . 0.0 109.748 -175.253 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.452 HG11 ' CE2' ' A' ' 82' ' ' TYR . 2.8 p -132.52 146.48 32.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.175 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.663 ' HG3' ' O ' ' A' ' 80' ' ' SER . 79.7 tttt -121.49 147.69 45.44 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.026 -178.58 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 1.652 ' HE1' ' CE2' ' A' ' 77' ' ' TYR . 63.4 t80 -145.66 109.79 4.91 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -179.795 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 23.0 t 52.16 37.6 22.17 Favored 'General case' 0 CA--C 1.55 0.972 0 C-N-CA 123.629 0.772 . . . . 0.0 111.544 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.81 10.38 63.08 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 120.62 -0.8 . . . . 0.0 113.644 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.663 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 15.4 t -83.3 179.0 7.81 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 177.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.4 t -156.07 108.42 2.59 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 0.529 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 6.8 p90 -149.39 164.42 21.07 Favored Pre-proline 0 C--N 1.306 -1.314 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 -173.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . 0.421 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 97.4 Cg_endo -72.29 149.21 50.77 Favored 'Trans proline' 0 C--N 1.362 1.238 0 C-N-CA 122.224 1.949 . . . . 0.0 113.669 -175.36 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 1.658 ' HD2' ' CD1' ' A' ' 84' ' ' PHE . 55.5 t80 -119.33 133.48 23.76 Favored Pre-proline 0 N--CA 1.428 -1.55 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.894 178.677 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.629 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 61.6 Cg_endo -72.18 146.8 87.13 Favored 'Cis proline' 0 N--CA 1.477 0.539 0 C-N-CA 123.016 -1.66 . . . . 0.0 111.389 -2.315 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.7 t -71.77 179.83 2.96 Favored 'General case' 0 C--O 1.246 0.881 0 C-N-CA 119.776 -0.77 . . . . 0.0 109.075 -178.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 45.2 p -131.74 -39.09 1.12 Allowed 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 114.087 1.143 . . . . 0.0 114.087 -170.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 23.0 t -102.29 -69.45 0.79 Allowed 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 -172.616 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . 0.41 ' HA ' ' O ' ' A' ' 59' ' ' GLN . 0.3 OUTLIER -178.58 -176.2 0.47 Allowed 'General case' 0 N--CA 1.437 -1.112 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 179.378 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.409 ' HB ' ' HD2' ' A' ' 91' ' ' PRO . 1.9 p -101.11 174.81 2.68 Favored Pre-proline 0 C--N 1.286 -2.158 0 C-N-CA 123.19 0.596 . . . . 0.0 111.977 178.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . 0.409 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 22.3 Cg_endo -60.06 158.53 29.51 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 122.47 2.113 . . . . 0.0 111.439 171.47 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.3 tmm_? -77.03 114.14 15.51 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-N 114.836 -1.074 . . . . 0.0 108.781 -176.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 85.1 t -124.94 129.24 73.48 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 CA-C-O 121.544 0.687 . . . . 0.0 111.843 -177.379 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 66.2 t -114.25 123.74 70.22 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.253 177.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . 1.636 ' HD2' ' CD1' ' A' ' 95' ' ' TYR . 3.7 m-85 -73.85 133.32 43.16 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 175.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.73 55.05 0.88 Allowed 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 174.874 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' SER . . . . . 0.529 ' CB ' ' HG3' ' A' ' 101' ' ' LYS . 50.6 m -135.3 175.59 9.45 Favored 'General case' 0 N--CA 1.434 -1.228 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 -177.458 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -142.93 55.58 1.39 Allowed 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 122.033 0.92 . . . . 0.0 111.536 177.226 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.1 t -171.28 176.06 4.02 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 106.715 -1.587 . . . . 0.0 106.715 179.233 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . 0.444 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 11.0 p-10 -72.02 99.33 2.25 Favored 'General case' 0 CA--C 1.501 -0.937 0 CA-C-O 122.503 1.144 . . . . 0.0 109.608 177.395 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . 0.529 ' HG3' ' CB ' ' A' ' 97' ' ' SER . 57.4 mmtt -102.37 138.61 19.74 Favored Pre-proline 0 N--CA 1.415 -2.187 0 CA-C-N 113.524 -1.671 . . . . 0.0 110.277 -176.519 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.585 ' HB3' ' O ' ' A' ' 39' ' ' SER . 53.6 Cg_exo -49.67 139.54 31.01 Favored 'Trans proline' 0 N--CA 1.448 -1.202 0 C-N-CA 124.018 3.145 . . . . 0.0 112.86 -179.511 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.7 t90 -89.59 102.83 4.98 Favored Pre-proline 0 C--N 1.296 -1.751 0 N-CA-C 104.999 -2.223 . . . . 0.0 104.999 176.461 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 74.4 Cg_endo -75.55 88.72 1.26 Allowed 'Trans proline' 0 N--CA 1.451 -1.02 0 C-N-CA 121.877 1.718 . . . . 0.0 113.116 -170.411 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 94.2 t -138.52 143.93 31.33 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.604 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -149.04 133.78 17.85 Favored 'General case' 0 C--N 1.289 -2.025 0 CA-C-O 120.81 0.338 . . . . 0.0 110.251 178.046 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.42 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 17.4 mt -101.19 102.9 13.9 Favored 'General case' 0 C--N 1.288 -2.097 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.752 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.538 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 32.3 m-85 -83.4 77.62 9.78 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 177.828 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.589 HD22 ' CD2' ' A' ' 84' ' ' PHE . 3.3 mm? -102.38 124.98 48.92 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 176.362 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -129.69 145.96 59.2 Favored Pre-proline 0 N--CA 1.406 -2.669 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 -174.709 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -62.82 124.59 14.34 Favored 'Trans proline' 0 CA--C 1.497 -1.327 0 C-N-CA 123.038 2.492 . . . . 0.0 113.341 -176.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.655 ' O ' HG23 ' A' ' 30' ' ' VAL . 15.9 m -84.56 -155.45 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.399 -3.02 0 CA-C-N 114.246 -1.343 . . . . 0.0 108.161 172.017 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.7 t -83.38 -28.97 28.56 Favored 'General case' 0 C--N 1.263 -3.19 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -170.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 25.7 t -84.13 30.02 0.54 Allowed 'General case' 0 N--CA 1.426 -1.665 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.313 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -112.81 138.79 49.12 Favored 'General case' 0 N--CA 1.424 -1.736 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.069 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -177.28 135.91 2.94 Favored Glycine 0 N--CA 1.44 -1.063 0 N-CA-C 111.607 -0.597 . . . . 0.0 111.607 179.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 63.33 -152.34 47.36 Favored Glycine 0 CA--C 1.5 -0.853 0 CA-C-O 119.387 -0.674 . . . . 0.0 112.577 -178.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 57.7 t -60.56 98.72 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.248 0.98 0 CA-C-O 122.222 1.011 . . . . 0.0 111.161 -176.513 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.06 -24.1 15.48 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-N 114.147 -1.388 . . . . 0.0 110.756 -176.503 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.478 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.4 mt -133.63 137.58 52.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 178.47 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.412 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.3 mmpt? -114.57 138.74 50.27 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-O 120.914 0.387 . . . . 0.0 110.871 177.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.31 135.15 50.02 Favored 'General case' 0 N--CA 1.442 -0.851 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 178.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 88.12 -6.63 83.27 Favored Glycine 0 C--N 1.308 -0.974 0 N-CA-C 111.628 -0.589 . . . . 0.0 111.628 -179.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 64.9 m -96.78 149.28 22.01 Favored 'General case' 0 N--CA 1.427 -1.601 0 CA-C-O 121.285 0.564 . . . . 0.0 110.089 179.471 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.406 HD21 ' CZ ' ' A' ' 149' ' ' TYR . 3.2 tm? -78.98 125.0 28.8 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-N 114.782 -1.099 . . . . 0.0 108.587 -176.844 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.494 ' HB ' HG23 ' A' ' 67' ' ' VAL . 36.4 pt -109.61 -26.3 3.26 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -177.8 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.21 167.53 23.89 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -177.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.401 HG21 HD12 ' A' ' 125' ' ' LEU . 69.3 t -142.37 116.07 4.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 178.725 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 40.4 mt -119.29 147.91 43.76 Favored 'General case' 0 C--N 1.291 -1.976 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 179.183 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.577 HG22 ' NE2' ' A' ' 143' ' ' GLN . 5.4 mp -124.75 133.4 69.52 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 C-N-CA 119.53 -0.868 . . . . 0.0 110.653 177.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.534 ' O ' HD21 ' A' ' 131' ' ' LEU . 0.0 OUTLIER -100.35 135.67 41.43 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 175.971 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . 0.457 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 8.4 tpt180 -106.81 120.48 42.12 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -102.08 121.84 42.96 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 177.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 18.8 m -140.04 137.86 34.94 Favored 'General case' 0 C--N 1.291 -1.962 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 -179.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.578 ' CB ' HG21 ' A' ' 52' ' ' ILE . 8.7 p30 . . . . . 0 N--CA 1.442 -0.838 0 C-N-CA 118.809 -1.156 . . . . 0.0 112.389 179.018 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 . . . . . 0 N--CA 1.437 -1.111 0 N-CA-C 108.542 -0.911 . . . . 0.0 108.542 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . 0.577 ' NE2' HG22 ' A' ' 130' ' ' ILE . 19.4 pt20 -116.27 144.39 44.29 Favored 'General case' 0 C--N 1.295 -1.778 0 C-N-CA 119.981 -0.688 . . . . 0.0 111.409 176.215 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 1.666 ' HE1' ' CE2' ' A' ' 144' ' ' PHE . 3.7 m-30 -110.72 131.53 54.97 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 -178.104 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 49.6 t -90.98 130.53 40.01 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.897 0 O-C-N 123.553 0.533 . . . . 0.0 109.784 -179.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . 0.445 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.9 m95 -117.93 95.16 4.8 Favored 'General case' 0 C--N 1.279 -2.496 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 -179.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -77.62 114.79 16.82 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 23.2 mm -89.26 122.41 40.55 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.794 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -177.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 1.587 ' HE2' ' CE1' ' A' ' 149' ' ' TYR . 89.1 m-85 -118.27 152.83 35.0 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 121.509 0.671 . . . . 0.0 110.241 178.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -80.6 129.39 34.49 Favored 'General case' 0 N--CA 1.41 -2.472 0 CA-C-N 114.807 -1.088 . . . . 0.0 108.33 176.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 29.3 t-20 -91.7 -10.26 40.8 Favored 'General case' 0 C--N 1.29 -2.004 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 -177.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -155.09 145.83 22.37 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 113.991 -1.459 . . . . 0.0 109.19 -176.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -80.52 147.29 30.91 Favored 'General case' 0 C--N 1.323 -0.57 0 O-C-N 124.054 0.846 . . . . 0.0 110.861 -178.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.489 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.3 t -124.21 135.16 64.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.13 -177.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.9 t -117.74 135.98 56.4 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 79.4 t -98.54 103.21 17.39 Favored Pre-proline 0 C--N 1.295 -1.803 0 C-N-CA 123.464 0.706 . . . . 0.0 109.883 178.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.42 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 44.1 Cg_endo -71.26 -21.03 27.34 Favored 'Trans proline' 0 CA--C 1.516 -0.396 0 C-N-CA 122.172 1.915 . . . . 0.0 111.633 179.178 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 2.4 t . . . . . 0 C--O 1.249 1.073 0 C-N-CA 124.79 1.236 . . . . 0.0 114.061 176.874 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.491 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.434 -1.27 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.472 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 73.2 m -138.58 160.08 40.48 Favored 'General case' 0 C--N 1.3 -1.558 0 C-N-CA 119.624 -0.83 . . . . 0.0 111.591 -175.517 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.9 pptp? -144.43 159.53 42.58 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 122.747 0.419 . . . . 0.0 110.412 -178.123 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.545 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 81.5 p -95.51 176.57 6.12 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 121.433 0.635 . . . . 0.0 112.011 -178.518 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -76.76 -24.14 52.94 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.202 177.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.545 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 7.6 p30 -81.1 -33.54 33.24 Favored 'General case' 0 N--CA 1.448 -0.544 0 C-N-CA 119.272 -0.971 . . . . 0.0 109.549 179.247 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.82 17.86 1.15 Allowed Glycine 0 N--CA 1.439 -1.131 0 C-N-CA 119.699 -1.238 . . . . 0.0 113.404 175.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.9 m -88.69 99.75 12.59 Favored 'General case' 0 N--CA 1.431 -1.383 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.56 120.59 32.49 Favored 'General case' 0 C--N 1.291 -1.971 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.38 178.003 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.491 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 62.2 mt -102.25 115.69 64.16 Favored Pre-proline 0 C--N 1.288 -2.078 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 176.723 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -79.88 -179.81 5.63 Favored 'Trans proline' 0 N--CA 1.443 -1.445 0 C-N-CA 122.46 2.107 . . . . 0.0 111.189 177.044 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.9 mt -66.93 147.71 12.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.063 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.55 24.2 5.97 Favored Glycine 0 C--N 1.315 -0.615 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.517 178.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.0 173.17 49.45 Favored Glycine 0 C--N 1.316 -0.539 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 -178.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 159.03 -177.91 35.41 Favored Glycine 0 N--CA 1.431 -1.68 0 C-N-CA 120.283 -0.96 . . . . 0.0 111.497 177.053 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 25.5 p -151.54 141.46 22.02 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -178.073 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.9 160.46 38.83 Favored 'General case' 0 N--CA 1.425 -1.718 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 27.7 m-80 -112.83 109.05 18.27 Favored 'General case' 0 C--N 1.289 -2.037 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 177.344 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 43.2 t -94.09 137.18 23.52 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.245 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.483 -177.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 50.4 m-85 -122.83 115.69 22.41 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 120.919 0.39 . . . . 0.0 110.832 -177.201 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.404 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -125.65 132.9 70.32 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.244 -174.371 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -87.78 130.41 34.86 Favored 'General case' 0 C--N 1.298 -1.663 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.21 177.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -111.6 160.31 17.33 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 175.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.79 121.95 48.53 Favored Pre-proline 0 C--O 1.21 -1.016 0 O-C-N 124.235 0.959 . . . . 0.0 109.196 175.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.438 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 69.9 Cg_endo -74.76 -5.23 16.57 Favored 'Trans proline' 0 C--O 1.217 -0.542 0 C-N-CA 122.781 2.321 . . . . 0.0 113.555 -175.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.3 t -126.39 109.54 21.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 8.1 t -145.36 112.47 1.28 Allowed 'Isoleucine or valine' 0 C--O 1.186 -2.256 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 -176.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.658 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -101.09 156.14 17.59 Favored 'General case' 0 C--N 1.274 -2.68 0 C-N-CA 123.214 0.606 . . . . 0.0 111.474 179.657 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 38.0 t -45.51 120.55 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 C-N-CA 123.471 0.709 . . . . 0.0 112.019 176.621 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 99.82 0.74 56.32 Favored Glycine 0 CA--C 1.52 0.371 0 CA-C-N 115.542 -0.754 . . . . 0.0 112.825 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.658 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -73.11 -177.41 2.47 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 124.384 1.074 . . . . 0.0 110.977 177.706 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -127.38 92.9 3.6 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 107.769 -1.196 . . . . 0.0 107.769 177.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.6 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 20.2 tp -101.72 134.86 44.21 Favored 'General case' 0 C--N 1.283 -2.309 0 C-N-CA 118.725 -1.19 . . . . 0.0 109.381 176.843 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.9 p -141.96 132.38 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.386 -3.646 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.927 -178.135 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.588 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 42.2 t -92.12 89.95 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.55 0 CA-C-N 113.86 -1.518 . . . . 0.0 108.029 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -74.45 112.14 10.33 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 88.8 mt -95.68 1.03 53.31 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.026 0.441 . . . . 0.0 111.284 -179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 38.9 t -77.98 0.65 23.53 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 122.086 0.946 . . . . 0.0 109.439 -178.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.9 p -124.59 0.52 8.19 Favored 'General case' 0 C--N 1.281 -2.393 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.134 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.404 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 49.2 mm-40 -120.96 -24.56 5.57 Favored 'General case' 0 CA--C 1.504 -0.816 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.66 -172.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 18.2 mt -132.86 139.14 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 -176.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -134.2 161.14 35.73 Favored 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 -176.648 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.472 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 81.0 m -141.94 141.79 32.97 Favored 'General case' 0 C--N 1.284 -2.244 0 C-N-CA 122.886 0.475 . . . . 0.0 109.998 -177.068 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.6 p80 -145.3 156.69 43.96 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-O 121.312 0.577 . . . . 0.0 111.052 -174.272 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 2.9 p30 -107.42 121.06 43.83 Favored 'General case' 0 C--N 1.295 -1.783 0 CA-C-O 122.479 1.133 . . . . 0.0 113.304 178.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 13.7 p-10 -90.97 -23.37 20.44 Favored 'General case' 0 N--CA 1.42 -1.959 0 CA-C-N 113.417 -1.72 . . . . 0.0 109.529 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 1.653 ' HE2' ' CE1' ' A' ' 48' ' ' TYR . 60.7 m-85 -138.57 64.61 37.78 Favored Pre-proline 0 N--CA 1.472 0.636 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.871 176.157 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -67.5 -17.16 48.62 Favored 'Trans proline' 0 N--CA 1.481 0.784 0 C-N-CA 122.159 1.906 . . . . 0.0 112.787 -176.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -94.44 -27.63 15.91 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.903 -175.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.451 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -97.84 -30.41 12.78 Favored 'General case' 0 N--CA 1.413 -2.278 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 -171.344 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.492 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -119.57 141.4 39.79 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 CA-C-N 114.158 -1.383 . . . . 0.0 108.963 -176.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 5.4 t -88.89 131.94 34.9 Favored 'General case' 0 C--O 1.259 1.578 0 N-CA-C 104.09 -2.559 . . . . 0.0 104.09 171.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 34.0 m-20 -93.78 107.27 19.17 Favored 'General case' 0 C--N 1.271 -2.815 0 C-N-CA 118.952 -1.099 . . . . 0.0 110.152 -169.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 28.9 t80 -127.06 143.11 51.37 Favored 'General case' 0 C--N 1.289 -2.055 0 CA-C-N 114.04 -1.437 . . . . 0.0 108.908 -175.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.448 HG21 ' HG ' ' A' ' 131' ' ' LEU . 8.1 p -150.6 145.25 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.313 0 O-C-N 123.615 0.572 . . . . 0.0 110.087 -179.76 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.6 p -147.42 131.59 17.38 Favored 'General case' 0 N--CA 1.436 -1.129 0 C-N-CA 123.075 0.55 . . . . 0.0 109.769 174.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.444 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 1.1 tm? -71.2 102.14 2.46 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 175.091 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.4 tp-100 -52.53 -50.55 62.62 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 127.12 2.168 . . . . 0.0 111.697 -176.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 3.9 ptp180 -171.17 160.17 6.21 Favored 'General case' 0 N--CA 1.425 -1.684 0 CA-C-N 114.467 -1.242 . . . . 0.0 109.289 -176.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -135.84 148.22 19.55 Favored Glycine 0 N--CA 1.41 -3.097 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 179.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 63.2 m -129.38 143.81 50.99 Favored 'General case' 0 C--N 1.279 -2.469 0 C-N-CA 123.228 0.611 . . . . 0.0 109.573 -178.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.507 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -111.29 155.62 22.75 Favored 'General case' 0 CA--C 1.502 -0.87 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.487 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 68.0 m-85 -157.45 -178.52 7.4 Favored 'General case' 0 C--O 1.238 0.494 0 C-N-CA 124.235 1.014 . . . . 0.0 108.313 -177.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 62.45 -141.71 47.25 Favored Glycine 0 N--CA 1.453 -0.191 0 O-C-N 123.333 0.396 . . . . 0.0 112.707 177.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.24 -7.84 87.18 Favored Glycine 0 C--O 1.208 -1.482 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 177.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.487 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 86.6 t -69.72 -38.64 76.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 C-N-CA 123.752 0.821 . . . . 0.0 111.339 -176.488 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.507 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -85.44 -22.8 28.14 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 119.306 -0.957 . . . . 0.0 112.063 179.441 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 9.3 t -100.63 -51.39 3.61 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.144 0.497 . . . . 0.0 112.265 -172.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.445 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 47.7 m-20 -90.8 -24.57 20.28 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -174.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 1.643 ' HD1' ' CD2' ' A' ' 71' ' ' PHE . 89.2 m-85 -111.52 156.49 21.64 Favored 'General case' 0 N--CA 1.42 -1.951 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.292 179.104 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.5 t -162.97 138.57 6.89 Favored 'General case' 0 N--CA 1.406 -2.651 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 176.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.522 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.36 -104.65 0.18 Allowed Glycine 0 N--CA 1.409 -3.146 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 175.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.2 p -165.3 -179.86 5.83 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 124.547 1.139 . . . . 0.0 110.137 -176.261 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -131.81 145.33 35.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 123.313 0.645 . . . . 0.0 109.467 178.411 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.67 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.2 tttt -122.23 149.52 43.56 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.478 -177.614 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.419 ' CG ' HG22 ' A' ' 90' ' ' THR . 60.8 t80 -150.15 113.09 4.81 Favored 'General case' 0 C--O 1.214 -0.777 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 22.7 t 56.92 30.23 17.64 Favored 'General case' 0 CA--C 1.554 1.108 0 CA-C-O 121.884 0.85 . . . . 0.0 111.286 176.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.33 13.69 59.76 Favored Glycine 0 N--CA 1.437 -1.273 0 C-N-CA 120.208 -0.996 . . . . 0.0 113.086 -177.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.67 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 21.2 t -83.95 -179.35 7.24 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 175.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 8.2 t -157.37 110.48 2.51 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 179.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 0.423 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 7.4 p90 -149.68 162.52 28.11 Favored Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -174.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . 0.423 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 72.7 Cg_endo -68.2 149.08 75.91 Favored 'Trans proline' 0 C--N 1.36 1.174 0 C-N-CA 122.671 2.248 . . . . 0.0 113.528 -175.266 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.601 ' CD2' HD22 ' A' ' 109' ' ' LEU . 60.2 t80 -124.31 134.54 25.57 Favored Pre-proline 0 N--CA 1.442 -0.839 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.193 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.594 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 57.4 Cg_endo -70.57 145.08 80.29 Favored 'Cis proline' 0 C--O 1.239 0.568 0 C-N-CA 123.099 -1.625 . . . . 0.0 110.633 -3.255 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.7 t -73.65 -177.63 2.8 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -177.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 41.2 p -131.77 -35.87 1.24 Allowed 'General case' 0 N--CA 1.424 -1.772 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -172.438 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 49.5 m -110.1 -162.21 0.79 Allowed 'General case' 1 N--CA 1.317 -7.114 0 CA-C-N 113.45 -1.704 . . . . 0.0 107.663 179.265 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 27.0 tt0 -116.21 151.32 35.96 Favored 'General case' 1 C--N 1.244 -4.011 0 CA-C-N 113.443 -1.708 . . . . 0.0 109.115 -168.639 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.444 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 46.8 p -67.75 161.17 68.76 Favored Pre-proline 0 C--N 1.296 -1.748 0 C-N-CA 124.494 1.117 . . . . 0.0 113.245 -177.642 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -56.86 159.86 13.48 Favored 'Trans proline' 0 C--N 1.355 0.876 0 C-N-CA 124.068 3.179 . . . . 0.0 111.749 175.454 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.5 tmm_? -67.88 116.74 8.88 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.667 -176.024 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 72.7 t -132.05 137.18 55.31 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 C-N-CA 123.848 0.859 . . . . 0.0 108.687 -176.223 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.0 p -136.59 132.94 48.85 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.628 -175.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -82.9 101.5 11.06 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 120.937 0.398 . . . . 0.0 110.917 -178.395 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 36.7 m-80 -92.29 55.12 2.48 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-O 121.996 0.903 . . . . 0.0 108.837 176.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.3 m -145.4 128.63 16.74 Favored 'General case' 0 N--CA 1.428 -1.566 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 -178.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.5 ptm180 -104.51 63.7 0.74 Allowed 'General case' 0 C--N 1.304 -1.378 0 CA-C-O 122.643 1.211 . . . . 0.0 109.609 -179.091 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.1 t -170.41 -179.5 3.04 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 -172.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -86.25 124.81 33.04 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 6.8 mptt -127.32 143.9 48.84 Favored Pre-proline 0 C--N 1.277 -2.561 0 C-N-CA 124.463 1.105 . . . . 0.0 109.273 -179.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -68.23 147.27 72.12 Favored 'Trans proline' 0 C--O 1.244 0.787 0 C-N-CA 122.891 2.394 . . . . 0.0 112.12 178.118 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.2 t90 -85.56 107.45 12.47 Favored Pre-proline 0 C--N 1.323 -0.544 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 -177.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -76.73 88.2 1.4 Allowed 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 121.518 1.479 . . . . 0.0 112.905 -172.495 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 68.2 t -137.54 153.96 29.1 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.144 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 178.102 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.588 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -160.05 137.4 9.55 Favored 'General case' 0 CA--C 1.475 -1.94 0 O-C-N 123.406 0.441 . . . . 0.0 110.182 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.449 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 18.9 mt -105.79 99.85 9.43 Favored 'General case' 0 C--N 1.286 -2.171 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.388 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.522 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 42.4 m-85 -79.78 77.2 6.42 Favored 'General case' 0 C--N 1.313 -0.995 0 O-C-N 122.041 -0.412 . . . . 0.0 110.105 177.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.601 HD22 ' CD2' ' A' ' 84' ' ' PHE . 3.1 mm? -102.48 119.74 39.34 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-O 120.926 0.393 . . . . 0.0 110.219 177.653 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.54 147.39 52.74 Favored Pre-proline 0 N--CA 1.419 -1.98 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.725 -174.558 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.445 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 29.9 Cg_endo -62.24 118.55 5.44 Favored 'Trans proline' 0 C--O 1.246 0.899 0 C-N-CA 123.185 2.59 . . . . 0.0 112.835 -177.13 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 2.8 m -68.46 -116.43 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.192 -1.923 0 CA-C-N 114.007 -1.451 . . . . 0.0 112.71 175.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 22.8 t -112.21 -39.53 4.42 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.267 -0.895 . . . . 0.0 109.541 177.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 31.5 t -84.33 29.41 0.58 Allowed 'General case' 0 C--N 1.317 -0.804 0 C-N-CA 123.536 0.734 . . . . 0.0 111.342 -175.095 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -101.93 133.18 47.13 Favored 'General case' 0 N--CA 1.422 -1.84 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.336 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.97 139.84 5.19 Favored Glycine 0 N--CA 1.434 -1.436 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.017 178.19 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 59.71 -144.37 46.19 Favored Glycine 0 CA--C 1.495 -1.214 0 CA-C-O 119.288 -0.729 . . . . 0.0 112.738 -179.083 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.3 p -59.24 96.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 122.753 1.263 . . . . 0.0 111.575 -178.31 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.44 -25.85 14.65 Favored 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 114.754 -1.112 . . . . 0.0 111.49 -177.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.418 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 61.4 mt -134.72 139.66 47.14 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.326 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 3.7 mmpt? -114.85 137.32 52.1 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-O 121.089 0.471 . . . . 0.0 111.4 179.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.06 122.52 20.21 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.379 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 93.6 3.57 64.47 Favored Glycine 0 C--N 1.309 -0.948 0 N-CA-C 111.595 -0.602 . . . . 0.0 111.595 -177.458 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 32.9 t -102.21 143.62 31.77 Favored 'General case' 0 C--O 1.253 1.246 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 178.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -72.28 124.72 25.67 Favored 'General case' 0 N--CA 1.444 -0.727 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -179.683 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.471 ' HB ' HG23 ' A' ' 67' ' ' VAL . 39.0 pt -109.93 -27.43 2.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 N-CA-C 112.423 0.527 . . . . 0.0 112.423 -178.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.68 167.62 24.79 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 -177.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 71.2 t -142.97 116.38 3.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.576 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 59.9 mt -115.95 143.01 46.02 Favored 'General case' 0 C--N 1.288 -2.08 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 179.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.31 118.44 53.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 C-N-CA 119.402 -0.919 . . . . 0.0 110.322 179.184 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.476 ' O ' ' HB2' ' A' ' 143' ' ' GLN . 0.1 OUTLIER -88.76 150.09 23.12 Favored 'General case' 0 C--N 1.268 -2.957 0 C-N-CA 124.838 1.255 . . . . 0.0 108.485 178.227 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 19.3 ttp85 -123.38 137.4 54.83 Favored 'General case' 0 N--CA 1.414 -2.269 0 O-C-N 123.255 0.347 . . . . 0.0 111.549 178.443 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.407 ' OE1' HD22 ' A' ' 131' ' ' LEU . 13.3 mm100 -113.01 115.44 28.38 Favored 'General case' 0 N--CA 1.431 -1.398 0 CA-C-N 115.079 -0.964 . . . . 0.0 110.622 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 4.5 m -133.33 130.86 39.43 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 176.017 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.492 ' CB ' HG21 ' A' ' 52' ' ' ILE . 6.5 p30 . . . . . 0 C--O 1.214 -0.791 0 C-N-CA 118.464 -1.294 . . . . 0.0 112.232 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . 1.657 ' HD1' ' CD2' ' A' ' 142' ' ' PHE . 72.4 m-85 . . . . . 0 CA--C 1.49 -1.357 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . 0.476 ' HB2' ' O ' ' A' ' 131' ' ' LEU . 15.7 pt20 -138.58 141.92 39.21 Favored 'General case' 0 C--N 1.287 -2.15 0 C-N-CA 119.453 -0.899 . . . . 0.0 111.003 -178.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 1.658 ' HE2' ' CE1' ' A' ' 144' ' ' PHE . 7.5 m-30 -107.2 134.21 50.64 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 -175.619 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 45.3 t -93.26 130.82 41.75 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 O-C-N 123.492 0.495 . . . . 0.0 109.886 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . 0.436 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 64.1 m95 -120.69 100.03 6.88 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 -179.688 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -81.02 113.5 19.26 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 179.194 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 23.6 mm -88.43 121.55 38.86 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -178.044 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 1.616 ' HE2' ' CE1' ' A' ' 149' ' ' TYR . 95.7 m-85 -117.46 153.69 32.69 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 123.541 0.736 . . . . 0.0 109.834 177.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.0 131.94 35.16 Favored 'General case' 0 N--CA 1.416 -2.165 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 177.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 13.8 t-20 -95.06 -5.77 43.63 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -177.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -155.96 139.97 16.36 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.199 -1.364 . . . . 0.0 109.508 -177.078 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -78.16 145.04 35.86 Favored 'General case' 0 C--N 1.308 -1.2 0 O-C-N 124.212 0.945 . . . . 0.0 109.454 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.438 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 75.5 t -120.67 141.29 41.74 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 O-C-N 122.28 -0.263 . . . . 0.0 110.82 -177.009 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.2 t -120.48 136.11 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.234 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 179.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.7 t -101.74 103.95 31.82 Favored Pre-proline 0 C--N 1.289 -2.058 0 C-N-CA 123.173 0.589 . . . . 0.0 109.716 178.292 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -71.29 -19.47 29.15 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.031 1.821 . . . . 0.0 111.3 178.139 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 5.1 t . . . . . 0 C--O 1.246 0.872 0 C-N-CA 124.956 1.302 . . . . 0.0 113.262 176.233 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.491 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.419 -2.013 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 79.4 m -136.89 154.46 50.48 Favored 'General case' 0 C--N 1.291 -1.974 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.549 -174.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.44 162.52 35.57 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.608 -174.024 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.688 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 67.1 p -97.63 179.81 4.71 Favored 'General case' 0 C--N 1.301 -1.515 0 CA-C-O 121.192 0.52 . . . . 0.0 110.599 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -84.98 -19.75 31.59 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 114.93 -1.032 . . . . 0.0 108.73 179.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.688 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 1.5 p-10 -87.93 -17.46 31.29 Favored 'General case' 0 N--CA 1.417 -2.1 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.475 -179.532 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 119.24 11.63 7.34 Favored Glycine 0 CA--C 1.486 -1.729 0 C-N-CA 119.061 -1.543 . . . . 0.0 114.373 167.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.2 m -89.83 99.68 12.64 Favored 'General case' 0 N--CA 1.413 -2.308 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -90.66 121.65 32.75 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-N 115.071 -0.968 . . . . 0.0 108.513 177.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.491 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 66.4 mt -101.77 113.7 65.78 Favored Pre-proline 0 C--N 1.295 -1.768 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 178.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -75.54 170.6 19.92 Favored 'Trans proline' 0 C--O 1.25 1.092 0 C-N-CA 122.586 2.19 . . . . 0.0 111.527 178.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 63.1 mt -64.42 128.19 26.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.199 179.233 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.89 6.24 2.03 Favored Glycine 0 C--N 1.314 -0.669 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.742 -178.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.65 158.41 33.8 Favored Glycine 0 C--N 1.316 -0.558 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 166.04 -173.2 41.59 Favored Glycine 0 C--N 1.3 -1.434 0 C-N-CA 119.709 -1.234 . . . . 0.0 112.014 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.2 p -148.45 140.87 24.29 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -178.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -130.8 159.6 36.86 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 29.1 m-80 -108.55 109.89 21.23 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 176.414 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 38.3 t -96.15 138.9 20.33 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.689 -178.396 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -124.7 112.5 16.83 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 121.216 0.532 . . . . 0.0 111.312 -176.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.485 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.1 p -122.76 134.13 66.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.942 -175.363 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -98.07 119.69 37.15 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-O 121.47 0.652 . . . . 0.0 110.152 -178.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.401 ' CD1' ' HA ' ' A' ' 36' ' ' VAL . 2.7 mm? -97.06 161.72 13.7 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.359 -178.668 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.27 122.1 51.98 Favored Pre-proline 0 C--N 1.317 -0.817 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 173.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.457 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 63.1 Cg_endo -74.86 -2.22 12.21 Favored 'Trans proline' 0 CA--C 1.533 0.456 0 C-N-CA 122.771 2.314 . . . . 0.0 113.203 -176.357 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.425 HG11 ' HG3' ' A' ' 157' ' ' PRO . 73.5 t -127.16 115.26 40.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.479 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 3.3 t -149.84 118.99 0.98 Allowed 'Isoleucine or valine' 0 C--O 1.194 -1.833 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 -179.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.636 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -107.13 155.79 19.5 Favored 'General case' 0 C--N 1.278 -2.519 0 C-N-CA 122.787 0.435 . . . . 0.0 111.625 -179.592 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.439 HG11 ' O ' ' A' ' 112' ' ' VAL . 38.6 t -47.07 117.13 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 123.656 0.782 . . . . 0.0 111.765 177.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.79 -2.44 45.2 Favored Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 115.391 -0.822 . . . . 0.0 112.918 179.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.636 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -72.95 -176.91 2.21 Favored 'General case' 0 C--N 1.314 -0.948 0 C-N-CA 123.999 0.92 . . . . 0.0 110.58 177.419 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -134.44 98.21 4.02 Favored 'General case' 0 N--CA 1.427 -1.612 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 176.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.672 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 30.4 tp -93.69 147.01 23.42 Favored 'General case' 0 C--N 1.282 -2.354 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 93.8 t -135.28 120.94 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.507 0 CA-C-O 121.212 0.53 . . . . 0.0 109.973 -178.512 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.602 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 61.5 t -89.61 88.74 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.286 0 N-CA-C 106.349 -1.722 . . . . 0.0 106.349 174.203 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -81.67 110.12 16.72 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-O 121.202 0.525 . . . . 0.0 111.42 -177.281 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.5 mt -96.45 -3.0 44.21 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.438 -178.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.2 m -73.07 0.03 12.64 Favored 'General case' 0 CA--C 1.551 1.001 0 CA-C-O 122.151 0.977 . . . . 0.0 109.532 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.5 p -126.29 3.0 7.07 Favored 'General case' 0 C--N 1.295 -1.782 0 C-N-CA 123.712 0.805 . . . . 0.0 110.288 178.063 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.485 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 45.5 mm-40 -121.93 -23.47 5.43 Favored 'General case' 0 CA--C 1.506 -0.724 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.815 -173.458 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.8 mt -133.11 140.34 47.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.196 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -176.149 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.643 ' HE2' ' CE1' ' A' ' 43' ' ' PHE . 62.2 m-85 -137.62 153.46 49.89 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -176.507 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 66.6 m -128.64 134.94 48.68 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 123.537 0.735 . . . . 0.0 109.209 176.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 22.0 p80 -127.56 145.97 50.68 Favored 'General case' 0 C--N 1.291 -1.968 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.364 -177.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -99.85 99.41 10.2 Favored 'General case' 0 C--N 1.293 -1.877 0 C-N-CA 118.637 -1.225 . . . . 0.0 109.035 175.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -72.81 -9.79 59.07 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 125.145 1.378 . . . . 0.0 112.627 178.62 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 1.624 ' HE2' ' CE1' ' A' ' 48' ' ' TYR . 52.4 m-85 -144.63 68.1 14.54 Favored Pre-proline 0 N--CA 1.482 1.174 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 175.17 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -66.22 -5.33 12.23 Favored 'Trans proline' 0 N--CA 1.488 1.176 0 C-N-CA 123.376 2.717 . . . . 0.0 114.651 -172.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -117.99 -3.14 11.16 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-O 121.282 0.563 . . . . 0.0 109.692 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.436 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.6 OUTLIER -117.51 -30.15 5.6 Favored 'General case' 0 N--CA 1.421 -1.878 0 CA-C-O 121.608 0.718 . . . . 0.0 109.732 -175.117 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.595 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.6 mp -129.16 131.87 67.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 -177.455 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.4 t -76.94 146.37 37.6 Favored 'General case' 0 C--O 1.251 1.145 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.503 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 0.8 OUTLIER -83.34 108.45 16.54 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 -178.056 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 1.639 ' HD2' ' CD1' ' A' ' 55' ' ' TYR . 22.4 t80 -145.99 129.89 17.27 Favored 'General case' 0 C--N 1.28 -2.425 0 CA-C-O 121.224 0.535 . . . . 0.0 109.62 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.2 p -148.4 149.41 15.18 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.478 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 -178.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 5.3 p -150.33 136.36 18.55 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 178.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.446 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 38.0 tp -73.32 110.03 7.29 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 172.307 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -58.98 -55.64 32.5 Favored 'General case' 0 C--N 1.314 -0.969 0 C-N-CA 126.155 1.782 . . . . 0.0 110.584 179.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -165.55 160.21 17.46 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 -177.547 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -138.31 143.18 13.97 Favored Glycine 0 N--CA 1.405 -3.403 0 N-CA-C 108.89 -1.684 . . . . 0.0 108.89 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 68.4 m -129.88 148.97 51.81 Favored 'General case' 0 C--N 1.278 -2.503 0 C-N-CA 123.771 0.829 . . . . 0.0 109.513 -177.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.445 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -110.72 156.6 20.8 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 -178.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 1.652 ' HE1' ' CE2' ' A' ' 64' ' ' TYR . 91.8 m-85 -153.93 -179.59 8.0 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.459 0.704 . . . . 0.0 110.257 -177.169 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.6 -138.39 49.29 Favored Glycine 0 C--O 1.223 -0.566 0 O-C-N 123.944 0.777 . . . . 0.0 112.892 176.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.61 -3.3 89.73 Favored Glycine 0 N--CA 1.425 -2.061 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.628 177.428 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.477 HG23 ' HB ' ' A' ' 126' ' ' ILE . 79.8 t -73.99 -41.91 52.78 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 123.03 0.532 . . . . 0.0 111.464 -178.44 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.469 ' HG ' ' CA ' ' A' ' 64' ' ' TYR . 0.3 OUTLIER -80.17 -23.17 41.23 Favored 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 119.523 -0.871 . . . . 0.0 112.203 179.57 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 13.9 m -100.97 -46.67 5.02 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 115.011 1.486 . . . . 0.0 115.011 -174.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.487 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 38.6 m-80 -94.28 -19.92 20.25 Favored 'General case' 0 CA--C 1.494 -1.185 0 C-N-CA 119.87 -0.732 . . . . 0.0 109.48 -178.695 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 0.525 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 86.9 m-85 -111.76 162.62 15.05 Favored 'General case' 0 N--CA 1.423 -1.808 0 C-N-CA 120.214 -0.594 . . . . 0.0 110.143 179.024 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.2 t -169.57 130.88 1.09 Allowed 'General case' 0 N--CA 1.422 -1.865 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 176.094 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.514 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -164.18 -110.37 0.24 Allowed Glycine 0 N--CA 1.412 -2.958 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 175.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.1 p -158.27 -179.58 8.24 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 124.421 1.089 . . . . 0.0 110.353 -174.122 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -133.66 146.94 31.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 C-N-CA 122.965 0.506 . . . . 0.0 109.993 177.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.639 ' HG3' ' O ' ' A' ' 80' ' ' SER . 77.9 tttt -122.14 146.25 47.41 Favored 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 -178.783 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.472 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 56.9 t80 -145.27 106.58 4.2 Favored 'General case' 0 C--N 1.307 -1.242 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 -178.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 29.9 t 54.11 38.16 28.51 Favored 'General case' 0 CA--C 1.55 0.943 0 C-N-CA 123.435 0.694 . . . . 0.0 111.268 179.525 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.35 7.81 66.96 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 120.751 -0.738 . . . . 0.0 113.552 -179.02 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.639 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 15.2 t -79.64 174.32 11.69 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.486 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.5 p -152.06 100.33 2.62 Favored 'General case' 0 C--N 1.287 -2.146 0 CA-C-O 121.125 0.488 . . . . 0.0 109.747 -178.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 0.472 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 3.1 p90 -144.57 161.3 44.49 Favored Pre-proline 0 C--N 1.307 -1.243 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -173.64 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 59.9 Cg_endo -69.93 153.82 67.74 Favored 'Trans proline' 0 C--N 1.356 0.935 0 C-N-CA 123.018 2.479 . . . . 0.0 113.129 -174.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 1.665 ' HD2' ' CD1' ' A' ' 84' ' ' PHE . 56.3 t80 -129.53 128.96 23.15 Favored Pre-proline 0 C--N 1.316 -0.87 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.754 179.066 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.47 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 74.0 Cg_endo -69.16 148.65 85.78 Favored 'Cis proline' 0 CA--C 1.547 1.148 0 C-N-CA 122.789 -1.754 . . . . 0.0 110.374 -0.786 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.403 ' HA ' ' O ' ' A' ' 83' ' ' PRO . 7.6 t -62.81 -178.59 0.21 Allowed 'General case' 0 CA--C 1.555 1.169 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.733 -173.167 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 16.6 p -130.52 -17.09 3.34 Favored 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 115.845 -0.616 . . . . 0.0 112.489 -173.026 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 27.2 t -133.21 -80.04 0.48 Allowed 'General case' 0 N--CA 1.426 -1.664 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.389 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 179.85 -170.44 0.14 Allowed 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 -178.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.446 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 15.8 p -101.32 162.13 21.48 Favored Pre-proline 0 C--N 1.293 -1.872 0 N-CA-C 113.172 0.805 . . . . 0.0 113.172 178.376 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -63.13 163.68 22.1 Favored 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 123.309 2.673 . . . . 0.0 111.542 173.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.413 ' C ' ' HD2' ' A' ' 92' ' ' ARG . 3.8 tmm_? -72.81 123.48 23.45 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.901 -178.23 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 98.5 t -130.54 123.0 54.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.498 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 74.2 t -107.49 130.89 58.99 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 177.179 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . 1.654 ' HD1' ' CD2' ' A' ' 95' ' ' TYR . 1.8 m-85 -91.77 167.83 11.89 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 106.058 -1.831 . . . . 0.0 106.058 172.589 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -132.74 54.37 1.95 Allowed 'General case' 0 C--N 1.258 -3.377 0 N-CA-C 104.845 -2.28 . . . . 0.0 104.845 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' SER . . . . . 0.417 ' HB3' ' HG3' ' A' ' 101' ' ' LYS . 66.2 p -113.09 161.35 17.2 Favored 'General case' 0 N--CA 1.414 -2.226 0 N-CA-C 114.44 1.274 . . . . 0.0 114.44 -167.366 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 35.1 ptt180 -144.74 30.18 1.21 Allowed 'General case' 0 C--N 1.3 -1.56 0 CA-C-N 114.375 -1.284 . . . . 0.0 108.177 171.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.9 t -159.26 177.08 11.41 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-N 113.826 -1.533 . . . . 0.0 107.087 -179.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -71.26 111.48 6.64 Favored 'General case' 0 CA--C 1.5 -0.959 0 O-C-N 123.533 0.52 . . . . 0.0 109.632 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . 0.493 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 7.4 mmpt? -111.37 143.57 28.74 Favored Pre-proline 0 C--N 1.288 -2.092 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 174.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.471 ' O ' ' HD3' ' A' ' 104' ' ' PRO . 33.7 Cg_endo -67.12 144.29 68.66 Favored 'Trans proline' 0 N--CA 1.446 -1.317 0 C-N-CA 122.608 2.206 . . . . 0.0 111.95 -177.09 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 14.1 t90 -89.46 101.14 2.83 Favored Pre-proline 0 C--N 1.307 -1.248 0 N-CA-C 105.657 -1.979 . . . . 0.0 105.657 179.258 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . 0.471 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 73.2 Cg_endo -75.17 88.65 1.24 Allowed 'Trans proline' 0 N--CA 1.452 -0.926 0 C-N-CA 122.016 1.811 . . . . 0.0 112.841 -171.024 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 93.2 t -136.91 142.94 36.36 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.465 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.015 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.602 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.99 134.19 18.29 Favored 'General case' 0 N--CA 1.412 -2.346 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.335 178.758 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.416 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 19.0 mt -98.95 102.32 14.01 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.013 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.514 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 13.1 m-85 -79.01 65.41 4.18 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 122.955 0.502 . . . . 0.0 111.517 178.297 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.672 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.9 mm? -92.14 135.3 34.1 Favored 'General case' 0 C--O 1.205 -1.24 0 O-C-N 121.958 -0.464 . . . . 0.0 110.162 177.142 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.02 145.24 51.67 Favored Pre-proline 0 N--CA 1.418 -2.065 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.468 -176.836 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.487 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 24.3 Cg_endo -60.21 120.81 8.8 Favored 'Trans proline' 0 C--O 1.243 0.775 0 C-N-CA 123.402 2.735 . . . . 0.0 111.972 -177.292 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.439 ' O ' HG11 ' A' ' 30' ' ' VAL . 2.6 m -69.53 -115.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.189 -2.085 0 CA-C-N 114.436 -1.256 . . . . 0.0 112.668 177.193 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.3 m -110.92 -46.29 3.36 Favored 'General case' 0 C--N 1.29 -1.996 0 O-C-N 121.471 -0.768 . . . . 0.0 110.144 178.315 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 13.3 t -86.1 31.18 0.64 Allowed 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.898 -173.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -95.18 131.69 40.95 Favored 'General case' 0 N--CA 1.423 -1.803 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.421 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -168.66 139.82 5.85 Favored Glycine 0 N--CA 1.432 -1.579 0 C-N-CA 120.331 -0.938 . . . . 0.0 111.808 179.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 57.49 -144.48 40.38 Favored Glycine 0 CA--C 1.488 -1.607 0 C-N-CA 123.914 0.769 . . . . 0.0 113.072 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -58.67 94.48 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 122.821 1.296 . . . . 0.0 111.995 -177.559 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.16 -22.53 16.14 Favored 'General case' 0 C--N 1.297 -1.691 0 CA-C-N 114.774 -1.103 . . . . 0.0 111.398 -176.507 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.425 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 59.0 mt -136.48 137.74 47.49 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 107.853 -1.165 . . . . 0.0 107.853 177.389 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.428 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.6 mmpt? -112.0 139.59 47.38 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-O 120.831 0.348 . . . . 0.0 111.793 179.201 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.21 120.52 16.02 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 178.429 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.57 -5.54 64.7 Favored Glycine 0 C--N 1.309 -0.923 0 N-CA-C 111.733 -0.547 . . . . 0.0 111.733 -176.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 34.1 t -90.23 142.91 27.26 Favored 'General case' 0 C--O 1.252 1.194 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 30.1 tp -71.86 133.41 45.44 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 177.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.477 ' HB ' HG23 ' A' ' 67' ' ' VAL . 40.6 pt -118.8 -24.71 3.08 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.039 0 C-N-CA 120.347 -0.541 . . . . 0.0 112.28 -178.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . 0.425 ' HB1' ' HB ' ' A' ' 148' ' ' ILE . . . -163.97 164.38 23.2 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 120.966 -0.293 . . . . 0.0 110.449 -178.018 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 55.4 t -140.17 114.29 6.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 178.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 56.9 mt -118.26 147.08 43.79 Favored 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.431 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.8 mp -129.23 126.36 63.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 C-N-CA 120.16 -0.616 . . . . 0.0 110.065 178.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.489 ' C ' HD13 ' A' ' 131' ' ' LEU . 1.4 pp -92.26 150.56 20.8 Favored 'General case' 0 CA--C 1.476 -1.897 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 173.332 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 56.4 ttp180 -115.11 116.69 28.81 Favored 'General case' 0 C--N 1.25 -3.727 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 176.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -100.51 120.25 39.73 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 -175.1 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 5.4 m -133.58 144.26 49.19 Favored 'General case' 0 C--N 1.287 -2.125 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.595 ' CB ' HG21 ' A' ' 52' ' ' ILE . 8.0 p30 . . . . . 0 N--CA 1.436 -1.137 0 C-N-CA 118.227 -1.389 . . . . 0.0 111.877 174.437 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . 1.626 ' HE2' ' CE1' ' A' ' 142' ' ' PHE . 82.2 m-85 . . . . . 0 CA--C 1.491 -1.326 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -131.39 145.4 51.8 Favored 'General case' 0 N--CA 1.415 -2.193 0 C-N-CA 118.549 -1.26 . . . . 0.0 111.798 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 1.657 ' HD1' ' CD2' ' A' ' 144' ' ' PHE . 8.6 m-30 -113.77 126.75 55.56 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 108.266 -1.012 . . . . 0.0 108.266 -175.374 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 48.4 t -89.72 133.59 31.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 123.544 0.528 . . . . 0.0 110.304 -179.379 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 58.0 m95 -120.04 100.46 7.22 Favored 'General case' 0 C--N 1.285 -2.236 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 -179.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -82.77 111.83 19.05 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 106.608 -1.627 . . . . 0.0 106.608 178.112 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . 0.425 ' HB ' ' HB1' ' A' ' 127' ' ' ALA . 22.6 mm -86.72 121.57 37.81 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 -176.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 1.657 ' HE2' ' CE1' ' A' ' 149' ' ' TYR . 98.7 m-85 -118.26 154.66 31.9 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 177.631 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . 0.416 ' HB1' ' O ' ' A' ' 121' ' ' LYS . . . -80.96 128.0 33.2 Favored 'General case' 0 N--CA 1.406 -2.661 0 CA-C-N 115.243 -0.889 . . . . 0.0 108.699 176.167 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 37.0 t-20 -88.87 -8.9 53.43 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 106.719 -1.585 . . . . 0.0 106.719 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -156.0 139.75 16.13 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 113.679 -1.6 . . . . 0.0 109.605 -176.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -77.86 147.95 34.89 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 124.538 1.135 . . . . 0.0 110.067 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.457 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 73.7 t -123.58 138.1 54.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.913 -176.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.7 t -118.65 136.14 56.8 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.576 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.479 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 76.3 t -100.0 104.4 28.64 Favored Pre-proline 0 C--N 1.285 -2.224 0 C-N-CA 123.202 0.601 . . . . 0.0 109.416 178.26 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.425 ' HG3' HG11 ' A' ' 27' ' ' VAL . 33.7 Cg_endo -69.78 -25.12 28.84 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.121 1.881 . . . . 0.0 111.02 176.905 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.274 6.0 t . . . . . 0 C--O 1.247 0.928 0 O-C-N 124.638 1.211 . . . . 0.0 113.204 176.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.432 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.432 -1.329 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 65.1 m -130.73 158.3 40.49 Favored 'General case' 0 C--N 1.287 -2.112 0 C-N-CA 120.013 -0.675 . . . . 0.0 111.272 -172.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.415 ' HD2' ' O ' ' A' ' 5' ' ' THR . 0.0 OUTLIER -145.91 164.41 32.07 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.608 -175.002 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.561 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 68.1 p -99.91 -179.52 4.19 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-O 121.449 0.642 . . . . 0.0 111.787 -178.407 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.88 -20.44 38.83 Favored 'General case' 0 C--N 1.296 -1.72 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.108 177.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.561 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 0.8 OUTLIER -88.45 -25.83 22.43 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.094 -0.957 . . . . 0.0 112.186 -179.758 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 128.35 8.47 4.02 Favored Glycine 0 CA--C 1.496 -1.107 0 C-N-CA 119.354 -1.403 . . . . 0.0 114.241 170.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 m -83.49 98.86 9.76 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 -179.174 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.05 109.1 21.19 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.888 179.372 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.432 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 64.8 mt -86.17 120.24 72.24 Favored Pre-proline 0 C--N 1.305 -1.359 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 -177.673 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -79.06 168.39 20.64 Favored 'Trans proline' 0 C--O 1.252 1.204 0 C-N-CA 122.65 2.233 . . . . 0.0 110.742 178.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.3 mt -71.14 128.09 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.3 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 178.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 139.37 -8.68 3.19 Favored Glycine 0 C--N 1.296 -1.681 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -176.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.58 148.36 22.13 Favored Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.351 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.98 -174.05 46.15 Favored Glycine 0 N--CA 1.435 -1.37 0 C-N-CA 120.493 -0.861 . . . . 0.0 111.156 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 28.8 p -143.02 151.02 40.37 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.2 162.33 33.26 Favored 'General case' 0 N--CA 1.415 -2.223 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 -179.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -107.72 117.01 32.99 Favored 'General case' 0 C--N 1.278 -2.52 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 176.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.406 HG23 HG21 ' A' ' 5' ' ' THR . 40.7 t -105.43 132.04 53.31 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.778 0 CA-C-N 115.484 -0.78 . . . . 0.0 109.138 178.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.4 m-85 -118.52 123.04 44.13 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 -179.002 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.428 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.4 p -131.28 134.55 60.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.005 -176.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 5.6 p30 -98.03 119.17 36.18 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 121.737 0.78 . . . . 0.0 110.585 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -99.45 160.78 14.03 Favored 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 114.59 -1.187 . . . . 0.0 109.13 -177.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.03 121.51 46.68 Favored Pre-proline 0 C--O 1.212 -0.884 0 O-C-N 124.478 1.111 . . . . 0.0 109.076 176.108 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 73.4 Cg_endo -74.31 -2.62 12.61 Favored 'Trans proline' 0 C--O 1.22 -0.42 0 C-N-CA 122.811 2.341 . . . . 0.0 113.277 -175.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.41 HG11 ' HG3' ' A' ' 157' ' ' PRO . 86.0 t -126.54 109.74 21.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.48 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 4.2 t -145.05 110.82 1.15 Allowed 'Isoleucine or valine' 0 C--O 1.188 -2.167 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -177.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.646 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -98.32 153.12 18.76 Favored 'General case' 0 C--N 1.272 -2.789 0 C-N-CA 123.305 0.642 . . . . 0.0 111.766 -178.346 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 112' ' ' VAL . 40.5 t -46.8 115.74 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 123.318 0.647 . . . . 0.0 111.524 175.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 109.01 -8.13 33.37 Favored Glycine 0 C--N 1.322 -0.227 0 CA-C-N 115.445 -0.798 . . . . 0.0 112.558 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.646 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.3 OUTLIER -65.98 -177.38 0.48 Allowed 'General case' 0 C--N 1.317 -0.831 0 C-N-CA 124.468 1.107 . . . . 0.0 112.069 177.725 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -137.43 95.34 3.06 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 177.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.595 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 25.3 tp -93.5 146.29 23.89 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -177.466 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.2 t -132.9 120.01 39.46 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.75 0 CA-C-O 120.978 0.418 . . . . 0.0 110.184 -176.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.616 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 55.0 t -92.84 88.63 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.338 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 172.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -82.26 106.77 14.42 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.25 0.548 . . . . 0.0 110.63 -176.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 89.6 mt -90.27 -0.76 57.78 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.986 -177.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.7 t -78.18 0.88 23.25 Favored 'General case' 0 C--N 1.309 -1.184 0 CA-C-O 122.271 1.034 . . . . 0.0 109.134 -179.227 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.6 p -125.3 5.57 7.74 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.848 175.539 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.428 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 51.4 mm-40 -122.61 -26.59 4.51 Favored 'General case' 0 CA--C 1.501 -0.934 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.586 -173.812 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 18.3 mt -132.57 139.64 49.4 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 -175.27 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -138.28 144.71 40.61 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -175.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 72.7 m -121.32 135.11 55.14 Favored 'General case' 0 C--N 1.284 -2.275 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 177.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 22.8 p-80 -134.13 163.08 30.39 Favored 'General case' 0 C--N 1.309 -1.195 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -175.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.414 ' HB2' ' OD2' ' A' ' 54' ' ' ASP . 16.1 t-20 -113.25 111.46 22.08 Favored 'General case' 0 N--CA 1.423 -1.786 0 C-N-CA 118.574 -1.25 . . . . 0.0 111.047 179.187 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 17.4 p-10 -85.74 -4.7 59.23 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 124.573 1.149 . . . . 0.0 111.224 179.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -143.97 65.46 13.9 Favored Pre-proline 0 N--CA 1.477 0.877 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 174.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -72.32 3.98 3.71 Favored 'Trans proline' 0 N--CA 1.481 0.74 0 C-N-CA 123.498 2.799 . . . . 0.0 115.295 -169.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -114.33 -28.51 7.22 Favored 'General case' 0 C--N 1.285 -2.227 0 CA-C-O 121.735 0.779 . . . . 0.0 110.495 -178.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.454 ' HB ' HD11 ' A' ' 52' ' ' ILE . 0.0 OUTLIER -101.74 -30.07 11.53 Favored 'General case' 0 C--N 1.28 -2.455 0 CA-C-N 115.046 -0.979 . . . . 0.0 111.126 -174.063 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.454 HD11 ' HB ' ' A' ' 51' ' ' THR . 3.4 mp -121.0 132.37 70.65 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.661 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -176.748 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 15.1 t -79.46 145.96 33.0 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 177.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.415 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 1.2 m-20 -79.5 109.57 14.0 Favored 'General case' 0 C--N 1.282 -2.368 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 -179.496 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 1.626 ' HD1' ' CD2' ' A' ' 55' ' ' TYR . 0.6 OUTLIER -150.42 138.34 20.06 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 -170.705 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.9 p -151.31 153.45 9.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -178.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.11 128.83 12.39 Favored 'General case' 0 C--O 1.208 -1.109 0 CA-C-O 119.381 -0.343 . . . . 0.0 110.125 175.75 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.503 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 49.5 tp -75.24 109.2 8.54 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.828 0.823 . . . . 0.0 109.277 174.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 7.0 tp60 -55.47 -54.16 47.34 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 126.479 1.912 . . . . 0.0 111.461 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 8.4 ptp180 -169.88 159.6 7.97 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 -176.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -136.47 144.29 15.94 Favored Glycine 0 N--CA 1.406 -3.324 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 179.407 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 73.6 m -132.88 150.58 52.15 Favored 'General case' 0 C--N 1.281 -2.406 0 C-N-CA 123.459 0.704 . . . . 0.0 109.831 -177.53 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.479 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -113.51 158.51 20.64 Favored 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 179.516 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.519 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . 98.8 m-85 -155.2 -179.74 8.37 Favored 'General case' 0 C--N 1.342 0.276 0 C-N-CA 124.436 1.094 . . . . 0.0 109.678 -177.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.56 -142.22 45.64 Favored Glycine 0 C--O 1.238 0.383 0 O-C-N 123.794 0.684 . . . . 0.0 112.839 176.429 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' A' ' 119' ' ' ALA . . . -77.71 -7.81 87.26 Favored Glycine 0 N--CA 1.435 -1.387 0 C-N-CA 120.77 -0.729 . . . . 0.0 111.482 177.638 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.517 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 99.3 t -71.0 -42.14 76.94 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.368 0 C-N-CA 123.279 0.632 . . . . 0.0 111.428 -179.207 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.519 ' HG ' ' CA ' ' A' ' 64' ' ' TYR . 0.2 OUTLIER -85.41 -14.82 45.08 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 118.554 -1.258 . . . . 0.0 112.405 178.851 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 8.8 t -100.33 -48.89 4.43 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 120.324 -0.55 . . . . 0.0 111.651 -175.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.431 ' O ' HG23 ' A' ' 112' ' ' VAL . 35.1 m-80 -95.67 -22.24 17.69 Favored 'General case' 0 CA--C 1.497 -1.087 0 C-N-CA 120.472 -0.491 . . . . 0.0 110.187 -176.39 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 0.464 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 95.8 m-85 -109.43 154.02 23.19 Favored 'General case' 0 N--CA 1.423 -1.778 0 C-N-CA 120.061 -0.656 . . . . 0.0 110.78 -179.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.9 t -165.0 121.1 1.42 Allowed 'General case' 0 N--CA 1.416 -2.126 0 N-CA-C 106.822 -1.548 . . . . 0.0 106.822 174.117 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.429 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -152.83 -113.29 0.53 Allowed Glycine 0 N--CA 1.408 -3.232 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 177.673 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.42 HG23 ' HA ' ' A' ' 83' ' ' PRO . 1.0 OUTLIER -152.75 179.3 8.75 Favored 'General case' 0 C--N 1.287 -2.128 0 C-N-CA 123.101 0.56 . . . . 0.0 110.557 -174.718 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.6 p -136.69 145.43 30.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 C-N-CA 123.004 0.522 . . . . 0.0 109.653 178.563 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.617 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.3 tttt -124.54 144.24 50.24 Favored 'General case' 0 N--CA 1.417 -2.094 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 1.653 ' HE2' ' CE1' ' A' ' 77' ' ' TYR . 62.7 t80 -145.56 115.15 7.23 Favored 'General case' 0 C--N 1.289 -2.047 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 -178.607 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 15.1 m 52.76 40.58 30.75 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 114.187 1.18 . . . . 0.0 114.187 175.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 80.76 10.48 85.09 Favored Glycine 0 N--CA 1.442 -0.96 0 C-N-CA 119.986 -1.102 . . . . 0.0 112.606 179.439 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.617 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 8.9 t -85.41 -179.7 6.99 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 177.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 31.5 t -157.03 112.22 2.82 Favored 'General case' 0 C--N 1.287 -2.122 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -178.47 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 0.452 ' HH ' HD21 ' A' ' 58' ' ' LEU . 4.9 p90 -155.27 161.51 29.3 Favored Pre-proline 0 CA--C 1.556 1.182 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -175.463 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . 0.42 ' HA ' HG23 ' A' ' 74' ' ' THR . 56.5 Cg_endo -69.86 153.19 68.76 Favored 'Trans proline' 0 C--N 1.36 1.173 0 C-N-CA 122.979 2.453 . . . . 0.0 112.931 -177.643 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 1.669 ' HD2' ' CD1' ' A' ' 84' ' ' PHE . 63.2 t80 -124.57 130.55 24.25 Favored Pre-proline 0 N--CA 1.442 -0.862 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.469 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.517 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 72.2 Cg_endo -69.92 151.62 92.01 Favored 'Cis proline' 0 CA--C 1.542 0.897 0 C-N-CA 122.999 -1.667 . . . . 0.0 110.124 -1.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' THR . . . . . 0.401 ' HA ' ' O ' ' A' ' 83' ' ' PRO . 8.9 t -58.36 -178.0 0.04 OUTLIER 'General case' 0 CA--C 1.552 1.02 0 CA-C-O 122.088 0.947 . . . . 0.0 112.9 -173.711 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 10.1 p -119.43 -20.8 7.69 Favored 'General case' 0 N--CA 1.423 -1.812 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.778 -175.048 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 23.1 t -141.95 -82.47 0.2 Allowed 'General case' 0 N--CA 1.432 -1.336 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.964 -177.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -170.89 -172.87 1.22 Allowed 'General case' 0 C--O 1.241 0.631 0 N-CA-C 104.536 -2.394 . . . . 0.0 104.536 -177.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.503 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 42.0 p -100.9 158.18 32.29 Favored Pre-proline 0 C--N 1.293 -1.86 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.375 176.39 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -59.26 161.2 17.17 Favored 'Trans proline' 0 C--O 1.243 0.771 0 C-N-CA 123.16 2.573 . . . . 0.0 110.769 173.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.2 tmm_? -69.25 120.64 15.4 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.445 -178.438 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 72.4 t -128.09 124.68 63.05 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-O 121.633 0.73 . . . . 0.0 111.05 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 70.5 t -112.64 126.16 70.0 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.893 0 CA-C-N 115.095 -0.957 . . . . 0.0 108.853 176.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . 1.63 ' HD1' ' CD2' ' A' ' 95' ' ' TYR . 3.2 m-85 -72.43 110.63 6.97 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 175.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -81.79 61.76 5.29 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.328 -0.989 . . . . 0.0 108.328 176.624 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.7 m -142.35 -168.52 2.75 Favored 'General case' 0 N--CA 1.419 -1.982 0 C-N-CA 125.34 1.456 . . . . 0.0 107.685 -177.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 34.0 ptt180 -163.23 34.76 0.09 Allowed 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 106.465 -1.68 . . . . 0.0 106.465 176.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.4 t -160.45 175.9 12.25 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 114.755 -1.112 . . . . 0.0 109.036 -168.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -70.7 114.01 8.35 Favored 'General case' 0 C--O 1.239 0.513 0 CA-C-O 122.021 0.915 . . . . 0.0 111.746 -176.297 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.6 mptm? -127.48 143.52 47.64 Favored Pre-proline 0 C--N 1.292 -1.907 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.382 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -63.29 147.22 93.92 Favored 'Trans proline' 0 C--O 1.247 0.961 0 C-N-CA 122.693 2.262 . . . . 0.0 111.78 177.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . 0.509 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 9.6 t90 -86.46 111.85 42.21 Favored Pre-proline 0 C--N 1.304 -1.378 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 -178.091 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_endo -82.04 87.12 1.45 Allowed 'Trans proline' 0 N--CA 1.439 -1.698 0 C-N-CA 121.031 1.154 . . . . 0.0 112.122 -172.245 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 80.2 t -137.56 146.33 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.668 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 176.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.616 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -153.66 132.28 12.21 Favored 'General case' 0 C--N 1.287 -2.143 0 O-C-N 123.41 0.444 . . . . 0.0 110.428 178.049 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 16.9 mt -97.01 101.02 12.52 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 178.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 1.623 ' HD1' ' CD2' ' A' ' 108' ' ' TYR . 53.7 m-85 -79.33 73.04 5.96 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 120.884 0.373 . . . . 0.0 110.673 177.421 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.595 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.7 mm? -87.08 150.62 23.88 Favored 'General case' 0 C--O 1.192 -1.966 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.474 176.575 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.57 139.57 13.15 Favored Pre-proline 0 C--N 1.278 -2.501 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.611 -179.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.42 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 18.0 Cg_endo -60.16 121.55 9.97 Favored 'Trans proline' 0 C--O 1.247 0.969 0 C-N-CA 123.189 2.593 . . . . 0.0 111.87 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.48 ' O ' HG23 ' A' ' 30' ' ' VAL . 3.5 m -70.3 -123.08 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.182 -2.478 0 CA-C-N 114.77 -1.105 . . . . 0.0 111.478 175.655 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 30.9 m -111.95 -19.39 12.38 Favored 'General case' 0 C--N 1.282 -2.331 0 CA-C-O 122.548 1.166 . . . . 0.0 108.877 177.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 1.2 m -85.37 6.79 24.99 Favored 'General case' 0 N--CA 1.405 -2.696 0 CA-C-N 113.595 -1.639 . . . . 0.0 112.568 -173.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -97.6 138.18 35.4 Favored 'General case' 0 C--N 1.266 -3.051 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.192 -172.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -177.26 124.16 0.93 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.173 -1.013 . . . . 0.0 112.671 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.11 -147.72 50.34 Favored Glycine 0 CA--C 1.488 -1.645 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 -175.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 93.9 t -53.1 111.33 0.26 Allowed 'Isoleucine or valine' 0 C--O 1.248 0.997 0 CA-C-O 121.709 0.766 . . . . 0.0 110.741 -178.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . 0.457 ' O ' ' HA3' ' A' ' 66' ' ' GLY . . . -113.51 -22.66 10.21 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-N 114.212 -1.358 . . . . 0.0 111.619 -179.459 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.434 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.7 mt -135.01 137.72 50.13 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 178.374 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.481 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 5.3 mmpt? -112.49 141.48 46.18 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 121.144 0.497 . . . . 0.0 111.602 177.811 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -72.03 134.8 46.08 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.87 179.248 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 85.18 -1.23 88.78 Favored Glycine 0 C--N 1.312 -0.79 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.005 -179.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 59.8 m -96.5 148.73 22.52 Favored 'General case' 0 N--CA 1.421 -1.906 0 CA-C-O 120.94 0.4 . . . . 0.0 110.066 179.157 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.406 HD12 HG21 ' A' ' 128' ' ' VAL . 3.1 tm? -77.83 122.59 25.64 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -179.226 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.486 ' HB ' HG23 ' A' ' 67' ' ' VAL . 30.8 pt -109.42 -27.19 2.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 N-CA-C 112.853 0.686 . . . . 0.0 112.853 -177.379 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.49 166.68 26.79 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 -178.01 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.406 HG21 HD12 ' A' ' 125' ' ' LEU . 74.6 t -142.5 112.78 2.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 179.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 58.3 mt -115.87 146.77 41.73 Favored 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 178.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.482 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.7 mp -128.61 125.22 63.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 C-N-CA 120.028 -0.669 . . . . 0.0 109.227 178.541 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.435 ' C ' HD13 ' A' ' 131' ' ' LEU . 1.3 pp -91.0 148.96 22.04 Favored 'General case' 0 CA--C 1.478 -1.821 0 N-CA-C 106.004 -1.85 . . . . 0.0 106.004 174.453 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 32.1 ttt180 -118.78 123.91 45.95 Favored 'General case' 0 C--N 1.253 -3.592 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 176.189 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.471 ' HB2' ' O ' ' A' ' 142' ' ' PHE . 13.3 mm-40 -79.91 143.35 34.33 Favored 'General case' 0 N--CA 1.411 -2.376 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.525 179.463 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 17.7 m -154.33 127.36 8.3 Favored 'General case' 0 C--N 1.269 -2.929 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 170.282 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.416 ' HB2' HG21 ' A' ' 52' ' ' ILE . 15.7 p30 . . . . . 0 C--N 1.299 -1.588 0 C-N-CA 119.715 -0.794 . . . . 0.0 111.075 -178.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . 1.641 ' HD1' ' CD2' ' A' ' 142' ' ' PHE . 95.8 m-85 . . . . . 0 CA--C 1.513 -0.48 0 CA-C-O 120.918 0.39 . . . . 0.0 110.23 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 11.9 pt20 -126.79 144.62 50.9 Favored 'General case' 0 C--N 1.296 -1.757 0 C-N-CA 119.72 -0.792 . . . . 0.0 110.193 -179.046 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 11.0 m-30 -113.74 128.93 56.61 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 -175.278 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 47.4 t -90.96 134.06 30.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 123.478 0.486 . . . . 0.0 110.35 -177.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 59.9 m95 -120.69 98.6 6.1 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 -179.477 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 45.1 m-80 -81.21 110.85 17.08 Favored 'General case' 0 C--N 1.288 -2.086 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 23.3 mm -85.68 122.4 38.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 -177.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 1.651 ' HD2' ' CD1' ' A' ' 149' ' ' TYR . 98.0 m-85 -118.0 150.98 38.37 Favored 'General case' 0 C--N 1.295 -1.77 0 C-N-CA 123.552 0.741 . . . . 0.0 109.012 178.375 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.08 130.36 35.06 Favored 'General case' 0 N--CA 1.413 -2.317 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 176.522 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 29.8 t-20 -89.55 -15.7 32.31 Favored 'General case' 0 C--N 1.288 -2.1 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 -177.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -149.3 141.88 24.42 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 114.059 -1.428 . . . . 0.0 109.207 -174.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -85.94 138.03 32.3 Favored 'General case' 0 C--N 1.314 -0.949 0 O-C-N 123.944 0.777 . . . . 0.0 111.561 -178.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.454 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 75.1 t -112.21 141.42 27.79 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-N 115.015 -0.993 . . . . 0.0 111.894 -173.105 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 5.1 t -119.69 139.05 48.31 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.131 0 N-CA-C 108.12 -1.066 . . . . 0.0 108.12 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 62.1 t -103.2 102.24 27.23 Favored Pre-proline 0 C--N 1.285 -2.197 0 C-N-CA 123.89 0.876 . . . . 0.0 110.065 178.414 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.41 ' HG3' HG11 ' A' ' 27' ' ' VAL . 34.5 Cg_endo -68.3 -22.68 39.57 Favored 'Trans proline' 0 C--O 1.222 -0.305 0 C-N-CA 122.144 1.896 . . . . 0.0 111.589 178.278 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.25 7.4 t . . . . . 0 CA--C 1.547 0.85 0 C-N-CA 124.791 1.236 . . . . 0.0 113.714 175.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.497 ' HB1' ' CE1' ' A' ' 45' ' ' HIS . . . . . . . . 0 N--CA 1.429 -1.519 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.49 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 13.5 t -157.12 160.66 39.05 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.294 -175.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.27 164.3 31.81 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.455 -177.324 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.621 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 73.8 p -102.22 177.85 4.76 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-O 121.427 0.632 . . . . 0.0 111.024 -179.71 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.72 -18.27 44.92 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 114.71 -1.132 . . . . 0.0 109.347 179.131 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.621 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 1.0 OUTLIER -91.82 -24.42 19.38 Favored 'General case' 0 N--CA 1.432 -1.363 0 CA-C-N 114.893 -1.049 . . . . 0.0 111.822 -177.621 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 120.17 34.46 0.96 Allowed Glycine 0 CA--C 1.488 -1.614 0 C-N-CA 119.308 -1.425 . . . . 0.0 113.315 170.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -110.13 98.93 8.09 Favored 'General case' 0 N--CA 1.423 -1.823 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 176.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -90.97 123.18 34.26 Favored 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 115.157 -0.929 . . . . 0.0 109.451 177.03 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.404 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 68.3 mt -100.39 116.22 64.62 Favored Pre-proline 0 C--N 1.288 -2.07 0 N-CA-C 109.484 -0.562 . . . . 0.0 109.484 177.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -75.53 164.78 31.78 Favored 'Trans proline' 0 C--O 1.249 1.055 0 C-N-CA 122.661 2.241 . . . . 0.0 110.85 176.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.4 mt -69.49 121.03 18.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 148.77 -6.0 0.85 Allowed Glycine 0 C--N 1.305 -1.162 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 -174.142 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.0 149.39 23.81 Favored Glycine 0 N--CA 1.431 -1.665 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 176.83 178.57 46.68 Favored Glycine 0 N--CA 1.418 -2.502 0 C-N-CA 119.133 -1.508 . . . . 0.0 112.132 -179.218 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.9 p -140.67 142.08 34.96 Favored 'General case' 0 C--N 1.285 -2.226 0 N-CA-C 108.795 -0.816 . . . . 0.0 108.795 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.41 153.06 51.2 Favored 'General case' 0 CA--C 1.474 -1.969 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 -178.018 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -98.68 116.67 31.43 Favored 'General case' 0 C--N 1.278 -2.53 0 CA-C-N 114.751 -1.113 . . . . 0.0 108.19 174.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 26.1 t -103.76 127.39 57.9 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.573 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.211 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 1.658 ' HE2' ' CE1' ' A' ' 21' ' ' TYR . 54.2 m-85 -110.84 125.27 53.42 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 121.336 -0.146 . . . . 0.0 110.954 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 21.2 t -126.93 121.8 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.036 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -176.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -85.13 120.88 27.12 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-O 121.411 0.624 . . . . 0.0 110.432 175.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 50.7 mt -109.93 160.9 16.0 Favored 'General case' 0 N--CA 1.424 -1.755 0 CA-C-N 114.452 -1.249 . . . . 0.0 108.251 -175.263 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.5 121.18 58.61 Favored Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 124.65 1.219 . . . . 0.0 109.411 -179.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.466 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 59.2 Cg_endo -72.77 -3.39 13.46 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.86 2.373 . . . . 0.0 113.183 -177.465 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 65.1 t -122.21 110.58 27.53 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 178.041 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.431 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.7 t -141.78 108.87 2.07 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.105 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 -178.531 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.756 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -98.05 152.37 19.37 Favored 'General case' 0 C--N 1.277 -2.555 0 C-N-CA 122.861 0.464 . . . . 0.0 112.135 -179.561 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.444 HG11 ' O ' ' A' ' 112' ' ' VAL . 30.5 t -46.61 117.71 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.036 0 C-N-CA 123.784 0.834 . . . . 0.0 111.578 177.427 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.1 3.79 55.59 Favored Glycine 0 C--O 1.235 0.211 0 CA-C-N 115.527 -0.76 . . . . 0.0 112.848 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.756 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -76.11 -176.65 3.61 Favored 'General case' 0 C--N 1.311 -1.081 0 C-N-CA 124.49 1.116 . . . . 0.0 110.113 178.249 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 -130.73 90.57 2.93 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 178.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.645 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 21.9 tp -93.87 141.49 28.45 Favored 'General case' 0 C--N 1.29 -2.018 0 C-N-CA 119.062 -1.055 . . . . 0.0 109.003 178.746 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.6 t -134.35 122.62 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.813 0 CA-C-N 116.25 -0.432 . . . . 0.0 109.842 -174.205 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.623 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 57.0 t -92.43 87.96 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.35 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 172.337 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.522 ' O ' ' HG2' ' A' ' 41' ' ' GLN . 29.3 t70 -83.97 101.42 11.71 Favored 'General case' 0 CA--C 1.488 -1.429 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.809 -176.395 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.9 mt -80.9 -7.22 59.42 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.916 -177.666 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 24.8 t -71.72 -0.04 10.0 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.072 179.104 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 4.1 p -134.3 10.3 3.79 Favored 'General case' 0 N--CA 1.419 -1.982 0 CA-C-O 121.207 0.527 . . . . 0.0 110.049 176.082 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.522 ' HG2' ' O ' ' A' ' 37' ' ' ASP . 35.0 mm-40 -125.39 -20.96 4.65 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 -176.852 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.8 mt -134.6 136.77 52.19 Favored 'Isoleucine or valine' 0 C--O 1.239 0.517 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -177.396 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.664 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 56.0 m-85 -138.43 120.44 15.54 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -175.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.49 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 73.8 m -102.37 143.07 32.58 Favored 'General case' 0 C--N 1.282 -2.354 0 CA-C-O 121.451 0.643 . . . . 0.0 109.962 -178.157 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . 0.497 ' CE1' ' HB1' ' A' ' 2' ' ' ALA . 6.8 p80 -119.22 139.66 51.5 Favored 'General case' 0 C--N 1.288 -2.105 0 CA-C-O 121.73 0.776 . . . . 0.0 111.03 -176.393 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.612 ' HB2' ' CG ' ' A' ' 54' ' ' ASP . 3.7 p-10 -108.36 100.64 9.91 Favored 'General case' 0 N--CA 1.395 -3.202 0 CA-C-O 123.37 1.557 . . . . 0.0 107.436 -176.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -78.3 -32.94 49.62 Favored 'General case' 0 C--N 1.299 -1.592 0 CA-C-N 112.755 -2.02 . . . . 0.0 111.648 -168.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 1.663 ' HE1' ' CE2' ' A' ' 48' ' ' TYR . 39.2 m-85 -129.38 64.61 71.92 Favored Pre-proline 0 C--N 1.308 -1.208 0 C-N-CA 119.456 -0.898 . . . . 0.0 111.896 -174.841 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.58 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 56.2 Cg_endo -67.45 -7.98 20.77 Favored 'Trans proline' 0 N--CA 1.486 1.088 0 C-N-CA 122.847 2.365 . . . . 0.0 114.415 -173.866 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -110.62 -15.37 13.88 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 120.672 -0.411 . . . . 0.0 111.493 -176.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.46 ' HB ' HD13 ' A' ' 52' ' ' ILE . 1.8 m -115.9 -25.33 7.77 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-O 122.182 0.992 . . . . 0.0 109.779 -173.16 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.46 HD13 ' HB ' ' A' ' 51' ' ' THR . 2.6 mp -130.67 150.12 34.28 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.996 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 -176.64 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.9 t -94.35 125.23 38.86 Favored 'General case' 0 N--CA 1.413 -2.299 0 N-CA-C 104.154 -2.535 . . . . 0.0 104.154 171.44 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.612 ' CG ' ' HB2' ' A' ' 46' ' ' ASN . 9.9 m-20 -91.71 106.16 18.27 Favored 'General case' 0 C--N 1.259 -3.336 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 -178.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.505 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 9.5 t80 -130.85 135.24 47.53 Favored 'General case' 0 C--N 1.287 -2.123 0 CA-C-N 114.49 -1.232 . . . . 0.0 109.233 -174.617 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.552 ' CG2' ' HG ' ' A' ' 131' ' ' LEU . 13.7 p -141.85 150.43 19.26 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.173 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.256 -176.004 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.1 p -150.17 129.97 13.29 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 123.894 0.878 . . . . 0.0 108.883 176.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.48 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 36.9 tp -65.6 112.63 3.73 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 172.309 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.408 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 2.7 tp-100 -60.66 -59.39 5.47 Favored 'General case' 0 C--O 1.204 -1.339 0 CA-C-N 113.257 -1.792 . . . . 0.0 109.915 -177.624 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -166.74 155.74 10.67 Favored 'General case' 0 N--CA 1.419 -1.999 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -175.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -135.44 153.73 21.39 Favored Glycine 0 N--CA 1.412 -2.92 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 -177.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 24.1 m -138.61 144.58 39.82 Favored 'General case' 0 C--N 1.281 -2.4 0 C-N-CA 123.402 0.681 . . . . 0.0 110.595 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.559 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -106.64 157.96 17.31 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 125.081 1.353 . . . . 0.0 107.741 -179.52 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 1.642 ' HD2' ' CD1' ' A' ' 64' ' ' TYR . 94.4 m-85 -155.74 178.15 10.58 Favored 'General case' 0 C--O 1.208 -1.113 0 CA-C-N 118.901 0.773 . . . . 0.0 111.781 -177.037 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 53.39 -127.49 36.7 Favored Glycine 0 C--O 1.217 -0.924 0 CA-C-O 121.423 0.457 . . . . 0.0 112.883 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.73 -9.16 83.44 Favored Glycine 0 N--CA 1.42 -2.38 0 C-N-CA 120.388 -0.91 . . . . 0.0 113.132 178.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.776 HG23 ' O ' ' A' ' 64' ' ' TYR . 12.8 m -78.49 -27.14 14.13 Favored 'Isoleucine or valine' 0 C--O 1.201 -1.468 0 CA-C-N 118.515 1.157 . . . . 0.0 112.562 -175.27 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.559 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -91.32 -15.04 29.72 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 119.91 -0.716 . . . . 0.0 111.862 176.146 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 26.5 t -101.18 -59.04 1.77 Allowed 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.524 -176.2 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.554 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 34.6 m-80 -87.14 -24.42 24.51 Favored 'General case' 0 CA--C 1.486 -1.486 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -176.147 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 0.466 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 85.5 m-85 -111.43 163.63 13.81 Favored 'General case' 0 C--N 1.286 -2.186 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.064 -178.592 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.2 t -179.95 134.21 0.11 Allowed 'General case' 0 N--CA 1.426 -1.645 0 N-CA-C 107.235 -1.395 . . . . 0.0 107.235 178.035 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.467 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -167.31 -109.82 0.22 Allowed Glycine 0 N--CA 1.406 -3.355 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 174.765 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 3.1 p -149.65 177.04 10.13 Favored 'General case' 0 C--N 1.275 -2.631 0 C-N-CA 122.778 0.431 . . . . 0.0 111.019 -174.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -132.9 140.16 47.98 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.116 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.717 ' HG3' ' O ' ' A' ' 80' ' ' SER . 82.6 tttt -120.72 145.36 47.57 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.398 -177.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.44 ' CD2' HG22 ' A' ' 90' ' ' THR . 43.2 t80 -146.62 109.47 4.63 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.335 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 11.2 t 49.14 43.33 22.43 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 124.526 1.131 . . . . 0.0 111.912 178.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.9 11.95 62.81 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.22 -0.991 . . . . 0.0 113.107 178.221 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.717 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 23.5 t -88.77 -179.73 6.05 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 175.217 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.3 t -167.3 107.45 0.6 Allowed 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 179.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 1.603 ' HD2' ' CD1' ' A' ' 82' ' ' TYR . 2.1 p90 -144.3 158.19 55.12 Favored Pre-proline 0 C--N 1.287 -2.136 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 -173.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -67.96 144.77 65.55 Favored 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 122.614 2.21 . . . . 0.0 112.789 -175.016 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 1.659 ' HE1' ' CE2' ' A' ' 84' ' ' PHE . 60.8 t80 -118.41 134.73 23.42 Favored Pre-proline 0 C--N 1.31 -1.141 0 CA-C-N 116.233 -0.44 . . . . 0.0 109.977 -179.102 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.546 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 66.6 Cg_endo -72.22 143.75 78.19 Favored 'Cis proline' 0 CA--C 1.543 0.942 0 C-N-CA 123.189 -1.588 . . . . 0.0 111.465 -0.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.7 t -66.84 -177.03 0.55 Allowed 'General case' 0 CA--C 1.547 0.861 0 CA-C-N 115.161 -0.927 . . . . 0.0 111.941 -174.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 16.4 p -130.19 -46.23 1.11 Allowed 'General case' 0 N--CA 1.425 -1.679 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.699 -172.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.3 t -101.04 -97.68 0.26 Allowed 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -177.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -166.45 -166.66 0.9 Allowed 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 177.255 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.48 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 46.9 p -99.38 165.66 14.37 Favored Pre-proline 0 C--N 1.297 -1.68 0 N-CA-C 113.753 1.02 . . . . 0.0 113.753 -178.135 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 20.8 Cg_endo -61.65 169.72 6.6 Favored 'Trans proline' 0 C--O 1.247 0.929 0 C-N-CA 123.252 2.635 . . . . 0.0 110.682 171.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.505 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 3.2 tmm_? -80.25 123.07 27.64 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.03 -175.291 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 75.1 t -132.58 123.35 49.28 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.134 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.591 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 58.5 t -105.0 140.79 21.96 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.169 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 176.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . 0.477 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 4.7 m-85 -84.2 94.91 8.5 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-O 121.75 0.785 . . . . 0.0 109.677 175.667 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 15.6 m120 -87.32 74.72 9.41 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 43.4 t -150.12 -173.41 4.43 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 -175.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 37.9 ptt180 -145.56 24.21 1.4 Allowed 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 172.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.4 t -160.85 174.65 13.55 Favored 'General case' 0 N--CA 1.426 -1.644 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 -176.055 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -61.96 136.15 57.84 Favored 'General case' 0 C--N 1.318 -0.792 0 O-C-N 123.59 0.556 . . . . 0.0 110.643 179.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 14.3 mmtm -138.52 150.25 65.55 Favored Pre-proline 0 C--N 1.286 -2.179 0 C-N-CA 124.976 1.311 . . . . 0.0 108.405 176.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -62.74 149.19 92.06 Favored 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 122.631 2.221 . . . . 0.0 111.881 -178.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . 0.477 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 11.2 t90 -89.88 104.89 9.4 Favored Pre-proline 0 C--N 1.305 -1.365 0 N-CA-C 106.171 -1.788 . . . . 0.0 106.171 178.122 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -75.99 87.54 1.4 Allowed 'Trans proline' 0 N--CA 1.448 -1.157 0 C-N-CA 121.27 1.313 . . . . 0.0 112.663 -172.191 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.425 HG21 ' CD2' ' A' ' 77' ' ' TYR . 61.7 t -140.16 149.7 21.81 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.126 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.492 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.623 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -153.14 135.4 14.93 Favored 'General case' 0 C--N 1.289 -2.025 0 O-C-N 123.268 0.355 . . . . 0.0 110.366 177.002 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 20.5 mt -101.73 104.84 15.66 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 177.695 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 1.615 ' HE1' ' CE2' ' A' ' 108' ' ' TYR . 55.4 m-85 -82.42 72.19 9.48 Favored 'General case' 0 C--N 1.281 -2.411 0 CA-C-O 120.883 0.373 . . . . 0.0 110.491 177.284 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.645 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.3 mm? -90.28 119.16 30.35 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 175.047 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -126.97 146.77 58.82 Favored Pre-proline 0 N--CA 1.411 -2.419 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -177.285 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.554 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 21.4 Cg_endo -60.99 118.8 5.71 Favored 'Trans proline' 0 C--O 1.246 0.902 0 C-N-CA 123.484 2.79 . . . . 0.0 112.468 -178.331 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.444 ' O ' HG11 ' A' ' 30' ' ' VAL . 3.1 m -67.98 -115.83 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.187 -2.188 0 CA-C-N 114.406 -1.27 . . . . 0.0 112.737 176.025 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 32.5 m -111.4 -42.58 3.86 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.159 -0.963 . . . . 0.0 111.312 179.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 8.8 t -90.99 28.4 1.59 Allowed 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 121.636 0.731 . . . . 0.0 110.356 -173.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -89.39 132.0 35.19 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.91 140.69 6.19 Favored Glycine 0 N--CA 1.434 -1.488 0 C-N-CA 119.496 -1.335 . . . . 0.0 111.994 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 57.09 -144.38 39.35 Favored Glycine 0 CA--C 1.495 -1.186 0 CA-C-O 119.175 -0.791 . . . . 0.0 112.87 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.0 p -61.43 96.02 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.245 0.856 0 CA-C-O 122.876 1.322 . . . . 0.0 112.385 -177.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.18 -31.81 11.9 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 114.327 -1.306 . . . . 0.0 111.053 -178.382 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.408 ' HB ' HG21 ' A' ' 154' ' ' VAL . 70.5 mt -124.8 139.32 51.33 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 177.162 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 3.3 mmpt? -114.24 136.17 53.26 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.179 0.514 . . . . 0.0 111.065 178.023 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -72.66 122.94 22.27 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.102 -178.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 99.48 -5.53 58.76 Favored Glycine 0 N--CA 1.434 -1.482 0 N-CA-C 110.891 -0.884 . . . . 0.0 110.891 -178.167 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 49.9 m -97.05 149.07 22.35 Favored 'General case' 0 N--CA 1.422 -1.851 0 CA-C-O 121.518 0.675 . . . . 0.0 110.382 -179.669 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -75.69 127.76 33.75 Favored 'General case' 0 N--CA 1.429 -1.502 0 CA-C-N 114.203 -1.362 . . . . 0.0 108.656 -178.213 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.414 ' HB ' HG13 ' A' ' 67' ' ' VAL . 28.1 pt -113.16 -29.7 2.27 Favored 'Isoleucine or valine' 0 C--O 1.197 -1.679 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.733 178.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . 0.433 ' HB1' ' HB ' ' A' ' 148' ' ' ILE . . . -156.91 166.93 31.99 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.659 -177.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 54.8 t -141.35 114.52 4.57 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.089 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 178.219 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 64.5 mt -118.12 138.66 52.12 Favored 'General case' 0 C--N 1.288 -2.086 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 178.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.462 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.0 mp -120.03 127.81 75.91 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 C-N-CA 119.335 -0.946 . . . . 0.0 109.455 178.644 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.552 ' HG ' ' CG2' ' A' ' 56' ' ' VAL . 0.1 OUTLIER -99.17 130.18 45.47 Favored 'General case' 0 C--N 1.273 -2.758 0 C-N-CA 124.391 1.076 . . . . 0.0 110.994 -176.648 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . 0.424 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 14.6 mmm180 -97.99 113.34 25.16 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 123.428 0.691 . . . . 0.0 110.308 178.361 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.411 ' HG2' HD23 ' A' ' 131' ' ' LEU . 12.5 mm100 -92.43 134.66 34.73 Favored 'General case' 0 N--CA 1.404 -2.744 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 173.551 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.415 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 19.5 m -142.26 130.56 22.25 Favored 'General case' 0 C--N 1.28 -2.424 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 176.235 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 15.6 p30 . . . . . 0 C--N 1.307 -1.255 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.333 -179.267 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 . . . . . 0 N--CA 1.444 -0.739 0 N-CA-C 109.543 -0.539 . . . . 0.0 109.543 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . 0.413 ' HB3' ' HD2' ' A' ' 132' ' ' ARG . 12.9 pt20 -129.04 142.39 50.92 Favored 'General case' 0 N--CA 1.425 -1.719 0 C-N-CA 120.077 -0.649 . . . . 0.0 109.385 177.274 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 1.654 ' HE1' ' CE2' ' A' ' 144' ' ' PHE . 8.8 m-85 -109.93 136.63 48.91 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 -176.727 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 43.8 t -95.26 129.9 44.75 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 O-C-N 123.69 0.619 . . . . 0.0 109.638 -177.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . 0.437 ' CZ2' ' HB3' ' A' ' 3' ' ' CYS . 63.3 m95 -119.8 103.21 9.16 Favored 'General case' 0 C--N 1.282 -2.338 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -178.195 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . 0.463 ' N ' HD21 ' A' ' 147' ' ' ASN . 0.8 OUTLIER -83.89 112.1 19.83 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 179.554 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . 0.433 ' HB ' ' HB1' ' A' ' 127' ' ' ALA . 23.0 mm -87.45 122.65 39.49 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.187 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 -178.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -116.69 156.93 26.26 Favored 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 123.669 0.788 . . . . 0.0 109.267 179.198 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.46 130.52 34.57 Favored 'General case' 0 N--CA 1.396 -3.151 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 176.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 36.7 t-20 -89.13 -18.61 26.85 Favored 'General case' 0 C--N 1.285 -2.226 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 -177.521 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -147.66 143.71 27.85 Favored 'General case' 0 N--CA 1.429 -1.483 0 CA-C-N 114.013 -1.449 . . . . 0.0 109.284 -173.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -83.41 139.45 32.97 Favored 'General case' 0 C--N 1.312 -1.063 0 O-C-N 124.391 1.057 . . . . 0.0 109.698 -178.344 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.466 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 1.8 m -121.47 148.54 24.81 Favored 'Isoleucine or valine' 0 C--O 1.257 1.478 0 C-N-CA 120.138 -0.625 . . . . 0.0 111.259 -177.65 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.5 t -120.49 140.95 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.699 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 -179.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.431 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 71.4 t -102.24 104.62 38.12 Favored Pre-proline 0 C--N 1.288 -2.068 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 178.374 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.426 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 43.4 Cg_endo -71.29 -20.75 27.59 Favored 'Trans proline' 0 N--CA 1.462 -0.332 0 C-N-CA 122.404 2.069 . . . . 0.0 111.428 176.865 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.26 3.3 t . . . . . 0 C--O 1.247 0.951 0 C-N-CA 124.497 1.119 . . . . 0.0 113.775 175.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.492 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.431 -1.416 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.503 ' HB3' ' CZ2' ' A' ' 146' ' ' TRP . 10.6 t -156.92 164.0 38.52 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 118.604 -1.238 . . . . 0.0 110.677 -176.294 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.413 ' HG3' ' O ' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -147.2 159.86 43.14 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -177.003 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.41 HG21 HG23 ' A' ' 20' ' ' VAL . 63.9 p -99.8 173.66 6.58 Favored 'General case' 0 C--N 1.3 -1.578 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.727 178.815 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.0 -21.75 59.86 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 114.629 -1.169 . . . . 0.0 111.223 177.051 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -82.11 -35.43 28.58 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 119.574 -0.85 . . . . 0.0 110.411 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 133.49 16.45 1.17 Allowed Glycine 0 N--CA 1.434 -1.49 0 C-N-CA 119.709 -1.234 . . . . 0.0 112.955 178.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.3 m -91.53 105.46 17.77 Favored 'General case' 0 N--CA 1.428 -1.573 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 174.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -98.18 123.58 42.32 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 176.029 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.492 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 49.6 mt -104.17 117.81 58.48 Favored Pre-proline 0 C--N 1.29 -1.981 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 177.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -81.71 176.2 8.68 Favored 'Trans proline' 0 C--O 1.245 0.842 0 C-N-CA 122.601 2.2 . . . . 0.0 110.783 176.489 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 63.5 mt -67.1 129.15 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 N-CA-C 109.052 -0.722 . . . . 0.0 109.052 177.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 145.36 -8.95 1.67 Allowed Glycine 0 C--N 1.308 -0.98 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.004 -178.53 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.21 154.6 30.78 Favored Glycine 0 CA--C 1.504 -0.594 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 -178.281 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 160.39 -171.44 36.6 Favored Glycine 0 N--CA 1.428 -1.893 0 C-N-CA 119.851 -1.166 . . . . 0.0 111.169 -178.583 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.446 ' HB3' ' HB ' ' A' ' 145' ' ' VAL . 28.8 p -144.34 151.18 38.96 Favored 'General case' 0 C--N 1.291 -1.949 0 CA-C-O 120.797 0.332 . . . . 0.0 111.153 -177.073 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.16 162.52 32.29 Favored 'General case' 0 N--CA 1.421 -1.9 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -178.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -108.27 113.57 26.77 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.077 -0.965 . . . . 0.0 108.741 176.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.41 HG23 HG21 ' A' ' 5' ' ' THR . 40.0 t -103.71 116.78 48.11 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.757 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.403 -179.456 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 23.5 m-85 -102.07 119.15 38.34 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 120.602 0.239 . . . . 0.0 111.058 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 23.7 t -119.98 128.09 75.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.73 -174.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 48.1 m-80 -81.83 126.55 32.0 Favored 'General case' 0 CA--C 1.483 -1.604 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 176.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 28.8 mt -117.8 148.31 42.2 Favored 'General case' 0 C--N 1.28 -2.449 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 179.482 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -53.24 119.14 16.09 Favored Pre-proline 0 C--O 1.209 -1.071 0 O-C-N 124.923 1.389 . . . . 0.0 110.524 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.533 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 56.3 Cg_endo -72.01 -0.29 8.28 Favored 'Trans proline' 0 CA--C 1.535 0.531 0 C-N-CA 122.999 2.466 . . . . 0.0 113.531 -175.723 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 66.8 t -131.63 109.91 16.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.491 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 11.6 t -147.71 113.99 0.92 Allowed 'Isoleucine or valine' 0 C--O 1.186 -2.273 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 -177.343 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.783 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -100.15 157.65 16.42 Favored 'General case' 0 C--N 1.273 -2.738 0 C-N-CA 123.824 0.85 . . . . 0.0 111.636 -178.787 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.412 HG11 ' O ' ' A' ' 112' ' ' VAL . 38.5 t -49.79 120.13 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 CA-C-O 121.029 0.442 . . . . 0.0 111.188 176.323 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.31 8.95 58.37 Favored Glycine 0 CA--C 1.522 0.51 0 CA-C-N 115.57 -0.741 . . . . 0.0 112.808 -179.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.783 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -80.37 -175.29 5.05 Favored 'General case' 0 C--N 1.31 -1.11 0 C-N-CA 124.983 1.313 . . . . 0.0 108.237 175.762 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -133.78 95.4 3.45 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 177.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.612 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 24.7 tp -91.96 144.29 25.61 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 119.166 -1.013 . . . . 0.0 109.498 178.516 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 62.0 t -135.48 124.06 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.915 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 -177.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.566 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 44.9 t -92.87 88.52 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.183 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 173.067 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -79.08 104.19 9.54 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.981 -177.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.7 mt -85.55 -2.84 58.57 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.345 -179.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.402 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 36.6 t -73.58 -2.49 23.08 Favored 'General case' 0 CA--C 1.546 0.8 0 CA-C-O 121.715 0.769 . . . . 0.0 110.16 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.5 p -126.78 8.43 6.88 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.191 177.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 43.8 mm-40 -125.26 -27.08 3.54 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.226 -174.06 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.6 mt -133.79 135.75 54.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 -175.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.67 ' HE1' ' CE2' ' A' ' 43' ' ' PHE . 39.0 m-85 -138.31 120.1 15.28 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -176.377 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.454 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 74.3 m -102.94 145.29 30.06 Favored 'General case' 0 C--N 1.281 -2.385 0 CA-C-O 120.825 0.345 . . . . 0.0 110.333 -177.461 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 25.8 p-80 -134.56 149.42 50.63 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.112 -173.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 60.8 t30 -103.26 91.2 3.98 Favored 'General case' 0 C--N 1.291 -1.941 0 C-N-CA 118.786 -1.166 . . . . 0.0 109.882 172.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -61.46 -24.43 66.55 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 113.508 -1.678 . . . . 0.0 111.905 -177.608 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 1.668 ' HE2' ' CE1' ' A' ' 48' ' ' TYR . 50.6 m-85 -125.71 78.64 68.86 Favored Pre-proline 0 C--N 1.322 -0.629 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 -178.657 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -73.02 -7.42 20.65 Favored 'Trans proline' 0 C--N 1.332 -0.319 0 C-N-CA 122.631 2.221 . . . . 0.0 114.241 -173.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -112.45 -23.03 10.54 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 121.768 0.794 . . . . 0.0 109.786 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.488 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.6 OUTLIER -97.68 -30.1 13.02 Favored 'General case' 0 N--CA 1.407 -2.597 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.744 -169.82 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.533 HG21 ' CB ' ' A' ' 135' ' ' ASN . 3.0 mp -128.67 133.69 65.93 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.806 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.185 -176.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.9 t -75.88 145.64 40.38 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 174.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -81.47 108.72 15.3 Favored 'General case' 0 C--N 1.278 -2.509 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -174.013 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 77.3 t80 -147.9 138.85 23.31 Favored 'General case' 0 C--N 1.293 -1.865 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.203 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.425 HG21 ' HG ' ' A' ' 131' ' ' LEU . 14.5 p -152.19 147.19 15.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 C-N-CA 124.405 1.082 . . . . 0.0 109.371 176.538 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.88 127.29 10.7 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 123.401 0.68 . . . . 0.0 109.824 172.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.496 HD21 ' O ' ' A' ' 130' ' ' ILE . 1.1 tt -68.0 114.24 6.36 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 175.379 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.1 tp-100 -58.62 -63.87 1.13 Allowed 'General case' 0 C--O 1.206 -1.228 0 C-N-CA 124.718 1.207 . . . . 0.0 110.372 178.114 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -164.09 154.02 14.61 Favored 'General case' 0 N--CA 1.422 -1.834 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -173.689 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.484 ' O ' ' HB2' ' A' ' 85' ' ' PRO . . . -124.03 154.84 17.78 Favored Glycine 0 N--CA 1.409 -3.104 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 179.583 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 49.4 m -131.39 145.6 51.89 Favored 'General case' 0 C--N 1.28 -2.416 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.443 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -113.97 154.82 26.96 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 1.639 ' HD2' ' CD1' ' A' ' 64' ' ' TYR . 88.5 m-85 -156.63 -178.1 7.1 Favored 'General case' 0 C--O 1.238 0.479 0 C-N-CA 123.622 0.769 . . . . 0.0 109.506 -177.268 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 62.02 -137.71 45.98 Favored Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 115.783 -0.644 . . . . 0.0 113.148 175.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -84.32 -7.66 84.59 Favored Glycine 0 N--CA 1.42 -2.41 0 N-CA-C 111.336 -0.705 . . . . 0.0 111.336 177.221 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.472 HG23 ' HB ' ' A' ' 126' ' ' ILE . 94.5 t -70.0 -43.81 78.97 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.379 0 C-N-CA 123.056 0.543 . . . . 0.0 111.429 -178.525 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.476 ' HG ' ' CA ' ' A' ' 64' ' ' TYR . 0.2 OUTLIER -82.32 -16.99 47.35 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.129 -1.028 . . . . 0.0 111.978 -179.469 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 8.2 t -100.54 -51.92 3.48 Favored 'General case' 0 N--CA 1.444 -0.771 0 CA-C-N 115.86 -0.609 . . . . 0.0 112.125 -174.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.497 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 34.0 m-80 -93.77 -21.53 19.25 Favored 'General case' 0 CA--C 1.492 -1.272 0 C-N-CA 120.494 -0.482 . . . . 0.0 109.972 -175.308 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 0.55 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 78.2 m-85 -111.8 161.8 15.95 Favored 'General case' 0 N--CA 1.425 -1.712 0 C-N-CA 120.076 -0.65 . . . . 0.0 109.967 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 t -169.52 133.92 1.38 Allowed 'General case' 0 N--CA 1.419 -1.991 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 176.456 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.513 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -167.08 -111.92 0.25 Allowed Glycine 0 N--CA 1.402 -3.604 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 175.721 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.4 p -157.72 -179.46 8.18 Favored 'General case' 0 C--N 1.29 -2.016 0 C-N-CA 124.421 1.088 . . . . 0.0 110.02 -174.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.66 147.88 31.76 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.596 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.9 tttt -125.61 147.57 49.26 Favored 'General case' 0 N--CA 1.43 -1.446 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.839 -178.609 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 1.623 ' HE2' ' CE1' ' A' ' 77' ' ' TYR . 52.1 t80 -147.76 109.48 4.42 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 -178.192 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 9.2 t 50.8 43.7 28.16 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 124.079 0.952 . . . . 0.0 111.35 177.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.02 6.16 69.73 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 120.415 -0.898 . . . . 0.0 113.946 178.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.596 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 12.2 t -79.74 -178.86 6.6 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 117.436 0.618 . . . . 0.0 110.205 178.597 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 40.9 t -159.24 103.54 1.63 Allowed 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 -179.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 1.659 ' HD1' ' CD2' ' A' ' 82' ' ' TYR . 4.0 p90 -148.85 161.65 32.05 Favored Pre-proline 0 C--N 1.313 -0.991 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 -174.275 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -71.77 149.13 53.75 Favored 'Trans proline' 0 C--N 1.362 1.261 0 C-N-CA 122.494 2.129 . . . . 0.0 113.502 -174.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.643 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 56.8 t80 -120.45 137.36 26.08 Favored Pre-proline 0 N--CA 1.427 -1.597 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 178.738 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.643 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 66.2 Cg_endo -70.52 142.59 72.39 Favored 'Cis proline' 0 CA--C 1.542 0.916 0 C-N-CA 122.933 -1.695 . . . . 0.0 112.959 -1.487 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . 0.338 10.3 t -63.54 105.4 0.77 Allowed 'General case' 0 C--O 1.249 1.059 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 -179.361 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 7.3 p -77.54 -13.04 60.01 Favored 'General case' 0 C--N 1.282 -2.363 0 CA-C-N 112.975 -1.92 . . . . 0.0 110.779 -175.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.7 t -119.41 -82.96 0.65 Allowed 'General case' 0 N--CA 1.409 -2.497 0 C-N-CA 119.326 -0.95 . . . . 0.0 111.898 -173.632 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 172.4 177.95 0.08 Allowed 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.284 1.033 . . . . 0.0 108.695 -178.132 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 42.9 p -102.31 161.07 24.45 Favored Pre-proline 0 C--N 1.301 -1.51 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 177.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -61.22 162.58 19.5 Favored 'Trans proline' 0 CA--C 1.546 1.103 0 C-N-CA 123.427 2.751 . . . . 0.0 111.696 172.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.7 tmm_? -72.29 116.82 13.17 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 124.588 1.155 . . . . 0.0 109.874 -176.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 75.4 t -124.84 127.89 72.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 CA-C-O 121.348 0.594 . . . . 0.0 111.234 -178.437 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 77.0 t -107.13 123.18 62.13 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.214 178.177 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . 0.461 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 5.3 m-85 -78.34 156.29 29.65 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 173.066 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -128.67 34.24 4.53 Favored 'General case' 0 C--N 1.261 -3.276 0 N-CA-C 106.8 -1.556 . . . . 0.0 106.8 175.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' SER . . . . . 0.427 ' CB ' ' HG3' ' A' ' 101' ' ' LYS . 45.2 m -130.67 117.64 19.77 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 113.563 0.949 . . . . 0.0 113.563 -170.776 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 20.4 ptp180 -93.93 32.15 1.51 Allowed 'General case' 0 C--O 1.244 0.797 0 CA-C-O 122.332 1.063 . . . . 0.0 110.129 179.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 9.2 t -152.82 165.63 34.8 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 105.203 -2.147 . . . . 0.0 105.203 -178.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 16.9 p-10 -74.0 112.71 10.4 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-O 122.167 0.984 . . . . 0.0 111.099 -174.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . 0.427 ' HG3' ' CB ' ' A' ' 97' ' ' SER . 15.2 mmtm -122.98 145.27 45.28 Favored Pre-proline 0 C--N 1.284 -2.254 0 CA-C-N 114.235 -1.348 . . . . 0.0 108.618 -178.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.402 ' HB3' ' O ' ' A' ' 39' ' ' SER . 17.9 Cg_endo -56.17 142.27 86.89 Favored 'Trans proline' 0 N--CA 1.45 -1.053 0 C-N-CA 123.318 2.679 . . . . 0.0 113.7 -172.646 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . 0.461 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.7 t90 -89.67 106.07 12.89 Favored Pre-proline 0 C--N 1.298 -1.667 0 N-CA-C 105.27 -2.122 . . . . 0.0 105.27 178.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -76.25 87.48 1.43 Allowed 'Trans proline' 0 N--CA 1.435 -1.961 0 C-N-CA 121.228 1.285 . . . . 0.0 111.685 -173.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 64.9 t -138.86 145.83 27.15 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 177.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.566 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -152.01 135.52 16.1 Favored 'General case' 0 C--N 1.278 -2.534 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.262 177.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.412 ' HB2' ' CG2' ' A' ' 36' ' ' VAL . 21.4 mt -98.66 102.52 14.29 Favored 'General case' 0 C--N 1.287 -2.123 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 178.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.513 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 50.8 m-85 -83.86 73.57 10.3 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 120.951 0.405 . . . . 0.0 110.378 177.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.612 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.9 mm? -99.47 129.76 45.67 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 175.762 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -130.07 148.21 68.75 Favored Pre-proline 0 N--CA 1.413 -2.312 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 -178.141 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.497 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 20.4 Cg_endo -59.41 120.67 8.64 Favored 'Trans proline' 0 C--O 1.246 0.88 0 C-N-CA 123.283 2.655 . . . . 0.0 112.286 -178.262 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.412 ' O ' HG11 ' A' ' 30' ' ' VAL . 2.7 m -69.21 -116.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.184 -2.394 0 CA-C-N 114.26 -1.336 . . . . 0.0 113.194 176.857 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 21.4 m -112.18 -40.47 4.17 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.316 -0.865 . . . . 0.0 110.632 179.202 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 28.9 t -87.79 28.47 1.01 Allowed 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.697 -176.245 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -95.18 132.91 39.62 Favored 'General case' 0 N--CA 1.427 -1.597 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -171.54 144.24 8.04 Favored Glycine 0 N--CA 1.436 -1.335 0 C-N-CA 120.057 -1.068 . . . . 0.0 111.559 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . 0.46 ' O ' ' HA ' ' A' ' 155' ' ' VAL . . . 54.35 -145.7 26.54 Favored Glycine 0 CA--C 1.488 -1.613 0 C-N-CA 124.132 0.872 . . . . 0.0 113.0 -179.219 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 58.2 t -62.78 100.83 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.95 0 CA-C-O 121.602 0.715 . . . . 0.0 110.07 -177.31 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -99.33 -25.84 14.35 Favored 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 114.509 -1.223 . . . . 0.0 109.985 -179.331 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.473 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.0 mt -134.75 138.29 49.6 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -179.451 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.439 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.7 mmpt? -112.89 147.42 37.07 Favored 'General case' 0 C--N 1.31 -1.136 0 C-N-CA 122.692 0.397 . . . . 0.0 110.193 174.877 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.89 126.91 30.94 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 177.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.13 -8.33 67.35 Favored Glycine 0 C--N 1.312 -0.757 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -177.536 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 33.5 t -81.38 136.97 35.74 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 -179.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -72.35 121.85 20.18 Favored 'General case' 0 N--CA 1.429 -1.505 0 N-CA-C 106.491 -1.67 . . . . 0.0 106.491 175.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.472 ' HB ' HG23 ' A' ' 67' ' ' VAL . 27.7 pt -109.11 -27.42 2.93 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.915 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -177.128 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.28 169.38 20.76 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -177.6 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 76.7 t -144.11 113.38 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 179.161 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 46.2 mt -114.46 140.76 48.45 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.496 ' O ' HD21 ' A' ' 58' ' ' LEU . 4.0 mp -121.21 129.6 75.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 C-N-CA 118.844 -1.142 . . . . 0.0 110.787 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.523 ' O ' HD21 ' A' ' 131' ' ' LEU . 0.2 OUTLIER -103.19 131.9 49.87 Favored 'General case' 0 C--N 1.284 -2.24 0 C-N-CA 125.268 1.427 . . . . 0.0 110.553 -177.147 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 14.0 mmm180 -93.54 132.57 37.71 Favored 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 123.78 0.832 . . . . 0.0 110.699 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 5.1 tp-100 -113.28 114.6 26.92 Favored 'General case' 0 N--CA 1.422 -1.844 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 174.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 26.4 m -135.48 144.75 46.57 Favored 'General case' 0 C--N 1.286 -2.168 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 179.24 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.533 ' CB ' HG21 ' A' ' 52' ' ' ILE . 11.8 p30 . . . . . 0 N--CA 1.436 -1.173 0 C-N-CA 119.305 -0.958 . . . . 0.0 112.355 178.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 . . . . . 0 N--CA 1.429 -1.521 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . 0.401 ' HB2' ' O ' ' A' ' 131' ' ' LEU . 13.4 pt20 -138.72 149.8 45.46 Favored 'General case' 0 N--CA 1.415 -2.178 0 C-N-CA 120.383 -0.527 . . . . 0.0 110.628 178.187 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 1.646 ' HE2' ' CE1' ' A' ' 144' ' ' PHE . 8.4 m-30 -108.1 134.32 51.14 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -175.578 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . 0.446 ' HB ' ' HB3' ' A' ' 17' ' ' SER . 55.3 t -94.24 128.06 45.81 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 O-C-N 123.738 0.649 . . . . 0.0 110.137 -179.087 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . 0.503 ' CZ2' ' HB3' ' A' ' 3' ' ' CYS . 68.4 m95 -114.87 96.98 5.98 Favored 'General case' 0 C--N 1.275 -2.658 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -179.634 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 40.4 m-80 -80.01 112.73 17.6 Favored 'General case' 0 C--N 1.291 -1.959 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 24.4 mm -87.9 123.95 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.879 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 -177.064 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 1.646 ' HE2' ' CE1' ' A' ' 149' ' ' TYR . 95.6 m-85 -118.82 153.92 33.71 Favored 'General case' 0 C--N 1.288 -2.098 0 C-N-CA 124.105 0.962 . . . . 0.0 108.468 178.25 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.29 133.76 35.25 Favored 'General case' 0 N--CA 1.406 -2.635 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 176.114 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -92.29 -13.15 30.78 Favored 'General case' 0 C--N 1.284 -2.26 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 -177.073 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -153.89 148.11 25.85 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 113.834 -1.53 . . . . 0.0 108.824 -176.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -82.12 149.02 28.22 Favored 'General case' 0 C--N 1.322 -0.628 0 O-C-N 123.958 0.786 . . . . 0.0 111.096 -178.436 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 73.7 t -124.62 133.68 68.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.346 -176.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 117' ' ' GLY . 8.4 t -116.71 136.35 54.06 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 72.3 t -100.02 103.52 23.04 Favored Pre-proline 0 C--N 1.292 -1.895 0 C-N-CA 123.384 0.674 . . . . 0.0 109.324 178.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -68.47 -27.1 33.81 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 122.423 2.082 . . . . 0.0 111.781 179.222 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 4.4 t . . . . . 0 CA--C 1.548 0.895 0 C-N-CA 125.109 1.364 . . . . 0.0 113.515 176.892 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.475 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.443 -0.791 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.407 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 70.9 m -136.02 159.41 41.77 Favored 'General case' 0 C--N 1.301 -1.5 0 C-N-CA 120.741 -0.384 . . . . 0.0 111.127 -175.348 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.447 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -143.73 161.05 39.6 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.172 0.51 . . . . 0.0 111.197 -176.187 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 72.0 p -102.25 168.88 9.07 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.335 177.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.99 -7.12 53.89 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 114.103 -1.408 . . . . 0.0 112.009 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 4.7 p30 -90.65 -31.29 16.69 Favored 'General case' 0 CA--C 1.511 -0.537 0 C-N-CA 118.458 -1.297 . . . . 0.0 108.234 176.219 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 133.24 2.57 3.68 Favored Glycine 0 N--CA 1.431 -1.678 0 C-N-CA 120.29 -0.957 . . . . 0.0 113.029 177.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.6 m -77.91 102.31 7.24 Favored 'General case' 0 N--CA 1.442 -0.869 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.26 117.59 30.54 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 175.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.475 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 62.1 mt -92.69 115.62 65.15 Favored Pre-proline 0 C--N 1.301 -1.529 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 179.348 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_endo -78.36 -179.83 5.82 Favored 'Trans proline' 0 C--O 1.248 0.981 0 C-N-CA 122.643 2.229 . . . . 0.0 111.526 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.5 mt -70.62 129.55 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.18 1.09 3.29 Favored Glycine 0 C--N 1.305 -1.162 0 C-N-CA 120.886 -0.673 . . . . 0.0 111.607 -178.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.75 171.41 46.91 Favored Glycine 0 C--O 1.244 0.773 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.289 -179.607 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 150.9 -169.11 30.66 Favored Glycine 0 N--CA 1.438 -1.182 0 C-N-CA 120.474 -0.869 . . . . 0.0 111.352 177.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 87.0 p -141.93 157.5 44.89 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -141.04 162.83 34.57 Favored 'General case' 0 N--CA 1.42 -1.965 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -110.03 111.33 22.64 Favored 'General case' 0 C--N 1.285 -2.207 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.256 178.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 41.5 t -100.75 135.83 35.07 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.441 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.513 -178.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 69.2 m-85 -125.29 128.51 48.36 Favored 'General case' 0 CA--C 1.492 -1.272 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -177.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.449 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.2 p -139.63 136.33 39.84 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 O-C-N 123.78 0.675 . . . . 0.0 110.974 -177.084 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 -88.79 128.29 35.63 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 178.089 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -107.11 160.05 15.85 Favored 'General case' 0 C--N 1.284 -2.272 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 176.15 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.45 120.66 37.63 Favored Pre-proline 0 C--O 1.209 -1.046 0 O-C-N 124.505 1.128 . . . . 0.0 109.365 176.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.485 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 62.4 Cg_endo -74.14 0.45 8.43 Favored 'Trans proline' 0 CA--C 1.537 0.667 0 C-N-CA 122.668 2.245 . . . . 0.0 113.514 -176.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.415 HG11 ' HG3' ' A' ' 157' ' ' PRO . 93.7 t -131.49 111.43 19.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 178.455 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.466 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 9.3 t -147.76 112.96 0.83 Allowed 'Isoleucine or valine' 0 C--O 1.194 -1.845 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 -177.453 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.661 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -101.05 154.75 18.44 Favored 'General case' 0 C--N 1.277 -2.571 0 C-N-CA 123.746 0.818 . . . . 0.0 111.062 -179.354 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 112' ' ' VAL . 99.1 t -46.12 117.84 0.39 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.478 0 C-N-CA 123.379 0.672 . . . . 0.0 111.338 175.614 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.1 1.36 54.63 Favored Glycine 0 C--N 1.311 -0.815 0 CA-C-N 115.253 -0.885 . . . . 0.0 113.101 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.661 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -74.42 -175.91 2.51 Favored 'General case' 0 C--N 1.315 -0.914 0 C-N-CA 124.551 1.141 . . . . 0.0 109.967 175.336 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -134.45 96.02 3.5 Favored 'General case' 0 N--CA 1.428 -1.559 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 177.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.578 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 28.8 tp -93.15 142.52 27.21 Favored 'General case' 0 C--N 1.284 -2.247 0 C-N-CA 119.773 -0.771 . . . . 0.0 109.929 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.0 t -135.01 122.08 35.89 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.719 0 CA-C-O 121.168 0.508 . . . . 0.0 109.901 -176.533 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.592 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 47.8 t -92.94 89.07 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.27 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 174.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -78.03 106.76 10.11 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.248 -177.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.6 mt -93.79 -1.68 54.65 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 121.365 0.602 . . . . 0.0 111.025 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.9 t -76.37 1.28 16.74 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.974 -178.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.3 p -129.55 8.93 5.46 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 123.614 0.765 . . . . 0.0 109.869 176.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.449 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 45.6 mm-40 -125.23 -24.73 3.93 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.505 -174.808 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.0 mt -133.71 141.59 43.78 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 -177.115 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.654 ' HD2' ' CD1' ' A' ' 43' ' ' PHE . 57.6 m-85 -141.24 161.14 38.59 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -176.199 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.407 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 69.3 m -138.69 138.77 38.06 Favored 'General case' 0 C--N 1.299 -1.618 0 C-N-CA 123.059 0.544 . . . . 0.0 110.953 -178.609 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 29.4 p-80 -134.12 148.94 51.05 Favored 'General case' 0 C--O 1.247 0.965 0 CA-C-O 121.378 0.609 . . . . 0.0 111.961 -175.386 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.484 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 3.4 p30 -105.37 118.87 37.66 Favored 'General case' 0 CA--C 1.485 -1.553 0 CA-C-O 122.193 0.997 . . . . 0.0 112.832 179.485 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -88.43 -25.94 22.38 Favored 'General case' 0 C--N 1.286 -2.189 0 CA-C-N 113.79 -1.55 . . . . 0.0 109.511 177.006 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 1.664 ' HD2' ' CD1' ' A' ' 48' ' ' TYR . 29.0 m-85 -138.51 66.87 44.03 Favored Pre-proline 0 N--CA 1.477 0.919 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.175 177.489 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.484 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 55.8 Cg_endo -68.52 -8.03 21.99 Favored 'Trans proline' 0 N--CA 1.485 1.024 0 C-N-CA 122.923 2.415 . . . . 0.0 113.96 -174.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -117.29 -9.29 10.97 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 120.025 -0.67 . . . . 0.0 111.115 -178.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.455 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.3 OUTLIER -103.88 -30.33 10.41 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 -176.378 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.455 HD13 ' HB ' ' A' ' 51' ' ' THR . 2.5 mp -124.2 140.09 48.61 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.309 0 CA-C-N 114.143 -1.389 . . . . 0.0 108.057 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 4.9 t -81.83 130.28 35.02 Favored 'General case' 0 N--CA 1.424 -1.773 0 N-CA-C 105.329 -2.101 . . . . 0.0 105.329 173.228 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.493 ' O ' HG21 ' A' ' 94' ' ' VAL . 42.2 m-20 -88.86 106.36 18.34 Favored 'General case' 0 C--N 1.282 -2.369 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -173.491 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.487 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 19.8 t80 -134.7 123.9 24.42 Favored 'General case' 0 C--N 1.296 -1.746 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.88 -172.592 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 93.3 t -124.83 141.66 44.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 CA-C-N 114.632 -1.167 . . . . 0.0 109.398 -176.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -148.36 127.85 13.16 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 173.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.52 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 59.5 tp -67.71 115.98 7.89 Favored 'General case' 0 N--CA 1.442 -0.85 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 174.19 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.432 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 3.9 tp-100 -60.43 -52.67 64.23 Favored 'General case' 0 C--O 1.214 -0.786 0 CA-C-N 114.402 -1.272 . . . . 0.0 110.404 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . 0.432 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 10.1 ptp180 -169.46 159.88 8.84 Favored 'General case' 0 N--CA 1.418 -2.028 0 CA-C-N 114.095 -1.411 . . . . 0.0 107.501 -175.049 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -136.42 136.06 8.15 Favored Glycine 1 N--CA 1.393 -4.205 0 N-CA-C 107.93 -2.068 . . . . 0.0 107.93 178.362 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 67.9 m -124.73 147.06 48.85 Favored 'General case' 0 C--N 1.272 -2.797 0 O-C-N 124.29 0.641 . . . . 0.0 110.361 -175.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.507 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -109.54 159.78 16.79 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 -178.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 1.62 ' HD2' ' CD1' ' A' ' 64' ' ' TYR . 90.6 m-85 -155.99 -179.68 8.37 Favored 'General case' 0 N--CA 1.464 0.26 0 C-N-CA 123.83 0.852 . . . . 0.0 109.438 -176.185 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.87 -138.71 46.84 Favored Glycine 0 CA--C 1.506 -0.52 0 O-C-N 123.73 0.644 . . . . 0.0 112.84 177.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.35 -6.04 89.56 Favored Glycine 0 C--O 1.201 -1.93 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 176.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.508 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 97.0 t -71.78 -38.17 64.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 123.041 0.536 . . . . 0.0 111.269 -178.262 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.507 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.11 -18.55 32.03 Favored 'General case' 0 C--N 1.297 -1.711 0 C-N-CA 118.513 -1.275 . . . . 0.0 112.232 179.416 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 22.5 t -100.29 -46.62 5.21 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.288 0.566 . . . . 0.0 112.028 -175.073 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.47 ' O ' HG23 ' A' ' 112' ' ' VAL . 44.7 m-20 -97.62 -20.75 17.45 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -174.183 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 1.641 ' HD2' ' CD1' ' A' ' 71' ' ' PHE . 95.6 m-85 -112.23 151.54 29.48 Favored 'General case' 0 N--CA 1.428 -1.544 0 CA-C-O 122.199 1.0 . . . . 0.0 111.618 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.1 m -158.69 124.15 4.37 Favored 'General case' 0 N--CA 1.393 -3.285 0 CA-C-N 113.587 -1.642 . . . . 0.0 109.96 179.236 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.504 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -161.13 -112.77 0.29 Allowed Glycine 0 N--CA 1.409 -3.156 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 175.631 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -158.04 179.84 8.8 Favored 'General case' 0 C--N 1.284 -2.242 0 C-N-CA 123.798 0.839 . . . . 0.0 110.238 -175.669 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -134.55 146.89 30.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 C-N-CA 123.172 0.589 . . . . 0.0 109.468 178.387 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.631 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.3 tttt -124.31 143.17 50.72 Favored 'General case' 0 N--CA 1.421 -1.901 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.5 -179.27 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 1.657 ' HE2' ' CE1' ' A' ' 77' ' ' TYR . 59.2 t80 -143.61 110.34 5.58 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 115.197 -0.91 . . . . 0.0 108.891 -177.551 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 23.0 t 53.95 37.2 26.19 Favored 'General case' 0 CA--C 1.557 1.241 0 C-N-CA 123.634 0.774 . . . . 0.0 111.386 175.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.44 10.48 63.68 Favored Glycine 0 C--O 1.216 -1.012 0 C-N-CA 120.849 -0.691 . . . . 0.0 113.874 -179.281 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.631 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 8.4 t -86.21 -179.29 6.69 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 117.584 0.692 . . . . 0.0 109.414 178.511 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 31.6 t -155.73 110.47 2.92 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -179.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 0.455 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 5.3 p90 -154.24 161.31 29.59 Favored Pre-proline 0 CA--C 1.548 0.885 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 -175.12 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . 0.428 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 60.1 Cg_endo -68.7 149.45 73.38 Favored 'Trans proline' 0 C--N 1.36 1.18 0 C-N-CA 122.936 2.424 . . . . 0.0 113.563 -175.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.544 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 59.3 t80 -124.07 133.21 24.49 Favored Pre-proline 0 N--CA 1.437 -1.078 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.932 179.005 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.544 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 60.5 Cg_endo -71.99 148.45 90.87 Favored 'Cis proline' 0 C--O 1.239 0.533 0 C-N-CA 122.796 -1.752 . . . . 0.0 110.232 -3.319 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.8 t -72.61 -175.99 1.81 Allowed 'General case' 0 C--O 1.246 0.903 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -178.225 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 22.6 p -130.69 -35.81 1.44 Allowed 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 122.088 0.947 . . . . 0.0 108.524 -172.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 49.4 m -105.34 -141.84 0.37 Allowed 'General case' 1 N--CA 1.343 -5.778 0 CA-C-N 114.093 -1.412 . . . . 0.0 108.24 178.368 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -123.49 -171.32 2.29 Favored 'General case' 0 C--N 1.275 -2.64 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -174.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.52 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 39.9 p -100.75 167.03 11.44 Favored Pre-proline 0 C--N 1.295 -1.764 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 177.402 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -57.39 166.47 4.56 Favored 'Trans proline' 0 C--O 1.247 0.953 0 C-N-CA 123.263 2.642 . . . . 0.0 112.286 171.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.487 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 1.7 tmm_? -75.21 121.32 21.95 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 114.597 -1.183 . . . . 0.0 108.52 -178.382 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 72.8 t -136.47 117.92 19.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 C-N-CA 123.41 0.684 . . . . 0.0 109.749 -176.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.493 HG21 ' O ' ' A' ' 54' ' ' ASP . 1.5 p -115.67 132.02 66.32 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.361 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.89 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . 1.63 ' HD1' ' CD2' ' A' ' 95' ' ' TYR . 6.3 m-85 -77.0 100.29 5.58 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.216 0.531 . . . . 0.0 111.096 -178.41 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . 0.409 HD21 ' N ' ' A' ' 96' ' ' ASN . 0.8 OUTLIER -94.89 59.88 2.39 Favored 'General case' 0 C--N 1.308 -1.237 0 CA-C-O 121.372 0.606 . . . . 0.0 109.556 179.047 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 51.0 m -154.47 141.76 19.56 Favored 'General case' 0 C--N 1.31 -1.114 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.7 ptp180 -109.02 69.68 0.71 Allowed 'General case' 0 C--N 1.304 -1.376 0 CA-C-O 122.044 0.926 . . . . 0.0 111.464 -177.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.2 t -179.46 168.53 1.44 Allowed 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 179.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -72.35 113.11 9.03 Favored 'General case' 0 CA--C 1.501 -0.94 0 CA-C-O 121.799 0.809 . . . . 0.0 109.461 -179.107 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -118.46 139.73 27.31 Favored Pre-proline 0 C--N 1.274 -2.71 0 CA-C-N 114.249 -1.341 . . . . 0.0 108.693 -177.099 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_endo -57.16 152.26 46.14 Favored 'Trans proline' 0 C--O 1.245 0.841 0 C-N-CA 123.278 2.652 . . . . 0.0 113.107 179.202 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . 0.445 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 12.6 t90 -91.42 106.62 17.19 Favored Pre-proline 0 N--CA 1.438 -1.048 0 N-CA-C 106.317 -1.735 . . . . 0.0 106.317 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -77.52 88.21 1.44 Allowed 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 121.388 1.392 . . . . 0.0 112.927 -172.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 98.0 t -137.62 145.09 29.76 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.306 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 176.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.592 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.87 136.73 18.18 Favored 'General case' 0 C--N 1.292 -1.9 0 O-C-N 123.237 0.336 . . . . 0.0 110.172 178.438 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 20.3 mt -101.28 102.71 13.62 Favored 'General case' 0 C--N 1.292 -1.909 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.087 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.504 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 19.3 m-85 -81.53 74.0 8.54 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 120.812 0.339 . . . . 0.0 110.436 177.44 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.578 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.2 mm? -91.52 151.08 20.91 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 176.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -149.3 143.7 17.18 Favored Pre-proline 0 N--CA 1.405 -2.702 0 C-N-CA 119.996 -0.682 . . . . 0.0 110.136 179.516 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -64.9 127.48 18.7 Favored 'Trans proline' 0 N--CA 1.45 -1.051 0 C-N-CA 123.383 2.722 . . . . 0.0 113.149 -177.3 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.528 ' O ' HG23 ' A' ' 30' ' ' VAL . 27.1 m -87.25 -155.84 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.399 -3.014 0 CA-C-N 114.438 -1.255 . . . . 0.0 108.639 172.432 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 6.1 m -80.51 -30.55 37.26 Favored 'General case' 0 C--N 1.261 -3.269 0 CA-C-O 121.425 0.631 . . . . 0.0 110.48 -168.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.5 t -82.9 9.55 9.74 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.888 -177.195 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -90.72 131.52 36.35 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.334 -0.988 . . . . 0.0 108.334 178.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.3 125.68 1.16 Allowed Glycine 0 C--N 1.306 -1.095 0 C-N-CA 120.571 -0.823 . . . . 0.0 111.727 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.84 -147.26 49.37 Favored Glycine 0 CA--C 1.486 -1.773 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -175.229 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 60.3 t -57.31 112.04 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 117.213 0.507 . . . . 0.0 110.113 -177.144 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -110.25 -28.69 8.5 Favored 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.068 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.432 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 59.0 mt -129.03 138.07 55.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.149 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.408 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 5.1 mmpt? -114.92 141.84 47.4 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 121.112 0.482 . . . . 0.0 110.835 178.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.44 135.26 49.98 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.691 -179.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 82.72 -4.14 80.3 Favored Glycine 0 C--O 1.242 0.61 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.216 178.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 19.4 m -94.71 149.41 21.27 Favored 'General case' 0 N--CA 1.417 -2.084 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 -179.214 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 28.2 tp -74.79 133.37 41.95 Favored 'General case' 0 N--CA 1.434 -1.231 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.123 -177.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.491 ' HB ' HG23 ' A' ' 67' ' ' VAL . 34.5 pt -118.26 -26.67 2.51 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 C-N-CA 120.481 -0.488 . . . . 0.0 112.174 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.9 163.58 29.07 Favored 'General case' 0 N--CA 1.434 -1.24 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.252 -177.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 55.9 t -139.7 115.63 8.74 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.937 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 178.222 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 68.7 mt -117.74 145.74 44.25 Favored 'General case' 0 C--N 1.281 -2.398 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 179.415 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.48 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.7 mp -128.7 119.47 49.97 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 C-N-CA 119.794 -0.762 . . . . 0.0 109.629 178.767 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.525 ' C ' HD13 ' A' ' 131' ' ' LEU . 0.6 OUTLIER -88.77 147.02 24.66 Favored 'General case' 0 CA--C 1.481 -1.677 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 173.978 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 60.0 ttp180 -115.0 122.0 44.87 Favored 'General case' 0 C--N 1.248 -3.832 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 177.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -85.86 139.26 31.41 Favored 'General case' 0 N--CA 1.417 -2.076 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 176.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.426 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 25.8 m -145.1 133.23 21.49 Favored 'General case' 0 C--N 1.261 -3.253 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 173.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 32.9 p30 . . . . . 0 C--N 1.298 -1.637 0 CA-C-O 120.906 0.384 . . . . 0.0 110.18 -178.368 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 . . . . . 0 N--CA 1.44 -0.941 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . 0.418 ' HB2' ' O ' ' A' ' 131' ' ' LEU . 13.9 pt20 -126.09 150.48 48.15 Favored 'General case' 0 C--N 1.288 -2.107 0 C-N-CA 119.877 -0.729 . . . . 0.0 110.623 -179.113 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 1.636 ' HE1' ' CE2' ' A' ' 144' ' ' PHE . 12.5 m-30 -113.67 127.47 56.06 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -174.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 50.0 t -92.42 132.11 37.64 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.987 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.93 -178.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 54.3 m95 -120.97 101.14 7.49 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -177.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 50.0 m-80 -84.5 115.01 22.35 Favored 'General case' 0 C--N 1.285 -2.233 0 N-CA-C 107.691 -1.226 . . . . 0.0 107.691 178.68 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 20.2 mm -88.55 121.8 39.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -177.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -117.7 151.7 36.74 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.143 177.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.22 131.39 35.23 Favored 'General case' 0 N--CA 1.412 -2.336 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 177.049 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -88.21 -16.36 33.49 Favored 'General case' 0 C--N 1.287 -2.128 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -178.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -148.08 143.96 27.54 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 114.566 -1.197 . . . . 0.0 109.997 -174.447 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -79.08 139.53 38.08 Favored 'General case' 0 C--N 1.309 -1.163 0 O-C-N 124.285 0.991 . . . . 0.0 110.995 179.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.485 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 73.0 t -115.12 138.47 45.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.851 -176.432 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 8.3 t -119.56 135.9 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.394 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 75.3 t -99.81 105.03 32.07 Favored Pre-proline 0 C--N 1.286 -2.174 0 C-N-CA 124.091 0.956 . . . . 0.0 109.834 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.461 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 40.6 Cg_endo -70.71 -21.77 28.62 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.233 1.955 . . . . 0.0 111.797 177.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.27 3.7 t . . . . . 0 C--N 1.355 0.841 0 C-N-CA 124.978 1.311 . . . . 0.0 114.095 175.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.61 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.44 -0.945 0 CA-C-O 120.557 0.217 . . . . 0.0 110.881 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.512 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 11.5 t -151.61 156.61 40.8 Favored 'General case' 0 N--CA 1.433 -1.276 0 C-N-CA 119.931 -0.708 . . . . 0.0 109.766 -177.241 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.1 pptp? -141.44 163.08 33.89 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-O 121.049 0.452 . . . . 0.0 111.576 -175.065 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 71.3 p -104.6 172.94 6.52 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 121.859 0.837 . . . . 0.0 110.406 -179.687 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -78.81 -10.31 59.74 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 113.745 -1.57 . . . . 0.0 110.991 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -92.16 -33.97 14.51 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 118.318 -1.353 . . . . 0.0 109.124 175.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 137.47 5.58 1.74 Allowed Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 119.231 -1.461 . . . . 0.0 113.437 176.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.3 m -80.18 100.22 8.18 Favored 'General case' 0 N--CA 1.433 -1.275 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -97.29 111.08 23.48 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.323 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.61 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 59.3 mt -88.87 121.94 69.42 Favored Pre-proline 0 C--N 1.307 -1.243 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 179.488 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -81.52 -179.56 5.02 Favored 'Trans proline' 0 C--O 1.241 0.668 0 C-N-CA 122.899 2.399 . . . . 0.0 111.937 178.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.6 mt -69.23 141.51 17.25 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.832 179.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.89 -1.74 17.4 Favored Glycine 0 N--CA 1.438 -1.191 0 C-N-CA 119.887 -1.149 . . . . 0.0 112.472 179.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 103.27 171.25 25.99 Favored Glycine 0 C--N 1.309 -0.972 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 157.22 -175.28 34.69 Favored Glycine 0 C--N 1.312 -0.759 0 C-N-CA 120.354 -0.927 . . . . 0.0 111.867 178.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 m -146.27 143.54 29.25 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 179.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.92 166.33 23.57 Favored 'General case' 0 N--CA 1.425 -1.71 0 CA-C-O 121.249 0.547 . . . . 0.0 109.788 -177.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -111.03 115.52 29.61 Favored 'General case' 0 C--N 1.28 -2.442 0 CA-C-N 114.533 -1.212 . . . . 0.0 108.822 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.7 t -103.26 140.08 22.44 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.947 0 CA-C-N 115.266 -0.879 . . . . 0.0 108.762 178.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 1.652 ' HE2' ' CE1' ' A' ' 21' ' ' TYR . 43.7 m-85 -126.1 136.23 52.66 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 -179.707 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.426 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.4 p -146.04 135.51 17.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 123.724 0.64 . . . . 0.0 110.519 -178.769 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.6 p30 -95.83 123.24 39.32 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 121.759 0.79 . . . . 0.0 111.367 179.375 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -103.48 160.93 14.29 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 113.922 -1.49 . . . . 0.0 108.208 -177.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.76 122.41 56.58 Favored Pre-proline 0 C--N 1.313 -0.994 0 O-C-N 124.764 1.29 . . . . 0.0 109.405 178.23 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.425 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 61.0 Cg_endo -75.21 3.08 6.04 Favored 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 122.661 2.241 . . . . 0.0 112.89 -178.592 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.7 t -125.98 109.54 21.73 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.503 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 177.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.443 ' O ' HG11 ' A' ' 156' ' ' VAL . 1.6 t -143.17 99.89 0.7 Allowed 'Isoleucine or valine' 0 C--O 1.183 -2.403 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 -178.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.455 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -91.63 151.38 20.72 Favored 'General case' 0 C--N 1.269 -2.893 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -179.199 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.477 HG11 ' O ' ' A' ' 112' ' ' VAL . 24.7 t -46.85 115.23 0.25 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.709 0 C-N-CA 123.615 0.766 . . . . 0.0 111.501 177.078 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.84 3.28 42.74 Favored Glycine 0 N--CA 1.446 -0.697 0 CA-C-N 114.759 -1.109 . . . . 0.0 112.755 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.455 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -73.78 -178.37 3.16 Favored 'General case' 0 C--N 1.309 -1.159 0 C-N-CA 123.542 0.737 . . . . 0.0 111.427 175.57 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -134.67 89.03 2.5 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 177.075 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.651 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.3 tp -90.21 144.67 25.65 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.102 -176.599 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.4 t -134.12 125.79 48.75 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.633 0 CA-C-O 121.298 0.57 . . . . 0.0 110.585 -176.642 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.598 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 48.9 t -95.96 89.25 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.049 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 174.057 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -82.81 113.05 20.18 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-O 121.15 0.5 . . . . 0.0 111.216 -178.11 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.3 mt -96.1 -2.7 46.03 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.983 -178.704 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -74.07 0.36 14.0 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-O 122.118 0.961 . . . . 0.0 109.733 -178.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.5 p -127.36 6.82 6.38 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 123.771 0.828 . . . . 0.0 109.819 178.09 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.426 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 45.7 mm-40 -124.03 -21.42 5.07 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.706 -174.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.6 mt -132.87 136.72 55.21 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.133 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 -175.155 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.635 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 42.9 m-85 -142.84 124.36 14.84 Favored 'General case' 0 CA--C 1.504 -0.798 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -175.671 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.512 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 83.3 m -101.02 140.31 35.48 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 -179.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.4 p80 -132.19 139.36 48.32 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 121.852 0.834 . . . . 0.0 112.313 -171.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 8.7 p30 -103.44 107.26 18.02 Favored 'General case' 0 C--N 1.292 -1.899 0 CA-C-N 115.1 -0.954 . . . . 0.0 113.342 -178.272 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -84.24 -14.33 50.22 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 121.881 0.848 . . . . 0.0 109.531 175.588 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 47.2 m-85 -134.52 66.0 68.88 Favored Pre-proline 0 C--N 1.318 -0.761 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 177.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -73.05 -5.56 17.42 Favored 'Trans proline' 0 N--CA 1.486 1.056 0 C-N-CA 123.188 2.592 . . . . 0.0 113.978 -172.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -120.41 -13.34 8.85 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 121.469 0.652 . . . . 0.0 110.204 -179.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.404 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -94.78 -30.17 14.38 Favored 'General case' 0 N--CA 1.421 -1.88 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -174.904 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.591 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -122.92 138.2 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.508 0 CA-C-N 113.529 -1.669 . . . . 0.0 107.924 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 7.3 t -80.7 136.39 36.17 Favored 'General case' 0 N--CA 1.427 -1.607 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 174.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.416 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 19.3 m-20 -84.79 108.16 17.33 Favored 'General case' 0 C--N 1.286 -2.163 0 CA-C-O 121.541 0.686 . . . . 0.0 110.506 -171.869 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.42 ' CE2' ' HB ' ' A' ' 134' ' ' THR . 34.0 t80 -138.46 143.36 39.61 Favored 'General case' 0 C--N 1.284 -2.275 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.242 -178.399 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.416 HG22 HD11 ' A' ' 131' ' ' LEU . 12.6 p -148.59 148.66 15.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 177.026 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.04 137.59 19.89 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 123.599 0.562 . . . . 0.0 109.992 174.029 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.403 HD21 ' O ' ' A' ' 130' ' ' ILE . 0.3 OUTLIER -74.52 106.64 6.21 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 105.048 -2.204 . . . . 0.0 105.048 175.119 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 6.6 tp60 -56.05 -64.9 0.71 Allowed 'General case' 0 C--O 1.202 -1.399 0 C-N-CA 126.372 1.869 . . . . 0.0 109.968 177.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 8.3 ptp180 -158.3 153.59 25.75 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 -179.189 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -134.98 137.97 9.66 Favored Glycine 0 CA--C 1.463 -3.159 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 -178.308 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 66.4 m -126.33 151.95 46.88 Favored 'General case' 0 C--N 1.28 -2.419 0 C-N-CA 123.822 0.849 . . . . 0.0 109.784 -174.704 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.508 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -115.74 157.92 23.59 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -178.134 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 1.659 ' HE1' ' CE2' ' A' ' 64' ' ' TYR . 91.9 m-85 -156.02 -179.45 8.15 Favored 'General case' 0 C--O 1.237 0.415 0 C-N-CA 124.328 1.051 . . . . 0.0 109.042 -177.412 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.25 -148.41 29.27 Favored Glycine 0 C--N 1.33 0.205 0 O-C-N 123.566 0.541 . . . . 0.0 113.533 178.68 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.41 -10.91 71.15 Favored Glycine 0 C--O 1.206 -1.598 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.754 178.101 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.51 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 97.0 t -69.05 -40.68 81.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 C-N-CA 123.9 0.88 . . . . 0.0 111.483 -177.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.508 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -84.2 -20.5 32.24 Favored 'General case' 0 N--CA 1.433 -1.289 0 C-N-CA 118.759 -1.176 . . . . 0.0 112.14 179.09 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 31.7 t -98.37 -60.2 1.6 Allowed 'General case' 0 N--CA 1.442 -0.838 0 CA-C-N 115.932 -0.576 . . . . 0.0 112.004 -174.466 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.467 ' O ' HG23 ' A' ' 112' ' ' VAL . 48.6 m-20 -85.77 -25.74 26.2 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.427 -172.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 0.537 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 91.6 m-85 -106.56 158.83 16.63 Favored 'General case' 0 N--CA 1.42 -1.956 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.03 177.363 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.0 t -167.98 137.39 2.55 Favored 'General case' 0 N--CA 1.411 -2.411 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 176.155 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.49 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.25 -107.86 0.2 Allowed Glycine 0 N--CA 1.411 -2.978 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 175.883 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.5 p -158.71 -179.88 8.47 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 123.791 0.836 . . . . 0.0 110.871 -175.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.416 HG11 ' CE2' ' A' ' 82' ' ' TYR . 2.6 p -132.11 144.96 35.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 177.662 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.68 ' HG3' ' O ' ' A' ' 80' ' ' SER . 73.6 tttt -123.73 142.98 50.58 Favored 'General case' 0 N--CA 1.424 -1.769 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.969 -177.503 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.558 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 68.3 t80 -141.42 111.44 6.71 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 115.458 -0.792 . . . . 0.0 108.87 -177.802 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 9.3 t 52.61 34.19 15.26 Favored 'General case' 0 CA--C 1.561 1.366 0 CA-C-O 121.717 0.77 . . . . 0.0 111.071 179.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.65 10.0 63.83 Favored Glycine 0 CA--C 1.532 1.101 0 C-N-CA 120.83 -0.7 . . . . 0.0 114.169 -179.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.68 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 21.8 t -79.98 179.54 7.54 Favored 'General case' 0 CA--C 1.549 0.924 0 CA-C-N 117.446 0.623 . . . . 0.0 109.376 177.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 17.5 p -153.27 109.11 3.29 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-O 121.548 0.69 . . . . 0.0 110.049 178.322 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 0.558 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 4.2 p90 -151.08 158.33 34.77 Favored Pre-proline 0 C--N 1.302 -1.465 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 -175.123 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.77 147.41 69.13 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.95 2.433 . . . . 0.0 113.256 -175.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.581 ' CD2' HD22 ' A' ' 109' ' ' LEU . 66.6 t80 -121.23 132.84 24.11 Favored Pre-proline 0 N--CA 1.441 -0.88 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.535 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.539 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 60.6 Cg_endo -69.25 146.19 80.39 Favored 'Cis proline' 0 CA--C 1.538 0.702 0 C-N-CA 123.562 -1.432 . . . . 0.0 111.308 0.208 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.3 t -70.74 -178.07 1.75 Allowed 'General case' 0 CA--C 1.554 1.097 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.31 -177.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 10.0 p -130.51 -34.33 1.58 Allowed 'General case' 0 C--O 1.243 0.711 0 N-CA-C 114.827 1.418 . . . . 0.0 114.827 -169.132 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.1 t -118.74 -69.44 0.85 Allowed 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 119.978 -0.689 . . . . 0.0 111.021 -174.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 178.25 -179.71 0.31 Allowed 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 -178.176 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.1 p -102.54 164.49 15.56 Favored Pre-proline 0 C--N 1.284 -2.26 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -66.46 160.61 44.89 Favored 'Trans proline' 0 C--N 1.365 1.406 0 C-N-CA 122.523 2.149 . . . . 0.0 110.504 173.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 6.8 tmm_? -72.73 128.2 34.82 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-N 115.64 -0.709 . . . . 0.0 112.166 -174.074 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 90.0 t -133.26 117.95 30.21 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 115.211 -0.904 . . . . 0.0 109.514 177.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 87.4 t -94.95 137.65 22.78 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 175.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . 0.416 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.2 m-85 -89.62 93.97 9.68 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 175.183 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 13.3 m120 -89.13 69.21 8.32 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 178.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.8 m -143.35 148.2 35.88 Favored 'General case' 0 N--CA 1.429 -1.515 0 CA-C-N 114.539 -1.21 . . . . 0.0 109.719 -176.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -112.64 45.48 1.31 Allowed 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 121.288 0.566 . . . . 0.0 111.303 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.1 t -171.52 179.92 2.75 Favored 'General case' 0 N--CA 1.439 -1.025 0 N-CA-C 106.332 -1.729 . . . . 0.0 106.332 -177.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -75.72 135.28 40.37 Favored 'General case' 0 C--O 1.249 1.051 0 CA-C-O 121.635 0.731 . . . . 0.0 109.37 -179.28 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 62.3 mmtt -128.31 141.0 39.94 Favored Pre-proline 0 C--N 1.28 -2.415 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.623 -177.187 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.45 ' O ' ' HD3' ' A' ' 104' ' ' PRO . 32.2 Cg_endo -64.38 142.31 78.36 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 123.508 2.806 . . . . 0.0 111.276 -179.281 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 10.7 t90 -86.5 104.23 5.36 Favored Pre-proline 0 C--N 1.308 -1.228 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 -177.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . 0.45 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 65.1 Cg_endo -75.91 88.61 1.3 Allowed 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 121.944 1.763 . . . . 0.0 113.1 -172.156 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 99.1 t -138.28 144.63 30.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.598 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.67 135.09 19.52 Favored 'General case' 0 N--CA 1.417 -2.092 0 CA-C-N 116.519 -0.309 . . . . 0.0 110.545 177.779 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.423 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 18.6 mt -99.94 103.18 14.73 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.275 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.49 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 22.1 m-85 -82.14 72.18 9.2 Favored 'General case' 0 C--N 1.296 -1.743 0 O-C-N 122.363 -0.211 . . . . 0.0 111.031 177.424 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.651 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -96.96 127.17 42.66 Favored 'General case' 0 C--O 1.207 -1.146 0 CA-C-O 120.571 0.224 . . . . 0.0 110.616 177.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -127.54 144.73 52.03 Favored Pre-proline 0 N--CA 1.417 -2.079 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.055 -175.731 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -62.32 118.19 5.07 Favored 'Trans proline' 0 C--O 1.241 0.664 0 C-N-CA 123.164 2.576 . . . . 0.0 111.684 -178.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.477 ' O ' HG11 ' A' ' 30' ' ' VAL . 3.8 m -68.34 -112.82 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.191 -2.001 0 O-C-N 124.38 1.05 . . . . 0.0 113.07 176.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 11.7 p -111.68 -46.26 3.27 Favored 'General case' 0 C--N 1.294 -1.832 0 CA-C-O 121.369 0.604 . . . . 0.0 110.904 179.667 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 11.6 t -82.45 25.69 0.61 Allowed 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 121.937 0.875 . . . . 0.0 111.021 -175.077 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -96.38 131.1 43.28 Favored 'General case' 0 N--CA 1.414 -2.265 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.29 129.54 1.7 Allowed Glycine 0 N--CA 1.436 -1.321 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.072 -178.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.5 -149.78 51.05 Favored Glycine 0 N--CA 1.434 -1.451 0 CA-C-O 119.376 -0.68 . . . . 0.0 111.93 -178.187 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.424 ' CG1' ' HE3' ' A' ' 121' ' ' LYS . 76.9 t -58.14 99.87 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 121.728 0.775 . . . . 0.0 111.088 -177.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.07 -37.76 9.61 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 114.878 -1.056 . . . . 0.0 110.577 -178.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.421 ' HB ' HG21 ' A' ' 154' ' ' VAL . 72.9 mt -118.02 139.04 46.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 178.686 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.455 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.0 mmpt? -115.17 141.82 47.5 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 122.823 0.449 . . . . 0.0 110.375 176.375 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.0 132.63 46.21 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.423 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 87.28 -1.23 86.15 Favored Glycine 0 N--CA 1.431 -1.695 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.779 -178.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 32.1 t -90.92 140.78 29.5 Favored 'General case' 0 N--CA 1.42 -1.972 0 N-CA-C 108.577 -0.898 . . . . 0.0 108.577 178.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -68.83 126.63 30.37 Favored 'General case' 0 N--CA 1.427 -1.61 0 N-CA-C 106.411 -1.699 . . . . 0.0 106.411 175.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.488 ' HB ' HG23 ' A' ' 67' ' ' VAL . 29.6 pt -113.67 -27.15 2.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -178.562 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.28 167.96 24.95 Favored 'General case' 0 N--CA 1.443 -0.825 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 -177.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 64.4 t -142.33 113.54 3.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 179.429 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 37.3 mt -118.04 143.49 46.38 Favored 'General case' 0 C--N 1.288 -2.094 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 179.704 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.403 ' O ' HD21 ' A' ' 58' ' ' LEU . 4.9 mp -123.39 128.43 74.74 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.133 0 C-N-CA 119.709 -0.796 . . . . 0.0 109.411 178.811 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.422 HD12 ' HG2' ' A' ' 133' ' ' GLN . 1.1 pp -94.34 147.25 23.4 Favored 'General case' 0 CA--C 1.472 -2.05 0 N-CA-C 105.614 -1.995 . . . . 0.0 105.614 172.369 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 59.7 ttt180 -116.57 132.72 56.61 Favored 'General case' 0 N--CA 1.386 -3.635 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 173.435 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.422 ' HG2' HD12 ' A' ' 131' ' ' LEU . 17.0 mm-40 -90.38 148.06 23.06 Favored 'General case' 0 N--CA 1.402 -2.863 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.706 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.42 ' HB ' ' CE2' ' A' ' 55' ' ' TYR . 27.6 m -154.58 138.14 15.99 Favored 'General case' 0 C--N 1.276 -2.622 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 169.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.591 ' CB ' HG21 ' A' ' 52' ' ' ILE . 6.1 p30 . . . . . 0 C--N 1.319 -0.741 0 C-N-CA 119.585 -0.846 . . . . 0.0 111.332 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 . . . . . 0 N--CA 1.434 -1.275 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -134.47 146.54 49.86 Favored 'General case' 0 N--CA 1.42 -1.962 0 C-N-CA 118.571 -1.252 . . . . 0.0 111.93 -176.331 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 1.647 ' HD1' ' CD2' ' A' ' 144' ' ' PHE . 10.8 m-30 -111.3 126.95 55.44 Favored 'General case' 0 C--N 1.31 -1.13 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -177.263 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.0 t -91.68 132.29 36.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -178.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 55.4 m95 -118.29 101.53 8.27 Favored 'General case' 0 C--N 1.282 -2.334 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 42.5 m-80 -80.88 112.98 18.77 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 178.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 23.7 mm -87.19 122.16 38.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 -177.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -116.51 153.78 31.55 Favored 'General case' 0 C--N 1.293 -1.882 0 C-N-CA 123.242 0.617 . . . . 0.0 109.525 178.208 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.76 130.3 35.11 Favored 'General case' 0 N--CA 1.412 -2.364 0 CA-C-N 115.197 -0.91 . . . . 0.0 108.741 176.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -85.82 -20.69 28.79 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -178.16 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -149.86 147.32 27.81 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 114.21 -1.359 . . . . 0.0 109.269 -173.448 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 16.8 p-10 -89.83 136.73 32.87 Favored 'General case' 0 C--N 1.31 -1.112 0 O-C-N 123.948 0.78 . . . . 0.0 111.119 -177.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.425 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 2.0 m -115.65 150.99 17.46 Favored 'Isoleucine or valine' 0 C--O 1.252 1.222 0 CA-C-O 121.053 0.454 . . . . 0.0 111.434 -174.489 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.8 t -122.32 139.42 49.31 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.016 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.208 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.443 HG11 ' O ' ' A' ' 28' ' ' VAL . 75.7 t -100.8 99.4 10.2 Favored Pre-proline 0 C--N 1.293 -1.85 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -68.06 -28.47 34.88 Favored 'Trans proline' 0 C--O 1.24 0.591 0 C-N-CA 122.269 1.979 . . . . 0.0 111.954 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.4 t . . . . . 0 C--O 1.249 1.06 0 O-C-N 125.091 1.495 . . . . 0.0 113.799 178.488 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.403 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.426 -1.666 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.419 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 10.4 t -154.71 157.63 38.35 Favored 'General case' 0 C--N 1.299 -1.626 0 C-N-CA 119.423 -0.911 . . . . 0.0 109.719 -176.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.36 163.76 33.57 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.558 -175.174 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.498 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 76.2 p -102.02 176.7 5.11 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.591 0.71 . . . . 0.0 110.859 -178.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.88 -1.09 46.51 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.453 -1.249 . . . . 0.0 111.091 179.143 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.498 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 8.5 p30 -100.08 -25.58 14.25 Favored 'General case' 0 N--CA 1.446 -0.67 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.685 174.707 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 128.19 5.22 5.24 Favored Glycine 0 CA--C 1.507 -0.461 0 C-N-CA 119.838 -1.173 . . . . 0.0 113.22 175.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.0 m -81.33 99.63 8.76 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.58 122.42 34.98 Favored 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 115.45 -0.795 . . . . 0.0 108.925 176.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.403 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 66.3 mt -95.13 115.89 65.83 Favored Pre-proline 0 C--N 1.293 -1.88 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 178.018 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.8 163.78 37.79 Favored 'Trans proline' 0 C--O 1.25 1.099 0 C-N-CA 122.156 1.904 . . . . 0.0 110.294 177.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 23.5 mt -67.48 126.18 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.101 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.65 -14.83 1.4 Allowed Glycine 0 C--N 1.297 -1.592 0 C-N-CA 120.491 -0.861 . . . . 0.0 111.62 -175.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 95.17 134.5 7.71 Favored Glycine 0 C--N 1.31 -0.883 0 C-N-CA 120.376 -0.916 . . . . 0.0 111.459 -179.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -178.76 -166.97 35.71 Favored Glycine 0 C--N 1.299 -1.501 0 N-CA-C 109.916 -1.273 . . . . 0.0 109.916 -178.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.432 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 60.0 p -140.23 150.53 44.23 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 117.457 0.629 . . . . 0.0 110.261 -179.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -134.17 161.53 34.64 Favored 'General case' 0 N--CA 1.422 -1.831 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 177.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 19.8 m-80 -116.5 111.13 19.53 Favored 'General case' 0 C--N 1.284 -2.248 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 178.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.406 HG23 ' HA ' ' A' ' 148' ' ' ILE . 1.1 m -92.63 149.71 4.1 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.462 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 -178.611 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 55.5 m-85 -132.04 113.71 13.7 Favored 'General case' 0 CA--C 1.492 -1.277 0 O-C-N 122.089 -0.382 . . . . 0.0 110.485 -176.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.456 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.5 p -120.93 132.84 69.41 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 CA-C-O 121.451 0.643 . . . . 0.0 111.423 -174.583 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 30.6 m-80 -88.17 123.24 32.62 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 50.0 mt -108.69 159.24 16.9 Favored 'General case' 0 C--N 1.276 -2.61 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 179.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.0 120.57 43.78 Favored Pre-proline 0 C--N 1.3 -1.552 0 O-C-N 124.37 1.044 . . . . 0.0 109.523 179.323 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.493 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 66.6 Cg_endo -74.09 -2.93 12.98 Favored 'Trans proline' 0 CA--C 1.531 0.369 0 C-N-CA 122.758 2.305 . . . . 0.0 113.503 -175.647 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.439 HG11 ' HG3' ' A' ' 157' ' ' PRO . 99.4 t -128.2 109.75 20.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.391 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.45 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 12.5 t -147.1 107.48 0.63 Allowed 'Isoleucine or valine' 0 C--O 1.19 -2.068 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -176.472 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.576 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -95.48 156.96 16.11 Favored 'General case' 0 C--N 1.271 -2.819 0 C-N-CA 122.863 0.465 . . . . 0.0 112.12 -179.911 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.441 HG11 ' O ' ' A' ' 112' ' ' VAL . 41.2 t -44.12 115.25 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.674 0 C-N-CA 124.296 1.038 . . . . 0.0 112.07 175.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.19 1.39 51.19 Favored Glycine 0 C--N 1.316 -0.536 0 CA-C-N 115.386 -0.825 . . . . 0.0 113.233 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.576 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -74.1 -176.32 2.52 Favored 'General case' 0 C--N 1.315 -0.916 0 C-N-CA 124.164 0.986 . . . . 0.0 111.005 176.408 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -130.78 93.07 3.34 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 177.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.622 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 19.8 tp -93.41 141.88 27.96 Favored 'General case' 0 C--N 1.29 -1.982 0 C-N-CA 119.348 -0.941 . . . . 0.0 109.545 178.34 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.3 t -135.77 128.3 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.978 0 N-CA-C 109.433 -0.581 . . . . 0.0 109.433 -176.111 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.596 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 56.3 t -97.59 88.87 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.405 -2.721 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 174.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -83.36 115.89 22.22 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 120.822 0.344 . . . . 0.0 110.639 -178.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 80.5 mt -97.27 4.19 51.02 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.369 -179.143 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 33.3 t -77.28 -0.17 24.4 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 122.371 1.081 . . . . 0.0 109.115 -178.397 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.1 p -128.07 3.68 5.87 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 114.977 -1.01 . . . . 0.0 110.13 179.129 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.456 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 54.2 mm-40 -122.34 -22.22 5.59 Favored 'General case' 0 CA--C 1.503 -0.858 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.282 -172.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 24.3 mt -136.79 135.64 48.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.032 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 -175.261 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.639 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 61.3 m-85 -138.53 125.26 20.92 Favored 'General case' 0 CA--C 1.501 -0.919 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 -175.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.419 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 73.7 m -108.2 143.33 37.14 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 30.7 p80 -134.23 156.53 48.22 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-O 120.914 0.388 . . . . 0.0 110.589 -175.536 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.678 ' ND2' ' HA ' ' A' ' 49' ' ' PRO . 56.4 t30 -113.74 100.4 8.44 Favored 'General case' 0 N--CA 1.421 -1.916 0 CA-C-O 122.734 1.254 . . . . 0.0 110.772 176.604 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -60.75 -32.21 71.51 Favored 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 127.021 2.128 . . . . 0.0 112.728 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -130.46 77.2 76.39 Favored Pre-proline 0 C--N 1.318 -0.803 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.678 ' HA ' ' ND2' ' A' ' 46' ' ' ASN . 64.7 Cg_endo -68.42 -4.69 13.41 Favored 'Trans proline' 0 N--CA 1.484 0.93 0 C-N-CA 123.529 2.819 . . . . 0.0 115.95 -169.846 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -118.92 -15.72 9.31 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 121.596 0.713 . . . . 0.0 109.944 178.77 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.411 ' HB ' HD13 ' A' ' 52' ' ' ILE . 2.0 m -96.84 -30.64 13.04 Favored 'General case' 0 N--CA 1.408 -2.573 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -175.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.646 HG21 ' CB ' ' A' ' 135' ' ' ASN . 3.4 mp -132.65 140.47 47.43 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.244 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 179.063 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.8 t -87.83 150.66 23.4 Favored 'General case' 0 C--O 1.254 1.302 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 177.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.445 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 0.9 OUTLIER -79.97 107.91 13.13 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 -178.598 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 76.5 t80 -143.69 144.04 31.69 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -176.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.458 HG11 ' OH ' ' A' ' 77' ' ' TYR . 6.2 p -152.08 150.33 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.179 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 177.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -151.2 133.11 15.07 Favored 'General case' 0 C--O 1.208 -1.079 0 CA-C-O 119.455 -0.307 . . . . 0.0 110.296 175.193 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.505 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 47.9 tp -76.56 106.48 8.23 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 121.132 0.491 . . . . 0.0 109.861 176.617 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.7 tp-100 -53.84 -52.69 59.58 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 125.77 1.628 . . . . 0.0 111.717 177.661 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 1.1 ptp180 -166.37 157.89 13.33 Favored 'General case' 0 C--N 1.307 -1.258 0 N-CA-C 107.597 -1.261 . . . . 0.0 107.597 -179.017 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.13 115.23 0.86 Allowed Glycine 0 N--CA 1.399 -3.814 0 N-CA-C 108.992 -1.643 . . . . 0.0 108.992 -178.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 67.2 m -110.26 147.17 34.35 Favored 'General case' 0 C--N 1.28 -2.423 0 C-N-CA 124.471 1.108 . . . . 0.0 110.338 -171.13 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.536 ' HB3' ' CE2' ' A' ' 84' ' ' PHE . . . -108.83 157.8 18.26 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.487 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 86.9 m-85 -157.01 -179.35 8.12 Favored 'General case' 0 C--O 1.237 0.403 0 C-N-CA 124.21 1.004 . . . . 0.0 108.683 -178.532 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 60.2 -140.68 47.96 Favored Glycine 0 CA--C 1.5 -0.899 0 O-C-N 123.915 0.759 . . . . 0.0 112.851 176.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.09 -12.54 84.54 Favored Glycine 0 N--CA 1.431 -1.669 0 C-N-CA 120.54 -0.838 . . . . 0.0 111.375 177.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.487 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 82.4 t -68.45 -39.45 80.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 C-N-CA 123.522 0.729 . . . . 0.0 111.927 -176.293 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.514 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -87.54 -16.23 35.21 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 118.981 -1.088 . . . . 0.0 112.272 178.897 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 8.0 t -101.06 -58.05 1.97 Allowed 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.329 0.585 . . . . 0.0 111.399 -174.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.484 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 47.6 m-20 -87.09 -25.31 24.21 Favored 'General case' 0 CA--C 1.492 -1.283 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.133 -174.673 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 1.622 ' HD2' ' CD1' ' A' ' 71' ' ' PHE . 83.7 m-85 -108.24 158.19 17.68 Favored 'General case' 0 N--CA 1.415 -2.223 0 C-N-CA 120.03 -0.668 . . . . 0.0 110.352 179.342 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.6 t -164.91 135.76 4.02 Favored 'General case' 0 N--CA 1.409 -2.522 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 176.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.43 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.31 -109.12 0.22 Allowed Glycine 0 N--CA 1.406 -3.356 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 174.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.429 HG23 ' HA ' ' A' ' 83' ' ' PRO . 1.3 p -159.72 179.33 8.95 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 123.695 0.798 . . . . 0.0 110.827 -174.198 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.5 p -132.55 145.47 34.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 178.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.628 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.2 tttt -124.08 144.87 49.62 Favored 'General case' 0 N--CA 1.417 -2.084 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.471 -179.4 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.458 ' OH ' HG11 ' A' ' 56' ' ' VAL . 59.2 t80 -146.33 114.71 6.7 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -178.638 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.0 m 54.05 36.68 25.2 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 113.974 1.101 . . . . 0.0 113.974 177.431 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.16 12.19 81.23 Favored Glycine 0 C--N 1.309 -0.917 0 C-N-CA 119.579 -1.296 . . . . 0.0 112.587 -178.593 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.628 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 7.9 t -83.8 178.87 7.74 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 176.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 48.8 p -154.74 111.04 3.23 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 -178.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 1.622 ' HD2' ' CD1' ' A' ' 82' ' ' TYR . 3.4 p90 -154.73 158.86 32.26 Favored Pre-proline 0 C--N 1.305 -1.331 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 -175.315 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . 0.429 ' HA ' HG23 ' A' ' 74' ' ' THR . 73.0 Cg_endo -71.31 147.91 54.07 Favored 'Trans proline' 0 C--N 1.355 0.904 0 C-N-CA 123.089 2.526 . . . . 0.0 113.259 -176.594 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 1.664 ' HE1' ' CE2' ' A' ' 84' ' ' PHE . 48.3 t80 -119.35 135.63 24.1 Favored Pre-proline 0 N--CA 1.433 -1.291 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.082 -178.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.515 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 57.0 Cg_endo -71.18 148.15 89.12 Favored 'Cis proline' 0 CA--C 1.538 0.678 0 C-N-CA 122.741 -1.774 . . . . 0.0 110.365 -1.532 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 7.9 t -65.64 -175.24 0.26 Allowed 'General case' 0 CA--C 1.55 0.976 0 C-N-CA 122.616 0.366 . . . . 0.0 110.288 -178.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 13.9 p -122.42 -36.45 2.94 Favored 'General case' 0 N--CA 1.432 -1.334 0 CA-C-O 121.664 0.745 . . . . 0.0 109.017 -172.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.4 t -132.49 -137.51 0.19 Allowed 'General case' 1 N--CA 1.364 -4.77 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 176.154 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -105.67 156.99 17.73 Favored 'General case' 0 C--N 1.264 -3.12 0 C-N-CA 125.958 1.703 . . . . 0.0 109.377 -170.595 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.505 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 23.7 p -74.76 162.27 74.27 Favored Pre-proline 0 C--N 1.31 -1.14 0 C-N-CA 123.322 0.649 . . . . 0.0 111.203 178.467 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -59.05 162.7 13.12 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 122.976 2.451 . . . . 0.0 111.236 176.137 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.5 tmm_? -68.92 125.98 28.35 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -176.272 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 71.5 t -140.14 128.48 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.83 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 -177.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.44 HG21 ' O ' ' A' ' 54' ' ' ASP . 1.9 p -124.68 132.37 71.41 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.378 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.206 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . 0.496 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 3.4 m-85 -81.03 140.27 35.25 Favored 'General case' 0 C--N 1.298 -1.662 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 177.795 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -108.37 28.14 8.64 Favored 'General case' 0 C--N 1.292 -1.899 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' SER . . . . . 0.455 ' OG ' ' HB3' ' A' ' 95' ' ' TYR . 5.0 p -84.08 178.93 7.64 Favored 'General case' 0 N--CA 1.423 -1.807 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.918 -175.802 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -151.27 32.38 0.59 Allowed 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 171.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.1 t -163.62 -176.45 4.68 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 -176.484 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -76.84 134.25 39.1 Favored 'General case' 0 CA--C 1.506 -0.736 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.131 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . 0.487 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 7.8 mmpt? -137.39 152.4 73.13 Favored Pre-proline 0 C--N 1.29 -2.015 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -67.63 147.15 75.66 Favored 'Trans proline' 0 N--CA 1.443 -1.445 0 C-N-CA 122.305 2.003 . . . . 0.0 111.998 -177.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . 0.496 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.0 t90 -88.0 111.41 42.53 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . 0.43 ' HD3' ' OH ' ' A' ' 95' ' ' TYR . 2.5 Cg_endo -79.47 87.6 1.53 Allowed 'Trans proline' 0 N--CA 1.443 -1.448 0 C-N-CA 121.386 1.39 . . . . 0.0 112.069 -172.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 95.9 t -140.13 142.75 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.339 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 177.488 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.596 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.58 135.62 17.65 Favored 'General case' 0 N--CA 1.421 -1.899 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 178.158 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.418 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 16.8 mt -101.89 103.38 14.05 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 1.59 ' HE2' ' CE1' ' A' ' 108' ' ' TYR . 25.7 m-85 -84.38 76.62 10.12 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 120.767 0.318 . . . . 0.0 110.24 178.477 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.622 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.2 mm? -103.33 131.04 50.72 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 177.405 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.23 147.61 66.44 Favored Pre-proline 0 N--CA 1.418 -2.029 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.528 -175.317 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.484 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 30.3 Cg_endo -62.04 121.08 8.97 Favored 'Trans proline' 0 C--O 1.25 1.083 0 C-N-CA 123.068 2.512 . . . . 0.0 111.841 -178.188 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.475 HG23 ' O ' ' A' ' 70' ' ' ASN . 4.2 m -69.89 -120.52 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.186 -2.242 0 CA-C-N 114.026 -1.443 . . . . 0.0 111.218 175.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 23.0 t -111.06 -35.82 5.81 Favored 'General case' 0 C--N 1.291 -1.94 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 175.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 27.6 t -82.06 36.8 0.47 Allowed 'General case' 0 N--CA 1.441 -0.919 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.919 -176.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -117.02 133.47 55.96 Favored 'General case' 0 N--CA 1.418 -2.043 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 177.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -172.95 129.55 1.72 Allowed Glycine 0 N--CA 1.437 -1.24 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.21 -146.06 48.46 Favored Glycine 0 CA--C 1.491 -1.454 0 CA-C-O 119.143 -0.809 . . . . 0.0 111.781 -177.396 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.2 p -58.05 101.27 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-O 122.598 1.19 . . . . 0.0 112.157 -177.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -102.03 -23.09 14.14 Favored 'General case' 0 C--N 1.294 -1.827 0 CA-C-N 114.674 -1.148 . . . . 0.0 111.001 -178.484 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.47 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 65.3 mt -136.56 137.14 48.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.329 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.492 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.1 mmpt? -113.3 137.58 51.28 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-O 120.864 0.364 . . . . 0.0 110.664 176.657 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.94 134.82 48.79 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.749 -0.66 . . . . 0.0 109.833 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 85.17 6.96 83.91 Favored Glycine 0 C--N 1.303 -1.273 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.768 -178.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 49.4 m -109.44 144.58 37.48 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 177.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -70.38 126.57 30.02 Favored 'General case' 0 N--CA 1.443 -0.783 0 CA-C-N 115.045 -0.98 . . . . 0.0 108.58 -178.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.475 ' HB ' HG23 ' A' ' 67' ' ' VAL . 34.4 pt -113.0 -26.05 3.21 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 N-CA-C 112.469 0.544 . . . . 0.0 112.469 -179.39 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -160.82 165.29 30.51 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 -178.07 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 63.7 t -140.63 112.88 4.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 179.062 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 50.9 mt -117.1 143.99 45.17 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.408 ' O ' HD13 ' A' ' 58' ' ' LEU . 5.0 mp -128.9 123.77 59.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.054 0 C-N-CA 119.616 -0.834 . . . . 0.0 109.946 179.206 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.45 ' C ' HD13 ' A' ' 131' ' ' LEU . 1.4 pp -88.72 147.03 24.7 Favored 'General case' 0 CA--C 1.477 -1.855 0 N-CA-C 106.304 -1.739 . . . . 0.0 106.304 174.512 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 37.3 ttp180 -112.42 123.41 50.22 Favored 'General case' 0 C--N 1.258 -3.39 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 173.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.28 135.88 33.65 Favored 'General case' 0 N--CA 1.408 -2.53 0 N-CA-C 105.625 -1.991 . . . . 0.0 105.625 -176.407 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 35.2 m -147.29 147.22 30.16 Favored 'General case' 0 C--N 1.269 -2.919 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 175.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.646 ' CB ' HG21 ' A' ' 52' ' ' ILE . 11.5 p30 . . . . . 0 N--CA 1.438 -1.036 0 C-N-CA 119.708 -0.797 . . . . 0.0 110.983 178.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . 1.645 ' HE1' ' CE2' ' A' ' 142' ' ' PHE . 61.6 m-85 . . . . . 0 N--CA 1.426 -1.642 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -123.8 146.61 48.22 Favored 'General case' 0 C--N 1.286 -2.162 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.042 -177.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 9.8 m-30 -113.01 125.88 54.9 Favored 'General case' 0 C--N 1.309 -1.156 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 -176.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . 0.432 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 58.3 t -89.27 134.31 28.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 O-C-N 123.553 0.533 . . . . 0.0 110.409 -177.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 58.9 m95 -120.26 97.03 5.39 Favored 'General case' 0 C--N 1.284 -2.246 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 -78.34 113.1 16.01 Favored 'General case' 0 C--N 1.283 -2.318 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 177.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . 0.406 ' HA ' HG23 ' A' ' 20' ' ' VAL . 22.8 mm -88.74 122.17 39.81 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -177.183 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 1.625 ' HD2' ' CD1' ' A' ' 149' ' ' TYR . 47.4 m-85 -118.11 153.04 34.43 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.509 0.671 . . . . 0.0 109.809 178.061 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -78.98 128.89 33.85 Favored 'General case' 0 N--CA 1.409 -2.517 0 CA-C-N 114.609 -1.178 . . . . 0.0 108.159 175.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -88.71 -15.5 34.66 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -178.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -151.01 145.39 25.5 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 113.578 -1.646 . . . . 0.0 109.641 -175.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -79.92 144.63 33.2 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 124.019 0.928 . . . . 0.0 110.753 -178.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.493 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 71.2 t -121.54 134.62 64.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.11 -176.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.5 t -118.58 134.43 62.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 -179.447 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.45 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 75.5 t -97.46 101.68 10.82 Favored Pre-proline 0 C--N 1.292 -1.934 0 C-N-CA 123.889 0.876 . . . . 0.0 108.778 177.633 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.439 ' HG3' HG11 ' A' ' 27' ' ' VAL . 35.8 Cg_endo -67.22 -28.38 40.33 Favored 'Trans proline' 0 CA--C 1.511 -0.643 0 C-N-CA 121.893 1.729 . . . . 0.0 112.018 -178.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 8.0 t . . . . . 0 CA--C 1.559 1.298 0 O-C-N 124.827 1.329 . . . . 0.0 112.831 176.87 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.509 -0.63 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.414 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 74.1 m -134.17 161.94 33.52 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 119.747 -0.781 . . . . 0.0 112.211 -173.703 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -146.78 161.67 40.16 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.215 -176.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.439 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 72.7 p -99.48 179.56 4.52 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 121.225 0.536 . . . . 0.0 111.557 -178.716 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.58 -26.62 50.92 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.862 177.14 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.439 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 5.6 p30 -79.4 -31.33 42.73 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 119.433 -0.907 . . . . 0.0 109.414 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 129.08 20.42 1.45 Allowed Glycine 0 N--CA 1.431 -1.687 0 C-N-CA 119.911 -1.138 . . . . 0.0 112.933 173.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.6 m -87.98 99.31 12.06 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.06 121.32 32.76 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 115.795 -0.638 . . . . 0.0 109.539 177.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 63.5 mt -99.82 116.67 64.54 Favored Pre-proline 0 C--N 1.29 -1.99 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 177.293 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -77.39 168.57 22.66 Favored 'Trans proline' 0 C--O 1.251 1.151 0 C-N-CA 122.45 2.1 . . . . 0.0 110.912 177.704 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 64.9 mt -66.56 124.91 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 145.04 -5.0 1.42 Allowed Glycine 0 C--N 1.303 -1.304 0 CA-C-N 115.723 -0.671 . . . . 0.0 111.636 -176.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 94.37 161.17 34.75 Favored Glycine 0 N--CA 1.439 -1.145 0 N-CA-C 110.122 -1.191 . . . . 0.0 110.122 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 159.38 -167.01 34.96 Favored Glycine 0 CA--C 1.486 -1.758 0 C-N-CA 119.484 -1.341 . . . . 0.0 111.342 179.044 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 49.9 p -147.08 152.37 38.41 Favored 'General case' 0 N--CA 1.424 -1.761 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -178.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -138.39 163.41 31.95 Favored 'General case' 0 N--CA 1.417 -2.082 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.013 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -108.42 118.14 35.99 Favored 'General case' 0 N--CA 1.406 -2.662 0 CA-C-N 114.342 -1.299 . . . . 0.0 107.964 176.457 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 49.3 t -104.96 130.5 55.95 Favored 'Isoleucine or valine' 0 C--N 1.264 -3.113 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.142 178.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 1.625 ' HD1' ' CD2' ' A' ' 21' ' ' TYR . 45.7 m-85 -118.75 128.09 54.17 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -179.352 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.473 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -138.01 137.26 44.75 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 O-C-N 124.128 0.893 . . . . 0.0 110.932 -176.545 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 37.3 m-80 -90.28 139.63 30.47 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 178.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.463 HD23 HG21 ' A' ' 36' ' ' VAL . 5.1 mp -122.72 161.95 22.93 Favored 'General case' 0 C--N 1.282 -2.367 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.183 176.852 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.03 120.85 54.26 Favored Pre-proline 0 C--N 1.316 -0.863 0 O-C-N 124.653 1.221 . . . . 0.0 109.404 178.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.434 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 73.5 Cg_endo -75.68 3.75 5.68 Favored 'Trans proline' 0 CA--C 1.532 0.392 0 C-N-CA 122.846 2.364 . . . . 0.0 113.398 -176.154 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.4 t -132.0 109.79 15.84 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 178.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.502 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.1 t -141.85 107.7 1.78 Allowed 'Isoleucine or valine' 0 C--O 1.182 -2.448 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -176.639 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.662 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -96.4 150.36 20.67 Favored 'General case' 0 C--N 1.269 -2.895 0 O-C-N 122.036 -0.415 . . . . 0.0 111.303 -179.864 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.431 HG11 ' O ' ' A' ' 112' ' ' VAL . 35.0 t -45.81 117.44 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 123.445 0.698 . . . . 0.0 111.976 176.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.62 1.61 53.01 Favored Glycine 0 CA--C 1.523 0.576 0 CA-C-N 115.414 -0.812 . . . . 0.0 112.829 -178.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.662 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.1 OUTLIER -73.02 -178.0 2.64 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 123.891 0.876 . . . . 0.0 110.034 177.639 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -130.22 86.82 2.44 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 177.636 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.615 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 20.2 tp -89.94 145.49 25.08 Favored 'General case' 0 C--N 1.294 -1.824 0 C-N-CA 119.765 -0.774 . . . . 0.0 109.259 -179.256 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 73.7 t -137.73 134.5 45.8 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.73 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -178.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.541 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 21.0 t -99.99 89.62 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.41 -2.426 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 174.32 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -83.35 114.95 21.78 Favored 'General case' 0 C--N 1.3 -1.562 0 C-N-CA 119.91 -0.716 . . . . 0.0 111.125 -176.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 82.7 mt -99.78 -2.39 35.24 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.69 -177.397 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.6 m -73.68 -2.08 21.7 Favored 'General case' 0 C--O 1.208 -1.13 0 CA-C-O 122.222 1.011 . . . . 0.0 109.191 -179.503 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.2 p -126.21 7.48 7.17 Favored 'General case' 0 N--CA 1.419 -1.985 0 CA-C-N 115.151 -0.931 . . . . 0.0 109.776 179.002 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.473 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 48.6 mm-40 -125.42 -20.23 4.83 Favored 'General case' 0 CA--C 1.508 -0.648 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.9 -174.692 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.5 mt -135.3 137.31 50.23 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 -176.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.644 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 74.8 m-85 -137.68 153.67 49.78 Favored 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 -176.07 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.414 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 90.5 m -132.23 134.91 45.87 Favored 'General case' 0 C--N 1.28 -2.419 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.875 -178.637 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 18.7 p-80 -122.64 131.0 53.61 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.428 -175.486 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 4.2 p-10 -77.83 118.17 19.9 Favored 'General case' 0 N--CA 1.422 -1.83 0 CA-C-O 122.09 0.948 . . . . 0.0 108.963 178.426 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -97.24 -27.1 14.68 Favored 'General case' 0 C--N 1.274 -2.696 0 CA-C-N 114.154 -1.385 . . . . 0.0 110.387 -177.022 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 1.646 ' HD1' ' CD2' ' A' ' 48' ' ' TYR . 37.5 m-85 -148.93 68.43 9.63 Favored Pre-proline 0 N--CA 1.483 1.182 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.469 ' HA ' ' OD2' ' A' ' 54' ' ' ASP . 58.4 Cg_endo -67.85 -11.72 33.01 Favored 'Trans proline' 0 N--CA 1.481 0.766 0 C-N-CA 122.925 2.417 . . . . 0.0 114.281 -171.587 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -114.58 -14.03 12.11 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 121.208 0.528 . . . . 0.0 110.565 -177.474 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.469 ' HB ' HD13 ' A' ' 52' ' ' ILE . 1.3 m -101.87 -29.24 11.96 Favored 'General case' 0 N--CA 1.424 -1.731 0 CA-C-O 122.047 0.927 . . . . 0.0 108.881 -173.28 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.469 HD13 ' HB ' ' A' ' 51' ' ' THR . 3.4 mp -128.56 141.21 47.14 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.168 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 178.403 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 14.5 t -74.52 136.35 42.18 Favored 'General case' 0 N--CA 1.428 -1.563 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 174.071 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.487 ' O ' HG21 ' A' ' 94' ' ' VAL . 51.3 m-20 -95.98 105.82 17.9 Favored 'General case' 0 C--N 1.263 -3.173 0 C-N-CA 118.457 -1.297 . . . . 0.0 108.404 -179.305 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.492 ' CD2' ' HB ' ' A' ' 134' ' ' THR . 15.8 t80 -142.21 139.44 32.02 Favored 'General case' 0 C--N 1.289 -2.052 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.482 -173.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.4 ' CG2' ' HG ' ' A' ' 131' ' ' LEU . 14.9 p -148.56 156.01 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.943 0 O-C-N 123.832 0.708 . . . . 0.0 109.991 -178.44 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.29 135.54 17.94 Favored 'General case' 0 N--CA 1.422 -1.845 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 176.24 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.506 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 32.5 tp -70.6 110.44 5.45 Favored 'General case' 0 N--CA 1.427 -1.579 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 170.553 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -57.6 -56.63 19.41 Favored 'General case' 0 C--O 1.206 -1.227 0 CA-C-N 113.576 -1.647 . . . . 0.0 109.479 -177.58 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 10.5 ptp180 -164.09 156.56 17.25 Favored 'General case' 0 N--CA 1.41 -2.461 0 CA-C-N 114.364 -1.289 . . . . 0.0 108.472 -177.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -140.58 135.83 7.26 Favored Glycine 0 N--CA 1.4 -3.712 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -179.535 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 46.0 m -124.81 147.68 48.59 Favored 'General case' 0 C--N 1.276 -2.591 0 C-N-CA 124.139 0.975 . . . . 0.0 110.473 -175.694 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.489 ' HB3' ' CE2' ' A' ' 84' ' ' PHE . . . -106.81 158.83 16.69 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.533 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 97.1 m-85 -154.61 175.4 13.7 Favored 'General case' 0 C--N 1.341 0.231 0 C-N-CA 124.139 0.975 . . . . 0.0 109.864 -177.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.02 -143.28 45.84 Favored Glycine 0 N--CA 1.446 -0.671 0 O-C-N 123.791 0.682 . . . . 0.0 113.104 176.486 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.36 -13.12 73.59 Favored Glycine 0 C--O 1.202 -1.868 0 C-N-CA 120.962 -0.637 . . . . 0.0 111.742 177.063 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.533 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 94.7 t -70.29 -36.75 68.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 123.414 0.686 . . . . 0.0 112.043 -177.64 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.484 ' HG ' ' CA ' ' A' ' 64' ' ' TYR . 0.2 OUTLIER -90.04 -18.54 25.76 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.58 -1.248 . . . . 0.0 112.374 177.248 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 5.0 t -99.88 -51.13 3.8 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.369 -172.134 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.421 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 67.7 m-20 -96.2 -23.18 16.84 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 -174.683 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 1.661 ' HD2' ' CD1' ' A' ' 71' ' ' PHE . 89.6 m-85 -110.73 156.3 21.24 Favored 'General case' 0 N--CA 1.422 -1.868 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 177.588 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.0 t -165.59 127.89 2.06 Favored 'General case' 0 N--CA 1.411 -2.409 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 176.513 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.29 -111.24 0.27 Allowed Glycine 0 N--CA 1.407 -3.233 0 N-CA-C 111.574 -0.61 . . . . 0.0 111.574 176.462 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -153.63 -179.91 8.23 Favored 'General case' 0 C--N 1.291 -1.941 0 C-N-CA 123.933 0.893 . . . . 0.0 110.366 -173.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 3.2 p -135.8 151.51 29.61 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.242 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.682 ' HG3' ' O ' ' A' ' 80' ' ' SER . 72.3 tttt -130.91 147.53 52.57 Favored 'General case' 0 N--CA 1.423 -1.794 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -178.676 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.406 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 47.5 t80 -148.13 108.67 4.15 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 -177.199 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 13.8 t 51.21 44.62 28.68 Favored 'General case' 0 CA--C 1.553 1.06 0 C-N-CA 123.433 0.693 . . . . 0.0 111.197 175.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 81.22 20.89 63.75 Favored Glycine 0 CA--C 1.525 0.671 0 C-N-CA 120.264 -0.97 . . . . 0.0 113.115 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.682 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 16.3 t -90.53 179.26 5.89 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 106.927 -1.508 . . . . 0.0 106.927 174.649 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 10.9 m -157.47 103.55 1.96 Allowed 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 178.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 0.406 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.6 p90 -147.65 158.75 42.59 Favored Pre-proline 0 C--N 1.308 -1.222 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -172.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -68.78 150.16 73.65 Favored 'Trans proline' 0 C--N 1.356 0.964 0 C-N-CA 122.933 2.422 . . . . 0.0 112.837 -177.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.548 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 47.3 t80 -124.5 134.77 25.83 Favored Pre-proline 0 N--CA 1.431 -1.402 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 179.293 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.548 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 59.3 Cg_endo -71.03 145.61 82.69 Favored 'Cis proline' 0 CA--C 1.554 1.51 0 C-N-CA 123.105 -1.623 . . . . 0.0 111.153 -2.438 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.2 t -68.43 -176.81 0.81 Allowed 'General case' 0 N--CA 1.489 1.52 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.32 -175.398 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 56.1 p -124.89 -47.34 1.8 Allowed 'General case' 0 N--CA 1.436 -1.164 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -172.362 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 10.0 t -105.4 -65.19 1.07 Allowed 'General case' 0 N--CA 1.437 -1.123 0 C-N-CA 120.39 -0.524 . . . . 0.0 111.246 -174.242 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 176.23 -172.98 0.09 Allowed 'General case' 0 C--O 1.247 0.97 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 -175.546 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.506 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 42.4 p -100.9 168.44 9.24 Favored Pre-proline 0 C--N 1.297 -1.708 0 O-C-N 123.429 0.455 . . . . 0.0 111.707 175.326 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . 0.415 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 19.0 Cg_endo -55.78 165.19 3.84 Favored 'Trans proline' 0 CA--C 1.547 1.158 0 C-N-CA 123.232 2.621 . . . . 0.0 111.962 171.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.414 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 1.7 tmm_? -76.68 112.75 13.58 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -176.587 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 76.4 t -126.4 128.33 71.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-O 121.522 0.677 . . . . 0.0 110.15 -176.305 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.487 HG21 ' O ' ' A' ' 54' ' ' ASP . 0.2 OUTLIER -121.71 132.32 71.08 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 CA-C-N 115.038 -0.983 . . . . 0.0 110.776 -177.571 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . 1.627 ' HE2' ' CE1' ' A' ' 95' ' ' TYR . 7.2 m-85 -80.78 101.04 9.09 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.19 -178.084 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 16.7 m120 -96.63 64.31 2.13 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.6 m -142.02 178.1 7.76 Favored 'General case' 0 N--CA 1.434 -1.229 0 O-C-N 121.778 -0.576 . . . . 0.0 110.844 -174.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 6.8 ptp180 -141.22 45.75 1.75 Allowed 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.066 0.46 . . . . 0.0 110.446 -178.678 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.0 t -170.53 177.44 4.0 Favored 'General case' 0 C--O 1.245 0.847 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 -174.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -73.03 98.16 2.48 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 173.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 10.0 tptp -97.1 142.59 24.76 Favored Pre-proline 0 C--N 1.277 -2.587 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -62.91 154.72 64.72 Favored 'Trans proline' 0 C--N 1.324 -0.75 0 C-N-CA 122.428 2.086 . . . . 0.0 112.395 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . 0.479 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 15.4 t90 -95.71 100.94 6.96 Favored Pre-proline 0 C--N 1.306 -1.32 0 N-CA-C 105.102 -2.184 . . . . 0.0 105.102 175.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -74.57 88.63 1.16 Allowed 'Trans proline' 0 N--CA 1.454 -0.837 0 C-N-CA 121.782 1.655 . . . . 0.0 113.341 -170.052 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 96.9 t -138.61 145.12 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.193 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.541 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.65 138.47 19.92 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 177.269 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.479 ' O ' HG22 ' A' ' 36' ' ' VAL . 17.7 mt -102.82 104.3 14.56 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 1.589 ' HD1' ' CD2' ' A' ' 108' ' ' TYR . 9.5 m-85 -81.32 67.33 7.22 Favored 'General case' 0 C--N 1.295 -1.788 0 O-C-N 122.023 -0.423 . . . . 0.0 111.355 179.206 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.615 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.4 mm? -92.84 134.54 34.97 Favored 'General case' 0 C--O 1.208 -1.127 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 176.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.62 148.11 62.33 Favored Pre-proline 0 C--N 1.294 -1.829 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -176.18 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.421 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 28.8 Cg_endo -62.98 121.46 9.35 Favored 'Trans proline' 0 C--O 1.243 0.753 0 C-N-CA 123.235 2.624 . . . . 0.0 112.555 -176.726 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.431 ' O ' HG11 ' A' ' 30' ' ' VAL . 2.4 m -71.86 -116.9 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.186 -2.237 0 CA-C-N 114.225 -1.352 . . . . 0.0 112.715 176.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' SER . . . . . 0.413 ' C ' ' H ' ' A' ' 115' ' ' ALA . 28.9 t -112.54 -37.54 4.9 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 177.191 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 47.9 m -73.42 16.21 0.2 Allowed 'General case' 0 N--CA 1.399 -2.999 0 C-N-CA 125.997 1.719 . . . . 0.0 113.653 -176.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.413 ' H ' ' C ' ' A' ' 113' ' ' SER . . . -102.7 131.69 49.34 Favored 'General case' 0 N--CA 1.411 -2.399 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -176.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.94 129.33 1.62 Allowed Glycine 0 N--CA 1.434 -1.447 0 N-CA-C 110.634 -0.987 . . . . 0.0 110.634 179.377 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.89 -151.29 51.92 Favored Glycine 0 CA--C 1.5 -0.888 0 CA-C-O 119.085 -0.842 . . . . 0.0 111.53 -176.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.9 p -54.86 104.6 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 122.233 1.016 . . . . 0.0 111.914 -177.518 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.85 -31.2 9.4 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 115.043 -0.981 . . . . 0.0 111.461 -177.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 69.7 mt -124.4 140.86 46.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 177.186 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 2.8 mmpt? -117.67 139.44 51.01 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-O 121.001 0.429 . . . . 0.0 111.073 178.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.7 131.67 44.95 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.406 -0.815 . . . . 0.0 110.769 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 87.31 -7.9 78.97 Favored Glycine 0 C--N 1.309 -0.931 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.079 -179.58 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 25.3 m -90.69 148.59 22.5 Favored 'General case' 0 N--CA 1.425 -1.716 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 24.9 tp -73.76 133.0 43.22 Favored 'General case' 0 N--CA 1.436 -1.132 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.229 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.476 ' HB ' HG23 ' A' ' 67' ' ' VAL . 37.9 pt -118.42 -24.44 3.25 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 C-N-CA 120.432 -0.507 . . . . 0.0 112.352 -179.519 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . 0.437 ' HB1' ' HB ' ' A' ' 148' ' ' ILE . . . -163.3 164.33 24.92 Favored 'General case' 0 N--CA 1.439 -0.977 0 CA-C-O 120.538 0.209 . . . . 0.0 110.614 -178.633 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 53.5 t -140.74 114.36 5.36 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 178.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 54.3 mt -117.55 139.01 51.52 Favored 'General case' 0 C--N 1.287 -2.12 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.43 ' O ' HD13 ' A' ' 58' ' ' LEU . 5.0 mp -117.33 122.29 69.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 C-N-CA 119.314 -0.954 . . . . 0.0 109.918 177.372 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.496 ' O ' HD21 ' A' ' 131' ' ' LEU . 0.0 OUTLIER -90.44 132.73 35.47 Favored 'General case' 0 C--N 1.275 -2.649 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 177.439 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 17.7 tpt85 -106.85 109.54 21.47 Favored 'General case' 0 C--N 1.274 -2.709 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.149 -176.05 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -88.34 132.67 34.33 Favored 'General case' 0 CA--C 1.484 -1.574 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 175.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.492 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 11.7 m -136.41 133.57 36.83 Favored 'General case' 0 C--N 1.273 -2.724 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 177.636 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 16.3 p30 . . . . . 0 C--N 1.31 -1.141 0 CA-C-O 121.404 0.621 . . . . 0.0 111.634 -179.185 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 . . . . . 0 N--CA 1.44 -0.952 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . 0.402 HE21 HG22 ' A' ' 130' ' ' ILE . 16.6 pt20 -119.92 143.72 47.82 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 178.42 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 9.6 m-30 -112.48 134.35 54.06 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -176.513 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 47.4 t -91.51 131.09 39.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 CA-C-O 121.155 0.502 . . . . 0.0 110.08 -179.096 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . 0.415 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 65.3 m95 -120.23 97.96 5.84 Favored 'General case' 0 C--N 1.284 -2.274 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -179.217 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 36.9 m-80 -80.35 114.1 19.01 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 106.992 -1.485 . . . . 0.0 106.992 178.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . 0.437 ' HB ' ' HB1' ' A' ' 127' ' ' ALA . 22.5 mm -89.3 122.53 40.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 -177.784 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 1.662 ' HD2' ' CD1' ' A' ' 149' ' ' TYR . 94.6 m-85 -120.31 152.75 37.39 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 123.428 0.691 . . . . 0.0 109.605 178.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.73 132.92 34.82 Favored 'General case' 0 N--CA 1.418 -2.03 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 177.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -90.1 -15.45 31.66 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 -178.19 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -149.27 144.52 26.56 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 114.049 -1.432 . . . . 0.0 109.431 -175.665 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -85.76 148.08 26.02 Favored 'General case' 0 C--N 1.315 -0.906 0 O-C-N 124.022 0.826 . . . . 0.0 109.292 -178.145 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.434 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 2.2 m -126.56 148.34 31.31 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 C-N-CA 120.256 -0.578 . . . . 0.0 110.557 -176.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.5 t -120.14 140.6 43.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.032 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 -179.144 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.502 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 79.4 t -101.57 101.63 18.46 Favored Pre-proline 0 C--N 1.297 -1.676 0 C-N-CA 123.871 0.868 . . . . 0.0 109.706 178.233 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -68.28 -25.85 36.17 Favored 'Trans proline' 0 CA--C 1.518 -0.304 0 C-N-CA 122.315 2.01 . . . . 0.0 112.378 178.661 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 5.8 t . . . . . 0 CA--C 1.559 1.31 0 O-C-N 124.646 1.216 . . . . 0.0 113.352 176.506 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.502 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.44 -0.934 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.421 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 68.4 m -142.41 159.0 43.09 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 120.274 -0.57 . . . . 0.0 110.912 -174.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.412 ' HD2' ' O ' ' A' ' 5' ' ' THR . 0.0 OUTLIER -146.12 156.87 43.74 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-O 121.14 0.495 . . . . 0.0 109.978 -177.469 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.412 ' O ' ' HD2' ' A' ' 4' ' ' LYS . 41.1 p -91.83 176.08 6.65 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.613 -179.178 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -85.23 -5.08 59.34 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 114.866 -1.061 . . . . 0.0 110.838 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.96 -34.49 8.92 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.877 -179.689 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 140.06 7.27 0.99 Allowed Glycine 0 C--N 1.316 -0.529 0 C-N-CA 118.796 -1.668 . . . . 0.0 115.236 172.289 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.7 m -87.37 102.3 14.39 Favored 'General case' 0 C--N 1.296 -1.755 0 O-C-N 121.892 -0.77 . . . . 0.0 109.039 177.164 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.57 122.12 37.98 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 115.396 -0.82 . . . . 0.0 108.84 175.404 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.502 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 63.7 mt -102.01 116.15 63.64 Favored Pre-proline 0 C--N 1.298 -1.649 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.187 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.25 173.8 12.11 Favored 'Trans proline' 0 C--O 1.247 0.954 0 C-N-CA 122.814 2.343 . . . . 0.0 111.469 178.069 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 58.8 mt -66.64 129.59 31.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 178.215 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 140.14 -6.79 2.85 Favored Glycine 0 C--N 1.303 -1.252 0 N-CA-C 111.358 -0.697 . . . . 0.0 111.358 -178.705 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 96.84 156.26 30.76 Favored Glycine 0 N--CA 1.438 -1.199 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -179.108 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 170.33 -175.46 44.25 Favored Glycine 0 N--CA 1.428 -1.886 0 C-N-CA 119.822 -1.18 . . . . 0.0 111.142 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.6 m -144.96 148.88 34.3 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 178.631 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.98 165.4 26.08 Favored 'General case' 0 CA--C 1.48 -1.727 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -114.85 110.09 19.14 Favored 'General case' 0 C--N 1.278 -2.543 0 CA-C-N 114.098 -1.41 . . . . 0.0 107.482 177.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.405 HG23 ' HA ' ' A' ' 148' ' ' ILE . 1.3 m -97.65 142.08 14.91 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.321 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.694 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.2 m-85 -124.07 124.56 42.79 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 121.039 0.447 . . . . 0.0 110.989 -178.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 2.9 p -138.43 134.85 43.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.825 -178.067 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -94.33 128.06 40.6 Favored 'General case' 0 C--N 1.294 -1.811 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.867 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -104.82 160.51 14.94 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.097 -0.956 . . . . 0.0 108.581 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.75 123.33 57.46 Favored Pre-proline 0 C--O 1.211 -0.949 0 O-C-N 124.258 0.974 . . . . 0.0 109.241 176.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.474 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 74.1 Cg_endo -76.57 -0.34 10.35 Favored 'Trans proline' 0 CA--C 1.536 0.592 0 C-N-CA 122.5 2.133 . . . . 0.0 113.567 -175.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.5 t -128.85 109.77 19.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 179.57 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 5.2 t -145.09 104.69 0.71 Allowed 'Isoleucine or valine' 0 C--O 1.198 -1.639 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -178.078 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.481 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -94.36 154.84 17.28 Favored 'General case' 0 C--N 1.275 -2.668 0 C-N-CA 123.212 0.605 . . . . 0.0 111.61 -179.902 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.401 HG11 ' O ' ' A' ' 112' ' ' VAL . 42.5 t -44.7 116.53 0.23 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.361 0 C-N-CA 124.103 0.961 . . . . 0.0 111.402 175.486 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.72 0.2 45.84 Favored Glycine 0 CA--C 1.521 0.458 0 CA-C-N 115.06 -0.973 . . . . 0.0 113.186 179.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.481 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -72.78 -177.63 2.41 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 123.779 0.831 . . . . 0.0 111.768 176.702 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -128.84 87.39 2.57 Favored 'General case' 0 CA--C 1.49 -1.337 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 177.307 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.629 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 21.6 tp -96.24 135.23 38.33 Favored 'General case' 0 N--CA 1.423 -1.824 0 C-N-CA 119.23 -0.988 . . . . 0.0 109.64 179.256 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.6 p -141.64 132.49 26.31 Favored 'Isoleucine or valine' 0 N--CA 1.387 -3.599 0 CA-C-O 122.208 1.004 . . . . 0.0 112.859 -178.077 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.608 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 41.9 t -91.74 89.7 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.661 0 CA-C-N 113.507 -1.678 . . . . 0.0 107.664 178.364 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -77.78 106.91 9.91 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 88.3 mt -93.93 -1.22 54.99 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.701 -178.495 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.621 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 0.7 OUTLIER -68.99 -10.57 58.15 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-O 122.396 1.093 . . . . 0.0 109.741 -178.638 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.6 p -121.47 5.52 10.13 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 115.083 -0.962 . . . . 0.0 110.748 179.054 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 49.2 mm-40 -120.0 -21.98 6.89 Favored 'General case' 0 CA--C 1.511 -0.555 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.614 -174.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 29.9 mt -135.06 138.95 48.12 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.011 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -178.09 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -136.96 147.87 46.6 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 -177.052 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.421 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 88.9 m -123.55 136.55 54.6 Favored 'General case' 0 C--N 1.29 -1.981 0 CA-C-O 120.864 0.364 . . . . 0.0 110.991 178.8 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 16.4 p80 -130.91 162.6 29.3 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.423 0.63 . . . . 0.0 110.46 -175.424 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -112.56 121.17 44.03 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 121.828 0.823 . . . . 0.0 111.993 177.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 22.5 p-10 -96.98 -13.32 22.41 Favored 'General case' 0 N--CA 1.427 -1.583 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.588 178.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -147.3 69.24 11.53 Favored Pre-proline 0 C--O 1.22 -0.481 0 CA-C-N 115.503 -0.771 . . . . 0.0 108.935 175.464 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -68.52 -12.82 35.86 Favored 'Trans proline' 0 N--CA 1.483 0.895 0 C-N-CA 122.091 1.861 . . . . 0.0 112.903 -177.176 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -101.44 -25.03 14.07 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-O 121.353 0.597 . . . . 0.0 110.589 -176.513 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.488 ' HB ' HD13 ' A' ' 52' ' ' ILE . 1.3 m -102.09 -26.81 13.24 Favored 'General case' 0 N--CA 1.42 -1.97 0 CA-C-O 121.69 0.757 . . . . 0.0 109.289 -172.387 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.523 HG21 ' CB ' ' A' ' 135' ' ' ASN . 3.2 mp -129.31 127.73 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.263 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 -178.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.1 t -73.63 145.7 45.16 Favored 'General case' 0 C--O 1.256 1.399 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -85.3 107.62 17.41 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -176.629 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 1.65 ' HE2' ' CE1' ' A' ' 55' ' ' TYR . 17.3 t80 -149.35 138.83 21.61 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -177.555 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.485 HG11 ' HH ' ' A' ' 77' ' ' TYR . 13.4 p -150.64 149.97 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.564 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.25 -178.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -150.3 131.02 14.07 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 172.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.526 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 53.4 tp -66.5 110.82 3.3 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 171.858 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.454 ' NE2' ' HD3' ' A' ' 132' ' ' ARG . 3.0 tp-100 -55.48 -50.86 68.79 Favored 'General case' 0 C--N 1.314 -0.96 0 C-N-CA 126.123 1.769 . . . . 0.0 111.564 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -170.44 155.77 5.24 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -177.418 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -132.32 136.07 8.52 Favored Glycine 1 N--CA 1.395 -4.077 0 N-CA-C 107.986 -2.046 . . . . 0.0 107.986 178.413 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 47.8 m -124.17 147.91 47.64 Favored 'General case' 0 C--N 1.271 -2.809 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -176.303 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.53 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -115.46 156.09 26.28 Favored 'General case' 0 C--N 1.306 -1.315 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 -179.339 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 1.655 ' HD2' ' CD1' ' A' ' 64' ' ' TYR . 92.8 m-85 -155.13 -178.95 7.61 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 123.832 0.853 . . . . 0.0 109.045 -177.351 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 62.46 -136.75 44.87 Favored Glycine 0 C--O 1.222 -0.612 0 N-CA-C 111.723 -0.551 . . . . 0.0 111.723 179.344 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -88.38 -3.91 77.83 Favored Glycine 0 C--O 1.206 -1.607 0 C-N-CA 120.537 -0.839 . . . . 0.0 111.133 176.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.525 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 76.1 t -71.35 -36.31 60.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 C-N-CA 123.876 0.87 . . . . 0.0 111.576 -176.11 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.53 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -85.31 -25.73 27.0 Favored 'General case' 0 C--N 1.297 -1.681 0 C-N-CA 119.915 -0.714 . . . . 0.0 112.486 178.451 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 21.0 m -101.04 -52.83 3.18 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 -173.13 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.434 ' O ' HG23 ' A' ' 112' ' ' VAL . 53.9 m-20 -88.52 -28.41 20.81 Favored 'General case' 0 CA--C 1.488 -1.426 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 -175.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 1.643 ' HD1' ' CD2' ' A' ' 71' ' ' PHE . 90.2 m-85 -104.55 155.29 18.96 Favored 'General case' 0 N--CA 1.41 -2.463 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 175.465 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 15.5 t -167.03 120.34 0.98 Allowed 'General case' 0 N--CA 1.417 -2.106 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 177.013 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.458 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -154.81 -112.66 0.45 Allowed Glycine 0 N--CA 1.402 -3.63 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 175.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.415 HG23 ' HA ' ' A' ' 83' ' ' PRO . 8.3 p -151.69 -179.93 7.85 Favored 'General case' 0 C--N 1.293 -1.862 0 CA-C-O 121.157 0.503 . . . . 0.0 110.662 -173.796 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.43 ' HB ' ' HB2' ' A' ' 84' ' ' PHE . 2.5 p -132.27 146.03 33.71 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.156 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 177.868 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.643 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.1 tttt -123.92 142.85 50.77 Favored 'General case' 0 N--CA 1.409 -2.514 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 178.621 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.485 ' HH ' HG11 ' A' ' 56' ' ' VAL . 59.9 t80 -145.49 112.57 6.07 Favored 'General case' 0 C--N 1.286 -2.159 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 -179.124 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.3 m 55.28 37.37 28.79 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 113.678 0.992 . . . . 0.0 113.678 176.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.44 5.84 81.68 Favored Glycine 0 N--CA 1.432 -1.587 0 C-N-CA 120.422 -0.894 . . . . 0.0 112.58 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.643 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 11.0 t -80.34 174.59 11.45 Favored 'General case' 0 C--N 1.317 -0.844 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.532 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 9.3 p -154.13 100.43 2.32 Favored 'General case' 0 C--N 1.284 -2.257 0 CA-C-O 120.98 0.419 . . . . 0.0 110.182 -176.624 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 2.9 p90 -147.07 159.62 42.25 Favored Pre-proline 0 C--N 1.297 -1.701 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -173.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . 0.415 ' HA ' HG23 ' A' ' 74' ' ' THR . 44.9 Cg_endo -67.53 149.1 79.76 Favored 'Trans proline' 0 C--N 1.354 0.845 0 C-N-CA 123.161 2.574 . . . . 0.0 113.228 -177.142 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.593 ' CD2' HD22 ' A' ' 109' ' ' LEU . 64.5 t80 -124.99 134.7 25.94 Favored Pre-proline 0 C--N 1.315 -0.903 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.128 -179.677 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.534 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 73.9 Cg_endo -72.85 146.39 86.73 Favored 'Cis proline' 0 C--O 1.244 0.788 0 C-N-CA 122.91 -1.704 . . . . 0.0 110.543 -1.487 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.2 t -65.54 -176.76 0.37 Allowed 'General case' 0 CA--C 1.551 0.987 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.394 -175.304 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.2 p -129.03 2.65 5.27 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-O 121.368 0.604 . . . . 0.0 110.709 -173.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.6 t -161.75 -125.03 0.02 OUTLIER 'General case' 0 N--CA 1.396 -3.146 0 N-CA-C 105.282 -2.118 . . . . 0.0 105.282 179.025 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -129.7 -170.35 2.28 Favored 'General case' 0 C--N 1.291 -1.963 0 N-CA-C 110.475 -0.194 . . . . 0.0 110.475 -176.244 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 44.1 p -95.25 166.8 14.05 Favored Pre-proline 0 C--N 1.302 -1.462 0 CA-C-N 116.18 -0.463 . . . . 0.0 112.205 178.581 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -62.29 165.09 15.76 Favored 'Trans proline' 0 CA--C 1.544 1.001 0 C-N-CA 123.02 2.48 . . . . 0.0 110.879 172.037 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.402 ' C ' ' HD2' ' A' ' 92' ' ' ARG . 4.9 tmm_? -71.3 120.7 17.25 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.163 0.506 . . . . 0.0 109.838 -178.707 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 76.0 t -128.32 119.55 50.88 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.238 -178.104 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 59.6 t -94.64 141.11 15.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 176.349 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . 0.533 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 1.3 m-85 -91.38 134.78 34.32 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 175.884 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -115.33 86.16 2.41 Favored 'General case' 0 C--N 1.276 -2.609 0 N-CA-C 106.29 -1.744 . . . . 0.0 106.29 177.616 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' SER . . . . . 0.425 ' HB3' ' CG ' ' A' ' 101' ' ' LYS . 5.0 p -142.34 154.58 44.78 Favored 'General case' 0 N--CA 1.413 -2.286 0 CA-C-N 115.161 -0.927 . . . . 0.0 112.718 -173.034 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 10.3 ptp180 -135.0 19.37 3.46 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 171.121 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.0 t -164.09 -175.4 3.99 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 105.981 -1.859 . . . . 0.0 105.981 -178.592 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -76.77 122.55 24.92 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.88 0.848 . . . . 0.0 110.666 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . 0.425 ' CG ' ' HB3' ' A' ' 97' ' ' SER . 30.6 mmtp -109.68 139.51 21.29 Favored Pre-proline 0 C--N 1.293 -1.858 0 CA-C-N 115.032 -0.985 . . . . 0.0 110.002 177.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.621 ' HB3' ' O ' ' A' ' 39' ' ' SER . 52.3 Cg_exo -55.21 144.36 71.0 Favored 'Trans proline' 0 CA--C 1.505 -0.931 0 C-N-CA 123.726 2.951 . . . . 0.0 111.722 176.447 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . 0.533 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 9.1 t90 -91.63 103.63 8.27 Favored Pre-proline 0 C--N 1.294 -1.839 0 N-CA-C 106.044 -1.836 . . . . 0.0 106.044 178.821 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -76.58 88.63 1.35 Allowed 'Trans proline' 0 N--CA 1.446 -1.281 0 C-N-CA 121.624 1.549 . . . . 0.0 111.644 -172.206 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.4 HG21 ' CD2' ' A' ' 77' ' ' TYR . 85.0 t -138.77 142.19 35.05 Favored 'Isoleucine or valine' 0 CA--C 1.485 -1.534 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 179.131 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.608 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.97 133.91 18.05 Favored 'General case' 0 N--CA 1.411 -2.404 0 CA-C-O 120.968 0.413 . . . . 0.0 110.681 179.177 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.46 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 20.0 mt -100.96 99.93 10.47 Favored 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 179.099 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 1.658 ' HD2' ' CD1' ' A' ' 108' ' ' TYR . 76.7 m-85 -80.74 78.81 7.48 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 177.523 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.629 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.3 mm? -102.96 118.99 38.04 Favored 'General case' 0 CA--C 1.49 -1.331 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 177.375 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.8 145.83 46.49 Favored Pre-proline 0 N--CA 1.407 -2.577 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.079 -175.146 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.421 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 36.7 Cg_endo -63.1 119.51 6.61 Favored 'Trans proline' 0 C--O 1.248 1.018 0 C-N-CA 123.347 2.698 . . . . 0.0 112.265 -177.331 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 70' ' ' ASN . 3.2 m -67.62 -118.09 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.182 -2.464 0 CA-C-N 114.023 -1.444 . . . . 0.0 112.59 175.72 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.4 m -112.73 -38.08 4.69 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-O 122.334 1.064 . . . . 0.0 108.141 179.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 64.4 m -82.11 31.77 0.38 Allowed 'General case' 0 N--CA 1.394 -3.271 0 CA-C-N 113.356 -1.747 . . . . 0.0 113.151 -177.692 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -108.63 139.05 43.96 Favored 'General case' 0 C--N 1.288 -2.078 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -174.83 139.04 4.64 Favored Glycine 0 N--CA 1.44 -1.068 0 C-N-CA 119.951 -1.119 . . . . 0.0 112.193 179.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 57.61 -149.7 32.3 Favored Glycine 0 CA--C 1.491 -1.453 0 O-C-N 124.783 0.931 . . . . 0.0 112.542 -178.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.407 ' CG2' ' HE3' ' A' ' 121' ' ' LYS . 7.3 p -57.3 101.7 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 CA-C-O 122.507 1.146 . . . . 0.0 111.607 -178.628 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -100.61 -27.06 13.59 Favored 'General case' 0 C--N 1.295 -1.773 0 CA-C-N 114.826 -1.079 . . . . 0.0 110.679 -177.675 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.425 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 58.7 mt -133.26 136.98 54.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 -178.866 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.446 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.4 mmpt? -112.73 142.64 45.12 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 121.028 0.442 . . . . 0.0 110.706 176.35 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.23 132.02 45.83 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.169 179.243 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 91.63 -10.42 74.72 Favored Glycine 0 N--CA 1.435 -1.405 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.584 -179.363 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 40.2 t -86.18 143.11 28.16 Favored 'General case' 0 N--CA 1.43 -1.43 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 -178.074 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -71.2 122.19 19.73 Favored 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 177.11 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.487 ' HB ' HG23 ' A' ' 67' ' ' VAL . 33.7 pt -109.24 -27.78 2.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-N 116.041 -0.527 . . . . 0.0 112.303 -178.554 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -160.3 166.78 28.86 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -177.461 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 75.7 t -141.87 113.43 3.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 179.737 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 67.5 mt -115.33 134.67 54.9 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.212 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.509 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.4 mp -117.69 128.17 74.93 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.818 0 C-N-CA 119.196 -1.002 . . . . 0.0 109.748 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.45 ' O ' HD21 ' A' ' 131' ' ' LEU . 0.2 OUTLIER -101.24 131.08 47.42 Favored 'General case' 0 C--N 1.276 -2.623 0 C-N-CA 123.989 0.916 . . . . 0.0 111.443 -176.481 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . 0.454 ' HD3' ' NE2' ' A' ' 59' ' ' GLN . 26.9 mmm180 -87.41 128.09 35.21 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 123.529 0.731 . . . . 0.0 110.826 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.467 ' HA ' ' NE2' ' A' ' 133' ' ' GLN . 13.1 mm-40 -101.36 122.24 43.37 Favored 'General case' 0 N--CA 1.412 -2.356 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 168.05 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.426 ' HB ' ' CE2' ' A' ' 55' ' ' TYR . 23.4 m -140.28 129.49 23.73 Favored 'General case' 0 C--N 1.279 -2.468 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.382 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.523 ' CB ' HG21 ' A' ' 52' ' ' ILE . 28.0 p30 . . . . . 0 C--N 1.281 -2.387 0 CA-C-O 121.221 0.534 . . . . 0.0 110.539 -175.582 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . 1.604 ' HD1' ' CD2' ' A' ' 142' ' ' PHE . 84.7 m-85 . . . . . 0 CA--C 1.51 -0.577 0 CA-C-O 121.207 0.527 . . . . 0.0 110.897 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.3 pt20 -137.38 149.82 47.23 Favored 'General case' 0 N--CA 1.418 -2.06 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 177.253 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 10.0 m-30 -111.34 132.46 54.39 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 -176.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 50.6 t -92.82 131.69 39.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.024 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . 0.436 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.5 m95 -119.55 100.81 7.51 Favored 'General case' 0 C--N 1.277 -2.577 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 46.4 m-80 -80.69 113.86 19.18 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 178.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . 0.405 ' HA ' HG23 ' A' ' 20' ' ' VAL . 22.7 mm -87.35 122.51 39.25 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.936 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 -178.587 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 1.613 ' HE1' ' CE2' ' A' ' 149' ' ' TYR . 95.5 m-85 -118.16 148.54 42.25 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.617 178.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -80.49 129.52 34.57 Favored 'General case' 0 N--CA 1.409 -2.502 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 176.51 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 36.1 t-20 -87.75 -16.51 34.01 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -178.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -147.49 144.85 28.87 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 114.103 -1.408 . . . . 0.0 108.795 -174.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 21.7 p-10 -82.96 144.17 30.18 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 124.232 0.957 . . . . 0.0 111.398 -178.119 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.474 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.2 t -120.42 138.71 50.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.634 -175.191 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 4.0 t -119.58 137.92 51.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.638 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 71.9 t -102.17 103.34 29.71 Favored Pre-proline 0 C--N 1.29 -1.979 0 C-N-CA 123.479 0.711 . . . . 0.0 109.847 178.634 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.468 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 56.1 Cg_endo -71.68 -16.95 29.95 Favored 'Trans proline' 0 C--O 1.226 -0.093 0 C-N-CA 122.187 1.925 . . . . 0.0 111.781 178.039 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.254 3.9 t . . . . . 0 C--N 1.351 0.666 0 C-N-CA 125.082 1.353 . . . . 0.0 113.84 175.411 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.495 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 CA--C 1.485 -1.554 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.516 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 12.5 m -128.65 159.2 36.35 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 109.03 -0.729 . . . . 0.0 109.03 -176.54 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.413 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -147.56 159.57 43.6 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 120.858 0.361 . . . . 0.0 110.421 -173.961 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.651 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 71.8 p -97.31 177.26 5.61 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 121.523 0.678 . . . . 0.0 110.553 -178.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -83.03 -17.95 41.48 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 114.869 -1.06 . . . . 0.0 109.655 179.06 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.651 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 1.3 p-10 -92.26 -17.71 24.41 Favored 'General case' 0 N--CA 1.43 -1.446 0 CA-C-N 114.739 -1.119 . . . . 0.0 111.795 -177.65 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.05 29.22 2.43 Favored Glycine 0 CA--C 1.484 -1.885 0 C-N-CA 119.925 -1.131 . . . . 0.0 113.971 166.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.9 m -107.64 99.51 8.99 Favored 'General case' 0 N--CA 1.415 -2.216 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.054 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.07 116.36 28.74 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.584 177.513 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.495 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 64.0 mt -84.73 122.77 74.69 Favored Pre-proline 0 C--N 1.301 -1.528 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.712 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -75.33 170.95 19.22 Favored 'Trans proline' 0 C--O 1.246 0.886 0 C-N-CA 122.933 2.422 . . . . 0.0 111.995 -179.12 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 34.4 mt -73.37 118.82 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.126 0.488 . . . . 0.0 111.002 -176.491 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 133.9 38.4 0.21 Allowed Glycine 0 C--N 1.301 -1.386 0 CA-C-N 115.238 -0.892 . . . . 0.0 111.334 177.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 72.02 176.3 26.71 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.542 -176.415 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.14 -177.94 28.83 Favored Glycine 0 C--N 1.296 -1.672 0 C-N-CA 120.103 -1.046 . . . . 0.0 111.219 176.624 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.445 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 52.5 p -141.03 150.31 42.84 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -139.29 165.03 28.27 Favored 'General case' 0 CA--C 1.474 -1.968 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -109.39 123.44 49.33 Favored 'General case' 0 C--N 1.262 -3.229 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 175.112 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.428 HG23 ' HA ' ' A' ' 148' ' ' ILE . 1.2 m -105.31 145.09 13.98 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.608 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.336 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -124.75 112.74 17.07 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-O 121.286 0.565 . . . . 0.0 110.764 -178.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.458 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -119.36 132.31 69.53 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.194 0 CA-C-N 115.126 -0.943 . . . . 0.0 111.627 -174.783 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -92.31 127.16 37.69 Favored 'General case' 0 C--N 1.288 -2.075 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.08 178.284 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -110.51 160.53 16.55 Favored 'General case' 0 C--N 1.288 -2.073 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.145 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -61.0 122.91 72.76 Favored Pre-proline 0 C--N 1.317 -0.808 0 O-C-N 124.107 0.879 . . . . 0.0 109.125 176.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.466 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 74.3 Cg_endo -74.65 4.31 4.67 Favored 'Trans proline' 0 C--O 1.237 0.462 0 C-N-CA 122.785 2.323 . . . . 0.0 113.088 -177.468 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.6 t -128.08 112.29 26.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 107.097 -1.445 . . . . 0.0 107.097 178.555 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.8 t -145.43 101.31 0.56 Allowed 'Isoleucine or valine' 0 C--O 1.181 -2.549 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 -178.219 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.442 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.7 OUTLIER -92.38 150.55 20.75 Favored 'General case' 0 C--N 1.267 -2.987 0 O-C-N 122.16 -0.338 . . . . 0.0 111.214 179.416 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.497 HG23 ' O ' ' A' ' 112' ' ' VAL . 46.8 t -44.72 119.14 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 123.63 0.772 . . . . 0.0 111.363 175.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.12 2.5 54.61 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.482 -0.781 . . . . 0.0 112.743 -179.264 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.442 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -73.83 -178.07 3.07 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 123.076 0.55 . . . . 0.0 111.448 175.331 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -132.91 91.48 2.9 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 176.46 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.658 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.7 tp -92.26 146.44 23.71 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -179.177 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 48.5 t -133.2 129.92 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.838 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 -178.183 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.566 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 51.6 t -99.93 88.82 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.41 -2.446 0 N-CA-C 105.642 -1.984 . . . . 0.0 105.642 172.499 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -85.25 117.49 24.22 Favored 'General case' 0 CA--C 1.484 -1.561 0 C-N-CA 119.949 -0.7 . . . . 0.0 110.382 -176.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 82.4 mt -98.88 -1.84 39.15 Favored 'General case' 0 C--N 1.296 -1.744 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.365 -177.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.463 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 1.3 m -75.64 0.31 18.01 Favored 'General case' 0 CA--C 1.549 0.93 0 CA-C-O 122.394 1.093 . . . . 0.0 108.959 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.0 p -127.33 6.53 6.38 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 114.718 -1.128 . . . . 0.0 110.229 177.164 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.458 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 46.6 mm-40 -125.28 -22.46 4.36 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-O 121.082 0.467 . . . . 0.0 110.649 -175.161 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 36.6 mt -135.07 141.29 43.31 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 108.188 -1.042 . . . . 0.0 108.188 -175.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.413 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 41.4 m-85 -142.79 158.74 43.33 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 -177.5 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.516 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 17.0 t -138.66 147.25 42.62 Favored 'General case' 0 C--N 1.289 -2.029 0 C-N-CA 120.377 -0.529 . . . . 0.0 109.67 175.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . 0.438 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 7.3 p-80 -119.96 130.05 54.59 Favored 'General case' 0 C--O 1.256 1.408 0 CA-C-O 122.323 1.059 . . . . 0.0 111.472 -178.435 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 22.3 p-10 -91.24 89.84 7.5 Favored 'General case' 0 C--N 1.278 -2.511 0 CA-C-O 122.968 1.366 . . . . 0.0 109.913 178.044 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -71.18 -24.79 62.31 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 113.875 -1.511 . . . . 0.0 111.377 -177.223 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 1.646 ' HE2' ' CE1' ' A' ' 48' ' ' TYR . 43.3 m-85 -126.06 79.37 69.44 Favored Pre-proline 0 N--CA 1.479 0.979 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 178.007 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -85.56 -2.8 9.2 Favored 'Trans proline' 0 C--N 1.321 -0.892 0 C-N-CA 122.0 1.8 . . . . 0.0 113.528 -175.098 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -111.76 -23.76 10.42 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.068 -179.392 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.422 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.0 OUTLIER -99.42 -30.63 12.08 Favored 'General case' 0 C--N 1.292 -1.898 0 CA-C-O 121.837 0.827 . . . . 0.0 109.987 -175.329 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.56 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.5 mp -118.6 138.66 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.616 0 CA-C-N 114.898 -1.046 . . . . 0.0 108.308 -179.456 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.7 t -78.75 134.05 37.07 Favored 'General case' 0 N--CA 1.417 -2.1 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 174.344 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.488 ' O ' HG21 ' A' ' 94' ' ' VAL . 7.6 m-20 -80.14 107.17 12.71 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 -172.333 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 49.9 t80 -142.85 133.44 25.09 Favored 'General case' 0 C--N 1.284 -2.271 0 CA-C-N 116.331 -0.395 . . . . 0.0 109.999 -172.254 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.455 HG13 ' OH ' ' A' ' 77' ' ' TYR . 42.3 t -141.73 134.14 28.41 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 C-N-CA 123.374 0.67 . . . . 0.0 109.635 -178.449 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -143.81 115.48 8.17 Favored 'General case' 0 N--CA 1.434 -1.226 0 O-C-N 123.387 0.43 . . . . 0.0 111.335 177.555 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.526 HD13 ' O ' ' A' ' 130' ' ' ILE . 55.5 tp -54.57 110.78 0.68 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.584 0.706 . . . . 0.0 110.169 171.085 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.3 tp-100 -58.85 -51.79 68.49 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 126.292 1.837 . . . . 0.0 111.828 179.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 6.9 ptp180 -169.73 157.35 6.89 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -176.275 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -137.38 136.56 8.33 Favored Glycine 0 N--CA 1.415 -2.756 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 -179.462 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 70.3 m -126.71 146.22 50.3 Favored 'General case' 0 C--N 1.283 -2.324 0 C-N-CA 123.093 0.557 . . . . 0.0 110.69 -175.275 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.492 ' HB3' ' CE2' ' A' ' 84' ' ' PHE . . . -109.96 156.79 20.0 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 -179.189 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.511 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . 90.8 m-85 -155.9 -179.47 8.16 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 123.963 0.905 . . . . 0.0 109.075 -178.192 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.01 -139.22 48.98 Favored Glycine 0 N--CA 1.45 -0.396 0 O-C-N 123.621 0.576 . . . . 0.0 113.328 177.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.6 -9.05 87.37 Favored Glycine 0 C--O 1.201 -1.922 0 C-N-CA 120.329 -0.938 . . . . 0.0 111.379 178.166 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.504 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 87.5 t -70.81 -42.7 77.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 C-N-CA 123.137 0.575 . . . . 0.0 111.44 -176.583 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.511 ' HG ' ' CA ' ' A' ' 64' ' ' TYR . 0.3 OUTLIER -83.4 -21.61 32.97 Favored 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.4 -0.92 . . . . 0.0 112.518 -179.649 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 21.0 m -101.05 -47.8 4.64 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 114.041 1.126 . . . . 0.0 114.041 -174.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 47.5 m-20 -96.71 -20.63 18.11 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 -175.039 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 0.538 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 92.0 m-85 -110.78 157.09 20.18 Favored 'General case' 0 N--CA 1.424 -1.75 0 C-N-CA 120.032 -0.667 . . . . 0.0 110.418 178.053 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.8 t -160.95 123.09 3.09 Favored 'General case' 0 N--CA 1.422 -1.853 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 177.097 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.532 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -158.48 -106.97 0.23 Allowed Glycine 0 N--CA 1.412 -2.93 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 177.456 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -165.2 -179.4 5.6 Favored 'General case' 0 C--N 1.313 -0.998 0 C-N-CA 124.525 1.13 . . . . 0.0 110.358 -175.389 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.6 p -131.93 148.3 32.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 C-N-CA 123.626 0.77 . . . . 0.0 109.301 177.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.61 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.3 tttt -126.12 143.27 51.19 Favored 'General case' 0 N--CA 1.426 -1.638 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.455 ' OH ' HG13 ' A' ' 56' ' ' VAL . 67.5 t80 -144.31 110.12 5.32 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.258 -177.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 25.3 t 51.24 40.71 26.74 Favored 'General case' 0 CA--C 1.551 0.983 0 C-N-CA 123.584 0.754 . . . . 0.0 111.526 177.576 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.83 14.01 61.7 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.333 -0.937 . . . . 0.0 113.811 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.61 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 13.0 t -86.48 -178.9 6.53 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 175.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 26.1 p -159.48 103.78 1.6 Allowed 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.513 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 0.488 ' HH ' HD21 ' A' ' 58' ' ' LEU . 2.9 p90 -149.53 160.13 34.93 Favored Pre-proline 0 C--N 1.303 -1.428 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 -173.057 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 42.5 Cg_endo -67.25 146.92 77.46 Favored 'Trans proline' 0 C--N 1.358 1.053 0 C-N-CA 122.837 2.358 . . . . 0.0 112.887 -177.071 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.549 ' CD2' HD22 ' A' ' 109' ' ' LEU . 64.2 t80 -122.63 134.59 25.03 Favored Pre-proline 0 N--CA 1.435 -1.223 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.432 -179.769 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.528 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 64.3 Cg_endo -71.08 147.06 86.51 Favored 'Cis proline' 0 CA--C 1.54 0.786 0 C-N-CA 123.229 -1.571 . . . . 0.0 110.602 -2.497 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.8 t -64.68 -176.8 0.27 Allowed 'General case' 0 C--O 1.248 0.981 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.685 -175.403 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 16.8 p -130.31 0.73 4.6 Favored 'General case' 0 N--CA 1.424 -1.761 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.014 -171.133 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 26.5 t -161.36 -137.51 0.04 OUTLIER 'General case' 0 N--CA 1.379 -3.993 0 N-CA-C 106.56 -1.645 . . . . 0.0 106.56 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -121.39 156.58 32.36 Favored 'General case' 0 C--N 1.267 -2.991 0 C-N-CA 127.015 2.126 . . . . 0.0 107.337 -172.309 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.464 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 19.6 p -78.6 162.37 65.94 Favored Pre-proline 0 C--N 1.302 -1.483 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 -177.396 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.99 165.49 5.0 Favored 'Trans proline' 0 C--N 1.359 1.104 0 C-N-CA 124.044 3.163 . . . . 0.0 112.148 174.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.6 tmm_? -70.3 119.7 14.87 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 114.759 -1.11 . . . . 0.0 109.657 -176.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 60.4 t -131.27 130.35 63.13 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 C-N-CA 123.671 0.788 . . . . 0.0 110.211 -175.531 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.488 HG21 ' O ' ' A' ' 54' ' ' ASP . 1.4 p -129.74 125.45 61.03 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.953 0 CA-C-N 115.009 -0.996 . . . . 0.0 110.341 -174.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -73.15 104.08 4.1 Favored 'General case' 0 C--O 1.211 -0.938 0 CA-C-O 121.105 0.478 . . . . 0.0 111.092 -178.519 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -90.11 62.55 5.56 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-O 121.016 0.436 . . . . 0.0 109.836 179.197 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.0 t -152.59 -170.07 3.53 Favored 'General case' 0 N--CA 1.437 -1.092 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 -178.288 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 17.0 ptm180 -149.1 38.34 0.8 Allowed 'General case' 0 C--N 1.316 -0.875 0 CA-C-O 121.014 0.435 . . . . 0.0 110.437 -176.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 12.6 t -159.51 -177.8 6.67 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -178.007 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . 0.438 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 9.6 p-10 -79.45 99.92 7.44 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-O 122.41 1.1 . . . . 0.0 109.653 -179.231 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . 0.452 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 7.0 mmpt? -102.37 149.73 36.93 Favored Pre-proline 0 C--N 1.296 -1.749 0 CA-C-N 114.535 -1.212 . . . . 0.0 109.755 -177.836 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.463 ' HB3' ' O ' ' A' ' 39' ' ' SER . 22.5 Cg_exo -59.16 153.35 53.12 Favored 'Trans proline' 0 N--CA 1.449 -1.133 0 C-N-CA 123.36 2.707 . . . . 0.0 112.907 178.089 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 12.6 t90 -95.75 102.15 9.65 Favored Pre-proline 0 C--N 1.289 -2.053 0 N-CA-C 105.688 -1.967 . . . . 0.0 105.688 176.357 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -73.93 88.96 1.04 Allowed 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 122.079 1.852 . . . . 0.0 112.956 -172.267 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 59.9 t -138.75 146.45 26.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.566 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.57 135.67 16.63 Favored 'General case' 0 C--N 1.287 -2.144 0 CA-C-O 120.89 0.376 . . . . 0.0 110.414 178.033 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.422 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 15.6 mt -101.25 103.12 14.12 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.447 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.532 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 45.5 m-85 -82.2 73.23 9.25 Favored 'General case' 0 C--N 1.293 -1.863 0 O-C-N 122.279 -0.263 . . . . 0.0 110.824 178.369 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.658 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -98.5 136.03 39.2 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 176.867 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -137.5 144.73 46.26 Favored Pre-proline 0 C--N 1.293 -1.883 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.098 -175.199 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -62.38 122.31 10.67 Favored 'Trans proline' 0 C--O 1.248 0.99 0 C-N-CA 123.537 2.825 . . . . 0.0 113.12 -176.14 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.497 ' O ' HG23 ' A' ' 30' ' ' VAL . 2.7 m -73.85 -120.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.168 -3.201 0 CA-C-N 114.507 -1.224 . . . . 0.0 112.344 174.806 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 27.9 t -111.94 -32.37 6.62 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 -179.116 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 68.3 m -79.97 21.6 0.55 Allowed 'General case' 0 N--CA 1.398 -3.07 0 C-N-CA 125.612 1.565 . . . . 0.0 112.777 -179.532 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -107.5 128.16 54.25 Favored 'General case' 0 N--CA 1.412 -2.326 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 -179.218 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.63 133.09 2.71 Favored Glycine 0 C--N 1.297 -1.605 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 -179.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 62.47 -148.55 49.02 Favored Glycine 0 CA--C 1.489 -1.567 0 CA-C-O 119.24 -0.755 . . . . 0.0 111.782 -177.573 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 60.7 t -56.93 105.72 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 117.225 0.513 . . . . 0.0 110.536 -178.283 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -102.97 -40.93 6.3 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.58 179.481 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.407 ' HB ' HG21 ' A' ' 154' ' ' VAL . 72.7 mt -115.29 137.66 48.11 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 178.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.436 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.9 mmpt? -115.07 136.63 52.92 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-O 121.289 0.566 . . . . 0.0 111.636 178.885 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.15 126.87 30.91 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.828 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 92.95 -5.13 75.83 Favored Glycine 0 N--CA 1.437 -1.298 0 CA-C-N 115.694 -0.684 . . . . 0.0 111.756 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 21.2 m -94.91 145.17 25.1 Favored 'General case' 0 N--CA 1.428 -1.544 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 179.802 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.41 HD12 HG21 ' A' ' 128' ' ' VAL . 2.9 tm? -71.35 124.74 25.25 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 108.204 -1.035 . . . . 0.0 108.204 178.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.463 ' HB ' HG23 ' A' ' 67' ' ' VAL . 31.8 pt -111.09 -25.36 3.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 112.322 0.49 . . . . 0.0 112.322 -179.002 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . 0.416 ' HB1' ' HB ' ' A' ' 148' ' ' ILE . . . -162.05 167.51 24.24 Favored 'General case' 0 CA--C 1.508 -0.653 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 -178.022 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.41 HG21 HD12 ' A' ' 125' ' ' LEU . 63.8 t -142.3 116.02 4.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 178.878 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . 0.404 HD12 HD22 ' A' ' 107' ' ' LEU . 67.9 mt -119.02 146.99 44.59 Favored 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.613 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.526 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.4 mp -127.73 126.38 66.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 C-N-CA 119.271 -0.972 . . . . 0.0 110.832 177.519 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.463 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.3 OUTLIER -88.1 145.5 25.91 Favored 'General case' 0 C--N 1.283 -2.313 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 176.332 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 16.2 ttp180 -128.58 130.08 46.86 Favored 'General case' 0 C--N 1.277 -2.549 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 173.023 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 8.6 tm0? -108.71 129.04 55.36 Favored 'General case' 0 N--CA 1.412 -2.347 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 -178.728 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 6.9 m -135.75 139.75 43.82 Favored 'General case' 0 C--N 1.287 -2.116 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.56 ' CB ' HG21 ' A' ' 52' ' ' ILE . 9.4 p30 . . . . . 0 N--CA 1.433 -1.278 0 C-N-CA 117.309 -1.756 . . . . 0.0 113.449 177.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 . . . . . 0 CA--C 1.501 -0.933 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . 0.415 HE21 HG22 ' A' ' 130' ' ' ILE . 20.1 pt20 -123.54 134.73 53.81 Favored 'General case' 0 N--CA 1.423 -1.806 0 C-N-CA 119.838 -0.745 . . . . 0.0 111.102 177.512 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 6.9 m-30 -107.57 125.66 51.58 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 -176.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . 0.445 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 46.9 t -89.51 135.28 26.46 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 CA-C-O 121.161 0.505 . . . . 0.0 110.284 -178.473 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . 0.463 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 64.8 m95 -122.12 102.53 8.2 Favored 'General case' 0 C--N 1.281 -2.377 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.692 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.8 m-80 -81.65 109.22 15.87 Favored 'General case' 0 C--N 1.289 -2.025 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 178.04 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . 0.428 ' HA ' HG23 ' A' ' 20' ' ' VAL . 21.3 mm -82.47 119.92 32.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 -177.191 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 1.638 ' HE1' ' CE2' ' A' ' 149' ' ' TYR . 81.8 m-85 -116.77 151.6 36.12 Favored 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 123.169 0.588 . . . . 0.0 109.678 178.469 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.14 128.92 34.28 Favored 'General case' 0 N--CA 1.411 -2.399 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 177.119 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -91.38 -11.36 38.03 Favored 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 107.435 -1.32 . . . . 0.0 107.435 -177.563 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -153.22 143.01 22.03 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 114.292 -1.322 . . . . 0.0 109.379 -177.053 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -84.26 145.68 28.18 Favored 'General case' 0 C--N 1.316 -0.85 0 O-C-N 123.971 0.795 . . . . 0.0 109.553 -179.02 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.466 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 1.6 m -124.44 147.48 28.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.855 -178.248 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.7 t -120.14 139.93 45.85 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.538 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 -179.626 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.405 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 70.5 t -100.93 100.3 12.52 Favored Pre-proline 0 C--N 1.29 -1.983 0 C-N-CA 123.666 0.786 . . . . 0.0 109.402 177.336 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -68.18 -23.95 38.76 Favored 'Trans proline' 0 CA--C 1.517 -0.365 0 C-N-CA 122.427 2.085 . . . . 0.0 111.649 178.038 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.269 5.3 t . . . . . 0 C--O 1.249 1.058 0 O-C-N 125.0 1.437 . . . . 0.0 113.383 177.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.439 -0.984 0 CA-C-O 120.857 0.36 . . . . 0.0 111.49 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 77.0 m -137.4 152.18 49.36 Favored 'General case' 0 N--CA 1.429 -1.496 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.958 -177.414 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -141.17 167.13 22.91 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.763 -178.093 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.5 p -103.67 171.88 7.12 Favored 'General case' 0 CA--C 1.497 -1.066 0 CA-C-O 121.483 0.658 . . . . 0.0 110.733 -179.276 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.96 -4.82 54.09 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-N 114.034 -1.439 . . . . 0.0 111.755 178.325 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 2.0 p30 -96.88 -30.92 12.85 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 118.184 -1.407 . . . . 0.0 109.314 177.829 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 139.13 0.46 2.16 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 119.896 -1.145 . . . . 0.0 113.047 175.388 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -81.07 105.25 12.14 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -100.85 119.45 38.68 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 176.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 60.3 mt -90.76 123.83 63.91 Favored Pre-proline 0 C--N 1.3 -1.567 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -80.66 168.75 17.53 Favored 'Trans proline' 0 C--O 1.248 0.98 0 C-N-CA 122.7 2.267 . . . . 0.0 111.173 178.049 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.1 mt -63.75 127.56 24.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 133.77 8.72 2.12 Favored Glycine 0 C--N 1.319 -0.373 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.612 -179.562 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 86.69 172.69 48.61 Favored Glycine 0 C--N 1.318 -0.425 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.415 -177.542 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.45 -168.78 30.97 Favored Glycine 0 C--N 1.299 -1.526 0 C-N-CA 119.916 -1.135 . . . . 0.0 111.498 177.1 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 14.4 p -140.1 155.81 46.84 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.401 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -143.63 162.24 36.43 Favored 'General case' 0 N--CA 1.424 -1.736 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 177.308 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -107.83 116.18 31.48 Favored 'General case' 0 C--N 1.281 -2.388 0 CA-C-N 114.808 -1.087 . . . . 0.0 108.746 177.57 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 44.1 t -103.86 135.03 43.44 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.008 0 CA-C-N 115.133 -0.94 . . . . 0.0 108.668 179.202 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 -122.99 134.78 54.31 Favored 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -179.113 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.451 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.5 p -144.42 136.29 21.87 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.674 0 O-C-N 123.727 0.642 . . . . 0.0 111.095 -178.722 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 47.9 m-80 -89.67 126.79 35.78 Favored 'General case' 0 C--N 1.296 -1.76 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.458 178.442 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -106.56 161.19 14.83 Favored 'General case' 0 C--N 1.283 -2.298 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 177.631 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.8 124.81 81.19 Favored Pre-proline 0 C--N 1.315 -0.933 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 175.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 68.1 Cg_endo -74.83 0.84 8.33 Favored 'Trans proline' 0 N--CA 1.474 0.382 0 C-N-CA 122.954 2.436 . . . . 0.0 113.021 -177.253 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.422 HG11 ' HG3' ' A' ' 157' ' ' PRO . 87.3 t -129.6 111.85 23.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.525 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.7 t -143.33 114.94 2.73 Favored 'Isoleucine or valine' 0 C--O 1.182 -2.489 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -177.219 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.716 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -104.98 148.68 26.46 Favored 'General case' 0 C--N 1.271 -2.819 0 O-C-N 121.987 -0.445 . . . . 0.0 110.91 -179.447 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.513 HG23 ' O ' ' A' ' 112' ' ' VAL . 95.8 t -47.97 116.93 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 123.082 0.553 . . . . 0.0 111.377 178.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 109.41 -9.25 32.96 Favored Glycine 0 C--N 1.307 -1.033 0 CA-C-N 115.238 -0.892 . . . . 0.0 112.357 -178.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.716 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -67.87 -177.62 0.84 Allowed 'General case' 0 CA--C 1.508 -0.672 0 C-N-CA 124.631 1.172 . . . . 0.0 110.956 179.63 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -129.89 92.12 3.26 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 178.231 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.635 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.8 tp -94.25 142.52 27.31 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 119.056 -1.057 . . . . 0.0 109.301 179.226 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 39.6 t -132.34 124.78 52.72 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.215 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 -175.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.559 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 47.3 t -96.19 87.82 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.4 -2.931 0 N-CA-C 105.26 -2.126 . . . . 0.0 105.26 172.107 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -82.5 112.55 19.53 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 120.962 0.411 . . . . 0.0 110.984 -177.757 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 84.6 mt -98.21 0.31 45.56 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.017 -178.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.4 m -76.35 1.67 15.59 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-O 122.332 1.063 . . . . 0.0 109.045 -179.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.8 p -130.64 5.58 4.69 Favored 'General case' 0 N--CA 1.428 -1.562 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.15 176.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.451 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 49.7 mm-40 -124.38 -22.12 4.77 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 121.193 0.521 . . . . 0.0 111.019 -174.684 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.2 mt -131.56 140.83 47.31 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 -176.231 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.64 ' HD2' ' CD1' ' A' ' 43' ' ' PHE . 69.0 m-85 -139.25 154.93 48.06 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -174.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 96.2 m -137.69 136.52 37.48 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 123.751 0.82 . . . . 0.0 110.787 -179.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.4 p-80 -131.92 129.67 40.58 Favored 'General case' 0 C--N 1.295 -1.761 0 CA-C-O 122.381 1.086 . . . . 0.0 112.123 -177.581 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.747 ' OD1' ' HA ' ' A' ' 49' ' ' PRO . 3.3 t-20 -85.23 92.07 8.32 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-N 114.446 -1.252 . . . . 0.0 107.928 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 20.1 m-20 -54.48 -36.6 64.33 Favored 'General case' 0 N--CA 1.493 1.684 0 C-N-CA 123.475 0.71 . . . . 0.0 111.069 -178.255 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 1.644 ' HD2' ' CD1' ' A' ' 48' ' ' TYR . 44.7 m-85 -122.46 86.0 48.35 Favored Pre-proline 0 C--N 1.299 -1.599 0 N-CA-C 108.223 -1.028 . . . . 0.0 108.223 -175.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.747 ' HA ' ' OD1' ' A' ' 46' ' ' ASN . 72.7 Cg_endo -73.19 -5.98 18.12 Favored 'Trans proline' 0 CA--C 1.508 -0.81 0 C-N-CA 122.486 2.124 . . . . 0.0 115.081 -170.128 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -121.3 -20.35 6.72 Favored 'General case' 0 C--N 1.282 -2.342 0 CA-C-O 121.268 0.556 . . . . 0.0 110.649 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.469 ' HB ' HD13 ' A' ' 52' ' ' ILE . 1.6 m -98.4 -30.7 12.41 Favored 'General case' 0 N--CA 1.414 -2.231 0 C-N-CA 119.54 -0.864 . . . . 0.0 109.102 -170.785 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.469 HD13 ' HB ' ' A' ' 51' ' ' THR . 2.7 mp -130.03 123.72 56.89 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 CA-C-N 114.878 -1.055 . . . . 0.0 110.035 -175.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 4.4 t -75.71 134.67 40.46 Favored 'General case' 0 N--CA 1.425 -1.684 0 N-CA-C 106.08 -1.822 . . . . 0.0 106.08 173.597 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.509 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 9.5 t70 -90.31 108.88 20.04 Favored 'General case' 0 C--N 1.271 -2.806 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 -178.431 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.572 ' CD2' ' HB ' ' A' ' 134' ' ' THR . 4.7 t80 -128.47 110.06 11.96 Favored 'General case' 0 C--N 1.291 -1.938 0 CA-C-O 122.109 0.957 . . . . 0.0 110.93 -175.22 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.423 ' HA ' ' O ' ' A' ' 132' ' ' ARG . 73.9 t -114.7 142.17 28.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 CA-C-N 113.629 -1.623 . . . . 0.0 110.94 -177.749 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.3 p -143.67 134.18 24.84 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 170.061 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.431 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 0.8 OUTLIER -73.51 109.97 7.44 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 175.771 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.4 tp-100 -57.58 -62.2 1.96 Allowed 'General case' 0 C--O 1.202 -1.428 0 C-N-CA 125.416 1.486 . . . . 0.0 109.958 -178.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.91 146.11 14.26 Favored 'General case' 0 N--CA 1.418 -2.072 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 -178.216 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -126.68 137.66 10.15 Favored Glycine 0 N--CA 1.398 -3.852 0 N-CA-C 108.193 -1.963 . . . . 0.0 108.193 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 63.4 m -124.0 148.29 47.1 Favored 'General case' 0 C--N 1.268 -2.949 0 C-N-CA 123.599 0.76 . . . . 0.0 109.33 -175.057 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.52 ' HB3' ' CE2' ' A' ' 84' ' ' PHE . . . -114.27 158.1 21.85 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 -179.593 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 1.643 ' HD1' ' CD2' ' A' ' 64' ' ' TYR . 85.0 m-85 -156.35 -178.42 7.32 Favored 'General case' 0 C--O 1.243 0.719 0 C-N-CA 124.214 1.005 . . . . 0.0 108.347 -178.111 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.79 -138.14 49.7 Favored Glycine 0 N--CA 1.452 -0.299 0 O-C-N 123.596 0.56 . . . . 0.0 112.81 178.562 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.91 -9.41 85.42 Favored Glycine 0 C--O 1.205 -1.706 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.651 177.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.477 HG23 ' HB ' ' A' ' 126' ' ' ILE . 84.5 t -68.53 -42.92 83.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 C-N-CA 122.934 0.493 . . . . 0.0 111.362 -177.508 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.509 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -82.45 -17.65 44.56 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.331 -0.948 . . . . 0.0 112.133 179.603 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 14.6 t -100.74 -59.64 1.66 Allowed 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.971 -172.631 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.434 ' O ' HG23 ' A' ' 112' ' ' VAL . 44.2 m-20 -91.1 -23.51 20.28 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.672 -172.323 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 1.637 ' HD2' ' CD1' ' A' ' 71' ' ' PHE . 93.1 m-85 -106.7 155.62 19.49 Favored 'General case' 0 N--CA 1.42 -1.959 0 C-N-CA 119.647 -0.821 . . . . 0.0 109.532 177.077 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.5 t -163.18 126.99 2.85 Favored 'General case' 0 N--CA 1.41 -2.464 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.419 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.425 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -163.07 -109.59 0.23 Allowed Glycine 0 N--CA 1.407 -3.287 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 177.294 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -159.99 178.69 9.46 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 123.348 0.659 . . . . 0.0 110.273 -173.739 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -131.77 142.85 42.01 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 178.171 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.706 ' HG3' ' O ' ' A' ' 80' ' ' SER . 71.7 tttt -118.76 139.12 52.08 Favored 'General case' 0 N--CA 1.423 -1.814 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.793 -179.573 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.483 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 67.5 t80 -138.96 110.05 6.83 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.071 -178.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.6 t 49.68 41.92 22.61 Favored 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 124.133 0.973 . . . . 0.0 111.937 174.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.43 11.03 63.04 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 120.519 -0.848 . . . . 0.0 113.746 179.265 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.706 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 10.1 t -93.56 177.84 5.89 Favored 'General case' 0 C--O 1.206 -1.219 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 176.694 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 74.9 m -160.02 105.52 1.56 Allowed 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 177.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 1.638 ' HD2' ' CD1' ' A' ' 82' ' ' TYR . 5.8 p90 -142.64 164.53 32.1 Favored Pre-proline 0 C--N 1.297 -1.688 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 -172.46 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . 0.418 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 73.9 Cg_endo -71.95 148.26 51.03 Favored 'Trans proline' 0 C--N 1.352 0.731 0 C-N-CA 122.376 2.051 . . . . 0.0 113.402 -174.436 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.614 ' CD2' HD22 ' A' ' 109' ' ' LEU . 55.3 t80 -120.7 139.7 29.39 Favored Pre-proline 0 N--CA 1.429 -1.499 0 CA-C-N 115.608 -0.723 . . . . 0.0 109.267 179.398 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.605 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 55.8 Cg_endo -70.12 144.54 77.7 Favored 'Cis proline' 0 CA--C 1.537 0.653 0 C-N-CA 123.115 -1.619 . . . . 0.0 110.541 -4.848 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 5.6 t -67.44 -179.59 1.08 Allowed 'General case' 0 CA--C 1.556 1.182 0 CA-C-O 121.081 0.467 . . . . 0.0 111.236 -175.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 22.1 p -131.11 -24.63 2.32 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -168.439 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 24.8 t -129.84 -68.5 0.71 Allowed 'General case' 0 C--N 1.31 -1.117 0 C-N-CA 119.854 -0.738 . . . . 0.0 110.83 -173.36 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 178.77 -177.01 0.25 Allowed 'General case' 0 C--O 1.243 0.747 0 C-N-CA 124.454 1.102 . . . . 0.0 108.44 175.631 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.431 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 48.9 p -100.15 166.9 11.85 Favored Pre-proline 0 C--N 1.302 -1.477 0 O-C-N 123.582 0.551 . . . . 0.0 110.978 177.324 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -57.89 160.21 15.82 Favored 'Trans proline' 0 C--O 1.248 1.012 0 C-N-CA 123.027 2.484 . . . . 0.0 110.941 171.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.523 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 0.8 OUTLIER -72.32 120.51 18.03 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.368 -177.26 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 57.5 t -129.42 119.01 47.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.893 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 97.6 t -105.64 132.5 52.44 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 CA-C-N 115.12 -0.945 . . . . 0.0 108.868 177.04 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . 0.509 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 11.8 m-85 -81.6 112.07 18.48 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 175.746 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -103.69 75.73 1.33 Allowed 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 -179.493 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 70.7 m -161.08 170.05 21.23 Favored 'General case' 0 C--N 1.318 -0.801 0 C-N-CA 124.303 1.041 . . . . 0.0 109.435 -177.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.0 ptm180 -128.06 38.78 3.96 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-O 121.946 0.879 . . . . 0.0 110.07 178.013 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.8 t -156.72 167.73 29.56 Favored 'General case' 0 N--CA 1.426 -1.648 0 N-CA-C 107.272 -1.381 . . . . 0.0 107.272 -177.134 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -73.69 123.58 24.34 Favored 'General case' 0 C--N 1.311 -1.1 0 O-C-N 123.784 0.677 . . . . 0.0 110.579 -178.594 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.5 mptm? -120.07 144.23 37.22 Favored Pre-proline 0 C--N 1.28 -2.428 0 CA-C-N 114.642 -1.163 . . . . 0.0 108.558 179.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.43 ' O ' ' HD3' ' A' ' 104' ' ' PRO . 43.3 Cg_endo -65.9 150.13 85.91 Favored 'Trans proline' 0 C--O 1.248 1.009 0 C-N-CA 122.242 1.961 . . . . 0.0 111.456 177.343 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 16.4 t90 -87.16 105.26 7.82 Favored Pre-proline 0 C--N 1.315 -0.912 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 -179.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . 0.43 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 64.4 Cg_endo -74.69 88.53 1.19 Allowed 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 121.544 1.496 . . . . 0.0 112.58 -173.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 97.4 t -138.44 142.88 33.93 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.309 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.106 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.559 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.94 132.5 16.75 Favored 'General case' 0 N--CA 1.41 -2.428 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.109 178.51 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.444 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 19.5 mt -97.05 102.37 14.13 Favored 'General case' 0 C--N 1.287 -2.123 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.639 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 1.655 ' HE1' ' CE2' ' A' ' 108' ' ' TYR . 63.0 m-85 -83.11 74.39 9.99 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-O 121.105 0.479 . . . . 0.0 110.231 177.45 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.635 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.8 mm? -97.93 130.35 44.81 Favored 'General case' 0 CA--C 1.484 -1.582 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 175.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -135.05 144.09 48.73 Favored Pre-proline 0 N--CA 1.397 -3.077 0 N-CA-C 108.947 -0.761 . . . . 0.0 108.947 -174.452 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -63.13 126.72 18.49 Favored 'Trans proline' 0 CA--C 1.496 -1.401 0 C-N-CA 123.2 2.6 . . . . 0.0 113.993 -174.395 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.513 ' O ' HG23 ' A' ' 30' ' ' VAL . 16.1 m -91.65 -158.03 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.395 -3.206 0 CA-C-N 114.221 -1.354 . . . . 0.0 108.66 171.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 29.4 m -76.0 -32.01 59.21 Favored 'General case' 0 C--N 1.26 -3.322 0 CA-C-O 121.366 0.603 . . . . 0.0 110.883 -168.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 7.2 t -80.26 10.12 4.9 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-O 121.736 0.779 . . . . 0.0 110.64 -177.3 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -95.09 135.55 36.5 Favored 'General case' 0 N--CA 1.42 -1.955 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.002 179.005 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -179.6 132.07 1.78 Allowed Glycine 0 N--CA 1.433 -1.517 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 63.6 -150.05 49.92 Favored Glycine 0 C--N 1.306 -1.133 0 CA-C-O 119.167 -0.796 . . . . 0.0 112.128 -177.247 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -56.7 103.82 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.242 0.679 0 CA-C-O 122.404 1.097 . . . . 0.0 111.804 -177.402 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -103.24 -36.77 7.96 Favored 'General case' 0 C--N 1.293 -1.884 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.676 -178.695 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 73.1 mt -120.54 138.47 50.92 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 3.9 mmpt? -112.99 140.05 48.13 Favored 'General case' 0 C--N 1.313 -1.009 0 C-N-CA 122.727 0.411 . . . . 0.0 110.171 177.655 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -73.5 134.74 43.95 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.03 179.091 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 82.95 4.59 89.94 Favored Glycine 0 C--N 1.314 -0.648 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -178.524 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 8.5 t -100.87 140.7 34.79 Favored 'General case' 0 N--CA 1.415 -2.214 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -178.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -71.4 122.15 19.84 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 178.201 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.477 ' HB ' HG23 ' A' ' 67' ' ' VAL . 34.2 pt -109.48 -27.21 2.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.218 -177.872 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -160.57 166.99 28.05 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 -177.554 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 59.7 t -143.06 114.93 2.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 179.184 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 34.3 mt -118.2 135.83 54.01 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.429 HG22 HE21 ' A' ' 143' ' ' GLN . 4.3 mp -115.72 128.05 73.1 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 C-N-CA 118.636 -1.226 . . . . 0.0 109.937 177.8 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.514 ' O ' HD21 ' A' ' 131' ' ' LEU . 0.0 OUTLIER -97.05 133.5 41.63 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.159 178.497 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . 0.423 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 7.4 mmm180 -91.72 127.48 37.19 Favored 'General case' 0 C--N 1.281 -2.396 0 C-N-CA 123.714 0.806 . . . . 0.0 109.374 176.709 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.411 HE21 ' HA ' ' A' ' 133' ' ' GLN . 0.0 OUTLIER -103.98 130.52 51.63 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 105.75 -1.944 . . . . 0.0 105.75 174.087 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.572 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 12.9 m -145.2 143.92 30.56 Favored 'General case' 0 C--N 1.273 -2.757 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 177.396 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.45 ' HB2' HG21 ' A' ' 52' ' ' ILE . 19.3 p30 . . . . . 0 C--N 1.309 -1.169 0 C-N-CA 119.695 -0.802 . . . . 0.0 110.624 179.058 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . 1.651 ' HE2' ' CE1' ' A' ' 142' ' ' PHE . 76.4 m-85 . . . . . 0 N--CA 1.431 -1.398 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . 0.429 HE21 HG22 ' A' ' 130' ' ' ILE . 18.5 pt20 -137.27 141.27 41.97 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.662 178.169 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 1.662 ' HD2' ' CD1' ' A' ' 144' ' ' PHE . 5.4 m-30 -108.58 131.66 54.64 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -176.165 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 48.1 t -90.89 127.52 43.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 O-C-N 123.579 0.549 . . . . 0.0 109.893 -178.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . 0.431 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 65.3 m95 -114.88 100.07 7.95 Favored 'General case' 0 C--N 1.273 -2.728 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 -178.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 42.2 m-80 -82.67 112.83 19.89 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 23.0 mm -88.45 121.09 38.32 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -177.434 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 1.647 ' HE1' ' CE2' ' A' ' 149' ' ' TYR . 97.3 m-85 -116.79 149.07 40.56 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 177.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.09 131.43 35.3 Favored 'General case' 0 N--CA 1.41 -2.453 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 176.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 13.9 t-20 -91.03 -11.24 39.4 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 -178.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -147.88 142.85 26.94 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.155 -176.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -85.62 136.8 33.23 Favored 'General case' 0 C--N 1.313 -1.0 0 O-C-N 123.97 0.794 . . . . 0.0 109.663 178.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.43 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 1.5 m -119.92 149.52 22.6 Favored 'Isoleucine or valine' 0 C--O 1.254 1.316 0 CA-C-O 120.928 0.394 . . . . 0.0 110.785 -175.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -121.53 142.69 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.276 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -179.376 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.525 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.5 t -102.56 102.37 25.6 Favored Pre-proline 0 C--N 1.296 -1.745 0 C-N-CA 123.384 0.674 . . . . 0.0 109.82 178.131 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.422 ' HG3' HG11 ' A' ' 27' ' ' VAL . 29.2 Cg_endo -67.5 -28.64 38.3 Favored 'Trans proline' 0 CA--C 1.506 -0.878 0 C-N-CA 122.295 1.997 . . . . 0.0 111.7 177.519 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.255 6.1 t . . . . . 0 C--O 1.256 1.401 0 O-C-N 124.483 1.114 . . . . 0.0 112.519 178.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.412 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 CA--C 1.458 -2.562 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 11.1 m -126.01 163.05 23.88 Favored 'General case' 0 C--N 1.26 -3.31 0 C-N-CA 119.148 -1.021 . . . . 0.0 109.155 -171.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -146.35 159.25 43.62 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-O 120.958 0.409 . . . . 0.0 110.522 -174.479 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.608 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 73.4 p -99.62 176.13 5.58 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 121.277 0.561 . . . . 0.0 111.09 -179.382 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.52 -12.93 59.85 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.186 178.175 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.608 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 8.8 p30 -89.48 -31.31 17.73 Favored 'General case' 0 N--CA 1.435 -1.213 0 C-N-CA 119.081 -1.047 . . . . 0.0 109.896 175.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.48 5.66 3.22 Favored Glycine 0 N--CA 1.44 -1.054 0 C-N-CA 119.325 -1.417 . . . . 0.0 113.743 175.354 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.405 ' O ' ' HA ' ' A' ' 4' ' ' LYS . 5.1 m -79.18 99.62 7.09 Favored 'General case' 0 N--CA 1.433 -1.276 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 -179.736 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.53 117.92 30.46 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 176.369 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.412 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 71.5 mt -93.46 123.29 60.76 Favored Pre-proline 0 C--N 1.297 -1.68 0 N-CA-C 108.498 -0.926 . . . . 0.0 108.498 179.292 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -77.81 167.47 23.81 Favored 'Trans proline' 0 C--O 1.248 0.982 0 C-N-CA 122.84 2.36 . . . . 0.0 111.498 179.261 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 60.3 mt -69.88 120.58 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.912 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.61 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 140.16 20.12 0.37 Allowed Glycine 0 C--N 1.298 -1.534 0 CA-C-N 115.533 -0.758 . . . . 0.0 112.677 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 84.26 158.81 28.56 Favored Glycine 0 C--O 1.236 0.258 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 -177.121 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 163.83 -175.74 39.96 Favored Glycine 0 N--CA 1.435 -1.372 0 C-N-CA 119.825 -1.179 . . . . 0.0 111.49 178.472 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 37.3 p -146.14 147.55 31.64 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.047 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.09 161.44 35.32 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 179.342 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 21.9 m-80 -113.29 109.81 19.34 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 106.493 -1.669 . . . . 0.0 106.493 176.755 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 40.2 t -94.35 134.69 31.02 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.493 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 -178.273 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 1.64 ' HD2' ' CD1' ' A' ' 21' ' ' TYR . 78.3 m-85 -116.46 120.13 37.82 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 117.775 0.261 . . . . 0.0 110.986 -178.541 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 17.6 t -123.02 127.99 74.94 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-O 120.975 0.416 . . . . 0.0 111.036 -175.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -82.12 124.41 29.83 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 177.323 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 38.0 mt -115.51 154.2 29.76 Favored 'General case' 0 C--N 1.28 -2.453 0 CA-C-N 115.397 -0.82 . . . . 0.0 108.858 -179.086 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.76 120.83 44.9 Favored Pre-proline 0 C--N 1.314 -0.96 0 O-C-N 124.485 1.115 . . . . 0.0 110.123 -178.826 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.45 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 61.0 Cg_endo -72.22 -2.09 11.1 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.885 2.39 . . . . 0.0 113.427 -176.694 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.4 t -124.07 109.57 23.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 178.23 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.492 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.7 t -139.81 107.08 2.71 Favored 'Isoleucine or valine' 0 C--O 1.182 -2.479 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -178.258 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.726 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -97.72 148.54 23.24 Favored 'General case' 0 C--N 1.265 -3.095 0 C-N-CA 122.894 0.477 . . . . 0.0 111.015 -179.606 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.519 HG23 ' O ' ' A' ' 112' ' ' VAL . 91.0 t -47.69 116.52 0.38 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.638 0 C-N-CA 122.961 0.505 . . . . 0.0 111.435 176.038 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.09 9.87 43.94 Favored Glycine 0 CA--C 1.523 0.567 0 CA-C-N 114.905 -1.043 . . . . 0.0 112.137 -178.178 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.726 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -78.62 -176.71 4.99 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 124.603 1.161 . . . . 0.0 109.653 175.147 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -131.95 83.49 2.09 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 175.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.516 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 19.8 tp -91.37 134.22 34.79 Favored 'General case' 0 N--CA 1.426 -1.642 0 C-N-CA 119.42 -0.912 . . . . 0.0 108.915 179.438 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.451 ' HA ' ' O ' ' A' ' 107' ' ' LEU . 1.8 p -141.35 136.26 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.383 -3.803 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.191 -177.691 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.593 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 34.0 t -98.59 89.29 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.412 -2.343 0 CA-C-N 113.551 -1.659 . . . . 0.0 107.904 178.65 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -77.48 118.11 19.6 Favored 'General case' 0 CA--C 1.489 -1.391 0 C-N-CA 120.047 -0.661 . . . . 0.0 110.201 177.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 92.4 mt -96.64 -0.18 48.9 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.545 -0.752 . . . . 0.0 111.632 -178.01 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 26.4 t -74.63 -7.49 53.37 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.854 0.835 . . . . 0.0 109.659 -179.381 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.9 p -117.86 2.19 12.16 Favored 'General case' 0 C--N 1.279 -2.478 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.3 178.021 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 44.2 mm-40 -120.64 -22.83 6.22 Favored 'General case' 0 C--O 1.243 0.736 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.501 -173.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 20.1 mt -136.45 140.08 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.629 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 -176.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 59.8 m-85 -139.9 162.33 35.43 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 -177.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 20.1 t -145.08 141.91 29.24 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 120.181 -0.608 . . . . 0.0 110.39 175.847 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . 0.4 ' NE2' ' HB1' ' A' ' 2' ' ' ALA . 19.8 p-80 -119.74 165.03 15.06 Favored 'General case' 0 C--O 1.255 1.389 0 CA-C-O 122.242 1.02 . . . . 0.0 110.376 -178.801 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.459 HD21 ' CG ' ' A' ' 54' ' ' ASP . 3.2 m120 -110.72 108.49 18.39 Favored 'General case' 0 C--N 1.271 -2.818 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 -175.017 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -84.0 -25.46 29.95 Favored 'General case' 0 N--CA 1.436 -1.166 0 C-N-CA 118.129 -1.428 . . . . 0.0 109.946 -177.618 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 -132.67 64.99 73.44 Favored Pre-proline 0 N--CA 1.472 0.668 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.186 178.03 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -70.02 1.04 4.98 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 C-N-CA 123.257 2.638 . . . . 0.0 114.159 -174.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -116.6 -20.13 9.72 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-O 121.189 0.519 . . . . 0.0 110.303 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.412 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -104.04 -27.83 11.88 Favored 'General case' 0 N--CA 1.422 -1.857 0 CA-C-O 122.055 0.931 . . . . 0.0 108.717 -172.875 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.53 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -128.9 142.98 42.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 CA-C-N 114.711 -1.131 . . . . 0.0 109.04 -176.817 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 4.2 t -89.2 133.23 34.51 Favored 'General case' 0 N--CA 1.433 -1.294 0 N-CA-C 104.917 -2.253 . . . . 0.0 104.917 170.209 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.459 ' CG ' HD21 ' A' ' 46' ' ' ASN . 11.1 m-20 -92.79 106.5 18.46 Favored 'General case' 0 C--N 1.27 -2.879 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 -178.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.422 ' HB3' ' O ' ' A' ' 134' ' ' THR . 52.9 t80 -118.0 127.94 54.3 Favored 'General case' 0 C--N 1.274 -2.692 0 CA-C-N 114.29 -1.323 . . . . 0.0 108.855 -174.589 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.459 HG11 ' HH ' ' A' ' 77' ' ' TYR . 14.9 p -134.48 138.91 48.92 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.578 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.411 -175.307 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 4.3 p -146.7 131.03 17.54 Favored 'General case' 0 C--N 1.282 -2.352 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 174.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.518 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 55.1 tp -64.52 116.89 6.61 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 173.213 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -61.06 -49.42 77.42 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 113.802 -1.545 . . . . 0.0 109.307 -178.589 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -175.79 161.76 2.58 Favored 'General case' 0 N--CA 1.42 -1.951 0 CA-C-N 114.504 -1.226 . . . . 0.0 107.979 -178.311 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -136.6 136.52 8.42 Favored Glycine 0 N--CA 1.403 -3.514 0 N-CA-C 108.729 -1.748 . . . . 0.0 108.729 -179.47 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.2 m -123.66 146.87 47.9 Favored 'General case' 0 C--N 1.282 -2.35 0 O-C-N 124.394 0.702 . . . . 0.0 109.753 -176.095 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.484 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -112.17 156.07 22.91 Favored 'General case' 0 CA--C 1.503 -0.831 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 -178.845 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.469 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 88.5 m-85 -156.32 -178.93 7.69 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 124.309 1.044 . . . . 0.0 109.144 -177.616 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 63.01 -139.71 44.95 Favored Glycine 0 C--O 1.221 -0.672 0 O-C-N 123.367 0.417 . . . . 0.0 112.164 177.647 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.99 -6.98 86.12 Favored Glycine 0 C--O 1.203 -1.833 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.043 177.061 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.471 HG23 ' HB ' ' A' ' 126' ' ' ILE . 73.2 t -69.6 -38.52 76.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 C-N-CA 123.587 0.755 . . . . 0.0 111.815 -176.359 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.484 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -85.62 -21.72 28.3 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.954 -0.699 . . . . 0.0 112.194 179.136 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 14.0 m -100.89 -50.75 3.74 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 -173.389 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.405 ' O ' HG23 ' A' ' 112' ' ' VAL . 46.1 m-20 -93.36 -22.67 18.8 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 -176.028 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 1.625 ' HD2' ' CD1' ' A' ' 71' ' ' PHE . 84.0 m-85 -110.29 160.77 16.25 Favored 'General case' 0 N--CA 1.417 -2.112 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 177.411 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.5 t -166.76 131.68 2.12 Favored 'General case' 0 N--CA 1.415 -2.204 0 N-CA-C 106.049 -1.834 . . . . 0.0 106.049 175.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.439 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -166.76 -112.47 0.26 Allowed Glycine 0 N--CA 1.401 -3.66 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 175.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -157.28 179.37 9.33 Favored 'General case' 0 C--N 1.281 -2.373 0 C-N-CA 123.685 0.794 . . . . 0.0 110.714 -172.324 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.418 HG11 ' CE2' ' A' ' 82' ' ' TYR . 2.6 p -134.97 148.17 29.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 178.347 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.68 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.1 tttt -125.73 150.04 48.03 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.156 -178.188 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.467 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 57.3 t80 -151.6 116.18 5.11 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 -178.15 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 2.7 m 53.79 33.87 17.91 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 179.116 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 85.6 9.67 78.14 Favored Glycine 0 CA--C 1.526 0.721 0 C-N-CA 120.291 -0.957 . . . . 0.0 112.923 -178.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.68 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 9.4 t -80.23 -179.69 7.21 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.098 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 11.4 p -154.63 110.17 3.14 Favored 'General case' 0 C--N 1.289 -2.039 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.05 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 0.467 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 5.0 p90 -153.01 159.55 32.08 Favored Pre-proline 0 CA--C 1.551 1.001 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -174.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -67.53 150.0 80.02 Favored 'Trans proline' 0 C--N 1.362 1.269 0 C-N-CA 123.059 2.506 . . . . 0.0 113.442 -176.096 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 1.655 ' HD2' ' CD1' ' A' ' 84' ' ' PHE . 55.6 t80 -125.92 132.76 24.42 Favored Pre-proline 0 N--CA 1.445 -0.709 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.027 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.429 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 69.6 Cg_endo -72.64 144.41 80.63 Favored 'Cis proline' 0 C--O 1.245 0.856 0 C-N-CA 122.786 -1.756 . . . . 0.0 110.313 -1.342 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.3 t -66.87 -176.68 0.53 Allowed 'General case' 0 CA--C 1.546 0.824 0 CA-C-N 115.571 -0.741 . . . . 0.0 112.219 -173.028 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 12.9 p -119.06 -49.39 2.41 Favored 'General case' 0 N--CA 1.419 -2.004 0 CA-C-N 115.362 -0.835 . . . . 0.0 111.23 -173.073 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.7 t -104.78 -81.28 0.53 Allowed 'General case' 0 N--CA 1.424 -1.759 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.992 -174.502 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -175.64 -170.09 0.39 Allowed 'General case' 0 C--O 1.238 0.462 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 -175.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.518 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 56.2 p -101.44 164.39 16.05 Favored Pre-proline 0 C--N 1.303 -1.418 0 N-CA-C 112.817 0.673 . . . . 0.0 112.817 176.22 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . 0.428 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 22.8 Cg_endo -60.7 172.12 3.05 Favored 'Trans proline' 0 CA--C 1.552 1.41 0 C-N-CA 123.194 2.596 . . . . 0.0 111.891 173.482 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.2 tmm_? -73.74 119.6 18.19 Favored 'General case' 0 C--N 1.323 -0.584 0 C-N-CA 123.674 0.79 . . . . 0.0 110.068 -173.734 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 75.5 t -138.45 139.07 42.15 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -177.536 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.94 142.0 32.95 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.974 0 C-N-CA 122.978 0.511 . . . . 0.0 109.869 -176.225 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . 0.519 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 4.9 m-85 -95.68 105.38 17.37 Favored 'General case' 0 C--N 1.309 -1.184 0 C-N-CA 123.186 0.594 . . . . 0.0 109.853 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -93.01 50.89 1.6 Allowed 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 121.618 0.723 . . . . 0.0 109.271 177.2 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 12.2 p -117.47 178.4 4.4 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.023 -0.989 . . . . 0.0 110.841 -175.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 36.1 ptt180 -144.35 36.9 1.22 Allowed 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 172.408 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.8 t -158.31 171.77 19.57 Favored 'General case' 0 C--N 1.312 -1.036 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 -173.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.45 99.32 4.15 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -98.05 139.37 21.21 Favored Pre-proline 0 C--N 1.287 -2.118 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.292 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -60.19 147.57 92.95 Favored 'Trans proline' 0 C--O 1.245 0.844 0 C-N-CA 122.938 2.425 . . . . 0.0 112.134 178.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . 0.519 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 11.4 t90 -93.64 106.51 21.5 Favored Pre-proline 0 C--N 1.311 -1.094 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 -178.341 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -77.04 88.79 1.37 Allowed 'Trans proline' 0 N--CA 1.455 -0.756 0 C-N-CA 121.984 1.79 . . . . 0.0 113.212 -172.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.433 HG21 ' CD2' ' A' ' 77' ' ' TYR . 66.6 t -140.12 146.43 24.8 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.296 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 178.014 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.593 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.69 134.98 17.01 Favored 'General case' 0 C--N 1.291 -1.947 0 CA-C-O 120.659 0.266 . . . . 0.0 110.919 177.592 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.451 ' O ' ' HA ' ' A' ' 35' ' ' VAL . 18.4 mt -101.11 100.04 10.55 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 179.682 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.439 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 58.8 m-85 -81.66 76.43 8.57 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 110.299 -0.26 . . . . 0.0 110.299 177.27 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.603 HD22 ' CD2' ' A' ' 84' ' ' PHE . 3.1 mm? -101.4 125.51 48.05 Favored 'General case' 0 CA--C 1.485 -1.528 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 176.02 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -126.68 148.05 63.27 Favored Pre-proline 0 N--CA 1.398 -3.036 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -175.075 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.403 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 28.6 Cg_endo -62.14 123.72 13.04 Favored 'Trans proline' 0 N--CA 1.446 -1.322 0 C-N-CA 123.132 2.555 . . . . 0.0 113.611 -176.522 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.519 ' O ' HG23 ' A' ' 30' ' ' VAL . 17.9 m -85.95 -157.69 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.398 -3.053 0 CA-C-N 114.34 -1.3 . . . . 0.0 108.696 171.225 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 15.8 t -81.83 -24.69 35.7 Favored 'General case' 0 C--N 1.254 -3.586 0 CA-C-O 121.755 0.788 . . . . 0.0 109.034 -171.175 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 28.0 t -80.85 18.23 1.03 Allowed 'General case' 0 N--CA 1.434 -1.267 0 CA-C-N 115.228 -0.896 . . . . 0.0 110.433 178.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -106.81 138.8 42.3 Favored 'General case' 0 N--CA 1.421 -1.887 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.373 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 177.19 125.42 0.9 Allowed Glycine 0 N--CA 1.441 -0.999 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 179.599 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 68.75 -149.54 49.6 Favored Glycine 0 CA--C 1.496 -1.096 0 CA-C-O 119.07 -0.85 . . . . 0.0 111.38 -176.404 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 57.7 t -58.91 105.71 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-O 121.718 0.771 . . . . 0.0 111.018 -176.564 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -105.77 -34.67 7.61 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 114.785 -1.098 . . . . 0.0 111.128 -178.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.412 ' HB ' HG21 ' A' ' 154' ' ' VAL . 70.4 mt -119.7 136.98 55.09 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.062 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.85 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.461 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.2 mmpt? -113.39 138.5 49.97 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-O 121.035 0.445 . . . . 0.0 110.428 177.043 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -72.31 137.57 46.78 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.957 179.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 82.16 5.17 89.89 Favored Glycine 0 C--N 1.31 -0.868 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.864 -179.123 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 44.6 m -104.66 141.1 37.05 Favored 'General case' 0 N--CA 1.421 -1.903 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -67.35 123.81 21.38 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 178.049 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.471 ' HB ' HG23 ' A' ' 67' ' ' VAL . 28.6 pt -111.44 -26.21 3.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 116.129 -0.487 . . . . 0.0 112.16 -178.675 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.59 168.41 23.56 Favored 'General case' 0 N--CA 1.443 -0.784 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -178.254 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 77.2 t -142.68 114.9 3.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 62.7 mt -116.23 143.88 44.94 Favored 'General case' 0 C--N 1.286 -2.16 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 178.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.516 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.9 mp -123.94 123.35 66.67 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.101 178.422 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.497 ' O ' HD21 ' A' ' 131' ' ' LEU . 0.0 OUTLIER -89.11 134.7 33.91 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 176.718 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 12.4 tpt180 -101.79 109.56 21.35 Favored 'General case' 0 C--N 1.277 -2.553 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 179.114 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.452 ' CG ' HD22 ' A' ' 131' ' ' LEU . 10.1 mm-40 -100.8 105.12 16.4 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 176.536 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.422 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 7.7 m -124.17 136.02 53.89 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 179.205 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.53 ' CB ' HG21 ' A' ' 52' ' ' ILE . 7.9 p30 . . . . . 0 C--N 1.32 -0.691 0 C-N-CA 117.831 -1.548 . . . . 0.0 112.336 178.441 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . 1.664 ' HE2' ' CE1' ' A' ' 142' ' ' PHE . 74.0 m-85 . . . . . 0 N--CA 1.417 -2.118 0 N-CA-C 109.681 -0.488 . . . . 0.0 109.681 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . 0.448 ' NE2' HG22 ' A' ' 130' ' ' ILE . 20.9 pt20 -108.22 133.46 52.43 Favored 'General case' 0 N--CA 1.413 -2.308 0 CA-C-O 121.493 0.663 . . . . 0.0 110.033 177.073 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.454 ' HB2' HD23 ' A' ' 131' ' ' LEU . 8.0 m-30 -103.02 133.77 47.58 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 -176.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 46.6 t -91.44 129.91 41.42 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.929 0 CA-C-O 121.115 0.484 . . . . 0.0 109.766 -178.514 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . 0.46 ' CZ2' ' HB2' ' A' ' 3' ' ' CYS . 62.2 m95 -120.22 96.2 5.06 Favored 'General case' 0 C--N 1.277 -2.568 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -80.22 114.73 19.34 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 25.5 mm -87.42 123.31 40.07 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.799 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 -177.506 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 1.649 ' HD1' ' CD2' ' A' ' 149' ' ' TYR . 58.7 m-85 -116.79 151.09 37.22 Favored 'General case' 0 C--N 1.292 -1.909 0 C-N-CA 124.207 1.003 . . . . 0.0 109.349 178.171 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.68 131.81 35.28 Favored 'General case' 0 N--CA 1.411 -2.419 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 175.635 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 17.8 t-20 -93.15 -11.39 32.93 Favored 'General case' 0 C--N 1.292 -1.919 0 CA-C-O 122.469 1.128 . . . . 0.0 108.033 -176.506 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -152.02 143.62 23.53 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 114.023 -1.444 . . . . 0.0 109.41 -177.457 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -86.4 139.49 30.89 Favored 'General case' 0 C--N 1.309 -1.173 0 O-C-N 124.133 0.896 . . . . 0.0 110.183 -179.389 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.45 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 1.8 m -120.38 153.05 23.42 Favored 'Isoleucine or valine' 0 C--O 1.251 1.144 0 CA-C-O 120.94 0.4 . . . . 0.0 111.217 -175.599 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.0 t -123.14 142.63 39.03 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.2 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.492 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 77.1 t -104.26 102.46 32.96 Favored Pre-proline 0 C--N 1.289 -2.039 0 C-N-CA 123.444 0.698 . . . . 0.0 110.039 179.179 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.44 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 29.7 Cg_endo -67.26 -23.23 45.32 Favored 'Trans proline' 0 C--O 1.219 -0.437 0 C-N-CA 122.498 2.132 . . . . 0.0 111.56 176.656 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.287 5.1 t . . . . . 0 C--O 1.258 1.515 0 CA-C-O 117.45 -1.262 . . . . 0.0 113.768 176.054 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.504 -0.823 0 CA-C-O 120.72 0.295 . . . . 0.0 110.695 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.418 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 76.9 m -145.48 159.31 43.29 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -178.813 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.406 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -145.55 155.56 43.14 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-O 121.451 0.643 . . . . 0.0 110.164 -177.37 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 44.7 p -92.36 177.33 6.17 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.856 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.91 -17.13 48.26 Favored 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.953 179.148 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -90.76 -24.93 20.22 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.582 -177.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 131.73 -3.11 5.33 Favored Glycine 0 CA--C 1.494 -1.233 0 C-N-CA 119.271 -1.442 . . . . 0.0 114.428 169.321 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.7 m -80.55 100.05 8.39 Favored 'General case' 0 C--N 1.285 -2.211 0 CA-C-O 121.453 0.644 . . . . 0.0 109.536 -178.221 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -94.56 124.75 38.78 Favored 'General case' 0 N--CA 1.424 -1.77 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.115 176.72 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 69.6 mt -92.11 116.45 66.48 Favored Pre-proline 0 C--N 1.278 -2.539 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 177.72 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -75.9 177.09 9.18 Favored 'Trans proline' 0 C--O 1.245 0.841 0 C-N-CA 122.54 2.16 . . . . 0.0 111.719 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 67.9 mt -70.23 128.4 33.48 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.4 179.564 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 128.89 5.19 4.93 Favored Glycine 0 N--CA 1.432 -1.576 0 C-N-CA 120.372 -0.918 . . . . 0.0 111.69 -178.19 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 86.07 169.74 46.25 Favored Glycine 0 N--CA 1.439 -1.106 0 C-N-CA 120.511 -0.852 . . . . 0.0 111.588 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.86 -174.85 30.83 Favored Glycine 0 CA--C 1.487 -1.686 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 178.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.3 m -134.1 159.37 41.06 Favored 'General case' 0 C--N 1.296 -1.759 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 -179.131 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -141.46 165.51 27.31 Favored 'General case' 0 N--CA 1.42 -1.935 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 177.21 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -116.1 104.41 11.52 Favored 'General case' 0 C--N 1.273 -2.73 0 CA-C-N 114.002 -1.453 . . . . 0.0 108.913 178.079 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.42 HG23 ' HA ' ' A' ' 148' ' ' ILE . 1.3 m -91.68 146.4 6.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 -178.563 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 1.648 ' HE2' ' CE1' ' A' ' 21' ' ' TYR . 54.8 m-85 -128.93 112.51 14.16 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-O 121.03 0.443 . . . . 0.0 111.28 -177.502 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.459 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.6 p -118.69 129.78 74.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 CA-C-O 121.692 0.758 . . . . 0.0 111.995 -174.626 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.3 m-80 -84.52 126.06 32.96 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 177.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 23.0 mt -113.06 157.31 21.74 Favored 'General case' 0 C--N 1.272 -2.777 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 -179.155 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.36 120.74 46.79 Favored Pre-proline 0 C--N 1.313 -1.011 0 O-C-N 124.207 0.942 . . . . 0.0 109.723 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.447 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 60.6 Cg_endo -74.2 -0.12 9.19 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.657 2.238 . . . . 0.0 112.616 -177.536 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 94.9 t -125.3 109.95 23.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 177.639 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.479 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.6 t -140.91 107.02 1.97 Allowed 'Isoleucine or valine' 0 C--O 1.179 -2.622 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 -179.544 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.597 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -98.64 148.86 23.38 Favored 'General case' 0 C--N 1.265 -3.089 0 O-C-N 122.13 -0.356 . . . . 0.0 111.266 -179.5 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.411 HG11 ' O ' ' A' ' 112' ' ' VAL . 22.2 t -43.8 117.04 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.528 0 C-N-CA 123.571 0.748 . . . . 0.0 111.501 175.759 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.84 -1.07 48.36 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-N 115.002 -0.999 . . . . 0.0 113.063 -179.035 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.597 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -71.48 -177.04 1.7 Allowed 'General case' 0 C--N 1.318 -0.802 0 C-N-CA 124.496 1.118 . . . . 0.0 111.237 177.784 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -133.41 87.61 2.41 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 177.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.613 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.5 tp -88.76 140.3 29.59 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 -178.69 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.2 t -134.11 125.4 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.172 0 CA-C-O 121.113 0.483 . . . . 0.0 109.787 -175.472 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.582 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 41.1 t -95.78 88.2 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.399 -2.994 0 N-CA-C 105.713 -1.958 . . . . 0.0 105.713 174.196 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -80.57 116.07 20.42 Favored 'General case' 0 CA--C 1.486 -1.482 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.0 mt -97.52 0.06 46.86 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.249 -177.459 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.548 ' OG ' ' HA ' ' A' ' 104' ' ' PRO . 19.6 m -81.22 -2.37 48.5 Favored 'General case' 0 C--N 1.29 -1.988 0 CA-C-O 122.658 1.218 . . . . 0.0 109.703 -179.296 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.4 p -118.8 1.58 11.57 Favored 'General case' 0 C--N 1.275 -2.663 0 CA-C-N 114.807 -1.088 . . . . 0.0 109.811 175.725 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.459 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 44.8 mm-40 -122.41 -23.09 5.31 Favored 'General case' 0 CA--C 1.512 -0.497 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.329 -174.566 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 29.0 mt -135.68 139.2 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.229 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -176.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.61 ' HE2' ' CE1' ' A' ' 43' ' ' PHE . 65.7 m-85 -137.52 151.79 48.8 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 -177.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.418 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 67.7 m -128.28 138.53 52.46 Favored 'General case' 0 C--N 1.276 -2.622 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 176.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.2 p80 -125.11 129.26 49.84 Favored 'General case' 0 C--N 1.295 -1.774 0 CA-C-O 121.955 0.883 . . . . 0.0 110.773 -177.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.538 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 24.4 p-10 -95.76 96.5 9.02 Favored 'General case' 0 C--N 1.279 -2.477 0 CA-C-O 122.466 1.127 . . . . 0.0 110.072 -179.214 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -74.7 -23.55 58.63 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 114.108 -1.405 . . . . 0.0 111.538 -174.466 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -128.91 65.23 72.89 Favored Pre-proline 0 N--CA 1.479 1.019 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.103 179.648 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.538 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 60.3 Cg_endo -68.85 -12.31 34.14 Favored 'Trans proline' 0 N--CA 1.483 0.881 0 C-N-CA 122.809 2.34 . . . . 0.0 114.148 -172.471 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -108.08 -21.15 12.92 Favored 'General case' 0 C--N 1.292 -1.894 0 C-N-CA 119.977 -0.689 . . . . 0.0 110.343 -176.662 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.405 ' HB ' HD13 ' A' ' 52' ' ' ILE . 1.8 m -96.21 -30.34 13.53 Favored 'General case' 0 N--CA 1.416 -2.154 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 -172.544 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.62 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -121.98 143.29 35.07 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.213 0 CA-C-N 113.991 -1.459 . . . . 0.0 108.737 -177.119 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.1 t -88.82 125.83 35.08 Favored 'General case' 0 N--CA 1.419 -2.014 0 N-CA-C 103.944 -2.613 . . . . 0.0 103.944 170.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 -90.61 107.18 19.01 Favored 'General case' 0 C--N 1.263 -3.18 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -172.63 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 0.466 ' HB3' ' O ' ' A' ' 134' ' ' THR . 34.2 t80 -126.02 117.72 23.83 Favored 'General case' 0 C--N 1.274 -2.7 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.489 -173.39 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.534 HG13 ' OH ' ' A' ' 77' ' ' TYR . 49.0 t -121.85 130.84 74.24 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.298 -175.517 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.1 p -143.45 113.43 7.19 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 123.923 0.764 . . . . 0.0 111.239 177.683 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.494 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 54.3 tp -55.34 109.7 0.58 Allowed 'General case' 0 C--N 1.311 -1.106 0 CA-C-O 121.313 0.578 . . . . 0.0 110.174 172.108 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.491 ' NE2' ' HD3' ' A' ' 132' ' ' ARG . 3.4 tp-100 -54.91 -53.64 52.96 Favored 'General case' 0 C--O 1.209 -1.04 0 C-N-CA 126.041 1.736 . . . . 0.0 110.911 178.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -171.06 160.9 6.65 Favored 'General case' 0 N--CA 1.425 -1.71 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 -176.198 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -139.3 133.44 6.15 Favored Glycine 1 N--CA 1.391 -4.321 0 N-CA-C 108.041 -2.024 . . . . 0.0 108.041 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.2 m -120.76 151.6 39.36 Favored 'General case' 0 C--N 1.276 -2.599 0 O-C-N 124.956 1.033 . . . . 0.0 108.582 -174.145 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.544 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -116.16 157.67 24.45 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 -178.654 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.546 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 96.1 m-85 -155.69 176.8 12.14 Favored 'General case' 0 C--N 1.35 0.616 0 C-N-CA 124.246 1.018 . . . . 0.0 109.587 -177.283 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . 0.409 ' O ' HD13 ' A' ' 68' ' ' LEU . . . 58.35 -147.52 38.86 Favored Glycine 0 CA--C 1.52 0.365 0 O-C-N 123.61 0.569 . . . . 0.0 112.81 178.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -70.58 -10.34 66.77 Favored Glycine 0 C--O 1.205 -1.665 0 O-C-N 122.052 -0.676 . . . . 0.0 111.976 177.106 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.546 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 92.8 t -70.53 -36.75 67.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 123.544 0.737 . . . . 0.0 111.322 -177.172 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.544 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.71 -23.09 25.67 Favored 'General case' 0 N--CA 1.421 -1.883 0 C-N-CA 118.6 -1.24 . . . . 0.0 112.144 179.179 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 17.1 t -101.77 -55.46 2.5 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 112.952 0.723 . . . . 0.0 112.952 -175.213 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 72.4 m-20 -83.91 -27.43 28.6 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 -174.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 0.53 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 90.0 m-85 -107.02 159.19 16.47 Favored 'General case' 0 N--CA 1.421 -1.917 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 176.463 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.8 t -168.09 136.24 2.3 Favored 'General case' 0 N--CA 1.41 -2.431 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 176.292 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.428 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -169.37 -108.21 0.21 Allowed Glycine 0 N--CA 1.411 -3.027 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 175.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.442 HG23 ' HA ' ' A' ' 83' ' ' PRO . 1.1 p -159.21 -179.96 8.46 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 123.829 0.852 . . . . 0.0 110.547 -173.225 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.05 146.73 29.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 C-N-CA 123.435 0.694 . . . . 0.0 109.143 178.614 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.616 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.1 tttt -125.17 142.17 51.66 Favored 'General case' 0 N--CA 1.417 -2.095 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.518 -179.442 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.534 ' OH ' HG13 ' A' ' 56' ' ' VAL . 72.4 t80 -144.48 111.06 5.64 Favored 'General case' 0 C--N 1.295 -1.796 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.13 -177.195 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 35.1 t 55.14 34.33 22.39 Favored 'General case' 0 C--N 1.317 -0.825 0 C-N-CA 123.416 0.686 . . . . 0.0 111.164 178.212 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.08 10.52 64.32 Favored Glycine 0 N--CA 1.44 -1.079 0 C-N-CA 120.486 -0.864 . . . . 0.0 113.566 -178.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.616 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 20.8 t -79.84 179.8 7.36 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.551 0.676 . . . . 0.0 109.31 178.484 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 9.7 p -156.55 90.35 1.16 Allowed 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.623 0.725 . . . . 0.0 110.637 -176.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 1.638 ' HE2' ' CE1' ' A' ' 82' ' ' TYR . 1.5 p90 -139.85 158.31 67.9 Favored Pre-proline 0 C--N 1.297 -1.69 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 -173.098 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . 0.442 ' HA ' HG23 ' A' ' 74' ' ' THR . 58.9 Cg_endo -69.35 151.03 71.39 Favored 'Trans proline' 0 C--N 1.354 0.842 0 C-N-CA 123.148 2.565 . . . . 0.0 113.154 -177.081 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 1.651 ' HE1' ' CE2' ' A' ' 84' ' ' PHE . 58.0 t80 -122.74 133.21 24.33 Favored Pre-proline 0 N--CA 1.439 -1.011 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.018 -179.541 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.474 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 79.3 Cg_endo -71.43 149.78 92.7 Favored 'Cis proline' 0 CA--C 1.534 0.511 0 C-N-CA 122.71 -1.787 . . . . 0.0 109.73 -0.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.0 t -61.06 -175.54 0.05 OUTLIER 'General case' 0 CA--C 1.562 1.415 0 C-N-CA 123.399 0.679 . . . . 0.0 112.595 -175.462 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 12.4 p -104.97 -50.53 3.23 Favored 'General case' 0 N--CA 1.408 -2.563 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 -177.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.6 t -128.43 -109.19 0.29 Allowed 'General case' 0 N--CA 1.402 -2.873 0 CA-C-N 114.346 -1.297 . . . . 0.0 108.591 178.338 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -125.35 -171.68 2.42 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 118.539 0.609 . . . . 0.0 112.503 -176.692 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.494 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 36.1 p -93.95 167.57 13.4 Favored Pre-proline 0 C--N 1.309 -1.189 0 N-CA-C 112.924 0.713 . . . . 0.0 112.924 -178.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -62.82 175.87 2.11 Favored 'Trans proline' 0 CA--C 1.552 1.386 0 C-N-CA 123.087 2.524 . . . . 0.0 111.904 172.424 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.4 tmm_? -74.84 129.5 37.79 Favored 'General case' 0 C--O 1.243 0.761 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.004 -175.469 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.473 ' HB ' ' O ' ' A' ' 56' ' ' VAL . 65.3 t -140.09 132.57 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 C-N-CA 123.718 0.807 . . . . 0.0 109.801 -176.497 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 1.9 p -131.08 136.41 57.95 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.411 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 177.461 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . 1.637 ' HE2' ' CE1' ' A' ' 95' ' ' TYR . 6.1 m-85 -79.8 116.47 19.98 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-O 121.388 0.613 . . . . 0.0 110.525 -179.745 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 -102.22 68.46 1.09 Allowed 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 177.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 46.0 t -147.64 179.23 7.84 Favored 'General case' 0 N--CA 1.426 -1.646 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 -175.578 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 31.8 ptt180 -151.11 42.12 0.76 Allowed 'General case' 0 C--N 1.31 -1.146 0 C-N-CA 124.036 0.934 . . . . 0.0 108.51 171.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 11.0 t -169.72 172.32 6.87 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-N 114.525 -1.216 . . . . 0.0 108.23 -177.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -59.34 119.87 8.24 Favored 'General case' 0 N--CA 1.474 0.768 0 O-C-N 123.756 0.66 . . . . 0.0 110.493 178.357 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 55.9 mmtt -120.2 143.19 35.12 Favored Pre-proline 0 C--N 1.287 -2.143 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.994 178.364 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -67.16 139.19 49.71 Favored 'Trans proline' 0 N--CA 1.44 -1.676 0 C-N-CA 122.392 2.061 . . . . 0.0 110.32 177.252 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 14.4 t90 -80.34 109.69 13.69 Favored Pre-proline 0 C--N 1.307 -1.243 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 -177.476 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . 0.548 ' HA ' ' OG ' ' A' ' 39' ' ' SER . 60.7 Cg_endo -74.85 87.7 1.28 Allowed 'Trans proline' 0 N--CA 1.451 -0.982 0 C-N-CA 121.12 1.213 . . . . 0.0 112.844 -172.376 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 59.7 t -144.9 145.18 21.24 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.359 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 179.579 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.582 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.65 136.27 17.03 Favored 'General case' 0 C--N 1.288 -2.07 0 O-C-N 123.569 0.543 . . . . 0.0 110.116 177.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.41 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 17.7 mt -101.81 105.12 15.92 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 177.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 1.602 ' HE2' ' CE1' ' A' ' 108' ' ' TYR . 39.3 m-85 -85.29 80.49 9.15 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 177.481 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.613 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.2 mm? -105.12 125.32 50.85 Favored 'General case' 0 CA--C 1.491 -1.327 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 177.441 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -128.04 146.63 59.99 Favored Pre-proline 0 N--CA 1.412 -2.363 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.62 -175.542 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -61.14 117.6 4.39 Favored 'Trans proline' 0 C--O 1.245 0.863 0 C-N-CA 123.424 2.749 . . . . 0.0 112.369 -178.458 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.411 ' O ' HG11 ' A' ' 30' ' ' VAL . 2.7 m -67.04 -114.14 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.202 -1.447 0 CA-C-N 114.289 -1.323 . . . . 0.0 112.752 176.735 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 41.7 m -112.56 -43.4 3.48 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.287 -0.883 . . . . 0.0 110.441 175.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 22.7 t -82.82 30.2 0.44 Allowed 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.067 -174.726 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -101.79 130.94 48.33 Favored 'General case' 0 N--CA 1.418 -2.035 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.2 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.28 141.06 6.45 Favored Glycine 0 N--CA 1.432 -1.596 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 58.81 -149.23 37.78 Favored Glycine 0 C--O 1.219 -0.812 0 CA-C-O 119.244 -0.753 . . . . 0.0 113.307 -179.087 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 99.5 t -56.56 96.75 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 121.581 0.705 . . . . 0.0 111.26 -178.207 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -99.4 -27.78 13.58 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.365 -177.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 68.9 mt -126.84 138.53 54.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 177.105 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 4.2 mmpt? -111.02 138.05 47.9 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-O 121.341 0.591 . . . . 0.0 111.207 178.409 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.56 128.57 36.96 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.46 178.029 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 92.05 -7.16 78.96 Favored Glycine 0 N--CA 1.428 -1.89 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.093 -179.349 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 91.9 p -90.85 143.9 26.25 Favored 'General case' 0 C--O 1.253 1.253 0 C-N-CA 119.495 -0.882 . . . . 0.0 109.525 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -70.72 122.37 19.69 Favored 'General case' 0 N--CA 1.435 -1.22 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 177.367 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.494 ' HB ' HG23 ' A' ' 67' ' ' VAL . 31.6 pt -109.02 -24.47 4.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -177.116 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.72 167.32 23.22 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 -177.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 76.9 t -141.62 114.93 4.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 179.506 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 52.7 mt -117.97 144.68 45.32 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 178.484 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.473 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.4 mp -127.41 130.19 70.67 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 C-N-CA 119.41 -0.916 . . . . 0.0 110.639 179.006 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.424 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.9 OUTLIER -94.75 128.99 41.85 Favored 'General case' 0 C--N 1.29 -1.982 0 C-N-CA 123.855 0.862 . . . . 0.0 111.477 -179.607 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . 0.491 ' HD3' ' NE2' ' A' ' 59' ' ' GLN . 25.9 mmm180 -94.58 120.55 34.99 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 173.185 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.403 ' C ' ' HG1' ' A' ' 134' ' ' THR . 7.4 tp-100 -103.38 137.23 41.78 Favored 'General case' 0 N--CA 1.427 -1.59 0 N-CA-C 105.937 -1.875 . . . . 0.0 105.937 169.495 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.466 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 27.8 m -150.23 134.76 17.38 Favored 'General case' 0 C--N 1.278 -2.527 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 173.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.62 ' CB ' HG21 ' A' ' 52' ' ' ILE . 8.7 p30 . . . . . 0 N--CA 1.437 -1.108 0 C-N-CA 118.966 -1.094 . . . . 0.0 112.057 179.753 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . 1.667 ' HD2' ' CD1' ' A' ' 142' ' ' PHE . 82.0 m-85 . . . . . 0 N--CA 1.421 -1.881 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 11.4 pt20 -121.98 138.24 54.5 Favored 'General case' 0 N--CA 1.416 -2.152 0 C-N-CA 119.251 -0.98 . . . . 0.0 109.844 178.837 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 1.65 ' HE1' ' CE2' ' A' ' 144' ' ' PHE . 11.8 m-30 -105.12 128.98 53.62 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 -176.755 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.6 t -94.67 133.88 34.07 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.116 0 CA-C-O 121.143 0.497 . . . . 0.0 110.24 -178.152 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . 0.424 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.2 m95 -120.19 96.83 5.32 Favored 'General case' 0 C--N 1.286 -2.179 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.134 -177.224 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 44.3 m-80 -79.15 112.92 16.85 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 176.383 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . 0.42 ' HA ' HG23 ' A' ' 20' ' ' VAL . 23.9 mm -87.74 120.55 37.02 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 -177.604 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 1.653 ' HE2' ' CE1' ' A' ' 149' ' ' TYR . 96.0 m-85 -115.45 153.59 30.82 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 177.593 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.51 132.44 34.2 Favored 'General case' 0 N--CA 1.406 -2.63 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 177.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -90.02 -17.18 28.3 Favored 'General case' 0 C--N 1.286 -2.189 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 -176.115 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -146.18 144.31 29.85 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 114.088 -1.415 . . . . 0.0 110.123 -174.755 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -83.45 138.22 33.56 Favored 'General case' 0 C--N 1.317 -0.819 0 O-C-N 124.314 1.009 . . . . 0.0 109.697 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.447 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 2.0 m -119.83 151.83 22.44 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 C-N-CA 120.634 -0.426 . . . . 0.0 111.045 -176.898 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.2 t -123.78 140.96 45.69 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 -179.139 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.479 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.4 t -103.2 100.35 17.42 Favored Pre-proline 0 C--N 1.291 -1.945 0 C-N-CA 123.435 0.694 . . . . 0.0 109.864 178.43 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.445 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 35.2 Cg_endo -68.17 -21.04 42.85 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.52 2.147 . . . . 0.0 111.403 177.111 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.1 t . . . . . 0 C--O 1.257 1.453 0 C-N-CA 124.789 1.236 . . . . 0.0 114.128 175.531 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.446 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.44 -0.945 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 9.6 t -144.32 157.25 44.37 Favored 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 118.864 -1.134 . . . . 0.0 110.175 -175.347 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.407 ' HE3' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.48 164.9 29.49 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-O 121.254 0.55 . . . . 0.0 110.961 -175.335 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.402 HG21 HG23 ' A' ' 20' ' ' VAL . 82.1 p -102.18 176.81 5.07 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.841 -178.61 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.3 -16.51 56.25 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 114.402 -1.272 . . . . 0.0 110.722 176.038 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -90.93 -26.49 19.26 Favored 'General case' 0 CA--C 1.515 -0.375 0 C-N-CA 118.856 -1.137 . . . . 0.0 111.341 -177.467 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.48 4.87 3.43 Favored Glycine 0 CA--C 1.499 -0.932 0 C-N-CA 119.889 -1.148 . . . . 0.0 113.322 171.261 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.6 m -82.67 107.48 15.34 Favored 'General case' 0 N--CA 1.424 -1.759 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.404 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -102.53 109.99 21.78 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.43 176.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.446 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 54.8 mt -82.62 124.63 77.34 Favored Pre-proline 0 C--N 1.305 -1.338 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -176.688 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -81.36 161.94 19.83 Favored 'Trans proline' 0 C--O 1.246 0.924 0 C-N-CA 122.61 2.207 . . . . 0.0 111.922 179.073 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 58.0 mt -66.27 133.0 31.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.09 179.544 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 126.57 12.24 3.44 Favored Glycine 0 C--N 1.306 -1.1 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.238 -178.661 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.97 148.84 18.93 Favored Glycine 0 C--O 1.241 0.564 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 -178.054 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.62 -172.36 45.17 Favored Glycine 0 CA--C 1.491 -1.415 0 C-N-CA 119.453 -1.356 . . . . 0.0 112.493 -179.693 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.7 p -146.55 151.76 37.86 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 122.654 0.382 . . . . 0.0 110.325 -177.729 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -140.38 166.47 24.63 Favored 'General case' 0 N--CA 1.433 -1.283 0 CA-C-O 121.617 0.722 . . . . 0.0 109.89 178.33 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.39 101.54 8.49 Favored 'General case' 0 C--N 1.28 -2.423 0 CA-C-N 113.833 -1.531 . . . . 0.0 109.307 179.412 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.402 HG23 HG21 ' A' ' 5' ' ' THR . 40.4 t -92.25 134.4 30.53 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.802 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.563 -178.73 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 55.2 m-85 -119.6 126.73 51.9 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 -179.088 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.426 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.7 p -136.86 133.22 48.12 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.249 -177.047 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -93.67 129.77 39.85 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 121.643 0.735 . . . . 0.0 110.482 178.312 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -108.25 160.58 15.73 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 114.466 -1.243 . . . . 0.0 108.196 -179.704 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -59.08 123.7 70.66 Favored Pre-proline 0 C--N 1.314 -0.958 0 O-C-N 124.387 1.054 . . . . 0.0 109.233 177.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 61.8 Cg_endo -74.94 -2.06 12.03 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.632 2.221 . . . . 0.0 113.159 -177.544 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.5 t -122.95 109.76 24.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 178.186 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.45 ' O ' HG11 ' A' ' 156' ' ' VAL . 1.7 t -141.1 102.16 1.17 Allowed 'Isoleucine or valine' 0 C--O 1.183 -2.436 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -177.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.578 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -94.01 152.22 18.97 Favored 'General case' 0 C--N 1.274 -2.689 0 O-C-N 122.149 -0.344 . . . . 0.0 111.471 179.878 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.408 HG11 ' O ' ' A' ' 112' ' ' VAL . 35.0 t -45.71 119.88 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 123.26 0.624 . . . . 0.0 112.156 176.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.83 1.6 55.13 Favored Glycine 0 N--CA 1.46 0.252 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.595 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.578 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.4 OUTLIER -71.49 -178.53 2.19 Favored 'General case' 0 C--N 1.312 -1.048 0 C-N-CA 124.158 0.983 . . . . 0.0 111.226 177.246 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -129.73 85.06 2.26 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 176.157 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.586 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 17.1 tp -92.98 134.94 34.62 Favored 'General case' 0 N--CA 1.423 -1.806 0 C-N-CA 119.446 -0.902 . . . . 0.0 108.727 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 2.0 p -141.61 132.38 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.515 0 CA-C-O 122.016 0.913 . . . . 0.0 112.366 -177.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.604 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 42.5 t -89.31 90.0 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.264 0 CA-C-N 113.665 -1.607 . . . . 0.0 108.376 179.156 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -73.96 103.39 4.44 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 -179.561 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.4 mt -89.94 -3.82 57.83 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 120.75 0.31 . . . . 0.0 111.782 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -73.43 0.81 11.2 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 122.07 0.938 . . . . 0.0 111.574 178.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.9 p -126.72 5.89 6.73 Favored 'General case' 0 N--CA 1.418 -2.033 0 CA-C-N 115.203 -0.908 . . . . 0.0 109.866 176.645 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.426 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 43.9 mm-40 -123.7 -23.15 4.78 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.958 -174.754 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.7 mt -133.7 137.56 52.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 -176.158 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.407 ' HB2' ' HE3' ' A' ' 4' ' ' LYS . 41.7 m-85 -142.41 124.37 15.27 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -175.136 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 81.7 m -101.27 147.27 26.49 Favored 'General case' 0 C--N 1.291 -1.957 0 N-CA-C 109.46 -0.571 . . . . 0.0 109.46 -179.361 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . 0.416 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 37.0 p-80 -136.7 129.79 31.13 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-O 121.763 0.792 . . . . 0.0 111.649 -173.813 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.457 ' ND2' ' HA ' ' A' ' 49' ' ' PRO . 41.7 t30 -93.05 102.25 14.58 Favored 'General case' 0 C--N 1.28 -2.446 0 C-N-CA 119.991 -0.684 . . . . 0.0 110.533 179.233 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -56.22 -27.91 56.48 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 124.804 1.241 . . . . 0.0 111.016 179.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 0.431 ' HB2' HD11 ' A' ' 52' ' ' ILE . 38.8 m-85 -125.84 79.17 68.82 Favored Pre-proline 0 C--N 1.309 -1.169 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 -177.383 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HA ' ' ND2' ' A' ' 46' ' ' ASN . 57.8 Cg_endo -67.89 -7.33 19.33 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.852 2.368 . . . . 0.0 115.19 -170.503 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -120.76 -11.37 9.01 Favored 'General case' 0 C--N 1.311 -1.068 0 C-N-CA 120.253 -0.579 . . . . 0.0 111.073 -179.391 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.446 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.9 OUTLIER -104.79 -30.23 10.03 Favored 'General case' 0 N--CA 1.435 -1.206 0 CA-C-O 122.128 0.966 . . . . 0.0 109.128 -171.631 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.446 HD13 ' HB ' ' A' ' 51' ' ' THR . 2.0 mp -121.29 136.27 58.75 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.167 0 CA-C-N 114.351 -1.295 . . . . 0.0 109.807 -177.321 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 1.8 t -90.25 126.6 35.89 Favored 'General case' 0 N--CA 1.417 -2.08 0 N-CA-C 102.984 -2.969 . . . . 0.0 102.984 170.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.453 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 13.3 t70 -83.55 112.73 20.26 Favored 'General case' 0 C--N 1.274 -2.693 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 -172.155 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 1.655 ' HD1' ' CD2' ' A' ' 55' ' ' TYR . 22.0 t80 -127.77 123.31 34.97 Favored 'General case' 0 C--N 1.272 -2.801 0 CA-C-O 122.054 0.931 . . . . 0.0 110.671 -175.355 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.45 HG21 ' HG ' ' A' ' 131' ' ' LEU . 14.1 p -126.68 148.65 31.42 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.469 0 CA-C-N 114.334 -1.303 . . . . 0.0 109.802 -177.377 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.56 121.7 8.32 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.365 175.473 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.489 HD13 ' O ' ' A' ' 130' ' ' ILE . 53.0 tp -65.33 115.56 5.75 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 173.274 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.417 ' NE2' ' HD3' ' A' ' 132' ' ' ARG . 3.8 tp-100 -62.67 -61.65 2.27 Favored 'General case' 0 C--O 1.209 -1.038 0 C-N-CA 125.419 1.488 . . . . 0.0 109.499 178.764 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 9.9 ptp180 -158.61 159.36 35.36 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-N 114.513 -1.222 . . . . 0.0 108.227 -176.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -141.12 131.54 4.94 Favored Glycine 0 N--CA 1.399 -3.808 0 N-CA-C 108.478 -1.849 . . . . 0.0 108.478 -179.707 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 69.5 m -120.14 145.9 46.49 Favored 'General case' 0 C--N 1.28 -2.44 0 O-C-N 124.679 0.87 . . . . 0.0 110.475 -173.807 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.535 ' HB3' ' CE2' ' A' ' 84' ' ' PHE . . . -108.2 157.08 18.63 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 1.656 ' HE1' ' CE2' ' A' ' 64' ' ' TYR . 94.2 m-85 -157.07 -179.44 8.21 Favored 'General case' 0 C--O 1.235 0.325 0 C-N-CA 124.776 1.231 . . . . 0.0 108.949 -178.069 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 61.11 -144.19 48.63 Favored Glycine 0 CA--C 1.506 -0.516 0 O-C-N 123.489 0.493 . . . . 0.0 112.313 177.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -76.33 -9.58 85.75 Favored Glycine 0 C--O 1.2 -2.028 0 C-N-CA 120.892 -0.67 . . . . 0.0 111.698 176.425 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.513 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 80.1 t -68.63 -41.59 82.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 123.341 0.656 . . . . 0.0 111.796 -177.691 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.517 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -84.95 -16.47 40.87 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.154 -1.019 . . . . 0.0 112.072 178.727 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 22.7 t -100.6 -59.8 1.64 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.461 0.648 . . . . 0.0 111.692 -174.595 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.441 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 63.3 m-20 -86.32 -25.84 25.22 Favored 'General case' 0 CA--C 1.488 -1.426 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.403 -174.14 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 1.645 ' HD2' ' CD1' ' A' ' 71' ' ' PHE . 85.8 m-85 -107.66 160.93 15.32 Favored 'General case' 0 N--CA 1.412 -2.334 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.166 178.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.9 t -169.1 139.17 2.23 Favored 'General case' 0 N--CA 1.406 -2.626 0 N-CA-C 106.136 -1.802 . . . . 0.0 106.136 176.483 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.447 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -172.84 -104.23 0.17 Allowed Glycine 0 N--CA 1.411 -3.025 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 175.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.418 HG23 ' HA ' ' A' ' 83' ' ' PRO . 1.3 p -162.9 -179.61 6.9 Favored 'General case' 0 C--N 1.311 -1.106 0 C-N-CA 124.088 0.955 . . . . 0.0 110.895 -175.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -132.27 145.51 34.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 177.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.657 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.5 tttt -122.85 146.4 47.59 Favored 'General case' 0 N--CA 1.419 -2.007 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.443 -179.456 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.476 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 68.8 t80 -145.53 109.68 4.9 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.3 m 54.24 44.08 29.6 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 176.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 81.72 7.17 88.42 Favored Glycine 0 C--N 1.31 -0.873 0 C-N-CA 119.901 -1.142 . . . . 0.0 112.914 -179.589 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.657 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 13.0 t -82.08 174.24 11.41 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 178.038 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 21.8 t -153.14 111.75 3.71 Favored 'General case' 0 C--N 1.28 -2.435 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 -179.268 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 0.476 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 4.7 p90 -154.77 160.5 30.85 Favored Pre-proline 0 CA--C 1.551 1.001 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -174.579 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . 0.418 ' HA ' HG23 ' A' ' 74' ' ' THR . 50.0 Cg_endo -68.45 150.0 75.23 Favored 'Trans proline' 0 C--N 1.36 1.144 0 C-N-CA 122.942 2.428 . . . . 0.0 113.496 -176.756 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.591 ' CD2' HD22 ' A' ' 109' ' ' LEU . 53.1 t80 -124.86 133.79 25.1 Favored Pre-proline 0 N--CA 1.441 -0.882 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.777 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.515 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 59.3 Cg_endo -70.25 148.3 87.54 Favored 'Cis proline' 0 CA--C 1.541 0.848 0 C-N-CA 122.682 -1.799 . . . . 0.0 109.747 -2.032 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 8.8 t -67.08 -178.23 0.76 Allowed 'General case' 0 CA--C 1.55 0.967 0 CA-C-O 121.972 0.891 . . . . 0.0 111.742 -174.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 13.2 p -127.67 -28.68 2.71 Favored 'General case' 0 N--CA 1.425 -1.677 0 CA-C-N 114.929 -1.032 . . . . 0.0 112.931 -169.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.7 t -128.1 -79.9 0.58 Allowed 'General case' 0 N--CA 1.432 -1.373 0 C-N-CA 119.086 -1.046 . . . . 0.0 111.726 -176.483 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -170.98 -177.99 2.37 Favored 'General case' 0 C--O 1.246 0.906 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 -179.513 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.43 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 15.6 p -101.54 165.8 13.41 Favored Pre-proline 0 C--N 1.296 -1.758 0 N-CA-C 113.241 0.83 . . . . 0.0 113.241 -179.527 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -64.08 158.4 48.13 Favored 'Trans proline' 0 C--N 1.361 1.235 0 C-N-CA 122.784 2.323 . . . . 0.0 111.772 173.083 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.583 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 4.6 tmm_? -72.33 119.38 16.44 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 114.679 -1.146 . . . . 0.0 109.574 -177.843 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 86.0 t -131.77 120.19 44.05 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.723 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 84.2 t -108.99 126.09 66.04 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.637 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . 1.641 ' HD2' ' CD1' ' A' ' 95' ' ' TYR . 5.5 m-85 -76.65 105.15 7.54 Favored 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 123.816 0.847 . . . . 0.0 109.971 177.563 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 34.2 m-80 -96.34 57.63 1.7 Allowed 'General case' 0 C--N 1.287 -2.144 0 CA-C-O 122.462 1.125 . . . . 0.0 108.783 178.081 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 33.0 m -124.3 174.29 7.82 Favored 'General case' 0 N--CA 1.418 -2.073 0 CA-C-N 113.775 -1.557 . . . . 0.0 109.27 -176.449 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.0 ptp180 -127.93 12.33 6.7 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 112.142 0.423 . . . . 0.0 112.142 -176.727 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.1 t -160.51 -171.77 3.28 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -177.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . 0.416 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 3.7 p30 -67.79 132.15 46.88 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.076 0.465 . . . . 0.0 109.853 178.661 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 12.5 mmtm -139.75 146.75 48.72 Favored Pre-proline 0 C--N 1.291 -1.945 0 C-N-CA 124.553 1.141 . . . . 0.0 109.034 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -61.61 147.0 96.41 Favored 'Trans proline' 0 C--O 1.25 1.089 0 C-N-CA 123.321 2.681 . . . . 0.0 113.412 -175.113 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . 0.575 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 8.6 t90 -92.61 105.61 15.23 Favored Pre-proline 0 C--N 1.31 -1.124 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -74.76 89.11 1.15 Allowed 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 121.983 1.789 . . . . 0.0 112.584 -174.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 90.7 t -139.02 143.68 31.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 N-CA-C 107.313 -1.365 . . . . 0.0 107.313 176.32 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.604 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -149.9 136.38 19.09 Favored 'General case' 0 N--CA 1.412 -2.371 0 CA-C-O 120.831 0.348 . . . . 0.0 110.48 178.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.435 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 18.4 mt -103.21 100.09 9.98 Favored 'General case' 0 C--N 1.289 -2.06 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.283 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.447 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 55.8 m-85 -80.39 76.48 7.2 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 178.053 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.591 HD22 ' CD2' ' A' ' 84' ' ' PHE . 3.1 mm? -102.93 122.6 44.92 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 177.054 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -125.09 147.01 55.65 Favored Pre-proline 0 N--CA 1.41 -2.465 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.154 -173.678 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.441 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 30.7 Cg_endo -61.8 117.82 4.67 Favored 'Trans proline' 0 C--O 1.245 0.864 0 C-N-CA 123.167 2.578 . . . . 0.0 111.768 -177.514 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 70' ' ' ASN . 2.6 m -65.3 -116.28 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.192 -1.934 0 CA-C-N 114.365 -1.289 . . . . 0.0 113.546 177.501 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 17.8 m -111.9 -41.74 3.94 Favored 'General case' 0 C--N 1.287 -2.115 0 O-C-N 121.464 -0.772 . . . . 0.0 110.624 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 5.8 t -93.14 28.27 2.21 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.911 0.862 . . . . 0.0 110.589 -173.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -89.62 135.04 33.84 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 178.442 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -172.03 143.57 7.55 Favored Glycine 0 N--CA 1.432 -1.632 0 C-N-CA 120.083 -1.056 . . . . 0.0 111.294 179.497 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . 0.427 ' HA2' ' CG1' ' A' ' 155' ' ' VAL . . . 57.24 -147.06 35.65 Favored Glycine 0 CA--C 1.497 -1.091 0 CA-C-O 119.177 -0.791 . . . . 0.0 112.87 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 97.5 t -56.77 99.85 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-O 121.937 0.875 . . . . 0.0 110.867 -179.069 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -100.25 -35.34 9.66 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.966 -178.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.408 ' HB ' HG21 ' A' ' 154' ' ' VAL . 69.8 mt -121.72 137.39 55.51 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 178.48 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 3.9 mmpt? -111.07 136.46 50.06 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 122.991 0.516 . . . . 0.0 111.212 178.462 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.63 134.51 46.41 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.263 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 86.29 -4.49 85.99 Favored Glycine 0 N--CA 1.442 -0.904 0 N-CA-C 111.709 -0.556 . . . . 0.0 111.709 -179.171 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 37.5 m -96.06 151.01 19.85 Favored 'General case' 0 N--CA 1.427 -1.578 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -178.17 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.405 HD12 HG21 ' A' ' 128' ' ' VAL . 3.3 tm? -77.75 121.3 23.86 Favored 'General case' 0 N--CA 1.427 -1.594 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 -177.533 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.476 ' HB ' HG23 ' A' ' 67' ' ' VAL . 36.7 pt -108.12 -27.18 3.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 CA-C-N 116.157 -0.474 . . . . 0.0 112.139 -178.024 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.75 167.41 25.03 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 110.243 -0.28 . . . . 0.0 110.243 -178.315 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.405 HG21 HD12 ' A' ' 125' ' ' LEU . 64.8 t -142.16 113.61 3.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 179.88 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 63.5 mt -114.64 139.55 49.55 Favored 'General case' 0 C--N 1.289 -2.053 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.662 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.489 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.3 mp -119.13 124.0 72.36 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 119.326 -0.95 . . . . 0.0 110.105 178.435 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.515 ' O ' HD21 ' A' ' 131' ' ' LEU . 0.1 OUTLIER -99.19 131.84 44.94 Favored 'General case' 0 C--N 1.278 -2.52 0 C-N-CA 124.236 1.015 . . . . 0.0 111.033 -176.869 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . 0.417 ' HD3' ' NE2' ' A' ' 59' ' ' GLN . 12.5 mmm180 -95.56 125.13 39.94 Favored 'General case' 0 C--N 1.295 -1.802 0 C-N-CA 124.108 0.963 . . . . 0.0 109.481 179.454 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.417 HE21 ' HA ' ' A' ' 133' ' ' GLN . 0.0 OUTLIER -107.18 113.12 26.35 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 177.52 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.458 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 26.2 m -136.25 141.85 43.95 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.441 ' CB ' HG21 ' A' ' 52' ' ' ILE . 8.9 p30 . . . . . 0 C--N 1.312 -1.063 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.469 175.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 . . . . . 0 CA--C 1.508 -0.667 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -127.01 146.41 50.36 Favored 'General case' 0 N--CA 1.424 -1.757 0 CA-C-O 121.324 0.583 . . . . 0.0 110.891 178.618 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.412 ' HB2' HD23 ' A' ' 131' ' ' LEU . 11.9 m-30 -113.24 135.82 53.41 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 -176.736 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 49.3 t -92.44 130.69 41.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 122.802 0.441 . . . . 0.0 109.837 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . 0.441 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 61.8 m95 -119.38 101.08 7.71 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.804 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 48.7 m-80 -79.79 114.65 18.87 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 177.757 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 26.1 mm -88.05 120.24 36.75 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.947 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 -178.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 1.644 ' HD1' ' CD2' ' A' ' 149' ' ' TYR . 96.3 m-85 -116.09 150.3 37.56 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.507 179.022 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.8 131.23 35.2 Favored 'General case' 0 N--CA 1.406 -2.636 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 176.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -88.93 -16.49 31.7 Favored 'General case' 0 C--N 1.288 -2.081 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -178.027 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -147.29 141.14 25.79 Favored 'General case' 0 N--CA 1.434 -1.249 0 CA-C-N 114.224 -1.353 . . . . 0.0 110.32 -173.423 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -80.84 139.47 35.95 Favored 'General case' 0 C--N 1.311 -1.088 0 O-C-N 124.3 1.0 . . . . 0.0 109.348 178.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.408 HG21 ' HB ' ' A' ' 120' ' ' ILE . 2.2 m -120.91 153.29 24.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 120.715 -0.394 . . . . 0.0 110.713 -177.713 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . 0.427 ' CG1' ' HA2' ' A' ' 117' ' ' GLY . 2.9 t -124.21 142.47 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.032 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 -178.769 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.45 HG11 ' O ' ' A' ' 28' ' ' VAL . 70.4 t -103.95 102.59 32.51 Favored Pre-proline 0 C--N 1.291 -1.952 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 177.475 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.408 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 20.6 Cg_endo -66.22 -26.92 49.0 Favored 'Trans proline' 0 C--O 1.212 -0.809 0 C-N-CA 122.426 2.084 . . . . 0.0 111.924 177.665 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 6.6 t . . . . . 0 C--O 1.252 1.23 0 C-N-CA 124.425 1.09 . . . . 0.0 113.229 176.367 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.429 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.435 -1.204 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 16.4 t -154.83 157.29 37.68 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.772 -0.771 . . . . 0.0 109.436 -176.331 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.491 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.37 161.91 37.79 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-O 121.131 0.491 . . . . 0.0 110.856 -175.195 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.527 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 50.5 p -101.56 172.46 6.95 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-O 121.949 0.881 . . . . 0.0 110.426 178.139 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.58 -10.15 59.19 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 113.591 -1.64 . . . . 0.0 111.607 -178.123 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.527 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 6.2 p30 -87.14 -33.24 19.49 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 119.301 -0.96 . . . . 0.0 108.562 176.281 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.55 3.82 3.66 Favored Glycine 0 N--CA 1.441 -1.019 0 C-N-CA 120.139 -1.029 . . . . 0.0 112.702 178.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.9 m -78.48 99.44 6.45 Favored 'General case' 0 N--CA 1.433 -1.306 0 CA-C-N 117.129 0.465 . . . . 0.0 109.886 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -93.47 119.46 32.59 Favored 'General case' 0 N--CA 1.424 -1.764 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 176.347 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.429 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 72.4 mt -85.63 124.84 70.7 Favored Pre-proline 0 C--N 1.285 -2.238 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -77.8 167.0 24.55 Favored 'Trans proline' 0 N--CA 1.448 -1.169 0 C-N-CA 122.673 2.249 . . . . 0.0 110.623 178.226 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 55.3 mt -73.29 125.8 32.88 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 -178.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 138.34 7.48 1.26 Allowed Glycine 0 C--N 1.308 -1.013 0 C-N-CA 120.564 -0.826 . . . . 0.0 112.888 -179.026 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.12 142.89 9.17 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 -177.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -179.67 -168.37 38.39 Favored Glycine 0 CA--C 1.49 -1.487 0 C-N-CA 120.031 -1.081 . . . . 0.0 111.42 -179.032 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.455 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 20.4 p -149.6 147.02 27.63 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.23 162.83 31.87 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 179.589 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 26.8 m-80 -114.74 112.32 22.64 Favored 'General case' 0 C--N 1.29 -2.0 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 178.11 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 1.8 m -96.04 148.63 5.15 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.231 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 -179.33 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 1.653 ' HD1' ' CD2' ' A' ' 21' ' ' TYR . 32.5 m-85 -130.73 130.47 43.84 Favored 'General case' 0 CA--C 1.492 -1.285 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 -179.11 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.506 ' HB ' ' HG2' ' A' ' 41' ' ' GLN . 2.9 p -133.55 132.13 57.37 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.925 0 O-C-N 124.098 0.874 . . . . 0.0 110.572 -176.148 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -92.12 128.37 37.94 Favored 'General case' 0 C--N 1.286 -2.157 0 CA-C-O 121.629 0.728 . . . . 0.0 109.8 177.48 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -106.89 161.32 14.81 Favored 'General case' 0 C--N 1.28 -2.419 0 CA-C-N 114.341 -1.299 . . . . 0.0 108.036 179.634 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.52 121.61 61.76 Favored Pre-proline 0 C--N 1.304 -1.391 0 O-C-N 124.144 0.903 . . . . 0.0 108.779 176.069 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.478 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 64.5 Cg_endo -74.26 -1.16 10.58 Favored 'Trans proline' 0 CA--C 1.531 0.355 0 C-N-CA 122.851 2.368 . . . . 0.0 113.431 -176.818 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.441 HG11 ' HG3' ' A' ' 157' ' ' PRO . 94.9 t -125.92 110.56 24.26 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 176.609 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.511 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.1 t -142.14 106.25 1.43 Allowed 'Isoleucine or valine' 0 C--O 1.182 -2.479 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 -176.551 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.574 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -95.7 150.58 20.22 Favored 'General case' 0 C--N 1.268 -2.972 0 C-N-CA 122.888 0.475 . . . . 0.0 111.617 -179.745 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.637 HG23 ' O ' ' A' ' 112' ' ' VAL . 75.7 t -46.1 118.79 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 123.472 0.709 . . . . 0.0 111.38 176.649 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 105.01 -3.99 41.43 Favored Glycine 0 C--N 1.318 -0.468 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.642 -179.659 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.574 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.6 OUTLIER -68.81 -178.0 1.11 Allowed 'General case' 0 CA--C 1.499 -1.013 0 C-N-CA 124.555 1.142 . . . . 0.0 111.544 178.286 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -127.39 87.53 2.65 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 174.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.542 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 14.9 tp -96.63 133.95 40.49 Favored 'General case' 0 N--CA 1.405 -2.688 0 C-N-CA 118.852 -1.139 . . . . 0.0 108.029 177.419 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.407 ' CG2' ' HB2' ' A' ' 106' ' ' ALA . 2.0 p -141.19 129.72 23.52 Favored 'Isoleucine or valine' 1 N--CA 1.377 -4.107 0 CA-C-O 122.022 0.915 . . . . 0.0 111.183 -179.666 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.607 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 44.8 t -90.12 89.1 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.385 -3.713 0 CA-C-N 113.081 -1.872 . . . . 0.0 107.159 -178.728 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -75.87 133.31 40.61 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 176.566 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 86.9 mt -115.14 11.43 16.34 Favored 'General case' 0 C--N 1.295 -1.779 0 O-C-N 123.838 0.711 . . . . 0.0 111.26 179.225 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.662 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 1.5 m -87.0 1.69 51.98 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 -174.698 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.2 m -120.47 0.68 10.57 Favored 'General case' 0 N--CA 1.394 -3.232 0 CA-C-O 122.168 0.985 . . . . 0.0 108.779 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.506 ' HG2' ' HB ' ' A' ' 22' ' ' VAL . 22.1 mp0 -120.78 -34.22 3.61 Favored 'General case' 0 CA--C 1.473 -1.986 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.285 -172.282 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 23.1 mt -119.56 137.11 54.53 Favored 'Isoleucine or valine' 0 C--N 1.267 -2.981 0 CA-C-N 114.903 -1.044 . . . . 0.0 108.988 -177.45 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.491 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 42.4 m-85 -142.07 124.45 15.67 Favored 'General case' 0 CA--C 1.511 -0.553 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -176.469 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 81.9 m -106.57 140.17 39.87 Favored 'General case' 0 C--N 1.287 -2.142 0 CA-C-O 121.107 0.48 . . . . 0.0 110.618 -177.882 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . 0.426 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 5.1 p80 -124.28 132.85 53.59 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 122.356 1.074 . . . . 0.0 113.433 -174.565 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.447 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 14.8 p-10 -93.15 93.6 8.36 Favored 'General case' 0 C--N 1.279 -2.464 0 CA-C-N 114.299 -1.319 . . . . 0.0 109.46 177.51 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -78.3 -21.04 50.28 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.773 -1.103 . . . . 0.0 111.288 -176.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 1.622 ' HE1' ' CE2' ' A' ' 48' ' ' TYR . 72.2 m-85 -136.51 70.72 59.96 Favored Pre-proline 0 C--N 1.313 -0.987 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 176.475 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.447 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 56.0 Cg_endo -70.14 -10.98 29.5 Favored 'Trans proline' 0 N--CA 1.483 0.874 0 C-N-CA 122.698 2.266 . . . . 0.0 112.52 -176.205 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -107.32 -17.44 14.14 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-O 121.402 0.62 . . . . 0.0 110.035 -176.102 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.469 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -101.8 -30.71 11.13 Favored 'General case' 0 N--CA 1.414 -2.259 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 -175.818 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.671 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.9 mp -129.05 139.69 51.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.3 t -80.33 147.45 31.09 Favored 'General case' 0 C--O 1.252 1.204 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 178.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -80.73 107.68 13.75 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 -173.295 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 1.637 ' HE1' ' CE2' ' A' ' 55' ' ' TYR . 75.1 t80 -150.84 145.7 25.86 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.319 -175.31 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.44 HG11 ' HH ' ' A' ' 77' ' ' TYR . 11.4 p -153.92 152.28 10.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 174.572 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -151.36 138.02 18.79 Favored 'General case' 0 C--O 1.207 -1.149 0 CA-C-O 119.102 -0.475 . . . . 0.0 110.263 174.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.515 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 50.4 tp -76.17 113.14 13.38 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 174.016 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.4 tp-100 -59.52 -51.53 69.47 Favored 'General case' 0 C--N 1.316 -0.878 0 C-N-CA 125.549 1.539 . . . . 0.0 111.102 -179.327 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -172.81 157.11 3.61 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 -177.832 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -131.84 146.71 18.26 Favored Glycine 0 N--CA 1.41 -3.036 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 -178.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 69.9 m -130.16 148.89 52.05 Favored 'General case' 0 C--N 1.286 -2.177 0 O-C-N 124.52 0.776 . . . . 0.0 109.666 -178.046 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.472 ' HB3' ' CE2' ' A' ' 84' ' ' PHE . . . -113.53 157.77 21.6 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 1.656 ' HE2' ' CE1' ' A' ' 64' ' ' TYR . 97.5 m-85 -155.18 179.25 9.33 Favored 'General case' 0 C--N 1.345 0.396 0 C-N-CA 124.497 1.119 . . . . 0.0 109.59 -177.376 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 55.13 -145.42 30.47 Favored Glycine 0 C--N 1.331 0.299 0 O-C-N 123.975 0.797 . . . . 0.0 113.475 176.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.63 -13.03 74.51 Favored Glycine 0 C--O 1.205 -1.704 0 C-N-CA 120.957 -0.639 . . . . 0.0 111.692 178.263 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.527 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 98.6 t -67.21 -42.7 88.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 C-N-CA 123.359 0.663 . . . . 0.0 111.528 -178.234 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.471 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -84.81 -15.13 45.91 Favored 'General case' 0 C--N 1.308 -1.235 0 C-N-CA 119.112 -1.035 . . . . 0.0 112.055 179.531 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 36.5 t -100.31 -59.98 1.61 Allowed 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.851 -174.634 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.526 ' O ' HG23 ' A' ' 112' ' ' VAL . 46.9 m-20 -92.13 -23.95 19.26 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.076 -171.784 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 1.628 ' HE2' ' CE1' ' A' ' 71' ' ' PHE . 88.6 m-85 -106.9 154.83 20.47 Favored 'General case' 0 N--CA 1.42 -1.933 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.399 179.505 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.3 t -162.09 136.49 6.78 Favored 'General case' 0 N--CA 1.407 -2.594 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.557 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -168.69 -103.43 0.17 Allowed Glycine 0 C--N 1.275 -2.843 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 175.003 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -168.22 179.97 4.29 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 124.688 1.195 . . . . 0.0 109.264 -176.337 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.418 ' HB ' ' HB2' ' A' ' 84' ' ' PHE . 2.9 p -129.5 148.23 33.27 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 N-CA-C 109.684 -0.488 . . . . 0.0 109.684 178.643 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.558 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.2 tttt -127.19 144.26 51.08 Favored 'General case' 0 N--CA 1.427 -1.621 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.214 -179.189 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 1.627 ' HD2' ' CD1' ' A' ' 77' ' ' TYR . 58.6 t80 -140.89 104.72 4.74 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.27 -0.877 . . . . 0.0 108.86 -179.106 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 15.5 t 48.58 48.18 19.88 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 124.39 1.076 . . . . 0.0 111.834 177.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.59 5.36 69.21 Favored Glycine 0 N--CA 1.441 -0.991 0 CA-C-N 115.497 -0.774 . . . . 0.0 114.219 178.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.558 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 17.8 t -80.08 178.93 7.9 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 24.3 p -155.89 108.77 2.67 Favored 'General case' 0 C--N 1.293 -1.879 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.439 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 0.504 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.8 p90 -155.38 158.67 31.98 Favored Pre-proline 0 C--N 1.314 -0.947 0 O-C-N 122.195 -0.316 . . . . 0.0 110.258 -174.223 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -67.25 147.71 79.02 Favored 'Trans proline' 0 C--N 1.364 1.343 0 C-N-CA 123.28 2.654 . . . . 0.0 113.362 -177.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.614 ' CD2' HD22 ' A' ' 109' ' ' LEU . 63.6 t80 -123.13 135.27 25.75 Favored Pre-proline 0 N--CA 1.435 -1.201 0 CA-C-N 115.615 -0.72 . . . . 0.0 109.817 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.513 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 73.9 Cg_endo -72.59 145.22 83.1 Favored 'Cis proline' 0 CA--C 1.541 0.832 0 C-N-CA 123.144 -1.607 . . . . 0.0 110.411 -3.692 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.1 t -69.81 -177.02 1.18 Allowed 'General case' 0 CA--C 1.553 1.085 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.453 -176.12 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 39.4 p -122.61 -34.97 3.15 Favored 'General case' 0 N--CA 1.439 -0.994 0 CA-C-O 121.431 0.634 . . . . 0.0 110.354 -170.072 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.0 t -126.83 -131.46 0.24 Allowed 'General case' 0 N--CA 1.389 -3.492 0 N-CA-C 104.416 -2.438 . . . . 0.0 104.416 174.798 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -113.64 -169.86 1.59 Allowed 'General case' 0 C--N 1.286 -2.169 0 N-CA-C 113.05 0.759 . . . . 0.0 113.05 -173.19 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.515 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 35.0 p -97.49 170.52 7.09 Favored Pre-proline 0 C--N 1.31 -1.114 0 CA-C-N 115.439 -0.8 . . . . 0.0 111.843 178.601 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . 0.416 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 37.2 Cg_endo -65.4 166.39 19.59 Favored 'Trans proline' 0 C--O 1.251 1.148 0 C-N-CA 122.277 1.985 . . . . 0.0 109.707 170.044 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 47.7 ttp180 -73.32 140.12 46.52 Favored 'General case' 0 C--N 1.308 -1.212 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.768 -179.356 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 56.2 t -141.07 120.61 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.898 0 CA-C-N 114.925 -1.034 . . . . 0.0 109.314 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 70.8 t -95.39 140.51 16.79 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.896 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 175.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . 1.642 ' HD1' ' CD2' ' A' ' 95' ' ' TYR . 1.7 m-85 -87.85 100.75 13.11 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 175.412 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 17.4 m120 -89.11 60.27 5.31 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.649 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.6 m -135.3 178.3 7.14 Favored 'General case' 0 N--CA 1.425 -1.716 0 CA-C-N 114.44 -1.254 . . . . 0.0 109.076 -174.385 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 16.9 ptp180 -148.81 45.01 1.01 Allowed 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 122.007 0.908 . . . . 0.0 109.462 175.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.3 t -170.58 -175.36 1.84 Allowed 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 -176.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . 0.426 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 9.2 p-10 -77.06 99.0 5.18 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-O 122.153 0.977 . . . . 0.0 108.398 172.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 2.8 tptm -101.04 136.17 19.79 Favored Pre-proline 0 N--CA 1.405 -2.724 0 CA-C-N 114.939 -1.028 . . . . 0.0 108.233 -177.851 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.662 ' HB3' ' O ' ' A' ' 39' ' ' SER . 80.0 Cg_exo -48.43 139.66 22.31 Favored 'Trans proline' 0 C--N 1.324 -0.752 0 C-N-CA 123.939 3.093 . . . . 0.0 113.658 177.383 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.5 t90 -90.11 105.69 12.17 Favored Pre-proline 0 C--N 1.31 -1.146 0 N-CA-C 106.754 -1.573 . . . . 0.0 106.754 -178.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -73.78 89.27 1.0 Allowed 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.293 1.995 . . . . 0.0 112.686 -173.464 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.409 HG21 ' CD2' ' A' ' 77' ' ' TYR . 90.1 t -136.31 145.2 31.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 177.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.607 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.96 133.08 15.28 Favored 'General case' 0 N--CA 1.417 -2.078 0 CA-C-O 121.06 0.457 . . . . 0.0 110.766 178.071 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.4 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 14.2 mt -101.93 100.12 10.39 Favored 'General case' 0 C--N 1.288 -2.086 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 179.03 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 1.624 ' HE2' ' CE1' ' A' ' 108' ' ' TYR . 63.1 m-85 -77.38 78.24 3.91 Favored 'General case' 0 C--N 1.306 -1.298 0 O-C-N 122.067 -0.395 . . . . 0.0 110.255 177.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.614 HD22 ' CD2' ' A' ' 84' ' ' PHE . 3.0 mm? -104.56 118.24 36.11 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-O 121.167 0.508 . . . . 0.0 110.066 176.732 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.79 145.93 46.75 Favored Pre-proline 0 N--CA 1.414 -2.238 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.889 -173.628 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -63.43 121.61 9.47 Favored 'Trans proline' 0 CA--C 1.5 -1.195 0 C-N-CA 122.986 2.457 . . . . 0.0 113.57 -175.23 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.637 ' O ' HG23 ' A' ' 30' ' ' VAL . 19.8 m -82.0 -155.27 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.399 -3.0 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.108 171.498 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 8.5 m -79.73 -29.92 40.73 Favored 'General case' 0 C--N 1.257 -3.447 0 CA-C-O 121.515 0.674 . . . . 0.0 110.721 -167.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 5.3 t -91.47 25.5 2.6 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-O 121.664 0.745 . . . . 0.0 110.514 -176.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -102.83 128.74 49.47 Favored 'General case' 0 N--CA 1.418 -2.061 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.99 128.88 1.72 Allowed Glycine 0 C--N 1.307 -1.048 0 C-N-CA 120.151 -1.023 . . . . 0.0 111.765 -178.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.24 -152.71 52.81 Favored Glycine 0 CA--C 1.493 -1.343 0 CA-C-O 118.925 -0.931 . . . . 0.0 111.532 -176.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 63.4 t -55.85 106.04 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.246 0.914 0 CA-C-O 121.586 0.708 . . . . 0.0 110.79 -177.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -106.27 -33.07 7.91 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 114.535 -1.211 . . . . 0.0 110.622 -178.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 74.8 mt -121.54 139.91 47.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 177.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 3.8 mmpt? -115.47 136.41 53.11 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 123.138 0.575 . . . . 0.0 110.973 178.547 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -72.13 131.11 42.37 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.709 178.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 92.29 -5.3 77.93 Favored Glycine 0 C--N 1.309 -0.953 0 N-CA-C 111.561 -0.616 . . . . 0.0 111.561 -178.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 61.3 m -98.4 149.04 23.08 Favored 'General case' 0 N--CA 1.425 -1.719 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 179.556 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 26.6 tp -72.69 138.19 46.45 Favored 'General case' 0 N--CA 1.433 -1.31 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.14 178.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.483 ' HB ' HG23 ' A' ' 67' ' ' VAL . 34.4 pt -121.27 -27.08 2.02 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 N-CA-C 112.392 0.516 . . . . 0.0 112.392 178.708 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.93 168.79 20.68 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -177.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 75.1 t -143.55 116.18 3.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 179.176 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 63.4 mt -117.37 154.46 31.27 Favored 'General case' 0 C--N 1.283 -2.297 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 179.173 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.481 ' O ' HD13 ' A' ' 58' ' ' LEU . 5.0 mp -135.73 127.69 45.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.821 -0.549 . . . . 0.0 109.704 177.623 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.493 ' C ' HD13 ' A' ' 131' ' ' LEU . 1.2 pp -89.34 150.18 22.69 Favored 'General case' 0 CA--C 1.484 -1.592 0 N-CA-C 106.673 -1.602 . . . . 0.0 106.673 173.693 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 54.5 ttp180 -115.71 120.93 40.95 Favored 'General case' 0 C--N 1.269 -2.917 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 176.862 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 21.9 tp60 -93.96 121.22 35.2 Favored 'General case' 0 N--CA 1.422 -1.83 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -175.076 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 27.7 m -133.47 149.78 51.74 Favored 'General case' 0 C--N 1.292 -1.92 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 174.6 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.671 ' CB ' HG21 ' A' ' 52' ' ' ILE . 8.0 p30 . . . . . 0 C--O 1.213 -0.866 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.59 175.723 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . 1.641 ' HD2' ' CD1' ' A' ' 142' ' ' PHE . 53.1 m-85 . . . . . 0 N--CA 1.421 -1.888 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -131.37 144.23 51.07 Favored 'General case' 0 N--CA 1.407 -2.6 0 C-N-CA 118.416 -1.314 . . . . 0.0 110.963 179.249 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 1.635 ' HD1' ' CD2' ' A' ' 144' ' ' PHE . 11.0 m-30 -110.7 125.92 53.99 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 -176.367 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . 0.455 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 48.7 t -88.22 134.44 28.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 CA-C-O 121.076 0.465 . . . . 0.0 110.196 -178.549 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 65.8 m95 -120.79 94.39 4.34 Favored 'General case' 0 C--N 1.285 -2.239 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -179.209 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -78.72 114.95 18.08 Favored 'General case' 0 C--N 1.286 -2.19 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 178.53 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 18.3 mm -90.18 120.33 38.81 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 -176.548 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -117.52 155.08 30.38 Favored 'General case' 0 CA--C 1.488 -1.405 0 CA-C-O 121.324 0.583 . . . . 0.0 109.919 177.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.54 131.21 35.22 Favored 'General case' 0 N--CA 1.407 -2.606 0 CA-C-N 115.01 -0.995 . . . . 0.0 108.82 176.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 40.3 t-20 -91.32 -13.35 32.75 Favored 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 -177.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -152.01 145.72 25.03 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 114.169 -1.378 . . . . 0.0 109.67 -175.389 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -84.44 144.89 28.47 Favored 'General case' 0 C--N 1.319 -0.739 0 O-C-N 124.317 1.011 . . . . 0.0 109.195 -178.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.478 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 1.5 m -125.21 148.96 29.6 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.9 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 9.3 t -124.66 138.32 54.45 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 N-CA-C 107.686 -1.228 . . . . 0.0 107.686 -178.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 81.5 t -100.04 101.8 15.53 Favored Pre-proline 0 C--N 1.292 -1.892 0 C-N-CA 123.677 0.791 . . . . 0.0 109.982 179.368 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.441 ' HG3' HG11 ' A' ' 27' ' ' VAL . 35.2 Cg_endo -70.12 -23.52 29.07 Favored 'Trans proline' 0 CA--C 1.509 -0.749 0 C-N-CA 122.319 2.013 . . . . 0.0 111.801 178.62 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.1 t . . . . . 0 C--O 1.248 0.99 0 O-C-N 124.716 1.26 . . . . 0.0 112.404 179.359 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.438 -1.046 0 N-CA-C 102.837 -3.023 . . . . 0.0 102.837 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.465 ' HB3' ' CZ2' ' A' ' 146' ' ' TRP . 11.5 t -150.5 158.32 44.02 Favored 'General case' 0 C--N 1.283 -2.318 0 C-N-CA 117.232 -1.787 . . . . 0.0 111.081 -174.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -144.26 160.88 40.24 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 121.474 0.654 . . . . 0.0 110.713 -175.816 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 57.2 p -97.68 178.73 5.07 Favored 'General case' 0 C--N 1.293 -1.888 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.648 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -82.04 -21.01 37.16 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.712 178.514 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -87.09 -29.07 22.15 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.997 -176.224 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.16 7.52 2.85 Favored Glycine 0 C--N 1.307 -1.073 0 C-N-CA 119.222 -1.466 . . . . 0.0 114.34 171.308 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.0 m -86.94 101.09 13.09 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 177.216 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -97.06 119.92 36.46 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-N 115.484 -0.78 . . . . 0.0 108.945 176.025 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 50.9 mt -97.7 116.46 65.77 Favored Pre-proline 0 C--N 1.297 -1.7 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.564 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -79.42 176.75 9.31 Favored 'Trans proline' 0 C--O 1.25 1.075 0 C-N-CA 122.653 2.236 . . . . 0.0 110.387 177.331 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 56.7 mt -72.04 125.35 30.52 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.343 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 177.669 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 149.22 -6.45 0.81 Allowed Glycine 0 C--N 1.299 -1.48 0 CA-C-N 115.6 -0.727 . . . . 0.0 112.001 -176.482 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.17 156.77 33.06 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 120.709 -0.758 . . . . 0.0 111.373 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.34 -165.83 34.0 Favored Glycine 0 N--CA 1.419 -2.456 0 C-N-CA 119.818 -1.182 . . . . 0.0 111.604 178.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 59.8 p -145.7 155.17 42.81 Favored 'General case' 0 N--CA 1.417 -2.077 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 -177.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.81 155.64 50.03 Favored 'General case' 0 N--CA 1.416 -2.151 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 177.284 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -105.01 109.97 22.18 Favored 'General case' 0 C--N 1.279 -2.459 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 174.778 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.2 t -97.33 135.52 31.33 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -177.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 77.7 m-85 -116.62 126.82 53.8 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -178.547 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.461 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.5 p -135.54 129.45 49.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.195 -176.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -94.52 126.02 39.53 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-O 121.683 0.754 . . . . 0.0 110.423 178.197 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -103.44 162.59 12.9 Favored 'General case' 0 C--N 1.286 -2.157 0 CA-C-N 114.278 -1.328 . . . . 0.0 108.019 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . 0.445 ' C ' ' H ' ' A' ' 27' ' ' VAL . . . -54.48 126.07 54.39 Favored Pre-proline 0 CA--C 1.499 -0.998 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 174.722 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.503 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 72.7 Cg_endo -77.44 9.77 2.74 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 122.484 2.123 . . . . 0.0 110.925 179.2 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.445 ' H ' ' C ' ' A' ' 25' ' ' ALA . 14.1 p -138.35 115.97 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.916 0 CA-C-N 114.827 -1.079 . . . . 0.0 108.365 -178.316 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.4 t -150.02 120.05 1.06 Allowed 'Isoleucine or valine' 0 C--O 1.191 -1.985 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 -179.006 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.593 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -107.24 147.85 29.67 Favored 'General case' 0 C--N 1.267 -2.999 0 C-N-CA 122.505 0.322 . . . . 0.0 110.76 -179.973 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.548 HG23 ' O ' ' A' ' 112' ' ' VAL . 98.7 t -43.67 117.35 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 123.329 0.652 . . . . 0.0 111.539 176.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.56 -1.72 42.57 Favored Glycine 0 C--N 1.319 -0.396 0 CA-C-N 114.779 -1.101 . . . . 0.0 112.809 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.593 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -73.35 -176.69 2.31 Favored 'General case' 0 C--N 1.315 -0.896 0 C-N-CA 124.011 0.924 . . . . 0.0 110.775 177.37 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -129.5 83.35 2.13 Favored 'General case' 0 CA--C 1.49 -1.327 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.238 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.557 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 19.1 tp -90.72 133.23 35.31 Favored 'General case' 0 N--CA 1.419 -1.977 0 C-N-CA 119.151 -1.019 . . . . 0.0 108.516 178.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.407 ' CG2' ' HB2' ' A' ' 106' ' ' ALA . 2.2 p -141.44 133.92 29.22 Favored 'Isoleucine or valine' 0 N--CA 1.383 -3.792 0 CA-C-O 121.882 0.848 . . . . 0.0 111.728 -178.572 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.621 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 45.6 t -89.2 89.92 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.52 0 CA-C-N 113.732 -1.577 . . . . 0.0 108.333 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -76.53 109.72 10.49 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 120.876 0.37 . . . . 0.0 110.89 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 93.0 mt -92.29 -1.54 57.01 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 115.905 -0.588 . . . . 0.0 112.549 -178.698 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 89.9 p -76.81 1.08 18.41 Favored 'General case' 0 N--CA 1.474 0.762 0 CA-C-O 123.0 1.381 . . . . 0.0 109.754 -179.649 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.7 p -123.92 6.64 8.66 Favored 'General case' 0 C--N 1.276 -2.628 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.881 179.184 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.461 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 42.4 mm-40 -127.14 -25.14 3.31 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.604 -175.232 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 23.1 mt -132.64 137.44 54.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 -175.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.672 ' HE1' ' CE2' ' A' ' 43' ' ' PHE . 40.4 m-85 -140.65 123.41 16.28 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -176.305 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 79.7 m -103.71 142.9 33.54 Favored 'General case' 0 C--N 1.271 -2.82 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 -178.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 p80 -136.75 168.06 20.26 Favored 'General case' 0 C--N 1.294 -1.836 0 CA-C-O 121.335 0.588 . . . . 0.0 110.787 -172.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.448 ' HB3' ' OD1' ' A' ' 54' ' ' ASP . 5.4 p30 -112.41 100.0 8.43 Favored 'General case' 0 C--N 1.281 -2.383 0 CA-C-O 122.2 1.0 . . . . 0.0 111.814 175.566 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -76.26 -31.21 58.17 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 178.192 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 1.664 ' HE1' ' CE2' ' A' ' 48' ' ' TYR . 23.2 m-85 -127.88 87.97 54.4 Favored Pre-proline 0 N--CA 1.435 -1.22 0 N-CA-C 106.004 -1.851 . . . . 0.0 106.004 177.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -88.59 -13.34 3.4 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 122.319 2.013 . . . . 0.0 113.976 -176.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -110.92 -12.35 14.25 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.622 -0.831 . . . . 0.0 110.756 -176.116 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.46 ' OG1' ' HB3' ' A' ' 48' ' ' TYR . 0.0 OUTLIER -101.4 -31.36 10.97 Favored 'General case' 0 N--CA 1.417 -2.115 0 CA-C-N 115.406 -0.815 . . . . 0.0 110.194 179.771 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.592 HG21 ' CB ' ' A' ' 135' ' ' ASN . 3.1 mp -121.9 126.54 74.67 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.592 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.6 t -72.75 135.06 45.25 Favored 'General case' 0 N--CA 1.421 -1.901 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 174.602 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.448 ' OD1' ' HB3' ' A' ' 46' ' ' ASN . 58.7 m-20 -87.06 107.6 18.51 Favored 'General case' 0 C--N 1.278 -2.506 0 CA-C-O 121.939 0.876 . . . . 0.0 111.343 -171.093 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 1.65 ' HD2' ' CD1' ' A' ' 55' ' ' TYR . 70.4 t80 -137.91 145.8 42.54 Favored 'General case' 0 C--N 1.29 -1.997 0 CA-C-N 114.078 -1.419 . . . . 0.0 108.058 -175.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.9 p -152.25 148.38 14.39 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.786 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.309 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -151.34 140.37 21.09 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 174.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.555 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 50.5 tp -75.19 117.76 17.37 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 173.346 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.483 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 3.6 tp-100 -65.54 -44.92 85.35 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.456 -1.247 . . . . 0.0 110.458 -177.851 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . 0.483 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 10.4 ptp180 -176.97 161.87 1.99 Allowed 'General case' 0 N--CA 1.432 -1.34 0 O-C-N 124.708 1.255 . . . . 0.0 108.423 -176.407 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.08 129.53 3.8 Favored Glycine 0 N--CA 1.408 -3.174 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -178.302 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 54.2 m -117.35 149.38 40.59 Favored 'General case' 0 C--N 1.291 -1.944 0 C-N-CA 124.099 0.96 . . . . 0.0 110.461 -174.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.509 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -113.37 156.16 23.93 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 1.654 ' HE1' ' CE2' ' A' ' 64' ' ' TYR . 88.4 m-85 -154.6 -179.92 8.44 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 124.155 0.982 . . . . 0.0 108.867 -178.407 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 57.79 -143.56 42.39 Favored Glycine 0 C--N 1.325 -0.081 0 O-C-N 123.891 0.744 . . . . 0.0 113.513 176.13 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -72.97 -14.23 78.78 Favored Glycine 0 C--O 1.209 -1.468 0 C-N-CA 120.846 -0.693 . . . . 0.0 111.717 177.565 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.52 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 95.2 t -67.59 -39.37 82.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 123.804 0.842 . . . . 0.0 111.606 -177.717 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.509 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -87.1 -19.03 29.13 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 118.67 -1.212 . . . . 0.0 112.192 178.027 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 6.2 t -98.36 -56.58 2.43 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.537 -172.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.486 ' O ' HG23 ' A' ' 112' ' ' VAL . 41.3 m-20 -92.03 -22.97 19.67 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.24 -173.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 0.538 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 92.0 m-85 -108.73 156.93 19.03 Favored 'General case' 0 N--CA 1.419 -1.999 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.489 178.598 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 12.7 t -161.38 136.41 7.46 Favored 'General case' 0 N--CA 1.403 -2.787 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 176.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.509 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.97 -111.67 0.26 Allowed Glycine 0 N--CA 1.398 -3.893 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 174.19 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.2 p -159.66 -179.92 8.3 Favored 'General case' 0 C--N 1.297 -1.684 0 C-N-CA 124.001 0.92 . . . . 0.0 110.425 -172.743 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -132.1 145.9 34.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 178.202 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.669 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.2 tttt -126.58 145.45 50.53 Favored 'General case' 0 N--CA 1.427 -1.585 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -178.189 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 1.657 ' HD2' ' CD1' ' A' ' 77' ' ' TYR . 58.9 t80 -145.63 110.69 5.23 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 -177.691 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 44.9 t 53.27 37.08 24.36 Favored 'General case' 0 CA--C 1.55 0.963 0 C-N-CA 123.35 0.66 . . . . 0.0 111.982 178.04 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.32 8.54 66.2 Favored Glycine 0 CA--C 1.525 0.698 0 C-N-CA 120.301 -0.952 . . . . 0.0 113.663 -179.384 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.669 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 20.8 t -81.59 -179.79 7.52 Favored 'General case' 0 CA--C 1.544 0.735 0 CA-C-N 117.383 0.592 . . . . 0.0 109.51 178.412 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.0 p -156.78 109.22 2.51 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 1.623 ' HD1' ' CD2' ' A' ' 82' ' ' TYR . 2.3 p90 -151.89 158.71 33.84 Favored Pre-proline 0 C--N 1.306 -1.323 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 -175.52 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -68.73 150.94 74.69 Favored 'Trans proline' 0 C--N 1.354 0.817 0 C-N-CA 122.879 2.386 . . . . 0.0 113.096 -176.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.568 ' CD2' HD22 ' A' ' 109' ' ' LEU . 54.0 t80 -124.46 132.15 24.26 Favored Pre-proline 0 N--CA 1.442 -0.867 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.219 -179.684 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.48 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 72.4 Cg_endo -72.53 148.2 90.99 Favored 'Cis proline' 0 CA--C 1.535 0.558 0 C-N-CA 122.8 -1.75 . . . . 0.0 109.984 -0.873 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.0 t -67.09 -177.49 0.66 Allowed 'General case' 0 C--O 1.248 1.017 0 CA-C-O 121.367 0.603 . . . . 0.0 111.29 -175.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.8 p -120.7 -25.13 5.55 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 115.286 -0.87 . . . . 0.0 110.647 -173.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 t -135.38 -107.95 0.21 Allowed 'General case' 0 N--CA 1.419 -1.985 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 178.555 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . 0.409 ' HB2' ' O ' ' A' ' 58' ' ' LEU . 0.0 OUTLIER -144.44 -165.66 2.19 Favored 'General case' 0 N--CA 1.445 -0.723 0 CA-C-N 118.251 0.478 . . . . 0.0 110.749 -177.508 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.555 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 58.3 p -100.26 168.16 9.83 Favored Pre-proline 0 C--N 1.306 -1.286 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 179.55 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -63.62 172.26 5.88 Favored 'Trans proline' 0 C--O 1.251 1.139 0 C-N-CA 123.062 2.508 . . . . 0.0 110.48 170.02 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 41.2 ttp180 -71.49 142.32 50.16 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.12 -177.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 64.0 t -151.16 131.57 4.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 124.355 1.062 . . . . 0.0 108.427 -179.048 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.424 HG21 ' O ' ' A' ' 54' ' ' ASP . 2.2 p -128.93 141.46 46.55 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 108.253 -1.018 . . . . 0.0 108.253 -178.729 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -92.99 108.33 19.92 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-O 121.251 0.548 . . . . 0.0 111.234 -178.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -94.38 45.97 1.14 Allowed 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.6 t -124.03 -176.57 3.52 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 -175.77 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 37.8 ptt180 -148.14 33.78 0.82 Allowed 'General case' 0 C--N 1.314 -0.948 0 CA-C-O 121.879 0.847 . . . . 0.0 109.619 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.1 t -165.58 -178.97 5.16 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 -178.52 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -77.12 130.15 36.97 Favored 'General case' 0 CA--C 1.501 -0.928 0 CA-C-O 121.515 0.674 . . . . 0.0 109.956 -179.748 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 15.8 mmtm -129.72 141.35 41.52 Favored Pre-proline 0 C--N 1.287 -2.137 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.08 -179.558 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -61.53 137.58 70.31 Favored 'Trans proline' 0 CA--C 1.499 -1.246 0 C-N-CA 123.571 2.847 . . . . 0.0 112.7 -174.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.6 t90 -81.5 108.58 11.22 Favored Pre-proline 0 C--N 1.304 -1.409 0 N-CA-C 106.393 -1.706 . . . . 0.0 106.393 -177.479 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -76.22 87.69 1.41 Allowed 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 121.231 1.287 . . . . 0.0 112.718 -172.045 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.43 HG21 ' CD2' ' A' ' 77' ' ' TYR . 57.6 t -137.83 146.53 27.18 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.203 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 177.544 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.621 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.38 134.73 16.09 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 177.446 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 16.7 mt -102.87 99.95 9.9 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.443 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 1.635 ' HE2' ' CE1' ' A' ' 108' ' ' TYR . 71.5 m-85 -78.36 81.36 4.71 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 177.513 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.568 HD22 ' CD2' ' A' ' 84' ' ' PHE . 3.1 mm? -107.1 118.6 37.13 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 176.366 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -120.99 148.41 48.72 Favored Pre-proline 0 N--CA 1.41 -2.448 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.253 -173.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -66.13 120.96 8.18 Favored 'Trans proline' 0 N--CA 1.44 -1.646 0 C-N-CA 122.892 2.395 . . . . 0.0 113.47 -175.055 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.548 ' O ' HG23 ' A' ' 30' ' ' VAL . 21.7 m -81.03 -157.29 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.393 -3.297 0 CA-C-N 114.49 -1.232 . . . . 0.0 108.814 170.75 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 30.9 m -82.96 -26.47 31.34 Favored 'General case' 0 C--N 1.252 -3.645 0 CA-C-O 121.699 0.761 . . . . 0.0 110.912 -170.127 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 19.6 t -83.36 13.64 4.21 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.197 -0.911 . . . . 0.0 110.189 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -98.3 125.31 43.35 Favored 'General case' 0 N--CA 1.428 -1.557 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.569 179.352 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -168.67 129.74 1.94 Allowed Glycine 0 N--CA 1.431 -1.642 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 178.687 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.71 -148.8 49.94 Favored Glycine 0 CA--C 1.493 -1.322 0 CA-C-O 119.232 -0.76 . . . . 0.0 111.883 -177.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.434 ' CG1' ' HE3' ' A' ' 121' ' ' LYS . 65.9 t -60.04 101.66 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.248 0.991 0 CA-C-O 122.078 0.942 . . . . 0.0 111.117 -176.435 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -101.57 -23.11 14.34 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 114.137 -1.392 . . . . 0.0 111.498 -177.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.42 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 61.8 mt -136.7 141.21 41.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.68 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.46 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.6 mmpt? -116.2 141.31 48.31 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 120.843 0.354 . . . . 0.0 110.347 177.006 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.06 148.07 50.58 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.725 179.667 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 71.78 14.37 75.49 Favored Glycine 0 C--O 1.218 -0.845 0 CA-C-N 115.828 -0.623 . . . . 0.0 111.555 178.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 20.0 m -119.08 143.4 47.16 Favored 'General case' 0 N--CA 1.421 -1.891 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -175.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -68.6 127.05 31.61 Favored 'General case' 0 C--O 1.242 0.659 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.167 -178.032 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.465 ' HB ' HG23 ' A' ' 67' ' ' VAL . 27.9 pt -115.9 -26.91 2.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -159.92 168.13 26.42 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -178.041 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 65.7 t -142.64 114.06 3.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.443 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 56.8 mt -115.43 155.76 26.85 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 178.3 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.519 ' O ' HD11 ' A' ' 58' ' ' LEU . 5.1 mp -135.68 131.13 50.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 CA-C-N 118.52 0.6 . . . . 0.0 109.751 177.733 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . . . . . . . . . 1.8 pp -92.58 139.79 30.21 Favored 'General case' 0 CA--C 1.489 -1.399 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 172.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 27.1 tpt180 -97.31 108.0 20.64 Favored 'General case' 0 C--N 1.251 -3.714 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 19.4 tp60 -87.67 118.6 27.27 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -177.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 22.2 m -137.03 140.52 42.14 Favored 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 173.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.592 ' CB ' HG21 ' A' ' 52' ' ' ILE . 10.8 p30 . . . . . 0 N--CA 1.444 -0.751 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.899 178.008 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . 1.596 ' HE1' ' CE2' ' A' ' 142' ' ' PHE . 78.0 m-85 . . . . . 0 N--CA 1.425 -1.723 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -141.86 149.46 40.3 Favored 'General case' 0 C--N 1.282 -2.366 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 176.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 9.7 m-30 -109.26 125.25 52.07 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 -174.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 48.2 t -89.27 135.52 25.75 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.926 0 O-C-N 123.749 0.656 . . . . 0.0 110.074 -178.209 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . 0.465 ' CZ2' ' HB3' ' A' ' 3' ' ' CYS . 61.6 m95 -120.38 96.26 5.07 Favored 'General case' 0 C--N 1.284 -2.246 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 -179.317 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 37.3 m-80 -80.58 112.83 18.31 Favored 'General case' 0 C--N 1.291 -1.946 0 N-CA-C 106.587 -1.634 . . . . 0.0 106.587 179.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 28.1 mm -87.48 122.83 39.72 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -176.193 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 1.621 ' HD1' ' CD2' ' A' ' 149' ' ' TYR . 61.2 m-85 -117.12 151.9 35.85 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 123.786 0.834 . . . . 0.0 109.442 178.464 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.68 130.21 34.98 Favored 'General case' 0 N--CA 1.413 -2.318 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 176.064 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 39.6 t-20 -89.12 -17.52 29.05 Favored 'General case' 0 C--N 1.288 -2.068 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 -178.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -147.17 143.04 27.93 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-N 114.418 -1.265 . . . . 0.0 109.462 -174.477 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -86.07 138.66 31.78 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 124.083 0.865 . . . . 0.0 111.477 -178.733 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.503 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.8 t -114.44 137.82 46.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 114.946 -1.025 . . . . 0.0 112.334 -171.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -117.79 138.28 48.99 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.351 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 177.494 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.452 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 53.2 t -101.89 103.66 30.52 Favored Pre-proline 0 C--N 1.29 -1.979 0 C-N-CA 123.618 0.767 . . . . 0.0 109.756 178.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.45 ' HD2' ' O ' ' A' ' 28' ' ' VAL . 30.8 Cg_endo -68.08 -26.11 37.17 Favored 'Trans proline' 0 CA--C 1.506 -0.908 0 C-N-CA 122.429 2.086 . . . . 0.0 111.878 177.295 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.4 t . . . . . 0 C--N 1.349 0.578 0 O-C-N 124.748 1.28 . . . . 0.0 112.33 179.233 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.469 ' HB1' ' NE2' ' A' ' 45' ' ' HIS . . . . . . . . 0 CA--C 1.492 -1.258 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.4 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 63.1 m -134.39 155.41 50.34 Favored 'General case' 0 C--N 1.288 -2.071 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.786 -174.105 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.5 155.52 43.15 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-O 121.223 0.535 . . . . 0.0 109.917 -176.333 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.402 HG21 HG23 ' A' ' 20' ' ' VAL . 72.9 p -92.25 175.01 7.01 Favored 'General case' 0 C--N 1.292 -1.922 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.77 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -85.61 -11.49 53.81 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.278 -1.328 . . . . 0.0 109.716 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -95.21 -27.35 15.57 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-N 115.138 -0.937 . . . . 0.0 111.751 -178.279 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 136.64 1.04 2.8 Favored Glycine 0 C--O 1.222 -0.621 0 C-N-CA 119.155 -1.498 . . . . 0.0 114.845 169.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.2 m -87.86 105.94 17.76 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 121.455 0.645 . . . . 0.0 109.579 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -98.99 119.55 37.97 Favored 'General case' 0 C--N 1.291 -1.953 0 CA-C-N 114.735 -1.12 . . . . 0.0 109.224 176.402 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.439 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 60.0 mt -100.36 114.66 65.79 Favored Pre-proline 0 C--N 1.303 -1.429 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.102 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_endo -76.59 171.87 17.26 Favored 'Trans proline' 0 C--O 1.249 1.037 0 C-N-CA 122.385 2.057 . . . . 0.0 111.354 177.262 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 68.4 mt -58.06 134.03 22.85 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.967 179.031 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 128.59 2.75 5.74 Favored Glycine 0 C--N 1.303 -1.257 0 C-N-CA 120.344 -0.931 . . . . 0.0 112.466 179.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.04 164.89 34.82 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.13 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.74 -166.51 34.44 Favored Glycine 0 C--N 1.295 -1.743 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.701 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.1 p -141.24 154.33 45.72 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -178.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -143.37 159.38 42.48 Favored 'General case' 0 N--CA 1.421 -1.88 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.36 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.8 p30 -103.22 122.87 45.65 Favored 'General case' 0 C--N 1.275 -2.67 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 173.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.402 HG23 HG21 ' A' ' 5' ' ' THR . 40.3 t -106.81 129.71 59.95 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.76 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.737 177.826 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 -112.88 121.17 43.88 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 120.982 0.42 . . . . 0.0 111.23 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.492 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.3 p -133.92 130.24 55.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-N 115.318 -0.856 . . . . 0.0 111.164 -178.667 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -92.25 130.83 37.85 Favored 'General case' 0 C--N 1.296 -1.758 0 CA-C-O 121.37 0.605 . . . . 0.0 110.429 177.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . 0.43 HD22 HG23 ' A' ' 36' ' ' VAL . 6.9 mp -109.18 161.85 14.83 Favored 'General case' 0 C--N 1.287 -2.118 0 CA-C-N 114.489 -1.232 . . . . 0.0 108.877 179.454 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.01 121.1 48.17 Favored Pre-proline 0 C--O 1.209 -1.06 0 O-C-N 124.777 1.298 . . . . 0.0 109.486 179.177 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 66.1 Cg_endo -75.7 -0.91 10.72 Favored 'Trans proline' 0 CA--C 1.531 0.332 0 C-N-CA 122.906 2.404 . . . . 0.0 113.539 -176.78 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 96.0 t -127.93 109.63 20.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 178.407 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.498 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 5.7 t -145.59 112.43 1.22 Allowed 'Isoleucine or valine' 0 C--O 1.189 -2.116 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 -177.558 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.443 ' H ' ' HG3' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -100.78 152.12 20.88 Favored 'General case' 0 C--N 1.266 -3.064 0 C-N-CA 123.138 0.575 . . . . 0.0 111.004 -179.843 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 41.5 t -43.81 116.51 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 123.727 0.811 . . . . 0.0 111.631 175.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.51 -5.52 35.39 Favored Glycine 0 C--O 1.227 -0.296 0 CA-C-N 115.421 -0.808 . . . . 0.0 112.99 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.443 ' HG3' ' H ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -69.34 -177.89 1.24 Allowed 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 123.669 0.788 . . . . 0.0 111.786 177.817 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -126.62 86.19 2.48 Favored 'General case' 0 CA--C 1.482 -1.646 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 176.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.605 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 24.4 tp -95.73 134.98 38.02 Favored 'General case' 0 N--CA 1.41 -2.433 0 C-N-CA 119.202 -0.999 . . . . 0.0 109.453 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.7 p -141.78 137.79 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.38 -3.941 0 CA-C-N 114.729 -1.123 . . . . 0.0 112.07 -177.633 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.603 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 58.4 t -90.48 89.89 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.335 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 176.26 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -76.01 106.57 7.68 Favored 'General case' 0 C--N 1.297 -1.717 0 C-N-CA 120.057 -0.657 . . . . 0.0 109.669 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.8 mt -95.03 -1.16 52.87 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.822 -179.188 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 15.2 m -77.41 0.58 21.98 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-O 122.074 0.94 . . . . 0.0 109.478 -177.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.2 p -128.46 5.39 5.68 Favored 'General case' 0 N--CA 1.421 -1.901 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.157 178.776 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.492 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 47.1 mm-40 -122.74 -24.21 4.91 Favored 'General case' 0 CA--C 1.503 -0.835 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.73 -174.385 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.7 mt -130.47 140.07 49.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 -176.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.633 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 55.7 m-85 -138.13 149.74 46.18 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 -176.631 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.4 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 70.2 m -125.87 134.08 51.73 Favored 'General case' 0 C--N 1.289 -2.047 0 C-N-CA 122.794 0.437 . . . . 0.0 110.061 176.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . 0.469 ' NE2' ' HB1' ' A' ' 2' ' ' ALA . 11.6 p-80 -119.35 150.79 39.57 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-O 121.998 0.904 . . . . 0.0 110.386 -177.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -99.35 101.99 13.44 Favored 'General case' 0 C--N 1.272 -2.789 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 -179.022 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 18.3 p-10 -86.62 -17.63 33.4 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 -179.247 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 67.3 m-85 -138.47 62.79 31.66 Favored Pre-proline 0 N--CA 1.477 0.91 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 175.184 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.8 -3.31 11.79 Favored 'Trans proline' 0 N--CA 1.485 0.971 0 C-N-CA 123.208 2.605 . . . . 0.0 114.454 -171.074 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -115.54 -17.35 11.2 Favored 'General case' 0 C--N 1.299 -1.625 0 CA-C-O 121.286 0.565 . . . . 0.0 110.272 -178.137 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.415 ' HB ' HD13 ' A' ' 52' ' ' ILE . 1.9 m -102.23 -30.36 11.15 Favored 'General case' 0 N--CA 1.424 -1.766 0 CA-C-O 122.064 0.935 . . . . 0.0 108.826 -174.38 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.482 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.0 mp -123.58 137.07 58.02 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.493 0 CA-C-N 114.164 -1.38 . . . . 0.0 109.043 -178.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 3.9 t -83.97 122.35 28.63 Favored 'General case' 0 N--CA 1.419 -1.986 0 N-CA-C 102.68 -3.082 . . . . 0.0 102.68 168.431 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -88.98 107.76 19.21 Favored 'General case' 0 C--N 1.261 -3.268 0 C-N-CA 118.313 -1.355 . . . . 0.0 109.013 -172.338 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 1.653 ' HD1' ' CD2' ' A' ' 55' ' ' TYR . 17.0 t80 -122.63 131.58 53.88 Favored 'General case' 0 C--N 1.285 -2.204 0 CA-C-N 114.382 -1.281 . . . . 0.0 109.638 -174.727 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.408 ' CG2' ' HG ' ' A' ' 131' ' ' LEU . 14.9 p -136.87 144.8 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.138 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.685 -175.705 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -150.02 118.49 6.49 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 178.04 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.519 HD13 ' O ' ' A' ' 130' ' ' ILE . 48.0 tp -53.91 111.03 0.67 Allowed 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 169.884 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 -59.74 -51.06 71.37 Favored 'General case' 0 C--O 1.21 -0.976 0 C-N-CA 125.793 1.637 . . . . 0.0 110.574 179.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 11.0 ptp180 -170.01 158.68 7.25 Favored 'General case' 0 N--CA 1.428 -1.567 0 CA-C-N 115.172 -0.922 . . . . 0.0 108.804 -176.328 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -134.6 145.74 17.8 Favored Glycine 0 N--CA 1.405 -3.433 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 179.319 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 72.3 m -132.88 150.85 52.12 Favored 'General case' 0 C--N 1.283 -2.326 0 C-N-CA 124.062 0.945 . . . . 0.0 109.918 -177.322 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.494 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -115.3 157.77 23.32 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 -178.545 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 1.667 ' HE1' ' CE2' ' A' ' 64' ' ' TYR . 95.9 m-85 -155.09 -179.6 8.22 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 124.302 1.041 . . . . 0.0 109.008 -178.403 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 54.77 -140.05 38.7 Favored Glycine 0 N--CA 1.455 -0.093 0 O-C-N 123.812 0.695 . . . . 0.0 113.464 178.195 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -73.35 -15.46 78.94 Favored Glycine 0 C--O 1.2 -2.014 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.004 178.344 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.548 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 84.4 t -67.12 -40.03 84.44 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 C-N-CA 123.637 0.775 . . . . 0.0 111.78 -176.823 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.502 ' HG ' ' CA ' ' A' ' 64' ' ' TYR . 0.3 OUTLIER -87.99 -16.43 33.76 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 118.919 -1.112 . . . . 0.0 112.158 178.326 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 23.2 t -100.74 -59.13 1.75 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-O 121.328 0.585 . . . . 0.0 111.992 -174.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.43 ' O ' HG23 ' A' ' 112' ' ' VAL . 34.0 m-20 -90.69 -22.44 21.14 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.875 -171.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 1.623 ' HE1' ' CE2' ' A' ' 71' ' ' PHE . 90.4 m-85 -110.63 157.16 20.0 Favored 'General case' 0 N--CA 1.422 -1.854 0 C-N-CA 119.97 -0.692 . . . . 0.0 110.594 178.759 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.4 t -166.17 130.63 2.21 Favored 'General case' 0 N--CA 1.417 -2.075 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 176.269 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.49 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -160.98 -99.77 0.15 Allowed Glycine 0 C--N 1.286 -2.199 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 177.664 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.418 HG21 ' O ' ' A' ' 73' ' ' GLY . 0.7 OUTLIER -168.89 -179.97 3.9 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.893 1.277 . . . . 0.0 109.97 -177.643 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.0 147.03 32.36 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 C-N-CA 123.255 0.622 . . . . 0.0 109.536 178.324 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.578 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.9 tttt -124.68 147.92 48.29 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.239 -179.43 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 61.3 t80 -148.4 108.8 4.13 Favored 'General case' 0 C--N 1.314 -0.965 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 -179.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 11.2 t 51.78 43.04 30.33 Favored 'General case' 0 C--N 1.315 -0.926 0 C-N-CA 124.251 1.02 . . . . 0.0 111.546 177.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.78 8.26 70.07 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.188 -1.006 . . . . 0.0 113.435 179.038 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.578 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 23.0 t -80.68 -179.66 7.34 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 177.297 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 12.3 p -158.89 106.61 1.84 Allowed 'General case' 0 C--N 1.288 -2.1 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 2.6 p90 -151.52 158.45 34.29 Favored Pre-proline 0 C--N 1.308 -1.205 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -174.449 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . 0.4 ' HA ' HG23 ' A' ' 74' ' ' THR . 44.9 Cg_endo -67.16 148.9 81.64 Favored 'Trans proline' 0 C--N 1.36 1.16 0 C-N-CA 123.092 2.528 . . . . 0.0 112.703 -177.053 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.573 ' CD2' HD22 ' A' ' 109' ' ' LEU . 60.6 t80 -122.07 131.7 24.37 Favored Pre-proline 0 C--N 1.312 -1.035 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.694 -179.447 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.535 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 72.7 Cg_endo -70.89 150.27 92.73 Favored 'Cis proline' 0 CA--C 1.539 0.731 0 C-N-CA 122.956 -1.685 . . . . 0.0 109.915 -1.296 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.9 t -59.47 -177.99 0.06 Allowed 'General case' 0 CA--C 1.559 1.309 0 CA-C-O 121.928 0.87 . . . . 0.0 112.504 -174.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.1 p -115.0 -15.6 11.75 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-N 115.34 -0.846 . . . . 0.0 110.067 -173.596 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.6 t -158.15 -109.53 0.02 OUTLIER 'General case' 0 N--CA 1.415 -2.213 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 178.457 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . 0.401 ' HB2' ' O ' ' A' ' 58' ' ' LEU . 0.5 OUTLIER -132.93 -164.01 1.42 Allowed 'General case' 0 N--CA 1.436 -1.16 0 CA-C-N 118.349 0.522 . . . . 0.0 111.723 179.295 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.452 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 10.8 p -100.14 164.56 16.16 Favored Pre-proline 0 C--N 1.299 -1.606 0 C-N-CA 123.618 0.767 . . . . 0.0 112.405 -177.642 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -65.98 168.74 14.79 Favored 'Trans proline' 0 C--N 1.36 1.148 0 C-N-CA 123.411 2.741 . . . . 0.0 111.21 174.359 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.564 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 3.2 tmm_? -70.2 128.44 36.26 Favored 'General case' 0 N--CA 1.44 -0.964 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 -178.77 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 74.0 t -142.59 120.92 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.666 0 C-N-CA 124.439 1.095 . . . . 0.0 108.11 -178.381 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.0 p -119.81 140.32 44.22 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.209 0 CA-C-O 120.956 0.408 . . . . 0.0 110.775 -177.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . 0.475 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 9.5 m-85 -94.26 112.46 24.26 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 177.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 13.9 m120 -97.49 8.64 44.25 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-O 121.657 0.741 . . . . 0.0 109.218 178.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.8 m -76.7 -175.95 3.61 Favored 'General case' 0 N--CA 1.427 -1.6 0 C-N-CA 124.729 1.212 . . . . 0.0 109.988 -177.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 15.0 ptp180 -143.64 30.57 1.34 Allowed 'General case' 0 C--N 1.309 -1.174 0 CA-C-O 121.001 0.429 . . . . 0.0 110.611 177.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.1 t -163.48 -178.01 5.61 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -175.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -67.31 99.37 0.71 Allowed 'General case' 0 C--O 1.242 0.691 0 O-C-N 123.894 0.746 . . . . 0.0 109.772 178.016 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 11.2 mptt -104.96 141.43 22.53 Favored Pre-proline 0 C--N 1.283 -2.306 0 N-CA-C 106.86 -1.533 . . . . 0.0 106.86 175.641 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -60.85 147.05 96.51 Favored 'Trans proline' 0 C--O 1.243 0.771 0 C-N-CA 122.409 2.073 . . . . 0.0 112.23 -177.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . 0.475 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 11.9 t90 -91.25 104.66 10.28 Favored Pre-proline 0 C--N 1.309 -1.167 0 N-CA-C 105.387 -2.079 . . . . 0.0 105.387 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -75.51 88.12 1.31 Allowed 'Trans proline' 0 N--CA 1.445 -1.366 0 C-N-CA 121.449 1.433 . . . . 0.0 113.0 -171.052 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 72.4 t -136.15 150.78 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.333 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 177.456 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.603 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -156.87 134.45 10.77 Favored 'General case' 0 N--CA 1.421 -1.893 0 O-C-N 123.633 0.583 . . . . 0.0 109.758 176.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 19.7 mt -103.45 99.86 9.71 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.437 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 1.618 ' HD2' ' CD1' ' A' ' 108' ' ' TYR . 65.4 m-85 -78.55 81.56 4.87 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 178.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.605 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.0 mm? -107.03 117.03 32.98 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-O 121.122 0.487 . . . . 0.0 110.629 176.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -120.17 146.88 43.5 Favored Pre-proline 0 N--CA 1.413 -2.3 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.319 -174.54 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -61.0 119.96 7.41 Favored 'Trans proline' 0 C--O 1.249 1.067 0 C-N-CA 123.226 2.618 . . . . 0.0 112.309 -177.538 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 70' ' ' ASN . 3.0 m -68.35 -118.5 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.193 -1.891 0 CA-C-N 114.261 -1.336 . . . . 0.0 111.862 173.783 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.8 t -112.87 -33.11 6.18 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 175.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 36.3 m -80.03 34.5 0.3 Allowed 'General case' 0 N--CA 1.399 -2.982 0 C-N-CA 125.698 1.599 . . . . 0.0 112.742 -178.169 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -118.12 130.01 55.87 Favored 'General case' 0 C--N 1.281 -2.397 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.365 179.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -170.08 128.18 1.6 Allowed Glycine 0 C--O 1.239 0.467 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.647 179.405 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 65.98 -150.48 51.84 Favored Glycine 0 CA--C 1.499 -0.964 0 CA-C-O 118.985 -0.897 . . . . 0.0 111.589 -176.097 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 95.1 t -56.93 105.2 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.873 0.844 . . . . 0.0 111.435 -178.291 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -105.41 -21.58 13.2 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-N 114.327 -1.306 . . . . 0.0 110.919 -177.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.465 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 63.6 mt -135.84 140.54 44.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.445 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.3 mmpt? -115.87 139.56 50.09 Favored 'General case' 0 C--N 1.317 -0.817 0 C-N-CA 122.319 0.248 . . . . 0.0 111.232 178.071 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.53 134.73 47.96 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.227 179.38 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 87.01 -7.91 78.55 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 121.353 -0.451 . . . . 0.0 112.115 -179.233 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 34.7 t -96.11 143.63 27.07 Favored 'General case' 0 N--CA 1.422 -1.843 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.415 HD12 HG21 ' A' ' 128' ' ' VAL . 3.0 tm? -69.86 128.21 35.58 Favored 'General case' 0 N--CA 1.436 -1.17 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.384 -178.463 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.478 ' HB ' HG23 ' A' ' 67' ' ' VAL . 32.6 pt -112.43 -27.05 2.86 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 N-CA-C 112.327 0.492 . . . . 0.0 112.327 -179.886 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.84 168.03 23.76 Favored 'General case' 0 CA--C 1.505 -0.765 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -178.283 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.415 HG21 HD12 ' A' ' 125' ' ' LEU . 59.9 t -142.03 116.94 5.25 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 179.112 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 68.3 mt -117.46 137.58 52.43 Favored 'General case' 0 C--N 1.28 -2.444 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 178.483 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.519 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.3 mp -118.57 122.71 70.15 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 C-N-CA 119.015 -1.074 . . . . 0.0 109.934 177.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.561 ' O ' ' HB2' ' A' ' 143' ' ' GLN . 0.8 OUTLIER -88.53 141.35 28.6 Favored 'General case' 0 C--N 1.266 -3.064 0 C-N-CA 125.053 1.341 . . . . 0.0 108.166 177.554 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 24.9 ttp180 -122.35 131.01 53.69 Favored 'General case' 0 N--CA 1.409 -2.497 0 C-N-CA 120.153 -0.619 . . . . 0.0 109.815 174.307 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.417 HE21 ' HA ' ' A' ' 133' ' ' GLN . 0.0 OUTLIER -98.28 143.66 28.53 Favored 'General case' 0 N--CA 1.42 -1.942 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 -179.487 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.444 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 11.0 m -154.78 138.04 15.73 Favored 'General case' 0 C--N 1.281 -2.402 0 N-CA-C 106.488 -1.671 . . . . 0.0 106.488 173.649 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.482 ' CB ' HG21 ' A' ' 52' ' ' ILE . 11.0 p30 . . . . . 0 C--N 1.318 -0.782 0 CA-C-N 119.227 0.921 . . . . 0.0 112.515 176.108 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 . . . . . 0 N--CA 1.426 -1.673 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . 0.561 ' HB2' ' O ' ' A' ' 131' ' ' LEU . 13.9 pt20 -124.49 142.55 51.24 Favored 'General case' 0 N--CA 1.415 -2.215 0 C-N-CA 118.541 -1.264 . . . . 0.0 111.844 178.534 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 1.655 ' HE1' ' CE2' ' A' ' 144' ' ' PHE . 3.3 m-30 -106.69 129.37 54.6 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -175.344 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 48.5 t -94.53 129.18 45.12 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -178.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . 0.464 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 60.4 m95 -118.47 103.09 9.43 Favored 'General case' 0 C--N 1.278 -2.507 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.141 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 36.8 m-80 -82.05 110.86 17.67 Favored 'General case' 0 C--N 1.286 -2.159 0 N-CA-C 106.699 -1.593 . . . . 0.0 106.699 178.155 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 23.4 mm -85.52 121.14 36.8 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.903 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 -178.046 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 1.602 ' HE1' ' CE2' ' A' ' 149' ' ' TYR . 93.8 m-85 -117.72 151.3 37.55 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 123.618 0.767 . . . . 0.0 109.676 178.463 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -79.97 130.84 35.59 Favored 'General case' 0 N--CA 1.413 -2.295 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 175.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 -92.32 -6.43 50.29 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 -179.317 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -155.39 142.45 19.2 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.205 -176.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -86.83 136.15 33.08 Favored 'General case' 0 C--N 1.309 -1.173 0 O-C-N 123.998 0.811 . . . . 0.0 112.004 -177.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.508 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.7 t -110.32 140.79 27.81 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 CA-C-N 114.966 -1.016 . . . . 0.0 111.987 -171.79 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 13.9 t -122.93 137.45 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.045 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 -179.529 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.498 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 70.0 t -103.28 103.27 33.95 Favored Pre-proline 0 C--N 1.286 -2.165 0 C-N-CA 123.699 0.799 . . . . 0.0 110.106 179.534 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -69.47 -21.88 34.18 Favored 'Trans proline' 0 N--CA 1.463 -0.312 0 C-N-CA 121.959 1.772 . . . . 0.0 111.346 177.322 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.6 t . . . . . 0 C--O 1.244 0.784 0 C-N-CA 124.698 1.199 . . . . 0.0 113.251 176.802 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.414 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.439 -1.005 0 CA-C-O 120.782 0.325 . . . . 0.0 111.04 . . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 80.0 m -143.67 159.05 43.16 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -177.478 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.6 pptp? -141.8 164.51 29.99 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-O 121.384 0.612 . . . . 0.0 111.621 -176.35 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.407 HG21 HG23 ' A' ' 20' ' ' VAL . 76.7 p -103.25 167.27 9.93 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.168 179.257 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.34 -9.49 58.65 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-N 113.729 -1.578 . . . . 0.0 112.474 179.563 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -94.37 -33.42 13.18 Favored 'General case' 0 C--O 1.239 0.516 0 C-N-CA 119.105 -1.038 . . . . 0.0 109.078 179.381 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 139.3 4.8 1.42 Allowed Glycine 0 N--CA 1.426 -1.972 0 C-N-CA 119.345 -1.407 . . . . 0.0 113.708 176.861 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.0 m -84.54 106.99 16.53 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 177.765 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -99.93 117.2 33.72 Favored 'General case' 0 C--N 1.286 -2.175 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 175.996 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.414 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 62.0 mt -84.21 116.95 67.37 Favored Pre-proline 0 C--N 1.308 -1.212 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 -179.711 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -76.96 166.8 26.23 Favored 'Trans proline' 0 N--CA 1.443 -1.497 0 C-N-CA 122.271 1.981 . . . . 0.0 111.381 179.167 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 72.1 mt -62.19 133.24 28.04 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.97 -179.894 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 126.96 4.44 6.04 Favored Glycine 0 C--N 1.311 -0.838 0 C-N-CA 120.506 -0.854 . . . . 0.0 112.466 178.916 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.04 146.44 6.48 Favored Glycine 0 N--CA 1.442 -0.944 0 C-N-CA 120.494 -0.86 . . . . 0.0 111.174 -177.025 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 177.62 -173.94 46.5 Favored Glycine 0 C--N 1.296 -1.666 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -179.231 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 60.3 p -134.06 151.12 51.27 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -179.651 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.49 168.67 18.81 Favored 'General case' 0 N--CA 1.432 -1.364 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.56 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 16.0 m-80 -118.14 108.69 15.49 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 -179.489 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.407 HG23 HG21 ' A' ' 5' ' ' THR . 46.9 t -94.72 136.64 25.33 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.018 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 -179.705 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 86.4 m-85 -125.1 117.39 23.83 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -177.333 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 2.7 p -124.3 129.52 73.96 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.833 0 CA-C-O 121.704 0.764 . . . . 0.0 111.479 -176.913 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -82.26 124.62 30.11 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-N 114.988 -1.005 . . . . 0.0 108.459 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 35.5 mt -113.44 156.16 24.01 Favored 'General case' 0 C--N 1.276 -2.593 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 179.951 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.53 121.67 50.16 Favored Pre-proline 0 C--O 1.201 -1.483 0 O-C-N 124.207 0.942 . . . . 0.0 109.899 -179.311 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.477 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 62.3 Cg_endo -71.37 -2.46 11.27 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 C-N-CA 123.185 2.59 . . . . 0.0 113.294 -176.699 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.456 HG12 ' HG3' ' A' ' 157' ' ' PRO . 64.8 t -130.4 111.26 20.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.94 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 5.8 t -145.76 110.3 0.98 Allowed 'Isoleucine or valine' 0 C--O 1.191 -2.024 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 -179.383 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.546 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -99.68 156.62 16.99 Favored 'General case' 0 C--N 1.264 -3.109 0 C-N-CA 122.94 0.496 . . . . 0.0 111.18 -179.539 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 25.4 t -47.93 116.5 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 123.887 0.875 . . . . 0.0 111.675 177.299 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.87 0.51 45.46 Favored Glycine 0 N--CA 1.444 -0.827 0 CA-C-N 115.36 -0.836 . . . . 0.0 112.983 -179.96 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.546 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -73.73 -177.05 2.6 Favored 'General case' 0 C--N 1.315 -0.893 0 C-N-CA 123.888 0.875 . . . . 0.0 111.099 176.221 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -128.39 87.88 2.66 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 178.484 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.638 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 18.7 tp -97.35 132.67 42.85 Favored 'General case' 0 N--CA 1.417 -2.091 0 C-N-CA 118.663 -1.215 . . . . 0.0 108.753 178.095 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 2.1 p -141.41 129.55 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.386 -3.65 0 CA-C-N 114.859 -1.064 . . . . 0.0 111.618 -177.747 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.627 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 46.8 t -90.54 89.22 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.393 -3.277 0 CA-C-N 113.374 -1.739 . . . . 0.0 107.825 -179.039 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -77.98 112.22 14.67 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 121.015 0.436 . . . . 0.0 109.952 179.08 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 92.1 mt -96.3 -0.54 49.47 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.337 -177.766 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 35.6 t -74.56 0.97 13.17 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.847 0.832 . . . . 0.0 110.366 -179.561 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.8 p -126.85 3.32 6.65 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.086 178.597 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 47.9 mm-40 -121.8 -26.79 4.78 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.686 -172.925 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 20.6 mt -130.43 139.63 50.85 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 -175.525 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -139.48 158.74 43.63 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 -176.095 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 49.1 m -136.21 141.47 44.0 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 123.472 0.709 . . . . 0.0 109.972 179.58 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 5.6 p80 -136.92 153.47 50.72 Favored 'General case' 0 N--CA 1.43 -1.47 0 CA-C-O 121.9 0.857 . . . . 0.0 110.681 -178.427 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.46 HD22 ' HA ' ' A' ' 98' ' ' ARG . 6.6 p30 -95.01 109.93 21.9 Favored 'General case' 0 C--N 1.277 -2.556 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.408 177.187 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -73.87 -28.98 61.84 Favored 'General case' 0 C--N 1.297 -1.674 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.931 -179.429 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -136.52 79.6 41.0 Favored Pre-proline 0 C--N 1.313 -0.996 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 175.569 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.54 5.01 2.6 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 C-N-CA 123.257 2.638 . . . . 0.0 113.023 -176.164 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -120.34 -13.31 8.88 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.594 179.144 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.419 ' HB ' HD13 ' A' ' 52' ' ' ILE . 2.6 m -117.14 -25.64 7.07 Favored 'General case' 0 N--CA 1.422 -1.859 0 CA-C-O 121.408 0.623 . . . . 0.0 110.789 -172.575 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.419 HD13 ' HB ' ' A' ' 51' ' ' THR . 2.7 mp -128.95 130.48 68.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 CA-C-N 115.971 -0.558 . . . . 0.0 109.5 -175.581 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.4 t -75.63 146.48 40.26 Favored 'General case' 0 N--CA 1.441 -0.923 0 O-C-N 123.714 0.634 . . . . 0.0 109.707 -179.695 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.435 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 3.0 m-20 -89.96 109.97 20.97 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 115.426 -0.807 . . . . 0.0 109.341 -174.178 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 1.664 ' HE2' ' CE1' ' A' ' 55' ' ' TYR . 82.2 t80 -146.03 141.68 27.87 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -179.128 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.1 p -151.44 144.78 16.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 175.802 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.27 131.7 14.7 Favored 'General case' 0 C--O 1.212 -0.904 0 CA-C-O 119.759 -0.162 . . . . 0.0 110.575 175.654 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.539 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 56.8 tp -72.84 107.88 5.49 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.157 0.504 . . . . 0.0 109.984 176.827 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.451 ' NE2' ' HD3' ' A' ' 132' ' ' ARG . 3.0 tp-100 -51.55 -53.63 35.89 Favored 'General case' 0 C--O 1.207 -1.138 0 C-N-CA 125.554 1.541 . . . . 0.0 111.149 175.825 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . 0.403 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 2.8 ptp180 -168.62 161.4 11.39 Favored 'General case' 0 CA--C 1.493 -1.235 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 -178.072 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.1 123.52 2.23 Favored Glycine 0 N--CA 1.404 -3.485 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -178.771 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 68.9 m -115.62 149.79 37.73 Favored 'General case' 0 C--N 1.284 -2.245 0 C-N-CA 124.297 1.039 . . . . 0.0 110.32 -173.804 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.504 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -112.7 157.75 20.9 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 -179.302 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 1.648 ' HE1' ' CE2' ' A' ' 64' ' ' TYR . 88.6 m-85 -156.7 -178.91 7.7 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 124.316 1.047 . . . . 0.0 109.037 -177.68 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 60.71 -143.08 48.26 Favored Glycine 0 C--N 1.33 0.231 0 O-C-N 123.465 0.478 . . . . 0.0 112.512 177.785 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . 0.42 ' HA3' ' O ' ' A' ' 119' ' ' ALA . . . -78.94 -7.77 88.21 Favored Glycine 0 C--O 1.21 -1.382 0 C-N-CA 120.978 -0.629 . . . . 0.0 111.876 176.773 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.503 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 89.5 t -69.4 -39.96 79.4 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 C-N-CA 123.72 0.808 . . . . 0.0 111.535 -178.4 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.504 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.01 -15.97 39.74 Favored 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 119.171 -1.012 . . . . 0.0 112.053 178.836 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 16.9 t -99.67 -56.9 2.27 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.057 0.456 . . . . 0.0 111.324 -175.221 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.485 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 37.4 m-80 -85.67 -29.09 24.27 Favored 'General case' 0 CA--C 1.486 -1.513 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 -176.09 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 0.513 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 81.2 m-85 -106.79 157.39 17.78 Favored 'General case' 0 N--CA 1.416 -2.172 0 C-N-CA 119.365 -0.934 . . . . 0.0 110.38 -178.362 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.0 t -168.58 128.14 1.17 Allowed 'General case' 0 N--CA 1.42 -1.933 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 175.503 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.513 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -158.37 -109.92 0.28 Allowed Glycine 0 N--CA 1.404 -3.445 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 174.91 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 74' ' ' THR . . . . . 0.43 HG23 ' HA ' ' A' ' 83' ' ' PRO . 3.5 p -156.09 179.99 8.7 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 123.591 0.756 . . . . 0.0 109.859 -176.196 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -130.34 146.76 33.56 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.082 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 177.891 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.634 ' HG3' ' O ' ' A' ' 80' ' ' SER . 82.3 tttt -124.63 142.91 51.03 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.225 -179.564 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 1.617 ' HE2' ' CE1' ' A' ' 77' ' ' TYR . 51.5 t80 -142.51 107.87 5.02 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 -178.998 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 33.0 t 54.04 36.85 25.59 Favored 'General case' 0 CA--C 1.555 1.149 0 CA-C-O 121.541 0.686 . . . . 0.0 111.373 179.364 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.416 ' HA2' ' CE ' ' A' ' 76' ' ' LYS . . . 90.39 9.32 65.15 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.321 -0.942 . . . . 0.0 113.514 -178.645 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.634 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 22.9 t -79.96 172.53 13.66 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 177.425 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 6.2 p -152.84 100.58 2.53 Favored 'General case' 0 C--N 1.277 -2.58 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -177.757 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 0.442 ' HH ' HD21 ' A' ' 58' ' ' LEU . 1.6 p90 -144.93 159.52 49.81 Favored Pre-proline 0 C--N 1.301 -1.506 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -173.731 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . 0.43 ' HA ' HG23 ' A' ' 74' ' ' THR . 47.3 Cg_endo -66.68 151.97 81.59 Favored 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 122.97 2.446 . . . . 0.0 112.734 -176.959 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 1.667 ' HE1' ' CE2' ' A' ' 84' ' ' PHE . 57.6 t80 -127.48 130.34 23.71 Favored Pre-proline 0 N--CA 1.438 -1.042 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.675 179.654 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.49 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 59.8 Cg_endo -69.37 149.46 87.67 Favored 'Cis proline' 0 C--O 1.244 0.803 0 C-N-CA 122.972 -1.678 . . . . 0.0 110.509 -0.393 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.8 t -63.73 -176.56 0.18 Allowed 'General case' 0 CA--C 1.55 0.966 0 CA-C-O 121.298 0.57 . . . . 0.0 111.745 -175.233 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.1 p -113.15 -39.31 4.21 Favored 'General case' 0 N--CA 1.418 -2.041 0 CA-C-O 121.658 0.742 . . . . 0.0 109.303 -175.267 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 14.0 t -129.82 -107.59 0.28 Allowed 'General case' 0 N--CA 1.401 -2.878 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.259 -179.784 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -134.92 -166.82 1.88 Allowed 'General case' 0 N--CA 1.438 -1.04 0 CA-C-N 117.854 0.297 . . . . 0.0 110.633 -177.821 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.539 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 36.4 p -99.49 170.86 6.27 Favored Pre-proline 0 C--N 1.309 -1.153 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 178.174 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . 0.412 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 23.2 Cg_endo -61.34 161.75 22.58 Favored 'Trans proline' 0 C--O 1.249 1.033 0 C-N-CA 122.913 2.409 . . . . 0.0 111.099 169.636 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.7 tmm_? -78.44 119.97 22.51 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 -178.433 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 92.4 t -126.97 126.51 68.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 O-C-N 123.599 0.562 . . . . 0.0 110.189 -178.612 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 75.3 t -107.9 131.16 58.95 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 176.701 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . 0.435 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.0 m-85 -77.77 131.11 37.48 Favored 'General case' 0 C--N 1.309 -1.186 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 175.795 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -117.05 58.56 0.77 Allowed 'General case' 0 C--N 1.285 -2.233 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 -179.826 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 21.0 m -143.11 157.35 44.6 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.598 -176.231 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . 0.46 ' HA ' HD22 ' A' ' 46' ' ' ASN . 14.7 ptp180 -121.83 37.61 4.32 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.845 0.831 . . . . 0.0 109.694 178.128 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 7.7 t -157.26 172.23 18.99 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 -176.028 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -73.26 120.67 19.2 Favored 'General case' 0 C--O 1.244 0.808 0 CA-C-O 121.391 0.615 . . . . 0.0 109.471 -179.203 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -117.92 142.32 30.66 Favored Pre-proline 0 C--N 1.277 -2.545 0 CA-C-N 115.128 -0.942 . . . . 0.0 110.423 -177.212 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -65.81 147.39 85.36 Favored 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.771 2.314 . . . . 0.0 111.834 176.807 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 13.8 t90 -89.17 108.88 27.01 Favored Pre-proline 0 C--N 1.31 -1.143 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 -177.205 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_endo -77.5 88.18 1.44 Allowed 'Trans proline' 0 N--CA 1.45 -1.046 0 C-N-CA 121.641 1.561 . . . . 0.0 113.38 -172.989 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.43 HG21 ' CD2' ' A' ' 77' ' ' TYR . 64.0 t -135.9 148.87 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.183 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 176.069 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.627 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -152.85 131.35 12.19 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-O 120.92 0.391 . . . . 0.0 110.375 177.198 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.409 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 16.7 mt -100.9 99.98 10.55 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.585 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 1.613 ' HD1' ' CD2' ' A' ' 108' ' ' TYR . 51.3 m-85 -78.17 80.36 4.59 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 177.397 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.638 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.7 mm? -104.02 116.66 32.63 Favored 'General case' 0 CA--C 1.491 -1.325 0 CA-C-O 120.997 0.427 . . . . 0.0 110.523 176.681 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.69 146.75 51.26 Favored Pre-proline 0 N--CA 1.407 -2.593 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.447 -175.535 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.485 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 18.8 Cg_endo -60.7 122.16 10.83 Favored 'Trans proline' 0 N--CA 1.447 -1.236 0 C-N-CA 122.987 2.458 . . . . 0.0 112.334 -178.248 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.472 HG23 ' O ' ' A' ' 70' ' ' ASN . 3.3 m -70.0 -120.52 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.195 -1.772 0 CA-C-N 113.831 -1.531 . . . . 0.0 111.78 174.874 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 33.4 t -111.69 -34.57 6.01 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 174.355 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 20.0 t -85.56 40.91 0.87 Allowed 'General case' 0 N--CA 1.431 -1.386 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.572 -177.347 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -114.06 135.88 53.53 Favored 'General case' 0 N--CA 1.418 -2.075 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 176.89 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -176.32 135.1 2.79 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 120.053 -1.07 . . . . 0.0 111.927 178.96 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 63.41 -151.07 48.95 Favored Glycine 0 CA--C 1.498 -1.016 0 CA-C-O 119.269 -0.74 . . . . 0.0 112.757 -178.642 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 98.4 t -58.32 99.46 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 122.06 0.933 . . . . 0.0 110.981 -177.648 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . 0.42 ' O ' ' HA3' ' A' ' 66' ' ' GLY . . . -99.68 -25.43 14.4 Favored 'General case' 0 C--N 1.295 -1.795 0 CA-C-N 114.608 -1.178 . . . . 0.0 110.735 -177.371 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.507 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 55.2 mt -134.56 138.01 50.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 -179.188 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.454 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 5.0 mmpt? -112.36 138.02 49.69 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-O 121.084 0.469 . . . . 0.0 111.184 177.375 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.45 125.15 25.98 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 177.74 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 93.97 -2.47 69.22 Favored Glycine 0 C--N 1.31 -0.885 0 N-CA-C 111.644 -0.582 . . . . 0.0 111.644 -178.13 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 28.8 t -96.13 143.84 26.9 Favored 'General case' 0 N--CA 1.431 -1.409 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 -179.913 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -71.53 124.0 23.68 Favored 'General case' 0 N--CA 1.435 -1.183 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.349 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.48 ' HB ' HG23 ' A' ' 67' ' ' VAL . 30.6 pt -111.63 -26.17 3.23 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -178.54 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . 0.402 ' HB1' ' HB ' ' A' ' 148' ' ' ILE . . . -160.75 168.2 25.28 Favored 'General case' 0 N--CA 1.443 -0.796 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 -178.196 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 70.5 t -143.0 114.06 2.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.903 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 55.8 mt -116.67 147.89 41.53 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.184 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.469 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.5 mp -133.01 127.69 55.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.849 -0.532 . . . . 0.0 110.002 179.714 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . . . . . . . . . 2.3 pp -96.4 147.04 24.23 Favored 'General case' 0 CA--C 1.496 -1.119 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 177.419 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . 0.451 ' HD3' ' NE2' ' A' ' 59' ' ' GLN . 26.5 mmm-85 -96.49 118.39 32.89 Favored 'General case' 0 C--N 1.277 -2.576 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 172.858 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 7.1 tp-100 -96.02 122.03 38.41 Favored 'General case' 0 N--CA 1.421 -1.911 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 173.151 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 22.1 m -134.61 134.01 40.79 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 177.085 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 27.2 p30 . . . . . 0 C--N 1.31 -1.11 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.819 -179.736 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 . . . . . 0 N--CA 1.412 -2.328 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 12.6 pt20 -115.08 132.12 56.71 Favored 'General case' 0 N--CA 1.407 -2.624 0 C-N-CA 119.037 -1.065 . . . . 0.0 110.248 -177.86 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 1.606 ' HD1' ' CD2' ' A' ' 144' ' ' PHE . 11.1 m-30 -100.77 129.35 46.64 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.206 -0.906 . . . . 0.0 108.785 -175.087 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 47.1 t -93.3 130.83 41.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 123.764 0.665 . . . . 0.0 109.973 -178.016 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 63.9 m95 -118.21 97.92 6.03 Favored 'General case' 0 C--N 1.275 -2.636 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 -178.853 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 47.2 m-80 -80.18 112.3 17.37 Favored 'General case' 0 C--N 1.285 -2.223 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 178.249 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . 0.402 ' HB ' ' HB1' ' A' ' 127' ' ' ALA . 24.0 mm -86.03 122.06 38.12 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.819 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 -177.96 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -116.63 153.31 32.52 Favored 'General case' 0 C--N 1.286 -2.156 0 C-N-CA 124.052 0.941 . . . . 0.0 108.685 177.716 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.37 133.72 35.23 Favored 'General case' 0 N--CA 1.407 -2.585 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 176.066 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -92.94 -8.92 41.8 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -177.457 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -150.04 143.93 25.46 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 113.937 -1.483 . . . . 0.0 110.008 -176.653 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -84.65 136.16 33.87 Favored 'General case' 0 C--N 1.312 -1.033 0 O-C-N 123.966 0.791 . . . . 0.0 110.419 179.43 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.507 ' HB ' ' HB ' ' A' ' 120' ' ' ILE . 69.6 t -118.59 140.05 43.64 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.978 -173.642 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -119.78 138.34 50.71 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.136 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 178.476 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.436 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 71.6 t -99.93 101.13 13.02 Favored Pre-proline 0 C--N 1.293 -1.889 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 176.688 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.456 ' HG3' HG12 ' A' ' 27' ' ' VAL . 21.4 Cg_endo -67.47 -29.72 37.07 Favored 'Trans proline' 0 CA--C 1.504 -1.002 0 C-N-CA 122.215 1.943 . . . . 0.0 111.511 179.075 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 6.1 t . . . . . 0 C--O 1.267 1.974 0 O-C-N 125.002 1.439 . . . . 0.0 112.534 179.387 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.427 ' HB1' ' NE2' ' A' ' 45' ' ' HIS . . . . . . . . 0 CA--C 1.499 -1.015 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 . . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 12.4 t -148.76 156.76 42.8 Favored 'General case' 0 N--CA 1.426 -1.642 0 C-N-CA 119.395 -0.922 . . . . 0.0 109.711 -175.25 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.462 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -143.64 161.71 37.82 Favored 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.408 -175.102 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.643 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 54.9 p -97.64 -179.96 4.63 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-O 121.015 0.436 . . . . 0.0 110.71 179.679 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.44 -22.56 38.09 Favored 'General case' 0 C--N 1.298 -1.642 0 CA-C-O 121.551 0.691 . . . . 0.0 109.206 177.848 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.643 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 0.9 OUTLIER -85.74 -28.89 24.31 Favored 'General case' 0 N--CA 1.433 -1.297 0 CA-C-N 114.821 -1.082 . . . . 0.0 112.518 -175.784 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 130.43 22.79 1.05 Allowed Glycine 0 CA--C 1.49 -1.488 0 C-N-CA 118.868 -1.634 . . . . 0.0 113.974 171.588 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -103.04 99.42 9.3 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.363 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -94.25 114.15 26.19 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 115.879 -0.601 . . . . 0.0 109.399 176.825 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.421 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 68.5 mt -84.55 126.91 67.7 Favored Pre-proline 0 C--N 1.3 -1.582 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -179.171 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_endo -80.2 164.53 21.94 Favored 'Trans proline' 0 C--O 1.246 0.921 0 C-N-CA 122.614 2.209 . . . . 0.0 111.369 178.405 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.5 mt -65.91 126.31 24.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.984 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.57 10.02 1.49 Allowed Glycine 0 C--N 1.307 -1.028 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.613 -179.577 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.03 161.31 36.82 Favored Glycine 0 C--N 1.319 -0.392 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -177.924 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 161.61 -172.97 37.92 Favored Glycine 0 CA--C 1.495 -1.169 0 C-N-CA 119.938 -1.125 . . . . 0.0 111.331 178.448 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.413 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 65.2 p -144.51 144.03 31.14 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.306 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -130.98 162.16 30.36 Favored 'General case' 0 N--CA 1.415 -2.192 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.286 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -111.96 116.11 30.06 Favored 'General case' 0 C--N 1.271 -2.838 0 N-CA-C 107.043 -1.465 . . . . 0.0 107.043 174.773 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.424 HG23 ' HA ' ' A' ' 148' ' ' ILE . 1.2 m -99.63 139.03 22.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.683 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 179.22 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 1.623 ' HE1' ' CE2' ' A' ' 21' ' ' TYR . 23.7 m-85 -117.72 115.98 26.12 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-O 120.879 0.371 . . . . 0.0 111.994 -179.715 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 19.3 t -115.68 129.34 72.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.805 -173.819 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -89.27 119.75 30.03 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 177.778 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 28.1 mt -110.74 152.24 26.81 Favored 'General case' 0 C--N 1.282 -2.333 0 CA-C-N 115.051 -0.977 . . . . 0.0 108.984 -176.939 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -52.73 119.32 15.48 Favored Pre-proline 0 C--O 1.204 -1.296 0 O-C-N 124.513 1.133 . . . . 0.0 110.326 179.319 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.506 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 60.9 Cg_endo -73.83 -0.53 9.56 Favored 'Trans proline' 0 CA--C 1.544 0.993 0 C-N-CA 122.502 2.135 . . . . 0.0 113.616 -175.584 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 98.4 t -131.06 109.61 16.75 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 178.161 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.44 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 14.0 t -146.12 108.38 0.8 Allowed 'Isoleucine or valine' 0 C--O 1.193 -1.909 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 -177.248 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.531 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -95.87 154.22 17.34 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 123.864 0.865 . . . . 0.0 111.031 -179.84 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.538 HG23 ' O ' ' A' ' 112' ' ' VAL . 99.1 t -47.18 117.55 0.42 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.328 0 C-N-CA 123.436 0.694 . . . . 0.0 111.197 176.482 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.92 0.38 45.27 Favored Glycine 0 C--N 1.312 -0.803 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.924 -179.634 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.531 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -74.9 -176.7 3.0 Favored 'General case' 0 C--N 1.316 -0.884 0 C-N-CA 123.751 0.821 . . . . 0.0 110.329 175.876 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -127.09 89.75 3.03 Favored 'General case' 0 CA--C 1.491 -1.32 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 177.721 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.557 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 20.0 tp -98.34 133.68 42.4 Favored 'General case' 0 C--N 1.295 -1.8 0 C-N-CA 118.898 -1.121 . . . . 0.0 109.256 177.158 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 2.1 p -141.56 130.75 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.382 -3.854 0 CA-C-N 114.797 -1.092 . . . . 0.0 112.075 -178.028 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.608 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 47.8 t -87.61 89.56 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.576 0 CA-C-N 113.832 -1.531 . . . . 0.0 107.266 178.801 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.415 ' O ' ' HG2' ' A' ' 41' ' ' GLN . 18.2 t70 -77.26 102.83 6.87 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-O 120.708 0.289 . . . . 0.0 110.683 -179.173 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.3 mt -85.08 -3.65 58.87 Favored 'General case' 0 C--N 1.311 -1.094 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.306 -178.512 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 35.2 t -73.27 0.1 12.91 Favored 'General case' 0 CA--C 1.542 0.636 0 CA-C-O 121.478 0.656 . . . . 0.0 110.135 -179.624 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.3 p -130.2 5.23 4.85 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.206 176.468 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.415 ' HG2' ' O ' ' A' ' 37' ' ' ASP . 48.6 mm-40 -120.45 -20.75 7.08 Favored 'General case' 0 C--O 1.239 0.511 0 CA-C-O 121.03 0.443 . . . . 0.0 110.299 -174.177 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 37.4 mt -138.75 138.7 41.92 Favored 'Isoleucine or valine' 0 C--O 1.243 0.714 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 -177.103 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.634 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 48.7 m-85 -142.47 127.44 18.37 Favored 'General case' 0 N--CA 1.476 0.862 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -176.836 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 75.8 m -109.17 138.69 45.14 Favored 'General case' 0 C--N 1.295 -1.776 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -178.648 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . 0.427 ' NE2' ' HB1' ' A' ' 2' ' ' ALA . 10.9 p-80 -121.07 154.34 36.24 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-O 122.335 1.064 . . . . 0.0 112.085 -176.47 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.42 HD21 ' CG ' ' A' ' 54' ' ' ASP . 3.0 m120 -96.9 114.81 26.46 Favored 'General case' 0 C--N 1.28 -2.434 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -179.423 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -77.09 -32.51 56.71 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.301 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 38.4 m-85 -138.68 83.03 20.38 Favored Pre-proline 0 C--N 1.315 -0.934 0 CA-C-N 114.331 -1.304 . . . . 0.0 108.921 -176.955 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.95 3.68 5.88 Favored 'Trans proline' 0 CA--C 1.541 0.831 0 C-N-CA 122.59 2.194 . . . . 0.0 113.685 -176.06 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -117.64 -22.35 8.11 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 121.268 0.556 . . . . 0.0 110.434 178.275 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.438 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.7 OUTLIER -98.49 -28.72 13.48 Favored 'General case' 0 N--CA 1.424 -1.741 0 CA-C-O 122.074 0.94 . . . . 0.0 109.244 -172.035 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.468 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -122.67 135.79 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.087 0 CA-C-N 114.306 -1.316 . . . . 0.0 109.648 -178.346 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 3.3 t -86.42 124.29 32.59 Favored 'General case' 0 N--CA 1.417 -2.114 0 N-CA-C 103.022 -2.955 . . . . 0.0 103.022 169.22 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.42 ' CG ' HD21 ' A' ' 46' ' ' ASN . 16.1 m-20 -91.47 107.88 19.51 Favored 'General case' 0 C--N 1.271 -2.811 0 C-N-CA 118.815 -1.154 . . . . 0.0 109.433 -169.005 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 22.0 t80 -117.89 139.56 50.95 Favored 'General case' 0 C--N 1.273 -2.746 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.588 -175.74 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.435 HG21 ' HG ' ' A' ' 131' ' ' LEU . 12.9 p -145.59 145.39 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.794 0 O-C-N 123.626 0.579 . . . . 0.0 109.815 -179.577 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -149.4 125.11 10.44 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.085 174.584 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.479 HD13 ' O ' ' A' ' 130' ' ' ILE . 41.9 tp -61.82 110.35 1.51 Allowed 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 169.975 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.6 tp-100 -60.18 -56.95 15.34 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 126.63 1.972 . . . . 0.0 109.861 -179.074 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 10.8 ptp180 -164.14 160.16 21.11 Favored 'General case' 0 N--CA 1.426 -1.634 0 CA-C-N 114.505 -1.225 . . . . 0.0 108.874 -175.274 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -141.38 139.96 9.9 Favored Glycine 0 N--CA 1.411 -2.998 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -178.756 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 73.2 m -126.06 150.63 48.0 Favored 'General case' 0 C--N 1.289 -2.025 0 C-N-CA 124.139 0.976 . . . . 0.0 110.266 -176.807 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.464 ' HB3' ' CE2' ' A' ' 84' ' ' PHE . . . -114.2 157.69 22.34 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.202 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.485 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 87.0 m-85 -155.13 -178.88 7.56 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 124.12 0.968 . . . . 0.0 109.244 -178.609 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 60.25 -138.65 48.54 Favored Glycine 0 C--O 1.228 -0.279 0 O-C-N 123.537 0.523 . . . . 0.0 113.236 176.886 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.44 -8.79 85.76 Favored Glycine 0 N--CA 1.432 -1.631 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.355 177.037 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.485 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 84.0 t -69.13 -41.25 81.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 C-N-CA 123.52 0.728 . . . . 0.0 111.572 -176.709 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.444 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -83.21 -21.01 33.55 Favored 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.73 -0.788 . . . . 0.0 112.359 179.692 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 18.4 m -101.71 -50.69 3.63 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 115.25 1.574 . . . . 0.0 115.25 -174.802 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.485 ' O ' HG23 ' A' ' 112' ' ' VAL . 47.7 m-20 -93.73 -23.45 18.2 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -175.628 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 0.522 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 88.2 m-85 -108.1 159.24 16.73 Favored 'General case' 0 N--CA 1.423 -1.802 0 C-N-CA 120.02 -0.672 . . . . 0.0 109.324 176.979 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.6 t -167.5 125.11 1.21 Allowed 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 175.617 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.482 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -159.51 -110.28 0.27 Allowed Glycine 0 N--CA 1.407 -3.284 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 176.648 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.3 p -156.96 179.97 8.78 Favored 'General case' 0 C--N 1.296 -1.744 0 C-N-CA 123.531 0.733 . . . . 0.0 110.965 -173.101 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.42 HG11 ' CE2' ' A' ' 82' ' ' TYR . 2.6 p -133.69 144.37 36.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.919 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.68 ' HG3' ' O ' ' A' ' 80' ' ' SER . 86.0 tttt -123.42 150.19 44.09 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.318 -178.699 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.416 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 60.8 t80 -148.94 109.42 4.19 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 -178.812 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.6 t 51.48 41.01 28.07 Favored 'General case' 0 CA--C 1.554 1.105 0 C-N-CA 124.32 1.048 . . . . 0.0 111.396 178.037 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.83 6.73 67.08 Favored Glycine 0 CA--C 1.526 0.756 0 CA-C-N 115.615 -0.721 . . . . 0.0 113.987 179.82 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.68 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 22.8 t -79.57 179.98 7.18 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 178.43 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 3.6 p -157.99 107.15 2.06 Favored 'General case' 0 C--N 1.292 -1.896 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 -179.489 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 1.623 ' HD1' ' CD2' ' A' ' 82' ' ' TYR . 2.5 p90 -151.49 158.44 34.32 Favored Pre-proline 0 C--N 1.308 -1.228 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 -174.418 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.25 148.54 68.58 Favored 'Trans proline' 0 C--N 1.358 1.033 0 C-N-CA 122.819 2.346 . . . . 0.0 112.977 -176.385 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.582 ' CD2' HD22 ' A' ' 109' ' ' LEU . 63.0 t80 -121.92 133.4 24.29 Favored Pre-proline 0 N--CA 1.438 -1.058 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.773 179.98 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.505 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 74.1 Cg_endo -71.15 146.63 85.49 Favored 'Cis proline' 0 CA--C 1.548 1.223 0 C-N-CA 123.079 -1.634 . . . . 0.0 110.56 -1.856 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.1 t -64.13 -176.74 0.22 Allowed 'General case' 0 CA--C 1.558 1.262 0 C-N-CA 123.547 0.739 . . . . 0.0 112.279 -174.015 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 19.9 p -129.54 -27.6 2.37 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 113.161 0.8 . . . . 0.0 113.161 -172.449 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 t -127.62 -73.46 0.6 Allowed 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 119.736 -0.786 . . . . 0.0 110.684 -178.45 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -177.78 -174.57 0.46 Allowed 'General case' 0 C--O 1.243 0.726 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 -176.684 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.446 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 12.4 p -102.07 163.28 18.05 Favored Pre-proline 0 C--N 1.299 -1.592 0 O-C-N 123.432 0.458 . . . . 0.0 112.196 178.083 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -64.55 157.48 54.98 Favored 'Trans proline' 0 C--N 1.36 1.176 0 C-N-CA 122.669 2.246 . . . . 0.0 111.576 174.996 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.4 tmm_? -68.79 110.81 4.51 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 114.898 -1.046 . . . . 0.0 110.209 -175.757 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 71.0 t -122.35 132.83 70.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.826 -178.093 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 95.6 t -117.24 136.25 55.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 115.3 -0.863 . . . . 0.0 109.494 178.97 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . 0.484 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 4.1 m-85 -82.99 94.97 7.88 Favored 'General case' 0 CA--C 1.499 -0.985 0 CA-C-O 121.41 0.624 . . . . 0.0 110.348 177.516 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 17.6 m120 -89.26 61.13 5.59 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 178.754 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.6 m -143.67 -179.3 6.36 Favored 'General case' 0 N--CA 1.423 -1.798 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 -176.959 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 4.5 ptm180 -146.08 50.7 1.16 Allowed 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 121.425 0.631 . . . . 0.0 109.979 179.998 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.0 t -169.87 177.41 4.4 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -175.201 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -71.77 98.02 1.89 Allowed 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 106.608 -1.627 . . . . 0.0 106.608 173.07 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 11.5 tptt -103.14 139.33 20.01 Favored Pre-proline 0 N--CA 1.407 -2.602 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 -177.678 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_endo -58.9 147.26 90.23 Favored 'Trans proline' 0 CA--C 1.511 -0.632 0 C-N-CA 122.605 2.203 . . . . 0.0 112.631 -176.993 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . 0.484 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.1 t90 -90.48 105.93 13.41 Favored Pre-proline 0 C--N 1.302 -1.472 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 178.6 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -77.83 87.94 1.47 Allowed 'Trans proline' 0 N--CA 1.443 -1.456 0 C-N-CA 121.616 1.544 . . . . 0.0 112.21 -173.094 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 86.7 t -139.01 147.03 25.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 N-CA-C 106.879 -1.526 . . . . 0.0 106.879 177.851 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.608 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -153.14 134.26 14.1 Favored 'General case' 0 C--N 1.284 -2.265 0 CA-C-O 120.811 0.338 . . . . 0.0 110.381 178.522 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.441 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 18.7 mt -101.6 99.86 10.2 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 179.151 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.482 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 74.2 m-85 -79.59 77.43 6.19 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 177.746 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.582 HD22 ' CD2' ' A' ' 84' ' ' PHE . 3.2 mm? -102.54 118.72 37.47 Favored 'General case' 0 CA--C 1.488 -1.414 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 176.365 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -122.18 146.91 47.97 Favored Pre-proline 0 N--CA 1.402 -2.867 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -174.964 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -63.4 123.14 11.61 Favored 'Trans proline' 0 CA--C 1.491 -1.625 0 C-N-CA 123.245 2.63 . . . . 0.0 113.379 -175.469 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.538 ' O ' HG23 ' A' ' 30' ' ' VAL . 24.3 m -83.22 -159.25 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.385 -3.689 0 CA-C-N 114.181 -1.372 . . . . 0.0 108.871 171.15 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.8 m -79.21 -29.56 42.86 Favored 'General case' 0 C--N 1.252 -3.631 0 CA-C-O 121.464 0.65 . . . . 0.0 110.296 -170.352 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 11.3 t -82.52 25.5 0.63 Allowed 'General case' 0 N--CA 1.428 -1.53 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.188 -179.77 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -109.17 136.75 48.15 Favored 'General case' 0 N--CA 1.422 -1.842 0 O-C-N 121.828 -0.545 . . . . 0.0 109.818 178.847 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -174.91 134.49 2.77 Favored Glycine 0 N--CA 1.432 -1.6 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 178.332 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 60.49 -149.3 43.29 Favored Glycine 0 CA--C 1.494 -1.221 0 CA-C-O 119.32 -0.711 . . . . 0.0 112.151 -177.637 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 94.0 t -57.95 105.11 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-O 121.923 0.868 . . . . 0.0 111.261 -177.884 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.37 -22.22 13.37 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 114.51 -1.223 . . . . 0.0 110.62 -178.772 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.444 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 67.9 mt -136.83 138.13 46.44 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 179.474 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.43 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.6 mmpt? -116.6 143.01 46.14 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.066 0.46 . . . . 0.0 109.79 174.744 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.5 131.05 42.74 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.891 -179.17 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.63 -6.07 64.87 Favored Glycine 0 N--CA 1.44 -1.083 0 C-N-CA 121.231 -0.509 . . . . 0.0 112.157 -179.316 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 27.2 m -94.9 147.53 23.27 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-O 120.778 0.323 . . . . 0.0 110.747 -179.302 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -74.25 124.04 25.66 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.271 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.475 ' HB ' HG23 ' A' ' 67' ' ' VAL . 31.2 pt -111.27 -26.28 3.2 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -178.555 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.83 168.52 22.93 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 -177.679 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 73.7 t -143.4 114.44 2.54 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.487 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 62.9 mt -116.01 142.5 46.72 Favored 'General case' 0 C--N 1.291 -1.968 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 178.631 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.479 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.9 mp -121.08 126.54 75.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 C-N-CA 119.272 -0.971 . . . . 0.0 110.77 177.477 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.538 HD22 ' OE1' ' A' ' 133' ' ' GLN . 0.2 OUTLIER -98.05 131.41 44.49 Favored 'General case' 0 C--N 1.271 -2.813 0 C-N-CA 124.68 1.192 . . . . 0.0 109.182 179.422 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . 0.525 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 12.6 tpt180 -104.9 124.53 49.64 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -179.86 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.538 ' OE1' HD22 ' A' ' 131' ' ' LEU . 12.6 mm100 -105.84 118.54 36.87 Favored 'General case' 0 C--N 1.319 -0.72 0 O-C-N 123.592 0.557 . . . . 0.0 110.345 179.242 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 5.1 m -136.6 149.7 48.18 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 106.377 -1.712 . . . . 0.0 106.377 177.462 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.468 ' CB ' HG21 ' A' ' 52' ' ' ILE . 12.6 p30 . . . . . 0 C--N 1.324 -0.529 0 C-N-CA 119.458 -0.897 . . . . 0.0 112.249 175.555 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . 1.642 ' HE1' ' CE2' ' A' ' 142' ' ' PHE . 72.1 m-85 . . . . . 0 N--CA 1.437 -1.077 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 . . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . 0.525 ' HB3' ' HD2' ' A' ' 132' ' ' ARG . 14.0 pt20 -129.34 145.92 51.3 Favored 'General case' 0 N--CA 1.417 -2.089 0 C-N-CA 119.812 -0.755 . . . . 0.0 111.336 177.851 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.402 ' HB2' HD23 ' A' ' 131' ' ' LEU . 11.0 m-30 -109.5 130.44 55.5 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 -178.007 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . 0.413 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 61.9 t -90.36 131.77 36.69 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.053 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 179.86 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . 0.441 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 69.2 m95 -119.9 97.96 5.87 Favored 'General case' 0 C--N 1.275 -2.636 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 -179.273 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 49.2 m-80 -80.01 114.7 19.11 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 178.634 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . 0.424 ' HA ' HG23 ' A' ' 20' ' ' VAL . 23.6 mm -88.21 122.06 39.31 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 -177.718 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 1.6 ' HD1' ' CD2' ' A' ' 149' ' ' TYR . 76.9 m-85 -118.19 156.1 29.33 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 123.241 0.616 . . . . 0.0 109.697 178.506 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -84.1 131.61 34.77 Favored 'General case' 0 N--CA 1.414 -2.258 0 CA-C-N 115.238 -0.892 . . . . 0.0 108.682 177.33 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -95.75 -12.12 25.9 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 -176.812 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -155.08 146.49 22.99 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 113.84 -1.527 . . . . 0.0 108.326 -178.089 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 17.8 p-10 -86.05 148.15 25.86 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 124.152 0.981 . . . . 0.0 111.564 -177.181 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.506 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 77.7 t -123.57 136.04 61.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-N 115.459 -0.792 . . . . 0.0 111.194 -174.542 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.5 t -118.29 135.1 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.767 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.44 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.1 t -99.37 103.77 22.73 Favored Pre-proline 0 C--N 1.291 -1.975 0 C-N-CA 123.867 0.867 . . . . 0.0 109.871 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.451 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 50.1 Cg_endo -72.77 -17.11 26.11 Favored 'Trans proline' 0 C--N 1.333 -0.289 0 C-N-CA 122.034 1.822 . . . . 0.0 111.424 178.021 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.273 4.0 t . . . . . 0 C--O 1.239 0.543 0 C-N-CA 125.414 1.486 . . . . 0.0 113.568 177.75 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.455 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.436 -1.136 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 . . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.454 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 14.7 t -148.78 157.01 43.13 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.394 -0.922 . . . . 0.0 109.958 -177.006 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.463 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.91 156.28 43.9 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 121.868 0.842 . . . . 0.0 111.434 -174.789 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 36.3 p -94.97 171.47 8.74 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.749 178.402 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -80.7 -10.93 59.7 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 114.661 -1.154 . . . . 0.0 110.332 -179.127 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -93.06 -33.22 14.18 Favored 'General case' 0 N--CA 1.431 -1.384 0 CA-C-N 114.96 -1.018 . . . . 0.0 111.796 -177.556 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 142.88 -1.59 1.53 Allowed Glycine 0 CA--C 1.507 -0.448 0 C-N-CA 119.158 -1.496 . . . . 0.0 114.462 171.461 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.4 m -86.35 104.99 16.38 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 122.202 -0.587 . . . . 0.0 110.93 -178.441 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -96.31 118.66 33.31 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 173.773 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.455 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 66.2 mt -89.84 122.58 67.8 Favored Pre-proline 0 C--N 1.297 -1.694 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 -179.649 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -77.24 171.91 16.95 Favored 'Trans proline' 0 C--O 1.239 0.563 0 C-N-CA 122.939 2.426 . . . . 0.0 111.582 179.6 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.7 mt -72.85 120.1 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.807 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 179.155 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 140.98 23.36 0.25 Allowed Glycine 0 C--N 1.301 -1.415 0 CA-C-N 115.393 -0.822 . . . . 0.0 112.027 -179.668 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 73.79 167.41 14.75 Favored Glycine 0 C--N 1.335 0.494 0 C-N-CA 121.156 -0.545 . . . . 0.0 112.309 -177.28 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 153.97 -172.01 32.64 Favored Glycine 0 CA--C 1.483 -1.966 0 C-N-CA 120.087 -1.054 . . . . 0.0 110.925 176.229 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.411 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 78.3 p -141.43 156.27 45.8 Favored 'General case' 0 N--CA 1.42 -1.953 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 178.918 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -137.23 160.22 39.66 Favored 'General case' 0 N--CA 1.422 -1.864 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 177.536 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 18.9 m-80 -114.15 109.89 19.12 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 105.143 -2.169 . . . . 0.0 105.143 175.713 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.449 HG23 ' HA ' ' A' ' 148' ' ' ILE . 0.8 OUTLIER -91.84 143.2 11.8 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.328 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 -178.132 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 63.2 m-85 -119.52 116.07 25.32 Favored 'General case' 0 C--N 1.297 -1.711 0 C-N-CA 120.803 -0.359 . . . . 0.0 111.557 -179.249 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 22.0 t -119.58 132.75 68.49 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.041 -174.888 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 -88.6 123.09 32.75 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 176.881 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -104.14 160.44 14.86 Favored 'General case' 0 C--N 1.287 -2.143 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.502 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -59.33 123.71 71.48 Favored Pre-proline 0 C--N 1.316 -0.886 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.382 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 88.0 Cg_endo -78.53 1.58 8.91 Favored 'Trans proline' 0 C--N 1.33 -0.427 0 C-N-CA 122.78 2.32 . . . . 0.0 113.159 -175.264 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 98.7 t -129.53 109.77 18.83 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 177.311 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.449 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.0 t -143.03 103.53 0.92 Allowed 'Isoleucine or valine' 0 C--O 1.18 -2.585 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -176.347 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.723 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -95.16 155.27 16.8 Favored 'General case' 0 C--N 1.272 -2.783 0 C-N-CA 122.364 0.266 . . . . 0.0 111.01 -179.838 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.608 HG23 ' O ' ' A' ' 112' ' ' VAL . 87.5 t -46.94 118.71 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 C-N-CA 123.06 0.544 . . . . 0.0 111.064 175.387 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.98 9.61 57.05 Favored Glycine 0 C--N 1.31 -0.887 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.939 179.467 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.723 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -80.77 -177.72 6.46 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 175.413 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -130.88 87.65 2.51 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 178.859 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.654 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 27.1 tp -88.1 144.56 26.42 Favored 'General case' 0 C--N 1.292 -1.906 0 C-N-CA 119.589 -0.844 . . . . 0.0 109.685 -178.803 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.7 t -137.7 130.33 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.882 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 -177.597 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.579 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 40.3 t -97.54 88.75 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.413 -2.304 0 N-CA-C 105.685 -1.968 . . . . 0.0 105.685 172.734 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -82.03 109.74 16.64 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -177.781 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.9 mt -92.47 -1.32 57.06 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-O 121.072 0.463 . . . . 0.0 111.284 -178.012 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.559 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 34.1 t -76.25 0.27 19.81 Favored 'General case' 0 C--N 1.31 -1.121 0 CA-C-O 121.652 0.739 . . . . 0.0 109.459 -178.713 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.6 p -129.81 5.51 5.04 Favored 'General case' 0 N--CA 1.412 -2.33 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.599 178.83 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 48.9 mm-40 -124.69 -21.13 4.88 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.854 -173.89 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 39.0 mt -134.8 138.73 48.81 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 -177.333 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.463 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 49.5 m-85 -142.32 128.63 19.95 Favored 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -176.065 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.454 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 85.0 m -107.57 145.9 32.61 Favored 'General case' 0 C--N 1.284 -2.251 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.032 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 12.1 p80 -131.62 128.35 38.95 Favored 'General case' 0 C--N 1.296 -1.728 0 CA-C-O 122.16 0.981 . . . . 0.0 111.744 -176.516 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 20.8 p-10 -97.11 89.66 4.87 Favored 'General case' 0 C--N 1.282 -2.335 0 CA-C-O 122.257 1.027 . . . . 0.0 108.693 178.572 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . 0.55 ' HB2' ' CD2' ' A' ' 48' ' ' TYR . 1.4 m-20 -51.74 -43.62 62.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.25 -175.676 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 0.55 ' CD2' ' HB2' ' A' ' 47' ' ' ASP . 29.2 m-85 -121.84 83.27 43.01 Favored Pre-proline 0 C--N 1.315 -0.913 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 -175.278 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -83.01 -5.51 11.32 Favored 'Trans proline' 0 C--O 1.234 0.29 0 C-N-CA 122.99 2.46 . . . . 0.0 112.786 -173.606 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -103.78 -23.35 13.42 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.023 -178.09 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.48 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.3 OUTLIER -100.33 -30.76 11.69 Favored 'General case' 0 N--CA 1.415 -2.222 0 CA-C-O 122.02 0.914 . . . . 0.0 108.867 -176.0 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.546 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.9 mp -128.96 134.9 63.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 CA-C-N 114.636 -1.166 . . . . 0.0 109.927 -176.584 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 5.9 t -86.51 139.05 31.24 Favored 'General case' 0 N--CA 1.438 -1.052 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 171.5 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.421 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 14.6 t70 -96.07 108.78 21.25 Favored 'General case' 0 C--N 1.275 -2.664 0 C-N-CA 119.673 -0.811 . . . . 0.0 109.147 -175.832 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 23.6 t80 -122.64 122.15 38.12 Favored 'General case' 0 C--N 1.288 -2.065 0 CA-C-O 121.799 0.809 . . . . 0.0 110.065 -177.702 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.445 HG13 ' OH ' ' A' ' 77' ' ' TYR . 85.3 t -125.95 138.52 54.29 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 CA-C-N 114.169 -1.378 . . . . 0.0 110.067 -176.084 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -144.46 135.3 24.97 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 172.602 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.533 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 38.9 tp -74.58 104.91 5.45 Favored 'General case' 0 N--CA 1.436 -1.132 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 175.429 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -52.96 -54.2 38.49 Favored 'General case' 0 C--O 1.201 -1.457 0 C-N-CA 126.278 1.831 . . . . 0.0 111.048 -179.55 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -165.52 156.35 13.74 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 -177.766 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.87 118.34 1.11 Allowed Glycine 0 N--CA 1.398 -3.846 0 N-CA-C 108.941 -1.663 . . . . 0.0 108.941 -178.099 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 52.8 m -114.52 146.56 40.58 Favored 'General case' 0 C--N 1.279 -2.472 0 C-N-CA 124.584 1.153 . . . . 0.0 110.029 -170.859 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.511 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -106.26 156.66 18.25 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 123.496 0.718 . . . . 0.0 109.112 -178.715 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.505 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 99.5 m-85 -154.48 -179.35 7.88 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 124.08 0.952 . . . . 0.0 109.742 -176.978 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.06 -136.44 51.18 Favored Glycine 0 N--CA 1.458 0.121 0 O-C-N 123.653 0.595 . . . . 0.0 112.669 178.012 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.79 -9.07 83.49 Favored Glycine 0 C--O 1.206 -1.635 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 177.477 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.505 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 77.7 t -69.67 -36.42 70.36 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 C-N-CA 123.745 0.818 . . . . 0.0 111.852 -176.107 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.511 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -87.16 -20.25 27.28 Favored 'General case' 0 C--N 1.297 -1.684 0 C-N-CA 119.216 -0.993 . . . . 0.0 112.296 178.306 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 9.6 t -101.03 -52.79 3.2 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.472 0.653 . . . . 0.0 112.195 -173.757 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.464 ' O ' HG23 ' A' ' 112' ' ' VAL . 31.6 m-20 -91.78 -25.81 18.85 Favored 'General case' 0 CA--C 1.49 -1.353 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -173.69 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 1.627 ' HD2' ' CD1' ' A' ' 71' ' ' PHE . 86.1 m-85 -106.61 155.85 19.21 Favored 'General case' 0 N--CA 1.416 -2.152 0 C-N-CA 120.008 -0.677 . . . . 0.0 109.291 177.254 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.3 t -165.48 117.83 1.14 Allowed 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 176.992 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.515 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -153.56 -111.88 0.46 Allowed Glycine 0 N--CA 1.412 -2.924 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 176.714 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.9 p -154.51 -179.72 8.23 Favored 'General case' 0 C--N 1.297 -1.687 0 C-N-CA 123.561 0.744 . . . . 0.0 110.93 -173.66 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -133.95 144.02 36.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 C-N-CA 123.319 0.648 . . . . 0.0 109.874 177.762 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.607 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.0 tttt -121.68 142.82 49.78 Favored 'General case' 0 N--CA 1.432 -1.374 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.648 178.767 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 1.663 ' HE2' ' CE1' ' A' ' 77' ' ' TYR . 62.6 t80 -142.42 110.35 5.89 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.517 -179.055 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.9 t 49.77 38.9 16.66 Favored 'General case' 0 CA--C 1.557 1.231 0 C-N-CA 124.43 1.092 . . . . 0.0 111.735 176.017 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.28 18.3 50.05 Favored Glycine 0 CA--C 1.524 0.596 0 C-N-CA 120.922 -0.656 . . . . 0.0 113.624 -179.404 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.607 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 12.2 t -92.73 -179.84 5.27 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 174.597 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 56.3 p -157.87 105.53 1.99 Allowed 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 179.652 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 1.614 ' HD1' ' CD2' ' A' ' 82' ' ' TYR . 2.7 p90 -150.73 160.83 31.79 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 -173.791 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . 0.409 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 45.0 Cg_endo -68.51 148.19 72.35 Favored 'Trans proline' 0 C--N 1.357 0.984 0 C-N-CA 122.935 2.423 . . . . 0.0 113.357 -177.788 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 1.668 ' HE1' ' CE2' ' A' ' 84' ' ' PHE . 60.5 t80 -123.61 134.15 25.08 Favored Pre-proline 0 N--CA 1.433 -1.289 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.484 -179.431 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.459 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 60.2 Cg_endo -70.54 148.76 89.19 Favored 'Cis proline' 0 CA--C 1.541 0.862 0 C-N-CA 122.77 -1.763 . . . . 0.0 110.469 -0.838 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.2 t -67.24 -177.22 0.65 Allowed 'General case' 0 CA--C 1.549 0.919 0 CA-C-O 121.266 0.555 . . . . 0.0 110.997 -176.86 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 18.5 p -130.39 -19.88 3.04 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 112.597 0.592 . . . . 0.0 112.597 -173.459 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 21.6 t -130.71 -89.36 0.47 Allowed 'General case' 0 C--O 1.204 -1.335 0 C-N-CA 120.429 -0.508 . . . . 0.0 110.309 -179.988 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -166.58 -173.01 2.33 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 177.888 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 61.8 p -100.32 163.48 18.17 Favored Pre-proline 0 C--N 1.304 -1.387 0 N-CA-C 112.795 0.665 . . . . 0.0 112.795 179.798 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_endo -56.65 165.27 4.83 Favored 'Trans proline' 0 C--O 1.248 0.99 0 C-N-CA 123.518 2.812 . . . . 0.0 111.43 172.711 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -74.47 122.17 22.62 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.479 -175.959 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 73.2 t -134.9 133.46 53.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 -178.348 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.418 HG21 ' O ' ' A' ' 54' ' ' ASP . 1.5 p -132.97 134.6 57.94 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.292 0 CA-C-N 115.971 -0.558 . . . . 0.0 109.596 -178.55 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . 1.646 ' HE2' ' CE1' ' A' ' 95' ' ' TYR . 2.6 m-85 -83.07 117.91 23.18 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 179.182 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -102.07 27.56 6.52 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.756 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.9 m -99.23 -171.56 2.1 Favored 'General case' 0 N--CA 1.426 -1.628 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.291 -178.328 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -151.15 43.58 0.79 Allowed 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.465 0.65 . . . . 0.0 110.39 175.769 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.3 t -168.18 -178.63 3.73 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -176.735 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -67.18 106.78 2.11 Favored 'General case' 0 CA--C 1.511 -0.542 0 C-N-CA 123.344 0.658 . . . . 0.0 109.39 179.607 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -112.6 135.1 21.52 Favored Pre-proline 0 C--N 1.293 -1.866 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 176.342 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . 0.559 ' HB3' ' O ' ' A' ' 39' ' ' SER . 51.4 Cg_exo -53.69 139.61 67.41 Favored 'Trans proline' 0 CA--C 1.503 -1.067 0 C-N-CA 123.865 3.043 . . . . 0.0 112.295 177.357 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 15.5 t90 -85.0 106.85 9.74 Favored Pre-proline 0 C--N 1.298 -1.655 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 179.161 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . 0.402 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 60.2 Cg_endo -77.0 88.22 1.42 Allowed 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 121.368 1.379 . . . . 0.0 113.096 -172.952 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 92.6 t -140.62 146.88 23.6 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.103 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 178.127 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.579 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.38 135.05 17.43 Favored 'General case' 0 C--N 1.294 -1.817 0 CA-C-O 120.757 0.313 . . . . 0.0 110.431 177.34 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . 0.427 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 20.1 mt -100.97 105.18 16.38 Favored 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 178.083 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.515 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 43.9 m-85 -83.63 72.58 10.31 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 120.67 0.272 . . . . 0.0 110.716 178.095 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.654 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -98.66 129.17 45.14 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 176.342 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.42 146.89 63.43 Favored Pre-proline 0 N--CA 1.41 -2.426 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 -175.9 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.432 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 40.4 Cg_endo -65.37 126.07 15.61 Favored 'Trans proline' 0 CA--C 1.496 -1.416 0 C-N-CA 123.133 2.555 . . . . 0.0 113.002 -175.181 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.608 ' O ' HG23 ' A' ' 30' ' ' VAL . 16.7 m -84.3 -154.78 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.401 -2.889 0 CA-C-N 114.518 -1.219 . . . . 0.0 108.044 171.667 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 18.5 m -82.76 -30.32 29.05 Favored 'General case' 0 C--N 1.255 -3.508 0 CA-C-O 121.497 0.665 . . . . 0.0 110.025 -170.609 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 18.1 t -84.73 30.81 0.55 Allowed 'General case' 0 N--CA 1.435 -1.201 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.156 -179.821 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -112.23 138.12 49.37 Favored 'General case' 0 N--CA 1.422 -1.831 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.874 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -179.22 128.01 1.2 Allowed Glycine 0 N--CA 1.437 -1.239 0 C-N-CA 120.367 -0.92 . . . . 0.0 112.425 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 68.32 -149.05 49.54 Favored Glycine 0 CA--C 1.486 -1.728 0 CA-C-O 119.125 -0.819 . . . . 0.0 111.928 -177.436 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 57.4 t -59.85 103.4 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 CA-C-N 117.308 0.554 . . . . 0.0 110.088 -177.126 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -103.78 -29.16 11.2 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.953 -178.223 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 73.6 mt -126.69 137.48 57.7 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.849 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 176.947 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.405 ' HA ' ' HE2' ' A' ' 121' ' ' LYS . 3.9 mmpt? -114.06 141.87 46.9 Favored 'General case' 0 C--N 1.31 -1.131 0 C-N-CA 122.959 0.504 . . . . 0.0 110.121 177.048 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -73.03 135.71 44.94 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.286 179.677 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 84.49 11.31 77.98 Favored Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 111.59 -0.604 . . . . 0.0 111.59 -179.016 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 27.3 t -113.98 147.76 38.06 Favored 'General case' 0 N--CA 1.433 -1.324 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 -179.332 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 23.1 tp -73.52 134.99 43.96 Favored 'General case' 0 CA--C 1.506 -0.747 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.795 -179.801 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.467 ' HB ' HG23 ' A' ' 67' ' ' VAL . 35.8 pt -120.12 -25.0 2.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.717 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 179.215 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -163.35 166.0 23.43 Favored 'General case' 0 C--O 1.21 -1.017 0 N-CA-C 110.312 -0.255 . . . . 0.0 110.312 -178.022 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 67.1 t -139.48 113.18 6.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.3 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 48.1 mt -118.48 143.29 46.81 Favored 'General case' 0 C--N 1.29 -1.995 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 179.751 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.583 HG22 ' NE2' ' A' ' 143' ' ' GLN . 5.3 mp -124.23 128.52 73.92 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 C-N-CA 119.7 -0.8 . . . . 0.0 110.67 178.419 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.565 ' O ' HD21 ' A' ' 131' ' ' LEU . 0.0 OUTLIER -96.11 135.15 38.28 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 175.433 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . 0.479 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 8.8 tpt180 -97.92 122.26 40.83 Favored 'General case' 0 C--N 1.285 -2.223 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.573 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . 0.424 ' NE2' HG23 ' A' ' 56' ' ' VAL . 0.0 OUTLIER -105.82 104.7 14.47 Favored 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 123.406 0.682 . . . . 0.0 109.268 -177.587 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 6.9 m -127.34 142.14 51.52 Favored 'General case' 0 C--N 1.284 -2.255 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 179.197 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.546 ' CB ' HG21 ' A' ' 52' ' ' ILE . 9.1 p30 . . . . . 0 C--N 1.309 -1.166 0 C-N-CA 119.988 -0.685 . . . . 0.0 110.446 176.498 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 . . . . . 0 N--CA 1.441 -0.912 0 CA-C-O 120.992 0.425 . . . . 0.0 109.935 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . 0.583 ' NE2' HG22 ' A' ' 130' ' ' ILE . 17.3 pt20 -134.79 143.93 47.36 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 175.514 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 1.657 ' HE2' ' CE1' ' A' ' 144' ' ' PHE . 9.4 m-30 -109.65 130.38 55.52 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 -179.175 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . 0.411 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 52.2 t -90.81 132.27 35.82 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 O-C-N 123.592 0.557 . . . . 0.0 109.799 -178.617 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . 0.408 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 61.9 m95 -117.47 96.18 5.29 Favored 'General case' 0 C--N 1.279 -2.48 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 -179.304 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.9 m-80 -79.45 112.63 16.89 Favored 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 177.989 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . 0.449 ' HA ' HG23 ' A' ' 20' ' ' VAL . 26.6 mm -86.37 122.14 38.33 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.816 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -175.799 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 1.662 ' HD2' ' CD1' ' A' ' 149' ' ' TYR . 40.6 m-85 -117.25 156.2 28.16 Favored 'General case' 0 CA--C 1.487 -1.474 0 CA-C-O 121.633 0.73 . . . . 0.0 110.605 179.222 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -84.28 129.37 34.89 Favored 'General case' 0 N--CA 1.405 -2.685 0 CA-C-N 114.544 -1.207 . . . . 0.0 108.684 175.808 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 15.8 t-20 -91.43 -13.77 31.74 Favored 'General case' 0 C--N 1.29 -2.008 0 N-CA-C 107.383 -1.339 . . . . 0.0 107.383 -178.793 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -150.14 143.62 25.17 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 113.633 -1.621 . . . . 0.0 109.008 -175.201 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -86.37 144.79 27.17 Favored 'General case' 0 C--N 1.307 -1.249 0 O-C-N 124.241 0.963 . . . . 0.0 110.169 -179.777 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.453 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 1.5 m -123.96 150.52 28.46 Favored 'Isoleucine or valine' 0 C--O 1.253 1.249 0 C-N-CA 120.701 -0.4 . . . . 0.0 111.24 -177.284 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.2 t -124.32 138.27 54.4 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.124 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -179.613 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.449 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 79.0 t -100.21 100.83 12.64 Favored Pre-proline 0 C--N 1.296 -1.759 0 C-N-CA 123.983 0.913 . . . . 0.0 109.453 178.06 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . 0.458 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 27.5 Cg_endo -66.37 -26.19 48.47 Favored 'Trans proline' 0 CA--C 1.515 -0.428 0 C-N-CA 122.208 1.939 . . . . 0.0 111.773 178.908 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.3 t . . . . . 0 C--O 1.254 1.312 0 O-C-N 124.516 1.135 . . . . 0.0 113.223 176.882 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.446 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.429 -1.482 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 . . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.491 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 13.6 t -147.4 159.37 43.77 Favored 'General case' 0 N--CA 1.428 -1.555 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.647 -174.784 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.504 ' HE3' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.81 168.72 19.54 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-O 121.36 0.6 . . . . 0.0 110.747 -173.717 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.555 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 76.2 p -105.5 175.82 5.37 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.08 0.467 . . . . 0.0 110.798 179.771 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -73.66 -22.05 60.08 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.627 178.651 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.555 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 7.4 p30 -84.28 -33.33 24.01 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 120.256 -0.578 . . . . 0.0 110.641 -177.784 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 135.13 9.47 1.66 Allowed Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 119.564 -1.303 . . . . 0.0 113.699 176.808 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -85.16 100.02 11.46 Favored 'General case' 0 N--CA 1.433 -1.317 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.884 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.1 117.33 30.0 Favored 'General case' 0 C--N 1.297 -1.71 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.591 178.638 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.446 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 67.3 mt -86.63 127.26 61.16 Favored Pre-proline 0 C--N 1.299 -1.627 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 178.692 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -81.06 169.34 16.28 Favored 'Trans proline' 0 C--O 1.248 0.984 0 C-N-CA 122.78 2.32 . . . . 0.0 111.305 177.985 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 61.3 mt -69.16 132.11 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 177.855 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.404 ' HA2' ' CD2' ' A' ' 142' ' ' PHE . . . 129.89 -5.22 6.12 Favored Glycine 0 C--N 1.3 -1.462 0 C-N-CA 120.172 -1.013 . . . . 0.0 111.507 -179.528 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 101.42 163.6 27.33 Favored Glycine 0 N--CA 1.432 -1.595 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 -177.694 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 160.41 -177.45 36.84 Favored Glycine 0 C--N 1.297 -1.614 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 178.612 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.402 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 59.7 p -138.99 147.74 42.55 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.763 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -132.0 161.05 34.1 Favored 'General case' 0 N--CA 1.426 -1.63 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 177.999 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 -116.2 109.06 16.93 Favored 'General case' 0 C--N 1.289 -2.055 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 177.784 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . 0.432 HG23 ' HA ' ' A' ' 148' ' ' ILE . 1.3 m -91.1 147.68 5.08 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.416 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 -177.893 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.7 m-85 -131.04 118.87 21.2 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -177.354 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.472 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -125.43 135.63 63.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.108 -176.389 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 30.7 m-80 -91.08 122.7 33.95 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 179.988 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -101.94 160.61 14.34 Favored 'General case' 0 C--N 1.285 -2.223 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 178.103 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.2 122.21 52.48 Favored Pre-proline 0 C--N 1.314 -0.955 0 O-C-N 124.116 0.885 . . . . 0.0 108.728 174.76 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.497 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 72.8 Cg_endo -74.71 -1.84 11.67 Favored 'Trans proline' 0 CA--C 1.533 0.441 0 C-N-CA 122.895 2.397 . . . . 0.0 112.968 -176.148 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 95.6 t -129.11 111.27 22.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 -179.995 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 10.3 t -148.19 111.1 0.68 Allowed 'Isoleucine or valine' 0 C--O 1.188 -2.17 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -177.341 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.587 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -96.83 154.65 17.17 Favored 'General case' 0 C--N 1.272 -2.775 0 C-N-CA 123.646 0.778 . . . . 0.0 110.962 179.834 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.622 HG23 ' O ' ' A' ' 112' ' ' VAL . 71.5 t -46.67 122.66 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 C-N-CA 123.051 0.541 . . . . 0.0 110.734 176.24 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.25 1.24 58.16 Favored Glycine 0 C--N 1.315 -0.592 0 CA-C-N 115.536 -0.756 . . . . 0.0 112.919 179.663 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.587 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -73.38 -176.98 2.42 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 123.396 0.678 . . . . 0.0 110.678 175.93 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -131.42 92.13 3.12 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.131 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.647 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 28.5 tp -94.09 141.05 28.99 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 119.444 -0.902 . . . . 0.0 109.906 -179.66 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 56.9 t -131.87 120.93 45.98 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.019 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.022 -176.443 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.59 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 48.3 t -90.86 88.21 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.89 0 N-CA-C 105.249 -2.13 . . . . 0.0 105.249 173.655 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -83.26 109.75 17.5 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.318 -177.473 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 84.2 mt -95.0 -3.64 48.04 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.111 -178.164 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.408 ' HA ' ' O ' ' A' ' 103' ' ' TRP . 1.1 m -71.15 0.15 8.38 Favored 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 114.831 -1.077 . . . . 0.0 110.125 -179.945 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.5 p -133.21 6.86 3.9 Favored 'General case' 0 N--CA 1.425 -1.677 0 C-N-CA 124.24 1.016 . . . . 0.0 109.911 178.639 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.472 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 46.2 mm-40 -122.23 -19.28 6.57 Favored 'General case' 0 CA--C 1.507 -0.699 0 CA-C-O 121.067 0.461 . . . . 0.0 110.717 -174.557 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 45.2 mt -134.36 138.24 50.2 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -176.219 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.504 ' HB2' ' HE3' ' A' ' 4' ' ' LYS . 72.8 m-85 -143.02 143.44 31.9 Favored 'General case' 0 CA--C 1.492 -1.27 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -174.467 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . 0.491 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 64.8 m -126.87 140.64 52.19 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 -176.327 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -121.89 151.17 40.98 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.313 0.578 . . . . 0.0 110.256 -176.203 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.638 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 24.0 p-10 -107.18 104.06 13.6 Favored 'General case' 0 N--CA 1.411 -2.387 0 CA-C-O 122.886 1.327 . . . . 0.0 110.068 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -74.84 -34.64 62.35 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 112.942 -1.935 . . . . 0.0 111.319 -174.847 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . 1.671 ' HE1' ' CE2' ' A' ' 48' ' ' TYR . 49.5 m-85 -134.23 72.79 70.76 Favored Pre-proline 0 C--N 1.3 -1.566 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.539 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.638 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 58.7 Cg_endo -72.34 -3.05 12.64 Favored 'Trans proline' 0 C--N 1.334 -0.224 0 C-N-CA 122.775 2.317 . . . . 0.0 113.386 -174.378 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -118.83 -4.19 10.7 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 121.138 0.494 . . . . 0.0 109.799 -178.278 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.453 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -117.99 -29.1 5.72 Favored 'General case' 0 N--CA 1.418 -2.033 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.883 -174.016 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.453 HD13 ' HB ' ' A' ' 51' ' ' THR . 3.0 mp -130.6 134.84 61.54 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.487 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.5 t -69.57 139.74 53.75 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 108.957 -0.756 . . . . 0.0 108.957 177.463 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -86.76 107.96 18.49 Favored 'General case' 0 C--N 1.285 -2.207 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -173.347 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 1.667 ' HD1' ' CD2' ' A' ' 55' ' ' TYR . 73.1 t80 -150.16 145.35 26.24 Favored 'General case' 0 C--N 1.295 -1.794 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.427 -171.357 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.488 HG11 ' HB2' ' A' ' 131' ' ' LEU . 59.9 t -150.66 139.67 15.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 C-N-CA 124.559 1.144 . . . . 0.0 108.666 177.655 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -147.27 122.61 10.29 Favored 'General case' 0 C--O 1.21 -0.992 0 O-C-N 123.311 0.382 . . . . 0.0 110.607 174.617 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.513 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 63.5 tp -64.77 114.92 4.79 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-O 121.315 0.579 . . . . 0.0 110.004 177.195 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . 0.417 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 4.2 tp-100 -59.12 -60.02 4.53 Favored 'General case' 0 C--N 1.315 -0.933 0 C-N-CA 126.287 1.835 . . . . 0.0 110.555 176.566 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . 0.402 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 4.5 ptp180 -163.06 161.91 25.56 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 115.052 -0.976 . . . . 0.0 108.424 -177.011 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.44 131.25 4.59 Favored Glycine 0 N--CA 1.401 -3.641 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 -179.384 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 49.1 m -120.07 149.52 42.05 Favored 'General case' 0 C--N 1.288 -2.089 0 C-N-CA 124.072 0.949 . . . . 0.0 110.395 -174.575 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.552 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -111.5 153.4 26.26 Favored 'General case' 0 N--CA 1.486 1.356 0 CA-C-O 117.792 -1.099 . . . . 0.0 108.398 -179.457 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 1.658 ' HE1' ' CE2' ' A' ' 64' ' ' TYR . 95.2 m-85 -158.35 -179.75 8.39 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 123.646 0.779 . . . . 0.0 111.277 -176.951 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.91 -134.02 51.03 Favored Glycine 0 C--N 1.317 -0.485 0 C-N-CA 121.409 -0.424 . . . . 0.0 112.265 179.769 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.62 -10.22 83.6 Favored Glycine 0 N--CA 1.422 -2.25 0 C-N-CA 120.327 -0.939 . . . . 0.0 112.839 177.306 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.789 HG23 ' O ' ' A' ' 64' ' ' TYR . 12.5 m -73.84 -28.6 24.47 Favored 'Isoleucine or valine' 0 C--O 1.205 -1.252 0 CA-C-N 118.295 1.048 . . . . 0.0 112.262 -174.143 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.552 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -91.14 -19.94 22.54 Favored 'General case' 0 C--N 1.297 -1.675 0 C-N-CA 119.876 -0.73 . . . . 0.0 111.895 177.664 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 7.4 t -100.45 -49.35 4.26 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.481 0.658 . . . . 0.0 111.239 -173.627 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.501 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 49.6 m-20 -96.99 -17.82 19.81 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -174.332 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 1.593 ' HD1' ' CD2' ' A' ' 71' ' ' PHE . 87.2 m-85 -119.31 163.55 16.98 Favored 'General case' 0 C--N 1.294 -1.812 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.957 -179.329 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.2 t -173.06 132.6 0.51 Allowed 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 178.729 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.508 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -167.15 -112.5 0.26 Allowed Glycine 0 N--CA 1.406 -3.334 0 N-CA-C 110.624 -0.99 . . . . 0.0 110.624 174.178 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.2 p -154.93 -179.96 8.55 Favored 'General case' 0 C--N 1.292 -1.921 0 C-N-CA 123.628 0.771 . . . . 0.0 110.403 -172.933 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.409 ' HB ' ' CD1' ' A' ' 84' ' ' PHE . 2.5 p -134.27 145.5 32.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.319 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.741 ' HG3' ' O ' ' A' ' 80' ' ' SER . 71.0 tttt -123.22 142.99 50.34 Favored 'General case' 0 N--CA 1.416 -2.139 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.397 -179.395 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 1.669 ' HD2' ' CD1' ' A' ' 77' ' ' TYR . 71.7 t80 -143.81 112.0 6.3 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.521 -178.429 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 14.7 t 52.78 37.94 25.21 Favored 'General case' 0 CA--C 1.561 1.4 0 CA-C-O 122.025 0.917 . . . . 0.0 110.875 175.951 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.08 10.37 64.49 Favored Glycine 0 CA--C 1.528 0.903 0 CA-C-N 115.684 -0.689 . . . . 0.0 113.731 179.934 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.741 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 21.6 t -84.94 -179.72 7.13 Favored 'General case' 0 C--O 1.206 -1.211 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 177.836 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 48.5 m -159.06 108.83 1.95 Allowed 'General case' 0 C--N 1.279 -2.483 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 177.297 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 1.624 ' HE2' ' CE1' ' A' ' 82' ' ' TYR . 4.0 p90 -149.38 163.1 26.5 Favored Pre-proline 0 C--N 1.306 -1.308 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -174.517 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . 0.426 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 58.6 Cg_endo -68.99 148.79 70.85 Favored 'Trans proline' 0 C--N 1.358 1.057 0 C-N-CA 122.612 2.208 . . . . 0.0 113.425 -175.862 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.475 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 51.6 t80 -123.72 132.76 24.3 Favored Pre-proline 0 N--CA 1.435 -1.18 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 179.383 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.475 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 66.8 Cg_endo -72.22 147.58 89.11 Favored 'Cis proline' 0 CA--C 1.542 0.914 0 C-N-CA 122.734 -1.777 . . . . 0.0 110.497 -1.369 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.5 t -68.28 -175.84 0.67 Allowed 'General case' 0 CA--C 1.55 0.955 0 CA-C-O 121.229 0.537 . . . . 0.0 111.04 -176.181 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 7.9 p -130.37 -42.88 1.17 Allowed 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 116.07 -0.514 . . . . 0.0 112.289 -175.554 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.2 t -101.3 -86.63 0.4 Allowed 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.592 -175.467 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -170.19 -169.68 0.88 Allowed 'General case' 0 N--CA 1.438 -1.043 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 177.825 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.513 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 21.4 p -101.37 162.77 19.45 Favored Pre-proline 0 C--N 1.302 -1.477 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 177.325 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -63.79 159.4 41.78 Favored 'Trans proline' 0 C--N 1.358 1.059 0 C-N-CA 122.748 2.299 . . . . 0.0 111.64 174.526 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.7 tmm_? -65.35 118.29 9.14 Favored 'General case' 0 C--N 1.315 -0.918 0 C-N-CA 124.695 1.198 . . . . 0.0 109.554 -177.523 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 68.5 t -127.81 128.82 69.68 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.329 -177.07 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 74.2 t -114.29 140.73 33.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.402 179.416 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -87.36 95.65 10.07 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.24 0.543 . . . . 0.0 110.093 177.931 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -86.97 64.57 8.55 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 121.183 0.516 . . . . 0.0 110.392 -179.046 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.5 m -155.21 -179.59 8.23 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 -179.527 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . 0.513 ' HA ' HD22 ' A' ' 46' ' ' ASN . 16.7 ptm180 -141.28 50.32 1.61 Allowed 'General case' 0 N--CA 1.44 -0.971 0 CA-C-O 121.899 0.857 . . . . 0.0 110.128 178.996 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 6.9 t -163.39 170.75 17.02 Favored 'General case' 0 N--CA 1.424 -1.733 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 -178.868 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -69.92 101.59 1.79 Allowed 'General case' 0 C--O 1.251 1.169 0 CA-C-O 122.581 1.182 . . . . 0.0 108.755 178.242 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.8 tptm -101.1 137.02 19.6 Favored Pre-proline 0 C--N 1.268 -2.945 0 CA-C-N 113.002 -1.908 . . . . 0.0 109.368 -175.878 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -64.74 146.09 87.81 Favored 'Trans proline' 0 C--O 1.246 0.904 0 C-N-CA 122.673 2.248 . . . . 0.0 111.892 177.073 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . 0.408 ' O ' ' HA ' ' A' ' 39' ' ' SER . 15.7 t90 -86.95 108.61 19.33 Favored Pre-proline 0 N--CA 1.44 -0.932 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 -178.563 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -76.63 89.01 1.32 Allowed 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 121.864 1.709 . . . . 0.0 113.154 -173.273 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 81.2 t -139.89 145.86 25.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.038 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 177.824 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.59 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -149.92 136.31 19.01 Favored 'General case' 0 C--N 1.287 -2.121 0 CA-C-O 120.95 0.405 . . . . 0.0 110.223 177.586 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 15.9 mt -103.69 106.08 16.49 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 178.335 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 0.508 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 14.6 m-85 -83.01 75.0 9.92 Favored 'General case' 0 C--N 1.284 -2.249 0 N-CA-C 110.159 -0.312 . . . . 0.0 110.159 177.849 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.647 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -95.83 124.96 40.08 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 174.776 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -128.97 146.25 59.87 Favored Pre-proline 0 N--CA 1.409 -2.492 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 -176.86 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.501 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 36.2 Cg_endo -63.78 126.01 16.56 Favored 'Trans proline' 0 N--CA 1.444 -1.424 0 C-N-CA 122.712 2.274 . . . . 0.0 113.685 -175.813 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.622 ' O ' HG23 ' A' ' 30' ' ' VAL . 13.9 m -85.62 -155.96 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.392 -3.346 0 CA-C-N 114.007 -1.451 . . . . 0.0 108.465 171.648 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 14.4 m -79.86 -33.39 40.15 Favored 'General case' 0 C--N 1.262 -3.225 0 CA-C-O 121.446 0.641 . . . . 0.0 110.12 -170.36 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.2 t -83.19 26.89 0.6 Allowed 'General case' 0 N--CA 1.425 -1.684 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.558 -178.137 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -107.8 134.35 50.87 Favored 'General case' 0 N--CA 1.424 -1.766 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 178.478 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -176.78 129.21 1.44 Allowed Glycine 0 N--CA 1.437 -1.235 0 C-N-CA 120.571 -0.824 . . . . 0.0 111.469 178.814 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.4 -150.71 52.01 Favored Glycine 0 CA--C 1.495 -1.204 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 -176.305 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -55.9 105.99 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 CA-C-O 122.522 1.153 . . . . 0.0 111.932 -178.211 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -106.61 -28.33 10.3 Favored 'General case' 0 C--N 1.294 -1.812 0 CA-C-N 114.51 -1.223 . . . . 0.0 111.375 -177.922 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.403 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 54.8 mt -130.07 135.01 61.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.118 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.423 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.1 mmpt? -109.84 141.48 42.47 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-O 121.164 0.507 . . . . 0.0 111.123 176.767 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -72.09 123.28 22.52 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.429 178.965 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 97.94 -0.0 58.95 Favored Glycine 0 C--N 1.306 -1.097 0 N-CA-C 111.316 -0.714 . . . . 0.0 111.316 -176.613 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 31.0 t -97.16 145.42 26.04 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.329 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.41 HD21 ' CZ ' ' A' ' 149' ' ' TYR . 3.2 tm? -76.84 123.43 26.23 Favored 'General case' 0 N--CA 1.431 -1.38 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.82 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.437 ' HB ' HG13 ' A' ' 67' ' ' VAL . 28.4 pt -108.63 -29.75 2.53 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.745 -179.746 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . 0.419 ' HB1' ' HB ' ' A' ' 148' ' ' ILE . . . -158.88 168.5 26.64 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 119.46 -0.896 . . . . 0.0 110.639 -177.238 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 72.3 t -142.12 113.48 3.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 179.021 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 57.0 mt -117.24 151.53 36.73 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 178.533 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . 0.511 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.5 mp -135.71 129.69 48.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 178.027 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.488 ' HB2' HG11 ' A' ' 56' ' ' VAL . 1.2 pp -97.34 142.0 29.75 Favored 'General case' 0 CA--C 1.499 -0.991 0 C-N-CA 119.864 -0.734 . . . . 0.0 109.022 177.352 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . 0.417 ' HG2' ' HB2' ' A' ' 59' ' ' GLN . 15.4 mmm180 -96.64 116.11 28.55 Favored 'General case' 0 C--N 1.279 -2.477 0 C-N-CA 124.264 1.026 . . . . 0.0 108.551 175.848 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 26.2 tp60 -85.12 135.48 33.96 Favored 'General case' 0 N--CA 1.413 -2.302 0 N-CA-C 105.55 -2.019 . . . . 0.0 105.55 174.966 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.512 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 25.2 m -139.0 135.33 34.17 Favored 'General case' 0 C--N 1.262 -3.199 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 174.807 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 24.1 p-10 . . . . . 0 C--N 1.303 -1.446 0 CA-C-O 121.695 0.759 . . . . 0.0 110.909 -176.742 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . 1.67 ' HE1' ' CE2' ' A' ' 142' ' ' PHE . 74.7 m-85 . . . . . 0 N--CA 1.43 -1.474 0 N-CA-C 107.243 -1.392 . . . . 0.0 107.243 . . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -132.48 144.89 50.76 Favored 'General case' 0 C--N 1.292 -1.911 0 C-N-CA 118.937 -1.105 . . . . 0.0 111.341 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 10.2 m-30 -109.24 127.52 54.32 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -177.078 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . 0.402 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 48.5 t -91.17 137.04 22.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 123.538 0.524 . . . . 0.0 110.18 -178.027 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 60.6 m95 -125.35 96.56 4.87 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 -178.084 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -81.56 114.44 20.27 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 178.146 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . 0.432 ' HA ' HG23 ' A' ' 20' ' ' VAL . 20.9 mm -88.0 122.85 40.12 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -176.268 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 1.61 ' HD1' ' CD2' ' A' ' 149' ' ' TYR . 83.4 m-85 -119.01 152.92 35.53 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.822 178.584 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.12 129.6 35.04 Favored 'General case' 0 N--CA 1.407 -2.591 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 177.211 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 10.9 t-20 -90.47 -12.89 35.98 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 122.452 1.12 . . . . 0.0 108.082 -177.088 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -149.03 144.47 26.74 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 113.964 -1.471 . . . . 0.0 108.911 -175.133 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 17.3 p-10 -86.63 141.92 28.62 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 123.982 0.801 . . . . 0.0 111.762 -179.11 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.497 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 70.5 t -117.46 139.04 46.14 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 CA-C-N 115.228 -0.897 . . . . 0.0 111.632 -173.597 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -120.1 132.3 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 179.21 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . 0.462 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 71.7 t -97.71 103.59 17.4 Favored Pre-proline 0 C--N 1.292 -1.904 0 C-N-CA 123.933 0.893 . . . . 0.0 109.927 179.909 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 23.2 Cg_endo -68.15 -27.41 35.43 Favored 'Trans proline' 0 CA--C 1.509 -0.754 0 C-N-CA 121.978 1.786 . . . . 0.0 111.816 179.719 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 5.0 t . . . . . 0 CA--C 1.549 0.94 0 C-N-CA 124.706 1.202 . . . . 0.0 113.628 177.911 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 2' ' ' ALA . . . . . 0.476 ' HB1' ' CE1' ' A' ' 45' ' ' HIS . . . . . . . . 0 N--CA 1.436 -1.148 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 . . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 64.4 m -144.99 168.47 20.2 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 120.193 -0.603 . . . . 0.0 110.726 -176.616 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.42 ' HA ' ' O ' ' A' ' 9' ' ' THR . 0.3 OUTLIER -148.82 162.2 40.28 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 123.632 0.773 . . . . 0.0 109.477 178.868 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 5' ' ' THR . . . . . 0.461 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 71.9 p -100.24 175.86 5.58 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 121.394 0.616 . . . . 0.0 110.414 -179.744 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.29 -13.54 59.92 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-N 114.371 -1.286 . . . . 0.0 110.654 179.157 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.461 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 5.3 p30 -87.82 -34.31 18.3 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 118.895 -1.122 . . . . 0.0 108.63 175.265 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 134.19 7.2 2.29 Favored Glycine 0 N--CA 1.436 -1.304 0 C-N-CA 120.0 -1.095 . . . . 0.0 113.301 177.049 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.42 ' O ' ' HA ' ' A' ' 4' ' ' LYS . 5.1 m -76.55 99.28 4.91 Favored 'General case' 0 N--CA 1.442 -0.873 0 CA-C-N 117.601 0.7 . . . . 0.0 109.121 179.869 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.55 118.43 30.99 Favored 'General case' 0 C--N 1.294 -1.819 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.271 178.314 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.417 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 62.4 mt -96.53 118.79 64.98 Favored Pre-proline 0 C--N 1.302 -1.459 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 177.233 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -79.12 174.85 11.55 Favored 'Trans proline' 0 C--O 1.252 1.193 0 C-N-CA 122.637 2.224 . . . . 0.0 110.655 177.935 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 53.8 mt -71.99 119.85 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.247 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 177.217 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 151.76 -12.11 0.73 Allowed Glycine 0 C--N 1.291 -1.96 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -172.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 94.24 161.2 34.88 Favored Glycine 0 N--CA 1.433 -1.547 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 177.651 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 162.05 -167.92 36.9 Favored Glycine 0 CA--C 1.473 -2.564 0 C-N-CA 118.888 -1.625 . . . . 0.0 111.904 179.109 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 14.5 m -144.6 147.64 33.39 Favored 'General case' 0 C--N 1.286 -2.19 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 -179.386 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.22 156.44 48.98 Favored 'General case' 0 N--CA 1.426 -1.637 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 -179.134 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -104.78 111.02 23.6 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 179.91 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 41.3 t -98.68 139.59 20.26 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.901 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.347 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 1.665 ' HE2' ' CE1' ' A' ' 21' ' ' TYR . 56.2 m-85 -128.66 119.09 24.04 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -177.288 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . 0.458 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.9 p -122.74 129.75 74.96 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-O 121.884 0.85 . . . . 0.0 111.089 -175.899 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -88.73 119.17 28.97 Favored 'General case' 0 C--N 1.291 -1.974 0 CA-C-N 114.847 -1.07 . . . . 0.0 109.439 179.546 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 27.8 mt -107.06 160.79 15.29 Favored 'General case' 0 C--N 1.28 -2.453 0 CA-C-N 114.625 -1.17 . . . . 0.0 109.185 -177.58 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.5 121.56 49.22 Favored Pre-proline 0 C--O 1.206 -1.2 0 O-C-N 124.01 0.819 . . . . 0.0 108.871 177.826 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 26' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 60.1 Cg_endo -73.99 -2.47 12.32 Favored 'Trans proline' 0 CA--C 1.53 0.282 0 C-N-CA 122.786 2.324 . . . . 0.0 113.302 -175.627 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 96.0 t -127.83 109.96 21.04 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -179.308 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 5.8 t -146.57 106.74 0.66 Allowed 'Isoleucine or valine' 0 C--O 1.189 -2.114 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -178.035 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 29' ' ' ASN . . . . . 0.567 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -94.27 153.98 17.76 Favored 'General case' 0 C--N 1.277 -2.581 0 C-N-CA 123.246 0.618 . . . . 0.0 111.506 179.983 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 112' ' ' VAL . 85.5 t -50.66 118.98 0.84 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.738 0 C-N-CA 123.274 0.629 . . . . 0.0 111.051 179.405 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.37 7.88 50.92 Favored Glycine 0 C--N 1.309 -0.917 0 CA-C-N 114.98 -1.009 . . . . 0.0 112.138 -178.527 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . 0.567 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -78.66 -177.24 5.28 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 123.493 0.717 . . . . 0.0 109.633 173.09 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -132.93 92.4 3.03 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 177.984 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.669 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 23.9 tp -92.67 145.51 24.37 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 119.705 -0.798 . . . . 0.0 109.247 179.407 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.9 t -136.09 121.74 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.584 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -177.536 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.625 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 62.0 t -91.74 88.62 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.406 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 175.298 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -84.2 115.53 22.48 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 120.008 -0.677 . . . . 0.0 110.641 -178.681 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.4 mt -94.7 -1.23 53.43 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.718 -179.313 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 31.6 t -75.04 2.17 11.24 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.925 0.869 . . . . 0.0 109.477 178.797 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.5 p -129.25 4.26 5.21 Favored 'General case' 0 C--N 1.288 -2.074 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.46 176.348 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . 0.458 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 42.7 mm-40 -124.58 -20.8 5.01 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-O 121.091 0.472 . . . . 0.0 110.726 -174.651 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 26.8 mt -133.82 136.47 53.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.978 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -176.32 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.642 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 62.5 m-85 -133.49 139.75 46.84 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 -176.938 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 60.5 m -125.03 134.22 52.65 Favored 'General case' 0 C--N 1.272 -2.784 0 CA-C-O 121.273 0.559 . . . . 0.0 111.743 -177.783 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . 0.476 ' CE1' ' HB1' ' A' ' 2' ' ' ALA . 10.5 p80 -119.9 129.89 54.58 Favored 'General case' 0 C--N 1.295 -1.772 0 CA-C-O 121.816 0.817 . . . . 0.0 110.775 -178.118 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 46' ' ' ASN . . . . . 0.59 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 4.8 p-10 -97.84 95.0 7.23 Favored 'General case' 0 C--N 1.275 -2.658 0 CA-C-O 123.053 1.406 . . . . 0.0 107.567 178.317 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.54 -19.93 51.8 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-N 113.64 -1.618 . . . . 0.0 113.715 -172.304 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -135.24 65.05 62.77 Favored Pre-proline 0 C--N 1.313 -0.98 0 C-N-CA 120.147 -0.621 . . . . 0.0 110.947 178.758 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 49' ' ' PRO . . . . . 0.59 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 35.7 Cg_endo -64.98 -18.48 62.3 Favored 'Trans proline' 0 C--N 1.355 0.895 0 C-N-CA 123.182 2.588 . . . . 0.0 115.302 -171.213 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -108.14 -15.98 14.37 Favored 'General case' 0 C--N 1.289 -2.045 0 C-N-CA 119.66 -0.816 . . . . 0.0 110.641 -176.249 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 51' ' ' THR . . . . . 0.489 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -101.14 -31.22 11.14 Favored 'General case' 0 N--CA 1.415 -2.211 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 -174.11 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.489 HD13 ' HB ' ' A' ' 51' ' ' THR . 3.2 mp -126.47 141.87 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.348 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 178.969 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 7.5 t -86.78 122.13 30.23 Favored 'General case' 0 N--CA 1.405 -2.698 0 N-CA-C 103.462 -2.792 . . . . 0.0 103.462 172.205 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 54' ' ' ASP . . . . . 0.473 ' OD2' ' HB2' ' A' ' 46' ' ' ASN . 17.1 m-20 -93.39 106.02 18.03 Favored 'General case' 0 C--N 1.256 -3.484 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 -175.125 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 55' ' ' TYR . . . . . 1.662 ' HE2' ' CE1' ' A' ' 55' ' ' TYR . 10.7 t80 -123.13 133.43 54.27 Favored 'General case' 0 C--N 1.285 -2.22 0 CA-C-N 113.852 -1.522 . . . . 0.0 109.974 -172.613 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.2 t -128.46 142.99 42.42 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 115.285 -0.87 . . . . 0.0 109.27 -174.966 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.12 128.93 12.46 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 123.715 0.634 . . . . 0.0 109.332 172.619 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.511 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 34.3 tp -71.2 102.86 2.63 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 173.353 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.5 tp-100 -56.22 -56.66 18.28 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 112.9 -1.954 . . . . 0.0 110.019 -176.928 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 6.1 ptp180 -158.76 151.14 21.61 Favored 'General case' 0 N--CA 1.41 -2.47 0 CA-C-N 114.251 -1.34 . . . . 0.0 108.197 -177.956 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.79 123.99 2.26 Favored Glycine 0 N--CA 1.405 -3.412 0 N-CA-C 108.611 -1.795 . . . . 0.0 108.611 -178.656 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 66.0 m -116.47 148.18 41.0 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 124.519 1.127 . . . . 0.0 110.83 -171.529 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 63' ' ' ALA . . . . . 0.491 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -107.72 154.99 20.68 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.266 1.026 . . . . 0.0 108.62 -179.852 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 64' ' ' TYR . . . . . 0.756 ' O ' HG23 ' A' ' 67' ' ' VAL . 87.4 m-85 -156.06 -179.35 8.05 Favored 'General case' 0 N--CA 1.483 1.193 0 CA-C-N 118.351 0.523 . . . . 0.0 111.852 -176.956 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.33 -122.0 26.22 Favored Glycine 0 C--N 1.319 -0.393 0 CA-C-N 116.281 -0.418 . . . . 0.0 113.068 178.384 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -91.06 -10.38 62.64 Favored Glycine 0 N--CA 1.417 -2.57 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.843 177.076 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.756 HG23 ' O ' ' A' ' 64' ' ' TYR . 12.5 m -76.77 -25.59 15.95 Favored 'Isoleucine or valine' 0 C--O 1.206 -1.23 0 CA-C-N 118.174 0.987 . . . . 0.0 112.289 -172.1 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.491 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -90.66 -23.75 20.68 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 121.495 0.664 . . . . 0.0 111.74 177.701 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 21.7 m -102.03 -52.91 3.05 Favored 'General case' 0 C--N 1.305 -1.366 0 N-CA-C 113.943 1.09 . . . . 0.0 113.943 -175.226 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 70' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 53.7 m-20 -88.09 -22.63 24.03 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 -177.41 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 71' ' ' PHE . . . . . 0.466 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 87.6 m-85 -115.48 164.12 14.75 Favored 'General case' 0 C--N 1.294 -1.842 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.944 179.832 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.3 t -172.63 134.22 0.63 Allowed 'General case' 0 N--CA 1.416 -2.13 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 177.266 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.616 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -165.58 -114.75 0.3 Allowed Glycine 0 N--CA 1.398 -3.847 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 173.401 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -153.52 -179.85 8.15 Favored 'General case' 0 C--N 1.273 -2.728 0 C-N-CA 124.176 0.991 . . . . 0.0 110.113 -173.917 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -132.7 152.04 35.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 C-N-CA 122.714 0.406 . . . . 0.0 109.958 178.586 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 76' ' ' LYS . . . . . 0.634 ' HG3' ' O ' ' A' ' 80' ' ' SER . 81.4 tttt -129.04 145.67 51.2 Favored 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 123.79 0.836 . . . . 0.0 110.128 -179.475 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 77' ' ' TYR . . . . . 0.409 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 58.1 t80 -147.28 112.49 5.52 Favored 'General case' 0 C--N 1.314 -0.96 0 O-C-N 123.777 0.673 . . . . 0.0 109.301 -178.655 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 23.0 t 54.97 36.28 26.48 Favored 'General case' 0 CA--C 1.551 1.003 0 C-N-CA 123.627 0.771 . . . . 0.0 110.448 177.188 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.58 8.18 66.05 Favored Glycine 0 CA--C 1.529 0.941 0 CA-C-N 115.459 -0.791 . . . . 0.0 114.095 -179.421 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 80' ' ' SER . . . . . 0.634 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 17.3 t -79.68 -179.52 6.94 Favored 'General case' 0 CA--C 1.543 0.682 0 CA-C-N 117.275 0.537 . . . . 0.0 109.994 -179.678 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 22.6 t -157.08 111.88 2.76 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 178.713 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 82' ' ' TYR . . . . . 1.642 ' HE2' ' CE1' ' A' ' 82' ' ' TYR . 2.6 p90 -154.6 161.42 29.4 Favored Pre-proline 0 CA--C 1.552 1.056 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -175.5 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -67.97 150.53 78.01 Favored 'Trans proline' 0 C--N 1.361 1.218 0 C-N-CA 122.884 2.389 . . . . 0.0 113.503 -176.761 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 1.67 ' HD2' ' CD1' ' A' ' 84' ' ' PHE . 57.8 t80 -126.39 132.65 24.4 Favored Pre-proline 0 N--CA 1.44 -0.967 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.067 179.785 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 85' ' ' PRO . . . . . 0.481 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 62.4 Cg_endo -69.95 147.07 84.29 Favored 'Cis proline' 0 CA--C 1.549 1.254 0 C-N-CA 123.125 -1.615 . . . . 0.0 111.16 -1.21 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.1 t -69.35 -176.98 1.04 Allowed 'General case' 0 CA--C 1.549 0.941 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.014 -175.294 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 14.1 p -127.41 -42.6 1.65 Allowed 'General case' 0 N--CA 1.432 -1.346 0 N-CA-C 112.799 0.666 . . . . 0.0 112.799 -172.418 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.6 t -108.12 -72.17 0.73 Allowed 'General case' 0 N--CA 1.432 -1.334 0 C-N-CA 119.74 -0.784 . . . . 0.0 111.527 -175.533 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 176.6 -177.42 0.14 Allowed 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 -174.991 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.511 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 43.5 p -101.32 168.44 9.15 Favored Pre-proline 0 C--N 1.295 -1.781 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 178.555 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 91' ' ' PRO . . . . . 0.406 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 12.1 Cg_endo -54.43 164.73 2.72 Favored 'Trans proline' 0 C--O 1.252 1.175 0 C-N-CA 123.162 2.574 . . . . 0.0 112.188 171.305 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.546 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 1.7 tmm_? -84.82 101.44 12.27 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.131 -172.625 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 87.6 t -114.14 121.22 65.84 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 CA-C-N 114.893 -1.049 . . . . 0.0 111.402 -176.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 93.5 t -108.28 142.29 21.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 CA-C-N 115.106 -0.952 . . . . 0.0 108.739 177.72 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -98.52 110.6 23.17 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 176.085 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 46.2 m-80 -108.46 32.16 5.05 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-O 121.708 0.766 . . . . 0.0 110.075 178.891 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.3 m -85.16 -172.53 4.22 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.375 -177.674 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 16.4 ptp180 -145.99 36.46 1.03 Allowed 'General case' 0 C--N 1.307 -1.242 0 CA-C-O 121.85 0.833 . . . . 0.0 109.688 178.079 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 12.4 t -168.89 177.69 4.88 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 105.435 -2.061 . . . . 0.0 105.435 -178.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . 0.402 ' CB ' ' HB3' ' A' ' 45' ' ' HIS . 1.5 p-10 -84.75 127.71 34.25 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 178.509 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 101' ' ' LYS . . . . . 0.464 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 6.5 mmpt? -117.66 147.34 40.72 Favored Pre-proline 0 C--N 1.28 -2.447 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.666 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -67.62 143.5 62.61 Favored 'Trans proline' 0 N--CA 1.44 -1.626 0 C-N-CA 122.375 2.05 . . . . 0.0 111.013 -178.718 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 14.7 t90 -80.81 107.95 8.76 Favored Pre-proline 0 C--N 1.305 -1.361 0 N-CA-C 106.595 -1.632 . . . . 0.0 106.595 -176.742 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -77.25 88.98 1.36 Allowed 'Trans proline' 0 N--CA 1.443 -1.459 0 C-N-CA 121.276 1.317 . . . . 0.0 112.683 -172.273 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 96.3 t -139.9 144.34 28.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 177.291 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 106' ' ' ALA . . . . . 0.625 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -147.84 134.47 19.87 Favored 'General case' 0 N--CA 1.419 -1.98 0 CA-C-O 120.785 0.326 . . . . 0.0 110.155 178.096 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 17.7 mt -101.73 104.3 15.1 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.242 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 108' ' ' TYR . . . . . 1.619 ' HE2' ' CE1' ' A' ' 108' ' ' TYR . 16.5 m-85 -79.56 68.42 5.6 Favored 'General case' 0 C--N 1.287 -2.123 0 CA-C-O 120.514 0.197 . . . . 0.0 111.167 177.814 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.669 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -90.59 128.53 36.62 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 175.358 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.15 145.29 56.73 Favored Pre-proline 0 N--CA 1.416 -2.154 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.182 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 111' ' ' PRO . . . . . 0.474 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 30.7 Cg_endo -63.17 124.5 14.01 Favored 'Trans proline' 0 CA--C 1.498 -1.3 0 C-N-CA 122.927 2.418 . . . . 0.0 113.936 -176.24 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 112' ' ' VAL . . . . . 0.525 ' O ' HG23 ' A' ' 30' ' ' VAL . 19.5 m -86.36 -158.67 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.391 -3.419 0 CA-C-N 114.242 -1.345 . . . . 0.0 108.19 171.187 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 44.9 m -81.2 -22.35 38.91 Favored 'General case' 0 C--N 1.254 -3.575 0 O-C-N 121.636 -0.665 . . . . 0.0 111.069 -171.792 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.3 t -81.8 12.19 4.21 Favored 'General case' 0 CA--C 1.549 0.931 0 CA-C-O 121.771 0.796 . . . . 0.0 109.977 179.491 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.45 ' HB1' ' O ' ' A' ' 70' ' ' ASN . . . -98.98 135.42 40.41 Favored 'General case' 0 N--CA 1.419 -2.017 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.455 -179.708 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -179.82 122.96 0.81 Allowed Glycine 0 C--O 1.245 0.842 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 179.266 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 70.0 -155.01 53.09 Favored Glycine 0 C--N 1.307 -1.075 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 -174.922 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.1 p -53.88 106.86 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 122.541 1.162 . . . . 0.0 112.123 -178.174 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -108.56 -22.04 12.45 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 114.302 -1.317 . . . . 0.0 111.159 -176.848 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 120' ' ' ILE . . . . . 0.483 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.2 mt -136.34 133.47 49.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.053 0 N-CA-C 107.516 -1.291 . . . . 0.0 107.516 178.341 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 3.0 mmpt? -111.53 139.09 47.25 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 177.384 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.32 125.96 27.75 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 177.922 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 101.36 -10.77 58.14 Favored Glycine 0 N--CA 1.428 -1.885 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.298 -178.089 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 97.8 p -94.05 148.64 21.97 Favored 'General case' 0 C--O 1.252 1.22 0 C-N-CA 119.861 -0.736 . . . . 0.0 110.241 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . 0.414 HD12 HG21 ' A' ' 128' ' ' VAL . 3.0 tm? -76.35 124.15 27.06 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-N 115.011 -0.995 . . . . 0.0 108.878 -179.202 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 126' ' ' ILE . . . . . 0.431 ' HB ' HG13 ' A' ' 67' ' ' VAL . 27.6 pt -108.38 -29.92 2.53 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.389 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.878 179.901 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 127' ' ' ALA . . . . . 0.414 ' HB1' ' HB ' ' A' ' 148' ' ' ILE . . . -157.97 165.5 34.99 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.605 -0.838 . . . . 0.0 110.376 -176.595 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.414 HG21 HD12 ' A' ' 125' ' ' LEU . 64.4 t -139.6 114.18 7.37 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.796 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 177.929 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 40.0 mt -119.58 145.49 46.35 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 179.971 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 5.4 mp -129.64 128.85 66.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 C-N-CA 120.324 -0.551 . . . . 0.0 110.078 177.155 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 131' ' ' LEU . . . . . 0.472 ' C ' HD13 ' A' ' 131' ' ' LEU . 1.5 pp -92.62 138.31 31.61 Favored 'General case' 0 N--CA 1.424 -1.733 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 172.856 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 3.9 tpm_? -97.24 112.95 24.52 Favored 'General case' 0 C--N 1.249 -3.803 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 176.256 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.1 130.46 40.26 Favored 'General case' 0 N--CA 1.422 -1.849 0 N-CA-C 104.991 -2.226 . . . . 0.0 104.991 177.686 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 63.6 m -137.92 138.65 39.22 Favored 'General case' 0 C--N 1.273 -2.731 0 C-N-CA 120.396 -0.522 . . . . 0.0 110.179 174.277 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.455 ' CB ' HG21 ' A' ' 52' ' ' ILE . 20.0 p30 . . . . . 0 C--N 1.306 -1.302 0 CA-C-O 121.524 0.678 . . . . 0.0 112.051 -175.717 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 . . . . . 0 N--CA 1.436 -1.174 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -130.22 141.32 50.65 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.647 179.884 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 1.662 ' HE2' ' CE1' ' A' ' 144' ' ' PHE . 7.0 m-30 -104.6 127.99 52.48 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 -175.575 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 57.6 t -93.24 136.24 25.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -178.923 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 66.9 m95 -123.87 95.79 4.7 Favored 'General case' 0 C--N 1.281 -2.381 0 N-CA-C 108.272 -1.011 . . . . 0.0 108.272 -177.19 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -80.94 114.17 19.64 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 177.961 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 148' ' ' ILE . . . . . 0.414 ' HB ' ' HB1' ' A' ' 127' ' ' ALA . 22.6 mm -89.92 122.03 40.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 -175.785 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 149' ' ' TYR . . . . . 1.653 ' HE2' ' CE1' ' A' ' 149' ' ' TYR . 96.8 m-85 -118.14 157.99 25.89 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 178.241 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.6 131.89 35.29 Favored 'General case' 0 N--CA 1.407 -2.599 0 CA-C-N 115.002 -0.999 . . . . 0.0 108.523 176.216 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 34.2 t-20 -95.52 -8.96 33.76 Favored 'General case' 0 C--N 1.29 -2.007 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 -178.401 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 3.4 t30 -153.79 145.43 23.31 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 113.869 -1.514 . . . . 0.0 108.713 -175.959 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -84.8 140.41 31.23 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 124.138 0.899 . . . . 0.0 111.198 -178.539 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 70.3 t -118.17 134.66 61.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.015 -176.653 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.1 t -119.24 133.08 67.21 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.545 0 N-CA-C 107.178 -1.415 . . . . 0.0 107.178 -179.966 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 75.2 t -97.65 102.64 13.66 Favored Pre-proline 0 C--N 1.289 -2.033 0 C-N-CA 123.375 0.67 . . . . 0.0 109.962 179.389 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -70.58 -24.55 25.8 Favored 'Trans proline' 0 CA--C 1.516 -0.403 0 C-N-CA 121.87 1.714 . . . . 0.0 111.584 -179.261 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 7.3 t . . . . . 0 CA--C 1.545 0.779 0 C-N-CA 125.303 1.441 . . . . 0.0 112.723 176.95 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.444 ' H1 ' HD12 ' A' ' 13' ' ' ILE . 37.1 t80 . . . . . 0 CA--C 1.496 -1.11 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.601 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . -141.11 -171.3 3.24 Favored 'General case' 0 C--N 1.296 -1.748 0 CA-C-N 115.212 -0.904 . . . . 0.0 109.876 -173.349 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 15.7 t -152.15 158.31 42.75 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 -176.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.489 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -143.38 161.54 38.11 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 121.178 0.513 . . . . 0.0 111.208 -174.271 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.504 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 74.9 p -100.38 175.98 5.52 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.383 0.611 . . . . 0.0 110.653 179.203 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -76.41 -19.52 58.02 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.776 178.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.504 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 6.2 p30 -83.52 -34.0 25.38 Favored 'General case' 0 CA--C 1.514 -0.433 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.732 -179.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 130.32 27.31 0.76 Allowed Glycine 0 N--CA 1.441 -1.022 0 C-N-CA 119.907 -1.139 . . . . 0.0 112.348 177.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 9.2 m -99.82 99.37 10.16 Favored 'General case' 0 N--CA 1.423 -1.816 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 177.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.5 122.57 35.06 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 176.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.601 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 65.3 mt -97.63 117.59 65.14 Favored Pre-proline 0 C--N 1.294 -1.817 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 178.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -75.33 171.36 18.41 Favored 'Trans proline' 0 C--O 1.245 0.845 0 C-N-CA 122.62 2.213 . . . . 0.0 111.673 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.444 HD12 ' H1 ' ' A' ' 1' ' ' PHE . 69.6 mt -67.17 127.57 28.95 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.568 179.285 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 138.37 0.66 2.35 Favored Glycine 0 C--N 1.303 -1.3 0 C-N-CA 120.852 -0.69 . . . . 0.0 111.957 -177.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.49 168.87 43.72 Favored Glycine 0 N--CA 1.427 -1.921 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -178.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 155.49 -165.3 32.4 Favored Glycine 0 C--N 1.288 -2.135 0 C-N-CA 120.06 -1.067 . . . . 0.0 110.879 178.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.455 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 58.1 p -150.28 147.06 27.19 Favored 'General case' 0 N--CA 1.422 -1.868 0 CA-C-N 116.844 0.322 . . . . 0.0 110.373 -177.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -132.43 163.52 28.58 Favored 'General case' 0 N--CA 1.428 -1.556 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 178.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -116.71 107.52 14.78 Favored 'General case' 0 C--N 1.292 -1.929 0 N-CA-C 106.997 -1.482 . . . . 0.0 106.997 178.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 1.4 m -91.44 150.07 3.89 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.35 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -179.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 62.5 m-85 -131.92 112.16 12.18 Favored 'General case' 0 CA--C 1.485 -1.537 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -177.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.475 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 4.5 p -117.1 132.4 66.97 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.293 0 CA-C-O 121.815 0.817 . . . . 0.0 111.535 -173.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . 0.405 ' HB3' ' HB3' ' A' ' 151' ' ' ASN . 2.1 p30 -98.12 123.57 42.23 Favored 'General case' 0 C--N 1.286 -2.176 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.171 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -106.83 160.55 15.42 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 114.408 -1.269 . . . . 0.0 108.051 -178.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -54.92 121.46 35.31 Favored Pre-proline 0 C--N 1.308 -1.233 0 O-C-N 124.381 1.051 . . . . 0.0 109.284 175.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.44 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 63.8 Cg_endo -74.79 1.47 7.57 Favored 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 122.926 2.417 . . . . 0.0 113.035 -177.274 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.419 HG11 ' HG3' ' A' ' 157' ' ' PRO . 86.0 t -128.82 110.11 20.33 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 178.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.498 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 4.5 t -145.96 111.65 1.06 Allowed 'Isoleucine or valine' 0 C--O 1.185 -2.293 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 -179.352 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.587 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -100.57 152.52 20.32 Favored 'General case' 0 C--N 1.267 -2.998 0 C-N-CA 122.707 0.403 . . . . 0.0 111.381 -178.236 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.449 HG11 ' O ' ' A' ' 112' ' ' VAL . 38.9 t -46.37 113.85 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.612 0 C-N-CA 123.314 0.646 . . . . 0.0 111.596 176.633 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 105.29 3.73 41.19 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 114.929 -1.032 . . . . 0.0 112.855 -179.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.587 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -76.29 -177.35 4.01 Favored 'General case' 0 C--N 1.311 -1.069 0 C-N-CA 123.911 0.884 . . . . 0.0 110.067 175.641 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -133.54 91.59 2.87 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 177.11 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.655 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 28.4 tp -91.58 144.41 25.57 Favored 'General case' 0 C--N 1.292 -1.934 0 C-N-CA 119.964 -0.694 . . . . 0.0 109.781 -179.035 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 60.0 t -136.16 125.0 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -177.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.582 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 60.8 t -91.19 88.82 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.523 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 175.246 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -77.84 114.62 16.87 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -178.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 75.6 mt -98.0 -1.4 42.73 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-O 121.577 0.703 . . . . 0.0 110.983 -178.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.522 ' OG ' ' HA ' ' A' ' 104' ' ' PRO . 22.6 m -80.61 0.66 33.12 Favored 'General case' 0 C--N 1.29 -1.982 0 CA-C-O 122.321 1.058 . . . . 0.0 110.166 -178.322 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.2 p -121.59 4.07 10.13 Favored 'General case' 0 N--CA 1.417 -2.123 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.646 176.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.475 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 44.4 mm-40 -125.32 -21.87 4.48 Favored 'General case' 0 C--O 1.239 0.528 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.128 -174.317 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 30.8 mt -135.24 138.22 48.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -175.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.489 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 38.9 m-85 -143.43 130.38 20.55 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -176.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 73.3 m -109.48 151.11 27.15 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 120.976 0.417 . . . . 0.0 110.263 -178.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 7.6 p80 -138.06 129.98 28.49 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.72 0.771 . . . . 0.0 112.034 -175.141 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 46.7 t30 -99.43 99.85 10.81 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.195 -1.002 . . . . 0.0 109.98 176.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -72.37 -12.3 61.06 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 113.771 -1.559 . . . . 0.0 111.231 -176.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 1.622 ' HD1' ' CD2' ' A' ' 48' ' ' TYR . 91.4 m-85 -127.6 71.17 77.39 Favored Pre-proline 0 C--N 1.32 -0.689 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.05 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -70.27 -13.14 33.06 Favored 'Trans proline' 0 C--N 1.332 -0.302 0 C-N-CA 122.491 2.127 . . . . 0.0 113.836 -172.425 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -110.77 -16.89 13.48 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.354 0.597 . . . . 0.0 110.167 -177.471 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.449 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.6 OUTLIER -102.4 -30.94 10.73 Favored 'General case' 0 N--CA 1.404 -2.747 0 CA-C-O 121.648 0.737 . . . . 0.0 109.194 -171.476 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.614 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.5 mp -127.93 135.76 62.08 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 CA-C-N 114.97 -1.014 . . . . 0.0 109.071 -176.401 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.9 t -77.73 142.14 38.89 Favored 'General case' 0 C--O 1.248 1.014 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 175.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -82.44 107.29 14.98 Favored 'General case' 0 C--N 1.286 -2.187 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 -175.349 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 1.656 ' HD1' ' CD2' ' A' ' 55' ' ' TYR . 31.8 t80 -144.88 137.04 26.0 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-O 120.761 0.315 . . . . 0.0 110.476 -176.027 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.9 p -150.02 150.56 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-N 116.308 -0.406 . . . . 0.0 109.951 179.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.29 136.21 18.48 Favored 'General case' 0 C--N 1.311 -1.073 0 C-N-CA 123.298 0.639 . . . . 0.0 109.401 176.616 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.517 HD13 ' O ' ' A' ' 130' ' ' ILE . 43.5 tp -73.85 115.5 13.36 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 171.872 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.592 ' NE2' ' HD3' ' A' ' 132' ' ' ARG . 3.4 tp-100 -59.56 -51.32 70.33 Favored 'General case' 0 C--N 1.312 -1.064 0 C-N-CA 124.764 1.226 . . . . 0.0 111.588 178.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 9.4 ptp180 -171.51 160.42 5.92 Favored 'General case' 0 CA--C 1.5 -0.969 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 -174.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -139.27 146.78 18.54 Favored Glycine 0 N--CA 1.404 -3.454 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 64.4 m -131.48 150.66 52.07 Favored 'General case' 0 C--N 1.285 -2.231 0 C-N-CA 123.455 0.702 . . . . 0.0 109.568 -177.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.536 ' HB3' ' CE2' ' A' ' 84' ' ' PHE . . . -117.3 154.51 31.11 Favored 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -178.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.486 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . 90.9 m-85 -154.4 -179.5 8.0 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 123.71 0.804 . . . . 0.0 109.487 -178.33 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 63.84 -130.97 39.9 Favored Glycine 0 CA--C 1.507 -0.421 0 CA-C-N 116.305 -0.407 . . . . 0.0 113.287 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -90.07 -6.28 69.46 Favored Glycine 0 C--O 1.199 -2.065 0 C-N-CA 120.523 -0.846 . . . . 0.0 111.187 176.14 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.479 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 76.5 t -70.81 -41.63 77.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 122.867 0.467 . . . . 0.0 111.309 -176.442 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.509 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -82.13 -24.67 34.95 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 121.452 0.644 . . . . 0.0 112.367 -179.999 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 28.5 m -101.29 -50.82 3.66 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 114.269 1.211 . . . . 0.0 114.269 -173.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.427 ' O ' HG23 ' A' ' 112' ' ' VAL . 67.4 m-20 -89.87 -23.76 21.56 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 -176.141 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 0.533 ' CB ' ' HB3' ' A' ' 109' ' ' LEU . 86.1 m-85 -112.35 162.17 15.85 Favored 'General case' 0 N--CA 1.427 -1.601 0 CA-C-O 121.75 0.786 . . . . 0.0 111.42 179.686 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.456 ' HB2' HG11 ' A' ' 112' ' ' VAL . 5.5 m -165.94 140.24 4.52 Favored 'General case' 0 N--CA 1.4 -2.969 0 C-N-CA 125.906 1.683 . . . . 0.0 109.177 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.448 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -172.73 -100.35 0.13 Allowed Glycine 0 C--N 1.279 -2.629 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 174.14 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.41 HG21 ' O ' ' A' ' 73' ' ' GLY . 1.1 p -169.94 179.41 3.62 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 125.655 1.582 . . . . 0.0 109.365 -179.468 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.5 p -127.96 144.93 36.11 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.788 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 177.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.616 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.9 tttt -124.91 143.9 50.62 Favored 'General case' 0 N--CA 1.416 -2.13 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.456 -176.013 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 1.631 ' HD2' ' CD1' ' A' ' 77' ' ' TYR . 51.8 t80 -146.69 110.23 4.86 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 114.94 -1.027 . . . . 0.0 108.453 -178.467 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 32.7 t 54.76 39.47 31.39 Favored 'General case' 0 CA--C 1.556 1.202 0 CA-C-O 122.341 1.067 . . . . 0.0 110.86 177.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.5 16.93 69.79 Favored Glycine 0 N--CA 1.438 -1.196 0 CA-C-N 115.416 -0.811 . . . . 0.0 113.191 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.616 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 10.8 t -84.99 -179.74 7.12 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.118 -1.068 . . . . 0.0 108.118 175.445 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.0 t -160.25 97.57 1.25 Allowed 'General case' 0 C--N 1.29 -2.008 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 -178.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 0.443 ' HH ' HD21 ' A' ' 58' ' ' LEU . 3.2 p90 -138.75 159.17 68.38 Favored Pre-proline 0 C--N 1.296 -1.732 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 -174.116 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -68.47 147.27 70.65 Favored 'Trans proline' 0 C--N 1.352 0.729 0 C-N-CA 122.406 2.07 . . . . 0.0 112.799 -174.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.596 ' CD2' HD22 ' A' ' 109' ' ' LEU . 63.0 t80 -121.63 130.93 24.56 Favored Pre-proline 0 C--N 1.305 -1.339 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.17 -179.793 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.482 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 73.4 Cg_endo -73.79 147.63 90.04 Favored 'Cis proline' 0 C--O 1.25 1.087 0 C-N-CA 123.117 -1.618 . . . . 0.0 110.093 -2.331 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.6 t -68.16 -177.06 0.8 Allowed 'General case' 0 CA--C 1.548 0.877 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.259 -174.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 18.9 p -123.42 -12.44 7.76 Favored 'General case' 0 N--CA 1.435 -1.185 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.279 -173.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.8 t -152.05 -124.33 0.04 OUTLIER 'General case' 0 N--CA 1.393 -3.282 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -126.9 -169.15 1.98 Allowed 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 112.249 0.463 . . . . 0.0 112.249 -173.041 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.517 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 45.3 p -100.42 170.67 6.36 Favored Pre-proline 0 C--N 1.313 -0.983 0 C-N-CA 123.302 0.641 . . . . 0.0 112.685 179.058 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . 0.413 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 19.6 Cg_endo -59.53 166.09 8.47 Favored 'Trans proline' 0 C--O 1.246 0.904 0 C-N-CA 122.976 2.451 . . . . 0.0 111.779 170.46 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.1 tmm_? -80.58 117.99 21.77 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 -178.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 69.2 t -127.58 128.51 69.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 CA-C-O 121.353 0.597 . . . . 0.0 111.41 -175.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 81.4 t -106.18 138.31 32.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.554 179.536 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . 1.664 ' HD1' ' CD2' ' A' ' 95' ' ' TYR . 3.1 m-85 -87.59 116.66 25.86 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 175.054 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -97.72 45.25 1.03 Allowed 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 57.7 m -151.77 125.29 8.9 Favored 'General case' 0 N--CA 1.433 -1.298 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.733 -176.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 10.6 ptp180 -102.22 64.02 0.91 Allowed 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 122.044 0.926 . . . . 0.0 111.159 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.8 t -171.22 172.87 5.14 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 -178.438 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -65.12 100.78 0.46 Allowed 'General case' 0 C--N 1.324 -0.508 0 O-C-N 123.71 0.631 . . . . 0.0 110.049 -179.485 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -111.76 138.54 21.61 Favored Pre-proline 0 C--N 1.293 -1.863 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 178.151 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -56.08 148.39 59.17 Favored 'Trans proline' 0 C--O 1.246 0.897 0 C-N-CA 123.27 2.647 . . . . 0.0 112.633 179.09 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . 0.447 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.4 t90 -88.9 112.34 50.12 Favored Pre-proline 0 C--N 1.293 -1.849 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 -179.357 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.522 ' HA ' ' OG ' ' A' ' 39' ' ' SER . 68.0 Cg_endo -75.58 87.57 1.36 Allowed 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 121.816 1.677 . . . . 0.0 112.426 -173.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 67.0 t -144.61 143.48 22.88 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.435 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 -179.396 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.582 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.14 135.72 17.09 Favored 'General case' 0 N--CA 1.415 -2.214 0 O-C-N 123.705 0.628 . . . . 0.0 110.285 177.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.428 HD11 ' CZ ' ' A' ' 84' ' ' PHE . 15.4 mt -100.83 104.71 15.95 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 178.066 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 1.625 ' HE2' ' CE1' ' A' ' 108' ' ' TYR . 12.4 m-85 -81.03 91.92 6.15 Favored 'General case' 0 C--N 1.285 -2.231 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 177.203 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.655 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.9 mm? -118.87 120.51 37.53 Favored 'General case' 0 C--N 1.292 -1.932 0 CA-C-O 120.742 0.306 . . . . 0.0 110.179 178.128 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.406 ' O ' ' HA ' ' A' ' 71' ' ' PHE . 0.3 OUTLIER -123.35 145.78 47.59 Favored Pre-proline 0 N--CA 1.413 -2.306 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.997 -175.085 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.425 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 25.7 Cg_endo -61.7 119.57 6.77 Favored 'Trans proline' 0 C--O 1.247 0.972 0 C-N-CA 123.202 2.601 . . . . 0.0 112.21 -177.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.456 HG11 ' HB2' ' A' ' 72' ' ' SER . 3.6 m -67.74 -117.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.188 -2.173 0 CA-C-N 114.09 -1.414 . . . . 0.0 113.081 175.57 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 41.3 t -112.67 -39.54 4.29 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 178.164 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 66.6 m -78.73 30.35 0.2 Allowed 'General case' 0 N--CA 1.392 -3.356 0 CA-C-N 113.596 -1.638 . . . . 0.0 112.952 -177.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -111.06 140.09 45.89 Favored 'General case' 0 N--CA 1.411 -2.399 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 177.29 128.27 1.13 Allowed Glycine 0 N--CA 1.438 -1.173 0 N-CA-C 111.385 -0.686 . . . . 0.0 111.385 -178.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 65.83 -149.13 51.46 Favored Glycine 0 N--CA 1.443 -0.874 0 CA-C-O 119.02 -0.878 . . . . 0.0 111.408 -176.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -54.51 105.8 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 CA-C-O 122.645 1.212 . . . . 0.0 112.741 -177.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.55 -31.44 9.44 Favored 'General case' 0 C--N 1.295 -1.789 0 CA-C-N 114.735 -1.12 . . . . 0.0 110.936 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.403 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 54.9 mt -128.18 140.07 50.18 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -179.871 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.421 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.7 mmpt? -115.12 133.9 55.63 Favored 'General case' 0 C--N 1.313 -1.009 0 C-N-CA 122.959 0.504 . . . . 0.0 111.584 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.18 133.34 48.71 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.651 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 86.06 0.35 87.21 Favored Glycine 0 C--O 1.242 0.624 0 C-N-CA 121.282 -0.485 . . . . 0.0 112.203 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 19.9 t -101.93 151.06 22.56 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 -178.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -77.92 123.69 27.09 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 -178.328 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.459 ' HB ' HG23 ' A' ' 67' ' ' VAL . 35.1 pt -110.08 -25.83 3.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 N-CA-C 112.578 0.585 . . . . 0.0 112.578 -178.729 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . 0.405 ' HB1' ' HB ' ' A' ' 148' ' ' ILE . . . -162.02 168.97 21.87 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -178.236 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 70.3 t -143.5 115.82 2.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.41 HD12 HD22 ' A' ' 107' ' ' LEU . 68.7 mt -117.79 146.9 43.49 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 178.141 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.517 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.6 mp -125.28 128.35 72.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 C-N-CA 119.727 -0.789 . . . . 0.0 110.42 177.475 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.431 HD22 ' HG2' ' A' ' 133' ' ' GLN . 0.0 OUTLIER -102.28 136.42 42.14 Favored 'General case' 0 C--N 1.29 -2.0 0 C-N-CA 123.664 0.786 . . . . 0.0 111.998 -177.352 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . 0.592 ' HD3' ' NE2' ' A' ' 59' ' ' GLN . 30.2 mmm180 -95.93 119.36 34.28 Favored 'General case' 0 C--N 1.294 -1.838 0 C-N-CA 124.365 1.066 . . . . 0.0 110.643 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.574 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 15.7 mm-40 -102.63 113.87 27.61 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 172.455 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 33.2 m -140.17 144.32 36.57 Favored 'General case' 0 C--N 1.289 -2.057 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -177.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.614 ' CB ' HG21 ' A' ' 52' ' ' ILE . 11.6 p30 -142.8 167.96 20.84 Favored 'General case' 0 N--CA 1.435 -1.18 0 C-N-CA 120.059 -0.656 . . . . 0.0 111.161 179.531 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -84.37 -17.26 39.98 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 113.421 -1.718 . . . . 0.0 112.43 -171.128 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . 1.665 ' HD2' ' CD1' ' A' ' 137' ' ' TYR . 53.9 t80 -97.81 -67.58 0.84 Allowed 'General case' 0 C--N 1.294 -1.82 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.822 -171.042 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 70.4 m-20 -83.1 -31.12 27.44 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-O 121.343 0.592 . . . . 0.0 111.28 -176.739 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 25.0 t 62.46 27.96 16.56 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 113.958 -1.474 . . . . 0.0 110.242 -177.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 11.8 p-10 -79.45 72.88 6.11 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 122.854 1.312 . . . . 0.0 109.825 177.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . 0.574 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 10.0 p-10 -78.28 72.74 4.82 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 113.362 -1.744 . . . . 0.0 113.01 -174.34 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -93.09 156.86 16.6 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 176.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 12.9 pt20 -125.71 146.78 49.6 Favored 'General case' 0 N--CA 1.418 -2.065 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.487 -179.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 12.3 m-30 -112.51 133.01 54.8 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 108.577 -0.898 . . . . 0.0 108.577 -176.447 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . 0.455 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 59.5 t -89.87 133.74 30.98 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 178.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . 0.431 ' NE1' ' HB3' ' A' ' 131' ' ' LEU . 70.3 m95 -121.84 97.04 5.31 Favored 'General case' 0 C--N 1.284 -2.281 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 -179.112 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 45.0 m-80 -79.17 114.99 18.55 Favored 'General case' 0 C--N 1.288 -2.08 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . 0.405 ' HB ' ' HB1' ' A' ' 127' ' ' ALA . 24.7 mm -88.36 120.62 37.55 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 -177.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -116.77 154.54 30.48 Favored 'General case' 0 CA--C 1.49 -1.328 0 C-N-CA 123.278 0.631 . . . . 0.0 110.012 178.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.44 129.38 34.62 Favored 'General case' 0 N--CA 1.417 -2.123 0 CA-C-N 115.221 -0.899 . . . . 0.0 109.075 176.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . 0.405 ' HB3' ' HB3' ' A' ' 23' ' ' ASN . 13.3 t-20 -87.75 -17.19 32.21 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 -178.282 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -153.47 144.04 22.54 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 113.708 -1.587 . . . . 0.0 109.507 -173.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -80.87 144.97 31.59 Favored 'General case' 0 C--N 1.317 -0.836 0 O-C-N 124.059 0.85 . . . . 0.0 109.838 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.44 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 74.4 t -121.92 139.26 49.51 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 C-N-CA 122.741 0.416 . . . . 0.0 111.391 -176.156 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.9 t -118.66 141.04 40.17 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.498 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 73.2 t -104.05 100.97 23.07 Favored Pre-proline 0 C--N 1.296 -1.719 0 C-N-CA 123.51 0.724 . . . . 0.0 110.116 178.025 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.419 ' HG3' HG11 ' A' ' 27' ' ' VAL . 33.3 Cg_endo -69.23 -23.99 32.62 Favored 'Trans proline' 0 C--O 1.236 0.402 0 C-N-CA 122.35 2.033 . . . . 0.0 111.84 178.68 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.4 t . . . . . 0 C--O 1.239 0.536 0 C-N-CA 125.077 1.351 . . . . 0.0 113.772 177.502 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 1.658 ' HD2' ' CD1' ' A' ' 1' ' ' PHE . 44.2 t80 . . . . . 0 CA--C 1.482 -1.666 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.504 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . -138.57 -177.49 4.88 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.408 ' HB3' ' CZ2' ' A' ' 146' ' ' TRP . 13.7 t -152.06 159.06 43.78 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.391 -0.924 . . . . 0.0 109.848 -176.156 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.447 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -147.0 155.48 42.28 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 121.29 0.567 . . . . 0.0 110.549 -176.352 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 41.2 p -92.43 174.51 7.25 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.222 178.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.99 -19.53 47.61 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.053 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -85.08 -33.81 22.36 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 114.784 -1.098 . . . . 0.0 111.856 -176.468 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 136.36 5.71 2.0 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 119.649 -1.262 . . . . 0.0 113.733 173.259 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.9 m -89.33 105.5 17.84 Favored 'General case' 0 N--CA 1.423 -1.782 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -103.47 115.71 31.05 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.026 179.635 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.504 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 55.6 mt -90.69 127.83 50.82 Favored Pre-proline 0 C--N 1.295 -1.763 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -86.01 179.62 3.64 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 122.83 2.353 . . . . 0.0 111.546 177.054 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 58.6 mt -69.42 133.79 31.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 177.071 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 127.6 9.24 4.05 Favored Glycine 0 C--N 1.306 -1.13 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.873 -179.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.22 170.19 44.57 Favored Glycine 0 N--CA 1.437 -1.267 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 -177.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.71 -173.85 35.72 Favored Glycine 0 CA--C 1.48 -2.147 0 C-N-CA 119.911 -1.138 . . . . 0.0 111.414 177.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 52.5 p -142.29 144.62 33.35 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -133.21 167.09 21.0 Favored 'General case' 0 N--CA 1.423 -1.793 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 178.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -120.05 104.69 10.34 Favored 'General case' 0 C--N 1.266 -3.025 0 CA-C-N 114.258 -1.337 . . . . 0.0 108.402 178.522 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 1.2 m -89.72 146.78 5.76 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -178.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 1.645 ' HD1' ' CD2' ' A' ' 21' ' ' TYR . 51.6 m-85 -128.17 115.72 18.82 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 120.859 0.361 . . . . 0.0 111.18 -177.56 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.46 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.6 p -123.35 129.67 74.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 CA-C-O 121.663 0.744 . . . . 0.0 111.201 -176.013 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.3 p30 -86.85 123.42 31.97 Favored 'General case' 0 C--N 1.293 -1.855 0 CA-C-N 115.007 -0.997 . . . . 0.0 108.851 177.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 19.5 mt -108.2 160.38 15.88 Favored 'General case' 0 C--N 1.275 -2.656 0 CA-C-N 114.661 -1.154 . . . . 0.0 108.162 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -59.3 118.7 32.75 Favored Pre-proline 0 C--N 1.305 -1.366 0 O-C-N 124.004 0.815 . . . . 0.0 109.869 179.228 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.489 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 56.3 Cg_endo -70.06 -5.22 15.89 Favored 'Trans proline' 0 CA--C 1.54 0.822 0 C-N-CA 122.819 2.346 . . . . 0.0 113.752 -175.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 86.2 t -128.16 111.76 25.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 179.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.464 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 10.6 t -146.49 110.58 0.87 Allowed 'Isoleucine or valine' 0 C--O 1.191 -2.014 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -178.059 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.756 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -96.53 155.73 16.64 Favored 'General case' 0 C--N 1.278 -2.51 0 C-N-CA 124.009 0.924 . . . . 0.0 111.404 -178.678 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.655 HG23 ' O ' ' A' ' 112' ' ' VAL . 89.2 t -46.41 122.88 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 123.121 0.568 . . . . 0.0 111.358 176.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.11 4.8 61.13 Favored Glycine 0 C--N 1.31 -0.911 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.498 178.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.756 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -77.35 -176.26 4.08 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 124.345 1.058 . . . . 0.0 109.648 177.673 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -132.48 92.11 3.03 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.558 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 21.9 tp -93.67 142.7 27.06 Favored 'General case' 0 C--N 1.299 -1.63 0 C-N-CA 120.04 -0.664 . . . . 0.0 109.408 178.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 52.7 t -134.97 118.47 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.967 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 -175.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.604 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 48.7 t -90.6 88.1 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.876 0 N-CA-C 105.586 -2.005 . . . . 0.0 105.586 174.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -85.4 112.41 20.83 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-O 120.973 0.416 . . . . 0.0 110.598 -177.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 83.6 mt -96.11 -3.13 45.16 Favored 'General case' 0 C--N 1.299 -1.627 0 CA-C-N 115.006 -0.997 . . . . 0.0 110.419 -177.639 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.585 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 1.9 m -73.42 1.1 10.42 Favored 'General case' 0 CA--C 1.55 0.955 0 CA-C-O 121.903 0.859 . . . . 0.0 109.47 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.3 p -130.58 6.76 4.8 Favored 'General case' 0 N--CA 1.424 -1.738 0 C-N-CA 124.286 1.034 . . . . 0.0 109.993 178.195 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.46 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 48.4 mm-40 -123.99 -19.87 5.53 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-O 121.085 0.469 . . . . 0.0 110.585 -175.179 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 36.8 mt -134.85 135.07 53.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -176.021 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.633 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 47.7 m-85 -139.11 121.58 16.15 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 120.928 0.394 . . . . 0.0 110.302 -175.475 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.4 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 71.1 m -104.54 140.05 38.54 Favored 'General case' 0 C--N 1.286 -2.175 0 CA-C-O 121.097 0.475 . . . . 0.0 110.256 -177.378 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . 0.444 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 25.2 p-80 -131.12 151.85 51.02 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 121.781 0.801 . . . . 0.0 112.589 -172.269 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.453 ' HB3' ' OD2' ' A' ' 54' ' ' ASP . 19.0 p30 -103.59 127.7 50.97 Favored 'General case' 0 N--CA 1.405 -2.692 0 CA-C-O 122.607 1.194 . . . . 0.0 110.6 174.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -94.14 -28.43 15.69 Favored 'General case' 0 C--N 1.268 -2.961 0 CA-C-N 113.429 -1.714 . . . . 0.0 108.945 -179.249 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -135.58 71.45 65.37 Favored Pre-proline 0 C--N 1.311 -1.084 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.343 178.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -69.97 3.56 2.8 Favored 'Trans proline' 0 N--CA 1.493 1.454 0 C-N-CA 123.425 2.75 . . . . 0.0 113.648 -174.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -120.12 -18.81 7.98 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 121.198 0.523 . . . . 0.0 110.093 -179.455 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.439 ' HB ' HD13 ' A' ' 52' ' ' ILE . 1.1 m -103.08 -30.06 10.97 Favored 'General case' 0 N--CA 1.422 -1.831 0 CA-C-O 122.016 0.913 . . . . 0.0 109.148 -173.335 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.578 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.6 mp -124.38 131.55 72.63 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 CA-C-N 114.811 -1.086 . . . . 0.0 108.173 -178.484 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.0 t -77.25 140.46 40.09 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 106.668 -1.605 . . . . 0.0 106.668 176.599 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.459 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 8.0 m-20 -82.75 107.45 15.39 Favored 'General case' 0 C--N 1.283 -2.322 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 -178.203 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 1.666 ' HD1' ' CD2' ' A' ' 55' ' ' TYR . 29.4 t80 -137.95 128.25 26.16 Favored 'General case' 0 C--N 1.272 -2.771 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -179.765 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.9 p -147.43 149.5 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.327 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -177.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -148.21 133.92 18.89 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 175.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.516 HD22 ' O ' ' A' ' 130' ' ' ILE . 0.7 OUTLIER -68.87 113.0 5.9 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 103.717 -2.697 . . . . 0.0 103.717 171.404 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.41 ' O ' ' HA ' ' A' ' 89' ' ' GLU . 3.4 tp-100 -57.76 -64.29 0.95 Allowed 'General case' 0 C--O 1.198 -1.628 0 C-N-CA 125.893 1.677 . . . . 0.0 109.822 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -165.08 154.15 12.52 Favored 'General case' 0 N--CA 1.424 -1.75 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 -175.725 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -120.82 164.28 14.18 Favored Glycine 0 N--CA 1.43 -1.728 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 -178.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 66.2 m -145.56 144.14 30.33 Favored 'General case' 0 C--N 1.286 -2.165 0 N-CA-C 108.455 -0.942 . . . . 0.0 108.455 178.064 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.557 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -113.15 156.83 22.52 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 1.665 ' HE1' ' CE2' ' A' ' 64' ' ' TYR . 98.5 m-85 -155.2 -179.43 8.07 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 123.849 0.86 . . . . 0.0 110.002 -176.331 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.41 -140.58 42.76 Favored Glycine 0 N--CA 1.461 0.353 0 O-C-N 123.753 0.658 . . . . 0.0 113.126 178.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.78 -10.28 86.33 Favored Glycine 0 C--O 1.209 -1.444 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.525 177.106 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.522 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 91.6 t -68.43 -38.48 79.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 C-N-CA 123.82 0.848 . . . . 0.0 111.697 -176.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.557 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.25 -18.18 32.76 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.422 -0.911 . . . . 0.0 112.198 178.388 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 16.1 t -100.55 -59.41 1.71 Allowed 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.887 -173.086 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.496 ' O ' HG23 ' A' ' 112' ' ' VAL . 37.1 m-20 -90.36 -26.51 19.89 Favored 'General case' 0 CA--C 1.493 -1.222 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.167 -172.339 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 0.551 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 90.1 m-85 -103.98 150.64 24.04 Favored 'General case' 0 N--CA 1.42 -1.951 0 C-N-CA 119.726 -0.789 . . . . 0.0 108.888 176.734 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.3 t -160.88 119.88 2.58 Favored 'General case' 0 N--CA 1.421 -1.881 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 177.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.538 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -152.68 -107.0 0.31 Allowed Glycine 0 N--CA 1.424 -2.139 0 N-CA-C 111.386 -0.685 . . . . 0.0 111.386 177.045 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -164.18 -179.5 6.19 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 124.689 1.195 . . . . 0.0 109.748 -175.253 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.452 HG11 ' CE2' ' A' ' 82' ' ' TYR . 2.8 p -132.52 146.48 32.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.175 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.663 ' HG3' ' O ' ' A' ' 80' ' ' SER . 79.7 tttt -121.49 147.69 45.44 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.026 -178.58 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 1.652 ' HE1' ' CE2' ' A' ' 77' ' ' TYR . 63.4 t80 -145.66 109.79 4.91 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -179.795 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 23.0 t 52.16 37.6 22.17 Favored 'General case' 0 CA--C 1.55 0.972 0 C-N-CA 123.629 0.772 . . . . 0.0 111.544 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.81 10.38 63.08 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 120.62 -0.8 . . . . 0.0 113.644 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.663 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 15.4 t -83.3 179.0 7.81 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 177.387 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.4 t -156.07 108.42 2.59 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 0.529 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 6.8 p90 -149.39 164.42 21.07 Favored Pre-proline 0 C--N 1.306 -1.314 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 -173.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.421 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 97.4 Cg_endo -72.29 149.21 50.77 Favored 'Trans proline' 0 C--N 1.362 1.238 0 C-N-CA 122.224 1.949 . . . . 0.0 113.669 -175.36 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 1.658 ' HD2' ' CD1' ' A' ' 84' ' ' PHE . 55.5 t80 -119.33 133.48 23.76 Favored Pre-proline 0 N--CA 1.428 -1.55 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.894 178.677 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.629 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 61.6 Cg_endo -72.18 146.8 87.13 Favored 'Cis proline' 0 N--CA 1.477 0.539 0 C-N-CA 123.016 -1.66 . . . . 0.0 111.389 -2.315 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.7 t -71.77 179.83 2.96 Favored 'General case' 0 C--O 1.246 0.881 0 C-N-CA 119.776 -0.77 . . . . 0.0 109.075 -178.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 45.2 p -131.74 -39.09 1.12 Allowed 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 114.087 1.143 . . . . 0.0 114.087 -170.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 23.0 t -102.29 -69.45 0.79 Allowed 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 -172.616 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . 0.41 ' HA ' ' O ' ' A' ' 59' ' ' GLN . 0.3 OUTLIER -178.58 -176.2 0.47 Allowed 'General case' 0 N--CA 1.437 -1.112 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 179.378 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.409 ' HB ' ' HD2' ' A' ' 91' ' ' PRO . 1.9 p -101.11 174.81 2.68 Favored Pre-proline 0 C--N 1.286 -2.158 0 C-N-CA 123.19 0.596 . . . . 0.0 111.977 178.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . 0.409 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 22.3 Cg_endo -60.06 158.53 29.51 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 122.47 2.113 . . . . 0.0 111.439 171.47 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.3 tmm_? -77.03 114.14 15.51 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-N 114.836 -1.074 . . . . 0.0 108.781 -176.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 85.1 t -124.94 129.24 73.48 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 CA-C-O 121.544 0.687 . . . . 0.0 111.843 -177.379 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 66.2 t -114.25 123.74 70.22 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.253 177.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . 1.636 ' HD2' ' CD1' ' A' ' 95' ' ' TYR . 3.7 m-85 -73.85 133.32 43.16 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 175.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.73 55.05 0.88 Allowed 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 174.874 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' SER . . . . . 0.529 ' CB ' ' HG3' ' A' ' 101' ' ' LYS . 50.6 m -135.3 175.59 9.45 Favored 'General case' 0 N--CA 1.434 -1.228 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 -177.458 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -142.93 55.58 1.39 Allowed 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 122.033 0.92 . . . . 0.0 111.536 177.226 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.1 t -171.28 176.06 4.02 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 106.715 -1.587 . . . . 0.0 106.715 179.233 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . 0.444 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 11.0 p-10 -72.02 99.33 2.25 Favored 'General case' 0 CA--C 1.501 -0.937 0 CA-C-O 122.503 1.144 . . . . 0.0 109.608 177.395 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . 0.529 ' HG3' ' CB ' ' A' ' 97' ' ' SER . 57.4 mmtt -102.37 138.61 19.74 Favored Pre-proline 0 N--CA 1.415 -2.187 0 CA-C-N 113.524 -1.671 . . . . 0.0 110.277 -176.519 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.585 ' HB3' ' O ' ' A' ' 39' ' ' SER . 53.6 Cg_exo -49.67 139.54 31.01 Favored 'Trans proline' 0 N--CA 1.448 -1.202 0 C-N-CA 124.018 3.145 . . . . 0.0 112.86 -179.511 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.7 t90 -89.59 102.83 4.98 Favored Pre-proline 0 C--N 1.296 -1.751 0 N-CA-C 104.999 -2.223 . . . . 0.0 104.999 176.461 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 74.4 Cg_endo -75.55 88.72 1.26 Allowed 'Trans proline' 0 N--CA 1.451 -1.02 0 C-N-CA 121.877 1.718 . . . . 0.0 113.116 -170.411 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 94.2 t -138.52 143.93 31.33 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.604 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -149.04 133.78 17.85 Favored 'General case' 0 C--N 1.289 -2.025 0 CA-C-O 120.81 0.338 . . . . 0.0 110.251 178.046 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.42 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 17.4 mt -101.19 102.9 13.9 Favored 'General case' 0 C--N 1.288 -2.097 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.752 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.538 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 32.3 m-85 -83.4 77.62 9.78 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 177.828 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.589 HD22 ' CD2' ' A' ' 84' ' ' PHE . 3.3 mm? -102.38 124.98 48.92 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 176.362 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -129.69 145.96 59.2 Favored Pre-proline 0 N--CA 1.406 -2.669 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 -174.709 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -62.82 124.59 14.34 Favored 'Trans proline' 0 CA--C 1.497 -1.327 0 C-N-CA 123.038 2.492 . . . . 0.0 113.341 -176.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.655 ' O ' HG23 ' A' ' 30' ' ' VAL . 15.9 m -84.56 -155.45 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.399 -3.02 0 CA-C-N 114.246 -1.343 . . . . 0.0 108.161 172.017 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.7 t -83.38 -28.97 28.56 Favored 'General case' 0 C--N 1.263 -3.19 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -170.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 25.7 t -84.13 30.02 0.54 Allowed 'General case' 0 N--CA 1.426 -1.665 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.313 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -112.81 138.79 49.12 Favored 'General case' 0 N--CA 1.424 -1.736 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.069 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -177.28 135.91 2.94 Favored Glycine 0 N--CA 1.44 -1.063 0 N-CA-C 111.607 -0.597 . . . . 0.0 111.607 179.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 63.33 -152.34 47.36 Favored Glycine 0 CA--C 1.5 -0.853 0 CA-C-O 119.387 -0.674 . . . . 0.0 112.577 -178.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 57.7 t -60.56 98.72 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.248 0.98 0 CA-C-O 122.222 1.011 . . . . 0.0 111.161 -176.513 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.06 -24.1 15.48 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-N 114.147 -1.388 . . . . 0.0 110.756 -176.503 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.478 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.4 mt -133.63 137.58 52.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 178.47 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.412 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.3 mmpt? -114.57 138.74 50.27 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-O 120.914 0.387 . . . . 0.0 110.871 177.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.31 135.15 50.02 Favored 'General case' 0 N--CA 1.442 -0.851 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 178.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 88.12 -6.63 83.27 Favored Glycine 0 C--N 1.308 -0.974 0 N-CA-C 111.628 -0.589 . . . . 0.0 111.628 -179.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 64.9 m -96.78 149.28 22.01 Favored 'General case' 0 N--CA 1.427 -1.601 0 CA-C-O 121.285 0.564 . . . . 0.0 110.089 179.471 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.406 HD21 ' CZ ' ' A' ' 149' ' ' TYR . 3.2 tm? -78.98 125.0 28.8 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-N 114.782 -1.099 . . . . 0.0 108.587 -176.844 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.494 ' HB ' HG23 ' A' ' 67' ' ' VAL . 36.4 pt -109.61 -26.3 3.26 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -177.8 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.21 167.53 23.89 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -177.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.401 HG21 HD12 ' A' ' 125' ' ' LEU . 69.3 t -142.37 116.07 4.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 178.725 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 40.4 mt -119.29 147.91 43.76 Favored 'General case' 0 C--N 1.291 -1.976 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 179.183 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.577 HG22 ' NE2' ' A' ' 143' ' ' GLN . 5.4 mp -124.75 133.4 69.52 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 C-N-CA 119.53 -0.868 . . . . 0.0 110.653 177.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.534 ' O ' HD21 ' A' ' 131' ' ' LEU . 0.0 OUTLIER -100.35 135.67 41.43 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 175.971 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . 0.457 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 8.4 tpt180 -106.81 120.48 42.12 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.547 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 6.2 tp-100 -102.08 121.84 42.96 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 177.734 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 18.8 m -140.04 137.86 34.94 Favored 'General case' 0 C--N 1.291 -1.962 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 -179.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.578 ' CB ' HG21 ' A' ' 52' ' ' ILE . 8.7 p30 -133.83 173.75 11.21 Favored 'General case' 0 N--CA 1.442 -0.838 0 C-N-CA 118.809 -1.156 . . . . 0.0 112.389 179.018 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 6.7 p30 -91.79 -15.28 28.5 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.029 -1.441 . . . . 0.0 112.289 -169.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . 1.634 ' HD2' ' CD1' ' A' ' 137' ' ' TYR . 39.5 t80 -103.74 -57.19 2.08 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.03 0.443 . . . . 0.0 111.801 -172.193 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 87.1 m-20 -100.69 167.9 10.03 Favored 'General case' 0 CA--C 1.476 -1.88 0 CA-C-O 121.612 0.72 . . . . 0.0 109.971 178.039 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 17.3 m -96.37 32.3 2.02 Favored 'General case' 0 N--CA 1.414 -2.266 0 CA-C-N 114.026 -1.443 . . . . 0.0 108.585 177.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -82.84 50.96 1.8 Allowed 'General case' 0 N--CA 1.476 0.839 0 CA-C-O 121.749 0.785 . . . . 0.0 111.249 -178.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . 0.547 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 12.2 t70 -86.34 97.62 10.52 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 114.455 -1.248 . . . . 0.0 109.041 178.282 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -134.85 155.5 50.55 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.542 -0.911 . . . . 0.0 108.542 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . 0.577 ' NE2' HG22 ' A' ' 130' ' ' ILE . 19.4 pt20 -116.27 144.39 44.29 Favored 'General case' 0 C--N 1.295 -1.778 0 C-N-CA 119.981 -0.688 . . . . 0.0 111.409 176.215 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 1.666 ' HE1' ' CE2' ' A' ' 144' ' ' PHE . 3.7 m-30 -110.72 131.53 54.97 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 -178.104 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 49.6 t -90.98 130.53 40.01 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.897 0 O-C-N 123.553 0.533 . . . . 0.0 109.784 -179.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . 0.445 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.9 m95 -117.93 95.16 4.8 Favored 'General case' 0 C--N 1.279 -2.496 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 -179.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -77.62 114.79 16.82 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 23.2 mm -89.26 122.41 40.55 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.794 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -177.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 1.587 ' HE2' ' CE1' ' A' ' 149' ' ' TYR . 89.1 m-85 -118.27 152.83 35.0 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 121.509 0.671 . . . . 0.0 110.241 178.871 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -80.6 129.39 34.49 Favored 'General case' 0 N--CA 1.41 -2.472 0 CA-C-N 114.807 -1.088 . . . . 0.0 108.33 176.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 29.3 t-20 -91.7 -10.26 40.8 Favored 'General case' 0 C--N 1.29 -2.004 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 -177.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -155.09 145.83 22.37 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 113.991 -1.459 . . . . 0.0 109.19 -176.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -80.52 147.29 30.91 Favored 'General case' 0 C--N 1.323 -0.57 0 O-C-N 124.054 0.846 . . . . 0.0 110.861 -178.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.489 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.3 t -124.21 135.16 64.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.13 -177.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.9 t -117.74 135.98 56.4 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 79.4 t -98.54 103.21 17.39 Favored Pre-proline 0 C--N 1.295 -1.803 0 C-N-CA 123.464 0.706 . . . . 0.0 109.883 178.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.42 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 44.1 Cg_endo -71.26 -21.03 27.34 Favored 'Trans proline' 0 CA--C 1.516 -0.396 0 C-N-CA 122.172 1.915 . . . . 0.0 111.633 179.178 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 2.4 t . . . . . 0 C--O 1.249 1.073 0 C-N-CA 124.79 1.236 . . . . 0.0 114.061 176.874 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 1.647 ' HD2' ' CD1' ' A' ' 1' ' ' PHE . 43.9 t80 . . . . . 0 CA--C 1.488 -1.411 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.491 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . -147.61 176.65 9.91 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 174.065 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.472 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 73.2 m -138.58 160.08 40.48 Favored 'General case' 0 C--N 1.3 -1.558 0 C-N-CA 119.624 -0.83 . . . . 0.0 111.591 -175.517 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.9 pptp? -144.43 159.53 42.58 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 122.747 0.419 . . . . 0.0 110.412 -178.123 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.545 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 81.5 p -95.51 176.57 6.12 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 121.433 0.635 . . . . 0.0 112.011 -178.518 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -76.76 -24.14 52.94 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.202 177.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.545 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 7.6 p30 -81.1 -33.54 33.24 Favored 'General case' 0 N--CA 1.448 -0.544 0 C-N-CA 119.272 -0.971 . . . . 0.0 109.549 179.247 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.82 17.86 1.15 Allowed Glycine 0 N--CA 1.439 -1.131 0 C-N-CA 119.699 -1.238 . . . . 0.0 113.404 175.852 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.9 m -88.69 99.75 12.59 Favored 'General case' 0 N--CA 1.431 -1.383 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.56 120.59 32.49 Favored 'General case' 0 C--N 1.291 -1.971 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.38 178.003 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.491 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 62.2 mt -102.25 115.69 64.16 Favored Pre-proline 0 C--N 1.288 -2.078 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 176.723 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -79.88 -179.81 5.63 Favored 'Trans proline' 0 N--CA 1.443 -1.445 0 C-N-CA 122.46 2.107 . . . . 0.0 111.189 177.044 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.9 mt -66.93 147.71 12.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.063 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.55 24.2 5.97 Favored Glycine 0 C--N 1.315 -0.615 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.517 178.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.0 173.17 49.45 Favored Glycine 0 C--N 1.316 -0.539 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 -178.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 159.03 -177.91 35.41 Favored Glycine 0 N--CA 1.431 -1.68 0 C-N-CA 120.283 -0.96 . . . . 0.0 111.497 177.053 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 25.5 p -151.54 141.46 22.02 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -178.073 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.9 160.46 38.83 Favored 'General case' 0 N--CA 1.425 -1.718 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 27.7 m-80 -112.83 109.05 18.27 Favored 'General case' 0 C--N 1.289 -2.037 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 177.344 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 43.2 t -94.09 137.18 23.52 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.245 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.483 -177.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 50.4 m-85 -122.83 115.69 22.41 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 120.919 0.39 . . . . 0.0 110.832 -177.201 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.404 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -125.65 132.9 70.32 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.244 -174.371 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -87.78 130.41 34.86 Favored 'General case' 0 C--N 1.298 -1.663 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.21 177.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -111.6 160.31 17.33 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 175.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.79 121.95 48.53 Favored Pre-proline 0 C--O 1.21 -1.016 0 O-C-N 124.235 0.959 . . . . 0.0 109.196 175.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.438 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 69.9 Cg_endo -74.76 -5.23 16.57 Favored 'Trans proline' 0 C--O 1.217 -0.542 0 C-N-CA 122.781 2.321 . . . . 0.0 113.555 -175.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.3 t -126.39 109.54 21.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 8.1 t -145.36 112.47 1.28 Allowed 'Isoleucine or valine' 0 C--O 1.186 -2.256 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 -176.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.658 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -101.09 156.14 17.59 Favored 'General case' 0 C--N 1.274 -2.68 0 C-N-CA 123.214 0.606 . . . . 0.0 111.474 179.657 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 38.0 t -45.51 120.55 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 C-N-CA 123.471 0.709 . . . . 0.0 112.019 176.621 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 99.82 0.74 56.32 Favored Glycine 0 CA--C 1.52 0.371 0 CA-C-N 115.542 -0.754 . . . . 0.0 112.825 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.658 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -73.11 -177.41 2.47 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 124.384 1.074 . . . . 0.0 110.977 177.706 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -127.38 92.9 3.6 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 107.769 -1.196 . . . . 0.0 107.769 177.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.6 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 20.2 tp -101.72 134.86 44.21 Favored 'General case' 0 C--N 1.283 -2.309 0 C-N-CA 118.725 -1.19 . . . . 0.0 109.381 176.843 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.9 p -141.96 132.38 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.386 -3.646 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.927 -178.135 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.588 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 42.2 t -92.12 89.95 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.55 0 CA-C-N 113.86 -1.518 . . . . 0.0 108.029 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -74.45 112.14 10.33 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 88.8 mt -95.68 1.03 53.31 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.026 0.441 . . . . 0.0 111.284 -179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 38.9 t -77.98 0.65 23.53 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 122.086 0.946 . . . . 0.0 109.439 -178.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.9 p -124.59 0.52 8.19 Favored 'General case' 0 C--N 1.281 -2.393 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.134 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.404 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 49.2 mm-40 -120.96 -24.56 5.57 Favored 'General case' 0 CA--C 1.504 -0.816 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.66 -172.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 18.2 mt -132.86 139.14 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 -176.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 78.3 m-85 -134.2 161.14 35.73 Favored 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 -176.648 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.636 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 81.0 m -141.94 141.79 32.97 Favored 'General case' 0 C--N 1.284 -2.244 0 C-N-CA 122.886 0.475 . . . . 0.0 109.998 -177.068 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.6 p80 -145.3 156.69 43.96 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-O 121.312 0.577 . . . . 0.0 111.052 -174.272 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.408 ' HA ' ' HA ' ' A' ' 1' ' ' PHE . 2.9 p30 -107.42 121.06 43.83 Favored 'General case' 0 C--N 1.295 -1.783 0 CA-C-O 122.479 1.133 . . . . 0.0 113.304 178.907 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 13.7 p-10 -90.97 -23.37 20.44 Favored 'General case' 0 N--CA 1.42 -1.959 0 CA-C-N 113.417 -1.72 . . . . 0.0 109.529 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 1.653 ' HE2' ' CE1' ' A' ' 48' ' ' TYR . 60.7 m-85 -138.57 64.61 37.78 Favored Pre-proline 0 N--CA 1.472 0.636 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.871 176.157 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -67.5 -17.16 48.62 Favored 'Trans proline' 0 N--CA 1.481 0.784 0 C-N-CA 122.159 1.906 . . . . 0.0 112.787 -176.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -94.44 -27.63 15.91 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.903 -175.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.451 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -97.84 -30.41 12.78 Favored 'General case' 0 N--CA 1.413 -2.278 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 -171.344 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.492 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -119.57 141.4 39.79 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 CA-C-N 114.158 -1.383 . . . . 0.0 108.963 -176.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 5.4 t -88.89 131.94 34.9 Favored 'General case' 0 C--O 1.259 1.578 0 N-CA-C 104.09 -2.559 . . . . 0.0 104.09 171.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.659 ' OD1' ' HB2' ' A' ' 1' ' ' PHE . 34.0 m-20 -93.78 107.27 19.17 Favored 'General case' 0 C--N 1.271 -2.815 0 C-N-CA 118.952 -1.099 . . . . 0.0 110.152 -169.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 28.9 t80 -127.06 143.11 51.37 Favored 'General case' 0 C--N 1.289 -2.055 0 CA-C-N 114.04 -1.437 . . . . 0.0 108.908 -175.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.448 HG21 ' HG ' ' A' ' 131' ' ' LEU . 8.1 p -150.6 145.25 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.313 0 O-C-N 123.615 0.572 . . . . 0.0 110.087 -179.76 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.6 p -147.42 131.59 17.38 Favored 'General case' 0 N--CA 1.436 -1.129 0 C-N-CA 123.075 0.55 . . . . 0.0 109.769 174.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.444 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 1.1 tm? -71.2 102.14 2.46 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 175.091 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.4 tp-100 -52.53 -50.55 62.62 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 127.12 2.168 . . . . 0.0 111.697 -176.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 3.9 ptp180 -171.17 160.17 6.21 Favored 'General case' 0 N--CA 1.425 -1.684 0 CA-C-N 114.467 -1.242 . . . . 0.0 109.289 -176.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -135.84 148.22 19.55 Favored Glycine 0 N--CA 1.41 -3.097 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 179.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 63.2 m -129.38 143.81 50.99 Favored 'General case' 0 C--N 1.279 -2.469 0 C-N-CA 123.228 0.611 . . . . 0.0 109.573 -178.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.507 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -111.29 155.62 22.75 Favored 'General case' 0 CA--C 1.502 -0.87 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.487 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 68.0 m-85 -157.45 -178.52 7.4 Favored 'General case' 0 C--O 1.238 0.494 0 C-N-CA 124.235 1.014 . . . . 0.0 108.313 -177.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 62.45 -141.71 47.25 Favored Glycine 0 N--CA 1.453 -0.191 0 O-C-N 123.333 0.396 . . . . 0.0 112.707 177.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.24 -7.84 87.18 Favored Glycine 0 C--O 1.208 -1.482 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 177.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.487 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 86.6 t -69.72 -38.64 76.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 C-N-CA 123.752 0.821 . . . . 0.0 111.339 -176.488 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.507 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -85.44 -22.8 28.14 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 119.306 -0.957 . . . . 0.0 112.063 179.441 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 9.3 t -100.63 -51.39 3.61 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.144 0.497 . . . . 0.0 112.265 -172.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.445 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 47.7 m-20 -90.8 -24.57 20.28 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -174.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 1.643 ' HD1' ' CD2' ' A' ' 71' ' ' PHE . 89.2 m-85 -111.52 156.49 21.64 Favored 'General case' 0 N--CA 1.42 -1.951 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.292 179.104 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.5 t -162.97 138.57 6.89 Favored 'General case' 0 N--CA 1.406 -2.651 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 176.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.522 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.36 -104.65 0.18 Allowed Glycine 0 N--CA 1.409 -3.146 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 175.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.2 p -165.3 -179.86 5.83 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 124.547 1.139 . . . . 0.0 110.137 -176.261 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -131.81 145.33 35.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 123.313 0.645 . . . . 0.0 109.467 178.411 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.67 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.2 tttt -122.23 149.52 43.56 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.478 -177.614 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.419 ' CG ' HG22 ' A' ' 90' ' ' THR . 60.8 t80 -150.15 113.09 4.81 Favored 'General case' 0 C--O 1.214 -0.777 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 22.7 t 56.92 30.23 17.64 Favored 'General case' 0 CA--C 1.554 1.108 0 CA-C-O 121.884 0.85 . . . . 0.0 111.286 176.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.33 13.69 59.76 Favored Glycine 0 N--CA 1.437 -1.273 0 C-N-CA 120.208 -0.996 . . . . 0.0 113.086 -177.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.67 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 21.2 t -83.95 -179.35 7.24 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 175.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 8.2 t -157.37 110.48 2.51 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 179.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 0.423 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 7.4 p90 -149.68 162.52 28.11 Favored Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -174.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.423 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 72.7 Cg_endo -68.2 149.08 75.91 Favored 'Trans proline' 0 C--N 1.36 1.174 0 C-N-CA 122.671 2.248 . . . . 0.0 113.528 -175.266 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.601 ' CD2' HD22 ' A' ' 109' ' ' LEU . 60.2 t80 -124.31 134.54 25.57 Favored Pre-proline 0 N--CA 1.442 -0.839 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.193 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.594 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 57.4 Cg_endo -70.57 145.08 80.29 Favored 'Cis proline' 0 C--O 1.239 0.568 0 C-N-CA 123.099 -1.625 . . . . 0.0 110.633 -3.255 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.7 t -73.65 -177.63 2.8 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -177.664 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 41.2 p -131.77 -35.87 1.24 Allowed 'General case' 0 N--CA 1.424 -1.772 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -172.438 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 49.5 m -110.1 -162.21 0.79 Allowed 'General case' 1 N--CA 1.317 -7.114 0 CA-C-N 113.45 -1.704 . . . . 0.0 107.663 179.265 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 27.0 tt0 -116.21 151.32 35.96 Favored 'General case' 1 C--N 1.244 -4.011 0 CA-C-N 113.443 -1.708 . . . . 0.0 109.115 -168.639 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.444 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 46.8 p -67.75 161.17 68.76 Favored Pre-proline 0 C--N 1.296 -1.748 0 C-N-CA 124.494 1.117 . . . . 0.0 113.245 -177.642 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -56.86 159.86 13.48 Favored 'Trans proline' 0 C--N 1.355 0.876 0 C-N-CA 124.068 3.179 . . . . 0.0 111.749 175.454 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.5 tmm_? -67.88 116.74 8.88 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.667 -176.024 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 72.7 t -132.05 137.18 55.31 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 C-N-CA 123.848 0.859 . . . . 0.0 108.687 -176.223 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.0 p -136.59 132.94 48.85 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.628 -175.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -82.9 101.5 11.06 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 120.937 0.398 . . . . 0.0 110.917 -178.395 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 36.7 m-80 -92.29 55.12 2.48 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-O 121.996 0.903 . . . . 0.0 108.837 176.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.3 m -145.4 128.63 16.74 Favored 'General case' 0 N--CA 1.428 -1.566 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 -178.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.5 ptm180 -104.51 63.7 0.74 Allowed 'General case' 0 C--N 1.304 -1.378 0 CA-C-O 122.643 1.211 . . . . 0.0 109.609 -179.091 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.1 t -170.41 -179.5 3.04 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 -172.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -86.25 124.81 33.04 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 6.8 mptt -127.32 143.9 48.84 Favored Pre-proline 0 C--N 1.277 -2.561 0 C-N-CA 124.463 1.105 . . . . 0.0 109.273 -179.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -68.23 147.27 72.12 Favored 'Trans proline' 0 C--O 1.244 0.787 0 C-N-CA 122.891 2.394 . . . . 0.0 112.12 178.118 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.2 t90 -85.56 107.45 12.47 Favored Pre-proline 0 C--N 1.323 -0.544 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 -177.287 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -76.73 88.2 1.4 Allowed 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 121.518 1.479 . . . . 0.0 112.905 -172.495 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 68.2 t -137.54 153.96 29.1 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.144 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 178.102 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.588 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -160.05 137.4 9.55 Favored 'General case' 0 CA--C 1.475 -1.94 0 O-C-N 123.406 0.441 . . . . 0.0 110.182 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.449 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 18.9 mt -105.79 99.85 9.43 Favored 'General case' 0 C--N 1.286 -2.171 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.388 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.522 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 42.4 m-85 -79.78 77.2 6.42 Favored 'General case' 0 C--N 1.313 -0.995 0 O-C-N 122.041 -0.412 . . . . 0.0 110.105 177.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.601 HD22 ' CD2' ' A' ' 84' ' ' PHE . 3.1 mm? -102.48 119.74 39.34 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-O 120.926 0.393 . . . . 0.0 110.219 177.653 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.54 147.39 52.74 Favored Pre-proline 0 N--CA 1.419 -1.98 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.725 -174.558 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.445 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 29.9 Cg_endo -62.24 118.55 5.44 Favored 'Trans proline' 0 C--O 1.246 0.899 0 C-N-CA 123.185 2.59 . . . . 0.0 112.835 -177.13 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . . . . . . . . . 2.8 m -68.46 -116.43 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.192 -1.923 0 CA-C-N 114.007 -1.451 . . . . 0.0 112.71 175.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 22.8 t -112.21 -39.53 4.42 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.267 -0.895 . . . . 0.0 109.541 177.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 31.5 t -84.33 29.41 0.58 Allowed 'General case' 0 C--N 1.317 -0.804 0 C-N-CA 123.536 0.734 . . . . 0.0 111.342 -175.095 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -101.93 133.18 47.13 Favored 'General case' 0 N--CA 1.422 -1.84 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.336 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.97 139.84 5.19 Favored Glycine 0 N--CA 1.434 -1.436 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.017 178.19 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 59.71 -144.37 46.19 Favored Glycine 0 CA--C 1.495 -1.214 0 CA-C-O 119.288 -0.729 . . . . 0.0 112.738 -179.083 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.3 p -59.24 96.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 122.753 1.263 . . . . 0.0 111.575 -178.31 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.44 -25.85 14.65 Favored 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 114.754 -1.112 . . . . 0.0 111.49 -177.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.418 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 61.4 mt -134.72 139.66 47.14 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.326 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 3.7 mmpt? -114.85 137.32 52.1 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-O 121.089 0.471 . . . . 0.0 111.4 179.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.06 122.52 20.21 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.379 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 93.6 3.57 64.47 Favored Glycine 0 C--N 1.309 -0.948 0 N-CA-C 111.595 -0.602 . . . . 0.0 111.595 -177.458 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 32.9 t -102.21 143.62 31.77 Favored 'General case' 0 C--O 1.253 1.246 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 178.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -72.28 124.72 25.67 Favored 'General case' 0 N--CA 1.444 -0.727 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -179.683 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.471 ' HB ' HG23 ' A' ' 67' ' ' VAL . 39.0 pt -109.93 -27.43 2.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 N-CA-C 112.423 0.527 . . . . 0.0 112.423 -178.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.68 167.62 24.79 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 -177.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 71.2 t -142.97 116.38 3.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.576 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 59.9 mt -115.95 143.01 46.02 Favored 'General case' 0 C--N 1.288 -2.08 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 179.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.31 118.44 53.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 C-N-CA 119.402 -0.919 . . . . 0.0 110.322 179.184 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.476 ' O ' ' HB2' ' A' ' 143' ' ' GLN . 0.1 OUTLIER -88.76 150.09 23.12 Favored 'General case' 0 C--N 1.268 -2.957 0 C-N-CA 124.838 1.255 . . . . 0.0 108.485 178.227 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 19.3 ttp85 -123.38 137.4 54.83 Favored 'General case' 0 N--CA 1.414 -2.269 0 O-C-N 123.255 0.347 . . . . 0.0 111.549 178.443 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.485 ' NE2' ' HD1' ' A' ' 1' ' ' PHE . 13.3 mm100 -113.01 115.44 28.38 Favored 'General case' 0 N--CA 1.431 -1.398 0 CA-C-N 115.079 -0.964 . . . . 0.0 110.622 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 4.5 m -133.33 130.86 39.43 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 176.017 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.492 ' CB ' HG21 ' A' ' 52' ' ' ILE . 6.5 p30 -132.8 159.15 40.61 Favored 'General case' 0 C--O 1.214 -0.791 0 C-N-CA 118.464 -1.294 . . . . 0.0 112.232 179.416 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -70.64 -25.7 63.13 Favored 'General case' 0 N--CA 1.487 1.409 0 CA-C-N 113.906 -1.497 . . . . 0.0 113.297 -170.662 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -89.98 -58.85 2.36 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-O 121.057 0.456 . . . . 0.0 111.097 -174.175 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . 0.452 ' HB3' ' OD2' ' A' ' 140' ' ' ASP . 19.6 m120 -70.98 -36.63 72.59 Favored 'General case' 0 CA--C 1.472 -2.034 0 CA-C-O 121.655 0.74 . . . . 0.0 111.184 -178.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 49.7 m 66.4 17.19 10.63 Favored 'General case' 0 N--CA 1.436 -1.165 0 CA-C-N 113.515 -1.675 . . . . 0.0 109.881 -176.266 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . 0.458 ' HB3' ' CE2' ' A' ' 142' ' ' PHE . 19.5 m-20 -78.62 150.16 32.76 Favored 'General case' 0 N--CA 1.419 -1.995 0 CA-C-N 113.588 -1.642 . . . . 0.0 109.206 176.7 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -135.68 105.12 6.03 Favored 'General case' 0 C--N 1.274 -2.69 0 CA-C-N 114.482 -1.236 . . . . 0.0 108.344 -178.623 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . 1.657 ' HD1' ' CD2' ' A' ' 142' ' ' PHE . 72.4 m-85 -129.51 160.66 32.51 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.793 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . 0.476 ' HB2' ' O ' ' A' ' 131' ' ' LEU . 15.7 pt20 -138.58 141.92 39.21 Favored 'General case' 0 C--N 1.287 -2.15 0 C-N-CA 119.453 -0.899 . . . . 0.0 111.003 -178.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 1.658 ' HE2' ' CE1' ' A' ' 144' ' ' PHE . 7.5 m-30 -107.2 134.21 50.64 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 -175.619 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 45.3 t -93.26 130.82 41.75 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 O-C-N 123.492 0.495 . . . . 0.0 109.886 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . 0.436 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 64.1 m95 -120.69 100.03 6.88 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 -179.688 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -81.02 113.5 19.26 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 179.194 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 23.6 mm -88.43 121.55 38.86 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -178.044 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 1.616 ' HE2' ' CE1' ' A' ' 149' ' ' TYR . 95.7 m-85 -117.46 153.69 32.69 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 123.541 0.736 . . . . 0.0 109.834 177.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.0 131.94 35.16 Favored 'General case' 0 N--CA 1.416 -2.165 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 177.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 13.8 t-20 -95.06 -5.77 43.63 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -177.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -155.96 139.97 16.36 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.199 -1.364 . . . . 0.0 109.508 -177.078 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -78.16 145.04 35.86 Favored 'General case' 0 C--N 1.308 -1.2 0 O-C-N 124.212 0.945 . . . . 0.0 109.454 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.438 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 75.5 t -120.67 141.29 41.74 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 O-C-N 122.28 -0.263 . . . . 0.0 110.82 -177.009 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.2 t -120.48 136.11 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.234 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 179.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.7 t -101.74 103.95 31.82 Favored Pre-proline 0 C--N 1.289 -2.058 0 C-N-CA 123.173 0.589 . . . . 0.0 109.716 178.292 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -71.29 -19.47 29.15 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.031 1.821 . . . . 0.0 111.3 178.139 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 5.1 t . . . . . 0 C--O 1.246 0.872 0 C-N-CA 124.956 1.302 . . . . 0.0 113.262 176.233 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 56.6 t80 . . . . . 0 CA--C 1.484 -1.568 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.491 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . -136.87 176.25 8.88 Favored 'General case' 0 C--N 1.276 -2.602 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -178.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 79.4 m -136.89 154.46 50.48 Favored 'General case' 0 C--N 1.291 -1.974 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.549 -174.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.44 162.52 35.57 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.608 -174.024 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.688 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 67.1 p -97.63 179.81 4.71 Favored 'General case' 0 C--N 1.301 -1.515 0 CA-C-O 121.192 0.52 . . . . 0.0 110.599 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -84.98 -19.75 31.59 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 114.93 -1.032 . . . . 0.0 108.73 179.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.688 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 1.5 p-10 -87.93 -17.46 31.29 Favored 'General case' 0 N--CA 1.417 -2.1 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.475 -179.532 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 119.24 11.63 7.34 Favored Glycine 0 CA--C 1.486 -1.729 0 C-N-CA 119.061 -1.543 . . . . 0.0 114.373 167.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.2 m -89.83 99.68 12.64 Favored 'General case' 0 N--CA 1.413 -2.308 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -90.66 121.65 32.75 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-N 115.071 -0.968 . . . . 0.0 108.513 177.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.491 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 66.4 mt -101.77 113.7 65.78 Favored Pre-proline 0 C--N 1.295 -1.768 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 178.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -75.54 170.6 19.92 Favored 'Trans proline' 0 C--O 1.25 1.092 0 C-N-CA 122.586 2.19 . . . . 0.0 111.527 178.828 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 63.1 mt -64.42 128.19 26.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.199 179.233 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.89 6.24 2.03 Favored Glycine 0 C--N 1.314 -0.669 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.742 -178.822 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.65 158.41 33.8 Favored Glycine 0 C--N 1.316 -0.558 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 166.04 -173.2 41.59 Favored Glycine 0 C--N 1.3 -1.434 0 C-N-CA 119.709 -1.234 . . . . 0.0 112.014 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.2 p -148.45 140.87 24.29 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -178.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -130.8 159.6 36.86 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 29.1 m-80 -108.55 109.89 21.23 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 176.414 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 38.3 t -96.15 138.9 20.33 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.689 -178.396 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -124.7 112.5 16.83 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 121.216 0.532 . . . . 0.0 111.312 -176.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.485 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.1 p -122.76 134.13 66.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.942 -175.363 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -98.07 119.69 37.15 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-O 121.47 0.652 . . . . 0.0 110.152 -178.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.401 ' CD1' ' HA ' ' A' ' 36' ' ' VAL . 2.7 mm? -97.06 161.72 13.7 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.359 -178.668 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.27 122.1 51.98 Favored Pre-proline 0 C--N 1.317 -0.817 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 173.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.457 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 63.1 Cg_endo -74.86 -2.22 12.21 Favored 'Trans proline' 0 CA--C 1.533 0.456 0 C-N-CA 122.771 2.314 . . . . 0.0 113.203 -176.357 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.425 HG11 ' HG3' ' A' ' 157' ' ' PRO . 73.5 t -127.16 115.26 40.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.479 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 3.3 t -149.84 118.99 0.98 Allowed 'Isoleucine or valine' 0 C--O 1.194 -1.833 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 -179.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.636 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -107.13 155.79 19.5 Favored 'General case' 0 C--N 1.278 -2.519 0 C-N-CA 122.787 0.435 . . . . 0.0 111.625 -179.592 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.439 HG11 ' O ' ' A' ' 112' ' ' VAL . 38.6 t -47.07 117.13 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 123.656 0.782 . . . . 0.0 111.765 177.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.79 -2.44 45.2 Favored Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 115.391 -0.822 . . . . 0.0 112.918 179.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.636 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -72.95 -176.91 2.21 Favored 'General case' 0 C--N 1.314 -0.948 0 C-N-CA 123.999 0.92 . . . . 0.0 110.58 177.419 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -134.44 98.21 4.02 Favored 'General case' 0 N--CA 1.427 -1.612 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 176.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.672 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 30.4 tp -93.69 147.01 23.42 Favored 'General case' 0 C--N 1.282 -2.354 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 93.8 t -135.28 120.94 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.507 0 CA-C-O 121.212 0.53 . . . . 0.0 109.973 -178.512 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.602 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 61.5 t -89.61 88.74 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.286 0 N-CA-C 106.349 -1.722 . . . . 0.0 106.349 174.203 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -81.67 110.12 16.72 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-O 121.202 0.525 . . . . 0.0 111.42 -177.281 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.5 mt -96.45 -3.0 44.21 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.438 -178.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.2 m -73.07 0.03 12.64 Favored 'General case' 0 CA--C 1.551 1.001 0 CA-C-O 122.151 0.977 . . . . 0.0 109.532 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.5 p -126.29 3.0 7.07 Favored 'General case' 0 C--N 1.295 -1.782 0 C-N-CA 123.712 0.805 . . . . 0.0 110.288 178.063 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.485 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 45.5 mm-40 -121.93 -23.47 5.43 Favored 'General case' 0 CA--C 1.506 -0.724 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.815 -173.458 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.8 mt -133.11 140.34 47.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.196 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -176.149 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.643 ' HE2' ' CE1' ' A' ' 43' ' ' PHE . 62.2 m-85 -137.62 153.46 49.89 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -176.507 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 66.6 m -128.64 134.94 48.68 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 123.537 0.735 . . . . 0.0 109.209 176.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 22.0 p80 -127.56 145.97 50.68 Favored 'General case' 0 C--N 1.291 -1.968 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.364 -177.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -99.85 99.41 10.2 Favored 'General case' 0 C--N 1.293 -1.877 0 C-N-CA 118.637 -1.225 . . . . 0.0 109.035 175.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -72.81 -9.79 59.07 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 125.145 1.378 . . . . 0.0 112.627 178.62 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 1.624 ' HE2' ' CE1' ' A' ' 48' ' ' TYR . 52.4 m-85 -144.63 68.1 14.54 Favored Pre-proline 0 N--CA 1.482 1.174 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 175.17 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -66.22 -5.33 12.23 Favored 'Trans proline' 0 N--CA 1.488 1.176 0 C-N-CA 123.376 2.717 . . . . 0.0 114.651 -172.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -117.99 -3.14 11.16 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-O 121.282 0.563 . . . . 0.0 109.692 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.436 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.6 OUTLIER -117.51 -30.15 5.6 Favored 'General case' 0 N--CA 1.421 -1.878 0 CA-C-O 121.608 0.718 . . . . 0.0 109.732 -175.117 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.595 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.6 mp -129.16 131.87 67.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 -177.455 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.4 t -76.94 146.37 37.6 Favored 'General case' 0 C--O 1.251 1.145 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.503 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 0.8 OUTLIER -83.34 108.45 16.54 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 -178.056 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 1.639 ' HD2' ' CD1' ' A' ' 55' ' ' TYR . 22.4 t80 -145.99 129.89 17.27 Favored 'General case' 0 C--N 1.28 -2.425 0 CA-C-O 121.224 0.535 . . . . 0.0 109.62 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 6.2 p -148.4 149.41 15.18 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.478 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 -178.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 5.3 p -150.33 136.36 18.55 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 178.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.446 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 38.0 tp -73.32 110.03 7.29 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 172.307 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -58.98 -55.64 32.5 Favored 'General case' 0 C--N 1.314 -0.969 0 C-N-CA 126.155 1.782 . . . . 0.0 110.584 179.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -165.55 160.21 17.46 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 -177.547 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -138.31 143.18 13.97 Favored Glycine 0 N--CA 1.405 -3.403 0 N-CA-C 108.89 -1.684 . . . . 0.0 108.89 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 68.4 m -129.88 148.97 51.81 Favored 'General case' 0 C--N 1.278 -2.503 0 C-N-CA 123.771 0.829 . . . . 0.0 109.513 -177.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.445 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -110.72 156.6 20.8 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 -178.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 1.652 ' HE1' ' CE2' ' A' ' 64' ' ' TYR . 91.8 m-85 -153.93 -179.59 8.0 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.459 0.704 . . . . 0.0 110.257 -177.169 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.6 -138.39 49.29 Favored Glycine 0 C--O 1.223 -0.566 0 O-C-N 123.944 0.777 . . . . 0.0 112.892 176.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.61 -3.3 89.73 Favored Glycine 0 N--CA 1.425 -2.061 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.628 177.428 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.477 HG23 ' HB ' ' A' ' 126' ' ' ILE . 79.8 t -73.99 -41.91 52.78 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 123.03 0.532 . . . . 0.0 111.464 -178.44 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.469 ' HG ' ' CA ' ' A' ' 64' ' ' TYR . 0.3 OUTLIER -80.17 -23.17 41.23 Favored 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 119.523 -0.871 . . . . 0.0 112.203 179.57 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 13.9 m -100.97 -46.67 5.02 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 115.011 1.486 . . . . 0.0 115.011 -174.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.487 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 38.6 m-80 -94.28 -19.92 20.25 Favored 'General case' 0 CA--C 1.494 -1.185 0 C-N-CA 119.87 -0.732 . . . . 0.0 109.48 -178.695 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 0.525 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 86.9 m-85 -111.76 162.62 15.05 Favored 'General case' 0 N--CA 1.423 -1.808 0 C-N-CA 120.214 -0.594 . . . . 0.0 110.143 179.024 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.2 t -169.57 130.88 1.09 Allowed 'General case' 0 N--CA 1.422 -1.865 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 176.094 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.514 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -164.18 -110.37 0.24 Allowed Glycine 0 N--CA 1.412 -2.958 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 175.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.1 p -158.27 -179.58 8.24 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 124.421 1.089 . . . . 0.0 110.353 -174.122 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -133.66 146.94 31.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 C-N-CA 122.965 0.506 . . . . 0.0 109.993 177.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.639 ' HG3' ' O ' ' A' ' 80' ' ' SER . 77.9 tttt -122.14 146.25 47.41 Favored 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 -178.783 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.472 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 56.9 t80 -145.27 106.58 4.2 Favored 'General case' 0 C--N 1.307 -1.242 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 -178.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 29.9 t 54.11 38.16 28.51 Favored 'General case' 0 CA--C 1.55 0.943 0 C-N-CA 123.435 0.694 . . . . 0.0 111.268 179.525 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.35 7.81 66.96 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 120.751 -0.738 . . . . 0.0 113.552 -179.02 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.639 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 15.2 t -79.64 174.32 11.69 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.486 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.5 p -152.06 100.33 2.62 Favored 'General case' 0 C--N 1.287 -2.146 0 CA-C-O 121.125 0.488 . . . . 0.0 109.747 -178.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 0.472 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 3.1 p90 -144.57 161.3 44.49 Favored Pre-proline 0 C--N 1.307 -1.243 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -173.64 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 59.9 Cg_endo -69.93 153.82 67.74 Favored 'Trans proline' 0 C--N 1.356 0.935 0 C-N-CA 123.018 2.479 . . . . 0.0 113.129 -174.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 1.665 ' HD2' ' CD1' ' A' ' 84' ' ' PHE . 56.3 t80 -129.53 128.96 23.15 Favored Pre-proline 0 C--N 1.316 -0.87 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.754 179.066 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.47 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 74.0 Cg_endo -69.16 148.65 85.78 Favored 'Cis proline' 0 CA--C 1.547 1.148 0 C-N-CA 122.789 -1.754 . . . . 0.0 110.374 -0.786 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.403 ' HA ' ' O ' ' A' ' 83' ' ' PRO . 7.6 t -62.81 -178.59 0.21 Allowed 'General case' 0 CA--C 1.555 1.169 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.733 -173.167 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 16.6 p -130.52 -17.09 3.34 Favored 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 115.845 -0.616 . . . . 0.0 112.489 -173.026 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 27.2 t -133.21 -80.04 0.48 Allowed 'General case' 0 N--CA 1.426 -1.664 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.389 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 179.85 -170.44 0.14 Allowed 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 -178.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.446 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 15.8 p -101.32 162.13 21.48 Favored Pre-proline 0 C--N 1.293 -1.872 0 N-CA-C 113.172 0.805 . . . . 0.0 113.172 178.376 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -63.13 163.68 22.1 Favored 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 123.309 2.673 . . . . 0.0 111.542 173.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.413 ' C ' ' HD2' ' A' ' 92' ' ' ARG . 3.8 tmm_? -72.81 123.48 23.45 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.901 -178.23 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 98.5 t -130.54 123.0 54.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.498 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 74.2 t -107.49 130.89 58.99 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 177.179 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . 1.654 ' HD1' ' CD2' ' A' ' 95' ' ' TYR . 1.8 m-85 -91.77 167.83 11.89 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 106.058 -1.831 . . . . 0.0 106.058 172.589 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -132.74 54.37 1.95 Allowed 'General case' 0 C--N 1.258 -3.377 0 N-CA-C 104.845 -2.28 . . . . 0.0 104.845 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' SER . . . . . 0.417 ' HB3' ' HG3' ' A' ' 101' ' ' LYS . 66.2 p -113.09 161.35 17.2 Favored 'General case' 0 N--CA 1.414 -2.226 0 N-CA-C 114.44 1.274 . . . . 0.0 114.44 -167.366 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 35.1 ptt180 -144.74 30.18 1.21 Allowed 'General case' 0 C--N 1.3 -1.56 0 CA-C-N 114.375 -1.284 . . . . 0.0 108.177 171.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.9 t -159.26 177.08 11.41 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-N 113.826 -1.533 . . . . 0.0 107.087 -179.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -71.26 111.48 6.64 Favored 'General case' 0 CA--C 1.5 -0.959 0 O-C-N 123.533 0.52 . . . . 0.0 109.632 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . 0.493 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 7.4 mmpt? -111.37 143.57 28.74 Favored Pre-proline 0 C--N 1.288 -2.092 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 174.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.471 ' O ' ' HD3' ' A' ' 104' ' ' PRO . 33.7 Cg_endo -67.12 144.29 68.66 Favored 'Trans proline' 0 N--CA 1.446 -1.317 0 C-N-CA 122.608 2.206 . . . . 0.0 111.95 -177.09 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 14.1 t90 -89.46 101.14 2.83 Favored Pre-proline 0 C--N 1.307 -1.248 0 N-CA-C 105.657 -1.979 . . . . 0.0 105.657 179.258 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.471 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 73.2 Cg_endo -75.17 88.65 1.24 Allowed 'Trans proline' 0 N--CA 1.452 -0.926 0 C-N-CA 122.016 1.811 . . . . 0.0 112.841 -171.024 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 93.2 t -136.91 142.94 36.36 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.465 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.015 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.602 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.99 134.19 18.29 Favored 'General case' 0 N--CA 1.412 -2.346 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.335 178.758 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.416 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 19.0 mt -98.95 102.32 14.01 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.013 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.514 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 13.1 m-85 -79.01 65.41 4.18 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 122.955 0.502 . . . . 0.0 111.517 178.297 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.672 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.9 mm? -92.14 135.3 34.1 Favored 'General case' 0 C--O 1.205 -1.24 0 O-C-N 121.958 -0.464 . . . . 0.0 110.162 177.142 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.02 145.24 51.67 Favored Pre-proline 0 N--CA 1.418 -2.065 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.468 -176.836 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.487 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 24.3 Cg_endo -60.21 120.81 8.8 Favored 'Trans proline' 0 C--O 1.243 0.775 0 C-N-CA 123.402 2.735 . . . . 0.0 111.972 -177.292 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.439 ' O ' HG11 ' A' ' 30' ' ' VAL . 2.6 m -69.53 -115.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.189 -2.085 0 CA-C-N 114.436 -1.256 . . . . 0.0 112.668 177.193 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.3 m -110.92 -46.29 3.36 Favored 'General case' 0 C--N 1.29 -1.996 0 O-C-N 121.471 -0.768 . . . . 0.0 110.144 178.315 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 13.3 t -86.1 31.18 0.64 Allowed 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.898 -173.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -95.18 131.69 40.95 Favored 'General case' 0 N--CA 1.423 -1.803 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.421 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -168.66 139.82 5.85 Favored Glycine 0 N--CA 1.432 -1.579 0 C-N-CA 120.331 -0.938 . . . . 0.0 111.808 179.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 57.49 -144.48 40.38 Favored Glycine 0 CA--C 1.488 -1.607 0 C-N-CA 123.914 0.769 . . . . 0.0 113.072 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -58.67 94.48 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 122.821 1.296 . . . . 0.0 111.995 -177.559 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.16 -22.53 16.14 Favored 'General case' 0 C--N 1.297 -1.691 0 CA-C-N 114.774 -1.103 . . . . 0.0 111.398 -176.507 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.425 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 59.0 mt -136.48 137.74 47.49 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 107.853 -1.165 . . . . 0.0 107.853 177.389 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.428 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.6 mmpt? -112.0 139.59 47.38 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-O 120.831 0.348 . . . . 0.0 111.793 179.201 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.21 120.52 16.02 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 178.429 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.57 -5.54 64.7 Favored Glycine 0 C--N 1.309 -0.923 0 N-CA-C 111.733 -0.547 . . . . 0.0 111.733 -176.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 34.1 t -90.23 142.91 27.26 Favored 'General case' 0 C--O 1.252 1.194 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 30.1 tp -71.86 133.41 45.44 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 177.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.477 ' HB ' HG23 ' A' ' 67' ' ' VAL . 40.6 pt -118.8 -24.71 3.08 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.039 0 C-N-CA 120.347 -0.541 . . . . 0.0 112.28 -178.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . 0.425 ' HB1' ' HB ' ' A' ' 148' ' ' ILE . . . -163.97 164.38 23.2 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 120.966 -0.293 . . . . 0.0 110.449 -178.018 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 55.4 t -140.17 114.29 6.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 178.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 56.9 mt -118.26 147.08 43.79 Favored 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.431 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.8 mp -129.23 126.36 63.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 C-N-CA 120.16 -0.616 . . . . 0.0 110.065 178.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.489 ' C ' HD13 ' A' ' 131' ' ' LEU . 1.4 pp -92.26 150.56 20.8 Favored 'General case' 0 CA--C 1.476 -1.897 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 173.332 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 56.4 ttp180 -115.11 116.69 28.81 Favored 'General case' 0 C--N 1.25 -3.727 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 176.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.415 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 0.0 OUTLIER -100.51 120.25 39.73 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 -175.1 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 5.4 m -133.58 144.26 49.19 Favored 'General case' 0 C--N 1.287 -2.125 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.595 ' CB ' HG21 ' A' ' 52' ' ' ILE . 8.0 p30 -132.83 165.59 24.24 Favored 'General case' 0 N--CA 1.436 -1.137 0 C-N-CA 118.227 -1.389 . . . . 0.0 111.877 174.437 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 3.5 p30 -86.12 -16.16 38.86 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 113.81 -1.541 . . . . 0.0 112.147 -170.571 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 37.2 t80 -98.51 -61.41 1.38 Allowed 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.336 0.589 . . . . 0.0 111.195 -173.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -89.62 163.55 15.11 Favored 'General case' 0 C--N 1.284 -2.239 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.807 178.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 22.8 t -88.25 40.78 0.97 Allowed 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -88.59 111.16 21.56 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 108.266 -1.012 . . . . 0.0 108.266 178.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . 0.415 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 25.9 t70 -145.15 79.52 1.59 Allowed 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 107.442 -1.318 . . . . 0.0 107.442 179.219 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . 1.626 ' HE2' ' CE1' ' A' ' 142' ' ' PHE . 82.2 m-85 -121.83 167.93 12.43 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 114.734 -1.121 . . . . 0.0 108.032 -175.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -131.39 145.4 51.8 Favored 'General case' 0 N--CA 1.415 -2.193 0 C-N-CA 118.549 -1.26 . . . . 0.0 111.798 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 1.657 ' HD1' ' CD2' ' A' ' 144' ' ' PHE . 8.6 m-30 -113.77 126.75 55.56 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 108.266 -1.012 . . . . 0.0 108.266 -175.374 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 48.4 t -89.72 133.59 31.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 123.544 0.528 . . . . 0.0 110.304 -179.379 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 58.0 m95 -120.04 100.46 7.22 Favored 'General case' 0 C--N 1.285 -2.236 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 -179.678 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -82.77 111.83 19.05 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 106.608 -1.627 . . . . 0.0 106.608 178.112 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . 0.425 ' HB ' ' HB1' ' A' ' 127' ' ' ALA . 22.6 mm -86.72 121.57 37.81 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 -176.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 1.657 ' HE2' ' CE1' ' A' ' 149' ' ' TYR . 98.7 m-85 -118.26 154.66 31.9 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 177.631 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . 0.416 ' HB1' ' O ' ' A' ' 121' ' ' LYS . . . -80.96 128.0 33.2 Favored 'General case' 0 N--CA 1.406 -2.661 0 CA-C-N 115.243 -0.889 . . . . 0.0 108.699 176.167 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 37.0 t-20 -88.87 -8.9 53.43 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 106.719 -1.585 . . . . 0.0 106.719 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -156.0 139.75 16.13 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 113.679 -1.6 . . . . 0.0 109.605 -176.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -77.86 147.95 34.89 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 124.538 1.135 . . . . 0.0 110.067 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.457 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 73.7 t -123.58 138.1 54.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.913 -176.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.7 t -118.65 136.14 56.8 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.576 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.479 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 76.3 t -100.0 104.4 28.64 Favored Pre-proline 0 C--N 1.285 -2.224 0 C-N-CA 123.202 0.601 . . . . 0.0 109.416 178.26 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.425 ' HG3' HG11 ' A' ' 27' ' ' VAL . 33.7 Cg_endo -69.78 -25.12 28.84 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.121 1.881 . . . . 0.0 111.02 176.905 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.274 6.0 t . . . . . 0 C--O 1.247 0.928 0 O-C-N 124.638 1.211 . . . . 0.0 113.204 176.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.535 ' CZ ' ' HB3' ' A' ' 44' ' ' CYS . 61.8 t80 . . . . . 0 CA--C 1.487 -1.466 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.432 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . -149.49 169.41 20.97 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 -179.411 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 65.1 m -130.73 158.3 40.49 Favored 'General case' 0 C--N 1.287 -2.112 0 C-N-CA 120.013 -0.675 . . . . 0.0 111.272 -172.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.415 ' HD2' ' O ' ' A' ' 5' ' ' THR . 0.0 OUTLIER -145.91 164.41 32.07 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.608 -175.002 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.561 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 68.1 p -99.91 -179.52 4.19 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-O 121.449 0.642 . . . . 0.0 111.787 -178.407 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.88 -20.44 38.83 Favored 'General case' 0 C--N 1.296 -1.72 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.108 177.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.561 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 0.8 OUTLIER -88.45 -25.83 22.43 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.094 -0.957 . . . . 0.0 112.186 -179.758 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 128.35 8.47 4.02 Favored Glycine 0 CA--C 1.496 -1.107 0 C-N-CA 119.354 -1.403 . . . . 0.0 114.241 170.232 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 m -83.49 98.86 9.76 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 -179.174 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.05 109.1 21.19 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.888 179.372 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.432 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 64.8 mt -86.17 120.24 72.24 Favored Pre-proline 0 C--N 1.305 -1.359 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 -177.673 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -79.06 168.39 20.64 Favored 'Trans proline' 0 C--O 1.252 1.204 0 C-N-CA 122.65 2.233 . . . . 0.0 110.742 178.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.3 mt -71.14 128.09 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.3 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 178.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 139.37 -8.68 3.19 Favored Glycine 0 C--N 1.296 -1.681 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -176.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.58 148.36 22.13 Favored Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.351 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.98 -174.05 46.15 Favored Glycine 0 N--CA 1.435 -1.37 0 C-N-CA 120.493 -0.861 . . . . 0.0 111.156 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 28.8 p -143.02 151.02 40.37 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.2 162.33 33.26 Favored 'General case' 0 N--CA 1.415 -2.223 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 -179.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -107.72 117.01 32.99 Favored 'General case' 0 C--N 1.278 -2.52 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 176.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.406 HG23 HG21 ' A' ' 5' ' ' THR . 40.7 t -105.43 132.04 53.31 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.778 0 CA-C-N 115.484 -0.78 . . . . 0.0 109.138 178.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.4 m-85 -118.52 123.04 44.13 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 -179.002 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.428 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.4 p -131.28 134.55 60.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.005 -176.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 5.6 p30 -98.03 119.17 36.18 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 121.737 0.78 . . . . 0.0 110.585 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -99.45 160.78 14.03 Favored 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 114.59 -1.187 . . . . 0.0 109.13 -177.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.03 121.51 46.68 Favored Pre-proline 0 C--O 1.212 -0.884 0 O-C-N 124.478 1.111 . . . . 0.0 109.076 176.108 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 73.4 Cg_endo -74.31 -2.62 12.61 Favored 'Trans proline' 0 C--O 1.22 -0.42 0 C-N-CA 122.811 2.341 . . . . 0.0 113.277 -175.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.41 HG11 ' HG3' ' A' ' 157' ' ' PRO . 86.0 t -126.54 109.74 21.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.48 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 4.2 t -145.05 110.82 1.15 Allowed 'Isoleucine or valine' 0 C--O 1.188 -2.167 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -177.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.646 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -98.32 153.12 18.76 Favored 'General case' 0 C--N 1.272 -2.789 0 C-N-CA 123.305 0.642 . . . . 0.0 111.766 -178.346 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.48 HG23 ' O ' ' A' ' 112' ' ' VAL . 40.5 t -46.8 115.74 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 123.318 0.647 . . . . 0.0 111.524 175.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 109.01 -8.13 33.37 Favored Glycine 0 C--N 1.322 -0.227 0 CA-C-N 115.445 -0.798 . . . . 0.0 112.558 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.646 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.3 OUTLIER -65.98 -177.38 0.48 Allowed 'General case' 0 C--N 1.317 -0.831 0 C-N-CA 124.468 1.107 . . . . 0.0 112.069 177.725 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -137.43 95.34 3.06 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 177.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.595 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 25.3 tp -93.5 146.29 23.89 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -177.466 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.2 t -132.9 120.01 39.46 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.75 0 CA-C-O 120.978 0.418 . . . . 0.0 110.184 -176.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.616 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 55.0 t -92.84 88.63 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.338 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 172.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -82.26 106.77 14.42 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.25 0.548 . . . . 0.0 110.63 -176.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 89.6 mt -90.27 -0.76 57.78 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.986 -177.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.7 t -78.18 0.88 23.25 Favored 'General case' 0 C--N 1.309 -1.184 0 CA-C-O 122.271 1.034 . . . . 0.0 109.134 -179.227 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.6 p -125.3 5.57 7.74 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.848 175.539 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.428 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 51.4 mm-40 -122.61 -26.59 4.51 Favored 'General case' 0 CA--C 1.501 -0.934 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.586 -173.812 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 18.3 mt -132.57 139.64 49.4 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 -175.27 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 70.2 m-85 -138.28 144.71 40.61 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -175.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.535 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 72.7 m -121.32 135.11 55.14 Favored 'General case' 0 C--N 1.284 -2.275 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 177.698 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 22.8 p-80 -134.13 163.08 30.39 Favored 'General case' 0 C--N 1.309 -1.195 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -175.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.521 ' HA ' ' HA ' ' A' ' 1' ' ' PHE . 16.1 t-20 -113.25 111.46 22.08 Favored 'General case' 0 N--CA 1.423 -1.786 0 C-N-CA 118.574 -1.25 . . . . 0.0 111.047 179.187 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 17.4 p-10 -85.74 -4.7 59.23 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 124.573 1.149 . . . . 0.0 111.224 179.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 85.4 m-85 -143.97 65.46 13.9 Favored Pre-proline 0 N--CA 1.477 0.877 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 174.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -72.32 3.98 3.71 Favored 'Trans proline' 0 N--CA 1.481 0.74 0 C-N-CA 123.498 2.799 . . . . 0.0 115.295 -169.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -114.33 -28.51 7.22 Favored 'General case' 0 C--N 1.285 -2.227 0 CA-C-O 121.735 0.779 . . . . 0.0 110.495 -178.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.454 ' HB ' HD11 ' A' ' 52' ' ' ILE . 0.0 OUTLIER -101.74 -30.07 11.53 Favored 'General case' 0 C--N 1.28 -2.455 0 CA-C-N 115.046 -0.979 . . . . 0.0 111.126 -174.063 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.454 HD11 ' HB ' ' A' ' 51' ' ' THR . 3.4 mp -121.0 132.37 70.65 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.661 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -176.748 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 15.1 t -79.46 145.96 33.0 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 177.768 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.415 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 1.2 m-20 -79.5 109.57 14.0 Favored 'General case' 0 C--N 1.282 -2.368 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 -179.496 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 1.626 ' HD1' ' CD2' ' A' ' 55' ' ' TYR . 0.6 OUTLIER -150.42 138.34 20.06 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 -170.705 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.9 p -151.31 153.45 9.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -178.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.11 128.83 12.39 Favored 'General case' 0 C--O 1.208 -1.109 0 CA-C-O 119.381 -0.343 . . . . 0.0 110.125 175.75 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.503 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 49.5 tp -75.24 109.2 8.54 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.828 0.823 . . . . 0.0 109.277 174.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 7.0 tp60 -55.47 -54.16 47.34 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 126.479 1.912 . . . . 0.0 111.461 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 8.4 ptp180 -169.88 159.6 7.97 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 -176.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -136.47 144.29 15.94 Favored Glycine 0 N--CA 1.406 -3.324 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 179.407 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 73.6 m -132.88 150.58 52.15 Favored 'General case' 0 C--N 1.281 -2.406 0 C-N-CA 123.459 0.704 . . . . 0.0 109.831 -177.53 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.479 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -113.51 158.51 20.64 Favored 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 179.516 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.519 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . 98.8 m-85 -155.2 -179.74 8.37 Favored 'General case' 0 C--N 1.342 0.276 0 C-N-CA 124.436 1.094 . . . . 0.0 109.678 -177.842 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.56 -142.22 45.64 Favored Glycine 0 C--O 1.238 0.383 0 O-C-N 123.794 0.684 . . . . 0.0 112.839 176.429 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' A' ' 119' ' ' ALA . . . -77.71 -7.81 87.26 Favored Glycine 0 N--CA 1.435 -1.387 0 C-N-CA 120.77 -0.729 . . . . 0.0 111.482 177.638 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.517 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 99.3 t -71.0 -42.14 76.94 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.368 0 C-N-CA 123.279 0.632 . . . . 0.0 111.428 -179.207 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.519 ' HG ' ' CA ' ' A' ' 64' ' ' TYR . 0.2 OUTLIER -85.41 -14.82 45.08 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 118.554 -1.258 . . . . 0.0 112.405 178.851 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 8.8 t -100.33 -48.89 4.43 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 120.324 -0.55 . . . . 0.0 111.651 -175.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.431 ' O ' HG23 ' A' ' 112' ' ' VAL . 35.1 m-80 -95.67 -22.24 17.69 Favored 'General case' 0 CA--C 1.497 -1.087 0 C-N-CA 120.472 -0.491 . . . . 0.0 110.187 -176.39 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 0.464 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 95.8 m-85 -109.43 154.02 23.19 Favored 'General case' 0 N--CA 1.423 -1.778 0 C-N-CA 120.061 -0.656 . . . . 0.0 110.78 -179.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.9 t -165.0 121.1 1.42 Allowed 'General case' 0 N--CA 1.416 -2.126 0 N-CA-C 106.822 -1.548 . . . . 0.0 106.822 174.117 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.429 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -152.83 -113.29 0.53 Allowed Glycine 0 N--CA 1.408 -3.232 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 177.673 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.42 HG23 ' HA ' ' A' ' 83' ' ' PRO . 1.0 OUTLIER -152.75 179.3 8.75 Favored 'General case' 0 C--N 1.287 -2.128 0 C-N-CA 123.101 0.56 . . . . 0.0 110.557 -174.718 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.6 p -136.69 145.43 30.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 C-N-CA 123.004 0.522 . . . . 0.0 109.653 178.563 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.617 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.3 tttt -124.54 144.24 50.24 Favored 'General case' 0 N--CA 1.417 -2.094 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 1.653 ' HE2' ' CE1' ' A' ' 77' ' ' TYR . 62.7 t80 -145.56 115.15 7.23 Favored 'General case' 0 C--N 1.289 -2.047 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 -178.607 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 15.1 m 52.76 40.58 30.75 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 114.187 1.18 . . . . 0.0 114.187 175.55 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 80.76 10.48 85.09 Favored Glycine 0 N--CA 1.442 -0.96 0 C-N-CA 119.986 -1.102 . . . . 0.0 112.606 179.439 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.617 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 8.9 t -85.41 -179.7 6.99 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 177.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 31.5 t -157.03 112.22 2.82 Favored 'General case' 0 C--N 1.287 -2.122 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -178.47 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 0.452 ' HH ' HD21 ' A' ' 58' ' ' LEU . 4.9 p90 -155.27 161.51 29.3 Favored Pre-proline 0 CA--C 1.556 1.182 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -175.463 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.42 ' HA ' HG23 ' A' ' 74' ' ' THR . 56.5 Cg_endo -69.86 153.19 68.76 Favored 'Trans proline' 0 C--N 1.36 1.173 0 C-N-CA 122.979 2.453 . . . . 0.0 112.931 -177.643 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 1.669 ' HD2' ' CD1' ' A' ' 84' ' ' PHE . 63.2 t80 -124.57 130.55 24.25 Favored Pre-proline 0 N--CA 1.442 -0.862 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.469 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.517 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 72.2 Cg_endo -69.92 151.62 92.01 Favored 'Cis proline' 0 CA--C 1.542 0.897 0 C-N-CA 122.999 -1.667 . . . . 0.0 110.124 -1.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' THR . . . . . 0.401 ' HA ' ' O ' ' A' ' 83' ' ' PRO . 8.9 t -58.36 -178.0 0.04 OUTLIER 'General case' 0 CA--C 1.552 1.02 0 CA-C-O 122.088 0.947 . . . . 0.0 112.9 -173.711 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 10.1 p -119.43 -20.8 7.69 Favored 'General case' 0 N--CA 1.423 -1.812 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.778 -175.048 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 23.1 t -141.95 -82.47 0.2 Allowed 'General case' 0 N--CA 1.432 -1.336 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.964 -177.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -170.89 -172.87 1.22 Allowed 'General case' 0 C--O 1.241 0.631 0 N-CA-C 104.536 -2.394 . . . . 0.0 104.536 -177.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.503 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 42.0 p -100.9 158.18 32.29 Favored Pre-proline 0 C--N 1.293 -1.86 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.375 176.39 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -59.26 161.2 17.17 Favored 'Trans proline' 0 C--O 1.243 0.771 0 C-N-CA 123.16 2.573 . . . . 0.0 110.769 173.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.2 tmm_? -69.25 120.64 15.4 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.445 -178.438 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 72.4 t -128.09 124.68 63.05 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-O 121.633 0.73 . . . . 0.0 111.05 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 70.5 t -112.64 126.16 70.0 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.893 0 CA-C-N 115.095 -0.957 . . . . 0.0 108.853 176.639 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . 1.63 ' HD1' ' CD2' ' A' ' 95' ' ' TYR . 3.2 m-85 -72.43 110.63 6.97 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 175.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -81.79 61.76 5.29 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.328 -0.989 . . . . 0.0 108.328 176.624 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.7 m -142.35 -168.52 2.75 Favored 'General case' 0 N--CA 1.419 -1.982 0 C-N-CA 125.34 1.456 . . . . 0.0 107.685 -177.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 34.0 ptt180 -163.23 34.76 0.09 Allowed 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 106.465 -1.68 . . . . 0.0 106.465 176.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.4 t -160.45 175.9 12.25 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 114.755 -1.112 . . . . 0.0 109.036 -168.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -70.7 114.01 8.35 Favored 'General case' 0 C--O 1.239 0.513 0 CA-C-O 122.021 0.915 . . . . 0.0 111.746 -176.297 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.6 mptm? -127.48 143.52 47.64 Favored Pre-proline 0 C--N 1.292 -1.907 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.382 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -63.29 147.22 93.92 Favored 'Trans proline' 0 C--O 1.247 0.961 0 C-N-CA 122.693 2.262 . . . . 0.0 111.78 177.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . 0.509 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 9.6 t90 -86.46 111.85 42.21 Favored Pre-proline 0 C--N 1.304 -1.378 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 -178.091 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_endo -82.04 87.12 1.45 Allowed 'Trans proline' 0 N--CA 1.439 -1.698 0 C-N-CA 121.031 1.154 . . . . 0.0 112.122 -172.245 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 80.2 t -137.56 146.33 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.668 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 176.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.616 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -153.66 132.28 12.21 Favored 'General case' 0 C--N 1.287 -2.143 0 O-C-N 123.41 0.444 . . . . 0.0 110.428 178.049 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 16.9 mt -97.01 101.02 12.52 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 178.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 1.623 ' HD1' ' CD2' ' A' ' 108' ' ' TYR . 53.7 m-85 -79.33 73.04 5.96 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 120.884 0.373 . . . . 0.0 110.673 177.421 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.595 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.7 mm? -87.08 150.62 23.88 Favored 'General case' 0 C--O 1.192 -1.966 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.474 176.575 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.57 139.57 13.15 Favored Pre-proline 0 C--N 1.278 -2.501 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.611 -179.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.42 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 18.0 Cg_endo -60.16 121.55 9.97 Favored 'Trans proline' 0 C--O 1.247 0.969 0 C-N-CA 123.189 2.593 . . . . 0.0 111.87 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.48 ' O ' HG23 ' A' ' 30' ' ' VAL . 3.5 m -70.3 -123.08 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.182 -2.478 0 CA-C-N 114.77 -1.105 . . . . 0.0 111.478 175.655 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 30.9 m -111.95 -19.39 12.38 Favored 'General case' 0 C--N 1.282 -2.331 0 CA-C-O 122.548 1.166 . . . . 0.0 108.877 177.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 1.2 m -85.37 6.79 24.99 Favored 'General case' 0 N--CA 1.405 -2.696 0 CA-C-N 113.595 -1.639 . . . . 0.0 112.568 -173.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -97.6 138.18 35.4 Favored 'General case' 0 C--N 1.266 -3.051 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.192 -172.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -177.26 124.16 0.93 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.173 -1.013 . . . . 0.0 112.671 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.11 -147.72 50.34 Favored Glycine 0 CA--C 1.488 -1.645 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 -175.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 93.9 t -53.1 111.33 0.26 Allowed 'Isoleucine or valine' 0 C--O 1.248 0.997 0 CA-C-O 121.709 0.766 . . . . 0.0 110.741 -178.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . 0.457 ' O ' ' HA3' ' A' ' 66' ' ' GLY . . . -113.51 -22.66 10.21 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-N 114.212 -1.358 . . . . 0.0 111.619 -179.459 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.434 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.7 mt -135.01 137.72 50.13 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 178.374 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.481 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 5.3 mmpt? -112.49 141.48 46.18 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 121.144 0.497 . . . . 0.0 111.602 177.811 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -72.03 134.8 46.08 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.87 179.248 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 85.18 -1.23 88.78 Favored Glycine 0 C--N 1.312 -0.79 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.005 -179.338 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 59.8 m -96.5 148.73 22.52 Favored 'General case' 0 N--CA 1.421 -1.906 0 CA-C-O 120.94 0.4 . . . . 0.0 110.066 179.157 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.406 HD12 HG21 ' A' ' 128' ' ' VAL . 3.1 tm? -77.83 122.59 25.64 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -179.226 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.486 ' HB ' HG23 ' A' ' 67' ' ' VAL . 30.8 pt -109.42 -27.19 2.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 N-CA-C 112.853 0.686 . . . . 0.0 112.853 -177.379 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.49 166.68 26.79 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 -178.01 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.406 HG21 HD12 ' A' ' 125' ' ' LEU . 74.6 t -142.5 112.78 2.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 179.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 58.3 mt -115.87 146.77 41.73 Favored 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 178.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.482 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.7 mp -128.61 125.22 63.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 C-N-CA 120.028 -0.669 . . . . 0.0 109.227 178.541 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.435 ' C ' HD13 ' A' ' 131' ' ' LEU . 1.3 pp -91.0 148.96 22.04 Favored 'General case' 0 CA--C 1.478 -1.821 0 N-CA-C 106.004 -1.85 . . . . 0.0 106.004 174.453 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 32.1 ttt180 -118.78 123.91 45.95 Favored 'General case' 0 C--N 1.253 -3.592 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 176.189 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.471 ' HB2' ' O ' ' A' ' 142' ' ' PHE . 13.3 mm-40 -79.91 143.35 34.33 Favored 'General case' 0 N--CA 1.411 -2.376 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.525 179.463 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.512 ' HA ' ' OD1' ' A' ' 141' ' ' ASP . 17.7 m -154.33 127.36 8.3 Favored 'General case' 0 C--N 1.269 -2.929 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 170.282 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.431 HD22 ' HB2' ' A' ' 138' ' ' ASN . 15.7 p30 -128.53 -168.71 1.95 Allowed 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.715 -0.794 . . . . 0.0 111.075 -178.713 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 6.5 p30 -110.39 3.28 19.6 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 120.907 0.384 . . . . 0.0 111.196 -174.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . 1.659 ' HD2' ' CD1' ' A' ' 137' ' ' TYR . 92.7 t80 -122.16 -68.13 0.91 Allowed 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.83 -170.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . 0.431 ' HB2' HD22 ' A' ' 135' ' ' ASN . 19.7 m120 -76.8 166.43 23.36 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.861 177.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 19.8 t -113.17 26.5 10.41 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 105.994 -1.854 . . . . 0.0 105.994 172.087 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -94.85 45.51 1.11 Allowed 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 113.372 -1.74 . . . . 0.0 108.167 -178.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . 0.512 ' OD1' ' HA ' ' A' ' 134' ' ' THR . 9.4 m-20 -81.68 74.34 8.67 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 114.783 -1.098 . . . . 0.0 109.062 -177.153 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . 1.641 ' HD1' ' CD2' ' A' ' 142' ' ' PHE . 95.8 m-85 -91.27 178.09 6.07 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.23 -179.5 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 11.9 pt20 -126.79 144.62 50.9 Favored 'General case' 0 C--N 1.296 -1.757 0 C-N-CA 119.72 -0.792 . . . . 0.0 110.193 -179.046 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 11.0 m-30 -113.74 128.93 56.61 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 -175.278 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 47.4 t -90.96 134.06 30.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 123.478 0.486 . . . . 0.0 110.35 -177.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 59.9 m95 -120.69 98.6 6.1 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 -179.477 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 45.1 m-80 -81.21 110.85 17.08 Favored 'General case' 0 C--N 1.288 -2.086 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 23.3 mm -85.68 122.4 38.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 -177.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 1.651 ' HD2' ' CD1' ' A' ' 149' ' ' TYR . 98.0 m-85 -118.0 150.98 38.37 Favored 'General case' 0 C--N 1.295 -1.77 0 C-N-CA 123.552 0.741 . . . . 0.0 109.012 178.375 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.08 130.36 35.06 Favored 'General case' 0 N--CA 1.413 -2.317 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 176.522 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 29.8 t-20 -89.55 -15.7 32.31 Favored 'General case' 0 C--N 1.288 -2.1 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 -177.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -149.3 141.88 24.42 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 114.059 -1.428 . . . . 0.0 109.207 -174.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -85.94 138.03 32.3 Favored 'General case' 0 C--N 1.314 -0.949 0 O-C-N 123.944 0.777 . . . . 0.0 111.561 -178.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.454 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 75.1 t -112.21 141.42 27.79 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-N 115.015 -0.993 . . . . 0.0 111.894 -173.105 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 5.1 t -119.69 139.05 48.31 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.131 0 N-CA-C 108.12 -1.066 . . . . 0.0 108.12 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 62.1 t -103.2 102.24 27.23 Favored Pre-proline 0 C--N 1.285 -2.197 0 C-N-CA 123.89 0.876 . . . . 0.0 110.065 178.414 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.41 ' HG3' HG11 ' A' ' 27' ' ' VAL . 34.5 Cg_endo -68.3 -22.68 39.57 Favored 'Trans proline' 0 C--O 1.222 -0.305 0 C-N-CA 122.144 1.896 . . . . 0.0 111.589 178.278 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.25 7.4 t . . . . . 0 CA--C 1.547 0.85 0 C-N-CA 124.791 1.236 . . . . 0.0 113.714 175.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 1.624 ' HD1' ' CD2' ' A' ' 1' ' ' PHE . 24.2 t80 . . . . . 0 N--CA 1.425 -1.718 0 CA-C-O 121.915 0.865 . . . . 0.0 110.183 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.497 ' HB1' ' CE1' ' A' ' 45' ' ' HIS . . . -121.37 -177.76 3.61 Favored 'General case' 0 C--N 1.289 -2.05 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.202 176.4 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.49 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 13.5 t -157.12 160.66 39.05 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.294 -175.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.27 164.3 31.81 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.455 -177.324 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.621 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 73.8 p -102.22 177.85 4.76 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-O 121.427 0.632 . . . . 0.0 111.024 -179.71 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.72 -18.27 44.92 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 114.71 -1.132 . . . . 0.0 109.347 179.131 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.621 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 1.0 OUTLIER -91.82 -24.42 19.38 Favored 'General case' 0 N--CA 1.432 -1.363 0 CA-C-N 114.893 -1.049 . . . . 0.0 111.822 -177.621 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 120.17 34.46 0.96 Allowed Glycine 0 CA--C 1.488 -1.614 0 C-N-CA 119.308 -1.425 . . . . 0.0 113.315 170.005 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -110.13 98.93 8.09 Favored 'General case' 0 N--CA 1.423 -1.823 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 176.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -90.97 123.18 34.26 Favored 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 115.157 -0.929 . . . . 0.0 109.451 177.03 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.404 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 68.3 mt -100.39 116.22 64.62 Favored Pre-proline 0 C--N 1.288 -2.07 0 N-CA-C 109.484 -0.562 . . . . 0.0 109.484 177.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -75.53 164.78 31.78 Favored 'Trans proline' 0 C--O 1.249 1.055 0 C-N-CA 122.661 2.241 . . . . 0.0 110.85 176.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.4 mt -69.49 121.03 18.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 148.77 -6.0 0.85 Allowed Glycine 0 C--N 1.305 -1.162 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 -174.142 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.0 149.39 23.81 Favored Glycine 0 N--CA 1.431 -1.665 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 176.83 178.57 46.68 Favored Glycine 0 N--CA 1.418 -2.502 0 C-N-CA 119.133 -1.508 . . . . 0.0 112.132 -179.218 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.9 p -140.67 142.08 34.96 Favored 'General case' 0 C--N 1.285 -2.226 0 N-CA-C 108.795 -0.816 . . . . 0.0 108.795 -179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.41 153.06 51.2 Favored 'General case' 0 CA--C 1.474 -1.969 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 -178.018 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -98.68 116.67 31.43 Favored 'General case' 0 C--N 1.278 -2.53 0 CA-C-N 114.751 -1.113 . . . . 0.0 108.19 174.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 26.1 t -103.76 127.39 57.9 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.573 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.211 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 1.658 ' HE2' ' CE1' ' A' ' 21' ' ' TYR . 54.2 m-85 -110.84 125.27 53.42 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 121.336 -0.146 . . . . 0.0 110.954 -179.389 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 21.2 t -126.93 121.8 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.036 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -176.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -85.13 120.88 27.12 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-O 121.411 0.624 . . . . 0.0 110.432 175.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 50.7 mt -109.93 160.9 16.0 Favored 'General case' 0 N--CA 1.424 -1.755 0 CA-C-N 114.452 -1.249 . . . . 0.0 108.251 -175.263 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.5 121.18 58.61 Favored Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 124.65 1.219 . . . . 0.0 109.411 -179.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.466 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 59.2 Cg_endo -72.77 -3.39 13.46 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.86 2.373 . . . . 0.0 113.183 -177.465 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 65.1 t -122.21 110.58 27.53 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 178.041 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.431 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.7 t -141.78 108.87 2.07 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.105 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 -178.531 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.756 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -98.05 152.37 19.37 Favored 'General case' 0 C--N 1.277 -2.555 0 C-N-CA 122.861 0.464 . . . . 0.0 112.135 -179.561 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.444 HG11 ' O ' ' A' ' 112' ' ' VAL . 30.5 t -46.61 117.71 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.036 0 C-N-CA 123.784 0.834 . . . . 0.0 111.578 177.427 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.1 3.79 55.59 Favored Glycine 0 C--O 1.235 0.211 0 CA-C-N 115.527 -0.76 . . . . 0.0 112.848 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.756 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -76.11 -176.65 3.61 Favored 'General case' 0 C--N 1.311 -1.081 0 C-N-CA 124.49 1.116 . . . . 0.0 110.113 178.249 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 -130.73 90.57 2.93 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 178.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.645 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 21.9 tp -93.87 141.49 28.45 Favored 'General case' 0 C--N 1.29 -2.018 0 C-N-CA 119.062 -1.055 . . . . 0.0 109.003 178.746 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.6 t -134.35 122.62 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.813 0 CA-C-N 116.25 -0.432 . . . . 0.0 109.842 -174.205 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.623 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 57.0 t -92.43 87.96 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.35 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 172.337 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.522 ' O ' ' HG2' ' A' ' 41' ' ' GLN . 29.3 t70 -83.97 101.42 11.71 Favored 'General case' 0 CA--C 1.488 -1.429 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.809 -176.395 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.9 mt -80.9 -7.22 59.42 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.916 -177.666 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 24.8 t -71.72 -0.04 10.0 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.072 179.104 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 4.1 p -134.3 10.3 3.79 Favored 'General case' 0 N--CA 1.419 -1.982 0 CA-C-O 121.207 0.527 . . . . 0.0 110.049 176.082 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.522 ' HG2' ' O ' ' A' ' 37' ' ' ASP . 35.0 mm-40 -125.39 -20.96 4.65 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 -176.852 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.8 mt -134.6 136.77 52.19 Favored 'Isoleucine or valine' 0 C--O 1.239 0.517 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -177.396 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.664 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 56.0 m-85 -138.43 120.44 15.54 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -175.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.49 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 73.8 m -102.37 143.07 32.58 Favored 'General case' 0 C--N 1.282 -2.354 0 CA-C-O 121.451 0.643 . . . . 0.0 109.962 -178.157 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . 0.497 ' CE1' ' HB1' ' A' ' 2' ' ' ALA . 6.8 p80 -119.22 139.66 51.5 Favored 'General case' 0 C--N 1.288 -2.105 0 CA-C-O 121.73 0.776 . . . . 0.0 111.03 -176.393 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.612 ' HB2' ' CG ' ' A' ' 54' ' ' ASP . 3.7 p-10 -108.36 100.64 9.91 Favored 'General case' 0 N--CA 1.395 -3.202 0 CA-C-O 123.37 1.557 . . . . 0.0 107.436 -176.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -78.3 -32.94 49.62 Favored 'General case' 0 C--N 1.299 -1.592 0 CA-C-N 112.755 -2.02 . . . . 0.0 111.648 -168.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 1.663 ' HE1' ' CE2' ' A' ' 48' ' ' TYR . 39.2 m-85 -129.38 64.61 71.92 Favored Pre-proline 0 C--N 1.308 -1.208 0 C-N-CA 119.456 -0.898 . . . . 0.0 111.896 -174.841 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.58 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 56.2 Cg_endo -67.45 -7.98 20.77 Favored 'Trans proline' 0 N--CA 1.486 1.088 0 C-N-CA 122.847 2.365 . . . . 0.0 114.415 -173.866 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -110.62 -15.37 13.88 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 120.672 -0.411 . . . . 0.0 111.493 -176.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.46 ' HB ' HD13 ' A' ' 52' ' ' ILE . 1.8 m -115.9 -25.33 7.77 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-O 122.182 0.992 . . . . 0.0 109.779 -173.16 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.46 HD13 ' HB ' ' A' ' 51' ' ' THR . 2.6 mp -130.67 150.12 34.28 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.996 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 -176.64 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.9 t -94.35 125.23 38.86 Favored 'General case' 0 N--CA 1.413 -2.299 0 N-CA-C 104.154 -2.535 . . . . 0.0 104.154 171.44 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.612 ' CG ' ' HB2' ' A' ' 46' ' ' ASN . 9.9 m-20 -91.71 106.16 18.27 Favored 'General case' 0 C--N 1.259 -3.336 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 -178.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.505 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 9.5 t80 -130.85 135.24 47.53 Favored 'General case' 0 C--N 1.287 -2.123 0 CA-C-N 114.49 -1.232 . . . . 0.0 109.233 -174.617 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.552 ' CG2' ' HG ' ' A' ' 131' ' ' LEU . 13.7 p -141.85 150.43 19.26 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.173 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.256 -176.004 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.1 p -150.17 129.97 13.29 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 123.894 0.878 . . . . 0.0 108.883 176.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.48 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 36.9 tp -65.6 112.63 3.73 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 172.309 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.408 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 2.7 tp-100 -60.66 -59.39 5.47 Favored 'General case' 0 C--O 1.204 -1.339 0 CA-C-N 113.257 -1.792 . . . . 0.0 109.915 -177.624 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -166.74 155.74 10.67 Favored 'General case' 0 N--CA 1.419 -1.999 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -175.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -135.44 153.73 21.39 Favored Glycine 0 N--CA 1.412 -2.92 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 -177.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 24.1 m -138.61 144.58 39.82 Favored 'General case' 0 C--N 1.281 -2.4 0 C-N-CA 123.402 0.681 . . . . 0.0 110.595 -178.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.559 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -106.64 157.96 17.31 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 125.081 1.353 . . . . 0.0 107.741 -179.52 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 1.642 ' HD2' ' CD1' ' A' ' 64' ' ' TYR . 94.4 m-85 -155.74 178.15 10.58 Favored 'General case' 0 C--O 1.208 -1.113 0 CA-C-N 118.901 0.773 . . . . 0.0 111.781 -177.037 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 53.39 -127.49 36.7 Favored Glycine 0 C--O 1.217 -0.924 0 CA-C-O 121.423 0.457 . . . . 0.0 112.883 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.73 -9.16 83.44 Favored Glycine 0 N--CA 1.42 -2.38 0 C-N-CA 120.388 -0.91 . . . . 0.0 113.132 178.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.776 HG23 ' O ' ' A' ' 64' ' ' TYR . 12.8 m -78.49 -27.14 14.13 Favored 'Isoleucine or valine' 0 C--O 1.201 -1.468 0 CA-C-N 118.515 1.157 . . . . 0.0 112.562 -175.27 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.559 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -91.32 -15.04 29.72 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 119.91 -0.716 . . . . 0.0 111.862 176.146 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 26.5 t -101.18 -59.04 1.77 Allowed 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.524 -176.2 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.554 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 34.6 m-80 -87.14 -24.42 24.51 Favored 'General case' 0 CA--C 1.486 -1.486 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -176.147 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 0.466 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 85.5 m-85 -111.43 163.63 13.81 Favored 'General case' 0 C--N 1.286 -2.186 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.064 -178.592 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.2 t -179.95 134.21 0.11 Allowed 'General case' 0 N--CA 1.426 -1.645 0 N-CA-C 107.235 -1.395 . . . . 0.0 107.235 178.035 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.467 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -167.31 -109.82 0.22 Allowed Glycine 0 N--CA 1.406 -3.355 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 174.765 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 3.1 p -149.65 177.04 10.13 Favored 'General case' 0 C--N 1.275 -2.631 0 C-N-CA 122.778 0.431 . . . . 0.0 111.019 -174.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -132.9 140.16 47.98 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.116 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.717 ' HG3' ' O ' ' A' ' 80' ' ' SER . 82.6 tttt -120.72 145.36 47.57 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.398 -177.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.44 ' CD2' HG22 ' A' ' 90' ' ' THR . 43.2 t80 -146.62 109.47 4.63 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.335 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 11.2 t 49.14 43.33 22.43 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 124.526 1.131 . . . . 0.0 111.912 178.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.9 11.95 62.81 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.22 -0.991 . . . . 0.0 113.107 178.221 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.717 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 23.5 t -88.77 -179.73 6.05 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 175.217 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.3 t -167.3 107.45 0.6 Allowed 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 179.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 1.603 ' HD2' ' CD1' ' A' ' 82' ' ' TYR . 2.1 p90 -144.3 158.19 55.12 Favored Pre-proline 0 C--N 1.287 -2.136 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 -173.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -67.96 144.77 65.55 Favored 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 122.614 2.21 . . . . 0.0 112.789 -175.016 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 1.659 ' HE1' ' CE2' ' A' ' 84' ' ' PHE . 60.8 t80 -118.41 134.73 23.42 Favored Pre-proline 0 C--N 1.31 -1.141 0 CA-C-N 116.233 -0.44 . . . . 0.0 109.977 -179.102 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.546 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 66.6 Cg_endo -72.22 143.75 78.19 Favored 'Cis proline' 0 CA--C 1.543 0.942 0 C-N-CA 123.189 -1.588 . . . . 0.0 111.465 -0.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.7 t -66.84 -177.03 0.55 Allowed 'General case' 0 CA--C 1.547 0.861 0 CA-C-N 115.161 -0.927 . . . . 0.0 111.941 -174.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 16.4 p -130.19 -46.23 1.11 Allowed 'General case' 0 N--CA 1.425 -1.679 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.699 -172.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.3 t -101.04 -97.68 0.26 Allowed 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -177.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -166.45 -166.66 0.9 Allowed 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 177.255 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.48 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 46.9 p -99.38 165.66 14.37 Favored Pre-proline 0 C--N 1.297 -1.68 0 N-CA-C 113.753 1.02 . . . . 0.0 113.753 -178.135 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 20.8 Cg_endo -61.65 169.72 6.6 Favored 'Trans proline' 0 C--O 1.247 0.929 0 C-N-CA 123.252 2.635 . . . . 0.0 110.682 171.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.505 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 3.2 tmm_? -80.25 123.07 27.64 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.03 -175.291 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 75.1 t -132.58 123.35 49.28 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.134 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.591 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 58.5 t -105.0 140.79 21.96 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.169 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 176.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . 0.477 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 4.7 m-85 -84.2 94.91 8.5 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-O 121.75 0.785 . . . . 0.0 109.677 175.667 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 15.6 m120 -87.32 74.72 9.41 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 43.4 t -150.12 -173.41 4.43 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 -175.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 37.9 ptt180 -145.56 24.21 1.4 Allowed 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 172.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.4 t -160.85 174.65 13.55 Favored 'General case' 0 N--CA 1.426 -1.644 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 -176.055 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -61.96 136.15 57.84 Favored 'General case' 0 C--N 1.318 -0.792 0 O-C-N 123.59 0.556 . . . . 0.0 110.643 179.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 14.3 mmtm -138.52 150.25 65.55 Favored Pre-proline 0 C--N 1.286 -2.179 0 C-N-CA 124.976 1.311 . . . . 0.0 108.405 176.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -62.74 149.19 92.06 Favored 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 122.631 2.221 . . . . 0.0 111.881 -178.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . 0.477 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 11.2 t90 -89.88 104.89 9.4 Favored Pre-proline 0 C--N 1.305 -1.365 0 N-CA-C 106.171 -1.788 . . . . 0.0 106.171 178.122 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -75.99 87.54 1.4 Allowed 'Trans proline' 0 N--CA 1.448 -1.157 0 C-N-CA 121.27 1.313 . . . . 0.0 112.663 -172.191 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.425 HG21 ' CD2' ' A' ' 77' ' ' TYR . 61.7 t -140.16 149.7 21.81 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.126 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.492 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.623 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -153.14 135.4 14.93 Favored 'General case' 0 C--N 1.289 -2.025 0 O-C-N 123.268 0.355 . . . . 0.0 110.366 177.002 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 20.5 mt -101.73 104.84 15.66 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 177.695 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 1.615 ' HE1' ' CE2' ' A' ' 108' ' ' TYR . 55.4 m-85 -82.42 72.19 9.48 Favored 'General case' 0 C--N 1.281 -2.411 0 CA-C-O 120.883 0.373 . . . . 0.0 110.491 177.284 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.645 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.3 mm? -90.28 119.16 30.35 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 175.047 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -126.97 146.77 58.82 Favored Pre-proline 0 N--CA 1.411 -2.419 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -177.285 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.554 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 21.4 Cg_endo -60.99 118.8 5.71 Favored 'Trans proline' 0 C--O 1.246 0.902 0 C-N-CA 123.484 2.79 . . . . 0.0 112.468 -178.331 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.444 ' O ' HG11 ' A' ' 30' ' ' VAL . 3.1 m -67.98 -115.83 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.187 -2.188 0 CA-C-N 114.406 -1.27 . . . . 0.0 112.737 176.025 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 32.5 m -111.4 -42.58 3.86 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.159 -0.963 . . . . 0.0 111.312 179.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 8.8 t -90.99 28.4 1.59 Allowed 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 121.636 0.731 . . . . 0.0 110.356 -173.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -89.39 132.0 35.19 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.91 140.69 6.19 Favored Glycine 0 N--CA 1.434 -1.488 0 C-N-CA 119.496 -1.335 . . . . 0.0 111.994 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 57.09 -144.38 39.35 Favored Glycine 0 CA--C 1.495 -1.186 0 CA-C-O 119.175 -0.791 . . . . 0.0 112.87 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.0 p -61.43 96.02 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.245 0.856 0 CA-C-O 122.876 1.322 . . . . 0.0 112.385 -177.536 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.18 -31.81 11.9 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 114.327 -1.306 . . . . 0.0 111.053 -178.382 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.408 ' HB ' HG21 ' A' ' 154' ' ' VAL . 70.5 mt -124.8 139.32 51.33 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 177.162 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 3.3 mmpt? -114.24 136.17 53.26 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.179 0.514 . . . . 0.0 111.065 178.023 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -72.66 122.94 22.27 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.102 -178.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 99.48 -5.53 58.76 Favored Glycine 0 N--CA 1.434 -1.482 0 N-CA-C 110.891 -0.884 . . . . 0.0 110.891 -178.167 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 49.9 m -97.05 149.07 22.35 Favored 'General case' 0 N--CA 1.422 -1.851 0 CA-C-O 121.518 0.675 . . . . 0.0 110.382 -179.669 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -75.69 127.76 33.75 Favored 'General case' 0 N--CA 1.429 -1.502 0 CA-C-N 114.203 -1.362 . . . . 0.0 108.656 -178.213 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.414 ' HB ' HG13 ' A' ' 67' ' ' VAL . 28.1 pt -113.16 -29.7 2.27 Favored 'Isoleucine or valine' 0 C--O 1.197 -1.679 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.733 178.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . 0.433 ' HB1' ' HB ' ' A' ' 148' ' ' ILE . . . -156.91 166.93 31.99 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.659 -177.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 54.8 t -141.35 114.52 4.57 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.089 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 178.219 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 64.5 mt -118.12 138.66 52.12 Favored 'General case' 0 C--N 1.288 -2.086 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 178.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.462 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.0 mp -120.03 127.81 75.91 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 C-N-CA 119.335 -0.946 . . . . 0.0 109.455 178.644 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.552 ' HG ' ' CG2' ' A' ' 56' ' ' VAL . 0.1 OUTLIER -99.17 130.18 45.47 Favored 'General case' 0 C--N 1.273 -2.758 0 C-N-CA 124.391 1.076 . . . . 0.0 110.994 -176.648 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . 0.424 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 14.6 mmm180 -97.99 113.34 25.16 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 123.428 0.691 . . . . 0.0 110.308 178.361 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.73 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 12.5 mm100 -92.43 134.66 34.73 Favored 'General case' 0 N--CA 1.404 -2.744 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 173.551 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.415 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 19.5 m -142.26 130.56 22.25 Favored 'General case' 0 C--N 1.28 -2.424 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 176.235 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 15.6 p30 -120.39 161.49 21.11 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.333 -179.267 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 8.3 p30 -100.49 -5.89 26.33 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.794 -174.335 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 68.5 t80 -107.36 -71.59 0.75 Allowed 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.458 -171.455 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -75.26 177.02 6.84 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 175.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 17.3 t -115.36 33.45 5.44 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 174.009 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -93.74 40.0 1.07 Allowed 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 114.359 -1.291 . . . . 0.0 110.648 -179.463 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 13.3 p-10 -83.91 80.98 8.97 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-O 122.706 1.241 . . . . 0.0 109.978 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -96.47 176.21 6.12 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 114.536 -1.211 . . . . 0.0 109.543 179.166 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . 0.413 ' HB3' ' HD2' ' A' ' 132' ' ' ARG . 12.9 pt20 -129.04 142.39 50.92 Favored 'General case' 0 N--CA 1.425 -1.719 0 C-N-CA 120.077 -0.649 . . . . 0.0 109.385 177.274 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 1.654 ' HE1' ' CE2' ' A' ' 144' ' ' PHE . 8.8 m-85 -109.93 136.63 48.91 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 -176.727 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 43.8 t -95.26 129.9 44.75 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 O-C-N 123.69 0.619 . . . . 0.0 109.638 -177.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . 0.437 ' CZ2' ' HB3' ' A' ' 3' ' ' CYS . 63.3 m95 -119.8 103.21 9.16 Favored 'General case' 0 C--N 1.282 -2.338 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -178.195 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . 0.463 ' N ' HD21 ' A' ' 147' ' ' ASN . 0.8 OUTLIER -83.89 112.1 19.83 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 179.554 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . 0.433 ' HB ' ' HB1' ' A' ' 127' ' ' ALA . 23.0 mm -87.45 122.65 39.49 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.187 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 -178.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -116.69 156.93 26.26 Favored 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 123.669 0.788 . . . . 0.0 109.267 179.198 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.46 130.52 34.57 Favored 'General case' 0 N--CA 1.396 -3.151 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 176.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 36.7 t-20 -89.13 -18.61 26.85 Favored 'General case' 0 C--N 1.285 -2.226 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 -177.521 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -147.66 143.71 27.85 Favored 'General case' 0 N--CA 1.429 -1.483 0 CA-C-N 114.013 -1.449 . . . . 0.0 109.284 -173.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -83.41 139.45 32.97 Favored 'General case' 0 C--N 1.312 -1.063 0 O-C-N 124.391 1.057 . . . . 0.0 109.698 -178.344 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.466 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 1.8 m -121.47 148.54 24.81 Favored 'Isoleucine or valine' 0 C--O 1.257 1.478 0 C-N-CA 120.138 -0.625 . . . . 0.0 111.259 -177.65 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.5 t -120.49 140.95 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.699 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 -179.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.431 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 71.4 t -102.24 104.62 38.12 Favored Pre-proline 0 C--N 1.288 -2.068 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 178.374 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.426 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 43.4 Cg_endo -71.29 -20.75 27.59 Favored 'Trans proline' 0 N--CA 1.462 -0.332 0 C-N-CA 122.404 2.069 . . . . 0.0 111.428 176.865 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.26 3.3 t . . . . . 0 C--O 1.247 0.951 0 C-N-CA 124.497 1.119 . . . . 0.0 113.775 175.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 1.661 ' HE2' ' CE1' ' A' ' 1' ' ' PHE . 52.3 t80 . . . . . 0 CA--C 1.501 -0.935 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.492 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . -144.1 -170.86 3.44 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 -179.366 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.503 ' HB3' ' CZ2' ' A' ' 146' ' ' TRP . 10.6 t -156.92 164.0 38.52 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 118.604 -1.238 . . . . 0.0 110.677 -176.294 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.413 ' HG3' ' O ' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -147.2 159.86 43.14 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -177.003 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.41 HG21 HG23 ' A' ' 20' ' ' VAL . 63.9 p -99.8 173.66 6.58 Favored 'General case' 0 C--N 1.3 -1.578 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.727 178.815 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.0 -21.75 59.86 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 114.629 -1.169 . . . . 0.0 111.223 177.051 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -82.11 -35.43 28.58 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 119.574 -0.85 . . . . 0.0 110.411 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 133.49 16.45 1.17 Allowed Glycine 0 N--CA 1.434 -1.49 0 C-N-CA 119.709 -1.234 . . . . 0.0 112.955 178.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.3 m -91.53 105.46 17.77 Favored 'General case' 0 N--CA 1.428 -1.573 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 174.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -98.18 123.58 42.32 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 176.029 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.492 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 49.6 mt -104.17 117.81 58.48 Favored Pre-proline 0 C--N 1.29 -1.981 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 177.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -81.71 176.2 8.68 Favored 'Trans proline' 0 C--O 1.245 0.842 0 C-N-CA 122.601 2.2 . . . . 0.0 110.783 176.489 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 63.5 mt -67.1 129.15 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 N-CA-C 109.052 -0.722 . . . . 0.0 109.052 177.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 145.36 -8.95 1.67 Allowed Glycine 0 C--N 1.308 -0.98 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.004 -178.53 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.21 154.6 30.78 Favored Glycine 0 CA--C 1.504 -0.594 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 -178.281 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 160.39 -171.44 36.6 Favored Glycine 0 N--CA 1.428 -1.893 0 C-N-CA 119.851 -1.166 . . . . 0.0 111.169 -178.583 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.446 ' HB3' ' HB ' ' A' ' 145' ' ' VAL . 28.8 p -144.34 151.18 38.96 Favored 'General case' 0 C--N 1.291 -1.949 0 CA-C-O 120.797 0.332 . . . . 0.0 111.153 -177.073 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.16 162.52 32.29 Favored 'General case' 0 N--CA 1.421 -1.9 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -178.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -108.27 113.57 26.77 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.077 -0.965 . . . . 0.0 108.741 176.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.41 HG23 HG21 ' A' ' 5' ' ' THR . 40.0 t -103.71 116.78 48.11 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.757 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.403 -179.456 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 23.5 m-85 -102.07 119.15 38.34 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 120.602 0.239 . . . . 0.0 111.058 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 23.7 t -119.98 128.09 75.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.73 -174.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 48.1 m-80 -81.83 126.55 32.0 Favored 'General case' 0 CA--C 1.483 -1.604 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 176.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 28.8 mt -117.8 148.31 42.2 Favored 'General case' 0 C--N 1.28 -2.449 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 179.482 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -53.24 119.14 16.09 Favored Pre-proline 0 C--O 1.209 -1.071 0 O-C-N 124.923 1.389 . . . . 0.0 110.524 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.533 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 56.3 Cg_endo -72.01 -0.29 8.28 Favored 'Trans proline' 0 CA--C 1.535 0.531 0 C-N-CA 122.999 2.466 . . . . 0.0 113.531 -175.723 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 66.8 t -131.63 109.91 16.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.491 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 11.6 t -147.71 113.99 0.92 Allowed 'Isoleucine or valine' 0 C--O 1.186 -2.273 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 -177.343 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.783 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -100.15 157.65 16.42 Favored 'General case' 0 C--N 1.273 -2.738 0 C-N-CA 123.824 0.85 . . . . 0.0 111.636 -178.787 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.412 HG11 ' O ' ' A' ' 112' ' ' VAL . 38.5 t -49.79 120.13 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 CA-C-O 121.029 0.442 . . . . 0.0 111.188 176.323 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.31 8.95 58.37 Favored Glycine 0 CA--C 1.522 0.51 0 CA-C-N 115.57 -0.741 . . . . 0.0 112.808 -179.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.783 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -80.37 -175.29 5.05 Favored 'General case' 0 C--N 1.31 -1.11 0 C-N-CA 124.983 1.313 . . . . 0.0 108.237 175.762 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -133.78 95.4 3.45 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 177.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.612 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 24.7 tp -91.96 144.29 25.61 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 119.166 -1.013 . . . . 0.0 109.498 178.516 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 62.0 t -135.48 124.06 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.915 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 -177.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.566 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 44.9 t -92.87 88.52 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.183 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 173.067 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -79.08 104.19 9.54 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.981 -177.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.7 mt -85.55 -2.84 58.57 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.345 -179.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.402 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 36.6 t -73.58 -2.49 23.08 Favored 'General case' 0 CA--C 1.546 0.8 0 CA-C-O 121.715 0.769 . . . . 0.0 110.16 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.5 p -126.78 8.43 6.88 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.191 177.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 43.8 mm-40 -125.26 -27.08 3.54 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.226 -174.06 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.6 mt -133.79 135.75 54.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 -175.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.67 ' HE1' ' CE2' ' A' ' 43' ' ' PHE . 39.0 m-85 -138.31 120.1 15.28 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -176.377 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.454 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 74.3 m -102.94 145.29 30.06 Favored 'General case' 0 C--N 1.281 -2.385 0 CA-C-O 120.825 0.345 . . . . 0.0 110.333 -177.461 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 25.8 p-80 -134.56 149.42 50.63 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.112 -173.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.472 ' HA ' ' HA ' ' A' ' 1' ' ' PHE . 60.8 t30 -103.26 91.2 3.98 Favored 'General case' 0 C--N 1.291 -1.941 0 C-N-CA 118.786 -1.166 . . . . 0.0 109.882 172.66 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -61.46 -24.43 66.55 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 113.508 -1.678 . . . . 0.0 111.905 -177.608 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 1.668 ' HE2' ' CE1' ' A' ' 48' ' ' TYR . 50.6 m-85 -125.71 78.64 68.86 Favored Pre-proline 0 C--N 1.322 -0.629 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 -178.657 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -73.02 -7.42 20.65 Favored 'Trans proline' 0 C--N 1.332 -0.319 0 C-N-CA 122.631 2.221 . . . . 0.0 114.241 -173.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -112.45 -23.03 10.54 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 121.768 0.794 . . . . 0.0 109.786 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.488 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.6 OUTLIER -97.68 -30.1 13.02 Favored 'General case' 0 N--CA 1.407 -2.597 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.744 -169.82 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.533 HG21 ' CB ' ' A' ' 135' ' ' ASN . 3.0 mp -128.67 133.69 65.93 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.806 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.185 -176.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.9 t -75.88 145.64 40.38 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 174.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -81.47 108.72 15.3 Favored 'General case' 0 C--N 1.278 -2.509 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -174.013 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 77.3 t80 -147.9 138.85 23.31 Favored 'General case' 0 C--N 1.293 -1.865 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.203 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.425 HG21 ' HG ' ' A' ' 131' ' ' LEU . 14.5 p -152.19 147.19 15.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 C-N-CA 124.405 1.082 . . . . 0.0 109.371 176.538 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.88 127.29 10.7 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 123.401 0.68 . . . . 0.0 109.824 172.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.496 HD21 ' O ' ' A' ' 130' ' ' ILE . 1.1 tt -68.0 114.24 6.36 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 175.379 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.1 tp-100 -58.62 -63.87 1.13 Allowed 'General case' 0 C--O 1.206 -1.228 0 C-N-CA 124.718 1.207 . . . . 0.0 110.372 178.114 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -164.09 154.02 14.61 Favored 'General case' 0 N--CA 1.422 -1.834 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -173.689 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.484 ' O ' ' HB2' ' A' ' 85' ' ' PRO . . . -124.03 154.84 17.78 Favored Glycine 0 N--CA 1.409 -3.104 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 179.583 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 49.4 m -131.39 145.6 51.89 Favored 'General case' 0 C--N 1.28 -2.416 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.443 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -113.97 154.82 26.96 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 1.639 ' HD2' ' CD1' ' A' ' 64' ' ' TYR . 88.5 m-85 -156.63 -178.1 7.1 Favored 'General case' 0 C--O 1.238 0.479 0 C-N-CA 123.622 0.769 . . . . 0.0 109.506 -177.268 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 62.02 -137.71 45.98 Favored Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 115.783 -0.644 . . . . 0.0 113.148 175.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -84.32 -7.66 84.59 Favored Glycine 0 N--CA 1.42 -2.41 0 N-CA-C 111.336 -0.705 . . . . 0.0 111.336 177.221 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.472 HG23 ' HB ' ' A' ' 126' ' ' ILE . 94.5 t -70.0 -43.81 78.97 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.379 0 C-N-CA 123.056 0.543 . . . . 0.0 111.429 -178.525 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.476 ' HG ' ' CA ' ' A' ' 64' ' ' TYR . 0.2 OUTLIER -82.32 -16.99 47.35 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.129 -1.028 . . . . 0.0 111.978 -179.469 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 8.2 t -100.54 -51.92 3.48 Favored 'General case' 0 N--CA 1.444 -0.771 0 CA-C-N 115.86 -0.609 . . . . 0.0 112.125 -174.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.497 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 34.0 m-80 -93.77 -21.53 19.25 Favored 'General case' 0 CA--C 1.492 -1.272 0 C-N-CA 120.494 -0.482 . . . . 0.0 109.972 -175.308 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 0.55 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 78.2 m-85 -111.8 161.8 15.95 Favored 'General case' 0 N--CA 1.425 -1.712 0 C-N-CA 120.076 -0.65 . . . . 0.0 109.967 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 t -169.52 133.92 1.38 Allowed 'General case' 0 N--CA 1.419 -1.991 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 176.456 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.513 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -167.08 -111.92 0.25 Allowed Glycine 0 N--CA 1.402 -3.604 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 175.721 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.4 p -157.72 -179.46 8.18 Favored 'General case' 0 C--N 1.29 -2.016 0 C-N-CA 124.421 1.088 . . . . 0.0 110.02 -174.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.66 147.88 31.76 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.596 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.9 tttt -125.61 147.57 49.26 Favored 'General case' 0 N--CA 1.43 -1.446 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.839 -178.609 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 1.623 ' HE2' ' CE1' ' A' ' 77' ' ' TYR . 52.1 t80 -147.76 109.48 4.42 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 -178.192 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 9.2 t 50.8 43.7 28.16 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 124.079 0.952 . . . . 0.0 111.35 177.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.02 6.16 69.73 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 120.415 -0.898 . . . . 0.0 113.946 178.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.596 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 12.2 t -79.74 -178.86 6.6 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 117.436 0.618 . . . . 0.0 110.205 178.597 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 40.9 t -159.24 103.54 1.63 Allowed 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 -179.4 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 1.659 ' HD1' ' CD2' ' A' ' 82' ' ' TYR . 4.0 p90 -148.85 161.65 32.05 Favored Pre-proline 0 C--N 1.313 -0.991 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 -174.275 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -71.77 149.13 53.75 Favored 'Trans proline' 0 C--N 1.362 1.261 0 C-N-CA 122.494 2.129 . . . . 0.0 113.502 -174.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.643 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 56.8 t80 -120.45 137.36 26.08 Favored Pre-proline 0 N--CA 1.427 -1.597 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 178.738 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.643 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 66.2 Cg_endo -70.52 142.59 72.39 Favored 'Cis proline' 0 CA--C 1.542 0.916 0 C-N-CA 122.933 -1.695 . . . . 0.0 112.959 -1.487 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . 0.338 10.3 t -63.54 105.4 0.77 Allowed 'General case' 0 C--O 1.249 1.059 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 -179.361 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 7.3 p -77.54 -13.04 60.01 Favored 'General case' 0 C--N 1.282 -2.363 0 CA-C-N 112.975 -1.92 . . . . 0.0 110.779 -175.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.7 t -119.41 -82.96 0.65 Allowed 'General case' 0 N--CA 1.409 -2.497 0 C-N-CA 119.326 -0.95 . . . . 0.0 111.898 -173.632 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 172.4 177.95 0.08 Allowed 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.284 1.033 . . . . 0.0 108.695 -178.132 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 42.9 p -102.31 161.07 24.45 Favored Pre-proline 0 C--N 1.301 -1.51 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 177.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -61.22 162.58 19.5 Favored 'Trans proline' 0 CA--C 1.546 1.103 0 C-N-CA 123.427 2.751 . . . . 0.0 111.696 172.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.7 tmm_? -72.29 116.82 13.17 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 124.588 1.155 . . . . 0.0 109.874 -176.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 75.4 t -124.84 127.89 72.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 CA-C-O 121.348 0.594 . . . . 0.0 111.234 -178.437 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 77.0 t -107.13 123.18 62.13 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.214 178.177 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . 0.461 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 5.3 m-85 -78.34 156.29 29.65 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 173.066 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -128.67 34.24 4.53 Favored 'General case' 0 C--N 1.261 -3.276 0 N-CA-C 106.8 -1.556 . . . . 0.0 106.8 175.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' SER . . . . . 0.427 ' CB ' ' HG3' ' A' ' 101' ' ' LYS . 45.2 m -130.67 117.64 19.77 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 113.563 0.949 . . . . 0.0 113.563 -170.776 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 20.4 ptp180 -93.93 32.15 1.51 Allowed 'General case' 0 C--O 1.244 0.797 0 CA-C-O 122.332 1.063 . . . . 0.0 110.129 179.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 9.2 t -152.82 165.63 34.8 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 105.203 -2.147 . . . . 0.0 105.203 -178.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 16.9 p-10 -74.0 112.71 10.4 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-O 122.167 0.984 . . . . 0.0 111.099 -174.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . 0.427 ' HG3' ' CB ' ' A' ' 97' ' ' SER . 15.2 mmtm -122.98 145.27 45.28 Favored Pre-proline 0 C--N 1.284 -2.254 0 CA-C-N 114.235 -1.348 . . . . 0.0 108.618 -178.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.402 ' HB3' ' O ' ' A' ' 39' ' ' SER . 17.9 Cg_endo -56.17 142.27 86.89 Favored 'Trans proline' 0 N--CA 1.45 -1.053 0 C-N-CA 123.318 2.679 . . . . 0.0 113.7 -172.646 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . 0.461 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.7 t90 -89.67 106.07 12.89 Favored Pre-proline 0 C--N 1.298 -1.667 0 N-CA-C 105.27 -2.122 . . . . 0.0 105.27 178.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -76.25 87.48 1.43 Allowed 'Trans proline' 0 N--CA 1.435 -1.961 0 C-N-CA 121.228 1.285 . . . . 0.0 111.685 -173.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 64.9 t -138.86 145.83 27.15 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 177.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.566 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -152.01 135.52 16.1 Favored 'General case' 0 C--N 1.278 -2.534 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.262 177.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.412 ' HB2' ' CG2' ' A' ' 36' ' ' VAL . 21.4 mt -98.66 102.52 14.29 Favored 'General case' 0 C--N 1.287 -2.123 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 178.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.513 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 50.8 m-85 -83.86 73.57 10.3 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 120.951 0.405 . . . . 0.0 110.378 177.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.612 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.9 mm? -99.47 129.76 45.67 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 175.762 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -130.07 148.21 68.75 Favored Pre-proline 0 N--CA 1.413 -2.312 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 -178.141 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.497 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 20.4 Cg_endo -59.41 120.67 8.64 Favored 'Trans proline' 0 C--O 1.246 0.88 0 C-N-CA 123.283 2.655 . . . . 0.0 112.286 -178.262 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.412 ' O ' HG11 ' A' ' 30' ' ' VAL . 2.7 m -69.21 -116.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.184 -2.394 0 CA-C-N 114.26 -1.336 . . . . 0.0 113.194 176.857 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 21.4 m -112.18 -40.47 4.17 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.316 -0.865 . . . . 0.0 110.632 179.202 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 28.9 t -87.79 28.47 1.01 Allowed 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.697 -176.245 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -95.18 132.91 39.62 Favored 'General case' 0 N--CA 1.427 -1.597 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -171.54 144.24 8.04 Favored Glycine 0 N--CA 1.436 -1.335 0 C-N-CA 120.057 -1.068 . . . . 0.0 111.559 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . 0.46 ' O ' ' HA ' ' A' ' 155' ' ' VAL . . . 54.35 -145.7 26.54 Favored Glycine 0 CA--C 1.488 -1.613 0 C-N-CA 124.132 0.872 . . . . 0.0 113.0 -179.219 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 58.2 t -62.78 100.83 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.95 0 CA-C-O 121.602 0.715 . . . . 0.0 110.07 -177.31 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -99.33 -25.84 14.35 Favored 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 114.509 -1.223 . . . . 0.0 109.985 -179.331 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.473 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.0 mt -134.75 138.29 49.6 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -179.451 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.439 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.7 mmpt? -112.89 147.42 37.07 Favored 'General case' 0 C--N 1.31 -1.136 0 C-N-CA 122.692 0.397 . . . . 0.0 110.193 174.877 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.89 126.91 30.94 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 177.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.13 -8.33 67.35 Favored Glycine 0 C--N 1.312 -0.757 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -177.536 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 33.5 t -81.38 136.97 35.74 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 -179.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -72.35 121.85 20.18 Favored 'General case' 0 N--CA 1.429 -1.505 0 N-CA-C 106.491 -1.67 . . . . 0.0 106.491 175.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.472 ' HB ' HG23 ' A' ' 67' ' ' VAL . 27.7 pt -109.11 -27.42 2.93 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.915 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -177.128 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.28 169.38 20.76 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -177.6 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 76.7 t -144.11 113.38 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 179.161 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 46.2 mt -114.46 140.76 48.45 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.496 ' O ' HD21 ' A' ' 58' ' ' LEU . 4.0 mp -121.21 129.6 75.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 C-N-CA 118.844 -1.142 . . . . 0.0 110.787 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.523 ' O ' HD21 ' A' ' 131' ' ' LEU . 0.2 OUTLIER -103.19 131.9 49.87 Favored 'General case' 0 C--N 1.284 -2.24 0 C-N-CA 125.268 1.427 . . . . 0.0 110.553 -177.147 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 14.0 mmm180 -93.54 132.57 37.71 Favored 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 123.78 0.832 . . . . 0.0 110.699 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 5.1 tp-100 -113.28 114.6 26.92 Favored 'General case' 0 N--CA 1.422 -1.844 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 174.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 26.4 m -135.48 144.75 46.57 Favored 'General case' 0 C--N 1.286 -2.168 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 179.24 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.533 ' CB ' HG21 ' A' ' 52' ' ' ILE . 11.8 p30 -147.59 -169.32 3.29 Favored 'General case' 0 N--CA 1.436 -1.173 0 C-N-CA 119.305 -0.958 . . . . 0.0 112.355 178.816 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 8.7 p30 -92.97 -25.91 17.79 Favored 'General case' 0 C--N 1.308 -1.2 0 CA-C-O 121.389 0.614 . . . . 0.0 111.6 -175.365 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 50.5 t80 -98.02 -56.97 2.33 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.947 -169.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . 0.413 ' HB2' HD22 ' A' ' 135' ' ' ASN . 18.5 m120 -83.27 140.82 32.28 Favored 'General case' 0 CA--C 1.48 -1.74 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.723 177.414 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 39.3 m -93.73 12.33 25.99 Favored 'General case' 0 C--N 1.287 -2.148 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 173.067 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -79.54 60.8 3.37 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 126.352 1.861 . . . . 0.0 110.036 179.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -82.83 81.53 8.51 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-O 122.486 1.136 . . . . 0.0 110.634 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -102.6 177.29 4.9 Favored 'General case' 0 N--CA 1.429 -1.521 0 CA-C-N 114.949 -1.023 . . . . 0.0 108.258 177.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . 0.401 ' HB2' ' O ' ' A' ' 131' ' ' LEU . 13.4 pt20 -138.72 149.8 45.46 Favored 'General case' 0 N--CA 1.415 -2.178 0 C-N-CA 120.383 -0.527 . . . . 0.0 110.628 178.187 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 1.646 ' HE2' ' CE1' ' A' ' 144' ' ' PHE . 8.4 m-30 -108.1 134.32 51.14 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -175.578 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . 0.446 ' HB ' ' HB3' ' A' ' 17' ' ' SER . 55.3 t -94.24 128.06 45.81 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 O-C-N 123.738 0.649 . . . . 0.0 110.137 -179.087 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . 0.503 ' CZ2' ' HB3' ' A' ' 3' ' ' CYS . 68.4 m95 -114.87 96.98 5.98 Favored 'General case' 0 C--N 1.275 -2.658 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -179.634 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 40.4 m-80 -80.01 112.73 17.6 Favored 'General case' 0 C--N 1.291 -1.959 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 24.4 mm -87.9 123.95 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.879 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 -177.064 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 1.646 ' HE2' ' CE1' ' A' ' 149' ' ' TYR . 95.6 m-85 -118.82 153.92 33.71 Favored 'General case' 0 C--N 1.288 -2.098 0 C-N-CA 124.105 0.962 . . . . 0.0 108.468 178.25 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.29 133.76 35.25 Favored 'General case' 0 N--CA 1.406 -2.635 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 176.114 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -92.29 -13.15 30.78 Favored 'General case' 0 C--N 1.284 -2.26 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 -177.073 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -153.89 148.11 25.85 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 113.834 -1.53 . . . . 0.0 108.824 -176.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -82.12 149.02 28.22 Favored 'General case' 0 C--N 1.322 -0.628 0 O-C-N 123.958 0.786 . . . . 0.0 111.096 -178.436 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 73.7 t -124.62 133.68 68.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.346 -176.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 117' ' ' GLY . 8.4 t -116.71 136.35 54.06 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 72.3 t -100.02 103.52 23.04 Favored Pre-proline 0 C--N 1.292 -1.895 0 C-N-CA 123.384 0.674 . . . . 0.0 109.324 178.704 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -68.47 -27.1 33.81 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 122.423 2.082 . . . . 0.0 111.781 179.222 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 4.4 t . . . . . 0 CA--C 1.548 0.895 0 C-N-CA 125.109 1.364 . . . . 0.0 113.515 176.892 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.604 ' CZ ' ' HB3' ' A' ' 44' ' ' CYS . 55.4 t80 . . . . . 0 CA--C 1.485 -1.551 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.475 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . -141.16 171.4 14.11 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 176.107 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.407 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 70.9 m -136.02 159.41 41.77 Favored 'General case' 0 C--N 1.301 -1.5 0 C-N-CA 120.741 -0.384 . . . . 0.0 111.127 -175.348 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.447 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -143.73 161.05 39.6 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.172 0.51 . . . . 0.0 111.197 -176.187 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 72.0 p -102.25 168.88 9.07 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.335 177.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.99 -7.12 53.89 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 114.103 -1.408 . . . . 0.0 112.009 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 4.7 p30 -90.65 -31.29 16.69 Favored 'General case' 0 CA--C 1.511 -0.537 0 C-N-CA 118.458 -1.297 . . . . 0.0 108.234 176.219 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 133.24 2.57 3.68 Favored Glycine 0 N--CA 1.431 -1.678 0 C-N-CA 120.29 -0.957 . . . . 0.0 113.029 177.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.6 m -77.91 102.31 7.24 Favored 'General case' 0 N--CA 1.442 -0.869 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.26 117.59 30.54 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 175.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.475 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 62.1 mt -92.69 115.62 65.15 Favored Pre-proline 0 C--N 1.301 -1.529 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 179.348 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_endo -78.36 -179.83 5.82 Favored 'Trans proline' 0 C--O 1.248 0.981 0 C-N-CA 122.643 2.229 . . . . 0.0 111.526 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.5 mt -70.62 129.55 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.18 1.09 3.29 Favored Glycine 0 C--N 1.305 -1.162 0 C-N-CA 120.886 -0.673 . . . . 0.0 111.607 -178.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.75 171.41 46.91 Favored Glycine 0 C--O 1.244 0.773 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.289 -179.607 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 150.9 -169.11 30.66 Favored Glycine 0 N--CA 1.438 -1.182 0 C-N-CA 120.474 -0.869 . . . . 0.0 111.352 177.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 87.0 p -141.93 157.5 44.89 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -141.04 162.83 34.57 Favored 'General case' 0 N--CA 1.42 -1.965 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -110.03 111.33 22.64 Favored 'General case' 0 C--N 1.285 -2.207 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.256 178.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 41.5 t -100.75 135.83 35.07 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.441 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.513 -178.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 69.2 m-85 -125.29 128.51 48.36 Favored 'General case' 0 CA--C 1.492 -1.272 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -177.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.449 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.2 p -139.63 136.33 39.84 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 O-C-N 123.78 0.675 . . . . 0.0 110.974 -177.084 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 -88.79 128.29 35.63 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 178.089 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -107.11 160.05 15.85 Favored 'General case' 0 C--N 1.284 -2.272 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 176.15 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.45 120.66 37.63 Favored Pre-proline 0 C--O 1.209 -1.046 0 O-C-N 124.505 1.128 . . . . 0.0 109.365 176.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.485 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 62.4 Cg_endo -74.14 0.45 8.43 Favored 'Trans proline' 0 CA--C 1.537 0.667 0 C-N-CA 122.668 2.245 . . . . 0.0 113.514 -176.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.415 HG11 ' HG3' ' A' ' 157' ' ' PRO . 93.7 t -131.49 111.43 19.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 178.455 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.466 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 9.3 t -147.76 112.96 0.83 Allowed 'Isoleucine or valine' 0 C--O 1.194 -1.845 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 -177.453 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.661 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -101.05 154.75 18.44 Favored 'General case' 0 C--N 1.277 -2.571 0 C-N-CA 123.746 0.818 . . . . 0.0 111.062 -179.354 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 112' ' ' VAL . 99.1 t -46.12 117.84 0.39 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.478 0 C-N-CA 123.379 0.672 . . . . 0.0 111.338 175.614 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.1 1.36 54.63 Favored Glycine 0 C--N 1.311 -0.815 0 CA-C-N 115.253 -0.885 . . . . 0.0 113.101 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.661 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -74.42 -175.91 2.51 Favored 'General case' 0 C--N 1.315 -0.914 0 C-N-CA 124.551 1.141 . . . . 0.0 109.967 175.336 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -134.45 96.02 3.5 Favored 'General case' 0 N--CA 1.428 -1.559 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 177.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.578 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 28.8 tp -93.15 142.52 27.21 Favored 'General case' 0 C--N 1.284 -2.247 0 C-N-CA 119.773 -0.771 . . . . 0.0 109.929 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.0 t -135.01 122.08 35.89 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.719 0 CA-C-O 121.168 0.508 . . . . 0.0 109.901 -176.533 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.592 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 47.8 t -92.94 89.07 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.27 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 174.859 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -78.03 106.76 10.11 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.248 -177.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.6 mt -93.79 -1.68 54.65 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 121.365 0.602 . . . . 0.0 111.025 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.9 t -76.37 1.28 16.74 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.974 -178.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.3 p -129.55 8.93 5.46 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 123.614 0.765 . . . . 0.0 109.869 176.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.449 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 45.6 mm-40 -125.23 -24.73 3.93 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.505 -174.808 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.0 mt -133.71 141.59 43.78 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 -177.115 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.654 ' HD2' ' CD1' ' A' ' 43' ' ' PHE . 57.6 m-85 -141.24 161.14 38.59 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -176.199 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.604 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 69.3 m -138.69 138.77 38.06 Favored 'General case' 0 C--N 1.299 -1.618 0 C-N-CA 123.059 0.544 . . . . 0.0 110.953 -178.609 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 29.4 p-80 -134.12 148.94 51.05 Favored 'General case' 0 C--O 1.247 0.965 0 CA-C-O 121.378 0.609 . . . . 0.0 111.961 -175.386 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.484 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 3.4 p30 -105.37 118.87 37.66 Favored 'General case' 0 CA--C 1.485 -1.553 0 CA-C-O 122.193 0.997 . . . . 0.0 112.832 179.485 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -88.43 -25.94 22.38 Favored 'General case' 0 C--N 1.286 -2.189 0 CA-C-N 113.79 -1.55 . . . . 0.0 109.511 177.006 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 1.664 ' HD2' ' CD1' ' A' ' 48' ' ' TYR . 29.0 m-85 -138.51 66.87 44.03 Favored Pre-proline 0 N--CA 1.477 0.919 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.175 177.489 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.484 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 55.8 Cg_endo -68.52 -8.03 21.99 Favored 'Trans proline' 0 N--CA 1.485 1.024 0 C-N-CA 122.923 2.415 . . . . 0.0 113.96 -174.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -117.29 -9.29 10.97 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 120.025 -0.67 . . . . 0.0 111.115 -178.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.455 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.3 OUTLIER -103.88 -30.33 10.41 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 -176.378 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.455 HD13 ' HB ' ' A' ' 51' ' ' THR . 2.5 mp -124.2 140.09 48.61 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.309 0 CA-C-N 114.143 -1.389 . . . . 0.0 108.057 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 4.9 t -81.83 130.28 35.02 Favored 'General case' 0 N--CA 1.424 -1.773 0 N-CA-C 105.329 -2.101 . . . . 0.0 105.329 173.228 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.493 ' O ' HG21 ' A' ' 94' ' ' VAL . 42.2 m-20 -88.86 106.36 18.34 Favored 'General case' 0 C--N 1.282 -2.369 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -173.491 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.487 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 19.8 t80 -134.7 123.9 24.42 Favored 'General case' 0 C--N 1.296 -1.746 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.88 -172.592 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 93.3 t -124.83 141.66 44.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 CA-C-N 114.632 -1.167 . . . . 0.0 109.398 -176.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -148.36 127.85 13.16 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 173.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.52 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 59.5 tp -67.71 115.98 7.89 Favored 'General case' 0 N--CA 1.442 -0.85 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 174.19 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.432 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 3.9 tp-100 -60.43 -52.67 64.23 Favored 'General case' 0 C--O 1.214 -0.786 0 CA-C-N 114.402 -1.272 . . . . 0.0 110.404 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . 0.432 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 10.1 ptp180 -169.46 159.88 8.84 Favored 'General case' 0 N--CA 1.418 -2.028 0 CA-C-N 114.095 -1.411 . . . . 0.0 107.501 -175.049 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -136.42 136.06 8.15 Favored Glycine 1 N--CA 1.393 -4.205 0 N-CA-C 107.93 -2.068 . . . . 0.0 107.93 178.362 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 67.9 m -124.73 147.06 48.85 Favored 'General case' 0 C--N 1.272 -2.797 0 O-C-N 124.29 0.641 . . . . 0.0 110.361 -175.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.507 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -109.54 159.78 16.79 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 -178.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 1.62 ' HD2' ' CD1' ' A' ' 64' ' ' TYR . 90.6 m-85 -155.99 -179.68 8.37 Favored 'General case' 0 N--CA 1.464 0.26 0 C-N-CA 123.83 0.852 . . . . 0.0 109.438 -176.185 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.87 -138.71 46.84 Favored Glycine 0 CA--C 1.506 -0.52 0 O-C-N 123.73 0.644 . . . . 0.0 112.84 177.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.35 -6.04 89.56 Favored Glycine 0 C--O 1.201 -1.93 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 176.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.508 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 97.0 t -71.78 -38.17 64.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 123.041 0.536 . . . . 0.0 111.269 -178.262 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.507 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.11 -18.55 32.03 Favored 'General case' 0 C--N 1.297 -1.711 0 C-N-CA 118.513 -1.275 . . . . 0.0 112.232 179.416 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 22.5 t -100.29 -46.62 5.21 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.288 0.566 . . . . 0.0 112.028 -175.073 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.47 ' O ' HG23 ' A' ' 112' ' ' VAL . 44.7 m-20 -97.62 -20.75 17.45 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -174.183 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 1.641 ' HD2' ' CD1' ' A' ' 71' ' ' PHE . 95.6 m-85 -112.23 151.54 29.48 Favored 'General case' 0 N--CA 1.428 -1.544 0 CA-C-O 122.199 1.0 . . . . 0.0 111.618 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.1 m -158.69 124.15 4.37 Favored 'General case' 0 N--CA 1.393 -3.285 0 CA-C-N 113.587 -1.642 . . . . 0.0 109.96 179.236 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.504 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -161.13 -112.77 0.29 Allowed Glycine 0 N--CA 1.409 -3.156 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 175.631 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -158.04 179.84 8.8 Favored 'General case' 0 C--N 1.284 -2.242 0 C-N-CA 123.798 0.839 . . . . 0.0 110.238 -175.669 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -134.55 146.89 30.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 C-N-CA 123.172 0.589 . . . . 0.0 109.468 178.387 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.631 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.3 tttt -124.31 143.17 50.72 Favored 'General case' 0 N--CA 1.421 -1.901 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.5 -179.27 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 1.657 ' HE2' ' CE1' ' A' ' 77' ' ' TYR . 59.2 t80 -143.61 110.34 5.58 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 115.197 -0.91 . . . . 0.0 108.891 -177.551 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 23.0 t 53.95 37.2 26.19 Favored 'General case' 0 CA--C 1.557 1.241 0 C-N-CA 123.634 0.774 . . . . 0.0 111.386 175.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.44 10.48 63.68 Favored Glycine 0 C--O 1.216 -1.012 0 C-N-CA 120.849 -0.691 . . . . 0.0 113.874 -179.281 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.631 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 8.4 t -86.21 -179.29 6.69 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 117.584 0.692 . . . . 0.0 109.414 178.511 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 31.6 t -155.73 110.47 2.92 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -179.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 0.455 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 5.3 p90 -154.24 161.31 29.59 Favored Pre-proline 0 CA--C 1.548 0.885 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 -175.12 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.428 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 60.1 Cg_endo -68.7 149.45 73.38 Favored 'Trans proline' 0 C--N 1.36 1.18 0 C-N-CA 122.936 2.424 . . . . 0.0 113.563 -175.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.544 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 59.3 t80 -124.07 133.21 24.49 Favored Pre-proline 0 N--CA 1.437 -1.078 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.932 179.005 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.544 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 60.5 Cg_endo -71.99 148.45 90.87 Favored 'Cis proline' 0 C--O 1.239 0.533 0 C-N-CA 122.796 -1.752 . . . . 0.0 110.232 -3.319 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.8 t -72.61 -175.99 1.81 Allowed 'General case' 0 C--O 1.246 0.903 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -178.225 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 22.6 p -130.69 -35.81 1.44 Allowed 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 122.088 0.947 . . . . 0.0 108.524 -172.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 49.4 m -105.34 -141.84 0.37 Allowed 'General case' 1 N--CA 1.343 -5.778 0 CA-C-N 114.093 -1.412 . . . . 0.0 108.24 178.368 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -123.49 -171.32 2.29 Favored 'General case' 0 C--N 1.275 -2.64 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -174.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.52 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 39.9 p -100.75 167.03 11.44 Favored Pre-proline 0 C--N 1.295 -1.764 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 177.402 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -57.39 166.47 4.56 Favored 'Trans proline' 0 C--O 1.247 0.953 0 C-N-CA 123.263 2.642 . . . . 0.0 112.286 171.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.487 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 1.7 tmm_? -75.21 121.32 21.95 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 114.597 -1.183 . . . . 0.0 108.52 -178.382 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 72.8 t -136.47 117.92 19.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 C-N-CA 123.41 0.684 . . . . 0.0 109.749 -176.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.493 HG21 ' O ' ' A' ' 54' ' ' ASP . 1.5 p -115.67 132.02 66.32 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.361 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.89 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . 1.63 ' HD1' ' CD2' ' A' ' 95' ' ' TYR . 6.3 m-85 -77.0 100.29 5.58 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.216 0.531 . . . . 0.0 111.096 -178.41 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . 0.409 HD21 ' N ' ' A' ' 96' ' ' ASN . 0.8 OUTLIER -94.89 59.88 2.39 Favored 'General case' 0 C--N 1.308 -1.237 0 CA-C-O 121.372 0.606 . . . . 0.0 109.556 179.047 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 51.0 m -154.47 141.76 19.56 Favored 'General case' 0 C--N 1.31 -1.114 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.7 ptp180 -109.02 69.68 0.71 Allowed 'General case' 0 C--N 1.304 -1.376 0 CA-C-O 122.044 0.926 . . . . 0.0 111.464 -177.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.2 t -179.46 168.53 1.44 Allowed 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 179.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -72.35 113.11 9.03 Favored 'General case' 0 CA--C 1.501 -0.94 0 CA-C-O 121.799 0.809 . . . . 0.0 109.461 -179.107 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -118.46 139.73 27.31 Favored Pre-proline 0 C--N 1.274 -2.71 0 CA-C-N 114.249 -1.341 . . . . 0.0 108.693 -177.099 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 12.6 Cg_endo -57.16 152.26 46.14 Favored 'Trans proline' 0 C--O 1.245 0.841 0 C-N-CA 123.278 2.652 . . . . 0.0 113.107 179.202 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . 0.445 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 12.6 t90 -91.42 106.62 17.19 Favored Pre-proline 0 N--CA 1.438 -1.048 0 N-CA-C 106.317 -1.735 . . . . 0.0 106.317 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -77.52 88.21 1.44 Allowed 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 121.388 1.392 . . . . 0.0 112.927 -172.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 98.0 t -137.62 145.09 29.76 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.306 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 176.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.592 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.87 136.73 18.18 Favored 'General case' 0 C--N 1.292 -1.9 0 O-C-N 123.237 0.336 . . . . 0.0 110.172 178.438 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 20.3 mt -101.28 102.71 13.62 Favored 'General case' 0 C--N 1.292 -1.909 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.087 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.504 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 19.3 m-85 -81.53 74.0 8.54 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 120.812 0.339 . . . . 0.0 110.436 177.44 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.578 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.2 mm? -91.52 151.08 20.91 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 176.83 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -149.3 143.7 17.18 Favored Pre-proline 0 N--CA 1.405 -2.702 0 C-N-CA 119.996 -0.682 . . . . 0.0 110.136 179.516 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -64.9 127.48 18.7 Favored 'Trans proline' 0 N--CA 1.45 -1.051 0 C-N-CA 123.383 2.722 . . . . 0.0 113.149 -177.3 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.528 ' O ' HG23 ' A' ' 30' ' ' VAL . 27.1 m -87.25 -155.84 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.399 -3.014 0 CA-C-N 114.438 -1.255 . . . . 0.0 108.639 172.432 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 6.1 m -80.51 -30.55 37.26 Favored 'General case' 0 C--N 1.261 -3.269 0 CA-C-O 121.425 0.631 . . . . 0.0 110.48 -168.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.5 t -82.9 9.55 9.74 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.888 -177.195 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -90.72 131.52 36.35 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.334 -0.988 . . . . 0.0 108.334 178.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.3 125.68 1.16 Allowed Glycine 0 C--N 1.306 -1.095 0 C-N-CA 120.571 -0.823 . . . . 0.0 111.727 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.84 -147.26 49.37 Favored Glycine 0 CA--C 1.486 -1.773 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -175.229 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 60.3 t -57.31 112.04 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 117.213 0.507 . . . . 0.0 110.113 -177.144 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -110.25 -28.69 8.5 Favored 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.068 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.432 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 59.0 mt -129.03 138.07 55.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.149 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.408 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 5.1 mmpt? -114.92 141.84 47.4 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 121.112 0.482 . . . . 0.0 110.835 178.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.44 135.26 49.98 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.691 -179.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 82.72 -4.14 80.3 Favored Glycine 0 C--O 1.242 0.61 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.216 178.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 19.4 m -94.71 149.41 21.27 Favored 'General case' 0 N--CA 1.417 -2.084 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 -179.214 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 28.2 tp -74.79 133.37 41.95 Favored 'General case' 0 N--CA 1.434 -1.231 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.123 -177.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.491 ' HB ' HG23 ' A' ' 67' ' ' VAL . 34.5 pt -118.26 -26.67 2.51 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 C-N-CA 120.481 -0.488 . . . . 0.0 112.174 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.9 163.58 29.07 Favored 'General case' 0 N--CA 1.434 -1.24 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.252 -177.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 55.9 t -139.7 115.63 8.74 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.937 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 178.222 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 68.7 mt -117.74 145.74 44.25 Favored 'General case' 0 C--N 1.281 -2.398 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 179.415 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.48 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.7 mp -128.7 119.47 49.97 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 C-N-CA 119.794 -0.762 . . . . 0.0 109.629 178.767 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.525 ' C ' HD13 ' A' ' 131' ' ' LEU . 0.6 OUTLIER -88.77 147.02 24.66 Favored 'General case' 0 CA--C 1.481 -1.677 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 173.978 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 60.0 ttp180 -115.0 122.0 44.87 Favored 'General case' 0 C--N 1.248 -3.832 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 177.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -85.86 139.26 31.41 Favored 'General case' 0 N--CA 1.417 -2.076 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 176.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.426 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 25.8 m -145.1 133.23 21.49 Favored 'General case' 0 C--N 1.261 -3.253 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 173.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 32.9 p30 -132.29 161.39 33.63 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-O 120.906 0.384 . . . . 0.0 110.18 -178.368 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 8.1 p30 -93.89 -19.11 21.26 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.448 -173.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 88.5 t80 -91.31 -71.06 0.65 Allowed 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 115.067 -0.97 . . . . 0.0 111.346 -171.115 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 18.5 m120 -63.16 -46.49 86.94 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-O 121.366 0.603 . . . . 0.0 111.966 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 23.1 t 78.97 8.55 1.92 Allowed 'General case' 0 C--N 1.332 -0.191 0 C-N-CA 126.267 1.827 . . . . 0.0 109.297 -177.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . 0.527 ' HB3' ' CE2' ' A' ' 142' ' ' PHE . 2.0 m-20 -88.29 81.77 7.22 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 114.526 -1.215 . . . . 0.0 108.047 177.367 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -85.11 105.08 15.57 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-O 121.777 0.799 . . . . 0.0 111.298 -177.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . 0.527 ' CE2' ' HB3' ' A' ' 140' ' ' ASP . 72.6 m-85 -110.37 160.07 16.9 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . 0.418 ' HB2' ' O ' ' A' ' 131' ' ' LEU . 13.9 pt20 -126.09 150.48 48.15 Favored 'General case' 0 C--N 1.288 -2.107 0 C-N-CA 119.877 -0.729 . . . . 0.0 110.623 -179.113 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 1.636 ' HE1' ' CE2' ' A' ' 144' ' ' PHE . 12.5 m-30 -113.67 127.47 56.06 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -174.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 50.0 t -92.42 132.11 37.64 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.987 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.93 -178.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 54.3 m95 -120.97 101.14 7.49 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -177.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 50.0 m-80 -84.5 115.01 22.35 Favored 'General case' 0 C--N 1.285 -2.233 0 N-CA-C 107.691 -1.226 . . . . 0.0 107.691 178.68 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 20.2 mm -88.55 121.8 39.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -177.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -117.7 151.7 36.74 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.143 177.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.22 131.39 35.23 Favored 'General case' 0 N--CA 1.412 -2.336 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 177.049 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -88.21 -16.36 33.49 Favored 'General case' 0 C--N 1.287 -2.128 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -178.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -148.08 143.96 27.54 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 114.566 -1.197 . . . . 0.0 109.997 -174.447 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -79.08 139.53 38.08 Favored 'General case' 0 C--N 1.309 -1.163 0 O-C-N 124.285 0.991 . . . . 0.0 110.995 179.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.485 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 73.0 t -115.12 138.47 45.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.851 -176.432 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 8.3 t -119.56 135.9 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.394 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 75.3 t -99.81 105.03 32.07 Favored Pre-proline 0 C--N 1.286 -2.174 0 C-N-CA 124.091 0.956 . . . . 0.0 109.834 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.461 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 40.6 Cg_endo -70.71 -21.77 28.62 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.233 1.955 . . . . 0.0 111.797 177.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.27 3.7 t . . . . . 0 C--N 1.355 0.841 0 C-N-CA 124.978 1.311 . . . . 0.0 114.095 175.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 25.1 p90 . . . . . 0 C--O 1.213 -0.847 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.61 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . -113.33 177.16 4.73 Favored 'General case' 0 N--CA 1.44 -0.945 0 CA-C-N 118.836 0.744 . . . . 0.0 110.881 -173.238 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.512 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 11.5 t -151.61 156.61 40.8 Favored 'General case' 0 N--CA 1.433 -1.276 0 C-N-CA 119.931 -0.708 . . . . 0.0 109.766 -177.241 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.1 pptp? -141.44 163.08 33.89 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-O 121.049 0.452 . . . . 0.0 111.576 -175.065 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 71.3 p -104.6 172.94 6.52 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 121.859 0.837 . . . . 0.0 110.406 -179.687 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -78.81 -10.31 59.74 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 113.745 -1.57 . . . . 0.0 110.991 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -92.16 -33.97 14.51 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 118.318 -1.353 . . . . 0.0 109.124 175.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 137.47 5.58 1.74 Allowed Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 119.231 -1.461 . . . . 0.0 113.437 176.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.3 m -80.18 100.22 8.18 Favored 'General case' 0 N--CA 1.433 -1.275 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -97.29 111.08 23.48 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.323 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.61 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 59.3 mt -88.87 121.94 69.42 Favored Pre-proline 0 C--N 1.307 -1.243 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 179.488 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -81.52 -179.56 5.02 Favored 'Trans proline' 0 C--O 1.241 0.668 0 C-N-CA 122.899 2.399 . . . . 0.0 111.937 178.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.6 mt -69.23 141.51 17.25 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.832 179.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.89 -1.74 17.4 Favored Glycine 0 N--CA 1.438 -1.191 0 C-N-CA 119.887 -1.149 . . . . 0.0 112.472 179.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 103.27 171.25 25.99 Favored Glycine 0 C--N 1.309 -0.972 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 157.22 -175.28 34.69 Favored Glycine 0 C--N 1.312 -0.759 0 C-N-CA 120.354 -0.927 . . . . 0.0 111.867 178.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 m -146.27 143.54 29.25 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 179.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.92 166.33 23.57 Favored 'General case' 0 N--CA 1.425 -1.71 0 CA-C-O 121.249 0.547 . . . . 0.0 109.788 -177.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -111.03 115.52 29.61 Favored 'General case' 0 C--N 1.28 -2.442 0 CA-C-N 114.533 -1.212 . . . . 0.0 108.822 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 39.7 t -103.26 140.08 22.44 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.947 0 CA-C-N 115.266 -0.879 . . . . 0.0 108.762 178.052 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 1.652 ' HE2' ' CE1' ' A' ' 21' ' ' TYR . 43.7 m-85 -126.1 136.23 52.66 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 -179.707 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.426 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.4 p -146.04 135.51 17.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 123.724 0.64 . . . . 0.0 110.519 -178.769 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.6 p30 -95.83 123.24 39.32 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 121.759 0.79 . . . . 0.0 111.367 179.375 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -103.48 160.93 14.29 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 113.922 -1.49 . . . . 0.0 108.208 -177.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.76 122.41 56.58 Favored Pre-proline 0 C--N 1.313 -0.994 0 O-C-N 124.764 1.29 . . . . 0.0 109.405 178.23 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.425 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 61.0 Cg_endo -75.21 3.08 6.04 Favored 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 122.661 2.241 . . . . 0.0 112.89 -178.592 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.7 t -125.98 109.54 21.73 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.503 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 177.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.443 ' O ' HG11 ' A' ' 156' ' ' VAL . 1.6 t -143.17 99.89 0.7 Allowed 'Isoleucine or valine' 0 C--O 1.183 -2.403 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 -178.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.455 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -91.63 151.38 20.72 Favored 'General case' 0 C--N 1.269 -2.893 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -179.199 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.477 HG11 ' O ' ' A' ' 112' ' ' VAL . 24.7 t -46.85 115.23 0.25 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.709 0 C-N-CA 123.615 0.766 . . . . 0.0 111.501 177.078 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.84 3.28 42.74 Favored Glycine 0 N--CA 1.446 -0.697 0 CA-C-N 114.759 -1.109 . . . . 0.0 112.755 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.455 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -73.78 -178.37 3.16 Favored 'General case' 0 C--N 1.309 -1.159 0 C-N-CA 123.542 0.737 . . . . 0.0 111.427 175.57 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -134.67 89.03 2.5 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 177.075 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.651 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.3 tp -90.21 144.67 25.65 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.102 -176.599 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.4 t -134.12 125.79 48.75 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.633 0 CA-C-O 121.298 0.57 . . . . 0.0 110.585 -176.642 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.598 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 48.9 t -95.96 89.25 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.049 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 174.057 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -82.81 113.05 20.18 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-O 121.15 0.5 . . . . 0.0 111.216 -178.11 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.3 mt -96.1 -2.7 46.03 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.983 -178.704 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -74.07 0.36 14.0 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-O 122.118 0.961 . . . . 0.0 109.733 -178.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.5 p -127.36 6.82 6.38 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 123.771 0.828 . . . . 0.0 109.819 178.09 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.426 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 45.7 mm-40 -124.03 -21.42 5.07 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.706 -174.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.6 mt -132.87 136.72 55.21 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.133 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 -175.155 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.635 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 42.9 m-85 -142.84 124.36 14.84 Favored 'General case' 0 CA--C 1.504 -0.798 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -175.671 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.512 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 83.3 m -101.02 140.31 35.48 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 -179.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.4 p80 -132.19 139.36 48.32 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 121.852 0.834 . . . . 0.0 112.313 -171.748 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 8.7 p30 -103.44 107.26 18.02 Favored 'General case' 0 C--N 1.292 -1.899 0 CA-C-N 115.1 -0.954 . . . . 0.0 113.342 -178.272 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -84.24 -14.33 50.22 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 121.881 0.848 . . . . 0.0 109.531 175.588 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 47.2 m-85 -134.52 66.0 68.88 Favored Pre-proline 0 C--N 1.318 -0.761 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 177.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -73.05 -5.56 17.42 Favored 'Trans proline' 0 N--CA 1.486 1.056 0 C-N-CA 123.188 2.592 . . . . 0.0 113.978 -172.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -120.41 -13.34 8.85 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 121.469 0.652 . . . . 0.0 110.204 -179.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.404 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -94.78 -30.17 14.38 Favored 'General case' 0 N--CA 1.421 -1.88 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -174.904 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.591 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -122.92 138.2 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.508 0 CA-C-N 113.529 -1.669 . . . . 0.0 107.924 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 7.3 t -80.7 136.39 36.17 Favored 'General case' 0 N--CA 1.427 -1.607 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 174.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.416 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 19.3 m-20 -84.79 108.16 17.33 Favored 'General case' 0 C--N 1.286 -2.163 0 CA-C-O 121.541 0.686 . . . . 0.0 110.506 -171.869 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.42 ' CE2' ' HB ' ' A' ' 134' ' ' THR . 34.0 t80 -138.46 143.36 39.61 Favored 'General case' 0 C--N 1.284 -2.275 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.242 -178.399 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.416 HG22 HD11 ' A' ' 131' ' ' LEU . 12.6 p -148.59 148.66 15.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 177.026 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.04 137.59 19.89 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 123.599 0.562 . . . . 0.0 109.992 174.029 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.403 HD21 ' O ' ' A' ' 130' ' ' ILE . 0.3 OUTLIER -74.52 106.64 6.21 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 105.048 -2.204 . . . . 0.0 105.048 175.119 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 6.6 tp60 -56.05 -64.9 0.71 Allowed 'General case' 0 C--O 1.202 -1.399 0 C-N-CA 126.372 1.869 . . . . 0.0 109.968 177.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 8.3 ptp180 -158.3 153.59 25.75 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 -179.189 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -134.98 137.97 9.66 Favored Glycine 0 CA--C 1.463 -3.159 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 -178.308 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 66.4 m -126.33 151.95 46.88 Favored 'General case' 0 C--N 1.28 -2.419 0 C-N-CA 123.822 0.849 . . . . 0.0 109.784 -174.704 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.508 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -115.74 157.92 23.59 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -178.134 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 1.659 ' HE1' ' CE2' ' A' ' 64' ' ' TYR . 91.9 m-85 -156.02 -179.45 8.15 Favored 'General case' 0 C--O 1.237 0.415 0 C-N-CA 124.328 1.051 . . . . 0.0 109.042 -177.412 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.25 -148.41 29.27 Favored Glycine 0 C--N 1.33 0.205 0 O-C-N 123.566 0.541 . . . . 0.0 113.533 178.68 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.41 -10.91 71.15 Favored Glycine 0 C--O 1.206 -1.598 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.754 178.101 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.51 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 97.0 t -69.05 -40.68 81.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 C-N-CA 123.9 0.88 . . . . 0.0 111.483 -177.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.508 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -84.2 -20.5 32.24 Favored 'General case' 0 N--CA 1.433 -1.289 0 C-N-CA 118.759 -1.176 . . . . 0.0 112.14 179.09 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 31.7 t -98.37 -60.2 1.6 Allowed 'General case' 0 N--CA 1.442 -0.838 0 CA-C-N 115.932 -0.576 . . . . 0.0 112.004 -174.466 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.467 ' O ' HG23 ' A' ' 112' ' ' VAL . 48.6 m-20 -85.77 -25.74 26.2 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.427 -172.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 0.537 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 91.6 m-85 -106.56 158.83 16.63 Favored 'General case' 0 N--CA 1.42 -1.956 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.03 177.363 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.0 t -167.98 137.39 2.55 Favored 'General case' 0 N--CA 1.411 -2.411 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 176.155 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.49 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.25 -107.86 0.2 Allowed Glycine 0 N--CA 1.411 -2.978 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 175.883 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.5 p -158.71 -179.88 8.47 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 123.791 0.836 . . . . 0.0 110.871 -175.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.416 HG11 ' CE2' ' A' ' 82' ' ' TYR . 2.6 p -132.11 144.96 35.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 177.662 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.68 ' HG3' ' O ' ' A' ' 80' ' ' SER . 73.6 tttt -123.73 142.98 50.58 Favored 'General case' 0 N--CA 1.424 -1.769 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.969 -177.503 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.558 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 68.3 t80 -141.42 111.44 6.71 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 115.458 -0.792 . . . . 0.0 108.87 -177.802 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 9.3 t 52.61 34.19 15.26 Favored 'General case' 0 CA--C 1.561 1.366 0 CA-C-O 121.717 0.77 . . . . 0.0 111.071 179.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.65 10.0 63.83 Favored Glycine 0 CA--C 1.532 1.101 0 C-N-CA 120.83 -0.7 . . . . 0.0 114.169 -179.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.68 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 21.8 t -79.98 179.54 7.54 Favored 'General case' 0 CA--C 1.549 0.924 0 CA-C-N 117.446 0.623 . . . . 0.0 109.376 177.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 17.5 p -153.27 109.11 3.29 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-O 121.548 0.69 . . . . 0.0 110.049 178.322 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 0.558 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 4.2 p90 -151.08 158.33 34.77 Favored Pre-proline 0 C--N 1.302 -1.465 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 -175.123 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.77 147.41 69.13 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.95 2.433 . . . . 0.0 113.256 -175.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.581 ' CD2' HD22 ' A' ' 109' ' ' LEU . 66.6 t80 -121.23 132.84 24.11 Favored Pre-proline 0 N--CA 1.441 -0.88 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.535 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.539 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 60.6 Cg_endo -69.25 146.19 80.39 Favored 'Cis proline' 0 CA--C 1.538 0.702 0 C-N-CA 123.562 -1.432 . . . . 0.0 111.308 0.208 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.3 t -70.74 -178.07 1.75 Allowed 'General case' 0 CA--C 1.554 1.097 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.31 -177.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 10.0 p -130.51 -34.33 1.58 Allowed 'General case' 0 C--O 1.243 0.711 0 N-CA-C 114.827 1.418 . . . . 0.0 114.827 -169.132 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.1 t -118.74 -69.44 0.85 Allowed 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 119.978 -0.689 . . . . 0.0 111.021 -174.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 178.25 -179.71 0.31 Allowed 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 -178.176 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.1 p -102.54 164.49 15.56 Favored Pre-proline 0 C--N 1.284 -2.26 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -66.46 160.61 44.89 Favored 'Trans proline' 0 C--N 1.365 1.406 0 C-N-CA 122.523 2.149 . . . . 0.0 110.504 173.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 6.8 tmm_? -72.73 128.2 34.82 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-N 115.64 -0.709 . . . . 0.0 112.166 -174.074 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 90.0 t -133.26 117.95 30.21 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 115.211 -0.904 . . . . 0.0 109.514 177.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 87.4 t -94.95 137.65 22.78 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 175.899 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . 0.416 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.2 m-85 -89.62 93.97 9.68 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 175.183 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 13.3 m120 -89.13 69.21 8.32 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 178.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.8 m -143.35 148.2 35.88 Favored 'General case' 0 N--CA 1.429 -1.515 0 CA-C-N 114.539 -1.21 . . . . 0.0 109.719 -176.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -112.64 45.48 1.31 Allowed 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 121.288 0.566 . . . . 0.0 111.303 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.1 t -171.52 179.92 2.75 Favored 'General case' 0 N--CA 1.439 -1.025 0 N-CA-C 106.332 -1.729 . . . . 0.0 106.332 -177.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -75.72 135.28 40.37 Favored 'General case' 0 C--O 1.249 1.051 0 CA-C-O 121.635 0.731 . . . . 0.0 109.37 -179.28 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 62.3 mmtt -128.31 141.0 39.94 Favored Pre-proline 0 C--N 1.28 -2.415 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.623 -177.187 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.45 ' O ' ' HD3' ' A' ' 104' ' ' PRO . 32.2 Cg_endo -64.38 142.31 78.36 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 123.508 2.806 . . . . 0.0 111.276 -179.281 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 10.7 t90 -86.5 104.23 5.36 Favored Pre-proline 0 C--N 1.308 -1.228 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 -177.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.45 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 65.1 Cg_endo -75.91 88.61 1.3 Allowed 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 121.944 1.763 . . . . 0.0 113.1 -172.156 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 99.1 t -138.28 144.63 30.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.598 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.67 135.09 19.52 Favored 'General case' 0 N--CA 1.417 -2.092 0 CA-C-N 116.519 -0.309 . . . . 0.0 110.545 177.779 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.423 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 18.6 mt -99.94 103.18 14.73 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.275 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.49 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 22.1 m-85 -82.14 72.18 9.2 Favored 'General case' 0 C--N 1.296 -1.743 0 O-C-N 122.363 -0.211 . . . . 0.0 111.031 177.424 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.651 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -96.96 127.17 42.66 Favored 'General case' 0 C--O 1.207 -1.146 0 CA-C-O 120.571 0.224 . . . . 0.0 110.616 177.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -127.54 144.73 52.03 Favored Pre-proline 0 N--CA 1.417 -2.079 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.055 -175.731 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -62.32 118.19 5.07 Favored 'Trans proline' 0 C--O 1.241 0.664 0 C-N-CA 123.164 2.576 . . . . 0.0 111.684 -178.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.477 ' O ' HG11 ' A' ' 30' ' ' VAL . 3.8 m -68.34 -112.82 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.191 -2.001 0 O-C-N 124.38 1.05 . . . . 0.0 113.07 176.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 11.7 p -111.68 -46.26 3.27 Favored 'General case' 0 C--N 1.294 -1.832 0 CA-C-O 121.369 0.604 . . . . 0.0 110.904 179.667 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 11.6 t -82.45 25.69 0.61 Allowed 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 121.937 0.875 . . . . 0.0 111.021 -175.077 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -96.38 131.1 43.28 Favored 'General case' 0 N--CA 1.414 -2.265 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.29 129.54 1.7 Allowed Glycine 0 N--CA 1.436 -1.321 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.072 -178.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.5 -149.78 51.05 Favored Glycine 0 N--CA 1.434 -1.451 0 CA-C-O 119.376 -0.68 . . . . 0.0 111.93 -178.187 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.424 ' CG1' ' HE3' ' A' ' 121' ' ' LYS . 76.9 t -58.14 99.87 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 121.728 0.775 . . . . 0.0 111.088 -177.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.07 -37.76 9.61 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 114.878 -1.056 . . . . 0.0 110.577 -178.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.421 ' HB ' HG21 ' A' ' 154' ' ' VAL . 72.9 mt -118.02 139.04 46.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 178.686 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.455 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.0 mmpt? -115.17 141.82 47.5 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 122.823 0.449 . . . . 0.0 110.375 176.375 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.0 132.63 46.21 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.423 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 87.28 -1.23 86.15 Favored Glycine 0 N--CA 1.431 -1.695 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.779 -178.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 32.1 t -90.92 140.78 29.5 Favored 'General case' 0 N--CA 1.42 -1.972 0 N-CA-C 108.577 -0.898 . . . . 0.0 108.577 178.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -68.83 126.63 30.37 Favored 'General case' 0 N--CA 1.427 -1.61 0 N-CA-C 106.411 -1.699 . . . . 0.0 106.411 175.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.488 ' HB ' HG23 ' A' ' 67' ' ' VAL . 29.6 pt -113.67 -27.15 2.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -178.562 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.28 167.96 24.95 Favored 'General case' 0 N--CA 1.443 -0.825 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 -177.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 64.4 t -142.33 113.54 3.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 179.429 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 37.3 mt -118.04 143.49 46.38 Favored 'General case' 0 C--N 1.288 -2.094 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 179.704 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.403 ' O ' HD21 ' A' ' 58' ' ' LEU . 4.9 mp -123.39 128.43 74.74 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.133 0 C-N-CA 119.709 -0.796 . . . . 0.0 109.411 178.811 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.422 HD12 ' HG2' ' A' ' 133' ' ' GLN . 1.1 pp -94.34 147.25 23.4 Favored 'General case' 0 CA--C 1.472 -2.05 0 N-CA-C 105.614 -1.995 . . . . 0.0 105.614 172.369 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 59.7 ttt180 -116.57 132.72 56.61 Favored 'General case' 0 N--CA 1.386 -3.635 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 173.435 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.66 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 17.0 mm-40 -90.38 148.06 23.06 Favored 'General case' 0 N--CA 1.402 -2.863 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.706 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.42 ' HB ' ' CE2' ' A' ' 55' ' ' TYR . 27.6 m -154.58 138.14 15.99 Favored 'General case' 0 C--N 1.276 -2.622 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 169.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.591 ' CB ' HG21 ' A' ' 52' ' ' ILE . 6.1 p30 -145.18 172.14 13.54 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 119.585 -0.846 . . . . 0.0 111.332 175.171 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -85.91 -12.65 50.04 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 114.174 -1.375 . . . . 0.0 112.747 -168.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 70.8 t80 -113.57 -69.65 0.85 Allowed 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 112.03 0.382 . . . . 0.0 112.03 -171.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . 0.474 ' C ' ' H ' ' A' ' 140' ' ' ASP . 11.8 m120 -81.47 161.79 23.52 Favored 'General case' 0 CA--C 1.489 -1.366 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.035 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 23.2 t -87.03 41.11 0.95 Allowed 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 107.686 -1.227 . . . . 0.0 107.686 175.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . 0.545 ' HB3' ' ND2' ' A' ' 135' ' ' ASN . 12.6 t0 -81.21 70.63 8.1 Favored 'General case' 0 N--CA 1.436 -1.146 0 CA-C-N 114.346 -1.297 . . . . 0.0 107.598 176.157 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . 0.66 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 7.4 p-10 -119.11 35.78 4.7 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 113.411 -1.722 . . . . 0.0 108.088 177.497 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -90.1 176.41 6.79 Favored 'General case' 0 N--CA 1.434 -1.275 0 CA-C-N 113.32 -1.764 . . . . 0.0 107.869 -178.604 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -134.47 146.54 49.86 Favored 'General case' 0 N--CA 1.42 -1.962 0 C-N-CA 118.571 -1.252 . . . . 0.0 111.93 -176.331 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 1.647 ' HD1' ' CD2' ' A' ' 144' ' ' PHE . 10.8 m-30 -111.3 126.95 55.44 Favored 'General case' 0 C--N 1.31 -1.13 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -177.263 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.0 t -91.68 132.29 36.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -178.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 55.4 m95 -118.29 101.53 8.27 Favored 'General case' 0 C--N 1.282 -2.334 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 42.5 m-80 -80.88 112.98 18.77 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 178.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 23.7 mm -87.19 122.16 38.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 -177.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -116.51 153.78 31.55 Favored 'General case' 0 C--N 1.293 -1.882 0 C-N-CA 123.242 0.617 . . . . 0.0 109.525 178.208 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.76 130.3 35.11 Favored 'General case' 0 N--CA 1.412 -2.364 0 CA-C-N 115.197 -0.91 . . . . 0.0 108.741 176.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -85.82 -20.69 28.79 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -178.16 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -149.86 147.32 27.81 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 114.21 -1.359 . . . . 0.0 109.269 -173.448 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 16.8 p-10 -89.83 136.73 32.87 Favored 'General case' 0 C--N 1.31 -1.112 0 O-C-N 123.948 0.78 . . . . 0.0 111.119 -177.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.425 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 2.0 m -115.65 150.99 17.46 Favored 'Isoleucine or valine' 0 C--O 1.252 1.222 0 CA-C-O 121.053 0.454 . . . . 0.0 111.434 -174.489 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.8 t -122.32 139.42 49.31 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.016 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.208 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.443 HG11 ' O ' ' A' ' 28' ' ' VAL . 75.7 t -100.8 99.4 10.2 Favored Pre-proline 0 C--N 1.293 -1.85 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -68.06 -28.47 34.88 Favored 'Trans proline' 0 C--O 1.24 0.591 0 C-N-CA 122.269 1.979 . . . . 0.0 111.954 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.4 t . . . . . 0 C--O 1.249 1.06 0 O-C-N 125.091 1.495 . . . . 0.0 113.799 178.488 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.414 ' HA ' ' HA ' ' A' ' 46' ' ' ASN . 43.4 t80 . . . . . 0 CA--C 1.49 -1.336 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.403 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . -135.67 -174.4 3.64 Favored 'General case' 0 C--N 1.284 -2.28 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.515 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.419 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 10.4 t -154.71 157.63 38.35 Favored 'General case' 0 C--N 1.299 -1.626 0 C-N-CA 119.423 -0.911 . . . . 0.0 109.719 -176.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.36 163.76 33.57 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.558 -175.174 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.498 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 76.2 p -102.02 176.7 5.11 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.591 0.71 . . . . 0.0 110.859 -178.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.88 -1.09 46.51 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.453 -1.249 . . . . 0.0 111.091 179.143 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.498 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 8.5 p30 -100.08 -25.58 14.25 Favored 'General case' 0 N--CA 1.446 -0.67 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.685 174.707 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 128.19 5.22 5.24 Favored Glycine 0 CA--C 1.507 -0.461 0 C-N-CA 119.838 -1.173 . . . . 0.0 113.22 175.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.0 m -81.33 99.63 8.76 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.58 122.42 34.98 Favored 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 115.45 -0.795 . . . . 0.0 108.925 176.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.403 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 66.3 mt -95.13 115.89 65.83 Favored Pre-proline 0 C--N 1.293 -1.88 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 178.018 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.8 163.78 37.79 Favored 'Trans proline' 0 C--O 1.25 1.099 0 C-N-CA 122.156 1.904 . . . . 0.0 110.294 177.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 23.5 mt -67.48 126.18 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.101 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.65 -14.83 1.4 Allowed Glycine 0 C--N 1.297 -1.592 0 C-N-CA 120.491 -0.861 . . . . 0.0 111.62 -175.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 95.17 134.5 7.71 Favored Glycine 0 C--N 1.31 -0.883 0 C-N-CA 120.376 -0.916 . . . . 0.0 111.459 -179.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -178.76 -166.97 35.71 Favored Glycine 0 C--N 1.299 -1.501 0 N-CA-C 109.916 -1.273 . . . . 0.0 109.916 -178.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.432 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 60.0 p -140.23 150.53 44.23 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 117.457 0.629 . . . . 0.0 110.261 -179.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -134.17 161.53 34.64 Favored 'General case' 0 N--CA 1.422 -1.831 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 177.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 19.8 m-80 -116.5 111.13 19.53 Favored 'General case' 0 C--N 1.284 -2.248 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 178.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.406 HG23 ' HA ' ' A' ' 148' ' ' ILE . 1.1 m -92.63 149.71 4.1 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.462 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 -178.611 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 55.5 m-85 -132.04 113.71 13.7 Favored 'General case' 0 CA--C 1.492 -1.277 0 O-C-N 122.089 -0.382 . . . . 0.0 110.485 -176.665 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.456 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.5 p -120.93 132.84 69.41 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 CA-C-O 121.451 0.643 . . . . 0.0 111.423 -174.583 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 30.6 m-80 -88.17 123.24 32.62 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 50.0 mt -108.69 159.24 16.9 Favored 'General case' 0 C--N 1.276 -2.61 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 179.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.0 120.57 43.78 Favored Pre-proline 0 C--N 1.3 -1.552 0 O-C-N 124.37 1.044 . . . . 0.0 109.523 179.323 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.493 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 66.6 Cg_endo -74.09 -2.93 12.98 Favored 'Trans proline' 0 CA--C 1.531 0.369 0 C-N-CA 122.758 2.305 . . . . 0.0 113.503 -175.647 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.439 HG11 ' HG3' ' A' ' 157' ' ' PRO . 99.4 t -128.2 109.75 20.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.391 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.45 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 12.5 t -147.1 107.48 0.63 Allowed 'Isoleucine or valine' 0 C--O 1.19 -2.068 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -176.472 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.576 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -95.48 156.96 16.11 Favored 'General case' 0 C--N 1.271 -2.819 0 C-N-CA 122.863 0.465 . . . . 0.0 112.12 -179.911 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.441 HG11 ' O ' ' A' ' 112' ' ' VAL . 41.2 t -44.12 115.25 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.674 0 C-N-CA 124.296 1.038 . . . . 0.0 112.07 175.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.19 1.39 51.19 Favored Glycine 0 C--N 1.316 -0.536 0 CA-C-N 115.386 -0.825 . . . . 0.0 113.233 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.576 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -74.1 -176.32 2.52 Favored 'General case' 0 C--N 1.315 -0.916 0 C-N-CA 124.164 0.986 . . . . 0.0 111.005 176.408 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -130.78 93.07 3.34 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 177.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.622 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 19.8 tp -93.41 141.88 27.96 Favored 'General case' 0 C--N 1.29 -1.982 0 C-N-CA 119.348 -0.941 . . . . 0.0 109.545 178.34 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.3 t -135.77 128.3 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.978 0 N-CA-C 109.433 -0.581 . . . . 0.0 109.433 -176.111 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.596 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 56.3 t -97.59 88.87 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.405 -2.721 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 174.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -83.36 115.89 22.22 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 120.822 0.344 . . . . 0.0 110.639 -178.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 80.5 mt -97.27 4.19 51.02 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.369 -179.143 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 33.3 t -77.28 -0.17 24.4 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 122.371 1.081 . . . . 0.0 109.115 -178.397 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.1 p -128.07 3.68 5.87 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 114.977 -1.01 . . . . 0.0 110.13 179.129 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.456 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 54.2 mm-40 -122.34 -22.22 5.59 Favored 'General case' 0 CA--C 1.503 -0.858 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.282 -172.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 24.3 mt -136.79 135.64 48.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.032 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 -175.261 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.639 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 61.3 m-85 -138.53 125.26 20.92 Favored 'General case' 0 CA--C 1.501 -0.919 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 -175.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.419 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 73.7 m -108.2 143.33 37.14 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 30.7 p80 -134.23 156.53 48.22 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-O 120.914 0.388 . . . . 0.0 110.589 -175.536 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.678 ' ND2' ' HA ' ' A' ' 49' ' ' PRO . 56.4 t30 -113.74 100.4 8.44 Favored 'General case' 0 N--CA 1.421 -1.916 0 CA-C-O 122.734 1.254 . . . . 0.0 110.772 176.604 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -60.75 -32.21 71.51 Favored 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 127.021 2.128 . . . . 0.0 112.728 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -130.46 77.2 76.39 Favored Pre-proline 0 C--N 1.318 -0.803 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.678 ' HA ' ' ND2' ' A' ' 46' ' ' ASN . 64.7 Cg_endo -68.42 -4.69 13.41 Favored 'Trans proline' 0 N--CA 1.484 0.93 0 C-N-CA 123.529 2.819 . . . . 0.0 115.95 -169.846 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -118.92 -15.72 9.31 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 121.596 0.713 . . . . 0.0 109.944 178.77 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.411 ' HB ' HD13 ' A' ' 52' ' ' ILE . 2.0 m -96.84 -30.64 13.04 Favored 'General case' 0 N--CA 1.408 -2.573 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -175.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.646 HG21 ' CB ' ' A' ' 135' ' ' ASN . 3.4 mp -132.65 140.47 47.43 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.244 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 179.063 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.8 t -87.83 150.66 23.4 Favored 'General case' 0 C--O 1.254 1.302 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 177.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.445 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 0.9 OUTLIER -79.97 107.91 13.13 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 -178.598 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 76.5 t80 -143.69 144.04 31.69 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -176.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.458 HG11 ' OH ' ' A' ' 77' ' ' TYR . 6.2 p -152.08 150.33 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.179 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 177.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -151.2 133.11 15.07 Favored 'General case' 0 C--O 1.208 -1.079 0 CA-C-O 119.455 -0.307 . . . . 0.0 110.296 175.193 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.505 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 47.9 tp -76.56 106.48 8.23 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 121.132 0.491 . . . . 0.0 109.861 176.617 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.7 tp-100 -53.84 -52.69 59.58 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 125.77 1.628 . . . . 0.0 111.717 177.661 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 1.1 ptp180 -166.37 157.89 13.33 Favored 'General case' 0 C--N 1.307 -1.258 0 N-CA-C 107.597 -1.261 . . . . 0.0 107.597 -179.017 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.13 115.23 0.86 Allowed Glycine 0 N--CA 1.399 -3.814 0 N-CA-C 108.992 -1.643 . . . . 0.0 108.992 -178.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 67.2 m -110.26 147.17 34.35 Favored 'General case' 0 C--N 1.28 -2.423 0 C-N-CA 124.471 1.108 . . . . 0.0 110.338 -171.13 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.536 ' HB3' ' CE2' ' A' ' 84' ' ' PHE . . . -108.83 157.8 18.26 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.487 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 86.9 m-85 -157.01 -179.35 8.12 Favored 'General case' 0 C--O 1.237 0.403 0 C-N-CA 124.21 1.004 . . . . 0.0 108.683 -178.532 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 60.2 -140.68 47.96 Favored Glycine 0 CA--C 1.5 -0.899 0 O-C-N 123.915 0.759 . . . . 0.0 112.851 176.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.09 -12.54 84.54 Favored Glycine 0 N--CA 1.431 -1.669 0 C-N-CA 120.54 -0.838 . . . . 0.0 111.375 177.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.487 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 82.4 t -68.45 -39.45 80.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 C-N-CA 123.522 0.729 . . . . 0.0 111.927 -176.293 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.514 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -87.54 -16.23 35.21 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 118.981 -1.088 . . . . 0.0 112.272 178.897 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 8.0 t -101.06 -58.05 1.97 Allowed 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.329 0.585 . . . . 0.0 111.399 -174.704 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.484 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 47.6 m-20 -87.09 -25.31 24.21 Favored 'General case' 0 CA--C 1.492 -1.283 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.133 -174.673 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 1.622 ' HD2' ' CD1' ' A' ' 71' ' ' PHE . 83.7 m-85 -108.24 158.19 17.68 Favored 'General case' 0 N--CA 1.415 -2.223 0 C-N-CA 120.03 -0.668 . . . . 0.0 110.352 179.342 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.6 t -164.91 135.76 4.02 Favored 'General case' 0 N--CA 1.409 -2.522 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 176.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.43 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.31 -109.12 0.22 Allowed Glycine 0 N--CA 1.406 -3.356 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 174.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.429 HG23 ' HA ' ' A' ' 83' ' ' PRO . 1.3 p -159.72 179.33 8.95 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 123.695 0.798 . . . . 0.0 110.827 -174.198 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.5 p -132.55 145.47 34.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 178.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.628 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.2 tttt -124.08 144.87 49.62 Favored 'General case' 0 N--CA 1.417 -2.084 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.471 -179.4 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.458 ' OH ' HG11 ' A' ' 56' ' ' VAL . 59.2 t80 -146.33 114.71 6.7 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -178.638 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.0 m 54.05 36.68 25.2 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 113.974 1.101 . . . . 0.0 113.974 177.431 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.16 12.19 81.23 Favored Glycine 0 C--N 1.309 -0.917 0 C-N-CA 119.579 -1.296 . . . . 0.0 112.587 -178.593 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.628 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 7.9 t -83.8 178.87 7.74 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 176.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 48.8 p -154.74 111.04 3.23 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 -178.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 1.622 ' HD2' ' CD1' ' A' ' 82' ' ' TYR . 3.4 p90 -154.73 158.86 32.26 Favored Pre-proline 0 C--N 1.305 -1.331 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 -175.315 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.429 ' HA ' HG23 ' A' ' 74' ' ' THR . 73.0 Cg_endo -71.31 147.91 54.07 Favored 'Trans proline' 0 C--N 1.355 0.904 0 C-N-CA 123.089 2.526 . . . . 0.0 113.259 -176.594 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 1.664 ' HE1' ' CE2' ' A' ' 84' ' ' PHE . 48.3 t80 -119.35 135.63 24.1 Favored Pre-proline 0 N--CA 1.433 -1.291 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.082 -178.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.515 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 57.0 Cg_endo -71.18 148.15 89.12 Favored 'Cis proline' 0 CA--C 1.538 0.678 0 C-N-CA 122.741 -1.774 . . . . 0.0 110.365 -1.532 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 7.9 t -65.64 -175.24 0.26 Allowed 'General case' 0 CA--C 1.55 0.976 0 C-N-CA 122.616 0.366 . . . . 0.0 110.288 -178.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 13.9 p -122.42 -36.45 2.94 Favored 'General case' 0 N--CA 1.432 -1.334 0 CA-C-O 121.664 0.745 . . . . 0.0 109.017 -172.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.4 t -132.49 -137.51 0.19 Allowed 'General case' 1 N--CA 1.364 -4.77 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 176.154 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 19.6 tt0 -105.67 156.99 17.73 Favored 'General case' 0 C--N 1.264 -3.12 0 C-N-CA 125.958 1.703 . . . . 0.0 109.377 -170.595 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.505 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 23.7 p -74.76 162.27 74.27 Favored Pre-proline 0 C--N 1.31 -1.14 0 C-N-CA 123.322 0.649 . . . . 0.0 111.203 178.467 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -59.05 162.7 13.12 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 122.976 2.451 . . . . 0.0 111.236 176.137 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.5 tmm_? -68.92 125.98 28.35 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -176.272 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 71.5 t -140.14 128.48 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.83 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 -177.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.44 HG21 ' O ' ' A' ' 54' ' ' ASP . 1.9 p -124.68 132.37 71.41 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.378 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.206 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . 0.496 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 3.4 m-85 -81.03 140.27 35.25 Favored 'General case' 0 C--N 1.298 -1.662 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 177.795 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -108.37 28.14 8.64 Favored 'General case' 0 C--N 1.292 -1.899 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' SER . . . . . 0.455 ' OG ' ' HB3' ' A' ' 95' ' ' TYR . 5.0 p -84.08 178.93 7.64 Favored 'General case' 0 N--CA 1.423 -1.807 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.918 -175.802 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -151.27 32.38 0.59 Allowed 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 171.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.1 t -163.62 -176.45 4.68 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 -176.484 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -76.84 134.25 39.1 Favored 'General case' 0 CA--C 1.506 -0.736 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.131 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . 0.487 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 7.8 mmpt? -137.39 152.4 73.13 Favored Pre-proline 0 C--N 1.29 -2.015 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -67.63 147.15 75.66 Favored 'Trans proline' 0 N--CA 1.443 -1.445 0 C-N-CA 122.305 2.003 . . . . 0.0 111.998 -177.733 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . 0.496 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.0 t90 -88.0 111.41 42.53 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.43 ' HD3' ' OH ' ' A' ' 95' ' ' TYR . 2.5 Cg_endo -79.47 87.6 1.53 Allowed 'Trans proline' 0 N--CA 1.443 -1.448 0 C-N-CA 121.386 1.39 . . . . 0.0 112.069 -172.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 95.9 t -140.13 142.75 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.339 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 177.488 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.596 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.58 135.62 17.65 Favored 'General case' 0 N--CA 1.421 -1.899 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 178.158 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.418 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 16.8 mt -101.89 103.38 14.05 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 1.59 ' HE2' ' CE1' ' A' ' 108' ' ' TYR . 25.7 m-85 -84.38 76.62 10.12 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 120.767 0.318 . . . . 0.0 110.24 178.477 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.622 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.2 mm? -103.33 131.04 50.72 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 177.405 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.23 147.61 66.44 Favored Pre-proline 0 N--CA 1.418 -2.029 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.528 -175.317 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.484 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 30.3 Cg_endo -62.04 121.08 8.97 Favored 'Trans proline' 0 C--O 1.25 1.083 0 C-N-CA 123.068 2.512 . . . . 0.0 111.841 -178.188 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.475 HG23 ' O ' ' A' ' 70' ' ' ASN . 4.2 m -69.89 -120.52 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.186 -2.242 0 CA-C-N 114.026 -1.443 . . . . 0.0 111.218 175.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 23.0 t -111.06 -35.82 5.81 Favored 'General case' 0 C--N 1.291 -1.94 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 175.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 27.6 t -82.06 36.8 0.47 Allowed 'General case' 0 N--CA 1.441 -0.919 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.919 -176.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -117.02 133.47 55.96 Favored 'General case' 0 N--CA 1.418 -2.043 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 177.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -172.95 129.55 1.72 Allowed Glycine 0 N--CA 1.437 -1.24 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.21 -146.06 48.46 Favored Glycine 0 CA--C 1.491 -1.454 0 CA-C-O 119.143 -0.809 . . . . 0.0 111.781 -177.396 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.2 p -58.05 101.27 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-O 122.598 1.19 . . . . 0.0 112.157 -177.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -102.03 -23.09 14.14 Favored 'General case' 0 C--N 1.294 -1.827 0 CA-C-N 114.674 -1.148 . . . . 0.0 111.001 -178.484 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.47 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 65.3 mt -136.56 137.14 48.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.329 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.492 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.1 mmpt? -113.3 137.58 51.28 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-O 120.864 0.364 . . . . 0.0 110.664 176.657 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.94 134.82 48.79 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.749 -0.66 . . . . 0.0 109.833 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 85.17 6.96 83.91 Favored Glycine 0 C--N 1.303 -1.273 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.768 -178.808 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 49.4 m -109.44 144.58 37.48 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 177.518 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -70.38 126.57 30.02 Favored 'General case' 0 N--CA 1.443 -0.783 0 CA-C-N 115.045 -0.98 . . . . 0.0 108.58 -178.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.475 ' HB ' HG23 ' A' ' 67' ' ' VAL . 34.4 pt -113.0 -26.05 3.21 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 N-CA-C 112.469 0.544 . . . . 0.0 112.469 -179.39 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -160.82 165.29 30.51 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 -178.07 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 63.7 t -140.63 112.88 4.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 179.062 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 50.9 mt -117.1 143.99 45.17 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.408 ' O ' HD13 ' A' ' 58' ' ' LEU . 5.0 mp -128.9 123.77 59.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.054 0 C-N-CA 119.616 -0.834 . . . . 0.0 109.946 179.206 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.45 ' C ' HD13 ' A' ' 131' ' ' LEU . 1.4 pp -88.72 147.03 24.7 Favored 'General case' 0 CA--C 1.477 -1.855 0 N-CA-C 106.304 -1.739 . . . . 0.0 106.304 174.512 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 37.3 ttp180 -112.42 123.41 50.22 Favored 'General case' 0 C--N 1.258 -3.39 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 173.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.28 135.88 33.65 Favored 'General case' 0 N--CA 1.408 -2.53 0 N-CA-C 105.625 -1.991 . . . . 0.0 105.625 -176.407 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 35.2 m -147.29 147.22 30.16 Favored 'General case' 0 C--N 1.269 -2.919 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 175.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.646 ' CB ' HG21 ' A' ' 52' ' ' ILE . 11.5 p30 -143.61 173.0 12.04 Favored 'General case' 0 N--CA 1.438 -1.036 0 C-N-CA 119.708 -0.797 . . . . 0.0 110.983 178.453 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -87.11 -4.61 59.15 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 114.705 -1.134 . . . . 0.0 112.097 -170.27 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -116.79 -69.05 0.88 Allowed 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 112.621 0.6 . . . . 0.0 112.621 -172.32 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 57.7 m-20 -94.9 158.75 15.35 Favored 'General case' 0 CA--C 1.479 -1.763 0 CA-C-O 121.146 0.498 . . . . 0.0 111.19 -177.193 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 9.5 t -93.27 49.15 1.37 Allowed 'General case' 0 N--CA 1.416 -2.157 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 173.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -92.35 36.35 1.0 Allowed 'General case' 0 CA--C 1.506 -0.722 0 CA-C-N 114.844 -1.071 . . . . 0.0 108.406 173.407 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 5.6 p-10 -80.87 69.64 7.48 Favored 'General case' 0 N--CA 1.433 -1.294 0 CA-C-N 114.294 -1.321 . . . . 0.0 111.25 -178.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . 1.645 ' HE1' ' CE2' ' A' ' 142' ' ' PHE . 61.6 m-85 -105.7 172.73 6.64 Favored 'General case' 0 N--CA 1.426 -1.642 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 178.129 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -123.8 146.61 48.22 Favored 'General case' 0 C--N 1.286 -2.162 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.042 -177.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 9.8 m-30 -113.01 125.88 54.9 Favored 'General case' 0 C--N 1.309 -1.156 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 -176.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . 0.432 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 58.3 t -89.27 134.31 28.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 O-C-N 123.553 0.533 . . . . 0.0 110.409 -177.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 58.9 m95 -120.26 97.03 5.39 Favored 'General case' 0 C--N 1.284 -2.246 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 -78.34 113.1 16.01 Favored 'General case' 0 C--N 1.283 -2.318 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 177.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . 0.406 ' HA ' HG23 ' A' ' 20' ' ' VAL . 22.8 mm -88.74 122.17 39.81 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -177.183 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 1.625 ' HD2' ' CD1' ' A' ' 149' ' ' TYR . 47.4 m-85 -118.11 153.04 34.43 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.509 0.671 . . . . 0.0 109.809 178.061 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -78.98 128.89 33.85 Favored 'General case' 0 N--CA 1.409 -2.517 0 CA-C-N 114.609 -1.178 . . . . 0.0 108.159 175.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -88.71 -15.5 34.66 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -178.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -151.01 145.39 25.5 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 113.578 -1.646 . . . . 0.0 109.641 -175.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -79.92 144.63 33.2 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 124.019 0.928 . . . . 0.0 110.753 -178.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.493 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 71.2 t -121.54 134.62 64.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.11 -176.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.5 t -118.58 134.43 62.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 -179.447 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.45 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 75.5 t -97.46 101.68 10.82 Favored Pre-proline 0 C--N 1.292 -1.934 0 C-N-CA 123.889 0.876 . . . . 0.0 108.778 177.633 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.439 ' HG3' HG11 ' A' ' 27' ' ' VAL . 35.8 Cg_endo -67.22 -28.38 40.33 Favored 'Trans proline' 0 CA--C 1.511 -0.643 0 C-N-CA 121.893 1.729 . . . . 0.0 112.018 -178.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 8.0 t . . . . . 0 CA--C 1.559 1.298 0 O-C-N 124.827 1.329 . . . . 0.0 112.831 176.87 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.541 ' CD2' ' HB3' ' A' ' 44' ' ' CYS . 44.4 p90 . . . . . 0 CA--C 1.501 -0.933 0 N-CA-C 110.681 -0.118 . . . . 0.0 110.681 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -124.6 173.63 8.38 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 175.379 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.414 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 74.1 m -134.17 161.94 33.52 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 119.747 -0.781 . . . . 0.0 112.211 -173.703 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -146.78 161.67 40.16 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.215 -176.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.439 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 72.7 p -99.48 179.56 4.52 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 121.225 0.536 . . . . 0.0 111.557 -178.716 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.58 -26.62 50.92 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.862 177.14 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.439 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 5.6 p30 -79.4 -31.33 42.73 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 119.433 -0.907 . . . . 0.0 109.414 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 129.08 20.42 1.45 Allowed Glycine 0 N--CA 1.431 -1.687 0 C-N-CA 119.911 -1.138 . . . . 0.0 112.933 173.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.6 m -87.98 99.31 12.06 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.06 121.32 32.76 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 115.795 -0.638 . . . . 0.0 109.539 177.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 63.5 mt -99.82 116.67 64.54 Favored Pre-proline 0 C--N 1.29 -1.99 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 177.293 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -77.39 168.57 22.66 Favored 'Trans proline' 0 C--O 1.251 1.151 0 C-N-CA 122.45 2.1 . . . . 0.0 110.912 177.704 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 64.9 mt -66.56 124.91 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 145.04 -5.0 1.42 Allowed Glycine 0 C--N 1.303 -1.304 0 CA-C-N 115.723 -0.671 . . . . 0.0 111.636 -176.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 94.37 161.17 34.75 Favored Glycine 0 N--CA 1.439 -1.145 0 N-CA-C 110.122 -1.191 . . . . 0.0 110.122 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 159.38 -167.01 34.96 Favored Glycine 0 CA--C 1.486 -1.758 0 C-N-CA 119.484 -1.341 . . . . 0.0 111.342 179.044 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 49.9 p -147.08 152.37 38.41 Favored 'General case' 0 N--CA 1.424 -1.761 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -178.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -138.39 163.41 31.95 Favored 'General case' 0 N--CA 1.417 -2.082 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.013 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -108.42 118.14 35.99 Favored 'General case' 0 N--CA 1.406 -2.662 0 CA-C-N 114.342 -1.299 . . . . 0.0 107.964 176.457 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 49.3 t -104.96 130.5 55.95 Favored 'Isoleucine or valine' 0 C--N 1.264 -3.113 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.142 178.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 1.625 ' HD1' ' CD2' ' A' ' 21' ' ' TYR . 45.7 m-85 -118.75 128.09 54.17 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -179.352 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.473 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -138.01 137.26 44.75 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 O-C-N 124.128 0.893 . . . . 0.0 110.932 -176.545 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 37.3 m-80 -90.28 139.63 30.47 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 178.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.463 HD23 HG21 ' A' ' 36' ' ' VAL . 5.1 mp -122.72 161.95 22.93 Favored 'General case' 0 C--N 1.282 -2.367 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.183 176.852 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.03 120.85 54.26 Favored Pre-proline 0 C--N 1.316 -0.863 0 O-C-N 124.653 1.221 . . . . 0.0 109.404 178.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.434 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 73.5 Cg_endo -75.68 3.75 5.68 Favored 'Trans proline' 0 CA--C 1.532 0.392 0 C-N-CA 122.846 2.364 . . . . 0.0 113.398 -176.154 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.4 t -132.0 109.79 15.84 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 178.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.502 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.1 t -141.85 107.7 1.78 Allowed 'Isoleucine or valine' 0 C--O 1.182 -2.448 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -176.639 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.662 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -96.4 150.36 20.67 Favored 'General case' 0 C--N 1.269 -2.895 0 O-C-N 122.036 -0.415 . . . . 0.0 111.303 -179.864 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.431 HG11 ' O ' ' A' ' 112' ' ' VAL . 35.0 t -45.81 117.44 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 123.445 0.698 . . . . 0.0 111.976 176.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.62 1.61 53.01 Favored Glycine 0 CA--C 1.523 0.576 0 CA-C-N 115.414 -0.812 . . . . 0.0 112.829 -178.644 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.662 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.1 OUTLIER -73.02 -178.0 2.64 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 123.891 0.876 . . . . 0.0 110.034 177.639 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -130.22 86.82 2.44 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 177.636 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.615 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 20.2 tp -89.94 145.49 25.08 Favored 'General case' 0 C--N 1.294 -1.824 0 C-N-CA 119.765 -0.774 . . . . 0.0 109.259 -179.256 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 73.7 t -137.73 134.5 45.8 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.73 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -178.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.541 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 21.0 t -99.99 89.62 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.41 -2.426 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 174.32 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -83.35 114.95 21.78 Favored 'General case' 0 C--N 1.3 -1.562 0 C-N-CA 119.91 -0.716 . . . . 0.0 111.125 -176.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 82.7 mt -99.78 -2.39 35.24 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.69 -177.397 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.6 m -73.68 -2.08 21.7 Favored 'General case' 0 C--O 1.208 -1.13 0 CA-C-O 122.222 1.011 . . . . 0.0 109.191 -179.503 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.2 p -126.21 7.48 7.17 Favored 'General case' 0 N--CA 1.419 -1.985 0 CA-C-N 115.151 -0.931 . . . . 0.0 109.776 179.002 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.473 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 48.6 mm-40 -125.42 -20.23 4.83 Favored 'General case' 0 CA--C 1.508 -0.648 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.9 -174.692 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.5 mt -135.3 137.31 50.23 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 -176.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.644 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 74.8 m-85 -137.68 153.67 49.78 Favored 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 -176.07 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.541 ' HB3' ' CD2' ' A' ' 1' ' ' PHE . 90.5 m -132.23 134.91 45.87 Favored 'General case' 0 C--N 1.28 -2.419 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.875 -178.637 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . 0.533 ' O ' ' HB2' ' A' ' 1' ' ' PHE . 18.7 p-80 -122.64 131.0 53.61 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.428 -175.486 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.426 ' HA ' ' CB ' ' A' ' 1' ' ' PHE . 4.2 p-10 -77.83 118.17 19.9 Favored 'General case' 0 N--CA 1.422 -1.83 0 CA-C-O 122.09 0.948 . . . . 0.0 108.963 178.426 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . 0.499 ' OD1' ' HA ' ' A' ' 1' ' ' PHE . 3.9 p30 -97.24 -27.1 14.68 Favored 'General case' 0 C--N 1.274 -2.696 0 CA-C-N 114.154 -1.385 . . . . 0.0 110.387 -177.022 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 1.646 ' HD1' ' CD2' ' A' ' 48' ' ' TYR . 37.5 m-85 -148.93 68.43 9.63 Favored Pre-proline 0 N--CA 1.483 1.182 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.469 ' HA ' ' OD2' ' A' ' 54' ' ' ASP . 58.4 Cg_endo -67.85 -11.72 33.01 Favored 'Trans proline' 0 N--CA 1.481 0.766 0 C-N-CA 122.925 2.417 . . . . 0.0 114.281 -171.587 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -114.58 -14.03 12.11 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 121.208 0.528 . . . . 0.0 110.565 -177.474 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.469 ' HB ' HD13 ' A' ' 52' ' ' ILE . 1.3 m -101.87 -29.24 11.96 Favored 'General case' 0 N--CA 1.424 -1.731 0 CA-C-O 122.047 0.927 . . . . 0.0 108.881 -173.28 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.469 HD13 ' HB ' ' A' ' 51' ' ' THR . 3.4 mp -128.56 141.21 47.14 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.168 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 178.403 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' THR . . . . . 0.416 ' CG2' HD21 ' A' ' 136' ' ' ASN . 14.5 t -74.52 136.35 42.18 Favored 'General case' 0 N--CA 1.428 -1.563 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 174.071 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.487 ' O ' HG21 ' A' ' 94' ' ' VAL . 51.3 m-20 -95.98 105.82 17.9 Favored 'General case' 0 C--N 1.263 -3.173 0 C-N-CA 118.457 -1.297 . . . . 0.0 108.404 -179.305 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.492 ' CD2' ' HB ' ' A' ' 134' ' ' THR . 15.8 t80 -142.21 139.44 32.02 Favored 'General case' 0 C--N 1.289 -2.052 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.482 -173.963 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.4 ' CG2' ' HG ' ' A' ' 131' ' ' LEU . 14.9 p -148.56 156.01 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.943 0 O-C-N 123.832 0.708 . . . . 0.0 109.991 -178.44 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.29 135.54 17.94 Favored 'General case' 0 N--CA 1.422 -1.845 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 176.24 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.506 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 32.5 tp -70.6 110.44 5.45 Favored 'General case' 0 N--CA 1.427 -1.579 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 170.553 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -57.6 -56.63 19.41 Favored 'General case' 0 C--O 1.206 -1.227 0 CA-C-N 113.576 -1.647 . . . . 0.0 109.479 -177.58 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 10.5 ptp180 -164.09 156.56 17.25 Favored 'General case' 0 N--CA 1.41 -2.461 0 CA-C-N 114.364 -1.289 . . . . 0.0 108.472 -177.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -140.58 135.83 7.26 Favored Glycine 0 N--CA 1.4 -3.712 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -179.535 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 46.0 m -124.81 147.68 48.59 Favored 'General case' 0 C--N 1.276 -2.591 0 C-N-CA 124.139 0.975 . . . . 0.0 110.473 -175.694 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.489 ' HB3' ' CE2' ' A' ' 84' ' ' PHE . . . -106.81 158.83 16.69 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.533 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 97.1 m-85 -154.61 175.4 13.7 Favored 'General case' 0 C--N 1.341 0.231 0 C-N-CA 124.139 0.975 . . . . 0.0 109.864 -177.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.02 -143.28 45.84 Favored Glycine 0 N--CA 1.446 -0.671 0 O-C-N 123.791 0.682 . . . . 0.0 113.104 176.486 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.36 -13.12 73.59 Favored Glycine 0 C--O 1.202 -1.868 0 C-N-CA 120.962 -0.637 . . . . 0.0 111.742 177.063 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.533 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 94.7 t -70.29 -36.75 68.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 123.414 0.686 . . . . 0.0 112.043 -177.64 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.484 ' HG ' ' CA ' ' A' ' 64' ' ' TYR . 0.2 OUTLIER -90.04 -18.54 25.76 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.58 -1.248 . . . . 0.0 112.374 177.248 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 5.0 t -99.88 -51.13 3.8 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.369 -172.134 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.421 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 67.7 m-20 -96.2 -23.18 16.84 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 -174.683 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 1.661 ' HD2' ' CD1' ' A' ' 71' ' ' PHE . 89.6 m-85 -110.73 156.3 21.24 Favored 'General case' 0 N--CA 1.422 -1.868 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 177.588 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.0 t -165.59 127.89 2.06 Favored 'General case' 0 N--CA 1.411 -2.409 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 176.513 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.29 -111.24 0.27 Allowed Glycine 0 N--CA 1.407 -3.233 0 N-CA-C 111.574 -0.61 . . . . 0.0 111.574 176.462 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -153.63 -179.91 8.23 Favored 'General case' 0 C--N 1.291 -1.941 0 C-N-CA 123.933 0.893 . . . . 0.0 110.366 -173.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 3.2 p -135.8 151.51 29.61 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.242 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.682 ' HG3' ' O ' ' A' ' 80' ' ' SER . 72.3 tttt -130.91 147.53 52.57 Favored 'General case' 0 N--CA 1.423 -1.794 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -178.676 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.406 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 47.5 t80 -148.13 108.67 4.15 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 -177.199 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 13.8 t 51.21 44.62 28.68 Favored 'General case' 0 CA--C 1.553 1.06 0 C-N-CA 123.433 0.693 . . . . 0.0 111.197 175.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 81.22 20.89 63.75 Favored Glycine 0 CA--C 1.525 0.671 0 C-N-CA 120.264 -0.97 . . . . 0.0 113.115 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.682 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 16.3 t -90.53 179.26 5.89 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 106.927 -1.508 . . . . 0.0 106.927 174.649 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 10.9 m -157.47 103.55 1.96 Allowed 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 178.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 0.406 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.6 p90 -147.65 158.75 42.59 Favored Pre-proline 0 C--N 1.308 -1.222 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -172.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -68.78 150.16 73.65 Favored 'Trans proline' 0 C--N 1.356 0.964 0 C-N-CA 122.933 2.422 . . . . 0.0 112.837 -177.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.548 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 47.3 t80 -124.5 134.77 25.83 Favored Pre-proline 0 N--CA 1.431 -1.402 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 179.293 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.548 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 59.3 Cg_endo -71.03 145.61 82.69 Favored 'Cis proline' 0 CA--C 1.554 1.51 0 C-N-CA 123.105 -1.623 . . . . 0.0 111.153 -2.438 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.2 t -68.43 -176.81 0.81 Allowed 'General case' 0 N--CA 1.489 1.52 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.32 -175.398 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 56.1 p -124.89 -47.34 1.8 Allowed 'General case' 0 N--CA 1.436 -1.164 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -172.362 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 10.0 t -105.4 -65.19 1.07 Allowed 'General case' 0 N--CA 1.437 -1.123 0 C-N-CA 120.39 -0.524 . . . . 0.0 111.246 -174.242 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 176.23 -172.98 0.09 Allowed 'General case' 0 C--O 1.247 0.97 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 -175.546 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.506 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 42.4 p -100.9 168.44 9.24 Favored Pre-proline 0 C--N 1.297 -1.708 0 O-C-N 123.429 0.455 . . . . 0.0 111.707 175.326 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . 0.415 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 19.0 Cg_endo -55.78 165.19 3.84 Favored 'Trans proline' 0 CA--C 1.547 1.158 0 C-N-CA 123.232 2.621 . . . . 0.0 111.962 171.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.414 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 1.7 tmm_? -76.68 112.75 13.58 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -176.587 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 76.4 t -126.4 128.33 71.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-O 121.522 0.677 . . . . 0.0 110.15 -176.305 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.487 HG21 ' O ' ' A' ' 54' ' ' ASP . 0.2 OUTLIER -121.71 132.32 71.08 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 CA-C-N 115.038 -0.983 . . . . 0.0 110.776 -177.571 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . 1.627 ' HE2' ' CE1' ' A' ' 95' ' ' TYR . 7.2 m-85 -80.78 101.04 9.09 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.19 -178.084 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 16.7 m120 -96.63 64.31 2.13 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.6 m -142.02 178.1 7.76 Favored 'General case' 0 N--CA 1.434 -1.229 0 O-C-N 121.778 -0.576 . . . . 0.0 110.844 -174.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 6.8 ptp180 -141.22 45.75 1.75 Allowed 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.066 0.46 . . . . 0.0 110.446 -178.678 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.0 t -170.53 177.44 4.0 Favored 'General case' 0 C--O 1.245 0.847 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 -174.824 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -73.03 98.16 2.48 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 173.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 10.0 tptp -97.1 142.59 24.76 Favored Pre-proline 0 C--N 1.277 -2.587 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -62.91 154.72 64.72 Favored 'Trans proline' 0 C--N 1.324 -0.75 0 C-N-CA 122.428 2.086 . . . . 0.0 112.395 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . 0.479 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 15.4 t90 -95.71 100.94 6.96 Favored Pre-proline 0 C--N 1.306 -1.32 0 N-CA-C 105.102 -2.184 . . . . 0.0 105.102 175.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 59.6 Cg_endo -74.57 88.63 1.16 Allowed 'Trans proline' 0 N--CA 1.454 -0.837 0 C-N-CA 121.782 1.655 . . . . 0.0 113.341 -170.052 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 96.9 t -138.61 145.12 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.193 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.541 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.65 138.47 19.92 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 177.269 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.479 ' O ' HG22 ' A' ' 36' ' ' VAL . 17.7 mt -102.82 104.3 14.56 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 1.589 ' HD1' ' CD2' ' A' ' 108' ' ' TYR . 9.5 m-85 -81.32 67.33 7.22 Favored 'General case' 0 C--N 1.295 -1.788 0 O-C-N 122.023 -0.423 . . . . 0.0 111.355 179.206 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.615 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.4 mm? -92.84 134.54 34.97 Favored 'General case' 0 C--O 1.208 -1.127 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 176.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.62 148.11 62.33 Favored Pre-proline 0 C--N 1.294 -1.829 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -176.18 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.421 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 28.8 Cg_endo -62.98 121.46 9.35 Favored 'Trans proline' 0 C--O 1.243 0.753 0 C-N-CA 123.235 2.624 . . . . 0.0 112.555 -176.726 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.431 ' O ' HG11 ' A' ' 30' ' ' VAL . 2.4 m -71.86 -116.9 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.186 -2.237 0 CA-C-N 114.225 -1.352 . . . . 0.0 112.715 176.914 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.413 ' C ' ' H ' ' A' ' 115' ' ' ALA . 28.9 t -112.54 -37.54 4.9 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 177.191 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 47.9 m -73.42 16.21 0.2 Allowed 'General case' 0 N--CA 1.399 -2.999 0 C-N-CA 125.997 1.719 . . . . 0.0 113.653 -176.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.413 ' H ' ' C ' ' A' ' 113' ' ' SER . . . -102.7 131.69 49.34 Favored 'General case' 0 N--CA 1.411 -2.399 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -176.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.94 129.33 1.62 Allowed Glycine 0 N--CA 1.434 -1.447 0 N-CA-C 110.634 -0.987 . . . . 0.0 110.634 179.377 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.89 -151.29 51.92 Favored Glycine 0 CA--C 1.5 -0.888 0 CA-C-O 119.085 -0.842 . . . . 0.0 111.53 -176.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.9 p -54.86 104.6 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 122.233 1.016 . . . . 0.0 111.914 -177.518 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.85 -31.2 9.4 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 115.043 -0.981 . . . . 0.0 111.461 -177.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 69.7 mt -124.4 140.86 46.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 177.186 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 2.8 mmpt? -117.67 139.44 51.01 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-O 121.001 0.429 . . . . 0.0 111.073 178.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.7 131.67 44.95 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.406 -0.815 . . . . 0.0 110.769 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 87.31 -7.9 78.97 Favored Glycine 0 C--N 1.309 -0.931 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.079 -179.58 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 25.3 m -90.69 148.59 22.5 Favored 'General case' 0 N--CA 1.425 -1.716 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 24.9 tp -73.76 133.0 43.22 Favored 'General case' 0 N--CA 1.436 -1.132 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.229 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.476 ' HB ' HG23 ' A' ' 67' ' ' VAL . 37.9 pt -118.42 -24.44 3.25 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 C-N-CA 120.432 -0.507 . . . . 0.0 112.352 -179.519 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . 0.437 ' HB1' ' HB ' ' A' ' 148' ' ' ILE . . . -163.3 164.33 24.92 Favored 'General case' 0 N--CA 1.439 -0.977 0 CA-C-O 120.538 0.209 . . . . 0.0 110.614 -178.633 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 53.5 t -140.74 114.36 5.36 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 178.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 54.3 mt -117.55 139.01 51.52 Favored 'General case' 0 C--N 1.287 -2.12 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.43 ' O ' HD13 ' A' ' 58' ' ' LEU . 5.0 mp -117.33 122.29 69.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 C-N-CA 119.314 -0.954 . . . . 0.0 109.918 177.372 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.496 ' O ' HD21 ' A' ' 131' ' ' LEU . 0.0 OUTLIER -90.44 132.73 35.47 Favored 'General case' 0 C--N 1.275 -2.649 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 177.439 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 17.7 tpt85 -106.85 109.54 21.47 Favored 'General case' 0 C--N 1.274 -2.709 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.149 -176.05 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -88.34 132.67 34.33 Favored 'General case' 0 CA--C 1.484 -1.574 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 175.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.492 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 11.7 m -136.41 133.57 36.83 Favored 'General case' 0 C--N 1.273 -2.724 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 177.636 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 16.3 p30 -128.59 153.96 46.7 Favored 'General case' 0 C--N 1.31 -1.141 0 CA-C-O 121.404 0.621 . . . . 0.0 111.634 -179.185 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . 0.416 HD21 ' CG2' ' A' ' 53' ' ' THR . 7.0 p30 -94.39 -21.19 19.1 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 114.763 -1.108 . . . . 0.0 110.793 -174.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 50.5 t80 -86.44 -70.66 0.59 Allowed 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.577 -172.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -89.91 177.53 6.46 Favored 'General case' 0 C--N 1.283 -2.294 0 CA-C-N 115.791 -0.641 . . . . 0.0 109.407 175.678 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 66.9 m -109.73 43.47 1.33 Allowed 'General case' 0 C--N 1.284 -2.267 0 CA-C-O 122.726 1.251 . . . . 0.0 107.628 175.359 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -102.97 46.07 0.93 Allowed 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 113.96 -1.473 . . . . 0.0 108.809 -179.491 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -87.74 83.56 7.15 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 114.605 -1.179 . . . . 0.0 109.7 -179.44 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -104.39 163.64 12.3 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.869 -179.141 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . 0.402 HE21 HG22 ' A' ' 130' ' ' ILE . 16.6 pt20 -119.92 143.72 47.82 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 178.42 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 9.6 m-30 -112.48 134.35 54.06 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -176.513 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 47.4 t -91.51 131.09 39.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 CA-C-O 121.155 0.502 . . . . 0.0 110.08 -179.096 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . 0.415 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 65.3 m95 -120.23 97.96 5.84 Favored 'General case' 0 C--N 1.284 -2.274 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -179.217 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 36.9 m-80 -80.35 114.1 19.01 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 106.992 -1.485 . . . . 0.0 106.992 178.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . 0.437 ' HB ' ' HB1' ' A' ' 127' ' ' ALA . 22.5 mm -89.3 122.53 40.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 -177.784 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 1.662 ' HD2' ' CD1' ' A' ' 149' ' ' TYR . 94.6 m-85 -120.31 152.75 37.39 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 123.428 0.691 . . . . 0.0 109.605 178.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.73 132.92 34.82 Favored 'General case' 0 N--CA 1.418 -2.03 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 177.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -90.1 -15.45 31.66 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 -178.19 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -149.27 144.52 26.56 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 114.049 -1.432 . . . . 0.0 109.431 -175.665 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -85.76 148.08 26.02 Favored 'General case' 0 C--N 1.315 -0.906 0 O-C-N 124.022 0.826 . . . . 0.0 109.292 -178.145 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.434 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 2.2 m -126.56 148.34 31.31 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 C-N-CA 120.256 -0.578 . . . . 0.0 110.557 -176.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.5 t -120.14 140.6 43.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.032 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 -179.144 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.502 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 79.4 t -101.57 101.63 18.46 Favored Pre-proline 0 C--N 1.297 -1.676 0 C-N-CA 123.871 0.868 . . . . 0.0 109.706 178.233 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -68.28 -25.85 36.17 Favored 'Trans proline' 0 CA--C 1.518 -0.304 0 C-N-CA 122.315 2.01 . . . . 0.0 112.378 178.661 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 5.8 t . . . . . 0 CA--C 1.559 1.31 0 O-C-N 124.646 1.216 . . . . 0.0 113.352 176.506 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 1.613 ' HD2' ' CD1' ' A' ' 1' ' ' PHE . 50.2 t80 . . . . . 0 CA--C 1.494 -1.203 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.502 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . -149.47 176.92 10.18 Favored 'General case' 0 C--N 1.296 -1.723 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 -179.237 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.421 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 68.4 m -142.41 159.0 43.09 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 120.274 -0.57 . . . . 0.0 110.912 -174.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.412 ' HD2' ' O ' ' A' ' 5' ' ' THR . 0.0 OUTLIER -146.12 156.87 43.74 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-O 121.14 0.495 . . . . 0.0 109.978 -177.469 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.412 ' O ' ' HD2' ' A' ' 4' ' ' LYS . 41.1 p -91.83 176.08 6.65 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.613 -179.178 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -85.23 -5.08 59.34 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 114.866 -1.061 . . . . 0.0 110.838 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.96 -34.49 8.92 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.877 -179.689 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 140.06 7.27 0.99 Allowed Glycine 0 C--N 1.316 -0.529 0 C-N-CA 118.796 -1.668 . . . . 0.0 115.236 172.289 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.7 m -87.37 102.3 14.39 Favored 'General case' 0 C--N 1.296 -1.755 0 O-C-N 121.892 -0.77 . . . . 0.0 109.039 177.164 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.57 122.12 37.98 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 115.396 -0.82 . . . . 0.0 108.84 175.404 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.502 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 63.7 mt -102.01 116.15 63.64 Favored Pre-proline 0 C--N 1.298 -1.649 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.187 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.25 173.8 12.11 Favored 'Trans proline' 0 C--O 1.247 0.954 0 C-N-CA 122.814 2.343 . . . . 0.0 111.469 178.069 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 58.8 mt -66.64 129.59 31.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 178.215 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 140.14 -6.79 2.85 Favored Glycine 0 C--N 1.303 -1.252 0 N-CA-C 111.358 -0.697 . . . . 0.0 111.358 -178.705 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 96.84 156.26 30.76 Favored Glycine 0 N--CA 1.438 -1.199 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -179.108 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 170.33 -175.46 44.25 Favored Glycine 0 N--CA 1.428 -1.886 0 C-N-CA 119.822 -1.18 . . . . 0.0 111.142 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.6 m -144.96 148.88 34.3 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 178.631 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.98 165.4 26.08 Favored 'General case' 0 CA--C 1.48 -1.727 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -114.85 110.09 19.14 Favored 'General case' 0 C--N 1.278 -2.543 0 CA-C-N 114.098 -1.41 . . . . 0.0 107.482 177.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.405 HG23 ' HA ' ' A' ' 148' ' ' ILE . 1.3 m -97.65 142.08 14.91 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.321 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.694 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.2 m-85 -124.07 124.56 42.79 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 121.039 0.447 . . . . 0.0 110.989 -178.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 2.9 p -138.43 134.85 43.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.825 -178.067 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -94.33 128.06 40.6 Favored 'General case' 0 C--N 1.294 -1.811 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.867 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -104.82 160.51 14.94 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.097 -0.956 . . . . 0.0 108.581 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.75 123.33 57.46 Favored Pre-proline 0 C--O 1.211 -0.949 0 O-C-N 124.258 0.974 . . . . 0.0 109.241 176.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.474 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 74.1 Cg_endo -76.57 -0.34 10.35 Favored 'Trans proline' 0 CA--C 1.536 0.592 0 C-N-CA 122.5 2.133 . . . . 0.0 113.567 -175.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.5 t -128.85 109.77 19.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 179.57 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 5.2 t -145.09 104.69 0.71 Allowed 'Isoleucine or valine' 0 C--O 1.198 -1.639 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -178.078 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.481 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -94.36 154.84 17.28 Favored 'General case' 0 C--N 1.275 -2.668 0 C-N-CA 123.212 0.605 . . . . 0.0 111.61 -179.902 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.401 HG11 ' O ' ' A' ' 112' ' ' VAL . 42.5 t -44.7 116.53 0.23 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.361 0 C-N-CA 124.103 0.961 . . . . 0.0 111.402 175.486 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.72 0.2 45.84 Favored Glycine 0 CA--C 1.521 0.458 0 CA-C-N 115.06 -0.973 . . . . 0.0 113.186 179.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.481 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -72.78 -177.63 2.41 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 123.779 0.831 . . . . 0.0 111.768 176.702 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -128.84 87.39 2.57 Favored 'General case' 0 CA--C 1.49 -1.337 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 177.307 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.629 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 21.6 tp -96.24 135.23 38.33 Favored 'General case' 0 N--CA 1.423 -1.824 0 C-N-CA 119.23 -0.988 . . . . 0.0 109.64 179.256 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.6 p -141.64 132.49 26.31 Favored 'Isoleucine or valine' 0 N--CA 1.387 -3.599 0 CA-C-O 122.208 1.004 . . . . 0.0 112.859 -178.077 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.608 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 41.9 t -91.74 89.7 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.661 0 CA-C-N 113.507 -1.678 . . . . 0.0 107.664 178.364 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -77.78 106.91 9.91 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 88.3 mt -93.93 -1.22 54.99 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.701 -178.495 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.621 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 0.7 OUTLIER -68.99 -10.57 58.15 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-O 122.396 1.093 . . . . 0.0 109.741 -178.638 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.6 p -121.47 5.52 10.13 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 115.083 -0.962 . . . . 0.0 110.748 179.054 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 49.2 mm-40 -120.0 -21.98 6.89 Favored 'General case' 0 CA--C 1.511 -0.555 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.614 -174.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 29.9 mt -135.06 138.95 48.12 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.011 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -178.09 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -136.96 147.87 46.6 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 -177.052 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.484 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 88.9 m -123.55 136.55 54.6 Favored 'General case' 0 C--N 1.29 -1.981 0 CA-C-O 120.864 0.364 . . . . 0.0 110.991 178.8 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 16.4 p80 -130.91 162.6 29.3 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.423 0.63 . . . . 0.0 110.46 -175.424 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -112.56 121.17 44.03 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 121.828 0.823 . . . . 0.0 111.993 177.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 22.5 p-10 -96.98 -13.32 22.41 Favored 'General case' 0 N--CA 1.427 -1.583 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.588 178.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 83.4 m-85 -147.3 69.24 11.53 Favored Pre-proline 0 C--O 1.22 -0.481 0 CA-C-N 115.503 -0.771 . . . . 0.0 108.935 175.464 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -68.52 -12.82 35.86 Favored 'Trans proline' 0 N--CA 1.483 0.895 0 C-N-CA 122.091 1.861 . . . . 0.0 112.903 -177.176 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -101.44 -25.03 14.07 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-O 121.353 0.597 . . . . 0.0 110.589 -176.513 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.488 ' HB ' HD13 ' A' ' 52' ' ' ILE . 1.3 m -102.09 -26.81 13.24 Favored 'General case' 0 N--CA 1.42 -1.97 0 CA-C-O 121.69 0.757 . . . . 0.0 109.289 -172.387 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.523 HG21 ' CB ' ' A' ' 135' ' ' ASN . 3.2 mp -129.31 127.73 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.263 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 -178.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.1 t -73.63 145.7 45.16 Favored 'General case' 0 C--O 1.256 1.399 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -85.3 107.62 17.41 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -176.629 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 1.65 ' HE2' ' CE1' ' A' ' 55' ' ' TYR . 17.3 t80 -149.35 138.83 21.61 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -177.555 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.485 HG11 ' HH ' ' A' ' 77' ' ' TYR . 13.4 p -150.64 149.97 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.564 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.25 -178.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -150.3 131.02 14.07 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 172.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.526 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 53.4 tp -66.5 110.82 3.3 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 171.858 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.454 ' NE2' ' HD3' ' A' ' 132' ' ' ARG . 3.0 tp-100 -55.48 -50.86 68.79 Favored 'General case' 0 C--N 1.314 -0.96 0 C-N-CA 126.123 1.769 . . . . 0.0 111.564 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -170.44 155.77 5.24 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -177.418 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -132.32 136.07 8.52 Favored Glycine 1 N--CA 1.395 -4.077 0 N-CA-C 107.986 -2.046 . . . . 0.0 107.986 178.413 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 47.8 m -124.17 147.91 47.64 Favored 'General case' 0 C--N 1.271 -2.809 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -176.303 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.53 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -115.46 156.09 26.28 Favored 'General case' 0 C--N 1.306 -1.315 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 -179.339 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 1.655 ' HD2' ' CD1' ' A' ' 64' ' ' TYR . 92.8 m-85 -155.13 -178.95 7.61 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 123.832 0.853 . . . . 0.0 109.045 -177.351 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 62.46 -136.75 44.87 Favored Glycine 0 C--O 1.222 -0.612 0 N-CA-C 111.723 -0.551 . . . . 0.0 111.723 179.344 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -88.38 -3.91 77.83 Favored Glycine 0 C--O 1.206 -1.607 0 C-N-CA 120.537 -0.839 . . . . 0.0 111.133 176.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.525 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 76.1 t -71.35 -36.31 60.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 C-N-CA 123.876 0.87 . . . . 0.0 111.576 -176.11 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.53 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -85.31 -25.73 27.0 Favored 'General case' 0 C--N 1.297 -1.681 0 C-N-CA 119.915 -0.714 . . . . 0.0 112.486 178.451 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 21.0 m -101.04 -52.83 3.18 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 -173.13 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.434 ' O ' HG23 ' A' ' 112' ' ' VAL . 53.9 m-20 -88.52 -28.41 20.81 Favored 'General case' 0 CA--C 1.488 -1.426 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 -175.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 1.643 ' HD1' ' CD2' ' A' ' 71' ' ' PHE . 90.2 m-85 -104.55 155.29 18.96 Favored 'General case' 0 N--CA 1.41 -2.463 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 175.465 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 15.5 t -167.03 120.34 0.98 Allowed 'General case' 0 N--CA 1.417 -2.106 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 177.013 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.458 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -154.81 -112.66 0.45 Allowed Glycine 0 N--CA 1.402 -3.63 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 175.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.415 HG23 ' HA ' ' A' ' 83' ' ' PRO . 8.3 p -151.69 -179.93 7.85 Favored 'General case' 0 C--N 1.293 -1.862 0 CA-C-O 121.157 0.503 . . . . 0.0 110.662 -173.796 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.43 ' HB ' ' HB2' ' A' ' 84' ' ' PHE . 2.5 p -132.27 146.03 33.71 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.156 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 177.868 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.643 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.1 tttt -123.92 142.85 50.77 Favored 'General case' 0 N--CA 1.409 -2.514 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 178.621 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.485 ' HH ' HG11 ' A' ' 56' ' ' VAL . 59.9 t80 -145.49 112.57 6.07 Favored 'General case' 0 C--N 1.286 -2.159 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 -179.124 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.3 m 55.28 37.37 28.79 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 113.678 0.992 . . . . 0.0 113.678 176.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.44 5.84 81.68 Favored Glycine 0 N--CA 1.432 -1.587 0 C-N-CA 120.422 -0.894 . . . . 0.0 112.58 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.643 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 11.0 t -80.34 174.59 11.45 Favored 'General case' 0 C--N 1.317 -0.844 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.532 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 9.3 p -154.13 100.43 2.32 Favored 'General case' 0 C--N 1.284 -2.257 0 CA-C-O 120.98 0.419 . . . . 0.0 110.182 -176.624 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 2.9 p90 -147.07 159.62 42.25 Favored Pre-proline 0 C--N 1.297 -1.701 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -173.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.415 ' HA ' HG23 ' A' ' 74' ' ' THR . 44.9 Cg_endo -67.53 149.1 79.76 Favored 'Trans proline' 0 C--N 1.354 0.845 0 C-N-CA 123.161 2.574 . . . . 0.0 113.228 -177.142 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.593 ' CD2' HD22 ' A' ' 109' ' ' LEU . 64.5 t80 -124.99 134.7 25.94 Favored Pre-proline 0 C--N 1.315 -0.903 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.128 -179.677 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.534 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 73.9 Cg_endo -72.85 146.39 86.73 Favored 'Cis proline' 0 C--O 1.244 0.788 0 C-N-CA 122.91 -1.704 . . . . 0.0 110.543 -1.487 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.2 t -65.54 -176.76 0.37 Allowed 'General case' 0 CA--C 1.551 0.987 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.394 -175.304 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.2 p -129.03 2.65 5.27 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-O 121.368 0.604 . . . . 0.0 110.709 -173.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.6 t -161.75 -125.03 0.02 OUTLIER 'General case' 0 N--CA 1.396 -3.146 0 N-CA-C 105.282 -2.118 . . . . 0.0 105.282 179.025 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -129.7 -170.35 2.28 Favored 'General case' 0 C--N 1.291 -1.963 0 N-CA-C 110.475 -0.194 . . . . 0.0 110.475 -176.244 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 44.1 p -95.25 166.8 14.05 Favored Pre-proline 0 C--N 1.302 -1.462 0 CA-C-N 116.18 -0.463 . . . . 0.0 112.205 178.581 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -62.29 165.09 15.76 Favored 'Trans proline' 0 CA--C 1.544 1.001 0 C-N-CA 123.02 2.48 . . . . 0.0 110.879 172.037 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.402 ' C ' ' HD2' ' A' ' 92' ' ' ARG . 4.9 tmm_? -71.3 120.7 17.25 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.163 0.506 . . . . 0.0 109.838 -178.707 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 76.0 t -128.32 119.55 50.88 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.238 -178.104 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 59.6 t -94.64 141.11 15.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 176.349 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . 0.533 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 1.3 m-85 -91.38 134.78 34.32 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 175.884 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -115.33 86.16 2.41 Favored 'General case' 0 C--N 1.276 -2.609 0 N-CA-C 106.29 -1.744 . . . . 0.0 106.29 177.616 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' SER . . . . . 0.425 ' HB3' ' CG ' ' A' ' 101' ' ' LYS . 5.0 p -142.34 154.58 44.78 Favored 'General case' 0 N--CA 1.413 -2.286 0 CA-C-N 115.161 -0.927 . . . . 0.0 112.718 -173.034 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 10.3 ptp180 -135.0 19.37 3.46 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 171.121 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.0 t -164.09 -175.4 3.99 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 105.981 -1.859 . . . . 0.0 105.981 -178.592 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -76.77 122.55 24.92 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.88 0.848 . . . . 0.0 110.666 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . 0.425 ' CG ' ' HB3' ' A' ' 97' ' ' SER . 30.6 mmtp -109.68 139.51 21.29 Favored Pre-proline 0 C--N 1.293 -1.858 0 CA-C-N 115.032 -0.985 . . . . 0.0 110.002 177.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.621 ' HB3' ' O ' ' A' ' 39' ' ' SER . 52.3 Cg_exo -55.21 144.36 71.0 Favored 'Trans proline' 0 CA--C 1.505 -0.931 0 C-N-CA 123.726 2.951 . . . . 0.0 111.722 176.447 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . 0.533 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 9.1 t90 -91.63 103.63 8.27 Favored Pre-proline 0 C--N 1.294 -1.839 0 N-CA-C 106.044 -1.836 . . . . 0.0 106.044 178.821 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -76.58 88.63 1.35 Allowed 'Trans proline' 0 N--CA 1.446 -1.281 0 C-N-CA 121.624 1.549 . . . . 0.0 111.644 -172.206 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.4 HG21 ' CD2' ' A' ' 77' ' ' TYR . 85.0 t -138.77 142.19 35.05 Favored 'Isoleucine or valine' 0 CA--C 1.485 -1.534 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 179.131 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.608 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.97 133.91 18.05 Favored 'General case' 0 N--CA 1.411 -2.404 0 CA-C-O 120.968 0.413 . . . . 0.0 110.681 179.177 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.46 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 20.0 mt -100.96 99.93 10.47 Favored 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 179.099 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 1.658 ' HD2' ' CD1' ' A' ' 108' ' ' TYR . 76.7 m-85 -80.74 78.81 7.48 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 177.523 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.629 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.3 mm? -102.96 118.99 38.04 Favored 'General case' 0 CA--C 1.49 -1.331 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 177.375 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.8 145.83 46.49 Favored Pre-proline 0 N--CA 1.407 -2.577 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.079 -175.146 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.421 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 36.7 Cg_endo -63.1 119.51 6.61 Favored 'Trans proline' 0 C--O 1.248 1.018 0 C-N-CA 123.347 2.698 . . . . 0.0 112.265 -177.331 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 70' ' ' ASN . 3.2 m -67.62 -118.09 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.182 -2.464 0 CA-C-N 114.023 -1.444 . . . . 0.0 112.59 175.72 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.4 m -112.73 -38.08 4.69 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-O 122.334 1.064 . . . . 0.0 108.141 179.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 64.4 m -82.11 31.77 0.38 Allowed 'General case' 0 N--CA 1.394 -3.271 0 CA-C-N 113.356 -1.747 . . . . 0.0 113.151 -177.692 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -108.63 139.05 43.96 Favored 'General case' 0 C--N 1.288 -2.078 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -174.83 139.04 4.64 Favored Glycine 0 N--CA 1.44 -1.068 0 C-N-CA 119.951 -1.119 . . . . 0.0 112.193 179.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 57.61 -149.7 32.3 Favored Glycine 0 CA--C 1.491 -1.453 0 O-C-N 124.783 0.931 . . . . 0.0 112.542 -178.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.407 ' CG2' ' HE3' ' A' ' 121' ' ' LYS . 7.3 p -57.3 101.7 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 CA-C-O 122.507 1.146 . . . . 0.0 111.607 -178.628 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -100.61 -27.06 13.59 Favored 'General case' 0 C--N 1.295 -1.773 0 CA-C-N 114.826 -1.079 . . . . 0.0 110.679 -177.675 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.425 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 58.7 mt -133.26 136.98 54.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 -178.866 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.446 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.4 mmpt? -112.73 142.64 45.12 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 121.028 0.442 . . . . 0.0 110.706 176.35 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.23 132.02 45.83 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.169 179.243 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 91.63 -10.42 74.72 Favored Glycine 0 N--CA 1.435 -1.405 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.584 -179.363 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 40.2 t -86.18 143.11 28.16 Favored 'General case' 0 N--CA 1.43 -1.43 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 -178.074 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -71.2 122.19 19.73 Favored 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 177.11 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.487 ' HB ' HG23 ' A' ' 67' ' ' VAL . 33.7 pt -109.24 -27.78 2.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-N 116.041 -0.527 . . . . 0.0 112.303 -178.554 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -160.3 166.78 28.86 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -177.461 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 75.7 t -141.87 113.43 3.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 179.737 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 67.5 mt -115.33 134.67 54.9 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.212 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.509 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.4 mp -117.69 128.17 74.93 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.818 0 C-N-CA 119.196 -1.002 . . . . 0.0 109.748 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.45 ' O ' HD21 ' A' ' 131' ' ' LEU . 0.2 OUTLIER -101.24 131.08 47.42 Favored 'General case' 0 C--N 1.276 -2.623 0 C-N-CA 123.989 0.916 . . . . 0.0 111.443 -176.481 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . 0.454 ' HD3' ' NE2' ' A' ' 59' ' ' GLN . 26.9 mmm180 -87.41 128.09 35.21 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 123.529 0.731 . . . . 0.0 110.826 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.467 ' HA ' ' NE2' ' A' ' 133' ' ' GLN . 13.1 mm-40 -101.36 122.24 43.37 Favored 'General case' 0 N--CA 1.412 -2.356 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 168.05 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.426 ' HB ' ' CE2' ' A' ' 55' ' ' TYR . 23.4 m -140.28 129.49 23.73 Favored 'General case' 0 C--N 1.279 -2.468 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.382 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.523 ' CB ' HG21 ' A' ' 52' ' ' ILE . 28.0 p30 -132.02 177.08 7.83 Favored 'General case' 0 C--N 1.281 -2.387 0 CA-C-O 121.221 0.534 . . . . 0.0 110.539 -175.582 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -104.43 6.36 34.91 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.788 -174.079 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 74.4 t80 -125.07 -69.68 0.78 Allowed 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 115.191 1.552 . . . . 0.0 115.191 -170.137 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . 0.423 ' HB2' HD22 ' A' ' 135' ' ' ASN . 18.0 m120 -58.97 -34.85 72.29 Favored 'General case' 0 CA--C 1.484 -1.571 0 N-CA-C 116.507 2.04 . . . . 0.0 116.507 -168.693 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 19.7 m 73.57 11.59 4.73 Favored 'General case' 0 C--N 1.324 -0.543 0 O-C-N 124.494 1.121 . . . . 0.0 109.168 -174.145 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . 0.473 ' HB3' ' CE2' ' A' ' 142' ' ' PHE . 13.9 m-20 -110.47 69.77 0.7 Allowed 'General case' 0 CA--C 1.496 -1.097 0 CA-C-N 113.686 -1.597 . . . . 0.0 107.78 178.136 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -91.41 82.59 5.39 Favored 'General case' 0 C--N 1.288 -2.096 0 CA-C-N 115.265 -0.88 . . . . 0.0 109.142 -175.648 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . 1.604 ' HD1' ' CD2' ' A' ' 142' ' ' PHE . 84.7 m-85 -90.59 -179.27 5.52 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.897 -178.38 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.3 pt20 -137.38 149.82 47.23 Favored 'General case' 0 N--CA 1.418 -2.06 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 177.253 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 10.0 m-30 -111.34 132.46 54.39 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 -176.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 50.6 t -92.82 131.69 39.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.024 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . 0.436 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.5 m95 -119.55 100.81 7.51 Favored 'General case' 0 C--N 1.277 -2.577 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 46.4 m-80 -80.69 113.86 19.18 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 178.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . 0.405 ' HA ' HG23 ' A' ' 20' ' ' VAL . 22.7 mm -87.35 122.51 39.25 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.936 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 -178.587 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 1.613 ' HE1' ' CE2' ' A' ' 149' ' ' TYR . 95.5 m-85 -118.16 148.54 42.25 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.617 178.814 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -80.49 129.52 34.57 Favored 'General case' 0 N--CA 1.409 -2.502 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 176.51 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 36.1 t-20 -87.75 -16.51 34.01 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -178.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -147.49 144.85 28.87 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 114.103 -1.408 . . . . 0.0 108.795 -174.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 21.7 p-10 -82.96 144.17 30.18 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 124.232 0.957 . . . . 0.0 111.398 -178.119 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.474 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.2 t -120.42 138.71 50.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.634 -175.191 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 4.0 t -119.58 137.92 51.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.638 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 71.9 t -102.17 103.34 29.71 Favored Pre-proline 0 C--N 1.29 -1.979 0 C-N-CA 123.479 0.711 . . . . 0.0 109.847 178.634 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.468 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 56.1 Cg_endo -71.68 -16.95 29.95 Favored 'Trans proline' 0 C--O 1.226 -0.093 0 C-N-CA 122.187 1.925 . . . . 0.0 111.781 178.039 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.254 3.9 t . . . . . 0 C--N 1.351 0.666 0 C-N-CA 125.082 1.353 . . . . 0.0 113.84 175.411 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 1.602 ' HE1' ' CE2' ' A' ' 1' ' ' PHE . 11.2 t80 . . . . . 0 CA--C 1.49 -1.349 0 N-CA-C 104.353 -2.462 . . . . 0.0 104.353 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.495 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . -163.28 164.91 24.74 Favored 'General case' 0 CA--C 1.485 -1.554 0 O-C-N 123.744 0.653 . . . . 0.0 109.279 -174.172 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.516 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 12.5 m -128.65 159.2 36.35 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 109.03 -0.729 . . . . 0.0 109.03 -176.54 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.413 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -147.56 159.57 43.6 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 120.858 0.361 . . . . 0.0 110.421 -173.961 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.651 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 71.8 p -97.31 177.26 5.61 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 121.523 0.678 . . . . 0.0 110.553 -178.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -83.03 -17.95 41.48 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 114.869 -1.06 . . . . 0.0 109.655 179.06 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.651 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 1.3 p-10 -92.26 -17.71 24.41 Favored 'General case' 0 N--CA 1.43 -1.446 0 CA-C-N 114.739 -1.119 . . . . 0.0 111.795 -177.65 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.05 29.22 2.43 Favored Glycine 0 CA--C 1.484 -1.885 0 C-N-CA 119.925 -1.131 . . . . 0.0 113.971 166.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.9 m -107.64 99.51 8.99 Favored 'General case' 0 N--CA 1.415 -2.216 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.054 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.07 116.36 28.74 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.584 177.513 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.495 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 64.0 mt -84.73 122.77 74.69 Favored Pre-proline 0 C--N 1.301 -1.528 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.712 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -75.33 170.95 19.22 Favored 'Trans proline' 0 C--O 1.246 0.886 0 C-N-CA 122.933 2.422 . . . . 0.0 111.995 -179.12 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.435 HG12 ' O ' ' A' ' 1' ' ' PHE . 34.4 mt -73.37 118.82 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.126 0.488 . . . . 0.0 111.002 -176.491 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 133.9 38.4 0.21 Allowed Glycine 0 C--N 1.301 -1.386 0 CA-C-N 115.238 -0.892 . . . . 0.0 111.334 177.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 72.02 176.3 26.71 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.542 -176.415 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.14 -177.94 28.83 Favored Glycine 0 C--N 1.296 -1.672 0 C-N-CA 120.103 -1.046 . . . . 0.0 111.219 176.624 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.445 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 52.5 p -141.03 150.31 42.84 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -139.29 165.03 28.27 Favored 'General case' 0 CA--C 1.474 -1.968 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -109.39 123.44 49.33 Favored 'General case' 0 C--N 1.262 -3.229 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 175.112 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.428 HG23 ' HA ' ' A' ' 148' ' ' ILE . 1.2 m -105.31 145.09 13.98 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.608 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.336 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -124.75 112.74 17.07 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-O 121.286 0.565 . . . . 0.0 110.764 -178.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.458 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -119.36 132.31 69.53 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.194 0 CA-C-N 115.126 -0.943 . . . . 0.0 111.627 -174.783 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -92.31 127.16 37.69 Favored 'General case' 0 C--N 1.288 -2.075 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.08 178.284 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -110.51 160.53 16.55 Favored 'General case' 0 C--N 1.288 -2.073 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.145 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -61.0 122.91 72.76 Favored Pre-proline 0 C--N 1.317 -0.808 0 O-C-N 124.107 0.879 . . . . 0.0 109.125 176.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.466 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 74.3 Cg_endo -74.65 4.31 4.67 Favored 'Trans proline' 0 C--O 1.237 0.462 0 C-N-CA 122.785 2.323 . . . . 0.0 113.088 -177.468 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.6 t -128.08 112.29 26.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 107.097 -1.445 . . . . 0.0 107.097 178.555 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.8 t -145.43 101.31 0.56 Allowed 'Isoleucine or valine' 0 C--O 1.181 -2.549 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 -178.219 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.442 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.7 OUTLIER -92.38 150.55 20.75 Favored 'General case' 0 C--N 1.267 -2.987 0 O-C-N 122.16 -0.338 . . . . 0.0 111.214 179.416 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.497 HG23 ' O ' ' A' ' 112' ' ' VAL . 46.8 t -44.72 119.14 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 123.63 0.772 . . . . 0.0 111.363 175.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.12 2.5 54.61 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.482 -0.781 . . . . 0.0 112.743 -179.264 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.442 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -73.83 -178.07 3.07 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 123.076 0.55 . . . . 0.0 111.448 175.331 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -132.91 91.48 2.9 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 176.46 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.658 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.7 tp -92.26 146.44 23.71 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -179.177 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 48.5 t -133.2 129.92 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.838 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 -178.183 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.566 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 51.6 t -99.93 88.82 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.41 -2.446 0 N-CA-C 105.642 -1.984 . . . . 0.0 105.642 172.499 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -85.25 117.49 24.22 Favored 'General case' 0 CA--C 1.484 -1.561 0 C-N-CA 119.949 -0.7 . . . . 0.0 110.382 -176.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 82.4 mt -98.88 -1.84 39.15 Favored 'General case' 0 C--N 1.296 -1.744 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.365 -177.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.463 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 1.3 m -75.64 0.31 18.01 Favored 'General case' 0 CA--C 1.549 0.93 0 CA-C-O 122.394 1.093 . . . . 0.0 108.959 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.0 p -127.33 6.53 6.38 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 114.718 -1.128 . . . . 0.0 110.229 177.164 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.458 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 46.6 mm-40 -125.28 -22.46 4.36 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-O 121.082 0.467 . . . . 0.0 110.649 -175.161 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 36.6 mt -135.07 141.29 43.31 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 108.188 -1.042 . . . . 0.0 108.188 -175.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.413 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 41.4 m-85 -142.79 158.74 43.33 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 -177.5 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.516 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 17.0 t -138.66 147.25 42.62 Favored 'General case' 0 C--N 1.289 -2.029 0 C-N-CA 120.377 -0.529 . . . . 0.0 109.67 175.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . 0.438 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 7.3 p-80 -119.96 130.05 54.59 Favored 'General case' 0 C--O 1.256 1.408 0 CA-C-O 122.323 1.059 . . . . 0.0 111.472 -178.435 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 22.3 p-10 -91.24 89.84 7.5 Favored 'General case' 0 C--N 1.278 -2.511 0 CA-C-O 122.968 1.366 . . . . 0.0 109.913 178.044 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -71.18 -24.79 62.31 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 113.875 -1.511 . . . . 0.0 111.377 -177.223 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 1.646 ' HE2' ' CE1' ' A' ' 48' ' ' TYR . 43.3 m-85 -126.06 79.37 69.44 Favored Pre-proline 0 N--CA 1.479 0.979 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 178.007 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -85.56 -2.8 9.2 Favored 'Trans proline' 0 C--N 1.321 -0.892 0 C-N-CA 122.0 1.8 . . . . 0.0 113.528 -175.098 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -111.76 -23.76 10.42 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.068 -179.392 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.422 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.0 OUTLIER -99.42 -30.63 12.08 Favored 'General case' 0 C--N 1.292 -1.898 0 CA-C-O 121.837 0.827 . . . . 0.0 109.987 -175.329 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.56 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.5 mp -118.6 138.66 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.616 0 CA-C-N 114.898 -1.046 . . . . 0.0 108.308 -179.456 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.7 t -78.75 134.05 37.07 Favored 'General case' 0 N--CA 1.417 -2.1 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 174.344 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.488 ' O ' HG21 ' A' ' 94' ' ' VAL . 7.6 m-20 -80.14 107.17 12.71 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 -172.333 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 49.9 t80 -142.85 133.44 25.09 Favored 'General case' 0 C--N 1.284 -2.271 0 CA-C-N 116.331 -0.395 . . . . 0.0 109.999 -172.254 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.455 HG13 ' OH ' ' A' ' 77' ' ' TYR . 42.3 t -141.73 134.14 28.41 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 C-N-CA 123.374 0.67 . . . . 0.0 109.635 -178.449 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -143.81 115.48 8.17 Favored 'General case' 0 N--CA 1.434 -1.226 0 O-C-N 123.387 0.43 . . . . 0.0 111.335 177.555 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.526 HD13 ' O ' ' A' ' 130' ' ' ILE . 55.5 tp -54.57 110.78 0.68 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.584 0.706 . . . . 0.0 110.169 171.085 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.3 tp-100 -58.85 -51.79 68.49 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 126.292 1.837 . . . . 0.0 111.828 179.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 6.9 ptp180 -169.73 157.35 6.89 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -176.275 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -137.38 136.56 8.33 Favored Glycine 0 N--CA 1.415 -2.756 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 -179.462 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 70.3 m -126.71 146.22 50.3 Favored 'General case' 0 C--N 1.283 -2.324 0 C-N-CA 123.093 0.557 . . . . 0.0 110.69 -175.275 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.492 ' HB3' ' CE2' ' A' ' 84' ' ' PHE . . . -109.96 156.79 20.0 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 -179.189 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.511 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . 90.8 m-85 -155.9 -179.47 8.16 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 123.963 0.905 . . . . 0.0 109.075 -178.192 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.01 -139.22 48.98 Favored Glycine 0 N--CA 1.45 -0.396 0 O-C-N 123.621 0.576 . . . . 0.0 113.328 177.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.6 -9.05 87.37 Favored Glycine 0 C--O 1.201 -1.922 0 C-N-CA 120.329 -0.938 . . . . 0.0 111.379 178.166 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.504 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 87.5 t -70.81 -42.7 77.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 C-N-CA 123.137 0.575 . . . . 0.0 111.44 -176.583 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.511 ' HG ' ' CA ' ' A' ' 64' ' ' TYR . 0.3 OUTLIER -83.4 -21.61 32.97 Favored 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.4 -0.92 . . . . 0.0 112.518 -179.649 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 21.0 m -101.05 -47.8 4.64 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 114.041 1.126 . . . . 0.0 114.041 -174.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 47.5 m-20 -96.71 -20.63 18.11 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 -175.039 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 0.538 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 92.0 m-85 -110.78 157.09 20.18 Favored 'General case' 0 N--CA 1.424 -1.75 0 C-N-CA 120.032 -0.667 . . . . 0.0 110.418 178.053 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.8 t -160.95 123.09 3.09 Favored 'General case' 0 N--CA 1.422 -1.853 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 177.097 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.532 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -158.48 -106.97 0.23 Allowed Glycine 0 N--CA 1.412 -2.93 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 177.456 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -165.2 -179.4 5.6 Favored 'General case' 0 C--N 1.313 -0.998 0 C-N-CA 124.525 1.13 . . . . 0.0 110.358 -175.389 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.6 p -131.93 148.3 32.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 C-N-CA 123.626 0.77 . . . . 0.0 109.301 177.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.61 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.3 tttt -126.12 143.27 51.19 Favored 'General case' 0 N--CA 1.426 -1.638 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.455 ' OH ' HG13 ' A' ' 56' ' ' VAL . 67.5 t80 -144.31 110.12 5.32 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.258 -177.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 25.3 t 51.24 40.71 26.74 Favored 'General case' 0 CA--C 1.551 0.983 0 C-N-CA 123.584 0.754 . . . . 0.0 111.526 177.576 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.83 14.01 61.7 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.333 -0.937 . . . . 0.0 113.811 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.61 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 13.0 t -86.48 -178.9 6.53 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 175.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 26.1 p -159.48 103.78 1.6 Allowed 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.513 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 0.488 ' HH ' HD21 ' A' ' 58' ' ' LEU . 2.9 p90 -149.53 160.13 34.93 Favored Pre-proline 0 C--N 1.303 -1.428 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 -173.057 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 42.5 Cg_endo -67.25 146.92 77.46 Favored 'Trans proline' 0 C--N 1.358 1.053 0 C-N-CA 122.837 2.358 . . . . 0.0 112.887 -177.071 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.549 ' CD2' HD22 ' A' ' 109' ' ' LEU . 64.2 t80 -122.63 134.59 25.03 Favored Pre-proline 0 N--CA 1.435 -1.223 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.432 -179.769 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.528 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 64.3 Cg_endo -71.08 147.06 86.51 Favored 'Cis proline' 0 CA--C 1.54 0.786 0 C-N-CA 123.229 -1.571 . . . . 0.0 110.602 -2.497 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.8 t -64.68 -176.8 0.27 Allowed 'General case' 0 C--O 1.248 0.981 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.685 -175.403 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 16.8 p -130.31 0.73 4.6 Favored 'General case' 0 N--CA 1.424 -1.761 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.014 -171.133 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 26.5 t -161.36 -137.51 0.04 OUTLIER 'General case' 0 N--CA 1.379 -3.993 0 N-CA-C 106.56 -1.645 . . . . 0.0 106.56 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -121.39 156.58 32.36 Favored 'General case' 0 C--N 1.267 -2.991 0 C-N-CA 127.015 2.126 . . . . 0.0 107.337 -172.309 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.464 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 19.6 p -78.6 162.37 65.94 Favored Pre-proline 0 C--N 1.302 -1.483 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 -177.396 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.99 165.49 5.0 Favored 'Trans proline' 0 C--N 1.359 1.104 0 C-N-CA 124.044 3.163 . . . . 0.0 112.148 174.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.6 tmm_? -70.3 119.7 14.87 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 114.759 -1.11 . . . . 0.0 109.657 -176.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 60.4 t -131.27 130.35 63.13 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 C-N-CA 123.671 0.788 . . . . 0.0 110.211 -175.531 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.488 HG21 ' O ' ' A' ' 54' ' ' ASP . 1.4 p -129.74 125.45 61.03 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.953 0 CA-C-N 115.009 -0.996 . . . . 0.0 110.341 -174.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -73.15 104.08 4.1 Favored 'General case' 0 C--O 1.211 -0.938 0 CA-C-O 121.105 0.478 . . . . 0.0 111.092 -178.519 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -90.11 62.55 5.56 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-O 121.016 0.436 . . . . 0.0 109.836 179.197 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.0 t -152.59 -170.07 3.53 Favored 'General case' 0 N--CA 1.437 -1.092 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 -178.288 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 17.0 ptm180 -149.1 38.34 0.8 Allowed 'General case' 0 C--N 1.316 -0.875 0 CA-C-O 121.014 0.435 . . . . 0.0 110.437 -176.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 12.6 t -159.51 -177.8 6.67 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -178.007 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . 0.438 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 9.6 p-10 -79.45 99.92 7.44 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-O 122.41 1.1 . . . . 0.0 109.653 -179.231 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . 0.452 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 7.0 mmpt? -102.37 149.73 36.93 Favored Pre-proline 0 C--N 1.296 -1.749 0 CA-C-N 114.535 -1.212 . . . . 0.0 109.755 -177.836 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.463 ' HB3' ' O ' ' A' ' 39' ' ' SER . 22.5 Cg_exo -59.16 153.35 53.12 Favored 'Trans proline' 0 N--CA 1.449 -1.133 0 C-N-CA 123.36 2.707 . . . . 0.0 112.907 178.089 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 12.6 t90 -95.75 102.15 9.65 Favored Pre-proline 0 C--N 1.289 -2.053 0 N-CA-C 105.688 -1.967 . . . . 0.0 105.688 176.357 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -73.93 88.96 1.04 Allowed 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 122.079 1.852 . . . . 0.0 112.956 -172.267 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 59.9 t -138.75 146.45 26.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.566 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.57 135.67 16.63 Favored 'General case' 0 C--N 1.287 -2.144 0 CA-C-O 120.89 0.376 . . . . 0.0 110.414 178.033 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.422 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 15.6 mt -101.25 103.12 14.12 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.447 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.532 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 45.5 m-85 -82.2 73.23 9.25 Favored 'General case' 0 C--N 1.293 -1.863 0 O-C-N 122.279 -0.263 . . . . 0.0 110.824 178.369 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.658 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -98.5 136.03 39.2 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 176.867 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -137.5 144.73 46.26 Favored Pre-proline 0 C--N 1.293 -1.883 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.098 -175.199 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -62.38 122.31 10.67 Favored 'Trans proline' 0 C--O 1.248 0.99 0 C-N-CA 123.537 2.825 . . . . 0.0 113.12 -176.14 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.497 ' O ' HG23 ' A' ' 30' ' ' VAL . 2.7 m -73.85 -120.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.168 -3.201 0 CA-C-N 114.507 -1.224 . . . . 0.0 112.344 174.806 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 27.9 t -111.94 -32.37 6.62 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 -179.116 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 68.3 m -79.97 21.6 0.55 Allowed 'General case' 0 N--CA 1.398 -3.07 0 C-N-CA 125.612 1.565 . . . . 0.0 112.777 -179.532 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -107.5 128.16 54.25 Favored 'General case' 0 N--CA 1.412 -2.326 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 -179.218 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.63 133.09 2.71 Favored Glycine 0 C--N 1.297 -1.605 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 -179.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 62.47 -148.55 49.02 Favored Glycine 0 CA--C 1.489 -1.567 0 CA-C-O 119.24 -0.755 . . . . 0.0 111.782 -177.573 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 60.7 t -56.93 105.72 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 117.225 0.513 . . . . 0.0 110.536 -178.283 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -102.97 -40.93 6.3 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.58 179.481 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.407 ' HB ' HG21 ' A' ' 154' ' ' VAL . 72.7 mt -115.29 137.66 48.11 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 178.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.436 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.9 mmpt? -115.07 136.63 52.92 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-O 121.289 0.566 . . . . 0.0 111.636 178.885 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.15 126.87 30.91 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.828 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 92.95 -5.13 75.83 Favored Glycine 0 N--CA 1.437 -1.298 0 CA-C-N 115.694 -0.684 . . . . 0.0 111.756 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 21.2 m -94.91 145.17 25.1 Favored 'General case' 0 N--CA 1.428 -1.544 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 179.802 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.41 HD12 HG21 ' A' ' 128' ' ' VAL . 2.9 tm? -71.35 124.74 25.25 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 108.204 -1.035 . . . . 0.0 108.204 178.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.463 ' HB ' HG23 ' A' ' 67' ' ' VAL . 31.8 pt -111.09 -25.36 3.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 112.322 0.49 . . . . 0.0 112.322 -179.002 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . 0.416 ' HB1' ' HB ' ' A' ' 148' ' ' ILE . . . -162.05 167.51 24.24 Favored 'General case' 0 CA--C 1.508 -0.653 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 -178.022 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.41 HG21 HD12 ' A' ' 125' ' ' LEU . 63.8 t -142.3 116.02 4.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 178.878 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . 0.404 HD12 HD22 ' A' ' 107' ' ' LEU . 67.9 mt -119.02 146.99 44.59 Favored 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.613 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.526 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.4 mp -127.73 126.38 66.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 C-N-CA 119.271 -0.972 . . . . 0.0 110.832 177.519 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.463 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.3 OUTLIER -88.1 145.5 25.91 Favored 'General case' 0 C--N 1.283 -2.313 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 176.332 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . 0.418 ' HD2' ' OD2' ' A' ' 141' ' ' ASP . 16.2 ttp180 -128.58 130.08 46.86 Favored 'General case' 0 C--N 1.277 -2.549 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 173.023 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 8.6 tm0? -108.71 129.04 55.36 Favored 'General case' 0 N--CA 1.412 -2.347 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 -178.728 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 6.9 m -135.75 139.75 43.82 Favored 'General case' 0 C--N 1.287 -2.116 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.56 ' CB ' HG21 ' A' ' 52' ' ' ILE . 9.4 p30 -133.09 178.78 6.63 Favored 'General case' 0 N--CA 1.433 -1.278 0 C-N-CA 117.309 -1.756 . . . . 0.0 113.449 177.927 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -88.34 -31.86 18.7 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 121.577 0.703 . . . . 0.0 111.261 -174.143 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 9.5 t80 -82.38 -63.58 1.35 Allowed 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.135 -0.938 . . . . 0.0 110.165 -173.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 7.8 m-20 -94.56 149.39 21.29 Favored 'General case' 0 C--N 1.287 -2.14 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.606 176.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 41.8 m -96.36 27.67 3.65 Favored 'General case' 0 C--N 1.279 -2.483 0 CA-C-N 115.187 -0.915 . . . . 0.0 108.919 179.135 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . 0.528 ' HB3' ' CE2' ' A' ' 142' ' ' PHE . 24.6 m-20 -82.38 90.3 6.68 Favored 'General case' 0 CA--C 1.499 -1.017 0 CA-C-N 114.765 -1.107 . . . . 0.0 110.447 179.841 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . 0.418 ' OD2' ' HD2' ' A' ' 132' ' ' ARG . 27.6 t70 -93.01 85.35 5.09 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-N 114.985 -1.007 . . . . 0.0 108.461 -179.498 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . 0.528 ' CE2' ' HB3' ' A' ' 140' ' ' ASP . 43.7 m-85 -101.35 146.07 28.06 Favored 'General case' 0 C--N 1.312 -1.064 0 O-C-N 122.176 -0.328 . . . . 0.0 110.238 -178.593 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . 0.415 HE21 HG22 ' A' ' 130' ' ' ILE . 20.1 pt20 -123.54 134.73 53.81 Favored 'General case' 0 N--CA 1.423 -1.806 0 C-N-CA 119.838 -0.745 . . . . 0.0 111.102 177.512 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 6.9 m-30 -107.57 125.66 51.58 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 -176.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . 0.445 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 46.9 t -89.51 135.28 26.46 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 CA-C-O 121.161 0.505 . . . . 0.0 110.284 -178.473 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . 0.463 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 64.8 m95 -122.12 102.53 8.2 Favored 'General case' 0 C--N 1.281 -2.377 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.692 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.8 m-80 -81.65 109.22 15.87 Favored 'General case' 0 C--N 1.289 -2.025 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 178.04 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . 0.428 ' HA ' HG23 ' A' ' 20' ' ' VAL . 21.3 mm -82.47 119.92 32.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 -177.191 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 1.638 ' HE1' ' CE2' ' A' ' 149' ' ' TYR . 81.8 m-85 -116.77 151.6 36.12 Favored 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 123.169 0.588 . . . . 0.0 109.678 178.469 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.14 128.92 34.28 Favored 'General case' 0 N--CA 1.411 -2.399 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 177.119 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -91.38 -11.36 38.03 Favored 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 107.435 -1.32 . . . . 0.0 107.435 -177.563 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -153.22 143.01 22.03 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 114.292 -1.322 . . . . 0.0 109.379 -177.053 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -84.26 145.68 28.18 Favored 'General case' 0 C--N 1.316 -0.85 0 O-C-N 123.971 0.795 . . . . 0.0 109.553 -179.02 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.466 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 1.6 m -124.44 147.48 28.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.855 -178.248 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.7 t -120.14 139.93 45.85 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.538 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 -179.626 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.405 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 70.5 t -100.93 100.3 12.52 Favored Pre-proline 0 C--N 1.29 -1.983 0 C-N-CA 123.666 0.786 . . . . 0.0 109.402 177.336 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -68.18 -23.95 38.76 Favored 'Trans proline' 0 CA--C 1.517 -0.365 0 C-N-CA 122.427 2.085 . . . . 0.0 111.649 178.038 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.269 5.3 t . . . . . 0 C--O 1.249 1.058 0 O-C-N 125.0 1.437 . . . . 0.0 113.383 177.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.578 ' CZ ' ' HB3' ' A' ' 133' ' ' GLN . 0.1 OUTLIER . . . . . 0 CA--C 1.487 -1.443 0 N-CA-C 105.418 -2.067 . . . . 0.0 105.418 . . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -148.32 174.51 11.95 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.588 -0.845 . . . . 0.0 111.49 -173.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 77.0 m -137.4 152.18 49.36 Favored 'General case' 0 N--CA 1.429 -1.496 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.958 -177.414 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -141.17 167.13 22.91 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.763 -178.093 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 82.5 p -103.67 171.88 7.12 Favored 'General case' 0 CA--C 1.497 -1.066 0 CA-C-O 121.483 0.658 . . . . 0.0 110.733 -179.276 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.96 -4.82 54.09 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-N 114.034 -1.439 . . . . 0.0 111.755 178.325 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 2.0 p30 -96.88 -30.92 12.85 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 118.184 -1.407 . . . . 0.0 109.314 177.829 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 139.13 0.46 2.16 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 119.896 -1.145 . . . . 0.0 113.047 175.388 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -81.07 105.25 12.14 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -100.85 119.45 38.68 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 176.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 60.3 mt -90.76 123.83 63.91 Favored Pre-proline 0 C--N 1.3 -1.567 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -80.66 168.75 17.53 Favored 'Trans proline' 0 C--O 1.248 0.98 0 C-N-CA 122.7 2.267 . . . . 0.0 111.173 178.049 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.1 mt -63.75 127.56 24.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 133.77 8.72 2.12 Favored Glycine 0 C--N 1.319 -0.373 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.612 -179.562 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 86.69 172.69 48.61 Favored Glycine 0 C--N 1.318 -0.425 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.415 -177.542 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.45 -168.78 30.97 Favored Glycine 0 C--N 1.299 -1.526 0 C-N-CA 119.916 -1.135 . . . . 0.0 111.498 177.1 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 14.4 p -140.1 155.81 46.84 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.401 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -143.63 162.24 36.43 Favored 'General case' 0 N--CA 1.424 -1.736 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 177.308 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -107.83 116.18 31.48 Favored 'General case' 0 C--N 1.281 -2.388 0 CA-C-N 114.808 -1.087 . . . . 0.0 108.746 177.57 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 44.1 t -103.86 135.03 43.44 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.008 0 CA-C-N 115.133 -0.94 . . . . 0.0 108.668 179.202 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 -122.99 134.78 54.31 Favored 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -179.113 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.451 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.5 p -144.42 136.29 21.87 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.674 0 O-C-N 123.727 0.642 . . . . 0.0 111.095 -178.722 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 47.9 m-80 -89.67 126.79 35.78 Favored 'General case' 0 C--N 1.296 -1.76 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.458 178.442 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -106.56 161.19 14.83 Favored 'General case' 0 C--N 1.283 -2.298 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 177.631 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.8 124.81 81.19 Favored Pre-proline 0 C--N 1.315 -0.933 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 175.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.43 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 68.1 Cg_endo -74.83 0.84 8.33 Favored 'Trans proline' 0 N--CA 1.474 0.382 0 C-N-CA 122.954 2.436 . . . . 0.0 113.021 -177.253 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.422 HG11 ' HG3' ' A' ' 157' ' ' PRO . 87.3 t -129.6 111.85 23.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.525 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.7 t -143.33 114.94 2.73 Favored 'Isoleucine or valine' 0 C--O 1.182 -2.489 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -177.219 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.716 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -104.98 148.68 26.46 Favored 'General case' 0 C--N 1.271 -2.819 0 O-C-N 121.987 -0.445 . . . . 0.0 110.91 -179.447 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.513 HG23 ' O ' ' A' ' 112' ' ' VAL . 95.8 t -47.97 116.93 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 123.082 0.553 . . . . 0.0 111.377 178.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 109.41 -9.25 32.96 Favored Glycine 0 C--N 1.307 -1.033 0 CA-C-N 115.238 -0.892 . . . . 0.0 112.357 -178.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.716 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -67.87 -177.62 0.84 Allowed 'General case' 0 CA--C 1.508 -0.672 0 C-N-CA 124.631 1.172 . . . . 0.0 110.956 179.63 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -129.89 92.12 3.26 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 178.231 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.635 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.8 tp -94.25 142.52 27.31 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 119.056 -1.057 . . . . 0.0 109.301 179.226 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 39.6 t -132.34 124.78 52.72 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.215 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 -175.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.559 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 47.3 t -96.19 87.82 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.4 -2.931 0 N-CA-C 105.26 -2.126 . . . . 0.0 105.26 172.107 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -82.5 112.55 19.53 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 120.962 0.411 . . . . 0.0 110.984 -177.757 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 84.6 mt -98.21 0.31 45.56 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.017 -178.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.4 m -76.35 1.67 15.59 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-O 122.332 1.063 . . . . 0.0 109.045 -179.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.8 p -130.64 5.58 4.69 Favored 'General case' 0 N--CA 1.428 -1.562 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.15 176.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.451 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 49.7 mm-40 -124.38 -22.12 4.77 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 121.193 0.521 . . . . 0.0 111.019 -174.684 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.2 mt -131.56 140.83 47.31 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 -176.231 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.64 ' HD2' ' CD1' ' A' ' 43' ' ' PHE . 69.0 m-85 -139.25 154.93 48.06 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -174.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 96.2 m -137.69 136.52 37.48 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 123.751 0.82 . . . . 0.0 110.787 -179.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.4 p-80 -131.92 129.67 40.58 Favored 'General case' 0 C--N 1.295 -1.761 0 CA-C-O 122.381 1.086 . . . . 0.0 112.123 -177.581 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.747 ' OD1' ' HA ' ' A' ' 49' ' ' PRO . 3.3 t-20 -85.23 92.07 8.32 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-N 114.446 -1.252 . . . . 0.0 107.928 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 20.1 m-20 -54.48 -36.6 64.33 Favored 'General case' 0 N--CA 1.493 1.684 0 C-N-CA 123.475 0.71 . . . . 0.0 111.069 -178.255 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 1.644 ' HD2' ' CD1' ' A' ' 48' ' ' TYR . 44.7 m-85 -122.46 86.0 48.35 Favored Pre-proline 0 C--N 1.299 -1.599 0 N-CA-C 108.223 -1.028 . . . . 0.0 108.223 -175.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.747 ' HA ' ' OD1' ' A' ' 46' ' ' ASN . 72.7 Cg_endo -73.19 -5.98 18.12 Favored 'Trans proline' 0 CA--C 1.508 -0.81 0 C-N-CA 122.486 2.124 . . . . 0.0 115.081 -170.128 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -121.3 -20.35 6.72 Favored 'General case' 0 C--N 1.282 -2.342 0 CA-C-O 121.268 0.556 . . . . 0.0 110.649 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.469 ' HB ' HD13 ' A' ' 52' ' ' ILE . 1.6 m -98.4 -30.7 12.41 Favored 'General case' 0 N--CA 1.414 -2.231 0 C-N-CA 119.54 -0.864 . . . . 0.0 109.102 -170.785 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.469 HD13 ' HB ' ' A' ' 51' ' ' THR . 2.7 mp -130.03 123.72 56.89 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 CA-C-N 114.878 -1.055 . . . . 0.0 110.035 -175.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 4.4 t -75.71 134.67 40.46 Favored 'General case' 0 N--CA 1.425 -1.684 0 N-CA-C 106.08 -1.822 . . . . 0.0 106.08 173.597 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.509 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 9.5 t70 -90.31 108.88 20.04 Favored 'General case' 0 C--N 1.271 -2.806 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 -178.431 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.572 ' CD2' ' HB ' ' A' ' 134' ' ' THR . 4.7 t80 -128.47 110.06 11.96 Favored 'General case' 0 C--N 1.291 -1.938 0 CA-C-O 122.109 0.957 . . . . 0.0 110.93 -175.22 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.423 ' HA ' ' O ' ' A' ' 132' ' ' ARG . 73.9 t -114.7 142.17 28.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 CA-C-N 113.629 -1.623 . . . . 0.0 110.94 -177.749 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.3 p -143.67 134.18 24.84 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 170.061 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.431 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 0.8 OUTLIER -73.51 109.97 7.44 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 175.771 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.4 tp-100 -57.58 -62.2 1.96 Allowed 'General case' 0 C--O 1.202 -1.428 0 C-N-CA 125.416 1.486 . . . . 0.0 109.958 -178.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.91 146.11 14.26 Favored 'General case' 0 N--CA 1.418 -2.072 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 -178.216 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -126.68 137.66 10.15 Favored Glycine 0 N--CA 1.398 -3.852 0 N-CA-C 108.193 -1.963 . . . . 0.0 108.193 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 63.4 m -124.0 148.29 47.1 Favored 'General case' 0 C--N 1.268 -2.949 0 C-N-CA 123.599 0.76 . . . . 0.0 109.33 -175.057 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.52 ' HB3' ' CE2' ' A' ' 84' ' ' PHE . . . -114.27 158.1 21.85 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 -179.593 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 1.643 ' HD1' ' CD2' ' A' ' 64' ' ' TYR . 85.0 m-85 -156.35 -178.42 7.32 Favored 'General case' 0 C--O 1.243 0.719 0 C-N-CA 124.214 1.005 . . . . 0.0 108.347 -178.111 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.79 -138.14 49.7 Favored Glycine 0 N--CA 1.452 -0.299 0 O-C-N 123.596 0.56 . . . . 0.0 112.81 178.562 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.91 -9.41 85.42 Favored Glycine 0 C--O 1.205 -1.706 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.651 177.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.477 HG23 ' HB ' ' A' ' 126' ' ' ILE . 84.5 t -68.53 -42.92 83.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 C-N-CA 122.934 0.493 . . . . 0.0 111.362 -177.508 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.509 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -82.45 -17.65 44.56 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.331 -0.948 . . . . 0.0 112.133 179.603 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 14.6 t -100.74 -59.64 1.66 Allowed 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.971 -172.631 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.434 ' O ' HG23 ' A' ' 112' ' ' VAL . 44.2 m-20 -91.1 -23.51 20.28 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.672 -172.323 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 1.637 ' HD2' ' CD1' ' A' ' 71' ' ' PHE . 93.1 m-85 -106.7 155.62 19.49 Favored 'General case' 0 N--CA 1.42 -1.959 0 C-N-CA 119.647 -0.821 . . . . 0.0 109.532 177.077 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.5 t -163.18 126.99 2.85 Favored 'General case' 0 N--CA 1.41 -2.464 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.419 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.425 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -163.07 -109.59 0.23 Allowed Glycine 0 N--CA 1.407 -3.287 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 177.294 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -159.99 178.69 9.46 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 123.348 0.659 . . . . 0.0 110.273 -173.739 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -131.77 142.85 42.01 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 178.171 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.706 ' HG3' ' O ' ' A' ' 80' ' ' SER . 71.7 tttt -118.76 139.12 52.08 Favored 'General case' 0 N--CA 1.423 -1.814 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.793 -179.573 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.483 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 67.5 t80 -138.96 110.05 6.83 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.071 -178.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.6 t 49.68 41.92 22.61 Favored 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 124.133 0.973 . . . . 0.0 111.937 174.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.43 11.03 63.04 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 120.519 -0.848 . . . . 0.0 113.746 179.265 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.706 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 10.1 t -93.56 177.84 5.89 Favored 'General case' 0 C--O 1.206 -1.219 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 176.694 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 74.9 m -160.02 105.52 1.56 Allowed 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 177.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 1.638 ' HD2' ' CD1' ' A' ' 82' ' ' TYR . 5.8 p90 -142.64 164.53 32.1 Favored Pre-proline 0 C--N 1.297 -1.688 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 -172.46 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.418 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 73.9 Cg_endo -71.95 148.26 51.03 Favored 'Trans proline' 0 C--N 1.352 0.731 0 C-N-CA 122.376 2.051 . . . . 0.0 113.402 -174.436 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.614 ' CD2' HD22 ' A' ' 109' ' ' LEU . 55.3 t80 -120.7 139.7 29.39 Favored Pre-proline 0 N--CA 1.429 -1.499 0 CA-C-N 115.608 -0.723 . . . . 0.0 109.267 179.398 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.605 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 55.8 Cg_endo -70.12 144.54 77.7 Favored 'Cis proline' 0 CA--C 1.537 0.653 0 C-N-CA 123.115 -1.619 . . . . 0.0 110.541 -4.848 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 5.6 t -67.44 -179.59 1.08 Allowed 'General case' 0 CA--C 1.556 1.182 0 CA-C-O 121.081 0.467 . . . . 0.0 111.236 -175.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 22.1 p -131.11 -24.63 2.32 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -168.439 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 24.8 t -129.84 -68.5 0.71 Allowed 'General case' 0 C--N 1.31 -1.117 0 C-N-CA 119.854 -0.738 . . . . 0.0 110.83 -173.36 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 178.77 -177.01 0.25 Allowed 'General case' 0 C--O 1.243 0.747 0 C-N-CA 124.454 1.102 . . . . 0.0 108.44 175.631 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.431 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 48.9 p -100.15 166.9 11.85 Favored Pre-proline 0 C--N 1.302 -1.477 0 O-C-N 123.582 0.551 . . . . 0.0 110.978 177.324 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -57.89 160.21 15.82 Favored 'Trans proline' 0 C--O 1.248 1.012 0 C-N-CA 123.027 2.484 . . . . 0.0 110.941 171.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.523 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 0.8 OUTLIER -72.32 120.51 18.03 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.368 -177.26 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 57.5 t -129.42 119.01 47.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.893 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 97.6 t -105.64 132.5 52.44 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 CA-C-N 115.12 -0.945 . . . . 0.0 108.868 177.04 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . 0.509 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 11.8 m-85 -81.6 112.07 18.48 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 175.746 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -103.69 75.73 1.33 Allowed 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 -179.493 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 70.7 m -161.08 170.05 21.23 Favored 'General case' 0 C--N 1.318 -0.801 0 C-N-CA 124.303 1.041 . . . . 0.0 109.435 -177.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.0 ptm180 -128.06 38.78 3.96 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-O 121.946 0.879 . . . . 0.0 110.07 178.013 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.8 t -156.72 167.73 29.56 Favored 'General case' 0 N--CA 1.426 -1.648 0 N-CA-C 107.272 -1.381 . . . . 0.0 107.272 -177.134 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -73.69 123.58 24.34 Favored 'General case' 0 C--N 1.311 -1.1 0 O-C-N 123.784 0.677 . . . . 0.0 110.579 -178.594 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.5 mptm? -120.07 144.23 37.22 Favored Pre-proline 0 C--N 1.28 -2.428 0 CA-C-N 114.642 -1.163 . . . . 0.0 108.558 179.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.43 ' O ' ' HD3' ' A' ' 104' ' ' PRO . 43.3 Cg_endo -65.9 150.13 85.91 Favored 'Trans proline' 0 C--O 1.248 1.009 0 C-N-CA 122.242 1.961 . . . . 0.0 111.456 177.343 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 16.4 t90 -87.16 105.26 7.82 Favored Pre-proline 0 C--N 1.315 -0.912 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 -179.576 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.43 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 64.4 Cg_endo -74.69 88.53 1.19 Allowed 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 121.544 1.496 . . . . 0.0 112.58 -173.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 97.4 t -138.44 142.88 33.93 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.309 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.106 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.559 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.94 132.5 16.75 Favored 'General case' 0 N--CA 1.41 -2.428 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.109 178.51 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.444 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 19.5 mt -97.05 102.37 14.13 Favored 'General case' 0 C--N 1.287 -2.123 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.639 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 1.655 ' HE1' ' CE2' ' A' ' 108' ' ' TYR . 63.0 m-85 -83.11 74.39 9.99 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-O 121.105 0.479 . . . . 0.0 110.231 177.45 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.635 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.8 mm? -97.93 130.35 44.81 Favored 'General case' 0 CA--C 1.484 -1.582 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 175.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -135.05 144.09 48.73 Favored Pre-proline 0 N--CA 1.397 -3.077 0 N-CA-C 108.947 -0.761 . . . . 0.0 108.947 -174.452 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -63.13 126.72 18.49 Favored 'Trans proline' 0 CA--C 1.496 -1.401 0 C-N-CA 123.2 2.6 . . . . 0.0 113.993 -174.395 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.513 ' O ' HG23 ' A' ' 30' ' ' VAL . 16.1 m -91.65 -158.03 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.395 -3.206 0 CA-C-N 114.221 -1.354 . . . . 0.0 108.66 171.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 29.4 m -76.0 -32.01 59.21 Favored 'General case' 0 C--N 1.26 -3.322 0 CA-C-O 121.366 0.603 . . . . 0.0 110.883 -168.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 7.2 t -80.26 10.12 4.9 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-O 121.736 0.779 . . . . 0.0 110.64 -177.3 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -95.09 135.55 36.5 Favored 'General case' 0 N--CA 1.42 -1.955 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.002 179.005 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -179.6 132.07 1.78 Allowed Glycine 0 N--CA 1.433 -1.517 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 63.6 -150.05 49.92 Favored Glycine 0 C--N 1.306 -1.133 0 CA-C-O 119.167 -0.796 . . . . 0.0 112.128 -177.247 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -56.7 103.82 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.242 0.679 0 CA-C-O 122.404 1.097 . . . . 0.0 111.804 -177.402 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -103.24 -36.77 7.96 Favored 'General case' 0 C--N 1.293 -1.884 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.676 -178.695 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 73.1 mt -120.54 138.47 50.92 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 3.9 mmpt? -112.99 140.05 48.13 Favored 'General case' 0 C--N 1.313 -1.009 0 C-N-CA 122.727 0.411 . . . . 0.0 110.171 177.655 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -73.5 134.74 43.95 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.03 179.091 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 82.95 4.59 89.94 Favored Glycine 0 C--N 1.314 -0.648 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -178.524 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 8.5 t -100.87 140.7 34.79 Favored 'General case' 0 N--CA 1.415 -2.214 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -178.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -71.4 122.15 19.84 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 178.201 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.477 ' HB ' HG23 ' A' ' 67' ' ' VAL . 34.2 pt -109.48 -27.21 2.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.218 -177.872 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -160.57 166.99 28.05 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 -177.554 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 59.7 t -143.06 114.93 2.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 179.184 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 34.3 mt -118.2 135.83 54.01 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.429 HG22 HE21 ' A' ' 143' ' ' GLN . 4.3 mp -115.72 128.05 73.1 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 C-N-CA 118.636 -1.226 . . . . 0.0 109.937 177.8 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.514 ' O ' HD21 ' A' ' 131' ' ' LEU . 0.0 OUTLIER -97.05 133.5 41.63 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.159 178.497 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . 0.423 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 7.4 mmm180 -91.72 127.48 37.19 Favored 'General case' 0 C--N 1.281 -2.396 0 C-N-CA 123.714 0.806 . . . . 0.0 109.374 176.709 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.578 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 0.0 OUTLIER -103.98 130.52 51.63 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 105.75 -1.944 . . . . 0.0 105.75 174.087 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.572 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 12.9 m -145.2 143.92 30.56 Favored 'General case' 0 C--N 1.273 -2.757 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 177.396 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.45 ' HB2' HG21 ' A' ' 52' ' ' ILE . 19.3 p30 -142.93 159.4 42.32 Favored 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 119.695 -0.802 . . . . 0.0 110.624 179.058 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 6.5 p30 -86.74 -6.38 58.84 Favored 'General case' 0 C--N 1.309 -1.184 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.477 -170.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . 1.67 ' HD2' ' CD1' ' A' ' 137' ' ' TYR . 58.4 t80 -108.07 -67.32 0.97 Allowed 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.647 -172.157 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -82.84 -26.16 31.92 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -177.009 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 23.8 t 67.87 43.27 1.75 Allowed 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 -171.397 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 -70.86 62.96 0.29 Allowed 'General case' 0 N--CA 1.482 1.17 0 CA-C-N 114.828 -1.078 . . . . 0.0 110.009 175.506 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . 0.405 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 1.3 m-20 -77.62 66.04 3.24 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 125.046 1.338 . . . . 0.0 110.932 -178.851 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . 1.651 ' HE2' ' CE1' ' A' ' 142' ' ' PHE . 76.4 m-85 -110.04 167.32 10.26 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.204 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . 0.429 HE21 HG22 ' A' ' 130' ' ' ILE . 18.5 pt20 -137.27 141.27 41.97 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.662 178.169 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 1.662 ' HD2' ' CD1' ' A' ' 144' ' ' PHE . 5.4 m-30 -108.58 131.66 54.64 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -176.165 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 48.1 t -90.89 127.52 43.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 O-C-N 123.579 0.549 . . . . 0.0 109.893 -178.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . 0.431 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 65.3 m95 -114.88 100.07 7.95 Favored 'General case' 0 C--N 1.273 -2.728 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 -178.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 42.2 m-80 -82.67 112.83 19.89 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 23.0 mm -88.45 121.09 38.32 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -177.434 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 1.647 ' HE1' ' CE2' ' A' ' 149' ' ' TYR . 97.3 m-85 -116.79 149.07 40.56 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 177.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.09 131.43 35.3 Favored 'General case' 0 N--CA 1.41 -2.453 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 176.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 13.9 t-20 -91.03 -11.24 39.4 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 -178.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -147.88 142.85 26.94 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.155 -176.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -85.62 136.8 33.23 Favored 'General case' 0 C--N 1.313 -1.0 0 O-C-N 123.97 0.794 . . . . 0.0 109.663 178.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.43 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 1.5 m -119.92 149.52 22.6 Favored 'Isoleucine or valine' 0 C--O 1.254 1.316 0 CA-C-O 120.928 0.394 . . . . 0.0 110.785 -175.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -121.53 142.69 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.276 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -179.376 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.525 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.5 t -102.56 102.37 25.6 Favored Pre-proline 0 C--N 1.296 -1.745 0 C-N-CA 123.384 0.674 . . . . 0.0 109.82 178.131 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.422 ' HG3' HG11 ' A' ' 27' ' ' VAL . 29.2 Cg_endo -67.5 -28.64 38.3 Favored 'Trans proline' 0 CA--C 1.506 -0.878 0 C-N-CA 122.295 1.997 . . . . 0.0 111.7 177.519 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.255 6.1 t . . . . . 0 C--O 1.256 1.401 0 O-C-N 124.483 1.114 . . . . 0.0 112.519 178.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 1.627 ' HE1' ' CE2' ' A' ' 1' ' ' PHE 1.002 17.1 m-85 . . . . . 0 CA--C 1.46 -2.514 0 N-CA-C 119.514 3.153 . . . . 0.0 119.514 . . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.412 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . -131.7 140.85 49.4 Favored 'General case' 0 C--N 1.271 -2.822 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 167.188 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 11.1 m -126.01 163.05 23.88 Favored 'General case' 0 C--N 1.26 -3.31 0 C-N-CA 119.148 -1.021 . . . . 0.0 109.155 -171.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.405 ' HA ' ' O ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -146.35 159.25 43.62 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-O 120.958 0.409 . . . . 0.0 110.522 -174.479 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.608 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 73.4 p -99.62 176.13 5.58 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 121.277 0.561 . . . . 0.0 111.09 -179.382 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.52 -12.93 59.85 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.186 178.175 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.608 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 8.8 p30 -89.48 -31.31 17.73 Favored 'General case' 0 N--CA 1.435 -1.213 0 C-N-CA 119.081 -1.047 . . . . 0.0 109.896 175.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.48 5.66 3.22 Favored Glycine 0 N--CA 1.44 -1.054 0 C-N-CA 119.325 -1.417 . . . . 0.0 113.743 175.354 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.405 ' O ' ' HA ' ' A' ' 4' ' ' LYS . 5.1 m -79.18 99.62 7.09 Favored 'General case' 0 N--CA 1.433 -1.276 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 -179.736 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.53 117.92 30.46 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 176.369 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.412 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 71.5 mt -93.46 123.29 60.76 Favored Pre-proline 0 C--N 1.297 -1.68 0 N-CA-C 108.498 -0.926 . . . . 0.0 108.498 179.292 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -77.81 167.47 23.81 Favored 'Trans proline' 0 C--O 1.248 0.982 0 C-N-CA 122.84 2.36 . . . . 0.0 111.498 179.261 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.412 HG12 ' O ' ' A' ' 1' ' ' PHE . 60.3 mt -69.88 120.58 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.912 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.61 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 140.16 20.12 0.37 Allowed Glycine 0 C--N 1.298 -1.534 0 CA-C-N 115.533 -0.758 . . . . 0.0 112.677 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 84.26 158.81 28.56 Favored Glycine 0 C--O 1.236 0.258 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 -177.121 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 163.83 -175.74 39.96 Favored Glycine 0 N--CA 1.435 -1.372 0 C-N-CA 119.825 -1.179 . . . . 0.0 111.49 178.472 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 37.3 p -146.14 147.55 31.64 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.047 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.09 161.44 35.32 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 179.342 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 21.9 m-80 -113.29 109.81 19.34 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 106.493 -1.669 . . . . 0.0 106.493 176.755 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 40.2 t -94.35 134.69 31.02 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.493 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 -178.273 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 1.64 ' HD2' ' CD1' ' A' ' 21' ' ' TYR . 78.3 m-85 -116.46 120.13 37.82 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 117.775 0.261 . . . . 0.0 110.986 -178.541 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 17.6 t -123.02 127.99 74.94 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-O 120.975 0.416 . . . . 0.0 111.036 -175.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -82.12 124.41 29.83 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 177.323 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 38.0 mt -115.51 154.2 29.76 Favored 'General case' 0 C--N 1.28 -2.453 0 CA-C-N 115.397 -0.82 . . . . 0.0 108.858 -179.086 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.76 120.83 44.9 Favored Pre-proline 0 C--N 1.314 -0.96 0 O-C-N 124.485 1.115 . . . . 0.0 110.123 -178.826 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.45 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 61.0 Cg_endo -72.22 -2.09 11.1 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.885 2.39 . . . . 0.0 113.427 -176.694 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.4 t -124.07 109.57 23.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 178.23 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.492 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.7 t -139.81 107.08 2.71 Favored 'Isoleucine or valine' 0 C--O 1.182 -2.479 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -178.258 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.726 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -97.72 148.54 23.24 Favored 'General case' 0 C--N 1.265 -3.095 0 C-N-CA 122.894 0.477 . . . . 0.0 111.015 -179.606 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.519 HG23 ' O ' ' A' ' 112' ' ' VAL . 91.0 t -47.69 116.52 0.38 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.638 0 C-N-CA 122.961 0.505 . . . . 0.0 111.435 176.038 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.09 9.87 43.94 Favored Glycine 0 CA--C 1.523 0.567 0 CA-C-N 114.905 -1.043 . . . . 0.0 112.137 -178.178 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.726 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -78.62 -176.71 4.99 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 124.603 1.161 . . . . 0.0 109.653 175.147 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -131.95 83.49 2.09 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 175.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.516 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 19.8 tp -91.37 134.22 34.79 Favored 'General case' 0 N--CA 1.426 -1.642 0 C-N-CA 119.42 -0.912 . . . . 0.0 108.915 179.438 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.451 ' HA ' ' O ' ' A' ' 107' ' ' LEU . 1.8 p -141.35 136.26 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.383 -3.803 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.191 -177.691 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.593 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 34.0 t -98.59 89.29 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.412 -2.343 0 CA-C-N 113.551 -1.659 . . . . 0.0 107.904 178.65 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -77.48 118.11 19.6 Favored 'General case' 0 CA--C 1.489 -1.391 0 C-N-CA 120.047 -0.661 . . . . 0.0 110.201 177.816 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 92.4 mt -96.64 -0.18 48.9 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.545 -0.752 . . . . 0.0 111.632 -178.01 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 26.4 t -74.63 -7.49 53.37 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.854 0.835 . . . . 0.0 109.659 -179.381 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.9 p -117.86 2.19 12.16 Favored 'General case' 0 C--N 1.279 -2.478 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.3 178.021 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 44.2 mm-40 -120.64 -22.83 6.22 Favored 'General case' 0 C--O 1.243 0.736 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.501 -173.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 20.1 mt -136.45 140.08 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.629 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 -176.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 59.8 m-85 -139.9 162.33 35.43 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 -177.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 20.1 t -145.08 141.91 29.24 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 120.181 -0.608 . . . . 0.0 110.39 175.847 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . 0.4 ' NE2' ' HB1' ' A' ' 2' ' ' ALA . 19.8 p-80 -119.74 165.03 15.06 Favored 'General case' 0 C--O 1.255 1.389 0 CA-C-O 122.242 1.02 . . . . 0.0 110.376 -178.801 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.459 HD21 ' CG ' ' A' ' 54' ' ' ASP . 3.2 m120 -110.72 108.49 18.39 Favored 'General case' 0 C--N 1.271 -2.818 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 -175.017 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -84.0 -25.46 29.95 Favored 'General case' 0 N--CA 1.436 -1.166 0 C-N-CA 118.129 -1.428 . . . . 0.0 109.946 -177.618 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 -132.67 64.99 73.44 Favored Pre-proline 0 N--CA 1.472 0.668 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.186 178.03 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -70.02 1.04 4.98 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 C-N-CA 123.257 2.638 . . . . 0.0 114.159 -174.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -116.6 -20.13 9.72 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-O 121.189 0.519 . . . . 0.0 110.303 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.412 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -104.04 -27.83 11.88 Favored 'General case' 0 N--CA 1.422 -1.857 0 CA-C-O 122.055 0.931 . . . . 0.0 108.717 -172.875 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.53 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -128.9 142.98 42.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 CA-C-N 114.711 -1.131 . . . . 0.0 109.04 -176.817 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 4.2 t -89.2 133.23 34.51 Favored 'General case' 0 N--CA 1.433 -1.294 0 N-CA-C 104.917 -2.253 . . . . 0.0 104.917 170.209 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.459 ' CG ' HD21 ' A' ' 46' ' ' ASN . 11.1 m-20 -92.79 106.5 18.46 Favored 'General case' 0 C--N 1.27 -2.879 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 -178.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.422 ' HB3' ' O ' ' A' ' 134' ' ' THR . 52.9 t80 -118.0 127.94 54.3 Favored 'General case' 0 C--N 1.274 -2.692 0 CA-C-N 114.29 -1.323 . . . . 0.0 108.855 -174.589 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.459 HG11 ' HH ' ' A' ' 77' ' ' TYR . 14.9 p -134.48 138.91 48.92 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.578 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.411 -175.307 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 4.3 p -146.7 131.03 17.54 Favored 'General case' 0 C--N 1.282 -2.352 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 174.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.518 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 55.1 tp -64.52 116.89 6.61 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 173.213 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -61.06 -49.42 77.42 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 113.802 -1.545 . . . . 0.0 109.307 -178.589 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -175.79 161.76 2.58 Favored 'General case' 0 N--CA 1.42 -1.951 0 CA-C-N 114.504 -1.226 . . . . 0.0 107.979 -178.311 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -136.6 136.52 8.42 Favored Glycine 0 N--CA 1.403 -3.514 0 N-CA-C 108.729 -1.748 . . . . 0.0 108.729 -179.47 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.2 m -123.66 146.87 47.9 Favored 'General case' 0 C--N 1.282 -2.35 0 O-C-N 124.394 0.702 . . . . 0.0 109.753 -176.095 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.484 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -112.17 156.07 22.91 Favored 'General case' 0 CA--C 1.503 -0.831 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 -178.845 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.469 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 88.5 m-85 -156.32 -178.93 7.69 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 124.309 1.044 . . . . 0.0 109.144 -177.616 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 63.01 -139.71 44.95 Favored Glycine 0 C--O 1.221 -0.672 0 O-C-N 123.367 0.417 . . . . 0.0 112.164 177.647 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.99 -6.98 86.12 Favored Glycine 0 C--O 1.203 -1.833 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.043 177.061 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.471 HG23 ' HB ' ' A' ' 126' ' ' ILE . 73.2 t -69.6 -38.52 76.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 C-N-CA 123.587 0.755 . . . . 0.0 111.815 -176.359 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.484 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -85.62 -21.72 28.3 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.954 -0.699 . . . . 0.0 112.194 179.136 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 14.0 m -100.89 -50.75 3.74 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 -173.389 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.405 ' O ' HG23 ' A' ' 112' ' ' VAL . 46.1 m-20 -93.36 -22.67 18.8 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 -176.028 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 1.625 ' HD2' ' CD1' ' A' ' 71' ' ' PHE . 84.0 m-85 -110.29 160.77 16.25 Favored 'General case' 0 N--CA 1.417 -2.112 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 177.411 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.5 t -166.76 131.68 2.12 Favored 'General case' 0 N--CA 1.415 -2.204 0 N-CA-C 106.049 -1.834 . . . . 0.0 106.049 175.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.439 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -166.76 -112.47 0.26 Allowed Glycine 0 N--CA 1.401 -3.66 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 175.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -157.28 179.37 9.33 Favored 'General case' 0 C--N 1.281 -2.373 0 C-N-CA 123.685 0.794 . . . . 0.0 110.714 -172.324 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.418 HG11 ' CE2' ' A' ' 82' ' ' TYR . 2.6 p -134.97 148.17 29.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 178.347 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.68 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.1 tttt -125.73 150.04 48.03 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.156 -178.188 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.467 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 57.3 t80 -151.6 116.18 5.11 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 -178.15 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 2.7 m 53.79 33.87 17.91 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 179.116 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 85.6 9.67 78.14 Favored Glycine 0 CA--C 1.526 0.721 0 C-N-CA 120.291 -0.957 . . . . 0.0 112.923 -178.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.68 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 9.4 t -80.23 -179.69 7.21 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.098 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 11.4 p -154.63 110.17 3.14 Favored 'General case' 0 C--N 1.289 -2.039 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.05 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 0.467 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 5.0 p90 -153.01 159.55 32.08 Favored Pre-proline 0 CA--C 1.551 1.001 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -174.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -67.53 150.0 80.02 Favored 'Trans proline' 0 C--N 1.362 1.269 0 C-N-CA 123.059 2.506 . . . . 0.0 113.442 -176.096 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 1.655 ' HD2' ' CD1' ' A' ' 84' ' ' PHE . 55.6 t80 -125.92 132.76 24.42 Favored Pre-proline 0 N--CA 1.445 -0.709 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.027 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.429 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 69.6 Cg_endo -72.64 144.41 80.63 Favored 'Cis proline' 0 C--O 1.245 0.856 0 C-N-CA 122.786 -1.756 . . . . 0.0 110.313 -1.342 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.3 t -66.87 -176.68 0.53 Allowed 'General case' 0 CA--C 1.546 0.824 0 CA-C-N 115.571 -0.741 . . . . 0.0 112.219 -173.028 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 12.9 p -119.06 -49.39 2.41 Favored 'General case' 0 N--CA 1.419 -2.004 0 CA-C-N 115.362 -0.835 . . . . 0.0 111.23 -173.073 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.7 t -104.78 -81.28 0.53 Allowed 'General case' 0 N--CA 1.424 -1.759 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.992 -174.502 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -175.64 -170.09 0.39 Allowed 'General case' 0 C--O 1.238 0.462 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 -175.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.518 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 56.2 p -101.44 164.39 16.05 Favored Pre-proline 0 C--N 1.303 -1.418 0 N-CA-C 112.817 0.673 . . . . 0.0 112.817 176.22 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . 0.428 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 22.8 Cg_endo -60.7 172.12 3.05 Favored 'Trans proline' 0 CA--C 1.552 1.41 0 C-N-CA 123.194 2.596 . . . . 0.0 111.891 173.482 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.2 tmm_? -73.74 119.6 18.19 Favored 'General case' 0 C--N 1.323 -0.584 0 C-N-CA 123.674 0.79 . . . . 0.0 110.068 -173.734 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 75.5 t -138.45 139.07 42.15 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -177.536 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.94 142.0 32.95 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.974 0 C-N-CA 122.978 0.511 . . . . 0.0 109.869 -176.225 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . 0.519 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 4.9 m-85 -95.68 105.38 17.37 Favored 'General case' 0 C--N 1.309 -1.184 0 C-N-CA 123.186 0.594 . . . . 0.0 109.853 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -93.01 50.89 1.6 Allowed 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 121.618 0.723 . . . . 0.0 109.271 177.2 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 12.2 p -117.47 178.4 4.4 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.023 -0.989 . . . . 0.0 110.841 -175.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 36.1 ptt180 -144.35 36.9 1.22 Allowed 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 172.408 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.8 t -158.31 171.77 19.57 Favored 'General case' 0 C--N 1.312 -1.036 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 -173.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.45 99.32 4.15 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -98.05 139.37 21.21 Favored Pre-proline 0 C--N 1.287 -2.118 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.292 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -60.19 147.57 92.95 Favored 'Trans proline' 0 C--O 1.245 0.844 0 C-N-CA 122.938 2.425 . . . . 0.0 112.134 178.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . 0.519 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 11.4 t90 -93.64 106.51 21.5 Favored Pre-proline 0 C--N 1.311 -1.094 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 -178.341 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -77.04 88.79 1.37 Allowed 'Trans proline' 0 N--CA 1.455 -0.756 0 C-N-CA 121.984 1.79 . . . . 0.0 113.212 -172.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.433 HG21 ' CD2' ' A' ' 77' ' ' TYR . 66.6 t -140.12 146.43 24.8 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.296 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 178.014 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.593 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.69 134.98 17.01 Favored 'General case' 0 C--N 1.291 -1.947 0 CA-C-O 120.659 0.266 . . . . 0.0 110.919 177.592 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.451 ' O ' ' HA ' ' A' ' 35' ' ' VAL . 18.4 mt -101.11 100.04 10.55 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 179.682 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.439 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 58.8 m-85 -81.66 76.43 8.57 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 110.299 -0.26 . . . . 0.0 110.299 177.27 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.603 HD22 ' CD2' ' A' ' 84' ' ' PHE . 3.1 mm? -101.4 125.51 48.05 Favored 'General case' 0 CA--C 1.485 -1.528 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 176.02 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -126.68 148.05 63.27 Favored Pre-proline 0 N--CA 1.398 -3.036 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -175.075 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.403 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 28.6 Cg_endo -62.14 123.72 13.04 Favored 'Trans proline' 0 N--CA 1.446 -1.322 0 C-N-CA 123.132 2.555 . . . . 0.0 113.611 -176.522 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.519 ' O ' HG23 ' A' ' 30' ' ' VAL . 17.9 m -85.95 -157.69 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.398 -3.053 0 CA-C-N 114.34 -1.3 . . . . 0.0 108.696 171.225 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 15.8 t -81.83 -24.69 35.7 Favored 'General case' 0 C--N 1.254 -3.586 0 CA-C-O 121.755 0.788 . . . . 0.0 109.034 -171.175 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 28.0 t -80.85 18.23 1.03 Allowed 'General case' 0 N--CA 1.434 -1.267 0 CA-C-N 115.228 -0.896 . . . . 0.0 110.433 178.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -106.81 138.8 42.3 Favored 'General case' 0 N--CA 1.421 -1.887 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.373 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 177.19 125.42 0.9 Allowed Glycine 0 N--CA 1.441 -0.999 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 179.599 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 68.75 -149.54 49.6 Favored Glycine 0 CA--C 1.496 -1.096 0 CA-C-O 119.07 -0.85 . . . . 0.0 111.38 -176.404 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 57.7 t -58.91 105.71 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-O 121.718 0.771 . . . . 0.0 111.018 -176.564 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -105.77 -34.67 7.61 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 114.785 -1.098 . . . . 0.0 111.128 -178.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.412 ' HB ' HG21 ' A' ' 154' ' ' VAL . 70.4 mt -119.7 136.98 55.09 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.062 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.85 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.461 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.2 mmpt? -113.39 138.5 49.97 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-O 121.035 0.445 . . . . 0.0 110.428 177.043 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -72.31 137.57 46.78 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.957 179.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 82.16 5.17 89.89 Favored Glycine 0 C--N 1.31 -0.868 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.864 -179.123 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 44.6 m -104.66 141.1 37.05 Favored 'General case' 0 N--CA 1.421 -1.903 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -67.35 123.81 21.38 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 178.049 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.471 ' HB ' HG23 ' A' ' 67' ' ' VAL . 28.6 pt -111.44 -26.21 3.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 116.129 -0.487 . . . . 0.0 112.16 -178.675 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.59 168.41 23.56 Favored 'General case' 0 N--CA 1.443 -0.784 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -178.254 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 77.2 t -142.68 114.9 3.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 62.7 mt -116.23 143.88 44.94 Favored 'General case' 0 C--N 1.286 -2.16 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 178.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.516 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.9 mp -123.94 123.35 66.67 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.101 178.422 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.497 ' O ' HD21 ' A' ' 131' ' ' LEU . 0.0 OUTLIER -89.11 134.7 33.91 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 176.718 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 12.4 tpt180 -101.79 109.56 21.35 Favored 'General case' 0 C--N 1.277 -2.553 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 179.114 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.499 ' HB3' ' CE2' ' A' ' 1' ' ' PHE . 10.1 mm-40 -100.8 105.12 16.4 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 176.536 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.422 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 7.7 m -124.17 136.02 53.89 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 179.205 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.53 ' CB ' HG21 ' A' ' 52' ' ' ILE . 7.9 p30 -120.8 167.95 11.96 Favored 'General case' 0 C--N 1.32 -0.691 0 C-N-CA 117.831 -1.548 . . . . 0.0 112.336 178.441 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 5.0 p30 -89.37 -5.17 57.69 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 114.535 -1.211 . . . . 0.0 111.982 -170.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . 1.63 ' HD2' ' CD1' ' A' ' 137' ' ' TYR . 30.4 t80 -113.51 -69.75 0.84 Allowed 'General case' 0 C--N 1.301 -1.539 0 CA-C-O 120.74 0.305 . . . . 0.0 111.639 -173.68 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -88.23 166.35 14.4 Favored 'General case' 0 CA--C 1.472 -2.024 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 23.8 m -87.11 39.46 0.86 Allowed 'General case' 0 C--N 1.27 -2.869 0 CA-C-N 114.409 -1.269 . . . . 0.0 109.658 177.231 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -87.34 53.42 2.8 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.561 -177.652 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -85.39 96.34 9.53 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 176.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . 1.664 ' HE2' ' CE1' ' A' ' 142' ' ' PHE . 74.0 m-85 -130.52 137.03 49.53 Favored 'General case' 0 N--CA 1.417 -2.118 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.681 -179.048 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . 0.448 ' NE2' HG22 ' A' ' 130' ' ' ILE . 20.9 pt20 -108.22 133.46 52.43 Favored 'General case' 0 N--CA 1.413 -2.308 0 CA-C-O 121.493 0.663 . . . . 0.0 110.033 177.073 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.454 ' HB2' HD23 ' A' ' 131' ' ' LEU . 8.0 m-30 -103.02 133.77 47.58 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 -176.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 46.6 t -91.44 129.91 41.42 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.929 0 CA-C-O 121.115 0.484 . . . . 0.0 109.766 -178.514 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . 0.46 ' CZ2' ' HB2' ' A' ' 3' ' ' CYS . 62.2 m95 -120.22 96.2 5.06 Favored 'General case' 0 C--N 1.277 -2.568 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -80.22 114.73 19.34 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 25.5 mm -87.42 123.31 40.07 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.799 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 -177.506 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 1.649 ' HD1' ' CD2' ' A' ' 149' ' ' TYR . 58.7 m-85 -116.79 151.09 37.22 Favored 'General case' 0 C--N 1.292 -1.909 0 C-N-CA 124.207 1.003 . . . . 0.0 109.349 178.171 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.68 131.81 35.28 Favored 'General case' 0 N--CA 1.411 -2.419 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 175.635 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 17.8 t-20 -93.15 -11.39 32.93 Favored 'General case' 0 C--N 1.292 -1.919 0 CA-C-O 122.469 1.128 . . . . 0.0 108.033 -176.506 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -152.02 143.62 23.53 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 114.023 -1.444 . . . . 0.0 109.41 -177.457 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -86.4 139.49 30.89 Favored 'General case' 0 C--N 1.309 -1.173 0 O-C-N 124.133 0.896 . . . . 0.0 110.183 -179.389 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.45 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 1.8 m -120.38 153.05 23.42 Favored 'Isoleucine or valine' 0 C--O 1.251 1.144 0 CA-C-O 120.94 0.4 . . . . 0.0 111.217 -175.599 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.0 t -123.14 142.63 39.03 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.2 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.492 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 77.1 t -104.26 102.46 32.96 Favored Pre-proline 0 C--N 1.289 -2.039 0 C-N-CA 123.444 0.698 . . . . 0.0 110.039 179.179 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.44 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 29.7 Cg_endo -67.26 -23.23 45.32 Favored 'Trans proline' 0 C--O 1.219 -0.437 0 C-N-CA 122.498 2.132 . . . . 0.0 111.56 176.656 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.287 5.1 t . . . . . 0 C--O 1.258 1.515 0 CA-C-O 117.45 -1.262 . . . . 0.0 113.768 176.054 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.443 ' CZ ' ' HB3' ' A' ' 44' ' ' CYS . 66.1 t80 . . . . . 0 CA--C 1.499 -0.988 0 N-CA-C 107.442 -1.318 . . . . 0.0 107.442 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -145.66 170.17 17.01 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.695 178.378 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.418 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 76.9 m -145.48 159.31 43.29 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -178.813 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.406 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -145.55 155.56 43.14 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-O 121.451 0.643 . . . . 0.0 110.164 -177.37 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 44.7 p -92.36 177.33 6.17 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.856 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.91 -17.13 48.26 Favored 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.953 179.148 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -90.76 -24.93 20.22 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.582 -177.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 131.73 -3.11 5.33 Favored Glycine 0 CA--C 1.494 -1.233 0 C-N-CA 119.271 -1.442 . . . . 0.0 114.428 169.321 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.7 m -80.55 100.05 8.39 Favored 'General case' 0 C--N 1.285 -2.211 0 CA-C-O 121.453 0.644 . . . . 0.0 109.536 -178.221 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -94.56 124.75 38.78 Favored 'General case' 0 N--CA 1.424 -1.77 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.115 176.72 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 69.6 mt -92.11 116.45 66.48 Favored Pre-proline 0 C--N 1.278 -2.539 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 177.72 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -75.9 177.09 9.18 Favored 'Trans proline' 0 C--O 1.245 0.841 0 C-N-CA 122.54 2.16 . . . . 0.0 111.719 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 67.9 mt -70.23 128.4 33.48 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.4 179.564 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 128.89 5.19 4.93 Favored Glycine 0 N--CA 1.432 -1.576 0 C-N-CA 120.372 -0.918 . . . . 0.0 111.69 -178.19 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 86.07 169.74 46.25 Favored Glycine 0 N--CA 1.439 -1.106 0 C-N-CA 120.511 -0.852 . . . . 0.0 111.588 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.86 -174.85 30.83 Favored Glycine 0 CA--C 1.487 -1.686 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 178.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.3 m -134.1 159.37 41.06 Favored 'General case' 0 C--N 1.296 -1.759 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 -179.131 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -141.46 165.51 27.31 Favored 'General case' 0 N--CA 1.42 -1.935 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 177.21 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -116.1 104.41 11.52 Favored 'General case' 0 C--N 1.273 -2.73 0 CA-C-N 114.002 -1.453 . . . . 0.0 108.913 178.079 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.42 HG23 ' HA ' ' A' ' 148' ' ' ILE . 1.3 m -91.68 146.4 6.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 -178.563 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 1.648 ' HE2' ' CE1' ' A' ' 21' ' ' TYR . 54.8 m-85 -128.93 112.51 14.16 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-O 121.03 0.443 . . . . 0.0 111.28 -177.502 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.459 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.6 p -118.69 129.78 74.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 CA-C-O 121.692 0.758 . . . . 0.0 111.995 -174.626 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.3 m-80 -84.52 126.06 32.96 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 177.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 23.0 mt -113.06 157.31 21.74 Favored 'General case' 0 C--N 1.272 -2.777 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 -179.155 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.36 120.74 46.79 Favored Pre-proline 0 C--N 1.313 -1.011 0 O-C-N 124.207 0.942 . . . . 0.0 109.723 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.447 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 60.6 Cg_endo -74.2 -0.12 9.19 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.657 2.238 . . . . 0.0 112.616 -177.536 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 94.9 t -125.3 109.95 23.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 177.639 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.479 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.6 t -140.91 107.02 1.97 Allowed 'Isoleucine or valine' 0 C--O 1.179 -2.622 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 -179.544 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.597 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -98.64 148.86 23.38 Favored 'General case' 0 C--N 1.265 -3.089 0 O-C-N 122.13 -0.356 . . . . 0.0 111.266 -179.5 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.411 HG11 ' O ' ' A' ' 112' ' ' VAL . 22.2 t -43.8 117.04 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.528 0 C-N-CA 123.571 0.748 . . . . 0.0 111.501 175.759 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.84 -1.07 48.36 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-N 115.002 -0.999 . . . . 0.0 113.063 -179.035 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.597 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -71.48 -177.04 1.7 Allowed 'General case' 0 C--N 1.318 -0.802 0 C-N-CA 124.496 1.118 . . . . 0.0 111.237 177.784 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -133.41 87.61 2.41 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 177.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.613 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.5 tp -88.76 140.3 29.59 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 -178.69 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.2 t -134.11 125.4 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.172 0 CA-C-O 121.113 0.483 . . . . 0.0 109.787 -175.472 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.582 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 41.1 t -95.78 88.2 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.399 -2.994 0 N-CA-C 105.713 -1.958 . . . . 0.0 105.713 174.196 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -80.57 116.07 20.42 Favored 'General case' 0 CA--C 1.486 -1.482 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.0 mt -97.52 0.06 46.86 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.249 -177.459 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.548 ' OG ' ' HA ' ' A' ' 104' ' ' PRO . 19.6 m -81.22 -2.37 48.5 Favored 'General case' 0 C--N 1.29 -1.988 0 CA-C-O 122.658 1.218 . . . . 0.0 109.703 -179.296 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.4 p -118.8 1.58 11.57 Favored 'General case' 0 C--N 1.275 -2.663 0 CA-C-N 114.807 -1.088 . . . . 0.0 109.811 175.725 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.459 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 44.8 mm-40 -122.41 -23.09 5.31 Favored 'General case' 0 CA--C 1.512 -0.497 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.329 -174.566 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 29.0 mt -135.68 139.2 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.229 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -176.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.61 ' HE2' ' CE1' ' A' ' 43' ' ' PHE . 65.7 m-85 -137.52 151.79 48.8 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 -177.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.443 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 67.7 m -128.28 138.53 52.46 Favored 'General case' 0 C--N 1.276 -2.622 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 176.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.2 p80 -125.11 129.26 49.84 Favored 'General case' 0 C--N 1.295 -1.774 0 CA-C-O 121.955 0.883 . . . . 0.0 110.773 -177.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.538 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 24.4 p-10 -95.76 96.5 9.02 Favored 'General case' 0 C--N 1.279 -2.477 0 CA-C-O 122.466 1.127 . . . . 0.0 110.072 -179.214 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -74.7 -23.55 58.63 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 114.108 -1.405 . . . . 0.0 111.538 -174.466 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -128.91 65.23 72.89 Favored Pre-proline 0 N--CA 1.479 1.019 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.103 179.648 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.538 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 60.3 Cg_endo -68.85 -12.31 34.14 Favored 'Trans proline' 0 N--CA 1.483 0.881 0 C-N-CA 122.809 2.34 . . . . 0.0 114.148 -172.471 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -108.08 -21.15 12.92 Favored 'General case' 0 C--N 1.292 -1.894 0 C-N-CA 119.977 -0.689 . . . . 0.0 110.343 -176.662 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.405 ' HB ' HD13 ' A' ' 52' ' ' ILE . 1.8 m -96.21 -30.34 13.53 Favored 'General case' 0 N--CA 1.416 -2.154 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 -172.544 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.62 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -121.98 143.29 35.07 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.213 0 CA-C-N 113.991 -1.459 . . . . 0.0 108.737 -177.119 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.1 t -88.82 125.83 35.08 Favored 'General case' 0 N--CA 1.419 -2.014 0 N-CA-C 103.944 -2.613 . . . . 0.0 103.944 170.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 -90.61 107.18 19.01 Favored 'General case' 0 C--N 1.263 -3.18 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -172.63 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 0.466 ' HB3' ' O ' ' A' ' 134' ' ' THR . 34.2 t80 -126.02 117.72 23.83 Favored 'General case' 0 C--N 1.274 -2.7 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.489 -173.39 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.534 HG13 ' OH ' ' A' ' 77' ' ' TYR . 49.0 t -121.85 130.84 74.24 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.298 -175.517 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.1 p -143.45 113.43 7.19 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 123.923 0.764 . . . . 0.0 111.239 177.683 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.494 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 54.3 tp -55.34 109.7 0.58 Allowed 'General case' 0 C--N 1.311 -1.106 0 CA-C-O 121.313 0.578 . . . . 0.0 110.174 172.108 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.491 ' NE2' ' HD3' ' A' ' 132' ' ' ARG . 3.4 tp-100 -54.91 -53.64 52.96 Favored 'General case' 0 C--O 1.209 -1.04 0 C-N-CA 126.041 1.736 . . . . 0.0 110.911 178.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -171.06 160.9 6.65 Favored 'General case' 0 N--CA 1.425 -1.71 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 -176.198 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -139.3 133.44 6.15 Favored Glycine 1 N--CA 1.391 -4.321 0 N-CA-C 108.041 -2.024 . . . . 0.0 108.041 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.2 m -120.76 151.6 39.36 Favored 'General case' 0 C--N 1.276 -2.599 0 O-C-N 124.956 1.033 . . . . 0.0 108.582 -174.145 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.544 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -116.16 157.67 24.45 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 -178.654 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.546 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 96.1 m-85 -155.69 176.8 12.14 Favored 'General case' 0 C--N 1.35 0.616 0 C-N-CA 124.246 1.018 . . . . 0.0 109.587 -177.283 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . 0.409 ' O ' HD13 ' A' ' 68' ' ' LEU . . . 58.35 -147.52 38.86 Favored Glycine 0 CA--C 1.52 0.365 0 O-C-N 123.61 0.569 . . . . 0.0 112.81 178.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -70.58 -10.34 66.77 Favored Glycine 0 C--O 1.205 -1.665 0 O-C-N 122.052 -0.676 . . . . 0.0 111.976 177.106 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.546 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 92.8 t -70.53 -36.75 67.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 123.544 0.737 . . . . 0.0 111.322 -177.172 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.544 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.71 -23.09 25.67 Favored 'General case' 0 N--CA 1.421 -1.883 0 C-N-CA 118.6 -1.24 . . . . 0.0 112.144 179.179 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 17.1 t -101.77 -55.46 2.5 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 112.952 0.723 . . . . 0.0 112.952 -175.213 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 72.4 m-20 -83.91 -27.43 28.6 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 -174.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 0.53 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 90.0 m-85 -107.02 159.19 16.47 Favored 'General case' 0 N--CA 1.421 -1.917 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 176.463 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.8 t -168.09 136.24 2.3 Favored 'General case' 0 N--CA 1.41 -2.431 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 176.292 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.428 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -169.37 -108.21 0.21 Allowed Glycine 0 N--CA 1.411 -3.027 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 175.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.442 HG23 ' HA ' ' A' ' 83' ' ' PRO . 1.1 p -159.21 -179.96 8.46 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 123.829 0.852 . . . . 0.0 110.547 -173.225 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.05 146.73 29.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 C-N-CA 123.435 0.694 . . . . 0.0 109.143 178.614 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.616 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.1 tttt -125.17 142.17 51.66 Favored 'General case' 0 N--CA 1.417 -2.095 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.518 -179.442 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.534 ' OH ' HG13 ' A' ' 56' ' ' VAL . 72.4 t80 -144.48 111.06 5.64 Favored 'General case' 0 C--N 1.295 -1.796 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.13 -177.195 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 35.1 t 55.14 34.33 22.39 Favored 'General case' 0 C--N 1.317 -0.825 0 C-N-CA 123.416 0.686 . . . . 0.0 111.164 178.212 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.08 10.52 64.32 Favored Glycine 0 N--CA 1.44 -1.079 0 C-N-CA 120.486 -0.864 . . . . 0.0 113.566 -178.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.616 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 20.8 t -79.84 179.8 7.36 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.551 0.676 . . . . 0.0 109.31 178.484 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 9.7 p -156.55 90.35 1.16 Allowed 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.623 0.725 . . . . 0.0 110.637 -176.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 1.638 ' HE2' ' CE1' ' A' ' 82' ' ' TYR . 1.5 p90 -139.85 158.31 67.9 Favored Pre-proline 0 C--N 1.297 -1.69 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 -173.098 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.442 ' HA ' HG23 ' A' ' 74' ' ' THR . 58.9 Cg_endo -69.35 151.03 71.39 Favored 'Trans proline' 0 C--N 1.354 0.842 0 C-N-CA 123.148 2.565 . . . . 0.0 113.154 -177.081 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 1.651 ' HE1' ' CE2' ' A' ' 84' ' ' PHE . 58.0 t80 -122.74 133.21 24.33 Favored Pre-proline 0 N--CA 1.439 -1.011 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.018 -179.541 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.474 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 79.3 Cg_endo -71.43 149.78 92.7 Favored 'Cis proline' 0 CA--C 1.534 0.511 0 C-N-CA 122.71 -1.787 . . . . 0.0 109.73 -0.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.0 t -61.06 -175.54 0.05 OUTLIER 'General case' 0 CA--C 1.562 1.415 0 C-N-CA 123.399 0.679 . . . . 0.0 112.595 -175.462 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 12.4 p -104.97 -50.53 3.23 Favored 'General case' 0 N--CA 1.408 -2.563 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 -177.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.6 t -128.43 -109.19 0.29 Allowed 'General case' 0 N--CA 1.402 -2.873 0 CA-C-N 114.346 -1.297 . . . . 0.0 108.591 178.338 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -125.35 -171.68 2.42 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 118.539 0.609 . . . . 0.0 112.503 -176.692 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.494 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 36.1 p -93.95 167.57 13.4 Favored Pre-proline 0 C--N 1.309 -1.189 0 N-CA-C 112.924 0.713 . . . . 0.0 112.924 -178.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -62.82 175.87 2.11 Favored 'Trans proline' 0 CA--C 1.552 1.386 0 C-N-CA 123.087 2.524 . . . . 0.0 111.904 172.424 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.4 tmm_? -74.84 129.5 37.79 Favored 'General case' 0 C--O 1.243 0.761 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.004 -175.469 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.473 ' HB ' ' O ' ' A' ' 56' ' ' VAL . 65.3 t -140.09 132.57 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 C-N-CA 123.718 0.807 . . . . 0.0 109.801 -176.497 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 1.9 p -131.08 136.41 57.95 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.411 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 177.461 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . 1.637 ' HE2' ' CE1' ' A' ' 95' ' ' TYR . 6.1 m-85 -79.8 116.47 19.98 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-O 121.388 0.613 . . . . 0.0 110.525 -179.745 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 -102.22 68.46 1.09 Allowed 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 177.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 46.0 t -147.64 179.23 7.84 Favored 'General case' 0 N--CA 1.426 -1.646 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 -175.578 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 31.8 ptt180 -151.11 42.12 0.76 Allowed 'General case' 0 C--N 1.31 -1.146 0 C-N-CA 124.036 0.934 . . . . 0.0 108.51 171.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 11.0 t -169.72 172.32 6.87 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-N 114.525 -1.216 . . . . 0.0 108.23 -177.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -59.34 119.87 8.24 Favored 'General case' 0 N--CA 1.474 0.768 0 O-C-N 123.756 0.66 . . . . 0.0 110.493 178.357 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 55.9 mmtt -120.2 143.19 35.12 Favored Pre-proline 0 C--N 1.287 -2.143 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.994 178.364 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -67.16 139.19 49.71 Favored 'Trans proline' 0 N--CA 1.44 -1.676 0 C-N-CA 122.392 2.061 . . . . 0.0 110.32 177.252 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 14.4 t90 -80.34 109.69 13.69 Favored Pre-proline 0 C--N 1.307 -1.243 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 -177.476 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.548 ' HA ' ' OG ' ' A' ' 39' ' ' SER . 60.7 Cg_endo -74.85 87.7 1.28 Allowed 'Trans proline' 0 N--CA 1.451 -0.982 0 C-N-CA 121.12 1.213 . . . . 0.0 112.844 -172.376 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 59.7 t -144.9 145.18 21.24 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.359 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 179.579 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.582 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.65 136.27 17.03 Favored 'General case' 0 C--N 1.288 -2.07 0 O-C-N 123.569 0.543 . . . . 0.0 110.116 177.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.41 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 17.7 mt -101.81 105.12 15.92 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 177.936 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 1.602 ' HE2' ' CE1' ' A' ' 108' ' ' TYR . 39.3 m-85 -85.29 80.49 9.15 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 177.481 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.613 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.2 mm? -105.12 125.32 50.85 Favored 'General case' 0 CA--C 1.491 -1.327 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 177.441 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -128.04 146.63 59.99 Favored Pre-proline 0 N--CA 1.412 -2.363 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.62 -175.542 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 23.1 Cg_endo -61.14 117.6 4.39 Favored 'Trans proline' 0 C--O 1.245 0.863 0 C-N-CA 123.424 2.749 . . . . 0.0 112.369 -178.458 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.411 ' O ' HG11 ' A' ' 30' ' ' VAL . 2.7 m -67.04 -114.14 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.202 -1.447 0 CA-C-N 114.289 -1.323 . . . . 0.0 112.752 176.735 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 41.7 m -112.56 -43.4 3.48 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.287 -0.883 . . . . 0.0 110.441 175.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 22.7 t -82.82 30.2 0.44 Allowed 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.067 -174.726 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -101.79 130.94 48.33 Favored 'General case' 0 N--CA 1.418 -2.035 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.2 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.28 141.06 6.45 Favored Glycine 0 N--CA 1.432 -1.596 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 58.81 -149.23 37.78 Favored Glycine 0 C--O 1.219 -0.812 0 CA-C-O 119.244 -0.753 . . . . 0.0 113.307 -179.087 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 99.5 t -56.56 96.75 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 121.581 0.705 . . . . 0.0 111.26 -178.207 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -99.4 -27.78 13.58 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.365 -177.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 68.9 mt -126.84 138.53 54.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 177.105 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 4.2 mmpt? -111.02 138.05 47.9 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-O 121.341 0.591 . . . . 0.0 111.207 178.409 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.56 128.57 36.96 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.46 178.029 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 92.05 -7.16 78.96 Favored Glycine 0 N--CA 1.428 -1.89 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.093 -179.349 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 91.9 p -90.85 143.9 26.25 Favored 'General case' 0 C--O 1.253 1.253 0 C-N-CA 119.495 -0.882 . . . . 0.0 109.525 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -70.72 122.37 19.69 Favored 'General case' 0 N--CA 1.435 -1.22 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 177.367 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.494 ' HB ' HG23 ' A' ' 67' ' ' VAL . 31.6 pt -109.02 -24.47 4.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -177.116 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.72 167.32 23.22 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 -177.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 76.9 t -141.62 114.93 4.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 179.506 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 52.7 mt -117.97 144.68 45.32 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 178.484 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.473 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.4 mp -127.41 130.19 70.67 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 C-N-CA 119.41 -0.916 . . . . 0.0 110.639 179.006 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.424 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.9 OUTLIER -94.75 128.99 41.85 Favored 'General case' 0 C--N 1.29 -1.982 0 C-N-CA 123.855 0.862 . . . . 0.0 111.477 -179.607 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . 0.491 ' HD3' ' NE2' ' A' ' 59' ' ' GLN . 25.9 mmm180 -94.58 120.55 34.99 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 173.185 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.548 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 7.4 tp-100 -103.38 137.23 41.78 Favored 'General case' 0 N--CA 1.427 -1.59 0 N-CA-C 105.937 -1.875 . . . . 0.0 105.937 169.495 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.466 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 27.8 m -150.23 134.76 17.38 Favored 'General case' 0 C--N 1.278 -2.527 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 173.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.62 ' CB ' HG21 ' A' ' 52' ' ' ILE . 8.7 p30 -133.81 169.0 17.7 Favored 'General case' 0 N--CA 1.437 -1.108 0 C-N-CA 118.966 -1.094 . . . . 0.0 112.057 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -91.58 -2.1 57.25 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 113.852 -1.522 . . . . 0.0 112.329 -170.826 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . 1.632 ' HD2' ' CD1' ' A' ' 137' ' ' TYR . 65.8 t80 -113.1 -63.39 1.45 Allowed 'General case' 0 C--N 1.296 -1.752 0 CA-C-O 121.154 0.502 . . . . 0.0 111.59 -174.327 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 70.7 m-20 -100.01 177.1 5.2 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.245 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 21.0 t -97.1 39.07 1.2 Allowed 'General case' 0 N--CA 1.431 -1.386 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 176.089 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . 0.548 ' HB3' ' ND2' ' A' ' 135' ' ' ASN . 29.7 t0 -83.31 66.07 8.62 Favored 'General case' 0 CA--C 1.512 -0.509 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 174.159 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . 0.548 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 5.6 p-10 -114.1 47.79 1.16 Allowed 'General case' 0 N--CA 1.423 -1.81 0 CA-C-N 112.766 -2.015 . . . . 0.0 108.165 179.021 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . 1.667 ' HD2' ' CD1' ' A' ' 142' ' ' PHE . 82.0 m-85 -90.92 161.86 15.01 Favored 'General case' 0 N--CA 1.421 -1.881 0 CA-C-N 114.013 -1.449 . . . . 0.0 109.284 -179.557 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 11.4 pt20 -121.98 138.24 54.5 Favored 'General case' 0 N--CA 1.416 -2.152 0 C-N-CA 119.251 -0.98 . . . . 0.0 109.844 178.837 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 1.65 ' HE1' ' CE2' ' A' ' 144' ' ' PHE . 11.8 m-30 -105.12 128.98 53.62 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 -176.755 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.6 t -94.67 133.88 34.07 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.116 0 CA-C-O 121.143 0.497 . . . . 0.0 110.24 -178.152 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . 0.424 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.2 m95 -120.19 96.83 5.32 Favored 'General case' 0 C--N 1.286 -2.179 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.134 -177.224 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 44.3 m-80 -79.15 112.92 16.85 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 176.383 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . 0.42 ' HA ' HG23 ' A' ' 20' ' ' VAL . 23.9 mm -87.74 120.55 37.02 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 -177.604 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 1.653 ' HE2' ' CE1' ' A' ' 149' ' ' TYR . 96.0 m-85 -115.45 153.59 30.82 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 177.593 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.51 132.44 34.2 Favored 'General case' 0 N--CA 1.406 -2.63 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 177.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -90.02 -17.18 28.3 Favored 'General case' 0 C--N 1.286 -2.189 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 -176.115 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -146.18 144.31 29.85 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 114.088 -1.415 . . . . 0.0 110.123 -174.755 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -83.45 138.22 33.56 Favored 'General case' 0 C--N 1.317 -0.819 0 O-C-N 124.314 1.009 . . . . 0.0 109.697 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.447 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 2.0 m -119.83 151.83 22.44 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 C-N-CA 120.634 -0.426 . . . . 0.0 111.045 -176.898 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.2 t -123.78 140.96 45.69 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 -179.139 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.479 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.4 t -103.2 100.35 17.42 Favored Pre-proline 0 C--N 1.291 -1.945 0 C-N-CA 123.435 0.694 . . . . 0.0 109.864 178.43 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.445 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 35.2 Cg_endo -68.17 -21.04 42.85 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.52 2.147 . . . . 0.0 111.403 177.111 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.1 t . . . . . 0 C--O 1.257 1.453 0 C-N-CA 124.789 1.236 . . . . 0.0 114.128 175.531 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.556 ' CZ ' ' HB3' ' A' ' 133' ' ' GLN . 0.8 OUTLIER . . . . . 0 N--CA 1.436 -1.158 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 . . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.446 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . -148.03 -175.76 5.01 Favored 'General case' 0 C--N 1.277 -2.574 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 -175.6 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 9.6 t -144.32 157.25 44.37 Favored 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 118.864 -1.134 . . . . 0.0 110.175 -175.347 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.407 ' HE3' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.48 164.9 29.49 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-O 121.254 0.55 . . . . 0.0 110.961 -175.335 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.402 HG21 HG23 ' A' ' 20' ' ' VAL . 82.1 p -102.18 176.81 5.07 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.841 -178.61 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.3 -16.51 56.25 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 114.402 -1.272 . . . . 0.0 110.722 176.038 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -90.93 -26.49 19.26 Favored 'General case' 0 CA--C 1.515 -0.375 0 C-N-CA 118.856 -1.137 . . . . 0.0 111.341 -177.467 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.48 4.87 3.43 Favored Glycine 0 CA--C 1.499 -0.932 0 C-N-CA 119.889 -1.148 . . . . 0.0 113.322 171.261 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.6 m -82.67 107.48 15.34 Favored 'General case' 0 N--CA 1.424 -1.759 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.404 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -102.53 109.99 21.78 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.43 176.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.446 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 54.8 mt -82.62 124.63 77.34 Favored Pre-proline 0 C--N 1.305 -1.338 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -176.688 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -81.36 161.94 19.83 Favored 'Trans proline' 0 C--O 1.246 0.924 0 C-N-CA 122.61 2.207 . . . . 0.0 111.922 179.073 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.408 HD12 ' N ' ' A' ' 1' ' ' PHE . 58.0 mt -66.27 133.0 31.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.09 179.544 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 126.57 12.24 3.44 Favored Glycine 0 C--N 1.306 -1.1 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.238 -178.661 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.97 148.84 18.93 Favored Glycine 0 C--O 1.241 0.564 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 -178.054 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.62 -172.36 45.17 Favored Glycine 0 CA--C 1.491 -1.415 0 C-N-CA 119.453 -1.356 . . . . 0.0 112.493 -179.693 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.7 p -146.55 151.76 37.86 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 122.654 0.382 . . . . 0.0 110.325 -177.729 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -140.38 166.47 24.63 Favored 'General case' 0 N--CA 1.433 -1.283 0 CA-C-O 121.617 0.722 . . . . 0.0 109.89 178.33 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.39 101.54 8.49 Favored 'General case' 0 C--N 1.28 -2.423 0 CA-C-N 113.833 -1.531 . . . . 0.0 109.307 179.412 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.402 HG23 HG21 ' A' ' 5' ' ' THR . 40.4 t -92.25 134.4 30.53 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.802 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.563 -178.73 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 55.2 m-85 -119.6 126.73 51.9 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 -179.088 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.426 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.7 p -136.86 133.22 48.12 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.249 -177.047 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -93.67 129.77 39.85 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 121.643 0.735 . . . . 0.0 110.482 178.312 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -108.25 160.58 15.73 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 114.466 -1.243 . . . . 0.0 108.196 -179.704 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -59.08 123.7 70.66 Favored Pre-proline 0 C--N 1.314 -0.958 0 O-C-N 124.387 1.054 . . . . 0.0 109.233 177.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . . . . . . . . . 61.8 Cg_endo -74.94 -2.06 12.03 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.632 2.221 . . . . 0.0 113.159 -177.544 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.5 t -122.95 109.76 24.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 178.186 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.45 ' O ' HG11 ' A' ' 156' ' ' VAL . 1.7 t -141.1 102.16 1.17 Allowed 'Isoleucine or valine' 0 C--O 1.183 -2.436 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -177.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.578 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -94.01 152.22 18.97 Favored 'General case' 0 C--N 1.274 -2.689 0 O-C-N 122.149 -0.344 . . . . 0.0 111.471 179.878 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.408 HG11 ' O ' ' A' ' 112' ' ' VAL . 35.0 t -45.71 119.88 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 123.26 0.624 . . . . 0.0 112.156 176.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.83 1.6 55.13 Favored Glycine 0 N--CA 1.46 0.252 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.595 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.578 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.4 OUTLIER -71.49 -178.53 2.19 Favored 'General case' 0 C--N 1.312 -1.048 0 C-N-CA 124.158 0.983 . . . . 0.0 111.226 177.246 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -129.73 85.06 2.26 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 176.157 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.586 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 17.1 tp -92.98 134.94 34.62 Favored 'General case' 0 N--CA 1.423 -1.806 0 C-N-CA 119.446 -0.902 . . . . 0.0 108.727 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 2.0 p -141.61 132.38 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.515 0 CA-C-O 122.016 0.913 . . . . 0.0 112.366 -177.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.604 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 42.5 t -89.31 90.0 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.264 0 CA-C-N 113.665 -1.607 . . . . 0.0 108.376 179.156 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -73.96 103.39 4.44 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 -179.561 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.4 mt -89.94 -3.82 57.83 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 120.75 0.31 . . . . 0.0 111.782 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -73.43 0.81 11.2 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 122.07 0.938 . . . . 0.0 111.574 178.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.9 p -126.72 5.89 6.73 Favored 'General case' 0 N--CA 1.418 -2.033 0 CA-C-N 115.203 -0.908 . . . . 0.0 109.866 176.645 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.426 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 43.9 mm-40 -123.7 -23.15 4.78 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.958 -174.754 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.7 mt -133.7 137.56 52.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 -176.158 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.407 ' HB2' ' HE3' ' A' ' 4' ' ' LYS . 41.7 m-85 -142.41 124.37 15.27 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -175.136 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 81.7 m -101.27 147.27 26.49 Favored 'General case' 0 C--N 1.291 -1.957 0 N-CA-C 109.46 -0.571 . . . . 0.0 109.46 -179.361 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . 0.416 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 37.0 p-80 -136.7 129.79 31.13 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-O 121.763 0.792 . . . . 0.0 111.649 -173.813 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.457 ' ND2' ' HA ' ' A' ' 49' ' ' PRO . 41.7 t30 -93.05 102.25 14.58 Favored 'General case' 0 C--N 1.28 -2.446 0 C-N-CA 119.991 -0.684 . . . . 0.0 110.533 179.233 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -56.22 -27.91 56.48 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 124.804 1.241 . . . . 0.0 111.016 179.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 0.431 ' HB2' HD11 ' A' ' 52' ' ' ILE . 38.8 m-85 -125.84 79.17 68.82 Favored Pre-proline 0 C--N 1.309 -1.169 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 -177.383 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.457 ' HA ' ' ND2' ' A' ' 46' ' ' ASN . 57.8 Cg_endo -67.89 -7.33 19.33 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.852 2.368 . . . . 0.0 115.19 -170.503 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -120.76 -11.37 9.01 Favored 'General case' 0 C--N 1.311 -1.068 0 C-N-CA 120.253 -0.579 . . . . 0.0 111.073 -179.391 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.446 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.9 OUTLIER -104.79 -30.23 10.03 Favored 'General case' 0 N--CA 1.435 -1.206 0 CA-C-O 122.128 0.966 . . . . 0.0 109.128 -171.631 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.446 HD13 ' HB ' ' A' ' 51' ' ' THR . 2.0 mp -121.29 136.27 58.75 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.167 0 CA-C-N 114.351 -1.295 . . . . 0.0 109.807 -177.321 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 1.8 t -90.25 126.6 35.89 Favored 'General case' 0 N--CA 1.417 -2.08 0 N-CA-C 102.984 -2.969 . . . . 0.0 102.984 170.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.517 ' OD2' ' HB2' ' A' ' 1' ' ' PHE . 13.3 t70 -83.55 112.73 20.26 Favored 'General case' 0 C--N 1.274 -2.693 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 -172.155 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 1.655 ' HD1' ' CD2' ' A' ' 55' ' ' TYR . 22.0 t80 -127.77 123.31 34.97 Favored 'General case' 0 C--N 1.272 -2.801 0 CA-C-O 122.054 0.931 . . . . 0.0 110.671 -175.355 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.45 HG21 ' HG ' ' A' ' 131' ' ' LEU . 14.1 p -126.68 148.65 31.42 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.469 0 CA-C-N 114.334 -1.303 . . . . 0.0 109.802 -177.377 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.56 121.7 8.32 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.365 175.473 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.489 HD13 ' O ' ' A' ' 130' ' ' ILE . 53.0 tp -65.33 115.56 5.75 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 173.274 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.417 ' NE2' ' HD3' ' A' ' 132' ' ' ARG . 3.8 tp-100 -62.67 -61.65 2.27 Favored 'General case' 0 C--O 1.209 -1.038 0 C-N-CA 125.419 1.488 . . . . 0.0 109.499 178.764 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 9.9 ptp180 -158.61 159.36 35.36 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-N 114.513 -1.222 . . . . 0.0 108.227 -176.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -141.12 131.54 4.94 Favored Glycine 0 N--CA 1.399 -3.808 0 N-CA-C 108.478 -1.849 . . . . 0.0 108.478 -179.707 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 69.5 m -120.14 145.9 46.49 Favored 'General case' 0 C--N 1.28 -2.44 0 O-C-N 124.679 0.87 . . . . 0.0 110.475 -173.807 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.535 ' HB3' ' CE2' ' A' ' 84' ' ' PHE . . . -108.2 157.08 18.63 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 1.656 ' HE1' ' CE2' ' A' ' 64' ' ' TYR . 94.2 m-85 -157.07 -179.44 8.21 Favored 'General case' 0 C--O 1.235 0.325 0 C-N-CA 124.776 1.231 . . . . 0.0 108.949 -178.069 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 61.11 -144.19 48.63 Favored Glycine 0 CA--C 1.506 -0.516 0 O-C-N 123.489 0.493 . . . . 0.0 112.313 177.594 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -76.33 -9.58 85.75 Favored Glycine 0 C--O 1.2 -2.028 0 C-N-CA 120.892 -0.67 . . . . 0.0 111.698 176.425 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.513 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 80.1 t -68.63 -41.59 82.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 123.341 0.656 . . . . 0.0 111.796 -177.691 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.517 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -84.95 -16.47 40.87 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.154 -1.019 . . . . 0.0 112.072 178.727 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 22.7 t -100.6 -59.8 1.64 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.461 0.648 . . . . 0.0 111.692 -174.595 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.441 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 63.3 m-20 -86.32 -25.84 25.22 Favored 'General case' 0 CA--C 1.488 -1.426 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.403 -174.14 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 1.645 ' HD2' ' CD1' ' A' ' 71' ' ' PHE . 85.8 m-85 -107.66 160.93 15.32 Favored 'General case' 0 N--CA 1.412 -2.334 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.166 178.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.9 t -169.1 139.17 2.23 Favored 'General case' 0 N--CA 1.406 -2.626 0 N-CA-C 106.136 -1.802 . . . . 0.0 106.136 176.483 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.447 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -172.84 -104.23 0.17 Allowed Glycine 0 N--CA 1.411 -3.025 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 175.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.418 HG23 ' HA ' ' A' ' 83' ' ' PRO . 1.3 p -162.9 -179.61 6.9 Favored 'General case' 0 C--N 1.311 -1.106 0 C-N-CA 124.088 0.955 . . . . 0.0 110.895 -175.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -132.27 145.51 34.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 177.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.657 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.5 tttt -122.85 146.4 47.59 Favored 'General case' 0 N--CA 1.419 -2.007 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.443 -179.456 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.476 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 68.8 t80 -145.53 109.68 4.9 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.3 m 54.24 44.08 29.6 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 176.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 81.72 7.17 88.42 Favored Glycine 0 C--N 1.31 -0.873 0 C-N-CA 119.901 -1.142 . . . . 0.0 112.914 -179.589 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.657 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 13.0 t -82.08 174.24 11.41 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 178.038 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 21.8 t -153.14 111.75 3.71 Favored 'General case' 0 C--N 1.28 -2.435 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 -179.268 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 0.476 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 4.7 p90 -154.77 160.5 30.85 Favored Pre-proline 0 CA--C 1.551 1.001 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -174.579 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.418 ' HA ' HG23 ' A' ' 74' ' ' THR . 50.0 Cg_endo -68.45 150.0 75.23 Favored 'Trans proline' 0 C--N 1.36 1.144 0 C-N-CA 122.942 2.428 . . . . 0.0 113.496 -176.756 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.591 ' CD2' HD22 ' A' ' 109' ' ' LEU . 53.1 t80 -124.86 133.79 25.1 Favored Pre-proline 0 N--CA 1.441 -0.882 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.777 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.515 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 59.3 Cg_endo -70.25 148.3 87.54 Favored 'Cis proline' 0 CA--C 1.541 0.848 0 C-N-CA 122.682 -1.799 . . . . 0.0 109.747 -2.032 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 8.8 t -67.08 -178.23 0.76 Allowed 'General case' 0 CA--C 1.55 0.967 0 CA-C-O 121.972 0.891 . . . . 0.0 111.742 -174.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 13.2 p -127.67 -28.68 2.71 Favored 'General case' 0 N--CA 1.425 -1.677 0 CA-C-N 114.929 -1.032 . . . . 0.0 112.931 -169.343 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.7 t -128.1 -79.9 0.58 Allowed 'General case' 0 N--CA 1.432 -1.373 0 C-N-CA 119.086 -1.046 . . . . 0.0 111.726 -176.483 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -170.98 -177.99 2.37 Favored 'General case' 0 C--O 1.246 0.906 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 -179.513 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.43 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 15.6 p -101.54 165.8 13.41 Favored Pre-proline 0 C--N 1.296 -1.758 0 N-CA-C 113.241 0.83 . . . . 0.0 113.241 -179.527 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -64.08 158.4 48.13 Favored 'Trans proline' 0 C--N 1.361 1.235 0 C-N-CA 122.784 2.323 . . . . 0.0 111.772 173.083 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.583 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 4.6 tmm_? -72.33 119.38 16.44 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 114.679 -1.146 . . . . 0.0 109.574 -177.843 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 86.0 t -131.77 120.19 44.05 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.723 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 84.2 t -108.99 126.09 66.04 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.637 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . 1.641 ' HD2' ' CD1' ' A' ' 95' ' ' TYR . 5.5 m-85 -76.65 105.15 7.54 Favored 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 123.816 0.847 . . . . 0.0 109.971 177.563 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 34.2 m-80 -96.34 57.63 1.7 Allowed 'General case' 0 C--N 1.287 -2.144 0 CA-C-O 122.462 1.125 . . . . 0.0 108.783 178.081 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 33.0 m -124.3 174.29 7.82 Favored 'General case' 0 N--CA 1.418 -2.073 0 CA-C-N 113.775 -1.557 . . . . 0.0 109.27 -176.449 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.0 ptp180 -127.93 12.33 6.7 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 112.142 0.423 . . . . 0.0 112.142 -176.727 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.1 t -160.51 -171.77 3.28 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -177.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . 0.416 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 3.7 p30 -67.79 132.15 46.88 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.076 0.465 . . . . 0.0 109.853 178.661 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 12.5 mmtm -139.75 146.75 48.72 Favored Pre-proline 0 C--N 1.291 -1.945 0 C-N-CA 124.553 1.141 . . . . 0.0 109.034 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -61.61 147.0 96.41 Favored 'Trans proline' 0 C--O 1.25 1.089 0 C-N-CA 123.321 2.681 . . . . 0.0 113.412 -175.113 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . 0.575 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 8.6 t90 -92.61 105.61 15.23 Favored Pre-proline 0 C--N 1.31 -1.124 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -74.76 89.11 1.15 Allowed 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 121.983 1.789 . . . . 0.0 112.584 -174.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 90.7 t -139.02 143.68 31.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 N-CA-C 107.313 -1.365 . . . . 0.0 107.313 176.32 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.604 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -149.9 136.38 19.09 Favored 'General case' 0 N--CA 1.412 -2.371 0 CA-C-O 120.831 0.348 . . . . 0.0 110.48 178.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.435 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 18.4 mt -103.21 100.09 9.98 Favored 'General case' 0 C--N 1.289 -2.06 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.283 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.447 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 55.8 m-85 -80.39 76.48 7.2 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 178.053 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.591 HD22 ' CD2' ' A' ' 84' ' ' PHE . 3.1 mm? -102.93 122.6 44.92 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 177.054 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -125.09 147.01 55.65 Favored Pre-proline 0 N--CA 1.41 -2.465 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.154 -173.678 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.441 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 30.7 Cg_endo -61.8 117.82 4.67 Favored 'Trans proline' 0 C--O 1.245 0.864 0 C-N-CA 123.167 2.578 . . . . 0.0 111.768 -177.514 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 70' ' ' ASN . 2.6 m -65.3 -116.28 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.192 -1.934 0 CA-C-N 114.365 -1.289 . . . . 0.0 113.546 177.501 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 17.8 m -111.9 -41.74 3.94 Favored 'General case' 0 C--N 1.287 -2.115 0 O-C-N 121.464 -0.772 . . . . 0.0 110.624 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 5.8 t -93.14 28.27 2.21 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.911 0.862 . . . . 0.0 110.589 -173.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -89.62 135.04 33.84 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 178.442 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -172.03 143.57 7.55 Favored Glycine 0 N--CA 1.432 -1.632 0 C-N-CA 120.083 -1.056 . . . . 0.0 111.294 179.497 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . 0.427 ' HA2' ' CG1' ' A' ' 155' ' ' VAL . . . 57.24 -147.06 35.65 Favored Glycine 0 CA--C 1.497 -1.091 0 CA-C-O 119.177 -0.791 . . . . 0.0 112.87 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 97.5 t -56.77 99.85 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-O 121.937 0.875 . . . . 0.0 110.867 -179.069 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -100.25 -35.34 9.66 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.966 -178.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.408 ' HB ' HG21 ' A' ' 154' ' ' VAL . 69.8 mt -121.72 137.39 55.51 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 178.48 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 3.9 mmpt? -111.07 136.46 50.06 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 122.991 0.516 . . . . 0.0 111.212 178.462 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.63 134.51 46.41 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.263 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 86.29 -4.49 85.99 Favored Glycine 0 N--CA 1.442 -0.904 0 N-CA-C 111.709 -0.556 . . . . 0.0 111.709 -179.171 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 37.5 m -96.06 151.01 19.85 Favored 'General case' 0 N--CA 1.427 -1.578 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -178.17 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.405 HD12 HG21 ' A' ' 128' ' ' VAL . 3.3 tm? -77.75 121.3 23.86 Favored 'General case' 0 N--CA 1.427 -1.594 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 -177.533 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.476 ' HB ' HG23 ' A' ' 67' ' ' VAL . 36.7 pt -108.12 -27.18 3.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 CA-C-N 116.157 -0.474 . . . . 0.0 112.139 -178.024 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.75 167.41 25.03 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 110.243 -0.28 . . . . 0.0 110.243 -178.315 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.405 HG21 HD12 ' A' ' 125' ' ' LEU . 64.8 t -142.16 113.61 3.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 179.88 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 63.5 mt -114.64 139.55 49.55 Favored 'General case' 0 C--N 1.289 -2.053 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.662 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.489 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.3 mp -119.13 124.0 72.36 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 119.326 -0.95 . . . . 0.0 110.105 178.435 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.515 ' O ' HD21 ' A' ' 131' ' ' LEU . 0.1 OUTLIER -99.19 131.84 44.94 Favored 'General case' 0 C--N 1.278 -2.52 0 C-N-CA 124.236 1.015 . . . . 0.0 111.033 -176.869 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . 0.417 ' HD3' ' NE2' ' A' ' 59' ' ' GLN . 12.5 mmm180 -95.56 125.13 39.94 Favored 'General case' 0 C--N 1.295 -1.802 0 C-N-CA 124.108 0.963 . . . . 0.0 109.481 179.454 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.556 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 0.0 OUTLIER -107.18 113.12 26.35 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 177.52 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.458 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 26.2 m -136.25 141.85 43.95 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.441 ' CB ' HG21 ' A' ' 52' ' ' ILE . 8.9 p30 -141.86 168.39 19.87 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.469 175.475 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -75.82 -14.93 60.3 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 114.678 -1.146 . . . . 0.0 112.627 -170.747 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . 1.643 ' HD1' ' CD2' ' A' ' 137' ' ' TYR . 73.1 t80 -107.78 -62.07 1.49 Allowed 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 122.863 0.465 . . . . 0.0 111.41 -174.171 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . 0.42 ' HB2' HD22 ' A' ' 135' ' ' ASN . 14.9 m120 -77.43 144.62 37.7 Favored 'General case' 0 CA--C 1.485 -1.534 0 CA-C-O 121.325 0.583 . . . . 0.0 110.172 178.516 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 25.5 m -91.65 11.2 25.15 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 114.516 -1.22 . . . . 0.0 107.998 172.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -74.09 70.4 1.56 Allowed 'General case' 0 CA--C 1.512 -0.501 0 C-N-CA 125.382 1.473 . . . . 0.0 109.554 177.22 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -93.28 92.06 7.53 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-N 113.764 -1.562 . . . . 0.0 109.288 -176.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -127.24 164.4 21.79 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.957 -176.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -127.01 146.41 50.36 Favored 'General case' 0 N--CA 1.424 -1.757 0 CA-C-O 121.324 0.583 . . . . 0.0 110.891 178.618 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.412 ' HB2' HD23 ' A' ' 131' ' ' LEU . 11.9 m-30 -113.24 135.82 53.41 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 -176.736 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 49.3 t -92.44 130.69 41.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 122.802 0.441 . . . . 0.0 109.837 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . 0.441 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 61.8 m95 -119.38 101.08 7.71 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.804 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 48.7 m-80 -79.79 114.65 18.87 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 177.757 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 26.1 mm -88.05 120.24 36.75 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.947 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 -178.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 1.644 ' HD1' ' CD2' ' A' ' 149' ' ' TYR . 96.3 m-85 -116.09 150.3 37.56 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.507 179.022 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.8 131.23 35.2 Favored 'General case' 0 N--CA 1.406 -2.636 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 176.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -88.93 -16.49 31.7 Favored 'General case' 0 C--N 1.288 -2.081 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -178.027 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -147.29 141.14 25.79 Favored 'General case' 0 N--CA 1.434 -1.249 0 CA-C-N 114.224 -1.353 . . . . 0.0 110.32 -173.423 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -80.84 139.47 35.95 Favored 'General case' 0 C--N 1.311 -1.088 0 O-C-N 124.3 1.0 . . . . 0.0 109.348 178.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.408 HG21 ' HB ' ' A' ' 120' ' ' ILE . 2.2 m -120.91 153.29 24.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 120.715 -0.394 . . . . 0.0 110.713 -177.713 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . 0.427 ' CG1' ' HA2' ' A' ' 117' ' ' GLY . 2.9 t -124.21 142.47 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.032 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 -178.769 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.45 HG11 ' O ' ' A' ' 28' ' ' VAL . 70.4 t -103.95 102.59 32.51 Favored Pre-proline 0 C--N 1.291 -1.952 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 177.475 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.408 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 20.6 Cg_endo -66.22 -26.92 49.0 Favored 'Trans proline' 0 C--O 1.212 -0.809 0 C-N-CA 122.426 2.084 . . . . 0.0 111.924 177.665 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 6.6 t . . . . . 0 C--O 1.252 1.23 0 C-N-CA 124.425 1.09 . . . . 0.0 113.229 176.367 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 12.5 t80 . . . . . 0 CA--C 1.498 -1.054 0 N-CA-C 105.605 -1.998 . . . . 0.0 105.605 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.429 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . -146.29 -176.63 5.24 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 -179.489 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 16.4 t -154.83 157.29 37.68 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.772 -0.771 . . . . 0.0 109.436 -176.331 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.491 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.37 161.91 37.79 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-O 121.131 0.491 . . . . 0.0 110.856 -175.195 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.527 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 50.5 p -101.56 172.46 6.95 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-O 121.949 0.881 . . . . 0.0 110.426 178.139 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.58 -10.15 59.19 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 113.591 -1.64 . . . . 0.0 111.607 -178.123 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.527 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 6.2 p30 -87.14 -33.24 19.49 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 119.301 -0.96 . . . . 0.0 108.562 176.281 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.55 3.82 3.66 Favored Glycine 0 N--CA 1.441 -1.019 0 C-N-CA 120.139 -1.029 . . . . 0.0 112.702 178.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.9 m -78.48 99.44 6.45 Favored 'General case' 0 N--CA 1.433 -1.306 0 CA-C-N 117.129 0.465 . . . . 0.0 109.886 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -93.47 119.46 32.59 Favored 'General case' 0 N--CA 1.424 -1.764 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 176.347 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.429 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 72.4 mt -85.63 124.84 70.7 Favored Pre-proline 0 C--N 1.285 -2.238 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -77.8 167.0 24.55 Favored 'Trans proline' 0 N--CA 1.448 -1.169 0 C-N-CA 122.673 2.249 . . . . 0.0 110.623 178.226 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 55.3 mt -73.29 125.8 32.88 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 -178.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 138.34 7.48 1.26 Allowed Glycine 0 C--N 1.308 -1.013 0 C-N-CA 120.564 -0.826 . . . . 0.0 112.888 -179.026 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.12 142.89 9.17 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 -177.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -179.67 -168.37 38.39 Favored Glycine 0 CA--C 1.49 -1.487 0 C-N-CA 120.031 -1.081 . . . . 0.0 111.42 -179.032 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.455 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 20.4 p -149.6 147.02 27.63 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.23 162.83 31.87 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 179.589 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 26.8 m-80 -114.74 112.32 22.64 Favored 'General case' 0 C--N 1.29 -2.0 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 178.11 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 1.8 m -96.04 148.63 5.15 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.231 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 -179.33 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 1.653 ' HD1' ' CD2' ' A' ' 21' ' ' TYR . 32.5 m-85 -130.73 130.47 43.84 Favored 'General case' 0 CA--C 1.492 -1.285 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 -179.11 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.506 ' HB ' ' HG2' ' A' ' 41' ' ' GLN . 2.9 p -133.55 132.13 57.37 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.925 0 O-C-N 124.098 0.874 . . . . 0.0 110.572 -176.148 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -92.12 128.37 37.94 Favored 'General case' 0 C--N 1.286 -2.157 0 CA-C-O 121.629 0.728 . . . . 0.0 109.8 177.48 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -106.89 161.32 14.81 Favored 'General case' 0 C--N 1.28 -2.419 0 CA-C-N 114.341 -1.299 . . . . 0.0 108.036 179.634 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.52 121.61 61.76 Favored Pre-proline 0 C--N 1.304 -1.391 0 O-C-N 124.144 0.903 . . . . 0.0 108.779 176.069 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.478 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 64.5 Cg_endo -74.26 -1.16 10.58 Favored 'Trans proline' 0 CA--C 1.531 0.355 0 C-N-CA 122.851 2.368 . . . . 0.0 113.431 -176.818 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.441 HG11 ' HG3' ' A' ' 157' ' ' PRO . 94.9 t -125.92 110.56 24.26 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 176.609 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.511 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.1 t -142.14 106.25 1.43 Allowed 'Isoleucine or valine' 0 C--O 1.182 -2.479 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 -176.551 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.574 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -95.7 150.58 20.22 Favored 'General case' 0 C--N 1.268 -2.972 0 C-N-CA 122.888 0.475 . . . . 0.0 111.617 -179.745 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.637 HG23 ' O ' ' A' ' 112' ' ' VAL . 75.7 t -46.1 118.79 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 123.472 0.709 . . . . 0.0 111.38 176.649 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 105.01 -3.99 41.43 Favored Glycine 0 C--N 1.318 -0.468 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.642 -179.659 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.574 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.6 OUTLIER -68.81 -178.0 1.11 Allowed 'General case' 0 CA--C 1.499 -1.013 0 C-N-CA 124.555 1.142 . . . . 0.0 111.544 178.286 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -127.39 87.53 2.65 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 174.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.542 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 14.9 tp -96.63 133.95 40.49 Favored 'General case' 0 N--CA 1.405 -2.688 0 C-N-CA 118.852 -1.139 . . . . 0.0 108.029 177.419 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.407 ' CG2' ' HB2' ' A' ' 106' ' ' ALA . 2.0 p -141.19 129.72 23.52 Favored 'Isoleucine or valine' 1 N--CA 1.377 -4.107 0 CA-C-O 122.022 0.915 . . . . 0.0 111.183 -179.666 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.607 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 44.8 t -90.12 89.1 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.385 -3.713 0 CA-C-N 113.081 -1.872 . . . . 0.0 107.159 -178.728 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -75.87 133.31 40.61 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 176.566 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 86.9 mt -115.14 11.43 16.34 Favored 'General case' 0 C--N 1.295 -1.779 0 O-C-N 123.838 0.711 . . . . 0.0 111.26 179.225 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.662 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 1.5 m -87.0 1.69 51.98 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 -174.698 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.2 m -120.47 0.68 10.57 Favored 'General case' 0 N--CA 1.394 -3.232 0 CA-C-O 122.168 0.985 . . . . 0.0 108.779 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.506 ' HG2' ' HB ' ' A' ' 22' ' ' VAL . 22.1 mp0 -120.78 -34.22 3.61 Favored 'General case' 0 CA--C 1.473 -1.986 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.285 -172.282 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 23.1 mt -119.56 137.11 54.53 Favored 'Isoleucine or valine' 0 C--N 1.267 -2.981 0 CA-C-N 114.903 -1.044 . . . . 0.0 108.988 -177.45 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.491 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 42.4 m-85 -142.07 124.45 15.67 Favored 'General case' 0 CA--C 1.511 -0.553 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -176.469 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 81.9 m -106.57 140.17 39.87 Favored 'General case' 0 C--N 1.287 -2.142 0 CA-C-O 121.107 0.48 . . . . 0.0 110.618 -177.882 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . 0.426 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 5.1 p80 -124.28 132.85 53.59 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 122.356 1.074 . . . . 0.0 113.433 -174.565 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.447 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 14.8 p-10 -93.15 93.6 8.36 Favored 'General case' 0 C--N 1.279 -2.464 0 CA-C-N 114.299 -1.319 . . . . 0.0 109.46 177.51 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -78.3 -21.04 50.28 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.773 -1.103 . . . . 0.0 111.288 -176.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 1.622 ' HE1' ' CE2' ' A' ' 48' ' ' TYR . 72.2 m-85 -136.51 70.72 59.96 Favored Pre-proline 0 C--N 1.313 -0.987 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 176.475 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.447 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 56.0 Cg_endo -70.14 -10.98 29.5 Favored 'Trans proline' 0 N--CA 1.483 0.874 0 C-N-CA 122.698 2.266 . . . . 0.0 112.52 -176.205 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -107.32 -17.44 14.14 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-O 121.402 0.62 . . . . 0.0 110.035 -176.102 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.469 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -101.8 -30.71 11.13 Favored 'General case' 0 N--CA 1.414 -2.259 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 -175.818 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.671 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.9 mp -129.05 139.69 51.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.3 t -80.33 147.45 31.09 Favored 'General case' 0 C--O 1.252 1.204 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 178.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -80.73 107.68 13.75 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 -173.295 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 1.637 ' HE1' ' CE2' ' A' ' 55' ' ' TYR . 75.1 t80 -150.84 145.7 25.86 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.319 -175.31 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.44 HG11 ' HH ' ' A' ' 77' ' ' TYR . 11.4 p -153.92 152.28 10.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 174.572 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -151.36 138.02 18.79 Favored 'General case' 0 C--O 1.207 -1.149 0 CA-C-O 119.102 -0.475 . . . . 0.0 110.263 174.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.515 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 50.4 tp -76.17 113.14 13.38 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 174.016 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.4 tp-100 -59.52 -51.53 69.47 Favored 'General case' 0 C--N 1.316 -0.878 0 C-N-CA 125.549 1.539 . . . . 0.0 111.102 -179.327 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -172.81 157.11 3.61 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 -177.832 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -131.84 146.71 18.26 Favored Glycine 0 N--CA 1.41 -3.036 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 -178.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 69.9 m -130.16 148.89 52.05 Favored 'General case' 0 C--N 1.286 -2.177 0 O-C-N 124.52 0.776 . . . . 0.0 109.666 -178.046 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.472 ' HB3' ' CE2' ' A' ' 84' ' ' PHE . . . -113.53 157.77 21.6 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 1.656 ' HE2' ' CE1' ' A' ' 64' ' ' TYR . 97.5 m-85 -155.18 179.25 9.33 Favored 'General case' 0 C--N 1.345 0.396 0 C-N-CA 124.497 1.119 . . . . 0.0 109.59 -177.376 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 55.13 -145.42 30.47 Favored Glycine 0 C--N 1.331 0.299 0 O-C-N 123.975 0.797 . . . . 0.0 113.475 176.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.63 -13.03 74.51 Favored Glycine 0 C--O 1.205 -1.704 0 C-N-CA 120.957 -0.639 . . . . 0.0 111.692 178.263 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.527 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 98.6 t -67.21 -42.7 88.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 C-N-CA 123.359 0.663 . . . . 0.0 111.528 -178.234 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.471 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -84.81 -15.13 45.91 Favored 'General case' 0 C--N 1.308 -1.235 0 C-N-CA 119.112 -1.035 . . . . 0.0 112.055 179.531 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 36.5 t -100.31 -59.98 1.61 Allowed 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.851 -174.634 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.526 ' O ' HG23 ' A' ' 112' ' ' VAL . 46.9 m-20 -92.13 -23.95 19.26 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.076 -171.784 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 1.628 ' HE2' ' CE1' ' A' ' 71' ' ' PHE . 88.6 m-85 -106.9 154.83 20.47 Favored 'General case' 0 N--CA 1.42 -1.933 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.399 179.505 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.3 t -162.09 136.49 6.78 Favored 'General case' 0 N--CA 1.407 -2.594 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.557 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -168.69 -103.43 0.17 Allowed Glycine 0 C--N 1.275 -2.843 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 175.003 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -168.22 179.97 4.29 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 124.688 1.195 . . . . 0.0 109.264 -176.337 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.418 ' HB ' ' HB2' ' A' ' 84' ' ' PHE . 2.9 p -129.5 148.23 33.27 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 N-CA-C 109.684 -0.488 . . . . 0.0 109.684 178.643 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.558 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.2 tttt -127.19 144.26 51.08 Favored 'General case' 0 N--CA 1.427 -1.621 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.214 -179.189 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 1.627 ' HD2' ' CD1' ' A' ' 77' ' ' TYR . 58.6 t80 -140.89 104.72 4.74 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.27 -0.877 . . . . 0.0 108.86 -179.106 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 15.5 t 48.58 48.18 19.88 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 124.39 1.076 . . . . 0.0 111.834 177.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.59 5.36 69.21 Favored Glycine 0 N--CA 1.441 -0.991 0 CA-C-N 115.497 -0.774 . . . . 0.0 114.219 178.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.558 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 17.8 t -80.08 178.93 7.9 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 24.3 p -155.89 108.77 2.67 Favored 'General case' 0 C--N 1.293 -1.879 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.439 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 0.504 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.8 p90 -155.38 158.67 31.98 Favored Pre-proline 0 C--N 1.314 -0.947 0 O-C-N 122.195 -0.316 . . . . 0.0 110.258 -174.223 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -67.25 147.71 79.02 Favored 'Trans proline' 0 C--N 1.364 1.343 0 C-N-CA 123.28 2.654 . . . . 0.0 113.362 -177.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.614 ' CD2' HD22 ' A' ' 109' ' ' LEU . 63.6 t80 -123.13 135.27 25.75 Favored Pre-proline 0 N--CA 1.435 -1.201 0 CA-C-N 115.615 -0.72 . . . . 0.0 109.817 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.513 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 73.9 Cg_endo -72.59 145.22 83.1 Favored 'Cis proline' 0 CA--C 1.541 0.832 0 C-N-CA 123.144 -1.607 . . . . 0.0 110.411 -3.692 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.1 t -69.81 -177.02 1.18 Allowed 'General case' 0 CA--C 1.553 1.085 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.453 -176.12 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 39.4 p -122.61 -34.97 3.15 Favored 'General case' 0 N--CA 1.439 -0.994 0 CA-C-O 121.431 0.634 . . . . 0.0 110.354 -170.072 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.0 t -126.83 -131.46 0.24 Allowed 'General case' 0 N--CA 1.389 -3.492 0 N-CA-C 104.416 -2.438 . . . . 0.0 104.416 174.798 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -113.64 -169.86 1.59 Allowed 'General case' 0 C--N 1.286 -2.169 0 N-CA-C 113.05 0.759 . . . . 0.0 113.05 -173.19 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.515 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 35.0 p -97.49 170.52 7.09 Favored Pre-proline 0 C--N 1.31 -1.114 0 CA-C-N 115.439 -0.8 . . . . 0.0 111.843 178.601 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . 0.416 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 37.2 Cg_endo -65.4 166.39 19.59 Favored 'Trans proline' 0 C--O 1.251 1.148 0 C-N-CA 122.277 1.985 . . . . 0.0 109.707 170.044 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 47.7 ttp180 -73.32 140.12 46.52 Favored 'General case' 0 C--N 1.308 -1.212 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.768 -179.356 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 56.2 t -141.07 120.61 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.898 0 CA-C-N 114.925 -1.034 . . . . 0.0 109.314 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 70.8 t -95.39 140.51 16.79 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.896 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 175.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . 1.642 ' HD1' ' CD2' ' A' ' 95' ' ' TYR . 1.7 m-85 -87.85 100.75 13.11 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 175.412 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 17.4 m120 -89.11 60.27 5.31 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.649 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.6 m -135.3 178.3 7.14 Favored 'General case' 0 N--CA 1.425 -1.716 0 CA-C-N 114.44 -1.254 . . . . 0.0 109.076 -174.385 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 16.9 ptp180 -148.81 45.01 1.01 Allowed 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 122.007 0.908 . . . . 0.0 109.462 175.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.3 t -170.58 -175.36 1.84 Allowed 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 -176.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . 0.426 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 9.2 p-10 -77.06 99.0 5.18 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-O 122.153 0.977 . . . . 0.0 108.398 172.957 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 2.8 tptm -101.04 136.17 19.79 Favored Pre-proline 0 N--CA 1.405 -2.724 0 CA-C-N 114.939 -1.028 . . . . 0.0 108.233 -177.851 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.662 ' HB3' ' O ' ' A' ' 39' ' ' SER . 80.0 Cg_exo -48.43 139.66 22.31 Favored 'Trans proline' 0 C--N 1.324 -0.752 0 C-N-CA 123.939 3.093 . . . . 0.0 113.658 177.383 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.5 t90 -90.11 105.69 12.17 Favored Pre-proline 0 C--N 1.31 -1.146 0 N-CA-C 106.754 -1.573 . . . . 0.0 106.754 -178.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -73.78 89.27 1.0 Allowed 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.293 1.995 . . . . 0.0 112.686 -173.464 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.409 HG21 ' CD2' ' A' ' 77' ' ' TYR . 90.1 t -136.31 145.2 31.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 177.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.607 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.96 133.08 15.28 Favored 'General case' 0 N--CA 1.417 -2.078 0 CA-C-O 121.06 0.457 . . . . 0.0 110.766 178.071 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.4 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 14.2 mt -101.93 100.12 10.39 Favored 'General case' 0 C--N 1.288 -2.086 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 179.03 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 1.624 ' HE2' ' CE1' ' A' ' 108' ' ' TYR . 63.1 m-85 -77.38 78.24 3.91 Favored 'General case' 0 C--N 1.306 -1.298 0 O-C-N 122.067 -0.395 . . . . 0.0 110.255 177.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.614 HD22 ' CD2' ' A' ' 84' ' ' PHE . 3.0 mm? -104.56 118.24 36.11 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-O 121.167 0.508 . . . . 0.0 110.066 176.732 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.79 145.93 46.75 Favored Pre-proline 0 N--CA 1.414 -2.238 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.889 -173.628 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -63.43 121.61 9.47 Favored 'Trans proline' 0 CA--C 1.5 -1.195 0 C-N-CA 122.986 2.457 . . . . 0.0 113.57 -175.23 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.637 ' O ' HG23 ' A' ' 30' ' ' VAL . 19.8 m -82.0 -155.27 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.399 -3.0 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.108 171.498 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 8.5 m -79.73 -29.92 40.73 Favored 'General case' 0 C--N 1.257 -3.447 0 CA-C-O 121.515 0.674 . . . . 0.0 110.721 -167.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 5.3 t -91.47 25.5 2.6 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-O 121.664 0.745 . . . . 0.0 110.514 -176.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -102.83 128.74 49.47 Favored 'General case' 0 N--CA 1.418 -2.061 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.99 128.88 1.72 Allowed Glycine 0 C--N 1.307 -1.048 0 C-N-CA 120.151 -1.023 . . . . 0.0 111.765 -178.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.24 -152.71 52.81 Favored Glycine 0 CA--C 1.493 -1.343 0 CA-C-O 118.925 -0.931 . . . . 0.0 111.532 -176.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 63.4 t -55.85 106.04 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.246 0.914 0 CA-C-O 121.586 0.708 . . . . 0.0 110.79 -177.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -106.27 -33.07 7.91 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 114.535 -1.211 . . . . 0.0 110.622 -178.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 74.8 mt -121.54 139.91 47.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 177.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 3.8 mmpt? -115.47 136.41 53.11 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 123.138 0.575 . . . . 0.0 110.973 178.547 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -72.13 131.11 42.37 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.709 178.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 92.29 -5.3 77.93 Favored Glycine 0 C--N 1.309 -0.953 0 N-CA-C 111.561 -0.616 . . . . 0.0 111.561 -178.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 61.3 m -98.4 149.04 23.08 Favored 'General case' 0 N--CA 1.425 -1.719 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 179.556 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 26.6 tp -72.69 138.19 46.45 Favored 'General case' 0 N--CA 1.433 -1.31 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.14 178.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.483 ' HB ' HG23 ' A' ' 67' ' ' VAL . 34.4 pt -121.27 -27.08 2.02 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 N-CA-C 112.392 0.516 . . . . 0.0 112.392 178.708 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.93 168.79 20.68 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -177.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 75.1 t -143.55 116.18 3.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 179.176 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 63.4 mt -117.37 154.46 31.27 Favored 'General case' 0 C--N 1.283 -2.297 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 179.173 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.481 ' O ' HD13 ' A' ' 58' ' ' LEU . 5.0 mp -135.73 127.69 45.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.821 -0.549 . . . . 0.0 109.704 177.623 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.493 ' C ' HD13 ' A' ' 131' ' ' LEU . 1.2 pp -89.34 150.18 22.69 Favored 'General case' 0 CA--C 1.484 -1.592 0 N-CA-C 106.673 -1.602 . . . . 0.0 106.673 173.693 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 54.5 ttp180 -115.71 120.93 40.95 Favored 'General case' 0 C--N 1.269 -2.917 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 176.862 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.686 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 21.9 tp60 -93.96 121.22 35.2 Favored 'General case' 0 N--CA 1.422 -1.83 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -175.076 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 27.7 m -133.47 149.78 51.74 Favored 'General case' 0 C--N 1.292 -1.92 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 174.6 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.671 ' CB ' HG21 ' A' ' 52' ' ' ILE . 8.0 p30 -149.09 166.87 27.45 Favored 'General case' 0 C--O 1.213 -0.866 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.59 175.723 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -82.14 -17.22 47.15 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 114.21 -1.359 . . . . 0.0 112.714 -170.797 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 44.5 t80 -99.58 -65.66 0.95 Allowed 'General case' 0 C--N 1.295 -1.779 0 CA-C-O 121.173 0.511 . . . . 0.0 110.459 -173.424 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 -97.1 155.98 16.58 Favored 'General case' 0 C--N 1.287 -2.144 0 N-CA-C 108.615 -0.884 . . . . 0.0 108.615 177.796 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 10.9 p -91.39 45.75 1.26 Allowed 'General case' 0 C--N 1.277 -2.555 0 CA-C-N 115.549 -0.751 . . . . 0.0 109.054 176.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 63.0 m-20 -78.51 51.65 1.08 Allowed 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.664 -178.026 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . 0.686 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 2.8 m-20 -76.26 71.73 2.99 Favored 'General case' 0 CA--C 1.505 -0.777 0 CA-C-O 121.058 0.456 . . . . 0.0 110.124 177.746 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . 1.641 ' HD2' ' CD1' ' A' ' 142' ' ' PHE . 53.1 m-85 -105.41 165.02 11.42 Favored 'General case' 0 N--CA 1.421 -1.888 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.058 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -131.37 144.23 51.07 Favored 'General case' 0 N--CA 1.407 -2.6 0 C-N-CA 118.416 -1.314 . . . . 0.0 110.963 179.249 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 1.635 ' HD1' ' CD2' ' A' ' 144' ' ' PHE . 11.0 m-30 -110.7 125.92 53.99 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 -176.367 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . 0.455 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 48.7 t -88.22 134.44 28.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 CA-C-O 121.076 0.465 . . . . 0.0 110.196 -178.549 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 65.8 m95 -120.79 94.39 4.34 Favored 'General case' 0 C--N 1.285 -2.239 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -179.209 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -78.72 114.95 18.08 Favored 'General case' 0 C--N 1.286 -2.19 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 178.53 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 18.3 mm -90.18 120.33 38.81 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 -176.548 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -117.52 155.08 30.38 Favored 'General case' 0 CA--C 1.488 -1.405 0 CA-C-O 121.324 0.583 . . . . 0.0 109.919 177.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.54 131.21 35.22 Favored 'General case' 0 N--CA 1.407 -2.606 0 CA-C-N 115.01 -0.995 . . . . 0.0 108.82 176.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 40.3 t-20 -91.32 -13.35 32.75 Favored 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 -177.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -152.01 145.72 25.03 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 114.169 -1.378 . . . . 0.0 109.67 -175.389 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -84.44 144.89 28.47 Favored 'General case' 0 C--N 1.319 -0.739 0 O-C-N 124.317 1.011 . . . . 0.0 109.195 -178.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.478 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 1.5 m -125.21 148.96 29.6 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.9 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 9.3 t -124.66 138.32 54.45 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 N-CA-C 107.686 -1.228 . . . . 0.0 107.686 -178.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 81.5 t -100.04 101.8 15.53 Favored Pre-proline 0 C--N 1.292 -1.892 0 C-N-CA 123.677 0.791 . . . . 0.0 109.982 179.368 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.441 ' HG3' HG11 ' A' ' 27' ' ' VAL . 35.2 Cg_endo -70.12 -23.52 29.07 Favored 'Trans proline' 0 CA--C 1.509 -0.749 0 C-N-CA 122.319 2.013 . . . . 0.0 111.801 178.62 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.1 t . . . . . 0 C--O 1.248 0.99 0 O-C-N 124.716 1.26 . . . . 0.0 112.404 179.359 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 1.663 ' HD1' ' CD2' ' A' ' 1' ' ' PHE . 4.0 t80 . . . . . 0 C--O 1.215 -0.714 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -161.49 179.78 7.96 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 102.837 -3.023 . . . . 0.0 102.837 169.004 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.465 ' HB3' ' CZ2' ' A' ' 146' ' ' TRP . 11.5 t -150.5 158.32 44.02 Favored 'General case' 0 C--N 1.283 -2.318 0 C-N-CA 117.232 -1.787 . . . . 0.0 111.081 -174.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -144.26 160.88 40.24 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 121.474 0.654 . . . . 0.0 110.713 -175.816 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 57.2 p -97.68 178.73 5.07 Favored 'General case' 0 C--N 1.293 -1.888 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.648 -179.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -82.04 -21.01 37.16 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.712 178.514 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -87.09 -29.07 22.15 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.997 -176.224 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.16 7.52 2.85 Favored Glycine 0 C--N 1.307 -1.073 0 C-N-CA 119.222 -1.466 . . . . 0.0 114.34 171.308 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.0 m -86.94 101.09 13.09 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 177.216 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -97.06 119.92 36.46 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-N 115.484 -0.78 . . . . 0.0 108.945 176.025 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 50.9 mt -97.7 116.46 65.77 Favored Pre-proline 0 C--N 1.297 -1.7 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.564 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -79.42 176.75 9.31 Favored 'Trans proline' 0 C--O 1.25 1.075 0 C-N-CA 122.653 2.236 . . . . 0.0 110.387 177.331 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 56.7 mt -72.04 125.35 30.52 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.343 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 177.669 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 149.22 -6.45 0.81 Allowed Glycine 0 C--N 1.299 -1.48 0 CA-C-N 115.6 -0.727 . . . . 0.0 112.001 -176.482 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.17 156.77 33.06 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 120.709 -0.758 . . . . 0.0 111.373 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.34 -165.83 34.0 Favored Glycine 0 N--CA 1.419 -2.456 0 C-N-CA 119.818 -1.182 . . . . 0.0 111.604 178.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 59.8 p -145.7 155.17 42.81 Favored 'General case' 0 N--CA 1.417 -2.077 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 -177.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.81 155.64 50.03 Favored 'General case' 0 N--CA 1.416 -2.151 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 177.284 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -105.01 109.97 22.18 Favored 'General case' 0 C--N 1.279 -2.459 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 174.778 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 34.2 t -97.33 135.52 31.33 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -177.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 77.7 m-85 -116.62 126.82 53.8 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -178.547 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.461 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.5 p -135.54 129.45 49.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.195 -176.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -94.52 126.02 39.53 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-O 121.683 0.754 . . . . 0.0 110.423 178.197 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -103.44 162.59 12.9 Favored 'General case' 0 C--N 1.286 -2.157 0 CA-C-N 114.278 -1.328 . . . . 0.0 108.019 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . 0.445 ' C ' ' H ' ' A' ' 27' ' ' VAL . . . -54.48 126.07 54.39 Favored Pre-proline 0 CA--C 1.499 -0.998 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 174.722 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.503 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 72.7 Cg_endo -77.44 9.77 2.74 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 122.484 2.123 . . . . 0.0 110.925 179.2 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.445 ' H ' ' C ' ' A' ' 25' ' ' ALA . 14.1 p -138.35 115.97 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.916 0 CA-C-N 114.827 -1.079 . . . . 0.0 108.365 -178.316 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.4 t -150.02 120.05 1.06 Allowed 'Isoleucine or valine' 0 C--O 1.191 -1.985 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 -179.006 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.593 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -107.24 147.85 29.67 Favored 'General case' 0 C--N 1.267 -2.999 0 C-N-CA 122.505 0.322 . . . . 0.0 110.76 -179.973 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.548 HG23 ' O ' ' A' ' 112' ' ' VAL . 98.7 t -43.67 117.35 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 123.329 0.652 . . . . 0.0 111.539 176.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.56 -1.72 42.57 Favored Glycine 0 C--N 1.319 -0.396 0 CA-C-N 114.779 -1.101 . . . . 0.0 112.809 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.593 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -73.35 -176.69 2.31 Favored 'General case' 0 C--N 1.315 -0.896 0 C-N-CA 124.011 0.924 . . . . 0.0 110.775 177.37 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -129.5 83.35 2.13 Favored 'General case' 0 CA--C 1.49 -1.327 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.238 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.557 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 19.1 tp -90.72 133.23 35.31 Favored 'General case' 0 N--CA 1.419 -1.977 0 C-N-CA 119.151 -1.019 . . . . 0.0 108.516 178.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.407 ' CG2' ' HB2' ' A' ' 106' ' ' ALA . 2.2 p -141.44 133.92 29.22 Favored 'Isoleucine or valine' 0 N--CA 1.383 -3.792 0 CA-C-O 121.882 0.848 . . . . 0.0 111.728 -178.572 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.621 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 45.6 t -89.2 89.92 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.52 0 CA-C-N 113.732 -1.577 . . . . 0.0 108.333 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -76.53 109.72 10.49 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 120.876 0.37 . . . . 0.0 110.89 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 93.0 mt -92.29 -1.54 57.01 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 115.905 -0.588 . . . . 0.0 112.549 -178.698 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 89.9 p -76.81 1.08 18.41 Favored 'General case' 0 N--CA 1.474 0.762 0 CA-C-O 123.0 1.381 . . . . 0.0 109.754 -179.649 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.7 p -123.92 6.64 8.66 Favored 'General case' 0 C--N 1.276 -2.628 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.881 179.184 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.461 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 42.4 mm-40 -127.14 -25.14 3.31 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.604 -175.232 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 23.1 mt -132.64 137.44 54.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 -175.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.672 ' HE1' ' CE2' ' A' ' 43' ' ' PHE . 40.4 m-85 -140.65 123.41 16.28 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -176.305 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.456 ' HB3' ' CE1' ' A' ' 1' ' ' PHE . 79.7 m -103.71 142.9 33.54 Favored 'General case' 0 C--N 1.271 -2.82 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 -178.729 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 p80 -136.75 168.06 20.26 Favored 'General case' 0 C--N 1.294 -1.836 0 CA-C-O 121.335 0.588 . . . . 0.0 110.787 -172.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.448 ' HB3' ' OD1' ' A' ' 54' ' ' ASP . 5.4 p30 -112.41 100.0 8.43 Favored 'General case' 0 C--N 1.281 -2.383 0 CA-C-O 122.2 1.0 . . . . 0.0 111.814 175.566 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -76.26 -31.21 58.17 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 178.192 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 1.664 ' HE1' ' CE2' ' A' ' 48' ' ' TYR . 23.2 m-85 -127.88 87.97 54.4 Favored Pre-proline 0 N--CA 1.435 -1.22 0 N-CA-C 106.004 -1.851 . . . . 0.0 106.004 177.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -88.59 -13.34 3.4 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 122.319 2.013 . . . . 0.0 113.976 -176.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -110.92 -12.35 14.25 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.622 -0.831 . . . . 0.0 110.756 -176.116 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.46 ' OG1' ' HB3' ' A' ' 48' ' ' TYR . 0.0 OUTLIER -101.4 -31.36 10.97 Favored 'General case' 0 N--CA 1.417 -2.115 0 CA-C-N 115.406 -0.815 . . . . 0.0 110.194 179.771 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.592 HG21 ' CB ' ' A' ' 135' ' ' ASN . 3.1 mp -121.9 126.54 74.67 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.592 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.6 t -72.75 135.06 45.25 Favored 'General case' 0 N--CA 1.421 -1.901 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 174.602 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.448 ' OD1' ' HB3' ' A' ' 46' ' ' ASN . 58.7 m-20 -87.06 107.6 18.51 Favored 'General case' 0 C--N 1.278 -2.506 0 CA-C-O 121.939 0.876 . . . . 0.0 111.343 -171.093 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 1.65 ' HD2' ' CD1' ' A' ' 55' ' ' TYR . 70.4 t80 -137.91 145.8 42.54 Favored 'General case' 0 C--N 1.29 -1.997 0 CA-C-N 114.078 -1.419 . . . . 0.0 108.058 -175.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.576 ' HB ' ' CZ ' ' A' ' 1' ' ' PHE . 11.9 p -152.25 148.38 14.39 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.786 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.309 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -151.34 140.37 21.09 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 174.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.555 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 50.5 tp -75.19 117.76 17.37 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 173.346 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.483 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 3.6 tp-100 -65.54 -44.92 85.35 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.456 -1.247 . . . . 0.0 110.458 -177.851 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . 0.483 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 10.4 ptp180 -176.97 161.87 1.99 Allowed 'General case' 0 N--CA 1.432 -1.34 0 O-C-N 124.708 1.255 . . . . 0.0 108.423 -176.407 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -143.08 129.53 3.8 Favored Glycine 0 N--CA 1.408 -3.174 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -178.302 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 54.2 m -117.35 149.38 40.59 Favored 'General case' 0 C--N 1.291 -1.944 0 C-N-CA 124.099 0.96 . . . . 0.0 110.461 -174.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.509 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -113.37 156.16 23.93 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 1.654 ' HE1' ' CE2' ' A' ' 64' ' ' TYR . 88.4 m-85 -154.6 -179.92 8.44 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 124.155 0.982 . . . . 0.0 108.867 -178.407 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 57.79 -143.56 42.39 Favored Glycine 0 C--N 1.325 -0.081 0 O-C-N 123.891 0.744 . . . . 0.0 113.513 176.13 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -72.97 -14.23 78.78 Favored Glycine 0 C--O 1.209 -1.468 0 C-N-CA 120.846 -0.693 . . . . 0.0 111.717 177.565 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.52 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 95.2 t -67.59 -39.37 82.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 123.804 0.842 . . . . 0.0 111.606 -177.717 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.509 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -87.1 -19.03 29.13 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 118.67 -1.212 . . . . 0.0 112.192 178.027 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 6.2 t -98.36 -56.58 2.43 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.537 -172.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.486 ' O ' HG23 ' A' ' 112' ' ' VAL . 41.3 m-20 -92.03 -22.97 19.67 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.24 -173.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 0.538 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 92.0 m-85 -108.73 156.93 19.03 Favored 'General case' 0 N--CA 1.419 -1.999 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.489 178.598 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 12.7 t -161.38 136.41 7.46 Favored 'General case' 0 N--CA 1.403 -2.787 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 176.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.509 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.97 -111.67 0.26 Allowed Glycine 0 N--CA 1.398 -3.893 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 174.19 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.2 p -159.66 -179.92 8.3 Favored 'General case' 0 C--N 1.297 -1.684 0 C-N-CA 124.001 0.92 . . . . 0.0 110.425 -172.743 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -132.1 145.9 34.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 178.202 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.669 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.2 tttt -126.58 145.45 50.53 Favored 'General case' 0 N--CA 1.427 -1.585 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -178.189 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 1.657 ' HD2' ' CD1' ' A' ' 77' ' ' TYR . 58.9 t80 -145.63 110.69 5.23 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 -177.691 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 44.9 t 53.27 37.08 24.36 Favored 'General case' 0 CA--C 1.55 0.963 0 C-N-CA 123.35 0.66 . . . . 0.0 111.982 178.04 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.32 8.54 66.2 Favored Glycine 0 CA--C 1.525 0.698 0 C-N-CA 120.301 -0.952 . . . . 0.0 113.663 -179.384 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.669 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 20.8 t -81.59 -179.79 7.52 Favored 'General case' 0 CA--C 1.544 0.735 0 CA-C-N 117.383 0.592 . . . . 0.0 109.51 178.412 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.0 p -156.78 109.22 2.51 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 1.623 ' HD1' ' CD2' ' A' ' 82' ' ' TYR . 2.3 p90 -151.89 158.71 33.84 Favored Pre-proline 0 C--N 1.306 -1.323 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 -175.52 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -68.73 150.94 74.69 Favored 'Trans proline' 0 C--N 1.354 0.817 0 C-N-CA 122.879 2.386 . . . . 0.0 113.096 -176.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.568 ' CD2' HD22 ' A' ' 109' ' ' LEU . 54.0 t80 -124.46 132.15 24.26 Favored Pre-proline 0 N--CA 1.442 -0.867 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.219 -179.684 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.48 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 72.4 Cg_endo -72.53 148.2 90.99 Favored 'Cis proline' 0 CA--C 1.535 0.558 0 C-N-CA 122.8 -1.75 . . . . 0.0 109.984 -0.873 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.0 t -67.09 -177.49 0.66 Allowed 'General case' 0 C--O 1.248 1.017 0 CA-C-O 121.367 0.603 . . . . 0.0 111.29 -175.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.8 p -120.7 -25.13 5.55 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 115.286 -0.87 . . . . 0.0 110.647 -173.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 t -135.38 -107.95 0.21 Allowed 'General case' 0 N--CA 1.419 -1.985 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 178.555 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . 0.409 ' HB2' ' O ' ' A' ' 58' ' ' LEU . 0.0 OUTLIER -144.44 -165.66 2.19 Favored 'General case' 0 N--CA 1.445 -0.723 0 CA-C-N 118.251 0.478 . . . . 0.0 110.749 -177.508 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.555 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 58.3 p -100.26 168.16 9.83 Favored Pre-proline 0 C--N 1.306 -1.286 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 179.55 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -63.62 172.26 5.88 Favored 'Trans proline' 0 C--O 1.251 1.139 0 C-N-CA 123.062 2.508 . . . . 0.0 110.48 170.02 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 41.2 ttp180 -71.49 142.32 50.16 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.12 -177.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 64.0 t -151.16 131.57 4.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 124.355 1.062 . . . . 0.0 108.427 -179.048 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.424 HG21 ' O ' ' A' ' 54' ' ' ASP . 2.2 p -128.93 141.46 46.55 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 108.253 -1.018 . . . . 0.0 108.253 -178.729 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -92.99 108.33 19.92 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-O 121.251 0.548 . . . . 0.0 111.234 -178.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -94.38 45.97 1.14 Allowed 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.6 t -124.03 -176.57 3.52 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 -175.77 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 37.8 ptt180 -148.14 33.78 0.82 Allowed 'General case' 0 C--N 1.314 -0.948 0 CA-C-O 121.879 0.847 . . . . 0.0 109.619 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.1 t -165.58 -178.97 5.16 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 -178.52 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -77.12 130.15 36.97 Favored 'General case' 0 CA--C 1.501 -0.928 0 CA-C-O 121.515 0.674 . . . . 0.0 109.956 -179.748 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 15.8 mmtm -129.72 141.35 41.52 Favored Pre-proline 0 C--N 1.287 -2.137 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.08 -179.558 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -61.53 137.58 70.31 Favored 'Trans proline' 0 CA--C 1.499 -1.246 0 C-N-CA 123.571 2.847 . . . . 0.0 112.7 -174.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.6 t90 -81.5 108.58 11.22 Favored Pre-proline 0 C--N 1.304 -1.409 0 N-CA-C 106.393 -1.706 . . . . 0.0 106.393 -177.479 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -76.22 87.69 1.41 Allowed 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 121.231 1.287 . . . . 0.0 112.718 -172.045 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.43 HG21 ' CD2' ' A' ' 77' ' ' TYR . 57.6 t -137.83 146.53 27.18 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.203 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 177.544 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.621 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.38 134.73 16.09 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 177.446 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 16.7 mt -102.87 99.95 9.9 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.443 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 1.635 ' HE2' ' CE1' ' A' ' 108' ' ' TYR . 71.5 m-85 -78.36 81.36 4.71 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 177.513 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.568 HD22 ' CD2' ' A' ' 84' ' ' PHE . 3.1 mm? -107.1 118.6 37.13 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 176.366 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -120.99 148.41 48.72 Favored Pre-proline 0 N--CA 1.41 -2.448 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.253 -173.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -66.13 120.96 8.18 Favored 'Trans proline' 0 N--CA 1.44 -1.646 0 C-N-CA 122.892 2.395 . . . . 0.0 113.47 -175.055 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.548 ' O ' HG23 ' A' ' 30' ' ' VAL . 21.7 m -81.03 -157.29 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.393 -3.297 0 CA-C-N 114.49 -1.232 . . . . 0.0 108.814 170.75 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 30.9 m -82.96 -26.47 31.34 Favored 'General case' 0 C--N 1.252 -3.645 0 CA-C-O 121.699 0.761 . . . . 0.0 110.912 -170.127 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 19.6 t -83.36 13.64 4.21 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.197 -0.911 . . . . 0.0 110.189 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -98.3 125.31 43.35 Favored 'General case' 0 N--CA 1.428 -1.557 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.569 179.352 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -168.67 129.74 1.94 Allowed Glycine 0 N--CA 1.431 -1.642 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 178.687 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.71 -148.8 49.94 Favored Glycine 0 CA--C 1.493 -1.322 0 CA-C-O 119.232 -0.76 . . . . 0.0 111.883 -177.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.434 ' CG1' ' HE3' ' A' ' 121' ' ' LYS . 65.9 t -60.04 101.66 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.248 0.991 0 CA-C-O 122.078 0.942 . . . . 0.0 111.117 -176.435 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -101.57 -23.11 14.34 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 114.137 -1.392 . . . . 0.0 111.498 -177.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.42 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 61.8 mt -136.7 141.21 41.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.68 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.46 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.6 mmpt? -116.2 141.31 48.31 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 120.843 0.354 . . . . 0.0 110.347 177.006 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.06 148.07 50.58 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.725 179.667 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 71.78 14.37 75.49 Favored Glycine 0 C--O 1.218 -0.845 0 CA-C-N 115.828 -0.623 . . . . 0.0 111.555 178.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 20.0 m -119.08 143.4 47.16 Favored 'General case' 0 N--CA 1.421 -1.891 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -175.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -68.6 127.05 31.61 Favored 'General case' 0 C--O 1.242 0.659 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.167 -178.032 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.465 ' HB ' HG23 ' A' ' 67' ' ' VAL . 27.9 pt -115.9 -26.91 2.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -159.92 168.13 26.42 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -178.041 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 65.7 t -142.64 114.06 3.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.443 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 56.8 mt -115.43 155.76 26.85 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 178.3 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.519 ' O ' HD11 ' A' ' 58' ' ' LEU . 5.1 mp -135.68 131.13 50.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 CA-C-N 118.52 0.6 . . . . 0.0 109.751 177.733 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . . . . . . . . . 1.8 pp -92.58 139.79 30.21 Favored 'General case' 0 CA--C 1.489 -1.399 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 172.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 27.1 tpt180 -97.31 108.0 20.64 Favored 'General case' 0 C--N 1.251 -3.714 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 19.4 tp60 -87.67 118.6 27.27 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -177.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 22.2 m -137.03 140.52 42.14 Favored 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 173.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.592 ' CB ' HG21 ' A' ' 52' ' ' ILE . 10.8 p30 -146.82 175.54 10.56 Favored 'General case' 0 N--CA 1.444 -0.751 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.899 178.008 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 7.3 p30 -89.21 -13.76 37.51 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.546 -1.206 . . . . 0.0 113.158 -169.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 48.5 t80 -105.42 -57.09 2.08 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-O 120.868 0.366 . . . . 0.0 111.829 -172.277 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . 0.42 ' HB3' ' OD1' ' A' ' 140' ' ' ASP . 18.5 m120 -84.24 145.78 28.14 Favored 'General case' 0 CA--C 1.483 -1.621 0 CA-C-O 121.221 0.534 . . . . 0.0 109.886 178.656 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 9.1 p -97.7 22.01 9.64 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 172.372 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . 0.42 ' OD1' ' HB3' ' A' ' 138' ' ' ASN . 1.8 m-20 -90.3 58.9 4.2 Favored 'General case' 0 N--CA 1.432 -1.336 0 CA-C-N 113.085 -1.871 . . . . 0.0 107.911 -178.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -77.64 73.7 4.2 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 122.269 1.033 . . . . 0.0 110.923 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . 1.596 ' HE1' ' CE2' ' A' ' 142' ' ' PHE . 78.0 m-85 -93.96 179.99 5.16 Favored 'General case' 0 N--CA 1.425 -1.723 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 176.153 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -141.86 149.46 40.3 Favored 'General case' 0 C--N 1.282 -2.366 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 176.918 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 9.7 m-30 -109.26 125.25 52.07 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 -174.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 48.2 t -89.27 135.52 25.75 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.926 0 O-C-N 123.749 0.656 . . . . 0.0 110.074 -178.209 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . 0.465 ' CZ2' ' HB3' ' A' ' 3' ' ' CYS . 61.6 m95 -120.38 96.26 5.07 Favored 'General case' 0 C--N 1.284 -2.246 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 -179.317 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 37.3 m-80 -80.58 112.83 18.31 Favored 'General case' 0 C--N 1.291 -1.946 0 N-CA-C 106.587 -1.634 . . . . 0.0 106.587 179.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 28.1 mm -87.48 122.83 39.72 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -176.193 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 1.621 ' HD1' ' CD2' ' A' ' 149' ' ' TYR . 61.2 m-85 -117.12 151.9 35.85 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 123.786 0.834 . . . . 0.0 109.442 178.464 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.68 130.21 34.98 Favored 'General case' 0 N--CA 1.413 -2.318 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 176.064 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 39.6 t-20 -89.12 -17.52 29.05 Favored 'General case' 0 C--N 1.288 -2.068 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 -178.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -147.17 143.04 27.93 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-N 114.418 -1.265 . . . . 0.0 109.462 -174.477 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 12.8 p-10 -86.07 138.66 31.78 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 124.083 0.865 . . . . 0.0 111.477 -178.733 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.503 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.8 t -114.44 137.82 46.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 114.946 -1.025 . . . . 0.0 112.334 -171.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -117.79 138.28 48.99 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.351 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 177.494 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.452 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 53.2 t -101.89 103.66 30.52 Favored Pre-proline 0 C--N 1.29 -1.979 0 C-N-CA 123.618 0.767 . . . . 0.0 109.756 178.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.45 ' HD2' ' O ' ' A' ' 28' ' ' VAL . 30.8 Cg_endo -68.08 -26.11 37.17 Favored 'Trans proline' 0 CA--C 1.506 -0.908 0 C-N-CA 122.429 2.086 . . . . 0.0 111.878 177.295 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.4 t . . . . . 0 C--N 1.349 0.578 0 O-C-N 124.748 1.28 . . . . 0.0 112.33 179.233 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 1.66 ' HD2' ' CD1' ' A' ' 1' ' ' PHE . 0.1 OUTLIER . . . . . 0 CA--C 1.495 -1.157 0 N-CA-C 113.802 1.038 . . . . 0.0 113.802 . . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.469 ' HB1' ' NE2' ' A' ' 45' ' ' HIS . . . -148.47 162.49 39.51 Favored 'General case' 0 C--N 1.29 -2.001 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 167.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.4 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 63.1 m -134.39 155.41 50.34 Favored 'General case' 0 C--N 1.288 -2.071 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.786 -174.105 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.5 155.52 43.15 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-O 121.223 0.535 . . . . 0.0 109.917 -176.333 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.402 HG21 HG23 ' A' ' 20' ' ' VAL . 72.9 p -92.25 175.01 7.01 Favored 'General case' 0 C--N 1.292 -1.922 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.77 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -85.61 -11.49 53.81 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.278 -1.328 . . . . 0.0 109.716 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -95.21 -27.35 15.57 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-N 115.138 -0.937 . . . . 0.0 111.751 -178.279 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 136.64 1.04 2.8 Favored Glycine 0 C--O 1.222 -0.621 0 C-N-CA 119.155 -1.498 . . . . 0.0 114.845 169.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.2 m -87.86 105.94 17.76 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 121.455 0.645 . . . . 0.0 109.579 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -98.99 119.55 37.97 Favored 'General case' 0 C--N 1.291 -1.953 0 CA-C-N 114.735 -1.12 . . . . 0.0 109.224 176.402 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.439 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 60.0 mt -100.36 114.66 65.79 Favored Pre-proline 0 C--N 1.303 -1.429 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.102 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_endo -76.59 171.87 17.26 Favored 'Trans proline' 0 C--O 1.249 1.037 0 C-N-CA 122.385 2.057 . . . . 0.0 111.354 177.262 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 68.4 mt -58.06 134.03 22.85 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.967 179.031 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 128.59 2.75 5.74 Favored Glycine 0 C--N 1.303 -1.257 0 C-N-CA 120.344 -0.931 . . . . 0.0 112.466 179.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.04 164.89 34.82 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.13 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.74 -166.51 34.44 Favored Glycine 0 C--N 1.295 -1.743 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.701 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.1 p -141.24 154.33 45.72 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -178.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -143.37 159.38 42.48 Favored 'General case' 0 N--CA 1.421 -1.88 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.36 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.8 p30 -103.22 122.87 45.65 Favored 'General case' 0 C--N 1.275 -2.67 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 173.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.402 HG23 HG21 ' A' ' 5' ' ' THR . 40.3 t -106.81 129.71 59.95 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.76 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.737 177.826 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 -112.88 121.17 43.88 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 120.982 0.42 . . . . 0.0 111.23 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.492 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.3 p -133.92 130.24 55.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-N 115.318 -0.856 . . . . 0.0 111.164 -178.667 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -92.25 130.83 37.85 Favored 'General case' 0 C--N 1.296 -1.758 0 CA-C-O 121.37 0.605 . . . . 0.0 110.429 177.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . 0.43 HD22 HG23 ' A' ' 36' ' ' VAL . 6.9 mp -109.18 161.85 14.83 Favored 'General case' 0 C--N 1.287 -2.118 0 CA-C-N 114.489 -1.232 . . . . 0.0 108.877 179.454 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.01 121.1 48.17 Favored Pre-proline 0 C--O 1.209 -1.06 0 O-C-N 124.777 1.298 . . . . 0.0 109.486 179.177 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 66.1 Cg_endo -75.7 -0.91 10.72 Favored 'Trans proline' 0 CA--C 1.531 0.332 0 C-N-CA 122.906 2.404 . . . . 0.0 113.539 -176.78 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 96.0 t -127.93 109.63 20.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 178.407 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.498 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 5.7 t -145.59 112.43 1.22 Allowed 'Isoleucine or valine' 0 C--O 1.189 -2.116 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 -177.558 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.443 ' H ' ' HG3' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -100.78 152.12 20.88 Favored 'General case' 0 C--N 1.266 -3.064 0 C-N-CA 123.138 0.575 . . . . 0.0 111.004 -179.843 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 41.5 t -43.81 116.51 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 123.727 0.811 . . . . 0.0 111.631 175.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.51 -5.52 35.39 Favored Glycine 0 C--O 1.227 -0.296 0 CA-C-N 115.421 -0.808 . . . . 0.0 112.99 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.443 ' HG3' ' H ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -69.34 -177.89 1.24 Allowed 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 123.669 0.788 . . . . 0.0 111.786 177.817 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -126.62 86.19 2.48 Favored 'General case' 0 CA--C 1.482 -1.646 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 176.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.605 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 24.4 tp -95.73 134.98 38.02 Favored 'General case' 0 N--CA 1.41 -2.433 0 C-N-CA 119.202 -0.999 . . . . 0.0 109.453 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.7 p -141.78 137.79 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.38 -3.941 0 CA-C-N 114.729 -1.123 . . . . 0.0 112.07 -177.633 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.603 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 58.4 t -90.48 89.89 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.335 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 176.26 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -76.01 106.57 7.68 Favored 'General case' 0 C--N 1.297 -1.717 0 C-N-CA 120.057 -0.657 . . . . 0.0 109.669 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.8 mt -95.03 -1.16 52.87 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.822 -179.188 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 15.2 m -77.41 0.58 21.98 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-O 122.074 0.94 . . . . 0.0 109.478 -177.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.2 p -128.46 5.39 5.68 Favored 'General case' 0 N--CA 1.421 -1.901 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.157 178.776 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.492 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 47.1 mm-40 -122.74 -24.21 4.91 Favored 'General case' 0 CA--C 1.503 -0.835 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.73 -174.385 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.7 mt -130.47 140.07 49.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 -176.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.633 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 55.7 m-85 -138.13 149.74 46.18 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 -176.631 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.4 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 70.2 m -125.87 134.08 51.73 Favored 'General case' 0 C--N 1.289 -2.047 0 C-N-CA 122.794 0.437 . . . . 0.0 110.061 176.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . 0.469 ' NE2' ' HB1' ' A' ' 2' ' ' ALA . 11.6 p-80 -119.35 150.79 39.57 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-O 121.998 0.904 . . . . 0.0 110.386 -177.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -99.35 101.99 13.44 Favored 'General case' 0 C--N 1.272 -2.789 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 -179.022 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 18.3 p-10 -86.62 -17.63 33.4 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 -179.247 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 67.3 m-85 -138.47 62.79 31.66 Favored Pre-proline 0 N--CA 1.477 0.91 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 175.184 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.8 -3.31 11.79 Favored 'Trans proline' 0 N--CA 1.485 0.971 0 C-N-CA 123.208 2.605 . . . . 0.0 114.454 -171.074 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -115.54 -17.35 11.2 Favored 'General case' 0 C--N 1.299 -1.625 0 CA-C-O 121.286 0.565 . . . . 0.0 110.272 -178.137 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.415 ' HB ' HD13 ' A' ' 52' ' ' ILE . 1.9 m -102.23 -30.36 11.15 Favored 'General case' 0 N--CA 1.424 -1.766 0 CA-C-O 122.064 0.935 . . . . 0.0 108.826 -174.38 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.482 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.0 mp -123.58 137.07 58.02 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.493 0 CA-C-N 114.164 -1.38 . . . . 0.0 109.043 -178.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 3.9 t -83.97 122.35 28.63 Favored 'General case' 0 N--CA 1.419 -1.986 0 N-CA-C 102.68 -3.082 . . . . 0.0 102.68 168.431 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -88.98 107.76 19.21 Favored 'General case' 0 C--N 1.261 -3.268 0 C-N-CA 118.313 -1.355 . . . . 0.0 109.013 -172.338 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 1.653 ' HD1' ' CD2' ' A' ' 55' ' ' TYR . 17.0 t80 -122.63 131.58 53.88 Favored 'General case' 0 C--N 1.285 -2.204 0 CA-C-N 114.382 -1.281 . . . . 0.0 109.638 -174.727 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.408 ' CG2' ' HG ' ' A' ' 131' ' ' LEU . 14.9 p -136.87 144.8 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.138 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.685 -175.705 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -150.02 118.49 6.49 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 178.04 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.519 HD13 ' O ' ' A' ' 130' ' ' ILE . 48.0 tp -53.91 111.03 0.67 Allowed 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 169.884 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 -59.74 -51.06 71.37 Favored 'General case' 0 C--O 1.21 -0.976 0 C-N-CA 125.793 1.637 . . . . 0.0 110.574 179.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 11.0 ptp180 -170.01 158.68 7.25 Favored 'General case' 0 N--CA 1.428 -1.567 0 CA-C-N 115.172 -0.922 . . . . 0.0 108.804 -176.328 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -134.6 145.74 17.8 Favored Glycine 0 N--CA 1.405 -3.433 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 179.319 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 72.3 m -132.88 150.85 52.12 Favored 'General case' 0 C--N 1.283 -2.326 0 C-N-CA 124.062 0.945 . . . . 0.0 109.918 -177.322 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.494 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -115.3 157.77 23.32 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 -178.545 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 1.667 ' HE1' ' CE2' ' A' ' 64' ' ' TYR . 95.9 m-85 -155.09 -179.6 8.22 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 124.302 1.041 . . . . 0.0 109.008 -178.403 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 54.77 -140.05 38.7 Favored Glycine 0 N--CA 1.455 -0.093 0 O-C-N 123.812 0.695 . . . . 0.0 113.464 178.195 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -73.35 -15.46 78.94 Favored Glycine 0 C--O 1.2 -2.014 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.004 178.344 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.548 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 84.4 t -67.12 -40.03 84.44 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 C-N-CA 123.637 0.775 . . . . 0.0 111.78 -176.823 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.502 ' HG ' ' CA ' ' A' ' 64' ' ' TYR . 0.3 OUTLIER -87.99 -16.43 33.76 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 118.919 -1.112 . . . . 0.0 112.158 178.326 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 23.2 t -100.74 -59.13 1.75 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-O 121.328 0.585 . . . . 0.0 111.992 -174.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.43 ' O ' HG23 ' A' ' 112' ' ' VAL . 34.0 m-20 -90.69 -22.44 21.14 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.875 -171.893 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 1.623 ' HE1' ' CE2' ' A' ' 71' ' ' PHE . 90.4 m-85 -110.63 157.16 20.0 Favored 'General case' 0 N--CA 1.422 -1.854 0 C-N-CA 119.97 -0.692 . . . . 0.0 110.594 178.759 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.4 t -166.17 130.63 2.21 Favored 'General case' 0 N--CA 1.417 -2.075 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 176.269 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.49 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -160.98 -99.77 0.15 Allowed Glycine 0 C--N 1.286 -2.199 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 177.664 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.418 HG21 ' O ' ' A' ' 73' ' ' GLY . 0.7 OUTLIER -168.89 -179.97 3.9 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.893 1.277 . . . . 0.0 109.97 -177.643 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.0 147.03 32.36 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 C-N-CA 123.255 0.622 . . . . 0.0 109.536 178.324 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.578 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.9 tttt -124.68 147.92 48.29 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.239 -179.43 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . . . . . . . . . 61.3 t80 -148.4 108.8 4.13 Favored 'General case' 0 C--N 1.314 -0.965 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 -179.429 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 11.2 t 51.78 43.04 30.33 Favored 'General case' 0 C--N 1.315 -0.926 0 C-N-CA 124.251 1.02 . . . . 0.0 111.546 177.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.78 8.26 70.07 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.188 -1.006 . . . . 0.0 113.435 179.038 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.578 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 23.0 t -80.68 -179.66 7.34 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 177.297 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 12.3 p -158.89 106.61 1.84 Allowed 'General case' 0 C--N 1.288 -2.1 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 2.6 p90 -151.52 158.45 34.29 Favored Pre-proline 0 C--N 1.308 -1.205 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -174.449 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.4 ' HA ' HG23 ' A' ' 74' ' ' THR . 44.9 Cg_endo -67.16 148.9 81.64 Favored 'Trans proline' 0 C--N 1.36 1.16 0 C-N-CA 123.092 2.528 . . . . 0.0 112.703 -177.053 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.573 ' CD2' HD22 ' A' ' 109' ' ' LEU . 60.6 t80 -122.07 131.7 24.37 Favored Pre-proline 0 C--N 1.312 -1.035 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.694 -179.447 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.535 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 72.7 Cg_endo -70.89 150.27 92.73 Favored 'Cis proline' 0 CA--C 1.539 0.731 0 C-N-CA 122.956 -1.685 . . . . 0.0 109.915 -1.296 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.9 t -59.47 -177.99 0.06 Allowed 'General case' 0 CA--C 1.559 1.309 0 CA-C-O 121.928 0.87 . . . . 0.0 112.504 -174.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.1 p -115.0 -15.6 11.75 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-N 115.34 -0.846 . . . . 0.0 110.067 -173.596 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.6 t -158.15 -109.53 0.02 OUTLIER 'General case' 0 N--CA 1.415 -2.213 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 178.457 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . 0.401 ' HB2' ' O ' ' A' ' 58' ' ' LEU . 0.5 OUTLIER -132.93 -164.01 1.42 Allowed 'General case' 0 N--CA 1.436 -1.16 0 CA-C-N 118.349 0.522 . . . . 0.0 111.723 179.295 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.452 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 10.8 p -100.14 164.56 16.16 Favored Pre-proline 0 C--N 1.299 -1.606 0 C-N-CA 123.618 0.767 . . . . 0.0 112.405 -177.642 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -65.98 168.74 14.79 Favored 'Trans proline' 0 C--N 1.36 1.148 0 C-N-CA 123.411 2.741 . . . . 0.0 111.21 174.359 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.564 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 3.2 tmm_? -70.2 128.44 36.26 Favored 'General case' 0 N--CA 1.44 -0.964 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 -178.77 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 74.0 t -142.59 120.92 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.666 0 C-N-CA 124.439 1.095 . . . . 0.0 108.11 -178.381 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.0 p -119.81 140.32 44.22 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.209 0 CA-C-O 120.956 0.408 . . . . 0.0 110.775 -177.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . 0.475 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 9.5 m-85 -94.26 112.46 24.26 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 177.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 13.9 m120 -97.49 8.64 44.25 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-O 121.657 0.741 . . . . 0.0 109.218 178.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.8 m -76.7 -175.95 3.61 Favored 'General case' 0 N--CA 1.427 -1.6 0 C-N-CA 124.729 1.212 . . . . 0.0 109.988 -177.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 15.0 ptp180 -143.64 30.57 1.34 Allowed 'General case' 0 C--N 1.309 -1.174 0 CA-C-O 121.001 0.429 . . . . 0.0 110.611 177.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.1 t -163.48 -178.01 5.61 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -175.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -67.31 99.37 0.71 Allowed 'General case' 0 C--O 1.242 0.691 0 O-C-N 123.894 0.746 . . . . 0.0 109.772 178.016 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 11.2 mptt -104.96 141.43 22.53 Favored Pre-proline 0 C--N 1.283 -2.306 0 N-CA-C 106.86 -1.533 . . . . 0.0 106.86 175.641 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -60.85 147.05 96.51 Favored 'Trans proline' 0 C--O 1.243 0.771 0 C-N-CA 122.409 2.073 . . . . 0.0 112.23 -177.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . 0.475 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 11.9 t90 -91.25 104.66 10.28 Favored Pre-proline 0 C--N 1.309 -1.167 0 N-CA-C 105.387 -2.079 . . . . 0.0 105.387 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -75.51 88.12 1.31 Allowed 'Trans proline' 0 N--CA 1.445 -1.366 0 C-N-CA 121.449 1.433 . . . . 0.0 113.0 -171.052 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 72.4 t -136.15 150.78 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.333 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 177.456 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.603 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -156.87 134.45 10.77 Favored 'General case' 0 N--CA 1.421 -1.893 0 O-C-N 123.633 0.583 . . . . 0.0 109.758 176.773 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 19.7 mt -103.45 99.86 9.71 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.437 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 1.618 ' HD2' ' CD1' ' A' ' 108' ' ' TYR . 65.4 m-85 -78.55 81.56 4.87 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 178.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.605 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.0 mm? -107.03 117.03 32.98 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-O 121.122 0.487 . . . . 0.0 110.629 176.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -120.17 146.88 43.5 Favored Pre-proline 0 N--CA 1.413 -2.3 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.319 -174.54 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -61.0 119.96 7.41 Favored 'Trans proline' 0 C--O 1.249 1.067 0 C-N-CA 123.226 2.618 . . . . 0.0 112.309 -177.538 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 70' ' ' ASN . 3.0 m -68.35 -118.5 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.193 -1.891 0 CA-C-N 114.261 -1.336 . . . . 0.0 111.862 173.783 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.8 t -112.87 -33.11 6.18 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 175.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 36.3 m -80.03 34.5 0.3 Allowed 'General case' 0 N--CA 1.399 -2.982 0 C-N-CA 125.698 1.599 . . . . 0.0 112.742 -178.169 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -118.12 130.01 55.87 Favored 'General case' 0 C--N 1.281 -2.397 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.365 179.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -170.08 128.18 1.6 Allowed Glycine 0 C--O 1.239 0.467 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.647 179.405 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 65.98 -150.48 51.84 Favored Glycine 0 CA--C 1.499 -0.964 0 CA-C-O 118.985 -0.897 . . . . 0.0 111.589 -176.097 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 95.1 t -56.93 105.2 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.873 0.844 . . . . 0.0 111.435 -178.291 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -105.41 -21.58 13.2 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-N 114.327 -1.306 . . . . 0.0 110.919 -177.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.465 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 63.6 mt -135.84 140.54 44.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.445 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.3 mmpt? -115.87 139.56 50.09 Favored 'General case' 0 C--N 1.317 -0.817 0 C-N-CA 122.319 0.248 . . . . 0.0 111.232 178.071 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.53 134.73 47.96 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.227 179.38 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 87.01 -7.91 78.55 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 121.353 -0.451 . . . . 0.0 112.115 -179.233 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 34.7 t -96.11 143.63 27.07 Favored 'General case' 0 N--CA 1.422 -1.843 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.415 HD12 HG21 ' A' ' 128' ' ' VAL . 3.0 tm? -69.86 128.21 35.58 Favored 'General case' 0 N--CA 1.436 -1.17 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.384 -178.463 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.478 ' HB ' HG23 ' A' ' 67' ' ' VAL . 32.6 pt -112.43 -27.05 2.86 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 N-CA-C 112.327 0.492 . . . . 0.0 112.327 -179.886 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.84 168.03 23.76 Favored 'General case' 0 CA--C 1.505 -0.765 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -178.283 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.415 HG21 HD12 ' A' ' 125' ' ' LEU . 59.9 t -142.03 116.94 5.25 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 179.112 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 68.3 mt -117.46 137.58 52.43 Favored 'General case' 0 C--N 1.28 -2.444 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 178.483 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.519 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.3 mp -118.57 122.71 70.15 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 C-N-CA 119.015 -1.074 . . . . 0.0 109.934 177.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.561 ' O ' ' HB2' ' A' ' 143' ' ' GLN . 0.8 OUTLIER -88.53 141.35 28.6 Favored 'General case' 0 C--N 1.266 -3.064 0 C-N-CA 125.053 1.341 . . . . 0.0 108.166 177.554 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 24.9 ttp180 -122.35 131.01 53.69 Favored 'General case' 0 N--CA 1.409 -2.497 0 C-N-CA 120.153 -0.619 . . . . 0.0 109.815 174.307 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.666 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 0.0 OUTLIER -98.28 143.66 28.53 Favored 'General case' 0 N--CA 1.42 -1.942 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 -179.487 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.444 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 11.0 m -154.78 138.04 15.73 Favored 'General case' 0 C--N 1.281 -2.402 0 N-CA-C 106.488 -1.671 . . . . 0.0 106.488 173.649 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.482 ' CB ' HG21 ' A' ' 52' ' ' ILE . 11.0 p30 -135.6 -177.17 4.55 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 119.227 0.921 . . . . 0.0 112.515 176.108 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 9.4 p30 -88.54 -29.05 20.36 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.472 0.653 . . . . 0.0 112.023 -174.602 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 82.5 t80 -92.59 -68.01 0.82 Allowed 'General case' 0 C--N 1.291 -1.947 0 C-N-CA 123.975 0.91 . . . . 0.0 110.814 -169.181 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -89.36 170.71 10.32 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.31 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' SER . . . . . 0.405 ' C ' ' H ' ' A' ' 141' ' ' ASP . 26.7 t -101.97 58.37 0.83 Allowed 'General case' 0 N--CA 1.397 -3.092 0 N-CA-C 106.12 -1.807 . . . . 0.0 106.12 172.402 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 -81.64 45.73 0.91 Allowed 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.608 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . 0.576 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 2.9 m-20 -79.64 53.82 1.67 Allowed 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 124.4 1.08 . . . . 0.0 109.005 -179.056 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -101.73 156.44 17.5 Favored 'General case' 0 N--CA 1.426 -1.673 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 179.548 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . 0.561 ' HB2' ' O ' ' A' ' 131' ' ' LEU . 13.9 pt20 -124.49 142.55 51.24 Favored 'General case' 0 N--CA 1.415 -2.215 0 C-N-CA 118.541 -1.264 . . . . 0.0 111.844 178.534 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 1.655 ' HE1' ' CE2' ' A' ' 144' ' ' PHE . 3.3 m-30 -106.69 129.37 54.6 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -175.344 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 48.5 t -94.53 129.18 45.12 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -178.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . 0.464 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 60.4 m95 -118.47 103.09 9.43 Favored 'General case' 0 C--N 1.278 -2.507 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.141 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 36.8 m-80 -82.05 110.86 17.67 Favored 'General case' 0 C--N 1.286 -2.159 0 N-CA-C 106.699 -1.593 . . . . 0.0 106.699 178.155 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 23.4 mm -85.52 121.14 36.8 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.903 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 -178.046 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 1.602 ' HE1' ' CE2' ' A' ' 149' ' ' TYR . 93.8 m-85 -117.72 151.3 37.55 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 123.618 0.767 . . . . 0.0 109.676 178.463 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -79.97 130.84 35.59 Favored 'General case' 0 N--CA 1.413 -2.295 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 175.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 -92.32 -6.43 50.29 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 -179.317 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -155.39 142.45 19.2 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.205 -176.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 17.5 p-10 -86.83 136.15 33.08 Favored 'General case' 0 C--N 1.309 -1.173 0 O-C-N 123.998 0.811 . . . . 0.0 112.004 -177.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.508 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.7 t -110.32 140.79 27.81 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 CA-C-N 114.966 -1.016 . . . . 0.0 111.987 -171.79 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 13.9 t -122.93 137.45 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.045 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 -179.529 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.498 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 70.0 t -103.28 103.27 33.95 Favored Pre-proline 0 C--N 1.286 -2.165 0 C-N-CA 123.699 0.799 . . . . 0.0 110.106 179.534 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -69.47 -21.88 34.18 Favored 'Trans proline' 0 N--CA 1.463 -0.312 0 C-N-CA 121.959 1.772 . . . . 0.0 111.346 177.322 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.6 t . . . . . 0 C--O 1.244 0.784 0 C-N-CA 124.698 1.199 . . . . 0.0 113.251 176.802 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 33.3 t80 . . . . . 0 CA--C 1.503 -0.839 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.414 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . -145.73 170.1 17.18 Favored 'General case' 0 N--CA 1.439 -1.005 0 C-N-CA 119.943 -0.703 . . . . 0.0 111.04 -177.697 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 80.0 m -143.67 159.05 43.16 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -177.478 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.6 pptp? -141.8 164.51 29.99 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-O 121.384 0.612 . . . . 0.0 111.621 -176.35 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.407 HG21 HG23 ' A' ' 20' ' ' VAL . 76.7 p -103.25 167.27 9.93 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.168 179.257 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.34 -9.49 58.65 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-N 113.729 -1.578 . . . . 0.0 112.474 179.563 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -94.37 -33.42 13.18 Favored 'General case' 0 C--O 1.239 0.516 0 C-N-CA 119.105 -1.038 . . . . 0.0 109.078 179.381 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 139.3 4.8 1.42 Allowed Glycine 0 N--CA 1.426 -1.972 0 C-N-CA 119.345 -1.407 . . . . 0.0 113.708 176.861 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.0 m -84.54 106.99 16.53 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 177.765 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -99.93 117.2 33.72 Favored 'General case' 0 C--N 1.286 -2.175 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 175.996 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.414 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 62.0 mt -84.21 116.95 67.37 Favored Pre-proline 0 C--N 1.308 -1.212 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 -179.711 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -76.96 166.8 26.23 Favored 'Trans proline' 0 N--CA 1.443 -1.497 0 C-N-CA 122.271 1.981 . . . . 0.0 111.381 179.167 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 72.1 mt -62.19 133.24 28.04 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.97 -179.894 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 126.96 4.44 6.04 Favored Glycine 0 C--N 1.311 -0.838 0 C-N-CA 120.506 -0.854 . . . . 0.0 112.466 178.916 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.04 146.44 6.48 Favored Glycine 0 N--CA 1.442 -0.944 0 C-N-CA 120.494 -0.86 . . . . 0.0 111.174 -177.025 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 177.62 -173.94 46.5 Favored Glycine 0 C--N 1.296 -1.666 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -179.231 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 60.3 p -134.06 151.12 51.27 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -179.651 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.49 168.67 18.81 Favored 'General case' 0 N--CA 1.432 -1.364 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.56 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 16.0 m-80 -118.14 108.69 15.49 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 -179.489 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.407 HG23 HG21 ' A' ' 5' ' ' THR . 46.9 t -94.72 136.64 25.33 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.018 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 -179.705 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 86.4 m-85 -125.1 117.39 23.83 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -177.333 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 2.7 p -124.3 129.52 73.96 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.833 0 CA-C-O 121.704 0.764 . . . . 0.0 111.479 -176.913 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -82.26 124.62 30.11 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-N 114.988 -1.005 . . . . 0.0 108.459 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 35.5 mt -113.44 156.16 24.01 Favored 'General case' 0 C--N 1.276 -2.593 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 179.951 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.53 121.67 50.16 Favored Pre-proline 0 C--O 1.201 -1.483 0 O-C-N 124.207 0.942 . . . . 0.0 109.899 -179.311 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.477 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 62.3 Cg_endo -71.37 -2.46 11.27 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 C-N-CA 123.185 2.59 . . . . 0.0 113.294 -176.699 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.456 HG12 ' HG3' ' A' ' 157' ' ' PRO . 64.8 t -130.4 111.26 20.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.94 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 5.8 t -145.76 110.3 0.98 Allowed 'Isoleucine or valine' 0 C--O 1.191 -2.024 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 -179.383 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.546 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -99.68 156.62 16.99 Favored 'General case' 0 C--N 1.264 -3.109 0 C-N-CA 122.94 0.496 . . . . 0.0 111.18 -179.539 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 25.4 t -47.93 116.5 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 123.887 0.875 . . . . 0.0 111.675 177.299 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.87 0.51 45.46 Favored Glycine 0 N--CA 1.444 -0.827 0 CA-C-N 115.36 -0.836 . . . . 0.0 112.983 -179.96 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.546 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -73.73 -177.05 2.6 Favored 'General case' 0 C--N 1.315 -0.893 0 C-N-CA 123.888 0.875 . . . . 0.0 111.099 176.221 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -128.39 87.88 2.66 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 178.484 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.638 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 18.7 tp -97.35 132.67 42.85 Favored 'General case' 0 N--CA 1.417 -2.091 0 C-N-CA 118.663 -1.215 . . . . 0.0 108.753 178.095 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 2.1 p -141.41 129.55 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.386 -3.65 0 CA-C-N 114.859 -1.064 . . . . 0.0 111.618 -177.747 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.627 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 46.8 t -90.54 89.22 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.393 -3.277 0 CA-C-N 113.374 -1.739 . . . . 0.0 107.825 -179.039 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -77.98 112.22 14.67 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 121.015 0.436 . . . . 0.0 109.952 179.08 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 92.1 mt -96.3 -0.54 49.47 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.337 -177.766 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 35.6 t -74.56 0.97 13.17 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.847 0.832 . . . . 0.0 110.366 -179.561 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.8 p -126.85 3.32 6.65 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.086 178.597 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 47.9 mm-40 -121.8 -26.79 4.78 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.686 -172.925 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 20.6 mt -130.43 139.63 50.85 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 -175.525 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -139.48 158.74 43.63 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 -176.095 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 49.1 m -136.21 141.47 44.0 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 123.472 0.709 . . . . 0.0 109.972 179.58 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 5.6 p80 -136.92 153.47 50.72 Favored 'General case' 0 N--CA 1.43 -1.47 0 CA-C-O 121.9 0.857 . . . . 0.0 110.681 -178.427 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.46 HD22 ' HA ' ' A' ' 98' ' ' ARG . 6.6 p30 -95.01 109.93 21.9 Favored 'General case' 0 C--N 1.277 -2.556 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.408 177.187 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -73.87 -28.98 61.84 Favored 'General case' 0 C--N 1.297 -1.674 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.931 -179.429 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -136.52 79.6 41.0 Favored Pre-proline 0 C--N 1.313 -0.996 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 175.569 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.54 5.01 2.6 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 C-N-CA 123.257 2.638 . . . . 0.0 113.023 -176.164 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -120.34 -13.31 8.88 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.594 179.144 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.419 ' HB ' HD13 ' A' ' 52' ' ' ILE . 2.6 m -117.14 -25.64 7.07 Favored 'General case' 0 N--CA 1.422 -1.859 0 CA-C-O 121.408 0.623 . . . . 0.0 110.789 -172.575 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.419 HD13 ' HB ' ' A' ' 51' ' ' THR . 2.7 mp -128.95 130.48 68.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 CA-C-N 115.971 -0.558 . . . . 0.0 109.5 -175.581 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.4 t -75.63 146.48 40.26 Favored 'General case' 0 N--CA 1.441 -0.923 0 O-C-N 123.714 0.634 . . . . 0.0 109.707 -179.695 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.435 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 3.0 m-20 -89.96 109.97 20.97 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 115.426 -0.807 . . . . 0.0 109.341 -174.178 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 1.664 ' HE2' ' CE1' ' A' ' 55' ' ' TYR . 82.2 t80 -146.03 141.68 27.87 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -179.128 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.1 p -151.44 144.78 16.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 175.802 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.27 131.7 14.7 Favored 'General case' 0 C--O 1.212 -0.904 0 CA-C-O 119.759 -0.162 . . . . 0.0 110.575 175.654 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.539 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 56.8 tp -72.84 107.88 5.49 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.157 0.504 . . . . 0.0 109.984 176.827 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.451 ' NE2' ' HD3' ' A' ' 132' ' ' ARG . 3.0 tp-100 -51.55 -53.63 35.89 Favored 'General case' 0 C--O 1.207 -1.138 0 C-N-CA 125.554 1.541 . . . . 0.0 111.149 175.825 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . 0.403 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 2.8 ptp180 -168.62 161.4 11.39 Favored 'General case' 0 CA--C 1.493 -1.235 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 -178.072 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.1 123.52 2.23 Favored Glycine 0 N--CA 1.404 -3.485 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -178.771 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 68.9 m -115.62 149.79 37.73 Favored 'General case' 0 C--N 1.284 -2.245 0 C-N-CA 124.297 1.039 . . . . 0.0 110.32 -173.804 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.504 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -112.7 157.75 20.9 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 -179.302 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 1.648 ' HE1' ' CE2' ' A' ' 64' ' ' TYR . 88.6 m-85 -156.7 -178.91 7.7 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 124.316 1.047 . . . . 0.0 109.037 -177.68 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 60.71 -143.08 48.26 Favored Glycine 0 C--N 1.33 0.231 0 O-C-N 123.465 0.478 . . . . 0.0 112.512 177.785 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . 0.42 ' HA3' ' O ' ' A' ' 119' ' ' ALA . . . -78.94 -7.77 88.21 Favored Glycine 0 C--O 1.21 -1.382 0 C-N-CA 120.978 -0.629 . . . . 0.0 111.876 176.773 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.503 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 89.5 t -69.4 -39.96 79.4 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 C-N-CA 123.72 0.808 . . . . 0.0 111.535 -178.4 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.504 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.01 -15.97 39.74 Favored 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 119.171 -1.012 . . . . 0.0 112.053 178.836 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 16.9 t -99.67 -56.9 2.27 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.057 0.456 . . . . 0.0 111.324 -175.221 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.485 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 37.4 m-80 -85.67 -29.09 24.27 Favored 'General case' 0 CA--C 1.486 -1.513 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 -176.09 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 0.513 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 81.2 m-85 -106.79 157.39 17.78 Favored 'General case' 0 N--CA 1.416 -2.172 0 C-N-CA 119.365 -0.934 . . . . 0.0 110.38 -178.362 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.0 t -168.58 128.14 1.17 Allowed 'General case' 0 N--CA 1.42 -1.933 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 175.503 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.513 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -158.37 -109.92 0.28 Allowed Glycine 0 N--CA 1.404 -3.445 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 174.91 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' THR . . . . . 0.43 HG23 ' HA ' ' A' ' 83' ' ' PRO . 3.5 p -156.09 179.99 8.7 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 123.591 0.756 . . . . 0.0 109.859 -176.196 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -130.34 146.76 33.56 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.082 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 177.891 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.634 ' HG3' ' O ' ' A' ' 80' ' ' SER . 82.3 tttt -124.63 142.91 51.03 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.225 -179.564 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 1.617 ' HE2' ' CE1' ' A' ' 77' ' ' TYR . 51.5 t80 -142.51 107.87 5.02 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 -178.998 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 33.0 t 54.04 36.85 25.59 Favored 'General case' 0 CA--C 1.555 1.149 0 CA-C-O 121.541 0.686 . . . . 0.0 111.373 179.364 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.416 ' HA2' ' CE ' ' A' ' 76' ' ' LYS . . . 90.39 9.32 65.15 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.321 -0.942 . . . . 0.0 113.514 -178.645 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.634 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 22.9 t -79.96 172.53 13.66 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 177.425 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 6.2 p -152.84 100.58 2.53 Favored 'General case' 0 C--N 1.277 -2.58 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -177.757 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 0.442 ' HH ' HD21 ' A' ' 58' ' ' LEU . 1.6 p90 -144.93 159.52 49.81 Favored Pre-proline 0 C--N 1.301 -1.506 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -173.731 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.43 ' HA ' HG23 ' A' ' 74' ' ' THR . 47.3 Cg_endo -66.68 151.97 81.59 Favored 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 122.97 2.446 . . . . 0.0 112.734 -176.959 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 1.667 ' HE1' ' CE2' ' A' ' 84' ' ' PHE . 57.6 t80 -127.48 130.34 23.71 Favored Pre-proline 0 N--CA 1.438 -1.042 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.675 179.654 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.49 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 59.8 Cg_endo -69.37 149.46 87.67 Favored 'Cis proline' 0 C--O 1.244 0.803 0 C-N-CA 122.972 -1.678 . . . . 0.0 110.509 -0.393 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.8 t -63.73 -176.56 0.18 Allowed 'General case' 0 CA--C 1.55 0.966 0 CA-C-O 121.298 0.57 . . . . 0.0 111.745 -175.233 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.1 p -113.15 -39.31 4.21 Favored 'General case' 0 N--CA 1.418 -2.041 0 CA-C-O 121.658 0.742 . . . . 0.0 109.303 -175.267 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 14.0 t -129.82 -107.59 0.28 Allowed 'General case' 0 N--CA 1.401 -2.878 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.259 -179.784 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -134.92 -166.82 1.88 Allowed 'General case' 0 N--CA 1.438 -1.04 0 CA-C-N 117.854 0.297 . . . . 0.0 110.633 -177.821 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.539 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 36.4 p -99.49 170.86 6.27 Favored Pre-proline 0 C--N 1.309 -1.153 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 178.174 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . 0.412 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 23.2 Cg_endo -61.34 161.75 22.58 Favored 'Trans proline' 0 C--O 1.249 1.033 0 C-N-CA 122.913 2.409 . . . . 0.0 111.099 169.636 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.7 tmm_? -78.44 119.97 22.51 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 -178.433 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 92.4 t -126.97 126.51 68.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 O-C-N 123.599 0.562 . . . . 0.0 110.189 -178.612 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 75.3 t -107.9 131.16 58.95 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 176.701 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . 0.435 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.0 m-85 -77.77 131.11 37.48 Favored 'General case' 0 C--N 1.309 -1.186 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 175.795 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -117.05 58.56 0.77 Allowed 'General case' 0 C--N 1.285 -2.233 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 -179.826 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 21.0 m -143.11 157.35 44.6 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.598 -176.231 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . 0.46 ' HA ' HD22 ' A' ' 46' ' ' ASN . 14.7 ptp180 -121.83 37.61 4.32 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.845 0.831 . . . . 0.0 109.694 178.128 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 7.7 t -157.26 172.23 18.99 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 -176.028 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -73.26 120.67 19.2 Favored 'General case' 0 C--O 1.244 0.808 0 CA-C-O 121.391 0.615 . . . . 0.0 109.471 -179.203 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -117.92 142.32 30.66 Favored Pre-proline 0 C--N 1.277 -2.545 0 CA-C-N 115.128 -0.942 . . . . 0.0 110.423 -177.212 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -65.81 147.39 85.36 Favored 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.771 2.314 . . . . 0.0 111.834 176.807 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 13.8 t90 -89.17 108.88 27.01 Favored Pre-proline 0 C--N 1.31 -1.143 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 -177.205 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_endo -77.5 88.18 1.44 Allowed 'Trans proline' 0 N--CA 1.45 -1.046 0 C-N-CA 121.641 1.561 . . . . 0.0 113.38 -172.989 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.43 HG21 ' CD2' ' A' ' 77' ' ' TYR . 64.0 t -135.9 148.87 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.183 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 176.069 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.627 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -152.85 131.35 12.19 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-O 120.92 0.391 . . . . 0.0 110.375 177.198 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.409 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 16.7 mt -100.9 99.98 10.55 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.585 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 1.613 ' HD1' ' CD2' ' A' ' 108' ' ' TYR . 51.3 m-85 -78.17 80.36 4.59 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 177.397 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.638 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.7 mm? -104.02 116.66 32.63 Favored 'General case' 0 CA--C 1.491 -1.325 0 CA-C-O 120.997 0.427 . . . . 0.0 110.523 176.681 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.69 146.75 51.26 Favored Pre-proline 0 N--CA 1.407 -2.593 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.447 -175.535 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.485 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 18.8 Cg_endo -60.7 122.16 10.83 Favored 'Trans proline' 0 N--CA 1.447 -1.236 0 C-N-CA 122.987 2.458 . . . . 0.0 112.334 -178.248 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.472 HG23 ' O ' ' A' ' 70' ' ' ASN . 3.3 m -70.0 -120.52 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.195 -1.772 0 CA-C-N 113.831 -1.531 . . . . 0.0 111.78 174.874 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 33.4 t -111.69 -34.57 6.01 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 174.355 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 20.0 t -85.56 40.91 0.87 Allowed 'General case' 0 N--CA 1.431 -1.386 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.572 -177.347 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -114.06 135.88 53.53 Favored 'General case' 0 N--CA 1.418 -2.075 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 176.89 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -176.32 135.1 2.79 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 120.053 -1.07 . . . . 0.0 111.927 178.96 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 63.41 -151.07 48.95 Favored Glycine 0 CA--C 1.498 -1.016 0 CA-C-O 119.269 -0.74 . . . . 0.0 112.757 -178.642 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 98.4 t -58.32 99.46 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 122.06 0.933 . . . . 0.0 110.981 -177.648 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . 0.42 ' O ' ' HA3' ' A' ' 66' ' ' GLY . . . -99.68 -25.43 14.4 Favored 'General case' 0 C--N 1.295 -1.795 0 CA-C-N 114.608 -1.178 . . . . 0.0 110.735 -177.371 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.507 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 55.2 mt -134.56 138.01 50.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 -179.188 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.454 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 5.0 mmpt? -112.36 138.02 49.69 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-O 121.084 0.469 . . . . 0.0 111.184 177.375 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.45 125.15 25.98 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 177.74 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 93.97 -2.47 69.22 Favored Glycine 0 C--N 1.31 -0.885 0 N-CA-C 111.644 -0.582 . . . . 0.0 111.644 -178.13 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 28.8 t -96.13 143.84 26.9 Favored 'General case' 0 N--CA 1.431 -1.409 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 -179.913 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -71.53 124.0 23.68 Favored 'General case' 0 N--CA 1.435 -1.183 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.349 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.48 ' HB ' HG23 ' A' ' 67' ' ' VAL . 30.6 pt -111.63 -26.17 3.23 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -178.54 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . 0.402 ' HB1' ' HB ' ' A' ' 148' ' ' ILE . . . -160.75 168.2 25.28 Favored 'General case' 0 N--CA 1.443 -0.796 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 -178.196 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 70.5 t -143.0 114.06 2.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.903 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 55.8 mt -116.67 147.89 41.53 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.184 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.469 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.5 mp -133.01 127.69 55.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.849 -0.532 . . . . 0.0 110.002 179.714 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . . . . . . . . . 2.3 pp -96.4 147.04 24.23 Favored 'General case' 0 CA--C 1.496 -1.119 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 177.419 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . 0.451 ' HD3' ' NE2' ' A' ' 59' ' ' GLN . 26.5 mmm-85 -96.49 118.39 32.89 Favored 'General case' 0 C--N 1.277 -2.576 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 172.858 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.693 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 7.1 tp-100 -96.02 122.03 38.41 Favored 'General case' 0 N--CA 1.421 -1.911 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 173.151 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 22.1 m -134.61 134.01 40.79 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 177.085 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 27.2 p30 -136.41 -174.27 3.65 Favored 'General case' 0 C--N 1.31 -1.11 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.819 -179.736 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 7.7 p30 -109.04 -0.78 19.32 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.226 -172.425 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 74.6 t80 -127.43 -72.02 0.65 Allowed 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 114.699 1.37 . . . . 0.0 114.699 -168.717 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . 0.592 ' HB3' ' OD1' ' A' ' 140' ' ' ASP . 0.1 OUTLIER -78.66 -7.63 57.86 Favored 'General case' 0 N--CA 1.43 -1.426 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -169.052 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 18.9 t 69.83 17.47 7.6 Favored 'General case' 0 C--O 1.24 0.605 0 C-N-CA 123.953 0.901 . . . . 0.0 110.691 174.484 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . 0.592 ' OD1' ' HB3' ' A' ' 138' ' ' ASN . 5.9 p-10 -79.04 56.41 1.98 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.943 0.878 . . . . 0.0 112.53 179.443 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . 0.693 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 14.3 t70 -77.74 84.96 4.06 Favored 'General case' 0 CA--C 1.499 -1.016 0 CA-C-N 114.407 -1.27 . . . . 0.0 107.806 173.163 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -126.26 157.09 39.21 Favored 'General case' 0 C--N 1.282 -2.352 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 178.997 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 12.6 pt20 -115.08 132.12 56.71 Favored 'General case' 0 N--CA 1.407 -2.624 0 C-N-CA 119.037 -1.065 . . . . 0.0 110.248 -177.86 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 1.606 ' HD1' ' CD2' ' A' ' 144' ' ' PHE . 11.1 m-30 -100.77 129.35 46.64 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.206 -0.906 . . . . 0.0 108.785 -175.087 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 47.1 t -93.3 130.83 41.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 123.764 0.665 . . . . 0.0 109.973 -178.016 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 63.9 m95 -118.21 97.92 6.03 Favored 'General case' 0 C--N 1.275 -2.636 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 -178.853 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 47.2 m-80 -80.18 112.3 17.37 Favored 'General case' 0 C--N 1.285 -2.223 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 178.249 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . 0.402 ' HB ' ' HB1' ' A' ' 127' ' ' ALA . 24.0 mm -86.03 122.06 38.12 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.819 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 -177.96 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -116.63 153.31 32.52 Favored 'General case' 0 C--N 1.286 -2.156 0 C-N-CA 124.052 0.941 . . . . 0.0 108.685 177.716 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.37 133.72 35.23 Favored 'General case' 0 N--CA 1.407 -2.585 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 176.066 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -92.94 -8.92 41.8 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -177.457 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -150.04 143.93 25.46 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 113.937 -1.483 . . . . 0.0 110.008 -176.653 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -84.65 136.16 33.87 Favored 'General case' 0 C--N 1.312 -1.033 0 O-C-N 123.966 0.791 . . . . 0.0 110.419 179.43 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.507 ' HB ' ' HB ' ' A' ' 120' ' ' ILE . 69.6 t -118.59 140.05 43.64 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.978 -173.642 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -119.78 138.34 50.71 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.136 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 178.476 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.436 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 71.6 t -99.93 101.13 13.02 Favored Pre-proline 0 C--N 1.293 -1.889 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 176.688 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.456 ' HG3' HG12 ' A' ' 27' ' ' VAL . 21.4 Cg_endo -67.47 -29.72 37.07 Favored 'Trans proline' 0 CA--C 1.504 -1.002 0 C-N-CA 122.215 1.943 . . . . 0.0 111.511 179.075 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 6.1 t . . . . . 0 C--O 1.267 1.974 0 O-C-N 125.002 1.439 . . . . 0.0 112.534 179.387 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 1.668 ' HD1' ' CD2' ' A' ' 1' ' ' PHE . 0.0 OUTLIER . . . . . 0 CA--C 1.496 -1.122 0 CA-C-O 120.84 0.352 . . . . 0.0 110.964 . . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.427 ' HB1' ' NE2' ' A' ' 45' ' ' HIS . . . -142.97 -178.87 6.04 Favored 'General case' 0 C--N 1.284 -2.275 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.052 178.487 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 12.4 t -148.76 156.76 42.8 Favored 'General case' 0 N--CA 1.426 -1.642 0 C-N-CA 119.395 -0.922 . . . . 0.0 109.711 -175.25 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.462 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -143.64 161.71 37.82 Favored 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.408 -175.102 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.643 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 54.9 p -97.64 -179.96 4.63 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-O 121.015 0.436 . . . . 0.0 110.71 179.679 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.44 -22.56 38.09 Favored 'General case' 0 C--N 1.298 -1.642 0 CA-C-O 121.551 0.691 . . . . 0.0 109.206 177.848 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.643 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 0.9 OUTLIER -85.74 -28.89 24.31 Favored 'General case' 0 N--CA 1.433 -1.297 0 CA-C-N 114.821 -1.082 . . . . 0.0 112.518 -175.784 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 130.43 22.79 1.05 Allowed Glycine 0 CA--C 1.49 -1.488 0 C-N-CA 118.868 -1.634 . . . . 0.0 113.974 171.588 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -103.04 99.42 9.3 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.363 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -94.25 114.15 26.19 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 115.879 -0.601 . . . . 0.0 109.399 176.825 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.421 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 68.5 mt -84.55 126.91 67.7 Favored Pre-proline 0 C--N 1.3 -1.582 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -179.171 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_endo -80.2 164.53 21.94 Favored 'Trans proline' 0 C--O 1.246 0.921 0 C-N-CA 122.614 2.209 . . . . 0.0 111.369 178.405 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.5 mt -65.91 126.31 24.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.984 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.57 10.02 1.49 Allowed Glycine 0 C--N 1.307 -1.028 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.613 -179.577 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.03 161.31 36.82 Favored Glycine 0 C--N 1.319 -0.392 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -177.924 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 161.61 -172.97 37.92 Favored Glycine 0 CA--C 1.495 -1.169 0 C-N-CA 119.938 -1.125 . . . . 0.0 111.331 178.448 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.413 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 65.2 p -144.51 144.03 31.14 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.306 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -130.98 162.16 30.36 Favored 'General case' 0 N--CA 1.415 -2.192 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.286 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -111.96 116.11 30.06 Favored 'General case' 0 C--N 1.271 -2.838 0 N-CA-C 107.043 -1.465 . . . . 0.0 107.043 174.773 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.424 HG23 ' HA ' ' A' ' 148' ' ' ILE . 1.2 m -99.63 139.03 22.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.683 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 179.22 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 1.623 ' HE1' ' CE2' ' A' ' 21' ' ' TYR . 23.7 m-85 -117.72 115.98 26.12 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-O 120.879 0.371 . . . . 0.0 111.994 -179.715 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 19.3 t -115.68 129.34 72.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.805 -173.819 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -89.27 119.75 30.03 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 177.778 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 28.1 mt -110.74 152.24 26.81 Favored 'General case' 0 C--N 1.282 -2.333 0 CA-C-N 115.051 -0.977 . . . . 0.0 108.984 -176.939 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -52.73 119.32 15.48 Favored Pre-proline 0 C--O 1.204 -1.296 0 O-C-N 124.513 1.133 . . . . 0.0 110.326 179.319 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.506 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 60.9 Cg_endo -73.83 -0.53 9.56 Favored 'Trans proline' 0 CA--C 1.544 0.993 0 C-N-CA 122.502 2.135 . . . . 0.0 113.616 -175.584 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 98.4 t -131.06 109.61 16.75 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 178.161 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.44 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 14.0 t -146.12 108.38 0.8 Allowed 'Isoleucine or valine' 0 C--O 1.193 -1.909 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 -177.248 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.531 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -95.87 154.22 17.34 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 123.864 0.865 . . . . 0.0 111.031 -179.84 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.538 HG23 ' O ' ' A' ' 112' ' ' VAL . 99.1 t -47.18 117.55 0.42 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.328 0 C-N-CA 123.436 0.694 . . . . 0.0 111.197 176.482 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.92 0.38 45.27 Favored Glycine 0 C--N 1.312 -0.803 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.924 -179.634 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.531 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -74.9 -176.7 3.0 Favored 'General case' 0 C--N 1.316 -0.884 0 C-N-CA 123.751 0.821 . . . . 0.0 110.329 175.876 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -127.09 89.75 3.03 Favored 'General case' 0 CA--C 1.491 -1.32 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 177.721 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.557 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 20.0 tp -98.34 133.68 42.4 Favored 'General case' 0 C--N 1.295 -1.8 0 C-N-CA 118.898 -1.121 . . . . 0.0 109.256 177.158 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 2.1 p -141.56 130.75 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.382 -3.854 0 CA-C-N 114.797 -1.092 . . . . 0.0 112.075 -178.028 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.608 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 47.8 t -87.61 89.56 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.576 0 CA-C-N 113.832 -1.531 . . . . 0.0 107.266 178.801 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.415 ' O ' ' HG2' ' A' ' 41' ' ' GLN . 18.2 t70 -77.26 102.83 6.87 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-O 120.708 0.289 . . . . 0.0 110.683 -179.173 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.3 mt -85.08 -3.65 58.87 Favored 'General case' 0 C--N 1.311 -1.094 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.306 -178.512 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 35.2 t -73.27 0.1 12.91 Favored 'General case' 0 CA--C 1.542 0.636 0 CA-C-O 121.478 0.656 . . . . 0.0 110.135 -179.624 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.3 p -130.2 5.23 4.85 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.206 176.468 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.415 ' HG2' ' O ' ' A' ' 37' ' ' ASP . 48.6 mm-40 -120.45 -20.75 7.08 Favored 'General case' 0 C--O 1.239 0.511 0 CA-C-O 121.03 0.443 . . . . 0.0 110.299 -174.177 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 37.4 mt -138.75 138.7 41.92 Favored 'Isoleucine or valine' 0 C--O 1.243 0.714 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 -177.103 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.634 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 48.7 m-85 -142.47 127.44 18.37 Favored 'General case' 0 N--CA 1.476 0.862 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -176.836 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.469 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 75.8 m -109.17 138.69 45.14 Favored 'General case' 0 C--N 1.295 -1.776 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -178.648 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . 0.427 ' NE2' ' HB1' ' A' ' 2' ' ' ALA . 10.9 p-80 -121.07 154.34 36.24 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-O 122.335 1.064 . . . . 0.0 112.085 -176.47 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.42 HD21 ' CG ' ' A' ' 54' ' ' ASP . 3.0 m120 -96.9 114.81 26.46 Favored 'General case' 0 C--N 1.28 -2.434 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -179.423 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -77.09 -32.51 56.71 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.301 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 38.4 m-85 -138.68 83.03 20.38 Favored Pre-proline 0 C--N 1.315 -0.934 0 CA-C-N 114.331 -1.304 . . . . 0.0 108.921 -176.955 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.95 3.68 5.88 Favored 'Trans proline' 0 CA--C 1.541 0.831 0 C-N-CA 122.59 2.194 . . . . 0.0 113.685 -176.06 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -117.64 -22.35 8.11 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 121.268 0.556 . . . . 0.0 110.434 178.275 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.438 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.7 OUTLIER -98.49 -28.72 13.48 Favored 'General case' 0 N--CA 1.424 -1.741 0 CA-C-O 122.074 0.94 . . . . 0.0 109.244 -172.035 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.468 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -122.67 135.79 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.087 0 CA-C-N 114.306 -1.316 . . . . 0.0 109.648 -178.346 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 3.3 t -86.42 124.29 32.59 Favored 'General case' 0 N--CA 1.417 -2.114 0 N-CA-C 103.022 -2.955 . . . . 0.0 103.022 169.22 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.629 ' OD1' ' HB3' ' A' ' 1' ' ' PHE . 16.1 m-20 -91.47 107.88 19.51 Favored 'General case' 0 C--N 1.271 -2.811 0 C-N-CA 118.815 -1.154 . . . . 0.0 109.433 -169.005 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 22.0 t80 -117.89 139.56 50.95 Favored 'General case' 0 C--N 1.273 -2.746 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.588 -175.74 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.435 HG21 ' HG ' ' A' ' 131' ' ' LEU . 12.9 p -145.59 145.39 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.794 0 O-C-N 123.626 0.579 . . . . 0.0 109.815 -179.577 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -149.4 125.11 10.44 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.085 174.584 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.479 HD13 ' O ' ' A' ' 130' ' ' ILE . 41.9 tp -61.82 110.35 1.51 Allowed 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 169.975 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.6 tp-100 -60.18 -56.95 15.34 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 126.63 1.972 . . . . 0.0 109.861 -179.074 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 10.8 ptp180 -164.14 160.16 21.11 Favored 'General case' 0 N--CA 1.426 -1.634 0 CA-C-N 114.505 -1.225 . . . . 0.0 108.874 -175.274 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -141.38 139.96 9.9 Favored Glycine 0 N--CA 1.411 -2.998 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -178.756 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 73.2 m -126.06 150.63 48.0 Favored 'General case' 0 C--N 1.289 -2.025 0 C-N-CA 124.139 0.976 . . . . 0.0 110.266 -176.807 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.464 ' HB3' ' CE2' ' A' ' 84' ' ' PHE . . . -114.2 157.69 22.34 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.202 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.485 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 87.0 m-85 -155.13 -178.88 7.56 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 124.12 0.968 . . . . 0.0 109.244 -178.609 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 60.25 -138.65 48.54 Favored Glycine 0 C--O 1.228 -0.279 0 O-C-N 123.537 0.523 . . . . 0.0 113.236 176.886 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.44 -8.79 85.76 Favored Glycine 0 N--CA 1.432 -1.631 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.355 177.037 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.485 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 84.0 t -69.13 -41.25 81.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 C-N-CA 123.52 0.728 . . . . 0.0 111.572 -176.709 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.444 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -83.21 -21.01 33.55 Favored 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.73 -0.788 . . . . 0.0 112.359 179.692 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 18.4 m -101.71 -50.69 3.63 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 115.25 1.574 . . . . 0.0 115.25 -174.802 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.485 ' O ' HG23 ' A' ' 112' ' ' VAL . 47.7 m-20 -93.73 -23.45 18.2 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -175.628 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 0.522 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 88.2 m-85 -108.1 159.24 16.73 Favored 'General case' 0 N--CA 1.423 -1.802 0 C-N-CA 120.02 -0.672 . . . . 0.0 109.324 176.979 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.6 t -167.5 125.11 1.21 Allowed 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 175.617 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.482 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -159.51 -110.28 0.27 Allowed Glycine 0 N--CA 1.407 -3.284 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 176.648 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.3 p -156.96 179.97 8.78 Favored 'General case' 0 C--N 1.296 -1.744 0 C-N-CA 123.531 0.733 . . . . 0.0 110.965 -173.101 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.42 HG11 ' CE2' ' A' ' 82' ' ' TYR . 2.6 p -133.69 144.37 36.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.919 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.68 ' HG3' ' O ' ' A' ' 80' ' ' SER . 86.0 tttt -123.42 150.19 44.09 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.318 -178.699 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.416 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 60.8 t80 -148.94 109.42 4.19 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 -178.812 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.6 t 51.48 41.01 28.07 Favored 'General case' 0 CA--C 1.554 1.105 0 C-N-CA 124.32 1.048 . . . . 0.0 111.396 178.037 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.83 6.73 67.08 Favored Glycine 0 CA--C 1.526 0.756 0 CA-C-N 115.615 -0.721 . . . . 0.0 113.987 179.82 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.68 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 22.8 t -79.57 179.98 7.18 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 178.43 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 3.6 p -157.99 107.15 2.06 Favored 'General case' 0 C--N 1.292 -1.896 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 -179.489 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 1.623 ' HD1' ' CD2' ' A' ' 82' ' ' TYR . 2.5 p90 -151.49 158.44 34.32 Favored Pre-proline 0 C--N 1.308 -1.228 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 -174.418 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.25 148.54 68.58 Favored 'Trans proline' 0 C--N 1.358 1.033 0 C-N-CA 122.819 2.346 . . . . 0.0 112.977 -176.385 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.582 ' CD2' HD22 ' A' ' 109' ' ' LEU . 63.0 t80 -121.92 133.4 24.29 Favored Pre-proline 0 N--CA 1.438 -1.058 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.773 179.98 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.505 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 74.1 Cg_endo -71.15 146.63 85.49 Favored 'Cis proline' 0 CA--C 1.548 1.223 0 C-N-CA 123.079 -1.634 . . . . 0.0 110.56 -1.856 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.1 t -64.13 -176.74 0.22 Allowed 'General case' 0 CA--C 1.558 1.262 0 C-N-CA 123.547 0.739 . . . . 0.0 112.279 -174.015 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 19.9 p -129.54 -27.6 2.37 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 113.161 0.8 . . . . 0.0 113.161 -172.449 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 t -127.62 -73.46 0.6 Allowed 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 119.736 -0.786 . . . . 0.0 110.684 -178.45 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -177.78 -174.57 0.46 Allowed 'General case' 0 C--O 1.243 0.726 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 -176.684 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.446 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 12.4 p -102.07 163.28 18.05 Favored Pre-proline 0 C--N 1.299 -1.592 0 O-C-N 123.432 0.458 . . . . 0.0 112.196 178.083 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -64.55 157.48 54.98 Favored 'Trans proline' 0 C--N 1.36 1.176 0 C-N-CA 122.669 2.246 . . . . 0.0 111.576 174.996 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.4 tmm_? -68.79 110.81 4.51 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 114.898 -1.046 . . . . 0.0 110.209 -175.757 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 71.0 t -122.35 132.83 70.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.826 -178.093 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 95.6 t -117.24 136.25 55.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 115.3 -0.863 . . . . 0.0 109.494 178.97 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . 0.484 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 4.1 m-85 -82.99 94.97 7.88 Favored 'General case' 0 CA--C 1.499 -0.985 0 CA-C-O 121.41 0.624 . . . . 0.0 110.348 177.516 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 17.6 m120 -89.26 61.13 5.59 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 178.754 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.6 m -143.67 -179.3 6.36 Favored 'General case' 0 N--CA 1.423 -1.798 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 -176.959 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 4.5 ptm180 -146.08 50.7 1.16 Allowed 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 121.425 0.631 . . . . 0.0 109.979 179.998 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.0 t -169.87 177.41 4.4 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -175.201 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -71.77 98.02 1.89 Allowed 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 106.608 -1.627 . . . . 0.0 106.608 173.07 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 11.5 tptt -103.14 139.33 20.01 Favored Pre-proline 0 N--CA 1.407 -2.602 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 -177.678 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_endo -58.9 147.26 90.23 Favored 'Trans proline' 0 CA--C 1.511 -0.632 0 C-N-CA 122.605 2.203 . . . . 0.0 112.631 -176.993 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . 0.484 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.1 t90 -90.48 105.93 13.41 Favored Pre-proline 0 C--N 1.302 -1.472 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 178.6 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -77.83 87.94 1.47 Allowed 'Trans proline' 0 N--CA 1.443 -1.456 0 C-N-CA 121.616 1.544 . . . . 0.0 112.21 -173.094 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 86.7 t -139.01 147.03 25.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 N-CA-C 106.879 -1.526 . . . . 0.0 106.879 177.851 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.608 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -153.14 134.26 14.1 Favored 'General case' 0 C--N 1.284 -2.265 0 CA-C-O 120.811 0.338 . . . . 0.0 110.381 178.522 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.441 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 18.7 mt -101.6 99.86 10.2 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 179.151 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.482 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 74.2 m-85 -79.59 77.43 6.19 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 177.746 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.582 HD22 ' CD2' ' A' ' 84' ' ' PHE . 3.2 mm? -102.54 118.72 37.47 Favored 'General case' 0 CA--C 1.488 -1.414 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 176.365 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -122.18 146.91 47.97 Favored Pre-proline 0 N--CA 1.402 -2.867 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -174.964 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -63.4 123.14 11.61 Favored 'Trans proline' 0 CA--C 1.491 -1.625 0 C-N-CA 123.245 2.63 . . . . 0.0 113.379 -175.469 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.538 ' O ' HG23 ' A' ' 30' ' ' VAL . 24.3 m -83.22 -159.25 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.385 -3.689 0 CA-C-N 114.181 -1.372 . . . . 0.0 108.871 171.15 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.8 m -79.21 -29.56 42.86 Favored 'General case' 0 C--N 1.252 -3.631 0 CA-C-O 121.464 0.65 . . . . 0.0 110.296 -170.352 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 11.3 t -82.52 25.5 0.63 Allowed 'General case' 0 N--CA 1.428 -1.53 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.188 -179.77 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -109.17 136.75 48.15 Favored 'General case' 0 N--CA 1.422 -1.842 0 O-C-N 121.828 -0.545 . . . . 0.0 109.818 178.847 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -174.91 134.49 2.77 Favored Glycine 0 N--CA 1.432 -1.6 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 178.332 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 60.49 -149.3 43.29 Favored Glycine 0 CA--C 1.494 -1.221 0 CA-C-O 119.32 -0.711 . . . . 0.0 112.151 -177.637 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 94.0 t -57.95 105.11 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-O 121.923 0.868 . . . . 0.0 111.261 -177.884 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.37 -22.22 13.37 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 114.51 -1.223 . . . . 0.0 110.62 -178.772 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.444 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 67.9 mt -136.83 138.13 46.44 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 179.474 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.43 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.6 mmpt? -116.6 143.01 46.14 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.066 0.46 . . . . 0.0 109.79 174.744 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.5 131.05 42.74 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.891 -179.17 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.63 -6.07 64.87 Favored Glycine 0 N--CA 1.44 -1.083 0 C-N-CA 121.231 -0.509 . . . . 0.0 112.157 -179.316 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 27.2 m -94.9 147.53 23.27 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-O 120.778 0.323 . . . . 0.0 110.747 -179.302 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -74.25 124.04 25.66 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.271 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.475 ' HB ' HG23 ' A' ' 67' ' ' VAL . 31.2 pt -111.27 -26.28 3.2 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -178.555 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.83 168.52 22.93 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 -177.679 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 73.7 t -143.4 114.44 2.54 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.487 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 62.9 mt -116.01 142.5 46.72 Favored 'General case' 0 C--N 1.291 -1.968 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 178.631 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.479 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.9 mp -121.08 126.54 75.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 C-N-CA 119.272 -0.971 . . . . 0.0 110.77 177.477 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.538 HD22 ' OE1' ' A' ' 133' ' ' GLN . 0.2 OUTLIER -98.05 131.41 44.49 Favored 'General case' 0 C--N 1.271 -2.813 0 C-N-CA 124.68 1.192 . . . . 0.0 109.182 179.422 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . 0.525 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 12.6 tpt180 -104.9 124.53 49.64 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -179.86 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.571 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 12.6 mm100 -105.84 118.54 36.87 Favored 'General case' 0 C--N 1.319 -0.72 0 O-C-N 123.592 0.557 . . . . 0.0 110.345 179.242 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 5.1 m -136.6 149.7 48.18 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 106.377 -1.712 . . . . 0.0 106.377 177.462 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.468 ' CB ' HG21 ' A' ' 52' ' ' ILE . 12.6 p30 -144.86 178.82 7.74 Favored 'General case' 0 C--N 1.324 -0.529 0 C-N-CA 119.458 -0.897 . . . . 0.0 112.249 175.555 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 8.9 p30 -80.15 -24.53 40.36 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-O 121.253 0.549 . . . . 0.0 112.231 -175.135 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 85.3 t80 -97.09 -65.35 0.97 Allowed 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 123.589 0.756 . . . . 0.0 111.026 -170.357 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 17.5 m120 -74.52 150.18 39.92 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 123.202 0.601 . . . . 0.0 110.773 179.061 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 21.4 t -97.05 7.87 45.71 Favored 'General case' 0 C--N 1.309 -1.192 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 172.524 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -72.06 63.26 0.49 Allowed 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 125.872 1.669 . . . . 0.0 110.844 179.661 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -86.55 89.62 7.97 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 115.229 -0.896 . . . . 0.0 109.644 179.495 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . 1.642 ' HE1' ' CE2' ' A' ' 142' ' ' PHE . 72.1 m-85 -119.34 167.45 11.89 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.314 -178.354 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . 0.525 ' HB3' ' HD2' ' A' ' 132' ' ' ARG . 14.0 pt20 -129.34 145.92 51.3 Favored 'General case' 0 N--CA 1.417 -2.089 0 C-N-CA 119.812 -0.755 . . . . 0.0 111.336 177.851 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.402 ' HB2' HD23 ' A' ' 131' ' ' LEU . 11.0 m-30 -109.5 130.44 55.5 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 -178.007 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . 0.413 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 61.9 t -90.36 131.77 36.69 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.053 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 179.86 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . 0.441 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 69.2 m95 -119.9 97.96 5.87 Favored 'General case' 0 C--N 1.275 -2.636 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 -179.273 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 49.2 m-80 -80.01 114.7 19.11 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 178.634 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . 0.424 ' HA ' HG23 ' A' ' 20' ' ' VAL . 23.6 mm -88.21 122.06 39.31 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 -177.718 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 1.6 ' HD1' ' CD2' ' A' ' 149' ' ' TYR . 76.9 m-85 -118.19 156.1 29.33 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 123.241 0.616 . . . . 0.0 109.697 178.506 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -84.1 131.61 34.77 Favored 'General case' 0 N--CA 1.414 -2.258 0 CA-C-N 115.238 -0.892 . . . . 0.0 108.682 177.33 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -95.75 -12.12 25.9 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 -176.812 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -155.08 146.49 22.99 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 113.84 -1.527 . . . . 0.0 108.326 -178.089 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 17.8 p-10 -86.05 148.15 25.86 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 124.152 0.981 . . . . 0.0 111.564 -177.181 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.506 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 77.7 t -123.57 136.04 61.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-N 115.459 -0.792 . . . . 0.0 111.194 -174.542 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.5 t -118.29 135.1 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.767 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.44 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.1 t -99.37 103.77 22.73 Favored Pre-proline 0 C--N 1.291 -1.975 0 C-N-CA 123.867 0.867 . . . . 0.0 109.871 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.451 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 50.1 Cg_endo -72.77 -17.11 26.11 Favored 'Trans proline' 0 C--N 1.333 -0.289 0 C-N-CA 122.034 1.822 . . . . 0.0 111.424 178.021 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.273 4.0 t . . . . . 0 C--O 1.239 0.543 0 C-N-CA 125.414 1.486 . . . . 0.0 113.568 177.75 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 0.553 ' CZ ' ' HB3' ' A' ' 133' ' ' GLN . 0.3 OUTLIER . . . . . 0 CA--C 1.5 -0.976 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 . . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.455 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . -147.51 -175.32 4.81 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 -175.289 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.454 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 14.7 t -148.78 157.01 43.13 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.394 -0.922 . . . . 0.0 109.958 -177.006 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.463 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.91 156.28 43.9 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 121.868 0.842 . . . . 0.0 111.434 -174.789 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 36.3 p -94.97 171.47 8.74 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.749 178.402 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -80.7 -10.93 59.7 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 114.661 -1.154 . . . . 0.0 110.332 -179.127 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -93.06 -33.22 14.18 Favored 'General case' 0 N--CA 1.431 -1.384 0 CA-C-N 114.96 -1.018 . . . . 0.0 111.796 -177.556 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 142.88 -1.59 1.53 Allowed Glycine 0 CA--C 1.507 -0.448 0 C-N-CA 119.158 -1.496 . . . . 0.0 114.462 171.461 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.4 m -86.35 104.99 16.38 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 122.202 -0.587 . . . . 0.0 110.93 -178.441 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -96.31 118.66 33.31 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 173.773 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.455 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 66.2 mt -89.84 122.58 67.8 Favored Pre-proline 0 C--N 1.297 -1.694 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 -179.649 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -77.24 171.91 16.95 Favored 'Trans proline' 0 C--O 1.239 0.563 0 C-N-CA 122.939 2.426 . . . . 0.0 111.582 179.6 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.7 mt -72.85 120.1 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.807 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 179.155 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 140.98 23.36 0.25 Allowed Glycine 0 C--N 1.301 -1.415 0 CA-C-N 115.393 -0.822 . . . . 0.0 112.027 -179.668 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 73.79 167.41 14.75 Favored Glycine 0 C--N 1.335 0.494 0 C-N-CA 121.156 -0.545 . . . . 0.0 112.309 -177.28 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 153.97 -172.01 32.64 Favored Glycine 0 CA--C 1.483 -1.966 0 C-N-CA 120.087 -1.054 . . . . 0.0 110.925 176.229 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.411 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 78.3 p -141.43 156.27 45.8 Favored 'General case' 0 N--CA 1.42 -1.953 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 178.918 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -137.23 160.22 39.66 Favored 'General case' 0 N--CA 1.422 -1.864 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 177.536 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 18.9 m-80 -114.15 109.89 19.12 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 105.143 -2.169 . . . . 0.0 105.143 175.713 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.449 HG23 ' HA ' ' A' ' 148' ' ' ILE . 0.8 OUTLIER -91.84 143.2 11.8 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.328 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 -178.132 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 63.2 m-85 -119.52 116.07 25.32 Favored 'General case' 0 C--N 1.297 -1.711 0 C-N-CA 120.803 -0.359 . . . . 0.0 111.557 -179.249 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 22.0 t -119.58 132.75 68.49 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.041 -174.888 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 -88.6 123.09 32.75 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 176.881 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -104.14 160.44 14.86 Favored 'General case' 0 C--N 1.287 -2.143 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.502 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -59.33 123.71 71.48 Favored Pre-proline 0 C--N 1.316 -0.886 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.382 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 88.0 Cg_endo -78.53 1.58 8.91 Favored 'Trans proline' 0 C--N 1.33 -0.427 0 C-N-CA 122.78 2.32 . . . . 0.0 113.159 -175.264 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 98.7 t -129.53 109.77 18.83 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 177.311 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.449 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.0 t -143.03 103.53 0.92 Allowed 'Isoleucine or valine' 0 C--O 1.18 -2.585 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -176.347 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.723 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -95.16 155.27 16.8 Favored 'General case' 0 C--N 1.272 -2.783 0 C-N-CA 122.364 0.266 . . . . 0.0 111.01 -179.838 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.608 HG23 ' O ' ' A' ' 112' ' ' VAL . 87.5 t -46.94 118.71 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 C-N-CA 123.06 0.544 . . . . 0.0 111.064 175.387 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.98 9.61 57.05 Favored Glycine 0 C--N 1.31 -0.887 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.939 179.467 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.723 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -80.77 -177.72 6.46 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 175.413 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -130.88 87.65 2.51 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 178.859 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.654 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 27.1 tp -88.1 144.56 26.42 Favored 'General case' 0 C--N 1.292 -1.906 0 C-N-CA 119.589 -0.844 . . . . 0.0 109.685 -178.803 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.7 t -137.7 130.33 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.882 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 -177.597 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.579 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 40.3 t -97.54 88.75 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.413 -2.304 0 N-CA-C 105.685 -1.968 . . . . 0.0 105.685 172.734 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -82.03 109.74 16.64 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -177.781 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.9 mt -92.47 -1.32 57.06 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-O 121.072 0.463 . . . . 0.0 111.284 -178.012 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.559 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 34.1 t -76.25 0.27 19.81 Favored 'General case' 0 C--N 1.31 -1.121 0 CA-C-O 121.652 0.739 . . . . 0.0 109.459 -178.713 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.6 p -129.81 5.51 5.04 Favored 'General case' 0 N--CA 1.412 -2.33 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.599 178.83 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 48.9 mm-40 -124.69 -21.13 4.88 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.854 -173.89 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 39.0 mt -134.8 138.73 48.81 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 -177.333 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.463 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 49.5 m-85 -142.32 128.63 19.95 Favored 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -176.065 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.454 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 85.0 m -107.57 145.9 32.61 Favored 'General case' 0 C--N 1.284 -2.251 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.032 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 12.1 p80 -131.62 128.35 38.95 Favored 'General case' 0 C--N 1.296 -1.728 0 CA-C-O 122.16 0.981 . . . . 0.0 111.744 -176.516 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 20.8 p-10 -97.11 89.66 4.87 Favored 'General case' 0 C--N 1.282 -2.335 0 CA-C-O 122.257 1.027 . . . . 0.0 108.693 178.572 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . 0.55 ' HB2' ' CD2' ' A' ' 48' ' ' TYR . 1.4 m-20 -51.74 -43.62 62.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.25 -175.676 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 0.55 ' CD2' ' HB2' ' A' ' 47' ' ' ASP . 29.2 m-85 -121.84 83.27 43.01 Favored Pre-proline 0 C--N 1.315 -0.913 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 -175.278 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -83.01 -5.51 11.32 Favored 'Trans proline' 0 C--O 1.234 0.29 0 C-N-CA 122.99 2.46 . . . . 0.0 112.786 -173.606 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -103.78 -23.35 13.42 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.023 -178.09 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.48 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.3 OUTLIER -100.33 -30.76 11.69 Favored 'General case' 0 N--CA 1.415 -2.222 0 CA-C-O 122.02 0.914 . . . . 0.0 108.867 -176.0 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.546 HG21 ' CB ' ' A' ' 135' ' ' ASN . 2.9 mp -128.96 134.9 63.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 CA-C-N 114.636 -1.166 . . . . 0.0 109.927 -176.584 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 5.9 t -86.51 139.05 31.24 Favored 'General case' 0 N--CA 1.438 -1.052 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 171.5 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.421 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 14.6 t70 -96.07 108.78 21.25 Favored 'General case' 0 C--N 1.275 -2.664 0 C-N-CA 119.673 -0.811 . . . . 0.0 109.147 -175.832 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 23.6 t80 -122.64 122.15 38.12 Favored 'General case' 0 C--N 1.288 -2.065 0 CA-C-O 121.799 0.809 . . . . 0.0 110.065 -177.702 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.445 HG13 ' OH ' ' A' ' 77' ' ' TYR . 85.3 t -125.95 138.52 54.29 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 CA-C-N 114.169 -1.378 . . . . 0.0 110.067 -176.084 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -144.46 135.3 24.97 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 172.602 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.533 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 38.9 tp -74.58 104.91 5.45 Favored 'General case' 0 N--CA 1.436 -1.132 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 175.429 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -52.96 -54.2 38.49 Favored 'General case' 0 C--O 1.201 -1.457 0 C-N-CA 126.278 1.831 . . . . 0.0 111.048 -179.55 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -165.52 156.35 13.74 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 -177.766 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.87 118.34 1.11 Allowed Glycine 0 N--CA 1.398 -3.846 0 N-CA-C 108.941 -1.663 . . . . 0.0 108.941 -178.099 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 52.8 m -114.52 146.56 40.58 Favored 'General case' 0 C--N 1.279 -2.472 0 C-N-CA 124.584 1.153 . . . . 0.0 110.029 -170.859 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.511 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -106.26 156.66 18.25 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 123.496 0.718 . . . . 0.0 109.112 -178.715 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.505 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 99.5 m-85 -154.48 -179.35 7.88 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 124.08 0.952 . . . . 0.0 109.742 -176.978 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.06 -136.44 51.18 Favored Glycine 0 N--CA 1.458 0.121 0 O-C-N 123.653 0.595 . . . . 0.0 112.669 178.012 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.79 -9.07 83.49 Favored Glycine 0 C--O 1.206 -1.635 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 177.477 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.505 ' HB ' ' O ' ' A' ' 64' ' ' TYR . 77.7 t -69.67 -36.42 70.36 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 C-N-CA 123.745 0.818 . . . . 0.0 111.852 -176.107 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.511 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -87.16 -20.25 27.28 Favored 'General case' 0 C--N 1.297 -1.684 0 C-N-CA 119.216 -0.993 . . . . 0.0 112.296 178.306 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 9.6 t -101.03 -52.79 3.2 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.472 0.653 . . . . 0.0 112.195 -173.757 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.464 ' O ' HG23 ' A' ' 112' ' ' VAL . 31.6 m-20 -91.78 -25.81 18.85 Favored 'General case' 0 CA--C 1.49 -1.353 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -173.69 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 1.627 ' HD2' ' CD1' ' A' ' 71' ' ' PHE . 86.1 m-85 -106.61 155.85 19.21 Favored 'General case' 0 N--CA 1.416 -2.152 0 C-N-CA 120.008 -0.677 . . . . 0.0 109.291 177.254 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.3 t -165.48 117.83 1.14 Allowed 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 176.992 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.515 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -153.56 -111.88 0.46 Allowed Glycine 0 N--CA 1.412 -2.924 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 176.714 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.9 p -154.51 -179.72 8.23 Favored 'General case' 0 C--N 1.297 -1.687 0 C-N-CA 123.561 0.744 . . . . 0.0 110.93 -173.66 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -133.95 144.02 36.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 C-N-CA 123.319 0.648 . . . . 0.0 109.874 177.762 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.607 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.0 tttt -121.68 142.82 49.78 Favored 'General case' 0 N--CA 1.432 -1.374 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.648 178.767 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 1.663 ' HE2' ' CE1' ' A' ' 77' ' ' TYR . 62.6 t80 -142.42 110.35 5.89 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.517 -179.055 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.9 t 49.77 38.9 16.66 Favored 'General case' 0 CA--C 1.557 1.231 0 C-N-CA 124.43 1.092 . . . . 0.0 111.735 176.017 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.28 18.3 50.05 Favored Glycine 0 CA--C 1.524 0.596 0 C-N-CA 120.922 -0.656 . . . . 0.0 113.624 -179.404 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.607 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 12.2 t -92.73 -179.84 5.27 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 174.597 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 56.3 p -157.87 105.53 1.99 Allowed 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 179.652 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 1.614 ' HD1' ' CD2' ' A' ' 82' ' ' TYR . 2.7 p90 -150.73 160.83 31.79 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 -173.791 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.409 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 45.0 Cg_endo -68.51 148.19 72.35 Favored 'Trans proline' 0 C--N 1.357 0.984 0 C-N-CA 122.935 2.423 . . . . 0.0 113.357 -177.788 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 1.668 ' HE1' ' CE2' ' A' ' 84' ' ' PHE . 60.5 t80 -123.61 134.15 25.08 Favored Pre-proline 0 N--CA 1.433 -1.289 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.484 -179.431 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.459 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 60.2 Cg_endo -70.54 148.76 89.19 Favored 'Cis proline' 0 CA--C 1.541 0.862 0 C-N-CA 122.77 -1.763 . . . . 0.0 110.469 -0.838 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.2 t -67.24 -177.22 0.65 Allowed 'General case' 0 CA--C 1.549 0.919 0 CA-C-O 121.266 0.555 . . . . 0.0 110.997 -176.86 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 18.5 p -130.39 -19.88 3.04 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 112.597 0.592 . . . . 0.0 112.597 -173.459 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 21.6 t -130.71 -89.36 0.47 Allowed 'General case' 0 C--O 1.204 -1.335 0 C-N-CA 120.429 -0.508 . . . . 0.0 110.309 -179.988 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -166.58 -173.01 2.33 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 177.888 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 61.8 p -100.32 163.48 18.17 Favored Pre-proline 0 C--N 1.304 -1.387 0 N-CA-C 112.795 0.665 . . . . 0.0 112.795 179.798 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_endo -56.65 165.27 4.83 Favored 'Trans proline' 0 C--O 1.248 0.99 0 C-N-CA 123.518 2.812 . . . . 0.0 111.43 172.711 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -74.47 122.17 22.62 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.479 -175.959 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 73.2 t -134.9 133.46 53.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 -178.348 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.418 HG21 ' O ' ' A' ' 54' ' ' ASP . 1.5 p -132.97 134.6 57.94 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.292 0 CA-C-N 115.971 -0.558 . . . . 0.0 109.596 -178.55 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . 1.646 ' HE2' ' CE1' ' A' ' 95' ' ' TYR . 2.6 m-85 -83.07 117.91 23.18 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 179.182 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -102.07 27.56 6.52 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.756 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.9 m -99.23 -171.56 2.1 Favored 'General case' 0 N--CA 1.426 -1.628 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.291 -178.328 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -151.15 43.58 0.79 Allowed 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.465 0.65 . . . . 0.0 110.39 175.769 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.3 t -168.18 -178.63 3.73 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -176.735 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -67.18 106.78 2.11 Favored 'General case' 0 CA--C 1.511 -0.542 0 C-N-CA 123.344 0.658 . . . . 0.0 109.39 179.607 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -112.6 135.1 21.52 Favored Pre-proline 0 C--N 1.293 -1.866 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 176.342 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . 0.559 ' HB3' ' O ' ' A' ' 39' ' ' SER . 51.4 Cg_exo -53.69 139.61 67.41 Favored 'Trans proline' 0 CA--C 1.503 -1.067 0 C-N-CA 123.865 3.043 . . . . 0.0 112.295 177.357 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 15.5 t90 -85.0 106.85 9.74 Favored Pre-proline 0 C--N 1.298 -1.655 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 179.161 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . 0.402 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 60.2 Cg_endo -77.0 88.22 1.42 Allowed 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 121.368 1.379 . . . . 0.0 113.096 -172.952 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 92.6 t -140.62 146.88 23.6 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.103 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 178.127 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.579 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.38 135.05 17.43 Favored 'General case' 0 C--N 1.294 -1.817 0 CA-C-O 120.757 0.313 . . . . 0.0 110.431 177.34 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . 0.427 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 20.1 mt -100.97 105.18 16.38 Favored 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 178.083 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.515 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 43.9 m-85 -83.63 72.58 10.31 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 120.67 0.272 . . . . 0.0 110.716 178.095 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.654 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -98.66 129.17 45.14 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 176.342 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.42 146.89 63.43 Favored Pre-proline 0 N--CA 1.41 -2.426 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 -175.9 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.432 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 40.4 Cg_endo -65.37 126.07 15.61 Favored 'Trans proline' 0 CA--C 1.496 -1.416 0 C-N-CA 123.133 2.555 . . . . 0.0 113.002 -175.181 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.608 ' O ' HG23 ' A' ' 30' ' ' VAL . 16.7 m -84.3 -154.78 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.401 -2.889 0 CA-C-N 114.518 -1.219 . . . . 0.0 108.044 171.667 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 18.5 m -82.76 -30.32 29.05 Favored 'General case' 0 C--N 1.255 -3.508 0 CA-C-O 121.497 0.665 . . . . 0.0 110.025 -170.609 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 18.1 t -84.73 30.81 0.55 Allowed 'General case' 0 N--CA 1.435 -1.201 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.156 -179.821 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -112.23 138.12 49.37 Favored 'General case' 0 N--CA 1.422 -1.831 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.874 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -179.22 128.01 1.2 Allowed Glycine 0 N--CA 1.437 -1.239 0 C-N-CA 120.367 -0.92 . . . . 0.0 112.425 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 68.32 -149.05 49.54 Favored Glycine 0 CA--C 1.486 -1.728 0 CA-C-O 119.125 -0.819 . . . . 0.0 111.928 -177.436 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 57.4 t -59.85 103.4 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 CA-C-N 117.308 0.554 . . . . 0.0 110.088 -177.126 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -103.78 -29.16 11.2 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.953 -178.223 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . . . . . . . . . 73.6 mt -126.69 137.48 57.7 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.849 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 176.947 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.405 ' HA ' ' HE2' ' A' ' 121' ' ' LYS . 3.9 mmpt? -114.06 141.87 46.9 Favored 'General case' 0 C--N 1.31 -1.131 0 C-N-CA 122.959 0.504 . . . . 0.0 110.121 177.048 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -73.03 135.71 44.94 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.286 179.677 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 84.49 11.31 77.98 Favored Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 111.59 -0.604 . . . . 0.0 111.59 -179.016 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 27.3 t -113.98 147.76 38.06 Favored 'General case' 0 N--CA 1.433 -1.324 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 -179.332 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 23.1 tp -73.52 134.99 43.96 Favored 'General case' 0 CA--C 1.506 -0.747 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.795 -179.801 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.467 ' HB ' HG23 ' A' ' 67' ' ' VAL . 35.8 pt -120.12 -25.0 2.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.717 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 179.215 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -163.35 166.0 23.43 Favored 'General case' 0 C--O 1.21 -1.017 0 N-CA-C 110.312 -0.255 . . . . 0.0 110.312 -178.022 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 67.1 t -139.48 113.18 6.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.3 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 48.1 mt -118.48 143.29 46.81 Favored 'General case' 0 C--N 1.29 -1.995 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 179.751 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.583 HG22 ' NE2' ' A' ' 143' ' ' GLN . 5.3 mp -124.23 128.52 73.92 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 C-N-CA 119.7 -0.8 . . . . 0.0 110.67 178.419 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.565 ' O ' HD21 ' A' ' 131' ' ' LEU . 0.0 OUTLIER -96.11 135.15 38.28 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 175.433 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . 0.479 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 8.8 tpt180 -97.92 122.26 40.83 Favored 'General case' 0 C--N 1.285 -2.223 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.573 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . 0.553 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 0.0 OUTLIER -105.82 104.7 14.47 Favored 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 123.406 0.682 . . . . 0.0 109.268 -177.587 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 6.9 m -127.34 142.14 51.52 Favored 'General case' 0 C--N 1.284 -2.255 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 179.197 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.546 ' CB ' HG21 ' A' ' 52' ' ' ILE . 9.1 p30 -132.01 170.87 14.33 Favored 'General case' 0 C--N 1.309 -1.166 0 C-N-CA 119.988 -0.685 . . . . 0.0 110.446 176.498 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 4.7 p30 -85.98 -10.86 54.39 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 114.676 -1.147 . . . . 0.0 112.474 -170.668 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 60.1 t80 -109.39 -62.16 1.53 Allowed 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 112.316 0.488 . . . . 0.0 112.316 -171.957 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 16.9 m120 -80.22 148.5 30.8 Favored 'General case' 0 CA--C 1.49 -1.328 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.774 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 20.2 p -88.24 10.14 20.62 Favored 'General case' 0 C--N 1.298 -1.63 0 CA-C-O 121.79 0.805 . . . . 0.0 109.88 176.964 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -78.68 94.5 5.08 Favored 'General case' 0 CA--C 1.505 -0.764 0 CA-C-N 114.466 -1.243 . . . . 0.0 109.147 177.8 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -112.83 106.7 15.08 Favored 'General case' 0 C--N 1.292 -1.895 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.958 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -128.14 173.51 10.03 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 120.992 0.425 . . . . 0.0 109.935 -176.741 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . 0.583 ' NE2' HG22 ' A' ' 130' ' ' ILE . 17.3 pt20 -134.79 143.93 47.36 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 175.514 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 1.657 ' HE2' ' CE1' ' A' ' 144' ' ' PHE . 9.4 m-30 -109.65 130.38 55.52 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 -179.175 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . 0.411 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 52.2 t -90.81 132.27 35.82 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 O-C-N 123.592 0.557 . . . . 0.0 109.799 -178.617 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . 0.408 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 61.9 m95 -117.47 96.18 5.29 Favored 'General case' 0 C--N 1.279 -2.48 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 -179.304 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.9 m-80 -79.45 112.63 16.89 Favored 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 177.989 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . 0.449 ' HA ' HG23 ' A' ' 20' ' ' VAL . 26.6 mm -86.37 122.14 38.33 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.816 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -175.799 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 1.662 ' HD2' ' CD1' ' A' ' 149' ' ' TYR . 40.6 m-85 -117.25 156.2 28.16 Favored 'General case' 0 CA--C 1.487 -1.474 0 CA-C-O 121.633 0.73 . . . . 0.0 110.605 179.222 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -84.28 129.37 34.89 Favored 'General case' 0 N--CA 1.405 -2.685 0 CA-C-N 114.544 -1.207 . . . . 0.0 108.684 175.808 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 15.8 t-20 -91.43 -13.77 31.74 Favored 'General case' 0 C--N 1.29 -2.008 0 N-CA-C 107.383 -1.339 . . . . 0.0 107.383 -178.793 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -150.14 143.62 25.17 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 113.633 -1.621 . . . . 0.0 109.008 -175.201 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -86.37 144.79 27.17 Favored 'General case' 0 C--N 1.307 -1.249 0 O-C-N 124.241 0.963 . . . . 0.0 110.169 -179.777 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.453 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 1.5 m -123.96 150.52 28.46 Favored 'Isoleucine or valine' 0 C--O 1.253 1.249 0 C-N-CA 120.701 -0.4 . . . . 0.0 111.24 -177.284 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.2 t -124.32 138.27 54.4 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.124 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -179.613 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.449 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 79.0 t -100.21 100.83 12.64 Favored Pre-proline 0 C--N 1.296 -1.759 0 C-N-CA 123.983 0.913 . . . . 0.0 109.453 178.06 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . 0.458 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 27.5 Cg_endo -66.37 -26.19 48.47 Favored 'Trans proline' 0 CA--C 1.515 -0.428 0 C-N-CA 122.208 1.939 . . . . 0.0 111.773 178.908 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.3 t . . . . . 0 C--O 1.254 1.312 0 O-C-N 124.516 1.135 . . . . 0.0 113.223 176.882 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 1.667 ' HE2' ' CE1' ' A' ' 1' ' ' PHE . 30.6 t80 . . . . . 0 CA--C 1.479 -1.753 0 N-CA-C 105.331 -2.1 . . . . 0.0 105.331 . . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.446 ' HB2' ' O ' ' A' ' 11' ' ' ILE . . . -140.3 176.41 8.79 Favored 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -178.191 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.491 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 13.6 t -147.4 159.37 43.77 Favored 'General case' 0 N--CA 1.428 -1.555 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.647 -174.784 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.504 ' HE3' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.81 168.72 19.54 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-O 121.36 0.6 . . . . 0.0 110.747 -173.717 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.555 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 76.2 p -105.5 175.82 5.37 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.08 0.467 . . . . 0.0 110.798 179.771 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -73.66 -22.05 60.08 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.627 178.651 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.555 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 7.4 p30 -84.28 -33.33 24.01 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 120.256 -0.578 . . . . 0.0 110.641 -177.784 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 135.13 9.47 1.66 Allowed Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 119.564 -1.303 . . . . 0.0 113.699 176.808 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -85.16 100.02 11.46 Favored 'General case' 0 N--CA 1.433 -1.317 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.884 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.1 117.33 30.0 Favored 'General case' 0 C--N 1.297 -1.71 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.591 178.638 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.446 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 67.3 mt -86.63 127.26 61.16 Favored Pre-proline 0 C--N 1.299 -1.627 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 178.692 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -81.06 169.34 16.28 Favored 'Trans proline' 0 C--O 1.248 0.984 0 C-N-CA 122.78 2.32 . . . . 0.0 111.305 177.985 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 61.3 mt -69.16 132.11 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 177.855 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.404 ' HA2' ' CD2' ' A' ' 142' ' ' PHE . . . 129.89 -5.22 6.12 Favored Glycine 0 C--N 1.3 -1.462 0 C-N-CA 120.172 -1.013 . . . . 0.0 111.507 -179.528 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 101.42 163.6 27.33 Favored Glycine 0 N--CA 1.432 -1.595 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 -177.694 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 160.41 -177.45 36.84 Favored Glycine 0 C--N 1.297 -1.614 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 178.612 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.402 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 59.7 p -138.99 147.74 42.55 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.763 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -132.0 161.05 34.1 Favored 'General case' 0 N--CA 1.426 -1.63 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 177.999 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 -116.2 109.06 16.93 Favored 'General case' 0 C--N 1.289 -2.055 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 177.784 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.432 HG23 ' HA ' ' A' ' 148' ' ' ILE . 1.3 m -91.1 147.68 5.08 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.416 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 -177.893 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.7 m-85 -131.04 118.87 21.2 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -177.354 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.472 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -125.43 135.63 63.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.108 -176.389 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 30.7 m-80 -91.08 122.7 33.95 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 179.988 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -101.94 160.61 14.34 Favored 'General case' 0 C--N 1.285 -2.223 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 178.103 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.2 122.21 52.48 Favored Pre-proline 0 C--N 1.314 -0.955 0 O-C-N 124.116 0.885 . . . . 0.0 108.728 174.76 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.497 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 72.8 Cg_endo -74.71 -1.84 11.67 Favored 'Trans proline' 0 CA--C 1.533 0.441 0 C-N-CA 122.895 2.397 . . . . 0.0 112.968 -176.148 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 95.6 t -129.11 111.27 22.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 -179.995 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 10.3 t -148.19 111.1 0.68 Allowed 'Isoleucine or valine' 0 C--O 1.188 -2.17 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -177.341 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.587 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -96.83 154.65 17.17 Favored 'General case' 0 C--N 1.272 -2.775 0 C-N-CA 123.646 0.778 . . . . 0.0 110.962 179.834 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.622 HG23 ' O ' ' A' ' 112' ' ' VAL . 71.5 t -46.67 122.66 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 C-N-CA 123.051 0.541 . . . . 0.0 110.734 176.24 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.25 1.24 58.16 Favored Glycine 0 C--N 1.315 -0.592 0 CA-C-N 115.536 -0.756 . . . . 0.0 112.919 179.663 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.587 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -73.38 -176.98 2.42 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 123.396 0.678 . . . . 0.0 110.678 175.93 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -131.42 92.13 3.12 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.131 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.647 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 28.5 tp -94.09 141.05 28.99 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 119.444 -0.902 . . . . 0.0 109.906 -179.66 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 56.9 t -131.87 120.93 45.98 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.019 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.022 -176.443 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.59 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 48.3 t -90.86 88.21 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.89 0 N-CA-C 105.249 -2.13 . . . . 0.0 105.249 173.655 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -83.26 109.75 17.5 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.318 -177.473 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 84.2 mt -95.0 -3.64 48.04 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.111 -178.164 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.408 ' HA ' ' O ' ' A' ' 103' ' ' TRP . 1.1 m -71.15 0.15 8.38 Favored 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 114.831 -1.077 . . . . 0.0 110.125 -179.945 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.5 p -133.21 6.86 3.9 Favored 'General case' 0 N--CA 1.425 -1.677 0 C-N-CA 124.24 1.016 . . . . 0.0 109.911 178.639 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.472 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 46.2 mm-40 -122.23 -19.28 6.57 Favored 'General case' 0 CA--C 1.507 -0.699 0 CA-C-O 121.067 0.461 . . . . 0.0 110.717 -174.557 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 45.2 mt -134.36 138.24 50.2 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -176.219 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.504 ' HB2' ' HE3' ' A' ' 4' ' ' LYS . 72.8 m-85 -143.02 143.44 31.9 Favored 'General case' 0 CA--C 1.492 -1.27 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -174.467 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.491 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 64.8 m -126.87 140.64 52.19 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 -176.327 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -121.89 151.17 40.98 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.313 0.578 . . . . 0.0 110.256 -176.203 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.638 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 24.0 p-10 -107.18 104.06 13.6 Favored 'General case' 0 N--CA 1.411 -2.387 0 CA-C-O 122.886 1.327 . . . . 0.0 110.068 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -74.84 -34.64 62.35 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 112.942 -1.935 . . . . 0.0 111.319 -174.847 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . 1.671 ' HE1' ' CE2' ' A' ' 48' ' ' TYR . 49.5 m-85 -134.23 72.79 70.76 Favored Pre-proline 0 C--N 1.3 -1.566 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.539 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.638 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 58.7 Cg_endo -72.34 -3.05 12.64 Favored 'Trans proline' 0 C--N 1.334 -0.224 0 C-N-CA 122.775 2.317 . . . . 0.0 113.386 -174.378 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -118.83 -4.19 10.7 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 121.138 0.494 . . . . 0.0 109.799 -178.278 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.453 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -117.99 -29.1 5.72 Favored 'General case' 0 N--CA 1.418 -2.033 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.883 -174.016 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.453 HD13 ' HB ' ' A' ' 51' ' ' THR . 3.0 mp -130.6 134.84 61.54 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.487 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.5 t -69.57 139.74 53.75 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 108.957 -0.756 . . . . 0.0 108.957 177.463 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -86.76 107.96 18.49 Favored 'General case' 0 C--N 1.285 -2.207 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -173.347 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 1.667 ' HD1' ' CD2' ' A' ' 55' ' ' TYR . 73.1 t80 -150.16 145.35 26.24 Favored 'General case' 0 C--N 1.295 -1.794 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.427 -171.357 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.488 HG11 ' HB2' ' A' ' 131' ' ' LEU . 59.9 t -150.66 139.67 15.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 C-N-CA 124.559 1.144 . . . . 0.0 108.666 177.655 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -147.27 122.61 10.29 Favored 'General case' 0 C--O 1.21 -0.992 0 O-C-N 123.311 0.382 . . . . 0.0 110.607 174.617 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.513 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 63.5 tp -64.77 114.92 4.79 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-O 121.315 0.579 . . . . 0.0 110.004 177.195 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.417 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 4.2 tp-100 -59.12 -60.02 4.53 Favored 'General case' 0 C--N 1.315 -0.933 0 C-N-CA 126.287 1.835 . . . . 0.0 110.555 176.566 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . 0.402 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 4.5 ptp180 -163.06 161.91 25.56 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 115.052 -0.976 . . . . 0.0 108.424 -177.011 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.44 131.25 4.59 Favored Glycine 0 N--CA 1.401 -3.641 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 -179.384 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 49.1 m -120.07 149.52 42.05 Favored 'General case' 0 C--N 1.288 -2.089 0 C-N-CA 124.072 0.949 . . . . 0.0 110.395 -174.575 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.552 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -111.5 153.4 26.26 Favored 'General case' 0 N--CA 1.486 1.356 0 CA-C-O 117.792 -1.099 . . . . 0.0 108.398 -179.457 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 1.658 ' HE1' ' CE2' ' A' ' 64' ' ' TYR . 95.2 m-85 -158.35 -179.75 8.39 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 123.646 0.779 . . . . 0.0 111.277 -176.951 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.91 -134.02 51.03 Favored Glycine 0 C--N 1.317 -0.485 0 C-N-CA 121.409 -0.424 . . . . 0.0 112.265 179.769 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.62 -10.22 83.6 Favored Glycine 0 N--CA 1.422 -2.25 0 C-N-CA 120.327 -0.939 . . . . 0.0 112.839 177.306 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.789 HG23 ' O ' ' A' ' 64' ' ' TYR . 12.5 m -73.84 -28.6 24.47 Favored 'Isoleucine or valine' 0 C--O 1.205 -1.252 0 CA-C-N 118.295 1.048 . . . . 0.0 112.262 -174.143 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.552 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -91.14 -19.94 22.54 Favored 'General case' 0 C--N 1.297 -1.675 0 C-N-CA 119.876 -0.73 . . . . 0.0 111.895 177.664 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 7.4 t -100.45 -49.35 4.26 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.481 0.658 . . . . 0.0 111.239 -173.627 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.501 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 49.6 m-20 -96.99 -17.82 19.81 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -174.332 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 1.593 ' HD1' ' CD2' ' A' ' 71' ' ' PHE . 87.2 m-85 -119.31 163.55 16.98 Favored 'General case' 0 C--N 1.294 -1.812 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.957 -179.329 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.2 t -173.06 132.6 0.51 Allowed 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 178.729 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.508 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -167.15 -112.5 0.26 Allowed Glycine 0 N--CA 1.406 -3.334 0 N-CA-C 110.624 -0.99 . . . . 0.0 110.624 174.178 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.2 p -154.93 -179.96 8.55 Favored 'General case' 0 C--N 1.292 -1.921 0 C-N-CA 123.628 0.771 . . . . 0.0 110.403 -172.933 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.409 ' HB ' ' CD1' ' A' ' 84' ' ' PHE . 2.5 p -134.27 145.5 32.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.319 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.741 ' HG3' ' O ' ' A' ' 80' ' ' SER . 71.0 tttt -123.22 142.99 50.34 Favored 'General case' 0 N--CA 1.416 -2.139 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.397 -179.395 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 1.669 ' HD2' ' CD1' ' A' ' 77' ' ' TYR . 71.7 t80 -143.81 112.0 6.3 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.521 -178.429 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 14.7 t 52.78 37.94 25.21 Favored 'General case' 0 CA--C 1.561 1.4 0 CA-C-O 122.025 0.917 . . . . 0.0 110.875 175.951 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.08 10.37 64.49 Favored Glycine 0 CA--C 1.528 0.903 0 CA-C-N 115.684 -0.689 . . . . 0.0 113.731 179.934 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.741 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 21.6 t -84.94 -179.72 7.13 Favored 'General case' 0 C--O 1.206 -1.211 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 177.836 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 48.5 m -159.06 108.83 1.95 Allowed 'General case' 0 C--N 1.279 -2.483 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 177.297 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 1.624 ' HE2' ' CE1' ' A' ' 82' ' ' TYR . 4.0 p90 -149.38 163.1 26.5 Favored Pre-proline 0 C--N 1.306 -1.308 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -174.517 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.426 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 58.6 Cg_endo -68.99 148.79 70.85 Favored 'Trans proline' 0 C--N 1.358 1.057 0 C-N-CA 122.612 2.208 . . . . 0.0 113.425 -175.862 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.475 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 51.6 t80 -123.72 132.76 24.3 Favored Pre-proline 0 N--CA 1.435 -1.18 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 179.383 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.475 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 66.8 Cg_endo -72.22 147.58 89.11 Favored 'Cis proline' 0 CA--C 1.542 0.914 0 C-N-CA 122.734 -1.777 . . . . 0.0 110.497 -1.369 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.5 t -68.28 -175.84 0.67 Allowed 'General case' 0 CA--C 1.55 0.955 0 CA-C-O 121.229 0.537 . . . . 0.0 111.04 -176.181 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 7.9 p -130.37 -42.88 1.17 Allowed 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 116.07 -0.514 . . . . 0.0 112.289 -175.554 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.2 t -101.3 -86.63 0.4 Allowed 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.592 -175.467 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -170.19 -169.68 0.88 Allowed 'General case' 0 N--CA 1.438 -1.043 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 177.825 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.513 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 21.4 p -101.37 162.77 19.45 Favored Pre-proline 0 C--N 1.302 -1.477 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 177.325 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -63.79 159.4 41.78 Favored 'Trans proline' 0 C--N 1.358 1.059 0 C-N-CA 122.748 2.299 . . . . 0.0 111.64 174.526 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.7 tmm_? -65.35 118.29 9.14 Favored 'General case' 0 C--N 1.315 -0.918 0 C-N-CA 124.695 1.198 . . . . 0.0 109.554 -177.523 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 68.5 t -127.81 128.82 69.68 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.329 -177.07 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 74.2 t -114.29 140.73 33.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.402 179.416 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -87.36 95.65 10.07 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.24 0.543 . . . . 0.0 110.093 177.931 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -86.97 64.57 8.55 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 121.183 0.516 . . . . 0.0 110.392 -179.046 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.5 m -155.21 -179.59 8.23 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 -179.527 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . 0.513 ' HA ' HD22 ' A' ' 46' ' ' ASN . 16.7 ptm180 -141.28 50.32 1.61 Allowed 'General case' 0 N--CA 1.44 -0.971 0 CA-C-O 121.899 0.857 . . . . 0.0 110.128 178.996 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 6.9 t -163.39 170.75 17.02 Favored 'General case' 0 N--CA 1.424 -1.733 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 -178.868 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -69.92 101.59 1.79 Allowed 'General case' 0 C--O 1.251 1.169 0 CA-C-O 122.581 1.182 . . . . 0.0 108.755 178.242 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.8 tptm -101.1 137.02 19.6 Favored Pre-proline 0 C--N 1.268 -2.945 0 CA-C-N 113.002 -1.908 . . . . 0.0 109.368 -175.878 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -64.74 146.09 87.81 Favored 'Trans proline' 0 C--O 1.246 0.904 0 C-N-CA 122.673 2.248 . . . . 0.0 111.892 177.073 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . 0.408 ' O ' ' HA ' ' A' ' 39' ' ' SER . 15.7 t90 -86.95 108.61 19.33 Favored Pre-proline 0 N--CA 1.44 -0.932 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 -178.563 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -76.63 89.01 1.32 Allowed 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 121.864 1.709 . . . . 0.0 113.154 -173.273 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 81.2 t -139.89 145.86 25.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.038 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 177.824 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.59 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -149.92 136.31 19.01 Favored 'General case' 0 C--N 1.287 -2.121 0 CA-C-O 120.95 0.405 . . . . 0.0 110.223 177.586 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 15.9 mt -103.69 106.08 16.49 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 178.335 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 0.508 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 14.6 m-85 -83.01 75.0 9.92 Favored 'General case' 0 C--N 1.284 -2.249 0 N-CA-C 110.159 -0.312 . . . . 0.0 110.159 177.849 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.647 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -95.83 124.96 40.08 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 174.776 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -128.97 146.25 59.87 Favored Pre-proline 0 N--CA 1.409 -2.492 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 -176.86 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.501 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 36.2 Cg_endo -63.78 126.01 16.56 Favored 'Trans proline' 0 N--CA 1.444 -1.424 0 C-N-CA 122.712 2.274 . . . . 0.0 113.685 -175.813 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.622 ' O ' HG23 ' A' ' 30' ' ' VAL . 13.9 m -85.62 -155.96 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.392 -3.346 0 CA-C-N 114.007 -1.451 . . . . 0.0 108.465 171.648 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 14.4 m -79.86 -33.39 40.15 Favored 'General case' 0 C--N 1.262 -3.225 0 CA-C-O 121.446 0.641 . . . . 0.0 110.12 -170.36 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.2 t -83.19 26.89 0.6 Allowed 'General case' 0 N--CA 1.425 -1.684 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.558 -178.137 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -107.8 134.35 50.87 Favored 'General case' 0 N--CA 1.424 -1.766 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 178.478 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -176.78 129.21 1.44 Allowed Glycine 0 N--CA 1.437 -1.235 0 C-N-CA 120.571 -0.824 . . . . 0.0 111.469 178.814 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.4 -150.71 52.01 Favored Glycine 0 CA--C 1.495 -1.204 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 -176.305 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -55.9 105.99 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 CA-C-O 122.522 1.153 . . . . 0.0 111.932 -178.211 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -106.61 -28.33 10.3 Favored 'General case' 0 C--N 1.294 -1.812 0 CA-C-N 114.51 -1.223 . . . . 0.0 111.375 -177.922 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.403 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 54.8 mt -130.07 135.01 61.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.118 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.423 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.1 mmpt? -109.84 141.48 42.47 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-O 121.164 0.507 . . . . 0.0 111.123 176.767 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -72.09 123.28 22.52 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.429 178.965 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 97.94 -0.0 58.95 Favored Glycine 0 C--N 1.306 -1.097 0 N-CA-C 111.316 -0.714 . . . . 0.0 111.316 -176.613 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 31.0 t -97.16 145.42 26.04 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.329 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.41 HD21 ' CZ ' ' A' ' 149' ' ' TYR . 3.2 tm? -76.84 123.43 26.23 Favored 'General case' 0 N--CA 1.431 -1.38 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.82 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.437 ' HB ' HG13 ' A' ' 67' ' ' VAL . 28.4 pt -108.63 -29.75 2.53 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.745 -179.746 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . 0.419 ' HB1' ' HB ' ' A' ' 148' ' ' ILE . . . -158.88 168.5 26.64 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 119.46 -0.896 . . . . 0.0 110.639 -177.238 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 72.3 t -142.12 113.48 3.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 179.021 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 57.0 mt -117.24 151.53 36.73 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 178.533 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . 0.511 ' O ' HD13 ' A' ' 58' ' ' LEU . 4.5 mp -135.71 129.69 48.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 178.027 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.488 ' HB2' HG11 ' A' ' 56' ' ' VAL . 1.2 pp -97.34 142.0 29.75 Favored 'General case' 0 CA--C 1.499 -0.991 0 C-N-CA 119.864 -0.734 . . . . 0.0 109.022 177.352 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . 0.417 ' HG2' ' HB2' ' A' ' 59' ' ' GLN . 15.4 mmm180 -96.64 116.11 28.55 Favored 'General case' 0 C--N 1.279 -2.477 0 C-N-CA 124.264 1.026 . . . . 0.0 108.551 175.848 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 26.2 tp60 -85.12 135.48 33.96 Favored 'General case' 0 N--CA 1.413 -2.302 0 N-CA-C 105.55 -2.019 . . . . 0.0 105.55 174.966 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.512 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 25.2 m -139.0 135.33 34.17 Favored 'General case' 0 C--N 1.262 -3.199 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 174.807 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 24.1 p-10 -142.85 145.91 33.62 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-O 121.695 0.759 . . . . 0.0 110.909 -176.742 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -86.18 -31.21 21.89 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 114.512 -1.222 . . . . 0.0 112.806 -170.115 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . 1.656 ' HD2' ' CD1' ' A' ' 137' ' ' TYR . 72.4 t80 -80.95 -65.09 1.06 Allowed 'General case' 0 C--N 1.315 -0.905 0 C-N-CA 123.314 0.646 . . . . 0.0 110.434 -174.408 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -93.92 169.35 10.35 Favored 'General case' 0 CA--C 1.479 -1.786 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 173.532 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 14.9 p -107.46 58.35 0.62 Allowed 'General case' 0 C--N 1.276 -2.611 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 175.454 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 72.0 m-20 -97.43 39.44 1.2 Allowed 'General case' 0 CA--C 1.499 -1.014 0 CA-C-N 114.038 -1.437 . . . . 0.0 108.627 179.964 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -80.77 72.73 7.75 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-O 122.639 1.209 . . . . 0.0 110.165 -179.009 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . 1.67 ' HE1' ' CE2' ' A' ' 142' ' ' PHE . 74.7 m-85 -101.01 -179.53 4.07 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 107.243 -1.392 . . . . 0.0 107.243 177.713 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -132.48 144.89 50.76 Favored 'General case' 0 C--N 1.292 -1.911 0 C-N-CA 118.937 -1.105 . . . . 0.0 111.341 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 10.2 m-30 -109.24 127.52 54.32 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -177.078 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . 0.402 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 48.5 t -91.17 137.04 22.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 123.538 0.524 . . . . 0.0 110.18 -178.027 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 60.6 m95 -125.35 96.56 4.87 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 -178.084 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -81.56 114.44 20.27 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 178.146 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . 0.432 ' HA ' HG23 ' A' ' 20' ' ' VAL . 20.9 mm -88.0 122.85 40.12 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -176.268 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 1.61 ' HD1' ' CD2' ' A' ' 149' ' ' TYR . 83.4 m-85 -119.01 152.92 35.53 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.822 178.584 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.12 129.6 35.04 Favored 'General case' 0 N--CA 1.407 -2.591 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 177.211 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 10.9 t-20 -90.47 -12.89 35.98 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 122.452 1.12 . . . . 0.0 108.082 -177.088 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -149.03 144.47 26.74 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 113.964 -1.471 . . . . 0.0 108.911 -175.133 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 17.3 p-10 -86.63 141.92 28.62 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 123.982 0.801 . . . . 0.0 111.762 -179.11 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.497 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 70.5 t -117.46 139.04 46.14 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 CA-C-N 115.228 -0.897 . . . . 0.0 111.632 -173.597 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -120.1 132.3 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 179.21 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . 0.462 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 71.7 t -97.71 103.59 17.4 Favored Pre-proline 0 C--N 1.292 -1.904 0 C-N-CA 123.933 0.893 . . . . 0.0 109.927 179.909 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 23.2 Cg_endo -68.15 -27.41 35.43 Favored 'Trans proline' 0 CA--C 1.509 -0.754 0 C-N-CA 121.978 1.786 . . . . 0.0 111.816 179.719 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 5.0 t . . . . . 0 CA--C 1.549 0.94 0 C-N-CA 124.706 1.202 . . . . 0.0 113.628 177.911 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' PHE . . . . . 1.599 ' HE2' ' CE1' ' A' ' 1' ' ' PHE . 59.4 t80 . . . . . 0 CA--C 1.49 -1.356 0 CA-C-O 120.5 0.191 . . . . 0.0 111.001 . . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.476 ' HB1' ' CE1' ' A' ' 45' ' ' HIS . . . -147.88 173.67 12.61 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 172.344 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 64.4 m -144.99 168.47 20.2 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 120.193 -0.603 . . . . 0.0 110.726 -176.616 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.42 ' HA ' ' O ' ' A' ' 9' ' ' THR . 0.3 OUTLIER -148.82 162.2 40.28 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 123.632 0.773 . . . . 0.0 109.477 178.868 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' THR . . . . . 0.461 ' HG1' ' ND2' ' A' ' 7' ' ' ASN . 71.9 p -100.24 175.86 5.58 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 121.394 0.616 . . . . 0.0 110.414 -179.744 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.29 -13.54 59.92 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-N 114.371 -1.286 . . . . 0.0 110.654 179.157 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.461 ' ND2' ' HG1' ' A' ' 5' ' ' THR . 5.3 p30 -87.82 -34.31 18.3 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 118.895 -1.122 . . . . 0.0 108.63 175.265 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 134.19 7.2 2.29 Favored Glycine 0 N--CA 1.436 -1.304 0 C-N-CA 120.0 -1.095 . . . . 0.0 113.301 177.049 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.42 ' O ' ' HA ' ' A' ' 4' ' ' LYS . 5.1 m -76.55 99.28 4.91 Favored 'General case' 0 N--CA 1.442 -0.873 0 CA-C-N 117.601 0.7 . . . . 0.0 109.121 179.869 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.55 118.43 30.99 Favored 'General case' 0 C--N 1.294 -1.819 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.271 178.314 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.417 ' O ' ' HB2' ' A' ' 2' ' ' ALA . 62.4 mt -96.53 118.79 64.98 Favored Pre-proline 0 C--N 1.302 -1.459 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 177.233 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -79.12 174.85 11.55 Favored 'Trans proline' 0 C--O 1.252 1.193 0 C-N-CA 122.637 2.224 . . . . 0.0 110.655 177.935 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 53.8 mt -71.99 119.85 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.247 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 177.217 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 151.76 -12.11 0.73 Allowed Glycine 0 C--N 1.291 -1.96 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -172.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 94.24 161.2 34.88 Favored Glycine 0 N--CA 1.433 -1.547 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 177.651 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 162.05 -167.92 36.9 Favored Glycine 0 CA--C 1.473 -2.564 0 C-N-CA 118.888 -1.625 . . . . 0.0 111.904 179.109 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 14.5 m -144.6 147.64 33.39 Favored 'General case' 0 C--N 1.286 -2.19 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 -179.386 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.22 156.44 48.98 Favored 'General case' 0 N--CA 1.426 -1.637 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 -179.134 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -104.78 111.02 23.6 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 179.91 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 41.3 t -98.68 139.59 20.26 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.901 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.347 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 1.665 ' HE2' ' CE1' ' A' ' 21' ' ' TYR . 56.2 m-85 -128.66 119.09 24.04 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -177.288 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . 0.458 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.9 p -122.74 129.75 74.96 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-O 121.884 0.85 . . . . 0.0 111.089 -175.899 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -88.73 119.17 28.97 Favored 'General case' 0 C--N 1.291 -1.974 0 CA-C-N 114.847 -1.07 . . . . 0.0 109.439 179.546 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 27.8 mt -107.06 160.79 15.29 Favored 'General case' 0 C--N 1.28 -2.453 0 CA-C-N 114.625 -1.17 . . . . 0.0 109.185 -177.58 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.5 121.56 49.22 Favored Pre-proline 0 C--O 1.206 -1.2 0 O-C-N 124.01 0.819 . . . . 0.0 108.871 177.826 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 60.1 Cg_endo -73.99 -2.47 12.32 Favored 'Trans proline' 0 CA--C 1.53 0.282 0 C-N-CA 122.786 2.324 . . . . 0.0 113.302 -175.627 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 96.0 t -127.83 109.96 21.04 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -179.308 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 5.8 t -146.57 106.74 0.66 Allowed 'Isoleucine or valine' 0 C--O 1.189 -2.114 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -178.035 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' ASN . . . . . 0.567 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -94.27 153.98 17.76 Favored 'General case' 0 C--N 1.277 -2.581 0 C-N-CA 123.246 0.618 . . . . 0.0 111.506 179.983 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 112' ' ' VAL . 85.5 t -50.66 118.98 0.84 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.738 0 C-N-CA 123.274 0.629 . . . . 0.0 111.051 179.405 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.37 7.88 50.92 Favored Glycine 0 C--N 1.309 -0.917 0 CA-C-N 114.98 -1.009 . . . . 0.0 112.138 -178.527 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . 0.567 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -78.66 -177.24 5.28 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 123.493 0.717 . . . . 0.0 109.633 173.09 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -132.93 92.4 3.03 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 177.984 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.669 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 23.9 tp -92.67 145.51 24.37 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 119.705 -0.798 . . . . 0.0 109.247 179.407 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.9 t -136.09 121.74 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.584 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -177.536 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.625 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 62.0 t -91.74 88.62 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.406 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 175.298 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -84.2 115.53 22.48 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 120.008 -0.677 . . . . 0.0 110.641 -178.681 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.4 mt -94.7 -1.23 53.43 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.718 -179.313 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 31.6 t -75.04 2.17 11.24 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.925 0.869 . . . . 0.0 109.477 178.797 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.5 p -129.25 4.26 5.21 Favored 'General case' 0 C--N 1.288 -2.074 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.46 176.348 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.458 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 42.7 mm-40 -124.58 -20.8 5.01 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-O 121.091 0.472 . . . . 0.0 110.726 -174.651 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 26.8 mt -133.82 136.47 53.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.978 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -176.32 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.642 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 62.5 m-85 -133.49 139.75 46.84 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 -176.938 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 44' ' ' CYS . . . . . 0.583 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 60.5 m -125.03 134.22 52.65 Favored 'General case' 0 C--N 1.272 -2.784 0 CA-C-O 121.273 0.559 . . . . 0.0 111.743 -177.783 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . 0.476 ' CE1' ' HB1' ' A' ' 2' ' ' ALA . 10.5 p80 -119.9 129.89 54.58 Favored 'General case' 0 C--N 1.295 -1.772 0 CA-C-O 121.816 0.817 . . . . 0.0 110.775 -178.118 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 46' ' ' ASN . . . . . 0.59 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 4.8 p-10 -97.84 95.0 7.23 Favored 'General case' 0 C--N 1.275 -2.658 0 CA-C-O 123.053 1.406 . . . . 0.0 107.567 178.317 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.54 -19.93 51.8 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-N 113.64 -1.618 . . . . 0.0 113.715 -172.304 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -135.24 65.05 62.77 Favored Pre-proline 0 C--N 1.313 -0.98 0 C-N-CA 120.147 -0.621 . . . . 0.0 110.947 178.758 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 49' ' ' PRO . . . . . 0.59 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 35.7 Cg_endo -64.98 -18.48 62.3 Favored 'Trans proline' 0 C--N 1.355 0.895 0 C-N-CA 123.182 2.588 . . . . 0.0 115.302 -171.213 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -108.14 -15.98 14.37 Favored 'General case' 0 C--N 1.289 -2.045 0 C-N-CA 119.66 -0.816 . . . . 0.0 110.641 -176.249 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 51' ' ' THR . . . . . 0.489 ' HB ' HD13 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -101.14 -31.22 11.14 Favored 'General case' 0 N--CA 1.415 -2.211 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 -174.11 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.489 HD13 ' HB ' ' A' ' 51' ' ' THR . 3.2 mp -126.47 141.87 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.348 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 178.969 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 7.5 t -86.78 122.13 30.23 Favored 'General case' 0 N--CA 1.405 -2.698 0 N-CA-C 103.462 -2.792 . . . . 0.0 103.462 172.205 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 54' ' ' ASP . . . . . 0.548 ' OD1' ' HB2' ' A' ' 1' ' ' PHE . 17.1 m-20 -93.39 106.02 18.03 Favored 'General case' 0 C--N 1.256 -3.484 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 -175.125 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 55' ' ' TYR . . . . . 1.662 ' HE2' ' CE1' ' A' ' 55' ' ' TYR . 10.7 t80 -123.13 133.43 54.27 Favored 'General case' 0 C--N 1.285 -2.22 0 CA-C-N 113.852 -1.522 . . . . 0.0 109.974 -172.613 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.2 t -128.46 142.99 42.42 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 115.285 -0.87 . . . . 0.0 109.27 -174.966 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.12 128.93 12.46 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 123.715 0.634 . . . . 0.0 109.332 172.619 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.511 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 34.3 tp -71.2 102.86 2.63 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 173.353 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.5 tp-100 -56.22 -56.66 18.28 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 112.9 -1.954 . . . . 0.0 110.019 -176.928 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 6.1 ptp180 -158.76 151.14 21.61 Favored 'General case' 0 N--CA 1.41 -2.47 0 CA-C-N 114.251 -1.34 . . . . 0.0 108.197 -177.956 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.79 123.99 2.26 Favored Glycine 0 N--CA 1.405 -3.412 0 N-CA-C 108.611 -1.795 . . . . 0.0 108.611 -178.656 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 66.0 m -116.47 148.18 41.0 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 124.519 1.127 . . . . 0.0 110.83 -171.529 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 63' ' ' ALA . . . . . 0.491 ' O ' HD21 ' A' ' 68' ' ' LEU . . . -107.72 154.99 20.68 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.266 1.026 . . . . 0.0 108.62 -179.852 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 64' ' ' TYR . . . . . 0.756 ' O ' HG23 ' A' ' 67' ' ' VAL . 87.4 m-85 -156.06 -179.35 8.05 Favored 'General case' 0 N--CA 1.483 1.193 0 CA-C-N 118.351 0.523 . . . . 0.0 111.852 -176.956 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.33 -122.0 26.22 Favored Glycine 0 C--N 1.319 -0.393 0 CA-C-N 116.281 -0.418 . . . . 0.0 113.068 178.384 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -91.06 -10.38 62.64 Favored Glycine 0 N--CA 1.417 -2.57 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.843 177.076 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.756 HG23 ' O ' ' A' ' 64' ' ' TYR . 12.5 m -76.77 -25.59 15.95 Favored 'Isoleucine or valine' 0 C--O 1.206 -1.23 0 CA-C-N 118.174 0.987 . . . . 0.0 112.289 -172.1 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.491 HD21 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -90.66 -23.75 20.68 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 121.495 0.664 . . . . 0.0 111.74 177.701 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 21.7 m -102.03 -52.91 3.05 Favored 'General case' 0 C--N 1.305 -1.366 0 N-CA-C 113.943 1.09 . . . . 0.0 113.943 -175.226 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 70' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 53.7 m-20 -88.09 -22.63 24.03 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 -177.41 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 71' ' ' PHE . . . . . 0.466 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 87.6 m-85 -115.48 164.12 14.75 Favored 'General case' 0 C--N 1.294 -1.842 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.944 179.832 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.3 t -172.63 134.22 0.63 Allowed 'General case' 0 N--CA 1.416 -2.13 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 177.266 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.616 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -165.58 -114.75 0.3 Allowed Glycine 0 N--CA 1.398 -3.847 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 173.401 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -153.52 -179.85 8.15 Favored 'General case' 0 C--N 1.273 -2.728 0 C-N-CA 124.176 0.991 . . . . 0.0 110.113 -173.917 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -132.7 152.04 35.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 C-N-CA 122.714 0.406 . . . . 0.0 109.958 178.586 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 76' ' ' LYS . . . . . 0.634 ' HG3' ' O ' ' A' ' 80' ' ' SER . 81.4 tttt -129.04 145.67 51.2 Favored 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 123.79 0.836 . . . . 0.0 110.128 -179.475 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 77' ' ' TYR . . . . . 0.409 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 58.1 t80 -147.28 112.49 5.52 Favored 'General case' 0 C--N 1.314 -0.96 0 O-C-N 123.777 0.673 . . . . 0.0 109.301 -178.655 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 23.0 t 54.97 36.28 26.48 Favored 'General case' 0 CA--C 1.551 1.003 0 C-N-CA 123.627 0.771 . . . . 0.0 110.448 177.188 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.58 8.18 66.05 Favored Glycine 0 CA--C 1.529 0.941 0 CA-C-N 115.459 -0.791 . . . . 0.0 114.095 -179.421 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 80' ' ' SER . . . . . 0.634 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 17.3 t -79.68 -179.52 6.94 Favored 'General case' 0 CA--C 1.543 0.682 0 CA-C-N 117.275 0.537 . . . . 0.0 109.994 -179.678 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 22.6 t -157.08 111.88 2.76 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 178.713 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 82' ' ' TYR . . . . . 1.642 ' HE2' ' CE1' ' A' ' 82' ' ' TYR . 2.6 p90 -154.6 161.42 29.4 Favored Pre-proline 0 CA--C 1.552 1.056 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -175.5 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -67.97 150.53 78.01 Favored 'Trans proline' 0 C--N 1.361 1.218 0 C-N-CA 122.884 2.389 . . . . 0.0 113.503 -176.761 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 1.67 ' HD2' ' CD1' ' A' ' 84' ' ' PHE . 57.8 t80 -126.39 132.65 24.4 Favored Pre-proline 0 N--CA 1.44 -0.967 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.067 179.785 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 85' ' ' PRO . . . . . 0.481 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 62.4 Cg_endo -69.95 147.07 84.29 Favored 'Cis proline' 0 CA--C 1.549 1.254 0 C-N-CA 123.125 -1.615 . . . . 0.0 111.16 -1.21 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.1 t -69.35 -176.98 1.04 Allowed 'General case' 0 CA--C 1.549 0.941 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.014 -175.294 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 14.1 p -127.41 -42.6 1.65 Allowed 'General case' 0 N--CA 1.432 -1.346 0 N-CA-C 112.799 0.666 . . . . 0.0 112.799 -172.418 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.6 t -108.12 -72.17 0.73 Allowed 'General case' 0 N--CA 1.432 -1.334 0 C-N-CA 119.74 -0.784 . . . . 0.0 111.527 -175.533 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 176.6 -177.42 0.14 Allowed 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 -174.991 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.511 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 43.5 p -101.32 168.44 9.15 Favored Pre-proline 0 C--N 1.295 -1.781 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 178.555 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 91' ' ' PRO . . . . . 0.406 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 12.1 Cg_endo -54.43 164.73 2.72 Favored 'Trans proline' 0 C--O 1.252 1.175 0 C-N-CA 123.162 2.574 . . . . 0.0 112.188 171.305 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.546 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 1.7 tmm_? -84.82 101.44 12.27 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.131 -172.625 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 87.6 t -114.14 121.22 65.84 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 CA-C-N 114.893 -1.049 . . . . 0.0 111.402 -176.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 93.5 t -108.28 142.29 21.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 CA-C-N 115.106 -0.952 . . . . 0.0 108.739 177.72 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -98.52 110.6 23.17 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 176.085 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 46.2 m-80 -108.46 32.16 5.05 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-O 121.708 0.766 . . . . 0.0 110.075 178.891 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.3 m -85.16 -172.53 4.22 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.375 -177.674 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 16.4 ptp180 -145.99 36.46 1.03 Allowed 'General case' 0 C--N 1.307 -1.242 0 CA-C-O 121.85 0.833 . . . . 0.0 109.688 178.079 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 12.4 t -168.89 177.69 4.88 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 105.435 -2.061 . . . . 0.0 105.435 -178.995 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . 0.402 ' CB ' ' HB3' ' A' ' 45' ' ' HIS . 1.5 p-10 -84.75 127.71 34.25 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 178.509 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 101' ' ' LYS . . . . . 0.464 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 6.5 mmpt? -117.66 147.34 40.72 Favored Pre-proline 0 C--N 1.28 -2.447 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.666 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -67.62 143.5 62.61 Favored 'Trans proline' 0 N--CA 1.44 -1.626 0 C-N-CA 122.375 2.05 . . . . 0.0 111.013 -178.718 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 14.7 t90 -80.81 107.95 8.76 Favored Pre-proline 0 C--N 1.305 -1.361 0 N-CA-C 106.595 -1.632 . . . . 0.0 106.595 -176.742 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -77.25 88.98 1.36 Allowed 'Trans proline' 0 N--CA 1.443 -1.459 0 C-N-CA 121.276 1.317 . . . . 0.0 112.683 -172.273 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 96.3 t -139.9 144.34 28.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 177.291 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 106' ' ' ALA . . . . . 0.625 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -147.84 134.47 19.87 Favored 'General case' 0 N--CA 1.419 -1.98 0 CA-C-O 120.785 0.326 . . . . 0.0 110.155 178.096 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 107' ' ' LEU . . . . . . . . . . . . . 17.7 mt -101.73 104.3 15.1 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.242 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 108' ' ' TYR . . . . . 1.619 ' HE2' ' CE1' ' A' ' 108' ' ' TYR . 16.5 m-85 -79.56 68.42 5.6 Favored 'General case' 0 C--N 1.287 -2.123 0 CA-C-O 120.514 0.197 . . . . 0.0 111.167 177.814 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.669 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -90.59 128.53 36.62 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 175.358 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.15 145.29 56.73 Favored Pre-proline 0 N--CA 1.416 -2.154 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.182 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . 0.474 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 30.7 Cg_endo -63.17 124.5 14.01 Favored 'Trans proline' 0 CA--C 1.498 -1.3 0 C-N-CA 122.927 2.418 . . . . 0.0 113.936 -176.24 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 112' ' ' VAL . . . . . 0.525 ' O ' HG23 ' A' ' 30' ' ' VAL . 19.5 m -86.36 -158.67 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.391 -3.419 0 CA-C-N 114.242 -1.345 . . . . 0.0 108.19 171.187 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 44.9 m -81.2 -22.35 38.91 Favored 'General case' 0 C--N 1.254 -3.575 0 O-C-N 121.636 -0.665 . . . . 0.0 111.069 -171.792 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.3 t -81.8 12.19 4.21 Favored 'General case' 0 CA--C 1.549 0.931 0 CA-C-O 121.771 0.796 . . . . 0.0 109.977 179.491 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.45 ' HB1' ' O ' ' A' ' 70' ' ' ASN . . . -98.98 135.42 40.41 Favored 'General case' 0 N--CA 1.419 -2.017 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.455 -179.708 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -179.82 122.96 0.81 Allowed Glycine 0 C--O 1.245 0.842 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 179.266 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 70.0 -155.01 53.09 Favored Glycine 0 C--N 1.307 -1.075 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 -174.922 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.1 p -53.88 106.86 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 122.541 1.162 . . . . 0.0 112.123 -178.174 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -108.56 -22.04 12.45 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 114.302 -1.317 . . . . 0.0 111.159 -176.848 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 120' ' ' ILE . . . . . 0.483 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.2 mt -136.34 133.47 49.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.053 0 N-CA-C 107.516 -1.291 . . . . 0.0 107.516 178.341 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 3.0 mmpt? -111.53 139.09 47.25 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 177.384 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.32 125.96 27.75 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 177.922 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 101.36 -10.77 58.14 Favored Glycine 0 N--CA 1.428 -1.885 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.298 -178.089 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 97.8 p -94.05 148.64 21.97 Favored 'General case' 0 C--O 1.252 1.22 0 C-N-CA 119.861 -0.736 . . . . 0.0 110.241 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . 0.414 HD12 HG21 ' A' ' 128' ' ' VAL . 3.0 tm? -76.35 124.15 27.06 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-N 115.011 -0.995 . . . . 0.0 108.878 -179.202 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 126' ' ' ILE . . . . . 0.431 ' HB ' HG13 ' A' ' 67' ' ' VAL . 27.6 pt -108.38 -29.92 2.53 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.389 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.878 179.901 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 127' ' ' ALA . . . . . 0.414 ' HB1' ' HB ' ' A' ' 148' ' ' ILE . . . -157.97 165.5 34.99 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.605 -0.838 . . . . 0.0 110.376 -176.595 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.414 HG21 HD12 ' A' ' 125' ' ' LEU . 64.4 t -139.6 114.18 7.37 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.796 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 177.929 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 40.0 mt -119.58 145.49 46.35 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 179.971 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 5.4 mp -129.64 128.85 66.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 C-N-CA 120.324 -0.551 . . . . 0.0 110.078 177.155 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 131' ' ' LEU . . . . . 0.472 ' C ' HD13 ' A' ' 131' ' ' LEU . 1.5 pp -92.62 138.31 31.61 Favored 'General case' 0 N--CA 1.424 -1.733 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 172.856 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 3.9 tpm_? -97.24 112.95 24.52 Favored 'General case' 0 C--N 1.249 -3.803 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 176.256 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.1 130.46 40.26 Favored 'General case' 0 N--CA 1.422 -1.849 0 N-CA-C 104.991 -2.226 . . . . 0.0 104.991 177.686 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.402 ' HA ' ' HB2' ' A' ' 141' ' ' ASP . 63.6 m -137.92 138.65 39.22 Favored 'General case' 0 C--N 1.273 -2.731 0 C-N-CA 120.396 -0.522 . . . . 0.0 110.179 174.277 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.455 ' CB ' HG21 ' A' ' 52' ' ' ILE . 20.0 p30 -126.93 170.38 12.32 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 121.524 0.678 . . . . 0.0 112.051 -175.717 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 9.5 p30 -106.67 -20.83 13.23 Favored 'General case' 0 N--CA 1.473 0.7 0 CA-C-N 114.825 -1.08 . . . . 0.0 110.903 -174.782 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . 1.66 ' HE2' ' CE1' ' A' ' 137' ' ' TYR . 73.8 t80 -89.2 -72.91 0.53 Allowed 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 115.395 -0.821 . . . . 0.0 110.078 -170.813 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -86.29 -178.56 6.5 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 175.507 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 69.9 m -117.96 27.0 9.27 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-O 121.799 0.809 . . . . 0.0 108.974 176.683 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 7.1 p30 -91.93 48.89 1.48 Allowed 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 122.192 0.996 . . . . 0.0 110.619 179.203 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 141' ' ' ASP . . . . . 0.402 ' HB2' ' HA ' ' A' ' 134' ' ' THR . 7.8 p-10 -84.52 86.25 7.31 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-O 122.867 1.318 . . . . 0.0 110.066 179.15 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -99.16 175.51 5.87 Favored 'General case' 0 C--N 1.289 -2.029 0 CA-C-N 114.594 -1.185 . . . . 0.0 109.42 179.451 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -130.22 141.32 50.65 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.647 179.884 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 1.662 ' HE2' ' CE1' ' A' ' 144' ' ' PHE . 7.0 m-30 -104.6 127.99 52.48 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 -175.575 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 57.6 t -93.24 136.24 25.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -178.923 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 66.9 m95 -123.87 95.79 4.7 Favored 'General case' 0 C--N 1.281 -2.381 0 N-CA-C 108.272 -1.011 . . . . 0.0 108.272 -177.19 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -80.94 114.17 19.64 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 177.961 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 148' ' ' ILE . . . . . 0.414 ' HB ' ' HB1' ' A' ' 127' ' ' ALA . 22.6 mm -89.92 122.03 40.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 -175.785 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 149' ' ' TYR . . . . . 1.653 ' HE2' ' CE1' ' A' ' 149' ' ' TYR . 96.8 m-85 -118.14 157.99 25.89 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 178.241 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.6 131.89 35.29 Favored 'General case' 0 N--CA 1.407 -2.599 0 CA-C-N 115.002 -0.999 . . . . 0.0 108.523 176.216 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 34.2 t-20 -95.52 -8.96 33.76 Favored 'General case' 0 C--N 1.29 -2.007 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 -178.401 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 3.4 t30 -153.79 145.43 23.31 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 113.869 -1.514 . . . . 0.0 108.713 -175.959 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -84.8 140.41 31.23 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 124.138 0.899 . . . . 0.0 111.198 -178.539 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 70.3 t -118.17 134.66 61.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.015 -176.653 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.1 t -119.24 133.08 67.21 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.545 0 N-CA-C 107.178 -1.415 . . . . 0.0 107.178 -179.966 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 75.2 t -97.65 102.64 13.66 Favored Pre-proline 0 C--N 1.289 -2.033 0 C-N-CA 123.375 0.67 . . . . 0.0 109.962 179.389 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -70.58 -24.55 25.8 Favored 'Trans proline' 0 CA--C 1.516 -0.403 0 C-N-CA 121.87 1.714 . . . . 0.0 111.584 -179.261 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 7.3 t . . . . . 0 CA--C 1.545 0.779 0 C-N-CA 125.303 1.441 . . . . 0.0 112.723 176.95 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.62 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.43 -1.472 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 15.7 t -152.15 158.31 42.75 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 -176.747 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.612 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -143.38 161.54 38.11 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 121.178 0.513 . . . . 0.0 111.208 -174.271 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.9 p -100.38 175.98 5.52 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.383 0.611 . . . . 0.0 110.653 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -76.41 -19.52 58.02 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.776 178.813 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -83.52 -34.0 25.38 Favored 'General case' 0 CA--C 1.514 -0.433 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.732 -179.528 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 130.32 27.31 0.76 Allowed Glycine 0 N--CA 1.441 -1.022 0 C-N-CA 119.907 -1.139 . . . . 0.0 112.348 177.321 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.403 ' O ' ' HA ' ' A' ' 4' ' ' LYS . 9.2 m -99.82 99.37 10.16 Favored 'General case' 0 N--CA 1.423 -1.816 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 177.831 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.5 122.57 35.06 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 176.109 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.62 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 65.3 mt -97.63 117.59 65.14 Favored Pre-proline 0 C--N 1.294 -1.817 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 178.676 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -75.33 171.36 18.41 Favored 'Trans proline' 0 C--O 1.245 0.845 0 C-N-CA 122.62 2.213 . . . . 0.0 111.673 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 69.6 mt -67.17 127.57 28.95 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.568 179.285 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 138.37 0.66 2.35 Favored Glycine 0 C--N 1.303 -1.3 0 C-N-CA 120.852 -0.69 . . . . 0.0 111.957 -177.93 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.49 168.87 43.72 Favored Glycine 0 N--CA 1.427 -1.921 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -178.808 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 155.49 -165.3 32.4 Favored Glycine 0 C--N 1.288 -2.135 0 C-N-CA 120.06 -1.067 . . . . 0.0 110.879 178.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.475 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 58.1 p -150.28 147.06 27.19 Favored 'General case' 0 N--CA 1.422 -1.868 0 CA-C-N 116.844 0.322 . . . . 0.0 110.373 -177.849 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -132.43 163.52 28.58 Favored 'General case' 0 N--CA 1.428 -1.556 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 178.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -116.71 107.52 14.78 Favored 'General case' 0 C--N 1.292 -1.929 0 N-CA-C 106.997 -1.482 . . . . 0.0 106.997 178.616 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.427 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.4 m -91.44 150.07 3.89 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.35 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -179.403 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 62.5 m-85 -131.92 112.16 12.18 Favored 'General case' 0 CA--C 1.485 -1.537 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -177.248 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.541 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 4.5 p -117.1 132.4 66.97 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.293 0 CA-C-O 121.815 0.817 . . . . 0.0 111.535 -173.728 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.456 ' HB3' ' HB3' ' A' ' 151' ' ' ASN . 2.1 p30 -98.12 123.57 42.23 Favored 'General case' 0 C--N 1.286 -2.176 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.171 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.403 HD11 ' HA ' ' A' ' 36' ' ' VAL . 2.5 mm? -106.83 160.55 15.42 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 114.408 -1.269 . . . . 0.0 108.051 -178.712 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -54.92 121.46 35.31 Favored Pre-proline 0 C--N 1.308 -1.233 0 O-C-N 124.381 1.051 . . . . 0.0 109.284 175.501 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 63.8 Cg_endo -74.79 1.47 7.57 Favored 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 122.926 2.417 . . . . 0.0 113.035 -177.274 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.464 HG13 ' HG3' ' A' ' 157' ' ' PRO . 86.0 t -128.82 110.11 20.33 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 178.839 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.511 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 4.5 t -145.96 111.65 1.06 Allowed 'Isoleucine or valine' 0 C--O 1.185 -2.293 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 -179.352 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.59 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -100.57 152.52 20.32 Favored 'General case' 0 C--N 1.267 -2.998 0 C-N-CA 122.707 0.403 . . . . 0.0 111.381 -178.236 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.403 HG13 ' O ' ' A' ' 112' ' ' VAL . 38.9 t -46.37 113.85 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.612 0 C-N-CA 123.314 0.646 . . . . 0.0 111.596 176.633 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 105.29 3.73 41.19 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 114.929 -1.032 . . . . 0.0 112.855 -179.375 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.59 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.4 OUTLIER -76.29 -177.35 4.01 Favored 'General case' 0 C--N 1.311 -1.069 0 C-N-CA 123.911 0.884 . . . . 0.0 110.067 175.641 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -133.54 91.59 2.87 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 177.11 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.673 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 28.4 tp -91.58 144.41 25.57 Favored 'General case' 0 C--N 1.292 -1.934 0 C-N-CA 119.964 -0.694 . . . . 0.0 109.781 -179.035 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 60.0 t -136.16 125.0 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -177.487 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.572 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 60.8 t -91.19 88.82 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.523 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 175.246 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -77.84 114.62 16.87 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -178.237 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 75.6 mt -98.0 -1.4 42.73 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-O 121.577 0.703 . . . . 0.0 110.983 -178.685 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.566 ' OG ' ' HA ' ' A' ' 104' ' ' PRO . 22.6 m -80.61 0.66 33.12 Favored 'General case' 0 C--N 1.29 -1.982 0 CA-C-O 122.321 1.058 . . . . 0.0 110.166 -178.322 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.2 p -121.59 4.07 10.13 Favored 'General case' 0 N--CA 1.417 -2.123 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.646 176.074 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.541 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 44.4 mm-40 -125.32 -21.87 4.48 Favored 'General case' 0 C--O 1.239 0.528 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.128 -174.317 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 30.8 mt -135.24 138.22 48.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -175.572 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.612 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 38.9 m-85 -143.43 130.38 20.55 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -176.434 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 73.3 m -109.48 151.11 27.15 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 120.976 0.417 . . . . 0.0 110.263 -178.572 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 7.6 p80 -138.06 129.98 28.49 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.72 0.771 . . . . 0.0 112.034 -175.141 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 46.7 t30 -99.43 99.85 10.81 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.195 -1.002 . . . . 0.0 109.98 176.574 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -72.37 -12.3 61.06 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 113.771 -1.559 . . . . 0.0 111.231 -176.633 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -127.6 71.17 77.39 Favored Pre-proline 0 C--N 1.32 -0.689 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.05 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -70.27 -13.14 33.06 Favored 'Trans proline' 0 C--N 1.332 -0.302 0 C-N-CA 122.491 2.127 . . . . 0.0 113.836 -172.425 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -110.77 -16.89 13.48 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.354 0.597 . . . . 0.0 110.167 -177.471 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.562 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.6 OUTLIER -102.4 -30.94 10.73 Favored 'General case' 0 N--CA 1.404 -2.747 0 CA-C-O 121.648 0.737 . . . . 0.0 109.194 -171.476 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.694 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.5 mp -127.93 135.76 62.08 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 CA-C-N 114.97 -1.014 . . . . 0.0 109.071 -176.401 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.9 t -77.73 142.14 38.89 Favored 'General case' 0 C--O 1.248 1.014 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 175.867 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -82.44 107.29 14.98 Favored 'General case' 0 C--N 1.286 -2.187 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 -175.349 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 31.8 t80 -144.88 137.04 26.0 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-O 120.761 0.315 . . . . 0.0 110.476 -176.027 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.408 HG23 ' HG ' ' A' ' 131' ' ' LEU . 11.9 p -150.02 150.56 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-N 116.308 -0.406 . . . . 0.0 109.951 179.642 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.29 136.21 18.48 Favored 'General case' 0 C--N 1.311 -1.073 0 C-N-CA 123.298 0.639 . . . . 0.0 109.401 176.616 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.533 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 43.5 tp -73.85 115.5 13.36 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 171.872 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.604 ' NE2' ' HD3' ' A' ' 132' ' ' ARG . 3.4 tp-100 -59.56 -51.32 70.33 Favored 'General case' 0 C--N 1.312 -1.064 0 C-N-CA 124.764 1.226 . . . . 0.0 111.588 178.772 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 9.4 ptp180 -171.51 160.42 5.92 Favored 'General case' 0 CA--C 1.5 -0.969 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 -174.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -139.27 146.78 18.54 Favored Glycine 0 N--CA 1.404 -3.454 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.753 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 64.4 m -131.48 150.66 52.07 Favored 'General case' 0 C--N 1.285 -2.231 0 C-N-CA 123.455 0.702 . . . . 0.0 109.568 -177.544 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.549 ' HB2' ' CE2' ' A' ' 84' ' ' PHE . . . -117.3 154.51 31.11 Favored 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -178.881 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.452 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . 90.9 m-85 -154.4 -179.5 8.0 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 123.71 0.804 . . . . 0.0 109.487 -178.33 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 63.84 -130.97 39.9 Favored Glycine 0 CA--C 1.507 -0.421 0 CA-C-N 116.305 -0.407 . . . . 0.0 113.287 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -90.07 -6.28 69.46 Favored Glycine 0 C--O 1.199 -2.065 0 C-N-CA 120.523 -0.846 . . . . 0.0 111.187 176.14 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.757 HG21 ' HB ' ' A' ' 126' ' ' ILE . 76.5 t -70.81 -41.63 77.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 122.867 0.467 . . . . 0.0 111.309 -176.442 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.521 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -82.13 -24.67 34.95 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 121.452 0.644 . . . . 0.0 112.367 -179.999 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 28.5 m -101.29 -50.82 3.66 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 114.269 1.211 . . . . 0.0 114.269 -173.636 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.459 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 67.4 m-20 -89.87 -23.76 21.56 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 -176.141 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.674 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 86.1 m-85 -112.35 162.17 15.85 Favored 'General case' 0 N--CA 1.427 -1.601 0 CA-C-O 121.75 0.786 . . . . 0.0 111.42 179.686 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.502 ' HB2' HG13 ' A' ' 112' ' ' VAL . 5.5 m -165.94 140.24 4.52 Favored 'General case' 0 N--CA 1.4 -2.969 0 C-N-CA 125.906 1.683 . . . . 0.0 109.177 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.441 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -172.73 -100.35 0.13 Allowed Glycine 0 C--N 1.279 -2.629 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 174.14 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.427 HG23 ' O ' ' A' ' 73' ' ' GLY . 1.1 p -169.94 179.41 3.62 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 125.655 1.582 . . . . 0.0 109.365 -179.468 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.403 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.5 p -127.96 144.93 36.11 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.788 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 177.475 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.615 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.9 tttt -124.91 143.9 50.62 Favored 'General case' 0 N--CA 1.416 -2.13 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.456 -176.013 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.446 ' CD2' HG22 ' A' ' 105' ' ' VAL . 51.8 t80 -146.69 110.23 4.86 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 114.94 -1.027 . . . . 0.0 108.453 -178.467 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 32.7 t 54.76 39.47 31.39 Favored 'General case' 0 CA--C 1.556 1.202 0 CA-C-O 122.341 1.067 . . . . 0.0 110.86 177.432 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.5 16.93 69.79 Favored Glycine 0 N--CA 1.438 -1.196 0 CA-C-N 115.416 -0.811 . . . . 0.0 113.191 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.615 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 10.8 t -84.99 -179.74 7.12 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.118 -1.068 . . . . 0.0 108.118 175.445 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.0 t -160.25 97.57 1.25 Allowed 'General case' 0 C--N 1.29 -2.008 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 -178.402 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.429 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 3.2 p90 -138.75 159.17 68.38 Favored Pre-proline 0 C--N 1.296 -1.732 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 -174.116 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.406 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 55.4 Cg_endo -68.47 147.27 70.65 Favored 'Trans proline' 0 C--N 1.352 0.729 0 C-N-CA 122.406 2.07 . . . . 0.0 112.799 -174.252 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.618 ' CD2' HD21 ' A' ' 109' ' ' LEU . 63.0 t80 -121.63 130.93 24.56 Favored Pre-proline 0 C--N 1.305 -1.339 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.17 -179.793 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.466 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 73.4 Cg_endo -73.79 147.63 90.04 Favored 'Cis proline' 0 C--O 1.25 1.087 0 C-N-CA 123.117 -1.618 . . . . 0.0 110.093 -2.331 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.6 t -68.16 -177.06 0.8 Allowed 'General case' 0 CA--C 1.548 0.877 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.259 -174.772 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 18.9 p -123.42 -12.44 7.76 Favored 'General case' 0 N--CA 1.435 -1.185 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.279 -173.711 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.8 t -152.05 -124.33 0.04 OUTLIER 'General case' 0 N--CA 1.393 -3.282 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -126.9 -169.15 1.98 Allowed 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 112.249 0.463 . . . . 0.0 112.249 -173.041 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 45.3 p -100.42 170.67 6.36 Favored Pre-proline 0 C--N 1.313 -0.983 0 C-N-CA 123.302 0.641 . . . . 0.0 112.685 179.058 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' PRO . . . . . 0.447 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 19.6 Cg_endo -59.53 166.09 8.47 Favored 'Trans proline' 0 C--O 1.246 0.904 0 C-N-CA 122.976 2.451 . . . . 0.0 111.779 170.46 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.1 tmm_? -80.58 117.99 21.77 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 -178.607 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 69.2 t -127.58 128.51 69.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 CA-C-O 121.353 0.597 . . . . 0.0 111.41 -175.578 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 81.4 t -106.18 138.31 32.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.554 179.536 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.433 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 3.1 m-85 -87.59 116.66 25.86 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 175.054 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -97.72 45.25 1.03 Allowed 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 57.7 m -151.77 125.29 8.9 Favored 'General case' 0 N--CA 1.433 -1.298 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.733 -176.429 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 10.6 ptp180 -102.22 64.02 0.91 Allowed 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 122.044 0.926 . . . . 0.0 111.159 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.8 t -171.22 172.87 5.14 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 -178.438 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -65.12 100.78 0.46 Allowed 'General case' 0 C--N 1.324 -0.508 0 O-C-N 123.71 0.631 . . . . 0.0 110.049 -179.485 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -111.76 138.54 21.61 Favored Pre-proline 0 C--N 1.293 -1.863 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 178.151 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -56.08 148.39 59.17 Favored 'Trans proline' 0 C--O 1.246 0.897 0 C-N-CA 123.27 2.647 . . . . 0.0 112.633 179.09 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' TRP . . . . . 0.433 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.4 t90 -88.9 112.34 50.12 Favored Pre-proline 0 C--N 1.293 -1.849 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 -179.357 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' PRO . . . . . 0.566 ' HA ' ' OG ' ' A' ' 39' ' ' SER . 68.0 Cg_endo -75.58 87.57 1.36 Allowed 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 121.816 1.677 . . . . 0.0 112.426 -173.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.446 HG22 ' CD2' ' A' ' 77' ' ' TYR . 67.0 t -144.61 143.48 22.88 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.435 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 -179.396 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.572 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.14 135.72 17.09 Favored 'General case' 0 N--CA 1.415 -2.214 0 O-C-N 123.705 0.628 . . . . 0.0 110.285 177.768 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.492 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 15.4 mt -100.83 104.71 15.95 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 178.066 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.441 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 12.4 m-85 -81.03 91.92 6.15 Favored 'General case' 0 C--N 1.285 -2.231 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 177.203 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.674 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 2.9 mm? -118.87 120.51 37.53 Favored 'General case' 0 C--N 1.292 -1.932 0 CA-C-O 120.742 0.306 . . . . 0.0 110.179 178.128 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.35 145.78 47.59 Favored Pre-proline 0 N--CA 1.413 -2.306 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.997 -175.085 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.459 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 25.7 Cg_endo -61.7 119.57 6.77 Favored 'Trans proline' 0 C--O 1.247 0.972 0 C-N-CA 123.202 2.601 . . . . 0.0 112.21 -177.776 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.502 HG13 ' HB2' ' A' ' 72' ' ' SER . 3.6 m -67.74 -117.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.188 -2.173 0 CA-C-N 114.09 -1.414 . . . . 0.0 113.081 175.57 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 41.3 t -112.67 -39.54 4.29 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 178.164 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 66.6 m -78.73 30.35 0.2 Allowed 'General case' 0 N--CA 1.392 -3.356 0 CA-C-N 113.596 -1.638 . . . . 0.0 112.952 -177.884 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -111.06 140.09 45.89 Favored 'General case' 0 N--CA 1.411 -2.399 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 177.29 128.27 1.13 Allowed Glycine 0 N--CA 1.438 -1.173 0 N-CA-C 111.385 -0.686 . . . . 0.0 111.385 -178.887 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 65.83 -149.13 51.46 Favored Glycine 0 N--CA 1.443 -0.874 0 CA-C-O 119.02 -0.878 . . . . 0.0 111.408 -176.203 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -54.51 105.8 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 CA-C-O 122.645 1.212 . . . . 0.0 112.741 -177.796 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.55 -31.44 9.44 Favored 'General case' 0 C--N 1.295 -1.789 0 CA-C-N 114.735 -1.12 . . . . 0.0 110.936 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.439 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 54.9 mt -128.18 140.07 50.18 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -179.871 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.461 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.7 mmpt? -115.12 133.9 55.63 Favored 'General case' 0 C--N 1.313 -1.009 0 C-N-CA 122.959 0.504 . . . . 0.0 111.584 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.18 133.34 48.71 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.651 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 86.06 0.35 87.21 Favored Glycine 0 C--O 1.242 0.624 0 C-N-CA 121.282 -0.485 . . . . 0.0 112.203 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 19.9 t -101.93 151.06 22.56 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 -178.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -77.92 123.69 27.09 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 -178.328 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.757 ' HB ' HG21 ' A' ' 67' ' ' VAL . 35.1 pt -110.08 -25.83 3.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 N-CA-C 112.578 0.585 . . . . 0.0 112.578 -178.729 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' ALA . . . . . 0.428 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -162.02 168.97 21.87 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -178.236 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 70.3 t -143.5 115.82 2.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.485 HD11 HD21 ' A' ' 107' ' ' LEU . 68.7 mt -117.79 146.9 43.49 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 178.141 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.531 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.6 mp -125.28 128.35 72.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 C-N-CA 119.727 -0.789 . . . . 0.0 110.42 177.475 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.537 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.0 OUTLIER -102.28 136.42 42.14 Favored 'General case' 0 C--N 1.29 -2.0 0 C-N-CA 123.664 0.786 . . . . 0.0 111.998 -177.352 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 132' ' ' ARG . . . . . 0.604 ' HD3' ' NE2' ' A' ' 59' ' ' GLN . 30.2 mmm180 -95.93 119.36 34.28 Favored 'General case' 0 C--N 1.294 -1.838 0 C-N-CA 124.365 1.066 . . . . 0.0 110.643 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 133' ' ' GLN . . . . . 0.487 ' HG2' HD21 ' A' ' 131' ' ' LEU . 13.8 mm100 -102.63 113.87 27.61 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 172.455 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 33.2 m -140.17 144.32 36.57 Favored 'General case' 0 C--N 1.289 -2.057 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -177.799 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.694 ' CB ' HG23 ' A' ' 52' ' ' ILE . 11.6 p30 . . . . . 0 N--CA 1.435 -1.18 0 C-N-CA 120.059 -0.656 . . . . 0.0 111.161 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 . . . . . 0 N--CA 1.423 -1.784 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 12.9 pt20 -125.71 146.78 49.6 Favored 'General case' 0 N--CA 1.418 -2.065 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.487 -179.721 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.415 ' HB2' HD22 ' A' ' 131' ' ' LEU . 12.3 m-30 -112.51 133.01 54.8 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 108.577 -0.898 . . . . 0.0 108.577 -176.447 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.475 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 59.5 t -89.87 133.74 30.98 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 178.868 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 146' ' ' TRP . . . . . 0.537 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 70.3 m95 -121.84 97.04 5.31 Favored 'General case' 0 C--N 1.284 -2.281 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 -179.112 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 45.0 m-80 -79.17 114.99 18.55 Favored 'General case' 0 C--N 1.288 -2.08 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.428 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 24.7 mm -88.36 120.62 37.55 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 -177.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -116.77 154.54 30.48 Favored 'General case' 0 CA--C 1.49 -1.328 0 C-N-CA 123.278 0.631 . . . . 0.0 110.012 178.504 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.44 129.38 34.62 Favored 'General case' 0 N--CA 1.417 -2.123 0 CA-C-N 115.221 -0.899 . . . . 0.0 109.075 176.78 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' ASN . . . . . 0.456 ' HB3' ' HB3' ' A' ' 23' ' ' ASN . 13.3 t-20 -87.75 -17.19 32.21 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 -178.282 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -153.47 144.04 22.54 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 113.708 -1.587 . . . . 0.0 109.507 -173.41 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -80.87 144.97 31.59 Favored 'General case' 0 C--N 1.317 -0.836 0 O-C-N 124.059 0.85 . . . . 0.0 109.838 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.453 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 74.4 t -121.92 139.26 49.51 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 C-N-CA 122.741 0.416 . . . . 0.0 111.391 -176.156 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.9 t -118.66 141.04 40.17 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 73.2 t -104.05 100.97 23.07 Favored Pre-proline 0 C--N 1.296 -1.719 0 C-N-CA 123.51 0.724 . . . . 0.0 110.116 178.025 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.464 ' HG3' HG13 ' A' ' 27' ' ' VAL . 33.3 Cg_endo -69.23 -23.99 32.62 Favored 'Trans proline' 0 C--O 1.236 0.402 0 C-N-CA 122.35 2.033 . . . . 0.0 111.84 178.68 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.4 t . . . . . 0 C--O 1.239 0.536 0 C-N-CA 125.077 1.351 . . . . 0.0 113.772 177.502 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.512 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.433 -1.299 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 13.7 t -152.06 159.06 43.78 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.391 -0.924 . . . . 0.0 109.848 -176.156 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.513 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -147.0 155.48 42.28 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 121.29 0.567 . . . . 0.0 110.549 -176.352 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 41.2 p -92.43 174.51 7.25 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.222 178.745 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.99 -19.53 47.61 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.053 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -85.08 -33.81 22.36 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 114.784 -1.098 . . . . 0.0 111.856 -176.468 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 136.36 5.71 2.0 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 119.649 -1.262 . . . . 0.0 113.733 173.259 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.9 m -89.33 105.5 17.84 Favored 'General case' 0 N--CA 1.423 -1.782 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -103.47 115.71 31.05 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.026 179.635 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.512 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 55.6 mt -90.69 127.83 50.82 Favored Pre-proline 0 C--N 1.295 -1.763 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -86.01 179.62 3.64 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 122.83 2.353 . . . . 0.0 111.546 177.054 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 58.6 mt -69.42 133.79 31.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 177.071 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 127.6 9.24 4.05 Favored Glycine 0 C--N 1.306 -1.13 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.873 -179.099 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.22 170.19 44.57 Favored Glycine 0 N--CA 1.437 -1.267 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 -177.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.71 -173.85 35.72 Favored Glycine 0 CA--C 1.48 -2.147 0 C-N-CA 119.911 -1.138 . . . . 0.0 111.414 177.836 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 52.5 p -142.29 144.62 33.35 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -133.21 167.09 21.0 Favored 'General case' 0 N--CA 1.423 -1.793 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 178.345 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -120.05 104.69 10.34 Favored 'General case' 0 C--N 1.266 -3.025 0 CA-C-N 114.258 -1.337 . . . . 0.0 108.402 178.522 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.409 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.2 m -89.72 146.78 5.76 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -178.78 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 51.6 m-85 -128.17 115.72 18.82 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 120.859 0.361 . . . . 0.0 111.18 -177.56 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.526 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.6 p -123.35 129.67 74.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 CA-C-O 121.663 0.744 . . . . 0.0 111.201 -176.013 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.3 p30 -86.85 123.42 31.97 Favored 'General case' 0 C--N 1.293 -1.855 0 CA-C-N 115.007 -0.997 . . . . 0.0 108.851 177.897 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 19.5 mt -108.2 160.38 15.88 Favored 'General case' 0 C--N 1.275 -2.656 0 CA-C-N 114.661 -1.154 . . . . 0.0 108.162 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -59.3 118.7 32.75 Favored Pre-proline 0 C--N 1.305 -1.366 0 O-C-N 124.004 0.815 . . . . 0.0 109.869 179.228 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.552 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 56.3 Cg_endo -70.06 -5.22 15.89 Favored 'Trans proline' 0 CA--C 1.54 0.822 0 C-N-CA 122.819 2.346 . . . . 0.0 113.752 -175.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.408 HG13 ' HG3' ' A' ' 157' ' ' PRO . 86.2 t -128.16 111.76 25.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 179.439 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.48 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 10.6 t -146.49 110.58 0.87 Allowed 'Isoleucine or valine' 0 C--O 1.191 -2.014 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -178.059 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.766 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -96.53 155.73 16.64 Favored 'General case' 0 C--N 1.278 -2.51 0 C-N-CA 124.009 0.924 . . . . 0.0 111.404 -178.678 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.626 HG22 ' O ' ' A' ' 112' ' ' VAL . 89.2 t -46.41 122.88 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 123.121 0.568 . . . . 0.0 111.358 176.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.11 4.8 61.13 Favored Glycine 0 C--N 1.31 -0.911 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.498 178.71 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.766 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -77.35 -176.26 4.08 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 124.345 1.058 . . . . 0.0 109.648 177.673 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 65.3 t30 -132.48 92.11 3.03 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.572 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 21.9 tp -93.67 142.7 27.06 Favored 'General case' 0 C--N 1.299 -1.63 0 C-N-CA 120.04 -0.664 . . . . 0.0 109.408 178.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 52.7 t -134.97 118.47 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.967 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 -175.769 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.59 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 48.7 t -90.6 88.1 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.876 0 N-CA-C 105.586 -2.005 . . . . 0.0 105.586 174.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -85.4 112.41 20.83 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-O 120.973 0.416 . . . . 0.0 110.598 -177.76 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 83.6 mt -96.11 -3.13 45.16 Favored 'General case' 0 C--N 1.299 -1.627 0 CA-C-N 115.006 -0.997 . . . . 0.0 110.419 -177.639 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.606 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 1.9 m -73.42 1.1 10.42 Favored 'General case' 0 CA--C 1.55 0.955 0 CA-C-O 121.903 0.859 . . . . 0.0 109.47 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.3 p -130.58 6.76 4.8 Favored 'General case' 0 N--CA 1.424 -1.738 0 C-N-CA 124.286 1.034 . . . . 0.0 109.993 178.195 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.526 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 48.4 mm-40 -123.99 -19.87 5.53 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-O 121.085 0.469 . . . . 0.0 110.585 -175.179 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 36.8 mt -134.85 135.07 53.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -176.021 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.513 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 47.7 m-85 -139.11 121.58 16.15 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 120.928 0.394 . . . . 0.0 110.302 -175.475 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 71.1 m -104.54 140.05 38.54 Favored 'General case' 0 C--N 1.286 -2.175 0 CA-C-O 121.097 0.475 . . . . 0.0 110.256 -177.378 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' HIS . . . . . 0.474 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 25.2 p-80 -131.12 151.85 51.02 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 121.781 0.801 . . . . 0.0 112.589 -172.269 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.459 ' HB3' ' OD2' ' A' ' 54' ' ' ASP . 19.0 p30 -103.59 127.7 50.97 Favored 'General case' 0 N--CA 1.405 -2.692 0 CA-C-O 122.607 1.194 . . . . 0.0 110.6 174.886 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -94.14 -28.43 15.69 Favored 'General case' 0 C--N 1.268 -2.961 0 CA-C-N 113.429 -1.714 . . . . 0.0 108.945 -179.249 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -135.58 71.45 65.37 Favored Pre-proline 0 C--N 1.311 -1.084 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.343 178.132 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -69.97 3.56 2.8 Favored 'Trans proline' 0 N--CA 1.493 1.454 0 C-N-CA 123.425 2.75 . . . . 0.0 113.648 -174.894 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -120.12 -18.81 7.98 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 121.198 0.523 . . . . 0.0 110.093 -179.455 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.52 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.1 m -103.08 -30.06 10.97 Favored 'General case' 0 N--CA 1.422 -1.831 0 CA-C-O 122.016 0.913 . . . . 0.0 109.148 -173.335 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.609 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.6 mp -124.38 131.55 72.63 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 CA-C-N 114.811 -1.086 . . . . 0.0 108.173 -178.484 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.0 t -77.25 140.46 40.09 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 106.668 -1.605 . . . . 0.0 106.668 176.599 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.549 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 8.0 m-20 -82.75 107.45 15.39 Favored 'General case' 0 C--N 1.283 -2.322 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 -178.203 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 29.4 t80 -137.95 128.25 26.16 Favored 'General case' 0 C--N 1.272 -2.771 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -179.765 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.9 p -147.43 149.5 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.327 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -177.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -148.21 133.92 18.89 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 175.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.527 HD23 ' O ' ' A' ' 130' ' ' ILE . 0.7 OUTLIER -68.87 113.0 5.9 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 103.717 -2.697 . . . . 0.0 103.717 171.404 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.439 ' O ' ' HA ' ' A' ' 89' ' ' GLU . 3.4 tp-100 -57.76 -64.29 0.95 Allowed 'General case' 0 C--O 1.198 -1.628 0 C-N-CA 125.893 1.677 . . . . 0.0 109.822 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -165.08 154.15 12.52 Favored 'General case' 0 N--CA 1.424 -1.75 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 -175.725 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -120.82 164.28 14.18 Favored Glycine 0 N--CA 1.43 -1.728 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 -178.572 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 66.2 m -145.56 144.14 30.33 Favored 'General case' 0 C--N 1.286 -2.165 0 N-CA-C 108.455 -0.942 . . . . 0.0 108.455 178.064 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.588 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -113.15 156.83 22.52 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.5 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 98.5 m-85 -155.2 -179.43 8.07 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 123.849 0.86 . . . . 0.0 110.002 -176.331 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.41 -140.58 42.76 Favored Glycine 0 N--CA 1.461 0.353 0 O-C-N 123.753 0.658 . . . . 0.0 113.126 178.816 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.78 -10.28 86.33 Favored Glycine 0 C--O 1.209 -1.444 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.525 177.106 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.807 HG21 ' HB ' ' A' ' 126' ' ' ILE . 91.6 t -68.43 -38.48 79.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 C-N-CA 123.82 0.848 . . . . 0.0 111.697 -176.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.588 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.25 -18.18 32.76 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.422 -0.911 . . . . 0.0 112.198 178.388 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 16.1 t -100.55 -59.41 1.71 Allowed 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.887 -173.086 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.509 ' O ' HG22 ' A' ' 112' ' ' VAL . 37.1 m-20 -90.36 -26.51 19.89 Favored 'General case' 0 CA--C 1.493 -1.222 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.167 -172.339 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.686 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 90.1 m-85 -103.98 150.64 24.04 Favored 'General case' 0 N--CA 1.42 -1.951 0 C-N-CA 119.726 -0.789 . . . . 0.0 108.888 176.734 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.3 t -160.88 119.88 2.58 Favored 'General case' 0 N--CA 1.421 -1.881 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 177.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.538 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -152.68 -107.0 0.31 Allowed Glycine 0 N--CA 1.424 -2.139 0 N-CA-C 111.386 -0.685 . . . . 0.0 111.386 177.045 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -164.18 -179.5 6.19 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 124.689 1.195 . . . . 0.0 109.748 -175.253 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.451 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.8 p -132.52 146.48 32.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.175 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.662 ' HG3' ' O ' ' A' ' 80' ' ' SER . 79.7 tttt -121.49 147.69 45.44 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.026 -178.58 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.546 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 63.4 t80 -145.66 109.79 4.91 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -179.795 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 23.0 t 52.16 37.6 22.17 Favored 'General case' 0 CA--C 1.55 0.972 0 C-N-CA 123.629 0.772 . . . . 0.0 111.544 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.81 10.38 63.08 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 120.62 -0.8 . . . . 0.0 113.644 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.662 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 15.4 t -83.3 179.0 7.81 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 177.387 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.4 t -156.07 108.42 2.59 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.779 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.546 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 6.8 p90 -149.39 164.42 21.07 Favored Pre-proline 0 C--N 1.306 -1.314 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 -173.889 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.468 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 97.4 Cg_endo -72.29 149.21 50.77 Favored 'Trans proline' 0 C--N 1.362 1.238 0 C-N-CA 122.224 1.949 . . . . 0.0 113.669 -175.36 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.631 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 55.5 t80 -119.33 133.48 23.76 Favored Pre-proline 0 N--CA 1.428 -1.55 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.894 178.677 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.631 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 61.6 Cg_endo -72.18 146.8 87.13 Favored 'Cis proline' 0 N--CA 1.477 0.539 0 C-N-CA 123.016 -1.66 . . . . 0.0 111.389 -2.315 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.7 t -71.77 179.83 2.96 Favored 'General case' 0 C--O 1.246 0.881 0 C-N-CA 119.776 -0.77 . . . . 0.0 109.075 -178.625 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 45.2 p -131.74 -39.09 1.12 Allowed 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 114.087 1.143 . . . . 0.0 114.087 -170.449 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 23.0 t -102.29 -69.45 0.79 Allowed 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 -172.616 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' GLU . . . . . 0.439 ' HA ' ' O ' ' A' ' 59' ' ' GLN . 0.3 OUTLIER -178.58 -176.2 0.47 Allowed 'General case' 0 N--CA 1.437 -1.112 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 179.378 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.458 ' HB ' ' HD2' ' A' ' 91' ' ' PRO . 1.9 p -101.11 174.81 2.68 Favored Pre-proline 0 C--N 1.286 -2.158 0 C-N-CA 123.19 0.596 . . . . 0.0 111.977 178.885 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' PRO . . . . . 0.458 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 22.3 Cg_endo -60.06 158.53 29.51 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 122.47 2.113 . . . . 0.0 111.439 171.47 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.3 tmm_? -77.03 114.14 15.51 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-N 114.836 -1.074 . . . . 0.0 108.781 -176.63 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 85.1 t -124.94 129.24 73.48 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 CA-C-O 121.544 0.687 . . . . 0.0 111.843 -177.379 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 66.2 t -114.25 123.74 70.22 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.253 177.708 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.549 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.7 m-85 -73.85 133.32 43.16 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 175.751 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 -117.73 55.05 0.88 Allowed 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 174.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' SER . . . . . 0.562 ' CB ' ' HG3' ' A' ' 101' ' ' LYS . 50.6 m -135.3 175.59 9.45 Favored 'General case' 0 N--CA 1.434 -1.228 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 -177.458 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -142.93 55.58 1.39 Allowed 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 122.033 0.92 . . . . 0.0 111.536 177.226 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.1 t -171.28 176.06 4.02 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 106.715 -1.587 . . . . 0.0 106.715 179.233 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ASP . . . . . 0.474 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 11.0 p-10 -72.02 99.33 2.25 Favored 'General case' 0 CA--C 1.501 -0.937 0 CA-C-O 122.503 1.144 . . . . 0.0 109.608 177.395 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' LYS . . . . . 0.562 ' HG3' ' CB ' ' A' ' 97' ' ' SER . 57.4 mmtt -102.37 138.61 19.74 Favored Pre-proline 0 N--CA 1.415 -2.187 0 CA-C-N 113.524 -1.671 . . . . 0.0 110.277 -176.519 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.606 ' HB3' ' O ' ' A' ' 39' ' ' SER . 53.6 Cg_exo -49.67 139.54 31.01 Favored 'Trans proline' 0 N--CA 1.448 -1.202 0 C-N-CA 124.018 3.145 . . . . 0.0 112.86 -179.511 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.7 t90 -89.59 102.83 4.98 Favored Pre-proline 0 C--N 1.296 -1.751 0 N-CA-C 104.999 -2.223 . . . . 0.0 104.999 176.461 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' PRO . . . . . 0.436 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 74.4 Cg_endo -75.55 88.72 1.26 Allowed 'Trans proline' 0 N--CA 1.451 -1.02 0 C-N-CA 121.877 1.718 . . . . 0.0 113.116 -170.411 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.412 HG22 ' HD1' ' A' ' 77' ' ' TYR . 94.2 t -138.52 143.93 31.33 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.59 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -149.04 133.78 17.85 Favored 'General case' 0 C--N 1.289 -2.025 0 CA-C-O 120.81 0.338 . . . . 0.0 110.251 178.046 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.537 HD21 HD11 ' A' ' 129' ' ' LEU . 17.4 mt -101.19 102.9 13.9 Favored 'General case' 0 C--N 1.288 -2.097 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.752 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.538 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 32.3 m-85 -83.4 77.62 9.78 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 177.828 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.686 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.3 mm? -102.38 124.98 48.92 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 176.362 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -129.69 145.96 59.2 Favored Pre-proline 0 N--CA 1.406 -2.669 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 -174.709 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.436 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 34.0 Cg_endo -62.82 124.59 14.34 Favored 'Trans proline' 0 CA--C 1.497 -1.327 0 C-N-CA 123.038 2.492 . . . . 0.0 113.341 -176.101 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.626 ' O ' HG22 ' A' ' 30' ' ' VAL . 15.9 m -84.56 -155.45 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.399 -3.02 0 CA-C-N 114.246 -1.343 . . . . 0.0 108.161 172.017 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.7 t -83.38 -28.97 28.56 Favored 'General case' 0 C--N 1.263 -3.19 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -170.148 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 25.7 t -84.13 30.02 0.54 Allowed 'General case' 0 N--CA 1.426 -1.665 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.313 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -112.81 138.79 49.12 Favored 'General case' 0 N--CA 1.424 -1.736 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.069 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -177.28 135.91 2.94 Favored Glycine 0 N--CA 1.44 -1.063 0 N-CA-C 111.607 -0.597 . . . . 0.0 111.607 179.493 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 63.33 -152.34 47.36 Favored Glycine 0 CA--C 1.5 -0.853 0 CA-C-O 119.387 -0.674 . . . . 0.0 112.577 -178.735 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 57.7 t -60.56 98.72 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.248 0.98 0 CA-C-O 122.222 1.011 . . . . 0.0 111.161 -176.513 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.06 -24.1 15.48 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-N 114.147 -1.388 . . . . 0.0 110.756 -176.503 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.533 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.4 mt -133.63 137.58 52.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 178.47 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.46 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.3 mmpt? -114.57 138.74 50.27 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-O 120.914 0.387 . . . . 0.0 110.871 177.78 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.31 135.15 50.02 Favored 'General case' 0 N--CA 1.442 -0.851 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 178.578 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 88.12 -6.63 83.27 Favored Glycine 0 C--N 1.308 -0.974 0 N-CA-C 111.628 -0.589 . . . . 0.0 111.628 -179.343 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 64.9 m -96.78 149.28 22.01 Favored 'General case' 0 N--CA 1.427 -1.601 0 CA-C-O 121.285 0.564 . . . . 0.0 110.089 179.471 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.437 HD11 HG23 ' A' ' 128' ' ' VAL . 3.2 tm? -78.98 125.0 28.8 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-N 114.782 -1.099 . . . . 0.0 108.587 -176.844 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.807 ' HB ' HG21 ' A' ' 67' ' ' VAL . 36.4 pt -109.61 -26.3 3.26 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -177.8 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.21 167.53 23.89 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -177.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.437 HG23 HD11 ' A' ' 125' ' ' LEU . 69.3 t -142.37 116.07 4.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 178.725 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.537 HD11 HD21 ' A' ' 107' ' ' LEU . 40.4 mt -119.29 147.91 43.76 Favored 'General case' 0 C--N 1.291 -1.976 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 179.183 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.585 HG21 HE21 ' A' ' 143' ' ' GLN . 5.4 mp -124.75 133.4 69.52 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 C-N-CA 119.53 -0.868 . . . . 0.0 110.653 177.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.572 HD22 ' HB2' ' A' ' 144' ' ' PHE . 0.0 OUTLIER -100.35 135.67 41.43 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 175.971 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 132' ' ' ARG . . . . . 0.508 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 8.4 tpt180 -106.81 120.48 42.12 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 45.3 tp60 -102.08 121.84 42.96 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 177.734 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 18.8 m -140.04 137.86 34.94 Favored 'General case' 0 C--N 1.291 -1.962 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 -179.502 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.609 ' CB ' HG23 ' A' ' 52' ' ' ILE . 8.7 p30 . . . . . 0 N--CA 1.442 -0.838 0 C-N-CA 118.809 -1.156 . . . . 0.0 112.389 179.018 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 . . . . . 0 N--CA 1.437 -1.111 0 N-CA-C 108.542 -0.911 . . . . 0.0 108.542 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 143' ' ' GLN . . . . . 0.585 HE21 HG21 ' A' ' 130' ' ' ILE . 19.4 pt20 -116.27 144.39 44.29 Favored 'General case' 0 C--N 1.295 -1.778 0 C-N-CA 119.981 -0.688 . . . . 0.0 111.409 176.215 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.572 ' HB2' HD22 ' A' ' 131' ' ' LEU . 3.7 m-30 -110.72 131.53 54.97 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 -178.104 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 49.6 t -90.98 130.53 40.01 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.897 0 O-C-N 123.553 0.533 . . . . 0.0 109.784 -179.456 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 146' ' ' TRP . . . . . 0.543 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.9 m95 -117.93 95.16 4.8 Favored 'General case' 0 C--N 1.279 -2.496 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 -179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -77.62 114.79 16.82 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.308 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.409 ' HA ' HG22 ' A' ' 20' ' ' VAL . 23.2 mm -89.26 122.41 40.55 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.794 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -177.436 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 149' ' ' TYR . . . . . 0.412 ' CZ ' HD23 ' A' ' 125' ' ' LEU . 89.1 m-85 -118.27 152.83 35.0 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 121.509 0.671 . . . . 0.0 110.241 178.871 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -80.6 129.39 34.49 Favored 'General case' 0 N--CA 1.41 -2.472 0 CA-C-N 114.807 -1.088 . . . . 0.0 108.33 176.19 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 29.3 t-20 -91.7 -10.26 40.8 Favored 'General case' 0 C--N 1.29 -2.004 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 -177.839 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -155.09 145.83 22.37 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 113.991 -1.459 . . . . 0.0 109.19 -176.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -80.52 147.29 30.91 Favored 'General case' 0 C--N 1.323 -0.57 0 O-C-N 124.054 0.846 . . . . 0.0 110.861 -178.889 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.552 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.3 t -124.21 135.16 64.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.13 -177.68 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.9 t -117.74 135.98 56.4 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 79.4 t -98.54 103.21 17.39 Favored Pre-proline 0 C--N 1.295 -1.803 0 C-N-CA 123.464 0.706 . . . . 0.0 109.883 178.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.483 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 44.1 Cg_endo -71.26 -21.03 27.34 Favored 'Trans proline' 0 CA--C 1.516 -0.396 0 C-N-CA 122.172 1.915 . . . . 0.0 111.633 179.178 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 2.4 t . . . . . 0 C--O 1.249 1.073 0 C-N-CA 124.79 1.236 . . . . 0.0 114.061 176.874 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.496 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.434 -1.27 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.49 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 73.2 m -138.58 160.08 40.48 Favored 'General case' 0 C--N 1.3 -1.558 0 C-N-CA 119.624 -0.83 . . . . 0.0 111.591 -175.517 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.9 pptp? -144.43 159.53 42.58 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 122.747 0.419 . . . . 0.0 110.412 -178.123 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.509 HG22 HG22 ' A' ' 20' ' ' VAL . 81.5 p -95.51 176.57 6.12 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 121.433 0.635 . . . . 0.0 112.011 -178.518 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -76.76 -24.14 52.94 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.202 177.815 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -81.1 -33.54 33.24 Favored 'General case' 0 N--CA 1.448 -0.544 0 C-N-CA 119.272 -0.971 . . . . 0.0 109.549 179.247 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.82 17.86 1.15 Allowed Glycine 0 N--CA 1.439 -1.131 0 C-N-CA 119.699 -1.238 . . . . 0.0 113.404 175.852 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.9 m -88.69 99.75 12.59 Favored 'General case' 0 N--CA 1.431 -1.383 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.56 120.59 32.49 Favored 'General case' 0 C--N 1.291 -1.971 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.38 178.003 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.496 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 62.2 mt -102.25 115.69 64.16 Favored Pre-proline 0 C--N 1.288 -2.078 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 176.723 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -79.88 -179.81 5.63 Favored 'Trans proline' 0 N--CA 1.443 -1.445 0 C-N-CA 122.46 2.107 . . . . 0.0 111.189 177.044 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.9 mt -66.93 147.71 12.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.063 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.55 24.2 5.97 Favored Glycine 0 C--N 1.315 -0.615 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.517 178.799 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.0 173.17 49.45 Favored Glycine 0 C--N 1.316 -0.539 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 -178.873 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 159.03 -177.91 35.41 Favored Glycine 0 N--CA 1.431 -1.68 0 C-N-CA 120.283 -0.96 . . . . 0.0 111.497 177.053 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 25.5 p -151.54 141.46 22.02 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -178.073 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.9 160.46 38.83 Favored 'General case' 0 N--CA 1.425 -1.718 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 27.7 m-80 -112.83 109.05 18.27 Favored 'General case' 0 C--N 1.289 -2.037 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 177.344 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.509 HG22 HG22 ' A' ' 5' ' ' THR . 43.2 t -94.09 137.18 23.52 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.245 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.483 -177.842 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 50.4 m-85 -122.83 115.69 22.41 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 120.919 0.39 . . . . 0.0 110.832 -177.201 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.458 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -125.65 132.9 70.32 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.244 -174.371 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -87.78 130.41 34.86 Favored 'General case' 0 C--N 1.298 -1.663 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.21 177.893 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.415 HD11 HG22 ' A' ' 36' ' ' VAL . 2.7 mm? -111.6 160.31 17.33 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 175.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.79 121.95 48.53 Favored Pre-proline 0 C--O 1.21 -1.016 0 O-C-N 124.235 0.959 . . . . 0.0 109.196 175.499 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 69.9 Cg_endo -74.76 -5.23 16.57 Favored 'Trans proline' 0 C--O 1.217 -0.542 0 C-N-CA 122.781 2.321 . . . . 0.0 113.555 -175.864 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.3 t -126.39 109.54 21.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.495 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 8.1 t -145.36 112.47 1.28 Allowed 'Isoleucine or valine' 0 C--O 1.186 -2.256 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 -176.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.662 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -101.09 156.14 17.59 Favored 'General case' 0 C--N 1.274 -2.68 0 C-N-CA 123.214 0.606 . . . . 0.0 111.474 179.657 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 38.0 t -45.51 120.55 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 C-N-CA 123.471 0.709 . . . . 0.0 112.019 176.621 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 99.82 0.74 56.32 Favored Glycine 0 CA--C 1.52 0.371 0 CA-C-N 115.542 -0.754 . . . . 0.0 112.825 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.662 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -73.11 -177.41 2.47 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 124.384 1.074 . . . . 0.0 110.977 177.706 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 66.6 t30 -127.38 92.9 3.6 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 107.769 -1.196 . . . . 0.0 107.769 177.323 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.606 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 20.2 tp -101.72 134.86 44.21 Favored 'General case' 0 C--N 1.283 -2.309 0 C-N-CA 118.725 -1.19 . . . . 0.0 109.381 176.843 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.9 p -141.96 132.38 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.386 -3.646 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.927 -178.135 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.578 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 42.2 t -92.12 89.95 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.55 0 CA-C-N 113.86 -1.518 . . . . 0.0 108.029 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -74.45 112.14 10.33 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 88.8 mt -95.68 1.03 53.31 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.026 0.441 . . . . 0.0 111.284 -179.638 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 38.9 t -77.98 0.65 23.53 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 122.086 0.946 . . . . 0.0 109.439 -178.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.9 p -124.59 0.52 8.19 Favored 'General case' 0 C--N 1.281 -2.393 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.134 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.458 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 49.2 mm-40 -120.96 -24.56 5.57 Favored 'General case' 0 CA--C 1.504 -0.816 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.66 -172.744 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 18.2 mt -132.86 139.14 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 -176.206 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.418 ' HA ' ' HA ' ' A' ' 102' ' ' PRO . 78.3 m-85 -134.2 161.14 35.73 Favored 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 -176.648 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.49 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 81.0 m -141.94 141.79 32.97 Favored 'General case' 0 C--N 1.284 -2.244 0 C-N-CA 122.886 0.475 . . . . 0.0 109.998 -177.068 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.6 p80 -145.3 156.69 43.96 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-O 121.312 0.577 . . . . 0.0 111.052 -174.272 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 2.9 p30 -107.42 121.06 43.83 Favored 'General case' 0 C--N 1.295 -1.783 0 CA-C-O 122.479 1.133 . . . . 0.0 113.304 178.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 13.7 p-10 -90.97 -23.37 20.44 Favored 'General case' 0 N--CA 1.42 -1.959 0 CA-C-N 113.417 -1.72 . . . . 0.0 109.529 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.419 ' HB2' HD13 ' A' ' 52' ' ' ILE . 60.7 m-85 -138.57 64.61 37.78 Favored Pre-proline 0 N--CA 1.472 0.636 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.871 176.157 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -67.5 -17.16 48.62 Favored 'Trans proline' 0 N--CA 1.481 0.784 0 C-N-CA 122.159 1.906 . . . . 0.0 112.787 -176.263 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -94.44 -27.63 15.91 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.903 -175.927 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.566 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -97.84 -30.41 12.78 Favored 'General case' 0 N--CA 1.413 -2.278 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 -171.344 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.566 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.1 mp -119.57 141.4 39.79 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 CA-C-N 114.158 -1.383 . . . . 0.0 108.963 -176.73 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 5.4 t -88.89 131.94 34.9 Favored 'General case' 0 C--O 1.259 1.578 0 N-CA-C 104.09 -2.559 . . . . 0.0 104.09 171.439 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 34.0 m-20 -93.78 107.27 19.17 Favored 'General case' 0 C--N 1.271 -2.815 0 C-N-CA 118.952 -1.099 . . . . 0.0 110.152 -169.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 28.9 t80 -127.06 143.11 51.37 Favored 'General case' 0 C--N 1.289 -2.055 0 CA-C-N 114.04 -1.437 . . . . 0.0 108.908 -175.665 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.532 HG23 ' HG ' ' A' ' 131' ' ' LEU . 8.1 p -150.6 145.25 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.313 0 O-C-N 123.615 0.572 . . . . 0.0 110.087 -179.76 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.6 p -147.42 131.59 17.38 Favored 'General case' 0 N--CA 1.436 -1.129 0 C-N-CA 123.075 0.55 . . . . 0.0 109.769 174.527 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.457 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 1.1 tm? -71.2 102.14 2.46 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 175.091 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 8.3 tp60 -52.53 -50.55 62.62 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 127.12 2.168 . . . . 0.0 111.697 -176.772 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 3.9 ptp180 -171.17 160.17 6.21 Favored 'General case' 0 N--CA 1.425 -1.684 0 CA-C-N 114.467 -1.242 . . . . 0.0 109.289 -176.497 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -135.84 148.22 19.55 Favored Glycine 0 N--CA 1.41 -3.097 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 179.553 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 63.2 m -129.38 143.81 50.99 Favored 'General case' 0 C--N 1.279 -2.469 0 C-N-CA 123.228 0.611 . . . . 0.0 109.573 -178.681 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.508 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -111.29 155.62 22.75 Favored 'General case' 0 CA--C 1.502 -0.87 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.469 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 68.0 m-85 -157.45 -178.52 7.4 Favored 'General case' 0 C--O 1.238 0.494 0 C-N-CA 124.235 1.014 . . . . 0.0 108.313 -177.765 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 62.45 -141.71 47.25 Favored Glycine 0 N--CA 1.453 -0.191 0 O-C-N 123.333 0.396 . . . . 0.0 112.707 177.611 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.24 -7.84 87.18 Favored Glycine 0 C--O 1.208 -1.482 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 177.811 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.805 HG21 ' HB ' ' A' ' 126' ' ' ILE . 86.6 t -69.72 -38.64 76.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 C-N-CA 123.752 0.821 . . . . 0.0 111.339 -176.488 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.508 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -85.44 -22.8 28.14 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 119.306 -0.957 . . . . 0.0 112.063 179.441 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 9.3 t -100.63 -51.39 3.61 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.144 0.497 . . . . 0.0 112.265 -172.625 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.487 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 47.7 m-20 -90.8 -24.57 20.28 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -174.732 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.663 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 89.2 m-85 -111.52 156.49 21.64 Favored 'General case' 0 N--CA 1.42 -1.951 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.292 179.104 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.5 t -162.97 138.57 6.89 Favored 'General case' 0 N--CA 1.406 -2.651 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 176.599 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.519 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.36 -104.65 0.18 Allowed Glycine 0 N--CA 1.409 -3.146 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 175.338 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.2 p -165.3 -179.86 5.83 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 124.547 1.139 . . . . 0.0 110.137 -176.261 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.413 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.7 p -131.81 145.33 35.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 123.313 0.645 . . . . 0.0 109.467 178.411 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.672 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.2 tttt -122.23 149.52 43.56 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.478 -177.614 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.461 ' CD2' HG22 ' A' ' 105' ' ' VAL . 60.8 t80 -150.15 113.09 4.81 Favored 'General case' 0 C--O 1.214 -0.777 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 22.7 t 56.92 30.23 17.64 Favored 'General case' 0 CA--C 1.554 1.108 0 CA-C-O 121.884 0.85 . . . . 0.0 111.286 176.872 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.33 13.69 59.76 Favored Glycine 0 N--CA 1.437 -1.273 0 C-N-CA 120.208 -0.996 . . . . 0.0 113.086 -177.856 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.672 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 21.2 t -83.95 -179.35 7.24 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 175.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 8.2 t -157.37 110.48 2.51 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 179.152 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.47 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 7.4 p90 -149.68 162.52 28.11 Favored Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -174.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.47 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 72.7 Cg_endo -68.2 149.08 75.91 Favored 'Trans proline' 0 C--N 1.36 1.174 0 C-N-CA 122.671 2.248 . . . . 0.0 113.528 -175.266 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.617 ' CD2' HD21 ' A' ' 109' ' ' LEU . 60.2 t80 -124.31 134.54 25.57 Favored Pre-proline 0 N--CA 1.442 -0.839 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.193 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.582 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 57.4 Cg_endo -70.57 145.08 80.29 Favored 'Cis proline' 0 C--O 1.239 0.568 0 C-N-CA 123.099 -1.625 . . . . 0.0 110.633 -3.255 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.7 t -73.65 -177.63 2.8 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -177.664 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 41.2 p -131.77 -35.87 1.24 Allowed 'General case' 0 N--CA 1.424 -1.772 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -172.438 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 49.5 m -110.1 -162.21 0.79 Allowed 'General case' 1 N--CA 1.317 -7.114 0 CA-C-N 113.45 -1.704 . . . . 0.0 107.663 179.265 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 27.0 tt0 -116.21 151.32 35.96 Favored 'General case' 1 C--N 1.244 -4.011 0 CA-C-N 113.443 -1.708 . . . . 0.0 109.115 -168.639 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.457 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 46.8 p -67.75 161.17 68.76 Favored Pre-proline 0 C--N 1.296 -1.748 0 C-N-CA 124.494 1.117 . . . . 0.0 113.245 -177.642 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -56.86 159.86 13.48 Favored 'Trans proline' 0 C--N 1.355 0.876 0 C-N-CA 124.068 3.179 . . . . 0.0 111.749 175.454 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.5 tmm_? -67.88 116.74 8.88 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.667 -176.024 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 72.7 t -132.05 137.18 55.31 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 C-N-CA 123.848 0.859 . . . . 0.0 108.687 -176.223 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.0 p -136.59 132.94 48.85 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.628 -175.191 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -82.9 101.5 11.06 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 120.937 0.398 . . . . 0.0 110.917 -178.395 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 36.7 m-80 -92.29 55.12 2.48 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-O 121.996 0.903 . . . . 0.0 108.837 176.196 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.3 m -145.4 128.63 16.74 Favored 'General case' 0 N--CA 1.428 -1.566 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 -178.239 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.5 ptm180 -104.51 63.7 0.74 Allowed 'General case' 0 C--N 1.304 -1.378 0 CA-C-O 122.643 1.211 . . . . 0.0 109.609 -179.091 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' THR . . . . . 0.405 HG23 ' HD3' ' A' ' 101' ' ' LYS . 10.1 t -170.41 -179.5 3.04 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 -172.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -86.25 124.81 33.04 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' LYS . . . . . 0.411 ' HD2' ' HA ' ' A' ' 101' ' ' LYS . 6.8 mptt -127.32 143.9 48.84 Favored Pre-proline 0 C--N 1.277 -2.561 0 C-N-CA 124.463 1.105 . . . . 0.0 109.273 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.418 ' HA ' ' HA ' ' A' ' 43' ' ' PHE . 41.0 Cg_endo -68.23 147.27 72.12 Favored 'Trans proline' 0 C--O 1.244 0.787 0 C-N-CA 122.891 2.394 . . . . 0.0 112.12 178.118 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.2 t90 -85.56 107.45 12.47 Favored Pre-proline 0 C--N 1.323 -0.544 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 -177.287 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -76.73 88.2 1.4 Allowed 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 121.518 1.479 . . . . 0.0 112.905 -172.495 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.461 HG22 ' CD2' ' A' ' 77' ' ' TYR . 68.2 t -137.54 153.96 29.1 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.144 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 178.102 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.578 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -160.05 137.4 9.55 Favored 'General case' 0 CA--C 1.475 -1.94 0 O-C-N 123.406 0.441 . . . . 0.0 110.182 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.469 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 18.9 mt -105.79 99.85 9.43 Favored 'General case' 0 C--N 1.286 -2.171 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.388 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.519 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 42.4 m-85 -79.78 77.2 6.42 Favored 'General case' 0 C--N 1.313 -0.995 0 O-C-N 122.041 -0.412 . . . . 0.0 110.105 177.943 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.663 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.1 mm? -102.48 119.74 39.34 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-O 120.926 0.393 . . . . 0.0 110.219 177.653 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.54 147.39 52.74 Favored Pre-proline 0 N--CA 1.419 -1.98 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.725 -174.558 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.487 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 29.9 Cg_endo -62.24 118.55 5.44 Favored 'Trans proline' 0 C--O 1.246 0.899 0 C-N-CA 123.185 2.59 . . . . 0.0 112.835 -177.13 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.443 HG22 ' H ' ' A' ' 112' ' ' VAL . 2.8 m -68.46 -116.43 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.192 -1.923 0 CA-C-N 114.007 -1.451 . . . . 0.0 112.71 175.52 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 22.8 t -112.21 -39.53 4.42 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.267 -0.895 . . . . 0.0 109.541 177.367 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 31.5 t -84.33 29.41 0.58 Allowed 'General case' 0 C--N 1.317 -0.804 0 C-N-CA 123.536 0.734 . . . . 0.0 111.342 -175.095 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -101.93 133.18 47.13 Favored 'General case' 0 N--CA 1.422 -1.84 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.336 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.97 139.84 5.19 Favored Glycine 0 N--CA 1.434 -1.436 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.017 178.19 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 59.71 -144.37 46.19 Favored Glycine 0 CA--C 1.495 -1.214 0 CA-C-O 119.288 -0.729 . . . . 0.0 112.738 -179.083 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.3 p -59.24 96.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 122.753 1.263 . . . . 0.0 111.575 -178.31 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.44 -25.85 14.65 Favored 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 114.754 -1.112 . . . . 0.0 111.49 -177.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.451 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 61.4 mt -134.72 139.66 47.14 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.326 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 3.7 mmpt? -114.85 137.32 52.1 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-O 121.089 0.471 . . . . 0.0 111.4 179.474 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.06 122.52 20.21 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.379 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 93.6 3.57 64.47 Favored Glycine 0 C--N 1.309 -0.948 0 N-CA-C 111.595 -0.602 . . . . 0.0 111.595 -177.458 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 32.9 t -102.21 143.62 31.77 Favored 'General case' 0 C--O 1.253 1.246 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 178.538 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.431 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -72.28 124.72 25.67 Favored 'General case' 0 N--CA 1.444 -0.727 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.805 ' HB ' HG21 ' A' ' 67' ' ' VAL . 39.0 pt -109.93 -27.43 2.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 N-CA-C 112.423 0.527 . . . . 0.0 112.423 -178.686 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' ALA . . . . . 0.4 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.68 167.62 24.79 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 -177.679 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.431 HG23 HD11 ' A' ' 125' ' ' LEU . 71.2 t -142.97 116.38 3.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.576 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.44 HD11 HD21 ' A' ' 107' ' ' LEU . 59.9 mt -115.95 143.01 46.02 Favored 'General case' 0 C--N 1.288 -2.08 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 179.536 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.31 118.44 53.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 C-N-CA 119.402 -0.919 . . . . 0.0 110.322 179.184 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.532 ' HG ' HG23 ' A' ' 56' ' ' VAL . 0.1 OUTLIER -88.76 150.09 23.12 Favored 'General case' 0 C--N 1.268 -2.957 0 C-N-CA 124.838 1.255 . . . . 0.0 108.485 178.227 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 19.3 ttp85 -123.38 137.4 54.83 Favored 'General case' 0 N--CA 1.414 -2.269 0 O-C-N 123.255 0.347 . . . . 0.0 111.549 178.443 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' GLN . . . . . 0.411 ' OE1' HD21 ' A' ' 131' ' ' LEU . 13.3 mm100 -113.01 115.44 28.38 Favored 'General case' 0 N--CA 1.431 -1.398 0 CA-C-N 115.079 -0.964 . . . . 0.0 110.622 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 4.5 m -133.33 130.86 39.43 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 176.017 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.529 ' CB ' HG23 ' A' ' 52' ' ' ILE . 6.5 p30 . . . . . 0 C--O 1.214 -0.791 0 C-N-CA 118.464 -1.294 . . . . 0.0 112.232 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 . . . . . 0 CA--C 1.49 -1.357 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 143' ' ' GLN . . . . . 0.41 ' HB2' ' O ' ' A' ' 131' ' ' LEU . 6.8 pt20 -138.58 141.92 39.21 Favored 'General case' 0 C--N 1.287 -2.15 0 C-N-CA 119.453 -0.899 . . . . 0.0 111.003 -178.582 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 7.5 m-30 -107.2 134.21 50.64 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 -175.619 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 45.3 t -93.26 130.82 41.75 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 O-C-N 123.492 0.495 . . . . 0.0 109.886 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 146' ' ' TRP . . . . . 0.513 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 64.1 m95 -120.69 100.03 6.88 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 -179.688 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -81.02 113.5 19.26 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 179.194 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.4 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 23.6 mm -88.43 121.55 38.86 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -178.044 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -117.46 153.69 32.69 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 123.541 0.736 . . . . 0.0 109.834 177.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.0 131.94 35.16 Favored 'General case' 0 N--CA 1.416 -2.165 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 177.124 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 13.8 t-20 -95.06 -5.77 43.63 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -177.896 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 -155.96 139.97 16.36 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.199 -1.364 . . . . 0.0 109.508 -177.078 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -78.16 145.04 35.86 Favored 'General case' 0 C--N 1.308 -1.2 0 O-C-N 124.212 0.945 . . . . 0.0 109.454 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.46 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 75.5 t -120.67 141.29 41.74 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 O-C-N 122.28 -0.263 . . . . 0.0 110.82 -177.009 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.2 t -120.48 136.11 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.234 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 179.153 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.495 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.7 t -101.74 103.95 31.82 Favored Pre-proline 0 C--N 1.289 -2.058 0 C-N-CA 123.173 0.589 . . . . 0.0 109.716 178.292 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.449 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 44.2 Cg_endo -71.29 -19.47 29.15 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.031 1.821 . . . . 0.0 111.3 178.139 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 158' ' ' THR . . . . . 0.418 ' HB ' HG12 ' A' ' 156' ' ' VAL . 5.1 t . . . . . 0 C--O 1.246 0.872 0 C-N-CA 124.956 1.302 . . . . 0.0 113.262 176.233 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.501 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.419 -2.013 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 79.4 m -136.89 154.46 50.48 Favored 'General case' 0 C--N 1.291 -1.974 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.549 -174.59 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.44 162.52 35.57 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.608 -174.024 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.546 HG22 HG22 ' A' ' 20' ' ' VAL . 67.1 p -97.63 179.81 4.71 Favored 'General case' 0 C--N 1.301 -1.515 0 CA-C-O 121.192 0.52 . . . . 0.0 110.599 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -84.98 -19.75 31.59 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 114.93 -1.032 . . . . 0.0 108.73 179.298 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -87.93 -17.46 31.29 Favored 'General case' 0 N--CA 1.417 -2.1 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.475 -179.532 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 119.24 11.63 7.34 Favored Glycine 0 CA--C 1.486 -1.729 0 C-N-CA 119.061 -1.543 . . . . 0.0 114.373 167.676 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.2 m -89.83 99.68 12.64 Favored 'General case' 0 N--CA 1.413 -2.308 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -90.66 121.65 32.75 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-N 115.071 -0.968 . . . . 0.0 108.513 177.023 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.501 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 66.4 mt -101.77 113.7 65.78 Favored Pre-proline 0 C--N 1.295 -1.768 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 178.229 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -75.54 170.6 19.92 Favored 'Trans proline' 0 C--O 1.25 1.092 0 C-N-CA 122.586 2.19 . . . . 0.0 111.527 178.828 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 63.1 mt -64.42 128.19 26.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.199 179.233 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.89 6.24 2.03 Favored Glycine 0 C--N 1.314 -0.669 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.742 -178.822 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.65 158.41 33.8 Favored Glycine 0 C--N 1.316 -0.558 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 166.04 -173.2 41.59 Favored Glycine 0 C--N 1.3 -1.434 0 C-N-CA 119.709 -1.234 . . . . 0.0 112.014 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.2 p -148.45 140.87 24.29 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -178.533 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -130.8 159.6 36.86 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 29.1 m-80 -108.55 109.89 21.23 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 176.414 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.546 HG22 HG22 ' A' ' 5' ' ' THR . 38.3 t -96.15 138.9 20.33 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.689 -178.396 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -124.7 112.5 16.83 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 121.216 0.532 . . . . 0.0 111.312 -176.857 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.582 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.1 p -122.76 134.13 66.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.942 -175.363 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -98.07 119.69 37.15 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-O 121.47 0.652 . . . . 0.0 110.152 -178.845 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.428 ' CD1' ' HA ' ' A' ' 36' ' ' VAL . 2.7 mm? -97.06 161.72 13.7 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.359 -178.668 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.27 122.1 51.98 Favored Pre-proline 0 C--N 1.317 -0.817 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 173.846 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.494 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 63.1 Cg_endo -74.86 -2.22 12.21 Favored 'Trans proline' 0 CA--C 1.533 0.456 0 C-N-CA 122.771 2.314 . . . . 0.0 113.203 -176.357 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.454 HG13 ' HG3' ' A' ' 157' ' ' PRO . 73.5 t -127.16 115.26 40.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.502 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 3.3 t -149.84 118.99 0.98 Allowed 'Isoleucine or valine' 0 C--O 1.194 -1.833 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 -179.643 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.64 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -107.13 155.79 19.5 Favored 'General case' 0 C--N 1.278 -2.519 0 C-N-CA 122.787 0.435 . . . . 0.0 111.625 -179.592 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.434 HG13 ' O ' ' A' ' 112' ' ' VAL . 38.6 t -47.07 117.13 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 123.656 0.782 . . . . 0.0 111.765 177.755 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.79 -2.44 45.2 Favored Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 115.391 -0.822 . . . . 0.0 112.918 179.562 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.64 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.6 OUTLIER -72.95 -176.91 2.21 Favored 'General case' 0 C--N 1.314 -0.948 0 C-N-CA 123.999 0.92 . . . . 0.0 110.58 177.419 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 36.8 t-20 -134.44 98.21 4.02 Favored 'General case' 0 N--CA 1.427 -1.612 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 176.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.684 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 30.4 tp -93.69 147.01 23.42 Favored 'General case' 0 C--N 1.282 -2.354 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 93.8 t -135.28 120.94 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.507 0 CA-C-O 121.212 0.53 . . . . 0.0 109.973 -178.512 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.599 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 61.5 t -89.61 88.74 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.286 0 N-CA-C 106.349 -1.722 . . . . 0.0 106.349 174.203 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -81.67 110.12 16.72 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-O 121.202 0.525 . . . . 0.0 111.42 -177.281 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.5 mt -96.45 -3.0 44.21 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.438 -178.665 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.2 m -73.07 0.03 12.64 Favored 'General case' 0 CA--C 1.551 1.001 0 CA-C-O 122.151 0.977 . . . . 0.0 109.532 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.5 p -126.29 3.0 7.07 Favored 'General case' 0 C--N 1.295 -1.782 0 C-N-CA 123.712 0.805 . . . . 0.0 110.288 178.063 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.582 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 45.5 mm-40 -121.93 -23.47 5.43 Favored 'General case' 0 CA--C 1.506 -0.724 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.815 -173.458 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.8 mt -133.11 140.34 47.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.196 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -176.149 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -137.62 153.46 49.89 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -176.507 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 66.6 m -128.64 134.94 48.68 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 123.537 0.735 . . . . 0.0 109.209 176.384 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' HIS . . . . . 0.425 ' HB3' ' HA ' ' A' ' 100' ' ' ASP . 22.0 p80 -127.56 145.97 50.68 Favored 'General case' 0 C--N 1.291 -1.968 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.364 -177.011 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.417 HD22 ' CG ' ' A' ' 54' ' ' ASP . 27.4 t-20 -99.85 99.41 10.2 Favored 'General case' 0 C--N 1.293 -1.877 0 C-N-CA 118.637 -1.225 . . . . 0.0 109.035 175.666 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -72.81 -9.79 59.07 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 125.145 1.378 . . . . 0.0 112.627 178.62 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -144.63 68.1 14.54 Favored Pre-proline 0 N--CA 1.482 1.174 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 175.17 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -66.22 -5.33 12.23 Favored 'Trans proline' 0 N--CA 1.488 1.176 0 C-N-CA 123.376 2.717 . . . . 0.0 114.651 -172.817 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -117.99 -3.14 11.16 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-O 121.282 0.563 . . . . 0.0 109.692 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.501 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.6 OUTLIER -117.51 -30.15 5.6 Favored 'General case' 0 N--CA 1.421 -1.878 0 CA-C-O 121.608 0.718 . . . . 0.0 109.732 -175.117 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.648 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.6 mp -129.16 131.87 67.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 -177.455 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.4 t -76.94 146.37 37.6 Favored 'General case' 0 C--O 1.251 1.145 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.612 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 0.8 OUTLIER -83.34 108.45 16.54 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 -178.056 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 22.4 t80 -145.99 129.89 17.27 Favored 'General case' 0 C--N 1.28 -2.425 0 CA-C-O 121.224 0.535 . . . . 0.0 109.62 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.574 HG23 HD13 ' A' ' 131' ' ' LEU . 6.2 p -148.4 149.41 15.18 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.478 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 -178.316 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 5.3 p -150.33 136.36 18.55 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 178.303 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.459 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 38.0 tp -73.32 110.03 7.29 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 172.307 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -58.98 -55.64 32.5 Favored 'General case' 0 C--N 1.314 -0.969 0 C-N-CA 126.155 1.782 . . . . 0.0 110.584 179.557 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -165.55 160.21 17.46 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 -177.547 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -138.31 143.18 13.97 Favored Glycine 0 N--CA 1.405 -3.403 0 N-CA-C 108.89 -1.684 . . . . 0.0 108.89 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 68.4 m -129.88 148.97 51.81 Favored 'General case' 0 C--N 1.278 -2.503 0 C-N-CA 123.771 0.829 . . . . 0.0 109.513 -177.694 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.493 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -110.72 156.6 20.8 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 -178.909 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.445 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 91.8 m-85 -153.93 -179.59 8.0 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.459 0.704 . . . . 0.0 110.257 -177.169 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.6 -138.39 49.29 Favored Glycine 0 C--O 1.223 -0.566 0 O-C-N 123.944 0.777 . . . . 0.0 112.892 176.385 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.61 -3.3 89.73 Favored Glycine 0 N--CA 1.425 -2.061 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.628 177.428 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.787 HG21 ' HB ' ' A' ' 126' ' ' ILE . 79.8 t -73.99 -41.91 52.78 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 123.03 0.532 . . . . 0.0 111.464 -178.44 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.493 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -80.17 -23.17 41.23 Favored 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 119.523 -0.871 . . . . 0.0 112.203 179.57 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 13.9 m -100.97 -46.67 5.02 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 115.011 1.486 . . . . 0.0 115.011 -174.899 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.522 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 25.9 m120 -94.28 -19.92 20.25 Favored 'General case' 0 CA--C 1.494 -1.185 0 C-N-CA 119.87 -0.732 . . . . 0.0 109.48 -178.695 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.659 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 86.9 m-85 -111.76 162.62 15.05 Favored 'General case' 0 N--CA 1.423 -1.808 0 C-N-CA 120.214 -0.594 . . . . 0.0 110.143 179.024 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.2 t -169.57 130.88 1.09 Allowed 'General case' 0 N--CA 1.422 -1.865 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 176.094 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.513 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -164.18 -110.37 0.24 Allowed Glycine 0 N--CA 1.412 -2.958 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 175.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.1 p -158.27 -179.58 8.24 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 124.421 1.089 . . . . 0.0 110.353 -174.122 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -133.66 146.94 31.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 C-N-CA 122.965 0.506 . . . . 0.0 109.993 177.278 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.64 ' HG3' ' O ' ' A' ' 80' ' ' SER . 77.9 tttt -122.14 146.25 47.41 Favored 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 -178.783 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.489 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 56.9 t80 -145.27 106.58 4.2 Favored 'General case' 0 C--N 1.307 -1.242 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 -178.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 29.9 t 54.11 38.16 28.51 Favored 'General case' 0 CA--C 1.55 0.943 0 C-N-CA 123.435 0.694 . . . . 0.0 111.268 179.525 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.35 7.81 66.96 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 120.751 -0.738 . . . . 0.0 113.552 -179.02 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.64 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 15.2 t -79.64 174.32 11.69 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.486 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.5 p -152.06 100.33 2.62 Favored 'General case' 0 C--N 1.287 -2.146 0 CA-C-O 121.125 0.488 . . . . 0.0 109.747 -178.667 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.489 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 3.1 p90 -144.57 161.3 44.49 Favored Pre-proline 0 C--N 1.307 -1.243 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -173.64 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.453 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 59.9 Cg_endo -69.93 153.82 67.74 Favored 'Trans proline' 0 C--N 1.356 0.935 0 C-N-CA 123.018 2.479 . . . . 0.0 113.129 -174.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.556 ' CD2' HD21 ' A' ' 109' ' ' LEU . 56.3 t80 -129.53 128.96 23.15 Favored Pre-proline 0 C--N 1.316 -0.87 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.754 179.066 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.452 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 74.0 Cg_endo -69.16 148.65 85.78 Favored 'Cis proline' 0 CA--C 1.547 1.148 0 C-N-CA 122.789 -1.754 . . . . 0.0 110.374 -0.786 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 7.6 t -62.81 -178.59 0.21 Allowed 'General case' 0 CA--C 1.555 1.169 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.733 -173.167 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 16.6 p -130.52 -17.09 3.34 Favored 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 115.845 -0.616 . . . . 0.0 112.489 -173.026 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 27.2 t -133.21 -80.04 0.48 Allowed 'General case' 0 N--CA 1.426 -1.664 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.389 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 179.85 -170.44 0.14 Allowed 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 -178.879 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.459 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 15.8 p -101.32 162.13 21.48 Favored Pre-proline 0 C--N 1.293 -1.872 0 N-CA-C 113.172 0.805 . . . . 0.0 113.172 178.376 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -63.13 163.68 22.1 Favored 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 123.309 2.673 . . . . 0.0 111.542 173.33 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.41 ' C ' ' HD2' ' A' ' 92' ' ' ARG . 3.8 tmm_? -72.81 123.48 23.45 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.901 -178.23 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 98.5 t -130.54 123.0 54.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.498 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 74.2 t -107.49 130.89 58.99 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 177.179 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.612 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 1.8 m-85 -91.77 167.83 11.89 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 106.058 -1.831 . . . . 0.0 106.058 172.589 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -132.74 54.37 1.95 Allowed 'General case' 0 C--N 1.258 -3.377 0 N-CA-C 104.845 -2.28 . . . . 0.0 104.845 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' SER . . . . . 0.481 ' HB3' ' HG3' ' A' ' 101' ' ' LYS . 66.2 p -113.09 161.35 17.2 Favored 'General case' 0 N--CA 1.414 -2.226 0 N-CA-C 114.44 1.274 . . . . 0.0 114.44 -167.366 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 35.1 ptt180 -144.74 30.18 1.21 Allowed 'General case' 0 C--N 1.3 -1.56 0 CA-C-N 114.375 -1.284 . . . . 0.0 108.177 171.189 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.9 t -159.26 177.08 11.41 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-N 113.826 -1.533 . . . . 0.0 107.087 -179.541 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ASP . . . . . 0.425 ' HA ' ' HB3' ' A' ' 45' ' ' HIS . 5.3 m-20 -71.26 111.48 6.64 Favored 'General case' 0 CA--C 1.5 -0.959 0 O-C-N 123.533 0.52 . . . . 0.0 109.632 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' LYS . . . . . 0.607 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 7.4 mmpt? -111.37 143.57 28.74 Favored Pre-proline 0 C--N 1.288 -2.092 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 174.33 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.484 ' O ' ' HD3' ' A' ' 104' ' ' PRO . 33.7 Cg_endo -67.12 144.29 68.66 Favored 'Trans proline' 0 N--CA 1.446 -1.317 0 C-N-CA 122.608 2.206 . . . . 0.0 111.95 -177.09 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 14.1 t90 -89.46 101.14 2.83 Favored Pre-proline 0 C--N 1.307 -1.248 0 N-CA-C 105.657 -1.979 . . . . 0.0 105.657 179.258 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' PRO . . . . . 0.484 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 73.2 Cg_endo -75.17 88.65 1.24 Allowed 'Trans proline' 0 N--CA 1.452 -0.926 0 C-N-CA 122.016 1.811 . . . . 0.0 112.841 -171.024 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.453 HG22 ' CD2' ' A' ' 77' ' ' TYR . 93.2 t -136.91 142.94 36.36 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.465 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.015 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.599 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.99 134.19 18.29 Favored 'General case' 0 N--CA 1.412 -2.346 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.335 178.758 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.498 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 19.0 mt -98.95 102.32 14.01 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.013 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.513 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 13.1 m-85 -79.01 65.41 4.18 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 122.955 0.502 . . . . 0.0 111.517 178.297 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.684 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.9 mm? -92.14 135.3 34.1 Favored 'General case' 0 C--O 1.205 -1.24 0 O-C-N 121.958 -0.464 . . . . 0.0 110.162 177.142 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.02 145.24 51.67 Favored Pre-proline 0 N--CA 1.418 -2.065 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.468 -176.836 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.522 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 24.3 Cg_endo -60.21 120.81 8.8 Favored 'Trans proline' 0 C--O 1.243 0.775 0 C-N-CA 123.402 2.735 . . . . 0.0 111.972 -177.292 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.434 ' O ' HG13 ' A' ' 30' ' ' VAL . 2.6 m -69.53 -115.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.189 -2.085 0 CA-C-N 114.436 -1.256 . . . . 0.0 112.668 177.193 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.3 m -110.92 -46.29 3.36 Favored 'General case' 0 C--N 1.29 -1.996 0 O-C-N 121.471 -0.768 . . . . 0.0 110.144 178.315 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 13.3 t -86.1 31.18 0.64 Allowed 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.898 -173.164 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -95.18 131.69 40.95 Favored 'General case' 0 N--CA 1.423 -1.803 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.421 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -168.66 139.82 5.85 Favored Glycine 0 N--CA 1.432 -1.579 0 C-N-CA 120.331 -0.938 . . . . 0.0 111.808 179.277 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 57.49 -144.48 40.38 Favored Glycine 0 CA--C 1.488 -1.607 0 C-N-CA 123.914 0.769 . . . . 0.0 113.072 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -58.67 94.48 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 122.821 1.296 . . . . 0.0 111.995 -177.559 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.16 -22.53 16.14 Favored 'General case' 0 C--N 1.297 -1.691 0 CA-C-N 114.774 -1.103 . . . . 0.0 111.398 -176.507 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.473 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 59.0 mt -136.48 137.74 47.49 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 107.853 -1.165 . . . . 0.0 107.853 177.389 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.481 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.6 mmpt? -112.0 139.59 47.38 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-O 120.831 0.348 . . . . 0.0 111.793 179.201 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.21 120.52 16.02 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 178.429 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.57 -5.54 64.7 Favored Glycine 0 C--N 1.309 -0.923 0 N-CA-C 111.733 -0.547 . . . . 0.0 111.733 -176.726 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 34.1 t -90.23 142.91 27.26 Favored 'General case' 0 C--O 1.252 1.194 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.243 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 30.1 tp -71.86 133.41 45.44 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 177.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.787 ' HB ' HG21 ' A' ' 67' ' ' VAL . 40.6 pt -118.8 -24.71 3.08 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.039 0 C-N-CA 120.347 -0.541 . . . . 0.0 112.28 -178.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' ALA . . . . . 0.445 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -163.97 164.38 23.2 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 120.966 -0.293 . . . . 0.0 110.449 -178.018 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 55.4 t -140.17 114.29 6.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 178.12 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.471 HD11 HD21 ' A' ' 107' ' ' LEU . 56.9 mt -118.26 147.08 43.79 Favored 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.453 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.8 mp -129.23 126.36 63.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 C-N-CA 120.16 -0.616 . . . . 0.0 110.065 178.749 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.574 HD13 HG23 ' A' ' 56' ' ' VAL . 1.4 pp -92.26 150.56 20.8 Favored 'General case' 0 CA--C 1.476 -1.897 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 173.332 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 56.4 ttp180 -115.11 116.69 28.81 Favored 'General case' 0 C--N 1.25 -3.727 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 176.17 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -100.51 120.25 39.73 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 -175.1 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 5.4 m -133.58 144.26 49.19 Favored 'General case' 0 C--N 1.287 -2.125 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.648 ' CB ' HG23 ' A' ' 52' ' ' ILE . 8.0 p30 . . . . . 0 N--CA 1.436 -1.137 0 C-N-CA 118.227 -1.389 . . . . 0.0 111.877 174.437 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 . . . . . 0 CA--C 1.491 -1.326 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -131.39 145.4 51.8 Favored 'General case' 0 N--CA 1.415 -2.193 0 C-N-CA 118.549 -1.26 . . . . 0.0 111.798 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 8.6 m-30 -113.77 126.75 55.56 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 108.266 -1.012 . . . . 0.0 108.266 -175.374 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 48.4 t -89.72 133.59 31.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 123.544 0.528 . . . . 0.0 110.304 -179.379 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 58.0 m95 -120.04 100.46 7.22 Favored 'General case' 0 C--N 1.285 -2.236 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 -179.678 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -82.77 111.83 19.05 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 106.608 -1.627 . . . . 0.0 106.608 178.112 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.445 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 22.6 mm -86.72 121.57 37.81 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 -176.891 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -118.26 154.66 31.9 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 177.631 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 121' ' ' LYS . . . -80.96 128.0 33.2 Favored 'General case' 0 N--CA 1.406 -2.661 0 CA-C-N 115.243 -0.889 . . . . 0.0 108.699 176.167 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 37.0 t-20 -88.87 -8.9 53.43 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 106.719 -1.585 . . . . 0.0 106.719 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 5.0 t-20 -156.0 139.75 16.13 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 113.679 -1.6 . . . . 0.0 109.605 -176.881 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -77.86 147.95 34.89 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 124.538 1.135 . . . . 0.0 110.067 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.494 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 73.7 t -123.58 138.1 54.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.913 -176.757 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.7 t -118.65 136.14 56.8 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.576 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.502 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 76.3 t -100.0 104.4 28.64 Favored Pre-proline 0 C--N 1.285 -2.224 0 C-N-CA 123.202 0.601 . . . . 0.0 109.416 178.26 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.454 ' HG3' HG13 ' A' ' 27' ' ' VAL . 33.7 Cg_endo -69.78 -25.12 28.84 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.121 1.881 . . . . 0.0 111.02 176.905 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 158' ' ' THR . . . . . 0.451 ' HB ' HG12 ' A' ' 156' ' ' VAL 0.274 6.0 t . . . . . 0 C--O 1.247 0.928 0 O-C-N 124.638 1.211 . . . . 0.0 113.204 176.712 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.449 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.432 -1.329 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 65.1 m -130.73 158.3 40.49 Favored 'General case' 0 C--N 1.287 -2.112 0 C-N-CA 120.013 -0.675 . . . . 0.0 111.272 -172.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.457 ' HD2' ' O ' ' A' ' 5' ' ' THR . 0.0 OUTLIER -145.91 164.41 32.07 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.608 -175.002 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.556 HG22 HG22 ' A' ' 20' ' ' VAL . 68.1 p -99.91 -179.52 4.19 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-O 121.449 0.642 . . . . 0.0 111.787 -178.407 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.88 -20.44 38.83 Favored 'General case' 0 C--N 1.296 -1.72 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.108 177.876 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -88.45 -25.83 22.43 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.094 -0.957 . . . . 0.0 112.186 -179.758 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 128.35 8.47 4.02 Favored Glycine 0 CA--C 1.496 -1.107 0 C-N-CA 119.354 -1.403 . . . . 0.0 114.241 170.232 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 m -83.49 98.86 9.76 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 -179.174 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.05 109.1 21.19 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.888 179.372 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.449 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 64.8 mt -86.17 120.24 72.24 Favored Pre-proline 0 C--N 1.305 -1.359 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 -177.673 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -79.06 168.39 20.64 Favored 'Trans proline' 0 C--O 1.252 1.204 0 C-N-CA 122.65 2.233 . . . . 0.0 110.742 178.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.3 mt -71.14 128.09 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.3 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 178.808 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 139.37 -8.68 3.19 Favored Glycine 0 C--N 1.296 -1.681 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -176.238 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.58 148.36 22.13 Favored Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.351 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.98 -174.05 46.15 Favored Glycine 0 N--CA 1.435 -1.37 0 C-N-CA 120.493 -0.861 . . . . 0.0 111.156 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 28.8 p -143.02 151.02 40.37 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.2 162.33 33.26 Favored 'General case' 0 N--CA 1.415 -2.223 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 -179.355 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -107.72 117.01 32.99 Favored 'General case' 0 C--N 1.278 -2.52 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 176.036 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.556 HG22 HG22 ' A' ' 5' ' ' THR . 40.7 t -105.43 132.04 53.31 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.778 0 CA-C-N 115.484 -0.78 . . . . 0.0 109.138 178.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.4 m-85 -118.52 123.04 44.13 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 -179.002 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.482 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.4 p -131.28 134.55 60.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.005 -176.889 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 5.6 p30 -98.03 119.17 36.18 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 121.737 0.78 . . . . 0.0 110.585 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.422 HD11 HG22 ' A' ' 36' ' ' VAL . 2.8 mm? -99.45 160.78 14.03 Favored 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 114.59 -1.187 . . . . 0.0 109.13 -177.88 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.03 121.51 46.68 Favored Pre-proline 0 C--O 1.212 -0.884 0 O-C-N 124.478 1.111 . . . . 0.0 109.076 176.108 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 73.4 Cg_endo -74.31 -2.62 12.61 Favored 'Trans proline' 0 C--O 1.22 -0.42 0 C-N-CA 122.811 2.341 . . . . 0.0 113.277 -175.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.446 HG13 ' HG3' ' A' ' 157' ' ' PRO . 86.0 t -126.54 109.74 21.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.494 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 4.2 t -145.05 110.82 1.15 Allowed 'Isoleucine or valine' 0 C--O 1.188 -2.167 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -177.933 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.654 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -98.32 153.12 18.76 Favored 'General case' 0 C--N 1.272 -2.789 0 C-N-CA 123.305 0.642 . . . . 0.0 111.766 -178.346 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.412 HG22 ' O ' ' A' ' 112' ' ' VAL . 40.5 t -46.8 115.74 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 123.318 0.647 . . . . 0.0 111.524 175.892 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 109.01 -8.13 33.37 Favored Glycine 0 C--N 1.322 -0.227 0 CA-C-N 115.445 -0.798 . . . . 0.0 112.558 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.654 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.3 OUTLIER -65.98 -177.38 0.48 Allowed 'General case' 0 C--N 1.317 -0.831 0 C-N-CA 124.468 1.107 . . . . 0.0 112.069 177.725 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -137.43 95.34 3.06 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 177.765 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.616 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 25.3 tp -93.5 146.29 23.89 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -177.466 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.2 t -132.9 120.01 39.46 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.75 0 CA-C-O 120.978 0.418 . . . . 0.0 110.184 -176.069 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.613 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 55.0 t -92.84 88.63 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.338 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 172.763 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -82.26 106.77 14.42 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.25 0.548 . . . . 0.0 110.63 -176.549 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 89.6 mt -90.27 -0.76 57.78 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.986 -177.721 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.7 t -78.18 0.88 23.25 Favored 'General case' 0 C--N 1.309 -1.184 0 CA-C-O 122.271 1.034 . . . . 0.0 109.134 -179.227 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.6 p -125.3 5.57 7.74 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.848 175.539 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.482 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 51.4 mm-40 -122.61 -26.59 4.51 Favored 'General case' 0 CA--C 1.501 -0.934 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.586 -173.812 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 18.3 mt -132.57 139.64 49.4 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 -175.27 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.401 ' HB2' ' HE3' ' A' ' 4' ' ' LYS . 70.2 m-85 -138.28 144.71 40.61 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -175.839 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 72.7 m -121.32 135.11 55.14 Favored 'General case' 0 C--N 1.284 -2.275 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 177.698 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 22.8 p-80 -134.13 163.08 30.39 Favored 'General case' 0 C--N 1.309 -1.195 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -175.812 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.427 ' HB2' ' OD2' ' A' ' 54' ' ' ASP . 16.1 t-20 -113.25 111.46 22.08 Favored 'General case' 0 N--CA 1.423 -1.786 0 C-N-CA 118.574 -1.25 . . . . 0.0 111.047 179.187 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 17.4 p-10 -85.74 -4.7 59.23 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 124.573 1.149 . . . . 0.0 111.224 179.586 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.458 ' HB2' HD13 ' A' ' 52' ' ' ILE . 85.4 m-85 -143.97 65.46 13.9 Favored Pre-proline 0 N--CA 1.477 0.877 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 174.575 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.452 ' HB2' ' HB2' ' A' ' 98' ' ' ARG . 68.5 Cg_endo -72.32 3.98 3.71 Favored 'Trans proline' 0 N--CA 1.481 0.74 0 C-N-CA 123.498 2.799 . . . . 0.0 115.295 -169.751 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -114.33 -28.51 7.22 Favored 'General case' 0 C--N 1.285 -2.227 0 CA-C-O 121.735 0.779 . . . . 0.0 110.495 -178.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.557 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.0 OUTLIER -101.74 -30.07 11.53 Favored 'General case' 0 C--N 1.28 -2.455 0 CA-C-N 115.046 -0.979 . . . . 0.0 111.126 -174.063 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.557 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.4 mp -121.0 132.37 70.65 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.661 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -176.748 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 15.1 t -79.46 145.96 33.0 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 177.768 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.521 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 1.2 m-20 -79.5 109.57 14.0 Favored 'General case' 0 C--N 1.282 -2.368 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 -179.496 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -150.42 138.34 20.06 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 -170.705 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.444 HG23 HD13 ' A' ' 131' ' ' LEU . 14.9 p -151.31 153.45 9.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -178.6 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.11 128.83 12.39 Favored 'General case' 0 C--O 1.208 -1.109 0 CA-C-O 119.381 -0.343 . . . . 0.0 110.125 175.75 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.516 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 49.5 tp -75.24 109.2 8.54 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.828 0.823 . . . . 0.0 109.277 174.53 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 7.0 tp60 -55.47 -54.16 47.34 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 126.479 1.912 . . . . 0.0 111.461 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 8.4 ptp180 -169.88 159.6 7.97 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 -176.692 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.408 ' H ' HG22 ' A' ' 86' ' ' THR . . . -136.47 144.29 15.94 Favored Glycine 0 N--CA 1.406 -3.324 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 73.6 m -132.88 150.58 52.15 Favored 'General case' 0 C--N 1.281 -2.406 0 C-N-CA 123.459 0.704 . . . . 0.0 109.831 -177.53 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.524 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -113.51 158.51 20.64 Favored 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 179.516 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.5 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . 98.8 m-85 -155.2 -179.74 8.37 Favored 'General case' 0 C--N 1.342 0.276 0 C-N-CA 124.436 1.094 . . . . 0.0 109.678 -177.842 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.56 -142.22 45.64 Favored Glycine 0 C--O 1.238 0.383 0 O-C-N 123.794 0.684 . . . . 0.0 112.839 176.429 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.455 ' HA3' ' O ' ' A' ' 119' ' ' ALA . . . -77.71 -7.81 87.26 Favored Glycine 0 N--CA 1.435 -1.387 0 C-N-CA 120.77 -0.729 . . . . 0.0 111.482 177.638 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.824 HG21 ' HB ' ' A' ' 126' ' ' ILE . 99.3 t -71.0 -42.14 76.94 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.368 0 C-N-CA 123.279 0.632 . . . . 0.0 111.428 -179.207 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.524 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -85.41 -14.82 45.08 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 118.554 -1.258 . . . . 0.0 112.405 178.851 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 8.8 t -100.33 -48.89 4.43 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 120.324 -0.55 . . . . 0.0 111.651 -175.494 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.47 ' O ' HG22 ' A' ' 112' ' ' VAL . 26.4 m120 -95.67 -22.24 17.69 Favored 'General case' 0 CA--C 1.497 -1.087 0 C-N-CA 120.472 -0.491 . . . . 0.0 110.187 -176.39 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.561 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 95.8 m-85 -109.43 154.02 23.19 Favored 'General case' 0 N--CA 1.423 -1.778 0 C-N-CA 120.061 -0.656 . . . . 0.0 110.78 -179.448 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.9 t -165.0 121.1 1.42 Allowed 'General case' 0 N--CA 1.416 -2.126 0 N-CA-C 106.822 -1.548 . . . . 0.0 106.822 174.117 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.422 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -152.83 -113.29 0.53 Allowed Glycine 0 N--CA 1.408 -3.232 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 177.673 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.466 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.0 OUTLIER -152.75 179.3 8.75 Favored 'General case' 0 C--N 1.287 -2.128 0 C-N-CA 123.101 0.56 . . . . 0.0 110.557 -174.718 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.6 p -136.69 145.43 30.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 C-N-CA 123.004 0.522 . . . . 0.0 109.653 178.563 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.626 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.3 tttt -124.54 144.24 50.24 Favored 'General case' 0 N--CA 1.417 -2.094 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.49 ' CD2' HG22 ' A' ' 105' ' ' VAL . 62.7 t80 -145.56 115.15 7.23 Favored 'General case' 0 C--N 1.289 -2.047 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 -178.607 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 15.1 m 52.76 40.58 30.75 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 114.187 1.18 . . . . 0.0 114.187 175.55 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 80.76 10.48 85.09 Favored Glycine 0 N--CA 1.442 -0.96 0 C-N-CA 119.986 -1.102 . . . . 0.0 112.606 179.439 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.626 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 8.9 t -85.41 -179.7 6.99 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 177.88 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 31.5 t -157.03 112.22 2.82 Favored 'General case' 0 C--N 1.287 -2.122 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -178.47 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.456 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 4.9 p90 -155.27 161.51 29.3 Favored Pre-proline 0 CA--C 1.556 1.182 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -175.463 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.466 ' HA ' HG22 ' A' ' 74' ' ' THR . 56.5 Cg_endo -69.86 153.19 68.76 Favored 'Trans proline' 0 C--N 1.36 1.173 0 C-N-CA 122.979 2.453 . . . . 0.0 112.931 -177.643 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.501 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 63.2 t80 -124.57 130.55 24.25 Favored Pre-proline 0 N--CA 1.442 -0.862 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.469 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.501 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 72.2 Cg_endo -69.92 151.62 92.01 Favored 'Cis proline' 0 CA--C 1.542 0.897 0 C-N-CA 122.999 -1.667 . . . . 0.0 110.124 -1.596 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.408 HG22 ' H ' ' A' ' 61' ' ' GLY . 8.9 t -58.36 -178.0 0.04 OUTLIER 'General case' 0 CA--C 1.552 1.02 0 CA-C-O 122.088 0.947 . . . . 0.0 112.9 -173.711 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 10.1 p -119.43 -20.8 7.69 Favored 'General case' 0 N--CA 1.423 -1.812 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.778 -175.048 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 23.1 t -141.95 -82.47 0.2 Allowed 'General case' 0 N--CA 1.432 -1.336 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.964 -177.118 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -170.89 -172.87 1.22 Allowed 'General case' 0 C--O 1.241 0.631 0 N-CA-C 104.536 -2.394 . . . . 0.0 104.536 -177.338 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.516 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 42.0 p -100.9 158.18 32.29 Favored Pre-proline 0 C--N 1.293 -1.86 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.375 176.39 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -59.26 161.2 17.17 Favored 'Trans proline' 0 C--O 1.243 0.771 0 C-N-CA 123.16 2.573 . . . . 0.0 110.769 173.536 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.2 tmm_? -69.25 120.64 15.4 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.445 -178.438 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 72.4 t -128.09 124.68 63.05 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-O 121.633 0.73 . . . . 0.0 111.05 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 70.5 t -112.64 126.16 70.0 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.893 0 CA-C-N 115.095 -0.957 . . . . 0.0 108.853 176.639 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.521 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.2 m-85 -72.43 110.63 6.97 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 175.53 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -81.79 61.76 5.29 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.328 -0.989 . . . . 0.0 108.328 176.624 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.7 m -142.35 -168.52 2.75 Favored 'General case' 0 N--CA 1.419 -1.982 0 C-N-CA 125.34 1.456 . . . . 0.0 107.685 -177.481 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.452 ' HB2' ' HB2' ' A' ' 49' ' ' PRO . 34.0 ptt180 -163.23 34.76 0.09 Allowed 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 106.465 -1.68 . . . . 0.0 106.465 176.842 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.4 t -160.45 175.9 12.25 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 114.755 -1.112 . . . . 0.0 109.036 -168.698 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -70.7 114.01 8.35 Favored 'General case' 0 C--O 1.239 0.513 0 CA-C-O 122.021 0.915 . . . . 0.0 111.746 -176.297 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.6 mptm? -127.48 143.52 47.64 Favored Pre-proline 0 C--N 1.292 -1.907 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.382 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -63.29 147.22 93.92 Favored 'Trans proline' 0 C--O 1.247 0.961 0 C-N-CA 122.693 2.262 . . . . 0.0 111.78 177.214 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' TRP . . . . . 0.509 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 9.6 t90 -86.46 111.85 42.21 Favored Pre-proline 0 C--N 1.304 -1.378 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 -178.091 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_endo -82.04 87.12 1.45 Allowed 'Trans proline' 0 N--CA 1.439 -1.698 0 C-N-CA 121.031 1.154 . . . . 0.0 112.122 -172.245 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.49 HG22 ' CD2' ' A' ' 77' ' ' TYR . 80.2 t -137.56 146.33 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.668 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 176.852 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.613 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -153.66 132.28 12.21 Favored 'General case' 0 C--N 1.287 -2.143 0 O-C-N 123.41 0.444 . . . . 0.0 110.428 178.049 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.477 HD21 HD11 ' A' ' 129' ' ' LEU . 16.9 mt -97.01 101.02 12.52 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.422 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 53.7 m-85 -79.33 73.04 5.96 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 120.884 0.373 . . . . 0.0 110.673 177.421 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.63 ' HG ' HG13 ' A' ' 67' ' ' VAL . 2.7 mm? -87.08 150.62 23.88 Favored 'General case' 0 C--O 1.192 -1.966 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.474 176.575 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.57 139.57 13.15 Favored Pre-proline 0 C--N 1.278 -2.501 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.611 -179.456 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 18.0 Cg_endo -60.16 121.55 9.97 Favored 'Trans proline' 0 C--O 1.247 0.969 0 C-N-CA 123.189 2.593 . . . . 0.0 111.87 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.47 HG22 ' O ' ' A' ' 70' ' ' ASN . 3.5 m -70.3 -123.08 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.182 -2.478 0 CA-C-N 114.77 -1.105 . . . . 0.0 111.478 175.655 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 30.9 m -111.95 -19.39 12.38 Favored 'General case' 0 C--N 1.282 -2.331 0 CA-C-O 122.548 1.166 . . . . 0.0 108.877 177.392 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.446 ' H ' HG23 ' A' ' 112' ' ' VAL . 1.2 m -85.37 6.79 24.99 Favored 'General case' 0 N--CA 1.405 -2.696 0 CA-C-N 113.595 -1.639 . . . . 0.0 112.568 -173.301 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -97.6 138.18 35.4 Favored 'General case' 0 C--N 1.266 -3.051 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.192 -172.242 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -177.26 124.16 0.93 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.173 -1.013 . . . . 0.0 112.671 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.11 -147.72 50.34 Favored Glycine 0 CA--C 1.488 -1.645 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 -175.554 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.408 ' CG1' ' HE3' ' A' ' 121' ' ' LYS . 93.9 t -53.1 111.33 0.26 Allowed 'Isoleucine or valine' 0 C--O 1.248 0.997 0 CA-C-O 121.709 0.766 . . . . 0.0 110.741 -178.717 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' ALA . . . . . 0.455 ' O ' ' HA3' ' A' ' 66' ' ' GLY . . . -113.51 -22.66 10.21 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-N 114.212 -1.358 . . . . 0.0 111.619 -179.459 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.472 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.7 mt -135.01 137.72 50.13 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 178.374 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.575 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 5.3 mmpt? -112.49 141.48 46.18 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 121.144 0.497 . . . . 0.0 111.602 177.811 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 0.408 ' H ' ' HB3' ' A' ' 153' ' ' ASP . . . -72.03 134.8 46.08 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.87 179.248 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 85.18 -1.23 88.78 Favored Glycine 0 C--N 1.312 -0.79 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.005 -179.338 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 59.8 m -96.5 148.73 22.52 Favored 'General case' 0 N--CA 1.421 -1.906 0 CA-C-O 120.94 0.4 . . . . 0.0 110.066 179.157 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.447 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -77.83 122.59 25.64 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -179.226 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.824 ' HB ' HG21 ' A' ' 67' ' ' VAL . 30.8 pt -109.42 -27.19 2.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 N-CA-C 112.853 0.686 . . . . 0.0 112.853 -177.379 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' ALA . . . . . 0.421 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.49 166.68 26.79 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 -178.01 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.447 HG23 HD11 ' A' ' 125' ' ' LEU . 74.6 t -142.5 112.78 2.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 179.515 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.477 HD11 HD21 ' A' ' 107' ' ' LEU . 58.3 mt -115.87 146.77 41.73 Favored 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 178.786 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.496 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.7 mp -128.61 125.22 63.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 C-N-CA 120.028 -0.669 . . . . 0.0 109.227 178.541 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.444 HD13 HG23 ' A' ' 56' ' ' VAL . 1.3 pp -91.0 148.96 22.04 Favored 'General case' 0 CA--C 1.478 -1.821 0 N-CA-C 106.004 -1.85 . . . . 0.0 106.004 174.453 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 32.1 ttt180 -118.78 123.91 45.95 Favored 'General case' 0 C--N 1.253 -3.592 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 176.189 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' GLN . . . . . 0.476 ' HB2' ' O ' ' A' ' 142' ' ' PHE . 9.3 mm100 -79.91 143.35 34.33 Favored 'General case' 0 N--CA 1.411 -2.376 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.525 179.463 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 17.7 m -154.33 127.36 8.3 Favored 'General case' 0 C--N 1.269 -2.929 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 170.282 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.486 ' HB2' HG23 ' A' ' 52' ' ' ILE . 15.7 p30 . . . . . 0 C--N 1.299 -1.588 0 C-N-CA 119.715 -0.794 . . . . 0.0 111.075 -178.713 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' PHE . . . . . 0.476 ' O ' ' HB2' ' A' ' 133' ' ' GLN . 95.8 m-85 . . . . . 0 CA--C 1.513 -0.48 0 CA-C-O 120.918 0.39 . . . . 0.0 110.23 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 11.9 pt20 -126.79 144.62 50.9 Favored 'General case' 0 C--N 1.296 -1.757 0 C-N-CA 119.72 -0.792 . . . . 0.0 110.193 -179.046 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 11.0 m-30 -113.74 128.93 56.61 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 -175.278 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 47.4 t -90.96 134.06 30.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 123.478 0.486 . . . . 0.0 110.35 -177.721 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 59.9 m95 -120.69 98.6 6.1 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 -179.477 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 45.1 m-80 -81.21 110.85 17.08 Favored 'General case' 0 C--N 1.288 -2.086 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.446 HG22 HD11 ' A' ' 126' ' ' ILE . 23.3 mm -85.68 122.4 38.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 -177.534 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -118.0 150.98 38.37 Favored 'General case' 0 C--N 1.295 -1.77 0 C-N-CA 123.552 0.741 . . . . 0.0 109.012 178.375 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.08 130.36 35.06 Favored 'General case' 0 N--CA 1.413 -2.317 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 176.522 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 29.8 t-20 -89.55 -15.7 32.31 Favored 'General case' 0 C--N 1.288 -2.1 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 -177.761 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -149.3 141.88 24.42 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 114.059 -1.428 . . . . 0.0 109.207 -174.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 153' ' ' ASP . . . . . 0.408 ' HB3' ' H ' ' A' ' 122' ' ' ALA . 8.7 p-10 -85.94 138.03 32.3 Favored 'General case' 0 C--N 1.314 -0.949 0 O-C-N 123.944 0.777 . . . . 0.0 111.561 -178.474 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.472 ' HB ' ' HB ' ' A' ' 120' ' ' ILE . 75.1 t -112.21 141.42 27.79 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-N 115.015 -0.993 . . . . 0.0 111.894 -173.105 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 5.1 t -119.69 139.05 48.31 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.131 0 N-CA-C 108.12 -1.066 . . . . 0.0 108.12 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.494 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 62.1 t -103.2 102.24 27.23 Favored Pre-proline 0 C--N 1.285 -2.197 0 C-N-CA 123.89 0.876 . . . . 0.0 110.065 178.414 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.463 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 34.5 Cg_endo -68.3 -22.68 39.57 Favored 'Trans proline' 0 C--O 1.222 -0.305 0 C-N-CA 122.144 1.896 . . . . 0.0 111.589 178.278 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 158' ' ' THR . . . . . 0.474 ' HB ' HG12 ' A' ' 156' ' ' VAL 0.25 7.4 t . . . . . 0 CA--C 1.547 0.85 0 C-N-CA 124.791 1.236 . . . . 0.0 113.714 175.69 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.506 ' HB3' ' CE1' ' A' ' 45' ' ' HIS . . . . . . . . 0 N--CA 1.429 -1.519 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.528 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 13.5 t -157.12 160.66 39.05 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.294 -175.701 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.27 164.3 31.81 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.455 -177.324 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.552 HG22 HG22 ' A' ' 20' ' ' VAL . 73.8 p -102.22 177.85 4.76 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-O 121.427 0.632 . . . . 0.0 111.024 -179.71 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.72 -18.27 44.92 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 114.71 -1.132 . . . . 0.0 109.347 179.131 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -91.82 -24.42 19.38 Favored 'General case' 0 N--CA 1.432 -1.363 0 CA-C-N 114.893 -1.049 . . . . 0.0 111.822 -177.621 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 120.17 34.46 0.96 Allowed Glycine 0 CA--C 1.488 -1.614 0 C-N-CA 119.308 -1.425 . . . . 0.0 113.315 170.005 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -110.13 98.93 8.09 Favored 'General case' 0 N--CA 1.423 -1.823 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 176.501 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -90.97 123.18 34.26 Favored 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 115.157 -0.929 . . . . 0.0 109.451 177.03 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.403 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 68.3 mt -100.39 116.22 64.62 Favored Pre-proline 0 C--N 1.288 -2.07 0 N-CA-C 109.484 -0.562 . . . . 0.0 109.484 177.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -75.53 164.78 31.78 Favored 'Trans proline' 0 C--O 1.249 1.055 0 C-N-CA 122.661 2.241 . . . . 0.0 110.85 176.782 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.4 mt -69.49 121.03 18.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 148.77 -6.0 0.85 Allowed Glycine 0 C--N 1.305 -1.162 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 -174.142 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.0 149.39 23.81 Favored Glycine 0 N--CA 1.431 -1.665 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 176.83 178.57 46.68 Favored Glycine 0 N--CA 1.418 -2.502 0 C-N-CA 119.133 -1.508 . . . . 0.0 112.132 -179.218 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.416 ' HA ' ' O ' ' A' ' 145' ' ' VAL . 7.9 p -140.67 142.08 34.96 Favored 'General case' 0 C--N 1.285 -2.226 0 N-CA-C 108.795 -0.816 . . . . 0.0 108.795 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.41 153.06 51.2 Favored 'General case' 0 CA--C 1.474 -1.969 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 -178.018 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -98.68 116.67 31.43 Favored 'General case' 0 C--N 1.278 -2.53 0 CA-C-N 114.751 -1.113 . . . . 0.0 108.19 174.817 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.552 HG22 HG22 ' A' ' 5' ' ' THR . 26.1 t -103.76 127.39 57.9 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.573 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 54.2 m-85 -110.84 125.27 53.42 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 121.336 -0.146 . . . . 0.0 110.954 -179.389 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.486 HG22 ' HG3' ' A' ' 41' ' ' GLN . 21.2 t -126.93 121.8 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.036 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -176.691 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -85.13 120.88 27.12 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-O 121.411 0.624 . . . . 0.0 110.432 175.738 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 50.7 mt -109.93 160.9 16.0 Favored 'General case' 0 N--CA 1.424 -1.755 0 CA-C-N 114.452 -1.249 . . . . 0.0 108.251 -175.263 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.5 121.18 58.61 Favored Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 124.65 1.219 . . . . 0.0 109.411 -179.678 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 59.2 Cg_endo -72.77 -3.39 13.46 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.86 2.373 . . . . 0.0 113.183 -177.465 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.401 HG13 ' HG3' ' A' ' 157' ' ' PRO . 65.1 t -122.21 110.58 27.53 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 178.041 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.7 t -141.78 108.87 2.07 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.105 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 -178.531 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.766 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -98.05 152.37 19.37 Favored 'General case' 0 C--N 1.277 -2.555 0 C-N-CA 122.861 0.464 . . . . 0.0 112.135 -179.561 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.45 HG13 ' O ' ' A' ' 112' ' ' VAL . 30.5 t -46.61 117.71 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.036 0 C-N-CA 123.784 0.834 . . . . 0.0 111.578 177.427 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.1 3.79 55.59 Favored Glycine 0 C--O 1.235 0.211 0 CA-C-N 115.527 -0.76 . . . . 0.0 112.848 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.766 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -76.11 -176.65 3.61 Favored 'General case' 0 C--N 1.311 -1.081 0 C-N-CA 124.49 1.116 . . . . 0.0 110.113 178.249 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -130.73 90.57 2.93 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 178.848 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.658 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 21.9 tp -93.87 141.49 28.45 Favored 'General case' 0 C--N 1.29 -2.018 0 C-N-CA 119.062 -1.055 . . . . 0.0 109.003 178.746 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.6 t -134.35 122.62 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.813 0 CA-C-N 116.25 -0.432 . . . . 0.0 109.842 -174.205 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.609 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 57.0 t -92.43 87.96 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.35 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 172.337 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.548 ' O ' ' HG2' ' A' ' 41' ' ' GLN . 29.3 t70 -83.97 101.42 11.71 Favored 'General case' 0 CA--C 1.488 -1.429 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.809 -176.395 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.9 mt -80.9 -7.22 59.42 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.916 -177.666 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 24.8 t -71.72 -0.04 10.0 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.072 179.104 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 4.1 p -134.3 10.3 3.79 Favored 'General case' 0 N--CA 1.419 -1.982 0 CA-C-O 121.207 0.527 . . . . 0.0 110.049 176.082 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.548 ' HG2' ' O ' ' A' ' 37' ' ' ASP . 35.0 mm-40 -125.39 -20.96 4.65 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 -176.852 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.8 mt -134.6 136.77 52.19 Favored 'Isoleucine or valine' 0 C--O 1.239 0.517 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -177.396 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -138.43 120.44 15.54 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -175.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.528 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 73.8 m -102.37 143.07 32.58 Favored 'General case' 0 C--N 1.282 -2.354 0 CA-C-O 121.451 0.643 . . . . 0.0 109.962 -178.157 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' HIS . . . . . 0.506 ' CE1' ' HB3' ' A' ' 2' ' ' ALA . 6.8 p80 -119.22 139.66 51.5 Favored 'General case' 0 C--N 1.288 -2.105 0 CA-C-O 121.73 0.776 . . . . 0.0 111.03 -176.393 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.629 ' HB2' ' CG ' ' A' ' 54' ' ' ASP . 3.7 p-10 -108.36 100.64 9.91 Favored 'General case' 0 N--CA 1.395 -3.202 0 CA-C-O 123.37 1.557 . . . . 0.0 107.436 -176.688 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -78.3 -32.94 49.62 Favored 'General case' 0 C--N 1.299 -1.592 0 CA-C-N 112.755 -2.02 . . . . 0.0 111.648 -168.495 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.401 ' HB2' ' HB ' ' A' ' 52' ' ' ILE . 39.2 m-85 -129.38 64.61 71.92 Favored Pre-proline 0 C--N 1.308 -1.208 0 C-N-CA 119.456 -0.898 . . . . 0.0 111.896 -174.841 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.58 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 56.2 Cg_endo -67.45 -7.98 20.77 Favored 'Trans proline' 0 N--CA 1.486 1.088 0 C-N-CA 122.847 2.365 . . . . 0.0 114.415 -173.866 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -110.62 -15.37 13.88 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 120.672 -0.411 . . . . 0.0 111.493 -176.753 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.554 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.8 m -115.9 -25.33 7.77 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-O 122.182 0.992 . . . . 0.0 109.779 -173.16 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.554 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.6 mp -130.67 150.12 34.28 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.996 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 -176.64 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.9 t -94.35 125.23 38.86 Favored 'General case' 0 N--CA 1.413 -2.299 0 N-CA-C 104.154 -2.535 . . . . 0.0 104.154 171.44 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.629 ' CG ' ' HB2' ' A' ' 46' ' ' ASN . 9.9 m-20 -91.71 106.16 18.27 Favored 'General case' 0 C--N 1.259 -3.336 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 -178.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.505 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 9.5 t80 -130.85 135.24 47.53 Favored 'General case' 0 C--N 1.287 -2.123 0 CA-C-N 114.49 -1.232 . . . . 0.0 109.233 -174.617 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.573 ' CG2' ' HG ' ' A' ' 131' ' ' LEU . 13.7 p -141.85 150.43 19.26 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.173 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.256 -176.004 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.1 p -150.17 129.97 13.29 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 123.894 0.878 . . . . 0.0 108.883 176.672 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.493 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 36.9 tp -65.6 112.63 3.73 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 172.309 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.477 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 2.7 tp-100 -60.66 -59.39 5.47 Favored 'General case' 0 C--O 1.204 -1.339 0 CA-C-N 113.257 -1.792 . . . . 0.0 109.915 -177.624 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -166.74 155.74 10.67 Favored 'General case' 0 N--CA 1.419 -1.999 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -175.801 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -135.44 153.73 21.39 Favored Glycine 0 N--CA 1.412 -2.92 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 -177.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.414 ' HA ' ' HB3' ' A' ' 85' ' ' PRO . 24.1 m -138.61 144.58 39.82 Favored 'General case' 0 C--N 1.281 -2.4 0 C-N-CA 123.402 0.681 . . . . 0.0 110.595 -178.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.57 ' HB1' HG23 ' A' ' 67' ' ' VAL . . . -106.64 157.96 17.31 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 125.081 1.353 . . . . 0.0 107.741 -179.52 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.787 ' O ' HG22 ' A' ' 67' ' ' VAL . 94.4 m-85 -155.74 178.15 10.58 Favored 'General case' 0 C--O 1.208 -1.113 0 CA-C-N 118.901 0.773 . . . . 0.0 111.781 -177.037 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 53.39 -127.49 36.7 Favored Glycine 0 C--O 1.217 -0.924 0 CA-C-O 121.423 0.457 . . . . 0.0 112.883 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.73 -9.16 83.44 Favored Glycine 0 N--CA 1.42 -2.38 0 C-N-CA 120.388 -0.91 . . . . 0.0 113.132 178.845 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.787 HG22 ' O ' ' A' ' 64' ' ' TYR . 12.8 m -78.49 -27.14 14.13 Favored 'Isoleucine or valine' 0 C--O 1.201 -1.468 0 CA-C-N 118.515 1.157 . . . . 0.0 112.562 -175.27 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.551 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -91.32 -15.04 29.72 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 119.91 -0.716 . . . . 0.0 111.862 176.146 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 26.5 t -101.18 -59.04 1.77 Allowed 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.524 -176.2 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.581 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 34.6 m-80 -87.14 -24.42 24.51 Favored 'General case' 0 CA--C 1.486 -1.486 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -176.147 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.574 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 85.5 m-85 -111.43 163.63 13.81 Favored 'General case' 0 C--N 1.286 -2.186 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.064 -178.592 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.2 t -179.95 134.21 0.11 Allowed 'General case' 0 N--CA 1.426 -1.645 0 N-CA-C 107.235 -1.395 . . . . 0.0 107.235 178.035 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.467 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -167.31 -109.82 0.22 Allowed Glycine 0 N--CA 1.406 -3.355 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 174.765 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 3.1 p -149.65 177.04 10.13 Favored 'General case' 0 C--N 1.275 -2.631 0 C-N-CA 122.778 0.431 . . . . 0.0 111.019 -174.681 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -132.9 140.16 47.98 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.116 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.722 ' HG3' ' O ' ' A' ' 80' ' ' SER . 82.6 tttt -120.72 145.36 47.57 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.398 -177.973 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.487 ' CD2' HG22 ' A' ' 105' ' ' VAL . 43.2 t80 -146.62 109.47 4.63 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.335 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 11.2 t 49.14 43.33 22.43 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 124.526 1.131 . . . . 0.0 111.912 178.393 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.9 11.95 62.81 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.22 -0.991 . . . . 0.0 113.107 178.221 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.722 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 23.5 t -88.77 -179.73 6.05 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 175.217 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.3 t -167.3 107.45 0.6 Allowed 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 179.31 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 2.1 p90 -144.3 158.19 55.12 Favored Pre-proline 0 C--N 1.287 -2.136 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 -173.909 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -67.96 144.77 65.55 Favored 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 122.614 2.21 . . . . 0.0 112.789 -175.016 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.547 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 60.8 t80 -118.41 134.73 23.42 Favored Pre-proline 0 C--N 1.31 -1.141 0 CA-C-N 116.233 -0.44 . . . . 0.0 109.977 -179.102 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.547 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 66.6 Cg_endo -72.22 143.75 78.19 Favored 'Cis proline' 0 CA--C 1.543 0.942 0 C-N-CA 123.189 -1.588 . . . . 0.0 111.465 -0.899 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.7 t -66.84 -177.03 0.55 Allowed 'General case' 0 CA--C 1.547 0.861 0 CA-C-N 115.161 -0.927 . . . . 0.0 111.941 -174.822 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 16.4 p -130.19 -46.23 1.11 Allowed 'General case' 0 N--CA 1.425 -1.679 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.699 -172.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.3 t -101.04 -97.68 0.26 Allowed 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -177.375 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -166.45 -166.66 0.9 Allowed 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 177.255 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.493 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 46.9 p -99.38 165.66 14.37 Favored Pre-proline 0 C--N 1.297 -1.68 0 N-CA-C 113.753 1.02 . . . . 0.0 113.753 -178.135 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 20.8 Cg_endo -61.65 169.72 6.6 Favored 'Trans proline' 0 C--O 1.247 0.929 0 C-N-CA 123.252 2.635 . . . . 0.0 110.682 171.017 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.505 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 3.2 tmm_? -80.25 123.07 27.64 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.03 -175.291 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 75.1 t -132.58 123.35 49.28 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.134 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.591 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 58.5 t -105.0 140.79 21.96 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.169 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 176.776 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.479 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 4.7 m-85 -84.2 94.91 8.5 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-O 121.75 0.785 . . . . 0.0 109.677 175.667 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 15.6 m120 -87.32 74.72 9.41 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 43.4 t -150.12 -173.41 4.43 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 -175.897 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 37.9 ptt180 -145.56 24.21 1.4 Allowed 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 172.889 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.4 t -160.85 174.65 13.55 Favored 'General case' 0 N--CA 1.426 -1.644 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 -176.055 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -61.96 136.15 57.84 Favored 'General case' 0 C--N 1.318 -0.792 0 O-C-N 123.59 0.556 . . . . 0.0 110.643 179.346 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 14.3 mmtm -138.52 150.25 65.55 Favored Pre-proline 0 C--N 1.286 -2.179 0 C-N-CA 124.976 1.311 . . . . 0.0 108.405 176.655 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -62.74 149.19 92.06 Favored 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 122.631 2.221 . . . . 0.0 111.881 -178.589 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' TRP . . . . . 0.479 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 11.2 t90 -89.88 104.89 9.4 Favored Pre-proline 0 C--N 1.305 -1.365 0 N-CA-C 106.171 -1.788 . . . . 0.0 106.171 178.122 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -75.99 87.54 1.4 Allowed 'Trans proline' 0 N--CA 1.448 -1.157 0 C-N-CA 121.27 1.313 . . . . 0.0 112.663 -172.191 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.487 HG22 ' CD2' ' A' ' 77' ' ' TYR . 61.7 t -140.16 149.7 21.81 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.126 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.492 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.609 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -153.14 135.4 14.93 Favored 'General case' 0 C--N 1.289 -2.025 0 O-C-N 123.268 0.355 . . . . 0.0 110.366 177.002 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.504 HD21 HD11 ' A' ' 129' ' ' LEU . 20.5 mt -101.73 104.84 15.66 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 177.695 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.467 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 55.4 m-85 -82.42 72.19 9.48 Favored 'General case' 0 C--N 1.281 -2.411 0 CA-C-O 120.883 0.373 . . . . 0.0 110.491 177.284 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.658 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.3 mm? -90.28 119.16 30.35 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 175.047 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -126.97 146.77 58.82 Favored Pre-proline 0 N--CA 1.411 -2.419 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -177.285 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.581 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 21.4 Cg_endo -60.99 118.8 5.71 Favored 'Trans proline' 0 C--O 1.246 0.902 0 C-N-CA 123.484 2.79 . . . . 0.0 112.468 -178.331 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.45 ' O ' HG13 ' A' ' 30' ' ' VAL . 3.1 m -67.98 -115.83 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.187 -2.188 0 CA-C-N 114.406 -1.27 . . . . 0.0 112.737 176.025 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 32.5 m -111.4 -42.58 3.86 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.159 -0.963 . . . . 0.0 111.312 179.468 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 8.8 t -90.99 28.4 1.59 Allowed 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 121.636 0.731 . . . . 0.0 110.356 -173.624 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -89.39 132.0 35.19 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.394 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.91 140.69 6.19 Favored Glycine 0 N--CA 1.434 -1.488 0 C-N-CA 119.496 -1.335 . . . . 0.0 111.994 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 57.09 -144.38 39.35 Favored Glycine 0 CA--C 1.495 -1.186 0 CA-C-O 119.175 -0.791 . . . . 0.0 112.87 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.0 p -61.43 96.02 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.245 0.856 0 CA-C-O 122.876 1.322 . . . . 0.0 112.385 -177.536 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.18 -31.81 11.9 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 114.327 -1.306 . . . . 0.0 111.053 -178.382 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.552 ' HB ' HG22 ' A' ' 154' ' ' VAL . 70.5 mt -124.8 139.32 51.33 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 177.162 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.404 ' HA ' ' HE2' ' A' ' 121' ' ' LYS . 3.3 mmpt? -114.24 136.17 53.26 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.179 0.514 . . . . 0.0 111.065 178.023 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -72.66 122.94 22.27 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.102 -178.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 99.48 -5.53 58.76 Favored Glycine 0 N--CA 1.434 -1.482 0 N-CA-C 110.891 -0.884 . . . . 0.0 110.891 -178.167 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 49.9 m -97.05 149.07 22.35 Favored 'General case' 0 N--CA 1.422 -1.851 0 CA-C-O 121.518 0.675 . . . . 0.0 110.382 -179.669 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.416 HD11 HG23 ' A' ' 128' ' ' VAL . 3.0 tm? -75.69 127.76 33.75 Favored 'General case' 0 N--CA 1.429 -1.502 0 CA-C-N 114.203 -1.362 . . . . 0.0 108.656 -178.213 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.541 ' HB ' HG11 ' A' ' 67' ' ' VAL . 28.1 pt -113.16 -29.7 2.27 Favored 'Isoleucine or valine' 0 C--O 1.197 -1.679 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.733 178.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' ALA . . . . . 0.493 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -156.91 166.93 31.99 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.659 -177.575 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.416 HG23 HD11 ' A' ' 125' ' ' LEU . 54.8 t -141.35 114.52 4.57 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.089 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 178.219 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.504 HD11 HD21 ' A' ' 107' ' ' LEU . 64.5 mt -118.12 138.66 52.12 Favored 'General case' 0 C--N 1.288 -2.086 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 178.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.47 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.0 mp -120.03 127.81 75.91 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 C-N-CA 119.335 -0.946 . . . . 0.0 109.455 178.644 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.573 ' HG ' ' CG2' ' A' ' 56' ' ' VAL . 0.1 OUTLIER -99.17 130.18 45.47 Favored 'General case' 0 C--N 1.273 -2.758 0 C-N-CA 124.391 1.076 . . . . 0.0 110.994 -176.648 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 132' ' ' ARG . . . . . 0.477 ' HG2' ' HB2' ' A' ' 59' ' ' GLN . 14.6 mmm180 -97.99 113.34 25.16 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 123.428 0.691 . . . . 0.0 110.308 178.361 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 133' ' ' GLN . . . . . 0.494 ' HG2' HD21 ' A' ' 131' ' ' LEU . 12.5 mm100 -92.43 134.66 34.73 Favored 'General case' 0 N--CA 1.404 -2.744 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 173.551 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.428 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 19.5 m -142.26 130.56 22.25 Favored 'General case' 0 C--N 1.28 -2.424 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 176.235 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 15.6 p30 . . . . . 0 C--N 1.307 -1.255 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.333 -179.267 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 . . . . . 0 N--CA 1.444 -0.739 0 N-CA-C 109.543 -0.539 . . . . 0.0 109.543 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 143' ' ' GLN . . . . . 0.464 ' HB3' ' HD2' ' A' ' 132' ' ' ARG . 12.9 pt20 -129.04 142.39 50.92 Favored 'General case' 0 N--CA 1.425 -1.719 0 C-N-CA 120.077 -0.649 . . . . 0.0 109.385 177.274 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -109.93 136.63 48.91 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 -176.727 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.416 ' O ' ' HA ' ' A' ' 17' ' ' SER . 43.8 t -95.26 129.9 44.75 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 O-C-N 123.69 0.619 . . . . 0.0 109.638 -177.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 146' ' ' TRP . . . . . 0.484 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 63.3 m95 -119.8 103.21 9.16 Favored 'General case' 0 C--N 1.282 -2.338 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -178.195 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -83.89 112.1 19.83 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 179.554 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.493 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 23.0 mm -87.45 122.65 39.49 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.187 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 -178.363 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -116.69 156.93 26.26 Favored 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 123.669 0.788 . . . . 0.0 109.267 179.198 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.46 130.52 34.57 Favored 'General case' 0 N--CA 1.396 -3.151 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 176.475 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 36.7 t-20 -89.13 -18.61 26.85 Favored 'General case' 0 C--N 1.285 -2.226 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 -177.521 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -147.66 143.71 27.85 Favored 'General case' 0 N--CA 1.429 -1.483 0 CA-C-N 114.013 -1.449 . . . . 0.0 109.284 -173.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -83.41 139.45 32.97 Favored 'General case' 0 C--N 1.312 -1.063 0 O-C-N 124.391 1.057 . . . . 0.0 109.698 -178.344 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.552 HG22 ' HB ' ' A' ' 120' ' ' ILE . 1.8 m -121.47 148.54 24.81 Favored 'Isoleucine or valine' 0 C--O 1.257 1.478 0 C-N-CA 120.138 -0.625 . . . . 0.0 111.259 -177.65 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.5 t -120.49 140.95 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.699 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 -179.058 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.455 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 71.4 t -102.24 104.62 38.12 Favored Pre-proline 0 C--N 1.288 -2.068 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 178.374 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.486 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 43.4 Cg_endo -71.29 -20.75 27.59 Favored 'Trans proline' 0 N--CA 1.462 -0.332 0 C-N-CA 122.404 2.069 . . . . 0.0 111.428 176.865 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 158' ' ' THR . . . . . 0.425 ' HA ' ' H ' ' A' ' 30' ' ' VAL 0.26 3.3 t . . . . . 0 C--O 1.247 0.951 0 C-N-CA 124.497 1.119 . . . . 0.0 113.775 175.904 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.515 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.431 -1.416 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.531 ' HB3' ' CZ2' ' A' ' 146' ' ' TRP . 10.6 t -156.92 164.0 38.52 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 118.604 -1.238 . . . . 0.0 110.677 -176.294 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.414 ' HG3' ' O ' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -147.2 159.86 43.14 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -177.003 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.608 HG22 HG22 ' A' ' 20' ' ' VAL . 63.9 p -99.8 173.66 6.58 Favored 'General case' 0 C--N 1.3 -1.578 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.727 178.815 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.0 -21.75 59.86 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 114.629 -1.169 . . . . 0.0 111.223 177.051 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -82.11 -35.43 28.58 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 119.574 -0.85 . . . . 0.0 110.411 -178.24 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 133.49 16.45 1.17 Allowed Glycine 0 N--CA 1.434 -1.49 0 C-N-CA 119.709 -1.234 . . . . 0.0 112.955 178.267 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.3 m -91.53 105.46 17.77 Favored 'General case' 0 N--CA 1.428 -1.573 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 174.548 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -98.18 123.58 42.32 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 176.029 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.515 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 49.6 mt -104.17 117.81 58.48 Favored Pre-proline 0 C--N 1.29 -1.981 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 177.478 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -81.71 176.2 8.68 Favored 'Trans proline' 0 C--O 1.245 0.842 0 C-N-CA 122.601 2.2 . . . . 0.0 110.783 176.489 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 63.5 mt -67.1 129.15 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 N-CA-C 109.052 -0.722 . . . . 0.0 109.052 177.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 145.36 -8.95 1.67 Allowed Glycine 0 C--N 1.308 -0.98 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.004 -178.53 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.21 154.6 30.78 Favored Glycine 0 CA--C 1.504 -0.594 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 -178.281 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 160.39 -171.44 36.6 Favored Glycine 0 N--CA 1.428 -1.893 0 C-N-CA 119.851 -1.166 . . . . 0.0 111.169 -178.583 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.527 ' HB3' ' HB ' ' A' ' 145' ' ' VAL . 28.8 p -144.34 151.18 38.96 Favored 'General case' 0 C--N 1.291 -1.949 0 CA-C-O 120.797 0.332 . . . . 0.0 111.153 -177.073 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.16 162.52 32.29 Favored 'General case' 0 N--CA 1.421 -1.9 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -178.919 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.432 HD21 ' HE1' ' A' ' 21' ' ' TYR . 4.7 p-10 -108.27 113.57 26.77 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.077 -0.965 . . . . 0.0 108.741 176.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.608 HG22 HG22 ' A' ' 5' ' ' THR . 40.0 t -103.71 116.78 48.11 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.757 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.403 -179.456 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.432 ' HE1' HD21 ' A' ' 19' ' ' ASN . 23.5 m-85 -102.07 119.15 38.34 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 120.602 0.239 . . . . 0.0 111.058 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.478 HG22 ' HG3' ' A' ' 41' ' ' GLN . 23.7 t -119.98 128.09 75.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.73 -174.815 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 48.1 m-80 -81.83 126.55 32.0 Favored 'General case' 0 CA--C 1.483 -1.604 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 176.385 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.423 HD21 HG22 ' A' ' 36' ' ' VAL . 28.8 mt -117.8 148.31 42.2 Favored 'General case' 0 C--N 1.28 -2.449 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 179.482 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -53.24 119.14 16.09 Favored Pre-proline 0 C--O 1.209 -1.071 0 O-C-N 124.923 1.389 . . . . 0.0 110.524 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.599 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 56.3 Cg_endo -72.01 -0.29 8.28 Favored 'Trans proline' 0 CA--C 1.535 0.531 0 C-N-CA 122.999 2.466 . . . . 0.0 113.531 -175.723 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.412 HG13 ' HG3' ' A' ' 157' ' ' PRO . 66.8 t -131.63 109.91 16.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 179.815 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.513 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 11.6 t -147.71 113.99 0.92 Allowed 'Isoleucine or valine' 0 C--O 1.186 -2.273 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 -177.343 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.794 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -100.15 157.65 16.42 Favored 'General case' 0 C--N 1.273 -2.738 0 C-N-CA 123.824 0.85 . . . . 0.0 111.636 -178.787 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.408 HG13 ' O ' ' A' ' 112' ' ' VAL . 38.5 t -49.79 120.13 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 CA-C-O 121.029 0.442 . . . . 0.0 111.188 176.323 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.31 8.95 58.37 Favored Glycine 0 CA--C 1.522 0.51 0 CA-C-N 115.57 -0.741 . . . . 0.0 112.808 -179.595 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.794 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -80.37 -175.29 5.05 Favored 'General case' 0 C--N 1.31 -1.11 0 C-N-CA 124.983 1.313 . . . . 0.0 108.237 175.762 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 18.7 t-20 -133.78 95.4 3.45 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 177.814 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.621 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 24.7 tp -91.96 144.29 25.61 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 119.166 -1.013 . . . . 0.0 109.498 178.516 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 62.0 t -135.48 124.06 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.915 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 -177.55 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.565 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 44.9 t -92.87 88.52 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.183 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 173.067 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.43 ' O ' ' HG2' ' A' ' 41' ' ' GLN . 32.5 t70 -79.08 104.19 9.54 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.981 -177.139 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.7 mt -85.55 -2.84 58.57 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.345 -179.059 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.429 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 36.6 t -73.58 -2.49 23.08 Favored 'General case' 0 CA--C 1.546 0.8 0 CA-C-O 121.715 0.769 . . . . 0.0 110.16 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.5 p -126.78 8.43 6.88 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.191 177.399 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.478 ' HG3' HG22 ' A' ' 22' ' ' VAL . 43.8 mm-40 -125.26 -27.08 3.54 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.226 -174.06 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.6 mt -133.79 135.75 54.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 -175.624 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.414 ' O ' ' HG3' ' A' ' 4' ' ' LYS . 39.0 m-85 -138.31 120.1 15.28 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -176.377 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.498 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 74.3 m -102.94 145.29 30.06 Favored 'General case' 0 C--N 1.281 -2.385 0 CA-C-O 120.825 0.345 . . . . 0.0 110.333 -177.461 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' HIS . . . . . 0.435 ' HB3' ' HA ' ' A' ' 100' ' ' ASP . 25.8 p-80 -134.56 149.42 50.63 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.112 -173.778 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 60.8 t30 -103.26 91.2 3.98 Favored 'General case' 0 C--N 1.291 -1.941 0 C-N-CA 118.786 -1.166 . . . . 0.0 109.882 172.66 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -61.46 -24.43 66.55 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 113.508 -1.678 . . . . 0.0 111.905 -177.608 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 50.6 m-85 -125.71 78.64 68.86 Favored Pre-proline 0 C--N 1.322 -0.629 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 -178.657 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -73.02 -7.42 20.65 Favored 'Trans proline' 0 C--N 1.332 -0.319 0 C-N-CA 122.631 2.221 . . . . 0.0 114.241 -173.193 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -112.45 -23.03 10.54 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 121.768 0.794 . . . . 0.0 109.786 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.579 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.6 OUTLIER -97.68 -30.1 13.02 Favored 'General case' 0 N--CA 1.407 -2.597 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.744 -169.82 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.579 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.0 mp -128.67 133.69 65.93 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.806 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.185 -176.915 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.9 t -75.88 145.64 40.38 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 174.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.428 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 3.0 m-20 -81.47 108.72 15.3 Favored 'General case' 0 C--N 1.278 -2.509 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -174.013 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 77.3 t80 -147.9 138.85 23.31 Favored 'General case' 0 C--N 1.293 -1.865 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.203 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.483 HG23 ' HG ' ' A' ' 131' ' ' LEU . 14.5 p -152.19 147.19 15.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 C-N-CA 124.405 1.082 . . . . 0.0 109.371 176.538 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.88 127.29 10.7 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 123.401 0.68 . . . . 0.0 109.824 172.927 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.498 HD23 ' O ' ' A' ' 130' ' ' ILE . 1.1 tt -68.0 114.24 6.36 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 175.379 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.1 tp-100 -58.62 -63.87 1.13 Allowed 'General case' 0 C--O 1.206 -1.228 0 C-N-CA 124.718 1.207 . . . . 0.0 110.372 178.114 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.435 ' HA ' HG23 ' A' ' 86' ' ' THR . 0.0 OUTLIER -164.09 154.02 14.61 Favored 'General case' 0 N--CA 1.422 -1.834 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -173.689 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.475 ' O ' ' HB2' ' A' ' 85' ' ' PRO . . . -124.03 154.84 17.78 Favored Glycine 0 N--CA 1.409 -3.104 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 179.583 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 49.4 m -131.39 145.6 51.89 Favored 'General case' 0 C--N 1.28 -2.416 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.478 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -113.97 154.82 26.96 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.914 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.453 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . 88.5 m-85 -156.63 -178.1 7.1 Favored 'General case' 0 C--O 1.238 0.479 0 C-N-CA 123.622 0.769 . . . . 0.0 109.506 -177.268 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 62.02 -137.71 45.98 Favored Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 115.783 -0.644 . . . . 0.0 113.148 175.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -84.32 -7.66 84.59 Favored Glycine 0 N--CA 1.42 -2.41 0 N-CA-C 111.336 -0.705 . . . . 0.0 111.336 177.221 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.786 HG21 ' HB ' ' A' ' 126' ' ' ILE . 94.5 t -70.0 -43.81 78.97 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.379 0 C-N-CA 123.056 0.543 . . . . 0.0 111.429 -178.525 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.478 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -82.32 -16.99 47.35 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.129 -1.028 . . . . 0.0 111.978 -179.469 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 8.2 t -100.54 -51.92 3.48 Favored 'General case' 0 N--CA 1.444 -0.771 0 CA-C-N 115.86 -0.609 . . . . 0.0 112.125 -174.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.536 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 34.0 m-80 -93.77 -21.53 19.25 Favored 'General case' 0 CA--C 1.492 -1.272 0 C-N-CA 120.494 -0.482 . . . . 0.0 109.972 -175.308 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.671 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 78.2 m-85 -111.8 161.8 15.95 Favored 'General case' 0 N--CA 1.425 -1.712 0 C-N-CA 120.076 -0.65 . . . . 0.0 109.967 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 t -169.52 133.92 1.38 Allowed 'General case' 0 N--CA 1.419 -1.991 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 176.456 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.492 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -167.08 -111.92 0.25 Allowed Glycine 0 N--CA 1.402 -3.604 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 175.721 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.4 p -157.72 -179.46 8.18 Favored 'General case' 0 C--N 1.29 -2.016 0 C-N-CA 124.421 1.088 . . . . 0.0 110.02 -174.142 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.423 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.6 p -132.66 147.88 31.76 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.734 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.601 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.9 tttt -125.61 147.57 49.26 Favored 'General case' 0 N--CA 1.43 -1.446 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.839 -178.609 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.522 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 52.1 t80 -147.76 109.48 4.42 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 -178.192 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 9.2 t 50.8 43.7 28.16 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 124.079 0.952 . . . . 0.0 111.35 177.564 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.02 6.16 69.73 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 120.415 -0.898 . . . . 0.0 113.946 178.826 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.601 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 12.2 t -79.74 -178.86 6.6 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 117.436 0.618 . . . . 0.0 110.205 178.597 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 40.9 t -159.24 103.54 1.63 Allowed 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 -179.4 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.522 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 4.0 p90 -148.85 161.65 32.05 Favored Pre-proline 0 C--N 1.313 -0.991 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 -174.275 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.439 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 84.9 Cg_endo -71.77 149.13 53.75 Favored 'Trans proline' 0 C--N 1.362 1.261 0 C-N-CA 122.494 2.129 . . . . 0.0 113.502 -174.386 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.656 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 56.8 t80 -120.45 137.36 26.08 Favored Pre-proline 0 N--CA 1.427 -1.597 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 178.738 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.656 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 66.2 Cg_endo -70.52 142.59 72.39 Favored 'Cis proline' 0 CA--C 1.542 0.916 0 C-N-CA 122.933 -1.695 . . . . 0.0 112.959 -1.487 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.435 HG23 ' HA ' ' A' ' 60' ' ' ARG 0.338 10.3 t -63.54 105.4 0.77 Allowed 'General case' 0 C--O 1.249 1.059 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 -179.361 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 7.3 p -77.54 -13.04 60.01 Favored 'General case' 0 C--N 1.282 -2.363 0 CA-C-N 112.975 -1.92 . . . . 0.0 110.779 -175.562 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.7 t -119.41 -82.96 0.65 Allowed 'General case' 0 N--CA 1.409 -2.497 0 C-N-CA 119.326 -0.95 . . . . 0.0 111.898 -173.632 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 172.4 177.95 0.08 Allowed 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.284 1.033 . . . . 0.0 108.695 -178.132 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.426 HG21 ' CD2' ' A' ' 77' ' ' TYR . 42.9 p -102.31 161.07 24.45 Favored Pre-proline 0 C--N 1.301 -1.51 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 177.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -61.22 162.58 19.5 Favored 'Trans proline' 0 CA--C 1.546 1.103 0 C-N-CA 123.427 2.751 . . . . 0.0 111.696 172.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.7 tmm_? -72.29 116.82 13.17 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 124.588 1.155 . . . . 0.0 109.874 -176.291 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 75.4 t -124.84 127.89 72.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 CA-C-O 121.348 0.594 . . . . 0.0 111.234 -178.437 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 77.0 t -107.13 123.18 62.13 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.214 178.177 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.453 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 5.3 m-85 -78.34 156.29 29.65 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 173.066 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -128.67 34.24 4.53 Favored 'General case' 0 C--N 1.261 -3.276 0 N-CA-C 106.8 -1.556 . . . . 0.0 106.8 175.698 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' SER . . . . . 0.445 ' CB ' ' HG3' ' A' ' 101' ' ' LYS . 45.2 m -130.67 117.64 19.77 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 113.563 0.949 . . . . 0.0 113.563 -170.776 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 20.4 ptp180 -93.93 32.15 1.51 Allowed 'General case' 0 C--O 1.244 0.797 0 CA-C-O 122.332 1.063 . . . . 0.0 110.129 179.345 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 9.2 t -152.82 165.63 34.8 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 105.203 -2.147 . . . . 0.0 105.203 -178.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ASP . . . . . 0.435 ' HA ' ' HB3' ' A' ' 45' ' ' HIS . 16.9 p-10 -74.0 112.71 10.4 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-O 122.167 0.984 . . . . 0.0 111.099 -174.565 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' LYS . . . . . 0.445 ' HG3' ' CB ' ' A' ' 97' ' ' SER . 15.2 mmtm -122.98 145.27 45.28 Favored Pre-proline 0 C--N 1.284 -2.254 0 CA-C-N 114.235 -1.348 . . . . 0.0 108.618 -178.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.429 ' HB3' ' O ' ' A' ' 39' ' ' SER . 17.9 Cg_endo -56.17 142.27 86.89 Favored 'Trans proline' 0 N--CA 1.45 -1.053 0 C-N-CA 123.318 2.679 . . . . 0.0 113.7 -172.646 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' TRP . . . . . 0.453 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.7 t90 -89.67 106.07 12.89 Favored Pre-proline 0 C--N 1.298 -1.667 0 N-CA-C 105.27 -2.122 . . . . 0.0 105.27 178.936 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -76.25 87.48 1.43 Allowed 'Trans proline' 0 N--CA 1.435 -1.961 0 C-N-CA 121.228 1.285 . . . . 0.0 111.685 -173.339 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.473 HG22 ' CD2' ' A' ' 77' ' ' TYR . 64.9 t -138.86 145.83 27.15 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 177.658 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.565 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -152.01 135.52 16.1 Favored 'General case' 0 C--N 1.278 -2.534 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.262 177.856 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.494 HD21 HD11 ' A' ' 129' ' ' LEU . 21.4 mt -98.66 102.52 14.29 Favored 'General case' 0 C--N 1.287 -2.123 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 178.782 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.492 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 50.8 m-85 -83.86 73.57 10.3 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 120.951 0.405 . . . . 0.0 110.378 177.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.671 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 2.9 mm? -99.47 129.76 45.67 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 175.762 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -130.07 148.21 68.75 Favored Pre-proline 0 N--CA 1.413 -2.312 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 -178.141 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.536 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 20.4 Cg_endo -59.41 120.67 8.64 Favored 'Trans proline' 0 C--O 1.246 0.88 0 C-N-CA 123.283 2.655 . . . . 0.0 112.286 -178.262 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.416 HG22 ' H ' ' A' ' 112' ' ' VAL . 2.7 m -69.21 -116.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.184 -2.394 0 CA-C-N 114.26 -1.336 . . . . 0.0 113.194 176.857 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 21.4 m -112.18 -40.47 4.17 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.316 -0.865 . . . . 0.0 110.632 179.202 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 28.9 t -87.79 28.47 1.01 Allowed 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.697 -176.245 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -95.18 132.91 39.62 Favored 'General case' 0 N--CA 1.427 -1.597 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -171.54 144.24 8.04 Favored Glycine 0 N--CA 1.436 -1.335 0 C-N-CA 120.057 -1.068 . . . . 0.0 111.559 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.454 ' O ' ' HA ' ' A' ' 155' ' ' VAL . . . 54.35 -145.7 26.54 Favored Glycine 0 CA--C 1.488 -1.613 0 C-N-CA 124.132 0.872 . . . . 0.0 113.0 -179.219 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 58.2 t -62.78 100.83 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.95 0 CA-C-O 121.602 0.715 . . . . 0.0 110.07 -177.31 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -99.33 -25.84 14.35 Favored 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 114.509 -1.223 . . . . 0.0 109.985 -179.331 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.523 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.0 mt -134.75 138.29 49.6 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -179.451 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.491 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.7 mmpt? -112.89 147.42 37.07 Favored 'General case' 0 C--N 1.31 -1.136 0 C-N-CA 122.692 0.397 . . . . 0.0 110.193 174.877 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.89 126.91 30.94 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 177.692 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.13 -8.33 67.35 Favored Glycine 0 C--N 1.312 -0.757 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -177.536 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 33.5 t -81.38 136.97 35.74 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 -179.763 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -72.35 121.85 20.18 Favored 'General case' 0 N--CA 1.429 -1.505 0 N-CA-C 106.491 -1.67 . . . . 0.0 106.491 175.813 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.786 ' HB ' HG21 ' A' ' 67' ' ' VAL . 27.7 pt -109.11 -27.42 2.93 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.915 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -177.128 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.28 169.38 20.76 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -177.6 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 76.7 t -144.11 113.38 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 179.161 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.494 HD11 HD21 ' A' ' 107' ' ' LEU . 46.2 mt -114.46 140.76 48.45 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.775 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.498 ' O ' HD23 ' A' ' 58' ' ' LEU . 4.0 mp -121.21 129.6 75.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 C-N-CA 118.844 -1.142 . . . . 0.0 110.787 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.556 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.2 OUTLIER -103.19 131.9 49.87 Favored 'General case' 0 C--N 1.284 -2.24 0 C-N-CA 125.268 1.427 . . . . 0.0 110.553 -177.147 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 132' ' ' ARG . . . . . 0.424 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 14.0 mmm180 -93.54 132.57 37.71 Favored 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 123.78 0.832 . . . . 0.0 110.699 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 133' ' ' GLN . . . . . 0.416 ' HA ' ' NE2' ' A' ' 133' ' ' GLN . 5.1 tp-100 -113.28 114.6 26.92 Favored 'General case' 0 N--CA 1.422 -1.844 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 174.749 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 26.4 m -135.48 144.75 46.57 Favored 'General case' 0 C--N 1.286 -2.168 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 179.24 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.558 ' CB ' HG23 ' A' ' 52' ' ' ILE . 11.8 p30 . . . . . 0 N--CA 1.436 -1.173 0 C-N-CA 119.305 -0.958 . . . . 0.0 112.355 178.816 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 . . . . . 0 N--CA 1.429 -1.521 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 143' ' ' GLN . . . . . 0.424 ' HB3' ' HD2' ' A' ' 132' ' ' ARG . 13.4 pt20 -138.72 149.8 45.46 Favored 'General case' 0 N--CA 1.415 -2.178 0 C-N-CA 120.383 -0.527 . . . . 0.0 110.628 178.187 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 8.4 m-30 -108.1 134.32 51.14 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -175.578 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.527 ' HB ' ' HB3' ' A' ' 17' ' ' SER . 55.3 t -94.24 128.06 45.81 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 O-C-N 123.738 0.649 . . . . 0.0 110.137 -179.087 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 146' ' ' TRP . . . . . 0.556 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.4 m95 -114.87 96.98 5.98 Favored 'General case' 0 C--N 1.275 -2.658 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -179.634 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 40.4 m-80 -80.01 112.73 17.6 Favored 'General case' 0 C--N 1.291 -1.959 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.454 HG22 HD11 ' A' ' 126' ' ' ILE . 24.4 mm -87.9 123.95 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.879 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 -177.064 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -118.82 153.92 33.71 Favored 'General case' 0 C--N 1.288 -2.098 0 C-N-CA 124.105 0.962 . . . . 0.0 108.468 178.25 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.403 ' HB3' ' O ' ' A' ' 121' ' ' LYS . . . -82.29 133.76 35.25 Favored 'General case' 0 N--CA 1.406 -2.635 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 176.114 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -92.29 -13.15 30.78 Favored 'General case' 0 C--N 1.284 -2.26 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 -177.073 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -153.89 148.11 25.85 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 113.834 -1.53 . . . . 0.0 108.824 -176.694 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -82.12 149.02 28.22 Favored 'General case' 0 C--N 1.322 -0.628 0 O-C-N 123.958 0.786 . . . . 0.0 111.096 -178.436 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.599 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 73.7 t -124.62 133.68 68.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.346 -176.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.454 ' HA ' ' O ' ' A' ' 117' ' ' GLY . 8.4 t -116.71 136.35 54.06 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.513 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 72.3 t -100.02 103.52 23.04 Favored Pre-proline 0 C--N 1.292 -1.895 0 C-N-CA 123.384 0.674 . . . . 0.0 109.324 178.704 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.412 ' HG3' HG13 ' A' ' 27' ' ' VAL . 33.3 Cg_endo -68.47 -27.1 33.81 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 122.423 2.082 . . . . 0.0 111.781 179.222 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 158' ' ' THR . . . . . 0.416 ' HB ' HG12 ' A' ' 156' ' ' VAL . 4.4 t . . . . . 0 CA--C 1.548 0.895 0 C-N-CA 125.109 1.364 . . . . 0.0 113.515 176.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.481 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.443 -0.791 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 70.9 m -136.02 159.41 41.77 Favored 'General case' 0 C--N 1.301 -1.5 0 C-N-CA 120.741 -0.384 . . . . 0.0 111.127 -175.348 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.416 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -143.73 161.05 39.6 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.172 0.51 . . . . 0.0 111.197 -176.187 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.521 HG22 HG22 ' A' ' 20' ' ' VAL . 72.0 p -102.25 168.88 9.07 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.335 177.793 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.99 -7.12 53.89 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 114.103 -1.408 . . . . 0.0 112.009 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -90.65 -31.29 16.69 Favored 'General case' 0 CA--C 1.511 -0.537 0 C-N-CA 118.458 -1.297 . . . . 0.0 108.234 176.219 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 133.24 2.57 3.68 Favored Glycine 0 N--CA 1.431 -1.678 0 C-N-CA 120.29 -0.957 . . . . 0.0 113.029 177.599 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.6 m -77.91 102.31 7.24 Favored 'General case' 0 N--CA 1.442 -0.869 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.193 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.26 117.59 30.54 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 175.12 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.481 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 62.1 mt -92.69 115.62 65.15 Favored Pre-proline 0 C--N 1.301 -1.529 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 179.348 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_endo -78.36 -179.83 5.82 Favored 'Trans proline' 0 C--O 1.248 0.981 0 C-N-CA 122.643 2.229 . . . . 0.0 111.526 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.5 mt -70.62 129.55 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.18 1.09 3.29 Favored Glycine 0 C--N 1.305 -1.162 0 C-N-CA 120.886 -0.673 . . . . 0.0 111.607 -178.881 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.75 171.41 46.91 Favored Glycine 0 C--O 1.244 0.773 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.289 -179.607 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 150.9 -169.11 30.66 Favored Glycine 0 N--CA 1.438 -1.182 0 C-N-CA 120.474 -0.869 . . . . 0.0 111.352 177.835 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 87.0 p -141.93 157.5 44.89 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -141.04 162.83 34.57 Favored 'General case' 0 N--CA 1.42 -1.965 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -110.03 111.33 22.64 Favored 'General case' 0 C--N 1.285 -2.207 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.256 178.63 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.521 HG22 HG22 ' A' ' 5' ' ' THR . 41.5 t -100.75 135.83 35.07 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.441 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.513 -178.779 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 69.2 m-85 -125.29 128.51 48.36 Favored 'General case' 0 CA--C 1.492 -1.272 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -177.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.514 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.2 p -139.63 136.33 39.84 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 O-C-N 123.78 0.675 . . . . 0.0 110.974 -177.084 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 -88.79 128.29 35.63 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 178.089 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.441 HD11 HG22 ' A' ' 36' ' ' VAL . 2.7 mm? -107.11 160.05 15.85 Favored 'General case' 0 C--N 1.284 -2.272 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 176.15 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.45 120.66 37.63 Favored Pre-proline 0 C--O 1.209 -1.046 0 O-C-N 124.505 1.128 . . . . 0.0 109.365 176.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.515 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 62.4 Cg_endo -74.14 0.45 8.43 Favored 'Trans proline' 0 CA--C 1.537 0.667 0 C-N-CA 122.668 2.245 . . . . 0.0 113.514 -176.88 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.45 HG13 ' HG3' ' A' ' 157' ' ' PRO . 93.7 t -131.49 111.43 19.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 178.455 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.476 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 9.3 t -147.76 112.96 0.83 Allowed 'Isoleucine or valine' 0 C--O 1.194 -1.845 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 -177.453 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.666 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -101.05 154.75 18.44 Favored 'General case' 0 C--N 1.277 -2.571 0 C-N-CA 123.746 0.818 . . . . 0.0 111.062 -179.354 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.543 HG22 ' O ' ' A' ' 112' ' ' VAL . 99.1 t -46.12 117.84 0.39 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.478 0 C-N-CA 123.379 0.672 . . . . 0.0 111.338 175.614 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.1 1.36 54.63 Favored Glycine 0 C--N 1.311 -0.815 0 CA-C-N 115.253 -0.885 . . . . 0.0 113.101 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.666 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -74.42 -175.91 2.51 Favored 'General case' 0 C--N 1.315 -0.914 0 C-N-CA 124.551 1.141 . . . . 0.0 109.967 175.336 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 66.5 t30 -134.45 96.02 3.5 Favored 'General case' 0 N--CA 1.428 -1.559 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 177.689 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.596 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 28.8 tp -93.15 142.52 27.21 Favored 'General case' 0 C--N 1.284 -2.247 0 C-N-CA 119.773 -0.771 . . . . 0.0 109.929 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.0 t -135.01 122.08 35.89 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.719 0 CA-C-O 121.168 0.508 . . . . 0.0 109.901 -176.533 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.585 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 47.8 t -92.94 89.07 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.27 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 174.859 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -78.03 106.76 10.11 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.248 -177.568 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.6 mt -93.79 -1.68 54.65 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 121.365 0.602 . . . . 0.0 111.025 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.9 t -76.37 1.28 16.74 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.974 -178.868 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.3 p -129.55 8.93 5.46 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 123.614 0.765 . . . . 0.0 109.869 176.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.514 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 45.6 mm-40 -125.23 -24.73 3.93 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.505 -174.808 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.0 mt -133.71 141.59 43.78 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 -177.115 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.472 ' HA ' ' HA ' ' A' ' 102' ' ' PRO . 57.6 m-85 -141.24 161.14 38.59 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -176.199 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 69.3 m -138.69 138.77 38.06 Favored 'General case' 0 C--N 1.299 -1.618 0 C-N-CA 123.059 0.544 . . . . 0.0 110.953 -178.609 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 29.4 p-80 -134.12 148.94 51.05 Favored 'General case' 0 C--O 1.247 0.965 0 CA-C-O 121.378 0.609 . . . . 0.0 111.961 -175.386 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.496 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 3.4 p30 -105.37 118.87 37.66 Favored 'General case' 0 CA--C 1.485 -1.553 0 CA-C-O 122.193 0.997 . . . . 0.0 112.832 179.485 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -88.43 -25.94 22.38 Favored 'General case' 0 C--N 1.286 -2.189 0 CA-C-N 113.79 -1.55 . . . . 0.0 109.511 177.006 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.414 ' HB2' HD13 ' A' ' 52' ' ' ILE . 29.0 m-85 -138.51 66.87 44.03 Favored Pre-proline 0 N--CA 1.477 0.919 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.175 177.489 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.496 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 55.8 Cg_endo -68.52 -8.03 21.99 Favored 'Trans proline' 0 N--CA 1.485 1.024 0 C-N-CA 122.923 2.415 . . . . 0.0 113.96 -174.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -117.29 -9.29 10.97 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 120.025 -0.67 . . . . 0.0 111.115 -178.835 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.544 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.3 OUTLIER -103.88 -30.33 10.41 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 -176.378 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.544 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.5 mp -124.2 140.09 48.61 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.309 0 CA-C-N 114.143 -1.389 . . . . 0.0 108.057 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 4.9 t -81.83 130.28 35.02 Favored 'General case' 0 N--CA 1.424 -1.773 0 N-CA-C 105.329 -2.101 . . . . 0.0 105.329 173.228 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.503 ' O ' HG23 ' A' ' 94' ' ' VAL . 42.2 m-20 -88.86 106.36 18.34 Favored 'General case' 0 C--N 1.282 -2.369 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -173.491 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.47 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 19.8 t80 -134.7 123.9 24.42 Favored 'General case' 0 C--N 1.296 -1.746 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.88 -172.592 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.476 HG13 HD13 ' A' ' 131' ' ' LEU . 93.3 t -124.83 141.66 44.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 CA-C-N 114.632 -1.167 . . . . 0.0 109.398 -176.801 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -148.36 127.85 13.16 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 173.651 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.532 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 59.5 tp -67.71 115.98 7.89 Favored 'General case' 0 N--CA 1.442 -0.85 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 174.19 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.462 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 38.5 tp60 -60.43 -52.67 64.23 Favored 'General case' 0 C--O 1.214 -0.786 0 CA-C-N 114.402 -1.272 . . . . 0.0 110.404 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.462 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 10.1 ptp180 -169.46 159.88 8.84 Favored 'General case' 0 N--CA 1.418 -2.028 0 CA-C-N 114.095 -1.411 . . . . 0.0 107.501 -175.049 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -136.42 136.06 8.15 Favored Glycine 1 N--CA 1.393 -4.205 0 N-CA-C 107.93 -2.068 . . . . 0.0 107.93 178.362 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 67.9 m -124.73 147.06 48.85 Favored 'General case' 0 C--N 1.272 -2.797 0 O-C-N 124.29 0.641 . . . . 0.0 110.361 -175.67 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.525 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -109.54 159.78 16.79 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 -178.956 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.489 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 90.6 m-85 -155.99 -179.68 8.37 Favored 'General case' 0 N--CA 1.464 0.26 0 C-N-CA 123.83 0.852 . . . . 0.0 109.438 -176.185 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.87 -138.71 46.84 Favored Glycine 0 CA--C 1.506 -0.52 0 O-C-N 123.73 0.644 . . . . 0.0 112.84 177.29 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.35 -6.04 89.56 Favored Glycine 0 C--O 1.201 -1.93 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 176.836 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.775 HG21 ' HB ' ' A' ' 126' ' ' ILE . 97.0 t -71.78 -38.17 64.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 123.041 0.536 . . . . 0.0 111.269 -178.262 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.525 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.11 -18.55 32.03 Favored 'General case' 0 C--N 1.297 -1.711 0 C-N-CA 118.513 -1.275 . . . . 0.0 112.232 179.416 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 22.5 t -100.29 -46.62 5.21 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.288 0.566 . . . . 0.0 112.028 -175.073 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.47 ' O ' HG22 ' A' ' 112' ' ' VAL . 44.7 m-20 -97.62 -20.75 17.45 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -174.183 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.595 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 95.6 m-85 -112.23 151.54 29.48 Favored 'General case' 0 N--CA 1.428 -1.544 0 CA-C-O 122.199 1.0 . . . . 0.0 111.618 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.421 ' HB2' ' CG1' ' A' ' 112' ' ' VAL . 4.1 m -158.69 124.15 4.37 Favored 'General case' 0 N--CA 1.393 -3.285 0 CA-C-N 113.587 -1.642 . . . . 0.0 109.96 179.236 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.503 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -161.13 -112.77 0.29 Allowed Glycine 0 N--CA 1.409 -3.156 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 175.631 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.409 HG22 ' HA ' ' A' ' 83' ' ' PRO . 0.9 OUTLIER -158.04 179.84 8.8 Favored 'General case' 0 C--N 1.284 -2.242 0 C-N-CA 123.798 0.839 . . . . 0.0 110.238 -175.669 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -134.55 146.89 30.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 C-N-CA 123.172 0.589 . . . . 0.0 109.468 178.387 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.633 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.3 tttt -124.31 143.17 50.72 Favored 'General case' 0 N--CA 1.421 -1.901 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.5 -179.27 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.47 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 59.2 t80 -143.61 110.34 5.58 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 115.197 -0.91 . . . . 0.0 108.891 -177.551 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 23.0 t 53.95 37.2 26.19 Favored 'General case' 0 CA--C 1.557 1.241 0 C-N-CA 123.634 0.774 . . . . 0.0 111.386 175.741 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.44 10.48 63.68 Favored Glycine 0 C--O 1.216 -1.012 0 C-N-CA 120.849 -0.691 . . . . 0.0 113.874 -179.281 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.633 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 8.4 t -86.21 -179.29 6.69 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 117.584 0.692 . . . . 0.0 109.414 178.511 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 31.6 t -155.73 110.47 2.92 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -179.564 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.477 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 5.3 p90 -154.24 161.31 29.59 Favored Pre-proline 0 CA--C 1.548 0.885 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 -175.12 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.477 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 60.1 Cg_endo -68.7 149.45 73.38 Favored 'Trans proline' 0 C--N 1.36 1.18 0 C-N-CA 122.936 2.424 . . . . 0.0 113.563 -175.86 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.536 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 59.3 t80 -124.07 133.21 24.49 Favored Pre-proline 0 N--CA 1.437 -1.078 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.932 179.005 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.536 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 60.5 Cg_endo -71.99 148.45 90.87 Favored 'Cis proline' 0 C--O 1.239 0.533 0 C-N-CA 122.796 -1.752 . . . . 0.0 110.232 -3.319 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.8 t -72.61 -175.99 1.81 Allowed 'General case' 0 C--O 1.246 0.903 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -178.225 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 22.6 p -130.69 -35.81 1.44 Allowed 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 122.088 0.947 . . . . 0.0 108.524 -172.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 49.4 m -105.34 -141.84 0.37 Allowed 'General case' 1 N--CA 1.343 -5.778 0 CA-C-N 114.093 -1.412 . . . . 0.0 108.24 178.368 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -123.49 -171.32 2.29 Favored 'General case' 0 C--N 1.275 -2.64 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -174.338 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.532 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 39.9 p -100.75 167.03 11.44 Favored Pre-proline 0 C--N 1.295 -1.764 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 177.402 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' PRO . . . . . 0.44 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 18.9 Cg_endo -57.39 166.47 4.56 Favored 'Trans proline' 0 C--O 1.247 0.953 0 C-N-CA 123.263 2.642 . . . . 0.0 112.286 171.773 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.47 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 1.7 tmm_? -75.21 121.32 21.95 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 114.597 -1.183 . . . . 0.0 108.52 -178.382 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 72.8 t -136.47 117.92 19.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 C-N-CA 123.41 0.684 . . . . 0.0 109.749 -176.838 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 54' ' ' ASP . 1.5 p -115.67 132.02 66.32 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.361 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.89 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.442 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 6.3 m-85 -77.0 100.29 5.58 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.216 0.531 . . . . 0.0 111.096 -178.41 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -94.89 59.88 2.39 Favored 'General case' 0 C--N 1.308 -1.237 0 CA-C-O 121.372 0.606 . . . . 0.0 109.556 179.047 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 51.0 m -154.47 141.76 19.56 Favored 'General case' 0 C--N 1.31 -1.114 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.7 ptp180 -109.02 69.68 0.71 Allowed 'General case' 0 C--N 1.304 -1.376 0 CA-C-O 122.044 0.926 . . . . 0.0 111.464 -177.725 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.2 t -179.46 168.53 1.44 Allowed 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 179.116 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -72.35 113.11 9.03 Favored 'General case' 0 CA--C 1.501 -0.94 0 CA-C-O 121.799 0.809 . . . . 0.0 109.461 -179.107 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -118.46 139.73 27.31 Favored Pre-proline 0 C--N 1.274 -2.71 0 CA-C-N 114.249 -1.341 . . . . 0.0 108.693 -177.099 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.472 ' HA ' ' HA ' ' A' ' 43' ' ' PHE . 12.6 Cg_endo -57.16 152.26 46.14 Favored 'Trans proline' 0 C--O 1.245 0.841 0 C-N-CA 123.278 2.652 . . . . 0.0 113.107 179.202 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' TRP . . . . . 0.442 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 12.6 t90 -91.42 106.62 17.19 Favored Pre-proline 0 N--CA 1.438 -1.048 0 N-CA-C 106.317 -1.735 . . . . 0.0 106.317 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -77.52 88.21 1.44 Allowed 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 121.388 1.392 . . . . 0.0 112.927 -172.932 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.404 HG22 ' CD2' ' A' ' 77' ' ' TYR . 98.0 t -137.62 145.09 29.76 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.306 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 176.632 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.585 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.87 136.73 18.18 Favored 'General case' 0 C--N 1.292 -1.9 0 O-C-N 123.237 0.336 . . . . 0.0 110.172 178.438 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.474 HD21 HD11 ' A' ' 129' ' ' LEU . 20.3 mt -101.28 102.71 13.62 Favored 'General case' 0 C--N 1.292 -1.909 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.087 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.503 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 19.3 m-85 -81.53 74.0 8.54 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 120.812 0.339 . . . . 0.0 110.436 177.44 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.596 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.2 mm? -91.52 151.08 20.91 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 176.83 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -149.3 143.7 17.18 Favored Pre-proline 0 N--CA 1.405 -2.702 0 C-N-CA 119.996 -0.682 . . . . 0.0 110.136 179.516 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -64.9 127.48 18.7 Favored 'Trans proline' 0 N--CA 1.45 -1.051 0 C-N-CA 123.383 2.722 . . . . 0.0 113.149 -177.3 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.543 ' O ' HG22 ' A' ' 30' ' ' VAL . 27.1 m -87.25 -155.84 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.399 -3.014 0 CA-C-N 114.438 -1.255 . . . . 0.0 108.639 172.432 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 6.1 m -80.51 -30.55 37.26 Favored 'General case' 0 C--N 1.261 -3.269 0 CA-C-O 121.425 0.631 . . . . 0.0 110.48 -168.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.5 t -82.9 9.55 9.74 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.888 -177.195 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.413 ' HB1' HG21 ' A' ' 156' ' ' VAL . . . -90.72 131.52 36.35 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.334 -0.988 . . . . 0.0 108.334 178.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.3 125.68 1.16 Allowed Glycine 0 C--N 1.306 -1.095 0 C-N-CA 120.571 -0.823 . . . . 0.0 111.727 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.84 -147.26 49.37 Favored Glycine 0 CA--C 1.486 -1.773 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -175.229 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.437 HG11 ' HE3' ' A' ' 121' ' ' LYS . 60.3 t -57.31 112.04 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 117.213 0.507 . . . . 0.0 110.113 -177.144 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -110.25 -28.69 8.5 Favored 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.068 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.467 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 59.0 mt -129.03 138.07 55.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.149 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.451 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 5.1 mmpt? -114.92 141.84 47.4 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 121.112 0.482 . . . . 0.0 110.835 178.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.44 135.26 49.98 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.691 -179.765 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 82.72 -4.14 80.3 Favored Glycine 0 C--O 1.242 0.61 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.216 178.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 19.4 m -94.71 149.41 21.27 Favored 'General case' 0 N--CA 1.417 -2.084 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 -179.214 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 28.2 tp -74.79 133.37 41.95 Favored 'General case' 0 N--CA 1.434 -1.231 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.123 -177.455 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.775 ' HB ' HG21 ' A' ' 67' ' ' VAL . 34.5 pt -118.26 -26.67 2.51 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 C-N-CA 120.481 -0.488 . . . . 0.0 112.174 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 127' ' ' ALA . . . . . 0.42 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.9 163.58 29.07 Favored 'General case' 0 N--CA 1.434 -1.24 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.252 -177.711 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 55.9 t -139.7 115.63 8.74 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.937 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 178.222 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.474 HD11 HD21 ' A' ' 107' ' ' LEU . 68.7 mt -117.74 145.74 44.25 Favored 'General case' 0 C--N 1.281 -2.398 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 179.415 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.496 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.7 mp -128.7 119.47 49.97 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 C-N-CA 119.794 -0.762 . . . . 0.0 109.629 178.767 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.501 ' C ' HD12 ' A' ' 131' ' ' LEU . 0.6 OUTLIER -88.77 147.02 24.66 Favored 'General case' 0 CA--C 1.481 -1.677 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 173.978 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 60.0 ttp180 -115.0 122.0 44.87 Favored 'General case' 0 C--N 1.248 -3.832 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 177.74 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -85.86 139.26 31.41 Favored 'General case' 0 N--CA 1.417 -2.076 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 176.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.434 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 25.8 m -145.1 133.23 21.49 Favored 'General case' 0 C--N 1.261 -3.253 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 173.905 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.484 ' HB2' HG23 ' A' ' 52' ' ' ILE . 32.9 p30 . . . . . 0 C--N 1.298 -1.637 0 CA-C-O 120.906 0.384 . . . . 0.0 110.18 -178.368 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 . . . . . 0 N--CA 1.44 -0.941 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 143' ' ' GLN . . . . . 0.432 ' HB2' ' O ' ' A' ' 131' ' ' LEU . 3.3 pt20 -126.09 150.48 48.15 Favored 'General case' 0 C--N 1.288 -2.107 0 C-N-CA 119.877 -0.729 . . . . 0.0 110.623 -179.113 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 12.5 m-30 -113.67 127.47 56.06 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -174.822 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 50.0 t -92.42 132.11 37.64 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.987 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.93 -178.745 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 54.3 m95 -120.97 101.14 7.49 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -177.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 50.0 m-80 -84.5 115.01 22.35 Favored 'General case' 0 C--N 1.285 -2.233 0 N-CA-C 107.691 -1.226 . . . . 0.0 107.691 178.68 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.42 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 20.2 mm -88.55 121.8 39.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -177.204 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -117.7 151.7 36.74 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.143 177.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.22 131.39 35.23 Favored 'General case' 0 N--CA 1.412 -2.336 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 177.049 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -88.21 -16.36 33.49 Favored 'General case' 0 C--N 1.287 -2.128 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -178.502 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -148.08 143.96 27.54 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 114.566 -1.197 . . . . 0.0 109.997 -174.447 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -79.08 139.53 38.08 Favored 'General case' 0 C--N 1.309 -1.163 0 O-C-N 124.285 0.991 . . . . 0.0 110.995 179.568 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.515 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 73.0 t -115.12 138.47 45.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.851 -176.432 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 8.3 t -119.56 135.9 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.394 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 75.3 t -99.81 105.03 32.07 Favored Pre-proline 0 C--N 1.286 -2.174 0 C-N-CA 124.091 0.956 . . . . 0.0 109.834 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.493 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 40.6 Cg_endo -70.71 -21.77 28.62 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.233 1.955 . . . . 0.0 111.797 177.852 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.27 3.7 t . . . . . 0 C--N 1.355 0.841 0 C-N-CA 124.978 1.311 . . . . 0.0 114.095 175.665 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.6 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.44 -0.945 0 CA-C-O 120.557 0.217 . . . . 0.0 110.881 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 11.5 t -151.61 156.61 40.8 Favored 'General case' 0 N--CA 1.433 -1.276 0 C-N-CA 119.931 -0.708 . . . . 0.0 109.766 -177.241 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.1 pptp? -141.44 163.08 33.89 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-O 121.049 0.452 . . . . 0.0 111.576 -175.065 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.481 HG22 HG22 ' A' ' 20' ' ' VAL . 71.3 p -104.6 172.94 6.52 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 121.859 0.837 . . . . 0.0 110.406 -179.687 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -78.81 -10.31 59.74 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 113.745 -1.57 . . . . 0.0 110.991 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -92.16 -33.97 14.51 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 118.318 -1.353 . . . . 0.0 109.124 175.749 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 137.47 5.58 1.74 Allowed Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 119.231 -1.461 . . . . 0.0 113.437 176.17 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.3 m -80.18 100.22 8.18 Favored 'General case' 0 N--CA 1.433 -1.275 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -97.29 111.08 23.48 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.323 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.6 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 59.3 mt -88.87 121.94 69.42 Favored Pre-proline 0 C--N 1.307 -1.243 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 179.488 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -81.52 -179.56 5.02 Favored 'Trans proline' 0 C--O 1.241 0.668 0 C-N-CA 122.899 2.399 . . . . 0.0 111.937 178.183 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.6 mt -69.23 141.51 17.25 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.832 179.423 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.89 -1.74 17.4 Favored Glycine 0 N--CA 1.438 -1.191 0 C-N-CA 119.887 -1.149 . . . . 0.0 112.472 179.284 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 103.27 171.25 25.99 Favored Glycine 0 C--N 1.309 -0.972 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.654 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 157.22 -175.28 34.69 Favored Glycine 0 C--N 1.312 -0.759 0 C-N-CA 120.354 -0.927 . . . . 0.0 111.867 178.345 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 m -146.27 143.54 29.25 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 179.453 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.92 166.33 23.57 Favored 'General case' 0 N--CA 1.425 -1.71 0 CA-C-O 121.249 0.547 . . . . 0.0 109.788 -177.854 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -111.03 115.52 29.61 Favored 'General case' 0 C--N 1.28 -2.442 0 CA-C-N 114.533 -1.212 . . . . 0.0 108.822 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.481 HG22 HG22 ' A' ' 5' ' ' THR . 39.7 t -103.26 140.08 22.44 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.947 0 CA-C-N 115.266 -0.879 . . . . 0.0 108.762 178.052 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.7 m-85 -126.1 136.23 52.66 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.477 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.4 p -146.04 135.51 17.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 123.724 0.64 . . . . 0.0 110.519 -178.769 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -95.83 123.24 39.32 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 121.759 0.79 . . . . 0.0 111.367 179.375 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.407 HD11 HG22 ' A' ' 36' ' ' VAL . 2.6 mm? -103.48 160.93 14.29 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 113.922 -1.49 . . . . 0.0 108.208 -177.93 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.76 122.41 56.58 Favored Pre-proline 0 C--N 1.313 -0.994 0 O-C-N 124.764 1.29 . . . . 0.0 109.405 178.23 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 61.0 Cg_endo -75.21 3.08 6.04 Favored 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 122.661 2.241 . . . . 0.0 112.89 -178.592 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.429 HG13 ' HG3' ' A' ' 157' ' ' PRO . 46.7 t -125.98 109.54 21.73 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.503 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 177.749 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.451 ' O ' HG13 ' A' ' 156' ' ' VAL . 1.6 t -143.17 99.89 0.7 Allowed 'Isoleucine or valine' 0 C--O 1.183 -2.403 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 -178.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.462 ' H ' ' HG3' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -91.63 151.38 20.72 Favored 'General case' 0 C--N 1.269 -2.893 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -179.199 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.447 HG13 ' O ' ' A' ' 112' ' ' VAL . 24.7 t -46.85 115.23 0.25 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.709 0 C-N-CA 123.615 0.766 . . . . 0.0 111.501 177.078 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.84 3.28 42.74 Favored Glycine 0 N--CA 1.446 -0.697 0 CA-C-N 114.759 -1.109 . . . . 0.0 112.755 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.462 ' HG3' ' H ' ' A' ' 29' ' ' ASN . 2.2 mm-40 -73.78 -178.37 3.16 Favored 'General case' 0 C--N 1.309 -1.159 0 C-N-CA 123.542 0.737 . . . . 0.0 111.427 175.57 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 67.3 t30 -134.67 89.03 2.5 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 177.075 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.675 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.3 tp -90.21 144.67 25.65 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.102 -176.599 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.4 t -134.12 125.79 48.75 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.633 0 CA-C-O 121.298 0.57 . . . . 0.0 110.585 -176.642 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.596 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 48.9 t -95.96 89.25 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.049 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 174.057 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -82.81 113.05 20.18 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-O 121.15 0.5 . . . . 0.0 111.216 -178.11 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.3 mt -96.1 -2.7 46.03 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.983 -178.704 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -74.07 0.36 14.0 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-O 122.118 0.961 . . . . 0.0 109.733 -178.684 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.5 p -127.36 6.82 6.38 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 123.771 0.828 . . . . 0.0 109.819 178.09 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.477 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 45.7 mm-40 -124.03 -21.42 5.07 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.706 -174.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.6 mt -132.87 136.72 55.21 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.133 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 -175.155 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -142.84 124.36 14.84 Favored 'General case' 0 CA--C 1.504 -0.798 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -175.671 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 83.3 m -101.02 140.31 35.48 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 -179.657 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.4 p80 -132.19 139.36 48.32 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 121.852 0.834 . . . . 0.0 112.313 -171.748 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 8.7 p30 -103.44 107.26 18.02 Favored 'General case' 0 C--N 1.292 -1.899 0 CA-C-N 115.1 -0.954 . . . . 0.0 113.342 -178.272 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -84.24 -14.33 50.22 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 121.881 0.848 . . . . 0.0 109.531 175.588 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.419 ' HB2' HD13 ' A' ' 52' ' ' ILE . 47.2 m-85 -134.52 66.0 68.88 Favored Pre-proline 0 C--N 1.318 -0.761 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 177.492 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -73.05 -5.56 17.42 Favored 'Trans proline' 0 N--CA 1.486 1.056 0 C-N-CA 123.188 2.592 . . . . 0.0 113.978 -172.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -120.41 -13.34 8.85 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 121.469 0.652 . . . . 0.0 110.204 -179.539 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.475 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -94.78 -30.17 14.38 Favored 'General case' 0 N--CA 1.421 -1.88 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -174.904 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.622 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -122.92 138.2 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.508 0 CA-C-N 113.529 -1.669 . . . . 0.0 107.924 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 7.3 t -80.7 136.39 36.17 Favored 'General case' 0 N--CA 1.427 -1.607 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 174.804 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.507 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 19.3 m-20 -84.79 108.16 17.33 Favored 'General case' 0 C--N 1.286 -2.163 0 CA-C-O 121.541 0.686 . . . . 0.0 110.506 -171.869 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.456 ' HE1' ' HG2' ' A' ' 92' ' ' ARG . 34.0 t80 -138.46 143.36 39.61 Favored 'General case' 0 C--N 1.284 -2.275 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.242 -178.399 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.597 HG23 HD13 ' A' ' 131' ' ' LEU . 12.6 p -148.59 148.66 15.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 177.026 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.04 137.59 19.89 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 123.599 0.562 . . . . 0.0 109.992 174.029 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.416 HD23 ' O ' ' A' ' 130' ' ' ILE . 0.3 OUTLIER -74.52 106.64 6.21 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 105.048 -2.204 . . . . 0.0 105.048 175.119 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 6.6 tp60 -56.05 -64.9 0.71 Allowed 'General case' 0 C--O 1.202 -1.399 0 C-N-CA 126.372 1.869 . . . . 0.0 109.968 177.897 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 8.3 ptp180 -158.3 153.59 25.75 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 -179.189 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -134.98 137.97 9.66 Favored Glycine 0 CA--C 1.463 -3.159 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 -178.308 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 66.4 m -126.33 151.95 46.88 Favored 'General case' 0 C--N 1.28 -2.419 0 C-N-CA 123.822 0.849 . . . . 0.0 109.784 -174.704 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.525 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -115.74 157.92 23.59 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -178.134 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.484 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 91.9 m-85 -156.02 -179.45 8.15 Favored 'General case' 0 C--O 1.237 0.415 0 C-N-CA 124.328 1.051 . . . . 0.0 109.042 -177.412 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.25 -148.41 29.27 Favored Glycine 0 C--N 1.33 0.205 0 O-C-N 123.566 0.541 . . . . 0.0 113.533 178.68 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.41 -10.91 71.15 Favored Glycine 0 C--O 1.206 -1.598 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.754 178.101 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.796 HG21 ' HB ' ' A' ' 126' ' ' ILE . 97.0 t -69.05 -40.68 81.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 C-N-CA 123.9 0.88 . . . . 0.0 111.483 -177.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.525 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -84.2 -20.5 32.24 Favored 'General case' 0 N--CA 1.433 -1.289 0 C-N-CA 118.759 -1.176 . . . . 0.0 112.14 179.09 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 31.7 t -98.37 -60.2 1.6 Allowed 'General case' 0 N--CA 1.442 -0.838 0 CA-C-N 115.932 -0.576 . . . . 0.0 112.004 -174.466 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.474 ' O ' HG22 ' A' ' 112' ' ' VAL . 48.6 m-20 -85.77 -25.74 26.2 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.427 -172.774 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.67 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 91.6 m-85 -106.56 158.83 16.63 Favored 'General case' 0 N--CA 1.42 -1.956 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.03 177.363 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.0 t -167.98 137.39 2.55 Favored 'General case' 0 N--CA 1.411 -2.411 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 176.155 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.475 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.25 -107.86 0.2 Allowed Glycine 0 N--CA 1.411 -2.978 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 175.883 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.5 p -158.71 -179.88 8.47 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 123.791 0.836 . . . . 0.0 110.871 -175.727 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.412 ' HB ' ' HB2' ' A' ' 84' ' ' PHE . 2.6 p -132.11 144.96 35.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 177.662 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.685 ' HG3' ' O ' ' A' ' 80' ' ' SER . 73.6 tttt -123.73 142.98 50.58 Favored 'General case' 0 N--CA 1.424 -1.769 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.969 -177.503 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.577 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 68.3 t80 -141.42 111.44 6.71 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 115.458 -0.792 . . . . 0.0 108.87 -177.802 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 9.3 t 52.61 34.19 15.26 Favored 'General case' 0 CA--C 1.561 1.366 0 CA-C-O 121.717 0.77 . . . . 0.0 111.071 179.517 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.417 ' HA2' ' HE2' ' A' ' 76' ' ' LYS . . . 90.65 10.0 63.83 Favored Glycine 0 CA--C 1.532 1.101 0 C-N-CA 120.83 -0.7 . . . . 0.0 114.169 -179.237 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.685 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 21.8 t -79.98 179.54 7.54 Favored 'General case' 0 CA--C 1.549 0.924 0 CA-C-N 117.446 0.623 . . . . 0.0 109.376 177.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 17.5 p -153.27 109.11 3.29 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-O 121.548 0.69 . . . . 0.0 110.049 178.322 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.577 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 4.2 p90 -151.08 158.33 34.77 Favored Pre-proline 0 C--N 1.302 -1.465 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 -175.123 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.77 147.41 69.13 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.95 2.433 . . . . 0.0 113.256 -175.643 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.608 ' CD2' HD21 ' A' ' 109' ' ' LEU . 66.6 t80 -121.23 132.84 24.11 Favored Pre-proline 0 N--CA 1.441 -0.88 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.535 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.54 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 60.6 Cg_endo -69.25 146.19 80.39 Favored 'Cis proline' 0 CA--C 1.538 0.702 0 C-N-CA 123.562 -1.432 . . . . 0.0 111.308 0.208 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.3 t -70.74 -178.07 1.75 Allowed 'General case' 0 CA--C 1.554 1.097 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.31 -177.284 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 10.0 p -130.51 -34.33 1.58 Allowed 'General case' 0 C--O 1.243 0.711 0 N-CA-C 114.827 1.418 . . . . 0.0 114.827 -169.132 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.1 t -118.74 -69.44 0.85 Allowed 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 119.978 -0.689 . . . . 0.0 111.021 -174.293 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 178.25 -179.71 0.31 Allowed 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 -178.176 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.1 p -102.54 164.49 15.56 Favored Pre-proline 0 C--N 1.284 -2.26 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -66.46 160.61 44.89 Favored 'Trans proline' 0 C--N 1.365 1.406 0 C-N-CA 122.523 2.149 . . . . 0.0 110.504 173.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.49 ' HD3' HG23 ' A' ' 94' ' ' VAL . 6.8 tmm_? -72.73 128.2 34.82 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-N 115.64 -0.709 . . . . 0.0 112.166 -174.074 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 90.0 t -133.26 117.95 30.21 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 115.211 -0.904 . . . . 0.0 109.514 177.88 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.49 HG23 ' HD3' ' A' ' 92' ' ' ARG . 87.4 t -94.95 137.65 22.78 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 175.899 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.507 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.2 m-85 -89.62 93.97 9.68 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 175.183 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 13.3 m120 -89.13 69.21 8.32 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 178.577 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.8 m -143.35 148.2 35.88 Favored 'General case' 0 N--CA 1.429 -1.515 0 CA-C-N 114.539 -1.21 . . . . 0.0 109.719 -176.19 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -112.64 45.48 1.31 Allowed 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 121.288 0.566 . . . . 0.0 111.303 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.1 t -171.52 179.92 2.75 Favored 'General case' 0 N--CA 1.439 -1.025 0 N-CA-C 106.332 -1.729 . . . . 0.0 106.332 -177.699 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -75.72 135.28 40.37 Favored 'General case' 0 C--O 1.249 1.051 0 CA-C-O 121.635 0.731 . . . . 0.0 109.37 -179.28 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 62.3 mmtt -128.31 141.0 39.94 Favored Pre-proline 0 C--N 1.28 -2.415 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.623 -177.187 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.455 ' O ' ' HD3' ' A' ' 104' ' ' PRO . 32.2 Cg_endo -64.38 142.31 78.36 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 123.508 2.806 . . . . 0.0 111.276 -179.281 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 10.7 t90 -86.5 104.23 5.36 Favored Pre-proline 0 C--N 1.308 -1.228 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 -177.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' PRO . . . . . 0.455 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 65.1 Cg_endo -75.91 88.61 1.3 Allowed 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 121.944 1.763 . . . . 0.0 113.1 -172.156 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 99.1 t -138.28 144.63 30.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.596 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.67 135.09 19.52 Favored 'General case' 0 N--CA 1.417 -2.092 0 CA-C-N 116.519 -0.309 . . . . 0.0 110.545 177.779 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.51 HD21 HD11 ' A' ' 129' ' ' LEU . 18.6 mt -99.94 103.18 14.73 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.275 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.475 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 22.1 m-85 -82.14 72.18 9.2 Favored 'General case' 0 C--N 1.296 -1.743 0 O-C-N 122.363 -0.211 . . . . 0.0 111.031 177.424 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.675 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -96.96 127.17 42.66 Favored 'General case' 0 C--O 1.207 -1.146 0 CA-C-O 120.571 0.224 . . . . 0.0 110.616 177.819 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -127.54 144.73 52.03 Favored Pre-proline 0 N--CA 1.417 -2.079 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.055 -175.731 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.437 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 28.4 Cg_endo -62.32 118.19 5.07 Favored 'Trans proline' 0 C--O 1.241 0.664 0 C-N-CA 123.164 2.576 . . . . 0.0 111.684 -178.389 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.474 HG22 ' O ' ' A' ' 70' ' ' ASN . 3.8 m -68.34 -112.82 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.191 -2.001 0 O-C-N 124.38 1.05 . . . . 0.0 113.07 176.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 11.7 p -111.68 -46.26 3.27 Favored 'General case' 0 C--N 1.294 -1.832 0 CA-C-O 121.369 0.604 . . . . 0.0 110.904 179.667 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 11.6 t -82.45 25.69 0.61 Allowed 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 121.937 0.875 . . . . 0.0 111.021 -175.077 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -96.38 131.1 43.28 Favored 'General case' 0 N--CA 1.414 -2.265 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.29 129.54 1.7 Allowed Glycine 0 N--CA 1.436 -1.321 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.072 -178.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.5 -149.78 51.05 Favored Glycine 0 N--CA 1.434 -1.451 0 CA-C-O 119.376 -0.68 . . . . 0.0 111.93 -178.187 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.442 ' CG1' ' HE3' ' A' ' 121' ' ' LYS . 76.9 t -58.14 99.87 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 121.728 0.775 . . . . 0.0 111.088 -177.701 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.07 -37.76 9.61 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 114.878 -1.056 . . . . 0.0 110.577 -178.913 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.536 ' HB ' HG22 ' A' ' 154' ' ' VAL . 72.9 mt -118.02 139.04 46.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 178.686 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.523 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.0 mmpt? -115.17 141.82 47.5 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 122.823 0.449 . . . . 0.0 110.375 176.375 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.0 132.63 46.21 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.423 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 87.28 -1.23 86.15 Favored Glycine 0 N--CA 1.431 -1.695 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.779 -178.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 32.1 t -90.92 140.78 29.5 Favored 'General case' 0 N--CA 1.42 -1.972 0 N-CA-C 108.577 -0.898 . . . . 0.0 108.577 178.826 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.415 HD11 HG23 ' A' ' 128' ' ' VAL . 3.0 tm? -68.83 126.63 30.37 Favored 'General case' 0 N--CA 1.427 -1.61 0 N-CA-C 106.411 -1.699 . . . . 0.0 106.411 175.163 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.796 ' HB ' HG21 ' A' ' 67' ' ' VAL . 29.6 pt -113.67 -27.15 2.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -178.562 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.28 167.96 24.95 Favored 'General case' 0 N--CA 1.443 -0.825 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 -177.8 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.415 HG23 HD11 ' A' ' 125' ' ' LEU . 64.4 t -142.33 113.54 3.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 179.429 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.51 HD11 HD21 ' A' ' 107' ' ' LEU . 37.3 mt -118.04 143.49 46.38 Favored 'General case' 0 C--N 1.288 -2.094 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 179.704 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.416 ' O ' HD23 ' A' ' 58' ' ' LEU . 4.9 mp -123.39 128.43 74.74 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.133 0 C-N-CA 119.709 -0.796 . . . . 0.0 109.411 178.811 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.597 HD13 HG23 ' A' ' 56' ' ' VAL . 1.1 pp -94.34 147.25 23.4 Favored 'General case' 0 CA--C 1.472 -2.05 0 N-CA-C 105.614 -1.995 . . . . 0.0 105.614 172.369 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 59.7 ttt180 -116.57 132.72 56.61 Favored 'General case' 0 N--CA 1.386 -3.635 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 173.435 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' GLN . . . . . 0.466 ' HG2' HD11 ' A' ' 131' ' ' LEU . 11.7 mm100 -90.38 148.06 23.06 Favored 'General case' 0 N--CA 1.402 -2.863 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.706 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.428 ' HB ' ' CE2' ' A' ' 55' ' ' TYR . 27.6 m -154.58 138.14 15.99 Favored 'General case' 0 C--N 1.276 -2.622 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 169.699 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.622 ' CB ' HG23 ' A' ' 52' ' ' ILE . 6.1 p30 . . . . . 0 C--N 1.319 -0.741 0 C-N-CA 119.585 -0.846 . . . . 0.0 111.332 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 . . . . . 0 N--CA 1.434 -1.275 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -134.47 146.54 49.86 Favored 'General case' 0 N--CA 1.42 -1.962 0 C-N-CA 118.571 -1.252 . . . . 0.0 111.93 -176.331 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 10.8 m-30 -111.3 126.95 55.44 Favored 'General case' 0 C--N 1.31 -1.13 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -177.263 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.0 t -91.68 132.29 36.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -178.426 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 55.4 m95 -118.29 101.53 8.27 Favored 'General case' 0 C--N 1.282 -2.334 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 42.5 m-80 -80.88 112.98 18.77 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 178.021 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.42 HG22 HD11 ' A' ' 126' ' ' ILE . 23.7 mm -87.19 122.16 38.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 -177.9 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -116.51 153.78 31.55 Favored 'General case' 0 C--N 1.293 -1.882 0 C-N-CA 123.242 0.617 . . . . 0.0 109.525 178.208 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.76 130.3 35.11 Favored 'General case' 0 N--CA 1.412 -2.364 0 CA-C-N 115.197 -0.91 . . . . 0.0 108.741 176.674 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -85.82 -20.69 28.79 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -178.16 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -149.86 147.32 27.81 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 114.21 -1.359 . . . . 0.0 109.269 -173.448 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 16.8 p-10 -89.83 136.73 32.87 Favored 'General case' 0 C--N 1.31 -1.112 0 O-C-N 123.948 0.78 . . . . 0.0 111.119 -177.858 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.536 HG22 ' HB ' ' A' ' 120' ' ' ILE . 2.0 m -115.65 150.99 17.46 Favored 'Isoleucine or valine' 0 C--O 1.252 1.222 0 CA-C-O 121.053 0.454 . . . . 0.0 111.434 -174.489 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.8 t -122.32 139.42 49.31 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.016 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.208 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.451 HG13 ' O ' ' A' ' 28' ' ' VAL . 75.7 t -100.8 99.4 10.2 Favored Pre-proline 0 C--N 1.293 -1.85 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.429 ' HG3' HG13 ' A' ' 27' ' ' VAL . 33.9 Cg_endo -68.06 -28.47 34.88 Favored 'Trans proline' 0 C--O 1.24 0.591 0 C-N-CA 122.269 1.979 . . . . 0.0 111.954 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.4 t . . . . . 0 C--O 1.249 1.06 0 O-C-N 125.091 1.495 . . . . 0.0 113.799 178.488 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.419 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.426 -1.666 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.464 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 10.4 t -154.71 157.63 38.35 Favored 'General case' 0 C--N 1.299 -1.626 0 C-N-CA 119.423 -0.911 . . . . 0.0 109.719 -176.505 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.406 ' HE3' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -145.36 163.76 33.57 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.558 -175.174 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 76.2 p -102.02 176.7 5.11 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.591 0.71 . . . . 0.0 110.859 -178.946 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.88 -1.09 46.51 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.453 -1.249 . . . . 0.0 111.091 179.143 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -100.08 -25.58 14.25 Favored 'General case' 0 N--CA 1.446 -0.67 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.685 174.707 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 128.19 5.22 5.24 Favored Glycine 0 CA--C 1.507 -0.461 0 C-N-CA 119.838 -1.173 . . . . 0.0 113.22 175.029 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.0 m -81.33 99.63 8.76 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.58 122.42 34.98 Favored 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 115.45 -0.795 . . . . 0.0 108.925 176.49 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.419 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 66.3 mt -95.13 115.89 65.83 Favored Pre-proline 0 C--N 1.293 -1.88 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 178.018 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.8 163.78 37.79 Favored 'Trans proline' 0 C--O 1.25 1.099 0 C-N-CA 122.156 1.904 . . . . 0.0 110.294 177.67 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.402 HD11 ' OD2' ' A' ' 47' ' ' ASP . 23.5 mt -67.48 126.18 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.101 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.65 -14.83 1.4 Allowed Glycine 0 C--N 1.297 -1.592 0 C-N-CA 120.491 -0.861 . . . . 0.0 111.62 -175.365 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 95.17 134.5 7.71 Favored Glycine 0 C--N 1.31 -0.883 0 C-N-CA 120.376 -0.916 . . . . 0.0 111.459 -179.633 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -178.76 -166.97 35.71 Favored Glycine 0 C--N 1.299 -1.501 0 N-CA-C 109.916 -1.273 . . . . 0.0 109.916 -178.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.451 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 60.0 p -140.23 150.53 44.23 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 117.457 0.629 . . . . 0.0 110.261 -179.406 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -134.17 161.53 34.64 Favored 'General case' 0 N--CA 1.422 -1.831 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 177.567 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 19.8 m-80 -116.5 111.13 19.53 Favored 'General case' 0 C--N 1.284 -2.248 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 178.733 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.432 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.1 m -92.63 149.71 4.1 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.462 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 -178.611 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 55.5 m-85 -132.04 113.71 13.7 Favored 'General case' 0 CA--C 1.492 -1.277 0 O-C-N 122.089 -0.382 . . . . 0.0 110.485 -176.665 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.516 HG11 HG13 ' A' ' 36' ' ' VAL . 3.5 p -120.93 132.84 69.41 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 CA-C-O 121.451 0.643 . . . . 0.0 111.423 -174.583 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 30.6 m-80 -88.17 123.24 32.62 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 50.0 mt -108.69 159.24 16.9 Favored 'General case' 0 C--N 1.276 -2.61 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 179.666 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.0 120.57 43.78 Favored Pre-proline 0 C--N 1.3 -1.552 0 O-C-N 124.37 1.044 . . . . 0.0 109.523 179.323 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.552 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 66.6 Cg_endo -74.09 -2.93 12.98 Favored 'Trans proline' 0 CA--C 1.531 0.369 0 C-N-CA 122.758 2.305 . . . . 0.0 113.503 -175.647 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.468 HG13 ' HG3' ' A' ' 157' ' ' PRO . 99.4 t -128.2 109.75 20.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.391 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 12.5 t -147.1 107.48 0.63 Allowed 'Isoleucine or valine' 0 C--O 1.19 -2.068 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -176.472 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.578 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -95.48 156.96 16.11 Favored 'General case' 0 C--N 1.271 -2.819 0 C-N-CA 122.863 0.465 . . . . 0.0 112.12 -179.911 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.432 HG13 ' O ' ' A' ' 112' ' ' VAL . 41.2 t -44.12 115.25 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.674 0 C-N-CA 124.296 1.038 . . . . 0.0 112.07 175.678 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.19 1.39 51.19 Favored Glycine 0 C--N 1.316 -0.536 0 CA-C-N 115.386 -0.825 . . . . 0.0 113.233 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.578 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.9 OUTLIER -74.1 -176.32 2.52 Favored 'General case' 0 C--N 1.315 -0.916 0 C-N-CA 124.164 0.986 . . . . 0.0 111.005 176.408 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 64.1 t30 -130.78 93.07 3.34 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 177.679 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.632 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 19.8 tp -93.41 141.88 27.96 Favored 'General case' 0 C--N 1.29 -1.982 0 C-N-CA 119.348 -0.941 . . . . 0.0 109.545 178.34 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.3 t -135.77 128.3 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.978 0 N-CA-C 109.433 -0.581 . . . . 0.0 109.433 -176.111 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.586 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 56.3 t -97.59 88.87 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.405 -2.721 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 174.661 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -83.36 115.89 22.22 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 120.822 0.344 . . . . 0.0 110.639 -178.24 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 80.5 mt -97.27 4.19 51.02 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.369 -179.143 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 33.3 t -77.28 -0.17 24.4 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 122.371 1.081 . . . . 0.0 109.115 -178.397 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.1 p -128.07 3.68 5.87 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 114.977 -1.01 . . . . 0.0 110.13 179.129 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.515 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 54.2 mm-40 -122.34 -22.22 5.59 Favored 'General case' 0 CA--C 1.503 -0.858 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.282 -172.918 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 24.3 mt -136.79 135.64 48.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.032 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 -175.261 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.406 ' HB2' ' HE3' ' A' ' 4' ' ' LYS . 61.3 m-85 -138.53 125.26 20.92 Favored 'General case' 0 CA--C 1.501 -0.919 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 -175.832 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.464 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 73.7 m -108.2 143.33 37.14 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.905 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 24.1 p-80 -134.23 156.53 48.22 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-O 120.914 0.388 . . . . 0.0 110.589 -175.536 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.665 ' ND2' ' HA ' ' A' ' 49' ' ' PRO . 56.4 t30 -113.74 100.4 8.44 Favored 'General case' 0 N--CA 1.421 -1.916 0 CA-C-O 122.734 1.254 . . . . 0.0 110.772 176.604 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ASP . . . . . 0.402 ' OD2' HD11 ' A' ' 13' ' ' ILE . 0.0 OUTLIER -60.75 -32.21 71.51 Favored 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 127.021 2.128 . . . . 0.0 112.728 179.942 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -130.46 77.2 76.39 Favored Pre-proline 0 C--N 1.318 -0.803 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.489 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.665 ' HA ' ' ND2' ' A' ' 46' ' ' ASN . 64.7 Cg_endo -68.42 -4.69 13.41 Favored 'Trans proline' 0 N--CA 1.484 0.93 0 C-N-CA 123.529 2.819 . . . . 0.0 115.95 -169.846 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -118.92 -15.72 9.31 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 121.596 0.713 . . . . 0.0 109.944 178.77 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.45 ' HB ' HD12 ' A' ' 52' ' ' ILE . 2.0 m -96.84 -30.64 13.04 Favored 'General case' 0 N--CA 1.408 -2.573 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -175.658 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.668 HG23 ' CB ' ' A' ' 135' ' ' ASN . 3.4 mp -132.65 140.47 47.43 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.244 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 179.063 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.8 t -87.83 150.66 23.4 Favored 'General case' 0 C--O 1.254 1.302 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 177.772 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.562 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 0.9 OUTLIER -79.97 107.91 13.13 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 -178.598 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 76.5 t80 -143.69 144.04 31.69 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -176.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.468 HG13 ' OH ' ' A' ' 77' ' ' TYR . 6.2 p -152.08 150.33 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.179 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 177.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -151.2 133.11 15.07 Favored 'General case' 0 C--O 1.208 -1.079 0 CA-C-O 119.455 -0.307 . . . . 0.0 110.296 175.193 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.521 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 47.9 tp -76.56 106.48 8.23 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 121.132 0.491 . . . . 0.0 109.861 176.617 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.7 tp-100 -53.84 -52.69 59.58 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 125.77 1.628 . . . . 0.0 111.717 177.661 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.403 ' HG3' HD13 ' A' ' 130' ' ' ILE . 1.1 ptp180 -166.37 157.89 13.33 Favored 'General case' 0 C--N 1.307 -1.258 0 N-CA-C 107.597 -1.261 . . . . 0.0 107.597 -179.017 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.13 115.23 0.86 Allowed Glycine 0 N--CA 1.399 -3.814 0 N-CA-C 108.992 -1.643 . . . . 0.0 108.992 -178.339 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 67.2 m -110.26 147.17 34.35 Favored 'General case' 0 C--N 1.28 -2.423 0 C-N-CA 124.471 1.108 . . . . 0.0 110.338 -171.13 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.547 ' HB2' ' CE2' ' A' ' 84' ' ' PHE . . . -108.83 157.8 18.26 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.47 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 86.9 m-85 -157.01 -179.35 8.12 Favored 'General case' 0 C--O 1.237 0.403 0 C-N-CA 124.21 1.004 . . . . 0.0 108.683 -178.532 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 60.2 -140.68 47.96 Favored Glycine 0 CA--C 1.5 -0.899 0 O-C-N 123.915 0.759 . . . . 0.0 112.851 176.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.09 -12.54 84.54 Favored Glycine 0 N--CA 1.431 -1.669 0 C-N-CA 120.54 -0.838 . . . . 0.0 111.375 177.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.75 HG21 ' HB ' ' A' ' 126' ' ' ILE . 82.4 t -68.45 -39.45 80.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 C-N-CA 123.522 0.729 . . . . 0.0 111.927 -176.293 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.522 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -87.54 -16.23 35.21 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 118.981 -1.088 . . . . 0.0 112.272 178.897 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 8.0 t -101.06 -58.05 1.97 Allowed 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.329 0.585 . . . . 0.0 111.399 -174.704 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.511 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 47.6 m-20 -87.09 -25.31 24.21 Favored 'General case' 0 CA--C 1.492 -1.283 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.133 -174.673 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.673 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 83.7 m-85 -108.24 158.19 17.68 Favored 'General case' 0 N--CA 1.415 -2.223 0 C-N-CA 120.03 -0.668 . . . . 0.0 110.352 179.342 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.6 t -164.91 135.76 4.02 Favored 'General case' 0 N--CA 1.409 -2.522 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 176.571 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.424 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.31 -109.12 0.22 Allowed Glycine 0 N--CA 1.406 -3.356 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 174.862 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.447 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.3 p -159.72 179.33 8.95 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 123.695 0.798 . . . . 0.0 110.827 -174.198 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.5 p -132.55 145.47 34.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 178.756 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.633 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.2 tttt -124.08 144.87 49.62 Favored 'General case' 0 N--CA 1.417 -2.084 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.471 -179.4 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.468 ' OH ' HG13 ' A' ' 56' ' ' VAL . 59.2 t80 -146.33 114.71 6.7 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -178.638 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.0 m 54.05 36.68 25.2 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 113.974 1.101 . . . . 0.0 113.974 177.431 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.16 12.19 81.23 Favored Glycine 0 C--N 1.309 -0.917 0 C-N-CA 119.579 -1.296 . . . . 0.0 112.587 -178.593 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.633 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 7.9 t -83.8 178.87 7.74 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 176.913 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 48.8 p -154.74 111.04 3.23 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 -178.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.442 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 3.4 p90 -154.73 158.86 32.26 Favored Pre-proline 0 C--N 1.305 -1.331 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 -175.315 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.447 ' HA ' HG22 ' A' ' 74' ' ' THR . 73.0 Cg_endo -71.31 147.91 54.07 Favored 'Trans proline' 0 C--N 1.355 0.904 0 C-N-CA 123.089 2.526 . . . . 0.0 113.259 -176.594 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.59 ' CD2' HD21 ' A' ' 109' ' ' LEU . 48.3 t80 -119.35 135.63 24.1 Favored Pre-proline 0 N--CA 1.433 -1.291 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.082 -178.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.518 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 57.0 Cg_endo -71.18 148.15 89.12 Favored 'Cis proline' 0 CA--C 1.538 0.678 0 C-N-CA 122.741 -1.774 . . . . 0.0 110.365 -1.532 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 7.9 t -65.64 -175.24 0.26 Allowed 'General case' 0 CA--C 1.55 0.976 0 C-N-CA 122.616 0.366 . . . . 0.0 110.288 -178.87 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 13.9 p -122.42 -36.45 2.94 Favored 'General case' 0 N--CA 1.432 -1.334 0 CA-C-O 121.664 0.745 . . . . 0.0 109.017 -172.846 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.4 t -132.49 -137.51 0.19 Allowed 'General case' 1 N--CA 1.364 -4.77 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 176.154 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' GLU . . . . . 0.442 ' HA ' ' O ' ' A' ' 58' ' ' LEU . 19.6 tt0 -105.67 156.99 17.73 Favored 'General case' 0 C--N 1.264 -3.12 0 C-N-CA 125.958 1.703 . . . . 0.0 109.377 -170.595 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.521 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 23.7 p -74.76 162.27 74.27 Favored Pre-proline 0 C--N 1.31 -1.14 0 C-N-CA 123.322 0.649 . . . . 0.0 111.203 178.467 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -59.05 162.7 13.12 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 122.976 2.451 . . . . 0.0 111.236 176.137 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.5 tmm_? -68.92 125.98 28.35 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -176.272 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 71.5 t -140.14 128.48 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.83 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 -177.39 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 54' ' ' ASP . 1.9 p -124.68 132.37 71.41 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.378 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.206 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.562 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.4 m-85 -81.03 140.27 35.25 Favored 'General case' 0 C--N 1.298 -1.662 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 177.795 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -108.37 28.14 8.64 Favored 'General case' 0 C--N 1.292 -1.899 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' SER . . . . . 0.444 ' OG ' ' HB3' ' A' ' 95' ' ' TYR . 5.0 p -84.08 178.93 7.64 Favored 'General case' 0 N--CA 1.423 -1.807 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.918 -175.802 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -151.27 32.38 0.59 Allowed 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 171.613 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.1 t -163.62 -176.45 4.68 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 -176.484 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -76.84 134.25 39.1 Favored 'General case' 0 CA--C 1.506 -0.736 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.131 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' LYS . . . . . 0.584 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 7.8 mmpt? -137.39 152.4 73.13 Favored Pre-proline 0 C--N 1.29 -2.015 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -67.63 147.15 75.66 Favored 'Trans proline' 0 N--CA 1.443 -1.445 0 C-N-CA 122.305 2.003 . . . . 0.0 111.998 -177.733 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' TRP . . . . . 0.489 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.0 t90 -88.0 111.41 42.53 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' PRO . . . . . 0.462 ' HD3' ' OH ' ' A' ' 95' ' ' TYR . 2.5 Cg_endo -79.47 87.6 1.53 Allowed 'Trans proline' 0 N--CA 1.443 -1.448 0 C-N-CA 121.386 1.39 . . . . 0.0 112.069 -172.705 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.406 HG22 ' HD2' ' A' ' 77' ' ' TYR . 95.9 t -140.13 142.75 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.339 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 177.488 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.586 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.58 135.62 17.65 Favored 'General case' 0 N--CA 1.421 -1.899 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 178.158 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.491 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 16.8 mt -101.89 103.38 14.05 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.424 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 25.7 m-85 -84.38 76.62 10.12 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 120.767 0.318 . . . . 0.0 110.24 178.477 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.673 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.2 mm? -103.33 131.04 50.72 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 177.405 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.23 147.61 66.44 Favored Pre-proline 0 N--CA 1.418 -2.029 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.528 -175.317 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.511 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 30.3 Cg_endo -62.04 121.08 8.97 Favored 'Trans proline' 0 C--O 1.25 1.083 0 C-N-CA 123.068 2.512 . . . . 0.0 111.841 -178.188 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.509 HG22 ' O ' ' A' ' 70' ' ' ASN . 4.2 m -69.89 -120.52 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.186 -2.242 0 CA-C-N 114.026 -1.443 . . . . 0.0 111.218 175.919 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 23.0 t -111.06 -35.82 5.81 Favored 'General case' 0 C--N 1.291 -1.94 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 175.532 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 27.6 t -82.06 36.8 0.47 Allowed 'General case' 0 N--CA 1.441 -0.919 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.919 -176.834 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -117.02 133.47 55.96 Favored 'General case' 0 N--CA 1.418 -2.043 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 177.891 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -172.95 129.55 1.72 Allowed Glycine 0 N--CA 1.437 -1.24 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.21 -146.06 48.46 Favored Glycine 0 CA--C 1.491 -1.454 0 CA-C-O 119.143 -0.809 . . . . 0.0 111.781 -177.396 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.2 p -58.05 101.27 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-O 122.598 1.19 . . . . 0.0 112.157 -177.458 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -102.03 -23.09 14.14 Favored 'General case' 0 C--N 1.294 -1.827 0 CA-C-N 114.674 -1.148 . . . . 0.0 111.001 -178.484 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.519 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 65.3 mt -136.56 137.14 48.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.329 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.554 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.1 mmpt? -113.3 137.58 51.28 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-O 120.864 0.364 . . . . 0.0 110.664 176.657 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.94 134.82 48.79 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.749 -0.66 . . . . 0.0 109.833 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 85.17 6.96 83.91 Favored Glycine 0 C--N 1.303 -1.273 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.768 -178.808 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 49.4 m -109.44 144.58 37.48 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 177.518 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.438 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -70.38 126.57 30.02 Favored 'General case' 0 N--CA 1.443 -0.783 0 CA-C-N 115.045 -0.98 . . . . 0.0 108.58 -178.776 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.75 ' HB ' HG21 ' A' ' 67' ' ' VAL . 34.4 pt -113.0 -26.05 3.21 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 N-CA-C 112.469 0.544 . . . . 0.0 112.469 -179.39 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' ALA . . . . . 0.42 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -160.82 165.29 30.51 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 -178.07 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.438 HG23 HD11 ' A' ' 125' ' ' LEU . 63.7 t -140.63 112.88 4.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 179.062 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.487 HD11 HD21 ' A' ' 107' ' ' LEU . 50.9 mt -117.1 143.99 45.17 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.44 ' O ' HD12 ' A' ' 58' ' ' LEU . 5.0 mp -128.9 123.77 59.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.054 0 C-N-CA 119.616 -0.834 . . . . 0.0 109.946 179.206 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.439 ' C ' HD12 ' A' ' 131' ' ' LEU . 1.4 pp -88.72 147.03 24.7 Favored 'General case' 0 CA--C 1.477 -1.855 0 N-CA-C 106.304 -1.739 . . . . 0.0 106.304 174.512 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 37.3 ttp180 -112.42 123.41 50.22 Favored 'General case' 0 C--N 1.258 -3.39 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 173.755 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.28 135.88 33.65 Favored 'General case' 0 N--CA 1.408 -2.53 0 N-CA-C 105.625 -1.991 . . . . 0.0 105.625 -176.407 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 35.2 m -147.29 147.22 30.16 Favored 'General case' 0 C--N 1.269 -2.919 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 175.012 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.668 ' CB ' HG23 ' A' ' 52' ' ' ILE . 11.5 p30 . . . . . 0 N--CA 1.438 -1.036 0 C-N-CA 119.708 -0.797 . . . . 0.0 110.983 178.453 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 . . . . . 0 N--CA 1.426 -1.642 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -123.8 146.61 48.22 Favored 'General case' 0 C--N 1.286 -2.162 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.042 -177.614 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 9.8 m-30 -113.01 125.88 54.9 Favored 'General case' 0 C--N 1.309 -1.156 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 -176.033 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.451 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 58.3 t -89.27 134.31 28.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 O-C-N 123.553 0.533 . . . . 0.0 110.409 -177.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 58.9 m95 -120.26 97.03 5.39 Favored 'General case' 0 C--N 1.284 -2.246 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 -78.34 113.1 16.01 Favored 'General case' 0 C--N 1.283 -2.318 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 177.741 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.432 ' HA ' HG22 ' A' ' 20' ' ' VAL . 22.8 mm -88.74 122.17 39.81 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -177.183 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 47.4 m-85 -118.11 153.04 34.43 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.509 0.671 . . . . 0.0 109.809 178.061 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -78.98 128.89 33.85 Favored 'General case' 0 N--CA 1.409 -2.517 0 CA-C-N 114.609 -1.178 . . . . 0.0 108.159 175.284 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -88.71 -15.5 34.66 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -178.404 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -151.01 145.39 25.5 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 113.578 -1.646 . . . . 0.0 109.641 -175.696 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -79.92 144.63 33.2 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 124.019 0.928 . . . . 0.0 110.753 -178.624 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.552 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 71.2 t -121.54 134.62 64.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.11 -176.937 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.5 t -118.58 134.43 62.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 -179.447 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.47 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 75.5 t -97.46 101.68 10.82 Favored Pre-proline 0 C--N 1.292 -1.934 0 C-N-CA 123.889 0.876 . . . . 0.0 108.778 177.633 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.468 ' HG3' HG13 ' A' ' 27' ' ' VAL . 35.8 Cg_endo -67.22 -28.38 40.33 Favored 'Trans proline' 0 CA--C 1.511 -0.643 0 C-N-CA 121.893 1.729 . . . . 0.0 112.018 -178.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 158' ' ' THR . . . . . 0.403 ' HB ' HG12 ' A' ' 156' ' ' VAL . 8.0 t . . . . . 0 CA--C 1.559 1.298 0 O-C-N 124.827 1.329 . . . . 0.0 112.831 176.87 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.509 -0.63 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.433 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 74.1 m -134.17 161.94 33.52 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 119.747 -0.781 . . . . 0.0 112.211 -173.703 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.463 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -146.78 161.67 40.16 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.215 -176.84 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.451 HG22 HG22 ' A' ' 20' ' ' VAL . 72.7 p -99.48 179.56 4.52 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 121.225 0.536 . . . . 0.0 111.557 -178.716 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.58 -26.62 50.92 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.862 177.14 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -79.4 -31.33 42.73 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 119.433 -0.907 . . . . 0.0 109.414 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 129.08 20.42 1.45 Allowed Glycine 0 N--CA 1.431 -1.687 0 C-N-CA 119.911 -1.138 . . . . 0.0 112.933 173.76 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.42 ' O ' ' HA ' ' A' ' 4' ' ' LYS . 2.6 m -87.98 99.31 12.06 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.565 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.06 121.32 32.76 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 115.795 -0.638 . . . . 0.0 109.539 177.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 63.5 mt -99.82 116.67 64.54 Favored Pre-proline 0 C--N 1.29 -1.99 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 177.293 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -77.39 168.57 22.66 Favored 'Trans proline' 0 C--O 1.251 1.151 0 C-N-CA 122.45 2.1 . . . . 0.0 110.912 177.704 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 64.9 mt -66.56 124.91 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.595 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 145.04 -5.0 1.42 Allowed Glycine 0 C--N 1.303 -1.304 0 CA-C-N 115.723 -0.671 . . . . 0.0 111.636 -176.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 94.37 161.17 34.75 Favored Glycine 0 N--CA 1.439 -1.145 0 N-CA-C 110.122 -1.191 . . . . 0.0 110.122 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 159.38 -167.01 34.96 Favored Glycine 0 CA--C 1.486 -1.758 0 C-N-CA 119.484 -1.341 . . . . 0.0 111.342 179.044 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 49.9 p -147.08 152.37 38.41 Favored 'General case' 0 N--CA 1.424 -1.761 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -178.506 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -138.39 163.41 31.95 Favored 'General case' 0 N--CA 1.417 -2.082 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.013 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -108.42 118.14 35.99 Favored 'General case' 0 N--CA 1.406 -2.662 0 CA-C-N 114.342 -1.299 . . . . 0.0 107.964 176.457 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.451 HG22 HG22 ' A' ' 5' ' ' THR . 49.3 t -104.96 130.5 55.95 Favored 'Isoleucine or valine' 0 C--N 1.264 -3.113 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.142 178.776 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -118.75 128.09 54.17 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -179.352 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.55 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -138.01 137.26 44.75 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 O-C-N 124.128 0.893 . . . . 0.0 110.932 -176.545 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 37.3 m-80 -90.28 139.63 30.47 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 178.776 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.7 HD21 HG22 ' A' ' 36' ' ' VAL . 5.1 mp -122.72 161.95 22.93 Favored 'General case' 0 C--N 1.282 -2.367 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.183 176.852 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.03 120.85 54.26 Favored Pre-proline 0 C--N 1.316 -0.863 0 O-C-N 124.653 1.221 . . . . 0.0 109.404 178.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 73.5 Cg_endo -75.68 3.75 5.68 Favored 'Trans proline' 0 CA--C 1.532 0.392 0 C-N-CA 122.846 2.364 . . . . 0.0 113.398 -176.154 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.4 t -132.0 109.79 15.84 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 178.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.52 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.1 t -141.85 107.7 1.78 Allowed 'Isoleucine or valine' 0 C--O 1.182 -2.448 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -176.639 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.664 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -96.4 150.36 20.67 Favored 'General case' 0 C--N 1.269 -2.895 0 O-C-N 122.036 -0.415 . . . . 0.0 111.303 -179.864 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.402 HG13 ' O ' ' A' ' 112' ' ' VAL . 35.0 t -45.81 117.44 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 123.445 0.698 . . . . 0.0 111.976 176.953 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.62 1.61 53.01 Favored Glycine 0 CA--C 1.523 0.576 0 CA-C-N 115.414 -0.812 . . . . 0.0 112.829 -178.644 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.664 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.1 OUTLIER -73.02 -178.0 2.64 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 123.891 0.876 . . . . 0.0 110.034 177.639 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -130.22 86.82 2.44 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 177.636 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.624 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 20.2 tp -89.94 145.49 25.08 Favored 'General case' 0 C--N 1.294 -1.824 0 C-N-CA 119.765 -0.774 . . . . 0.0 109.259 -179.256 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 73.7 t -137.73 134.5 45.8 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.73 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -178.812 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.7 HG22 HD21 ' A' ' 24' ' ' LEU . 21.0 t -99.99 89.62 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.41 -2.426 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 174.32 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -83.35 114.95 21.78 Favored 'General case' 0 C--N 1.3 -1.562 0 C-N-CA 119.91 -0.716 . . . . 0.0 111.125 -176.895 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 82.7 mt -99.78 -2.39 35.24 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.69 -177.397 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.6 m -73.68 -2.08 21.7 Favored 'General case' 0 C--O 1.208 -1.13 0 CA-C-O 122.222 1.011 . . . . 0.0 109.191 -179.503 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.2 p -126.21 7.48 7.17 Favored 'General case' 0 N--CA 1.419 -1.985 0 CA-C-N 115.151 -0.931 . . . . 0.0 109.776 179.002 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.55 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 48.6 mm-40 -125.42 -20.23 4.83 Favored 'General case' 0 CA--C 1.508 -0.648 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.9 -174.692 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.5 mt -135.3 137.31 50.23 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 -176.588 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.463 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 74.8 m-85 -137.68 153.67 49.78 Favored 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 -176.07 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.433 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 90.5 m -132.23 134.91 45.87 Favored 'General case' 0 C--N 1.28 -2.419 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.875 -178.637 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 18.7 p-80 -122.64 131.0 53.61 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.428 -175.486 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.401 HD21 ' HA ' ' A' ' 98' ' ' ARG . 4.2 p-10 -77.83 118.17 19.9 Favored 'General case' 0 N--CA 1.422 -1.83 0 CA-C-O 122.09 0.948 . . . . 0.0 108.963 178.426 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -97.24 -27.1 14.68 Favored 'General case' 0 C--N 1.274 -2.696 0 CA-C-N 114.154 -1.385 . . . . 0.0 110.387 -177.022 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 37.5 m-85 -148.93 68.43 9.63 Favored Pre-proline 0 N--CA 1.483 1.182 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.416 ' HA ' ' OD2' ' A' ' 54' ' ' ASP . 58.4 Cg_endo -67.85 -11.72 33.01 Favored 'Trans proline' 0 N--CA 1.481 0.766 0 C-N-CA 122.925 2.417 . . . . 0.0 114.281 -171.587 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -114.58 -14.03 12.11 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 121.208 0.528 . . . . 0.0 110.565 -177.474 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.517 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.3 m -101.87 -29.24 11.96 Favored 'General case' 0 N--CA 1.424 -1.731 0 CA-C-O 122.047 0.927 . . . . 0.0 108.881 -173.28 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.517 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.4 mp -128.56 141.21 47.14 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.168 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 178.403 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 14.5 t -74.52 136.35 42.18 Favored 'General case' 0 N--CA 1.428 -1.563 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 174.071 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.49 ' O ' HG23 ' A' ' 94' ' ' VAL . 51.3 m-20 -95.98 105.82 17.9 Favored 'General case' 0 C--N 1.263 -3.173 0 C-N-CA 118.457 -1.297 . . . . 0.0 108.404 -179.305 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.505 ' CD2' ' HB ' ' A' ' 134' ' ' THR . 15.8 t80 -142.21 139.44 32.02 Favored 'General case' 0 C--N 1.289 -2.052 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.482 -173.963 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.423 ' CG2' ' HG ' ' A' ' 131' ' ' LEU . 14.9 p -148.56 156.01 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.943 0 O-C-N 123.832 0.708 . . . . 0.0 109.991 -178.44 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.29 135.54 17.94 Favored 'General case' 0 N--CA 1.422 -1.845 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 176.24 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.521 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 32.5 tp -70.6 110.44 5.45 Favored 'General case' 0 N--CA 1.427 -1.579 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 170.553 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.412 ' HB2' ' HB2' ' A' ' 132' ' ' ARG . 12.0 tp60 -57.6 -56.63 19.41 Favored 'General case' 0 C--O 1.206 -1.227 0 CA-C-N 113.576 -1.647 . . . . 0.0 109.479 -177.58 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 10.5 ptp180 -164.09 156.56 17.25 Favored 'General case' 0 N--CA 1.41 -2.461 0 CA-C-N 114.364 -1.289 . . . . 0.0 108.472 -177.998 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -140.58 135.83 7.26 Favored Glycine 0 N--CA 1.4 -3.712 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -179.535 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 46.0 m -124.81 147.68 48.59 Favored 'General case' 0 C--N 1.276 -2.591 0 C-N-CA 124.139 0.975 . . . . 0.0 110.473 -175.694 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.506 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -106.81 158.83 16.69 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.508 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 97.1 m-85 -154.61 175.4 13.7 Favored 'General case' 0 C--N 1.341 0.231 0 C-N-CA 124.139 0.975 . . . . 0.0 109.864 -177.87 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.02 -143.28 45.84 Favored Glycine 0 N--CA 1.446 -0.671 0 O-C-N 123.791 0.682 . . . . 0.0 113.104 176.486 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.36 -13.12 73.59 Favored Glycine 0 C--O 1.202 -1.868 0 C-N-CA 120.962 -0.637 . . . . 0.0 111.742 177.063 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.855 HG21 ' HB ' ' A' ' 126' ' ' ILE . 94.7 t -70.29 -36.75 68.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 123.414 0.686 . . . . 0.0 112.043 -177.64 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.506 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -90.04 -18.54 25.76 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.58 -1.248 . . . . 0.0 112.374 177.248 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 5.0 t -99.88 -51.13 3.8 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.369 -172.134 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.456 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 67.7 m-20 -96.2 -23.18 16.84 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 -174.683 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.645 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 89.6 m-85 -110.73 156.3 21.24 Favored 'General case' 0 N--CA 1.422 -1.868 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 177.588 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.0 t -165.59 127.89 2.06 Favored 'General case' 0 N--CA 1.411 -2.409 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 176.513 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.29 -111.24 0.27 Allowed Glycine 0 N--CA 1.407 -3.233 0 N-CA-C 111.574 -0.61 . . . . 0.0 111.574 176.462 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -153.63 -179.91 8.23 Favored 'General case' 0 C--N 1.291 -1.941 0 C-N-CA 123.933 0.893 . . . . 0.0 110.366 -173.843 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 3.2 p -135.8 151.51 29.61 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.242 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.691 ' HG3' ' O ' ' A' ' 80' ' ' SER . 72.3 tttt -130.91 147.53 52.57 Favored 'General case' 0 N--CA 1.423 -1.794 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -178.676 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.448 ' CD2' HG22 ' A' ' 105' ' ' VAL . 47.5 t80 -148.13 108.67 4.15 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 -177.199 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 13.8 t 51.21 44.62 28.68 Favored 'General case' 0 CA--C 1.553 1.06 0 C-N-CA 123.433 0.693 . . . . 0.0 111.197 175.834 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 81.22 20.89 63.75 Favored Glycine 0 CA--C 1.525 0.671 0 C-N-CA 120.264 -0.97 . . . . 0.0 113.115 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.691 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 16.3 t -90.53 179.26 5.89 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 106.927 -1.508 . . . . 0.0 106.927 174.649 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 10.9 m -157.47 103.55 1.96 Allowed 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 178.875 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.423 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.6 p90 -147.65 158.75 42.59 Favored Pre-proline 0 C--N 1.308 -1.222 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -172.875 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.417 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 56.6 Cg_endo -68.78 150.16 73.65 Favored 'Trans proline' 0 C--N 1.356 0.964 0 C-N-CA 122.933 2.422 . . . . 0.0 112.837 -177.654 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.541 ' CD2' HD21 ' A' ' 109' ' ' LEU . 47.3 t80 -124.5 134.77 25.83 Favored Pre-proline 0 N--CA 1.431 -1.402 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 179.293 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.54 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 59.3 Cg_endo -71.03 145.61 82.69 Favored 'Cis proline' 0 CA--C 1.554 1.51 0 C-N-CA 123.105 -1.623 . . . . 0.0 111.153 -2.438 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.2 t -68.43 -176.81 0.81 Allowed 'General case' 0 N--CA 1.489 1.52 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.32 -175.398 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 56.1 p -124.89 -47.34 1.8 Allowed 'General case' 0 N--CA 1.436 -1.164 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -172.362 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 10.0 t -105.4 -65.19 1.07 Allowed 'General case' 0 N--CA 1.437 -1.123 0 C-N-CA 120.39 -0.524 . . . . 0.0 111.246 -174.242 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 176.23 -172.98 0.09 Allowed 'General case' 0 C--O 1.247 0.97 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 -175.546 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.521 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 42.4 p -100.9 168.44 9.24 Favored Pre-proline 0 C--N 1.297 -1.708 0 O-C-N 123.429 0.455 . . . . 0.0 111.707 175.326 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' PRO . . . . . 0.453 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 19.0 Cg_endo -55.78 165.19 3.84 Favored 'Trans proline' 0 CA--C 1.547 1.158 0 C-N-CA 123.232 2.621 . . . . 0.0 111.962 171.864 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.403 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 1.7 tmm_? -76.68 112.75 13.58 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -176.587 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 76.4 t -126.4 128.33 71.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-O 121.522 0.677 . . . . 0.0 110.15 -176.305 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 54' ' ' ASP . 0.2 OUTLIER -121.71 132.32 71.08 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 CA-C-N 115.038 -0.983 . . . . 0.0 110.776 -177.571 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.49 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 7.2 m-85 -80.78 101.04 9.09 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.19 -178.084 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 -96.63 64.31 2.13 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.6 m -142.02 178.1 7.76 Favored 'General case' 0 N--CA 1.434 -1.229 0 O-C-N 121.778 -0.576 . . . . 0.0 110.844 -174.24 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.401 ' HA ' HD21 ' A' ' 46' ' ' ASN . 6.8 ptp180 -141.22 45.75 1.75 Allowed 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.066 0.46 . . . . 0.0 110.446 -178.678 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.0 t -170.53 177.44 4.0 Favored 'General case' 0 C--O 1.245 0.847 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 -174.824 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -73.03 98.16 2.48 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 173.51 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 10.0 tptp -97.1 142.59 24.76 Favored Pre-proline 0 C--N 1.277 -2.587 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.415 ' O ' ' HD3' ' A' ' 104' ' ' PRO . 26.8 Cg_endo -62.91 154.72 64.72 Favored 'Trans proline' 0 C--N 1.324 -0.75 0 C-N-CA 122.428 2.086 . . . . 0.0 112.395 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' TRP . . . . . 0.49 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 15.4 t90 -95.71 100.94 6.96 Favored Pre-proline 0 C--N 1.306 -1.32 0 N-CA-C 105.102 -2.184 . . . . 0.0 105.102 175.929 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' PRO . . . . . 0.415 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 59.6 Cg_endo -74.57 88.63 1.16 Allowed 'Trans proline' 0 N--CA 1.454 -0.837 0 C-N-CA 121.782 1.655 . . . . 0.0 113.341 -170.052 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.448 HG22 ' CD2' ' A' ' 77' ' ' TYR . 96.9 t -138.61 145.12 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.193 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.91 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.534 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.65 138.47 19.92 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 177.269 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.475 ' HB2' ' CG2' ' A' ' 36' ' ' VAL . 17.7 mt -102.82 104.3 14.56 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.93 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 9.5 m-85 -81.32 67.33 7.22 Favored 'General case' 0 C--N 1.295 -1.788 0 O-C-N 122.023 -0.423 . . . . 0.0 111.355 179.206 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.645 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.4 mm? -92.84 134.54 34.97 Favored 'General case' 0 C--O 1.208 -1.127 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 176.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.62 148.11 62.33 Favored Pre-proline 0 C--N 1.294 -1.829 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -176.18 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.456 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 28.8 Cg_endo -62.98 121.46 9.35 Favored 'Trans proline' 0 C--O 1.243 0.753 0 C-N-CA 123.235 2.624 . . . . 0.0 112.555 -176.726 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.402 ' O ' HG13 ' A' ' 30' ' ' VAL . 2.4 m -71.86 -116.9 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.186 -2.237 0 CA-C-N 114.225 -1.352 . . . . 0.0 112.715 176.914 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 28.9 t -112.54 -37.54 4.9 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 177.191 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 47.9 m -73.42 16.21 0.2 Allowed 'General case' 0 N--CA 1.399 -2.999 0 C-N-CA 125.997 1.719 . . . . 0.0 113.653 -176.737 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -102.7 131.69 49.34 Favored 'General case' 0 N--CA 1.411 -2.399 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -176.966 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.94 129.33 1.62 Allowed Glycine 0 N--CA 1.434 -1.447 0 N-CA-C 110.634 -0.987 . . . . 0.0 110.634 179.377 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.89 -151.29 51.92 Favored Glycine 0 CA--C 1.5 -0.888 0 CA-C-O 119.085 -0.842 . . . . 0.0 111.53 -176.757 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.9 p -54.86 104.6 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 122.233 1.016 . . . . 0.0 111.914 -177.518 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.85 -31.2 9.4 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 115.043 -0.981 . . . . 0.0 111.461 -177.166 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.53 ' HB ' HG22 ' A' ' 154' ' ' VAL . 69.7 mt -124.4 140.86 46.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 177.186 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.42 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 2.8 mmpt? -117.67 139.44 51.01 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-O 121.001 0.429 . . . . 0.0 111.073 178.483 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.7 131.67 44.95 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.406 -0.815 . . . . 0.0 110.769 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 87.31 -7.9 78.97 Favored Glycine 0 C--N 1.309 -0.931 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.079 -179.58 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 25.3 m -90.69 148.59 22.5 Favored 'General case' 0 N--CA 1.425 -1.716 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 24.9 tp -73.76 133.0 43.22 Favored 'General case' 0 N--CA 1.436 -1.132 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.229 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.855 ' HB ' HG21 ' A' ' 67' ' ' VAL . 37.9 pt -118.42 -24.44 3.25 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 C-N-CA 120.432 -0.507 . . . . 0.0 112.352 -179.519 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 127' ' ' ALA . . . . . 0.47 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -163.3 164.33 24.92 Favored 'General case' 0 N--CA 1.439 -0.977 0 CA-C-O 120.538 0.209 . . . . 0.0 110.614 -178.633 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 53.5 t -140.74 114.36 5.36 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 178.4 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.41 HD11 HD21 ' A' ' 107' ' ' LEU . 54.3 mt -117.55 139.01 51.52 Favored 'General case' 0 C--N 1.287 -2.12 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.449 ' O ' HD12 ' A' ' 58' ' ' LEU . 5.0 mp -117.33 122.29 69.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 C-N-CA 119.314 -0.954 . . . . 0.0 109.918 177.372 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.494 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.0 OUTLIER -90.44 132.73 35.47 Favored 'General case' 0 C--N 1.275 -2.649 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 177.439 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 132' ' ' ARG . . . . . 0.412 ' HB2' ' HB2' ' A' ' 59' ' ' GLN . 17.7 tpt85 -106.85 109.54 21.47 Favored 'General case' 0 C--N 1.274 -2.709 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.149 -176.05 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -88.34 132.67 34.33 Favored 'General case' 0 CA--C 1.484 -1.574 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 175.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.505 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 11.7 m -136.41 133.57 36.83 Favored 'General case' 0 C--N 1.273 -2.724 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 177.636 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 16.3 p30 . . . . . 0 C--N 1.31 -1.141 0 CA-C-O 121.404 0.621 . . . . 0.0 111.634 -179.185 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 . . . . . 0 N--CA 1.44 -0.952 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -119.92 143.72 47.82 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 178.42 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.478 ' HB2' HD22 ' A' ' 131' ' ' LEU . 9.6 m-30 -112.48 134.35 54.06 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -176.513 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 47.4 t -91.51 131.09 39.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 CA-C-O 121.155 0.502 . . . . 0.0 110.08 -179.096 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 146' ' ' TRP . . . . . 0.494 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 65.3 m95 -120.23 97.96 5.84 Favored 'General case' 0 C--N 1.284 -2.274 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -179.217 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 36.9 m-80 -80.35 114.1 19.01 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 106.992 -1.485 . . . . 0.0 106.992 178.588 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.47 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 22.5 mm -89.3 122.53 40.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 -177.784 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -120.31 152.75 37.39 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 123.428 0.691 . . . . 0.0 109.605 178.803 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.73 132.92 34.82 Favored 'General case' 0 N--CA 1.418 -2.03 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 177.81 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -90.1 -15.45 31.66 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 -178.19 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -149.27 144.52 26.56 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 114.049 -1.432 . . . . 0.0 109.431 -175.665 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -85.76 148.08 26.02 Favored 'General case' 0 C--N 1.315 -0.906 0 O-C-N 124.022 0.826 . . . . 0.0 109.292 -178.145 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.53 HG22 ' HB ' ' A' ' 120' ' ' ILE . 2.2 m -126.56 148.34 31.31 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 C-N-CA 120.256 -0.578 . . . . 0.0 110.557 -176.941 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.5 t -120.14 140.6 43.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.032 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 -179.144 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.52 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 79.4 t -101.57 101.63 18.46 Favored Pre-proline 0 C--N 1.297 -1.676 0 C-N-CA 123.871 0.868 . . . . 0.0 109.706 178.233 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.451 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 30.3 Cg_endo -68.28 -25.85 36.17 Favored 'Trans proline' 0 CA--C 1.518 -0.304 0 C-N-CA 122.315 2.01 . . . . 0.0 112.378 178.661 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 5.8 t . . . . . 0 CA--C 1.559 1.31 0 O-C-N 124.646 1.216 . . . . 0.0 113.352 176.506 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.511 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.44 -0.934 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.445 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 68.4 m -142.41 159.0 43.09 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 120.274 -0.57 . . . . 0.0 110.912 -174.924 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.438 ' HD2' ' O ' ' A' ' 5' ' ' THR . 0.0 OUTLIER -146.12 156.87 43.74 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-O 121.14 0.495 . . . . 0.0 109.978 -177.469 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.438 ' O ' ' HD2' ' A' ' 4' ' ' LYS . 41.1 p -91.83 176.08 6.65 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.613 -179.178 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -85.23 -5.08 59.34 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 114.866 -1.061 . . . . 0.0 110.838 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.96 -34.49 8.92 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.877 -179.689 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 140.06 7.27 0.99 Allowed Glycine 0 C--N 1.316 -0.529 0 C-N-CA 118.796 -1.668 . . . . 0.0 115.236 172.289 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.7 m -87.37 102.3 14.39 Favored 'General case' 0 C--N 1.296 -1.755 0 O-C-N 121.892 -0.77 . . . . 0.0 109.039 177.164 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.57 122.12 37.98 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 115.396 -0.82 . . . . 0.0 108.84 175.404 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.511 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 63.7 mt -102.01 116.15 63.64 Favored Pre-proline 0 C--N 1.298 -1.649 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.187 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.25 173.8 12.11 Favored 'Trans proline' 0 C--O 1.247 0.954 0 C-N-CA 122.814 2.343 . . . . 0.0 111.469 178.069 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 58.8 mt -66.64 129.59 31.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 178.215 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 140.14 -6.79 2.85 Favored Glycine 0 C--N 1.303 -1.252 0 N-CA-C 111.358 -0.697 . . . . 0.0 111.358 -178.705 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 96.84 156.26 30.76 Favored Glycine 0 N--CA 1.438 -1.199 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -179.108 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 170.33 -175.46 44.25 Favored Glycine 0 N--CA 1.428 -1.886 0 C-N-CA 119.822 -1.18 . . . . 0.0 111.142 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.6 m -144.96 148.88 34.3 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 178.631 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.98 165.4 26.08 Favored 'General case' 0 CA--C 1.48 -1.727 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -114.85 110.09 19.14 Favored 'General case' 0 C--N 1.278 -2.543 0 CA-C-N 114.098 -1.41 . . . . 0.0 107.482 177.25 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.436 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.3 m -97.65 142.08 14.91 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.321 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.694 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.2 m-85 -124.07 124.56 42.79 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 121.039 0.447 . . . . 0.0 110.989 -178.84 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.466 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.9 p -138.43 134.85 43.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.825 -178.067 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -94.33 128.06 40.6 Favored 'General case' 0 C--N 1.294 -1.811 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.867 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -104.82 160.51 14.94 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.097 -0.956 . . . . 0.0 108.581 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.75 123.33 57.46 Favored Pre-proline 0 C--O 1.211 -0.949 0 O-C-N 124.258 0.974 . . . . 0.0 109.241 176.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 74.1 Cg_endo -76.57 -0.34 10.35 Favored 'Trans proline' 0 CA--C 1.536 0.592 0 C-N-CA 122.5 2.133 . . . . 0.0 113.567 -175.947 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.5 t -128.85 109.77 19.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 179.57 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.428 HG21 HD22 ' A' ' 34' ' ' LEU . 5.2 t -145.09 104.69 0.71 Allowed 'Isoleucine or valine' 0 C--O 1.198 -1.639 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -178.078 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.523 ' HB3' ' HG2' ' A' ' 157' ' ' PRO . 0.5 OUTLIER -94.36 154.84 17.28 Favored 'General case' 0 C--N 1.275 -2.668 0 C-N-CA 123.212 0.605 . . . . 0.0 111.61 -179.902 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.433 ' H ' ' HA ' ' A' ' 158' ' ' THR . 42.5 t -44.7 116.53 0.23 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.361 0 C-N-CA 124.103 0.961 . . . . 0.0 111.402 175.486 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.72 0.2 45.84 Favored Glycine 0 CA--C 1.521 0.458 0 CA-C-N 115.06 -0.973 . . . . 0.0 113.186 179.701 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.478 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 1.4 mm-40 -72.78 -177.63 2.41 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 123.779 0.831 . . . . 0.0 111.768 176.702 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -128.84 87.39 2.57 Favored 'General case' 0 CA--C 1.49 -1.337 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 177.307 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.631 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 21.6 tp -96.24 135.23 38.33 Favored 'General case' 0 N--CA 1.423 -1.824 0 C-N-CA 119.23 -0.988 . . . . 0.0 109.64 179.256 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.6 p -141.64 132.49 26.31 Favored 'Isoleucine or valine' 0 N--CA 1.387 -3.599 0 CA-C-O 122.208 1.004 . . . . 0.0 112.859 -178.077 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.604 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 41.9 t -91.74 89.7 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.661 0 CA-C-N 113.507 -1.678 . . . . 0.0 107.664 178.364 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -77.78 106.91 9.91 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 88.3 mt -93.93 -1.22 54.99 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.701 -178.495 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.637 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 0.7 OUTLIER -68.99 -10.57 58.15 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-O 122.396 1.093 . . . . 0.0 109.741 -178.638 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.6 p -121.47 5.52 10.13 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 115.083 -0.962 . . . . 0.0 110.748 179.054 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.466 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 49.2 mm-40 -120.0 -21.98 6.89 Favored 'General case' 0 CA--C 1.511 -0.555 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.614 -174.635 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 29.9 mt -135.06 138.95 48.12 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.011 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -178.09 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -136.96 147.87 46.6 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 -177.052 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.445 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 88.9 m -123.55 136.55 54.6 Favored 'General case' 0 C--N 1.29 -1.981 0 CA-C-O 120.864 0.364 . . . . 0.0 110.991 178.8 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 16.4 p80 -130.91 162.6 29.3 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.423 0.63 . . . . 0.0 110.46 -175.424 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -112.56 121.17 44.03 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 121.828 0.823 . . . . 0.0 111.993 177.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 22.5 p-10 -96.98 -13.32 22.41 Favored 'General case' 0 N--CA 1.427 -1.583 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.588 178.851 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.418 ' HB2' HD13 ' A' ' 52' ' ' ILE . 83.4 m-85 -147.3 69.24 11.53 Favored Pre-proline 0 C--O 1.22 -0.481 0 CA-C-N 115.503 -0.771 . . . . 0.0 108.935 175.464 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -68.52 -12.82 35.86 Favored 'Trans proline' 0 N--CA 1.483 0.895 0 C-N-CA 122.091 1.861 . . . . 0.0 112.903 -177.176 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -101.44 -25.03 14.07 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-O 121.353 0.597 . . . . 0.0 110.589 -176.513 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.582 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.3 m -102.09 -26.81 13.24 Favored 'General case' 0 N--CA 1.42 -1.97 0 CA-C-O 121.69 0.757 . . . . 0.0 109.289 -172.387 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.582 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.2 mp -129.31 127.73 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.263 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 -178.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.1 t -73.63 145.7 45.16 Favored 'General case' 0 C--O 1.256 1.399 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -85.3 107.62 17.41 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -176.629 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.44 ' CE2' ' HB ' ' A' ' 134' ' ' THR . 17.3 t80 -149.35 138.83 21.61 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -177.555 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.503 HG23 ' HG ' ' A' ' 131' ' ' LEU . 13.4 p -150.64 149.97 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.564 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.25 -178.93 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -150.3 131.02 14.07 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 172.744 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.541 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 53.4 tp -66.5 110.82 3.3 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 171.858 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.494 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 3.0 tp-100 -55.48 -50.86 68.79 Favored 'General case' 0 C--N 1.314 -0.96 0 C-N-CA 126.123 1.769 . . . . 0.0 111.564 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -170.44 155.77 5.24 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -177.418 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -132.32 136.07 8.52 Favored Glycine 1 N--CA 1.395 -4.077 0 N-CA-C 107.986 -2.046 . . . . 0.0 107.986 178.413 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 47.8 m -124.17 147.91 47.64 Favored 'General case' 0 C--N 1.271 -2.809 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -176.303 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.563 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -115.46 156.09 26.28 Favored 'General case' 0 C--N 1.306 -1.315 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 -179.339 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.505 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 92.8 m-85 -155.13 -178.95 7.61 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 123.832 0.853 . . . . 0.0 109.045 -177.351 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 62.46 -136.75 44.87 Favored Glycine 0 C--O 1.222 -0.612 0 N-CA-C 111.723 -0.551 . . . . 0.0 111.723 179.344 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -88.38 -3.91 77.83 Favored Glycine 0 C--O 1.206 -1.607 0 C-N-CA 120.537 -0.839 . . . . 0.0 111.133 176.762 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.738 HG21 ' HB ' ' A' ' 126' ' ' ILE . 76.1 t -71.35 -36.31 60.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 C-N-CA 123.876 0.87 . . . . 0.0 111.576 -176.11 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.563 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -85.31 -25.73 27.0 Favored 'General case' 0 C--N 1.297 -1.681 0 C-N-CA 119.915 -0.714 . . . . 0.0 112.486 178.451 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 21.0 m -101.04 -52.83 3.18 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 -173.13 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.483 ' O ' HG22 ' A' ' 112' ' ' VAL . 53.9 m-20 -88.52 -28.41 20.81 Favored 'General case' 0 CA--C 1.488 -1.426 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 -175.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.656 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 90.2 m-85 -104.55 155.29 18.96 Favored 'General case' 0 N--CA 1.41 -2.463 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 175.465 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.415 ' HB3' ' CG1' ' A' ' 112' ' ' VAL . 15.5 t -167.03 120.34 0.98 Allowed 'General case' 0 N--CA 1.417 -2.106 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 177.013 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.454 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -154.81 -112.66 0.45 Allowed Glycine 0 N--CA 1.402 -3.63 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 175.948 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 8.3 p -151.69 -179.93 7.85 Favored 'General case' 0 C--N 1.293 -1.862 0 CA-C-O 121.157 0.503 . . . . 0.0 110.662 -173.796 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.443 ' HB ' ' HB2' ' A' ' 84' ' ' PHE . 2.5 p -132.27 146.03 33.71 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.156 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 177.868 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.643 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.1 tttt -123.92 142.85 50.77 Favored 'General case' 0 N--CA 1.409 -2.514 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 178.621 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.482 ' CG ' HG21 ' A' ' 90' ' ' THR . 59.9 t80 -145.49 112.57 6.07 Favored 'General case' 0 C--N 1.286 -2.159 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 -179.124 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.3 m 55.28 37.37 28.79 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 113.678 0.992 . . . . 0.0 113.678 176.562 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.44 5.84 81.68 Favored Glycine 0 N--CA 1.432 -1.587 0 C-N-CA 120.422 -0.894 . . . . 0.0 112.58 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.643 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 11.0 t -80.34 174.59 11.45 Favored 'General case' 0 C--N 1.317 -0.844 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.532 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 9.3 p -154.13 100.43 2.32 Favored 'General case' 0 C--N 1.284 -2.257 0 CA-C-O 120.98 0.419 . . . . 0.0 110.182 -176.624 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 2.9 p90 -147.07 159.62 42.25 Favored Pre-proline 0 C--N 1.297 -1.701 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -173.69 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -67.53 149.1 79.76 Favored 'Trans proline' 0 C--N 1.354 0.845 0 C-N-CA 123.161 2.574 . . . . 0.0 113.228 -177.142 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.62 ' CD2' HD21 ' A' ' 109' ' ' LEU . 64.5 t80 -124.99 134.7 25.94 Favored Pre-proline 0 C--N 1.315 -0.903 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.128 -179.677 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.525 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 73.9 Cg_endo -72.85 146.39 86.73 Favored 'Cis proline' 0 C--O 1.244 0.788 0 C-N-CA 122.91 -1.704 . . . . 0.0 110.543 -1.487 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.2 t -65.54 -176.76 0.37 Allowed 'General case' 0 CA--C 1.551 0.987 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.394 -175.304 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.2 p -129.03 2.65 5.27 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-O 121.368 0.604 . . . . 0.0 110.709 -173.527 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.6 t -161.75 -125.03 0.02 OUTLIER 'General case' 0 N--CA 1.396 -3.146 0 N-CA-C 105.282 -2.118 . . . . 0.0 105.282 179.025 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -129.7 -170.35 2.28 Favored 'General case' 0 C--N 1.291 -1.963 0 N-CA-C 110.475 -0.194 . . . . 0.0 110.475 -176.244 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.541 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 44.1 p -95.25 166.8 14.05 Favored Pre-proline 0 C--N 1.302 -1.462 0 CA-C-N 116.18 -0.463 . . . . 0.0 112.205 178.581 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -62.29 165.09 15.76 Favored 'Trans proline' 0 CA--C 1.544 1.001 0 C-N-CA 123.02 2.48 . . . . 0.0 110.879 172.037 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.401 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 4.9 tmm_? -71.3 120.7 17.25 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.163 0.506 . . . . 0.0 109.838 -178.707 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 76.0 t -128.32 119.55 50.88 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.238 -178.104 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 59.6 t -94.64 141.11 15.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 176.349 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.534 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 1.3 m-85 -91.38 134.78 34.32 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 175.884 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 -115.33 86.16 2.41 Favored 'General case' 0 C--N 1.276 -2.609 0 N-CA-C 106.29 -1.744 . . . . 0.0 106.29 177.616 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' SER . . . . . 0.442 ' HB3' ' CG ' ' A' ' 101' ' ' LYS . 5.0 p -142.34 154.58 44.78 Favored 'General case' 0 N--CA 1.413 -2.286 0 CA-C-N 115.161 -0.927 . . . . 0.0 112.718 -173.034 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 10.3 ptp180 -135.0 19.37 3.46 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 171.121 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.0 t -164.09 -175.4 3.99 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 105.981 -1.859 . . . . 0.0 105.981 -178.592 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -76.77 122.55 24.92 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.88 0.848 . . . . 0.0 110.666 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' LYS . . . . . 0.442 ' CG ' ' HB3' ' A' ' 97' ' ' SER . 30.6 mmtp -109.68 139.51 21.29 Favored Pre-proline 0 C--N 1.293 -1.858 0 CA-C-N 115.032 -0.985 . . . . 0.0 110.002 177.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.637 ' HB3' ' O ' ' A' ' 39' ' ' SER . 52.3 Cg_exo -55.21 144.36 71.0 Favored 'Trans proline' 0 CA--C 1.505 -0.931 0 C-N-CA 123.726 2.951 . . . . 0.0 111.722 176.447 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' TRP . . . . . 0.534 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 9.1 t90 -91.63 103.63 8.27 Favored Pre-proline 0 C--N 1.294 -1.839 0 N-CA-C 106.044 -1.836 . . . . 0.0 106.044 178.821 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -76.58 88.63 1.35 Allowed 'Trans proline' 0 N--CA 1.446 -1.281 0 C-N-CA 121.624 1.549 . . . . 0.0 111.644 -172.206 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.455 HG22 ' CD2' ' A' ' 77' ' ' TYR . 85.0 t -138.77 142.19 35.05 Favored 'Isoleucine or valine' 0 CA--C 1.485 -1.534 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 179.131 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.604 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.97 133.91 18.05 Favored 'General case' 0 N--CA 1.411 -2.404 0 CA-C-O 120.968 0.413 . . . . 0.0 110.681 179.177 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.485 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 20.0 mt -100.96 99.93 10.47 Favored 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 179.099 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.454 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 76.7 m-85 -80.74 78.81 7.48 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 177.523 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.656 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.3 mm? -102.96 118.99 38.04 Favored 'General case' 0 CA--C 1.49 -1.331 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 177.375 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.8 145.83 46.49 Favored Pre-proline 0 N--CA 1.407 -2.577 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.079 -175.146 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.452 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 36.7 Cg_endo -63.1 119.51 6.61 Favored 'Trans proline' 0 C--O 1.248 1.018 0 C-N-CA 123.347 2.698 . . . . 0.0 112.265 -177.331 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.483 HG22 ' O ' ' A' ' 70' ' ' ASN . 3.2 m -67.62 -118.09 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.182 -2.464 0 CA-C-N 114.023 -1.444 . . . . 0.0 112.59 175.72 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.4 m -112.73 -38.08 4.69 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-O 122.334 1.064 . . . . 0.0 108.141 179.388 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 64.4 m -82.11 31.77 0.38 Allowed 'General case' 0 N--CA 1.394 -3.271 0 CA-C-N 113.356 -1.747 . . . . 0.0 113.151 -177.692 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -108.63 139.05 43.96 Favored 'General case' 0 C--N 1.288 -2.078 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -174.83 139.04 4.64 Favored Glycine 0 N--CA 1.44 -1.068 0 C-N-CA 119.951 -1.119 . . . . 0.0 112.193 179.386 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 57.61 -149.7 32.3 Favored Glycine 0 CA--C 1.491 -1.453 0 O-C-N 124.783 0.931 . . . . 0.0 112.542 -178.854 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.431 ' CG2' ' HE3' ' A' ' 121' ' ' LYS . 7.3 p -57.3 101.7 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 CA-C-O 122.507 1.146 . . . . 0.0 111.607 -178.628 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -100.61 -27.06 13.59 Favored 'General case' 0 C--N 1.295 -1.773 0 CA-C-N 114.826 -1.079 . . . . 0.0 110.679 -177.675 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.472 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 58.7 mt -133.26 136.98 54.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 -178.866 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.529 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.4 mmpt? -112.73 142.64 45.12 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 121.028 0.442 . . . . 0.0 110.706 176.35 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.23 132.02 45.83 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.169 179.243 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 91.63 -10.42 74.72 Favored Glycine 0 N--CA 1.435 -1.405 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.584 -179.363 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 40.2 t -86.18 143.11 28.16 Favored 'General case' 0 N--CA 1.43 -1.43 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 -178.074 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.44 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -71.2 122.19 19.73 Favored 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 177.11 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.738 ' HB ' HG21 ' A' ' 67' ' ' VAL . 33.7 pt -109.24 -27.78 2.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-N 116.041 -0.527 . . . . 0.0 112.303 -178.554 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -160.3 166.78 28.86 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -177.461 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.44 HG23 HD11 ' A' ' 125' ' ' LEU . 75.7 t -141.87 113.43 3.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 179.737 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.481 HD11 HD21 ' A' ' 107' ' ' LEU . 67.5 mt -115.33 134.67 54.9 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.212 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.525 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.4 mp -117.69 128.17 74.93 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.818 0 C-N-CA 119.196 -1.002 . . . . 0.0 109.748 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.516 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.2 OUTLIER -101.24 131.08 47.42 Favored 'General case' 0 C--N 1.276 -2.623 0 C-N-CA 123.989 0.916 . . . . 0.0 111.443 -176.481 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 132' ' ' ARG . . . . . 0.494 ' HG2' ' HB2' ' A' ' 59' ' ' GLN . 26.9 mmm180 -87.41 128.09 35.21 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 123.529 0.731 . . . . 0.0 110.826 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -101.36 122.24 43.37 Favored 'General case' 0 N--CA 1.412 -2.356 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 168.05 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.44 ' HB ' ' CE2' ' A' ' 55' ' ' TYR . 23.4 m -140.28 129.49 23.73 Favored 'General case' 0 C--N 1.279 -2.468 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.382 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.547 ' CB ' HG23 ' A' ' 52' ' ' ILE . 28.0 p30 . . . . . 0 C--N 1.281 -2.387 0 CA-C-O 121.221 0.534 . . . . 0.0 110.539 -175.582 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 . . . . . 0 CA--C 1.51 -0.577 0 CA-C-O 121.207 0.527 . . . . 0.0 110.897 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.3 pt20 -137.38 149.82 47.23 Favored 'General case' 0 N--CA 1.418 -2.06 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 177.253 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 10.0 m-30 -111.34 132.46 54.39 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 -176.841 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 50.6 t -92.82 131.69 39.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.024 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 146' ' ' TRP . . . . . 0.516 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.5 m95 -119.55 100.81 7.51 Favored 'General case' 0 C--N 1.277 -2.577 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 46.4 m-80 -80.69 113.86 19.18 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 178.368 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.436 ' HA ' HG22 ' A' ' 20' ' ' VAL . 22.7 mm -87.35 122.51 39.25 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.936 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 -178.587 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -118.16 148.54 42.25 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.617 178.814 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -80.49 129.52 34.57 Favored 'General case' 0 N--CA 1.409 -2.502 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 176.51 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -87.75 -16.51 34.01 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -178.745 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -147.49 144.85 28.87 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 114.103 -1.408 . . . . 0.0 108.795 -174.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 21.7 p-10 -82.96 144.17 30.18 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 124.232 0.957 . . . . 0.0 111.398 -178.119 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.2 t -120.42 138.71 50.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.634 -175.191 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 4.0 t -119.58 137.92 51.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.638 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 71.9 t -102.17 103.34 29.71 Favored Pre-proline 0 C--N 1.29 -1.979 0 C-N-CA 123.479 0.711 . . . . 0.0 109.847 178.634 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.523 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 56.1 Cg_endo -71.68 -16.95 29.95 Favored 'Trans proline' 0 C--O 1.226 -0.093 0 C-N-CA 122.187 1.925 . . . . 0.0 111.781 178.039 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 158' ' ' THR . . . . . 0.433 ' HA ' ' H ' ' A' ' 30' ' ' VAL 0.254 3.9 t . . . . . 0 C--N 1.351 0.666 0 C-N-CA 125.082 1.353 . . . . 0.0 113.84 175.411 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.514 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 CA--C 1.485 -1.554 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.601 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 12.5 m -128.65 159.2 36.35 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 109.03 -0.729 . . . . 0.0 109.03 -176.54 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.491 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -147.56 159.57 43.6 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 120.858 0.361 . . . . 0.0 110.421 -173.961 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 71.8 p -97.31 177.26 5.61 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 121.523 0.678 . . . . 0.0 110.553 -178.96 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -83.03 -17.95 41.48 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 114.869 -1.06 . . . . 0.0 109.655 179.06 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -92.26 -17.71 24.41 Favored 'General case' 0 N--CA 1.43 -1.446 0 CA-C-N 114.739 -1.119 . . . . 0.0 111.795 -177.65 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.05 29.22 2.43 Favored Glycine 0 CA--C 1.484 -1.885 0 C-N-CA 119.925 -1.131 . . . . 0.0 113.971 166.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.9 m -107.64 99.51 8.99 Favored 'General case' 0 N--CA 1.415 -2.216 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.054 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.07 116.36 28.74 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.584 177.513 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.514 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 64.0 mt -84.73 122.77 74.69 Favored Pre-proline 0 C--N 1.301 -1.528 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.712 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -75.33 170.95 19.22 Favored 'Trans proline' 0 C--O 1.246 0.886 0 C-N-CA 122.933 2.422 . . . . 0.0 111.995 -179.12 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 34.4 mt -73.37 118.82 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.126 0.488 . . . . 0.0 111.002 -176.491 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 133.9 38.4 0.21 Allowed Glycine 0 C--N 1.301 -1.386 0 CA-C-N 115.238 -0.892 . . . . 0.0 111.334 177.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 72.02 176.3 26.71 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.542 -176.415 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.14 -177.94 28.83 Favored Glycine 0 C--N 1.296 -1.672 0 C-N-CA 120.103 -1.046 . . . . 0.0 111.219 176.624 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.459 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 52.5 p -141.03 150.31 42.84 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -139.29 165.03 28.27 Favored 'General case' 0 CA--C 1.474 -1.968 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.737 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -109.39 123.44 49.33 Favored 'General case' 0 C--N 1.262 -3.229 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 175.112 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.474 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.2 m -105.31 145.09 13.98 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.608 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.336 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -124.75 112.74 17.07 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-O 121.286 0.565 . . . . 0.0 110.764 -178.401 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.533 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -119.36 132.31 69.53 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.194 0 CA-C-N 115.126 -0.943 . . . . 0.0 111.627 -174.783 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -92.31 127.16 37.69 Favored 'General case' 0 C--N 1.288 -2.075 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.08 178.284 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -110.51 160.53 16.55 Favored 'General case' 0 C--N 1.288 -2.073 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.145 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -61.0 122.91 72.76 Favored Pre-proline 0 C--N 1.317 -0.808 0 O-C-N 124.107 0.879 . . . . 0.0 109.125 176.653 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.502 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 74.3 Cg_endo -74.65 4.31 4.67 Favored 'Trans proline' 0 C--O 1.237 0.462 0 C-N-CA 122.785 2.323 . . . . 0.0 113.088 -177.468 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.6 t -128.08 112.29 26.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 107.097 -1.445 . . . . 0.0 107.097 178.555 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.426 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.8 t -145.43 101.31 0.56 Allowed 'Isoleucine or valine' 0 C--O 1.181 -2.549 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 -178.219 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.444 ' H ' ' HG3' ' A' ' 32' ' ' GLN . 0.7 OUTLIER -92.38 150.55 20.75 Favored 'General case' 0 C--N 1.267 -2.987 0 O-C-N 122.16 -0.338 . . . . 0.0 111.214 179.416 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.437 HG22 ' O ' ' A' ' 112' ' ' VAL . 46.8 t -44.72 119.14 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 123.63 0.772 . . . . 0.0 111.363 175.986 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.12 2.5 54.61 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.482 -0.781 . . . . 0.0 112.743 -179.264 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.444 ' HG3' ' H ' ' A' ' 29' ' ' ASN . 1.7 mm-40 -73.83 -178.07 3.07 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 123.076 0.55 . . . . 0.0 111.448 175.331 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -132.91 91.48 2.9 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 176.46 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.664 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.7 tp -92.26 146.44 23.71 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -179.177 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 48.5 t -133.2 129.92 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.838 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 -178.183 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.56 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 51.6 t -99.93 88.82 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.41 -2.446 0 N-CA-C 105.642 -1.984 . . . . 0.0 105.642 172.499 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -85.25 117.49 24.22 Favored 'General case' 0 CA--C 1.484 -1.561 0 C-N-CA 119.949 -0.7 . . . . 0.0 110.382 -176.91 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 82.4 mt -98.88 -1.84 39.15 Favored 'General case' 0 C--N 1.296 -1.744 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.365 -177.862 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.491 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 1.3 m -75.64 0.31 18.01 Favored 'General case' 0 CA--C 1.549 0.93 0 CA-C-O 122.394 1.093 . . . . 0.0 108.959 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.0 p -127.33 6.53 6.38 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 114.718 -1.128 . . . . 0.0 110.229 177.164 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.533 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 46.6 mm-40 -125.28 -22.46 4.36 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-O 121.082 0.467 . . . . 0.0 110.649 -175.161 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 36.6 mt -135.07 141.29 43.31 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 108.188 -1.042 . . . . 0.0 108.188 -175.805 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.491 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 41.4 m-85 -142.79 158.74 43.33 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 -177.5 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.601 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 17.0 t -138.66 147.25 42.62 Favored 'General case' 0 C--N 1.289 -2.029 0 C-N-CA 120.377 -0.529 . . . . 0.0 109.67 175.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' HIS . . . . . 0.492 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 7.3 p-80 -119.96 130.05 54.59 Favored 'General case' 0 C--O 1.256 1.408 0 CA-C-O 122.323 1.059 . . . . 0.0 111.472 -178.435 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.407 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 22.3 p-10 -91.24 89.84 7.5 Favored 'General case' 0 C--N 1.278 -2.511 0 CA-C-O 122.968 1.366 . . . . 0.0 109.913 178.044 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -71.18 -24.79 62.31 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 113.875 -1.511 . . . . 0.0 111.377 -177.223 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 43.3 m-85 -126.06 79.37 69.44 Favored Pre-proline 0 N--CA 1.479 0.979 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 178.007 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.407 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 73.4 Cg_endo -85.56 -2.8 9.2 Favored 'Trans proline' 0 C--N 1.321 -0.892 0 C-N-CA 122.0 1.8 . . . . 0.0 113.528 -175.098 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -111.76 -23.76 10.42 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.068 -179.392 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.427 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.0 OUTLIER -99.42 -30.63 12.08 Favored 'General case' 0 C--N 1.292 -1.898 0 CA-C-O 121.837 0.827 . . . . 0.0 109.987 -175.329 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.601 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.5 mp -118.6 138.66 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.616 0 CA-C-N 114.898 -1.046 . . . . 0.0 108.308 -179.456 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.7 t -78.75 134.05 37.07 Favored 'General case' 0 N--CA 1.417 -2.1 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 174.344 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.495 ' O ' HG23 ' A' ' 94' ' ' VAL . 7.6 m-20 -80.14 107.17 12.71 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 -172.333 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 49.9 t80 -142.85 133.44 25.09 Favored 'General case' 0 C--N 1.284 -2.271 0 CA-C-N 116.331 -0.395 . . . . 0.0 109.999 -172.254 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.453 HG12 ' OH ' ' A' ' 77' ' ' TYR . 42.3 t -141.73 134.14 28.41 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 C-N-CA 123.374 0.67 . . . . 0.0 109.635 -178.449 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -143.81 115.48 8.17 Favored 'General case' 0 N--CA 1.434 -1.226 0 O-C-N 123.387 0.43 . . . . 0.0 111.335 177.555 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.537 HD12 ' O ' ' A' ' 130' ' ' ILE . 55.5 tp -54.57 110.78 0.68 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.584 0.706 . . . . 0.0 110.169 171.085 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.43 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 10.9 tp60 -58.85 -51.79 68.49 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 126.292 1.837 . . . . 0.0 111.828 179.24 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.43 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 6.9 ptp180 -169.73 157.35 6.89 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -176.275 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -137.38 136.56 8.33 Favored Glycine 0 N--CA 1.415 -2.756 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 -179.462 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 70.3 m -126.71 146.22 50.3 Favored 'General case' 0 C--N 1.283 -2.324 0 C-N-CA 123.093 0.557 . . . . 0.0 110.69 -175.275 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.503 ' HB2' ' CE2' ' A' ' 84' ' ' PHE . . . -109.96 156.79 20.0 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 -179.189 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.483 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 90.8 m-85 -155.9 -179.47 8.16 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 123.963 0.905 . . . . 0.0 109.075 -178.192 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.01 -139.22 48.98 Favored Glycine 0 N--CA 1.45 -0.396 0 O-C-N 123.621 0.576 . . . . 0.0 113.328 177.234 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.6 -9.05 87.37 Favored Glycine 0 C--O 1.201 -1.922 0 C-N-CA 120.329 -0.938 . . . . 0.0 111.379 178.166 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.74 HG21 ' HB ' ' A' ' 126' ' ' ILE . 87.5 t -70.81 -42.7 77.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 C-N-CA 123.137 0.575 . . . . 0.0 111.44 -176.583 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.499 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -83.4 -21.61 32.97 Favored 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.4 -0.92 . . . . 0.0 112.518 -179.649 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 21.0 m -101.05 -47.8 4.64 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 114.041 1.126 . . . . 0.0 114.041 -174.617 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 47.5 m-20 -96.71 -20.63 18.11 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 -175.039 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.664 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 92.0 m-85 -110.78 157.09 20.18 Favored 'General case' 0 N--CA 1.424 -1.75 0 C-N-CA 120.032 -0.667 . . . . 0.0 110.418 178.053 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.8 t -160.95 123.09 3.09 Favored 'General case' 0 N--CA 1.422 -1.853 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 177.097 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.527 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -158.48 -106.97 0.23 Allowed Glycine 0 N--CA 1.412 -2.93 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 177.456 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -165.2 -179.4 5.6 Favored 'General case' 0 C--N 1.313 -0.998 0 C-N-CA 124.525 1.13 . . . . 0.0 110.358 -175.389 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.6 p -131.93 148.3 32.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 C-N-CA 123.626 0.77 . . . . 0.0 109.301 177.363 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.614 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.3 tttt -126.12 143.27 51.19 Favored 'General case' 0 N--CA 1.426 -1.638 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.497 ' CD1' HG22 ' A' ' 105' ' ' VAL . 67.5 t80 -144.31 110.12 5.32 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.258 -177.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 25.3 t 51.24 40.71 26.74 Favored 'General case' 0 CA--C 1.551 0.983 0 C-N-CA 123.584 0.754 . . . . 0.0 111.526 177.576 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.83 14.01 61.7 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.333 -0.937 . . . . 0.0 113.811 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.614 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 13.0 t -86.48 -178.9 6.53 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 175.772 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 26.1 p -159.48 103.78 1.6 Allowed 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.513 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.433 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.9 p90 -149.53 160.13 34.93 Favored Pre-proline 0 C--N 1.303 -1.428 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 -173.057 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.431 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 42.5 Cg_endo -67.25 146.92 77.46 Favored 'Trans proline' 0 C--N 1.358 1.053 0 C-N-CA 122.837 2.358 . . . . 0.0 112.887 -177.071 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.569 ' CD2' HD21 ' A' ' 109' ' ' LEU . 64.2 t80 -122.63 134.59 25.03 Favored Pre-proline 0 N--CA 1.435 -1.223 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.432 -179.769 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.517 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 64.3 Cg_endo -71.08 147.06 86.51 Favored 'Cis proline' 0 CA--C 1.54 0.786 0 C-N-CA 123.229 -1.571 . . . . 0.0 110.602 -2.497 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.8 t -64.68 -176.8 0.27 Allowed 'General case' 0 C--O 1.248 0.981 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.685 -175.403 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 16.8 p -130.31 0.73 4.6 Favored 'General case' 0 N--CA 1.424 -1.761 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.014 -171.133 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 26.5 t -161.36 -137.51 0.04 OUTLIER 'General case' 0 N--CA 1.379 -3.993 0 N-CA-C 106.56 -1.645 . . . . 0.0 106.56 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -121.39 156.58 32.36 Favored 'General case' 0 C--N 1.267 -2.991 0 C-N-CA 127.015 2.126 . . . . 0.0 107.337 -172.309 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.475 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 19.6 p -78.6 162.37 65.94 Favored Pre-proline 0 C--N 1.302 -1.483 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 -177.396 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.99 165.49 5.0 Favored 'Trans proline' 0 C--N 1.359 1.104 0 C-N-CA 124.044 3.163 . . . . 0.0 112.148 174.96 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.6 tmm_? -70.3 119.7 14.87 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 114.759 -1.11 . . . . 0.0 109.657 -176.083 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 60.4 t -131.27 130.35 63.13 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 C-N-CA 123.671 0.788 . . . . 0.0 110.211 -175.531 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.495 HG23 ' O ' ' A' ' 54' ' ' ASP . 1.4 p -129.74 125.45 61.03 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.953 0 CA-C-N 115.009 -0.996 . . . . 0.0 110.341 -174.884 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -73.15 104.08 4.1 Favored 'General case' 0 C--O 1.211 -0.938 0 CA-C-O 121.105 0.478 . . . . 0.0 111.092 -178.519 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -90.11 62.55 5.56 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-O 121.016 0.436 . . . . 0.0 109.836 179.197 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.0 t -152.59 -170.07 3.53 Favored 'General case' 0 N--CA 1.437 -1.092 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 -178.288 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 17.0 ptm180 -149.1 38.34 0.8 Allowed 'General case' 0 C--N 1.316 -0.875 0 CA-C-O 121.014 0.435 . . . . 0.0 110.437 -176.833 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 12.6 t -159.51 -177.8 6.67 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -178.007 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' ASP . . . . . 0.492 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 9.6 p-10 -79.45 99.92 7.44 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-O 122.41 1.1 . . . . 0.0 109.653 -179.231 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' LYS . . . . . 0.533 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 7.0 mmpt? -102.37 149.73 36.93 Favored Pre-proline 0 C--N 1.296 -1.749 0 CA-C-N 114.535 -1.212 . . . . 0.0 109.755 -177.836 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.491 ' HB3' ' O ' ' A' ' 39' ' ' SER . 22.5 Cg_exo -59.16 153.35 53.12 Favored 'Trans proline' 0 N--CA 1.449 -1.133 0 C-N-CA 123.36 2.707 . . . . 0.0 112.907 178.089 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 12.6 t90 -95.75 102.15 9.65 Favored Pre-proline 0 C--N 1.289 -2.053 0 N-CA-C 105.688 -1.967 . . . . 0.0 105.688 176.357 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' PRO . . . . . 0.401 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 56.5 Cg_endo -73.93 88.96 1.04 Allowed 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 122.079 1.852 . . . . 0.0 112.956 -172.267 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.497 HG22 ' CD1' ' A' ' 77' ' ' TYR . 59.9 t -138.75 146.45 26.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.91 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.56 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.57 135.67 16.63 Favored 'General case' 0 C--N 1.287 -2.144 0 CA-C-O 120.89 0.376 . . . . 0.0 110.414 178.033 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.5 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 15.6 mt -101.25 103.12 14.12 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.447 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.527 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 45.5 m-85 -82.2 73.23 9.25 Favored 'General case' 0 C--N 1.293 -1.863 0 O-C-N 122.279 -0.263 . . . . 0.0 110.824 178.369 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.664 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -98.5 136.03 39.2 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 176.867 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -137.5 144.73 46.26 Favored Pre-proline 0 C--N 1.293 -1.883 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.098 -175.199 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -62.38 122.31 10.67 Favored 'Trans proline' 0 C--O 1.248 0.99 0 C-N-CA 123.537 2.825 . . . . 0.0 113.12 -176.14 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.437 ' O ' HG22 ' A' ' 30' ' ' VAL . 2.7 m -73.85 -120.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.168 -3.201 0 CA-C-N 114.507 -1.224 . . . . 0.0 112.344 174.806 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 27.9 t -111.94 -32.37 6.62 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 -179.116 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 68.3 m -79.97 21.6 0.55 Allowed 'General case' 0 N--CA 1.398 -3.07 0 C-N-CA 125.612 1.565 . . . . 0.0 112.777 -179.532 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -107.5 128.16 54.25 Favored 'General case' 0 N--CA 1.412 -2.326 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 -179.218 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.63 133.09 2.71 Favored Glycine 0 C--N 1.297 -1.605 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 -179.24 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 62.47 -148.55 49.02 Favored Glycine 0 CA--C 1.489 -1.567 0 CA-C-O 119.24 -0.755 . . . . 0.0 111.782 -177.573 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 60.7 t -56.93 105.72 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 117.225 0.513 . . . . 0.0 110.536 -178.283 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -102.97 -40.93 6.3 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.58 179.481 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.521 ' HB ' HG22 ' A' ' 154' ' ' VAL . 72.7 mt -115.29 137.66 48.11 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 178.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.501 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.9 mmpt? -115.07 136.63 52.92 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-O 121.289 0.566 . . . . 0.0 111.636 178.885 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.15 126.87 30.91 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.828 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 92.95 -5.13 75.83 Favored Glycine 0 N--CA 1.437 -1.298 0 CA-C-N 115.694 -0.684 . . . . 0.0 111.756 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 21.2 m -94.91 145.17 25.1 Favored 'General case' 0 N--CA 1.428 -1.544 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 179.802 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.454 HD11 HG23 ' A' ' 128' ' ' VAL . 2.9 tm? -71.35 124.74 25.25 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 108.204 -1.035 . . . . 0.0 108.204 178.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.74 ' HB ' HG21 ' A' ' 67' ' ' VAL . 31.8 pt -111.09 -25.36 3.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 112.322 0.49 . . . . 0.0 112.322 -179.002 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' ALA . . . . . 0.448 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -162.05 167.51 24.24 Favored 'General case' 0 CA--C 1.508 -0.653 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 -178.022 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.454 HG23 HD11 ' A' ' 125' ' ' LEU . 63.8 t -142.3 116.02 4.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 178.878 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.49 HD11 HD21 ' A' ' 107' ' ' LEU . 67.9 mt -119.02 146.99 44.59 Favored 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.613 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.537 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.4 mp -127.73 126.38 66.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 C-N-CA 119.271 -0.972 . . . . 0.0 110.832 177.519 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.55 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.3 OUTLIER -88.1 145.5 25.91 Favored 'General case' 0 C--N 1.283 -2.313 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 176.332 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 132' ' ' ARG . . . . . 0.44 HH11 ' HD2' ' A' ' 132' ' ' ARG . 16.2 ttp180 -128.58 130.08 46.86 Favored 'General case' 0 C--N 1.277 -2.549 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 173.023 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 8.6 tm0? -108.71 129.04 55.36 Favored 'General case' 0 N--CA 1.412 -2.347 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 -178.728 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 6.9 m -135.75 139.75 43.82 Favored 'General case' 0 C--N 1.287 -2.116 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.601 ' CB ' HG23 ' A' ' 52' ' ' ILE . 9.4 p30 . . . . . 0 N--CA 1.433 -1.278 0 C-N-CA 117.309 -1.756 . . . . 0.0 113.449 177.927 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 . . . . . 0 CA--C 1.501 -0.933 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 7.1 pt20 -123.54 134.73 53.81 Favored 'General case' 0 N--CA 1.423 -1.806 0 C-N-CA 119.838 -0.745 . . . . 0.0 111.102 177.512 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 6.9 m-30 -107.57 125.66 51.58 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 -176.602 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.459 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 46.9 t -89.51 135.28 26.46 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 CA-C-O 121.161 0.505 . . . . 0.0 110.284 -178.473 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 146' ' ' TRP . . . . . 0.55 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 64.8 m95 -122.12 102.53 8.2 Favored 'General case' 0 C--N 1.281 -2.377 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.692 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.8 m-80 -81.65 109.22 15.87 Favored 'General case' 0 C--N 1.289 -2.025 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 178.04 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.474 ' HA ' HG22 ' A' ' 20' ' ' VAL . 21.3 mm -82.47 119.92 32.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 -177.191 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 -116.77 151.6 36.12 Favored 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 123.169 0.588 . . . . 0.0 109.678 178.469 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.14 128.92 34.28 Favored 'General case' 0 N--CA 1.411 -2.399 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 177.119 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -91.38 -11.36 38.03 Favored 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 107.435 -1.32 . . . . 0.0 107.435 -177.563 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -153.22 143.01 22.03 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 114.292 -1.322 . . . . 0.0 109.379 -177.053 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -84.26 145.68 28.18 Favored 'General case' 0 C--N 1.316 -0.85 0 O-C-N 123.971 0.795 . . . . 0.0 109.553 -179.02 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.521 HG22 ' HB ' ' A' ' 120' ' ' ILE . 1.6 m -124.44 147.48 28.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.855 -178.248 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.7 t -120.14 139.93 45.85 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.538 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 -179.626 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.426 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 70.5 t -100.93 100.3 12.52 Favored Pre-proline 0 C--N 1.29 -1.983 0 C-N-CA 123.666 0.786 . . . . 0.0 109.402 177.336 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.422 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 29.7 Cg_endo -68.18 -23.95 38.76 Favored 'Trans proline' 0 CA--C 1.517 -0.365 0 C-N-CA 122.427 2.085 . . . . 0.0 111.649 178.038 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 158' ' ' THR . . . . . 0.405 ' HB ' HG12 ' A' ' 156' ' ' VAL 0.269 5.3 t . . . . . 0 C--O 1.249 1.058 0 O-C-N 125.0 1.437 . . . . 0.0 113.383 177.845 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.439 -0.984 0 CA-C-O 120.857 0.36 . . . . 0.0 111.49 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.42 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 77.0 m -137.4 152.18 49.36 Favored 'General case' 0 N--CA 1.429 -1.496 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.958 -177.414 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -141.17 167.13 22.91 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.763 -178.093 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.523 HG22 HG22 ' A' ' 20' ' ' VAL . 82.5 p -103.67 171.88 7.12 Favored 'General case' 0 CA--C 1.497 -1.066 0 CA-C-O 121.483 0.658 . . . . 0.0 110.733 -179.276 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.96 -4.82 54.09 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-N 114.034 -1.439 . . . . 0.0 111.755 178.325 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -96.88 -30.92 12.85 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 118.184 -1.407 . . . . 0.0 109.314 177.829 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 139.13 0.46 2.16 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 119.896 -1.145 . . . . 0.0 113.047 175.388 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -81.07 105.25 12.14 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -100.85 119.45 38.68 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 176.852 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 60.3 mt -90.76 123.83 63.91 Favored Pre-proline 0 C--N 1.3 -1.567 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -80.66 168.75 17.53 Favored 'Trans proline' 0 C--O 1.248 0.98 0 C-N-CA 122.7 2.267 . . . . 0.0 111.173 178.049 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.1 mt -63.75 127.56 24.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 133.77 8.72 2.12 Favored Glycine 0 C--N 1.319 -0.373 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.612 -179.562 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 86.69 172.69 48.61 Favored Glycine 0 C--N 1.318 -0.425 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.415 -177.542 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.45 -168.78 30.97 Favored Glycine 0 C--N 1.299 -1.526 0 C-N-CA 119.916 -1.135 . . . . 0.0 111.498 177.1 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 14.4 p -140.1 155.81 46.84 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.401 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -143.63 162.24 36.43 Favored 'General case' 0 N--CA 1.424 -1.736 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 177.308 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -107.83 116.18 31.48 Favored 'General case' 0 C--N 1.281 -2.388 0 CA-C-N 114.808 -1.087 . . . . 0.0 108.746 177.57 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.523 HG22 HG22 ' A' ' 5' ' ' THR . 44.1 t -103.86 135.03 43.44 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.008 0 CA-C-N 115.133 -0.94 . . . . 0.0 108.668 179.202 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 -122.99 134.78 54.31 Favored 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -179.113 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.51 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.5 p -144.42 136.29 21.87 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.674 0 O-C-N 123.727 0.642 . . . . 0.0 111.095 -178.722 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 47.9 m-80 -89.67 126.79 35.78 Favored 'General case' 0 C--N 1.296 -1.76 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.458 178.442 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.408 HD11 HG22 ' A' ' 36' ' ' VAL . 2.7 mm? -106.56 161.19 14.83 Favored 'General case' 0 C--N 1.283 -2.298 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 177.631 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.8 124.81 81.19 Favored Pre-proline 0 C--N 1.315 -0.933 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 175.789 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.466 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 68.1 Cg_endo -74.83 0.84 8.33 Favored 'Trans proline' 0 N--CA 1.474 0.382 0 C-N-CA 122.954 2.436 . . . . 0.0 113.021 -177.253 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.476 HG13 ' HG3' ' A' ' 157' ' ' PRO . 87.3 t -129.6 111.85 23.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.7 t -143.33 114.94 2.73 Favored 'Isoleucine or valine' 0 C--O 1.182 -2.489 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -177.219 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.725 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -104.98 148.68 26.46 Favored 'General case' 0 C--N 1.271 -2.819 0 O-C-N 121.987 -0.445 . . . . 0.0 110.91 -179.447 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.499 HG22 ' O ' ' A' ' 112' ' ' VAL . 95.8 t -47.97 116.93 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 123.082 0.553 . . . . 0.0 111.377 178.702 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 109.41 -9.25 32.96 Favored Glycine 0 C--N 1.307 -1.033 0 CA-C-N 115.238 -0.892 . . . . 0.0 112.357 -178.602 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.725 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -67.87 -177.62 0.84 Allowed 'General case' 0 CA--C 1.508 -0.672 0 C-N-CA 124.631 1.172 . . . . 0.0 110.956 179.63 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 63.8 t30 -129.89 92.12 3.26 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 178.231 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.641 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.8 tp -94.25 142.52 27.31 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 119.056 -1.057 . . . . 0.0 109.301 179.226 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 39.6 t -132.34 124.78 52.72 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.215 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 -175.904 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.552 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 47.3 t -96.19 87.82 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.4 -2.931 0 N-CA-C 105.26 -2.126 . . . . 0.0 105.26 172.107 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -82.5 112.55 19.53 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 120.962 0.411 . . . . 0.0 110.984 -177.757 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 84.6 mt -98.21 0.31 45.56 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.017 -178.725 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.4 m -76.35 1.67 15.59 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-O 122.332 1.063 . . . . 0.0 109.045 -179.576 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.8 p -130.64 5.58 4.69 Favored 'General case' 0 N--CA 1.428 -1.562 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.15 176.844 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.51 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 49.7 mm-40 -124.38 -22.12 4.77 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 121.193 0.521 . . . . 0.0 111.019 -174.684 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.2 mt -131.56 140.83 47.31 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 -176.231 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.451 ' HA ' ' HA ' ' A' ' 102' ' ' PRO . 69.0 m-85 -139.25 154.93 48.06 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -174.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.42 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 96.2 m -137.69 136.52 37.48 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 123.751 0.82 . . . . 0.0 110.787 -179.646 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.4 p-80 -131.92 129.67 40.58 Favored 'General case' 0 C--N 1.295 -1.761 0 CA-C-O 122.381 1.086 . . . . 0.0 112.123 -177.581 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.735 ' OD1' ' HA ' ' A' ' 49' ' ' PRO . 3.3 t-20 -85.23 92.07 8.32 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-N 114.446 -1.252 . . . . 0.0 107.928 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 20.1 m-20 -54.48 -36.6 64.33 Favored 'General case' 0 N--CA 1.493 1.684 0 C-N-CA 123.475 0.71 . . . . 0.0 111.069 -178.255 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 44.7 m-85 -122.46 86.0 48.35 Favored Pre-proline 0 C--N 1.299 -1.599 0 N-CA-C 108.223 -1.028 . . . . 0.0 108.223 -175.963 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.735 ' HA ' ' OD1' ' A' ' 46' ' ' ASN . 72.7 Cg_endo -73.19 -5.98 18.12 Favored 'Trans proline' 0 CA--C 1.508 -0.81 0 C-N-CA 122.486 2.124 . . . . 0.0 115.081 -170.128 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -121.3 -20.35 6.72 Favored 'General case' 0 C--N 1.282 -2.342 0 CA-C-O 121.268 0.556 . . . . 0.0 110.649 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.56 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.6 m -98.4 -30.7 12.41 Favored 'General case' 0 N--CA 1.414 -2.231 0 C-N-CA 119.54 -0.864 . . . . 0.0 109.102 -170.785 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.567 HG23 ' HB2' ' A' ' 135' ' ' ASN . 2.7 mp -130.03 123.72 56.89 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 CA-C-N 114.878 -1.055 . . . . 0.0 110.035 -175.938 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 4.4 t -75.71 134.67 40.46 Favored 'General case' 0 N--CA 1.425 -1.684 0 N-CA-C 106.08 -1.822 . . . . 0.0 106.08 173.597 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.57 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 9.5 t70 -90.31 108.88 20.04 Favored 'General case' 0 C--N 1.271 -2.806 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 -178.431 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.585 ' CD2' ' HB ' ' A' ' 134' ' ' THR . 4.7 t80 -128.47 110.06 11.96 Favored 'General case' 0 C--N 1.291 -1.938 0 CA-C-O 122.109 0.957 . . . . 0.0 110.93 -175.22 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.433 ' HA ' ' O ' ' A' ' 132' ' ' ARG . 73.9 t -114.7 142.17 28.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 CA-C-N 113.629 -1.623 . . . . 0.0 110.94 -177.749 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.3 p -143.67 134.18 24.84 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 170.061 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.542 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.8 OUTLIER -73.51 109.97 7.44 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 175.771 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 10.2 tp60 -57.58 -62.2 1.96 Allowed 'General case' 0 C--O 1.202 -1.428 0 C-N-CA 125.416 1.486 . . . . 0.0 109.958 -178.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.91 146.11 14.26 Favored 'General case' 0 N--CA 1.418 -2.072 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 -178.216 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -126.68 137.66 10.15 Favored Glycine 0 N--CA 1.398 -3.852 0 N-CA-C 108.193 -1.963 . . . . 0.0 108.193 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 63.4 m -124.0 148.29 47.1 Favored 'General case' 0 C--N 1.268 -2.949 0 C-N-CA 123.599 0.76 . . . . 0.0 109.33 -175.057 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.519 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -114.27 158.1 21.85 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 -179.593 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.432 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 85.0 m-85 -156.35 -178.42 7.32 Favored 'General case' 0 C--O 1.243 0.719 0 C-N-CA 124.214 1.005 . . . . 0.0 108.347 -178.111 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.79 -138.14 49.7 Favored Glycine 0 N--CA 1.452 -0.299 0 O-C-N 123.596 0.56 . . . . 0.0 112.81 178.562 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.91 -9.41 85.42 Favored Glycine 0 C--O 1.205 -1.706 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.651 177.713 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.747 HG21 ' HB ' ' A' ' 126' ' ' ILE . 84.5 t -68.53 -42.92 83.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 C-N-CA 122.934 0.493 . . . . 0.0 111.362 -177.508 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.519 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -82.45 -17.65 44.56 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.331 -0.948 . . . . 0.0 112.133 179.603 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 14.6 t -100.74 -59.64 1.66 Allowed 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.971 -172.631 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.456 ' O ' HG22 ' A' ' 112' ' ' VAL . 44.2 m-20 -91.1 -23.51 20.28 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.672 -172.323 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.669 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 93.1 m-85 -106.7 155.62 19.49 Favored 'General case' 0 N--CA 1.42 -1.959 0 C-N-CA 119.647 -0.821 . . . . 0.0 109.532 177.077 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.5 t -163.18 126.99 2.85 Favored 'General case' 0 N--CA 1.41 -2.464 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.419 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.416 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -163.07 -109.59 0.23 Allowed Glycine 0 N--CA 1.407 -3.287 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 177.294 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -159.99 178.69 9.46 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 123.348 0.659 . . . . 0.0 110.273 -173.739 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -131.77 142.85 42.01 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 178.171 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.708 ' HG3' ' O ' ' A' ' 80' ' ' SER . 71.7 tttt -118.76 139.12 52.08 Favored 'General case' 0 N--CA 1.423 -1.814 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.793 -179.573 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.494 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 67.5 t80 -138.96 110.05 6.83 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.071 -178.913 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.6 t 49.68 41.92 22.61 Favored 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 124.133 0.973 . . . . 0.0 111.937 174.833 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.43 11.03 63.04 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 120.519 -0.848 . . . . 0.0 113.746 179.265 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.708 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 10.1 t -93.56 177.84 5.89 Favored 'General case' 0 C--O 1.206 -1.219 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 176.694 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 74.9 m -160.02 105.52 1.56 Allowed 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 177.813 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.494 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 5.8 p90 -142.64 164.53 32.1 Favored Pre-proline 0 C--N 1.297 -1.688 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 -172.46 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.474 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 73.9 Cg_endo -71.95 148.26 51.03 Favored 'Trans proline' 0 C--N 1.352 0.731 0 C-N-CA 122.376 2.051 . . . . 0.0 113.402 -174.436 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.627 ' CD2' HD21 ' A' ' 109' ' ' LEU . 55.3 t80 -120.7 139.7 29.39 Favored Pre-proline 0 N--CA 1.429 -1.499 0 CA-C-N 115.608 -0.723 . . . . 0.0 109.267 179.398 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.606 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 55.8 Cg_endo -70.12 144.54 77.7 Favored 'Cis proline' 0 CA--C 1.537 0.653 0 C-N-CA 123.115 -1.619 . . . . 0.0 110.541 -4.848 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 5.6 t -67.44 -179.59 1.08 Allowed 'General case' 0 CA--C 1.556 1.182 0 CA-C-O 121.081 0.467 . . . . 0.0 111.236 -175.844 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 22.1 p -131.11 -24.63 2.32 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -168.439 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 24.8 t -129.84 -68.5 0.71 Allowed 'General case' 0 C--N 1.31 -1.117 0 C-N-CA 119.854 -0.738 . . . . 0.0 110.83 -173.36 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 178.77 -177.01 0.25 Allowed 'General case' 0 C--O 1.243 0.747 0 C-N-CA 124.454 1.102 . . . . 0.0 108.44 175.631 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.542 HG23 ' HB3' ' A' ' 58' ' ' LEU . 48.9 p -100.15 166.9 11.85 Favored Pre-proline 0 C--N 1.302 -1.477 0 O-C-N 123.582 0.551 . . . . 0.0 110.978 177.324 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -57.89 160.21 15.82 Favored 'Trans proline' 0 C--O 1.248 1.012 0 C-N-CA 123.027 2.484 . . . . 0.0 110.941 171.713 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.538 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 0.8 OUTLIER -72.32 120.51 18.03 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.368 -177.26 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 57.5 t -129.42 119.01 47.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.893 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 97.6 t -105.64 132.5 52.44 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 CA-C-N 115.12 -0.945 . . . . 0.0 108.868 177.04 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.57 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 11.8 m-85 -81.6 112.07 18.48 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 175.746 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -103.69 75.73 1.33 Allowed 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 -179.493 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 70.7 m -161.08 170.05 21.23 Favored 'General case' 0 C--N 1.318 -0.801 0 C-N-CA 124.303 1.041 . . . . 0.0 109.435 -177.907 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.0 ptm180 -128.06 38.78 3.96 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-O 121.946 0.879 . . . . 0.0 110.07 178.013 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.8 t -156.72 167.73 29.56 Favored 'General case' 0 N--CA 1.426 -1.648 0 N-CA-C 107.272 -1.381 . . . . 0.0 107.272 -177.134 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -73.69 123.58 24.34 Favored 'General case' 0 C--N 1.311 -1.1 0 O-C-N 123.784 0.677 . . . . 0.0 110.579 -178.594 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.5 mptm? -120.07 144.23 37.22 Favored Pre-proline 0 C--N 1.28 -2.428 0 CA-C-N 114.642 -1.163 . . . . 0.0 108.558 179.527 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.451 ' HA ' ' HA ' ' A' ' 43' ' ' PHE . 43.3 Cg_endo -65.9 150.13 85.91 Favored 'Trans proline' 0 C--O 1.248 1.009 0 C-N-CA 122.242 1.961 . . . . 0.0 111.456 177.343 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 16.4 t90 -87.16 105.26 7.82 Favored Pre-proline 0 C--N 1.315 -0.912 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 -179.576 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 64.4 Cg_endo -74.69 88.53 1.19 Allowed 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 121.544 1.496 . . . . 0.0 112.58 -173.241 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 97.4 t -138.44 142.88 33.93 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.309 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.106 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.552 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.94 132.5 16.75 Favored 'General case' 0 N--CA 1.41 -2.428 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.109 178.51 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.512 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 19.5 mt -97.05 102.37 14.13 Favored 'General case' 0 C--N 1.287 -2.123 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.639 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.416 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 63.0 m-85 -83.11 74.39 9.99 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-O 121.105 0.479 . . . . 0.0 110.231 177.45 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.669 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 2.8 mm? -97.93 130.35 44.81 Favored 'General case' 0 CA--C 1.484 -1.582 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 175.94 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -135.05 144.09 48.73 Favored Pre-proline 0 N--CA 1.397 -3.077 0 N-CA-C 108.947 -0.761 . . . . 0.0 108.947 -174.452 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -63.13 126.72 18.49 Favored 'Trans proline' 0 CA--C 1.496 -1.401 0 C-N-CA 123.2 2.6 . . . . 0.0 113.993 -174.395 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.499 ' O ' HG22 ' A' ' 30' ' ' VAL . 16.1 m -91.65 -158.03 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.395 -3.206 0 CA-C-N 114.221 -1.354 . . . . 0.0 108.66 171.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 29.4 m -76.0 -32.01 59.21 Favored 'General case' 0 C--N 1.26 -3.322 0 CA-C-O 121.366 0.603 . . . . 0.0 110.883 -168.995 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 7.2 t -80.26 10.12 4.9 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-O 121.736 0.779 . . . . 0.0 110.64 -177.3 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.4 ' HB1' HG21 ' A' ' 156' ' ' VAL . . . -95.09 135.55 36.5 Favored 'General case' 0 N--CA 1.42 -1.955 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.002 179.005 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -179.6 132.07 1.78 Allowed Glycine 0 N--CA 1.433 -1.517 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 63.6 -150.05 49.92 Favored Glycine 0 C--N 1.306 -1.133 0 CA-C-O 119.167 -0.796 . . . . 0.0 112.128 -177.247 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -56.7 103.82 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.242 0.679 0 CA-C-O 122.404 1.097 . . . . 0.0 111.804 -177.402 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -103.24 -36.77 7.96 Favored 'General case' 0 C--N 1.293 -1.884 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.676 -178.695 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.528 ' HB ' HG22 ' A' ' 154' ' ' VAL . 73.1 mt -120.54 138.47 50.92 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.706 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.436 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.9 mmpt? -112.99 140.05 48.13 Favored 'General case' 0 C--N 1.313 -1.009 0 C-N-CA 122.727 0.411 . . . . 0.0 110.171 177.655 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -73.5 134.74 43.95 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.03 179.091 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 82.95 4.59 89.94 Favored Glycine 0 C--N 1.314 -0.648 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -178.524 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 8.5 t -100.87 140.7 34.79 Favored 'General case' 0 N--CA 1.415 -2.214 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -178.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.43 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -71.4 122.15 19.84 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 178.201 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.747 ' HB ' HG21 ' A' ' 67' ' ' VAL . 34.2 pt -109.48 -27.21 2.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.218 -177.872 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -160.57 166.99 28.05 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 -177.554 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.43 HG23 HD11 ' A' ' 125' ' ' LEU . 59.7 t -143.06 114.93 2.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 179.184 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.464 HD11 HD21 ' A' ' 107' ' ' LEU . 34.3 mt -118.2 135.83 54.01 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.639 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 4.3 mp -115.72 128.05 73.1 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 C-N-CA 118.636 -1.226 . . . . 0.0 109.937 177.8 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.526 HD23 ' O ' ' A' ' 131' ' ' LEU . 0.0 OUTLIER -97.05 133.5 41.63 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.159 178.497 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 132' ' ' ARG . . . . . 0.433 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 7.4 mmm180 -91.72 127.48 37.19 Favored 'General case' 0 C--N 1.281 -2.396 0 C-N-CA 123.714 0.806 . . . . 0.0 109.374 176.709 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 20.1 mm-40 -103.98 130.52 51.63 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 105.75 -1.944 . . . . 0.0 105.75 174.087 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.585 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 12.9 m -145.2 143.92 30.56 Favored 'General case' 0 C--N 1.273 -2.757 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 177.396 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.567 ' HB2' HG23 ' A' ' 52' ' ' ILE . 19.3 p30 . . . . . 0 C--N 1.309 -1.169 0 C-N-CA 119.695 -0.802 . . . . 0.0 110.624 179.058 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 76.4 m-85 . . . . . 0 N--CA 1.431 -1.398 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -137.27 141.27 41.97 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.662 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.48 ' HB2' HD22 ' A' ' 131' ' ' LEU . 5.4 m-30 -108.58 131.66 54.64 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -176.165 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 48.1 t -90.89 127.52 43.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 O-C-N 123.579 0.549 . . . . 0.0 109.893 -178.84 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 146' ' ' TRP . . . . . 0.515 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 65.3 m95 -114.88 100.07 7.95 Favored 'General case' 0 C--N 1.273 -2.728 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 -178.992 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 42.2 m-80 -82.67 112.83 19.89 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 23.0 mm -88.45 121.09 38.32 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -177.434 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -116.79 149.07 40.56 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 177.935 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.09 131.43 35.3 Favored 'General case' 0 N--CA 1.41 -2.453 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 176.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 13.9 t-20 -91.03 -11.24 39.4 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 -178.246 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -147.88 142.85 26.94 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.155 -176.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -85.62 136.8 33.23 Favored 'General case' 0 C--N 1.313 -1.0 0 O-C-N 123.97 0.794 . . . . 0.0 109.663 178.898 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.528 HG22 ' HB ' ' A' ' 120' ' ' ILE . 1.5 m -119.92 149.52 22.6 Favored 'Isoleucine or valine' 0 C--O 1.254 1.316 0 CA-C-O 120.928 0.394 . . . . 0.0 110.785 -175.943 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -121.53 142.69 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.276 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -179.376 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.545 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.5 t -102.56 102.37 25.6 Favored Pre-proline 0 C--N 1.296 -1.745 0 C-N-CA 123.384 0.674 . . . . 0.0 109.82 178.131 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.476 ' HG3' HG13 ' A' ' 27' ' ' VAL . 29.2 Cg_endo -67.5 -28.64 38.3 Favored 'Trans proline' 0 CA--C 1.506 -0.878 0 C-N-CA 122.295 1.997 . . . . 0.0 111.7 177.519 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.255 6.1 t . . . . . 0 C--O 1.256 1.401 0 O-C-N 124.483 1.114 . . . . 0.0 112.519 178.809 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.458 -2.562 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.58 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 11.1 m -126.01 163.05 23.88 Favored 'General case' 0 C--N 1.26 -3.31 0 C-N-CA 119.148 -1.021 . . . . 0.0 109.155 -171.94 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.436 ' HA ' ' O ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -146.35 159.25 43.62 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-O 120.958 0.409 . . . . 0.0 110.522 -174.479 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.512 HG22 HG22 ' A' ' 20' ' ' VAL . 73.4 p -99.62 176.13 5.58 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 121.277 0.561 . . . . 0.0 111.09 -179.382 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.52 -12.93 59.85 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.186 178.175 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -89.48 -31.31 17.73 Favored 'General case' 0 N--CA 1.435 -1.213 0 C-N-CA 119.081 -1.047 . . . . 0.0 109.896 175.789 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.48 5.66 3.22 Favored Glycine 0 N--CA 1.44 -1.054 0 C-N-CA 119.325 -1.417 . . . . 0.0 113.743 175.354 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.436 ' O ' ' HA ' ' A' ' 4' ' ' LYS . 5.1 m -79.18 99.62 7.09 Favored 'General case' 0 N--CA 1.433 -1.276 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 -179.736 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.53 117.92 30.46 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 176.369 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 71.5 mt -93.46 123.29 60.76 Favored Pre-proline 0 C--N 1.297 -1.68 0 N-CA-C 108.498 -0.926 . . . . 0.0 108.498 179.292 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -77.81 167.47 23.81 Favored 'Trans proline' 0 C--O 1.248 0.982 0 C-N-CA 122.84 2.36 . . . . 0.0 111.498 179.261 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 60.3 mt -69.88 120.58 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.912 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.61 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 140.16 20.12 0.37 Allowed Glycine 0 C--N 1.298 -1.534 0 CA-C-N 115.533 -0.758 . . . . 0.0 112.677 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 84.26 158.81 28.56 Favored Glycine 0 C--O 1.236 0.258 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 -177.121 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 163.83 -175.74 39.96 Favored Glycine 0 N--CA 1.435 -1.372 0 C-N-CA 119.825 -1.179 . . . . 0.0 111.49 178.472 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 37.3 p -146.14 147.55 31.64 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.047 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.09 161.44 35.32 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 179.342 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 21.9 m-80 -113.29 109.81 19.34 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 106.493 -1.669 . . . . 0.0 106.493 176.755 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.512 HG22 HG22 ' A' ' 5' ' ' THR . 40.2 t -94.35 134.69 31.02 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.493 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 -178.273 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 78.3 m-85 -116.46 120.13 37.82 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 117.775 0.261 . . . . 0.0 110.986 -178.541 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.457 HG22 ' HG3' ' A' ' 41' ' ' GLN . 17.6 t -123.02 127.99 74.94 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-O 120.975 0.416 . . . . 0.0 111.036 -175.898 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -82.12 124.41 29.83 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 177.323 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 38.0 mt -115.51 154.2 29.76 Favored 'General case' 0 C--N 1.28 -2.453 0 CA-C-N 115.397 -0.82 . . . . 0.0 108.858 -179.086 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.76 120.83 44.9 Favored Pre-proline 0 C--N 1.314 -0.96 0 O-C-N 124.485 1.115 . . . . 0.0 110.123 -178.826 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 61.0 Cg_endo -72.22 -2.09 11.1 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.885 2.39 . . . . 0.0 113.427 -176.694 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.4 t -124.07 109.57 23.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 178.23 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.505 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.7 t -139.81 107.08 2.71 Favored 'Isoleucine or valine' 0 C--O 1.182 -2.479 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -178.258 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.729 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -97.72 148.54 23.24 Favored 'General case' 0 C--N 1.265 -3.095 0 C-N-CA 122.894 0.477 . . . . 0.0 111.015 -179.606 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.493 HG22 ' O ' ' A' ' 112' ' ' VAL . 91.0 t -47.69 116.52 0.38 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.638 0 C-N-CA 122.961 0.505 . . . . 0.0 111.435 176.038 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.09 9.87 43.94 Favored Glycine 0 CA--C 1.523 0.567 0 CA-C-N 114.905 -1.043 . . . . 0.0 112.137 -178.178 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.729 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -78.62 -176.71 4.99 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 124.603 1.161 . . . . 0.0 109.653 175.147 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -131.95 83.49 2.09 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 175.909 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.524 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 19.8 tp -91.37 134.22 34.79 Favored 'General case' 0 N--CA 1.426 -1.642 0 C-N-CA 119.42 -0.912 . . . . 0.0 108.915 179.438 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.447 ' HA ' ' O ' ' A' ' 107' ' ' LEU . 1.8 p -141.35 136.26 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.383 -3.803 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.191 -177.691 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.593 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 34.0 t -98.59 89.29 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.412 -2.343 0 CA-C-N 113.551 -1.659 . . . . 0.0 107.904 178.65 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -77.48 118.11 19.6 Favored 'General case' 0 CA--C 1.489 -1.391 0 C-N-CA 120.047 -0.661 . . . . 0.0 110.201 177.816 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 92.4 mt -96.64 -0.18 48.9 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.545 -0.752 . . . . 0.0 111.632 -178.01 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 26.4 t -74.63 -7.49 53.37 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.854 0.835 . . . . 0.0 109.659 -179.381 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.9 p -117.86 2.19 12.16 Favored 'General case' 0 C--N 1.279 -2.478 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.3 178.021 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.457 ' HG3' HG22 ' A' ' 22' ' ' VAL . 44.2 mm-40 -120.64 -22.83 6.22 Favored 'General case' 0 C--O 1.243 0.736 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.501 -173.904 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 20.1 mt -136.45 140.08 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.629 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 -176.795 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.407 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 59.8 m-85 -139.9 162.33 35.43 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 -177.648 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.58 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 20.1 t -145.08 141.91 29.24 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 120.181 -0.608 . . . . 0.0 110.39 175.847 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 19.8 p-80 -119.74 165.03 15.06 Favored 'General case' 0 C--O 1.255 1.389 0 CA-C-O 122.242 1.02 . . . . 0.0 110.376 -178.801 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -110.72 108.49 18.39 Favored 'General case' 0 C--N 1.271 -2.818 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 -175.017 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -84.0 -25.46 29.95 Favored 'General case' 0 N--CA 1.436 -1.166 0 C-N-CA 118.129 -1.428 . . . . 0.0 109.946 -177.618 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 -132.67 64.99 73.44 Favored Pre-proline 0 N--CA 1.472 0.668 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.186 178.03 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -70.02 1.04 4.98 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 C-N-CA 123.257 2.638 . . . . 0.0 114.159 -174.33 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -116.6 -20.13 9.72 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-O 121.189 0.519 . . . . 0.0 110.303 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.534 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -104.04 -27.83 11.88 Favored 'General case' 0 N--CA 1.422 -1.857 0 CA-C-O 122.055 0.931 . . . . 0.0 108.717 -172.875 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.56 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -128.9 142.98 42.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 CA-C-N 114.711 -1.131 . . . . 0.0 109.04 -176.817 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 4.2 t -89.2 133.23 34.51 Favored 'General case' 0 N--CA 1.433 -1.294 0 N-CA-C 104.917 -2.253 . . . . 0.0 104.917 170.209 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -92.79 106.5 18.46 Favored 'General case' 0 C--N 1.27 -2.879 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 -178.978 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.435 ' HB3' ' O ' ' A' ' 134' ' ' THR . 52.9 t80 -118.0 127.94 54.3 Favored 'General case' 0 C--N 1.274 -2.692 0 CA-C-N 114.29 -1.323 . . . . 0.0 108.855 -174.589 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.504 HG21 HD12 ' A' ' 131' ' ' LEU . 14.9 p -134.48 138.91 48.92 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.578 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.411 -175.307 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 4.3 p -146.7 131.03 17.54 Favored 'General case' 0 C--N 1.282 -2.352 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 174.431 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.559 ' HB3' HG23 ' A' ' 90' ' ' THR . 55.1 tp -64.52 116.89 6.61 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 173.213 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 5.7 tp60 -61.06 -49.42 77.42 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 113.802 -1.545 . . . . 0.0 109.307 -178.589 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -175.79 161.76 2.58 Favored 'General case' 0 N--CA 1.42 -1.951 0 CA-C-N 114.504 -1.226 . . . . 0.0 107.979 -178.311 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -136.6 136.52 8.42 Favored Glycine 0 N--CA 1.403 -3.514 0 N-CA-C 108.729 -1.748 . . . . 0.0 108.729 -179.47 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.2 m -123.66 146.87 47.9 Favored 'General case' 0 C--N 1.282 -2.35 0 O-C-N 124.394 0.702 . . . . 0.0 109.753 -176.095 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.506 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -112.17 156.07 22.91 Favored 'General case' 0 CA--C 1.503 -0.831 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 -178.845 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.449 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 88.5 m-85 -156.32 -178.93 7.69 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 124.309 1.044 . . . . 0.0 109.144 -177.616 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 63.01 -139.71 44.95 Favored Glycine 0 C--O 1.221 -0.672 0 O-C-N 123.367 0.417 . . . . 0.0 112.164 177.647 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.99 -6.98 86.12 Favored Glycine 0 C--O 1.203 -1.833 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.043 177.061 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.796 HG21 ' HB ' ' A' ' 126' ' ' ILE . 73.2 t -69.6 -38.52 76.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 C-N-CA 123.587 0.755 . . . . 0.0 111.815 -176.359 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.506 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -85.62 -21.72 28.3 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.954 -0.699 . . . . 0.0 112.194 179.136 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 14.0 m -100.89 -50.75 3.74 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 -173.389 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.446 ' O ' HG22 ' A' ' 112' ' ' VAL . 46.1 m-20 -93.36 -22.67 18.8 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 -176.028 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.627 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 84.0 m-85 -110.29 160.77 16.25 Favored 'General case' 0 N--CA 1.417 -2.112 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 177.411 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.5 t -166.76 131.68 2.12 Favored 'General case' 0 N--CA 1.415 -2.204 0 N-CA-C 106.049 -1.834 . . . . 0.0 106.049 175.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.427 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -166.76 -112.47 0.26 Allowed Glycine 0 N--CA 1.401 -3.66 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 175.855 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.435 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.0 OUTLIER -157.28 179.37 9.33 Favored 'General case' 0 C--N 1.281 -2.373 0 C-N-CA 123.685 0.794 . . . . 0.0 110.714 -172.324 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.446 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.6 p -134.97 148.17 29.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 178.347 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.688 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.1 tttt -125.73 150.04 48.03 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.156 -178.188 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.51 ' CD2' HG22 ' A' ' 105' ' ' VAL . 57.3 t80 -151.6 116.18 5.11 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 -178.15 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 2.7 m 53.79 33.87 17.91 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 179.116 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 85.6 9.67 78.14 Favored Glycine 0 CA--C 1.526 0.721 0 C-N-CA 120.291 -0.957 . . . . 0.0 112.923 -178.714 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.688 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 9.4 t -80.23 -179.69 7.21 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.098 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 11.4 p -154.63 110.17 3.14 Favored 'General case' 0 C--N 1.289 -2.039 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.05 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.484 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 5.0 p90 -153.01 159.55 32.08 Favored Pre-proline 0 CA--C 1.551 1.001 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -174.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.435 ' HA ' HG22 ' A' ' 74' ' ' THR . 44.3 Cg_endo -67.53 150.0 80.02 Favored 'Trans proline' 0 C--N 1.362 1.269 0 C-N-CA 123.059 2.506 . . . . 0.0 113.442 -176.096 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.621 ' CD2' HD21 ' A' ' 109' ' ' LEU . 55.6 t80 -125.92 132.76 24.42 Favored Pre-proline 0 N--CA 1.445 -0.709 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.027 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.416 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 69.6 Cg_endo -72.64 144.41 80.63 Favored 'Cis proline' 0 C--O 1.245 0.856 0 C-N-CA 122.786 -1.756 . . . . 0.0 110.313 -1.342 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.3 t -66.87 -176.68 0.53 Allowed 'General case' 0 CA--C 1.546 0.824 0 CA-C-N 115.571 -0.741 . . . . 0.0 112.219 -173.028 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 12.9 p -119.06 -49.39 2.41 Favored 'General case' 0 N--CA 1.419 -2.004 0 CA-C-N 115.362 -0.835 . . . . 0.0 111.23 -173.073 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.7 t -104.78 -81.28 0.53 Allowed 'General case' 0 N--CA 1.424 -1.759 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.992 -174.502 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -175.64 -170.09 0.39 Allowed 'General case' 0 C--O 1.238 0.462 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 -175.759 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.559 HG23 ' HB3' ' A' ' 58' ' ' LEU . 56.2 p -101.44 164.39 16.05 Favored Pre-proline 0 C--N 1.303 -1.418 0 N-CA-C 112.817 0.673 . . . . 0.0 112.817 176.22 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' PRO . . . . . 0.467 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 22.8 Cg_endo -60.7 172.12 3.05 Favored 'Trans proline' 0 CA--C 1.552 1.41 0 C-N-CA 123.194 2.596 . . . . 0.0 111.891 173.482 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.2 tmm_? -73.74 119.6 18.19 Favored 'General case' 0 C--N 1.323 -0.584 0 C-N-CA 123.674 0.79 . . . . 0.0 110.068 -173.734 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 75.5 t -138.45 139.07 42.15 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -177.536 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.94 142.0 32.95 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.974 0 C-N-CA 122.978 0.511 . . . . 0.0 109.869 -176.225 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.521 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 4.9 m-85 -95.68 105.38 17.37 Favored 'General case' 0 C--N 1.309 -1.184 0 C-N-CA 123.186 0.594 . . . . 0.0 109.853 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -93.01 50.89 1.6 Allowed 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 121.618 0.723 . . . . 0.0 109.271 177.2 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 12.2 p -117.47 178.4 4.4 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.023 -0.989 . . . . 0.0 110.841 -175.687 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 36.1 ptt180 -144.35 36.9 1.22 Allowed 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 172.408 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.8 t -158.31 171.77 19.57 Favored 'General case' 0 C--N 1.312 -1.036 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 -173.842 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.45 99.32 4.15 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -98.05 139.37 21.21 Favored Pre-proline 0 C--N 1.287 -2.118 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.292 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -60.19 147.57 92.95 Favored 'Trans proline' 0 C--O 1.245 0.844 0 C-N-CA 122.938 2.425 . . . . 0.0 112.134 178.711 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' TRP . . . . . 0.521 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 11.4 t90 -93.64 106.51 21.5 Favored Pre-proline 0 C--N 1.311 -1.094 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 -178.341 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -77.04 88.79 1.37 Allowed 'Trans proline' 0 N--CA 1.455 -0.756 0 C-N-CA 121.984 1.79 . . . . 0.0 113.212 -172.717 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.51 HG22 ' CD2' ' A' ' 77' ' ' TYR . 66.6 t -140.12 146.43 24.8 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.296 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 178.014 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.593 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.69 134.98 17.01 Favored 'General case' 0 C--N 1.291 -1.947 0 CA-C-O 120.659 0.266 . . . . 0.0 110.919 177.592 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.495 HD21 HD11 ' A' ' 129' ' ' LEU . 18.4 mt -101.11 100.04 10.55 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 179.682 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.427 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 58.8 m-85 -81.66 76.43 8.57 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 110.299 -0.26 . . . . 0.0 110.299 177.27 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.627 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.1 mm? -101.4 125.51 48.05 Favored 'General case' 0 CA--C 1.485 -1.528 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 176.02 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -126.68 148.05 63.27 Favored Pre-proline 0 N--CA 1.398 -3.036 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -175.075 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.422 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 28.6 Cg_endo -62.14 123.72 13.04 Favored 'Trans proline' 0 N--CA 1.446 -1.322 0 C-N-CA 123.132 2.555 . . . . 0.0 113.611 -176.522 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.493 ' O ' HG22 ' A' ' 30' ' ' VAL . 17.9 m -85.95 -157.69 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.398 -3.053 0 CA-C-N 114.34 -1.3 . . . . 0.0 108.696 171.225 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 15.8 t -81.83 -24.69 35.7 Favored 'General case' 0 C--N 1.254 -3.586 0 CA-C-O 121.755 0.788 . . . . 0.0 109.034 -171.175 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 28.0 t -80.85 18.23 1.03 Allowed 'General case' 0 N--CA 1.434 -1.267 0 CA-C-N 115.228 -0.896 . . . . 0.0 110.433 178.431 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -106.81 138.8 42.3 Favored 'General case' 0 N--CA 1.421 -1.887 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.373 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 177.19 125.42 0.9 Allowed Glycine 0 N--CA 1.441 -0.999 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 179.599 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 68.75 -149.54 49.6 Favored Glycine 0 CA--C 1.496 -1.096 0 CA-C-O 119.07 -0.85 . . . . 0.0 111.38 -176.404 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 57.7 t -58.91 105.71 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-O 121.718 0.771 . . . . 0.0 111.018 -176.564 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -105.77 -34.67 7.61 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 114.785 -1.098 . . . . 0.0 111.128 -178.819 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.539 ' HB ' HG22 ' A' ' 154' ' ' VAL . 70.4 mt -119.7 136.98 55.09 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.062 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.85 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.525 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.2 mmpt? -113.39 138.5 49.97 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-O 121.035 0.445 . . . . 0.0 110.428 177.043 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 0.42 ' H ' ' HB3' ' A' ' 153' ' ' ASP . . . -72.31 137.57 46.78 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.957 179.648 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 82.16 5.17 89.89 Favored Glycine 0 C--N 1.31 -0.868 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.864 -179.123 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 44.6 m -104.66 141.1 37.05 Favored 'General case' 0 N--CA 1.421 -1.903 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -67.35 123.81 21.38 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 178.049 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.796 ' HB ' HG21 ' A' ' 67' ' ' VAL . 28.6 pt -111.44 -26.21 3.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 116.129 -0.487 . . . . 0.0 112.16 -178.675 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 127' ' ' ALA . . . . . 0.401 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.59 168.41 23.56 Favored 'General case' 0 N--CA 1.443 -0.784 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -178.254 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 77.2 t -142.68 114.9 3.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.495 HD11 HD21 ' A' ' 107' ' ' LEU . 62.7 mt -116.23 143.88 44.94 Favored 'General case' 0 C--N 1.286 -2.16 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 178.714 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.529 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.9 mp -123.94 123.35 66.67 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.101 178.422 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.601 HD22 ' HB2' ' A' ' 144' ' ' PHE . 0.0 OUTLIER -89.11 134.7 33.91 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 176.718 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 132' ' ' ARG . . . . . 0.409 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 12.4 tpt180 -101.79 109.56 21.35 Favored 'General case' 0 C--N 1.277 -2.553 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 179.114 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 9.0 mm100 -100.8 105.12 16.4 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 176.536 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.435 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 7.7 m -124.17 136.02 53.89 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 179.205 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.56 ' CB ' HG23 ' A' ' 52' ' ' ILE . 7.9 p30 . . . . . 0 C--N 1.32 -0.691 0 C-N-CA 117.831 -1.548 . . . . 0.0 112.336 178.441 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 . . . . . 0 N--CA 1.417 -2.118 0 N-CA-C 109.681 -0.488 . . . . 0.0 109.681 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 143' ' ' GLN . . . . . 0.487 ' HB2' HG22 ' A' ' 130' ' ' ILE . 7.0 pt20 -108.22 133.46 52.43 Favored 'General case' 0 N--CA 1.413 -2.308 0 CA-C-O 121.493 0.663 . . . . 0.0 110.033 177.073 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.601 ' HB2' HD22 ' A' ' 131' ' ' LEU . 8.0 m-30 -103.02 133.77 47.58 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 -176.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 46.6 t -91.44 129.91 41.42 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.929 0 CA-C-O 121.115 0.484 . . . . 0.0 109.766 -178.514 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 146' ' ' TRP . . . . . 0.512 ' CZ2' ' HB2' ' A' ' 3' ' ' CYS . 62.2 m95 -120.22 96.2 5.06 Favored 'General case' 0 C--N 1.277 -2.568 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -80.22 114.73 19.34 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.411 HG22 HD11 ' A' ' 126' ' ' ILE . 25.5 mm -87.42 123.31 40.07 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.799 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 -177.506 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -116.79 151.09 37.22 Favored 'General case' 0 C--N 1.292 -1.909 0 C-N-CA 124.207 1.003 . . . . 0.0 109.349 178.171 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.68 131.81 35.28 Favored 'General case' 0 N--CA 1.411 -2.419 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 175.635 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -93.15 -11.39 32.93 Favored 'General case' 0 C--N 1.292 -1.919 0 CA-C-O 122.469 1.128 . . . . 0.0 108.033 -176.506 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -152.02 143.62 23.53 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 114.023 -1.444 . . . . 0.0 109.41 -177.457 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 153' ' ' ASP . . . . . 0.42 ' HB3' ' H ' ' A' ' 122' ' ' ALA . 6.4 p-10 -86.4 139.49 30.89 Favored 'General case' 0 C--N 1.309 -1.173 0 O-C-N 124.133 0.896 . . . . 0.0 110.183 -179.389 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.539 HG22 ' HB ' ' A' ' 120' ' ' ILE . 1.8 m -120.38 153.05 23.42 Favored 'Isoleucine or valine' 0 C--O 1.251 1.144 0 CA-C-O 120.94 0.4 . . . . 0.0 111.217 -175.599 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.0 t -123.14 142.63 39.03 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.2 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 77.1 t -104.26 102.46 32.96 Favored Pre-proline 0 C--N 1.289 -2.039 0 C-N-CA 123.444 0.698 . . . . 0.0 110.039 179.179 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.505 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 29.7 Cg_endo -67.26 -23.23 45.32 Favored 'Trans proline' 0 C--O 1.219 -0.437 0 C-N-CA 122.498 2.132 . . . . 0.0 111.56 176.656 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 158' ' ' THR . . . . . 0.448 ' HB ' HG12 ' A' ' 156' ' ' VAL 0.287 5.1 t . . . . . 0 C--O 1.258 1.515 0 CA-C-O 117.45 -1.262 . . . . 0.0 113.768 176.054 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.504 -0.823 0 CA-C-O 120.72 0.295 . . . . 0.0 110.695 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 76.9 m -145.48 159.31 43.29 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -178.813 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.42 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -145.55 155.56 43.14 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-O 121.451 0.643 . . . . 0.0 110.164 -177.37 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 44.7 p -92.36 177.33 6.17 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.856 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.91 -17.13 48.26 Favored 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.953 179.148 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -90.76 -24.93 20.22 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.582 -177.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 131.73 -3.11 5.33 Favored Glycine 0 CA--C 1.494 -1.233 0 C-N-CA 119.271 -1.442 . . . . 0.0 114.428 169.321 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.7 m -80.55 100.05 8.39 Favored 'General case' 0 C--N 1.285 -2.211 0 CA-C-O 121.453 0.644 . . . . 0.0 109.536 -178.221 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.401 ' HA ' ' HA ' ' A' ' 4' ' ' LYS . . . -94.56 124.75 38.78 Favored 'General case' 0 N--CA 1.424 -1.77 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.115 176.72 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 69.6 mt -92.11 116.45 66.48 Favored Pre-proline 0 C--N 1.278 -2.539 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 177.72 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -75.9 177.09 9.18 Favored 'Trans proline' 0 C--O 1.245 0.841 0 C-N-CA 122.54 2.16 . . . . 0.0 111.719 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 67.9 mt -70.23 128.4 33.48 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.4 179.564 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 128.89 5.19 4.93 Favored Glycine 0 N--CA 1.432 -1.576 0 C-N-CA 120.372 -0.918 . . . . 0.0 111.69 -178.19 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 86.07 169.74 46.25 Favored Glycine 0 N--CA 1.439 -1.106 0 C-N-CA 120.511 -0.852 . . . . 0.0 111.588 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.86 -174.85 30.83 Favored Glycine 0 CA--C 1.487 -1.686 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 178.853 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.3 m -134.1 159.37 41.06 Favored 'General case' 0 C--N 1.296 -1.759 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 -179.131 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -141.46 165.51 27.31 Favored 'General case' 0 N--CA 1.42 -1.935 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 177.21 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -116.1 104.41 11.52 Favored 'General case' 0 C--N 1.273 -2.73 0 CA-C-N 114.002 -1.453 . . . . 0.0 108.913 178.079 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.456 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.3 m -91.68 146.4 6.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 -178.563 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -128.93 112.51 14.16 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-O 121.03 0.443 . . . . 0.0 111.28 -177.502 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.524 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.6 p -118.69 129.78 74.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 CA-C-O 121.692 0.758 . . . . 0.0 111.995 -174.626 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.3 m-80 -84.52 126.06 32.96 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 177.677 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 23.0 mt -113.06 157.31 21.74 Favored 'General case' 0 C--N 1.272 -2.777 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 -179.155 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.36 120.74 46.79 Favored Pre-proline 0 C--N 1.313 -1.011 0 O-C-N 124.207 0.942 . . . . 0.0 109.723 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.473 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 60.6 Cg_endo -74.2 -0.12 9.19 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.657 2.238 . . . . 0.0 112.616 -177.536 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.433 HG13 ' HG3' ' A' ' 157' ' ' PRO . 94.9 t -125.3 109.95 23.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 177.639 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.6 t -140.91 107.02 1.97 Allowed 'Isoleucine or valine' 0 C--O 1.179 -2.622 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 -179.544 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.592 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -98.64 148.86 23.38 Favored 'General case' 0 C--N 1.265 -3.089 0 O-C-N 122.13 -0.356 . . . . 0.0 111.266 -179.5 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.423 ' H ' ' HA ' ' A' ' 158' ' ' THR . 22.2 t -43.8 117.04 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.528 0 C-N-CA 123.571 0.748 . . . . 0.0 111.501 175.759 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.84 -1.07 48.36 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-N 115.002 -0.999 . . . . 0.0 113.063 -179.035 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.592 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.8 OUTLIER -71.48 -177.04 1.7 Allowed 'General case' 0 C--N 1.318 -0.802 0 C-N-CA 124.496 1.118 . . . . 0.0 111.237 177.784 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 64.1 t30 -133.41 87.61 2.41 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 177.775 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.625 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.5 tp -88.76 140.3 29.59 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 -178.69 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.2 t -134.11 125.4 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.172 0 CA-C-O 121.113 0.483 . . . . 0.0 109.787 -175.472 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.57 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 41.1 t -95.78 88.2 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.399 -2.994 0 N-CA-C 105.713 -1.958 . . . . 0.0 105.713 174.196 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -80.57 116.07 20.42 Favored 'General case' 0 CA--C 1.486 -1.482 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.0 mt -97.52 0.06 46.86 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.249 -177.459 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.588 ' OG ' ' HA ' ' A' ' 104' ' ' PRO . 19.6 m -81.22 -2.37 48.5 Favored 'General case' 0 C--N 1.29 -1.988 0 CA-C-O 122.658 1.218 . . . . 0.0 109.703 -179.296 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.4 p -118.8 1.58 11.57 Favored 'General case' 0 C--N 1.275 -2.663 0 CA-C-N 114.807 -1.088 . . . . 0.0 109.811 175.725 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.524 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 44.8 mm-40 -122.41 -23.09 5.31 Favored 'General case' 0 CA--C 1.512 -0.497 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.329 -174.566 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 29.0 mt -135.68 139.2 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.229 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -176.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.42 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 65.7 m-85 -137.52 151.79 48.8 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 -177.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 67.7 m -128.28 138.53 52.46 Favored 'General case' 0 C--N 1.276 -2.622 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 176.846 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.2 p80 -125.11 129.26 49.84 Favored 'General case' 0 C--N 1.295 -1.774 0 CA-C-O 121.955 0.883 . . . . 0.0 110.773 -177.843 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.548 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 24.4 p-10 -95.76 96.5 9.02 Favored 'General case' 0 C--N 1.279 -2.477 0 CA-C-O 122.466 1.127 . . . . 0.0 110.072 -179.214 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -74.7 -23.55 58.63 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 114.108 -1.405 . . . . 0.0 111.538 -174.466 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -128.91 65.23 72.89 Favored Pre-proline 0 N--CA 1.479 1.019 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.103 179.648 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.548 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 60.3 Cg_endo -68.85 -12.31 34.14 Favored 'Trans proline' 0 N--CA 1.483 0.881 0 C-N-CA 122.809 2.34 . . . . 0.0 114.148 -172.471 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -108.08 -21.15 12.92 Favored 'General case' 0 C--N 1.292 -1.894 0 C-N-CA 119.977 -0.689 . . . . 0.0 110.343 -176.662 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.504 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.8 m -96.21 -30.34 13.53 Favored 'General case' 0 N--CA 1.416 -2.154 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 -172.544 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.657 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -121.98 143.29 35.07 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.213 0 CA-C-N 113.991 -1.459 . . . . 0.0 108.737 -177.119 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.1 t -88.82 125.83 35.08 Favored 'General case' 0 N--CA 1.419 -2.014 0 N-CA-C 103.944 -2.613 . . . . 0.0 103.944 170.923 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 -90.61 107.18 19.01 Favored 'General case' 0 C--N 1.263 -3.18 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -172.63 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.469 ' HB3' ' O ' ' A' ' 134' ' ' THR . 34.2 t80 -126.02 117.72 23.83 Favored 'General case' 0 C--N 1.274 -2.7 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.489 -173.39 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.537 HG12 ' OH ' ' A' ' 77' ' ' TYR . 49.0 t -121.85 130.84 74.24 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.298 -175.517 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.1 p -143.45 113.43 7.19 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 123.923 0.764 . . . . 0.0 111.239 177.683 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.505 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 54.3 tp -55.34 109.7 0.58 Allowed 'General case' 0 C--N 1.311 -1.106 0 CA-C-O 121.313 0.578 . . . . 0.0 110.174 172.108 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.43 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 11.8 tp60 -54.91 -53.64 52.96 Favored 'General case' 0 C--O 1.209 -1.04 0 C-N-CA 126.041 1.736 . . . . 0.0 110.911 178.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -171.06 160.9 6.65 Favored 'General case' 0 N--CA 1.425 -1.71 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 -176.198 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -139.3 133.44 6.15 Favored Glycine 1 N--CA 1.391 -4.321 0 N-CA-C 108.041 -2.024 . . . . 0.0 108.041 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.2 m -120.76 151.6 39.36 Favored 'General case' 0 C--N 1.276 -2.599 0 O-C-N 124.956 1.033 . . . . 0.0 108.582 -174.145 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.563 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -116.16 157.67 24.45 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 -178.654 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.527 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 96.1 m-85 -155.69 176.8 12.14 Favored 'General case' 0 C--N 1.35 0.616 0 C-N-CA 124.246 1.018 . . . . 0.0 109.587 -177.283 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.35 -147.52 38.86 Favored Glycine 0 CA--C 1.52 0.365 0 O-C-N 123.61 0.569 . . . . 0.0 112.81 178.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -70.58 -10.34 66.77 Favored Glycine 0 C--O 1.205 -1.665 0 O-C-N 122.052 -0.676 . . . . 0.0 111.976 177.106 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.773 HG21 ' HB ' ' A' ' 126' ' ' ILE . 92.8 t -70.53 -36.75 67.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 123.544 0.737 . . . . 0.0 111.322 -177.172 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.563 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.71 -23.09 25.67 Favored 'General case' 0 N--CA 1.421 -1.883 0 C-N-CA 118.6 -1.24 . . . . 0.0 112.144 179.179 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 17.1 t -101.77 -55.46 2.5 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 112.952 0.723 . . . . 0.0 112.952 -175.213 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.443 ' O ' HG22 ' A' ' 112' ' ' VAL . 72.4 m-20 -83.91 -27.43 28.6 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 -174.769 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.637 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 90.0 m-85 -107.02 159.19 16.47 Favored 'General case' 0 N--CA 1.421 -1.917 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 176.463 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.8 t -168.09 136.24 2.3 Favored 'General case' 0 N--CA 1.41 -2.431 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 176.292 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.421 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -169.37 -108.21 0.21 Allowed Glycine 0 N--CA 1.411 -3.027 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 175.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.541 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.1 p -159.21 -179.96 8.46 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 123.829 0.852 . . . . 0.0 110.547 -173.225 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.05 146.73 29.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 C-N-CA 123.435 0.694 . . . . 0.0 109.143 178.614 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.616 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.1 tttt -125.17 142.17 51.66 Favored 'General case' 0 N--CA 1.417 -2.095 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.518 -179.442 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.537 ' OH ' HG12 ' A' ' 56' ' ' VAL . 72.4 t80 -144.48 111.06 5.64 Favored 'General case' 0 C--N 1.295 -1.796 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.13 -177.195 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 35.1 t 55.14 34.33 22.39 Favored 'General case' 0 C--N 1.317 -0.825 0 C-N-CA 123.416 0.686 . . . . 0.0 111.164 178.212 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.08 10.52 64.32 Favored Glycine 0 N--CA 1.44 -1.079 0 C-N-CA 120.486 -0.864 . . . . 0.0 113.566 -178.877 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.616 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 20.8 t -79.84 179.8 7.36 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.551 0.676 . . . . 0.0 109.31 178.484 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 9.7 p -156.55 90.35 1.16 Allowed 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.623 0.725 . . . . 0.0 110.637 -176.707 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.439 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 1.5 p90 -139.85 158.31 67.9 Favored Pre-proline 0 C--N 1.297 -1.69 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 -173.098 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.541 ' HA ' HG22 ' A' ' 74' ' ' THR . 58.9 Cg_endo -69.35 151.03 71.39 Favored 'Trans proline' 0 C--N 1.354 0.842 0 C-N-CA 123.148 2.565 . . . . 0.0 113.154 -177.081 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.596 ' CD2' HD21 ' A' ' 109' ' ' LEU . 58.0 t80 -122.74 133.21 24.33 Favored Pre-proline 0 N--CA 1.439 -1.011 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.018 -179.541 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.463 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 79.3 Cg_endo -71.43 149.78 92.7 Favored 'Cis proline' 0 CA--C 1.534 0.511 0 C-N-CA 122.71 -1.787 . . . . 0.0 109.73 -0.956 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.0 t -61.06 -175.54 0.05 OUTLIER 'General case' 0 CA--C 1.562 1.415 0 C-N-CA 123.399 0.679 . . . . 0.0 112.595 -175.462 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 12.4 p -104.97 -50.53 3.23 Favored 'General case' 0 N--CA 1.408 -2.563 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 -177.742 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.6 t -128.43 -109.19 0.29 Allowed 'General case' 0 N--CA 1.402 -2.873 0 CA-C-N 114.346 -1.297 . . . . 0.0 108.591 178.338 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -125.35 -171.68 2.42 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 118.539 0.609 . . . . 0.0 112.503 -176.692 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.505 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 36.1 p -93.95 167.57 13.4 Favored Pre-proline 0 C--N 1.309 -1.189 0 N-CA-C 112.924 0.713 . . . . 0.0 112.924 -178.908 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -62.82 175.87 2.11 Favored 'Trans proline' 0 CA--C 1.552 1.386 0 C-N-CA 123.087 2.524 . . . . 0.0 111.904 172.424 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.4 ' HG2' ' CE2' ' A' ' 55' ' ' TYR . 1.4 tmm_? -74.84 129.5 37.79 Favored 'General case' 0 C--O 1.243 0.761 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.004 -175.469 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.492 ' HB ' ' O ' ' A' ' 56' ' ' VAL . 65.3 t -140.09 132.57 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 C-N-CA 123.718 0.807 . . . . 0.0 109.801 -176.497 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 1.9 p -131.08 136.41 57.95 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.411 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 177.461 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 6.1 m-85 -79.8 116.47 19.98 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-O 121.388 0.613 . . . . 0.0 110.525 -179.745 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 -102.22 68.46 1.09 Allowed 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 177.816 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 46.0 t -147.64 179.23 7.84 Favored 'General case' 0 N--CA 1.426 -1.646 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 -175.578 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 31.8 ptt180 -151.11 42.12 0.76 Allowed 'General case' 0 C--N 1.31 -1.146 0 C-N-CA 124.036 0.934 . . . . 0.0 108.51 171.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 11.0 t -169.72 172.32 6.87 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-N 114.525 -1.216 . . . . 0.0 108.23 -177.792 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -59.34 119.87 8.24 Favored 'General case' 0 N--CA 1.474 0.768 0 O-C-N 123.756 0.66 . . . . 0.0 110.493 178.357 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 55.9 mmtt -120.2 143.19 35.12 Favored Pre-proline 0 C--N 1.287 -2.143 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.994 178.364 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -67.16 139.19 49.71 Favored 'Trans proline' 0 N--CA 1.44 -1.676 0 C-N-CA 122.392 2.061 . . . . 0.0 110.32 177.252 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 14.4 t90 -80.34 109.69 13.69 Favored Pre-proline 0 C--N 1.307 -1.243 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 -177.476 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' PRO . . . . . 0.588 ' HA ' ' OG ' ' A' ' 39' ' ' SER . 60.7 Cg_endo -74.85 87.7 1.28 Allowed 'Trans proline' 0 N--CA 1.451 -0.982 0 C-N-CA 121.12 1.213 . . . . 0.0 112.844 -172.376 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.505 HG22 ' CD1' ' A' ' 77' ' ' TYR . 59.7 t -144.9 145.18 21.24 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.359 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 179.579 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.57 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.65 136.27 17.03 Favored 'General case' 0 C--N 1.288 -2.07 0 O-C-N 123.569 0.543 . . . . 0.0 110.116 177.917 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.464 HD21 HD11 ' A' ' 129' ' ' LEU . 17.7 mt -101.81 105.12 15.92 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 177.936 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.421 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 39.3 m-85 -85.29 80.49 9.15 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 177.481 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.637 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.2 mm? -105.12 125.32 50.85 Favored 'General case' 0 CA--C 1.491 -1.327 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 177.441 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -128.04 146.63 59.99 Favored Pre-proline 0 N--CA 1.412 -2.363 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.62 -175.542 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.438 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 23.1 Cg_endo -61.14 117.6 4.39 Favored 'Trans proline' 0 C--O 1.245 0.863 0 C-N-CA 123.424 2.749 . . . . 0.0 112.369 -178.458 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.443 HG22 ' O ' ' A' ' 70' ' ' ASN . 2.7 m -67.04 -114.14 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.202 -1.447 0 CA-C-N 114.289 -1.323 . . . . 0.0 112.752 176.735 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 41.7 m -112.56 -43.4 3.48 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.287 -0.883 . . . . 0.0 110.441 175.777 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 22.7 t -82.82 30.2 0.44 Allowed 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.067 -174.726 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -101.79 130.94 48.33 Favored 'General case' 0 N--CA 1.418 -2.035 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.2 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.28 141.06 6.45 Favored Glycine 0 N--CA 1.432 -1.596 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 58.81 -149.23 37.78 Favored Glycine 0 C--O 1.219 -0.812 0 CA-C-O 119.244 -0.753 . . . . 0.0 113.307 -179.087 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 99.5 t -56.56 96.75 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 121.581 0.705 . . . . 0.0 111.26 -178.207 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -99.4 -27.78 13.58 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.365 -177.951 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.583 ' HB ' HG22 ' A' ' 154' ' ' VAL . 68.9 mt -126.84 138.53 54.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 177.105 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.424 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.2 mmpt? -111.02 138.05 47.9 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-O 121.341 0.591 . . . . 0.0 111.207 178.409 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.56 128.57 36.96 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.46 178.029 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 92.05 -7.16 78.96 Favored Glycine 0 N--CA 1.428 -1.89 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.093 -179.349 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 91.9 p -90.85 143.9 26.25 Favored 'General case' 0 C--O 1.253 1.253 0 C-N-CA 119.495 -0.882 . . . . 0.0 109.525 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.437 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -70.72 122.37 19.69 Favored 'General case' 0 N--CA 1.435 -1.22 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 177.367 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.773 ' HB ' HG21 ' A' ' 67' ' ' VAL . 31.6 pt -109.02 -24.47 4.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -177.116 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.72 167.32 23.22 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 -177.9 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.437 HG23 HD11 ' A' ' 125' ' ' LEU . 76.9 t -141.62 114.93 4.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 179.506 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.464 HD11 HD21 ' A' ' 107' ' ' LEU . 52.7 mt -117.97 144.68 45.32 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 178.484 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.488 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.4 mp -127.41 130.19 70.67 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 C-N-CA 119.41 -0.916 . . . . 0.0 110.639 179.006 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.471 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.9 OUTLIER -94.75 128.99 41.85 Favored 'General case' 0 C--N 1.29 -1.982 0 C-N-CA 123.855 0.862 . . . . 0.0 111.477 -179.607 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 132' ' ' ARG . . . . . 0.43 ' HG2' ' HB2' ' A' ' 59' ' ' GLN . 25.9 mmm180 -94.58 120.55 34.99 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 173.185 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -103.38 137.23 41.78 Favored 'General case' 0 N--CA 1.427 -1.59 0 N-CA-C 105.937 -1.875 . . . . 0.0 105.937 169.495 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.469 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 27.8 m -150.23 134.76 17.38 Favored 'General case' 0 C--N 1.278 -2.527 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 173.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.657 ' CB ' HG23 ' A' ' 52' ' ' ILE . 8.7 p30 . . . . . 0 N--CA 1.437 -1.108 0 C-N-CA 118.966 -1.094 . . . . 0.0 112.057 179.753 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 82.0 m-85 . . . . . 0 N--CA 1.421 -1.881 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 11.4 pt20 -121.98 138.24 54.5 Favored 'General case' 0 N--CA 1.416 -2.152 0 C-N-CA 119.251 -0.98 . . . . 0.0 109.844 178.837 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 11.8 m-30 -105.12 128.98 53.62 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 -176.755 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.6 t -94.67 133.88 34.07 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.116 0 CA-C-O 121.143 0.497 . . . . 0.0 110.24 -178.152 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 146' ' ' TRP . . . . . 0.471 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.2 m95 -120.19 96.83 5.32 Favored 'General case' 0 C--N 1.286 -2.179 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.134 -177.224 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 44.3 m-80 -79.15 112.92 16.85 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 176.383 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.456 ' HA ' HG22 ' A' ' 20' ' ' VAL . 23.9 mm -87.74 120.55 37.02 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 -177.604 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -115.45 153.59 30.82 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 177.593 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.51 132.44 34.2 Favored 'General case' 0 N--CA 1.406 -2.63 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 177.667 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -90.02 -17.18 28.3 Favored 'General case' 0 C--N 1.286 -2.189 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 -176.115 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -146.18 144.31 29.85 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 114.088 -1.415 . . . . 0.0 110.123 -174.755 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -83.45 138.22 33.56 Favored 'General case' 0 C--N 1.317 -0.819 0 O-C-N 124.314 1.009 . . . . 0.0 109.697 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.583 HG22 ' HB ' ' A' ' 120' ' ' ILE . 2.0 m -119.83 151.83 22.44 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 C-N-CA 120.634 -0.426 . . . . 0.0 111.045 -176.898 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.2 t -123.78 140.96 45.69 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 -179.139 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.497 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.4 t -103.2 100.35 17.42 Favored Pre-proline 0 C--N 1.291 -1.945 0 C-N-CA 123.435 0.694 . . . . 0.0 109.864 178.43 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.495 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 35.2 Cg_endo -68.17 -21.04 42.85 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.52 2.147 . . . . 0.0 111.403 177.111 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 158' ' ' THR . . . . . 0.423 ' HA ' ' H ' ' A' ' 30' ' ' VAL . 3.1 t . . . . . 0 C--O 1.257 1.453 0 C-N-CA 124.789 1.236 . . . . 0.0 114.128 175.531 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.46 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.44 -0.945 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.5 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 9.6 t -144.32 157.25 44.37 Favored 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 118.864 -1.134 . . . . 0.0 110.175 -175.347 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.44 ' HE3' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.48 164.9 29.49 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-O 121.254 0.55 . . . . 0.0 110.961 -175.335 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.586 HG22 HG22 ' A' ' 20' ' ' VAL . 82.1 p -102.18 176.81 5.07 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.841 -178.61 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.3 -16.51 56.25 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 114.402 -1.272 . . . . 0.0 110.722 176.038 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -90.93 -26.49 19.26 Favored 'General case' 0 CA--C 1.515 -0.375 0 C-N-CA 118.856 -1.137 . . . . 0.0 111.341 -177.467 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.48 4.87 3.43 Favored Glycine 0 CA--C 1.499 -0.932 0 C-N-CA 119.889 -1.148 . . . . 0.0 113.322 171.261 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.6 m -82.67 107.48 15.34 Favored 'General case' 0 N--CA 1.424 -1.759 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.404 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -102.53 109.99 21.78 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.43 176.613 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.46 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 54.8 mt -82.62 124.63 77.34 Favored Pre-proline 0 C--N 1.305 -1.338 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -176.688 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -81.36 161.94 19.83 Favored 'Trans proline' 0 C--O 1.246 0.924 0 C-N-CA 122.61 2.207 . . . . 0.0 111.922 179.073 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 58.0 mt -66.27 133.0 31.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.09 179.544 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 126.57 12.24 3.44 Favored Glycine 0 C--N 1.306 -1.1 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.238 -178.661 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.97 148.84 18.93 Favored Glycine 0 C--O 1.241 0.564 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 -178.054 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.62 -172.36 45.17 Favored Glycine 0 CA--C 1.491 -1.415 0 C-N-CA 119.453 -1.356 . . . . 0.0 112.493 -179.693 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.7 p -146.55 151.76 37.86 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 122.654 0.382 . . . . 0.0 110.325 -177.729 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -140.38 166.47 24.63 Favored 'General case' 0 N--CA 1.433 -1.283 0 CA-C-O 121.617 0.722 . . . . 0.0 109.89 178.33 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.39 101.54 8.49 Favored 'General case' 0 C--N 1.28 -2.423 0 CA-C-N 113.833 -1.531 . . . . 0.0 109.307 179.412 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.586 HG22 HG22 ' A' ' 5' ' ' THR . 40.4 t -92.25 134.4 30.53 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.802 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.563 -178.73 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 55.2 m-85 -119.6 126.73 51.9 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 -179.088 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.492 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.7 p -136.86 133.22 48.12 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.249 -177.047 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -93.67 129.77 39.85 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 121.643 0.735 . . . . 0.0 110.482 178.312 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -108.25 160.58 15.73 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 114.466 -1.243 . . . . 0.0 108.196 -179.704 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -59.08 123.7 70.66 Favored Pre-proline 0 C--N 1.314 -0.958 0 O-C-N 124.387 1.054 . . . . 0.0 109.233 177.886 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.426 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 61.8 Cg_endo -74.94 -2.06 12.03 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.632 2.221 . . . . 0.0 113.159 -177.544 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.421 HG13 ' HG3' ' A' ' 157' ' ' PRO . 60.5 t -122.95 109.76 24.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 178.186 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.464 ' O ' HG13 ' A' ' 156' ' ' VAL . 1.7 t -141.1 102.16 1.17 Allowed 'Isoleucine or valine' 0 C--O 1.183 -2.436 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -177.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.58 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -94.01 152.22 18.97 Favored 'General case' 0 C--N 1.274 -2.689 0 O-C-N 122.149 -0.344 . . . . 0.0 111.471 179.878 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.401 HG13 ' O ' ' A' ' 112' ' ' VAL . 35.0 t -45.71 119.88 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 123.26 0.624 . . . . 0.0 112.156 176.912 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.83 1.6 55.13 Favored Glycine 0 N--CA 1.46 0.252 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.595 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.58 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.4 OUTLIER -71.49 -178.53 2.19 Favored 'General case' 0 C--N 1.312 -1.048 0 C-N-CA 124.158 0.983 . . . . 0.0 111.226 177.246 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -129.73 85.06 2.26 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 176.157 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.593 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 17.1 tp -92.98 134.94 34.62 Favored 'General case' 0 N--CA 1.423 -1.806 0 C-N-CA 119.446 -0.902 . . . . 0.0 108.727 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 2.0 p -141.61 132.38 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.515 0 CA-C-O 122.016 0.913 . . . . 0.0 112.366 -177.694 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.604 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 42.5 t -89.31 90.0 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.264 0 CA-C-N 113.665 -1.607 . . . . 0.0 108.376 179.156 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -73.96 103.39 4.44 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 -179.561 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.4 mt -89.94 -3.82 57.83 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 120.75 0.31 . . . . 0.0 111.782 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -73.43 0.81 11.2 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 122.07 0.938 . . . . 0.0 111.574 178.982 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.9 p -126.72 5.89 6.73 Favored 'General case' 0 N--CA 1.418 -2.033 0 CA-C-N 115.203 -0.908 . . . . 0.0 109.866 176.645 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.492 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 43.9 mm-40 -123.7 -23.15 4.78 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.958 -174.754 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.7 mt -133.7 137.56 52.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 -176.158 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.44 ' HB2' ' HE3' ' A' ' 4' ' ' LYS . 41.7 m-85 -142.41 124.37 15.27 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -175.136 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.5 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 81.7 m -101.27 147.27 26.49 Favored 'General case' 0 C--N 1.291 -1.957 0 N-CA-C 109.46 -0.571 . . . . 0.0 109.46 -179.361 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' HIS . . . . . 0.464 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 37.0 p-80 -136.7 129.79 31.13 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-O 121.763 0.792 . . . . 0.0 111.649 -173.813 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.496 ' ND2' ' HA ' ' A' ' 49' ' ' PRO . 41.7 t30 -93.05 102.25 14.58 Favored 'General case' 0 C--N 1.28 -2.446 0 C-N-CA 119.991 -0.684 . . . . 0.0 110.533 179.233 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -56.22 -27.91 56.48 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 124.804 1.241 . . . . 0.0 111.016 179.747 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.476 ' HB2' HD13 ' A' ' 52' ' ' ILE . 38.8 m-85 -125.84 79.17 68.82 Favored Pre-proline 0 C--N 1.309 -1.169 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 -177.383 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.496 ' HA ' ' ND2' ' A' ' 46' ' ' ASN . 57.8 Cg_endo -67.89 -7.33 19.33 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.852 2.368 . . . . 0.0 115.19 -170.503 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -120.76 -11.37 9.01 Favored 'General case' 0 C--N 1.311 -1.068 0 C-N-CA 120.253 -0.579 . . . . 0.0 111.073 -179.391 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.49 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.9 OUTLIER -104.79 -30.23 10.03 Favored 'General case' 0 N--CA 1.435 -1.206 0 CA-C-O 122.128 0.966 . . . . 0.0 109.128 -171.631 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.49 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.0 mp -121.29 136.27 58.75 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.167 0 CA-C-N 114.351 -1.295 . . . . 0.0 109.807 -177.321 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 1.8 t -90.25 126.6 35.89 Favored 'General case' 0 N--CA 1.417 -2.08 0 N-CA-C 102.984 -2.969 . . . . 0.0 102.984 170.06 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.549 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 13.3 t70 -83.55 112.73 20.26 Favored 'General case' 0 C--N 1.274 -2.693 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 -172.155 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.575 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 22.0 t80 -127.77 123.31 34.97 Favored 'General case' 0 C--N 1.272 -2.801 0 CA-C-O 122.054 0.931 . . . . 0.0 110.671 -175.355 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.51 HG23 ' HG ' ' A' ' 131' ' ' LEU . 14.1 p -126.68 148.65 31.42 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.469 0 CA-C-N 114.334 -1.303 . . . . 0.0 109.802 -177.377 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.56 121.7 8.32 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.365 175.473 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.502 HD12 ' O ' ' A' ' 130' ' ' ILE . 53.0 tp -65.33 115.56 5.75 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 173.274 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.475 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 3.8 tp-100 -62.67 -61.65 2.27 Favored 'General case' 0 C--O 1.209 -1.038 0 C-N-CA 125.419 1.488 . . . . 0.0 109.499 178.764 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.414 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 9.9 ptp180 -158.61 159.36 35.36 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-N 114.513 -1.222 . . . . 0.0 108.227 -176.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.4 ' H ' HG22 ' A' ' 86' ' ' THR . . . -141.12 131.54 4.94 Favored Glycine 0 N--CA 1.399 -3.808 0 N-CA-C 108.478 -1.849 . . . . 0.0 108.478 -179.707 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 69.5 m -120.14 145.9 46.49 Favored 'General case' 0 C--N 1.28 -2.44 0 O-C-N 124.679 0.87 . . . . 0.0 110.475 -173.807 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.557 ' HB2' ' CE2' ' A' ' 84' ' ' PHE . . . -108.2 157.08 18.63 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.497 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 94.2 m-85 -157.07 -179.44 8.21 Favored 'General case' 0 C--O 1.235 0.325 0 C-N-CA 124.776 1.231 . . . . 0.0 108.949 -178.069 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 61.11 -144.19 48.63 Favored Glycine 0 CA--C 1.506 -0.516 0 O-C-N 123.489 0.493 . . . . 0.0 112.313 177.594 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -76.33 -9.58 85.75 Favored Glycine 0 C--O 1.2 -2.028 0 C-N-CA 120.892 -0.67 . . . . 0.0 111.698 176.425 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.755 HG21 ' HB ' ' A' ' 126' ' ' ILE . 80.1 t -68.63 -41.59 82.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 123.341 0.656 . . . . 0.0 111.796 -177.691 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.531 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -84.95 -16.47 40.87 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.154 -1.019 . . . . 0.0 112.072 178.727 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 22.7 t -100.6 -59.8 1.64 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.461 0.648 . . . . 0.0 111.692 -174.595 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 63.3 m-20 -86.32 -25.84 25.22 Favored 'General case' 0 CA--C 1.488 -1.426 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.403 -174.14 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.673 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 85.8 m-85 -107.66 160.93 15.32 Favored 'General case' 0 N--CA 1.412 -2.334 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.166 178.933 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.9 t -169.1 139.17 2.23 Favored 'General case' 0 N--CA 1.406 -2.626 0 N-CA-C 106.136 -1.802 . . . . 0.0 106.136 176.483 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.438 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -172.84 -104.23 0.17 Allowed Glycine 0 N--CA 1.411 -3.025 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 175.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.416 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.3 p -162.9 -179.61 6.9 Favored 'General case' 0 C--N 1.311 -1.106 0 C-N-CA 124.088 0.955 . . . . 0.0 110.895 -175.905 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -132.27 145.51 34.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 177.995 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.661 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.5 tttt -122.85 146.4 47.59 Favored 'General case' 0 N--CA 1.419 -2.007 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.443 -179.456 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.491 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 68.8 t80 -145.53 109.68 4.9 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.3 m 54.24 44.08 29.6 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 176.921 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 81.72 7.17 88.42 Favored Glycine 0 C--N 1.31 -0.873 0 C-N-CA 119.901 -1.142 . . . . 0.0 112.914 -179.589 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.661 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 13.0 t -82.08 174.24 11.41 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 178.038 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 21.8 t -153.14 111.75 3.71 Favored 'General case' 0 C--N 1.28 -2.435 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 -179.268 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.491 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 4.7 p90 -154.77 160.5 30.85 Favored Pre-proline 0 CA--C 1.551 1.001 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -174.579 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.427 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 50.0 Cg_endo -68.45 150.0 75.23 Favored 'Trans proline' 0 C--N 1.36 1.144 0 C-N-CA 122.942 2.428 . . . . 0.0 113.496 -176.756 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.607 ' CD2' HD21 ' A' ' 109' ' ' LEU . 53.1 t80 -124.86 133.79 25.1 Favored Pre-proline 0 N--CA 1.441 -0.882 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.777 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.5 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 59.3 Cg_endo -70.25 148.3 87.54 Favored 'Cis proline' 0 CA--C 1.541 0.848 0 C-N-CA 122.682 -1.799 . . . . 0.0 109.747 -2.032 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.4 HG22 ' H ' ' A' ' 61' ' ' GLY . 8.8 t -67.08 -178.23 0.76 Allowed 'General case' 0 CA--C 1.55 0.967 0 CA-C-O 121.972 0.891 . . . . 0.0 111.742 -174.849 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 13.2 p -127.67 -28.68 2.71 Favored 'General case' 0 N--CA 1.425 -1.677 0 CA-C-N 114.929 -1.032 . . . . 0.0 112.931 -169.343 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.7 t -128.1 -79.9 0.58 Allowed 'General case' 0 N--CA 1.432 -1.373 0 C-N-CA 119.086 -1.046 . . . . 0.0 111.726 -176.483 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -170.98 -177.99 2.37 Favored 'General case' 0 C--O 1.246 0.906 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 -179.513 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.441 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 15.6 p -101.54 165.8 13.41 Favored Pre-proline 0 C--N 1.296 -1.758 0 N-CA-C 113.241 0.83 . . . . 0.0 113.241 -179.527 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' PRO . . . . . 0.415 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 36.3 Cg_endo -64.08 158.4 48.13 Favored 'Trans proline' 0 C--N 1.361 1.235 0 C-N-CA 122.784 2.323 . . . . 0.0 111.772 173.083 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.575 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 4.6 tmm_? -72.33 119.38 16.44 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 114.679 -1.146 . . . . 0.0 109.574 -177.843 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 86.0 t -131.77 120.19 44.05 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.723 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.452 HG23 HH11 ' A' ' 92' ' ' ARG . 84.2 t -108.99 126.09 66.04 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.637 179.669 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.569 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 5.5 m-85 -76.65 105.15 7.54 Favored 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 123.816 0.847 . . . . 0.0 109.971 177.563 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 34.2 m-80 -96.34 57.63 1.7 Allowed 'General case' 0 C--N 1.287 -2.144 0 CA-C-O 122.462 1.125 . . . . 0.0 108.783 178.081 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 33.0 m -124.3 174.29 7.82 Favored 'General case' 0 N--CA 1.418 -2.073 0 CA-C-N 113.775 -1.557 . . . . 0.0 109.27 -176.449 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.0 ptp180 -127.93 12.33 6.7 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 112.142 0.423 . . . . 0.0 112.142 -176.727 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.1 t -160.51 -171.77 3.28 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -177.738 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' ASP . . . . . 0.464 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 3.7 p30 -67.79 132.15 46.88 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.076 0.465 . . . . 0.0 109.853 178.661 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 12.5 mmtm -139.75 146.75 48.72 Favored Pre-proline 0 C--N 1.291 -1.945 0 C-N-CA 124.553 1.141 . . . . 0.0 109.034 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -61.61 147.0 96.41 Favored 'Trans proline' 0 C--O 1.25 1.089 0 C-N-CA 123.321 2.681 . . . . 0.0 113.412 -175.113 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' TRP . . . . . 0.569 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 8.6 t90 -92.61 105.61 15.23 Favored Pre-proline 0 C--N 1.31 -1.124 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -74.76 89.11 1.15 Allowed 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 121.983 1.789 . . . . 0.0 112.584 -174.935 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 90.7 t -139.02 143.68 31.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 N-CA-C 107.313 -1.365 . . . . 0.0 107.313 176.32 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.604 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -149.9 136.38 19.09 Favored 'General case' 0 N--CA 1.412 -2.371 0 CA-C-O 120.831 0.348 . . . . 0.0 110.48 178.939 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.453 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 18.4 mt -103.21 100.09 9.98 Favored 'General case' 0 C--N 1.289 -2.06 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.283 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.438 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 55.8 m-85 -80.39 76.48 7.2 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 178.053 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.673 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.1 mm? -102.93 122.6 44.92 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 177.054 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -125.09 147.01 55.65 Favored Pre-proline 0 N--CA 1.41 -2.465 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.154 -173.678 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.478 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 30.7 Cg_endo -61.8 117.82 4.67 Favored 'Trans proline' 0 C--O 1.245 0.864 0 C-N-CA 123.167 2.578 . . . . 0.0 111.768 -177.514 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 70' ' ' ASN . 2.6 m -65.3 -116.28 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.192 -1.934 0 CA-C-N 114.365 -1.289 . . . . 0.0 113.546 177.501 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 17.8 m -111.9 -41.74 3.94 Favored 'General case' 0 C--N 1.287 -2.115 0 O-C-N 121.464 -0.772 . . . . 0.0 110.624 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 5.8 t -93.14 28.27 2.21 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.911 0.862 . . . . 0.0 110.589 -173.713 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -89.62 135.04 33.84 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 178.442 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -172.03 143.57 7.55 Favored Glycine 0 N--CA 1.432 -1.632 0 C-N-CA 120.083 -1.056 . . . . 0.0 111.294 179.497 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' GLY . . . . . 0.407 ' HA2' ' CG1' ' A' ' 155' ' ' VAL . . . 57.24 -147.06 35.65 Favored Glycine 0 CA--C 1.497 -1.091 0 CA-C-O 119.177 -0.791 . . . . 0.0 112.87 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.403 HG11 ' HE3' ' A' ' 121' ' ' LYS . 97.5 t -56.77 99.85 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-O 121.937 0.875 . . . . 0.0 110.867 -179.069 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -100.25 -35.34 9.66 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.966 -178.874 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.547 ' HB ' HG22 ' A' ' 154' ' ' VAL . 69.8 mt -121.72 137.39 55.51 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 178.48 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.423 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.9 mmpt? -111.07 136.46 50.06 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 122.991 0.516 . . . . 0.0 111.212 178.462 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.63 134.51 46.41 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.263 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 86.29 -4.49 85.99 Favored Glycine 0 N--CA 1.442 -0.904 0 N-CA-C 111.709 -0.556 . . . . 0.0 111.709 -179.171 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 37.5 m -96.06 151.01 19.85 Favored 'General case' 0 N--CA 1.427 -1.578 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -178.17 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.454 HD11 HG23 ' A' ' 128' ' ' VAL . 3.3 tm? -77.75 121.3 23.86 Favored 'General case' 0 N--CA 1.427 -1.594 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 -177.533 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.755 ' HB ' HG21 ' A' ' 67' ' ' VAL . 36.7 pt -108.12 -27.18 3.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 CA-C-N 116.157 -0.474 . . . . 0.0 112.139 -178.024 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 127' ' ' ALA . . . . . 0.403 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.75 167.41 25.03 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 110.243 -0.28 . . . . 0.0 110.243 -178.315 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.454 HG23 HD11 ' A' ' 125' ' ' LEU . 64.8 t -142.16 113.61 3.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 179.88 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 63.5 mt -114.64 139.55 49.55 Favored 'General case' 0 C--N 1.289 -2.053 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.662 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.502 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.3 mp -119.13 124.0 72.36 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 119.326 -0.95 . . . . 0.0 110.105 178.435 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.525 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.1 OUTLIER -99.19 131.84 44.94 Favored 'General case' 0 C--N 1.278 -2.52 0 C-N-CA 124.236 1.015 . . . . 0.0 111.033 -176.869 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 132' ' ' ARG . . . . . 0.475 ' HG2' ' HB2' ' A' ' 59' ' ' GLN . 12.5 mmm180 -95.56 125.13 39.94 Favored 'General case' 0 C--N 1.295 -1.802 0 C-N-CA 124.108 0.963 . . . . 0.0 109.481 179.454 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 20.9 mm-40 -107.18 113.12 26.35 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 177.52 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.478 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 26.2 m -136.25 141.85 43.95 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.478 ' CB ' HG23 ' A' ' 52' ' ' ILE . 8.9 p30 . . . . . 0 C--N 1.312 -1.063 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.469 175.475 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 . . . . . 0 CA--C 1.508 -0.667 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -127.01 146.41 50.36 Favored 'General case' 0 N--CA 1.424 -1.757 0 CA-C-O 121.324 0.583 . . . . 0.0 110.891 178.618 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.465 ' HB2' HD22 ' A' ' 131' ' ' LEU . 11.9 m-30 -113.24 135.82 53.41 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 -176.736 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 49.3 t -92.44 130.69 41.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 122.802 0.441 . . . . 0.0 109.837 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 146' ' ' TRP . . . . . 0.525 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 61.8 m95 -119.38 101.08 7.71 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.804 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 48.7 m-80 -79.79 114.65 18.87 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 177.757 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.419 HG22 HD11 ' A' ' 126' ' ' ILE . 26.1 mm -88.05 120.24 36.75 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.947 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 -178.918 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -116.09 150.3 37.56 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.507 179.022 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.8 131.23 35.2 Favored 'General case' 0 N--CA 1.406 -2.636 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 176.517 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -88.93 -16.49 31.7 Favored 'General case' 0 C--N 1.288 -2.081 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -178.027 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -147.29 141.14 25.79 Favored 'General case' 0 N--CA 1.434 -1.249 0 CA-C-N 114.224 -1.353 . . . . 0.0 110.32 -173.423 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -80.84 139.47 35.95 Favored 'General case' 0 C--N 1.311 -1.088 0 O-C-N 124.3 1.0 . . . . 0.0 109.348 178.885 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.547 HG22 ' HB ' ' A' ' 120' ' ' ILE . 2.2 m -120.91 153.29 24.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 120.715 -0.394 . . . . 0.0 110.713 -177.713 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 155' ' ' VAL . . . . . 0.407 ' CG1' ' HA2' ' A' ' 117' ' ' GLY . 2.9 t -124.21 142.47 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.032 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 -178.769 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.464 HG13 ' O ' ' A' ' 28' ' ' VAL . 70.4 t -103.95 102.59 32.51 Favored Pre-proline 0 C--N 1.291 -1.952 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 177.475 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.491 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 20.6 Cg_endo -66.22 -26.92 49.0 Favored 'Trans proline' 0 C--O 1.212 -0.809 0 C-N-CA 122.426 2.084 . . . . 0.0 111.924 177.665 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 158' ' ' THR . . . . . 0.431 ' HB ' HG12 ' A' ' 156' ' ' VAL . 6.6 t . . . . . 0 C--O 1.252 1.23 0 C-N-CA 124.425 1.09 . . . . 0.0 113.229 176.367 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.436 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.435 -1.204 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.495 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 16.4 t -154.83 157.29 37.68 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.772 -0.771 . . . . 0.0 109.436 -176.331 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.648 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.37 161.91 37.79 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-O 121.131 0.491 . . . . 0.0 110.856 -175.195 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 50.5 p -101.56 172.46 6.95 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-O 121.949 0.881 . . . . 0.0 110.426 178.139 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.58 -10.15 59.19 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 113.591 -1.64 . . . . 0.0 111.607 -178.123 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -87.14 -33.24 19.49 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 119.301 -0.96 . . . . 0.0 108.562 176.281 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.55 3.82 3.66 Favored Glycine 0 N--CA 1.441 -1.019 0 C-N-CA 120.139 -1.029 . . . . 0.0 112.702 178.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.9 m -78.48 99.44 6.45 Favored 'General case' 0 N--CA 1.433 -1.306 0 CA-C-N 117.129 0.465 . . . . 0.0 109.886 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -93.47 119.46 32.59 Favored 'General case' 0 N--CA 1.424 -1.764 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 176.347 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.436 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 72.4 mt -85.63 124.84 70.7 Favored Pre-proline 0 C--N 1.285 -2.238 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -77.8 167.0 24.55 Favored 'Trans proline' 0 N--CA 1.448 -1.169 0 C-N-CA 122.673 2.249 . . . . 0.0 110.623 178.226 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 55.3 mt -73.29 125.8 32.88 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 -178.558 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 138.34 7.48 1.26 Allowed Glycine 0 C--N 1.308 -1.013 0 C-N-CA 120.564 -0.826 . . . . 0.0 112.888 -179.026 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.12 142.89 9.17 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 -177.731 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -179.67 -168.37 38.39 Favored Glycine 0 CA--C 1.49 -1.487 0 C-N-CA 120.031 -1.081 . . . . 0.0 111.42 -179.032 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.475 ' HB3' ' HB ' ' A' ' 145' ' ' VAL . 20.4 p -149.6 147.02 27.63 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.23 162.83 31.87 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 179.589 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 26.8 m-80 -114.74 112.32 22.64 Favored 'General case' 0 C--N 1.29 -2.0 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 178.11 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.406 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.8 m -96.04 148.63 5.15 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.231 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 -179.33 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -130.73 130.47 43.84 Favored 'General case' 0 CA--C 1.492 -1.285 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 -179.11 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.616 ' HB ' ' HG2' ' A' ' 41' ' ' GLN . 2.9 p -133.55 132.13 57.37 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.925 0 O-C-N 124.098 0.874 . . . . 0.0 110.572 -176.148 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -92.12 128.37 37.94 Favored 'General case' 0 C--N 1.286 -2.157 0 CA-C-O 121.629 0.728 . . . . 0.0 109.8 177.48 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -106.89 161.32 14.81 Favored 'General case' 0 C--N 1.28 -2.419 0 CA-C-N 114.341 -1.299 . . . . 0.0 108.036 179.634 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.52 121.61 61.76 Favored Pre-proline 0 C--N 1.304 -1.391 0 O-C-N 124.144 0.903 . . . . 0.0 108.779 176.069 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.523 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 64.5 Cg_endo -74.26 -1.16 10.58 Favored 'Trans proline' 0 CA--C 1.531 0.355 0 C-N-CA 122.851 2.368 . . . . 0.0 113.431 -176.818 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.485 HG13 ' HG3' ' A' ' 157' ' ' PRO . 94.9 t -125.92 110.56 24.26 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 176.609 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.525 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.1 t -142.14 106.25 1.43 Allowed 'Isoleucine or valine' 0 C--O 1.182 -2.479 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 -176.551 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.574 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -95.7 150.58 20.22 Favored 'General case' 0 C--N 1.268 -2.972 0 C-N-CA 122.888 0.475 . . . . 0.0 111.617 -179.745 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.567 HG22 ' O ' ' A' ' 112' ' ' VAL . 75.7 t -46.1 118.79 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 123.472 0.709 . . . . 0.0 111.38 176.649 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 105.01 -3.99 41.43 Favored Glycine 0 C--N 1.318 -0.468 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.642 -179.659 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.574 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.6 OUTLIER -68.81 -178.0 1.11 Allowed 'General case' 0 CA--C 1.499 -1.013 0 C-N-CA 124.555 1.142 . . . . 0.0 111.544 178.286 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 66.9 t30 -127.39 87.53 2.65 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 174.877 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.546 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 14.9 tp -96.63 133.95 40.49 Favored 'General case' 0 N--CA 1.405 -2.688 0 C-N-CA 118.852 -1.139 . . . . 0.0 108.029 177.419 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.453 ' CG2' ' HB1' ' A' ' 106' ' ' ALA . 2.0 p -141.19 129.72 23.52 Favored 'Isoleucine or valine' 1 N--CA 1.377 -4.107 0 CA-C-O 122.022 0.915 . . . . 0.0 111.183 -179.666 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.585 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 44.8 t -90.12 89.1 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.385 -3.713 0 CA-C-N 113.081 -1.872 . . . . 0.0 107.159 -178.728 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -75.87 133.31 40.61 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 176.566 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.402 ' HA ' ' OE1' ' A' ' 41' ' ' GLN . 86.9 mt -115.14 11.43 16.34 Favored 'General case' 0 C--N 1.295 -1.779 0 O-C-N 123.838 0.711 . . . . 0.0 111.26 179.225 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.682 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 1.5 m -87.0 1.69 51.98 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 -174.698 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.2 m -120.47 0.68 10.57 Favored 'General case' 0 N--CA 1.394 -3.232 0 CA-C-O 122.168 0.985 . . . . 0.0 108.779 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.616 ' HG2' ' HB ' ' A' ' 22' ' ' VAL . 22.1 mp0 -120.78 -34.22 3.61 Favored 'General case' 0 CA--C 1.473 -1.986 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.285 -172.282 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 23.1 mt -119.56 137.11 54.53 Favored 'Isoleucine or valine' 0 C--N 1.267 -2.981 0 CA-C-N 114.903 -1.044 . . . . 0.0 108.988 -177.45 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.648 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 42.4 m-85 -142.07 124.45 15.67 Favored 'General case' 0 CA--C 1.511 -0.553 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -176.469 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.495 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 81.9 m -106.57 140.17 39.87 Favored 'General case' 0 C--N 1.287 -2.142 0 CA-C-O 121.107 0.48 . . . . 0.0 110.618 -177.882 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' HIS . . . . . 0.461 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 5.1 p80 -124.28 132.85 53.59 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 122.356 1.074 . . . . 0.0 113.433 -174.565 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.46 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 14.8 p-10 -93.15 93.6 8.36 Favored 'General case' 0 C--N 1.279 -2.464 0 CA-C-N 114.299 -1.319 . . . . 0.0 109.46 177.51 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -78.3 -21.04 50.28 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.773 -1.103 . . . . 0.0 111.288 -176.977 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 72.2 m-85 -136.51 70.72 59.96 Favored Pre-proline 0 C--N 1.313 -0.987 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 176.475 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.46 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 56.0 Cg_endo -70.14 -10.98 29.5 Favored 'Trans proline' 0 N--CA 1.483 0.874 0 C-N-CA 122.698 2.266 . . . . 0.0 112.52 -176.205 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -107.32 -17.44 14.14 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-O 121.402 0.62 . . . . 0.0 110.035 -176.102 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.567 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -101.8 -30.71 11.13 Favored 'General case' 0 N--CA 1.414 -2.259 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 -175.818 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.699 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.9 mp -129.05 139.69 51.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.3 t -80.33 147.45 31.09 Favored 'General case' 0 C--O 1.252 1.204 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 178.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -80.73 107.68 13.75 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 -173.295 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.421 ' HE1' ' HG3' ' A' ' 92' ' ' ARG . 75.1 t80 -150.84 145.7 25.86 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.319 -175.31 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.423 HG23 HD13 ' A' ' 131' ' ' LEU . 11.4 p -153.92 152.28 10.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 174.572 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -151.36 138.02 18.79 Favored 'General case' 0 C--O 1.207 -1.149 0 CA-C-O 119.102 -0.475 . . . . 0.0 110.263 174.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.53 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 50.4 tp -76.17 113.14 13.38 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 174.016 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.4 tp-100 -59.52 -51.53 69.47 Favored 'General case' 0 C--N 1.316 -0.878 0 C-N-CA 125.549 1.539 . . . . 0.0 111.102 -179.327 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -172.81 157.11 3.61 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 -177.832 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -131.84 146.71 18.26 Favored Glycine 0 N--CA 1.41 -3.036 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 -178.813 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 69.9 m -130.16 148.89 52.05 Favored 'General case' 0 C--N 1.286 -2.177 0 O-C-N 124.52 0.776 . . . . 0.0 109.666 -178.046 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.512 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -113.53 157.77 21.6 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.512 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 97.5 m-85 -155.18 179.25 9.33 Favored 'General case' 0 C--N 1.345 0.396 0 C-N-CA 124.497 1.119 . . . . 0.0 109.59 -177.376 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 55.13 -145.42 30.47 Favored Glycine 0 C--N 1.331 0.299 0 O-C-N 123.975 0.797 . . . . 0.0 113.475 176.964 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.63 -13.03 74.51 Favored Glycine 0 C--O 1.205 -1.704 0 C-N-CA 120.957 -0.639 . . . . 0.0 111.692 178.263 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.826 HG21 ' HB ' ' A' ' 126' ' ' ILE . 98.6 t -67.21 -42.7 88.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 C-N-CA 123.359 0.663 . . . . 0.0 111.528 -178.234 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.512 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -84.81 -15.13 45.91 Favored 'General case' 0 C--N 1.308 -1.235 0 C-N-CA 119.112 -1.035 . . . . 0.0 112.055 179.531 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 36.5 t -100.31 -59.98 1.61 Allowed 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.851 -174.634 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.537 ' O ' HG22 ' A' ' 112' ' ' VAL . 46.9 m-20 -92.13 -23.95 19.26 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.076 -171.784 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.685 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 88.6 m-85 -106.9 154.83 20.47 Favored 'General case' 0 N--CA 1.42 -1.933 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.399 179.505 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.3 t -162.09 136.49 6.78 Favored 'General case' 0 N--CA 1.407 -2.594 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.68 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.546 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -168.69 -103.43 0.17 Allowed Glycine 0 C--N 1.275 -2.843 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 175.003 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.424 HG22 ' HA ' ' A' ' 83' ' ' PRO . 0.7 OUTLIER -168.22 179.97 4.29 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 124.688 1.195 . . . . 0.0 109.264 -176.337 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.42 ' HB ' ' HB2' ' A' ' 84' ' ' PHE . 2.9 p -129.5 148.23 33.27 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 N-CA-C 109.684 -0.488 . . . . 0.0 109.684 178.643 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.555 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.2 tttt -127.19 144.26 51.08 Favored 'General case' 0 N--CA 1.427 -1.621 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.214 -179.189 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.519 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 58.6 t80 -140.89 104.72 4.74 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.27 -0.877 . . . . 0.0 108.86 -179.106 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 15.5 t 48.58 48.18 19.88 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 124.39 1.076 . . . . 0.0 111.834 177.914 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.59 5.36 69.21 Favored Glycine 0 N--CA 1.441 -0.991 0 CA-C-N 115.497 -0.774 . . . . 0.0 114.219 178.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.555 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 17.8 t -80.08 178.93 7.9 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.911 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 24.3 p -155.89 108.77 2.67 Favored 'General case' 0 C--N 1.293 -1.879 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.439 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.519 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.8 p90 -155.38 158.67 31.98 Favored Pre-proline 0 C--N 1.314 -0.947 0 O-C-N 122.195 -0.316 . . . . 0.0 110.258 -174.223 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.424 ' HA ' HG22 ' A' ' 74' ' ' THR . 43.4 Cg_endo -67.25 147.71 79.02 Favored 'Trans proline' 0 C--N 1.364 1.343 0 C-N-CA 123.28 2.654 . . . . 0.0 113.362 -177.848 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.63 ' CD2' HD21 ' A' ' 109' ' ' LEU . 63.6 t80 -123.13 135.27 25.75 Favored Pre-proline 0 N--CA 1.435 -1.201 0 CA-C-N 115.615 -0.72 . . . . 0.0 109.817 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.498 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 73.9 Cg_endo -72.59 145.22 83.1 Favored 'Cis proline' 0 CA--C 1.541 0.832 0 C-N-CA 123.144 -1.607 . . . . 0.0 110.411 -3.692 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.1 t -69.81 -177.02 1.18 Allowed 'General case' 0 CA--C 1.553 1.085 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.453 -176.12 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 39.4 p -122.61 -34.97 3.15 Favored 'General case' 0 N--CA 1.439 -0.994 0 CA-C-O 121.431 0.634 . . . . 0.0 110.354 -170.072 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.0 t -126.83 -131.46 0.24 Allowed 'General case' 0 N--CA 1.389 -3.492 0 N-CA-C 104.416 -2.438 . . . . 0.0 104.416 174.798 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -113.64 -169.86 1.59 Allowed 'General case' 0 C--N 1.286 -2.169 0 N-CA-C 113.05 0.759 . . . . 0.0 113.05 -173.19 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.53 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 35.0 p -97.49 170.52 7.09 Favored Pre-proline 0 C--N 1.31 -1.114 0 CA-C-N 115.439 -0.8 . . . . 0.0 111.843 178.601 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' PRO . . . . . 0.452 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 37.2 Cg_endo -65.4 166.39 19.59 Favored 'Trans proline' 0 C--O 1.251 1.148 0 C-N-CA 122.277 1.985 . . . . 0.0 109.707 170.044 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.421 ' HG3' ' HE1' ' A' ' 55' ' ' TYR . 47.7 ttp180 -73.32 140.12 46.52 Favored 'General case' 0 C--N 1.308 -1.212 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.768 -179.356 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 56.2 t -141.07 120.61 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.898 0 CA-C-N 114.925 -1.034 . . . . 0.0 109.314 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 70.8 t -95.39 140.51 16.79 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.896 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 175.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -87.85 100.75 13.11 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 175.412 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 17.4 m120 -89.11 60.27 5.31 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.649 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.6 m -135.3 178.3 7.14 Favored 'General case' 0 N--CA 1.425 -1.716 0 CA-C-N 114.44 -1.254 . . . . 0.0 109.076 -174.385 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 16.9 ptp180 -148.81 45.01 1.01 Allowed 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 122.007 0.908 . . . . 0.0 109.462 175.863 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.3 t -170.58 -175.36 1.84 Allowed 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 -176.842 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' ASP . . . . . 0.461 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 9.2 p-10 -77.06 99.0 5.18 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-O 122.153 0.977 . . . . 0.0 108.398 172.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' LYS . . . . . 0.404 ' HG3' ' HD2' ' A' ' 102' ' ' PRO . 2.8 tptm -101.04 136.17 19.79 Favored Pre-proline 0 N--CA 1.405 -2.724 0 CA-C-N 114.939 -1.028 . . . . 0.0 108.233 -177.851 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.682 ' HB3' ' O ' ' A' ' 39' ' ' SER . 80.0 Cg_exo -48.43 139.66 22.31 Favored 'Trans proline' 0 C--N 1.324 -0.752 0 C-N-CA 123.939 3.093 . . . . 0.0 113.658 177.383 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.5 t90 -90.11 105.69 12.17 Favored Pre-proline 0 C--N 1.31 -1.146 0 N-CA-C 106.754 -1.573 . . . . 0.0 106.754 -178.888 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -73.78 89.27 1.0 Allowed 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.293 1.995 . . . . 0.0 112.686 -173.464 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.48 HG22 ' CD2' ' A' ' 77' ' ' TYR . 90.1 t -136.31 145.2 31.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 177.939 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.585 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.96 133.08 15.28 Favored 'General case' 0 N--CA 1.417 -2.078 0 CA-C-O 121.06 0.457 . . . . 0.0 110.766 178.071 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.475 HD21 HD11 ' A' ' 129' ' ' LEU . 14.2 mt -101.93 100.12 10.39 Favored 'General case' 0 C--N 1.288 -2.086 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 179.03 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.546 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 63.1 m-85 -77.38 78.24 3.91 Favored 'General case' 0 C--N 1.306 -1.298 0 O-C-N 122.067 -0.395 . . . . 0.0 110.255 177.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.685 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.0 mm? -104.56 118.24 36.11 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-O 121.167 0.508 . . . . 0.0 110.066 176.732 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.79 145.93 46.75 Favored Pre-proline 0 N--CA 1.414 -2.238 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.889 -173.628 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -63.43 121.61 9.47 Favored 'Trans proline' 0 CA--C 1.5 -1.195 0 C-N-CA 122.986 2.457 . . . . 0.0 113.57 -175.23 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.567 ' O ' HG22 ' A' ' 30' ' ' VAL . 19.8 m -82.0 -155.27 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.399 -3.0 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.108 171.498 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 8.5 m -79.73 -29.92 40.73 Favored 'General case' 0 C--N 1.257 -3.447 0 CA-C-O 121.515 0.674 . . . . 0.0 110.721 -167.799 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 5.3 t -91.47 25.5 2.6 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-O 121.664 0.745 . . . . 0.0 110.514 -176.977 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.419 ' HB1' HG21 ' A' ' 156' ' ' VAL . . . -102.83 128.74 49.47 Favored 'General case' 0 N--CA 1.418 -2.061 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.883 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.99 128.88 1.72 Allowed Glycine 0 C--N 1.307 -1.048 0 C-N-CA 120.151 -1.023 . . . . 0.0 111.765 -178.913 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.24 -152.71 52.81 Favored Glycine 0 CA--C 1.493 -1.343 0 CA-C-O 118.925 -0.931 . . . . 0.0 111.532 -176.879 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 63.4 t -55.85 106.04 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.246 0.914 0 CA-C-O 121.586 0.708 . . . . 0.0 110.79 -177.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -106.27 -33.07 7.91 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 114.535 -1.211 . . . . 0.0 110.622 -178.871 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.499 ' HB ' HG22 ' A' ' 154' ' ' VAL . 74.8 mt -121.54 139.91 47.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 177.526 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.421 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.8 mmpt? -115.47 136.41 53.11 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 123.138 0.575 . . . . 0.0 110.973 178.547 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -72.13 131.11 42.37 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.709 178.821 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 92.29 -5.3 77.93 Favored Glycine 0 C--N 1.309 -0.953 0 N-CA-C 111.561 -0.616 . . . . 0.0 111.561 -178.463 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 61.3 m -98.4 149.04 23.08 Favored 'General case' 0 N--CA 1.425 -1.719 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 179.556 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 26.6 tp -72.69 138.19 46.45 Favored 'General case' 0 N--CA 1.433 -1.31 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.14 178.695 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.826 ' HB ' HG21 ' A' ' 67' ' ' VAL . 34.4 pt -121.27 -27.08 2.02 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 N-CA-C 112.392 0.516 . . . . 0.0 112.392 178.708 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.93 168.79 20.68 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -177.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 75.1 t -143.55 116.18 3.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 179.176 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.475 HD11 HD21 ' A' ' 107' ' ' LEU . 63.4 mt -117.37 154.46 31.27 Favored 'General case' 0 C--N 1.283 -2.297 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 179.173 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.494 ' O ' HD12 ' A' ' 58' ' ' LEU . 5.0 mp -135.73 127.69 45.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.821 -0.549 . . . . 0.0 109.704 177.623 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.454 ' C ' HD12 ' A' ' 131' ' ' LEU . 1.2 pp -89.34 150.18 22.69 Favored 'General case' 0 CA--C 1.484 -1.592 0 N-CA-C 106.673 -1.602 . . . . 0.0 106.673 173.693 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 54.5 ttp180 -115.71 120.93 40.95 Favored 'General case' 0 C--N 1.269 -2.917 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 176.862 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 21.9 tp60 -93.96 121.22 35.2 Favored 'General case' 0 N--CA 1.422 -1.83 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -175.076 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 27.7 m -133.47 149.78 51.74 Favored 'General case' 0 C--N 1.292 -1.92 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 174.6 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.699 ' CB ' HG23 ' A' ' 52' ' ' ILE . 8.0 p30 . . . . . 0 C--O 1.213 -0.866 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.59 175.723 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 . . . . . 0 N--CA 1.421 -1.888 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -131.37 144.23 51.07 Favored 'General case' 0 N--CA 1.407 -2.6 0 C-N-CA 118.416 -1.314 . . . . 0.0 110.963 179.249 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 11.0 m-30 -110.7 125.92 53.99 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 -176.367 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.475 ' HB ' ' HB3' ' A' ' 17' ' ' SER . 48.7 t -88.22 134.44 28.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 CA-C-O 121.076 0.465 . . . . 0.0 110.196 -178.549 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 65.8 m95 -120.79 94.39 4.34 Favored 'General case' 0 C--N 1.285 -2.239 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -179.209 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -78.72 114.95 18.08 Favored 'General case' 0 C--N 1.286 -2.19 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 178.53 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.406 ' HA ' HG22 ' A' ' 20' ' ' VAL . 18.3 mm -90.18 120.33 38.81 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 -176.548 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -117.52 155.08 30.38 Favored 'General case' 0 CA--C 1.488 -1.405 0 CA-C-O 121.324 0.583 . . . . 0.0 109.919 177.977 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.54 131.21 35.22 Favored 'General case' 0 N--CA 1.407 -2.606 0 CA-C-N 115.01 -0.995 . . . . 0.0 108.82 176.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -91.32 -13.35 32.75 Favored 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 -177.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -152.01 145.72 25.03 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 114.169 -1.378 . . . . 0.0 109.67 -175.389 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -84.44 144.89 28.47 Favored 'General case' 0 C--N 1.319 -0.739 0 O-C-N 124.317 1.011 . . . . 0.0 109.195 -178.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.523 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 1.5 m -125.21 148.96 29.6 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.9 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 9.3 t -124.66 138.32 54.45 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 N-CA-C 107.686 -1.228 . . . . 0.0 107.686 -178.629 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.525 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 81.5 t -100.04 101.8 15.53 Favored Pre-proline 0 C--N 1.292 -1.892 0 C-N-CA 123.677 0.791 . . . . 0.0 109.982 179.368 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.485 ' HG3' HG13 ' A' ' 27' ' ' VAL . 35.2 Cg_endo -70.12 -23.52 29.07 Favored 'Trans proline' 0 CA--C 1.509 -0.749 0 C-N-CA 122.319 2.013 . . . . 0.0 111.801 178.62 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.1 t . . . . . 0 C--O 1.248 0.99 0 O-C-N 124.716 1.26 . . . . 0.0 112.404 179.359 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.438 -1.046 0 N-CA-C 102.837 -3.023 . . . . 0.0 102.837 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.483 ' HB3' ' CZ2' ' A' ' 146' ' ' TRP . 11.5 t -150.5 158.32 44.02 Favored 'General case' 0 C--N 1.283 -2.318 0 C-N-CA 117.232 -1.787 . . . . 0.0 111.081 -174.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.435 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.26 160.88 40.24 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 121.474 0.654 . . . . 0.0 110.713 -175.816 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.583 HG22 HG22 ' A' ' 20' ' ' VAL . 57.2 p -97.68 178.73 5.07 Favored 'General case' 0 C--N 1.293 -1.888 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.648 -179.666 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -82.04 -21.01 37.16 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.712 178.514 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -87.09 -29.07 22.15 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.997 -176.224 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.16 7.52 2.85 Favored Glycine 0 C--N 1.307 -1.073 0 C-N-CA 119.222 -1.466 . . . . 0.0 114.34 171.308 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.0 m -86.94 101.09 13.09 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 177.216 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -97.06 119.92 36.46 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-N 115.484 -0.78 . . . . 0.0 108.945 176.025 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 50.9 mt -97.7 116.46 65.77 Favored Pre-proline 0 C--N 1.297 -1.7 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.564 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -79.42 176.75 9.31 Favored 'Trans proline' 0 C--O 1.25 1.075 0 C-N-CA 122.653 2.236 . . . . 0.0 110.387 177.331 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 56.7 mt -72.04 125.35 30.52 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.343 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 177.669 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 149.22 -6.45 0.81 Allowed Glycine 0 C--N 1.299 -1.48 0 CA-C-N 115.6 -0.727 . . . . 0.0 112.001 -176.482 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.17 156.77 33.06 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 120.709 -0.758 . . . . 0.0 111.373 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.34 -165.83 34.0 Favored Glycine 0 N--CA 1.419 -2.456 0 C-N-CA 119.818 -1.182 . . . . 0.0 111.604 178.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 145' ' ' VAL . 59.8 p -145.7 155.17 42.81 Favored 'General case' 0 N--CA 1.417 -2.077 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 -177.923 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.81 155.64 50.03 Favored 'General case' 0 N--CA 1.416 -2.151 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 177.284 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -105.01 109.97 22.18 Favored 'General case' 0 C--N 1.279 -2.459 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 174.778 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.583 HG22 HG22 ' A' ' 5' ' ' THR . 34.2 t -97.33 135.52 31.33 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -177.933 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 77.7 m-85 -116.62 126.82 53.8 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -178.547 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.524 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.5 p -135.54 129.45 49.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.195 -176.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ASN . . . . . 0.416 ' HB3' ' HB3' ' A' ' 151' ' ' ASN . 8.0 p30 -94.52 126.02 39.53 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-O 121.683 0.754 . . . . 0.0 110.423 178.197 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -103.44 162.59 12.9 Favored 'General case' 0 C--N 1.286 -2.157 0 CA-C-N 114.278 -1.328 . . . . 0.0 108.019 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ALA . . . . . 0.407 ' C ' ' H ' ' A' ' 27' ' ' VAL . . . -54.48 126.07 54.39 Favored Pre-proline 0 CA--C 1.499 -0.998 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 174.722 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.529 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 72.7 Cg_endo -77.44 9.77 2.74 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 122.484 2.123 . . . . 0.0 110.925 179.2 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.407 ' H ' ' C ' ' A' ' 25' ' ' ALA . 14.1 p -138.35 115.97 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.916 0 CA-C-N 114.827 -1.079 . . . . 0.0 108.365 -178.316 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.4 t -150.02 120.05 1.06 Allowed 'Isoleucine or valine' 0 C--O 1.191 -1.985 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 -179.006 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.589 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -107.24 147.85 29.67 Favored 'General case' 0 C--N 1.267 -2.999 0 C-N-CA 122.505 0.322 . . . . 0.0 110.76 -179.973 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.532 HG22 ' O ' ' A' ' 112' ' ' VAL . 98.7 t -43.67 117.35 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 123.329 0.652 . . . . 0.0 111.539 176.845 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.56 -1.72 42.57 Favored Glycine 0 C--N 1.319 -0.396 0 CA-C-N 114.779 -1.101 . . . . 0.0 112.809 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.589 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.6 OUTLIER -73.35 -176.69 2.31 Favored 'General case' 0 C--N 1.315 -0.896 0 C-N-CA 124.011 0.924 . . . . 0.0 110.775 177.37 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 66.8 t30 -129.5 83.35 2.13 Favored 'General case' 0 CA--C 1.49 -1.327 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.238 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.562 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 19.1 tp -90.72 133.23 35.31 Favored 'General case' 0 N--CA 1.419 -1.977 0 C-N-CA 119.151 -1.019 . . . . 0.0 108.516 178.904 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.447 ' CG2' ' HB1' ' A' ' 106' ' ' ALA . 2.2 p -141.44 133.92 29.22 Favored 'Isoleucine or valine' 0 N--CA 1.383 -3.792 0 CA-C-O 121.882 0.848 . . . . 0.0 111.728 -178.572 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.62 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 45.6 t -89.2 89.92 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.52 0 CA-C-N 113.732 -1.577 . . . . 0.0 108.333 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -76.53 109.72 10.49 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 120.876 0.37 . . . . 0.0 110.89 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 93.0 mt -92.29 -1.54 57.01 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 115.905 -0.588 . . . . 0.0 112.549 -178.698 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 89.9 p -76.81 1.08 18.41 Favored 'General case' 0 N--CA 1.474 0.762 0 CA-C-O 123.0 1.381 . . . . 0.0 109.754 -179.649 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.7 p -123.92 6.64 8.66 Favored 'General case' 0 C--N 1.276 -2.628 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.881 179.184 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.524 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 42.4 mm-40 -127.14 -25.14 3.31 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.604 -175.232 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 23.1 mt -132.64 137.44 54.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 -175.916 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.435 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 40.4 m-85 -140.65 123.41 16.28 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -176.305 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.425 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 79.7 m -103.71 142.9 33.54 Favored 'General case' 0 C--N 1.271 -2.82 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 -178.729 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' HIS . . . . . 0.437 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 10.1 p80 -136.75 168.06 20.26 Favored 'General case' 0 C--N 1.294 -1.836 0 CA-C-O 121.335 0.588 . . . . 0.0 110.787 -172.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.455 ' HB3' ' OD1' ' A' ' 54' ' ' ASP . 5.4 p30 -112.41 100.0 8.43 Favored 'General case' 0 C--N 1.281 -2.383 0 CA-C-O 122.2 1.0 . . . . 0.0 111.814 175.566 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -76.26 -31.21 58.17 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 178.192 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.47 ' HB3' ' OG1' ' A' ' 51' ' ' THR . 23.2 m-85 -127.88 87.97 54.4 Favored Pre-proline 0 N--CA 1.435 -1.22 0 N-CA-C 106.004 -1.851 . . . . 0.0 106.004 177.883 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -88.59 -13.34 3.4 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 122.319 2.013 . . . . 0.0 113.976 -176.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -110.92 -12.35 14.25 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.622 -0.831 . . . . 0.0 110.756 -176.116 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.47 ' OG1' ' HB3' ' A' ' 48' ' ' TYR . 0.0 OUTLIER -101.4 -31.36 10.97 Favored 'General case' 0 N--CA 1.417 -2.115 0 CA-C-N 115.406 -0.815 . . . . 0.0 110.194 179.771 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.634 HG23 ' CB ' ' A' ' 135' ' ' ASN . 3.1 mp -121.9 126.54 74.67 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.592 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.6 t -72.75 135.06 45.25 Favored 'General case' 0 N--CA 1.421 -1.901 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 174.602 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.455 ' OD1' ' HB3' ' A' ' 46' ' ' ASN . 58.7 m-20 -87.06 107.6 18.51 Favored 'General case' 0 C--N 1.278 -2.506 0 CA-C-O 121.939 0.876 . . . . 0.0 111.343 -171.093 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 70.4 t80 -137.91 145.8 42.54 Favored 'General case' 0 C--N 1.29 -1.997 0 CA-C-N 114.078 -1.419 . . . . 0.0 108.058 -175.904 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.433 HG23 HD13 ' A' ' 131' ' ' LEU . 11.9 p -152.25 148.38 14.39 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.786 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.309 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -151.34 140.37 21.09 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 174.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.573 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 50.5 tp -75.19 117.76 17.37 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 173.346 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.514 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 3.6 tp-100 -65.54 -44.92 85.35 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.456 -1.247 . . . . 0.0 110.458 -177.851 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.514 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 10.4 ptp180 -176.97 161.87 1.99 Allowed 'General case' 0 N--CA 1.432 -1.34 0 O-C-N 124.708 1.255 . . . . 0.0 108.423 -176.407 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.405 ' H ' HG22 ' A' ' 86' ' ' THR . . . -143.08 129.53 3.8 Favored Glycine 0 N--CA 1.408 -3.174 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -178.302 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 54.2 m -117.35 149.38 40.59 Favored 'General case' 0 C--N 1.291 -1.944 0 C-N-CA 124.099 0.96 . . . . 0.0 110.461 -174.801 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.522 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -113.37 156.16 23.93 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.497 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 88.4 m-85 -154.6 -179.92 8.44 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 124.155 0.982 . . . . 0.0 108.867 -178.407 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 57.79 -143.56 42.39 Favored Glycine 0 C--N 1.325 -0.081 0 O-C-N 123.891 0.744 . . . . 0.0 113.513 176.13 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -72.97 -14.23 78.78 Favored Glycine 0 C--O 1.209 -1.468 0 C-N-CA 120.846 -0.693 . . . . 0.0 111.717 177.565 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.78 HG21 ' HB ' ' A' ' 126' ' ' ILE . 95.2 t -67.59 -39.37 82.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 123.804 0.842 . . . . 0.0 111.606 -177.717 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.522 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -87.1 -19.03 29.13 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 118.67 -1.212 . . . . 0.0 112.192 178.027 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 6.2 t -98.36 -56.58 2.43 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.537 -172.5 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.491 ' O ' HG22 ' A' ' 112' ' ' VAL . 41.3 m-20 -92.03 -22.97 19.67 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.24 -173.894 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.656 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 92.0 m-85 -108.73 156.93 19.03 Favored 'General case' 0 N--CA 1.419 -1.999 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.489 178.598 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 12.7 t -161.38 136.41 7.46 Favored 'General case' 0 N--CA 1.403 -2.787 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 176.801 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.498 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.97 -111.67 0.26 Allowed Glycine 0 N--CA 1.398 -3.893 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 174.19 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.2 p -159.66 -179.92 8.3 Favored 'General case' 0 C--N 1.297 -1.684 0 C-N-CA 124.001 0.92 . . . . 0.0 110.425 -172.743 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -132.1 145.9 34.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 178.202 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.673 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.2 tttt -126.58 145.45 50.53 Favored 'General case' 0 N--CA 1.427 -1.585 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -178.189 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.532 ' CD2' HG22 ' A' ' 105' ' ' VAL . 58.9 t80 -145.63 110.69 5.23 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 -177.691 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 44.9 t 53.27 37.08 24.36 Favored 'General case' 0 CA--C 1.55 0.963 0 C-N-CA 123.35 0.66 . . . . 0.0 111.982 178.04 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.32 8.54 66.2 Favored Glycine 0 CA--C 1.525 0.698 0 C-N-CA 120.301 -0.952 . . . . 0.0 113.663 -179.384 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.673 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 20.8 t -81.59 -179.79 7.52 Favored 'General case' 0 CA--C 1.544 0.735 0 CA-C-N 117.383 0.592 . . . . 0.0 109.51 178.412 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.0 p -156.78 109.22 2.51 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.418 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.3 p90 -151.89 158.71 33.84 Favored Pre-proline 0 C--N 1.306 -1.323 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 -175.52 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -68.73 150.94 74.69 Favored 'Trans proline' 0 C--N 1.354 0.817 0 C-N-CA 122.879 2.386 . . . . 0.0 113.096 -176.471 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.592 ' CD2' HD21 ' A' ' 109' ' ' LEU . 54.0 t80 -124.46 132.15 24.26 Favored Pre-proline 0 N--CA 1.442 -0.867 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.219 -179.684 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.468 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 72.4 Cg_endo -72.53 148.2 90.99 Favored 'Cis proline' 0 CA--C 1.535 0.558 0 C-N-CA 122.8 -1.75 . . . . 0.0 109.984 -0.873 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.405 HG22 ' H ' ' A' ' 61' ' ' GLY . 9.0 t -67.09 -177.49 0.66 Allowed 'General case' 0 C--O 1.248 1.017 0 CA-C-O 121.367 0.603 . . . . 0.0 111.29 -175.499 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.8 p -120.7 -25.13 5.55 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 115.286 -0.87 . . . . 0.0 110.647 -173.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 t -135.38 -107.95 0.21 Allowed 'General case' 0 N--CA 1.419 -1.985 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 178.555 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' GLU . . . . . 0.425 ' HB2' ' O ' ' A' ' 58' ' ' LEU . 0.0 OUTLIER -144.44 -165.66 2.19 Favored 'General case' 0 N--CA 1.445 -0.723 0 CA-C-N 118.251 0.478 . . . . 0.0 110.749 -177.508 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.573 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 58.3 p -100.26 168.16 9.83 Favored Pre-proline 0 C--N 1.306 -1.286 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 179.55 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' PRO . . . . . 0.407 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 34.4 Cg_endo -63.62 172.26 5.88 Favored 'Trans proline' 0 C--O 1.251 1.139 0 C-N-CA 123.062 2.508 . . . . 0.0 110.48 170.02 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 41.2 ttp180 -71.49 142.32 50.16 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.12 -177.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 64.0 t -151.16 131.57 4.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 124.355 1.062 . . . . 0.0 108.427 -179.048 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 54' ' ' ASP . 2.2 p -128.93 141.46 46.55 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 108.253 -1.018 . . . . 0.0 108.253 -178.729 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -92.99 108.33 19.92 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-O 121.251 0.548 . . . . 0.0 111.234 -178.745 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -94.38 45.97 1.14 Allowed 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.6 t -124.03 -176.57 3.52 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 -175.77 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 37.8 ptt180 -148.14 33.78 0.82 Allowed 'General case' 0 C--N 1.314 -0.948 0 CA-C-O 121.879 0.847 . . . . 0.0 109.619 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.1 t -165.58 -178.97 5.16 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 -178.52 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' ASP . . . . . 0.437 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 3.7 p30 -77.12 130.15 36.97 Favored 'General case' 0 CA--C 1.501 -0.928 0 CA-C-O 121.515 0.674 . . . . 0.0 109.956 -179.748 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 15.8 mmtm -129.72 141.35 41.52 Favored Pre-proline 0 C--N 1.287 -2.137 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.08 -179.558 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -61.53 137.58 70.31 Favored 'Trans proline' 0 CA--C 1.499 -1.246 0 C-N-CA 123.571 2.847 . . . . 0.0 112.7 -174.919 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.6 t90 -81.5 108.58 11.22 Favored Pre-proline 0 C--N 1.304 -1.409 0 N-CA-C 106.393 -1.706 . . . . 0.0 106.393 -177.479 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -76.22 87.69 1.41 Allowed 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 121.231 1.287 . . . . 0.0 112.718 -172.045 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.532 HG22 ' CD2' ' A' ' 77' ' ' TYR . 57.6 t -137.83 146.53 27.18 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.203 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 177.544 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.62 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.38 134.73 16.09 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 177.446 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.469 HD21 HD11 ' A' ' 129' ' ' LEU . 16.7 mt -102.87 99.95 9.9 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.443 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.498 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 71.5 m-85 -78.36 81.36 4.71 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 177.513 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.656 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.1 mm? -107.1 118.6 37.13 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 176.366 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -120.99 148.41 48.72 Favored Pre-proline 0 N--CA 1.41 -2.448 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.253 -173.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -66.13 120.96 8.18 Favored 'Trans proline' 0 N--CA 1.44 -1.646 0 C-N-CA 122.892 2.395 . . . . 0.0 113.47 -175.055 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.532 ' O ' HG22 ' A' ' 30' ' ' VAL . 21.7 m -81.03 -157.29 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.393 -3.297 0 CA-C-N 114.49 -1.232 . . . . 0.0 108.814 170.75 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 30.9 m -82.96 -26.47 31.34 Favored 'General case' 0 C--N 1.252 -3.645 0 CA-C-O 121.699 0.761 . . . . 0.0 110.912 -170.127 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 19.6 t -83.36 13.64 4.21 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.197 -0.911 . . . . 0.0 110.189 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -98.3 125.31 43.35 Favored 'General case' 0 N--CA 1.428 -1.557 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.569 179.352 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -168.67 129.74 1.94 Allowed Glycine 0 N--CA 1.431 -1.642 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 178.687 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.71 -148.8 49.94 Favored Glycine 0 CA--C 1.493 -1.322 0 CA-C-O 119.232 -0.76 . . . . 0.0 111.883 -177.81 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.451 ' CG1' ' HE3' ' A' ' 121' ' ' LYS . 65.9 t -60.04 101.66 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.248 0.991 0 CA-C-O 122.078 0.942 . . . . 0.0 111.117 -176.435 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -101.57 -23.11 14.34 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 114.137 -1.392 . . . . 0.0 111.498 -177.709 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.459 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 61.8 mt -136.7 141.21 41.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.68 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.548 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.6 mmpt? -116.2 141.31 48.31 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 120.843 0.354 . . . . 0.0 110.347 177.006 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 0.4 ' H ' ' HB3' ' A' ' 153' ' ' ASP . . . -69.06 148.07 50.58 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.725 179.667 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 71.78 14.37 75.49 Favored Glycine 0 C--O 1.218 -0.845 0 CA-C-N 115.828 -0.623 . . . . 0.0 111.555 178.911 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 20.0 m -119.08 143.4 47.16 Favored 'General case' 0 N--CA 1.421 -1.891 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -175.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -68.6 127.05 31.61 Favored 'General case' 0 C--O 1.242 0.659 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.167 -178.032 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.78 ' HB ' HG21 ' A' ' 67' ' ' VAL . 27.9 pt -115.9 -26.91 2.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 127' ' ' ALA . . . . . 0.411 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -159.92 168.13 26.42 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -178.041 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 65.7 t -142.64 114.06 3.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.443 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.469 HD11 HD21 ' A' ' 107' ' ' LEU . 56.8 mt -115.43 155.76 26.85 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 178.3 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.523 ' O ' HD12 ' A' ' 58' ' ' LEU . 5.1 mp -135.68 131.13 50.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 CA-C-N 118.52 0.6 . . . . 0.0 109.751 177.733 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.433 HD13 HG23 ' A' ' 56' ' ' VAL . 1.8 pp -92.58 139.79 30.21 Favored 'General case' 0 CA--C 1.489 -1.399 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 172.624 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 27.1 tpt180 -97.31 108.0 20.64 Favored 'General case' 0 C--N 1.251 -3.714 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 5.2 tp-100 -87.67 118.6 27.27 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -177.825 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 22.2 m -137.03 140.52 42.14 Favored 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 173.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.634 ' CB ' HG23 ' A' ' 52' ' ' ILE . 10.8 p30 . . . . . 0 N--CA 1.444 -0.751 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.899 178.008 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 . . . . . 0 N--CA 1.425 -1.723 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -141.86 149.46 40.3 Favored 'General case' 0 C--N 1.282 -2.366 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 176.918 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 9.7 m-30 -109.26 125.25 52.07 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 -174.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 17' ' ' SER . 48.2 t -89.27 135.52 25.75 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.926 0 O-C-N 123.749 0.656 . . . . 0.0 110.074 -178.209 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 146' ' ' TRP . . . . . 0.483 ' CZ2' ' HB3' ' A' ' 3' ' ' CYS . 61.6 m95 -120.38 96.26 5.07 Favored 'General case' 0 C--N 1.284 -2.246 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 -179.317 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 37.3 m-80 -80.58 112.83 18.31 Favored 'General case' 0 C--N 1.291 -1.946 0 N-CA-C 106.587 -1.634 . . . . 0.0 106.587 179.784 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.433 HG22 HD11 ' A' ' 126' ' ' ILE . 28.1 mm -87.48 122.83 39.72 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -176.193 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -117.12 151.9 35.85 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 123.786 0.834 . . . . 0.0 109.442 178.464 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.68 130.21 34.98 Favored 'General case' 0 N--CA 1.413 -2.318 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 176.064 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 151' ' ' ASN . . . . . 0.416 ' HB3' ' HB3' ' A' ' 23' ' ' ASN . 39.6 t-20 -89.12 -17.52 29.05 Favored 'General case' 0 C--N 1.288 -2.068 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 -178.831 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -147.17 143.04 27.93 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-N 114.418 -1.265 . . . . 0.0 109.462 -174.477 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 153' ' ' ASP . . . . . 0.4 ' HB3' ' H ' ' A' ' 122' ' ' ALA . 12.8 p-10 -86.07 138.66 31.78 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 124.083 0.865 . . . . 0.0 111.477 -178.733 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.529 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.8 t -114.44 137.82 46.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 114.946 -1.025 . . . . 0.0 112.334 -171.875 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -117.79 138.28 48.99 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.351 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 177.494 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.471 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 53.2 t -101.89 103.66 30.52 Favored Pre-proline 0 C--N 1.29 -1.979 0 C-N-CA 123.618 0.767 . . . . 0.0 109.756 178.84 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.453 ' HD2' ' O ' ' A' ' 28' ' ' VAL . 30.8 Cg_endo -68.08 -26.11 37.17 Favored 'Trans proline' 0 CA--C 1.506 -0.908 0 C-N-CA 122.429 2.086 . . . . 0.0 111.878 177.295 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.4 t . . . . . 0 C--N 1.349 0.578 0 O-C-N 124.748 1.28 . . . . 0.0 112.33 179.233 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.479 ' HB3' ' NE2' ' A' ' 45' ' ' HIS . . . . . . . . 0 CA--C 1.492 -1.258 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.418 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 63.1 m -134.39 155.41 50.34 Favored 'General case' 0 C--N 1.288 -2.071 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.786 -174.105 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.5 155.52 43.15 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-O 121.223 0.535 . . . . 0.0 109.917 -176.333 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.602 HG22 HG22 ' A' ' 20' ' ' VAL . 72.9 p -92.25 175.01 7.01 Favored 'General case' 0 C--N 1.292 -1.922 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.77 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -85.61 -11.49 53.81 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.278 -1.328 . . . . 0.0 109.716 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -95.21 -27.35 15.57 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-N 115.138 -0.937 . . . . 0.0 111.751 -178.279 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 136.64 1.04 2.8 Favored Glycine 0 C--O 1.222 -0.621 0 C-N-CA 119.155 -1.498 . . . . 0.0 114.845 169.445 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.2 m -87.86 105.94 17.76 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 121.455 0.645 . . . . 0.0 109.579 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -98.99 119.55 37.97 Favored 'General case' 0 C--N 1.291 -1.953 0 CA-C-N 114.735 -1.12 . . . . 0.0 109.224 176.402 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.435 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 60.0 mt -100.36 114.66 65.79 Favored Pre-proline 0 C--N 1.303 -1.429 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.102 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_endo -76.59 171.87 17.26 Favored 'Trans proline' 0 C--O 1.249 1.037 0 C-N-CA 122.385 2.057 . . . . 0.0 111.354 177.262 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 68.4 mt -58.06 134.03 22.85 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.967 179.031 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 128.59 2.75 5.74 Favored Glycine 0 C--N 1.303 -1.257 0 C-N-CA 120.344 -0.931 . . . . 0.0 112.466 179.461 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.04 164.89 34.82 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.13 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.74 -166.51 34.44 Favored Glycine 0 C--N 1.295 -1.743 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.701 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.1 p -141.24 154.33 45.72 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -178.903 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -143.37 159.38 42.48 Favored 'General case' 0 N--CA 1.421 -1.88 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.36 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -103.22 122.87 45.65 Favored 'General case' 0 C--N 1.275 -2.67 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 173.839 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.602 HG22 HG22 ' A' ' 5' ' ' THR . 40.3 t -106.81 129.71 59.95 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.76 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.737 177.826 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 -112.88 121.17 43.88 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 120.982 0.42 . . . . 0.0 111.23 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.589 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.3 p -133.92 130.24 55.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-N 115.318 -0.856 . . . . 0.0 111.164 -178.667 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -92.25 130.83 37.85 Favored 'General case' 0 C--N 1.296 -1.758 0 CA-C-O 121.37 0.605 . . . . 0.0 110.429 177.915 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.683 HD21 HG22 ' A' ' 36' ' ' VAL . 6.9 mp -109.18 161.85 14.83 Favored 'General case' 0 C--N 1.287 -2.118 0 CA-C-N 114.489 -1.232 . . . . 0.0 108.877 179.454 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.01 121.1 48.17 Favored Pre-proline 0 C--O 1.209 -1.06 0 O-C-N 124.777 1.298 . . . . 0.0 109.486 179.177 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.511 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 66.1 Cg_endo -75.7 -0.91 10.72 Favored 'Trans proline' 0 CA--C 1.531 0.332 0 C-N-CA 122.906 2.404 . . . . 0.0 113.539 -176.78 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 96.0 t -127.93 109.63 20.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 178.407 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.567 HG21 HD22 ' A' ' 34' ' ' LEU . 5.7 t -145.59 112.43 1.22 Allowed 'Isoleucine or valine' 0 C--O 1.189 -2.116 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 -177.558 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.488 ' H ' ' HG3' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -100.78 152.12 20.88 Favored 'General case' 0 C--N 1.266 -3.064 0 C-N-CA 123.138 0.575 . . . . 0.0 111.004 -179.843 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 41.5 t -43.81 116.51 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 123.727 0.811 . . . . 0.0 111.631 175.948 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.51 -5.52 35.39 Favored Glycine 0 C--O 1.227 -0.296 0 CA-C-N 115.421 -0.808 . . . . 0.0 112.99 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.488 ' HG3' ' H ' ' A' ' 29' ' ' ASN . 1.3 mm-40 -69.34 -177.89 1.24 Allowed 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 123.669 0.788 . . . . 0.0 111.786 177.817 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 67.1 t30 -126.62 86.19 2.48 Favored 'General case' 0 CA--C 1.482 -1.646 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 176.724 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.609 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 24.4 tp -95.73 134.98 38.02 Favored 'General case' 0 N--CA 1.41 -2.433 0 C-N-CA 119.202 -0.999 . . . . 0.0 109.453 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.421 ' CG2' ' HB1' ' A' ' 106' ' ' ALA . 1.7 p -141.78 137.79 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.38 -3.941 0 CA-C-N 114.729 -1.123 . . . . 0.0 112.07 -177.633 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.683 HG22 HD21 ' A' ' 24' ' ' LEU . 58.4 t -90.48 89.89 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.335 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 176.26 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -76.01 106.57 7.68 Favored 'General case' 0 C--N 1.297 -1.717 0 C-N-CA 120.057 -0.657 . . . . 0.0 109.669 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.8 mt -95.03 -1.16 52.87 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.822 -179.188 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 15.2 m -77.41 0.58 21.98 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-O 122.074 0.94 . . . . 0.0 109.478 -177.598 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.2 p -128.46 5.39 5.68 Favored 'General case' 0 N--CA 1.421 -1.901 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.157 178.776 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.589 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 47.1 mm-40 -122.74 -24.21 4.91 Favored 'General case' 0 CA--C 1.503 -0.835 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.73 -174.385 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.7 mt -130.47 140.07 49.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 -176.976 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -138.13 149.74 46.18 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 -176.631 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.418 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 70.2 m -125.87 134.08 51.73 Favored 'General case' 0 C--N 1.289 -2.047 0 C-N-CA 122.794 0.437 . . . . 0.0 110.061 176.952 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' HIS . . . . . 0.479 ' NE2' ' HB3' ' A' ' 2' ' ' ALA . 11.6 p-80 -119.35 150.79 39.57 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-O 121.998 0.904 . . . . 0.0 110.386 -177.941 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -99.35 101.99 13.44 Favored 'General case' 0 C--N 1.272 -2.789 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 -179.022 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 18.3 p-10 -86.62 -17.63 33.4 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 -179.247 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 67.3 m-85 -138.47 62.79 31.66 Favored Pre-proline 0 N--CA 1.477 0.91 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 175.184 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.8 -3.31 11.79 Favored 'Trans proline' 0 N--CA 1.485 0.971 0 C-N-CA 123.208 2.605 . . . . 0.0 114.454 -171.074 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -115.54 -17.35 11.2 Favored 'General case' 0 C--N 1.299 -1.625 0 CA-C-O 121.286 0.565 . . . . 0.0 110.272 -178.137 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.464 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.9 m -102.23 -30.36 11.15 Favored 'General case' 0 N--CA 1.424 -1.766 0 CA-C-O 122.064 0.935 . . . . 0.0 108.826 -174.38 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.52 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.0 mp -123.58 137.07 58.02 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.493 0 CA-C-N 114.164 -1.38 . . . . 0.0 109.043 -178.903 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 3.9 t -83.97 122.35 28.63 Favored 'General case' 0 N--CA 1.419 -1.986 0 N-CA-C 102.68 -3.082 . . . . 0.0 102.68 168.431 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -88.98 107.76 19.21 Favored 'General case' 0 C--N 1.261 -3.268 0 C-N-CA 118.313 -1.355 . . . . 0.0 109.013 -172.338 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.557 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 17.0 t80 -122.63 131.58 53.88 Favored 'General case' 0 C--N 1.285 -2.204 0 CA-C-N 114.382 -1.281 . . . . 0.0 109.638 -174.727 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.455 ' CG2' ' HG ' ' A' ' 131' ' ' LEU . 14.9 p -136.87 144.8 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.138 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.685 -175.705 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -150.02 118.49 6.49 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 178.04 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.535 HD12 ' O ' ' A' ' 130' ' ' ILE . 48.0 tp -53.91 111.03 0.67 Allowed 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 169.884 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.428 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 3.1 tp-100 -59.74 -51.06 71.37 Favored 'General case' 0 C--O 1.21 -0.976 0 C-N-CA 125.793 1.637 . . . . 0.0 110.574 179.862 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.428 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 11.0 ptp180 -170.01 158.68 7.25 Favored 'General case' 0 N--CA 1.428 -1.567 0 CA-C-N 115.172 -0.922 . . . . 0.0 108.804 -176.328 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -134.6 145.74 17.8 Favored Glycine 0 N--CA 1.405 -3.433 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 179.319 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 72.3 m -132.88 150.85 52.12 Favored 'General case' 0 C--N 1.283 -2.326 0 C-N-CA 124.062 0.945 . . . . 0.0 109.918 -177.322 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.517 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -115.3 157.77 23.32 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 -178.545 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.523 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 95.9 m-85 -155.09 -179.6 8.22 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 124.302 1.041 . . . . 0.0 109.008 -178.403 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 54.77 -140.05 38.7 Favored Glycine 0 N--CA 1.455 -0.093 0 O-C-N 123.812 0.695 . . . . 0.0 113.464 178.195 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -73.35 -15.46 78.94 Favored Glycine 0 C--O 1.2 -2.014 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.004 178.344 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.755 HG21 ' HB ' ' A' ' 126' ' ' ILE . 84.4 t -67.12 -40.03 84.44 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 C-N-CA 123.637 0.775 . . . . 0.0 111.78 -176.823 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.517 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -87.99 -16.43 33.76 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 118.919 -1.112 . . . . 0.0 112.158 178.326 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 23.2 t -100.74 -59.13 1.75 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-O 121.328 0.585 . . . . 0.0 111.992 -174.976 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.491 ' O ' HG22 ' A' ' 112' ' ' VAL . 34.0 m-20 -90.69 -22.44 21.14 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.875 -171.893 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.636 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 90.4 m-85 -110.63 157.16 20.0 Favored 'General case' 0 N--CA 1.422 -1.854 0 C-N-CA 119.97 -0.692 . . . . 0.0 110.594 178.759 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.4 t -166.17 130.63 2.21 Favored 'General case' 0 N--CA 1.417 -2.075 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 176.269 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.478 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -160.98 -99.77 0.15 Allowed Glycine 0 C--N 1.286 -2.199 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 177.664 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.451 HG22 ' HA ' ' A' ' 83' ' ' PRO . 0.7 OUTLIER -168.89 -179.97 3.9 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.893 1.277 . . . . 0.0 109.97 -177.643 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.0 147.03 32.36 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 C-N-CA 123.255 0.622 . . . . 0.0 109.536 178.324 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.576 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.9 tttt -124.68 147.92 48.29 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.239 -179.43 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.441 ' CD2' HG22 ' A' ' 105' ' ' VAL . 61.3 t80 -148.4 108.8 4.13 Favored 'General case' 0 C--N 1.314 -0.965 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 -179.429 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 11.2 t 51.78 43.04 30.33 Favored 'General case' 0 C--N 1.315 -0.926 0 C-N-CA 124.251 1.02 . . . . 0.0 111.546 177.841 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.78 8.26 70.07 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.188 -1.006 . . . . 0.0 113.435 179.038 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.576 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 23.0 t -80.68 -179.66 7.34 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 177.297 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 12.3 p -158.89 106.61 1.84 Allowed 'General case' 0 C--N 1.288 -2.1 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 2.6 p90 -151.52 158.45 34.29 Favored Pre-proline 0 C--N 1.308 -1.205 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -174.449 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.451 ' HA ' HG22 ' A' ' 74' ' ' THR . 44.9 Cg_endo -67.16 148.9 81.64 Favored 'Trans proline' 0 C--N 1.36 1.16 0 C-N-CA 123.092 2.528 . . . . 0.0 112.703 -177.053 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.588 ' CD2' HD21 ' A' ' 109' ' ' LEU . 60.6 t80 -122.07 131.7 24.37 Favored Pre-proline 0 C--N 1.312 -1.035 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.694 -179.447 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.516 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 72.7 Cg_endo -70.89 150.27 92.73 Favored 'Cis proline' 0 CA--C 1.539 0.731 0 C-N-CA 122.956 -1.685 . . . . 0.0 109.915 -1.296 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.9 t -59.47 -177.99 0.06 Allowed 'General case' 0 CA--C 1.559 1.309 0 CA-C-O 121.928 0.87 . . . . 0.0 112.504 -174.955 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.1 p -115.0 -15.6 11.75 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-N 115.34 -0.846 . . . . 0.0 110.067 -173.596 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.6 t -158.15 -109.53 0.02 OUTLIER 'General case' 0 N--CA 1.415 -2.213 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 178.457 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' GLU . . . . . 0.412 ' HB2' ' O ' ' A' ' 58' ' ' LEU . 0.5 OUTLIER -132.93 -164.01 1.42 Allowed 'General case' 0 N--CA 1.436 -1.16 0 CA-C-N 118.349 0.522 . . . . 0.0 111.723 179.295 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.464 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 10.8 p -100.14 164.56 16.16 Favored Pre-proline 0 C--N 1.299 -1.606 0 C-N-CA 123.618 0.767 . . . . 0.0 112.405 -177.642 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -65.98 168.74 14.79 Favored 'Trans proline' 0 C--N 1.36 1.148 0 C-N-CA 123.411 2.741 . . . . 0.0 111.21 174.359 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.557 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 3.2 tmm_? -70.2 128.44 36.26 Favored 'General case' 0 N--CA 1.44 -0.964 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 -178.77 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 74.0 t -142.59 120.92 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.666 0 C-N-CA 124.439 1.095 . . . . 0.0 108.11 -178.381 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.0 p -119.81 140.32 44.22 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.209 0 CA-C-O 120.956 0.408 . . . . 0.0 110.775 -177.896 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.47 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 9.5 m-85 -94.26 112.46 24.26 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 177.907 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 13.9 m120 -97.49 8.64 44.25 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-O 121.657 0.741 . . . . 0.0 109.218 178.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.8 m -76.7 -175.95 3.61 Favored 'General case' 0 N--CA 1.427 -1.6 0 C-N-CA 124.729 1.212 . . . . 0.0 109.988 -177.896 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 15.0 ptp180 -143.64 30.57 1.34 Allowed 'General case' 0 C--N 1.309 -1.174 0 CA-C-O 121.001 0.429 . . . . 0.0 110.611 177.812 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.1 t -163.48 -178.01 5.61 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -175.598 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -67.31 99.37 0.71 Allowed 'General case' 0 C--O 1.242 0.691 0 O-C-N 123.894 0.746 . . . . 0.0 109.772 178.016 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 11.2 mptt -104.96 141.43 22.53 Favored Pre-proline 0 C--N 1.283 -2.306 0 N-CA-C 106.86 -1.533 . . . . 0.0 106.86 175.641 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -60.85 147.05 96.51 Favored 'Trans proline' 0 C--O 1.243 0.771 0 C-N-CA 122.409 2.073 . . . . 0.0 112.23 -177.664 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' TRP . . . . . 0.47 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 11.9 t90 -91.25 104.66 10.28 Favored Pre-proline 0 C--N 1.309 -1.167 0 N-CA-C 105.387 -2.079 . . . . 0.0 105.387 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -75.51 88.12 1.31 Allowed 'Trans proline' 0 N--CA 1.445 -1.366 0 C-N-CA 121.449 1.433 . . . . 0.0 113.0 -171.052 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.441 HG22 ' CD2' ' A' ' 77' ' ' TYR . 72.4 t -136.15 150.78 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.333 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 177.456 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.595 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -156.87 134.45 10.77 Favored 'General case' 0 N--CA 1.421 -1.893 0 O-C-N 123.633 0.583 . . . . 0.0 109.758 176.773 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.464 HD21 HD11 ' A' ' 129' ' ' LEU . 19.7 mt -103.45 99.86 9.71 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.437 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.478 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 65.4 m-85 -78.55 81.56 4.87 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 178.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.636 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.0 mm? -107.03 117.03 32.98 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-O 121.122 0.487 . . . . 0.0 110.629 176.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -120.17 146.88 43.5 Favored Pre-proline 0 N--CA 1.413 -2.3 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.319 -174.54 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -61.0 119.96 7.41 Favored 'Trans proline' 0 C--O 1.249 1.067 0 C-N-CA 123.226 2.618 . . . . 0.0 112.309 -177.538 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.491 HG22 ' O ' ' A' ' 70' ' ' ASN . 3.0 m -68.35 -118.5 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.193 -1.891 0 CA-C-N 114.261 -1.336 . . . . 0.0 111.862 173.783 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.8 t -112.87 -33.11 6.18 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 175.891 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 36.3 m -80.03 34.5 0.3 Allowed 'General case' 0 N--CA 1.399 -2.982 0 C-N-CA 125.698 1.599 . . . . 0.0 112.742 -178.169 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -118.12 130.01 55.87 Favored 'General case' 0 C--N 1.281 -2.397 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.365 179.396 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -170.08 128.18 1.6 Allowed Glycine 0 C--O 1.239 0.467 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.647 179.405 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 65.98 -150.48 51.84 Favored Glycine 0 CA--C 1.499 -0.964 0 CA-C-O 118.985 -0.897 . . . . 0.0 111.589 -176.097 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.406 HG11 ' HE3' ' A' ' 121' ' ' LYS . 95.1 t -56.93 105.2 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.873 0.844 . . . . 0.0 111.435 -178.291 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -105.41 -21.58 13.2 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-N 114.327 -1.306 . . . . 0.0 110.919 -177.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.509 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 63.6 mt -135.84 140.54 44.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.517 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.3 mmpt? -115.87 139.56 50.09 Favored 'General case' 0 C--N 1.317 -0.817 0 C-N-CA 122.319 0.248 . . . . 0.0 111.232 178.071 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 0.409 ' H ' ' HB3' ' A' ' 153' ' ' ASP . . . -70.53 134.73 47.96 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.227 179.38 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 87.01 -7.91 78.55 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 121.353 -0.451 . . . . 0.0 112.115 -179.233 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 34.7 t -96.11 143.63 27.07 Favored 'General case' 0 N--CA 1.422 -1.843 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.463 HD11 HG23 ' A' ' 128' ' ' VAL . 3.0 tm? -69.86 128.21 35.58 Favored 'General case' 0 N--CA 1.436 -1.17 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.384 -178.463 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.755 ' HB ' HG21 ' A' ' 67' ' ' VAL . 32.6 pt -112.43 -27.05 2.86 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 N-CA-C 112.327 0.492 . . . . 0.0 112.327 -179.886 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.84 168.03 23.76 Favored 'General case' 0 CA--C 1.505 -0.765 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -178.283 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.463 HG23 HD11 ' A' ' 125' ' ' LEU . 59.9 t -142.03 116.94 5.25 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 179.112 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.464 HD11 HD21 ' A' ' 107' ' ' LEU . 68.3 mt -117.46 137.58 52.43 Favored 'General case' 0 C--N 1.28 -2.444 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 178.483 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.535 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.3 mp -118.57 122.71 70.15 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 C-N-CA 119.015 -1.074 . . . . 0.0 109.934 177.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.548 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.8 OUTLIER -88.53 141.35 28.6 Favored 'General case' 0 C--N 1.266 -3.064 0 C-N-CA 125.053 1.341 . . . . 0.0 108.166 177.554 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 24.9 ttp180 -122.35 131.01 53.69 Favored 'General case' 0 N--CA 1.409 -2.497 0 C-N-CA 120.153 -0.619 . . . . 0.0 109.815 174.307 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 20.9 mm-40 -98.28 143.66 28.53 Favored 'General case' 0 N--CA 1.42 -1.942 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 -179.487 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.465 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 11.0 m -154.78 138.04 15.73 Favored 'General case' 0 C--N 1.281 -2.402 0 N-CA-C 106.488 -1.671 . . . . 0.0 106.488 173.649 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.52 ' CB ' HG23 ' A' ' 52' ' ' ILE . 11.0 p30 . . . . . 0 C--N 1.318 -0.782 0 CA-C-N 119.227 0.921 . . . . 0.0 112.515 176.108 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 . . . . . 0 N--CA 1.426 -1.673 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 143' ' ' GLN . . . . . 0.519 ' HB2' ' O ' ' A' ' 131' ' ' LEU . 13.9 pt20 -124.49 142.55 51.24 Favored 'General case' 0 N--CA 1.415 -2.215 0 C-N-CA 118.541 -1.264 . . . . 0.0 111.844 178.534 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 -106.69 129.37 54.6 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -175.344 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 48.5 t -94.53 129.18 45.12 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -178.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 146' ' ' TRP . . . . . 0.548 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 60.4 m95 -118.47 103.09 9.43 Favored 'General case' 0 C--N 1.278 -2.507 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.141 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 36.8 m-80 -82.05 110.86 17.67 Favored 'General case' 0 C--N 1.286 -2.159 0 N-CA-C 106.699 -1.593 . . . . 0.0 106.699 178.155 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.416 HG22 HD11 ' A' ' 126' ' ' ILE . 23.4 mm -85.52 121.14 36.8 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.903 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 -178.046 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 93.8 m-85 -117.72 151.3 37.55 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 123.618 0.767 . . . . 0.0 109.676 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -79.97 130.84 35.59 Favored 'General case' 0 N--CA 1.413 -2.295 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 175.642 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 -92.32 -6.43 50.29 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 -179.317 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -155.39 142.45 19.2 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.205 -176.908 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 153' ' ' ASP . . . . . 0.409 ' HB3' ' H ' ' A' ' 122' ' ' ALA . 17.5 p-10 -86.83 136.15 33.08 Favored 'General case' 0 C--N 1.309 -1.173 0 O-C-N 123.998 0.811 . . . . 0.0 112.004 -177.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.511 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.7 t -110.32 140.79 27.81 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 CA-C-N 114.966 -1.016 . . . . 0.0 111.987 -171.79 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 13.9 t -122.93 137.45 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.045 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 -179.529 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.507 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 70.0 t -103.28 103.27 33.95 Favored Pre-proline 0 C--N 1.286 -2.165 0 C-N-CA 123.699 0.799 . . . . 0.0 110.106 179.534 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.434 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 38.0 Cg_endo -69.47 -21.88 34.18 Favored 'Trans proline' 0 N--CA 1.463 -0.312 0 C-N-CA 121.959 1.772 . . . . 0.0 111.346 177.322 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 158' ' ' THR . . . . . 0.403 ' HB ' HG12 ' A' ' 156' ' ' VAL . 3.6 t . . . . . 0 C--O 1.244 0.784 0 C-N-CA 124.698 1.199 . . . . 0.0 113.251 176.802 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.408 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.439 -1.005 0 CA-C-O 120.782 0.325 . . . . 0.0 111.04 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.404 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 80.0 m -143.67 159.05 43.16 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -177.478 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.6 pptp? -141.8 164.51 29.99 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-O 121.384 0.612 . . . . 0.0 111.621 -176.35 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.565 HG22 HG22 ' A' ' 20' ' ' VAL . 76.7 p -103.25 167.27 9.93 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.168 179.257 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.34 -9.49 58.65 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-N 113.729 -1.578 . . . . 0.0 112.474 179.563 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -94.37 -33.42 13.18 Favored 'General case' 0 C--O 1.239 0.516 0 C-N-CA 119.105 -1.038 . . . . 0.0 109.078 179.381 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 139.3 4.8 1.42 Allowed Glycine 0 N--CA 1.426 -1.972 0 C-N-CA 119.345 -1.407 . . . . 0.0 113.708 176.861 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.0 m -84.54 106.99 16.53 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 177.765 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -99.93 117.2 33.72 Favored 'General case' 0 C--N 1.286 -2.175 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 175.996 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.408 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 62.0 mt -84.21 116.95 67.37 Favored Pre-proline 0 C--N 1.308 -1.212 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 -179.711 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -76.96 166.8 26.23 Favored 'Trans proline' 0 N--CA 1.443 -1.497 0 C-N-CA 122.271 1.981 . . . . 0.0 111.381 179.167 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 72.1 mt -62.19 133.24 28.04 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.97 -179.894 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 126.96 4.44 6.04 Favored Glycine 0 C--N 1.311 -0.838 0 C-N-CA 120.506 -0.854 . . . . 0.0 112.466 178.916 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.04 146.44 6.48 Favored Glycine 0 N--CA 1.442 -0.944 0 C-N-CA 120.494 -0.86 . . . . 0.0 111.174 -177.025 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 177.62 -173.94 46.5 Favored Glycine 0 C--N 1.296 -1.666 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -179.231 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 60.3 p -134.06 151.12 51.27 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -179.651 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.49 168.67 18.81 Favored 'General case' 0 N--CA 1.432 -1.364 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.56 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 16.0 m-80 -118.14 108.69 15.49 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 -179.489 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.565 HG22 HG22 ' A' ' 5' ' ' THR . 46.9 t -94.72 136.64 25.33 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.018 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 -179.705 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 86.4 m-85 -125.1 117.39 23.83 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -177.333 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.479 HG11 HG13 ' A' ' 36' ' ' VAL . 2.7 p -124.3 129.52 73.96 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.833 0 CA-C-O 121.704 0.764 . . . . 0.0 111.479 -176.913 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -82.26 124.62 30.11 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-N 114.988 -1.005 . . . . 0.0 108.459 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 35.5 mt -113.44 156.16 24.01 Favored 'General case' 0 C--N 1.276 -2.593 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 179.951 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.53 121.67 50.16 Favored Pre-proline 0 C--O 1.201 -1.483 0 O-C-N 124.207 0.942 . . . . 0.0 109.899 -179.311 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.505 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 62.3 Cg_endo -71.37 -2.46 11.27 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 C-N-CA 123.185 2.59 . . . . 0.0 113.294 -176.699 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.528 HG13 ' HG3' ' A' ' 157' ' ' PRO . 64.8 t -130.4 111.26 20.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.94 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.458 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 5.8 t -145.76 110.3 0.98 Allowed 'Isoleucine or valine' 0 C--O 1.191 -2.024 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 -179.383 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.552 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -99.68 156.62 16.99 Favored 'General case' 0 C--N 1.264 -3.109 0 C-N-CA 122.94 0.496 . . . . 0.0 111.18 -179.539 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 25.4 t -47.93 116.5 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 123.887 0.875 . . . . 0.0 111.675 177.299 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.87 0.51 45.46 Favored Glycine 0 N--CA 1.444 -0.827 0 CA-C-N 115.36 -0.836 . . . . 0.0 112.983 -179.96 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.552 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.9 OUTLIER -73.73 -177.05 2.6 Favored 'General case' 0 C--N 1.315 -0.893 0 C-N-CA 123.888 0.875 . . . . 0.0 111.099 176.221 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 65.5 t30 -128.39 87.88 2.66 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 178.484 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.643 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 18.7 tp -97.35 132.67 42.85 Favored 'General case' 0 N--CA 1.417 -2.091 0 C-N-CA 118.663 -1.215 . . . . 0.0 108.753 178.095 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 2.1 p -141.41 129.55 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.386 -3.65 0 CA-C-N 114.859 -1.064 . . . . 0.0 111.618 -177.747 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.609 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 46.8 t -90.54 89.22 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.393 -3.277 0 CA-C-N 113.374 -1.739 . . . . 0.0 107.825 -179.039 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -77.98 112.22 14.67 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 121.015 0.436 . . . . 0.0 109.952 179.08 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 92.1 mt -96.3 -0.54 49.47 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.337 -177.766 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 35.6 t -74.56 0.97 13.17 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.847 0.832 . . . . 0.0 110.366 -179.561 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.8 p -126.85 3.32 6.65 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.086 178.597 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.422 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 47.9 mm-40 -121.8 -26.79 4.78 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.686 -172.925 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 20.6 mt -130.43 139.63 50.85 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 -175.525 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -139.48 158.74 43.63 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 -176.095 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.404 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 49.1 m -136.21 141.47 44.0 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 123.472 0.709 . . . . 0.0 109.972 179.58 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 5.6 p80 -136.92 153.47 50.72 Favored 'General case' 0 N--CA 1.43 -1.47 0 CA-C-O 121.9 0.857 . . . . 0.0 110.681 -178.427 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.467 HD21 ' HA ' ' A' ' 98' ' ' ARG . 6.6 p30 -95.01 109.93 21.9 Favored 'General case' 0 C--N 1.277 -2.556 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.408 177.187 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -73.87 -28.98 61.84 Favored 'General case' 0 C--N 1.297 -1.674 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.931 -179.429 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -136.52 79.6 41.0 Favored Pre-proline 0 C--N 1.313 -0.996 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 175.569 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.54 5.01 2.6 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 C-N-CA 123.257 2.638 . . . . 0.0 113.023 -176.164 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -120.34 -13.31 8.88 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.594 179.144 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.452 ' HB ' HD12 ' A' ' 52' ' ' ILE . 2.6 m -117.14 -25.64 7.07 Favored 'General case' 0 N--CA 1.422 -1.859 0 CA-C-O 121.408 0.623 . . . . 0.0 110.789 -172.575 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.452 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.7 mp -128.95 130.48 68.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 CA-C-N 115.971 -0.558 . . . . 0.0 109.5 -175.581 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.4 t -75.63 146.48 40.26 Favored 'General case' 0 N--CA 1.441 -0.923 0 O-C-N 123.714 0.634 . . . . 0.0 109.707 -179.695 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.555 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 3.0 m-20 -89.96 109.97 20.97 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 115.426 -0.807 . . . . 0.0 109.341 -174.178 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 82.2 t80 -146.03 141.68 27.87 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -179.128 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.1 p -151.44 144.78 16.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 175.802 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.27 131.7 14.7 Favored 'General case' 0 C--O 1.212 -0.904 0 CA-C-O 119.759 -0.162 . . . . 0.0 110.575 175.654 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.555 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 56.8 tp -72.84 107.88 5.49 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.157 0.504 . . . . 0.0 109.984 176.827 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.467 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 3.0 tp-100 -51.55 -53.63 35.89 Favored 'General case' 0 C--O 1.207 -1.138 0 C-N-CA 125.554 1.541 . . . . 0.0 111.149 175.825 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.467 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 2.8 ptp180 -168.62 161.4 11.39 Favored 'General case' 0 CA--C 1.493 -1.235 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 -178.072 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.411 ' H ' HG22 ' A' ' 86' ' ' THR . . . -142.1 123.52 2.23 Favored Glycine 0 N--CA 1.404 -3.485 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -178.771 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.412 ' HA ' ' HB3' ' A' ' 85' ' ' PRO . 68.9 m -115.62 149.79 37.73 Favored 'General case' 0 C--N 1.284 -2.245 0 C-N-CA 124.297 1.039 . . . . 0.0 110.32 -173.804 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.522 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -112.7 157.75 20.9 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 -179.302 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.476 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 88.6 m-85 -156.7 -178.91 7.7 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 124.316 1.047 . . . . 0.0 109.037 -177.68 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 60.71 -143.08 48.26 Favored Glycine 0 C--N 1.33 0.231 0 O-C-N 123.465 0.478 . . . . 0.0 112.512 177.785 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 66' ' ' GLY . . . . . 0.408 ' HA3' ' O ' ' A' ' 119' ' ' ALA . . . -78.94 -7.77 88.21 Favored Glycine 0 C--O 1.21 -1.382 0 C-N-CA 120.978 -0.629 . . . . 0.0 111.876 176.773 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.848 HG21 ' HB ' ' A' ' 126' ' ' ILE . 89.5 t -69.4 -39.96 79.4 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 C-N-CA 123.72 0.808 . . . . 0.0 111.535 -178.4 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.522 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.01 -15.97 39.74 Favored 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 119.171 -1.012 . . . . 0.0 112.053 178.836 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 16.9 t -99.67 -56.9 2.27 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.057 0.456 . . . . 0.0 111.324 -175.221 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.525 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 37.4 m-80 -85.67 -29.09 24.27 Favored 'General case' 0 CA--C 1.486 -1.513 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 -176.09 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.646 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 81.2 m-85 -106.79 157.39 17.78 Favored 'General case' 0 N--CA 1.416 -2.172 0 C-N-CA 119.365 -0.934 . . . . 0.0 110.38 -178.362 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.0 t -168.58 128.14 1.17 Allowed 'General case' 0 N--CA 1.42 -1.933 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 175.503 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.497 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -158.37 -109.92 0.28 Allowed Glycine 0 N--CA 1.404 -3.445 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 174.91 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.434 HG22 ' HA ' ' A' ' 83' ' ' PRO . 3.5 p -156.09 179.99 8.7 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 123.591 0.756 . . . . 0.0 109.859 -176.196 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -130.34 146.76 33.56 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.082 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 177.891 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.635 ' HG3' ' O ' ' A' ' 80' ' ' SER . 82.3 tttt -124.63 142.91 51.03 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.225 -179.564 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.496 ' CD2' HG22 ' A' ' 105' ' ' VAL . 51.5 t80 -142.51 107.87 5.02 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 -178.998 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 33.0 t 54.04 36.85 25.59 Favored 'General case' 0 CA--C 1.555 1.149 0 CA-C-O 121.541 0.686 . . . . 0.0 111.373 179.364 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.427 ' HA2' ' CE ' ' A' ' 76' ' ' LYS . . . 90.39 9.32 65.15 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.321 -0.942 . . . . 0.0 113.514 -178.645 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.635 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 22.9 t -79.96 172.53 13.66 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 177.425 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 6.2 p -152.84 100.58 2.53 Favored 'General case' 0 C--N 1.277 -2.58 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -177.757 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.445 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 1.6 p90 -144.93 159.52 49.81 Favored Pre-proline 0 C--N 1.301 -1.506 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -173.731 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.434 ' HA ' HG22 ' A' ' 74' ' ' THR . 47.3 Cg_endo -66.68 151.97 81.59 Favored 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 122.97 2.446 . . . . 0.0 112.734 -176.959 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.616 ' CD2' HD21 ' A' ' 109' ' ' LEU . 57.6 t80 -127.48 130.34 23.71 Favored Pre-proline 0 N--CA 1.438 -1.042 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.675 179.654 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.492 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 59.8 Cg_endo -69.37 149.46 87.67 Favored 'Cis proline' 0 C--O 1.244 0.803 0 C-N-CA 122.972 -1.678 . . . . 0.0 110.509 -0.393 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.411 HG22 ' H ' ' A' ' 61' ' ' GLY . 9.8 t -63.73 -176.56 0.18 Allowed 'General case' 0 CA--C 1.55 0.966 0 CA-C-O 121.298 0.57 . . . . 0.0 111.745 -175.233 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.1 p -113.15 -39.31 4.21 Favored 'General case' 0 N--CA 1.418 -2.041 0 CA-C-O 121.658 0.742 . . . . 0.0 109.303 -175.267 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 14.0 t -129.82 -107.59 0.28 Allowed 'General case' 0 N--CA 1.401 -2.878 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.259 -179.784 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -134.92 -166.82 1.88 Allowed 'General case' 0 N--CA 1.438 -1.04 0 CA-C-N 117.854 0.297 . . . . 0.0 110.633 -177.821 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.555 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 36.4 p -99.49 170.86 6.27 Favored Pre-proline 0 C--N 1.309 -1.153 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 178.174 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 91' ' ' PRO . . . . . 0.444 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 23.2 Cg_endo -61.34 161.75 22.58 Favored 'Trans proline' 0 C--O 1.249 1.033 0 C-N-CA 122.913 2.409 . . . . 0.0 111.099 169.636 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.7 tmm_? -78.44 119.97 22.51 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 -178.433 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 92.4 t -126.97 126.51 68.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 O-C-N 123.599 0.562 . . . . 0.0 110.189 -178.612 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 75.3 t -107.9 131.16 58.95 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 176.701 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.555 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.0 m-85 -77.77 131.11 37.48 Favored 'General case' 0 C--N 1.309 -1.186 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 175.795 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -117.05 58.56 0.77 Allowed 'General case' 0 C--N 1.285 -2.233 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 -179.826 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 21.0 m -143.11 157.35 44.6 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.598 -176.231 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.467 ' HA ' HD21 ' A' ' 46' ' ' ASN . 14.7 ptp180 -121.83 37.61 4.32 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.845 0.831 . . . . 0.0 109.694 178.128 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 7.7 t -157.26 172.23 18.99 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 -176.028 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -73.26 120.67 19.2 Favored 'General case' 0 C--O 1.244 0.808 0 CA-C-O 121.391 0.615 . . . . 0.0 109.471 -179.203 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -117.92 142.32 30.66 Favored Pre-proline 0 C--N 1.277 -2.545 0 CA-C-N 115.128 -0.942 . . . . 0.0 110.423 -177.212 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -65.81 147.39 85.36 Favored 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.771 2.314 . . . . 0.0 111.834 176.807 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 13.8 t90 -89.17 108.88 27.01 Favored Pre-proline 0 C--N 1.31 -1.143 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 -177.205 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_endo -77.5 88.18 1.44 Allowed 'Trans proline' 0 N--CA 1.45 -1.046 0 C-N-CA 121.641 1.561 . . . . 0.0 113.38 -172.989 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.496 HG22 ' CD2' ' A' ' 77' ' ' TYR . 64.0 t -135.9 148.87 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.183 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 176.069 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.609 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -152.85 131.35 12.19 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-O 120.92 0.391 . . . . 0.0 110.375 177.198 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.47 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 16.7 mt -100.9 99.98 10.55 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.585 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.497 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 51.3 m-85 -78.17 80.36 4.59 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 177.397 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.646 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 2.7 mm? -104.02 116.66 32.63 Favored 'General case' 0 CA--C 1.491 -1.325 0 CA-C-O 120.997 0.427 . . . . 0.0 110.523 176.681 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.69 146.75 51.26 Favored Pre-proline 0 N--CA 1.407 -2.593 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.447 -175.535 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.525 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 18.8 Cg_endo -60.7 122.16 10.83 Favored 'Trans proline' 0 N--CA 1.447 -1.236 0 C-N-CA 122.987 2.458 . . . . 0.0 112.334 -178.248 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.516 HG22 ' O ' ' A' ' 70' ' ' ASN . 3.3 m -70.0 -120.52 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.195 -1.772 0 CA-C-N 113.831 -1.531 . . . . 0.0 111.78 174.874 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 33.4 t -111.69 -34.57 6.01 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 174.355 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 20.0 t -85.56 40.91 0.87 Allowed 'General case' 0 N--CA 1.431 -1.386 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.572 -177.347 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -114.06 135.88 53.53 Favored 'General case' 0 N--CA 1.418 -2.075 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 176.89 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -176.32 135.1 2.79 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 120.053 -1.07 . . . . 0.0 111.927 178.96 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 63.41 -151.07 48.95 Favored Glycine 0 CA--C 1.498 -1.016 0 CA-C-O 119.269 -0.74 . . . . 0.0 112.757 -178.642 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 98.4 t -58.32 99.46 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 122.06 0.933 . . . . 0.0 110.981 -177.648 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 119' ' ' ALA . . . . . 0.408 ' O ' ' HA3' ' A' ' 66' ' ' GLY . . . -99.68 -25.43 14.4 Favored 'General case' 0 C--N 1.295 -1.795 0 CA-C-N 114.608 -1.178 . . . . 0.0 110.735 -177.371 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.565 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 55.2 mt -134.56 138.01 50.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 -179.188 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.511 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 5.0 mmpt? -112.36 138.02 49.69 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-O 121.084 0.469 . . . . 0.0 111.184 177.375 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.45 125.15 25.98 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 177.74 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 93.97 -2.47 69.22 Favored Glycine 0 C--N 1.31 -0.885 0 N-CA-C 111.644 -0.582 . . . . 0.0 111.644 -178.13 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 28.8 t -96.13 143.84 26.9 Favored 'General case' 0 N--CA 1.431 -1.409 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 -179.913 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.434 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -71.53 124.0 23.68 Favored 'General case' 0 N--CA 1.435 -1.183 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.349 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.848 ' HB ' HG21 ' A' ' 67' ' ' VAL . 30.6 pt -111.63 -26.17 3.23 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -178.54 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 127' ' ' ALA . . . . . 0.431 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -160.75 168.2 25.28 Favored 'General case' 0 N--CA 1.443 -0.796 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 -178.196 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.434 HG23 HD11 ' A' ' 125' ' ' LEU . 70.5 t -143.0 114.06 2.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.903 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.44 HD11 HD21 ' A' ' 107' ' ' LEU . 55.8 mt -116.67 147.89 41.53 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.184 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.485 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.5 mp -133.01 127.69 55.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.849 -0.532 . . . . 0.0 110.002 179.714 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 131' ' ' LEU . . . . . . . . . . . . . 2.3 pp -96.4 147.04 24.23 Favored 'General case' 0 CA--C 1.496 -1.119 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 177.419 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 132' ' ' ARG . . . . . 0.464 ' HD3' ' NE2' ' A' ' 59' ' ' GLN . 26.5 mmm-85 -96.49 118.39 32.89 Favored 'General case' 0 C--N 1.277 -2.576 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 172.858 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 49.6 tp60 -96.02 122.03 38.41 Favored 'General case' 0 N--CA 1.421 -1.911 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 173.151 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 22.1 m -134.61 134.01 40.79 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 177.085 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.432 ' CB ' HG23 ' A' ' 52' ' ' ILE . 27.2 p30 . . . . . 0 C--N 1.31 -1.11 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.819 -179.736 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 . . . . . 0 N--CA 1.412 -2.328 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 12.6 pt20 -115.08 132.12 56.71 Favored 'General case' 0 N--CA 1.407 -2.624 0 C-N-CA 119.037 -1.065 . . . . 0.0 110.248 -177.86 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 11.1 m-30 -100.77 129.35 46.64 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.206 -0.906 . . . . 0.0 108.785 -175.087 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 47.1 t -93.3 130.83 41.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 123.764 0.665 . . . . 0.0 109.973 -178.016 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 63.9 m95 -118.21 97.92 6.03 Favored 'General case' 0 C--N 1.275 -2.636 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 -178.853 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 47.2 m-80 -80.18 112.3 17.37 Favored 'General case' 0 C--N 1.285 -2.223 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 178.249 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.431 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 24.0 mm -86.03 122.06 38.12 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.819 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 -177.96 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -116.63 153.31 32.52 Favored 'General case' 0 C--N 1.286 -2.156 0 C-N-CA 124.052 0.941 . . . . 0.0 108.685 177.716 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.37 133.72 35.23 Favored 'General case' 0 N--CA 1.407 -2.585 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 176.066 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -92.94 -8.92 41.8 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -177.457 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 8.5 t-20 -150.04 143.93 25.46 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 113.937 -1.483 . . . . 0.0 110.008 -176.653 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -84.65 136.16 33.87 Favored 'General case' 0 C--N 1.312 -1.033 0 O-C-N 123.966 0.791 . . . . 0.0 110.419 179.43 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.565 ' HB ' ' HB ' ' A' ' 120' ' ' ILE . 69.6 t -118.59 140.05 43.64 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.978 -173.642 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -119.78 138.34 50.71 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.136 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 178.476 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.458 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 71.6 t -99.93 101.13 13.02 Favored Pre-proline 0 C--N 1.293 -1.889 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 176.688 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.528 ' HG3' HG13 ' A' ' 27' ' ' VAL . 21.4 Cg_endo -67.47 -29.72 37.07 Favored 'Trans proline' 0 CA--C 1.504 -1.002 0 C-N-CA 122.215 1.943 . . . . 0.0 111.511 179.075 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 6.1 t . . . . . 0 C--O 1.267 1.974 0 O-C-N 125.002 1.439 . . . . 0.0 112.534 179.387 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.427 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 CA--C 1.499 -1.015 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 . . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 12.4 t -148.76 156.76 42.8 Favored 'General case' 0 N--CA 1.426 -1.642 0 C-N-CA 119.395 -0.922 . . . . 0.0 109.711 -175.25 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.547 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -143.64 161.71 37.82 Favored 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.408 -175.102 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 54.9 p -97.64 -179.96 4.63 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-O 121.015 0.436 . . . . 0.0 110.71 179.679 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.44 -22.56 38.09 Favored 'General case' 0 C--N 1.298 -1.642 0 CA-C-O 121.551 0.691 . . . . 0.0 109.206 177.848 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -85.74 -28.89 24.31 Favored 'General case' 0 N--CA 1.433 -1.297 0 CA-C-N 114.821 -1.082 . . . . 0.0 112.518 -175.784 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 130.43 22.79 1.05 Allowed Glycine 0 CA--C 1.49 -1.488 0 C-N-CA 118.868 -1.634 . . . . 0.0 113.974 171.588 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -103.04 99.42 9.3 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.363 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -94.25 114.15 26.19 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 115.879 -0.601 . . . . 0.0 109.399 176.825 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.427 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 68.5 mt -84.55 126.91 67.7 Favored Pre-proline 0 C--N 1.3 -1.582 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -179.171 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_endo -80.2 164.53 21.94 Favored 'Trans proline' 0 C--O 1.246 0.921 0 C-N-CA 122.614 2.209 . . . . 0.0 111.369 178.405 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.5 mt -65.91 126.31 24.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.984 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.57 10.02 1.49 Allowed Glycine 0 C--N 1.307 -1.028 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.613 -179.577 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.03 161.31 36.82 Favored Glycine 0 C--N 1.319 -0.392 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -177.924 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 161.61 -172.97 37.92 Favored Glycine 0 CA--C 1.495 -1.169 0 C-N-CA 119.938 -1.125 . . . . 0.0 111.331 178.448 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.435 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 65.2 p -144.51 144.03 31.14 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.306 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -130.98 162.16 30.36 Favored 'General case' 0 N--CA 1.415 -2.192 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.286 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -111.96 116.11 30.06 Favored 'General case' 0 C--N 1.271 -2.838 0 N-CA-C 107.043 -1.465 . . . . 0.0 107.043 174.773 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.464 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.2 m -99.63 139.03 22.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.683 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 179.22 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 23.7 m-85 -117.72 115.98 26.12 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-O 120.879 0.371 . . . . 0.0 111.994 -179.715 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.516 HG22 ' HG3' ' A' ' 41' ' ' GLN . 19.3 t -115.68 129.34 72.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.805 -173.819 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -89.27 119.75 30.03 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 177.778 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 28.1 mt -110.74 152.24 26.81 Favored 'General case' 0 C--N 1.282 -2.333 0 CA-C-N 115.051 -0.977 . . . . 0.0 108.984 -176.939 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -52.73 119.32 15.48 Favored Pre-proline 0 C--O 1.204 -1.296 0 O-C-N 124.513 1.133 . . . . 0.0 110.326 179.319 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.576 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 60.9 Cg_endo -73.83 -0.53 9.56 Favored 'Trans proline' 0 CA--C 1.544 0.993 0 C-N-CA 122.502 2.135 . . . . 0.0 113.616 -175.584 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.445 HG13 ' HG3' ' A' ' 157' ' ' PRO . 98.4 t -131.06 109.61 16.75 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 178.161 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.449 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 14.0 t -146.12 108.38 0.8 Allowed 'Isoleucine or valine' 0 C--O 1.193 -1.909 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 -177.248 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.537 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -95.87 154.22 17.34 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 123.864 0.865 . . . . 0.0 111.031 -179.84 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.526 HG22 ' O ' ' A' ' 112' ' ' VAL . 99.1 t -47.18 117.55 0.42 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.328 0 C-N-CA 123.436 0.694 . . . . 0.0 111.197 176.482 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.92 0.38 45.27 Favored Glycine 0 C--N 1.312 -0.803 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.924 -179.634 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.537 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.7 OUTLIER -74.9 -176.7 3.0 Favored 'General case' 0 C--N 1.316 -0.884 0 C-N-CA 123.751 0.821 . . . . 0.0 110.329 175.876 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 67.1 t30 -127.09 89.75 3.03 Favored 'General case' 0 CA--C 1.491 -1.32 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 177.721 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.559 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 20.0 tp -98.34 133.68 42.4 Favored 'General case' 0 C--N 1.295 -1.8 0 C-N-CA 118.898 -1.121 . . . . 0.0 109.256 177.158 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.405 ' CG2' ' HB1' ' A' ' 106' ' ' ALA . 2.1 p -141.56 130.75 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.382 -3.854 0 CA-C-N 114.797 -1.092 . . . . 0.0 112.075 -178.028 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.6 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 47.8 t -87.61 89.56 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.576 0 CA-C-N 113.832 -1.531 . . . . 0.0 107.266 178.801 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.47 ' O ' ' HG2' ' A' ' 41' ' ' GLN . 18.2 t70 -77.26 102.83 6.87 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-O 120.708 0.289 . . . . 0.0 110.683 -179.173 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.3 mt -85.08 -3.65 58.87 Favored 'General case' 0 C--N 1.311 -1.094 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.306 -178.512 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 35.2 t -73.27 0.1 12.91 Favored 'General case' 0 CA--C 1.542 0.636 0 CA-C-O 121.478 0.656 . . . . 0.0 110.135 -179.624 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.3 p -130.2 5.23 4.85 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.206 176.468 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.516 ' HG3' HG22 ' A' ' 22' ' ' VAL . 48.6 mm-40 -120.45 -20.75 7.08 Favored 'General case' 0 C--O 1.239 0.511 0 CA-C-O 121.03 0.443 . . . . 0.0 110.299 -174.177 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.401 HD11 HG11 ' A' ' 20' ' ' VAL . 37.4 mt -138.75 138.7 41.92 Favored 'Isoleucine or valine' 0 C--O 1.243 0.714 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 -177.103 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.547 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 48.7 m-85 -142.47 127.44 18.37 Favored 'General case' 0 N--CA 1.476 0.862 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -176.836 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 75.8 m -109.17 138.69 45.14 Favored 'General case' 0 C--N 1.295 -1.776 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -178.648 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 45' ' ' HIS . . . . . 0.421 ' NE2' ' HB3' ' A' ' 2' ' ' ALA . 10.9 p-80 -121.07 154.34 36.24 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-O 122.335 1.064 . . . . 0.0 112.085 -176.47 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.486 HD22 ' CG ' ' A' ' 54' ' ' ASP . 3.0 m120 -96.9 114.81 26.46 Favored 'General case' 0 C--N 1.28 -2.434 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -179.423 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -77.09 -32.51 56.71 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.301 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 38.4 m-85 -138.68 83.03 20.38 Favored Pre-proline 0 C--N 1.315 -0.934 0 CA-C-N 114.331 -1.304 . . . . 0.0 108.921 -176.955 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.95 3.68 5.88 Favored 'Trans proline' 0 CA--C 1.541 0.831 0 C-N-CA 122.59 2.194 . . . . 0.0 113.685 -176.06 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -117.64 -22.35 8.11 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 121.268 0.556 . . . . 0.0 110.434 178.275 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.516 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.7 OUTLIER -98.49 -28.72 13.48 Favored 'General case' 0 N--CA 1.424 -1.741 0 CA-C-O 122.074 0.94 . . . . 0.0 109.244 -172.035 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.516 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.1 mp -122.67 135.79 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.087 0 CA-C-N 114.306 -1.316 . . . . 0.0 109.648 -178.346 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 3.3 t -86.42 124.29 32.59 Favored 'General case' 0 N--CA 1.417 -2.114 0 N-CA-C 103.022 -2.955 . . . . 0.0 103.022 169.22 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.486 ' CG ' HD22 ' A' ' 46' ' ' ASN . 16.1 m-20 -91.47 107.88 19.51 Favored 'General case' 0 C--N 1.271 -2.811 0 C-N-CA 118.815 -1.154 . . . . 0.0 109.433 -169.005 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 22.0 t80 -117.89 139.56 50.95 Favored 'General case' 0 C--N 1.273 -2.746 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.588 -175.74 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.507 HG23 ' HG ' ' A' ' 131' ' ' LEU . 12.9 p -145.59 145.39 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.794 0 O-C-N 123.626 0.579 . . . . 0.0 109.815 -179.577 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -149.4 125.11 10.44 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.085 174.584 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.505 HD12 ' O ' ' A' ' 130' ' ' ILE . 41.9 tp -61.82 110.35 1.51 Allowed 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 169.975 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.6 tp-100 -60.18 -56.95 15.34 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 126.63 1.972 . . . . 0.0 109.861 -179.074 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 10.8 ptp180 -164.14 160.16 21.11 Favored 'General case' 0 N--CA 1.426 -1.634 0 CA-C-N 114.505 -1.225 . . . . 0.0 108.874 -175.274 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -141.38 139.96 9.9 Favored Glycine 0 N--CA 1.411 -2.998 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -178.756 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 73.2 m -126.06 150.63 48.0 Favored 'General case' 0 C--N 1.289 -2.025 0 C-N-CA 124.139 0.976 . . . . 0.0 110.266 -176.807 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.48 ' HB2' ' CE2' ' A' ' 84' ' ' PHE . . . -114.2 157.69 22.34 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.202 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.461 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 87.0 m-85 -155.13 -178.88 7.56 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 124.12 0.968 . . . . 0.0 109.244 -178.609 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 60.25 -138.65 48.54 Favored Glycine 0 C--O 1.228 -0.279 0 O-C-N 123.537 0.523 . . . . 0.0 113.236 176.886 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.44 -8.79 85.76 Favored Glycine 0 N--CA 1.432 -1.631 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.355 177.037 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.815 HG21 ' HB ' ' A' ' 126' ' ' ILE . 84.0 t -69.13 -41.25 81.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 C-N-CA 123.52 0.728 . . . . 0.0 111.572 -176.709 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.471 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -83.21 -21.01 33.55 Favored 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.73 -0.788 . . . . 0.0 112.359 179.692 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 18.4 m -101.71 -50.69 3.63 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 115.25 1.574 . . . . 0.0 115.25 -174.802 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.493 ' O ' HG22 ' A' ' 112' ' ' VAL . 47.7 m-20 -93.73 -23.45 18.2 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -175.628 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.625 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 88.2 m-85 -108.1 159.24 16.73 Favored 'General case' 0 N--CA 1.423 -1.802 0 C-N-CA 120.02 -0.672 . . . . 0.0 109.324 176.979 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.6 t -167.5 125.11 1.21 Allowed 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 175.617 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.475 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -159.51 -110.28 0.27 Allowed Glycine 0 N--CA 1.407 -3.284 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 176.648 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.3 p -156.96 179.97 8.78 Favored 'General case' 0 C--N 1.296 -1.744 0 C-N-CA 123.531 0.733 . . . . 0.0 110.965 -173.101 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.429 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.6 p -133.69 144.37 36.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.919 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.678 ' HG3' ' O ' ' A' ' 80' ' ' SER . 86.0 tttt -123.42 150.19 44.09 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.318 -178.699 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.441 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 60.8 t80 -148.94 109.42 4.19 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 -178.812 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.6 t 51.48 41.01 28.07 Favored 'General case' 0 CA--C 1.554 1.105 0 C-N-CA 124.32 1.048 . . . . 0.0 111.396 178.037 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.83 6.73 67.08 Favored Glycine 0 CA--C 1.526 0.756 0 CA-C-N 115.615 -0.721 . . . . 0.0 113.987 179.82 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.678 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 22.8 t -79.57 179.98 7.18 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 178.43 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 3.6 p -157.99 107.15 2.06 Favored 'General case' 0 C--N 1.292 -1.896 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 -179.489 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.441 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.5 p90 -151.49 158.44 34.32 Favored Pre-proline 0 C--N 1.308 -1.228 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 -174.418 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.25 148.54 68.58 Favored 'Trans proline' 0 C--N 1.358 1.033 0 C-N-CA 122.819 2.346 . . . . 0.0 112.977 -176.385 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.601 ' CD2' HD21 ' A' ' 109' ' ' LEU . 63.0 t80 -121.92 133.4 24.29 Favored Pre-proline 0 N--CA 1.438 -1.058 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.773 179.98 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.493 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 74.1 Cg_endo -71.15 146.63 85.49 Favored 'Cis proline' 0 CA--C 1.548 1.223 0 C-N-CA 123.079 -1.634 . . . . 0.0 110.56 -1.856 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.1 t -64.13 -176.74 0.22 Allowed 'General case' 0 CA--C 1.558 1.262 0 C-N-CA 123.547 0.739 . . . . 0.0 112.279 -174.015 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 19.9 p -129.54 -27.6 2.37 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 113.161 0.8 . . . . 0.0 113.161 -172.449 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 t -127.62 -73.46 0.6 Allowed 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 119.736 -0.786 . . . . 0.0 110.684 -178.45 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -177.78 -174.57 0.46 Allowed 'General case' 0 C--O 1.243 0.726 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 -176.684 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.456 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 12.4 p -102.07 163.28 18.05 Favored Pre-proline 0 C--N 1.299 -1.592 0 O-C-N 123.432 0.458 . . . . 0.0 112.196 178.083 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -64.55 157.48 54.98 Favored 'Trans proline' 0 C--N 1.36 1.176 0 C-N-CA 122.669 2.246 . . . . 0.0 111.576 174.996 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.4 tmm_? -68.79 110.81 4.51 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 114.898 -1.046 . . . . 0.0 110.209 -175.757 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 71.0 t -122.35 132.83 70.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.826 -178.093 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 95.6 t -117.24 136.25 55.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 115.3 -0.863 . . . . 0.0 109.494 178.97 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.485 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 4.1 m-85 -82.99 94.97 7.88 Favored 'General case' 0 CA--C 1.499 -0.985 0 CA-C-O 121.41 0.624 . . . . 0.0 110.348 177.516 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -89.26 61.13 5.59 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 178.754 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.6 m -143.67 -179.3 6.36 Favored 'General case' 0 N--CA 1.423 -1.798 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 -176.959 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 4.5 ptm180 -146.08 50.7 1.16 Allowed 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 121.425 0.631 . . . . 0.0 109.979 179.998 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.0 t -169.87 177.41 4.4 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -175.201 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -71.77 98.02 1.89 Allowed 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 106.608 -1.627 . . . . 0.0 106.608 173.07 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 11.5 tptt -103.14 139.33 20.01 Favored Pre-proline 0 N--CA 1.407 -2.602 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 -177.678 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_endo -58.9 147.26 90.23 Favored 'Trans proline' 0 CA--C 1.511 -0.632 0 C-N-CA 122.605 2.203 . . . . 0.0 112.631 -176.993 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 103' ' ' TRP . . . . . 0.485 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.1 t90 -90.48 105.93 13.41 Favored Pre-proline 0 C--N 1.302 -1.472 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 178.6 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -77.83 87.94 1.47 Allowed 'Trans proline' 0 N--CA 1.443 -1.456 0 C-N-CA 121.616 1.544 . . . . 0.0 112.21 -173.094 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.438 HG22 ' CD2' ' A' ' 77' ' ' TYR . 86.7 t -139.01 147.03 25.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 N-CA-C 106.879 -1.526 . . . . 0.0 106.879 177.851 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.6 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -153.14 134.26 14.1 Favored 'General case' 0 C--N 1.284 -2.265 0 CA-C-O 120.811 0.338 . . . . 0.0 110.381 178.522 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.47 HD21 HD11 ' A' ' 129' ' ' LEU . 18.7 mt -101.6 99.86 10.2 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 179.151 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.475 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 74.2 m-85 -79.59 77.43 6.19 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 177.746 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.625 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.2 mm? -102.54 118.72 37.47 Favored 'General case' 0 CA--C 1.488 -1.414 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 176.365 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -122.18 146.91 47.97 Favored Pre-proline 0 N--CA 1.402 -2.867 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -174.964 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -63.4 123.14 11.61 Favored 'Trans proline' 0 CA--C 1.491 -1.625 0 C-N-CA 123.245 2.63 . . . . 0.0 113.379 -175.469 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.526 ' O ' HG22 ' A' ' 30' ' ' VAL . 24.3 m -83.22 -159.25 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.385 -3.689 0 CA-C-N 114.181 -1.372 . . . . 0.0 108.871 171.15 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.8 m -79.21 -29.56 42.86 Favored 'General case' 0 C--N 1.252 -3.631 0 CA-C-O 121.464 0.65 . . . . 0.0 110.296 -170.352 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 11.3 t -82.52 25.5 0.63 Allowed 'General case' 0 N--CA 1.428 -1.53 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.188 -179.77 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -109.17 136.75 48.15 Favored 'General case' 0 N--CA 1.422 -1.842 0 O-C-N 121.828 -0.545 . . . . 0.0 109.818 178.847 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -174.91 134.49 2.77 Favored Glycine 0 N--CA 1.432 -1.6 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 178.332 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 60.49 -149.3 43.29 Favored Glycine 0 CA--C 1.494 -1.221 0 CA-C-O 119.32 -0.711 . . . . 0.0 112.151 -177.637 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 94.0 t -57.95 105.11 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-O 121.923 0.868 . . . . 0.0 111.261 -177.884 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.37 -22.22 13.37 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 114.51 -1.223 . . . . 0.0 110.62 -178.772 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.483 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 67.9 mt -136.83 138.13 46.44 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 179.474 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.509 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.6 mmpt? -116.6 143.01 46.14 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.066 0.46 . . . . 0.0 109.79 174.744 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.5 131.05 42.74 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.891 -179.17 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.63 -6.07 64.87 Favored Glycine 0 N--CA 1.44 -1.083 0 C-N-CA 121.231 -0.509 . . . . 0.0 112.157 -179.316 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 27.2 m -94.9 147.53 23.27 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-O 120.778 0.323 . . . . 0.0 110.747 -179.302 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -74.25 124.04 25.66 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.271 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.815 ' HB ' HG21 ' A' ' 67' ' ' VAL . 31.2 pt -111.27 -26.28 3.2 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -178.555 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 127' ' ' ALA . . . . . 0.42 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.83 168.52 22.93 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 -177.679 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 73.7 t -143.4 114.44 2.54 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.487 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.47 HD11 HD21 ' A' ' 107' ' ' LEU . 62.9 mt -116.01 142.5 46.72 Favored 'General case' 0 C--N 1.291 -1.968 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 178.631 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.505 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.9 mp -121.08 126.54 75.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 C-N-CA 119.272 -0.971 . . . . 0.0 110.77 177.477 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.527 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.2 OUTLIER -98.05 131.41 44.49 Favored 'General case' 0 C--N 1.271 -2.813 0 C-N-CA 124.68 1.192 . . . . 0.0 109.182 179.422 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 132' ' ' ARG . . . . . 0.636 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 12.6 tpt180 -104.9 124.53 49.64 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -179.86 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 133' ' ' GLN . . . . . 0.525 ' OE1' HD21 ' A' ' 131' ' ' LEU . 12.6 mm100 -105.84 118.54 36.87 Favored 'General case' 0 C--N 1.319 -0.72 0 O-C-N 123.592 0.557 . . . . 0.0 110.345 179.242 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 5.1 m -136.6 149.7 48.18 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 106.377 -1.712 . . . . 0.0 106.377 177.462 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.49 ' CB ' HG23 ' A' ' 52' ' ' ILE . 12.6 p30 . . . . . 0 C--N 1.324 -0.529 0 C-N-CA 119.458 -0.897 . . . . 0.0 112.249 175.555 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 . . . . . 0 N--CA 1.437 -1.077 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 143' ' ' GLN . . . . . 0.636 ' HB3' ' HD2' ' A' ' 132' ' ' ARG . 14.0 pt20 -129.34 145.92 51.3 Favored 'General case' 0 N--CA 1.417 -2.089 0 C-N-CA 119.812 -0.755 . . . . 0.0 111.336 177.851 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.447 ' HB2' HD22 ' A' ' 131' ' ' LEU . 11.0 m-30 -109.5 130.44 55.5 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 -178.007 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.435 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 61.9 t -90.36 131.77 36.69 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.053 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 179.86 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 146' ' ' TRP . . . . . 0.527 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 69.2 m95 -119.9 97.96 5.87 Favored 'General case' 0 C--N 1.275 -2.636 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 -179.273 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 49.2 m-80 -80.01 114.7 19.11 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 178.634 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.464 ' HA ' HG22 ' A' ' 20' ' ' VAL . 23.6 mm -88.21 122.06 39.31 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 -177.718 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -118.19 156.1 29.33 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 123.241 0.616 . . . . 0.0 109.697 178.506 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -84.1 131.61 34.77 Favored 'General case' 0 N--CA 1.414 -2.258 0 CA-C-N 115.238 -0.892 . . . . 0.0 108.682 177.33 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -95.75 -12.12 25.9 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 -176.812 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -155.08 146.49 22.99 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 113.84 -1.527 . . . . 0.0 108.326 -178.089 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 17.8 p-10 -86.05 148.15 25.86 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 124.152 0.981 . . . . 0.0 111.564 -177.181 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.576 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 77.7 t -123.57 136.04 61.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-N 115.459 -0.792 . . . . 0.0 111.194 -174.542 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.5 t -118.29 135.1 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.767 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.449 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.1 t -99.37 103.77 22.73 Favored Pre-proline 0 C--N 1.291 -1.975 0 C-N-CA 123.867 0.867 . . . . 0.0 109.871 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.486 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 50.1 Cg_endo -72.77 -17.11 26.11 Favored 'Trans proline' 0 C--N 1.333 -0.289 0 C-N-CA 122.034 1.822 . . . . 0.0 111.424 178.021 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.273 4.0 t . . . . . 0 C--O 1.239 0.543 0 C-N-CA 125.414 1.486 . . . . 0.0 113.568 177.75 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.484 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.436 -1.136 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 . . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 14.7 t -148.78 157.01 43.13 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.394 -0.922 . . . . 0.0 109.958 -177.006 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.495 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.91 156.28 43.9 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 121.868 0.842 . . . . 0.0 111.434 -174.789 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 36.3 p -94.97 171.47 8.74 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.749 178.402 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -80.7 -10.93 59.7 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 114.661 -1.154 . . . . 0.0 110.332 -179.127 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -93.06 -33.22 14.18 Favored 'General case' 0 N--CA 1.431 -1.384 0 CA-C-N 114.96 -1.018 . . . . 0.0 111.796 -177.556 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 142.88 -1.59 1.53 Allowed Glycine 0 CA--C 1.507 -0.448 0 C-N-CA 119.158 -1.496 . . . . 0.0 114.462 171.461 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.4 m -86.35 104.99 16.38 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 122.202 -0.587 . . . . 0.0 110.93 -178.441 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -96.31 118.66 33.31 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 173.773 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.484 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 66.2 mt -89.84 122.58 67.8 Favored Pre-proline 0 C--N 1.297 -1.694 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 -179.649 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -77.24 171.91 16.95 Favored 'Trans proline' 0 C--O 1.239 0.563 0 C-N-CA 122.939 2.426 . . . . 0.0 111.582 179.6 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.7 mt -72.85 120.1 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.807 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 179.155 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 140.98 23.36 0.25 Allowed Glycine 0 C--N 1.301 -1.415 0 CA-C-N 115.393 -0.822 . . . . 0.0 112.027 -179.668 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 73.79 167.41 14.75 Favored Glycine 0 C--N 1.335 0.494 0 C-N-CA 121.156 -0.545 . . . . 0.0 112.309 -177.28 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 153.97 -172.01 32.64 Favored Glycine 0 CA--C 1.483 -1.966 0 C-N-CA 120.087 -1.054 . . . . 0.0 110.925 176.229 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.43 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 78.3 p -141.43 156.27 45.8 Favored 'General case' 0 N--CA 1.42 -1.953 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 178.918 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -137.23 160.22 39.66 Favored 'General case' 0 N--CA 1.422 -1.864 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 177.536 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.417 HD21 ' HE1' ' A' ' 149' ' ' TYR . 11.4 m120 -114.15 109.89 19.12 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 105.143 -2.169 . . . . 0.0 105.143 175.713 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.495 HG22 ' HA ' ' A' ' 148' ' ' ILE . 0.8 OUTLIER -91.84 143.2 11.8 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.328 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 -178.132 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 63.2 m-85 -119.52 116.07 25.32 Favored 'General case' 0 C--N 1.297 -1.711 0 C-N-CA 120.803 -0.359 . . . . 0.0 111.557 -179.249 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.436 HG22 ' HG3' ' A' ' 41' ' ' GLN . 22.0 t -119.58 132.75 68.49 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.041 -174.888 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 -88.6 123.09 32.75 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 176.881 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.467 HD11 HG22 ' A' ' 36' ' ' VAL . 2.9 mm? -104.14 160.44 14.86 Favored 'General case' 0 C--N 1.287 -2.143 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.502 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -59.33 123.71 71.48 Favored Pre-proline 0 C--N 1.316 -0.886 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.382 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 88.0 Cg_endo -78.53 1.58 8.91 Favored 'Trans proline' 0 C--N 1.33 -0.427 0 C-N-CA 122.78 2.32 . . . . 0.0 113.159 -175.264 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 98.7 t -129.53 109.77 18.83 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 177.311 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.0 t -143.03 103.53 0.92 Allowed 'Isoleucine or valine' 0 C--O 1.18 -2.585 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -176.347 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.728 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -95.16 155.27 16.8 Favored 'General case' 0 C--N 1.272 -2.783 0 C-N-CA 122.364 0.266 . . . . 0.0 111.01 -179.838 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.606 HG22 ' O ' ' A' ' 112' ' ' VAL . 87.5 t -46.94 118.71 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 C-N-CA 123.06 0.544 . . . . 0.0 111.064 175.387 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.98 9.61 57.05 Favored Glycine 0 C--N 1.31 -0.887 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.939 179.467 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.728 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -80.77 -177.72 6.46 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 175.413 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 27.3 t-20 -130.88 87.65 2.51 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 178.859 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.66 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 27.1 tp -88.1 144.56 26.42 Favored 'General case' 0 C--N 1.292 -1.906 0 C-N-CA 119.589 -0.844 . . . . 0.0 109.685 -178.803 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.7 t -137.7 130.33 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.882 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 -177.597 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.565 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 40.3 t -97.54 88.75 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.413 -2.304 0 N-CA-C 105.685 -1.968 . . . . 0.0 105.685 172.734 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.411 ' O ' ' HG2' ' A' ' 41' ' ' GLN . 12.9 t70 -82.03 109.74 16.64 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -177.781 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.9 mt -92.47 -1.32 57.06 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-O 121.072 0.463 . . . . 0.0 111.284 -178.012 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.579 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 34.1 t -76.25 0.27 19.81 Favored 'General case' 0 C--N 1.31 -1.121 0 CA-C-O 121.652 0.739 . . . . 0.0 109.459 -178.713 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.6 p -129.81 5.51 5.04 Favored 'General case' 0 N--CA 1.412 -2.33 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.599 178.83 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.436 ' HG3' HG22 ' A' ' 22' ' ' VAL . 48.9 mm-40 -124.69 -21.13 4.88 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.854 -173.89 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 39.0 mt -134.8 138.73 48.81 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 -177.333 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.495 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 49.5 m-85 -142.32 128.63 19.95 Favored 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -176.065 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 85.0 m -107.57 145.9 32.61 Favored 'General case' 0 C--N 1.284 -2.251 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.032 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 12.1 p80 -131.62 128.35 38.95 Favored 'General case' 0 C--N 1.296 -1.728 0 CA-C-O 122.16 0.981 . . . . 0.0 111.744 -176.516 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 20.8 p-10 -97.11 89.66 4.87 Favored 'General case' 0 C--N 1.282 -2.335 0 CA-C-O 122.257 1.027 . . . . 0.0 108.693 178.572 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 47' ' ' ASP . . . . . 0.586 ' HB2' ' CD2' ' A' ' 48' ' ' TYR . 1.4 m-20 -51.74 -43.62 62.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.25 -175.676 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 48' ' ' TYR . . . . . 0.586 ' CD2' ' HB2' ' A' ' 47' ' ' ASP . 29.2 m-85 -121.84 83.27 43.01 Favored Pre-proline 0 C--N 1.315 -0.913 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 -175.278 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -83.01 -5.51 11.32 Favored 'Trans proline' 0 C--O 1.234 0.29 0 C-N-CA 122.99 2.46 . . . . 0.0 112.786 -173.606 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -103.78 -23.35 13.42 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.023 -178.09 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.711 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.3 OUTLIER -100.33 -30.76 11.69 Favored 'General case' 0 N--CA 1.415 -2.222 0 CA-C-O 122.02 0.914 . . . . 0.0 108.867 -176.0 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.711 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.9 mp -128.96 134.9 63.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 CA-C-N 114.636 -1.166 . . . . 0.0 109.927 -176.584 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 5.9 t -86.51 139.05 31.24 Favored 'General case' 0 N--CA 1.438 -1.052 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 171.5 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.464 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 14.6 t70 -96.07 108.78 21.25 Favored 'General case' 0 C--N 1.275 -2.664 0 C-N-CA 119.673 -0.811 . . . . 0.0 109.147 -175.832 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 23.6 t80 -122.64 122.15 38.12 Favored 'General case' 0 C--N 1.288 -2.065 0 CA-C-O 121.799 0.809 . . . . 0.0 110.065 -177.702 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.422 ' CG1' HD12 ' A' ' 131' ' ' LEU . 85.3 t -125.95 138.52 54.29 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 CA-C-N 114.169 -1.378 . . . . 0.0 110.067 -176.084 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -144.46 135.3 24.97 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 172.602 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.547 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 38.9 tp -74.58 104.91 5.45 Favored 'General case' 0 N--CA 1.436 -1.132 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 175.429 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -52.96 -54.2 38.49 Favored 'General case' 0 C--O 1.201 -1.457 0 C-N-CA 126.278 1.831 . . . . 0.0 111.048 -179.55 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.405 ' HG3' HD13 ' A' ' 130' ' ' ILE . 0.4 OUTLIER -165.52 156.35 13.74 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 -177.766 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.87 118.34 1.11 Allowed Glycine 0 N--CA 1.398 -3.846 0 N-CA-C 108.941 -1.663 . . . . 0.0 108.941 -178.099 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.403 ' HA ' ' HB3' ' A' ' 85' ' ' PRO . 52.8 m -114.52 146.56 40.58 Favored 'General case' 0 C--N 1.279 -2.472 0 C-N-CA 124.584 1.153 . . . . 0.0 110.029 -170.859 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.527 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -106.26 156.66 18.25 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 123.496 0.718 . . . . 0.0 109.112 -178.715 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.484 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 99.5 m-85 -154.48 -179.35 7.88 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 124.08 0.952 . . . . 0.0 109.742 -176.978 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.06 -136.44 51.18 Favored Glycine 0 N--CA 1.458 0.121 0 O-C-N 123.653 0.595 . . . . 0.0 112.669 178.012 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.79 -9.07 83.49 Favored Glycine 0 C--O 1.206 -1.635 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 177.477 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.826 HG21 ' HB ' ' A' ' 126' ' ' ILE . 77.7 t -69.67 -36.42 70.36 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 C-N-CA 123.745 0.818 . . . . 0.0 111.852 -176.107 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.527 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -87.16 -20.25 27.28 Favored 'General case' 0 C--N 1.297 -1.684 0 C-N-CA 119.216 -0.993 . . . . 0.0 112.296 178.306 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 9.6 t -101.03 -52.79 3.2 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.472 0.653 . . . . 0.0 112.195 -173.757 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.485 ' O ' HG22 ' A' ' 112' ' ' VAL . 31.6 m-20 -91.78 -25.81 18.85 Favored 'General case' 0 CA--C 1.49 -1.353 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -173.69 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.639 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 86.1 m-85 -106.61 155.85 19.21 Favored 'General case' 0 N--CA 1.416 -2.152 0 C-N-CA 120.008 -0.677 . . . . 0.0 109.291 177.254 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.3 t -165.48 117.83 1.14 Allowed 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 176.992 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.506 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -153.56 -111.88 0.46 Allowed Glycine 0 N--CA 1.412 -2.924 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 176.714 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.9 p -154.51 -179.72 8.23 Favored 'General case' 0 C--N 1.297 -1.687 0 C-N-CA 123.561 0.744 . . . . 0.0 110.93 -173.66 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -133.95 144.02 36.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 C-N-CA 123.319 0.648 . . . . 0.0 109.874 177.762 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.61 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.0 tttt -121.68 142.82 49.78 Favored 'General case' 0 N--CA 1.432 -1.374 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.648 178.767 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.46 ' CD2' HG22 ' A' ' 105' ' ' VAL . 62.6 t80 -142.42 110.35 5.89 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.517 -179.055 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.9 t 49.77 38.9 16.66 Favored 'General case' 0 CA--C 1.557 1.231 0 C-N-CA 124.43 1.092 . . . . 0.0 111.735 176.017 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.28 18.3 50.05 Favored Glycine 0 CA--C 1.524 0.596 0 C-N-CA 120.922 -0.656 . . . . 0.0 113.624 -179.404 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.61 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 12.2 t -92.73 -179.84 5.27 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 174.597 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 56.3 p -157.87 105.53 1.99 Allowed 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 179.652 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.443 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 2.7 p90 -150.73 160.83 31.79 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 -173.791 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.443 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 45.0 Cg_endo -68.51 148.19 72.35 Favored 'Trans proline' 0 C--N 1.357 0.984 0 C-N-CA 122.935 2.423 . . . . 0.0 113.357 -177.788 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.602 ' CD2' HD21 ' A' ' 109' ' ' LEU . 60.5 t80 -123.61 134.15 25.08 Favored Pre-proline 0 N--CA 1.433 -1.289 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.484 -179.431 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.46 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 60.2 Cg_endo -70.54 148.76 89.19 Favored 'Cis proline' 0 CA--C 1.541 0.862 0 C-N-CA 122.77 -1.763 . . . . 0.0 110.469 -0.838 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.2 t -67.24 -177.22 0.65 Allowed 'General case' 0 CA--C 1.549 0.919 0 CA-C-O 121.266 0.555 . . . . 0.0 110.997 -176.86 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 18.5 p -130.39 -19.88 3.04 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 112.597 0.592 . . . . 0.0 112.597 -173.459 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 21.6 t -130.71 -89.36 0.47 Allowed 'General case' 0 C--O 1.204 -1.335 0 C-N-CA 120.429 -0.508 . . . . 0.0 110.309 -179.988 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -166.58 -173.01 2.33 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 177.888 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.547 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 61.8 p -100.32 163.48 18.17 Favored Pre-proline 0 C--N 1.304 -1.387 0 N-CA-C 112.795 0.665 . . . . 0.0 112.795 179.798 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_endo -56.65 165.27 4.83 Favored 'Trans proline' 0 C--O 1.248 0.99 0 C-N-CA 123.518 2.812 . . . . 0.0 111.43 172.711 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -74.47 122.17 22.62 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.479 -175.959 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 73.2 t -134.9 133.46 53.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 -178.348 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 54' ' ' ASP . 1.5 p -132.97 134.6 57.94 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.292 0 CA-C-N 115.971 -0.558 . . . . 0.0 109.596 -178.55 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.464 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 2.6 m-85 -83.07 117.91 23.18 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 179.182 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -102.07 27.56 6.52 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.756 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.9 m -99.23 -171.56 2.1 Favored 'General case' 0 N--CA 1.426 -1.628 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.291 -178.328 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -151.15 43.58 0.79 Allowed 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.465 0.65 . . . . 0.0 110.39 175.769 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.3 t -168.18 -178.63 3.73 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -176.735 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -67.18 106.78 2.11 Favored 'General case' 0 CA--C 1.511 -0.542 0 C-N-CA 123.344 0.658 . . . . 0.0 109.39 179.607 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -112.6 135.1 21.52 Favored Pre-proline 0 C--N 1.293 -1.866 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 176.342 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.579 ' HB3' ' O ' ' A' ' 39' ' ' SER . 51.4 Cg_exo -53.69 139.61 67.41 Favored 'Trans proline' 0 CA--C 1.503 -1.067 0 C-N-CA 123.865 3.043 . . . . 0.0 112.295 177.357 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 15.5 t90 -85.0 106.85 9.74 Favored Pre-proline 0 C--N 1.298 -1.655 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 179.161 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 104' ' ' PRO . . . . . 0.403 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 60.2 Cg_endo -77.0 88.22 1.42 Allowed 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 121.368 1.379 . . . . 0.0 113.096 -172.952 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.46 HG22 ' CD2' ' A' ' 77' ' ' TYR . 92.6 t -140.62 146.88 23.6 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.103 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 178.127 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.565 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.38 135.05 17.43 Favored 'General case' 0 C--N 1.294 -1.817 0 CA-C-O 120.757 0.313 . . . . 0.0 110.431 177.34 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.496 HD21 HD11 ' A' ' 129' ' ' LEU . 20.1 mt -100.97 105.18 16.38 Favored 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 178.083 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.506 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 43.9 m-85 -83.63 72.58 10.31 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 120.67 0.272 . . . . 0.0 110.716 178.095 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.66 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -98.66 129.17 45.14 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 176.342 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.42 146.89 63.43 Favored Pre-proline 0 N--CA 1.41 -2.426 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 -175.9 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.458 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 40.4 Cg_endo -65.37 126.07 15.61 Favored 'Trans proline' 0 CA--C 1.496 -1.416 0 C-N-CA 123.133 2.555 . . . . 0.0 113.002 -175.181 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.606 ' O ' HG22 ' A' ' 30' ' ' VAL . 16.7 m -84.3 -154.78 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.401 -2.889 0 CA-C-N 114.518 -1.219 . . . . 0.0 108.044 171.667 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 18.5 m -82.76 -30.32 29.05 Favored 'General case' 0 C--N 1.255 -3.508 0 CA-C-O 121.497 0.665 . . . . 0.0 110.025 -170.609 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 18.1 t -84.73 30.81 0.55 Allowed 'General case' 0 N--CA 1.435 -1.201 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.156 -179.821 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -112.23 138.12 49.37 Favored 'General case' 0 N--CA 1.422 -1.831 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.874 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -179.22 128.01 1.2 Allowed Glycine 0 N--CA 1.437 -1.239 0 C-N-CA 120.367 -0.92 . . . . 0.0 112.425 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 68.32 -149.05 49.54 Favored Glycine 0 CA--C 1.486 -1.728 0 CA-C-O 119.125 -0.819 . . . . 0.0 111.928 -177.436 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 57.4 t -59.85 103.4 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 CA-C-N 117.308 0.554 . . . . 0.0 110.088 -177.126 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -103.78 -29.16 11.2 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.953 -178.223 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.527 ' HB ' HG22 ' A' ' 154' ' ' VAL . 73.6 mt -126.69 137.48 57.7 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.849 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 176.947 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.46 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.9 mmpt? -114.06 141.87 46.9 Favored 'General case' 0 C--N 1.31 -1.131 0 C-N-CA 122.959 0.504 . . . . 0.0 110.121 177.048 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -73.03 135.71 44.94 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.286 179.677 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 84.49 11.31 77.98 Favored Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 111.59 -0.604 . . . . 0.0 111.59 -179.016 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 27.3 t -113.98 147.76 38.06 Favored 'General case' 0 N--CA 1.433 -1.324 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 -179.332 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 23.1 tp -73.52 134.99 43.96 Favored 'General case' 0 CA--C 1.506 -0.747 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.795 -179.801 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.826 ' HB ' HG21 ' A' ' 67' ' ' VAL . 35.8 pt -120.12 -25.0 2.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.717 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 179.215 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 127' ' ' ALA . . . . . 0.408 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -163.35 166.0 23.43 Favored 'General case' 0 C--O 1.21 -1.017 0 N-CA-C 110.312 -0.255 . . . . 0.0 110.312 -178.022 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 67.1 t -139.48 113.18 6.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.3 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.496 HD11 HD21 ' A' ' 107' ' ' LEU . 48.1 mt -118.48 143.29 46.81 Favored 'General case' 0 C--N 1.29 -1.995 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 179.751 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.573 HG21 ' NE2' ' A' ' 143' ' ' GLN . 5.3 mp -124.23 128.52 73.92 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 C-N-CA 119.7 -0.8 . . . . 0.0 110.67 178.419 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.566 HD23 ' O ' ' A' ' 131' ' ' LEU . 0.0 OUTLIER -96.11 135.15 38.28 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 175.433 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 132' ' ' ARG . . . . . 0.539 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 8.8 tpt180 -97.92 122.26 40.83 Favored 'General case' 0 C--N 1.285 -2.223 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.573 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 20.5 mm-40 -105.82 104.7 14.47 Favored 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 123.406 0.682 . . . . 0.0 109.268 -177.587 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 6.9 m -127.34 142.14 51.52 Favored 'General case' 0 C--N 1.284 -2.255 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 179.197 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.587 ' CB ' HG23 ' A' ' 52' ' ' ILE . 9.1 p30 . . . . . 0 C--N 1.309 -1.166 0 C-N-CA 119.988 -0.685 . . . . 0.0 110.446 176.498 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 . . . . . 0 N--CA 1.441 -0.912 0 CA-C-O 120.992 0.425 . . . . 0.0 109.935 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 143' ' ' GLN . . . . . 0.573 ' NE2' HG21 ' A' ' 130' ' ' ILE . 17.3 pt20 -134.79 143.93 47.36 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 175.514 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.496 ' HB2' HD22 ' A' ' 131' ' ' LEU . 9.4 m-30 -109.65 130.38 55.52 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 -179.175 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.43 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 52.2 t -90.81 132.27 35.82 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 O-C-N 123.592 0.557 . . . . 0.0 109.799 -178.617 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 146' ' ' TRP . . . . . 0.474 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 61.9 m95 -117.47 96.18 5.29 Favored 'General case' 0 C--N 1.279 -2.48 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 -179.304 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.9 m-80 -79.45 112.63 16.89 Favored 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 177.989 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.495 ' HA ' HG22 ' A' ' 20' ' ' VAL . 26.6 mm -86.37 122.14 38.33 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.816 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -175.799 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 149' ' ' TYR . . . . . 0.417 ' HE1' HD21 ' A' ' 19' ' ' ASN . 40.6 m-85 -117.25 156.2 28.16 Favored 'General case' 0 CA--C 1.487 -1.474 0 CA-C-O 121.633 0.73 . . . . 0.0 110.605 179.222 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -84.28 129.37 34.89 Favored 'General case' 0 N--CA 1.405 -2.685 0 CA-C-N 114.544 -1.207 . . . . 0.0 108.684 175.808 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 15.8 t-20 -91.43 -13.77 31.74 Favored 'General case' 0 C--N 1.29 -2.008 0 N-CA-C 107.383 -1.339 . . . . 0.0 107.383 -178.793 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -150.14 143.62 25.17 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 113.633 -1.621 . . . . 0.0 109.008 -175.201 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -86.37 144.79 27.17 Favored 'General case' 0 C--N 1.307 -1.249 0 O-C-N 124.241 0.963 . . . . 0.0 110.169 -179.777 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.527 HG22 ' HB ' ' A' ' 120' ' ' ILE . 1.5 m -123.96 150.52 28.46 Favored 'Isoleucine or valine' 0 C--O 1.253 1.249 0 C-N-CA 120.701 -0.4 . . . . 0.0 111.24 -177.284 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.2 t -124.32 138.27 54.4 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.124 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -179.613 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.462 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 79.0 t -100.21 100.83 12.64 Favored Pre-proline 0 C--N 1.296 -1.759 0 C-N-CA 123.983 0.913 . . . . 0.0 109.453 178.06 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.502 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 27.5 Cg_endo -66.37 -26.19 48.47 Favored 'Trans proline' 0 CA--C 1.515 -0.428 0 C-N-CA 122.208 1.939 . . . . 0.0 111.773 178.908 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.3 t . . . . . 0 C--O 1.254 1.312 0 O-C-N 124.516 1.135 . . . . 0.0 113.223 176.882 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.458 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.429 -1.482 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 . . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 13.6 t -147.4 159.37 43.77 Favored 'General case' 0 N--CA 1.428 -1.555 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.647 -174.784 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.587 ' HE3' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.81 168.72 19.54 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-O 121.36 0.6 . . . . 0.0 110.747 -173.717 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 76.2 p -105.5 175.82 5.37 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.08 0.467 . . . . 0.0 110.798 179.771 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -73.66 -22.05 60.08 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.627 178.651 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -84.28 -33.33 24.01 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 120.256 -0.578 . . . . 0.0 110.641 -177.784 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 135.13 9.47 1.66 Allowed Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 119.564 -1.303 . . . . 0.0 113.699 176.808 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -85.16 100.02 11.46 Favored 'General case' 0 N--CA 1.433 -1.317 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.884 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.1 117.33 30.0 Favored 'General case' 0 C--N 1.297 -1.71 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.591 178.638 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.458 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 67.3 mt -86.63 127.26 61.16 Favored Pre-proline 0 C--N 1.299 -1.627 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 178.692 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -81.06 169.34 16.28 Favored 'Trans proline' 0 C--O 1.248 0.984 0 C-N-CA 122.78 2.32 . . . . 0.0 111.305 177.985 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 61.3 mt -69.16 132.11 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 177.855 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 129.89 -5.22 6.12 Favored Glycine 0 C--N 1.3 -1.462 0 C-N-CA 120.172 -1.013 . . . . 0.0 111.507 -179.528 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 101.42 163.6 27.33 Favored Glycine 0 N--CA 1.432 -1.595 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 -177.694 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 160.41 -177.45 36.84 Favored Glycine 0 C--N 1.297 -1.614 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 178.612 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.415 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 59.7 p -138.99 147.74 42.55 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.763 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -132.0 161.05 34.1 Favored 'General case' 0 N--CA 1.426 -1.63 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 177.999 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 -116.2 109.06 16.93 Favored 'General case' 0 C--N 1.289 -2.055 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 177.784 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.455 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.3 m -91.1 147.68 5.08 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.416 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 -177.893 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.7 m-85 -131.04 118.87 21.2 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -177.354 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.538 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -125.43 135.63 63.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.108 -176.389 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 30.7 m-80 -91.08 122.7 33.95 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 179.988 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 24' ' ' LEU . . . . . 0.411 HD11 HG22 ' A' ' 36' ' ' VAL . 2.8 mm? -101.94 160.61 14.34 Favored 'General case' 0 C--N 1.285 -2.223 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 178.103 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.2 122.21 52.48 Favored Pre-proline 0 C--N 1.314 -0.955 0 O-C-N 124.116 0.885 . . . . 0.0 108.728 174.76 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.531 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 72.8 Cg_endo -74.71 -1.84 11.67 Favored 'Trans proline' 0 CA--C 1.533 0.441 0 C-N-CA 122.895 2.397 . . . . 0.0 112.968 -176.148 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.408 HG13 ' HG3' ' A' ' 157' ' ' PRO . 95.6 t -129.11 111.27 22.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.475 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 10.3 t -148.19 111.1 0.68 Allowed 'Isoleucine or valine' 0 C--O 1.188 -2.17 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -177.341 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.592 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -96.83 154.65 17.17 Favored 'General case' 0 C--N 1.272 -2.775 0 C-N-CA 123.646 0.778 . . . . 0.0 110.962 179.834 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.581 HG22 ' O ' ' A' ' 112' ' ' VAL . 71.5 t -46.67 122.66 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 C-N-CA 123.051 0.541 . . . . 0.0 110.734 176.24 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.25 1.24 58.16 Favored Glycine 0 C--N 1.315 -0.592 0 CA-C-N 115.536 -0.756 . . . . 0.0 112.919 179.663 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.592 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.7 OUTLIER -73.38 -176.98 2.42 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 123.396 0.678 . . . . 0.0 110.678 175.93 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 64.7 t30 -131.42 92.13 3.12 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.131 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.654 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 28.5 tp -94.09 141.05 28.99 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 119.444 -0.902 . . . . 0.0 109.906 -179.66 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 56.9 t -131.87 120.93 45.98 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.019 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.022 -176.443 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.573 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 48.3 t -90.86 88.21 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.89 0 N-CA-C 105.249 -2.13 . . . . 0.0 105.249 173.655 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -83.26 109.75 17.5 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.318 -177.473 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.415 ' HA ' ' HG2' ' A' ' 41' ' ' GLN . 84.2 mt -95.0 -3.64 48.04 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.111 -178.164 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.1 m -71.15 0.15 8.38 Favored 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 114.831 -1.077 . . . . 0.0 110.125 -179.945 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.5 p -133.21 6.86 3.9 Favored 'General case' 0 N--CA 1.425 -1.677 0 C-N-CA 124.24 1.016 . . . . 0.0 109.911 178.639 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.538 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 46.2 mm-40 -122.23 -19.28 6.57 Favored 'General case' 0 CA--C 1.507 -0.699 0 CA-C-O 121.067 0.461 . . . . 0.0 110.717 -174.557 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 45.2 mt -134.36 138.24 50.2 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -176.219 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.587 ' HB2' ' HE3' ' A' ' 4' ' ' LYS . 72.8 m-85 -143.02 143.44 31.9 Favored 'General case' 0 CA--C 1.492 -1.27 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -174.467 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 44' ' ' CYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 64.8 m -126.87 140.64 52.19 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 -176.327 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -121.89 151.17 40.98 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.313 0.578 . . . . 0.0 110.256 -176.203 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.653 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 24.0 p-10 -107.18 104.06 13.6 Favored 'General case' 0 N--CA 1.411 -2.387 0 CA-C-O 122.886 1.327 . . . . 0.0 110.068 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -74.84 -34.64 62.35 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 112.942 -1.935 . . . . 0.0 111.319 -174.847 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 49.5 m-85 -134.23 72.79 70.76 Favored Pre-proline 0 C--N 1.3 -1.566 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.539 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.653 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 58.7 Cg_endo -72.34 -3.05 12.64 Favored 'Trans proline' 0 C--N 1.334 -0.224 0 C-N-CA 122.775 2.317 . . . . 0.0 113.386 -174.378 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -118.83 -4.19 10.7 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 121.138 0.494 . . . . 0.0 109.799 -178.278 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.52 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -117.99 -29.1 5.72 Favored 'General case' 0 N--CA 1.418 -2.033 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.883 -174.016 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.52 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.0 mp -130.6 134.84 61.54 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.487 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.5 t -69.57 139.74 53.75 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 108.957 -0.756 . . . . 0.0 108.957 177.463 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -86.76 107.96 18.49 Favored 'General case' 0 C--N 1.285 -2.207 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -173.347 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.504 ' CD2' ' HB ' ' A' ' 134' ' ' THR . 73.1 t80 -150.16 145.35 26.24 Favored 'General case' 0 C--N 1.295 -1.794 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.427 -171.357 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.495 HG13 ' HB2' ' A' ' 131' ' ' LEU . 59.9 t -150.66 139.67 15.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 C-N-CA 124.559 1.144 . . . . 0.0 108.666 177.655 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -147.27 122.61 10.29 Favored 'General case' 0 C--O 1.21 -0.992 0 O-C-N 123.311 0.382 . . . . 0.0 110.607 174.617 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.527 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 63.5 tp -64.77 114.92 4.79 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-O 121.315 0.579 . . . . 0.0 110.004 177.195 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 59' ' ' GLN . . . . . 0.472 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 4.2 tp-100 -59.12 -60.02 4.53 Favored 'General case' 0 C--N 1.315 -0.933 0 C-N-CA 126.287 1.835 . . . . 0.0 110.555 176.566 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 60' ' ' ARG . . . . . 0.454 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 4.5 ptp180 -163.06 161.91 25.56 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 115.052 -0.976 . . . . 0.0 108.424 -177.011 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.403 ' H ' HG22 ' A' ' 86' ' ' THR . . . -142.44 131.25 4.59 Favored Glycine 0 N--CA 1.401 -3.641 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 -179.384 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.412 ' HA ' ' HB3' ' A' ' 85' ' ' PRO . 49.1 m -120.07 149.52 42.05 Favored 'General case' 0 C--N 1.288 -2.089 0 C-N-CA 124.072 0.949 . . . . 0.0 110.395 -174.575 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.544 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -111.5 153.4 26.26 Favored 'General case' 0 N--CA 1.486 1.356 0 CA-C-O 117.792 -1.099 . . . . 0.0 108.398 -179.457 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.8 ' O ' HG22 ' A' ' 67' ' ' VAL . 95.2 m-85 -158.35 -179.75 8.39 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 123.646 0.779 . . . . 0.0 111.277 -176.951 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.91 -134.02 51.03 Favored Glycine 0 C--N 1.317 -0.485 0 C-N-CA 121.409 -0.424 . . . . 0.0 112.265 179.769 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.62 -10.22 83.6 Favored Glycine 0 N--CA 1.422 -2.25 0 C-N-CA 120.327 -0.939 . . . . 0.0 112.839 177.306 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.8 HG22 ' O ' ' A' ' 64' ' ' TYR . 12.5 m -73.84 -28.6 24.47 Favored 'Isoleucine or valine' 0 C--O 1.205 -1.252 0 CA-C-N 118.295 1.048 . . . . 0.0 112.262 -174.143 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.544 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -91.14 -19.94 22.54 Favored 'General case' 0 C--N 1.297 -1.675 0 C-N-CA 119.876 -0.73 . . . . 0.0 111.895 177.664 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 7.4 t -100.45 -49.35 4.26 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.481 0.658 . . . . 0.0 111.239 -173.627 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.509 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 49.6 m-20 -96.99 -17.82 19.81 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -174.332 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.566 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 87.2 m-85 -119.31 163.55 16.98 Favored 'General case' 0 C--N 1.294 -1.812 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.957 -179.329 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.2 t -173.06 132.6 0.51 Allowed 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 178.729 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.498 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -167.15 -112.5 0.26 Allowed Glycine 0 N--CA 1.406 -3.334 0 N-CA-C 110.624 -0.99 . . . . 0.0 110.624 174.178 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.411 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.2 p -154.93 -179.96 8.55 Favored 'General case' 0 C--N 1.292 -1.921 0 C-N-CA 123.628 0.771 . . . . 0.0 110.403 -172.933 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.402 ' HB ' ' CD1' ' A' ' 84' ' ' PHE . 2.5 p -134.27 145.5 32.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.319 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.731 ' HG3' ' O ' ' A' ' 80' ' ' SER . 71.0 tttt -123.22 142.99 50.34 Favored 'General case' 0 N--CA 1.416 -2.139 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.397 -179.395 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.479 ' CD1' HG22 ' A' ' 105' ' ' VAL . 71.7 t80 -143.81 112.0 6.3 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.521 -178.429 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 14.7 t 52.78 37.94 25.21 Favored 'General case' 0 CA--C 1.561 1.4 0 CA-C-O 122.025 0.917 . . . . 0.0 110.875 175.951 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.08 10.37 64.49 Favored Glycine 0 CA--C 1.528 0.903 0 CA-C-N 115.684 -0.689 . . . . 0.0 113.731 179.934 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.731 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 21.6 t -84.94 -179.72 7.13 Favored 'General case' 0 C--O 1.206 -1.211 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 177.836 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 48.5 m -159.06 108.83 1.95 Allowed 'General case' 0 C--N 1.279 -2.483 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 177.297 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.475 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 4.0 p90 -149.38 163.1 26.5 Favored Pre-proline 0 C--N 1.306 -1.308 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -174.517 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.475 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 58.6 Cg_endo -68.99 148.79 70.85 Favored 'Trans proline' 0 C--N 1.358 1.057 0 C-N-CA 122.612 2.208 . . . . 0.0 113.425 -175.862 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.509 ' CD2' HD21 ' A' ' 109' ' ' LEU . 51.6 t80 -123.72 132.76 24.3 Favored Pre-proline 0 N--CA 1.435 -1.18 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 179.383 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.47 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 66.8 Cg_endo -72.22 147.58 89.11 Favored 'Cis proline' 0 CA--C 1.542 0.914 0 C-N-CA 122.734 -1.777 . . . . 0.0 110.497 -1.369 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 86' ' ' THR . . . . . 0.403 HG22 ' H ' ' A' ' 61' ' ' GLY . 11.5 t -68.28 -175.84 0.67 Allowed 'General case' 0 CA--C 1.55 0.955 0 CA-C-O 121.229 0.537 . . . . 0.0 111.04 -176.181 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 7.9 p -130.37 -42.88 1.17 Allowed 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 116.07 -0.514 . . . . 0.0 112.289 -175.554 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.2 t -101.3 -86.63 0.4 Allowed 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.592 -175.467 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -170.19 -169.68 0.88 Allowed 'General case' 0 N--CA 1.438 -1.043 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 177.825 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.527 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 21.4 p -101.37 162.77 19.45 Favored Pre-proline 0 C--N 1.302 -1.477 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 177.325 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -63.79 159.4 41.78 Favored 'Trans proline' 0 C--N 1.358 1.059 0 C-N-CA 122.748 2.299 . . . . 0.0 111.64 174.526 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.7 tmm_? -65.35 118.29 9.14 Favored 'General case' 0 C--N 1.315 -0.918 0 C-N-CA 124.695 1.198 . . . . 0.0 109.554 -177.523 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 68.5 t -127.81 128.82 69.68 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.329 -177.07 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 74.2 t -114.29 140.73 33.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.402 179.416 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -87.36 95.65 10.07 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.24 0.543 . . . . 0.0 110.093 177.931 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -86.97 64.57 8.55 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 121.183 0.516 . . . . 0.0 110.392 -179.046 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.5 m -155.21 -179.59 8.23 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 -179.527 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 98' ' ' ARG . . . . . 0.556 ' HA ' HD21 ' A' ' 46' ' ' ASN . 16.7 ptm180 -141.28 50.32 1.61 Allowed 'General case' 0 N--CA 1.44 -0.971 0 CA-C-O 121.899 0.857 . . . . 0.0 110.128 178.996 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 6.9 t -163.39 170.75 17.02 Favored 'General case' 0 N--CA 1.424 -1.733 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 -178.868 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -69.92 101.59 1.79 Allowed 'General case' 0 C--O 1.251 1.169 0 CA-C-O 122.581 1.182 . . . . 0.0 108.755 178.242 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.8 tptm -101.1 137.02 19.6 Favored Pre-proline 0 C--N 1.268 -2.945 0 CA-C-N 113.002 -1.908 . . . . 0.0 109.368 -175.878 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -64.74 146.09 87.81 Favored 'Trans proline' 0 C--O 1.246 0.904 0 C-N-CA 122.673 2.248 . . . . 0.0 111.892 177.073 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 103' ' ' TRP . . . . . 0.404 ' NE1' HG11 ' A' ' 56' ' ' VAL . 15.7 t90 -86.95 108.61 19.33 Favored Pre-proline 0 N--CA 1.44 -0.932 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 -178.563 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -76.63 89.01 1.32 Allowed 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 121.864 1.709 . . . . 0.0 113.154 -173.273 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.479 HG22 ' CD1' ' A' ' 77' ' ' TYR . 81.2 t -139.89 145.86 25.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.038 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 177.824 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.573 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -149.92 136.31 19.01 Favored 'General case' 0 C--N 1.287 -2.121 0 CA-C-O 120.95 0.405 . . . . 0.0 110.223 177.586 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.454 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 15.9 mt -103.69 106.08 16.49 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 178.335 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.498 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 14.6 m-85 -83.01 75.0 9.92 Favored 'General case' 0 C--N 1.284 -2.249 0 N-CA-C 110.159 -0.312 . . . . 0.0 110.159 177.849 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.654 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -95.83 124.96 40.08 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 174.776 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -128.97 146.25 59.87 Favored Pre-proline 0 N--CA 1.409 -2.492 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 -176.86 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.509 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 36.2 Cg_endo -63.78 126.01 16.56 Favored 'Trans proline' 0 N--CA 1.444 -1.424 0 C-N-CA 122.712 2.274 . . . . 0.0 113.685 -175.813 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.581 ' O ' HG22 ' A' ' 30' ' ' VAL . 13.9 m -85.62 -155.96 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.392 -3.346 0 CA-C-N 114.007 -1.451 . . . . 0.0 108.465 171.648 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 14.4 m -79.86 -33.39 40.15 Favored 'General case' 0 C--N 1.262 -3.225 0 CA-C-O 121.446 0.641 . . . . 0.0 110.12 -170.36 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.2 t -83.19 26.89 0.6 Allowed 'General case' 0 N--CA 1.425 -1.684 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.558 -178.137 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.424 ' HB2' ' O ' ' A' ' 70' ' ' ASN . . . -107.8 134.35 50.87 Favored 'General case' 0 N--CA 1.424 -1.766 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 178.478 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -176.78 129.21 1.44 Allowed Glycine 0 N--CA 1.437 -1.235 0 C-N-CA 120.571 -0.824 . . . . 0.0 111.469 178.814 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.4 -150.71 52.01 Favored Glycine 0 CA--C 1.495 -1.204 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 -176.305 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -55.9 105.99 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 CA-C-O 122.522 1.153 . . . . 0.0 111.932 -178.211 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -106.61 -28.33 10.3 Favored 'General case' 0 C--N 1.294 -1.812 0 CA-C-N 114.51 -1.223 . . . . 0.0 111.375 -177.922 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.443 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 54.8 mt -130.07 135.01 61.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.118 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.507 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.1 mmpt? -109.84 141.48 42.47 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-O 121.164 0.507 . . . . 0.0 111.123 176.767 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 122' ' ' ALA . . . . . 0.4 ' H ' ' HB3' ' A' ' 153' ' ' ASP . . . -72.09 123.28 22.52 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.429 178.965 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 97.94 -0.0 58.95 Favored Glycine 0 C--N 1.306 -1.097 0 N-CA-C 111.316 -0.714 . . . . 0.0 111.316 -176.613 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 31.0 t -97.16 145.42 26.04 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.329 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.416 HD23 ' CZ ' ' A' ' 149' ' ' TYR . 3.2 tm? -76.84 123.43 26.23 Favored 'General case' 0 N--CA 1.431 -1.38 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.82 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.556 ' HB ' HG11 ' A' ' 67' ' ' VAL . 28.4 pt -108.63 -29.75 2.53 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.745 -179.746 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 127' ' ' ALA . . . . . 0.464 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -158.88 168.5 26.64 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 119.46 -0.896 . . . . 0.0 110.639 -177.238 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.405 HG23 HD11 ' A' ' 125' ' ' LEU . 72.3 t -142.12 113.48 3.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 179.021 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.412 HD11 HD21 ' A' ' 107' ' ' LEU . 57.0 mt -117.24 151.53 36.73 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 178.533 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 130' ' ' ILE . . . . . 0.522 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.5 mp -135.71 129.69 48.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 178.027 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.495 ' HB2' HG13 ' A' ' 56' ' ' VAL . 1.2 pp -97.34 142.0 29.75 Favored 'General case' 0 CA--C 1.499 -0.991 0 C-N-CA 119.864 -0.734 . . . . 0.0 109.022 177.352 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 132' ' ' ARG . . . . . 0.472 ' HG2' ' HB2' ' A' ' 59' ' ' GLN . 15.4 mmm180 -96.64 116.11 28.55 Favored 'General case' 0 C--N 1.279 -2.477 0 C-N-CA 124.264 1.026 . . . . 0.0 108.551 175.848 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 26.2 tp60 -85.12 135.48 33.96 Favored 'General case' 0 N--CA 1.413 -2.302 0 N-CA-C 105.55 -2.019 . . . . 0.0 105.55 174.966 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.504 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 25.2 m -139.0 135.33 34.17 Favored 'General case' 0 C--N 1.262 -3.199 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 174.807 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.52 ' HB2' HG23 ' A' ' 52' ' ' ILE . 24.1 p-10 . . . . . 0 C--N 1.303 -1.446 0 CA-C-O 121.695 0.759 . . . . 0.0 110.909 -176.742 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 . . . . . 0 N--CA 1.43 -1.474 0 N-CA-C 107.243 -1.392 . . . . 0.0 107.243 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -132.48 144.89 50.76 Favored 'General case' 0 C--N 1.292 -1.911 0 C-N-CA 118.937 -1.105 . . . . 0.0 111.341 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 10.2 m-30 -109.24 127.52 54.32 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -177.078 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 145' ' ' VAL . . . . . 0.415 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 48.5 t -91.17 137.04 22.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 123.538 0.524 . . . . 0.0 110.18 -178.027 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 60.6 m95 -125.35 96.56 4.87 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 -178.084 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -81.56 114.44 20.27 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 178.146 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.464 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 20.9 mm -88.0 122.85 40.12 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -176.268 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 149' ' ' TYR . . . . . 0.416 ' CZ ' HD23 ' A' ' 125' ' ' LEU . 83.4 m-85 -119.01 152.92 35.53 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.822 178.584 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.12 129.6 35.04 Favored 'General case' 0 N--CA 1.407 -2.591 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 177.211 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 10.9 t-20 -90.47 -12.89 35.98 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 122.452 1.12 . . . . 0.0 108.082 -177.088 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 5.6 t-20 -149.03 144.47 26.74 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 113.964 -1.471 . . . . 0.0 108.911 -175.133 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 153' ' ' ASP . . . . . 0.4 ' HB3' ' H ' ' A' ' 122' ' ' ALA . 17.3 p-10 -86.63 141.92 28.62 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 123.982 0.801 . . . . 0.0 111.762 -179.11 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.531 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 70.5 t -117.46 139.04 46.14 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 CA-C-N 115.228 -0.897 . . . . 0.0 111.632 -173.597 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -120.1 132.3 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 179.21 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.475 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 71.7 t -97.71 103.59 17.4 Favored Pre-proline 0 C--N 1.292 -1.904 0 C-N-CA 123.933 0.893 . . . . 0.0 109.927 179.909 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 157' ' ' PRO . . . . . 0.411 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 23.2 Cg_endo -68.15 -27.41 35.43 Favored 'Trans proline' 0 CA--C 1.509 -0.754 0 C-N-CA 121.978 1.786 . . . . 0.0 111.816 179.719 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 5.0 t . . . . . 0 CA--C 1.549 0.94 0 C-N-CA 124.706 1.202 . . . . 0.0 113.628 177.911 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 2' ' ' ALA . . . . . 0.422 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.436 -1.148 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 . . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.455 ' HB2' ' CZ2' ' A' ' 146' ' ' TRP . 64.4 m -144.99 168.47 20.2 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 120.193 -0.603 . . . . 0.0 110.726 -176.616 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 4' ' ' LYS . . . . . 0.455 ' HA ' ' O ' ' A' ' 9' ' ' THR . 0.3 OUTLIER -148.82 162.2 40.28 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 123.632 0.773 . . . . 0.0 109.477 178.868 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 5' ' ' THR . . . . . 0.501 HG22 HG22 ' A' ' 20' ' ' VAL . 71.9 p -100.24 175.86 5.58 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 121.394 0.616 . . . . 0.0 110.414 -179.744 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.29 -13.54 59.92 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-N 114.371 -1.286 . . . . 0.0 110.654 179.157 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -87.82 -34.31 18.3 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 118.895 -1.122 . . . . 0.0 108.63 175.265 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 134.19 7.2 2.29 Favored Glycine 0 N--CA 1.436 -1.304 0 C-N-CA 120.0 -1.095 . . . . 0.0 113.301 177.049 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.455 ' O ' ' HA ' ' A' ' 4' ' ' LYS . 5.1 m -76.55 99.28 4.91 Favored 'General case' 0 N--CA 1.442 -0.873 0 CA-C-N 117.601 0.7 . . . . 0.0 109.121 179.869 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.55 118.43 30.99 Favored 'General case' 0 C--N 1.294 -1.819 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.271 178.314 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.422 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 62.4 mt -96.53 118.79 64.98 Favored Pre-proline 0 C--N 1.302 -1.459 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 177.233 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -79.12 174.85 11.55 Favored 'Trans proline' 0 C--O 1.252 1.193 0 C-N-CA 122.637 2.224 . . . . 0.0 110.655 177.935 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 53.8 mt -71.99 119.85 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.247 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 177.217 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 151.76 -12.11 0.73 Allowed Glycine 0 C--N 1.291 -1.96 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -172.995 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 94.24 161.2 34.88 Favored Glycine 0 N--CA 1.433 -1.547 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 177.651 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 162.05 -167.92 36.9 Favored Glycine 0 CA--C 1.473 -2.564 0 C-N-CA 118.888 -1.625 . . . . 0.0 111.904 179.109 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 14.5 m -144.6 147.64 33.39 Favored 'General case' 0 C--N 1.286 -2.19 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 -179.386 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.22 156.44 48.98 Favored 'General case' 0 N--CA 1.426 -1.637 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 -179.134 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -104.78 111.02 23.6 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 179.91 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 20' ' ' VAL . . . . . 0.501 HG22 HG22 ' A' ' 5' ' ' THR . 41.3 t -98.68 139.59 20.26 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.901 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.347 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -128.66 119.09 24.04 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -177.288 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 22' ' ' VAL . . . . . 0.53 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.9 p -122.74 129.75 74.96 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-O 121.884 0.85 . . . . 0.0 111.089 -175.899 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -88.73 119.17 28.97 Favored 'General case' 0 C--N 1.291 -1.974 0 CA-C-N 114.847 -1.07 . . . . 0.0 109.439 179.546 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 27.8 mt -107.06 160.79 15.29 Favored 'General case' 0 C--N 1.28 -2.453 0 CA-C-N 114.625 -1.17 . . . . 0.0 109.185 -177.58 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.5 121.56 49.22 Favored Pre-proline 0 C--O 1.206 -1.2 0 O-C-N 124.01 0.819 . . . . 0.0 108.871 177.826 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 26' ' ' PRO . . . . . 0.557 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 60.1 Cg_endo -73.99 -2.47 12.32 Favored 'Trans proline' 0 CA--C 1.53 0.282 0 C-N-CA 122.786 2.324 . . . . 0.0 113.302 -175.627 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 96.0 t -127.83 109.96 21.04 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -179.308 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.421 HG21 HD22 ' A' ' 34' ' ' LEU . 5.8 t -146.57 106.74 0.66 Allowed 'Isoleucine or valine' 0 C--O 1.189 -2.114 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -178.035 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 29' ' ' ASN . . . . . 0.568 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.7 OUTLIER -94.27 153.98 17.76 Favored 'General case' 0 C--N 1.277 -2.581 0 C-N-CA 123.246 0.618 . . . . 0.0 111.506 179.983 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.52 HG22 ' O ' ' A' ' 112' ' ' VAL . 85.5 t -50.66 118.98 0.84 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.738 0 C-N-CA 123.274 0.629 . . . . 0.0 111.051 179.405 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.37 7.88 50.92 Favored Glycine 0 C--N 1.309 -0.917 0 CA-C-N 114.98 -1.009 . . . . 0.0 112.138 -178.527 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 32' ' ' GLN . . . . . 0.568 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.8 OUTLIER -78.66 -177.24 5.28 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 123.493 0.717 . . . . 0.0 109.633 173.09 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -132.93 92.4 3.03 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 177.984 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.68 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 23.9 tp -92.67 145.51 24.37 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 119.705 -0.798 . . . . 0.0 109.247 179.407 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.9 t -136.09 121.74 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.584 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -177.536 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.622 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 62.0 t -91.74 88.62 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.406 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 175.298 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -84.2 115.53 22.48 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 120.008 -0.677 . . . . 0.0 110.641 -178.681 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.4 mt -94.7 -1.23 53.43 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.718 -179.313 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 31.6 t -75.04 2.17 11.24 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.925 0.869 . . . . 0.0 109.477 178.797 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.5 p -129.25 4.26 5.21 Favored 'General case' 0 C--N 1.288 -2.074 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.46 176.348 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 41' ' ' GLN . . . . . 0.53 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 42.7 mm-40 -124.58 -20.8 5.01 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-O 121.091 0.472 . . . . 0.0 110.726 -174.651 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 26.8 mt -133.82 136.47 53.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.978 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -176.32 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.448 ' HA ' ' HA ' ' A' ' 102' ' ' PRO . 62.5 m-85 -133.49 139.75 46.84 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 -176.938 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 60.5 m -125.03 134.22 52.65 Favored 'General case' 0 C--N 1.272 -2.784 0 CA-C-O 121.273 0.559 . . . . 0.0 111.743 -177.783 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 45' ' ' HIS . . . . . 0.413 ' HB3' ' CB ' ' A' ' 100' ' ' ASP . 23.6 p-80 -119.9 129.89 54.58 Favored 'General case' 0 C--N 1.295 -1.772 0 CA-C-O 121.816 0.817 . . . . 0.0 110.775 -178.118 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 46' ' ' ASN . . . . . 0.599 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 4.8 p-10 -97.84 95.0 7.23 Favored 'General case' 0 C--N 1.275 -2.658 0 CA-C-O 123.053 1.406 . . . . 0.0 107.567 178.317 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.54 -19.93 51.8 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-N 113.64 -1.618 . . . . 0.0 113.715 -172.304 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -135.24 65.05 62.77 Favored Pre-proline 0 C--N 1.313 -0.98 0 C-N-CA 120.147 -0.621 . . . . 0.0 110.947 178.758 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 49' ' ' PRO . . . . . 0.599 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 35.7 Cg_endo -64.98 -18.48 62.3 Favored 'Trans proline' 0 C--N 1.355 0.895 0 C-N-CA 123.182 2.588 . . . . 0.0 115.302 -171.213 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -108.14 -15.98 14.37 Favored 'General case' 0 C--N 1.289 -2.045 0 C-N-CA 119.66 -0.816 . . . . 0.0 110.641 -176.249 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 51' ' ' THR . . . . . 0.575 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -101.14 -31.22 11.14 Favored 'General case' 0 N--CA 1.415 -2.211 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 -174.11 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.575 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.2 mp -126.47 141.87 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.348 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 178.969 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 7.5 t -86.78 122.13 30.23 Favored 'General case' 0 N--CA 1.405 -2.698 0 N-CA-C 103.462 -2.792 . . . . 0.0 103.462 172.205 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 54' ' ' ASP . . . . . 0.482 ' OD2' ' HB2' ' A' ' 46' ' ' ASN . 17.1 m-20 -93.39 106.02 18.03 Favored 'General case' 0 C--N 1.256 -3.484 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 -175.125 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 55' ' ' TYR . . . . . 0.552 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 10.7 t80 -123.13 133.43 54.27 Favored 'General case' 0 C--N 1.285 -2.22 0 CA-C-N 113.852 -1.522 . . . . 0.0 109.974 -172.613 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.2 t -128.46 142.99 42.42 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 115.285 -0.87 . . . . 0.0 109.27 -174.966 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.12 128.93 12.46 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 123.715 0.634 . . . . 0.0 109.332 172.619 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.525 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 34.3 tp -71.2 102.86 2.63 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 173.353 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.5 tp-100 -56.22 -56.66 18.28 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 112.9 -1.954 . . . . 0.0 110.019 -176.928 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 6.1 ptp180 -158.76 151.14 21.61 Favored 'General case' 0 N--CA 1.41 -2.47 0 CA-C-N 114.251 -1.34 . . . . 0.0 108.197 -177.956 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.79 123.99 2.26 Favored Glycine 0 N--CA 1.405 -3.412 0 N-CA-C 108.611 -1.795 . . . . 0.0 108.611 -178.656 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.421 ' HA ' ' HB3' ' A' ' 85' ' ' PRO . 66.0 m -116.47 148.18 41.0 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 124.519 1.127 . . . . 0.0 110.83 -171.529 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 63' ' ' ALA . . . . . 0.511 ' HB1' HG23 ' A' ' 67' ' ' VAL . . . -107.72 154.99 20.68 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.266 1.026 . . . . 0.0 108.62 -179.852 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 64' ' ' TYR . . . . . 0.767 ' O ' HG22 ' A' ' 67' ' ' VAL . 87.4 m-85 -156.06 -179.35 8.05 Favored 'General case' 0 N--CA 1.483 1.193 0 CA-C-N 118.351 0.523 . . . . 0.0 111.852 -176.956 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.33 -122.0 26.22 Favored Glycine 0 C--N 1.319 -0.393 0 CA-C-N 116.281 -0.418 . . . . 0.0 113.068 178.384 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -91.06 -10.38 62.64 Favored Glycine 0 N--CA 1.417 -2.57 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.843 177.076 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.767 HG22 ' O ' ' A' ' 64' ' ' TYR . 12.5 m -76.77 -25.59 15.95 Favored 'Isoleucine or valine' 0 C--O 1.206 -1.23 0 CA-C-N 118.174 0.987 . . . . 0.0 112.289 -172.1 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.505 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -90.66 -23.75 20.68 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 121.495 0.664 . . . . 0.0 111.74 177.701 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 69' ' ' SER . . . . . 0.402 ' N ' HD12 ' A' ' 68' ' ' LEU . 21.7 m -102.03 -52.91 3.05 Favored 'General case' 0 C--N 1.305 -1.366 0 N-CA-C 113.943 1.09 . . . . 0.0 113.943 -175.226 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 70' ' ' ASN . . . . . 0.496 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 53.7 m-20 -88.09 -22.63 24.03 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 -177.41 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 71' ' ' PHE . . . . . 0.556 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 87.6 m-85 -115.48 164.12 14.75 Favored 'General case' 0 C--N 1.294 -1.842 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.944 179.832 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.3 t -172.63 134.22 0.63 Allowed 'General case' 0 N--CA 1.416 -2.13 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 177.266 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.613 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -165.58 -114.75 0.3 Allowed Glycine 0 N--CA 1.398 -3.847 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 173.401 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 74' ' ' THR . . . . . 0.411 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.0 OUTLIER -153.52 -179.85 8.15 Favored 'General case' 0 C--N 1.273 -2.728 0 C-N-CA 124.176 0.991 . . . . 0.0 110.113 -173.917 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -132.7 152.04 35.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 C-N-CA 122.714 0.406 . . . . 0.0 109.958 178.586 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 76' ' ' LYS . . . . . 0.636 ' HG3' ' O ' ' A' ' 80' ' ' SER . 81.4 tttt -129.04 145.67 51.2 Favored 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 123.79 0.836 . . . . 0.0 110.128 -179.475 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 77' ' ' TYR . . . . . 0.424 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 58.1 t80 -147.28 112.49 5.52 Favored 'General case' 0 C--N 1.314 -0.96 0 O-C-N 123.777 0.673 . . . . 0.0 109.301 -178.655 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 23.0 t 54.97 36.28 26.48 Favored 'General case' 0 CA--C 1.551 1.003 0 C-N-CA 123.627 0.771 . . . . 0.0 110.448 177.188 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.58 8.18 66.05 Favored Glycine 0 CA--C 1.529 0.941 0 CA-C-N 115.459 -0.791 . . . . 0.0 114.095 -179.421 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 80' ' ' SER . . . . . 0.636 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 17.3 t -79.68 -179.52 6.94 Favored 'General case' 0 CA--C 1.543 0.682 0 CA-C-N 117.275 0.537 . . . . 0.0 109.994 -179.678 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 22.6 t -157.08 111.88 2.76 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 178.713 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 82' ' ' TYR . . . . . 0.433 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 2.6 p90 -154.6 161.42 29.4 Favored Pre-proline 0 CA--C 1.552 1.056 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -175.5 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 83' ' ' PRO . . . . . 0.433 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 54.0 Cg_endo -67.97 150.53 78.01 Favored 'Trans proline' 0 C--N 1.361 1.218 0 C-N-CA 122.884 2.389 . . . . 0.0 113.503 -176.761 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.474 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 57.8 t80 -126.39 132.65 24.4 Favored Pre-proline 0 N--CA 1.44 -0.967 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.067 179.785 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 85' ' ' PRO . . . . . 0.474 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 62.4 Cg_endo -69.95 147.07 84.29 Favored 'Cis proline' 0 CA--C 1.549 1.254 0 C-N-CA 123.125 -1.615 . . . . 0.0 111.16 -1.21 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.1 t -69.35 -176.98 1.04 Allowed 'General case' 0 CA--C 1.549 0.941 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.014 -175.294 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 14.1 p -127.41 -42.6 1.65 Allowed 'General case' 0 N--CA 1.432 -1.346 0 N-CA-C 112.799 0.666 . . . . 0.0 112.799 -172.418 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.6 t -108.12 -72.17 0.73 Allowed 'General case' 0 N--CA 1.432 -1.334 0 C-N-CA 119.74 -0.784 . . . . 0.0 111.527 -175.533 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 176.6 -177.42 0.14 Allowed 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 -174.991 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.525 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 43.5 p -101.32 168.44 9.15 Favored Pre-proline 0 C--N 1.295 -1.781 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 178.555 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 91' ' ' PRO . . . . . 0.443 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 12.1 Cg_endo -54.43 164.73 2.72 Favored 'Trans proline' 0 C--O 1.252 1.175 0 C-N-CA 123.162 2.574 . . . . 0.0 112.188 171.305 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.552 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 1.7 tmm_? -84.82 101.44 12.27 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.131 -172.625 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 87.6 t -114.14 121.22 65.84 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 CA-C-N 114.893 -1.049 . . . . 0.0 111.402 -176.995 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 93.5 t -108.28 142.29 21.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 CA-C-N 115.106 -0.952 . . . . 0.0 108.739 177.72 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -98.52 110.6 23.17 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 176.085 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 46.2 m-80 -108.46 32.16 5.05 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-O 121.708 0.766 . . . . 0.0 110.075 178.891 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.3 m -85.16 -172.53 4.22 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.375 -177.674 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 16.4 ptp180 -145.99 36.46 1.03 Allowed 'General case' 0 C--N 1.307 -1.242 0 CA-C-O 121.85 0.833 . . . . 0.0 109.688 178.079 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 12.4 t -168.89 177.69 4.88 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 105.435 -2.061 . . . . 0.0 105.435 -178.995 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 100' ' ' ASP . . . . . 0.413 ' CB ' ' HB3' ' A' ' 45' ' ' HIS . 1.5 p-10 -84.75 127.71 34.25 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 178.509 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 101' ' ' LYS . . . . . 0.549 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 6.5 mmpt? -117.66 147.34 40.72 Favored Pre-proline 0 C--N 1.28 -2.447 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.666 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 102' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 43' ' ' PHE . 31.0 Cg_endo -67.62 143.5 62.61 Favored 'Trans proline' 0 N--CA 1.44 -1.626 0 C-N-CA 122.375 2.05 . . . . 0.0 111.013 -178.718 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 14.7 t90 -80.81 107.95 8.76 Favored Pre-proline 0 C--N 1.305 -1.361 0 N-CA-C 106.595 -1.632 . . . . 0.0 106.595 -176.742 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -77.25 88.98 1.36 Allowed 'Trans proline' 0 N--CA 1.443 -1.459 0 C-N-CA 121.276 1.317 . . . . 0.0 112.683 -172.273 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 96.3 t -139.9 144.34 28.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 177.291 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 106' ' ' ALA . . . . . 0.622 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -147.84 134.47 19.87 Favored 'General case' 0 N--CA 1.419 -1.98 0 CA-C-O 120.785 0.326 . . . . 0.0 110.155 178.096 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 107' ' ' LEU . . . . . 0.469 HD21 HD11 ' A' ' 129' ' ' LEU . 17.7 mt -101.73 104.3 15.1 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.242 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 108' ' ' TYR . . . . . 0.613 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 16.5 m-85 -79.56 68.42 5.6 Favored 'General case' 0 C--N 1.287 -2.123 0 CA-C-O 120.514 0.197 . . . . 0.0 111.167 177.814 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.68 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -90.59 128.53 36.62 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 175.358 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.15 145.29 56.73 Favored Pre-proline 0 N--CA 1.416 -2.154 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.182 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 111' ' ' PRO . . . . . 0.496 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 30.7 Cg_endo -63.17 124.5 14.01 Favored 'Trans proline' 0 CA--C 1.498 -1.3 0 C-N-CA 122.927 2.418 . . . . 0.0 113.936 -176.24 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 112' ' ' VAL . . . . . 0.52 ' O ' HG22 ' A' ' 30' ' ' VAL . 19.5 m -86.36 -158.67 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.391 -3.419 0 CA-C-N 114.242 -1.345 . . . . 0.0 108.19 171.187 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 44.9 m -81.2 -22.35 38.91 Favored 'General case' 0 C--N 1.254 -3.575 0 O-C-N 121.636 -0.665 . . . . 0.0 111.069 -171.792 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.3 t -81.8 12.19 4.21 Favored 'General case' 0 CA--C 1.549 0.931 0 CA-C-O 121.771 0.796 . . . . 0.0 109.977 179.491 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.477 ' HB2' ' O ' ' A' ' 70' ' ' ASN . . . -98.98 135.42 40.41 Favored 'General case' 0 N--CA 1.419 -2.017 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.455 -179.708 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -179.82 122.96 0.81 Allowed Glycine 0 C--O 1.245 0.842 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 179.266 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 70.0 -155.01 53.09 Favored Glycine 0 C--N 1.307 -1.075 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 -174.922 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.1 p -53.88 106.86 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 122.541 1.162 . . . . 0.0 112.123 -178.174 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -108.56 -22.04 12.45 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 114.302 -1.317 . . . . 0.0 111.159 -176.848 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 120' ' ' ILE . . . . . 0.549 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.2 mt -136.34 133.47 49.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.053 0 N-CA-C 107.516 -1.291 . . . . 0.0 107.516 178.341 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.435 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.0 mmpt? -111.53 139.09 47.25 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 177.384 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.32 125.96 27.75 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 177.922 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 101.36 -10.77 58.14 Favored Glycine 0 N--CA 1.428 -1.885 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.298 -178.089 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 97.8 p -94.05 148.64 21.97 Favored 'General case' 0 C--O 1.252 1.22 0 C-N-CA 119.861 -0.736 . . . . 0.0 110.241 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 125' ' ' LEU . . . . . 0.445 HD11 HG23 ' A' ' 128' ' ' VAL . 3.0 tm? -76.35 124.15 27.06 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-N 115.011 -0.995 . . . . 0.0 108.878 -179.202 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 126' ' ' ILE . . . . . 0.582 ' HB ' HG11 ' A' ' 67' ' ' VAL . 27.6 pt -108.38 -29.92 2.53 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.389 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.878 179.901 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 127' ' ' ALA . . . . . 0.446 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -157.97 165.5 34.99 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.605 -0.838 . . . . 0.0 110.376 -176.595 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.445 HG23 HD11 ' A' ' 125' ' ' LEU . 64.4 t -139.6 114.18 7.37 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.796 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 177.929 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 129' ' ' LEU . . . . . 0.469 HD11 HD21 ' A' ' 107' ' ' LEU . 40.0 mt -119.58 145.49 46.35 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 5.4 mp -129.64 128.85 66.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 C-N-CA 120.324 -0.551 . . . . 0.0 110.078 177.155 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 131' ' ' LEU . . . . . 0.432 ' C ' HD12 ' A' ' 131' ' ' LEU . 1.5 pp -92.62 138.31 31.61 Favored 'General case' 0 N--CA 1.424 -1.733 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 172.856 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 132' ' ' ARG . . . . . 0.449 ' HE ' ' HB3' ' A' ' 143' ' ' GLN . 3.9 tpm_? -97.24 112.95 24.52 Favored 'General case' 0 C--N 1.249 -3.803 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 176.256 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.1 130.46 40.26 Favored 'General case' 0 N--CA 1.422 -1.849 0 N-CA-C 104.991 -2.226 . . . . 0.0 104.991 177.686 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 63.6 m -137.92 138.65 39.22 Favored 'General case' 0 C--N 1.273 -2.731 0 C-N-CA 120.396 -0.522 . . . . 0.0 110.179 174.277 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.489 ' CB ' HG23 ' A' ' 52' ' ' ILE . 20.0 p30 . . . . . 0 C--N 1.306 -1.302 0 CA-C-O 121.524 0.678 . . . . 0.0 112.051 -175.717 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 . . . . . 0 N--CA 1.436 -1.174 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 143' ' ' GLN . . . . . 0.449 ' HB3' ' HE ' ' A' ' 132' ' ' ARG . 13.7 pt20 -130.22 141.32 50.65 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.647 179.884 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 7.0 m-30 -104.6 127.99 52.48 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 -175.575 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 57.6 t -93.24 136.24 25.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -178.923 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 146' ' ' TRP . . . . . 0.455 ' CZ2' ' HB2' ' A' ' 3' ' ' CYS . 66.9 m95 -123.87 95.79 4.7 Favored 'General case' 0 C--N 1.281 -2.381 0 N-CA-C 108.272 -1.011 . . . . 0.0 108.272 -177.19 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -80.94 114.17 19.64 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 177.961 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 148' ' ' ILE . . . . . 0.449 HG22 HD11 ' A' ' 126' ' ' ILE . 22.6 mm -89.92 122.03 40.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 -175.785 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -118.14 157.99 25.89 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 178.241 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.6 131.89 35.29 Favored 'General case' 0 N--CA 1.407 -2.599 0 CA-C-N 115.002 -0.999 . . . . 0.0 108.523 176.216 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 34.2 t-20 -95.52 -8.96 33.76 Favored 'General case' 0 C--N 1.29 -2.007 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 -178.401 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -153.79 145.43 23.31 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 113.869 -1.514 . . . . 0.0 108.713 -175.959 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -84.8 140.41 31.23 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 124.138 0.899 . . . . 0.0 111.198 -178.539 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.557 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 70.3 t -118.17 134.66 61.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.015 -176.653 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.1 t -119.24 133.08 67.21 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.545 0 N-CA-C 107.178 -1.415 . . . . 0.0 107.178 -179.966 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 156' ' ' VAL . . . . . 0.453 HG12 ' HB ' ' A' ' 158' ' ' THR . 75.2 t -97.65 102.64 13.66 Favored Pre-proline 0 C--N 1.289 -2.033 0 C-N-CA 123.375 0.67 . . . . 0.0 109.962 179.389 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -70.58 -24.55 25.8 Favored 'Trans proline' 0 CA--C 1.516 -0.403 0 C-N-CA 121.87 1.714 . . . . 0.0 111.584 -179.261 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 158' ' ' THR . . . . . 0.453 ' HB ' HG12 ' A' ' 156' ' ' VAL . 7.3 t . . . . . 0 CA--C 1.545 0.779 0 C-N-CA 125.303 1.441 . . . . 0.0 112.723 176.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 37.1 t80 . . . . . 0 CA--C 1.496 -1.11 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.62 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -141.11 -171.3 3.24 Favored 'General case' 0 C--N 1.296 -1.748 0 CA-C-N 115.212 -0.904 . . . . 0.0 109.876 -173.349 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 15.7 t -152.15 158.31 42.75 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 -176.747 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.612 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -143.38 161.54 38.11 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 121.178 0.513 . . . . 0.0 111.208 -174.271 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.9 p -100.38 175.98 5.52 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.383 0.611 . . . . 0.0 110.653 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -76.41 -19.52 58.02 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.776 178.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -83.52 -34.0 25.38 Favored 'General case' 0 CA--C 1.514 -0.433 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.732 -179.528 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 130.32 27.31 0.76 Allowed Glycine 0 N--CA 1.441 -1.022 0 C-N-CA 119.907 -1.139 . . . . 0.0 112.348 177.321 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.403 ' O ' ' HA ' ' A' ' 4' ' ' LYS . 9.2 m -99.82 99.37 10.16 Favored 'General case' 0 N--CA 1.423 -1.816 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 177.831 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.5 122.57 35.06 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 176.109 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.62 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 65.3 mt -97.63 117.59 65.14 Favored Pre-proline 0 C--N 1.294 -1.817 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 178.676 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -75.33 171.36 18.41 Favored 'Trans proline' 0 C--O 1.245 0.845 0 C-N-CA 122.62 2.213 . . . . 0.0 111.673 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 69.6 mt -67.17 127.57 28.95 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.568 179.285 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 138.37 0.66 2.35 Favored Glycine 0 C--N 1.303 -1.3 0 C-N-CA 120.852 -0.69 . . . . 0.0 111.957 -177.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.49 168.87 43.72 Favored Glycine 0 N--CA 1.427 -1.921 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -178.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 155.49 -165.3 32.4 Favored Glycine 0 C--N 1.288 -2.135 0 C-N-CA 120.06 -1.067 . . . . 0.0 110.879 178.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.475 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 58.1 p -150.28 147.06 27.19 Favored 'General case' 0 N--CA 1.422 -1.868 0 CA-C-N 116.844 0.322 . . . . 0.0 110.373 -177.849 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -132.43 163.52 28.58 Favored 'General case' 0 N--CA 1.428 -1.556 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 178.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -116.71 107.52 14.78 Favored 'General case' 0 C--N 1.292 -1.929 0 N-CA-C 106.997 -1.482 . . . . 0.0 106.997 178.616 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.427 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.4 m -91.44 150.07 3.89 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.35 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -179.403 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 62.5 m-85 -131.92 112.16 12.18 Favored 'General case' 0 CA--C 1.485 -1.537 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -177.248 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.541 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 4.5 p -117.1 132.4 66.97 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.293 0 CA-C-O 121.815 0.817 . . . . 0.0 111.535 -173.728 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.456 ' HB3' ' HB3' ' A' ' 151' ' ' ASN . 2.1 p30 -98.12 123.57 42.23 Favored 'General case' 0 C--N 1.286 -2.176 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.171 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.403 HD11 ' HA ' ' A' ' 36' ' ' VAL . 2.5 mm? -106.83 160.55 15.42 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 114.408 -1.269 . . . . 0.0 108.051 -178.712 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -54.92 121.46 35.31 Favored Pre-proline 0 C--N 1.308 -1.233 0 O-C-N 124.381 1.051 . . . . 0.0 109.284 175.501 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 63.8 Cg_endo -74.79 1.47 7.57 Favored 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 122.926 2.417 . . . . 0.0 113.035 -177.274 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.464 HG13 ' HG3' ' A' ' 157' ' ' PRO . 86.0 t -128.82 110.11 20.33 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 178.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.511 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 4.5 t -145.96 111.65 1.06 Allowed 'Isoleucine or valine' 0 C--O 1.185 -2.293 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 -179.352 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.59 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -100.57 152.52 20.32 Favored 'General case' 0 C--N 1.267 -2.998 0 C-N-CA 122.707 0.403 . . . . 0.0 111.381 -178.236 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.403 HG13 ' O ' ' A' ' 112' ' ' VAL . 38.9 t -46.37 113.85 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.612 0 C-N-CA 123.314 0.646 . . . . 0.0 111.596 176.633 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 105.29 3.73 41.19 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 114.929 -1.032 . . . . 0.0 112.855 -179.375 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.59 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.4 OUTLIER -76.29 -177.35 4.01 Favored 'General case' 0 C--N 1.311 -1.069 0 C-N-CA 123.911 0.884 . . . . 0.0 110.067 175.641 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 -133.54 91.59 2.87 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 177.11 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.673 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 28.4 tp -91.58 144.41 25.57 Favored 'General case' 0 C--N 1.292 -1.934 0 C-N-CA 119.964 -0.694 . . . . 0.0 109.781 -179.035 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 60.0 t -136.16 125.0 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -177.487 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.572 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 60.8 t -91.19 88.82 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.523 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 175.246 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -77.84 114.62 16.87 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -178.237 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 75.6 mt -98.0 -1.4 42.73 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-O 121.577 0.703 . . . . 0.0 110.983 -178.685 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.566 ' OG ' ' HA ' ' A' ' 104' ' ' PRO . 22.6 m -80.61 0.66 33.12 Favored 'General case' 0 C--N 1.29 -1.982 0 CA-C-O 122.321 1.058 . . . . 0.0 110.166 -178.322 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.2 p -121.59 4.07 10.13 Favored 'General case' 0 N--CA 1.417 -2.123 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.646 176.074 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.541 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 44.4 mm-40 -125.32 -21.87 4.48 Favored 'General case' 0 C--O 1.239 0.528 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.128 -174.317 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 30.8 mt -135.24 138.22 48.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -175.572 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.612 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 38.9 m-85 -143.43 130.38 20.55 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -176.434 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 73.3 m -109.48 151.11 27.15 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 120.976 0.417 . . . . 0.0 110.263 -178.572 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 7.6 p80 -138.06 129.98 28.49 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.72 0.771 . . . . 0.0 112.034 -175.141 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 46.7 t30 -99.43 99.85 10.81 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.195 -1.002 . . . . 0.0 109.98 176.574 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -72.37 -12.3 61.06 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 113.771 -1.559 . . . . 0.0 111.231 -176.633 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -127.6 71.17 77.39 Favored Pre-proline 0 C--N 1.32 -0.689 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.05 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -70.27 -13.14 33.06 Favored 'Trans proline' 0 C--N 1.332 -0.302 0 C-N-CA 122.491 2.127 . . . . 0.0 113.836 -172.425 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -110.77 -16.89 13.48 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.354 0.597 . . . . 0.0 110.167 -177.471 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.562 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.6 OUTLIER -102.4 -30.94 10.73 Favored 'General case' 0 N--CA 1.404 -2.747 0 CA-C-O 121.648 0.737 . . . . 0.0 109.194 -171.476 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.694 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.5 mp -127.93 135.76 62.08 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 CA-C-N 114.97 -1.014 . . . . 0.0 109.071 -176.401 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.9 t -77.73 142.14 38.89 Favored 'General case' 0 C--O 1.248 1.014 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 175.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -82.44 107.29 14.98 Favored 'General case' 0 C--N 1.286 -2.187 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 -175.349 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 31.8 t80 -144.88 137.04 26.0 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-O 120.761 0.315 . . . . 0.0 110.476 -176.027 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.408 HG23 ' HG ' ' A' ' 131' ' ' LEU . 11.9 p -150.02 150.56 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-N 116.308 -0.406 . . . . 0.0 109.951 179.642 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.29 136.21 18.48 Favored 'General case' 0 C--N 1.311 -1.073 0 C-N-CA 123.298 0.639 . . . . 0.0 109.401 176.616 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.533 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 43.5 tp -73.85 115.5 13.36 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 171.872 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.604 ' NE2' ' HD3' ' A' ' 132' ' ' ARG . 3.4 tp-100 -59.56 -51.32 70.33 Favored 'General case' 0 C--N 1.312 -1.064 0 C-N-CA 124.764 1.226 . . . . 0.0 111.588 178.772 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 9.4 ptp180 -171.51 160.42 5.92 Favored 'General case' 0 CA--C 1.5 -0.969 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 -174.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -139.27 146.78 18.54 Favored Glycine 0 N--CA 1.404 -3.454 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.753 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 64.4 m -131.48 150.66 52.07 Favored 'General case' 0 C--N 1.285 -2.231 0 C-N-CA 123.455 0.702 . . . . 0.0 109.568 -177.544 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.549 ' HB2' ' CE2' ' A' ' 84' ' ' PHE . . . -117.3 154.51 31.11 Favored 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -178.881 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.452 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . 90.9 m-85 -154.4 -179.5 8.0 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 123.71 0.804 . . . . 0.0 109.487 -178.33 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 63.84 -130.97 39.9 Favored Glycine 0 CA--C 1.507 -0.421 0 CA-C-N 116.305 -0.407 . . . . 0.0 113.287 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -90.07 -6.28 69.46 Favored Glycine 0 C--O 1.199 -2.065 0 C-N-CA 120.523 -0.846 . . . . 0.0 111.187 176.14 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.757 HG21 ' HB ' ' A' ' 126' ' ' ILE . 76.5 t -70.81 -41.63 77.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 122.867 0.467 . . . . 0.0 111.309 -176.442 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.521 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -82.13 -24.67 34.95 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 121.452 0.644 . . . . 0.0 112.367 -179.999 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 28.5 m -101.29 -50.82 3.66 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 114.269 1.211 . . . . 0.0 114.269 -173.636 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.459 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 67.4 m-20 -89.87 -23.76 21.56 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 -176.141 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.674 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 86.1 m-85 -112.35 162.17 15.85 Favored 'General case' 0 N--CA 1.427 -1.601 0 CA-C-O 121.75 0.786 . . . . 0.0 111.42 179.686 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.502 ' HB2' HG13 ' A' ' 112' ' ' VAL . 5.5 m -165.94 140.24 4.52 Favored 'General case' 0 N--CA 1.4 -2.969 0 C-N-CA 125.906 1.683 . . . . 0.0 109.177 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.441 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -172.73 -100.35 0.13 Allowed Glycine 0 C--N 1.279 -2.629 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 174.14 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.427 HG23 ' O ' ' A' ' 73' ' ' GLY . 1.1 p -169.94 179.41 3.62 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 125.655 1.582 . . . . 0.0 109.365 -179.468 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.403 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.5 p -127.96 144.93 36.11 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.788 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 177.475 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.615 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.9 tttt -124.91 143.9 50.62 Favored 'General case' 0 N--CA 1.416 -2.13 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.456 -176.013 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.446 ' CD2' HG22 ' A' ' 105' ' ' VAL . 51.8 t80 -146.69 110.23 4.86 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 114.94 -1.027 . . . . 0.0 108.453 -178.467 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 32.7 t 54.76 39.47 31.39 Favored 'General case' 0 CA--C 1.556 1.202 0 CA-C-O 122.341 1.067 . . . . 0.0 110.86 177.432 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.5 16.93 69.79 Favored Glycine 0 N--CA 1.438 -1.196 0 CA-C-N 115.416 -0.811 . . . . 0.0 113.191 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.615 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 10.8 t -84.99 -179.74 7.12 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.118 -1.068 . . . . 0.0 108.118 175.445 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.0 t -160.25 97.57 1.25 Allowed 'General case' 0 C--N 1.29 -2.008 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 -178.402 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.429 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 3.2 p90 -138.75 159.17 68.38 Favored Pre-proline 0 C--N 1.296 -1.732 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 -174.116 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.406 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 55.4 Cg_endo -68.47 147.27 70.65 Favored 'Trans proline' 0 C--N 1.352 0.729 0 C-N-CA 122.406 2.07 . . . . 0.0 112.799 -174.252 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.618 ' CD2' HD21 ' A' ' 109' ' ' LEU . 63.0 t80 -121.63 130.93 24.56 Favored Pre-proline 0 C--N 1.305 -1.339 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.17 -179.793 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.466 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 73.4 Cg_endo -73.79 147.63 90.04 Favored 'Cis proline' 0 C--O 1.25 1.087 0 C-N-CA 123.117 -1.618 . . . . 0.0 110.093 -2.331 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.6 t -68.16 -177.06 0.8 Allowed 'General case' 0 CA--C 1.548 0.877 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.259 -174.772 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 18.9 p -123.42 -12.44 7.76 Favored 'General case' 0 N--CA 1.435 -1.185 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.279 -173.711 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.8 t -152.05 -124.33 0.04 OUTLIER 'General case' 0 N--CA 1.393 -3.282 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -126.9 -169.15 1.98 Allowed 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 112.249 0.463 . . . . 0.0 112.249 -173.041 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 45.3 p -100.42 170.67 6.36 Favored Pre-proline 0 C--N 1.313 -0.983 0 C-N-CA 123.302 0.641 . . . . 0.0 112.685 179.058 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' PRO . . . . . 0.447 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 19.6 Cg_endo -59.53 166.09 8.47 Favored 'Trans proline' 0 C--O 1.246 0.904 0 C-N-CA 122.976 2.451 . . . . 0.0 111.779 170.46 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.1 tmm_? -80.58 117.99 21.77 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 -178.607 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 69.2 t -127.58 128.51 69.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 CA-C-O 121.353 0.597 . . . . 0.0 111.41 -175.578 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 81.4 t -106.18 138.31 32.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.554 179.536 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.433 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 3.1 m-85 -87.59 116.66 25.86 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 175.054 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -97.72 45.25 1.03 Allowed 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 57.7 m -151.77 125.29 8.9 Favored 'General case' 0 N--CA 1.433 -1.298 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.733 -176.429 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 10.6 ptp180 -102.22 64.02 0.91 Allowed 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 122.044 0.926 . . . . 0.0 111.159 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.8 t -171.22 172.87 5.14 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 -178.438 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -65.12 100.78 0.46 Allowed 'General case' 0 C--N 1.324 -0.508 0 O-C-N 123.71 0.631 . . . . 0.0 110.049 -179.485 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -111.76 138.54 21.61 Favored Pre-proline 0 C--N 1.293 -1.863 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 178.151 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -56.08 148.39 59.17 Favored 'Trans proline' 0 C--O 1.246 0.897 0 C-N-CA 123.27 2.647 . . . . 0.0 112.633 179.09 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' TRP . . . . . 0.433 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.4 t90 -88.9 112.34 50.12 Favored Pre-proline 0 C--N 1.293 -1.849 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 -179.357 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.566 ' HA ' ' OG ' ' A' ' 39' ' ' SER . 68.0 Cg_endo -75.58 87.57 1.36 Allowed 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 121.816 1.677 . . . . 0.0 112.426 -173.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.446 HG22 ' CD2' ' A' ' 77' ' ' TYR . 67.0 t -144.61 143.48 22.88 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.435 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 -179.396 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.572 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.14 135.72 17.09 Favored 'General case' 0 N--CA 1.415 -2.214 0 O-C-N 123.705 0.628 . . . . 0.0 110.285 177.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.492 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 15.4 mt -100.83 104.71 15.95 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 178.066 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.441 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 12.4 m-85 -81.03 91.92 6.15 Favored 'General case' 0 C--N 1.285 -2.231 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 177.203 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.674 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 2.9 mm? -118.87 120.51 37.53 Favored 'General case' 0 C--N 1.292 -1.932 0 CA-C-O 120.742 0.306 . . . . 0.0 110.179 178.128 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.35 145.78 47.59 Favored Pre-proline 0 N--CA 1.413 -2.306 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.997 -175.085 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.459 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 25.7 Cg_endo -61.7 119.57 6.77 Favored 'Trans proline' 0 C--O 1.247 0.972 0 C-N-CA 123.202 2.601 . . . . 0.0 112.21 -177.776 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.502 HG13 ' HB2' ' A' ' 72' ' ' SER . 3.6 m -67.74 -117.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.188 -2.173 0 CA-C-N 114.09 -1.414 . . . . 0.0 113.081 175.57 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 41.3 t -112.67 -39.54 4.29 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 178.164 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 66.6 m -78.73 30.35 0.2 Allowed 'General case' 0 N--CA 1.392 -3.356 0 CA-C-N 113.596 -1.638 . . . . 0.0 112.952 -177.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -111.06 140.09 45.89 Favored 'General case' 0 N--CA 1.411 -2.399 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 177.29 128.27 1.13 Allowed Glycine 0 N--CA 1.438 -1.173 0 N-CA-C 111.385 -0.686 . . . . 0.0 111.385 -178.887 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 65.83 -149.13 51.46 Favored Glycine 0 N--CA 1.443 -0.874 0 CA-C-O 119.02 -0.878 . . . . 0.0 111.408 -176.203 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -54.51 105.8 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 CA-C-O 122.645 1.212 . . . . 0.0 112.741 -177.796 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.55 -31.44 9.44 Favored 'General case' 0 C--N 1.295 -1.789 0 CA-C-N 114.735 -1.12 . . . . 0.0 110.936 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.439 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 54.9 mt -128.18 140.07 50.18 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -179.871 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.461 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.7 mmpt? -115.12 133.9 55.63 Favored 'General case' 0 C--N 1.313 -1.009 0 C-N-CA 122.959 0.504 . . . . 0.0 111.584 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.18 133.34 48.71 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.651 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 86.06 0.35 87.21 Favored Glycine 0 C--O 1.242 0.624 0 C-N-CA 121.282 -0.485 . . . . 0.0 112.203 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 19.9 t -101.93 151.06 22.56 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 -178.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -77.92 123.69 27.09 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 -178.328 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.757 ' HB ' HG21 ' A' ' 67' ' ' VAL . 35.1 pt -110.08 -25.83 3.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 N-CA-C 112.578 0.585 . . . . 0.0 112.578 -178.729 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' ALA . . . . . 0.428 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -162.02 168.97 21.87 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -178.236 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 70.3 t -143.5 115.82 2.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.485 HD11 HD21 ' A' ' 107' ' ' LEU . 68.7 mt -117.79 146.9 43.49 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 178.141 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.531 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.6 mp -125.28 128.35 72.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 C-N-CA 119.727 -0.789 . . . . 0.0 110.42 177.475 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.537 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.0 OUTLIER -102.28 136.42 42.14 Favored 'General case' 0 C--N 1.29 -2.0 0 C-N-CA 123.664 0.786 . . . . 0.0 111.998 -177.352 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.604 ' HD3' ' NE2' ' A' ' 59' ' ' GLN . 30.2 mmm180 -95.93 119.36 34.28 Favored 'General case' 0 C--N 1.294 -1.838 0 C-N-CA 124.365 1.066 . . . . 0.0 110.643 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.596 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 13.8 mm100 -102.63 113.87 27.61 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 172.455 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 33.2 m -140.17 144.32 36.57 Favored 'General case' 0 C--N 1.289 -2.057 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -177.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.694 ' CB ' HG23 ' A' ' 52' ' ' ILE . 11.6 p30 -142.8 167.96 20.84 Favored 'General case' 0 N--CA 1.435 -1.18 0 C-N-CA 120.059 -0.656 . . . . 0.0 111.161 179.531 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 2.1 p-10 -84.37 -17.26 39.98 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 113.421 -1.718 . . . . 0.0 112.43 -171.128 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 53.9 t80 -97.81 -67.58 0.84 Allowed 'General case' 0 C--N 1.294 -1.82 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.822 -171.042 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 70.4 m-20 -83.1 -31.12 27.44 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-O 121.343 0.592 . . . . 0.0 111.28 -176.739 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 25.0 t 62.46 27.96 16.56 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 113.958 -1.474 . . . . 0.0 110.242 -177.32 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ASP . . . . . 0.4 ' HB2' ' CE2' ' A' ' 142' ' ' PHE . 11.8 p-10 -79.45 72.88 6.11 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 122.854 1.312 . . . . 0.0 109.825 177.448 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' ASP . . . . . 0.596 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 10.0 p-10 -78.28 72.74 4.82 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 113.362 -1.744 . . . . 0.0 113.01 -174.34 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' PHE . . . . . 0.4 ' CE2' ' HB2' ' A' ' 140' ' ' ASP . 74.6 m-85 -93.09 156.86 16.6 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 176.584 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 12.9 pt20 -125.71 146.78 49.6 Favored 'General case' 0 N--CA 1.418 -2.065 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.487 -179.721 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.415 ' HB2' HD22 ' A' ' 131' ' ' LEU . 12.3 m-30 -112.51 133.01 54.8 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 108.577 -0.898 . . . . 0.0 108.577 -176.447 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.475 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 59.5 t -89.87 133.74 30.98 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 178.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' TRP . . . . . 0.537 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 70.3 m95 -121.84 97.04 5.31 Favored 'General case' 0 C--N 1.284 -2.281 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 -179.112 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 45.0 m-80 -79.17 114.99 18.55 Favored 'General case' 0 C--N 1.288 -2.08 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.428 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 24.7 mm -88.36 120.62 37.55 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 -177.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -116.77 154.54 30.48 Favored 'General case' 0 CA--C 1.49 -1.328 0 C-N-CA 123.278 0.631 . . . . 0.0 110.012 178.504 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.44 129.38 34.62 Favored 'General case' 0 N--CA 1.417 -2.123 0 CA-C-N 115.221 -0.899 . . . . 0.0 109.075 176.78 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' ASN . . . . . 0.456 ' HB3' ' HB3' ' A' ' 23' ' ' ASN . 13.3 t-20 -87.75 -17.19 32.21 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 -178.282 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -153.47 144.04 22.54 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 113.708 -1.587 . . . . 0.0 109.507 -173.41 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -80.87 144.97 31.59 Favored 'General case' 0 C--N 1.317 -0.836 0 O-C-N 124.059 0.85 . . . . 0.0 109.838 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.453 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 74.4 t -121.92 139.26 49.51 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 C-N-CA 122.741 0.416 . . . . 0.0 111.391 -176.156 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.9 t -118.66 141.04 40.17 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 73.2 t -104.05 100.97 23.07 Favored Pre-proline 0 C--N 1.296 -1.719 0 C-N-CA 123.51 0.724 . . . . 0.0 110.116 178.025 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.464 ' HG3' HG13 ' A' ' 27' ' ' VAL . 33.3 Cg_endo -69.23 -23.99 32.62 Favored 'Trans proline' 0 C--O 1.236 0.402 0 C-N-CA 122.35 2.033 . . . . 0.0 111.84 178.68 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.4 t . . . . . 0 C--O 1.239 0.536 0 C-N-CA 125.077 1.351 . . . . 0.0 113.772 177.502 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 44.2 t80 . . . . . 0 CA--C 1.482 -1.666 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.512 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -138.57 -177.49 4.88 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 13.7 t -152.06 159.06 43.78 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.391 -0.924 . . . . 0.0 109.848 -176.156 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.513 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -147.0 155.48 42.28 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 121.29 0.567 . . . . 0.0 110.549 -176.352 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 41.2 p -92.43 174.51 7.25 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.222 178.745 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.99 -19.53 47.61 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.053 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -85.08 -33.81 22.36 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 114.784 -1.098 . . . . 0.0 111.856 -176.468 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 136.36 5.71 2.0 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 119.649 -1.262 . . . . 0.0 113.733 173.259 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.9 m -89.33 105.5 17.84 Favored 'General case' 0 N--CA 1.423 -1.782 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -103.47 115.71 31.05 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.026 179.635 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.512 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 55.6 mt -90.69 127.83 50.82 Favored Pre-proline 0 C--N 1.295 -1.763 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -86.01 179.62 3.64 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 122.83 2.353 . . . . 0.0 111.546 177.054 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 58.6 mt -69.42 133.79 31.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 177.071 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 127.6 9.24 4.05 Favored Glycine 0 C--N 1.306 -1.13 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.873 -179.099 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.22 170.19 44.57 Favored Glycine 0 N--CA 1.437 -1.267 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 -177.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.71 -173.85 35.72 Favored Glycine 0 CA--C 1.48 -2.147 0 C-N-CA 119.911 -1.138 . . . . 0.0 111.414 177.836 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 52.5 p -142.29 144.62 33.35 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -133.21 167.09 21.0 Favored 'General case' 0 N--CA 1.423 -1.793 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 178.345 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -120.05 104.69 10.34 Favored 'General case' 0 C--N 1.266 -3.025 0 CA-C-N 114.258 -1.337 . . . . 0.0 108.402 178.522 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.409 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.2 m -89.72 146.78 5.76 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -178.78 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 51.6 m-85 -128.17 115.72 18.82 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 120.859 0.361 . . . . 0.0 111.18 -177.56 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.526 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.6 p -123.35 129.67 74.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 CA-C-O 121.663 0.744 . . . . 0.0 111.201 -176.013 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.3 p30 -86.85 123.42 31.97 Favored 'General case' 0 C--N 1.293 -1.855 0 CA-C-N 115.007 -0.997 . . . . 0.0 108.851 177.897 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 19.5 mt -108.2 160.38 15.88 Favored 'General case' 0 C--N 1.275 -2.656 0 CA-C-N 114.661 -1.154 . . . . 0.0 108.162 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -59.3 118.7 32.75 Favored Pre-proline 0 C--N 1.305 -1.366 0 O-C-N 124.004 0.815 . . . . 0.0 109.869 179.228 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.552 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 56.3 Cg_endo -70.06 -5.22 15.89 Favored 'Trans proline' 0 CA--C 1.54 0.822 0 C-N-CA 122.819 2.346 . . . . 0.0 113.752 -175.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.408 HG13 ' HG3' ' A' ' 157' ' ' PRO . 86.2 t -128.16 111.76 25.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 179.439 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.48 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 10.6 t -146.49 110.58 0.87 Allowed 'Isoleucine or valine' 0 C--O 1.191 -2.014 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -178.059 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.766 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -96.53 155.73 16.64 Favored 'General case' 0 C--N 1.278 -2.51 0 C-N-CA 124.009 0.924 . . . . 0.0 111.404 -178.678 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.626 HG22 ' O ' ' A' ' 112' ' ' VAL . 89.2 t -46.41 122.88 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 123.121 0.568 . . . . 0.0 111.358 176.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.11 4.8 61.13 Favored Glycine 0 C--N 1.31 -0.911 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.498 178.71 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.766 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -77.35 -176.26 4.08 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 124.345 1.058 . . . . 0.0 109.648 177.673 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 65.3 t30 -132.48 92.11 3.03 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.572 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 21.9 tp -93.67 142.7 27.06 Favored 'General case' 0 C--N 1.299 -1.63 0 C-N-CA 120.04 -0.664 . . . . 0.0 109.408 178.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 52.7 t -134.97 118.47 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.967 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 -175.769 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.59 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 48.7 t -90.6 88.1 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.876 0 N-CA-C 105.586 -2.005 . . . . 0.0 105.586 174.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -85.4 112.41 20.83 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-O 120.973 0.416 . . . . 0.0 110.598 -177.76 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 83.6 mt -96.11 -3.13 45.16 Favored 'General case' 0 C--N 1.299 -1.627 0 CA-C-N 115.006 -0.997 . . . . 0.0 110.419 -177.639 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.606 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 1.9 m -73.42 1.1 10.42 Favored 'General case' 0 CA--C 1.55 0.955 0 CA-C-O 121.903 0.859 . . . . 0.0 109.47 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.3 p -130.58 6.76 4.8 Favored 'General case' 0 N--CA 1.424 -1.738 0 C-N-CA 124.286 1.034 . . . . 0.0 109.993 178.195 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.526 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 48.4 mm-40 -123.99 -19.87 5.53 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-O 121.085 0.469 . . . . 0.0 110.585 -175.179 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 36.8 mt -134.85 135.07 53.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -176.021 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.513 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 47.7 m-85 -139.11 121.58 16.15 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 120.928 0.394 . . . . 0.0 110.302 -175.475 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 71.1 m -104.54 140.05 38.54 Favored 'General case' 0 C--N 1.286 -2.175 0 CA-C-O 121.097 0.475 . . . . 0.0 110.256 -177.378 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.474 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 25.2 p-80 -131.12 151.85 51.02 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 121.781 0.801 . . . . 0.0 112.589 -172.269 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.459 ' HB3' ' OD2' ' A' ' 54' ' ' ASP . 19.0 p30 -103.59 127.7 50.97 Favored 'General case' 0 N--CA 1.405 -2.692 0 CA-C-O 122.607 1.194 . . . . 0.0 110.6 174.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -94.14 -28.43 15.69 Favored 'General case' 0 C--N 1.268 -2.961 0 CA-C-N 113.429 -1.714 . . . . 0.0 108.945 -179.249 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -135.58 71.45 65.37 Favored Pre-proline 0 C--N 1.311 -1.084 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.343 178.132 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -69.97 3.56 2.8 Favored 'Trans proline' 0 N--CA 1.493 1.454 0 C-N-CA 123.425 2.75 . . . . 0.0 113.648 -174.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -120.12 -18.81 7.98 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 121.198 0.523 . . . . 0.0 110.093 -179.455 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.52 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.1 m -103.08 -30.06 10.97 Favored 'General case' 0 N--CA 1.422 -1.831 0 CA-C-O 122.016 0.913 . . . . 0.0 109.148 -173.335 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.609 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.6 mp -124.38 131.55 72.63 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 CA-C-N 114.811 -1.086 . . . . 0.0 108.173 -178.484 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.0 t -77.25 140.46 40.09 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 106.668 -1.605 . . . . 0.0 106.668 176.599 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.549 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 8.0 m-20 -82.75 107.45 15.39 Favored 'General case' 0 C--N 1.283 -2.322 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 -178.203 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 29.4 t80 -137.95 128.25 26.16 Favored 'General case' 0 C--N 1.272 -2.771 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -179.765 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.9 p -147.43 149.5 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.327 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -177.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -148.21 133.92 18.89 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 175.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.527 HD23 ' O ' ' A' ' 130' ' ' ILE . 0.7 OUTLIER -68.87 113.0 5.9 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 103.717 -2.697 . . . . 0.0 103.717 171.404 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.439 ' O ' ' HA ' ' A' ' 89' ' ' GLU . 3.4 tp-100 -57.76 -64.29 0.95 Allowed 'General case' 0 C--O 1.198 -1.628 0 C-N-CA 125.893 1.677 . . . . 0.0 109.822 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -165.08 154.15 12.52 Favored 'General case' 0 N--CA 1.424 -1.75 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 -175.725 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -120.82 164.28 14.18 Favored Glycine 0 N--CA 1.43 -1.728 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 -178.572 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 66.2 m -145.56 144.14 30.33 Favored 'General case' 0 C--N 1.286 -2.165 0 N-CA-C 108.455 -0.942 . . . . 0.0 108.455 178.064 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.588 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -113.15 156.83 22.52 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.5 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 98.5 m-85 -155.2 -179.43 8.07 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 123.849 0.86 . . . . 0.0 110.002 -176.331 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.41 -140.58 42.76 Favored Glycine 0 N--CA 1.461 0.353 0 O-C-N 123.753 0.658 . . . . 0.0 113.126 178.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.78 -10.28 86.33 Favored Glycine 0 C--O 1.209 -1.444 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.525 177.106 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.807 HG21 ' HB ' ' A' ' 126' ' ' ILE . 91.6 t -68.43 -38.48 79.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 C-N-CA 123.82 0.848 . . . . 0.0 111.697 -176.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.588 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.25 -18.18 32.76 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.422 -0.911 . . . . 0.0 112.198 178.388 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 16.1 t -100.55 -59.41 1.71 Allowed 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.887 -173.086 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.509 ' O ' HG22 ' A' ' 112' ' ' VAL . 37.1 m-20 -90.36 -26.51 19.89 Favored 'General case' 0 CA--C 1.493 -1.222 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.167 -172.339 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.686 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 90.1 m-85 -103.98 150.64 24.04 Favored 'General case' 0 N--CA 1.42 -1.951 0 C-N-CA 119.726 -0.789 . . . . 0.0 108.888 176.734 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.3 t -160.88 119.88 2.58 Favored 'General case' 0 N--CA 1.421 -1.881 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 177.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.538 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -152.68 -107.0 0.31 Allowed Glycine 0 N--CA 1.424 -2.139 0 N-CA-C 111.386 -0.685 . . . . 0.0 111.386 177.045 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -164.18 -179.5 6.19 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 124.689 1.195 . . . . 0.0 109.748 -175.253 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.451 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.8 p -132.52 146.48 32.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.175 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.662 ' HG3' ' O ' ' A' ' 80' ' ' SER . 79.7 tttt -121.49 147.69 45.44 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.026 -178.58 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.546 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 63.4 t80 -145.66 109.79 4.91 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -179.795 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 23.0 t 52.16 37.6 22.17 Favored 'General case' 0 CA--C 1.55 0.972 0 C-N-CA 123.629 0.772 . . . . 0.0 111.544 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.81 10.38 63.08 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 120.62 -0.8 . . . . 0.0 113.644 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.662 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 15.4 t -83.3 179.0 7.81 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 177.387 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.4 t -156.07 108.42 2.59 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.779 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.546 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 6.8 p90 -149.39 164.42 21.07 Favored Pre-proline 0 C--N 1.306 -1.314 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 -173.889 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.468 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 97.4 Cg_endo -72.29 149.21 50.77 Favored 'Trans proline' 0 C--N 1.362 1.238 0 C-N-CA 122.224 1.949 . . . . 0.0 113.669 -175.36 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.631 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 55.5 t80 -119.33 133.48 23.76 Favored Pre-proline 0 N--CA 1.428 -1.55 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.894 178.677 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.631 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 61.6 Cg_endo -72.18 146.8 87.13 Favored 'Cis proline' 0 N--CA 1.477 0.539 0 C-N-CA 123.016 -1.66 . . . . 0.0 111.389 -2.315 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.7 t -71.77 179.83 2.96 Favored 'General case' 0 C--O 1.246 0.881 0 C-N-CA 119.776 -0.77 . . . . 0.0 109.075 -178.625 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 45.2 p -131.74 -39.09 1.12 Allowed 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 114.087 1.143 . . . . 0.0 114.087 -170.449 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 23.0 t -102.29 -69.45 0.79 Allowed 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 -172.616 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLU . . . . . 0.439 ' HA ' ' O ' ' A' ' 59' ' ' GLN . 0.3 OUTLIER -178.58 -176.2 0.47 Allowed 'General case' 0 N--CA 1.437 -1.112 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 179.378 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.458 ' HB ' ' HD2' ' A' ' 91' ' ' PRO . 1.9 p -101.11 174.81 2.68 Favored Pre-proline 0 C--N 1.286 -2.158 0 C-N-CA 123.19 0.596 . . . . 0.0 111.977 178.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' PRO . . . . . 0.458 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 22.3 Cg_endo -60.06 158.53 29.51 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 122.47 2.113 . . . . 0.0 111.439 171.47 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.3 tmm_? -77.03 114.14 15.51 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-N 114.836 -1.074 . . . . 0.0 108.781 -176.63 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 85.1 t -124.94 129.24 73.48 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 CA-C-O 121.544 0.687 . . . . 0.0 111.843 -177.379 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 66.2 t -114.25 123.74 70.22 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.253 177.708 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.549 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.7 m-85 -73.85 133.32 43.16 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 175.751 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 -117.73 55.05 0.88 Allowed 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 174.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' SER . . . . . 0.562 ' CB ' ' HG3' ' A' ' 101' ' ' LYS . 50.6 m -135.3 175.59 9.45 Favored 'General case' 0 N--CA 1.434 -1.228 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 -177.458 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -142.93 55.58 1.39 Allowed 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 122.033 0.92 . . . . 0.0 111.536 177.226 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.1 t -171.28 176.06 4.02 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 106.715 -1.587 . . . . 0.0 106.715 179.233 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ASP . . . . . 0.474 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 11.0 p-10 -72.02 99.33 2.25 Favored 'General case' 0 CA--C 1.501 -0.937 0 CA-C-O 122.503 1.144 . . . . 0.0 109.608 177.395 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' LYS . . . . . 0.562 ' HG3' ' CB ' ' A' ' 97' ' ' SER . 57.4 mmtt -102.37 138.61 19.74 Favored Pre-proline 0 N--CA 1.415 -2.187 0 CA-C-N 113.524 -1.671 . . . . 0.0 110.277 -176.519 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.606 ' HB3' ' O ' ' A' ' 39' ' ' SER . 53.6 Cg_exo -49.67 139.54 31.01 Favored 'Trans proline' 0 N--CA 1.448 -1.202 0 C-N-CA 124.018 3.145 . . . . 0.0 112.86 -179.511 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.7 t90 -89.59 102.83 4.98 Favored Pre-proline 0 C--N 1.296 -1.751 0 N-CA-C 104.999 -2.223 . . . . 0.0 104.999 176.461 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.436 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 74.4 Cg_endo -75.55 88.72 1.26 Allowed 'Trans proline' 0 N--CA 1.451 -1.02 0 C-N-CA 121.877 1.718 . . . . 0.0 113.116 -170.411 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.412 HG22 ' HD1' ' A' ' 77' ' ' TYR . 94.2 t -138.52 143.93 31.33 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.59 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -149.04 133.78 17.85 Favored 'General case' 0 C--N 1.289 -2.025 0 CA-C-O 120.81 0.338 . . . . 0.0 110.251 178.046 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.537 HD21 HD11 ' A' ' 129' ' ' LEU . 17.4 mt -101.19 102.9 13.9 Favored 'General case' 0 C--N 1.288 -2.097 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.752 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.538 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 32.3 m-85 -83.4 77.62 9.78 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 177.828 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.686 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.3 mm? -102.38 124.98 48.92 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 176.362 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -129.69 145.96 59.2 Favored Pre-proline 0 N--CA 1.406 -2.669 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 -174.709 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.436 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 34.0 Cg_endo -62.82 124.59 14.34 Favored 'Trans proline' 0 CA--C 1.497 -1.327 0 C-N-CA 123.038 2.492 . . . . 0.0 113.341 -176.101 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.626 ' O ' HG22 ' A' ' 30' ' ' VAL . 15.9 m -84.56 -155.45 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.399 -3.02 0 CA-C-N 114.246 -1.343 . . . . 0.0 108.161 172.017 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.7 t -83.38 -28.97 28.56 Favored 'General case' 0 C--N 1.263 -3.19 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -170.148 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 25.7 t -84.13 30.02 0.54 Allowed 'General case' 0 N--CA 1.426 -1.665 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.313 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -112.81 138.79 49.12 Favored 'General case' 0 N--CA 1.424 -1.736 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.069 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -177.28 135.91 2.94 Favored Glycine 0 N--CA 1.44 -1.063 0 N-CA-C 111.607 -0.597 . . . . 0.0 111.607 179.493 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 63.33 -152.34 47.36 Favored Glycine 0 CA--C 1.5 -0.853 0 CA-C-O 119.387 -0.674 . . . . 0.0 112.577 -178.735 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 57.7 t -60.56 98.72 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.248 0.98 0 CA-C-O 122.222 1.011 . . . . 0.0 111.161 -176.513 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.06 -24.1 15.48 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-N 114.147 -1.388 . . . . 0.0 110.756 -176.503 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.533 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.4 mt -133.63 137.58 52.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 178.47 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.46 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.3 mmpt? -114.57 138.74 50.27 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-O 120.914 0.387 . . . . 0.0 110.871 177.78 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.31 135.15 50.02 Favored 'General case' 0 N--CA 1.442 -0.851 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 178.578 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 88.12 -6.63 83.27 Favored Glycine 0 C--N 1.308 -0.974 0 N-CA-C 111.628 -0.589 . . . . 0.0 111.628 -179.343 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 64.9 m -96.78 149.28 22.01 Favored 'General case' 0 N--CA 1.427 -1.601 0 CA-C-O 121.285 0.564 . . . . 0.0 110.089 179.471 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.437 HD11 HG23 ' A' ' 128' ' ' VAL . 3.2 tm? -78.98 125.0 28.8 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-N 114.782 -1.099 . . . . 0.0 108.587 -176.844 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.807 ' HB ' HG21 ' A' ' 67' ' ' VAL . 36.4 pt -109.61 -26.3 3.26 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -177.8 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.21 167.53 23.89 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -177.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.437 HG23 HD11 ' A' ' 125' ' ' LEU . 69.3 t -142.37 116.07 4.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 178.725 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.537 HD11 HD21 ' A' ' 107' ' ' LEU . 40.4 mt -119.29 147.91 43.76 Favored 'General case' 0 C--N 1.291 -1.976 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 179.183 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.585 HG21 HE21 ' A' ' 143' ' ' GLN . 5.4 mp -124.75 133.4 69.52 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 C-N-CA 119.53 -0.868 . . . . 0.0 110.653 177.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.572 HD22 ' HB2' ' A' ' 144' ' ' PHE . 0.0 OUTLIER -100.35 135.67 41.43 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 175.971 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.508 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 8.4 tpt180 -106.81 120.48 42.12 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.567 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 45.3 tp60 -102.08 121.84 42.96 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 177.734 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 18.8 m -140.04 137.86 34.94 Favored 'General case' 0 C--N 1.291 -1.962 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 -179.502 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.609 ' CB ' HG23 ' A' ' 52' ' ' ILE . 8.7 p30 -133.83 173.75 11.21 Favored 'General case' 0 N--CA 1.442 -0.838 0 C-N-CA 118.809 -1.156 . . . . 0.0 112.389 179.018 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -91.79 -15.28 28.5 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.029 -1.441 . . . . 0.0 112.289 -169.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 39.5 t80 -103.74 -57.19 2.08 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.03 0.443 . . . . 0.0 111.801 -172.193 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 87.1 m-20 -100.69 167.9 10.03 Favored 'General case' 0 CA--C 1.476 -1.88 0 CA-C-O 121.612 0.72 . . . . 0.0 109.971 178.039 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 17.3 m -96.37 32.3 2.02 Favored 'General case' 0 N--CA 1.414 -2.266 0 CA-C-N 114.026 -1.443 . . . . 0.0 108.585 177.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -82.84 50.96 1.8 Allowed 'General case' 0 N--CA 1.476 0.839 0 CA-C-O 121.749 0.785 . . . . 0.0 111.249 -178.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' ASP . . . . . 0.567 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 12.2 t70 -86.34 97.62 10.52 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 114.455 -1.248 . . . . 0.0 109.041 178.282 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -134.85 155.5 50.55 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.542 -0.911 . . . . 0.0 108.542 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' GLN . . . . . 0.585 HE21 HG21 ' A' ' 130' ' ' ILE . 19.4 pt20 -116.27 144.39 44.29 Favored 'General case' 0 C--N 1.295 -1.778 0 C-N-CA 119.981 -0.688 . . . . 0.0 111.409 176.215 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.572 ' HB2' HD22 ' A' ' 131' ' ' LEU . 3.7 m-30 -110.72 131.53 54.97 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 -178.104 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 49.6 t -90.98 130.53 40.01 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.897 0 O-C-N 123.553 0.533 . . . . 0.0 109.784 -179.456 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' TRP . . . . . 0.543 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.9 m95 -117.93 95.16 4.8 Favored 'General case' 0 C--N 1.279 -2.496 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 -179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -77.62 114.79 16.82 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.308 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.409 ' HA ' HG22 ' A' ' 20' ' ' VAL . 23.2 mm -89.26 122.41 40.55 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.794 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -177.436 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.412 ' CZ ' HD23 ' A' ' 125' ' ' LEU . 89.1 m-85 -118.27 152.83 35.0 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 121.509 0.671 . . . . 0.0 110.241 178.871 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -80.6 129.39 34.49 Favored 'General case' 0 N--CA 1.41 -2.472 0 CA-C-N 114.807 -1.088 . . . . 0.0 108.33 176.19 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 29.3 t-20 -91.7 -10.26 40.8 Favored 'General case' 0 C--N 1.29 -2.004 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 -177.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 5.2 t-20 -155.09 145.83 22.37 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 113.991 -1.459 . . . . 0.0 109.19 -176.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -80.52 147.29 30.91 Favored 'General case' 0 C--N 1.323 -0.57 0 O-C-N 124.054 0.846 . . . . 0.0 110.861 -178.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.552 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.3 t -124.21 135.16 64.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.13 -177.68 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.9 t -117.74 135.98 56.4 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 79.4 t -98.54 103.21 17.39 Favored Pre-proline 0 C--N 1.295 -1.803 0 C-N-CA 123.464 0.706 . . . . 0.0 109.883 178.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.483 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 44.1 Cg_endo -71.26 -21.03 27.34 Favored 'Trans proline' 0 CA--C 1.516 -0.396 0 C-N-CA 122.172 1.915 . . . . 0.0 111.633 179.178 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 2.4 t . . . . . 0 C--O 1.249 1.073 0 C-N-CA 124.79 1.236 . . . . 0.0 114.061 176.874 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.655 ' CZ ' ' HB3' ' A' ' 44' ' ' CYS . 43.9 t80 . . . . . 0 CA--C 1.488 -1.411 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.496 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -147.61 176.65 9.91 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 174.065 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.49 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 73.2 m -138.58 160.08 40.48 Favored 'General case' 0 C--N 1.3 -1.558 0 C-N-CA 119.624 -0.83 . . . . 0.0 111.591 -175.517 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.9 pptp? -144.43 159.53 42.58 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 122.747 0.419 . . . . 0.0 110.412 -178.123 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.509 HG22 HG22 ' A' ' 20' ' ' VAL . 81.5 p -95.51 176.57 6.12 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 121.433 0.635 . . . . 0.0 112.011 -178.518 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -76.76 -24.14 52.94 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.202 177.815 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -81.1 -33.54 33.24 Favored 'General case' 0 N--CA 1.448 -0.544 0 C-N-CA 119.272 -0.971 . . . . 0.0 109.549 179.247 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.82 17.86 1.15 Allowed Glycine 0 N--CA 1.439 -1.131 0 C-N-CA 119.699 -1.238 . . . . 0.0 113.404 175.852 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.9 m -88.69 99.75 12.59 Favored 'General case' 0 N--CA 1.431 -1.383 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.56 120.59 32.49 Favored 'General case' 0 C--N 1.291 -1.971 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.38 178.003 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.496 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 62.2 mt -102.25 115.69 64.16 Favored Pre-proline 0 C--N 1.288 -2.078 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 176.723 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -79.88 -179.81 5.63 Favored 'Trans proline' 0 N--CA 1.443 -1.445 0 C-N-CA 122.46 2.107 . . . . 0.0 111.189 177.044 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.9 mt -66.93 147.71 12.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.063 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.55 24.2 5.97 Favored Glycine 0 C--N 1.315 -0.615 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.517 178.799 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.0 173.17 49.45 Favored Glycine 0 C--N 1.316 -0.539 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 -178.873 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 159.03 -177.91 35.41 Favored Glycine 0 N--CA 1.431 -1.68 0 C-N-CA 120.283 -0.96 . . . . 0.0 111.497 177.053 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 25.5 p -151.54 141.46 22.02 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -178.073 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.9 160.46 38.83 Favored 'General case' 0 N--CA 1.425 -1.718 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 27.7 m-80 -112.83 109.05 18.27 Favored 'General case' 0 C--N 1.289 -2.037 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 177.344 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.509 HG22 HG22 ' A' ' 5' ' ' THR . 43.2 t -94.09 137.18 23.52 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.245 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.483 -177.842 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 50.4 m-85 -122.83 115.69 22.41 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 120.919 0.39 . . . . 0.0 110.832 -177.201 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.458 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -125.65 132.9 70.32 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.244 -174.371 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -87.78 130.41 34.86 Favored 'General case' 0 C--N 1.298 -1.663 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.21 177.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.415 HD11 HG22 ' A' ' 36' ' ' VAL . 2.7 mm? -111.6 160.31 17.33 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 175.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.79 121.95 48.53 Favored Pre-proline 0 C--O 1.21 -1.016 0 O-C-N 124.235 0.959 . . . . 0.0 109.196 175.499 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 69.9 Cg_endo -74.76 -5.23 16.57 Favored 'Trans proline' 0 C--O 1.217 -0.542 0 C-N-CA 122.781 2.321 . . . . 0.0 113.555 -175.864 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.3 t -126.39 109.54 21.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.495 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 8.1 t -145.36 112.47 1.28 Allowed 'Isoleucine or valine' 0 C--O 1.186 -2.256 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 -176.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.662 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -101.09 156.14 17.59 Favored 'General case' 0 C--N 1.274 -2.68 0 C-N-CA 123.214 0.606 . . . . 0.0 111.474 179.657 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 38.0 t -45.51 120.55 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 C-N-CA 123.471 0.709 . . . . 0.0 112.019 176.621 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 99.82 0.74 56.32 Favored Glycine 0 CA--C 1.52 0.371 0 CA-C-N 115.542 -0.754 . . . . 0.0 112.825 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.662 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -73.11 -177.41 2.47 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 124.384 1.074 . . . . 0.0 110.977 177.706 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 66.6 t30 -127.38 92.9 3.6 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 107.769 -1.196 . . . . 0.0 107.769 177.323 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.606 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 20.2 tp -101.72 134.86 44.21 Favored 'General case' 0 C--N 1.283 -2.309 0 C-N-CA 118.725 -1.19 . . . . 0.0 109.381 176.843 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.9 p -141.96 132.38 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.386 -3.646 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.927 -178.135 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.578 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 42.2 t -92.12 89.95 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.55 0 CA-C-N 113.86 -1.518 . . . . 0.0 108.029 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -74.45 112.14 10.33 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 88.8 mt -95.68 1.03 53.31 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.026 0.441 . . . . 0.0 111.284 -179.638 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 38.9 t -77.98 0.65 23.53 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 122.086 0.946 . . . . 0.0 109.439 -178.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.9 p -124.59 0.52 8.19 Favored 'General case' 0 C--N 1.281 -2.393 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.134 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.458 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 49.2 mm-40 -120.96 -24.56 5.57 Favored 'General case' 0 CA--C 1.504 -0.816 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.66 -172.744 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 18.2 mt -132.86 139.14 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 -176.206 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.418 ' HA ' ' HA ' ' A' ' 102' ' ' PRO . 78.3 m-85 -134.2 161.14 35.73 Favored 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 -176.648 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.655 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 81.0 m -141.94 141.79 32.97 Favored 'General case' 0 C--N 1.284 -2.244 0 C-N-CA 122.886 0.475 . . . . 0.0 109.998 -177.068 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.6 p80 -145.3 156.69 43.96 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-O 121.312 0.577 . . . . 0.0 111.052 -174.272 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.451 ' HA ' ' HA ' ' A' ' 1' ' ' PHE . 2.9 p30 -107.42 121.06 43.83 Favored 'General case' 0 C--N 1.295 -1.783 0 CA-C-O 122.479 1.133 . . . . 0.0 113.304 178.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 13.7 p-10 -90.97 -23.37 20.44 Favored 'General case' 0 N--CA 1.42 -1.959 0 CA-C-N 113.417 -1.72 . . . . 0.0 109.529 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.419 ' HB2' HD13 ' A' ' 52' ' ' ILE . 60.7 m-85 -138.57 64.61 37.78 Favored Pre-proline 0 N--CA 1.472 0.636 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.871 176.157 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -67.5 -17.16 48.62 Favored 'Trans proline' 0 N--CA 1.481 0.784 0 C-N-CA 122.159 1.906 . . . . 0.0 112.787 -176.263 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -94.44 -27.63 15.91 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.903 -175.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.566 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -97.84 -30.41 12.78 Favored 'General case' 0 N--CA 1.413 -2.278 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 -171.344 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.566 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.1 mp -119.57 141.4 39.79 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 CA-C-N 114.158 -1.383 . . . . 0.0 108.963 -176.73 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 5.4 t -88.89 131.94 34.9 Favored 'General case' 0 C--O 1.259 1.578 0 N-CA-C 104.09 -2.559 . . . . 0.0 104.09 171.439 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.651 ' OD1' ' HB2' ' A' ' 1' ' ' PHE . 34.0 m-20 -93.78 107.27 19.17 Favored 'General case' 0 C--N 1.271 -2.815 0 C-N-CA 118.952 -1.099 . . . . 0.0 110.152 -169.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 28.9 t80 -127.06 143.11 51.37 Favored 'General case' 0 C--N 1.289 -2.055 0 CA-C-N 114.04 -1.437 . . . . 0.0 108.908 -175.665 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.532 HG23 ' HG ' ' A' ' 131' ' ' LEU . 8.1 p -150.6 145.25 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.313 0 O-C-N 123.615 0.572 . . . . 0.0 110.087 -179.76 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.6 p -147.42 131.59 17.38 Favored 'General case' 0 N--CA 1.436 -1.129 0 C-N-CA 123.075 0.55 . . . . 0.0 109.769 174.527 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.457 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 1.1 tm? -71.2 102.14 2.46 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 175.091 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 8.3 tp60 -52.53 -50.55 62.62 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 127.12 2.168 . . . . 0.0 111.697 -176.772 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 3.9 ptp180 -171.17 160.17 6.21 Favored 'General case' 0 N--CA 1.425 -1.684 0 CA-C-N 114.467 -1.242 . . . . 0.0 109.289 -176.497 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -135.84 148.22 19.55 Favored Glycine 0 N--CA 1.41 -3.097 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 179.553 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 63.2 m -129.38 143.81 50.99 Favored 'General case' 0 C--N 1.279 -2.469 0 C-N-CA 123.228 0.611 . . . . 0.0 109.573 -178.681 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.508 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -111.29 155.62 22.75 Favored 'General case' 0 CA--C 1.502 -0.87 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.469 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 68.0 m-85 -157.45 -178.52 7.4 Favored 'General case' 0 C--O 1.238 0.494 0 C-N-CA 124.235 1.014 . . . . 0.0 108.313 -177.765 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 62.45 -141.71 47.25 Favored Glycine 0 N--CA 1.453 -0.191 0 O-C-N 123.333 0.396 . . . . 0.0 112.707 177.611 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.24 -7.84 87.18 Favored Glycine 0 C--O 1.208 -1.482 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 177.811 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.805 HG21 ' HB ' ' A' ' 126' ' ' ILE . 86.6 t -69.72 -38.64 76.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 C-N-CA 123.752 0.821 . . . . 0.0 111.339 -176.488 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.508 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -85.44 -22.8 28.14 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 119.306 -0.957 . . . . 0.0 112.063 179.441 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 9.3 t -100.63 -51.39 3.61 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.144 0.497 . . . . 0.0 112.265 -172.625 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.487 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 47.7 m-20 -90.8 -24.57 20.28 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -174.732 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.663 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 89.2 m-85 -111.52 156.49 21.64 Favored 'General case' 0 N--CA 1.42 -1.951 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.292 179.104 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.5 t -162.97 138.57 6.89 Favored 'General case' 0 N--CA 1.406 -2.651 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 176.599 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.519 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.36 -104.65 0.18 Allowed Glycine 0 N--CA 1.409 -3.146 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 175.338 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.2 p -165.3 -179.86 5.83 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 124.547 1.139 . . . . 0.0 110.137 -176.261 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.413 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.7 p -131.81 145.33 35.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 123.313 0.645 . . . . 0.0 109.467 178.411 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.672 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.2 tttt -122.23 149.52 43.56 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.478 -177.614 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.461 ' CD2' HG22 ' A' ' 105' ' ' VAL . 60.8 t80 -150.15 113.09 4.81 Favored 'General case' 0 C--O 1.214 -0.777 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 22.7 t 56.92 30.23 17.64 Favored 'General case' 0 CA--C 1.554 1.108 0 CA-C-O 121.884 0.85 . . . . 0.0 111.286 176.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.33 13.69 59.76 Favored Glycine 0 N--CA 1.437 -1.273 0 C-N-CA 120.208 -0.996 . . . . 0.0 113.086 -177.856 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.672 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 21.2 t -83.95 -179.35 7.24 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 175.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 8.2 t -157.37 110.48 2.51 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 179.152 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.47 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 7.4 p90 -149.68 162.52 28.11 Favored Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -174.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.47 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 72.7 Cg_endo -68.2 149.08 75.91 Favored 'Trans proline' 0 C--N 1.36 1.174 0 C-N-CA 122.671 2.248 . . . . 0.0 113.528 -175.266 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.617 ' CD2' HD21 ' A' ' 109' ' ' LEU . 60.2 t80 -124.31 134.54 25.57 Favored Pre-proline 0 N--CA 1.442 -0.839 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.193 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.582 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 57.4 Cg_endo -70.57 145.08 80.29 Favored 'Cis proline' 0 C--O 1.239 0.568 0 C-N-CA 123.099 -1.625 . . . . 0.0 110.633 -3.255 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.7 t -73.65 -177.63 2.8 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -177.664 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 41.2 p -131.77 -35.87 1.24 Allowed 'General case' 0 N--CA 1.424 -1.772 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -172.438 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 49.5 m -110.1 -162.21 0.79 Allowed 'General case' 1 N--CA 1.317 -7.114 0 CA-C-N 113.45 -1.704 . . . . 0.0 107.663 179.265 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 27.0 tt0 -116.21 151.32 35.96 Favored 'General case' 1 C--N 1.244 -4.011 0 CA-C-N 113.443 -1.708 . . . . 0.0 109.115 -168.639 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.457 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 46.8 p -67.75 161.17 68.76 Favored Pre-proline 0 C--N 1.296 -1.748 0 C-N-CA 124.494 1.117 . . . . 0.0 113.245 -177.642 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -56.86 159.86 13.48 Favored 'Trans proline' 0 C--N 1.355 0.876 0 C-N-CA 124.068 3.179 . . . . 0.0 111.749 175.454 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.5 tmm_? -67.88 116.74 8.88 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.667 -176.024 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 72.7 t -132.05 137.18 55.31 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 C-N-CA 123.848 0.859 . . . . 0.0 108.687 -176.223 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.0 p -136.59 132.94 48.85 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.628 -175.191 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -82.9 101.5 11.06 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 120.937 0.398 . . . . 0.0 110.917 -178.395 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 36.7 m-80 -92.29 55.12 2.48 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-O 121.996 0.903 . . . . 0.0 108.837 176.196 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.3 m -145.4 128.63 16.74 Favored 'General case' 0 N--CA 1.428 -1.566 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 -178.239 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.5 ptm180 -104.51 63.7 0.74 Allowed 'General case' 0 C--N 1.304 -1.378 0 CA-C-O 122.643 1.211 . . . . 0.0 109.609 -179.091 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' THR . . . . . 0.405 HG23 ' HD3' ' A' ' 101' ' ' LYS . 10.1 t -170.41 -179.5 3.04 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 -172.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -86.25 124.81 33.04 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' LYS . . . . . 0.411 ' HD2' ' HA ' ' A' ' 101' ' ' LYS . 6.8 mptt -127.32 143.9 48.84 Favored Pre-proline 0 C--N 1.277 -2.561 0 C-N-CA 124.463 1.105 . . . . 0.0 109.273 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.418 ' HA ' ' HA ' ' A' ' 43' ' ' PHE . 41.0 Cg_endo -68.23 147.27 72.12 Favored 'Trans proline' 0 C--O 1.244 0.787 0 C-N-CA 122.891 2.394 . . . . 0.0 112.12 178.118 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.2 t90 -85.56 107.45 12.47 Favored Pre-proline 0 C--N 1.323 -0.544 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 -177.287 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -76.73 88.2 1.4 Allowed 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 121.518 1.479 . . . . 0.0 112.905 -172.495 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.461 HG22 ' CD2' ' A' ' 77' ' ' TYR . 68.2 t -137.54 153.96 29.1 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.144 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 178.102 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.578 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -160.05 137.4 9.55 Favored 'General case' 0 CA--C 1.475 -1.94 0 O-C-N 123.406 0.441 . . . . 0.0 110.182 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.469 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 18.9 mt -105.79 99.85 9.43 Favored 'General case' 0 C--N 1.286 -2.171 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.388 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.519 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 42.4 m-85 -79.78 77.2 6.42 Favored 'General case' 0 C--N 1.313 -0.995 0 O-C-N 122.041 -0.412 . . . . 0.0 110.105 177.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.663 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.1 mm? -102.48 119.74 39.34 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-O 120.926 0.393 . . . . 0.0 110.219 177.653 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.54 147.39 52.74 Favored Pre-proline 0 N--CA 1.419 -1.98 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.725 -174.558 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.487 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 29.9 Cg_endo -62.24 118.55 5.44 Favored 'Trans proline' 0 C--O 1.246 0.899 0 C-N-CA 123.185 2.59 . . . . 0.0 112.835 -177.13 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.443 HG22 ' H ' ' A' ' 112' ' ' VAL . 2.8 m -68.46 -116.43 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.192 -1.923 0 CA-C-N 114.007 -1.451 . . . . 0.0 112.71 175.52 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 22.8 t -112.21 -39.53 4.42 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.267 -0.895 . . . . 0.0 109.541 177.367 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 31.5 t -84.33 29.41 0.58 Allowed 'General case' 0 C--N 1.317 -0.804 0 C-N-CA 123.536 0.734 . . . . 0.0 111.342 -175.095 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -101.93 133.18 47.13 Favored 'General case' 0 N--CA 1.422 -1.84 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.336 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.97 139.84 5.19 Favored Glycine 0 N--CA 1.434 -1.436 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.017 178.19 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 59.71 -144.37 46.19 Favored Glycine 0 CA--C 1.495 -1.214 0 CA-C-O 119.288 -0.729 . . . . 0.0 112.738 -179.083 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.3 p -59.24 96.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 122.753 1.263 . . . . 0.0 111.575 -178.31 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.44 -25.85 14.65 Favored 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 114.754 -1.112 . . . . 0.0 111.49 -177.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.451 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 61.4 mt -134.72 139.66 47.14 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.326 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 3.7 mmpt? -114.85 137.32 52.1 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-O 121.089 0.471 . . . . 0.0 111.4 179.474 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.06 122.52 20.21 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.379 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 93.6 3.57 64.47 Favored Glycine 0 C--N 1.309 -0.948 0 N-CA-C 111.595 -0.602 . . . . 0.0 111.595 -177.458 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 32.9 t -102.21 143.62 31.77 Favored 'General case' 0 C--O 1.253 1.246 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 178.538 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.431 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -72.28 124.72 25.67 Favored 'General case' 0 N--CA 1.444 -0.727 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.805 ' HB ' HG21 ' A' ' 67' ' ' VAL . 39.0 pt -109.93 -27.43 2.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 N-CA-C 112.423 0.527 . . . . 0.0 112.423 -178.686 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' ALA . . . . . 0.4 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.68 167.62 24.79 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 -177.679 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.431 HG23 HD11 ' A' ' 125' ' ' LEU . 71.2 t -142.97 116.38 3.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.576 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.44 HD11 HD21 ' A' ' 107' ' ' LEU . 59.9 mt -115.95 143.01 46.02 Favored 'General case' 0 C--N 1.288 -2.08 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 179.536 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.31 118.44 53.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 C-N-CA 119.402 -0.919 . . . . 0.0 110.322 179.184 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.532 ' HG ' HG23 ' A' ' 56' ' ' VAL . 0.1 OUTLIER -88.76 150.09 23.12 Favored 'General case' 0 C--N 1.268 -2.957 0 C-N-CA 124.838 1.255 . . . . 0.0 108.485 178.227 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 19.3 ttp85 -123.38 137.4 54.83 Favored 'General case' 0 N--CA 1.414 -2.269 0 O-C-N 123.255 0.347 . . . . 0.0 111.549 178.443 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.483 ' NE2' ' HD2' ' A' ' 1' ' ' PHE . 13.3 mm100 -113.01 115.44 28.38 Favored 'General case' 0 N--CA 1.431 -1.398 0 CA-C-N 115.079 -0.964 . . . . 0.0 110.622 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 4.5 m -133.33 130.86 39.43 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 176.017 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.529 ' CB ' HG23 ' A' ' 52' ' ' ILE . 6.5 p30 -132.8 159.15 40.61 Favored 'General case' 0 C--O 1.214 -0.791 0 C-N-CA 118.464 -1.294 . . . . 0.0 112.232 179.416 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -70.64 -25.7 63.13 Favored 'General case' 0 N--CA 1.487 1.409 0 CA-C-N 113.906 -1.497 . . . . 0.0 113.297 -170.662 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -89.98 -58.85 2.36 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-O 121.057 0.456 . . . . 0.0 111.097 -174.175 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' ASN . . . . . 0.458 ' HB3' ' OD2' ' A' ' 140' ' ' ASP . 19.6 m120 -70.98 -36.63 72.59 Favored 'General case' 0 CA--C 1.472 -2.034 0 CA-C-O 121.655 0.74 . . . . 0.0 111.184 -178.896 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 49.7 m 66.4 17.19 10.63 Favored 'General case' 0 N--CA 1.436 -1.165 0 CA-C-N 113.515 -1.675 . . . . 0.0 109.881 -176.266 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' ASP . . . . . 0.468 ' HB3' ' CE2' ' A' ' 142' ' ' PHE . 19.5 m-20 -78.62 150.16 32.76 Favored 'General case' 0 N--CA 1.419 -1.995 0 CA-C-N 113.588 -1.642 . . . . 0.0 109.206 176.7 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -135.68 105.12 6.03 Favored 'General case' 0 C--N 1.274 -2.69 0 CA-C-N 114.482 -1.236 . . . . 0.0 108.344 -178.623 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' PHE . . . . . 0.468 ' CE2' ' HB3' ' A' ' 140' ' ' ASP . 72.4 m-85 -129.51 160.66 32.51 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.793 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' GLN . . . . . 0.41 ' HB2' ' O ' ' A' ' 131' ' ' LEU . 6.8 pt20 -138.58 141.92 39.21 Favored 'General case' 0 C--N 1.287 -2.15 0 C-N-CA 119.453 -0.899 . . . . 0.0 111.003 -178.582 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 7.5 m-30 -107.2 134.21 50.64 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 -175.619 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 45.3 t -93.26 130.82 41.75 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 O-C-N 123.492 0.495 . . . . 0.0 109.886 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' TRP . . . . . 0.513 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 64.1 m95 -120.69 100.03 6.88 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 -179.688 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -81.02 113.5 19.26 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 179.194 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.4 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 23.6 mm -88.43 121.55 38.86 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -178.044 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -117.46 153.69 32.69 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 123.541 0.736 . . . . 0.0 109.834 177.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.0 131.94 35.16 Favored 'General case' 0 N--CA 1.416 -2.165 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 177.124 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 13.8 t-20 -95.06 -5.77 43.63 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -177.896 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 8.8 t-20 -155.96 139.97 16.36 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.199 -1.364 . . . . 0.0 109.508 -177.078 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -78.16 145.04 35.86 Favored 'General case' 0 C--N 1.308 -1.2 0 O-C-N 124.212 0.945 . . . . 0.0 109.454 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.46 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 75.5 t -120.67 141.29 41.74 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 O-C-N 122.28 -0.263 . . . . 0.0 110.82 -177.009 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.2 t -120.48 136.11 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.234 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 179.153 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.495 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.7 t -101.74 103.95 31.82 Favored Pre-proline 0 C--N 1.289 -2.058 0 C-N-CA 123.173 0.589 . . . . 0.0 109.716 178.292 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.449 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 44.2 Cg_endo -71.29 -19.47 29.15 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.031 1.821 . . . . 0.0 111.3 178.139 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.418 ' HB ' HG12 ' A' ' 156' ' ' VAL . 5.1 t . . . . . 0 C--O 1.246 0.872 0 C-N-CA 124.956 1.302 . . . . 0.0 113.262 176.233 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 56.6 t80 . . . . . 0 CA--C 1.484 -1.568 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.501 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -136.87 176.25 8.88 Favored 'General case' 0 C--N 1.276 -2.602 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -178.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 79.4 m -136.89 154.46 50.48 Favored 'General case' 0 C--N 1.291 -1.974 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.549 -174.59 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.44 162.52 35.57 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.608 -174.024 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.546 HG22 HG22 ' A' ' 20' ' ' VAL . 67.1 p -97.63 179.81 4.71 Favored 'General case' 0 C--N 1.301 -1.515 0 CA-C-O 121.192 0.52 . . . . 0.0 110.599 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -84.98 -19.75 31.59 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 114.93 -1.032 . . . . 0.0 108.73 179.298 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -87.93 -17.46 31.29 Favored 'General case' 0 N--CA 1.417 -2.1 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.475 -179.532 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 119.24 11.63 7.34 Favored Glycine 0 CA--C 1.486 -1.729 0 C-N-CA 119.061 -1.543 . . . . 0.0 114.373 167.676 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.2 m -89.83 99.68 12.64 Favored 'General case' 0 N--CA 1.413 -2.308 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -90.66 121.65 32.75 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-N 115.071 -0.968 . . . . 0.0 108.513 177.023 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.501 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 66.4 mt -101.77 113.7 65.78 Favored Pre-proline 0 C--N 1.295 -1.768 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 178.229 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -75.54 170.6 19.92 Favored 'Trans proline' 0 C--O 1.25 1.092 0 C-N-CA 122.586 2.19 . . . . 0.0 111.527 178.828 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 63.1 mt -64.42 128.19 26.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.199 179.233 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.89 6.24 2.03 Favored Glycine 0 C--N 1.314 -0.669 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.742 -178.822 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.65 158.41 33.8 Favored Glycine 0 C--N 1.316 -0.558 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 166.04 -173.2 41.59 Favored Glycine 0 C--N 1.3 -1.434 0 C-N-CA 119.709 -1.234 . . . . 0.0 112.014 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.2 p -148.45 140.87 24.29 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -178.533 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -130.8 159.6 36.86 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 29.1 m-80 -108.55 109.89 21.23 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 176.414 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.546 HG22 HG22 ' A' ' 5' ' ' THR . 38.3 t -96.15 138.9 20.33 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.689 -178.396 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -124.7 112.5 16.83 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 121.216 0.532 . . . . 0.0 111.312 -176.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.582 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.1 p -122.76 134.13 66.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.942 -175.363 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -98.07 119.69 37.15 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-O 121.47 0.652 . . . . 0.0 110.152 -178.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.428 ' CD1' ' HA ' ' A' ' 36' ' ' VAL . 2.7 mm? -97.06 161.72 13.7 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.359 -178.668 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.27 122.1 51.98 Favored Pre-proline 0 C--N 1.317 -0.817 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 173.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.494 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 63.1 Cg_endo -74.86 -2.22 12.21 Favored 'Trans proline' 0 CA--C 1.533 0.456 0 C-N-CA 122.771 2.314 . . . . 0.0 113.203 -176.357 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.454 HG13 ' HG3' ' A' ' 157' ' ' PRO . 73.5 t -127.16 115.26 40.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.502 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 3.3 t -149.84 118.99 0.98 Allowed 'Isoleucine or valine' 0 C--O 1.194 -1.833 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 -179.643 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.64 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -107.13 155.79 19.5 Favored 'General case' 0 C--N 1.278 -2.519 0 C-N-CA 122.787 0.435 . . . . 0.0 111.625 -179.592 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.434 HG13 ' O ' ' A' ' 112' ' ' VAL . 38.6 t -47.07 117.13 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 123.656 0.782 . . . . 0.0 111.765 177.755 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.79 -2.44 45.2 Favored Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 115.391 -0.822 . . . . 0.0 112.918 179.562 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.64 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.6 OUTLIER -72.95 -176.91 2.21 Favored 'General case' 0 C--N 1.314 -0.948 0 C-N-CA 123.999 0.92 . . . . 0.0 110.58 177.419 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 36.8 t-20 -134.44 98.21 4.02 Favored 'General case' 0 N--CA 1.427 -1.612 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 176.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.684 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 30.4 tp -93.69 147.01 23.42 Favored 'General case' 0 C--N 1.282 -2.354 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 93.8 t -135.28 120.94 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.507 0 CA-C-O 121.212 0.53 . . . . 0.0 109.973 -178.512 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.599 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 61.5 t -89.61 88.74 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.286 0 N-CA-C 106.349 -1.722 . . . . 0.0 106.349 174.203 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -81.67 110.12 16.72 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-O 121.202 0.525 . . . . 0.0 111.42 -177.281 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.5 mt -96.45 -3.0 44.21 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.438 -178.665 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.2 m -73.07 0.03 12.64 Favored 'General case' 0 CA--C 1.551 1.001 0 CA-C-O 122.151 0.977 . . . . 0.0 109.532 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.5 p -126.29 3.0 7.07 Favored 'General case' 0 C--N 1.295 -1.782 0 C-N-CA 123.712 0.805 . . . . 0.0 110.288 178.063 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.582 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 45.5 mm-40 -121.93 -23.47 5.43 Favored 'General case' 0 CA--C 1.506 -0.724 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.815 -173.458 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.8 mt -133.11 140.34 47.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.196 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -176.149 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -137.62 153.46 49.89 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -176.507 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 66.6 m -128.64 134.94 48.68 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 123.537 0.735 . . . . 0.0 109.209 176.384 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.425 ' HB3' ' HA ' ' A' ' 100' ' ' ASP . 22.0 p80 -127.56 145.97 50.68 Favored 'General case' 0 C--N 1.291 -1.968 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.364 -177.011 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.417 HD22 ' CG ' ' A' ' 54' ' ' ASP . 27.4 t-20 -99.85 99.41 10.2 Favored 'General case' 0 C--N 1.293 -1.877 0 C-N-CA 118.637 -1.225 . . . . 0.0 109.035 175.666 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -72.81 -9.79 59.07 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 125.145 1.378 . . . . 0.0 112.627 178.62 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -144.63 68.1 14.54 Favored Pre-proline 0 N--CA 1.482 1.174 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 175.17 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -66.22 -5.33 12.23 Favored 'Trans proline' 0 N--CA 1.488 1.176 0 C-N-CA 123.376 2.717 . . . . 0.0 114.651 -172.817 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -117.99 -3.14 11.16 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-O 121.282 0.563 . . . . 0.0 109.692 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.501 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.6 OUTLIER -117.51 -30.15 5.6 Favored 'General case' 0 N--CA 1.421 -1.878 0 CA-C-O 121.608 0.718 . . . . 0.0 109.732 -175.117 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.648 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.6 mp -129.16 131.87 67.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 -177.455 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.4 t -76.94 146.37 37.6 Favored 'General case' 0 C--O 1.251 1.145 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.612 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 0.8 OUTLIER -83.34 108.45 16.54 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 -178.056 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 22.4 t80 -145.99 129.89 17.27 Favored 'General case' 0 C--N 1.28 -2.425 0 CA-C-O 121.224 0.535 . . . . 0.0 109.62 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.574 HG23 HD13 ' A' ' 131' ' ' LEU . 6.2 p -148.4 149.41 15.18 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.478 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 -178.316 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 5.3 p -150.33 136.36 18.55 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 178.303 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.459 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 38.0 tp -73.32 110.03 7.29 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 172.307 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -58.98 -55.64 32.5 Favored 'General case' 0 C--N 1.314 -0.969 0 C-N-CA 126.155 1.782 . . . . 0.0 110.584 179.557 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -165.55 160.21 17.46 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 -177.547 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -138.31 143.18 13.97 Favored Glycine 0 N--CA 1.405 -3.403 0 N-CA-C 108.89 -1.684 . . . . 0.0 108.89 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 68.4 m -129.88 148.97 51.81 Favored 'General case' 0 C--N 1.278 -2.503 0 C-N-CA 123.771 0.829 . . . . 0.0 109.513 -177.694 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.493 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -110.72 156.6 20.8 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 -178.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.445 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 91.8 m-85 -153.93 -179.59 8.0 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.459 0.704 . . . . 0.0 110.257 -177.169 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.6 -138.39 49.29 Favored Glycine 0 C--O 1.223 -0.566 0 O-C-N 123.944 0.777 . . . . 0.0 112.892 176.385 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.61 -3.3 89.73 Favored Glycine 0 N--CA 1.425 -2.061 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.628 177.428 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.787 HG21 ' HB ' ' A' ' 126' ' ' ILE . 79.8 t -73.99 -41.91 52.78 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 123.03 0.532 . . . . 0.0 111.464 -178.44 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.493 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -80.17 -23.17 41.23 Favored 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 119.523 -0.871 . . . . 0.0 112.203 179.57 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 13.9 m -100.97 -46.67 5.02 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 115.011 1.486 . . . . 0.0 115.011 -174.899 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.522 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 25.9 m120 -94.28 -19.92 20.25 Favored 'General case' 0 CA--C 1.494 -1.185 0 C-N-CA 119.87 -0.732 . . . . 0.0 109.48 -178.695 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.659 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 86.9 m-85 -111.76 162.62 15.05 Favored 'General case' 0 N--CA 1.423 -1.808 0 C-N-CA 120.214 -0.594 . . . . 0.0 110.143 179.024 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.2 t -169.57 130.88 1.09 Allowed 'General case' 0 N--CA 1.422 -1.865 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 176.094 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.513 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -164.18 -110.37 0.24 Allowed Glycine 0 N--CA 1.412 -2.958 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 175.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.1 p -158.27 -179.58 8.24 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 124.421 1.089 . . . . 0.0 110.353 -174.122 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -133.66 146.94 31.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 C-N-CA 122.965 0.506 . . . . 0.0 109.993 177.278 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.64 ' HG3' ' O ' ' A' ' 80' ' ' SER . 77.9 tttt -122.14 146.25 47.41 Favored 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 -178.783 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.489 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 56.9 t80 -145.27 106.58 4.2 Favored 'General case' 0 C--N 1.307 -1.242 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 -178.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 29.9 t 54.11 38.16 28.51 Favored 'General case' 0 CA--C 1.55 0.943 0 C-N-CA 123.435 0.694 . . . . 0.0 111.268 179.525 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.35 7.81 66.96 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 120.751 -0.738 . . . . 0.0 113.552 -179.02 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.64 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 15.2 t -79.64 174.32 11.69 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.486 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.5 p -152.06 100.33 2.62 Favored 'General case' 0 C--N 1.287 -2.146 0 CA-C-O 121.125 0.488 . . . . 0.0 109.747 -178.667 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.489 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 3.1 p90 -144.57 161.3 44.49 Favored Pre-proline 0 C--N 1.307 -1.243 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -173.64 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.453 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 59.9 Cg_endo -69.93 153.82 67.74 Favored 'Trans proline' 0 C--N 1.356 0.935 0 C-N-CA 123.018 2.479 . . . . 0.0 113.129 -174.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.556 ' CD2' HD21 ' A' ' 109' ' ' LEU . 56.3 t80 -129.53 128.96 23.15 Favored Pre-proline 0 C--N 1.316 -0.87 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.754 179.066 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.452 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 74.0 Cg_endo -69.16 148.65 85.78 Favored 'Cis proline' 0 CA--C 1.547 1.148 0 C-N-CA 122.789 -1.754 . . . . 0.0 110.374 -0.786 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 7.6 t -62.81 -178.59 0.21 Allowed 'General case' 0 CA--C 1.555 1.169 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.733 -173.167 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 16.6 p -130.52 -17.09 3.34 Favored 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 115.845 -0.616 . . . . 0.0 112.489 -173.026 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 27.2 t -133.21 -80.04 0.48 Allowed 'General case' 0 N--CA 1.426 -1.664 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.389 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 179.85 -170.44 0.14 Allowed 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 -178.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.459 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 15.8 p -101.32 162.13 21.48 Favored Pre-proline 0 C--N 1.293 -1.872 0 N-CA-C 113.172 0.805 . . . . 0.0 113.172 178.376 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -63.13 163.68 22.1 Favored 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 123.309 2.673 . . . . 0.0 111.542 173.33 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.41 ' C ' ' HD2' ' A' ' 92' ' ' ARG . 3.8 tmm_? -72.81 123.48 23.45 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.901 -178.23 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 98.5 t -130.54 123.0 54.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.498 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 74.2 t -107.49 130.89 58.99 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 177.179 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.612 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 1.8 m-85 -91.77 167.83 11.89 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 106.058 -1.831 . . . . 0.0 106.058 172.589 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -132.74 54.37 1.95 Allowed 'General case' 0 C--N 1.258 -3.377 0 N-CA-C 104.845 -2.28 . . . . 0.0 104.845 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' SER . . . . . 0.481 ' HB3' ' HG3' ' A' ' 101' ' ' LYS . 66.2 p -113.09 161.35 17.2 Favored 'General case' 0 N--CA 1.414 -2.226 0 N-CA-C 114.44 1.274 . . . . 0.0 114.44 -167.366 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 35.1 ptt180 -144.74 30.18 1.21 Allowed 'General case' 0 C--N 1.3 -1.56 0 CA-C-N 114.375 -1.284 . . . . 0.0 108.177 171.189 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.9 t -159.26 177.08 11.41 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-N 113.826 -1.533 . . . . 0.0 107.087 -179.541 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ASP . . . . . 0.425 ' HA ' ' HB3' ' A' ' 45' ' ' HIS . 5.3 m-20 -71.26 111.48 6.64 Favored 'General case' 0 CA--C 1.5 -0.959 0 O-C-N 123.533 0.52 . . . . 0.0 109.632 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' LYS . . . . . 0.607 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 7.4 mmpt? -111.37 143.57 28.74 Favored Pre-proline 0 C--N 1.288 -2.092 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 174.33 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.484 ' O ' ' HD3' ' A' ' 104' ' ' PRO . 33.7 Cg_endo -67.12 144.29 68.66 Favored 'Trans proline' 0 N--CA 1.446 -1.317 0 C-N-CA 122.608 2.206 . . . . 0.0 111.95 -177.09 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 14.1 t90 -89.46 101.14 2.83 Favored Pre-proline 0 C--N 1.307 -1.248 0 N-CA-C 105.657 -1.979 . . . . 0.0 105.657 179.258 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.484 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 73.2 Cg_endo -75.17 88.65 1.24 Allowed 'Trans proline' 0 N--CA 1.452 -0.926 0 C-N-CA 122.016 1.811 . . . . 0.0 112.841 -171.024 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.453 HG22 ' CD2' ' A' ' 77' ' ' TYR . 93.2 t -136.91 142.94 36.36 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.465 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.015 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.599 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.99 134.19 18.29 Favored 'General case' 0 N--CA 1.412 -2.346 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.335 178.758 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.498 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 19.0 mt -98.95 102.32 14.01 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.013 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.513 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 13.1 m-85 -79.01 65.41 4.18 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 122.955 0.502 . . . . 0.0 111.517 178.297 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.684 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.9 mm? -92.14 135.3 34.1 Favored 'General case' 0 C--O 1.205 -1.24 0 O-C-N 121.958 -0.464 . . . . 0.0 110.162 177.142 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.02 145.24 51.67 Favored Pre-proline 0 N--CA 1.418 -2.065 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.468 -176.836 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.522 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 24.3 Cg_endo -60.21 120.81 8.8 Favored 'Trans proline' 0 C--O 1.243 0.775 0 C-N-CA 123.402 2.735 . . . . 0.0 111.972 -177.292 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.434 ' O ' HG13 ' A' ' 30' ' ' VAL . 2.6 m -69.53 -115.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.189 -2.085 0 CA-C-N 114.436 -1.256 . . . . 0.0 112.668 177.193 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.3 m -110.92 -46.29 3.36 Favored 'General case' 0 C--N 1.29 -1.996 0 O-C-N 121.471 -0.768 . . . . 0.0 110.144 178.315 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 13.3 t -86.1 31.18 0.64 Allowed 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.898 -173.164 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -95.18 131.69 40.95 Favored 'General case' 0 N--CA 1.423 -1.803 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.421 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -168.66 139.82 5.85 Favored Glycine 0 N--CA 1.432 -1.579 0 C-N-CA 120.331 -0.938 . . . . 0.0 111.808 179.277 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 57.49 -144.48 40.38 Favored Glycine 0 CA--C 1.488 -1.607 0 C-N-CA 123.914 0.769 . . . . 0.0 113.072 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -58.67 94.48 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 122.821 1.296 . . . . 0.0 111.995 -177.559 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.16 -22.53 16.14 Favored 'General case' 0 C--N 1.297 -1.691 0 CA-C-N 114.774 -1.103 . . . . 0.0 111.398 -176.507 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.473 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 59.0 mt -136.48 137.74 47.49 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 107.853 -1.165 . . . . 0.0 107.853 177.389 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.481 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.6 mmpt? -112.0 139.59 47.38 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-O 120.831 0.348 . . . . 0.0 111.793 179.201 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.21 120.52 16.02 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 178.429 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.57 -5.54 64.7 Favored Glycine 0 C--N 1.309 -0.923 0 N-CA-C 111.733 -0.547 . . . . 0.0 111.733 -176.726 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 34.1 t -90.23 142.91 27.26 Favored 'General case' 0 C--O 1.252 1.194 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.243 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 30.1 tp -71.86 133.41 45.44 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 177.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.787 ' HB ' HG21 ' A' ' 67' ' ' VAL . 40.6 pt -118.8 -24.71 3.08 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.039 0 C-N-CA 120.347 -0.541 . . . . 0.0 112.28 -178.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' ALA . . . . . 0.445 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -163.97 164.38 23.2 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 120.966 -0.293 . . . . 0.0 110.449 -178.018 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 55.4 t -140.17 114.29 6.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 178.12 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.471 HD11 HD21 ' A' ' 107' ' ' LEU . 56.9 mt -118.26 147.08 43.79 Favored 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.453 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.8 mp -129.23 126.36 63.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 C-N-CA 120.16 -0.616 . . . . 0.0 110.065 178.749 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.574 HD13 HG23 ' A' ' 56' ' ' VAL . 1.4 pp -92.26 150.56 20.8 Favored 'General case' 0 CA--C 1.476 -1.897 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 173.332 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 56.4 ttp180 -115.11 116.69 28.81 Favored 'General case' 0 C--N 1.25 -3.727 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 176.17 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -100.51 120.25 39.73 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 -175.1 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 5.4 m -133.58 144.26 49.19 Favored 'General case' 0 C--N 1.287 -2.125 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.648 ' CB ' HG23 ' A' ' 52' ' ' ILE . 8.0 p30 -132.83 165.59 24.24 Favored 'General case' 0 N--CA 1.436 -1.137 0 C-N-CA 118.227 -1.389 . . . . 0.0 111.877 174.437 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -86.12 -16.16 38.86 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 113.81 -1.541 . . . . 0.0 112.147 -170.571 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 37.2 t80 -98.51 -61.41 1.38 Allowed 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.336 0.589 . . . . 0.0 111.195 -173.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -89.62 163.55 15.11 Favored 'General case' 0 C--N 1.284 -2.239 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.807 178.313 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 22.8 t -88.25 40.78 0.97 Allowed 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.538 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -88.59 111.16 21.56 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 108.266 -1.012 . . . . 0.0 108.266 178.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -145.15 79.52 1.59 Allowed 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 107.442 -1.318 . . . . 0.0 107.442 179.219 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -121.83 167.93 12.43 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 114.734 -1.121 . . . . 0.0 108.032 -175.792 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -131.39 145.4 51.8 Favored 'General case' 0 N--CA 1.415 -2.193 0 C-N-CA 118.549 -1.26 . . . . 0.0 111.798 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 8.6 m-30 -113.77 126.75 55.56 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 108.266 -1.012 . . . . 0.0 108.266 -175.374 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 48.4 t -89.72 133.59 31.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 123.544 0.528 . . . . 0.0 110.304 -179.379 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 58.0 m95 -120.04 100.46 7.22 Favored 'General case' 0 C--N 1.285 -2.236 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 -179.678 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -82.77 111.83 19.05 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 106.608 -1.627 . . . . 0.0 106.608 178.112 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.445 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 22.6 mm -86.72 121.57 37.81 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 -176.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -118.26 154.66 31.9 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 177.631 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 121' ' ' LYS . . . -80.96 128.0 33.2 Favored 'General case' 0 N--CA 1.406 -2.661 0 CA-C-N 115.243 -0.889 . . . . 0.0 108.699 176.167 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 37.0 t-20 -88.87 -8.9 53.43 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 106.719 -1.585 . . . . 0.0 106.719 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 5.0 t-20 -156.0 139.75 16.13 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 113.679 -1.6 . . . . 0.0 109.605 -176.881 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -77.86 147.95 34.89 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 124.538 1.135 . . . . 0.0 110.067 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.494 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 73.7 t -123.58 138.1 54.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.913 -176.757 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.7 t -118.65 136.14 56.8 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.576 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.502 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 76.3 t -100.0 104.4 28.64 Favored Pre-proline 0 C--N 1.285 -2.224 0 C-N-CA 123.202 0.601 . . . . 0.0 109.416 178.26 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.454 ' HG3' HG13 ' A' ' 27' ' ' VAL . 33.7 Cg_endo -69.78 -25.12 28.84 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.121 1.881 . . . . 0.0 111.02 176.905 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.451 ' HB ' HG12 ' A' ' 156' ' ' VAL 0.274 6.0 t . . . . . 0 C--O 1.247 0.928 0 O-C-N 124.638 1.211 . . . . 0.0 113.204 176.712 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.563 ' HA ' ' HA ' ' A' ' 46' ' ' ASN . 61.8 t80 . . . . . 0 CA--C 1.487 -1.466 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.449 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -149.49 169.41 20.97 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 -179.411 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 65.1 m -130.73 158.3 40.49 Favored 'General case' 0 C--N 1.287 -2.112 0 C-N-CA 120.013 -0.675 . . . . 0.0 111.272 -172.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.457 ' HD2' ' O ' ' A' ' 5' ' ' THR . 0.0 OUTLIER -145.91 164.41 32.07 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.608 -175.002 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.556 HG22 HG22 ' A' ' 20' ' ' VAL . 68.1 p -99.91 -179.52 4.19 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-O 121.449 0.642 . . . . 0.0 111.787 -178.407 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.88 -20.44 38.83 Favored 'General case' 0 C--N 1.296 -1.72 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.108 177.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -88.45 -25.83 22.43 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.094 -0.957 . . . . 0.0 112.186 -179.758 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 128.35 8.47 4.02 Favored Glycine 0 CA--C 1.496 -1.107 0 C-N-CA 119.354 -1.403 . . . . 0.0 114.241 170.232 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 m -83.49 98.86 9.76 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 -179.174 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.05 109.1 21.19 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.888 179.372 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.449 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 64.8 mt -86.17 120.24 72.24 Favored Pre-proline 0 C--N 1.305 -1.359 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 -177.673 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -79.06 168.39 20.64 Favored 'Trans proline' 0 C--O 1.252 1.204 0 C-N-CA 122.65 2.233 . . . . 0.0 110.742 178.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.3 mt -71.14 128.09 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.3 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 178.808 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 139.37 -8.68 3.19 Favored Glycine 0 C--N 1.296 -1.681 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -176.238 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.58 148.36 22.13 Favored Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.351 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.98 -174.05 46.15 Favored Glycine 0 N--CA 1.435 -1.37 0 C-N-CA 120.493 -0.861 . . . . 0.0 111.156 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 28.8 p -143.02 151.02 40.37 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.2 162.33 33.26 Favored 'General case' 0 N--CA 1.415 -2.223 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 -179.355 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -107.72 117.01 32.99 Favored 'General case' 0 C--N 1.278 -2.52 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 176.036 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.556 HG22 HG22 ' A' ' 5' ' ' THR . 40.7 t -105.43 132.04 53.31 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.778 0 CA-C-N 115.484 -0.78 . . . . 0.0 109.138 178.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.4 m-85 -118.52 123.04 44.13 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 -179.002 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.482 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.4 p -131.28 134.55 60.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.005 -176.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 5.6 p30 -98.03 119.17 36.18 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 121.737 0.78 . . . . 0.0 110.585 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.422 HD11 HG22 ' A' ' 36' ' ' VAL . 2.8 mm? -99.45 160.78 14.03 Favored 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 114.59 -1.187 . . . . 0.0 109.13 -177.88 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.03 121.51 46.68 Favored Pre-proline 0 C--O 1.212 -0.884 0 O-C-N 124.478 1.111 . . . . 0.0 109.076 176.108 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 73.4 Cg_endo -74.31 -2.62 12.61 Favored 'Trans proline' 0 C--O 1.22 -0.42 0 C-N-CA 122.811 2.341 . . . . 0.0 113.277 -175.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.446 HG13 ' HG3' ' A' ' 157' ' ' PRO . 86.0 t -126.54 109.74 21.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.494 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 4.2 t -145.05 110.82 1.15 Allowed 'Isoleucine or valine' 0 C--O 1.188 -2.167 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -177.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.654 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -98.32 153.12 18.76 Favored 'General case' 0 C--N 1.272 -2.789 0 C-N-CA 123.305 0.642 . . . . 0.0 111.766 -178.346 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.412 HG22 ' O ' ' A' ' 112' ' ' VAL . 40.5 t -46.8 115.74 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 123.318 0.647 . . . . 0.0 111.524 175.892 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 109.01 -8.13 33.37 Favored Glycine 0 C--N 1.322 -0.227 0 CA-C-N 115.445 -0.798 . . . . 0.0 112.558 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.654 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.3 OUTLIER -65.98 -177.38 0.48 Allowed 'General case' 0 C--N 1.317 -0.831 0 C-N-CA 124.468 1.107 . . . . 0.0 112.069 177.725 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -137.43 95.34 3.06 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 177.765 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.616 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 25.3 tp -93.5 146.29 23.89 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -177.466 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.2 t -132.9 120.01 39.46 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.75 0 CA-C-O 120.978 0.418 . . . . 0.0 110.184 -176.069 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.613 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 55.0 t -92.84 88.63 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.338 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 172.763 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -82.26 106.77 14.42 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.25 0.548 . . . . 0.0 110.63 -176.549 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 89.6 mt -90.27 -0.76 57.78 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.986 -177.721 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.7 t -78.18 0.88 23.25 Favored 'General case' 0 C--N 1.309 -1.184 0 CA-C-O 122.271 1.034 . . . . 0.0 109.134 -179.227 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.6 p -125.3 5.57 7.74 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.848 175.539 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.482 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 51.4 mm-40 -122.61 -26.59 4.51 Favored 'General case' 0 CA--C 1.501 -0.934 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.586 -173.812 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 18.3 mt -132.57 139.64 49.4 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 -175.27 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.401 ' HB2' ' HE3' ' A' ' 4' ' ' LYS . 70.2 m-85 -138.28 144.71 40.61 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -175.839 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.556 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 72.7 m -121.32 135.11 55.14 Favored 'General case' 0 C--N 1.284 -2.275 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 177.698 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 22.8 p-80 -134.13 163.08 30.39 Favored 'General case' 0 C--N 1.309 -1.195 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -175.812 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.563 ' HA ' ' HA ' ' A' ' 1' ' ' PHE . 16.1 t-20 -113.25 111.46 22.08 Favored 'General case' 0 N--CA 1.423 -1.786 0 C-N-CA 118.574 -1.25 . . . . 0.0 111.047 179.187 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 17.4 p-10 -85.74 -4.7 59.23 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 124.573 1.149 . . . . 0.0 111.224 179.586 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.458 ' HB2' HD13 ' A' ' 52' ' ' ILE . 85.4 m-85 -143.97 65.46 13.9 Favored Pre-proline 0 N--CA 1.477 0.877 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 174.575 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.452 ' HB2' ' HB2' ' A' ' 98' ' ' ARG . 68.5 Cg_endo -72.32 3.98 3.71 Favored 'Trans proline' 0 N--CA 1.481 0.74 0 C-N-CA 123.498 2.799 . . . . 0.0 115.295 -169.751 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -114.33 -28.51 7.22 Favored 'General case' 0 C--N 1.285 -2.227 0 CA-C-O 121.735 0.779 . . . . 0.0 110.495 -178.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.557 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.0 OUTLIER -101.74 -30.07 11.53 Favored 'General case' 0 C--N 1.28 -2.455 0 CA-C-N 115.046 -0.979 . . . . 0.0 111.126 -174.063 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.557 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.4 mp -121.0 132.37 70.65 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.661 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -176.748 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 15.1 t -79.46 145.96 33.0 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 177.768 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.521 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 1.2 m-20 -79.5 109.57 14.0 Favored 'General case' 0 C--N 1.282 -2.368 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 -179.496 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -150.42 138.34 20.06 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 -170.705 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.444 HG23 HD13 ' A' ' 131' ' ' LEU . 14.9 p -151.31 153.45 9.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -178.6 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.11 128.83 12.39 Favored 'General case' 0 C--O 1.208 -1.109 0 CA-C-O 119.381 -0.343 . . . . 0.0 110.125 175.75 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.516 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 49.5 tp -75.24 109.2 8.54 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.828 0.823 . . . . 0.0 109.277 174.53 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 7.0 tp60 -55.47 -54.16 47.34 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 126.479 1.912 . . . . 0.0 111.461 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 8.4 ptp180 -169.88 159.6 7.97 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 -176.692 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.408 ' H ' HG22 ' A' ' 86' ' ' THR . . . -136.47 144.29 15.94 Favored Glycine 0 N--CA 1.406 -3.324 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 73.6 m -132.88 150.58 52.15 Favored 'General case' 0 C--N 1.281 -2.406 0 C-N-CA 123.459 0.704 . . . . 0.0 109.831 -177.53 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.524 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -113.51 158.51 20.64 Favored 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 179.516 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.5 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . 98.8 m-85 -155.2 -179.74 8.37 Favored 'General case' 0 C--N 1.342 0.276 0 C-N-CA 124.436 1.094 . . . . 0.0 109.678 -177.842 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.56 -142.22 45.64 Favored Glycine 0 C--O 1.238 0.383 0 O-C-N 123.794 0.684 . . . . 0.0 112.839 176.429 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.455 ' HA3' ' O ' ' A' ' 119' ' ' ALA . . . -77.71 -7.81 87.26 Favored Glycine 0 N--CA 1.435 -1.387 0 C-N-CA 120.77 -0.729 . . . . 0.0 111.482 177.638 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.824 HG21 ' HB ' ' A' ' 126' ' ' ILE . 99.3 t -71.0 -42.14 76.94 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.368 0 C-N-CA 123.279 0.632 . . . . 0.0 111.428 -179.207 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.524 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -85.41 -14.82 45.08 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 118.554 -1.258 . . . . 0.0 112.405 178.851 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 8.8 t -100.33 -48.89 4.43 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 120.324 -0.55 . . . . 0.0 111.651 -175.494 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.47 ' O ' HG22 ' A' ' 112' ' ' VAL . 26.4 m120 -95.67 -22.24 17.69 Favored 'General case' 0 CA--C 1.497 -1.087 0 C-N-CA 120.472 -0.491 . . . . 0.0 110.187 -176.39 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.561 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 95.8 m-85 -109.43 154.02 23.19 Favored 'General case' 0 N--CA 1.423 -1.778 0 C-N-CA 120.061 -0.656 . . . . 0.0 110.78 -179.448 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.9 t -165.0 121.1 1.42 Allowed 'General case' 0 N--CA 1.416 -2.126 0 N-CA-C 106.822 -1.548 . . . . 0.0 106.822 174.117 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.422 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -152.83 -113.29 0.53 Allowed Glycine 0 N--CA 1.408 -3.232 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 177.673 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.466 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.0 OUTLIER -152.75 179.3 8.75 Favored 'General case' 0 C--N 1.287 -2.128 0 C-N-CA 123.101 0.56 . . . . 0.0 110.557 -174.718 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.6 p -136.69 145.43 30.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 C-N-CA 123.004 0.522 . . . . 0.0 109.653 178.563 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.626 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.3 tttt -124.54 144.24 50.24 Favored 'General case' 0 N--CA 1.417 -2.094 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.49 ' CD2' HG22 ' A' ' 105' ' ' VAL . 62.7 t80 -145.56 115.15 7.23 Favored 'General case' 0 C--N 1.289 -2.047 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 -178.607 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 15.1 m 52.76 40.58 30.75 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 114.187 1.18 . . . . 0.0 114.187 175.55 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 80.76 10.48 85.09 Favored Glycine 0 N--CA 1.442 -0.96 0 C-N-CA 119.986 -1.102 . . . . 0.0 112.606 179.439 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.626 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 8.9 t -85.41 -179.7 6.99 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 177.88 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 31.5 t -157.03 112.22 2.82 Favored 'General case' 0 C--N 1.287 -2.122 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -178.47 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.456 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 4.9 p90 -155.27 161.51 29.3 Favored Pre-proline 0 CA--C 1.556 1.182 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -175.463 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.466 ' HA ' HG22 ' A' ' 74' ' ' THR . 56.5 Cg_endo -69.86 153.19 68.76 Favored 'Trans proline' 0 C--N 1.36 1.173 0 C-N-CA 122.979 2.453 . . . . 0.0 112.931 -177.643 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.501 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 63.2 t80 -124.57 130.55 24.25 Favored Pre-proline 0 N--CA 1.442 -0.862 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.469 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.501 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 72.2 Cg_endo -69.92 151.62 92.01 Favored 'Cis proline' 0 CA--C 1.542 0.897 0 C-N-CA 122.999 -1.667 . . . . 0.0 110.124 -1.596 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.408 HG22 ' H ' ' A' ' 61' ' ' GLY . 8.9 t -58.36 -178.0 0.04 OUTLIER 'General case' 0 CA--C 1.552 1.02 0 CA-C-O 122.088 0.947 . . . . 0.0 112.9 -173.711 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 10.1 p -119.43 -20.8 7.69 Favored 'General case' 0 N--CA 1.423 -1.812 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.778 -175.048 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 23.1 t -141.95 -82.47 0.2 Allowed 'General case' 0 N--CA 1.432 -1.336 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.964 -177.118 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -170.89 -172.87 1.22 Allowed 'General case' 0 C--O 1.241 0.631 0 N-CA-C 104.536 -2.394 . . . . 0.0 104.536 -177.338 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.516 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 42.0 p -100.9 158.18 32.29 Favored Pre-proline 0 C--N 1.293 -1.86 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.375 176.39 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -59.26 161.2 17.17 Favored 'Trans proline' 0 C--O 1.243 0.771 0 C-N-CA 123.16 2.573 . . . . 0.0 110.769 173.536 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.2 tmm_? -69.25 120.64 15.4 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.445 -178.438 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 72.4 t -128.09 124.68 63.05 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-O 121.633 0.73 . . . . 0.0 111.05 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 70.5 t -112.64 126.16 70.0 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.893 0 CA-C-N 115.095 -0.957 . . . . 0.0 108.853 176.639 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.521 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.2 m-85 -72.43 110.63 6.97 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 175.53 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -81.79 61.76 5.29 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.328 -0.989 . . . . 0.0 108.328 176.624 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.7 m -142.35 -168.52 2.75 Favored 'General case' 0 N--CA 1.419 -1.982 0 C-N-CA 125.34 1.456 . . . . 0.0 107.685 -177.481 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.452 ' HB2' ' HB2' ' A' ' 49' ' ' PRO . 34.0 ptt180 -163.23 34.76 0.09 Allowed 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 106.465 -1.68 . . . . 0.0 106.465 176.842 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.4 t -160.45 175.9 12.25 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 114.755 -1.112 . . . . 0.0 109.036 -168.698 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -70.7 114.01 8.35 Favored 'General case' 0 C--O 1.239 0.513 0 CA-C-O 122.021 0.915 . . . . 0.0 111.746 -176.297 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.6 mptm? -127.48 143.52 47.64 Favored Pre-proline 0 C--N 1.292 -1.907 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.382 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -63.29 147.22 93.92 Favored 'Trans proline' 0 C--O 1.247 0.961 0 C-N-CA 122.693 2.262 . . . . 0.0 111.78 177.214 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' TRP . . . . . 0.509 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 9.6 t90 -86.46 111.85 42.21 Favored Pre-proline 0 C--N 1.304 -1.378 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 -178.091 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_endo -82.04 87.12 1.45 Allowed 'Trans proline' 0 N--CA 1.439 -1.698 0 C-N-CA 121.031 1.154 . . . . 0.0 112.122 -172.245 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.49 HG22 ' CD2' ' A' ' 77' ' ' TYR . 80.2 t -137.56 146.33 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.668 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 176.852 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.613 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -153.66 132.28 12.21 Favored 'General case' 0 C--N 1.287 -2.143 0 O-C-N 123.41 0.444 . . . . 0.0 110.428 178.049 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.477 HD21 HD11 ' A' ' 129' ' ' LEU . 16.9 mt -97.01 101.02 12.52 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.422 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 53.7 m-85 -79.33 73.04 5.96 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 120.884 0.373 . . . . 0.0 110.673 177.421 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.63 ' HG ' HG13 ' A' ' 67' ' ' VAL . 2.7 mm? -87.08 150.62 23.88 Favored 'General case' 0 C--O 1.192 -1.966 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.474 176.575 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.57 139.57 13.15 Favored Pre-proline 0 C--N 1.278 -2.501 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.611 -179.456 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 18.0 Cg_endo -60.16 121.55 9.97 Favored 'Trans proline' 0 C--O 1.247 0.969 0 C-N-CA 123.189 2.593 . . . . 0.0 111.87 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.47 HG22 ' O ' ' A' ' 70' ' ' ASN . 3.5 m -70.3 -123.08 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.182 -2.478 0 CA-C-N 114.77 -1.105 . . . . 0.0 111.478 175.655 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 30.9 m -111.95 -19.39 12.38 Favored 'General case' 0 C--N 1.282 -2.331 0 CA-C-O 122.548 1.166 . . . . 0.0 108.877 177.392 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.446 ' H ' HG23 ' A' ' 112' ' ' VAL . 1.2 m -85.37 6.79 24.99 Favored 'General case' 0 N--CA 1.405 -2.696 0 CA-C-N 113.595 -1.639 . . . . 0.0 112.568 -173.301 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -97.6 138.18 35.4 Favored 'General case' 0 C--N 1.266 -3.051 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.192 -172.242 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -177.26 124.16 0.93 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.173 -1.013 . . . . 0.0 112.671 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.11 -147.72 50.34 Favored Glycine 0 CA--C 1.488 -1.645 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 -175.554 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.408 ' CG1' ' HE3' ' A' ' 121' ' ' LYS . 93.9 t -53.1 111.33 0.26 Allowed 'Isoleucine or valine' 0 C--O 1.248 0.997 0 CA-C-O 121.709 0.766 . . . . 0.0 110.741 -178.717 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' ALA . . . . . 0.455 ' O ' ' HA3' ' A' ' 66' ' ' GLY . . . -113.51 -22.66 10.21 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-N 114.212 -1.358 . . . . 0.0 111.619 -179.459 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.472 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.7 mt -135.01 137.72 50.13 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 178.374 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.575 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 5.3 mmpt? -112.49 141.48 46.18 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 121.144 0.497 . . . . 0.0 111.602 177.811 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.408 ' H ' ' HB3' ' A' ' 153' ' ' ASP . . . -72.03 134.8 46.08 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.87 179.248 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 85.18 -1.23 88.78 Favored Glycine 0 C--N 1.312 -0.79 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.005 -179.338 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 59.8 m -96.5 148.73 22.52 Favored 'General case' 0 N--CA 1.421 -1.906 0 CA-C-O 120.94 0.4 . . . . 0.0 110.066 179.157 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.447 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -77.83 122.59 25.64 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -179.226 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.824 ' HB ' HG21 ' A' ' 67' ' ' VAL . 30.8 pt -109.42 -27.19 2.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 N-CA-C 112.853 0.686 . . . . 0.0 112.853 -177.379 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' ALA . . . . . 0.421 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.49 166.68 26.79 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 -178.01 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.447 HG23 HD11 ' A' ' 125' ' ' LEU . 74.6 t -142.5 112.78 2.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 179.515 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.477 HD11 HD21 ' A' ' 107' ' ' LEU . 58.3 mt -115.87 146.77 41.73 Favored 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 178.786 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.496 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.7 mp -128.61 125.22 63.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 C-N-CA 120.028 -0.669 . . . . 0.0 109.227 178.541 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.444 HD13 HG23 ' A' ' 56' ' ' VAL . 1.3 pp -91.0 148.96 22.04 Favored 'General case' 0 CA--C 1.478 -1.821 0 N-CA-C 106.004 -1.85 . . . . 0.0 106.004 174.453 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 32.1 ttt180 -118.78 123.91 45.95 Favored 'General case' 0 C--N 1.253 -3.592 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 176.189 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.476 ' HB2' ' O ' ' A' ' 142' ' ' PHE . 13.3 mm-40 -79.91 143.35 34.33 Favored 'General case' 0 N--CA 1.411 -2.376 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.525 179.463 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.488 ' HA ' ' OD1' ' A' ' 141' ' ' ASP . 17.7 m -154.33 127.36 8.3 Favored 'General case' 0 C--N 1.269 -2.929 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 170.282 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.486 ' HB2' HG23 ' A' ' 52' ' ' ILE . 15.7 p30 -128.53 -168.71 1.95 Allowed 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.715 -0.794 . . . . 0.0 111.075 -178.713 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -110.39 3.28 19.6 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 120.907 0.384 . . . . 0.0 111.196 -174.605 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 92.7 t80 -122.16 -68.13 0.91 Allowed 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.83 -170.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' ASN . . . . . 0.452 ' HB2' HD21 ' A' ' 135' ' ' ASN . 19.7 m120 -76.8 166.43 23.36 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.861 177.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 19.8 t -113.17 26.5 10.41 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 105.994 -1.854 . . . . 0.0 105.994 172.087 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' ASP . . . . . 0.426 ' OD1' ' HB3' ' A' ' 138' ' ' ASN . 4.0 m-20 -94.85 45.51 1.11 Allowed 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 113.372 -1.74 . . . . 0.0 108.167 -178.887 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 141' ' ' ASP . . . . . 0.488 ' OD1' ' HA ' ' A' ' 134' ' ' THR . 9.4 m-20 -81.68 74.34 8.67 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 114.783 -1.098 . . . . 0.0 109.062 -177.153 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' PHE . . . . . 0.476 ' O ' ' HB2' ' A' ' 133' ' ' GLN . 95.8 m-85 -91.27 178.09 6.07 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.23 -179.5 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 11.9 pt20 -126.79 144.62 50.9 Favored 'General case' 0 C--N 1.296 -1.757 0 C-N-CA 119.72 -0.792 . . . . 0.0 110.193 -179.046 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 11.0 m-30 -113.74 128.93 56.61 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 -175.278 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 47.4 t -90.96 134.06 30.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 123.478 0.486 . . . . 0.0 110.35 -177.721 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 59.9 m95 -120.69 98.6 6.1 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 -179.477 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 45.1 m-80 -81.21 110.85 17.08 Favored 'General case' 0 C--N 1.288 -2.086 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.446 HG22 HD11 ' A' ' 126' ' ' ILE . 23.3 mm -85.68 122.4 38.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 -177.534 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -118.0 150.98 38.37 Favored 'General case' 0 C--N 1.295 -1.77 0 C-N-CA 123.552 0.741 . . . . 0.0 109.012 178.375 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.08 130.36 35.06 Favored 'General case' 0 N--CA 1.413 -2.317 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 176.522 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 29.8 t-20 -89.55 -15.7 32.31 Favored 'General case' 0 C--N 1.288 -2.1 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 -177.761 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -149.3 141.88 24.42 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 114.059 -1.428 . . . . 0.0 109.207 -174.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 153' ' ' ASP . . . . . 0.408 ' HB3' ' H ' ' A' ' 122' ' ' ALA . 8.7 p-10 -85.94 138.03 32.3 Favored 'General case' 0 C--N 1.314 -0.949 0 O-C-N 123.944 0.777 . . . . 0.0 111.561 -178.474 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.472 ' HB ' ' HB ' ' A' ' 120' ' ' ILE . 75.1 t -112.21 141.42 27.79 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-N 115.015 -0.993 . . . . 0.0 111.894 -173.105 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 5.1 t -119.69 139.05 48.31 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.131 0 N-CA-C 108.12 -1.066 . . . . 0.0 108.12 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.494 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 62.1 t -103.2 102.24 27.23 Favored Pre-proline 0 C--N 1.285 -2.197 0 C-N-CA 123.89 0.876 . . . . 0.0 110.065 178.414 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.463 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 34.5 Cg_endo -68.3 -22.68 39.57 Favored 'Trans proline' 0 C--O 1.222 -0.305 0 C-N-CA 122.144 1.896 . . . . 0.0 111.589 178.278 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.474 ' HB ' HG12 ' A' ' 156' ' ' VAL 0.25 7.4 t . . . . . 0 CA--C 1.547 0.85 0 C-N-CA 124.791 1.236 . . . . 0.0 113.714 175.69 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.741 ' CZ ' ' HB3' ' A' ' 133' ' ' GLN . 24.2 t80 . . . . . 0 N--CA 1.425 -1.718 0 CA-C-O 121.915 0.865 . . . . 0.0 110.183 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.506 ' HB3' ' CE1' ' A' ' 45' ' ' HIS . . . -121.37 -177.76 3.61 Favored 'General case' 0 C--N 1.289 -2.05 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.202 176.4 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.528 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 13.5 t -157.12 160.66 39.05 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.294 -175.701 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.27 164.3 31.81 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.455 -177.324 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.552 HG22 HG22 ' A' ' 20' ' ' VAL . 73.8 p -102.22 177.85 4.76 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-O 121.427 0.632 . . . . 0.0 111.024 -179.71 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.72 -18.27 44.92 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 114.71 -1.132 . . . . 0.0 109.347 179.131 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -91.82 -24.42 19.38 Favored 'General case' 0 N--CA 1.432 -1.363 0 CA-C-N 114.893 -1.049 . . . . 0.0 111.822 -177.621 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 120.17 34.46 0.96 Allowed Glycine 0 CA--C 1.488 -1.614 0 C-N-CA 119.308 -1.425 . . . . 0.0 113.315 170.005 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -110.13 98.93 8.09 Favored 'General case' 0 N--CA 1.423 -1.823 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 176.501 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -90.97 123.18 34.26 Favored 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 115.157 -0.929 . . . . 0.0 109.451 177.03 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.403 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 68.3 mt -100.39 116.22 64.62 Favored Pre-proline 0 C--N 1.288 -2.07 0 N-CA-C 109.484 -0.562 . . . . 0.0 109.484 177.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -75.53 164.78 31.78 Favored 'Trans proline' 0 C--O 1.249 1.055 0 C-N-CA 122.661 2.241 . . . . 0.0 110.85 176.782 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.4 mt -69.49 121.03 18.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 148.77 -6.0 0.85 Allowed Glycine 0 C--N 1.305 -1.162 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 -174.142 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.0 149.39 23.81 Favored Glycine 0 N--CA 1.431 -1.665 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 176.83 178.57 46.68 Favored Glycine 0 N--CA 1.418 -2.502 0 C-N-CA 119.133 -1.508 . . . . 0.0 112.132 -179.218 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.416 ' HA ' ' O ' ' A' ' 145' ' ' VAL . 7.9 p -140.67 142.08 34.96 Favored 'General case' 0 C--N 1.285 -2.226 0 N-CA-C 108.795 -0.816 . . . . 0.0 108.795 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.41 153.06 51.2 Favored 'General case' 0 CA--C 1.474 -1.969 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 -178.018 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -98.68 116.67 31.43 Favored 'General case' 0 C--N 1.278 -2.53 0 CA-C-N 114.751 -1.113 . . . . 0.0 108.19 174.817 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.552 HG22 HG22 ' A' ' 5' ' ' THR . 26.1 t -103.76 127.39 57.9 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.573 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 54.2 m-85 -110.84 125.27 53.42 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 121.336 -0.146 . . . . 0.0 110.954 -179.389 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.486 HG22 ' HG3' ' A' ' 41' ' ' GLN . 21.2 t -126.93 121.8 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.036 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -176.691 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -85.13 120.88 27.12 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-O 121.411 0.624 . . . . 0.0 110.432 175.738 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 50.7 mt -109.93 160.9 16.0 Favored 'General case' 0 N--CA 1.424 -1.755 0 CA-C-N 114.452 -1.249 . . . . 0.0 108.251 -175.263 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.5 121.18 58.61 Favored Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 124.65 1.219 . . . . 0.0 109.411 -179.678 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 59.2 Cg_endo -72.77 -3.39 13.46 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.86 2.373 . . . . 0.0 113.183 -177.465 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.401 HG13 ' HG3' ' A' ' 157' ' ' PRO . 65.1 t -122.21 110.58 27.53 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 178.041 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.7 t -141.78 108.87 2.07 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.105 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 -178.531 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.766 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -98.05 152.37 19.37 Favored 'General case' 0 C--N 1.277 -2.555 0 C-N-CA 122.861 0.464 . . . . 0.0 112.135 -179.561 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.45 HG13 ' O ' ' A' ' 112' ' ' VAL . 30.5 t -46.61 117.71 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.036 0 C-N-CA 123.784 0.834 . . . . 0.0 111.578 177.427 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.1 3.79 55.59 Favored Glycine 0 C--O 1.235 0.211 0 CA-C-N 115.527 -0.76 . . . . 0.0 112.848 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.766 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -76.11 -176.65 3.61 Favored 'General case' 0 C--N 1.311 -1.081 0 C-N-CA 124.49 1.116 . . . . 0.0 110.113 178.249 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -130.73 90.57 2.93 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 178.848 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.658 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 21.9 tp -93.87 141.49 28.45 Favored 'General case' 0 C--N 1.29 -2.018 0 C-N-CA 119.062 -1.055 . . . . 0.0 109.003 178.746 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.6 t -134.35 122.62 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.813 0 CA-C-N 116.25 -0.432 . . . . 0.0 109.842 -174.205 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.609 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 57.0 t -92.43 87.96 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.35 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 172.337 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.548 ' O ' ' HG2' ' A' ' 41' ' ' GLN . 29.3 t70 -83.97 101.42 11.71 Favored 'General case' 0 CA--C 1.488 -1.429 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.809 -176.395 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.9 mt -80.9 -7.22 59.42 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.916 -177.666 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 24.8 t -71.72 -0.04 10.0 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.072 179.104 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 4.1 p -134.3 10.3 3.79 Favored 'General case' 0 N--CA 1.419 -1.982 0 CA-C-O 121.207 0.527 . . . . 0.0 110.049 176.082 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.548 ' HG2' ' O ' ' A' ' 37' ' ' ASP . 35.0 mm-40 -125.39 -20.96 4.65 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 -176.852 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.8 mt -134.6 136.77 52.19 Favored 'Isoleucine or valine' 0 C--O 1.239 0.517 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -177.396 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -138.43 120.44 15.54 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -175.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.528 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 73.8 m -102.37 143.07 32.58 Favored 'General case' 0 C--N 1.282 -2.354 0 CA-C-O 121.451 0.643 . . . . 0.0 109.962 -178.157 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.506 ' CE1' ' HB3' ' A' ' 2' ' ' ALA . 6.8 p80 -119.22 139.66 51.5 Favored 'General case' 0 C--N 1.288 -2.105 0 CA-C-O 121.73 0.776 . . . . 0.0 111.03 -176.393 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.629 ' HB2' ' CG ' ' A' ' 54' ' ' ASP . 3.7 p-10 -108.36 100.64 9.91 Favored 'General case' 0 N--CA 1.395 -3.202 0 CA-C-O 123.37 1.557 . . . . 0.0 107.436 -176.688 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -78.3 -32.94 49.62 Favored 'General case' 0 C--N 1.299 -1.592 0 CA-C-N 112.755 -2.02 . . . . 0.0 111.648 -168.495 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.401 ' HB2' ' HB ' ' A' ' 52' ' ' ILE . 39.2 m-85 -129.38 64.61 71.92 Favored Pre-proline 0 C--N 1.308 -1.208 0 C-N-CA 119.456 -0.898 . . . . 0.0 111.896 -174.841 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.58 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 56.2 Cg_endo -67.45 -7.98 20.77 Favored 'Trans proline' 0 N--CA 1.486 1.088 0 C-N-CA 122.847 2.365 . . . . 0.0 114.415 -173.866 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -110.62 -15.37 13.88 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 120.672 -0.411 . . . . 0.0 111.493 -176.753 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.554 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.8 m -115.9 -25.33 7.77 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-O 122.182 0.992 . . . . 0.0 109.779 -173.16 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.554 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.6 mp -130.67 150.12 34.28 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.996 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 -176.64 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.9 t -94.35 125.23 38.86 Favored 'General case' 0 N--CA 1.413 -2.299 0 N-CA-C 104.154 -2.535 . . . . 0.0 104.154 171.44 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.629 ' CG ' ' HB2' ' A' ' 46' ' ' ASN . 9.9 m-20 -91.71 106.16 18.27 Favored 'General case' 0 C--N 1.259 -3.336 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 -178.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.505 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 9.5 t80 -130.85 135.24 47.53 Favored 'General case' 0 C--N 1.287 -2.123 0 CA-C-N 114.49 -1.232 . . . . 0.0 109.233 -174.617 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.573 ' CG2' ' HG ' ' A' ' 131' ' ' LEU . 13.7 p -141.85 150.43 19.26 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.173 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.256 -176.004 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.1 p -150.17 129.97 13.29 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 123.894 0.878 . . . . 0.0 108.883 176.672 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.493 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 36.9 tp -65.6 112.63 3.73 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 172.309 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.477 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 2.7 tp-100 -60.66 -59.39 5.47 Favored 'General case' 0 C--O 1.204 -1.339 0 CA-C-N 113.257 -1.792 . . . . 0.0 109.915 -177.624 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -166.74 155.74 10.67 Favored 'General case' 0 N--CA 1.419 -1.999 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -175.801 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -135.44 153.73 21.39 Favored Glycine 0 N--CA 1.412 -2.92 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 -177.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.414 ' HA ' ' HB3' ' A' ' 85' ' ' PRO . 24.1 m -138.61 144.58 39.82 Favored 'General case' 0 C--N 1.281 -2.4 0 C-N-CA 123.402 0.681 . . . . 0.0 110.595 -178.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.57 ' HB1' HG23 ' A' ' 67' ' ' VAL . . . -106.64 157.96 17.31 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 125.081 1.353 . . . . 0.0 107.741 -179.52 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.787 ' O ' HG22 ' A' ' 67' ' ' VAL . 94.4 m-85 -155.74 178.15 10.58 Favored 'General case' 0 C--O 1.208 -1.113 0 CA-C-N 118.901 0.773 . . . . 0.0 111.781 -177.037 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 53.39 -127.49 36.7 Favored Glycine 0 C--O 1.217 -0.924 0 CA-C-O 121.423 0.457 . . . . 0.0 112.883 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.73 -9.16 83.44 Favored Glycine 0 N--CA 1.42 -2.38 0 C-N-CA 120.388 -0.91 . . . . 0.0 113.132 178.845 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.787 HG22 ' O ' ' A' ' 64' ' ' TYR . 12.8 m -78.49 -27.14 14.13 Favored 'Isoleucine or valine' 0 C--O 1.201 -1.468 0 CA-C-N 118.515 1.157 . . . . 0.0 112.562 -175.27 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.551 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -91.32 -15.04 29.72 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 119.91 -0.716 . . . . 0.0 111.862 176.146 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 26.5 t -101.18 -59.04 1.77 Allowed 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.524 -176.2 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.581 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 34.6 m-80 -87.14 -24.42 24.51 Favored 'General case' 0 CA--C 1.486 -1.486 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -176.147 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.574 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 85.5 m-85 -111.43 163.63 13.81 Favored 'General case' 0 C--N 1.286 -2.186 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.064 -178.592 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.2 t -179.95 134.21 0.11 Allowed 'General case' 0 N--CA 1.426 -1.645 0 N-CA-C 107.235 -1.395 . . . . 0.0 107.235 178.035 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.467 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -167.31 -109.82 0.22 Allowed Glycine 0 N--CA 1.406 -3.355 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 174.765 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 3.1 p -149.65 177.04 10.13 Favored 'General case' 0 C--N 1.275 -2.631 0 C-N-CA 122.778 0.431 . . . . 0.0 111.019 -174.681 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -132.9 140.16 47.98 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.116 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.722 ' HG3' ' O ' ' A' ' 80' ' ' SER . 82.6 tttt -120.72 145.36 47.57 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.398 -177.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.487 ' CD2' HG22 ' A' ' 105' ' ' VAL . 43.2 t80 -146.62 109.47 4.63 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.335 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 11.2 t 49.14 43.33 22.43 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 124.526 1.131 . . . . 0.0 111.912 178.393 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.9 11.95 62.81 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.22 -0.991 . . . . 0.0 113.107 178.221 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.722 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 23.5 t -88.77 -179.73 6.05 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 175.217 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.3 t -167.3 107.45 0.6 Allowed 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 179.31 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 2.1 p90 -144.3 158.19 55.12 Favored Pre-proline 0 C--N 1.287 -2.136 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 -173.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -67.96 144.77 65.55 Favored 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 122.614 2.21 . . . . 0.0 112.789 -175.016 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.547 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 60.8 t80 -118.41 134.73 23.42 Favored Pre-proline 0 C--N 1.31 -1.141 0 CA-C-N 116.233 -0.44 . . . . 0.0 109.977 -179.102 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.547 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 66.6 Cg_endo -72.22 143.75 78.19 Favored 'Cis proline' 0 CA--C 1.543 0.942 0 C-N-CA 123.189 -1.588 . . . . 0.0 111.465 -0.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.7 t -66.84 -177.03 0.55 Allowed 'General case' 0 CA--C 1.547 0.861 0 CA-C-N 115.161 -0.927 . . . . 0.0 111.941 -174.822 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 16.4 p -130.19 -46.23 1.11 Allowed 'General case' 0 N--CA 1.425 -1.679 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.699 -172.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.3 t -101.04 -97.68 0.26 Allowed 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -177.375 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -166.45 -166.66 0.9 Allowed 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 177.255 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.493 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 46.9 p -99.38 165.66 14.37 Favored Pre-proline 0 C--N 1.297 -1.68 0 N-CA-C 113.753 1.02 . . . . 0.0 113.753 -178.135 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 20.8 Cg_endo -61.65 169.72 6.6 Favored 'Trans proline' 0 C--O 1.247 0.929 0 C-N-CA 123.252 2.635 . . . . 0.0 110.682 171.017 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.505 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 3.2 tmm_? -80.25 123.07 27.64 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.03 -175.291 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 75.1 t -132.58 123.35 49.28 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.134 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.591 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 58.5 t -105.0 140.79 21.96 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.169 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 176.776 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.479 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 4.7 m-85 -84.2 94.91 8.5 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-O 121.75 0.785 . . . . 0.0 109.677 175.667 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 15.6 m120 -87.32 74.72 9.41 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 43.4 t -150.12 -173.41 4.43 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 -175.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 37.9 ptt180 -145.56 24.21 1.4 Allowed 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 172.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.4 t -160.85 174.65 13.55 Favored 'General case' 0 N--CA 1.426 -1.644 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 -176.055 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -61.96 136.15 57.84 Favored 'General case' 0 C--N 1.318 -0.792 0 O-C-N 123.59 0.556 . . . . 0.0 110.643 179.346 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 14.3 mmtm -138.52 150.25 65.55 Favored Pre-proline 0 C--N 1.286 -2.179 0 C-N-CA 124.976 1.311 . . . . 0.0 108.405 176.655 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -62.74 149.19 92.06 Favored 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 122.631 2.221 . . . . 0.0 111.881 -178.589 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' TRP . . . . . 0.479 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 11.2 t90 -89.88 104.89 9.4 Favored Pre-proline 0 C--N 1.305 -1.365 0 N-CA-C 106.171 -1.788 . . . . 0.0 106.171 178.122 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -75.99 87.54 1.4 Allowed 'Trans proline' 0 N--CA 1.448 -1.157 0 C-N-CA 121.27 1.313 . . . . 0.0 112.663 -172.191 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.487 HG22 ' CD2' ' A' ' 77' ' ' TYR . 61.7 t -140.16 149.7 21.81 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.126 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.492 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.609 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -153.14 135.4 14.93 Favored 'General case' 0 C--N 1.289 -2.025 0 O-C-N 123.268 0.355 . . . . 0.0 110.366 177.002 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.504 HD21 HD11 ' A' ' 129' ' ' LEU . 20.5 mt -101.73 104.84 15.66 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 177.695 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.467 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 55.4 m-85 -82.42 72.19 9.48 Favored 'General case' 0 C--N 1.281 -2.411 0 CA-C-O 120.883 0.373 . . . . 0.0 110.491 177.284 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.658 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.3 mm? -90.28 119.16 30.35 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 175.047 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -126.97 146.77 58.82 Favored Pre-proline 0 N--CA 1.411 -2.419 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -177.285 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.581 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 21.4 Cg_endo -60.99 118.8 5.71 Favored 'Trans proline' 0 C--O 1.246 0.902 0 C-N-CA 123.484 2.79 . . . . 0.0 112.468 -178.331 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.45 ' O ' HG13 ' A' ' 30' ' ' VAL . 3.1 m -67.98 -115.83 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.187 -2.188 0 CA-C-N 114.406 -1.27 . . . . 0.0 112.737 176.025 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 32.5 m -111.4 -42.58 3.86 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.159 -0.963 . . . . 0.0 111.312 179.468 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 8.8 t -90.99 28.4 1.59 Allowed 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 121.636 0.731 . . . . 0.0 110.356 -173.624 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -89.39 132.0 35.19 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.394 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.91 140.69 6.19 Favored Glycine 0 N--CA 1.434 -1.488 0 C-N-CA 119.496 -1.335 . . . . 0.0 111.994 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 57.09 -144.38 39.35 Favored Glycine 0 CA--C 1.495 -1.186 0 CA-C-O 119.175 -0.791 . . . . 0.0 112.87 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.0 p -61.43 96.02 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.245 0.856 0 CA-C-O 122.876 1.322 . . . . 0.0 112.385 -177.536 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.18 -31.81 11.9 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 114.327 -1.306 . . . . 0.0 111.053 -178.382 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.552 ' HB ' HG22 ' A' ' 154' ' ' VAL . 70.5 mt -124.8 139.32 51.33 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 177.162 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.404 ' HA ' ' HE2' ' A' ' 121' ' ' LYS . 3.3 mmpt? -114.24 136.17 53.26 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.179 0.514 . . . . 0.0 111.065 178.023 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -72.66 122.94 22.27 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.102 -178.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 99.48 -5.53 58.76 Favored Glycine 0 N--CA 1.434 -1.482 0 N-CA-C 110.891 -0.884 . . . . 0.0 110.891 -178.167 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 49.9 m -97.05 149.07 22.35 Favored 'General case' 0 N--CA 1.422 -1.851 0 CA-C-O 121.518 0.675 . . . . 0.0 110.382 -179.669 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.416 HD11 HG23 ' A' ' 128' ' ' VAL . 3.0 tm? -75.69 127.76 33.75 Favored 'General case' 0 N--CA 1.429 -1.502 0 CA-C-N 114.203 -1.362 . . . . 0.0 108.656 -178.213 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.541 ' HB ' HG11 ' A' ' 67' ' ' VAL . 28.1 pt -113.16 -29.7 2.27 Favored 'Isoleucine or valine' 0 C--O 1.197 -1.679 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.733 178.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' ALA . . . . . 0.493 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -156.91 166.93 31.99 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.659 -177.575 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.416 HG23 HD11 ' A' ' 125' ' ' LEU . 54.8 t -141.35 114.52 4.57 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.089 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 178.219 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.504 HD11 HD21 ' A' ' 107' ' ' LEU . 64.5 mt -118.12 138.66 52.12 Favored 'General case' 0 C--N 1.288 -2.086 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 178.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.47 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.0 mp -120.03 127.81 75.91 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 C-N-CA 119.335 -0.946 . . . . 0.0 109.455 178.644 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.573 ' HG ' ' CG2' ' A' ' 56' ' ' VAL . 0.1 OUTLIER -99.17 130.18 45.47 Favored 'General case' 0 C--N 1.273 -2.758 0 C-N-CA 124.391 1.076 . . . . 0.0 110.994 -176.648 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.477 ' HG2' ' HB2' ' A' ' 59' ' ' GLN . 14.6 mmm180 -97.99 113.34 25.16 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 123.428 0.691 . . . . 0.0 110.308 178.361 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.741 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 12.5 mm100 -92.43 134.66 34.73 Favored 'General case' 0 N--CA 1.404 -2.744 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 173.551 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.428 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 19.5 m -142.26 130.56 22.25 Favored 'General case' 0 C--N 1.28 -2.424 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 176.235 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 15.6 p30 -120.39 161.49 21.11 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.333 -179.267 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -100.49 -5.89 26.33 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.794 -174.335 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 68.5 t80 -107.36 -71.59 0.75 Allowed 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.458 -171.455 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -75.26 177.02 6.84 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 175.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 17.3 t -115.36 33.45 5.44 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 174.009 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -93.74 40.0 1.07 Allowed 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 114.359 -1.291 . . . . 0.0 110.648 -179.463 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 13.3 p-10 -83.91 80.98 8.97 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-O 122.706 1.241 . . . . 0.0 109.978 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -96.47 176.21 6.12 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 114.536 -1.211 . . . . 0.0 109.543 179.166 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' GLN . . . . . 0.464 ' HB3' ' HD2' ' A' ' 132' ' ' ARG . 12.9 pt20 -129.04 142.39 50.92 Favored 'General case' 0 N--CA 1.425 -1.719 0 C-N-CA 120.077 -0.649 . . . . 0.0 109.385 177.274 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -109.93 136.63 48.91 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 -176.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.416 ' O ' ' HA ' ' A' ' 17' ' ' SER . 43.8 t -95.26 129.9 44.75 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 O-C-N 123.69 0.619 . . . . 0.0 109.638 -177.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 146' ' ' TRP . . . . . 0.484 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 63.3 m95 -119.8 103.21 9.16 Favored 'General case' 0 C--N 1.282 -2.338 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -178.195 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -83.89 112.1 19.83 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 179.554 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.493 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 23.0 mm -87.45 122.65 39.49 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.187 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 -178.363 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -116.69 156.93 26.26 Favored 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 123.669 0.788 . . . . 0.0 109.267 179.198 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.46 130.52 34.57 Favored 'General case' 0 N--CA 1.396 -3.151 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 176.475 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 36.7 t-20 -89.13 -18.61 26.85 Favored 'General case' 0 C--N 1.285 -2.226 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 -177.521 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -147.66 143.71 27.85 Favored 'General case' 0 N--CA 1.429 -1.483 0 CA-C-N 114.013 -1.449 . . . . 0.0 109.284 -173.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -83.41 139.45 32.97 Favored 'General case' 0 C--N 1.312 -1.063 0 O-C-N 124.391 1.057 . . . . 0.0 109.698 -178.344 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.552 HG22 ' HB ' ' A' ' 120' ' ' ILE . 1.8 m -121.47 148.54 24.81 Favored 'Isoleucine or valine' 0 C--O 1.257 1.478 0 C-N-CA 120.138 -0.625 . . . . 0.0 111.259 -177.65 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.5 t -120.49 140.95 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.699 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 -179.058 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.455 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 71.4 t -102.24 104.62 38.12 Favored Pre-proline 0 C--N 1.288 -2.068 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 178.374 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.486 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 43.4 Cg_endo -71.29 -20.75 27.59 Favored 'Trans proline' 0 N--CA 1.462 -0.332 0 C-N-CA 122.404 2.069 . . . . 0.0 111.428 176.865 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.425 ' HA ' ' H ' ' A' ' 30' ' ' VAL 0.26 3.3 t . . . . . 0 C--O 1.247 0.951 0 C-N-CA 124.497 1.119 . . . . 0.0 113.775 175.904 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.519 ' HA ' ' HA ' ' A' ' 46' ' ' ASN . 52.3 t80 . . . . . 0 CA--C 1.501 -0.935 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.515 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -144.1 -170.86 3.44 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 -179.366 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.531 ' HB3' ' CZ2' ' A' ' 146' ' ' TRP . 10.6 t -156.92 164.0 38.52 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 118.604 -1.238 . . . . 0.0 110.677 -176.294 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.414 ' HG3' ' O ' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -147.2 159.86 43.14 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -177.003 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.608 HG22 HG22 ' A' ' 20' ' ' VAL . 63.9 p -99.8 173.66 6.58 Favored 'General case' 0 C--N 1.3 -1.578 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.727 178.815 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.0 -21.75 59.86 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 114.629 -1.169 . . . . 0.0 111.223 177.051 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -82.11 -35.43 28.58 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 119.574 -0.85 . . . . 0.0 110.411 -178.24 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 133.49 16.45 1.17 Allowed Glycine 0 N--CA 1.434 -1.49 0 C-N-CA 119.709 -1.234 . . . . 0.0 112.955 178.267 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.3 m -91.53 105.46 17.77 Favored 'General case' 0 N--CA 1.428 -1.573 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 174.548 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -98.18 123.58 42.32 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 176.029 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.515 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 49.6 mt -104.17 117.81 58.48 Favored Pre-proline 0 C--N 1.29 -1.981 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 177.478 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -81.71 176.2 8.68 Favored 'Trans proline' 0 C--O 1.245 0.842 0 C-N-CA 122.601 2.2 . . . . 0.0 110.783 176.489 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 63.5 mt -67.1 129.15 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 N-CA-C 109.052 -0.722 . . . . 0.0 109.052 177.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 145.36 -8.95 1.67 Allowed Glycine 0 C--N 1.308 -0.98 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.004 -178.53 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.21 154.6 30.78 Favored Glycine 0 CA--C 1.504 -0.594 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 -178.281 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 160.39 -171.44 36.6 Favored Glycine 0 N--CA 1.428 -1.893 0 C-N-CA 119.851 -1.166 . . . . 0.0 111.169 -178.583 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.527 ' HB3' ' HB ' ' A' ' 145' ' ' VAL . 28.8 p -144.34 151.18 38.96 Favored 'General case' 0 C--N 1.291 -1.949 0 CA-C-O 120.797 0.332 . . . . 0.0 111.153 -177.073 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.16 162.52 32.29 Favored 'General case' 0 N--CA 1.421 -1.9 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -178.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.432 HD21 ' HE1' ' A' ' 21' ' ' TYR . 4.7 p-10 -108.27 113.57 26.77 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.077 -0.965 . . . . 0.0 108.741 176.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.608 HG22 HG22 ' A' ' 5' ' ' THR . 40.0 t -103.71 116.78 48.11 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.757 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.403 -179.456 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.432 ' HE1' HD21 ' A' ' 19' ' ' ASN . 23.5 m-85 -102.07 119.15 38.34 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 120.602 0.239 . . . . 0.0 111.058 179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.478 HG22 ' HG3' ' A' ' 41' ' ' GLN . 23.7 t -119.98 128.09 75.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.73 -174.815 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 48.1 m-80 -81.83 126.55 32.0 Favored 'General case' 0 CA--C 1.483 -1.604 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 176.385 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.423 HD21 HG22 ' A' ' 36' ' ' VAL . 28.8 mt -117.8 148.31 42.2 Favored 'General case' 0 C--N 1.28 -2.449 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 179.482 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -53.24 119.14 16.09 Favored Pre-proline 0 C--O 1.209 -1.071 0 O-C-N 124.923 1.389 . . . . 0.0 110.524 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.599 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 56.3 Cg_endo -72.01 -0.29 8.28 Favored 'Trans proline' 0 CA--C 1.535 0.531 0 C-N-CA 122.999 2.466 . . . . 0.0 113.531 -175.723 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.412 HG13 ' HG3' ' A' ' 157' ' ' PRO . 66.8 t -131.63 109.91 16.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 179.815 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.513 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 11.6 t -147.71 113.99 0.92 Allowed 'Isoleucine or valine' 0 C--O 1.186 -2.273 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 -177.343 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.794 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -100.15 157.65 16.42 Favored 'General case' 0 C--N 1.273 -2.738 0 C-N-CA 123.824 0.85 . . . . 0.0 111.636 -178.787 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.408 HG13 ' O ' ' A' ' 112' ' ' VAL . 38.5 t -49.79 120.13 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 CA-C-O 121.029 0.442 . . . . 0.0 111.188 176.323 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.31 8.95 58.37 Favored Glycine 0 CA--C 1.522 0.51 0 CA-C-N 115.57 -0.741 . . . . 0.0 112.808 -179.595 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.794 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -80.37 -175.29 5.05 Favored 'General case' 0 C--N 1.31 -1.11 0 C-N-CA 124.983 1.313 . . . . 0.0 108.237 175.762 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 18.7 t-20 -133.78 95.4 3.45 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 177.814 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.621 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 24.7 tp -91.96 144.29 25.61 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 119.166 -1.013 . . . . 0.0 109.498 178.516 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 62.0 t -135.48 124.06 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.915 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 -177.55 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.565 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 44.9 t -92.87 88.52 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.183 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 173.067 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.43 ' O ' ' HG2' ' A' ' 41' ' ' GLN . 32.5 t70 -79.08 104.19 9.54 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.981 -177.139 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.7 mt -85.55 -2.84 58.57 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.345 -179.059 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.429 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 36.6 t -73.58 -2.49 23.08 Favored 'General case' 0 CA--C 1.546 0.8 0 CA-C-O 121.715 0.769 . . . . 0.0 110.16 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.5 p -126.78 8.43 6.88 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.191 177.399 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.478 ' HG3' HG22 ' A' ' 22' ' ' VAL . 43.8 mm-40 -125.26 -27.08 3.54 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.226 -174.06 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.6 mt -133.79 135.75 54.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 -175.624 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.414 ' O ' ' HG3' ' A' ' 4' ' ' LYS . 39.0 m-85 -138.31 120.1 15.28 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -176.377 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.498 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 74.3 m -102.94 145.29 30.06 Favored 'General case' 0 C--N 1.281 -2.385 0 CA-C-O 120.825 0.345 . . . . 0.0 110.333 -177.461 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.435 ' HB3' ' HA ' ' A' ' 100' ' ' ASP . 25.8 p-80 -134.56 149.42 50.63 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.112 -173.778 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.519 ' HA ' ' HA ' ' A' ' 1' ' ' PHE . 60.8 t30 -103.26 91.2 3.98 Favored 'General case' 0 C--N 1.291 -1.941 0 C-N-CA 118.786 -1.166 . . . . 0.0 109.882 172.66 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -61.46 -24.43 66.55 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 113.508 -1.678 . . . . 0.0 111.905 -177.608 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 50.6 m-85 -125.71 78.64 68.86 Favored Pre-proline 0 C--N 1.322 -0.629 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 -178.657 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -73.02 -7.42 20.65 Favored 'Trans proline' 0 C--N 1.332 -0.319 0 C-N-CA 122.631 2.221 . . . . 0.0 114.241 -173.193 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -112.45 -23.03 10.54 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 121.768 0.794 . . . . 0.0 109.786 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.579 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.6 OUTLIER -97.68 -30.1 13.02 Favored 'General case' 0 N--CA 1.407 -2.597 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.744 -169.82 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.579 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.0 mp -128.67 133.69 65.93 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.806 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.185 -176.915 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.9 t -75.88 145.64 40.38 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 174.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.428 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 3.0 m-20 -81.47 108.72 15.3 Favored 'General case' 0 C--N 1.278 -2.509 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -174.013 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 77.3 t80 -147.9 138.85 23.31 Favored 'General case' 0 C--N 1.293 -1.865 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.203 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.483 HG23 ' HG ' ' A' ' 131' ' ' LEU . 14.5 p -152.19 147.19 15.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 C-N-CA 124.405 1.082 . . . . 0.0 109.371 176.538 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.88 127.29 10.7 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 123.401 0.68 . . . . 0.0 109.824 172.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.498 HD23 ' O ' ' A' ' 130' ' ' ILE . 1.1 tt -68.0 114.24 6.36 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 175.379 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.1 tp-100 -58.62 -63.87 1.13 Allowed 'General case' 0 C--O 1.206 -1.228 0 C-N-CA 124.718 1.207 . . . . 0.0 110.372 178.114 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.435 ' HA ' HG23 ' A' ' 86' ' ' THR . 0.0 OUTLIER -164.09 154.02 14.61 Favored 'General case' 0 N--CA 1.422 -1.834 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -173.689 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.475 ' O ' ' HB2' ' A' ' 85' ' ' PRO . . . -124.03 154.84 17.78 Favored Glycine 0 N--CA 1.409 -3.104 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 179.583 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 49.4 m -131.39 145.6 51.89 Favored 'General case' 0 C--N 1.28 -2.416 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.478 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -113.97 154.82 26.96 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.914 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.453 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . 88.5 m-85 -156.63 -178.1 7.1 Favored 'General case' 0 C--O 1.238 0.479 0 C-N-CA 123.622 0.769 . . . . 0.0 109.506 -177.268 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 62.02 -137.71 45.98 Favored Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 115.783 -0.644 . . . . 0.0 113.148 175.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -84.32 -7.66 84.59 Favored Glycine 0 N--CA 1.42 -2.41 0 N-CA-C 111.336 -0.705 . . . . 0.0 111.336 177.221 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.786 HG21 ' HB ' ' A' ' 126' ' ' ILE . 94.5 t -70.0 -43.81 78.97 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.379 0 C-N-CA 123.056 0.543 . . . . 0.0 111.429 -178.525 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.478 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -82.32 -16.99 47.35 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.129 -1.028 . . . . 0.0 111.978 -179.469 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 8.2 t -100.54 -51.92 3.48 Favored 'General case' 0 N--CA 1.444 -0.771 0 CA-C-N 115.86 -0.609 . . . . 0.0 112.125 -174.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.536 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 34.0 m-80 -93.77 -21.53 19.25 Favored 'General case' 0 CA--C 1.492 -1.272 0 C-N-CA 120.494 -0.482 . . . . 0.0 109.972 -175.308 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.671 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 78.2 m-85 -111.8 161.8 15.95 Favored 'General case' 0 N--CA 1.425 -1.712 0 C-N-CA 120.076 -0.65 . . . . 0.0 109.967 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 t -169.52 133.92 1.38 Allowed 'General case' 0 N--CA 1.419 -1.991 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 176.456 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.492 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -167.08 -111.92 0.25 Allowed Glycine 0 N--CA 1.402 -3.604 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 175.721 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.4 p -157.72 -179.46 8.18 Favored 'General case' 0 C--N 1.29 -2.016 0 C-N-CA 124.421 1.088 . . . . 0.0 110.02 -174.142 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.423 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.6 p -132.66 147.88 31.76 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.734 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.601 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.9 tttt -125.61 147.57 49.26 Favored 'General case' 0 N--CA 1.43 -1.446 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.839 -178.609 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.522 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 52.1 t80 -147.76 109.48 4.42 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 -178.192 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 9.2 t 50.8 43.7 28.16 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 124.079 0.952 . . . . 0.0 111.35 177.564 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.02 6.16 69.73 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 120.415 -0.898 . . . . 0.0 113.946 178.826 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.601 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 12.2 t -79.74 -178.86 6.6 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 117.436 0.618 . . . . 0.0 110.205 178.597 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 40.9 t -159.24 103.54 1.63 Allowed 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 -179.4 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.522 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 4.0 p90 -148.85 161.65 32.05 Favored Pre-proline 0 C--N 1.313 -0.991 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 -174.275 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.439 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 84.9 Cg_endo -71.77 149.13 53.75 Favored 'Trans proline' 0 C--N 1.362 1.261 0 C-N-CA 122.494 2.129 . . . . 0.0 113.502 -174.386 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.656 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 56.8 t80 -120.45 137.36 26.08 Favored Pre-proline 0 N--CA 1.427 -1.597 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 178.738 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.656 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 66.2 Cg_endo -70.52 142.59 72.39 Favored 'Cis proline' 0 CA--C 1.542 0.916 0 C-N-CA 122.933 -1.695 . . . . 0.0 112.959 -1.487 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.435 HG23 ' HA ' ' A' ' 60' ' ' ARG 0.338 10.3 t -63.54 105.4 0.77 Allowed 'General case' 0 C--O 1.249 1.059 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 -179.361 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 7.3 p -77.54 -13.04 60.01 Favored 'General case' 0 C--N 1.282 -2.363 0 CA-C-N 112.975 -1.92 . . . . 0.0 110.779 -175.562 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.7 t -119.41 -82.96 0.65 Allowed 'General case' 0 N--CA 1.409 -2.497 0 C-N-CA 119.326 -0.95 . . . . 0.0 111.898 -173.632 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 172.4 177.95 0.08 Allowed 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.284 1.033 . . . . 0.0 108.695 -178.132 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.426 HG21 ' CD2' ' A' ' 77' ' ' TYR . 42.9 p -102.31 161.07 24.45 Favored Pre-proline 0 C--N 1.301 -1.51 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 177.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -61.22 162.58 19.5 Favored 'Trans proline' 0 CA--C 1.546 1.103 0 C-N-CA 123.427 2.751 . . . . 0.0 111.696 172.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.7 tmm_? -72.29 116.82 13.17 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 124.588 1.155 . . . . 0.0 109.874 -176.291 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 75.4 t -124.84 127.89 72.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 CA-C-O 121.348 0.594 . . . . 0.0 111.234 -178.437 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 77.0 t -107.13 123.18 62.13 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.214 178.177 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.453 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 5.3 m-85 -78.34 156.29 29.65 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 173.066 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -128.67 34.24 4.53 Favored 'General case' 0 C--N 1.261 -3.276 0 N-CA-C 106.8 -1.556 . . . . 0.0 106.8 175.698 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' SER . . . . . 0.445 ' CB ' ' HG3' ' A' ' 101' ' ' LYS . 45.2 m -130.67 117.64 19.77 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 113.563 0.949 . . . . 0.0 113.563 -170.776 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 20.4 ptp180 -93.93 32.15 1.51 Allowed 'General case' 0 C--O 1.244 0.797 0 CA-C-O 122.332 1.063 . . . . 0.0 110.129 179.345 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 9.2 t -152.82 165.63 34.8 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 105.203 -2.147 . . . . 0.0 105.203 -178.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ASP . . . . . 0.435 ' HA ' ' HB3' ' A' ' 45' ' ' HIS . 16.9 p-10 -74.0 112.71 10.4 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-O 122.167 0.984 . . . . 0.0 111.099 -174.565 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' LYS . . . . . 0.445 ' HG3' ' CB ' ' A' ' 97' ' ' SER . 15.2 mmtm -122.98 145.27 45.28 Favored Pre-proline 0 C--N 1.284 -2.254 0 CA-C-N 114.235 -1.348 . . . . 0.0 108.618 -178.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.429 ' HB3' ' O ' ' A' ' 39' ' ' SER . 17.9 Cg_endo -56.17 142.27 86.89 Favored 'Trans proline' 0 N--CA 1.45 -1.053 0 C-N-CA 123.318 2.679 . . . . 0.0 113.7 -172.646 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' TRP . . . . . 0.453 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.7 t90 -89.67 106.07 12.89 Favored Pre-proline 0 C--N 1.298 -1.667 0 N-CA-C 105.27 -2.122 . . . . 0.0 105.27 178.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -76.25 87.48 1.43 Allowed 'Trans proline' 0 N--CA 1.435 -1.961 0 C-N-CA 121.228 1.285 . . . . 0.0 111.685 -173.339 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.473 HG22 ' CD2' ' A' ' 77' ' ' TYR . 64.9 t -138.86 145.83 27.15 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 177.658 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.565 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -152.01 135.52 16.1 Favored 'General case' 0 C--N 1.278 -2.534 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.262 177.856 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.494 HD21 HD11 ' A' ' 129' ' ' LEU . 21.4 mt -98.66 102.52 14.29 Favored 'General case' 0 C--N 1.287 -2.123 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 178.782 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.492 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 50.8 m-85 -83.86 73.57 10.3 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 120.951 0.405 . . . . 0.0 110.378 177.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.671 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 2.9 mm? -99.47 129.76 45.67 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 175.762 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -130.07 148.21 68.75 Favored Pre-proline 0 N--CA 1.413 -2.312 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 -178.141 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.536 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 20.4 Cg_endo -59.41 120.67 8.64 Favored 'Trans proline' 0 C--O 1.246 0.88 0 C-N-CA 123.283 2.655 . . . . 0.0 112.286 -178.262 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.416 HG22 ' H ' ' A' ' 112' ' ' VAL . 2.7 m -69.21 -116.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.184 -2.394 0 CA-C-N 114.26 -1.336 . . . . 0.0 113.194 176.857 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 21.4 m -112.18 -40.47 4.17 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.316 -0.865 . . . . 0.0 110.632 179.202 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 28.9 t -87.79 28.47 1.01 Allowed 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.697 -176.245 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -95.18 132.91 39.62 Favored 'General case' 0 N--CA 1.427 -1.597 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -171.54 144.24 8.04 Favored Glycine 0 N--CA 1.436 -1.335 0 C-N-CA 120.057 -1.068 . . . . 0.0 111.559 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.454 ' O ' ' HA ' ' A' ' 155' ' ' VAL . . . 54.35 -145.7 26.54 Favored Glycine 0 CA--C 1.488 -1.613 0 C-N-CA 124.132 0.872 . . . . 0.0 113.0 -179.219 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 58.2 t -62.78 100.83 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.95 0 CA-C-O 121.602 0.715 . . . . 0.0 110.07 -177.31 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -99.33 -25.84 14.35 Favored 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 114.509 -1.223 . . . . 0.0 109.985 -179.331 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.523 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.0 mt -134.75 138.29 49.6 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -179.451 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.491 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.7 mmpt? -112.89 147.42 37.07 Favored 'General case' 0 C--N 1.31 -1.136 0 C-N-CA 122.692 0.397 . . . . 0.0 110.193 174.877 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.89 126.91 30.94 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 177.692 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.13 -8.33 67.35 Favored Glycine 0 C--N 1.312 -0.757 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -177.536 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 33.5 t -81.38 136.97 35.74 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 -179.763 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -72.35 121.85 20.18 Favored 'General case' 0 N--CA 1.429 -1.505 0 N-CA-C 106.491 -1.67 . . . . 0.0 106.491 175.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.786 ' HB ' HG21 ' A' ' 67' ' ' VAL . 27.7 pt -109.11 -27.42 2.93 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.915 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -177.128 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.28 169.38 20.76 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -177.6 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 76.7 t -144.11 113.38 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 179.161 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.494 HD11 HD21 ' A' ' 107' ' ' LEU . 46.2 mt -114.46 140.76 48.45 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.775 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.498 ' O ' HD23 ' A' ' 58' ' ' LEU . 4.0 mp -121.21 129.6 75.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 C-N-CA 118.844 -1.142 . . . . 0.0 110.787 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.556 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.2 OUTLIER -103.19 131.9 49.87 Favored 'General case' 0 C--N 1.284 -2.24 0 C-N-CA 125.268 1.427 . . . . 0.0 110.553 -177.147 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.424 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 14.0 mmm180 -93.54 132.57 37.71 Favored 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 123.78 0.832 . . . . 0.0 110.699 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.416 ' HA ' ' NE2' ' A' ' 133' ' ' GLN . 5.1 tp-100 -113.28 114.6 26.92 Favored 'General case' 0 N--CA 1.422 -1.844 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 174.749 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 26.4 m -135.48 144.75 46.57 Favored 'General case' 0 C--N 1.286 -2.168 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 179.24 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.558 ' CB ' HG23 ' A' ' 52' ' ' ILE . 11.8 p30 -147.59 -169.32 3.29 Favored 'General case' 0 N--CA 1.436 -1.173 0 C-N-CA 119.305 -0.958 . . . . 0.0 112.355 178.816 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -92.97 -25.91 17.79 Favored 'General case' 0 C--N 1.308 -1.2 0 CA-C-O 121.389 0.614 . . . . 0.0 111.6 -175.365 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 50.5 t80 -98.02 -56.97 2.33 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.947 -169.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' ASN . . . . . 0.427 ' HB3' ' H ' ' A' ' 140' ' ' ASP . 18.5 m120 -83.27 140.82 32.28 Favored 'General case' 0 CA--C 1.48 -1.74 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.723 177.414 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 39.3 m -93.73 12.33 25.99 Favored 'General case' 0 C--N 1.287 -2.148 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 173.067 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' ASP . . . . . 0.427 ' H ' ' HB3' ' A' ' 138' ' ' ASN . 4.3 m-20 -79.54 60.8 3.37 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 126.352 1.861 . . . . 0.0 110.036 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -82.83 81.53 8.51 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-O 122.486 1.136 . . . . 0.0 110.634 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -102.6 177.29 4.9 Favored 'General case' 0 N--CA 1.429 -1.521 0 CA-C-N 114.949 -1.023 . . . . 0.0 108.258 177.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' GLN . . . . . 0.424 ' HB3' ' HD2' ' A' ' 132' ' ' ARG . 13.4 pt20 -138.72 149.8 45.46 Favored 'General case' 0 N--CA 1.415 -2.178 0 C-N-CA 120.383 -0.527 . . . . 0.0 110.628 178.187 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 8.4 m-30 -108.1 134.32 51.14 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -175.578 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.527 ' HB ' ' HB3' ' A' ' 17' ' ' SER . 55.3 t -94.24 128.06 45.81 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 O-C-N 123.738 0.649 . . . . 0.0 110.137 -179.087 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' TRP . . . . . 0.556 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.4 m95 -114.87 96.98 5.98 Favored 'General case' 0 C--N 1.275 -2.658 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -179.634 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 40.4 m-80 -80.01 112.73 17.6 Favored 'General case' 0 C--N 1.291 -1.959 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.454 HG22 HD11 ' A' ' 126' ' ' ILE . 24.4 mm -87.9 123.95 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.879 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 -177.064 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -118.82 153.92 33.71 Favored 'General case' 0 C--N 1.288 -2.098 0 C-N-CA 124.105 0.962 . . . . 0.0 108.468 178.25 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.403 ' HB3' ' O ' ' A' ' 121' ' ' LYS . . . -82.29 133.76 35.25 Favored 'General case' 0 N--CA 1.406 -2.635 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 176.114 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -92.29 -13.15 30.78 Favored 'General case' 0 C--N 1.284 -2.26 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 -177.073 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -153.89 148.11 25.85 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 113.834 -1.53 . . . . 0.0 108.824 -176.694 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -82.12 149.02 28.22 Favored 'General case' 0 C--N 1.322 -0.628 0 O-C-N 123.958 0.786 . . . . 0.0 111.096 -178.436 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.599 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 73.7 t -124.62 133.68 68.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.346 -176.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.454 ' HA ' ' O ' ' A' ' 117' ' ' GLY . 8.4 t -116.71 136.35 54.06 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.513 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 72.3 t -100.02 103.52 23.04 Favored Pre-proline 0 C--N 1.292 -1.895 0 C-N-CA 123.384 0.674 . . . . 0.0 109.324 178.704 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.412 ' HG3' HG13 ' A' ' 27' ' ' VAL . 33.3 Cg_endo -68.47 -27.1 33.81 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 122.423 2.082 . . . . 0.0 111.781 179.222 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.416 ' HB ' HG12 ' A' ' 156' ' ' VAL . 4.4 t . . . . . 0 CA--C 1.548 0.895 0 C-N-CA 125.109 1.364 . . . . 0.0 113.515 176.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.634 ' CZ ' ' HB3' ' A' ' 44' ' ' CYS . 55.4 t80 . . . . . 0 CA--C 1.485 -1.551 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.481 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -141.16 171.4 14.11 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 176.107 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 70.9 m -136.02 159.41 41.77 Favored 'General case' 0 C--N 1.301 -1.5 0 C-N-CA 120.741 -0.384 . . . . 0.0 111.127 -175.348 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.416 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -143.73 161.05 39.6 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.172 0.51 . . . . 0.0 111.197 -176.187 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.521 HG22 HG22 ' A' ' 20' ' ' VAL . 72.0 p -102.25 168.88 9.07 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.335 177.793 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.99 -7.12 53.89 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 114.103 -1.408 . . . . 0.0 112.009 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -90.65 -31.29 16.69 Favored 'General case' 0 CA--C 1.511 -0.537 0 C-N-CA 118.458 -1.297 . . . . 0.0 108.234 176.219 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 133.24 2.57 3.68 Favored Glycine 0 N--CA 1.431 -1.678 0 C-N-CA 120.29 -0.957 . . . . 0.0 113.029 177.599 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.6 m -77.91 102.31 7.24 Favored 'General case' 0 N--CA 1.442 -0.869 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.193 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.26 117.59 30.54 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 175.12 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.481 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 62.1 mt -92.69 115.62 65.15 Favored Pre-proline 0 C--N 1.301 -1.529 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 179.348 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_endo -78.36 -179.83 5.82 Favored 'Trans proline' 0 C--O 1.248 0.981 0 C-N-CA 122.643 2.229 . . . . 0.0 111.526 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.5 mt -70.62 129.55 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.18 1.09 3.29 Favored Glycine 0 C--N 1.305 -1.162 0 C-N-CA 120.886 -0.673 . . . . 0.0 111.607 -178.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.75 171.41 46.91 Favored Glycine 0 C--O 1.244 0.773 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.289 -179.607 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 150.9 -169.11 30.66 Favored Glycine 0 N--CA 1.438 -1.182 0 C-N-CA 120.474 -0.869 . . . . 0.0 111.352 177.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 87.0 p -141.93 157.5 44.89 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -141.04 162.83 34.57 Favored 'General case' 0 N--CA 1.42 -1.965 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -110.03 111.33 22.64 Favored 'General case' 0 C--N 1.285 -2.207 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.256 178.63 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.521 HG22 HG22 ' A' ' 5' ' ' THR . 41.5 t -100.75 135.83 35.07 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.441 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.513 -178.779 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 69.2 m-85 -125.29 128.51 48.36 Favored 'General case' 0 CA--C 1.492 -1.272 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -177.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.514 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.2 p -139.63 136.33 39.84 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 O-C-N 123.78 0.675 . . . . 0.0 110.974 -177.084 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 -88.79 128.29 35.63 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 178.089 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.441 HD11 HG22 ' A' ' 36' ' ' VAL . 2.7 mm? -107.11 160.05 15.85 Favored 'General case' 0 C--N 1.284 -2.272 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 176.15 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.45 120.66 37.63 Favored Pre-proline 0 C--O 1.209 -1.046 0 O-C-N 124.505 1.128 . . . . 0.0 109.365 176.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.515 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 62.4 Cg_endo -74.14 0.45 8.43 Favored 'Trans proline' 0 CA--C 1.537 0.667 0 C-N-CA 122.668 2.245 . . . . 0.0 113.514 -176.88 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.45 HG13 ' HG3' ' A' ' 157' ' ' PRO . 93.7 t -131.49 111.43 19.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 178.455 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.476 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 9.3 t -147.76 112.96 0.83 Allowed 'Isoleucine or valine' 0 C--O 1.194 -1.845 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 -177.453 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.666 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -101.05 154.75 18.44 Favored 'General case' 0 C--N 1.277 -2.571 0 C-N-CA 123.746 0.818 . . . . 0.0 111.062 -179.354 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.543 HG22 ' O ' ' A' ' 112' ' ' VAL . 99.1 t -46.12 117.84 0.39 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.478 0 C-N-CA 123.379 0.672 . . . . 0.0 111.338 175.614 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.1 1.36 54.63 Favored Glycine 0 C--N 1.311 -0.815 0 CA-C-N 115.253 -0.885 . . . . 0.0 113.101 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.666 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -74.42 -175.91 2.51 Favored 'General case' 0 C--N 1.315 -0.914 0 C-N-CA 124.551 1.141 . . . . 0.0 109.967 175.336 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 66.5 t30 -134.45 96.02 3.5 Favored 'General case' 0 N--CA 1.428 -1.559 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 177.689 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.596 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 28.8 tp -93.15 142.52 27.21 Favored 'General case' 0 C--N 1.284 -2.247 0 C-N-CA 119.773 -0.771 . . . . 0.0 109.929 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.0 t -135.01 122.08 35.89 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.719 0 CA-C-O 121.168 0.508 . . . . 0.0 109.901 -176.533 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.585 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 47.8 t -92.94 89.07 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.27 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 174.859 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -78.03 106.76 10.11 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.248 -177.568 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.6 mt -93.79 -1.68 54.65 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 121.365 0.602 . . . . 0.0 111.025 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.9 t -76.37 1.28 16.74 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.974 -178.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.3 p -129.55 8.93 5.46 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 123.614 0.765 . . . . 0.0 109.869 176.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.514 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 45.6 mm-40 -125.23 -24.73 3.93 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.505 -174.808 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.0 mt -133.71 141.59 43.78 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 -177.115 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.472 ' HA ' ' HA ' ' A' ' 102' ' ' PRO . 57.6 m-85 -141.24 161.14 38.59 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -176.199 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.634 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 69.3 m -138.69 138.77 38.06 Favored 'General case' 0 C--N 1.299 -1.618 0 C-N-CA 123.059 0.544 . . . . 0.0 110.953 -178.609 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 29.4 p-80 -134.12 148.94 51.05 Favored 'General case' 0 C--O 1.247 0.965 0 CA-C-O 121.378 0.609 . . . . 0.0 111.961 -175.386 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.496 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 3.4 p30 -105.37 118.87 37.66 Favored 'General case' 0 CA--C 1.485 -1.553 0 CA-C-O 122.193 0.997 . . . . 0.0 112.832 179.485 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -88.43 -25.94 22.38 Favored 'General case' 0 C--N 1.286 -2.189 0 CA-C-N 113.79 -1.55 . . . . 0.0 109.511 177.006 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.414 ' HB2' HD13 ' A' ' 52' ' ' ILE . 29.0 m-85 -138.51 66.87 44.03 Favored Pre-proline 0 N--CA 1.477 0.919 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.175 177.489 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.496 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 55.8 Cg_endo -68.52 -8.03 21.99 Favored 'Trans proline' 0 N--CA 1.485 1.024 0 C-N-CA 122.923 2.415 . . . . 0.0 113.96 -174.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -117.29 -9.29 10.97 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 120.025 -0.67 . . . . 0.0 111.115 -178.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.544 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.3 OUTLIER -103.88 -30.33 10.41 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 -176.378 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.544 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.5 mp -124.2 140.09 48.61 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.309 0 CA-C-N 114.143 -1.389 . . . . 0.0 108.057 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 4.9 t -81.83 130.28 35.02 Favored 'General case' 0 N--CA 1.424 -1.773 0 N-CA-C 105.329 -2.101 . . . . 0.0 105.329 173.228 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.503 ' O ' HG23 ' A' ' 94' ' ' VAL . 42.2 m-20 -88.86 106.36 18.34 Favored 'General case' 0 C--N 1.282 -2.369 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -173.491 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.47 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 19.8 t80 -134.7 123.9 24.42 Favored 'General case' 0 C--N 1.296 -1.746 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.88 -172.592 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.476 HG13 HD13 ' A' ' 131' ' ' LEU . 93.3 t -124.83 141.66 44.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 CA-C-N 114.632 -1.167 . . . . 0.0 109.398 -176.801 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -148.36 127.85 13.16 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 173.651 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.532 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 59.5 tp -67.71 115.98 7.89 Favored 'General case' 0 N--CA 1.442 -0.85 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 174.19 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.462 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 38.5 tp60 -60.43 -52.67 64.23 Favored 'General case' 0 C--O 1.214 -0.786 0 CA-C-N 114.402 -1.272 . . . . 0.0 110.404 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.462 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 10.1 ptp180 -169.46 159.88 8.84 Favored 'General case' 0 N--CA 1.418 -2.028 0 CA-C-N 114.095 -1.411 . . . . 0.0 107.501 -175.049 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -136.42 136.06 8.15 Favored Glycine 1 N--CA 1.393 -4.205 0 N-CA-C 107.93 -2.068 . . . . 0.0 107.93 178.362 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 67.9 m -124.73 147.06 48.85 Favored 'General case' 0 C--N 1.272 -2.797 0 O-C-N 124.29 0.641 . . . . 0.0 110.361 -175.67 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.525 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -109.54 159.78 16.79 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 -178.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.489 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 90.6 m-85 -155.99 -179.68 8.37 Favored 'General case' 0 N--CA 1.464 0.26 0 C-N-CA 123.83 0.852 . . . . 0.0 109.438 -176.185 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.87 -138.71 46.84 Favored Glycine 0 CA--C 1.506 -0.52 0 O-C-N 123.73 0.644 . . . . 0.0 112.84 177.29 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.35 -6.04 89.56 Favored Glycine 0 C--O 1.201 -1.93 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 176.836 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.775 HG21 ' HB ' ' A' ' 126' ' ' ILE . 97.0 t -71.78 -38.17 64.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 123.041 0.536 . . . . 0.0 111.269 -178.262 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.525 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.11 -18.55 32.03 Favored 'General case' 0 C--N 1.297 -1.711 0 C-N-CA 118.513 -1.275 . . . . 0.0 112.232 179.416 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 22.5 t -100.29 -46.62 5.21 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.288 0.566 . . . . 0.0 112.028 -175.073 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.47 ' O ' HG22 ' A' ' 112' ' ' VAL . 44.7 m-20 -97.62 -20.75 17.45 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -174.183 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.595 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 95.6 m-85 -112.23 151.54 29.48 Favored 'General case' 0 N--CA 1.428 -1.544 0 CA-C-O 122.199 1.0 . . . . 0.0 111.618 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.421 ' HB2' ' CG1' ' A' ' 112' ' ' VAL . 4.1 m -158.69 124.15 4.37 Favored 'General case' 0 N--CA 1.393 -3.285 0 CA-C-N 113.587 -1.642 . . . . 0.0 109.96 179.236 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.503 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -161.13 -112.77 0.29 Allowed Glycine 0 N--CA 1.409 -3.156 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 175.631 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.409 HG22 ' HA ' ' A' ' 83' ' ' PRO . 0.9 OUTLIER -158.04 179.84 8.8 Favored 'General case' 0 C--N 1.284 -2.242 0 C-N-CA 123.798 0.839 . . . . 0.0 110.238 -175.669 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -134.55 146.89 30.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 C-N-CA 123.172 0.589 . . . . 0.0 109.468 178.387 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.633 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.3 tttt -124.31 143.17 50.72 Favored 'General case' 0 N--CA 1.421 -1.901 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.5 -179.27 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.47 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 59.2 t80 -143.61 110.34 5.58 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 115.197 -0.91 . . . . 0.0 108.891 -177.551 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 23.0 t 53.95 37.2 26.19 Favored 'General case' 0 CA--C 1.557 1.241 0 C-N-CA 123.634 0.774 . . . . 0.0 111.386 175.741 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.44 10.48 63.68 Favored Glycine 0 C--O 1.216 -1.012 0 C-N-CA 120.849 -0.691 . . . . 0.0 113.874 -179.281 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.633 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 8.4 t -86.21 -179.29 6.69 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 117.584 0.692 . . . . 0.0 109.414 178.511 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 31.6 t -155.73 110.47 2.92 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -179.564 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.477 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 5.3 p90 -154.24 161.31 29.59 Favored Pre-proline 0 CA--C 1.548 0.885 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 -175.12 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.477 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 60.1 Cg_endo -68.7 149.45 73.38 Favored 'Trans proline' 0 C--N 1.36 1.18 0 C-N-CA 122.936 2.424 . . . . 0.0 113.563 -175.86 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.536 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 59.3 t80 -124.07 133.21 24.49 Favored Pre-proline 0 N--CA 1.437 -1.078 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.932 179.005 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.536 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 60.5 Cg_endo -71.99 148.45 90.87 Favored 'Cis proline' 0 C--O 1.239 0.533 0 C-N-CA 122.796 -1.752 . . . . 0.0 110.232 -3.319 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.8 t -72.61 -175.99 1.81 Allowed 'General case' 0 C--O 1.246 0.903 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -178.225 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 22.6 p -130.69 -35.81 1.44 Allowed 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 122.088 0.947 . . . . 0.0 108.524 -172.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 49.4 m -105.34 -141.84 0.37 Allowed 'General case' 1 N--CA 1.343 -5.778 0 CA-C-N 114.093 -1.412 . . . . 0.0 108.24 178.368 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -123.49 -171.32 2.29 Favored 'General case' 0 C--N 1.275 -2.64 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -174.338 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.532 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 39.9 p -100.75 167.03 11.44 Favored Pre-proline 0 C--N 1.295 -1.764 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 177.402 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' PRO . . . . . 0.44 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 18.9 Cg_endo -57.39 166.47 4.56 Favored 'Trans proline' 0 C--O 1.247 0.953 0 C-N-CA 123.263 2.642 . . . . 0.0 112.286 171.773 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.47 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 1.7 tmm_? -75.21 121.32 21.95 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 114.597 -1.183 . . . . 0.0 108.52 -178.382 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 72.8 t -136.47 117.92 19.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 C-N-CA 123.41 0.684 . . . . 0.0 109.749 -176.838 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 54' ' ' ASP . 1.5 p -115.67 132.02 66.32 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.361 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.89 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.442 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 6.3 m-85 -77.0 100.29 5.58 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.216 0.531 . . . . 0.0 111.096 -178.41 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -94.89 59.88 2.39 Favored 'General case' 0 C--N 1.308 -1.237 0 CA-C-O 121.372 0.606 . . . . 0.0 109.556 179.047 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 51.0 m -154.47 141.76 19.56 Favored 'General case' 0 C--N 1.31 -1.114 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.7 ptp180 -109.02 69.68 0.71 Allowed 'General case' 0 C--N 1.304 -1.376 0 CA-C-O 122.044 0.926 . . . . 0.0 111.464 -177.725 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.2 t -179.46 168.53 1.44 Allowed 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 179.116 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -72.35 113.11 9.03 Favored 'General case' 0 CA--C 1.501 -0.94 0 CA-C-O 121.799 0.809 . . . . 0.0 109.461 -179.107 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -118.46 139.73 27.31 Favored Pre-proline 0 C--N 1.274 -2.71 0 CA-C-N 114.249 -1.341 . . . . 0.0 108.693 -177.099 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.472 ' HA ' ' HA ' ' A' ' 43' ' ' PHE . 12.6 Cg_endo -57.16 152.26 46.14 Favored 'Trans proline' 0 C--O 1.245 0.841 0 C-N-CA 123.278 2.652 . . . . 0.0 113.107 179.202 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' TRP . . . . . 0.442 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 12.6 t90 -91.42 106.62 17.19 Favored Pre-proline 0 N--CA 1.438 -1.048 0 N-CA-C 106.317 -1.735 . . . . 0.0 106.317 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -77.52 88.21 1.44 Allowed 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 121.388 1.392 . . . . 0.0 112.927 -172.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.404 HG22 ' CD2' ' A' ' 77' ' ' TYR . 98.0 t -137.62 145.09 29.76 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.306 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 176.632 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.585 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.87 136.73 18.18 Favored 'General case' 0 C--N 1.292 -1.9 0 O-C-N 123.237 0.336 . . . . 0.0 110.172 178.438 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.474 HD21 HD11 ' A' ' 129' ' ' LEU . 20.3 mt -101.28 102.71 13.62 Favored 'General case' 0 C--N 1.292 -1.909 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.087 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.503 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 19.3 m-85 -81.53 74.0 8.54 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 120.812 0.339 . . . . 0.0 110.436 177.44 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.596 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.2 mm? -91.52 151.08 20.91 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 176.83 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -149.3 143.7 17.18 Favored Pre-proline 0 N--CA 1.405 -2.702 0 C-N-CA 119.996 -0.682 . . . . 0.0 110.136 179.516 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -64.9 127.48 18.7 Favored 'Trans proline' 0 N--CA 1.45 -1.051 0 C-N-CA 123.383 2.722 . . . . 0.0 113.149 -177.3 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.543 ' O ' HG22 ' A' ' 30' ' ' VAL . 27.1 m -87.25 -155.84 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.399 -3.014 0 CA-C-N 114.438 -1.255 . . . . 0.0 108.639 172.432 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 6.1 m -80.51 -30.55 37.26 Favored 'General case' 0 C--N 1.261 -3.269 0 CA-C-O 121.425 0.631 . . . . 0.0 110.48 -168.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.5 t -82.9 9.55 9.74 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.888 -177.195 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.413 ' HB1' HG21 ' A' ' 156' ' ' VAL . . . -90.72 131.52 36.35 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.334 -0.988 . . . . 0.0 108.334 178.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.3 125.68 1.16 Allowed Glycine 0 C--N 1.306 -1.095 0 C-N-CA 120.571 -0.823 . . . . 0.0 111.727 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.84 -147.26 49.37 Favored Glycine 0 CA--C 1.486 -1.773 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -175.229 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.437 HG11 ' HE3' ' A' ' 121' ' ' LYS . 60.3 t -57.31 112.04 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 117.213 0.507 . . . . 0.0 110.113 -177.144 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -110.25 -28.69 8.5 Favored 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.068 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.467 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 59.0 mt -129.03 138.07 55.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.149 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.451 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 5.1 mmpt? -114.92 141.84 47.4 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 121.112 0.482 . . . . 0.0 110.835 178.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.44 135.26 49.98 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.691 -179.765 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 82.72 -4.14 80.3 Favored Glycine 0 C--O 1.242 0.61 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.216 178.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 19.4 m -94.71 149.41 21.27 Favored 'General case' 0 N--CA 1.417 -2.084 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 -179.214 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 28.2 tp -74.79 133.37 41.95 Favored 'General case' 0 N--CA 1.434 -1.231 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.123 -177.455 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.775 ' HB ' HG21 ' A' ' 67' ' ' VAL . 34.5 pt -118.26 -26.67 2.51 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 C-N-CA 120.481 -0.488 . . . . 0.0 112.174 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 127' ' ' ALA . . . . . 0.42 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.9 163.58 29.07 Favored 'General case' 0 N--CA 1.434 -1.24 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.252 -177.711 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 55.9 t -139.7 115.63 8.74 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.937 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 178.222 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.474 HD11 HD21 ' A' ' 107' ' ' LEU . 68.7 mt -117.74 145.74 44.25 Favored 'General case' 0 C--N 1.281 -2.398 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 179.415 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.496 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.7 mp -128.7 119.47 49.97 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 C-N-CA 119.794 -0.762 . . . . 0.0 109.629 178.767 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.501 ' C ' HD12 ' A' ' 131' ' ' LEU . 0.6 OUTLIER -88.77 147.02 24.66 Favored 'General case' 0 CA--C 1.481 -1.677 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 173.978 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 60.0 ttp180 -115.0 122.0 44.87 Favored 'General case' 0 C--N 1.248 -3.832 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 177.74 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -85.86 139.26 31.41 Favored 'General case' 0 N--CA 1.417 -2.076 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 176.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.434 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 25.8 m -145.1 133.23 21.49 Favored 'General case' 0 C--N 1.261 -3.253 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 173.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.484 ' HB2' HG23 ' A' ' 52' ' ' ILE . 32.9 p30 -132.29 161.39 33.63 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-O 120.906 0.384 . . . . 0.0 110.18 -178.368 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 2.3 p-10 -93.89 -19.11 21.26 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.448 -173.82 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 88.5 t80 -91.31 -71.06 0.65 Allowed 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 115.067 -0.97 . . . . 0.0 111.346 -171.115 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 18.5 m120 -63.16 -46.49 86.94 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-O 121.366 0.603 . . . . 0.0 111.966 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 23.1 t 78.97 8.55 1.92 Allowed 'General case' 0 C--N 1.332 -0.191 0 C-N-CA 126.267 1.827 . . . . 0.0 109.297 -177.819 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' ASP . . . . . 0.539 ' HB3' ' CE2' ' A' ' 142' ' ' PHE . 2.0 m-20 -88.29 81.77 7.22 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 114.526 -1.215 . . . . 0.0 108.047 177.367 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -85.11 105.08 15.57 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-O 121.777 0.799 . . . . 0.0 111.298 -177.458 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' PHE . . . . . 0.539 ' CE2' ' HB3' ' A' ' 140' ' ' ASP . 72.6 m-85 -110.37 160.07 16.9 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.914 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 143' ' ' GLN . . . . . 0.432 ' HB2' ' O ' ' A' ' 131' ' ' LEU . 3.3 pt20 -126.09 150.48 48.15 Favored 'General case' 0 C--N 1.288 -2.107 0 C-N-CA 119.877 -0.729 . . . . 0.0 110.623 -179.113 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 12.5 m-30 -113.67 127.47 56.06 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -174.822 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 50.0 t -92.42 132.11 37.64 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.987 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.93 -178.745 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 54.3 m95 -120.97 101.14 7.49 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -177.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 50.0 m-80 -84.5 115.01 22.35 Favored 'General case' 0 C--N 1.285 -2.233 0 N-CA-C 107.691 -1.226 . . . . 0.0 107.691 178.68 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.42 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 20.2 mm -88.55 121.8 39.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -177.204 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -117.7 151.7 36.74 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.143 177.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.22 131.39 35.23 Favored 'General case' 0 N--CA 1.412 -2.336 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 177.049 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -88.21 -16.36 33.49 Favored 'General case' 0 C--N 1.287 -2.128 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -178.502 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -148.08 143.96 27.54 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 114.566 -1.197 . . . . 0.0 109.997 -174.447 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -79.08 139.53 38.08 Favored 'General case' 0 C--N 1.309 -1.163 0 O-C-N 124.285 0.991 . . . . 0.0 110.995 179.568 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.515 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 73.0 t -115.12 138.47 45.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.851 -176.432 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 8.3 t -119.56 135.9 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.394 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 75.3 t -99.81 105.03 32.07 Favored Pre-proline 0 C--N 1.286 -2.174 0 C-N-CA 124.091 0.956 . . . . 0.0 109.834 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.493 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 40.6 Cg_endo -70.71 -21.77 28.62 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.233 1.955 . . . . 0.0 111.797 177.852 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.27 3.7 t . . . . . 0 C--N 1.355 0.841 0 C-N-CA 124.978 1.311 . . . . 0.0 114.095 175.665 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 25.1 p90 . . . . . 0 C--O 1.213 -0.847 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.6 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -113.33 177.16 4.73 Favored 'General case' 0 N--CA 1.44 -0.945 0 CA-C-N 118.836 0.744 . . . . 0.0 110.881 -173.238 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 11.5 t -151.61 156.61 40.8 Favored 'General case' 0 N--CA 1.433 -1.276 0 C-N-CA 119.931 -0.708 . . . . 0.0 109.766 -177.241 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.1 pptp? -141.44 163.08 33.89 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-O 121.049 0.452 . . . . 0.0 111.576 -175.065 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.481 HG22 HG22 ' A' ' 20' ' ' VAL . 71.3 p -104.6 172.94 6.52 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 121.859 0.837 . . . . 0.0 110.406 -179.687 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -78.81 -10.31 59.74 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 113.745 -1.57 . . . . 0.0 110.991 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -92.16 -33.97 14.51 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 118.318 -1.353 . . . . 0.0 109.124 175.749 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 137.47 5.58 1.74 Allowed Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 119.231 -1.461 . . . . 0.0 113.437 176.17 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.3 m -80.18 100.22 8.18 Favored 'General case' 0 N--CA 1.433 -1.275 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -97.29 111.08 23.48 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.323 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.6 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 59.3 mt -88.87 121.94 69.42 Favored Pre-proline 0 C--N 1.307 -1.243 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 179.488 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -81.52 -179.56 5.02 Favored 'Trans proline' 0 C--O 1.241 0.668 0 C-N-CA 122.899 2.399 . . . . 0.0 111.937 178.183 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.6 mt -69.23 141.51 17.25 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.832 179.423 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.89 -1.74 17.4 Favored Glycine 0 N--CA 1.438 -1.191 0 C-N-CA 119.887 -1.149 . . . . 0.0 112.472 179.284 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 103.27 171.25 25.99 Favored Glycine 0 C--N 1.309 -0.972 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.654 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 157.22 -175.28 34.69 Favored Glycine 0 C--N 1.312 -0.759 0 C-N-CA 120.354 -0.927 . . . . 0.0 111.867 178.345 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 m -146.27 143.54 29.25 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 179.453 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.92 166.33 23.57 Favored 'General case' 0 N--CA 1.425 -1.71 0 CA-C-O 121.249 0.547 . . . . 0.0 109.788 -177.854 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -111.03 115.52 29.61 Favored 'General case' 0 C--N 1.28 -2.442 0 CA-C-N 114.533 -1.212 . . . . 0.0 108.822 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.481 HG22 HG22 ' A' ' 5' ' ' THR . 39.7 t -103.26 140.08 22.44 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.947 0 CA-C-N 115.266 -0.879 . . . . 0.0 108.762 178.052 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.7 m-85 -126.1 136.23 52.66 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.477 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.4 p -146.04 135.51 17.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 123.724 0.64 . . . . 0.0 110.519 -178.769 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -95.83 123.24 39.32 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 121.759 0.79 . . . . 0.0 111.367 179.375 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.407 HD11 HG22 ' A' ' 36' ' ' VAL . 2.6 mm? -103.48 160.93 14.29 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 113.922 -1.49 . . . . 0.0 108.208 -177.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.76 122.41 56.58 Favored Pre-proline 0 C--N 1.313 -0.994 0 O-C-N 124.764 1.29 . . . . 0.0 109.405 178.23 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 61.0 Cg_endo -75.21 3.08 6.04 Favored 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 122.661 2.241 . . . . 0.0 112.89 -178.592 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.429 HG13 ' HG3' ' A' ' 157' ' ' PRO . 46.7 t -125.98 109.54 21.73 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.503 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 177.749 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.451 ' O ' HG13 ' A' ' 156' ' ' VAL . 1.6 t -143.17 99.89 0.7 Allowed 'Isoleucine or valine' 0 C--O 1.183 -2.403 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 -178.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.462 ' H ' ' HG3' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -91.63 151.38 20.72 Favored 'General case' 0 C--N 1.269 -2.893 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -179.199 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.447 HG13 ' O ' ' A' ' 112' ' ' VAL . 24.7 t -46.85 115.23 0.25 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.709 0 C-N-CA 123.615 0.766 . . . . 0.0 111.501 177.078 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.84 3.28 42.74 Favored Glycine 0 N--CA 1.446 -0.697 0 CA-C-N 114.759 -1.109 . . . . 0.0 112.755 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.462 ' HG3' ' H ' ' A' ' 29' ' ' ASN . 2.2 mm-40 -73.78 -178.37 3.16 Favored 'General case' 0 C--N 1.309 -1.159 0 C-N-CA 123.542 0.737 . . . . 0.0 111.427 175.57 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 67.3 t30 -134.67 89.03 2.5 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 177.075 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.675 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.3 tp -90.21 144.67 25.65 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.102 -176.599 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.4 t -134.12 125.79 48.75 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.633 0 CA-C-O 121.298 0.57 . . . . 0.0 110.585 -176.642 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.596 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 48.9 t -95.96 89.25 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.049 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 174.057 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -82.81 113.05 20.18 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-O 121.15 0.5 . . . . 0.0 111.216 -178.11 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.3 mt -96.1 -2.7 46.03 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.983 -178.704 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -74.07 0.36 14.0 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-O 122.118 0.961 . . . . 0.0 109.733 -178.684 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.5 p -127.36 6.82 6.38 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 123.771 0.828 . . . . 0.0 109.819 178.09 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.477 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 45.7 mm-40 -124.03 -21.42 5.07 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.706 -174.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.6 mt -132.87 136.72 55.21 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.133 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 -175.155 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -142.84 124.36 14.84 Favored 'General case' 0 CA--C 1.504 -0.798 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -175.671 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 83.3 m -101.02 140.31 35.48 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 -179.657 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.4 p80 -132.19 139.36 48.32 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 121.852 0.834 . . . . 0.0 112.313 -171.748 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 8.7 p30 -103.44 107.26 18.02 Favored 'General case' 0 C--N 1.292 -1.899 0 CA-C-N 115.1 -0.954 . . . . 0.0 113.342 -178.272 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -84.24 -14.33 50.22 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 121.881 0.848 . . . . 0.0 109.531 175.588 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.419 ' HB2' HD13 ' A' ' 52' ' ' ILE . 47.2 m-85 -134.52 66.0 68.88 Favored Pre-proline 0 C--N 1.318 -0.761 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 177.492 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -73.05 -5.56 17.42 Favored 'Trans proline' 0 N--CA 1.486 1.056 0 C-N-CA 123.188 2.592 . . . . 0.0 113.978 -172.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -120.41 -13.34 8.85 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 121.469 0.652 . . . . 0.0 110.204 -179.539 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.475 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -94.78 -30.17 14.38 Favored 'General case' 0 N--CA 1.421 -1.88 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -174.904 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.622 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -122.92 138.2 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.508 0 CA-C-N 113.529 -1.669 . . . . 0.0 107.924 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 7.3 t -80.7 136.39 36.17 Favored 'General case' 0 N--CA 1.427 -1.607 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 174.804 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.507 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 19.3 m-20 -84.79 108.16 17.33 Favored 'General case' 0 C--N 1.286 -2.163 0 CA-C-O 121.541 0.686 . . . . 0.0 110.506 -171.869 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.456 ' HE1' ' HG2' ' A' ' 92' ' ' ARG . 34.0 t80 -138.46 143.36 39.61 Favored 'General case' 0 C--N 1.284 -2.275 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.242 -178.399 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.597 HG23 HD13 ' A' ' 131' ' ' LEU . 12.6 p -148.59 148.66 15.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 177.026 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.04 137.59 19.89 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 123.599 0.562 . . . . 0.0 109.992 174.029 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.416 HD23 ' O ' ' A' ' 130' ' ' ILE . 0.3 OUTLIER -74.52 106.64 6.21 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 105.048 -2.204 . . . . 0.0 105.048 175.119 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 6.6 tp60 -56.05 -64.9 0.71 Allowed 'General case' 0 C--O 1.202 -1.399 0 C-N-CA 126.372 1.869 . . . . 0.0 109.968 177.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 8.3 ptp180 -158.3 153.59 25.75 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 -179.189 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -134.98 137.97 9.66 Favored Glycine 0 CA--C 1.463 -3.159 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 -178.308 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 66.4 m -126.33 151.95 46.88 Favored 'General case' 0 C--N 1.28 -2.419 0 C-N-CA 123.822 0.849 . . . . 0.0 109.784 -174.704 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.525 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -115.74 157.92 23.59 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -178.134 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.484 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 91.9 m-85 -156.02 -179.45 8.15 Favored 'General case' 0 C--O 1.237 0.415 0 C-N-CA 124.328 1.051 . . . . 0.0 109.042 -177.412 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.25 -148.41 29.27 Favored Glycine 0 C--N 1.33 0.205 0 O-C-N 123.566 0.541 . . . . 0.0 113.533 178.68 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.41 -10.91 71.15 Favored Glycine 0 C--O 1.206 -1.598 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.754 178.101 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.796 HG21 ' HB ' ' A' ' 126' ' ' ILE . 97.0 t -69.05 -40.68 81.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 C-N-CA 123.9 0.88 . . . . 0.0 111.483 -177.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.525 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -84.2 -20.5 32.24 Favored 'General case' 0 N--CA 1.433 -1.289 0 C-N-CA 118.759 -1.176 . . . . 0.0 112.14 179.09 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 31.7 t -98.37 -60.2 1.6 Allowed 'General case' 0 N--CA 1.442 -0.838 0 CA-C-N 115.932 -0.576 . . . . 0.0 112.004 -174.466 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.474 ' O ' HG22 ' A' ' 112' ' ' VAL . 48.6 m-20 -85.77 -25.74 26.2 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.427 -172.774 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.67 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 91.6 m-85 -106.56 158.83 16.63 Favored 'General case' 0 N--CA 1.42 -1.956 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.03 177.363 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.0 t -167.98 137.39 2.55 Favored 'General case' 0 N--CA 1.411 -2.411 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 176.155 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.475 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.25 -107.86 0.2 Allowed Glycine 0 N--CA 1.411 -2.978 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 175.883 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.5 p -158.71 -179.88 8.47 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 123.791 0.836 . . . . 0.0 110.871 -175.727 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.412 ' HB ' ' HB2' ' A' ' 84' ' ' PHE . 2.6 p -132.11 144.96 35.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 177.662 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.685 ' HG3' ' O ' ' A' ' 80' ' ' SER . 73.6 tttt -123.73 142.98 50.58 Favored 'General case' 0 N--CA 1.424 -1.769 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.969 -177.503 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.577 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 68.3 t80 -141.42 111.44 6.71 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 115.458 -0.792 . . . . 0.0 108.87 -177.802 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 9.3 t 52.61 34.19 15.26 Favored 'General case' 0 CA--C 1.561 1.366 0 CA-C-O 121.717 0.77 . . . . 0.0 111.071 179.517 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.417 ' HA2' ' HE2' ' A' ' 76' ' ' LYS . . . 90.65 10.0 63.83 Favored Glycine 0 CA--C 1.532 1.101 0 C-N-CA 120.83 -0.7 . . . . 0.0 114.169 -179.237 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.685 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 21.8 t -79.98 179.54 7.54 Favored 'General case' 0 CA--C 1.549 0.924 0 CA-C-N 117.446 0.623 . . . . 0.0 109.376 177.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 17.5 p -153.27 109.11 3.29 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-O 121.548 0.69 . . . . 0.0 110.049 178.322 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.577 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 4.2 p90 -151.08 158.33 34.77 Favored Pre-proline 0 C--N 1.302 -1.465 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 -175.123 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.77 147.41 69.13 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.95 2.433 . . . . 0.0 113.256 -175.643 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.608 ' CD2' HD21 ' A' ' 109' ' ' LEU . 66.6 t80 -121.23 132.84 24.11 Favored Pre-proline 0 N--CA 1.441 -0.88 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.535 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.54 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 60.6 Cg_endo -69.25 146.19 80.39 Favored 'Cis proline' 0 CA--C 1.538 0.702 0 C-N-CA 123.562 -1.432 . . . . 0.0 111.308 0.208 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.3 t -70.74 -178.07 1.75 Allowed 'General case' 0 CA--C 1.554 1.097 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.31 -177.284 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 10.0 p -130.51 -34.33 1.58 Allowed 'General case' 0 C--O 1.243 0.711 0 N-CA-C 114.827 1.418 . . . . 0.0 114.827 -169.132 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.1 t -118.74 -69.44 0.85 Allowed 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 119.978 -0.689 . . . . 0.0 111.021 -174.293 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 178.25 -179.71 0.31 Allowed 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 -178.176 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.1 p -102.54 164.49 15.56 Favored Pre-proline 0 C--N 1.284 -2.26 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -66.46 160.61 44.89 Favored 'Trans proline' 0 C--N 1.365 1.406 0 C-N-CA 122.523 2.149 . . . . 0.0 110.504 173.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.49 ' HD3' HG23 ' A' ' 94' ' ' VAL . 6.8 tmm_? -72.73 128.2 34.82 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-N 115.64 -0.709 . . . . 0.0 112.166 -174.074 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 90.0 t -133.26 117.95 30.21 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 115.211 -0.904 . . . . 0.0 109.514 177.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.49 HG23 ' HD3' ' A' ' 92' ' ' ARG . 87.4 t -94.95 137.65 22.78 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 175.899 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.507 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.2 m-85 -89.62 93.97 9.68 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 175.183 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 13.3 m120 -89.13 69.21 8.32 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 178.577 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.8 m -143.35 148.2 35.88 Favored 'General case' 0 N--CA 1.429 -1.515 0 CA-C-N 114.539 -1.21 . . . . 0.0 109.719 -176.19 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -112.64 45.48 1.31 Allowed 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 121.288 0.566 . . . . 0.0 111.303 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.1 t -171.52 179.92 2.75 Favored 'General case' 0 N--CA 1.439 -1.025 0 N-CA-C 106.332 -1.729 . . . . 0.0 106.332 -177.699 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -75.72 135.28 40.37 Favored 'General case' 0 C--O 1.249 1.051 0 CA-C-O 121.635 0.731 . . . . 0.0 109.37 -179.28 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 62.3 mmtt -128.31 141.0 39.94 Favored Pre-proline 0 C--N 1.28 -2.415 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.623 -177.187 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.455 ' O ' ' HD3' ' A' ' 104' ' ' PRO . 32.2 Cg_endo -64.38 142.31 78.36 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 123.508 2.806 . . . . 0.0 111.276 -179.281 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 10.7 t90 -86.5 104.23 5.36 Favored Pre-proline 0 C--N 1.308 -1.228 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 -177.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.455 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 65.1 Cg_endo -75.91 88.61 1.3 Allowed 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 121.944 1.763 . . . . 0.0 113.1 -172.156 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 99.1 t -138.28 144.63 30.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.596 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.67 135.09 19.52 Favored 'General case' 0 N--CA 1.417 -2.092 0 CA-C-N 116.519 -0.309 . . . . 0.0 110.545 177.779 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.51 HD21 HD11 ' A' ' 129' ' ' LEU . 18.6 mt -99.94 103.18 14.73 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.275 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.475 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 22.1 m-85 -82.14 72.18 9.2 Favored 'General case' 0 C--N 1.296 -1.743 0 O-C-N 122.363 -0.211 . . . . 0.0 111.031 177.424 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.675 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -96.96 127.17 42.66 Favored 'General case' 0 C--O 1.207 -1.146 0 CA-C-O 120.571 0.224 . . . . 0.0 110.616 177.819 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -127.54 144.73 52.03 Favored Pre-proline 0 N--CA 1.417 -2.079 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.055 -175.731 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.437 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 28.4 Cg_endo -62.32 118.19 5.07 Favored 'Trans proline' 0 C--O 1.241 0.664 0 C-N-CA 123.164 2.576 . . . . 0.0 111.684 -178.389 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.474 HG22 ' O ' ' A' ' 70' ' ' ASN . 3.8 m -68.34 -112.82 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.191 -2.001 0 O-C-N 124.38 1.05 . . . . 0.0 113.07 176.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 11.7 p -111.68 -46.26 3.27 Favored 'General case' 0 C--N 1.294 -1.832 0 CA-C-O 121.369 0.604 . . . . 0.0 110.904 179.667 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 11.6 t -82.45 25.69 0.61 Allowed 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 121.937 0.875 . . . . 0.0 111.021 -175.077 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -96.38 131.1 43.28 Favored 'General case' 0 N--CA 1.414 -2.265 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.29 129.54 1.7 Allowed Glycine 0 N--CA 1.436 -1.321 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.072 -178.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.5 -149.78 51.05 Favored Glycine 0 N--CA 1.434 -1.451 0 CA-C-O 119.376 -0.68 . . . . 0.0 111.93 -178.187 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.442 ' CG1' ' HE3' ' A' ' 121' ' ' LYS . 76.9 t -58.14 99.87 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 121.728 0.775 . . . . 0.0 111.088 -177.701 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.07 -37.76 9.61 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 114.878 -1.056 . . . . 0.0 110.577 -178.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.536 ' HB ' HG22 ' A' ' 154' ' ' VAL . 72.9 mt -118.02 139.04 46.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 178.686 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.523 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.0 mmpt? -115.17 141.82 47.5 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 122.823 0.449 . . . . 0.0 110.375 176.375 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.0 132.63 46.21 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.423 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 87.28 -1.23 86.15 Favored Glycine 0 N--CA 1.431 -1.695 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.779 -178.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 32.1 t -90.92 140.78 29.5 Favored 'General case' 0 N--CA 1.42 -1.972 0 N-CA-C 108.577 -0.898 . . . . 0.0 108.577 178.826 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.415 HD11 HG23 ' A' ' 128' ' ' VAL . 3.0 tm? -68.83 126.63 30.37 Favored 'General case' 0 N--CA 1.427 -1.61 0 N-CA-C 106.411 -1.699 . . . . 0.0 106.411 175.163 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.796 ' HB ' HG21 ' A' ' 67' ' ' VAL . 29.6 pt -113.67 -27.15 2.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -178.562 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.28 167.96 24.95 Favored 'General case' 0 N--CA 1.443 -0.825 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 -177.8 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.415 HG23 HD11 ' A' ' 125' ' ' LEU . 64.4 t -142.33 113.54 3.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 179.429 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.51 HD11 HD21 ' A' ' 107' ' ' LEU . 37.3 mt -118.04 143.49 46.38 Favored 'General case' 0 C--N 1.288 -2.094 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 179.704 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.416 ' O ' HD23 ' A' ' 58' ' ' LEU . 4.9 mp -123.39 128.43 74.74 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.133 0 C-N-CA 119.709 -0.796 . . . . 0.0 109.411 178.811 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.597 HD13 HG23 ' A' ' 56' ' ' VAL . 1.1 pp -94.34 147.25 23.4 Favored 'General case' 0 CA--C 1.472 -2.05 0 N-CA-C 105.614 -1.995 . . . . 0.0 105.614 172.369 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 59.7 ttt180 -116.57 132.72 56.61 Favored 'General case' 0 N--CA 1.386 -3.635 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 173.435 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.653 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 17.0 mm-40 -90.38 148.06 23.06 Favored 'General case' 0 N--CA 1.402 -2.863 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.706 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.428 ' HB ' ' CE2' ' A' ' 55' ' ' TYR . 27.6 m -154.58 138.14 15.99 Favored 'General case' 0 C--N 1.276 -2.622 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 169.699 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.622 ' CB ' HG23 ' A' ' 52' ' ' ILE . 6.1 p30 -145.18 172.14 13.54 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 119.585 -0.846 . . . . 0.0 111.332 175.171 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -85.91 -12.65 50.04 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 114.174 -1.375 . . . . 0.0 112.747 -168.766 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 70.8 t80 -113.57 -69.65 0.85 Allowed 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 112.03 0.382 . . . . 0.0 112.03 -171.753 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' ASN . . . . . 0.466 ' HB2' HD21 ' A' ' 135' ' ' ASN . 11.8 m120 -81.47 161.79 23.52 Favored 'General case' 0 CA--C 1.489 -1.366 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.035 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 23.2 t -87.03 41.11 0.95 Allowed 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 107.686 -1.227 . . . . 0.0 107.686 175.543 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' ASP . . . . . 0.557 ' HB3' ' ND2' ' A' ' 135' ' ' ASN . 12.6 t0 -81.21 70.63 8.1 Favored 'General case' 0 N--CA 1.436 -1.146 0 CA-C-N 114.346 -1.297 . . . . 0.0 107.598 176.157 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 141' ' ' ASP . . . . . 0.653 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 7.4 p-10 -119.11 35.78 4.7 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 113.411 -1.722 . . . . 0.0 108.088 177.497 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -90.1 176.41 6.79 Favored 'General case' 0 N--CA 1.434 -1.275 0 CA-C-N 113.32 -1.764 . . . . 0.0 107.869 -178.604 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -134.47 146.54 49.86 Favored 'General case' 0 N--CA 1.42 -1.962 0 C-N-CA 118.571 -1.252 . . . . 0.0 111.93 -176.331 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 10.8 m-30 -111.3 126.95 55.44 Favored 'General case' 0 C--N 1.31 -1.13 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -177.263 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.0 t -91.68 132.29 36.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -178.426 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 55.4 m95 -118.29 101.53 8.27 Favored 'General case' 0 C--N 1.282 -2.334 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 42.5 m-80 -80.88 112.98 18.77 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 178.021 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.42 HG22 HD11 ' A' ' 126' ' ' ILE . 23.7 mm -87.19 122.16 38.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 -177.9 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -116.51 153.78 31.55 Favored 'General case' 0 C--N 1.293 -1.882 0 C-N-CA 123.242 0.617 . . . . 0.0 109.525 178.208 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.76 130.3 35.11 Favored 'General case' 0 N--CA 1.412 -2.364 0 CA-C-N 115.197 -0.91 . . . . 0.0 108.741 176.674 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -85.82 -20.69 28.79 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -178.16 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -149.86 147.32 27.81 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 114.21 -1.359 . . . . 0.0 109.269 -173.448 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 16.8 p-10 -89.83 136.73 32.87 Favored 'General case' 0 C--N 1.31 -1.112 0 O-C-N 123.948 0.78 . . . . 0.0 111.119 -177.858 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.536 HG22 ' HB ' ' A' ' 120' ' ' ILE . 2.0 m -115.65 150.99 17.46 Favored 'Isoleucine or valine' 0 C--O 1.252 1.222 0 CA-C-O 121.053 0.454 . . . . 0.0 111.434 -174.489 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.8 t -122.32 139.42 49.31 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.016 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.208 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.451 HG13 ' O ' ' A' ' 28' ' ' VAL . 75.7 t -100.8 99.4 10.2 Favored Pre-proline 0 C--N 1.293 -1.85 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.429 ' HG3' HG13 ' A' ' 27' ' ' VAL . 33.9 Cg_endo -68.06 -28.47 34.88 Favored 'Trans proline' 0 C--O 1.24 0.591 0 C-N-CA 122.269 1.979 . . . . 0.0 111.954 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.4 t . . . . . 0 C--O 1.249 1.06 0 O-C-N 125.091 1.495 . . . . 0.0 113.799 178.488 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.445 ' HA ' ' HA ' ' A' ' 46' ' ' ASN . 43.4 t80 . . . . . 0 CA--C 1.49 -1.336 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.419 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -135.67 -174.4 3.64 Favored 'General case' 0 C--N 1.284 -2.28 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.515 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.464 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 10.4 t -154.71 157.63 38.35 Favored 'General case' 0 C--N 1.299 -1.626 0 C-N-CA 119.423 -0.911 . . . . 0.0 109.719 -176.505 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.406 ' HE3' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -145.36 163.76 33.57 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.558 -175.174 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 76.2 p -102.02 176.7 5.11 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.591 0.71 . . . . 0.0 110.859 -178.946 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.88 -1.09 46.51 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.453 -1.249 . . . . 0.0 111.091 179.143 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -100.08 -25.58 14.25 Favored 'General case' 0 N--CA 1.446 -0.67 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.685 174.707 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 128.19 5.22 5.24 Favored Glycine 0 CA--C 1.507 -0.461 0 C-N-CA 119.838 -1.173 . . . . 0.0 113.22 175.029 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.0 m -81.33 99.63 8.76 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.58 122.42 34.98 Favored 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 115.45 -0.795 . . . . 0.0 108.925 176.49 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.419 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 66.3 mt -95.13 115.89 65.83 Favored Pre-proline 0 C--N 1.293 -1.88 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 178.018 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.8 163.78 37.79 Favored 'Trans proline' 0 C--O 1.25 1.099 0 C-N-CA 122.156 1.904 . . . . 0.0 110.294 177.67 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.402 HD11 ' OD2' ' A' ' 47' ' ' ASP . 23.5 mt -67.48 126.18 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.101 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.65 -14.83 1.4 Allowed Glycine 0 C--N 1.297 -1.592 0 C-N-CA 120.491 -0.861 . . . . 0.0 111.62 -175.365 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 95.17 134.5 7.71 Favored Glycine 0 C--N 1.31 -0.883 0 C-N-CA 120.376 -0.916 . . . . 0.0 111.459 -179.633 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -178.76 -166.97 35.71 Favored Glycine 0 C--N 1.299 -1.501 0 N-CA-C 109.916 -1.273 . . . . 0.0 109.916 -178.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.451 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 60.0 p -140.23 150.53 44.23 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 117.457 0.629 . . . . 0.0 110.261 -179.406 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -134.17 161.53 34.64 Favored 'General case' 0 N--CA 1.422 -1.831 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 177.567 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 19.8 m-80 -116.5 111.13 19.53 Favored 'General case' 0 C--N 1.284 -2.248 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 178.733 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.432 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.1 m -92.63 149.71 4.1 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.462 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 -178.611 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 55.5 m-85 -132.04 113.71 13.7 Favored 'General case' 0 CA--C 1.492 -1.277 0 O-C-N 122.089 -0.382 . . . . 0.0 110.485 -176.665 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.516 HG11 HG13 ' A' ' 36' ' ' VAL . 3.5 p -120.93 132.84 69.41 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 CA-C-O 121.451 0.643 . . . . 0.0 111.423 -174.583 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 30.6 m-80 -88.17 123.24 32.62 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 50.0 mt -108.69 159.24 16.9 Favored 'General case' 0 C--N 1.276 -2.61 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 179.666 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.0 120.57 43.78 Favored Pre-proline 0 C--N 1.3 -1.552 0 O-C-N 124.37 1.044 . . . . 0.0 109.523 179.323 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.552 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 66.6 Cg_endo -74.09 -2.93 12.98 Favored 'Trans proline' 0 CA--C 1.531 0.369 0 C-N-CA 122.758 2.305 . . . . 0.0 113.503 -175.647 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.468 HG13 ' HG3' ' A' ' 157' ' ' PRO . 99.4 t -128.2 109.75 20.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.391 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 12.5 t -147.1 107.48 0.63 Allowed 'Isoleucine or valine' 0 C--O 1.19 -2.068 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -176.472 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.578 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -95.48 156.96 16.11 Favored 'General case' 0 C--N 1.271 -2.819 0 C-N-CA 122.863 0.465 . . . . 0.0 112.12 -179.911 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.432 HG13 ' O ' ' A' ' 112' ' ' VAL . 41.2 t -44.12 115.25 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.674 0 C-N-CA 124.296 1.038 . . . . 0.0 112.07 175.678 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.19 1.39 51.19 Favored Glycine 0 C--N 1.316 -0.536 0 CA-C-N 115.386 -0.825 . . . . 0.0 113.233 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.578 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.9 OUTLIER -74.1 -176.32 2.52 Favored 'General case' 0 C--N 1.315 -0.916 0 C-N-CA 124.164 0.986 . . . . 0.0 111.005 176.408 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 64.1 t30 -130.78 93.07 3.34 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 177.679 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.632 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 19.8 tp -93.41 141.88 27.96 Favored 'General case' 0 C--N 1.29 -1.982 0 C-N-CA 119.348 -0.941 . . . . 0.0 109.545 178.34 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.3 t -135.77 128.3 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.978 0 N-CA-C 109.433 -0.581 . . . . 0.0 109.433 -176.111 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.586 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 56.3 t -97.59 88.87 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.405 -2.721 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 174.661 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -83.36 115.89 22.22 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 120.822 0.344 . . . . 0.0 110.639 -178.24 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 80.5 mt -97.27 4.19 51.02 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.369 -179.143 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 33.3 t -77.28 -0.17 24.4 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 122.371 1.081 . . . . 0.0 109.115 -178.397 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.1 p -128.07 3.68 5.87 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 114.977 -1.01 . . . . 0.0 110.13 179.129 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.515 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 54.2 mm-40 -122.34 -22.22 5.59 Favored 'General case' 0 CA--C 1.503 -0.858 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.282 -172.918 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 24.3 mt -136.79 135.64 48.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.032 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 -175.261 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.406 ' HB2' ' HE3' ' A' ' 4' ' ' LYS . 61.3 m-85 -138.53 125.26 20.92 Favored 'General case' 0 CA--C 1.501 -0.919 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 -175.832 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.464 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 73.7 m -108.2 143.33 37.14 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 24.1 p-80 -134.23 156.53 48.22 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-O 120.914 0.388 . . . . 0.0 110.589 -175.536 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.665 ' ND2' ' HA ' ' A' ' 49' ' ' PRO . 56.4 t30 -113.74 100.4 8.44 Favored 'General case' 0 N--CA 1.421 -1.916 0 CA-C-O 122.734 1.254 . . . . 0.0 110.772 176.604 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ASP . . . . . 0.402 ' OD2' HD11 ' A' ' 13' ' ' ILE . 0.0 OUTLIER -60.75 -32.21 71.51 Favored 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 127.021 2.128 . . . . 0.0 112.728 179.942 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -130.46 77.2 76.39 Favored Pre-proline 0 C--N 1.318 -0.803 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.489 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.665 ' HA ' ' ND2' ' A' ' 46' ' ' ASN . 64.7 Cg_endo -68.42 -4.69 13.41 Favored 'Trans proline' 0 N--CA 1.484 0.93 0 C-N-CA 123.529 2.819 . . . . 0.0 115.95 -169.846 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -118.92 -15.72 9.31 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 121.596 0.713 . . . . 0.0 109.944 178.77 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.45 ' HB ' HD12 ' A' ' 52' ' ' ILE . 2.0 m -96.84 -30.64 13.04 Favored 'General case' 0 N--CA 1.408 -2.573 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -175.658 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.668 HG23 ' CB ' ' A' ' 135' ' ' ASN . 3.4 mp -132.65 140.47 47.43 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.244 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 179.063 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.8 t -87.83 150.66 23.4 Favored 'General case' 0 C--O 1.254 1.302 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 177.772 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.562 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 0.9 OUTLIER -79.97 107.91 13.13 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 -178.598 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 76.5 t80 -143.69 144.04 31.69 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -176.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.468 HG13 ' OH ' ' A' ' 77' ' ' TYR . 6.2 p -152.08 150.33 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.179 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 177.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -151.2 133.11 15.07 Favored 'General case' 0 C--O 1.208 -1.079 0 CA-C-O 119.455 -0.307 . . . . 0.0 110.296 175.193 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.521 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 47.9 tp -76.56 106.48 8.23 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 121.132 0.491 . . . . 0.0 109.861 176.617 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.7 tp-100 -53.84 -52.69 59.58 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 125.77 1.628 . . . . 0.0 111.717 177.661 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.403 ' HG3' HD13 ' A' ' 130' ' ' ILE . 1.1 ptp180 -166.37 157.89 13.33 Favored 'General case' 0 C--N 1.307 -1.258 0 N-CA-C 107.597 -1.261 . . . . 0.0 107.597 -179.017 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.13 115.23 0.86 Allowed Glycine 0 N--CA 1.399 -3.814 0 N-CA-C 108.992 -1.643 . . . . 0.0 108.992 -178.339 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 67.2 m -110.26 147.17 34.35 Favored 'General case' 0 C--N 1.28 -2.423 0 C-N-CA 124.471 1.108 . . . . 0.0 110.338 -171.13 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.547 ' HB2' ' CE2' ' A' ' 84' ' ' PHE . . . -108.83 157.8 18.26 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.47 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 86.9 m-85 -157.01 -179.35 8.12 Favored 'General case' 0 C--O 1.237 0.403 0 C-N-CA 124.21 1.004 . . . . 0.0 108.683 -178.532 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 60.2 -140.68 47.96 Favored Glycine 0 CA--C 1.5 -0.899 0 O-C-N 123.915 0.759 . . . . 0.0 112.851 176.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.09 -12.54 84.54 Favored Glycine 0 N--CA 1.431 -1.669 0 C-N-CA 120.54 -0.838 . . . . 0.0 111.375 177.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.75 HG21 ' HB ' ' A' ' 126' ' ' ILE . 82.4 t -68.45 -39.45 80.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 C-N-CA 123.522 0.729 . . . . 0.0 111.927 -176.293 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.522 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -87.54 -16.23 35.21 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 118.981 -1.088 . . . . 0.0 112.272 178.897 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 8.0 t -101.06 -58.05 1.97 Allowed 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.329 0.585 . . . . 0.0 111.399 -174.704 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.511 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 47.6 m-20 -87.09 -25.31 24.21 Favored 'General case' 0 CA--C 1.492 -1.283 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.133 -174.673 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.673 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 83.7 m-85 -108.24 158.19 17.68 Favored 'General case' 0 N--CA 1.415 -2.223 0 C-N-CA 120.03 -0.668 . . . . 0.0 110.352 179.342 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.6 t -164.91 135.76 4.02 Favored 'General case' 0 N--CA 1.409 -2.522 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 176.571 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.424 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.31 -109.12 0.22 Allowed Glycine 0 N--CA 1.406 -3.356 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 174.862 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.447 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.3 p -159.72 179.33 8.95 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 123.695 0.798 . . . . 0.0 110.827 -174.198 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.5 p -132.55 145.47 34.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 178.756 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.633 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.2 tttt -124.08 144.87 49.62 Favored 'General case' 0 N--CA 1.417 -2.084 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.471 -179.4 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.468 ' OH ' HG13 ' A' ' 56' ' ' VAL . 59.2 t80 -146.33 114.71 6.7 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -178.638 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.0 m 54.05 36.68 25.2 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 113.974 1.101 . . . . 0.0 113.974 177.431 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.16 12.19 81.23 Favored Glycine 0 C--N 1.309 -0.917 0 C-N-CA 119.579 -1.296 . . . . 0.0 112.587 -178.593 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.633 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 7.9 t -83.8 178.87 7.74 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 176.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 48.8 p -154.74 111.04 3.23 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 -178.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.442 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 3.4 p90 -154.73 158.86 32.26 Favored Pre-proline 0 C--N 1.305 -1.331 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 -175.315 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.447 ' HA ' HG22 ' A' ' 74' ' ' THR . 73.0 Cg_endo -71.31 147.91 54.07 Favored 'Trans proline' 0 C--N 1.355 0.904 0 C-N-CA 123.089 2.526 . . . . 0.0 113.259 -176.594 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.59 ' CD2' HD21 ' A' ' 109' ' ' LEU . 48.3 t80 -119.35 135.63 24.1 Favored Pre-proline 0 N--CA 1.433 -1.291 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.082 -178.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.518 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 57.0 Cg_endo -71.18 148.15 89.12 Favored 'Cis proline' 0 CA--C 1.538 0.678 0 C-N-CA 122.741 -1.774 . . . . 0.0 110.365 -1.532 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 7.9 t -65.64 -175.24 0.26 Allowed 'General case' 0 CA--C 1.55 0.976 0 C-N-CA 122.616 0.366 . . . . 0.0 110.288 -178.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 13.9 p -122.42 -36.45 2.94 Favored 'General case' 0 N--CA 1.432 -1.334 0 CA-C-O 121.664 0.745 . . . . 0.0 109.017 -172.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.4 t -132.49 -137.51 0.19 Allowed 'General case' 1 N--CA 1.364 -4.77 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 176.154 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLU . . . . . 0.442 ' HA ' ' O ' ' A' ' 58' ' ' LEU . 19.6 tt0 -105.67 156.99 17.73 Favored 'General case' 0 C--N 1.264 -3.12 0 C-N-CA 125.958 1.703 . . . . 0.0 109.377 -170.595 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.521 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 23.7 p -74.76 162.27 74.27 Favored Pre-proline 0 C--N 1.31 -1.14 0 C-N-CA 123.322 0.649 . . . . 0.0 111.203 178.467 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -59.05 162.7 13.12 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 122.976 2.451 . . . . 0.0 111.236 176.137 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.5 tmm_? -68.92 125.98 28.35 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -176.272 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 71.5 t -140.14 128.48 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.83 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 -177.39 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 54' ' ' ASP . 1.9 p -124.68 132.37 71.41 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.378 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.206 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.562 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.4 m-85 -81.03 140.27 35.25 Favored 'General case' 0 C--N 1.298 -1.662 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 177.795 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -108.37 28.14 8.64 Favored 'General case' 0 C--N 1.292 -1.899 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' SER . . . . . 0.444 ' OG ' ' HB3' ' A' ' 95' ' ' TYR . 5.0 p -84.08 178.93 7.64 Favored 'General case' 0 N--CA 1.423 -1.807 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.918 -175.802 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -151.27 32.38 0.59 Allowed 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 171.613 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.1 t -163.62 -176.45 4.68 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 -176.484 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -76.84 134.25 39.1 Favored 'General case' 0 CA--C 1.506 -0.736 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.131 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' LYS . . . . . 0.584 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 7.8 mmpt? -137.39 152.4 73.13 Favored Pre-proline 0 C--N 1.29 -2.015 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -67.63 147.15 75.66 Favored 'Trans proline' 0 N--CA 1.443 -1.445 0 C-N-CA 122.305 2.003 . . . . 0.0 111.998 -177.733 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' TRP . . . . . 0.489 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.0 t90 -88.0 111.41 42.53 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.462 ' HD3' ' OH ' ' A' ' 95' ' ' TYR . 2.5 Cg_endo -79.47 87.6 1.53 Allowed 'Trans proline' 0 N--CA 1.443 -1.448 0 C-N-CA 121.386 1.39 . . . . 0.0 112.069 -172.705 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.406 HG22 ' HD2' ' A' ' 77' ' ' TYR . 95.9 t -140.13 142.75 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.339 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 177.488 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.586 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.58 135.62 17.65 Favored 'General case' 0 N--CA 1.421 -1.899 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 178.158 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.491 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 16.8 mt -101.89 103.38 14.05 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.424 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 25.7 m-85 -84.38 76.62 10.12 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 120.767 0.318 . . . . 0.0 110.24 178.477 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.673 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.2 mm? -103.33 131.04 50.72 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 177.405 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.23 147.61 66.44 Favored Pre-proline 0 N--CA 1.418 -2.029 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.528 -175.317 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.511 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 30.3 Cg_endo -62.04 121.08 8.97 Favored 'Trans proline' 0 C--O 1.25 1.083 0 C-N-CA 123.068 2.512 . . . . 0.0 111.841 -178.188 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.509 HG22 ' O ' ' A' ' 70' ' ' ASN . 4.2 m -69.89 -120.52 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.186 -2.242 0 CA-C-N 114.026 -1.443 . . . . 0.0 111.218 175.919 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 23.0 t -111.06 -35.82 5.81 Favored 'General case' 0 C--N 1.291 -1.94 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 175.532 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 27.6 t -82.06 36.8 0.47 Allowed 'General case' 0 N--CA 1.441 -0.919 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.919 -176.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -117.02 133.47 55.96 Favored 'General case' 0 N--CA 1.418 -2.043 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 177.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -172.95 129.55 1.72 Allowed Glycine 0 N--CA 1.437 -1.24 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.21 -146.06 48.46 Favored Glycine 0 CA--C 1.491 -1.454 0 CA-C-O 119.143 -0.809 . . . . 0.0 111.781 -177.396 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.2 p -58.05 101.27 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-O 122.598 1.19 . . . . 0.0 112.157 -177.458 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -102.03 -23.09 14.14 Favored 'General case' 0 C--N 1.294 -1.827 0 CA-C-N 114.674 -1.148 . . . . 0.0 111.001 -178.484 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.519 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 65.3 mt -136.56 137.14 48.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.329 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.554 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.1 mmpt? -113.3 137.58 51.28 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-O 120.864 0.364 . . . . 0.0 110.664 176.657 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.94 134.82 48.79 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.749 -0.66 . . . . 0.0 109.833 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 85.17 6.96 83.91 Favored Glycine 0 C--N 1.303 -1.273 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.768 -178.808 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 49.4 m -109.44 144.58 37.48 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 177.518 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.438 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -70.38 126.57 30.02 Favored 'General case' 0 N--CA 1.443 -0.783 0 CA-C-N 115.045 -0.98 . . . . 0.0 108.58 -178.776 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.75 ' HB ' HG21 ' A' ' 67' ' ' VAL . 34.4 pt -113.0 -26.05 3.21 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 N-CA-C 112.469 0.544 . . . . 0.0 112.469 -179.39 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' ALA . . . . . 0.42 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -160.82 165.29 30.51 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 -178.07 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.438 HG23 HD11 ' A' ' 125' ' ' LEU . 63.7 t -140.63 112.88 4.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 179.062 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.487 HD11 HD21 ' A' ' 107' ' ' LEU . 50.9 mt -117.1 143.99 45.17 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.44 ' O ' HD12 ' A' ' 58' ' ' LEU . 5.0 mp -128.9 123.77 59.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.054 0 C-N-CA 119.616 -0.834 . . . . 0.0 109.946 179.206 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.439 ' C ' HD12 ' A' ' 131' ' ' LEU . 1.4 pp -88.72 147.03 24.7 Favored 'General case' 0 CA--C 1.477 -1.855 0 N-CA-C 106.304 -1.739 . . . . 0.0 106.304 174.512 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 37.3 ttp180 -112.42 123.41 50.22 Favored 'General case' 0 C--N 1.258 -3.39 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 173.755 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.434 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 0.0 OUTLIER -92.28 135.88 33.65 Favored 'General case' 0 N--CA 1.408 -2.53 0 N-CA-C 105.625 -1.991 . . . . 0.0 105.625 -176.407 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 35.2 m -147.29 147.22 30.16 Favored 'General case' 0 C--N 1.269 -2.919 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 175.012 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.668 ' CB ' HG23 ' A' ' 52' ' ' ILE . 11.5 p30 -143.61 173.0 12.04 Favored 'General case' 0 N--CA 1.438 -1.036 0 C-N-CA 119.708 -0.797 . . . . 0.0 110.983 178.453 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -87.11 -4.61 59.15 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 114.705 -1.134 . . . . 0.0 112.097 -170.27 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -116.79 -69.05 0.88 Allowed 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 112.621 0.6 . . . . 0.0 112.621 -172.32 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 57.7 m-20 -94.9 158.75 15.35 Favored 'General case' 0 CA--C 1.479 -1.763 0 CA-C-O 121.146 0.498 . . . . 0.0 111.19 -177.193 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 9.5 t -93.27 49.15 1.37 Allowed 'General case' 0 N--CA 1.416 -2.157 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 173.806 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -92.35 36.35 1.0 Allowed 'General case' 0 CA--C 1.506 -0.722 0 CA-C-N 114.844 -1.071 . . . . 0.0 108.406 173.407 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' ASP . . . . . 0.434 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 5.6 p-10 -80.87 69.64 7.48 Favored 'General case' 0 N--CA 1.433 -1.294 0 CA-C-N 114.294 -1.321 . . . . 0.0 111.25 -178.781 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 -105.7 172.73 6.64 Favored 'General case' 0 N--CA 1.426 -1.642 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 178.129 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -123.8 146.61 48.22 Favored 'General case' 0 C--N 1.286 -2.162 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.042 -177.614 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 9.8 m-30 -113.01 125.88 54.9 Favored 'General case' 0 C--N 1.309 -1.156 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 -176.033 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.451 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 58.3 t -89.27 134.31 28.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 O-C-N 123.553 0.533 . . . . 0.0 110.409 -177.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 58.9 m95 -120.26 97.03 5.39 Favored 'General case' 0 C--N 1.284 -2.246 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 -78.34 113.1 16.01 Favored 'General case' 0 C--N 1.283 -2.318 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 177.741 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.432 ' HA ' HG22 ' A' ' 20' ' ' VAL . 22.8 mm -88.74 122.17 39.81 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -177.183 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 47.4 m-85 -118.11 153.04 34.43 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.509 0.671 . . . . 0.0 109.809 178.061 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -78.98 128.89 33.85 Favored 'General case' 0 N--CA 1.409 -2.517 0 CA-C-N 114.609 -1.178 . . . . 0.0 108.159 175.284 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -88.71 -15.5 34.66 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -178.404 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -151.01 145.39 25.5 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 113.578 -1.646 . . . . 0.0 109.641 -175.696 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -79.92 144.63 33.2 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 124.019 0.928 . . . . 0.0 110.753 -178.624 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.552 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 71.2 t -121.54 134.62 64.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.11 -176.937 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.5 t -118.58 134.43 62.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 -179.447 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.47 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 75.5 t -97.46 101.68 10.82 Favored Pre-proline 0 C--N 1.292 -1.934 0 C-N-CA 123.889 0.876 . . . . 0.0 108.778 177.633 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.468 ' HG3' HG13 ' A' ' 27' ' ' VAL . 35.8 Cg_endo -67.22 -28.38 40.33 Favored 'Trans proline' 0 CA--C 1.511 -0.643 0 C-N-CA 121.893 1.729 . . . . 0.0 112.018 -178.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.403 ' HB ' HG12 ' A' ' 156' ' ' VAL . 8.0 t . . . . . 0 CA--C 1.559 1.298 0 O-C-N 124.827 1.329 . . . . 0.0 112.831 176.87 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.555 ' HB2' ' O ' ' A' ' 45' ' ' HIS . 44.4 p90 . . . . . 0 CA--C 1.501 -0.933 0 N-CA-C 110.681 -0.118 . . . . 0.0 110.681 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -124.6 173.63 8.38 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 175.379 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.433 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 74.1 m -134.17 161.94 33.52 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 119.747 -0.781 . . . . 0.0 112.211 -173.703 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.463 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -146.78 161.67 40.16 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.215 -176.84 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.451 HG22 HG22 ' A' ' 20' ' ' VAL . 72.7 p -99.48 179.56 4.52 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 121.225 0.536 . . . . 0.0 111.557 -178.716 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.58 -26.62 50.92 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.862 177.14 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -79.4 -31.33 42.73 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 119.433 -0.907 . . . . 0.0 109.414 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 129.08 20.42 1.45 Allowed Glycine 0 N--CA 1.431 -1.687 0 C-N-CA 119.911 -1.138 . . . . 0.0 112.933 173.76 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.42 ' O ' ' HA ' ' A' ' 4' ' ' LYS . 2.6 m -87.98 99.31 12.06 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.565 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.06 121.32 32.76 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 115.795 -0.638 . . . . 0.0 109.539 177.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 63.5 mt -99.82 116.67 64.54 Favored Pre-proline 0 C--N 1.29 -1.99 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 177.293 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -77.39 168.57 22.66 Favored 'Trans proline' 0 C--O 1.251 1.151 0 C-N-CA 122.45 2.1 . . . . 0.0 110.912 177.704 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 64.9 mt -66.56 124.91 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.595 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 145.04 -5.0 1.42 Allowed Glycine 0 C--N 1.303 -1.304 0 CA-C-N 115.723 -0.671 . . . . 0.0 111.636 -176.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 94.37 161.17 34.75 Favored Glycine 0 N--CA 1.439 -1.145 0 N-CA-C 110.122 -1.191 . . . . 0.0 110.122 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 159.38 -167.01 34.96 Favored Glycine 0 CA--C 1.486 -1.758 0 C-N-CA 119.484 -1.341 . . . . 0.0 111.342 179.044 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 49.9 p -147.08 152.37 38.41 Favored 'General case' 0 N--CA 1.424 -1.761 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -178.506 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -138.39 163.41 31.95 Favored 'General case' 0 N--CA 1.417 -2.082 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.013 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -108.42 118.14 35.99 Favored 'General case' 0 N--CA 1.406 -2.662 0 CA-C-N 114.342 -1.299 . . . . 0.0 107.964 176.457 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.451 HG22 HG22 ' A' ' 5' ' ' THR . 49.3 t -104.96 130.5 55.95 Favored 'Isoleucine or valine' 0 C--N 1.264 -3.113 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.142 178.776 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -118.75 128.09 54.17 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -179.352 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.55 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -138.01 137.26 44.75 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 O-C-N 124.128 0.893 . . . . 0.0 110.932 -176.545 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 37.3 m-80 -90.28 139.63 30.47 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 178.776 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.7 HD21 HG22 ' A' ' 36' ' ' VAL . 5.1 mp -122.72 161.95 22.93 Favored 'General case' 0 C--N 1.282 -2.367 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.183 176.852 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.03 120.85 54.26 Favored Pre-proline 0 C--N 1.316 -0.863 0 O-C-N 124.653 1.221 . . . . 0.0 109.404 178.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 73.5 Cg_endo -75.68 3.75 5.68 Favored 'Trans proline' 0 CA--C 1.532 0.392 0 C-N-CA 122.846 2.364 . . . . 0.0 113.398 -176.154 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.4 t -132.0 109.79 15.84 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 178.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.52 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.1 t -141.85 107.7 1.78 Allowed 'Isoleucine or valine' 0 C--O 1.182 -2.448 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -176.639 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.664 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -96.4 150.36 20.67 Favored 'General case' 0 C--N 1.269 -2.895 0 O-C-N 122.036 -0.415 . . . . 0.0 111.303 -179.864 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.402 HG13 ' O ' ' A' ' 112' ' ' VAL . 35.0 t -45.81 117.44 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 123.445 0.698 . . . . 0.0 111.976 176.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.62 1.61 53.01 Favored Glycine 0 CA--C 1.523 0.576 0 CA-C-N 115.414 -0.812 . . . . 0.0 112.829 -178.644 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.664 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.1 OUTLIER -73.02 -178.0 2.64 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 123.891 0.876 . . . . 0.0 110.034 177.639 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 17.7 t-20 -130.22 86.82 2.44 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 177.636 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.624 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 20.2 tp -89.94 145.49 25.08 Favored 'General case' 0 C--N 1.294 -1.824 0 C-N-CA 119.765 -0.774 . . . . 0.0 109.259 -179.256 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 73.7 t -137.73 134.5 45.8 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.73 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -178.812 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.7 HG22 HD21 ' A' ' 24' ' ' LEU . 21.0 t -99.99 89.62 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.41 -2.426 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 174.32 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -83.35 114.95 21.78 Favored 'General case' 0 C--N 1.3 -1.562 0 C-N-CA 119.91 -0.716 . . . . 0.0 111.125 -176.895 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 82.7 mt -99.78 -2.39 35.24 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.69 -177.397 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.6 m -73.68 -2.08 21.7 Favored 'General case' 0 C--O 1.208 -1.13 0 CA-C-O 122.222 1.011 . . . . 0.0 109.191 -179.503 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.2 p -126.21 7.48 7.17 Favored 'General case' 0 N--CA 1.419 -1.985 0 CA-C-N 115.151 -0.931 . . . . 0.0 109.776 179.002 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.55 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 48.6 mm-40 -125.42 -20.23 4.83 Favored 'General case' 0 CA--C 1.508 -0.648 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.9 -174.692 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.5 mt -135.3 137.31 50.23 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 -176.588 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.463 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 74.8 m-85 -137.68 153.67 49.78 Favored 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 -176.07 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.549 ' HB3' ' CD2' ' A' ' 1' ' ' PHE . 90.5 m -132.23 134.91 45.87 Favored 'General case' 0 C--N 1.28 -2.419 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.875 -178.637 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.555 ' O ' ' HB2' ' A' ' 1' ' ' PHE . 18.7 p-80 -122.64 131.0 53.61 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.428 -175.486 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.431 ' HA ' ' HB3' ' A' ' 1' ' ' PHE . 4.2 p-10 -77.83 118.17 19.9 Favored 'General case' 0 N--CA 1.422 -1.83 0 CA-C-O 122.09 0.948 . . . . 0.0 108.963 178.426 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ASP . . . . . 0.491 ' OD1' ' HA ' ' A' ' 1' ' ' PHE . 3.9 p30 -97.24 -27.1 14.68 Favored 'General case' 0 C--N 1.274 -2.696 0 CA-C-N 114.154 -1.385 . . . . 0.0 110.387 -177.022 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 37.5 m-85 -148.93 68.43 9.63 Favored Pre-proline 0 N--CA 1.483 1.182 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.416 ' HA ' ' OD2' ' A' ' 54' ' ' ASP . 58.4 Cg_endo -67.85 -11.72 33.01 Favored 'Trans proline' 0 N--CA 1.481 0.766 0 C-N-CA 122.925 2.417 . . . . 0.0 114.281 -171.587 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -114.58 -14.03 12.11 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 121.208 0.528 . . . . 0.0 110.565 -177.474 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.517 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.3 m -101.87 -29.24 11.96 Favored 'General case' 0 N--CA 1.424 -1.731 0 CA-C-O 122.047 0.927 . . . . 0.0 108.881 -173.28 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.517 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.4 mp -128.56 141.21 47.14 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.168 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 178.403 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 14.5 t -74.52 136.35 42.18 Favored 'General case' 0 N--CA 1.428 -1.563 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 174.071 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.49 ' O ' HG23 ' A' ' 94' ' ' VAL . 51.3 m-20 -95.98 105.82 17.9 Favored 'General case' 0 C--N 1.263 -3.173 0 C-N-CA 118.457 -1.297 . . . . 0.0 108.404 -179.305 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.505 ' CD2' ' HB ' ' A' ' 134' ' ' THR . 15.8 t80 -142.21 139.44 32.02 Favored 'General case' 0 C--N 1.289 -2.052 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.482 -173.963 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.423 ' CG2' ' HG ' ' A' ' 131' ' ' LEU . 14.9 p -148.56 156.01 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.943 0 O-C-N 123.832 0.708 . . . . 0.0 109.991 -178.44 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.29 135.54 17.94 Favored 'General case' 0 N--CA 1.422 -1.845 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 176.24 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.521 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 32.5 tp -70.6 110.44 5.45 Favored 'General case' 0 N--CA 1.427 -1.579 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 170.553 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.412 ' HB2' ' HB2' ' A' ' 132' ' ' ARG . 12.0 tp60 -57.6 -56.63 19.41 Favored 'General case' 0 C--O 1.206 -1.227 0 CA-C-N 113.576 -1.647 . . . . 0.0 109.479 -177.58 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 10.5 ptp180 -164.09 156.56 17.25 Favored 'General case' 0 N--CA 1.41 -2.461 0 CA-C-N 114.364 -1.289 . . . . 0.0 108.472 -177.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -140.58 135.83 7.26 Favored Glycine 0 N--CA 1.4 -3.712 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -179.535 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 46.0 m -124.81 147.68 48.59 Favored 'General case' 0 C--N 1.276 -2.591 0 C-N-CA 124.139 0.975 . . . . 0.0 110.473 -175.694 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.506 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -106.81 158.83 16.69 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.508 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 97.1 m-85 -154.61 175.4 13.7 Favored 'General case' 0 C--N 1.341 0.231 0 C-N-CA 124.139 0.975 . . . . 0.0 109.864 -177.87 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.02 -143.28 45.84 Favored Glycine 0 N--CA 1.446 -0.671 0 O-C-N 123.791 0.682 . . . . 0.0 113.104 176.486 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.36 -13.12 73.59 Favored Glycine 0 C--O 1.202 -1.868 0 C-N-CA 120.962 -0.637 . . . . 0.0 111.742 177.063 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.855 HG21 ' HB ' ' A' ' 126' ' ' ILE . 94.7 t -70.29 -36.75 68.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 123.414 0.686 . . . . 0.0 112.043 -177.64 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.506 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -90.04 -18.54 25.76 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.58 -1.248 . . . . 0.0 112.374 177.248 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 5.0 t -99.88 -51.13 3.8 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.369 -172.134 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.456 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 67.7 m-20 -96.2 -23.18 16.84 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 -174.683 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.645 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 89.6 m-85 -110.73 156.3 21.24 Favored 'General case' 0 N--CA 1.422 -1.868 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 177.588 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.0 t -165.59 127.89 2.06 Favored 'General case' 0 N--CA 1.411 -2.409 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 176.513 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.29 -111.24 0.27 Allowed Glycine 0 N--CA 1.407 -3.233 0 N-CA-C 111.574 -0.61 . . . . 0.0 111.574 176.462 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -153.63 -179.91 8.23 Favored 'General case' 0 C--N 1.291 -1.941 0 C-N-CA 123.933 0.893 . . . . 0.0 110.366 -173.843 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 3.2 p -135.8 151.51 29.61 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.242 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.691 ' HG3' ' O ' ' A' ' 80' ' ' SER . 72.3 tttt -130.91 147.53 52.57 Favored 'General case' 0 N--CA 1.423 -1.794 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -178.676 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.448 ' CD2' HG22 ' A' ' 105' ' ' VAL . 47.5 t80 -148.13 108.67 4.15 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 -177.199 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 13.8 t 51.21 44.62 28.68 Favored 'General case' 0 CA--C 1.553 1.06 0 C-N-CA 123.433 0.693 . . . . 0.0 111.197 175.834 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 81.22 20.89 63.75 Favored Glycine 0 CA--C 1.525 0.671 0 C-N-CA 120.264 -0.97 . . . . 0.0 113.115 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.691 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 16.3 t -90.53 179.26 5.89 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 106.927 -1.508 . . . . 0.0 106.927 174.649 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 10.9 m -157.47 103.55 1.96 Allowed 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 178.875 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.423 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.6 p90 -147.65 158.75 42.59 Favored Pre-proline 0 C--N 1.308 -1.222 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -172.875 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.417 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 56.6 Cg_endo -68.78 150.16 73.65 Favored 'Trans proline' 0 C--N 1.356 0.964 0 C-N-CA 122.933 2.422 . . . . 0.0 112.837 -177.654 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.541 ' CD2' HD21 ' A' ' 109' ' ' LEU . 47.3 t80 -124.5 134.77 25.83 Favored Pre-proline 0 N--CA 1.431 -1.402 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 179.293 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.54 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 59.3 Cg_endo -71.03 145.61 82.69 Favored 'Cis proline' 0 CA--C 1.554 1.51 0 C-N-CA 123.105 -1.623 . . . . 0.0 111.153 -2.438 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.2 t -68.43 -176.81 0.81 Allowed 'General case' 0 N--CA 1.489 1.52 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.32 -175.398 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 56.1 p -124.89 -47.34 1.8 Allowed 'General case' 0 N--CA 1.436 -1.164 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -172.362 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 10.0 t -105.4 -65.19 1.07 Allowed 'General case' 0 N--CA 1.437 -1.123 0 C-N-CA 120.39 -0.524 . . . . 0.0 111.246 -174.242 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 176.23 -172.98 0.09 Allowed 'General case' 0 C--O 1.247 0.97 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 -175.546 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.521 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 42.4 p -100.9 168.44 9.24 Favored Pre-proline 0 C--N 1.297 -1.708 0 O-C-N 123.429 0.455 . . . . 0.0 111.707 175.326 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' PRO . . . . . 0.453 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 19.0 Cg_endo -55.78 165.19 3.84 Favored 'Trans proline' 0 CA--C 1.547 1.158 0 C-N-CA 123.232 2.621 . . . . 0.0 111.962 171.864 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.403 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 1.7 tmm_? -76.68 112.75 13.58 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -176.587 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 76.4 t -126.4 128.33 71.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-O 121.522 0.677 . . . . 0.0 110.15 -176.305 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 54' ' ' ASP . 0.2 OUTLIER -121.71 132.32 71.08 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 CA-C-N 115.038 -0.983 . . . . 0.0 110.776 -177.571 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.49 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 7.2 m-85 -80.78 101.04 9.09 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.19 -178.084 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 -96.63 64.31 2.13 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.6 m -142.02 178.1 7.76 Favored 'General case' 0 N--CA 1.434 -1.229 0 O-C-N 121.778 -0.576 . . . . 0.0 110.844 -174.24 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.401 ' HA ' HD21 ' A' ' 46' ' ' ASN . 6.8 ptp180 -141.22 45.75 1.75 Allowed 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.066 0.46 . . . . 0.0 110.446 -178.678 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.0 t -170.53 177.44 4.0 Favored 'General case' 0 C--O 1.245 0.847 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 -174.824 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -73.03 98.16 2.48 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 173.51 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 10.0 tptp -97.1 142.59 24.76 Favored Pre-proline 0 C--N 1.277 -2.587 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.415 ' O ' ' HD3' ' A' ' 104' ' ' PRO . 26.8 Cg_endo -62.91 154.72 64.72 Favored 'Trans proline' 0 C--N 1.324 -0.75 0 C-N-CA 122.428 2.086 . . . . 0.0 112.395 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' TRP . . . . . 0.49 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 15.4 t90 -95.71 100.94 6.96 Favored Pre-proline 0 C--N 1.306 -1.32 0 N-CA-C 105.102 -2.184 . . . . 0.0 105.102 175.929 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.415 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 59.6 Cg_endo -74.57 88.63 1.16 Allowed 'Trans proline' 0 N--CA 1.454 -0.837 0 C-N-CA 121.782 1.655 . . . . 0.0 113.341 -170.052 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.448 HG22 ' CD2' ' A' ' 77' ' ' TYR . 96.9 t -138.61 145.12 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.193 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.91 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.534 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.65 138.47 19.92 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 177.269 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.475 ' HB2' ' CG2' ' A' ' 36' ' ' VAL . 17.7 mt -102.82 104.3 14.56 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.93 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 9.5 m-85 -81.32 67.33 7.22 Favored 'General case' 0 C--N 1.295 -1.788 0 O-C-N 122.023 -0.423 . . . . 0.0 111.355 179.206 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.645 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.4 mm? -92.84 134.54 34.97 Favored 'General case' 0 C--O 1.208 -1.127 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 176.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.62 148.11 62.33 Favored Pre-proline 0 C--N 1.294 -1.829 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -176.18 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.456 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 28.8 Cg_endo -62.98 121.46 9.35 Favored 'Trans proline' 0 C--O 1.243 0.753 0 C-N-CA 123.235 2.624 . . . . 0.0 112.555 -176.726 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.402 ' O ' HG13 ' A' ' 30' ' ' VAL . 2.4 m -71.86 -116.9 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.186 -2.237 0 CA-C-N 114.225 -1.352 . . . . 0.0 112.715 176.914 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 28.9 t -112.54 -37.54 4.9 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 177.191 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 47.9 m -73.42 16.21 0.2 Allowed 'General case' 0 N--CA 1.399 -2.999 0 C-N-CA 125.997 1.719 . . . . 0.0 113.653 -176.737 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -102.7 131.69 49.34 Favored 'General case' 0 N--CA 1.411 -2.399 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -176.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.94 129.33 1.62 Allowed Glycine 0 N--CA 1.434 -1.447 0 N-CA-C 110.634 -0.987 . . . . 0.0 110.634 179.377 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.89 -151.29 51.92 Favored Glycine 0 CA--C 1.5 -0.888 0 CA-C-O 119.085 -0.842 . . . . 0.0 111.53 -176.757 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.9 p -54.86 104.6 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 122.233 1.016 . . . . 0.0 111.914 -177.518 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.85 -31.2 9.4 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 115.043 -0.981 . . . . 0.0 111.461 -177.166 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.53 ' HB ' HG22 ' A' ' 154' ' ' VAL . 69.7 mt -124.4 140.86 46.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 177.186 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.42 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 2.8 mmpt? -117.67 139.44 51.01 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-O 121.001 0.429 . . . . 0.0 111.073 178.483 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.7 131.67 44.95 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.406 -0.815 . . . . 0.0 110.769 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 87.31 -7.9 78.97 Favored Glycine 0 C--N 1.309 -0.931 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.079 -179.58 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 25.3 m -90.69 148.59 22.5 Favored 'General case' 0 N--CA 1.425 -1.716 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 24.9 tp -73.76 133.0 43.22 Favored 'General case' 0 N--CA 1.436 -1.132 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.229 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.855 ' HB ' HG21 ' A' ' 67' ' ' VAL . 37.9 pt -118.42 -24.44 3.25 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 C-N-CA 120.432 -0.507 . . . . 0.0 112.352 -179.519 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 127' ' ' ALA . . . . . 0.47 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -163.3 164.33 24.92 Favored 'General case' 0 N--CA 1.439 -0.977 0 CA-C-O 120.538 0.209 . . . . 0.0 110.614 -178.633 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 53.5 t -140.74 114.36 5.36 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 178.4 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.41 HD11 HD21 ' A' ' 107' ' ' LEU . 54.3 mt -117.55 139.01 51.52 Favored 'General case' 0 C--N 1.287 -2.12 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.449 ' O ' HD12 ' A' ' 58' ' ' LEU . 5.0 mp -117.33 122.29 69.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 C-N-CA 119.314 -0.954 . . . . 0.0 109.918 177.372 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.494 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.0 OUTLIER -90.44 132.73 35.47 Favored 'General case' 0 C--N 1.275 -2.649 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 177.439 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.412 ' HB2' ' HB2' ' A' ' 59' ' ' GLN . 17.7 tpt85 -106.85 109.54 21.47 Favored 'General case' 0 C--N 1.274 -2.709 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.149 -176.05 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -88.34 132.67 34.33 Favored 'General case' 0 CA--C 1.484 -1.574 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 175.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.505 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 11.7 m -136.41 133.57 36.83 Favored 'General case' 0 C--N 1.273 -2.724 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 177.636 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.442 HD21 ' HB2' ' A' ' 140' ' ' ASP . 16.3 p30 -128.59 153.96 46.7 Favored 'General case' 0 C--N 1.31 -1.141 0 CA-C-O 121.404 0.621 . . . . 0.0 111.634 -179.185 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -94.39 -21.19 19.1 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 114.763 -1.108 . . . . 0.0 110.793 -174.916 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 50.5 t80 -86.44 -70.66 0.59 Allowed 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.577 -172.424 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -89.91 177.53 6.46 Favored 'General case' 0 C--N 1.283 -2.294 0 CA-C-N 115.791 -0.641 . . . . 0.0 109.407 175.678 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 66.9 m -109.73 43.47 1.33 Allowed 'General case' 0 C--N 1.284 -2.267 0 CA-C-O 122.726 1.251 . . . . 0.0 107.628 175.359 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' ASP . . . . . 0.442 ' HB2' HD21 ' A' ' 135' ' ' ASN . 1.5 m-20 -102.97 46.07 0.93 Allowed 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 113.96 -1.473 . . . . 0.0 108.809 -179.491 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -87.74 83.56 7.15 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 114.605 -1.179 . . . . 0.0 109.7 -179.44 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -104.39 163.64 12.3 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.869 -179.141 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 5.9 pt20 -119.92 143.72 47.82 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 178.42 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.478 ' HB2' HD22 ' A' ' 131' ' ' LEU . 9.6 m-30 -112.48 134.35 54.06 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -176.513 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 47.4 t -91.51 131.09 39.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 CA-C-O 121.155 0.502 . . . . 0.0 110.08 -179.096 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 146' ' ' TRP . . . . . 0.494 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 65.3 m95 -120.23 97.96 5.84 Favored 'General case' 0 C--N 1.284 -2.274 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -179.217 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 36.9 m-80 -80.35 114.1 19.01 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 106.992 -1.485 . . . . 0.0 106.992 178.588 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.47 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 22.5 mm -89.3 122.53 40.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 -177.784 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -120.31 152.75 37.39 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 123.428 0.691 . . . . 0.0 109.605 178.803 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.73 132.92 34.82 Favored 'General case' 0 N--CA 1.418 -2.03 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 177.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -90.1 -15.45 31.66 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 -178.19 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -149.27 144.52 26.56 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 114.049 -1.432 . . . . 0.0 109.431 -175.665 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -85.76 148.08 26.02 Favored 'General case' 0 C--N 1.315 -0.906 0 O-C-N 124.022 0.826 . . . . 0.0 109.292 -178.145 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.53 HG22 ' HB ' ' A' ' 120' ' ' ILE . 2.2 m -126.56 148.34 31.31 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 C-N-CA 120.256 -0.578 . . . . 0.0 110.557 -176.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.5 t -120.14 140.6 43.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.032 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 -179.144 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.52 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 79.4 t -101.57 101.63 18.46 Favored Pre-proline 0 C--N 1.297 -1.676 0 C-N-CA 123.871 0.868 . . . . 0.0 109.706 178.233 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.451 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 30.3 Cg_endo -68.28 -25.85 36.17 Favored 'Trans proline' 0 CA--C 1.518 -0.304 0 C-N-CA 122.315 2.01 . . . . 0.0 112.378 178.661 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 5.8 t . . . . . 0 CA--C 1.559 1.31 0 O-C-N 124.646 1.216 . . . . 0.0 113.352 176.506 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.503 ' CZ ' ' HB3' ' A' ' 44' ' ' CYS . 50.2 t80 . . . . . 0 CA--C 1.494 -1.203 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.511 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -149.47 176.92 10.18 Favored 'General case' 0 C--N 1.296 -1.723 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 -179.237 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.445 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 68.4 m -142.41 159.0 43.09 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 120.274 -0.57 . . . . 0.0 110.912 -174.924 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.438 ' HD2' ' O ' ' A' ' 5' ' ' THR . 0.0 OUTLIER -146.12 156.87 43.74 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-O 121.14 0.495 . . . . 0.0 109.978 -177.469 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.438 ' O ' ' HD2' ' A' ' 4' ' ' LYS . 41.1 p -91.83 176.08 6.65 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.613 -179.178 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -85.23 -5.08 59.34 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 114.866 -1.061 . . . . 0.0 110.838 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.96 -34.49 8.92 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.877 -179.689 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 140.06 7.27 0.99 Allowed Glycine 0 C--N 1.316 -0.529 0 C-N-CA 118.796 -1.668 . . . . 0.0 115.236 172.289 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.7 m -87.37 102.3 14.39 Favored 'General case' 0 C--N 1.296 -1.755 0 O-C-N 121.892 -0.77 . . . . 0.0 109.039 177.164 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.57 122.12 37.98 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 115.396 -0.82 . . . . 0.0 108.84 175.404 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.511 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 63.7 mt -102.01 116.15 63.64 Favored Pre-proline 0 C--N 1.298 -1.649 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.187 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.25 173.8 12.11 Favored 'Trans proline' 0 C--O 1.247 0.954 0 C-N-CA 122.814 2.343 . . . . 0.0 111.469 178.069 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 58.8 mt -66.64 129.59 31.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 178.215 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 140.14 -6.79 2.85 Favored Glycine 0 C--N 1.303 -1.252 0 N-CA-C 111.358 -0.697 . . . . 0.0 111.358 -178.705 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 96.84 156.26 30.76 Favored Glycine 0 N--CA 1.438 -1.199 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -179.108 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 170.33 -175.46 44.25 Favored Glycine 0 N--CA 1.428 -1.886 0 C-N-CA 119.822 -1.18 . . . . 0.0 111.142 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.6 m -144.96 148.88 34.3 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 178.631 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.98 165.4 26.08 Favored 'General case' 0 CA--C 1.48 -1.727 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -114.85 110.09 19.14 Favored 'General case' 0 C--N 1.278 -2.543 0 CA-C-N 114.098 -1.41 . . . . 0.0 107.482 177.25 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.436 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.3 m -97.65 142.08 14.91 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.321 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.694 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.2 m-85 -124.07 124.56 42.79 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 121.039 0.447 . . . . 0.0 110.989 -178.84 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.466 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.9 p -138.43 134.85 43.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.825 -178.067 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -94.33 128.06 40.6 Favored 'General case' 0 C--N 1.294 -1.811 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.867 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -104.82 160.51 14.94 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.097 -0.956 . . . . 0.0 108.581 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.75 123.33 57.46 Favored Pre-proline 0 C--O 1.211 -0.949 0 O-C-N 124.258 0.974 . . . . 0.0 109.241 176.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 74.1 Cg_endo -76.57 -0.34 10.35 Favored 'Trans proline' 0 CA--C 1.536 0.592 0 C-N-CA 122.5 2.133 . . . . 0.0 113.567 -175.947 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.5 t -128.85 109.77 19.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 179.57 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.428 HG21 HD22 ' A' ' 34' ' ' LEU . 5.2 t -145.09 104.69 0.71 Allowed 'Isoleucine or valine' 0 C--O 1.198 -1.639 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -178.078 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.523 ' HB3' ' HG2' ' A' ' 157' ' ' PRO . 0.5 OUTLIER -94.36 154.84 17.28 Favored 'General case' 0 C--N 1.275 -2.668 0 C-N-CA 123.212 0.605 . . . . 0.0 111.61 -179.902 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.433 ' H ' ' HA ' ' A' ' 158' ' ' THR . 42.5 t -44.7 116.53 0.23 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.361 0 C-N-CA 124.103 0.961 . . . . 0.0 111.402 175.486 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.72 0.2 45.84 Favored Glycine 0 CA--C 1.521 0.458 0 CA-C-N 115.06 -0.973 . . . . 0.0 113.186 179.701 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.478 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 1.4 mm-40 -72.78 -177.63 2.41 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 123.779 0.831 . . . . 0.0 111.768 176.702 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 66.3 t30 -128.84 87.39 2.57 Favored 'General case' 0 CA--C 1.49 -1.337 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 177.307 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.631 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 21.6 tp -96.24 135.23 38.33 Favored 'General case' 0 N--CA 1.423 -1.824 0 C-N-CA 119.23 -0.988 . . . . 0.0 109.64 179.256 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.6 p -141.64 132.49 26.31 Favored 'Isoleucine or valine' 0 N--CA 1.387 -3.599 0 CA-C-O 122.208 1.004 . . . . 0.0 112.859 -178.077 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.604 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 41.9 t -91.74 89.7 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.661 0 CA-C-N 113.507 -1.678 . . . . 0.0 107.664 178.364 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -77.78 106.91 9.91 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 88.3 mt -93.93 -1.22 54.99 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.701 -178.495 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.637 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 0.7 OUTLIER -68.99 -10.57 58.15 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-O 122.396 1.093 . . . . 0.0 109.741 -178.638 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.6 p -121.47 5.52 10.13 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 115.083 -0.962 . . . . 0.0 110.748 179.054 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.466 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 49.2 mm-40 -120.0 -21.98 6.89 Favored 'General case' 0 CA--C 1.511 -0.555 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.614 -174.635 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 29.9 mt -135.06 138.95 48.12 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.011 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -178.09 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -136.96 147.87 46.6 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 -177.052 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.503 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 88.9 m -123.55 136.55 54.6 Favored 'General case' 0 C--N 1.29 -1.981 0 CA-C-O 120.864 0.364 . . . . 0.0 110.991 178.8 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 16.4 p80 -130.91 162.6 29.3 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.423 0.63 . . . . 0.0 110.46 -175.424 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -112.56 121.17 44.03 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 121.828 0.823 . . . . 0.0 111.993 177.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 22.5 p-10 -96.98 -13.32 22.41 Favored 'General case' 0 N--CA 1.427 -1.583 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.588 178.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.418 ' HB2' HD13 ' A' ' 52' ' ' ILE . 83.4 m-85 -147.3 69.24 11.53 Favored Pre-proline 0 C--O 1.22 -0.481 0 CA-C-N 115.503 -0.771 . . . . 0.0 108.935 175.464 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -68.52 -12.82 35.86 Favored 'Trans proline' 0 N--CA 1.483 0.895 0 C-N-CA 122.091 1.861 . . . . 0.0 112.903 -177.176 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -101.44 -25.03 14.07 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-O 121.353 0.597 . . . . 0.0 110.589 -176.513 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.582 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.3 m -102.09 -26.81 13.24 Favored 'General case' 0 N--CA 1.42 -1.97 0 CA-C-O 121.69 0.757 . . . . 0.0 109.289 -172.387 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.582 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.2 mp -129.31 127.73 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.263 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 -178.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.1 t -73.63 145.7 45.16 Favored 'General case' 0 C--O 1.256 1.399 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -85.3 107.62 17.41 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -176.629 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.44 ' CE2' ' HB ' ' A' ' 134' ' ' THR . 17.3 t80 -149.35 138.83 21.61 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -177.555 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.503 HG23 ' HG ' ' A' ' 131' ' ' LEU . 13.4 p -150.64 149.97 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.564 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.25 -178.93 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -150.3 131.02 14.07 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 172.744 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.541 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 53.4 tp -66.5 110.82 3.3 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 171.858 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.494 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 3.0 tp-100 -55.48 -50.86 68.79 Favored 'General case' 0 C--N 1.314 -0.96 0 C-N-CA 126.123 1.769 . . . . 0.0 111.564 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -170.44 155.77 5.24 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -177.418 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -132.32 136.07 8.52 Favored Glycine 1 N--CA 1.395 -4.077 0 N-CA-C 107.986 -2.046 . . . . 0.0 107.986 178.413 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 47.8 m -124.17 147.91 47.64 Favored 'General case' 0 C--N 1.271 -2.809 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -176.303 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.563 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -115.46 156.09 26.28 Favored 'General case' 0 C--N 1.306 -1.315 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 -179.339 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.505 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 92.8 m-85 -155.13 -178.95 7.61 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 123.832 0.853 . . . . 0.0 109.045 -177.351 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 62.46 -136.75 44.87 Favored Glycine 0 C--O 1.222 -0.612 0 N-CA-C 111.723 -0.551 . . . . 0.0 111.723 179.344 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -88.38 -3.91 77.83 Favored Glycine 0 C--O 1.206 -1.607 0 C-N-CA 120.537 -0.839 . . . . 0.0 111.133 176.762 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.738 HG21 ' HB ' ' A' ' 126' ' ' ILE . 76.1 t -71.35 -36.31 60.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 C-N-CA 123.876 0.87 . . . . 0.0 111.576 -176.11 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.563 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -85.31 -25.73 27.0 Favored 'General case' 0 C--N 1.297 -1.681 0 C-N-CA 119.915 -0.714 . . . . 0.0 112.486 178.451 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 21.0 m -101.04 -52.83 3.18 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 -173.13 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.483 ' O ' HG22 ' A' ' 112' ' ' VAL . 53.9 m-20 -88.52 -28.41 20.81 Favored 'General case' 0 CA--C 1.488 -1.426 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 -175.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.656 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 90.2 m-85 -104.55 155.29 18.96 Favored 'General case' 0 N--CA 1.41 -2.463 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 175.465 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.415 ' HB3' ' CG1' ' A' ' 112' ' ' VAL . 15.5 t -167.03 120.34 0.98 Allowed 'General case' 0 N--CA 1.417 -2.106 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 177.013 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.454 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -154.81 -112.66 0.45 Allowed Glycine 0 N--CA 1.402 -3.63 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 175.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 8.3 p -151.69 -179.93 7.85 Favored 'General case' 0 C--N 1.293 -1.862 0 CA-C-O 121.157 0.503 . . . . 0.0 110.662 -173.796 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.443 ' HB ' ' HB2' ' A' ' 84' ' ' PHE . 2.5 p -132.27 146.03 33.71 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.156 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 177.868 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.643 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.1 tttt -123.92 142.85 50.77 Favored 'General case' 0 N--CA 1.409 -2.514 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 178.621 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.482 ' CG ' HG21 ' A' ' 90' ' ' THR . 59.9 t80 -145.49 112.57 6.07 Favored 'General case' 0 C--N 1.286 -2.159 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 -179.124 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.3 m 55.28 37.37 28.79 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 113.678 0.992 . . . . 0.0 113.678 176.562 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.44 5.84 81.68 Favored Glycine 0 N--CA 1.432 -1.587 0 C-N-CA 120.422 -0.894 . . . . 0.0 112.58 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.643 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 11.0 t -80.34 174.59 11.45 Favored 'General case' 0 C--N 1.317 -0.844 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.532 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 9.3 p -154.13 100.43 2.32 Favored 'General case' 0 C--N 1.284 -2.257 0 CA-C-O 120.98 0.419 . . . . 0.0 110.182 -176.624 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 2.9 p90 -147.07 159.62 42.25 Favored Pre-proline 0 C--N 1.297 -1.701 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -173.69 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -67.53 149.1 79.76 Favored 'Trans proline' 0 C--N 1.354 0.845 0 C-N-CA 123.161 2.574 . . . . 0.0 113.228 -177.142 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.62 ' CD2' HD21 ' A' ' 109' ' ' LEU . 64.5 t80 -124.99 134.7 25.94 Favored Pre-proline 0 C--N 1.315 -0.903 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.128 -179.677 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.525 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 73.9 Cg_endo -72.85 146.39 86.73 Favored 'Cis proline' 0 C--O 1.244 0.788 0 C-N-CA 122.91 -1.704 . . . . 0.0 110.543 -1.487 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.2 t -65.54 -176.76 0.37 Allowed 'General case' 0 CA--C 1.551 0.987 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.394 -175.304 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.2 p -129.03 2.65 5.27 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-O 121.368 0.604 . . . . 0.0 110.709 -173.527 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.6 t -161.75 -125.03 0.02 OUTLIER 'General case' 0 N--CA 1.396 -3.146 0 N-CA-C 105.282 -2.118 . . . . 0.0 105.282 179.025 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -129.7 -170.35 2.28 Favored 'General case' 0 C--N 1.291 -1.963 0 N-CA-C 110.475 -0.194 . . . . 0.0 110.475 -176.244 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.541 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 44.1 p -95.25 166.8 14.05 Favored Pre-proline 0 C--N 1.302 -1.462 0 CA-C-N 116.18 -0.463 . . . . 0.0 112.205 178.581 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -62.29 165.09 15.76 Favored 'Trans proline' 0 CA--C 1.544 1.001 0 C-N-CA 123.02 2.48 . . . . 0.0 110.879 172.037 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.401 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 4.9 tmm_? -71.3 120.7 17.25 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.163 0.506 . . . . 0.0 109.838 -178.707 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 76.0 t -128.32 119.55 50.88 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.238 -178.104 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 59.6 t -94.64 141.11 15.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 176.349 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.534 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 1.3 m-85 -91.38 134.78 34.32 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 175.884 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 -115.33 86.16 2.41 Favored 'General case' 0 C--N 1.276 -2.609 0 N-CA-C 106.29 -1.744 . . . . 0.0 106.29 177.616 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' SER . . . . . 0.442 ' HB3' ' CG ' ' A' ' 101' ' ' LYS . 5.0 p -142.34 154.58 44.78 Favored 'General case' 0 N--CA 1.413 -2.286 0 CA-C-N 115.161 -0.927 . . . . 0.0 112.718 -173.034 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 10.3 ptp180 -135.0 19.37 3.46 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 171.121 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.0 t -164.09 -175.4 3.99 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 105.981 -1.859 . . . . 0.0 105.981 -178.592 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -76.77 122.55 24.92 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.88 0.848 . . . . 0.0 110.666 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' LYS . . . . . 0.442 ' CG ' ' HB3' ' A' ' 97' ' ' SER . 30.6 mmtp -109.68 139.51 21.29 Favored Pre-proline 0 C--N 1.293 -1.858 0 CA-C-N 115.032 -0.985 . . . . 0.0 110.002 177.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.637 ' HB3' ' O ' ' A' ' 39' ' ' SER . 52.3 Cg_exo -55.21 144.36 71.0 Favored 'Trans proline' 0 CA--C 1.505 -0.931 0 C-N-CA 123.726 2.951 . . . . 0.0 111.722 176.447 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' TRP . . . . . 0.534 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 9.1 t90 -91.63 103.63 8.27 Favored Pre-proline 0 C--N 1.294 -1.839 0 N-CA-C 106.044 -1.836 . . . . 0.0 106.044 178.821 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -76.58 88.63 1.35 Allowed 'Trans proline' 0 N--CA 1.446 -1.281 0 C-N-CA 121.624 1.549 . . . . 0.0 111.644 -172.206 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.455 HG22 ' CD2' ' A' ' 77' ' ' TYR . 85.0 t -138.77 142.19 35.05 Favored 'Isoleucine or valine' 0 CA--C 1.485 -1.534 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 179.131 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.604 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.97 133.91 18.05 Favored 'General case' 0 N--CA 1.411 -2.404 0 CA-C-O 120.968 0.413 . . . . 0.0 110.681 179.177 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.485 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 20.0 mt -100.96 99.93 10.47 Favored 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 179.099 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.454 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 76.7 m-85 -80.74 78.81 7.48 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 177.523 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.656 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.3 mm? -102.96 118.99 38.04 Favored 'General case' 0 CA--C 1.49 -1.331 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 177.375 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.8 145.83 46.49 Favored Pre-proline 0 N--CA 1.407 -2.577 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.079 -175.146 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.452 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 36.7 Cg_endo -63.1 119.51 6.61 Favored 'Trans proline' 0 C--O 1.248 1.018 0 C-N-CA 123.347 2.698 . . . . 0.0 112.265 -177.331 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.483 HG22 ' O ' ' A' ' 70' ' ' ASN . 3.2 m -67.62 -118.09 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.182 -2.464 0 CA-C-N 114.023 -1.444 . . . . 0.0 112.59 175.72 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.4 m -112.73 -38.08 4.69 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-O 122.334 1.064 . . . . 0.0 108.141 179.388 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 64.4 m -82.11 31.77 0.38 Allowed 'General case' 0 N--CA 1.394 -3.271 0 CA-C-N 113.356 -1.747 . . . . 0.0 113.151 -177.692 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -108.63 139.05 43.96 Favored 'General case' 0 C--N 1.288 -2.078 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -174.83 139.04 4.64 Favored Glycine 0 N--CA 1.44 -1.068 0 C-N-CA 119.951 -1.119 . . . . 0.0 112.193 179.386 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 57.61 -149.7 32.3 Favored Glycine 0 CA--C 1.491 -1.453 0 O-C-N 124.783 0.931 . . . . 0.0 112.542 -178.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.431 ' CG2' ' HE3' ' A' ' 121' ' ' LYS . 7.3 p -57.3 101.7 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 CA-C-O 122.507 1.146 . . . . 0.0 111.607 -178.628 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -100.61 -27.06 13.59 Favored 'General case' 0 C--N 1.295 -1.773 0 CA-C-N 114.826 -1.079 . . . . 0.0 110.679 -177.675 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.472 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 58.7 mt -133.26 136.98 54.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 -178.866 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.529 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.4 mmpt? -112.73 142.64 45.12 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 121.028 0.442 . . . . 0.0 110.706 176.35 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.23 132.02 45.83 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.169 179.243 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 91.63 -10.42 74.72 Favored Glycine 0 N--CA 1.435 -1.405 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.584 -179.363 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 40.2 t -86.18 143.11 28.16 Favored 'General case' 0 N--CA 1.43 -1.43 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 -178.074 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.44 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -71.2 122.19 19.73 Favored 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 177.11 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.738 ' HB ' HG21 ' A' ' 67' ' ' VAL . 33.7 pt -109.24 -27.78 2.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-N 116.041 -0.527 . . . . 0.0 112.303 -178.554 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -160.3 166.78 28.86 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -177.461 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.44 HG23 HD11 ' A' ' 125' ' ' LEU . 75.7 t -141.87 113.43 3.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 179.737 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.481 HD11 HD21 ' A' ' 107' ' ' LEU . 67.5 mt -115.33 134.67 54.9 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.212 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.525 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.4 mp -117.69 128.17 74.93 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.818 0 C-N-CA 119.196 -1.002 . . . . 0.0 109.748 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.516 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.2 OUTLIER -101.24 131.08 47.42 Favored 'General case' 0 C--N 1.276 -2.623 0 C-N-CA 123.989 0.916 . . . . 0.0 111.443 -176.481 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.494 ' HG2' ' HB2' ' A' ' 59' ' ' GLN . 26.9 mmm180 -87.41 128.09 35.21 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 123.529 0.731 . . . . 0.0 110.826 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.516 ' HA ' ' NE2' ' A' ' 133' ' ' GLN . 13.1 mm-40 -101.36 122.24 43.37 Favored 'General case' 0 N--CA 1.412 -2.356 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 168.05 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.44 ' HB ' ' CE2' ' A' ' 55' ' ' TYR . 23.4 m -140.28 129.49 23.73 Favored 'General case' 0 C--N 1.279 -2.468 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.382 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.547 ' CB ' HG23 ' A' ' 52' ' ' ILE . 28.0 p30 -132.02 177.08 7.83 Favored 'General case' 0 C--N 1.281 -2.387 0 CA-C-O 121.221 0.534 . . . . 0.0 110.539 -175.582 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 2.7 p-10 -104.43 6.36 34.91 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.788 -174.079 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 74.4 t80 -125.07 -69.68 0.78 Allowed 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 115.191 1.552 . . . . 0.0 115.191 -170.137 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' ASN . . . . . 0.46 ' HB2' HD21 ' A' ' 135' ' ' ASN . 18.0 m120 -58.97 -34.85 72.29 Favored 'General case' 0 CA--C 1.484 -1.571 0 N-CA-C 116.507 2.04 . . . . 0.0 116.507 -168.693 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 19.7 m 73.57 11.59 4.73 Favored 'General case' 0 C--N 1.324 -0.543 0 O-C-N 124.494 1.121 . . . . 0.0 109.168 -174.145 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 140' ' ' ASP . . . . . 0.486 ' HB3' ' CE2' ' A' ' 142' ' ' PHE . 13.9 m-20 -110.47 69.77 0.7 Allowed 'General case' 0 CA--C 1.496 -1.097 0 CA-C-N 113.686 -1.597 . . . . 0.0 107.78 178.136 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -91.41 82.59 5.39 Favored 'General case' 0 C--N 1.288 -2.096 0 CA-C-N 115.265 -0.88 . . . . 0.0 109.142 -175.648 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 142' ' ' PHE . . . . . 0.486 ' CE2' ' HB3' ' A' ' 140' ' ' ASP . 84.7 m-85 -90.59 -179.27 5.52 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.897 -178.38 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.3 pt20 -137.38 149.82 47.23 Favored 'General case' 0 N--CA 1.418 -2.06 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 177.253 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 10.0 m-30 -111.34 132.46 54.39 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 -176.841 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 50.6 t -92.82 131.69 39.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.024 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 146' ' ' TRP . . . . . 0.516 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.5 m95 -119.55 100.81 7.51 Favored 'General case' 0 C--N 1.277 -2.577 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 46.4 m-80 -80.69 113.86 19.18 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 178.368 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.436 ' HA ' HG22 ' A' ' 20' ' ' VAL . 22.7 mm -87.35 122.51 39.25 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.936 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 -178.587 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -118.16 148.54 42.25 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.617 178.814 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -80.49 129.52 34.57 Favored 'General case' 0 N--CA 1.409 -2.502 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 176.51 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -87.75 -16.51 34.01 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -178.745 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -147.49 144.85 28.87 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 114.103 -1.408 . . . . 0.0 108.795 -174.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 21.7 p-10 -82.96 144.17 30.18 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 124.232 0.957 . . . . 0.0 111.398 -178.119 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.2 t -120.42 138.71 50.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.634 -175.191 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 4.0 t -119.58 137.92 51.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.638 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 71.9 t -102.17 103.34 29.71 Favored Pre-proline 0 C--N 1.29 -1.979 0 C-N-CA 123.479 0.711 . . . . 0.0 109.847 178.634 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.523 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 56.1 Cg_endo -71.68 -16.95 29.95 Favored 'Trans proline' 0 C--O 1.226 -0.093 0 C-N-CA 122.187 1.925 . . . . 0.0 111.781 178.039 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.433 ' HA ' ' H ' ' A' ' 30' ' ' VAL 0.254 3.9 t . . . . . 0 C--N 1.351 0.666 0 C-N-CA 125.082 1.353 . . . . 0.0 113.84 175.411 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.443 ' O ' HG12 ' A' ' 13' ' ' ILE . 11.2 t80 . . . . . 0 CA--C 1.49 -1.349 0 N-CA-C 104.353 -2.462 . . . . 0.0 104.353 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.514 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -163.28 164.91 24.74 Favored 'General case' 0 CA--C 1.485 -1.554 0 O-C-N 123.744 0.653 . . . . 0.0 109.279 -174.172 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.601 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 12.5 m -128.65 159.2 36.35 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 109.03 -0.729 . . . . 0.0 109.03 -176.54 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.491 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -147.56 159.57 43.6 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 120.858 0.361 . . . . 0.0 110.421 -173.961 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 71.8 p -97.31 177.26 5.61 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 121.523 0.678 . . . . 0.0 110.553 -178.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -83.03 -17.95 41.48 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 114.869 -1.06 . . . . 0.0 109.655 179.06 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -92.26 -17.71 24.41 Favored 'General case' 0 N--CA 1.43 -1.446 0 CA-C-N 114.739 -1.119 . . . . 0.0 111.795 -177.65 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.05 29.22 2.43 Favored Glycine 0 CA--C 1.484 -1.885 0 C-N-CA 119.925 -1.131 . . . . 0.0 113.971 166.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.9 m -107.64 99.51 8.99 Favored 'General case' 0 N--CA 1.415 -2.216 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.054 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.07 116.36 28.74 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.584 177.513 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.514 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 64.0 mt -84.73 122.77 74.69 Favored Pre-proline 0 C--N 1.301 -1.528 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.712 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -75.33 170.95 19.22 Favored 'Trans proline' 0 C--O 1.246 0.886 0 C-N-CA 122.933 2.422 . . . . 0.0 111.995 -179.12 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.443 HG12 ' O ' ' A' ' 1' ' ' PHE . 34.4 mt -73.37 118.82 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.126 0.488 . . . . 0.0 111.002 -176.491 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 133.9 38.4 0.21 Allowed Glycine 0 C--N 1.301 -1.386 0 CA-C-N 115.238 -0.892 . . . . 0.0 111.334 177.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 72.02 176.3 26.71 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.542 -176.415 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.14 -177.94 28.83 Favored Glycine 0 C--N 1.296 -1.672 0 C-N-CA 120.103 -1.046 . . . . 0.0 111.219 176.624 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.459 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 52.5 p -141.03 150.31 42.84 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -139.29 165.03 28.27 Favored 'General case' 0 CA--C 1.474 -1.968 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.737 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -109.39 123.44 49.33 Favored 'General case' 0 C--N 1.262 -3.229 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 175.112 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.474 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.2 m -105.31 145.09 13.98 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.608 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.336 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -124.75 112.74 17.07 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-O 121.286 0.565 . . . . 0.0 110.764 -178.401 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.533 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -119.36 132.31 69.53 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.194 0 CA-C-N 115.126 -0.943 . . . . 0.0 111.627 -174.783 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -92.31 127.16 37.69 Favored 'General case' 0 C--N 1.288 -2.075 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.08 178.284 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -110.51 160.53 16.55 Favored 'General case' 0 C--N 1.288 -2.073 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.145 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -61.0 122.91 72.76 Favored Pre-proline 0 C--N 1.317 -0.808 0 O-C-N 124.107 0.879 . . . . 0.0 109.125 176.653 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.502 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 74.3 Cg_endo -74.65 4.31 4.67 Favored 'Trans proline' 0 C--O 1.237 0.462 0 C-N-CA 122.785 2.323 . . . . 0.0 113.088 -177.468 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.6 t -128.08 112.29 26.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 107.097 -1.445 . . . . 0.0 107.097 178.555 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.426 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.8 t -145.43 101.31 0.56 Allowed 'Isoleucine or valine' 0 C--O 1.181 -2.549 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 -178.219 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.444 ' H ' ' HG3' ' A' ' 32' ' ' GLN . 0.7 OUTLIER -92.38 150.55 20.75 Favored 'General case' 0 C--N 1.267 -2.987 0 O-C-N 122.16 -0.338 . . . . 0.0 111.214 179.416 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.437 HG22 ' O ' ' A' ' 112' ' ' VAL . 46.8 t -44.72 119.14 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 123.63 0.772 . . . . 0.0 111.363 175.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.12 2.5 54.61 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.482 -0.781 . . . . 0.0 112.743 -179.264 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.444 ' HG3' ' H ' ' A' ' 29' ' ' ASN . 1.7 mm-40 -73.83 -178.07 3.07 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 123.076 0.55 . . . . 0.0 111.448 175.331 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 20.4 t-20 -132.91 91.48 2.9 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 176.46 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.664 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.7 tp -92.26 146.44 23.71 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -179.177 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 48.5 t -133.2 129.92 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.838 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 -178.183 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.56 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 51.6 t -99.93 88.82 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.41 -2.446 0 N-CA-C 105.642 -1.984 . . . . 0.0 105.642 172.499 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -85.25 117.49 24.22 Favored 'General case' 0 CA--C 1.484 -1.561 0 C-N-CA 119.949 -0.7 . . . . 0.0 110.382 -176.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 82.4 mt -98.88 -1.84 39.15 Favored 'General case' 0 C--N 1.296 -1.744 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.365 -177.862 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.491 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 1.3 m -75.64 0.31 18.01 Favored 'General case' 0 CA--C 1.549 0.93 0 CA-C-O 122.394 1.093 . . . . 0.0 108.959 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.0 p -127.33 6.53 6.38 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 114.718 -1.128 . . . . 0.0 110.229 177.164 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.533 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 46.6 mm-40 -125.28 -22.46 4.36 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-O 121.082 0.467 . . . . 0.0 110.649 -175.161 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 36.6 mt -135.07 141.29 43.31 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 108.188 -1.042 . . . . 0.0 108.188 -175.805 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.491 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 41.4 m-85 -142.79 158.74 43.33 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 -177.5 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.601 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 17.0 t -138.66 147.25 42.62 Favored 'General case' 0 C--N 1.289 -2.029 0 C-N-CA 120.377 -0.529 . . . . 0.0 109.67 175.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.492 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 7.3 p-80 -119.96 130.05 54.59 Favored 'General case' 0 C--O 1.256 1.408 0 CA-C-O 122.323 1.059 . . . . 0.0 111.472 -178.435 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.407 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 22.3 p-10 -91.24 89.84 7.5 Favored 'General case' 0 C--N 1.278 -2.511 0 CA-C-O 122.968 1.366 . . . . 0.0 109.913 178.044 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -71.18 -24.79 62.31 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 113.875 -1.511 . . . . 0.0 111.377 -177.223 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 43.3 m-85 -126.06 79.37 69.44 Favored Pre-proline 0 N--CA 1.479 0.979 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 178.007 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.407 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 73.4 Cg_endo -85.56 -2.8 9.2 Favored 'Trans proline' 0 C--N 1.321 -0.892 0 C-N-CA 122.0 1.8 . . . . 0.0 113.528 -175.098 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -111.76 -23.76 10.42 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.068 -179.392 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.427 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.0 OUTLIER -99.42 -30.63 12.08 Favored 'General case' 0 C--N 1.292 -1.898 0 CA-C-O 121.837 0.827 . . . . 0.0 109.987 -175.329 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.601 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.5 mp -118.6 138.66 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.616 0 CA-C-N 114.898 -1.046 . . . . 0.0 108.308 -179.456 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.7 t -78.75 134.05 37.07 Favored 'General case' 0 N--CA 1.417 -2.1 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 174.344 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.495 ' O ' HG23 ' A' ' 94' ' ' VAL . 7.6 m-20 -80.14 107.17 12.71 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 -172.333 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 49.9 t80 -142.85 133.44 25.09 Favored 'General case' 0 C--N 1.284 -2.271 0 CA-C-N 116.331 -0.395 . . . . 0.0 109.999 -172.254 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.453 HG12 ' OH ' ' A' ' 77' ' ' TYR . 42.3 t -141.73 134.14 28.41 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 C-N-CA 123.374 0.67 . . . . 0.0 109.635 -178.449 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -143.81 115.48 8.17 Favored 'General case' 0 N--CA 1.434 -1.226 0 O-C-N 123.387 0.43 . . . . 0.0 111.335 177.555 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.537 HD12 ' O ' ' A' ' 130' ' ' ILE . 55.5 tp -54.57 110.78 0.68 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.584 0.706 . . . . 0.0 110.169 171.085 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.43 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 10.9 tp60 -58.85 -51.79 68.49 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 126.292 1.837 . . . . 0.0 111.828 179.24 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.43 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 6.9 ptp180 -169.73 157.35 6.89 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -176.275 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -137.38 136.56 8.33 Favored Glycine 0 N--CA 1.415 -2.756 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 -179.462 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 70.3 m -126.71 146.22 50.3 Favored 'General case' 0 C--N 1.283 -2.324 0 C-N-CA 123.093 0.557 . . . . 0.0 110.69 -175.275 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.503 ' HB2' ' CE2' ' A' ' 84' ' ' PHE . . . -109.96 156.79 20.0 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 -179.189 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.483 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 90.8 m-85 -155.9 -179.47 8.16 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 123.963 0.905 . . . . 0.0 109.075 -178.192 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.01 -139.22 48.98 Favored Glycine 0 N--CA 1.45 -0.396 0 O-C-N 123.621 0.576 . . . . 0.0 113.328 177.234 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.6 -9.05 87.37 Favored Glycine 0 C--O 1.201 -1.922 0 C-N-CA 120.329 -0.938 . . . . 0.0 111.379 178.166 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.74 HG21 ' HB ' ' A' ' 126' ' ' ILE . 87.5 t -70.81 -42.7 77.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 C-N-CA 123.137 0.575 . . . . 0.0 111.44 -176.583 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.499 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -83.4 -21.61 32.97 Favored 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.4 -0.92 . . . . 0.0 112.518 -179.649 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 21.0 m -101.05 -47.8 4.64 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 114.041 1.126 . . . . 0.0 114.041 -174.617 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 47.5 m-20 -96.71 -20.63 18.11 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 -175.039 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.664 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 92.0 m-85 -110.78 157.09 20.18 Favored 'General case' 0 N--CA 1.424 -1.75 0 C-N-CA 120.032 -0.667 . . . . 0.0 110.418 178.053 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.8 t -160.95 123.09 3.09 Favored 'General case' 0 N--CA 1.422 -1.853 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 177.097 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.527 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -158.48 -106.97 0.23 Allowed Glycine 0 N--CA 1.412 -2.93 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 177.456 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -165.2 -179.4 5.6 Favored 'General case' 0 C--N 1.313 -0.998 0 C-N-CA 124.525 1.13 . . . . 0.0 110.358 -175.389 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.6 p -131.93 148.3 32.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 C-N-CA 123.626 0.77 . . . . 0.0 109.301 177.363 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.614 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.3 tttt -126.12 143.27 51.19 Favored 'General case' 0 N--CA 1.426 -1.638 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.497 ' CD1' HG22 ' A' ' 105' ' ' VAL . 67.5 t80 -144.31 110.12 5.32 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.258 -177.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 25.3 t 51.24 40.71 26.74 Favored 'General case' 0 CA--C 1.551 0.983 0 C-N-CA 123.584 0.754 . . . . 0.0 111.526 177.576 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.83 14.01 61.7 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.333 -0.937 . . . . 0.0 113.811 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.614 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 13.0 t -86.48 -178.9 6.53 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 175.772 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 26.1 p -159.48 103.78 1.6 Allowed 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.513 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.433 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.9 p90 -149.53 160.13 34.93 Favored Pre-proline 0 C--N 1.303 -1.428 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 -173.057 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.431 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 42.5 Cg_endo -67.25 146.92 77.46 Favored 'Trans proline' 0 C--N 1.358 1.053 0 C-N-CA 122.837 2.358 . . . . 0.0 112.887 -177.071 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.569 ' CD2' HD21 ' A' ' 109' ' ' LEU . 64.2 t80 -122.63 134.59 25.03 Favored Pre-proline 0 N--CA 1.435 -1.223 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.432 -179.769 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.517 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 64.3 Cg_endo -71.08 147.06 86.51 Favored 'Cis proline' 0 CA--C 1.54 0.786 0 C-N-CA 123.229 -1.571 . . . . 0.0 110.602 -2.497 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.8 t -64.68 -176.8 0.27 Allowed 'General case' 0 C--O 1.248 0.981 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.685 -175.403 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 16.8 p -130.31 0.73 4.6 Favored 'General case' 0 N--CA 1.424 -1.761 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.014 -171.133 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 26.5 t -161.36 -137.51 0.04 OUTLIER 'General case' 0 N--CA 1.379 -3.993 0 N-CA-C 106.56 -1.645 . . . . 0.0 106.56 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -121.39 156.58 32.36 Favored 'General case' 0 C--N 1.267 -2.991 0 C-N-CA 127.015 2.126 . . . . 0.0 107.337 -172.309 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.475 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 19.6 p -78.6 162.37 65.94 Favored Pre-proline 0 C--N 1.302 -1.483 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 -177.396 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.99 165.49 5.0 Favored 'Trans proline' 0 C--N 1.359 1.104 0 C-N-CA 124.044 3.163 . . . . 0.0 112.148 174.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.6 tmm_? -70.3 119.7 14.87 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 114.759 -1.11 . . . . 0.0 109.657 -176.083 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 60.4 t -131.27 130.35 63.13 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 C-N-CA 123.671 0.788 . . . . 0.0 110.211 -175.531 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.495 HG23 ' O ' ' A' ' 54' ' ' ASP . 1.4 p -129.74 125.45 61.03 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.953 0 CA-C-N 115.009 -0.996 . . . . 0.0 110.341 -174.884 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -73.15 104.08 4.1 Favored 'General case' 0 C--O 1.211 -0.938 0 CA-C-O 121.105 0.478 . . . . 0.0 111.092 -178.519 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -90.11 62.55 5.56 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-O 121.016 0.436 . . . . 0.0 109.836 179.197 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.0 t -152.59 -170.07 3.53 Favored 'General case' 0 N--CA 1.437 -1.092 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 -178.288 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 17.0 ptm180 -149.1 38.34 0.8 Allowed 'General case' 0 C--N 1.316 -0.875 0 CA-C-O 121.014 0.435 . . . . 0.0 110.437 -176.833 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 12.6 t -159.51 -177.8 6.67 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -178.007 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ASP . . . . . 0.492 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 9.6 p-10 -79.45 99.92 7.44 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-O 122.41 1.1 . . . . 0.0 109.653 -179.231 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' LYS . . . . . 0.533 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 7.0 mmpt? -102.37 149.73 36.93 Favored Pre-proline 0 C--N 1.296 -1.749 0 CA-C-N 114.535 -1.212 . . . . 0.0 109.755 -177.836 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.491 ' HB3' ' O ' ' A' ' 39' ' ' SER . 22.5 Cg_exo -59.16 153.35 53.12 Favored 'Trans proline' 0 N--CA 1.449 -1.133 0 C-N-CA 123.36 2.707 . . . . 0.0 112.907 178.089 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 12.6 t90 -95.75 102.15 9.65 Favored Pre-proline 0 C--N 1.289 -2.053 0 N-CA-C 105.688 -1.967 . . . . 0.0 105.688 176.357 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.401 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 56.5 Cg_endo -73.93 88.96 1.04 Allowed 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 122.079 1.852 . . . . 0.0 112.956 -172.267 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.497 HG22 ' CD1' ' A' ' 77' ' ' TYR . 59.9 t -138.75 146.45 26.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.91 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.56 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.57 135.67 16.63 Favored 'General case' 0 C--N 1.287 -2.144 0 CA-C-O 120.89 0.376 . . . . 0.0 110.414 178.033 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.5 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 15.6 mt -101.25 103.12 14.12 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.447 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.527 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 45.5 m-85 -82.2 73.23 9.25 Favored 'General case' 0 C--N 1.293 -1.863 0 O-C-N 122.279 -0.263 . . . . 0.0 110.824 178.369 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.664 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -98.5 136.03 39.2 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 176.867 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -137.5 144.73 46.26 Favored Pre-proline 0 C--N 1.293 -1.883 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.098 -175.199 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -62.38 122.31 10.67 Favored 'Trans proline' 0 C--O 1.248 0.99 0 C-N-CA 123.537 2.825 . . . . 0.0 113.12 -176.14 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.437 ' O ' HG22 ' A' ' 30' ' ' VAL . 2.7 m -73.85 -120.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.168 -3.201 0 CA-C-N 114.507 -1.224 . . . . 0.0 112.344 174.806 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 27.9 t -111.94 -32.37 6.62 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 -179.116 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 68.3 m -79.97 21.6 0.55 Allowed 'General case' 0 N--CA 1.398 -3.07 0 C-N-CA 125.612 1.565 . . . . 0.0 112.777 -179.532 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -107.5 128.16 54.25 Favored 'General case' 0 N--CA 1.412 -2.326 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 -179.218 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.63 133.09 2.71 Favored Glycine 0 C--N 1.297 -1.605 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 -179.24 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 62.47 -148.55 49.02 Favored Glycine 0 CA--C 1.489 -1.567 0 CA-C-O 119.24 -0.755 . . . . 0.0 111.782 -177.573 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 60.7 t -56.93 105.72 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 117.225 0.513 . . . . 0.0 110.536 -178.283 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -102.97 -40.93 6.3 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.58 179.481 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.521 ' HB ' HG22 ' A' ' 154' ' ' VAL . 72.7 mt -115.29 137.66 48.11 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 178.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.501 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.9 mmpt? -115.07 136.63 52.92 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-O 121.289 0.566 . . . . 0.0 111.636 178.885 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.15 126.87 30.91 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.828 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 92.95 -5.13 75.83 Favored Glycine 0 N--CA 1.437 -1.298 0 CA-C-N 115.694 -0.684 . . . . 0.0 111.756 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 21.2 m -94.91 145.17 25.1 Favored 'General case' 0 N--CA 1.428 -1.544 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 179.802 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.454 HD11 HG23 ' A' ' 128' ' ' VAL . 2.9 tm? -71.35 124.74 25.25 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 108.204 -1.035 . . . . 0.0 108.204 178.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.74 ' HB ' HG21 ' A' ' 67' ' ' VAL . 31.8 pt -111.09 -25.36 3.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 112.322 0.49 . . . . 0.0 112.322 -179.002 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' ALA . . . . . 0.448 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -162.05 167.51 24.24 Favored 'General case' 0 CA--C 1.508 -0.653 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 -178.022 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.454 HG23 HD11 ' A' ' 125' ' ' LEU . 63.8 t -142.3 116.02 4.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 178.878 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.49 HD11 HD21 ' A' ' 107' ' ' LEU . 67.9 mt -119.02 146.99 44.59 Favored 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.613 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.537 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.4 mp -127.73 126.38 66.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 C-N-CA 119.271 -0.972 . . . . 0.0 110.832 177.519 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.55 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.3 OUTLIER -88.1 145.5 25.91 Favored 'General case' 0 C--N 1.283 -2.313 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 176.332 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.44 HH11 ' HD2' ' A' ' 132' ' ' ARG . 16.2 ttp180 -128.58 130.08 46.86 Favored 'General case' 0 C--N 1.277 -2.549 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 173.023 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 8.6 tm0? -108.71 129.04 55.36 Favored 'General case' 0 N--CA 1.412 -2.347 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 -178.728 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 6.9 m -135.75 139.75 43.82 Favored 'General case' 0 C--N 1.287 -2.116 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.601 ' CB ' HG23 ' A' ' 52' ' ' ILE . 9.4 p30 -133.09 178.78 6.63 Favored 'General case' 0 N--CA 1.433 -1.278 0 C-N-CA 117.309 -1.756 . . . . 0.0 113.449 177.927 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -88.34 -31.86 18.7 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 121.577 0.703 . . . . 0.0 111.261 -174.143 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 9.5 t80 -82.38 -63.58 1.35 Allowed 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.135 -0.938 . . . . 0.0 110.165 -173.894 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 7.8 m-20 -94.56 149.39 21.29 Favored 'General case' 0 C--N 1.287 -2.14 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.606 176.714 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 41.8 m -96.36 27.67 3.65 Favored 'General case' 0 C--N 1.279 -2.483 0 CA-C-N 115.187 -0.915 . . . . 0.0 108.919 179.135 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 140' ' ' ASP . . . . . 0.532 ' HB3' ' CE2' ' A' ' 142' ' ' PHE . 24.6 m-20 -82.38 90.3 6.68 Favored 'General case' 0 CA--C 1.499 -1.017 0 CA-C-N 114.765 -1.107 . . . . 0.0 110.447 179.841 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 141' ' ' ASP . . . . . 0.427 ' OD2' ' HD2' ' A' ' 132' ' ' ARG . 27.6 t70 -93.01 85.35 5.09 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-N 114.985 -1.007 . . . . 0.0 108.461 -179.498 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 142' ' ' PHE . . . . . 0.532 ' CE2' ' HB3' ' A' ' 140' ' ' ASP . 43.7 m-85 -101.35 146.07 28.06 Favored 'General case' 0 C--N 1.312 -1.064 0 O-C-N 122.176 -0.328 . . . . 0.0 110.238 -178.593 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 7.1 pt20 -123.54 134.73 53.81 Favored 'General case' 0 N--CA 1.423 -1.806 0 C-N-CA 119.838 -0.745 . . . . 0.0 111.102 177.512 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 6.9 m-30 -107.57 125.66 51.58 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 -176.602 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.459 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 46.9 t -89.51 135.28 26.46 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 CA-C-O 121.161 0.505 . . . . 0.0 110.284 -178.473 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' TRP . . . . . 0.55 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 64.8 m95 -122.12 102.53 8.2 Favored 'General case' 0 C--N 1.281 -2.377 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.692 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.8 m-80 -81.65 109.22 15.87 Favored 'General case' 0 C--N 1.289 -2.025 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 178.04 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.474 ' HA ' HG22 ' A' ' 20' ' ' VAL . 21.3 mm -82.47 119.92 32.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 -177.191 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 -116.77 151.6 36.12 Favored 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 123.169 0.588 . . . . 0.0 109.678 178.469 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.14 128.92 34.28 Favored 'General case' 0 N--CA 1.411 -2.399 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 177.119 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -91.38 -11.36 38.03 Favored 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 107.435 -1.32 . . . . 0.0 107.435 -177.563 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -153.22 143.01 22.03 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 114.292 -1.322 . . . . 0.0 109.379 -177.053 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -84.26 145.68 28.18 Favored 'General case' 0 C--N 1.316 -0.85 0 O-C-N 123.971 0.795 . . . . 0.0 109.553 -179.02 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.521 HG22 ' HB ' ' A' ' 120' ' ' ILE . 1.6 m -124.44 147.48 28.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.855 -178.248 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.7 t -120.14 139.93 45.85 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.538 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 -179.626 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.426 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 70.5 t -100.93 100.3 12.52 Favored Pre-proline 0 C--N 1.29 -1.983 0 C-N-CA 123.666 0.786 . . . . 0.0 109.402 177.336 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.422 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 29.7 Cg_endo -68.18 -23.95 38.76 Favored 'Trans proline' 0 CA--C 1.517 -0.365 0 C-N-CA 122.427 2.085 . . . . 0.0 111.649 178.038 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.405 ' HB ' HG12 ' A' ' 156' ' ' VAL 0.269 5.3 t . . . . . 0 C--O 1.249 1.058 0 O-C-N 125.0 1.437 . . . . 0.0 113.383 177.845 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.588 ' CZ ' ' HB3' ' A' ' 133' ' ' GLN . 0.1 OUTLIER . . . . . 0 CA--C 1.487 -1.443 0 N-CA-C 105.418 -2.067 . . . . 0.0 105.418 . . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -148.32 174.51 11.95 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.588 -0.845 . . . . 0.0 111.49 -173.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.42 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 77.0 m -137.4 152.18 49.36 Favored 'General case' 0 N--CA 1.429 -1.496 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.958 -177.414 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -141.17 167.13 22.91 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.763 -178.093 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.523 HG22 HG22 ' A' ' 20' ' ' VAL . 82.5 p -103.67 171.88 7.12 Favored 'General case' 0 CA--C 1.497 -1.066 0 CA-C-O 121.483 0.658 . . . . 0.0 110.733 -179.276 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.96 -4.82 54.09 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-N 114.034 -1.439 . . . . 0.0 111.755 178.325 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -96.88 -30.92 12.85 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 118.184 -1.407 . . . . 0.0 109.314 177.829 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 139.13 0.46 2.16 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 119.896 -1.145 . . . . 0.0 113.047 175.388 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -81.07 105.25 12.14 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -100.85 119.45 38.68 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 176.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 60.3 mt -90.76 123.83 63.91 Favored Pre-proline 0 C--N 1.3 -1.567 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -80.66 168.75 17.53 Favored 'Trans proline' 0 C--O 1.248 0.98 0 C-N-CA 122.7 2.267 . . . . 0.0 111.173 178.049 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.1 mt -63.75 127.56 24.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 133.77 8.72 2.12 Favored Glycine 0 C--N 1.319 -0.373 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.612 -179.562 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 86.69 172.69 48.61 Favored Glycine 0 C--N 1.318 -0.425 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.415 -177.542 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.45 -168.78 30.97 Favored Glycine 0 C--N 1.299 -1.526 0 C-N-CA 119.916 -1.135 . . . . 0.0 111.498 177.1 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 14.4 p -140.1 155.81 46.84 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.401 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -143.63 162.24 36.43 Favored 'General case' 0 N--CA 1.424 -1.736 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 177.308 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -107.83 116.18 31.48 Favored 'General case' 0 C--N 1.281 -2.388 0 CA-C-N 114.808 -1.087 . . . . 0.0 108.746 177.57 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.523 HG22 HG22 ' A' ' 5' ' ' THR . 44.1 t -103.86 135.03 43.44 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.008 0 CA-C-N 115.133 -0.94 . . . . 0.0 108.668 179.202 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 -122.99 134.78 54.31 Favored 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -179.113 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.51 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.5 p -144.42 136.29 21.87 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.674 0 O-C-N 123.727 0.642 . . . . 0.0 111.095 -178.722 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 47.9 m-80 -89.67 126.79 35.78 Favored 'General case' 0 C--N 1.296 -1.76 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.458 178.442 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.408 HD11 HG22 ' A' ' 36' ' ' VAL . 2.7 mm? -106.56 161.19 14.83 Favored 'General case' 0 C--N 1.283 -2.298 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 177.631 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.8 124.81 81.19 Favored Pre-proline 0 C--N 1.315 -0.933 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 175.789 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.466 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 68.1 Cg_endo -74.83 0.84 8.33 Favored 'Trans proline' 0 N--CA 1.474 0.382 0 C-N-CA 122.954 2.436 . . . . 0.0 113.021 -177.253 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.476 HG13 ' HG3' ' A' ' 157' ' ' PRO . 87.3 t -129.6 111.85 23.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.7 t -143.33 114.94 2.73 Favored 'Isoleucine or valine' 0 C--O 1.182 -2.489 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -177.219 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.725 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -104.98 148.68 26.46 Favored 'General case' 0 C--N 1.271 -2.819 0 O-C-N 121.987 -0.445 . . . . 0.0 110.91 -179.447 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.499 HG22 ' O ' ' A' ' 112' ' ' VAL . 95.8 t -47.97 116.93 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 123.082 0.553 . . . . 0.0 111.377 178.702 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 109.41 -9.25 32.96 Favored Glycine 0 C--N 1.307 -1.033 0 CA-C-N 115.238 -0.892 . . . . 0.0 112.357 -178.602 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.725 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -67.87 -177.62 0.84 Allowed 'General case' 0 CA--C 1.508 -0.672 0 C-N-CA 124.631 1.172 . . . . 0.0 110.956 179.63 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 63.8 t30 -129.89 92.12 3.26 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 178.231 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.641 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.8 tp -94.25 142.52 27.31 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 119.056 -1.057 . . . . 0.0 109.301 179.226 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 39.6 t -132.34 124.78 52.72 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.215 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 -175.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.552 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 47.3 t -96.19 87.82 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.4 -2.931 0 N-CA-C 105.26 -2.126 . . . . 0.0 105.26 172.107 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -82.5 112.55 19.53 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 120.962 0.411 . . . . 0.0 110.984 -177.757 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 84.6 mt -98.21 0.31 45.56 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.017 -178.725 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.4 m -76.35 1.67 15.59 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-O 122.332 1.063 . . . . 0.0 109.045 -179.576 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.8 p -130.64 5.58 4.69 Favored 'General case' 0 N--CA 1.428 -1.562 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.15 176.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.51 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 49.7 mm-40 -124.38 -22.12 4.77 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 121.193 0.521 . . . . 0.0 111.019 -174.684 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.2 mt -131.56 140.83 47.31 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 -176.231 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.451 ' HA ' ' HA ' ' A' ' 102' ' ' PRO . 69.0 m-85 -139.25 154.93 48.06 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -174.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.42 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 96.2 m -137.69 136.52 37.48 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 123.751 0.82 . . . . 0.0 110.787 -179.646 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.4 p-80 -131.92 129.67 40.58 Favored 'General case' 0 C--N 1.295 -1.761 0 CA-C-O 122.381 1.086 . . . . 0.0 112.123 -177.581 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.735 ' OD1' ' HA ' ' A' ' 49' ' ' PRO . 3.3 t-20 -85.23 92.07 8.32 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-N 114.446 -1.252 . . . . 0.0 107.928 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ASP . . . . . 0.43 ' H ' ' HA ' ' A' ' 1' ' ' PHE . 20.1 m-20 -54.48 -36.6 64.33 Favored 'General case' 0 N--CA 1.493 1.684 0 C-N-CA 123.475 0.71 . . . . 0.0 111.069 -178.255 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 44.7 m-85 -122.46 86.0 48.35 Favored Pre-proline 0 C--N 1.299 -1.599 0 N-CA-C 108.223 -1.028 . . . . 0.0 108.223 -175.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.735 ' HA ' ' OD1' ' A' ' 46' ' ' ASN . 72.7 Cg_endo -73.19 -5.98 18.12 Favored 'Trans proline' 0 CA--C 1.508 -0.81 0 C-N-CA 122.486 2.124 . . . . 0.0 115.081 -170.128 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -121.3 -20.35 6.72 Favored 'General case' 0 C--N 1.282 -2.342 0 CA-C-O 121.268 0.556 . . . . 0.0 110.649 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.56 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.6 m -98.4 -30.7 12.41 Favored 'General case' 0 N--CA 1.414 -2.231 0 C-N-CA 119.54 -0.864 . . . . 0.0 109.102 -170.785 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.567 HG23 ' HB2' ' A' ' 135' ' ' ASN . 2.7 mp -130.03 123.72 56.89 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 CA-C-N 114.878 -1.055 . . . . 0.0 110.035 -175.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 4.4 t -75.71 134.67 40.46 Favored 'General case' 0 N--CA 1.425 -1.684 0 N-CA-C 106.08 -1.822 . . . . 0.0 106.08 173.597 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.57 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 9.5 t70 -90.31 108.88 20.04 Favored 'General case' 0 C--N 1.271 -2.806 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 -178.431 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.585 ' CD2' ' HB ' ' A' ' 134' ' ' THR . 4.7 t80 -128.47 110.06 11.96 Favored 'General case' 0 C--N 1.291 -1.938 0 CA-C-O 122.109 0.957 . . . . 0.0 110.93 -175.22 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.433 ' HA ' ' O ' ' A' ' 132' ' ' ARG . 73.9 t -114.7 142.17 28.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 CA-C-N 113.629 -1.623 . . . . 0.0 110.94 -177.749 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.3 p -143.67 134.18 24.84 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 170.061 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.542 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.8 OUTLIER -73.51 109.97 7.44 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 175.771 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 10.2 tp60 -57.58 -62.2 1.96 Allowed 'General case' 0 C--O 1.202 -1.428 0 C-N-CA 125.416 1.486 . . . . 0.0 109.958 -178.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.91 146.11 14.26 Favored 'General case' 0 N--CA 1.418 -2.072 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 -178.216 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -126.68 137.66 10.15 Favored Glycine 0 N--CA 1.398 -3.852 0 N-CA-C 108.193 -1.963 . . . . 0.0 108.193 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 63.4 m -124.0 148.29 47.1 Favored 'General case' 0 C--N 1.268 -2.949 0 C-N-CA 123.599 0.76 . . . . 0.0 109.33 -175.057 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.519 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -114.27 158.1 21.85 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 -179.593 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.432 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 85.0 m-85 -156.35 -178.42 7.32 Favored 'General case' 0 C--O 1.243 0.719 0 C-N-CA 124.214 1.005 . . . . 0.0 108.347 -178.111 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.79 -138.14 49.7 Favored Glycine 0 N--CA 1.452 -0.299 0 O-C-N 123.596 0.56 . . . . 0.0 112.81 178.562 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.91 -9.41 85.42 Favored Glycine 0 C--O 1.205 -1.706 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.651 177.713 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.747 HG21 ' HB ' ' A' ' 126' ' ' ILE . 84.5 t -68.53 -42.92 83.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 C-N-CA 122.934 0.493 . . . . 0.0 111.362 -177.508 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.519 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -82.45 -17.65 44.56 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.331 -0.948 . . . . 0.0 112.133 179.603 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 14.6 t -100.74 -59.64 1.66 Allowed 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.971 -172.631 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.456 ' O ' HG22 ' A' ' 112' ' ' VAL . 44.2 m-20 -91.1 -23.51 20.28 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.672 -172.323 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.669 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 93.1 m-85 -106.7 155.62 19.49 Favored 'General case' 0 N--CA 1.42 -1.959 0 C-N-CA 119.647 -0.821 . . . . 0.0 109.532 177.077 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.5 t -163.18 126.99 2.85 Favored 'General case' 0 N--CA 1.41 -2.464 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.419 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.416 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -163.07 -109.59 0.23 Allowed Glycine 0 N--CA 1.407 -3.287 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 177.294 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -159.99 178.69 9.46 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 123.348 0.659 . . . . 0.0 110.273 -173.739 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -131.77 142.85 42.01 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 178.171 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.708 ' HG3' ' O ' ' A' ' 80' ' ' SER . 71.7 tttt -118.76 139.12 52.08 Favored 'General case' 0 N--CA 1.423 -1.814 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.793 -179.573 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.494 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 67.5 t80 -138.96 110.05 6.83 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.071 -178.913 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.6 t 49.68 41.92 22.61 Favored 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 124.133 0.973 . . . . 0.0 111.937 174.833 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.43 11.03 63.04 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 120.519 -0.848 . . . . 0.0 113.746 179.265 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.708 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 10.1 t -93.56 177.84 5.89 Favored 'General case' 0 C--O 1.206 -1.219 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 176.694 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 74.9 m -160.02 105.52 1.56 Allowed 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 177.813 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.494 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 5.8 p90 -142.64 164.53 32.1 Favored Pre-proline 0 C--N 1.297 -1.688 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 -172.46 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.474 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 73.9 Cg_endo -71.95 148.26 51.03 Favored 'Trans proline' 0 C--N 1.352 0.731 0 C-N-CA 122.376 2.051 . . . . 0.0 113.402 -174.436 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.627 ' CD2' HD21 ' A' ' 109' ' ' LEU . 55.3 t80 -120.7 139.7 29.39 Favored Pre-proline 0 N--CA 1.429 -1.499 0 CA-C-N 115.608 -0.723 . . . . 0.0 109.267 179.398 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.606 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 55.8 Cg_endo -70.12 144.54 77.7 Favored 'Cis proline' 0 CA--C 1.537 0.653 0 C-N-CA 123.115 -1.619 . . . . 0.0 110.541 -4.848 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 5.6 t -67.44 -179.59 1.08 Allowed 'General case' 0 CA--C 1.556 1.182 0 CA-C-O 121.081 0.467 . . . . 0.0 111.236 -175.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 22.1 p -131.11 -24.63 2.32 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -168.439 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 24.8 t -129.84 -68.5 0.71 Allowed 'General case' 0 C--N 1.31 -1.117 0 C-N-CA 119.854 -0.738 . . . . 0.0 110.83 -173.36 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 178.77 -177.01 0.25 Allowed 'General case' 0 C--O 1.243 0.747 0 C-N-CA 124.454 1.102 . . . . 0.0 108.44 175.631 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.542 HG23 ' HB3' ' A' ' 58' ' ' LEU . 48.9 p -100.15 166.9 11.85 Favored Pre-proline 0 C--N 1.302 -1.477 0 O-C-N 123.582 0.551 . . . . 0.0 110.978 177.324 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -57.89 160.21 15.82 Favored 'Trans proline' 0 C--O 1.248 1.012 0 C-N-CA 123.027 2.484 . . . . 0.0 110.941 171.713 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.538 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 0.8 OUTLIER -72.32 120.51 18.03 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.368 -177.26 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 57.5 t -129.42 119.01 47.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.893 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 97.6 t -105.64 132.5 52.44 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 CA-C-N 115.12 -0.945 . . . . 0.0 108.868 177.04 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.57 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 11.8 m-85 -81.6 112.07 18.48 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 175.746 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -103.69 75.73 1.33 Allowed 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 -179.493 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 70.7 m -161.08 170.05 21.23 Favored 'General case' 0 C--N 1.318 -0.801 0 C-N-CA 124.303 1.041 . . . . 0.0 109.435 -177.907 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.0 ptm180 -128.06 38.78 3.96 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-O 121.946 0.879 . . . . 0.0 110.07 178.013 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.8 t -156.72 167.73 29.56 Favored 'General case' 0 N--CA 1.426 -1.648 0 N-CA-C 107.272 -1.381 . . . . 0.0 107.272 -177.134 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -73.69 123.58 24.34 Favored 'General case' 0 C--N 1.311 -1.1 0 O-C-N 123.784 0.677 . . . . 0.0 110.579 -178.594 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.5 mptm? -120.07 144.23 37.22 Favored Pre-proline 0 C--N 1.28 -2.428 0 CA-C-N 114.642 -1.163 . . . . 0.0 108.558 179.527 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.451 ' HA ' ' HA ' ' A' ' 43' ' ' PHE . 43.3 Cg_endo -65.9 150.13 85.91 Favored 'Trans proline' 0 C--O 1.248 1.009 0 C-N-CA 122.242 1.961 . . . . 0.0 111.456 177.343 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 16.4 t90 -87.16 105.26 7.82 Favored Pre-proline 0 C--N 1.315 -0.912 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 -179.576 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 64.4 Cg_endo -74.69 88.53 1.19 Allowed 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 121.544 1.496 . . . . 0.0 112.58 -173.241 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 97.4 t -138.44 142.88 33.93 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.309 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.106 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.552 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.94 132.5 16.75 Favored 'General case' 0 N--CA 1.41 -2.428 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.109 178.51 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.512 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 19.5 mt -97.05 102.37 14.13 Favored 'General case' 0 C--N 1.287 -2.123 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.639 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.416 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 63.0 m-85 -83.11 74.39 9.99 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-O 121.105 0.479 . . . . 0.0 110.231 177.45 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.669 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 2.8 mm? -97.93 130.35 44.81 Favored 'General case' 0 CA--C 1.484 -1.582 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 175.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -135.05 144.09 48.73 Favored Pre-proline 0 N--CA 1.397 -3.077 0 N-CA-C 108.947 -0.761 . . . . 0.0 108.947 -174.452 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -63.13 126.72 18.49 Favored 'Trans proline' 0 CA--C 1.496 -1.401 0 C-N-CA 123.2 2.6 . . . . 0.0 113.993 -174.395 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.499 ' O ' HG22 ' A' ' 30' ' ' VAL . 16.1 m -91.65 -158.03 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.395 -3.206 0 CA-C-N 114.221 -1.354 . . . . 0.0 108.66 171.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 29.4 m -76.0 -32.01 59.21 Favored 'General case' 0 C--N 1.26 -3.322 0 CA-C-O 121.366 0.603 . . . . 0.0 110.883 -168.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 7.2 t -80.26 10.12 4.9 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-O 121.736 0.779 . . . . 0.0 110.64 -177.3 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.4 ' HB1' HG21 ' A' ' 156' ' ' VAL . . . -95.09 135.55 36.5 Favored 'General case' 0 N--CA 1.42 -1.955 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.002 179.005 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -179.6 132.07 1.78 Allowed Glycine 0 N--CA 1.433 -1.517 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 63.6 -150.05 49.92 Favored Glycine 0 C--N 1.306 -1.133 0 CA-C-O 119.167 -0.796 . . . . 0.0 112.128 -177.247 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -56.7 103.82 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.242 0.679 0 CA-C-O 122.404 1.097 . . . . 0.0 111.804 -177.402 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -103.24 -36.77 7.96 Favored 'General case' 0 C--N 1.293 -1.884 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.676 -178.695 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.528 ' HB ' HG22 ' A' ' 154' ' ' VAL . 73.1 mt -120.54 138.47 50.92 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.706 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.436 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.9 mmpt? -112.99 140.05 48.13 Favored 'General case' 0 C--N 1.313 -1.009 0 C-N-CA 122.727 0.411 . . . . 0.0 110.171 177.655 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -73.5 134.74 43.95 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.03 179.091 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 82.95 4.59 89.94 Favored Glycine 0 C--N 1.314 -0.648 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -178.524 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 8.5 t -100.87 140.7 34.79 Favored 'General case' 0 N--CA 1.415 -2.214 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -178.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.43 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -71.4 122.15 19.84 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 178.201 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.747 ' HB ' HG21 ' A' ' 67' ' ' VAL . 34.2 pt -109.48 -27.21 2.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.218 -177.872 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -160.57 166.99 28.05 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 -177.554 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.43 HG23 HD11 ' A' ' 125' ' ' LEU . 59.7 t -143.06 114.93 2.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 179.184 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.464 HD11 HD21 ' A' ' 107' ' ' LEU . 34.3 mt -118.2 135.83 54.01 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.639 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 4.3 mp -115.72 128.05 73.1 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 C-N-CA 118.636 -1.226 . . . . 0.0 109.937 177.8 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.526 HD23 ' O ' ' A' ' 131' ' ' LEU . 0.0 OUTLIER -97.05 133.5 41.63 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.159 178.497 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.433 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 7.4 mmm180 -91.72 127.48 37.19 Favored 'General case' 0 C--N 1.281 -2.396 0 C-N-CA 123.714 0.806 . . . . 0.0 109.374 176.709 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.588 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 20.1 mm-40 -103.98 130.52 51.63 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 105.75 -1.944 . . . . 0.0 105.75 174.087 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.585 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 12.9 m -145.2 143.92 30.56 Favored 'General case' 0 C--N 1.273 -2.757 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 177.396 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.567 ' HB2' HG23 ' A' ' 52' ' ' ILE . 19.3 p30 -142.93 159.4 42.32 Favored 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 119.695 -0.802 . . . . 0.0 110.624 179.058 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -86.74 -6.38 58.84 Favored 'General case' 0 C--N 1.309 -1.184 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.477 -170.511 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 58.4 t80 -108.07 -67.32 0.97 Allowed 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.647 -172.157 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -82.84 -26.16 31.92 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -177.009 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 23.8 t 67.87 43.27 1.75 Allowed 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 -171.397 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 -70.86 62.96 0.29 Allowed 'General case' 0 N--CA 1.482 1.17 0 CA-C-N 114.828 -1.078 . . . . 0.0 110.009 175.506 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' ASP . . . . . 0.424 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 1.3 m-20 -77.62 66.04 3.24 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 125.046 1.338 . . . . 0.0 110.932 -178.851 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 76.4 m-85 -110.04 167.32 10.26 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.204 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -137.27 141.27 41.97 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.662 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.48 ' HB2' HD22 ' A' ' 131' ' ' LEU . 5.4 m-30 -108.58 131.66 54.64 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -176.165 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 48.1 t -90.89 127.52 43.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 O-C-N 123.579 0.549 . . . . 0.0 109.893 -178.84 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 146' ' ' TRP . . . . . 0.515 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 65.3 m95 -114.88 100.07 7.95 Favored 'General case' 0 C--N 1.273 -2.728 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 -178.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 42.2 m-80 -82.67 112.83 19.89 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 23.0 mm -88.45 121.09 38.32 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -177.434 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -116.79 149.07 40.56 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 177.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.09 131.43 35.3 Favored 'General case' 0 N--CA 1.41 -2.453 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 176.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 13.9 t-20 -91.03 -11.24 39.4 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 -178.246 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -147.88 142.85 26.94 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.155 -176.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -85.62 136.8 33.23 Favored 'General case' 0 C--N 1.313 -1.0 0 O-C-N 123.97 0.794 . . . . 0.0 109.663 178.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.528 HG22 ' HB ' ' A' ' 120' ' ' ILE . 1.5 m -119.92 149.52 22.6 Favored 'Isoleucine or valine' 0 C--O 1.254 1.316 0 CA-C-O 120.928 0.394 . . . . 0.0 110.785 -175.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -121.53 142.69 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.276 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -179.376 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.545 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.5 t -102.56 102.37 25.6 Favored Pre-proline 0 C--N 1.296 -1.745 0 C-N-CA 123.384 0.674 . . . . 0.0 109.82 178.131 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.476 ' HG3' HG13 ' A' ' 27' ' ' VAL . 29.2 Cg_endo -67.5 -28.64 38.3 Favored 'Trans proline' 0 CA--C 1.506 -0.878 0 C-N-CA 122.295 1.997 . . . . 0.0 111.7 177.519 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.255 6.1 t . . . . . 0 C--O 1.256 1.401 0 O-C-N 124.483 1.114 . . . . 0.0 112.519 178.809 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.511 ' CE2' ' HB3' ' A' ' 133' ' ' GLN 1.002 17.1 m-85 . . . . . 0 CA--C 1.46 -2.514 0 N-CA-C 119.514 3.153 . . . . 0.0 119.514 . . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -131.7 140.85 49.4 Favored 'General case' 0 C--N 1.271 -2.822 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 167.188 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.58 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 11.1 m -126.01 163.05 23.88 Favored 'General case' 0 C--N 1.26 -3.31 0 C-N-CA 119.148 -1.021 . . . . 0.0 109.155 -171.94 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.436 ' HA ' ' O ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -146.35 159.25 43.62 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-O 120.958 0.409 . . . . 0.0 110.522 -174.479 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.512 HG22 HG22 ' A' ' 20' ' ' VAL . 73.4 p -99.62 176.13 5.58 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 121.277 0.561 . . . . 0.0 111.09 -179.382 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.52 -12.93 59.85 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.186 178.175 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -89.48 -31.31 17.73 Favored 'General case' 0 N--CA 1.435 -1.213 0 C-N-CA 119.081 -1.047 . . . . 0.0 109.896 175.789 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.48 5.66 3.22 Favored Glycine 0 N--CA 1.44 -1.054 0 C-N-CA 119.325 -1.417 . . . . 0.0 113.743 175.354 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.436 ' O ' ' HA ' ' A' ' 4' ' ' LYS . 5.1 m -79.18 99.62 7.09 Favored 'General case' 0 N--CA 1.433 -1.276 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 -179.736 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.53 117.92 30.46 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 176.369 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 71.5 mt -93.46 123.29 60.76 Favored Pre-proline 0 C--N 1.297 -1.68 0 N-CA-C 108.498 -0.926 . . . . 0.0 108.498 179.292 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -77.81 167.47 23.81 Favored 'Trans proline' 0 C--O 1.248 0.982 0 C-N-CA 122.84 2.36 . . . . 0.0 111.498 179.261 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.428 HG12 ' O ' ' A' ' 1' ' ' PHE . 60.3 mt -69.88 120.58 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.912 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.61 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 140.16 20.12 0.37 Allowed Glycine 0 C--N 1.298 -1.534 0 CA-C-N 115.533 -0.758 . . . . 0.0 112.677 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 84.26 158.81 28.56 Favored Glycine 0 C--O 1.236 0.258 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 -177.121 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 163.83 -175.74 39.96 Favored Glycine 0 N--CA 1.435 -1.372 0 C-N-CA 119.825 -1.179 . . . . 0.0 111.49 178.472 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 37.3 p -146.14 147.55 31.64 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.047 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.09 161.44 35.32 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 179.342 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 21.9 m-80 -113.29 109.81 19.34 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 106.493 -1.669 . . . . 0.0 106.493 176.755 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.512 HG22 HG22 ' A' ' 5' ' ' THR . 40.2 t -94.35 134.69 31.02 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.493 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 -178.273 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 78.3 m-85 -116.46 120.13 37.82 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 117.775 0.261 . . . . 0.0 110.986 -178.541 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.457 HG22 ' HG3' ' A' ' 41' ' ' GLN . 17.6 t -123.02 127.99 74.94 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-O 120.975 0.416 . . . . 0.0 111.036 -175.898 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -82.12 124.41 29.83 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 177.323 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 38.0 mt -115.51 154.2 29.76 Favored 'General case' 0 C--N 1.28 -2.453 0 CA-C-N 115.397 -0.82 . . . . 0.0 108.858 -179.086 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.76 120.83 44.9 Favored Pre-proline 0 C--N 1.314 -0.96 0 O-C-N 124.485 1.115 . . . . 0.0 110.123 -178.826 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 61.0 Cg_endo -72.22 -2.09 11.1 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.885 2.39 . . . . 0.0 113.427 -176.694 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.4 t -124.07 109.57 23.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 178.23 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.505 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.7 t -139.81 107.08 2.71 Favored 'Isoleucine or valine' 0 C--O 1.182 -2.479 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -178.258 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.729 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -97.72 148.54 23.24 Favored 'General case' 0 C--N 1.265 -3.095 0 C-N-CA 122.894 0.477 . . . . 0.0 111.015 -179.606 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.493 HG22 ' O ' ' A' ' 112' ' ' VAL . 91.0 t -47.69 116.52 0.38 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.638 0 C-N-CA 122.961 0.505 . . . . 0.0 111.435 176.038 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.09 9.87 43.94 Favored Glycine 0 CA--C 1.523 0.567 0 CA-C-N 114.905 -1.043 . . . . 0.0 112.137 -178.178 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.729 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -78.62 -176.71 4.99 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 124.603 1.161 . . . . 0.0 109.653 175.147 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -131.95 83.49 2.09 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 175.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.524 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 19.8 tp -91.37 134.22 34.79 Favored 'General case' 0 N--CA 1.426 -1.642 0 C-N-CA 119.42 -0.912 . . . . 0.0 108.915 179.438 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.447 ' HA ' ' O ' ' A' ' 107' ' ' LEU . 1.8 p -141.35 136.26 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.383 -3.803 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.191 -177.691 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.593 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 34.0 t -98.59 89.29 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.412 -2.343 0 CA-C-N 113.551 -1.659 . . . . 0.0 107.904 178.65 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -77.48 118.11 19.6 Favored 'General case' 0 CA--C 1.489 -1.391 0 C-N-CA 120.047 -0.661 . . . . 0.0 110.201 177.816 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 92.4 mt -96.64 -0.18 48.9 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.545 -0.752 . . . . 0.0 111.632 -178.01 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 26.4 t -74.63 -7.49 53.37 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.854 0.835 . . . . 0.0 109.659 -179.381 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.9 p -117.86 2.19 12.16 Favored 'General case' 0 C--N 1.279 -2.478 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.3 178.021 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.457 ' HG3' HG22 ' A' ' 22' ' ' VAL . 44.2 mm-40 -120.64 -22.83 6.22 Favored 'General case' 0 C--O 1.243 0.736 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.501 -173.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 20.1 mt -136.45 140.08 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.629 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 -176.795 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.407 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 59.8 m-85 -139.9 162.33 35.43 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 -177.648 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.58 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 20.1 t -145.08 141.91 29.24 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 120.181 -0.608 . . . . 0.0 110.39 175.847 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 19.8 p-80 -119.74 165.03 15.06 Favored 'General case' 0 C--O 1.255 1.389 0 CA-C-O 122.242 1.02 . . . . 0.0 110.376 -178.801 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -110.72 108.49 18.39 Favored 'General case' 0 C--N 1.271 -2.818 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 -175.017 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -84.0 -25.46 29.95 Favored 'General case' 0 N--CA 1.436 -1.166 0 C-N-CA 118.129 -1.428 . . . . 0.0 109.946 -177.618 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 -132.67 64.99 73.44 Favored Pre-proline 0 N--CA 1.472 0.668 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.186 178.03 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -70.02 1.04 4.98 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 C-N-CA 123.257 2.638 . . . . 0.0 114.159 -174.33 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -116.6 -20.13 9.72 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-O 121.189 0.519 . . . . 0.0 110.303 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.534 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -104.04 -27.83 11.88 Favored 'General case' 0 N--CA 1.422 -1.857 0 CA-C-O 122.055 0.931 . . . . 0.0 108.717 -172.875 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.56 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -128.9 142.98 42.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 CA-C-N 114.711 -1.131 . . . . 0.0 109.04 -176.817 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 4.2 t -89.2 133.23 34.51 Favored 'General case' 0 N--CA 1.433 -1.294 0 N-CA-C 104.917 -2.253 . . . . 0.0 104.917 170.209 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 11.1 m-20 -92.79 106.5 18.46 Favored 'General case' 0 C--N 1.27 -2.879 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 -178.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.435 ' HB3' ' O ' ' A' ' 134' ' ' THR . 52.9 t80 -118.0 127.94 54.3 Favored 'General case' 0 C--N 1.274 -2.692 0 CA-C-N 114.29 -1.323 . . . . 0.0 108.855 -174.589 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.504 HG21 HD12 ' A' ' 131' ' ' LEU . 14.9 p -134.48 138.91 48.92 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.578 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.411 -175.307 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 4.3 p -146.7 131.03 17.54 Favored 'General case' 0 C--N 1.282 -2.352 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 174.431 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.559 ' HB3' HG23 ' A' ' 90' ' ' THR . 55.1 tp -64.52 116.89 6.61 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 173.213 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 5.7 tp60 -61.06 -49.42 77.42 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 113.802 -1.545 . . . . 0.0 109.307 -178.589 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -175.79 161.76 2.58 Favored 'General case' 0 N--CA 1.42 -1.951 0 CA-C-N 114.504 -1.226 . . . . 0.0 107.979 -178.311 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -136.6 136.52 8.42 Favored Glycine 0 N--CA 1.403 -3.514 0 N-CA-C 108.729 -1.748 . . . . 0.0 108.729 -179.47 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.2 m -123.66 146.87 47.9 Favored 'General case' 0 C--N 1.282 -2.35 0 O-C-N 124.394 0.702 . . . . 0.0 109.753 -176.095 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.506 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -112.17 156.07 22.91 Favored 'General case' 0 CA--C 1.503 -0.831 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 -178.845 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.449 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 88.5 m-85 -156.32 -178.93 7.69 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 124.309 1.044 . . . . 0.0 109.144 -177.616 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 63.01 -139.71 44.95 Favored Glycine 0 C--O 1.221 -0.672 0 O-C-N 123.367 0.417 . . . . 0.0 112.164 177.647 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.99 -6.98 86.12 Favored Glycine 0 C--O 1.203 -1.833 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.043 177.061 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.796 HG21 ' HB ' ' A' ' 126' ' ' ILE . 73.2 t -69.6 -38.52 76.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 C-N-CA 123.587 0.755 . . . . 0.0 111.815 -176.359 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.506 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -85.62 -21.72 28.3 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.954 -0.699 . . . . 0.0 112.194 179.136 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 14.0 m -100.89 -50.75 3.74 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 -173.389 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.446 ' O ' HG22 ' A' ' 112' ' ' VAL . 46.1 m-20 -93.36 -22.67 18.8 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 -176.028 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.627 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 84.0 m-85 -110.29 160.77 16.25 Favored 'General case' 0 N--CA 1.417 -2.112 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 177.411 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.5 t -166.76 131.68 2.12 Favored 'General case' 0 N--CA 1.415 -2.204 0 N-CA-C 106.049 -1.834 . . . . 0.0 106.049 175.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.427 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -166.76 -112.47 0.26 Allowed Glycine 0 N--CA 1.401 -3.66 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 175.855 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.435 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.0 OUTLIER -157.28 179.37 9.33 Favored 'General case' 0 C--N 1.281 -2.373 0 C-N-CA 123.685 0.794 . . . . 0.0 110.714 -172.324 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.446 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.6 p -134.97 148.17 29.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 178.347 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.688 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.1 tttt -125.73 150.04 48.03 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.156 -178.188 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.51 ' CD2' HG22 ' A' ' 105' ' ' VAL . 57.3 t80 -151.6 116.18 5.11 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 -178.15 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 2.7 m 53.79 33.87 17.91 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 179.116 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 85.6 9.67 78.14 Favored Glycine 0 CA--C 1.526 0.721 0 C-N-CA 120.291 -0.957 . . . . 0.0 112.923 -178.714 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.688 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 9.4 t -80.23 -179.69 7.21 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.098 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 11.4 p -154.63 110.17 3.14 Favored 'General case' 0 C--N 1.289 -2.039 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.05 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.484 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 5.0 p90 -153.01 159.55 32.08 Favored Pre-proline 0 CA--C 1.551 1.001 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -174.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.435 ' HA ' HG22 ' A' ' 74' ' ' THR . 44.3 Cg_endo -67.53 150.0 80.02 Favored 'Trans proline' 0 C--N 1.362 1.269 0 C-N-CA 123.059 2.506 . . . . 0.0 113.442 -176.096 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.621 ' CD2' HD21 ' A' ' 109' ' ' LEU . 55.6 t80 -125.92 132.76 24.42 Favored Pre-proline 0 N--CA 1.445 -0.709 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.027 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.416 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 69.6 Cg_endo -72.64 144.41 80.63 Favored 'Cis proline' 0 C--O 1.245 0.856 0 C-N-CA 122.786 -1.756 . . . . 0.0 110.313 -1.342 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.3 t -66.87 -176.68 0.53 Allowed 'General case' 0 CA--C 1.546 0.824 0 CA-C-N 115.571 -0.741 . . . . 0.0 112.219 -173.028 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 12.9 p -119.06 -49.39 2.41 Favored 'General case' 0 N--CA 1.419 -2.004 0 CA-C-N 115.362 -0.835 . . . . 0.0 111.23 -173.073 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.7 t -104.78 -81.28 0.53 Allowed 'General case' 0 N--CA 1.424 -1.759 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.992 -174.502 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -175.64 -170.09 0.39 Allowed 'General case' 0 C--O 1.238 0.462 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 -175.759 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.559 HG23 ' HB3' ' A' ' 58' ' ' LEU . 56.2 p -101.44 164.39 16.05 Favored Pre-proline 0 C--N 1.303 -1.418 0 N-CA-C 112.817 0.673 . . . . 0.0 112.817 176.22 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' PRO . . . . . 0.467 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 22.8 Cg_endo -60.7 172.12 3.05 Favored 'Trans proline' 0 CA--C 1.552 1.41 0 C-N-CA 123.194 2.596 . . . . 0.0 111.891 173.482 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.2 tmm_? -73.74 119.6 18.19 Favored 'General case' 0 C--N 1.323 -0.584 0 C-N-CA 123.674 0.79 . . . . 0.0 110.068 -173.734 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 75.5 t -138.45 139.07 42.15 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -177.536 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.94 142.0 32.95 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.974 0 C-N-CA 122.978 0.511 . . . . 0.0 109.869 -176.225 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.521 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 4.9 m-85 -95.68 105.38 17.37 Favored 'General case' 0 C--N 1.309 -1.184 0 C-N-CA 123.186 0.594 . . . . 0.0 109.853 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -93.01 50.89 1.6 Allowed 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 121.618 0.723 . . . . 0.0 109.271 177.2 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 12.2 p -117.47 178.4 4.4 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.023 -0.989 . . . . 0.0 110.841 -175.687 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 36.1 ptt180 -144.35 36.9 1.22 Allowed 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 172.408 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.8 t -158.31 171.77 19.57 Favored 'General case' 0 C--N 1.312 -1.036 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 -173.842 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.45 99.32 4.15 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -98.05 139.37 21.21 Favored Pre-proline 0 C--N 1.287 -2.118 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.292 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -60.19 147.57 92.95 Favored 'Trans proline' 0 C--O 1.245 0.844 0 C-N-CA 122.938 2.425 . . . . 0.0 112.134 178.711 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' TRP . . . . . 0.521 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 11.4 t90 -93.64 106.51 21.5 Favored Pre-proline 0 C--N 1.311 -1.094 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 -178.341 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -77.04 88.79 1.37 Allowed 'Trans proline' 0 N--CA 1.455 -0.756 0 C-N-CA 121.984 1.79 . . . . 0.0 113.212 -172.717 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.51 HG22 ' CD2' ' A' ' 77' ' ' TYR . 66.6 t -140.12 146.43 24.8 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.296 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 178.014 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.593 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.69 134.98 17.01 Favored 'General case' 0 C--N 1.291 -1.947 0 CA-C-O 120.659 0.266 . . . . 0.0 110.919 177.592 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.495 HD21 HD11 ' A' ' 129' ' ' LEU . 18.4 mt -101.11 100.04 10.55 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 179.682 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.427 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 58.8 m-85 -81.66 76.43 8.57 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 110.299 -0.26 . . . . 0.0 110.299 177.27 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.627 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.1 mm? -101.4 125.51 48.05 Favored 'General case' 0 CA--C 1.485 -1.528 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 176.02 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -126.68 148.05 63.27 Favored Pre-proline 0 N--CA 1.398 -3.036 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -175.075 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.422 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 28.6 Cg_endo -62.14 123.72 13.04 Favored 'Trans proline' 0 N--CA 1.446 -1.322 0 C-N-CA 123.132 2.555 . . . . 0.0 113.611 -176.522 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.493 ' O ' HG22 ' A' ' 30' ' ' VAL . 17.9 m -85.95 -157.69 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.398 -3.053 0 CA-C-N 114.34 -1.3 . . . . 0.0 108.696 171.225 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 15.8 t -81.83 -24.69 35.7 Favored 'General case' 0 C--N 1.254 -3.586 0 CA-C-O 121.755 0.788 . . . . 0.0 109.034 -171.175 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 28.0 t -80.85 18.23 1.03 Allowed 'General case' 0 N--CA 1.434 -1.267 0 CA-C-N 115.228 -0.896 . . . . 0.0 110.433 178.431 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -106.81 138.8 42.3 Favored 'General case' 0 N--CA 1.421 -1.887 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.373 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 177.19 125.42 0.9 Allowed Glycine 0 N--CA 1.441 -0.999 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 179.599 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 68.75 -149.54 49.6 Favored Glycine 0 CA--C 1.496 -1.096 0 CA-C-O 119.07 -0.85 . . . . 0.0 111.38 -176.404 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 57.7 t -58.91 105.71 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-O 121.718 0.771 . . . . 0.0 111.018 -176.564 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -105.77 -34.67 7.61 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 114.785 -1.098 . . . . 0.0 111.128 -178.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.539 ' HB ' HG22 ' A' ' 154' ' ' VAL . 70.4 mt -119.7 136.98 55.09 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.062 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.85 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.525 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.2 mmpt? -113.39 138.5 49.97 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-O 121.035 0.445 . . . . 0.0 110.428 177.043 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.42 ' H ' ' HB3' ' A' ' 153' ' ' ASP . . . -72.31 137.57 46.78 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.957 179.648 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 82.16 5.17 89.89 Favored Glycine 0 C--N 1.31 -0.868 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.864 -179.123 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 44.6 m -104.66 141.1 37.05 Favored 'General case' 0 N--CA 1.421 -1.903 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -67.35 123.81 21.38 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 178.049 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.796 ' HB ' HG21 ' A' ' 67' ' ' VAL . 28.6 pt -111.44 -26.21 3.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 116.129 -0.487 . . . . 0.0 112.16 -178.675 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 127' ' ' ALA . . . . . 0.401 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.59 168.41 23.56 Favored 'General case' 0 N--CA 1.443 -0.784 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -178.254 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 77.2 t -142.68 114.9 3.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.495 HD11 HD21 ' A' ' 107' ' ' LEU . 62.7 mt -116.23 143.88 44.94 Favored 'General case' 0 C--N 1.286 -2.16 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 178.714 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.529 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.9 mp -123.94 123.35 66.67 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.101 178.422 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.601 HD22 ' HB2' ' A' ' 144' ' ' PHE . 0.0 OUTLIER -89.11 134.7 33.91 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 176.718 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.409 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 12.4 tpt180 -101.79 109.56 21.35 Favored 'General case' 0 C--N 1.277 -2.553 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 179.114 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.511 ' HB3' ' CE2' ' A' ' 1' ' ' PHE . 10.1 mm-40 -100.8 105.12 16.4 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 176.536 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.435 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 7.7 m -124.17 136.02 53.89 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 179.205 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.56 ' CB ' HG23 ' A' ' 52' ' ' ILE . 7.9 p30 -120.8 167.95 11.96 Favored 'General case' 0 C--N 1.32 -0.691 0 C-N-CA 117.831 -1.548 . . . . 0.0 112.336 178.441 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -89.37 -5.17 57.69 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 114.535 -1.211 . . . . 0.0 111.982 -170.651 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 30.4 t80 -113.51 -69.75 0.84 Allowed 'General case' 0 C--N 1.301 -1.539 0 CA-C-O 120.74 0.305 . . . . 0.0 111.639 -173.68 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -88.23 166.35 14.4 Favored 'General case' 0 CA--C 1.472 -2.024 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 23.8 m -87.11 39.46 0.86 Allowed 'General case' 0 C--N 1.27 -2.869 0 CA-C-N 114.409 -1.269 . . . . 0.0 109.658 177.231 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -87.34 53.42 2.8 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.561 -177.652 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -85.39 96.34 9.53 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 176.714 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -130.52 137.03 49.53 Favored 'General case' 0 N--CA 1.417 -2.118 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.681 -179.048 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 143' ' ' GLN . . . . . 0.487 ' HB2' HG22 ' A' ' 130' ' ' ILE . 7.0 pt20 -108.22 133.46 52.43 Favored 'General case' 0 N--CA 1.413 -2.308 0 CA-C-O 121.493 0.663 . . . . 0.0 110.033 177.073 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.601 ' HB2' HD22 ' A' ' 131' ' ' LEU . 8.0 m-30 -103.02 133.77 47.58 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 -176.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 46.6 t -91.44 129.91 41.42 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.929 0 CA-C-O 121.115 0.484 . . . . 0.0 109.766 -178.514 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 146' ' ' TRP . . . . . 0.512 ' CZ2' ' HB2' ' A' ' 3' ' ' CYS . 62.2 m95 -120.22 96.2 5.06 Favored 'General case' 0 C--N 1.277 -2.568 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -80.22 114.73 19.34 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.411 HG22 HD11 ' A' ' 126' ' ' ILE . 25.5 mm -87.42 123.31 40.07 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.799 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 -177.506 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -116.79 151.09 37.22 Favored 'General case' 0 C--N 1.292 -1.909 0 C-N-CA 124.207 1.003 . . . . 0.0 109.349 178.171 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.68 131.81 35.28 Favored 'General case' 0 N--CA 1.411 -2.419 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 175.635 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -93.15 -11.39 32.93 Favored 'General case' 0 C--N 1.292 -1.919 0 CA-C-O 122.469 1.128 . . . . 0.0 108.033 -176.506 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -152.02 143.62 23.53 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 114.023 -1.444 . . . . 0.0 109.41 -177.457 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 153' ' ' ASP . . . . . 0.42 ' HB3' ' H ' ' A' ' 122' ' ' ALA . 6.4 p-10 -86.4 139.49 30.89 Favored 'General case' 0 C--N 1.309 -1.173 0 O-C-N 124.133 0.896 . . . . 0.0 110.183 -179.389 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.539 HG22 ' HB ' ' A' ' 120' ' ' ILE . 1.8 m -120.38 153.05 23.42 Favored 'Isoleucine or valine' 0 C--O 1.251 1.144 0 CA-C-O 120.94 0.4 . . . . 0.0 111.217 -175.599 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.0 t -123.14 142.63 39.03 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.2 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 77.1 t -104.26 102.46 32.96 Favored Pre-proline 0 C--N 1.289 -2.039 0 C-N-CA 123.444 0.698 . . . . 0.0 110.039 179.179 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.505 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 29.7 Cg_endo -67.26 -23.23 45.32 Favored 'Trans proline' 0 C--O 1.219 -0.437 0 C-N-CA 122.498 2.132 . . . . 0.0 111.56 176.656 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.448 ' HB ' HG12 ' A' ' 156' ' ' VAL 0.287 5.1 t . . . . . 0 C--O 1.258 1.515 0 CA-C-O 117.45 -1.262 . . . . 0.0 113.768 176.054 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.46 ' CZ ' ' HB3' ' A' ' 44' ' ' CYS . 66.1 t80 . . . . . 0 CA--C 1.499 -0.988 0 N-CA-C 107.442 -1.318 . . . . 0.0 107.442 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -145.66 170.17 17.01 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.695 178.378 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 76.9 m -145.48 159.31 43.29 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -178.813 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.42 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -145.55 155.56 43.14 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-O 121.451 0.643 . . . . 0.0 110.164 -177.37 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 44.7 p -92.36 177.33 6.17 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.856 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.91 -17.13 48.26 Favored 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.953 179.148 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -90.76 -24.93 20.22 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.582 -177.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 131.73 -3.11 5.33 Favored Glycine 0 CA--C 1.494 -1.233 0 C-N-CA 119.271 -1.442 . . . . 0.0 114.428 169.321 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.7 m -80.55 100.05 8.39 Favored 'General case' 0 C--N 1.285 -2.211 0 CA-C-O 121.453 0.644 . . . . 0.0 109.536 -178.221 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.401 ' HA ' ' HA ' ' A' ' 4' ' ' LYS . . . -94.56 124.75 38.78 Favored 'General case' 0 N--CA 1.424 -1.77 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.115 176.72 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 69.6 mt -92.11 116.45 66.48 Favored Pre-proline 0 C--N 1.278 -2.539 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 177.72 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -75.9 177.09 9.18 Favored 'Trans proline' 0 C--O 1.245 0.841 0 C-N-CA 122.54 2.16 . . . . 0.0 111.719 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 67.9 mt -70.23 128.4 33.48 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.4 179.564 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 128.89 5.19 4.93 Favored Glycine 0 N--CA 1.432 -1.576 0 C-N-CA 120.372 -0.918 . . . . 0.0 111.69 -178.19 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 86.07 169.74 46.25 Favored Glycine 0 N--CA 1.439 -1.106 0 C-N-CA 120.511 -0.852 . . . . 0.0 111.588 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.86 -174.85 30.83 Favored Glycine 0 CA--C 1.487 -1.686 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 178.853 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.3 m -134.1 159.37 41.06 Favored 'General case' 0 C--N 1.296 -1.759 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 -179.131 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -141.46 165.51 27.31 Favored 'General case' 0 N--CA 1.42 -1.935 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 177.21 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -116.1 104.41 11.52 Favored 'General case' 0 C--N 1.273 -2.73 0 CA-C-N 114.002 -1.453 . . . . 0.0 108.913 178.079 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.456 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.3 m -91.68 146.4 6.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 -178.563 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -128.93 112.51 14.16 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-O 121.03 0.443 . . . . 0.0 111.28 -177.502 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.524 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.6 p -118.69 129.78 74.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 CA-C-O 121.692 0.758 . . . . 0.0 111.995 -174.626 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.3 m-80 -84.52 126.06 32.96 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 177.677 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 23.0 mt -113.06 157.31 21.74 Favored 'General case' 0 C--N 1.272 -2.777 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 -179.155 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.36 120.74 46.79 Favored Pre-proline 0 C--N 1.313 -1.011 0 O-C-N 124.207 0.942 . . . . 0.0 109.723 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.473 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 60.6 Cg_endo -74.2 -0.12 9.19 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.657 2.238 . . . . 0.0 112.616 -177.536 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.433 HG13 ' HG3' ' A' ' 157' ' ' PRO . 94.9 t -125.3 109.95 23.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 177.639 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.6 t -140.91 107.02 1.97 Allowed 'Isoleucine or valine' 0 C--O 1.179 -2.622 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 -179.544 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.592 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -98.64 148.86 23.38 Favored 'General case' 0 C--N 1.265 -3.089 0 O-C-N 122.13 -0.356 . . . . 0.0 111.266 -179.5 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.423 ' H ' ' HA ' ' A' ' 158' ' ' THR . 22.2 t -43.8 117.04 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.528 0 C-N-CA 123.571 0.748 . . . . 0.0 111.501 175.759 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.84 -1.07 48.36 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-N 115.002 -0.999 . . . . 0.0 113.063 -179.035 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.592 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.8 OUTLIER -71.48 -177.04 1.7 Allowed 'General case' 0 C--N 1.318 -0.802 0 C-N-CA 124.496 1.118 . . . . 0.0 111.237 177.784 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 64.1 t30 -133.41 87.61 2.41 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 177.775 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.625 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.5 tp -88.76 140.3 29.59 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 -178.69 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.2 t -134.11 125.4 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.172 0 CA-C-O 121.113 0.483 . . . . 0.0 109.787 -175.472 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.57 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 41.1 t -95.78 88.2 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.399 -2.994 0 N-CA-C 105.713 -1.958 . . . . 0.0 105.713 174.196 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -80.57 116.07 20.42 Favored 'General case' 0 CA--C 1.486 -1.482 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.0 mt -97.52 0.06 46.86 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.249 -177.459 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.588 ' OG ' ' HA ' ' A' ' 104' ' ' PRO . 19.6 m -81.22 -2.37 48.5 Favored 'General case' 0 C--N 1.29 -1.988 0 CA-C-O 122.658 1.218 . . . . 0.0 109.703 -179.296 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.4 p -118.8 1.58 11.57 Favored 'General case' 0 C--N 1.275 -2.663 0 CA-C-N 114.807 -1.088 . . . . 0.0 109.811 175.725 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.524 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 44.8 mm-40 -122.41 -23.09 5.31 Favored 'General case' 0 CA--C 1.512 -0.497 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.329 -174.566 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 29.0 mt -135.68 139.2 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.229 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -176.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.42 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 65.7 m-85 -137.52 151.79 48.8 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 -177.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.46 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 67.7 m -128.28 138.53 52.46 Favored 'General case' 0 C--N 1.276 -2.622 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 176.846 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.2 p80 -125.11 129.26 49.84 Favored 'General case' 0 C--N 1.295 -1.774 0 CA-C-O 121.955 0.883 . . . . 0.0 110.773 -177.843 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.548 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 24.4 p-10 -95.76 96.5 9.02 Favored 'General case' 0 C--N 1.279 -2.477 0 CA-C-O 122.466 1.127 . . . . 0.0 110.072 -179.214 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -74.7 -23.55 58.63 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 114.108 -1.405 . . . . 0.0 111.538 -174.466 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -128.91 65.23 72.89 Favored Pre-proline 0 N--CA 1.479 1.019 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.103 179.648 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.548 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 60.3 Cg_endo -68.85 -12.31 34.14 Favored 'Trans proline' 0 N--CA 1.483 0.881 0 C-N-CA 122.809 2.34 . . . . 0.0 114.148 -172.471 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -108.08 -21.15 12.92 Favored 'General case' 0 C--N 1.292 -1.894 0 C-N-CA 119.977 -0.689 . . . . 0.0 110.343 -176.662 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.504 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.8 m -96.21 -30.34 13.53 Favored 'General case' 0 N--CA 1.416 -2.154 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 -172.544 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.657 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -121.98 143.29 35.07 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.213 0 CA-C-N 113.991 -1.459 . . . . 0.0 108.737 -177.119 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.1 t -88.82 125.83 35.08 Favored 'General case' 0 N--CA 1.419 -2.014 0 N-CA-C 103.944 -2.613 . . . . 0.0 103.944 170.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 -90.61 107.18 19.01 Favored 'General case' 0 C--N 1.263 -3.18 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -172.63 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.469 ' HB3' ' O ' ' A' ' 134' ' ' THR . 34.2 t80 -126.02 117.72 23.83 Favored 'General case' 0 C--N 1.274 -2.7 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.489 -173.39 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.537 HG12 ' OH ' ' A' ' 77' ' ' TYR . 49.0 t -121.85 130.84 74.24 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.298 -175.517 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.1 p -143.45 113.43 7.19 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 123.923 0.764 . . . . 0.0 111.239 177.683 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.505 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 54.3 tp -55.34 109.7 0.58 Allowed 'General case' 0 C--N 1.311 -1.106 0 CA-C-O 121.313 0.578 . . . . 0.0 110.174 172.108 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.43 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 11.8 tp60 -54.91 -53.64 52.96 Favored 'General case' 0 C--O 1.209 -1.04 0 C-N-CA 126.041 1.736 . . . . 0.0 110.911 178.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -171.06 160.9 6.65 Favored 'General case' 0 N--CA 1.425 -1.71 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 -176.198 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -139.3 133.44 6.15 Favored Glycine 1 N--CA 1.391 -4.321 0 N-CA-C 108.041 -2.024 . . . . 0.0 108.041 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.2 m -120.76 151.6 39.36 Favored 'General case' 0 C--N 1.276 -2.599 0 O-C-N 124.956 1.033 . . . . 0.0 108.582 -174.145 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.563 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -116.16 157.67 24.45 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 -178.654 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.527 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 96.1 m-85 -155.69 176.8 12.14 Favored 'General case' 0 C--N 1.35 0.616 0 C-N-CA 124.246 1.018 . . . . 0.0 109.587 -177.283 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.35 -147.52 38.86 Favored Glycine 0 CA--C 1.52 0.365 0 O-C-N 123.61 0.569 . . . . 0.0 112.81 178.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -70.58 -10.34 66.77 Favored Glycine 0 C--O 1.205 -1.665 0 O-C-N 122.052 -0.676 . . . . 0.0 111.976 177.106 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.773 HG21 ' HB ' ' A' ' 126' ' ' ILE . 92.8 t -70.53 -36.75 67.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 123.544 0.737 . . . . 0.0 111.322 -177.172 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.563 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.71 -23.09 25.67 Favored 'General case' 0 N--CA 1.421 -1.883 0 C-N-CA 118.6 -1.24 . . . . 0.0 112.144 179.179 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 17.1 t -101.77 -55.46 2.5 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 112.952 0.723 . . . . 0.0 112.952 -175.213 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.443 ' O ' HG22 ' A' ' 112' ' ' VAL . 72.4 m-20 -83.91 -27.43 28.6 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 -174.769 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.637 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 90.0 m-85 -107.02 159.19 16.47 Favored 'General case' 0 N--CA 1.421 -1.917 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 176.463 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.8 t -168.09 136.24 2.3 Favored 'General case' 0 N--CA 1.41 -2.431 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 176.292 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.421 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -169.37 -108.21 0.21 Allowed Glycine 0 N--CA 1.411 -3.027 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 175.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.541 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.1 p -159.21 -179.96 8.46 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 123.829 0.852 . . . . 0.0 110.547 -173.225 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.05 146.73 29.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 C-N-CA 123.435 0.694 . . . . 0.0 109.143 178.614 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.616 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.1 tttt -125.17 142.17 51.66 Favored 'General case' 0 N--CA 1.417 -2.095 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.518 -179.442 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.537 ' OH ' HG12 ' A' ' 56' ' ' VAL . 72.4 t80 -144.48 111.06 5.64 Favored 'General case' 0 C--N 1.295 -1.796 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.13 -177.195 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 35.1 t 55.14 34.33 22.39 Favored 'General case' 0 C--N 1.317 -0.825 0 C-N-CA 123.416 0.686 . . . . 0.0 111.164 178.212 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.08 10.52 64.32 Favored Glycine 0 N--CA 1.44 -1.079 0 C-N-CA 120.486 -0.864 . . . . 0.0 113.566 -178.877 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.616 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 20.8 t -79.84 179.8 7.36 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.551 0.676 . . . . 0.0 109.31 178.484 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 9.7 p -156.55 90.35 1.16 Allowed 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.623 0.725 . . . . 0.0 110.637 -176.707 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.439 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 1.5 p90 -139.85 158.31 67.9 Favored Pre-proline 0 C--N 1.297 -1.69 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 -173.098 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.541 ' HA ' HG22 ' A' ' 74' ' ' THR . 58.9 Cg_endo -69.35 151.03 71.39 Favored 'Trans proline' 0 C--N 1.354 0.842 0 C-N-CA 123.148 2.565 . . . . 0.0 113.154 -177.081 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.596 ' CD2' HD21 ' A' ' 109' ' ' LEU . 58.0 t80 -122.74 133.21 24.33 Favored Pre-proline 0 N--CA 1.439 -1.011 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.018 -179.541 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.463 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 79.3 Cg_endo -71.43 149.78 92.7 Favored 'Cis proline' 0 CA--C 1.534 0.511 0 C-N-CA 122.71 -1.787 . . . . 0.0 109.73 -0.956 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.0 t -61.06 -175.54 0.05 OUTLIER 'General case' 0 CA--C 1.562 1.415 0 C-N-CA 123.399 0.679 . . . . 0.0 112.595 -175.462 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 12.4 p -104.97 -50.53 3.23 Favored 'General case' 0 N--CA 1.408 -2.563 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 -177.742 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.6 t -128.43 -109.19 0.29 Allowed 'General case' 0 N--CA 1.402 -2.873 0 CA-C-N 114.346 -1.297 . . . . 0.0 108.591 178.338 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -125.35 -171.68 2.42 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 118.539 0.609 . . . . 0.0 112.503 -176.692 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.505 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 36.1 p -93.95 167.57 13.4 Favored Pre-proline 0 C--N 1.309 -1.189 0 N-CA-C 112.924 0.713 . . . . 0.0 112.924 -178.908 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -62.82 175.87 2.11 Favored 'Trans proline' 0 CA--C 1.552 1.386 0 C-N-CA 123.087 2.524 . . . . 0.0 111.904 172.424 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.4 ' HG2' ' CE2' ' A' ' 55' ' ' TYR . 1.4 tmm_? -74.84 129.5 37.79 Favored 'General case' 0 C--O 1.243 0.761 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.004 -175.469 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.492 ' HB ' ' O ' ' A' ' 56' ' ' VAL . 65.3 t -140.09 132.57 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 C-N-CA 123.718 0.807 . . . . 0.0 109.801 -176.497 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 1.9 p -131.08 136.41 57.95 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.411 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 177.461 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 6.1 m-85 -79.8 116.47 19.98 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-O 121.388 0.613 . . . . 0.0 110.525 -179.745 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 -102.22 68.46 1.09 Allowed 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 177.816 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 46.0 t -147.64 179.23 7.84 Favored 'General case' 0 N--CA 1.426 -1.646 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 -175.578 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 31.8 ptt180 -151.11 42.12 0.76 Allowed 'General case' 0 C--N 1.31 -1.146 0 C-N-CA 124.036 0.934 . . . . 0.0 108.51 171.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 11.0 t -169.72 172.32 6.87 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-N 114.525 -1.216 . . . . 0.0 108.23 -177.792 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -59.34 119.87 8.24 Favored 'General case' 0 N--CA 1.474 0.768 0 O-C-N 123.756 0.66 . . . . 0.0 110.493 178.357 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 55.9 mmtt -120.2 143.19 35.12 Favored Pre-proline 0 C--N 1.287 -2.143 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.994 178.364 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -67.16 139.19 49.71 Favored 'Trans proline' 0 N--CA 1.44 -1.676 0 C-N-CA 122.392 2.061 . . . . 0.0 110.32 177.252 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 14.4 t90 -80.34 109.69 13.69 Favored Pre-proline 0 C--N 1.307 -1.243 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 -177.476 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.588 ' HA ' ' OG ' ' A' ' 39' ' ' SER . 60.7 Cg_endo -74.85 87.7 1.28 Allowed 'Trans proline' 0 N--CA 1.451 -0.982 0 C-N-CA 121.12 1.213 . . . . 0.0 112.844 -172.376 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.505 HG22 ' CD1' ' A' ' 77' ' ' TYR . 59.7 t -144.9 145.18 21.24 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.359 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 179.579 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.57 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.65 136.27 17.03 Favored 'General case' 0 C--N 1.288 -2.07 0 O-C-N 123.569 0.543 . . . . 0.0 110.116 177.917 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.464 HD21 HD11 ' A' ' 129' ' ' LEU . 17.7 mt -101.81 105.12 15.92 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 177.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.421 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 39.3 m-85 -85.29 80.49 9.15 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 177.481 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.637 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.2 mm? -105.12 125.32 50.85 Favored 'General case' 0 CA--C 1.491 -1.327 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 177.441 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -128.04 146.63 59.99 Favored Pre-proline 0 N--CA 1.412 -2.363 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.62 -175.542 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.438 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 23.1 Cg_endo -61.14 117.6 4.39 Favored 'Trans proline' 0 C--O 1.245 0.863 0 C-N-CA 123.424 2.749 . . . . 0.0 112.369 -178.458 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.443 HG22 ' O ' ' A' ' 70' ' ' ASN . 2.7 m -67.04 -114.14 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.202 -1.447 0 CA-C-N 114.289 -1.323 . . . . 0.0 112.752 176.735 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 41.7 m -112.56 -43.4 3.48 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.287 -0.883 . . . . 0.0 110.441 175.777 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 22.7 t -82.82 30.2 0.44 Allowed 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.067 -174.726 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -101.79 130.94 48.33 Favored 'General case' 0 N--CA 1.418 -2.035 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.2 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.28 141.06 6.45 Favored Glycine 0 N--CA 1.432 -1.596 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 58.81 -149.23 37.78 Favored Glycine 0 C--O 1.219 -0.812 0 CA-C-O 119.244 -0.753 . . . . 0.0 113.307 -179.087 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 99.5 t -56.56 96.75 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 121.581 0.705 . . . . 0.0 111.26 -178.207 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -99.4 -27.78 13.58 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.365 -177.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.583 ' HB ' HG22 ' A' ' 154' ' ' VAL . 68.9 mt -126.84 138.53 54.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 177.105 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.424 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.2 mmpt? -111.02 138.05 47.9 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-O 121.341 0.591 . . . . 0.0 111.207 178.409 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.56 128.57 36.96 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.46 178.029 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 92.05 -7.16 78.96 Favored Glycine 0 N--CA 1.428 -1.89 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.093 -179.349 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 91.9 p -90.85 143.9 26.25 Favored 'General case' 0 C--O 1.253 1.253 0 C-N-CA 119.495 -0.882 . . . . 0.0 109.525 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.437 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -70.72 122.37 19.69 Favored 'General case' 0 N--CA 1.435 -1.22 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 177.367 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.773 ' HB ' HG21 ' A' ' 67' ' ' VAL . 31.6 pt -109.02 -24.47 4.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -177.116 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.72 167.32 23.22 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 -177.9 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.437 HG23 HD11 ' A' ' 125' ' ' LEU . 76.9 t -141.62 114.93 4.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 179.506 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.464 HD11 HD21 ' A' ' 107' ' ' LEU . 52.7 mt -117.97 144.68 45.32 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 178.484 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.488 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.4 mp -127.41 130.19 70.67 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 C-N-CA 119.41 -0.916 . . . . 0.0 110.639 179.006 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.471 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.9 OUTLIER -94.75 128.99 41.85 Favored 'General case' 0 C--N 1.29 -1.982 0 C-N-CA 123.855 0.862 . . . . 0.0 111.477 -179.607 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.43 ' HG2' ' HB2' ' A' ' 59' ' ' GLN . 25.9 mmm180 -94.58 120.55 34.99 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 173.185 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.567 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 7.4 tp-100 -103.38 137.23 41.78 Favored 'General case' 0 N--CA 1.427 -1.59 0 N-CA-C 105.937 -1.875 . . . . 0.0 105.937 169.495 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.469 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 27.8 m -150.23 134.76 17.38 Favored 'General case' 0 C--N 1.278 -2.527 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 173.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.657 ' CB ' HG23 ' A' ' 52' ' ' ILE . 8.7 p30 -133.81 169.0 17.7 Favored 'General case' 0 N--CA 1.437 -1.108 0 C-N-CA 118.966 -1.094 . . . . 0.0 112.057 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 2.7 p-10 -91.58 -2.1 57.25 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 113.852 -1.522 . . . . 0.0 112.329 -170.826 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 65.8 t80 -113.1 -63.39 1.45 Allowed 'General case' 0 C--N 1.296 -1.752 0 CA-C-O 121.154 0.502 . . . . 0.0 111.59 -174.327 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 70.7 m-20 -100.01 177.1 5.2 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.245 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 21.0 t -97.1 39.07 1.2 Allowed 'General case' 0 N--CA 1.431 -1.386 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 176.089 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 140' ' ' ASP . . . . . 0.56 ' HB3' ' ND2' ' A' ' 135' ' ' ASN . 29.7 t0 -83.31 66.07 8.62 Favored 'General case' 0 CA--C 1.512 -0.509 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 174.159 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 141' ' ' ASP . . . . . 0.567 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 5.6 p-10 -114.1 47.79 1.16 Allowed 'General case' 0 N--CA 1.423 -1.81 0 CA-C-N 112.766 -2.015 . . . . 0.0 108.165 179.021 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 82.0 m-85 -90.92 161.86 15.01 Favored 'General case' 0 N--CA 1.421 -1.881 0 CA-C-N 114.013 -1.449 . . . . 0.0 109.284 -179.557 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 11.4 pt20 -121.98 138.24 54.5 Favored 'General case' 0 N--CA 1.416 -2.152 0 C-N-CA 119.251 -0.98 . . . . 0.0 109.844 178.837 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 11.8 m-30 -105.12 128.98 53.62 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 -176.755 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.6 t -94.67 133.88 34.07 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.116 0 CA-C-O 121.143 0.497 . . . . 0.0 110.24 -178.152 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 146' ' ' TRP . . . . . 0.471 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.2 m95 -120.19 96.83 5.32 Favored 'General case' 0 C--N 1.286 -2.179 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.134 -177.224 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 44.3 m-80 -79.15 112.92 16.85 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 176.383 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.456 ' HA ' HG22 ' A' ' 20' ' ' VAL . 23.9 mm -87.74 120.55 37.02 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 -177.604 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -115.45 153.59 30.82 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 177.593 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.51 132.44 34.2 Favored 'General case' 0 N--CA 1.406 -2.63 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 177.667 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -90.02 -17.18 28.3 Favored 'General case' 0 C--N 1.286 -2.189 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 -176.115 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -146.18 144.31 29.85 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 114.088 -1.415 . . . . 0.0 110.123 -174.755 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -83.45 138.22 33.56 Favored 'General case' 0 C--N 1.317 -0.819 0 O-C-N 124.314 1.009 . . . . 0.0 109.697 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.583 HG22 ' HB ' ' A' ' 120' ' ' ILE . 2.0 m -119.83 151.83 22.44 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 C-N-CA 120.634 -0.426 . . . . 0.0 111.045 -176.898 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.2 t -123.78 140.96 45.69 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 -179.139 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.497 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.4 t -103.2 100.35 17.42 Favored Pre-proline 0 C--N 1.291 -1.945 0 C-N-CA 123.435 0.694 . . . . 0.0 109.864 178.43 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.495 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 35.2 Cg_endo -68.17 -21.04 42.85 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.52 2.147 . . . . 0.0 111.403 177.111 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.423 ' HA ' ' H ' ' A' ' 30' ' ' VAL . 3.1 t . . . . . 0 C--O 1.257 1.453 0 C-N-CA 124.789 1.236 . . . . 0.0 114.128 175.531 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.564 ' CZ ' ' HB3' ' A' ' 133' ' ' GLN . 0.8 OUTLIER . . . . . 0 N--CA 1.436 -1.158 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 . . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.46 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -148.03 -175.76 5.01 Favored 'General case' 0 C--N 1.277 -2.574 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 -175.6 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.5 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 9.6 t -144.32 157.25 44.37 Favored 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 118.864 -1.134 . . . . 0.0 110.175 -175.347 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.44 ' HE3' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.48 164.9 29.49 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-O 121.254 0.55 . . . . 0.0 110.961 -175.335 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.586 HG22 HG22 ' A' ' 20' ' ' VAL . 82.1 p -102.18 176.81 5.07 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.841 -178.61 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.3 -16.51 56.25 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 114.402 -1.272 . . . . 0.0 110.722 176.038 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -90.93 -26.49 19.26 Favored 'General case' 0 CA--C 1.515 -0.375 0 C-N-CA 118.856 -1.137 . . . . 0.0 111.341 -177.467 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.48 4.87 3.43 Favored Glycine 0 CA--C 1.499 -0.932 0 C-N-CA 119.889 -1.148 . . . . 0.0 113.322 171.261 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.6 m -82.67 107.48 15.34 Favored 'General case' 0 N--CA 1.424 -1.759 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.404 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -102.53 109.99 21.78 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.43 176.613 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.46 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 54.8 mt -82.62 124.63 77.34 Favored Pre-proline 0 C--N 1.305 -1.338 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -176.688 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -81.36 161.94 19.83 Favored 'Trans proline' 0 C--O 1.246 0.924 0 C-N-CA 122.61 2.207 . . . . 0.0 111.922 179.073 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.427 HD11 ' N ' ' A' ' 1' ' ' PHE . 58.0 mt -66.27 133.0 31.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.09 179.544 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 126.57 12.24 3.44 Favored Glycine 0 C--N 1.306 -1.1 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.238 -178.661 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.97 148.84 18.93 Favored Glycine 0 C--O 1.241 0.564 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 -178.054 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.62 -172.36 45.17 Favored Glycine 0 CA--C 1.491 -1.415 0 C-N-CA 119.453 -1.356 . . . . 0.0 112.493 -179.693 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.7 p -146.55 151.76 37.86 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 122.654 0.382 . . . . 0.0 110.325 -177.729 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -140.38 166.47 24.63 Favored 'General case' 0 N--CA 1.433 -1.283 0 CA-C-O 121.617 0.722 . . . . 0.0 109.89 178.33 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.39 101.54 8.49 Favored 'General case' 0 C--N 1.28 -2.423 0 CA-C-N 113.833 -1.531 . . . . 0.0 109.307 179.412 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.586 HG22 HG22 ' A' ' 5' ' ' THR . 40.4 t -92.25 134.4 30.53 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.802 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.563 -178.73 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 55.2 m-85 -119.6 126.73 51.9 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 -179.088 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.492 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.7 p -136.86 133.22 48.12 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.249 -177.047 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -93.67 129.77 39.85 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 121.643 0.735 . . . . 0.0 110.482 178.312 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -108.25 160.58 15.73 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 114.466 -1.243 . . . . 0.0 108.196 -179.704 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -59.08 123.7 70.66 Favored Pre-proline 0 C--N 1.314 -0.958 0 O-C-N 124.387 1.054 . . . . 0.0 109.233 177.886 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.426 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 61.8 Cg_endo -74.94 -2.06 12.03 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.632 2.221 . . . . 0.0 113.159 -177.544 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.421 HG13 ' HG3' ' A' ' 157' ' ' PRO . 60.5 t -122.95 109.76 24.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 178.186 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.464 ' O ' HG13 ' A' ' 156' ' ' VAL . 1.7 t -141.1 102.16 1.17 Allowed 'Isoleucine or valine' 0 C--O 1.183 -2.436 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -177.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.58 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -94.01 152.22 18.97 Favored 'General case' 0 C--N 1.274 -2.689 0 O-C-N 122.149 -0.344 . . . . 0.0 111.471 179.878 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.401 HG13 ' O ' ' A' ' 112' ' ' VAL . 35.0 t -45.71 119.88 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 123.26 0.624 . . . . 0.0 112.156 176.912 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.83 1.6 55.13 Favored Glycine 0 N--CA 1.46 0.252 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.595 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.58 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.4 OUTLIER -71.49 -178.53 2.19 Favored 'General case' 0 C--N 1.312 -1.048 0 C-N-CA 124.158 0.983 . . . . 0.0 111.226 177.246 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -129.73 85.06 2.26 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 176.157 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.593 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 17.1 tp -92.98 134.94 34.62 Favored 'General case' 0 N--CA 1.423 -1.806 0 C-N-CA 119.446 -0.902 . . . . 0.0 108.727 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 2.0 p -141.61 132.38 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.515 0 CA-C-O 122.016 0.913 . . . . 0.0 112.366 -177.694 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.604 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 42.5 t -89.31 90.0 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.264 0 CA-C-N 113.665 -1.607 . . . . 0.0 108.376 179.156 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -73.96 103.39 4.44 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 -179.561 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.4 mt -89.94 -3.82 57.83 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 120.75 0.31 . . . . 0.0 111.782 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -73.43 0.81 11.2 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 122.07 0.938 . . . . 0.0 111.574 178.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.9 p -126.72 5.89 6.73 Favored 'General case' 0 N--CA 1.418 -2.033 0 CA-C-N 115.203 -0.908 . . . . 0.0 109.866 176.645 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.492 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 43.9 mm-40 -123.7 -23.15 4.78 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.958 -174.754 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.7 mt -133.7 137.56 52.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 -176.158 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.44 ' HB2' ' HE3' ' A' ' 4' ' ' LYS . 41.7 m-85 -142.41 124.37 15.27 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -175.136 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.5 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 81.7 m -101.27 147.27 26.49 Favored 'General case' 0 C--N 1.291 -1.957 0 N-CA-C 109.46 -0.571 . . . . 0.0 109.46 -179.361 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.464 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 37.0 p-80 -136.7 129.79 31.13 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-O 121.763 0.792 . . . . 0.0 111.649 -173.813 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.505 ' HA ' ' HA ' ' A' ' 1' ' ' PHE . 41.7 t30 -93.05 102.25 14.58 Favored 'General case' 0 C--N 1.28 -2.446 0 C-N-CA 119.991 -0.684 . . . . 0.0 110.533 179.233 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -56.22 -27.91 56.48 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 124.804 1.241 . . . . 0.0 111.016 179.747 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.476 ' HB2' HD13 ' A' ' 52' ' ' ILE . 38.8 m-85 -125.84 79.17 68.82 Favored Pre-proline 0 C--N 1.309 -1.169 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 -177.383 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.496 ' HA ' ' ND2' ' A' ' 46' ' ' ASN . 57.8 Cg_endo -67.89 -7.33 19.33 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.852 2.368 . . . . 0.0 115.19 -170.503 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -120.76 -11.37 9.01 Favored 'General case' 0 C--N 1.311 -1.068 0 C-N-CA 120.253 -0.579 . . . . 0.0 111.073 -179.391 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.49 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.9 OUTLIER -104.79 -30.23 10.03 Favored 'General case' 0 N--CA 1.435 -1.206 0 CA-C-O 122.128 0.966 . . . . 0.0 109.128 -171.631 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.49 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.0 mp -121.29 136.27 58.75 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.167 0 CA-C-N 114.351 -1.295 . . . . 0.0 109.807 -177.321 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 1.8 t -90.25 126.6 35.89 Favored 'General case' 0 N--CA 1.417 -2.08 0 N-CA-C 102.984 -2.969 . . . . 0.0 102.984 170.06 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.549 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 13.3 t70 -83.55 112.73 20.26 Favored 'General case' 0 C--N 1.274 -2.693 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 -172.155 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.575 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 22.0 t80 -127.77 123.31 34.97 Favored 'General case' 0 C--N 1.272 -2.801 0 CA-C-O 122.054 0.931 . . . . 0.0 110.671 -175.355 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.51 HG23 ' HG ' ' A' ' 131' ' ' LEU . 14.1 p -126.68 148.65 31.42 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.469 0 CA-C-N 114.334 -1.303 . . . . 0.0 109.802 -177.377 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.56 121.7 8.32 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.365 175.473 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.502 HD12 ' O ' ' A' ' 130' ' ' ILE . 53.0 tp -65.33 115.56 5.75 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 173.274 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.475 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 3.8 tp-100 -62.67 -61.65 2.27 Favored 'General case' 0 C--O 1.209 -1.038 0 C-N-CA 125.419 1.488 . . . . 0.0 109.499 178.764 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.414 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 9.9 ptp180 -158.61 159.36 35.36 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-N 114.513 -1.222 . . . . 0.0 108.227 -176.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.4 ' H ' HG22 ' A' ' 86' ' ' THR . . . -141.12 131.54 4.94 Favored Glycine 0 N--CA 1.399 -3.808 0 N-CA-C 108.478 -1.849 . . . . 0.0 108.478 -179.707 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 69.5 m -120.14 145.9 46.49 Favored 'General case' 0 C--N 1.28 -2.44 0 O-C-N 124.679 0.87 . . . . 0.0 110.475 -173.807 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.557 ' HB2' ' CE2' ' A' ' 84' ' ' PHE . . . -108.2 157.08 18.63 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.497 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 94.2 m-85 -157.07 -179.44 8.21 Favored 'General case' 0 C--O 1.235 0.325 0 C-N-CA 124.776 1.231 . . . . 0.0 108.949 -178.069 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 61.11 -144.19 48.63 Favored Glycine 0 CA--C 1.506 -0.516 0 O-C-N 123.489 0.493 . . . . 0.0 112.313 177.594 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -76.33 -9.58 85.75 Favored Glycine 0 C--O 1.2 -2.028 0 C-N-CA 120.892 -0.67 . . . . 0.0 111.698 176.425 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.755 HG21 ' HB ' ' A' ' 126' ' ' ILE . 80.1 t -68.63 -41.59 82.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 123.341 0.656 . . . . 0.0 111.796 -177.691 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.531 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -84.95 -16.47 40.87 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.154 -1.019 . . . . 0.0 112.072 178.727 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 22.7 t -100.6 -59.8 1.64 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.461 0.648 . . . . 0.0 111.692 -174.595 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 63.3 m-20 -86.32 -25.84 25.22 Favored 'General case' 0 CA--C 1.488 -1.426 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.403 -174.14 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.673 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 85.8 m-85 -107.66 160.93 15.32 Favored 'General case' 0 N--CA 1.412 -2.334 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.166 178.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.9 t -169.1 139.17 2.23 Favored 'General case' 0 N--CA 1.406 -2.626 0 N-CA-C 106.136 -1.802 . . . . 0.0 106.136 176.483 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.438 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -172.84 -104.23 0.17 Allowed Glycine 0 N--CA 1.411 -3.025 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 175.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.416 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.3 p -162.9 -179.61 6.9 Favored 'General case' 0 C--N 1.311 -1.106 0 C-N-CA 124.088 0.955 . . . . 0.0 110.895 -175.905 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -132.27 145.51 34.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 177.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.661 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.5 tttt -122.85 146.4 47.59 Favored 'General case' 0 N--CA 1.419 -2.007 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.443 -179.456 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.491 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 68.8 t80 -145.53 109.68 4.9 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.3 m 54.24 44.08 29.6 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 176.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 81.72 7.17 88.42 Favored Glycine 0 C--N 1.31 -0.873 0 C-N-CA 119.901 -1.142 . . . . 0.0 112.914 -179.589 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.661 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 13.0 t -82.08 174.24 11.41 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 178.038 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 21.8 t -153.14 111.75 3.71 Favored 'General case' 0 C--N 1.28 -2.435 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 -179.268 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.491 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 4.7 p90 -154.77 160.5 30.85 Favored Pre-proline 0 CA--C 1.551 1.001 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -174.579 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.427 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 50.0 Cg_endo -68.45 150.0 75.23 Favored 'Trans proline' 0 C--N 1.36 1.144 0 C-N-CA 122.942 2.428 . . . . 0.0 113.496 -176.756 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.607 ' CD2' HD21 ' A' ' 109' ' ' LEU . 53.1 t80 -124.86 133.79 25.1 Favored Pre-proline 0 N--CA 1.441 -0.882 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.777 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.5 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 59.3 Cg_endo -70.25 148.3 87.54 Favored 'Cis proline' 0 CA--C 1.541 0.848 0 C-N-CA 122.682 -1.799 . . . . 0.0 109.747 -2.032 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.4 HG22 ' H ' ' A' ' 61' ' ' GLY . 8.8 t -67.08 -178.23 0.76 Allowed 'General case' 0 CA--C 1.55 0.967 0 CA-C-O 121.972 0.891 . . . . 0.0 111.742 -174.849 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 13.2 p -127.67 -28.68 2.71 Favored 'General case' 0 N--CA 1.425 -1.677 0 CA-C-N 114.929 -1.032 . . . . 0.0 112.931 -169.343 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.7 t -128.1 -79.9 0.58 Allowed 'General case' 0 N--CA 1.432 -1.373 0 C-N-CA 119.086 -1.046 . . . . 0.0 111.726 -176.483 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -170.98 -177.99 2.37 Favored 'General case' 0 C--O 1.246 0.906 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 -179.513 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.441 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 15.6 p -101.54 165.8 13.41 Favored Pre-proline 0 C--N 1.296 -1.758 0 N-CA-C 113.241 0.83 . . . . 0.0 113.241 -179.527 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' PRO . . . . . 0.415 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 36.3 Cg_endo -64.08 158.4 48.13 Favored 'Trans proline' 0 C--N 1.361 1.235 0 C-N-CA 122.784 2.323 . . . . 0.0 111.772 173.083 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.575 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 4.6 tmm_? -72.33 119.38 16.44 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 114.679 -1.146 . . . . 0.0 109.574 -177.843 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 86.0 t -131.77 120.19 44.05 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.723 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.452 HG23 HH11 ' A' ' 92' ' ' ARG . 84.2 t -108.99 126.09 66.04 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.637 179.669 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.569 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 5.5 m-85 -76.65 105.15 7.54 Favored 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 123.816 0.847 . . . . 0.0 109.971 177.563 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 34.2 m-80 -96.34 57.63 1.7 Allowed 'General case' 0 C--N 1.287 -2.144 0 CA-C-O 122.462 1.125 . . . . 0.0 108.783 178.081 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 33.0 m -124.3 174.29 7.82 Favored 'General case' 0 N--CA 1.418 -2.073 0 CA-C-N 113.775 -1.557 . . . . 0.0 109.27 -176.449 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.0 ptp180 -127.93 12.33 6.7 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 112.142 0.423 . . . . 0.0 112.142 -176.727 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.1 t -160.51 -171.77 3.28 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -177.738 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ASP . . . . . 0.464 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 3.7 p30 -67.79 132.15 46.88 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.076 0.465 . . . . 0.0 109.853 178.661 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 12.5 mmtm -139.75 146.75 48.72 Favored Pre-proline 0 C--N 1.291 -1.945 0 C-N-CA 124.553 1.141 . . . . 0.0 109.034 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -61.61 147.0 96.41 Favored 'Trans proline' 0 C--O 1.25 1.089 0 C-N-CA 123.321 2.681 . . . . 0.0 113.412 -175.113 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' TRP . . . . . 0.569 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 8.6 t90 -92.61 105.61 15.23 Favored Pre-proline 0 C--N 1.31 -1.124 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -74.76 89.11 1.15 Allowed 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 121.983 1.789 . . . . 0.0 112.584 -174.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 90.7 t -139.02 143.68 31.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 N-CA-C 107.313 -1.365 . . . . 0.0 107.313 176.32 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.604 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -149.9 136.38 19.09 Favored 'General case' 0 N--CA 1.412 -2.371 0 CA-C-O 120.831 0.348 . . . . 0.0 110.48 178.939 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.453 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 18.4 mt -103.21 100.09 9.98 Favored 'General case' 0 C--N 1.289 -2.06 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.283 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.438 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 55.8 m-85 -80.39 76.48 7.2 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 178.053 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.673 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.1 mm? -102.93 122.6 44.92 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 177.054 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -125.09 147.01 55.65 Favored Pre-proline 0 N--CA 1.41 -2.465 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.154 -173.678 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.478 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 30.7 Cg_endo -61.8 117.82 4.67 Favored 'Trans proline' 0 C--O 1.245 0.864 0 C-N-CA 123.167 2.578 . . . . 0.0 111.768 -177.514 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 70' ' ' ASN . 2.6 m -65.3 -116.28 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.192 -1.934 0 CA-C-N 114.365 -1.289 . . . . 0.0 113.546 177.501 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 17.8 m -111.9 -41.74 3.94 Favored 'General case' 0 C--N 1.287 -2.115 0 O-C-N 121.464 -0.772 . . . . 0.0 110.624 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 5.8 t -93.14 28.27 2.21 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.911 0.862 . . . . 0.0 110.589 -173.713 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -89.62 135.04 33.84 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 178.442 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -172.03 143.57 7.55 Favored Glycine 0 N--CA 1.432 -1.632 0 C-N-CA 120.083 -1.056 . . . . 0.0 111.294 179.497 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' GLY . . . . . 0.407 ' HA2' ' CG1' ' A' ' 155' ' ' VAL . . . 57.24 -147.06 35.65 Favored Glycine 0 CA--C 1.497 -1.091 0 CA-C-O 119.177 -0.791 . . . . 0.0 112.87 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.403 HG11 ' HE3' ' A' ' 121' ' ' LYS . 97.5 t -56.77 99.85 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-O 121.937 0.875 . . . . 0.0 110.867 -179.069 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -100.25 -35.34 9.66 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.966 -178.874 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.547 ' HB ' HG22 ' A' ' 154' ' ' VAL . 69.8 mt -121.72 137.39 55.51 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 178.48 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.423 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.9 mmpt? -111.07 136.46 50.06 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 122.991 0.516 . . . . 0.0 111.212 178.462 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.63 134.51 46.41 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.263 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 86.29 -4.49 85.99 Favored Glycine 0 N--CA 1.442 -0.904 0 N-CA-C 111.709 -0.556 . . . . 0.0 111.709 -179.171 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 37.5 m -96.06 151.01 19.85 Favored 'General case' 0 N--CA 1.427 -1.578 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -178.17 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.454 HD11 HG23 ' A' ' 128' ' ' VAL . 3.3 tm? -77.75 121.3 23.86 Favored 'General case' 0 N--CA 1.427 -1.594 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 -177.533 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.755 ' HB ' HG21 ' A' ' 67' ' ' VAL . 36.7 pt -108.12 -27.18 3.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 CA-C-N 116.157 -0.474 . . . . 0.0 112.139 -178.024 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' ALA . . . . . 0.403 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.75 167.41 25.03 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 110.243 -0.28 . . . . 0.0 110.243 -178.315 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.454 HG23 HD11 ' A' ' 125' ' ' LEU . 64.8 t -142.16 113.61 3.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 179.88 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 63.5 mt -114.64 139.55 49.55 Favored 'General case' 0 C--N 1.289 -2.053 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.662 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.502 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.3 mp -119.13 124.0 72.36 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 119.326 -0.95 . . . . 0.0 110.105 178.435 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.525 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.1 OUTLIER -99.19 131.84 44.94 Favored 'General case' 0 C--N 1.278 -2.52 0 C-N-CA 124.236 1.015 . . . . 0.0 111.033 -176.869 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.475 ' HG2' ' HB2' ' A' ' 59' ' ' GLN . 12.5 mmm180 -95.56 125.13 39.94 Favored 'General case' 0 C--N 1.295 -1.802 0 C-N-CA 124.108 0.963 . . . . 0.0 109.481 179.454 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.564 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 20.9 mm-40 -107.18 113.12 26.35 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 177.52 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.478 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 26.2 m -136.25 141.85 43.95 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.478 ' CB ' HG23 ' A' ' 52' ' ' ILE . 8.9 p30 -141.86 168.39 19.87 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.469 175.475 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -75.82 -14.93 60.3 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 114.678 -1.146 . . . . 0.0 112.627 -170.747 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 73.1 t80 -107.78 -62.07 1.49 Allowed 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 122.863 0.465 . . . . 0.0 111.41 -174.171 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' ASN . . . . . 0.427 ' HB3' ' H ' ' A' ' 140' ' ' ASP . 14.9 m120 -77.43 144.62 37.7 Favored 'General case' 0 CA--C 1.485 -1.534 0 CA-C-O 121.325 0.583 . . . . 0.0 110.172 178.516 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 25.5 m -91.65 11.2 25.15 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 114.516 -1.22 . . . . 0.0 107.998 172.836 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 140' ' ' ASP . . . . . 0.427 ' H ' ' HB3' ' A' ' 138' ' ' ASN . 12.2 m-20 -74.09 70.4 1.56 Allowed 'General case' 0 CA--C 1.512 -0.501 0 C-N-CA 125.382 1.473 . . . . 0.0 109.554 177.22 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -93.28 92.06 7.53 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-N 113.764 -1.562 . . . . 0.0 109.288 -176.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -127.24 164.4 21.79 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.957 -176.857 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -127.01 146.41 50.36 Favored 'General case' 0 N--CA 1.424 -1.757 0 CA-C-O 121.324 0.583 . . . . 0.0 110.891 178.618 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.465 ' HB2' HD22 ' A' ' 131' ' ' LEU . 11.9 m-30 -113.24 135.82 53.41 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 -176.736 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 49.3 t -92.44 130.69 41.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 122.802 0.441 . . . . 0.0 109.837 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 146' ' ' TRP . . . . . 0.525 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 61.8 m95 -119.38 101.08 7.71 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.804 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 48.7 m-80 -79.79 114.65 18.87 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 177.757 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.419 HG22 HD11 ' A' ' 126' ' ' ILE . 26.1 mm -88.05 120.24 36.75 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.947 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 -178.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -116.09 150.3 37.56 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.507 179.022 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.8 131.23 35.2 Favored 'General case' 0 N--CA 1.406 -2.636 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 176.517 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -88.93 -16.49 31.7 Favored 'General case' 0 C--N 1.288 -2.081 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -178.027 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -147.29 141.14 25.79 Favored 'General case' 0 N--CA 1.434 -1.249 0 CA-C-N 114.224 -1.353 . . . . 0.0 110.32 -173.423 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -80.84 139.47 35.95 Favored 'General case' 0 C--N 1.311 -1.088 0 O-C-N 124.3 1.0 . . . . 0.0 109.348 178.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.547 HG22 ' HB ' ' A' ' 120' ' ' ILE . 2.2 m -120.91 153.29 24.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 120.715 -0.394 . . . . 0.0 110.713 -177.713 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 155' ' ' VAL . . . . . 0.407 ' CG1' ' HA2' ' A' ' 117' ' ' GLY . 2.9 t -124.21 142.47 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.032 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 -178.769 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.464 HG13 ' O ' ' A' ' 28' ' ' VAL . 70.4 t -103.95 102.59 32.51 Favored Pre-proline 0 C--N 1.291 -1.952 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 177.475 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.491 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 20.6 Cg_endo -66.22 -26.92 49.0 Favored 'Trans proline' 0 C--O 1.212 -0.809 0 C-N-CA 122.426 2.084 . . . . 0.0 111.924 177.665 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.431 ' HB ' HG12 ' A' ' 156' ' ' VAL . 6.6 t . . . . . 0 C--O 1.252 1.23 0 C-N-CA 124.425 1.09 . . . . 0.0 113.229 176.367 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 12.5 t80 . . . . . 0 CA--C 1.498 -1.054 0 N-CA-C 105.605 -1.998 . . . . 0.0 105.605 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.436 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -146.29 -176.63 5.24 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 -179.489 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.495 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 16.4 t -154.83 157.29 37.68 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.772 -0.771 . . . . 0.0 109.436 -176.331 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.648 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.37 161.91 37.79 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-O 121.131 0.491 . . . . 0.0 110.856 -175.195 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 50.5 p -101.56 172.46 6.95 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-O 121.949 0.881 . . . . 0.0 110.426 178.139 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.58 -10.15 59.19 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 113.591 -1.64 . . . . 0.0 111.607 -178.123 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -87.14 -33.24 19.49 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 119.301 -0.96 . . . . 0.0 108.562 176.281 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.55 3.82 3.66 Favored Glycine 0 N--CA 1.441 -1.019 0 C-N-CA 120.139 -1.029 . . . . 0.0 112.702 178.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.9 m -78.48 99.44 6.45 Favored 'General case' 0 N--CA 1.433 -1.306 0 CA-C-N 117.129 0.465 . . . . 0.0 109.886 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -93.47 119.46 32.59 Favored 'General case' 0 N--CA 1.424 -1.764 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 176.347 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.436 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 72.4 mt -85.63 124.84 70.7 Favored Pre-proline 0 C--N 1.285 -2.238 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -77.8 167.0 24.55 Favored 'Trans proline' 0 N--CA 1.448 -1.169 0 C-N-CA 122.673 2.249 . . . . 0.0 110.623 178.226 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 55.3 mt -73.29 125.8 32.88 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 -178.558 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 138.34 7.48 1.26 Allowed Glycine 0 C--N 1.308 -1.013 0 C-N-CA 120.564 -0.826 . . . . 0.0 112.888 -179.026 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.12 142.89 9.17 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 -177.731 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -179.67 -168.37 38.39 Favored Glycine 0 CA--C 1.49 -1.487 0 C-N-CA 120.031 -1.081 . . . . 0.0 111.42 -179.032 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.475 ' HB3' ' HB ' ' A' ' 145' ' ' VAL . 20.4 p -149.6 147.02 27.63 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.23 162.83 31.87 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 179.589 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 26.8 m-80 -114.74 112.32 22.64 Favored 'General case' 0 C--N 1.29 -2.0 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 178.11 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.406 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.8 m -96.04 148.63 5.15 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.231 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 -179.33 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -130.73 130.47 43.84 Favored 'General case' 0 CA--C 1.492 -1.285 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 -179.11 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.616 ' HB ' ' HG2' ' A' ' 41' ' ' GLN . 2.9 p -133.55 132.13 57.37 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.925 0 O-C-N 124.098 0.874 . . . . 0.0 110.572 -176.148 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -92.12 128.37 37.94 Favored 'General case' 0 C--N 1.286 -2.157 0 CA-C-O 121.629 0.728 . . . . 0.0 109.8 177.48 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -106.89 161.32 14.81 Favored 'General case' 0 C--N 1.28 -2.419 0 CA-C-N 114.341 -1.299 . . . . 0.0 108.036 179.634 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.52 121.61 61.76 Favored Pre-proline 0 C--N 1.304 -1.391 0 O-C-N 124.144 0.903 . . . . 0.0 108.779 176.069 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.523 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 64.5 Cg_endo -74.26 -1.16 10.58 Favored 'Trans proline' 0 CA--C 1.531 0.355 0 C-N-CA 122.851 2.368 . . . . 0.0 113.431 -176.818 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.485 HG13 ' HG3' ' A' ' 157' ' ' PRO . 94.9 t -125.92 110.56 24.26 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 176.609 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.525 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.1 t -142.14 106.25 1.43 Allowed 'Isoleucine or valine' 0 C--O 1.182 -2.479 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 -176.551 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.574 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -95.7 150.58 20.22 Favored 'General case' 0 C--N 1.268 -2.972 0 C-N-CA 122.888 0.475 . . . . 0.0 111.617 -179.745 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.567 HG22 ' O ' ' A' ' 112' ' ' VAL . 75.7 t -46.1 118.79 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 123.472 0.709 . . . . 0.0 111.38 176.649 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 105.01 -3.99 41.43 Favored Glycine 0 C--N 1.318 -0.468 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.642 -179.659 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.574 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.6 OUTLIER -68.81 -178.0 1.11 Allowed 'General case' 0 CA--C 1.499 -1.013 0 C-N-CA 124.555 1.142 . . . . 0.0 111.544 178.286 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 66.9 t30 -127.39 87.53 2.65 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 174.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.546 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 14.9 tp -96.63 133.95 40.49 Favored 'General case' 0 N--CA 1.405 -2.688 0 C-N-CA 118.852 -1.139 . . . . 0.0 108.029 177.419 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.453 ' CG2' ' HB1' ' A' ' 106' ' ' ALA . 2.0 p -141.19 129.72 23.52 Favored 'Isoleucine or valine' 1 N--CA 1.377 -4.107 0 CA-C-O 122.022 0.915 . . . . 0.0 111.183 -179.666 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.585 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 44.8 t -90.12 89.1 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.385 -3.713 0 CA-C-N 113.081 -1.872 . . . . 0.0 107.159 -178.728 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -75.87 133.31 40.61 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 176.566 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.402 ' HA ' ' OE1' ' A' ' 41' ' ' GLN . 86.9 mt -115.14 11.43 16.34 Favored 'General case' 0 C--N 1.295 -1.779 0 O-C-N 123.838 0.711 . . . . 0.0 111.26 179.225 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.682 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 1.5 m -87.0 1.69 51.98 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 -174.698 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.2 m -120.47 0.68 10.57 Favored 'General case' 0 N--CA 1.394 -3.232 0 CA-C-O 122.168 0.985 . . . . 0.0 108.779 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.616 ' HG2' ' HB ' ' A' ' 22' ' ' VAL . 22.1 mp0 -120.78 -34.22 3.61 Favored 'General case' 0 CA--C 1.473 -1.986 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.285 -172.282 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 23.1 mt -119.56 137.11 54.53 Favored 'Isoleucine or valine' 0 C--N 1.267 -2.981 0 CA-C-N 114.903 -1.044 . . . . 0.0 108.988 -177.45 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.648 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 42.4 m-85 -142.07 124.45 15.67 Favored 'General case' 0 CA--C 1.511 -0.553 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -176.469 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.495 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 81.9 m -106.57 140.17 39.87 Favored 'General case' 0 C--N 1.287 -2.142 0 CA-C-O 121.107 0.48 . . . . 0.0 110.618 -177.882 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.461 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 5.1 p80 -124.28 132.85 53.59 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 122.356 1.074 . . . . 0.0 113.433 -174.565 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.46 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 14.8 p-10 -93.15 93.6 8.36 Favored 'General case' 0 C--N 1.279 -2.464 0 CA-C-N 114.299 -1.319 . . . . 0.0 109.46 177.51 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -78.3 -21.04 50.28 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.773 -1.103 . . . . 0.0 111.288 -176.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 72.2 m-85 -136.51 70.72 59.96 Favored Pre-proline 0 C--N 1.313 -0.987 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 176.475 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.46 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 56.0 Cg_endo -70.14 -10.98 29.5 Favored 'Trans proline' 0 N--CA 1.483 0.874 0 C-N-CA 122.698 2.266 . . . . 0.0 112.52 -176.205 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -107.32 -17.44 14.14 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-O 121.402 0.62 . . . . 0.0 110.035 -176.102 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.567 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -101.8 -30.71 11.13 Favored 'General case' 0 N--CA 1.414 -2.259 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 -175.818 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.699 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.9 mp -129.05 139.69 51.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.3 t -80.33 147.45 31.09 Favored 'General case' 0 C--O 1.252 1.204 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 178.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -80.73 107.68 13.75 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 -173.295 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.421 ' HE1' ' HG3' ' A' ' 92' ' ' ARG . 75.1 t80 -150.84 145.7 25.86 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.319 -175.31 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.423 HG23 HD13 ' A' ' 131' ' ' LEU . 11.4 p -153.92 152.28 10.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 174.572 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -151.36 138.02 18.79 Favored 'General case' 0 C--O 1.207 -1.149 0 CA-C-O 119.102 -0.475 . . . . 0.0 110.263 174.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.53 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 50.4 tp -76.17 113.14 13.38 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 174.016 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.4 tp-100 -59.52 -51.53 69.47 Favored 'General case' 0 C--N 1.316 -0.878 0 C-N-CA 125.549 1.539 . . . . 0.0 111.102 -179.327 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -172.81 157.11 3.61 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 -177.832 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -131.84 146.71 18.26 Favored Glycine 0 N--CA 1.41 -3.036 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 -178.813 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 69.9 m -130.16 148.89 52.05 Favored 'General case' 0 C--N 1.286 -2.177 0 O-C-N 124.52 0.776 . . . . 0.0 109.666 -178.046 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.512 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -113.53 157.77 21.6 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.512 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 97.5 m-85 -155.18 179.25 9.33 Favored 'General case' 0 C--N 1.345 0.396 0 C-N-CA 124.497 1.119 . . . . 0.0 109.59 -177.376 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 55.13 -145.42 30.47 Favored Glycine 0 C--N 1.331 0.299 0 O-C-N 123.975 0.797 . . . . 0.0 113.475 176.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.63 -13.03 74.51 Favored Glycine 0 C--O 1.205 -1.704 0 C-N-CA 120.957 -0.639 . . . . 0.0 111.692 178.263 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.826 HG21 ' HB ' ' A' ' 126' ' ' ILE . 98.6 t -67.21 -42.7 88.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 C-N-CA 123.359 0.663 . . . . 0.0 111.528 -178.234 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.512 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -84.81 -15.13 45.91 Favored 'General case' 0 C--N 1.308 -1.235 0 C-N-CA 119.112 -1.035 . . . . 0.0 112.055 179.531 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 36.5 t -100.31 -59.98 1.61 Allowed 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.851 -174.634 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.537 ' O ' HG22 ' A' ' 112' ' ' VAL . 46.9 m-20 -92.13 -23.95 19.26 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.076 -171.784 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.685 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 88.6 m-85 -106.9 154.83 20.47 Favored 'General case' 0 N--CA 1.42 -1.933 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.399 179.505 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.3 t -162.09 136.49 6.78 Favored 'General case' 0 N--CA 1.407 -2.594 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.68 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.546 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -168.69 -103.43 0.17 Allowed Glycine 0 C--N 1.275 -2.843 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 175.003 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.424 HG22 ' HA ' ' A' ' 83' ' ' PRO . 0.7 OUTLIER -168.22 179.97 4.29 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 124.688 1.195 . . . . 0.0 109.264 -176.337 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.42 ' HB ' ' HB2' ' A' ' 84' ' ' PHE . 2.9 p -129.5 148.23 33.27 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 N-CA-C 109.684 -0.488 . . . . 0.0 109.684 178.643 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.555 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.2 tttt -127.19 144.26 51.08 Favored 'General case' 0 N--CA 1.427 -1.621 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.214 -179.189 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.519 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 58.6 t80 -140.89 104.72 4.74 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.27 -0.877 . . . . 0.0 108.86 -179.106 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 15.5 t 48.58 48.18 19.88 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 124.39 1.076 . . . . 0.0 111.834 177.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.59 5.36 69.21 Favored Glycine 0 N--CA 1.441 -0.991 0 CA-C-N 115.497 -0.774 . . . . 0.0 114.219 178.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.555 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 17.8 t -80.08 178.93 7.9 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 24.3 p -155.89 108.77 2.67 Favored 'General case' 0 C--N 1.293 -1.879 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.439 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.519 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.8 p90 -155.38 158.67 31.98 Favored Pre-proline 0 C--N 1.314 -0.947 0 O-C-N 122.195 -0.316 . . . . 0.0 110.258 -174.223 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.424 ' HA ' HG22 ' A' ' 74' ' ' THR . 43.4 Cg_endo -67.25 147.71 79.02 Favored 'Trans proline' 0 C--N 1.364 1.343 0 C-N-CA 123.28 2.654 . . . . 0.0 113.362 -177.848 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.63 ' CD2' HD21 ' A' ' 109' ' ' LEU . 63.6 t80 -123.13 135.27 25.75 Favored Pre-proline 0 N--CA 1.435 -1.201 0 CA-C-N 115.615 -0.72 . . . . 0.0 109.817 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.498 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 73.9 Cg_endo -72.59 145.22 83.1 Favored 'Cis proline' 0 CA--C 1.541 0.832 0 C-N-CA 123.144 -1.607 . . . . 0.0 110.411 -3.692 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.1 t -69.81 -177.02 1.18 Allowed 'General case' 0 CA--C 1.553 1.085 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.453 -176.12 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 39.4 p -122.61 -34.97 3.15 Favored 'General case' 0 N--CA 1.439 -0.994 0 CA-C-O 121.431 0.634 . . . . 0.0 110.354 -170.072 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.0 t -126.83 -131.46 0.24 Allowed 'General case' 0 N--CA 1.389 -3.492 0 N-CA-C 104.416 -2.438 . . . . 0.0 104.416 174.798 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -113.64 -169.86 1.59 Allowed 'General case' 0 C--N 1.286 -2.169 0 N-CA-C 113.05 0.759 . . . . 0.0 113.05 -173.19 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.53 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 35.0 p -97.49 170.52 7.09 Favored Pre-proline 0 C--N 1.31 -1.114 0 CA-C-N 115.439 -0.8 . . . . 0.0 111.843 178.601 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' PRO . . . . . 0.452 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 37.2 Cg_endo -65.4 166.39 19.59 Favored 'Trans proline' 0 C--O 1.251 1.148 0 C-N-CA 122.277 1.985 . . . . 0.0 109.707 170.044 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.421 ' HG3' ' HE1' ' A' ' 55' ' ' TYR . 47.7 ttp180 -73.32 140.12 46.52 Favored 'General case' 0 C--N 1.308 -1.212 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.768 -179.356 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 56.2 t -141.07 120.61 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.898 0 CA-C-N 114.925 -1.034 . . . . 0.0 109.314 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 70.8 t -95.39 140.51 16.79 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.896 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 175.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -87.85 100.75 13.11 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 175.412 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 17.4 m120 -89.11 60.27 5.31 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.649 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.6 m -135.3 178.3 7.14 Favored 'General case' 0 N--CA 1.425 -1.716 0 CA-C-N 114.44 -1.254 . . . . 0.0 109.076 -174.385 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 16.9 ptp180 -148.81 45.01 1.01 Allowed 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 122.007 0.908 . . . . 0.0 109.462 175.863 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.3 t -170.58 -175.36 1.84 Allowed 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 -176.842 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ASP . . . . . 0.461 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 9.2 p-10 -77.06 99.0 5.18 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-O 122.153 0.977 . . . . 0.0 108.398 172.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' LYS . . . . . 0.404 ' HG3' ' HD2' ' A' ' 102' ' ' PRO . 2.8 tptm -101.04 136.17 19.79 Favored Pre-proline 0 N--CA 1.405 -2.724 0 CA-C-N 114.939 -1.028 . . . . 0.0 108.233 -177.851 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.682 ' HB3' ' O ' ' A' ' 39' ' ' SER . 80.0 Cg_exo -48.43 139.66 22.31 Favored 'Trans proline' 0 C--N 1.324 -0.752 0 C-N-CA 123.939 3.093 . . . . 0.0 113.658 177.383 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.5 t90 -90.11 105.69 12.17 Favored Pre-proline 0 C--N 1.31 -1.146 0 N-CA-C 106.754 -1.573 . . . . 0.0 106.754 -178.888 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -73.78 89.27 1.0 Allowed 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.293 1.995 . . . . 0.0 112.686 -173.464 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.48 HG22 ' CD2' ' A' ' 77' ' ' TYR . 90.1 t -136.31 145.2 31.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 177.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.585 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.96 133.08 15.28 Favored 'General case' 0 N--CA 1.417 -2.078 0 CA-C-O 121.06 0.457 . . . . 0.0 110.766 178.071 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.475 HD21 HD11 ' A' ' 129' ' ' LEU . 14.2 mt -101.93 100.12 10.39 Favored 'General case' 0 C--N 1.288 -2.086 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 179.03 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.546 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 63.1 m-85 -77.38 78.24 3.91 Favored 'General case' 0 C--N 1.306 -1.298 0 O-C-N 122.067 -0.395 . . . . 0.0 110.255 177.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.685 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.0 mm? -104.56 118.24 36.11 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-O 121.167 0.508 . . . . 0.0 110.066 176.732 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.79 145.93 46.75 Favored Pre-proline 0 N--CA 1.414 -2.238 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.889 -173.628 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -63.43 121.61 9.47 Favored 'Trans proline' 0 CA--C 1.5 -1.195 0 C-N-CA 122.986 2.457 . . . . 0.0 113.57 -175.23 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.567 ' O ' HG22 ' A' ' 30' ' ' VAL . 19.8 m -82.0 -155.27 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.399 -3.0 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.108 171.498 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 8.5 m -79.73 -29.92 40.73 Favored 'General case' 0 C--N 1.257 -3.447 0 CA-C-O 121.515 0.674 . . . . 0.0 110.721 -167.799 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 5.3 t -91.47 25.5 2.6 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-O 121.664 0.745 . . . . 0.0 110.514 -176.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.419 ' HB1' HG21 ' A' ' 156' ' ' VAL . . . -102.83 128.74 49.47 Favored 'General case' 0 N--CA 1.418 -2.061 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.883 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.99 128.88 1.72 Allowed Glycine 0 C--N 1.307 -1.048 0 C-N-CA 120.151 -1.023 . . . . 0.0 111.765 -178.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.24 -152.71 52.81 Favored Glycine 0 CA--C 1.493 -1.343 0 CA-C-O 118.925 -0.931 . . . . 0.0 111.532 -176.879 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 63.4 t -55.85 106.04 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.246 0.914 0 CA-C-O 121.586 0.708 . . . . 0.0 110.79 -177.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -106.27 -33.07 7.91 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 114.535 -1.211 . . . . 0.0 110.622 -178.871 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.499 ' HB ' HG22 ' A' ' 154' ' ' VAL . 74.8 mt -121.54 139.91 47.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 177.526 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.421 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.8 mmpt? -115.47 136.41 53.11 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 123.138 0.575 . . . . 0.0 110.973 178.547 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -72.13 131.11 42.37 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.709 178.821 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 92.29 -5.3 77.93 Favored Glycine 0 C--N 1.309 -0.953 0 N-CA-C 111.561 -0.616 . . . . 0.0 111.561 -178.463 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 61.3 m -98.4 149.04 23.08 Favored 'General case' 0 N--CA 1.425 -1.719 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 179.556 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 26.6 tp -72.69 138.19 46.45 Favored 'General case' 0 N--CA 1.433 -1.31 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.14 178.695 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.826 ' HB ' HG21 ' A' ' 67' ' ' VAL . 34.4 pt -121.27 -27.08 2.02 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 N-CA-C 112.392 0.516 . . . . 0.0 112.392 178.708 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.93 168.79 20.68 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -177.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 75.1 t -143.55 116.18 3.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 179.176 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.475 HD11 HD21 ' A' ' 107' ' ' LEU . 63.4 mt -117.37 154.46 31.27 Favored 'General case' 0 C--N 1.283 -2.297 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 179.173 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.494 ' O ' HD12 ' A' ' 58' ' ' LEU . 5.0 mp -135.73 127.69 45.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.821 -0.549 . . . . 0.0 109.704 177.623 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.454 ' C ' HD12 ' A' ' 131' ' ' LEU . 1.2 pp -89.34 150.18 22.69 Favored 'General case' 0 CA--C 1.484 -1.592 0 N-CA-C 106.673 -1.602 . . . . 0.0 106.673 173.693 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 54.5 ttp180 -115.71 120.93 40.95 Favored 'General case' 0 C--N 1.269 -2.917 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 176.862 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.685 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 21.9 tp60 -93.96 121.22 35.2 Favored 'General case' 0 N--CA 1.422 -1.83 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -175.076 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 27.7 m -133.47 149.78 51.74 Favored 'General case' 0 C--N 1.292 -1.92 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 174.6 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.699 ' CB ' HG23 ' A' ' 52' ' ' ILE . 8.0 p30 -149.09 166.87 27.45 Favored 'General case' 0 C--O 1.213 -0.866 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.59 175.723 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -82.14 -17.22 47.15 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 114.21 -1.359 . . . . 0.0 112.714 -170.797 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 44.5 t80 -99.58 -65.66 0.95 Allowed 'General case' 0 C--N 1.295 -1.779 0 CA-C-O 121.173 0.511 . . . . 0.0 110.459 -173.424 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 -97.1 155.98 16.58 Favored 'General case' 0 C--N 1.287 -2.144 0 N-CA-C 108.615 -0.884 . . . . 0.0 108.615 177.796 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 10.9 p -91.39 45.75 1.26 Allowed 'General case' 0 C--N 1.277 -2.555 0 CA-C-N 115.549 -0.751 . . . . 0.0 109.054 176.849 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 63.0 m-20 -78.51 51.65 1.08 Allowed 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.664 -178.026 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' ASP . . . . . 0.685 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 2.8 m-20 -76.26 71.73 2.99 Favored 'General case' 0 CA--C 1.505 -0.777 0 CA-C-O 121.058 0.456 . . . . 0.0 110.124 177.746 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -105.41 165.02 11.42 Favored 'General case' 0 N--CA 1.421 -1.888 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.058 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -131.37 144.23 51.07 Favored 'General case' 0 N--CA 1.407 -2.6 0 C-N-CA 118.416 -1.314 . . . . 0.0 110.963 179.249 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 11.0 m-30 -110.7 125.92 53.99 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 -176.367 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.475 ' HB ' ' HB3' ' A' ' 17' ' ' SER . 48.7 t -88.22 134.44 28.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 CA-C-O 121.076 0.465 . . . . 0.0 110.196 -178.549 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 65.8 m95 -120.79 94.39 4.34 Favored 'General case' 0 C--N 1.285 -2.239 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -179.209 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -78.72 114.95 18.08 Favored 'General case' 0 C--N 1.286 -2.19 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 178.53 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.406 ' HA ' HG22 ' A' ' 20' ' ' VAL . 18.3 mm -90.18 120.33 38.81 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 -176.548 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -117.52 155.08 30.38 Favored 'General case' 0 CA--C 1.488 -1.405 0 CA-C-O 121.324 0.583 . . . . 0.0 109.919 177.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.54 131.21 35.22 Favored 'General case' 0 N--CA 1.407 -2.606 0 CA-C-N 115.01 -0.995 . . . . 0.0 108.82 176.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -91.32 -13.35 32.75 Favored 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 -177.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 6.5 t-20 -152.01 145.72 25.03 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 114.169 -1.378 . . . . 0.0 109.67 -175.389 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -84.44 144.89 28.47 Favored 'General case' 0 C--N 1.319 -0.739 0 O-C-N 124.317 1.011 . . . . 0.0 109.195 -178.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.523 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 1.5 m -125.21 148.96 29.6 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.9 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 9.3 t -124.66 138.32 54.45 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 N-CA-C 107.686 -1.228 . . . . 0.0 107.686 -178.629 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.525 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 81.5 t -100.04 101.8 15.53 Favored Pre-proline 0 C--N 1.292 -1.892 0 C-N-CA 123.677 0.791 . . . . 0.0 109.982 179.368 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.485 ' HG3' HG13 ' A' ' 27' ' ' VAL . 35.2 Cg_endo -70.12 -23.52 29.07 Favored 'Trans proline' 0 CA--C 1.509 -0.749 0 C-N-CA 122.319 2.013 . . . . 0.0 111.801 178.62 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.1 t . . . . . 0 C--O 1.248 0.99 0 O-C-N 124.716 1.26 . . . . 0.0 112.404 179.359 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.583 ' CZ ' ' HB ' ' A' ' 56' ' ' VAL . 4.0 t80 . . . . . 0 C--O 1.215 -0.714 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -161.49 179.78 7.96 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 102.837 -3.023 . . . . 0.0 102.837 169.004 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.483 ' HB3' ' CZ2' ' A' ' 146' ' ' TRP . 11.5 t -150.5 158.32 44.02 Favored 'General case' 0 C--N 1.283 -2.318 0 C-N-CA 117.232 -1.787 . . . . 0.0 111.081 -174.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.435 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.26 160.88 40.24 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 121.474 0.654 . . . . 0.0 110.713 -175.816 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.583 HG22 HG22 ' A' ' 20' ' ' VAL . 57.2 p -97.68 178.73 5.07 Favored 'General case' 0 C--N 1.293 -1.888 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.648 -179.666 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -82.04 -21.01 37.16 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.712 178.514 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -87.09 -29.07 22.15 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.997 -176.224 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.16 7.52 2.85 Favored Glycine 0 C--N 1.307 -1.073 0 C-N-CA 119.222 -1.466 . . . . 0.0 114.34 171.308 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.0 m -86.94 101.09 13.09 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 177.216 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -97.06 119.92 36.46 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-N 115.484 -0.78 . . . . 0.0 108.945 176.025 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 50.9 mt -97.7 116.46 65.77 Favored Pre-proline 0 C--N 1.297 -1.7 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.564 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -79.42 176.75 9.31 Favored 'Trans proline' 0 C--O 1.25 1.075 0 C-N-CA 122.653 2.236 . . . . 0.0 110.387 177.331 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 56.7 mt -72.04 125.35 30.52 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.343 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 177.669 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 149.22 -6.45 0.81 Allowed Glycine 0 C--N 1.299 -1.48 0 CA-C-N 115.6 -0.727 . . . . 0.0 112.001 -176.482 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.17 156.77 33.06 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 120.709 -0.758 . . . . 0.0 111.373 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.34 -165.83 34.0 Favored Glycine 0 N--CA 1.419 -2.456 0 C-N-CA 119.818 -1.182 . . . . 0.0 111.604 178.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 145' ' ' VAL . 59.8 p -145.7 155.17 42.81 Favored 'General case' 0 N--CA 1.417 -2.077 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 -177.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.81 155.64 50.03 Favored 'General case' 0 N--CA 1.416 -2.151 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 177.284 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -105.01 109.97 22.18 Favored 'General case' 0 C--N 1.279 -2.459 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 174.778 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.583 HG22 HG22 ' A' ' 5' ' ' THR . 34.2 t -97.33 135.52 31.33 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -177.933 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 77.7 m-85 -116.62 126.82 53.8 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -178.547 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.524 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.5 p -135.54 129.45 49.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.195 -176.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ASN . . . . . 0.416 ' HB3' ' HB3' ' A' ' 151' ' ' ASN . 8.0 p30 -94.52 126.02 39.53 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-O 121.683 0.754 . . . . 0.0 110.423 178.197 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -103.44 162.59 12.9 Favored 'General case' 0 C--N 1.286 -2.157 0 CA-C-N 114.278 -1.328 . . . . 0.0 108.019 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ALA . . . . . 0.407 ' C ' ' H ' ' A' ' 27' ' ' VAL . . . -54.48 126.07 54.39 Favored Pre-proline 0 CA--C 1.499 -0.998 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 174.722 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.529 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 72.7 Cg_endo -77.44 9.77 2.74 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 122.484 2.123 . . . . 0.0 110.925 179.2 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.407 ' H ' ' C ' ' A' ' 25' ' ' ALA . 14.1 p -138.35 115.97 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.916 0 CA-C-N 114.827 -1.079 . . . . 0.0 108.365 -178.316 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.4 t -150.02 120.05 1.06 Allowed 'Isoleucine or valine' 0 C--O 1.191 -1.985 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 -179.006 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.589 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -107.24 147.85 29.67 Favored 'General case' 0 C--N 1.267 -2.999 0 C-N-CA 122.505 0.322 . . . . 0.0 110.76 -179.973 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.532 HG22 ' O ' ' A' ' 112' ' ' VAL . 98.7 t -43.67 117.35 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 123.329 0.652 . . . . 0.0 111.539 176.845 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.56 -1.72 42.57 Favored Glycine 0 C--N 1.319 -0.396 0 CA-C-N 114.779 -1.101 . . . . 0.0 112.809 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.589 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.6 OUTLIER -73.35 -176.69 2.31 Favored 'General case' 0 C--N 1.315 -0.896 0 C-N-CA 124.011 0.924 . . . . 0.0 110.775 177.37 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 66.8 t30 -129.5 83.35 2.13 Favored 'General case' 0 CA--C 1.49 -1.327 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.238 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.562 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 19.1 tp -90.72 133.23 35.31 Favored 'General case' 0 N--CA 1.419 -1.977 0 C-N-CA 119.151 -1.019 . . . . 0.0 108.516 178.904 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.447 ' CG2' ' HB1' ' A' ' 106' ' ' ALA . 2.2 p -141.44 133.92 29.22 Favored 'Isoleucine or valine' 0 N--CA 1.383 -3.792 0 CA-C-O 121.882 0.848 . . . . 0.0 111.728 -178.572 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.62 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 45.6 t -89.2 89.92 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.52 0 CA-C-N 113.732 -1.577 . . . . 0.0 108.333 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -76.53 109.72 10.49 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 120.876 0.37 . . . . 0.0 110.89 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 93.0 mt -92.29 -1.54 57.01 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 115.905 -0.588 . . . . 0.0 112.549 -178.698 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 89.9 p -76.81 1.08 18.41 Favored 'General case' 0 N--CA 1.474 0.762 0 CA-C-O 123.0 1.381 . . . . 0.0 109.754 -179.649 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.7 p -123.92 6.64 8.66 Favored 'General case' 0 C--N 1.276 -2.628 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.881 179.184 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.524 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 42.4 mm-40 -127.14 -25.14 3.31 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.604 -175.232 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 23.1 mt -132.64 137.44 54.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 -175.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.435 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 40.4 m-85 -140.65 123.41 16.28 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -176.305 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.454 ' HB3' ' CE1' ' A' ' 1' ' ' PHE . 79.7 m -103.71 142.9 33.54 Favored 'General case' 0 C--N 1.271 -2.82 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 -178.729 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.437 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 10.1 p80 -136.75 168.06 20.26 Favored 'General case' 0 C--N 1.294 -1.836 0 CA-C-O 121.335 0.588 . . . . 0.0 110.787 -172.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.455 ' HB3' ' OD1' ' A' ' 54' ' ' ASP . 5.4 p30 -112.41 100.0 8.43 Favored 'General case' 0 C--N 1.281 -2.383 0 CA-C-O 122.2 1.0 . . . . 0.0 111.814 175.566 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -76.26 -31.21 58.17 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 178.192 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.47 ' HB3' ' OG1' ' A' ' 51' ' ' THR . 23.2 m-85 -127.88 87.97 54.4 Favored Pre-proline 0 N--CA 1.435 -1.22 0 N-CA-C 106.004 -1.851 . . . . 0.0 106.004 177.883 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -88.59 -13.34 3.4 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 122.319 2.013 . . . . 0.0 113.976 -176.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -110.92 -12.35 14.25 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.622 -0.831 . . . . 0.0 110.756 -176.116 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.47 ' OG1' ' HB3' ' A' ' 48' ' ' TYR . 0.0 OUTLIER -101.4 -31.36 10.97 Favored 'General case' 0 N--CA 1.417 -2.115 0 CA-C-N 115.406 -0.815 . . . . 0.0 110.194 179.771 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.634 HG23 ' CB ' ' A' ' 135' ' ' ASN . 3.1 mp -121.9 126.54 74.67 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.592 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.6 t -72.75 135.06 45.25 Favored 'General case' 0 N--CA 1.421 -1.901 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 174.602 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.455 ' OD1' ' HB3' ' A' ' 46' ' ' ASN . 58.7 m-20 -87.06 107.6 18.51 Favored 'General case' 0 C--N 1.278 -2.506 0 CA-C-O 121.939 0.876 . . . . 0.0 111.343 -171.093 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 70.4 t80 -137.91 145.8 42.54 Favored 'General case' 0 C--N 1.29 -1.997 0 CA-C-N 114.078 -1.419 . . . . 0.0 108.058 -175.904 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.583 ' HB ' ' CZ ' ' A' ' 1' ' ' PHE . 11.9 p -152.25 148.38 14.39 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.786 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.309 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -151.34 140.37 21.09 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 174.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.573 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 50.5 tp -75.19 117.76 17.37 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 173.346 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.514 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 3.6 tp-100 -65.54 -44.92 85.35 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.456 -1.247 . . . . 0.0 110.458 -177.851 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.514 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 10.4 ptp180 -176.97 161.87 1.99 Allowed 'General case' 0 N--CA 1.432 -1.34 0 O-C-N 124.708 1.255 . . . . 0.0 108.423 -176.407 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.405 ' H ' HG22 ' A' ' 86' ' ' THR . . . -143.08 129.53 3.8 Favored Glycine 0 N--CA 1.408 -3.174 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -178.302 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 54.2 m -117.35 149.38 40.59 Favored 'General case' 0 C--N 1.291 -1.944 0 C-N-CA 124.099 0.96 . . . . 0.0 110.461 -174.801 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.522 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -113.37 156.16 23.93 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.497 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 88.4 m-85 -154.6 -179.92 8.44 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 124.155 0.982 . . . . 0.0 108.867 -178.407 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 57.79 -143.56 42.39 Favored Glycine 0 C--N 1.325 -0.081 0 O-C-N 123.891 0.744 . . . . 0.0 113.513 176.13 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -72.97 -14.23 78.78 Favored Glycine 0 C--O 1.209 -1.468 0 C-N-CA 120.846 -0.693 . . . . 0.0 111.717 177.565 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.78 HG21 ' HB ' ' A' ' 126' ' ' ILE . 95.2 t -67.59 -39.37 82.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 123.804 0.842 . . . . 0.0 111.606 -177.717 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.522 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -87.1 -19.03 29.13 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 118.67 -1.212 . . . . 0.0 112.192 178.027 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 6.2 t -98.36 -56.58 2.43 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.537 -172.5 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.491 ' O ' HG22 ' A' ' 112' ' ' VAL . 41.3 m-20 -92.03 -22.97 19.67 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.24 -173.894 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.656 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 92.0 m-85 -108.73 156.93 19.03 Favored 'General case' 0 N--CA 1.419 -1.999 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.489 178.598 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 12.7 t -161.38 136.41 7.46 Favored 'General case' 0 N--CA 1.403 -2.787 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 176.801 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.498 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.97 -111.67 0.26 Allowed Glycine 0 N--CA 1.398 -3.893 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 174.19 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.2 p -159.66 -179.92 8.3 Favored 'General case' 0 C--N 1.297 -1.684 0 C-N-CA 124.001 0.92 . . . . 0.0 110.425 -172.743 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -132.1 145.9 34.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 178.202 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.673 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.2 tttt -126.58 145.45 50.53 Favored 'General case' 0 N--CA 1.427 -1.585 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -178.189 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.532 ' CD2' HG22 ' A' ' 105' ' ' VAL . 58.9 t80 -145.63 110.69 5.23 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 -177.691 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 44.9 t 53.27 37.08 24.36 Favored 'General case' 0 CA--C 1.55 0.963 0 C-N-CA 123.35 0.66 . . . . 0.0 111.982 178.04 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.32 8.54 66.2 Favored Glycine 0 CA--C 1.525 0.698 0 C-N-CA 120.301 -0.952 . . . . 0.0 113.663 -179.384 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.673 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 20.8 t -81.59 -179.79 7.52 Favored 'General case' 0 CA--C 1.544 0.735 0 CA-C-N 117.383 0.592 . . . . 0.0 109.51 178.412 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.0 p -156.78 109.22 2.51 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.418 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.3 p90 -151.89 158.71 33.84 Favored Pre-proline 0 C--N 1.306 -1.323 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 -175.52 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -68.73 150.94 74.69 Favored 'Trans proline' 0 C--N 1.354 0.817 0 C-N-CA 122.879 2.386 . . . . 0.0 113.096 -176.471 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.592 ' CD2' HD21 ' A' ' 109' ' ' LEU . 54.0 t80 -124.46 132.15 24.26 Favored Pre-proline 0 N--CA 1.442 -0.867 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.219 -179.684 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.468 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 72.4 Cg_endo -72.53 148.2 90.99 Favored 'Cis proline' 0 CA--C 1.535 0.558 0 C-N-CA 122.8 -1.75 . . . . 0.0 109.984 -0.873 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.405 HG22 ' H ' ' A' ' 61' ' ' GLY . 9.0 t -67.09 -177.49 0.66 Allowed 'General case' 0 C--O 1.248 1.017 0 CA-C-O 121.367 0.603 . . . . 0.0 111.29 -175.499 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.8 p -120.7 -25.13 5.55 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 115.286 -0.87 . . . . 0.0 110.647 -173.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 t -135.38 -107.95 0.21 Allowed 'General case' 0 N--CA 1.419 -1.985 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 178.555 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLU . . . . . 0.425 ' HB2' ' O ' ' A' ' 58' ' ' LEU . 0.0 OUTLIER -144.44 -165.66 2.19 Favored 'General case' 0 N--CA 1.445 -0.723 0 CA-C-N 118.251 0.478 . . . . 0.0 110.749 -177.508 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.573 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 58.3 p -100.26 168.16 9.83 Favored Pre-proline 0 C--N 1.306 -1.286 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 179.55 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' PRO . . . . . 0.407 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 34.4 Cg_endo -63.62 172.26 5.88 Favored 'Trans proline' 0 C--O 1.251 1.139 0 C-N-CA 123.062 2.508 . . . . 0.0 110.48 170.02 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 41.2 ttp180 -71.49 142.32 50.16 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.12 -177.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 64.0 t -151.16 131.57 4.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 124.355 1.062 . . . . 0.0 108.427 -179.048 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 54' ' ' ASP . 2.2 p -128.93 141.46 46.55 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 108.253 -1.018 . . . . 0.0 108.253 -178.729 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -92.99 108.33 19.92 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-O 121.251 0.548 . . . . 0.0 111.234 -178.745 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -94.38 45.97 1.14 Allowed 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.6 t -124.03 -176.57 3.52 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 -175.77 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 37.8 ptt180 -148.14 33.78 0.82 Allowed 'General case' 0 C--N 1.314 -0.948 0 CA-C-O 121.879 0.847 . . . . 0.0 109.619 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.1 t -165.58 -178.97 5.16 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 -178.52 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ASP . . . . . 0.437 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 3.7 p30 -77.12 130.15 36.97 Favored 'General case' 0 CA--C 1.501 -0.928 0 CA-C-O 121.515 0.674 . . . . 0.0 109.956 -179.748 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 15.8 mmtm -129.72 141.35 41.52 Favored Pre-proline 0 C--N 1.287 -2.137 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.08 -179.558 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -61.53 137.58 70.31 Favored 'Trans proline' 0 CA--C 1.499 -1.246 0 C-N-CA 123.571 2.847 . . . . 0.0 112.7 -174.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.6 t90 -81.5 108.58 11.22 Favored Pre-proline 0 C--N 1.304 -1.409 0 N-CA-C 106.393 -1.706 . . . . 0.0 106.393 -177.479 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -76.22 87.69 1.41 Allowed 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 121.231 1.287 . . . . 0.0 112.718 -172.045 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.532 HG22 ' CD2' ' A' ' 77' ' ' TYR . 57.6 t -137.83 146.53 27.18 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.203 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 177.544 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.62 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.38 134.73 16.09 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 177.446 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.469 HD21 HD11 ' A' ' 129' ' ' LEU . 16.7 mt -102.87 99.95 9.9 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.443 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.498 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 71.5 m-85 -78.36 81.36 4.71 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 177.513 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.656 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.1 mm? -107.1 118.6 37.13 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 176.366 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -120.99 148.41 48.72 Favored Pre-proline 0 N--CA 1.41 -2.448 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.253 -173.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -66.13 120.96 8.18 Favored 'Trans proline' 0 N--CA 1.44 -1.646 0 C-N-CA 122.892 2.395 . . . . 0.0 113.47 -175.055 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.532 ' O ' HG22 ' A' ' 30' ' ' VAL . 21.7 m -81.03 -157.29 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.393 -3.297 0 CA-C-N 114.49 -1.232 . . . . 0.0 108.814 170.75 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 30.9 m -82.96 -26.47 31.34 Favored 'General case' 0 C--N 1.252 -3.645 0 CA-C-O 121.699 0.761 . . . . 0.0 110.912 -170.127 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 19.6 t -83.36 13.64 4.21 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.197 -0.911 . . . . 0.0 110.189 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -98.3 125.31 43.35 Favored 'General case' 0 N--CA 1.428 -1.557 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.569 179.352 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -168.67 129.74 1.94 Allowed Glycine 0 N--CA 1.431 -1.642 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 178.687 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.71 -148.8 49.94 Favored Glycine 0 CA--C 1.493 -1.322 0 CA-C-O 119.232 -0.76 . . . . 0.0 111.883 -177.81 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.451 ' CG1' ' HE3' ' A' ' 121' ' ' LYS . 65.9 t -60.04 101.66 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.248 0.991 0 CA-C-O 122.078 0.942 . . . . 0.0 111.117 -176.435 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -101.57 -23.11 14.34 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 114.137 -1.392 . . . . 0.0 111.498 -177.709 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.459 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 61.8 mt -136.7 141.21 41.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.68 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.548 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.6 mmpt? -116.2 141.31 48.31 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 120.843 0.354 . . . . 0.0 110.347 177.006 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.4 ' H ' ' HB3' ' A' ' 153' ' ' ASP . . . -69.06 148.07 50.58 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.725 179.667 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 71.78 14.37 75.49 Favored Glycine 0 C--O 1.218 -0.845 0 CA-C-N 115.828 -0.623 . . . . 0.0 111.555 178.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 20.0 m -119.08 143.4 47.16 Favored 'General case' 0 N--CA 1.421 -1.891 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -175.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -68.6 127.05 31.61 Favored 'General case' 0 C--O 1.242 0.659 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.167 -178.032 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.78 ' HB ' HG21 ' A' ' 67' ' ' VAL . 27.9 pt -115.9 -26.91 2.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 127' ' ' ALA . . . . . 0.411 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -159.92 168.13 26.42 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -178.041 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 65.7 t -142.64 114.06 3.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.443 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.469 HD11 HD21 ' A' ' 107' ' ' LEU . 56.8 mt -115.43 155.76 26.85 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 178.3 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.523 ' O ' HD12 ' A' ' 58' ' ' LEU . 5.1 mp -135.68 131.13 50.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 CA-C-N 118.52 0.6 . . . . 0.0 109.751 177.733 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.433 HD13 HG23 ' A' ' 56' ' ' VAL . 1.8 pp -92.58 139.79 30.21 Favored 'General case' 0 CA--C 1.489 -1.399 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 172.624 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 27.1 tpt180 -97.31 108.0 20.64 Favored 'General case' 0 C--N 1.251 -3.714 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.553 HE22 ' HD1' ' A' ' 1' ' ' PHE . 5.2 tp-100 -87.67 118.6 27.27 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -177.825 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 22.2 m -137.03 140.52 42.14 Favored 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 173.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.634 ' CB ' HG23 ' A' ' 52' ' ' ILE . 10.8 p30 -146.82 175.54 10.56 Favored 'General case' 0 N--CA 1.444 -0.751 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.899 178.008 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 2.3 p-10 -89.21 -13.76 37.51 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.546 -1.206 . . . . 0.0 113.158 -169.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 48.5 t80 -105.42 -57.09 2.08 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-O 120.868 0.366 . . . . 0.0 111.829 -172.277 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' ASN . . . . . 0.418 ' HB3' ' OD1' ' A' ' 140' ' ' ASP . 18.5 m120 -84.24 145.78 28.14 Favored 'General case' 0 CA--C 1.483 -1.621 0 CA-C-O 121.221 0.534 . . . . 0.0 109.886 178.656 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 9.1 p -97.7 22.01 9.64 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 172.372 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 140' ' ' ASP . . . . . 0.418 ' OD1' ' HB3' ' A' ' 138' ' ' ASN . 1.8 m-20 -90.3 58.9 4.2 Favored 'General case' 0 N--CA 1.432 -1.336 0 CA-C-N 113.085 -1.871 . . . . 0.0 107.911 -178.894 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -77.64 73.7 4.2 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 122.269 1.033 . . . . 0.0 110.923 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -93.96 179.99 5.16 Favored 'General case' 0 N--CA 1.425 -1.723 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 176.153 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -141.86 149.46 40.3 Favored 'General case' 0 C--N 1.282 -2.366 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 176.918 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 9.7 m-30 -109.26 125.25 52.07 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 -174.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 17' ' ' SER . 48.2 t -89.27 135.52 25.75 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.926 0 O-C-N 123.749 0.656 . . . . 0.0 110.074 -178.209 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 146' ' ' TRP . . . . . 0.483 ' CZ2' ' HB3' ' A' ' 3' ' ' CYS . 61.6 m95 -120.38 96.26 5.07 Favored 'General case' 0 C--N 1.284 -2.246 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 -179.317 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 37.3 m-80 -80.58 112.83 18.31 Favored 'General case' 0 C--N 1.291 -1.946 0 N-CA-C 106.587 -1.634 . . . . 0.0 106.587 179.784 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.433 HG22 HD11 ' A' ' 126' ' ' ILE . 28.1 mm -87.48 122.83 39.72 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -176.193 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -117.12 151.9 35.85 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 123.786 0.834 . . . . 0.0 109.442 178.464 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.68 130.21 34.98 Favored 'General case' 0 N--CA 1.413 -2.318 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 176.064 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' ASN . . . . . 0.416 ' HB3' ' HB3' ' A' ' 23' ' ' ASN . 39.6 t-20 -89.12 -17.52 29.05 Favored 'General case' 0 C--N 1.288 -2.068 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 -178.831 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -147.17 143.04 27.93 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-N 114.418 -1.265 . . . . 0.0 109.462 -174.477 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 153' ' ' ASP . . . . . 0.4 ' HB3' ' H ' ' A' ' 122' ' ' ALA . 12.8 p-10 -86.07 138.66 31.78 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 124.083 0.865 . . . . 0.0 111.477 -178.733 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.529 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.8 t -114.44 137.82 46.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 114.946 -1.025 . . . . 0.0 112.334 -171.875 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -117.79 138.28 48.99 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.351 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 177.494 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.471 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 53.2 t -101.89 103.66 30.52 Favored Pre-proline 0 C--N 1.29 -1.979 0 C-N-CA 123.618 0.767 . . . . 0.0 109.756 178.84 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.453 ' HD2' ' O ' ' A' ' 28' ' ' VAL . 30.8 Cg_endo -68.08 -26.11 37.17 Favored 'Trans proline' 0 CA--C 1.506 -0.908 0 C-N-CA 122.429 2.086 . . . . 0.0 111.878 177.295 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.4 t . . . . . 0 C--N 1.349 0.578 0 O-C-N 124.748 1.28 . . . . 0.0 112.33 179.233 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.676 ' CZ ' ' HB3' ' A' ' 133' ' ' GLN . 0.1 OUTLIER . . . . . 0 CA--C 1.495 -1.157 0 N-CA-C 113.802 1.038 . . . . 0.0 113.802 . . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.479 ' HB3' ' NE2' ' A' ' 45' ' ' HIS . . . -148.47 162.49 39.51 Favored 'General case' 0 C--N 1.29 -2.001 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 167.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.418 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 63.1 m -134.39 155.41 50.34 Favored 'General case' 0 C--N 1.288 -2.071 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.786 -174.105 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.5 155.52 43.15 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-O 121.223 0.535 . . . . 0.0 109.917 -176.333 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.602 HG22 HG22 ' A' ' 20' ' ' VAL . 72.9 p -92.25 175.01 7.01 Favored 'General case' 0 C--N 1.292 -1.922 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.77 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -85.61 -11.49 53.81 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.278 -1.328 . . . . 0.0 109.716 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -95.21 -27.35 15.57 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-N 115.138 -0.937 . . . . 0.0 111.751 -178.279 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 136.64 1.04 2.8 Favored Glycine 0 C--O 1.222 -0.621 0 C-N-CA 119.155 -1.498 . . . . 0.0 114.845 169.445 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.2 m -87.86 105.94 17.76 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 121.455 0.645 . . . . 0.0 109.579 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -98.99 119.55 37.97 Favored 'General case' 0 C--N 1.291 -1.953 0 CA-C-N 114.735 -1.12 . . . . 0.0 109.224 176.402 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.435 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 60.0 mt -100.36 114.66 65.79 Favored Pre-proline 0 C--N 1.303 -1.429 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.102 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_endo -76.59 171.87 17.26 Favored 'Trans proline' 0 C--O 1.249 1.037 0 C-N-CA 122.385 2.057 . . . . 0.0 111.354 177.262 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.419 HG12 ' O ' ' A' ' 1' ' ' PHE . 68.4 mt -58.06 134.03 22.85 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.967 179.031 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 128.59 2.75 5.74 Favored Glycine 0 C--N 1.303 -1.257 0 C-N-CA 120.344 -0.931 . . . . 0.0 112.466 179.461 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.04 164.89 34.82 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.13 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.74 -166.51 34.44 Favored Glycine 0 C--N 1.295 -1.743 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.701 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.1 p -141.24 154.33 45.72 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -178.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -143.37 159.38 42.48 Favored 'General case' 0 N--CA 1.421 -1.88 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.36 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -103.22 122.87 45.65 Favored 'General case' 0 C--N 1.275 -2.67 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 173.839 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.602 HG22 HG22 ' A' ' 5' ' ' THR . 40.3 t -106.81 129.71 59.95 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.76 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.737 177.826 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 -112.88 121.17 43.88 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 120.982 0.42 . . . . 0.0 111.23 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.589 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.3 p -133.92 130.24 55.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-N 115.318 -0.856 . . . . 0.0 111.164 -178.667 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -92.25 130.83 37.85 Favored 'General case' 0 C--N 1.296 -1.758 0 CA-C-O 121.37 0.605 . . . . 0.0 110.429 177.915 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.683 HD21 HG22 ' A' ' 36' ' ' VAL . 6.9 mp -109.18 161.85 14.83 Favored 'General case' 0 C--N 1.287 -2.118 0 CA-C-N 114.489 -1.232 . . . . 0.0 108.877 179.454 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.01 121.1 48.17 Favored Pre-proline 0 C--O 1.209 -1.06 0 O-C-N 124.777 1.298 . . . . 0.0 109.486 179.177 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.511 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 66.1 Cg_endo -75.7 -0.91 10.72 Favored 'Trans proline' 0 CA--C 1.531 0.332 0 C-N-CA 122.906 2.404 . . . . 0.0 113.539 -176.78 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 96.0 t -127.93 109.63 20.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 178.407 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.567 HG21 HD22 ' A' ' 34' ' ' LEU . 5.7 t -145.59 112.43 1.22 Allowed 'Isoleucine or valine' 0 C--O 1.189 -2.116 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 -177.558 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.488 ' H ' ' HG3' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -100.78 152.12 20.88 Favored 'General case' 0 C--N 1.266 -3.064 0 C-N-CA 123.138 0.575 . . . . 0.0 111.004 -179.843 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 41.5 t -43.81 116.51 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 123.727 0.811 . . . . 0.0 111.631 175.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.51 -5.52 35.39 Favored Glycine 0 C--O 1.227 -0.296 0 CA-C-N 115.421 -0.808 . . . . 0.0 112.99 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.488 ' HG3' ' H ' ' A' ' 29' ' ' ASN . 1.3 mm-40 -69.34 -177.89 1.24 Allowed 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 123.669 0.788 . . . . 0.0 111.786 177.817 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 67.1 t30 -126.62 86.19 2.48 Favored 'General case' 0 CA--C 1.482 -1.646 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 176.724 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.609 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 24.4 tp -95.73 134.98 38.02 Favored 'General case' 0 N--CA 1.41 -2.433 0 C-N-CA 119.202 -0.999 . . . . 0.0 109.453 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.421 ' CG2' ' HB1' ' A' ' 106' ' ' ALA . 1.7 p -141.78 137.79 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.38 -3.941 0 CA-C-N 114.729 -1.123 . . . . 0.0 112.07 -177.633 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.683 HG22 HD21 ' A' ' 24' ' ' LEU . 58.4 t -90.48 89.89 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.335 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 176.26 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -76.01 106.57 7.68 Favored 'General case' 0 C--N 1.297 -1.717 0 C-N-CA 120.057 -0.657 . . . . 0.0 109.669 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.8 mt -95.03 -1.16 52.87 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.822 -179.188 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 15.2 m -77.41 0.58 21.98 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-O 122.074 0.94 . . . . 0.0 109.478 -177.598 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.2 p -128.46 5.39 5.68 Favored 'General case' 0 N--CA 1.421 -1.901 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.157 178.776 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.589 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 47.1 mm-40 -122.74 -24.21 4.91 Favored 'General case' 0 CA--C 1.503 -0.835 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.73 -174.385 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.7 mt -130.47 140.07 49.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 -176.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -138.13 149.74 46.18 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 -176.631 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.418 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 70.2 m -125.87 134.08 51.73 Favored 'General case' 0 C--N 1.289 -2.047 0 C-N-CA 122.794 0.437 . . . . 0.0 110.061 176.952 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.479 ' NE2' ' HB3' ' A' ' 2' ' ' ALA . 11.6 p-80 -119.35 150.79 39.57 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-O 121.998 0.904 . . . . 0.0 110.386 -177.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -99.35 101.99 13.44 Favored 'General case' 0 C--N 1.272 -2.789 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 -179.022 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 18.3 p-10 -86.62 -17.63 33.4 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 -179.247 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 67.3 m-85 -138.47 62.79 31.66 Favored Pre-proline 0 N--CA 1.477 0.91 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 175.184 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.8 -3.31 11.79 Favored 'Trans proline' 0 N--CA 1.485 0.971 0 C-N-CA 123.208 2.605 . . . . 0.0 114.454 -171.074 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -115.54 -17.35 11.2 Favored 'General case' 0 C--N 1.299 -1.625 0 CA-C-O 121.286 0.565 . . . . 0.0 110.272 -178.137 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.464 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.9 m -102.23 -30.36 11.15 Favored 'General case' 0 N--CA 1.424 -1.766 0 CA-C-O 122.064 0.935 . . . . 0.0 108.826 -174.38 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.52 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.0 mp -123.58 137.07 58.02 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.493 0 CA-C-N 114.164 -1.38 . . . . 0.0 109.043 -178.903 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 3.9 t -83.97 122.35 28.63 Favored 'General case' 0 N--CA 1.419 -1.986 0 N-CA-C 102.68 -3.082 . . . . 0.0 102.68 168.431 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -88.98 107.76 19.21 Favored 'General case' 0 C--N 1.261 -3.268 0 C-N-CA 118.313 -1.355 . . . . 0.0 109.013 -172.338 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.557 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 17.0 t80 -122.63 131.58 53.88 Favored 'General case' 0 C--N 1.285 -2.204 0 CA-C-N 114.382 -1.281 . . . . 0.0 109.638 -174.727 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.455 ' CG2' ' HG ' ' A' ' 131' ' ' LEU . 14.9 p -136.87 144.8 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.138 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.685 -175.705 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -150.02 118.49 6.49 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 178.04 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.535 HD12 ' O ' ' A' ' 130' ' ' ILE . 48.0 tp -53.91 111.03 0.67 Allowed 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 169.884 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.428 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 3.1 tp-100 -59.74 -51.06 71.37 Favored 'General case' 0 C--O 1.21 -0.976 0 C-N-CA 125.793 1.637 . . . . 0.0 110.574 179.862 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.428 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 11.0 ptp180 -170.01 158.68 7.25 Favored 'General case' 0 N--CA 1.428 -1.567 0 CA-C-N 115.172 -0.922 . . . . 0.0 108.804 -176.328 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -134.6 145.74 17.8 Favored Glycine 0 N--CA 1.405 -3.433 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 179.319 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 72.3 m -132.88 150.85 52.12 Favored 'General case' 0 C--N 1.283 -2.326 0 C-N-CA 124.062 0.945 . . . . 0.0 109.918 -177.322 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.517 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -115.3 157.77 23.32 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 -178.545 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.523 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 95.9 m-85 -155.09 -179.6 8.22 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 124.302 1.041 . . . . 0.0 109.008 -178.403 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 54.77 -140.05 38.7 Favored Glycine 0 N--CA 1.455 -0.093 0 O-C-N 123.812 0.695 . . . . 0.0 113.464 178.195 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -73.35 -15.46 78.94 Favored Glycine 0 C--O 1.2 -2.014 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.004 178.344 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.755 HG21 ' HB ' ' A' ' 126' ' ' ILE . 84.4 t -67.12 -40.03 84.44 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 C-N-CA 123.637 0.775 . . . . 0.0 111.78 -176.823 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.517 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -87.99 -16.43 33.76 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 118.919 -1.112 . . . . 0.0 112.158 178.326 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 23.2 t -100.74 -59.13 1.75 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-O 121.328 0.585 . . . . 0.0 111.992 -174.976 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.491 ' O ' HG22 ' A' ' 112' ' ' VAL . 34.0 m-20 -90.69 -22.44 21.14 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.875 -171.893 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.636 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 90.4 m-85 -110.63 157.16 20.0 Favored 'General case' 0 N--CA 1.422 -1.854 0 C-N-CA 119.97 -0.692 . . . . 0.0 110.594 178.759 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.4 t -166.17 130.63 2.21 Favored 'General case' 0 N--CA 1.417 -2.075 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 176.269 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.478 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -160.98 -99.77 0.15 Allowed Glycine 0 C--N 1.286 -2.199 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 177.664 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.451 HG22 ' HA ' ' A' ' 83' ' ' PRO . 0.7 OUTLIER -168.89 -179.97 3.9 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.893 1.277 . . . . 0.0 109.97 -177.643 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.0 147.03 32.36 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 C-N-CA 123.255 0.622 . . . . 0.0 109.536 178.324 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.576 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.9 tttt -124.68 147.92 48.29 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.239 -179.43 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.441 ' CD2' HG22 ' A' ' 105' ' ' VAL . 61.3 t80 -148.4 108.8 4.13 Favored 'General case' 0 C--N 1.314 -0.965 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 -179.429 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 11.2 t 51.78 43.04 30.33 Favored 'General case' 0 C--N 1.315 -0.926 0 C-N-CA 124.251 1.02 . . . . 0.0 111.546 177.841 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.78 8.26 70.07 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.188 -1.006 . . . . 0.0 113.435 179.038 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.576 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 23.0 t -80.68 -179.66 7.34 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 177.297 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 12.3 p -158.89 106.61 1.84 Allowed 'General case' 0 C--N 1.288 -2.1 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 2.6 p90 -151.52 158.45 34.29 Favored Pre-proline 0 C--N 1.308 -1.205 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -174.449 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.451 ' HA ' HG22 ' A' ' 74' ' ' THR . 44.9 Cg_endo -67.16 148.9 81.64 Favored 'Trans proline' 0 C--N 1.36 1.16 0 C-N-CA 123.092 2.528 . . . . 0.0 112.703 -177.053 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.588 ' CD2' HD21 ' A' ' 109' ' ' LEU . 60.6 t80 -122.07 131.7 24.37 Favored Pre-proline 0 C--N 1.312 -1.035 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.694 -179.447 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.516 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 72.7 Cg_endo -70.89 150.27 92.73 Favored 'Cis proline' 0 CA--C 1.539 0.731 0 C-N-CA 122.956 -1.685 . . . . 0.0 109.915 -1.296 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.9 t -59.47 -177.99 0.06 Allowed 'General case' 0 CA--C 1.559 1.309 0 CA-C-O 121.928 0.87 . . . . 0.0 112.504 -174.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.1 p -115.0 -15.6 11.75 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-N 115.34 -0.846 . . . . 0.0 110.067 -173.596 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.6 t -158.15 -109.53 0.02 OUTLIER 'General case' 0 N--CA 1.415 -2.213 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 178.457 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLU . . . . . 0.412 ' HB2' ' O ' ' A' ' 58' ' ' LEU . 0.5 OUTLIER -132.93 -164.01 1.42 Allowed 'General case' 0 N--CA 1.436 -1.16 0 CA-C-N 118.349 0.522 . . . . 0.0 111.723 179.295 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.464 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 10.8 p -100.14 164.56 16.16 Favored Pre-proline 0 C--N 1.299 -1.606 0 C-N-CA 123.618 0.767 . . . . 0.0 112.405 -177.642 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -65.98 168.74 14.79 Favored 'Trans proline' 0 C--N 1.36 1.148 0 C-N-CA 123.411 2.741 . . . . 0.0 111.21 174.359 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.557 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 3.2 tmm_? -70.2 128.44 36.26 Favored 'General case' 0 N--CA 1.44 -0.964 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 -178.77 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 74.0 t -142.59 120.92 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.666 0 C-N-CA 124.439 1.095 . . . . 0.0 108.11 -178.381 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.0 p -119.81 140.32 44.22 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.209 0 CA-C-O 120.956 0.408 . . . . 0.0 110.775 -177.896 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.47 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 9.5 m-85 -94.26 112.46 24.26 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 177.907 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 13.9 m120 -97.49 8.64 44.25 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-O 121.657 0.741 . . . . 0.0 109.218 178.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.8 m -76.7 -175.95 3.61 Favored 'General case' 0 N--CA 1.427 -1.6 0 C-N-CA 124.729 1.212 . . . . 0.0 109.988 -177.896 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 15.0 ptp180 -143.64 30.57 1.34 Allowed 'General case' 0 C--N 1.309 -1.174 0 CA-C-O 121.001 0.429 . . . . 0.0 110.611 177.812 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.1 t -163.48 -178.01 5.61 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -175.598 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -67.31 99.37 0.71 Allowed 'General case' 0 C--O 1.242 0.691 0 O-C-N 123.894 0.746 . . . . 0.0 109.772 178.016 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 11.2 mptt -104.96 141.43 22.53 Favored Pre-proline 0 C--N 1.283 -2.306 0 N-CA-C 106.86 -1.533 . . . . 0.0 106.86 175.641 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -60.85 147.05 96.51 Favored 'Trans proline' 0 C--O 1.243 0.771 0 C-N-CA 122.409 2.073 . . . . 0.0 112.23 -177.664 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' TRP . . . . . 0.47 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 11.9 t90 -91.25 104.66 10.28 Favored Pre-proline 0 C--N 1.309 -1.167 0 N-CA-C 105.387 -2.079 . . . . 0.0 105.387 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -75.51 88.12 1.31 Allowed 'Trans proline' 0 N--CA 1.445 -1.366 0 C-N-CA 121.449 1.433 . . . . 0.0 113.0 -171.052 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.441 HG22 ' CD2' ' A' ' 77' ' ' TYR . 72.4 t -136.15 150.78 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.333 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 177.456 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.595 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -156.87 134.45 10.77 Favored 'General case' 0 N--CA 1.421 -1.893 0 O-C-N 123.633 0.583 . . . . 0.0 109.758 176.773 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.464 HD21 HD11 ' A' ' 129' ' ' LEU . 19.7 mt -103.45 99.86 9.71 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.437 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.478 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 65.4 m-85 -78.55 81.56 4.87 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 178.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.636 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.0 mm? -107.03 117.03 32.98 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-O 121.122 0.487 . . . . 0.0 110.629 176.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -120.17 146.88 43.5 Favored Pre-proline 0 N--CA 1.413 -2.3 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.319 -174.54 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -61.0 119.96 7.41 Favored 'Trans proline' 0 C--O 1.249 1.067 0 C-N-CA 123.226 2.618 . . . . 0.0 112.309 -177.538 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.491 HG22 ' O ' ' A' ' 70' ' ' ASN . 3.0 m -68.35 -118.5 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.193 -1.891 0 CA-C-N 114.261 -1.336 . . . . 0.0 111.862 173.783 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.8 t -112.87 -33.11 6.18 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 175.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 36.3 m -80.03 34.5 0.3 Allowed 'General case' 0 N--CA 1.399 -2.982 0 C-N-CA 125.698 1.599 . . . . 0.0 112.742 -178.169 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -118.12 130.01 55.87 Favored 'General case' 0 C--N 1.281 -2.397 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.365 179.396 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -170.08 128.18 1.6 Allowed Glycine 0 C--O 1.239 0.467 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.647 179.405 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 65.98 -150.48 51.84 Favored Glycine 0 CA--C 1.499 -0.964 0 CA-C-O 118.985 -0.897 . . . . 0.0 111.589 -176.097 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.406 HG11 ' HE3' ' A' ' 121' ' ' LYS . 95.1 t -56.93 105.2 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.873 0.844 . . . . 0.0 111.435 -178.291 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -105.41 -21.58 13.2 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-N 114.327 -1.306 . . . . 0.0 110.919 -177.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.509 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 63.6 mt -135.84 140.54 44.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.517 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.3 mmpt? -115.87 139.56 50.09 Favored 'General case' 0 C--N 1.317 -0.817 0 C-N-CA 122.319 0.248 . . . . 0.0 111.232 178.071 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.409 ' H ' ' HB3' ' A' ' 153' ' ' ASP . . . -70.53 134.73 47.96 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.227 179.38 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 87.01 -7.91 78.55 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 121.353 -0.451 . . . . 0.0 112.115 -179.233 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 34.7 t -96.11 143.63 27.07 Favored 'General case' 0 N--CA 1.422 -1.843 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.463 HD11 HG23 ' A' ' 128' ' ' VAL . 3.0 tm? -69.86 128.21 35.58 Favored 'General case' 0 N--CA 1.436 -1.17 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.384 -178.463 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.755 ' HB ' HG21 ' A' ' 67' ' ' VAL . 32.6 pt -112.43 -27.05 2.86 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 N-CA-C 112.327 0.492 . . . . 0.0 112.327 -179.886 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.84 168.03 23.76 Favored 'General case' 0 CA--C 1.505 -0.765 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -178.283 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.463 HG23 HD11 ' A' ' 125' ' ' LEU . 59.9 t -142.03 116.94 5.25 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 179.112 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.464 HD11 HD21 ' A' ' 107' ' ' LEU . 68.3 mt -117.46 137.58 52.43 Favored 'General case' 0 C--N 1.28 -2.444 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 178.483 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.535 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.3 mp -118.57 122.71 70.15 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 C-N-CA 119.015 -1.074 . . . . 0.0 109.934 177.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.548 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.8 OUTLIER -88.53 141.35 28.6 Favored 'General case' 0 C--N 1.266 -3.064 0 C-N-CA 125.053 1.341 . . . . 0.0 108.166 177.554 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 24.9 ttp180 -122.35 131.01 53.69 Favored 'General case' 0 N--CA 1.409 -2.497 0 C-N-CA 120.153 -0.619 . . . . 0.0 109.815 174.307 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.676 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 20.9 mm-40 -98.28 143.66 28.53 Favored 'General case' 0 N--CA 1.42 -1.942 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 -179.487 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.465 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 11.0 m -154.78 138.04 15.73 Favored 'General case' 0 C--N 1.281 -2.402 0 N-CA-C 106.488 -1.671 . . . . 0.0 106.488 173.649 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.52 ' CB ' HG23 ' A' ' 52' ' ' ILE . 11.0 p30 -135.6 -177.17 4.55 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 119.227 0.921 . . . . 0.0 112.515 176.108 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 2.3 p-10 -88.54 -29.05 20.36 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.472 0.653 . . . . 0.0 112.023 -174.602 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 82.5 t80 -92.59 -68.01 0.82 Allowed 'General case' 0 C--N 1.291 -1.947 0 C-N-CA 123.975 0.91 . . . . 0.0 110.814 -169.181 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -89.36 170.71 10.32 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.31 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 26.7 t -101.97 58.37 0.83 Allowed 'General case' 0 N--CA 1.397 -3.092 0 N-CA-C 106.12 -1.807 . . . . 0.0 106.12 172.402 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 -81.64 45.73 0.91 Allowed 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.608 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' ASP . . . . . 0.579 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 2.9 m-20 -79.64 53.82 1.67 Allowed 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 124.4 1.08 . . . . 0.0 109.005 -179.056 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -101.73 156.44 17.5 Favored 'General case' 0 N--CA 1.426 -1.673 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 179.548 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 143' ' ' GLN . . . . . 0.519 ' HB2' ' O ' ' A' ' 131' ' ' LEU . 13.9 pt20 -124.49 142.55 51.24 Favored 'General case' 0 N--CA 1.415 -2.215 0 C-N-CA 118.541 -1.264 . . . . 0.0 111.844 178.534 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 -106.69 129.37 54.6 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -175.344 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 48.5 t -94.53 129.18 45.12 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -178.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 146' ' ' TRP . . . . . 0.548 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 60.4 m95 -118.47 103.09 9.43 Favored 'General case' 0 C--N 1.278 -2.507 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.141 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 36.8 m-80 -82.05 110.86 17.67 Favored 'General case' 0 C--N 1.286 -2.159 0 N-CA-C 106.699 -1.593 . . . . 0.0 106.699 178.155 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.416 HG22 HD11 ' A' ' 126' ' ' ILE . 23.4 mm -85.52 121.14 36.8 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.903 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 -178.046 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 93.8 m-85 -117.72 151.3 37.55 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 123.618 0.767 . . . . 0.0 109.676 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -79.97 130.84 35.59 Favored 'General case' 0 N--CA 1.413 -2.295 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 175.642 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 -92.32 -6.43 50.29 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 -179.317 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -155.39 142.45 19.2 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.205 -176.908 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' ASP . . . . . 0.409 ' HB3' ' H ' ' A' ' 122' ' ' ALA . 17.5 p-10 -86.83 136.15 33.08 Favored 'General case' 0 C--N 1.309 -1.173 0 O-C-N 123.998 0.811 . . . . 0.0 112.004 -177.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.511 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.7 t -110.32 140.79 27.81 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 CA-C-N 114.966 -1.016 . . . . 0.0 111.987 -171.79 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 13.9 t -122.93 137.45 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.045 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 -179.529 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.507 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 70.0 t -103.28 103.27 33.95 Favored Pre-proline 0 C--N 1.286 -2.165 0 C-N-CA 123.699 0.799 . . . . 0.0 110.106 179.534 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.434 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 38.0 Cg_endo -69.47 -21.88 34.18 Favored 'Trans proline' 0 N--CA 1.463 -0.312 0 C-N-CA 121.959 1.772 . . . . 0.0 111.346 177.322 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.403 ' HB ' HG12 ' A' ' 156' ' ' VAL . 3.6 t . . . . . 0 C--O 1.244 0.784 0 C-N-CA 124.698 1.199 . . . . 0.0 113.251 176.802 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 33.3 t80 . . . . . 0 CA--C 1.503 -0.839 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.408 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -145.73 170.1 17.18 Favored 'General case' 0 N--CA 1.439 -1.005 0 C-N-CA 119.943 -0.703 . . . . 0.0 111.04 -177.697 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.404 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 80.0 m -143.67 159.05 43.16 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -177.478 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.6 pptp? -141.8 164.51 29.99 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-O 121.384 0.612 . . . . 0.0 111.621 -176.35 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.565 HG22 HG22 ' A' ' 20' ' ' VAL . 76.7 p -103.25 167.27 9.93 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.168 179.257 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.34 -9.49 58.65 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-N 113.729 -1.578 . . . . 0.0 112.474 179.563 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -94.37 -33.42 13.18 Favored 'General case' 0 C--O 1.239 0.516 0 C-N-CA 119.105 -1.038 . . . . 0.0 109.078 179.381 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 139.3 4.8 1.42 Allowed Glycine 0 N--CA 1.426 -1.972 0 C-N-CA 119.345 -1.407 . . . . 0.0 113.708 176.861 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.0 m -84.54 106.99 16.53 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 177.765 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -99.93 117.2 33.72 Favored 'General case' 0 C--N 1.286 -2.175 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 175.996 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.408 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 62.0 mt -84.21 116.95 67.37 Favored Pre-proline 0 C--N 1.308 -1.212 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 -179.711 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -76.96 166.8 26.23 Favored 'Trans proline' 0 N--CA 1.443 -1.497 0 C-N-CA 122.271 1.981 . . . . 0.0 111.381 179.167 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 72.1 mt -62.19 133.24 28.04 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.97 -179.894 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 126.96 4.44 6.04 Favored Glycine 0 C--N 1.311 -0.838 0 C-N-CA 120.506 -0.854 . . . . 0.0 112.466 178.916 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.04 146.44 6.48 Favored Glycine 0 N--CA 1.442 -0.944 0 C-N-CA 120.494 -0.86 . . . . 0.0 111.174 -177.025 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 177.62 -173.94 46.5 Favored Glycine 0 C--N 1.296 -1.666 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -179.231 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 60.3 p -134.06 151.12 51.27 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -179.651 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.49 168.67 18.81 Favored 'General case' 0 N--CA 1.432 -1.364 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.56 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 16.0 m-80 -118.14 108.69 15.49 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 -179.489 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.565 HG22 HG22 ' A' ' 5' ' ' THR . 46.9 t -94.72 136.64 25.33 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.018 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 -179.705 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 86.4 m-85 -125.1 117.39 23.83 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -177.333 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.479 HG11 HG13 ' A' ' 36' ' ' VAL . 2.7 p -124.3 129.52 73.96 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.833 0 CA-C-O 121.704 0.764 . . . . 0.0 111.479 -176.913 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -82.26 124.62 30.11 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-N 114.988 -1.005 . . . . 0.0 108.459 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 35.5 mt -113.44 156.16 24.01 Favored 'General case' 0 C--N 1.276 -2.593 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 179.951 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.53 121.67 50.16 Favored Pre-proline 0 C--O 1.201 -1.483 0 O-C-N 124.207 0.942 . . . . 0.0 109.899 -179.311 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.505 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 62.3 Cg_endo -71.37 -2.46 11.27 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 C-N-CA 123.185 2.59 . . . . 0.0 113.294 -176.699 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.528 HG13 ' HG3' ' A' ' 157' ' ' PRO . 64.8 t -130.4 111.26 20.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.94 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.458 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 5.8 t -145.76 110.3 0.98 Allowed 'Isoleucine or valine' 0 C--O 1.191 -2.024 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 -179.383 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.552 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -99.68 156.62 16.99 Favored 'General case' 0 C--N 1.264 -3.109 0 C-N-CA 122.94 0.496 . . . . 0.0 111.18 -179.539 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 25.4 t -47.93 116.5 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 123.887 0.875 . . . . 0.0 111.675 177.299 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.87 0.51 45.46 Favored Glycine 0 N--CA 1.444 -0.827 0 CA-C-N 115.36 -0.836 . . . . 0.0 112.983 -179.96 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.552 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.9 OUTLIER -73.73 -177.05 2.6 Favored 'General case' 0 C--N 1.315 -0.893 0 C-N-CA 123.888 0.875 . . . . 0.0 111.099 176.221 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 65.5 t30 -128.39 87.88 2.66 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 178.484 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.643 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 18.7 tp -97.35 132.67 42.85 Favored 'General case' 0 N--CA 1.417 -2.091 0 C-N-CA 118.663 -1.215 . . . . 0.0 108.753 178.095 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 2.1 p -141.41 129.55 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.386 -3.65 0 CA-C-N 114.859 -1.064 . . . . 0.0 111.618 -177.747 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.609 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 46.8 t -90.54 89.22 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.393 -3.277 0 CA-C-N 113.374 -1.739 . . . . 0.0 107.825 -179.039 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -77.98 112.22 14.67 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 121.015 0.436 . . . . 0.0 109.952 179.08 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 92.1 mt -96.3 -0.54 49.47 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.337 -177.766 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 35.6 t -74.56 0.97 13.17 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.847 0.832 . . . . 0.0 110.366 -179.561 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.8 p -126.85 3.32 6.65 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.086 178.597 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.422 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 47.9 mm-40 -121.8 -26.79 4.78 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.686 -172.925 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 20.6 mt -130.43 139.63 50.85 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 -175.525 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -139.48 158.74 43.63 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 -176.095 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.404 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 49.1 m -136.21 141.47 44.0 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 123.472 0.709 . . . . 0.0 109.972 179.58 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 5.6 p80 -136.92 153.47 50.72 Favored 'General case' 0 N--CA 1.43 -1.47 0 CA-C-O 121.9 0.857 . . . . 0.0 110.681 -178.427 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.467 HD21 ' HA ' ' A' ' 98' ' ' ARG . 6.6 p30 -95.01 109.93 21.9 Favored 'General case' 0 C--N 1.277 -2.556 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.408 177.187 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -73.87 -28.98 61.84 Favored 'General case' 0 C--N 1.297 -1.674 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.931 -179.429 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -136.52 79.6 41.0 Favored Pre-proline 0 C--N 1.313 -0.996 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 175.569 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.54 5.01 2.6 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 C-N-CA 123.257 2.638 . . . . 0.0 113.023 -176.164 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -120.34 -13.31 8.88 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.594 179.144 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.452 ' HB ' HD12 ' A' ' 52' ' ' ILE . 2.6 m -117.14 -25.64 7.07 Favored 'General case' 0 N--CA 1.422 -1.859 0 CA-C-O 121.408 0.623 . . . . 0.0 110.789 -172.575 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.452 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.7 mp -128.95 130.48 68.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 CA-C-N 115.971 -0.558 . . . . 0.0 109.5 -175.581 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.4 t -75.63 146.48 40.26 Favored 'General case' 0 N--CA 1.441 -0.923 0 O-C-N 123.714 0.634 . . . . 0.0 109.707 -179.695 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.555 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 3.0 m-20 -89.96 109.97 20.97 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 115.426 -0.807 . . . . 0.0 109.341 -174.178 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 82.2 t80 -146.03 141.68 27.87 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -179.128 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.1 p -151.44 144.78 16.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 175.802 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.27 131.7 14.7 Favored 'General case' 0 C--O 1.212 -0.904 0 CA-C-O 119.759 -0.162 . . . . 0.0 110.575 175.654 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.555 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 56.8 tp -72.84 107.88 5.49 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.157 0.504 . . . . 0.0 109.984 176.827 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.467 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 3.0 tp-100 -51.55 -53.63 35.89 Favored 'General case' 0 C--O 1.207 -1.138 0 C-N-CA 125.554 1.541 . . . . 0.0 111.149 175.825 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.467 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 2.8 ptp180 -168.62 161.4 11.39 Favored 'General case' 0 CA--C 1.493 -1.235 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 -178.072 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.411 ' H ' HG22 ' A' ' 86' ' ' THR . . . -142.1 123.52 2.23 Favored Glycine 0 N--CA 1.404 -3.485 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -178.771 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.412 ' HA ' ' HB3' ' A' ' 85' ' ' PRO . 68.9 m -115.62 149.79 37.73 Favored 'General case' 0 C--N 1.284 -2.245 0 C-N-CA 124.297 1.039 . . . . 0.0 110.32 -173.804 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.522 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -112.7 157.75 20.9 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 -179.302 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.476 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 88.6 m-85 -156.7 -178.91 7.7 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 124.316 1.047 . . . . 0.0 109.037 -177.68 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 60.71 -143.08 48.26 Favored Glycine 0 C--N 1.33 0.231 0 O-C-N 123.465 0.478 . . . . 0.0 112.512 177.785 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 66' ' ' GLY . . . . . 0.408 ' HA3' ' O ' ' A' ' 119' ' ' ALA . . . -78.94 -7.77 88.21 Favored Glycine 0 C--O 1.21 -1.382 0 C-N-CA 120.978 -0.629 . . . . 0.0 111.876 176.773 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.848 HG21 ' HB ' ' A' ' 126' ' ' ILE . 89.5 t -69.4 -39.96 79.4 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 C-N-CA 123.72 0.808 . . . . 0.0 111.535 -178.4 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.522 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.01 -15.97 39.74 Favored 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 119.171 -1.012 . . . . 0.0 112.053 178.836 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 16.9 t -99.67 -56.9 2.27 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.057 0.456 . . . . 0.0 111.324 -175.221 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.525 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 37.4 m-80 -85.67 -29.09 24.27 Favored 'General case' 0 CA--C 1.486 -1.513 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 -176.09 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.646 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 81.2 m-85 -106.79 157.39 17.78 Favored 'General case' 0 N--CA 1.416 -2.172 0 C-N-CA 119.365 -0.934 . . . . 0.0 110.38 -178.362 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.0 t -168.58 128.14 1.17 Allowed 'General case' 0 N--CA 1.42 -1.933 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 175.503 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.497 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -158.37 -109.92 0.28 Allowed Glycine 0 N--CA 1.404 -3.445 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 174.91 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.434 HG22 ' HA ' ' A' ' 83' ' ' PRO . 3.5 p -156.09 179.99 8.7 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 123.591 0.756 . . . . 0.0 109.859 -176.196 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -130.34 146.76 33.56 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.082 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 177.891 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.635 ' HG3' ' O ' ' A' ' 80' ' ' SER . 82.3 tttt -124.63 142.91 51.03 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.225 -179.564 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.496 ' CD2' HG22 ' A' ' 105' ' ' VAL . 51.5 t80 -142.51 107.87 5.02 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 -178.998 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 33.0 t 54.04 36.85 25.59 Favored 'General case' 0 CA--C 1.555 1.149 0 CA-C-O 121.541 0.686 . . . . 0.0 111.373 179.364 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.427 ' HA2' ' CE ' ' A' ' 76' ' ' LYS . . . 90.39 9.32 65.15 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.321 -0.942 . . . . 0.0 113.514 -178.645 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.635 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 22.9 t -79.96 172.53 13.66 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 177.425 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 6.2 p -152.84 100.58 2.53 Favored 'General case' 0 C--N 1.277 -2.58 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -177.757 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.445 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 1.6 p90 -144.93 159.52 49.81 Favored Pre-proline 0 C--N 1.301 -1.506 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -173.731 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.434 ' HA ' HG22 ' A' ' 74' ' ' THR . 47.3 Cg_endo -66.68 151.97 81.59 Favored 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 122.97 2.446 . . . . 0.0 112.734 -176.959 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.616 ' CD2' HD21 ' A' ' 109' ' ' LEU . 57.6 t80 -127.48 130.34 23.71 Favored Pre-proline 0 N--CA 1.438 -1.042 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.675 179.654 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.492 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 59.8 Cg_endo -69.37 149.46 87.67 Favored 'Cis proline' 0 C--O 1.244 0.803 0 C-N-CA 122.972 -1.678 . . . . 0.0 110.509 -0.393 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.411 HG22 ' H ' ' A' ' 61' ' ' GLY . 9.8 t -63.73 -176.56 0.18 Allowed 'General case' 0 CA--C 1.55 0.966 0 CA-C-O 121.298 0.57 . . . . 0.0 111.745 -175.233 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.1 p -113.15 -39.31 4.21 Favored 'General case' 0 N--CA 1.418 -2.041 0 CA-C-O 121.658 0.742 . . . . 0.0 109.303 -175.267 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 14.0 t -129.82 -107.59 0.28 Allowed 'General case' 0 N--CA 1.401 -2.878 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.259 -179.784 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -134.92 -166.82 1.88 Allowed 'General case' 0 N--CA 1.438 -1.04 0 CA-C-N 117.854 0.297 . . . . 0.0 110.633 -177.821 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.555 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 36.4 p -99.49 170.86 6.27 Favored Pre-proline 0 C--N 1.309 -1.153 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 178.174 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 91' ' ' PRO . . . . . 0.444 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 23.2 Cg_endo -61.34 161.75 22.58 Favored 'Trans proline' 0 C--O 1.249 1.033 0 C-N-CA 122.913 2.409 . . . . 0.0 111.099 169.636 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.7 tmm_? -78.44 119.97 22.51 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 -178.433 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 92.4 t -126.97 126.51 68.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 O-C-N 123.599 0.562 . . . . 0.0 110.189 -178.612 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 75.3 t -107.9 131.16 58.95 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 176.701 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.555 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.0 m-85 -77.77 131.11 37.48 Favored 'General case' 0 C--N 1.309 -1.186 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 175.795 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 84.4 m-20 -117.05 58.56 0.77 Allowed 'General case' 0 C--N 1.285 -2.233 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 -179.826 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 21.0 m -143.11 157.35 44.6 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.598 -176.231 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.467 ' HA ' HD21 ' A' ' 46' ' ' ASN . 14.7 ptp180 -121.83 37.61 4.32 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.845 0.831 . . . . 0.0 109.694 178.128 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 7.7 t -157.26 172.23 18.99 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 -176.028 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -73.26 120.67 19.2 Favored 'General case' 0 C--O 1.244 0.808 0 CA-C-O 121.391 0.615 . . . . 0.0 109.471 -179.203 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -117.92 142.32 30.66 Favored Pre-proline 0 C--N 1.277 -2.545 0 CA-C-N 115.128 -0.942 . . . . 0.0 110.423 -177.212 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -65.81 147.39 85.36 Favored 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.771 2.314 . . . . 0.0 111.834 176.807 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 13.8 t90 -89.17 108.88 27.01 Favored Pre-proline 0 C--N 1.31 -1.143 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 -177.205 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_endo -77.5 88.18 1.44 Allowed 'Trans proline' 0 N--CA 1.45 -1.046 0 C-N-CA 121.641 1.561 . . . . 0.0 113.38 -172.989 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.496 HG22 ' CD2' ' A' ' 77' ' ' TYR . 64.0 t -135.9 148.87 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.183 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 176.069 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.609 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -152.85 131.35 12.19 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-O 120.92 0.391 . . . . 0.0 110.375 177.198 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.47 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 16.7 mt -100.9 99.98 10.55 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.585 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.497 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 51.3 m-85 -78.17 80.36 4.59 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 177.397 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.646 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 2.7 mm? -104.02 116.66 32.63 Favored 'General case' 0 CA--C 1.491 -1.325 0 CA-C-O 120.997 0.427 . . . . 0.0 110.523 176.681 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.69 146.75 51.26 Favored Pre-proline 0 N--CA 1.407 -2.593 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.447 -175.535 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.525 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 18.8 Cg_endo -60.7 122.16 10.83 Favored 'Trans proline' 0 N--CA 1.447 -1.236 0 C-N-CA 122.987 2.458 . . . . 0.0 112.334 -178.248 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.516 HG22 ' O ' ' A' ' 70' ' ' ASN . 3.3 m -70.0 -120.52 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.195 -1.772 0 CA-C-N 113.831 -1.531 . . . . 0.0 111.78 174.874 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 33.4 t -111.69 -34.57 6.01 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 174.355 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 20.0 t -85.56 40.91 0.87 Allowed 'General case' 0 N--CA 1.431 -1.386 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.572 -177.347 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -114.06 135.88 53.53 Favored 'General case' 0 N--CA 1.418 -2.075 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 176.89 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -176.32 135.1 2.79 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 120.053 -1.07 . . . . 0.0 111.927 178.96 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 63.41 -151.07 48.95 Favored Glycine 0 CA--C 1.498 -1.016 0 CA-C-O 119.269 -0.74 . . . . 0.0 112.757 -178.642 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 98.4 t -58.32 99.46 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 122.06 0.933 . . . . 0.0 110.981 -177.648 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 119' ' ' ALA . . . . . 0.408 ' O ' ' HA3' ' A' ' 66' ' ' GLY . . . -99.68 -25.43 14.4 Favored 'General case' 0 C--N 1.295 -1.795 0 CA-C-N 114.608 -1.178 . . . . 0.0 110.735 -177.371 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.565 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 55.2 mt -134.56 138.01 50.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 -179.188 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.511 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 5.0 mmpt? -112.36 138.02 49.69 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-O 121.084 0.469 . . . . 0.0 111.184 177.375 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.45 125.15 25.98 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 177.74 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 93.97 -2.47 69.22 Favored Glycine 0 C--N 1.31 -0.885 0 N-CA-C 111.644 -0.582 . . . . 0.0 111.644 -178.13 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 28.8 t -96.13 143.84 26.9 Favored 'General case' 0 N--CA 1.431 -1.409 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 -179.913 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.434 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -71.53 124.0 23.68 Favored 'General case' 0 N--CA 1.435 -1.183 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.349 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.848 ' HB ' HG21 ' A' ' 67' ' ' VAL . 30.6 pt -111.63 -26.17 3.23 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -178.54 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 127' ' ' ALA . . . . . 0.431 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -160.75 168.2 25.28 Favored 'General case' 0 N--CA 1.443 -0.796 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 -178.196 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.434 HG23 HD11 ' A' ' 125' ' ' LEU . 70.5 t -143.0 114.06 2.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.903 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.44 HD11 HD21 ' A' ' 107' ' ' LEU . 55.8 mt -116.67 147.89 41.53 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.184 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.485 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.5 mp -133.01 127.69 55.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.849 -0.532 . . . . 0.0 110.002 179.714 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 131' ' ' LEU . . . . . . . . . . . . . 2.3 pp -96.4 147.04 24.23 Favored 'General case' 0 CA--C 1.496 -1.119 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 177.419 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.464 ' HD3' ' NE2' ' A' ' 59' ' ' GLN . 26.5 mmm-85 -96.49 118.39 32.89 Favored 'General case' 0 C--N 1.277 -2.576 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 172.858 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.704 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 49.6 tp60 -96.02 122.03 38.41 Favored 'General case' 0 N--CA 1.421 -1.911 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 173.151 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 22.1 m -134.61 134.01 40.79 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 177.085 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.432 ' CB ' HG23 ' A' ' 52' ' ' ILE . 27.2 p30 -136.41 -174.27 3.65 Favored 'General case' 0 C--N 1.31 -1.11 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.819 -179.736 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -109.04 -0.78 19.32 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.226 -172.425 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 74.6 t80 -127.43 -72.02 0.65 Allowed 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 114.699 1.37 . . . . 0.0 114.699 -168.717 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 138' ' ' ASN . . . . . 0.615 ' HB3' ' OD1' ' A' ' 140' ' ' ASP . 2.6 t-20 -78.66 -7.63 57.86 Favored 'General case' 0 N--CA 1.43 -1.426 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -169.052 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 18.9 t 69.83 17.47 7.6 Favored 'General case' 0 C--O 1.24 0.605 0 C-N-CA 123.953 0.901 . . . . 0.0 110.691 174.484 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 140' ' ' ASP . . . . . 0.615 ' OD1' ' HB3' ' A' ' 138' ' ' ASN . 5.9 p-10 -79.04 56.41 1.98 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.943 0.878 . . . . 0.0 112.53 179.443 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 141' ' ' ASP . . . . . 0.704 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 14.3 t70 -77.74 84.96 4.06 Favored 'General case' 0 CA--C 1.499 -1.016 0 CA-C-N 114.407 -1.27 . . . . 0.0 107.806 173.163 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -126.26 157.09 39.21 Favored 'General case' 0 C--N 1.282 -2.352 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 178.997 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 12.6 pt20 -115.08 132.12 56.71 Favored 'General case' 0 N--CA 1.407 -2.624 0 C-N-CA 119.037 -1.065 . . . . 0.0 110.248 -177.86 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 11.1 m-30 -100.77 129.35 46.64 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.206 -0.906 . . . . 0.0 108.785 -175.087 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 47.1 t -93.3 130.83 41.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 123.764 0.665 . . . . 0.0 109.973 -178.016 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 63.9 m95 -118.21 97.92 6.03 Favored 'General case' 0 C--N 1.275 -2.636 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 -178.853 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 47.2 m-80 -80.18 112.3 17.37 Favored 'General case' 0 C--N 1.285 -2.223 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 178.249 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.431 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 24.0 mm -86.03 122.06 38.12 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.819 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 -177.96 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -116.63 153.31 32.52 Favored 'General case' 0 C--N 1.286 -2.156 0 C-N-CA 124.052 0.941 . . . . 0.0 108.685 177.716 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.37 133.72 35.23 Favored 'General case' 0 N--CA 1.407 -2.585 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 176.066 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -92.94 -8.92 41.8 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -177.457 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 8.5 t-20 -150.04 143.93 25.46 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 113.937 -1.483 . . . . 0.0 110.008 -176.653 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -84.65 136.16 33.87 Favored 'General case' 0 C--N 1.312 -1.033 0 O-C-N 123.966 0.791 . . . . 0.0 110.419 179.43 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.565 ' HB ' ' HB ' ' A' ' 120' ' ' ILE . 69.6 t -118.59 140.05 43.64 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.978 -173.642 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -119.78 138.34 50.71 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.136 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 178.476 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.458 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 71.6 t -99.93 101.13 13.02 Favored Pre-proline 0 C--N 1.293 -1.889 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 176.688 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.528 ' HG3' HG13 ' A' ' 27' ' ' VAL . 21.4 Cg_endo -67.47 -29.72 37.07 Favored 'Trans proline' 0 CA--C 1.504 -1.002 0 C-N-CA 122.215 1.943 . . . . 0.0 111.511 179.075 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 6.1 t . . . . . 0 C--O 1.267 1.974 0 O-C-N 125.002 1.439 . . . . 0.0 112.534 179.387 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.639 ' HB3' ' OD1' ' A' ' 54' ' ' ASP . 0.0 OUTLIER . . . . . 0 CA--C 1.496 -1.122 0 CA-C-O 120.84 0.352 . . . . 0.0 110.964 . . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.427 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -142.97 -178.87 6.04 Favored 'General case' 0 C--N 1.284 -2.275 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.052 178.487 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 12.4 t -148.76 156.76 42.8 Favored 'General case' 0 N--CA 1.426 -1.642 0 C-N-CA 119.395 -0.922 . . . . 0.0 109.711 -175.25 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.547 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -143.64 161.71 37.82 Favored 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.408 -175.102 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 54.9 p -97.64 -179.96 4.63 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-O 121.015 0.436 . . . . 0.0 110.71 179.679 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.44 -22.56 38.09 Favored 'General case' 0 C--N 1.298 -1.642 0 CA-C-O 121.551 0.691 . . . . 0.0 109.206 177.848 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -85.74 -28.89 24.31 Favored 'General case' 0 N--CA 1.433 -1.297 0 CA-C-N 114.821 -1.082 . . . . 0.0 112.518 -175.784 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 130.43 22.79 1.05 Allowed Glycine 0 CA--C 1.49 -1.488 0 C-N-CA 118.868 -1.634 . . . . 0.0 113.974 171.588 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -103.04 99.42 9.3 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.363 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -94.25 114.15 26.19 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 115.879 -0.601 . . . . 0.0 109.399 176.825 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.427 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 68.5 mt -84.55 126.91 67.7 Favored Pre-proline 0 C--N 1.3 -1.582 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -179.171 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_endo -80.2 164.53 21.94 Favored 'Trans proline' 0 C--O 1.246 0.921 0 C-N-CA 122.614 2.209 . . . . 0.0 111.369 178.405 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.5 mt -65.91 126.31 24.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.984 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.57 10.02 1.49 Allowed Glycine 0 C--N 1.307 -1.028 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.613 -179.577 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.03 161.31 36.82 Favored Glycine 0 C--N 1.319 -0.392 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -177.924 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 161.61 -172.97 37.92 Favored Glycine 0 CA--C 1.495 -1.169 0 C-N-CA 119.938 -1.125 . . . . 0.0 111.331 178.448 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.435 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 65.2 p -144.51 144.03 31.14 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.306 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -130.98 162.16 30.36 Favored 'General case' 0 N--CA 1.415 -2.192 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.286 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -111.96 116.11 30.06 Favored 'General case' 0 C--N 1.271 -2.838 0 N-CA-C 107.043 -1.465 . . . . 0.0 107.043 174.773 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.464 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.2 m -99.63 139.03 22.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.683 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 179.22 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 23.7 m-85 -117.72 115.98 26.12 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-O 120.879 0.371 . . . . 0.0 111.994 -179.715 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.516 HG22 ' HG3' ' A' ' 41' ' ' GLN . 19.3 t -115.68 129.34 72.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.805 -173.819 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -89.27 119.75 30.03 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 177.778 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 28.1 mt -110.74 152.24 26.81 Favored 'General case' 0 C--N 1.282 -2.333 0 CA-C-N 115.051 -0.977 . . . . 0.0 108.984 -176.939 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -52.73 119.32 15.48 Favored Pre-proline 0 C--O 1.204 -1.296 0 O-C-N 124.513 1.133 . . . . 0.0 110.326 179.319 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.576 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 60.9 Cg_endo -73.83 -0.53 9.56 Favored 'Trans proline' 0 CA--C 1.544 0.993 0 C-N-CA 122.502 2.135 . . . . 0.0 113.616 -175.584 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.445 HG13 ' HG3' ' A' ' 157' ' ' PRO . 98.4 t -131.06 109.61 16.75 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 178.161 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.449 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 14.0 t -146.12 108.38 0.8 Allowed 'Isoleucine or valine' 0 C--O 1.193 -1.909 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 -177.248 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.537 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -95.87 154.22 17.34 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 123.864 0.865 . . . . 0.0 111.031 -179.84 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.526 HG22 ' O ' ' A' ' 112' ' ' VAL . 99.1 t -47.18 117.55 0.42 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.328 0 C-N-CA 123.436 0.694 . . . . 0.0 111.197 176.482 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.92 0.38 45.27 Favored Glycine 0 C--N 1.312 -0.803 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.924 -179.634 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.537 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.7 OUTLIER -74.9 -176.7 3.0 Favored 'General case' 0 C--N 1.316 -0.884 0 C-N-CA 123.751 0.821 . . . . 0.0 110.329 175.876 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 67.1 t30 -127.09 89.75 3.03 Favored 'General case' 0 CA--C 1.491 -1.32 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 177.721 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.559 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 20.0 tp -98.34 133.68 42.4 Favored 'General case' 0 C--N 1.295 -1.8 0 C-N-CA 118.898 -1.121 . . . . 0.0 109.256 177.158 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.405 ' CG2' ' HB1' ' A' ' 106' ' ' ALA . 2.1 p -141.56 130.75 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.382 -3.854 0 CA-C-N 114.797 -1.092 . . . . 0.0 112.075 -178.028 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.6 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 47.8 t -87.61 89.56 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.576 0 CA-C-N 113.832 -1.531 . . . . 0.0 107.266 178.801 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.47 ' O ' ' HG2' ' A' ' 41' ' ' GLN . 18.2 t70 -77.26 102.83 6.87 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-O 120.708 0.289 . . . . 0.0 110.683 -179.173 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.3 mt -85.08 -3.65 58.87 Favored 'General case' 0 C--N 1.311 -1.094 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.306 -178.512 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 35.2 t -73.27 0.1 12.91 Favored 'General case' 0 CA--C 1.542 0.636 0 CA-C-O 121.478 0.656 . . . . 0.0 110.135 -179.624 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.3 p -130.2 5.23 4.85 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.206 176.468 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.516 ' HG3' HG22 ' A' ' 22' ' ' VAL . 48.6 mm-40 -120.45 -20.75 7.08 Favored 'General case' 0 C--O 1.239 0.511 0 CA-C-O 121.03 0.443 . . . . 0.0 110.299 -174.177 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.401 HD11 HG11 ' A' ' 20' ' ' VAL . 37.4 mt -138.75 138.7 41.92 Favored 'Isoleucine or valine' 0 C--O 1.243 0.714 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 -177.103 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.547 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 48.7 m-85 -142.47 127.44 18.37 Favored 'General case' 0 N--CA 1.476 0.862 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -176.836 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 75.8 m -109.17 138.69 45.14 Favored 'General case' 0 C--N 1.295 -1.776 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -178.648 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.421 ' NE2' ' HB3' ' A' ' 2' ' ' ALA . 10.9 p-80 -121.07 154.34 36.24 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-O 122.335 1.064 . . . . 0.0 112.085 -176.47 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.486 HD22 ' CG ' ' A' ' 54' ' ' ASP . 3.0 m120 -96.9 114.81 26.46 Favored 'General case' 0 C--N 1.28 -2.434 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -179.423 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -77.09 -32.51 56.71 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.301 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 38.4 m-85 -138.68 83.03 20.38 Favored Pre-proline 0 C--N 1.315 -0.934 0 CA-C-N 114.331 -1.304 . . . . 0.0 108.921 -176.955 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.95 3.68 5.88 Favored 'Trans proline' 0 CA--C 1.541 0.831 0 C-N-CA 122.59 2.194 . . . . 0.0 113.685 -176.06 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -117.64 -22.35 8.11 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 121.268 0.556 . . . . 0.0 110.434 178.275 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.516 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.7 OUTLIER -98.49 -28.72 13.48 Favored 'General case' 0 N--CA 1.424 -1.741 0 CA-C-O 122.074 0.94 . . . . 0.0 109.244 -172.035 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.516 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.1 mp -122.67 135.79 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.087 0 CA-C-N 114.306 -1.316 . . . . 0.0 109.648 -178.346 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 3.3 t -86.42 124.29 32.59 Favored 'General case' 0 N--CA 1.417 -2.114 0 N-CA-C 103.022 -2.955 . . . . 0.0 103.022 169.22 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.639 ' OD1' ' HB3' ' A' ' 1' ' ' PHE . 16.1 m-20 -91.47 107.88 19.51 Favored 'General case' 0 C--N 1.271 -2.811 0 C-N-CA 118.815 -1.154 . . . . 0.0 109.433 -169.005 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 22.0 t80 -117.89 139.56 50.95 Favored 'General case' 0 C--N 1.273 -2.746 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.588 -175.74 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.507 HG23 ' HG ' ' A' ' 131' ' ' LEU . 12.9 p -145.59 145.39 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.794 0 O-C-N 123.626 0.579 . . . . 0.0 109.815 -179.577 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -149.4 125.11 10.44 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.085 174.584 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.505 HD12 ' O ' ' A' ' 130' ' ' ILE . 41.9 tp -61.82 110.35 1.51 Allowed 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 169.975 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.6 tp-100 -60.18 -56.95 15.34 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 126.63 1.972 . . . . 0.0 109.861 -179.074 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 10.8 ptp180 -164.14 160.16 21.11 Favored 'General case' 0 N--CA 1.426 -1.634 0 CA-C-N 114.505 -1.225 . . . . 0.0 108.874 -175.274 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -141.38 139.96 9.9 Favored Glycine 0 N--CA 1.411 -2.998 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -178.756 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 73.2 m -126.06 150.63 48.0 Favored 'General case' 0 C--N 1.289 -2.025 0 C-N-CA 124.139 0.976 . . . . 0.0 110.266 -176.807 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.48 ' HB2' ' CE2' ' A' ' 84' ' ' PHE . . . -114.2 157.69 22.34 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.202 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.461 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 87.0 m-85 -155.13 -178.88 7.56 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 124.12 0.968 . . . . 0.0 109.244 -178.609 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 60.25 -138.65 48.54 Favored Glycine 0 C--O 1.228 -0.279 0 O-C-N 123.537 0.523 . . . . 0.0 113.236 176.886 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.44 -8.79 85.76 Favored Glycine 0 N--CA 1.432 -1.631 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.355 177.037 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.815 HG21 ' HB ' ' A' ' 126' ' ' ILE . 84.0 t -69.13 -41.25 81.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 C-N-CA 123.52 0.728 . . . . 0.0 111.572 -176.709 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.471 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -83.21 -21.01 33.55 Favored 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.73 -0.788 . . . . 0.0 112.359 179.692 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 18.4 m -101.71 -50.69 3.63 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 115.25 1.574 . . . . 0.0 115.25 -174.802 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.493 ' O ' HG22 ' A' ' 112' ' ' VAL . 47.7 m-20 -93.73 -23.45 18.2 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -175.628 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.625 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 88.2 m-85 -108.1 159.24 16.73 Favored 'General case' 0 N--CA 1.423 -1.802 0 C-N-CA 120.02 -0.672 . . . . 0.0 109.324 176.979 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.6 t -167.5 125.11 1.21 Allowed 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 175.617 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.475 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -159.51 -110.28 0.27 Allowed Glycine 0 N--CA 1.407 -3.284 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 176.648 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.3 p -156.96 179.97 8.78 Favored 'General case' 0 C--N 1.296 -1.744 0 C-N-CA 123.531 0.733 . . . . 0.0 110.965 -173.101 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.429 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.6 p -133.69 144.37 36.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.919 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.678 ' HG3' ' O ' ' A' ' 80' ' ' SER . 86.0 tttt -123.42 150.19 44.09 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.318 -178.699 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.441 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 60.8 t80 -148.94 109.42 4.19 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 -178.812 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.6 t 51.48 41.01 28.07 Favored 'General case' 0 CA--C 1.554 1.105 0 C-N-CA 124.32 1.048 . . . . 0.0 111.396 178.037 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.83 6.73 67.08 Favored Glycine 0 CA--C 1.526 0.756 0 CA-C-N 115.615 -0.721 . . . . 0.0 113.987 179.82 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.678 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 22.8 t -79.57 179.98 7.18 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 178.43 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 3.6 p -157.99 107.15 2.06 Favored 'General case' 0 C--N 1.292 -1.896 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 -179.489 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.441 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.5 p90 -151.49 158.44 34.32 Favored Pre-proline 0 C--N 1.308 -1.228 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 -174.418 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.25 148.54 68.58 Favored 'Trans proline' 0 C--N 1.358 1.033 0 C-N-CA 122.819 2.346 . . . . 0.0 112.977 -176.385 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.601 ' CD2' HD21 ' A' ' 109' ' ' LEU . 63.0 t80 -121.92 133.4 24.29 Favored Pre-proline 0 N--CA 1.438 -1.058 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.773 179.98 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.493 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 74.1 Cg_endo -71.15 146.63 85.49 Favored 'Cis proline' 0 CA--C 1.548 1.223 0 C-N-CA 123.079 -1.634 . . . . 0.0 110.56 -1.856 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.1 t -64.13 -176.74 0.22 Allowed 'General case' 0 CA--C 1.558 1.262 0 C-N-CA 123.547 0.739 . . . . 0.0 112.279 -174.015 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 19.9 p -129.54 -27.6 2.37 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 113.161 0.8 . . . . 0.0 113.161 -172.449 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 t -127.62 -73.46 0.6 Allowed 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 119.736 -0.786 . . . . 0.0 110.684 -178.45 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -177.78 -174.57 0.46 Allowed 'General case' 0 C--O 1.243 0.726 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 -176.684 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.456 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 12.4 p -102.07 163.28 18.05 Favored Pre-proline 0 C--N 1.299 -1.592 0 O-C-N 123.432 0.458 . . . . 0.0 112.196 178.083 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -64.55 157.48 54.98 Favored 'Trans proline' 0 C--N 1.36 1.176 0 C-N-CA 122.669 2.246 . . . . 0.0 111.576 174.996 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.4 tmm_? -68.79 110.81 4.51 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 114.898 -1.046 . . . . 0.0 110.209 -175.757 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 71.0 t -122.35 132.83 70.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.826 -178.093 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 95.6 t -117.24 136.25 55.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 115.3 -0.863 . . . . 0.0 109.494 178.97 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.485 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 4.1 m-85 -82.99 94.97 7.88 Favored 'General case' 0 CA--C 1.499 -0.985 0 CA-C-O 121.41 0.624 . . . . 0.0 110.348 177.516 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -89.26 61.13 5.59 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 178.754 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.6 m -143.67 -179.3 6.36 Favored 'General case' 0 N--CA 1.423 -1.798 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 -176.959 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 4.5 ptm180 -146.08 50.7 1.16 Allowed 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 121.425 0.631 . . . . 0.0 109.979 179.998 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.0 t -169.87 177.41 4.4 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -175.201 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -71.77 98.02 1.89 Allowed 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 106.608 -1.627 . . . . 0.0 106.608 173.07 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 11.5 tptt -103.14 139.33 20.01 Favored Pre-proline 0 N--CA 1.407 -2.602 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 -177.678 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_endo -58.9 147.26 90.23 Favored 'Trans proline' 0 CA--C 1.511 -0.632 0 C-N-CA 122.605 2.203 . . . . 0.0 112.631 -176.993 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 103' ' ' TRP . . . . . 0.485 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.1 t90 -90.48 105.93 13.41 Favored Pre-proline 0 C--N 1.302 -1.472 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 178.6 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -77.83 87.94 1.47 Allowed 'Trans proline' 0 N--CA 1.443 -1.456 0 C-N-CA 121.616 1.544 . . . . 0.0 112.21 -173.094 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.438 HG22 ' CD2' ' A' ' 77' ' ' TYR . 86.7 t -139.01 147.03 25.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 N-CA-C 106.879 -1.526 . . . . 0.0 106.879 177.851 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.6 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -153.14 134.26 14.1 Favored 'General case' 0 C--N 1.284 -2.265 0 CA-C-O 120.811 0.338 . . . . 0.0 110.381 178.522 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.47 HD21 HD11 ' A' ' 129' ' ' LEU . 18.7 mt -101.6 99.86 10.2 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 179.151 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.475 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 74.2 m-85 -79.59 77.43 6.19 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 177.746 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.625 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.2 mm? -102.54 118.72 37.47 Favored 'General case' 0 CA--C 1.488 -1.414 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 176.365 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -122.18 146.91 47.97 Favored Pre-proline 0 N--CA 1.402 -2.867 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -174.964 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -63.4 123.14 11.61 Favored 'Trans proline' 0 CA--C 1.491 -1.625 0 C-N-CA 123.245 2.63 . . . . 0.0 113.379 -175.469 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.526 ' O ' HG22 ' A' ' 30' ' ' VAL . 24.3 m -83.22 -159.25 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.385 -3.689 0 CA-C-N 114.181 -1.372 . . . . 0.0 108.871 171.15 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.8 m -79.21 -29.56 42.86 Favored 'General case' 0 C--N 1.252 -3.631 0 CA-C-O 121.464 0.65 . . . . 0.0 110.296 -170.352 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 11.3 t -82.52 25.5 0.63 Allowed 'General case' 0 N--CA 1.428 -1.53 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.188 -179.77 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -109.17 136.75 48.15 Favored 'General case' 0 N--CA 1.422 -1.842 0 O-C-N 121.828 -0.545 . . . . 0.0 109.818 178.847 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -174.91 134.49 2.77 Favored Glycine 0 N--CA 1.432 -1.6 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 178.332 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 60.49 -149.3 43.29 Favored Glycine 0 CA--C 1.494 -1.221 0 CA-C-O 119.32 -0.711 . . . . 0.0 112.151 -177.637 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 94.0 t -57.95 105.11 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-O 121.923 0.868 . . . . 0.0 111.261 -177.884 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.37 -22.22 13.37 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 114.51 -1.223 . . . . 0.0 110.62 -178.772 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.483 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 67.9 mt -136.83 138.13 46.44 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 179.474 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.509 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.6 mmpt? -116.6 143.01 46.14 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.066 0.46 . . . . 0.0 109.79 174.744 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.5 131.05 42.74 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.891 -179.17 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.63 -6.07 64.87 Favored Glycine 0 N--CA 1.44 -1.083 0 C-N-CA 121.231 -0.509 . . . . 0.0 112.157 -179.316 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 27.2 m -94.9 147.53 23.27 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-O 120.778 0.323 . . . . 0.0 110.747 -179.302 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -74.25 124.04 25.66 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.271 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.815 ' HB ' HG21 ' A' ' 67' ' ' VAL . 31.2 pt -111.27 -26.28 3.2 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -178.555 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 127' ' ' ALA . . . . . 0.42 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.83 168.52 22.93 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 -177.679 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 73.7 t -143.4 114.44 2.54 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.487 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.47 HD11 HD21 ' A' ' 107' ' ' LEU . 62.9 mt -116.01 142.5 46.72 Favored 'General case' 0 C--N 1.291 -1.968 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 178.631 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.505 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.9 mp -121.08 126.54 75.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 C-N-CA 119.272 -0.971 . . . . 0.0 110.77 177.477 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.527 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.2 OUTLIER -98.05 131.41 44.49 Favored 'General case' 0 C--N 1.271 -2.813 0 C-N-CA 124.68 1.192 . . . . 0.0 109.182 179.422 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.636 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 12.6 tpt180 -104.9 124.53 49.64 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -179.86 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.579 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 12.6 mm100 -105.84 118.54 36.87 Favored 'General case' 0 C--N 1.319 -0.72 0 O-C-N 123.592 0.557 . . . . 0.0 110.345 179.242 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 5.1 m -136.6 149.7 48.18 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 106.377 -1.712 . . . . 0.0 106.377 177.462 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.49 ' CB ' HG23 ' A' ' 52' ' ' ILE . 12.6 p30 -144.86 178.82 7.74 Favored 'General case' 0 C--N 1.324 -0.529 0 C-N-CA 119.458 -0.897 . . . . 0.0 112.249 175.555 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -80.15 -24.53 40.36 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-O 121.253 0.549 . . . . 0.0 112.231 -175.135 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 85.3 t80 -97.09 -65.35 0.97 Allowed 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 123.589 0.756 . . . . 0.0 111.026 -170.357 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 138' ' ' ASN . . . . . 0.45 ' HB3' ' H ' ' A' ' 140' ' ' ASP . 17.5 m120 -74.52 150.18 39.92 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 123.202 0.601 . . . . 0.0 110.773 179.061 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 21.4 t -97.05 7.87 45.71 Favored 'General case' 0 C--N 1.309 -1.192 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 172.524 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 140' ' ' ASP . . . . . 0.45 ' H ' ' HB3' ' A' ' 138' ' ' ASN . 5.1 m-20 -72.06 63.26 0.49 Allowed 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 125.872 1.669 . . . . 0.0 110.844 179.661 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -86.55 89.62 7.97 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 115.229 -0.896 . . . . 0.0 109.644 179.495 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -119.34 167.45 11.89 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.314 -178.354 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 143' ' ' GLN . . . . . 0.636 ' HB3' ' HD2' ' A' ' 132' ' ' ARG . 14.0 pt20 -129.34 145.92 51.3 Favored 'General case' 0 N--CA 1.417 -2.089 0 C-N-CA 119.812 -0.755 . . . . 0.0 111.336 177.851 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.447 ' HB2' HD22 ' A' ' 131' ' ' LEU . 11.0 m-30 -109.5 130.44 55.5 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 -178.007 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.435 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 61.9 t -90.36 131.77 36.69 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.053 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 179.86 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 146' ' ' TRP . . . . . 0.527 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 69.2 m95 -119.9 97.96 5.87 Favored 'General case' 0 C--N 1.275 -2.636 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 -179.273 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 49.2 m-80 -80.01 114.7 19.11 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 178.634 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.464 ' HA ' HG22 ' A' ' 20' ' ' VAL . 23.6 mm -88.21 122.06 39.31 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 -177.718 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -118.19 156.1 29.33 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 123.241 0.616 . . . . 0.0 109.697 178.506 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -84.1 131.61 34.77 Favored 'General case' 0 N--CA 1.414 -2.258 0 CA-C-N 115.238 -0.892 . . . . 0.0 108.682 177.33 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -95.75 -12.12 25.9 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 -176.812 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -155.08 146.49 22.99 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 113.84 -1.527 . . . . 0.0 108.326 -178.089 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 17.8 p-10 -86.05 148.15 25.86 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 124.152 0.981 . . . . 0.0 111.564 -177.181 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.576 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 77.7 t -123.57 136.04 61.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-N 115.459 -0.792 . . . . 0.0 111.194 -174.542 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.5 t -118.29 135.1 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.767 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.449 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.1 t -99.37 103.77 22.73 Favored Pre-proline 0 C--N 1.291 -1.975 0 C-N-CA 123.867 0.867 . . . . 0.0 109.871 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.486 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 50.1 Cg_endo -72.77 -17.11 26.11 Favored 'Trans proline' 0 C--N 1.333 -0.289 0 C-N-CA 122.034 1.822 . . . . 0.0 111.424 178.021 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.273 4.0 t . . . . . 0 C--O 1.239 0.543 0 C-N-CA 125.414 1.486 . . . . 0.0 113.568 177.75 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.563 ' CZ ' ' HB3' ' A' ' 133' ' ' GLN . 0.3 OUTLIER . . . . . 0 CA--C 1.5 -0.976 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 . . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.484 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -147.51 -175.32 4.81 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 -175.289 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 14.7 t -148.78 157.01 43.13 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.394 -0.922 . . . . 0.0 109.958 -177.006 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.495 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.91 156.28 43.9 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 121.868 0.842 . . . . 0.0 111.434 -174.789 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 36.3 p -94.97 171.47 8.74 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.749 178.402 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -80.7 -10.93 59.7 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 114.661 -1.154 . . . . 0.0 110.332 -179.127 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -93.06 -33.22 14.18 Favored 'General case' 0 N--CA 1.431 -1.384 0 CA-C-N 114.96 -1.018 . . . . 0.0 111.796 -177.556 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 142.88 -1.59 1.53 Allowed Glycine 0 CA--C 1.507 -0.448 0 C-N-CA 119.158 -1.496 . . . . 0.0 114.462 171.461 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.4 m -86.35 104.99 16.38 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 122.202 -0.587 . . . . 0.0 110.93 -178.441 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -96.31 118.66 33.31 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 173.773 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.484 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 66.2 mt -89.84 122.58 67.8 Favored Pre-proline 0 C--N 1.297 -1.694 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 -179.649 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -77.24 171.91 16.95 Favored 'Trans proline' 0 C--O 1.239 0.563 0 C-N-CA 122.939 2.426 . . . . 0.0 111.582 179.6 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.7 mt -72.85 120.1 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.807 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 179.155 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 140.98 23.36 0.25 Allowed Glycine 0 C--N 1.301 -1.415 0 CA-C-N 115.393 -0.822 . . . . 0.0 112.027 -179.668 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 73.79 167.41 14.75 Favored Glycine 0 C--N 1.335 0.494 0 C-N-CA 121.156 -0.545 . . . . 0.0 112.309 -177.28 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 153.97 -172.01 32.64 Favored Glycine 0 CA--C 1.483 -1.966 0 C-N-CA 120.087 -1.054 . . . . 0.0 110.925 176.229 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.43 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 78.3 p -141.43 156.27 45.8 Favored 'General case' 0 N--CA 1.42 -1.953 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 178.918 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -137.23 160.22 39.66 Favored 'General case' 0 N--CA 1.422 -1.864 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 177.536 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.417 HD21 ' HE1' ' A' ' 149' ' ' TYR . 11.4 m120 -114.15 109.89 19.12 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 105.143 -2.169 . . . . 0.0 105.143 175.713 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.495 HG22 ' HA ' ' A' ' 148' ' ' ILE . 0.8 OUTLIER -91.84 143.2 11.8 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.328 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 -178.132 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 63.2 m-85 -119.52 116.07 25.32 Favored 'General case' 0 C--N 1.297 -1.711 0 C-N-CA 120.803 -0.359 . . . . 0.0 111.557 -179.249 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.436 HG22 ' HG3' ' A' ' 41' ' ' GLN . 22.0 t -119.58 132.75 68.49 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.041 -174.888 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 -88.6 123.09 32.75 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 176.881 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.467 HD11 HG22 ' A' ' 36' ' ' VAL . 2.9 mm? -104.14 160.44 14.86 Favored 'General case' 0 C--N 1.287 -2.143 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.502 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -59.33 123.71 71.48 Favored Pre-proline 0 C--N 1.316 -0.886 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.382 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 88.0 Cg_endo -78.53 1.58 8.91 Favored 'Trans proline' 0 C--N 1.33 -0.427 0 C-N-CA 122.78 2.32 . . . . 0.0 113.159 -175.264 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 98.7 t -129.53 109.77 18.83 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 177.311 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.0 t -143.03 103.53 0.92 Allowed 'Isoleucine or valine' 0 C--O 1.18 -2.585 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -176.347 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.728 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -95.16 155.27 16.8 Favored 'General case' 0 C--N 1.272 -2.783 0 C-N-CA 122.364 0.266 . . . . 0.0 111.01 -179.838 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.606 HG22 ' O ' ' A' ' 112' ' ' VAL . 87.5 t -46.94 118.71 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 C-N-CA 123.06 0.544 . . . . 0.0 111.064 175.387 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.98 9.61 57.05 Favored Glycine 0 C--N 1.31 -0.887 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.939 179.467 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.728 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -80.77 -177.72 6.46 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 175.413 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 27.3 t-20 -130.88 87.65 2.51 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 178.859 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.66 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 27.1 tp -88.1 144.56 26.42 Favored 'General case' 0 C--N 1.292 -1.906 0 C-N-CA 119.589 -0.844 . . . . 0.0 109.685 -178.803 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.7 t -137.7 130.33 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.882 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 -177.597 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.565 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 40.3 t -97.54 88.75 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.413 -2.304 0 N-CA-C 105.685 -1.968 . . . . 0.0 105.685 172.734 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.411 ' O ' ' HG2' ' A' ' 41' ' ' GLN . 12.9 t70 -82.03 109.74 16.64 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -177.781 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.9 mt -92.47 -1.32 57.06 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-O 121.072 0.463 . . . . 0.0 111.284 -178.012 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.579 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 34.1 t -76.25 0.27 19.81 Favored 'General case' 0 C--N 1.31 -1.121 0 CA-C-O 121.652 0.739 . . . . 0.0 109.459 -178.713 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.6 p -129.81 5.51 5.04 Favored 'General case' 0 N--CA 1.412 -2.33 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.599 178.83 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.436 ' HG3' HG22 ' A' ' 22' ' ' VAL . 48.9 mm-40 -124.69 -21.13 4.88 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.854 -173.89 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 39.0 mt -134.8 138.73 48.81 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 -177.333 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.495 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 49.5 m-85 -142.32 128.63 19.95 Favored 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -176.065 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 85.0 m -107.57 145.9 32.61 Favored 'General case' 0 C--N 1.284 -2.251 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.032 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 12.1 p80 -131.62 128.35 38.95 Favored 'General case' 0 C--N 1.296 -1.728 0 CA-C-O 122.16 0.981 . . . . 0.0 111.744 -176.516 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 20.8 p-10 -97.11 89.66 4.87 Favored 'General case' 0 C--N 1.282 -2.335 0 CA-C-O 122.257 1.027 . . . . 0.0 108.693 178.572 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 47' ' ' ASP . . . . . 0.586 ' HB2' ' CD2' ' A' ' 48' ' ' TYR . 1.4 m-20 -51.74 -43.62 62.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.25 -175.676 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 48' ' ' TYR . . . . . 0.586 ' CD2' ' HB2' ' A' ' 47' ' ' ASP . 29.2 m-85 -121.84 83.27 43.01 Favored Pre-proline 0 C--N 1.315 -0.913 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 -175.278 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -83.01 -5.51 11.32 Favored 'Trans proline' 0 C--O 1.234 0.29 0 C-N-CA 122.99 2.46 . . . . 0.0 112.786 -173.606 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -103.78 -23.35 13.42 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.023 -178.09 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.711 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.3 OUTLIER -100.33 -30.76 11.69 Favored 'General case' 0 N--CA 1.415 -2.222 0 CA-C-O 122.02 0.914 . . . . 0.0 108.867 -176.0 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.711 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.9 mp -128.96 134.9 63.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 CA-C-N 114.636 -1.166 . . . . 0.0 109.927 -176.584 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 5.9 t -86.51 139.05 31.24 Favored 'General case' 0 N--CA 1.438 -1.052 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 171.5 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.464 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 14.6 t70 -96.07 108.78 21.25 Favored 'General case' 0 C--N 1.275 -2.664 0 C-N-CA 119.673 -0.811 . . . . 0.0 109.147 -175.832 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 23.6 t80 -122.64 122.15 38.12 Favored 'General case' 0 C--N 1.288 -2.065 0 CA-C-O 121.799 0.809 . . . . 0.0 110.065 -177.702 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.422 ' CG1' HD12 ' A' ' 131' ' ' LEU . 85.3 t -125.95 138.52 54.29 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 CA-C-N 114.169 -1.378 . . . . 0.0 110.067 -176.084 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -144.46 135.3 24.97 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 172.602 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.547 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 38.9 tp -74.58 104.91 5.45 Favored 'General case' 0 N--CA 1.436 -1.132 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 175.429 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -52.96 -54.2 38.49 Favored 'General case' 0 C--O 1.201 -1.457 0 C-N-CA 126.278 1.831 . . . . 0.0 111.048 -179.55 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.405 ' HG3' HD13 ' A' ' 130' ' ' ILE . 0.4 OUTLIER -165.52 156.35 13.74 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 -177.766 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.87 118.34 1.11 Allowed Glycine 0 N--CA 1.398 -3.846 0 N-CA-C 108.941 -1.663 . . . . 0.0 108.941 -178.099 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.403 ' HA ' ' HB3' ' A' ' 85' ' ' PRO . 52.8 m -114.52 146.56 40.58 Favored 'General case' 0 C--N 1.279 -2.472 0 C-N-CA 124.584 1.153 . . . . 0.0 110.029 -170.859 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.527 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -106.26 156.66 18.25 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 123.496 0.718 . . . . 0.0 109.112 -178.715 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.484 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 99.5 m-85 -154.48 -179.35 7.88 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 124.08 0.952 . . . . 0.0 109.742 -176.978 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.06 -136.44 51.18 Favored Glycine 0 N--CA 1.458 0.121 0 O-C-N 123.653 0.595 . . . . 0.0 112.669 178.012 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.79 -9.07 83.49 Favored Glycine 0 C--O 1.206 -1.635 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 177.477 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.826 HG21 ' HB ' ' A' ' 126' ' ' ILE . 77.7 t -69.67 -36.42 70.36 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 C-N-CA 123.745 0.818 . . . . 0.0 111.852 -176.107 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.527 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -87.16 -20.25 27.28 Favored 'General case' 0 C--N 1.297 -1.684 0 C-N-CA 119.216 -0.993 . . . . 0.0 112.296 178.306 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 9.6 t -101.03 -52.79 3.2 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.472 0.653 . . . . 0.0 112.195 -173.757 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.485 ' O ' HG22 ' A' ' 112' ' ' VAL . 31.6 m-20 -91.78 -25.81 18.85 Favored 'General case' 0 CA--C 1.49 -1.353 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -173.69 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.639 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 86.1 m-85 -106.61 155.85 19.21 Favored 'General case' 0 N--CA 1.416 -2.152 0 C-N-CA 120.008 -0.677 . . . . 0.0 109.291 177.254 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.3 t -165.48 117.83 1.14 Allowed 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 176.992 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.506 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -153.56 -111.88 0.46 Allowed Glycine 0 N--CA 1.412 -2.924 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 176.714 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.9 p -154.51 -179.72 8.23 Favored 'General case' 0 C--N 1.297 -1.687 0 C-N-CA 123.561 0.744 . . . . 0.0 110.93 -173.66 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -133.95 144.02 36.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 C-N-CA 123.319 0.648 . . . . 0.0 109.874 177.762 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.61 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.0 tttt -121.68 142.82 49.78 Favored 'General case' 0 N--CA 1.432 -1.374 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.648 178.767 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.46 ' CD2' HG22 ' A' ' 105' ' ' VAL . 62.6 t80 -142.42 110.35 5.89 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.517 -179.055 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.9 t 49.77 38.9 16.66 Favored 'General case' 0 CA--C 1.557 1.231 0 C-N-CA 124.43 1.092 . . . . 0.0 111.735 176.017 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.28 18.3 50.05 Favored Glycine 0 CA--C 1.524 0.596 0 C-N-CA 120.922 -0.656 . . . . 0.0 113.624 -179.404 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.61 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 12.2 t -92.73 -179.84 5.27 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 174.597 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 56.3 p -157.87 105.53 1.99 Allowed 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 179.652 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.443 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 2.7 p90 -150.73 160.83 31.79 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 -173.791 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.443 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 45.0 Cg_endo -68.51 148.19 72.35 Favored 'Trans proline' 0 C--N 1.357 0.984 0 C-N-CA 122.935 2.423 . . . . 0.0 113.357 -177.788 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.602 ' CD2' HD21 ' A' ' 109' ' ' LEU . 60.5 t80 -123.61 134.15 25.08 Favored Pre-proline 0 N--CA 1.433 -1.289 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.484 -179.431 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.46 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 60.2 Cg_endo -70.54 148.76 89.19 Favored 'Cis proline' 0 CA--C 1.541 0.862 0 C-N-CA 122.77 -1.763 . . . . 0.0 110.469 -0.838 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.2 t -67.24 -177.22 0.65 Allowed 'General case' 0 CA--C 1.549 0.919 0 CA-C-O 121.266 0.555 . . . . 0.0 110.997 -176.86 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 18.5 p -130.39 -19.88 3.04 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 112.597 0.592 . . . . 0.0 112.597 -173.459 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 21.6 t -130.71 -89.36 0.47 Allowed 'General case' 0 C--O 1.204 -1.335 0 C-N-CA 120.429 -0.508 . . . . 0.0 110.309 -179.988 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -166.58 -173.01 2.33 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 177.888 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.547 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 61.8 p -100.32 163.48 18.17 Favored Pre-proline 0 C--N 1.304 -1.387 0 N-CA-C 112.795 0.665 . . . . 0.0 112.795 179.798 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_endo -56.65 165.27 4.83 Favored 'Trans proline' 0 C--O 1.248 0.99 0 C-N-CA 123.518 2.812 . . . . 0.0 111.43 172.711 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -74.47 122.17 22.62 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.479 -175.959 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 73.2 t -134.9 133.46 53.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 -178.348 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 54' ' ' ASP . 1.5 p -132.97 134.6 57.94 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.292 0 CA-C-N 115.971 -0.558 . . . . 0.0 109.596 -178.55 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.464 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 2.6 m-85 -83.07 117.91 23.18 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 179.182 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -102.07 27.56 6.52 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.756 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.9 m -99.23 -171.56 2.1 Favored 'General case' 0 N--CA 1.426 -1.628 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.291 -178.328 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -151.15 43.58 0.79 Allowed 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.465 0.65 . . . . 0.0 110.39 175.769 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.3 t -168.18 -178.63 3.73 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -176.735 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -67.18 106.78 2.11 Favored 'General case' 0 CA--C 1.511 -0.542 0 C-N-CA 123.344 0.658 . . . . 0.0 109.39 179.607 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -112.6 135.1 21.52 Favored Pre-proline 0 C--N 1.293 -1.866 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 176.342 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.579 ' HB3' ' O ' ' A' ' 39' ' ' SER . 51.4 Cg_exo -53.69 139.61 67.41 Favored 'Trans proline' 0 CA--C 1.503 -1.067 0 C-N-CA 123.865 3.043 . . . . 0.0 112.295 177.357 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 15.5 t90 -85.0 106.85 9.74 Favored Pre-proline 0 C--N 1.298 -1.655 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 179.161 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 104' ' ' PRO . . . . . 0.403 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 60.2 Cg_endo -77.0 88.22 1.42 Allowed 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 121.368 1.379 . . . . 0.0 113.096 -172.952 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.46 HG22 ' CD2' ' A' ' 77' ' ' TYR . 92.6 t -140.62 146.88 23.6 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.103 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 178.127 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.565 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.38 135.05 17.43 Favored 'General case' 0 C--N 1.294 -1.817 0 CA-C-O 120.757 0.313 . . . . 0.0 110.431 177.34 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.496 HD21 HD11 ' A' ' 129' ' ' LEU . 20.1 mt -100.97 105.18 16.38 Favored 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 178.083 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.506 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 43.9 m-85 -83.63 72.58 10.31 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 120.67 0.272 . . . . 0.0 110.716 178.095 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.66 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -98.66 129.17 45.14 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 176.342 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.42 146.89 63.43 Favored Pre-proline 0 N--CA 1.41 -2.426 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 -175.9 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.458 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 40.4 Cg_endo -65.37 126.07 15.61 Favored 'Trans proline' 0 CA--C 1.496 -1.416 0 C-N-CA 123.133 2.555 . . . . 0.0 113.002 -175.181 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.606 ' O ' HG22 ' A' ' 30' ' ' VAL . 16.7 m -84.3 -154.78 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.401 -2.889 0 CA-C-N 114.518 -1.219 . . . . 0.0 108.044 171.667 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 18.5 m -82.76 -30.32 29.05 Favored 'General case' 0 C--N 1.255 -3.508 0 CA-C-O 121.497 0.665 . . . . 0.0 110.025 -170.609 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 18.1 t -84.73 30.81 0.55 Allowed 'General case' 0 N--CA 1.435 -1.201 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.156 -179.821 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -112.23 138.12 49.37 Favored 'General case' 0 N--CA 1.422 -1.831 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.874 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -179.22 128.01 1.2 Allowed Glycine 0 N--CA 1.437 -1.239 0 C-N-CA 120.367 -0.92 . . . . 0.0 112.425 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 68.32 -149.05 49.54 Favored Glycine 0 CA--C 1.486 -1.728 0 CA-C-O 119.125 -0.819 . . . . 0.0 111.928 -177.436 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 57.4 t -59.85 103.4 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 CA-C-N 117.308 0.554 . . . . 0.0 110.088 -177.126 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -103.78 -29.16 11.2 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.953 -178.223 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.527 ' HB ' HG22 ' A' ' 154' ' ' VAL . 73.6 mt -126.69 137.48 57.7 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.849 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 176.947 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.46 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.9 mmpt? -114.06 141.87 46.9 Favored 'General case' 0 C--N 1.31 -1.131 0 C-N-CA 122.959 0.504 . . . . 0.0 110.121 177.048 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -73.03 135.71 44.94 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.286 179.677 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 84.49 11.31 77.98 Favored Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 111.59 -0.604 . . . . 0.0 111.59 -179.016 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 27.3 t -113.98 147.76 38.06 Favored 'General case' 0 N--CA 1.433 -1.324 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 -179.332 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 23.1 tp -73.52 134.99 43.96 Favored 'General case' 0 CA--C 1.506 -0.747 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.795 -179.801 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.826 ' HB ' HG21 ' A' ' 67' ' ' VAL . 35.8 pt -120.12 -25.0 2.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.717 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 179.215 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 127' ' ' ALA . . . . . 0.408 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -163.35 166.0 23.43 Favored 'General case' 0 C--O 1.21 -1.017 0 N-CA-C 110.312 -0.255 . . . . 0.0 110.312 -178.022 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 67.1 t -139.48 113.18 6.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.3 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.496 HD11 HD21 ' A' ' 107' ' ' LEU . 48.1 mt -118.48 143.29 46.81 Favored 'General case' 0 C--N 1.29 -1.995 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 179.751 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.573 HG21 ' NE2' ' A' ' 143' ' ' GLN . 5.3 mp -124.23 128.52 73.92 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 C-N-CA 119.7 -0.8 . . . . 0.0 110.67 178.419 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.566 HD23 ' O ' ' A' ' 131' ' ' LEU . 0.0 OUTLIER -96.11 135.15 38.28 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 175.433 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.539 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 8.8 tpt180 -97.92 122.26 40.83 Favored 'General case' 0 C--N 1.285 -2.223 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.573 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 133' ' ' GLN . . . . . 0.563 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 20.5 mm-40 -105.82 104.7 14.47 Favored 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 123.406 0.682 . . . . 0.0 109.268 -177.587 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 6.9 m -127.34 142.14 51.52 Favored 'General case' 0 C--N 1.284 -2.255 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 179.197 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.587 ' CB ' HG23 ' A' ' 52' ' ' ILE . 9.1 p30 -132.01 170.87 14.33 Favored 'General case' 0 C--N 1.309 -1.166 0 C-N-CA 119.988 -0.685 . . . . 0.0 110.446 176.498 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -85.98 -10.86 54.39 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 114.676 -1.147 . . . . 0.0 112.474 -170.668 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 60.1 t80 -109.39 -62.16 1.53 Allowed 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 112.316 0.488 . . . . 0.0 112.316 -171.957 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 16.9 m120 -80.22 148.5 30.8 Favored 'General case' 0 CA--C 1.49 -1.328 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.774 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 20.2 p -88.24 10.14 20.62 Favored 'General case' 0 C--N 1.298 -1.63 0 CA-C-O 121.79 0.805 . . . . 0.0 109.88 176.964 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -78.68 94.5 5.08 Favored 'General case' 0 CA--C 1.505 -0.764 0 CA-C-N 114.466 -1.243 . . . . 0.0 109.147 177.8 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -112.83 106.7 15.08 Favored 'General case' 0 C--N 1.292 -1.895 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.958 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -128.14 173.51 10.03 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 120.992 0.425 . . . . 0.0 109.935 -176.741 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 143' ' ' GLN . . . . . 0.573 ' NE2' HG21 ' A' ' 130' ' ' ILE . 17.3 pt20 -134.79 143.93 47.36 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 175.514 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.496 ' HB2' HD22 ' A' ' 131' ' ' LEU . 9.4 m-30 -109.65 130.38 55.52 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 -179.175 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.43 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 52.2 t -90.81 132.27 35.82 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 O-C-N 123.592 0.557 . . . . 0.0 109.799 -178.617 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 146' ' ' TRP . . . . . 0.474 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 61.9 m95 -117.47 96.18 5.29 Favored 'General case' 0 C--N 1.279 -2.48 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 -179.304 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.9 m-80 -79.45 112.63 16.89 Favored 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 177.989 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.495 ' HA ' HG22 ' A' ' 20' ' ' VAL . 26.6 mm -86.37 122.14 38.33 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.816 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -175.799 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.417 ' HE1' HD21 ' A' ' 19' ' ' ASN . 40.6 m-85 -117.25 156.2 28.16 Favored 'General case' 0 CA--C 1.487 -1.474 0 CA-C-O 121.633 0.73 . . . . 0.0 110.605 179.222 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -84.28 129.37 34.89 Favored 'General case' 0 N--CA 1.405 -2.685 0 CA-C-N 114.544 -1.207 . . . . 0.0 108.684 175.808 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 15.8 t-20 -91.43 -13.77 31.74 Favored 'General case' 0 C--N 1.29 -2.008 0 N-CA-C 107.383 -1.339 . . . . 0.0 107.383 -178.793 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 6.7 t-20 -150.14 143.62 25.17 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 113.633 -1.621 . . . . 0.0 109.008 -175.201 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -86.37 144.79 27.17 Favored 'General case' 0 C--N 1.307 -1.249 0 O-C-N 124.241 0.963 . . . . 0.0 110.169 -179.777 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.527 HG22 ' HB ' ' A' ' 120' ' ' ILE . 1.5 m -123.96 150.52 28.46 Favored 'Isoleucine or valine' 0 C--O 1.253 1.249 0 C-N-CA 120.701 -0.4 . . . . 0.0 111.24 -177.284 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.2 t -124.32 138.27 54.4 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.124 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -179.613 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.462 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 79.0 t -100.21 100.83 12.64 Favored Pre-proline 0 C--N 1.296 -1.759 0 C-N-CA 123.983 0.913 . . . . 0.0 109.453 178.06 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.502 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 27.5 Cg_endo -66.37 -26.19 48.47 Favored 'Trans proline' 0 CA--C 1.515 -0.428 0 C-N-CA 122.208 1.939 . . . . 0.0 111.773 178.908 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.3 t . . . . . 0 C--O 1.254 1.312 0 O-C-N 124.516 1.135 . . . . 0.0 113.223 176.882 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 30.6 t80 . . . . . 0 CA--C 1.479 -1.753 0 N-CA-C 105.331 -2.1 . . . . 0.0 105.331 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.458 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -140.3 176.41 8.79 Favored 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -178.191 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 13.6 t -147.4 159.37 43.77 Favored 'General case' 0 N--CA 1.428 -1.555 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.647 -174.784 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.587 ' HE3' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.81 168.72 19.54 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-O 121.36 0.6 . . . . 0.0 110.747 -173.717 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 76.2 p -105.5 175.82 5.37 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.08 0.467 . . . . 0.0 110.798 179.771 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -73.66 -22.05 60.08 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.627 178.651 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -84.28 -33.33 24.01 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 120.256 -0.578 . . . . 0.0 110.641 -177.784 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 135.13 9.47 1.66 Allowed Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 119.564 -1.303 . . . . 0.0 113.699 176.808 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -85.16 100.02 11.46 Favored 'General case' 0 N--CA 1.433 -1.317 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.884 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.1 117.33 30.0 Favored 'General case' 0 C--N 1.297 -1.71 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.591 178.638 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.458 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 67.3 mt -86.63 127.26 61.16 Favored Pre-proline 0 C--N 1.299 -1.627 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 178.692 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -81.06 169.34 16.28 Favored 'Trans proline' 0 C--O 1.248 0.984 0 C-N-CA 122.78 2.32 . . . . 0.0 111.305 177.985 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 61.3 mt -69.16 132.11 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 177.855 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 129.89 -5.22 6.12 Favored Glycine 0 C--N 1.3 -1.462 0 C-N-CA 120.172 -1.013 . . . . 0.0 111.507 -179.528 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 101.42 163.6 27.33 Favored Glycine 0 N--CA 1.432 -1.595 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 -177.694 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 160.41 -177.45 36.84 Favored Glycine 0 C--N 1.297 -1.614 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 178.612 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.415 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 59.7 p -138.99 147.74 42.55 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.763 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -132.0 161.05 34.1 Favored 'General case' 0 N--CA 1.426 -1.63 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 177.999 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 -116.2 109.06 16.93 Favored 'General case' 0 C--N 1.289 -2.055 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 177.784 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.455 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.3 m -91.1 147.68 5.08 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.416 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 -177.893 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.7 m-85 -131.04 118.87 21.2 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -177.354 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.538 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -125.43 135.63 63.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.108 -176.389 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 30.7 m-80 -91.08 122.7 33.95 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 179.988 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 24' ' ' LEU . . . . . 0.411 HD11 HG22 ' A' ' 36' ' ' VAL . 2.8 mm? -101.94 160.61 14.34 Favored 'General case' 0 C--N 1.285 -2.223 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 178.103 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.2 122.21 52.48 Favored Pre-proline 0 C--N 1.314 -0.955 0 O-C-N 124.116 0.885 . . . . 0.0 108.728 174.76 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.531 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 72.8 Cg_endo -74.71 -1.84 11.67 Favored 'Trans proline' 0 CA--C 1.533 0.441 0 C-N-CA 122.895 2.397 . . . . 0.0 112.968 -176.148 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.408 HG13 ' HG3' ' A' ' 157' ' ' PRO . 95.6 t -129.11 111.27 22.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.475 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 10.3 t -148.19 111.1 0.68 Allowed 'Isoleucine or valine' 0 C--O 1.188 -2.17 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -177.341 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.592 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -96.83 154.65 17.17 Favored 'General case' 0 C--N 1.272 -2.775 0 C-N-CA 123.646 0.778 . . . . 0.0 110.962 179.834 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.581 HG22 ' O ' ' A' ' 112' ' ' VAL . 71.5 t -46.67 122.66 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 C-N-CA 123.051 0.541 . . . . 0.0 110.734 176.24 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.25 1.24 58.16 Favored Glycine 0 C--N 1.315 -0.592 0 CA-C-N 115.536 -0.756 . . . . 0.0 112.919 179.663 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.592 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.7 OUTLIER -73.38 -176.98 2.42 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 123.396 0.678 . . . . 0.0 110.678 175.93 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 64.7 t30 -131.42 92.13 3.12 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.131 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.654 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 28.5 tp -94.09 141.05 28.99 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 119.444 -0.902 . . . . 0.0 109.906 -179.66 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 56.9 t -131.87 120.93 45.98 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.019 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.022 -176.443 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.573 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 48.3 t -90.86 88.21 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.89 0 N-CA-C 105.249 -2.13 . . . . 0.0 105.249 173.655 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -83.26 109.75 17.5 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.318 -177.473 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.415 ' HA ' ' HG2' ' A' ' 41' ' ' GLN . 84.2 mt -95.0 -3.64 48.04 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.111 -178.164 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.1 m -71.15 0.15 8.38 Favored 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 114.831 -1.077 . . . . 0.0 110.125 -179.945 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.5 p -133.21 6.86 3.9 Favored 'General case' 0 N--CA 1.425 -1.677 0 C-N-CA 124.24 1.016 . . . . 0.0 109.911 178.639 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.538 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 46.2 mm-40 -122.23 -19.28 6.57 Favored 'General case' 0 CA--C 1.507 -0.699 0 CA-C-O 121.067 0.461 . . . . 0.0 110.717 -174.557 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 45.2 mt -134.36 138.24 50.2 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -176.219 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.587 ' HB2' ' HE3' ' A' ' 4' ' ' LYS . 72.8 m-85 -143.02 143.44 31.9 Favored 'General case' 0 CA--C 1.492 -1.27 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -174.467 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 64.8 m -126.87 140.64 52.19 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 -176.327 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -121.89 151.17 40.98 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.313 0.578 . . . . 0.0 110.256 -176.203 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.653 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 24.0 p-10 -107.18 104.06 13.6 Favored 'General case' 0 N--CA 1.411 -2.387 0 CA-C-O 122.886 1.327 . . . . 0.0 110.068 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -74.84 -34.64 62.35 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 112.942 -1.935 . . . . 0.0 111.319 -174.847 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 49.5 m-85 -134.23 72.79 70.76 Favored Pre-proline 0 C--N 1.3 -1.566 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.539 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.653 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 58.7 Cg_endo -72.34 -3.05 12.64 Favored 'Trans proline' 0 C--N 1.334 -0.224 0 C-N-CA 122.775 2.317 . . . . 0.0 113.386 -174.378 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -118.83 -4.19 10.7 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 121.138 0.494 . . . . 0.0 109.799 -178.278 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.52 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -117.99 -29.1 5.72 Favored 'General case' 0 N--CA 1.418 -2.033 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.883 -174.016 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.52 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.0 mp -130.6 134.84 61.54 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.487 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.5 t -69.57 139.74 53.75 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 108.957 -0.756 . . . . 0.0 108.957 177.463 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -86.76 107.96 18.49 Favored 'General case' 0 C--N 1.285 -2.207 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -173.347 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.504 ' CD2' ' HB ' ' A' ' 134' ' ' THR . 73.1 t80 -150.16 145.35 26.24 Favored 'General case' 0 C--N 1.295 -1.794 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.427 -171.357 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.495 HG13 ' HB2' ' A' ' 131' ' ' LEU . 59.9 t -150.66 139.67 15.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 C-N-CA 124.559 1.144 . . . . 0.0 108.666 177.655 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -147.27 122.61 10.29 Favored 'General case' 0 C--O 1.21 -0.992 0 O-C-N 123.311 0.382 . . . . 0.0 110.607 174.617 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.527 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 63.5 tp -64.77 114.92 4.79 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-O 121.315 0.579 . . . . 0.0 110.004 177.195 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.472 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 4.2 tp-100 -59.12 -60.02 4.53 Favored 'General case' 0 C--N 1.315 -0.933 0 C-N-CA 126.287 1.835 . . . . 0.0 110.555 176.566 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 60' ' ' ARG . . . . . 0.454 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 4.5 ptp180 -163.06 161.91 25.56 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 115.052 -0.976 . . . . 0.0 108.424 -177.011 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.403 ' H ' HG22 ' A' ' 86' ' ' THR . . . -142.44 131.25 4.59 Favored Glycine 0 N--CA 1.401 -3.641 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 -179.384 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.412 ' HA ' ' HB3' ' A' ' 85' ' ' PRO . 49.1 m -120.07 149.52 42.05 Favored 'General case' 0 C--N 1.288 -2.089 0 C-N-CA 124.072 0.949 . . . . 0.0 110.395 -174.575 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.544 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -111.5 153.4 26.26 Favored 'General case' 0 N--CA 1.486 1.356 0 CA-C-O 117.792 -1.099 . . . . 0.0 108.398 -179.457 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.8 ' O ' HG22 ' A' ' 67' ' ' VAL . 95.2 m-85 -158.35 -179.75 8.39 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 123.646 0.779 . . . . 0.0 111.277 -176.951 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.91 -134.02 51.03 Favored Glycine 0 C--N 1.317 -0.485 0 C-N-CA 121.409 -0.424 . . . . 0.0 112.265 179.769 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.62 -10.22 83.6 Favored Glycine 0 N--CA 1.422 -2.25 0 C-N-CA 120.327 -0.939 . . . . 0.0 112.839 177.306 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.8 HG22 ' O ' ' A' ' 64' ' ' TYR . 12.5 m -73.84 -28.6 24.47 Favored 'Isoleucine or valine' 0 C--O 1.205 -1.252 0 CA-C-N 118.295 1.048 . . . . 0.0 112.262 -174.143 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.544 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -91.14 -19.94 22.54 Favored 'General case' 0 C--N 1.297 -1.675 0 C-N-CA 119.876 -0.73 . . . . 0.0 111.895 177.664 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 7.4 t -100.45 -49.35 4.26 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.481 0.658 . . . . 0.0 111.239 -173.627 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.509 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 49.6 m-20 -96.99 -17.82 19.81 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -174.332 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.566 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 87.2 m-85 -119.31 163.55 16.98 Favored 'General case' 0 C--N 1.294 -1.812 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.957 -179.329 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.2 t -173.06 132.6 0.51 Allowed 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 178.729 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.498 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -167.15 -112.5 0.26 Allowed Glycine 0 N--CA 1.406 -3.334 0 N-CA-C 110.624 -0.99 . . . . 0.0 110.624 174.178 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.411 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.2 p -154.93 -179.96 8.55 Favored 'General case' 0 C--N 1.292 -1.921 0 C-N-CA 123.628 0.771 . . . . 0.0 110.403 -172.933 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.402 ' HB ' ' CD1' ' A' ' 84' ' ' PHE . 2.5 p -134.27 145.5 32.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.319 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.731 ' HG3' ' O ' ' A' ' 80' ' ' SER . 71.0 tttt -123.22 142.99 50.34 Favored 'General case' 0 N--CA 1.416 -2.139 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.397 -179.395 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.479 ' CD1' HG22 ' A' ' 105' ' ' VAL . 71.7 t80 -143.81 112.0 6.3 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.521 -178.429 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 14.7 t 52.78 37.94 25.21 Favored 'General case' 0 CA--C 1.561 1.4 0 CA-C-O 122.025 0.917 . . . . 0.0 110.875 175.951 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.08 10.37 64.49 Favored Glycine 0 CA--C 1.528 0.903 0 CA-C-N 115.684 -0.689 . . . . 0.0 113.731 179.934 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.731 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 21.6 t -84.94 -179.72 7.13 Favored 'General case' 0 C--O 1.206 -1.211 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 177.836 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 48.5 m -159.06 108.83 1.95 Allowed 'General case' 0 C--N 1.279 -2.483 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 177.297 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.475 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 4.0 p90 -149.38 163.1 26.5 Favored Pre-proline 0 C--N 1.306 -1.308 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -174.517 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.475 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 58.6 Cg_endo -68.99 148.79 70.85 Favored 'Trans proline' 0 C--N 1.358 1.057 0 C-N-CA 122.612 2.208 . . . . 0.0 113.425 -175.862 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.509 ' CD2' HD21 ' A' ' 109' ' ' LEU . 51.6 t80 -123.72 132.76 24.3 Favored Pre-proline 0 N--CA 1.435 -1.18 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 179.383 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.47 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 66.8 Cg_endo -72.22 147.58 89.11 Favored 'Cis proline' 0 CA--C 1.542 0.914 0 C-N-CA 122.734 -1.777 . . . . 0.0 110.497 -1.369 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 86' ' ' THR . . . . . 0.403 HG22 ' H ' ' A' ' 61' ' ' GLY . 11.5 t -68.28 -175.84 0.67 Allowed 'General case' 0 CA--C 1.55 0.955 0 CA-C-O 121.229 0.537 . . . . 0.0 111.04 -176.181 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 7.9 p -130.37 -42.88 1.17 Allowed 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 116.07 -0.514 . . . . 0.0 112.289 -175.554 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.2 t -101.3 -86.63 0.4 Allowed 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.592 -175.467 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -170.19 -169.68 0.88 Allowed 'General case' 0 N--CA 1.438 -1.043 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 177.825 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.527 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 21.4 p -101.37 162.77 19.45 Favored Pre-proline 0 C--N 1.302 -1.477 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 177.325 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -63.79 159.4 41.78 Favored 'Trans proline' 0 C--N 1.358 1.059 0 C-N-CA 122.748 2.299 . . . . 0.0 111.64 174.526 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.7 tmm_? -65.35 118.29 9.14 Favored 'General case' 0 C--N 1.315 -0.918 0 C-N-CA 124.695 1.198 . . . . 0.0 109.554 -177.523 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 68.5 t -127.81 128.82 69.68 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.329 -177.07 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 74.2 t -114.29 140.73 33.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.402 179.416 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -87.36 95.65 10.07 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.24 0.543 . . . . 0.0 110.093 177.931 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 91.2 m-20 -86.97 64.57 8.55 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 121.183 0.516 . . . . 0.0 110.392 -179.046 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.5 m -155.21 -179.59 8.23 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 -179.527 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 98' ' ' ARG . . . . . 0.556 ' HA ' HD21 ' A' ' 46' ' ' ASN . 16.7 ptm180 -141.28 50.32 1.61 Allowed 'General case' 0 N--CA 1.44 -0.971 0 CA-C-O 121.899 0.857 . . . . 0.0 110.128 178.996 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 6.9 t -163.39 170.75 17.02 Favored 'General case' 0 N--CA 1.424 -1.733 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 -178.868 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -69.92 101.59 1.79 Allowed 'General case' 0 C--O 1.251 1.169 0 CA-C-O 122.581 1.182 . . . . 0.0 108.755 178.242 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.8 tptm -101.1 137.02 19.6 Favored Pre-proline 0 C--N 1.268 -2.945 0 CA-C-N 113.002 -1.908 . . . . 0.0 109.368 -175.878 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -64.74 146.09 87.81 Favored 'Trans proline' 0 C--O 1.246 0.904 0 C-N-CA 122.673 2.248 . . . . 0.0 111.892 177.073 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 103' ' ' TRP . . . . . 0.404 ' NE1' HG11 ' A' ' 56' ' ' VAL . 15.7 t90 -86.95 108.61 19.33 Favored Pre-proline 0 N--CA 1.44 -0.932 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 -178.563 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -76.63 89.01 1.32 Allowed 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 121.864 1.709 . . . . 0.0 113.154 -173.273 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.479 HG22 ' CD1' ' A' ' 77' ' ' TYR . 81.2 t -139.89 145.86 25.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.038 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 177.824 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.573 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -149.92 136.31 19.01 Favored 'General case' 0 C--N 1.287 -2.121 0 CA-C-O 120.95 0.405 . . . . 0.0 110.223 177.586 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.454 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 15.9 mt -103.69 106.08 16.49 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 178.335 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.498 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 14.6 m-85 -83.01 75.0 9.92 Favored 'General case' 0 C--N 1.284 -2.249 0 N-CA-C 110.159 -0.312 . . . . 0.0 110.159 177.849 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.654 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -95.83 124.96 40.08 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 174.776 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -128.97 146.25 59.87 Favored Pre-proline 0 N--CA 1.409 -2.492 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 -176.86 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.509 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 36.2 Cg_endo -63.78 126.01 16.56 Favored 'Trans proline' 0 N--CA 1.444 -1.424 0 C-N-CA 122.712 2.274 . . . . 0.0 113.685 -175.813 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.581 ' O ' HG22 ' A' ' 30' ' ' VAL . 13.9 m -85.62 -155.96 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.392 -3.346 0 CA-C-N 114.007 -1.451 . . . . 0.0 108.465 171.648 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 14.4 m -79.86 -33.39 40.15 Favored 'General case' 0 C--N 1.262 -3.225 0 CA-C-O 121.446 0.641 . . . . 0.0 110.12 -170.36 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.2 t -83.19 26.89 0.6 Allowed 'General case' 0 N--CA 1.425 -1.684 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.558 -178.137 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.424 ' HB2' ' O ' ' A' ' 70' ' ' ASN . . . -107.8 134.35 50.87 Favored 'General case' 0 N--CA 1.424 -1.766 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 178.478 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -176.78 129.21 1.44 Allowed Glycine 0 N--CA 1.437 -1.235 0 C-N-CA 120.571 -0.824 . . . . 0.0 111.469 178.814 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.4 -150.71 52.01 Favored Glycine 0 CA--C 1.495 -1.204 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 -176.305 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -55.9 105.99 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 CA-C-O 122.522 1.153 . . . . 0.0 111.932 -178.211 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -106.61 -28.33 10.3 Favored 'General case' 0 C--N 1.294 -1.812 0 CA-C-N 114.51 -1.223 . . . . 0.0 111.375 -177.922 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.443 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 54.8 mt -130.07 135.01 61.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.118 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.507 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.1 mmpt? -109.84 141.48 42.47 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-O 121.164 0.507 . . . . 0.0 111.123 176.767 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 122' ' ' ALA . . . . . 0.4 ' H ' ' HB3' ' A' ' 153' ' ' ASP . . . -72.09 123.28 22.52 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.429 178.965 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 97.94 -0.0 58.95 Favored Glycine 0 C--N 1.306 -1.097 0 N-CA-C 111.316 -0.714 . . . . 0.0 111.316 -176.613 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 31.0 t -97.16 145.42 26.04 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.329 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.416 HD23 ' CZ ' ' A' ' 149' ' ' TYR . 3.2 tm? -76.84 123.43 26.23 Favored 'General case' 0 N--CA 1.431 -1.38 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.82 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.556 ' HB ' HG11 ' A' ' 67' ' ' VAL . 28.4 pt -108.63 -29.75 2.53 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.745 -179.746 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 127' ' ' ALA . . . . . 0.464 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -158.88 168.5 26.64 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 119.46 -0.896 . . . . 0.0 110.639 -177.238 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.405 HG23 HD11 ' A' ' 125' ' ' LEU . 72.3 t -142.12 113.48 3.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 179.021 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.412 HD11 HD21 ' A' ' 107' ' ' LEU . 57.0 mt -117.24 151.53 36.73 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 178.533 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 130' ' ' ILE . . . . . 0.522 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.5 mp -135.71 129.69 48.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 178.027 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.495 ' HB2' HG13 ' A' ' 56' ' ' VAL . 1.2 pp -97.34 142.0 29.75 Favored 'General case' 0 CA--C 1.499 -0.991 0 C-N-CA 119.864 -0.734 . . . . 0.0 109.022 177.352 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.472 ' HG2' ' HB2' ' A' ' 59' ' ' GLN . 15.4 mmm180 -96.64 116.11 28.55 Favored 'General case' 0 C--N 1.279 -2.477 0 C-N-CA 124.264 1.026 . . . . 0.0 108.551 175.848 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 8.2 tp-100 -85.12 135.48 33.96 Favored 'General case' 0 N--CA 1.413 -2.302 0 N-CA-C 105.55 -2.019 . . . . 0.0 105.55 174.966 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.504 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 25.2 m -139.0 135.33 34.17 Favored 'General case' 0 C--N 1.262 -3.199 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 174.807 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.52 ' HB2' HG23 ' A' ' 52' ' ' ILE . 24.1 p-10 -142.85 145.91 33.62 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-O 121.695 0.759 . . . . 0.0 110.909 -176.742 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 2.3 p-10 -86.18 -31.21 21.89 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 114.512 -1.222 . . . . 0.0 112.806 -170.115 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 72.4 t80 -80.95 -65.09 1.06 Allowed 'General case' 0 C--N 1.315 -0.905 0 C-N-CA 123.314 0.646 . . . . 0.0 110.434 -174.408 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -93.92 169.35 10.35 Favored 'General case' 0 CA--C 1.479 -1.786 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 173.532 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 14.9 p -107.46 58.35 0.62 Allowed 'General case' 0 C--N 1.276 -2.611 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 175.454 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 72.0 m-20 -97.43 39.44 1.2 Allowed 'General case' 0 CA--C 1.499 -1.014 0 CA-C-N 114.038 -1.437 . . . . 0.0 108.627 179.964 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -80.77 72.73 7.75 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-O 122.639 1.209 . . . . 0.0 110.165 -179.009 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -101.01 -179.53 4.07 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 107.243 -1.392 . . . . 0.0 107.243 177.713 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -132.48 144.89 50.76 Favored 'General case' 0 C--N 1.292 -1.911 0 C-N-CA 118.937 -1.105 . . . . 0.0 111.341 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 10.2 m-30 -109.24 127.52 54.32 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -177.078 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 145' ' ' VAL . . . . . 0.415 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 48.5 t -91.17 137.04 22.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 123.538 0.524 . . . . 0.0 110.18 -178.027 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 60.6 m95 -125.35 96.56 4.87 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 -178.084 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -81.56 114.44 20.27 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 178.146 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.464 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 20.9 mm -88.0 122.85 40.12 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -176.268 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 149' ' ' TYR . . . . . 0.416 ' CZ ' HD23 ' A' ' 125' ' ' LEU . 83.4 m-85 -119.01 152.92 35.53 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.822 178.584 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.12 129.6 35.04 Favored 'General case' 0 N--CA 1.407 -2.591 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 177.211 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 10.9 t-20 -90.47 -12.89 35.98 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 122.452 1.12 . . . . 0.0 108.082 -177.088 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 5.6 t-20 -149.03 144.47 26.74 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 113.964 -1.471 . . . . 0.0 108.911 -175.133 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 153' ' ' ASP . . . . . 0.4 ' HB3' ' H ' ' A' ' 122' ' ' ALA . 17.3 p-10 -86.63 141.92 28.62 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 123.982 0.801 . . . . 0.0 111.762 -179.11 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.531 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 70.5 t -117.46 139.04 46.14 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 CA-C-N 115.228 -0.897 . . . . 0.0 111.632 -173.597 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -120.1 132.3 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 179.21 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.475 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 71.7 t -97.71 103.59 17.4 Favored Pre-proline 0 C--N 1.292 -1.904 0 C-N-CA 123.933 0.893 . . . . 0.0 109.927 179.909 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 157' ' ' PRO . . . . . 0.411 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 23.2 Cg_endo -68.15 -27.41 35.43 Favored 'Trans proline' 0 CA--C 1.509 -0.754 0 C-N-CA 121.978 1.786 . . . . 0.0 111.816 179.719 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 5.0 t . . . . . 0 CA--C 1.549 0.94 0 C-N-CA 124.706 1.202 . . . . 0.0 113.628 177.911 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 1' ' ' PHE . . . . . 0.587 ' CZ ' ' HB3' ' A' ' 44' ' ' CYS . 59.4 t80 . . . . . 0 CA--C 1.49 -1.356 0 CA-C-O 120.5 0.191 . . . . 0.0 111.001 . . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.422 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -147.88 173.67 12.61 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 172.344 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.455 ' HB2' ' CZ2' ' A' ' 146' ' ' TRP . 64.4 m -144.99 168.47 20.2 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 120.193 -0.603 . . . . 0.0 110.726 -176.616 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.455 ' HA ' ' O ' ' A' ' 9' ' ' THR . 0.3 OUTLIER -148.82 162.2 40.28 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 123.632 0.773 . . . . 0.0 109.477 178.868 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 5' ' ' THR . . . . . 0.501 HG22 HG22 ' A' ' 20' ' ' VAL . 71.9 p -100.24 175.86 5.58 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 121.394 0.616 . . . . 0.0 110.414 -179.744 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.29 -13.54 59.92 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-N 114.371 -1.286 . . . . 0.0 110.654 179.157 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -87.82 -34.31 18.3 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 118.895 -1.122 . . . . 0.0 108.63 175.265 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 134.19 7.2 2.29 Favored Glycine 0 N--CA 1.436 -1.304 0 C-N-CA 120.0 -1.095 . . . . 0.0 113.301 177.049 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.455 ' O ' ' HA ' ' A' ' 4' ' ' LYS . 5.1 m -76.55 99.28 4.91 Favored 'General case' 0 N--CA 1.442 -0.873 0 CA-C-N 117.601 0.7 . . . . 0.0 109.121 179.869 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.55 118.43 30.99 Favored 'General case' 0 C--N 1.294 -1.819 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.271 178.314 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.422 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 62.4 mt -96.53 118.79 64.98 Favored Pre-proline 0 C--N 1.302 -1.459 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 177.233 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -79.12 174.85 11.55 Favored 'Trans proline' 0 C--O 1.252 1.193 0 C-N-CA 122.637 2.224 . . . . 0.0 110.655 177.935 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 53.8 mt -71.99 119.85 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.247 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 177.217 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 151.76 -12.11 0.73 Allowed Glycine 0 C--N 1.291 -1.96 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -172.995 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 94.24 161.2 34.88 Favored Glycine 0 N--CA 1.433 -1.547 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 177.651 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 162.05 -167.92 36.9 Favored Glycine 0 CA--C 1.473 -2.564 0 C-N-CA 118.888 -1.625 . . . . 0.0 111.904 179.109 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 14.5 m -144.6 147.64 33.39 Favored 'General case' 0 C--N 1.286 -2.19 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 -179.386 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.22 156.44 48.98 Favored 'General case' 0 N--CA 1.426 -1.637 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 -179.134 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -104.78 111.02 23.6 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 179.91 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.501 HG22 HG22 ' A' ' 5' ' ' THR . 41.3 t -98.68 139.59 20.26 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.901 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.347 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -128.66 119.09 24.04 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -177.288 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 22' ' ' VAL . . . . . 0.53 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.9 p -122.74 129.75 74.96 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-O 121.884 0.85 . . . . 0.0 111.089 -175.899 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -88.73 119.17 28.97 Favored 'General case' 0 C--N 1.291 -1.974 0 CA-C-N 114.847 -1.07 . . . . 0.0 109.439 179.546 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 27.8 mt -107.06 160.79 15.29 Favored 'General case' 0 C--N 1.28 -2.453 0 CA-C-N 114.625 -1.17 . . . . 0.0 109.185 -177.58 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.5 121.56 49.22 Favored Pre-proline 0 C--O 1.206 -1.2 0 O-C-N 124.01 0.819 . . . . 0.0 108.871 177.826 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 26' ' ' PRO . . . . . 0.557 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 60.1 Cg_endo -73.99 -2.47 12.32 Favored 'Trans proline' 0 CA--C 1.53 0.282 0 C-N-CA 122.786 2.324 . . . . 0.0 113.302 -175.627 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 96.0 t -127.83 109.96 21.04 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -179.308 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.421 HG21 HD22 ' A' ' 34' ' ' LEU . 5.8 t -146.57 106.74 0.66 Allowed 'Isoleucine or valine' 0 C--O 1.189 -2.114 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -178.035 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 29' ' ' ASN . . . . . 0.568 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.7 OUTLIER -94.27 153.98 17.76 Favored 'General case' 0 C--N 1.277 -2.581 0 C-N-CA 123.246 0.618 . . . . 0.0 111.506 179.983 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.52 HG22 ' O ' ' A' ' 112' ' ' VAL . 85.5 t -50.66 118.98 0.84 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.738 0 C-N-CA 123.274 0.629 . . . . 0.0 111.051 179.405 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.37 7.88 50.92 Favored Glycine 0 C--N 1.309 -0.917 0 CA-C-N 114.98 -1.009 . . . . 0.0 112.138 -178.527 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 32' ' ' GLN . . . . . 0.568 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.8 OUTLIER -78.66 -177.24 5.28 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 123.493 0.717 . . . . 0.0 109.633 173.09 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -132.93 92.4 3.03 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 177.984 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.68 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 23.9 tp -92.67 145.51 24.37 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 119.705 -0.798 . . . . 0.0 109.247 179.407 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.9 t -136.09 121.74 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.584 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -177.536 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.622 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 62.0 t -91.74 88.62 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.406 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 175.298 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -84.2 115.53 22.48 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 120.008 -0.677 . . . . 0.0 110.641 -178.681 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.4 mt -94.7 -1.23 53.43 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.718 -179.313 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 31.6 t -75.04 2.17 11.24 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.925 0.869 . . . . 0.0 109.477 178.797 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.5 p -129.25 4.26 5.21 Favored 'General case' 0 C--N 1.288 -2.074 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.46 176.348 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.53 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 42.7 mm-40 -124.58 -20.8 5.01 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-O 121.091 0.472 . . . . 0.0 110.726 -174.651 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 26.8 mt -133.82 136.47 53.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.978 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -176.32 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.448 ' HA ' ' HA ' ' A' ' 102' ' ' PRO . 62.5 m-85 -133.49 139.75 46.84 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 -176.938 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 44' ' ' CYS . . . . . 0.587 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 60.5 m -125.03 134.22 52.65 Favored 'General case' 0 C--N 1.272 -2.784 0 CA-C-O 121.273 0.559 . . . . 0.0 111.743 -177.783 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.413 ' HB3' ' CB ' ' A' ' 100' ' ' ASP . 23.6 p-80 -119.9 129.89 54.58 Favored 'General case' 0 C--N 1.295 -1.772 0 CA-C-O 121.816 0.817 . . . . 0.0 110.775 -178.118 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 46' ' ' ASN . . . . . 0.599 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 4.8 p-10 -97.84 95.0 7.23 Favored 'General case' 0 C--N 1.275 -2.658 0 CA-C-O 123.053 1.406 . . . . 0.0 107.567 178.317 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.54 -19.93 51.8 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-N 113.64 -1.618 . . . . 0.0 113.715 -172.304 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -135.24 65.05 62.77 Favored Pre-proline 0 C--N 1.313 -0.98 0 C-N-CA 120.147 -0.621 . . . . 0.0 110.947 178.758 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 49' ' ' PRO . . . . . 0.599 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 35.7 Cg_endo -64.98 -18.48 62.3 Favored 'Trans proline' 0 C--N 1.355 0.895 0 C-N-CA 123.182 2.588 . . . . 0.0 115.302 -171.213 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -108.14 -15.98 14.37 Favored 'General case' 0 C--N 1.289 -2.045 0 C-N-CA 119.66 -0.816 . . . . 0.0 110.641 -176.249 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 51' ' ' THR . . . . . 0.575 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -101.14 -31.22 11.14 Favored 'General case' 0 N--CA 1.415 -2.211 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 -174.11 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.575 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.2 mp -126.47 141.87 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.348 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 178.969 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 7.5 t -86.78 122.13 30.23 Favored 'General case' 0 N--CA 1.405 -2.698 0 N-CA-C 103.462 -2.792 . . . . 0.0 103.462 172.205 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 54' ' ' ASP . . . . . 0.532 ' OD1' ' HB2' ' A' ' 1' ' ' PHE . 17.1 m-20 -93.39 106.02 18.03 Favored 'General case' 0 C--N 1.256 -3.484 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 -175.125 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 55' ' ' TYR . . . . . 0.552 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 10.7 t80 -123.13 133.43 54.27 Favored 'General case' 0 C--N 1.285 -2.22 0 CA-C-N 113.852 -1.522 . . . . 0.0 109.974 -172.613 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.2 t -128.46 142.99 42.42 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 115.285 -0.87 . . . . 0.0 109.27 -174.966 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.12 128.93 12.46 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 123.715 0.634 . . . . 0.0 109.332 172.619 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.525 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 34.3 tp -71.2 102.86 2.63 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 173.353 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.5 tp-100 -56.22 -56.66 18.28 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 112.9 -1.954 . . . . 0.0 110.019 -176.928 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 6.1 ptp180 -158.76 151.14 21.61 Favored 'General case' 0 N--CA 1.41 -2.47 0 CA-C-N 114.251 -1.34 . . . . 0.0 108.197 -177.956 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.79 123.99 2.26 Favored Glycine 0 N--CA 1.405 -3.412 0 N-CA-C 108.611 -1.795 . . . . 0.0 108.611 -178.656 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.421 ' HA ' ' HB3' ' A' ' 85' ' ' PRO . 66.0 m -116.47 148.18 41.0 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 124.519 1.127 . . . . 0.0 110.83 -171.529 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 63' ' ' ALA . . . . . 0.511 ' HB1' HG23 ' A' ' 67' ' ' VAL . . . -107.72 154.99 20.68 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.266 1.026 . . . . 0.0 108.62 -179.852 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 64' ' ' TYR . . . . . 0.767 ' O ' HG22 ' A' ' 67' ' ' VAL . 87.4 m-85 -156.06 -179.35 8.05 Favored 'General case' 0 N--CA 1.483 1.193 0 CA-C-N 118.351 0.523 . . . . 0.0 111.852 -176.956 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.33 -122.0 26.22 Favored Glycine 0 C--N 1.319 -0.393 0 CA-C-N 116.281 -0.418 . . . . 0.0 113.068 178.384 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -91.06 -10.38 62.64 Favored Glycine 0 N--CA 1.417 -2.57 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.843 177.076 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.767 HG22 ' O ' ' A' ' 64' ' ' TYR . 12.5 m -76.77 -25.59 15.95 Favored 'Isoleucine or valine' 0 C--O 1.206 -1.23 0 CA-C-N 118.174 0.987 . . . . 0.0 112.289 -172.1 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.505 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -90.66 -23.75 20.68 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 121.495 0.664 . . . . 0.0 111.74 177.701 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 69' ' ' SER . . . . . 0.402 ' N ' HD12 ' A' ' 68' ' ' LEU . 21.7 m -102.03 -52.91 3.05 Favored 'General case' 0 C--N 1.305 -1.366 0 N-CA-C 113.943 1.09 . . . . 0.0 113.943 -175.226 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 70' ' ' ASN . . . . . 0.496 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 53.7 m-20 -88.09 -22.63 24.03 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 -177.41 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 71' ' ' PHE . . . . . 0.556 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 87.6 m-85 -115.48 164.12 14.75 Favored 'General case' 0 C--N 1.294 -1.842 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.944 179.832 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.3 t -172.63 134.22 0.63 Allowed 'General case' 0 N--CA 1.416 -2.13 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 177.266 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.613 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -165.58 -114.75 0.3 Allowed Glycine 0 N--CA 1.398 -3.847 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 173.401 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.411 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.0 OUTLIER -153.52 -179.85 8.15 Favored 'General case' 0 C--N 1.273 -2.728 0 C-N-CA 124.176 0.991 . . . . 0.0 110.113 -173.917 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -132.7 152.04 35.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 C-N-CA 122.714 0.406 . . . . 0.0 109.958 178.586 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 76' ' ' LYS . . . . . 0.636 ' HG3' ' O ' ' A' ' 80' ' ' SER . 81.4 tttt -129.04 145.67 51.2 Favored 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 123.79 0.836 . . . . 0.0 110.128 -179.475 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 77' ' ' TYR . . . . . 0.424 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 58.1 t80 -147.28 112.49 5.52 Favored 'General case' 0 C--N 1.314 -0.96 0 O-C-N 123.777 0.673 . . . . 0.0 109.301 -178.655 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 23.0 t 54.97 36.28 26.48 Favored 'General case' 0 CA--C 1.551 1.003 0 C-N-CA 123.627 0.771 . . . . 0.0 110.448 177.188 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.58 8.18 66.05 Favored Glycine 0 CA--C 1.529 0.941 0 CA-C-N 115.459 -0.791 . . . . 0.0 114.095 -179.421 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 80' ' ' SER . . . . . 0.636 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 17.3 t -79.68 -179.52 6.94 Favored 'General case' 0 CA--C 1.543 0.682 0 CA-C-N 117.275 0.537 . . . . 0.0 109.994 -179.678 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 22.6 t -157.08 111.88 2.76 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 178.713 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 82' ' ' TYR . . . . . 0.433 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 2.6 p90 -154.6 161.42 29.4 Favored Pre-proline 0 CA--C 1.552 1.056 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -175.5 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.433 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 54.0 Cg_endo -67.97 150.53 78.01 Favored 'Trans proline' 0 C--N 1.361 1.218 0 C-N-CA 122.884 2.389 . . . . 0.0 113.503 -176.761 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.474 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 57.8 t80 -126.39 132.65 24.4 Favored Pre-proline 0 N--CA 1.44 -0.967 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.067 179.785 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 85' ' ' PRO . . . . . 0.474 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 62.4 Cg_endo -69.95 147.07 84.29 Favored 'Cis proline' 0 CA--C 1.549 1.254 0 C-N-CA 123.125 -1.615 . . . . 0.0 111.16 -1.21 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.1 t -69.35 -176.98 1.04 Allowed 'General case' 0 CA--C 1.549 0.941 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.014 -175.294 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 14.1 p -127.41 -42.6 1.65 Allowed 'General case' 0 N--CA 1.432 -1.346 0 N-CA-C 112.799 0.666 . . . . 0.0 112.799 -172.418 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.6 t -108.12 -72.17 0.73 Allowed 'General case' 0 N--CA 1.432 -1.334 0 C-N-CA 119.74 -0.784 . . . . 0.0 111.527 -175.533 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 176.6 -177.42 0.14 Allowed 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 -174.991 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.525 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 43.5 p -101.32 168.44 9.15 Favored Pre-proline 0 C--N 1.295 -1.781 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 178.555 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 91' ' ' PRO . . . . . 0.443 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 12.1 Cg_endo -54.43 164.73 2.72 Favored 'Trans proline' 0 C--O 1.252 1.175 0 C-N-CA 123.162 2.574 . . . . 0.0 112.188 171.305 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.552 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 1.7 tmm_? -84.82 101.44 12.27 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.131 -172.625 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 87.6 t -114.14 121.22 65.84 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 CA-C-N 114.893 -1.049 . . . . 0.0 111.402 -176.995 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 93.5 t -108.28 142.29 21.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 CA-C-N 115.106 -0.952 . . . . 0.0 108.739 177.72 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -98.52 110.6 23.17 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 176.085 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 46.2 m-80 -108.46 32.16 5.05 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-O 121.708 0.766 . . . . 0.0 110.075 178.891 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.3 m -85.16 -172.53 4.22 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.375 -177.674 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 16.4 ptp180 -145.99 36.46 1.03 Allowed 'General case' 0 C--N 1.307 -1.242 0 CA-C-O 121.85 0.833 . . . . 0.0 109.688 178.079 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 12.4 t -168.89 177.69 4.88 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 105.435 -2.061 . . . . 0.0 105.435 -178.995 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 100' ' ' ASP . . . . . 0.413 ' CB ' ' HB3' ' A' ' 45' ' ' HIS . 1.5 p-10 -84.75 127.71 34.25 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 178.509 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 101' ' ' LYS . . . . . 0.549 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 6.5 mmpt? -117.66 147.34 40.72 Favored Pre-proline 0 C--N 1.28 -2.447 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.666 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 102' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 43' ' ' PHE . 31.0 Cg_endo -67.62 143.5 62.61 Favored 'Trans proline' 0 N--CA 1.44 -1.626 0 C-N-CA 122.375 2.05 . . . . 0.0 111.013 -178.718 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 14.7 t90 -80.81 107.95 8.76 Favored Pre-proline 0 C--N 1.305 -1.361 0 N-CA-C 106.595 -1.632 . . . . 0.0 106.595 -176.742 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -77.25 88.98 1.36 Allowed 'Trans proline' 0 N--CA 1.443 -1.459 0 C-N-CA 121.276 1.317 . . . . 0.0 112.683 -172.273 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 96.3 t -139.9 144.34 28.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 177.291 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 106' ' ' ALA . . . . . 0.622 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -147.84 134.47 19.87 Favored 'General case' 0 N--CA 1.419 -1.98 0 CA-C-O 120.785 0.326 . . . . 0.0 110.155 178.096 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 107' ' ' LEU . . . . . 0.469 HD21 HD11 ' A' ' 129' ' ' LEU . 17.7 mt -101.73 104.3 15.1 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.242 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 108' ' ' TYR . . . . . 0.613 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 16.5 m-85 -79.56 68.42 5.6 Favored 'General case' 0 C--N 1.287 -2.123 0 CA-C-O 120.514 0.197 . . . . 0.0 111.167 177.814 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.68 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -90.59 128.53 36.62 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 175.358 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.15 145.29 56.73 Favored Pre-proline 0 N--CA 1.416 -2.154 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.182 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 111' ' ' PRO . . . . . 0.496 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 30.7 Cg_endo -63.17 124.5 14.01 Favored 'Trans proline' 0 CA--C 1.498 -1.3 0 C-N-CA 122.927 2.418 . . . . 0.0 113.936 -176.24 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 112' ' ' VAL . . . . . 0.52 ' O ' HG22 ' A' ' 30' ' ' VAL . 19.5 m -86.36 -158.67 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.391 -3.419 0 CA-C-N 114.242 -1.345 . . . . 0.0 108.19 171.187 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 44.9 m -81.2 -22.35 38.91 Favored 'General case' 0 C--N 1.254 -3.575 0 O-C-N 121.636 -0.665 . . . . 0.0 111.069 -171.792 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.3 t -81.8 12.19 4.21 Favored 'General case' 0 CA--C 1.549 0.931 0 CA-C-O 121.771 0.796 . . . . 0.0 109.977 179.491 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.477 ' HB2' ' O ' ' A' ' 70' ' ' ASN . . . -98.98 135.42 40.41 Favored 'General case' 0 N--CA 1.419 -2.017 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.455 -179.708 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -179.82 122.96 0.81 Allowed Glycine 0 C--O 1.245 0.842 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 179.266 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 70.0 -155.01 53.09 Favored Glycine 0 C--N 1.307 -1.075 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 -174.922 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.1 p -53.88 106.86 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 122.541 1.162 . . . . 0.0 112.123 -178.174 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -108.56 -22.04 12.45 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 114.302 -1.317 . . . . 0.0 111.159 -176.848 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 120' ' ' ILE . . . . . 0.549 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.2 mt -136.34 133.47 49.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.053 0 N-CA-C 107.516 -1.291 . . . . 0.0 107.516 178.341 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.435 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.0 mmpt? -111.53 139.09 47.25 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 177.384 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.32 125.96 27.75 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 177.922 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 101.36 -10.77 58.14 Favored Glycine 0 N--CA 1.428 -1.885 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.298 -178.089 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 97.8 p -94.05 148.64 21.97 Favored 'General case' 0 C--O 1.252 1.22 0 C-N-CA 119.861 -0.736 . . . . 0.0 110.241 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 125' ' ' LEU . . . . . 0.445 HD11 HG23 ' A' ' 128' ' ' VAL . 3.0 tm? -76.35 124.15 27.06 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-N 115.011 -0.995 . . . . 0.0 108.878 -179.202 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 126' ' ' ILE . . . . . 0.582 ' HB ' HG11 ' A' ' 67' ' ' VAL . 27.6 pt -108.38 -29.92 2.53 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.389 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.878 179.901 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 127' ' ' ALA . . . . . 0.446 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -157.97 165.5 34.99 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.605 -0.838 . . . . 0.0 110.376 -176.595 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.445 HG23 HD11 ' A' ' 125' ' ' LEU . 64.4 t -139.6 114.18 7.37 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.796 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 177.929 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 129' ' ' LEU . . . . . 0.469 HD11 HD21 ' A' ' 107' ' ' LEU . 40.0 mt -119.58 145.49 46.35 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 5.4 mp -129.64 128.85 66.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 C-N-CA 120.324 -0.551 . . . . 0.0 110.078 177.155 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 131' ' ' LEU . . . . . 0.432 ' C ' HD12 ' A' ' 131' ' ' LEU . 1.5 pp -92.62 138.31 31.61 Favored 'General case' 0 N--CA 1.424 -1.733 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 172.856 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 132' ' ' ARG . . . . . 0.449 ' HE ' ' HB3' ' A' ' 143' ' ' GLN . 3.9 tpm_? -97.24 112.95 24.52 Favored 'General case' 0 C--N 1.249 -3.803 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 176.256 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.1 130.46 40.26 Favored 'General case' 0 N--CA 1.422 -1.849 0 N-CA-C 104.991 -2.226 . . . . 0.0 104.991 177.686 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.511 ' HA ' ' HB2' ' A' ' 141' ' ' ASP . 63.6 m -137.92 138.65 39.22 Favored 'General case' 0 C--N 1.273 -2.731 0 C-N-CA 120.396 -0.522 . . . . 0.0 110.179 174.277 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.489 ' CB ' HG23 ' A' ' 52' ' ' ILE . 20.0 p30 -126.93 170.38 12.32 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 121.524 0.678 . . . . 0.0 112.051 -175.717 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -106.67 -20.83 13.23 Favored 'General case' 0 N--CA 1.473 0.7 0 CA-C-N 114.825 -1.08 . . . . 0.0 110.903 -174.782 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 73.8 t80 -89.2 -72.91 0.53 Allowed 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 115.395 -0.821 . . . . 0.0 110.078 -170.813 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -86.29 -178.56 6.5 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 175.507 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 69.9 m -117.96 27.0 9.27 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-O 121.799 0.809 . . . . 0.0 108.974 176.683 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 7.1 p30 -91.93 48.89 1.48 Allowed 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 122.192 0.996 . . . . 0.0 110.619 179.203 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 141' ' ' ASP . . . . . 0.511 ' HB2' ' HA ' ' A' ' 134' ' ' THR . 7.8 p-10 -84.52 86.25 7.31 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-O 122.867 1.318 . . . . 0.0 110.066 179.15 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -99.16 175.51 5.87 Favored 'General case' 0 C--N 1.289 -2.029 0 CA-C-N 114.594 -1.185 . . . . 0.0 109.42 179.451 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 143' ' ' GLN . . . . . 0.449 ' HB3' ' HE ' ' A' ' 132' ' ' ARG . 13.7 pt20 -130.22 141.32 50.65 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.647 179.884 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 7.0 m-30 -104.6 127.99 52.48 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 -175.575 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 57.6 t -93.24 136.24 25.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -178.923 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 146' ' ' TRP . . . . . 0.455 ' CZ2' ' HB2' ' A' ' 3' ' ' CYS . 66.9 m95 -123.87 95.79 4.7 Favored 'General case' 0 C--N 1.281 -2.381 0 N-CA-C 108.272 -1.011 . . . . 0.0 108.272 -177.19 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -80.94 114.17 19.64 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 177.961 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 148' ' ' ILE . . . . . 0.449 HG22 HD11 ' A' ' 126' ' ' ILE . 22.6 mm -89.92 122.03 40.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 -175.785 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -118.14 157.99 25.89 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 178.241 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.6 131.89 35.29 Favored 'General case' 0 N--CA 1.407 -2.599 0 CA-C-N 115.002 -0.999 . . . . 0.0 108.523 176.216 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 34.2 t-20 -95.52 -8.96 33.76 Favored 'General case' 0 C--N 1.29 -2.007 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 -178.401 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -153.79 145.43 23.31 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 113.869 -1.514 . . . . 0.0 108.713 -175.959 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -84.8 140.41 31.23 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 124.138 0.899 . . . . 0.0 111.198 -178.539 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.557 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 70.3 t -118.17 134.66 61.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.015 -176.653 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.1 t -119.24 133.08 67.21 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.545 0 N-CA-C 107.178 -1.415 . . . . 0.0 107.178 -179.966 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 156' ' ' VAL . . . . . 0.453 HG12 ' HB ' ' A' ' 158' ' ' THR . 75.2 t -97.65 102.64 13.66 Favored Pre-proline 0 C--N 1.289 -2.033 0 C-N-CA 123.375 0.67 . . . . 0.0 109.962 179.389 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -70.58 -24.55 25.8 Favored 'Trans proline' 0 CA--C 1.516 -0.403 0 C-N-CA 121.87 1.714 . . . . 0.0 111.584 -179.261 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 158' ' ' THR . . . . . 0.453 ' HB ' HG12 ' A' ' 156' ' ' VAL . 7.3 t . . . . . 0 CA--C 1.545 0.779 0 C-N-CA 125.303 1.441 . . . . 0.0 112.723 176.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.62 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.43 -1.472 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 15.7 t -152.15 158.31 42.75 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 -176.747 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.612 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -143.38 161.54 38.11 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 121.178 0.513 . . . . 0.0 111.208 -174.271 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.9 p -100.38 175.98 5.52 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.383 0.611 . . . . 0.0 110.653 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -76.41 -19.52 58.02 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.776 178.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 6.2 p30 -83.52 -34.0 25.38 Favored 'General case' 0 CA--C 1.514 -0.433 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.732 -179.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 130.32 27.31 0.76 Allowed Glycine 0 N--CA 1.441 -1.022 0 C-N-CA 119.907 -1.139 . . . . 0.0 112.348 177.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.403 ' O ' ' HA ' ' A' ' 4' ' ' LYS . 9.2 m -99.82 99.37 10.16 Favored 'General case' 0 N--CA 1.423 -1.816 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 177.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.5 122.57 35.06 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 176.109 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.62 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 65.3 mt -97.63 117.59 65.14 Favored Pre-proline 0 C--N 1.294 -1.817 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 178.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -75.33 171.36 18.41 Favored 'Trans proline' 0 C--O 1.245 0.845 0 C-N-CA 122.62 2.213 . . . . 0.0 111.673 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 69.6 mt -67.17 127.57 28.95 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.568 179.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 138.37 0.66 2.35 Favored Glycine 0 C--N 1.303 -1.3 0 C-N-CA 120.852 -0.69 . . . . 0.0 111.957 -177.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.49 168.87 43.72 Favored Glycine 0 N--CA 1.427 -1.921 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -178.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 155.49 -165.3 32.4 Favored Glycine 0 C--N 1.288 -2.135 0 C-N-CA 120.06 -1.067 . . . . 0.0 110.879 178.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.475 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 58.1 p -150.28 147.06 27.19 Favored 'General case' 0 N--CA 1.422 -1.868 0 CA-C-N 116.844 0.322 . . . . 0.0 110.373 -177.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -132.43 163.52 28.58 Favored 'General case' 0 N--CA 1.428 -1.556 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 178.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -116.71 107.52 14.78 Favored 'General case' 0 C--N 1.292 -1.929 0 N-CA-C 106.997 -1.482 . . . . 0.0 106.997 178.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.427 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.4 m -91.44 150.07 3.89 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.35 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -179.403 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 62.5 m-85 -131.92 112.16 12.18 Favored 'General case' 0 CA--C 1.485 -1.537 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -177.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.541 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 4.5 p -117.1 132.4 66.97 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.293 0 CA-C-O 121.815 0.817 . . . . 0.0 111.535 -173.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.456 ' HB3' ' HB3' ' A' ' 151' ' ' ASN . 2.1 p30 -98.12 123.57 42.23 Favored 'General case' 0 C--N 1.286 -2.176 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.171 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.403 HD11 ' HA ' ' A' ' 36' ' ' VAL . 2.5 mm? -106.83 160.55 15.42 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 114.408 -1.269 . . . . 0.0 108.051 -178.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -54.92 121.46 35.31 Favored Pre-proline 0 C--N 1.308 -1.233 0 O-C-N 124.381 1.051 . . . . 0.0 109.284 175.501 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 63.8 Cg_endo -74.79 1.47 7.57 Favored 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 122.926 2.417 . . . . 0.0 113.035 -177.274 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.464 HG13 ' HG3' ' A' ' 157' ' ' PRO . 86.0 t -128.82 110.11 20.33 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 178.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.511 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 4.5 t -145.96 111.65 1.06 Allowed 'Isoleucine or valine' 0 C--O 1.185 -2.293 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 -179.352 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.59 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -100.57 152.52 20.32 Favored 'General case' 0 C--N 1.267 -2.998 0 C-N-CA 122.707 0.403 . . . . 0.0 111.381 -178.236 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.403 HG13 ' O ' ' A' ' 112' ' ' VAL . 38.9 t -46.37 113.85 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.612 0 C-N-CA 123.314 0.646 . . . . 0.0 111.596 176.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 105.29 3.73 41.19 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 114.929 -1.032 . . . . 0.0 112.855 -179.375 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.59 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -76.29 -177.35 4.01 Favored 'General case' 0 C--N 1.311 -1.069 0 C-N-CA 123.911 0.884 . . . . 0.0 110.067 175.641 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -133.54 91.59 2.87 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 177.11 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.673 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 28.4 tp -91.58 144.41 25.57 Favored 'General case' 0 C--N 1.292 -1.934 0 C-N-CA 119.964 -0.694 . . . . 0.0 109.781 -179.035 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 60.0 t -136.16 125.0 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -177.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.572 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 60.8 t -91.19 88.82 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.523 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 175.246 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -77.84 114.62 16.87 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -178.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 75.6 mt -98.0 -1.4 42.73 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-O 121.577 0.703 . . . . 0.0 110.983 -178.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.566 ' OG ' ' HA ' ' A' ' 104' ' ' PRO . 22.6 m -80.61 0.66 33.12 Favored 'General case' 0 C--N 1.29 -1.982 0 CA-C-O 122.321 1.058 . . . . 0.0 110.166 -178.322 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.2 p -121.59 4.07 10.13 Favored 'General case' 0 N--CA 1.417 -2.123 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.646 176.074 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.541 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 44.4 mm-40 -125.32 -21.87 4.48 Favored 'General case' 0 C--O 1.239 0.528 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.128 -174.317 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 30.8 mt -135.24 138.22 48.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -175.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.612 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 38.9 m-85 -143.43 130.38 20.55 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -176.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 73.3 m -109.48 151.11 27.15 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 120.976 0.417 . . . . 0.0 110.263 -178.572 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 7.6 p80 -138.06 129.98 28.49 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.72 0.771 . . . . 0.0 112.034 -175.141 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 46.7 t30 -99.43 99.85 10.81 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.195 -1.002 . . . . 0.0 109.98 176.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -72.37 -12.3 61.06 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 113.771 -1.559 . . . . 0.0 111.231 -176.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -127.6 71.17 77.39 Favored Pre-proline 0 C--N 1.32 -0.689 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -70.27 -13.14 33.06 Favored 'Trans proline' 0 C--N 1.332 -0.302 0 C-N-CA 122.491 2.127 . . . . 0.0 113.836 -172.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -110.77 -16.89 13.48 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.354 0.597 . . . . 0.0 110.167 -177.471 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.562 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.6 OUTLIER -102.4 -30.94 10.73 Favored 'General case' 0 N--CA 1.404 -2.747 0 CA-C-O 121.648 0.737 . . . . 0.0 109.194 -171.476 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.694 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.5 mp -127.93 135.76 62.08 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 CA-C-N 114.97 -1.014 . . . . 0.0 109.071 -176.401 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.9 t -77.73 142.14 38.89 Favored 'General case' 0 C--O 1.248 1.014 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 175.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -82.44 107.29 14.98 Favored 'General case' 0 C--N 1.286 -2.187 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 -175.349 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 31.8 t80 -144.88 137.04 26.0 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-O 120.761 0.315 . . . . 0.0 110.476 -176.027 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.408 HG23 ' HG ' ' A' ' 131' ' ' LEU . 11.9 p -150.02 150.56 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-N 116.308 -0.406 . . . . 0.0 109.951 179.642 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.29 136.21 18.48 Favored 'General case' 0 C--N 1.311 -1.073 0 C-N-CA 123.298 0.639 . . . . 0.0 109.401 176.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.533 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 43.5 tp -73.85 115.5 13.36 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 171.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.604 ' NE2' ' HD3' ' A' ' 132' ' ' ARG . 3.4 tp-100 -59.56 -51.32 70.33 Favored 'General case' 0 C--N 1.312 -1.064 0 C-N-CA 124.764 1.226 . . . . 0.0 111.588 178.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 9.4 ptp180 -171.51 160.42 5.92 Favored 'General case' 0 CA--C 1.5 -0.969 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 -174.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -139.27 146.78 18.54 Favored Glycine 0 N--CA 1.404 -3.454 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 64.4 m -131.48 150.66 52.07 Favored 'General case' 0 C--N 1.285 -2.231 0 C-N-CA 123.455 0.702 . . . . 0.0 109.568 -177.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.549 ' HB2' ' CE2' ' A' ' 84' ' ' PHE . . . -117.3 154.51 31.11 Favored 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -178.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.452 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . 90.9 m-85 -154.4 -179.5 8.0 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 123.71 0.804 . . . . 0.0 109.487 -178.33 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 63.84 -130.97 39.9 Favored Glycine 0 CA--C 1.507 -0.421 0 CA-C-N 116.305 -0.407 . . . . 0.0 113.287 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -90.07 -6.28 69.46 Favored Glycine 0 C--O 1.199 -2.065 0 C-N-CA 120.523 -0.846 . . . . 0.0 111.187 176.14 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.757 HG21 ' HB ' ' A' ' 126' ' ' ILE . 76.5 t -70.81 -41.63 77.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 122.867 0.467 . . . . 0.0 111.309 -176.442 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.521 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -82.13 -24.67 34.95 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 121.452 0.644 . . . . 0.0 112.367 -179.999 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 28.5 m -101.29 -50.82 3.66 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 114.269 1.211 . . . . 0.0 114.269 -173.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.459 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 67.4 m-20 -89.87 -23.76 21.56 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 -176.141 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.674 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 86.1 m-85 -112.35 162.17 15.85 Favored 'General case' 0 N--CA 1.427 -1.601 0 CA-C-O 121.75 0.786 . . . . 0.0 111.42 179.686 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.502 ' HB2' HG13 ' A' ' 112' ' ' VAL . 5.5 m -165.94 140.24 4.52 Favored 'General case' 0 N--CA 1.4 -2.969 0 C-N-CA 125.906 1.683 . . . . 0.0 109.177 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.441 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -172.73 -100.35 0.13 Allowed Glycine 0 C--N 1.279 -2.629 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 174.14 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.427 HG23 ' O ' ' A' ' 73' ' ' GLY . 1.1 p -169.94 179.41 3.62 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 125.655 1.582 . . . . 0.0 109.365 -179.468 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.403 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.5 p -127.96 144.93 36.11 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.788 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 177.475 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.615 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.9 tttt -124.91 143.9 50.62 Favored 'General case' 0 N--CA 1.416 -2.13 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.456 -176.013 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.446 ' CD2' HG22 ' A' ' 105' ' ' VAL . 51.8 t80 -146.69 110.23 4.86 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 114.94 -1.027 . . . . 0.0 108.453 -178.467 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 32.7 t 54.76 39.47 31.39 Favored 'General case' 0 CA--C 1.556 1.202 0 CA-C-O 122.341 1.067 . . . . 0.0 110.86 177.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.5 16.93 69.79 Favored Glycine 0 N--CA 1.438 -1.196 0 CA-C-N 115.416 -0.811 . . . . 0.0 113.191 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.615 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 10.8 t -84.99 -179.74 7.12 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.118 -1.068 . . . . 0.0 108.118 175.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.0 t -160.25 97.57 1.25 Allowed 'General case' 0 C--N 1.29 -2.008 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 -178.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.429 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 3.2 p90 -138.75 159.17 68.38 Favored Pre-proline 0 C--N 1.296 -1.732 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 -174.116 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.406 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 55.4 Cg_endo -68.47 147.27 70.65 Favored 'Trans proline' 0 C--N 1.352 0.729 0 C-N-CA 122.406 2.07 . . . . 0.0 112.799 -174.252 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.618 ' CD2' HD21 ' A' ' 109' ' ' LEU . 63.0 t80 -121.63 130.93 24.56 Favored Pre-proline 0 C--N 1.305 -1.339 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.17 -179.793 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.466 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 73.4 Cg_endo -73.79 147.63 90.04 Favored 'Cis proline' 0 C--O 1.25 1.087 0 C-N-CA 123.117 -1.618 . . . . 0.0 110.093 -2.331 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.6 t -68.16 -177.06 0.8 Allowed 'General case' 0 CA--C 1.548 0.877 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.259 -174.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 18.9 p -123.42 -12.44 7.76 Favored 'General case' 0 N--CA 1.435 -1.185 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.279 -173.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.8 t -152.05 -124.33 0.04 OUTLIER 'General case' 0 N--CA 1.393 -3.282 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -126.9 -169.15 1.98 Allowed 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 112.249 0.463 . . . . 0.0 112.249 -173.041 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 45.3 p -100.42 170.67 6.36 Favored Pre-proline 0 C--N 1.313 -0.983 0 C-N-CA 123.302 0.641 . . . . 0.0 112.685 179.058 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . 0.447 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 19.6 Cg_endo -59.53 166.09 8.47 Favored 'Trans proline' 0 C--O 1.246 0.904 0 C-N-CA 122.976 2.451 . . . . 0.0 111.779 170.46 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.1 tmm_? -80.58 117.99 21.77 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 -178.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 69.2 t -127.58 128.51 69.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 CA-C-O 121.353 0.597 . . . . 0.0 111.41 -175.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 81.4 t -106.18 138.31 32.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.554 179.536 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.433 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 3.1 m-85 -87.59 116.66 25.86 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 175.054 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -97.72 45.25 1.03 Allowed 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 57.7 m -151.77 125.29 8.9 Favored 'General case' 0 N--CA 1.433 -1.298 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.733 -176.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 10.6 ptp180 -102.22 64.02 0.91 Allowed 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 122.044 0.926 . . . . 0.0 111.159 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.8 t -171.22 172.87 5.14 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 -178.438 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -65.12 100.78 0.46 Allowed 'General case' 0 C--N 1.324 -0.508 0 O-C-N 123.71 0.631 . . . . 0.0 110.049 -179.485 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -111.76 138.54 21.61 Favored Pre-proline 0 C--N 1.293 -1.863 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 178.151 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -56.08 148.39 59.17 Favored 'Trans proline' 0 C--O 1.246 0.897 0 C-N-CA 123.27 2.647 . . . . 0.0 112.633 179.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . 0.433 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.4 t90 -88.9 112.34 50.12 Favored Pre-proline 0 C--N 1.293 -1.849 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 -179.357 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . 0.566 ' HA ' ' OG ' ' A' ' 39' ' ' SER . 68.0 Cg_endo -75.58 87.57 1.36 Allowed 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 121.816 1.677 . . . . 0.0 112.426 -173.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.446 HG22 ' CD2' ' A' ' 77' ' ' TYR . 67.0 t -144.61 143.48 22.88 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.435 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 -179.396 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.572 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.14 135.72 17.09 Favored 'General case' 0 N--CA 1.415 -2.214 0 O-C-N 123.705 0.628 . . . . 0.0 110.285 177.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.492 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 15.4 mt -100.83 104.71 15.95 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 178.066 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.441 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 12.4 m-85 -81.03 91.92 6.15 Favored 'General case' 0 C--N 1.285 -2.231 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 177.203 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.674 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 2.9 mm? -118.87 120.51 37.53 Favored 'General case' 0 C--N 1.292 -1.932 0 CA-C-O 120.742 0.306 . . . . 0.0 110.179 178.128 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.35 145.78 47.59 Favored Pre-proline 0 N--CA 1.413 -2.306 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.997 -175.085 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.459 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 25.7 Cg_endo -61.7 119.57 6.77 Favored 'Trans proline' 0 C--O 1.247 0.972 0 C-N-CA 123.202 2.601 . . . . 0.0 112.21 -177.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.502 HG13 ' HB2' ' A' ' 72' ' ' SER . 3.6 m -67.74 -117.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.188 -2.173 0 CA-C-N 114.09 -1.414 . . . . 0.0 113.081 175.57 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 41.3 t -112.67 -39.54 4.29 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 178.164 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 66.6 m -78.73 30.35 0.2 Allowed 'General case' 0 N--CA 1.392 -3.356 0 CA-C-N 113.596 -1.638 . . . . 0.0 112.952 -177.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -111.06 140.09 45.89 Favored 'General case' 0 N--CA 1.411 -2.399 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 177.29 128.27 1.13 Allowed Glycine 0 N--CA 1.438 -1.173 0 N-CA-C 111.385 -0.686 . . . . 0.0 111.385 -178.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 65.83 -149.13 51.46 Favored Glycine 0 N--CA 1.443 -0.874 0 CA-C-O 119.02 -0.878 . . . . 0.0 111.408 -176.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -54.51 105.8 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 CA-C-O 122.645 1.212 . . . . 0.0 112.741 -177.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.55 -31.44 9.44 Favored 'General case' 0 C--N 1.295 -1.789 0 CA-C-N 114.735 -1.12 . . . . 0.0 110.936 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.439 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 54.9 mt -128.18 140.07 50.18 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -179.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.461 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.7 mmpt? -115.12 133.9 55.63 Favored 'General case' 0 C--N 1.313 -1.009 0 C-N-CA 122.959 0.504 . . . . 0.0 111.584 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.18 133.34 48.71 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.651 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 86.06 0.35 87.21 Favored Glycine 0 C--O 1.242 0.624 0 C-N-CA 121.282 -0.485 . . . . 0.0 112.203 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 19.9 t -101.93 151.06 22.56 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 -178.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -77.92 123.69 27.09 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 -178.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.757 ' HB ' HG21 ' A' ' 67' ' ' VAL . 35.1 pt -110.08 -25.83 3.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 N-CA-C 112.578 0.585 . . . . 0.0 112.578 -178.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . 0.428 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -162.02 168.97 21.87 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -178.236 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 70.3 t -143.5 115.82 2.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.485 HD11 HD21 ' A' ' 107' ' ' LEU . 68.7 mt -117.79 146.9 43.49 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 178.141 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.531 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.6 mp -125.28 128.35 72.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 C-N-CA 119.727 -0.789 . . . . 0.0 110.42 177.475 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.537 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.0 OUTLIER -102.28 136.42 42.14 Favored 'General case' 0 C--N 1.29 -2.0 0 C-N-CA 123.664 0.786 . . . . 0.0 111.998 -177.352 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . 0.604 ' HD3' ' NE2' ' A' ' 59' ' ' GLN . 30.2 mmm180 -95.93 119.36 34.28 Favored 'General case' 0 C--N 1.294 -1.838 0 C-N-CA 124.365 1.066 . . . . 0.0 110.643 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.487 ' HG2' HD21 ' A' ' 131' ' ' LEU . 15.7 mm-40 -102.63 113.87 27.61 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 172.455 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 33.2 m -140.17 144.32 36.57 Favored 'General case' 0 C--N 1.289 -2.057 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -177.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.694 ' CB ' HG23 ' A' ' 52' ' ' ILE . 11.6 p30 . . . . . 0 N--CA 1.435 -1.18 0 C-N-CA 120.059 -0.656 . . . . 0.0 111.161 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 . . . . . 0 N--CA 1.423 -1.784 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 12.9 pt20 -125.71 146.78 49.6 Favored 'General case' 0 N--CA 1.418 -2.065 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.487 -179.721 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.415 ' HB2' HD22 ' A' ' 131' ' ' LEU . 12.3 m-30 -112.51 133.01 54.8 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 108.577 -0.898 . . . . 0.0 108.577 -176.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.475 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 59.5 t -89.87 133.74 30.98 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 178.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . 0.537 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 70.3 m95 -121.84 97.04 5.31 Favored 'General case' 0 C--N 1.284 -2.281 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 -179.112 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 45.0 m-80 -79.17 114.99 18.55 Favored 'General case' 0 C--N 1.288 -2.08 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.428 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 24.7 mm -88.36 120.62 37.55 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 -177.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -116.77 154.54 30.48 Favored 'General case' 0 CA--C 1.49 -1.328 0 C-N-CA 123.278 0.631 . . . . 0.0 110.012 178.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.44 129.38 34.62 Favored 'General case' 0 N--CA 1.417 -2.123 0 CA-C-N 115.221 -0.899 . . . . 0.0 109.075 176.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . 0.456 ' HB3' ' HB3' ' A' ' 23' ' ' ASN . 13.3 t-20 -87.75 -17.19 32.21 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 -178.282 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -153.47 144.04 22.54 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 113.708 -1.587 . . . . 0.0 109.507 -173.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -80.87 144.97 31.59 Favored 'General case' 0 C--N 1.317 -0.836 0 O-C-N 124.059 0.85 . . . . 0.0 109.838 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.453 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 74.4 t -121.92 139.26 49.51 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 C-N-CA 122.741 0.416 . . . . 0.0 111.391 -176.156 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.9 t -118.66 141.04 40.17 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 73.2 t -104.05 100.97 23.07 Favored Pre-proline 0 C--N 1.296 -1.719 0 C-N-CA 123.51 0.724 . . . . 0.0 110.116 178.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.464 ' HG3' HG13 ' A' ' 27' ' ' VAL . 33.3 Cg_endo -69.23 -23.99 32.62 Favored 'Trans proline' 0 C--O 1.236 0.402 0 C-N-CA 122.35 2.033 . . . . 0.0 111.84 178.68 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.4 t . . . . . 0 C--O 1.239 0.536 0 C-N-CA 125.077 1.351 . . . . 0.0 113.772 177.502 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.512 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.433 -1.299 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 13.7 t -152.06 159.06 43.78 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.391 -0.924 . . . . 0.0 109.848 -176.156 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.513 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -147.0 155.48 42.28 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 121.29 0.567 . . . . 0.0 110.549 -176.352 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 41.2 p -92.43 174.51 7.25 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.222 178.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.99 -19.53 47.61 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.053 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -85.08 -33.81 22.36 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 114.784 -1.098 . . . . 0.0 111.856 -176.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 136.36 5.71 2.0 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 119.649 -1.262 . . . . 0.0 113.733 173.259 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.9 m -89.33 105.5 17.84 Favored 'General case' 0 N--CA 1.423 -1.782 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -103.47 115.71 31.05 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.026 179.635 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.512 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 55.6 mt -90.69 127.83 50.82 Favored Pre-proline 0 C--N 1.295 -1.763 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -86.01 179.62 3.64 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 122.83 2.353 . . . . 0.0 111.546 177.054 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 58.6 mt -69.42 133.79 31.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 177.071 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 127.6 9.24 4.05 Favored Glycine 0 C--N 1.306 -1.13 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.873 -179.099 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.22 170.19 44.57 Favored Glycine 0 N--CA 1.437 -1.267 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 -177.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.71 -173.85 35.72 Favored Glycine 0 CA--C 1.48 -2.147 0 C-N-CA 119.911 -1.138 . . . . 0.0 111.414 177.836 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 52.5 p -142.29 144.62 33.35 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -133.21 167.09 21.0 Favored 'General case' 0 N--CA 1.423 -1.793 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 178.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -120.05 104.69 10.34 Favored 'General case' 0 C--N 1.266 -3.025 0 CA-C-N 114.258 -1.337 . . . . 0.0 108.402 178.522 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.409 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.2 m -89.72 146.78 5.76 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -178.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 51.6 m-85 -128.17 115.72 18.82 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 120.859 0.361 . . . . 0.0 111.18 -177.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.526 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.6 p -123.35 129.67 74.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 CA-C-O 121.663 0.744 . . . . 0.0 111.201 -176.013 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.3 p30 -86.85 123.42 31.97 Favored 'General case' 0 C--N 1.293 -1.855 0 CA-C-N 115.007 -0.997 . . . . 0.0 108.851 177.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 19.5 mt -108.2 160.38 15.88 Favored 'General case' 0 C--N 1.275 -2.656 0 CA-C-N 114.661 -1.154 . . . . 0.0 108.162 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -59.3 118.7 32.75 Favored Pre-proline 0 C--N 1.305 -1.366 0 O-C-N 124.004 0.815 . . . . 0.0 109.869 179.228 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.552 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 56.3 Cg_endo -70.06 -5.22 15.89 Favored 'Trans proline' 0 CA--C 1.54 0.822 0 C-N-CA 122.819 2.346 . . . . 0.0 113.752 -175.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.408 HG13 ' HG3' ' A' ' 157' ' ' PRO . 86.2 t -128.16 111.76 25.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 179.439 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.48 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 10.6 t -146.49 110.58 0.87 Allowed 'Isoleucine or valine' 0 C--O 1.191 -2.014 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -178.059 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.766 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -96.53 155.73 16.64 Favored 'General case' 0 C--N 1.278 -2.51 0 C-N-CA 124.009 0.924 . . . . 0.0 111.404 -178.678 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.626 HG22 ' O ' ' A' ' 112' ' ' VAL . 89.2 t -46.41 122.88 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 123.121 0.568 . . . . 0.0 111.358 176.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.11 4.8 61.13 Favored Glycine 0 C--N 1.31 -0.911 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.498 178.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.766 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -77.35 -176.26 4.08 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 124.345 1.058 . . . . 0.0 109.648 177.673 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -132.48 92.11 3.03 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.572 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 21.9 tp -93.67 142.7 27.06 Favored 'General case' 0 C--N 1.299 -1.63 0 C-N-CA 120.04 -0.664 . . . . 0.0 109.408 178.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 52.7 t -134.97 118.47 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.967 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 -175.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.59 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 48.7 t -90.6 88.1 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.876 0 N-CA-C 105.586 -2.005 . . . . 0.0 105.586 174.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -85.4 112.41 20.83 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-O 120.973 0.416 . . . . 0.0 110.598 -177.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 83.6 mt -96.11 -3.13 45.16 Favored 'General case' 0 C--N 1.299 -1.627 0 CA-C-N 115.006 -0.997 . . . . 0.0 110.419 -177.639 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.606 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 1.9 m -73.42 1.1 10.42 Favored 'General case' 0 CA--C 1.55 0.955 0 CA-C-O 121.903 0.859 . . . . 0.0 109.47 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.3 p -130.58 6.76 4.8 Favored 'General case' 0 N--CA 1.424 -1.738 0 C-N-CA 124.286 1.034 . . . . 0.0 109.993 178.195 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.526 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 48.4 mm-40 -123.99 -19.87 5.53 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-O 121.085 0.469 . . . . 0.0 110.585 -175.179 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 36.8 mt -134.85 135.07 53.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -176.021 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.513 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 47.7 m-85 -139.11 121.58 16.15 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 120.928 0.394 . . . . 0.0 110.302 -175.475 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 71.1 m -104.54 140.05 38.54 Favored 'General case' 0 C--N 1.286 -2.175 0 CA-C-O 121.097 0.475 . . . . 0.0 110.256 -177.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . 0.474 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 25.2 p-80 -131.12 151.85 51.02 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 121.781 0.801 . . . . 0.0 112.589 -172.269 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.459 ' HB3' ' OD2' ' A' ' 54' ' ' ASP . 19.0 p30 -103.59 127.7 50.97 Favored 'General case' 0 N--CA 1.405 -2.692 0 CA-C-O 122.607 1.194 . . . . 0.0 110.6 174.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -94.14 -28.43 15.69 Favored 'General case' 0 C--N 1.268 -2.961 0 CA-C-N 113.429 -1.714 . . . . 0.0 108.945 -179.249 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -135.58 71.45 65.37 Favored Pre-proline 0 C--N 1.311 -1.084 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.343 178.132 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -69.97 3.56 2.8 Favored 'Trans proline' 0 N--CA 1.493 1.454 0 C-N-CA 123.425 2.75 . . . . 0.0 113.648 -174.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -120.12 -18.81 7.98 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 121.198 0.523 . . . . 0.0 110.093 -179.455 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.52 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.1 m -103.08 -30.06 10.97 Favored 'General case' 0 N--CA 1.422 -1.831 0 CA-C-O 122.016 0.913 . . . . 0.0 109.148 -173.335 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.609 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.6 mp -124.38 131.55 72.63 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 CA-C-N 114.811 -1.086 . . . . 0.0 108.173 -178.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.0 t -77.25 140.46 40.09 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 106.668 -1.605 . . . . 0.0 106.668 176.599 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.549 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 8.0 m-20 -82.75 107.45 15.39 Favored 'General case' 0 C--N 1.283 -2.322 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 -178.203 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 29.4 t80 -137.95 128.25 26.16 Favored 'General case' 0 C--N 1.272 -2.771 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -179.765 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.9 p -147.43 149.5 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.327 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -177.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -148.21 133.92 18.89 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 175.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.527 HD23 ' O ' ' A' ' 130' ' ' ILE . 0.7 OUTLIER -68.87 113.0 5.9 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 103.717 -2.697 . . . . 0.0 103.717 171.404 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.439 ' O ' ' HA ' ' A' ' 89' ' ' GLU . 3.4 tp-100 -57.76 -64.29 0.95 Allowed 'General case' 0 C--O 1.198 -1.628 0 C-N-CA 125.893 1.677 . . . . 0.0 109.822 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -165.08 154.15 12.52 Favored 'General case' 0 N--CA 1.424 -1.75 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 -175.725 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -120.82 164.28 14.18 Favored Glycine 0 N--CA 1.43 -1.728 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 -178.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 66.2 m -145.56 144.14 30.33 Favored 'General case' 0 C--N 1.286 -2.165 0 N-CA-C 108.455 -0.942 . . . . 0.0 108.455 178.064 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.588 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -113.15 156.83 22.52 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.5 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 98.5 m-85 -155.2 -179.43 8.07 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 123.849 0.86 . . . . 0.0 110.002 -176.331 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.41 -140.58 42.76 Favored Glycine 0 N--CA 1.461 0.353 0 O-C-N 123.753 0.658 . . . . 0.0 113.126 178.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.78 -10.28 86.33 Favored Glycine 0 C--O 1.209 -1.444 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.525 177.106 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.807 HG21 ' HB ' ' A' ' 126' ' ' ILE . 91.6 t -68.43 -38.48 79.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 C-N-CA 123.82 0.848 . . . . 0.0 111.697 -176.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.588 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.25 -18.18 32.76 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.422 -0.911 . . . . 0.0 112.198 178.388 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 16.1 t -100.55 -59.41 1.71 Allowed 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.887 -173.086 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.509 ' O ' HG22 ' A' ' 112' ' ' VAL . 37.1 m-20 -90.36 -26.51 19.89 Favored 'General case' 0 CA--C 1.493 -1.222 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.167 -172.339 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.686 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 90.1 m-85 -103.98 150.64 24.04 Favored 'General case' 0 N--CA 1.42 -1.951 0 C-N-CA 119.726 -0.789 . . . . 0.0 108.888 176.734 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.3 t -160.88 119.88 2.58 Favored 'General case' 0 N--CA 1.421 -1.881 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 177.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.538 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -152.68 -107.0 0.31 Allowed Glycine 0 N--CA 1.424 -2.139 0 N-CA-C 111.386 -0.685 . . . . 0.0 111.386 177.045 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -164.18 -179.5 6.19 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 124.689 1.195 . . . . 0.0 109.748 -175.253 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.451 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.8 p -132.52 146.48 32.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.175 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.662 ' HG3' ' O ' ' A' ' 80' ' ' SER . 79.7 tttt -121.49 147.69 45.44 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.026 -178.58 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.546 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 63.4 t80 -145.66 109.79 4.91 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -179.795 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 23.0 t 52.16 37.6 22.17 Favored 'General case' 0 CA--C 1.55 0.972 0 C-N-CA 123.629 0.772 . . . . 0.0 111.544 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.81 10.38 63.08 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 120.62 -0.8 . . . . 0.0 113.644 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.662 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 15.4 t -83.3 179.0 7.81 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 177.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.4 t -156.07 108.42 2.59 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.546 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 6.8 p90 -149.39 164.42 21.07 Favored Pre-proline 0 C--N 1.306 -1.314 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 -173.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.468 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 97.4 Cg_endo -72.29 149.21 50.77 Favored 'Trans proline' 0 C--N 1.362 1.238 0 C-N-CA 122.224 1.949 . . . . 0.0 113.669 -175.36 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.631 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 55.5 t80 -119.33 133.48 23.76 Favored Pre-proline 0 N--CA 1.428 -1.55 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.894 178.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.631 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 61.6 Cg_endo -72.18 146.8 87.13 Favored 'Cis proline' 0 N--CA 1.477 0.539 0 C-N-CA 123.016 -1.66 . . . . 0.0 111.389 -2.315 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.7 t -71.77 179.83 2.96 Favored 'General case' 0 C--O 1.246 0.881 0 C-N-CA 119.776 -0.77 . . . . 0.0 109.075 -178.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 45.2 p -131.74 -39.09 1.12 Allowed 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 114.087 1.143 . . . . 0.0 114.087 -170.449 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 23.0 t -102.29 -69.45 0.79 Allowed 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 -172.616 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . 0.439 ' HA ' ' O ' ' A' ' 59' ' ' GLN . 0.3 OUTLIER -178.58 -176.2 0.47 Allowed 'General case' 0 N--CA 1.437 -1.112 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 179.378 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.458 ' HB ' ' HD2' ' A' ' 91' ' ' PRO . 1.9 p -101.11 174.81 2.68 Favored Pre-proline 0 C--N 1.286 -2.158 0 C-N-CA 123.19 0.596 . . . . 0.0 111.977 178.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . 0.458 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 22.3 Cg_endo -60.06 158.53 29.51 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 122.47 2.113 . . . . 0.0 111.439 171.47 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.3 tmm_? -77.03 114.14 15.51 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-N 114.836 -1.074 . . . . 0.0 108.781 -176.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 85.1 t -124.94 129.24 73.48 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 CA-C-O 121.544 0.687 . . . . 0.0 111.843 -177.379 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 66.2 t -114.25 123.74 70.22 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.253 177.708 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.549 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.7 m-85 -73.85 133.32 43.16 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 175.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.73 55.05 0.88 Allowed 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 174.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . 0.562 ' CB ' ' HG3' ' A' ' 101' ' ' LYS . 50.6 m -135.3 175.59 9.45 Favored 'General case' 0 N--CA 1.434 -1.228 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 -177.458 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -142.93 55.58 1.39 Allowed 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 122.033 0.92 . . . . 0.0 111.536 177.226 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.1 t -171.28 176.06 4.02 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 106.715 -1.587 . . . . 0.0 106.715 179.233 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . 0.474 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 11.0 p-10 -72.02 99.33 2.25 Favored 'General case' 0 CA--C 1.501 -0.937 0 CA-C-O 122.503 1.144 . . . . 0.0 109.608 177.395 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . 0.562 ' HG3' ' CB ' ' A' ' 97' ' ' SER . 57.4 mmtt -102.37 138.61 19.74 Favored Pre-proline 0 N--CA 1.415 -2.187 0 CA-C-N 113.524 -1.671 . . . . 0.0 110.277 -176.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.606 ' HB3' ' O ' ' A' ' 39' ' ' SER . 53.6 Cg_exo -49.67 139.54 31.01 Favored 'Trans proline' 0 N--CA 1.448 -1.202 0 C-N-CA 124.018 3.145 . . . . 0.0 112.86 -179.511 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.7 t90 -89.59 102.83 4.98 Favored Pre-proline 0 C--N 1.296 -1.751 0 N-CA-C 104.999 -2.223 . . . . 0.0 104.999 176.461 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . 0.436 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 74.4 Cg_endo -75.55 88.72 1.26 Allowed 'Trans proline' 0 N--CA 1.451 -1.02 0 C-N-CA 121.877 1.718 . . . . 0.0 113.116 -170.411 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.412 HG22 ' HD1' ' A' ' 77' ' ' TYR . 94.2 t -138.52 143.93 31.33 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.59 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -149.04 133.78 17.85 Favored 'General case' 0 C--N 1.289 -2.025 0 CA-C-O 120.81 0.338 . . . . 0.0 110.251 178.046 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.537 HD21 HD11 ' A' ' 129' ' ' LEU . 17.4 mt -101.19 102.9 13.9 Favored 'General case' 0 C--N 1.288 -2.097 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.752 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.538 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 32.3 m-85 -83.4 77.62 9.78 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 177.828 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.686 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.3 mm? -102.38 124.98 48.92 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 176.362 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -129.69 145.96 59.2 Favored Pre-proline 0 N--CA 1.406 -2.669 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 -174.709 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.436 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 34.0 Cg_endo -62.82 124.59 14.34 Favored 'Trans proline' 0 CA--C 1.497 -1.327 0 C-N-CA 123.038 2.492 . . . . 0.0 113.341 -176.101 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.626 ' O ' HG22 ' A' ' 30' ' ' VAL . 15.9 m -84.56 -155.45 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.399 -3.02 0 CA-C-N 114.246 -1.343 . . . . 0.0 108.161 172.017 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.7 t -83.38 -28.97 28.56 Favored 'General case' 0 C--N 1.263 -3.19 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -170.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 25.7 t -84.13 30.02 0.54 Allowed 'General case' 0 N--CA 1.426 -1.665 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.313 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -112.81 138.79 49.12 Favored 'General case' 0 N--CA 1.424 -1.736 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.069 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -177.28 135.91 2.94 Favored Glycine 0 N--CA 1.44 -1.063 0 N-CA-C 111.607 -0.597 . . . . 0.0 111.607 179.493 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 63.33 -152.34 47.36 Favored Glycine 0 CA--C 1.5 -0.853 0 CA-C-O 119.387 -0.674 . . . . 0.0 112.577 -178.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 57.7 t -60.56 98.72 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.248 0.98 0 CA-C-O 122.222 1.011 . . . . 0.0 111.161 -176.513 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.06 -24.1 15.48 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-N 114.147 -1.388 . . . . 0.0 110.756 -176.503 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.533 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.4 mt -133.63 137.58 52.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 178.47 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.46 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.3 mmpt? -114.57 138.74 50.27 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-O 120.914 0.387 . . . . 0.0 110.871 177.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.31 135.15 50.02 Favored 'General case' 0 N--CA 1.442 -0.851 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 178.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 88.12 -6.63 83.27 Favored Glycine 0 C--N 1.308 -0.974 0 N-CA-C 111.628 -0.589 . . . . 0.0 111.628 -179.343 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 64.9 m -96.78 149.28 22.01 Favored 'General case' 0 N--CA 1.427 -1.601 0 CA-C-O 121.285 0.564 . . . . 0.0 110.089 179.471 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.437 HD11 HG23 ' A' ' 128' ' ' VAL . 3.2 tm? -78.98 125.0 28.8 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-N 114.782 -1.099 . . . . 0.0 108.587 -176.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.807 ' HB ' HG21 ' A' ' 67' ' ' VAL . 36.4 pt -109.61 -26.3 3.26 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -177.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.21 167.53 23.89 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -177.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.437 HG23 HD11 ' A' ' 125' ' ' LEU . 69.3 t -142.37 116.07 4.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 178.725 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.537 HD11 HD21 ' A' ' 107' ' ' LEU . 40.4 mt -119.29 147.91 43.76 Favored 'General case' 0 C--N 1.291 -1.976 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 179.183 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.585 HG21 HE21 ' A' ' 143' ' ' GLN . 5.4 mp -124.75 133.4 69.52 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 C-N-CA 119.53 -0.868 . . . . 0.0 110.653 177.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.572 HD22 ' HB2' ' A' ' 144' ' ' PHE . 0.0 OUTLIER -100.35 135.67 41.43 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 175.971 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . 0.508 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 8.4 tpt180 -106.81 120.48 42.12 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -102.08 121.84 42.96 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 177.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 18.8 m -140.04 137.86 34.94 Favored 'General case' 0 C--N 1.291 -1.962 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 -179.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.609 ' CB ' HG23 ' A' ' 52' ' ' ILE . 8.7 p30 . . . . . 0 N--CA 1.442 -0.838 0 C-N-CA 118.809 -1.156 . . . . 0.0 112.389 179.018 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 . . . . . 0 N--CA 1.437 -1.111 0 N-CA-C 108.542 -0.911 . . . . 0.0 108.542 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . 0.585 HE21 HG21 ' A' ' 130' ' ' ILE . 19.4 pt20 -116.27 144.39 44.29 Favored 'General case' 0 C--N 1.295 -1.778 0 C-N-CA 119.981 -0.688 . . . . 0.0 111.409 176.215 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.572 ' HB2' HD22 ' A' ' 131' ' ' LEU . 3.7 m-30 -110.72 131.53 54.97 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 -178.104 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 49.6 t -90.98 130.53 40.01 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.897 0 O-C-N 123.553 0.533 . . . . 0.0 109.784 -179.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . 0.543 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.9 m95 -117.93 95.16 4.8 Favored 'General case' 0 C--N 1.279 -2.496 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 -179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -77.62 114.79 16.82 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.409 ' HA ' HG22 ' A' ' 20' ' ' VAL . 23.2 mm -89.26 122.41 40.55 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.794 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -177.436 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . 0.412 ' CZ ' HD23 ' A' ' 125' ' ' LEU . 89.1 m-85 -118.27 152.83 35.0 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 121.509 0.671 . . . . 0.0 110.241 178.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -80.6 129.39 34.49 Favored 'General case' 0 N--CA 1.41 -2.472 0 CA-C-N 114.807 -1.088 . . . . 0.0 108.33 176.19 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 29.3 t-20 -91.7 -10.26 40.8 Favored 'General case' 0 C--N 1.29 -2.004 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 -177.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -155.09 145.83 22.37 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 113.991 -1.459 . . . . 0.0 109.19 -176.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -80.52 147.29 30.91 Favored 'General case' 0 C--N 1.323 -0.57 0 O-C-N 124.054 0.846 . . . . 0.0 110.861 -178.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.552 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.3 t -124.21 135.16 64.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.13 -177.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.9 t -117.74 135.98 56.4 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 79.4 t -98.54 103.21 17.39 Favored Pre-proline 0 C--N 1.295 -1.803 0 C-N-CA 123.464 0.706 . . . . 0.0 109.883 178.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.483 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 44.1 Cg_endo -71.26 -21.03 27.34 Favored 'Trans proline' 0 CA--C 1.516 -0.396 0 C-N-CA 122.172 1.915 . . . . 0.0 111.633 179.178 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 2.4 t . . . . . 0 C--O 1.249 1.073 0 C-N-CA 124.79 1.236 . . . . 0.0 114.061 176.874 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.496 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.434 -1.27 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.49 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 73.2 m -138.58 160.08 40.48 Favored 'General case' 0 C--N 1.3 -1.558 0 C-N-CA 119.624 -0.83 . . . . 0.0 111.591 -175.517 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.9 pptp? -144.43 159.53 42.58 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 122.747 0.419 . . . . 0.0 110.412 -178.123 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.509 HG22 HG22 ' A' ' 20' ' ' VAL . 81.5 p -95.51 176.57 6.12 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 121.433 0.635 . . . . 0.0 112.011 -178.518 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -76.76 -24.14 52.94 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.202 177.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -81.1 -33.54 33.24 Favored 'General case' 0 N--CA 1.448 -0.544 0 C-N-CA 119.272 -0.971 . . . . 0.0 109.549 179.247 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.82 17.86 1.15 Allowed Glycine 0 N--CA 1.439 -1.131 0 C-N-CA 119.699 -1.238 . . . . 0.0 113.404 175.852 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.9 m -88.69 99.75 12.59 Favored 'General case' 0 N--CA 1.431 -1.383 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.56 120.59 32.49 Favored 'General case' 0 C--N 1.291 -1.971 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.38 178.003 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.496 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 62.2 mt -102.25 115.69 64.16 Favored Pre-proline 0 C--N 1.288 -2.078 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 176.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -79.88 -179.81 5.63 Favored 'Trans proline' 0 N--CA 1.443 -1.445 0 C-N-CA 122.46 2.107 . . . . 0.0 111.189 177.044 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.9 mt -66.93 147.71 12.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.063 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.55 24.2 5.97 Favored Glycine 0 C--N 1.315 -0.615 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.517 178.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.0 173.17 49.45 Favored Glycine 0 C--N 1.316 -0.539 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 -178.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 159.03 -177.91 35.41 Favored Glycine 0 N--CA 1.431 -1.68 0 C-N-CA 120.283 -0.96 . . . . 0.0 111.497 177.053 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 25.5 p -151.54 141.46 22.02 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -178.073 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.9 160.46 38.83 Favored 'General case' 0 N--CA 1.425 -1.718 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 27.7 m-80 -112.83 109.05 18.27 Favored 'General case' 0 C--N 1.289 -2.037 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 177.344 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.509 HG22 HG22 ' A' ' 5' ' ' THR . 43.2 t -94.09 137.18 23.52 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.245 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.483 -177.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 50.4 m-85 -122.83 115.69 22.41 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 120.919 0.39 . . . . 0.0 110.832 -177.201 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.458 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -125.65 132.9 70.32 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.244 -174.371 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -87.78 130.41 34.86 Favored 'General case' 0 C--N 1.298 -1.663 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.21 177.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.415 HD11 HG22 ' A' ' 36' ' ' VAL . 2.7 mm? -111.6 160.31 17.33 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 175.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.79 121.95 48.53 Favored Pre-proline 0 C--O 1.21 -1.016 0 O-C-N 124.235 0.959 . . . . 0.0 109.196 175.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 69.9 Cg_endo -74.76 -5.23 16.57 Favored 'Trans proline' 0 C--O 1.217 -0.542 0 C-N-CA 122.781 2.321 . . . . 0.0 113.555 -175.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.3 t -126.39 109.54 21.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.495 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 8.1 t -145.36 112.47 1.28 Allowed 'Isoleucine or valine' 0 C--O 1.186 -2.256 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 -176.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.662 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -101.09 156.14 17.59 Favored 'General case' 0 C--N 1.274 -2.68 0 C-N-CA 123.214 0.606 . . . . 0.0 111.474 179.657 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 38.0 t -45.51 120.55 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 C-N-CA 123.471 0.709 . . . . 0.0 112.019 176.621 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 99.82 0.74 56.32 Favored Glycine 0 CA--C 1.52 0.371 0 CA-C-N 115.542 -0.754 . . . . 0.0 112.825 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.662 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -73.11 -177.41 2.47 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 124.384 1.074 . . . . 0.0 110.977 177.706 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -127.38 92.9 3.6 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 107.769 -1.196 . . . . 0.0 107.769 177.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.606 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 20.2 tp -101.72 134.86 44.21 Favored 'General case' 0 C--N 1.283 -2.309 0 C-N-CA 118.725 -1.19 . . . . 0.0 109.381 176.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.9 p -141.96 132.38 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.386 -3.646 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.927 -178.135 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.578 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 42.2 t -92.12 89.95 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.55 0 CA-C-N 113.86 -1.518 . . . . 0.0 108.029 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -74.45 112.14 10.33 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 88.8 mt -95.68 1.03 53.31 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.026 0.441 . . . . 0.0 111.284 -179.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 38.9 t -77.98 0.65 23.53 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 122.086 0.946 . . . . 0.0 109.439 -178.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.9 p -124.59 0.52 8.19 Favored 'General case' 0 C--N 1.281 -2.393 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.134 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.458 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 49.2 mm-40 -120.96 -24.56 5.57 Favored 'General case' 0 CA--C 1.504 -0.816 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.66 -172.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 18.2 mt -132.86 139.14 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 -176.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.418 ' HA ' ' HA ' ' A' ' 102' ' ' PRO . 78.3 m-85 -134.2 161.14 35.73 Favored 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 -176.648 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.49 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 81.0 m -141.94 141.79 32.97 Favored 'General case' 0 C--N 1.284 -2.244 0 C-N-CA 122.886 0.475 . . . . 0.0 109.998 -177.068 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.6 p80 -145.3 156.69 43.96 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-O 121.312 0.577 . . . . 0.0 111.052 -174.272 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 2.9 p30 -107.42 121.06 43.83 Favored 'General case' 0 C--N 1.295 -1.783 0 CA-C-O 122.479 1.133 . . . . 0.0 113.304 178.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 13.7 p-10 -90.97 -23.37 20.44 Favored 'General case' 0 N--CA 1.42 -1.959 0 CA-C-N 113.417 -1.72 . . . . 0.0 109.529 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.419 ' HB2' HD13 ' A' ' 52' ' ' ILE . 60.7 m-85 -138.57 64.61 37.78 Favored Pre-proline 0 N--CA 1.472 0.636 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.871 176.157 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -67.5 -17.16 48.62 Favored 'Trans proline' 0 N--CA 1.481 0.784 0 C-N-CA 122.159 1.906 . . . . 0.0 112.787 -176.263 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -94.44 -27.63 15.91 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.903 -175.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.566 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -97.84 -30.41 12.78 Favored 'General case' 0 N--CA 1.413 -2.278 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 -171.344 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.566 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.1 mp -119.57 141.4 39.79 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 CA-C-N 114.158 -1.383 . . . . 0.0 108.963 -176.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 5.4 t -88.89 131.94 34.9 Favored 'General case' 0 C--O 1.259 1.578 0 N-CA-C 104.09 -2.559 . . . . 0.0 104.09 171.439 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 34.0 m-20 -93.78 107.27 19.17 Favored 'General case' 0 C--N 1.271 -2.815 0 C-N-CA 118.952 -1.099 . . . . 0.0 110.152 -169.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 28.9 t80 -127.06 143.11 51.37 Favored 'General case' 0 C--N 1.289 -2.055 0 CA-C-N 114.04 -1.437 . . . . 0.0 108.908 -175.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.532 HG23 ' HG ' ' A' ' 131' ' ' LEU . 8.1 p -150.6 145.25 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.313 0 O-C-N 123.615 0.572 . . . . 0.0 110.087 -179.76 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.6 p -147.42 131.59 17.38 Favored 'General case' 0 N--CA 1.436 -1.129 0 C-N-CA 123.075 0.55 . . . . 0.0 109.769 174.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.457 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 1.1 tm? -71.2 102.14 2.46 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 175.091 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.4 tp-100 -52.53 -50.55 62.62 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 127.12 2.168 . . . . 0.0 111.697 -176.772 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 3.9 ptp180 -171.17 160.17 6.21 Favored 'General case' 0 N--CA 1.425 -1.684 0 CA-C-N 114.467 -1.242 . . . . 0.0 109.289 -176.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -135.84 148.22 19.55 Favored Glycine 0 N--CA 1.41 -3.097 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 179.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 63.2 m -129.38 143.81 50.99 Favored 'General case' 0 C--N 1.279 -2.469 0 C-N-CA 123.228 0.611 . . . . 0.0 109.573 -178.681 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.508 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -111.29 155.62 22.75 Favored 'General case' 0 CA--C 1.502 -0.87 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.469 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 68.0 m-85 -157.45 -178.52 7.4 Favored 'General case' 0 C--O 1.238 0.494 0 C-N-CA 124.235 1.014 . . . . 0.0 108.313 -177.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 62.45 -141.71 47.25 Favored Glycine 0 N--CA 1.453 -0.191 0 O-C-N 123.333 0.396 . . . . 0.0 112.707 177.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.24 -7.84 87.18 Favored Glycine 0 C--O 1.208 -1.482 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 177.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.805 HG21 ' HB ' ' A' ' 126' ' ' ILE . 86.6 t -69.72 -38.64 76.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 C-N-CA 123.752 0.821 . . . . 0.0 111.339 -176.488 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.508 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -85.44 -22.8 28.14 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 119.306 -0.957 . . . . 0.0 112.063 179.441 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 9.3 t -100.63 -51.39 3.61 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.144 0.497 . . . . 0.0 112.265 -172.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.487 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 47.7 m-20 -90.8 -24.57 20.28 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -174.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.663 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 89.2 m-85 -111.52 156.49 21.64 Favored 'General case' 0 N--CA 1.42 -1.951 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.292 179.104 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.5 t -162.97 138.57 6.89 Favored 'General case' 0 N--CA 1.406 -2.651 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 176.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.519 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.36 -104.65 0.18 Allowed Glycine 0 N--CA 1.409 -3.146 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 175.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.2 p -165.3 -179.86 5.83 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 124.547 1.139 . . . . 0.0 110.137 -176.261 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.413 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.7 p -131.81 145.33 35.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 123.313 0.645 . . . . 0.0 109.467 178.411 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.672 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.2 tttt -122.23 149.52 43.56 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.478 -177.614 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.461 ' CD2' HG22 ' A' ' 105' ' ' VAL . 60.8 t80 -150.15 113.09 4.81 Favored 'General case' 0 C--O 1.214 -0.777 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 22.7 t 56.92 30.23 17.64 Favored 'General case' 0 CA--C 1.554 1.108 0 CA-C-O 121.884 0.85 . . . . 0.0 111.286 176.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.33 13.69 59.76 Favored Glycine 0 N--CA 1.437 -1.273 0 C-N-CA 120.208 -0.996 . . . . 0.0 113.086 -177.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.672 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 21.2 t -83.95 -179.35 7.24 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 175.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 8.2 t -157.37 110.48 2.51 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 179.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.47 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 7.4 p90 -149.68 162.52 28.11 Favored Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -174.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.47 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 72.7 Cg_endo -68.2 149.08 75.91 Favored 'Trans proline' 0 C--N 1.36 1.174 0 C-N-CA 122.671 2.248 . . . . 0.0 113.528 -175.266 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.617 ' CD2' HD21 ' A' ' 109' ' ' LEU . 60.2 t80 -124.31 134.54 25.57 Favored Pre-proline 0 N--CA 1.442 -0.839 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.193 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.582 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 57.4 Cg_endo -70.57 145.08 80.29 Favored 'Cis proline' 0 C--O 1.239 0.568 0 C-N-CA 123.099 -1.625 . . . . 0.0 110.633 -3.255 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.7 t -73.65 -177.63 2.8 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -177.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 41.2 p -131.77 -35.87 1.24 Allowed 'General case' 0 N--CA 1.424 -1.772 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -172.438 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 49.5 m -110.1 -162.21 0.79 Allowed 'General case' 1 N--CA 1.317 -7.114 0 CA-C-N 113.45 -1.704 . . . . 0.0 107.663 179.265 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 27.0 tt0 -116.21 151.32 35.96 Favored 'General case' 1 C--N 1.244 -4.011 0 CA-C-N 113.443 -1.708 . . . . 0.0 109.115 -168.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.457 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 46.8 p -67.75 161.17 68.76 Favored Pre-proline 0 C--N 1.296 -1.748 0 C-N-CA 124.494 1.117 . . . . 0.0 113.245 -177.642 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -56.86 159.86 13.48 Favored 'Trans proline' 0 C--N 1.355 0.876 0 C-N-CA 124.068 3.179 . . . . 0.0 111.749 175.454 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.5 tmm_? -67.88 116.74 8.88 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.667 -176.024 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 72.7 t -132.05 137.18 55.31 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 C-N-CA 123.848 0.859 . . . . 0.0 108.687 -176.223 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.0 p -136.59 132.94 48.85 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.628 -175.191 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -82.9 101.5 11.06 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 120.937 0.398 . . . . 0.0 110.917 -178.395 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 36.7 m-80 -92.29 55.12 2.48 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-O 121.996 0.903 . . . . 0.0 108.837 176.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.3 m -145.4 128.63 16.74 Favored 'General case' 0 N--CA 1.428 -1.566 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 -178.239 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.5 ptm180 -104.51 63.7 0.74 Allowed 'General case' 0 C--N 1.304 -1.378 0 CA-C-O 122.643 1.211 . . . . 0.0 109.609 -179.091 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . 0.405 HG23 ' HD3' ' A' ' 101' ' ' LYS . 10.1 t -170.41 -179.5 3.04 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 -172.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -86.25 124.81 33.04 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . 0.411 ' HD2' ' HA ' ' A' ' 101' ' ' LYS . 6.8 mptt -127.32 143.9 48.84 Favored Pre-proline 0 C--N 1.277 -2.561 0 C-N-CA 124.463 1.105 . . . . 0.0 109.273 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.418 ' HA ' ' HA ' ' A' ' 43' ' ' PHE . 41.0 Cg_endo -68.23 147.27 72.12 Favored 'Trans proline' 0 C--O 1.244 0.787 0 C-N-CA 122.891 2.394 . . . . 0.0 112.12 178.118 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.2 t90 -85.56 107.45 12.47 Favored Pre-proline 0 C--N 1.323 -0.544 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 -177.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -76.73 88.2 1.4 Allowed 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 121.518 1.479 . . . . 0.0 112.905 -172.495 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.461 HG22 ' CD2' ' A' ' 77' ' ' TYR . 68.2 t -137.54 153.96 29.1 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.144 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 178.102 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.578 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -160.05 137.4 9.55 Favored 'General case' 0 CA--C 1.475 -1.94 0 O-C-N 123.406 0.441 . . . . 0.0 110.182 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.469 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 18.9 mt -105.79 99.85 9.43 Favored 'General case' 0 C--N 1.286 -2.171 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.388 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.519 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 42.4 m-85 -79.78 77.2 6.42 Favored 'General case' 0 C--N 1.313 -0.995 0 O-C-N 122.041 -0.412 . . . . 0.0 110.105 177.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.663 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.1 mm? -102.48 119.74 39.34 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-O 120.926 0.393 . . . . 0.0 110.219 177.653 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.54 147.39 52.74 Favored Pre-proline 0 N--CA 1.419 -1.98 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.725 -174.558 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.487 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 29.9 Cg_endo -62.24 118.55 5.44 Favored 'Trans proline' 0 C--O 1.246 0.899 0 C-N-CA 123.185 2.59 . . . . 0.0 112.835 -177.13 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.443 HG22 ' H ' ' A' ' 112' ' ' VAL . 2.8 m -68.46 -116.43 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.192 -1.923 0 CA-C-N 114.007 -1.451 . . . . 0.0 112.71 175.52 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 22.8 t -112.21 -39.53 4.42 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.267 -0.895 . . . . 0.0 109.541 177.367 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 31.5 t -84.33 29.41 0.58 Allowed 'General case' 0 C--N 1.317 -0.804 0 C-N-CA 123.536 0.734 . . . . 0.0 111.342 -175.095 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -101.93 133.18 47.13 Favored 'General case' 0 N--CA 1.422 -1.84 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.336 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.97 139.84 5.19 Favored Glycine 0 N--CA 1.434 -1.436 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.017 178.19 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 59.71 -144.37 46.19 Favored Glycine 0 CA--C 1.495 -1.214 0 CA-C-O 119.288 -0.729 . . . . 0.0 112.738 -179.083 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.3 p -59.24 96.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 122.753 1.263 . . . . 0.0 111.575 -178.31 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.44 -25.85 14.65 Favored 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 114.754 -1.112 . . . . 0.0 111.49 -177.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.451 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 61.4 mt -134.72 139.66 47.14 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.326 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 3.7 mmpt? -114.85 137.32 52.1 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-O 121.089 0.471 . . . . 0.0 111.4 179.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.06 122.52 20.21 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.379 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 93.6 3.57 64.47 Favored Glycine 0 C--N 1.309 -0.948 0 N-CA-C 111.595 -0.602 . . . . 0.0 111.595 -177.458 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 32.9 t -102.21 143.62 31.77 Favored 'General case' 0 C--O 1.253 1.246 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 178.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.431 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -72.28 124.72 25.67 Favored 'General case' 0 N--CA 1.444 -0.727 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.805 ' HB ' HG21 ' A' ' 67' ' ' VAL . 39.0 pt -109.93 -27.43 2.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 N-CA-C 112.423 0.527 . . . . 0.0 112.423 -178.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . 0.4 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.68 167.62 24.79 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 -177.679 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.431 HG23 HD11 ' A' ' 125' ' ' LEU . 71.2 t -142.97 116.38 3.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.576 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.44 HD11 HD21 ' A' ' 107' ' ' LEU . 59.9 mt -115.95 143.01 46.02 Favored 'General case' 0 C--N 1.288 -2.08 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 179.536 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.644 HG21 HE21 ' A' ' 143' ' ' GLN . 3.8 mp -124.31 118.44 53.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 C-N-CA 119.402 -0.919 . . . . 0.0 110.322 179.184 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.532 ' HG ' HG23 ' A' ' 56' ' ' VAL . 0.1 OUTLIER -88.76 150.09 23.12 Favored 'General case' 0 C--N 1.268 -2.957 0 C-N-CA 124.838 1.255 . . . . 0.0 108.485 178.227 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 19.3 ttp85 -123.38 137.4 54.83 Favored 'General case' 0 N--CA 1.414 -2.269 0 O-C-N 123.255 0.347 . . . . 0.0 111.549 178.443 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.411 ' OE1' HD21 ' A' ' 131' ' ' LEU . 13.3 mm100 -113.01 115.44 28.38 Favored 'General case' 0 N--CA 1.431 -1.398 0 CA-C-N 115.079 -0.964 . . . . 0.0 110.622 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 4.5 m -133.33 130.86 39.43 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 176.017 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.529 ' CB ' HG23 ' A' ' 52' ' ' ILE . 6.5 p30 . . . . . 0 C--O 1.214 -0.791 0 C-N-CA 118.464 -1.294 . . . . 0.0 112.232 179.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 . . . . . 0 CA--C 1.49 -1.357 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . 0.644 HE21 HG21 ' A' ' 130' ' ' ILE . 15.7 pt20 -138.58 141.92 39.21 Favored 'General case' 0 C--N 1.287 -2.15 0 C-N-CA 119.453 -0.899 . . . . 0.0 111.003 -178.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 7.5 m-30 -107.2 134.21 50.64 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 -175.619 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 45.3 t -93.26 130.82 41.75 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 O-C-N 123.492 0.495 . . . . 0.0 109.886 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . 0.513 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 64.1 m95 -120.69 100.03 6.88 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 -179.688 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -81.02 113.5 19.26 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 179.194 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.4 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 23.6 mm -88.43 121.55 38.86 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -178.044 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -117.46 153.69 32.69 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 123.541 0.736 . . . . 0.0 109.834 177.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.0 131.94 35.16 Favored 'General case' 0 N--CA 1.416 -2.165 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 177.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 13.8 t-20 -95.06 -5.77 43.63 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -177.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -155.96 139.97 16.36 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.199 -1.364 . . . . 0.0 109.508 -177.078 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -78.16 145.04 35.86 Favored 'General case' 0 C--N 1.308 -1.2 0 O-C-N 124.212 0.945 . . . . 0.0 109.454 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.46 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 75.5 t -120.67 141.29 41.74 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 O-C-N 122.28 -0.263 . . . . 0.0 110.82 -177.009 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.2 t -120.48 136.11 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.234 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 179.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.495 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.7 t -101.74 103.95 31.82 Favored Pre-proline 0 C--N 1.289 -2.058 0 C-N-CA 123.173 0.589 . . . . 0.0 109.716 178.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.449 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 44.2 Cg_endo -71.29 -19.47 29.15 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.031 1.821 . . . . 0.0 111.3 178.139 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . 0.418 ' HB ' HG12 ' A' ' 156' ' ' VAL . 5.1 t . . . . . 0 C--O 1.246 0.872 0 C-N-CA 124.956 1.302 . . . . 0.0 113.262 176.233 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.501 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.419 -2.013 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 79.4 m -136.89 154.46 50.48 Favored 'General case' 0 C--N 1.291 -1.974 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.549 -174.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.44 162.52 35.57 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.608 -174.024 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.546 HG22 HG22 ' A' ' 20' ' ' VAL . 67.1 p -97.63 179.81 4.71 Favored 'General case' 0 C--N 1.301 -1.515 0 CA-C-O 121.192 0.52 . . . . 0.0 110.599 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -84.98 -19.75 31.59 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 114.93 -1.032 . . . . 0.0 108.73 179.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -87.93 -17.46 31.29 Favored 'General case' 0 N--CA 1.417 -2.1 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.475 -179.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 119.24 11.63 7.34 Favored Glycine 0 CA--C 1.486 -1.729 0 C-N-CA 119.061 -1.543 . . . . 0.0 114.373 167.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.2 m -89.83 99.68 12.64 Favored 'General case' 0 N--CA 1.413 -2.308 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -90.66 121.65 32.75 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-N 115.071 -0.968 . . . . 0.0 108.513 177.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.501 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 66.4 mt -101.77 113.7 65.78 Favored Pre-proline 0 C--N 1.295 -1.768 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 178.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -75.54 170.6 19.92 Favored 'Trans proline' 0 C--O 1.25 1.092 0 C-N-CA 122.586 2.19 . . . . 0.0 111.527 178.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 63.1 mt -64.42 128.19 26.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.199 179.233 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.89 6.24 2.03 Favored Glycine 0 C--N 1.314 -0.669 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.742 -178.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.65 158.41 33.8 Favored Glycine 0 C--N 1.316 -0.558 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 166.04 -173.2 41.59 Favored Glycine 0 C--N 1.3 -1.434 0 C-N-CA 119.709 -1.234 . . . . 0.0 112.014 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.2 p -148.45 140.87 24.29 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -178.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -130.8 159.6 36.86 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 29.1 m-80 -108.55 109.89 21.23 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 176.414 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.546 HG22 HG22 ' A' ' 5' ' ' THR . 38.3 t -96.15 138.9 20.33 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.689 -178.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -124.7 112.5 16.83 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 121.216 0.532 . . . . 0.0 111.312 -176.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.582 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.1 p -122.76 134.13 66.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.942 -175.363 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -98.07 119.69 37.15 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-O 121.47 0.652 . . . . 0.0 110.152 -178.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.428 ' CD1' ' HA ' ' A' ' 36' ' ' VAL . 2.7 mm? -97.06 161.72 13.7 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.359 -178.668 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.27 122.1 51.98 Favored Pre-proline 0 C--N 1.317 -0.817 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 173.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.494 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 63.1 Cg_endo -74.86 -2.22 12.21 Favored 'Trans proline' 0 CA--C 1.533 0.456 0 C-N-CA 122.771 2.314 . . . . 0.0 113.203 -176.357 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.454 HG13 ' HG3' ' A' ' 157' ' ' PRO . 73.5 t -127.16 115.26 40.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.502 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 3.3 t -149.84 118.99 0.98 Allowed 'Isoleucine or valine' 0 C--O 1.194 -1.833 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 -179.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.64 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -107.13 155.79 19.5 Favored 'General case' 0 C--N 1.278 -2.519 0 C-N-CA 122.787 0.435 . . . . 0.0 111.625 -179.592 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.434 HG13 ' O ' ' A' ' 112' ' ' VAL . 38.6 t -47.07 117.13 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 123.656 0.782 . . . . 0.0 111.765 177.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.79 -2.44 45.2 Favored Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 115.391 -0.822 . . . . 0.0 112.918 179.562 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.64 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -72.95 -176.91 2.21 Favored 'General case' 0 C--N 1.314 -0.948 0 C-N-CA 123.999 0.92 . . . . 0.0 110.58 177.419 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -134.44 98.21 4.02 Favored 'General case' 0 N--CA 1.427 -1.612 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 176.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.684 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 30.4 tp -93.69 147.01 23.42 Favored 'General case' 0 C--N 1.282 -2.354 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 93.8 t -135.28 120.94 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.507 0 CA-C-O 121.212 0.53 . . . . 0.0 109.973 -178.512 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.599 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 61.5 t -89.61 88.74 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.286 0 N-CA-C 106.349 -1.722 . . . . 0.0 106.349 174.203 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -81.67 110.12 16.72 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-O 121.202 0.525 . . . . 0.0 111.42 -177.281 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.5 mt -96.45 -3.0 44.21 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.438 -178.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.2 m -73.07 0.03 12.64 Favored 'General case' 0 CA--C 1.551 1.001 0 CA-C-O 122.151 0.977 . . . . 0.0 109.532 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.5 p -126.29 3.0 7.07 Favored 'General case' 0 C--N 1.295 -1.782 0 C-N-CA 123.712 0.805 . . . . 0.0 110.288 178.063 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.582 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 45.5 mm-40 -121.93 -23.47 5.43 Favored 'General case' 0 CA--C 1.506 -0.724 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.815 -173.458 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.8 mt -133.11 140.34 47.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.196 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -176.149 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -137.62 153.46 49.89 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -176.507 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 66.6 m -128.64 134.94 48.68 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 123.537 0.735 . . . . 0.0 109.209 176.384 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . 0.425 ' HB3' ' HA ' ' A' ' 100' ' ' ASP . 22.0 p80 -127.56 145.97 50.68 Favored 'General case' 0 C--N 1.291 -1.968 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.364 -177.011 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.417 HD22 ' CG ' ' A' ' 54' ' ' ASP . 27.4 t-20 -99.85 99.41 10.2 Favored 'General case' 0 C--N 1.293 -1.877 0 C-N-CA 118.637 -1.225 . . . . 0.0 109.035 175.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -72.81 -9.79 59.07 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 125.145 1.378 . . . . 0.0 112.627 178.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -144.63 68.1 14.54 Favored Pre-proline 0 N--CA 1.482 1.174 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 175.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -66.22 -5.33 12.23 Favored 'Trans proline' 0 N--CA 1.488 1.176 0 C-N-CA 123.376 2.717 . . . . 0.0 114.651 -172.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -117.99 -3.14 11.16 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-O 121.282 0.563 . . . . 0.0 109.692 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.501 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.6 OUTLIER -117.51 -30.15 5.6 Favored 'General case' 0 N--CA 1.421 -1.878 0 CA-C-O 121.608 0.718 . . . . 0.0 109.732 -175.117 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.648 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.6 mp -129.16 131.87 67.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 -177.455 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.4 t -76.94 146.37 37.6 Favored 'General case' 0 C--O 1.251 1.145 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.612 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 0.8 OUTLIER -83.34 108.45 16.54 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 -178.056 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 22.4 t80 -145.99 129.89 17.27 Favored 'General case' 0 C--N 1.28 -2.425 0 CA-C-O 121.224 0.535 . . . . 0.0 109.62 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.574 HG23 HD13 ' A' ' 131' ' ' LEU . 6.2 p -148.4 149.41 15.18 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.478 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 -178.316 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 5.3 p -150.33 136.36 18.55 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 178.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.459 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 38.0 tp -73.32 110.03 7.29 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 172.307 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -58.98 -55.64 32.5 Favored 'General case' 0 C--N 1.314 -0.969 0 C-N-CA 126.155 1.782 . . . . 0.0 110.584 179.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -165.55 160.21 17.46 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 -177.547 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -138.31 143.18 13.97 Favored Glycine 0 N--CA 1.405 -3.403 0 N-CA-C 108.89 -1.684 . . . . 0.0 108.89 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 68.4 m -129.88 148.97 51.81 Favored 'General case' 0 C--N 1.278 -2.503 0 C-N-CA 123.771 0.829 . . . . 0.0 109.513 -177.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.493 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -110.72 156.6 20.8 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 -178.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.445 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 91.8 m-85 -153.93 -179.59 8.0 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.459 0.704 . . . . 0.0 110.257 -177.169 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.6 -138.39 49.29 Favored Glycine 0 C--O 1.223 -0.566 0 O-C-N 123.944 0.777 . . . . 0.0 112.892 176.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.61 -3.3 89.73 Favored Glycine 0 N--CA 1.425 -2.061 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.628 177.428 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.787 HG21 ' HB ' ' A' ' 126' ' ' ILE . 79.8 t -73.99 -41.91 52.78 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 123.03 0.532 . . . . 0.0 111.464 -178.44 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.493 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -80.17 -23.17 41.23 Favored 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 119.523 -0.871 . . . . 0.0 112.203 179.57 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 13.9 m -100.97 -46.67 5.02 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 115.011 1.486 . . . . 0.0 115.011 -174.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.522 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 38.6 m-80 -94.28 -19.92 20.25 Favored 'General case' 0 CA--C 1.494 -1.185 0 C-N-CA 119.87 -0.732 . . . . 0.0 109.48 -178.695 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.659 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 86.9 m-85 -111.76 162.62 15.05 Favored 'General case' 0 N--CA 1.423 -1.808 0 C-N-CA 120.214 -0.594 . . . . 0.0 110.143 179.024 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.2 t -169.57 130.88 1.09 Allowed 'General case' 0 N--CA 1.422 -1.865 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 176.094 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.513 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -164.18 -110.37 0.24 Allowed Glycine 0 N--CA 1.412 -2.958 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 175.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.1 p -158.27 -179.58 8.24 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 124.421 1.089 . . . . 0.0 110.353 -174.122 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -133.66 146.94 31.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 C-N-CA 122.965 0.506 . . . . 0.0 109.993 177.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.64 ' HG3' ' O ' ' A' ' 80' ' ' SER . 77.9 tttt -122.14 146.25 47.41 Favored 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 -178.783 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.489 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 56.9 t80 -145.27 106.58 4.2 Favored 'General case' 0 C--N 1.307 -1.242 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 -178.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 29.9 t 54.11 38.16 28.51 Favored 'General case' 0 CA--C 1.55 0.943 0 C-N-CA 123.435 0.694 . . . . 0.0 111.268 179.525 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.35 7.81 66.96 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 120.751 -0.738 . . . . 0.0 113.552 -179.02 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.64 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 15.2 t -79.64 174.32 11.69 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.486 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.5 p -152.06 100.33 2.62 Favored 'General case' 0 C--N 1.287 -2.146 0 CA-C-O 121.125 0.488 . . . . 0.0 109.747 -178.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.489 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 3.1 p90 -144.57 161.3 44.49 Favored Pre-proline 0 C--N 1.307 -1.243 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -173.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.453 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 59.9 Cg_endo -69.93 153.82 67.74 Favored 'Trans proline' 0 C--N 1.356 0.935 0 C-N-CA 123.018 2.479 . . . . 0.0 113.129 -174.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.556 ' CD2' HD21 ' A' ' 109' ' ' LEU . 56.3 t80 -129.53 128.96 23.15 Favored Pre-proline 0 C--N 1.316 -0.87 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.754 179.066 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.452 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 74.0 Cg_endo -69.16 148.65 85.78 Favored 'Cis proline' 0 CA--C 1.547 1.148 0 C-N-CA 122.789 -1.754 . . . . 0.0 110.374 -0.786 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 7.6 t -62.81 -178.59 0.21 Allowed 'General case' 0 CA--C 1.555 1.169 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.733 -173.167 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 16.6 p -130.52 -17.09 3.34 Favored 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 115.845 -0.616 . . . . 0.0 112.489 -173.026 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 27.2 t -133.21 -80.04 0.48 Allowed 'General case' 0 N--CA 1.426 -1.664 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.389 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 179.85 -170.44 0.14 Allowed 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 -178.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.459 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 15.8 p -101.32 162.13 21.48 Favored Pre-proline 0 C--N 1.293 -1.872 0 N-CA-C 113.172 0.805 . . . . 0.0 113.172 178.376 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -63.13 163.68 22.1 Favored 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 123.309 2.673 . . . . 0.0 111.542 173.33 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.41 ' C ' ' HD2' ' A' ' 92' ' ' ARG . 3.8 tmm_? -72.81 123.48 23.45 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.901 -178.23 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 98.5 t -130.54 123.0 54.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.498 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 74.2 t -107.49 130.89 58.99 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 177.179 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.612 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 1.8 m-85 -91.77 167.83 11.89 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 106.058 -1.831 . . . . 0.0 106.058 172.589 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -132.74 54.37 1.95 Allowed 'General case' 0 C--N 1.258 -3.377 0 N-CA-C 104.845 -2.28 . . . . 0.0 104.845 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . 0.481 ' HB3' ' HG3' ' A' ' 101' ' ' LYS . 66.2 p -113.09 161.35 17.2 Favored 'General case' 0 N--CA 1.414 -2.226 0 N-CA-C 114.44 1.274 . . . . 0.0 114.44 -167.366 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 35.1 ptt180 -144.74 30.18 1.21 Allowed 'General case' 0 C--N 1.3 -1.56 0 CA-C-N 114.375 -1.284 . . . . 0.0 108.177 171.189 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.9 t -159.26 177.08 11.41 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-N 113.826 -1.533 . . . . 0.0 107.087 -179.541 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . 0.425 ' HA ' ' HB3' ' A' ' 45' ' ' HIS . 5.3 m-20 -71.26 111.48 6.64 Favored 'General case' 0 CA--C 1.5 -0.959 0 O-C-N 123.533 0.52 . . . . 0.0 109.632 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . 0.607 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 7.4 mmpt? -111.37 143.57 28.74 Favored Pre-proline 0 C--N 1.288 -2.092 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 174.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.484 ' O ' ' HD3' ' A' ' 104' ' ' PRO . 33.7 Cg_endo -67.12 144.29 68.66 Favored 'Trans proline' 0 N--CA 1.446 -1.317 0 C-N-CA 122.608 2.206 . . . . 0.0 111.95 -177.09 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 14.1 t90 -89.46 101.14 2.83 Favored Pre-proline 0 C--N 1.307 -1.248 0 N-CA-C 105.657 -1.979 . . . . 0.0 105.657 179.258 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . 0.484 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 73.2 Cg_endo -75.17 88.65 1.24 Allowed 'Trans proline' 0 N--CA 1.452 -0.926 0 C-N-CA 122.016 1.811 . . . . 0.0 112.841 -171.024 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.453 HG22 ' CD2' ' A' ' 77' ' ' TYR . 93.2 t -136.91 142.94 36.36 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.465 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.015 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.599 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.99 134.19 18.29 Favored 'General case' 0 N--CA 1.412 -2.346 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.335 178.758 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.498 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 19.0 mt -98.95 102.32 14.01 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.013 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.513 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 13.1 m-85 -79.01 65.41 4.18 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 122.955 0.502 . . . . 0.0 111.517 178.297 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.684 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.9 mm? -92.14 135.3 34.1 Favored 'General case' 0 C--O 1.205 -1.24 0 O-C-N 121.958 -0.464 . . . . 0.0 110.162 177.142 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.02 145.24 51.67 Favored Pre-proline 0 N--CA 1.418 -2.065 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.468 -176.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.522 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 24.3 Cg_endo -60.21 120.81 8.8 Favored 'Trans proline' 0 C--O 1.243 0.775 0 C-N-CA 123.402 2.735 . . . . 0.0 111.972 -177.292 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.434 ' O ' HG13 ' A' ' 30' ' ' VAL . 2.6 m -69.53 -115.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.189 -2.085 0 CA-C-N 114.436 -1.256 . . . . 0.0 112.668 177.193 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.3 m -110.92 -46.29 3.36 Favored 'General case' 0 C--N 1.29 -1.996 0 O-C-N 121.471 -0.768 . . . . 0.0 110.144 178.315 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 13.3 t -86.1 31.18 0.64 Allowed 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.898 -173.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -95.18 131.69 40.95 Favored 'General case' 0 N--CA 1.423 -1.803 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.421 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -168.66 139.82 5.85 Favored Glycine 0 N--CA 1.432 -1.579 0 C-N-CA 120.331 -0.938 . . . . 0.0 111.808 179.277 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 57.49 -144.48 40.38 Favored Glycine 0 CA--C 1.488 -1.607 0 C-N-CA 123.914 0.769 . . . . 0.0 113.072 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -58.67 94.48 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 122.821 1.296 . . . . 0.0 111.995 -177.559 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.16 -22.53 16.14 Favored 'General case' 0 C--N 1.297 -1.691 0 CA-C-N 114.774 -1.103 . . . . 0.0 111.398 -176.507 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.473 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 59.0 mt -136.48 137.74 47.49 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 107.853 -1.165 . . . . 0.0 107.853 177.389 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.481 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.6 mmpt? -112.0 139.59 47.38 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-O 120.831 0.348 . . . . 0.0 111.793 179.201 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.21 120.52 16.02 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 178.429 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.57 -5.54 64.7 Favored Glycine 0 C--N 1.309 -0.923 0 N-CA-C 111.733 -0.547 . . . . 0.0 111.733 -176.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 34.1 t -90.23 142.91 27.26 Favored 'General case' 0 C--O 1.252 1.194 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.243 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 30.1 tp -71.86 133.41 45.44 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 177.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.787 ' HB ' HG21 ' A' ' 67' ' ' VAL . 40.6 pt -118.8 -24.71 3.08 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.039 0 C-N-CA 120.347 -0.541 . . . . 0.0 112.28 -178.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . 0.445 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -163.97 164.38 23.2 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 120.966 -0.293 . . . . 0.0 110.449 -178.018 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 55.4 t -140.17 114.29 6.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 178.12 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.471 HD11 HD21 ' A' ' 107' ' ' LEU . 56.9 mt -118.26 147.08 43.79 Favored 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.453 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.8 mp -129.23 126.36 63.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 C-N-CA 120.16 -0.616 . . . . 0.0 110.065 178.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.574 HD13 HG23 ' A' ' 56' ' ' VAL . 1.4 pp -92.26 150.56 20.8 Favored 'General case' 0 CA--C 1.476 -1.897 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 173.332 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 56.4 ttp180 -115.11 116.69 28.81 Favored 'General case' 0 C--N 1.25 -3.727 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 176.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -100.51 120.25 39.73 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 -175.1 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 5.4 m -133.58 144.26 49.19 Favored 'General case' 0 C--N 1.287 -2.125 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.648 ' CB ' HG23 ' A' ' 52' ' ' ILE . 8.0 p30 . . . . . 0 N--CA 1.436 -1.137 0 C-N-CA 118.227 -1.389 . . . . 0.0 111.877 174.437 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 . . . . . 0 CA--C 1.491 -1.326 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -131.39 145.4 51.8 Favored 'General case' 0 N--CA 1.415 -2.193 0 C-N-CA 118.549 -1.26 . . . . 0.0 111.798 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 8.6 m-30 -113.77 126.75 55.56 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 108.266 -1.012 . . . . 0.0 108.266 -175.374 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 48.4 t -89.72 133.59 31.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 123.544 0.528 . . . . 0.0 110.304 -179.379 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 58.0 m95 -120.04 100.46 7.22 Favored 'General case' 0 C--N 1.285 -2.236 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 -179.678 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -82.77 111.83 19.05 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 106.608 -1.627 . . . . 0.0 106.608 178.112 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.445 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 22.6 mm -86.72 121.57 37.81 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 -176.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -118.26 154.66 31.9 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 177.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 121' ' ' LYS . . . -80.96 128.0 33.2 Favored 'General case' 0 N--CA 1.406 -2.661 0 CA-C-N 115.243 -0.889 . . . . 0.0 108.699 176.167 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 37.0 t-20 -88.87 -8.9 53.43 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 106.719 -1.585 . . . . 0.0 106.719 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -156.0 139.75 16.13 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 113.679 -1.6 . . . . 0.0 109.605 -176.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -77.86 147.95 34.89 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 124.538 1.135 . . . . 0.0 110.067 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.494 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 73.7 t -123.58 138.1 54.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.913 -176.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.7 t -118.65 136.14 56.8 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.576 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.502 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 76.3 t -100.0 104.4 28.64 Favored Pre-proline 0 C--N 1.285 -2.224 0 C-N-CA 123.202 0.601 . . . . 0.0 109.416 178.26 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.454 ' HG3' HG13 ' A' ' 27' ' ' VAL . 33.7 Cg_endo -69.78 -25.12 28.84 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.121 1.881 . . . . 0.0 111.02 176.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . 0.451 ' HB ' HG12 ' A' ' 156' ' ' VAL 0.274 6.0 t . . . . . 0 C--O 1.247 0.928 0 O-C-N 124.638 1.211 . . . . 0.0 113.204 176.712 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.449 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.432 -1.329 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 65.1 m -130.73 158.3 40.49 Favored 'General case' 0 C--N 1.287 -2.112 0 C-N-CA 120.013 -0.675 . . . . 0.0 111.272 -172.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.457 ' HD2' ' O ' ' A' ' 5' ' ' THR . 0.0 OUTLIER -145.91 164.41 32.07 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.608 -175.002 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.556 HG22 HG22 ' A' ' 20' ' ' VAL . 68.1 p -99.91 -179.52 4.19 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-O 121.449 0.642 . . . . 0.0 111.787 -178.407 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.88 -20.44 38.83 Favored 'General case' 0 C--N 1.296 -1.72 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.108 177.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -88.45 -25.83 22.43 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.094 -0.957 . . . . 0.0 112.186 -179.758 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 128.35 8.47 4.02 Favored Glycine 0 CA--C 1.496 -1.107 0 C-N-CA 119.354 -1.403 . . . . 0.0 114.241 170.232 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 m -83.49 98.86 9.76 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 -179.174 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.05 109.1 21.19 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.888 179.372 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.449 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 64.8 mt -86.17 120.24 72.24 Favored Pre-proline 0 C--N 1.305 -1.359 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 -177.673 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -79.06 168.39 20.64 Favored 'Trans proline' 0 C--O 1.252 1.204 0 C-N-CA 122.65 2.233 . . . . 0.0 110.742 178.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.3 mt -71.14 128.09 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.3 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 178.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 139.37 -8.68 3.19 Favored Glycine 0 C--N 1.296 -1.681 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -176.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.58 148.36 22.13 Favored Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.351 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.98 -174.05 46.15 Favored Glycine 0 N--CA 1.435 -1.37 0 C-N-CA 120.493 -0.861 . . . . 0.0 111.156 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 28.8 p -143.02 151.02 40.37 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.2 162.33 33.26 Favored 'General case' 0 N--CA 1.415 -2.223 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 -179.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -107.72 117.01 32.99 Favored 'General case' 0 C--N 1.278 -2.52 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 176.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.556 HG22 HG22 ' A' ' 5' ' ' THR . 40.7 t -105.43 132.04 53.31 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.778 0 CA-C-N 115.484 -0.78 . . . . 0.0 109.138 178.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.4 m-85 -118.52 123.04 44.13 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 -179.002 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.482 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.4 p -131.28 134.55 60.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.005 -176.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 5.6 p30 -98.03 119.17 36.18 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 121.737 0.78 . . . . 0.0 110.585 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.422 HD11 HG22 ' A' ' 36' ' ' VAL . 2.8 mm? -99.45 160.78 14.03 Favored 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 114.59 -1.187 . . . . 0.0 109.13 -177.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.03 121.51 46.68 Favored Pre-proline 0 C--O 1.212 -0.884 0 O-C-N 124.478 1.111 . . . . 0.0 109.076 176.108 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 73.4 Cg_endo -74.31 -2.62 12.61 Favored 'Trans proline' 0 C--O 1.22 -0.42 0 C-N-CA 122.811 2.341 . . . . 0.0 113.277 -175.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.446 HG13 ' HG3' ' A' ' 157' ' ' PRO . 86.0 t -126.54 109.74 21.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.494 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 4.2 t -145.05 110.82 1.15 Allowed 'Isoleucine or valine' 0 C--O 1.188 -2.167 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -177.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.654 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -98.32 153.12 18.76 Favored 'General case' 0 C--N 1.272 -2.789 0 C-N-CA 123.305 0.642 . . . . 0.0 111.766 -178.346 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.412 HG22 ' O ' ' A' ' 112' ' ' VAL . 40.5 t -46.8 115.74 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 123.318 0.647 . . . . 0.0 111.524 175.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 109.01 -8.13 33.37 Favored Glycine 0 C--N 1.322 -0.227 0 CA-C-N 115.445 -0.798 . . . . 0.0 112.558 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.654 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.3 OUTLIER -65.98 -177.38 0.48 Allowed 'General case' 0 C--N 1.317 -0.831 0 C-N-CA 124.468 1.107 . . . . 0.0 112.069 177.725 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -137.43 95.34 3.06 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 177.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.616 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 25.3 tp -93.5 146.29 23.89 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -177.466 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.2 t -132.9 120.01 39.46 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.75 0 CA-C-O 120.978 0.418 . . . . 0.0 110.184 -176.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.613 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 55.0 t -92.84 88.63 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.338 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 172.763 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -82.26 106.77 14.42 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.25 0.548 . . . . 0.0 110.63 -176.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 89.6 mt -90.27 -0.76 57.78 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.986 -177.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.7 t -78.18 0.88 23.25 Favored 'General case' 0 C--N 1.309 -1.184 0 CA-C-O 122.271 1.034 . . . . 0.0 109.134 -179.227 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.6 p -125.3 5.57 7.74 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.848 175.539 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.482 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 51.4 mm-40 -122.61 -26.59 4.51 Favored 'General case' 0 CA--C 1.501 -0.934 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.586 -173.812 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 18.3 mt -132.57 139.64 49.4 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 -175.27 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.401 ' HB2' ' HE3' ' A' ' 4' ' ' LYS . 70.2 m-85 -138.28 144.71 40.61 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -175.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 72.7 m -121.32 135.11 55.14 Favored 'General case' 0 C--N 1.284 -2.275 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 177.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 22.8 p-80 -134.13 163.08 30.39 Favored 'General case' 0 C--N 1.309 -1.195 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -175.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.427 ' HB2' ' OD2' ' A' ' 54' ' ' ASP . 16.1 t-20 -113.25 111.46 22.08 Favored 'General case' 0 N--CA 1.423 -1.786 0 C-N-CA 118.574 -1.25 . . . . 0.0 111.047 179.187 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 17.4 p-10 -85.74 -4.7 59.23 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 124.573 1.149 . . . . 0.0 111.224 179.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.458 ' HB2' HD13 ' A' ' 52' ' ' ILE . 85.4 m-85 -143.97 65.46 13.9 Favored Pre-proline 0 N--CA 1.477 0.877 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 174.575 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.452 ' HB2' ' HB2' ' A' ' 98' ' ' ARG . 68.5 Cg_endo -72.32 3.98 3.71 Favored 'Trans proline' 0 N--CA 1.481 0.74 0 C-N-CA 123.498 2.799 . . . . 0.0 115.295 -169.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -114.33 -28.51 7.22 Favored 'General case' 0 C--N 1.285 -2.227 0 CA-C-O 121.735 0.779 . . . . 0.0 110.495 -178.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.557 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.0 OUTLIER -101.74 -30.07 11.53 Favored 'General case' 0 C--N 1.28 -2.455 0 CA-C-N 115.046 -0.979 . . . . 0.0 111.126 -174.063 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.557 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.4 mp -121.0 132.37 70.65 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.661 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -176.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 15.1 t -79.46 145.96 33.0 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 177.768 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.521 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 1.2 m-20 -79.5 109.57 14.0 Favored 'General case' 0 C--N 1.282 -2.368 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 -179.496 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -150.42 138.34 20.06 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 -170.705 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.444 HG23 HD13 ' A' ' 131' ' ' LEU . 14.9 p -151.31 153.45 9.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -178.6 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.11 128.83 12.39 Favored 'General case' 0 C--O 1.208 -1.109 0 CA-C-O 119.381 -0.343 . . . . 0.0 110.125 175.75 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.516 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 49.5 tp -75.24 109.2 8.54 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.828 0.823 . . . . 0.0 109.277 174.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 7.0 tp60 -55.47 -54.16 47.34 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 126.479 1.912 . . . . 0.0 111.461 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 8.4 ptp180 -169.88 159.6 7.97 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 -176.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.408 ' H ' HG22 ' A' ' 86' ' ' THR . . . -136.47 144.29 15.94 Favored Glycine 0 N--CA 1.406 -3.324 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 73.6 m -132.88 150.58 52.15 Favored 'General case' 0 C--N 1.281 -2.406 0 C-N-CA 123.459 0.704 . . . . 0.0 109.831 -177.53 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.524 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -113.51 158.51 20.64 Favored 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 179.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.5 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . 98.8 m-85 -155.2 -179.74 8.37 Favored 'General case' 0 C--N 1.342 0.276 0 C-N-CA 124.436 1.094 . . . . 0.0 109.678 -177.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.56 -142.22 45.64 Favored Glycine 0 C--O 1.238 0.383 0 O-C-N 123.794 0.684 . . . . 0.0 112.839 176.429 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.455 ' HA3' ' O ' ' A' ' 119' ' ' ALA . . . -77.71 -7.81 87.26 Favored Glycine 0 N--CA 1.435 -1.387 0 C-N-CA 120.77 -0.729 . . . . 0.0 111.482 177.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.824 HG21 ' HB ' ' A' ' 126' ' ' ILE . 99.3 t -71.0 -42.14 76.94 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.368 0 C-N-CA 123.279 0.632 . . . . 0.0 111.428 -179.207 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.524 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -85.41 -14.82 45.08 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 118.554 -1.258 . . . . 0.0 112.405 178.851 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 8.8 t -100.33 -48.89 4.43 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 120.324 -0.55 . . . . 0.0 111.651 -175.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.47 ' O ' HG22 ' A' ' 112' ' ' VAL . 35.1 m-80 -95.67 -22.24 17.69 Favored 'General case' 0 CA--C 1.497 -1.087 0 C-N-CA 120.472 -0.491 . . . . 0.0 110.187 -176.39 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.561 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 95.8 m-85 -109.43 154.02 23.19 Favored 'General case' 0 N--CA 1.423 -1.778 0 C-N-CA 120.061 -0.656 . . . . 0.0 110.78 -179.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.9 t -165.0 121.1 1.42 Allowed 'General case' 0 N--CA 1.416 -2.126 0 N-CA-C 106.822 -1.548 . . . . 0.0 106.822 174.117 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.422 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -152.83 -113.29 0.53 Allowed Glycine 0 N--CA 1.408 -3.232 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 177.673 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.466 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.0 OUTLIER -152.75 179.3 8.75 Favored 'General case' 0 C--N 1.287 -2.128 0 C-N-CA 123.101 0.56 . . . . 0.0 110.557 -174.718 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.6 p -136.69 145.43 30.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 C-N-CA 123.004 0.522 . . . . 0.0 109.653 178.563 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.626 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.3 tttt -124.54 144.24 50.24 Favored 'General case' 0 N--CA 1.417 -2.094 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.49 ' CD2' HG22 ' A' ' 105' ' ' VAL . 62.7 t80 -145.56 115.15 7.23 Favored 'General case' 0 C--N 1.289 -2.047 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 -178.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 15.1 m 52.76 40.58 30.75 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 114.187 1.18 . . . . 0.0 114.187 175.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 80.76 10.48 85.09 Favored Glycine 0 N--CA 1.442 -0.96 0 C-N-CA 119.986 -1.102 . . . . 0.0 112.606 179.439 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.626 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 8.9 t -85.41 -179.7 6.99 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 177.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 31.5 t -157.03 112.22 2.82 Favored 'General case' 0 C--N 1.287 -2.122 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -178.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.456 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 4.9 p90 -155.27 161.51 29.3 Favored Pre-proline 0 CA--C 1.556 1.182 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -175.463 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.466 ' HA ' HG22 ' A' ' 74' ' ' THR . 56.5 Cg_endo -69.86 153.19 68.76 Favored 'Trans proline' 0 C--N 1.36 1.173 0 C-N-CA 122.979 2.453 . . . . 0.0 112.931 -177.643 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.501 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 63.2 t80 -124.57 130.55 24.25 Favored Pre-proline 0 N--CA 1.442 -0.862 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.469 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.501 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 72.2 Cg_endo -69.92 151.62 92.01 Favored 'Cis proline' 0 CA--C 1.542 0.897 0 C-N-CA 122.999 -1.667 . . . . 0.0 110.124 -1.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.408 HG22 ' H ' ' A' ' 61' ' ' GLY . 8.9 t -58.36 -178.0 0.04 OUTLIER 'General case' 0 CA--C 1.552 1.02 0 CA-C-O 122.088 0.947 . . . . 0.0 112.9 -173.711 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 10.1 p -119.43 -20.8 7.69 Favored 'General case' 0 N--CA 1.423 -1.812 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.778 -175.048 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 23.1 t -141.95 -82.47 0.2 Allowed 'General case' 0 N--CA 1.432 -1.336 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.964 -177.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -170.89 -172.87 1.22 Allowed 'General case' 0 C--O 1.241 0.631 0 N-CA-C 104.536 -2.394 . . . . 0.0 104.536 -177.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.516 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 42.0 p -100.9 158.18 32.29 Favored Pre-proline 0 C--N 1.293 -1.86 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.375 176.39 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -59.26 161.2 17.17 Favored 'Trans proline' 0 C--O 1.243 0.771 0 C-N-CA 123.16 2.573 . . . . 0.0 110.769 173.536 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.2 tmm_? -69.25 120.64 15.4 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.445 -178.438 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 72.4 t -128.09 124.68 63.05 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-O 121.633 0.73 . . . . 0.0 111.05 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 70.5 t -112.64 126.16 70.0 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.893 0 CA-C-N 115.095 -0.957 . . . . 0.0 108.853 176.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.521 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.2 m-85 -72.43 110.63 6.97 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 175.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -81.79 61.76 5.29 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.328 -0.989 . . . . 0.0 108.328 176.624 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.7 m -142.35 -168.52 2.75 Favored 'General case' 0 N--CA 1.419 -1.982 0 C-N-CA 125.34 1.456 . . . . 0.0 107.685 -177.481 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.452 ' HB2' ' HB2' ' A' ' 49' ' ' PRO . 34.0 ptt180 -163.23 34.76 0.09 Allowed 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 106.465 -1.68 . . . . 0.0 106.465 176.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.4 t -160.45 175.9 12.25 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 114.755 -1.112 . . . . 0.0 109.036 -168.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -70.7 114.01 8.35 Favored 'General case' 0 C--O 1.239 0.513 0 CA-C-O 122.021 0.915 . . . . 0.0 111.746 -176.297 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.6 mptm? -127.48 143.52 47.64 Favored Pre-proline 0 C--N 1.292 -1.907 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.382 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -63.29 147.22 93.92 Favored 'Trans proline' 0 C--O 1.247 0.961 0 C-N-CA 122.693 2.262 . . . . 0.0 111.78 177.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . 0.509 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 9.6 t90 -86.46 111.85 42.21 Favored Pre-proline 0 C--N 1.304 -1.378 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 -178.091 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_endo -82.04 87.12 1.45 Allowed 'Trans proline' 0 N--CA 1.439 -1.698 0 C-N-CA 121.031 1.154 . . . . 0.0 112.122 -172.245 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.49 HG22 ' CD2' ' A' ' 77' ' ' TYR . 80.2 t -137.56 146.33 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.668 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 176.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.613 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -153.66 132.28 12.21 Favored 'General case' 0 C--N 1.287 -2.143 0 O-C-N 123.41 0.444 . . . . 0.0 110.428 178.049 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.477 HD21 HD11 ' A' ' 129' ' ' LEU . 16.9 mt -97.01 101.02 12.52 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.422 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 53.7 m-85 -79.33 73.04 5.96 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 120.884 0.373 . . . . 0.0 110.673 177.421 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.63 ' HG ' HG13 ' A' ' 67' ' ' VAL . 2.7 mm? -87.08 150.62 23.88 Favored 'General case' 0 C--O 1.192 -1.966 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.474 176.575 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.57 139.57 13.15 Favored Pre-proline 0 C--N 1.278 -2.501 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.611 -179.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 18.0 Cg_endo -60.16 121.55 9.97 Favored 'Trans proline' 0 C--O 1.247 0.969 0 C-N-CA 123.189 2.593 . . . . 0.0 111.87 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.47 HG22 ' O ' ' A' ' 70' ' ' ASN . 3.5 m -70.3 -123.08 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.182 -2.478 0 CA-C-N 114.77 -1.105 . . . . 0.0 111.478 175.655 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 30.9 m -111.95 -19.39 12.38 Favored 'General case' 0 C--N 1.282 -2.331 0 CA-C-O 122.548 1.166 . . . . 0.0 108.877 177.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.446 ' H ' HG23 ' A' ' 112' ' ' VAL . 1.2 m -85.37 6.79 24.99 Favored 'General case' 0 N--CA 1.405 -2.696 0 CA-C-N 113.595 -1.639 . . . . 0.0 112.568 -173.301 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -97.6 138.18 35.4 Favored 'General case' 0 C--N 1.266 -3.051 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.192 -172.242 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -177.26 124.16 0.93 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.173 -1.013 . . . . 0.0 112.671 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.11 -147.72 50.34 Favored Glycine 0 CA--C 1.488 -1.645 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 -175.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.408 ' CG1' ' HE3' ' A' ' 121' ' ' LYS . 93.9 t -53.1 111.33 0.26 Allowed 'Isoleucine or valine' 0 C--O 1.248 0.997 0 CA-C-O 121.709 0.766 . . . . 0.0 110.741 -178.717 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . 0.455 ' O ' ' HA3' ' A' ' 66' ' ' GLY . . . -113.51 -22.66 10.21 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-N 114.212 -1.358 . . . . 0.0 111.619 -179.459 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.472 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.7 mt -135.01 137.72 50.13 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 178.374 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.575 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 5.3 mmpt? -112.49 141.48 46.18 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 121.144 0.497 . . . . 0.0 111.602 177.811 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 0.408 ' H ' ' HB3' ' A' ' 153' ' ' ASP . . . -72.03 134.8 46.08 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.87 179.248 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 85.18 -1.23 88.78 Favored Glycine 0 C--N 1.312 -0.79 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.005 -179.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 59.8 m -96.5 148.73 22.52 Favored 'General case' 0 N--CA 1.421 -1.906 0 CA-C-O 120.94 0.4 . . . . 0.0 110.066 179.157 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.447 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -77.83 122.59 25.64 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -179.226 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.824 ' HB ' HG21 ' A' ' 67' ' ' VAL . 30.8 pt -109.42 -27.19 2.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 N-CA-C 112.853 0.686 . . . . 0.0 112.853 -177.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . 0.421 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.49 166.68 26.79 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 -178.01 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.447 HG23 HD11 ' A' ' 125' ' ' LEU . 74.6 t -142.5 112.78 2.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 179.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.477 HD11 HD21 ' A' ' 107' ' ' LEU . 58.3 mt -115.87 146.77 41.73 Favored 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 178.786 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.496 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.7 mp -128.61 125.22 63.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 C-N-CA 120.028 -0.669 . . . . 0.0 109.227 178.541 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.444 HD13 HG23 ' A' ' 56' ' ' VAL . 1.3 pp -91.0 148.96 22.04 Favored 'General case' 0 CA--C 1.478 -1.821 0 N-CA-C 106.004 -1.85 . . . . 0.0 106.004 174.453 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 32.1 ttt180 -118.78 123.91 45.95 Favored 'General case' 0 C--N 1.253 -3.592 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 176.189 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.476 ' HB2' ' O ' ' A' ' 142' ' ' PHE . 13.3 mm-40 -79.91 143.35 34.33 Favored 'General case' 0 N--CA 1.411 -2.376 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.525 179.463 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 17.7 m -154.33 127.36 8.3 Favored 'General case' 0 C--N 1.269 -2.929 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 170.282 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.486 ' HB2' HG23 ' A' ' 52' ' ' ILE . 15.7 p30 . . . . . 0 C--N 1.299 -1.588 0 C-N-CA 119.715 -0.794 . . . . 0.0 111.075 -178.713 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . 0.476 ' O ' ' HB2' ' A' ' 133' ' ' GLN . 95.8 m-85 . . . . . 0 CA--C 1.513 -0.48 0 CA-C-O 120.918 0.39 . . . . 0.0 110.23 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 11.9 pt20 -126.79 144.62 50.9 Favored 'General case' 0 C--N 1.296 -1.757 0 C-N-CA 119.72 -0.792 . . . . 0.0 110.193 -179.046 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 11.0 m-30 -113.74 128.93 56.61 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 -175.278 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 47.4 t -90.96 134.06 30.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 123.478 0.486 . . . . 0.0 110.35 -177.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 59.9 m95 -120.69 98.6 6.1 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 -179.477 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 45.1 m-80 -81.21 110.85 17.08 Favored 'General case' 0 C--N 1.288 -2.086 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.446 HG22 HD11 ' A' ' 126' ' ' ILE . 23.3 mm -85.68 122.4 38.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 -177.534 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -118.0 150.98 38.37 Favored 'General case' 0 C--N 1.295 -1.77 0 C-N-CA 123.552 0.741 . . . . 0.0 109.012 178.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.08 130.36 35.06 Favored 'General case' 0 N--CA 1.413 -2.317 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 176.522 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 29.8 t-20 -89.55 -15.7 32.31 Favored 'General case' 0 C--N 1.288 -2.1 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 -177.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -149.3 141.88 24.42 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 114.059 -1.428 . . . . 0.0 109.207 -174.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . 0.408 ' HB3' ' H ' ' A' ' 122' ' ' ALA . 8.7 p-10 -85.94 138.03 32.3 Favored 'General case' 0 C--N 1.314 -0.949 0 O-C-N 123.944 0.777 . . . . 0.0 111.561 -178.474 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.472 ' HB ' ' HB ' ' A' ' 120' ' ' ILE . 75.1 t -112.21 141.42 27.79 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-N 115.015 -0.993 . . . . 0.0 111.894 -173.105 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 5.1 t -119.69 139.05 48.31 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.131 0 N-CA-C 108.12 -1.066 . . . . 0.0 108.12 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.494 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 62.1 t -103.2 102.24 27.23 Favored Pre-proline 0 C--N 1.285 -2.197 0 C-N-CA 123.89 0.876 . . . . 0.0 110.065 178.414 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.463 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 34.5 Cg_endo -68.3 -22.68 39.57 Favored 'Trans proline' 0 C--O 1.222 -0.305 0 C-N-CA 122.144 1.896 . . . . 0.0 111.589 178.278 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . 0.474 ' HB ' HG12 ' A' ' 156' ' ' VAL 0.25 7.4 t . . . . . 0 CA--C 1.547 0.85 0 C-N-CA 124.791 1.236 . . . . 0.0 113.714 175.69 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.506 ' HB3' ' CE1' ' A' ' 45' ' ' HIS . . . . . . . . 0 N--CA 1.429 -1.519 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.528 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 13.5 t -157.12 160.66 39.05 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.294 -175.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.27 164.3 31.81 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.455 -177.324 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.552 HG22 HG22 ' A' ' 20' ' ' VAL . 73.8 p -102.22 177.85 4.76 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-O 121.427 0.632 . . . . 0.0 111.024 -179.71 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.72 -18.27 44.92 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 114.71 -1.132 . . . . 0.0 109.347 179.131 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -91.82 -24.42 19.38 Favored 'General case' 0 N--CA 1.432 -1.363 0 CA-C-N 114.893 -1.049 . . . . 0.0 111.822 -177.621 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 120.17 34.46 0.96 Allowed Glycine 0 CA--C 1.488 -1.614 0 C-N-CA 119.308 -1.425 . . . . 0.0 113.315 170.005 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -110.13 98.93 8.09 Favored 'General case' 0 N--CA 1.423 -1.823 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 176.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -90.97 123.18 34.26 Favored 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 115.157 -0.929 . . . . 0.0 109.451 177.03 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.403 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 68.3 mt -100.39 116.22 64.62 Favored Pre-proline 0 C--N 1.288 -2.07 0 N-CA-C 109.484 -0.562 . . . . 0.0 109.484 177.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -75.53 164.78 31.78 Favored 'Trans proline' 0 C--O 1.249 1.055 0 C-N-CA 122.661 2.241 . . . . 0.0 110.85 176.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.4 mt -69.49 121.03 18.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 148.77 -6.0 0.85 Allowed Glycine 0 C--N 1.305 -1.162 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 -174.142 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.0 149.39 23.81 Favored Glycine 0 N--CA 1.431 -1.665 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 176.83 178.57 46.68 Favored Glycine 0 N--CA 1.418 -2.502 0 C-N-CA 119.133 -1.508 . . . . 0.0 112.132 -179.218 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.416 ' HA ' ' O ' ' A' ' 145' ' ' VAL . 7.9 p -140.67 142.08 34.96 Favored 'General case' 0 C--N 1.285 -2.226 0 N-CA-C 108.795 -0.816 . . . . 0.0 108.795 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.41 153.06 51.2 Favored 'General case' 0 CA--C 1.474 -1.969 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 -178.018 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -98.68 116.67 31.43 Favored 'General case' 0 C--N 1.278 -2.53 0 CA-C-N 114.751 -1.113 . . . . 0.0 108.19 174.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.552 HG22 HG22 ' A' ' 5' ' ' THR . 26.1 t -103.76 127.39 57.9 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.573 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 54.2 m-85 -110.84 125.27 53.42 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 121.336 -0.146 . . . . 0.0 110.954 -179.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.486 HG22 ' HG3' ' A' ' 41' ' ' GLN . 21.2 t -126.93 121.8 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.036 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -176.691 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -85.13 120.88 27.12 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-O 121.411 0.624 . . . . 0.0 110.432 175.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 50.7 mt -109.93 160.9 16.0 Favored 'General case' 0 N--CA 1.424 -1.755 0 CA-C-N 114.452 -1.249 . . . . 0.0 108.251 -175.263 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.5 121.18 58.61 Favored Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 124.65 1.219 . . . . 0.0 109.411 -179.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 59.2 Cg_endo -72.77 -3.39 13.46 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.86 2.373 . . . . 0.0 113.183 -177.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.401 HG13 ' HG3' ' A' ' 157' ' ' PRO . 65.1 t -122.21 110.58 27.53 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 178.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.7 t -141.78 108.87 2.07 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.105 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 -178.531 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.766 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -98.05 152.37 19.37 Favored 'General case' 0 C--N 1.277 -2.555 0 C-N-CA 122.861 0.464 . . . . 0.0 112.135 -179.561 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.45 HG13 ' O ' ' A' ' 112' ' ' VAL . 30.5 t -46.61 117.71 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.036 0 C-N-CA 123.784 0.834 . . . . 0.0 111.578 177.427 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.1 3.79 55.59 Favored Glycine 0 C--O 1.235 0.211 0 CA-C-N 115.527 -0.76 . . . . 0.0 112.848 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.766 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -76.11 -176.65 3.61 Favored 'General case' 0 C--N 1.311 -1.081 0 C-N-CA 124.49 1.116 . . . . 0.0 110.113 178.249 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 -130.73 90.57 2.93 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 178.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.658 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 21.9 tp -93.87 141.49 28.45 Favored 'General case' 0 C--N 1.29 -2.018 0 C-N-CA 119.062 -1.055 . . . . 0.0 109.003 178.746 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.6 t -134.35 122.62 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.813 0 CA-C-N 116.25 -0.432 . . . . 0.0 109.842 -174.205 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.609 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 57.0 t -92.43 87.96 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.35 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 172.337 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.548 ' O ' ' HG2' ' A' ' 41' ' ' GLN . 29.3 t70 -83.97 101.42 11.71 Favored 'General case' 0 CA--C 1.488 -1.429 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.809 -176.395 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.9 mt -80.9 -7.22 59.42 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.916 -177.666 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 24.8 t -71.72 -0.04 10.0 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.072 179.104 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 4.1 p -134.3 10.3 3.79 Favored 'General case' 0 N--CA 1.419 -1.982 0 CA-C-O 121.207 0.527 . . . . 0.0 110.049 176.082 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.548 ' HG2' ' O ' ' A' ' 37' ' ' ASP . 35.0 mm-40 -125.39 -20.96 4.65 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 -176.852 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.8 mt -134.6 136.77 52.19 Favored 'Isoleucine or valine' 0 C--O 1.239 0.517 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -177.396 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -138.43 120.44 15.54 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -175.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.528 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 73.8 m -102.37 143.07 32.58 Favored 'General case' 0 C--N 1.282 -2.354 0 CA-C-O 121.451 0.643 . . . . 0.0 109.962 -178.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . 0.506 ' CE1' ' HB3' ' A' ' 2' ' ' ALA . 6.8 p80 -119.22 139.66 51.5 Favored 'General case' 0 C--N 1.288 -2.105 0 CA-C-O 121.73 0.776 . . . . 0.0 111.03 -176.393 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.629 ' HB2' ' CG ' ' A' ' 54' ' ' ASP . 3.7 p-10 -108.36 100.64 9.91 Favored 'General case' 0 N--CA 1.395 -3.202 0 CA-C-O 123.37 1.557 . . . . 0.0 107.436 -176.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -78.3 -32.94 49.62 Favored 'General case' 0 C--N 1.299 -1.592 0 CA-C-N 112.755 -2.02 . . . . 0.0 111.648 -168.495 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.401 ' HB2' ' HB ' ' A' ' 52' ' ' ILE . 39.2 m-85 -129.38 64.61 71.92 Favored Pre-proline 0 C--N 1.308 -1.208 0 C-N-CA 119.456 -0.898 . . . . 0.0 111.896 -174.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.58 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 56.2 Cg_endo -67.45 -7.98 20.77 Favored 'Trans proline' 0 N--CA 1.486 1.088 0 C-N-CA 122.847 2.365 . . . . 0.0 114.415 -173.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -110.62 -15.37 13.88 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 120.672 -0.411 . . . . 0.0 111.493 -176.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.554 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.8 m -115.9 -25.33 7.77 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-O 122.182 0.992 . . . . 0.0 109.779 -173.16 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.554 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.6 mp -130.67 150.12 34.28 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.996 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 -176.64 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.9 t -94.35 125.23 38.86 Favored 'General case' 0 N--CA 1.413 -2.299 0 N-CA-C 104.154 -2.535 . . . . 0.0 104.154 171.44 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.629 ' CG ' ' HB2' ' A' ' 46' ' ' ASN . 9.9 m-20 -91.71 106.16 18.27 Favored 'General case' 0 C--N 1.259 -3.336 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 -178.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.505 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 9.5 t80 -130.85 135.24 47.53 Favored 'General case' 0 C--N 1.287 -2.123 0 CA-C-N 114.49 -1.232 . . . . 0.0 109.233 -174.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.573 ' CG2' ' HG ' ' A' ' 131' ' ' LEU . 13.7 p -141.85 150.43 19.26 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.173 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.256 -176.004 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.1 p -150.17 129.97 13.29 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 123.894 0.878 . . . . 0.0 108.883 176.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.493 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 36.9 tp -65.6 112.63 3.73 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 172.309 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.477 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 2.7 tp-100 -60.66 -59.39 5.47 Favored 'General case' 0 C--O 1.204 -1.339 0 CA-C-N 113.257 -1.792 . . . . 0.0 109.915 -177.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -166.74 155.74 10.67 Favored 'General case' 0 N--CA 1.419 -1.999 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -175.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -135.44 153.73 21.39 Favored Glycine 0 N--CA 1.412 -2.92 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 -177.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.414 ' HA ' ' HB3' ' A' ' 85' ' ' PRO . 24.1 m -138.61 144.58 39.82 Favored 'General case' 0 C--N 1.281 -2.4 0 C-N-CA 123.402 0.681 . . . . 0.0 110.595 -178.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.57 ' HB1' HG23 ' A' ' 67' ' ' VAL . . . -106.64 157.96 17.31 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 125.081 1.353 . . . . 0.0 107.741 -179.52 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.787 ' O ' HG22 ' A' ' 67' ' ' VAL . 94.4 m-85 -155.74 178.15 10.58 Favored 'General case' 0 C--O 1.208 -1.113 0 CA-C-N 118.901 0.773 . . . . 0.0 111.781 -177.037 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 53.39 -127.49 36.7 Favored Glycine 0 C--O 1.217 -0.924 0 CA-C-O 121.423 0.457 . . . . 0.0 112.883 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.73 -9.16 83.44 Favored Glycine 0 N--CA 1.42 -2.38 0 C-N-CA 120.388 -0.91 . . . . 0.0 113.132 178.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.787 HG22 ' O ' ' A' ' 64' ' ' TYR . 12.8 m -78.49 -27.14 14.13 Favored 'Isoleucine or valine' 0 C--O 1.201 -1.468 0 CA-C-N 118.515 1.157 . . . . 0.0 112.562 -175.27 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.551 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -91.32 -15.04 29.72 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 119.91 -0.716 . . . . 0.0 111.862 176.146 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 26.5 t -101.18 -59.04 1.77 Allowed 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.524 -176.2 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.581 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 34.6 m-80 -87.14 -24.42 24.51 Favored 'General case' 0 CA--C 1.486 -1.486 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -176.147 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.574 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 85.5 m-85 -111.43 163.63 13.81 Favored 'General case' 0 C--N 1.286 -2.186 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.064 -178.592 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.2 t -179.95 134.21 0.11 Allowed 'General case' 0 N--CA 1.426 -1.645 0 N-CA-C 107.235 -1.395 . . . . 0.0 107.235 178.035 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.467 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -167.31 -109.82 0.22 Allowed Glycine 0 N--CA 1.406 -3.355 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 174.765 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 3.1 p -149.65 177.04 10.13 Favored 'General case' 0 C--N 1.275 -2.631 0 C-N-CA 122.778 0.431 . . . . 0.0 111.019 -174.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -132.9 140.16 47.98 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.116 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.722 ' HG3' ' O ' ' A' ' 80' ' ' SER . 82.6 tttt -120.72 145.36 47.57 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.398 -177.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.487 ' CD2' HG22 ' A' ' 105' ' ' VAL . 43.2 t80 -146.62 109.47 4.63 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.335 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 11.2 t 49.14 43.33 22.43 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 124.526 1.131 . . . . 0.0 111.912 178.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.9 11.95 62.81 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.22 -0.991 . . . . 0.0 113.107 178.221 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.722 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 23.5 t -88.77 -179.73 6.05 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 175.217 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.3 t -167.3 107.45 0.6 Allowed 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 179.31 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 2.1 p90 -144.3 158.19 55.12 Favored Pre-proline 0 C--N 1.287 -2.136 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 -173.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -67.96 144.77 65.55 Favored 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 122.614 2.21 . . . . 0.0 112.789 -175.016 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.547 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 60.8 t80 -118.41 134.73 23.42 Favored Pre-proline 0 C--N 1.31 -1.141 0 CA-C-N 116.233 -0.44 . . . . 0.0 109.977 -179.102 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.547 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 66.6 Cg_endo -72.22 143.75 78.19 Favored 'Cis proline' 0 CA--C 1.543 0.942 0 C-N-CA 123.189 -1.588 . . . . 0.0 111.465 -0.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.7 t -66.84 -177.03 0.55 Allowed 'General case' 0 CA--C 1.547 0.861 0 CA-C-N 115.161 -0.927 . . . . 0.0 111.941 -174.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 16.4 p -130.19 -46.23 1.11 Allowed 'General case' 0 N--CA 1.425 -1.679 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.699 -172.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.3 t -101.04 -97.68 0.26 Allowed 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -177.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -166.45 -166.66 0.9 Allowed 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 177.255 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.493 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 46.9 p -99.38 165.66 14.37 Favored Pre-proline 0 C--N 1.297 -1.68 0 N-CA-C 113.753 1.02 . . . . 0.0 113.753 -178.135 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 20.8 Cg_endo -61.65 169.72 6.6 Favored 'Trans proline' 0 C--O 1.247 0.929 0 C-N-CA 123.252 2.635 . . . . 0.0 110.682 171.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.505 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 3.2 tmm_? -80.25 123.07 27.64 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.03 -175.291 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 75.1 t -132.58 123.35 49.28 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.134 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.591 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 58.5 t -105.0 140.79 21.96 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.169 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 176.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.479 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 4.7 m-85 -84.2 94.91 8.5 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-O 121.75 0.785 . . . . 0.0 109.677 175.667 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 15.6 m120 -87.32 74.72 9.41 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 43.4 t -150.12 -173.41 4.43 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 -175.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 37.9 ptt180 -145.56 24.21 1.4 Allowed 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 172.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.4 t -160.85 174.65 13.55 Favored 'General case' 0 N--CA 1.426 -1.644 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 -176.055 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -61.96 136.15 57.84 Favored 'General case' 0 C--N 1.318 -0.792 0 O-C-N 123.59 0.556 . . . . 0.0 110.643 179.346 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 14.3 mmtm -138.52 150.25 65.55 Favored Pre-proline 0 C--N 1.286 -2.179 0 C-N-CA 124.976 1.311 . . . . 0.0 108.405 176.655 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -62.74 149.19 92.06 Favored 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 122.631 2.221 . . . . 0.0 111.881 -178.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . 0.479 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 11.2 t90 -89.88 104.89 9.4 Favored Pre-proline 0 C--N 1.305 -1.365 0 N-CA-C 106.171 -1.788 . . . . 0.0 106.171 178.122 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -75.99 87.54 1.4 Allowed 'Trans proline' 0 N--CA 1.448 -1.157 0 C-N-CA 121.27 1.313 . . . . 0.0 112.663 -172.191 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.487 HG22 ' CD2' ' A' ' 77' ' ' TYR . 61.7 t -140.16 149.7 21.81 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.126 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.492 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.609 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -153.14 135.4 14.93 Favored 'General case' 0 C--N 1.289 -2.025 0 O-C-N 123.268 0.355 . . . . 0.0 110.366 177.002 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.504 HD21 HD11 ' A' ' 129' ' ' LEU . 20.5 mt -101.73 104.84 15.66 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 177.695 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.467 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 55.4 m-85 -82.42 72.19 9.48 Favored 'General case' 0 C--N 1.281 -2.411 0 CA-C-O 120.883 0.373 . . . . 0.0 110.491 177.284 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.658 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.3 mm? -90.28 119.16 30.35 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 175.047 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -126.97 146.77 58.82 Favored Pre-proline 0 N--CA 1.411 -2.419 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -177.285 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.581 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 21.4 Cg_endo -60.99 118.8 5.71 Favored 'Trans proline' 0 C--O 1.246 0.902 0 C-N-CA 123.484 2.79 . . . . 0.0 112.468 -178.331 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.45 ' O ' HG13 ' A' ' 30' ' ' VAL . 3.1 m -67.98 -115.83 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.187 -2.188 0 CA-C-N 114.406 -1.27 . . . . 0.0 112.737 176.025 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 32.5 m -111.4 -42.58 3.86 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.159 -0.963 . . . . 0.0 111.312 179.468 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 8.8 t -90.99 28.4 1.59 Allowed 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 121.636 0.731 . . . . 0.0 110.356 -173.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -89.39 132.0 35.19 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.91 140.69 6.19 Favored Glycine 0 N--CA 1.434 -1.488 0 C-N-CA 119.496 -1.335 . . . . 0.0 111.994 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 57.09 -144.38 39.35 Favored Glycine 0 CA--C 1.495 -1.186 0 CA-C-O 119.175 -0.791 . . . . 0.0 112.87 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.0 p -61.43 96.02 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.245 0.856 0 CA-C-O 122.876 1.322 . . . . 0.0 112.385 -177.536 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.18 -31.81 11.9 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 114.327 -1.306 . . . . 0.0 111.053 -178.382 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.552 ' HB ' HG22 ' A' ' 154' ' ' VAL . 70.5 mt -124.8 139.32 51.33 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 177.162 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.404 ' HA ' ' HE2' ' A' ' 121' ' ' LYS . 3.3 mmpt? -114.24 136.17 53.26 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.179 0.514 . . . . 0.0 111.065 178.023 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -72.66 122.94 22.27 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.102 -178.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 99.48 -5.53 58.76 Favored Glycine 0 N--CA 1.434 -1.482 0 N-CA-C 110.891 -0.884 . . . . 0.0 110.891 -178.167 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 49.9 m -97.05 149.07 22.35 Favored 'General case' 0 N--CA 1.422 -1.851 0 CA-C-O 121.518 0.675 . . . . 0.0 110.382 -179.669 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.416 HD11 HG23 ' A' ' 128' ' ' VAL . 3.0 tm? -75.69 127.76 33.75 Favored 'General case' 0 N--CA 1.429 -1.502 0 CA-C-N 114.203 -1.362 . . . . 0.0 108.656 -178.213 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.541 ' HB ' HG11 ' A' ' 67' ' ' VAL . 28.1 pt -113.16 -29.7 2.27 Favored 'Isoleucine or valine' 0 C--O 1.197 -1.679 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.733 178.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . 0.493 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -156.91 166.93 31.99 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.659 -177.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.416 HG23 HD11 ' A' ' 125' ' ' LEU . 54.8 t -141.35 114.52 4.57 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.089 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 178.219 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.504 HD11 HD21 ' A' ' 107' ' ' LEU . 64.5 mt -118.12 138.66 52.12 Favored 'General case' 0 C--N 1.288 -2.086 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 178.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.47 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.0 mp -120.03 127.81 75.91 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 C-N-CA 119.335 -0.946 . . . . 0.0 109.455 178.644 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.573 ' HG ' ' CG2' ' A' ' 56' ' ' VAL . 0.1 OUTLIER -99.17 130.18 45.47 Favored 'General case' 0 C--N 1.273 -2.758 0 C-N-CA 124.391 1.076 . . . . 0.0 110.994 -176.648 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . 0.477 ' HG2' ' HB2' ' A' ' 59' ' ' GLN . 14.6 mmm180 -97.99 113.34 25.16 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 123.428 0.691 . . . . 0.0 110.308 178.361 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.494 ' HG2' HD21 ' A' ' 131' ' ' LEU . 12.5 mm100 -92.43 134.66 34.73 Favored 'General case' 0 N--CA 1.404 -2.744 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 173.551 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.428 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 19.5 m -142.26 130.56 22.25 Favored 'General case' 0 C--N 1.28 -2.424 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 176.235 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 15.6 p30 . . . . . 0 C--N 1.307 -1.255 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.333 -179.267 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 . . . . . 0 N--CA 1.444 -0.739 0 N-CA-C 109.543 -0.539 . . . . 0.0 109.543 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . 0.464 ' HB3' ' HD2' ' A' ' 132' ' ' ARG . 12.9 pt20 -129.04 142.39 50.92 Favored 'General case' 0 N--CA 1.425 -1.719 0 C-N-CA 120.077 -0.649 . . . . 0.0 109.385 177.274 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -109.93 136.63 48.91 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 -176.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.416 ' O ' ' HA ' ' A' ' 17' ' ' SER . 43.8 t -95.26 129.9 44.75 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 O-C-N 123.69 0.619 . . . . 0.0 109.638 -177.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . 0.484 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 63.3 m95 -119.8 103.21 9.16 Favored 'General case' 0 C--N 1.282 -2.338 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -178.195 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . 0.474 ' N ' HD22 ' A' ' 147' ' ' ASN . 0.8 OUTLIER -83.89 112.1 19.83 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 179.554 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.493 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 23.0 mm -87.45 122.65 39.49 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.187 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 -178.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -116.69 156.93 26.26 Favored 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 123.669 0.788 . . . . 0.0 109.267 179.198 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.46 130.52 34.57 Favored 'General case' 0 N--CA 1.396 -3.151 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 176.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 36.7 t-20 -89.13 -18.61 26.85 Favored 'General case' 0 C--N 1.285 -2.226 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 -177.521 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -147.66 143.71 27.85 Favored 'General case' 0 N--CA 1.429 -1.483 0 CA-C-N 114.013 -1.449 . . . . 0.0 109.284 -173.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -83.41 139.45 32.97 Favored 'General case' 0 C--N 1.312 -1.063 0 O-C-N 124.391 1.057 . . . . 0.0 109.698 -178.344 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.552 HG22 ' HB ' ' A' ' 120' ' ' ILE . 1.8 m -121.47 148.54 24.81 Favored 'Isoleucine or valine' 0 C--O 1.257 1.478 0 C-N-CA 120.138 -0.625 . . . . 0.0 111.259 -177.65 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.5 t -120.49 140.95 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.699 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 -179.058 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.455 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 71.4 t -102.24 104.62 38.12 Favored Pre-proline 0 C--N 1.288 -2.068 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 178.374 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.486 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 43.4 Cg_endo -71.29 -20.75 27.59 Favored 'Trans proline' 0 N--CA 1.462 -0.332 0 C-N-CA 122.404 2.069 . . . . 0.0 111.428 176.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . 0.425 ' HA ' ' H ' ' A' ' 30' ' ' VAL 0.26 3.3 t . . . . . 0 C--O 1.247 0.951 0 C-N-CA 124.497 1.119 . . . . 0.0 113.775 175.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.515 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.431 -1.416 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.531 ' HB3' ' CZ2' ' A' ' 146' ' ' TRP . 10.6 t -156.92 164.0 38.52 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 118.604 -1.238 . . . . 0.0 110.677 -176.294 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.414 ' HG3' ' O ' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -147.2 159.86 43.14 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -177.003 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.608 HG22 HG22 ' A' ' 20' ' ' VAL . 63.9 p -99.8 173.66 6.58 Favored 'General case' 0 C--N 1.3 -1.578 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.727 178.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.0 -21.75 59.86 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 114.629 -1.169 . . . . 0.0 111.223 177.051 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -82.11 -35.43 28.58 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 119.574 -0.85 . . . . 0.0 110.411 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 133.49 16.45 1.17 Allowed Glycine 0 N--CA 1.434 -1.49 0 C-N-CA 119.709 -1.234 . . . . 0.0 112.955 178.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.3 m -91.53 105.46 17.77 Favored 'General case' 0 N--CA 1.428 -1.573 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 174.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -98.18 123.58 42.32 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 176.029 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.515 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 49.6 mt -104.17 117.81 58.48 Favored Pre-proline 0 C--N 1.29 -1.981 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 177.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -81.71 176.2 8.68 Favored 'Trans proline' 0 C--O 1.245 0.842 0 C-N-CA 122.601 2.2 . . . . 0.0 110.783 176.489 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 63.5 mt -67.1 129.15 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 N-CA-C 109.052 -0.722 . . . . 0.0 109.052 177.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 145.36 -8.95 1.67 Allowed Glycine 0 C--N 1.308 -0.98 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.004 -178.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.21 154.6 30.78 Favored Glycine 0 CA--C 1.504 -0.594 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 -178.281 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 160.39 -171.44 36.6 Favored Glycine 0 N--CA 1.428 -1.893 0 C-N-CA 119.851 -1.166 . . . . 0.0 111.169 -178.583 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.527 ' HB3' ' HB ' ' A' ' 145' ' ' VAL . 28.8 p -144.34 151.18 38.96 Favored 'General case' 0 C--N 1.291 -1.949 0 CA-C-O 120.797 0.332 . . . . 0.0 111.153 -177.073 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.16 162.52 32.29 Favored 'General case' 0 N--CA 1.421 -1.9 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -178.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -108.27 113.57 26.77 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.077 -0.965 . . . . 0.0 108.741 176.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.608 HG22 HG22 ' A' ' 5' ' ' THR . 40.0 t -103.71 116.78 48.11 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.757 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.403 -179.456 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 23.5 m-85 -102.07 119.15 38.34 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 120.602 0.239 . . . . 0.0 111.058 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.478 HG22 ' HG3' ' A' ' 41' ' ' GLN . 23.7 t -119.98 128.09 75.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.73 -174.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 48.1 m-80 -81.83 126.55 32.0 Favored 'General case' 0 CA--C 1.483 -1.604 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 176.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.423 HD21 HG22 ' A' ' 36' ' ' VAL . 28.8 mt -117.8 148.31 42.2 Favored 'General case' 0 C--N 1.28 -2.449 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 179.482 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -53.24 119.14 16.09 Favored Pre-proline 0 C--O 1.209 -1.071 0 O-C-N 124.923 1.389 . . . . 0.0 110.524 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.599 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 56.3 Cg_endo -72.01 -0.29 8.28 Favored 'Trans proline' 0 CA--C 1.535 0.531 0 C-N-CA 122.999 2.466 . . . . 0.0 113.531 -175.723 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.412 HG13 ' HG3' ' A' ' 157' ' ' PRO . 66.8 t -131.63 109.91 16.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 179.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.513 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 11.6 t -147.71 113.99 0.92 Allowed 'Isoleucine or valine' 0 C--O 1.186 -2.273 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 -177.343 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.794 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -100.15 157.65 16.42 Favored 'General case' 0 C--N 1.273 -2.738 0 C-N-CA 123.824 0.85 . . . . 0.0 111.636 -178.787 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.408 HG13 ' O ' ' A' ' 112' ' ' VAL . 38.5 t -49.79 120.13 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 CA-C-O 121.029 0.442 . . . . 0.0 111.188 176.323 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.31 8.95 58.37 Favored Glycine 0 CA--C 1.522 0.51 0 CA-C-N 115.57 -0.741 . . . . 0.0 112.808 -179.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.794 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -80.37 -175.29 5.05 Favored 'General case' 0 C--N 1.31 -1.11 0 C-N-CA 124.983 1.313 . . . . 0.0 108.237 175.762 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -133.78 95.4 3.45 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 177.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.621 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 24.7 tp -91.96 144.29 25.61 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 119.166 -1.013 . . . . 0.0 109.498 178.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 62.0 t -135.48 124.06 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.915 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 -177.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.565 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 44.9 t -92.87 88.52 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.183 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 173.067 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.43 ' O ' ' HG2' ' A' ' 41' ' ' GLN . 32.5 t70 -79.08 104.19 9.54 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.981 -177.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.7 mt -85.55 -2.84 58.57 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.345 -179.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.429 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 36.6 t -73.58 -2.49 23.08 Favored 'General case' 0 CA--C 1.546 0.8 0 CA-C-O 121.715 0.769 . . . . 0.0 110.16 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.5 p -126.78 8.43 6.88 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.191 177.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.478 ' HG3' HG22 ' A' ' 22' ' ' VAL . 43.8 mm-40 -125.26 -27.08 3.54 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.226 -174.06 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.6 mt -133.79 135.75 54.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 -175.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.414 ' O ' ' HG3' ' A' ' 4' ' ' LYS . 39.0 m-85 -138.31 120.1 15.28 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -176.377 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.498 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 74.3 m -102.94 145.29 30.06 Favored 'General case' 0 C--N 1.281 -2.385 0 CA-C-O 120.825 0.345 . . . . 0.0 110.333 -177.461 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . 0.435 ' HB3' ' HA ' ' A' ' 100' ' ' ASP . 25.8 p-80 -134.56 149.42 50.63 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.112 -173.778 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 60.8 t30 -103.26 91.2 3.98 Favored 'General case' 0 C--N 1.291 -1.941 0 C-N-CA 118.786 -1.166 . . . . 0.0 109.882 172.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -61.46 -24.43 66.55 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 113.508 -1.678 . . . . 0.0 111.905 -177.608 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 50.6 m-85 -125.71 78.64 68.86 Favored Pre-proline 0 C--N 1.322 -0.629 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 -178.657 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -73.02 -7.42 20.65 Favored 'Trans proline' 0 C--N 1.332 -0.319 0 C-N-CA 122.631 2.221 . . . . 0.0 114.241 -173.193 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -112.45 -23.03 10.54 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 121.768 0.794 . . . . 0.0 109.786 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.579 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.6 OUTLIER -97.68 -30.1 13.02 Favored 'General case' 0 N--CA 1.407 -2.597 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.744 -169.82 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.579 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.0 mp -128.67 133.69 65.93 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.806 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.185 -176.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.9 t -75.88 145.64 40.38 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 174.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.428 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 3.0 m-20 -81.47 108.72 15.3 Favored 'General case' 0 C--N 1.278 -2.509 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -174.013 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 77.3 t80 -147.9 138.85 23.31 Favored 'General case' 0 C--N 1.293 -1.865 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.203 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.483 HG23 ' HG ' ' A' ' 131' ' ' LEU . 14.5 p -152.19 147.19 15.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 C-N-CA 124.405 1.082 . . . . 0.0 109.371 176.538 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.88 127.29 10.7 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 123.401 0.68 . . . . 0.0 109.824 172.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.498 HD23 ' O ' ' A' ' 130' ' ' ILE . 1.1 tt -68.0 114.24 6.36 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 175.379 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.1 tp-100 -58.62 -63.87 1.13 Allowed 'General case' 0 C--O 1.206 -1.228 0 C-N-CA 124.718 1.207 . . . . 0.0 110.372 178.114 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.435 ' HA ' HG23 ' A' ' 86' ' ' THR . 0.0 OUTLIER -164.09 154.02 14.61 Favored 'General case' 0 N--CA 1.422 -1.834 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -173.689 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.475 ' O ' ' HB2' ' A' ' 85' ' ' PRO . . . -124.03 154.84 17.78 Favored Glycine 0 N--CA 1.409 -3.104 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 179.583 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 49.4 m -131.39 145.6 51.89 Favored 'General case' 0 C--N 1.28 -2.416 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.478 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -113.97 154.82 26.96 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.453 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . 88.5 m-85 -156.63 -178.1 7.1 Favored 'General case' 0 C--O 1.238 0.479 0 C-N-CA 123.622 0.769 . . . . 0.0 109.506 -177.268 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 62.02 -137.71 45.98 Favored Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 115.783 -0.644 . . . . 0.0 113.148 175.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -84.32 -7.66 84.59 Favored Glycine 0 N--CA 1.42 -2.41 0 N-CA-C 111.336 -0.705 . . . . 0.0 111.336 177.221 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.786 HG21 ' HB ' ' A' ' 126' ' ' ILE . 94.5 t -70.0 -43.81 78.97 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.379 0 C-N-CA 123.056 0.543 . . . . 0.0 111.429 -178.525 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.478 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -82.32 -16.99 47.35 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.129 -1.028 . . . . 0.0 111.978 -179.469 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 8.2 t -100.54 -51.92 3.48 Favored 'General case' 0 N--CA 1.444 -0.771 0 CA-C-N 115.86 -0.609 . . . . 0.0 112.125 -174.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.536 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 34.0 m-80 -93.77 -21.53 19.25 Favored 'General case' 0 CA--C 1.492 -1.272 0 C-N-CA 120.494 -0.482 . . . . 0.0 109.972 -175.308 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.671 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 78.2 m-85 -111.8 161.8 15.95 Favored 'General case' 0 N--CA 1.425 -1.712 0 C-N-CA 120.076 -0.65 . . . . 0.0 109.967 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 t -169.52 133.92 1.38 Allowed 'General case' 0 N--CA 1.419 -1.991 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 176.456 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.492 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -167.08 -111.92 0.25 Allowed Glycine 0 N--CA 1.402 -3.604 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 175.721 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.4 p -157.72 -179.46 8.18 Favored 'General case' 0 C--N 1.29 -2.016 0 C-N-CA 124.421 1.088 . . . . 0.0 110.02 -174.142 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.423 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.6 p -132.66 147.88 31.76 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.734 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.601 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.9 tttt -125.61 147.57 49.26 Favored 'General case' 0 N--CA 1.43 -1.446 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.839 -178.609 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.522 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 52.1 t80 -147.76 109.48 4.42 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 -178.192 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 9.2 t 50.8 43.7 28.16 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 124.079 0.952 . . . . 0.0 111.35 177.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.02 6.16 69.73 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 120.415 -0.898 . . . . 0.0 113.946 178.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.601 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 12.2 t -79.74 -178.86 6.6 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 117.436 0.618 . . . . 0.0 110.205 178.597 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 40.9 t -159.24 103.54 1.63 Allowed 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 -179.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.522 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 4.0 p90 -148.85 161.65 32.05 Favored Pre-proline 0 C--N 1.313 -0.991 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 -174.275 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.439 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 84.9 Cg_endo -71.77 149.13 53.75 Favored 'Trans proline' 0 C--N 1.362 1.261 0 C-N-CA 122.494 2.129 . . . . 0.0 113.502 -174.386 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.656 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 56.8 t80 -120.45 137.36 26.08 Favored Pre-proline 0 N--CA 1.427 -1.597 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 178.738 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.656 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 66.2 Cg_endo -70.52 142.59 72.39 Favored 'Cis proline' 0 CA--C 1.542 0.916 0 C-N-CA 122.933 -1.695 . . . . 0.0 112.959 -1.487 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.435 HG23 ' HA ' ' A' ' 60' ' ' ARG 0.338 10.3 t -63.54 105.4 0.77 Allowed 'General case' 0 C--O 1.249 1.059 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 -179.361 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 7.3 p -77.54 -13.04 60.01 Favored 'General case' 0 C--N 1.282 -2.363 0 CA-C-N 112.975 -1.92 . . . . 0.0 110.779 -175.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.7 t -119.41 -82.96 0.65 Allowed 'General case' 0 N--CA 1.409 -2.497 0 C-N-CA 119.326 -0.95 . . . . 0.0 111.898 -173.632 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 172.4 177.95 0.08 Allowed 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.284 1.033 . . . . 0.0 108.695 -178.132 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.426 HG21 ' CD2' ' A' ' 77' ' ' TYR . 42.9 p -102.31 161.07 24.45 Favored Pre-proline 0 C--N 1.301 -1.51 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 177.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -61.22 162.58 19.5 Favored 'Trans proline' 0 CA--C 1.546 1.103 0 C-N-CA 123.427 2.751 . . . . 0.0 111.696 172.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.7 tmm_? -72.29 116.82 13.17 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 124.588 1.155 . . . . 0.0 109.874 -176.291 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 75.4 t -124.84 127.89 72.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 CA-C-O 121.348 0.594 . . . . 0.0 111.234 -178.437 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 77.0 t -107.13 123.18 62.13 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.214 178.177 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.453 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 5.3 m-85 -78.34 156.29 29.65 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 173.066 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -128.67 34.24 4.53 Favored 'General case' 0 C--N 1.261 -3.276 0 N-CA-C 106.8 -1.556 . . . . 0.0 106.8 175.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . 0.445 ' CB ' ' HG3' ' A' ' 101' ' ' LYS . 45.2 m -130.67 117.64 19.77 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 113.563 0.949 . . . . 0.0 113.563 -170.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 20.4 ptp180 -93.93 32.15 1.51 Allowed 'General case' 0 C--O 1.244 0.797 0 CA-C-O 122.332 1.063 . . . . 0.0 110.129 179.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 9.2 t -152.82 165.63 34.8 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 105.203 -2.147 . . . . 0.0 105.203 -178.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . 0.435 ' HA ' ' HB3' ' A' ' 45' ' ' HIS . 16.9 p-10 -74.0 112.71 10.4 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-O 122.167 0.984 . . . . 0.0 111.099 -174.565 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . 0.445 ' HG3' ' CB ' ' A' ' 97' ' ' SER . 15.2 mmtm -122.98 145.27 45.28 Favored Pre-proline 0 C--N 1.284 -2.254 0 CA-C-N 114.235 -1.348 . . . . 0.0 108.618 -178.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.429 ' HB3' ' O ' ' A' ' 39' ' ' SER . 17.9 Cg_endo -56.17 142.27 86.89 Favored 'Trans proline' 0 N--CA 1.45 -1.053 0 C-N-CA 123.318 2.679 . . . . 0.0 113.7 -172.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . 0.453 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.7 t90 -89.67 106.07 12.89 Favored Pre-proline 0 C--N 1.298 -1.667 0 N-CA-C 105.27 -2.122 . . . . 0.0 105.27 178.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -76.25 87.48 1.43 Allowed 'Trans proline' 0 N--CA 1.435 -1.961 0 C-N-CA 121.228 1.285 . . . . 0.0 111.685 -173.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.473 HG22 ' CD2' ' A' ' 77' ' ' TYR . 64.9 t -138.86 145.83 27.15 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 177.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.565 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -152.01 135.52 16.1 Favored 'General case' 0 C--N 1.278 -2.534 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.262 177.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.494 HD21 HD11 ' A' ' 129' ' ' LEU . 21.4 mt -98.66 102.52 14.29 Favored 'General case' 0 C--N 1.287 -2.123 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 178.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.492 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 50.8 m-85 -83.86 73.57 10.3 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 120.951 0.405 . . . . 0.0 110.378 177.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.671 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 2.9 mm? -99.47 129.76 45.67 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 175.762 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -130.07 148.21 68.75 Favored Pre-proline 0 N--CA 1.413 -2.312 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 -178.141 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.536 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 20.4 Cg_endo -59.41 120.67 8.64 Favored 'Trans proline' 0 C--O 1.246 0.88 0 C-N-CA 123.283 2.655 . . . . 0.0 112.286 -178.262 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.416 HG22 ' H ' ' A' ' 112' ' ' VAL . 2.7 m -69.21 -116.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.184 -2.394 0 CA-C-N 114.26 -1.336 . . . . 0.0 113.194 176.857 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 21.4 m -112.18 -40.47 4.17 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.316 -0.865 . . . . 0.0 110.632 179.202 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 28.9 t -87.79 28.47 1.01 Allowed 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.697 -176.245 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -95.18 132.91 39.62 Favored 'General case' 0 N--CA 1.427 -1.597 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -171.54 144.24 8.04 Favored Glycine 0 N--CA 1.436 -1.335 0 C-N-CA 120.057 -1.068 . . . . 0.0 111.559 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.454 ' O ' ' HA ' ' A' ' 155' ' ' VAL . . . 54.35 -145.7 26.54 Favored Glycine 0 CA--C 1.488 -1.613 0 C-N-CA 124.132 0.872 . . . . 0.0 113.0 -179.219 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 58.2 t -62.78 100.83 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.95 0 CA-C-O 121.602 0.715 . . . . 0.0 110.07 -177.31 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -99.33 -25.84 14.35 Favored 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 114.509 -1.223 . . . . 0.0 109.985 -179.331 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.523 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.0 mt -134.75 138.29 49.6 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -179.451 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.491 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.7 mmpt? -112.89 147.42 37.07 Favored 'General case' 0 C--N 1.31 -1.136 0 C-N-CA 122.692 0.397 . . . . 0.0 110.193 174.877 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.89 126.91 30.94 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 177.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.13 -8.33 67.35 Favored Glycine 0 C--N 1.312 -0.757 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -177.536 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 33.5 t -81.38 136.97 35.74 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 -179.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -72.35 121.85 20.18 Favored 'General case' 0 N--CA 1.429 -1.505 0 N-CA-C 106.491 -1.67 . . . . 0.0 106.491 175.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.786 ' HB ' HG21 ' A' ' 67' ' ' VAL . 27.7 pt -109.11 -27.42 2.93 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.915 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -177.128 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.28 169.38 20.76 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -177.6 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 76.7 t -144.11 113.38 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 179.161 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.494 HD11 HD21 ' A' ' 107' ' ' LEU . 46.2 mt -114.46 140.76 48.45 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.775 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.498 ' O ' HD23 ' A' ' 58' ' ' LEU . 4.0 mp -121.21 129.6 75.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 C-N-CA 118.844 -1.142 . . . . 0.0 110.787 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.556 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.2 OUTLIER -103.19 131.9 49.87 Favored 'General case' 0 C--N 1.284 -2.24 0 C-N-CA 125.268 1.427 . . . . 0.0 110.553 -177.147 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . 0.424 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 14.0 mmm180 -93.54 132.57 37.71 Favored 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 123.78 0.832 . . . . 0.0 110.699 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.416 ' HA ' ' NE2' ' A' ' 133' ' ' GLN . 5.1 tp-100 -113.28 114.6 26.92 Favored 'General case' 0 N--CA 1.422 -1.844 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 174.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 26.4 m -135.48 144.75 46.57 Favored 'General case' 0 C--N 1.286 -2.168 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 179.24 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.558 ' CB ' HG23 ' A' ' 52' ' ' ILE . 11.8 p30 . . . . . 0 N--CA 1.436 -1.173 0 C-N-CA 119.305 -0.958 . . . . 0.0 112.355 178.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 . . . . . 0 N--CA 1.429 -1.521 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . 0.424 ' HB3' ' HD2' ' A' ' 132' ' ' ARG . 13.4 pt20 -138.72 149.8 45.46 Favored 'General case' 0 N--CA 1.415 -2.178 0 C-N-CA 120.383 -0.527 . . . . 0.0 110.628 178.187 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 8.4 m-30 -108.1 134.32 51.14 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -175.578 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.527 ' HB ' ' HB3' ' A' ' 17' ' ' SER . 55.3 t -94.24 128.06 45.81 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 O-C-N 123.738 0.649 . . . . 0.0 110.137 -179.087 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . 0.556 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.4 m95 -114.87 96.98 5.98 Favored 'General case' 0 C--N 1.275 -2.658 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -179.634 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 40.4 m-80 -80.01 112.73 17.6 Favored 'General case' 0 C--N 1.291 -1.959 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.454 HG22 HD11 ' A' ' 126' ' ' ILE . 24.4 mm -87.9 123.95 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.879 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 -177.064 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -118.82 153.92 33.71 Favored 'General case' 0 C--N 1.288 -2.098 0 C-N-CA 124.105 0.962 . . . . 0.0 108.468 178.25 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.403 ' HB3' ' O ' ' A' ' 121' ' ' LYS . . . -82.29 133.76 35.25 Favored 'General case' 0 N--CA 1.406 -2.635 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 176.114 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -92.29 -13.15 30.78 Favored 'General case' 0 C--N 1.284 -2.26 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 -177.073 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -153.89 148.11 25.85 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 113.834 -1.53 . . . . 0.0 108.824 -176.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -82.12 149.02 28.22 Favored 'General case' 0 C--N 1.322 -0.628 0 O-C-N 123.958 0.786 . . . . 0.0 111.096 -178.436 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.599 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 73.7 t -124.62 133.68 68.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.346 -176.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.454 ' HA ' ' O ' ' A' ' 117' ' ' GLY . 8.4 t -116.71 136.35 54.06 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.513 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 72.3 t -100.02 103.52 23.04 Favored Pre-proline 0 C--N 1.292 -1.895 0 C-N-CA 123.384 0.674 . . . . 0.0 109.324 178.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.412 ' HG3' HG13 ' A' ' 27' ' ' VAL . 33.3 Cg_endo -68.47 -27.1 33.81 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 122.423 2.082 . . . . 0.0 111.781 179.222 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . 0.416 ' HB ' HG12 ' A' ' 156' ' ' VAL . 4.4 t . . . . . 0 CA--C 1.548 0.895 0 C-N-CA 125.109 1.364 . . . . 0.0 113.515 176.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.481 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.443 -0.791 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 70.9 m -136.02 159.41 41.77 Favored 'General case' 0 C--N 1.301 -1.5 0 C-N-CA 120.741 -0.384 . . . . 0.0 111.127 -175.348 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.416 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -143.73 161.05 39.6 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.172 0.51 . . . . 0.0 111.197 -176.187 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.521 HG22 HG22 ' A' ' 20' ' ' VAL . 72.0 p -102.25 168.88 9.07 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.335 177.793 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.99 -7.12 53.89 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 114.103 -1.408 . . . . 0.0 112.009 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 4.7 p30 -90.65 -31.29 16.69 Favored 'General case' 0 CA--C 1.511 -0.537 0 C-N-CA 118.458 -1.297 . . . . 0.0 108.234 176.219 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 133.24 2.57 3.68 Favored Glycine 0 N--CA 1.431 -1.678 0 C-N-CA 120.29 -0.957 . . . . 0.0 113.029 177.599 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.6 m -77.91 102.31 7.24 Favored 'General case' 0 N--CA 1.442 -0.869 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.26 117.59 30.54 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 175.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.481 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 62.1 mt -92.69 115.62 65.15 Favored Pre-proline 0 C--N 1.301 -1.529 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 179.348 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_endo -78.36 -179.83 5.82 Favored 'Trans proline' 0 C--O 1.248 0.981 0 C-N-CA 122.643 2.229 . . . . 0.0 111.526 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.5 mt -70.62 129.55 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.18 1.09 3.29 Favored Glycine 0 C--N 1.305 -1.162 0 C-N-CA 120.886 -0.673 . . . . 0.0 111.607 -178.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.75 171.41 46.91 Favored Glycine 0 C--O 1.244 0.773 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.289 -179.607 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 150.9 -169.11 30.66 Favored Glycine 0 N--CA 1.438 -1.182 0 C-N-CA 120.474 -0.869 . . . . 0.0 111.352 177.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 87.0 p -141.93 157.5 44.89 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -141.04 162.83 34.57 Favored 'General case' 0 N--CA 1.42 -1.965 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -110.03 111.33 22.64 Favored 'General case' 0 C--N 1.285 -2.207 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.256 178.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.521 HG22 HG22 ' A' ' 5' ' ' THR . 41.5 t -100.75 135.83 35.07 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.441 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.513 -178.779 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 69.2 m-85 -125.29 128.51 48.36 Favored 'General case' 0 CA--C 1.492 -1.272 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -177.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.514 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.2 p -139.63 136.33 39.84 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 O-C-N 123.78 0.675 . . . . 0.0 110.974 -177.084 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 -88.79 128.29 35.63 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 178.089 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.441 HD11 HG22 ' A' ' 36' ' ' VAL . 2.7 mm? -107.11 160.05 15.85 Favored 'General case' 0 C--N 1.284 -2.272 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 176.15 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.45 120.66 37.63 Favored Pre-proline 0 C--O 1.209 -1.046 0 O-C-N 124.505 1.128 . . . . 0.0 109.365 176.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.515 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 62.4 Cg_endo -74.14 0.45 8.43 Favored 'Trans proline' 0 CA--C 1.537 0.667 0 C-N-CA 122.668 2.245 . . . . 0.0 113.514 -176.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.45 HG13 ' HG3' ' A' ' 157' ' ' PRO . 93.7 t -131.49 111.43 19.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 178.455 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.476 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 9.3 t -147.76 112.96 0.83 Allowed 'Isoleucine or valine' 0 C--O 1.194 -1.845 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 -177.453 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.666 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -101.05 154.75 18.44 Favored 'General case' 0 C--N 1.277 -2.571 0 C-N-CA 123.746 0.818 . . . . 0.0 111.062 -179.354 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.543 HG22 ' O ' ' A' ' 112' ' ' VAL . 99.1 t -46.12 117.84 0.39 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.478 0 C-N-CA 123.379 0.672 . . . . 0.0 111.338 175.614 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.1 1.36 54.63 Favored Glycine 0 C--N 1.311 -0.815 0 CA-C-N 115.253 -0.885 . . . . 0.0 113.101 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.666 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -74.42 -175.91 2.51 Favored 'General case' 0 C--N 1.315 -0.914 0 C-N-CA 124.551 1.141 . . . . 0.0 109.967 175.336 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -134.45 96.02 3.5 Favored 'General case' 0 N--CA 1.428 -1.559 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 177.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.596 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 28.8 tp -93.15 142.52 27.21 Favored 'General case' 0 C--N 1.284 -2.247 0 C-N-CA 119.773 -0.771 . . . . 0.0 109.929 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.0 t -135.01 122.08 35.89 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.719 0 CA-C-O 121.168 0.508 . . . . 0.0 109.901 -176.533 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.585 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 47.8 t -92.94 89.07 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.27 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 174.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -78.03 106.76 10.11 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.248 -177.568 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.6 mt -93.79 -1.68 54.65 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 121.365 0.602 . . . . 0.0 111.025 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.9 t -76.37 1.28 16.74 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.974 -178.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.3 p -129.55 8.93 5.46 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 123.614 0.765 . . . . 0.0 109.869 176.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.514 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 45.6 mm-40 -125.23 -24.73 3.93 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.505 -174.808 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.0 mt -133.71 141.59 43.78 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 -177.115 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.472 ' HA ' ' HA ' ' A' ' 102' ' ' PRO . 57.6 m-85 -141.24 161.14 38.59 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -176.199 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 69.3 m -138.69 138.77 38.06 Favored 'General case' 0 C--N 1.299 -1.618 0 C-N-CA 123.059 0.544 . . . . 0.0 110.953 -178.609 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 29.4 p-80 -134.12 148.94 51.05 Favored 'General case' 0 C--O 1.247 0.965 0 CA-C-O 121.378 0.609 . . . . 0.0 111.961 -175.386 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.496 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 3.4 p30 -105.37 118.87 37.66 Favored 'General case' 0 CA--C 1.485 -1.553 0 CA-C-O 122.193 0.997 . . . . 0.0 112.832 179.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -88.43 -25.94 22.38 Favored 'General case' 0 C--N 1.286 -2.189 0 CA-C-N 113.79 -1.55 . . . . 0.0 109.511 177.006 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.414 ' HB2' HD13 ' A' ' 52' ' ' ILE . 29.0 m-85 -138.51 66.87 44.03 Favored Pre-proline 0 N--CA 1.477 0.919 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.175 177.489 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.496 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 55.8 Cg_endo -68.52 -8.03 21.99 Favored 'Trans proline' 0 N--CA 1.485 1.024 0 C-N-CA 122.923 2.415 . . . . 0.0 113.96 -174.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -117.29 -9.29 10.97 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 120.025 -0.67 . . . . 0.0 111.115 -178.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.544 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.3 OUTLIER -103.88 -30.33 10.41 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 -176.378 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.544 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.5 mp -124.2 140.09 48.61 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.309 0 CA-C-N 114.143 -1.389 . . . . 0.0 108.057 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 4.9 t -81.83 130.28 35.02 Favored 'General case' 0 N--CA 1.424 -1.773 0 N-CA-C 105.329 -2.101 . . . . 0.0 105.329 173.228 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.503 ' O ' HG23 ' A' ' 94' ' ' VAL . 42.2 m-20 -88.86 106.36 18.34 Favored 'General case' 0 C--N 1.282 -2.369 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -173.491 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.47 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 19.8 t80 -134.7 123.9 24.42 Favored 'General case' 0 C--N 1.296 -1.746 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.88 -172.592 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.476 HG13 HD13 ' A' ' 131' ' ' LEU . 93.3 t -124.83 141.66 44.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 CA-C-N 114.632 -1.167 . . . . 0.0 109.398 -176.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -148.36 127.85 13.16 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 173.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.532 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 59.5 tp -67.71 115.98 7.89 Favored 'General case' 0 N--CA 1.442 -0.85 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 174.19 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.462 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 3.9 tp-100 -60.43 -52.67 64.23 Favored 'General case' 0 C--O 1.214 -0.786 0 CA-C-N 114.402 -1.272 . . . . 0.0 110.404 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.462 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 10.1 ptp180 -169.46 159.88 8.84 Favored 'General case' 0 N--CA 1.418 -2.028 0 CA-C-N 114.095 -1.411 . . . . 0.0 107.501 -175.049 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -136.42 136.06 8.15 Favored Glycine 1 N--CA 1.393 -4.205 0 N-CA-C 107.93 -2.068 . . . . 0.0 107.93 178.362 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 67.9 m -124.73 147.06 48.85 Favored 'General case' 0 C--N 1.272 -2.797 0 O-C-N 124.29 0.641 . . . . 0.0 110.361 -175.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.525 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -109.54 159.78 16.79 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 -178.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.489 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 90.6 m-85 -155.99 -179.68 8.37 Favored 'General case' 0 N--CA 1.464 0.26 0 C-N-CA 123.83 0.852 . . . . 0.0 109.438 -176.185 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.87 -138.71 46.84 Favored Glycine 0 CA--C 1.506 -0.52 0 O-C-N 123.73 0.644 . . . . 0.0 112.84 177.29 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.35 -6.04 89.56 Favored Glycine 0 C--O 1.201 -1.93 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 176.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.775 HG21 ' HB ' ' A' ' 126' ' ' ILE . 97.0 t -71.78 -38.17 64.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 123.041 0.536 . . . . 0.0 111.269 -178.262 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.525 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.11 -18.55 32.03 Favored 'General case' 0 C--N 1.297 -1.711 0 C-N-CA 118.513 -1.275 . . . . 0.0 112.232 179.416 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 22.5 t -100.29 -46.62 5.21 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.288 0.566 . . . . 0.0 112.028 -175.073 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.47 ' O ' HG22 ' A' ' 112' ' ' VAL . 44.7 m-20 -97.62 -20.75 17.45 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -174.183 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.595 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 95.6 m-85 -112.23 151.54 29.48 Favored 'General case' 0 N--CA 1.428 -1.544 0 CA-C-O 122.199 1.0 . . . . 0.0 111.618 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.421 ' HB2' ' CG1' ' A' ' 112' ' ' VAL . 4.1 m -158.69 124.15 4.37 Favored 'General case' 0 N--CA 1.393 -3.285 0 CA-C-N 113.587 -1.642 . . . . 0.0 109.96 179.236 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.503 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -161.13 -112.77 0.29 Allowed Glycine 0 N--CA 1.409 -3.156 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 175.631 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.409 HG22 ' HA ' ' A' ' 83' ' ' PRO . 0.9 OUTLIER -158.04 179.84 8.8 Favored 'General case' 0 C--N 1.284 -2.242 0 C-N-CA 123.798 0.839 . . . . 0.0 110.238 -175.669 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -134.55 146.89 30.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 C-N-CA 123.172 0.589 . . . . 0.0 109.468 178.387 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.633 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.3 tttt -124.31 143.17 50.72 Favored 'General case' 0 N--CA 1.421 -1.901 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.5 -179.27 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.47 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 59.2 t80 -143.61 110.34 5.58 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 115.197 -0.91 . . . . 0.0 108.891 -177.551 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 23.0 t 53.95 37.2 26.19 Favored 'General case' 0 CA--C 1.557 1.241 0 C-N-CA 123.634 0.774 . . . . 0.0 111.386 175.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.44 10.48 63.68 Favored Glycine 0 C--O 1.216 -1.012 0 C-N-CA 120.849 -0.691 . . . . 0.0 113.874 -179.281 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.633 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 8.4 t -86.21 -179.29 6.69 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 117.584 0.692 . . . . 0.0 109.414 178.511 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 31.6 t -155.73 110.47 2.92 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -179.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.477 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 5.3 p90 -154.24 161.31 29.59 Favored Pre-proline 0 CA--C 1.548 0.885 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 -175.12 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.477 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 60.1 Cg_endo -68.7 149.45 73.38 Favored 'Trans proline' 0 C--N 1.36 1.18 0 C-N-CA 122.936 2.424 . . . . 0.0 113.563 -175.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.536 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 59.3 t80 -124.07 133.21 24.49 Favored Pre-proline 0 N--CA 1.437 -1.078 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.932 179.005 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.536 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 60.5 Cg_endo -71.99 148.45 90.87 Favored 'Cis proline' 0 C--O 1.239 0.533 0 C-N-CA 122.796 -1.752 . . . . 0.0 110.232 -3.319 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.8 t -72.61 -175.99 1.81 Allowed 'General case' 0 C--O 1.246 0.903 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -178.225 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 22.6 p -130.69 -35.81 1.44 Allowed 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 122.088 0.947 . . . . 0.0 108.524 -172.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 49.4 m -105.34 -141.84 0.37 Allowed 'General case' 1 N--CA 1.343 -5.778 0 CA-C-N 114.093 -1.412 . . . . 0.0 108.24 178.368 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -123.49 -171.32 2.29 Favored 'General case' 0 C--N 1.275 -2.64 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -174.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.532 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 39.9 p -100.75 167.03 11.44 Favored Pre-proline 0 C--N 1.295 -1.764 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 177.402 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . 0.44 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 18.9 Cg_endo -57.39 166.47 4.56 Favored 'Trans proline' 0 C--O 1.247 0.953 0 C-N-CA 123.263 2.642 . . . . 0.0 112.286 171.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.47 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 1.7 tmm_? -75.21 121.32 21.95 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 114.597 -1.183 . . . . 0.0 108.52 -178.382 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 72.8 t -136.47 117.92 19.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 C-N-CA 123.41 0.684 . . . . 0.0 109.749 -176.838 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 54' ' ' ASP . 1.5 p -115.67 132.02 66.32 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.361 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.89 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.442 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 6.3 m-85 -77.0 100.29 5.58 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.216 0.531 . . . . 0.0 111.096 -178.41 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . 0.42 ' N ' HD22 ' A' ' 96' ' ' ASN . 0.8 OUTLIER -94.89 59.88 2.39 Favored 'General case' 0 C--N 1.308 -1.237 0 CA-C-O 121.372 0.606 . . . . 0.0 109.556 179.047 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 51.0 m -154.47 141.76 19.56 Favored 'General case' 0 C--N 1.31 -1.114 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.7 ptp180 -109.02 69.68 0.71 Allowed 'General case' 0 C--N 1.304 -1.376 0 CA-C-O 122.044 0.926 . . . . 0.0 111.464 -177.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.2 t -179.46 168.53 1.44 Allowed 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 179.116 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -72.35 113.11 9.03 Favored 'General case' 0 CA--C 1.501 -0.94 0 CA-C-O 121.799 0.809 . . . . 0.0 109.461 -179.107 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -118.46 139.73 27.31 Favored Pre-proline 0 C--N 1.274 -2.71 0 CA-C-N 114.249 -1.341 . . . . 0.0 108.693 -177.099 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.472 ' HA ' ' HA ' ' A' ' 43' ' ' PHE . 12.6 Cg_endo -57.16 152.26 46.14 Favored 'Trans proline' 0 C--O 1.245 0.841 0 C-N-CA 123.278 2.652 . . . . 0.0 113.107 179.202 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . 0.442 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 12.6 t90 -91.42 106.62 17.19 Favored Pre-proline 0 N--CA 1.438 -1.048 0 N-CA-C 106.317 -1.735 . . . . 0.0 106.317 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -77.52 88.21 1.44 Allowed 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 121.388 1.392 . . . . 0.0 112.927 -172.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.404 HG22 ' CD2' ' A' ' 77' ' ' TYR . 98.0 t -137.62 145.09 29.76 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.306 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 176.632 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.585 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.87 136.73 18.18 Favored 'General case' 0 C--N 1.292 -1.9 0 O-C-N 123.237 0.336 . . . . 0.0 110.172 178.438 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.474 HD21 HD11 ' A' ' 129' ' ' LEU . 20.3 mt -101.28 102.71 13.62 Favored 'General case' 0 C--N 1.292 -1.909 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.087 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.503 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 19.3 m-85 -81.53 74.0 8.54 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 120.812 0.339 . . . . 0.0 110.436 177.44 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.596 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.2 mm? -91.52 151.08 20.91 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 176.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -149.3 143.7 17.18 Favored Pre-proline 0 N--CA 1.405 -2.702 0 C-N-CA 119.996 -0.682 . . . . 0.0 110.136 179.516 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -64.9 127.48 18.7 Favored 'Trans proline' 0 N--CA 1.45 -1.051 0 C-N-CA 123.383 2.722 . . . . 0.0 113.149 -177.3 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.543 ' O ' HG22 ' A' ' 30' ' ' VAL . 27.1 m -87.25 -155.84 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.399 -3.014 0 CA-C-N 114.438 -1.255 . . . . 0.0 108.639 172.432 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 6.1 m -80.51 -30.55 37.26 Favored 'General case' 0 C--N 1.261 -3.269 0 CA-C-O 121.425 0.631 . . . . 0.0 110.48 -168.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.5 t -82.9 9.55 9.74 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.888 -177.195 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.413 ' HB1' HG21 ' A' ' 156' ' ' VAL . . . -90.72 131.52 36.35 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.334 -0.988 . . . . 0.0 108.334 178.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.3 125.68 1.16 Allowed Glycine 0 C--N 1.306 -1.095 0 C-N-CA 120.571 -0.823 . . . . 0.0 111.727 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.84 -147.26 49.37 Favored Glycine 0 CA--C 1.486 -1.773 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -175.229 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.437 HG11 ' HE3' ' A' ' 121' ' ' LYS . 60.3 t -57.31 112.04 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 117.213 0.507 . . . . 0.0 110.113 -177.144 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -110.25 -28.69 8.5 Favored 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.068 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.467 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 59.0 mt -129.03 138.07 55.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.149 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.451 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 5.1 mmpt? -114.92 141.84 47.4 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 121.112 0.482 . . . . 0.0 110.835 178.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.44 135.26 49.98 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.691 -179.765 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 82.72 -4.14 80.3 Favored Glycine 0 C--O 1.242 0.61 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.216 178.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 19.4 m -94.71 149.41 21.27 Favored 'General case' 0 N--CA 1.417 -2.084 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 -179.214 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 28.2 tp -74.79 133.37 41.95 Favored 'General case' 0 N--CA 1.434 -1.231 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.123 -177.455 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.775 ' HB ' HG21 ' A' ' 67' ' ' VAL . 34.5 pt -118.26 -26.67 2.51 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 C-N-CA 120.481 -0.488 . . . . 0.0 112.174 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . 0.42 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.9 163.58 29.07 Favored 'General case' 0 N--CA 1.434 -1.24 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.252 -177.711 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 55.9 t -139.7 115.63 8.74 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.937 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 178.222 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.474 HD11 HD21 ' A' ' 107' ' ' LEU . 68.7 mt -117.74 145.74 44.25 Favored 'General case' 0 C--N 1.281 -2.398 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 179.415 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.496 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.7 mp -128.7 119.47 49.97 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 C-N-CA 119.794 -0.762 . . . . 0.0 109.629 178.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.501 ' C ' HD12 ' A' ' 131' ' ' LEU . 0.6 OUTLIER -88.77 147.02 24.66 Favored 'General case' 0 CA--C 1.481 -1.677 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 173.978 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 60.0 ttp180 -115.0 122.0 44.87 Favored 'General case' 0 C--N 1.248 -3.832 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 177.74 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -85.86 139.26 31.41 Favored 'General case' 0 N--CA 1.417 -2.076 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 176.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.434 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 25.8 m -145.1 133.23 21.49 Favored 'General case' 0 C--N 1.261 -3.253 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 173.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.484 ' HB2' HG23 ' A' ' 52' ' ' ILE . 32.9 p30 . . . . . 0 C--N 1.298 -1.637 0 CA-C-O 120.906 0.384 . . . . 0.0 110.18 -178.368 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 . . . . . 0 N--CA 1.44 -0.941 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . 0.432 ' HB2' ' O ' ' A' ' 131' ' ' LEU . 13.9 pt20 -126.09 150.48 48.15 Favored 'General case' 0 C--N 1.288 -2.107 0 C-N-CA 119.877 -0.729 . . . . 0.0 110.623 -179.113 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 12.5 m-30 -113.67 127.47 56.06 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -174.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 50.0 t -92.42 132.11 37.64 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.987 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.93 -178.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 54.3 m95 -120.97 101.14 7.49 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -177.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 50.0 m-80 -84.5 115.01 22.35 Favored 'General case' 0 C--N 1.285 -2.233 0 N-CA-C 107.691 -1.226 . . . . 0.0 107.691 178.68 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.42 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 20.2 mm -88.55 121.8 39.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -177.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -117.7 151.7 36.74 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.143 177.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.22 131.39 35.23 Favored 'General case' 0 N--CA 1.412 -2.336 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 177.049 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -88.21 -16.36 33.49 Favored 'General case' 0 C--N 1.287 -2.128 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -178.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -148.08 143.96 27.54 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 114.566 -1.197 . . . . 0.0 109.997 -174.447 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -79.08 139.53 38.08 Favored 'General case' 0 C--N 1.309 -1.163 0 O-C-N 124.285 0.991 . . . . 0.0 110.995 179.568 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.515 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 73.0 t -115.12 138.47 45.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.851 -176.432 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 8.3 t -119.56 135.9 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.394 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 75.3 t -99.81 105.03 32.07 Favored Pre-proline 0 C--N 1.286 -2.174 0 C-N-CA 124.091 0.956 . . . . 0.0 109.834 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.493 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 40.6 Cg_endo -70.71 -21.77 28.62 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.233 1.955 . . . . 0.0 111.797 177.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.27 3.7 t . . . . . 0 C--N 1.355 0.841 0 C-N-CA 124.978 1.311 . . . . 0.0 114.095 175.665 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.6 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.44 -0.945 0 CA-C-O 120.557 0.217 . . . . 0.0 110.881 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 11.5 t -151.61 156.61 40.8 Favored 'General case' 0 N--CA 1.433 -1.276 0 C-N-CA 119.931 -0.708 . . . . 0.0 109.766 -177.241 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.1 pptp? -141.44 163.08 33.89 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-O 121.049 0.452 . . . . 0.0 111.576 -175.065 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.481 HG22 HG22 ' A' ' 20' ' ' VAL . 71.3 p -104.6 172.94 6.52 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 121.859 0.837 . . . . 0.0 110.406 -179.687 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -78.81 -10.31 59.74 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 113.745 -1.57 . . . . 0.0 110.991 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -92.16 -33.97 14.51 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 118.318 -1.353 . . . . 0.0 109.124 175.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 137.47 5.58 1.74 Allowed Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 119.231 -1.461 . . . . 0.0 113.437 176.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.3 m -80.18 100.22 8.18 Favored 'General case' 0 N--CA 1.433 -1.275 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -97.29 111.08 23.48 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.323 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.6 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 59.3 mt -88.87 121.94 69.42 Favored Pre-proline 0 C--N 1.307 -1.243 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 179.488 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -81.52 -179.56 5.02 Favored 'Trans proline' 0 C--O 1.241 0.668 0 C-N-CA 122.899 2.399 . . . . 0.0 111.937 178.183 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.6 mt -69.23 141.51 17.25 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.832 179.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.89 -1.74 17.4 Favored Glycine 0 N--CA 1.438 -1.191 0 C-N-CA 119.887 -1.149 . . . . 0.0 112.472 179.284 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 103.27 171.25 25.99 Favored Glycine 0 C--N 1.309 -0.972 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 157.22 -175.28 34.69 Favored Glycine 0 C--N 1.312 -0.759 0 C-N-CA 120.354 -0.927 . . . . 0.0 111.867 178.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 m -146.27 143.54 29.25 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 179.453 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.92 166.33 23.57 Favored 'General case' 0 N--CA 1.425 -1.71 0 CA-C-O 121.249 0.547 . . . . 0.0 109.788 -177.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -111.03 115.52 29.61 Favored 'General case' 0 C--N 1.28 -2.442 0 CA-C-N 114.533 -1.212 . . . . 0.0 108.822 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.481 HG22 HG22 ' A' ' 5' ' ' THR . 39.7 t -103.26 140.08 22.44 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.947 0 CA-C-N 115.266 -0.879 . . . . 0.0 108.762 178.052 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.7 m-85 -126.1 136.23 52.66 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.477 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.4 p -146.04 135.51 17.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 123.724 0.64 . . . . 0.0 110.519 -178.769 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.6 p30 -95.83 123.24 39.32 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 121.759 0.79 . . . . 0.0 111.367 179.375 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.407 HD11 HG22 ' A' ' 36' ' ' VAL . 2.6 mm? -103.48 160.93 14.29 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 113.922 -1.49 . . . . 0.0 108.208 -177.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.76 122.41 56.58 Favored Pre-proline 0 C--N 1.313 -0.994 0 O-C-N 124.764 1.29 . . . . 0.0 109.405 178.23 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 61.0 Cg_endo -75.21 3.08 6.04 Favored 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 122.661 2.241 . . . . 0.0 112.89 -178.592 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.429 HG13 ' HG3' ' A' ' 157' ' ' PRO . 46.7 t -125.98 109.54 21.73 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.503 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 177.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.451 ' O ' HG13 ' A' ' 156' ' ' VAL . 1.6 t -143.17 99.89 0.7 Allowed 'Isoleucine or valine' 0 C--O 1.183 -2.403 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 -178.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.462 ' H ' ' HG3' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -91.63 151.38 20.72 Favored 'General case' 0 C--N 1.269 -2.893 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -179.199 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.447 HG13 ' O ' ' A' ' 112' ' ' VAL . 24.7 t -46.85 115.23 0.25 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.709 0 C-N-CA 123.615 0.766 . . . . 0.0 111.501 177.078 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.84 3.28 42.74 Favored Glycine 0 N--CA 1.446 -0.697 0 CA-C-N 114.759 -1.109 . . . . 0.0 112.755 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.462 ' HG3' ' H ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -73.78 -178.37 3.16 Favored 'General case' 0 C--N 1.309 -1.159 0 C-N-CA 123.542 0.737 . . . . 0.0 111.427 175.57 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -134.67 89.03 2.5 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 177.075 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.675 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.3 tp -90.21 144.67 25.65 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.102 -176.599 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.4 t -134.12 125.79 48.75 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.633 0 CA-C-O 121.298 0.57 . . . . 0.0 110.585 -176.642 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.596 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 48.9 t -95.96 89.25 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.049 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 174.057 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -82.81 113.05 20.18 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-O 121.15 0.5 . . . . 0.0 111.216 -178.11 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.3 mt -96.1 -2.7 46.03 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.983 -178.704 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -74.07 0.36 14.0 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-O 122.118 0.961 . . . . 0.0 109.733 -178.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.5 p -127.36 6.82 6.38 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 123.771 0.828 . . . . 0.0 109.819 178.09 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.477 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 45.7 mm-40 -124.03 -21.42 5.07 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.706 -174.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.6 mt -132.87 136.72 55.21 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.133 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 -175.155 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -142.84 124.36 14.84 Favored 'General case' 0 CA--C 1.504 -0.798 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -175.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 83.3 m -101.02 140.31 35.48 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 -179.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.4 p80 -132.19 139.36 48.32 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 121.852 0.834 . . . . 0.0 112.313 -171.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 8.7 p30 -103.44 107.26 18.02 Favored 'General case' 0 C--N 1.292 -1.899 0 CA-C-N 115.1 -0.954 . . . . 0.0 113.342 -178.272 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -84.24 -14.33 50.22 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 121.881 0.848 . . . . 0.0 109.531 175.588 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.419 ' HB2' HD13 ' A' ' 52' ' ' ILE . 47.2 m-85 -134.52 66.0 68.88 Favored Pre-proline 0 C--N 1.318 -0.761 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 177.492 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -73.05 -5.56 17.42 Favored 'Trans proline' 0 N--CA 1.486 1.056 0 C-N-CA 123.188 2.592 . . . . 0.0 113.978 -172.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -120.41 -13.34 8.85 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 121.469 0.652 . . . . 0.0 110.204 -179.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.475 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -94.78 -30.17 14.38 Favored 'General case' 0 N--CA 1.421 -1.88 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -174.904 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.622 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -122.92 138.2 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.508 0 CA-C-N 113.529 -1.669 . . . . 0.0 107.924 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 7.3 t -80.7 136.39 36.17 Favored 'General case' 0 N--CA 1.427 -1.607 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 174.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.507 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 19.3 m-20 -84.79 108.16 17.33 Favored 'General case' 0 C--N 1.286 -2.163 0 CA-C-O 121.541 0.686 . . . . 0.0 110.506 -171.869 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.456 ' HE1' ' HG2' ' A' ' 92' ' ' ARG . 34.0 t80 -138.46 143.36 39.61 Favored 'General case' 0 C--N 1.284 -2.275 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.242 -178.399 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.597 HG23 HD13 ' A' ' 131' ' ' LEU . 12.6 p -148.59 148.66 15.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 177.026 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.04 137.59 19.89 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 123.599 0.562 . . . . 0.0 109.992 174.029 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.416 HD23 ' O ' ' A' ' 130' ' ' ILE . 0.3 OUTLIER -74.52 106.64 6.21 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 105.048 -2.204 . . . . 0.0 105.048 175.119 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 6.6 tp60 -56.05 -64.9 0.71 Allowed 'General case' 0 C--O 1.202 -1.399 0 C-N-CA 126.372 1.869 . . . . 0.0 109.968 177.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 8.3 ptp180 -158.3 153.59 25.75 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 -179.189 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -134.98 137.97 9.66 Favored Glycine 0 CA--C 1.463 -3.159 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 -178.308 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 66.4 m -126.33 151.95 46.88 Favored 'General case' 0 C--N 1.28 -2.419 0 C-N-CA 123.822 0.849 . . . . 0.0 109.784 -174.704 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.525 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -115.74 157.92 23.59 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -178.134 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.484 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 91.9 m-85 -156.02 -179.45 8.15 Favored 'General case' 0 C--O 1.237 0.415 0 C-N-CA 124.328 1.051 . . . . 0.0 109.042 -177.412 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.25 -148.41 29.27 Favored Glycine 0 C--N 1.33 0.205 0 O-C-N 123.566 0.541 . . . . 0.0 113.533 178.68 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.41 -10.91 71.15 Favored Glycine 0 C--O 1.206 -1.598 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.754 178.101 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.796 HG21 ' HB ' ' A' ' 126' ' ' ILE . 97.0 t -69.05 -40.68 81.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 C-N-CA 123.9 0.88 . . . . 0.0 111.483 -177.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.525 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -84.2 -20.5 32.24 Favored 'General case' 0 N--CA 1.433 -1.289 0 C-N-CA 118.759 -1.176 . . . . 0.0 112.14 179.09 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 31.7 t -98.37 -60.2 1.6 Allowed 'General case' 0 N--CA 1.442 -0.838 0 CA-C-N 115.932 -0.576 . . . . 0.0 112.004 -174.466 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.474 ' O ' HG22 ' A' ' 112' ' ' VAL . 48.6 m-20 -85.77 -25.74 26.2 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.427 -172.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.67 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 91.6 m-85 -106.56 158.83 16.63 Favored 'General case' 0 N--CA 1.42 -1.956 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.03 177.363 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.0 t -167.98 137.39 2.55 Favored 'General case' 0 N--CA 1.411 -2.411 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 176.155 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.475 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.25 -107.86 0.2 Allowed Glycine 0 N--CA 1.411 -2.978 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 175.883 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.5 p -158.71 -179.88 8.47 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 123.791 0.836 . . . . 0.0 110.871 -175.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.412 ' HB ' ' HB2' ' A' ' 84' ' ' PHE . 2.6 p -132.11 144.96 35.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 177.662 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.685 ' HG3' ' O ' ' A' ' 80' ' ' SER . 73.6 tttt -123.73 142.98 50.58 Favored 'General case' 0 N--CA 1.424 -1.769 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.969 -177.503 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.577 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 68.3 t80 -141.42 111.44 6.71 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 115.458 -0.792 . . . . 0.0 108.87 -177.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 9.3 t 52.61 34.19 15.26 Favored 'General case' 0 CA--C 1.561 1.366 0 CA-C-O 121.717 0.77 . . . . 0.0 111.071 179.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.417 ' HA2' ' HE2' ' A' ' 76' ' ' LYS . . . 90.65 10.0 63.83 Favored Glycine 0 CA--C 1.532 1.101 0 C-N-CA 120.83 -0.7 . . . . 0.0 114.169 -179.237 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.685 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 21.8 t -79.98 179.54 7.54 Favored 'General case' 0 CA--C 1.549 0.924 0 CA-C-N 117.446 0.623 . . . . 0.0 109.376 177.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 17.5 p -153.27 109.11 3.29 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-O 121.548 0.69 . . . . 0.0 110.049 178.322 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.577 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 4.2 p90 -151.08 158.33 34.77 Favored Pre-proline 0 C--N 1.302 -1.465 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 -175.123 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.77 147.41 69.13 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.95 2.433 . . . . 0.0 113.256 -175.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.608 ' CD2' HD21 ' A' ' 109' ' ' LEU . 66.6 t80 -121.23 132.84 24.11 Favored Pre-proline 0 N--CA 1.441 -0.88 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.535 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.54 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 60.6 Cg_endo -69.25 146.19 80.39 Favored 'Cis proline' 0 CA--C 1.538 0.702 0 C-N-CA 123.562 -1.432 . . . . 0.0 111.308 0.208 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.3 t -70.74 -178.07 1.75 Allowed 'General case' 0 CA--C 1.554 1.097 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.31 -177.284 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 10.0 p -130.51 -34.33 1.58 Allowed 'General case' 0 C--O 1.243 0.711 0 N-CA-C 114.827 1.418 . . . . 0.0 114.827 -169.132 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.1 t -118.74 -69.44 0.85 Allowed 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 119.978 -0.689 . . . . 0.0 111.021 -174.293 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 178.25 -179.71 0.31 Allowed 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 -178.176 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.1 p -102.54 164.49 15.56 Favored Pre-proline 0 C--N 1.284 -2.26 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -66.46 160.61 44.89 Favored 'Trans proline' 0 C--N 1.365 1.406 0 C-N-CA 122.523 2.149 . . . . 0.0 110.504 173.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.49 ' HD3' HG23 ' A' ' 94' ' ' VAL . 6.8 tmm_? -72.73 128.2 34.82 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-N 115.64 -0.709 . . . . 0.0 112.166 -174.074 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 90.0 t -133.26 117.95 30.21 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 115.211 -0.904 . . . . 0.0 109.514 177.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.49 HG23 ' HD3' ' A' ' 92' ' ' ARG . 87.4 t -94.95 137.65 22.78 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 175.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.507 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.2 m-85 -89.62 93.97 9.68 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 175.183 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 13.3 m120 -89.13 69.21 8.32 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 178.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.8 m -143.35 148.2 35.88 Favored 'General case' 0 N--CA 1.429 -1.515 0 CA-C-N 114.539 -1.21 . . . . 0.0 109.719 -176.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -112.64 45.48 1.31 Allowed 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 121.288 0.566 . . . . 0.0 111.303 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.1 t -171.52 179.92 2.75 Favored 'General case' 0 N--CA 1.439 -1.025 0 N-CA-C 106.332 -1.729 . . . . 0.0 106.332 -177.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -75.72 135.28 40.37 Favored 'General case' 0 C--O 1.249 1.051 0 CA-C-O 121.635 0.731 . . . . 0.0 109.37 -179.28 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 62.3 mmtt -128.31 141.0 39.94 Favored Pre-proline 0 C--N 1.28 -2.415 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.623 -177.187 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.455 ' O ' ' HD3' ' A' ' 104' ' ' PRO . 32.2 Cg_endo -64.38 142.31 78.36 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 123.508 2.806 . . . . 0.0 111.276 -179.281 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 10.7 t90 -86.5 104.23 5.36 Favored Pre-proline 0 C--N 1.308 -1.228 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 -177.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . 0.455 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 65.1 Cg_endo -75.91 88.61 1.3 Allowed 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 121.944 1.763 . . . . 0.0 113.1 -172.156 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 99.1 t -138.28 144.63 30.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.596 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.67 135.09 19.52 Favored 'General case' 0 N--CA 1.417 -2.092 0 CA-C-N 116.519 -0.309 . . . . 0.0 110.545 177.779 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.51 HD21 HD11 ' A' ' 129' ' ' LEU . 18.6 mt -99.94 103.18 14.73 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.275 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.475 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 22.1 m-85 -82.14 72.18 9.2 Favored 'General case' 0 C--N 1.296 -1.743 0 O-C-N 122.363 -0.211 . . . . 0.0 111.031 177.424 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.675 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -96.96 127.17 42.66 Favored 'General case' 0 C--O 1.207 -1.146 0 CA-C-O 120.571 0.224 . . . . 0.0 110.616 177.819 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -127.54 144.73 52.03 Favored Pre-proline 0 N--CA 1.417 -2.079 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.055 -175.731 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.437 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 28.4 Cg_endo -62.32 118.19 5.07 Favored 'Trans proline' 0 C--O 1.241 0.664 0 C-N-CA 123.164 2.576 . . . . 0.0 111.684 -178.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.474 HG22 ' O ' ' A' ' 70' ' ' ASN . 3.8 m -68.34 -112.82 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.191 -2.001 0 O-C-N 124.38 1.05 . . . . 0.0 113.07 176.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 11.7 p -111.68 -46.26 3.27 Favored 'General case' 0 C--N 1.294 -1.832 0 CA-C-O 121.369 0.604 . . . . 0.0 110.904 179.667 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 11.6 t -82.45 25.69 0.61 Allowed 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 121.937 0.875 . . . . 0.0 111.021 -175.077 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -96.38 131.1 43.28 Favored 'General case' 0 N--CA 1.414 -2.265 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.29 129.54 1.7 Allowed Glycine 0 N--CA 1.436 -1.321 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.072 -178.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.5 -149.78 51.05 Favored Glycine 0 N--CA 1.434 -1.451 0 CA-C-O 119.376 -0.68 . . . . 0.0 111.93 -178.187 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.442 ' CG1' ' HE3' ' A' ' 121' ' ' LYS . 76.9 t -58.14 99.87 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 121.728 0.775 . . . . 0.0 111.088 -177.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.07 -37.76 9.61 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 114.878 -1.056 . . . . 0.0 110.577 -178.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.536 ' HB ' HG22 ' A' ' 154' ' ' VAL . 72.9 mt -118.02 139.04 46.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 178.686 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.523 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.0 mmpt? -115.17 141.82 47.5 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 122.823 0.449 . . . . 0.0 110.375 176.375 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.0 132.63 46.21 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.423 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 87.28 -1.23 86.15 Favored Glycine 0 N--CA 1.431 -1.695 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.779 -178.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 32.1 t -90.92 140.78 29.5 Favored 'General case' 0 N--CA 1.42 -1.972 0 N-CA-C 108.577 -0.898 . . . . 0.0 108.577 178.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.415 HD11 HG23 ' A' ' 128' ' ' VAL . 3.0 tm? -68.83 126.63 30.37 Favored 'General case' 0 N--CA 1.427 -1.61 0 N-CA-C 106.411 -1.699 . . . . 0.0 106.411 175.163 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.796 ' HB ' HG21 ' A' ' 67' ' ' VAL . 29.6 pt -113.67 -27.15 2.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -178.562 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.28 167.96 24.95 Favored 'General case' 0 N--CA 1.443 -0.825 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 -177.8 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.415 HG23 HD11 ' A' ' 125' ' ' LEU . 64.4 t -142.33 113.54 3.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 179.429 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.51 HD11 HD21 ' A' ' 107' ' ' LEU . 37.3 mt -118.04 143.49 46.38 Favored 'General case' 0 C--N 1.288 -2.094 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 179.704 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.416 ' O ' HD23 ' A' ' 58' ' ' LEU . 4.9 mp -123.39 128.43 74.74 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.133 0 C-N-CA 119.709 -0.796 . . . . 0.0 109.411 178.811 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.597 HD13 HG23 ' A' ' 56' ' ' VAL . 1.1 pp -94.34 147.25 23.4 Favored 'General case' 0 CA--C 1.472 -2.05 0 N-CA-C 105.614 -1.995 . . . . 0.0 105.614 172.369 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 59.7 ttt180 -116.57 132.72 56.61 Favored 'General case' 0 N--CA 1.386 -3.635 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 173.435 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.466 ' HG2' HD11 ' A' ' 131' ' ' LEU . 17.0 mm-40 -90.38 148.06 23.06 Favored 'General case' 0 N--CA 1.402 -2.863 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.706 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.428 ' HB ' ' CE2' ' A' ' 55' ' ' TYR . 27.6 m -154.58 138.14 15.99 Favored 'General case' 0 C--N 1.276 -2.622 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 169.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.622 ' CB ' HG23 ' A' ' 52' ' ' ILE . 6.1 p30 . . . . . 0 C--N 1.319 -0.741 0 C-N-CA 119.585 -0.846 . . . . 0.0 111.332 175.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 . . . . . 0 N--CA 1.434 -1.275 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -134.47 146.54 49.86 Favored 'General case' 0 N--CA 1.42 -1.962 0 C-N-CA 118.571 -1.252 . . . . 0.0 111.93 -176.331 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 10.8 m-30 -111.3 126.95 55.44 Favored 'General case' 0 C--N 1.31 -1.13 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -177.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.0 t -91.68 132.29 36.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -178.426 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 55.4 m95 -118.29 101.53 8.27 Favored 'General case' 0 C--N 1.282 -2.334 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 42.5 m-80 -80.88 112.98 18.77 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 178.021 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.42 HG22 HD11 ' A' ' 126' ' ' ILE . 23.7 mm -87.19 122.16 38.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 -177.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -116.51 153.78 31.55 Favored 'General case' 0 C--N 1.293 -1.882 0 C-N-CA 123.242 0.617 . . . . 0.0 109.525 178.208 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.76 130.3 35.11 Favored 'General case' 0 N--CA 1.412 -2.364 0 CA-C-N 115.197 -0.91 . . . . 0.0 108.741 176.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -85.82 -20.69 28.79 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -178.16 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -149.86 147.32 27.81 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 114.21 -1.359 . . . . 0.0 109.269 -173.448 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 16.8 p-10 -89.83 136.73 32.87 Favored 'General case' 0 C--N 1.31 -1.112 0 O-C-N 123.948 0.78 . . . . 0.0 111.119 -177.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.536 HG22 ' HB ' ' A' ' 120' ' ' ILE . 2.0 m -115.65 150.99 17.46 Favored 'Isoleucine or valine' 0 C--O 1.252 1.222 0 CA-C-O 121.053 0.454 . . . . 0.0 111.434 -174.489 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.8 t -122.32 139.42 49.31 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.016 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.208 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.451 HG13 ' O ' ' A' ' 28' ' ' VAL . 75.7 t -100.8 99.4 10.2 Favored Pre-proline 0 C--N 1.293 -1.85 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.429 ' HG3' HG13 ' A' ' 27' ' ' VAL . 33.9 Cg_endo -68.06 -28.47 34.88 Favored 'Trans proline' 0 C--O 1.24 0.591 0 C-N-CA 122.269 1.979 . . . . 0.0 111.954 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.4 t . . . . . 0 C--O 1.249 1.06 0 O-C-N 125.091 1.495 . . . . 0.0 113.799 178.488 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.419 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.426 -1.666 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.464 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 10.4 t -154.71 157.63 38.35 Favored 'General case' 0 C--N 1.299 -1.626 0 C-N-CA 119.423 -0.911 . . . . 0.0 109.719 -176.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.406 ' HE3' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -145.36 163.76 33.57 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.558 -175.174 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 76.2 p -102.02 176.7 5.11 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.591 0.71 . . . . 0.0 110.859 -178.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.88 -1.09 46.51 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.453 -1.249 . . . . 0.0 111.091 179.143 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -100.08 -25.58 14.25 Favored 'General case' 0 N--CA 1.446 -0.67 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.685 174.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 128.19 5.22 5.24 Favored Glycine 0 CA--C 1.507 -0.461 0 C-N-CA 119.838 -1.173 . . . . 0.0 113.22 175.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.0 m -81.33 99.63 8.76 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.58 122.42 34.98 Favored 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 115.45 -0.795 . . . . 0.0 108.925 176.49 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.419 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 66.3 mt -95.13 115.89 65.83 Favored Pre-proline 0 C--N 1.293 -1.88 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 178.018 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.8 163.78 37.79 Favored 'Trans proline' 0 C--O 1.25 1.099 0 C-N-CA 122.156 1.904 . . . . 0.0 110.294 177.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.402 HD11 ' OD2' ' A' ' 47' ' ' ASP . 23.5 mt -67.48 126.18 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.101 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.65 -14.83 1.4 Allowed Glycine 0 C--N 1.297 -1.592 0 C-N-CA 120.491 -0.861 . . . . 0.0 111.62 -175.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 95.17 134.5 7.71 Favored Glycine 0 C--N 1.31 -0.883 0 C-N-CA 120.376 -0.916 . . . . 0.0 111.459 -179.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -178.76 -166.97 35.71 Favored Glycine 0 C--N 1.299 -1.501 0 N-CA-C 109.916 -1.273 . . . . 0.0 109.916 -178.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.451 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 60.0 p -140.23 150.53 44.23 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 117.457 0.629 . . . . 0.0 110.261 -179.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -134.17 161.53 34.64 Favored 'General case' 0 N--CA 1.422 -1.831 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 177.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 19.8 m-80 -116.5 111.13 19.53 Favored 'General case' 0 C--N 1.284 -2.248 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 178.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.432 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.1 m -92.63 149.71 4.1 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.462 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 -178.611 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 55.5 m-85 -132.04 113.71 13.7 Favored 'General case' 0 CA--C 1.492 -1.277 0 O-C-N 122.089 -0.382 . . . . 0.0 110.485 -176.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.516 HG11 HG13 ' A' ' 36' ' ' VAL . 3.5 p -120.93 132.84 69.41 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 CA-C-O 121.451 0.643 . . . . 0.0 111.423 -174.583 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 30.6 m-80 -88.17 123.24 32.62 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 50.0 mt -108.69 159.24 16.9 Favored 'General case' 0 C--N 1.276 -2.61 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 179.666 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.0 120.57 43.78 Favored Pre-proline 0 C--N 1.3 -1.552 0 O-C-N 124.37 1.044 . . . . 0.0 109.523 179.323 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.552 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 66.6 Cg_endo -74.09 -2.93 12.98 Favored 'Trans proline' 0 CA--C 1.531 0.369 0 C-N-CA 122.758 2.305 . . . . 0.0 113.503 -175.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.468 HG13 ' HG3' ' A' ' 157' ' ' PRO . 99.4 t -128.2 109.75 20.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.391 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 12.5 t -147.1 107.48 0.63 Allowed 'Isoleucine or valine' 0 C--O 1.19 -2.068 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -176.472 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.578 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -95.48 156.96 16.11 Favored 'General case' 0 C--N 1.271 -2.819 0 C-N-CA 122.863 0.465 . . . . 0.0 112.12 -179.911 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.432 HG13 ' O ' ' A' ' 112' ' ' VAL . 41.2 t -44.12 115.25 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.674 0 C-N-CA 124.296 1.038 . . . . 0.0 112.07 175.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.19 1.39 51.19 Favored Glycine 0 C--N 1.316 -0.536 0 CA-C-N 115.386 -0.825 . . . . 0.0 113.233 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.578 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -74.1 -176.32 2.52 Favored 'General case' 0 C--N 1.315 -0.916 0 C-N-CA 124.164 0.986 . . . . 0.0 111.005 176.408 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -130.78 93.07 3.34 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 177.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.632 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 19.8 tp -93.41 141.88 27.96 Favored 'General case' 0 C--N 1.29 -1.982 0 C-N-CA 119.348 -0.941 . . . . 0.0 109.545 178.34 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.3 t -135.77 128.3 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.978 0 N-CA-C 109.433 -0.581 . . . . 0.0 109.433 -176.111 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.586 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 56.3 t -97.59 88.87 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.405 -2.721 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 174.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -83.36 115.89 22.22 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 120.822 0.344 . . . . 0.0 110.639 -178.24 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 80.5 mt -97.27 4.19 51.02 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.369 -179.143 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 33.3 t -77.28 -0.17 24.4 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 122.371 1.081 . . . . 0.0 109.115 -178.397 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.1 p -128.07 3.68 5.87 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 114.977 -1.01 . . . . 0.0 110.13 179.129 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.515 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 54.2 mm-40 -122.34 -22.22 5.59 Favored 'General case' 0 CA--C 1.503 -0.858 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.282 -172.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 24.3 mt -136.79 135.64 48.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.032 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 -175.261 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.406 ' HB2' ' HE3' ' A' ' 4' ' ' LYS . 61.3 m-85 -138.53 125.26 20.92 Favored 'General case' 0 CA--C 1.501 -0.919 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 -175.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.464 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 73.7 m -108.2 143.33 37.14 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 30.7 p80 -134.23 156.53 48.22 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-O 120.914 0.388 . . . . 0.0 110.589 -175.536 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.665 ' ND2' ' HA ' ' A' ' 49' ' ' PRO . 56.4 t30 -113.74 100.4 8.44 Favored 'General case' 0 N--CA 1.421 -1.916 0 CA-C-O 122.734 1.254 . . . . 0.0 110.772 176.604 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . 0.402 ' OD2' HD11 ' A' ' 13' ' ' ILE . 0.0 OUTLIER -60.75 -32.21 71.51 Favored 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 127.021 2.128 . . . . 0.0 112.728 179.942 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -130.46 77.2 76.39 Favored Pre-proline 0 C--N 1.318 -0.803 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.665 ' HA ' ' ND2' ' A' ' 46' ' ' ASN . 64.7 Cg_endo -68.42 -4.69 13.41 Favored 'Trans proline' 0 N--CA 1.484 0.93 0 C-N-CA 123.529 2.819 . . . . 0.0 115.95 -169.846 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -118.92 -15.72 9.31 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 121.596 0.713 . . . . 0.0 109.944 178.77 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.45 ' HB ' HD12 ' A' ' 52' ' ' ILE . 2.0 m -96.84 -30.64 13.04 Favored 'General case' 0 N--CA 1.408 -2.573 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -175.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.668 HG23 ' CB ' ' A' ' 135' ' ' ASN . 3.4 mp -132.65 140.47 47.43 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.244 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 179.063 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.8 t -87.83 150.66 23.4 Favored 'General case' 0 C--O 1.254 1.302 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 177.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.562 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 0.9 OUTLIER -79.97 107.91 13.13 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 -178.598 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 76.5 t80 -143.69 144.04 31.69 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -176.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.468 HG13 ' OH ' ' A' ' 77' ' ' TYR . 6.2 p -152.08 150.33 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.179 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 177.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -151.2 133.11 15.07 Favored 'General case' 0 C--O 1.208 -1.079 0 CA-C-O 119.455 -0.307 . . . . 0.0 110.296 175.193 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.521 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 47.9 tp -76.56 106.48 8.23 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 121.132 0.491 . . . . 0.0 109.861 176.617 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.7 tp-100 -53.84 -52.69 59.58 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 125.77 1.628 . . . . 0.0 111.717 177.661 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.403 ' HG3' HD13 ' A' ' 130' ' ' ILE . 1.1 ptp180 -166.37 157.89 13.33 Favored 'General case' 0 C--N 1.307 -1.258 0 N-CA-C 107.597 -1.261 . . . . 0.0 107.597 -179.017 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.13 115.23 0.86 Allowed Glycine 0 N--CA 1.399 -3.814 0 N-CA-C 108.992 -1.643 . . . . 0.0 108.992 -178.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 67.2 m -110.26 147.17 34.35 Favored 'General case' 0 C--N 1.28 -2.423 0 C-N-CA 124.471 1.108 . . . . 0.0 110.338 -171.13 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.547 ' HB2' ' CE2' ' A' ' 84' ' ' PHE . . . -108.83 157.8 18.26 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.47 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 86.9 m-85 -157.01 -179.35 8.12 Favored 'General case' 0 C--O 1.237 0.403 0 C-N-CA 124.21 1.004 . . . . 0.0 108.683 -178.532 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 60.2 -140.68 47.96 Favored Glycine 0 CA--C 1.5 -0.899 0 O-C-N 123.915 0.759 . . . . 0.0 112.851 176.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.09 -12.54 84.54 Favored Glycine 0 N--CA 1.431 -1.669 0 C-N-CA 120.54 -0.838 . . . . 0.0 111.375 177.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.75 HG21 ' HB ' ' A' ' 126' ' ' ILE . 82.4 t -68.45 -39.45 80.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 C-N-CA 123.522 0.729 . . . . 0.0 111.927 -176.293 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.522 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -87.54 -16.23 35.21 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 118.981 -1.088 . . . . 0.0 112.272 178.897 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 8.0 t -101.06 -58.05 1.97 Allowed 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.329 0.585 . . . . 0.0 111.399 -174.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.511 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 47.6 m-20 -87.09 -25.31 24.21 Favored 'General case' 0 CA--C 1.492 -1.283 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.133 -174.673 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.673 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 83.7 m-85 -108.24 158.19 17.68 Favored 'General case' 0 N--CA 1.415 -2.223 0 C-N-CA 120.03 -0.668 . . . . 0.0 110.352 179.342 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.6 t -164.91 135.76 4.02 Favored 'General case' 0 N--CA 1.409 -2.522 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 176.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.424 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.31 -109.12 0.22 Allowed Glycine 0 N--CA 1.406 -3.356 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 174.862 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.447 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.3 p -159.72 179.33 8.95 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 123.695 0.798 . . . . 0.0 110.827 -174.198 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.5 p -132.55 145.47 34.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 178.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.633 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.2 tttt -124.08 144.87 49.62 Favored 'General case' 0 N--CA 1.417 -2.084 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.471 -179.4 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.468 ' OH ' HG13 ' A' ' 56' ' ' VAL . 59.2 t80 -146.33 114.71 6.7 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -178.638 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.0 m 54.05 36.68 25.2 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 113.974 1.101 . . . . 0.0 113.974 177.431 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.16 12.19 81.23 Favored Glycine 0 C--N 1.309 -0.917 0 C-N-CA 119.579 -1.296 . . . . 0.0 112.587 -178.593 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.633 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 7.9 t -83.8 178.87 7.74 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 176.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 48.8 p -154.74 111.04 3.23 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 -178.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.442 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 3.4 p90 -154.73 158.86 32.26 Favored Pre-proline 0 C--N 1.305 -1.331 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 -175.315 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.447 ' HA ' HG22 ' A' ' 74' ' ' THR . 73.0 Cg_endo -71.31 147.91 54.07 Favored 'Trans proline' 0 C--N 1.355 0.904 0 C-N-CA 123.089 2.526 . . . . 0.0 113.259 -176.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.59 ' CD2' HD21 ' A' ' 109' ' ' LEU . 48.3 t80 -119.35 135.63 24.1 Favored Pre-proline 0 N--CA 1.433 -1.291 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.082 -178.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.518 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 57.0 Cg_endo -71.18 148.15 89.12 Favored 'Cis proline' 0 CA--C 1.538 0.678 0 C-N-CA 122.741 -1.774 . . . . 0.0 110.365 -1.532 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 7.9 t -65.64 -175.24 0.26 Allowed 'General case' 0 CA--C 1.55 0.976 0 C-N-CA 122.616 0.366 . . . . 0.0 110.288 -178.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 13.9 p -122.42 -36.45 2.94 Favored 'General case' 0 N--CA 1.432 -1.334 0 CA-C-O 121.664 0.745 . . . . 0.0 109.017 -172.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.4 t -132.49 -137.51 0.19 Allowed 'General case' 1 N--CA 1.364 -4.77 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 176.154 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . 0.442 ' HA ' ' O ' ' A' ' 58' ' ' LEU . 19.6 tt0 -105.67 156.99 17.73 Favored 'General case' 0 C--N 1.264 -3.12 0 C-N-CA 125.958 1.703 . . . . 0.0 109.377 -170.595 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.521 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 23.7 p -74.76 162.27 74.27 Favored Pre-proline 0 C--N 1.31 -1.14 0 C-N-CA 123.322 0.649 . . . . 0.0 111.203 178.467 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -59.05 162.7 13.12 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 122.976 2.451 . . . . 0.0 111.236 176.137 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.5 tmm_? -68.92 125.98 28.35 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -176.272 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 71.5 t -140.14 128.48 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.83 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 -177.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 54' ' ' ASP . 1.9 p -124.68 132.37 71.41 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.378 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.206 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.562 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.4 m-85 -81.03 140.27 35.25 Favored 'General case' 0 C--N 1.298 -1.662 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 177.795 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -108.37 28.14 8.64 Favored 'General case' 0 C--N 1.292 -1.899 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . 0.444 ' OG ' ' HB3' ' A' ' 95' ' ' TYR . 5.0 p -84.08 178.93 7.64 Favored 'General case' 0 N--CA 1.423 -1.807 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.918 -175.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -151.27 32.38 0.59 Allowed 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 171.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.1 t -163.62 -176.45 4.68 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 -176.484 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -76.84 134.25 39.1 Favored 'General case' 0 CA--C 1.506 -0.736 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.131 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . 0.584 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 7.8 mmpt? -137.39 152.4 73.13 Favored Pre-proline 0 C--N 1.29 -2.015 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -67.63 147.15 75.66 Favored 'Trans proline' 0 N--CA 1.443 -1.445 0 C-N-CA 122.305 2.003 . . . . 0.0 111.998 -177.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . 0.489 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.0 t90 -88.0 111.41 42.53 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . 0.462 ' HD3' ' OH ' ' A' ' 95' ' ' TYR . 2.5 Cg_endo -79.47 87.6 1.53 Allowed 'Trans proline' 0 N--CA 1.443 -1.448 0 C-N-CA 121.386 1.39 . . . . 0.0 112.069 -172.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.406 HG22 ' HD2' ' A' ' 77' ' ' TYR . 95.9 t -140.13 142.75 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.339 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 177.488 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.586 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.58 135.62 17.65 Favored 'General case' 0 N--CA 1.421 -1.899 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 178.158 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.491 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 16.8 mt -101.89 103.38 14.05 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.424 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 25.7 m-85 -84.38 76.62 10.12 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 120.767 0.318 . . . . 0.0 110.24 178.477 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.673 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.2 mm? -103.33 131.04 50.72 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 177.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.23 147.61 66.44 Favored Pre-proline 0 N--CA 1.418 -2.029 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.528 -175.317 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.511 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 30.3 Cg_endo -62.04 121.08 8.97 Favored 'Trans proline' 0 C--O 1.25 1.083 0 C-N-CA 123.068 2.512 . . . . 0.0 111.841 -178.188 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.509 HG22 ' O ' ' A' ' 70' ' ' ASN . 4.2 m -69.89 -120.52 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.186 -2.242 0 CA-C-N 114.026 -1.443 . . . . 0.0 111.218 175.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 23.0 t -111.06 -35.82 5.81 Favored 'General case' 0 C--N 1.291 -1.94 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 175.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 27.6 t -82.06 36.8 0.47 Allowed 'General case' 0 N--CA 1.441 -0.919 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.919 -176.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -117.02 133.47 55.96 Favored 'General case' 0 N--CA 1.418 -2.043 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 177.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -172.95 129.55 1.72 Allowed Glycine 0 N--CA 1.437 -1.24 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.21 -146.06 48.46 Favored Glycine 0 CA--C 1.491 -1.454 0 CA-C-O 119.143 -0.809 . . . . 0.0 111.781 -177.396 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.2 p -58.05 101.27 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-O 122.598 1.19 . . . . 0.0 112.157 -177.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -102.03 -23.09 14.14 Favored 'General case' 0 C--N 1.294 -1.827 0 CA-C-N 114.674 -1.148 . . . . 0.0 111.001 -178.484 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.519 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 65.3 mt -136.56 137.14 48.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.329 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.554 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.1 mmpt? -113.3 137.58 51.28 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-O 120.864 0.364 . . . . 0.0 110.664 176.657 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.94 134.82 48.79 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.749 -0.66 . . . . 0.0 109.833 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 85.17 6.96 83.91 Favored Glycine 0 C--N 1.303 -1.273 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.768 -178.808 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 49.4 m -109.44 144.58 37.48 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 177.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.438 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -70.38 126.57 30.02 Favored 'General case' 0 N--CA 1.443 -0.783 0 CA-C-N 115.045 -0.98 . . . . 0.0 108.58 -178.776 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.75 ' HB ' HG21 ' A' ' 67' ' ' VAL . 34.4 pt -113.0 -26.05 3.21 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 N-CA-C 112.469 0.544 . . . . 0.0 112.469 -179.39 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . 0.42 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -160.82 165.29 30.51 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 -178.07 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.438 HG23 HD11 ' A' ' 125' ' ' LEU . 63.7 t -140.63 112.88 4.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 179.062 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.487 HD11 HD21 ' A' ' 107' ' ' LEU . 50.9 mt -117.1 143.99 45.17 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.44 ' O ' HD12 ' A' ' 58' ' ' LEU . 5.0 mp -128.9 123.77 59.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.054 0 C-N-CA 119.616 -0.834 . . . . 0.0 109.946 179.206 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.439 ' C ' HD12 ' A' ' 131' ' ' LEU . 1.4 pp -88.72 147.03 24.7 Favored 'General case' 0 CA--C 1.477 -1.855 0 N-CA-C 106.304 -1.739 . . . . 0.0 106.304 174.512 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 37.3 ttp180 -112.42 123.41 50.22 Favored 'General case' 0 C--N 1.258 -3.39 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 173.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.28 135.88 33.65 Favored 'General case' 0 N--CA 1.408 -2.53 0 N-CA-C 105.625 -1.991 . . . . 0.0 105.625 -176.407 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 35.2 m -147.29 147.22 30.16 Favored 'General case' 0 C--N 1.269 -2.919 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 175.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.668 ' CB ' HG23 ' A' ' 52' ' ' ILE . 11.5 p30 . . . . . 0 N--CA 1.438 -1.036 0 C-N-CA 119.708 -0.797 . . . . 0.0 110.983 178.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 . . . . . 0 N--CA 1.426 -1.642 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -123.8 146.61 48.22 Favored 'General case' 0 C--N 1.286 -2.162 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.042 -177.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 9.8 m-30 -113.01 125.88 54.9 Favored 'General case' 0 C--N 1.309 -1.156 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 -176.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.451 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 58.3 t -89.27 134.31 28.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 O-C-N 123.553 0.533 . . . . 0.0 110.409 -177.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 58.9 m95 -120.26 97.03 5.39 Favored 'General case' 0 C--N 1.284 -2.246 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 -78.34 113.1 16.01 Favored 'General case' 0 C--N 1.283 -2.318 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 177.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.432 ' HA ' HG22 ' A' ' 20' ' ' VAL . 22.8 mm -88.74 122.17 39.81 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -177.183 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 47.4 m-85 -118.11 153.04 34.43 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.509 0.671 . . . . 0.0 109.809 178.061 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -78.98 128.89 33.85 Favored 'General case' 0 N--CA 1.409 -2.517 0 CA-C-N 114.609 -1.178 . . . . 0.0 108.159 175.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -88.71 -15.5 34.66 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -178.404 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -151.01 145.39 25.5 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 113.578 -1.646 . . . . 0.0 109.641 -175.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -79.92 144.63 33.2 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 124.019 0.928 . . . . 0.0 110.753 -178.624 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.552 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 71.2 t -121.54 134.62 64.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.11 -176.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.5 t -118.58 134.43 62.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 -179.447 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.47 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 75.5 t -97.46 101.68 10.82 Favored Pre-proline 0 C--N 1.292 -1.934 0 C-N-CA 123.889 0.876 . . . . 0.0 108.778 177.633 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.468 ' HG3' HG13 ' A' ' 27' ' ' VAL . 35.8 Cg_endo -67.22 -28.38 40.33 Favored 'Trans proline' 0 CA--C 1.511 -0.643 0 C-N-CA 121.893 1.729 . . . . 0.0 112.018 -178.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . 0.403 ' HB ' HG12 ' A' ' 156' ' ' VAL . 8.0 t . . . . . 0 CA--C 1.559 1.298 0 O-C-N 124.827 1.329 . . . . 0.0 112.831 176.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.509 -0.63 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.433 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 74.1 m -134.17 161.94 33.52 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 119.747 -0.781 . . . . 0.0 112.211 -173.703 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.463 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -146.78 161.67 40.16 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.215 -176.84 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.451 HG22 HG22 ' A' ' 20' ' ' VAL . 72.7 p -99.48 179.56 4.52 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 121.225 0.536 . . . . 0.0 111.557 -178.716 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.58 -26.62 50.92 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.862 177.14 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 5.6 p30 -79.4 -31.33 42.73 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 119.433 -0.907 . . . . 0.0 109.414 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 129.08 20.42 1.45 Allowed Glycine 0 N--CA 1.431 -1.687 0 C-N-CA 119.911 -1.138 . . . . 0.0 112.933 173.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.42 ' O ' ' HA ' ' A' ' 4' ' ' LYS . 2.6 m -87.98 99.31 12.06 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.565 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.06 121.32 32.76 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 115.795 -0.638 . . . . 0.0 109.539 177.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 63.5 mt -99.82 116.67 64.54 Favored Pre-proline 0 C--N 1.29 -1.99 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 177.293 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -77.39 168.57 22.66 Favored 'Trans proline' 0 C--O 1.251 1.151 0 C-N-CA 122.45 2.1 . . . . 0.0 110.912 177.704 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 64.9 mt -66.56 124.91 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.595 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 145.04 -5.0 1.42 Allowed Glycine 0 C--N 1.303 -1.304 0 CA-C-N 115.723 -0.671 . . . . 0.0 111.636 -176.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 94.37 161.17 34.75 Favored Glycine 0 N--CA 1.439 -1.145 0 N-CA-C 110.122 -1.191 . . . . 0.0 110.122 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 159.38 -167.01 34.96 Favored Glycine 0 CA--C 1.486 -1.758 0 C-N-CA 119.484 -1.341 . . . . 0.0 111.342 179.044 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 49.9 p -147.08 152.37 38.41 Favored 'General case' 0 N--CA 1.424 -1.761 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -178.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -138.39 163.41 31.95 Favored 'General case' 0 N--CA 1.417 -2.082 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.013 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -108.42 118.14 35.99 Favored 'General case' 0 N--CA 1.406 -2.662 0 CA-C-N 114.342 -1.299 . . . . 0.0 107.964 176.457 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.451 HG22 HG22 ' A' ' 5' ' ' THR . 49.3 t -104.96 130.5 55.95 Favored 'Isoleucine or valine' 0 C--N 1.264 -3.113 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.142 178.776 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -118.75 128.09 54.17 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -179.352 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.55 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -138.01 137.26 44.75 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 O-C-N 124.128 0.893 . . . . 0.0 110.932 -176.545 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 37.3 m-80 -90.28 139.63 30.47 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 178.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.7 HD21 HG22 ' A' ' 36' ' ' VAL . 5.1 mp -122.72 161.95 22.93 Favored 'General case' 0 C--N 1.282 -2.367 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.183 176.852 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.03 120.85 54.26 Favored Pre-proline 0 C--N 1.316 -0.863 0 O-C-N 124.653 1.221 . . . . 0.0 109.404 178.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 73.5 Cg_endo -75.68 3.75 5.68 Favored 'Trans proline' 0 CA--C 1.532 0.392 0 C-N-CA 122.846 2.364 . . . . 0.0 113.398 -176.154 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.4 t -132.0 109.79 15.84 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 178.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.52 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.1 t -141.85 107.7 1.78 Allowed 'Isoleucine or valine' 0 C--O 1.182 -2.448 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -176.639 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.664 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -96.4 150.36 20.67 Favored 'General case' 0 C--N 1.269 -2.895 0 O-C-N 122.036 -0.415 . . . . 0.0 111.303 -179.864 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.402 HG13 ' O ' ' A' ' 112' ' ' VAL . 35.0 t -45.81 117.44 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 123.445 0.698 . . . . 0.0 111.976 176.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.62 1.61 53.01 Favored Glycine 0 CA--C 1.523 0.576 0 CA-C-N 115.414 -0.812 . . . . 0.0 112.829 -178.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.664 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.1 OUTLIER -73.02 -178.0 2.64 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 123.891 0.876 . . . . 0.0 110.034 177.639 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -130.22 86.82 2.44 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 177.636 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.624 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 20.2 tp -89.94 145.49 25.08 Favored 'General case' 0 C--N 1.294 -1.824 0 C-N-CA 119.765 -0.774 . . . . 0.0 109.259 -179.256 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 73.7 t -137.73 134.5 45.8 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.73 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -178.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.7 HG22 HD21 ' A' ' 24' ' ' LEU . 21.0 t -99.99 89.62 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.41 -2.426 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 174.32 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -83.35 114.95 21.78 Favored 'General case' 0 C--N 1.3 -1.562 0 C-N-CA 119.91 -0.716 . . . . 0.0 111.125 -176.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 82.7 mt -99.78 -2.39 35.24 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.69 -177.397 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.6 m -73.68 -2.08 21.7 Favored 'General case' 0 C--O 1.208 -1.13 0 CA-C-O 122.222 1.011 . . . . 0.0 109.191 -179.503 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.2 p -126.21 7.48 7.17 Favored 'General case' 0 N--CA 1.419 -1.985 0 CA-C-N 115.151 -0.931 . . . . 0.0 109.776 179.002 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.55 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 48.6 mm-40 -125.42 -20.23 4.83 Favored 'General case' 0 CA--C 1.508 -0.648 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.9 -174.692 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.5 mt -135.3 137.31 50.23 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 -176.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.463 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 74.8 m-85 -137.68 153.67 49.78 Favored 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 -176.07 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.433 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 90.5 m -132.23 134.91 45.87 Favored 'General case' 0 C--N 1.28 -2.419 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.875 -178.637 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 18.7 p-80 -122.64 131.0 53.61 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.428 -175.486 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.401 HD21 ' HA ' ' A' ' 98' ' ' ARG . 4.2 p-10 -77.83 118.17 19.9 Favored 'General case' 0 N--CA 1.422 -1.83 0 CA-C-O 122.09 0.948 . . . . 0.0 108.963 178.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -97.24 -27.1 14.68 Favored 'General case' 0 C--N 1.274 -2.696 0 CA-C-N 114.154 -1.385 . . . . 0.0 110.387 -177.022 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 37.5 m-85 -148.93 68.43 9.63 Favored Pre-proline 0 N--CA 1.483 1.182 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.416 ' HA ' ' OD2' ' A' ' 54' ' ' ASP . 58.4 Cg_endo -67.85 -11.72 33.01 Favored 'Trans proline' 0 N--CA 1.481 0.766 0 C-N-CA 122.925 2.417 . . . . 0.0 114.281 -171.587 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -114.58 -14.03 12.11 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 121.208 0.528 . . . . 0.0 110.565 -177.474 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.517 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.3 m -101.87 -29.24 11.96 Favored 'General case' 0 N--CA 1.424 -1.731 0 CA-C-O 122.047 0.927 . . . . 0.0 108.881 -173.28 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.517 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.4 mp -128.56 141.21 47.14 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.168 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 178.403 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 14.5 t -74.52 136.35 42.18 Favored 'General case' 0 N--CA 1.428 -1.563 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 174.071 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.49 ' O ' HG23 ' A' ' 94' ' ' VAL . 51.3 m-20 -95.98 105.82 17.9 Favored 'General case' 0 C--N 1.263 -3.173 0 C-N-CA 118.457 -1.297 . . . . 0.0 108.404 -179.305 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.505 ' CD2' ' HB ' ' A' ' 134' ' ' THR . 15.8 t80 -142.21 139.44 32.02 Favored 'General case' 0 C--N 1.289 -2.052 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.482 -173.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.423 ' CG2' ' HG ' ' A' ' 131' ' ' LEU . 14.9 p -148.56 156.01 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.943 0 O-C-N 123.832 0.708 . . . . 0.0 109.991 -178.44 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.29 135.54 17.94 Favored 'General case' 0 N--CA 1.422 -1.845 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 176.24 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.521 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 32.5 tp -70.6 110.44 5.45 Favored 'General case' 0 N--CA 1.427 -1.579 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 170.553 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.412 ' HB2' ' HB2' ' A' ' 132' ' ' ARG . 3.2 tp-100 -57.6 -56.63 19.41 Favored 'General case' 0 C--O 1.206 -1.227 0 CA-C-N 113.576 -1.647 . . . . 0.0 109.479 -177.58 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 10.5 ptp180 -164.09 156.56 17.25 Favored 'General case' 0 N--CA 1.41 -2.461 0 CA-C-N 114.364 -1.289 . . . . 0.0 108.472 -177.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -140.58 135.83 7.26 Favored Glycine 0 N--CA 1.4 -3.712 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -179.535 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 46.0 m -124.81 147.68 48.59 Favored 'General case' 0 C--N 1.276 -2.591 0 C-N-CA 124.139 0.975 . . . . 0.0 110.473 -175.694 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.506 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -106.81 158.83 16.69 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.508 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 97.1 m-85 -154.61 175.4 13.7 Favored 'General case' 0 C--N 1.341 0.231 0 C-N-CA 124.139 0.975 . . . . 0.0 109.864 -177.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.02 -143.28 45.84 Favored Glycine 0 N--CA 1.446 -0.671 0 O-C-N 123.791 0.682 . . . . 0.0 113.104 176.486 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.36 -13.12 73.59 Favored Glycine 0 C--O 1.202 -1.868 0 C-N-CA 120.962 -0.637 . . . . 0.0 111.742 177.063 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.855 HG21 ' HB ' ' A' ' 126' ' ' ILE . 94.7 t -70.29 -36.75 68.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 123.414 0.686 . . . . 0.0 112.043 -177.64 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.506 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -90.04 -18.54 25.76 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.58 -1.248 . . . . 0.0 112.374 177.248 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 5.0 t -99.88 -51.13 3.8 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.369 -172.134 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.456 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 67.7 m-20 -96.2 -23.18 16.84 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 -174.683 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.645 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 89.6 m-85 -110.73 156.3 21.24 Favored 'General case' 0 N--CA 1.422 -1.868 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 177.588 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.0 t -165.59 127.89 2.06 Favored 'General case' 0 N--CA 1.411 -2.409 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 176.513 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.29 -111.24 0.27 Allowed Glycine 0 N--CA 1.407 -3.233 0 N-CA-C 111.574 -0.61 . . . . 0.0 111.574 176.462 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -153.63 -179.91 8.23 Favored 'General case' 0 C--N 1.291 -1.941 0 C-N-CA 123.933 0.893 . . . . 0.0 110.366 -173.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 3.2 p -135.8 151.51 29.61 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.242 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.691 ' HG3' ' O ' ' A' ' 80' ' ' SER . 72.3 tttt -130.91 147.53 52.57 Favored 'General case' 0 N--CA 1.423 -1.794 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -178.676 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.448 ' CD2' HG22 ' A' ' 105' ' ' VAL . 47.5 t80 -148.13 108.67 4.15 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 -177.199 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 13.8 t 51.21 44.62 28.68 Favored 'General case' 0 CA--C 1.553 1.06 0 C-N-CA 123.433 0.693 . . . . 0.0 111.197 175.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 81.22 20.89 63.75 Favored Glycine 0 CA--C 1.525 0.671 0 C-N-CA 120.264 -0.97 . . . . 0.0 113.115 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.691 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 16.3 t -90.53 179.26 5.89 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 106.927 -1.508 . . . . 0.0 106.927 174.649 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 10.9 m -157.47 103.55 1.96 Allowed 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 178.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.423 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.6 p90 -147.65 158.75 42.59 Favored Pre-proline 0 C--N 1.308 -1.222 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -172.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.417 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 56.6 Cg_endo -68.78 150.16 73.65 Favored 'Trans proline' 0 C--N 1.356 0.964 0 C-N-CA 122.933 2.422 . . . . 0.0 112.837 -177.654 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.541 ' CD2' HD21 ' A' ' 109' ' ' LEU . 47.3 t80 -124.5 134.77 25.83 Favored Pre-proline 0 N--CA 1.431 -1.402 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 179.293 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.54 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 59.3 Cg_endo -71.03 145.61 82.69 Favored 'Cis proline' 0 CA--C 1.554 1.51 0 C-N-CA 123.105 -1.623 . . . . 0.0 111.153 -2.438 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.2 t -68.43 -176.81 0.81 Allowed 'General case' 0 N--CA 1.489 1.52 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.32 -175.398 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 56.1 p -124.89 -47.34 1.8 Allowed 'General case' 0 N--CA 1.436 -1.164 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -172.362 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 10.0 t -105.4 -65.19 1.07 Allowed 'General case' 0 N--CA 1.437 -1.123 0 C-N-CA 120.39 -0.524 . . . . 0.0 111.246 -174.242 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 176.23 -172.98 0.09 Allowed 'General case' 0 C--O 1.247 0.97 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 -175.546 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.521 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 42.4 p -100.9 168.44 9.24 Favored Pre-proline 0 C--N 1.297 -1.708 0 O-C-N 123.429 0.455 . . . . 0.0 111.707 175.326 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . 0.453 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 19.0 Cg_endo -55.78 165.19 3.84 Favored 'Trans proline' 0 CA--C 1.547 1.158 0 C-N-CA 123.232 2.621 . . . . 0.0 111.962 171.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.403 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 1.7 tmm_? -76.68 112.75 13.58 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -176.587 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 76.4 t -126.4 128.33 71.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-O 121.522 0.677 . . . . 0.0 110.15 -176.305 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 54' ' ' ASP . 0.2 OUTLIER -121.71 132.32 71.08 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 CA-C-N 115.038 -0.983 . . . . 0.0 110.776 -177.571 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.49 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 7.2 m-85 -80.78 101.04 9.09 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.19 -178.084 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 16.7 m120 -96.63 64.31 2.13 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.6 m -142.02 178.1 7.76 Favored 'General case' 0 N--CA 1.434 -1.229 0 O-C-N 121.778 -0.576 . . . . 0.0 110.844 -174.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.401 ' HA ' HD21 ' A' ' 46' ' ' ASN . 6.8 ptp180 -141.22 45.75 1.75 Allowed 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.066 0.46 . . . . 0.0 110.446 -178.678 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.0 t -170.53 177.44 4.0 Favored 'General case' 0 C--O 1.245 0.847 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 -174.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -73.03 98.16 2.48 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 173.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 10.0 tptp -97.1 142.59 24.76 Favored Pre-proline 0 C--N 1.277 -2.587 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.415 ' O ' ' HD3' ' A' ' 104' ' ' PRO . 26.8 Cg_endo -62.91 154.72 64.72 Favored 'Trans proline' 0 C--N 1.324 -0.75 0 C-N-CA 122.428 2.086 . . . . 0.0 112.395 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . 0.49 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 15.4 t90 -95.71 100.94 6.96 Favored Pre-proline 0 C--N 1.306 -1.32 0 N-CA-C 105.102 -2.184 . . . . 0.0 105.102 175.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . 0.415 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 59.6 Cg_endo -74.57 88.63 1.16 Allowed 'Trans proline' 0 N--CA 1.454 -0.837 0 C-N-CA 121.782 1.655 . . . . 0.0 113.341 -170.052 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.448 HG22 ' CD2' ' A' ' 77' ' ' TYR . 96.9 t -138.61 145.12 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.193 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.534 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.65 138.47 19.92 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 177.269 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.475 ' HB2' ' CG2' ' A' ' 36' ' ' VAL . 17.7 mt -102.82 104.3 14.56 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 9.5 m-85 -81.32 67.33 7.22 Favored 'General case' 0 C--N 1.295 -1.788 0 O-C-N 122.023 -0.423 . . . . 0.0 111.355 179.206 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.645 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.4 mm? -92.84 134.54 34.97 Favored 'General case' 0 C--O 1.208 -1.127 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 176.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.62 148.11 62.33 Favored Pre-proline 0 C--N 1.294 -1.829 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -176.18 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.456 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 28.8 Cg_endo -62.98 121.46 9.35 Favored 'Trans proline' 0 C--O 1.243 0.753 0 C-N-CA 123.235 2.624 . . . . 0.0 112.555 -176.726 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.402 ' O ' HG13 ' A' ' 30' ' ' VAL . 2.4 m -71.86 -116.9 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.186 -2.237 0 CA-C-N 114.225 -1.352 . . . . 0.0 112.715 176.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 28.9 t -112.54 -37.54 4.9 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 177.191 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 47.9 m -73.42 16.21 0.2 Allowed 'General case' 0 N--CA 1.399 -2.999 0 C-N-CA 125.997 1.719 . . . . 0.0 113.653 -176.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -102.7 131.69 49.34 Favored 'General case' 0 N--CA 1.411 -2.399 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -176.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.94 129.33 1.62 Allowed Glycine 0 N--CA 1.434 -1.447 0 N-CA-C 110.634 -0.987 . . . . 0.0 110.634 179.377 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.89 -151.29 51.92 Favored Glycine 0 CA--C 1.5 -0.888 0 CA-C-O 119.085 -0.842 . . . . 0.0 111.53 -176.757 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.9 p -54.86 104.6 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 122.233 1.016 . . . . 0.0 111.914 -177.518 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.85 -31.2 9.4 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 115.043 -0.981 . . . . 0.0 111.461 -177.166 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.53 ' HB ' HG22 ' A' ' 154' ' ' VAL . 69.7 mt -124.4 140.86 46.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 177.186 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.42 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 2.8 mmpt? -117.67 139.44 51.01 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-O 121.001 0.429 . . . . 0.0 111.073 178.483 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.7 131.67 44.95 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.406 -0.815 . . . . 0.0 110.769 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 87.31 -7.9 78.97 Favored Glycine 0 C--N 1.309 -0.931 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.079 -179.58 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 25.3 m -90.69 148.59 22.5 Favored 'General case' 0 N--CA 1.425 -1.716 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 24.9 tp -73.76 133.0 43.22 Favored 'General case' 0 N--CA 1.436 -1.132 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.229 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.855 ' HB ' HG21 ' A' ' 67' ' ' VAL . 37.9 pt -118.42 -24.44 3.25 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 C-N-CA 120.432 -0.507 . . . . 0.0 112.352 -179.519 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . 0.47 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -163.3 164.33 24.92 Favored 'General case' 0 N--CA 1.439 -0.977 0 CA-C-O 120.538 0.209 . . . . 0.0 110.614 -178.633 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 53.5 t -140.74 114.36 5.36 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 178.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.41 HD11 HD21 ' A' ' 107' ' ' LEU . 54.3 mt -117.55 139.01 51.52 Favored 'General case' 0 C--N 1.287 -2.12 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.54 HG21 HE21 ' A' ' 143' ' ' GLN . 5.0 mp -117.33 122.29 69.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 C-N-CA 119.314 -0.954 . . . . 0.0 109.918 177.372 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.494 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.0 OUTLIER -90.44 132.73 35.47 Favored 'General case' 0 C--N 1.275 -2.649 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 177.439 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . 0.412 ' HB2' ' HB2' ' A' ' 59' ' ' GLN . 17.7 tpt85 -106.85 109.54 21.47 Favored 'General case' 0 C--N 1.274 -2.709 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.149 -176.05 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -88.34 132.67 34.33 Favored 'General case' 0 CA--C 1.484 -1.574 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 175.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.505 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 11.7 m -136.41 133.57 36.83 Favored 'General case' 0 C--N 1.273 -2.724 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 177.636 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 16.3 p30 . . . . . 0 C--N 1.31 -1.141 0 CA-C-O 121.404 0.621 . . . . 0.0 111.634 -179.185 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 . . . . . 0 N--CA 1.44 -0.952 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . 0.54 HE21 HG21 ' A' ' 130' ' ' ILE . 16.6 pt20 -119.92 143.72 47.82 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 178.42 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.478 ' HB2' HD22 ' A' ' 131' ' ' LEU . 9.6 m-30 -112.48 134.35 54.06 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -176.513 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 47.4 t -91.51 131.09 39.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 CA-C-O 121.155 0.502 . . . . 0.0 110.08 -179.096 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . 0.494 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 65.3 m95 -120.23 97.96 5.84 Favored 'General case' 0 C--N 1.284 -2.274 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -179.217 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 36.9 m-80 -80.35 114.1 19.01 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 106.992 -1.485 . . . . 0.0 106.992 178.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.47 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 22.5 mm -89.3 122.53 40.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 -177.784 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -120.31 152.75 37.39 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 123.428 0.691 . . . . 0.0 109.605 178.803 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.73 132.92 34.82 Favored 'General case' 0 N--CA 1.418 -2.03 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 177.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -90.1 -15.45 31.66 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 -178.19 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -149.27 144.52 26.56 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 114.049 -1.432 . . . . 0.0 109.431 -175.665 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -85.76 148.08 26.02 Favored 'General case' 0 C--N 1.315 -0.906 0 O-C-N 124.022 0.826 . . . . 0.0 109.292 -178.145 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.53 HG22 ' HB ' ' A' ' 120' ' ' ILE . 2.2 m -126.56 148.34 31.31 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 C-N-CA 120.256 -0.578 . . . . 0.0 110.557 -176.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.5 t -120.14 140.6 43.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.032 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 -179.144 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.52 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 79.4 t -101.57 101.63 18.46 Favored Pre-proline 0 C--N 1.297 -1.676 0 C-N-CA 123.871 0.868 . . . . 0.0 109.706 178.233 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.451 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 30.3 Cg_endo -68.28 -25.85 36.17 Favored 'Trans proline' 0 CA--C 1.518 -0.304 0 C-N-CA 122.315 2.01 . . . . 0.0 112.378 178.661 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 5.8 t . . . . . 0 CA--C 1.559 1.31 0 O-C-N 124.646 1.216 . . . . 0.0 113.352 176.506 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.511 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.44 -0.934 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.445 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 68.4 m -142.41 159.0 43.09 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 120.274 -0.57 . . . . 0.0 110.912 -174.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.438 ' HD2' ' O ' ' A' ' 5' ' ' THR . 0.0 OUTLIER -146.12 156.87 43.74 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-O 121.14 0.495 . . . . 0.0 109.978 -177.469 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.438 ' O ' ' HD2' ' A' ' 4' ' ' LYS . 41.1 p -91.83 176.08 6.65 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.613 -179.178 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -85.23 -5.08 59.34 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 114.866 -1.061 . . . . 0.0 110.838 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.96 -34.49 8.92 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.877 -179.689 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 140.06 7.27 0.99 Allowed Glycine 0 C--N 1.316 -0.529 0 C-N-CA 118.796 -1.668 . . . . 0.0 115.236 172.289 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.7 m -87.37 102.3 14.39 Favored 'General case' 0 C--N 1.296 -1.755 0 O-C-N 121.892 -0.77 . . . . 0.0 109.039 177.164 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.57 122.12 37.98 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 115.396 -0.82 . . . . 0.0 108.84 175.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.511 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 63.7 mt -102.01 116.15 63.64 Favored Pre-proline 0 C--N 1.298 -1.649 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.187 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.25 173.8 12.11 Favored 'Trans proline' 0 C--O 1.247 0.954 0 C-N-CA 122.814 2.343 . . . . 0.0 111.469 178.069 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 58.8 mt -66.64 129.59 31.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 178.215 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 140.14 -6.79 2.85 Favored Glycine 0 C--N 1.303 -1.252 0 N-CA-C 111.358 -0.697 . . . . 0.0 111.358 -178.705 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 96.84 156.26 30.76 Favored Glycine 0 N--CA 1.438 -1.199 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -179.108 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 170.33 -175.46 44.25 Favored Glycine 0 N--CA 1.428 -1.886 0 C-N-CA 119.822 -1.18 . . . . 0.0 111.142 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.6 m -144.96 148.88 34.3 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 178.631 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.98 165.4 26.08 Favored 'General case' 0 CA--C 1.48 -1.727 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -114.85 110.09 19.14 Favored 'General case' 0 C--N 1.278 -2.543 0 CA-C-N 114.098 -1.41 . . . . 0.0 107.482 177.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.436 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.3 m -97.65 142.08 14.91 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.321 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.694 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.2 m-85 -124.07 124.56 42.79 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 121.039 0.447 . . . . 0.0 110.989 -178.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.466 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.9 p -138.43 134.85 43.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.825 -178.067 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -94.33 128.06 40.6 Favored 'General case' 0 C--N 1.294 -1.811 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.867 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -104.82 160.51 14.94 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.097 -0.956 . . . . 0.0 108.581 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.75 123.33 57.46 Favored Pre-proline 0 C--O 1.211 -0.949 0 O-C-N 124.258 0.974 . . . . 0.0 109.241 176.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 74.1 Cg_endo -76.57 -0.34 10.35 Favored 'Trans proline' 0 CA--C 1.536 0.592 0 C-N-CA 122.5 2.133 . . . . 0.0 113.567 -175.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.5 t -128.85 109.77 19.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 179.57 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.428 HG21 HD22 ' A' ' 34' ' ' LEU . 5.2 t -145.09 104.69 0.71 Allowed 'Isoleucine or valine' 0 C--O 1.198 -1.639 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -178.078 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.523 ' HB3' ' HG2' ' A' ' 157' ' ' PRO . 0.5 OUTLIER -94.36 154.84 17.28 Favored 'General case' 0 C--N 1.275 -2.668 0 C-N-CA 123.212 0.605 . . . . 0.0 111.61 -179.902 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.433 ' H ' ' HA ' ' A' ' 158' ' ' THR . 42.5 t -44.7 116.53 0.23 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.361 0 C-N-CA 124.103 0.961 . . . . 0.0 111.402 175.486 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.72 0.2 45.84 Favored Glycine 0 CA--C 1.521 0.458 0 CA-C-N 115.06 -0.973 . . . . 0.0 113.186 179.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.478 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -72.78 -177.63 2.41 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 123.779 0.831 . . . . 0.0 111.768 176.702 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -128.84 87.39 2.57 Favored 'General case' 0 CA--C 1.49 -1.337 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 177.307 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.631 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 21.6 tp -96.24 135.23 38.33 Favored 'General case' 0 N--CA 1.423 -1.824 0 C-N-CA 119.23 -0.988 . . . . 0.0 109.64 179.256 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.6 p -141.64 132.49 26.31 Favored 'Isoleucine or valine' 0 N--CA 1.387 -3.599 0 CA-C-O 122.208 1.004 . . . . 0.0 112.859 -178.077 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.604 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 41.9 t -91.74 89.7 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.661 0 CA-C-N 113.507 -1.678 . . . . 0.0 107.664 178.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -77.78 106.91 9.91 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 88.3 mt -93.93 -1.22 54.99 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.701 -178.495 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.637 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 0.7 OUTLIER -68.99 -10.57 58.15 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-O 122.396 1.093 . . . . 0.0 109.741 -178.638 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.6 p -121.47 5.52 10.13 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 115.083 -0.962 . . . . 0.0 110.748 179.054 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.466 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 49.2 mm-40 -120.0 -21.98 6.89 Favored 'General case' 0 CA--C 1.511 -0.555 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.614 -174.635 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 29.9 mt -135.06 138.95 48.12 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.011 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -178.09 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -136.96 147.87 46.6 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 -177.052 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.445 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 88.9 m -123.55 136.55 54.6 Favored 'General case' 0 C--N 1.29 -1.981 0 CA-C-O 120.864 0.364 . . . . 0.0 110.991 178.8 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 16.4 p80 -130.91 162.6 29.3 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.423 0.63 . . . . 0.0 110.46 -175.424 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -112.56 121.17 44.03 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 121.828 0.823 . . . . 0.0 111.993 177.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 22.5 p-10 -96.98 -13.32 22.41 Favored 'General case' 0 N--CA 1.427 -1.583 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.588 178.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.418 ' HB2' HD13 ' A' ' 52' ' ' ILE . 83.4 m-85 -147.3 69.24 11.53 Favored Pre-proline 0 C--O 1.22 -0.481 0 CA-C-N 115.503 -0.771 . . . . 0.0 108.935 175.464 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -68.52 -12.82 35.86 Favored 'Trans proline' 0 N--CA 1.483 0.895 0 C-N-CA 122.091 1.861 . . . . 0.0 112.903 -177.176 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -101.44 -25.03 14.07 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-O 121.353 0.597 . . . . 0.0 110.589 -176.513 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.582 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.3 m -102.09 -26.81 13.24 Favored 'General case' 0 N--CA 1.42 -1.97 0 CA-C-O 121.69 0.757 . . . . 0.0 109.289 -172.387 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.582 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.2 mp -129.31 127.73 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.263 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 -178.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.1 t -73.63 145.7 45.16 Favored 'General case' 0 C--O 1.256 1.399 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -85.3 107.62 17.41 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -176.629 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.44 ' CE2' ' HB ' ' A' ' 134' ' ' THR . 17.3 t80 -149.35 138.83 21.61 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -177.555 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.503 HG23 ' HG ' ' A' ' 131' ' ' LEU . 13.4 p -150.64 149.97 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.564 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.25 -178.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -150.3 131.02 14.07 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 172.744 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.541 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 53.4 tp -66.5 110.82 3.3 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 171.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.494 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 3.0 tp-100 -55.48 -50.86 68.79 Favored 'General case' 0 C--N 1.314 -0.96 0 C-N-CA 126.123 1.769 . . . . 0.0 111.564 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -170.44 155.77 5.24 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -177.418 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -132.32 136.07 8.52 Favored Glycine 1 N--CA 1.395 -4.077 0 N-CA-C 107.986 -2.046 . . . . 0.0 107.986 178.413 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 47.8 m -124.17 147.91 47.64 Favored 'General case' 0 C--N 1.271 -2.809 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -176.303 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.563 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -115.46 156.09 26.28 Favored 'General case' 0 C--N 1.306 -1.315 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 -179.339 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.505 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 92.8 m-85 -155.13 -178.95 7.61 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 123.832 0.853 . . . . 0.0 109.045 -177.351 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 62.46 -136.75 44.87 Favored Glycine 0 C--O 1.222 -0.612 0 N-CA-C 111.723 -0.551 . . . . 0.0 111.723 179.344 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -88.38 -3.91 77.83 Favored Glycine 0 C--O 1.206 -1.607 0 C-N-CA 120.537 -0.839 . . . . 0.0 111.133 176.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.738 HG21 ' HB ' ' A' ' 126' ' ' ILE . 76.1 t -71.35 -36.31 60.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 C-N-CA 123.876 0.87 . . . . 0.0 111.576 -176.11 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.563 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -85.31 -25.73 27.0 Favored 'General case' 0 C--N 1.297 -1.681 0 C-N-CA 119.915 -0.714 . . . . 0.0 112.486 178.451 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 21.0 m -101.04 -52.83 3.18 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 -173.13 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.483 ' O ' HG22 ' A' ' 112' ' ' VAL . 53.9 m-20 -88.52 -28.41 20.81 Favored 'General case' 0 CA--C 1.488 -1.426 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 -175.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.656 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 90.2 m-85 -104.55 155.29 18.96 Favored 'General case' 0 N--CA 1.41 -2.463 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 175.465 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.415 ' HB3' ' CG1' ' A' ' 112' ' ' VAL . 15.5 t -167.03 120.34 0.98 Allowed 'General case' 0 N--CA 1.417 -2.106 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 177.013 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.454 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -154.81 -112.66 0.45 Allowed Glycine 0 N--CA 1.402 -3.63 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 175.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 8.3 p -151.69 -179.93 7.85 Favored 'General case' 0 C--N 1.293 -1.862 0 CA-C-O 121.157 0.503 . . . . 0.0 110.662 -173.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.443 ' HB ' ' HB2' ' A' ' 84' ' ' PHE . 2.5 p -132.27 146.03 33.71 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.156 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 177.868 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.643 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.1 tttt -123.92 142.85 50.77 Favored 'General case' 0 N--CA 1.409 -2.514 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 178.621 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.482 ' CG ' HG21 ' A' ' 90' ' ' THR . 59.9 t80 -145.49 112.57 6.07 Favored 'General case' 0 C--N 1.286 -2.159 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 -179.124 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.3 m 55.28 37.37 28.79 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 113.678 0.992 . . . . 0.0 113.678 176.562 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.44 5.84 81.68 Favored Glycine 0 N--CA 1.432 -1.587 0 C-N-CA 120.422 -0.894 . . . . 0.0 112.58 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.643 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 11.0 t -80.34 174.59 11.45 Favored 'General case' 0 C--N 1.317 -0.844 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.532 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 9.3 p -154.13 100.43 2.32 Favored 'General case' 0 C--N 1.284 -2.257 0 CA-C-O 120.98 0.419 . . . . 0.0 110.182 -176.624 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 2.9 p90 -147.07 159.62 42.25 Favored Pre-proline 0 C--N 1.297 -1.701 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -173.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -67.53 149.1 79.76 Favored 'Trans proline' 0 C--N 1.354 0.845 0 C-N-CA 123.161 2.574 . . . . 0.0 113.228 -177.142 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.62 ' CD2' HD21 ' A' ' 109' ' ' LEU . 64.5 t80 -124.99 134.7 25.94 Favored Pre-proline 0 C--N 1.315 -0.903 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.128 -179.677 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.525 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 73.9 Cg_endo -72.85 146.39 86.73 Favored 'Cis proline' 0 C--O 1.244 0.788 0 C-N-CA 122.91 -1.704 . . . . 0.0 110.543 -1.487 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.2 t -65.54 -176.76 0.37 Allowed 'General case' 0 CA--C 1.551 0.987 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.394 -175.304 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.2 p -129.03 2.65 5.27 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-O 121.368 0.604 . . . . 0.0 110.709 -173.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.6 t -161.75 -125.03 0.02 OUTLIER 'General case' 0 N--CA 1.396 -3.146 0 N-CA-C 105.282 -2.118 . . . . 0.0 105.282 179.025 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -129.7 -170.35 2.28 Favored 'General case' 0 C--N 1.291 -1.963 0 N-CA-C 110.475 -0.194 . . . . 0.0 110.475 -176.244 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.541 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 44.1 p -95.25 166.8 14.05 Favored Pre-proline 0 C--N 1.302 -1.462 0 CA-C-N 116.18 -0.463 . . . . 0.0 112.205 178.581 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -62.29 165.09 15.76 Favored 'Trans proline' 0 CA--C 1.544 1.001 0 C-N-CA 123.02 2.48 . . . . 0.0 110.879 172.037 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.401 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 4.9 tmm_? -71.3 120.7 17.25 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.163 0.506 . . . . 0.0 109.838 -178.707 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 76.0 t -128.32 119.55 50.88 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.238 -178.104 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 59.6 t -94.64 141.11 15.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 176.349 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.534 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 1.3 m-85 -91.38 134.78 34.32 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 175.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -115.33 86.16 2.41 Favored 'General case' 0 C--N 1.276 -2.609 0 N-CA-C 106.29 -1.744 . . . . 0.0 106.29 177.616 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . 0.442 ' HB3' ' CG ' ' A' ' 101' ' ' LYS . 5.0 p -142.34 154.58 44.78 Favored 'General case' 0 N--CA 1.413 -2.286 0 CA-C-N 115.161 -0.927 . . . . 0.0 112.718 -173.034 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 10.3 ptp180 -135.0 19.37 3.46 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 171.121 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.0 t -164.09 -175.4 3.99 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 105.981 -1.859 . . . . 0.0 105.981 -178.592 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -76.77 122.55 24.92 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.88 0.848 . . . . 0.0 110.666 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . 0.442 ' CG ' ' HB3' ' A' ' 97' ' ' SER . 30.6 mmtp -109.68 139.51 21.29 Favored Pre-proline 0 C--N 1.293 -1.858 0 CA-C-N 115.032 -0.985 . . . . 0.0 110.002 177.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.637 ' HB3' ' O ' ' A' ' 39' ' ' SER . 52.3 Cg_exo -55.21 144.36 71.0 Favored 'Trans proline' 0 CA--C 1.505 -0.931 0 C-N-CA 123.726 2.951 . . . . 0.0 111.722 176.447 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . 0.534 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 9.1 t90 -91.63 103.63 8.27 Favored Pre-proline 0 C--N 1.294 -1.839 0 N-CA-C 106.044 -1.836 . . . . 0.0 106.044 178.821 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -76.58 88.63 1.35 Allowed 'Trans proline' 0 N--CA 1.446 -1.281 0 C-N-CA 121.624 1.549 . . . . 0.0 111.644 -172.206 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.455 HG22 ' CD2' ' A' ' 77' ' ' TYR . 85.0 t -138.77 142.19 35.05 Favored 'Isoleucine or valine' 0 CA--C 1.485 -1.534 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 179.131 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.604 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.97 133.91 18.05 Favored 'General case' 0 N--CA 1.411 -2.404 0 CA-C-O 120.968 0.413 . . . . 0.0 110.681 179.177 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.485 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 20.0 mt -100.96 99.93 10.47 Favored 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 179.099 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.454 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 76.7 m-85 -80.74 78.81 7.48 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 177.523 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.656 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.3 mm? -102.96 118.99 38.04 Favored 'General case' 0 CA--C 1.49 -1.331 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 177.375 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.8 145.83 46.49 Favored Pre-proline 0 N--CA 1.407 -2.577 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.079 -175.146 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.452 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 36.7 Cg_endo -63.1 119.51 6.61 Favored 'Trans proline' 0 C--O 1.248 1.018 0 C-N-CA 123.347 2.698 . . . . 0.0 112.265 -177.331 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.483 HG22 ' O ' ' A' ' 70' ' ' ASN . 3.2 m -67.62 -118.09 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.182 -2.464 0 CA-C-N 114.023 -1.444 . . . . 0.0 112.59 175.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.4 m -112.73 -38.08 4.69 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-O 122.334 1.064 . . . . 0.0 108.141 179.388 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 64.4 m -82.11 31.77 0.38 Allowed 'General case' 0 N--CA 1.394 -3.271 0 CA-C-N 113.356 -1.747 . . . . 0.0 113.151 -177.692 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -108.63 139.05 43.96 Favored 'General case' 0 C--N 1.288 -2.078 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -174.83 139.04 4.64 Favored Glycine 0 N--CA 1.44 -1.068 0 C-N-CA 119.951 -1.119 . . . . 0.0 112.193 179.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 57.61 -149.7 32.3 Favored Glycine 0 CA--C 1.491 -1.453 0 O-C-N 124.783 0.931 . . . . 0.0 112.542 -178.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.431 ' CG2' ' HE3' ' A' ' 121' ' ' LYS . 7.3 p -57.3 101.7 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 CA-C-O 122.507 1.146 . . . . 0.0 111.607 -178.628 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -100.61 -27.06 13.59 Favored 'General case' 0 C--N 1.295 -1.773 0 CA-C-N 114.826 -1.079 . . . . 0.0 110.679 -177.675 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.472 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 58.7 mt -133.26 136.98 54.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 -178.866 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.529 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.4 mmpt? -112.73 142.64 45.12 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 121.028 0.442 . . . . 0.0 110.706 176.35 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.23 132.02 45.83 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.169 179.243 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 91.63 -10.42 74.72 Favored Glycine 0 N--CA 1.435 -1.405 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.584 -179.363 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 40.2 t -86.18 143.11 28.16 Favored 'General case' 0 N--CA 1.43 -1.43 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 -178.074 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.44 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -71.2 122.19 19.73 Favored 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 177.11 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.738 ' HB ' HG21 ' A' ' 67' ' ' VAL . 33.7 pt -109.24 -27.78 2.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-N 116.041 -0.527 . . . . 0.0 112.303 -178.554 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -160.3 166.78 28.86 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -177.461 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.44 HG23 HD11 ' A' ' 125' ' ' LEU . 75.7 t -141.87 113.43 3.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 179.737 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.481 HD11 HD21 ' A' ' 107' ' ' LEU . 67.5 mt -115.33 134.67 54.9 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.212 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.525 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.4 mp -117.69 128.17 74.93 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.818 0 C-N-CA 119.196 -1.002 . . . . 0.0 109.748 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.516 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.2 OUTLIER -101.24 131.08 47.42 Favored 'General case' 0 C--N 1.276 -2.623 0 C-N-CA 123.989 0.916 . . . . 0.0 111.443 -176.481 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . 0.494 ' HG2' ' HB2' ' A' ' 59' ' ' GLN . 26.9 mmm180 -87.41 128.09 35.21 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 123.529 0.731 . . . . 0.0 110.826 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.516 ' HA ' ' NE2' ' A' ' 133' ' ' GLN . 13.1 mm-40 -101.36 122.24 43.37 Favored 'General case' 0 N--CA 1.412 -2.356 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 168.05 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.44 ' HB ' ' CE2' ' A' ' 55' ' ' TYR . 23.4 m -140.28 129.49 23.73 Favored 'General case' 0 C--N 1.279 -2.468 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.382 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.547 ' CB ' HG23 ' A' ' 52' ' ' ILE . 28.0 p30 . . . . . 0 C--N 1.281 -2.387 0 CA-C-O 121.221 0.534 . . . . 0.0 110.539 -175.582 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 . . . . . 0 CA--C 1.51 -0.577 0 CA-C-O 121.207 0.527 . . . . 0.0 110.897 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.3 pt20 -137.38 149.82 47.23 Favored 'General case' 0 N--CA 1.418 -2.06 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 177.253 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 10.0 m-30 -111.34 132.46 54.39 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 -176.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 50.6 t -92.82 131.69 39.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.024 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . 0.516 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.5 m95 -119.55 100.81 7.51 Favored 'General case' 0 C--N 1.277 -2.577 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 46.4 m-80 -80.69 113.86 19.18 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 178.368 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.436 ' HA ' HG22 ' A' ' 20' ' ' VAL . 22.7 mm -87.35 122.51 39.25 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.936 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 -178.587 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -118.16 148.54 42.25 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.617 178.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -80.49 129.52 34.57 Favored 'General case' 0 N--CA 1.409 -2.502 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 176.51 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 36.1 t-20 -87.75 -16.51 34.01 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -178.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -147.49 144.85 28.87 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 114.103 -1.408 . . . . 0.0 108.795 -174.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 21.7 p-10 -82.96 144.17 30.18 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 124.232 0.957 . . . . 0.0 111.398 -178.119 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.2 t -120.42 138.71 50.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.634 -175.191 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 4.0 t -119.58 137.92 51.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.638 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 71.9 t -102.17 103.34 29.71 Favored Pre-proline 0 C--N 1.29 -1.979 0 C-N-CA 123.479 0.711 . . . . 0.0 109.847 178.634 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.523 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 56.1 Cg_endo -71.68 -16.95 29.95 Favored 'Trans proline' 0 C--O 1.226 -0.093 0 C-N-CA 122.187 1.925 . . . . 0.0 111.781 178.039 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . 0.433 ' HA ' ' H ' ' A' ' 30' ' ' VAL 0.254 3.9 t . . . . . 0 C--N 1.351 0.666 0 C-N-CA 125.082 1.353 . . . . 0.0 113.84 175.411 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.514 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 CA--C 1.485 -1.554 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.601 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 12.5 m -128.65 159.2 36.35 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 109.03 -0.729 . . . . 0.0 109.03 -176.54 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.491 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -147.56 159.57 43.6 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 120.858 0.361 . . . . 0.0 110.421 -173.961 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 71.8 p -97.31 177.26 5.61 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 121.523 0.678 . . . . 0.0 110.553 -178.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -83.03 -17.95 41.48 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 114.869 -1.06 . . . . 0.0 109.655 179.06 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -92.26 -17.71 24.41 Favored 'General case' 0 N--CA 1.43 -1.446 0 CA-C-N 114.739 -1.119 . . . . 0.0 111.795 -177.65 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.05 29.22 2.43 Favored Glycine 0 CA--C 1.484 -1.885 0 C-N-CA 119.925 -1.131 . . . . 0.0 113.971 166.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.9 m -107.64 99.51 8.99 Favored 'General case' 0 N--CA 1.415 -2.216 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.054 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.07 116.36 28.74 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.584 177.513 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.514 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 64.0 mt -84.73 122.77 74.69 Favored Pre-proline 0 C--N 1.301 -1.528 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.712 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -75.33 170.95 19.22 Favored 'Trans proline' 0 C--O 1.246 0.886 0 C-N-CA 122.933 2.422 . . . . 0.0 111.995 -179.12 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 34.4 mt -73.37 118.82 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.126 0.488 . . . . 0.0 111.002 -176.491 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 133.9 38.4 0.21 Allowed Glycine 0 C--N 1.301 -1.386 0 CA-C-N 115.238 -0.892 . . . . 0.0 111.334 177.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 72.02 176.3 26.71 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.542 -176.415 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.14 -177.94 28.83 Favored Glycine 0 C--N 1.296 -1.672 0 C-N-CA 120.103 -1.046 . . . . 0.0 111.219 176.624 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.459 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 52.5 p -141.03 150.31 42.84 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -139.29 165.03 28.27 Favored 'General case' 0 CA--C 1.474 -1.968 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -109.39 123.44 49.33 Favored 'General case' 0 C--N 1.262 -3.229 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 175.112 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.474 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.2 m -105.31 145.09 13.98 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.608 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.336 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -124.75 112.74 17.07 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-O 121.286 0.565 . . . . 0.0 110.764 -178.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.533 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -119.36 132.31 69.53 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.194 0 CA-C-N 115.126 -0.943 . . . . 0.0 111.627 -174.783 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -92.31 127.16 37.69 Favored 'General case' 0 C--N 1.288 -2.075 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.08 178.284 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -110.51 160.53 16.55 Favored 'General case' 0 C--N 1.288 -2.073 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.145 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -61.0 122.91 72.76 Favored Pre-proline 0 C--N 1.317 -0.808 0 O-C-N 124.107 0.879 . . . . 0.0 109.125 176.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.502 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 74.3 Cg_endo -74.65 4.31 4.67 Favored 'Trans proline' 0 C--O 1.237 0.462 0 C-N-CA 122.785 2.323 . . . . 0.0 113.088 -177.468 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.6 t -128.08 112.29 26.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 107.097 -1.445 . . . . 0.0 107.097 178.555 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.426 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.8 t -145.43 101.31 0.56 Allowed 'Isoleucine or valine' 0 C--O 1.181 -2.549 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 -178.219 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.444 ' H ' ' HG3' ' A' ' 32' ' ' GLN . 0.7 OUTLIER -92.38 150.55 20.75 Favored 'General case' 0 C--N 1.267 -2.987 0 O-C-N 122.16 -0.338 . . . . 0.0 111.214 179.416 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.437 HG22 ' O ' ' A' ' 112' ' ' VAL . 46.8 t -44.72 119.14 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 123.63 0.772 . . . . 0.0 111.363 175.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.12 2.5 54.61 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.482 -0.781 . . . . 0.0 112.743 -179.264 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.444 ' HG3' ' H ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -73.83 -178.07 3.07 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 123.076 0.55 . . . . 0.0 111.448 175.331 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -132.91 91.48 2.9 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 176.46 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.664 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.7 tp -92.26 146.44 23.71 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -179.177 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 48.5 t -133.2 129.92 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.838 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 -178.183 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.56 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 51.6 t -99.93 88.82 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.41 -2.446 0 N-CA-C 105.642 -1.984 . . . . 0.0 105.642 172.499 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -85.25 117.49 24.22 Favored 'General case' 0 CA--C 1.484 -1.561 0 C-N-CA 119.949 -0.7 . . . . 0.0 110.382 -176.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 82.4 mt -98.88 -1.84 39.15 Favored 'General case' 0 C--N 1.296 -1.744 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.365 -177.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.491 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 1.3 m -75.64 0.31 18.01 Favored 'General case' 0 CA--C 1.549 0.93 0 CA-C-O 122.394 1.093 . . . . 0.0 108.959 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.0 p -127.33 6.53 6.38 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 114.718 -1.128 . . . . 0.0 110.229 177.164 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.533 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 46.6 mm-40 -125.28 -22.46 4.36 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-O 121.082 0.467 . . . . 0.0 110.649 -175.161 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 36.6 mt -135.07 141.29 43.31 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 108.188 -1.042 . . . . 0.0 108.188 -175.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.491 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 41.4 m-85 -142.79 158.74 43.33 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 -177.5 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.601 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 17.0 t -138.66 147.25 42.62 Favored 'General case' 0 C--N 1.289 -2.029 0 C-N-CA 120.377 -0.529 . . . . 0.0 109.67 175.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . 0.492 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 7.3 p-80 -119.96 130.05 54.59 Favored 'General case' 0 C--O 1.256 1.408 0 CA-C-O 122.323 1.059 . . . . 0.0 111.472 -178.435 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.407 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 22.3 p-10 -91.24 89.84 7.5 Favored 'General case' 0 C--N 1.278 -2.511 0 CA-C-O 122.968 1.366 . . . . 0.0 109.913 178.044 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -71.18 -24.79 62.31 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 113.875 -1.511 . . . . 0.0 111.377 -177.223 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 43.3 m-85 -126.06 79.37 69.44 Favored Pre-proline 0 N--CA 1.479 0.979 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 178.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.407 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 73.4 Cg_endo -85.56 -2.8 9.2 Favored 'Trans proline' 0 C--N 1.321 -0.892 0 C-N-CA 122.0 1.8 . . . . 0.0 113.528 -175.098 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -111.76 -23.76 10.42 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.068 -179.392 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.427 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.0 OUTLIER -99.42 -30.63 12.08 Favored 'General case' 0 C--N 1.292 -1.898 0 CA-C-O 121.837 0.827 . . . . 0.0 109.987 -175.329 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.601 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.5 mp -118.6 138.66 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.616 0 CA-C-N 114.898 -1.046 . . . . 0.0 108.308 -179.456 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.7 t -78.75 134.05 37.07 Favored 'General case' 0 N--CA 1.417 -2.1 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 174.344 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.495 ' O ' HG23 ' A' ' 94' ' ' VAL . 7.6 m-20 -80.14 107.17 12.71 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 -172.333 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 49.9 t80 -142.85 133.44 25.09 Favored 'General case' 0 C--N 1.284 -2.271 0 CA-C-N 116.331 -0.395 . . . . 0.0 109.999 -172.254 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.453 HG12 ' OH ' ' A' ' 77' ' ' TYR . 42.3 t -141.73 134.14 28.41 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 C-N-CA 123.374 0.67 . . . . 0.0 109.635 -178.449 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -143.81 115.48 8.17 Favored 'General case' 0 N--CA 1.434 -1.226 0 O-C-N 123.387 0.43 . . . . 0.0 111.335 177.555 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.537 HD12 ' O ' ' A' ' 130' ' ' ILE . 55.5 tp -54.57 110.78 0.68 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.584 0.706 . . . . 0.0 110.169 171.085 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.43 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 3.3 tp-100 -58.85 -51.79 68.49 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 126.292 1.837 . . . . 0.0 111.828 179.24 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.43 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 6.9 ptp180 -169.73 157.35 6.89 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -176.275 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -137.38 136.56 8.33 Favored Glycine 0 N--CA 1.415 -2.756 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 -179.462 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 70.3 m -126.71 146.22 50.3 Favored 'General case' 0 C--N 1.283 -2.324 0 C-N-CA 123.093 0.557 . . . . 0.0 110.69 -175.275 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.503 ' HB2' ' CE2' ' A' ' 84' ' ' PHE . . . -109.96 156.79 20.0 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 -179.189 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.483 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 90.8 m-85 -155.9 -179.47 8.16 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 123.963 0.905 . . . . 0.0 109.075 -178.192 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.01 -139.22 48.98 Favored Glycine 0 N--CA 1.45 -0.396 0 O-C-N 123.621 0.576 . . . . 0.0 113.328 177.234 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.6 -9.05 87.37 Favored Glycine 0 C--O 1.201 -1.922 0 C-N-CA 120.329 -0.938 . . . . 0.0 111.379 178.166 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.74 HG21 ' HB ' ' A' ' 126' ' ' ILE . 87.5 t -70.81 -42.7 77.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 C-N-CA 123.137 0.575 . . . . 0.0 111.44 -176.583 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.499 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -83.4 -21.61 32.97 Favored 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.4 -0.92 . . . . 0.0 112.518 -179.649 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 21.0 m -101.05 -47.8 4.64 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 114.041 1.126 . . . . 0.0 114.041 -174.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 47.5 m-20 -96.71 -20.63 18.11 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 -175.039 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.664 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 92.0 m-85 -110.78 157.09 20.18 Favored 'General case' 0 N--CA 1.424 -1.75 0 C-N-CA 120.032 -0.667 . . . . 0.0 110.418 178.053 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.8 t -160.95 123.09 3.09 Favored 'General case' 0 N--CA 1.422 -1.853 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 177.097 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.527 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -158.48 -106.97 0.23 Allowed Glycine 0 N--CA 1.412 -2.93 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 177.456 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -165.2 -179.4 5.6 Favored 'General case' 0 C--N 1.313 -0.998 0 C-N-CA 124.525 1.13 . . . . 0.0 110.358 -175.389 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.6 p -131.93 148.3 32.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 C-N-CA 123.626 0.77 . . . . 0.0 109.301 177.363 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.614 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.3 tttt -126.12 143.27 51.19 Favored 'General case' 0 N--CA 1.426 -1.638 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.497 ' CD1' HG22 ' A' ' 105' ' ' VAL . 67.5 t80 -144.31 110.12 5.32 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.258 -177.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 25.3 t 51.24 40.71 26.74 Favored 'General case' 0 CA--C 1.551 0.983 0 C-N-CA 123.584 0.754 . . . . 0.0 111.526 177.576 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.83 14.01 61.7 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.333 -0.937 . . . . 0.0 113.811 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.614 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 13.0 t -86.48 -178.9 6.53 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 175.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 26.1 p -159.48 103.78 1.6 Allowed 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.513 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.433 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.9 p90 -149.53 160.13 34.93 Favored Pre-proline 0 C--N 1.303 -1.428 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 -173.057 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.431 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 42.5 Cg_endo -67.25 146.92 77.46 Favored 'Trans proline' 0 C--N 1.358 1.053 0 C-N-CA 122.837 2.358 . . . . 0.0 112.887 -177.071 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.569 ' CD2' HD21 ' A' ' 109' ' ' LEU . 64.2 t80 -122.63 134.59 25.03 Favored Pre-proline 0 N--CA 1.435 -1.223 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.432 -179.769 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.517 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 64.3 Cg_endo -71.08 147.06 86.51 Favored 'Cis proline' 0 CA--C 1.54 0.786 0 C-N-CA 123.229 -1.571 . . . . 0.0 110.602 -2.497 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.8 t -64.68 -176.8 0.27 Allowed 'General case' 0 C--O 1.248 0.981 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.685 -175.403 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 16.8 p -130.31 0.73 4.6 Favored 'General case' 0 N--CA 1.424 -1.761 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.014 -171.133 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 26.5 t -161.36 -137.51 0.04 OUTLIER 'General case' 0 N--CA 1.379 -3.993 0 N-CA-C 106.56 -1.645 . . . . 0.0 106.56 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -121.39 156.58 32.36 Favored 'General case' 0 C--N 1.267 -2.991 0 C-N-CA 127.015 2.126 . . . . 0.0 107.337 -172.309 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.475 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 19.6 p -78.6 162.37 65.94 Favored Pre-proline 0 C--N 1.302 -1.483 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 -177.396 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.99 165.49 5.0 Favored 'Trans proline' 0 C--N 1.359 1.104 0 C-N-CA 124.044 3.163 . . . . 0.0 112.148 174.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.6 tmm_? -70.3 119.7 14.87 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 114.759 -1.11 . . . . 0.0 109.657 -176.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 60.4 t -131.27 130.35 63.13 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 C-N-CA 123.671 0.788 . . . . 0.0 110.211 -175.531 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.495 HG23 ' O ' ' A' ' 54' ' ' ASP . 1.4 p -129.74 125.45 61.03 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.953 0 CA-C-N 115.009 -0.996 . . . . 0.0 110.341 -174.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -73.15 104.08 4.1 Favored 'General case' 0 C--O 1.211 -0.938 0 CA-C-O 121.105 0.478 . . . . 0.0 111.092 -178.519 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -90.11 62.55 5.56 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-O 121.016 0.436 . . . . 0.0 109.836 179.197 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.0 t -152.59 -170.07 3.53 Favored 'General case' 0 N--CA 1.437 -1.092 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 -178.288 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 17.0 ptm180 -149.1 38.34 0.8 Allowed 'General case' 0 C--N 1.316 -0.875 0 CA-C-O 121.014 0.435 . . . . 0.0 110.437 -176.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 12.6 t -159.51 -177.8 6.67 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -178.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . 0.492 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 9.6 p-10 -79.45 99.92 7.44 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-O 122.41 1.1 . . . . 0.0 109.653 -179.231 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . 0.533 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 7.0 mmpt? -102.37 149.73 36.93 Favored Pre-proline 0 C--N 1.296 -1.749 0 CA-C-N 114.535 -1.212 . . . . 0.0 109.755 -177.836 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.491 ' HB3' ' O ' ' A' ' 39' ' ' SER . 22.5 Cg_exo -59.16 153.35 53.12 Favored 'Trans proline' 0 N--CA 1.449 -1.133 0 C-N-CA 123.36 2.707 . . . . 0.0 112.907 178.089 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 12.6 t90 -95.75 102.15 9.65 Favored Pre-proline 0 C--N 1.289 -2.053 0 N-CA-C 105.688 -1.967 . . . . 0.0 105.688 176.357 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . 0.401 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 56.5 Cg_endo -73.93 88.96 1.04 Allowed 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 122.079 1.852 . . . . 0.0 112.956 -172.267 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.497 HG22 ' CD1' ' A' ' 77' ' ' TYR . 59.9 t -138.75 146.45 26.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.56 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.57 135.67 16.63 Favored 'General case' 0 C--N 1.287 -2.144 0 CA-C-O 120.89 0.376 . . . . 0.0 110.414 178.033 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.5 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 15.6 mt -101.25 103.12 14.12 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.447 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.527 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 45.5 m-85 -82.2 73.23 9.25 Favored 'General case' 0 C--N 1.293 -1.863 0 O-C-N 122.279 -0.263 . . . . 0.0 110.824 178.369 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.664 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -98.5 136.03 39.2 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 176.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -137.5 144.73 46.26 Favored Pre-proline 0 C--N 1.293 -1.883 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.098 -175.199 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -62.38 122.31 10.67 Favored 'Trans proline' 0 C--O 1.248 0.99 0 C-N-CA 123.537 2.825 . . . . 0.0 113.12 -176.14 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.437 ' O ' HG22 ' A' ' 30' ' ' VAL . 2.7 m -73.85 -120.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.168 -3.201 0 CA-C-N 114.507 -1.224 . . . . 0.0 112.344 174.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 27.9 t -111.94 -32.37 6.62 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 -179.116 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 68.3 m -79.97 21.6 0.55 Allowed 'General case' 0 N--CA 1.398 -3.07 0 C-N-CA 125.612 1.565 . . . . 0.0 112.777 -179.532 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -107.5 128.16 54.25 Favored 'General case' 0 N--CA 1.412 -2.326 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 -179.218 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.63 133.09 2.71 Favored Glycine 0 C--N 1.297 -1.605 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 -179.24 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 62.47 -148.55 49.02 Favored Glycine 0 CA--C 1.489 -1.567 0 CA-C-O 119.24 -0.755 . . . . 0.0 111.782 -177.573 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 60.7 t -56.93 105.72 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 117.225 0.513 . . . . 0.0 110.536 -178.283 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -102.97 -40.93 6.3 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.58 179.481 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.521 ' HB ' HG22 ' A' ' 154' ' ' VAL . 72.7 mt -115.29 137.66 48.11 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 178.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.501 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.9 mmpt? -115.07 136.63 52.92 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-O 121.289 0.566 . . . . 0.0 111.636 178.885 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.15 126.87 30.91 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.828 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 92.95 -5.13 75.83 Favored Glycine 0 N--CA 1.437 -1.298 0 CA-C-N 115.694 -0.684 . . . . 0.0 111.756 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 21.2 m -94.91 145.17 25.1 Favored 'General case' 0 N--CA 1.428 -1.544 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 179.802 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.454 HD11 HG23 ' A' ' 128' ' ' VAL . 2.9 tm? -71.35 124.74 25.25 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 108.204 -1.035 . . . . 0.0 108.204 178.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.74 ' HB ' HG21 ' A' ' 67' ' ' VAL . 31.8 pt -111.09 -25.36 3.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 112.322 0.49 . . . . 0.0 112.322 -179.002 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . 0.448 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -162.05 167.51 24.24 Favored 'General case' 0 CA--C 1.508 -0.653 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 -178.022 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.454 HG23 HD11 ' A' ' 125' ' ' LEU . 63.8 t -142.3 116.02 4.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 178.878 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.49 HD11 HD21 ' A' ' 107' ' ' LEU . 67.9 mt -119.02 146.99 44.59 Favored 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.613 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.537 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.4 mp -127.73 126.38 66.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 C-N-CA 119.271 -0.972 . . . . 0.0 110.832 177.519 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.55 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.3 OUTLIER -88.1 145.5 25.91 Favored 'General case' 0 C--N 1.283 -2.313 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 176.332 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . 0.44 HH11 ' HD2' ' A' ' 132' ' ' ARG . 16.2 ttp180 -128.58 130.08 46.86 Favored 'General case' 0 C--N 1.277 -2.549 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 173.023 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 8.6 tm0? -108.71 129.04 55.36 Favored 'General case' 0 N--CA 1.412 -2.347 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 -178.728 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 6.9 m -135.75 139.75 43.82 Favored 'General case' 0 C--N 1.287 -2.116 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.601 ' CB ' HG23 ' A' ' 52' ' ' ILE . 9.4 p30 . . . . . 0 N--CA 1.433 -1.278 0 C-N-CA 117.309 -1.756 . . . . 0.0 113.449 177.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 43.7 m-85 . . . . . 0 CA--C 1.501 -0.933 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . 0.53 HE21 HG21 ' A' ' 130' ' ' ILE . 20.1 pt20 -123.54 134.73 53.81 Favored 'General case' 0 N--CA 1.423 -1.806 0 C-N-CA 119.838 -0.745 . . . . 0.0 111.102 177.512 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 6.9 m-30 -107.57 125.66 51.58 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 -176.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.459 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 46.9 t -89.51 135.28 26.46 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 CA-C-O 121.161 0.505 . . . . 0.0 110.284 -178.473 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . 0.55 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 64.8 m95 -122.12 102.53 8.2 Favored 'General case' 0 C--N 1.281 -2.377 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.692 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.8 m-80 -81.65 109.22 15.87 Favored 'General case' 0 C--N 1.289 -2.025 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 178.04 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.474 ' HA ' HG22 ' A' ' 20' ' ' VAL . 21.3 mm -82.47 119.92 32.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 -177.191 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 -116.77 151.6 36.12 Favored 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 123.169 0.588 . . . . 0.0 109.678 178.469 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.14 128.92 34.28 Favored 'General case' 0 N--CA 1.411 -2.399 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 177.119 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -91.38 -11.36 38.03 Favored 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 107.435 -1.32 . . . . 0.0 107.435 -177.563 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -153.22 143.01 22.03 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 114.292 -1.322 . . . . 0.0 109.379 -177.053 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -84.26 145.68 28.18 Favored 'General case' 0 C--N 1.316 -0.85 0 O-C-N 123.971 0.795 . . . . 0.0 109.553 -179.02 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.521 HG22 ' HB ' ' A' ' 120' ' ' ILE . 1.6 m -124.44 147.48 28.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.855 -178.248 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.7 t -120.14 139.93 45.85 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.538 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 -179.626 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.426 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 70.5 t -100.93 100.3 12.52 Favored Pre-proline 0 C--N 1.29 -1.983 0 C-N-CA 123.666 0.786 . . . . 0.0 109.402 177.336 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.422 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 29.7 Cg_endo -68.18 -23.95 38.76 Favored 'Trans proline' 0 CA--C 1.517 -0.365 0 C-N-CA 122.427 2.085 . . . . 0.0 111.649 178.038 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . 0.405 ' HB ' HG12 ' A' ' 156' ' ' VAL 0.269 5.3 t . . . . . 0 C--O 1.249 1.058 0 O-C-N 125.0 1.437 . . . . 0.0 113.383 177.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.439 -0.984 0 CA-C-O 120.857 0.36 . . . . 0.0 111.49 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.42 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 77.0 m -137.4 152.18 49.36 Favored 'General case' 0 N--CA 1.429 -1.496 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.958 -177.414 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -141.17 167.13 22.91 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.763 -178.093 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.523 HG22 HG22 ' A' ' 20' ' ' VAL . 82.5 p -103.67 171.88 7.12 Favored 'General case' 0 CA--C 1.497 -1.066 0 CA-C-O 121.483 0.658 . . . . 0.0 110.733 -179.276 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.96 -4.82 54.09 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-N 114.034 -1.439 . . . . 0.0 111.755 178.325 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 2.0 p30 -96.88 -30.92 12.85 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 118.184 -1.407 . . . . 0.0 109.314 177.829 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 139.13 0.46 2.16 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 119.896 -1.145 . . . . 0.0 113.047 175.388 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -81.07 105.25 12.14 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -100.85 119.45 38.68 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 176.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 60.3 mt -90.76 123.83 63.91 Favored Pre-proline 0 C--N 1.3 -1.567 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -80.66 168.75 17.53 Favored 'Trans proline' 0 C--O 1.248 0.98 0 C-N-CA 122.7 2.267 . . . . 0.0 111.173 178.049 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.1 mt -63.75 127.56 24.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 133.77 8.72 2.12 Favored Glycine 0 C--N 1.319 -0.373 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.612 -179.562 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 86.69 172.69 48.61 Favored Glycine 0 C--N 1.318 -0.425 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.415 -177.542 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.45 -168.78 30.97 Favored Glycine 0 C--N 1.299 -1.526 0 C-N-CA 119.916 -1.135 . . . . 0.0 111.498 177.1 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 14.4 p -140.1 155.81 46.84 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.401 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -143.63 162.24 36.43 Favored 'General case' 0 N--CA 1.424 -1.736 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 177.308 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -107.83 116.18 31.48 Favored 'General case' 0 C--N 1.281 -2.388 0 CA-C-N 114.808 -1.087 . . . . 0.0 108.746 177.57 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.523 HG22 HG22 ' A' ' 5' ' ' THR . 44.1 t -103.86 135.03 43.44 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.008 0 CA-C-N 115.133 -0.94 . . . . 0.0 108.668 179.202 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 -122.99 134.78 54.31 Favored 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -179.113 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.51 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.5 p -144.42 136.29 21.87 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.674 0 O-C-N 123.727 0.642 . . . . 0.0 111.095 -178.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 47.9 m-80 -89.67 126.79 35.78 Favored 'General case' 0 C--N 1.296 -1.76 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.458 178.442 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.408 HD11 HG22 ' A' ' 36' ' ' VAL . 2.7 mm? -106.56 161.19 14.83 Favored 'General case' 0 C--N 1.283 -2.298 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 177.631 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.8 124.81 81.19 Favored Pre-proline 0 C--N 1.315 -0.933 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 175.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.466 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 68.1 Cg_endo -74.83 0.84 8.33 Favored 'Trans proline' 0 N--CA 1.474 0.382 0 C-N-CA 122.954 2.436 . . . . 0.0 113.021 -177.253 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.476 HG13 ' HG3' ' A' ' 157' ' ' PRO . 87.3 t -129.6 111.85 23.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.7 t -143.33 114.94 2.73 Favored 'Isoleucine or valine' 0 C--O 1.182 -2.489 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -177.219 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.725 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -104.98 148.68 26.46 Favored 'General case' 0 C--N 1.271 -2.819 0 O-C-N 121.987 -0.445 . . . . 0.0 110.91 -179.447 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.499 HG22 ' O ' ' A' ' 112' ' ' VAL . 95.8 t -47.97 116.93 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 123.082 0.553 . . . . 0.0 111.377 178.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 109.41 -9.25 32.96 Favored Glycine 0 C--N 1.307 -1.033 0 CA-C-N 115.238 -0.892 . . . . 0.0 112.357 -178.602 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.725 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -67.87 -177.62 0.84 Allowed 'General case' 0 CA--C 1.508 -0.672 0 C-N-CA 124.631 1.172 . . . . 0.0 110.956 179.63 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -129.89 92.12 3.26 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 178.231 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.641 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.8 tp -94.25 142.52 27.31 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 119.056 -1.057 . . . . 0.0 109.301 179.226 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 39.6 t -132.34 124.78 52.72 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.215 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 -175.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.552 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 47.3 t -96.19 87.82 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.4 -2.931 0 N-CA-C 105.26 -2.126 . . . . 0.0 105.26 172.107 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -82.5 112.55 19.53 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 120.962 0.411 . . . . 0.0 110.984 -177.757 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 84.6 mt -98.21 0.31 45.56 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.017 -178.725 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.4 m -76.35 1.67 15.59 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-O 122.332 1.063 . . . . 0.0 109.045 -179.576 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.8 p -130.64 5.58 4.69 Favored 'General case' 0 N--CA 1.428 -1.562 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.15 176.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.51 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 49.7 mm-40 -124.38 -22.12 4.77 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 121.193 0.521 . . . . 0.0 111.019 -174.684 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.2 mt -131.56 140.83 47.31 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 -176.231 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.451 ' HA ' ' HA ' ' A' ' 102' ' ' PRO . 69.0 m-85 -139.25 154.93 48.06 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -174.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.42 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 96.2 m -137.69 136.52 37.48 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 123.751 0.82 . . . . 0.0 110.787 -179.646 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.4 p-80 -131.92 129.67 40.58 Favored 'General case' 0 C--N 1.295 -1.761 0 CA-C-O 122.381 1.086 . . . . 0.0 112.123 -177.581 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.735 ' OD1' ' HA ' ' A' ' 49' ' ' PRO . 3.3 t-20 -85.23 92.07 8.32 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-N 114.446 -1.252 . . . . 0.0 107.928 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 20.1 m-20 -54.48 -36.6 64.33 Favored 'General case' 0 N--CA 1.493 1.684 0 C-N-CA 123.475 0.71 . . . . 0.0 111.069 -178.255 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 44.7 m-85 -122.46 86.0 48.35 Favored Pre-proline 0 C--N 1.299 -1.599 0 N-CA-C 108.223 -1.028 . . . . 0.0 108.223 -175.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.735 ' HA ' ' OD1' ' A' ' 46' ' ' ASN . 72.7 Cg_endo -73.19 -5.98 18.12 Favored 'Trans proline' 0 CA--C 1.508 -0.81 0 C-N-CA 122.486 2.124 . . . . 0.0 115.081 -170.128 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -121.3 -20.35 6.72 Favored 'General case' 0 C--N 1.282 -2.342 0 CA-C-O 121.268 0.556 . . . . 0.0 110.649 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.56 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.6 m -98.4 -30.7 12.41 Favored 'General case' 0 N--CA 1.414 -2.231 0 C-N-CA 119.54 -0.864 . . . . 0.0 109.102 -170.785 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.567 HG23 ' HB2' ' A' ' 135' ' ' ASN . 2.7 mp -130.03 123.72 56.89 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 CA-C-N 114.878 -1.055 . . . . 0.0 110.035 -175.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 4.4 t -75.71 134.67 40.46 Favored 'General case' 0 N--CA 1.425 -1.684 0 N-CA-C 106.08 -1.822 . . . . 0.0 106.08 173.597 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.57 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 9.5 t70 -90.31 108.88 20.04 Favored 'General case' 0 C--N 1.271 -2.806 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 -178.431 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.585 ' CD2' ' HB ' ' A' ' 134' ' ' THR . 4.7 t80 -128.47 110.06 11.96 Favored 'General case' 0 C--N 1.291 -1.938 0 CA-C-O 122.109 0.957 . . . . 0.0 110.93 -175.22 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.433 ' HA ' ' O ' ' A' ' 132' ' ' ARG . 73.9 t -114.7 142.17 28.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 CA-C-N 113.629 -1.623 . . . . 0.0 110.94 -177.749 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.3 p -143.67 134.18 24.84 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 170.061 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.542 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.8 OUTLIER -73.51 109.97 7.44 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 175.771 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.4 tp-100 -57.58 -62.2 1.96 Allowed 'General case' 0 C--O 1.202 -1.428 0 C-N-CA 125.416 1.486 . . . . 0.0 109.958 -178.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.91 146.11 14.26 Favored 'General case' 0 N--CA 1.418 -2.072 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 -178.216 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -126.68 137.66 10.15 Favored Glycine 0 N--CA 1.398 -3.852 0 N-CA-C 108.193 -1.963 . . . . 0.0 108.193 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 63.4 m -124.0 148.29 47.1 Favored 'General case' 0 C--N 1.268 -2.949 0 C-N-CA 123.599 0.76 . . . . 0.0 109.33 -175.057 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.519 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -114.27 158.1 21.85 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 -179.593 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.432 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 85.0 m-85 -156.35 -178.42 7.32 Favored 'General case' 0 C--O 1.243 0.719 0 C-N-CA 124.214 1.005 . . . . 0.0 108.347 -178.111 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.79 -138.14 49.7 Favored Glycine 0 N--CA 1.452 -0.299 0 O-C-N 123.596 0.56 . . . . 0.0 112.81 178.562 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.91 -9.41 85.42 Favored Glycine 0 C--O 1.205 -1.706 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.651 177.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.747 HG21 ' HB ' ' A' ' 126' ' ' ILE . 84.5 t -68.53 -42.92 83.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 C-N-CA 122.934 0.493 . . . . 0.0 111.362 -177.508 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.519 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -82.45 -17.65 44.56 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.331 -0.948 . . . . 0.0 112.133 179.603 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 14.6 t -100.74 -59.64 1.66 Allowed 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.971 -172.631 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.456 ' O ' HG22 ' A' ' 112' ' ' VAL . 44.2 m-20 -91.1 -23.51 20.28 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.672 -172.323 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.669 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 93.1 m-85 -106.7 155.62 19.49 Favored 'General case' 0 N--CA 1.42 -1.959 0 C-N-CA 119.647 -0.821 . . . . 0.0 109.532 177.077 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.5 t -163.18 126.99 2.85 Favored 'General case' 0 N--CA 1.41 -2.464 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.419 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.416 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -163.07 -109.59 0.23 Allowed Glycine 0 N--CA 1.407 -3.287 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 177.294 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -159.99 178.69 9.46 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 123.348 0.659 . . . . 0.0 110.273 -173.739 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -131.77 142.85 42.01 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 178.171 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.708 ' HG3' ' O ' ' A' ' 80' ' ' SER . 71.7 tttt -118.76 139.12 52.08 Favored 'General case' 0 N--CA 1.423 -1.814 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.793 -179.573 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.494 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 67.5 t80 -138.96 110.05 6.83 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.071 -178.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.6 t 49.68 41.92 22.61 Favored 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 124.133 0.973 . . . . 0.0 111.937 174.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.43 11.03 63.04 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 120.519 -0.848 . . . . 0.0 113.746 179.265 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.708 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 10.1 t -93.56 177.84 5.89 Favored 'General case' 0 C--O 1.206 -1.219 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 176.694 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 74.9 m -160.02 105.52 1.56 Allowed 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 177.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.494 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 5.8 p90 -142.64 164.53 32.1 Favored Pre-proline 0 C--N 1.297 -1.688 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 -172.46 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.474 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 73.9 Cg_endo -71.95 148.26 51.03 Favored 'Trans proline' 0 C--N 1.352 0.731 0 C-N-CA 122.376 2.051 . . . . 0.0 113.402 -174.436 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.627 ' CD2' HD21 ' A' ' 109' ' ' LEU . 55.3 t80 -120.7 139.7 29.39 Favored Pre-proline 0 N--CA 1.429 -1.499 0 CA-C-N 115.608 -0.723 . . . . 0.0 109.267 179.398 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.606 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 55.8 Cg_endo -70.12 144.54 77.7 Favored 'Cis proline' 0 CA--C 1.537 0.653 0 C-N-CA 123.115 -1.619 . . . . 0.0 110.541 -4.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 5.6 t -67.44 -179.59 1.08 Allowed 'General case' 0 CA--C 1.556 1.182 0 CA-C-O 121.081 0.467 . . . . 0.0 111.236 -175.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 22.1 p -131.11 -24.63 2.32 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -168.439 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 24.8 t -129.84 -68.5 0.71 Allowed 'General case' 0 C--N 1.31 -1.117 0 C-N-CA 119.854 -0.738 . . . . 0.0 110.83 -173.36 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 178.77 -177.01 0.25 Allowed 'General case' 0 C--O 1.243 0.747 0 C-N-CA 124.454 1.102 . . . . 0.0 108.44 175.631 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.542 HG23 ' HB3' ' A' ' 58' ' ' LEU . 48.9 p -100.15 166.9 11.85 Favored Pre-proline 0 C--N 1.302 -1.477 0 O-C-N 123.582 0.551 . . . . 0.0 110.978 177.324 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -57.89 160.21 15.82 Favored 'Trans proline' 0 C--O 1.248 1.012 0 C-N-CA 123.027 2.484 . . . . 0.0 110.941 171.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.538 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 0.8 OUTLIER -72.32 120.51 18.03 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.368 -177.26 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 57.5 t -129.42 119.01 47.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.893 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 97.6 t -105.64 132.5 52.44 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 CA-C-N 115.12 -0.945 . . . . 0.0 108.868 177.04 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.57 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 11.8 m-85 -81.6 112.07 18.48 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 175.746 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -103.69 75.73 1.33 Allowed 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 -179.493 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 70.7 m -161.08 170.05 21.23 Favored 'General case' 0 C--N 1.318 -0.801 0 C-N-CA 124.303 1.041 . . . . 0.0 109.435 -177.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.0 ptm180 -128.06 38.78 3.96 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-O 121.946 0.879 . . . . 0.0 110.07 178.013 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.8 t -156.72 167.73 29.56 Favored 'General case' 0 N--CA 1.426 -1.648 0 N-CA-C 107.272 -1.381 . . . . 0.0 107.272 -177.134 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -73.69 123.58 24.34 Favored 'General case' 0 C--N 1.311 -1.1 0 O-C-N 123.784 0.677 . . . . 0.0 110.579 -178.594 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.5 mptm? -120.07 144.23 37.22 Favored Pre-proline 0 C--N 1.28 -2.428 0 CA-C-N 114.642 -1.163 . . . . 0.0 108.558 179.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.451 ' HA ' ' HA ' ' A' ' 43' ' ' PHE . 43.3 Cg_endo -65.9 150.13 85.91 Favored 'Trans proline' 0 C--O 1.248 1.009 0 C-N-CA 122.242 1.961 . . . . 0.0 111.456 177.343 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 16.4 t90 -87.16 105.26 7.82 Favored Pre-proline 0 C--N 1.315 -0.912 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 -179.576 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 64.4 Cg_endo -74.69 88.53 1.19 Allowed 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 121.544 1.496 . . . . 0.0 112.58 -173.241 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 97.4 t -138.44 142.88 33.93 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.309 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.106 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.552 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.94 132.5 16.75 Favored 'General case' 0 N--CA 1.41 -2.428 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.109 178.51 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.512 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 19.5 mt -97.05 102.37 14.13 Favored 'General case' 0 C--N 1.287 -2.123 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.639 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.416 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 63.0 m-85 -83.11 74.39 9.99 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-O 121.105 0.479 . . . . 0.0 110.231 177.45 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.669 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 2.8 mm? -97.93 130.35 44.81 Favored 'General case' 0 CA--C 1.484 -1.582 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 175.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -135.05 144.09 48.73 Favored Pre-proline 0 N--CA 1.397 -3.077 0 N-CA-C 108.947 -0.761 . . . . 0.0 108.947 -174.452 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -63.13 126.72 18.49 Favored 'Trans proline' 0 CA--C 1.496 -1.401 0 C-N-CA 123.2 2.6 . . . . 0.0 113.993 -174.395 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.499 ' O ' HG22 ' A' ' 30' ' ' VAL . 16.1 m -91.65 -158.03 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.395 -3.206 0 CA-C-N 114.221 -1.354 . . . . 0.0 108.66 171.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 29.4 m -76.0 -32.01 59.21 Favored 'General case' 0 C--N 1.26 -3.322 0 CA-C-O 121.366 0.603 . . . . 0.0 110.883 -168.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 7.2 t -80.26 10.12 4.9 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-O 121.736 0.779 . . . . 0.0 110.64 -177.3 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.4 ' HB1' HG21 ' A' ' 156' ' ' VAL . . . -95.09 135.55 36.5 Favored 'General case' 0 N--CA 1.42 -1.955 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.002 179.005 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -179.6 132.07 1.78 Allowed Glycine 0 N--CA 1.433 -1.517 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 63.6 -150.05 49.92 Favored Glycine 0 C--N 1.306 -1.133 0 CA-C-O 119.167 -0.796 . . . . 0.0 112.128 -177.247 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -56.7 103.82 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.242 0.679 0 CA-C-O 122.404 1.097 . . . . 0.0 111.804 -177.402 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -103.24 -36.77 7.96 Favored 'General case' 0 C--N 1.293 -1.884 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.676 -178.695 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.528 ' HB ' HG22 ' A' ' 154' ' ' VAL . 73.1 mt -120.54 138.47 50.92 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.436 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.9 mmpt? -112.99 140.05 48.13 Favored 'General case' 0 C--N 1.313 -1.009 0 C-N-CA 122.727 0.411 . . . . 0.0 110.171 177.655 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -73.5 134.74 43.95 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.03 179.091 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 82.95 4.59 89.94 Favored Glycine 0 C--N 1.314 -0.648 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -178.524 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 8.5 t -100.87 140.7 34.79 Favored 'General case' 0 N--CA 1.415 -2.214 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -178.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.43 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -71.4 122.15 19.84 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 178.201 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.747 ' HB ' HG21 ' A' ' 67' ' ' VAL . 34.2 pt -109.48 -27.21 2.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.218 -177.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -160.57 166.99 28.05 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 -177.554 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.43 HG23 HD11 ' A' ' 125' ' ' LEU . 59.7 t -143.06 114.93 2.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 179.184 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.464 HD11 HD21 ' A' ' 107' ' ' LEU . 34.3 mt -118.2 135.83 54.01 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.639 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.616 HG21 HE21 ' A' ' 143' ' ' GLN . 4.3 mp -115.72 128.05 73.1 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 C-N-CA 118.636 -1.226 . . . . 0.0 109.937 177.8 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.526 HD23 ' O ' ' A' ' 131' ' ' LEU . 0.0 OUTLIER -97.05 133.5 41.63 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.159 178.497 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . 0.433 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 7.4 mmm180 -91.72 127.48 37.19 Favored 'General case' 0 C--N 1.281 -2.396 0 C-N-CA 123.714 0.806 . . . . 0.0 109.374 176.709 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.524 HE21 ' HA ' ' A' ' 133' ' ' GLN . 0.0 OUTLIER -103.98 130.52 51.63 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 105.75 -1.944 . . . . 0.0 105.75 174.087 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.585 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 12.9 m -145.2 143.92 30.56 Favored 'General case' 0 C--N 1.273 -2.757 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 177.396 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.567 ' HB2' HG23 ' A' ' 52' ' ' ILE . 19.3 p30 . . . . . 0 C--N 1.309 -1.169 0 C-N-CA 119.695 -0.802 . . . . 0.0 110.624 179.058 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 76.4 m-85 . . . . . 0 N--CA 1.431 -1.398 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . 0.616 HE21 HG21 ' A' ' 130' ' ' ILE . 18.5 pt20 -137.27 141.27 41.97 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.662 178.169 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.48 ' HB2' HD22 ' A' ' 131' ' ' LEU . 5.4 m-30 -108.58 131.66 54.64 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -176.165 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 48.1 t -90.89 127.52 43.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 O-C-N 123.579 0.549 . . . . 0.0 109.893 -178.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . 0.515 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 65.3 m95 -114.88 100.07 7.95 Favored 'General case' 0 C--N 1.273 -2.728 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 -178.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 42.2 m-80 -82.67 112.83 19.89 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 23.0 mm -88.45 121.09 38.32 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -177.434 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -116.79 149.07 40.56 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 177.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.09 131.43 35.3 Favored 'General case' 0 N--CA 1.41 -2.453 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 176.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 13.9 t-20 -91.03 -11.24 39.4 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 -178.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -147.88 142.85 26.94 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.155 -176.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -85.62 136.8 33.23 Favored 'General case' 0 C--N 1.313 -1.0 0 O-C-N 123.97 0.794 . . . . 0.0 109.663 178.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.528 HG22 ' HB ' ' A' ' 120' ' ' ILE . 1.5 m -119.92 149.52 22.6 Favored 'Isoleucine or valine' 0 C--O 1.254 1.316 0 CA-C-O 120.928 0.394 . . . . 0.0 110.785 -175.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -121.53 142.69 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.276 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -179.376 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.545 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.5 t -102.56 102.37 25.6 Favored Pre-proline 0 C--N 1.296 -1.745 0 C-N-CA 123.384 0.674 . . . . 0.0 109.82 178.131 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.476 ' HG3' HG13 ' A' ' 27' ' ' VAL . 29.2 Cg_endo -67.5 -28.64 38.3 Favored 'Trans proline' 0 CA--C 1.506 -0.878 0 C-N-CA 122.295 1.997 . . . . 0.0 111.7 177.519 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.255 6.1 t . . . . . 0 C--O 1.256 1.401 0 O-C-N 124.483 1.114 . . . . 0.0 112.519 178.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.458 -2.562 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.58 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 11.1 m -126.01 163.05 23.88 Favored 'General case' 0 C--N 1.26 -3.31 0 C-N-CA 119.148 -1.021 . . . . 0.0 109.155 -171.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.436 ' HA ' ' O ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -146.35 159.25 43.62 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-O 120.958 0.409 . . . . 0.0 110.522 -174.479 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.512 HG22 HG22 ' A' ' 20' ' ' VAL . 73.4 p -99.62 176.13 5.58 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 121.277 0.561 . . . . 0.0 111.09 -179.382 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.52 -12.93 59.85 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.186 178.175 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -89.48 -31.31 17.73 Favored 'General case' 0 N--CA 1.435 -1.213 0 C-N-CA 119.081 -1.047 . . . . 0.0 109.896 175.789 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.48 5.66 3.22 Favored Glycine 0 N--CA 1.44 -1.054 0 C-N-CA 119.325 -1.417 . . . . 0.0 113.743 175.354 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.436 ' O ' ' HA ' ' A' ' 4' ' ' LYS . 5.1 m -79.18 99.62 7.09 Favored 'General case' 0 N--CA 1.433 -1.276 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 -179.736 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.53 117.92 30.46 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 176.369 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 71.5 mt -93.46 123.29 60.76 Favored Pre-proline 0 C--N 1.297 -1.68 0 N-CA-C 108.498 -0.926 . . . . 0.0 108.498 179.292 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -77.81 167.47 23.81 Favored 'Trans proline' 0 C--O 1.248 0.982 0 C-N-CA 122.84 2.36 . . . . 0.0 111.498 179.261 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 60.3 mt -69.88 120.58 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.912 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.61 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 140.16 20.12 0.37 Allowed Glycine 0 C--N 1.298 -1.534 0 CA-C-N 115.533 -0.758 . . . . 0.0 112.677 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 84.26 158.81 28.56 Favored Glycine 0 C--O 1.236 0.258 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 -177.121 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 163.83 -175.74 39.96 Favored Glycine 0 N--CA 1.435 -1.372 0 C-N-CA 119.825 -1.179 . . . . 0.0 111.49 178.472 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 37.3 p -146.14 147.55 31.64 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.047 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.09 161.44 35.32 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 179.342 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 21.9 m-80 -113.29 109.81 19.34 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 106.493 -1.669 . . . . 0.0 106.493 176.755 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.512 HG22 HG22 ' A' ' 5' ' ' THR . 40.2 t -94.35 134.69 31.02 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.493 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 -178.273 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 78.3 m-85 -116.46 120.13 37.82 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 117.775 0.261 . . . . 0.0 110.986 -178.541 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.457 HG22 ' HG3' ' A' ' 41' ' ' GLN . 17.6 t -123.02 127.99 74.94 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-O 120.975 0.416 . . . . 0.0 111.036 -175.898 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -82.12 124.41 29.83 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 177.323 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 38.0 mt -115.51 154.2 29.76 Favored 'General case' 0 C--N 1.28 -2.453 0 CA-C-N 115.397 -0.82 . . . . 0.0 108.858 -179.086 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.76 120.83 44.9 Favored Pre-proline 0 C--N 1.314 -0.96 0 O-C-N 124.485 1.115 . . . . 0.0 110.123 -178.826 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 61.0 Cg_endo -72.22 -2.09 11.1 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.885 2.39 . . . . 0.0 113.427 -176.694 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.4 t -124.07 109.57 23.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 178.23 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.505 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.7 t -139.81 107.08 2.71 Favored 'Isoleucine or valine' 0 C--O 1.182 -2.479 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -178.258 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.729 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -97.72 148.54 23.24 Favored 'General case' 0 C--N 1.265 -3.095 0 C-N-CA 122.894 0.477 . . . . 0.0 111.015 -179.606 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.493 HG22 ' O ' ' A' ' 112' ' ' VAL . 91.0 t -47.69 116.52 0.38 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.638 0 C-N-CA 122.961 0.505 . . . . 0.0 111.435 176.038 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.09 9.87 43.94 Favored Glycine 0 CA--C 1.523 0.567 0 CA-C-N 114.905 -1.043 . . . . 0.0 112.137 -178.178 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.729 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -78.62 -176.71 4.99 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 124.603 1.161 . . . . 0.0 109.653 175.147 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -131.95 83.49 2.09 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 175.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.524 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 19.8 tp -91.37 134.22 34.79 Favored 'General case' 0 N--CA 1.426 -1.642 0 C-N-CA 119.42 -0.912 . . . . 0.0 108.915 179.438 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.447 ' HA ' ' O ' ' A' ' 107' ' ' LEU . 1.8 p -141.35 136.26 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.383 -3.803 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.191 -177.691 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.593 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 34.0 t -98.59 89.29 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.412 -2.343 0 CA-C-N 113.551 -1.659 . . . . 0.0 107.904 178.65 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -77.48 118.11 19.6 Favored 'General case' 0 CA--C 1.489 -1.391 0 C-N-CA 120.047 -0.661 . . . . 0.0 110.201 177.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 92.4 mt -96.64 -0.18 48.9 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.545 -0.752 . . . . 0.0 111.632 -178.01 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 26.4 t -74.63 -7.49 53.37 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.854 0.835 . . . . 0.0 109.659 -179.381 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.9 p -117.86 2.19 12.16 Favored 'General case' 0 C--N 1.279 -2.478 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.3 178.021 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.457 ' HG3' HG22 ' A' ' 22' ' ' VAL . 44.2 mm-40 -120.64 -22.83 6.22 Favored 'General case' 0 C--O 1.243 0.736 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.501 -173.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 20.1 mt -136.45 140.08 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.629 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 -176.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.407 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 59.8 m-85 -139.9 162.33 35.43 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 -177.648 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.58 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 20.1 t -145.08 141.91 29.24 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 120.181 -0.608 . . . . 0.0 110.39 175.847 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 19.8 p-80 -119.74 165.03 15.06 Favored 'General case' 0 C--O 1.255 1.389 0 CA-C-O 122.242 1.02 . . . . 0.0 110.376 -178.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.52 HD22 ' CG ' ' A' ' 54' ' ' ASP . 3.2 m120 -110.72 108.49 18.39 Favored 'General case' 0 C--N 1.271 -2.818 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 -175.017 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -84.0 -25.46 29.95 Favored 'General case' 0 N--CA 1.436 -1.166 0 C-N-CA 118.129 -1.428 . . . . 0.0 109.946 -177.618 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 -132.67 64.99 73.44 Favored Pre-proline 0 N--CA 1.472 0.668 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.186 178.03 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -70.02 1.04 4.98 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 C-N-CA 123.257 2.638 . . . . 0.0 114.159 -174.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -116.6 -20.13 9.72 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-O 121.189 0.519 . . . . 0.0 110.303 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.534 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -104.04 -27.83 11.88 Favored 'General case' 0 N--CA 1.422 -1.857 0 CA-C-O 122.055 0.931 . . . . 0.0 108.717 -172.875 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.56 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -128.9 142.98 42.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 CA-C-N 114.711 -1.131 . . . . 0.0 109.04 -176.817 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 4.2 t -89.2 133.23 34.51 Favored 'General case' 0 N--CA 1.433 -1.294 0 N-CA-C 104.917 -2.253 . . . . 0.0 104.917 170.209 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.52 ' CG ' HD22 ' A' ' 46' ' ' ASN . 11.1 m-20 -92.79 106.5 18.46 Favored 'General case' 0 C--N 1.27 -2.879 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 -178.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.435 ' HB3' ' O ' ' A' ' 134' ' ' THR . 52.9 t80 -118.0 127.94 54.3 Favored 'General case' 0 C--N 1.274 -2.692 0 CA-C-N 114.29 -1.323 . . . . 0.0 108.855 -174.589 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.504 HG21 HD12 ' A' ' 131' ' ' LEU . 14.9 p -134.48 138.91 48.92 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.578 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.411 -175.307 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 4.3 p -146.7 131.03 17.54 Favored 'General case' 0 C--N 1.282 -2.352 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 174.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.559 ' HB3' HG23 ' A' ' 90' ' ' THR . 55.1 tp -64.52 116.89 6.61 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 173.213 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -61.06 -49.42 77.42 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 113.802 -1.545 . . . . 0.0 109.307 -178.589 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -175.79 161.76 2.58 Favored 'General case' 0 N--CA 1.42 -1.951 0 CA-C-N 114.504 -1.226 . . . . 0.0 107.979 -178.311 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -136.6 136.52 8.42 Favored Glycine 0 N--CA 1.403 -3.514 0 N-CA-C 108.729 -1.748 . . . . 0.0 108.729 -179.47 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.2 m -123.66 146.87 47.9 Favored 'General case' 0 C--N 1.282 -2.35 0 O-C-N 124.394 0.702 . . . . 0.0 109.753 -176.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.506 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -112.17 156.07 22.91 Favored 'General case' 0 CA--C 1.503 -0.831 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 -178.845 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.449 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 88.5 m-85 -156.32 -178.93 7.69 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 124.309 1.044 . . . . 0.0 109.144 -177.616 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 63.01 -139.71 44.95 Favored Glycine 0 C--O 1.221 -0.672 0 O-C-N 123.367 0.417 . . . . 0.0 112.164 177.647 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.99 -6.98 86.12 Favored Glycine 0 C--O 1.203 -1.833 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.043 177.061 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.796 HG21 ' HB ' ' A' ' 126' ' ' ILE . 73.2 t -69.6 -38.52 76.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 C-N-CA 123.587 0.755 . . . . 0.0 111.815 -176.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.506 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -85.62 -21.72 28.3 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.954 -0.699 . . . . 0.0 112.194 179.136 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 14.0 m -100.89 -50.75 3.74 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 -173.389 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.446 ' O ' HG22 ' A' ' 112' ' ' VAL . 46.1 m-20 -93.36 -22.67 18.8 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 -176.028 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.627 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 84.0 m-85 -110.29 160.77 16.25 Favored 'General case' 0 N--CA 1.417 -2.112 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 177.411 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.5 t -166.76 131.68 2.12 Favored 'General case' 0 N--CA 1.415 -2.204 0 N-CA-C 106.049 -1.834 . . . . 0.0 106.049 175.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.427 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -166.76 -112.47 0.26 Allowed Glycine 0 N--CA 1.401 -3.66 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 175.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.435 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.0 OUTLIER -157.28 179.37 9.33 Favored 'General case' 0 C--N 1.281 -2.373 0 C-N-CA 123.685 0.794 . . . . 0.0 110.714 -172.324 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.446 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.6 p -134.97 148.17 29.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 178.347 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.688 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.1 tttt -125.73 150.04 48.03 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.156 -178.188 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.51 ' CD2' HG22 ' A' ' 105' ' ' VAL . 57.3 t80 -151.6 116.18 5.11 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 -178.15 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 2.7 m 53.79 33.87 17.91 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 179.116 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 85.6 9.67 78.14 Favored Glycine 0 CA--C 1.526 0.721 0 C-N-CA 120.291 -0.957 . . . . 0.0 112.923 -178.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.688 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 9.4 t -80.23 -179.69 7.21 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.098 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 11.4 p -154.63 110.17 3.14 Favored 'General case' 0 C--N 1.289 -2.039 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.05 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.484 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 5.0 p90 -153.01 159.55 32.08 Favored Pre-proline 0 CA--C 1.551 1.001 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -174.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.435 ' HA ' HG22 ' A' ' 74' ' ' THR . 44.3 Cg_endo -67.53 150.0 80.02 Favored 'Trans proline' 0 C--N 1.362 1.269 0 C-N-CA 123.059 2.506 . . . . 0.0 113.442 -176.096 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.621 ' CD2' HD21 ' A' ' 109' ' ' LEU . 55.6 t80 -125.92 132.76 24.42 Favored Pre-proline 0 N--CA 1.445 -0.709 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.027 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.416 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 69.6 Cg_endo -72.64 144.41 80.63 Favored 'Cis proline' 0 C--O 1.245 0.856 0 C-N-CA 122.786 -1.756 . . . . 0.0 110.313 -1.342 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.3 t -66.87 -176.68 0.53 Allowed 'General case' 0 CA--C 1.546 0.824 0 CA-C-N 115.571 -0.741 . . . . 0.0 112.219 -173.028 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 12.9 p -119.06 -49.39 2.41 Favored 'General case' 0 N--CA 1.419 -2.004 0 CA-C-N 115.362 -0.835 . . . . 0.0 111.23 -173.073 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.7 t -104.78 -81.28 0.53 Allowed 'General case' 0 N--CA 1.424 -1.759 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.992 -174.502 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -175.64 -170.09 0.39 Allowed 'General case' 0 C--O 1.238 0.462 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 -175.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.559 HG23 ' HB3' ' A' ' 58' ' ' LEU . 56.2 p -101.44 164.39 16.05 Favored Pre-proline 0 C--N 1.303 -1.418 0 N-CA-C 112.817 0.673 . . . . 0.0 112.817 176.22 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . 0.467 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 22.8 Cg_endo -60.7 172.12 3.05 Favored 'Trans proline' 0 CA--C 1.552 1.41 0 C-N-CA 123.194 2.596 . . . . 0.0 111.891 173.482 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.2 tmm_? -73.74 119.6 18.19 Favored 'General case' 0 C--N 1.323 -0.584 0 C-N-CA 123.674 0.79 . . . . 0.0 110.068 -173.734 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 75.5 t -138.45 139.07 42.15 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -177.536 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.94 142.0 32.95 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.974 0 C-N-CA 122.978 0.511 . . . . 0.0 109.869 -176.225 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.521 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 4.9 m-85 -95.68 105.38 17.37 Favored 'General case' 0 C--N 1.309 -1.184 0 C-N-CA 123.186 0.594 . . . . 0.0 109.853 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . 0.411 HD22 ' N ' ' A' ' 96' ' ' ASN . 0.8 OUTLIER -93.01 50.89 1.6 Allowed 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 121.618 0.723 . . . . 0.0 109.271 177.2 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 12.2 p -117.47 178.4 4.4 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.023 -0.989 . . . . 0.0 110.841 -175.687 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 36.1 ptt180 -144.35 36.9 1.22 Allowed 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 172.408 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.8 t -158.31 171.77 19.57 Favored 'General case' 0 C--N 1.312 -1.036 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 -173.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.45 99.32 4.15 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -98.05 139.37 21.21 Favored Pre-proline 0 C--N 1.287 -2.118 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.292 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -60.19 147.57 92.95 Favored 'Trans proline' 0 C--O 1.245 0.844 0 C-N-CA 122.938 2.425 . . . . 0.0 112.134 178.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . 0.521 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 11.4 t90 -93.64 106.51 21.5 Favored Pre-proline 0 C--N 1.311 -1.094 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 -178.341 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -77.04 88.79 1.37 Allowed 'Trans proline' 0 N--CA 1.455 -0.756 0 C-N-CA 121.984 1.79 . . . . 0.0 113.212 -172.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.51 HG22 ' CD2' ' A' ' 77' ' ' TYR . 66.6 t -140.12 146.43 24.8 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.296 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 178.014 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.593 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.69 134.98 17.01 Favored 'General case' 0 C--N 1.291 -1.947 0 CA-C-O 120.659 0.266 . . . . 0.0 110.919 177.592 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.495 HD21 HD11 ' A' ' 129' ' ' LEU . 18.4 mt -101.11 100.04 10.55 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 179.682 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.427 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 58.8 m-85 -81.66 76.43 8.57 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 110.299 -0.26 . . . . 0.0 110.299 177.27 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.627 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.1 mm? -101.4 125.51 48.05 Favored 'General case' 0 CA--C 1.485 -1.528 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 176.02 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -126.68 148.05 63.27 Favored Pre-proline 0 N--CA 1.398 -3.036 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -175.075 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.422 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 28.6 Cg_endo -62.14 123.72 13.04 Favored 'Trans proline' 0 N--CA 1.446 -1.322 0 C-N-CA 123.132 2.555 . . . . 0.0 113.611 -176.522 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.493 ' O ' HG22 ' A' ' 30' ' ' VAL . 17.9 m -85.95 -157.69 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.398 -3.053 0 CA-C-N 114.34 -1.3 . . . . 0.0 108.696 171.225 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 15.8 t -81.83 -24.69 35.7 Favored 'General case' 0 C--N 1.254 -3.586 0 CA-C-O 121.755 0.788 . . . . 0.0 109.034 -171.175 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 28.0 t -80.85 18.23 1.03 Allowed 'General case' 0 N--CA 1.434 -1.267 0 CA-C-N 115.228 -0.896 . . . . 0.0 110.433 178.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -106.81 138.8 42.3 Favored 'General case' 0 N--CA 1.421 -1.887 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.373 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 177.19 125.42 0.9 Allowed Glycine 0 N--CA 1.441 -0.999 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 179.599 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 68.75 -149.54 49.6 Favored Glycine 0 CA--C 1.496 -1.096 0 CA-C-O 119.07 -0.85 . . . . 0.0 111.38 -176.404 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 57.7 t -58.91 105.71 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-O 121.718 0.771 . . . . 0.0 111.018 -176.564 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -105.77 -34.67 7.61 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 114.785 -1.098 . . . . 0.0 111.128 -178.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.539 ' HB ' HG22 ' A' ' 154' ' ' VAL . 70.4 mt -119.7 136.98 55.09 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.062 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.85 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.525 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.2 mmpt? -113.39 138.5 49.97 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-O 121.035 0.445 . . . . 0.0 110.428 177.043 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 0.42 ' H ' ' HB3' ' A' ' 153' ' ' ASP . . . -72.31 137.57 46.78 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.957 179.648 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 82.16 5.17 89.89 Favored Glycine 0 C--N 1.31 -0.868 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.864 -179.123 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 44.6 m -104.66 141.1 37.05 Favored 'General case' 0 N--CA 1.421 -1.903 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -67.35 123.81 21.38 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 178.049 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.796 ' HB ' HG21 ' A' ' 67' ' ' VAL . 28.6 pt -111.44 -26.21 3.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 116.129 -0.487 . . . . 0.0 112.16 -178.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . 0.401 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.59 168.41 23.56 Favored 'General case' 0 N--CA 1.443 -0.784 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -178.254 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 77.2 t -142.68 114.9 3.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.495 HD11 HD21 ' A' ' 107' ' ' LEU . 62.7 mt -116.23 143.88 44.94 Favored 'General case' 0 C--N 1.286 -2.16 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 178.714 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.551 HG21 HE21 ' A' ' 143' ' ' GLN . 4.9 mp -123.94 123.35 66.67 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.101 178.422 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.601 HD22 ' HB2' ' A' ' 144' ' ' PHE . 0.0 OUTLIER -89.11 134.7 33.91 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 176.718 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . 0.409 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 12.4 tpt180 -101.79 109.56 21.35 Favored 'General case' 0 C--N 1.277 -2.553 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 179.114 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 10.1 mm-40 -100.8 105.12 16.4 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 176.536 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.435 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 7.7 m -124.17 136.02 53.89 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 179.205 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.56 ' CB ' HG23 ' A' ' 52' ' ' ILE . 7.9 p30 . . . . . 0 C--N 1.32 -0.691 0 C-N-CA 117.831 -1.548 . . . . 0.0 112.336 178.441 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 . . . . . 0 N--CA 1.417 -2.118 0 N-CA-C 109.681 -0.488 . . . . 0.0 109.681 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . 0.551 HE21 HG21 ' A' ' 130' ' ' ILE . 20.9 pt20 -108.22 133.46 52.43 Favored 'General case' 0 N--CA 1.413 -2.308 0 CA-C-O 121.493 0.663 . . . . 0.0 110.033 177.073 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.601 ' HB2' HD22 ' A' ' 131' ' ' LEU . 8.0 m-30 -103.02 133.77 47.58 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 -176.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 46.6 t -91.44 129.91 41.42 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.929 0 CA-C-O 121.115 0.484 . . . . 0.0 109.766 -178.514 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . 0.512 ' CZ2' ' HB2' ' A' ' 3' ' ' CYS . 62.2 m95 -120.22 96.2 5.06 Favored 'General case' 0 C--N 1.277 -2.568 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -80.22 114.73 19.34 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.411 HG22 HD11 ' A' ' 126' ' ' ILE . 25.5 mm -87.42 123.31 40.07 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.799 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 -177.506 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -116.79 151.09 37.22 Favored 'General case' 0 C--N 1.292 -1.909 0 C-N-CA 124.207 1.003 . . . . 0.0 109.349 178.171 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.68 131.81 35.28 Favored 'General case' 0 N--CA 1.411 -2.419 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 175.635 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 17.8 t-20 -93.15 -11.39 32.93 Favored 'General case' 0 C--N 1.292 -1.919 0 CA-C-O 122.469 1.128 . . . . 0.0 108.033 -176.506 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -152.02 143.62 23.53 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 114.023 -1.444 . . . . 0.0 109.41 -177.457 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . 0.42 ' HB3' ' H ' ' A' ' 122' ' ' ALA . 6.4 p-10 -86.4 139.49 30.89 Favored 'General case' 0 C--N 1.309 -1.173 0 O-C-N 124.133 0.896 . . . . 0.0 110.183 -179.389 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.539 HG22 ' HB ' ' A' ' 120' ' ' ILE . 1.8 m -120.38 153.05 23.42 Favored 'Isoleucine or valine' 0 C--O 1.251 1.144 0 CA-C-O 120.94 0.4 . . . . 0.0 111.217 -175.599 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.0 t -123.14 142.63 39.03 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.2 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 77.1 t -104.26 102.46 32.96 Favored Pre-proline 0 C--N 1.289 -2.039 0 C-N-CA 123.444 0.698 . . . . 0.0 110.039 179.179 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.505 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 29.7 Cg_endo -67.26 -23.23 45.32 Favored 'Trans proline' 0 C--O 1.219 -0.437 0 C-N-CA 122.498 2.132 . . . . 0.0 111.56 176.656 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . 0.448 ' HB ' HG12 ' A' ' 156' ' ' VAL 0.287 5.1 t . . . . . 0 C--O 1.258 1.515 0 CA-C-O 117.45 -1.262 . . . . 0.0 113.768 176.054 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.504 -0.823 0 CA-C-O 120.72 0.295 . . . . 0.0 110.695 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 76.9 m -145.48 159.31 43.29 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -178.813 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.42 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -145.55 155.56 43.14 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-O 121.451 0.643 . . . . 0.0 110.164 -177.37 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 44.7 p -92.36 177.33 6.17 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.856 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.91 -17.13 48.26 Favored 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.953 179.148 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -90.76 -24.93 20.22 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.582 -177.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 131.73 -3.11 5.33 Favored Glycine 0 CA--C 1.494 -1.233 0 C-N-CA 119.271 -1.442 . . . . 0.0 114.428 169.321 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.7 m -80.55 100.05 8.39 Favored 'General case' 0 C--N 1.285 -2.211 0 CA-C-O 121.453 0.644 . . . . 0.0 109.536 -178.221 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.401 ' HA ' ' HA ' ' A' ' 4' ' ' LYS . . . -94.56 124.75 38.78 Favored 'General case' 0 N--CA 1.424 -1.77 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.115 176.72 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 69.6 mt -92.11 116.45 66.48 Favored Pre-proline 0 C--N 1.278 -2.539 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 177.72 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -75.9 177.09 9.18 Favored 'Trans proline' 0 C--O 1.245 0.841 0 C-N-CA 122.54 2.16 . . . . 0.0 111.719 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 67.9 mt -70.23 128.4 33.48 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.4 179.564 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 128.89 5.19 4.93 Favored Glycine 0 N--CA 1.432 -1.576 0 C-N-CA 120.372 -0.918 . . . . 0.0 111.69 -178.19 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 86.07 169.74 46.25 Favored Glycine 0 N--CA 1.439 -1.106 0 C-N-CA 120.511 -0.852 . . . . 0.0 111.588 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.86 -174.85 30.83 Favored Glycine 0 CA--C 1.487 -1.686 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 178.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.3 m -134.1 159.37 41.06 Favored 'General case' 0 C--N 1.296 -1.759 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 -179.131 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -141.46 165.51 27.31 Favored 'General case' 0 N--CA 1.42 -1.935 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 177.21 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -116.1 104.41 11.52 Favored 'General case' 0 C--N 1.273 -2.73 0 CA-C-N 114.002 -1.453 . . . . 0.0 108.913 178.079 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.456 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.3 m -91.68 146.4 6.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 -178.563 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -128.93 112.51 14.16 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-O 121.03 0.443 . . . . 0.0 111.28 -177.502 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.524 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.6 p -118.69 129.78 74.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 CA-C-O 121.692 0.758 . . . . 0.0 111.995 -174.626 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.3 m-80 -84.52 126.06 32.96 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 177.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 23.0 mt -113.06 157.31 21.74 Favored 'General case' 0 C--N 1.272 -2.777 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 -179.155 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.36 120.74 46.79 Favored Pre-proline 0 C--N 1.313 -1.011 0 O-C-N 124.207 0.942 . . . . 0.0 109.723 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.473 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 60.6 Cg_endo -74.2 -0.12 9.19 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.657 2.238 . . . . 0.0 112.616 -177.536 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.433 HG13 ' HG3' ' A' ' 157' ' ' PRO . 94.9 t -125.3 109.95 23.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 177.639 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.6 t -140.91 107.02 1.97 Allowed 'Isoleucine or valine' 0 C--O 1.179 -2.622 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 -179.544 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.592 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -98.64 148.86 23.38 Favored 'General case' 0 C--N 1.265 -3.089 0 O-C-N 122.13 -0.356 . . . . 0.0 111.266 -179.5 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.423 ' H ' ' HA ' ' A' ' 158' ' ' THR . 22.2 t -43.8 117.04 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.528 0 C-N-CA 123.571 0.748 . . . . 0.0 111.501 175.759 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.84 -1.07 48.36 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-N 115.002 -0.999 . . . . 0.0 113.063 -179.035 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.592 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -71.48 -177.04 1.7 Allowed 'General case' 0 C--N 1.318 -0.802 0 C-N-CA 124.496 1.118 . . . . 0.0 111.237 177.784 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -133.41 87.61 2.41 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 177.775 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.625 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.5 tp -88.76 140.3 29.59 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 -178.69 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.2 t -134.11 125.4 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.172 0 CA-C-O 121.113 0.483 . . . . 0.0 109.787 -175.472 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.57 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 41.1 t -95.78 88.2 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.399 -2.994 0 N-CA-C 105.713 -1.958 . . . . 0.0 105.713 174.196 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -80.57 116.07 20.42 Favored 'General case' 0 CA--C 1.486 -1.482 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.0 mt -97.52 0.06 46.86 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.249 -177.459 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.588 ' OG ' ' HA ' ' A' ' 104' ' ' PRO . 19.6 m -81.22 -2.37 48.5 Favored 'General case' 0 C--N 1.29 -1.988 0 CA-C-O 122.658 1.218 . . . . 0.0 109.703 -179.296 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.4 p -118.8 1.58 11.57 Favored 'General case' 0 C--N 1.275 -2.663 0 CA-C-N 114.807 -1.088 . . . . 0.0 109.811 175.725 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.524 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 44.8 mm-40 -122.41 -23.09 5.31 Favored 'General case' 0 CA--C 1.512 -0.497 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.329 -174.566 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 29.0 mt -135.68 139.2 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.229 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -176.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.42 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 65.7 m-85 -137.52 151.79 48.8 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 -177.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 67.7 m -128.28 138.53 52.46 Favored 'General case' 0 C--N 1.276 -2.622 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 176.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.2 p80 -125.11 129.26 49.84 Favored 'General case' 0 C--N 1.295 -1.774 0 CA-C-O 121.955 0.883 . . . . 0.0 110.773 -177.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.548 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 24.4 p-10 -95.76 96.5 9.02 Favored 'General case' 0 C--N 1.279 -2.477 0 CA-C-O 122.466 1.127 . . . . 0.0 110.072 -179.214 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -74.7 -23.55 58.63 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 114.108 -1.405 . . . . 0.0 111.538 -174.466 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -128.91 65.23 72.89 Favored Pre-proline 0 N--CA 1.479 1.019 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.103 179.648 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.548 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 60.3 Cg_endo -68.85 -12.31 34.14 Favored 'Trans proline' 0 N--CA 1.483 0.881 0 C-N-CA 122.809 2.34 . . . . 0.0 114.148 -172.471 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -108.08 -21.15 12.92 Favored 'General case' 0 C--N 1.292 -1.894 0 C-N-CA 119.977 -0.689 . . . . 0.0 110.343 -176.662 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.504 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.8 m -96.21 -30.34 13.53 Favored 'General case' 0 N--CA 1.416 -2.154 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 -172.544 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.657 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -121.98 143.29 35.07 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.213 0 CA-C-N 113.991 -1.459 . . . . 0.0 108.737 -177.119 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.1 t -88.82 125.83 35.08 Favored 'General case' 0 N--CA 1.419 -2.014 0 N-CA-C 103.944 -2.613 . . . . 0.0 103.944 170.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 -90.61 107.18 19.01 Favored 'General case' 0 C--N 1.263 -3.18 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -172.63 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.469 ' HB3' ' O ' ' A' ' 134' ' ' THR . 34.2 t80 -126.02 117.72 23.83 Favored 'General case' 0 C--N 1.274 -2.7 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.489 -173.39 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.537 HG12 ' OH ' ' A' ' 77' ' ' TYR . 49.0 t -121.85 130.84 74.24 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.298 -175.517 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.1 p -143.45 113.43 7.19 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 123.923 0.764 . . . . 0.0 111.239 177.683 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.505 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 54.3 tp -55.34 109.7 0.58 Allowed 'General case' 0 C--N 1.311 -1.106 0 CA-C-O 121.313 0.578 . . . . 0.0 110.174 172.108 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.5 ' NE2' ' HD3' ' A' ' 132' ' ' ARG . 3.4 tp-100 -54.91 -53.64 52.96 Favored 'General case' 0 C--O 1.209 -1.04 0 C-N-CA 126.041 1.736 . . . . 0.0 110.911 178.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -171.06 160.9 6.65 Favored 'General case' 0 N--CA 1.425 -1.71 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 -176.198 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -139.3 133.44 6.15 Favored Glycine 1 N--CA 1.391 -4.321 0 N-CA-C 108.041 -2.024 . . . . 0.0 108.041 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.2 m -120.76 151.6 39.36 Favored 'General case' 0 C--N 1.276 -2.599 0 O-C-N 124.956 1.033 . . . . 0.0 108.582 -174.145 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.563 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -116.16 157.67 24.45 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 -178.654 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.527 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 96.1 m-85 -155.69 176.8 12.14 Favored 'General case' 0 C--N 1.35 0.616 0 C-N-CA 124.246 1.018 . . . . 0.0 109.587 -177.283 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.35 -147.52 38.86 Favored Glycine 0 CA--C 1.52 0.365 0 O-C-N 123.61 0.569 . . . . 0.0 112.81 178.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -70.58 -10.34 66.77 Favored Glycine 0 C--O 1.205 -1.665 0 O-C-N 122.052 -0.676 . . . . 0.0 111.976 177.106 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.773 HG21 ' HB ' ' A' ' 126' ' ' ILE . 92.8 t -70.53 -36.75 67.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 123.544 0.737 . . . . 0.0 111.322 -177.172 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.563 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.71 -23.09 25.67 Favored 'General case' 0 N--CA 1.421 -1.883 0 C-N-CA 118.6 -1.24 . . . . 0.0 112.144 179.179 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 17.1 t -101.77 -55.46 2.5 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 112.952 0.723 . . . . 0.0 112.952 -175.213 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.443 ' O ' HG22 ' A' ' 112' ' ' VAL . 72.4 m-20 -83.91 -27.43 28.6 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 -174.769 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.637 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 90.0 m-85 -107.02 159.19 16.47 Favored 'General case' 0 N--CA 1.421 -1.917 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 176.463 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.8 t -168.09 136.24 2.3 Favored 'General case' 0 N--CA 1.41 -2.431 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 176.292 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.421 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -169.37 -108.21 0.21 Allowed Glycine 0 N--CA 1.411 -3.027 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 175.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.541 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.1 p -159.21 -179.96 8.46 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 123.829 0.852 . . . . 0.0 110.547 -173.225 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.05 146.73 29.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 C-N-CA 123.435 0.694 . . . . 0.0 109.143 178.614 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.616 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.1 tttt -125.17 142.17 51.66 Favored 'General case' 0 N--CA 1.417 -2.095 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.518 -179.442 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.537 ' OH ' HG12 ' A' ' 56' ' ' VAL . 72.4 t80 -144.48 111.06 5.64 Favored 'General case' 0 C--N 1.295 -1.796 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.13 -177.195 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 35.1 t 55.14 34.33 22.39 Favored 'General case' 0 C--N 1.317 -0.825 0 C-N-CA 123.416 0.686 . . . . 0.0 111.164 178.212 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.08 10.52 64.32 Favored Glycine 0 N--CA 1.44 -1.079 0 C-N-CA 120.486 -0.864 . . . . 0.0 113.566 -178.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.616 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 20.8 t -79.84 179.8 7.36 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.551 0.676 . . . . 0.0 109.31 178.484 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 9.7 p -156.55 90.35 1.16 Allowed 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.623 0.725 . . . . 0.0 110.637 -176.707 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.439 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 1.5 p90 -139.85 158.31 67.9 Favored Pre-proline 0 C--N 1.297 -1.69 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 -173.098 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.541 ' HA ' HG22 ' A' ' 74' ' ' THR . 58.9 Cg_endo -69.35 151.03 71.39 Favored 'Trans proline' 0 C--N 1.354 0.842 0 C-N-CA 123.148 2.565 . . . . 0.0 113.154 -177.081 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.596 ' CD2' HD21 ' A' ' 109' ' ' LEU . 58.0 t80 -122.74 133.21 24.33 Favored Pre-proline 0 N--CA 1.439 -1.011 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.018 -179.541 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.463 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 79.3 Cg_endo -71.43 149.78 92.7 Favored 'Cis proline' 0 CA--C 1.534 0.511 0 C-N-CA 122.71 -1.787 . . . . 0.0 109.73 -0.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.0 t -61.06 -175.54 0.05 OUTLIER 'General case' 0 CA--C 1.562 1.415 0 C-N-CA 123.399 0.679 . . . . 0.0 112.595 -175.462 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 12.4 p -104.97 -50.53 3.23 Favored 'General case' 0 N--CA 1.408 -2.563 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 -177.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.6 t -128.43 -109.19 0.29 Allowed 'General case' 0 N--CA 1.402 -2.873 0 CA-C-N 114.346 -1.297 . . . . 0.0 108.591 178.338 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -125.35 -171.68 2.42 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 118.539 0.609 . . . . 0.0 112.503 -176.692 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.505 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 36.1 p -93.95 167.57 13.4 Favored Pre-proline 0 C--N 1.309 -1.189 0 N-CA-C 112.924 0.713 . . . . 0.0 112.924 -178.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -62.82 175.87 2.11 Favored 'Trans proline' 0 CA--C 1.552 1.386 0 C-N-CA 123.087 2.524 . . . . 0.0 111.904 172.424 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.4 ' HG2' ' CE2' ' A' ' 55' ' ' TYR . 1.4 tmm_? -74.84 129.5 37.79 Favored 'General case' 0 C--O 1.243 0.761 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.004 -175.469 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.492 ' HB ' ' O ' ' A' ' 56' ' ' VAL . 65.3 t -140.09 132.57 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 C-N-CA 123.718 0.807 . . . . 0.0 109.801 -176.497 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 1.9 p -131.08 136.41 57.95 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.411 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 177.461 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 6.1 m-85 -79.8 116.47 19.98 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-O 121.388 0.613 . . . . 0.0 110.525 -179.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 -102.22 68.46 1.09 Allowed 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 177.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 46.0 t -147.64 179.23 7.84 Favored 'General case' 0 N--CA 1.426 -1.646 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 -175.578 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 31.8 ptt180 -151.11 42.12 0.76 Allowed 'General case' 0 C--N 1.31 -1.146 0 C-N-CA 124.036 0.934 . . . . 0.0 108.51 171.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 11.0 t -169.72 172.32 6.87 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-N 114.525 -1.216 . . . . 0.0 108.23 -177.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -59.34 119.87 8.24 Favored 'General case' 0 N--CA 1.474 0.768 0 O-C-N 123.756 0.66 . . . . 0.0 110.493 178.357 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 55.9 mmtt -120.2 143.19 35.12 Favored Pre-proline 0 C--N 1.287 -2.143 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.994 178.364 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -67.16 139.19 49.71 Favored 'Trans proline' 0 N--CA 1.44 -1.676 0 C-N-CA 122.392 2.061 . . . . 0.0 110.32 177.252 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 14.4 t90 -80.34 109.69 13.69 Favored Pre-proline 0 C--N 1.307 -1.243 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 -177.476 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . 0.588 ' HA ' ' OG ' ' A' ' 39' ' ' SER . 60.7 Cg_endo -74.85 87.7 1.28 Allowed 'Trans proline' 0 N--CA 1.451 -0.982 0 C-N-CA 121.12 1.213 . . . . 0.0 112.844 -172.376 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.505 HG22 ' CD1' ' A' ' 77' ' ' TYR . 59.7 t -144.9 145.18 21.24 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.359 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 179.579 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.57 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.65 136.27 17.03 Favored 'General case' 0 C--N 1.288 -2.07 0 O-C-N 123.569 0.543 . . . . 0.0 110.116 177.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.464 HD21 HD11 ' A' ' 129' ' ' LEU . 17.7 mt -101.81 105.12 15.92 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 177.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.421 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 39.3 m-85 -85.29 80.49 9.15 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 177.481 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.637 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.2 mm? -105.12 125.32 50.85 Favored 'General case' 0 CA--C 1.491 -1.327 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 177.441 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -128.04 146.63 59.99 Favored Pre-proline 0 N--CA 1.412 -2.363 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.62 -175.542 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.438 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 23.1 Cg_endo -61.14 117.6 4.39 Favored 'Trans proline' 0 C--O 1.245 0.863 0 C-N-CA 123.424 2.749 . . . . 0.0 112.369 -178.458 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.443 HG22 ' O ' ' A' ' 70' ' ' ASN . 2.7 m -67.04 -114.14 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.202 -1.447 0 CA-C-N 114.289 -1.323 . . . . 0.0 112.752 176.735 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 41.7 m -112.56 -43.4 3.48 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.287 -0.883 . . . . 0.0 110.441 175.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 22.7 t -82.82 30.2 0.44 Allowed 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.067 -174.726 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -101.79 130.94 48.33 Favored 'General case' 0 N--CA 1.418 -2.035 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.2 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.28 141.06 6.45 Favored Glycine 0 N--CA 1.432 -1.596 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 58.81 -149.23 37.78 Favored Glycine 0 C--O 1.219 -0.812 0 CA-C-O 119.244 -0.753 . . . . 0.0 113.307 -179.087 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 99.5 t -56.56 96.75 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 121.581 0.705 . . . . 0.0 111.26 -178.207 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -99.4 -27.78 13.58 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.365 -177.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.583 ' HB ' HG22 ' A' ' 154' ' ' VAL . 68.9 mt -126.84 138.53 54.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 177.105 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.424 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.2 mmpt? -111.02 138.05 47.9 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-O 121.341 0.591 . . . . 0.0 111.207 178.409 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.56 128.57 36.96 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.46 178.029 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 92.05 -7.16 78.96 Favored Glycine 0 N--CA 1.428 -1.89 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.093 -179.349 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 91.9 p -90.85 143.9 26.25 Favored 'General case' 0 C--O 1.253 1.253 0 C-N-CA 119.495 -0.882 . . . . 0.0 109.525 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.437 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -70.72 122.37 19.69 Favored 'General case' 0 N--CA 1.435 -1.22 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 177.367 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.773 ' HB ' HG21 ' A' ' 67' ' ' VAL . 31.6 pt -109.02 -24.47 4.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -177.116 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.72 167.32 23.22 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 -177.9 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.437 HG23 HD11 ' A' ' 125' ' ' LEU . 76.9 t -141.62 114.93 4.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 179.506 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.464 HD11 HD21 ' A' ' 107' ' ' LEU . 52.7 mt -117.97 144.68 45.32 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 178.484 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.488 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.4 mp -127.41 130.19 70.67 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 C-N-CA 119.41 -0.916 . . . . 0.0 110.639 179.006 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.471 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.9 OUTLIER -94.75 128.99 41.85 Favored 'General case' 0 C--N 1.29 -1.982 0 C-N-CA 123.855 0.862 . . . . 0.0 111.477 -179.607 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . 0.5 ' HD3' ' NE2' ' A' ' 59' ' ' GLN . 25.9 mmm180 -94.58 120.55 34.99 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 173.185 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -103.38 137.23 41.78 Favored 'General case' 0 N--CA 1.427 -1.59 0 N-CA-C 105.937 -1.875 . . . . 0.0 105.937 169.495 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.469 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 27.8 m -150.23 134.76 17.38 Favored 'General case' 0 C--N 1.278 -2.527 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 173.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.657 ' CB ' HG23 ' A' ' 52' ' ' ILE . 8.7 p30 . . . . . 0 N--CA 1.437 -1.108 0 C-N-CA 118.966 -1.094 . . . . 0.0 112.057 179.753 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 82.0 m-85 . . . . . 0 N--CA 1.421 -1.881 0 N-CA-C 109.284 -0.636 . . . . 0.0 109.284 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 11.4 pt20 -121.98 138.24 54.5 Favored 'General case' 0 N--CA 1.416 -2.152 0 C-N-CA 119.251 -0.98 . . . . 0.0 109.844 178.837 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 11.8 m-30 -105.12 128.98 53.62 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 -176.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.6 t -94.67 133.88 34.07 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.116 0 CA-C-O 121.143 0.497 . . . . 0.0 110.24 -178.152 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . 0.471 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.2 m95 -120.19 96.83 5.32 Favored 'General case' 0 C--N 1.286 -2.179 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.134 -177.224 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 44.3 m-80 -79.15 112.92 16.85 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 176.383 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.456 ' HA ' HG22 ' A' ' 20' ' ' VAL . 23.9 mm -87.74 120.55 37.02 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 -177.604 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -115.45 153.59 30.82 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 177.593 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.51 132.44 34.2 Favored 'General case' 0 N--CA 1.406 -2.63 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 177.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -90.02 -17.18 28.3 Favored 'General case' 0 C--N 1.286 -2.189 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 -176.115 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -146.18 144.31 29.85 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 114.088 -1.415 . . . . 0.0 110.123 -174.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -83.45 138.22 33.56 Favored 'General case' 0 C--N 1.317 -0.819 0 O-C-N 124.314 1.009 . . . . 0.0 109.697 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.583 HG22 ' HB ' ' A' ' 120' ' ' ILE . 2.0 m -119.83 151.83 22.44 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 C-N-CA 120.634 -0.426 . . . . 0.0 111.045 -176.898 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.2 t -123.78 140.96 45.69 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 -179.139 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.497 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.4 t -103.2 100.35 17.42 Favored Pre-proline 0 C--N 1.291 -1.945 0 C-N-CA 123.435 0.694 . . . . 0.0 109.864 178.43 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.495 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 35.2 Cg_endo -68.17 -21.04 42.85 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.52 2.147 . . . . 0.0 111.403 177.111 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . 0.423 ' HA ' ' H ' ' A' ' 30' ' ' VAL . 3.1 t . . . . . 0 C--O 1.257 1.453 0 C-N-CA 124.789 1.236 . . . . 0.0 114.128 175.531 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.46 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.44 -0.945 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.5 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 9.6 t -144.32 157.25 44.37 Favored 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 118.864 -1.134 . . . . 0.0 110.175 -175.347 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.44 ' HE3' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.48 164.9 29.49 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-O 121.254 0.55 . . . . 0.0 110.961 -175.335 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.586 HG22 HG22 ' A' ' 20' ' ' VAL . 82.1 p -102.18 176.81 5.07 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.841 -178.61 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.3 -16.51 56.25 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 114.402 -1.272 . . . . 0.0 110.722 176.038 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -90.93 -26.49 19.26 Favored 'General case' 0 CA--C 1.515 -0.375 0 C-N-CA 118.856 -1.137 . . . . 0.0 111.341 -177.467 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.48 4.87 3.43 Favored Glycine 0 CA--C 1.499 -0.932 0 C-N-CA 119.889 -1.148 . . . . 0.0 113.322 171.261 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.6 m -82.67 107.48 15.34 Favored 'General case' 0 N--CA 1.424 -1.759 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.404 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -102.53 109.99 21.78 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.43 176.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.46 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 54.8 mt -82.62 124.63 77.34 Favored Pre-proline 0 C--N 1.305 -1.338 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -176.688 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -81.36 161.94 19.83 Favored 'Trans proline' 0 C--O 1.246 0.924 0 C-N-CA 122.61 2.207 . . . . 0.0 111.922 179.073 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 58.0 mt -66.27 133.0 31.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.09 179.544 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 126.57 12.24 3.44 Favored Glycine 0 C--N 1.306 -1.1 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.238 -178.661 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.97 148.84 18.93 Favored Glycine 0 C--O 1.241 0.564 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 -178.054 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.62 -172.36 45.17 Favored Glycine 0 CA--C 1.491 -1.415 0 C-N-CA 119.453 -1.356 . . . . 0.0 112.493 -179.693 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.7 p -146.55 151.76 37.86 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 122.654 0.382 . . . . 0.0 110.325 -177.729 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -140.38 166.47 24.63 Favored 'General case' 0 N--CA 1.433 -1.283 0 CA-C-O 121.617 0.722 . . . . 0.0 109.89 178.33 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.39 101.54 8.49 Favored 'General case' 0 C--N 1.28 -2.423 0 CA-C-N 113.833 -1.531 . . . . 0.0 109.307 179.412 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.586 HG22 HG22 ' A' ' 5' ' ' THR . 40.4 t -92.25 134.4 30.53 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.802 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.563 -178.73 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 55.2 m-85 -119.6 126.73 51.9 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 -179.088 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.492 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.7 p -136.86 133.22 48.12 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.249 -177.047 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -93.67 129.77 39.85 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 121.643 0.735 . . . . 0.0 110.482 178.312 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -108.25 160.58 15.73 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 114.466 -1.243 . . . . 0.0 108.196 -179.704 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -59.08 123.7 70.66 Favored Pre-proline 0 C--N 1.314 -0.958 0 O-C-N 124.387 1.054 . . . . 0.0 109.233 177.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.426 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 61.8 Cg_endo -74.94 -2.06 12.03 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.632 2.221 . . . . 0.0 113.159 -177.544 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.421 HG13 ' HG3' ' A' ' 157' ' ' PRO . 60.5 t -122.95 109.76 24.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 178.186 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.464 ' O ' HG13 ' A' ' 156' ' ' VAL . 1.7 t -141.1 102.16 1.17 Allowed 'Isoleucine or valine' 0 C--O 1.183 -2.436 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -177.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.58 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -94.01 152.22 18.97 Favored 'General case' 0 C--N 1.274 -2.689 0 O-C-N 122.149 -0.344 . . . . 0.0 111.471 179.878 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.401 HG13 ' O ' ' A' ' 112' ' ' VAL . 35.0 t -45.71 119.88 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 123.26 0.624 . . . . 0.0 112.156 176.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.83 1.6 55.13 Favored Glycine 0 N--CA 1.46 0.252 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.595 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.58 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.4 OUTLIER -71.49 -178.53 2.19 Favored 'General case' 0 C--N 1.312 -1.048 0 C-N-CA 124.158 0.983 . . . . 0.0 111.226 177.246 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -129.73 85.06 2.26 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 176.157 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.593 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 17.1 tp -92.98 134.94 34.62 Favored 'General case' 0 N--CA 1.423 -1.806 0 C-N-CA 119.446 -0.902 . . . . 0.0 108.727 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 2.0 p -141.61 132.38 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.515 0 CA-C-O 122.016 0.913 . . . . 0.0 112.366 -177.694 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.604 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 42.5 t -89.31 90.0 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.264 0 CA-C-N 113.665 -1.607 . . . . 0.0 108.376 179.156 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -73.96 103.39 4.44 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 -179.561 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.4 mt -89.94 -3.82 57.83 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 120.75 0.31 . . . . 0.0 111.782 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -73.43 0.81 11.2 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 122.07 0.938 . . . . 0.0 111.574 178.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.9 p -126.72 5.89 6.73 Favored 'General case' 0 N--CA 1.418 -2.033 0 CA-C-N 115.203 -0.908 . . . . 0.0 109.866 176.645 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.492 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 43.9 mm-40 -123.7 -23.15 4.78 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.958 -174.754 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.7 mt -133.7 137.56 52.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 -176.158 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.44 ' HB2' ' HE3' ' A' ' 4' ' ' LYS . 41.7 m-85 -142.41 124.37 15.27 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -175.136 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.5 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 81.7 m -101.27 147.27 26.49 Favored 'General case' 0 C--N 1.291 -1.957 0 N-CA-C 109.46 -0.571 . . . . 0.0 109.46 -179.361 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . 0.464 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 37.0 p-80 -136.7 129.79 31.13 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-O 121.763 0.792 . . . . 0.0 111.649 -173.813 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.496 ' ND2' ' HA ' ' A' ' 49' ' ' PRO . 41.7 t30 -93.05 102.25 14.58 Favored 'General case' 0 C--N 1.28 -2.446 0 C-N-CA 119.991 -0.684 . . . . 0.0 110.533 179.233 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -56.22 -27.91 56.48 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 124.804 1.241 . . . . 0.0 111.016 179.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.476 ' HB2' HD13 ' A' ' 52' ' ' ILE . 38.8 m-85 -125.84 79.17 68.82 Favored Pre-proline 0 C--N 1.309 -1.169 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 -177.383 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.496 ' HA ' ' ND2' ' A' ' 46' ' ' ASN . 57.8 Cg_endo -67.89 -7.33 19.33 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.852 2.368 . . . . 0.0 115.19 -170.503 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -120.76 -11.37 9.01 Favored 'General case' 0 C--N 1.311 -1.068 0 C-N-CA 120.253 -0.579 . . . . 0.0 111.073 -179.391 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.49 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.9 OUTLIER -104.79 -30.23 10.03 Favored 'General case' 0 N--CA 1.435 -1.206 0 CA-C-O 122.128 0.966 . . . . 0.0 109.128 -171.631 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.49 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.0 mp -121.29 136.27 58.75 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.167 0 CA-C-N 114.351 -1.295 . . . . 0.0 109.807 -177.321 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 1.8 t -90.25 126.6 35.89 Favored 'General case' 0 N--CA 1.417 -2.08 0 N-CA-C 102.984 -2.969 . . . . 0.0 102.984 170.06 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.549 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 13.3 t70 -83.55 112.73 20.26 Favored 'General case' 0 C--N 1.274 -2.693 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 -172.155 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.575 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 22.0 t80 -127.77 123.31 34.97 Favored 'General case' 0 C--N 1.272 -2.801 0 CA-C-O 122.054 0.931 . . . . 0.0 110.671 -175.355 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.51 HG23 ' HG ' ' A' ' 131' ' ' LEU . 14.1 p -126.68 148.65 31.42 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.469 0 CA-C-N 114.334 -1.303 . . . . 0.0 109.802 -177.377 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.56 121.7 8.32 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.365 175.473 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.502 HD12 ' O ' ' A' ' 130' ' ' ILE . 53.0 tp -65.33 115.56 5.75 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 173.274 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.475 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 3.8 tp-100 -62.67 -61.65 2.27 Favored 'General case' 0 C--O 1.209 -1.038 0 C-N-CA 125.419 1.488 . . . . 0.0 109.499 178.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.414 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 9.9 ptp180 -158.61 159.36 35.36 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-N 114.513 -1.222 . . . . 0.0 108.227 -176.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.4 ' H ' HG22 ' A' ' 86' ' ' THR . . . -141.12 131.54 4.94 Favored Glycine 0 N--CA 1.399 -3.808 0 N-CA-C 108.478 -1.849 . . . . 0.0 108.478 -179.707 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 69.5 m -120.14 145.9 46.49 Favored 'General case' 0 C--N 1.28 -2.44 0 O-C-N 124.679 0.87 . . . . 0.0 110.475 -173.807 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.557 ' HB2' ' CE2' ' A' ' 84' ' ' PHE . . . -108.2 157.08 18.63 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.497 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 94.2 m-85 -157.07 -179.44 8.21 Favored 'General case' 0 C--O 1.235 0.325 0 C-N-CA 124.776 1.231 . . . . 0.0 108.949 -178.069 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 61.11 -144.19 48.63 Favored Glycine 0 CA--C 1.506 -0.516 0 O-C-N 123.489 0.493 . . . . 0.0 112.313 177.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -76.33 -9.58 85.75 Favored Glycine 0 C--O 1.2 -2.028 0 C-N-CA 120.892 -0.67 . . . . 0.0 111.698 176.425 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.755 HG21 ' HB ' ' A' ' 126' ' ' ILE . 80.1 t -68.63 -41.59 82.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 123.341 0.656 . . . . 0.0 111.796 -177.691 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.531 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -84.95 -16.47 40.87 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.154 -1.019 . . . . 0.0 112.072 178.727 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 22.7 t -100.6 -59.8 1.64 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.461 0.648 . . . . 0.0 111.692 -174.595 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 63.3 m-20 -86.32 -25.84 25.22 Favored 'General case' 0 CA--C 1.488 -1.426 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.403 -174.14 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.673 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 85.8 m-85 -107.66 160.93 15.32 Favored 'General case' 0 N--CA 1.412 -2.334 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.166 178.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.9 t -169.1 139.17 2.23 Favored 'General case' 0 N--CA 1.406 -2.626 0 N-CA-C 106.136 -1.802 . . . . 0.0 106.136 176.483 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.438 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -172.84 -104.23 0.17 Allowed Glycine 0 N--CA 1.411 -3.025 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 175.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.416 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.3 p -162.9 -179.61 6.9 Favored 'General case' 0 C--N 1.311 -1.106 0 C-N-CA 124.088 0.955 . . . . 0.0 110.895 -175.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -132.27 145.51 34.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 177.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.661 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.5 tttt -122.85 146.4 47.59 Favored 'General case' 0 N--CA 1.419 -2.007 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.443 -179.456 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.491 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 68.8 t80 -145.53 109.68 4.9 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.3 m 54.24 44.08 29.6 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 176.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 81.72 7.17 88.42 Favored Glycine 0 C--N 1.31 -0.873 0 C-N-CA 119.901 -1.142 . . . . 0.0 112.914 -179.589 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.661 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 13.0 t -82.08 174.24 11.41 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 178.038 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 21.8 t -153.14 111.75 3.71 Favored 'General case' 0 C--N 1.28 -2.435 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 -179.268 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.491 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 4.7 p90 -154.77 160.5 30.85 Favored Pre-proline 0 CA--C 1.551 1.001 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -174.579 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.427 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 50.0 Cg_endo -68.45 150.0 75.23 Favored 'Trans proline' 0 C--N 1.36 1.144 0 C-N-CA 122.942 2.428 . . . . 0.0 113.496 -176.756 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.607 ' CD2' HD21 ' A' ' 109' ' ' LEU . 53.1 t80 -124.86 133.79 25.1 Favored Pre-proline 0 N--CA 1.441 -0.882 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.777 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.5 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 59.3 Cg_endo -70.25 148.3 87.54 Favored 'Cis proline' 0 CA--C 1.541 0.848 0 C-N-CA 122.682 -1.799 . . . . 0.0 109.747 -2.032 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.4 HG22 ' H ' ' A' ' 61' ' ' GLY . 8.8 t -67.08 -178.23 0.76 Allowed 'General case' 0 CA--C 1.55 0.967 0 CA-C-O 121.972 0.891 . . . . 0.0 111.742 -174.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 13.2 p -127.67 -28.68 2.71 Favored 'General case' 0 N--CA 1.425 -1.677 0 CA-C-N 114.929 -1.032 . . . . 0.0 112.931 -169.343 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.7 t -128.1 -79.9 0.58 Allowed 'General case' 0 N--CA 1.432 -1.373 0 C-N-CA 119.086 -1.046 . . . . 0.0 111.726 -176.483 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -170.98 -177.99 2.37 Favored 'General case' 0 C--O 1.246 0.906 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 -179.513 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.441 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 15.6 p -101.54 165.8 13.41 Favored Pre-proline 0 C--N 1.296 -1.758 0 N-CA-C 113.241 0.83 . . . . 0.0 113.241 -179.527 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . 0.415 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 36.3 Cg_endo -64.08 158.4 48.13 Favored 'Trans proline' 0 C--N 1.361 1.235 0 C-N-CA 122.784 2.323 . . . . 0.0 111.772 173.083 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.575 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 4.6 tmm_? -72.33 119.38 16.44 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 114.679 -1.146 . . . . 0.0 109.574 -177.843 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 86.0 t -131.77 120.19 44.05 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.723 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.452 HG23 HH11 ' A' ' 92' ' ' ARG . 84.2 t -108.99 126.09 66.04 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.637 179.669 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.569 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 5.5 m-85 -76.65 105.15 7.54 Favored 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 123.816 0.847 . . . . 0.0 109.971 177.563 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 34.2 m-80 -96.34 57.63 1.7 Allowed 'General case' 0 C--N 1.287 -2.144 0 CA-C-O 122.462 1.125 . . . . 0.0 108.783 178.081 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 33.0 m -124.3 174.29 7.82 Favored 'General case' 0 N--CA 1.418 -2.073 0 CA-C-N 113.775 -1.557 . . . . 0.0 109.27 -176.449 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.0 ptp180 -127.93 12.33 6.7 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 112.142 0.423 . . . . 0.0 112.142 -176.727 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.1 t -160.51 -171.77 3.28 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -177.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . 0.464 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 3.7 p30 -67.79 132.15 46.88 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.076 0.465 . . . . 0.0 109.853 178.661 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 12.5 mmtm -139.75 146.75 48.72 Favored Pre-proline 0 C--N 1.291 -1.945 0 C-N-CA 124.553 1.141 . . . . 0.0 109.034 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -61.61 147.0 96.41 Favored 'Trans proline' 0 C--O 1.25 1.089 0 C-N-CA 123.321 2.681 . . . . 0.0 113.412 -175.113 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . 0.569 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 8.6 t90 -92.61 105.61 15.23 Favored Pre-proline 0 C--N 1.31 -1.124 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -74.76 89.11 1.15 Allowed 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 121.983 1.789 . . . . 0.0 112.584 -174.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 90.7 t -139.02 143.68 31.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 N-CA-C 107.313 -1.365 . . . . 0.0 107.313 176.32 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.604 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -149.9 136.38 19.09 Favored 'General case' 0 N--CA 1.412 -2.371 0 CA-C-O 120.831 0.348 . . . . 0.0 110.48 178.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.453 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 18.4 mt -103.21 100.09 9.98 Favored 'General case' 0 C--N 1.289 -2.06 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.283 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.438 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 55.8 m-85 -80.39 76.48 7.2 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 178.053 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.673 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.1 mm? -102.93 122.6 44.92 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 177.054 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -125.09 147.01 55.65 Favored Pre-proline 0 N--CA 1.41 -2.465 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.154 -173.678 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.478 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 30.7 Cg_endo -61.8 117.82 4.67 Favored 'Trans proline' 0 C--O 1.245 0.864 0 C-N-CA 123.167 2.578 . . . . 0.0 111.768 -177.514 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 70' ' ' ASN . 2.6 m -65.3 -116.28 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.192 -1.934 0 CA-C-N 114.365 -1.289 . . . . 0.0 113.546 177.501 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 17.8 m -111.9 -41.74 3.94 Favored 'General case' 0 C--N 1.287 -2.115 0 O-C-N 121.464 -0.772 . . . . 0.0 110.624 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 5.8 t -93.14 28.27 2.21 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.911 0.862 . . . . 0.0 110.589 -173.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -89.62 135.04 33.84 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 178.442 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -172.03 143.57 7.55 Favored Glycine 0 N--CA 1.432 -1.632 0 C-N-CA 120.083 -1.056 . . . . 0.0 111.294 179.497 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . 0.407 ' HA2' ' CG1' ' A' ' 155' ' ' VAL . . . 57.24 -147.06 35.65 Favored Glycine 0 CA--C 1.497 -1.091 0 CA-C-O 119.177 -0.791 . . . . 0.0 112.87 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.403 HG11 ' HE3' ' A' ' 121' ' ' LYS . 97.5 t -56.77 99.85 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-O 121.937 0.875 . . . . 0.0 110.867 -179.069 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -100.25 -35.34 9.66 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.966 -178.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.547 ' HB ' HG22 ' A' ' 154' ' ' VAL . 69.8 mt -121.72 137.39 55.51 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 178.48 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.423 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.9 mmpt? -111.07 136.46 50.06 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 122.991 0.516 . . . . 0.0 111.212 178.462 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.63 134.51 46.41 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.263 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 86.29 -4.49 85.99 Favored Glycine 0 N--CA 1.442 -0.904 0 N-CA-C 111.709 -0.556 . . . . 0.0 111.709 -179.171 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 37.5 m -96.06 151.01 19.85 Favored 'General case' 0 N--CA 1.427 -1.578 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -178.17 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.454 HD11 HG23 ' A' ' 128' ' ' VAL . 3.3 tm? -77.75 121.3 23.86 Favored 'General case' 0 N--CA 1.427 -1.594 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 -177.533 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.755 ' HB ' HG21 ' A' ' 67' ' ' VAL . 36.7 pt -108.12 -27.18 3.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 CA-C-N 116.157 -0.474 . . . . 0.0 112.139 -178.024 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . 0.403 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.75 167.41 25.03 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 110.243 -0.28 . . . . 0.0 110.243 -178.315 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.454 HG23 HD11 ' A' ' 125' ' ' LEU . 64.8 t -142.16 113.61 3.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 179.88 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 63.5 mt -114.64 139.55 49.55 Favored 'General case' 0 C--N 1.289 -2.053 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.662 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.502 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.3 mp -119.13 124.0 72.36 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 119.326 -0.95 . . . . 0.0 110.105 178.435 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.525 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.1 OUTLIER -99.19 131.84 44.94 Favored 'General case' 0 C--N 1.278 -2.52 0 C-N-CA 124.236 1.015 . . . . 0.0 111.033 -176.869 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . 0.475 ' HG2' ' HB2' ' A' ' 59' ' ' GLN . 12.5 mmm180 -95.56 125.13 39.94 Favored 'General case' 0 C--N 1.295 -1.802 0 C-N-CA 124.108 0.963 . . . . 0.0 109.481 179.454 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.507 HE21 ' HA ' ' A' ' 133' ' ' GLN . 0.0 OUTLIER -107.18 113.12 26.35 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 177.52 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.478 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 26.2 m -136.25 141.85 43.95 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.478 ' CB ' HG23 ' A' ' 52' ' ' ILE . 8.9 p30 . . . . . 0 C--N 1.312 -1.063 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.469 175.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 . . . . . 0 CA--C 1.508 -0.667 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -127.01 146.41 50.36 Favored 'General case' 0 N--CA 1.424 -1.757 0 CA-C-O 121.324 0.583 . . . . 0.0 110.891 178.618 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.465 ' HB2' HD22 ' A' ' 131' ' ' LEU . 11.9 m-30 -113.24 135.82 53.41 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 -176.736 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 49.3 t -92.44 130.69 41.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 122.802 0.441 . . . . 0.0 109.837 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . 0.525 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 61.8 m95 -119.38 101.08 7.71 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.804 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 48.7 m-80 -79.79 114.65 18.87 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 177.757 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.419 HG22 HD11 ' A' ' 126' ' ' ILE . 26.1 mm -88.05 120.24 36.75 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.947 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 -178.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -116.09 150.3 37.56 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.507 179.022 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.8 131.23 35.2 Favored 'General case' 0 N--CA 1.406 -2.636 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 176.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -88.93 -16.49 31.7 Favored 'General case' 0 C--N 1.288 -2.081 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -178.027 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -147.29 141.14 25.79 Favored 'General case' 0 N--CA 1.434 -1.249 0 CA-C-N 114.224 -1.353 . . . . 0.0 110.32 -173.423 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -80.84 139.47 35.95 Favored 'General case' 0 C--N 1.311 -1.088 0 O-C-N 124.3 1.0 . . . . 0.0 109.348 178.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.547 HG22 ' HB ' ' A' ' 120' ' ' ILE . 2.2 m -120.91 153.29 24.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 120.715 -0.394 . . . . 0.0 110.713 -177.713 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . 0.407 ' CG1' ' HA2' ' A' ' 117' ' ' GLY . 2.9 t -124.21 142.47 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.032 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 -178.769 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.464 HG13 ' O ' ' A' ' 28' ' ' VAL . 70.4 t -103.95 102.59 32.51 Favored Pre-proline 0 C--N 1.291 -1.952 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 177.475 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.491 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 20.6 Cg_endo -66.22 -26.92 49.0 Favored 'Trans proline' 0 C--O 1.212 -0.809 0 C-N-CA 122.426 2.084 . . . . 0.0 111.924 177.665 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . 0.431 ' HB ' HG12 ' A' ' 156' ' ' VAL . 6.6 t . . . . . 0 C--O 1.252 1.23 0 C-N-CA 124.425 1.09 . . . . 0.0 113.229 176.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.436 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.435 -1.204 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.495 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 16.4 t -154.83 157.29 37.68 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.772 -0.771 . . . . 0.0 109.436 -176.331 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.648 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.37 161.91 37.79 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-O 121.131 0.491 . . . . 0.0 110.856 -175.195 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 50.5 p -101.56 172.46 6.95 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-O 121.949 0.881 . . . . 0.0 110.426 178.139 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.58 -10.15 59.19 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 113.591 -1.64 . . . . 0.0 111.607 -178.123 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 6.2 p30 -87.14 -33.24 19.49 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 119.301 -0.96 . . . . 0.0 108.562 176.281 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.55 3.82 3.66 Favored Glycine 0 N--CA 1.441 -1.019 0 C-N-CA 120.139 -1.029 . . . . 0.0 112.702 178.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.9 m -78.48 99.44 6.45 Favored 'General case' 0 N--CA 1.433 -1.306 0 CA-C-N 117.129 0.465 . . . . 0.0 109.886 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -93.47 119.46 32.59 Favored 'General case' 0 N--CA 1.424 -1.764 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 176.347 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.436 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 72.4 mt -85.63 124.84 70.7 Favored Pre-proline 0 C--N 1.285 -2.238 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -77.8 167.0 24.55 Favored 'Trans proline' 0 N--CA 1.448 -1.169 0 C-N-CA 122.673 2.249 . . . . 0.0 110.623 178.226 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 55.3 mt -73.29 125.8 32.88 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 -178.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 138.34 7.48 1.26 Allowed Glycine 0 C--N 1.308 -1.013 0 C-N-CA 120.564 -0.826 . . . . 0.0 112.888 -179.026 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.12 142.89 9.17 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 -177.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -179.67 -168.37 38.39 Favored Glycine 0 CA--C 1.49 -1.487 0 C-N-CA 120.031 -1.081 . . . . 0.0 111.42 -179.032 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.475 ' HB3' ' HB ' ' A' ' 145' ' ' VAL . 20.4 p -149.6 147.02 27.63 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.23 162.83 31.87 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 179.589 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 26.8 m-80 -114.74 112.32 22.64 Favored 'General case' 0 C--N 1.29 -2.0 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 178.11 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.406 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.8 m -96.04 148.63 5.15 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.231 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 -179.33 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -130.73 130.47 43.84 Favored 'General case' 0 CA--C 1.492 -1.285 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 -179.11 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.616 ' HB ' ' HG2' ' A' ' 41' ' ' GLN . 2.9 p -133.55 132.13 57.37 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.925 0 O-C-N 124.098 0.874 . . . . 0.0 110.572 -176.148 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -92.12 128.37 37.94 Favored 'General case' 0 C--N 1.286 -2.157 0 CA-C-O 121.629 0.728 . . . . 0.0 109.8 177.48 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -106.89 161.32 14.81 Favored 'General case' 0 C--N 1.28 -2.419 0 CA-C-N 114.341 -1.299 . . . . 0.0 108.036 179.634 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.52 121.61 61.76 Favored Pre-proline 0 C--N 1.304 -1.391 0 O-C-N 124.144 0.903 . . . . 0.0 108.779 176.069 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.523 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 64.5 Cg_endo -74.26 -1.16 10.58 Favored 'Trans proline' 0 CA--C 1.531 0.355 0 C-N-CA 122.851 2.368 . . . . 0.0 113.431 -176.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.485 HG13 ' HG3' ' A' ' 157' ' ' PRO . 94.9 t -125.92 110.56 24.26 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 176.609 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.525 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.1 t -142.14 106.25 1.43 Allowed 'Isoleucine or valine' 0 C--O 1.182 -2.479 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 -176.551 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.574 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -95.7 150.58 20.22 Favored 'General case' 0 C--N 1.268 -2.972 0 C-N-CA 122.888 0.475 . . . . 0.0 111.617 -179.745 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.567 HG22 ' O ' ' A' ' 112' ' ' VAL . 75.7 t -46.1 118.79 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 123.472 0.709 . . . . 0.0 111.38 176.649 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 105.01 -3.99 41.43 Favored Glycine 0 C--N 1.318 -0.468 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.642 -179.659 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.574 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.6 OUTLIER -68.81 -178.0 1.11 Allowed 'General case' 0 CA--C 1.499 -1.013 0 C-N-CA 124.555 1.142 . . . . 0.0 111.544 178.286 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -127.39 87.53 2.65 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 174.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.546 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 14.9 tp -96.63 133.95 40.49 Favored 'General case' 0 N--CA 1.405 -2.688 0 C-N-CA 118.852 -1.139 . . . . 0.0 108.029 177.419 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.453 ' CG2' ' HB1' ' A' ' 106' ' ' ALA . 2.0 p -141.19 129.72 23.52 Favored 'Isoleucine or valine' 1 N--CA 1.377 -4.107 0 CA-C-O 122.022 0.915 . . . . 0.0 111.183 -179.666 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.585 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 44.8 t -90.12 89.1 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.385 -3.713 0 CA-C-N 113.081 -1.872 . . . . 0.0 107.159 -178.728 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -75.87 133.31 40.61 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 176.566 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.402 ' HA ' ' OE1' ' A' ' 41' ' ' GLN . 86.9 mt -115.14 11.43 16.34 Favored 'General case' 0 C--N 1.295 -1.779 0 O-C-N 123.838 0.711 . . . . 0.0 111.26 179.225 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.682 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 1.5 m -87.0 1.69 51.98 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 -174.698 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.2 m -120.47 0.68 10.57 Favored 'General case' 0 N--CA 1.394 -3.232 0 CA-C-O 122.168 0.985 . . . . 0.0 108.779 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.616 ' HG2' ' HB ' ' A' ' 22' ' ' VAL . 22.1 mp0 -120.78 -34.22 3.61 Favored 'General case' 0 CA--C 1.473 -1.986 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.285 -172.282 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 23.1 mt -119.56 137.11 54.53 Favored 'Isoleucine or valine' 0 C--N 1.267 -2.981 0 CA-C-N 114.903 -1.044 . . . . 0.0 108.988 -177.45 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.648 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 42.4 m-85 -142.07 124.45 15.67 Favored 'General case' 0 CA--C 1.511 -0.553 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -176.469 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.495 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 81.9 m -106.57 140.17 39.87 Favored 'General case' 0 C--N 1.287 -2.142 0 CA-C-O 121.107 0.48 . . . . 0.0 110.618 -177.882 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . 0.461 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 5.1 p80 -124.28 132.85 53.59 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 122.356 1.074 . . . . 0.0 113.433 -174.565 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.46 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 14.8 p-10 -93.15 93.6 8.36 Favored 'General case' 0 C--N 1.279 -2.464 0 CA-C-N 114.299 -1.319 . . . . 0.0 109.46 177.51 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -78.3 -21.04 50.28 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.773 -1.103 . . . . 0.0 111.288 -176.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 72.2 m-85 -136.51 70.72 59.96 Favored Pre-proline 0 C--N 1.313 -0.987 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 176.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.46 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 56.0 Cg_endo -70.14 -10.98 29.5 Favored 'Trans proline' 0 N--CA 1.483 0.874 0 C-N-CA 122.698 2.266 . . . . 0.0 112.52 -176.205 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -107.32 -17.44 14.14 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-O 121.402 0.62 . . . . 0.0 110.035 -176.102 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.567 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -101.8 -30.71 11.13 Favored 'General case' 0 N--CA 1.414 -2.259 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 -175.818 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.699 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.9 mp -129.05 139.69 51.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.3 t -80.33 147.45 31.09 Favored 'General case' 0 C--O 1.252 1.204 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 178.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -80.73 107.68 13.75 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 -173.295 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.421 ' HE1' ' HG3' ' A' ' 92' ' ' ARG . 75.1 t80 -150.84 145.7 25.86 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.319 -175.31 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.423 HG23 HD13 ' A' ' 131' ' ' LEU . 11.4 p -153.92 152.28 10.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 174.572 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -151.36 138.02 18.79 Favored 'General case' 0 C--O 1.207 -1.149 0 CA-C-O 119.102 -0.475 . . . . 0.0 110.263 174.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.53 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 50.4 tp -76.17 113.14 13.38 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 174.016 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.4 tp-100 -59.52 -51.53 69.47 Favored 'General case' 0 C--N 1.316 -0.878 0 C-N-CA 125.549 1.539 . . . . 0.0 111.102 -179.327 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -172.81 157.11 3.61 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 -177.832 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -131.84 146.71 18.26 Favored Glycine 0 N--CA 1.41 -3.036 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 -178.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 69.9 m -130.16 148.89 52.05 Favored 'General case' 0 C--N 1.286 -2.177 0 O-C-N 124.52 0.776 . . . . 0.0 109.666 -178.046 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.512 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -113.53 157.77 21.6 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.512 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 97.5 m-85 -155.18 179.25 9.33 Favored 'General case' 0 C--N 1.345 0.396 0 C-N-CA 124.497 1.119 . . . . 0.0 109.59 -177.376 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 55.13 -145.42 30.47 Favored Glycine 0 C--N 1.331 0.299 0 O-C-N 123.975 0.797 . . . . 0.0 113.475 176.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.63 -13.03 74.51 Favored Glycine 0 C--O 1.205 -1.704 0 C-N-CA 120.957 -0.639 . . . . 0.0 111.692 178.263 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.826 HG21 ' HB ' ' A' ' 126' ' ' ILE . 98.6 t -67.21 -42.7 88.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 C-N-CA 123.359 0.663 . . . . 0.0 111.528 -178.234 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.512 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -84.81 -15.13 45.91 Favored 'General case' 0 C--N 1.308 -1.235 0 C-N-CA 119.112 -1.035 . . . . 0.0 112.055 179.531 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 36.5 t -100.31 -59.98 1.61 Allowed 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.851 -174.634 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.537 ' O ' HG22 ' A' ' 112' ' ' VAL . 46.9 m-20 -92.13 -23.95 19.26 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.076 -171.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.685 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 88.6 m-85 -106.9 154.83 20.47 Favored 'General case' 0 N--CA 1.42 -1.933 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.399 179.505 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.3 t -162.09 136.49 6.78 Favored 'General case' 0 N--CA 1.407 -2.594 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.546 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -168.69 -103.43 0.17 Allowed Glycine 0 C--N 1.275 -2.843 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 175.003 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.424 HG22 ' HA ' ' A' ' 83' ' ' PRO . 0.7 OUTLIER -168.22 179.97 4.29 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 124.688 1.195 . . . . 0.0 109.264 -176.337 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.42 ' HB ' ' HB2' ' A' ' 84' ' ' PHE . 2.9 p -129.5 148.23 33.27 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 N-CA-C 109.684 -0.488 . . . . 0.0 109.684 178.643 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.555 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.2 tttt -127.19 144.26 51.08 Favored 'General case' 0 N--CA 1.427 -1.621 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.214 -179.189 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.519 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 58.6 t80 -140.89 104.72 4.74 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.27 -0.877 . . . . 0.0 108.86 -179.106 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 15.5 t 48.58 48.18 19.88 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 124.39 1.076 . . . . 0.0 111.834 177.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.59 5.36 69.21 Favored Glycine 0 N--CA 1.441 -0.991 0 CA-C-N 115.497 -0.774 . . . . 0.0 114.219 178.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.555 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 17.8 t -80.08 178.93 7.9 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 24.3 p -155.89 108.77 2.67 Favored 'General case' 0 C--N 1.293 -1.879 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.439 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.519 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.8 p90 -155.38 158.67 31.98 Favored Pre-proline 0 C--N 1.314 -0.947 0 O-C-N 122.195 -0.316 . . . . 0.0 110.258 -174.223 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.424 ' HA ' HG22 ' A' ' 74' ' ' THR . 43.4 Cg_endo -67.25 147.71 79.02 Favored 'Trans proline' 0 C--N 1.364 1.343 0 C-N-CA 123.28 2.654 . . . . 0.0 113.362 -177.848 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.63 ' CD2' HD21 ' A' ' 109' ' ' LEU . 63.6 t80 -123.13 135.27 25.75 Favored Pre-proline 0 N--CA 1.435 -1.201 0 CA-C-N 115.615 -0.72 . . . . 0.0 109.817 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.498 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 73.9 Cg_endo -72.59 145.22 83.1 Favored 'Cis proline' 0 CA--C 1.541 0.832 0 C-N-CA 123.144 -1.607 . . . . 0.0 110.411 -3.692 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.1 t -69.81 -177.02 1.18 Allowed 'General case' 0 CA--C 1.553 1.085 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.453 -176.12 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 39.4 p -122.61 -34.97 3.15 Favored 'General case' 0 N--CA 1.439 -0.994 0 CA-C-O 121.431 0.634 . . . . 0.0 110.354 -170.072 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.0 t -126.83 -131.46 0.24 Allowed 'General case' 0 N--CA 1.389 -3.492 0 N-CA-C 104.416 -2.438 . . . . 0.0 104.416 174.798 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -113.64 -169.86 1.59 Allowed 'General case' 0 C--N 1.286 -2.169 0 N-CA-C 113.05 0.759 . . . . 0.0 113.05 -173.19 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.53 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 35.0 p -97.49 170.52 7.09 Favored Pre-proline 0 C--N 1.31 -1.114 0 CA-C-N 115.439 -0.8 . . . . 0.0 111.843 178.601 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . 0.452 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 37.2 Cg_endo -65.4 166.39 19.59 Favored 'Trans proline' 0 C--O 1.251 1.148 0 C-N-CA 122.277 1.985 . . . . 0.0 109.707 170.044 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.421 ' HG3' ' HE1' ' A' ' 55' ' ' TYR . 47.7 ttp180 -73.32 140.12 46.52 Favored 'General case' 0 C--N 1.308 -1.212 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.768 -179.356 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 56.2 t -141.07 120.61 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.898 0 CA-C-N 114.925 -1.034 . . . . 0.0 109.314 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 70.8 t -95.39 140.51 16.79 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.896 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 175.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -87.85 100.75 13.11 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 175.412 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 17.4 m120 -89.11 60.27 5.31 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.649 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.6 m -135.3 178.3 7.14 Favored 'General case' 0 N--CA 1.425 -1.716 0 CA-C-N 114.44 -1.254 . . . . 0.0 109.076 -174.385 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 16.9 ptp180 -148.81 45.01 1.01 Allowed 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 122.007 0.908 . . . . 0.0 109.462 175.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.3 t -170.58 -175.36 1.84 Allowed 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 -176.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . 0.461 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 9.2 p-10 -77.06 99.0 5.18 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-O 122.153 0.977 . . . . 0.0 108.398 172.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . 0.404 ' HG3' ' HD2' ' A' ' 102' ' ' PRO . 2.8 tptm -101.04 136.17 19.79 Favored Pre-proline 0 N--CA 1.405 -2.724 0 CA-C-N 114.939 -1.028 . . . . 0.0 108.233 -177.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.682 ' HB3' ' O ' ' A' ' 39' ' ' SER . 80.0 Cg_exo -48.43 139.66 22.31 Favored 'Trans proline' 0 C--N 1.324 -0.752 0 C-N-CA 123.939 3.093 . . . . 0.0 113.658 177.383 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.5 t90 -90.11 105.69 12.17 Favored Pre-proline 0 C--N 1.31 -1.146 0 N-CA-C 106.754 -1.573 . . . . 0.0 106.754 -178.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -73.78 89.27 1.0 Allowed 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.293 1.995 . . . . 0.0 112.686 -173.464 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.48 HG22 ' CD2' ' A' ' 77' ' ' TYR . 90.1 t -136.31 145.2 31.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 177.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.585 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.96 133.08 15.28 Favored 'General case' 0 N--CA 1.417 -2.078 0 CA-C-O 121.06 0.457 . . . . 0.0 110.766 178.071 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.475 HD21 HD11 ' A' ' 129' ' ' LEU . 14.2 mt -101.93 100.12 10.39 Favored 'General case' 0 C--N 1.288 -2.086 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 179.03 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.546 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 63.1 m-85 -77.38 78.24 3.91 Favored 'General case' 0 C--N 1.306 -1.298 0 O-C-N 122.067 -0.395 . . . . 0.0 110.255 177.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.685 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.0 mm? -104.56 118.24 36.11 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-O 121.167 0.508 . . . . 0.0 110.066 176.732 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.79 145.93 46.75 Favored Pre-proline 0 N--CA 1.414 -2.238 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.889 -173.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -63.43 121.61 9.47 Favored 'Trans proline' 0 CA--C 1.5 -1.195 0 C-N-CA 122.986 2.457 . . . . 0.0 113.57 -175.23 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.567 ' O ' HG22 ' A' ' 30' ' ' VAL . 19.8 m -82.0 -155.27 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.399 -3.0 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.108 171.498 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 8.5 m -79.73 -29.92 40.73 Favored 'General case' 0 C--N 1.257 -3.447 0 CA-C-O 121.515 0.674 . . . . 0.0 110.721 -167.799 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 5.3 t -91.47 25.5 2.6 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-O 121.664 0.745 . . . . 0.0 110.514 -176.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.419 ' HB1' HG21 ' A' ' 156' ' ' VAL . . . -102.83 128.74 49.47 Favored 'General case' 0 N--CA 1.418 -2.061 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.99 128.88 1.72 Allowed Glycine 0 C--N 1.307 -1.048 0 C-N-CA 120.151 -1.023 . . . . 0.0 111.765 -178.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.24 -152.71 52.81 Favored Glycine 0 CA--C 1.493 -1.343 0 CA-C-O 118.925 -0.931 . . . . 0.0 111.532 -176.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 63.4 t -55.85 106.04 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.246 0.914 0 CA-C-O 121.586 0.708 . . . . 0.0 110.79 -177.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -106.27 -33.07 7.91 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 114.535 -1.211 . . . . 0.0 110.622 -178.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.499 ' HB ' HG22 ' A' ' 154' ' ' VAL . 74.8 mt -121.54 139.91 47.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 177.526 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.421 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.8 mmpt? -115.47 136.41 53.11 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 123.138 0.575 . . . . 0.0 110.973 178.547 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -72.13 131.11 42.37 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.709 178.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 92.29 -5.3 77.93 Favored Glycine 0 C--N 1.309 -0.953 0 N-CA-C 111.561 -0.616 . . . . 0.0 111.561 -178.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 61.3 m -98.4 149.04 23.08 Favored 'General case' 0 N--CA 1.425 -1.719 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 179.556 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 26.6 tp -72.69 138.19 46.45 Favored 'General case' 0 N--CA 1.433 -1.31 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.14 178.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.826 ' HB ' HG21 ' A' ' 67' ' ' VAL . 34.4 pt -121.27 -27.08 2.02 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 N-CA-C 112.392 0.516 . . . . 0.0 112.392 178.708 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.93 168.79 20.68 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -177.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 75.1 t -143.55 116.18 3.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 179.176 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.475 HD11 HD21 ' A' ' 107' ' ' LEU . 63.4 mt -117.37 154.46 31.27 Favored 'General case' 0 C--N 1.283 -2.297 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 179.173 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.494 ' O ' HD12 ' A' ' 58' ' ' LEU . 5.0 mp -135.73 127.69 45.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.821 -0.549 . . . . 0.0 109.704 177.623 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.454 ' C ' HD12 ' A' ' 131' ' ' LEU . 1.2 pp -89.34 150.18 22.69 Favored 'General case' 0 CA--C 1.484 -1.592 0 N-CA-C 106.673 -1.602 . . . . 0.0 106.673 173.693 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 54.5 ttp180 -115.71 120.93 40.95 Favored 'General case' 0 C--N 1.269 -2.917 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 176.862 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 21.9 tp60 -93.96 121.22 35.2 Favored 'General case' 0 N--CA 1.422 -1.83 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -175.076 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 27.7 m -133.47 149.78 51.74 Favored 'General case' 0 C--N 1.292 -1.92 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 174.6 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.699 ' CB ' HG23 ' A' ' 52' ' ' ILE . 8.0 p30 . . . . . 0 C--O 1.213 -0.866 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.59 175.723 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 . . . . . 0 N--CA 1.421 -1.888 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -131.37 144.23 51.07 Favored 'General case' 0 N--CA 1.407 -2.6 0 C-N-CA 118.416 -1.314 . . . . 0.0 110.963 179.249 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 11.0 m-30 -110.7 125.92 53.99 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 -176.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.475 ' HB ' ' HB3' ' A' ' 17' ' ' SER . 48.7 t -88.22 134.44 28.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 CA-C-O 121.076 0.465 . . . . 0.0 110.196 -178.549 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 65.8 m95 -120.79 94.39 4.34 Favored 'General case' 0 C--N 1.285 -2.239 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -179.209 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -78.72 114.95 18.08 Favored 'General case' 0 C--N 1.286 -2.19 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 178.53 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.406 ' HA ' HG22 ' A' ' 20' ' ' VAL . 18.3 mm -90.18 120.33 38.81 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 -176.548 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -117.52 155.08 30.38 Favored 'General case' 0 CA--C 1.488 -1.405 0 CA-C-O 121.324 0.583 . . . . 0.0 109.919 177.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.54 131.21 35.22 Favored 'General case' 0 N--CA 1.407 -2.606 0 CA-C-N 115.01 -0.995 . . . . 0.0 108.82 176.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 40.3 t-20 -91.32 -13.35 32.75 Favored 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 -177.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -152.01 145.72 25.03 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 114.169 -1.378 . . . . 0.0 109.67 -175.389 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -84.44 144.89 28.47 Favored 'General case' 0 C--N 1.319 -0.739 0 O-C-N 124.317 1.011 . . . . 0.0 109.195 -178.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.523 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 1.5 m -125.21 148.96 29.6 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.9 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 9.3 t -124.66 138.32 54.45 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 N-CA-C 107.686 -1.228 . . . . 0.0 107.686 -178.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.525 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 81.5 t -100.04 101.8 15.53 Favored Pre-proline 0 C--N 1.292 -1.892 0 C-N-CA 123.677 0.791 . . . . 0.0 109.982 179.368 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.485 ' HG3' HG13 ' A' ' 27' ' ' VAL . 35.2 Cg_endo -70.12 -23.52 29.07 Favored 'Trans proline' 0 CA--C 1.509 -0.749 0 C-N-CA 122.319 2.013 . . . . 0.0 111.801 178.62 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.1 t . . . . . 0 C--O 1.248 0.99 0 O-C-N 124.716 1.26 . . . . 0.0 112.404 179.359 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.438 -1.046 0 N-CA-C 102.837 -3.023 . . . . 0.0 102.837 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.483 ' HB3' ' CZ2' ' A' ' 146' ' ' TRP . 11.5 t -150.5 158.32 44.02 Favored 'General case' 0 C--N 1.283 -2.318 0 C-N-CA 117.232 -1.787 . . . . 0.0 111.081 -174.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.435 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.26 160.88 40.24 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 121.474 0.654 . . . . 0.0 110.713 -175.816 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.583 HG22 HG22 ' A' ' 20' ' ' VAL . 57.2 p -97.68 178.73 5.07 Favored 'General case' 0 C--N 1.293 -1.888 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.648 -179.666 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -82.04 -21.01 37.16 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.712 178.514 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -87.09 -29.07 22.15 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.997 -176.224 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.16 7.52 2.85 Favored Glycine 0 C--N 1.307 -1.073 0 C-N-CA 119.222 -1.466 . . . . 0.0 114.34 171.308 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.0 m -86.94 101.09 13.09 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 177.216 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -97.06 119.92 36.46 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-N 115.484 -0.78 . . . . 0.0 108.945 176.025 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 50.9 mt -97.7 116.46 65.77 Favored Pre-proline 0 C--N 1.297 -1.7 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.564 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -79.42 176.75 9.31 Favored 'Trans proline' 0 C--O 1.25 1.075 0 C-N-CA 122.653 2.236 . . . . 0.0 110.387 177.331 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 56.7 mt -72.04 125.35 30.52 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.343 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 177.669 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 149.22 -6.45 0.81 Allowed Glycine 0 C--N 1.299 -1.48 0 CA-C-N 115.6 -0.727 . . . . 0.0 112.001 -176.482 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.17 156.77 33.06 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 120.709 -0.758 . . . . 0.0 111.373 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.34 -165.83 34.0 Favored Glycine 0 N--CA 1.419 -2.456 0 C-N-CA 119.818 -1.182 . . . . 0.0 111.604 178.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 145' ' ' VAL . 59.8 p -145.7 155.17 42.81 Favored 'General case' 0 N--CA 1.417 -2.077 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 -177.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.81 155.64 50.03 Favored 'General case' 0 N--CA 1.416 -2.151 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 177.284 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -105.01 109.97 22.18 Favored 'General case' 0 C--N 1.279 -2.459 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 174.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.583 HG22 HG22 ' A' ' 5' ' ' THR . 34.2 t -97.33 135.52 31.33 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -177.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 77.7 m-85 -116.62 126.82 53.8 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -178.547 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.524 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.5 p -135.54 129.45 49.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.195 -176.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . 0.416 ' HB3' ' HB3' ' A' ' 151' ' ' ASN . 8.0 p30 -94.52 126.02 39.53 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-O 121.683 0.754 . . . . 0.0 110.423 178.197 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -103.44 162.59 12.9 Favored 'General case' 0 C--N 1.286 -2.157 0 CA-C-N 114.278 -1.328 . . . . 0.0 108.019 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . 0.407 ' C ' ' H ' ' A' ' 27' ' ' VAL . . . -54.48 126.07 54.39 Favored Pre-proline 0 CA--C 1.499 -0.998 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 174.722 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.529 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 72.7 Cg_endo -77.44 9.77 2.74 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 122.484 2.123 . . . . 0.0 110.925 179.2 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.407 ' H ' ' C ' ' A' ' 25' ' ' ALA . 14.1 p -138.35 115.97 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.916 0 CA-C-N 114.827 -1.079 . . . . 0.0 108.365 -178.316 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.4 t -150.02 120.05 1.06 Allowed 'Isoleucine or valine' 0 C--O 1.191 -1.985 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 -179.006 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.589 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -107.24 147.85 29.67 Favored 'General case' 0 C--N 1.267 -2.999 0 C-N-CA 122.505 0.322 . . . . 0.0 110.76 -179.973 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.532 HG22 ' O ' ' A' ' 112' ' ' VAL . 98.7 t -43.67 117.35 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 123.329 0.652 . . . . 0.0 111.539 176.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.56 -1.72 42.57 Favored Glycine 0 C--N 1.319 -0.396 0 CA-C-N 114.779 -1.101 . . . . 0.0 112.809 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.589 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -73.35 -176.69 2.31 Favored 'General case' 0 C--N 1.315 -0.896 0 C-N-CA 124.011 0.924 . . . . 0.0 110.775 177.37 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -129.5 83.35 2.13 Favored 'General case' 0 CA--C 1.49 -1.327 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.238 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.562 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 19.1 tp -90.72 133.23 35.31 Favored 'General case' 0 N--CA 1.419 -1.977 0 C-N-CA 119.151 -1.019 . . . . 0.0 108.516 178.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.447 ' CG2' ' HB1' ' A' ' 106' ' ' ALA . 2.2 p -141.44 133.92 29.22 Favored 'Isoleucine or valine' 0 N--CA 1.383 -3.792 0 CA-C-O 121.882 0.848 . . . . 0.0 111.728 -178.572 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.62 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 45.6 t -89.2 89.92 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.52 0 CA-C-N 113.732 -1.577 . . . . 0.0 108.333 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -76.53 109.72 10.49 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 120.876 0.37 . . . . 0.0 110.89 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 93.0 mt -92.29 -1.54 57.01 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 115.905 -0.588 . . . . 0.0 112.549 -178.698 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 89.9 p -76.81 1.08 18.41 Favored 'General case' 0 N--CA 1.474 0.762 0 CA-C-O 123.0 1.381 . . . . 0.0 109.754 -179.649 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.7 p -123.92 6.64 8.66 Favored 'General case' 0 C--N 1.276 -2.628 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.881 179.184 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.524 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 42.4 mm-40 -127.14 -25.14 3.31 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.604 -175.232 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 23.1 mt -132.64 137.44 54.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 -175.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.435 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 40.4 m-85 -140.65 123.41 16.28 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -176.305 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.425 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 79.7 m -103.71 142.9 33.54 Favored 'General case' 0 C--N 1.271 -2.82 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 -178.729 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . 0.437 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 10.1 p80 -136.75 168.06 20.26 Favored 'General case' 0 C--N 1.294 -1.836 0 CA-C-O 121.335 0.588 . . . . 0.0 110.787 -172.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.455 ' HB3' ' OD1' ' A' ' 54' ' ' ASP . 5.4 p30 -112.41 100.0 8.43 Favored 'General case' 0 C--N 1.281 -2.383 0 CA-C-O 122.2 1.0 . . . . 0.0 111.814 175.566 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -76.26 -31.21 58.17 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 178.192 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.47 ' HB3' ' OG1' ' A' ' 51' ' ' THR . 23.2 m-85 -127.88 87.97 54.4 Favored Pre-proline 0 N--CA 1.435 -1.22 0 N-CA-C 106.004 -1.851 . . . . 0.0 106.004 177.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -88.59 -13.34 3.4 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 122.319 2.013 . . . . 0.0 113.976 -176.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -110.92 -12.35 14.25 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.622 -0.831 . . . . 0.0 110.756 -176.116 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.47 ' OG1' ' HB3' ' A' ' 48' ' ' TYR . 0.0 OUTLIER -101.4 -31.36 10.97 Favored 'General case' 0 N--CA 1.417 -2.115 0 CA-C-N 115.406 -0.815 . . . . 0.0 110.194 179.771 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.634 HG23 ' CB ' ' A' ' 135' ' ' ASN . 3.1 mp -121.9 126.54 74.67 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.592 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.6 t -72.75 135.06 45.25 Favored 'General case' 0 N--CA 1.421 -1.901 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 174.602 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.455 ' OD1' ' HB3' ' A' ' 46' ' ' ASN . 58.7 m-20 -87.06 107.6 18.51 Favored 'General case' 0 C--N 1.278 -2.506 0 CA-C-O 121.939 0.876 . . . . 0.0 111.343 -171.093 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 70.4 t80 -137.91 145.8 42.54 Favored 'General case' 0 C--N 1.29 -1.997 0 CA-C-N 114.078 -1.419 . . . . 0.0 108.058 -175.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.433 HG23 HD13 ' A' ' 131' ' ' LEU . 11.9 p -152.25 148.38 14.39 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.786 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.309 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -151.34 140.37 21.09 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 174.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.573 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 50.5 tp -75.19 117.76 17.37 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 173.346 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.514 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 3.6 tp-100 -65.54 -44.92 85.35 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.456 -1.247 . . . . 0.0 110.458 -177.851 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.514 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 10.4 ptp180 -176.97 161.87 1.99 Allowed 'General case' 0 N--CA 1.432 -1.34 0 O-C-N 124.708 1.255 . . . . 0.0 108.423 -176.407 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.405 ' H ' HG22 ' A' ' 86' ' ' THR . . . -143.08 129.53 3.8 Favored Glycine 0 N--CA 1.408 -3.174 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -178.302 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 54.2 m -117.35 149.38 40.59 Favored 'General case' 0 C--N 1.291 -1.944 0 C-N-CA 124.099 0.96 . . . . 0.0 110.461 -174.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.522 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -113.37 156.16 23.93 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.497 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 88.4 m-85 -154.6 -179.92 8.44 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 124.155 0.982 . . . . 0.0 108.867 -178.407 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 57.79 -143.56 42.39 Favored Glycine 0 C--N 1.325 -0.081 0 O-C-N 123.891 0.744 . . . . 0.0 113.513 176.13 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -72.97 -14.23 78.78 Favored Glycine 0 C--O 1.209 -1.468 0 C-N-CA 120.846 -0.693 . . . . 0.0 111.717 177.565 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.78 HG21 ' HB ' ' A' ' 126' ' ' ILE . 95.2 t -67.59 -39.37 82.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 123.804 0.842 . . . . 0.0 111.606 -177.717 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.522 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -87.1 -19.03 29.13 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 118.67 -1.212 . . . . 0.0 112.192 178.027 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 6.2 t -98.36 -56.58 2.43 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.537 -172.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.491 ' O ' HG22 ' A' ' 112' ' ' VAL . 41.3 m-20 -92.03 -22.97 19.67 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.24 -173.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.656 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 92.0 m-85 -108.73 156.93 19.03 Favored 'General case' 0 N--CA 1.419 -1.999 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.489 178.598 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 12.7 t -161.38 136.41 7.46 Favored 'General case' 0 N--CA 1.403 -2.787 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 176.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.498 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.97 -111.67 0.26 Allowed Glycine 0 N--CA 1.398 -3.893 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 174.19 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.2 p -159.66 -179.92 8.3 Favored 'General case' 0 C--N 1.297 -1.684 0 C-N-CA 124.001 0.92 . . . . 0.0 110.425 -172.743 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -132.1 145.9 34.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 178.202 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.673 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.2 tttt -126.58 145.45 50.53 Favored 'General case' 0 N--CA 1.427 -1.585 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -178.189 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.532 ' CD2' HG22 ' A' ' 105' ' ' VAL . 58.9 t80 -145.63 110.69 5.23 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 -177.691 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 44.9 t 53.27 37.08 24.36 Favored 'General case' 0 CA--C 1.55 0.963 0 C-N-CA 123.35 0.66 . . . . 0.0 111.982 178.04 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.32 8.54 66.2 Favored Glycine 0 CA--C 1.525 0.698 0 C-N-CA 120.301 -0.952 . . . . 0.0 113.663 -179.384 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.673 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 20.8 t -81.59 -179.79 7.52 Favored 'General case' 0 CA--C 1.544 0.735 0 CA-C-N 117.383 0.592 . . . . 0.0 109.51 178.412 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.0 p -156.78 109.22 2.51 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.418 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.3 p90 -151.89 158.71 33.84 Favored Pre-proline 0 C--N 1.306 -1.323 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 -175.52 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -68.73 150.94 74.69 Favored 'Trans proline' 0 C--N 1.354 0.817 0 C-N-CA 122.879 2.386 . . . . 0.0 113.096 -176.471 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.592 ' CD2' HD21 ' A' ' 109' ' ' LEU . 54.0 t80 -124.46 132.15 24.26 Favored Pre-proline 0 N--CA 1.442 -0.867 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.219 -179.684 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.468 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 72.4 Cg_endo -72.53 148.2 90.99 Favored 'Cis proline' 0 CA--C 1.535 0.558 0 C-N-CA 122.8 -1.75 . . . . 0.0 109.984 -0.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.405 HG22 ' H ' ' A' ' 61' ' ' GLY . 9.0 t -67.09 -177.49 0.66 Allowed 'General case' 0 C--O 1.248 1.017 0 CA-C-O 121.367 0.603 . . . . 0.0 111.29 -175.499 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.8 p -120.7 -25.13 5.55 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 115.286 -0.87 . . . . 0.0 110.647 -173.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 t -135.38 -107.95 0.21 Allowed 'General case' 0 N--CA 1.419 -1.985 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 178.555 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . 0.425 ' HB2' ' O ' ' A' ' 58' ' ' LEU . 0.0 OUTLIER -144.44 -165.66 2.19 Favored 'General case' 0 N--CA 1.445 -0.723 0 CA-C-N 118.251 0.478 . . . . 0.0 110.749 -177.508 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.573 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 58.3 p -100.26 168.16 9.83 Favored Pre-proline 0 C--N 1.306 -1.286 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 179.55 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . 0.407 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 34.4 Cg_endo -63.62 172.26 5.88 Favored 'Trans proline' 0 C--O 1.251 1.139 0 C-N-CA 123.062 2.508 . . . . 0.0 110.48 170.02 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 41.2 ttp180 -71.49 142.32 50.16 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.12 -177.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 64.0 t -151.16 131.57 4.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 124.355 1.062 . . . . 0.0 108.427 -179.048 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 54' ' ' ASP . 2.2 p -128.93 141.46 46.55 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 108.253 -1.018 . . . . 0.0 108.253 -178.729 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -92.99 108.33 19.92 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-O 121.251 0.548 . . . . 0.0 111.234 -178.745 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -94.38 45.97 1.14 Allowed 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.6 t -124.03 -176.57 3.52 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 -175.77 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 37.8 ptt180 -148.14 33.78 0.82 Allowed 'General case' 0 C--N 1.314 -0.948 0 CA-C-O 121.879 0.847 . . . . 0.0 109.619 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.1 t -165.58 -178.97 5.16 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 -178.52 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . 0.437 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 3.7 p30 -77.12 130.15 36.97 Favored 'General case' 0 CA--C 1.501 -0.928 0 CA-C-O 121.515 0.674 . . . . 0.0 109.956 -179.748 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 15.8 mmtm -129.72 141.35 41.52 Favored Pre-proline 0 C--N 1.287 -2.137 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.08 -179.558 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -61.53 137.58 70.31 Favored 'Trans proline' 0 CA--C 1.499 -1.246 0 C-N-CA 123.571 2.847 . . . . 0.0 112.7 -174.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.6 t90 -81.5 108.58 11.22 Favored Pre-proline 0 C--N 1.304 -1.409 0 N-CA-C 106.393 -1.706 . . . . 0.0 106.393 -177.479 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -76.22 87.69 1.41 Allowed 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 121.231 1.287 . . . . 0.0 112.718 -172.045 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.532 HG22 ' CD2' ' A' ' 77' ' ' TYR . 57.6 t -137.83 146.53 27.18 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.203 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 177.544 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.62 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.38 134.73 16.09 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 177.446 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.469 HD21 HD11 ' A' ' 129' ' ' LEU . 16.7 mt -102.87 99.95 9.9 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.443 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.498 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 71.5 m-85 -78.36 81.36 4.71 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 177.513 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.656 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.1 mm? -107.1 118.6 37.13 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 176.366 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -120.99 148.41 48.72 Favored Pre-proline 0 N--CA 1.41 -2.448 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.253 -173.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -66.13 120.96 8.18 Favored 'Trans proline' 0 N--CA 1.44 -1.646 0 C-N-CA 122.892 2.395 . . . . 0.0 113.47 -175.055 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.532 ' O ' HG22 ' A' ' 30' ' ' VAL . 21.7 m -81.03 -157.29 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.393 -3.297 0 CA-C-N 114.49 -1.232 . . . . 0.0 108.814 170.75 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 30.9 m -82.96 -26.47 31.34 Favored 'General case' 0 C--N 1.252 -3.645 0 CA-C-O 121.699 0.761 . . . . 0.0 110.912 -170.127 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 19.6 t -83.36 13.64 4.21 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.197 -0.911 . . . . 0.0 110.189 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -98.3 125.31 43.35 Favored 'General case' 0 N--CA 1.428 -1.557 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.569 179.352 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -168.67 129.74 1.94 Allowed Glycine 0 N--CA 1.431 -1.642 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 178.687 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.71 -148.8 49.94 Favored Glycine 0 CA--C 1.493 -1.322 0 CA-C-O 119.232 -0.76 . . . . 0.0 111.883 -177.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.451 ' CG1' ' HE3' ' A' ' 121' ' ' LYS . 65.9 t -60.04 101.66 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.248 0.991 0 CA-C-O 122.078 0.942 . . . . 0.0 111.117 -176.435 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -101.57 -23.11 14.34 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 114.137 -1.392 . . . . 0.0 111.498 -177.709 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.459 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 61.8 mt -136.7 141.21 41.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.68 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.548 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.6 mmpt? -116.2 141.31 48.31 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 120.843 0.354 . . . . 0.0 110.347 177.006 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 0.4 ' H ' ' HB3' ' A' ' 153' ' ' ASP . . . -69.06 148.07 50.58 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.725 179.667 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 71.78 14.37 75.49 Favored Glycine 0 C--O 1.218 -0.845 0 CA-C-N 115.828 -0.623 . . . . 0.0 111.555 178.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 20.0 m -119.08 143.4 47.16 Favored 'General case' 0 N--CA 1.421 -1.891 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -175.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -68.6 127.05 31.61 Favored 'General case' 0 C--O 1.242 0.659 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.167 -178.032 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.78 ' HB ' HG21 ' A' ' 67' ' ' VAL . 27.9 pt -115.9 -26.91 2.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . 0.411 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -159.92 168.13 26.42 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -178.041 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 65.7 t -142.64 114.06 3.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.443 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.469 HD11 HD21 ' A' ' 107' ' ' LEU . 56.8 mt -115.43 155.76 26.85 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 178.3 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.523 ' O ' HD12 ' A' ' 58' ' ' LEU . 5.1 mp -135.68 131.13 50.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 CA-C-N 118.52 0.6 . . . . 0.0 109.751 177.733 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.433 HD13 HG23 ' A' ' 56' ' ' VAL . 1.8 pp -92.58 139.79 30.21 Favored 'General case' 0 CA--C 1.489 -1.399 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 172.624 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 27.1 tpt180 -97.31 108.0 20.64 Favored 'General case' 0 C--N 1.251 -3.714 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 19.4 tp60 -87.67 118.6 27.27 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -177.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 22.2 m -137.03 140.52 42.14 Favored 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 173.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.634 ' CB ' HG23 ' A' ' 52' ' ' ILE . 10.8 p30 . . . . . 0 N--CA 1.444 -0.751 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.899 178.008 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 . . . . . 0 N--CA 1.425 -1.723 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -141.86 149.46 40.3 Favored 'General case' 0 C--N 1.282 -2.366 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 176.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 9.7 m-30 -109.26 125.25 52.07 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 -174.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 17' ' ' SER . 48.2 t -89.27 135.52 25.75 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.926 0 O-C-N 123.749 0.656 . . . . 0.0 110.074 -178.209 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . 0.483 ' CZ2' ' HB3' ' A' ' 3' ' ' CYS . 61.6 m95 -120.38 96.26 5.07 Favored 'General case' 0 C--N 1.284 -2.246 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 -179.317 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 37.3 m-80 -80.58 112.83 18.31 Favored 'General case' 0 C--N 1.291 -1.946 0 N-CA-C 106.587 -1.634 . . . . 0.0 106.587 179.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.433 HG22 HD11 ' A' ' 126' ' ' ILE . 28.1 mm -87.48 122.83 39.72 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -176.193 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -117.12 151.9 35.85 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 123.786 0.834 . . . . 0.0 109.442 178.464 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.68 130.21 34.98 Favored 'General case' 0 N--CA 1.413 -2.318 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 176.064 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . 0.416 ' HB3' ' HB3' ' A' ' 23' ' ' ASN . 39.6 t-20 -89.12 -17.52 29.05 Favored 'General case' 0 C--N 1.288 -2.068 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 -178.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -147.17 143.04 27.93 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-N 114.418 -1.265 . . . . 0.0 109.462 -174.477 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . 0.4 ' HB3' ' H ' ' A' ' 122' ' ' ALA . 12.8 p-10 -86.07 138.66 31.78 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 124.083 0.865 . . . . 0.0 111.477 -178.733 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.529 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.8 t -114.44 137.82 46.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 114.946 -1.025 . . . . 0.0 112.334 -171.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -117.79 138.28 48.99 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.351 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 177.494 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.471 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 53.2 t -101.89 103.66 30.52 Favored Pre-proline 0 C--N 1.29 -1.979 0 C-N-CA 123.618 0.767 . . . . 0.0 109.756 178.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.453 ' HD2' ' O ' ' A' ' 28' ' ' VAL . 30.8 Cg_endo -68.08 -26.11 37.17 Favored 'Trans proline' 0 CA--C 1.506 -0.908 0 C-N-CA 122.429 2.086 . . . . 0.0 111.878 177.295 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.4 t . . . . . 0 C--N 1.349 0.578 0 O-C-N 124.748 1.28 . . . . 0.0 112.33 179.233 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.479 ' HB3' ' NE2' ' A' ' 45' ' ' HIS . . . . . . . . 0 CA--C 1.492 -1.258 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.418 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 63.1 m -134.39 155.41 50.34 Favored 'General case' 0 C--N 1.288 -2.071 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.786 -174.105 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.5 155.52 43.15 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-O 121.223 0.535 . . . . 0.0 109.917 -176.333 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.602 HG22 HG22 ' A' ' 20' ' ' VAL . 72.9 p -92.25 175.01 7.01 Favored 'General case' 0 C--N 1.292 -1.922 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.77 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -85.61 -11.49 53.81 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.278 -1.328 . . . . 0.0 109.716 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -95.21 -27.35 15.57 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-N 115.138 -0.937 . . . . 0.0 111.751 -178.279 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 136.64 1.04 2.8 Favored Glycine 0 C--O 1.222 -0.621 0 C-N-CA 119.155 -1.498 . . . . 0.0 114.845 169.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.2 m -87.86 105.94 17.76 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 121.455 0.645 . . . . 0.0 109.579 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -98.99 119.55 37.97 Favored 'General case' 0 C--N 1.291 -1.953 0 CA-C-N 114.735 -1.12 . . . . 0.0 109.224 176.402 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.435 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 60.0 mt -100.36 114.66 65.79 Favored Pre-proline 0 C--N 1.303 -1.429 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.102 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_endo -76.59 171.87 17.26 Favored 'Trans proline' 0 C--O 1.249 1.037 0 C-N-CA 122.385 2.057 . . . . 0.0 111.354 177.262 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 68.4 mt -58.06 134.03 22.85 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.967 179.031 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 128.59 2.75 5.74 Favored Glycine 0 C--N 1.303 -1.257 0 C-N-CA 120.344 -0.931 . . . . 0.0 112.466 179.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.04 164.89 34.82 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.13 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.74 -166.51 34.44 Favored Glycine 0 C--N 1.295 -1.743 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.701 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.1 p -141.24 154.33 45.72 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -178.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -143.37 159.38 42.48 Favored 'General case' 0 N--CA 1.421 -1.88 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.36 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.8 p30 -103.22 122.87 45.65 Favored 'General case' 0 C--N 1.275 -2.67 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 173.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.602 HG22 HG22 ' A' ' 5' ' ' THR . 40.3 t -106.81 129.71 59.95 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.76 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.737 177.826 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 -112.88 121.17 43.88 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 120.982 0.42 . . . . 0.0 111.23 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.589 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.3 p -133.92 130.24 55.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-N 115.318 -0.856 . . . . 0.0 111.164 -178.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -92.25 130.83 37.85 Favored 'General case' 0 C--N 1.296 -1.758 0 CA-C-O 121.37 0.605 . . . . 0.0 110.429 177.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.683 HD21 HG22 ' A' ' 36' ' ' VAL . 6.9 mp -109.18 161.85 14.83 Favored 'General case' 0 C--N 1.287 -2.118 0 CA-C-N 114.489 -1.232 . . . . 0.0 108.877 179.454 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.01 121.1 48.17 Favored Pre-proline 0 C--O 1.209 -1.06 0 O-C-N 124.777 1.298 . . . . 0.0 109.486 179.177 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.511 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 66.1 Cg_endo -75.7 -0.91 10.72 Favored 'Trans proline' 0 CA--C 1.531 0.332 0 C-N-CA 122.906 2.404 . . . . 0.0 113.539 -176.78 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 96.0 t -127.93 109.63 20.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 178.407 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.567 HG21 HD22 ' A' ' 34' ' ' LEU . 5.7 t -145.59 112.43 1.22 Allowed 'Isoleucine or valine' 0 C--O 1.189 -2.116 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 -177.558 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.488 ' H ' ' HG3' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -100.78 152.12 20.88 Favored 'General case' 0 C--N 1.266 -3.064 0 C-N-CA 123.138 0.575 . . . . 0.0 111.004 -179.843 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 41.5 t -43.81 116.51 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 123.727 0.811 . . . . 0.0 111.631 175.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.51 -5.52 35.39 Favored Glycine 0 C--O 1.227 -0.296 0 CA-C-N 115.421 -0.808 . . . . 0.0 112.99 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.488 ' HG3' ' H ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -69.34 -177.89 1.24 Allowed 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 123.669 0.788 . . . . 0.0 111.786 177.817 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -126.62 86.19 2.48 Favored 'General case' 0 CA--C 1.482 -1.646 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 176.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.609 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 24.4 tp -95.73 134.98 38.02 Favored 'General case' 0 N--CA 1.41 -2.433 0 C-N-CA 119.202 -0.999 . . . . 0.0 109.453 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.421 ' CG2' ' HB1' ' A' ' 106' ' ' ALA . 1.7 p -141.78 137.79 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.38 -3.941 0 CA-C-N 114.729 -1.123 . . . . 0.0 112.07 -177.633 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.683 HG22 HD21 ' A' ' 24' ' ' LEU . 58.4 t -90.48 89.89 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.335 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 176.26 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -76.01 106.57 7.68 Favored 'General case' 0 C--N 1.297 -1.717 0 C-N-CA 120.057 -0.657 . . . . 0.0 109.669 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.8 mt -95.03 -1.16 52.87 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.822 -179.188 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 15.2 m -77.41 0.58 21.98 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-O 122.074 0.94 . . . . 0.0 109.478 -177.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.2 p -128.46 5.39 5.68 Favored 'General case' 0 N--CA 1.421 -1.901 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.157 178.776 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.589 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 47.1 mm-40 -122.74 -24.21 4.91 Favored 'General case' 0 CA--C 1.503 -0.835 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.73 -174.385 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.7 mt -130.47 140.07 49.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 -176.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -138.13 149.74 46.18 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 -176.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.418 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 70.2 m -125.87 134.08 51.73 Favored 'General case' 0 C--N 1.289 -2.047 0 C-N-CA 122.794 0.437 . . . . 0.0 110.061 176.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . 0.479 ' NE2' ' HB3' ' A' ' 2' ' ' ALA . 11.6 p-80 -119.35 150.79 39.57 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-O 121.998 0.904 . . . . 0.0 110.386 -177.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -99.35 101.99 13.44 Favored 'General case' 0 C--N 1.272 -2.789 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 -179.022 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 18.3 p-10 -86.62 -17.63 33.4 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 -179.247 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 67.3 m-85 -138.47 62.79 31.66 Favored Pre-proline 0 N--CA 1.477 0.91 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 175.184 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.8 -3.31 11.79 Favored 'Trans proline' 0 N--CA 1.485 0.971 0 C-N-CA 123.208 2.605 . . . . 0.0 114.454 -171.074 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -115.54 -17.35 11.2 Favored 'General case' 0 C--N 1.299 -1.625 0 CA-C-O 121.286 0.565 . . . . 0.0 110.272 -178.137 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.464 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.9 m -102.23 -30.36 11.15 Favored 'General case' 0 N--CA 1.424 -1.766 0 CA-C-O 122.064 0.935 . . . . 0.0 108.826 -174.38 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.52 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.0 mp -123.58 137.07 58.02 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.493 0 CA-C-N 114.164 -1.38 . . . . 0.0 109.043 -178.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 3.9 t -83.97 122.35 28.63 Favored 'General case' 0 N--CA 1.419 -1.986 0 N-CA-C 102.68 -3.082 . . . . 0.0 102.68 168.431 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -88.98 107.76 19.21 Favored 'General case' 0 C--N 1.261 -3.268 0 C-N-CA 118.313 -1.355 . . . . 0.0 109.013 -172.338 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.557 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 17.0 t80 -122.63 131.58 53.88 Favored 'General case' 0 C--N 1.285 -2.204 0 CA-C-N 114.382 -1.281 . . . . 0.0 109.638 -174.727 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.455 ' CG2' ' HG ' ' A' ' 131' ' ' LEU . 14.9 p -136.87 144.8 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.138 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.685 -175.705 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -150.02 118.49 6.49 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 178.04 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.535 HD12 ' O ' ' A' ' 130' ' ' ILE . 48.0 tp -53.91 111.03 0.67 Allowed 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 169.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.428 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 3.1 tp-100 -59.74 -51.06 71.37 Favored 'General case' 0 C--O 1.21 -0.976 0 C-N-CA 125.793 1.637 . . . . 0.0 110.574 179.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.428 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 11.0 ptp180 -170.01 158.68 7.25 Favored 'General case' 0 N--CA 1.428 -1.567 0 CA-C-N 115.172 -0.922 . . . . 0.0 108.804 -176.328 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -134.6 145.74 17.8 Favored Glycine 0 N--CA 1.405 -3.433 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 179.319 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 72.3 m -132.88 150.85 52.12 Favored 'General case' 0 C--N 1.283 -2.326 0 C-N-CA 124.062 0.945 . . . . 0.0 109.918 -177.322 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.517 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -115.3 157.77 23.32 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 -178.545 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.523 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 95.9 m-85 -155.09 -179.6 8.22 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 124.302 1.041 . . . . 0.0 109.008 -178.403 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 54.77 -140.05 38.7 Favored Glycine 0 N--CA 1.455 -0.093 0 O-C-N 123.812 0.695 . . . . 0.0 113.464 178.195 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -73.35 -15.46 78.94 Favored Glycine 0 C--O 1.2 -2.014 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.004 178.344 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.755 HG21 ' HB ' ' A' ' 126' ' ' ILE . 84.4 t -67.12 -40.03 84.44 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 C-N-CA 123.637 0.775 . . . . 0.0 111.78 -176.823 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.517 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -87.99 -16.43 33.76 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 118.919 -1.112 . . . . 0.0 112.158 178.326 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 23.2 t -100.74 -59.13 1.75 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-O 121.328 0.585 . . . . 0.0 111.992 -174.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.491 ' O ' HG22 ' A' ' 112' ' ' VAL . 34.0 m-20 -90.69 -22.44 21.14 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.875 -171.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.636 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 90.4 m-85 -110.63 157.16 20.0 Favored 'General case' 0 N--CA 1.422 -1.854 0 C-N-CA 119.97 -0.692 . . . . 0.0 110.594 178.759 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.4 t -166.17 130.63 2.21 Favored 'General case' 0 N--CA 1.417 -2.075 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 176.269 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.478 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -160.98 -99.77 0.15 Allowed Glycine 0 C--N 1.286 -2.199 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 177.664 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.451 HG22 ' HA ' ' A' ' 83' ' ' PRO . 0.7 OUTLIER -168.89 -179.97 3.9 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.893 1.277 . . . . 0.0 109.97 -177.643 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.0 147.03 32.36 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 C-N-CA 123.255 0.622 . . . . 0.0 109.536 178.324 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.576 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.9 tttt -124.68 147.92 48.29 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.239 -179.43 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.441 ' CD2' HG22 ' A' ' 105' ' ' VAL . 61.3 t80 -148.4 108.8 4.13 Favored 'General case' 0 C--N 1.314 -0.965 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 -179.429 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 11.2 t 51.78 43.04 30.33 Favored 'General case' 0 C--N 1.315 -0.926 0 C-N-CA 124.251 1.02 . . . . 0.0 111.546 177.841 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.78 8.26 70.07 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.188 -1.006 . . . . 0.0 113.435 179.038 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.576 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 23.0 t -80.68 -179.66 7.34 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 177.297 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 12.3 p -158.89 106.61 1.84 Allowed 'General case' 0 C--N 1.288 -2.1 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 2.6 p90 -151.52 158.45 34.29 Favored Pre-proline 0 C--N 1.308 -1.205 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -174.449 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.451 ' HA ' HG22 ' A' ' 74' ' ' THR . 44.9 Cg_endo -67.16 148.9 81.64 Favored 'Trans proline' 0 C--N 1.36 1.16 0 C-N-CA 123.092 2.528 . . . . 0.0 112.703 -177.053 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.588 ' CD2' HD21 ' A' ' 109' ' ' LEU . 60.6 t80 -122.07 131.7 24.37 Favored Pre-proline 0 C--N 1.312 -1.035 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.694 -179.447 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.516 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 72.7 Cg_endo -70.89 150.27 92.73 Favored 'Cis proline' 0 CA--C 1.539 0.731 0 C-N-CA 122.956 -1.685 . . . . 0.0 109.915 -1.296 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.9 t -59.47 -177.99 0.06 Allowed 'General case' 0 CA--C 1.559 1.309 0 CA-C-O 121.928 0.87 . . . . 0.0 112.504 -174.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.1 p -115.0 -15.6 11.75 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-N 115.34 -0.846 . . . . 0.0 110.067 -173.596 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.6 t -158.15 -109.53 0.02 OUTLIER 'General case' 0 N--CA 1.415 -2.213 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 178.457 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . 0.412 ' HB2' ' O ' ' A' ' 58' ' ' LEU . 0.5 OUTLIER -132.93 -164.01 1.42 Allowed 'General case' 0 N--CA 1.436 -1.16 0 CA-C-N 118.349 0.522 . . . . 0.0 111.723 179.295 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.464 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 10.8 p -100.14 164.56 16.16 Favored Pre-proline 0 C--N 1.299 -1.606 0 C-N-CA 123.618 0.767 . . . . 0.0 112.405 -177.642 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -65.98 168.74 14.79 Favored 'Trans proline' 0 C--N 1.36 1.148 0 C-N-CA 123.411 2.741 . . . . 0.0 111.21 174.359 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.557 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 3.2 tmm_? -70.2 128.44 36.26 Favored 'General case' 0 N--CA 1.44 -0.964 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 -178.77 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 74.0 t -142.59 120.92 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.666 0 C-N-CA 124.439 1.095 . . . . 0.0 108.11 -178.381 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.0 p -119.81 140.32 44.22 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.209 0 CA-C-O 120.956 0.408 . . . . 0.0 110.775 -177.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.47 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 9.5 m-85 -94.26 112.46 24.26 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 177.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 13.9 m120 -97.49 8.64 44.25 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-O 121.657 0.741 . . . . 0.0 109.218 178.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.8 m -76.7 -175.95 3.61 Favored 'General case' 0 N--CA 1.427 -1.6 0 C-N-CA 124.729 1.212 . . . . 0.0 109.988 -177.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 15.0 ptp180 -143.64 30.57 1.34 Allowed 'General case' 0 C--N 1.309 -1.174 0 CA-C-O 121.001 0.429 . . . . 0.0 110.611 177.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.1 t -163.48 -178.01 5.61 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -175.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -67.31 99.37 0.71 Allowed 'General case' 0 C--O 1.242 0.691 0 O-C-N 123.894 0.746 . . . . 0.0 109.772 178.016 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 11.2 mptt -104.96 141.43 22.53 Favored Pre-proline 0 C--N 1.283 -2.306 0 N-CA-C 106.86 -1.533 . . . . 0.0 106.86 175.641 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -60.85 147.05 96.51 Favored 'Trans proline' 0 C--O 1.243 0.771 0 C-N-CA 122.409 2.073 . . . . 0.0 112.23 -177.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . 0.47 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 11.9 t90 -91.25 104.66 10.28 Favored Pre-proline 0 C--N 1.309 -1.167 0 N-CA-C 105.387 -2.079 . . . . 0.0 105.387 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -75.51 88.12 1.31 Allowed 'Trans proline' 0 N--CA 1.445 -1.366 0 C-N-CA 121.449 1.433 . . . . 0.0 113.0 -171.052 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.441 HG22 ' CD2' ' A' ' 77' ' ' TYR . 72.4 t -136.15 150.78 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.333 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 177.456 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.595 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -156.87 134.45 10.77 Favored 'General case' 0 N--CA 1.421 -1.893 0 O-C-N 123.633 0.583 . . . . 0.0 109.758 176.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.464 HD21 HD11 ' A' ' 129' ' ' LEU . 19.7 mt -103.45 99.86 9.71 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.437 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.478 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 65.4 m-85 -78.55 81.56 4.87 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 178.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.636 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.0 mm? -107.03 117.03 32.98 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-O 121.122 0.487 . . . . 0.0 110.629 176.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -120.17 146.88 43.5 Favored Pre-proline 0 N--CA 1.413 -2.3 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.319 -174.54 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -61.0 119.96 7.41 Favored 'Trans proline' 0 C--O 1.249 1.067 0 C-N-CA 123.226 2.618 . . . . 0.0 112.309 -177.538 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.491 HG22 ' O ' ' A' ' 70' ' ' ASN . 3.0 m -68.35 -118.5 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.193 -1.891 0 CA-C-N 114.261 -1.336 . . . . 0.0 111.862 173.783 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.8 t -112.87 -33.11 6.18 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 175.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 36.3 m -80.03 34.5 0.3 Allowed 'General case' 0 N--CA 1.399 -2.982 0 C-N-CA 125.698 1.599 . . . . 0.0 112.742 -178.169 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -118.12 130.01 55.87 Favored 'General case' 0 C--N 1.281 -2.397 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.365 179.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -170.08 128.18 1.6 Allowed Glycine 0 C--O 1.239 0.467 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.647 179.405 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 65.98 -150.48 51.84 Favored Glycine 0 CA--C 1.499 -0.964 0 CA-C-O 118.985 -0.897 . . . . 0.0 111.589 -176.097 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.406 HG11 ' HE3' ' A' ' 121' ' ' LYS . 95.1 t -56.93 105.2 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.873 0.844 . . . . 0.0 111.435 -178.291 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -105.41 -21.58 13.2 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-N 114.327 -1.306 . . . . 0.0 110.919 -177.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.509 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 63.6 mt -135.84 140.54 44.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.517 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.3 mmpt? -115.87 139.56 50.09 Favored 'General case' 0 C--N 1.317 -0.817 0 C-N-CA 122.319 0.248 . . . . 0.0 111.232 178.071 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 0.409 ' H ' ' HB3' ' A' ' 153' ' ' ASP . . . -70.53 134.73 47.96 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.227 179.38 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 87.01 -7.91 78.55 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 121.353 -0.451 . . . . 0.0 112.115 -179.233 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 34.7 t -96.11 143.63 27.07 Favored 'General case' 0 N--CA 1.422 -1.843 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.463 HD11 HG23 ' A' ' 128' ' ' VAL . 3.0 tm? -69.86 128.21 35.58 Favored 'General case' 0 N--CA 1.436 -1.17 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.384 -178.463 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.755 ' HB ' HG21 ' A' ' 67' ' ' VAL . 32.6 pt -112.43 -27.05 2.86 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 N-CA-C 112.327 0.492 . . . . 0.0 112.327 -179.886 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.84 168.03 23.76 Favored 'General case' 0 CA--C 1.505 -0.765 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -178.283 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.463 HG23 HD11 ' A' ' 125' ' ' LEU . 59.9 t -142.03 116.94 5.25 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 179.112 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.464 HD11 HD21 ' A' ' 107' ' ' LEU . 68.3 mt -117.46 137.58 52.43 Favored 'General case' 0 C--N 1.28 -2.444 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 178.483 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.535 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.3 mp -118.57 122.71 70.15 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 C-N-CA 119.015 -1.074 . . . . 0.0 109.934 177.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.548 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.8 OUTLIER -88.53 141.35 28.6 Favored 'General case' 0 C--N 1.266 -3.064 0 C-N-CA 125.053 1.341 . . . . 0.0 108.166 177.554 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 24.9 ttp180 -122.35 131.01 53.69 Favored 'General case' 0 N--CA 1.409 -2.497 0 C-N-CA 120.153 -0.619 . . . . 0.0 109.815 174.307 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.496 HE21 ' HA ' ' A' ' 133' ' ' GLN . 0.0 OUTLIER -98.28 143.66 28.53 Favored 'General case' 0 N--CA 1.42 -1.942 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 -179.487 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.465 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 11.0 m -154.78 138.04 15.73 Favored 'General case' 0 C--N 1.281 -2.402 0 N-CA-C 106.488 -1.671 . . . . 0.0 106.488 173.649 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.52 ' CB ' HG23 ' A' ' 52' ' ' ILE . 11.0 p30 . . . . . 0 C--N 1.318 -0.782 0 CA-C-N 119.227 0.921 . . . . 0.0 112.515 176.108 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 . . . . . 0 N--CA 1.426 -1.673 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . 0.519 ' HB2' ' O ' ' A' ' 131' ' ' LEU . 13.9 pt20 -124.49 142.55 51.24 Favored 'General case' 0 N--CA 1.415 -2.215 0 C-N-CA 118.541 -1.264 . . . . 0.0 111.844 178.534 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 -106.69 129.37 54.6 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -175.344 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 48.5 t -94.53 129.18 45.12 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -178.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . 0.548 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 60.4 m95 -118.47 103.09 9.43 Favored 'General case' 0 C--N 1.278 -2.507 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.141 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 36.8 m-80 -82.05 110.86 17.67 Favored 'General case' 0 C--N 1.286 -2.159 0 N-CA-C 106.699 -1.593 . . . . 0.0 106.699 178.155 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.416 HG22 HD11 ' A' ' 126' ' ' ILE . 23.4 mm -85.52 121.14 36.8 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.903 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 -178.046 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 93.8 m-85 -117.72 151.3 37.55 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 123.618 0.767 . . . . 0.0 109.676 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -79.97 130.84 35.59 Favored 'General case' 0 N--CA 1.413 -2.295 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 175.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 -92.32 -6.43 50.29 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 -179.317 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -155.39 142.45 19.2 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.205 -176.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . 0.409 ' HB3' ' H ' ' A' ' 122' ' ' ALA . 17.5 p-10 -86.83 136.15 33.08 Favored 'General case' 0 C--N 1.309 -1.173 0 O-C-N 123.998 0.811 . . . . 0.0 112.004 -177.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.511 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.7 t -110.32 140.79 27.81 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 CA-C-N 114.966 -1.016 . . . . 0.0 111.987 -171.79 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 13.9 t -122.93 137.45 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.045 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 -179.529 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.507 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 70.0 t -103.28 103.27 33.95 Favored Pre-proline 0 C--N 1.286 -2.165 0 C-N-CA 123.699 0.799 . . . . 0.0 110.106 179.534 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.434 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 38.0 Cg_endo -69.47 -21.88 34.18 Favored 'Trans proline' 0 N--CA 1.463 -0.312 0 C-N-CA 121.959 1.772 . . . . 0.0 111.346 177.322 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . 0.403 ' HB ' HG12 ' A' ' 156' ' ' VAL . 3.6 t . . . . . 0 C--O 1.244 0.784 0 C-N-CA 124.698 1.199 . . . . 0.0 113.251 176.802 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.408 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.439 -1.005 0 CA-C-O 120.782 0.325 . . . . 0.0 111.04 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.404 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 80.0 m -143.67 159.05 43.16 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -177.478 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.6 pptp? -141.8 164.51 29.99 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-O 121.384 0.612 . . . . 0.0 111.621 -176.35 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.565 HG22 HG22 ' A' ' 20' ' ' VAL . 76.7 p -103.25 167.27 9.93 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.168 179.257 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.34 -9.49 58.65 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-N 113.729 -1.578 . . . . 0.0 112.474 179.563 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -94.37 -33.42 13.18 Favored 'General case' 0 C--O 1.239 0.516 0 C-N-CA 119.105 -1.038 . . . . 0.0 109.078 179.381 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 139.3 4.8 1.42 Allowed Glycine 0 N--CA 1.426 -1.972 0 C-N-CA 119.345 -1.407 . . . . 0.0 113.708 176.861 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.0 m -84.54 106.99 16.53 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 177.765 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -99.93 117.2 33.72 Favored 'General case' 0 C--N 1.286 -2.175 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 175.996 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.408 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 62.0 mt -84.21 116.95 67.37 Favored Pre-proline 0 C--N 1.308 -1.212 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 -179.711 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -76.96 166.8 26.23 Favored 'Trans proline' 0 N--CA 1.443 -1.497 0 C-N-CA 122.271 1.981 . . . . 0.0 111.381 179.167 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 72.1 mt -62.19 133.24 28.04 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.97 -179.894 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 126.96 4.44 6.04 Favored Glycine 0 C--N 1.311 -0.838 0 C-N-CA 120.506 -0.854 . . . . 0.0 112.466 178.916 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.04 146.44 6.48 Favored Glycine 0 N--CA 1.442 -0.944 0 C-N-CA 120.494 -0.86 . . . . 0.0 111.174 -177.025 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 177.62 -173.94 46.5 Favored Glycine 0 C--N 1.296 -1.666 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -179.231 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 60.3 p -134.06 151.12 51.27 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -179.651 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.49 168.67 18.81 Favored 'General case' 0 N--CA 1.432 -1.364 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.56 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 16.0 m-80 -118.14 108.69 15.49 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 -179.489 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.565 HG22 HG22 ' A' ' 5' ' ' THR . 46.9 t -94.72 136.64 25.33 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.018 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 -179.705 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 86.4 m-85 -125.1 117.39 23.83 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -177.333 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.479 HG11 HG13 ' A' ' 36' ' ' VAL . 2.7 p -124.3 129.52 73.96 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.833 0 CA-C-O 121.704 0.764 . . . . 0.0 111.479 -176.913 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -82.26 124.62 30.11 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-N 114.988 -1.005 . . . . 0.0 108.459 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 35.5 mt -113.44 156.16 24.01 Favored 'General case' 0 C--N 1.276 -2.593 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 179.951 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.53 121.67 50.16 Favored Pre-proline 0 C--O 1.201 -1.483 0 O-C-N 124.207 0.942 . . . . 0.0 109.899 -179.311 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.505 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 62.3 Cg_endo -71.37 -2.46 11.27 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 C-N-CA 123.185 2.59 . . . . 0.0 113.294 -176.699 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.528 HG13 ' HG3' ' A' ' 157' ' ' PRO . 64.8 t -130.4 111.26 20.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.94 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.458 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 5.8 t -145.76 110.3 0.98 Allowed 'Isoleucine or valine' 0 C--O 1.191 -2.024 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 -179.383 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.552 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -99.68 156.62 16.99 Favored 'General case' 0 C--N 1.264 -3.109 0 C-N-CA 122.94 0.496 . . . . 0.0 111.18 -179.539 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 25.4 t -47.93 116.5 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 123.887 0.875 . . . . 0.0 111.675 177.299 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.87 0.51 45.46 Favored Glycine 0 N--CA 1.444 -0.827 0 CA-C-N 115.36 -0.836 . . . . 0.0 112.983 -179.96 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.552 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -73.73 -177.05 2.6 Favored 'General case' 0 C--N 1.315 -0.893 0 C-N-CA 123.888 0.875 . . . . 0.0 111.099 176.221 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -128.39 87.88 2.66 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 178.484 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.643 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 18.7 tp -97.35 132.67 42.85 Favored 'General case' 0 N--CA 1.417 -2.091 0 C-N-CA 118.663 -1.215 . . . . 0.0 108.753 178.095 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 2.1 p -141.41 129.55 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.386 -3.65 0 CA-C-N 114.859 -1.064 . . . . 0.0 111.618 -177.747 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.609 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 46.8 t -90.54 89.22 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.393 -3.277 0 CA-C-N 113.374 -1.739 . . . . 0.0 107.825 -179.039 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -77.98 112.22 14.67 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 121.015 0.436 . . . . 0.0 109.952 179.08 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 92.1 mt -96.3 -0.54 49.47 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.337 -177.766 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 35.6 t -74.56 0.97 13.17 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.847 0.832 . . . . 0.0 110.366 -179.561 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.8 p -126.85 3.32 6.65 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.086 178.597 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.422 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 47.9 mm-40 -121.8 -26.79 4.78 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.686 -172.925 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 20.6 mt -130.43 139.63 50.85 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 -175.525 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -139.48 158.74 43.63 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 -176.095 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.404 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 49.1 m -136.21 141.47 44.0 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 123.472 0.709 . . . . 0.0 109.972 179.58 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 5.6 p80 -136.92 153.47 50.72 Favored 'General case' 0 N--CA 1.43 -1.47 0 CA-C-O 121.9 0.857 . . . . 0.0 110.681 -178.427 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.467 HD21 ' HA ' ' A' ' 98' ' ' ARG . 6.6 p30 -95.01 109.93 21.9 Favored 'General case' 0 C--N 1.277 -2.556 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.408 177.187 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -73.87 -28.98 61.84 Favored 'General case' 0 C--N 1.297 -1.674 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.931 -179.429 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -136.52 79.6 41.0 Favored Pre-proline 0 C--N 1.313 -0.996 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 175.569 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.54 5.01 2.6 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 C-N-CA 123.257 2.638 . . . . 0.0 113.023 -176.164 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -120.34 -13.31 8.88 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.594 179.144 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.452 ' HB ' HD12 ' A' ' 52' ' ' ILE . 2.6 m -117.14 -25.64 7.07 Favored 'General case' 0 N--CA 1.422 -1.859 0 CA-C-O 121.408 0.623 . . . . 0.0 110.789 -172.575 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.452 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.7 mp -128.95 130.48 68.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 CA-C-N 115.971 -0.558 . . . . 0.0 109.5 -175.581 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.4 t -75.63 146.48 40.26 Favored 'General case' 0 N--CA 1.441 -0.923 0 O-C-N 123.714 0.634 . . . . 0.0 109.707 -179.695 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.555 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 3.0 m-20 -89.96 109.97 20.97 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 115.426 -0.807 . . . . 0.0 109.341 -174.178 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 82.2 t80 -146.03 141.68 27.87 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -179.128 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.1 p -151.44 144.78 16.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 175.802 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.27 131.7 14.7 Favored 'General case' 0 C--O 1.212 -0.904 0 CA-C-O 119.759 -0.162 . . . . 0.0 110.575 175.654 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.555 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 56.8 tp -72.84 107.88 5.49 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.157 0.504 . . . . 0.0 109.984 176.827 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.467 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 3.0 tp-100 -51.55 -53.63 35.89 Favored 'General case' 0 C--O 1.207 -1.138 0 C-N-CA 125.554 1.541 . . . . 0.0 111.149 175.825 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.467 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 2.8 ptp180 -168.62 161.4 11.39 Favored 'General case' 0 CA--C 1.493 -1.235 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 -178.072 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.411 ' H ' HG22 ' A' ' 86' ' ' THR . . . -142.1 123.52 2.23 Favored Glycine 0 N--CA 1.404 -3.485 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -178.771 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.412 ' HA ' ' HB3' ' A' ' 85' ' ' PRO . 68.9 m -115.62 149.79 37.73 Favored 'General case' 0 C--N 1.284 -2.245 0 C-N-CA 124.297 1.039 . . . . 0.0 110.32 -173.804 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.522 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -112.7 157.75 20.9 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 -179.302 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.476 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 88.6 m-85 -156.7 -178.91 7.7 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 124.316 1.047 . . . . 0.0 109.037 -177.68 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 60.71 -143.08 48.26 Favored Glycine 0 C--N 1.33 0.231 0 O-C-N 123.465 0.478 . . . . 0.0 112.512 177.785 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . 0.408 ' HA3' ' O ' ' A' ' 119' ' ' ALA . . . -78.94 -7.77 88.21 Favored Glycine 0 C--O 1.21 -1.382 0 C-N-CA 120.978 -0.629 . . . . 0.0 111.876 176.773 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.848 HG21 ' HB ' ' A' ' 126' ' ' ILE . 89.5 t -69.4 -39.96 79.4 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 C-N-CA 123.72 0.808 . . . . 0.0 111.535 -178.4 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.522 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.01 -15.97 39.74 Favored 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 119.171 -1.012 . . . . 0.0 112.053 178.836 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 16.9 t -99.67 -56.9 2.27 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.057 0.456 . . . . 0.0 111.324 -175.221 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.525 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 37.4 m-80 -85.67 -29.09 24.27 Favored 'General case' 0 CA--C 1.486 -1.513 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 -176.09 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.646 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 81.2 m-85 -106.79 157.39 17.78 Favored 'General case' 0 N--CA 1.416 -2.172 0 C-N-CA 119.365 -0.934 . . . . 0.0 110.38 -178.362 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.0 t -168.58 128.14 1.17 Allowed 'General case' 0 N--CA 1.42 -1.933 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 175.503 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.497 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -158.37 -109.92 0.28 Allowed Glycine 0 N--CA 1.404 -3.445 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 174.91 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.434 HG22 ' HA ' ' A' ' 83' ' ' PRO . 3.5 p -156.09 179.99 8.7 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 123.591 0.756 . . . . 0.0 109.859 -176.196 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -130.34 146.76 33.56 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.082 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 177.891 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.635 ' HG3' ' O ' ' A' ' 80' ' ' SER . 82.3 tttt -124.63 142.91 51.03 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.225 -179.564 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.496 ' CD2' HG22 ' A' ' 105' ' ' VAL . 51.5 t80 -142.51 107.87 5.02 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 -178.998 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 33.0 t 54.04 36.85 25.59 Favored 'General case' 0 CA--C 1.555 1.149 0 CA-C-O 121.541 0.686 . . . . 0.0 111.373 179.364 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.427 ' HA2' ' CE ' ' A' ' 76' ' ' LYS . . . 90.39 9.32 65.15 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.321 -0.942 . . . . 0.0 113.514 -178.645 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.635 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 22.9 t -79.96 172.53 13.66 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 177.425 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 6.2 p -152.84 100.58 2.53 Favored 'General case' 0 C--N 1.277 -2.58 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -177.757 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.445 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 1.6 p90 -144.93 159.52 49.81 Favored Pre-proline 0 C--N 1.301 -1.506 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -173.731 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.434 ' HA ' HG22 ' A' ' 74' ' ' THR . 47.3 Cg_endo -66.68 151.97 81.59 Favored 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 122.97 2.446 . . . . 0.0 112.734 -176.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.616 ' CD2' HD21 ' A' ' 109' ' ' LEU . 57.6 t80 -127.48 130.34 23.71 Favored Pre-proline 0 N--CA 1.438 -1.042 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.675 179.654 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.492 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 59.8 Cg_endo -69.37 149.46 87.67 Favored 'Cis proline' 0 C--O 1.244 0.803 0 C-N-CA 122.972 -1.678 . . . . 0.0 110.509 -0.393 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.411 HG22 ' H ' ' A' ' 61' ' ' GLY . 9.8 t -63.73 -176.56 0.18 Allowed 'General case' 0 CA--C 1.55 0.966 0 CA-C-O 121.298 0.57 . . . . 0.0 111.745 -175.233 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.1 p -113.15 -39.31 4.21 Favored 'General case' 0 N--CA 1.418 -2.041 0 CA-C-O 121.658 0.742 . . . . 0.0 109.303 -175.267 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 14.0 t -129.82 -107.59 0.28 Allowed 'General case' 0 N--CA 1.401 -2.878 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.259 -179.784 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -134.92 -166.82 1.88 Allowed 'General case' 0 N--CA 1.438 -1.04 0 CA-C-N 117.854 0.297 . . . . 0.0 110.633 -177.821 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.555 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 36.4 p -99.49 170.86 6.27 Favored Pre-proline 0 C--N 1.309 -1.153 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 178.174 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . 0.444 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 23.2 Cg_endo -61.34 161.75 22.58 Favored 'Trans proline' 0 C--O 1.249 1.033 0 C-N-CA 122.913 2.409 . . . . 0.0 111.099 169.636 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.7 tmm_? -78.44 119.97 22.51 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 -178.433 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 92.4 t -126.97 126.51 68.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 O-C-N 123.599 0.562 . . . . 0.0 110.189 -178.612 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 75.3 t -107.9 131.16 58.95 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 176.701 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.555 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.0 m-85 -77.77 131.11 37.48 Favored 'General case' 0 C--N 1.309 -1.186 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 175.795 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -117.05 58.56 0.77 Allowed 'General case' 0 C--N 1.285 -2.233 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 -179.826 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 21.0 m -143.11 157.35 44.6 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.598 -176.231 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.467 ' HA ' HD21 ' A' ' 46' ' ' ASN . 14.7 ptp180 -121.83 37.61 4.32 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.845 0.831 . . . . 0.0 109.694 178.128 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 7.7 t -157.26 172.23 18.99 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 -176.028 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -73.26 120.67 19.2 Favored 'General case' 0 C--O 1.244 0.808 0 CA-C-O 121.391 0.615 . . . . 0.0 109.471 -179.203 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -117.92 142.32 30.66 Favored Pre-proline 0 C--N 1.277 -2.545 0 CA-C-N 115.128 -0.942 . . . . 0.0 110.423 -177.212 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -65.81 147.39 85.36 Favored 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.771 2.314 . . . . 0.0 111.834 176.807 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 13.8 t90 -89.17 108.88 27.01 Favored Pre-proline 0 C--N 1.31 -1.143 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 -177.205 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_endo -77.5 88.18 1.44 Allowed 'Trans proline' 0 N--CA 1.45 -1.046 0 C-N-CA 121.641 1.561 . . . . 0.0 113.38 -172.989 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.496 HG22 ' CD2' ' A' ' 77' ' ' TYR . 64.0 t -135.9 148.87 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.183 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 176.069 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.609 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -152.85 131.35 12.19 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-O 120.92 0.391 . . . . 0.0 110.375 177.198 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.47 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 16.7 mt -100.9 99.98 10.55 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.585 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.497 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 51.3 m-85 -78.17 80.36 4.59 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 177.397 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.646 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 2.7 mm? -104.02 116.66 32.63 Favored 'General case' 0 CA--C 1.491 -1.325 0 CA-C-O 120.997 0.427 . . . . 0.0 110.523 176.681 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.69 146.75 51.26 Favored Pre-proline 0 N--CA 1.407 -2.593 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.447 -175.535 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.525 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 18.8 Cg_endo -60.7 122.16 10.83 Favored 'Trans proline' 0 N--CA 1.447 -1.236 0 C-N-CA 122.987 2.458 . . . . 0.0 112.334 -178.248 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.516 HG22 ' O ' ' A' ' 70' ' ' ASN . 3.3 m -70.0 -120.52 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.195 -1.772 0 CA-C-N 113.831 -1.531 . . . . 0.0 111.78 174.874 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 33.4 t -111.69 -34.57 6.01 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 174.355 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 20.0 t -85.56 40.91 0.87 Allowed 'General case' 0 N--CA 1.431 -1.386 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.572 -177.347 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -114.06 135.88 53.53 Favored 'General case' 0 N--CA 1.418 -2.075 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 176.89 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -176.32 135.1 2.79 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 120.053 -1.07 . . . . 0.0 111.927 178.96 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 63.41 -151.07 48.95 Favored Glycine 0 CA--C 1.498 -1.016 0 CA-C-O 119.269 -0.74 . . . . 0.0 112.757 -178.642 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 98.4 t -58.32 99.46 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 122.06 0.933 . . . . 0.0 110.981 -177.648 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . 0.408 ' O ' ' HA3' ' A' ' 66' ' ' GLY . . . -99.68 -25.43 14.4 Favored 'General case' 0 C--N 1.295 -1.795 0 CA-C-N 114.608 -1.178 . . . . 0.0 110.735 -177.371 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.565 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 55.2 mt -134.56 138.01 50.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 -179.188 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.511 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 5.0 mmpt? -112.36 138.02 49.69 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-O 121.084 0.469 . . . . 0.0 111.184 177.375 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.45 125.15 25.98 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 177.74 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 93.97 -2.47 69.22 Favored Glycine 0 C--N 1.31 -0.885 0 N-CA-C 111.644 -0.582 . . . . 0.0 111.644 -178.13 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 28.8 t -96.13 143.84 26.9 Favored 'General case' 0 N--CA 1.431 -1.409 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 -179.913 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.434 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -71.53 124.0 23.68 Favored 'General case' 0 N--CA 1.435 -1.183 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.349 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.848 ' HB ' HG21 ' A' ' 67' ' ' VAL . 30.6 pt -111.63 -26.17 3.23 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -178.54 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . 0.431 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -160.75 168.2 25.28 Favored 'General case' 0 N--CA 1.443 -0.796 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 -178.196 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.434 HG23 HD11 ' A' ' 125' ' ' LEU . 70.5 t -143.0 114.06 2.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.903 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.44 HD11 HD21 ' A' ' 107' ' ' LEU . 55.8 mt -116.67 147.89 41.53 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.184 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.485 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.5 mp -133.01 127.69 55.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.849 -0.532 . . . . 0.0 110.002 179.714 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . . . . . . . . . 2.3 pp -96.4 147.04 24.23 Favored 'General case' 0 CA--C 1.496 -1.119 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 177.419 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . 0.464 ' HD3' ' NE2' ' A' ' 59' ' ' GLN . 26.5 mmm-85 -96.49 118.39 32.89 Favored 'General case' 0 C--N 1.277 -2.576 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 172.858 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 7.1 tp-100 -96.02 122.03 38.41 Favored 'General case' 0 N--CA 1.421 -1.911 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 173.151 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 22.1 m -134.61 134.01 40.79 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 177.085 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.432 ' CB ' HG23 ' A' ' 52' ' ' ILE . 27.2 p30 . . . . . 0 C--N 1.31 -1.11 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.819 -179.736 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 . . . . . 0 N--CA 1.412 -2.328 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 12.6 pt20 -115.08 132.12 56.71 Favored 'General case' 0 N--CA 1.407 -2.624 0 C-N-CA 119.037 -1.065 . . . . 0.0 110.248 -177.86 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 11.1 m-30 -100.77 129.35 46.64 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.206 -0.906 . . . . 0.0 108.785 -175.087 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 47.1 t -93.3 130.83 41.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 123.764 0.665 . . . . 0.0 109.973 -178.016 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 63.9 m95 -118.21 97.92 6.03 Favored 'General case' 0 C--N 1.275 -2.636 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 -178.853 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 47.2 m-80 -80.18 112.3 17.37 Favored 'General case' 0 C--N 1.285 -2.223 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 178.249 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.431 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 24.0 mm -86.03 122.06 38.12 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.819 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 -177.96 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -116.63 153.31 32.52 Favored 'General case' 0 C--N 1.286 -2.156 0 C-N-CA 124.052 0.941 . . . . 0.0 108.685 177.716 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.37 133.72 35.23 Favored 'General case' 0 N--CA 1.407 -2.585 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 176.066 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -92.94 -8.92 41.8 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -177.457 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -150.04 143.93 25.46 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 113.937 -1.483 . . . . 0.0 110.008 -176.653 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -84.65 136.16 33.87 Favored 'General case' 0 C--N 1.312 -1.033 0 O-C-N 123.966 0.791 . . . . 0.0 110.419 179.43 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.565 ' HB ' ' HB ' ' A' ' 120' ' ' ILE . 69.6 t -118.59 140.05 43.64 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.978 -173.642 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -119.78 138.34 50.71 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.136 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 178.476 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.458 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 71.6 t -99.93 101.13 13.02 Favored Pre-proline 0 C--N 1.293 -1.889 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 176.688 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.528 ' HG3' HG13 ' A' ' 27' ' ' VAL . 21.4 Cg_endo -67.47 -29.72 37.07 Favored 'Trans proline' 0 CA--C 1.504 -1.002 0 C-N-CA 122.215 1.943 . . . . 0.0 111.511 179.075 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 6.1 t . . . . . 0 C--O 1.267 1.974 0 O-C-N 125.002 1.439 . . . . 0.0 112.534 179.387 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.427 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 CA--C 1.499 -1.015 0 N-CA-C 110.052 -0.351 . . . . 0.0 110.052 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 12.4 t -148.76 156.76 42.8 Favored 'General case' 0 N--CA 1.426 -1.642 0 C-N-CA 119.395 -0.922 . . . . 0.0 109.711 -175.25 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.547 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -143.64 161.71 37.82 Favored 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.408 -175.102 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 54.9 p -97.64 -179.96 4.63 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-O 121.015 0.436 . . . . 0.0 110.71 179.679 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.44 -22.56 38.09 Favored 'General case' 0 C--N 1.298 -1.642 0 CA-C-O 121.551 0.691 . . . . 0.0 109.206 177.848 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -85.74 -28.89 24.31 Favored 'General case' 0 N--CA 1.433 -1.297 0 CA-C-N 114.821 -1.082 . . . . 0.0 112.518 -175.784 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 130.43 22.79 1.05 Allowed Glycine 0 CA--C 1.49 -1.488 0 C-N-CA 118.868 -1.634 . . . . 0.0 113.974 171.588 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -103.04 99.42 9.3 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.363 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -94.25 114.15 26.19 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 115.879 -0.601 . . . . 0.0 109.399 176.825 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.427 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 68.5 mt -84.55 126.91 67.7 Favored Pre-proline 0 C--N 1.3 -1.582 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -179.171 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_endo -80.2 164.53 21.94 Favored 'Trans proline' 0 C--O 1.246 0.921 0 C-N-CA 122.614 2.209 . . . . 0.0 111.369 178.405 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.5 mt -65.91 126.31 24.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.984 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.57 10.02 1.49 Allowed Glycine 0 C--N 1.307 -1.028 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.613 -179.577 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.03 161.31 36.82 Favored Glycine 0 C--N 1.319 -0.392 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -177.924 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 161.61 -172.97 37.92 Favored Glycine 0 CA--C 1.495 -1.169 0 C-N-CA 119.938 -1.125 . . . . 0.0 111.331 178.448 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.435 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 65.2 p -144.51 144.03 31.14 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.306 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -130.98 162.16 30.36 Favored 'General case' 0 N--CA 1.415 -2.192 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.286 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -111.96 116.11 30.06 Favored 'General case' 0 C--N 1.271 -2.838 0 N-CA-C 107.043 -1.465 . . . . 0.0 107.043 174.773 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.464 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.2 m -99.63 139.03 22.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.683 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 179.22 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 23.7 m-85 -117.72 115.98 26.12 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-O 120.879 0.371 . . . . 0.0 111.994 -179.715 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.516 HG22 ' HG3' ' A' ' 41' ' ' GLN . 19.3 t -115.68 129.34 72.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.805 -173.819 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -89.27 119.75 30.03 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 177.778 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 28.1 mt -110.74 152.24 26.81 Favored 'General case' 0 C--N 1.282 -2.333 0 CA-C-N 115.051 -0.977 . . . . 0.0 108.984 -176.939 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -52.73 119.32 15.48 Favored Pre-proline 0 C--O 1.204 -1.296 0 O-C-N 124.513 1.133 . . . . 0.0 110.326 179.319 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.576 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 60.9 Cg_endo -73.83 -0.53 9.56 Favored 'Trans proline' 0 CA--C 1.544 0.993 0 C-N-CA 122.502 2.135 . . . . 0.0 113.616 -175.584 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.445 HG13 ' HG3' ' A' ' 157' ' ' PRO . 98.4 t -131.06 109.61 16.75 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 178.161 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.449 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 14.0 t -146.12 108.38 0.8 Allowed 'Isoleucine or valine' 0 C--O 1.193 -1.909 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 -177.248 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.537 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -95.87 154.22 17.34 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 123.864 0.865 . . . . 0.0 111.031 -179.84 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.526 HG22 ' O ' ' A' ' 112' ' ' VAL . 99.1 t -47.18 117.55 0.42 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.328 0 C-N-CA 123.436 0.694 . . . . 0.0 111.197 176.482 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.92 0.38 45.27 Favored Glycine 0 C--N 1.312 -0.803 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.924 -179.634 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.537 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -74.9 -176.7 3.0 Favored 'General case' 0 C--N 1.316 -0.884 0 C-N-CA 123.751 0.821 . . . . 0.0 110.329 175.876 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -127.09 89.75 3.03 Favored 'General case' 0 CA--C 1.491 -1.32 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 177.721 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.559 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 20.0 tp -98.34 133.68 42.4 Favored 'General case' 0 C--N 1.295 -1.8 0 C-N-CA 118.898 -1.121 . . . . 0.0 109.256 177.158 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.405 ' CG2' ' HB1' ' A' ' 106' ' ' ALA . 2.1 p -141.56 130.75 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.382 -3.854 0 CA-C-N 114.797 -1.092 . . . . 0.0 112.075 -178.028 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.6 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 47.8 t -87.61 89.56 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.576 0 CA-C-N 113.832 -1.531 . . . . 0.0 107.266 178.801 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.47 ' O ' ' HG2' ' A' ' 41' ' ' GLN . 18.2 t70 -77.26 102.83 6.87 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-O 120.708 0.289 . . . . 0.0 110.683 -179.173 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.3 mt -85.08 -3.65 58.87 Favored 'General case' 0 C--N 1.311 -1.094 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.306 -178.512 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 35.2 t -73.27 0.1 12.91 Favored 'General case' 0 CA--C 1.542 0.636 0 CA-C-O 121.478 0.656 . . . . 0.0 110.135 -179.624 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.3 p -130.2 5.23 4.85 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.206 176.468 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.516 ' HG3' HG22 ' A' ' 22' ' ' VAL . 48.6 mm-40 -120.45 -20.75 7.08 Favored 'General case' 0 C--O 1.239 0.511 0 CA-C-O 121.03 0.443 . . . . 0.0 110.299 -174.177 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.401 HD11 HG11 ' A' ' 20' ' ' VAL . 37.4 mt -138.75 138.7 41.92 Favored 'Isoleucine or valine' 0 C--O 1.243 0.714 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 -177.103 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.547 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 48.7 m-85 -142.47 127.44 18.37 Favored 'General case' 0 N--CA 1.476 0.862 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -176.836 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 75.8 m -109.17 138.69 45.14 Favored 'General case' 0 C--N 1.295 -1.776 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -178.648 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . 0.421 ' NE2' ' HB3' ' A' ' 2' ' ' ALA . 10.9 p-80 -121.07 154.34 36.24 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-O 122.335 1.064 . . . . 0.0 112.085 -176.47 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.486 HD22 ' CG ' ' A' ' 54' ' ' ASP . 3.0 m120 -96.9 114.81 26.46 Favored 'General case' 0 C--N 1.28 -2.434 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -179.423 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -77.09 -32.51 56.71 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.301 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 38.4 m-85 -138.68 83.03 20.38 Favored Pre-proline 0 C--N 1.315 -0.934 0 CA-C-N 114.331 -1.304 . . . . 0.0 108.921 -176.955 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.95 3.68 5.88 Favored 'Trans proline' 0 CA--C 1.541 0.831 0 C-N-CA 122.59 2.194 . . . . 0.0 113.685 -176.06 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -117.64 -22.35 8.11 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 121.268 0.556 . . . . 0.0 110.434 178.275 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.516 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.7 OUTLIER -98.49 -28.72 13.48 Favored 'General case' 0 N--CA 1.424 -1.741 0 CA-C-O 122.074 0.94 . . . . 0.0 109.244 -172.035 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.516 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.1 mp -122.67 135.79 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.087 0 CA-C-N 114.306 -1.316 . . . . 0.0 109.648 -178.346 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 3.3 t -86.42 124.29 32.59 Favored 'General case' 0 N--CA 1.417 -2.114 0 N-CA-C 103.022 -2.955 . . . . 0.0 103.022 169.22 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.486 ' CG ' HD22 ' A' ' 46' ' ' ASN . 16.1 m-20 -91.47 107.88 19.51 Favored 'General case' 0 C--N 1.271 -2.811 0 C-N-CA 118.815 -1.154 . . . . 0.0 109.433 -169.005 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 22.0 t80 -117.89 139.56 50.95 Favored 'General case' 0 C--N 1.273 -2.746 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.588 -175.74 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.507 HG23 ' HG ' ' A' ' 131' ' ' LEU . 12.9 p -145.59 145.39 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.794 0 O-C-N 123.626 0.579 . . . . 0.0 109.815 -179.577 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -149.4 125.11 10.44 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.085 174.584 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.505 HD12 ' O ' ' A' ' 130' ' ' ILE . 41.9 tp -61.82 110.35 1.51 Allowed 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 169.975 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.6 tp-100 -60.18 -56.95 15.34 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 126.63 1.972 . . . . 0.0 109.861 -179.074 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 10.8 ptp180 -164.14 160.16 21.11 Favored 'General case' 0 N--CA 1.426 -1.634 0 CA-C-N 114.505 -1.225 . . . . 0.0 108.874 -175.274 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -141.38 139.96 9.9 Favored Glycine 0 N--CA 1.411 -2.998 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -178.756 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 73.2 m -126.06 150.63 48.0 Favored 'General case' 0 C--N 1.289 -2.025 0 C-N-CA 124.139 0.976 . . . . 0.0 110.266 -176.807 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.48 ' HB2' ' CE2' ' A' ' 84' ' ' PHE . . . -114.2 157.69 22.34 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.202 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.461 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 87.0 m-85 -155.13 -178.88 7.56 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 124.12 0.968 . . . . 0.0 109.244 -178.609 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 60.25 -138.65 48.54 Favored Glycine 0 C--O 1.228 -0.279 0 O-C-N 123.537 0.523 . . . . 0.0 113.236 176.886 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.44 -8.79 85.76 Favored Glycine 0 N--CA 1.432 -1.631 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.355 177.037 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.815 HG21 ' HB ' ' A' ' 126' ' ' ILE . 84.0 t -69.13 -41.25 81.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 C-N-CA 123.52 0.728 . . . . 0.0 111.572 -176.709 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.471 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -83.21 -21.01 33.55 Favored 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.73 -0.788 . . . . 0.0 112.359 179.692 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 18.4 m -101.71 -50.69 3.63 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 115.25 1.574 . . . . 0.0 115.25 -174.802 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.493 ' O ' HG22 ' A' ' 112' ' ' VAL . 47.7 m-20 -93.73 -23.45 18.2 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -175.628 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.625 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 88.2 m-85 -108.1 159.24 16.73 Favored 'General case' 0 N--CA 1.423 -1.802 0 C-N-CA 120.02 -0.672 . . . . 0.0 109.324 176.979 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.6 t -167.5 125.11 1.21 Allowed 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 175.617 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.475 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -159.51 -110.28 0.27 Allowed Glycine 0 N--CA 1.407 -3.284 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 176.648 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.3 p -156.96 179.97 8.78 Favored 'General case' 0 C--N 1.296 -1.744 0 C-N-CA 123.531 0.733 . . . . 0.0 110.965 -173.101 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.429 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.6 p -133.69 144.37 36.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.919 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.678 ' HG3' ' O ' ' A' ' 80' ' ' SER . 86.0 tttt -123.42 150.19 44.09 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.318 -178.699 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.441 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 60.8 t80 -148.94 109.42 4.19 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 -178.812 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.6 t 51.48 41.01 28.07 Favored 'General case' 0 CA--C 1.554 1.105 0 C-N-CA 124.32 1.048 . . . . 0.0 111.396 178.037 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.83 6.73 67.08 Favored Glycine 0 CA--C 1.526 0.756 0 CA-C-N 115.615 -0.721 . . . . 0.0 113.987 179.82 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.678 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 22.8 t -79.57 179.98 7.18 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 178.43 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 3.6 p -157.99 107.15 2.06 Favored 'General case' 0 C--N 1.292 -1.896 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 -179.489 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.441 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.5 p90 -151.49 158.44 34.32 Favored Pre-proline 0 C--N 1.308 -1.228 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 -174.418 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.25 148.54 68.58 Favored 'Trans proline' 0 C--N 1.358 1.033 0 C-N-CA 122.819 2.346 . . . . 0.0 112.977 -176.385 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.601 ' CD2' HD21 ' A' ' 109' ' ' LEU . 63.0 t80 -121.92 133.4 24.29 Favored Pre-proline 0 N--CA 1.438 -1.058 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.773 179.98 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.493 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 74.1 Cg_endo -71.15 146.63 85.49 Favored 'Cis proline' 0 CA--C 1.548 1.223 0 C-N-CA 123.079 -1.634 . . . . 0.0 110.56 -1.856 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.1 t -64.13 -176.74 0.22 Allowed 'General case' 0 CA--C 1.558 1.262 0 C-N-CA 123.547 0.739 . . . . 0.0 112.279 -174.015 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 19.9 p -129.54 -27.6 2.37 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 113.161 0.8 . . . . 0.0 113.161 -172.449 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 t -127.62 -73.46 0.6 Allowed 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 119.736 -0.786 . . . . 0.0 110.684 -178.45 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -177.78 -174.57 0.46 Allowed 'General case' 0 C--O 1.243 0.726 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 -176.684 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.456 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 12.4 p -102.07 163.28 18.05 Favored Pre-proline 0 C--N 1.299 -1.592 0 O-C-N 123.432 0.458 . . . . 0.0 112.196 178.083 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -64.55 157.48 54.98 Favored 'Trans proline' 0 C--N 1.36 1.176 0 C-N-CA 122.669 2.246 . . . . 0.0 111.576 174.996 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.4 tmm_? -68.79 110.81 4.51 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 114.898 -1.046 . . . . 0.0 110.209 -175.757 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 71.0 t -122.35 132.83 70.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.826 -178.093 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 95.6 t -117.24 136.25 55.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 115.3 -0.863 . . . . 0.0 109.494 178.97 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.485 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 4.1 m-85 -82.99 94.97 7.88 Favored 'General case' 0 CA--C 1.499 -0.985 0 CA-C-O 121.41 0.624 . . . . 0.0 110.348 177.516 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 17.6 m120 -89.26 61.13 5.59 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 178.754 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.6 m -143.67 -179.3 6.36 Favored 'General case' 0 N--CA 1.423 -1.798 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 -176.959 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 4.5 ptm180 -146.08 50.7 1.16 Allowed 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 121.425 0.631 . . . . 0.0 109.979 179.998 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.0 t -169.87 177.41 4.4 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -175.201 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -71.77 98.02 1.89 Allowed 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 106.608 -1.627 . . . . 0.0 106.608 173.07 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 11.5 tptt -103.14 139.33 20.01 Favored Pre-proline 0 N--CA 1.407 -2.602 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 -177.678 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_endo -58.9 147.26 90.23 Favored 'Trans proline' 0 CA--C 1.511 -0.632 0 C-N-CA 122.605 2.203 . . . . 0.0 112.631 -176.993 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . 0.485 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.1 t90 -90.48 105.93 13.41 Favored Pre-proline 0 C--N 1.302 -1.472 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 178.6 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -77.83 87.94 1.47 Allowed 'Trans proline' 0 N--CA 1.443 -1.456 0 C-N-CA 121.616 1.544 . . . . 0.0 112.21 -173.094 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.438 HG22 ' CD2' ' A' ' 77' ' ' TYR . 86.7 t -139.01 147.03 25.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 N-CA-C 106.879 -1.526 . . . . 0.0 106.879 177.851 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.6 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -153.14 134.26 14.1 Favored 'General case' 0 C--N 1.284 -2.265 0 CA-C-O 120.811 0.338 . . . . 0.0 110.381 178.522 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.47 HD21 HD11 ' A' ' 129' ' ' LEU . 18.7 mt -101.6 99.86 10.2 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 179.151 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.475 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 74.2 m-85 -79.59 77.43 6.19 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 177.746 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.625 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.2 mm? -102.54 118.72 37.47 Favored 'General case' 0 CA--C 1.488 -1.414 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 176.365 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -122.18 146.91 47.97 Favored Pre-proline 0 N--CA 1.402 -2.867 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -174.964 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -63.4 123.14 11.61 Favored 'Trans proline' 0 CA--C 1.491 -1.625 0 C-N-CA 123.245 2.63 . . . . 0.0 113.379 -175.469 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.526 ' O ' HG22 ' A' ' 30' ' ' VAL . 24.3 m -83.22 -159.25 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.385 -3.689 0 CA-C-N 114.181 -1.372 . . . . 0.0 108.871 171.15 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.8 m -79.21 -29.56 42.86 Favored 'General case' 0 C--N 1.252 -3.631 0 CA-C-O 121.464 0.65 . . . . 0.0 110.296 -170.352 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 11.3 t -82.52 25.5 0.63 Allowed 'General case' 0 N--CA 1.428 -1.53 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.188 -179.77 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -109.17 136.75 48.15 Favored 'General case' 0 N--CA 1.422 -1.842 0 O-C-N 121.828 -0.545 . . . . 0.0 109.818 178.847 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -174.91 134.49 2.77 Favored Glycine 0 N--CA 1.432 -1.6 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 178.332 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 60.49 -149.3 43.29 Favored Glycine 0 CA--C 1.494 -1.221 0 CA-C-O 119.32 -0.711 . . . . 0.0 112.151 -177.637 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 94.0 t -57.95 105.11 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-O 121.923 0.868 . . . . 0.0 111.261 -177.884 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.37 -22.22 13.37 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 114.51 -1.223 . . . . 0.0 110.62 -178.772 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.483 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 67.9 mt -136.83 138.13 46.44 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 179.474 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.509 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.6 mmpt? -116.6 143.01 46.14 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.066 0.46 . . . . 0.0 109.79 174.744 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.5 131.05 42.74 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.891 -179.17 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.63 -6.07 64.87 Favored Glycine 0 N--CA 1.44 -1.083 0 C-N-CA 121.231 -0.509 . . . . 0.0 112.157 -179.316 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 27.2 m -94.9 147.53 23.27 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-O 120.778 0.323 . . . . 0.0 110.747 -179.302 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -74.25 124.04 25.66 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.271 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.815 ' HB ' HG21 ' A' ' 67' ' ' VAL . 31.2 pt -111.27 -26.28 3.2 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -178.555 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . 0.42 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.83 168.52 22.93 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 -177.679 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 73.7 t -143.4 114.44 2.54 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.487 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.47 HD11 HD21 ' A' ' 107' ' ' LEU . 62.9 mt -116.01 142.5 46.72 Favored 'General case' 0 C--N 1.291 -1.968 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 178.631 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.505 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.9 mp -121.08 126.54 75.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 C-N-CA 119.272 -0.971 . . . . 0.0 110.77 177.477 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.527 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.2 OUTLIER -98.05 131.41 44.49 Favored 'General case' 0 C--N 1.271 -2.813 0 C-N-CA 124.68 1.192 . . . . 0.0 109.182 179.422 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . 0.636 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 12.6 tpt180 -104.9 124.53 49.64 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -179.86 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.525 ' OE1' HD21 ' A' ' 131' ' ' LEU . 12.6 mm100 -105.84 118.54 36.87 Favored 'General case' 0 C--N 1.319 -0.72 0 O-C-N 123.592 0.557 . . . . 0.0 110.345 179.242 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 5.1 m -136.6 149.7 48.18 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 106.377 -1.712 . . . . 0.0 106.377 177.462 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.49 ' CB ' HG23 ' A' ' 52' ' ' ILE . 12.6 p30 . . . . . 0 C--N 1.324 -0.529 0 C-N-CA 119.458 -0.897 . . . . 0.0 112.249 175.555 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 . . . . . 0 N--CA 1.437 -1.077 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . 0.636 ' HB3' ' HD2' ' A' ' 132' ' ' ARG . 14.0 pt20 -129.34 145.92 51.3 Favored 'General case' 0 N--CA 1.417 -2.089 0 C-N-CA 119.812 -0.755 . . . . 0.0 111.336 177.851 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.447 ' HB2' HD22 ' A' ' 131' ' ' LEU . 11.0 m-30 -109.5 130.44 55.5 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 -178.007 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.435 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 61.9 t -90.36 131.77 36.69 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.053 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 179.86 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . 0.527 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 69.2 m95 -119.9 97.96 5.87 Favored 'General case' 0 C--N 1.275 -2.636 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 -179.273 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 49.2 m-80 -80.01 114.7 19.11 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 178.634 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.464 ' HA ' HG22 ' A' ' 20' ' ' VAL . 23.6 mm -88.21 122.06 39.31 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 -177.718 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -118.19 156.1 29.33 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 123.241 0.616 . . . . 0.0 109.697 178.506 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -84.1 131.61 34.77 Favored 'General case' 0 N--CA 1.414 -2.258 0 CA-C-N 115.238 -0.892 . . . . 0.0 108.682 177.33 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -95.75 -12.12 25.9 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 -176.812 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -155.08 146.49 22.99 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 113.84 -1.527 . . . . 0.0 108.326 -178.089 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 17.8 p-10 -86.05 148.15 25.86 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 124.152 0.981 . . . . 0.0 111.564 -177.181 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.576 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 77.7 t -123.57 136.04 61.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-N 115.459 -0.792 . . . . 0.0 111.194 -174.542 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.5 t -118.29 135.1 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.767 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.449 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.1 t -99.37 103.77 22.73 Favored Pre-proline 0 C--N 1.291 -1.975 0 C-N-CA 123.867 0.867 . . . . 0.0 109.871 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.486 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 50.1 Cg_endo -72.77 -17.11 26.11 Favored 'Trans proline' 0 C--N 1.333 -0.289 0 C-N-CA 122.034 1.822 . . . . 0.0 111.424 178.021 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.273 4.0 t . . . . . 0 C--O 1.239 0.543 0 C-N-CA 125.414 1.486 . . . . 0.0 113.568 177.75 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.484 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.436 -1.136 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 14.7 t -148.78 157.01 43.13 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.394 -0.922 . . . . 0.0 109.958 -177.006 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.495 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.91 156.28 43.9 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 121.868 0.842 . . . . 0.0 111.434 -174.789 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 36.3 p -94.97 171.47 8.74 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.749 178.402 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -80.7 -10.93 59.7 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 114.661 -1.154 . . . . 0.0 110.332 -179.127 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -93.06 -33.22 14.18 Favored 'General case' 0 N--CA 1.431 -1.384 0 CA-C-N 114.96 -1.018 . . . . 0.0 111.796 -177.556 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 142.88 -1.59 1.53 Allowed Glycine 0 CA--C 1.507 -0.448 0 C-N-CA 119.158 -1.496 . . . . 0.0 114.462 171.461 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.4 m -86.35 104.99 16.38 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 122.202 -0.587 . . . . 0.0 110.93 -178.441 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -96.31 118.66 33.31 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 173.773 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.484 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 66.2 mt -89.84 122.58 67.8 Favored Pre-proline 0 C--N 1.297 -1.694 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 -179.649 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -77.24 171.91 16.95 Favored 'Trans proline' 0 C--O 1.239 0.563 0 C-N-CA 122.939 2.426 . . . . 0.0 111.582 179.6 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.7 mt -72.85 120.1 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.807 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 179.155 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 140.98 23.36 0.25 Allowed Glycine 0 C--N 1.301 -1.415 0 CA-C-N 115.393 -0.822 . . . . 0.0 112.027 -179.668 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 73.79 167.41 14.75 Favored Glycine 0 C--N 1.335 0.494 0 C-N-CA 121.156 -0.545 . . . . 0.0 112.309 -177.28 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 153.97 -172.01 32.64 Favored Glycine 0 CA--C 1.483 -1.966 0 C-N-CA 120.087 -1.054 . . . . 0.0 110.925 176.229 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.43 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 78.3 p -141.43 156.27 45.8 Favored 'General case' 0 N--CA 1.42 -1.953 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 178.918 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -137.23 160.22 39.66 Favored 'General case' 0 N--CA 1.422 -1.864 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 177.536 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 18.9 m-80 -114.15 109.89 19.12 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 105.143 -2.169 . . . . 0.0 105.143 175.713 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.495 HG22 ' HA ' ' A' ' 148' ' ' ILE . 0.8 OUTLIER -91.84 143.2 11.8 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.328 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 -178.132 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 63.2 m-85 -119.52 116.07 25.32 Favored 'General case' 0 C--N 1.297 -1.711 0 C-N-CA 120.803 -0.359 . . . . 0.0 111.557 -179.249 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.436 HG22 ' HG3' ' A' ' 41' ' ' GLN . 22.0 t -119.58 132.75 68.49 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.041 -174.888 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 -88.6 123.09 32.75 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 176.881 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.467 HD11 HG22 ' A' ' 36' ' ' VAL . 2.9 mm? -104.14 160.44 14.86 Favored 'General case' 0 C--N 1.287 -2.143 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.502 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -59.33 123.71 71.48 Favored Pre-proline 0 C--N 1.316 -0.886 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.382 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 88.0 Cg_endo -78.53 1.58 8.91 Favored 'Trans proline' 0 C--N 1.33 -0.427 0 C-N-CA 122.78 2.32 . . . . 0.0 113.159 -175.264 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 98.7 t -129.53 109.77 18.83 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 177.311 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.0 t -143.03 103.53 0.92 Allowed 'Isoleucine or valine' 0 C--O 1.18 -2.585 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -176.347 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.728 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -95.16 155.27 16.8 Favored 'General case' 0 C--N 1.272 -2.783 0 C-N-CA 122.364 0.266 . . . . 0.0 111.01 -179.838 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.606 HG22 ' O ' ' A' ' 112' ' ' VAL . 87.5 t -46.94 118.71 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 C-N-CA 123.06 0.544 . . . . 0.0 111.064 175.387 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.98 9.61 57.05 Favored Glycine 0 C--N 1.31 -0.887 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.939 179.467 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.728 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -80.77 -177.72 6.46 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 175.413 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -130.88 87.65 2.51 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 178.859 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.66 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 27.1 tp -88.1 144.56 26.42 Favored 'General case' 0 C--N 1.292 -1.906 0 C-N-CA 119.589 -0.844 . . . . 0.0 109.685 -178.803 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.7 t -137.7 130.33 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.882 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 -177.597 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.565 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 40.3 t -97.54 88.75 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.413 -2.304 0 N-CA-C 105.685 -1.968 . . . . 0.0 105.685 172.734 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.411 ' O ' ' HG2' ' A' ' 41' ' ' GLN . 12.9 t70 -82.03 109.74 16.64 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -177.781 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.9 mt -92.47 -1.32 57.06 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-O 121.072 0.463 . . . . 0.0 111.284 -178.012 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.579 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 34.1 t -76.25 0.27 19.81 Favored 'General case' 0 C--N 1.31 -1.121 0 CA-C-O 121.652 0.739 . . . . 0.0 109.459 -178.713 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.6 p -129.81 5.51 5.04 Favored 'General case' 0 N--CA 1.412 -2.33 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.599 178.83 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.436 ' HG3' HG22 ' A' ' 22' ' ' VAL . 48.9 mm-40 -124.69 -21.13 4.88 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.854 -173.89 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 39.0 mt -134.8 138.73 48.81 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 -177.333 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.495 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 49.5 m-85 -142.32 128.63 19.95 Favored 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -176.065 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 85.0 m -107.57 145.9 32.61 Favored 'General case' 0 C--N 1.284 -2.251 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.032 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 12.1 p80 -131.62 128.35 38.95 Favored 'General case' 0 C--N 1.296 -1.728 0 CA-C-O 122.16 0.981 . . . . 0.0 111.744 -176.516 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 20.8 p-10 -97.11 89.66 4.87 Favored 'General case' 0 C--N 1.282 -2.335 0 CA-C-O 122.257 1.027 . . . . 0.0 108.693 178.572 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . 0.586 ' HB2' ' CD2' ' A' ' 48' ' ' TYR . 1.4 m-20 -51.74 -43.62 62.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.25 -175.676 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . 0.586 ' CD2' ' HB2' ' A' ' 47' ' ' ASP . 29.2 m-85 -121.84 83.27 43.01 Favored Pre-proline 0 C--N 1.315 -0.913 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 -175.278 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -83.01 -5.51 11.32 Favored 'Trans proline' 0 C--O 1.234 0.29 0 C-N-CA 122.99 2.46 . . . . 0.0 112.786 -173.606 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -103.78 -23.35 13.42 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.023 -178.09 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.711 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.3 OUTLIER -100.33 -30.76 11.69 Favored 'General case' 0 N--CA 1.415 -2.222 0 CA-C-O 122.02 0.914 . . . . 0.0 108.867 -176.0 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.711 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.9 mp -128.96 134.9 63.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 CA-C-N 114.636 -1.166 . . . . 0.0 109.927 -176.584 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 5.9 t -86.51 139.05 31.24 Favored 'General case' 0 N--CA 1.438 -1.052 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 171.5 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.464 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 14.6 t70 -96.07 108.78 21.25 Favored 'General case' 0 C--N 1.275 -2.664 0 C-N-CA 119.673 -0.811 . . . . 0.0 109.147 -175.832 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 23.6 t80 -122.64 122.15 38.12 Favored 'General case' 0 C--N 1.288 -2.065 0 CA-C-O 121.799 0.809 . . . . 0.0 110.065 -177.702 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.443 HG22 ' NE2' ' A' ' 133' ' ' GLN . 85.3 t -125.95 138.52 54.29 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 CA-C-N 114.169 -1.378 . . . . 0.0 110.067 -176.084 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -144.46 135.3 24.97 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 172.602 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.547 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 38.9 tp -74.58 104.91 5.45 Favored 'General case' 0 N--CA 1.436 -1.132 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 175.429 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -52.96 -54.2 38.49 Favored 'General case' 0 C--O 1.201 -1.457 0 C-N-CA 126.278 1.831 . . . . 0.0 111.048 -179.55 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.405 ' HG3' HD13 ' A' ' 130' ' ' ILE . 0.4 OUTLIER -165.52 156.35 13.74 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 -177.766 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.87 118.34 1.11 Allowed Glycine 0 N--CA 1.398 -3.846 0 N-CA-C 108.941 -1.663 . . . . 0.0 108.941 -178.099 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.403 ' HA ' ' HB3' ' A' ' 85' ' ' PRO . 52.8 m -114.52 146.56 40.58 Favored 'General case' 0 C--N 1.279 -2.472 0 C-N-CA 124.584 1.153 . . . . 0.0 110.029 -170.859 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.527 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -106.26 156.66 18.25 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 123.496 0.718 . . . . 0.0 109.112 -178.715 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.484 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 99.5 m-85 -154.48 -179.35 7.88 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 124.08 0.952 . . . . 0.0 109.742 -176.978 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.06 -136.44 51.18 Favored Glycine 0 N--CA 1.458 0.121 0 O-C-N 123.653 0.595 . . . . 0.0 112.669 178.012 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.79 -9.07 83.49 Favored Glycine 0 C--O 1.206 -1.635 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 177.477 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.826 HG21 ' HB ' ' A' ' 126' ' ' ILE . 77.7 t -69.67 -36.42 70.36 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 C-N-CA 123.745 0.818 . . . . 0.0 111.852 -176.107 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.527 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -87.16 -20.25 27.28 Favored 'General case' 0 C--N 1.297 -1.684 0 C-N-CA 119.216 -0.993 . . . . 0.0 112.296 178.306 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 9.6 t -101.03 -52.79 3.2 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.472 0.653 . . . . 0.0 112.195 -173.757 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.485 ' O ' HG22 ' A' ' 112' ' ' VAL . 31.6 m-20 -91.78 -25.81 18.85 Favored 'General case' 0 CA--C 1.49 -1.353 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -173.69 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.639 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 86.1 m-85 -106.61 155.85 19.21 Favored 'General case' 0 N--CA 1.416 -2.152 0 C-N-CA 120.008 -0.677 . . . . 0.0 109.291 177.254 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.3 t -165.48 117.83 1.14 Allowed 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 176.992 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.506 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -153.56 -111.88 0.46 Allowed Glycine 0 N--CA 1.412 -2.924 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 176.714 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.9 p -154.51 -179.72 8.23 Favored 'General case' 0 C--N 1.297 -1.687 0 C-N-CA 123.561 0.744 . . . . 0.0 110.93 -173.66 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -133.95 144.02 36.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 C-N-CA 123.319 0.648 . . . . 0.0 109.874 177.762 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.61 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.0 tttt -121.68 142.82 49.78 Favored 'General case' 0 N--CA 1.432 -1.374 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.648 178.767 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.46 ' CD2' HG22 ' A' ' 105' ' ' VAL . 62.6 t80 -142.42 110.35 5.89 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.517 -179.055 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.9 t 49.77 38.9 16.66 Favored 'General case' 0 CA--C 1.557 1.231 0 C-N-CA 124.43 1.092 . . . . 0.0 111.735 176.017 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.28 18.3 50.05 Favored Glycine 0 CA--C 1.524 0.596 0 C-N-CA 120.922 -0.656 . . . . 0.0 113.624 -179.404 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.61 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 12.2 t -92.73 -179.84 5.27 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 174.597 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 56.3 p -157.87 105.53 1.99 Allowed 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 179.652 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.443 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 2.7 p90 -150.73 160.83 31.79 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 -173.791 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.443 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 45.0 Cg_endo -68.51 148.19 72.35 Favored 'Trans proline' 0 C--N 1.357 0.984 0 C-N-CA 122.935 2.423 . . . . 0.0 113.357 -177.788 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.602 ' CD2' HD21 ' A' ' 109' ' ' LEU . 60.5 t80 -123.61 134.15 25.08 Favored Pre-proline 0 N--CA 1.433 -1.289 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.484 -179.431 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.46 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 60.2 Cg_endo -70.54 148.76 89.19 Favored 'Cis proline' 0 CA--C 1.541 0.862 0 C-N-CA 122.77 -1.763 . . . . 0.0 110.469 -0.838 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.2 t -67.24 -177.22 0.65 Allowed 'General case' 0 CA--C 1.549 0.919 0 CA-C-O 121.266 0.555 . . . . 0.0 110.997 -176.86 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 18.5 p -130.39 -19.88 3.04 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 112.597 0.592 . . . . 0.0 112.597 -173.459 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 21.6 t -130.71 -89.36 0.47 Allowed 'General case' 0 C--O 1.204 -1.335 0 C-N-CA 120.429 -0.508 . . . . 0.0 110.309 -179.988 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -166.58 -173.01 2.33 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 177.888 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.547 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 61.8 p -100.32 163.48 18.17 Favored Pre-proline 0 C--N 1.304 -1.387 0 N-CA-C 112.795 0.665 . . . . 0.0 112.795 179.798 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_endo -56.65 165.27 4.83 Favored 'Trans proline' 0 C--O 1.248 0.99 0 C-N-CA 123.518 2.812 . . . . 0.0 111.43 172.711 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -74.47 122.17 22.62 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.479 -175.959 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 73.2 t -134.9 133.46 53.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 -178.348 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 54' ' ' ASP . 1.5 p -132.97 134.6 57.94 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.292 0 CA-C-N 115.971 -0.558 . . . . 0.0 109.596 -178.55 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.464 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 2.6 m-85 -83.07 117.91 23.18 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 179.182 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -102.07 27.56 6.52 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.756 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.9 m -99.23 -171.56 2.1 Favored 'General case' 0 N--CA 1.426 -1.628 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.291 -178.328 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -151.15 43.58 0.79 Allowed 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.465 0.65 . . . . 0.0 110.39 175.769 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.3 t -168.18 -178.63 3.73 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -176.735 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -67.18 106.78 2.11 Favored 'General case' 0 CA--C 1.511 -0.542 0 C-N-CA 123.344 0.658 . . . . 0.0 109.39 179.607 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -112.6 135.1 21.52 Favored Pre-proline 0 C--N 1.293 -1.866 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 176.342 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.579 ' HB3' ' O ' ' A' ' 39' ' ' SER . 51.4 Cg_exo -53.69 139.61 67.41 Favored 'Trans proline' 0 CA--C 1.503 -1.067 0 C-N-CA 123.865 3.043 . . . . 0.0 112.295 177.357 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 15.5 t90 -85.0 106.85 9.74 Favored Pre-proline 0 C--N 1.298 -1.655 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 179.161 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . 0.403 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 60.2 Cg_endo -77.0 88.22 1.42 Allowed 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 121.368 1.379 . . . . 0.0 113.096 -172.952 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.46 HG22 ' CD2' ' A' ' 77' ' ' TYR . 92.6 t -140.62 146.88 23.6 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.103 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 178.127 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.565 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.38 135.05 17.43 Favored 'General case' 0 C--N 1.294 -1.817 0 CA-C-O 120.757 0.313 . . . . 0.0 110.431 177.34 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.496 HD21 HD11 ' A' ' 129' ' ' LEU . 20.1 mt -100.97 105.18 16.38 Favored 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 178.083 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.506 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 43.9 m-85 -83.63 72.58 10.31 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 120.67 0.272 . . . . 0.0 110.716 178.095 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.66 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -98.66 129.17 45.14 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 176.342 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.42 146.89 63.43 Favored Pre-proline 0 N--CA 1.41 -2.426 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 -175.9 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.458 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 40.4 Cg_endo -65.37 126.07 15.61 Favored 'Trans proline' 0 CA--C 1.496 -1.416 0 C-N-CA 123.133 2.555 . . . . 0.0 113.002 -175.181 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.606 ' O ' HG22 ' A' ' 30' ' ' VAL . 16.7 m -84.3 -154.78 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.401 -2.889 0 CA-C-N 114.518 -1.219 . . . . 0.0 108.044 171.667 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 18.5 m -82.76 -30.32 29.05 Favored 'General case' 0 C--N 1.255 -3.508 0 CA-C-O 121.497 0.665 . . . . 0.0 110.025 -170.609 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 18.1 t -84.73 30.81 0.55 Allowed 'General case' 0 N--CA 1.435 -1.201 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.156 -179.821 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -112.23 138.12 49.37 Favored 'General case' 0 N--CA 1.422 -1.831 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.874 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -179.22 128.01 1.2 Allowed Glycine 0 N--CA 1.437 -1.239 0 C-N-CA 120.367 -0.92 . . . . 0.0 112.425 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 68.32 -149.05 49.54 Favored Glycine 0 CA--C 1.486 -1.728 0 CA-C-O 119.125 -0.819 . . . . 0.0 111.928 -177.436 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 57.4 t -59.85 103.4 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 CA-C-N 117.308 0.554 . . . . 0.0 110.088 -177.126 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -103.78 -29.16 11.2 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.953 -178.223 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.527 ' HB ' HG22 ' A' ' 154' ' ' VAL . 73.6 mt -126.69 137.48 57.7 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.849 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 176.947 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.46 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.9 mmpt? -114.06 141.87 46.9 Favored 'General case' 0 C--N 1.31 -1.131 0 C-N-CA 122.959 0.504 . . . . 0.0 110.121 177.048 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -73.03 135.71 44.94 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.286 179.677 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 84.49 11.31 77.98 Favored Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 111.59 -0.604 . . . . 0.0 111.59 -179.016 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 27.3 t -113.98 147.76 38.06 Favored 'General case' 0 N--CA 1.433 -1.324 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 -179.332 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 23.1 tp -73.52 134.99 43.96 Favored 'General case' 0 CA--C 1.506 -0.747 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.795 -179.801 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.826 ' HB ' HG21 ' A' ' 67' ' ' VAL . 35.8 pt -120.12 -25.0 2.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.717 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 179.215 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . 0.408 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -163.35 166.0 23.43 Favored 'General case' 0 C--O 1.21 -1.017 0 N-CA-C 110.312 -0.255 . . . . 0.0 110.312 -178.022 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 67.1 t -139.48 113.18 6.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.3 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.496 HD11 HD21 ' A' ' 107' ' ' LEU . 48.1 mt -118.48 143.29 46.81 Favored 'General case' 0 C--N 1.29 -1.995 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 179.751 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.573 HG21 ' NE2' ' A' ' 143' ' ' GLN . 5.3 mp -124.23 128.52 73.92 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 C-N-CA 119.7 -0.8 . . . . 0.0 110.67 178.419 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.566 HD23 ' O ' ' A' ' 131' ' ' LEU . 0.0 OUTLIER -96.11 135.15 38.28 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 175.433 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . 0.539 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 8.8 tpt180 -97.92 122.26 40.83 Favored 'General case' 0 C--N 1.285 -2.223 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.573 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . 0.472 HE21 ' HA ' ' A' ' 133' ' ' GLN . 0.0 OUTLIER -105.82 104.7 14.47 Favored 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 123.406 0.682 . . . . 0.0 109.268 -177.587 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 6.9 m -127.34 142.14 51.52 Favored 'General case' 0 C--N 1.284 -2.255 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 179.197 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.587 ' CB ' HG23 ' A' ' 52' ' ' ILE . 9.1 p30 . . . . . 0 C--N 1.309 -1.166 0 C-N-CA 119.988 -0.685 . . . . 0.0 110.446 176.498 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 . . . . . 0 N--CA 1.441 -0.912 0 CA-C-O 120.992 0.425 . . . . 0.0 109.935 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . 0.573 ' NE2' HG21 ' A' ' 130' ' ' ILE . 17.3 pt20 -134.79 143.93 47.36 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 175.514 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.496 ' HB2' HD22 ' A' ' 131' ' ' LEU . 9.4 m-30 -109.65 130.38 55.52 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 -179.175 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.43 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 52.2 t -90.81 132.27 35.82 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 O-C-N 123.592 0.557 . . . . 0.0 109.799 -178.617 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . 0.474 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 61.9 m95 -117.47 96.18 5.29 Favored 'General case' 0 C--N 1.279 -2.48 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 -179.304 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.9 m-80 -79.45 112.63 16.89 Favored 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 177.989 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.495 ' HA ' HG22 ' A' ' 20' ' ' VAL . 26.6 mm -86.37 122.14 38.33 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.816 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -175.799 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 40.6 m-85 -117.25 156.2 28.16 Favored 'General case' 0 CA--C 1.487 -1.474 0 CA-C-O 121.633 0.73 . . . . 0.0 110.605 179.222 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -84.28 129.37 34.89 Favored 'General case' 0 N--CA 1.405 -2.685 0 CA-C-N 114.544 -1.207 . . . . 0.0 108.684 175.808 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 15.8 t-20 -91.43 -13.77 31.74 Favored 'General case' 0 C--N 1.29 -2.008 0 N-CA-C 107.383 -1.339 . . . . 0.0 107.383 -178.793 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -150.14 143.62 25.17 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 113.633 -1.621 . . . . 0.0 109.008 -175.201 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -86.37 144.79 27.17 Favored 'General case' 0 C--N 1.307 -1.249 0 O-C-N 124.241 0.963 . . . . 0.0 110.169 -179.777 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.527 HG22 ' HB ' ' A' ' 120' ' ' ILE . 1.5 m -123.96 150.52 28.46 Favored 'Isoleucine or valine' 0 C--O 1.253 1.249 0 C-N-CA 120.701 -0.4 . . . . 0.0 111.24 -177.284 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.2 t -124.32 138.27 54.4 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.124 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -179.613 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.462 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 79.0 t -100.21 100.83 12.64 Favored Pre-proline 0 C--N 1.296 -1.759 0 C-N-CA 123.983 0.913 . . . . 0.0 109.453 178.06 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.502 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 27.5 Cg_endo -66.37 -26.19 48.47 Favored 'Trans proline' 0 CA--C 1.515 -0.428 0 C-N-CA 122.208 1.939 . . . . 0.0 111.773 178.908 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.3 t . . . . . 0 C--O 1.254 1.312 0 O-C-N 124.516 1.135 . . . . 0.0 113.223 176.882 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.458 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . . . . . . 0 N--CA 1.429 -1.482 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 13.6 t -147.4 159.37 43.77 Favored 'General case' 0 N--CA 1.428 -1.555 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.647 -174.784 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.587 ' HE3' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.81 168.72 19.54 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-O 121.36 0.6 . . . . 0.0 110.747 -173.717 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 76.2 p -105.5 175.82 5.37 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.08 0.467 . . . . 0.0 110.798 179.771 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -73.66 -22.05 60.08 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.627 178.651 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -84.28 -33.33 24.01 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 120.256 -0.578 . . . . 0.0 110.641 -177.784 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 135.13 9.47 1.66 Allowed Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 119.564 -1.303 . . . . 0.0 113.699 176.808 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -85.16 100.02 11.46 Favored 'General case' 0 N--CA 1.433 -1.317 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.884 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.1 117.33 30.0 Favored 'General case' 0 C--N 1.297 -1.71 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.591 178.638 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.458 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 67.3 mt -86.63 127.26 61.16 Favored Pre-proline 0 C--N 1.299 -1.627 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 178.692 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -81.06 169.34 16.28 Favored 'Trans proline' 0 C--O 1.248 0.984 0 C-N-CA 122.78 2.32 . . . . 0.0 111.305 177.985 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 61.3 mt -69.16 132.11 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 177.855 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 129.89 -5.22 6.12 Favored Glycine 0 C--N 1.3 -1.462 0 C-N-CA 120.172 -1.013 . . . . 0.0 111.507 -179.528 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 101.42 163.6 27.33 Favored Glycine 0 N--CA 1.432 -1.595 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 -177.694 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 160.41 -177.45 36.84 Favored Glycine 0 C--N 1.297 -1.614 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 178.612 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.415 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 59.7 p -138.99 147.74 42.55 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.763 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -132.0 161.05 34.1 Favored 'General case' 0 N--CA 1.426 -1.63 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 177.999 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 -116.2 109.06 16.93 Favored 'General case' 0 C--N 1.289 -2.055 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 177.784 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.455 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.3 m -91.1 147.68 5.08 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.416 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 -177.893 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.7 m-85 -131.04 118.87 21.2 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -177.354 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.538 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -125.43 135.63 63.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.108 -176.389 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 30.7 m-80 -91.08 122.7 33.95 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 179.988 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . 0.411 HD11 HG22 ' A' ' 36' ' ' VAL . 2.8 mm? -101.94 160.61 14.34 Favored 'General case' 0 C--N 1.285 -2.223 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 178.103 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.2 122.21 52.48 Favored Pre-proline 0 C--N 1.314 -0.955 0 O-C-N 124.116 0.885 . . . . 0.0 108.728 174.76 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.531 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 72.8 Cg_endo -74.71 -1.84 11.67 Favored 'Trans proline' 0 CA--C 1.533 0.441 0 C-N-CA 122.895 2.397 . . . . 0.0 112.968 -176.148 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.408 HG13 ' HG3' ' A' ' 157' ' ' PRO . 95.6 t -129.11 111.27 22.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.475 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 10.3 t -148.19 111.1 0.68 Allowed 'Isoleucine or valine' 0 C--O 1.188 -2.17 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -177.341 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.592 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -96.83 154.65 17.17 Favored 'General case' 0 C--N 1.272 -2.775 0 C-N-CA 123.646 0.778 . . . . 0.0 110.962 179.834 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.581 HG22 ' O ' ' A' ' 112' ' ' VAL . 71.5 t -46.67 122.66 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 C-N-CA 123.051 0.541 . . . . 0.0 110.734 176.24 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.25 1.24 58.16 Favored Glycine 0 C--N 1.315 -0.592 0 CA-C-N 115.536 -0.756 . . . . 0.0 112.919 179.663 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.592 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -73.38 -176.98 2.42 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 123.396 0.678 . . . . 0.0 110.678 175.93 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -131.42 92.13 3.12 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.131 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.654 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 28.5 tp -94.09 141.05 28.99 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 119.444 -0.902 . . . . 0.0 109.906 -179.66 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 56.9 t -131.87 120.93 45.98 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.019 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.022 -176.443 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.573 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 48.3 t -90.86 88.21 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.89 0 N-CA-C 105.249 -2.13 . . . . 0.0 105.249 173.655 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -83.26 109.75 17.5 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.318 -177.473 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.415 ' HA ' ' HG2' ' A' ' 41' ' ' GLN . 84.2 mt -95.0 -3.64 48.04 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.111 -178.164 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.1 m -71.15 0.15 8.38 Favored 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 114.831 -1.077 . . . . 0.0 110.125 -179.945 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.5 p -133.21 6.86 3.9 Favored 'General case' 0 N--CA 1.425 -1.677 0 C-N-CA 124.24 1.016 . . . . 0.0 109.911 178.639 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.538 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 46.2 mm-40 -122.23 -19.28 6.57 Favored 'General case' 0 CA--C 1.507 -0.699 0 CA-C-O 121.067 0.461 . . . . 0.0 110.717 -174.557 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 45.2 mt -134.36 138.24 50.2 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -176.219 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.587 ' HB2' ' HE3' ' A' ' 4' ' ' LYS . 72.8 m-85 -143.02 143.44 31.9 Favored 'General case' 0 CA--C 1.492 -1.27 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -174.467 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 64.8 m -126.87 140.64 52.19 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 -176.327 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -121.89 151.17 40.98 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.313 0.578 . . . . 0.0 110.256 -176.203 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.653 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 24.0 p-10 -107.18 104.06 13.6 Favored 'General case' 0 N--CA 1.411 -2.387 0 CA-C-O 122.886 1.327 . . . . 0.0 110.068 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -74.84 -34.64 62.35 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 112.942 -1.935 . . . . 0.0 111.319 -174.847 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 49.5 m-85 -134.23 72.79 70.76 Favored Pre-proline 0 C--N 1.3 -1.566 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.539 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.653 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 58.7 Cg_endo -72.34 -3.05 12.64 Favored 'Trans proline' 0 C--N 1.334 -0.224 0 C-N-CA 122.775 2.317 . . . . 0.0 113.386 -174.378 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -118.83 -4.19 10.7 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 121.138 0.494 . . . . 0.0 109.799 -178.278 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.52 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -117.99 -29.1 5.72 Favored 'General case' 0 N--CA 1.418 -2.033 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.883 -174.016 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.52 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.0 mp -130.6 134.84 61.54 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.487 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.5 t -69.57 139.74 53.75 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 108.957 -0.756 . . . . 0.0 108.957 177.463 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -86.76 107.96 18.49 Favored 'General case' 0 C--N 1.285 -2.207 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -173.347 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.504 ' CD2' ' HB ' ' A' ' 134' ' ' THR . 73.1 t80 -150.16 145.35 26.24 Favored 'General case' 0 C--N 1.295 -1.794 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.427 -171.357 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.495 HG13 ' HB2' ' A' ' 131' ' ' LEU . 59.9 t -150.66 139.67 15.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 C-N-CA 124.559 1.144 . . . . 0.0 108.666 177.655 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -147.27 122.61 10.29 Favored 'General case' 0 C--O 1.21 -0.992 0 O-C-N 123.311 0.382 . . . . 0.0 110.607 174.617 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.527 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 63.5 tp -64.77 114.92 4.79 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-O 121.315 0.579 . . . . 0.0 110.004 177.195 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . 0.472 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 4.2 tp-100 -59.12 -60.02 4.53 Favored 'General case' 0 C--N 1.315 -0.933 0 C-N-CA 126.287 1.835 . . . . 0.0 110.555 176.566 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . 0.454 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 4.5 ptp180 -163.06 161.91 25.56 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 115.052 -0.976 . . . . 0.0 108.424 -177.011 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.403 ' H ' HG22 ' A' ' 86' ' ' THR . . . -142.44 131.25 4.59 Favored Glycine 0 N--CA 1.401 -3.641 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 -179.384 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.412 ' HA ' ' HB3' ' A' ' 85' ' ' PRO . 49.1 m -120.07 149.52 42.05 Favored 'General case' 0 C--N 1.288 -2.089 0 C-N-CA 124.072 0.949 . . . . 0.0 110.395 -174.575 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.544 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -111.5 153.4 26.26 Favored 'General case' 0 N--CA 1.486 1.356 0 CA-C-O 117.792 -1.099 . . . . 0.0 108.398 -179.457 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.8 ' O ' HG22 ' A' ' 67' ' ' VAL . 95.2 m-85 -158.35 -179.75 8.39 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 123.646 0.779 . . . . 0.0 111.277 -176.951 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.91 -134.02 51.03 Favored Glycine 0 C--N 1.317 -0.485 0 C-N-CA 121.409 -0.424 . . . . 0.0 112.265 179.769 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.62 -10.22 83.6 Favored Glycine 0 N--CA 1.422 -2.25 0 C-N-CA 120.327 -0.939 . . . . 0.0 112.839 177.306 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.8 HG22 ' O ' ' A' ' 64' ' ' TYR . 12.5 m -73.84 -28.6 24.47 Favored 'Isoleucine or valine' 0 C--O 1.205 -1.252 0 CA-C-N 118.295 1.048 . . . . 0.0 112.262 -174.143 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.544 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -91.14 -19.94 22.54 Favored 'General case' 0 C--N 1.297 -1.675 0 C-N-CA 119.876 -0.73 . . . . 0.0 111.895 177.664 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 7.4 t -100.45 -49.35 4.26 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.481 0.658 . . . . 0.0 111.239 -173.627 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.509 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 49.6 m-20 -96.99 -17.82 19.81 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -174.332 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.566 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 87.2 m-85 -119.31 163.55 16.98 Favored 'General case' 0 C--N 1.294 -1.812 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.957 -179.329 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.2 t -173.06 132.6 0.51 Allowed 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 178.729 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.498 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -167.15 -112.5 0.26 Allowed Glycine 0 N--CA 1.406 -3.334 0 N-CA-C 110.624 -0.99 . . . . 0.0 110.624 174.178 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.411 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.2 p -154.93 -179.96 8.55 Favored 'General case' 0 C--N 1.292 -1.921 0 C-N-CA 123.628 0.771 . . . . 0.0 110.403 -172.933 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.402 ' HB ' ' CD1' ' A' ' 84' ' ' PHE . 2.5 p -134.27 145.5 32.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.319 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.731 ' HG3' ' O ' ' A' ' 80' ' ' SER . 71.0 tttt -123.22 142.99 50.34 Favored 'General case' 0 N--CA 1.416 -2.139 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.397 -179.395 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.479 ' CD1' HG22 ' A' ' 105' ' ' VAL . 71.7 t80 -143.81 112.0 6.3 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.521 -178.429 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 14.7 t 52.78 37.94 25.21 Favored 'General case' 0 CA--C 1.561 1.4 0 CA-C-O 122.025 0.917 . . . . 0.0 110.875 175.951 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.08 10.37 64.49 Favored Glycine 0 CA--C 1.528 0.903 0 CA-C-N 115.684 -0.689 . . . . 0.0 113.731 179.934 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.731 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 21.6 t -84.94 -179.72 7.13 Favored 'General case' 0 C--O 1.206 -1.211 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 177.836 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 48.5 m -159.06 108.83 1.95 Allowed 'General case' 0 C--N 1.279 -2.483 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 177.297 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.475 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 4.0 p90 -149.38 163.1 26.5 Favored Pre-proline 0 C--N 1.306 -1.308 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -174.517 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.475 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 58.6 Cg_endo -68.99 148.79 70.85 Favored 'Trans proline' 0 C--N 1.358 1.057 0 C-N-CA 122.612 2.208 . . . . 0.0 113.425 -175.862 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.509 ' CD2' HD21 ' A' ' 109' ' ' LEU . 51.6 t80 -123.72 132.76 24.3 Favored Pre-proline 0 N--CA 1.435 -1.18 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 179.383 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.47 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 66.8 Cg_endo -72.22 147.58 89.11 Favored 'Cis proline' 0 CA--C 1.542 0.914 0 C-N-CA 122.734 -1.777 . . . . 0.0 110.497 -1.369 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . 0.403 HG22 ' H ' ' A' ' 61' ' ' GLY . 11.5 t -68.28 -175.84 0.67 Allowed 'General case' 0 CA--C 1.55 0.955 0 CA-C-O 121.229 0.537 . . . . 0.0 111.04 -176.181 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 7.9 p -130.37 -42.88 1.17 Allowed 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 116.07 -0.514 . . . . 0.0 112.289 -175.554 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.2 t -101.3 -86.63 0.4 Allowed 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.592 -175.467 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -170.19 -169.68 0.88 Allowed 'General case' 0 N--CA 1.438 -1.043 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 177.825 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.527 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 21.4 p -101.37 162.77 19.45 Favored Pre-proline 0 C--N 1.302 -1.477 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 177.325 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -63.79 159.4 41.78 Favored 'Trans proline' 0 C--N 1.358 1.059 0 C-N-CA 122.748 2.299 . . . . 0.0 111.64 174.526 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.7 tmm_? -65.35 118.29 9.14 Favored 'General case' 0 C--N 1.315 -0.918 0 C-N-CA 124.695 1.198 . . . . 0.0 109.554 -177.523 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 68.5 t -127.81 128.82 69.68 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.329 -177.07 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 74.2 t -114.29 140.73 33.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.402 179.416 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -87.36 95.65 10.07 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.24 0.543 . . . . 0.0 110.093 177.931 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -86.97 64.57 8.55 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 121.183 0.516 . . . . 0.0 110.392 -179.046 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.5 m -155.21 -179.59 8.23 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 -179.527 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . 0.556 ' HA ' HD21 ' A' ' 46' ' ' ASN . 16.7 ptm180 -141.28 50.32 1.61 Allowed 'General case' 0 N--CA 1.44 -0.971 0 CA-C-O 121.899 0.857 . . . . 0.0 110.128 178.996 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 6.9 t -163.39 170.75 17.02 Favored 'General case' 0 N--CA 1.424 -1.733 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 -178.868 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -69.92 101.59 1.79 Allowed 'General case' 0 C--O 1.251 1.169 0 CA-C-O 122.581 1.182 . . . . 0.0 108.755 178.242 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.8 tptm -101.1 137.02 19.6 Favored Pre-proline 0 C--N 1.268 -2.945 0 CA-C-N 113.002 -1.908 . . . . 0.0 109.368 -175.878 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -64.74 146.09 87.81 Favored 'Trans proline' 0 C--O 1.246 0.904 0 C-N-CA 122.673 2.248 . . . . 0.0 111.892 177.073 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . 0.404 ' NE1' HG11 ' A' ' 56' ' ' VAL . 15.7 t90 -86.95 108.61 19.33 Favored Pre-proline 0 N--CA 1.44 -0.932 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 -178.563 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -76.63 89.01 1.32 Allowed 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 121.864 1.709 . . . . 0.0 113.154 -173.273 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.479 HG22 ' CD1' ' A' ' 77' ' ' TYR . 81.2 t -139.89 145.86 25.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.038 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 177.824 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.573 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -149.92 136.31 19.01 Favored 'General case' 0 C--N 1.287 -2.121 0 CA-C-O 120.95 0.405 . . . . 0.0 110.223 177.586 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.454 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 15.9 mt -103.69 106.08 16.49 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 178.335 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.498 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 14.6 m-85 -83.01 75.0 9.92 Favored 'General case' 0 C--N 1.284 -2.249 0 N-CA-C 110.159 -0.312 . . . . 0.0 110.159 177.849 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.654 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -95.83 124.96 40.08 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 174.776 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -128.97 146.25 59.87 Favored Pre-proline 0 N--CA 1.409 -2.492 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 -176.86 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.509 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 36.2 Cg_endo -63.78 126.01 16.56 Favored 'Trans proline' 0 N--CA 1.444 -1.424 0 C-N-CA 122.712 2.274 . . . . 0.0 113.685 -175.813 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.581 ' O ' HG22 ' A' ' 30' ' ' VAL . 13.9 m -85.62 -155.96 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.392 -3.346 0 CA-C-N 114.007 -1.451 . . . . 0.0 108.465 171.648 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 14.4 m -79.86 -33.39 40.15 Favored 'General case' 0 C--N 1.262 -3.225 0 CA-C-O 121.446 0.641 . . . . 0.0 110.12 -170.36 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.2 t -83.19 26.89 0.6 Allowed 'General case' 0 N--CA 1.425 -1.684 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.558 -178.137 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.424 ' HB2' ' O ' ' A' ' 70' ' ' ASN . . . -107.8 134.35 50.87 Favored 'General case' 0 N--CA 1.424 -1.766 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 178.478 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -176.78 129.21 1.44 Allowed Glycine 0 N--CA 1.437 -1.235 0 C-N-CA 120.571 -0.824 . . . . 0.0 111.469 178.814 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.4 -150.71 52.01 Favored Glycine 0 CA--C 1.495 -1.204 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 -176.305 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -55.9 105.99 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 CA-C-O 122.522 1.153 . . . . 0.0 111.932 -178.211 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -106.61 -28.33 10.3 Favored 'General case' 0 C--N 1.294 -1.812 0 CA-C-N 114.51 -1.223 . . . . 0.0 111.375 -177.922 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.443 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 54.8 mt -130.07 135.01 61.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.118 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.507 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.1 mmpt? -109.84 141.48 42.47 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-O 121.164 0.507 . . . . 0.0 111.123 176.767 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . 0.4 ' H ' ' HB3' ' A' ' 153' ' ' ASP . . . -72.09 123.28 22.52 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.429 178.965 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 97.94 -0.0 58.95 Favored Glycine 0 C--N 1.306 -1.097 0 N-CA-C 111.316 -0.714 . . . . 0.0 111.316 -176.613 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 31.0 t -97.16 145.42 26.04 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.329 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.416 HD23 ' CZ ' ' A' ' 149' ' ' TYR . 3.2 tm? -76.84 123.43 26.23 Favored 'General case' 0 N--CA 1.431 -1.38 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.82 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.556 ' HB ' HG11 ' A' ' 67' ' ' VAL . 28.4 pt -108.63 -29.75 2.53 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.745 -179.746 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . 0.464 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -158.88 168.5 26.64 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 119.46 -0.896 . . . . 0.0 110.639 -177.238 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.405 HG23 HD11 ' A' ' 125' ' ' LEU . 72.3 t -142.12 113.48 3.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 179.021 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.412 HD11 HD21 ' A' ' 107' ' ' LEU . 57.0 mt -117.24 151.53 36.73 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 178.533 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . 0.522 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.5 mp -135.71 129.69 48.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 178.027 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.495 ' HB2' HG13 ' A' ' 56' ' ' VAL . 1.2 pp -97.34 142.0 29.75 Favored 'General case' 0 CA--C 1.499 -0.991 0 C-N-CA 119.864 -0.734 . . . . 0.0 109.022 177.352 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . 0.472 ' HG2' ' HB2' ' A' ' 59' ' ' GLN . 15.4 mmm180 -96.64 116.11 28.55 Favored 'General case' 0 C--N 1.279 -2.477 0 C-N-CA 124.264 1.026 . . . . 0.0 108.551 175.848 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 26.2 tp60 -85.12 135.48 33.96 Favored 'General case' 0 N--CA 1.413 -2.302 0 N-CA-C 105.55 -2.019 . . . . 0.0 105.55 174.966 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.504 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 25.2 m -139.0 135.33 34.17 Favored 'General case' 0 C--N 1.262 -3.199 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 174.807 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.52 ' HB2' HG23 ' A' ' 52' ' ' ILE . 24.1 p-10 . . . . . 0 C--N 1.303 -1.446 0 CA-C-O 121.695 0.759 . . . . 0.0 110.909 -176.742 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 . . . . . 0 N--CA 1.43 -1.474 0 N-CA-C 107.243 -1.392 . . . . 0.0 107.243 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -132.48 144.89 50.76 Favored 'General case' 0 C--N 1.292 -1.911 0 C-N-CA 118.937 -1.105 . . . . 0.0 111.341 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 10.2 m-30 -109.24 127.52 54.32 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -177.078 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . 0.415 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 48.5 t -91.17 137.04 22.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 123.538 0.524 . . . . 0.0 110.18 -178.027 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 60.6 m95 -125.35 96.56 4.87 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 -178.084 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -81.56 114.44 20.27 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 178.146 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.464 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 20.9 mm -88.0 122.85 40.12 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -176.268 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . 0.416 ' CZ ' HD23 ' A' ' 125' ' ' LEU . 83.4 m-85 -119.01 152.92 35.53 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.822 178.584 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.12 129.6 35.04 Favored 'General case' 0 N--CA 1.407 -2.591 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 177.211 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 10.9 t-20 -90.47 -12.89 35.98 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 122.452 1.12 . . . . 0.0 108.082 -177.088 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -149.03 144.47 26.74 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 113.964 -1.471 . . . . 0.0 108.911 -175.133 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . 0.4 ' HB3' ' H ' ' A' ' 122' ' ' ALA . 17.3 p-10 -86.63 141.92 28.62 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 123.982 0.801 . . . . 0.0 111.762 -179.11 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.531 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 70.5 t -117.46 139.04 46.14 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 CA-C-N 115.228 -0.897 . . . . 0.0 111.632 -173.597 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -120.1 132.3 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 179.21 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.475 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 71.7 t -97.71 103.59 17.4 Favored Pre-proline 0 C--N 1.292 -1.904 0 C-N-CA 123.933 0.893 . . . . 0.0 109.927 179.909 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . 0.411 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 23.2 Cg_endo -68.15 -27.41 35.43 Favored 'Trans proline' 0 CA--C 1.509 -0.754 0 C-N-CA 121.978 1.786 . . . . 0.0 111.816 179.719 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 5.0 t . . . . . 0 CA--C 1.549 0.94 0 C-N-CA 124.706 1.202 . . . . 0.0 113.628 177.911 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 2' ' ' ALA . . . . . 0.478 ' HB3' ' CE1' ' A' ' 45' ' ' HIS . . . . . . . . 0 N--CA 1.436 -1.148 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.455 ' HB2' ' CZ2' ' A' ' 146' ' ' TRP . 64.4 m -144.99 168.47 20.2 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 120.193 -0.603 . . . . 0.0 110.726 -176.616 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . 0.455 ' HA ' ' O ' ' A' ' 9' ' ' THR . 0.3 OUTLIER -148.82 162.2 40.28 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 123.632 0.773 . . . . 0.0 109.477 178.868 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 5' ' ' THR . . . . . 0.501 HG22 HG22 ' A' ' 20' ' ' VAL . 71.9 p -100.24 175.86 5.58 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 121.394 0.616 . . . . 0.0 110.414 -179.744 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.29 -13.54 59.92 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-N 114.371 -1.286 . . . . 0.0 110.654 179.157 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -87.82 -34.31 18.3 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 118.895 -1.122 . . . . 0.0 108.63 175.265 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 134.19 7.2 2.29 Favored Glycine 0 N--CA 1.436 -1.304 0 C-N-CA 120.0 -1.095 . . . . 0.0 113.301 177.049 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.455 ' O ' ' HA ' ' A' ' 4' ' ' LYS . 5.1 m -76.55 99.28 4.91 Favored 'General case' 0 N--CA 1.442 -0.873 0 CA-C-N 117.601 0.7 . . . . 0.0 109.121 179.869 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.55 118.43 30.99 Favored 'General case' 0 C--N 1.294 -1.819 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.271 178.314 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.422 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 62.4 mt -96.53 118.79 64.98 Favored Pre-proline 0 C--N 1.302 -1.459 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 177.233 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -79.12 174.85 11.55 Favored 'Trans proline' 0 C--O 1.252 1.193 0 C-N-CA 122.637 2.224 . . . . 0.0 110.655 177.935 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 53.8 mt -71.99 119.85 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.247 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 177.217 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 151.76 -12.11 0.73 Allowed Glycine 0 C--N 1.291 -1.96 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -172.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 94.24 161.2 34.88 Favored Glycine 0 N--CA 1.433 -1.547 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 177.651 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 162.05 -167.92 36.9 Favored Glycine 0 CA--C 1.473 -2.564 0 C-N-CA 118.888 -1.625 . . . . 0.0 111.904 179.109 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 14.5 m -144.6 147.64 33.39 Favored 'General case' 0 C--N 1.286 -2.19 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 -179.386 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.22 156.44 48.98 Favored 'General case' 0 N--CA 1.426 -1.637 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 -179.134 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -104.78 111.02 23.6 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 179.91 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' VAL . . . . . 0.501 HG22 HG22 ' A' ' 5' ' ' THR . 41.3 t -98.68 139.59 20.26 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.901 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.347 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -128.66 119.09 24.04 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -177.288 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . 0.53 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.9 p -122.74 129.75 74.96 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-O 121.884 0.85 . . . . 0.0 111.089 -175.899 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -88.73 119.17 28.97 Favored 'General case' 0 C--N 1.291 -1.974 0 CA-C-N 114.847 -1.07 . . . . 0.0 109.439 179.546 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 27.8 mt -107.06 160.79 15.29 Favored 'General case' 0 C--N 1.28 -2.453 0 CA-C-N 114.625 -1.17 . . . . 0.0 109.185 -177.58 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.5 121.56 49.22 Favored Pre-proline 0 C--O 1.206 -1.2 0 O-C-N 124.01 0.819 . . . . 0.0 108.871 177.826 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 26' ' ' PRO . . . . . 0.557 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 60.1 Cg_endo -73.99 -2.47 12.32 Favored 'Trans proline' 0 CA--C 1.53 0.282 0 C-N-CA 122.786 2.324 . . . . 0.0 113.302 -175.627 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 96.0 t -127.83 109.96 21.04 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -179.308 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.421 HG21 HD22 ' A' ' 34' ' ' LEU . 5.8 t -146.57 106.74 0.66 Allowed 'Isoleucine or valine' 0 C--O 1.189 -2.114 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -178.035 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 29' ' ' ASN . . . . . 0.568 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -94.27 153.98 17.76 Favored 'General case' 0 C--N 1.277 -2.581 0 C-N-CA 123.246 0.618 . . . . 0.0 111.506 179.983 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.52 HG22 ' O ' ' A' ' 112' ' ' VAL . 85.5 t -50.66 118.98 0.84 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.738 0 C-N-CA 123.274 0.629 . . . . 0.0 111.051 179.405 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.37 7.88 50.92 Favored Glycine 0 C--N 1.309 -0.917 0 CA-C-N 114.98 -1.009 . . . . 0.0 112.138 -178.527 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . 0.568 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -78.66 -177.24 5.28 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 123.493 0.717 . . . . 0.0 109.633 173.09 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -132.93 92.4 3.03 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 177.984 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.68 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 23.9 tp -92.67 145.51 24.37 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 119.705 -0.798 . . . . 0.0 109.247 179.407 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.9 t -136.09 121.74 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.584 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -177.536 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.622 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 62.0 t -91.74 88.62 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.406 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 175.298 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -84.2 115.53 22.48 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 120.008 -0.677 . . . . 0.0 110.641 -178.681 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.4 mt -94.7 -1.23 53.43 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.718 -179.313 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 31.6 t -75.04 2.17 11.24 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.925 0.869 . . . . 0.0 109.477 178.797 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.5 p -129.25 4.26 5.21 Favored 'General case' 0 C--N 1.288 -2.074 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.46 176.348 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . 0.53 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 42.7 mm-40 -124.58 -20.8 5.01 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-O 121.091 0.472 . . . . 0.0 110.726 -174.651 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 26.8 mt -133.82 136.47 53.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.978 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -176.32 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.448 ' HA ' ' HA ' ' A' ' 102' ' ' PRO . 62.5 m-85 -133.49 139.75 46.84 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 -176.938 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 60.5 m -125.03 134.22 52.65 Favored 'General case' 0 C--N 1.272 -2.784 0 CA-C-O 121.273 0.559 . . . . 0.0 111.743 -177.783 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . 0.478 ' CE1' ' HB3' ' A' ' 2' ' ' ALA . 10.5 p80 -119.9 129.89 54.58 Favored 'General case' 0 C--N 1.295 -1.772 0 CA-C-O 121.816 0.817 . . . . 0.0 110.775 -178.118 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 46' ' ' ASN . . . . . 0.599 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 4.8 p-10 -97.84 95.0 7.23 Favored 'General case' 0 C--N 1.275 -2.658 0 CA-C-O 123.053 1.406 . . . . 0.0 107.567 178.317 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.54 -19.93 51.8 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-N 113.64 -1.618 . . . . 0.0 113.715 -172.304 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -135.24 65.05 62.77 Favored Pre-proline 0 C--N 1.313 -0.98 0 C-N-CA 120.147 -0.621 . . . . 0.0 110.947 178.758 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 49' ' ' PRO . . . . . 0.599 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 35.7 Cg_endo -64.98 -18.48 62.3 Favored 'Trans proline' 0 C--N 1.355 0.895 0 C-N-CA 123.182 2.588 . . . . 0.0 115.302 -171.213 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -108.14 -15.98 14.37 Favored 'General case' 0 C--N 1.289 -2.045 0 C-N-CA 119.66 -0.816 . . . . 0.0 110.641 -176.249 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 51' ' ' THR . . . . . 0.575 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -101.14 -31.22 11.14 Favored 'General case' 0 N--CA 1.415 -2.211 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 -174.11 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.575 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.2 mp -126.47 141.87 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.348 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 178.969 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 7.5 t -86.78 122.13 30.23 Favored 'General case' 0 N--CA 1.405 -2.698 0 N-CA-C 103.462 -2.792 . . . . 0.0 103.462 172.205 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 54' ' ' ASP . . . . . 0.482 ' OD2' ' HB2' ' A' ' 46' ' ' ASN . 17.1 m-20 -93.39 106.02 18.03 Favored 'General case' 0 C--N 1.256 -3.484 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 -175.125 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 55' ' ' TYR . . . . . 0.552 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 10.7 t80 -123.13 133.43 54.27 Favored 'General case' 0 C--N 1.285 -2.22 0 CA-C-N 113.852 -1.522 . . . . 0.0 109.974 -172.613 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.2 t -128.46 142.99 42.42 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 115.285 -0.87 . . . . 0.0 109.27 -174.966 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.12 128.93 12.46 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 123.715 0.634 . . . . 0.0 109.332 172.619 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.525 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 34.3 tp -71.2 102.86 2.63 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 173.353 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.5 tp-100 -56.22 -56.66 18.28 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 112.9 -1.954 . . . . 0.0 110.019 -176.928 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 6.1 ptp180 -158.76 151.14 21.61 Favored 'General case' 0 N--CA 1.41 -2.47 0 CA-C-N 114.251 -1.34 . . . . 0.0 108.197 -177.956 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.79 123.99 2.26 Favored Glycine 0 N--CA 1.405 -3.412 0 N-CA-C 108.611 -1.795 . . . . 0.0 108.611 -178.656 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.421 ' HA ' ' HB3' ' A' ' 85' ' ' PRO . 66.0 m -116.47 148.18 41.0 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 124.519 1.127 . . . . 0.0 110.83 -171.529 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 63' ' ' ALA . . . . . 0.511 ' HB1' HG23 ' A' ' 67' ' ' VAL . . . -107.72 154.99 20.68 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.266 1.026 . . . . 0.0 108.62 -179.852 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 64' ' ' TYR . . . . . 0.767 ' O ' HG22 ' A' ' 67' ' ' VAL . 87.4 m-85 -156.06 -179.35 8.05 Favored 'General case' 0 N--CA 1.483 1.193 0 CA-C-N 118.351 0.523 . . . . 0.0 111.852 -176.956 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.33 -122.0 26.22 Favored Glycine 0 C--N 1.319 -0.393 0 CA-C-N 116.281 -0.418 . . . . 0.0 113.068 178.384 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -91.06 -10.38 62.64 Favored Glycine 0 N--CA 1.417 -2.57 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.843 177.076 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.767 HG22 ' O ' ' A' ' 64' ' ' TYR . 12.5 m -76.77 -25.59 15.95 Favored 'Isoleucine or valine' 0 C--O 1.206 -1.23 0 CA-C-N 118.174 0.987 . . . . 0.0 112.289 -172.1 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.505 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -90.66 -23.75 20.68 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 121.495 0.664 . . . . 0.0 111.74 177.701 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 69' ' ' SER . . . . . 0.402 ' N ' HD12 ' A' ' 68' ' ' LEU . 21.7 m -102.03 -52.91 3.05 Favored 'General case' 0 C--N 1.305 -1.366 0 N-CA-C 113.943 1.09 . . . . 0.0 113.943 -175.226 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 70' ' ' ASN . . . . . 0.496 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 53.7 m-20 -88.09 -22.63 24.03 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 -177.41 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 71' ' ' PHE . . . . . 0.556 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 87.6 m-85 -115.48 164.12 14.75 Favored 'General case' 0 C--N 1.294 -1.842 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.944 179.832 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.3 t -172.63 134.22 0.63 Allowed 'General case' 0 N--CA 1.416 -2.13 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 177.266 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.613 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -165.58 -114.75 0.3 Allowed Glycine 0 N--CA 1.398 -3.847 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 173.401 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 74' ' ' THR . . . . . 0.411 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.0 OUTLIER -153.52 -179.85 8.15 Favored 'General case' 0 C--N 1.273 -2.728 0 C-N-CA 124.176 0.991 . . . . 0.0 110.113 -173.917 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -132.7 152.04 35.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 C-N-CA 122.714 0.406 . . . . 0.0 109.958 178.586 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 76' ' ' LYS . . . . . 0.636 ' HG3' ' O ' ' A' ' 80' ' ' SER . 81.4 tttt -129.04 145.67 51.2 Favored 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 123.79 0.836 . . . . 0.0 110.128 -179.475 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 77' ' ' TYR . . . . . 0.424 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 58.1 t80 -147.28 112.49 5.52 Favored 'General case' 0 C--N 1.314 -0.96 0 O-C-N 123.777 0.673 . . . . 0.0 109.301 -178.655 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 23.0 t 54.97 36.28 26.48 Favored 'General case' 0 CA--C 1.551 1.003 0 C-N-CA 123.627 0.771 . . . . 0.0 110.448 177.188 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.58 8.18 66.05 Favored Glycine 0 CA--C 1.529 0.941 0 CA-C-N 115.459 -0.791 . . . . 0.0 114.095 -179.421 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . 0.636 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 17.3 t -79.68 -179.52 6.94 Favored 'General case' 0 CA--C 1.543 0.682 0 CA-C-N 117.275 0.537 . . . . 0.0 109.994 -179.678 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 22.6 t -157.08 111.88 2.76 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 178.713 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 82' ' ' TYR . . . . . 0.433 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 2.6 p90 -154.6 161.42 29.4 Favored Pre-proline 0 CA--C 1.552 1.056 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -175.5 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . 0.433 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 54.0 Cg_endo -67.97 150.53 78.01 Favored 'Trans proline' 0 C--N 1.361 1.218 0 C-N-CA 122.884 2.389 . . . . 0.0 113.503 -176.761 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.474 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 57.8 t80 -126.39 132.65 24.4 Favored Pre-proline 0 N--CA 1.44 -0.967 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.067 179.785 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 85' ' ' PRO . . . . . 0.474 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 62.4 Cg_endo -69.95 147.07 84.29 Favored 'Cis proline' 0 CA--C 1.549 1.254 0 C-N-CA 123.125 -1.615 . . . . 0.0 111.16 -1.21 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.1 t -69.35 -176.98 1.04 Allowed 'General case' 0 CA--C 1.549 0.941 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.014 -175.294 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 14.1 p -127.41 -42.6 1.65 Allowed 'General case' 0 N--CA 1.432 -1.346 0 N-CA-C 112.799 0.666 . . . . 0.0 112.799 -172.418 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.6 t -108.12 -72.17 0.73 Allowed 'General case' 0 N--CA 1.432 -1.334 0 C-N-CA 119.74 -0.784 . . . . 0.0 111.527 -175.533 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 176.6 -177.42 0.14 Allowed 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 -174.991 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.525 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 43.5 p -101.32 168.44 9.15 Favored Pre-proline 0 C--N 1.295 -1.781 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 178.555 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 91' ' ' PRO . . . . . 0.443 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 12.1 Cg_endo -54.43 164.73 2.72 Favored 'Trans proline' 0 C--O 1.252 1.175 0 C-N-CA 123.162 2.574 . . . . 0.0 112.188 171.305 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.552 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 1.7 tmm_? -84.82 101.44 12.27 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.131 -172.625 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 87.6 t -114.14 121.22 65.84 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 CA-C-N 114.893 -1.049 . . . . 0.0 111.402 -176.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 93.5 t -108.28 142.29 21.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 CA-C-N 115.106 -0.952 . . . . 0.0 108.739 177.72 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -98.52 110.6 23.17 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 176.085 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 46.2 m-80 -108.46 32.16 5.05 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-O 121.708 0.766 . . . . 0.0 110.075 178.891 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.3 m -85.16 -172.53 4.22 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.375 -177.674 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 16.4 ptp180 -145.99 36.46 1.03 Allowed 'General case' 0 C--N 1.307 -1.242 0 CA-C-O 121.85 0.833 . . . . 0.0 109.688 178.079 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 12.4 t -168.89 177.69 4.88 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 105.435 -2.061 . . . . 0.0 105.435 -178.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . 0.413 ' CB ' ' HB3' ' A' ' 45' ' ' HIS . 1.5 p-10 -84.75 127.71 34.25 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 178.509 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 101' ' ' LYS . . . . . 0.549 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 6.5 mmpt? -117.66 147.34 40.72 Favored Pre-proline 0 C--N 1.28 -2.447 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.666 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 43' ' ' PHE . 31.0 Cg_endo -67.62 143.5 62.61 Favored 'Trans proline' 0 N--CA 1.44 -1.626 0 C-N-CA 122.375 2.05 . . . . 0.0 111.013 -178.718 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 14.7 t90 -80.81 107.95 8.76 Favored Pre-proline 0 C--N 1.305 -1.361 0 N-CA-C 106.595 -1.632 . . . . 0.0 106.595 -176.742 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -77.25 88.98 1.36 Allowed 'Trans proline' 0 N--CA 1.443 -1.459 0 C-N-CA 121.276 1.317 . . . . 0.0 112.683 -172.273 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 96.3 t -139.9 144.34 28.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 177.291 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 106' ' ' ALA . . . . . 0.622 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -147.84 134.47 19.87 Favored 'General case' 0 N--CA 1.419 -1.98 0 CA-C-O 120.785 0.326 . . . . 0.0 110.155 178.096 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 107' ' ' LEU . . . . . 0.469 HD21 HD11 ' A' ' 129' ' ' LEU . 17.7 mt -101.73 104.3 15.1 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.242 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 108' ' ' TYR . . . . . 0.613 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 16.5 m-85 -79.56 68.42 5.6 Favored 'General case' 0 C--N 1.287 -2.123 0 CA-C-O 120.514 0.197 . . . . 0.0 111.167 177.814 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.68 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -90.59 128.53 36.62 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 175.358 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.15 145.29 56.73 Favored Pre-proline 0 N--CA 1.416 -2.154 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.182 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 111' ' ' PRO . . . . . 0.496 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 30.7 Cg_endo -63.17 124.5 14.01 Favored 'Trans proline' 0 CA--C 1.498 -1.3 0 C-N-CA 122.927 2.418 . . . . 0.0 113.936 -176.24 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 112' ' ' VAL . . . . . 0.52 ' O ' HG22 ' A' ' 30' ' ' VAL . 19.5 m -86.36 -158.67 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.391 -3.419 0 CA-C-N 114.242 -1.345 . . . . 0.0 108.19 171.187 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 44.9 m -81.2 -22.35 38.91 Favored 'General case' 0 C--N 1.254 -3.575 0 O-C-N 121.636 -0.665 . . . . 0.0 111.069 -171.792 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.3 t -81.8 12.19 4.21 Favored 'General case' 0 CA--C 1.549 0.931 0 CA-C-O 121.771 0.796 . . . . 0.0 109.977 179.491 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.477 ' HB2' ' O ' ' A' ' 70' ' ' ASN . . . -98.98 135.42 40.41 Favored 'General case' 0 N--CA 1.419 -2.017 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.455 -179.708 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -179.82 122.96 0.81 Allowed Glycine 0 C--O 1.245 0.842 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 179.266 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 70.0 -155.01 53.09 Favored Glycine 0 C--N 1.307 -1.075 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 -174.922 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.1 p -53.88 106.86 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 122.541 1.162 . . . . 0.0 112.123 -178.174 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -108.56 -22.04 12.45 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 114.302 -1.317 . . . . 0.0 111.159 -176.848 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 120' ' ' ILE . . . . . 0.549 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.2 mt -136.34 133.47 49.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.053 0 N-CA-C 107.516 -1.291 . . . . 0.0 107.516 178.341 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.435 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.0 mmpt? -111.53 139.09 47.25 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 177.384 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.32 125.96 27.75 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 177.922 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 101.36 -10.77 58.14 Favored Glycine 0 N--CA 1.428 -1.885 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.298 -178.089 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 97.8 p -94.05 148.64 21.97 Favored 'General case' 0 C--O 1.252 1.22 0 C-N-CA 119.861 -0.736 . . . . 0.0 110.241 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . 0.445 HD11 HG23 ' A' ' 128' ' ' VAL . 3.0 tm? -76.35 124.15 27.06 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-N 115.011 -0.995 . . . . 0.0 108.878 -179.202 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 126' ' ' ILE . . . . . 0.582 ' HB ' HG11 ' A' ' 67' ' ' VAL . 27.6 pt -108.38 -29.92 2.53 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.389 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.878 179.901 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 127' ' ' ALA . . . . . 0.446 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -157.97 165.5 34.99 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.605 -0.838 . . . . 0.0 110.376 -176.595 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.445 HG23 HD11 ' A' ' 125' ' ' LEU . 64.4 t -139.6 114.18 7.37 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.796 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 177.929 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . 0.469 HD11 HD21 ' A' ' 107' ' ' LEU . 40.0 mt -119.58 145.49 46.35 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 5.4 mp -129.64 128.85 66.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 C-N-CA 120.324 -0.551 . . . . 0.0 110.078 177.155 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 131' ' ' LEU . . . . . 0.432 ' C ' HD12 ' A' ' 131' ' ' LEU . 1.5 pp -92.62 138.31 31.61 Favored 'General case' 0 N--CA 1.424 -1.733 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 172.856 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 132' ' ' ARG . . . . . 0.449 ' HE ' ' HB3' ' A' ' 143' ' ' GLN . 3.9 tpm_? -97.24 112.95 24.52 Favored 'General case' 0 C--N 1.249 -3.803 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 176.256 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.1 130.46 40.26 Favored 'General case' 0 N--CA 1.422 -1.849 0 N-CA-C 104.991 -2.226 . . . . 0.0 104.991 177.686 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 63.6 m -137.92 138.65 39.22 Favored 'General case' 0 C--N 1.273 -2.731 0 C-N-CA 120.396 -0.522 . . . . 0.0 110.179 174.277 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.489 ' CB ' HG23 ' A' ' 52' ' ' ILE . 20.0 p30 . . . . . 0 C--N 1.306 -1.302 0 CA-C-O 121.524 0.678 . . . . 0.0 112.051 -175.717 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 . . . . . 0 N--CA 1.436 -1.174 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 143' ' ' GLN . . . . . 0.449 ' HB3' ' HE ' ' A' ' 132' ' ' ARG . 13.7 pt20 -130.22 141.32 50.65 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.647 179.884 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 7.0 m-30 -104.6 127.99 52.48 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 -175.575 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 57.6 t -93.24 136.24 25.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -178.923 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 146' ' ' TRP . . . . . 0.455 ' CZ2' ' HB2' ' A' ' 3' ' ' CYS . 66.9 m95 -123.87 95.79 4.7 Favored 'General case' 0 C--N 1.281 -2.381 0 N-CA-C 108.272 -1.011 . . . . 0.0 108.272 -177.19 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -80.94 114.17 19.64 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 177.961 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 148' ' ' ILE . . . . . 0.449 HG22 HD11 ' A' ' 126' ' ' ILE . 22.6 mm -89.92 122.03 40.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 -175.785 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -118.14 157.99 25.89 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 178.241 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.6 131.89 35.29 Favored 'General case' 0 N--CA 1.407 -2.599 0 CA-C-N 115.002 -0.999 . . . . 0.0 108.523 176.216 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 34.2 t-20 -95.52 -8.96 33.76 Favored 'General case' 0 C--N 1.29 -2.007 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 -178.401 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 3.4 t30 -153.79 145.43 23.31 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 113.869 -1.514 . . . . 0.0 108.713 -175.959 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -84.8 140.41 31.23 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 124.138 0.899 . . . . 0.0 111.198 -178.539 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.557 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 70.3 t -118.17 134.66 61.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.015 -176.653 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.1 t -119.24 133.08 67.21 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.545 0 N-CA-C 107.178 -1.415 . . . . 0.0 107.178 -179.966 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 156' ' ' VAL . . . . . 0.453 HG12 ' HB ' ' A' ' 158' ' ' THR . 75.2 t -97.65 102.64 13.66 Favored Pre-proline 0 C--N 1.289 -2.033 0 C-N-CA 123.375 0.67 . . . . 0.0 109.962 179.389 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -70.58 -24.55 25.8 Favored 'Trans proline' 0 CA--C 1.516 -0.403 0 C-N-CA 121.87 1.714 . . . . 0.0 111.584 -179.261 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 158' ' ' THR . . . . . 0.453 ' HB ' HG12 ' A' ' 156' ' ' VAL . 7.3 t . . . . . 0 CA--C 1.545 0.779 0 C-N-CA 125.303 1.441 . . . . 0.0 112.723 176.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 37.1 t80 . . . . . 0 CA--C 1.496 -1.11 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.62 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -141.11 -171.3 3.24 Favored 'General case' 0 C--N 1.296 -1.748 0 CA-C-N 115.212 -0.904 . . . . 0.0 109.876 -173.349 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 15.7 t -152.15 158.31 42.75 Favored 'General case' 0 C--N 1.303 -1.426 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 -176.747 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.612 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -143.38 161.54 38.11 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-O 121.178 0.513 . . . . 0.0 111.208 -174.271 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 74.9 p -100.38 175.98 5.52 Favored 'General case' 0 C--N 1.314 -0.955 0 CA-C-O 121.383 0.611 . . . . 0.0 110.653 179.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -76.41 -19.52 58.02 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.776 178.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 6.2 p30 -83.52 -34.0 25.38 Favored 'General case' 0 CA--C 1.514 -0.433 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.732 -179.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 130.32 27.31 0.76 Allowed Glycine 0 N--CA 1.441 -1.022 0 C-N-CA 119.907 -1.139 . . . . 0.0 112.348 177.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.403 ' O ' ' HA ' ' A' ' 4' ' ' LYS . 9.2 m -99.82 99.37 10.16 Favored 'General case' 0 N--CA 1.423 -1.816 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 177.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.5 122.57 35.06 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 107.983 -1.118 . . . . 0.0 107.983 176.109 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.62 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 65.3 mt -97.63 117.59 65.14 Favored Pre-proline 0 C--N 1.294 -1.817 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 178.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -75.33 171.36 18.41 Favored 'Trans proline' 0 C--O 1.245 0.845 0 C-N-CA 122.62 2.213 . . . . 0.0 111.673 178.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 69.6 mt -67.17 127.57 28.95 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.568 179.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 138.37 0.66 2.35 Favored Glycine 0 C--N 1.303 -1.3 0 C-N-CA 120.852 -0.69 . . . . 0.0 111.957 -177.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.49 168.87 43.72 Favored Glycine 0 N--CA 1.427 -1.921 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -178.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 155.49 -165.3 32.4 Favored Glycine 0 C--N 1.288 -2.135 0 C-N-CA 120.06 -1.067 . . . . 0.0 110.879 178.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.475 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 58.1 p -150.28 147.06 27.19 Favored 'General case' 0 N--CA 1.422 -1.868 0 CA-C-N 116.844 0.322 . . . . 0.0 110.373 -177.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -132.43 163.52 28.58 Favored 'General case' 0 N--CA 1.428 -1.556 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 178.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 18.1 m-80 -116.71 107.52 14.78 Favored 'General case' 0 C--N 1.292 -1.929 0 N-CA-C 106.997 -1.482 . . . . 0.0 106.997 178.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.427 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.4 m -91.44 150.07 3.89 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.35 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -179.403 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 62.5 m-85 -131.92 112.16 12.18 Favored 'General case' 0 CA--C 1.485 -1.537 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 -177.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.541 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 4.5 p -117.1 132.4 66.97 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.293 0 CA-C-O 121.815 0.817 . . . . 0.0 111.535 -173.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.456 ' HB3' ' HB3' ' A' ' 151' ' ' ASN . 2.1 p30 -98.12 123.57 42.23 Favored 'General case' 0 C--N 1.286 -2.176 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.171 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.403 HD11 ' HA ' ' A' ' 36' ' ' VAL . 2.5 mm? -106.83 160.55 15.42 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 114.408 -1.269 . . . . 0.0 108.051 -178.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -54.92 121.46 35.31 Favored Pre-proline 0 C--N 1.308 -1.233 0 O-C-N 124.381 1.051 . . . . 0.0 109.284 175.501 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 63.8 Cg_endo -74.79 1.47 7.57 Favored 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 122.926 2.417 . . . . 0.0 113.035 -177.274 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.464 HG13 ' HG3' ' A' ' 157' ' ' PRO . 86.0 t -128.82 110.11 20.33 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 178.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.511 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 4.5 t -145.96 111.65 1.06 Allowed 'Isoleucine or valine' 0 C--O 1.185 -2.293 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 -179.352 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.59 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -100.57 152.52 20.32 Favored 'General case' 0 C--N 1.267 -2.998 0 C-N-CA 122.707 0.403 . . . . 0.0 111.381 -178.236 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.403 HG13 ' O ' ' A' ' 112' ' ' VAL . 38.9 t -46.37 113.85 0.17 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.612 0 C-N-CA 123.314 0.646 . . . . 0.0 111.596 176.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 105.29 3.73 41.19 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 114.929 -1.032 . . . . 0.0 112.855 -179.375 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.59 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -76.29 -177.35 4.01 Favored 'General case' 0 C--N 1.311 -1.069 0 C-N-CA 123.911 0.884 . . . . 0.0 110.067 175.641 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -133.54 91.59 2.87 Favored 'General case' 0 C--N 1.308 -1.21 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 177.11 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.673 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 28.4 tp -91.58 144.41 25.57 Favored 'General case' 0 C--N 1.292 -1.934 0 C-N-CA 119.964 -0.694 . . . . 0.0 109.781 -179.035 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 60.0 t -136.16 125.0 37.86 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.456 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 -177.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.572 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 60.8 t -91.19 88.82 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.523 0 N-CA-C 106.763 -1.569 . . . . 0.0 106.763 175.246 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -77.84 114.62 16.87 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -178.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 75.6 mt -98.0 -1.4 42.73 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-O 121.577 0.703 . . . . 0.0 110.983 -178.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.566 ' OG ' ' HA ' ' A' ' 104' ' ' PRO . 22.6 m -80.61 0.66 33.12 Favored 'General case' 0 C--N 1.29 -1.982 0 CA-C-O 122.321 1.058 . . . . 0.0 110.166 -178.322 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.2 p -121.59 4.07 10.13 Favored 'General case' 0 N--CA 1.417 -2.123 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.646 176.074 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.541 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 44.4 mm-40 -125.32 -21.87 4.48 Favored 'General case' 0 C--O 1.239 0.528 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.128 -174.317 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 30.8 mt -135.24 138.22 48.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.796 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -175.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.612 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 38.9 m-85 -143.43 130.38 20.55 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -176.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 73.3 m -109.48 151.11 27.15 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 120.976 0.417 . . . . 0.0 110.263 -178.572 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 7.6 p80 -138.06 129.98 28.49 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.72 0.771 . . . . 0.0 112.034 -175.141 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 46.7 t30 -99.43 99.85 10.81 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.195 -1.002 . . . . 0.0 109.98 176.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -72.37 -12.3 61.06 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 113.771 -1.559 . . . . 0.0 111.231 -176.633 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -127.6 71.17 77.39 Favored Pre-proline 0 C--N 1.32 -0.689 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -70.27 -13.14 33.06 Favored 'Trans proline' 0 C--N 1.332 -0.302 0 C-N-CA 122.491 2.127 . . . . 0.0 113.836 -172.425 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -110.77 -16.89 13.48 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.354 0.597 . . . . 0.0 110.167 -177.471 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.562 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.6 OUTLIER -102.4 -30.94 10.73 Favored 'General case' 0 N--CA 1.404 -2.747 0 CA-C-O 121.648 0.737 . . . . 0.0 109.194 -171.476 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.694 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.5 mp -127.93 135.76 62.08 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.962 0 CA-C-N 114.97 -1.014 . . . . 0.0 109.071 -176.401 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.9 t -77.73 142.14 38.89 Favored 'General case' 0 C--O 1.248 1.014 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 175.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -82.44 107.29 14.98 Favored 'General case' 0 C--N 1.286 -2.187 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 -175.349 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 31.8 t80 -144.88 137.04 26.0 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-O 120.761 0.315 . . . . 0.0 110.476 -176.027 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.408 HG23 ' HG ' ' A' ' 131' ' ' LEU . 11.9 p -150.02 150.56 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.46 0 CA-C-N 116.308 -0.406 . . . . 0.0 109.951 179.642 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.29 136.21 18.48 Favored 'General case' 0 C--N 1.311 -1.073 0 C-N-CA 123.298 0.639 . . . . 0.0 109.401 176.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.533 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 43.5 tp -73.85 115.5 13.36 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 171.872 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.604 ' NE2' ' HD3' ' A' ' 132' ' ' ARG . 3.4 tp-100 -59.56 -51.32 70.33 Favored 'General case' 0 C--N 1.312 -1.064 0 C-N-CA 124.764 1.226 . . . . 0.0 111.588 178.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 9.4 ptp180 -171.51 160.42 5.92 Favored 'General case' 0 CA--C 1.5 -0.969 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 -174.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -139.27 146.78 18.54 Favored Glycine 0 N--CA 1.404 -3.454 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 64.4 m -131.48 150.66 52.07 Favored 'General case' 0 C--N 1.285 -2.231 0 C-N-CA 123.455 0.702 . . . . 0.0 109.568 -177.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.549 ' HB2' ' CE2' ' A' ' 84' ' ' PHE . . . -117.3 154.51 31.11 Favored 'General case' 0 CA--C 1.5 -0.977 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 -178.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.452 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . 90.9 m-85 -154.4 -179.5 8.0 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 123.71 0.804 . . . . 0.0 109.487 -178.33 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 63.84 -130.97 39.9 Favored Glycine 0 CA--C 1.507 -0.421 0 CA-C-N 116.305 -0.407 . . . . 0.0 113.287 176.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -90.07 -6.28 69.46 Favored Glycine 0 C--O 1.199 -2.065 0 C-N-CA 120.523 -0.846 . . . . 0.0 111.187 176.14 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.757 HG21 ' HB ' ' A' ' 126' ' ' ILE . 76.5 t -70.81 -41.63 77.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 122.867 0.467 . . . . 0.0 111.309 -176.442 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.521 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -82.13 -24.67 34.95 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 121.452 0.644 . . . . 0.0 112.367 -179.999 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 28.5 m -101.29 -50.82 3.66 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 114.269 1.211 . . . . 0.0 114.269 -173.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.459 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 67.4 m-20 -89.87 -23.76 21.56 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 109.118 -0.697 . . . . 0.0 109.118 -176.141 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.674 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 86.1 m-85 -112.35 162.17 15.85 Favored 'General case' 0 N--CA 1.427 -1.601 0 CA-C-O 121.75 0.786 . . . . 0.0 111.42 179.686 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.502 ' HB2' HG13 ' A' ' 112' ' ' VAL . 5.5 m -165.94 140.24 4.52 Favored 'General case' 0 N--CA 1.4 -2.969 0 C-N-CA 125.906 1.683 . . . . 0.0 109.177 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.441 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -172.73 -100.35 0.13 Allowed Glycine 0 C--N 1.279 -2.629 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 174.14 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.427 HG23 ' O ' ' A' ' 73' ' ' GLY . 1.1 p -169.94 179.41 3.62 Favored 'General case' 0 C--N 1.313 -0.982 0 C-N-CA 125.655 1.582 . . . . 0.0 109.365 -179.468 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.403 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.5 p -127.96 144.93 36.11 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.788 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 177.475 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.615 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.9 tttt -124.91 143.9 50.62 Favored 'General case' 0 N--CA 1.416 -2.13 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.456 -176.013 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.446 ' CD2' HG22 ' A' ' 105' ' ' VAL . 51.8 t80 -146.69 110.23 4.86 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 114.94 -1.027 . . . . 0.0 108.453 -178.467 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 32.7 t 54.76 39.47 31.39 Favored 'General case' 0 CA--C 1.556 1.202 0 CA-C-O 122.341 1.067 . . . . 0.0 110.86 177.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.5 16.93 69.79 Favored Glycine 0 N--CA 1.438 -1.196 0 CA-C-N 115.416 -0.811 . . . . 0.0 113.191 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.615 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 10.8 t -84.99 -179.74 7.12 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 108.118 -1.068 . . . . 0.0 108.118 175.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 23.0 t -160.25 97.57 1.25 Allowed 'General case' 0 C--N 1.29 -2.008 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 -178.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.429 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 3.2 p90 -138.75 159.17 68.38 Favored Pre-proline 0 C--N 1.296 -1.732 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 -174.116 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.406 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 55.4 Cg_endo -68.47 147.27 70.65 Favored 'Trans proline' 0 C--N 1.352 0.729 0 C-N-CA 122.406 2.07 . . . . 0.0 112.799 -174.252 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.618 ' CD2' HD21 ' A' ' 109' ' ' LEU . 63.0 t80 -121.63 130.93 24.56 Favored Pre-proline 0 C--N 1.305 -1.339 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.17 -179.793 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.466 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 73.4 Cg_endo -73.79 147.63 90.04 Favored 'Cis proline' 0 C--O 1.25 1.087 0 C-N-CA 123.117 -1.618 . . . . 0.0 110.093 -2.331 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.6 t -68.16 -177.06 0.8 Allowed 'General case' 0 CA--C 1.548 0.877 0 CA-C-N 115.622 -0.717 . . . . 0.0 111.259 -174.772 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 18.9 p -123.42 -12.44 7.76 Favored 'General case' 0 N--CA 1.435 -1.185 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.279 -173.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.8 t -152.05 -124.33 0.04 OUTLIER 'General case' 0 N--CA 1.393 -3.282 0 N-CA-C 106.83 -1.544 . . . . 0.0 106.83 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -126.9 -169.15 1.98 Allowed 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 112.249 0.463 . . . . 0.0 112.249 -173.041 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 45.3 p -100.42 170.67 6.36 Favored Pre-proline 0 C--N 1.313 -0.983 0 C-N-CA 123.302 0.641 . . . . 0.0 112.685 179.058 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . 0.447 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 19.6 Cg_endo -59.53 166.09 8.47 Favored 'Trans proline' 0 C--O 1.246 0.904 0 C-N-CA 122.976 2.451 . . . . 0.0 111.779 170.46 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.1 tmm_? -80.58 117.99 21.77 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 -178.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 69.2 t -127.58 128.51 69.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 CA-C-O 121.353 0.597 . . . . 0.0 111.41 -175.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 81.4 t -106.18 138.31 32.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.554 179.536 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.433 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 3.1 m-85 -87.59 116.66 25.86 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 175.054 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -97.72 45.25 1.03 Allowed 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 57.7 m -151.77 125.29 8.9 Favored 'General case' 0 N--CA 1.433 -1.298 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.733 -176.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 10.6 ptp180 -102.22 64.02 0.91 Allowed 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 122.044 0.926 . . . . 0.0 111.159 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.8 t -171.22 172.87 5.14 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 106.312 -1.736 . . . . 0.0 106.312 -178.438 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -65.12 100.78 0.46 Allowed 'General case' 0 C--N 1.324 -0.508 0 O-C-N 123.71 0.631 . . . . 0.0 110.049 -179.485 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -111.76 138.54 21.61 Favored Pre-proline 0 C--N 1.293 -1.863 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 178.151 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -56.08 148.39 59.17 Favored 'Trans proline' 0 C--O 1.246 0.897 0 C-N-CA 123.27 2.647 . . . . 0.0 112.633 179.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . 0.433 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.4 t90 -88.9 112.34 50.12 Favored Pre-proline 0 C--N 1.293 -1.849 0 N-CA-C 106.915 -1.513 . . . . 0.0 106.915 -179.357 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.566 ' HA ' ' OG ' ' A' ' 39' ' ' SER . 68.0 Cg_endo -75.58 87.57 1.36 Allowed 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 121.816 1.677 . . . . 0.0 112.426 -173.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.446 HG22 ' CD2' ' A' ' 77' ' ' TYR . 67.0 t -144.61 143.48 22.88 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.435 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 -179.396 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.572 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.14 135.72 17.09 Favored 'General case' 0 N--CA 1.415 -2.214 0 O-C-N 123.705 0.628 . . . . 0.0 110.285 177.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.492 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 15.4 mt -100.83 104.71 15.95 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 178.066 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.441 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 12.4 m-85 -81.03 91.92 6.15 Favored 'General case' 0 C--N 1.285 -2.231 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 177.203 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.674 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 2.9 mm? -118.87 120.51 37.53 Favored 'General case' 0 C--N 1.292 -1.932 0 CA-C-O 120.742 0.306 . . . . 0.0 110.179 178.128 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.35 145.78 47.59 Favored Pre-proline 0 N--CA 1.413 -2.306 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.997 -175.085 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.459 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 25.7 Cg_endo -61.7 119.57 6.77 Favored 'Trans proline' 0 C--O 1.247 0.972 0 C-N-CA 123.202 2.601 . . . . 0.0 112.21 -177.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.502 HG13 ' HB2' ' A' ' 72' ' ' SER . 3.6 m -67.74 -117.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.188 -2.173 0 CA-C-N 114.09 -1.414 . . . . 0.0 113.081 175.57 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 41.3 t -112.67 -39.54 4.29 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 178.164 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 66.6 m -78.73 30.35 0.2 Allowed 'General case' 0 N--CA 1.392 -3.356 0 CA-C-N 113.596 -1.638 . . . . 0.0 112.952 -177.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -111.06 140.09 45.89 Favored 'General case' 0 N--CA 1.411 -2.399 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 177.29 128.27 1.13 Allowed Glycine 0 N--CA 1.438 -1.173 0 N-CA-C 111.385 -0.686 . . . . 0.0 111.385 -178.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 65.83 -149.13 51.46 Favored Glycine 0 N--CA 1.443 -0.874 0 CA-C-O 119.02 -0.878 . . . . 0.0 111.408 -176.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -54.51 105.8 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 CA-C-O 122.645 1.212 . . . . 0.0 112.741 -177.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.55 -31.44 9.44 Favored 'General case' 0 C--N 1.295 -1.789 0 CA-C-N 114.735 -1.12 . . . . 0.0 110.936 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.439 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 54.9 mt -128.18 140.07 50.18 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 -179.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.461 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.7 mmpt? -115.12 133.9 55.63 Favored 'General case' 0 C--N 1.313 -1.009 0 C-N-CA 122.959 0.504 . . . . 0.0 111.584 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.18 133.34 48.71 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.651 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 86.06 0.35 87.21 Favored Glycine 0 C--O 1.242 0.624 0 C-N-CA 121.282 -0.485 . . . . 0.0 112.203 179.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 19.9 t -101.93 151.06 22.56 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 -178.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -77.92 123.69 27.09 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 -178.328 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.757 ' HB ' HG21 ' A' ' 67' ' ' VAL . 35.1 pt -110.08 -25.83 3.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 N-CA-C 112.578 0.585 . . . . 0.0 112.578 -178.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . 0.428 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -162.02 168.97 21.87 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -178.236 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 70.3 t -143.5 115.82 2.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 107.927 -1.138 . . . . 0.0 107.927 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.485 HD11 HD21 ' A' ' 107' ' ' LEU . 68.7 mt -117.79 146.9 43.49 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 178.141 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.531 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.6 mp -125.28 128.35 72.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 C-N-CA 119.727 -0.789 . . . . 0.0 110.42 177.475 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.537 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.0 OUTLIER -102.28 136.42 42.14 Favored 'General case' 0 C--N 1.29 -2.0 0 C-N-CA 123.664 0.786 . . . . 0.0 111.998 -177.352 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.604 ' HD3' ' NE2' ' A' ' 59' ' ' GLN . 30.2 mmm180 -95.93 119.36 34.28 Favored 'General case' 0 C--N 1.294 -1.838 0 C-N-CA 124.365 1.066 . . . . 0.0 110.643 -179.83 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.596 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 15.7 mm-40 -102.63 113.87 27.61 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 107.131 -1.433 . . . . 0.0 107.131 172.455 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 33.2 m -140.17 144.32 36.57 Favored 'General case' 0 C--N 1.289 -2.057 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -177.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.694 ' CB ' HG23 ' A' ' 52' ' ' ILE . 11.6 p30 -142.8 167.96 20.84 Favored 'General case' 0 N--CA 1.435 -1.18 0 C-N-CA 120.059 -0.656 . . . . 0.0 111.161 179.531 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -84.37 -17.26 39.98 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 113.421 -1.718 . . . . 0.0 112.43 -171.128 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 53.9 t80 -97.81 -67.58 0.84 Allowed 'General case' 0 C--N 1.294 -1.82 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.822 -171.042 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 70.4 m-20 -83.1 -31.12 27.44 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-O 121.343 0.592 . . . . 0.0 111.28 -176.739 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 25.0 t 62.46 27.96 16.56 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 113.958 -1.474 . . . . 0.0 110.242 -177.32 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . 0.4 ' HB2' ' CE2' ' A' ' 142' ' ' PHE . 11.8 p-10 -79.45 72.88 6.11 Favored 'General case' 0 N--CA 1.448 -0.529 0 CA-C-O 122.854 1.312 . . . . 0.0 109.825 177.448 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . 0.596 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 10.0 p-10 -78.28 72.74 4.82 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 113.362 -1.744 . . . . 0.0 113.01 -174.34 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . 0.4 ' CE2' ' HB2' ' A' ' 140' ' ' ASP . 74.6 m-85 -93.09 156.86 16.6 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 176.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 12.9 pt20 -125.71 146.78 49.6 Favored 'General case' 0 N--CA 1.418 -2.065 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.487 -179.721 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.415 ' HB2' HD22 ' A' ' 131' ' ' LEU . 12.3 m-30 -112.51 133.01 54.8 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 108.577 -0.898 . . . . 0.0 108.577 -176.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.475 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 59.5 t -89.87 133.74 30.98 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 178.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . 0.537 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 70.3 m95 -121.84 97.04 5.31 Favored 'General case' 0 C--N 1.284 -2.281 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 -179.112 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 45.0 m-80 -79.17 114.99 18.55 Favored 'General case' 0 C--N 1.288 -2.08 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 178.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.428 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 24.7 mm -88.36 120.62 37.55 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 -177.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -116.77 154.54 30.48 Favored 'General case' 0 CA--C 1.49 -1.328 0 C-N-CA 123.278 0.631 . . . . 0.0 110.012 178.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.44 129.38 34.62 Favored 'General case' 0 N--CA 1.417 -2.123 0 CA-C-N 115.221 -0.899 . . . . 0.0 109.075 176.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . 0.456 ' HB3' ' HB3' ' A' ' 23' ' ' ASN . 13.3 t-20 -87.75 -17.19 32.21 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 -178.282 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -153.47 144.04 22.54 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 113.708 -1.587 . . . . 0.0 109.507 -173.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -80.87 144.97 31.59 Favored 'General case' 0 C--N 1.317 -0.836 0 O-C-N 124.059 0.85 . . . . 0.0 109.838 179.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.453 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 74.4 t -121.92 139.26 49.51 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.74 0 C-N-CA 122.741 0.416 . . . . 0.0 111.391 -176.156 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.9 t -118.66 141.04 40.17 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 N-CA-C 108.377 -0.971 . . . . 0.0 108.377 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 73.2 t -104.05 100.97 23.07 Favored Pre-proline 0 C--N 1.296 -1.719 0 C-N-CA 123.51 0.724 . . . . 0.0 110.116 178.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.464 ' HG3' HG13 ' A' ' 27' ' ' VAL . 33.3 Cg_endo -69.23 -23.99 32.62 Favored 'Trans proline' 0 C--O 1.236 0.402 0 C-N-CA 122.35 2.033 . . . . 0.0 111.84 178.68 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.4 t . . . . . 0 C--O 1.239 0.536 0 C-N-CA 125.077 1.351 . . . . 0.0 113.772 177.502 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 44.2 t80 . . . . . 0 CA--C 1.482 -1.666 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.512 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -138.57 -177.49 4.88 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 13.7 t -152.06 159.06 43.78 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.391 -0.924 . . . . 0.0 109.848 -176.156 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.513 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -147.0 155.48 42.28 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 121.29 0.567 . . . . 0.0 110.549 -176.352 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 41.2 p -92.43 174.51 7.25 Favored 'General case' 0 C--N 1.293 -1.878 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.222 178.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.99 -19.53 47.61 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.053 -179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -85.08 -33.81 22.36 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 114.784 -1.098 . . . . 0.0 111.856 -176.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 136.36 5.71 2.0 Favored Glycine 0 N--CA 1.446 -0.641 0 C-N-CA 119.649 -1.262 . . . . 0.0 113.733 173.259 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.9 m -89.33 105.5 17.84 Favored 'General case' 0 N--CA 1.423 -1.782 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -103.47 115.71 31.05 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.026 179.635 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.512 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 55.6 mt -90.69 127.83 50.82 Favored Pre-proline 0 C--N 1.295 -1.763 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.735 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo -86.01 179.62 3.64 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 122.83 2.353 . . . . 0.0 111.546 177.054 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 58.6 mt -69.42 133.79 31.27 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 177.071 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 127.6 9.24 4.05 Favored Glycine 0 C--N 1.306 -1.13 0 C-N-CA 120.633 -0.794 . . . . 0.0 111.873 -179.099 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.22 170.19 44.57 Favored Glycine 0 N--CA 1.437 -1.267 0 N-CA-C 111.386 -0.686 . . . . 0.0 111.386 -177.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.71 -173.85 35.72 Favored Glycine 0 CA--C 1.48 -2.147 0 C-N-CA 119.911 -1.138 . . . . 0.0 111.414 177.836 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 52.5 p -142.29 144.62 33.35 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 -179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -133.21 167.09 21.0 Favored 'General case' 0 N--CA 1.423 -1.793 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 178.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -120.05 104.69 10.34 Favored 'General case' 0 C--N 1.266 -3.025 0 CA-C-N 114.258 -1.337 . . . . 0.0 108.402 178.522 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.409 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.2 m -89.72 146.78 5.76 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 -178.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 51.6 m-85 -128.17 115.72 18.82 Favored 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 120.859 0.361 . . . . 0.0 111.18 -177.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.526 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.6 p -123.35 129.67 74.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 CA-C-O 121.663 0.744 . . . . 0.0 111.201 -176.013 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.3 p30 -86.85 123.42 31.97 Favored 'General case' 0 C--N 1.293 -1.855 0 CA-C-N 115.007 -0.997 . . . . 0.0 108.851 177.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 19.5 mt -108.2 160.38 15.88 Favored 'General case' 0 C--N 1.275 -2.656 0 CA-C-N 114.661 -1.154 . . . . 0.0 108.162 -178.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -59.3 118.7 32.75 Favored Pre-proline 0 C--N 1.305 -1.366 0 O-C-N 124.004 0.815 . . . . 0.0 109.869 179.228 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.552 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 56.3 Cg_endo -70.06 -5.22 15.89 Favored 'Trans proline' 0 CA--C 1.54 0.822 0 C-N-CA 122.819 2.346 . . . . 0.0 113.752 -175.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.408 HG13 ' HG3' ' A' ' 157' ' ' PRO . 86.2 t -128.16 111.76 25.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 179.439 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.48 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 10.6 t -146.49 110.58 0.87 Allowed 'Isoleucine or valine' 0 C--O 1.191 -2.014 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -178.059 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.766 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -96.53 155.73 16.64 Favored 'General case' 0 C--N 1.278 -2.51 0 C-N-CA 124.009 0.924 . . . . 0.0 111.404 -178.678 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.626 HG22 ' O ' ' A' ' 112' ' ' VAL . 89.2 t -46.41 122.88 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 123.121 0.568 . . . . 0.0 111.358 176.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.11 4.8 61.13 Favored Glycine 0 C--N 1.31 -0.911 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.498 178.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.766 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -77.35 -176.26 4.08 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 124.345 1.058 . . . . 0.0 109.648 177.673 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -132.48 92.11 3.03 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.572 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 21.9 tp -93.67 142.7 27.06 Favored 'General case' 0 C--N 1.299 -1.63 0 C-N-CA 120.04 -0.664 . . . . 0.0 109.408 178.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 52.7 t -134.97 118.47 24.68 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.967 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 -175.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.59 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 48.7 t -90.6 88.1 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.876 0 N-CA-C 105.586 -2.005 . . . . 0.0 105.586 174.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -85.4 112.41 20.83 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-O 120.973 0.416 . . . . 0.0 110.598 -177.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 83.6 mt -96.11 -3.13 45.16 Favored 'General case' 0 C--N 1.299 -1.627 0 CA-C-N 115.006 -0.997 . . . . 0.0 110.419 -177.639 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.606 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 1.9 m -73.42 1.1 10.42 Favored 'General case' 0 CA--C 1.55 0.955 0 CA-C-O 121.903 0.859 . . . . 0.0 109.47 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.3 p -130.58 6.76 4.8 Favored 'General case' 0 N--CA 1.424 -1.738 0 C-N-CA 124.286 1.034 . . . . 0.0 109.993 178.195 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.526 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 48.4 mm-40 -123.99 -19.87 5.53 Favored 'General case' 0 CA--C 1.51 -0.584 0 CA-C-O 121.085 0.469 . . . . 0.0 110.585 -175.179 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 36.8 mt -134.85 135.07 53.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -176.021 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.513 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 47.7 m-85 -139.11 121.58 16.15 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 120.928 0.394 . . . . 0.0 110.302 -175.475 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.431 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 71.1 m -104.54 140.05 38.54 Favored 'General case' 0 C--N 1.286 -2.175 0 CA-C-O 121.097 0.475 . . . . 0.0 110.256 -177.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.474 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 25.2 p-80 -131.12 151.85 51.02 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 121.781 0.801 . . . . 0.0 112.589 -172.269 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.459 ' HB3' ' OD2' ' A' ' 54' ' ' ASP . 19.0 p30 -103.59 127.7 50.97 Favored 'General case' 0 N--CA 1.405 -2.692 0 CA-C-O 122.607 1.194 . . . . 0.0 110.6 174.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.4 p30 -94.14 -28.43 15.69 Favored 'General case' 0 C--N 1.268 -2.961 0 CA-C-N 113.429 -1.714 . . . . 0.0 108.945 -179.249 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -135.58 71.45 65.37 Favored Pre-proline 0 C--N 1.311 -1.084 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.343 178.132 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -69.97 3.56 2.8 Favored 'Trans proline' 0 N--CA 1.493 1.454 0 C-N-CA 123.425 2.75 . . . . 0.0 113.648 -174.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -120.12 -18.81 7.98 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 121.198 0.523 . . . . 0.0 110.093 -179.455 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.52 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.1 m -103.08 -30.06 10.97 Favored 'General case' 0 N--CA 1.422 -1.831 0 CA-C-O 122.016 0.913 . . . . 0.0 109.148 -173.335 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.609 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.6 mp -124.38 131.55 72.63 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 CA-C-N 114.811 -1.086 . . . . 0.0 108.173 -178.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.429 HG22 HD22 ' A' ' 136' ' ' ASN . 6.0 t -77.25 140.46 40.09 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 106.668 -1.605 . . . . 0.0 106.668 176.599 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.549 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 8.0 m-20 -82.75 107.45 15.39 Favored 'General case' 0 C--N 1.283 -2.322 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 -178.203 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 29.4 t80 -137.95 128.25 26.16 Favored 'General case' 0 C--N 1.272 -2.771 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -179.765 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.9 p -147.43 149.5 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.327 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -177.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -148.21 133.92 18.89 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 175.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.527 HD23 ' O ' ' A' ' 130' ' ' ILE . 0.7 OUTLIER -68.87 113.0 5.9 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 103.717 -2.697 . . . . 0.0 103.717 171.404 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.439 ' O ' ' HA ' ' A' ' 89' ' ' GLU . 3.4 tp-100 -57.76 -64.29 0.95 Allowed 'General case' 0 C--O 1.198 -1.628 0 C-N-CA 125.893 1.677 . . . . 0.0 109.822 179.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -165.08 154.15 12.52 Favored 'General case' 0 N--CA 1.424 -1.75 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 -175.725 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -120.82 164.28 14.18 Favored Glycine 0 N--CA 1.43 -1.728 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 -178.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 66.2 m -145.56 144.14 30.33 Favored 'General case' 0 C--N 1.286 -2.165 0 N-CA-C 108.455 -0.942 . . . . 0.0 108.455 178.064 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.588 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -113.15 156.83 22.52 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.5 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 98.5 m-85 -155.2 -179.43 8.07 Favored 'General case' 0 CA--C 1.533 0.305 0 C-N-CA 123.849 0.86 . . . . 0.0 110.002 -176.331 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.41 -140.58 42.76 Favored Glycine 0 N--CA 1.461 0.353 0 O-C-N 123.753 0.658 . . . . 0.0 113.126 178.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.78 -10.28 86.33 Favored Glycine 0 C--O 1.209 -1.444 0 C-N-CA 120.653 -0.784 . . . . 0.0 111.525 177.106 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.807 HG21 ' HB ' ' A' ' 126' ' ' ILE . 91.6 t -68.43 -38.48 79.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 C-N-CA 123.82 0.848 . . . . 0.0 111.697 -176.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.588 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.25 -18.18 32.76 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.422 -0.911 . . . . 0.0 112.198 178.388 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 16.1 t -100.55 -59.41 1.71 Allowed 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.887 -173.086 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.509 ' O ' HG22 ' A' ' 112' ' ' VAL . 37.1 m-20 -90.36 -26.51 19.89 Favored 'General case' 0 CA--C 1.493 -1.222 0 CA-C-N 115.32 -0.855 . . . . 0.0 109.167 -172.339 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.686 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 90.1 m-85 -103.98 150.64 24.04 Favored 'General case' 0 N--CA 1.42 -1.951 0 C-N-CA 119.726 -0.789 . . . . 0.0 108.888 176.734 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.3 t -160.88 119.88 2.58 Favored 'General case' 0 N--CA 1.421 -1.881 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 177.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.538 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -152.68 -107.0 0.31 Allowed Glycine 0 N--CA 1.424 -2.139 0 N-CA-C 111.386 -0.685 . . . . 0.0 111.386 177.045 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -164.18 -179.5 6.19 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 124.689 1.195 . . . . 0.0 109.748 -175.253 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.451 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.8 p -132.52 146.48 32.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.175 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.662 ' HG3' ' O ' ' A' ' 80' ' ' SER . 79.7 tttt -121.49 147.69 45.44 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.026 -178.58 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.546 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 63.4 t80 -145.66 109.79 4.91 Favored 'General case' 0 C--N 1.314 -0.936 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -179.795 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 23.0 t 52.16 37.6 22.17 Favored 'General case' 0 CA--C 1.55 0.972 0 C-N-CA 123.629 0.772 . . . . 0.0 111.544 178.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.81 10.38 63.08 Favored Glycine 0 CA--C 1.525 0.685 0 C-N-CA 120.62 -0.8 . . . . 0.0 113.644 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.662 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 15.4 t -83.3 179.0 7.81 Favored 'General case' 0 C--N 1.317 -0.827 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 177.387 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.4 t -156.07 108.42 2.59 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.779 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.546 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 6.8 p90 -149.39 164.42 21.07 Favored Pre-proline 0 C--N 1.306 -1.314 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 -173.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.468 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 97.4 Cg_endo -72.29 149.21 50.77 Favored 'Trans proline' 0 C--N 1.362 1.238 0 C-N-CA 122.224 1.949 . . . . 0.0 113.669 -175.36 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.631 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 55.5 t80 -119.33 133.48 23.76 Favored Pre-proline 0 N--CA 1.428 -1.55 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.894 178.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.631 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 61.6 Cg_endo -72.18 146.8 87.13 Favored 'Cis proline' 0 N--CA 1.477 0.539 0 C-N-CA 123.016 -1.66 . . . . 0.0 111.389 -2.315 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.7 t -71.77 179.83 2.96 Favored 'General case' 0 C--O 1.246 0.881 0 C-N-CA 119.776 -0.77 . . . . 0.0 109.075 -178.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 45.2 p -131.74 -39.09 1.12 Allowed 'General case' 0 C--N 1.318 -0.803 0 N-CA-C 114.087 1.143 . . . . 0.0 114.087 -170.449 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 23.0 t -102.29 -69.45 0.79 Allowed 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 -172.616 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . 0.439 ' HA ' ' O ' ' A' ' 59' ' ' GLN . 0.3 OUTLIER -178.58 -176.2 0.47 Allowed 'General case' 0 N--CA 1.437 -1.112 0 N-CA-C 106.199 -1.778 . . . . 0.0 106.199 179.378 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.458 ' HB ' ' HD2' ' A' ' 91' ' ' PRO . 1.9 p -101.11 174.81 2.68 Favored Pre-proline 0 C--N 1.286 -2.158 0 C-N-CA 123.19 0.596 . . . . 0.0 111.977 178.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . 0.458 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 22.3 Cg_endo -60.06 158.53 29.51 Favored 'Trans proline' 0 N--CA 1.455 -0.741 0 C-N-CA 122.47 2.113 . . . . 0.0 111.439 171.47 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.3 tmm_? -77.03 114.14 15.51 Favored 'General case' 0 C--N 1.293 -1.854 0 CA-C-N 114.836 -1.074 . . . . 0.0 108.781 -176.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 85.1 t -124.94 129.24 73.48 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 CA-C-O 121.544 0.687 . . . . 0.0 111.843 -177.379 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 66.2 t -114.25 123.74 70.22 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.191 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.253 177.708 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.549 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.7 m-85 -73.85 133.32 43.16 Favored 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 175.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.73 55.05 0.88 Allowed 'General case' 0 C--N 1.282 -2.337 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 174.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . 0.562 ' CB ' ' HG3' ' A' ' 101' ' ' LYS . 50.6 m -135.3 175.59 9.45 Favored 'General case' 0 N--CA 1.434 -1.228 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 -177.458 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -142.93 55.58 1.39 Allowed 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 122.033 0.92 . . . . 0.0 111.536 177.226 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.1 t -171.28 176.06 4.02 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 106.715 -1.587 . . . . 0.0 106.715 179.233 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . 0.474 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 11.0 p-10 -72.02 99.33 2.25 Favored 'General case' 0 CA--C 1.501 -0.937 0 CA-C-O 122.503 1.144 . . . . 0.0 109.608 177.395 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . 0.562 ' HG3' ' CB ' ' A' ' 97' ' ' SER . 57.4 mmtt -102.37 138.61 19.74 Favored Pre-proline 0 N--CA 1.415 -2.187 0 CA-C-N 113.524 -1.671 . . . . 0.0 110.277 -176.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.606 ' HB3' ' O ' ' A' ' 39' ' ' SER . 53.6 Cg_exo -49.67 139.54 31.01 Favored 'Trans proline' 0 N--CA 1.448 -1.202 0 C-N-CA 124.018 3.145 . . . . 0.0 112.86 -179.511 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.7 t90 -89.59 102.83 4.98 Favored Pre-proline 0 C--N 1.296 -1.751 0 N-CA-C 104.999 -2.223 . . . . 0.0 104.999 176.461 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.436 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 74.4 Cg_endo -75.55 88.72 1.26 Allowed 'Trans proline' 0 N--CA 1.451 -1.02 0 C-N-CA 121.877 1.718 . . . . 0.0 113.116 -170.411 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.412 HG22 ' HD1' ' A' ' 77' ' ' TYR . 94.2 t -138.52 143.93 31.33 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 N-CA-C 108.124 -1.065 . . . . 0.0 108.124 -179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.59 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -149.04 133.78 17.85 Favored 'General case' 0 C--N 1.289 -2.025 0 CA-C-O 120.81 0.338 . . . . 0.0 110.251 178.046 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.537 HD21 HD11 ' A' ' 129' ' ' LEU . 17.4 mt -101.19 102.9 13.9 Favored 'General case' 0 C--N 1.288 -2.097 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 178.752 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.538 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 32.3 m-85 -83.4 77.62 9.78 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.963 -0.384 . . . . 0.0 109.963 177.828 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.686 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.3 mm? -102.38 124.98 48.92 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 176.362 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -129.69 145.96 59.2 Favored Pre-proline 0 N--CA 1.406 -2.669 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 -174.709 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.436 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 34.0 Cg_endo -62.82 124.59 14.34 Favored 'Trans proline' 0 CA--C 1.497 -1.327 0 C-N-CA 123.038 2.492 . . . . 0.0 113.341 -176.101 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.626 ' O ' HG22 ' A' ' 30' ' ' VAL . 15.9 m -84.56 -155.45 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.399 -3.02 0 CA-C-N 114.246 -1.343 . . . . 0.0 108.161 172.017 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.7 t -83.38 -28.97 28.56 Favored 'General case' 0 C--N 1.263 -3.19 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -170.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 25.7 t -84.13 30.02 0.54 Allowed 'General case' 0 N--CA 1.426 -1.665 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.313 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -112.81 138.79 49.12 Favored 'General case' 0 N--CA 1.424 -1.736 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.069 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -177.28 135.91 2.94 Favored Glycine 0 N--CA 1.44 -1.063 0 N-CA-C 111.607 -0.597 . . . . 0.0 111.607 179.493 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 63.33 -152.34 47.36 Favored Glycine 0 CA--C 1.5 -0.853 0 CA-C-O 119.387 -0.674 . . . . 0.0 112.577 -178.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 57.7 t -60.56 98.72 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.248 0.98 0 CA-C-O 122.222 1.011 . . . . 0.0 111.161 -176.513 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.06 -24.1 15.48 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-N 114.147 -1.388 . . . . 0.0 110.756 -176.503 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.533 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.4 mt -133.63 137.58 52.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 178.47 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.46 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.3 mmpt? -114.57 138.74 50.27 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-O 120.914 0.387 . . . . 0.0 110.871 177.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.31 135.15 50.02 Favored 'General case' 0 N--CA 1.442 -0.851 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 178.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 88.12 -6.63 83.27 Favored Glycine 0 C--N 1.308 -0.974 0 N-CA-C 111.628 -0.589 . . . . 0.0 111.628 -179.343 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 64.9 m -96.78 149.28 22.01 Favored 'General case' 0 N--CA 1.427 -1.601 0 CA-C-O 121.285 0.564 . . . . 0.0 110.089 179.471 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.437 HD11 HG23 ' A' ' 128' ' ' VAL . 3.2 tm? -78.98 125.0 28.8 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-N 114.782 -1.099 . . . . 0.0 108.587 -176.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.807 ' HB ' HG21 ' A' ' 67' ' ' VAL . 36.4 pt -109.61 -26.3 3.26 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -177.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.21 167.53 23.89 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 110.164 -0.31 . . . . 0.0 110.164 -177.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.437 HG23 HD11 ' A' ' 125' ' ' LEU . 69.3 t -142.37 116.07 4.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 178.725 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.537 HD11 HD21 ' A' ' 107' ' ' LEU . 40.4 mt -119.29 147.91 43.76 Favored 'General case' 0 C--N 1.291 -1.976 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 179.183 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.585 HG21 HE21 ' A' ' 143' ' ' GLN . 5.4 mp -124.75 133.4 69.52 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 C-N-CA 119.53 -0.868 . . . . 0.0 110.653 177.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.572 HD22 ' HB2' ' A' ' 144' ' ' PHE . 0.0 OUTLIER -100.35 135.67 41.43 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 175.971 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.508 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 8.4 tpt180 -106.81 120.48 42.12 Favored 'General case' 0 C--N 1.287 -2.118 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.567 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 6.2 tp-100 -102.08 121.84 42.96 Favored 'General case' 0 CA--C 1.498 -1.054 0 N-CA-C 108.855 -0.795 . . . . 0.0 108.855 177.734 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 18.8 m -140.04 137.86 34.94 Favored 'General case' 0 C--N 1.291 -1.962 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 -179.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.609 ' CB ' HG23 ' A' ' 52' ' ' ILE . 8.7 p30 -133.83 173.75 11.21 Favored 'General case' 0 N--CA 1.442 -0.838 0 C-N-CA 118.809 -1.156 . . . . 0.0 112.389 179.018 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.429 HD22 HG22 ' A' ' 53' ' ' THR . 6.7 p30 -91.79 -15.28 28.5 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 114.029 -1.441 . . . . 0.0 112.289 -169.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 39.5 t80 -103.74 -57.19 2.08 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.03 0.443 . . . . 0.0 111.801 -172.193 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 87.1 m-20 -100.69 167.9 10.03 Favored 'General case' 0 CA--C 1.476 -1.88 0 CA-C-O 121.612 0.72 . . . . 0.0 109.971 178.039 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 17.3 m -96.37 32.3 2.02 Favored 'General case' 0 N--CA 1.414 -2.266 0 CA-C-N 114.026 -1.443 . . . . 0.0 108.585 177.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -82.84 50.96 1.8 Allowed 'General case' 0 N--CA 1.476 0.839 0 CA-C-O 121.749 0.785 . . . . 0.0 111.249 -178.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . 0.567 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 12.2 t70 -86.34 97.62 10.52 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 114.455 -1.248 . . . . 0.0 109.041 178.282 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -134.85 155.5 50.55 Favored 'General case' 0 C--N 1.309 -1.162 0 N-CA-C 108.542 -0.911 . . . . 0.0 108.542 -179.681 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . 0.585 HE21 HG21 ' A' ' 130' ' ' ILE . 19.4 pt20 -116.27 144.39 44.29 Favored 'General case' 0 C--N 1.295 -1.778 0 C-N-CA 119.981 -0.688 . . . . 0.0 111.409 176.215 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.572 ' HB2' HD22 ' A' ' 131' ' ' LEU . 3.7 m-30 -110.72 131.53 54.97 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 -178.104 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 49.6 t -90.98 130.53 40.01 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.897 0 O-C-N 123.553 0.533 . . . . 0.0 109.784 -179.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . 0.543 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.9 m95 -117.93 95.16 4.8 Favored 'General case' 0 C--N 1.279 -2.496 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 -179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -77.62 114.79 16.82 Favored 'General case' 0 C--N 1.296 -1.741 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 178.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.409 ' HA ' HG22 ' A' ' 20' ' ' VAL . 23.2 mm -89.26 122.41 40.55 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.794 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 -177.436 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . 0.412 ' CZ ' HD23 ' A' ' 125' ' ' LEU . 89.1 m-85 -118.27 152.83 35.0 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 121.509 0.671 . . . . 0.0 110.241 178.871 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -80.6 129.39 34.49 Favored 'General case' 0 N--CA 1.41 -2.472 0 CA-C-N 114.807 -1.088 . . . . 0.0 108.33 176.19 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 29.3 t-20 -91.7 -10.26 40.8 Favored 'General case' 0 C--N 1.29 -2.004 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 -177.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -155.09 145.83 22.37 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 113.991 -1.459 . . . . 0.0 109.19 -176.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.1 p-10 -80.52 147.29 30.91 Favored 'General case' 0 C--N 1.323 -0.57 0 O-C-N 124.054 0.846 . . . . 0.0 110.861 -178.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.552 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.3 t -124.21 135.16 64.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.13 -177.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.9 t -117.74 135.98 56.4 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 79.4 t -98.54 103.21 17.39 Favored Pre-proline 0 C--N 1.295 -1.803 0 C-N-CA 123.464 0.706 . . . . 0.0 109.883 178.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.483 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 44.1 Cg_endo -71.26 -21.03 27.34 Favored 'Trans proline' 0 CA--C 1.516 -0.396 0 C-N-CA 122.172 1.915 . . . . 0.0 111.633 179.178 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 2.4 t . . . . . 0 C--O 1.249 1.073 0 C-N-CA 124.79 1.236 . . . . 0.0 114.061 176.874 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.655 ' CZ ' ' HB3' ' A' ' 44' ' ' CYS . 43.9 t80 . . . . . 0 CA--C 1.488 -1.411 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.496 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -147.61 176.65 9.91 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 174.065 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.49 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 73.2 m -138.58 160.08 40.48 Favored 'General case' 0 C--N 1.3 -1.558 0 C-N-CA 119.624 -0.83 . . . . 0.0 111.591 -175.517 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.9 pptp? -144.43 159.53 42.58 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 122.747 0.419 . . . . 0.0 110.412 -178.123 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.509 HG22 HG22 ' A' ' 20' ' ' VAL . 81.5 p -95.51 176.57 6.12 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 121.433 0.635 . . . . 0.0 112.011 -178.518 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -76.76 -24.14 52.94 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.202 177.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -81.1 -33.54 33.24 Favored 'General case' 0 N--CA 1.448 -0.544 0 C-N-CA 119.272 -0.971 . . . . 0.0 109.549 179.247 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.82 17.86 1.15 Allowed Glycine 0 N--CA 1.439 -1.131 0 C-N-CA 119.699 -1.238 . . . . 0.0 113.404 175.852 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.9 m -88.69 99.75 12.59 Favored 'General case' 0 N--CA 1.431 -1.383 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 179.285 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.56 120.59 32.49 Favored 'General case' 0 C--N 1.291 -1.971 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.38 178.003 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.496 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 62.2 mt -102.25 115.69 64.16 Favored Pre-proline 0 C--N 1.288 -2.078 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 176.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -79.88 -179.81 5.63 Favored 'Trans proline' 0 N--CA 1.443 -1.445 0 C-N-CA 122.46 2.107 . . . . 0.0 111.189 177.044 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.9 mt -66.93 147.71 12.48 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 N-CA-C 109.794 -0.447 . . . . 0.0 109.794 -179.063 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.55 24.2 5.97 Favored Glycine 0 C--N 1.315 -0.615 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.517 178.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.0 173.17 49.45 Favored Glycine 0 C--N 1.316 -0.539 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 -178.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 159.03 -177.91 35.41 Favored Glycine 0 N--CA 1.431 -1.68 0 C-N-CA 120.283 -0.96 . . . . 0.0 111.497 177.053 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 25.5 p -151.54 141.46 22.02 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -178.073 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.9 160.46 38.83 Favored 'General case' 0 N--CA 1.425 -1.718 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 27.7 m-80 -112.83 109.05 18.27 Favored 'General case' 0 C--N 1.289 -2.037 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 177.344 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.509 HG22 HG22 ' A' ' 5' ' ' THR . 43.2 t -94.09 137.18 23.52 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.245 0 CA-C-N 115.568 -0.742 . . . . 0.0 109.483 -177.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 50.4 m-85 -122.83 115.69 22.41 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 120.919 0.39 . . . . 0.0 110.832 -177.201 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.458 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -125.65 132.9 70.32 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.244 -174.371 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -87.78 130.41 34.86 Favored 'General case' 0 C--N 1.298 -1.663 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.21 177.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.415 HD11 HG22 ' A' ' 36' ' ' VAL . 2.7 mm? -111.6 160.31 17.33 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 175.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.79 121.95 48.53 Favored Pre-proline 0 C--O 1.21 -1.016 0 O-C-N 124.235 0.959 . . . . 0.0 109.196 175.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 69.9 Cg_endo -74.76 -5.23 16.57 Favored 'Trans proline' 0 C--O 1.217 -0.542 0 C-N-CA 122.781 2.321 . . . . 0.0 113.555 -175.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.3 t -126.39 109.54 21.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.495 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 8.1 t -145.36 112.47 1.28 Allowed 'Isoleucine or valine' 0 C--O 1.186 -2.256 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 -176.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.662 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -101.09 156.14 17.59 Favored 'General case' 0 C--N 1.274 -2.68 0 C-N-CA 123.214 0.606 . . . . 0.0 111.474 179.657 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 38.0 t -45.51 120.55 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.791 0 C-N-CA 123.471 0.709 . . . . 0.0 112.019 176.621 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 99.82 0.74 56.32 Favored Glycine 0 CA--C 1.52 0.371 0 CA-C-N 115.542 -0.754 . . . . 0.0 112.825 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.662 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -73.11 -177.41 2.47 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 124.384 1.074 . . . . 0.0 110.977 177.706 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -127.38 92.9 3.6 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 107.769 -1.196 . . . . 0.0 107.769 177.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.606 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 20.2 tp -101.72 134.86 44.21 Favored 'General case' 0 C--N 1.283 -2.309 0 C-N-CA 118.725 -1.19 . . . . 0.0 109.381 176.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.9 p -141.96 132.38 24.98 Favored 'Isoleucine or valine' 0 N--CA 1.386 -3.646 0 CA-C-N 115.086 -0.961 . . . . 0.0 111.927 -178.135 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.578 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 42.2 t -92.12 89.95 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.55 0 CA-C-N 113.86 -1.518 . . . . 0.0 108.029 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -74.45 112.14 10.33 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 88.8 mt -95.68 1.03 53.31 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.026 0.441 . . . . 0.0 111.284 -179.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 38.9 t -77.98 0.65 23.53 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 122.086 0.946 . . . . 0.0 109.439 -178.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.9 p -124.59 0.52 8.19 Favored 'General case' 0 C--N 1.281 -2.393 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.134 179.145 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.458 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 49.2 mm-40 -120.96 -24.56 5.57 Favored 'General case' 0 CA--C 1.504 -0.816 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.66 -172.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 18.2 mt -132.86 139.14 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 -176.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.418 ' HA ' ' HA ' ' A' ' 102' ' ' PRO . 78.3 m-85 -134.2 161.14 35.73 Favored 'General case' 0 CA--C 1.496 -1.114 0 N-CA-C 109.311 -0.626 . . . . 0.0 109.311 -176.648 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.655 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 81.0 m -141.94 141.79 32.97 Favored 'General case' 0 C--N 1.284 -2.244 0 C-N-CA 122.886 0.475 . . . . 0.0 109.998 -177.068 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.6 p80 -145.3 156.69 43.96 Favored 'General case' 0 C--N 1.297 -1.679 0 CA-C-O 121.312 0.577 . . . . 0.0 111.052 -174.272 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.451 ' HA ' ' HA ' ' A' ' 1' ' ' PHE . 2.9 p30 -107.42 121.06 43.83 Favored 'General case' 0 C--N 1.295 -1.783 0 CA-C-O 122.479 1.133 . . . . 0.0 113.304 178.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 13.7 p-10 -90.97 -23.37 20.44 Favored 'General case' 0 N--CA 1.42 -1.959 0 CA-C-N 113.417 -1.72 . . . . 0.0 109.529 179.417 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.419 ' HB2' HD13 ' A' ' 52' ' ' ILE . 60.7 m-85 -138.57 64.61 37.78 Favored Pre-proline 0 N--CA 1.472 0.636 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.871 176.157 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -67.5 -17.16 48.62 Favored 'Trans proline' 0 N--CA 1.481 0.784 0 C-N-CA 122.159 1.906 . . . . 0.0 112.787 -176.263 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -94.44 -27.63 15.91 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.903 -175.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.566 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -97.84 -30.41 12.78 Favored 'General case' 0 N--CA 1.413 -2.278 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 -171.344 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.566 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.1 mp -119.57 141.4 39.79 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.949 0 CA-C-N 114.158 -1.383 . . . . 0.0 108.963 -176.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 5.4 t -88.89 131.94 34.9 Favored 'General case' 0 C--O 1.259 1.578 0 N-CA-C 104.09 -2.559 . . . . 0.0 104.09 171.439 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.651 ' OD1' ' HB2' ' A' ' 1' ' ' PHE . 34.0 m-20 -93.78 107.27 19.17 Favored 'General case' 0 C--N 1.271 -2.815 0 C-N-CA 118.952 -1.099 . . . . 0.0 110.152 -169.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 28.9 t80 -127.06 143.11 51.37 Favored 'General case' 0 C--N 1.289 -2.055 0 CA-C-N 114.04 -1.437 . . . . 0.0 108.908 -175.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.532 HG23 ' HG ' ' A' ' 131' ' ' LEU . 8.1 p -150.6 145.25 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.313 0 O-C-N 123.615 0.572 . . . . 0.0 110.087 -179.76 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 2.6 p -147.42 131.59 17.38 Favored 'General case' 0 N--CA 1.436 -1.129 0 C-N-CA 123.075 0.55 . . . . 0.0 109.769 174.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.457 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 1.1 tm? -71.2 102.14 2.46 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 175.091 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.4 tp-100 -52.53 -50.55 62.62 Favored 'General case' 0 N--CA 1.469 0.511 0 C-N-CA 127.12 2.168 . . . . 0.0 111.697 -176.772 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 3.9 ptp180 -171.17 160.17 6.21 Favored 'General case' 0 N--CA 1.425 -1.684 0 CA-C-N 114.467 -1.242 . . . . 0.0 109.289 -176.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -135.84 148.22 19.55 Favored Glycine 0 N--CA 1.41 -3.097 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 179.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 63.2 m -129.38 143.81 50.99 Favored 'General case' 0 C--N 1.279 -2.469 0 C-N-CA 123.228 0.611 . . . . 0.0 109.573 -178.681 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.508 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -111.29 155.62 22.75 Favored 'General case' 0 CA--C 1.502 -0.87 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -179.585 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.469 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 68.0 m-85 -157.45 -178.52 7.4 Favored 'General case' 0 C--O 1.238 0.494 0 C-N-CA 124.235 1.014 . . . . 0.0 108.313 -177.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 62.45 -141.71 47.25 Favored Glycine 0 N--CA 1.453 -0.191 0 O-C-N 123.333 0.396 . . . . 0.0 112.707 177.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.24 -7.84 87.18 Favored Glycine 0 C--O 1.208 -1.482 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 177.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.805 HG21 ' HB ' ' A' ' 126' ' ' ILE . 86.6 t -69.72 -38.64 76.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 C-N-CA 123.752 0.821 . . . . 0.0 111.339 -176.488 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.508 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -85.44 -22.8 28.14 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 119.306 -0.957 . . . . 0.0 112.063 179.441 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 9.3 t -100.63 -51.39 3.61 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.144 0.497 . . . . 0.0 112.265 -172.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.487 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 47.7 m-20 -90.8 -24.57 20.28 Favored 'General case' 0 C--N 1.31 -1.145 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -174.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.663 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 89.2 m-85 -111.52 156.49 21.64 Favored 'General case' 0 N--CA 1.42 -1.951 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.292 179.104 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.5 t -162.97 138.57 6.89 Favored 'General case' 0 N--CA 1.406 -2.651 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 176.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.519 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.36 -104.65 0.18 Allowed Glycine 0 N--CA 1.409 -3.146 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 175.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.2 p -165.3 -179.86 5.83 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 124.547 1.139 . . . . 0.0 110.137 -176.261 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.413 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.7 p -131.81 145.33 35.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 123.313 0.645 . . . . 0.0 109.467 178.411 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.672 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.2 tttt -122.23 149.52 43.56 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.478 -177.614 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.461 ' CD2' HG22 ' A' ' 105' ' ' VAL . 60.8 t80 -150.15 113.09 4.81 Favored 'General case' 0 C--O 1.214 -0.777 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 22.7 t 56.92 30.23 17.64 Favored 'General case' 0 CA--C 1.554 1.108 0 CA-C-O 121.884 0.85 . . . . 0.0 111.286 176.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.33 13.69 59.76 Favored Glycine 0 N--CA 1.437 -1.273 0 C-N-CA 120.208 -0.996 . . . . 0.0 113.086 -177.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.672 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 21.2 t -83.95 -179.35 7.24 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 175.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 8.2 t -157.37 110.48 2.51 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 179.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.47 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 7.4 p90 -149.68 162.52 28.11 Favored Pre-proline 0 C--N 1.305 -1.357 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 -174.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.47 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 72.7 Cg_endo -68.2 149.08 75.91 Favored 'Trans proline' 0 C--N 1.36 1.174 0 C-N-CA 122.671 2.248 . . . . 0.0 113.528 -175.266 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.617 ' CD2' HD21 ' A' ' 109' ' ' LEU . 60.2 t80 -124.31 134.54 25.57 Favored Pre-proline 0 N--CA 1.442 -0.839 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.193 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.582 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 57.4 Cg_endo -70.57 145.08 80.29 Favored 'Cis proline' 0 C--O 1.239 0.568 0 C-N-CA 123.099 -1.625 . . . . 0.0 110.633 -3.255 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.7 t -73.65 -177.63 2.8 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 -177.664 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 41.2 p -131.77 -35.87 1.24 Allowed 'General case' 0 N--CA 1.424 -1.772 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -172.438 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 49.5 m -110.1 -162.21 0.79 Allowed 'General case' 1 N--CA 1.317 -7.114 0 CA-C-N 113.45 -1.704 . . . . 0.0 107.663 179.265 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 27.0 tt0 -116.21 151.32 35.96 Favored 'General case' 1 C--N 1.244 -4.011 0 CA-C-N 113.443 -1.708 . . . . 0.0 109.115 -168.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.457 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 46.8 p -67.75 161.17 68.76 Favored Pre-proline 0 C--N 1.296 -1.748 0 C-N-CA 124.494 1.117 . . . . 0.0 113.245 -177.642 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -56.86 159.86 13.48 Favored 'Trans proline' 0 C--N 1.355 0.876 0 C-N-CA 124.068 3.179 . . . . 0.0 111.749 175.454 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.5 tmm_? -67.88 116.74 8.88 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.667 -176.024 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 72.7 t -132.05 137.18 55.31 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 C-N-CA 123.848 0.859 . . . . 0.0 108.687 -176.223 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.0 p -136.59 132.94 48.85 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.628 -175.191 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -82.9 101.5 11.06 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-O 120.937 0.398 . . . . 0.0 110.917 -178.395 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 36.7 m-80 -92.29 55.12 2.48 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-O 121.996 0.903 . . . . 0.0 108.837 176.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.3 m -145.4 128.63 16.74 Favored 'General case' 0 N--CA 1.428 -1.566 0 N-CA-C 107.464 -1.31 . . . . 0.0 107.464 -178.239 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.5 ptm180 -104.51 63.7 0.74 Allowed 'General case' 0 C--N 1.304 -1.378 0 CA-C-O 122.643 1.211 . . . . 0.0 109.609 -179.091 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . 0.405 HG23 ' HD3' ' A' ' 101' ' ' LYS . 10.1 t -170.41 -179.5 3.04 Favored 'General case' 0 N--CA 1.43 -1.443 0 N-CA-C 106.639 -1.615 . . . . 0.0 106.639 -172.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -86.25 124.81 33.04 Favored 'General case' 0 CA--C 1.498 -1.047 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 179.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . 0.411 ' HD2' ' HA ' ' A' ' 101' ' ' LYS . 6.8 mptt -127.32 143.9 48.84 Favored Pre-proline 0 C--N 1.277 -2.561 0 C-N-CA 124.463 1.105 . . . . 0.0 109.273 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.418 ' HA ' ' HA ' ' A' ' 43' ' ' PHE . 41.0 Cg_endo -68.23 147.27 72.12 Favored 'Trans proline' 0 C--O 1.244 0.787 0 C-N-CA 122.891 2.394 . . . . 0.0 112.12 178.118 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.2 t90 -85.56 107.45 12.47 Favored Pre-proline 0 C--N 1.323 -0.544 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 -177.287 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -76.73 88.2 1.4 Allowed 'Trans proline' 0 N--CA 1.455 -0.766 0 C-N-CA 121.518 1.479 . . . . 0.0 112.905 -172.495 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.461 HG22 ' CD2' ' A' ' 77' ' ' TYR . 68.2 t -137.54 153.96 29.1 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.144 0 N-CA-C 107.543 -1.28 . . . . 0.0 107.543 178.102 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.578 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -160.05 137.4 9.55 Favored 'General case' 0 CA--C 1.475 -1.94 0 O-C-N 123.406 0.441 . . . . 0.0 110.182 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.469 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 18.9 mt -105.79 99.85 9.43 Favored 'General case' 0 C--N 1.286 -2.171 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.388 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.519 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 42.4 m-85 -79.78 77.2 6.42 Favored 'General case' 0 C--N 1.313 -0.995 0 O-C-N 122.041 -0.412 . . . . 0.0 110.105 177.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.663 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.1 mm? -102.48 119.74 39.34 Favored 'General case' 0 C--N 1.308 -1.217 0 CA-C-O 120.926 0.393 . . . . 0.0 110.219 177.653 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.54 147.39 52.74 Favored Pre-proline 0 N--CA 1.419 -1.98 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.725 -174.558 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.487 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 29.9 Cg_endo -62.24 118.55 5.44 Favored 'Trans proline' 0 C--O 1.246 0.899 0 C-N-CA 123.185 2.59 . . . . 0.0 112.835 -177.13 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.443 HG22 ' H ' ' A' ' 112' ' ' VAL . 2.8 m -68.46 -116.43 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.192 -1.923 0 CA-C-N 114.007 -1.451 . . . . 0.0 112.71 175.52 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 22.8 t -112.21 -39.53 4.42 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.267 -0.895 . . . . 0.0 109.541 177.367 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 31.5 t -84.33 29.41 0.58 Allowed 'General case' 0 C--N 1.317 -0.804 0 C-N-CA 123.536 0.734 . . . . 0.0 111.342 -175.095 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -101.93 133.18 47.13 Favored 'General case' 0 N--CA 1.422 -1.84 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 179.336 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.97 139.84 5.19 Favored Glycine 0 N--CA 1.434 -1.436 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.017 178.19 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 59.71 -144.37 46.19 Favored Glycine 0 CA--C 1.495 -1.214 0 CA-C-O 119.288 -0.729 . . . . 0.0 112.738 -179.083 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.3 p -59.24 96.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 122.753 1.263 . . . . 0.0 111.575 -178.31 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.44 -25.85 14.65 Favored 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 114.754 -1.112 . . . . 0.0 111.49 -177.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.451 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 61.4 mt -134.72 139.66 47.14 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.928 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.326 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 3.7 mmpt? -114.85 137.32 52.1 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-O 121.089 0.471 . . . . 0.0 111.4 179.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.06 122.52 20.21 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.379 179.699 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 93.6 3.57 64.47 Favored Glycine 0 C--N 1.309 -0.948 0 N-CA-C 111.595 -0.602 . . . . 0.0 111.595 -177.458 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 32.9 t -102.21 143.62 31.77 Favored 'General case' 0 C--O 1.253 1.246 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 178.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.431 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -72.28 124.72 25.67 Favored 'General case' 0 N--CA 1.444 -0.727 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 -179.683 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.805 ' HB ' HG21 ' A' ' 67' ' ' VAL . 39.0 pt -109.93 -27.43 2.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 N-CA-C 112.423 0.527 . . . . 0.0 112.423 -178.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . 0.4 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.68 167.62 24.79 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 -177.679 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.431 HG23 HD11 ' A' ' 125' ' ' LEU . 71.2 t -142.97 116.38 3.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 107.175 -1.417 . . . . 0.0 107.175 178.576 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.44 HD11 HD21 ' A' ' 107' ' ' LEU . 59.9 mt -115.95 143.01 46.02 Favored 'General case' 0 C--N 1.288 -2.08 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 179.536 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.644 HG21 HE21 ' A' ' 143' ' ' GLN . 3.8 mp -124.31 118.44 53.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 C-N-CA 119.402 -0.919 . . . . 0.0 110.322 179.184 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.532 ' HG ' HG23 ' A' ' 56' ' ' VAL . 0.1 OUTLIER -88.76 150.09 23.12 Favored 'General case' 0 C--N 1.268 -2.957 0 C-N-CA 124.838 1.255 . . . . 0.0 108.485 178.227 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 19.3 ttp85 -123.38 137.4 54.83 Favored 'General case' 0 N--CA 1.414 -2.269 0 O-C-N 123.255 0.347 . . . . 0.0 111.549 178.443 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.483 ' NE2' ' HD2' ' A' ' 1' ' ' PHE . 13.3 mm100 -113.01 115.44 28.38 Favored 'General case' 0 N--CA 1.431 -1.398 0 CA-C-N 115.079 -0.964 . . . . 0.0 110.622 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 4.5 m -133.33 130.86 39.43 Favored 'General case' 0 C--N 1.293 -1.851 0 N-CA-C 106.994 -1.484 . . . . 0.0 106.994 176.017 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.529 ' CB ' HG23 ' A' ' 52' ' ' ILE . 6.5 p30 -132.8 159.15 40.61 Favored 'General case' 0 C--O 1.214 -0.791 0 C-N-CA 118.464 -1.294 . . . . 0.0 112.232 179.416 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -70.64 -25.7 63.13 Favored 'General case' 0 N--CA 1.487 1.409 0 CA-C-N 113.906 -1.497 . . . . 0.0 113.297 -170.662 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 45.3 t80 -89.98 -58.85 2.36 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-O 121.057 0.456 . . . . 0.0 111.097 -174.175 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . 0.458 ' HB3' ' OD2' ' A' ' 140' ' ' ASP . 19.6 m120 -70.98 -36.63 72.59 Favored 'General case' 0 CA--C 1.472 -2.034 0 CA-C-O 121.655 0.74 . . . . 0.0 111.184 -178.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 49.7 m 66.4 17.19 10.63 Favored 'General case' 0 N--CA 1.436 -1.165 0 CA-C-N 113.515 -1.675 . . . . 0.0 109.881 -176.266 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . 0.468 ' HB3' ' CE2' ' A' ' 142' ' ' PHE . 19.5 m-20 -78.62 150.16 32.76 Favored 'General case' 0 N--CA 1.419 -1.995 0 CA-C-N 113.588 -1.642 . . . . 0.0 109.206 176.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -135.68 105.12 6.03 Favored 'General case' 0 C--N 1.274 -2.69 0 CA-C-N 114.482 -1.236 . . . . 0.0 108.344 -178.623 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . 0.468 ' CE2' ' HB3' ' A' ' 140' ' ' ASP . 72.4 m-85 -129.51 160.66 32.51 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . 0.644 HE21 HG21 ' A' ' 130' ' ' ILE . 15.7 pt20 -138.58 141.92 39.21 Favored 'General case' 0 C--N 1.287 -2.15 0 C-N-CA 119.453 -0.899 . . . . 0.0 111.003 -178.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 7.5 m-30 -107.2 134.21 50.64 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 -175.619 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 45.3 t -93.26 130.82 41.75 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.936 0 O-C-N 123.492 0.495 . . . . 0.0 109.886 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . 0.513 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 64.1 m95 -120.69 100.03 6.88 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 -179.688 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -81.02 113.5 19.26 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 179.194 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.4 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 23.6 mm -88.43 121.55 38.86 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -178.044 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -117.46 153.69 32.69 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 123.541 0.736 . . . . 0.0 109.834 177.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.0 131.94 35.16 Favored 'General case' 0 N--CA 1.416 -2.165 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 177.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 13.8 t-20 -95.06 -5.77 43.63 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -177.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 3.1 t30 -155.96 139.97 16.36 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.199 -1.364 . . . . 0.0 109.508 -177.078 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -78.16 145.04 35.86 Favored 'General case' 0 C--N 1.308 -1.2 0 O-C-N 124.212 0.945 . . . . 0.0 109.454 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.46 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 75.5 t -120.67 141.29 41.74 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 O-C-N 122.28 -0.263 . . . . 0.0 110.82 -177.009 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.2 t -120.48 136.11 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.234 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 179.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.495 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.7 t -101.74 103.95 31.82 Favored Pre-proline 0 C--N 1.289 -2.058 0 C-N-CA 123.173 0.589 . . . . 0.0 109.716 178.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.449 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 44.2 Cg_endo -71.29 -19.47 29.15 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.031 1.821 . . . . 0.0 111.3 178.139 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.418 ' HB ' HG12 ' A' ' 156' ' ' VAL . 5.1 t . . . . . 0 C--O 1.246 0.872 0 C-N-CA 124.956 1.302 . . . . 0.0 113.262 176.233 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 56.6 t80 . . . . . 0 CA--C 1.484 -1.568 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.501 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -136.87 176.25 8.88 Favored 'General case' 0 C--N 1.276 -2.602 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 -178.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 79.4 m -136.89 154.46 50.48 Favored 'General case' 0 C--N 1.291 -1.974 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.549 -174.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -143.44 162.52 35.57 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-N 116.027 -0.533 . . . . 0.0 109.608 -174.024 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.546 HG22 HG22 ' A' ' 20' ' ' VAL . 67.1 p -97.63 179.81 4.71 Favored 'General case' 0 C--N 1.301 -1.515 0 CA-C-O 121.192 0.52 . . . . 0.0 110.599 179.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -84.98 -19.75 31.59 Favored 'General case' 0 C--N 1.308 -1.239 0 CA-C-N 114.93 -1.032 . . . . 0.0 108.73 179.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -87.93 -17.46 31.29 Favored 'General case' 0 N--CA 1.417 -2.1 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.475 -179.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 119.24 11.63 7.34 Favored Glycine 0 CA--C 1.486 -1.729 0 C-N-CA 119.061 -1.543 . . . . 0.0 114.373 167.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.2 m -89.83 99.68 12.64 Favored 'General case' 0 N--CA 1.413 -2.308 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -90.66 121.65 32.75 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-N 115.071 -0.968 . . . . 0.0 108.513 177.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.501 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 66.4 mt -101.77 113.7 65.78 Favored Pre-proline 0 C--N 1.295 -1.768 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 178.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -75.54 170.6 19.92 Favored 'Trans proline' 0 C--O 1.25 1.092 0 C-N-CA 122.586 2.19 . . . . 0.0 111.527 178.828 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 63.1 mt -64.42 128.19 26.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.199 179.233 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.89 6.24 2.03 Favored Glycine 0 C--N 1.314 -0.669 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.742 -178.822 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.65 158.41 33.8 Favored Glycine 0 C--N 1.316 -0.558 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 166.04 -173.2 41.59 Favored Glycine 0 C--N 1.3 -1.434 0 C-N-CA 119.709 -1.234 . . . . 0.0 112.014 179.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.2 p -148.45 140.87 24.29 Favored 'General case' 0 C--N 1.301 -1.539 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -178.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -130.8 159.6 36.86 Favored 'General case' 0 N--CA 1.429 -1.478 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 29.1 m-80 -108.55 109.89 21.23 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 176.414 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.546 HG22 HG22 ' A' ' 5' ' ' THR . 38.3 t -96.15 138.9 20.33 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.87 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.689 -178.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -124.7 112.5 16.83 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 121.216 0.532 . . . . 0.0 111.312 -176.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.582 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.1 p -122.76 134.13 66.85 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.942 -175.363 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -98.07 119.69 37.15 Favored 'General case' 0 C--N 1.294 -1.823 0 CA-C-O 121.47 0.652 . . . . 0.0 110.152 -178.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.428 ' CD1' ' HA ' ' A' ' 36' ' ' VAL . 2.7 mm? -97.06 161.72 13.7 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-N 114.659 -1.155 . . . . 0.0 109.359 -178.668 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.27 122.1 51.98 Favored Pre-proline 0 C--N 1.317 -0.817 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 173.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.494 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 63.1 Cg_endo -74.86 -2.22 12.21 Favored 'Trans proline' 0 CA--C 1.533 0.456 0 C-N-CA 122.771 2.314 . . . . 0.0 113.203 -176.357 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.454 HG13 ' HG3' ' A' ' 157' ' ' PRO . 73.5 t -127.16 115.26 40.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.502 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 3.3 t -149.84 118.99 0.98 Allowed 'Isoleucine or valine' 0 C--O 1.194 -1.833 0 N-CA-C 107.541 -1.281 . . . . 0.0 107.541 -179.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.64 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -107.13 155.79 19.5 Favored 'General case' 0 C--N 1.278 -2.519 0 C-N-CA 122.787 0.435 . . . . 0.0 111.625 -179.592 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.434 HG13 ' O ' ' A' ' 112' ' ' VAL . 38.6 t -47.07 117.13 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 123.656 0.782 . . . . 0.0 111.765 177.755 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.79 -2.44 45.2 Favored Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 115.391 -0.822 . . . . 0.0 112.918 179.562 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.64 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -72.95 -176.91 2.21 Favored 'General case' 0 C--N 1.314 -0.948 0 C-N-CA 123.999 0.92 . . . . 0.0 110.58 177.419 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -134.44 98.21 4.02 Favored 'General case' 0 N--CA 1.427 -1.612 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 176.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.684 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 30.4 tp -93.69 147.01 23.42 Favored 'General case' 0 C--N 1.282 -2.354 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 179.246 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 93.8 t -135.28 120.94 30.49 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.507 0 CA-C-O 121.212 0.53 . . . . 0.0 109.973 -178.512 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.599 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 61.5 t -89.61 88.74 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.286 0 N-CA-C 106.349 -1.722 . . . . 0.0 106.349 174.203 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -81.67 110.12 16.72 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-O 121.202 0.525 . . . . 0.0 111.42 -177.281 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.5 mt -96.45 -3.0 44.21 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.438 -178.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.2 m -73.07 0.03 12.64 Favored 'General case' 0 CA--C 1.551 1.001 0 CA-C-O 122.151 0.977 . . . . 0.0 109.532 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.5 p -126.29 3.0 7.07 Favored 'General case' 0 C--N 1.295 -1.782 0 C-N-CA 123.712 0.805 . . . . 0.0 110.288 178.063 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.582 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 45.5 mm-40 -121.93 -23.47 5.43 Favored 'General case' 0 CA--C 1.506 -0.724 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.815 -173.458 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.8 mt -133.11 140.34 47.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.196 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -176.149 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -137.62 153.46 49.89 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -176.507 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . . . . . . . . . 66.6 m -128.64 134.94 48.68 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 123.537 0.735 . . . . 0.0 109.209 176.384 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.425 ' HB3' ' HA ' ' A' ' 100' ' ' ASP . 22.0 p80 -127.56 145.97 50.68 Favored 'General case' 0 C--N 1.291 -1.968 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.364 -177.011 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.417 HD22 ' CG ' ' A' ' 54' ' ' ASP . 27.4 t-20 -99.85 99.41 10.2 Favored 'General case' 0 C--N 1.293 -1.877 0 C-N-CA 118.637 -1.225 . . . . 0.0 109.035 175.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -72.81 -9.79 59.07 Favored 'General case' 0 C--N 1.296 -1.739 0 C-N-CA 125.145 1.378 . . . . 0.0 112.627 178.62 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 52.4 m-85 -144.63 68.1 14.54 Favored Pre-proline 0 N--CA 1.482 1.174 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 175.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -66.22 -5.33 12.23 Favored 'Trans proline' 0 N--CA 1.488 1.176 0 C-N-CA 123.376 2.717 . . . . 0.0 114.651 -172.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -117.99 -3.14 11.16 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-O 121.282 0.563 . . . . 0.0 109.692 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.501 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.6 OUTLIER -117.51 -30.15 5.6 Favored 'General case' 0 N--CA 1.421 -1.878 0 CA-C-O 121.608 0.718 . . . . 0.0 109.732 -175.117 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.648 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.6 mp -129.16 131.87 67.48 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 -177.455 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.401 ' HB ' ' ND2' ' A' ' 136' ' ' ASN . 9.4 t -76.94 146.37 37.6 Favored 'General case' 0 C--O 1.251 1.145 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 177.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.612 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 0.8 OUTLIER -83.34 108.45 16.54 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 107.974 -1.121 . . . . 0.0 107.974 -178.056 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 22.4 t80 -145.99 129.89 17.27 Favored 'General case' 0 C--N 1.28 -2.425 0 CA-C-O 121.224 0.535 . . . . 0.0 109.62 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.574 HG23 HD13 ' A' ' 131' ' ' LEU . 6.2 p -148.4 149.41 15.18 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.478 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 -178.316 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 5.3 p -150.33 136.36 18.55 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 178.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.459 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 38.0 tp -73.32 110.03 7.29 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 172.307 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -58.98 -55.64 32.5 Favored 'General case' 0 C--N 1.314 -0.969 0 C-N-CA 126.155 1.782 . . . . 0.0 110.584 179.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -165.55 160.21 17.46 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 -177.547 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -138.31 143.18 13.97 Favored Glycine 0 N--CA 1.405 -3.403 0 N-CA-C 108.89 -1.684 . . . . 0.0 108.89 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 68.4 m -129.88 148.97 51.81 Favored 'General case' 0 C--N 1.278 -2.503 0 C-N-CA 123.771 0.829 . . . . 0.0 109.513 -177.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.493 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -110.72 156.6 20.8 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 -178.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.445 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 91.8 m-85 -153.93 -179.59 8.0 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.459 0.704 . . . . 0.0 110.257 -177.169 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.6 -138.39 49.29 Favored Glycine 0 C--O 1.223 -0.566 0 O-C-N 123.944 0.777 . . . . 0.0 112.892 176.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.61 -3.3 89.73 Favored Glycine 0 N--CA 1.425 -2.061 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.628 177.428 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.787 HG21 ' HB ' ' A' ' 126' ' ' ILE . 79.8 t -73.99 -41.91 52.78 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 123.03 0.532 . . . . 0.0 111.464 -178.44 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.493 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -80.17 -23.17 41.23 Favored 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 119.523 -0.871 . . . . 0.0 112.203 179.57 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 13.9 m -100.97 -46.67 5.02 Favored 'General case' 0 N--CA 1.43 -1.458 0 N-CA-C 115.011 1.486 . . . . 0.0 115.011 -174.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.522 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 38.6 m-80 -94.28 -19.92 20.25 Favored 'General case' 0 CA--C 1.494 -1.185 0 C-N-CA 119.87 -0.732 . . . . 0.0 109.48 -178.695 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.659 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 86.9 m-85 -111.76 162.62 15.05 Favored 'General case' 0 N--CA 1.423 -1.808 0 C-N-CA 120.214 -0.594 . . . . 0.0 110.143 179.024 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.2 t -169.57 130.88 1.09 Allowed 'General case' 0 N--CA 1.422 -1.865 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 176.094 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.513 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -164.18 -110.37 0.24 Allowed Glycine 0 N--CA 1.412 -2.958 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 175.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.1 p -158.27 -179.58 8.24 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 124.421 1.089 . . . . 0.0 110.353 -174.122 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -133.66 146.94 31.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 C-N-CA 122.965 0.506 . . . . 0.0 109.993 177.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.64 ' HG3' ' O ' ' A' ' 80' ' ' SER . 77.9 tttt -122.14 146.25 47.41 Favored 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 109.449 -0.574 . . . . 0.0 109.449 -178.783 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.489 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 56.9 t80 -145.27 106.58 4.2 Favored 'General case' 0 C--N 1.307 -1.242 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 -178.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 29.9 t 54.11 38.16 28.51 Favored 'General case' 0 CA--C 1.55 0.943 0 C-N-CA 123.435 0.694 . . . . 0.0 111.268 179.525 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.35 7.81 66.96 Favored Glycine 0 N--CA 1.444 -0.8 0 C-N-CA 120.751 -0.738 . . . . 0.0 113.552 -179.02 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.64 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 15.2 t -79.64 174.32 11.69 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.486 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.5 p -152.06 100.33 2.62 Favored 'General case' 0 C--N 1.287 -2.146 0 CA-C-O 121.125 0.488 . . . . 0.0 109.747 -178.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.489 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 3.1 p90 -144.57 161.3 44.49 Favored Pre-proline 0 C--N 1.307 -1.243 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -173.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.453 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 59.9 Cg_endo -69.93 153.82 67.74 Favored 'Trans proline' 0 C--N 1.356 0.935 0 C-N-CA 123.018 2.479 . . . . 0.0 113.129 -174.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.556 ' CD2' HD21 ' A' ' 109' ' ' LEU . 56.3 t80 -129.53 128.96 23.15 Favored Pre-proline 0 C--N 1.316 -0.87 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.754 179.066 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.452 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 74.0 Cg_endo -69.16 148.65 85.78 Favored 'Cis proline' 0 CA--C 1.547 1.148 0 C-N-CA 122.789 -1.754 . . . . 0.0 110.374 -0.786 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 7.6 t -62.81 -178.59 0.21 Allowed 'General case' 0 CA--C 1.555 1.169 0 CA-C-N 115.567 -0.742 . . . . 0.0 112.733 -173.167 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 16.6 p -130.52 -17.09 3.34 Favored 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 115.845 -0.616 . . . . 0.0 112.489 -173.026 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 27.2 t -133.21 -80.04 0.48 Allowed 'General case' 0 N--CA 1.426 -1.664 0 C-N-CA 120.665 -0.414 . . . . 0.0 110.389 -179.622 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.7 pt-20 179.85 -170.44 0.14 Allowed 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 -178.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.459 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 15.8 p -101.32 162.13 21.48 Favored Pre-proline 0 C--N 1.293 -1.872 0 N-CA-C 113.172 0.805 . . . . 0.0 113.172 178.376 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 28.5 Cg_endo -63.13 163.68 22.1 Favored 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 123.309 2.673 . . . . 0.0 111.542 173.33 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.41 ' C ' ' HD2' ' A' ' 92' ' ' ARG . 3.8 tmm_? -72.81 123.48 23.45 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.901 -178.23 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 98.5 t -130.54 123.0 54.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.498 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 74.2 t -107.49 130.89 58.99 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 177.179 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.612 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 1.8 m-85 -91.77 167.83 11.89 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 106.058 -1.831 . . . . 0.0 106.058 172.589 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 9.3 m120 -132.74 54.37 1.95 Allowed 'General case' 0 C--N 1.258 -3.377 0 N-CA-C 104.845 -2.28 . . . . 0.0 104.845 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . 0.481 ' HB3' ' HG3' ' A' ' 101' ' ' LYS . 66.2 p -113.09 161.35 17.2 Favored 'General case' 0 N--CA 1.414 -2.226 0 N-CA-C 114.44 1.274 . . . . 0.0 114.44 -167.366 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 35.1 ptt180 -144.74 30.18 1.21 Allowed 'General case' 0 C--N 1.3 -1.56 0 CA-C-N 114.375 -1.284 . . . . 0.0 108.177 171.189 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.9 t -159.26 177.08 11.41 Favored 'General case' 0 N--CA 1.438 -1.053 0 CA-C-N 113.826 -1.533 . . . . 0.0 107.087 -179.541 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . 0.425 ' HA ' ' HB3' ' A' ' 45' ' ' HIS . 5.3 m-20 -71.26 111.48 6.64 Favored 'General case' 0 CA--C 1.5 -0.959 0 O-C-N 123.533 0.52 . . . . 0.0 109.632 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . 0.607 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 7.4 mmpt? -111.37 143.57 28.74 Favored Pre-proline 0 C--N 1.288 -2.092 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 174.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.484 ' O ' ' HD3' ' A' ' 104' ' ' PRO . 33.7 Cg_endo -67.12 144.29 68.66 Favored 'Trans proline' 0 N--CA 1.446 -1.317 0 C-N-CA 122.608 2.206 . . . . 0.0 111.95 -177.09 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 14.1 t90 -89.46 101.14 2.83 Favored Pre-proline 0 C--N 1.307 -1.248 0 N-CA-C 105.657 -1.979 . . . . 0.0 105.657 179.258 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.484 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 73.2 Cg_endo -75.17 88.65 1.24 Allowed 'Trans proline' 0 N--CA 1.452 -0.926 0 C-N-CA 122.016 1.811 . . . . 0.0 112.841 -171.024 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.453 HG22 ' CD2' ' A' ' 77' ' ' TYR . 93.2 t -136.91 142.94 36.36 Favored 'Isoleucine or valine' 0 CA--C 1.487 -1.465 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 179.015 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.599 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.99 134.19 18.29 Favored 'General case' 0 N--CA 1.412 -2.346 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.335 178.758 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.498 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 19.0 mt -98.95 102.32 14.01 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 179.013 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.513 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 13.1 m-85 -79.01 65.41 4.18 Favored 'General case' 0 C--N 1.294 -1.81 0 C-N-CA 122.955 0.502 . . . . 0.0 111.517 178.297 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.684 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.9 mm? -92.14 135.3 34.1 Favored 'General case' 0 C--O 1.205 -1.24 0 O-C-N 121.958 -0.464 . . . . 0.0 110.162 177.142 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.02 145.24 51.67 Favored Pre-proline 0 N--CA 1.418 -2.065 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.468 -176.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.522 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 24.3 Cg_endo -60.21 120.81 8.8 Favored 'Trans proline' 0 C--O 1.243 0.775 0 C-N-CA 123.402 2.735 . . . . 0.0 111.972 -177.292 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.434 ' O ' HG13 ' A' ' 30' ' ' VAL . 2.6 m -69.53 -115.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.189 -2.085 0 CA-C-N 114.436 -1.256 . . . . 0.0 112.668 177.193 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.3 m -110.92 -46.29 3.36 Favored 'General case' 0 C--N 1.29 -1.996 0 O-C-N 121.471 -0.768 . . . . 0.0 110.144 178.315 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 13.3 t -86.1 31.18 0.64 Allowed 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.898 -173.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -95.18 131.69 40.95 Favored 'General case' 0 N--CA 1.423 -1.803 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 178.421 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -168.66 139.82 5.85 Favored Glycine 0 N--CA 1.432 -1.579 0 C-N-CA 120.331 -0.938 . . . . 0.0 111.808 179.277 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 57.49 -144.48 40.38 Favored Glycine 0 CA--C 1.488 -1.607 0 C-N-CA 123.914 0.769 . . . . 0.0 113.072 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -58.67 94.48 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 122.821 1.296 . . . . 0.0 111.995 -177.559 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.16 -22.53 16.14 Favored 'General case' 0 C--N 1.297 -1.691 0 CA-C-N 114.774 -1.103 . . . . 0.0 111.398 -176.507 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.473 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 59.0 mt -136.48 137.74 47.49 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 107.853 -1.165 . . . . 0.0 107.853 177.389 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.481 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.6 mmpt? -112.0 139.59 47.38 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-O 120.831 0.348 . . . . 0.0 111.793 179.201 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.21 120.52 16.02 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 178.429 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.57 -5.54 64.7 Favored Glycine 0 C--N 1.309 -0.923 0 N-CA-C 111.733 -0.547 . . . . 0.0 111.733 -176.726 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 34.1 t -90.23 142.91 27.26 Favored 'General case' 0 C--O 1.252 1.194 0 N-CA-C 108.029 -1.1 . . . . 0.0 108.029 178.243 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 30.1 tp -71.86 133.41 45.44 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 177.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.787 ' HB ' HG21 ' A' ' 67' ' ' VAL . 40.6 pt -118.8 -24.71 3.08 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.039 0 C-N-CA 120.347 -0.541 . . . . 0.0 112.28 -178.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . 0.445 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -163.97 164.38 23.2 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 120.966 -0.293 . . . . 0.0 110.449 -178.018 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 55.4 t -140.17 114.29 6.4 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 178.12 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.471 HD11 HD21 ' A' ' 107' ' ' LEU . 56.9 mt -118.26 147.08 43.79 Favored 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 108.169 -1.049 . . . . 0.0 108.169 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.453 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.8 mp -129.23 126.36 63.84 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 C-N-CA 120.16 -0.616 . . . . 0.0 110.065 178.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.574 HD13 HG23 ' A' ' 56' ' ' VAL . 1.4 pp -92.26 150.56 20.8 Favored 'General case' 0 CA--C 1.476 -1.897 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 173.332 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 56.4 ttp180 -115.11 116.69 28.81 Favored 'General case' 0 C--N 1.25 -3.727 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 176.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -100.51 120.25 39.73 Favored 'General case' 0 N--CA 1.445 -0.707 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 -175.1 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 5.4 m -133.58 144.26 49.19 Favored 'General case' 0 C--N 1.287 -2.125 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 179.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.648 ' CB ' HG23 ' A' ' 52' ' ' ILE . 8.0 p30 -132.83 165.59 24.24 Favored 'General case' 0 N--CA 1.436 -1.137 0 C-N-CA 118.227 -1.389 . . . . 0.0 111.877 174.437 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.401 ' ND2' ' HB ' ' A' ' 53' ' ' THR . 3.5 p30 -86.12 -16.16 38.86 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 113.81 -1.541 . . . . 0.0 112.147 -170.571 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 37.2 t80 -98.51 -61.41 1.38 Allowed 'General case' 0 C--N 1.3 -1.557 0 CA-C-O 121.336 0.589 . . . . 0.0 111.195 -173.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 3.0 m-20 -89.62 163.55 15.11 Favored 'General case' 0 C--N 1.284 -2.239 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.807 178.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 22.8 t -88.25 40.78 0.97 Allowed 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -88.59 111.16 21.56 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 108.266 -1.012 . . . . 0.0 108.266 178.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -145.15 79.52 1.59 Allowed 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 107.442 -1.318 . . . . 0.0 107.442 179.219 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 82.2 m-85 -121.83 167.93 12.43 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 114.734 -1.121 . . . . 0.0 108.032 -175.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -131.39 145.4 51.8 Favored 'General case' 0 N--CA 1.415 -2.193 0 C-N-CA 118.549 -1.26 . . . . 0.0 111.798 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 8.6 m-30 -113.77 126.75 55.56 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 108.266 -1.012 . . . . 0.0 108.266 -175.374 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 48.4 t -89.72 133.59 31.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 123.544 0.528 . . . . 0.0 110.304 -179.379 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 58.0 m95 -120.04 100.46 7.22 Favored 'General case' 0 C--N 1.285 -2.236 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 -179.678 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -82.77 111.83 19.05 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 106.608 -1.627 . . . . 0.0 106.608 178.112 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.445 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 22.6 mm -86.72 121.57 37.81 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.78 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 -176.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -118.26 154.66 31.9 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 177.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 121' ' ' LYS . . . -80.96 128.0 33.2 Favored 'General case' 0 N--CA 1.406 -2.661 0 CA-C-N 115.243 -0.889 . . . . 0.0 108.699 176.167 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 37.0 t-20 -88.87 -8.9 53.43 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 106.719 -1.585 . . . . 0.0 106.719 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -156.0 139.75 16.13 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 113.679 -1.6 . . . . 0.0 109.605 -176.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -77.86 147.95 34.89 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 124.538 1.135 . . . . 0.0 110.067 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.494 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 73.7 t -123.58 138.1 54.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.913 -176.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.7 t -118.65 136.14 56.8 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.576 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.502 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 76.3 t -100.0 104.4 28.64 Favored Pre-proline 0 C--N 1.285 -2.224 0 C-N-CA 123.202 0.601 . . . . 0.0 109.416 178.26 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.454 ' HG3' HG13 ' A' ' 27' ' ' VAL . 33.7 Cg_endo -69.78 -25.12 28.84 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.121 1.881 . . . . 0.0 111.02 176.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.451 ' HB ' HG12 ' A' ' 156' ' ' VAL 0.274 6.0 t . . . . . 0 C--O 1.247 0.928 0 O-C-N 124.638 1.211 . . . . 0.0 113.204 176.712 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.563 ' HA ' ' HA ' ' A' ' 46' ' ' ASN . 61.8 t80 . . . . . 0 CA--C 1.487 -1.466 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.449 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -149.49 169.41 20.97 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 -179.411 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 65.1 m -130.73 158.3 40.49 Favored 'General case' 0 C--N 1.287 -2.112 0 C-N-CA 120.013 -0.675 . . . . 0.0 111.272 -172.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.457 ' HD2' ' O ' ' A' ' 5' ' ' THR . 0.0 OUTLIER -145.91 164.41 32.07 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.608 -175.002 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.556 HG22 HG22 ' A' ' 20' ' ' VAL . 68.1 p -99.91 -179.52 4.19 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-O 121.449 0.642 . . . . 0.0 111.787 -178.407 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.88 -20.44 38.83 Favored 'General case' 0 C--N 1.296 -1.72 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.108 177.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -88.45 -25.83 22.43 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.094 -0.957 . . . . 0.0 112.186 -179.758 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 128.35 8.47 4.02 Favored Glycine 0 CA--C 1.496 -1.107 0 C-N-CA 119.354 -1.403 . . . . 0.0 114.241 170.232 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 m -83.49 98.86 9.76 Favored 'General case' 0 C--N 1.292 -1.93 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 -179.174 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.05 109.1 21.19 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.888 179.372 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.449 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 64.8 mt -86.17 120.24 72.24 Favored Pre-proline 0 C--N 1.305 -1.359 0 N-CA-C 109.325 -0.621 . . . . 0.0 109.325 -177.673 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -79.06 168.39 20.64 Favored 'Trans proline' 0 C--O 1.252 1.204 0 C-N-CA 122.65 2.233 . . . . 0.0 110.742 178.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.3 mt -71.14 128.09 33.88 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.3 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 178.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 139.37 -8.68 3.19 Favored Glycine 0 C--N 1.296 -1.681 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 -176.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.58 148.36 22.13 Favored Glycine 0 N--CA 1.442 -0.944 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.351 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.98 -174.05 46.15 Favored Glycine 0 N--CA 1.435 -1.37 0 C-N-CA 120.493 -0.861 . . . . 0.0 111.156 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 28.8 p -143.02 151.02 40.37 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.2 162.33 33.26 Favored 'General case' 0 N--CA 1.415 -2.223 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 -179.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -107.72 117.01 32.99 Favored 'General case' 0 C--N 1.278 -2.52 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 176.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.556 HG22 HG22 ' A' ' 5' ' ' THR . 40.7 t -105.43 132.04 53.31 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.778 0 CA-C-N 115.484 -0.78 . . . . 0.0 109.138 178.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.4 m-85 -118.52 123.04 44.13 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 -179.002 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.482 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.4 p -131.28 134.55 60.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 CA-C-N 115.645 -0.707 . . . . 0.0 111.005 -176.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 5.6 p30 -98.03 119.17 36.18 Favored 'General case' 0 C--N 1.304 -1.372 0 CA-C-O 121.737 0.78 . . . . 0.0 110.585 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.422 HD11 HG22 ' A' ' 36' ' ' VAL . 2.8 mm? -99.45 160.78 14.03 Favored 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 114.59 -1.187 . . . . 0.0 109.13 -177.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.03 121.51 46.68 Favored Pre-proline 0 C--O 1.212 -0.884 0 O-C-N 124.478 1.111 . . . . 0.0 109.076 176.108 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 73.4 Cg_endo -74.31 -2.62 12.61 Favored 'Trans proline' 0 C--O 1.22 -0.42 0 C-N-CA 122.811 2.341 . . . . 0.0 113.277 -175.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.446 HG13 ' HG3' ' A' ' 157' ' ' PRO . 86.0 t -126.54 109.74 21.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.494 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 4.2 t -145.05 110.82 1.15 Allowed 'Isoleucine or valine' 0 C--O 1.188 -2.167 0 N-CA-C 108.166 -1.05 . . . . 0.0 108.166 -177.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.654 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -98.32 153.12 18.76 Favored 'General case' 0 C--N 1.272 -2.789 0 C-N-CA 123.305 0.642 . . . . 0.0 111.766 -178.346 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.412 HG22 ' O ' ' A' ' 112' ' ' VAL . 40.5 t -46.8 115.74 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 123.318 0.647 . . . . 0.0 111.524 175.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 109.01 -8.13 33.37 Favored Glycine 0 C--N 1.322 -0.227 0 CA-C-N 115.445 -0.798 . . . . 0.0 112.558 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.654 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.3 OUTLIER -65.98 -177.38 0.48 Allowed 'General case' 0 C--N 1.317 -0.831 0 C-N-CA 124.468 1.107 . . . . 0.0 112.069 177.725 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -137.43 95.34 3.06 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 177.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.616 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 25.3 tp -93.5 146.29 23.89 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 -177.466 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.2 t -132.9 120.01 39.46 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.75 0 CA-C-O 120.978 0.418 . . . . 0.0 110.184 -176.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.613 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 55.0 t -92.84 88.63 2.6 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.338 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 172.763 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -82.26 106.77 14.42 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.25 0.548 . . . . 0.0 110.63 -176.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 89.6 mt -90.27 -0.76 57.78 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.986 -177.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 9.7 t -78.18 0.88 23.25 Favored 'General case' 0 C--N 1.309 -1.184 0 CA-C-O 122.271 1.034 . . . . 0.0 109.134 -179.227 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.6 p -125.3 5.57 7.74 Favored 'General case' 0 C--N 1.298 -1.658 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.848 175.539 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.482 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 51.4 mm-40 -122.61 -26.59 4.51 Favored 'General case' 0 CA--C 1.501 -0.934 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.586 -173.812 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 18.3 mt -132.57 139.64 49.4 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.233 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 -175.27 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.401 ' HB2' ' HE3' ' A' ' 4' ' ' LYS . 70.2 m-85 -138.28 144.71 40.61 Favored 'General case' 0 C--N 1.319 -0.757 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -175.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.556 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 72.7 m -121.32 135.11 55.14 Favored 'General case' 0 C--N 1.284 -2.275 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 177.698 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 22.8 p-80 -134.13 163.08 30.39 Favored 'General case' 0 C--N 1.309 -1.195 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 -175.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.563 ' HA ' ' HA ' ' A' ' 1' ' ' PHE . 16.1 t-20 -113.25 111.46 22.08 Favored 'General case' 0 N--CA 1.423 -1.786 0 C-N-CA 118.574 -1.25 . . . . 0.0 111.047 179.187 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 17.4 p-10 -85.74 -4.7 59.23 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 124.573 1.149 . . . . 0.0 111.224 179.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.458 ' HB2' HD13 ' A' ' 52' ' ' ILE . 85.4 m-85 -143.97 65.46 13.9 Favored Pre-proline 0 N--CA 1.477 0.877 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 174.575 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.452 ' HB2' ' HB2' ' A' ' 98' ' ' ARG . 68.5 Cg_endo -72.32 3.98 3.71 Favored 'Trans proline' 0 N--CA 1.481 0.74 0 C-N-CA 123.498 2.799 . . . . 0.0 115.295 -169.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -114.33 -28.51 7.22 Favored 'General case' 0 C--N 1.285 -2.227 0 CA-C-O 121.735 0.779 . . . . 0.0 110.495 -178.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.557 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.0 OUTLIER -101.74 -30.07 11.53 Favored 'General case' 0 C--N 1.28 -2.455 0 CA-C-N 115.046 -0.979 . . . . 0.0 111.126 -174.063 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.557 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.4 mp -121.0 132.37 70.65 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.661 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -176.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 15.1 t -79.46 145.96 33.0 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 177.768 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.521 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 1.2 m-20 -79.5 109.57 14.0 Favored 'General case' 0 C--N 1.282 -2.368 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 -179.496 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -150.42 138.34 20.06 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 -170.705 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.444 HG23 HD13 ' A' ' 131' ' ' LEU . 14.9 p -151.31 153.45 9.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -178.6 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -150.11 128.83 12.39 Favored 'General case' 0 C--O 1.208 -1.109 0 CA-C-O 119.381 -0.343 . . . . 0.0 110.125 175.75 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.516 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 49.5 tp -75.24 109.2 8.54 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.828 0.823 . . . . 0.0 109.277 174.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 7.0 tp60 -55.47 -54.16 47.34 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 126.479 1.912 . . . . 0.0 111.461 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 8.4 ptp180 -169.88 159.6 7.97 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 -176.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.408 ' H ' HG22 ' A' ' 86' ' ' THR . . . -136.47 144.29 15.94 Favored Glycine 0 N--CA 1.406 -3.324 0 N-CA-C 109.007 -1.637 . . . . 0.0 109.007 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 73.6 m -132.88 150.58 52.15 Favored 'General case' 0 C--N 1.281 -2.406 0 C-N-CA 123.459 0.704 . . . . 0.0 109.831 -177.53 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.524 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -113.51 158.51 20.64 Favored 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 179.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.5 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . 98.8 m-85 -155.2 -179.74 8.37 Favored 'General case' 0 C--N 1.342 0.276 0 C-N-CA 124.436 1.094 . . . . 0.0 109.678 -177.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.56 -142.22 45.64 Favored Glycine 0 C--O 1.238 0.383 0 O-C-N 123.794 0.684 . . . . 0.0 112.839 176.429 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.455 ' HA3' ' O ' ' A' ' 119' ' ' ALA . . . -77.71 -7.81 87.26 Favored Glycine 0 N--CA 1.435 -1.387 0 C-N-CA 120.77 -0.729 . . . . 0.0 111.482 177.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.824 HG21 ' HB ' ' A' ' 126' ' ' ILE . 99.3 t -71.0 -42.14 76.94 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.368 0 C-N-CA 123.279 0.632 . . . . 0.0 111.428 -179.207 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.524 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -85.41 -14.82 45.08 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 118.554 -1.258 . . . . 0.0 112.405 178.851 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 8.8 t -100.33 -48.89 4.43 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 120.324 -0.55 . . . . 0.0 111.651 -175.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.47 ' O ' HG22 ' A' ' 112' ' ' VAL . 35.1 m-80 -95.67 -22.24 17.69 Favored 'General case' 0 CA--C 1.497 -1.087 0 C-N-CA 120.472 -0.491 . . . . 0.0 110.187 -176.39 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.561 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 95.8 m-85 -109.43 154.02 23.19 Favored 'General case' 0 N--CA 1.423 -1.778 0 C-N-CA 120.061 -0.656 . . . . 0.0 110.78 -179.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.9 t -165.0 121.1 1.42 Allowed 'General case' 0 N--CA 1.416 -2.126 0 N-CA-C 106.822 -1.548 . . . . 0.0 106.822 174.117 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.422 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -152.83 -113.29 0.53 Allowed Glycine 0 N--CA 1.408 -3.232 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 177.673 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.466 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.0 OUTLIER -152.75 179.3 8.75 Favored 'General case' 0 C--N 1.287 -2.128 0 C-N-CA 123.101 0.56 . . . . 0.0 110.557 -174.718 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.6 p -136.69 145.43 30.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.749 0 C-N-CA 123.004 0.522 . . . . 0.0 109.653 178.563 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.626 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.3 tttt -124.54 144.24 50.24 Favored 'General case' 0 N--CA 1.417 -2.094 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.49 ' CD2' HG22 ' A' ' 105' ' ' VAL . 62.7 t80 -145.56 115.15 7.23 Favored 'General case' 0 C--N 1.289 -2.047 0 N-CA-C 107.358 -1.349 . . . . 0.0 107.358 -178.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 15.1 m 52.76 40.58 30.75 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 114.187 1.18 . . . . 0.0 114.187 175.55 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 80.76 10.48 85.09 Favored Glycine 0 N--CA 1.442 -0.96 0 C-N-CA 119.986 -1.102 . . . . 0.0 112.606 179.439 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.626 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 8.9 t -85.41 -179.7 6.99 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 177.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 31.5 t -157.03 112.22 2.82 Favored 'General case' 0 C--N 1.287 -2.122 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 -178.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.456 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 4.9 p90 -155.27 161.51 29.3 Favored Pre-proline 0 CA--C 1.556 1.182 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -175.463 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.466 ' HA ' HG22 ' A' ' 74' ' ' THR . 56.5 Cg_endo -69.86 153.19 68.76 Favored 'Trans proline' 0 C--N 1.36 1.173 0 C-N-CA 122.979 2.453 . . . . 0.0 112.931 -177.643 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.501 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 63.2 t80 -124.57 130.55 24.25 Favored Pre-proline 0 N--CA 1.442 -0.862 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.469 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.501 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 72.2 Cg_endo -69.92 151.62 92.01 Favored 'Cis proline' 0 CA--C 1.542 0.897 0 C-N-CA 122.999 -1.667 . . . . 0.0 110.124 -1.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.408 HG22 ' H ' ' A' ' 61' ' ' GLY . 8.9 t -58.36 -178.0 0.04 OUTLIER 'General case' 0 CA--C 1.552 1.02 0 CA-C-O 122.088 0.947 . . . . 0.0 112.9 -173.711 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 10.1 p -119.43 -20.8 7.69 Favored 'General case' 0 N--CA 1.423 -1.812 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.778 -175.048 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 23.1 t -141.95 -82.47 0.2 Allowed 'General case' 0 N--CA 1.432 -1.336 0 C-N-CA 120.544 -0.462 . . . . 0.0 110.964 -177.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -170.89 -172.87 1.22 Allowed 'General case' 0 C--O 1.241 0.631 0 N-CA-C 104.536 -2.394 . . . . 0.0 104.536 -177.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.516 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 42.0 p -100.9 158.18 32.29 Favored Pre-proline 0 C--N 1.293 -1.86 0 C-N-CA 120.52 -0.472 . . . . 0.0 111.375 176.39 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -59.26 161.2 17.17 Favored 'Trans proline' 0 C--O 1.243 0.771 0 C-N-CA 123.16 2.573 . . . . 0.0 110.769 173.536 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.2 tmm_? -69.25 120.64 15.4 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.445 -178.438 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 72.4 t -128.09 124.68 63.05 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-O 121.633 0.73 . . . . 0.0 111.05 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 70.5 t -112.64 126.16 70.0 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.893 0 CA-C-N 115.095 -0.957 . . . . 0.0 108.853 176.639 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.521 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.2 m-85 -72.43 110.63 6.97 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 175.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -81.79 61.76 5.29 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 108.328 -0.989 . . . . 0.0 108.328 176.624 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.7 m -142.35 -168.52 2.75 Favored 'General case' 0 N--CA 1.419 -1.982 0 C-N-CA 125.34 1.456 . . . . 0.0 107.685 -177.481 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.452 ' HB2' ' HB2' ' A' ' 49' ' ' PRO . 34.0 ptt180 -163.23 34.76 0.09 Allowed 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 106.465 -1.68 . . . . 0.0 106.465 176.842 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.4 t -160.45 175.9 12.25 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 114.755 -1.112 . . . . 0.0 109.036 -168.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 8.7 p-10 -70.7 114.01 8.35 Favored 'General case' 0 C--O 1.239 0.513 0 CA-C-O 122.021 0.915 . . . . 0.0 111.746 -176.297 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.6 mptm? -127.48 143.52 47.64 Favored Pre-proline 0 C--N 1.292 -1.907 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.382 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -63.29 147.22 93.92 Favored 'Trans proline' 0 C--O 1.247 0.961 0 C-N-CA 122.693 2.262 . . . . 0.0 111.78 177.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . 0.509 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 9.6 t90 -86.46 111.85 42.21 Favored Pre-proline 0 C--N 1.304 -1.378 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 -178.091 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_endo -82.04 87.12 1.45 Allowed 'Trans proline' 0 N--CA 1.439 -1.698 0 C-N-CA 121.031 1.154 . . . . 0.0 112.122 -172.245 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.49 HG22 ' CD2' ' A' ' 77' ' ' TYR . 80.2 t -137.56 146.33 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.668 0 N-CA-C 107.174 -1.417 . . . . 0.0 107.174 176.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.613 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -153.66 132.28 12.21 Favored 'General case' 0 C--N 1.287 -2.143 0 O-C-N 123.41 0.444 . . . . 0.0 110.428 178.049 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.477 HD21 HD11 ' A' ' 129' ' ' LEU . 16.9 mt -97.01 101.02 12.52 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.422 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 53.7 m-85 -79.33 73.04 5.96 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 120.884 0.373 . . . . 0.0 110.673 177.421 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.63 ' HG ' HG13 ' A' ' 67' ' ' VAL . 2.7 mm? -87.08 150.62 23.88 Favored 'General case' 0 C--O 1.192 -1.966 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.474 176.575 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.57 139.57 13.15 Favored Pre-proline 0 C--N 1.278 -2.501 0 CA-C-N 116.482 -0.326 . . . . 0.0 110.611 -179.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 18.0 Cg_endo -60.16 121.55 9.97 Favored 'Trans proline' 0 C--O 1.247 0.969 0 C-N-CA 123.189 2.593 . . . . 0.0 111.87 -179.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.47 HG22 ' O ' ' A' ' 70' ' ' ASN . 3.5 m -70.3 -123.08 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.182 -2.478 0 CA-C-N 114.77 -1.105 . . . . 0.0 111.478 175.655 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 30.9 m -111.95 -19.39 12.38 Favored 'General case' 0 C--N 1.282 -2.331 0 CA-C-O 122.548 1.166 . . . . 0.0 108.877 177.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.446 ' H ' HG23 ' A' ' 112' ' ' VAL . 1.2 m -85.37 6.79 24.99 Favored 'General case' 0 N--CA 1.405 -2.696 0 CA-C-N 113.595 -1.639 . . . . 0.0 112.568 -173.301 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -97.6 138.18 35.4 Favored 'General case' 0 C--N 1.266 -3.051 0 CA-C-N 115.174 -0.921 . . . . 0.0 111.192 -172.242 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -177.26 124.16 0.93 Allowed Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.173 -1.013 . . . . 0.0 112.671 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.11 -147.72 50.34 Favored Glycine 0 CA--C 1.488 -1.645 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 -175.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.408 ' CG1' ' HE3' ' A' ' 121' ' ' LYS . 93.9 t -53.1 111.33 0.26 Allowed 'Isoleucine or valine' 0 C--O 1.248 0.997 0 CA-C-O 121.709 0.766 . . . . 0.0 110.741 -178.717 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . 0.455 ' O ' ' HA3' ' A' ' 66' ' ' GLY . . . -113.51 -22.66 10.21 Favored 'General case' 0 C--N 1.299 -1.597 0 CA-C-N 114.212 -1.358 . . . . 0.0 111.619 -179.459 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.472 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.7 mt -135.01 137.72 50.13 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 178.374 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.575 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 5.3 mmpt? -112.49 141.48 46.18 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 121.144 0.497 . . . . 0.0 111.602 177.811 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.408 ' H ' ' HB3' ' A' ' 153' ' ' ASP . . . -72.03 134.8 46.08 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.87 179.248 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 85.18 -1.23 88.78 Favored Glycine 0 C--N 1.312 -0.79 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.005 -179.338 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 59.8 m -96.5 148.73 22.52 Favored 'General case' 0 N--CA 1.421 -1.906 0 CA-C-O 120.94 0.4 . . . . 0.0 110.066 179.157 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.447 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -77.83 122.59 25.64 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -179.226 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.824 ' HB ' HG21 ' A' ' 67' ' ' VAL . 30.8 pt -109.42 -27.19 2.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 N-CA-C 112.853 0.686 . . . . 0.0 112.853 -177.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . 0.421 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.49 166.68 26.79 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 110.288 -0.264 . . . . 0.0 110.288 -178.01 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.447 HG23 HD11 ' A' ' 125' ' ' LEU . 74.6 t -142.5 112.78 2.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 179.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.477 HD11 HD21 ' A' ' 107' ' ' LEU . 58.3 mt -115.87 146.77 41.73 Favored 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 178.786 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.496 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.7 mp -128.61 125.22 63.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 C-N-CA 120.028 -0.669 . . . . 0.0 109.227 178.541 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.444 HD13 HG23 ' A' ' 56' ' ' VAL . 1.3 pp -91.0 148.96 22.04 Favored 'General case' 0 CA--C 1.478 -1.821 0 N-CA-C 106.004 -1.85 . . . . 0.0 106.004 174.453 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 32.1 ttt180 -118.78 123.91 45.95 Favored 'General case' 0 C--N 1.253 -3.592 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 176.189 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.476 ' HB2' ' O ' ' A' ' 142' ' ' PHE . 13.3 mm-40 -79.91 143.35 34.33 Favored 'General case' 0 N--CA 1.411 -2.376 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.525 179.463 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.488 ' HA ' ' OD1' ' A' ' 141' ' ' ASP . 17.7 m -154.33 127.36 8.3 Favored 'General case' 0 C--N 1.269 -2.929 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 170.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.486 ' HB2' HG23 ' A' ' 52' ' ' ILE . 15.7 p30 -128.53 -168.71 1.95 Allowed 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.715 -0.794 . . . . 0.0 111.075 -178.713 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 6.5 p30 -110.39 3.28 19.6 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 120.907 0.384 . . . . 0.0 111.196 -174.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 92.7 t80 -122.16 -68.13 0.91 Allowed 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.83 -170.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . 0.452 ' HB2' HD21 ' A' ' 135' ' ' ASN . 19.7 m120 -76.8 166.43 23.36 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.861 177.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 19.8 t -113.17 26.5 10.41 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 105.994 -1.854 . . . . 0.0 105.994 172.087 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . 0.426 ' OD1' ' HB3' ' A' ' 138' ' ' ASN . 4.0 m-20 -94.85 45.51 1.11 Allowed 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 113.372 -1.74 . . . . 0.0 108.167 -178.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . 0.488 ' OD1' ' HA ' ' A' ' 134' ' ' THR . 9.4 m-20 -81.68 74.34 8.67 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 114.783 -1.098 . . . . 0.0 109.062 -177.153 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . 0.476 ' O ' ' HB2' ' A' ' 133' ' ' GLN . 95.8 m-85 -91.27 178.09 6.07 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.858 -0.61 . . . . 0.0 110.23 -179.5 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 11.9 pt20 -126.79 144.62 50.9 Favored 'General case' 0 C--N 1.296 -1.757 0 C-N-CA 119.72 -0.792 . . . . 0.0 110.193 -179.046 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 11.0 m-30 -113.74 128.93 56.61 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 -175.278 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 47.4 t -90.96 134.06 30.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 123.478 0.486 . . . . 0.0 110.35 -177.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 59.9 m95 -120.69 98.6 6.1 Favored 'General case' 0 C--N 1.288 -2.07 0 N-CA-C 108.761 -0.829 . . . . 0.0 108.761 -179.477 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 45.1 m-80 -81.21 110.85 17.08 Favored 'General case' 0 C--N 1.288 -2.086 0 N-CA-C 106.957 -1.497 . . . . 0.0 106.957 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.446 HG22 HD11 ' A' ' 126' ' ' ILE . 23.3 mm -85.68 122.4 38.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 108.503 -0.925 . . . . 0.0 108.503 -177.534 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -118.0 150.98 38.37 Favored 'General case' 0 C--N 1.295 -1.77 0 C-N-CA 123.552 0.741 . . . . 0.0 109.012 178.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.08 130.36 35.06 Favored 'General case' 0 N--CA 1.413 -2.317 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 176.522 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 29.8 t-20 -89.55 -15.7 32.31 Favored 'General case' 0 C--N 1.288 -2.1 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 -177.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -149.3 141.88 24.42 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 114.059 -1.428 . . . . 0.0 109.207 -174.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . 0.408 ' HB3' ' H ' ' A' ' 122' ' ' ALA . 8.7 p-10 -85.94 138.03 32.3 Favored 'General case' 0 C--N 1.314 -0.949 0 O-C-N 123.944 0.777 . . . . 0.0 111.561 -178.474 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.472 ' HB ' ' HB ' ' A' ' 120' ' ' ILE . 75.1 t -112.21 141.42 27.79 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-N 115.015 -0.993 . . . . 0.0 111.894 -173.105 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 5.1 t -119.69 139.05 48.31 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.131 0 N-CA-C 108.12 -1.066 . . . . 0.0 108.12 -179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.494 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 62.1 t -103.2 102.24 27.23 Favored Pre-proline 0 C--N 1.285 -2.197 0 C-N-CA 123.89 0.876 . . . . 0.0 110.065 178.414 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.463 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 34.5 Cg_endo -68.3 -22.68 39.57 Favored 'Trans proline' 0 C--O 1.222 -0.305 0 C-N-CA 122.144 1.896 . . . . 0.0 111.589 178.278 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.474 ' HB ' HG12 ' A' ' 156' ' ' VAL 0.25 7.4 t . . . . . 0 CA--C 1.547 0.85 0 C-N-CA 124.791 1.236 . . . . 0.0 113.714 175.69 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.741 ' CZ ' ' HB3' ' A' ' 133' ' ' GLN . 24.2 t80 . . . . . 0 N--CA 1.425 -1.718 0 CA-C-O 121.915 0.865 . . . . 0.0 110.183 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.506 ' HB3' ' CE1' ' A' ' 45' ' ' HIS . . . -121.37 -177.76 3.61 Favored 'General case' 0 C--N 1.289 -2.05 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.202 176.4 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.528 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 13.5 t -157.12 160.66 39.05 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.294 -175.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.27 164.3 31.81 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.455 -177.324 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.552 HG22 HG22 ' A' ' 20' ' ' VAL . 73.8 p -102.22 177.85 4.76 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-O 121.427 0.632 . . . . 0.0 111.024 -179.71 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.72 -18.27 44.92 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 114.71 -1.132 . . . . 0.0 109.347 179.131 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -91.82 -24.42 19.38 Favored 'General case' 0 N--CA 1.432 -1.363 0 CA-C-N 114.893 -1.049 . . . . 0.0 111.822 -177.621 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 120.17 34.46 0.96 Allowed Glycine 0 CA--C 1.488 -1.614 0 C-N-CA 119.308 -1.425 . . . . 0.0 113.315 170.005 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -110.13 98.93 8.09 Favored 'General case' 0 N--CA 1.423 -1.823 0 N-CA-C 107.842 -1.17 . . . . 0.0 107.842 176.501 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -90.97 123.18 34.26 Favored 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 115.157 -0.929 . . . . 0.0 109.451 177.03 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.403 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 68.3 mt -100.39 116.22 64.62 Favored Pre-proline 0 C--N 1.288 -2.07 0 N-CA-C 109.484 -0.562 . . . . 0.0 109.484 177.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -75.53 164.78 31.78 Favored 'Trans proline' 0 C--O 1.249 1.055 0 C-N-CA 122.661 2.241 . . . . 0.0 110.85 176.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.4 mt -69.49 121.03 18.12 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 148.77 -6.0 0.85 Allowed Glycine 0 C--N 1.305 -1.162 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 -174.142 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 100.0 149.39 23.81 Favored Glycine 0 N--CA 1.431 -1.665 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 176.83 178.57 46.68 Favored Glycine 0 N--CA 1.418 -2.502 0 C-N-CA 119.133 -1.508 . . . . 0.0 112.132 -179.218 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.416 ' HA ' ' O ' ' A' ' 145' ' ' VAL . 7.9 p -140.67 142.08 34.96 Favored 'General case' 0 C--N 1.285 -2.226 0 N-CA-C 108.795 -0.816 . . . . 0.0 108.795 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.41 153.06 51.2 Favored 'General case' 0 CA--C 1.474 -1.969 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 -178.018 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -98.68 116.67 31.43 Favored 'General case' 0 C--N 1.278 -2.53 0 CA-C-N 114.751 -1.113 . . . . 0.0 108.19 174.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.552 HG22 HG22 ' A' ' 5' ' ' THR . 26.1 t -103.76 127.39 57.9 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.573 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 54.2 m-85 -110.84 125.27 53.42 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 121.336 -0.146 . . . . 0.0 110.954 -179.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.486 HG22 ' HG3' ' A' ' 41' ' ' GLN . 21.2 t -126.93 121.8 58.96 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.036 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -176.691 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -85.13 120.88 27.12 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-O 121.411 0.624 . . . . 0.0 110.432 175.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 50.7 mt -109.93 160.9 16.0 Favored 'General case' 0 N--CA 1.424 -1.755 0 CA-C-N 114.452 -1.249 . . . . 0.0 108.251 -175.263 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.5 121.18 58.61 Favored Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 124.65 1.219 . . . . 0.0 109.411 -179.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 59.2 Cg_endo -72.77 -3.39 13.46 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 122.86 2.373 . . . . 0.0 113.183 -177.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.401 HG13 ' HG3' ' A' ' 157' ' ' PRO . 65.1 t -122.21 110.58 27.53 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 178.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.7 t -141.78 108.87 2.07 Favored 'Isoleucine or valine' 0 C--O 1.189 -2.105 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 -178.531 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.766 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -98.05 152.37 19.37 Favored 'General case' 0 C--N 1.277 -2.555 0 C-N-CA 122.861 0.464 . . . . 0.0 112.135 -179.561 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.45 HG13 ' O ' ' A' ' 112' ' ' VAL . 30.5 t -46.61 117.71 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.036 0 C-N-CA 123.784 0.834 . . . . 0.0 111.578 177.427 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.1 3.79 55.59 Favored Glycine 0 C--O 1.235 0.211 0 CA-C-N 115.527 -0.76 . . . . 0.0 112.848 179.852 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.766 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -76.11 -176.65 3.61 Favored 'General case' 0 C--N 1.311 -1.081 0 C-N-CA 124.49 1.116 . . . . 0.0 110.113 178.249 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.4 t-20 -130.73 90.57 2.93 Favored 'General case' 0 C--N 1.307 -1.244 0 N-CA-C 108.636 -0.875 . . . . 0.0 108.636 178.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.658 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 21.9 tp -93.87 141.49 28.45 Favored 'General case' 0 C--N 1.29 -2.018 0 C-N-CA 119.062 -1.055 . . . . 0.0 109.003 178.746 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 40.6 t -134.35 122.62 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.813 0 CA-C-N 116.25 -0.432 . . . . 0.0 109.842 -174.205 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.609 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 57.0 t -92.43 87.96 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.35 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 172.337 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.548 ' O ' ' HG2' ' A' ' 41' ' ' GLN . 29.3 t70 -83.97 101.42 11.71 Favored 'General case' 0 CA--C 1.488 -1.429 0 C-N-CA 120.637 -0.425 . . . . 0.0 110.809 -176.395 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.9 mt -80.9 -7.22 59.42 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.916 -177.666 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 24.8 t -71.72 -0.04 10.0 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.072 179.104 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 4.1 p -134.3 10.3 3.79 Favored 'General case' 0 N--CA 1.419 -1.982 0 CA-C-O 121.207 0.527 . . . . 0.0 110.049 176.082 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.548 ' HG2' ' O ' ' A' ' 37' ' ' ASP . 35.0 mm-40 -125.39 -20.96 4.65 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.985 -0.376 . . . . 0.0 109.985 -176.852 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.8 mt -134.6 136.77 52.19 Favored 'Isoleucine or valine' 0 C--O 1.239 0.517 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -177.396 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 56.0 m-85 -138.43 120.44 15.54 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 109.722 -0.473 . . . . 0.0 109.722 -175.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.528 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 73.8 m -102.37 143.07 32.58 Favored 'General case' 0 C--N 1.282 -2.354 0 CA-C-O 121.451 0.643 . . . . 0.0 109.962 -178.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.506 ' CE1' ' HB3' ' A' ' 2' ' ' ALA . 6.8 p80 -119.22 139.66 51.5 Favored 'General case' 0 C--N 1.288 -2.105 0 CA-C-O 121.73 0.776 . . . . 0.0 111.03 -176.393 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.629 ' HB2' ' CG ' ' A' ' 54' ' ' ASP . 3.7 p-10 -108.36 100.64 9.91 Favored 'General case' 0 N--CA 1.395 -3.202 0 CA-C-O 123.37 1.557 . . . . 0.0 107.436 -176.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -78.3 -32.94 49.62 Favored 'General case' 0 C--N 1.299 -1.592 0 CA-C-N 112.755 -2.02 . . . . 0.0 111.648 -168.495 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.401 ' HB2' ' HB ' ' A' ' 52' ' ' ILE . 39.2 m-85 -129.38 64.61 71.92 Favored Pre-proline 0 C--N 1.308 -1.208 0 C-N-CA 119.456 -0.898 . . . . 0.0 111.896 -174.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.58 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 56.2 Cg_endo -67.45 -7.98 20.77 Favored 'Trans proline' 0 N--CA 1.486 1.088 0 C-N-CA 122.847 2.365 . . . . 0.0 114.415 -173.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -110.62 -15.37 13.88 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 120.672 -0.411 . . . . 0.0 111.493 -176.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.554 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.8 m -115.9 -25.33 7.77 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-O 122.182 0.992 . . . . 0.0 109.779 -173.16 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.554 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.6 mp -130.67 150.12 34.28 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.996 0 N-CA-C 107.516 -1.29 . . . . 0.0 107.516 -176.64 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.9 t -94.35 125.23 38.86 Favored 'General case' 0 N--CA 1.413 -2.299 0 N-CA-C 104.154 -2.535 . . . . 0.0 104.154 171.44 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.629 ' CG ' ' HB2' ' A' ' 46' ' ' ASN . 9.9 m-20 -91.71 106.16 18.27 Favored 'General case' 0 C--N 1.259 -3.336 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 -178.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.505 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 9.5 t80 -130.85 135.24 47.53 Favored 'General case' 0 C--N 1.287 -2.123 0 CA-C-N 114.49 -1.232 . . . . 0.0 109.233 -174.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.573 ' CG2' ' HG ' ' A' ' 131' ' ' LEU . 13.7 p -141.85 150.43 19.26 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.173 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.256 -176.004 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.1 p -150.17 129.97 13.29 Favored 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 123.894 0.878 . . . . 0.0 108.883 176.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.493 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 36.9 tp -65.6 112.63 3.73 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 172.309 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.477 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 2.7 tp-100 -60.66 -59.39 5.47 Favored 'General case' 0 C--O 1.204 -1.339 0 CA-C-N 113.257 -1.792 . . . . 0.0 109.915 -177.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -166.74 155.74 10.67 Favored 'General case' 0 N--CA 1.419 -1.999 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 -175.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -135.44 153.73 21.39 Favored Glycine 0 N--CA 1.412 -2.92 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 -177.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.414 ' HA ' ' HB3' ' A' ' 85' ' ' PRO . 24.1 m -138.61 144.58 39.82 Favored 'General case' 0 C--N 1.281 -2.4 0 C-N-CA 123.402 0.681 . . . . 0.0 110.595 -178.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.57 ' HB1' HG23 ' A' ' 67' ' ' VAL . . . -106.64 157.96 17.31 Favored 'General case' 0 N--CA 1.473 0.692 0 C-N-CA 125.081 1.353 . . . . 0.0 107.741 -179.52 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.787 ' O ' HG22 ' A' ' 67' ' ' VAL . 94.4 m-85 -155.74 178.15 10.58 Favored 'General case' 0 C--O 1.208 -1.113 0 CA-C-N 118.901 0.773 . . . . 0.0 111.781 -177.037 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 53.39 -127.49 36.7 Favored Glycine 0 C--O 1.217 -0.924 0 CA-C-O 121.423 0.457 . . . . 0.0 112.883 179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.73 -9.16 83.44 Favored Glycine 0 N--CA 1.42 -2.38 0 C-N-CA 120.388 -0.91 . . . . 0.0 113.132 178.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.787 HG22 ' O ' ' A' ' 64' ' ' TYR . 12.8 m -78.49 -27.14 14.13 Favored 'Isoleucine or valine' 0 C--O 1.201 -1.468 0 CA-C-N 118.515 1.157 . . . . 0.0 112.562 -175.27 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.551 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -91.32 -15.04 29.72 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 119.91 -0.716 . . . . 0.0 111.862 176.146 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 26.5 t -101.18 -59.04 1.77 Allowed 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.524 -176.2 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.581 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 34.6 m-80 -87.14 -24.42 24.51 Favored 'General case' 0 CA--C 1.486 -1.486 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -176.147 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.574 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 85.5 m-85 -111.43 163.63 13.81 Favored 'General case' 0 C--N 1.286 -2.186 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.064 -178.592 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.2 t -179.95 134.21 0.11 Allowed 'General case' 0 N--CA 1.426 -1.645 0 N-CA-C 107.235 -1.395 . . . . 0.0 107.235 178.035 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.467 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -167.31 -109.82 0.22 Allowed Glycine 0 N--CA 1.406 -3.355 0 N-CA-C 110.851 -0.9 . . . . 0.0 110.851 174.765 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 3.1 p -149.65 177.04 10.13 Favored 'General case' 0 C--N 1.275 -2.631 0 C-N-CA 122.778 0.431 . . . . 0.0 111.019 -174.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -132.9 140.16 47.98 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.116 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 177.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.722 ' HG3' ' O ' ' A' ' 80' ' ' SER . 82.6 tttt -120.72 145.36 47.57 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.398 -177.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.487 ' CD2' HG22 ' A' ' 105' ' ' VAL . 43.2 t80 -146.62 109.47 4.63 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 -179.335 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 11.2 t 49.14 43.33 22.43 Favored 'General case' 0 CA--C 1.548 0.9 0 C-N-CA 124.526 1.131 . . . . 0.0 111.912 178.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.9 11.95 62.81 Favored Glycine 0 N--CA 1.444 -0.824 0 C-N-CA 120.22 -0.991 . . . . 0.0 113.107 178.221 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.722 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 23.5 t -88.77 -179.73 6.05 Favored 'General case' 0 C--N 1.313 -0.99 0 N-CA-C 107.591 -1.263 . . . . 0.0 107.591 175.217 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 20.3 t -167.3 107.45 0.6 Allowed 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 179.31 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 2.1 p90 -144.3 158.19 55.12 Favored Pre-proline 0 C--N 1.287 -2.136 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 -173.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -67.96 144.77 65.55 Favored 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 122.614 2.21 . . . . 0.0 112.789 -175.016 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.547 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 60.8 t80 -118.41 134.73 23.42 Favored Pre-proline 0 C--N 1.31 -1.141 0 CA-C-N 116.233 -0.44 . . . . 0.0 109.977 -179.102 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.547 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 66.6 Cg_endo -72.22 143.75 78.19 Favored 'Cis proline' 0 CA--C 1.543 0.942 0 C-N-CA 123.189 -1.588 . . . . 0.0 111.465 -0.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.7 t -66.84 -177.03 0.55 Allowed 'General case' 0 CA--C 1.547 0.861 0 CA-C-N 115.161 -0.927 . . . . 0.0 111.941 -174.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 16.4 p -130.19 -46.23 1.11 Allowed 'General case' 0 N--CA 1.425 -1.679 0 CA-C-N 115.271 -0.877 . . . . 0.0 111.699 -172.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.3 t -101.04 -97.68 0.26 Allowed 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 -177.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -166.45 -166.66 0.9 Allowed 'General case' 0 N--CA 1.438 -1.074 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 177.255 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.493 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 46.9 p -99.38 165.66 14.37 Favored Pre-proline 0 C--N 1.297 -1.68 0 N-CA-C 113.753 1.02 . . . . 0.0 113.753 -178.135 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 20.8 Cg_endo -61.65 169.72 6.6 Favored 'Trans proline' 0 C--O 1.247 0.929 0 C-N-CA 123.252 2.635 . . . . 0.0 110.682 171.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.505 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 3.2 tmm_? -80.25 123.07 27.64 Favored 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.03 -175.291 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 75.1 t -132.58 123.35 49.28 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.134 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.591 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 58.5 t -105.0 140.79 21.96 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.169 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 176.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.479 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 4.7 m-85 -84.2 94.91 8.5 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-O 121.75 0.785 . . . . 0.0 109.677 175.667 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 15.6 m120 -87.32 74.72 9.41 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 43.4 t -150.12 -173.41 4.43 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 106.667 -1.605 . . . . 0.0 106.667 -175.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 37.9 ptt180 -145.56 24.21 1.4 Allowed 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 172.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.4 t -160.85 174.65 13.55 Favored 'General case' 0 N--CA 1.426 -1.644 0 N-CA-C 107.591 -1.262 . . . . 0.0 107.591 -176.055 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -61.96 136.15 57.84 Favored 'General case' 0 C--N 1.318 -0.792 0 O-C-N 123.59 0.556 . . . . 0.0 110.643 179.346 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 14.3 mmtm -138.52 150.25 65.55 Favored Pre-proline 0 C--N 1.286 -2.179 0 C-N-CA 124.976 1.311 . . . . 0.0 108.405 176.655 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -62.74 149.19 92.06 Favored 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 122.631 2.221 . . . . 0.0 111.881 -178.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . 0.479 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 11.2 t90 -89.88 104.89 9.4 Favored Pre-proline 0 C--N 1.305 -1.365 0 N-CA-C 106.171 -1.788 . . . . 0.0 106.171 178.122 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -75.99 87.54 1.4 Allowed 'Trans proline' 0 N--CA 1.448 -1.157 0 C-N-CA 121.27 1.313 . . . . 0.0 112.663 -172.191 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.487 HG22 ' CD2' ' A' ' 77' ' ' TYR . 61.7 t -140.16 149.7 21.81 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.126 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.492 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.609 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -153.14 135.4 14.93 Favored 'General case' 0 C--N 1.289 -2.025 0 O-C-N 123.268 0.355 . . . . 0.0 110.366 177.002 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.504 HD21 HD11 ' A' ' 129' ' ' LEU . 20.5 mt -101.73 104.84 15.66 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 177.695 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.467 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 55.4 m-85 -82.42 72.19 9.48 Favored 'General case' 0 C--N 1.281 -2.411 0 CA-C-O 120.883 0.373 . . . . 0.0 110.491 177.284 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.658 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.3 mm? -90.28 119.16 30.35 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 175.047 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -126.97 146.77 58.82 Favored Pre-proline 0 N--CA 1.411 -2.419 0 N-CA-C 109.706 -0.479 . . . . 0.0 109.706 -177.285 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.581 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 21.4 Cg_endo -60.99 118.8 5.71 Favored 'Trans proline' 0 C--O 1.246 0.902 0 C-N-CA 123.484 2.79 . . . . 0.0 112.468 -178.331 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.45 ' O ' HG13 ' A' ' 30' ' ' VAL . 3.1 m -67.98 -115.83 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.187 -2.188 0 CA-C-N 114.406 -1.27 . . . . 0.0 112.737 176.025 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 32.5 m -111.4 -42.58 3.86 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.159 -0.963 . . . . 0.0 111.312 179.468 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 8.8 t -90.99 28.4 1.59 Allowed 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 121.636 0.731 . . . . 0.0 110.356 -173.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -89.39 132.0 35.19 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 178.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.91 140.69 6.19 Favored Glycine 0 N--CA 1.434 -1.488 0 C-N-CA 119.496 -1.335 . . . . 0.0 111.994 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 57.09 -144.38 39.35 Favored Glycine 0 CA--C 1.495 -1.186 0 CA-C-O 119.175 -0.791 . . . . 0.0 112.87 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.0 p -61.43 96.02 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.245 0.856 0 CA-C-O 122.876 1.322 . . . . 0.0 112.385 -177.536 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.18 -31.81 11.9 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 114.327 -1.306 . . . . 0.0 111.053 -178.382 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.552 ' HB ' HG22 ' A' ' 154' ' ' VAL . 70.5 mt -124.8 139.32 51.33 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 177.162 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.404 ' HA ' ' HE2' ' A' ' 121' ' ' LYS . 3.3 mmpt? -114.24 136.17 53.26 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.179 0.514 . . . . 0.0 111.065 178.023 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -72.66 122.94 22.27 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.102 -178.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 99.48 -5.53 58.76 Favored Glycine 0 N--CA 1.434 -1.482 0 N-CA-C 110.891 -0.884 . . . . 0.0 110.891 -178.167 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 49.9 m -97.05 149.07 22.35 Favored 'General case' 0 N--CA 1.422 -1.851 0 CA-C-O 121.518 0.675 . . . . 0.0 110.382 -179.669 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.416 HD11 HG23 ' A' ' 128' ' ' VAL . 3.0 tm? -75.69 127.76 33.75 Favored 'General case' 0 N--CA 1.429 -1.502 0 CA-C-N 114.203 -1.362 . . . . 0.0 108.656 -178.213 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.541 ' HB ' HG11 ' A' ' 67' ' ' VAL . 28.1 pt -113.16 -29.7 2.27 Favored 'Isoleucine or valine' 0 C--O 1.197 -1.679 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.733 178.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . 0.493 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -156.91 166.93 31.99 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.659 -177.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.416 HG23 HD11 ' A' ' 125' ' ' LEU . 54.8 t -141.35 114.52 4.57 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.089 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 178.219 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.504 HD11 HD21 ' A' ' 107' ' ' LEU . 64.5 mt -118.12 138.66 52.12 Favored 'General case' 0 C--N 1.288 -2.086 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 178.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.47 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.0 mp -120.03 127.81 75.91 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 C-N-CA 119.335 -0.946 . . . . 0.0 109.455 178.644 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.573 ' HG ' ' CG2' ' A' ' 56' ' ' VAL . 0.1 OUTLIER -99.17 130.18 45.47 Favored 'General case' 0 C--N 1.273 -2.758 0 C-N-CA 124.391 1.076 . . . . 0.0 110.994 -176.648 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.477 ' HG2' ' HB2' ' A' ' 59' ' ' GLN . 14.6 mmm180 -97.99 113.34 25.16 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 123.428 0.691 . . . . 0.0 110.308 178.361 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.741 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 12.5 mm100 -92.43 134.66 34.73 Favored 'General case' 0 N--CA 1.404 -2.744 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 173.551 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.428 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 19.5 m -142.26 130.56 22.25 Favored 'General case' 0 C--N 1.28 -2.424 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 176.235 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 15.6 p30 -120.39 161.49 21.11 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.333 -179.267 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 8.3 p30 -100.49 -5.89 26.33 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.794 -174.335 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 68.5 t80 -107.36 -71.59 0.75 Allowed 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.458 -171.455 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -75.26 177.02 6.84 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 175.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 17.3 t -115.36 33.45 5.44 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 106.656 -1.609 . . . . 0.0 106.656 174.009 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -93.74 40.0 1.07 Allowed 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 114.359 -1.291 . . . . 0.0 110.648 -179.463 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 13.3 p-10 -83.91 80.98 8.97 Favored 'General case' 0 C--N 1.304 -1.387 0 CA-C-O 122.706 1.241 . . . . 0.0 109.978 -179.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 98.1 m-85 -96.47 176.21 6.12 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 114.536 -1.211 . . . . 0.0 109.543 179.166 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . 0.464 ' HB3' ' HD2' ' A' ' 132' ' ' ARG . 12.9 pt20 -129.04 142.39 50.92 Favored 'General case' 0 N--CA 1.425 -1.719 0 C-N-CA 120.077 -0.649 . . . . 0.0 109.385 177.274 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -109.93 136.63 48.91 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 -176.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.416 ' O ' ' HA ' ' A' ' 17' ' ' SER . 43.8 t -95.26 129.9 44.75 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 O-C-N 123.69 0.619 . . . . 0.0 109.638 -177.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . 0.484 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 63.3 m95 -119.8 103.21 9.16 Favored 'General case' 0 C--N 1.282 -2.338 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 -178.195 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . 0.474 ' N ' HD22 ' A' ' 147' ' ' ASN . 0.8 OUTLIER -83.89 112.1 19.83 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 179.554 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.493 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 23.0 mm -87.45 122.65 39.49 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.187 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 -178.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -116.69 156.93 26.26 Favored 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 123.669 0.788 . . . . 0.0 109.267 179.198 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.46 130.52 34.57 Favored 'General case' 0 N--CA 1.396 -3.151 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 176.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 36.7 t-20 -89.13 -18.61 26.85 Favored 'General case' 0 C--N 1.285 -2.226 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 -177.521 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -147.66 143.71 27.85 Favored 'General case' 0 N--CA 1.429 -1.483 0 CA-C-N 114.013 -1.449 . . . . 0.0 109.284 -173.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -83.41 139.45 32.97 Favored 'General case' 0 C--N 1.312 -1.063 0 O-C-N 124.391 1.057 . . . . 0.0 109.698 -178.344 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.552 HG22 ' HB ' ' A' ' 120' ' ' ILE . 1.8 m -121.47 148.54 24.81 Favored 'Isoleucine or valine' 0 C--O 1.257 1.478 0 C-N-CA 120.138 -0.625 . . . . 0.0 111.259 -177.65 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.5 t -120.49 140.95 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.699 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 -179.058 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.455 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 71.4 t -102.24 104.62 38.12 Favored Pre-proline 0 C--N 1.288 -2.068 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 178.374 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.486 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 43.4 Cg_endo -71.29 -20.75 27.59 Favored 'Trans proline' 0 N--CA 1.462 -0.332 0 C-N-CA 122.404 2.069 . . . . 0.0 111.428 176.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.425 ' HA ' ' H ' ' A' ' 30' ' ' VAL 0.26 3.3 t . . . . . 0 C--O 1.247 0.951 0 C-N-CA 124.497 1.119 . . . . 0.0 113.775 175.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.519 ' HA ' ' HA ' ' A' ' 46' ' ' ASN . 52.3 t80 . . . . . 0 CA--C 1.501 -0.935 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.515 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -144.1 -170.86 3.44 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 106.64 -1.615 . . . . 0.0 106.64 -179.366 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.531 ' HB3' ' CZ2' ' A' ' 146' ' ' TRP . 10.6 t -156.92 164.0 38.52 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 118.604 -1.238 . . . . 0.0 110.677 -176.294 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.414 ' HG3' ' O ' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -147.2 159.86 43.14 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 -177.003 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.608 HG22 HG22 ' A' ' 20' ' ' VAL . 63.9 p -99.8 173.66 6.58 Favored 'General case' 0 C--N 1.3 -1.578 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.727 178.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.0 -21.75 59.86 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 114.629 -1.169 . . . . 0.0 111.223 177.051 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -82.11 -35.43 28.58 Favored 'General case' 0 C--O 1.238 0.492 0 C-N-CA 119.574 -0.85 . . . . 0.0 110.411 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 133.49 16.45 1.17 Allowed Glycine 0 N--CA 1.434 -1.49 0 C-N-CA 119.709 -1.234 . . . . 0.0 112.955 178.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.3 m -91.53 105.46 17.77 Favored 'General case' 0 N--CA 1.428 -1.573 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 174.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -98.18 123.58 42.32 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 176.029 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.515 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 49.6 mt -104.17 117.81 58.48 Favored Pre-proline 0 C--N 1.29 -1.981 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 177.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -81.71 176.2 8.68 Favored 'Trans proline' 0 C--O 1.245 0.842 0 C-N-CA 122.601 2.2 . . . . 0.0 110.783 176.489 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 63.5 mt -67.1 129.15 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 N-CA-C 109.052 -0.722 . . . . 0.0 109.052 177.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 145.36 -8.95 1.67 Allowed Glycine 0 C--N 1.308 -0.98 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.004 -178.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.21 154.6 30.78 Favored Glycine 0 CA--C 1.504 -0.594 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 -178.281 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 160.39 -171.44 36.6 Favored Glycine 0 N--CA 1.428 -1.893 0 C-N-CA 119.851 -1.166 . . . . 0.0 111.169 -178.583 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.527 ' HB3' ' HB ' ' A' ' 145' ' ' VAL . 28.8 p -144.34 151.18 38.96 Favored 'General case' 0 C--N 1.291 -1.949 0 CA-C-O 120.797 0.332 . . . . 0.0 111.153 -177.073 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.16 162.52 32.29 Favored 'General case' 0 N--CA 1.421 -1.9 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -178.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -108.27 113.57 26.77 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-N 115.077 -0.965 . . . . 0.0 108.741 176.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.608 HG22 HG22 ' A' ' 5' ' ' THR . 40.0 t -103.71 116.78 48.11 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.757 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.403 -179.456 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 23.5 m-85 -102.07 119.15 38.34 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-O 120.602 0.239 . . . . 0.0 111.058 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.478 HG22 ' HG3' ' A' ' 41' ' ' GLN . 23.7 t -119.98 128.09 75.92 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.239 0 CA-C-N 116.009 -0.542 . . . . 0.0 110.73 -174.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 48.1 m-80 -81.83 126.55 32.0 Favored 'General case' 0 CA--C 1.483 -1.604 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 176.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.423 HD21 HG22 ' A' ' 36' ' ' VAL . 28.8 mt -117.8 148.31 42.2 Favored 'General case' 0 C--N 1.28 -2.449 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 179.482 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -53.24 119.14 16.09 Favored Pre-proline 0 C--O 1.209 -1.071 0 O-C-N 124.923 1.389 . . . . 0.0 110.524 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.599 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 56.3 Cg_endo -72.01 -0.29 8.28 Favored 'Trans proline' 0 CA--C 1.535 0.531 0 C-N-CA 122.999 2.466 . . . . 0.0 113.531 -175.723 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.412 HG13 ' HG3' ' A' ' 157' ' ' PRO . 66.8 t -131.63 109.91 16.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 179.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.513 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 11.6 t -147.71 113.99 0.92 Allowed 'Isoleucine or valine' 0 C--O 1.186 -2.273 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 -177.343 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.794 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -100.15 157.65 16.42 Favored 'General case' 0 C--N 1.273 -2.738 0 C-N-CA 123.824 0.85 . . . . 0.0 111.636 -178.787 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.408 HG13 ' O ' ' A' ' 112' ' ' VAL . 38.5 t -49.79 120.13 0.98 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 CA-C-O 121.029 0.442 . . . . 0.0 111.188 176.323 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.31 8.95 58.37 Favored Glycine 0 CA--C 1.522 0.51 0 CA-C-N 115.57 -0.741 . . . . 0.0 112.808 -179.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.794 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -80.37 -175.29 5.05 Favored 'General case' 0 C--N 1.31 -1.11 0 C-N-CA 124.983 1.313 . . . . 0.0 108.237 175.762 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -133.78 95.4 3.45 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 177.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.621 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 24.7 tp -91.96 144.29 25.61 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 119.166 -1.013 . . . . 0.0 109.498 178.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 62.0 t -135.48 124.06 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.915 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 -177.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.565 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 44.9 t -92.87 88.52 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.183 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 173.067 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.43 ' O ' ' HG2' ' A' ' 41' ' ' GLN . 32.5 t70 -79.08 104.19 9.54 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.981 -177.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.7 mt -85.55 -2.84 58.57 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.345 -179.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.429 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 36.6 t -73.58 -2.49 23.08 Favored 'General case' 0 CA--C 1.546 0.8 0 CA-C-O 121.715 0.769 . . . . 0.0 110.16 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.5 p -126.78 8.43 6.88 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.191 177.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.478 ' HG3' HG22 ' A' ' 22' ' ' VAL . 43.8 mm-40 -125.26 -27.08 3.54 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.226 -174.06 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.6 mt -133.79 135.75 54.9 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.792 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 -175.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.414 ' O ' ' HG3' ' A' ' 4' ' ' LYS . 39.0 m-85 -138.31 120.1 15.28 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -176.377 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.498 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 74.3 m -102.94 145.29 30.06 Favored 'General case' 0 C--N 1.281 -2.385 0 CA-C-O 120.825 0.345 . . . . 0.0 110.333 -177.461 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.435 ' HB3' ' HA ' ' A' ' 100' ' ' ASP . 25.8 p-80 -134.56 149.42 50.63 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.112 -173.778 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.519 ' HA ' ' HA ' ' A' ' 1' ' ' PHE . 60.8 t30 -103.26 91.2 3.98 Favored 'General case' 0 C--N 1.291 -1.941 0 C-N-CA 118.786 -1.166 . . . . 0.0 109.882 172.66 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -61.46 -24.43 66.55 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 113.508 -1.678 . . . . 0.0 111.905 -177.608 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 50.6 m-85 -125.71 78.64 68.86 Favored Pre-proline 0 C--N 1.322 -0.629 0 N-CA-C 108.312 -0.996 . . . . 0.0 108.312 -178.657 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -73.02 -7.42 20.65 Favored 'Trans proline' 0 C--N 1.332 -0.319 0 C-N-CA 122.631 2.221 . . . . 0.0 114.241 -173.193 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -112.45 -23.03 10.54 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 121.768 0.794 . . . . 0.0 109.786 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.579 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.6 OUTLIER -97.68 -30.1 13.02 Favored 'General case' 0 N--CA 1.407 -2.597 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.744 -169.82 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.579 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.0 mp -128.67 133.69 65.93 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.806 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.185 -176.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.9 t -75.88 145.64 40.38 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 174.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.428 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 3.0 m-20 -81.47 108.72 15.3 Favored 'General case' 0 C--N 1.278 -2.509 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -174.013 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 77.3 t80 -147.9 138.85 23.31 Favored 'General case' 0 C--N 1.293 -1.865 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.203 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.483 HG23 ' HG ' ' A' ' 131' ' ' LEU . 14.5 p -152.19 147.19 15.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 C-N-CA 124.405 1.082 . . . . 0.0 109.371 176.538 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.88 127.29 10.7 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 123.401 0.68 . . . . 0.0 109.824 172.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.498 HD23 ' O ' ' A' ' 130' ' ' ILE . 1.1 tt -68.0 114.24 6.36 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 106.52 -1.659 . . . . 0.0 106.52 175.379 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.1 tp-100 -58.62 -63.87 1.13 Allowed 'General case' 0 C--O 1.206 -1.228 0 C-N-CA 124.718 1.207 . . . . 0.0 110.372 178.114 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.435 ' HA ' HG23 ' A' ' 86' ' ' THR . 0.0 OUTLIER -164.09 154.02 14.61 Favored 'General case' 0 N--CA 1.422 -1.834 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -173.689 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.475 ' O ' ' HB2' ' A' ' 85' ' ' PRO . . . -124.03 154.84 17.78 Favored Glycine 0 N--CA 1.409 -3.104 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 179.583 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 49.4 m -131.39 145.6 51.89 Favored 'General case' 0 C--N 1.28 -2.416 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.478 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -113.97 154.82 26.96 Favored 'General case' 0 CA--C 1.501 -0.909 0 N-CA-C 108.228 -1.027 . . . . 0.0 108.228 178.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.453 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . 88.5 m-85 -156.63 -178.1 7.1 Favored 'General case' 0 C--O 1.238 0.479 0 C-N-CA 123.622 0.769 . . . . 0.0 109.506 -177.268 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 62.02 -137.71 45.98 Favored Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 115.783 -0.644 . . . . 0.0 113.148 175.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -84.32 -7.66 84.59 Favored Glycine 0 N--CA 1.42 -2.41 0 N-CA-C 111.336 -0.705 . . . . 0.0 111.336 177.221 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.786 HG21 ' HB ' ' A' ' 126' ' ' ILE . 94.5 t -70.0 -43.81 78.97 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.379 0 C-N-CA 123.056 0.543 . . . . 0.0 111.429 -178.525 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.478 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -82.32 -16.99 47.35 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.129 -1.028 . . . . 0.0 111.978 -179.469 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 8.2 t -100.54 -51.92 3.48 Favored 'General case' 0 N--CA 1.444 -0.771 0 CA-C-N 115.86 -0.609 . . . . 0.0 112.125 -174.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.536 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 34.0 m-80 -93.77 -21.53 19.25 Favored 'General case' 0 CA--C 1.492 -1.272 0 C-N-CA 120.494 -0.482 . . . . 0.0 109.972 -175.308 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.671 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 78.2 m-85 -111.8 161.8 15.95 Favored 'General case' 0 N--CA 1.425 -1.712 0 C-N-CA 120.076 -0.65 . . . . 0.0 109.967 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.4 t -169.52 133.92 1.38 Allowed 'General case' 0 N--CA 1.419 -1.991 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 176.456 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.492 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -167.08 -111.92 0.25 Allowed Glycine 0 N--CA 1.402 -3.604 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 175.721 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.4 p -157.72 -179.46 8.18 Favored 'General case' 0 C--N 1.29 -2.016 0 C-N-CA 124.421 1.088 . . . . 0.0 110.02 -174.142 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.423 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.6 p -132.66 147.88 31.76 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 178.734 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.601 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.9 tttt -125.61 147.57 49.26 Favored 'General case' 0 N--CA 1.43 -1.446 0 CA-C-N 116.131 -0.486 . . . . 0.0 109.839 -178.609 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.522 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 52.1 t80 -147.76 109.48 4.42 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 108.474 -0.936 . . . . 0.0 108.474 -178.192 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 9.2 t 50.8 43.7 28.16 Favored 'General case' 0 CA--C 1.549 0.93 0 C-N-CA 124.079 0.952 . . . . 0.0 111.35 177.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.02 6.16 69.73 Favored Glycine 0 N--CA 1.448 -0.564 0 C-N-CA 120.415 -0.898 . . . . 0.0 113.946 178.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.601 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 12.2 t -79.74 -178.86 6.6 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 117.436 0.618 . . . . 0.0 110.205 178.597 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 40.9 t -159.24 103.54 1.63 Allowed 'General case' 0 C--N 1.295 -1.787 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 -179.4 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.522 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 4.0 p90 -148.85 161.65 32.05 Favored Pre-proline 0 C--N 1.313 -0.991 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 -174.275 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.439 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 84.9 Cg_endo -71.77 149.13 53.75 Favored 'Trans proline' 0 C--N 1.362 1.261 0 C-N-CA 122.494 2.129 . . . . 0.0 113.502 -174.386 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.656 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 56.8 t80 -120.45 137.36 26.08 Favored Pre-proline 0 N--CA 1.427 -1.597 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 178.738 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.656 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 66.2 Cg_endo -70.52 142.59 72.39 Favored 'Cis proline' 0 CA--C 1.542 0.916 0 C-N-CA 122.933 -1.695 . . . . 0.0 112.959 -1.487 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.435 HG23 ' HA ' ' A' ' 60' ' ' ARG 0.338 10.3 t -63.54 105.4 0.77 Allowed 'General case' 0 C--O 1.249 1.059 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 -179.361 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 7.3 p -77.54 -13.04 60.01 Favored 'General case' 0 C--N 1.282 -2.363 0 CA-C-N 112.975 -1.92 . . . . 0.0 110.779 -175.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.7 t -119.41 -82.96 0.65 Allowed 'General case' 0 N--CA 1.409 -2.497 0 C-N-CA 119.326 -0.95 . . . . 0.0 111.898 -173.632 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 172.4 177.95 0.08 Allowed 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 124.284 1.033 . . . . 0.0 108.695 -178.132 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.426 HG21 ' CD2' ' A' ' 77' ' ' TYR . 42.9 p -102.31 161.07 24.45 Favored Pre-proline 0 C--N 1.301 -1.51 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 177.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -61.22 162.58 19.5 Favored 'Trans proline' 0 CA--C 1.546 1.103 0 C-N-CA 123.427 2.751 . . . . 0.0 111.696 172.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.7 tmm_? -72.29 116.82 13.17 Favored 'General case' 0 C--N 1.319 -0.739 0 C-N-CA 124.588 1.155 . . . . 0.0 109.874 -176.291 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 75.4 t -124.84 127.89 72.88 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 CA-C-O 121.348 0.594 . . . . 0.0 111.234 -178.437 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 77.0 t -107.13 123.18 62.13 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.214 178.177 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.453 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 5.3 m-85 -78.34 156.29 29.65 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 173.066 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 12.6 m120 -128.67 34.24 4.53 Favored 'General case' 0 C--N 1.261 -3.276 0 N-CA-C 106.8 -1.556 . . . . 0.0 106.8 175.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . 0.445 ' CB ' ' HG3' ' A' ' 101' ' ' LYS . 45.2 m -130.67 117.64 19.77 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 113.563 0.949 . . . . 0.0 113.563 -170.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 20.4 ptp180 -93.93 32.15 1.51 Allowed 'General case' 0 C--O 1.244 0.797 0 CA-C-O 122.332 1.063 . . . . 0.0 110.129 179.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 9.2 t -152.82 165.63 34.8 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 105.203 -2.147 . . . . 0.0 105.203 -178.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . 0.435 ' HA ' ' HB3' ' A' ' 45' ' ' HIS . 16.9 p-10 -74.0 112.71 10.4 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-O 122.167 0.984 . . . . 0.0 111.099 -174.565 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . 0.445 ' HG3' ' CB ' ' A' ' 97' ' ' SER . 15.2 mmtm -122.98 145.27 45.28 Favored Pre-proline 0 C--N 1.284 -2.254 0 CA-C-N 114.235 -1.348 . . . . 0.0 108.618 -178.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.429 ' HB3' ' O ' ' A' ' 39' ' ' SER . 17.9 Cg_endo -56.17 142.27 86.89 Favored 'Trans proline' 0 N--CA 1.45 -1.053 0 C-N-CA 123.318 2.679 . . . . 0.0 113.7 -172.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . 0.453 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.7 t90 -89.67 106.07 12.89 Favored Pre-proline 0 C--N 1.298 -1.667 0 N-CA-C 105.27 -2.122 . . . . 0.0 105.27 178.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -76.25 87.48 1.43 Allowed 'Trans proline' 0 N--CA 1.435 -1.961 0 C-N-CA 121.228 1.285 . . . . 0.0 111.685 -173.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.473 HG22 ' CD2' ' A' ' 77' ' ' TYR . 64.9 t -138.86 145.83 27.15 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 177.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.565 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -152.01 135.52 16.1 Favored 'General case' 0 C--N 1.278 -2.534 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.262 177.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.494 HD21 HD11 ' A' ' 129' ' ' LEU . 21.4 mt -98.66 102.52 14.29 Favored 'General case' 0 C--N 1.287 -2.123 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 178.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.492 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 50.8 m-85 -83.86 73.57 10.3 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-O 120.951 0.405 . . . . 0.0 110.378 177.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.671 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 2.9 mm? -99.47 129.76 45.67 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 175.762 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -130.07 148.21 68.75 Favored Pre-proline 0 N--CA 1.413 -2.312 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 -178.141 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.536 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 20.4 Cg_endo -59.41 120.67 8.64 Favored 'Trans proline' 0 C--O 1.246 0.88 0 C-N-CA 123.283 2.655 . . . . 0.0 112.286 -178.262 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.416 HG22 ' H ' ' A' ' 112' ' ' VAL . 2.7 m -69.21 -116.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.184 -2.394 0 CA-C-N 114.26 -1.336 . . . . 0.0 113.194 176.857 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 21.4 m -112.18 -40.47 4.17 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.316 -0.865 . . . . 0.0 110.632 179.202 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 28.9 t -87.79 28.47 1.01 Allowed 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.697 -176.245 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -95.18 132.91 39.62 Favored 'General case' 0 N--CA 1.427 -1.597 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -171.54 144.24 8.04 Favored Glycine 0 N--CA 1.436 -1.335 0 C-N-CA 120.057 -1.068 . . . . 0.0 111.559 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.454 ' O ' ' HA ' ' A' ' 155' ' ' VAL . . . 54.35 -145.7 26.54 Favored Glycine 0 CA--C 1.488 -1.613 0 C-N-CA 124.132 0.872 . . . . 0.0 113.0 -179.219 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 58.2 t -62.78 100.83 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.95 0 CA-C-O 121.602 0.715 . . . . 0.0 110.07 -177.31 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -99.33 -25.84 14.35 Favored 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 114.509 -1.223 . . . . 0.0 109.985 -179.331 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.523 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.0 mt -134.75 138.29 49.6 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.89 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 -179.451 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.491 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.7 mmpt? -112.89 147.42 37.07 Favored 'General case' 0 C--N 1.31 -1.136 0 C-N-CA 122.692 0.397 . . . . 0.0 110.193 174.877 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.89 126.91 30.94 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 177.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.13 -8.33 67.35 Favored Glycine 0 C--N 1.312 -0.757 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -177.536 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 33.5 t -81.38 136.97 35.74 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 -179.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -72.35 121.85 20.18 Favored 'General case' 0 N--CA 1.429 -1.505 0 N-CA-C 106.491 -1.67 . . . . 0.0 106.491 175.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.786 ' HB ' HG21 ' A' ' 67' ' ' VAL . 27.7 pt -109.11 -27.42 2.93 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.915 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -177.128 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.28 169.38 20.76 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 -177.6 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 76.7 t -144.11 113.38 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 179.161 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.494 HD11 HD21 ' A' ' 107' ' ' LEU . 46.2 mt -114.46 140.76 48.45 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.775 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.498 ' O ' HD23 ' A' ' 58' ' ' LEU . 4.0 mp -121.21 129.6 75.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.63 0 C-N-CA 118.844 -1.142 . . . . 0.0 110.787 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.556 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.2 OUTLIER -103.19 131.9 49.87 Favored 'General case' 0 C--N 1.284 -2.24 0 C-N-CA 125.268 1.427 . . . . 0.0 110.553 -177.147 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.424 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 14.0 mmm180 -93.54 132.57 37.71 Favored 'General case' 0 C--N 1.3 -1.571 0 C-N-CA 123.78 0.832 . . . . 0.0 110.699 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.416 ' HA ' ' NE2' ' A' ' 133' ' ' GLN . 5.1 tp-100 -113.28 114.6 26.92 Favored 'General case' 0 N--CA 1.422 -1.844 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 174.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 26.4 m -135.48 144.75 46.57 Favored 'General case' 0 C--N 1.286 -2.168 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 179.24 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.558 ' CB ' HG23 ' A' ' 52' ' ' ILE . 11.8 p30 -147.59 -169.32 3.29 Favored 'General case' 0 N--CA 1.436 -1.173 0 C-N-CA 119.305 -0.958 . . . . 0.0 112.355 178.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 8.7 p30 -92.97 -25.91 17.79 Favored 'General case' 0 C--N 1.308 -1.2 0 CA-C-O 121.389 0.614 . . . . 0.0 111.6 -175.365 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 50.5 t80 -98.02 -56.97 2.33 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.947 -169.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . 0.427 ' HB3' ' H ' ' A' ' 140' ' ' ASP . 18.5 m120 -83.27 140.82 32.28 Favored 'General case' 0 CA--C 1.48 -1.74 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.723 177.414 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 39.3 m -93.73 12.33 25.99 Favored 'General case' 0 C--N 1.287 -2.148 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 173.067 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . 0.427 ' H ' ' HB3' ' A' ' 138' ' ' ASN . 4.3 m-20 -79.54 60.8 3.37 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 126.352 1.861 . . . . 0.0 110.036 179.417 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -82.83 81.53 8.51 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-O 122.486 1.136 . . . . 0.0 110.634 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 68.0 m-85 -102.6 177.29 4.9 Favored 'General case' 0 N--CA 1.429 -1.521 0 CA-C-N 114.949 -1.023 . . . . 0.0 108.258 177.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . 0.424 ' HB3' ' HD2' ' A' ' 132' ' ' ARG . 13.4 pt20 -138.72 149.8 45.46 Favored 'General case' 0 N--CA 1.415 -2.178 0 C-N-CA 120.383 -0.527 . . . . 0.0 110.628 178.187 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 8.4 m-30 -108.1 134.32 51.14 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 -175.578 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.527 ' HB ' ' HB3' ' A' ' 17' ' ' SER . 55.3 t -94.24 128.06 45.81 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 O-C-N 123.738 0.649 . . . . 0.0 110.137 -179.087 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . 0.556 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.4 m95 -114.87 96.98 5.98 Favored 'General case' 0 C--N 1.275 -2.658 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 -179.634 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 40.4 m-80 -80.01 112.73 17.6 Favored 'General case' 0 C--N 1.291 -1.959 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.454 HG22 HD11 ' A' ' 126' ' ' ILE . 24.4 mm -87.9 123.95 40.79 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.879 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 -177.064 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -118.82 153.92 33.71 Favored 'General case' 0 C--N 1.288 -2.098 0 C-N-CA 124.105 0.962 . . . . 0.0 108.468 178.25 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.403 ' HB3' ' O ' ' A' ' 121' ' ' LYS . . . -82.29 133.76 35.25 Favored 'General case' 0 N--CA 1.406 -2.635 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 176.114 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -92.29 -13.15 30.78 Favored 'General case' 0 C--N 1.284 -2.26 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 -177.073 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -153.89 148.11 25.85 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 113.834 -1.53 . . . . 0.0 108.824 -176.694 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.7 p-10 -82.12 149.02 28.22 Favored 'General case' 0 C--N 1.322 -0.628 0 O-C-N 123.958 0.786 . . . . 0.0 111.096 -178.436 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.599 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 73.7 t -124.62 133.68 68.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-N 115.741 -0.663 . . . . 0.0 111.346 -176.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.454 ' HA ' ' O ' ' A' ' 117' ' ' GLY . 8.4 t -116.71 136.35 54.06 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.374 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.513 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 72.3 t -100.02 103.52 23.04 Favored Pre-proline 0 C--N 1.292 -1.895 0 C-N-CA 123.384 0.674 . . . . 0.0 109.324 178.704 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.412 ' HG3' HG13 ' A' ' 27' ' ' VAL . 33.3 Cg_endo -68.47 -27.1 33.81 Favored 'Trans proline' 0 C--N 1.35 0.615 0 C-N-CA 122.423 2.082 . . . . 0.0 111.781 179.222 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.416 ' HB ' HG12 ' A' ' 156' ' ' VAL . 4.4 t . . . . . 0 CA--C 1.548 0.895 0 C-N-CA 125.109 1.364 . . . . 0.0 113.515 176.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.634 ' CZ ' ' HB3' ' A' ' 44' ' ' CYS . 55.4 t80 . . . . . 0 CA--C 1.485 -1.551 0 N-CA-C 107.316 -1.364 . . . . 0.0 107.316 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.481 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -141.16 171.4 14.11 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 176.107 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 70.9 m -136.02 159.41 41.77 Favored 'General case' 0 C--N 1.301 -1.5 0 C-N-CA 120.741 -0.384 . . . . 0.0 111.127 -175.348 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.416 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -143.73 161.05 39.6 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.172 0.51 . . . . 0.0 111.197 -176.187 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.521 HG22 HG22 ' A' ' 20' ' ' VAL . 72.0 p -102.25 168.88 9.07 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.335 177.793 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.99 -7.12 53.89 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 114.103 -1.408 . . . . 0.0 112.009 179.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 4.7 p30 -90.65 -31.29 16.69 Favored 'General case' 0 CA--C 1.511 -0.537 0 C-N-CA 118.458 -1.297 . . . . 0.0 108.234 176.219 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 133.24 2.57 3.68 Favored Glycine 0 N--CA 1.431 -1.678 0 C-N-CA 120.29 -0.957 . . . . 0.0 113.029 177.599 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.6 m -77.91 102.31 7.24 Favored 'General case' 0 N--CA 1.442 -0.869 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.26 117.59 30.54 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 175.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.481 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 62.1 mt -92.69 115.62 65.15 Favored Pre-proline 0 C--N 1.301 -1.529 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 179.348 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 80.3 Cg_endo -78.36 -179.83 5.82 Favored 'Trans proline' 0 C--O 1.248 0.981 0 C-N-CA 122.643 2.229 . . . . 0.0 111.526 179.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.5 mt -70.62 129.55 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.298 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.18 1.09 3.29 Favored Glycine 0 C--N 1.305 -1.162 0 C-N-CA 120.886 -0.673 . . . . 0.0 111.607 -178.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 87.75 171.41 46.91 Favored Glycine 0 C--O 1.244 0.773 0 C-N-CA 120.59 -0.814 . . . . 0.0 111.289 -179.607 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 150.9 -169.11 30.66 Favored Glycine 0 N--CA 1.438 -1.182 0 C-N-CA 120.474 -0.869 . . . . 0.0 111.352 177.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 87.0 p -141.93 157.5 44.89 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -141.04 162.83 34.57 Favored 'General case' 0 N--CA 1.42 -1.965 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.7 p30 -110.03 111.33 22.64 Favored 'General case' 0 C--N 1.285 -2.207 0 CA-C-N 114.941 -1.027 . . . . 0.0 109.256 178.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.521 HG22 HG22 ' A' ' 5' ' ' THR . 41.5 t -100.75 135.83 35.07 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.441 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.513 -178.779 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 69.2 m-85 -125.29 128.51 48.36 Favored 'General case' 0 CA--C 1.492 -1.272 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -177.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.514 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.2 p -139.63 136.33 39.84 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 O-C-N 123.78 0.675 . . . . 0.0 110.974 -177.084 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 -88.79 128.29 35.63 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 178.089 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.441 HD11 HG22 ' A' ' 36' ' ' VAL . 2.7 mm? -107.11 160.05 15.85 Favored 'General case' 0 C--N 1.284 -2.272 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 176.15 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.45 120.66 37.63 Favored Pre-proline 0 C--O 1.209 -1.046 0 O-C-N 124.505 1.128 . . . . 0.0 109.365 176.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.515 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 62.4 Cg_endo -74.14 0.45 8.43 Favored 'Trans proline' 0 CA--C 1.537 0.667 0 C-N-CA 122.668 2.245 . . . . 0.0 113.514 -176.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.45 HG13 ' HG3' ' A' ' 157' ' ' PRO . 93.7 t -131.49 111.43 19.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.24 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 178.455 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.476 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 9.3 t -147.76 112.96 0.83 Allowed 'Isoleucine or valine' 0 C--O 1.194 -1.845 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 -177.453 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.666 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -101.05 154.75 18.44 Favored 'General case' 0 C--N 1.277 -2.571 0 C-N-CA 123.746 0.818 . . . . 0.0 111.062 -179.354 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.543 HG22 ' O ' ' A' ' 112' ' ' VAL . 99.1 t -46.12 117.84 0.39 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.478 0 C-N-CA 123.379 0.672 . . . . 0.0 111.338 175.614 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.1 1.36 54.63 Favored Glycine 0 C--N 1.311 -0.815 0 CA-C-N 115.253 -0.885 . . . . 0.0 113.101 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.666 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -74.42 -175.91 2.51 Favored 'General case' 0 C--N 1.315 -0.914 0 C-N-CA 124.551 1.141 . . . . 0.0 109.967 175.336 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -134.45 96.02 3.5 Favored 'General case' 0 N--CA 1.428 -1.559 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 177.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.596 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 28.8 tp -93.15 142.52 27.21 Favored 'General case' 0 C--N 1.284 -2.247 0 C-N-CA 119.773 -0.771 . . . . 0.0 109.929 179.759 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.0 t -135.01 122.08 35.89 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.719 0 CA-C-O 121.168 0.508 . . . . 0.0 109.901 -176.533 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.585 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 47.8 t -92.94 89.07 2.68 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.27 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 174.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -78.03 106.76 10.11 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.248 -177.568 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.6 mt -93.79 -1.68 54.65 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-O 121.365 0.602 . . . . 0.0 111.025 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.9 t -76.37 1.28 16.74 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-N 115.405 -0.816 . . . . 0.0 109.974 -178.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.3 p -129.55 8.93 5.46 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 123.614 0.765 . . . . 0.0 109.869 176.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.514 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 45.6 mm-40 -125.23 -24.73 3.93 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-N 115.469 -0.787 . . . . 0.0 110.505 -174.808 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.0 mt -133.71 141.59 43.78 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 -177.115 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.472 ' HA ' ' HA ' ' A' ' 102' ' ' PRO . 57.6 m-85 -141.24 161.14 38.59 Favored 'General case' 0 C--N 1.32 -0.708 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -176.199 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.634 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 69.3 m -138.69 138.77 38.06 Favored 'General case' 0 C--N 1.299 -1.618 0 C-N-CA 123.059 0.544 . . . . 0.0 110.953 -178.609 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 29.4 p-80 -134.12 148.94 51.05 Favored 'General case' 0 C--O 1.247 0.965 0 CA-C-O 121.378 0.609 . . . . 0.0 111.961 -175.386 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.496 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 3.4 p30 -105.37 118.87 37.66 Favored 'General case' 0 CA--C 1.485 -1.553 0 CA-C-O 122.193 0.997 . . . . 0.0 112.832 179.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -88.43 -25.94 22.38 Favored 'General case' 0 C--N 1.286 -2.189 0 CA-C-N 113.79 -1.55 . . . . 0.0 109.511 177.006 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.414 ' HB2' HD13 ' A' ' 52' ' ' ILE . 29.0 m-85 -138.51 66.87 44.03 Favored Pre-proline 0 N--CA 1.477 0.919 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.175 177.489 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.496 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 55.8 Cg_endo -68.52 -8.03 21.99 Favored 'Trans proline' 0 N--CA 1.485 1.024 0 C-N-CA 122.923 2.415 . . . . 0.0 113.96 -174.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -117.29 -9.29 10.97 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 120.025 -0.67 . . . . 0.0 111.115 -178.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.544 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.3 OUTLIER -103.88 -30.33 10.41 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 -176.378 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.544 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.5 mp -124.2 140.09 48.61 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.309 0 CA-C-N 114.143 -1.389 . . . . 0.0 108.057 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 4.9 t -81.83 130.28 35.02 Favored 'General case' 0 N--CA 1.424 -1.773 0 N-CA-C 105.329 -2.101 . . . . 0.0 105.329 173.228 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.503 ' O ' HG23 ' A' ' 94' ' ' VAL . 42.2 m-20 -88.86 106.36 18.34 Favored 'General case' 0 C--N 1.282 -2.369 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 -173.491 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.47 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 19.8 t80 -134.7 123.9 24.42 Favored 'General case' 0 C--N 1.296 -1.746 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.88 -172.592 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.476 HG13 HD13 ' A' ' 131' ' ' LEU . 93.3 t -124.83 141.66 44.19 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 CA-C-N 114.632 -1.167 . . . . 0.0 109.398 -176.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -148.36 127.85 13.16 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 173.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.532 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 59.5 tp -67.71 115.98 7.89 Favored 'General case' 0 N--CA 1.442 -0.85 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 174.19 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.462 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 3.9 tp-100 -60.43 -52.67 64.23 Favored 'General case' 0 C--O 1.214 -0.786 0 CA-C-N 114.402 -1.272 . . . . 0.0 110.404 179.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.462 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 10.1 ptp180 -169.46 159.88 8.84 Favored 'General case' 0 N--CA 1.418 -2.028 0 CA-C-N 114.095 -1.411 . . . . 0.0 107.501 -175.049 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -136.42 136.06 8.15 Favored Glycine 1 N--CA 1.393 -4.205 0 N-CA-C 107.93 -2.068 . . . . 0.0 107.93 178.362 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 67.9 m -124.73 147.06 48.85 Favored 'General case' 0 C--N 1.272 -2.797 0 O-C-N 124.29 0.641 . . . . 0.0 110.361 -175.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.525 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -109.54 159.78 16.79 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 -178.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.489 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 90.6 m-85 -155.99 -179.68 8.37 Favored 'General case' 0 N--CA 1.464 0.26 0 C-N-CA 123.83 0.852 . . . . 0.0 109.438 -176.185 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.87 -138.71 46.84 Favored Glycine 0 CA--C 1.506 -0.52 0 O-C-N 123.73 0.644 . . . . 0.0 112.84 177.29 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.35 -6.04 89.56 Favored Glycine 0 C--O 1.201 -1.93 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 176.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.775 HG21 ' HB ' ' A' ' 126' ' ' ILE . 97.0 t -71.78 -38.17 64.81 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 123.041 0.536 . . . . 0.0 111.269 -178.262 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.525 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.11 -18.55 32.03 Favored 'General case' 0 C--N 1.297 -1.711 0 C-N-CA 118.513 -1.275 . . . . 0.0 112.232 179.416 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 22.5 t -100.29 -46.62 5.21 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 121.288 0.566 . . . . 0.0 112.028 -175.073 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.47 ' O ' HG22 ' A' ' 112' ' ' VAL . 44.7 m-20 -97.62 -20.75 17.45 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -174.183 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.595 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 95.6 m-85 -112.23 151.54 29.48 Favored 'General case' 0 N--CA 1.428 -1.544 0 CA-C-O 122.199 1.0 . . . . 0.0 111.618 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.421 ' HB2' ' CG1' ' A' ' 112' ' ' VAL . 4.1 m -158.69 124.15 4.37 Favored 'General case' 0 N--CA 1.393 -3.285 0 CA-C-N 113.587 -1.642 . . . . 0.0 109.96 179.236 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.503 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -161.13 -112.77 0.29 Allowed Glycine 0 N--CA 1.409 -3.156 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 175.631 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.409 HG22 ' HA ' ' A' ' 83' ' ' PRO . 0.9 OUTLIER -158.04 179.84 8.8 Favored 'General case' 0 C--N 1.284 -2.242 0 C-N-CA 123.798 0.839 . . . . 0.0 110.238 -175.669 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -134.55 146.89 30.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 C-N-CA 123.172 0.589 . . . . 0.0 109.468 178.387 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.633 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.3 tttt -124.31 143.17 50.72 Favored 'General case' 0 N--CA 1.421 -1.901 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.5 -179.27 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.47 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 59.2 t80 -143.61 110.34 5.58 Favored 'General case' 0 C--N 1.301 -1.532 0 CA-C-N 115.197 -0.91 . . . . 0.0 108.891 -177.551 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 23.0 t 53.95 37.2 26.19 Favored 'General case' 0 CA--C 1.557 1.241 0 C-N-CA 123.634 0.774 . . . . 0.0 111.386 175.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.44 10.48 63.68 Favored Glycine 0 C--O 1.216 -1.012 0 C-N-CA 120.849 -0.691 . . . . 0.0 113.874 -179.281 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.633 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 8.4 t -86.21 -179.29 6.69 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 117.584 0.692 . . . . 0.0 109.414 178.511 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 31.6 t -155.73 110.47 2.92 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 -179.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.477 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 5.3 p90 -154.24 161.31 29.59 Favored Pre-proline 0 CA--C 1.548 0.885 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 -175.12 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.477 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 60.1 Cg_endo -68.7 149.45 73.38 Favored 'Trans proline' 0 C--N 1.36 1.18 0 C-N-CA 122.936 2.424 . . . . 0.0 113.563 -175.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.536 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 59.3 t80 -124.07 133.21 24.49 Favored Pre-proline 0 N--CA 1.437 -1.078 0 CA-C-N 116.205 -0.452 . . . . 0.0 109.932 179.005 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.536 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 60.5 Cg_endo -71.99 148.45 90.87 Favored 'Cis proline' 0 C--O 1.239 0.533 0 C-N-CA 122.796 -1.752 . . . . 0.0 110.232 -3.319 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.8 t -72.61 -175.99 1.81 Allowed 'General case' 0 C--O 1.246 0.903 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -178.225 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 22.6 p -130.69 -35.81 1.44 Allowed 'General case' 0 N--CA 1.43 -1.444 0 CA-C-O 122.088 0.947 . . . . 0.0 108.524 -172.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 49.4 m -105.34 -141.84 0.37 Allowed 'General case' 1 N--CA 1.343 -5.778 0 CA-C-N 114.093 -1.412 . . . . 0.0 108.24 178.368 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.1 pt-20 -123.49 -171.32 2.29 Favored 'General case' 0 C--N 1.275 -2.64 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 -174.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.532 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 39.9 p -100.75 167.03 11.44 Favored Pre-proline 0 C--N 1.295 -1.764 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 177.402 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . 0.44 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 18.9 Cg_endo -57.39 166.47 4.56 Favored 'Trans proline' 0 C--O 1.247 0.953 0 C-N-CA 123.263 2.642 . . . . 0.0 112.286 171.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.47 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 1.7 tmm_? -75.21 121.32 21.95 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-N 114.597 -1.183 . . . . 0.0 108.52 -178.382 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 72.8 t -136.47 117.92 19.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 C-N-CA 123.41 0.684 . . . . 0.0 109.749 -176.838 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 54' ' ' ASP . 1.5 p -115.67 132.02 66.32 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.361 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.89 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.442 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 6.3 m-85 -77.0 100.29 5.58 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-O 121.216 0.531 . . . . 0.0 111.096 -178.41 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . 0.42 ' N ' HD22 ' A' ' 96' ' ' ASN . 0.8 OUTLIER -94.89 59.88 2.39 Favored 'General case' 0 C--N 1.308 -1.237 0 CA-C-O 121.372 0.606 . . . . 0.0 109.556 179.047 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 51.0 m -154.47 141.76 19.56 Favored 'General case' 0 C--N 1.31 -1.114 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 12.7 ptp180 -109.02 69.68 0.71 Allowed 'General case' 0 C--N 1.304 -1.376 0 CA-C-O 122.044 0.926 . . . . 0.0 111.464 -177.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.2 t -179.46 168.53 1.44 Allowed 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 179.116 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -72.35 113.11 9.03 Favored 'General case' 0 CA--C 1.501 -0.94 0 CA-C-O 121.799 0.809 . . . . 0.0 109.461 -179.107 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -118.46 139.73 27.31 Favored Pre-proline 0 C--N 1.274 -2.71 0 CA-C-N 114.249 -1.341 . . . . 0.0 108.693 -177.099 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.472 ' HA ' ' HA ' ' A' ' 43' ' ' PHE . 12.6 Cg_endo -57.16 152.26 46.14 Favored 'Trans proline' 0 C--O 1.245 0.841 0 C-N-CA 123.278 2.652 . . . . 0.0 113.107 179.202 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . 0.442 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 12.6 t90 -91.42 106.62 17.19 Favored Pre-proline 0 N--CA 1.438 -1.048 0 N-CA-C 106.317 -1.735 . . . . 0.0 106.317 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -77.52 88.21 1.44 Allowed 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 121.388 1.392 . . . . 0.0 112.927 -172.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.404 HG22 ' CD2' ' A' ' 77' ' ' TYR . 98.0 t -137.62 145.09 29.76 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.306 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 176.632 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.585 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.87 136.73 18.18 Favored 'General case' 0 C--N 1.292 -1.9 0 O-C-N 123.237 0.336 . . . . 0.0 110.172 178.438 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.474 HD21 HD11 ' A' ' 129' ' ' LEU . 20.3 mt -101.28 102.71 13.62 Favored 'General case' 0 C--N 1.292 -1.909 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 179.087 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.503 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 19.3 m-85 -81.53 74.0 8.54 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 120.812 0.339 . . . . 0.0 110.436 177.44 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.596 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 2.2 mm? -91.52 151.08 20.91 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 110.238 -0.282 . . . . 0.0 110.238 176.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -149.3 143.7 17.18 Favored Pre-proline 0 N--CA 1.405 -2.702 0 C-N-CA 119.996 -0.682 . . . . 0.0 110.136 179.516 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -64.9 127.48 18.7 Favored 'Trans proline' 0 N--CA 1.45 -1.051 0 C-N-CA 123.383 2.722 . . . . 0.0 113.149 -177.3 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.543 ' O ' HG22 ' A' ' 30' ' ' VAL . 27.1 m -87.25 -155.84 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.399 -3.014 0 CA-C-N 114.438 -1.255 . . . . 0.0 108.639 172.432 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 6.1 m -80.51 -30.55 37.26 Favored 'General case' 0 C--N 1.261 -3.269 0 CA-C-O 121.425 0.631 . . . . 0.0 110.48 -168.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.5 t -82.9 9.55 9.74 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.888 -177.195 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.413 ' HB1' HG21 ' A' ' 156' ' ' VAL . . . -90.72 131.52 36.35 Favored 'General case' 0 C--N 1.298 -1.644 0 N-CA-C 108.334 -0.988 . . . . 0.0 108.334 178.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.3 125.68 1.16 Allowed Glycine 0 C--N 1.306 -1.095 0 C-N-CA 120.571 -0.823 . . . . 0.0 111.727 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.84 -147.26 49.37 Favored Glycine 0 CA--C 1.486 -1.773 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -175.229 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.437 HG11 ' HE3' ' A' ' 121' ' ' LYS . 60.3 t -57.31 112.04 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.149 0 CA-C-N 117.213 0.507 . . . . 0.0 110.113 -177.144 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -110.25 -28.69 8.5 Favored 'General case' 0 C--N 1.297 -1.682 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.068 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.467 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 59.0 mt -129.03 138.07 55.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.149 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.451 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 5.1 mmpt? -114.92 141.84 47.4 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 121.112 0.482 . . . . 0.0 110.835 178.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.44 135.26 49.98 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.691 -179.765 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 82.72 -4.14 80.3 Favored Glycine 0 C--O 1.242 0.61 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.216 178.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 19.4 m -94.71 149.41 21.27 Favored 'General case' 0 N--CA 1.417 -2.084 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 -179.214 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 28.2 tp -74.79 133.37 41.95 Favored 'General case' 0 N--CA 1.434 -1.231 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.123 -177.455 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.775 ' HB ' HG21 ' A' ' 67' ' ' VAL . 34.5 pt -118.26 -26.67 2.51 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 C-N-CA 120.481 -0.488 . . . . 0.0 112.174 179.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . 0.42 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.9 163.58 29.07 Favored 'General case' 0 N--CA 1.434 -1.24 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.252 -177.711 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 55.9 t -139.7 115.63 8.74 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.937 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 178.222 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.474 HD11 HD21 ' A' ' 107' ' ' LEU . 68.7 mt -117.74 145.74 44.25 Favored 'General case' 0 C--N 1.281 -2.398 0 N-CA-C 107.926 -1.138 . . . . 0.0 107.926 179.415 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.496 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.7 mp -128.7 119.47 49.97 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 C-N-CA 119.794 -0.762 . . . . 0.0 109.629 178.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.501 ' C ' HD12 ' A' ' 131' ' ' LEU . 0.6 OUTLIER -88.77 147.02 24.66 Favored 'General case' 0 CA--C 1.481 -1.677 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 173.978 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 60.0 ttp180 -115.0 122.0 44.87 Favored 'General case' 0 C--N 1.248 -3.832 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 177.74 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 12.0 mm100 -85.86 139.26 31.41 Favored 'General case' 0 N--CA 1.417 -2.076 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 176.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.434 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 25.8 m -145.1 133.23 21.49 Favored 'General case' 0 C--N 1.261 -3.253 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 173.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.484 ' HB2' HG23 ' A' ' 52' ' ' ILE . 32.9 p30 -132.29 161.39 33.63 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-O 120.906 0.384 . . . . 0.0 110.18 -178.368 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 8.1 p30 -93.89 -19.11 21.26 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.448 -173.82 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 88.5 t80 -91.31 -71.06 0.65 Allowed 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 115.067 -0.97 . . . . 0.0 111.346 -171.115 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 18.5 m120 -63.16 -46.49 86.94 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-O 121.366 0.603 . . . . 0.0 111.966 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 23.1 t 78.97 8.55 1.92 Allowed 'General case' 0 C--N 1.332 -0.191 0 C-N-CA 126.267 1.827 . . . . 0.0 109.297 -177.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . 0.539 ' HB3' ' CE2' ' A' ' 142' ' ' PHE . 2.0 m-20 -88.29 81.77 7.22 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-N 114.526 -1.215 . . . . 0.0 108.047 177.367 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -85.11 105.08 15.57 Favored 'General case' 0 C--N 1.303 -1.417 0 CA-C-O 121.777 0.799 . . . . 0.0 111.298 -177.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . 0.539 ' CE2' ' HB3' ' A' ' 140' ' ' ASP . 72.6 m-85 -110.37 160.07 16.9 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . 0.432 ' HB2' ' O ' ' A' ' 131' ' ' LEU . 13.9 pt20 -126.09 150.48 48.15 Favored 'General case' 0 C--N 1.288 -2.107 0 C-N-CA 119.877 -0.729 . . . . 0.0 110.623 -179.113 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 12.5 m-30 -113.67 127.47 56.06 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 -174.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 50.0 t -92.42 132.11 37.64 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.987 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.93 -178.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 54.3 m95 -120.97 101.14 7.49 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -177.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 50.0 m-80 -84.5 115.01 22.35 Favored 'General case' 0 C--N 1.285 -2.233 0 N-CA-C 107.691 -1.226 . . . . 0.0 107.691 178.68 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.42 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 20.2 mm -88.55 121.8 39.24 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 -177.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 99.2 m-85 -117.7 151.7 36.74 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-N 115.684 -0.689 . . . . 0.0 109.143 177.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.22 131.39 35.23 Favored 'General case' 0 N--CA 1.412 -2.336 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 177.049 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 19.4 t-20 -88.21 -16.36 33.49 Favored 'General case' 0 C--N 1.287 -2.128 0 N-CA-C 107.905 -1.146 . . . . 0.0 107.905 -178.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.8 t30 -148.08 143.96 27.54 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 114.566 -1.197 . . . . 0.0 109.997 -174.447 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -79.08 139.53 38.08 Favored 'General case' 0 C--N 1.309 -1.163 0 O-C-N 124.285 0.991 . . . . 0.0 110.995 179.568 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.515 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 73.0 t -115.12 138.47 45.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.851 -176.432 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 8.3 t -119.56 135.9 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.394 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 75.3 t -99.81 105.03 32.07 Favored Pre-proline 0 C--N 1.286 -2.174 0 C-N-CA 124.091 0.956 . . . . 0.0 109.834 179.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.493 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 40.6 Cg_endo -70.71 -21.77 28.62 Favored 'Trans proline' 0 N--CA 1.463 -0.314 0 C-N-CA 122.233 1.955 . . . . 0.0 111.797 177.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.27 3.7 t . . . . . 0 C--N 1.355 0.841 0 C-N-CA 124.978 1.311 . . . . 0.0 114.095 175.665 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 25.1 p90 . . . . . 0 C--O 1.213 -0.847 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.6 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -113.33 177.16 4.73 Favored 'General case' 0 N--CA 1.44 -0.945 0 CA-C-N 118.836 0.744 . . . . 0.0 110.881 -173.238 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 11.5 t -151.61 156.61 40.8 Favored 'General case' 0 N--CA 1.433 -1.276 0 C-N-CA 119.931 -0.708 . . . . 0.0 109.766 -177.241 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.1 pptp? -141.44 163.08 33.89 Favored 'General case' 0 C--N 1.302 -1.473 0 CA-C-O 121.049 0.452 . . . . 0.0 111.576 -175.065 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.481 HG22 HG22 ' A' ' 20' ' ' VAL . 71.3 p -104.6 172.94 6.52 Favored 'General case' 0 C--N 1.313 -0.997 0 CA-C-O 121.859 0.837 . . . . 0.0 110.406 -179.687 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -78.81 -10.31 59.74 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 113.745 -1.57 . . . . 0.0 110.991 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -92.16 -33.97 14.51 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 118.318 -1.353 . . . . 0.0 109.124 175.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 137.47 5.58 1.74 Allowed Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 119.231 -1.461 . . . . 0.0 113.437 176.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.3 m -80.18 100.22 8.18 Favored 'General case' 0 N--CA 1.433 -1.275 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -97.29 111.08 23.48 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.323 179.597 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.6 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 59.3 mt -88.87 121.94 69.42 Favored Pre-proline 0 C--N 1.307 -1.243 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 179.488 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -81.52 -179.56 5.02 Favored 'Trans proline' 0 C--O 1.241 0.668 0 C-N-CA 122.899 2.399 . . . . 0.0 111.937 178.183 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.6 mt -69.23 141.51 17.25 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 CA-C-N 115.995 -0.548 . . . . 0.0 109.832 179.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.89 -1.74 17.4 Favored Glycine 0 N--CA 1.438 -1.191 0 C-N-CA 119.887 -1.149 . . . . 0.0 112.472 179.284 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 103.27 171.25 25.99 Favored Glycine 0 C--N 1.309 -0.972 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 -179.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 157.22 -175.28 34.69 Favored Glycine 0 C--N 1.312 -0.759 0 C-N-CA 120.354 -0.927 . . . . 0.0 111.867 178.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 m -146.27 143.54 29.25 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 179.453 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.92 166.33 23.57 Favored 'General case' 0 N--CA 1.425 -1.71 0 CA-C-O 121.249 0.547 . . . . 0.0 109.788 -177.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.8 p30 -111.03 115.52 29.61 Favored 'General case' 0 C--N 1.28 -2.442 0 CA-C-N 114.533 -1.212 . . . . 0.0 108.822 178.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.481 HG22 HG22 ' A' ' 5' ' ' THR . 39.7 t -103.26 140.08 22.44 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.947 0 CA-C-N 115.266 -0.879 . . . . 0.0 108.762 178.052 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 43.7 m-85 -126.1 136.23 52.66 Favored 'General case' 0 C--N 1.304 -1.405 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.477 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.4 p -146.04 135.51 17.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 123.724 0.64 . . . . 0.0 110.519 -178.769 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 1.6 p30 -95.83 123.24 39.32 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 121.759 0.79 . . . . 0.0 111.367 179.375 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.407 HD11 HG22 ' A' ' 36' ' ' VAL . 2.6 mm? -103.48 160.93 14.29 Favored 'General case' 0 C--N 1.299 -1.603 0 CA-C-N 113.922 -1.49 . . . . 0.0 108.208 -177.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.76 122.41 56.58 Favored Pre-proline 0 C--N 1.313 -0.994 0 O-C-N 124.764 1.29 . . . . 0.0 109.405 178.23 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 61.0 Cg_endo -75.21 3.08 6.04 Favored 'Trans proline' 0 N--CA 1.458 -0.608 0 C-N-CA 122.661 2.241 . . . . 0.0 112.89 -178.592 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.429 HG13 ' HG3' ' A' ' 157' ' ' PRO . 46.7 t -125.98 109.54 21.73 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.503 0 N-CA-C 107.153 -1.425 . . . . 0.0 107.153 177.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.451 ' O ' HG13 ' A' ' 156' ' ' VAL . 1.6 t -143.17 99.89 0.7 Allowed 'Isoleucine or valine' 0 C--O 1.183 -2.403 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 -178.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.462 ' H ' ' HG3' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -91.63 151.38 20.72 Favored 'General case' 0 C--N 1.269 -2.893 0 N-CA-C 112.015 0.376 . . . . 0.0 112.015 -179.199 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.447 HG13 ' O ' ' A' ' 112' ' ' VAL . 24.7 t -46.85 115.23 0.25 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.709 0 C-N-CA 123.615 0.766 . . . . 0.0 111.501 177.078 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.84 3.28 42.74 Favored Glycine 0 N--CA 1.446 -0.697 0 CA-C-N 114.759 -1.109 . . . . 0.0 112.755 -179.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.462 ' HG3' ' H ' ' A' ' 29' ' ' ASN . 0.2 OUTLIER -73.78 -178.37 3.16 Favored 'General case' 0 C--N 1.309 -1.159 0 C-N-CA 123.542 0.737 . . . . 0.0 111.427 175.57 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -134.67 89.03 2.5 Favored 'General case' 0 C--N 1.311 -1.086 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 177.075 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.675 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.3 tp -90.21 144.67 25.65 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.102 -176.599 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.4 t -134.12 125.79 48.75 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.633 0 CA-C-O 121.298 0.57 . . . . 0.0 110.585 -176.642 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.596 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 48.9 t -95.96 89.25 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.049 0 N-CA-C 106.806 -1.553 . . . . 0.0 106.806 174.057 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -82.81 113.05 20.18 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-O 121.15 0.5 . . . . 0.0 111.216 -178.11 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.3 mt -96.1 -2.7 46.03 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.983 -178.704 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -74.07 0.36 14.0 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-O 122.118 0.961 . . . . 0.0 109.733 -178.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.5 p -127.36 6.82 6.38 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 123.771 0.828 . . . . 0.0 109.819 178.09 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.477 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 45.7 mm-40 -124.03 -21.42 5.07 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.706 -174.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.6 mt -132.87 136.72 55.21 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.133 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 -175.155 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 42.9 m-85 -142.84 124.36 14.84 Favored 'General case' 0 CA--C 1.504 -0.798 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 -175.671 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.561 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 83.3 m -101.02 140.31 35.48 Favored 'General case' 0 C--N 1.284 -2.278 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 -179.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.4 p80 -132.19 139.36 48.32 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 121.852 0.834 . . . . 0.0 112.313 -171.748 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 8.7 p30 -103.44 107.26 18.02 Favored 'General case' 0 C--N 1.292 -1.899 0 CA-C-N 115.1 -0.954 . . . . 0.0 113.342 -178.272 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -84.24 -14.33 50.22 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 121.881 0.848 . . . . 0.0 109.531 175.588 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.419 ' HB2' HD13 ' A' ' 52' ' ' ILE . 47.2 m-85 -134.52 66.0 68.88 Favored Pre-proline 0 C--N 1.318 -0.761 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 177.492 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_endo -73.05 -5.56 17.42 Favored 'Trans proline' 0 N--CA 1.486 1.056 0 C-N-CA 123.188 2.592 . . . . 0.0 113.978 -172.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -120.41 -13.34 8.85 Favored 'General case' 0 C--N 1.296 -1.734 0 CA-C-O 121.469 0.652 . . . . 0.0 110.204 -179.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.475 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -94.78 -30.17 14.38 Favored 'General case' 0 N--CA 1.421 -1.88 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 -174.904 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.622 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -122.92 138.2 53.78 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.508 0 CA-C-N 113.529 -1.669 . . . . 0.0 107.924 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 7.3 t -80.7 136.39 36.17 Favored 'General case' 0 N--CA 1.427 -1.607 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 174.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.507 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 19.3 m-20 -84.79 108.16 17.33 Favored 'General case' 0 C--N 1.286 -2.163 0 CA-C-O 121.541 0.686 . . . . 0.0 110.506 -171.869 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.456 ' HE1' ' HG2' ' A' ' 92' ' ' ARG . 34.0 t80 -138.46 143.36 39.61 Favored 'General case' 0 C--N 1.284 -2.275 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.242 -178.399 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.597 HG23 HD13 ' A' ' 131' ' ' LEU . 12.6 p -148.59 148.66 15.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 177.026 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.04 137.59 19.89 Favored 'General case' 0 C--N 1.307 -1.269 0 O-C-N 123.599 0.562 . . . . 0.0 109.992 174.029 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.416 HD23 ' O ' ' A' ' 130' ' ' ILE . 0.3 OUTLIER -74.52 106.64 6.21 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 105.048 -2.204 . . . . 0.0 105.048 175.119 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 6.6 tp60 -56.05 -64.9 0.71 Allowed 'General case' 0 C--O 1.202 -1.399 0 C-N-CA 126.372 1.869 . . . . 0.0 109.968 177.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 8.3 ptp180 -158.3 153.59 25.75 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 108.269 -1.012 . . . . 0.0 108.269 -179.189 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -134.98 137.97 9.66 Favored Glycine 0 CA--C 1.463 -3.159 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 -178.308 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 66.4 m -126.33 151.95 46.88 Favored 'General case' 0 C--N 1.28 -2.419 0 C-N-CA 123.822 0.849 . . . . 0.0 109.784 -174.704 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.525 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -115.74 157.92 23.59 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 -178.134 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.484 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 91.9 m-85 -156.02 -179.45 8.15 Favored 'General case' 0 C--O 1.237 0.415 0 C-N-CA 124.328 1.051 . . . . 0.0 109.042 -177.412 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.25 -148.41 29.27 Favored Glycine 0 C--N 1.33 0.205 0 O-C-N 123.566 0.541 . . . . 0.0 113.533 178.68 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.41 -10.91 71.15 Favored Glycine 0 C--O 1.206 -1.598 0 C-N-CA 120.804 -0.712 . . . . 0.0 111.754 178.101 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.796 HG21 ' HB ' ' A' ' 126' ' ' ILE . 97.0 t -69.05 -40.68 81.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 C-N-CA 123.9 0.88 . . . . 0.0 111.483 -177.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.525 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -84.2 -20.5 32.24 Favored 'General case' 0 N--CA 1.433 -1.289 0 C-N-CA 118.759 -1.176 . . . . 0.0 112.14 179.09 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 31.7 t -98.37 -60.2 1.6 Allowed 'General case' 0 N--CA 1.442 -0.838 0 CA-C-N 115.932 -0.576 . . . . 0.0 112.004 -174.466 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.474 ' O ' HG22 ' A' ' 112' ' ' VAL . 48.6 m-20 -85.77 -25.74 26.2 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.427 -172.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.67 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 91.6 m-85 -106.56 158.83 16.63 Favored 'General case' 0 N--CA 1.42 -1.956 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.03 177.363 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.0 t -167.98 137.39 2.55 Favored 'General case' 0 N--CA 1.411 -2.411 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 176.155 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.475 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.25 -107.86 0.2 Allowed Glycine 0 N--CA 1.411 -2.978 0 N-CA-C 109.967 -1.253 . . . . 0.0 109.967 175.883 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.5 p -158.71 -179.88 8.47 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 123.791 0.836 . . . . 0.0 110.871 -175.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.412 ' HB ' ' HB2' ' A' ' 84' ' ' PHE . 2.6 p -132.11 144.96 35.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 177.662 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.685 ' HG3' ' O ' ' A' ' 80' ' ' SER . 73.6 tttt -123.73 142.98 50.58 Favored 'General case' 0 N--CA 1.424 -1.769 0 CA-C-N 115.999 -0.546 . . . . 0.0 109.969 -177.503 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.577 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 68.3 t80 -141.42 111.44 6.71 Favored 'General case' 0 C--N 1.304 -1.374 0 CA-C-N 115.458 -0.792 . . . . 0.0 108.87 -177.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 9.3 t 52.61 34.19 15.26 Favored 'General case' 0 CA--C 1.561 1.366 0 CA-C-O 121.717 0.77 . . . . 0.0 111.071 179.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.417 ' HA2' ' HE2' ' A' ' 76' ' ' LYS . . . 90.65 10.0 63.83 Favored Glycine 0 CA--C 1.532 1.101 0 C-N-CA 120.83 -0.7 . . . . 0.0 114.169 -179.237 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.685 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 21.8 t -79.98 179.54 7.54 Favored 'General case' 0 CA--C 1.549 0.924 0 CA-C-N 117.446 0.623 . . . . 0.0 109.376 177.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 17.5 p -153.27 109.11 3.29 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-O 121.548 0.69 . . . . 0.0 110.049 178.322 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.577 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 4.2 p90 -151.08 158.33 34.77 Favored Pre-proline 0 C--N 1.302 -1.465 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 -175.123 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.77 147.41 69.13 Favored 'Trans proline' 0 C--N 1.349 0.581 0 C-N-CA 122.95 2.433 . . . . 0.0 113.256 -175.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.608 ' CD2' HD21 ' A' ' 109' ' ' LEU . 66.6 t80 -121.23 132.84 24.11 Favored Pre-proline 0 N--CA 1.441 -0.88 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.535 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.54 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 60.6 Cg_endo -69.25 146.19 80.39 Favored 'Cis proline' 0 CA--C 1.538 0.702 0 C-N-CA 123.562 -1.432 . . . . 0.0 111.308 0.208 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.3 t -70.74 -178.07 1.75 Allowed 'General case' 0 CA--C 1.554 1.097 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.31 -177.284 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 10.0 p -130.51 -34.33 1.58 Allowed 'General case' 0 C--O 1.243 0.711 0 N-CA-C 114.827 1.418 . . . . 0.0 114.827 -169.132 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.1 t -118.74 -69.44 0.85 Allowed 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 119.978 -0.689 . . . . 0.0 111.021 -174.293 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 178.25 -179.71 0.31 Allowed 'General case' 0 N--CA 1.452 -0.372 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 -178.176 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 5.1 p -102.54 164.49 15.56 Favored Pre-proline 0 C--N 1.284 -2.26 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -66.46 160.61 44.89 Favored 'Trans proline' 0 C--N 1.365 1.406 0 C-N-CA 122.523 2.149 . . . . 0.0 110.504 173.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.49 ' HD3' HG23 ' A' ' 94' ' ' VAL . 6.8 tmm_? -72.73 128.2 34.82 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-N 115.64 -0.709 . . . . 0.0 112.166 -174.074 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 90.0 t -133.26 117.95 30.21 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 115.211 -0.904 . . . . 0.0 109.514 177.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.49 HG23 ' HD3' ' A' ' 92' ' ' ARG . 87.4 t -94.95 137.65 22.78 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 175.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.507 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.2 m-85 -89.62 93.97 9.68 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 175.183 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 13.3 m120 -89.13 69.21 8.32 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 178.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.8 m -143.35 148.2 35.88 Favored 'General case' 0 N--CA 1.429 -1.515 0 CA-C-N 114.539 -1.21 . . . . 0.0 109.719 -176.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 15.1 ptm180 -112.64 45.48 1.31 Allowed 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 121.288 0.566 . . . . 0.0 111.303 -179.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.1 t -171.52 179.92 2.75 Favored 'General case' 0 N--CA 1.439 -1.025 0 N-CA-C 106.332 -1.729 . . . . 0.0 106.332 -177.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -75.72 135.28 40.37 Favored 'General case' 0 C--O 1.249 1.051 0 CA-C-O 121.635 0.731 . . . . 0.0 109.37 -179.28 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 62.3 mmtt -128.31 141.0 39.94 Favored Pre-proline 0 C--N 1.28 -2.415 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.623 -177.187 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.455 ' O ' ' HD3' ' A' ' 104' ' ' PRO . 32.2 Cg_endo -64.38 142.31 78.36 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 123.508 2.806 . . . . 0.0 111.276 -179.281 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 10.7 t90 -86.5 104.23 5.36 Favored Pre-proline 0 C--N 1.308 -1.228 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 -177.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.455 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 65.1 Cg_endo -75.91 88.61 1.3 Allowed 'Trans proline' 0 N--CA 1.453 -0.873 0 C-N-CA 121.944 1.763 . . . . 0.0 113.1 -172.156 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 99.1 t -138.28 144.63 30.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.17 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.596 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.67 135.09 19.52 Favored 'General case' 0 N--CA 1.417 -2.092 0 CA-C-N 116.519 -0.309 . . . . 0.0 110.545 177.779 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.51 HD21 HD11 ' A' ' 129' ' ' LEU . 18.6 mt -99.94 103.18 14.73 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 178.275 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.475 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 22.1 m-85 -82.14 72.18 9.2 Favored 'General case' 0 C--N 1.296 -1.743 0 O-C-N 122.363 -0.211 . . . . 0.0 111.031 177.424 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.675 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -96.96 127.17 42.66 Favored 'General case' 0 C--O 1.207 -1.146 0 CA-C-O 120.571 0.224 . . . . 0.0 110.616 177.819 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -127.54 144.73 52.03 Favored Pre-proline 0 N--CA 1.417 -2.079 0 CA-C-N 116.29 -0.414 . . . . 0.0 111.055 -175.731 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.437 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 28.4 Cg_endo -62.32 118.19 5.07 Favored 'Trans proline' 0 C--O 1.241 0.664 0 C-N-CA 123.164 2.576 . . . . 0.0 111.684 -178.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.474 HG22 ' O ' ' A' ' 70' ' ' ASN . 3.8 m -68.34 -112.82 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.191 -2.001 0 O-C-N 124.38 1.05 . . . . 0.0 113.07 176.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 11.7 p -111.68 -46.26 3.27 Favored 'General case' 0 C--N 1.294 -1.832 0 CA-C-O 121.369 0.604 . . . . 0.0 110.904 179.667 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 11.6 t -82.45 25.69 0.61 Allowed 'General case' 0 C--N 1.318 -0.761 0 CA-C-O 121.937 0.875 . . . . 0.0 111.021 -175.077 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -96.38 131.1 43.28 Favored 'General case' 0 N--CA 1.414 -2.265 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.29 129.54 1.7 Allowed Glycine 0 N--CA 1.436 -1.321 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.072 -178.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.5 -149.78 51.05 Favored Glycine 0 N--CA 1.434 -1.451 0 CA-C-O 119.376 -0.68 . . . . 0.0 111.93 -178.187 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.442 ' CG1' ' HE3' ' A' ' 121' ' ' LYS . 76.9 t -58.14 99.87 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 121.728 0.775 . . . . 0.0 111.088 -177.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -98.07 -37.76 9.61 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 114.878 -1.056 . . . . 0.0 110.577 -178.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.536 ' HB ' HG22 ' A' ' 154' ' ' VAL . 72.9 mt -118.02 139.04 46.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.886 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 178.686 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.523 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.0 mmpt? -115.17 141.82 47.5 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 122.823 0.449 . . . . 0.0 110.375 176.375 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.0 132.63 46.21 Favored 'General case' 0 C--N 1.31 -1.136 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.423 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 87.28 -1.23 86.15 Favored Glycine 0 N--CA 1.431 -1.695 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.779 -178.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 32.1 t -90.92 140.78 29.5 Favored 'General case' 0 N--CA 1.42 -1.972 0 N-CA-C 108.577 -0.898 . . . . 0.0 108.577 178.826 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.415 HD11 HG23 ' A' ' 128' ' ' VAL . 3.0 tm? -68.83 126.63 30.37 Favored 'General case' 0 N--CA 1.427 -1.61 0 N-CA-C 106.411 -1.699 . . . . 0.0 106.411 175.163 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.796 ' HB ' HG21 ' A' ' 67' ' ' VAL . 29.6 pt -113.67 -27.15 2.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -178.562 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.28 167.96 24.95 Favored 'General case' 0 N--CA 1.443 -0.825 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 -177.8 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.415 HG23 HD11 ' A' ' 125' ' ' LEU . 64.4 t -142.33 113.54 3.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 179.429 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.51 HD11 HD21 ' A' ' 107' ' ' LEU . 37.3 mt -118.04 143.49 46.38 Favored 'General case' 0 C--N 1.288 -2.094 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 179.704 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.416 ' O ' HD23 ' A' ' 58' ' ' LEU . 4.9 mp -123.39 128.43 74.74 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.133 0 C-N-CA 119.709 -0.796 . . . . 0.0 109.411 178.811 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.597 HD13 HG23 ' A' ' 56' ' ' VAL . 1.1 pp -94.34 147.25 23.4 Favored 'General case' 0 CA--C 1.472 -2.05 0 N-CA-C 105.614 -1.995 . . . . 0.0 105.614 172.369 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 59.7 ttt180 -116.57 132.72 56.61 Favored 'General case' 0 N--CA 1.386 -3.635 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 173.435 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.653 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 17.0 mm-40 -90.38 148.06 23.06 Favored 'General case' 0 N--CA 1.402 -2.863 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 178.706 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.428 ' HB ' ' CE2' ' A' ' 55' ' ' TYR . 27.6 m -154.58 138.14 15.99 Favored 'General case' 0 C--N 1.276 -2.622 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 169.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.622 ' CB ' HG23 ' A' ' 52' ' ' ILE . 6.1 p30 -145.18 172.14 13.54 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 119.585 -0.846 . . . . 0.0 111.332 175.171 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -85.91 -12.65 50.04 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 114.174 -1.375 . . . . 0.0 112.747 -168.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 70.8 t80 -113.57 -69.65 0.85 Allowed 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 112.03 0.382 . . . . 0.0 112.03 -171.753 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . 0.466 ' HB2' HD21 ' A' ' 135' ' ' ASN . 11.8 m120 -81.47 161.79 23.52 Favored 'General case' 0 CA--C 1.489 -1.366 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.035 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 23.2 t -87.03 41.11 0.95 Allowed 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 107.686 -1.227 . . . . 0.0 107.686 175.543 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . 0.557 ' HB3' ' ND2' ' A' ' 135' ' ' ASN . 12.6 t0 -81.21 70.63 8.1 Favored 'General case' 0 N--CA 1.436 -1.146 0 CA-C-N 114.346 -1.297 . . . . 0.0 107.598 176.157 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . 0.653 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 7.4 p-10 -119.11 35.78 4.7 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 113.411 -1.722 . . . . 0.0 108.088 177.497 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 77.1 m-85 -90.1 176.41 6.79 Favored 'General case' 0 N--CA 1.434 -1.275 0 CA-C-N 113.32 -1.764 . . . . 0.0 107.869 -178.604 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -134.47 146.54 49.86 Favored 'General case' 0 N--CA 1.42 -1.962 0 C-N-CA 118.571 -1.252 . . . . 0.0 111.93 -176.331 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 10.8 m-30 -111.3 126.95 55.44 Favored 'General case' 0 C--N 1.31 -1.13 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -177.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.0 t -91.68 132.29 36.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 -178.426 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 55.4 m95 -118.29 101.53 8.27 Favored 'General case' 0 C--N 1.282 -2.334 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 42.5 m-80 -80.88 112.98 18.77 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 106.462 -1.681 . . . . 0.0 106.462 178.021 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.42 HG22 HD11 ' A' ' 126' ' ' ILE . 23.7 mm -87.19 122.16 38.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 -177.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -116.51 153.78 31.55 Favored 'General case' 0 C--N 1.293 -1.882 0 C-N-CA 123.242 0.617 . . . . 0.0 109.525 178.208 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.76 130.3 35.11 Favored 'General case' 0 N--CA 1.412 -2.364 0 CA-C-N 115.197 -0.91 . . . . 0.0 108.741 176.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -85.82 -20.69 28.79 Favored 'General case' 0 C--N 1.292 -1.898 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -178.16 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -149.86 147.32 27.81 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 114.21 -1.359 . . . . 0.0 109.269 -173.448 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 16.8 p-10 -89.83 136.73 32.87 Favored 'General case' 0 C--N 1.31 -1.112 0 O-C-N 123.948 0.78 . . . . 0.0 111.119 -177.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.536 HG22 ' HB ' ' A' ' 120' ' ' ILE . 2.0 m -115.65 150.99 17.46 Favored 'Isoleucine or valine' 0 C--O 1.252 1.222 0 CA-C-O 121.053 0.454 . . . . 0.0 111.434 -174.489 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.8 t -122.32 139.42 49.31 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.016 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.208 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.451 HG13 ' O ' ' A' ' 28' ' ' VAL . 75.7 t -100.8 99.4 10.2 Favored Pre-proline 0 C--N 1.293 -1.85 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.429 ' HG3' HG13 ' A' ' 27' ' ' VAL . 33.9 Cg_endo -68.06 -28.47 34.88 Favored 'Trans proline' 0 C--O 1.24 0.591 0 C-N-CA 122.269 1.979 . . . . 0.0 111.954 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.4 t . . . . . 0 C--O 1.249 1.06 0 O-C-N 125.091 1.495 . . . . 0.0 113.799 178.488 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.445 ' HA ' ' HA ' ' A' ' 46' ' ' ASN . 43.4 t80 . . . . . 0 CA--C 1.49 -1.336 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.419 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -135.67 -174.4 3.64 Favored 'General case' 0 C--N 1.284 -2.28 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.515 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.464 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 10.4 t -154.71 157.63 38.35 Favored 'General case' 0 C--N 1.299 -1.626 0 C-N-CA 119.423 -0.911 . . . . 0.0 109.719 -176.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.406 ' HE3' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -145.36 163.76 33.57 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.558 -175.174 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 76.2 p -102.02 176.7 5.11 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.591 0.71 . . . . 0.0 110.859 -178.946 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.88 -1.09 46.51 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 114.453 -1.249 . . . . 0.0 111.091 179.143 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -100.08 -25.58 14.25 Favored 'General case' 0 N--CA 1.446 -0.67 0 C-N-CA 119.227 -0.989 . . . . 0.0 109.685 174.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 128.19 5.22 5.24 Favored Glycine 0 CA--C 1.507 -0.461 0 C-N-CA 119.838 -1.173 . . . . 0.0 113.22 175.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.0 m -81.33 99.63 8.76 Favored 'General case' 0 N--CA 1.43 -1.453 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 -179.357 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.58 122.42 34.98 Favored 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 115.45 -0.795 . . . . 0.0 108.925 176.49 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.419 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 66.3 mt -95.13 115.89 65.83 Favored Pre-proline 0 C--N 1.293 -1.88 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 178.018 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.8 163.78 37.79 Favored 'Trans proline' 0 C--O 1.25 1.099 0 C-N-CA 122.156 1.904 . . . . 0.0 110.294 177.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.402 HD11 ' OD2' ' A' ' 47' ' ' ASP . 23.5 mt -67.48 126.18 26.59 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.101 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 147.65 -14.83 1.4 Allowed Glycine 0 C--N 1.297 -1.592 0 C-N-CA 120.491 -0.861 . . . . 0.0 111.62 -175.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 95.17 134.5 7.71 Favored Glycine 0 C--N 1.31 -0.883 0 C-N-CA 120.376 -0.916 . . . . 0.0 111.459 -179.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -178.76 -166.97 35.71 Favored Glycine 0 C--N 1.299 -1.501 0 N-CA-C 109.916 -1.273 . . . . 0.0 109.916 -178.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.451 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 60.0 p -140.23 150.53 44.23 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 117.457 0.629 . . . . 0.0 110.261 -179.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -134.17 161.53 34.64 Favored 'General case' 0 N--CA 1.422 -1.831 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 177.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 19.8 m-80 -116.5 111.13 19.53 Favored 'General case' 0 C--N 1.284 -2.248 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 178.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.432 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.1 m -92.63 149.71 4.1 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.462 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 -178.611 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 55.5 m-85 -132.04 113.71 13.7 Favored 'General case' 0 CA--C 1.492 -1.277 0 O-C-N 122.089 -0.382 . . . . 0.0 110.485 -176.665 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.516 HG11 HG13 ' A' ' 36' ' ' VAL . 3.5 p -120.93 132.84 69.41 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 CA-C-O 121.451 0.643 . . . . 0.0 111.423 -174.583 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 30.6 m-80 -88.17 123.24 32.62 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 50.0 mt -108.69 159.24 16.9 Favored 'General case' 0 C--N 1.276 -2.61 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 179.666 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.0 120.57 43.78 Favored Pre-proline 0 C--N 1.3 -1.552 0 O-C-N 124.37 1.044 . . . . 0.0 109.523 179.323 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.552 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 66.6 Cg_endo -74.09 -2.93 12.98 Favored 'Trans proline' 0 CA--C 1.531 0.369 0 C-N-CA 122.758 2.305 . . . . 0.0 113.503 -175.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.468 HG13 ' HG3' ' A' ' 157' ' ' PRO . 99.4 t -128.2 109.75 20.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 179.391 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 12.5 t -147.1 107.48 0.63 Allowed 'Isoleucine or valine' 0 C--O 1.19 -2.068 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 -176.472 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.578 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -95.48 156.96 16.11 Favored 'General case' 0 C--N 1.271 -2.819 0 C-N-CA 122.863 0.465 . . . . 0.0 112.12 -179.911 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.432 HG13 ' O ' ' A' ' 112' ' ' VAL . 41.2 t -44.12 115.25 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.674 0 C-N-CA 124.296 1.038 . . . . 0.0 112.07 175.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.19 1.39 51.19 Favored Glycine 0 C--N 1.316 -0.536 0 CA-C-N 115.386 -0.825 . . . . 0.0 113.233 179.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.578 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -74.1 -176.32 2.52 Favored 'General case' 0 C--N 1.315 -0.916 0 C-N-CA 124.164 0.986 . . . . 0.0 111.005 176.408 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -130.78 93.07 3.34 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 177.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.632 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 19.8 tp -93.41 141.88 27.96 Favored 'General case' 0 C--N 1.29 -1.982 0 C-N-CA 119.348 -0.941 . . . . 0.0 109.545 178.34 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 33.3 t -135.77 128.3 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.978 0 N-CA-C 109.433 -0.581 . . . . 0.0 109.433 -176.111 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.586 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 56.3 t -97.59 88.87 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.405 -2.721 0 N-CA-C 106.561 -1.644 . . . . 0.0 106.561 174.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -83.36 115.89 22.22 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 120.822 0.344 . . . . 0.0 110.639 -178.24 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 80.5 mt -97.27 4.19 51.02 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.369 -179.143 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 33.3 t -77.28 -0.17 24.4 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-O 122.371 1.081 . . . . 0.0 109.115 -178.397 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.1 p -128.07 3.68 5.87 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 114.977 -1.01 . . . . 0.0 110.13 179.129 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.515 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 54.2 mm-40 -122.34 -22.22 5.59 Favored 'General case' 0 CA--C 1.503 -0.858 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.282 -172.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 24.3 mt -136.79 135.64 48.37 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.032 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 -175.261 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.406 ' HB2' ' HE3' ' A' ' 4' ' ' LYS . 61.3 m-85 -138.53 125.26 20.92 Favored 'General case' 0 CA--C 1.501 -0.919 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 -175.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.464 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 73.7 m -108.2 143.33 37.14 Favored 'General case' 0 C--N 1.287 -2.151 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 30.7 p80 -134.23 156.53 48.22 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-O 120.914 0.388 . . . . 0.0 110.589 -175.536 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.665 ' ND2' ' HA ' ' A' ' 49' ' ' PRO . 56.4 t30 -113.74 100.4 8.44 Favored 'General case' 0 N--CA 1.421 -1.916 0 CA-C-O 122.734 1.254 . . . . 0.0 110.772 176.604 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . 0.402 ' OD2' HD11 ' A' ' 13' ' ' ILE . 0.0 OUTLIER -60.75 -32.21 71.51 Favored 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 127.021 2.128 . . . . 0.0 112.728 179.942 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 44.9 m-85 -130.46 77.2 76.39 Favored Pre-proline 0 C--N 1.318 -0.803 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.665 ' HA ' ' ND2' ' A' ' 46' ' ' ASN . 64.7 Cg_endo -68.42 -4.69 13.41 Favored 'Trans proline' 0 N--CA 1.484 0.93 0 C-N-CA 123.529 2.819 . . . . 0.0 115.95 -169.846 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -118.92 -15.72 9.31 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 121.596 0.713 . . . . 0.0 109.944 178.77 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.45 ' HB ' HD12 ' A' ' 52' ' ' ILE . 2.0 m -96.84 -30.64 13.04 Favored 'General case' 0 N--CA 1.408 -2.573 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -175.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.668 HG23 ' CB ' ' A' ' 135' ' ' ASN . 3.4 mp -132.65 140.47 47.43 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.244 0 N-CA-C 107.213 -1.403 . . . . 0.0 107.213 179.063 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.8 t -87.83 150.66 23.4 Favored 'General case' 0 C--O 1.254 1.302 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 177.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.562 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 0.9 OUTLIER -79.97 107.91 13.13 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 -178.598 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 76.5 t80 -143.69 144.04 31.69 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -176.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.468 HG13 ' OH ' ' A' ' 77' ' ' TYR . 6.2 p -152.08 150.33 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.179 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 177.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -151.2 133.11 15.07 Favored 'General case' 0 C--O 1.208 -1.079 0 CA-C-O 119.455 -0.307 . . . . 0.0 110.296 175.193 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.521 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 47.9 tp -76.56 106.48 8.23 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 121.132 0.491 . . . . 0.0 109.861 176.617 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.7 tp-100 -53.84 -52.69 59.58 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 125.77 1.628 . . . . 0.0 111.717 177.661 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.403 ' HG3' HD13 ' A' ' 130' ' ' ILE . 1.1 ptp180 -166.37 157.89 13.33 Favored 'General case' 0 C--N 1.307 -1.258 0 N-CA-C 107.597 -1.261 . . . . 0.0 107.597 -179.017 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.13 115.23 0.86 Allowed Glycine 0 N--CA 1.399 -3.814 0 N-CA-C 108.992 -1.643 . . . . 0.0 108.992 -178.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 67.2 m -110.26 147.17 34.35 Favored 'General case' 0 C--N 1.28 -2.423 0 C-N-CA 124.471 1.108 . . . . 0.0 110.338 -171.13 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.547 ' HB2' ' CE2' ' A' ' 84' ' ' PHE . . . -108.83 157.8 18.26 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.47 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 86.9 m-85 -157.01 -179.35 8.12 Favored 'General case' 0 C--O 1.237 0.403 0 C-N-CA 124.21 1.004 . . . . 0.0 108.683 -178.532 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 60.2 -140.68 47.96 Favored Glycine 0 CA--C 1.5 -0.899 0 O-C-N 123.915 0.759 . . . . 0.0 112.851 176.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -77.09 -12.54 84.54 Favored Glycine 0 N--CA 1.431 -1.669 0 C-N-CA 120.54 -0.838 . . . . 0.0 111.375 177.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.75 HG21 ' HB ' ' A' ' 126' ' ' ILE . 82.4 t -68.45 -39.45 80.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 C-N-CA 123.522 0.729 . . . . 0.0 111.927 -176.293 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.522 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -87.54 -16.23 35.21 Favored 'General case' 0 C--N 1.298 -1.661 0 C-N-CA 118.981 -1.088 . . . . 0.0 112.272 178.897 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 8.0 t -101.06 -58.05 1.97 Allowed 'General case' 0 C--N 1.318 -0.762 0 CA-C-O 121.329 0.585 . . . . 0.0 111.399 -174.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.511 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 47.6 m-20 -87.09 -25.31 24.21 Favored 'General case' 0 CA--C 1.492 -1.283 0 CA-C-N 115.59 -0.732 . . . . 0.0 109.133 -174.673 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.673 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 83.7 m-85 -108.24 158.19 17.68 Favored 'General case' 0 N--CA 1.415 -2.223 0 C-N-CA 120.03 -0.668 . . . . 0.0 110.352 179.342 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.6 t -164.91 135.76 4.02 Favored 'General case' 0 N--CA 1.409 -2.522 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 176.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.424 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.31 -109.12 0.22 Allowed Glycine 0 N--CA 1.406 -3.356 0 N-CA-C 110.373 -1.091 . . . . 0.0 110.373 174.862 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.447 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.3 p -159.72 179.33 8.95 Favored 'General case' 0 C--N 1.299 -1.629 0 C-N-CA 123.695 0.798 . . . . 0.0 110.827 -174.198 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.5 p -132.55 145.47 34.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 178.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.633 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.2 tttt -124.08 144.87 49.62 Favored 'General case' 0 N--CA 1.417 -2.084 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.471 -179.4 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.468 ' OH ' HG13 ' A' ' 56' ' ' VAL . 59.2 t80 -146.33 114.71 6.7 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -178.638 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.0 m 54.05 36.68 25.2 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 113.974 1.101 . . . . 0.0 113.974 177.431 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 82.16 12.19 81.23 Favored Glycine 0 C--N 1.309 -0.917 0 C-N-CA 119.579 -1.296 . . . . 0.0 112.587 -178.593 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.633 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 7.9 t -83.8 178.87 7.74 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 176.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 48.8 p -154.74 111.04 3.23 Favored 'General case' 0 C--N 1.289 -2.028 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 -178.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.442 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 3.4 p90 -154.73 158.86 32.26 Favored Pre-proline 0 C--N 1.305 -1.331 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 -175.315 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.447 ' HA ' HG22 ' A' ' 74' ' ' THR . 73.0 Cg_endo -71.31 147.91 54.07 Favored 'Trans proline' 0 C--N 1.355 0.904 0 C-N-CA 123.089 2.526 . . . . 0.0 113.259 -176.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.59 ' CD2' HD21 ' A' ' 109' ' ' LEU . 48.3 t80 -119.35 135.63 24.1 Favored Pre-proline 0 N--CA 1.433 -1.291 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.082 -178.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.518 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 57.0 Cg_endo -71.18 148.15 89.12 Favored 'Cis proline' 0 CA--C 1.538 0.678 0 C-N-CA 122.741 -1.774 . . . . 0.0 110.365 -1.532 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 7.9 t -65.64 -175.24 0.26 Allowed 'General case' 0 CA--C 1.55 0.976 0 C-N-CA 122.616 0.366 . . . . 0.0 110.288 -178.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 13.9 p -122.42 -36.45 2.94 Favored 'General case' 0 N--CA 1.432 -1.334 0 CA-C-O 121.664 0.745 . . . . 0.0 109.017 -172.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.4 t -132.49 -137.51 0.19 Allowed 'General case' 1 N--CA 1.364 -4.77 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 176.154 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . 0.442 ' HA ' ' O ' ' A' ' 58' ' ' LEU . 19.6 tt0 -105.67 156.99 17.73 Favored 'General case' 0 C--N 1.264 -3.12 0 C-N-CA 125.958 1.703 . . . . 0.0 109.377 -170.595 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.521 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 23.7 p -74.76 162.27 74.27 Favored Pre-proline 0 C--N 1.31 -1.14 0 C-N-CA 123.322 0.649 . . . . 0.0 111.203 178.467 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -59.05 162.7 13.12 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 122.976 2.451 . . . . 0.0 111.236 176.137 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.5 tmm_? -68.92 125.98 28.35 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -176.272 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 71.5 t -140.14 128.48 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.83 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 -177.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 54' ' ' ASP . 1.9 p -124.68 132.37 71.41 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.378 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.206 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.562 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.4 m-85 -81.03 140.27 35.25 Favored 'General case' 0 C--N 1.298 -1.662 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 177.795 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -108.37 28.14 8.64 Favored 'General case' 0 C--N 1.292 -1.899 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . 0.444 ' OG ' ' HB3' ' A' ' 95' ' ' TYR . 5.0 p -84.08 178.93 7.64 Favored 'General case' 0 N--CA 1.423 -1.807 0 CA-C-N 114.584 -1.189 . . . . 0.0 111.918 -175.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -151.27 32.38 0.59 Allowed 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 171.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.1 t -163.62 -176.45 4.68 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 107.457 -1.312 . . . . 0.0 107.457 -176.484 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -76.84 134.25 39.1 Favored 'General case' 0 CA--C 1.506 -0.736 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.131 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . 0.584 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 7.8 mmpt? -137.39 152.4 73.13 Favored Pre-proline 0 C--N 1.29 -2.015 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -67.63 147.15 75.66 Favored 'Trans proline' 0 N--CA 1.443 -1.445 0 C-N-CA 122.305 2.003 . . . . 0.0 111.998 -177.733 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . 0.489 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.0 t90 -88.0 111.41 42.53 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.462 ' HD3' ' OH ' ' A' ' 95' ' ' TYR . 2.5 Cg_endo -79.47 87.6 1.53 Allowed 'Trans proline' 0 N--CA 1.443 -1.448 0 C-N-CA 121.386 1.39 . . . . 0.0 112.069 -172.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.406 HG22 ' HD2' ' A' ' 77' ' ' TYR . 95.9 t -140.13 142.75 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.339 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 177.488 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.586 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.58 135.62 17.65 Favored 'General case' 0 N--CA 1.421 -1.899 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 178.158 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.491 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 16.8 mt -101.89 103.38 14.05 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 108.102 -1.073 . . . . 0.0 108.102 179.199 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.424 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 25.7 m-85 -84.38 76.62 10.12 Favored 'General case' 0 C--N 1.297 -1.709 0 CA-C-O 120.767 0.318 . . . . 0.0 110.24 178.477 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.673 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.2 mm? -103.33 131.04 50.72 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 177.405 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.23 147.61 66.44 Favored Pre-proline 0 N--CA 1.418 -2.029 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.528 -175.317 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.511 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 30.3 Cg_endo -62.04 121.08 8.97 Favored 'Trans proline' 0 C--O 1.25 1.083 0 C-N-CA 123.068 2.512 . . . . 0.0 111.841 -178.188 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.509 HG22 ' O ' ' A' ' 70' ' ' ASN . 4.2 m -69.89 -120.52 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.186 -2.242 0 CA-C-N 114.026 -1.443 . . . . 0.0 111.218 175.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 23.0 t -111.06 -35.82 5.81 Favored 'General case' 0 C--N 1.291 -1.94 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 175.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 27.6 t -82.06 36.8 0.47 Allowed 'General case' 0 N--CA 1.441 -0.919 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.919 -176.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -117.02 133.47 55.96 Favored 'General case' 0 N--CA 1.418 -2.043 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 177.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -172.95 129.55 1.72 Allowed Glycine 0 N--CA 1.437 -1.24 0 N-CA-C 111.436 -0.666 . . . . 0.0 111.436 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.21 -146.06 48.46 Favored Glycine 0 CA--C 1.491 -1.454 0 CA-C-O 119.143 -0.809 . . . . 0.0 111.781 -177.396 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.2 p -58.05 101.27 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -1.021 0 CA-C-O 122.598 1.19 . . . . 0.0 112.157 -177.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -102.03 -23.09 14.14 Favored 'General case' 0 C--N 1.294 -1.827 0 CA-C-N 114.674 -1.148 . . . . 0.0 111.001 -178.484 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.519 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 65.3 mt -136.56 137.14 48.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 179.329 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.554 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.1 mmpt? -113.3 137.58 51.28 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-O 120.864 0.364 . . . . 0.0 110.664 176.657 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.94 134.82 48.79 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-N 115.749 -0.66 . . . . 0.0 109.833 178.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 85.17 6.96 83.91 Favored Glycine 0 C--N 1.303 -1.273 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.768 -178.808 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 49.4 m -109.44 144.58 37.48 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 177.518 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.438 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -70.38 126.57 30.02 Favored 'General case' 0 N--CA 1.443 -0.783 0 CA-C-N 115.045 -0.98 . . . . 0.0 108.58 -178.776 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.75 ' HB ' HG21 ' A' ' 67' ' ' VAL . 34.4 pt -113.0 -26.05 3.21 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.257 0 N-CA-C 112.469 0.544 . . . . 0.0 112.469 -179.39 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . 0.42 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -160.82 165.29 30.51 Favored 'General case' 0 N--CA 1.445 -0.717 0 N-CA-C 110.189 -0.3 . . . . 0.0 110.189 -178.07 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.438 HG23 HD11 ' A' ' 125' ' ' LEU . 63.7 t -140.63 112.88 4.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 179.062 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.487 HD11 HD21 ' A' ' 107' ' ' LEU . 50.9 mt -117.1 143.99 45.17 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.44 ' O ' HD12 ' A' ' 58' ' ' LEU . 5.0 mp -128.9 123.77 59.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.054 0 C-N-CA 119.616 -0.834 . . . . 0.0 109.946 179.206 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.439 ' C ' HD12 ' A' ' 131' ' ' LEU . 1.4 pp -88.72 147.03 24.7 Favored 'General case' 0 CA--C 1.477 -1.855 0 N-CA-C 106.304 -1.739 . . . . 0.0 106.304 174.512 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 37.3 ttp180 -112.42 123.41 50.22 Favored 'General case' 0 C--N 1.258 -3.39 0 N-CA-C 107.4 -1.333 . . . . 0.0 107.4 173.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.434 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 0.0 OUTLIER -92.28 135.88 33.65 Favored 'General case' 0 N--CA 1.408 -2.53 0 N-CA-C 105.625 -1.991 . . . . 0.0 105.625 -176.407 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 35.2 m -147.29 147.22 30.16 Favored 'General case' 0 C--N 1.269 -2.919 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 175.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.668 ' CB ' HG23 ' A' ' 52' ' ' ILE . 11.5 p30 -143.61 173.0 12.04 Favored 'General case' 0 N--CA 1.438 -1.036 0 C-N-CA 119.708 -0.797 . . . . 0.0 110.983 178.453 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -87.11 -4.61 59.15 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 114.705 -1.134 . . . . 0.0 112.097 -170.27 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 42.6 t80 -116.79 -69.05 0.88 Allowed 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 112.621 0.6 . . . . 0.0 112.621 -172.32 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 57.7 m-20 -94.9 158.75 15.35 Favored 'General case' 0 CA--C 1.479 -1.763 0 CA-C-O 121.146 0.498 . . . . 0.0 111.19 -177.193 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 9.5 t -93.27 49.15 1.37 Allowed 'General case' 0 N--CA 1.416 -2.157 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 173.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -92.35 36.35 1.0 Allowed 'General case' 0 CA--C 1.506 -0.722 0 CA-C-N 114.844 -1.071 . . . . 0.0 108.406 173.407 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . 0.434 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 5.6 p-10 -80.87 69.64 7.48 Favored 'General case' 0 N--CA 1.433 -1.294 0 CA-C-N 114.294 -1.321 . . . . 0.0 111.25 -178.781 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 -105.7 172.73 6.64 Favored 'General case' 0 N--CA 1.426 -1.642 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 178.129 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -123.8 146.61 48.22 Favored 'General case' 0 C--N 1.286 -2.162 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.042 -177.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 9.8 m-30 -113.01 125.88 54.9 Favored 'General case' 0 C--N 1.309 -1.156 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 -176.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.451 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 58.3 t -89.27 134.31 28.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 O-C-N 123.553 0.533 . . . . 0.0 110.409 -177.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 58.9 m95 -120.26 97.03 5.39 Favored 'General case' 0 C--N 1.284 -2.246 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.6 m-80 -78.34 113.1 16.01 Favored 'General case' 0 C--N 1.283 -2.318 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 177.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.432 ' HA ' HG22 ' A' ' 20' ' ' VAL . 22.8 mm -88.74 122.17 39.81 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -177.183 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 47.4 m-85 -118.11 153.04 34.43 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-O 121.509 0.671 . . . . 0.0 109.809 178.061 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -78.98 128.89 33.85 Favored 'General case' 0 N--CA 1.409 -2.517 0 CA-C-N 114.609 -1.178 . . . . 0.0 108.159 175.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -88.71 -15.5 34.66 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 107.42 -1.326 . . . . 0.0 107.42 -178.404 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -151.01 145.39 25.5 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 113.578 -1.646 . . . . 0.0 109.641 -175.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 -79.92 144.63 33.2 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 124.019 0.928 . . . . 0.0 110.753 -178.624 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.552 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 71.2 t -121.54 134.62 64.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 CA-C-N 115.713 -0.676 . . . . 0.0 111.11 -176.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.5 t -118.58 134.43 62.22 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 -179.447 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.47 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 75.5 t -97.46 101.68 10.82 Favored Pre-proline 0 C--N 1.292 -1.934 0 C-N-CA 123.889 0.876 . . . . 0.0 108.778 177.633 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.468 ' HG3' HG13 ' A' ' 27' ' ' VAL . 35.8 Cg_endo -67.22 -28.38 40.33 Favored 'Trans proline' 0 CA--C 1.511 -0.643 0 C-N-CA 121.893 1.729 . . . . 0.0 112.018 -178.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.403 ' HB ' HG12 ' A' ' 156' ' ' VAL . 8.0 t . . . . . 0 CA--C 1.559 1.298 0 O-C-N 124.827 1.329 . . . . 0.0 112.831 176.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.555 ' HB2' ' O ' ' A' ' 45' ' ' HIS . 44.4 p90 . . . . . 0 CA--C 1.501 -0.933 0 N-CA-C 110.681 -0.118 . . . . 0.0 110.681 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -124.6 173.63 8.38 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 175.379 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.433 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 74.1 m -134.17 161.94 33.52 Favored 'General case' 0 C--N 1.301 -1.502 0 C-N-CA 119.747 -0.781 . . . . 0.0 112.211 -173.703 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.463 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -146.78 161.67 40.16 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.215 -176.84 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.451 HG22 HG22 ' A' ' 20' ' ' VAL . 72.7 p -99.48 179.56 4.52 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 121.225 0.536 . . . . 0.0 111.557 -178.716 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.58 -26.62 50.92 Favored 'General case' 0 C--N 1.295 -1.797 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.862 177.14 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 5.6 p30 -79.4 -31.33 42.73 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 119.433 -0.907 . . . . 0.0 109.414 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 129.08 20.42 1.45 Allowed Glycine 0 N--CA 1.431 -1.687 0 C-N-CA 119.911 -1.138 . . . . 0.0 112.933 173.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.42 ' O ' ' HA ' ' A' ' 4' ' ' LYS . 2.6 m -87.98 99.31 12.06 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.565 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.06 121.32 32.76 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 115.795 -0.638 . . . . 0.0 109.539 177.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 63.5 mt -99.82 116.67 64.54 Favored Pre-proline 0 C--N 1.29 -1.99 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 177.293 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -77.39 168.57 22.66 Favored 'Trans proline' 0 C--O 1.251 1.151 0 C-N-CA 122.45 2.1 . . . . 0.0 110.912 177.704 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 64.9 mt -66.56 124.91 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.84 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.595 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 145.04 -5.0 1.42 Allowed Glycine 0 C--N 1.303 -1.304 0 CA-C-N 115.723 -0.671 . . . . 0.0 111.636 -176.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 94.37 161.17 34.75 Favored Glycine 0 N--CA 1.439 -1.145 0 N-CA-C 110.122 -1.191 . . . . 0.0 110.122 -179.747 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 159.38 -167.01 34.96 Favored Glycine 0 CA--C 1.486 -1.758 0 C-N-CA 119.484 -1.341 . . . . 0.0 111.342 179.044 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 49.9 p -147.08 152.37 38.41 Favored 'General case' 0 N--CA 1.424 -1.761 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -178.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -138.39 163.41 31.95 Favored 'General case' 0 N--CA 1.417 -2.082 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 179.013 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -108.42 118.14 35.99 Favored 'General case' 0 N--CA 1.406 -2.662 0 CA-C-N 114.342 -1.299 . . . . 0.0 107.964 176.457 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.451 HG22 HG22 ' A' ' 5' ' ' THR . 49.3 t -104.96 130.5 55.95 Favored 'Isoleucine or valine' 0 C--N 1.264 -3.113 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.142 178.776 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -118.75 128.09 54.17 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -179.352 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.55 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -138.01 137.26 44.75 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 O-C-N 124.128 0.893 . . . . 0.0 110.932 -176.545 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 37.3 m-80 -90.28 139.63 30.47 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 108.319 -0.993 . . . . 0.0 108.319 178.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.7 HD21 HG22 ' A' ' 36' ' ' VAL . 5.1 mp -122.72 161.95 22.93 Favored 'General case' 0 C--N 1.282 -2.367 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.183 176.852 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.03 120.85 54.26 Favored Pre-proline 0 C--N 1.316 -0.863 0 O-C-N 124.653 1.221 . . . . 0.0 109.404 178.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 73.5 Cg_endo -75.68 3.75 5.68 Favored 'Trans proline' 0 CA--C 1.532 0.392 0 C-N-CA 122.846 2.364 . . . . 0.0 113.398 -176.154 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.4 t -132.0 109.79 15.84 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 178.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.52 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.1 t -141.85 107.7 1.78 Allowed 'Isoleucine or valine' 0 C--O 1.182 -2.448 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -176.639 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.664 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -96.4 150.36 20.67 Favored 'General case' 0 C--N 1.269 -2.895 0 O-C-N 122.036 -0.415 . . . . 0.0 111.303 -179.864 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.402 HG13 ' O ' ' A' ' 112' ' ' VAL . 35.0 t -45.81 117.44 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.966 0 C-N-CA 123.445 0.698 . . . . 0.0 111.976 176.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.62 1.61 53.01 Favored Glycine 0 CA--C 1.523 0.576 0 CA-C-N 115.414 -0.812 . . . . 0.0 112.829 -178.644 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.664 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.1 OUTLIER -73.02 -178.0 2.64 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 123.891 0.876 . . . . 0.0 110.034 177.639 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -130.22 86.82 2.44 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 177.636 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.624 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 20.2 tp -89.94 145.49 25.08 Favored 'General case' 0 C--N 1.294 -1.824 0 C-N-CA 119.765 -0.774 . . . . 0.0 109.259 -179.256 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 73.7 t -137.73 134.5 45.8 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.73 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -178.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.7 HG22 HD21 ' A' ' 24' ' ' LEU . 21.0 t -99.99 89.62 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.41 -2.426 0 N-CA-C 105.914 -1.884 . . . . 0.0 105.914 174.32 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -83.35 114.95 21.78 Favored 'General case' 0 C--N 1.3 -1.562 0 C-N-CA 119.91 -0.716 . . . . 0.0 111.125 -176.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 82.7 mt -99.78 -2.39 35.24 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-N 115.377 -0.829 . . . . 0.0 110.69 -177.397 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.6 m -73.68 -2.08 21.7 Favored 'General case' 0 C--O 1.208 -1.13 0 CA-C-O 122.222 1.011 . . . . 0.0 109.191 -179.503 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.2 p -126.21 7.48 7.17 Favored 'General case' 0 N--CA 1.419 -1.985 0 CA-C-N 115.151 -0.931 . . . . 0.0 109.776 179.002 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.55 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 48.6 mm-40 -125.42 -20.23 4.83 Favored 'General case' 0 CA--C 1.508 -0.648 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.9 -174.692 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.5 mt -135.3 137.31 50.23 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.971 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 -176.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.463 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 74.8 m-85 -137.68 153.67 49.78 Favored 'General case' 0 CA--C 1.499 -1.008 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 -176.07 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.549 ' HB3' ' CD2' ' A' ' 1' ' ' PHE . 90.5 m -132.23 134.91 45.87 Favored 'General case' 0 C--N 1.28 -2.419 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.875 -178.637 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.555 ' O ' ' HB2' ' A' ' 1' ' ' PHE . 18.7 p-80 -122.64 131.0 53.61 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.428 -175.486 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.431 ' HA ' ' HB3' ' A' ' 1' ' ' PHE . 4.2 p-10 -77.83 118.17 19.9 Favored 'General case' 0 N--CA 1.422 -1.83 0 CA-C-O 122.09 0.948 . . . . 0.0 108.963 178.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . 0.491 ' OD1' ' HA ' ' A' ' 1' ' ' PHE . 3.9 p30 -97.24 -27.1 14.68 Favored 'General case' 0 C--N 1.274 -2.696 0 CA-C-N 114.154 -1.385 . . . . 0.0 110.387 -177.022 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 37.5 m-85 -148.93 68.43 9.63 Favored Pre-proline 0 N--CA 1.483 1.182 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.416 ' HA ' ' OD2' ' A' ' 54' ' ' ASP . 58.4 Cg_endo -67.85 -11.72 33.01 Favored 'Trans proline' 0 N--CA 1.481 0.766 0 C-N-CA 122.925 2.417 . . . . 0.0 114.281 -171.587 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -114.58 -14.03 12.11 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 121.208 0.528 . . . . 0.0 110.565 -177.474 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.517 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.3 m -101.87 -29.24 11.96 Favored 'General case' 0 N--CA 1.424 -1.731 0 CA-C-O 122.047 0.927 . . . . 0.0 108.881 -173.28 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.517 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.4 mp -128.56 141.21 47.14 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.168 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 178.403 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.458 ' CG2' HD22 ' A' ' 136' ' ' ASN . 14.5 t -74.52 136.35 42.18 Favored 'General case' 0 N--CA 1.428 -1.563 0 N-CA-C 106.617 -1.623 . . . . 0.0 106.617 174.071 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.49 ' O ' HG23 ' A' ' 94' ' ' VAL . 51.3 m-20 -95.98 105.82 17.9 Favored 'General case' 0 C--N 1.263 -3.173 0 C-N-CA 118.457 -1.297 . . . . 0.0 108.404 -179.305 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.505 ' CD2' ' HB ' ' A' ' 134' ' ' THR . 15.8 t80 -142.21 139.44 32.02 Favored 'General case' 0 C--N 1.289 -2.052 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.482 -173.963 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.423 ' CG2' ' HG ' ' A' ' 131' ' ' LEU . 14.9 p -148.56 156.01 8.7 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.943 0 O-C-N 123.832 0.708 . . . . 0.0 109.991 -178.44 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.29 135.54 17.94 Favored 'General case' 0 N--CA 1.422 -1.845 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 176.24 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.521 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 32.5 tp -70.6 110.44 5.45 Favored 'General case' 0 N--CA 1.427 -1.579 0 N-CA-C 107.137 -1.431 . . . . 0.0 107.137 170.553 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.412 ' HB2' ' HB2' ' A' ' 132' ' ' ARG . 3.2 tp-100 -57.6 -56.63 19.41 Favored 'General case' 0 C--O 1.206 -1.227 0 CA-C-N 113.576 -1.647 . . . . 0.0 109.479 -177.58 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 10.5 ptp180 -164.09 156.56 17.25 Favored 'General case' 0 N--CA 1.41 -2.461 0 CA-C-N 114.364 -1.289 . . . . 0.0 108.472 -177.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -140.58 135.83 7.26 Favored Glycine 0 N--CA 1.4 -3.712 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -179.535 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 46.0 m -124.81 147.68 48.59 Favored 'General case' 0 C--N 1.276 -2.591 0 C-N-CA 124.139 0.975 . . . . 0.0 110.473 -175.694 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.506 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -106.81 158.83 16.69 Favored 'General case' 0 C--N 1.319 -0.718 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 -179.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.508 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 97.1 m-85 -154.61 175.4 13.7 Favored 'General case' 0 C--N 1.341 0.231 0 C-N-CA 124.139 0.975 . . . . 0.0 109.864 -177.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.02 -143.28 45.84 Favored Glycine 0 N--CA 1.446 -0.671 0 O-C-N 123.791 0.682 . . . . 0.0 113.104 176.486 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.36 -13.12 73.59 Favored Glycine 0 C--O 1.202 -1.868 0 C-N-CA 120.962 -0.637 . . . . 0.0 111.742 177.063 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.855 HG21 ' HB ' ' A' ' 126' ' ' ILE . 94.7 t -70.29 -36.75 68.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 123.414 0.686 . . . . 0.0 112.043 -177.64 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.506 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -90.04 -18.54 25.76 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 118.58 -1.248 . . . . 0.0 112.374 177.248 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 5.0 t -99.88 -51.13 3.8 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 115.601 -0.727 . . . . 0.0 111.369 -172.134 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.456 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 67.7 m-20 -96.2 -23.18 16.84 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 -174.683 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.645 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 89.6 m-85 -110.73 156.3 21.24 Favored 'General case' 0 N--CA 1.422 -1.868 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 177.588 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 5.0 t -165.59 127.89 2.06 Favored 'General case' 0 N--CA 1.411 -2.409 0 N-CA-C 106.999 -1.482 . . . . 0.0 106.999 176.513 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -161.29 -111.24 0.27 Allowed Glycine 0 N--CA 1.407 -3.233 0 N-CA-C 111.574 -0.61 . . . . 0.0 111.574 176.462 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -153.63 -179.91 8.23 Favored 'General case' 0 C--N 1.291 -1.941 0 C-N-CA 123.933 0.893 . . . . 0.0 110.366 -173.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 3.2 p -135.8 151.51 29.61 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 178.242 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.691 ' HG3' ' O ' ' A' ' 80' ' ' SER . 72.3 tttt -130.91 147.53 52.57 Favored 'General case' 0 N--CA 1.423 -1.794 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 -178.676 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.448 ' CD2' HG22 ' A' ' 105' ' ' VAL . 47.5 t80 -148.13 108.67 4.15 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 -177.199 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 13.8 t 51.21 44.62 28.68 Favored 'General case' 0 CA--C 1.553 1.06 0 C-N-CA 123.433 0.693 . . . . 0.0 111.197 175.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 81.22 20.89 63.75 Favored Glycine 0 CA--C 1.525 0.671 0 C-N-CA 120.264 -0.97 . . . . 0.0 113.115 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.691 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 16.3 t -90.53 179.26 5.89 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 106.927 -1.508 . . . . 0.0 106.927 174.649 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 10.9 m -157.47 103.55 1.96 Allowed 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 107.144 -1.428 . . . . 0.0 107.144 178.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.423 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.6 p90 -147.65 158.75 42.59 Favored Pre-proline 0 C--N 1.308 -1.222 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -172.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.417 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 56.6 Cg_endo -68.78 150.16 73.65 Favored 'Trans proline' 0 C--N 1.356 0.964 0 C-N-CA 122.933 2.422 . . . . 0.0 112.837 -177.654 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.541 ' CD2' HD21 ' A' ' 109' ' ' LEU . 47.3 t80 -124.5 134.77 25.83 Favored Pre-proline 0 N--CA 1.431 -1.402 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 179.293 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.54 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 59.3 Cg_endo -71.03 145.61 82.69 Favored 'Cis proline' 0 CA--C 1.554 1.51 0 C-N-CA 123.105 -1.623 . . . . 0.0 111.153 -2.438 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 13.2 t -68.43 -176.81 0.81 Allowed 'General case' 0 N--CA 1.489 1.52 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.32 -175.398 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 56.1 p -124.89 -47.34 1.8 Allowed 'General case' 0 N--CA 1.436 -1.164 0 N-CA-C 112.412 0.523 . . . . 0.0 112.412 -172.362 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 10.0 t -105.4 -65.19 1.07 Allowed 'General case' 0 N--CA 1.437 -1.123 0 C-N-CA 120.39 -0.524 . . . . 0.0 111.246 -174.242 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 176.23 -172.98 0.09 Allowed 'General case' 0 C--O 1.247 0.97 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 -175.546 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.521 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 42.4 p -100.9 168.44 9.24 Favored Pre-proline 0 C--N 1.297 -1.708 0 O-C-N 123.429 0.455 . . . . 0.0 111.707 175.326 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . 0.453 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 19.0 Cg_endo -55.78 165.19 3.84 Favored 'Trans proline' 0 CA--C 1.547 1.158 0 C-N-CA 123.232 2.621 . . . . 0.0 111.962 171.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.403 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 1.7 tmm_? -76.68 112.75 13.58 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 -176.587 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 76.4 t -126.4 128.33 71.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-O 121.522 0.677 . . . . 0.0 110.15 -176.305 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.49 HG23 ' O ' ' A' ' 54' ' ' ASP . 0.2 OUTLIER -121.71 132.32 71.08 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 CA-C-N 115.038 -0.983 . . . . 0.0 110.776 -177.571 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.49 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 7.2 m-85 -80.78 101.04 9.09 Favored 'General case' 0 CA--C 1.509 -0.624 0 CA-C-N 115.469 -0.787 . . . . 0.0 111.19 -178.084 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 16.7 m120 -96.63 64.31 2.13 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 107.708 -1.219 . . . . 0.0 107.708 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.6 m -142.02 178.1 7.76 Favored 'General case' 0 N--CA 1.434 -1.229 0 O-C-N 121.778 -0.576 . . . . 0.0 110.844 -174.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.401 ' HA ' HD21 ' A' ' 46' ' ' ASN . 6.8 ptp180 -141.22 45.75 1.75 Allowed 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.066 0.46 . . . . 0.0 110.446 -178.678 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.0 t -170.53 177.44 4.0 Favored 'General case' 0 C--O 1.245 0.847 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 -174.824 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 12.2 m-20 -73.03 98.16 2.48 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 106.461 -1.681 . . . . 0.0 106.461 173.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 10.0 tptp -97.1 142.59 24.76 Favored Pre-proline 0 C--N 1.277 -2.587 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.415 ' O ' ' HD3' ' A' ' 104' ' ' PRO . 26.8 Cg_endo -62.91 154.72 64.72 Favored 'Trans proline' 0 C--N 1.324 -0.75 0 C-N-CA 122.428 2.086 . . . . 0.0 112.395 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . 0.49 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 15.4 t90 -95.71 100.94 6.96 Favored Pre-proline 0 C--N 1.306 -1.32 0 N-CA-C 105.102 -2.184 . . . . 0.0 105.102 175.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.415 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 59.6 Cg_endo -74.57 88.63 1.16 Allowed 'Trans proline' 0 N--CA 1.454 -0.837 0 C-N-CA 121.782 1.655 . . . . 0.0 113.341 -170.052 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.448 HG22 ' CD2' ' A' ' 77' ' ' TYR . 96.9 t -138.61 145.12 28.56 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.193 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 178.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.534 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.65 138.47 19.92 Favored 'General case' 0 C--N 1.286 -2.176 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 177.269 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.475 ' HB2' ' CG2' ' A' ' 36' ' ' VAL . 17.7 mt -102.82 104.3 14.56 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . . . . . . . . . 9.5 m-85 -81.32 67.33 7.22 Favored 'General case' 0 C--N 1.295 -1.788 0 O-C-N 122.023 -0.423 . . . . 0.0 111.355 179.206 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.645 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.4 mm? -92.84 134.54 34.97 Favored 'General case' 0 C--O 1.208 -1.127 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 176.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -136.62 148.11 62.33 Favored Pre-proline 0 C--N 1.294 -1.829 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -176.18 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.456 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 28.8 Cg_endo -62.98 121.46 9.35 Favored 'Trans proline' 0 C--O 1.243 0.753 0 C-N-CA 123.235 2.624 . . . . 0.0 112.555 -176.726 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.402 ' O ' HG13 ' A' ' 30' ' ' VAL . 2.4 m -71.86 -116.9 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.186 -2.237 0 CA-C-N 114.225 -1.352 . . . . 0.0 112.715 176.914 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 28.9 t -112.54 -37.54 4.9 Favored 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 177.191 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 47.9 m -73.42 16.21 0.2 Allowed 'General case' 0 N--CA 1.399 -2.999 0 C-N-CA 125.997 1.719 . . . . 0.0 113.653 -176.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -102.7 131.69 49.34 Favored 'General case' 0 N--CA 1.411 -2.399 0 N-CA-C 109.83 -0.433 . . . . 0.0 109.83 -176.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -173.94 129.33 1.62 Allowed Glycine 0 N--CA 1.434 -1.447 0 N-CA-C 110.634 -0.987 . . . . 0.0 110.634 179.377 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.89 -151.29 51.92 Favored Glycine 0 CA--C 1.5 -0.888 0 CA-C-O 119.085 -0.842 . . . . 0.0 111.53 -176.757 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.9 p -54.86 104.6 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 122.233 1.016 . . . . 0.0 111.914 -177.518 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.85 -31.2 9.4 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 115.043 -0.981 . . . . 0.0 111.461 -177.166 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.53 ' HB ' HG22 ' A' ' 154' ' ' VAL . 69.7 mt -124.4 140.86 46.44 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 N-CA-C 108.187 -1.042 . . . . 0.0 108.187 177.186 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.42 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 2.8 mmpt? -117.67 139.44 51.01 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-O 121.001 0.429 . . . . 0.0 111.073 178.483 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.7 131.67 44.95 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.406 -0.815 . . . . 0.0 110.769 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 87.31 -7.9 78.97 Favored Glycine 0 C--N 1.309 -0.931 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.079 -179.58 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 25.3 m -90.69 148.59 22.5 Favored 'General case' 0 N--CA 1.425 -1.716 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 -179.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 24.9 tp -73.76 133.0 43.22 Favored 'General case' 0 N--CA 1.436 -1.132 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.229 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.855 ' HB ' HG21 ' A' ' 67' ' ' VAL . 37.9 pt -118.42 -24.44 3.25 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 C-N-CA 120.432 -0.507 . . . . 0.0 112.352 -179.519 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . 0.47 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -163.3 164.33 24.92 Favored 'General case' 0 N--CA 1.439 -0.977 0 CA-C-O 120.538 0.209 . . . . 0.0 110.614 -178.633 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 53.5 t -140.74 114.36 5.36 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 178.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.41 HD11 HD21 ' A' ' 107' ' ' LEU . 54.3 mt -117.55 139.01 51.52 Favored 'General case' 0 C--N 1.287 -2.12 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.54 HG21 HE21 ' A' ' 143' ' ' GLN . 5.0 mp -117.33 122.29 69.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.631 0 C-N-CA 119.314 -0.954 . . . . 0.0 109.918 177.372 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.494 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.0 OUTLIER -90.44 132.73 35.47 Favored 'General case' 0 C--N 1.275 -2.649 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 177.439 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.412 ' HB2' ' HB2' ' A' ' 59' ' ' GLN . 17.7 tpt85 -106.85 109.54 21.47 Favored 'General case' 0 C--N 1.274 -2.709 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.149 -176.05 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 14.1 mm100 -88.34 132.67 34.33 Favored 'General case' 0 CA--C 1.484 -1.574 0 N-CA-C 107.807 -1.183 . . . . 0.0 107.807 175.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.505 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 11.7 m -136.41 133.57 36.83 Favored 'General case' 0 C--N 1.273 -2.724 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 177.636 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.442 HD21 ' HB2' ' A' ' 140' ' ' ASP . 16.3 p30 -128.59 153.96 46.7 Favored 'General case' 0 C--N 1.31 -1.141 0 CA-C-O 121.404 0.621 . . . . 0.0 111.634 -179.185 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.458 HD22 ' CG2' ' A' ' 53' ' ' THR . 7.0 p30 -94.39 -21.19 19.1 Favored 'General case' 0 N--CA 1.476 0.848 0 CA-C-N 114.763 -1.108 . . . . 0.0 110.793 -174.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 50.5 t80 -86.44 -70.66 0.59 Allowed 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.577 -172.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 91.3 m-20 -89.91 177.53 6.46 Favored 'General case' 0 C--N 1.283 -2.294 0 CA-C-N 115.791 -0.641 . . . . 0.0 109.407 175.678 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 66.9 m -109.73 43.47 1.33 Allowed 'General case' 0 C--N 1.284 -2.267 0 CA-C-O 122.726 1.251 . . . . 0.0 107.628 175.359 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . 0.442 ' HB2' HD21 ' A' ' 135' ' ' ASN . 1.5 m-20 -102.97 46.07 0.93 Allowed 'General case' 0 C--N 1.312 -1.048 0 CA-C-N 113.96 -1.473 . . . . 0.0 108.809 -179.491 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 -87.74 83.56 7.15 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 114.605 -1.179 . . . . 0.0 109.7 -179.44 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -104.39 163.64 12.3 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 115.459 -0.791 . . . . 0.0 109.869 -179.141 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . 0.54 HE21 HG21 ' A' ' 130' ' ' ILE . 16.6 pt20 -119.92 143.72 47.82 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 110.04 -0.355 . . . . 0.0 110.04 178.42 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.478 ' HB2' HD22 ' A' ' 131' ' ' LEU . 9.6 m-30 -112.48 134.35 54.06 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -176.513 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 47.4 t -91.51 131.09 39.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.708 0 CA-C-O 121.155 0.502 . . . . 0.0 110.08 -179.096 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . 0.494 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 65.3 m95 -120.23 97.96 5.84 Favored 'General case' 0 C--N 1.284 -2.274 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -179.217 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 36.9 m-80 -80.35 114.1 19.01 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 106.992 -1.485 . . . . 0.0 106.992 178.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.47 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 22.5 mm -89.3 122.53 40.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.71 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 -177.784 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -120.31 152.75 37.39 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 123.428 0.691 . . . . 0.0 109.605 178.803 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.73 132.92 34.82 Favored 'General case' 0 N--CA 1.418 -2.03 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 177.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 12.5 t-20 -90.1 -15.45 31.66 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 -178.19 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -149.27 144.52 26.56 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 114.049 -1.432 . . . . 0.0 109.431 -175.665 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -85.76 148.08 26.02 Favored 'General case' 0 C--N 1.315 -0.906 0 O-C-N 124.022 0.826 . . . . 0.0 109.292 -178.145 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.53 HG22 ' HB ' ' A' ' 120' ' ' ILE . 2.2 m -126.56 148.34 31.31 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 C-N-CA 120.256 -0.578 . . . . 0.0 110.557 -176.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.5 t -120.14 140.6 43.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.032 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 -179.144 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.52 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 79.4 t -101.57 101.63 18.46 Favored Pre-proline 0 C--N 1.297 -1.676 0 C-N-CA 123.871 0.868 . . . . 0.0 109.706 178.233 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.451 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 30.3 Cg_endo -68.28 -25.85 36.17 Favored 'Trans proline' 0 CA--C 1.518 -0.304 0 C-N-CA 122.315 2.01 . . . . 0.0 112.378 178.661 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 5.8 t . . . . . 0 CA--C 1.559 1.31 0 O-C-N 124.646 1.216 . . . . 0.0 113.352 176.506 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.503 ' CZ ' ' HB3' ' A' ' 44' ' ' CYS . 50.2 t80 . . . . . 0 CA--C 1.494 -1.203 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.511 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -149.47 176.92 10.18 Favored 'General case' 0 C--N 1.296 -1.723 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 -179.237 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.445 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 68.4 m -142.41 159.0 43.09 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 120.274 -0.57 . . . . 0.0 110.912 -174.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.438 ' HD2' ' O ' ' A' ' 5' ' ' THR . 0.0 OUTLIER -146.12 156.87 43.74 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-O 121.14 0.495 . . . . 0.0 109.978 -177.469 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.438 ' O ' ' HD2' ' A' ' 4' ' ' LYS . 41.1 p -91.83 176.08 6.65 Favored 'General case' 0 C--N 1.298 -1.646 0 CA-C-N 115.748 -0.66 . . . . 0.0 111.613 -179.178 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -85.23 -5.08 59.34 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 114.866 -1.061 . . . . 0.0 110.838 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -102.96 -34.49 8.92 Favored 'General case' 0 C--N 1.31 -1.128 0 CA-C-N 115.172 -0.922 . . . . 0.0 111.877 -179.689 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 140.06 7.27 0.99 Allowed Glycine 0 C--N 1.316 -0.529 0 C-N-CA 118.796 -1.668 . . . . 0.0 115.236 172.289 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.7 m -87.37 102.3 14.39 Favored 'General case' 0 C--N 1.296 -1.755 0 O-C-N 121.892 -0.77 . . . . 0.0 109.039 177.164 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.57 122.12 37.98 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 115.396 -0.82 . . . . 0.0 108.84 175.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.511 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 63.7 mt -102.01 116.15 63.64 Favored Pre-proline 0 C--N 1.298 -1.649 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.187 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -80.25 173.8 12.11 Favored 'Trans proline' 0 C--O 1.247 0.954 0 C-N-CA 122.814 2.343 . . . . 0.0 111.469 178.069 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 58.8 mt -66.64 129.59 31.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 178.215 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 140.14 -6.79 2.85 Favored Glycine 0 C--N 1.303 -1.252 0 N-CA-C 111.358 -0.697 . . . . 0.0 111.358 -178.705 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 96.84 156.26 30.76 Favored Glycine 0 N--CA 1.438 -1.199 0 N-CA-C 110.104 -1.198 . . . . 0.0 110.104 -179.108 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 170.33 -175.46 44.25 Favored Glycine 0 N--CA 1.428 -1.886 0 C-N-CA 119.822 -1.18 . . . . 0.0 111.142 -179.43 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.6 m -144.96 148.88 34.3 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 178.631 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.98 165.4 26.08 Favored 'General case' 0 CA--C 1.48 -1.727 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -114.85 110.09 19.14 Favored 'General case' 0 C--N 1.278 -2.543 0 CA-C-N 114.098 -1.41 . . . . 0.0 107.482 177.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.436 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.3 m -97.65 142.08 14.91 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.321 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 179.694 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.2 m-85 -124.07 124.56 42.79 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 121.039 0.447 . . . . 0.0 110.989 -178.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.466 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.9 p -138.43 134.85 43.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.825 -178.067 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -94.33 128.06 40.6 Favored 'General case' 0 C--N 1.294 -1.811 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.867 179.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -104.82 160.51 14.94 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.097 -0.956 . . . . 0.0 108.581 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -56.75 123.33 57.46 Favored Pre-proline 0 C--O 1.211 -0.949 0 O-C-N 124.258 0.974 . . . . 0.0 109.241 176.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.491 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 74.1 Cg_endo -76.57 -0.34 10.35 Favored 'Trans proline' 0 CA--C 1.536 0.592 0 C-N-CA 122.5 2.133 . . . . 0.0 113.567 -175.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.5 t -128.85 109.77 19.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 N-CA-C 107.324 -1.361 . . . . 0.0 107.324 179.57 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.428 HG21 HD22 ' A' ' 34' ' ' LEU . 5.2 t -145.09 104.69 0.71 Allowed 'Isoleucine or valine' 0 C--O 1.198 -1.639 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 -178.078 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.523 ' HB3' ' HG2' ' A' ' 157' ' ' PRO . 0.5 OUTLIER -94.36 154.84 17.28 Favored 'General case' 0 C--N 1.275 -2.668 0 C-N-CA 123.212 0.605 . . . . 0.0 111.61 -179.902 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.433 ' H ' ' HA ' ' A' ' 158' ' ' THR . 42.5 t -44.7 116.53 0.23 Allowed 'Isoleucine or valine' 0 C--O 1.236 0.361 0 C-N-CA 124.103 0.961 . . . . 0.0 111.402 175.486 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.72 0.2 45.84 Favored Glycine 0 CA--C 1.521 0.458 0 CA-C-N 115.06 -0.973 . . . . 0.0 113.186 179.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.478 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -72.78 -177.63 2.41 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 123.779 0.831 . . . . 0.0 111.768 176.702 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -128.84 87.39 2.57 Favored 'General case' 0 CA--C 1.49 -1.337 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 177.307 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.631 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 21.6 tp -96.24 135.23 38.33 Favored 'General case' 0 N--CA 1.423 -1.824 0 C-N-CA 119.23 -0.988 . . . . 0.0 109.64 179.256 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 1.6 p -141.64 132.49 26.31 Favored 'Isoleucine or valine' 0 N--CA 1.387 -3.599 0 CA-C-O 122.208 1.004 . . . . 0.0 112.859 -178.077 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.604 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 41.9 t -91.74 89.7 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.661 0 CA-C-N 113.507 -1.678 . . . . 0.0 107.664 178.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.3 t70 -77.78 106.91 9.91 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.636 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 88.3 mt -93.93 -1.22 54.99 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.701 -178.495 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.637 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 0.7 OUTLIER -68.99 -10.57 58.15 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-O 122.396 1.093 . . . . 0.0 109.741 -178.638 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.6 p -121.47 5.52 10.13 Favored 'General case' 0 C--N 1.296 -1.756 0 CA-C-N 115.083 -0.962 . . . . 0.0 110.748 179.054 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.466 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 49.2 mm-40 -120.0 -21.98 6.89 Favored 'General case' 0 CA--C 1.511 -0.555 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.614 -174.635 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 29.9 mt -135.06 138.95 48.12 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.011 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -178.09 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -136.96 147.87 46.6 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 109.92 -0.4 . . . . 0.0 109.92 -177.052 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.503 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 88.9 m -123.55 136.55 54.6 Favored 'General case' 0 C--N 1.29 -1.981 0 CA-C-O 120.864 0.364 . . . . 0.0 110.991 178.8 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 16.4 p80 -130.91 162.6 29.3 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.423 0.63 . . . . 0.0 110.46 -175.424 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 14.1 p30 -112.56 121.17 44.03 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 121.828 0.823 . . . . 0.0 111.993 177.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 22.5 p-10 -96.98 -13.32 22.41 Favored 'General case' 0 N--CA 1.427 -1.583 0 CA-C-N 114.999 -1.0 . . . . 0.0 109.588 178.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.418 ' HB2' HD13 ' A' ' 52' ' ' ILE . 83.4 m-85 -147.3 69.24 11.53 Favored Pre-proline 0 C--O 1.22 -0.481 0 CA-C-N 115.503 -0.771 . . . . 0.0 108.935 175.464 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -68.52 -12.82 35.86 Favored 'Trans proline' 0 N--CA 1.483 0.895 0 C-N-CA 122.091 1.861 . . . . 0.0 112.903 -177.176 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -101.44 -25.03 14.07 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-O 121.353 0.597 . . . . 0.0 110.589 -176.513 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.582 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.3 m -102.09 -26.81 13.24 Favored 'General case' 0 N--CA 1.42 -1.97 0 CA-C-O 121.69 0.757 . . . . 0.0 109.289 -172.387 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.582 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.2 mp -129.31 127.73 65.65 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.263 0 N-CA-C 107.567 -1.271 . . . . 0.0 107.567 -178.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.409 HG22 HD22 ' A' ' 136' ' ' ASN . 13.1 t -73.63 145.7 45.16 Favored 'General case' 0 C--O 1.256 1.399 0 N-CA-C 108.447 -0.946 . . . . 0.0 108.447 179.794 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -85.3 107.62 17.41 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 -176.629 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.44 ' CE2' ' HB ' ' A' ' 134' ' ' THR . 17.3 t80 -149.35 138.83 21.61 Favored 'General case' 0 C--N 1.295 -1.766 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -177.555 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.503 HG23 ' HG ' ' A' ' 131' ' ' LEU . 13.4 p -150.64 149.97 13.87 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.564 0 CA-C-N 115.733 -0.667 . . . . 0.0 109.25 -178.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -150.3 131.02 14.07 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 172.744 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.541 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 53.4 tp -66.5 110.82 3.3 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 171.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.494 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 3.0 tp-100 -55.48 -50.86 68.79 Favored 'General case' 0 C--N 1.314 -0.96 0 C-N-CA 126.123 1.769 . . . . 0.0 111.564 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -170.44 155.77 5.24 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -177.418 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -132.32 136.07 8.52 Favored Glycine 1 N--CA 1.395 -4.077 0 N-CA-C 107.986 -2.046 . . . . 0.0 107.986 178.413 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 47.8 m -124.17 147.91 47.64 Favored 'General case' 0 C--N 1.271 -2.809 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 -176.303 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.563 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -115.46 156.09 26.28 Favored 'General case' 0 C--N 1.306 -1.315 0 N-CA-C 107.656 -1.239 . . . . 0.0 107.656 -179.339 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.505 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 92.8 m-85 -155.13 -178.95 7.61 Favored 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 123.832 0.853 . . . . 0.0 109.045 -177.351 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 62.46 -136.75 44.87 Favored Glycine 0 C--O 1.222 -0.612 0 N-CA-C 111.723 -0.551 . . . . 0.0 111.723 179.344 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -88.38 -3.91 77.83 Favored Glycine 0 C--O 1.206 -1.607 0 C-N-CA 120.537 -0.839 . . . . 0.0 111.133 176.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.738 HG21 ' HB ' ' A' ' 126' ' ' ILE . 76.1 t -71.35 -36.31 60.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 C-N-CA 123.876 0.87 . . . . 0.0 111.576 -176.11 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.563 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -85.31 -25.73 27.0 Favored 'General case' 0 C--N 1.297 -1.681 0 C-N-CA 119.915 -0.714 . . . . 0.0 112.486 178.451 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 21.0 m -101.04 -52.83 3.18 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 -173.13 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.483 ' O ' HG22 ' A' ' 112' ' ' VAL . 53.9 m-20 -88.52 -28.41 20.81 Favored 'General case' 0 CA--C 1.488 -1.426 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 -175.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.656 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 90.2 m-85 -104.55 155.29 18.96 Favored 'General case' 0 N--CA 1.41 -2.463 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 175.465 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.415 ' HB3' ' CG1' ' A' ' 112' ' ' VAL . 15.5 t -167.03 120.34 0.98 Allowed 'General case' 0 N--CA 1.417 -2.106 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 177.013 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.454 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -154.81 -112.66 0.45 Allowed Glycine 0 N--CA 1.402 -3.63 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 175.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 8.3 p -151.69 -179.93 7.85 Favored 'General case' 0 C--N 1.293 -1.862 0 CA-C-O 121.157 0.503 . . . . 0.0 110.662 -173.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.443 ' HB ' ' HB2' ' A' ' 84' ' ' PHE . 2.5 p -132.27 146.03 33.71 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.156 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 177.868 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.643 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.1 tttt -123.92 142.85 50.77 Favored 'General case' 0 N--CA 1.409 -2.514 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 178.621 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.482 ' CG ' HG21 ' A' ' 90' ' ' THR . 59.9 t80 -145.49 112.57 6.07 Favored 'General case' 0 C--N 1.286 -2.159 0 N-CA-C 107.344 -1.354 . . . . 0.0 107.344 -179.124 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.3 m 55.28 37.37 28.79 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 113.678 0.992 . . . . 0.0 113.678 176.562 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.44 5.84 81.68 Favored Glycine 0 N--CA 1.432 -1.587 0 C-N-CA 120.422 -0.894 . . . . 0.0 112.58 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.643 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 11.0 t -80.34 174.59 11.45 Favored 'General case' 0 C--N 1.317 -0.844 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 179.532 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 9.3 p -154.13 100.43 2.32 Favored 'General case' 0 C--N 1.284 -2.257 0 CA-C-O 120.98 0.419 . . . . 0.0 110.182 -176.624 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 2.9 p90 -147.07 159.62 42.25 Favored Pre-proline 0 C--N 1.297 -1.701 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -173.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -67.53 149.1 79.76 Favored 'Trans proline' 0 C--N 1.354 0.845 0 C-N-CA 123.161 2.574 . . . . 0.0 113.228 -177.142 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.62 ' CD2' HD21 ' A' ' 109' ' ' LEU . 64.5 t80 -124.99 134.7 25.94 Favored Pre-proline 0 C--N 1.315 -0.903 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.128 -179.677 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.525 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 73.9 Cg_endo -72.85 146.39 86.73 Favored 'Cis proline' 0 C--O 1.244 0.788 0 C-N-CA 122.91 -1.704 . . . . 0.0 110.543 -1.487 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.2 t -65.54 -176.76 0.37 Allowed 'General case' 0 CA--C 1.551 0.987 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.394 -175.304 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.2 p -129.03 2.65 5.27 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-O 121.368 0.604 . . . . 0.0 110.709 -173.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.6 t -161.75 -125.03 0.02 OUTLIER 'General case' 0 N--CA 1.396 -3.146 0 N-CA-C 105.282 -2.118 . . . . 0.0 105.282 179.025 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -129.7 -170.35 2.28 Favored 'General case' 0 C--N 1.291 -1.963 0 N-CA-C 110.475 -0.194 . . . . 0.0 110.475 -176.244 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.541 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 44.1 p -95.25 166.8 14.05 Favored Pre-proline 0 C--N 1.302 -1.462 0 CA-C-N 116.18 -0.463 . . . . 0.0 112.205 178.581 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -62.29 165.09 15.76 Favored 'Trans proline' 0 CA--C 1.544 1.001 0 C-N-CA 123.02 2.48 . . . . 0.0 110.879 172.037 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.401 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 4.9 tmm_? -71.3 120.7 17.25 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.163 0.506 . . . . 0.0 109.838 -178.707 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 76.0 t -128.32 119.55 50.88 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.238 -178.104 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 59.6 t -94.64 141.11 15.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 176.349 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.534 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 1.3 m-85 -91.38 134.78 34.32 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 175.884 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -115.33 86.16 2.41 Favored 'General case' 0 C--N 1.276 -2.609 0 N-CA-C 106.29 -1.744 . . . . 0.0 106.29 177.616 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . 0.442 ' HB3' ' CG ' ' A' ' 101' ' ' LYS . 5.0 p -142.34 154.58 44.78 Favored 'General case' 0 N--CA 1.413 -2.286 0 CA-C-N 115.161 -0.927 . . . . 0.0 112.718 -173.034 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 10.3 ptp180 -135.0 19.37 3.46 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 107.419 -1.326 . . . . 0.0 107.419 171.121 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.0 t -164.09 -175.4 3.99 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 105.981 -1.859 . . . . 0.0 105.981 -178.592 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -76.77 122.55 24.92 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 121.88 0.848 . . . . 0.0 110.666 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . 0.442 ' CG ' ' HB3' ' A' ' 97' ' ' SER . 30.6 mmtp -109.68 139.51 21.29 Favored Pre-proline 0 C--N 1.293 -1.858 0 CA-C-N 115.032 -0.985 . . . . 0.0 110.002 177.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.637 ' HB3' ' O ' ' A' ' 39' ' ' SER . 52.3 Cg_exo -55.21 144.36 71.0 Favored 'Trans proline' 0 CA--C 1.505 -0.931 0 C-N-CA 123.726 2.951 . . . . 0.0 111.722 176.447 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . 0.534 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 9.1 t90 -91.63 103.63 8.27 Favored Pre-proline 0 C--N 1.294 -1.839 0 N-CA-C 106.044 -1.836 . . . . 0.0 106.044 178.821 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -76.58 88.63 1.35 Allowed 'Trans proline' 0 N--CA 1.446 -1.281 0 C-N-CA 121.624 1.549 . . . . 0.0 111.644 -172.206 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.455 HG22 ' CD2' ' A' ' 77' ' ' TYR . 85.0 t -138.77 142.19 35.05 Favored 'Isoleucine or valine' 0 CA--C 1.485 -1.534 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 179.131 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.604 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.97 133.91 18.05 Favored 'General case' 0 N--CA 1.411 -2.404 0 CA-C-O 120.968 0.413 . . . . 0.0 110.681 179.177 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.485 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 20.0 mt -100.96 99.93 10.47 Favored 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 179.099 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.454 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 76.7 m-85 -80.74 78.81 7.48 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 177.523 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.656 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.3 mm? -102.96 118.99 38.04 Favored 'General case' 0 CA--C 1.49 -1.331 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 177.375 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.8 145.83 46.49 Favored Pre-proline 0 N--CA 1.407 -2.577 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.079 -175.146 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.452 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 36.7 Cg_endo -63.1 119.51 6.61 Favored 'Trans proline' 0 C--O 1.248 1.018 0 C-N-CA 123.347 2.698 . . . . 0.0 112.265 -177.331 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.483 HG22 ' O ' ' A' ' 70' ' ' ASN . 3.2 m -67.62 -118.09 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.182 -2.464 0 CA-C-N 114.023 -1.444 . . . . 0.0 112.59 175.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.4 m -112.73 -38.08 4.69 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-O 122.334 1.064 . . . . 0.0 108.141 179.388 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 64.4 m -82.11 31.77 0.38 Allowed 'General case' 0 N--CA 1.394 -3.271 0 CA-C-N 113.356 -1.747 . . . . 0.0 113.151 -177.692 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -108.63 139.05 43.96 Favored 'General case' 0 C--N 1.288 -2.078 0 N-CA-C 109.783 -0.451 . . . . 0.0 109.783 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -174.83 139.04 4.64 Favored Glycine 0 N--CA 1.44 -1.068 0 C-N-CA 119.951 -1.119 . . . . 0.0 112.193 179.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 57.61 -149.7 32.3 Favored Glycine 0 CA--C 1.491 -1.453 0 O-C-N 124.783 0.931 . . . . 0.0 112.542 -178.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.431 ' CG2' ' HE3' ' A' ' 121' ' ' LYS . 7.3 p -57.3 101.7 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.312 -1.039 0 CA-C-O 122.507 1.146 . . . . 0.0 111.607 -178.628 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -100.61 -27.06 13.59 Favored 'General case' 0 C--N 1.295 -1.773 0 CA-C-N 114.826 -1.079 . . . . 0.0 110.679 -177.675 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.472 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 58.7 mt -133.26 136.98 54.23 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 -178.866 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.529 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.4 mmpt? -112.73 142.64 45.12 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-O 121.028 0.442 . . . . 0.0 110.706 176.35 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.23 132.02 45.83 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.495 -0.775 . . . . 0.0 110.169 179.243 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 91.63 -10.42 74.72 Favored Glycine 0 N--CA 1.435 -1.405 0 CA-C-N 115.694 -0.685 . . . . 0.0 111.584 -179.363 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 40.2 t -86.18 143.11 28.16 Favored 'General case' 0 N--CA 1.43 -1.43 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 -178.074 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.44 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -71.2 122.19 19.73 Favored 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 107.583 -1.266 . . . . 0.0 107.583 177.11 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.738 ' HB ' HG21 ' A' ' 67' ' ' VAL . 33.7 pt -109.24 -27.78 2.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-N 116.041 -0.527 . . . . 0.0 112.303 -178.554 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -160.3 166.78 28.86 Favored 'General case' 0 C--N 1.315 -0.922 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 -177.461 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.44 HG23 HD11 ' A' ' 125' ' ' LEU . 75.7 t -141.87 113.43 3.5 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 179.737 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.481 HD11 HD21 ' A' ' 107' ' ' LEU . 67.5 mt -115.33 134.67 54.9 Favored 'General case' 0 C--N 1.286 -2.162 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 179.212 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.525 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.4 mp -117.69 128.17 74.93 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.818 0 C-N-CA 119.196 -1.002 . . . . 0.0 109.748 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.516 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.2 OUTLIER -101.24 131.08 47.42 Favored 'General case' 0 C--N 1.276 -2.623 0 C-N-CA 123.989 0.916 . . . . 0.0 111.443 -176.481 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.494 ' HG2' ' HB2' ' A' ' 59' ' ' GLN . 26.9 mmm180 -87.41 128.09 35.21 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 123.529 0.731 . . . . 0.0 110.826 179.572 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.516 ' HA ' ' NE2' ' A' ' 133' ' ' GLN . 13.1 mm-40 -101.36 122.24 43.37 Favored 'General case' 0 N--CA 1.412 -2.356 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 168.05 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.44 ' HB ' ' CE2' ' A' ' 55' ' ' TYR . 23.4 m -140.28 129.49 23.73 Favored 'General case' 0 C--N 1.279 -2.468 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 177.382 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.547 ' CB ' HG23 ' A' ' 52' ' ' ILE . 28.0 p30 -132.02 177.08 7.83 Favored 'General case' 0 C--N 1.281 -2.387 0 CA-C-O 121.221 0.534 . . . . 0.0 110.539 -175.582 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.409 HD22 HG22 ' A' ' 53' ' ' THR . 7.2 p30 -104.43 6.36 34.91 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.788 -174.079 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 74.4 t80 -125.07 -69.68 0.78 Allowed 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 115.191 1.552 . . . . 0.0 115.191 -170.137 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . 0.46 ' HB2' HD21 ' A' ' 135' ' ' ASN . 18.0 m120 -58.97 -34.85 72.29 Favored 'General case' 0 CA--C 1.484 -1.571 0 N-CA-C 116.507 2.04 . . . . 0.0 116.507 -168.693 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 19.7 m 73.57 11.59 4.73 Favored 'General case' 0 C--N 1.324 -0.543 0 O-C-N 124.494 1.121 . . . . 0.0 109.168 -174.145 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . 0.486 ' HB3' ' CE2' ' A' ' 142' ' ' PHE . 13.9 m-20 -110.47 69.77 0.7 Allowed 'General case' 0 CA--C 1.496 -1.097 0 CA-C-N 113.686 -1.597 . . . . 0.0 107.78 178.136 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -91.41 82.59 5.39 Favored 'General case' 0 C--N 1.288 -2.096 0 CA-C-N 115.265 -0.88 . . . . 0.0 109.142 -175.648 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . 0.486 ' CE2' ' HB3' ' A' ' 140' ' ' ASP . 84.7 m-85 -90.59 -179.27 5.52 Favored 'General case' 0 CA--C 1.51 -0.577 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.897 -178.38 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.3 pt20 -137.38 149.82 47.23 Favored 'General case' 0 N--CA 1.418 -2.06 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 177.253 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 10.0 m-30 -111.34 132.46 54.39 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 -176.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 50.6 t -92.82 131.69 39.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 -179.024 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . 0.516 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.5 m95 -119.55 100.81 7.51 Favored 'General case' 0 C--N 1.277 -2.577 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 46.4 m-80 -80.69 113.86 19.18 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 178.368 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.436 ' HA ' HG22 ' A' ' 20' ' ' VAL . 22.7 mm -87.35 122.51 39.25 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.936 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 -178.587 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -118.16 148.54 42.25 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.617 178.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -80.49 129.52 34.57 Favored 'General case' 0 N--CA 1.409 -2.502 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 176.51 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 36.1 t-20 -87.75 -16.51 34.01 Favored 'General case' 0 C--N 1.291 -1.955 0 N-CA-C 107.996 -1.113 . . . . 0.0 107.996 -178.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -147.49 144.85 28.87 Favored 'General case' 0 C--N 1.3 -1.546 0 CA-C-N 114.103 -1.408 . . . . 0.0 108.795 -174.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 21.7 p-10 -82.96 144.17 30.18 Favored 'General case' 0 C--N 1.305 -1.353 0 O-C-N 124.232 0.957 . . . . 0.0 111.398 -178.119 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.491 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.2 t -120.42 138.71 50.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.634 -175.191 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 4.0 t -119.58 137.92 51.9 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.897 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.638 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . . . . . . . . . 71.9 t -102.17 103.34 29.71 Favored Pre-proline 0 C--N 1.29 -1.979 0 C-N-CA 123.479 0.711 . . . . 0.0 109.847 178.634 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.523 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 56.1 Cg_endo -71.68 -16.95 29.95 Favored 'Trans proline' 0 C--O 1.226 -0.093 0 C-N-CA 122.187 1.925 . . . . 0.0 111.781 178.039 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.433 ' HA ' ' H ' ' A' ' 30' ' ' VAL 0.254 3.9 t . . . . . 0 C--N 1.351 0.666 0 C-N-CA 125.082 1.353 . . . . 0.0 113.84 175.411 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.443 ' O ' HG12 ' A' ' 13' ' ' ILE . 11.2 t80 . . . . . 0 CA--C 1.49 -1.349 0 N-CA-C 104.353 -2.462 . . . . 0.0 104.353 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.514 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -163.28 164.91 24.74 Favored 'General case' 0 CA--C 1.485 -1.554 0 O-C-N 123.744 0.653 . . . . 0.0 109.279 -174.172 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.601 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 12.5 m -128.65 159.2 36.35 Favored 'General case' 0 C--N 1.294 -1.835 0 N-CA-C 109.03 -0.729 . . . . 0.0 109.03 -176.54 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.491 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -147.56 159.57 43.6 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 120.858 0.361 . . . . 0.0 110.421 -173.961 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 71.8 p -97.31 177.26 5.61 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-O 121.523 0.678 . . . . 0.0 110.553 -178.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -83.03 -17.95 41.48 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 114.869 -1.06 . . . . 0.0 109.655 179.06 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -92.26 -17.71 24.41 Favored 'General case' 0 N--CA 1.43 -1.446 0 CA-C-N 114.739 -1.119 . . . . 0.0 111.795 -177.65 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.05 29.22 2.43 Favored Glycine 0 CA--C 1.484 -1.885 0 C-N-CA 119.925 -1.131 . . . . 0.0 113.971 166.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.9 m -107.64 99.51 8.99 Favored 'General case' 0 N--CA 1.415 -2.216 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.054 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -91.07 116.36 28.74 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.584 177.513 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.514 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 64.0 mt -84.73 122.77 74.69 Favored Pre-proline 0 C--N 1.301 -1.528 0 N-CA-C 109.155 -0.683 . . . . 0.0 109.155 179.712 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_endo -75.33 170.95 19.22 Favored 'Trans proline' 0 C--O 1.246 0.886 0 C-N-CA 122.933 2.422 . . . . 0.0 111.995 -179.12 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.443 HG12 ' O ' ' A' ' 1' ' ' PHE . 34.4 mt -73.37 118.82 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.552 0 CA-C-O 121.126 0.488 . . . . 0.0 111.002 -176.491 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 133.9 38.4 0.21 Allowed Glycine 0 C--N 1.301 -1.386 0 CA-C-N 115.238 -0.892 . . . . 0.0 111.334 177.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 72.02 176.3 26.71 Favored Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.703 -0.761 . . . . 0.0 111.542 -176.415 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.14 -177.94 28.83 Favored Glycine 0 C--N 1.296 -1.672 0 C-N-CA 120.103 -1.046 . . . . 0.0 111.219 176.624 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.459 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 52.5 p -141.03 150.31 42.84 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -139.29 165.03 28.27 Favored 'General case' 0 CA--C 1.474 -1.968 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -109.39 123.44 49.33 Favored 'General case' 0 C--N 1.262 -3.229 0 N-CA-C 106.943 -1.503 . . . . 0.0 106.943 175.112 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.474 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.2 m -105.31 145.09 13.98 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.608 0 N-CA-C 107.968 -1.123 . . . . 0.0 107.968 177.336 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 30.2 m-85 -124.75 112.74 17.07 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-O 121.286 0.565 . . . . 0.0 110.764 -178.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.533 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -119.36 132.31 69.53 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.194 0 CA-C-N 115.126 -0.943 . . . . 0.0 111.627 -174.783 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -92.31 127.16 37.69 Favored 'General case' 0 C--N 1.288 -2.075 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.08 178.284 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -110.51 160.53 16.55 Favored 'General case' 0 C--N 1.288 -2.073 0 CA-C-N 114.861 -1.063 . . . . 0.0 108.145 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -61.0 122.91 72.76 Favored Pre-proline 0 C--N 1.317 -0.808 0 O-C-N 124.107 0.879 . . . . 0.0 109.125 176.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.502 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 74.3 Cg_endo -74.65 4.31 4.67 Favored 'Trans proline' 0 C--O 1.237 0.462 0 C-N-CA 122.785 2.323 . . . . 0.0 113.088 -177.468 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 21.6 t -128.08 112.29 26.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 107.097 -1.445 . . . . 0.0 107.097 178.555 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.426 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.8 t -145.43 101.31 0.56 Allowed 'Isoleucine or valine' 0 C--O 1.181 -2.549 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 -178.219 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.444 ' H ' ' HG3' ' A' ' 32' ' ' GLN . 0.7 OUTLIER -92.38 150.55 20.75 Favored 'General case' 0 C--N 1.267 -2.987 0 O-C-N 122.16 -0.338 . . . . 0.0 111.214 179.416 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.437 HG22 ' O ' ' A' ' 112' ' ' VAL . 46.8 t -44.72 119.14 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.691 0 C-N-CA 123.63 0.772 . . . . 0.0 111.363 175.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.12 2.5 54.61 Favored Glycine 0 N--CA 1.45 -0.415 0 CA-C-N 115.482 -0.781 . . . . 0.0 112.743 -179.264 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.444 ' HG3' ' H ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -73.83 -178.07 3.07 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 123.076 0.55 . . . . 0.0 111.448 175.331 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -132.91 91.48 2.9 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 176.46 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.664 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.7 tp -92.26 146.44 23.71 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 -179.177 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 48.5 t -133.2 129.92 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.838 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 -178.183 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.56 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 51.6 t -99.93 88.82 1.6 Allowed 'Isoleucine or valine' 0 N--CA 1.41 -2.446 0 N-CA-C 105.642 -1.984 . . . . 0.0 105.642 172.499 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -85.25 117.49 24.22 Favored 'General case' 0 CA--C 1.484 -1.561 0 C-N-CA 119.949 -0.7 . . . . 0.0 110.382 -176.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 82.4 mt -98.88 -1.84 39.15 Favored 'General case' 0 C--N 1.296 -1.744 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.365 -177.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.491 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 1.3 m -75.64 0.31 18.01 Favored 'General case' 0 CA--C 1.549 0.93 0 CA-C-O 122.394 1.093 . . . . 0.0 108.959 179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.0 p -127.33 6.53 6.38 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 114.718 -1.128 . . . . 0.0 110.229 177.164 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.533 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 46.6 mm-40 -125.28 -22.46 4.36 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-O 121.082 0.467 . . . . 0.0 110.649 -175.161 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 36.6 mt -135.07 141.29 43.31 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 108.188 -1.042 . . . . 0.0 108.188 -175.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.491 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 41.4 m-85 -142.79 158.74 43.33 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 108.178 -1.045 . . . . 0.0 108.178 -177.5 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.601 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 17.0 t -138.66 147.25 42.62 Favored 'General case' 0 C--N 1.289 -2.029 0 C-N-CA 120.377 -0.529 . . . . 0.0 109.67 175.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.492 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 7.3 p-80 -119.96 130.05 54.59 Favored 'General case' 0 C--O 1.256 1.408 0 CA-C-O 122.323 1.059 . . . . 0.0 111.472 -178.435 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.407 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 22.3 p-10 -91.24 89.84 7.5 Favored 'General case' 0 C--N 1.278 -2.511 0 CA-C-O 122.968 1.366 . . . . 0.0 109.913 178.044 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 26.7 t70 -71.18 -24.79 62.31 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 113.875 -1.511 . . . . 0.0 111.377 -177.223 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 43.3 m-85 -126.06 79.37 69.44 Favored Pre-proline 0 N--CA 1.479 0.979 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 178.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.407 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 73.4 Cg_endo -85.56 -2.8 9.2 Favored 'Trans proline' 0 C--N 1.321 -0.892 0 C-N-CA 122.0 1.8 . . . . 0.0 113.528 -175.098 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -111.76 -23.76 10.42 Favored 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.068 -179.392 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.427 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.0 OUTLIER -99.42 -30.63 12.08 Favored 'General case' 0 C--N 1.292 -1.898 0 CA-C-O 121.837 0.827 . . . . 0.0 109.987 -175.329 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.601 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.5 mp -118.6 138.66 48.58 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.616 0 CA-C-N 114.898 -1.046 . . . . 0.0 108.308 -179.456 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.7 t -78.75 134.05 37.07 Favored 'General case' 0 N--CA 1.417 -2.1 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 174.344 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.495 ' O ' HG23 ' A' ' 94' ' ' VAL . 7.6 m-20 -80.14 107.17 12.71 Favored 'General case' 0 C--N 1.288 -2.077 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 -172.333 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 49.9 t80 -142.85 133.44 25.09 Favored 'General case' 0 C--N 1.284 -2.271 0 CA-C-N 116.331 -0.395 . . . . 0.0 109.999 -172.254 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.453 HG12 ' OH ' ' A' ' 77' ' ' TYR . 42.3 t -141.73 134.14 28.41 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 C-N-CA 123.374 0.67 . . . . 0.0 109.635 -178.449 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -143.81 115.48 8.17 Favored 'General case' 0 N--CA 1.434 -1.226 0 O-C-N 123.387 0.43 . . . . 0.0 111.335 177.555 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.537 HD12 ' O ' ' A' ' 130' ' ' ILE . 55.5 tp -54.57 110.78 0.68 Allowed 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.584 0.706 . . . . 0.0 110.169 171.085 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.43 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 3.3 tp-100 -58.85 -51.79 68.49 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 126.292 1.837 . . . . 0.0 111.828 179.24 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.43 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 6.9 ptp180 -169.73 157.35 6.89 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -176.275 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -137.38 136.56 8.33 Favored Glycine 0 N--CA 1.415 -2.756 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 -179.462 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 70.3 m -126.71 146.22 50.3 Favored 'General case' 0 C--N 1.283 -2.324 0 C-N-CA 123.093 0.557 . . . . 0.0 110.69 -175.275 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.503 ' HB2' ' CE2' ' A' ' 84' ' ' PHE . . . -109.96 156.79 20.0 Favored 'General case' 0 CA--C 1.497 -1.09 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 -179.189 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.483 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 90.8 m-85 -155.9 -179.47 8.16 Favored 'General case' 0 C--O 1.236 0.373 0 C-N-CA 123.963 0.905 . . . . 0.0 109.075 -178.192 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.01 -139.22 48.98 Favored Glycine 0 N--CA 1.45 -0.396 0 O-C-N 123.621 0.576 . . . . 0.0 113.328 177.234 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -78.6 -9.05 87.37 Favored Glycine 0 C--O 1.201 -1.922 0 C-N-CA 120.329 -0.938 . . . . 0.0 111.379 178.166 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.74 HG21 ' HB ' ' A' ' 126' ' ' ILE . 87.5 t -70.81 -42.7 77.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 C-N-CA 123.137 0.575 . . . . 0.0 111.44 -176.583 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.499 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -83.4 -21.61 32.97 Favored 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.4 -0.92 . . . . 0.0 112.518 -179.649 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 21.0 m -101.05 -47.8 4.64 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 114.041 1.126 . . . . 0.0 114.041 -174.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . . . . . . . . . 47.5 m-20 -96.71 -20.63 18.11 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 -175.039 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.664 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 92.0 m-85 -110.78 157.09 20.18 Favored 'General case' 0 N--CA 1.424 -1.75 0 C-N-CA 120.032 -0.667 . . . . 0.0 110.418 178.053 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 16.8 t -160.95 123.09 3.09 Favored 'General case' 0 N--CA 1.422 -1.853 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 177.097 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.527 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -158.48 -106.97 0.23 Allowed Glycine 0 N--CA 1.412 -2.93 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 177.456 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -165.2 -179.4 5.6 Favored 'General case' 0 C--N 1.313 -0.998 0 C-N-CA 124.525 1.13 . . . . 0.0 110.358 -175.389 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.6 p -131.93 148.3 32.3 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 C-N-CA 123.626 0.77 . . . . 0.0 109.301 177.363 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.614 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.3 tttt -126.12 143.27 51.19 Favored 'General case' 0 N--CA 1.426 -1.638 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.497 ' CD1' HG22 ' A' ' 105' ' ' VAL . 67.5 t80 -144.31 110.12 5.32 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.258 -177.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 25.3 t 51.24 40.71 26.74 Favored 'General case' 0 CA--C 1.551 0.983 0 C-N-CA 123.584 0.754 . . . . 0.0 111.526 177.576 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.83 14.01 61.7 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.333 -0.937 . . . . 0.0 113.811 179.763 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.614 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 13.0 t -86.48 -178.9 6.53 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 175.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 26.1 p -159.48 103.78 1.6 Allowed 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.44 -0.948 . . . . 0.0 108.44 178.513 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.433 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.9 p90 -149.53 160.13 34.93 Favored Pre-proline 0 C--N 1.303 -1.428 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 -173.057 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.431 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 42.5 Cg_endo -67.25 146.92 77.46 Favored 'Trans proline' 0 C--N 1.358 1.053 0 C-N-CA 122.837 2.358 . . . . 0.0 112.887 -177.071 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.569 ' CD2' HD21 ' A' ' 109' ' ' LEU . 64.2 t80 -122.63 134.59 25.03 Favored Pre-proline 0 N--CA 1.435 -1.223 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.432 -179.769 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.517 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 64.3 Cg_endo -71.08 147.06 86.51 Favored 'Cis proline' 0 CA--C 1.54 0.786 0 C-N-CA 123.229 -1.571 . . . . 0.0 110.602 -2.497 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 6.8 t -64.68 -176.8 0.27 Allowed 'General case' 0 C--O 1.248 0.981 0 CA-C-N 115.862 -0.608 . . . . 0.0 111.685 -175.403 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 16.8 p -130.31 0.73 4.6 Favored 'General case' 0 N--CA 1.424 -1.761 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.014 -171.133 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 26.5 t -161.36 -137.51 0.04 OUTLIER 'General case' 0 N--CA 1.379 -3.993 0 N-CA-C 106.56 -1.645 . . . . 0.0 106.56 -179.548 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 22.5 tt0 -121.39 156.58 32.36 Favored 'General case' 0 C--N 1.267 -2.991 0 C-N-CA 127.015 2.126 . . . . 0.0 107.337 -172.309 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.475 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 19.6 p -78.6 162.37 65.94 Favored Pre-proline 0 C--N 1.302 -1.483 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 -177.396 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -56.99 165.49 5.0 Favored 'Trans proline' 0 C--N 1.359 1.104 0 C-N-CA 124.044 3.163 . . . . 0.0 112.148 174.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.6 tmm_? -70.3 119.7 14.87 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 114.759 -1.11 . . . . 0.0 109.657 -176.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 60.4 t -131.27 130.35 63.13 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 C-N-CA 123.671 0.788 . . . . 0.0 110.211 -175.531 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.495 HG23 ' O ' ' A' ' 54' ' ' ASP . 1.4 p -129.74 125.45 61.03 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.953 0 CA-C-N 115.009 -0.996 . . . . 0.0 110.341 -174.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 5.7 m-85 -73.15 104.08 4.1 Favored 'General case' 0 C--O 1.211 -0.938 0 CA-C-O 121.105 0.478 . . . . 0.0 111.092 -178.519 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -90.11 62.55 5.56 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-O 121.016 0.436 . . . . 0.0 109.836 179.197 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.0 t -152.59 -170.07 3.53 Favored 'General case' 0 N--CA 1.437 -1.092 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 -178.288 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 17.0 ptm180 -149.1 38.34 0.8 Allowed 'General case' 0 C--N 1.316 -0.875 0 CA-C-O 121.014 0.435 . . . . 0.0 110.437 -176.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 12.6 t -159.51 -177.8 6.67 Favored 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 -178.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . 0.492 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 9.6 p-10 -79.45 99.92 7.44 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-O 122.41 1.1 . . . . 0.0 109.653 -179.231 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . 0.533 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 7.0 mmpt? -102.37 149.73 36.93 Favored Pre-proline 0 C--N 1.296 -1.749 0 CA-C-N 114.535 -1.212 . . . . 0.0 109.755 -177.836 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.491 ' HB3' ' O ' ' A' ' 39' ' ' SER . 22.5 Cg_exo -59.16 153.35 53.12 Favored 'Trans proline' 0 N--CA 1.449 -1.133 0 C-N-CA 123.36 2.707 . . . . 0.0 112.907 178.089 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 12.6 t90 -95.75 102.15 9.65 Favored Pre-proline 0 C--N 1.289 -2.053 0 N-CA-C 105.688 -1.967 . . . . 0.0 105.688 176.357 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.401 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 56.5 Cg_endo -73.93 88.96 1.04 Allowed 'Trans proline' 0 N--CA 1.451 -1.016 0 C-N-CA 122.079 1.852 . . . . 0.0 112.956 -172.267 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.497 HG22 ' CD1' ' A' ' 77' ' ' TYR . 59.9 t -138.75 146.45 26.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.56 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.57 135.67 16.63 Favored 'General case' 0 C--N 1.287 -2.144 0 CA-C-O 120.89 0.376 . . . . 0.0 110.414 178.033 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.5 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 15.6 mt -101.25 103.12 14.12 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.447 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.527 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 45.5 m-85 -82.2 73.23 9.25 Favored 'General case' 0 C--N 1.293 -1.863 0 O-C-N 122.279 -0.263 . . . . 0.0 110.824 178.369 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.664 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -98.5 136.03 39.2 Favored 'General case' 0 C--N 1.305 -1.332 0 N-CA-C 110.048 -0.353 . . . . 0.0 110.048 176.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -137.5 144.73 46.26 Favored Pre-proline 0 C--N 1.293 -1.883 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.098 -175.199 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 29.8 Cg_endo -62.38 122.31 10.67 Favored 'Trans proline' 0 C--O 1.248 0.99 0 C-N-CA 123.537 2.825 . . . . 0.0 113.12 -176.14 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.437 ' O ' HG22 ' A' ' 30' ' ' VAL . 2.7 m -73.85 -120.97 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.168 -3.201 0 CA-C-N 114.507 -1.224 . . . . 0.0 112.344 174.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 27.9 t -111.94 -32.37 6.62 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 -179.116 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 68.3 m -79.97 21.6 0.55 Allowed 'General case' 0 N--CA 1.398 -3.07 0 C-N-CA 125.612 1.565 . . . . 0.0 112.777 -179.532 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -107.5 128.16 54.25 Favored 'General case' 0 N--CA 1.412 -2.326 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 -179.218 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.63 133.09 2.71 Favored Glycine 0 C--N 1.297 -1.605 0 N-CA-C 111.191 -0.764 . . . . 0.0 111.191 -179.24 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 62.47 -148.55 49.02 Favored Glycine 0 CA--C 1.489 -1.567 0 CA-C-O 119.24 -0.755 . . . . 0.0 111.782 -177.573 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 60.7 t -56.93 105.72 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 CA-C-N 117.225 0.513 . . . . 0.0 110.536 -178.283 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -102.97 -40.93 6.3 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 115.065 -0.971 . . . . 0.0 110.58 179.481 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.521 ' HB ' HG22 ' A' ' 154' ' ' VAL . 72.7 mt -115.29 137.66 48.11 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 178.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.501 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.9 mmpt? -115.07 136.63 52.92 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-O 121.289 0.566 . . . . 0.0 111.636 178.885 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -68.15 126.87 30.91 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.828 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 92.95 -5.13 75.83 Favored Glycine 0 N--CA 1.437 -1.298 0 CA-C-N 115.694 -0.684 . . . . 0.0 111.756 179.455 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 21.2 m -94.91 145.17 25.1 Favored 'General case' 0 N--CA 1.428 -1.544 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 179.802 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.454 HD11 HG23 ' A' ' 128' ' ' VAL . 2.9 tm? -71.35 124.74 25.25 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 108.204 -1.035 . . . . 0.0 108.204 178.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.74 ' HB ' HG21 ' A' ' 67' ' ' VAL . 31.8 pt -111.09 -25.36 3.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 112.322 0.49 . . . . 0.0 112.322 -179.002 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . 0.448 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -162.05 167.51 24.24 Favored 'General case' 0 CA--C 1.508 -0.653 0 N-CA-C 110.122 -0.325 . . . . 0.0 110.122 -178.022 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.454 HG23 HD11 ' A' ' 125' ' ' LEU . 63.8 t -142.3 116.02 4.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 178.878 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.49 HD11 HD21 ' A' ' 107' ' ' LEU . 67.9 mt -119.02 146.99 44.59 Favored 'General case' 0 C--N 1.285 -2.214 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 178.613 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.537 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.4 mp -127.73 126.38 66.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 C-N-CA 119.271 -0.972 . . . . 0.0 110.832 177.519 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.55 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.3 OUTLIER -88.1 145.5 25.91 Favored 'General case' 0 C--N 1.283 -2.313 0 N-CA-C 108.03 -1.1 . . . . 0.0 108.03 176.332 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.44 HH11 ' HD2' ' A' ' 132' ' ' ARG . 16.2 ttp180 -128.58 130.08 46.86 Favored 'General case' 0 C--N 1.277 -2.549 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 173.023 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 8.6 tm0? -108.71 129.04 55.36 Favored 'General case' 0 N--CA 1.412 -2.347 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 -178.728 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 6.9 m -135.75 139.75 43.82 Favored 'General case' 0 C--N 1.287 -2.116 0 N-CA-C 105.978 -1.86 . . . . 0.0 105.978 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.601 ' CB ' HG23 ' A' ' 52' ' ' ILE . 9.4 p30 -133.09 178.78 6.63 Favored 'General case' 0 N--CA 1.433 -1.278 0 C-N-CA 117.309 -1.756 . . . . 0.0 113.449 177.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 7.6 p30 -88.34 -31.86 18.7 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 121.577 0.703 . . . . 0.0 111.261 -174.143 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 9.5 t80 -82.38 -63.58 1.35 Allowed 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.135 -0.938 . . . . 0.0 110.165 -173.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 7.8 m-20 -94.56 149.39 21.29 Favored 'General case' 0 C--N 1.287 -2.14 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.606 176.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 41.8 m -96.36 27.67 3.65 Favored 'General case' 0 C--N 1.279 -2.483 0 CA-C-N 115.187 -0.915 . . . . 0.0 108.919 179.135 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . 0.532 ' HB3' ' CE2' ' A' ' 142' ' ' PHE . 24.6 m-20 -82.38 90.3 6.68 Favored 'General case' 0 CA--C 1.499 -1.017 0 CA-C-N 114.765 -1.107 . . . . 0.0 110.447 179.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . 0.427 ' OD2' ' HD2' ' A' ' 132' ' ' ARG . 27.6 t70 -93.01 85.35 5.09 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-N 114.985 -1.007 . . . . 0.0 108.461 -179.498 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . 0.532 ' CE2' ' HB3' ' A' ' 140' ' ' ASP . 43.7 m-85 -101.35 146.07 28.06 Favored 'General case' 0 C--N 1.312 -1.064 0 O-C-N 122.176 -0.328 . . . . 0.0 110.238 -178.593 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . 0.53 HE21 HG21 ' A' ' 130' ' ' ILE . 20.1 pt20 -123.54 134.73 53.81 Favored 'General case' 0 N--CA 1.423 -1.806 0 C-N-CA 119.838 -0.745 . . . . 0.0 111.102 177.512 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 6.9 m-30 -107.57 125.66 51.58 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.655 -0.868 . . . . 0.0 108.655 -176.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.459 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 46.9 t -89.51 135.28 26.46 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 CA-C-O 121.161 0.505 . . . . 0.0 110.284 -178.473 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . 0.55 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 64.8 m95 -122.12 102.53 8.2 Favored 'General case' 0 C--N 1.281 -2.377 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 -179.692 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.8 m-80 -81.65 109.22 15.87 Favored 'General case' 0 C--N 1.289 -2.025 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 178.04 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.474 ' HA ' HG22 ' A' ' 20' ' ' VAL . 21.3 mm -82.47 119.92 32.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.734 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 -177.191 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 -116.77 151.6 36.12 Favored 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 123.169 0.588 . . . . 0.0 109.678 178.469 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.14 128.92 34.28 Favored 'General case' 0 N--CA 1.411 -2.399 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 177.119 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -91.38 -11.36 38.03 Favored 'General case' 0 C--N 1.294 -1.807 0 N-CA-C 107.435 -1.32 . . . . 0.0 107.435 -177.563 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -153.22 143.01 22.03 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 114.292 -1.322 . . . . 0.0 109.379 -177.053 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -84.26 145.68 28.18 Favored 'General case' 0 C--N 1.316 -0.85 0 O-C-N 123.971 0.795 . . . . 0.0 109.553 -179.02 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.521 HG22 ' HB ' ' A' ' 120' ' ' ILE . 1.6 m -124.44 147.48 28.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 C-N-CA 120.306 -0.558 . . . . 0.0 110.855 -178.248 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.7 t -120.14 139.93 45.85 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.538 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 -179.626 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.426 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 70.5 t -100.93 100.3 12.52 Favored Pre-proline 0 C--N 1.29 -1.983 0 C-N-CA 123.666 0.786 . . . . 0.0 109.402 177.336 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.422 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 29.7 Cg_endo -68.18 -23.95 38.76 Favored 'Trans proline' 0 CA--C 1.517 -0.365 0 C-N-CA 122.427 2.085 . . . . 0.0 111.649 178.038 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.405 ' HB ' HG12 ' A' ' 156' ' ' VAL 0.269 5.3 t . . . . . 0 C--O 1.249 1.058 0 O-C-N 125.0 1.437 . . . . 0.0 113.383 177.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.588 ' CZ ' ' HB3' ' A' ' 133' ' ' GLN . 0.1 OUTLIER . . . . . 0 CA--C 1.487 -1.443 0 N-CA-C 105.418 -2.067 . . . . 0.0 105.418 . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -148.32 174.51 11.95 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.588 -0.845 . . . . 0.0 111.49 -173.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.42 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 77.0 m -137.4 152.18 49.36 Favored 'General case' 0 N--CA 1.429 -1.496 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.958 -177.414 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -141.17 167.13 22.91 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.763 -178.093 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.523 HG22 HG22 ' A' ' 20' ' ' VAL . 82.5 p -103.67 171.88 7.12 Favored 'General case' 0 CA--C 1.497 -1.066 0 CA-C-O 121.483 0.658 . . . . 0.0 110.733 -179.276 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.96 -4.82 54.09 Favored 'General case' 0 C--N 1.298 -1.664 0 CA-C-N 114.034 -1.439 . . . . 0.0 111.755 178.325 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 2.0 p30 -96.88 -30.92 12.85 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 118.184 -1.407 . . . . 0.0 109.314 177.829 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 139.13 0.46 2.16 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 119.896 -1.145 . . . . 0.0 113.047 175.388 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -81.07 105.25 12.14 Favored 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 -179.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -100.85 119.45 38.68 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 176.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 60.3 mt -90.76 123.83 63.91 Favored Pre-proline 0 C--N 1.3 -1.567 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -80.66 168.75 17.53 Favored 'Trans proline' 0 C--O 1.248 0.98 0 C-N-CA 122.7 2.267 . . . . 0.0 111.173 178.049 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.1 mt -63.75 127.56 24.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 133.77 8.72 2.12 Favored Glycine 0 C--N 1.319 -0.373 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.612 -179.562 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 86.69 172.69 48.61 Favored Glycine 0 C--N 1.318 -0.425 0 C-N-CA 120.312 -0.947 . . . . 0.0 111.415 -177.542 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.45 -168.78 30.97 Favored Glycine 0 C--N 1.299 -1.526 0 C-N-CA 119.916 -1.135 . . . . 0.0 111.498 177.1 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 14.4 p -140.1 155.81 46.84 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.401 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -143.63 162.24 36.43 Favored 'General case' 0 N--CA 1.424 -1.736 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 177.308 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.1 p30 -107.83 116.18 31.48 Favored 'General case' 0 C--N 1.281 -2.388 0 CA-C-N 114.808 -1.087 . . . . 0.0 108.746 177.57 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.523 HG22 HG22 ' A' ' 5' ' ' THR . 44.1 t -103.86 135.03 43.44 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.008 0 CA-C-N 115.133 -0.94 . . . . 0.0 108.668 179.202 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 -122.99 134.78 54.31 Favored 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 -179.113 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.51 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 3.5 p -144.42 136.29 21.87 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.674 0 O-C-N 123.727 0.642 . . . . 0.0 111.095 -178.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 47.9 m-80 -89.67 126.79 35.78 Favored 'General case' 0 C--N 1.296 -1.76 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.458 178.442 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.408 HD11 HG22 ' A' ' 36' ' ' VAL . 2.7 mm? -106.56 161.19 14.83 Favored 'General case' 0 C--N 1.283 -2.298 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 177.631 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.8 124.81 81.19 Favored Pre-proline 0 C--N 1.315 -0.933 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 175.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.466 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 68.1 Cg_endo -74.83 0.84 8.33 Favored 'Trans proline' 0 N--CA 1.474 0.382 0 C-N-CA 122.954 2.436 . . . . 0.0 113.021 -177.253 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.476 HG13 ' HG3' ' A' ' 157' ' ' PRO . 87.3 t -129.6 111.85 23.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 107.693 -1.225 . . . . 0.0 107.693 179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.7 t -143.33 114.94 2.73 Favored 'Isoleucine or valine' 0 C--O 1.182 -2.489 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -177.219 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.725 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -104.98 148.68 26.46 Favored 'General case' 0 C--N 1.271 -2.819 0 O-C-N 121.987 -0.445 . . . . 0.0 110.91 -179.447 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.499 HG22 ' O ' ' A' ' 112' ' ' VAL . 95.8 t -47.97 116.93 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 123.082 0.553 . . . . 0.0 111.377 178.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 109.41 -9.25 32.96 Favored Glycine 0 C--N 1.307 -1.033 0 CA-C-N 115.238 -0.892 . . . . 0.0 112.357 -178.602 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.725 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -67.87 -177.62 0.84 Allowed 'General case' 0 CA--C 1.508 -0.672 0 C-N-CA 124.631 1.172 . . . . 0.0 110.956 179.63 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -129.89 92.12 3.26 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 107.814 -1.18 . . . . 0.0 107.814 178.231 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.641 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.8 tp -94.25 142.52 27.31 Favored 'General case' 0 C--N 1.285 -2.23 0 C-N-CA 119.056 -1.057 . . . . 0.0 109.301 179.226 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 39.6 t -132.34 124.78 52.72 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.215 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 -175.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.552 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 47.3 t -96.19 87.82 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.4 -2.931 0 N-CA-C 105.26 -2.126 . . . . 0.0 105.26 172.107 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -82.5 112.55 19.53 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 120.962 0.411 . . . . 0.0 110.984 -177.757 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 84.6 mt -98.21 0.31 45.56 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.017 -178.725 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.4 m -76.35 1.67 15.59 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-O 122.332 1.063 . . . . 0.0 109.045 -179.576 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.8 p -130.64 5.58 4.69 Favored 'General case' 0 N--CA 1.428 -1.562 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.15 176.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.51 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 49.7 mm-40 -124.38 -22.12 4.77 Favored 'General case' 0 C--O 1.24 0.584 0 CA-C-O 121.193 0.521 . . . . 0.0 111.019 -174.684 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 22.2 mt -131.56 140.83 47.31 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 -176.231 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.451 ' HA ' ' HA ' ' A' ' 102' ' ' PRO . 69.0 m-85 -139.25 154.93 48.06 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 110.138 -0.319 . . . . 0.0 110.138 -174.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.42 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 96.2 m -137.69 136.52 37.48 Favored 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 123.751 0.82 . . . . 0.0 110.787 -179.646 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.4 p-80 -131.92 129.67 40.58 Favored 'General case' 0 C--N 1.295 -1.761 0 CA-C-O 122.381 1.086 . . . . 0.0 112.123 -177.581 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.735 ' OD1' ' HA ' ' A' ' 49' ' ' PRO . 3.3 t-20 -85.23 92.07 8.32 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-N 114.446 -1.252 . . . . 0.0 107.928 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . 0.43 ' H ' ' HA ' ' A' ' 1' ' ' PHE . 20.1 m-20 -54.48 -36.6 64.33 Favored 'General case' 0 N--CA 1.493 1.684 0 C-N-CA 123.475 0.71 . . . . 0.0 111.069 -178.255 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 44.7 m-85 -122.46 86.0 48.35 Favored Pre-proline 0 C--N 1.299 -1.599 0 N-CA-C 108.223 -1.028 . . . . 0.0 108.223 -175.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.735 ' HA ' ' OD1' ' A' ' 46' ' ' ASN . 72.7 Cg_endo -73.19 -5.98 18.12 Favored 'Trans proline' 0 CA--C 1.508 -0.81 0 C-N-CA 122.486 2.124 . . . . 0.0 115.081 -170.128 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -121.3 -20.35 6.72 Favored 'General case' 0 C--N 1.282 -2.342 0 CA-C-O 121.268 0.556 . . . . 0.0 110.649 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.56 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.6 m -98.4 -30.7 12.41 Favored 'General case' 0 N--CA 1.414 -2.231 0 C-N-CA 119.54 -0.864 . . . . 0.0 109.102 -170.785 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.567 HG23 ' HB2' ' A' ' 135' ' ' ASN . 2.7 mp -130.03 123.72 56.89 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.791 0 CA-C-N 114.878 -1.055 . . . . 0.0 110.035 -175.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.446 HG22 HD22 ' A' ' 136' ' ' ASN . 4.4 t -75.71 134.67 40.46 Favored 'General case' 0 N--CA 1.425 -1.684 0 N-CA-C 106.08 -1.822 . . . . 0.0 106.08 173.597 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.57 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 9.5 t70 -90.31 108.88 20.04 Favored 'General case' 0 C--N 1.271 -2.806 0 N-CA-C 107.401 -1.333 . . . . 0.0 107.401 -178.431 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.585 ' CD2' ' HB ' ' A' ' 134' ' ' THR . 4.7 t80 -128.47 110.06 11.96 Favored 'General case' 0 C--N 1.291 -1.938 0 CA-C-O 122.109 0.957 . . . . 0.0 110.93 -175.22 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.433 ' HA ' ' O ' ' A' ' 132' ' ' ARG . 73.9 t -114.7 142.17 28.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 CA-C-N 113.629 -1.623 . . . . 0.0 110.94 -177.749 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.3 p -143.67 134.18 24.84 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 170.061 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.542 ' HB3' HG23 ' A' ' 90' ' ' THR . 0.8 OUTLIER -73.51 109.97 7.44 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 175.771 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.4 tp-100 -57.58 -62.2 1.96 Allowed 'General case' 0 C--O 1.202 -1.428 0 C-N-CA 125.416 1.486 . . . . 0.0 109.958 -178.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -160.91 146.11 14.26 Favored 'General case' 0 N--CA 1.418 -2.072 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 -178.216 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -126.68 137.66 10.15 Favored Glycine 0 N--CA 1.398 -3.852 0 N-CA-C 108.193 -1.963 . . . . 0.0 108.193 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 63.4 m -124.0 148.29 47.1 Favored 'General case' 0 C--N 1.268 -2.949 0 C-N-CA 123.599 0.76 . . . . 0.0 109.33 -175.057 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.519 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -114.27 158.1 21.85 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 -179.593 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.432 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 85.0 m-85 -156.35 -178.42 7.32 Favored 'General case' 0 C--O 1.243 0.719 0 C-N-CA 124.214 1.005 . . . . 0.0 108.347 -178.111 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.79 -138.14 49.7 Favored Glycine 0 N--CA 1.452 -0.299 0 O-C-N 123.596 0.56 . . . . 0.0 112.81 178.562 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -81.91 -9.41 85.42 Favored Glycine 0 C--O 1.205 -1.706 0 C-N-CA 120.891 -0.671 . . . . 0.0 111.651 177.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.747 HG21 ' HB ' ' A' ' 126' ' ' ILE . 84.5 t -68.53 -42.92 83.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 C-N-CA 122.934 0.493 . . . . 0.0 111.362 -177.508 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.519 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -82.45 -17.65 44.56 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.331 -0.948 . . . . 0.0 112.133 179.603 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 14.6 t -100.74 -59.64 1.66 Allowed 'General case' 0 C--N 1.311 -1.107 0 CA-C-N 115.444 -0.798 . . . . 0.0 111.971 -172.631 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.456 ' O ' HG22 ' A' ' 112' ' ' VAL . 44.2 m-20 -91.1 -23.51 20.28 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.672 -172.323 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.669 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 93.1 m-85 -106.7 155.62 19.49 Favored 'General case' 0 N--CA 1.42 -1.959 0 C-N-CA 119.647 -0.821 . . . . 0.0 109.532 177.077 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.5 t -163.18 126.99 2.85 Favored 'General case' 0 N--CA 1.41 -2.464 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.419 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.416 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -163.07 -109.59 0.23 Allowed Glycine 0 N--CA 1.407 -3.287 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 177.294 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -159.99 178.69 9.46 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 123.348 0.659 . . . . 0.0 110.273 -173.739 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -131.77 142.85 42.01 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 178.171 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.708 ' HG3' ' O ' ' A' ' 80' ' ' SER . 71.7 tttt -118.76 139.12 52.08 Favored 'General case' 0 N--CA 1.423 -1.814 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.793 -179.573 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.494 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 67.5 t80 -138.96 110.05 6.83 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.246 -0.888 . . . . 0.0 109.071 -178.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.6 t 49.68 41.92 22.61 Favored 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 124.133 0.973 . . . . 0.0 111.937 174.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.43 11.03 63.04 Favored Glycine 0 CA--C 1.525 0.694 0 C-N-CA 120.519 -0.848 . . . . 0.0 113.746 179.265 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.708 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 10.1 t -93.56 177.84 5.89 Favored 'General case' 0 C--O 1.206 -1.219 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 176.694 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 74.9 m -160.02 105.52 1.56 Allowed 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 177.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.494 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 5.8 p90 -142.64 164.53 32.1 Favored Pre-proline 0 C--N 1.297 -1.688 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 -172.46 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.474 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 73.9 Cg_endo -71.95 148.26 51.03 Favored 'Trans proline' 0 C--N 1.352 0.731 0 C-N-CA 122.376 2.051 . . . . 0.0 113.402 -174.436 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.627 ' CD2' HD21 ' A' ' 109' ' ' LEU . 55.3 t80 -120.7 139.7 29.39 Favored Pre-proline 0 N--CA 1.429 -1.499 0 CA-C-N 115.608 -0.723 . . . . 0.0 109.267 179.398 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.606 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 55.8 Cg_endo -70.12 144.54 77.7 Favored 'Cis proline' 0 CA--C 1.537 0.653 0 C-N-CA 123.115 -1.619 . . . . 0.0 110.541 -4.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 5.6 t -67.44 -179.59 1.08 Allowed 'General case' 0 CA--C 1.556 1.182 0 CA-C-O 121.081 0.467 . . . . 0.0 111.236 -175.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 22.1 p -131.11 -24.63 2.32 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -168.439 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 24.8 t -129.84 -68.5 0.71 Allowed 'General case' 0 C--N 1.31 -1.117 0 C-N-CA 119.854 -0.738 . . . . 0.0 110.83 -173.36 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 178.77 -177.01 0.25 Allowed 'General case' 0 C--O 1.243 0.747 0 C-N-CA 124.454 1.102 . . . . 0.0 108.44 175.631 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.542 HG23 ' HB3' ' A' ' 58' ' ' LEU . 48.9 p -100.15 166.9 11.85 Favored Pre-proline 0 C--N 1.302 -1.477 0 O-C-N 123.582 0.551 . . . . 0.0 110.978 177.324 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -57.89 160.21 15.82 Favored 'Trans proline' 0 C--O 1.248 1.012 0 C-N-CA 123.027 2.484 . . . . 0.0 110.941 171.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.538 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 0.8 OUTLIER -72.32 120.51 18.03 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.368 -177.26 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 57.5 t -129.42 119.01 47.33 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.146 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.893 -179.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 97.6 t -105.64 132.5 52.44 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 CA-C-N 115.12 -0.945 . . . . 0.0 108.868 177.04 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.57 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 11.8 m-85 -81.6 112.07 18.48 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 175.746 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 36.6 m-80 -103.69 75.73 1.33 Allowed 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 -179.493 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 70.7 m -161.08 170.05 21.23 Favored 'General case' 0 C--N 1.318 -0.801 0 C-N-CA 124.303 1.041 . . . . 0.0 109.435 -177.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.0 ptm180 -128.06 38.78 3.96 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-O 121.946 0.879 . . . . 0.0 110.07 178.013 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.8 t -156.72 167.73 29.56 Favored 'General case' 0 N--CA 1.426 -1.648 0 N-CA-C 107.272 -1.381 . . . . 0.0 107.272 -177.134 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -73.69 123.58 24.34 Favored 'General case' 0 C--N 1.311 -1.1 0 O-C-N 123.784 0.677 . . . . 0.0 110.579 -178.594 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.5 mptm? -120.07 144.23 37.22 Favored Pre-proline 0 C--N 1.28 -2.428 0 CA-C-N 114.642 -1.163 . . . . 0.0 108.558 179.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.451 ' HA ' ' HA ' ' A' ' 43' ' ' PHE . 43.3 Cg_endo -65.9 150.13 85.91 Favored 'Trans proline' 0 C--O 1.248 1.009 0 C-N-CA 122.242 1.961 . . . . 0.0 111.456 177.343 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 16.4 t90 -87.16 105.26 7.82 Favored Pre-proline 0 C--N 1.315 -0.912 0 N-CA-C 106.081 -1.822 . . . . 0.0 106.081 -179.576 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 64.4 Cg_endo -74.69 88.53 1.19 Allowed 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 121.544 1.496 . . . . 0.0 112.58 -173.241 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 97.4 t -138.44 142.88 33.93 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.309 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.106 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.552 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -148.94 132.5 16.75 Favored 'General case' 0 N--CA 1.41 -2.428 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.109 178.51 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.512 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 19.5 mt -97.05 102.37 14.13 Favored 'General case' 0 C--N 1.287 -2.123 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.639 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.416 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 63.0 m-85 -83.11 74.39 9.99 Favored 'General case' 0 C--N 1.296 -1.739 0 CA-C-O 121.105 0.479 . . . . 0.0 110.231 177.45 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.669 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 2.8 mm? -97.93 130.35 44.81 Favored 'General case' 0 CA--C 1.484 -1.582 0 N-CA-C 109.254 -0.647 . . . . 0.0 109.254 175.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -135.05 144.09 48.73 Favored Pre-proline 0 N--CA 1.397 -3.077 0 N-CA-C 108.947 -0.761 . . . . 0.0 108.947 -174.452 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_endo -63.13 126.72 18.49 Favored 'Trans proline' 0 CA--C 1.496 -1.401 0 C-N-CA 123.2 2.6 . . . . 0.0 113.993 -174.395 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.499 ' O ' HG22 ' A' ' 30' ' ' VAL . 16.1 m -91.65 -158.03 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.395 -3.206 0 CA-C-N 114.221 -1.354 . . . . 0.0 108.66 171.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 29.4 m -76.0 -32.01 59.21 Favored 'General case' 0 C--N 1.26 -3.322 0 CA-C-O 121.366 0.603 . . . . 0.0 110.883 -168.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 7.2 t -80.26 10.12 4.9 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-O 121.736 0.779 . . . . 0.0 110.64 -177.3 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.4 ' HB1' HG21 ' A' ' 156' ' ' VAL . . . -95.09 135.55 36.5 Favored 'General case' 0 N--CA 1.42 -1.955 0 CA-C-N 115.651 -0.704 . . . . 0.0 110.002 179.005 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -179.6 132.07 1.78 Allowed Glycine 0 N--CA 1.433 -1.517 0 N-CA-C 110.197 -1.161 . . . . 0.0 110.197 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 63.6 -150.05 49.92 Favored Glycine 0 C--N 1.306 -1.133 0 CA-C-O 119.167 -0.796 . . . . 0.0 112.128 -177.247 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -56.7 103.82 0.1 OUTLIER 'Isoleucine or valine' 0 C--O 1.242 0.679 0 CA-C-O 122.404 1.097 . . . . 0.0 111.804 -177.402 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -103.24 -36.77 7.96 Favored 'General case' 0 C--N 1.293 -1.884 0 CA-C-N 114.698 -1.137 . . . . 0.0 110.676 -178.695 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.528 ' HB ' HG22 ' A' ' 154' ' ' VAL . 73.1 mt -120.54 138.47 50.92 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.436 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.9 mmpt? -112.99 140.05 48.13 Favored 'General case' 0 C--N 1.313 -1.009 0 C-N-CA 122.727 0.411 . . . . 0.0 110.171 177.655 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -73.5 134.74 43.95 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.03 179.091 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 82.95 4.59 89.94 Favored Glycine 0 C--N 1.314 -0.648 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -178.524 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 8.5 t -100.87 140.7 34.79 Favored 'General case' 0 N--CA 1.415 -2.214 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -178.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.43 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -71.4 122.15 19.84 Favored 'General case' 0 N--CA 1.434 -1.235 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 178.201 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.747 ' HB ' HG21 ' A' ' 67' ' ' VAL . 34.2 pt -109.48 -27.21 2.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 CA-C-N 116.02 -0.536 . . . . 0.0 112.218 -177.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -160.57 166.99 28.05 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 110.227 -0.286 . . . . 0.0 110.227 -177.554 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.43 HG23 HD11 ' A' ' 125' ' ' LEU . 59.7 t -143.06 114.93 2.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.473 0 N-CA-C 107.493 -1.299 . . . . 0.0 107.493 179.184 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.464 HD11 HD21 ' A' ' 107' ' ' LEU . 34.3 mt -118.2 135.83 54.01 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.639 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.616 HG21 HE21 ' A' ' 143' ' ' GLN . 4.3 mp -115.72 128.05 73.1 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 C-N-CA 118.636 -1.226 . . . . 0.0 109.937 177.8 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.526 HD23 ' O ' ' A' ' 131' ' ' LEU . 0.0 OUTLIER -97.05 133.5 41.63 Favored 'General case' 0 C--N 1.292 -1.896 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.159 178.497 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.433 ' O ' ' HA ' ' A' ' 56' ' ' VAL . 7.4 mmm180 -91.72 127.48 37.19 Favored 'General case' 0 C--N 1.281 -2.396 0 C-N-CA 123.714 0.806 . . . . 0.0 109.374 176.709 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.588 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 0.0 OUTLIER -103.98 130.52 51.63 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 105.75 -1.944 . . . . 0.0 105.75 174.087 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.585 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 12.9 m -145.2 143.92 30.56 Favored 'General case' 0 C--N 1.273 -2.757 0 N-CA-C 106.892 -1.521 . . . . 0.0 106.892 177.396 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.567 ' HB2' HG23 ' A' ' 52' ' ' ILE . 19.3 p30 -142.93 159.4 42.32 Favored 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 119.695 -0.802 . . . . 0.0 110.624 179.058 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.446 HD22 HG22 ' A' ' 53' ' ' THR . 6.5 p30 -86.74 -6.38 58.84 Favored 'General case' 0 C--N 1.309 -1.184 0 CA-C-N 114.606 -1.179 . . . . 0.0 111.477 -170.511 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 58.4 t80 -108.07 -67.32 0.97 Allowed 'General case' 0 C--N 1.299 -1.588 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.647 -172.157 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -82.84 -26.16 31.92 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -177.009 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 23.8 t 67.87 43.27 1.75 Allowed 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 -171.397 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 -70.86 62.96 0.29 Allowed 'General case' 0 N--CA 1.482 1.17 0 CA-C-N 114.828 -1.078 . . . . 0.0 110.009 175.506 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . 0.424 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 1.3 m-20 -77.62 66.04 3.24 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 125.046 1.338 . . . . 0.0 110.932 -178.851 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 76.4 m-85 -110.04 167.32 10.26 Favored 'General case' 0 C--N 1.297 -1.709 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 178.204 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . 0.616 HE21 HG21 ' A' ' 130' ' ' ILE . 18.5 pt20 -137.27 141.27 41.97 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 120.125 -0.63 . . . . 0.0 110.662 178.169 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.48 ' HB2' HD22 ' A' ' 131' ' ' LEU . 5.4 m-30 -108.58 131.66 54.64 Favored 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 -176.165 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 48.1 t -90.89 127.52 43.28 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 O-C-N 123.579 0.549 . . . . 0.0 109.893 -178.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . 0.515 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 65.3 m95 -114.88 100.07 7.95 Favored 'General case' 0 C--N 1.273 -2.728 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 -178.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 42.2 m-80 -82.67 112.83 19.89 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 179.707 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . . . . . . . . . 23.0 mm -88.45 121.09 38.32 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.643 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 -177.434 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -116.79 149.07 40.56 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 177.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.09 131.43 35.3 Favored 'General case' 0 N--CA 1.41 -2.453 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 176.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 13.9 t-20 -91.03 -11.24 39.4 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 -178.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -147.88 142.85 26.94 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.155 -176.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -85.62 136.8 33.23 Favored 'General case' 0 C--N 1.313 -1.0 0 O-C-N 123.97 0.794 . . . . 0.0 109.663 178.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.528 HG22 ' HB ' ' A' ' 120' ' ' ILE . 1.5 m -119.92 149.52 22.6 Favored 'Isoleucine or valine' 0 C--O 1.254 1.316 0 CA-C-O 120.928 0.394 . . . . 0.0 110.785 -175.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -121.53 142.69 36.69 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.276 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 -179.376 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.545 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.5 t -102.56 102.37 25.6 Favored Pre-proline 0 C--N 1.296 -1.745 0 C-N-CA 123.384 0.674 . . . . 0.0 109.82 178.131 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.476 ' HG3' HG13 ' A' ' 27' ' ' VAL . 29.2 Cg_endo -67.5 -28.64 38.3 Favored 'Trans proline' 0 CA--C 1.506 -0.878 0 C-N-CA 122.295 1.997 . . . . 0.0 111.7 177.519 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.255 6.1 t . . . . . 0 C--O 1.256 1.401 0 O-C-N 124.483 1.114 . . . . 0.0 112.519 178.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.511 ' CE2' ' HB3' ' A' ' 133' ' ' GLN 1.002 17.1 m-85 . . . . . 0 CA--C 1.46 -2.514 0 N-CA-C 119.514 3.153 . . . . 0.0 119.514 . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -131.7 140.85 49.4 Favored 'General case' 0 C--N 1.271 -2.822 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 167.188 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.58 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 11.1 m -126.01 163.05 23.88 Favored 'General case' 0 C--N 1.26 -3.31 0 C-N-CA 119.148 -1.021 . . . . 0.0 109.155 -171.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.436 ' HA ' ' O ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -146.35 159.25 43.62 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-O 120.958 0.409 . . . . 0.0 110.522 -174.479 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.512 HG22 HG22 ' A' ' 20' ' ' VAL . 73.4 p -99.62 176.13 5.58 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 121.277 0.561 . . . . 0.0 111.09 -179.382 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.52 -12.93 59.85 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.186 178.175 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -89.48 -31.31 17.73 Favored 'General case' 0 N--CA 1.435 -1.213 0 C-N-CA 119.081 -1.047 . . . . 0.0 109.896 175.789 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.48 5.66 3.22 Favored Glycine 0 N--CA 1.44 -1.054 0 C-N-CA 119.325 -1.417 . . . . 0.0 113.743 175.354 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.436 ' O ' ' HA ' ' A' ' 4' ' ' LYS . 5.1 m -79.18 99.62 7.09 Favored 'General case' 0 N--CA 1.433 -1.276 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 -179.736 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.53 117.92 30.46 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 176.369 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 71.5 mt -93.46 123.29 60.76 Favored Pre-proline 0 C--N 1.297 -1.68 0 N-CA-C 108.498 -0.926 . . . . 0.0 108.498 179.292 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -77.81 167.47 23.81 Favored 'Trans proline' 0 C--O 1.248 0.982 0 C-N-CA 122.84 2.36 . . . . 0.0 111.498 179.261 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.428 HG12 ' O ' ' A' ' 1' ' ' PHE . 60.3 mt -69.88 120.58 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.912 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.61 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 140.16 20.12 0.37 Allowed Glycine 0 C--N 1.298 -1.534 0 CA-C-N 115.533 -0.758 . . . . 0.0 112.677 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 84.26 158.81 28.56 Favored Glycine 0 C--O 1.236 0.258 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 -177.121 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 163.83 -175.74 39.96 Favored Glycine 0 N--CA 1.435 -1.372 0 C-N-CA 119.825 -1.179 . . . . 0.0 111.49 178.472 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 37.3 p -146.14 147.55 31.64 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.047 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.09 161.44 35.32 Favored 'General case' 0 N--CA 1.431 -1.424 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 179.342 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 21.9 m-80 -113.29 109.81 19.34 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 106.493 -1.669 . . . . 0.0 106.493 176.755 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.512 HG22 HG22 ' A' ' 5' ' ' THR . 40.2 t -94.35 134.69 31.02 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.493 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 -178.273 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 78.3 m-85 -116.46 120.13 37.82 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-N 117.775 0.261 . . . . 0.0 110.986 -178.541 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.457 HG22 ' HG3' ' A' ' 41' ' ' GLN . 17.6 t -123.02 127.99 74.94 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 CA-C-O 120.975 0.416 . . . . 0.0 111.036 -175.898 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 44.0 m-80 -82.12 124.41 29.83 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 177.323 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 38.0 mt -115.51 154.2 29.76 Favored 'General case' 0 C--N 1.28 -2.453 0 CA-C-N 115.397 -0.82 . . . . 0.0 108.858 -179.086 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.76 120.83 44.9 Favored Pre-proline 0 C--N 1.314 -0.96 0 O-C-N 124.485 1.115 . . . . 0.0 110.123 -178.826 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 61.0 Cg_endo -72.22 -2.09 11.1 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.885 2.39 . . . . 0.0 113.427 -176.694 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.4 t -124.07 109.57 23.25 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 178.23 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.505 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.7 t -139.81 107.08 2.71 Favored 'Isoleucine or valine' 0 C--O 1.182 -2.479 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -178.258 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.729 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.3 OUTLIER -97.72 148.54 23.24 Favored 'General case' 0 C--N 1.265 -3.095 0 C-N-CA 122.894 0.477 . . . . 0.0 111.015 -179.606 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.493 HG22 ' O ' ' A' ' 112' ' ' VAL . 91.0 t -47.69 116.52 0.38 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.638 0 C-N-CA 122.961 0.505 . . . . 0.0 111.435 176.038 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.09 9.87 43.94 Favored Glycine 0 CA--C 1.523 0.567 0 CA-C-N 114.905 -1.043 . . . . 0.0 112.137 -178.178 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.729 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -78.62 -176.71 4.99 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 124.603 1.161 . . . . 0.0 109.653 175.147 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -131.95 83.49 2.09 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 175.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.524 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 19.8 tp -91.37 134.22 34.79 Favored 'General case' 0 N--CA 1.426 -1.642 0 C-N-CA 119.42 -0.912 . . . . 0.0 108.915 179.438 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.447 ' HA ' ' O ' ' A' ' 107' ' ' LEU . 1.8 p -141.35 136.26 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.383 -3.803 0 CA-C-N 114.747 -1.115 . . . . 0.0 111.191 -177.691 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.593 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 34.0 t -98.59 89.29 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.412 -2.343 0 CA-C-N 113.551 -1.659 . . . . 0.0 107.904 178.65 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -77.48 118.11 19.6 Favored 'General case' 0 CA--C 1.489 -1.391 0 C-N-CA 120.047 -0.661 . . . . 0.0 110.201 177.816 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 92.4 mt -96.64 -0.18 48.9 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.545 -0.752 . . . . 0.0 111.632 -178.01 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 26.4 t -74.63 -7.49 53.37 Favored 'General case' 0 C--N 1.315 -0.904 0 CA-C-O 121.854 0.835 . . . . 0.0 109.659 -179.381 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.9 p -117.86 2.19 12.16 Favored 'General case' 0 C--N 1.279 -2.478 0 CA-C-N 115.663 -0.699 . . . . 0.0 110.3 178.021 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.457 ' HG3' HG22 ' A' ' 22' ' ' VAL . 44.2 mm-40 -120.64 -22.83 6.22 Favored 'General case' 0 C--O 1.243 0.736 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.501 -173.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 20.1 mt -136.45 140.08 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.629 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 -176.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.407 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 59.8 m-85 -139.9 162.33 35.43 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 -177.648 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.58 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 20.1 t -145.08 141.91 29.24 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 120.181 -0.608 . . . . 0.0 110.39 175.847 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 19.8 p-80 -119.74 165.03 15.06 Favored 'General case' 0 C--O 1.255 1.389 0 CA-C-O 122.242 1.02 . . . . 0.0 110.376 -178.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.52 HD22 ' CG ' ' A' ' 54' ' ' ASP . 3.2 m120 -110.72 108.49 18.39 Favored 'General case' 0 C--N 1.271 -2.818 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 -175.017 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -84.0 -25.46 29.95 Favored 'General case' 0 N--CA 1.436 -1.166 0 C-N-CA 118.129 -1.428 . . . . 0.0 109.946 -177.618 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 -132.67 64.99 73.44 Favored Pre-proline 0 N--CA 1.472 0.668 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.186 178.03 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -70.02 1.04 4.98 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 C-N-CA 123.257 2.638 . . . . 0.0 114.159 -174.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -116.6 -20.13 9.72 Favored 'General case' 0 C--N 1.299 -1.6 0 CA-C-O 121.189 0.519 . . . . 0.0 110.303 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.534 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -104.04 -27.83 11.88 Favored 'General case' 0 N--CA 1.422 -1.857 0 CA-C-O 122.055 0.931 . . . . 0.0 108.717 -172.875 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.56 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -128.9 142.98 42.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.735 0 CA-C-N 114.711 -1.131 . . . . 0.0 109.04 -176.817 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.449 HG22 HD22 ' A' ' 136' ' ' ASN . 4.2 t -89.2 133.23 34.51 Favored 'General case' 0 N--CA 1.433 -1.294 0 N-CA-C 104.917 -2.253 . . . . 0.0 104.917 170.209 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.52 ' CG ' HD22 ' A' ' 46' ' ' ASN . 11.1 m-20 -92.79 106.5 18.46 Favored 'General case' 0 C--N 1.27 -2.879 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 -178.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.435 ' HB3' ' O ' ' A' ' 134' ' ' THR . 52.9 t80 -118.0 127.94 54.3 Favored 'General case' 0 C--N 1.274 -2.692 0 CA-C-N 114.29 -1.323 . . . . 0.0 108.855 -174.589 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.504 HG21 HD12 ' A' ' 131' ' ' LEU . 14.9 p -134.48 138.91 48.92 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.578 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.411 -175.307 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 4.3 p -146.7 131.03 17.54 Favored 'General case' 0 C--N 1.282 -2.352 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 174.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.559 ' HB3' HG23 ' A' ' 90' ' ' THR . 55.1 tp -64.52 116.89 6.61 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 173.213 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -61.06 -49.42 77.42 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 113.802 -1.545 . . . . 0.0 109.307 -178.589 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -175.79 161.76 2.58 Favored 'General case' 0 N--CA 1.42 -1.951 0 CA-C-N 114.504 -1.226 . . . . 0.0 107.979 -178.311 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -136.6 136.52 8.42 Favored Glycine 0 N--CA 1.403 -3.514 0 N-CA-C 108.729 -1.748 . . . . 0.0 108.729 -179.47 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 50.2 m -123.66 146.87 47.9 Favored 'General case' 0 C--N 1.282 -2.35 0 O-C-N 124.394 0.702 . . . . 0.0 109.753 -176.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.506 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -112.17 156.07 22.91 Favored 'General case' 0 CA--C 1.503 -0.831 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 -178.845 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.449 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 88.5 m-85 -156.32 -178.93 7.69 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 124.309 1.044 . . . . 0.0 109.144 -177.616 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 63.01 -139.71 44.95 Favored Glycine 0 C--O 1.221 -0.672 0 O-C-N 123.367 0.417 . . . . 0.0 112.164 177.647 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.99 -6.98 86.12 Favored Glycine 0 C--O 1.203 -1.833 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.043 177.061 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.796 HG21 ' HB ' ' A' ' 126' ' ' ILE . 73.2 t -69.6 -38.52 76.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 C-N-CA 123.587 0.755 . . . . 0.0 111.815 -176.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.506 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -85.62 -21.72 28.3 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.954 -0.699 . . . . 0.0 112.194 179.136 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 14.0 m -100.89 -50.75 3.74 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 -173.389 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.446 ' O ' HG22 ' A' ' 112' ' ' VAL . 46.1 m-20 -93.36 -22.67 18.8 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 -176.028 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.627 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 84.0 m-85 -110.29 160.77 16.25 Favored 'General case' 0 N--CA 1.417 -2.112 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 177.411 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.5 t -166.76 131.68 2.12 Favored 'General case' 0 N--CA 1.415 -2.204 0 N-CA-C 106.049 -1.834 . . . . 0.0 106.049 175.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.427 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -166.76 -112.47 0.26 Allowed Glycine 0 N--CA 1.401 -3.66 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 175.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.435 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.0 OUTLIER -157.28 179.37 9.33 Favored 'General case' 0 C--N 1.281 -2.373 0 C-N-CA 123.685 0.794 . . . . 0.0 110.714 -172.324 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.446 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.6 p -134.97 148.17 29.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 178.347 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.688 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.1 tttt -125.73 150.04 48.03 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.64 -0.709 . . . . 0.0 109.156 -178.188 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.51 ' CD2' HG22 ' A' ' 105' ' ' VAL . 57.3 t80 -151.6 116.18 5.11 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 -178.15 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 2.7 m 53.79 33.87 17.91 Favored 'General case' 0 N--CA 1.437 -1.11 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 179.116 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 85.6 9.67 78.14 Favored Glycine 0 CA--C 1.526 0.721 0 C-N-CA 120.291 -0.957 . . . . 0.0 112.923 -178.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.688 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 9.4 t -80.23 -179.69 7.21 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.098 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 11.4 p -154.63 110.17 3.14 Favored 'General case' 0 C--N 1.289 -2.039 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 -179.05 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.484 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 5.0 p90 -153.01 159.55 32.08 Favored Pre-proline 0 CA--C 1.551 1.001 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -174.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.435 ' HA ' HG22 ' A' ' 74' ' ' THR . 44.3 Cg_endo -67.53 150.0 80.02 Favored 'Trans proline' 0 C--N 1.362 1.269 0 C-N-CA 123.059 2.506 . . . . 0.0 113.442 -176.096 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.621 ' CD2' HD21 ' A' ' 109' ' ' LEU . 55.6 t80 -125.92 132.76 24.42 Favored Pre-proline 0 N--CA 1.445 -0.709 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 179.027 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.416 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 69.6 Cg_endo -72.64 144.41 80.63 Favored 'Cis proline' 0 C--O 1.245 0.856 0 C-N-CA 122.786 -1.756 . . . . 0.0 110.313 -1.342 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.3 t -66.87 -176.68 0.53 Allowed 'General case' 0 CA--C 1.546 0.824 0 CA-C-N 115.571 -0.741 . . . . 0.0 112.219 -173.028 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 12.9 p -119.06 -49.39 2.41 Favored 'General case' 0 N--CA 1.419 -2.004 0 CA-C-N 115.362 -0.835 . . . . 0.0 111.23 -173.073 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.7 t -104.78 -81.28 0.53 Allowed 'General case' 0 N--CA 1.424 -1.759 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.992 -174.502 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -175.64 -170.09 0.39 Allowed 'General case' 0 C--O 1.238 0.462 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 -175.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.559 HG23 ' HB3' ' A' ' 58' ' ' LEU . 56.2 p -101.44 164.39 16.05 Favored Pre-proline 0 C--N 1.303 -1.418 0 N-CA-C 112.817 0.673 . . . . 0.0 112.817 176.22 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . 0.467 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 22.8 Cg_endo -60.7 172.12 3.05 Favored 'Trans proline' 0 CA--C 1.552 1.41 0 C-N-CA 123.194 2.596 . . . . 0.0 111.891 173.482 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 2.2 tmm_? -73.74 119.6 18.19 Favored 'General case' 0 C--N 1.323 -0.584 0 C-N-CA 123.674 0.79 . . . . 0.0 110.068 -173.734 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 75.5 t -138.45 139.07 42.15 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.963 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -177.536 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.94 142.0 32.95 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.974 0 C-N-CA 122.978 0.511 . . . . 0.0 109.869 -176.225 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.521 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 4.9 m-85 -95.68 105.38 17.37 Favored 'General case' 0 C--N 1.309 -1.184 0 C-N-CA 123.186 0.594 . . . . 0.0 109.853 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . 0.411 HD22 ' N ' ' A' ' 96' ' ' ASN . 0.8 OUTLIER -93.01 50.89 1.6 Allowed 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 121.618 0.723 . . . . 0.0 109.271 177.2 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 12.2 p -117.47 178.4 4.4 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.023 -0.989 . . . . 0.0 110.841 -175.687 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 36.1 ptt180 -144.35 36.9 1.22 Allowed 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 172.408 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.8 t -158.31 171.77 19.57 Favored 'General case' 0 C--N 1.312 -1.036 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 -173.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.45 99.32 4.15 Favored 'General case' 0 CA--C 1.499 -0.991 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 -179.275 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -98.05 139.37 21.21 Favored Pre-proline 0 C--N 1.287 -2.118 0 N-CA-C 108.401 -0.963 . . . . 0.0 108.401 178.292 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -60.19 147.57 92.95 Favored 'Trans proline' 0 C--O 1.245 0.844 0 C-N-CA 122.938 2.425 . . . . 0.0 112.134 178.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . 0.521 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 11.4 t90 -93.64 106.51 21.5 Favored Pre-proline 0 C--N 1.311 -1.094 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 -178.341 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -77.04 88.79 1.37 Allowed 'Trans proline' 0 N--CA 1.455 -0.756 0 C-N-CA 121.984 1.79 . . . . 0.0 113.212 -172.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.51 HG22 ' CD2' ' A' ' 77' ' ' TYR . 66.6 t -140.12 146.43 24.8 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.296 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 178.014 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.593 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.69 134.98 17.01 Favored 'General case' 0 C--N 1.291 -1.947 0 CA-C-O 120.659 0.266 . . . . 0.0 110.919 177.592 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.495 HD21 HD11 ' A' ' 129' ' ' LEU . 18.4 mt -101.11 100.04 10.55 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 179.682 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.427 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 58.8 m-85 -81.66 76.43 8.57 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 110.299 -0.26 . . . . 0.0 110.299 177.27 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.627 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.1 mm? -101.4 125.51 48.05 Favored 'General case' 0 CA--C 1.485 -1.528 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 176.02 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -126.68 148.05 63.27 Favored Pre-proline 0 N--CA 1.398 -3.036 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -175.075 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.422 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 28.6 Cg_endo -62.14 123.72 13.04 Favored 'Trans proline' 0 N--CA 1.446 -1.322 0 C-N-CA 123.132 2.555 . . . . 0.0 113.611 -176.522 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.493 ' O ' HG22 ' A' ' 30' ' ' VAL . 17.9 m -85.95 -157.69 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.398 -3.053 0 CA-C-N 114.34 -1.3 . . . . 0.0 108.696 171.225 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 15.8 t -81.83 -24.69 35.7 Favored 'General case' 0 C--N 1.254 -3.586 0 CA-C-O 121.755 0.788 . . . . 0.0 109.034 -171.175 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 28.0 t -80.85 18.23 1.03 Allowed 'General case' 0 N--CA 1.434 -1.267 0 CA-C-N 115.228 -0.896 . . . . 0.0 110.433 178.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -106.81 138.8 42.3 Favored 'General case' 0 N--CA 1.421 -1.887 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 179.373 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . 177.19 125.42 0.9 Allowed Glycine 0 N--CA 1.441 -0.999 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 179.599 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 68.75 -149.54 49.6 Favored Glycine 0 CA--C 1.496 -1.096 0 CA-C-O 119.07 -0.85 . . . . 0.0 111.38 -176.404 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 57.7 t -58.91 105.71 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-O 121.718 0.771 . . . . 0.0 111.018 -176.564 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -105.77 -34.67 7.61 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 114.785 -1.098 . . . . 0.0 111.128 -178.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.539 ' HB ' HG22 ' A' ' 154' ' ' VAL . 70.4 mt -119.7 136.98 55.09 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.062 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.85 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.525 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.2 mmpt? -113.39 138.5 49.97 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-O 121.035 0.445 . . . . 0.0 110.428 177.043 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.42 ' H ' ' HB3' ' A' ' 153' ' ' ASP . . . -72.31 137.57 46.78 Favored 'General case' 0 C--N 1.308 -1.198 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.957 179.648 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 82.16 5.17 89.89 Favored Glycine 0 C--N 1.31 -0.868 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.864 -179.123 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 44.6 m -104.66 141.1 37.05 Favored 'General case' 0 N--CA 1.421 -1.903 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -67.35 123.81 21.38 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 178.049 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.796 ' HB ' HG21 ' A' ' 67' ' ' VAL . 28.6 pt -111.44 -26.21 3.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 116.129 -0.487 . . . . 0.0 112.16 -178.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . 0.401 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.59 168.41 23.56 Favored 'General case' 0 N--CA 1.443 -0.784 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -178.254 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 77.2 t -142.68 114.9 3.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 107.877 -1.157 . . . . 0.0 107.877 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.495 HD11 HD21 ' A' ' 107' ' ' LEU . 62.7 mt -116.23 143.88 44.94 Favored 'General case' 0 C--N 1.286 -2.16 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 178.714 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.551 HG21 HE21 ' A' ' 143' ' ' GLN . 4.9 mp -123.94 123.35 66.67 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.009 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.101 178.422 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.601 HD22 ' HB2' ' A' ' 144' ' ' PHE . 0.0 OUTLIER -89.11 134.7 33.91 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 176.718 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.409 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 12.4 tpt180 -101.79 109.56 21.35 Favored 'General case' 0 C--N 1.277 -2.553 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 179.114 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.511 ' HB3' ' CE2' ' A' ' 1' ' ' PHE . 10.1 mm-40 -100.8 105.12 16.4 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 176.536 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.435 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 7.7 m -124.17 136.02 53.89 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 106.602 -1.629 . . . . 0.0 106.602 179.205 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.56 ' CB ' HG23 ' A' ' 52' ' ' ILE . 7.9 p30 -120.8 167.95 11.96 Favored 'General case' 0 C--N 1.32 -0.691 0 C-N-CA 117.831 -1.548 . . . . 0.0 112.336 178.441 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.449 HD22 HG22 ' A' ' 53' ' ' THR . 5.0 p30 -89.37 -5.17 57.69 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 114.535 -1.211 . . . . 0.0 111.982 -170.651 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 30.4 t80 -113.51 -69.75 0.84 Allowed 'General case' 0 C--N 1.301 -1.539 0 CA-C-O 120.74 0.305 . . . . 0.0 111.639 -173.68 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -88.23 166.35 14.4 Favored 'General case' 0 CA--C 1.472 -2.024 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 23.8 m -87.11 39.46 0.86 Allowed 'General case' 0 C--N 1.27 -2.869 0 CA-C-N 114.409 -1.269 . . . . 0.0 109.658 177.231 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 71.5 m-20 -87.34 53.42 2.8 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.561 -177.652 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -85.39 96.34 9.53 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 176.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.0 m-85 -130.52 137.03 49.53 Favored 'General case' 0 N--CA 1.417 -2.118 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.681 -179.048 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . 0.551 HE21 HG21 ' A' ' 130' ' ' ILE . 20.9 pt20 -108.22 133.46 52.43 Favored 'General case' 0 N--CA 1.413 -2.308 0 CA-C-O 121.493 0.663 . . . . 0.0 110.033 177.073 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.601 ' HB2' HD22 ' A' ' 131' ' ' LEU . 8.0 m-30 -103.02 133.77 47.58 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 -176.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 46.6 t -91.44 129.91 41.42 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.929 0 CA-C-O 121.115 0.484 . . . . 0.0 109.766 -178.514 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . 0.512 ' CZ2' ' HB2' ' A' ' 3' ' ' CYS . 62.2 m95 -120.22 96.2 5.06 Favored 'General case' 0 C--N 1.277 -2.568 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 -179.825 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.7 m-80 -80.22 114.73 19.34 Favored 'General case' 0 C--N 1.295 -1.802 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.411 HG22 HD11 ' A' ' 126' ' ' ILE . 25.5 mm -87.42 123.31 40.07 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.799 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 -177.506 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -116.79 151.09 37.22 Favored 'General case' 0 C--N 1.292 -1.909 0 C-N-CA 124.207 1.003 . . . . 0.0 109.349 178.171 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.68 131.81 35.28 Favored 'General case' 0 N--CA 1.411 -2.419 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 175.635 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 17.8 t-20 -93.15 -11.39 32.93 Favored 'General case' 0 C--N 1.292 -1.919 0 CA-C-O 122.469 1.128 . . . . 0.0 108.033 -176.506 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -152.02 143.62 23.53 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 114.023 -1.444 . . . . 0.0 109.41 -177.457 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . 0.42 ' HB3' ' H ' ' A' ' 122' ' ' ALA . 6.4 p-10 -86.4 139.49 30.89 Favored 'General case' 0 C--N 1.309 -1.173 0 O-C-N 124.133 0.896 . . . . 0.0 110.183 -179.389 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.539 HG22 ' HB ' ' A' ' 120' ' ' ILE . 1.8 m -120.38 153.05 23.42 Favored 'Isoleucine or valine' 0 C--O 1.251 1.144 0 CA-C-O 120.94 0.4 . . . . 0.0 111.217 -175.599 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.0 t -123.14 142.63 39.03 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.2 0 N-CA-C 107.635 -1.246 . . . . 0.0 107.635 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.505 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 77.1 t -104.26 102.46 32.96 Favored Pre-proline 0 C--N 1.289 -2.039 0 C-N-CA 123.444 0.698 . . . . 0.0 110.039 179.179 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.505 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 29.7 Cg_endo -67.26 -23.23 45.32 Favored 'Trans proline' 0 C--O 1.219 -0.437 0 C-N-CA 122.498 2.132 . . . . 0.0 111.56 176.656 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.448 ' HB ' HG12 ' A' ' 156' ' ' VAL 0.287 5.1 t . . . . . 0 C--O 1.258 1.515 0 CA-C-O 117.45 -1.262 . . . . 0.0 113.768 176.054 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.46 ' CZ ' ' HB3' ' A' ' 44' ' ' CYS . 66.1 t80 . . . . . 0 CA--C 1.499 -0.988 0 N-CA-C 107.442 -1.318 . . . . 0.0 107.442 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -145.66 170.17 17.01 Favored 'General case' 0 C--N 1.312 -1.036 0 C-N-CA 120.32 -0.552 . . . . 0.0 110.695 178.378 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.456 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 76.9 m -145.48 159.31 43.29 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -178.813 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.42 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -145.55 155.56 43.14 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-O 121.451 0.643 . . . . 0.0 110.164 -177.37 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 44.7 p -92.36 177.33 6.17 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.856 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.91 -17.13 48.26 Favored 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.953 179.148 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.2 p-10 -90.76 -24.93 20.22 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.264 -0.88 . . . . 0.0 111.582 -177.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 131.73 -3.11 5.33 Favored Glycine 0 CA--C 1.494 -1.233 0 C-N-CA 119.271 -1.442 . . . . 0.0 114.428 169.321 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 6.7 m -80.55 100.05 8.39 Favored 'General case' 0 C--N 1.285 -2.211 0 CA-C-O 121.453 0.644 . . . . 0.0 109.536 -178.221 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.401 ' HA ' ' HA ' ' A' ' 4' ' ' LYS . . . -94.56 124.75 38.78 Favored 'General case' 0 N--CA 1.424 -1.77 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.115 176.72 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 69.6 mt -92.11 116.45 66.48 Favored Pre-proline 0 C--N 1.278 -2.539 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 177.72 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -75.9 177.09 9.18 Favored 'Trans proline' 0 C--O 1.245 0.841 0 C-N-CA 122.54 2.16 . . . . 0.0 111.719 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 67.9 mt -70.23 128.4 33.48 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.4 179.564 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 128.89 5.19 4.93 Favored Glycine 0 N--CA 1.432 -1.576 0 C-N-CA 120.372 -0.918 . . . . 0.0 111.69 -178.19 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 86.07 169.74 46.25 Favored Glycine 0 N--CA 1.439 -1.106 0 C-N-CA 120.511 -0.852 . . . . 0.0 111.588 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 151.86 -174.85 30.83 Favored Glycine 0 CA--C 1.487 -1.686 0 N-CA-C 110.662 -0.975 . . . . 0.0 110.662 178.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 19.3 m -134.1 159.37 41.06 Favored 'General case' 0 C--N 1.296 -1.759 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 -179.131 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -141.46 165.51 27.31 Favored 'General case' 0 N--CA 1.42 -1.935 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 177.21 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -116.1 104.41 11.52 Favored 'General case' 0 C--N 1.273 -2.73 0 CA-C-N 114.002 -1.453 . . . . 0.0 108.913 178.079 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.456 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.3 m -91.68 146.4 6.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 -178.563 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -128.93 112.51 14.16 Favored 'General case' 0 C--N 1.31 -1.144 0 CA-C-O 121.03 0.443 . . . . 0.0 111.28 -177.502 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.524 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.6 p -118.69 129.78 74.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.633 0 CA-C-O 121.692 0.758 . . . . 0.0 111.995 -174.626 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 43.3 m-80 -84.52 126.06 32.96 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 177.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 23.0 mt -113.06 157.31 21.74 Favored 'General case' 0 C--N 1.272 -2.777 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 -179.155 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.36 120.74 46.79 Favored Pre-proline 0 C--N 1.313 -1.011 0 O-C-N 124.207 0.942 . . . . 0.0 109.723 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.473 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 60.6 Cg_endo -74.2 -0.12 9.19 Favored 'Trans proline' 0 N--CA 1.463 -0.269 0 C-N-CA 122.657 2.238 . . . . 0.0 112.616 -177.536 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.433 HG13 ' HG3' ' A' ' 157' ' ' PRO . 94.9 t -125.3 109.95 23.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 N-CA-C 107.371 -1.344 . . . . 0.0 107.371 177.639 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 1.6 t -140.91 107.02 1.97 Allowed 'Isoleucine or valine' 0 C--O 1.179 -2.622 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 -179.544 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.592 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -98.64 148.86 23.38 Favored 'General case' 0 C--N 1.265 -3.089 0 O-C-N 122.13 -0.356 . . . . 0.0 111.266 -179.5 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.423 ' H ' ' HA ' ' A' ' 158' ' ' THR . 22.2 t -43.8 117.04 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.239 0.528 0 C-N-CA 123.571 0.748 . . . . 0.0 111.501 175.759 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.84 -1.07 48.36 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-N 115.002 -0.999 . . . . 0.0 113.063 -179.035 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.592 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -71.48 -177.04 1.7 Allowed 'General case' 0 C--N 1.318 -0.802 0 C-N-CA 124.496 1.118 . . . . 0.0 111.237 177.784 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 -133.41 87.61 2.41 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 177.775 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.625 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 22.5 tp -88.76 140.3 29.59 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 -178.69 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.2 t -134.11 125.4 48.14 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.172 0 CA-C-O 121.113 0.483 . . . . 0.0 109.787 -175.472 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.57 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 41.1 t -95.78 88.2 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.399 -2.994 0 N-CA-C 105.713 -1.958 . . . . 0.0 105.713 174.196 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -80.57 116.07 20.42 Favored 'General case' 0 CA--C 1.486 -1.482 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.0 mt -97.52 0.06 46.86 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.249 -177.459 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.588 ' OG ' ' HA ' ' A' ' 104' ' ' PRO . 19.6 m -81.22 -2.37 48.5 Favored 'General case' 0 C--N 1.29 -1.988 0 CA-C-O 122.658 1.218 . . . . 0.0 109.703 -179.296 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.4 p -118.8 1.58 11.57 Favored 'General case' 0 C--N 1.275 -2.663 0 CA-C-N 114.807 -1.088 . . . . 0.0 109.811 175.725 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.524 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 44.8 mm-40 -122.41 -23.09 5.31 Favored 'General case' 0 CA--C 1.512 -0.497 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.329 -174.566 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 29.0 mt -135.68 139.2 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.229 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -176.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.42 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 65.7 m-85 -137.52 151.79 48.8 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 -177.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.46 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 67.7 m -128.28 138.53 52.46 Favored 'General case' 0 C--N 1.276 -2.622 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 176.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.2 p80 -125.11 129.26 49.84 Favored 'General case' 0 C--N 1.295 -1.774 0 CA-C-O 121.955 0.883 . . . . 0.0 110.773 -177.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.548 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 24.4 p-10 -95.76 96.5 9.02 Favored 'General case' 0 C--N 1.279 -2.477 0 CA-C-O 122.466 1.127 . . . . 0.0 110.072 -179.214 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -74.7 -23.55 58.63 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 114.108 -1.405 . . . . 0.0 111.538 -174.466 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 49.8 m-85 -128.91 65.23 72.89 Favored Pre-proline 0 N--CA 1.479 1.019 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.103 179.648 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.548 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 60.3 Cg_endo -68.85 -12.31 34.14 Favored 'Trans proline' 0 N--CA 1.483 0.881 0 C-N-CA 122.809 2.34 . . . . 0.0 114.148 -172.471 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -108.08 -21.15 12.92 Favored 'General case' 0 C--N 1.292 -1.894 0 C-N-CA 119.977 -0.689 . . . . 0.0 110.343 -176.662 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.504 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.8 m -96.21 -30.34 13.53 Favored 'General case' 0 N--CA 1.416 -2.154 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 -172.544 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.657 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.1 mp -121.98 143.29 35.07 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.213 0 CA-C-N 113.991 -1.459 . . . . 0.0 108.737 -177.119 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 6.1 t -88.82 125.83 35.08 Favored 'General case' 0 N--CA 1.419 -2.014 0 N-CA-C 103.944 -2.613 . . . . 0.0 103.944 170.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 -90.61 107.18 19.01 Favored 'General case' 0 C--N 1.263 -3.18 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 -172.63 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.469 ' HB3' ' O ' ' A' ' 134' ' ' THR . 34.2 t80 -126.02 117.72 23.83 Favored 'General case' 0 C--N 1.274 -2.7 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.489 -173.39 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.537 HG12 ' OH ' ' A' ' 77' ' ' TYR . 49.0 t -121.85 130.84 74.24 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.298 -175.517 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.1 p -143.45 113.43 7.19 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 123.923 0.764 . . . . 0.0 111.239 177.683 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.505 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 54.3 tp -55.34 109.7 0.58 Allowed 'General case' 0 C--N 1.311 -1.106 0 CA-C-O 121.313 0.578 . . . . 0.0 110.174 172.108 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.5 ' NE2' ' HD3' ' A' ' 132' ' ' ARG . 3.4 tp-100 -54.91 -53.64 52.96 Favored 'General case' 0 C--O 1.209 -1.04 0 C-N-CA 126.041 1.736 . . . . 0.0 110.911 178.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -171.06 160.9 6.65 Favored 'General case' 0 N--CA 1.425 -1.71 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 -176.198 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -139.3 133.44 6.15 Favored Glycine 1 N--CA 1.391 -4.321 0 N-CA-C 108.041 -2.024 . . . . 0.0 108.041 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 19.2 m -120.76 151.6 39.36 Favored 'General case' 0 C--N 1.276 -2.599 0 O-C-N 124.956 1.033 . . . . 0.0 108.582 -174.145 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.563 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -116.16 157.67 24.45 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 -178.654 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.527 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 96.1 m-85 -155.69 176.8 12.14 Favored 'General case' 0 C--N 1.35 0.616 0 C-N-CA 124.246 1.018 . . . . 0.0 109.587 -177.283 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 58.35 -147.52 38.86 Favored Glycine 0 CA--C 1.52 0.365 0 O-C-N 123.61 0.569 . . . . 0.0 112.81 178.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -70.58 -10.34 66.77 Favored Glycine 0 C--O 1.205 -1.665 0 O-C-N 122.052 -0.676 . . . . 0.0 111.976 177.106 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.773 HG21 ' HB ' ' A' ' 126' ' ' ILE . 92.8 t -70.53 -36.75 67.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 123.544 0.737 . . . . 0.0 111.322 -177.172 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.563 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.71 -23.09 25.67 Favored 'General case' 0 N--CA 1.421 -1.883 0 C-N-CA 118.6 -1.24 . . . . 0.0 112.144 179.179 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 17.1 t -101.77 -55.46 2.5 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 112.952 0.723 . . . . 0.0 112.952 -175.213 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.443 ' O ' HG22 ' A' ' 112' ' ' VAL . 72.4 m-20 -83.91 -27.43 28.6 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 -174.769 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.637 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 90.0 m-85 -107.02 159.19 16.47 Favored 'General case' 0 N--CA 1.421 -1.917 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 176.463 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.8 t -168.09 136.24 2.3 Favored 'General case' 0 N--CA 1.41 -2.431 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 176.292 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.421 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -169.37 -108.21 0.21 Allowed Glycine 0 N--CA 1.411 -3.027 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 175.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.541 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.1 p -159.21 -179.96 8.46 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 123.829 0.852 . . . . 0.0 110.547 -173.225 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.4 p -135.05 146.73 29.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.677 0 C-N-CA 123.435 0.694 . . . . 0.0 109.143 178.614 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.616 ' HG3' ' O ' ' A' ' 80' ' ' SER . 84.1 tttt -125.17 142.17 51.66 Favored 'General case' 0 N--CA 1.417 -2.095 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.518 -179.442 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.537 ' OH ' HG12 ' A' ' 56' ' ' VAL . 72.4 t80 -144.48 111.06 5.64 Favored 'General case' 0 C--N 1.295 -1.796 0 CA-C-N 115.126 -0.943 . . . . 0.0 109.13 -177.195 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 35.1 t 55.14 34.33 22.39 Favored 'General case' 0 C--N 1.317 -0.825 0 C-N-CA 123.416 0.686 . . . . 0.0 111.164 178.212 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.08 10.52 64.32 Favored Glycine 0 N--CA 1.44 -1.079 0 C-N-CA 120.486 -0.864 . . . . 0.0 113.566 -178.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.616 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 20.8 t -79.84 179.8 7.36 Favored 'General case' 0 CA--C 1.541 0.61 0 CA-C-N 117.551 0.676 . . . . 0.0 109.31 178.484 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 9.7 p -156.55 90.35 1.16 Allowed 'General case' 0 C--N 1.299 -1.59 0 CA-C-O 121.623 0.725 . . . . 0.0 110.637 -176.707 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.439 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 1.5 p90 -139.85 158.31 67.9 Favored Pre-proline 0 C--N 1.297 -1.69 0 N-CA-C 109.328 -0.619 . . . . 0.0 109.328 -173.098 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.541 ' HA ' HG22 ' A' ' 74' ' ' THR . 58.9 Cg_endo -69.35 151.03 71.39 Favored 'Trans proline' 0 C--N 1.354 0.842 0 C-N-CA 123.148 2.565 . . . . 0.0 113.154 -177.081 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.596 ' CD2' HD21 ' A' ' 109' ' ' LEU . 58.0 t80 -122.74 133.21 24.33 Favored Pre-proline 0 N--CA 1.439 -1.011 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.018 -179.541 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.463 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 79.3 Cg_endo -71.43 149.78 92.7 Favored 'Cis proline' 0 CA--C 1.534 0.511 0 C-N-CA 122.71 -1.787 . . . . 0.0 109.73 -0.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 10.0 t -61.06 -175.54 0.05 OUTLIER 'General case' 0 CA--C 1.562 1.415 0 C-N-CA 123.399 0.679 . . . . 0.0 112.595 -175.462 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 12.4 p -104.97 -50.53 3.23 Favored 'General case' 0 N--CA 1.408 -2.563 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 -177.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.6 t -128.43 -109.19 0.29 Allowed 'General case' 0 N--CA 1.402 -2.873 0 CA-C-N 114.346 -1.297 . . . . 0.0 108.591 178.338 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -125.35 -171.68 2.42 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 118.539 0.609 . . . . 0.0 112.503 -176.692 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.505 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 36.1 p -93.95 167.57 13.4 Favored Pre-proline 0 C--N 1.309 -1.189 0 N-CA-C 112.924 0.713 . . . . 0.0 112.924 -178.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -62.82 175.87 2.11 Favored 'Trans proline' 0 CA--C 1.552 1.386 0 C-N-CA 123.087 2.524 . . . . 0.0 111.904 172.424 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.4 ' HG2' ' CE2' ' A' ' 55' ' ' TYR . 1.4 tmm_? -74.84 129.5 37.79 Favored 'General case' 0 C--O 1.243 0.761 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.004 -175.469 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.492 ' HB ' ' O ' ' A' ' 56' ' ' VAL . 65.3 t -140.09 132.57 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.037 0 C-N-CA 123.718 0.807 . . . . 0.0 109.801 -176.497 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 1.9 p -131.08 136.41 57.95 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.411 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 177.461 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 6.1 m-85 -79.8 116.47 19.98 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-O 121.388 0.613 . . . . 0.0 110.525 -179.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 41.6 m-80 -102.22 68.46 1.09 Allowed 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 177.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 46.0 t -147.64 179.23 7.84 Favored 'General case' 0 N--CA 1.426 -1.646 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 -175.578 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 31.8 ptt180 -151.11 42.12 0.76 Allowed 'General case' 0 C--N 1.31 -1.146 0 C-N-CA 124.036 0.934 . . . . 0.0 108.51 171.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 11.0 t -169.72 172.32 6.87 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-N 114.525 -1.216 . . . . 0.0 108.23 -177.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -59.34 119.87 8.24 Favored 'General case' 0 N--CA 1.474 0.768 0 O-C-N 123.756 0.66 . . . . 0.0 110.493 178.357 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 55.9 mmtt -120.2 143.19 35.12 Favored Pre-proline 0 C--N 1.287 -2.143 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.994 178.364 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -67.16 139.19 49.71 Favored 'Trans proline' 0 N--CA 1.44 -1.676 0 C-N-CA 122.392 2.061 . . . . 0.0 110.32 177.252 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 14.4 t90 -80.34 109.69 13.69 Favored Pre-proline 0 C--N 1.307 -1.243 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 -177.476 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.588 ' HA ' ' OG ' ' A' ' 39' ' ' SER . 60.7 Cg_endo -74.85 87.7 1.28 Allowed 'Trans proline' 0 N--CA 1.451 -0.982 0 C-N-CA 121.12 1.213 . . . . 0.0 112.844 -172.376 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.505 HG22 ' CD1' ' A' ' 77' ' ' TYR . 59.7 t -144.9 145.18 21.24 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.359 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 179.579 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.57 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.65 136.27 17.03 Favored 'General case' 0 C--N 1.288 -2.07 0 O-C-N 123.569 0.543 . . . . 0.0 110.116 177.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.464 HD21 HD11 ' A' ' 129' ' ' LEU . 17.7 mt -101.81 105.12 15.92 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 177.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.421 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 39.3 m-85 -85.29 80.49 9.15 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 177.481 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.637 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.2 mm? -105.12 125.32 50.85 Favored 'General case' 0 CA--C 1.491 -1.327 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 177.441 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -128.04 146.63 59.99 Favored Pre-proline 0 N--CA 1.412 -2.363 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.62 -175.542 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.438 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 23.1 Cg_endo -61.14 117.6 4.39 Favored 'Trans proline' 0 C--O 1.245 0.863 0 C-N-CA 123.424 2.749 . . . . 0.0 112.369 -178.458 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.443 HG22 ' O ' ' A' ' 70' ' ' ASN . 2.7 m -67.04 -114.14 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.202 -1.447 0 CA-C-N 114.289 -1.323 . . . . 0.0 112.752 176.735 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 41.7 m -112.56 -43.4 3.48 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.287 -0.883 . . . . 0.0 110.441 175.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 22.7 t -82.82 30.2 0.44 Allowed 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.067 -174.726 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -101.79 130.94 48.33 Favored 'General case' 0 N--CA 1.418 -2.035 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.2 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.28 141.06 6.45 Favored Glycine 0 N--CA 1.432 -1.596 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 179.048 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 58.81 -149.23 37.78 Favored Glycine 0 C--O 1.219 -0.812 0 CA-C-O 119.244 -0.753 . . . . 0.0 113.307 -179.087 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 99.5 t -56.56 96.75 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 121.581 0.705 . . . . 0.0 111.26 -178.207 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -99.4 -27.78 13.58 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.365 -177.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.583 ' HB ' HG22 ' A' ' 154' ' ' VAL . 68.9 mt -126.84 138.53 54.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 177.105 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.424 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.2 mmpt? -111.02 138.05 47.9 Favored 'General case' 0 C--N 1.315 -0.932 0 CA-C-O 121.341 0.591 . . . . 0.0 111.207 178.409 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -69.56 128.57 36.96 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.46 178.029 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 92.05 -7.16 78.96 Favored Glycine 0 N--CA 1.428 -1.89 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.093 -179.349 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 91.9 p -90.85 143.9 26.25 Favored 'General case' 0 C--O 1.253 1.253 0 C-N-CA 119.495 -0.882 . . . . 0.0 109.525 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.437 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -70.72 122.37 19.69 Favored 'General case' 0 N--CA 1.435 -1.22 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 177.367 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.773 ' HB ' HG21 ' A' ' 67' ' ' VAL . 31.6 pt -109.02 -24.47 4.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -177.116 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.72 167.32 23.22 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 -177.9 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.437 HG23 HD11 ' A' ' 125' ' ' LEU . 76.9 t -141.62 114.93 4.5 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 179.506 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.464 HD11 HD21 ' A' ' 107' ' ' LEU . 52.7 mt -117.97 144.68 45.32 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 108.315 -0.995 . . . . 0.0 108.315 178.484 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.488 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.4 mp -127.41 130.19 70.67 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 C-N-CA 119.41 -0.916 . . . . 0.0 110.639 179.006 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.471 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.9 OUTLIER -94.75 128.99 41.85 Favored 'General case' 0 C--N 1.29 -1.982 0 C-N-CA 123.855 0.862 . . . . 0.0 111.477 -179.607 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.5 ' HD3' ' NE2' ' A' ' 59' ' ' GLN . 25.9 mmm180 -94.58 120.55 34.99 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 109.136 -0.69 . . . . 0.0 109.136 173.185 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.567 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 7.4 tp-100 -103.38 137.23 41.78 Favored 'General case' 0 N--CA 1.427 -1.59 0 N-CA-C 105.937 -1.875 . . . . 0.0 105.937 169.495 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.469 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 27.8 m -150.23 134.76 17.38 Favored 'General case' 0 C--N 1.278 -2.527 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 173.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.657 ' CB ' HG23 ' A' ' 52' ' ' ILE . 8.7 p30 -133.81 169.0 17.7 Favored 'General case' 0 N--CA 1.437 -1.108 0 C-N-CA 118.966 -1.094 . . . . 0.0 112.057 179.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -91.58 -2.1 57.25 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 113.852 -1.522 . . . . 0.0 112.329 -170.826 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 65.8 t80 -113.1 -63.39 1.45 Allowed 'General case' 0 C--N 1.296 -1.752 0 CA-C-O 121.154 0.502 . . . . 0.0 111.59 -174.327 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 70.7 m-20 -100.01 177.1 5.2 Favored 'General case' 0 C--N 1.299 -1.628 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.245 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 21.0 t -97.1 39.07 1.2 Allowed 'General case' 0 N--CA 1.431 -1.386 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 176.089 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . 0.56 ' HB3' ' ND2' ' A' ' 135' ' ' ASN . 29.7 t0 -83.31 66.07 8.62 Favored 'General case' 0 CA--C 1.512 -0.509 0 N-CA-C 106.407 -1.701 . . . . 0.0 106.407 174.159 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . 0.567 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 5.6 p-10 -114.1 47.79 1.16 Allowed 'General case' 0 N--CA 1.423 -1.81 0 CA-C-N 112.766 -2.015 . . . . 0.0 108.165 179.021 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 82.0 m-85 -90.92 161.86 15.01 Favored 'General case' 0 N--CA 1.421 -1.881 0 CA-C-N 114.013 -1.449 . . . . 0.0 109.284 -179.557 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 11.4 pt20 -121.98 138.24 54.5 Favored 'General case' 0 N--CA 1.416 -2.152 0 C-N-CA 119.251 -0.98 . . . . 0.0 109.844 178.837 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 11.8 m-30 -105.12 128.98 53.62 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 -176.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 60.6 t -94.67 133.88 34.07 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.116 0 CA-C-O 121.143 0.497 . . . . 0.0 110.24 -178.152 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . 0.471 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 68.2 m95 -120.19 96.83 5.32 Favored 'General case' 0 C--N 1.286 -2.179 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.134 -177.224 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 44.3 m-80 -79.15 112.92 16.85 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 106.82 -1.548 . . . . 0.0 106.82 176.383 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.456 ' HA ' HG22 ' A' ' 20' ' ' VAL . 23.9 mm -87.74 120.55 37.02 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 -177.604 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -115.45 153.59 30.82 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 177.593 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.51 132.44 34.2 Favored 'General case' 0 N--CA 1.406 -2.63 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 177.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 23.6 t-20 -90.02 -17.18 28.3 Favored 'General case' 0 C--N 1.286 -2.189 0 N-CA-C 107.841 -1.17 . . . . 0.0 107.841 -176.115 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.7 t30 -146.18 144.31 29.85 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 114.088 -1.415 . . . . 0.0 110.123 -174.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 6.6 p-10 -83.45 138.22 33.56 Favored 'General case' 0 C--N 1.317 -0.819 0 O-C-N 124.314 1.009 . . . . 0.0 109.697 179.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.583 HG22 ' HB ' ' A' ' 120' ' ' ILE . 2.0 m -119.83 151.83 22.44 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 C-N-CA 120.634 -0.426 . . . . 0.0 111.045 -176.898 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.2 t -123.78 140.96 45.69 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.436 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 -179.139 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.497 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.4 t -103.2 100.35 17.42 Favored Pre-proline 0 C--N 1.291 -1.945 0 C-N-CA 123.435 0.694 . . . . 0.0 109.864 178.43 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.495 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 35.2 Cg_endo -68.17 -21.04 42.85 Favored 'Trans proline' 0 C--N 1.344 0.334 0 C-N-CA 122.52 2.147 . . . . 0.0 111.403 177.111 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.423 ' HA ' ' H ' ' A' ' 30' ' ' VAL . 3.1 t . . . . . 0 C--O 1.257 1.453 0 C-N-CA 124.789 1.236 . . . . 0.0 114.128 175.531 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.564 ' CZ ' ' HB3' ' A' ' 133' ' ' GLN . 0.8 OUTLIER . . . . . 0 N--CA 1.436 -1.158 0 N-CA-C 106.788 -1.56 . . . . 0.0 106.788 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.46 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -148.03 -175.76 5.01 Favored 'General case' 0 C--N 1.277 -2.574 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 -175.6 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.5 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 9.6 t -144.32 157.25 44.37 Favored 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 118.864 -1.134 . . . . 0.0 110.175 -175.347 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.44 ' HE3' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.48 164.9 29.49 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-O 121.254 0.55 . . . . 0.0 110.961 -175.335 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.586 HG22 HG22 ' A' ' 20' ' ' VAL . 82.1 p -102.18 176.81 5.07 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.841 -178.61 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -79.3 -16.51 56.25 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 114.402 -1.272 . . . . 0.0 110.722 176.038 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -90.93 -26.49 19.26 Favored 'General case' 0 CA--C 1.515 -0.375 0 C-N-CA 118.856 -1.137 . . . . 0.0 111.341 -177.467 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.48 4.87 3.43 Favored Glycine 0 CA--C 1.499 -0.932 0 C-N-CA 119.889 -1.148 . . . . 0.0 113.322 171.261 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.6 m -82.67 107.48 15.34 Favored 'General case' 0 N--CA 1.424 -1.759 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.404 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -102.53 109.99 21.78 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 115.813 -0.63 . . . . 0.0 109.43 176.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.46 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 54.8 mt -82.62 124.63 77.34 Favored Pre-proline 0 C--N 1.305 -1.338 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 -176.688 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -81.36 161.94 19.83 Favored 'Trans proline' 0 C--O 1.246 0.924 0 C-N-CA 122.61 2.207 . . . . 0.0 111.922 179.073 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.427 HD11 ' N ' ' A' ' 1' ' ' PHE . 58.0 mt -66.27 133.0 31.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 115.274 -0.876 . . . . 0.0 109.09 179.544 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 126.57 12.24 3.44 Favored Glycine 0 C--N 1.306 -1.1 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.238 -178.661 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.97 148.84 18.93 Favored Glycine 0 C--O 1.241 0.564 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 -178.054 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 173.62 -172.36 45.17 Favored Glycine 0 CA--C 1.491 -1.415 0 C-N-CA 119.453 -1.356 . . . . 0.0 112.493 -179.693 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.7 p -146.55 151.76 37.86 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 122.654 0.382 . . . . 0.0 110.325 -177.729 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -140.38 166.47 24.63 Favored 'General case' 0 N--CA 1.433 -1.283 0 CA-C-O 121.617 0.722 . . . . 0.0 109.89 178.33 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -117.39 101.54 8.49 Favored 'General case' 0 C--N 1.28 -2.423 0 CA-C-N 113.833 -1.531 . . . . 0.0 109.307 179.412 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.586 HG22 HG22 ' A' ' 5' ' ' THR . 40.4 t -92.25 134.4 30.53 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.802 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.563 -178.73 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 55.2 m-85 -119.6 126.73 51.9 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 -179.088 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.492 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.7 p -136.86 133.22 48.12 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 CA-C-N 115.719 -0.673 . . . . 0.0 111.249 -177.047 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 6.4 p30 -93.67 129.77 39.85 Favored 'General case' 0 C--N 1.297 -1.704 0 CA-C-O 121.643 0.735 . . . . 0.0 110.482 178.312 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -108.25 160.58 15.73 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 114.466 -1.243 . . . . 0.0 108.196 -179.704 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -59.08 123.7 70.66 Favored Pre-proline 0 C--N 1.314 -0.958 0 O-C-N 124.387 1.054 . . . . 0.0 109.233 177.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.426 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 61.8 Cg_endo -74.94 -2.06 12.03 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.632 2.221 . . . . 0.0 113.159 -177.544 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.421 HG13 ' HG3' ' A' ' 157' ' ' PRO . 60.5 t -122.95 109.76 24.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 107.555 -1.276 . . . . 0.0 107.555 178.186 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.464 ' O ' HG13 ' A' ' 156' ' ' VAL . 1.7 t -141.1 102.16 1.17 Allowed 'Isoleucine or valine' 0 C--O 1.183 -2.436 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 -177.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.58 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -94.01 152.22 18.97 Favored 'General case' 0 C--N 1.274 -2.689 0 O-C-N 122.149 -0.344 . . . . 0.0 111.471 179.878 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.401 HG13 ' O ' ' A' ' 112' ' ' VAL . 35.0 t -45.71 119.88 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 123.26 0.624 . . . . 0.0 112.156 176.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.83 1.6 55.13 Favored Glycine 0 N--CA 1.46 0.252 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.595 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.58 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.4 OUTLIER -71.49 -178.53 2.19 Favored 'General case' 0 C--N 1.312 -1.048 0 C-N-CA 124.158 0.983 . . . . 0.0 111.226 177.246 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -129.73 85.06 2.26 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 108.297 -1.001 . . . . 0.0 108.297 176.157 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.593 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 17.1 tp -92.98 134.94 34.62 Favored 'General case' 0 N--CA 1.423 -1.806 0 C-N-CA 119.446 -0.902 . . . . 0.0 108.727 179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 2.0 p -141.61 132.38 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.515 0 CA-C-O 122.016 0.913 . . . . 0.0 112.366 -177.694 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.604 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 42.5 t -89.31 90.0 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.264 0 CA-C-N 113.665 -1.607 . . . . 0.0 108.376 179.156 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -73.96 103.39 4.44 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 -179.561 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.4 mt -89.94 -3.82 57.83 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 120.75 0.31 . . . . 0.0 111.782 -179.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -73.43 0.81 11.2 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-O 122.07 0.938 . . . . 0.0 111.574 178.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.9 p -126.72 5.89 6.73 Favored 'General case' 0 N--CA 1.418 -2.033 0 CA-C-N 115.203 -0.908 . . . . 0.0 109.866 176.645 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.492 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 43.9 mm-40 -123.7 -23.15 4.78 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.958 -174.754 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 17.7 mt -133.7 137.56 52.41 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 -176.158 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.44 ' HB2' ' HE3' ' A' ' 4' ' ' LYS . 41.7 m-85 -142.41 124.37 15.27 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -175.136 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.5 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 81.7 m -101.27 147.27 26.49 Favored 'General case' 0 C--N 1.291 -1.957 0 N-CA-C 109.46 -0.571 . . . . 0.0 109.46 -179.361 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.464 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 37.0 p-80 -136.7 129.79 31.13 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-O 121.763 0.792 . . . . 0.0 111.649 -173.813 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.505 ' HA ' ' HA ' ' A' ' 1' ' ' PHE . 41.7 t30 -93.05 102.25 14.58 Favored 'General case' 0 C--N 1.28 -2.446 0 C-N-CA 119.991 -0.684 . . . . 0.0 110.533 179.233 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -56.22 -27.91 56.48 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 124.804 1.241 . . . . 0.0 111.016 179.747 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.476 ' HB2' HD13 ' A' ' 52' ' ' ILE . 38.8 m-85 -125.84 79.17 68.82 Favored Pre-proline 0 C--N 1.309 -1.169 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 -177.383 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.496 ' HA ' ' ND2' ' A' ' 46' ' ' ASN . 57.8 Cg_endo -67.89 -7.33 19.33 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.852 2.368 . . . . 0.0 115.19 -170.503 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -120.76 -11.37 9.01 Favored 'General case' 0 C--N 1.311 -1.068 0 C-N-CA 120.253 -0.579 . . . . 0.0 111.073 -179.391 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.49 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.9 OUTLIER -104.79 -30.23 10.03 Favored 'General case' 0 N--CA 1.435 -1.206 0 CA-C-O 122.128 0.966 . . . . 0.0 109.128 -171.631 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.49 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.0 mp -121.29 136.27 58.75 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.167 0 CA-C-N 114.351 -1.295 . . . . 0.0 109.807 -177.321 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.406 HG22 HD22 ' A' ' 136' ' ' ASN . 1.8 t -90.25 126.6 35.89 Favored 'General case' 0 N--CA 1.417 -2.08 0 N-CA-C 102.984 -2.969 . . . . 0.0 102.984 170.06 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.549 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 13.3 t70 -83.55 112.73 20.26 Favored 'General case' 0 C--N 1.274 -2.693 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 -172.155 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.575 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 22.0 t80 -127.77 123.31 34.97 Favored 'General case' 0 C--N 1.272 -2.801 0 CA-C-O 122.054 0.931 . . . . 0.0 110.671 -175.355 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.51 HG23 ' HG ' ' A' ' 131' ' ' LEU . 14.1 p -126.68 148.65 31.42 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.469 0 CA-C-N 114.334 -1.303 . . . . 0.0 109.802 -177.377 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -149.56 121.7 8.32 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 115.751 -0.659 . . . . 0.0 109.365 175.473 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.502 HD12 ' O ' ' A' ' 130' ' ' ILE . 53.0 tp -65.33 115.56 5.75 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 173.274 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.475 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 3.8 tp-100 -62.67 -61.65 2.27 Favored 'General case' 0 C--O 1.209 -1.038 0 C-N-CA 125.419 1.488 . . . . 0.0 109.499 178.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.414 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 9.9 ptp180 -158.61 159.36 35.36 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-N 114.513 -1.222 . . . . 0.0 108.227 -176.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.4 ' H ' HG22 ' A' ' 86' ' ' THR . . . -141.12 131.54 4.94 Favored Glycine 0 N--CA 1.399 -3.808 0 N-CA-C 108.478 -1.849 . . . . 0.0 108.478 -179.707 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 69.5 m -120.14 145.9 46.49 Favored 'General case' 0 C--N 1.28 -2.44 0 O-C-N 124.679 0.87 . . . . 0.0 110.475 -173.807 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.557 ' HB2' ' CE2' ' A' ' 84' ' ' PHE . . . -108.2 157.08 18.63 Favored 'General case' 0 CA--C 1.506 -0.735 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.497 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 94.2 m-85 -157.07 -179.44 8.21 Favored 'General case' 0 C--O 1.235 0.325 0 C-N-CA 124.776 1.231 . . . . 0.0 108.949 -178.069 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 61.11 -144.19 48.63 Favored Glycine 0 CA--C 1.506 -0.516 0 O-C-N 123.489 0.493 . . . . 0.0 112.313 177.594 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -76.33 -9.58 85.75 Favored Glycine 0 C--O 1.2 -2.028 0 C-N-CA 120.892 -0.67 . . . . 0.0 111.698 176.425 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.755 HG21 ' HB ' ' A' ' 126' ' ' ILE . 80.1 t -68.63 -41.59 82.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 123.341 0.656 . . . . 0.0 111.796 -177.691 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.531 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -84.95 -16.47 40.87 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.154 -1.019 . . . . 0.0 112.072 178.727 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 22.7 t -100.6 -59.8 1.64 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 121.461 0.648 . . . . 0.0 111.692 -174.595 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 63.3 m-20 -86.32 -25.84 25.22 Favored 'General case' 0 CA--C 1.488 -1.426 0 CA-C-N 115.793 -0.64 . . . . 0.0 109.403 -174.14 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.673 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 85.8 m-85 -107.66 160.93 15.32 Favored 'General case' 0 N--CA 1.412 -2.334 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.166 178.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.9 t -169.1 139.17 2.23 Favored 'General case' 0 N--CA 1.406 -2.626 0 N-CA-C 106.136 -1.802 . . . . 0.0 106.136 176.483 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.438 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -172.84 -104.23 0.17 Allowed Glycine 0 N--CA 1.411 -3.025 0 N-CA-C 109.843 -1.303 . . . . 0.0 109.843 175.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.416 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.3 p -162.9 -179.61 6.9 Favored 'General case' 0 C--N 1.311 -1.106 0 C-N-CA 124.088 0.955 . . . . 0.0 110.895 -175.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -132.27 145.51 34.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 177.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.661 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.5 tttt -122.85 146.4 47.59 Favored 'General case' 0 N--CA 1.419 -2.007 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.443 -179.456 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.491 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 68.8 t80 -145.53 109.68 4.9 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 4.3 m 54.24 44.08 29.6 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 176.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 81.72 7.17 88.42 Favored Glycine 0 C--N 1.31 -0.873 0 C-N-CA 119.901 -1.142 . . . . 0.0 112.914 -179.589 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.661 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 13.0 t -82.08 174.24 11.41 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 178.038 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 21.8 t -153.14 111.75 3.71 Favored 'General case' 0 C--N 1.28 -2.435 0 N-CA-C 107.411 -1.329 . . . . 0.0 107.411 -179.268 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.491 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 4.7 p90 -154.77 160.5 30.85 Favored Pre-proline 0 CA--C 1.551 1.001 0 N-CA-C 109.563 -0.532 . . . . 0.0 109.563 -174.579 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.427 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 50.0 Cg_endo -68.45 150.0 75.23 Favored 'Trans proline' 0 C--N 1.36 1.144 0 C-N-CA 122.942 2.428 . . . . 0.0 113.496 -176.756 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.607 ' CD2' HD21 ' A' ' 109' ' ' LEU . 53.1 t80 -124.86 133.79 25.1 Favored Pre-proline 0 N--CA 1.441 -0.882 0 CA-C-N 116.036 -0.529 . . . . 0.0 109.777 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.5 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 59.3 Cg_endo -70.25 148.3 87.54 Favored 'Cis proline' 0 CA--C 1.541 0.848 0 C-N-CA 122.682 -1.799 . . . . 0.0 109.747 -2.032 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.4 HG22 ' H ' ' A' ' 61' ' ' GLY . 8.8 t -67.08 -178.23 0.76 Allowed 'General case' 0 CA--C 1.55 0.967 0 CA-C-O 121.972 0.891 . . . . 0.0 111.742 -174.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 13.2 p -127.67 -28.68 2.71 Favored 'General case' 0 N--CA 1.425 -1.677 0 CA-C-N 114.929 -1.032 . . . . 0.0 112.931 -169.343 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.7 t -128.1 -79.9 0.58 Allowed 'General case' 0 N--CA 1.432 -1.373 0 C-N-CA 119.086 -1.046 . . . . 0.0 111.726 -176.483 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.5 pt-20 -170.98 -177.99 2.37 Favored 'General case' 0 C--O 1.246 0.906 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 -179.513 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.441 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 15.6 p -101.54 165.8 13.41 Favored Pre-proline 0 C--N 1.296 -1.758 0 N-CA-C 113.241 0.83 . . . . 0.0 113.241 -179.527 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . 0.415 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 36.3 Cg_endo -64.08 158.4 48.13 Favored 'Trans proline' 0 C--N 1.361 1.235 0 C-N-CA 122.784 2.323 . . . . 0.0 111.772 173.083 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.575 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 4.6 tmm_? -72.33 119.38 16.44 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 114.679 -1.146 . . . . 0.0 109.574 -177.843 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 86.0 t -131.77 120.19 44.05 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.723 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.452 HG23 HH11 ' A' ' 92' ' ' ARG . 84.2 t -108.99 126.09 66.04 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.637 179.669 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.569 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 5.5 m-85 -76.65 105.15 7.54 Favored 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 123.816 0.847 . . . . 0.0 109.971 177.563 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 34.2 m-80 -96.34 57.63 1.7 Allowed 'General case' 0 C--N 1.287 -2.144 0 CA-C-O 122.462 1.125 . . . . 0.0 108.783 178.081 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 33.0 m -124.3 174.29 7.82 Favored 'General case' 0 N--CA 1.418 -2.073 0 CA-C-N 113.775 -1.557 . . . . 0.0 109.27 -176.449 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 7.0 ptp180 -127.93 12.33 6.7 Favored 'General case' 0 C--N 1.317 -0.835 0 N-CA-C 112.142 0.423 . . . . 0.0 112.142 -176.727 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.1 t -160.51 -171.77 3.28 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 -177.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . 0.464 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 3.7 p30 -67.79 132.15 46.88 Favored 'General case' 0 CA--C 1.504 -0.826 0 CA-C-O 121.076 0.465 . . . . 0.0 109.853 178.661 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 12.5 mmtm -139.75 146.75 48.72 Favored Pre-proline 0 C--N 1.291 -1.945 0 C-N-CA 124.553 1.141 . . . . 0.0 109.034 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -61.61 147.0 96.41 Favored 'Trans proline' 0 C--O 1.25 1.089 0 C-N-CA 123.321 2.681 . . . . 0.0 113.412 -175.113 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . 0.569 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 8.6 t90 -92.61 105.61 15.23 Favored Pre-proline 0 C--N 1.31 -1.124 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -74.76 89.11 1.15 Allowed 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 121.983 1.789 . . . . 0.0 112.584 -174.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 90.7 t -139.02 143.68 31.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 N-CA-C 107.313 -1.365 . . . . 0.0 107.313 176.32 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.604 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -149.9 136.38 19.09 Favored 'General case' 0 N--CA 1.412 -2.371 0 CA-C-O 120.831 0.348 . . . . 0.0 110.48 178.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.453 ' HB3' ' CD2' ' A' ' 109' ' ' LEU . 18.4 mt -103.21 100.09 9.98 Favored 'General case' 0 C--N 1.289 -2.06 0 N-CA-C 108.63 -0.878 . . . . 0.0 108.63 179.283 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.438 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 55.8 m-85 -80.39 76.48 7.2 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 109.813 -0.44 . . . . 0.0 109.813 178.053 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.673 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.1 mm? -102.93 122.6 44.92 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 177.054 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -125.09 147.01 55.65 Favored Pre-proline 0 N--CA 1.41 -2.465 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.154 -173.678 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.478 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 30.7 Cg_endo -61.8 117.82 4.67 Favored 'Trans proline' 0 C--O 1.245 0.864 0 C-N-CA 123.167 2.578 . . . . 0.0 111.768 -177.514 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.459 HG22 ' O ' ' A' ' 70' ' ' ASN . 2.6 m -65.3 -116.28 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.192 -1.934 0 CA-C-N 114.365 -1.289 . . . . 0.0 113.546 177.501 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 17.8 m -111.9 -41.74 3.94 Favored 'General case' 0 C--N 1.287 -2.115 0 O-C-N 121.464 -0.772 . . . . 0.0 110.624 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 5.8 t -93.14 28.27 2.21 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.911 0.862 . . . . 0.0 110.589 -173.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -89.62 135.04 33.84 Favored 'General case' 0 N--CA 1.432 -1.355 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 178.442 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -172.03 143.57 7.55 Favored Glycine 0 N--CA 1.432 -1.632 0 C-N-CA 120.083 -1.056 . . . . 0.0 111.294 179.497 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . 0.407 ' HA2' ' CG1' ' A' ' 155' ' ' VAL . . . 57.24 -147.06 35.65 Favored Glycine 0 CA--C 1.497 -1.091 0 CA-C-O 119.177 -0.791 . . . . 0.0 112.87 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.403 HG11 ' HE3' ' A' ' 121' ' ' LYS . 97.5 t -56.77 99.85 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 CA-C-O 121.937 0.875 . . . . 0.0 110.867 -179.069 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -100.25 -35.34 9.66 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.966 -178.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.547 ' HB ' HG22 ' A' ' 154' ' ' VAL . 69.8 mt -121.72 137.39 55.51 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 178.48 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.423 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.9 mmpt? -111.07 136.46 50.06 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 122.991 0.516 . . . . 0.0 111.212 178.462 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.63 134.51 46.41 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.263 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 86.29 -4.49 85.99 Favored Glycine 0 N--CA 1.442 -0.904 0 N-CA-C 111.709 -0.556 . . . . 0.0 111.709 -179.171 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 37.5 m -96.06 151.01 19.85 Favored 'General case' 0 N--CA 1.427 -1.578 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 -178.17 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.454 HD11 HG23 ' A' ' 128' ' ' VAL . 3.3 tm? -77.75 121.3 23.86 Favored 'General case' 0 N--CA 1.427 -1.594 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 -177.533 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.755 ' HB ' HG21 ' A' ' 67' ' ' VAL . 36.7 pt -108.12 -27.18 3.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 CA-C-N 116.157 -0.474 . . . . 0.0 112.139 -178.024 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . 0.403 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.75 167.41 25.03 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 110.243 -0.28 . . . . 0.0 110.243 -178.315 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.454 HG23 HD11 ' A' ' 125' ' ' LEU . 64.8 t -142.16 113.61 3.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 179.88 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 63.5 mt -114.64 139.55 49.55 Favored 'General case' 0 C--N 1.289 -2.053 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 178.662 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.502 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.3 mp -119.13 124.0 72.36 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 119.326 -0.95 . . . . 0.0 110.105 178.435 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.525 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.1 OUTLIER -99.19 131.84 44.94 Favored 'General case' 0 C--N 1.278 -2.52 0 C-N-CA 124.236 1.015 . . . . 0.0 111.033 -176.869 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.475 ' HG2' ' HB2' ' A' ' 59' ' ' GLN . 12.5 mmm180 -95.56 125.13 39.94 Favored 'General case' 0 C--N 1.295 -1.802 0 C-N-CA 124.108 0.963 . . . . 0.0 109.481 179.454 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.564 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 0.0 OUTLIER -107.18 113.12 26.35 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 177.52 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.478 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 26.2 m -136.25 141.85 43.95 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.478 ' CB ' HG23 ' A' ' 52' ' ' ILE . 8.9 p30 -141.86 168.39 19.87 Favored 'General case' 0 C--N 1.312 -1.063 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.469 175.475 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.406 HD22 HG22 ' A' ' 53' ' ' THR . 5.5 p30 -75.82 -14.93 60.3 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 114.678 -1.146 . . . . 0.0 112.627 -170.747 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 73.1 t80 -107.78 -62.07 1.49 Allowed 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 122.863 0.465 . . . . 0.0 111.41 -174.171 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . 0.427 ' HB3' ' H ' ' A' ' 140' ' ' ASP . 14.9 m120 -77.43 144.62 37.7 Favored 'General case' 0 CA--C 1.485 -1.534 0 CA-C-O 121.325 0.583 . . . . 0.0 110.172 178.516 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 25.5 m -91.65 11.2 25.15 Favored 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 114.516 -1.22 . . . . 0.0 107.998 172.836 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . 0.427 ' H ' ' HB3' ' A' ' 138' ' ' ASN . 12.2 m-20 -74.09 70.4 1.56 Allowed 'General case' 0 CA--C 1.512 -0.501 0 C-N-CA 125.382 1.473 . . . . 0.0 109.554 177.22 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 15.3 t70 -93.28 92.06 7.53 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-N 113.764 -1.562 . . . . 0.0 109.288 -176.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -127.24 164.4 21.79 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.957 -176.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -127.01 146.41 50.36 Favored 'General case' 0 N--CA 1.424 -1.757 0 CA-C-O 121.324 0.583 . . . . 0.0 110.891 178.618 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.465 ' HB2' HD22 ' A' ' 131' ' ' LEU . 11.9 m-30 -113.24 135.82 53.41 Favored 'General case' 0 C--N 1.301 -1.5 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 -176.736 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 49.3 t -92.44 130.69 41.16 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 C-N-CA 122.802 0.441 . . . . 0.0 109.837 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . 0.525 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 61.8 m95 -119.38 101.08 7.71 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.804 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 48.7 m-80 -79.79 114.65 18.87 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 177.757 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.419 HG22 HD11 ' A' ' 126' ' ' ILE . 26.1 mm -88.05 120.24 36.75 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.947 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 -178.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -116.09 150.3 37.56 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.507 179.022 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.8 131.23 35.2 Favored 'General case' 0 N--CA 1.406 -2.636 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 176.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -88.93 -16.49 31.7 Favored 'General case' 0 C--N 1.288 -2.081 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 -178.027 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.4 t30 -147.29 141.14 25.79 Favored 'General case' 0 N--CA 1.434 -1.249 0 CA-C-N 114.224 -1.353 . . . . 0.0 110.32 -173.423 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -80.84 139.47 35.95 Favored 'General case' 0 C--N 1.311 -1.088 0 O-C-N 124.3 1.0 . . . . 0.0 109.348 178.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.547 HG22 ' HB ' ' A' ' 120' ' ' ILE . 2.2 m -120.91 153.29 24.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 120.715 -0.394 . . . . 0.0 110.713 -177.713 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . 0.407 ' CG1' ' HA2' ' A' ' 117' ' ' GLY . 2.9 t -124.21 142.47 40.88 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.032 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 -178.769 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.464 HG13 ' O ' ' A' ' 28' ' ' VAL . 70.4 t -103.95 102.59 32.51 Favored Pre-proline 0 C--N 1.291 -1.952 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 177.475 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.491 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 20.6 Cg_endo -66.22 -26.92 49.0 Favored 'Trans proline' 0 C--O 1.212 -0.809 0 C-N-CA 122.426 2.084 . . . . 0.0 111.924 177.665 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.431 ' HB ' HG12 ' A' ' 156' ' ' VAL . 6.6 t . . . . . 0 C--O 1.252 1.23 0 C-N-CA 124.425 1.09 . . . . 0.0 113.229 176.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 12.5 t80 . . . . . 0 CA--C 1.498 -1.054 0 N-CA-C 105.605 -1.998 . . . . 0.0 105.605 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.436 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -146.29 -176.63 5.24 Favored 'General case' 0 C--N 1.296 -1.746 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 -179.489 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.495 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 16.4 t -154.83 157.29 37.68 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.772 -0.771 . . . . 0.0 109.436 -176.331 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.648 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.37 161.91 37.79 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-O 121.131 0.491 . . . . 0.0 110.856 -175.195 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 50.5 p -101.56 172.46 6.95 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-O 121.949 0.881 . . . . 0.0 110.426 178.139 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -75.58 -10.15 59.19 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 113.591 -1.64 . . . . 0.0 111.607 -178.123 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 6.2 p30 -87.14 -33.24 19.49 Favored 'General case' 0 N--CA 1.446 -0.636 0 C-N-CA 119.301 -0.96 . . . . 0.0 108.562 176.281 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.55 3.82 3.66 Favored Glycine 0 N--CA 1.441 -1.019 0 C-N-CA 120.139 -1.029 . . . . 0.0 112.702 178.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 22.9 m -78.48 99.44 6.45 Favored 'General case' 0 N--CA 1.433 -1.306 0 CA-C-N 117.129 0.465 . . . . 0.0 109.886 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -93.47 119.46 32.59 Favored 'General case' 0 N--CA 1.424 -1.764 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 176.347 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.436 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 72.4 mt -85.63 124.84 70.7 Favored Pre-proline 0 C--N 1.285 -2.238 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_endo -77.8 167.0 24.55 Favored 'Trans proline' 0 N--CA 1.448 -1.169 0 C-N-CA 122.673 2.249 . . . . 0.0 110.623 178.226 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 55.3 mt -73.29 125.8 32.88 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 -178.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 138.34 7.48 1.26 Allowed Glycine 0 C--N 1.308 -1.013 0 C-N-CA 120.564 -0.826 . . . . 0.0 112.888 -179.026 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 89.12 142.89 9.17 Favored Glycine 0 N--CA 1.448 -0.531 0 N-CA-C 111.371 -0.692 . . . . 0.0 111.371 -177.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -179.67 -168.37 38.39 Favored Glycine 0 CA--C 1.49 -1.487 0 C-N-CA 120.031 -1.081 . . . . 0.0 111.42 -179.032 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.475 ' HB3' ' HB ' ' A' ' 145' ' ' VAL . 20.4 p -149.6 147.02 27.63 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -179.611 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -136.23 162.83 31.87 Favored 'General case' 0 N--CA 1.42 -1.964 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 179.589 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 26.8 m-80 -114.74 112.32 22.64 Favored 'General case' 0 C--N 1.29 -2.0 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 178.11 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.406 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.8 m -96.04 148.63 5.15 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.231 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 -179.33 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 32.5 m-85 -130.73 130.47 43.84 Favored 'General case' 0 CA--C 1.492 -1.285 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 -179.11 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.616 ' HB ' ' HG2' ' A' ' 41' ' ' GLN . 2.9 p -133.55 132.13 57.37 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.925 0 O-C-N 124.098 0.874 . . . . 0.0 110.572 -176.148 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -92.12 128.37 37.94 Favored 'General case' 0 C--N 1.286 -2.157 0 CA-C-O 121.629 0.728 . . . . 0.0 109.8 177.48 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -106.89 161.32 14.81 Favored 'General case' 0 C--N 1.28 -2.419 0 CA-C-N 114.341 -1.299 . . . . 0.0 108.036 179.634 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -60.52 121.61 61.76 Favored Pre-proline 0 C--N 1.304 -1.391 0 O-C-N 124.144 0.903 . . . . 0.0 108.779 176.069 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.523 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 64.5 Cg_endo -74.26 -1.16 10.58 Favored 'Trans proline' 0 CA--C 1.531 0.355 0 C-N-CA 122.851 2.368 . . . . 0.0 113.431 -176.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.485 HG13 ' HG3' ' A' ' 157' ' ' PRO . 94.9 t -125.92 110.56 24.26 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 176.609 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.525 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.1 t -142.14 106.25 1.43 Allowed 'Isoleucine or valine' 0 C--O 1.182 -2.479 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 -176.551 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.574 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -95.7 150.58 20.22 Favored 'General case' 0 C--N 1.268 -2.972 0 C-N-CA 122.888 0.475 . . . . 0.0 111.617 -179.745 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.567 HG22 ' O ' ' A' ' 112' ' ' VAL . 75.7 t -46.1 118.79 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 C-N-CA 123.472 0.709 . . . . 0.0 111.38 176.649 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 105.01 -3.99 41.43 Favored Glycine 0 C--N 1.318 -0.468 0 CA-C-N 115.672 -0.695 . . . . 0.0 112.642 -179.659 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.574 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.6 OUTLIER -68.81 -178.0 1.11 Allowed 'General case' 0 CA--C 1.499 -1.013 0 C-N-CA 124.555 1.142 . . . . 0.0 111.544 178.286 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.6 t-20 -127.39 87.53 2.65 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 174.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.546 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 14.9 tp -96.63 133.95 40.49 Favored 'General case' 0 N--CA 1.405 -2.688 0 C-N-CA 118.852 -1.139 . . . . 0.0 108.029 177.419 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.453 ' CG2' ' HB1' ' A' ' 106' ' ' ALA . 2.0 p -141.19 129.72 23.52 Favored 'Isoleucine or valine' 1 N--CA 1.377 -4.107 0 CA-C-O 122.022 0.915 . . . . 0.0 111.183 -179.666 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.585 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 44.8 t -90.12 89.1 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.385 -3.713 0 CA-C-N 113.081 -1.872 . . . . 0.0 107.159 -178.728 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -75.87 133.31 40.61 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 176.566 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.402 ' HA ' ' OE1' ' A' ' 41' ' ' GLN . 86.9 mt -115.14 11.43 16.34 Favored 'General case' 0 C--N 1.295 -1.779 0 O-C-N 123.838 0.711 . . . . 0.0 111.26 179.225 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.682 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 1.5 m -87.0 1.69 51.98 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 -174.698 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.2 m -120.47 0.68 10.57 Favored 'General case' 0 N--CA 1.394 -3.232 0 CA-C-O 122.168 0.985 . . . . 0.0 108.779 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.616 ' HG2' ' HB ' ' A' ' 22' ' ' VAL . 22.1 mp0 -120.78 -34.22 3.61 Favored 'General case' 0 CA--C 1.473 -1.986 0 CA-C-N 115.083 -0.962 . . . . 0.0 111.285 -172.282 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 23.1 mt -119.56 137.11 54.53 Favored 'Isoleucine or valine' 0 C--N 1.267 -2.981 0 CA-C-N 114.903 -1.044 . . . . 0.0 108.988 -177.45 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.648 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 42.4 m-85 -142.07 124.45 15.67 Favored 'General case' 0 CA--C 1.511 -0.553 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -176.469 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.495 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 81.9 m -106.57 140.17 39.87 Favored 'General case' 0 C--N 1.287 -2.142 0 CA-C-O 121.107 0.48 . . . . 0.0 110.618 -177.882 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.461 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 5.1 p80 -124.28 132.85 53.59 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 122.356 1.074 . . . . 0.0 113.433 -174.565 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.46 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 14.8 p-10 -93.15 93.6 8.36 Favored 'General case' 0 C--N 1.279 -2.464 0 CA-C-N 114.299 -1.319 . . . . 0.0 109.46 177.51 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 20.4 p-10 -78.3 -21.04 50.28 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 114.773 -1.103 . . . . 0.0 111.288 -176.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 72.2 m-85 -136.51 70.72 59.96 Favored Pre-proline 0 C--N 1.313 -0.987 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 176.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.46 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 56.0 Cg_endo -70.14 -10.98 29.5 Favored 'Trans proline' 0 N--CA 1.483 0.874 0 C-N-CA 122.698 2.266 . . . . 0.0 112.52 -176.205 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -107.32 -17.44 14.14 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-O 121.402 0.62 . . . . 0.0 110.035 -176.102 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.567 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -101.8 -30.71 11.13 Favored 'General case' 0 N--CA 1.414 -2.259 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 -175.818 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.699 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.9 mp -129.05 139.69 51.22 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.007 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.416 ' HB ' ' ND2' ' A' ' 136' ' ' ASN . 13.3 t -80.33 147.45 31.09 Favored 'General case' 0 C--O 1.252 1.204 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 178.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -80.73 107.68 13.75 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 -173.295 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.421 ' HE1' ' HG3' ' A' ' 92' ' ' ARG . 75.1 t80 -150.84 145.7 25.86 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.319 -175.31 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.423 HG23 HD13 ' A' ' 131' ' ' LEU . 11.4 p -153.92 152.28 10.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 174.572 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -151.36 138.02 18.79 Favored 'General case' 0 C--O 1.207 -1.149 0 CA-C-O 119.102 -0.475 . . . . 0.0 110.263 174.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.53 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 50.4 tp -76.17 113.14 13.38 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 174.016 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.4 tp-100 -59.52 -51.53 69.47 Favored 'General case' 0 C--N 1.316 -0.878 0 C-N-CA 125.549 1.539 . . . . 0.0 111.102 -179.327 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -172.81 157.11 3.61 Favored 'General case' 0 N--CA 1.43 -1.457 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 -177.832 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -131.84 146.71 18.26 Favored Glycine 0 N--CA 1.41 -3.036 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 -178.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 69.9 m -130.16 148.89 52.05 Favored 'General case' 0 C--N 1.286 -2.177 0 O-C-N 124.52 0.776 . . . . 0.0 109.666 -178.046 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.512 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -113.53 157.77 21.6 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.512 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 97.5 m-85 -155.18 179.25 9.33 Favored 'General case' 0 C--N 1.345 0.396 0 C-N-CA 124.497 1.119 . . . . 0.0 109.59 -177.376 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 55.13 -145.42 30.47 Favored Glycine 0 C--N 1.331 0.299 0 O-C-N 123.975 0.797 . . . . 0.0 113.475 176.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -71.63 -13.03 74.51 Favored Glycine 0 C--O 1.205 -1.704 0 C-N-CA 120.957 -0.639 . . . . 0.0 111.692 178.263 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.826 HG21 ' HB ' ' A' ' 126' ' ' ILE . 98.6 t -67.21 -42.7 88.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 C-N-CA 123.359 0.663 . . . . 0.0 111.528 -178.234 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.512 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -84.81 -15.13 45.91 Favored 'General case' 0 C--N 1.308 -1.235 0 C-N-CA 119.112 -1.035 . . . . 0.0 112.055 179.531 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 36.5 t -100.31 -59.98 1.61 Allowed 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 115.551 -0.75 . . . . 0.0 111.851 -174.634 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.537 ' O ' HG22 ' A' ' 112' ' ' VAL . 46.9 m-20 -92.13 -23.95 19.26 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.076 -171.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.685 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 88.6 m-85 -106.9 154.83 20.47 Favored 'General case' 0 N--CA 1.42 -1.933 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.399 179.505 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.3 t -162.09 136.49 6.78 Favored 'General case' 0 N--CA 1.407 -2.594 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 177.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.546 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -168.69 -103.43 0.17 Allowed Glycine 0 C--N 1.275 -2.843 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 175.003 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.424 HG22 ' HA ' ' A' ' 83' ' ' PRO . 0.7 OUTLIER -168.22 179.97 4.29 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 124.688 1.195 . . . . 0.0 109.264 -176.337 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.42 ' HB ' ' HB2' ' A' ' 84' ' ' PHE . 2.9 p -129.5 148.23 33.27 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.224 0 N-CA-C 109.684 -0.488 . . . . 0.0 109.684 178.643 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.555 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.2 tttt -127.19 144.26 51.08 Favored 'General case' 0 N--CA 1.427 -1.621 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.214 -179.189 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.519 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 58.6 t80 -140.89 104.72 4.74 Favored 'General case' 0 C--N 1.313 -1.01 0 CA-C-N 115.27 -0.877 . . . . 0.0 108.86 -179.106 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 15.5 t 48.58 48.18 19.88 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 124.39 1.076 . . . . 0.0 111.834 177.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.59 5.36 69.21 Favored Glycine 0 N--CA 1.441 -0.991 0 CA-C-N 115.497 -0.774 . . . . 0.0 114.219 178.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.555 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 17.8 t -80.08 178.93 7.9 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 177.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 24.3 p -155.89 108.77 2.67 Favored 'General case' 0 C--N 1.293 -1.879 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 179.439 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.519 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.8 p90 -155.38 158.67 31.98 Favored Pre-proline 0 C--N 1.314 -0.947 0 O-C-N 122.195 -0.316 . . . . 0.0 110.258 -174.223 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.424 ' HA ' HG22 ' A' ' 74' ' ' THR . 43.4 Cg_endo -67.25 147.71 79.02 Favored 'Trans proline' 0 C--N 1.364 1.343 0 C-N-CA 123.28 2.654 . . . . 0.0 113.362 -177.848 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.63 ' CD2' HD21 ' A' ' 109' ' ' LEU . 63.6 t80 -123.13 135.27 25.75 Favored Pre-proline 0 N--CA 1.435 -1.201 0 CA-C-N 115.615 -0.72 . . . . 0.0 109.817 -179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.498 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 73.9 Cg_endo -72.59 145.22 83.1 Favored 'Cis proline' 0 CA--C 1.541 0.832 0 C-N-CA 123.144 -1.607 . . . . 0.0 110.411 -3.692 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.1 t -69.81 -177.02 1.18 Allowed 'General case' 0 CA--C 1.553 1.085 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.453 -176.12 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 39.4 p -122.61 -34.97 3.15 Favored 'General case' 0 N--CA 1.439 -0.994 0 CA-C-O 121.431 0.634 . . . . 0.0 110.354 -170.072 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.0 t -126.83 -131.46 0.24 Allowed 'General case' 0 N--CA 1.389 -3.492 0 N-CA-C 104.416 -2.438 . . . . 0.0 104.416 174.798 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -113.64 -169.86 1.59 Allowed 'General case' 0 C--N 1.286 -2.169 0 N-CA-C 113.05 0.759 . . . . 0.0 113.05 -173.19 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.53 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 35.0 p -97.49 170.52 7.09 Favored Pre-proline 0 C--N 1.31 -1.114 0 CA-C-N 115.439 -0.8 . . . . 0.0 111.843 178.601 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . 0.452 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 37.2 Cg_endo -65.4 166.39 19.59 Favored 'Trans proline' 0 C--O 1.251 1.148 0 C-N-CA 122.277 1.985 . . . . 0.0 109.707 170.044 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.421 ' HG3' ' HE1' ' A' ' 55' ' ' TYR . 47.7 ttp180 -73.32 140.12 46.52 Favored 'General case' 0 C--N 1.308 -1.212 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.768 -179.356 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 56.2 t -141.07 120.61 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.898 0 CA-C-N 114.925 -1.034 . . . . 0.0 109.314 179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 70.8 t -95.39 140.51 16.79 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.896 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 175.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -87.85 100.75 13.11 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 175.412 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 17.4 m120 -89.11 60.27 5.31 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.649 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.6 m -135.3 178.3 7.14 Favored 'General case' 0 N--CA 1.425 -1.716 0 CA-C-N 114.44 -1.254 . . . . 0.0 109.076 -174.385 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 16.9 ptp180 -148.81 45.01 1.01 Allowed 'General case' 0 C--N 1.306 -1.295 0 CA-C-O 122.007 0.908 . . . . 0.0 109.462 175.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 10.3 t -170.58 -175.36 1.84 Allowed 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 107.245 -1.391 . . . . 0.0 107.245 -176.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . 0.461 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 9.2 p-10 -77.06 99.0 5.18 Favored 'General case' 0 N--CA 1.446 -0.664 0 CA-C-O 122.153 0.977 . . . . 0.0 108.398 172.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . 0.404 ' HG3' ' HD2' ' A' ' 102' ' ' PRO . 2.8 tptm -101.04 136.17 19.79 Favored Pre-proline 0 N--CA 1.405 -2.724 0 CA-C-N 114.939 -1.028 . . . . 0.0 108.233 -177.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.682 ' HB3' ' O ' ' A' ' 39' ' ' SER . 80.0 Cg_exo -48.43 139.66 22.31 Favored 'Trans proline' 0 C--N 1.324 -0.752 0 C-N-CA 123.939 3.093 . . . . 0.0 113.658 177.383 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.5 t90 -90.11 105.69 12.17 Favored Pre-proline 0 C--N 1.31 -1.146 0 N-CA-C 106.754 -1.573 . . . . 0.0 106.754 -178.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -73.78 89.27 1.0 Allowed 'Trans proline' 0 N--CA 1.455 -0.738 0 C-N-CA 122.293 1.995 . . . . 0.0 112.686 -173.464 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.48 HG22 ' CD2' ' A' ' 77' ' ' TYR . 90.1 t -136.31 145.2 31.09 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 177.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.585 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.96 133.08 15.28 Favored 'General case' 0 N--CA 1.417 -2.078 0 CA-C-O 121.06 0.457 . . . . 0.0 110.766 178.071 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.475 HD21 HD11 ' A' ' 129' ' ' LEU . 14.2 mt -101.93 100.12 10.39 Favored 'General case' 0 C--N 1.288 -2.086 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 179.03 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.546 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 63.1 m-85 -77.38 78.24 3.91 Favored 'General case' 0 C--N 1.306 -1.298 0 O-C-N 122.067 -0.395 . . . . 0.0 110.255 177.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.685 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.0 mm? -104.56 118.24 36.11 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-O 121.167 0.508 . . . . 0.0 110.066 176.732 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.79 145.93 46.75 Favored Pre-proline 0 N--CA 1.414 -2.238 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.889 -173.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -63.43 121.61 9.47 Favored 'Trans proline' 0 CA--C 1.5 -1.195 0 C-N-CA 122.986 2.457 . . . . 0.0 113.57 -175.23 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.567 ' O ' HG22 ' A' ' 30' ' ' VAL . 19.8 m -82.0 -155.27 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.399 -3.0 0 CA-C-N 114.758 -1.11 . . . . 0.0 109.108 171.498 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 8.5 m -79.73 -29.92 40.73 Favored 'General case' 0 C--N 1.257 -3.447 0 CA-C-O 121.515 0.674 . . . . 0.0 110.721 -167.799 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 5.3 t -91.47 25.5 2.6 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-O 121.664 0.745 . . . . 0.0 110.514 -176.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.419 ' HB1' HG21 ' A' ' 156' ' ' VAL . . . -102.83 128.74 49.47 Favored 'General case' 0 N--CA 1.418 -2.061 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -169.99 128.88 1.72 Allowed Glycine 0 C--N 1.307 -1.048 0 C-N-CA 120.151 -1.023 . . . . 0.0 111.765 -178.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.24 -152.71 52.81 Favored Glycine 0 CA--C 1.493 -1.343 0 CA-C-O 118.925 -0.931 . . . . 0.0 111.532 -176.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 63.4 t -55.85 106.04 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.246 0.914 0 CA-C-O 121.586 0.708 . . . . 0.0 110.79 -177.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -106.27 -33.07 7.91 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 114.535 -1.211 . . . . 0.0 110.622 -178.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.499 ' HB ' HG22 ' A' ' 154' ' ' VAL . 74.8 mt -121.54 139.91 47.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 177.526 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.421 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.8 mmpt? -115.47 136.41 53.11 Favored 'General case' 0 C--N 1.311 -1.083 0 C-N-CA 123.138 0.575 . . . . 0.0 110.973 178.547 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -72.13 131.11 42.37 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.709 178.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 92.29 -5.3 77.93 Favored Glycine 0 C--N 1.309 -0.953 0 N-CA-C 111.561 -0.616 . . . . 0.0 111.561 -178.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 61.3 m -98.4 149.04 23.08 Favored 'General case' 0 N--CA 1.425 -1.719 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 179.556 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 26.6 tp -72.69 138.19 46.45 Favored 'General case' 0 N--CA 1.433 -1.31 0 CA-C-N 115.244 -0.889 . . . . 0.0 109.14 178.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.826 ' HB ' HG21 ' A' ' 67' ' ' VAL . 34.4 pt -121.27 -27.08 2.02 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 N-CA-C 112.392 0.516 . . . . 0.0 112.392 178.708 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -162.93 168.79 20.68 Favored 'General case' 0 CA--C 1.501 -0.921 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -177.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 75.1 t -143.55 116.18 3.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 179.176 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.475 HD11 HD21 ' A' ' 107' ' ' LEU . 63.4 mt -117.37 154.46 31.27 Favored 'General case' 0 C--N 1.283 -2.297 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 179.173 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.494 ' O ' HD12 ' A' ' 58' ' ' LEU . 5.0 mp -135.73 127.69 45.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.821 -0.549 . . . . 0.0 109.704 177.623 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.454 ' C ' HD12 ' A' ' 131' ' ' LEU . 1.2 pp -89.34 150.18 22.69 Favored 'General case' 0 CA--C 1.484 -1.592 0 N-CA-C 106.673 -1.602 . . . . 0.0 106.673 173.693 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 54.5 ttp180 -115.71 120.93 40.95 Favored 'General case' 0 C--N 1.269 -2.917 0 N-CA-C 107.823 -1.177 . . . . 0.0 107.823 176.862 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.685 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 21.9 tp60 -93.96 121.22 35.2 Favored 'General case' 0 N--CA 1.422 -1.83 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 -175.076 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 27.7 m -133.47 149.78 51.74 Favored 'General case' 0 C--N 1.292 -1.92 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 174.6 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.699 ' CB ' HG23 ' A' ' 52' ' ' ILE . 8.0 p30 -149.09 166.87 27.45 Favored 'General case' 0 C--O 1.213 -0.866 0 C-N-CA 119.635 -0.826 . . . . 0.0 111.59 175.723 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.416 ' ND2' ' HB ' ' A' ' 53' ' ' THR . 7.0 p30 -82.14 -17.22 47.15 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 114.21 -1.359 . . . . 0.0 112.714 -170.797 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 44.5 t80 -99.58 -65.66 0.95 Allowed 'General case' 0 C--N 1.295 -1.779 0 CA-C-O 121.173 0.511 . . . . 0.0 110.459 -173.424 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 95.0 m-20 -97.1 155.98 16.58 Favored 'General case' 0 C--N 1.287 -2.144 0 N-CA-C 108.615 -0.884 . . . . 0.0 108.615 177.796 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 10.9 p -91.39 45.75 1.26 Allowed 'General case' 0 C--N 1.277 -2.555 0 CA-C-N 115.549 -0.751 . . . . 0.0 109.054 176.849 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 63.0 m-20 -78.51 51.65 1.08 Allowed 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.664 -178.026 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . 0.685 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 2.8 m-20 -76.26 71.73 2.99 Favored 'General case' 0 CA--C 1.505 -0.777 0 CA-C-O 121.058 0.456 . . . . 0.0 110.124 177.746 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -105.41 165.02 11.42 Favored 'General case' 0 N--CA 1.421 -1.888 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.058 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -131.37 144.23 51.07 Favored 'General case' 0 N--CA 1.407 -2.6 0 C-N-CA 118.416 -1.314 . . . . 0.0 110.963 179.249 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 11.0 m-30 -110.7 125.92 53.99 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 108.304 -0.999 . . . . 0.0 108.304 -176.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.475 ' HB ' ' HB3' ' A' ' 17' ' ' SER . 48.7 t -88.22 134.44 28.06 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.645 0 CA-C-O 121.076 0.465 . . . . 0.0 110.196 -178.549 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 65.8 m95 -120.79 94.39 4.34 Favored 'General case' 0 C--N 1.285 -2.239 0 N-CA-C 108.095 -1.076 . . . . 0.0 108.095 -179.209 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -78.72 114.95 18.08 Favored 'General case' 0 C--N 1.286 -2.19 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 178.53 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.406 ' HA ' HG22 ' A' ' 20' ' ' VAL . 18.3 mm -90.18 120.33 38.81 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 -176.548 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -117.52 155.08 30.38 Favored 'General case' 0 CA--C 1.488 -1.405 0 CA-C-O 121.324 0.583 . . . . 0.0 109.919 177.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.54 131.21 35.22 Favored 'General case' 0 N--CA 1.407 -2.606 0 CA-C-N 115.01 -0.995 . . . . 0.0 108.82 176.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 40.3 t-20 -91.32 -13.35 32.75 Favored 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 -177.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -152.01 145.72 25.03 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 114.169 -1.378 . . . . 0.0 109.67 -175.389 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -84.44 144.89 28.47 Favored 'General case' 0 C--N 1.319 -0.739 0 O-C-N 124.317 1.011 . . . . 0.0 109.195 -178.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.523 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 1.5 m -125.21 148.96 29.6 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.9 -179.698 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 9.3 t -124.66 138.32 54.45 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 N-CA-C 107.686 -1.228 . . . . 0.0 107.686 -178.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.525 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 81.5 t -100.04 101.8 15.53 Favored Pre-proline 0 C--N 1.292 -1.892 0 C-N-CA 123.677 0.791 . . . . 0.0 109.982 179.368 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.485 ' HG3' HG13 ' A' ' 27' ' ' VAL . 35.2 Cg_endo -70.12 -23.52 29.07 Favored 'Trans proline' 0 CA--C 1.509 -0.749 0 C-N-CA 122.319 2.013 . . . . 0.0 111.801 178.62 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.1 t . . . . . 0 C--O 1.248 0.99 0 O-C-N 124.716 1.26 . . . . 0.0 112.404 179.359 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.583 ' CZ ' ' HB ' ' A' ' 56' ' ' VAL . 4.0 t80 . . . . . 0 C--O 1.215 -0.714 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -161.49 179.78 7.96 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 102.837 -3.023 . . . . 0.0 102.837 169.004 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.483 ' HB3' ' CZ2' ' A' ' 146' ' ' TRP . 11.5 t -150.5 158.32 44.02 Favored 'General case' 0 C--N 1.283 -2.318 0 C-N-CA 117.232 -1.787 . . . . 0.0 111.081 -174.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.435 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.26 160.88 40.24 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 121.474 0.654 . . . . 0.0 110.713 -175.816 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.583 HG22 HG22 ' A' ' 20' ' ' VAL . 57.2 p -97.68 178.73 5.07 Favored 'General case' 0 C--N 1.293 -1.888 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.648 -179.666 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -82.04 -21.01 37.16 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.712 178.514 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.1 p-10 -87.09 -29.07 22.15 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-N 114.928 -1.033 . . . . 0.0 111.997 -176.224 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 132.16 7.52 2.85 Favored Glycine 0 C--N 1.307 -1.073 0 C-N-CA 119.222 -1.466 . . . . 0.0 114.34 171.308 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.0 m -86.94 101.09 13.09 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 177.216 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -97.06 119.92 36.46 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-N 115.484 -0.78 . . . . 0.0 108.945 176.025 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 50.9 mt -97.7 116.46 65.77 Favored Pre-proline 0 C--N 1.297 -1.7 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.564 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -79.42 176.75 9.31 Favored 'Trans proline' 0 C--O 1.25 1.075 0 C-N-CA 122.653 2.236 . . . . 0.0 110.387 177.331 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 56.7 mt -72.04 125.35 30.52 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.343 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 177.669 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 149.22 -6.45 0.81 Allowed Glycine 0 C--N 1.299 -1.48 0 CA-C-N 115.6 -0.727 . . . . 0.0 112.001 -176.482 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 91.17 156.77 33.06 Favored Glycine 0 N--CA 1.443 -0.896 0 C-N-CA 120.709 -0.758 . . . . 0.0 111.373 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.34 -165.83 34.0 Favored Glycine 0 N--CA 1.419 -2.456 0 C-N-CA 119.818 -1.182 . . . . 0.0 111.604 178.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 145' ' ' VAL . 59.8 p -145.7 155.17 42.81 Favored 'General case' 0 N--CA 1.417 -2.077 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 -177.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.81 155.64 50.03 Favored 'General case' 0 N--CA 1.416 -2.151 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 177.284 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -105.01 109.97 22.18 Favored 'General case' 0 C--N 1.279 -2.459 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 174.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.583 HG22 HG22 ' A' ' 5' ' ' THR . 34.2 t -97.33 135.52 31.33 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.112 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -177.933 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 77.7 m-85 -116.62 126.82 53.8 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -178.547 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.524 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.5 p -135.54 129.45 49.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.619 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.195 -176.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . 0.416 ' HB3' ' HB3' ' A' ' 151' ' ' ASN . 8.0 p30 -94.52 126.02 39.53 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-O 121.683 0.754 . . . . 0.0 110.423 178.197 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -103.44 162.59 12.9 Favored 'General case' 0 C--N 1.286 -2.157 0 CA-C-N 114.278 -1.328 . . . . 0.0 108.019 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . 0.407 ' C ' ' H ' ' A' ' 27' ' ' VAL . . . -54.48 126.07 54.39 Favored Pre-proline 0 CA--C 1.499 -0.998 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 174.722 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.529 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 72.7 Cg_endo -77.44 9.77 2.74 Favored 'Trans proline' 0 N--CA 1.455 -0.761 0 C-N-CA 122.484 2.123 . . . . 0.0 110.925 179.2 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.407 ' H ' ' C ' ' A' ' 25' ' ' ALA . 14.1 p -138.35 115.97 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.916 0 CA-C-N 114.827 -1.079 . . . . 0.0 108.365 -178.316 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.4 t -150.02 120.05 1.06 Allowed 'Isoleucine or valine' 0 C--O 1.191 -1.985 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 -179.006 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.589 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -107.24 147.85 29.67 Favored 'General case' 0 C--N 1.267 -2.999 0 C-N-CA 122.505 0.322 . . . . 0.0 110.76 -179.973 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.532 HG22 ' O ' ' A' ' 112' ' ' VAL . 98.7 t -43.67 117.35 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.741 0 C-N-CA 123.329 0.652 . . . . 0.0 111.539 176.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.56 -1.72 42.57 Favored Glycine 0 C--N 1.319 -0.396 0 CA-C-N 114.779 -1.101 . . . . 0.0 112.809 -179.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.589 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -73.35 -176.69 2.31 Favored 'General case' 0 C--N 1.315 -0.896 0 C-N-CA 124.011 0.924 . . . . 0.0 110.775 177.37 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -129.5 83.35 2.13 Favored 'General case' 0 CA--C 1.49 -1.327 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 178.238 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.562 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 19.1 tp -90.72 133.23 35.31 Favored 'General case' 0 N--CA 1.419 -1.977 0 C-N-CA 119.151 -1.019 . . . . 0.0 108.516 178.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.447 ' CG2' ' HB1' ' A' ' 106' ' ' ALA . 2.2 p -141.44 133.92 29.22 Favored 'Isoleucine or valine' 0 N--CA 1.383 -3.792 0 CA-C-O 121.882 0.848 . . . . 0.0 111.728 -178.572 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.62 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 45.6 t -89.2 89.92 3.26 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.52 0 CA-C-N 113.732 -1.577 . . . . 0.0 108.333 179.793 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 17.8 t70 -76.53 109.72 10.49 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-O 120.876 0.37 . . . . 0.0 110.89 179.531 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 93.0 mt -92.29 -1.54 57.01 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 115.905 -0.588 . . . . 0.0 112.549 -178.698 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 89.9 p -76.81 1.08 18.41 Favored 'General case' 0 N--CA 1.474 0.762 0 CA-C-O 123.0 1.381 . . . . 0.0 109.754 -179.649 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 2.7 p -123.92 6.64 8.66 Favored 'General case' 0 C--N 1.276 -2.628 0 CA-C-N 114.973 -1.012 . . . . 0.0 109.881 179.184 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.524 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 42.4 mm-40 -127.14 -25.14 3.31 Favored 'General case' 0 CA--C 1.517 -0.304 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.604 -175.232 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 23.1 mt -132.64 137.44 54.11 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 -175.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.435 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 40.4 m-85 -140.65 123.41 16.28 Favored 'General case' 0 CA--C 1.502 -0.896 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -176.305 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.454 ' HB3' ' CE1' ' A' ' 1' ' ' PHE . 79.7 m -103.71 142.9 33.54 Favored 'General case' 0 C--N 1.271 -2.82 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 -178.729 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.437 ' HB3' ' HB3' ' A' ' 100' ' ' ASP . 10.1 p80 -136.75 168.06 20.26 Favored 'General case' 0 C--N 1.294 -1.836 0 CA-C-O 121.335 0.588 . . . . 0.0 110.787 -172.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.455 ' HB3' ' OD1' ' A' ' 54' ' ' ASP . 5.4 p30 -112.41 100.0 8.43 Favored 'General case' 0 C--N 1.281 -2.383 0 CA-C-O 122.2 1.0 . . . . 0.0 111.814 175.566 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -76.26 -31.21 58.17 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 107.808 -1.182 . . . . 0.0 107.808 178.192 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.47 ' HB3' ' OG1' ' A' ' 51' ' ' THR . 23.2 m-85 -127.88 87.97 54.4 Favored Pre-proline 0 N--CA 1.435 -1.22 0 N-CA-C 106.004 -1.851 . . . . 0.0 106.004 177.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -88.59 -13.34 3.4 Favored 'Trans proline' 0 N--CA 1.455 -0.79 0 C-N-CA 122.319 2.013 . . . . 0.0 113.976 -176.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -110.92 -12.35 14.25 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.622 -0.831 . . . . 0.0 110.756 -176.116 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.47 ' OG1' ' HB3' ' A' ' 48' ' ' TYR . 0.0 OUTLIER -101.4 -31.36 10.97 Favored 'General case' 0 N--CA 1.417 -2.115 0 CA-C-N 115.406 -0.815 . . . . 0.0 110.194 179.771 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.634 HG23 ' CB ' ' A' ' 135' ' ' ASN . 3.1 mp -121.9 126.54 74.67 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.592 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 179.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.407 HG22 HD22 ' A' ' 136' ' ' ASN . 6.6 t -72.75 135.06 45.25 Favored 'General case' 0 N--CA 1.421 -1.901 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 174.602 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.455 ' OD1' ' HB3' ' A' ' 46' ' ' ASN . 58.7 m-20 -87.06 107.6 18.51 Favored 'General case' 0 C--N 1.278 -2.506 0 CA-C-O 121.939 0.876 . . . . 0.0 111.343 -171.093 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 70.4 t80 -137.91 145.8 42.54 Favored 'General case' 0 C--N 1.29 -1.997 0 CA-C-N 114.078 -1.419 . . . . 0.0 108.058 -175.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.583 ' HB ' ' CZ ' ' A' ' 1' ' ' PHE . 11.9 p -152.25 148.38 14.39 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.786 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.309 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -151.34 140.37 21.09 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 174.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.573 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 50.5 tp -75.19 117.76 17.37 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 173.346 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.514 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 3.6 tp-100 -65.54 -44.92 85.35 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 114.456 -1.247 . . . . 0.0 110.458 -177.851 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.514 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 10.4 ptp180 -176.97 161.87 1.99 Allowed 'General case' 0 N--CA 1.432 -1.34 0 O-C-N 124.708 1.255 . . . . 0.0 108.423 -176.407 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.405 ' H ' HG22 ' A' ' 86' ' ' THR . . . -143.08 129.53 3.8 Favored Glycine 0 N--CA 1.408 -3.174 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -178.302 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 54.2 m -117.35 149.38 40.59 Favored 'General case' 0 C--N 1.291 -1.944 0 C-N-CA 124.099 0.96 . . . . 0.0 110.461 -174.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.522 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -113.37 156.16 23.93 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.497 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 88.4 m-85 -154.6 -179.92 8.44 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 124.155 0.982 . . . . 0.0 108.867 -178.407 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 57.79 -143.56 42.39 Favored Glycine 0 C--N 1.325 -0.081 0 O-C-N 123.891 0.744 . . . . 0.0 113.513 176.13 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -72.97 -14.23 78.78 Favored Glycine 0 C--O 1.209 -1.468 0 C-N-CA 120.846 -0.693 . . . . 0.0 111.717 177.565 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.78 HG21 ' HB ' ' A' ' 126' ' ' ILE . 95.2 t -67.59 -39.37 82.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 123.804 0.842 . . . . 0.0 111.606 -177.717 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.522 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -87.1 -19.03 29.13 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 118.67 -1.212 . . . . 0.0 112.192 178.027 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 6.2 t -98.36 -56.58 2.43 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.537 -172.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.491 ' O ' HG22 ' A' ' 112' ' ' VAL . 41.3 m-20 -92.03 -22.97 19.67 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.24 -173.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.656 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 92.0 m-85 -108.73 156.93 19.03 Favored 'General case' 0 N--CA 1.419 -1.999 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.489 178.598 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 12.7 t -161.38 136.41 7.46 Favored 'General case' 0 N--CA 1.403 -2.787 0 N-CA-C 107.044 -1.465 . . . . 0.0 107.044 176.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.498 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -170.97 -111.67 0.26 Allowed Glycine 0 N--CA 1.398 -3.893 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 174.19 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.2 p -159.66 -179.92 8.3 Favored 'General case' 0 C--N 1.297 -1.684 0 C-N-CA 124.001 0.92 . . . . 0.0 110.425 -172.743 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -132.1 145.9 34.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 N-CA-C 109.646 -0.501 . . . . 0.0 109.646 178.202 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.673 ' HG3' ' O ' ' A' ' 80' ' ' SER . 83.2 tttt -126.58 145.45 50.53 Favored 'General case' 0 N--CA 1.427 -1.585 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 -178.189 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.532 ' CD2' HG22 ' A' ' 105' ' ' VAL . 58.9 t80 -145.63 110.69 5.23 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 -177.691 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 44.9 t 53.27 37.08 24.36 Favored 'General case' 0 CA--C 1.55 0.963 0 C-N-CA 123.35 0.66 . . . . 0.0 111.982 178.04 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.32 8.54 66.2 Favored Glycine 0 CA--C 1.525 0.698 0 C-N-CA 120.301 -0.952 . . . . 0.0 113.663 -179.384 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.673 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 20.8 t -81.59 -179.79 7.52 Favored 'General case' 0 CA--C 1.544 0.735 0 CA-C-N 117.383 0.592 . . . . 0.0 109.51 178.412 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 13.0 p -156.78 109.22 2.51 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.418 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.3 p90 -151.89 158.71 33.84 Favored Pre-proline 0 C--N 1.306 -1.323 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 -175.52 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -68.73 150.94 74.69 Favored 'Trans proline' 0 C--N 1.354 0.817 0 C-N-CA 122.879 2.386 . . . . 0.0 113.096 -176.471 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.592 ' CD2' HD21 ' A' ' 109' ' ' LEU . 54.0 t80 -124.46 132.15 24.26 Favored Pre-proline 0 N--CA 1.442 -0.867 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.219 -179.684 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.468 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 72.4 Cg_endo -72.53 148.2 90.99 Favored 'Cis proline' 0 CA--C 1.535 0.558 0 C-N-CA 122.8 -1.75 . . . . 0.0 109.984 -0.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.405 HG22 ' H ' ' A' ' 61' ' ' GLY . 9.0 t -67.09 -177.49 0.66 Allowed 'General case' 0 C--O 1.248 1.017 0 CA-C-O 121.367 0.603 . . . . 0.0 111.29 -175.499 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.8 p -120.7 -25.13 5.55 Favored 'General case' 0 N--CA 1.431 -1.39 0 CA-C-N 115.286 -0.87 . . . . 0.0 110.647 -173.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 t -135.38 -107.95 0.21 Allowed 'General case' 0 N--CA 1.419 -1.985 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 178.555 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . 0.425 ' HB2' ' O ' ' A' ' 58' ' ' LEU . 0.0 OUTLIER -144.44 -165.66 2.19 Favored 'General case' 0 N--CA 1.445 -0.723 0 CA-C-N 118.251 0.478 . . . . 0.0 110.749 -177.508 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.573 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 58.3 p -100.26 168.16 9.83 Favored Pre-proline 0 C--N 1.306 -1.286 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 179.55 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . 0.407 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 34.4 Cg_endo -63.62 172.26 5.88 Favored 'Trans proline' 0 C--O 1.251 1.139 0 C-N-CA 123.062 2.508 . . . . 0.0 110.48 170.02 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 41.2 ttp180 -71.49 142.32 50.16 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.12 -177.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 64.0 t -151.16 131.57 4.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 C-N-CA 124.355 1.062 . . . . 0.0 108.427 -179.048 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 54' ' ' ASP . 2.2 p -128.93 141.46 46.55 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.985 0 N-CA-C 108.253 -1.018 . . . . 0.0 108.253 -178.729 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 -92.99 108.33 19.92 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-O 121.251 0.548 . . . . 0.0 111.234 -178.745 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 13.7 m120 -94.38 45.97 1.14 Allowed 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.6 t -124.03 -176.57 3.52 Favored 'General case' 0 N--CA 1.437 -1.12 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 -175.77 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 37.8 ptt180 -148.14 33.78 0.82 Allowed 'General case' 0 C--N 1.314 -0.948 0 CA-C-O 121.879 0.847 . . . . 0.0 109.619 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 8.1 t -165.58 -178.97 5.16 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 -178.52 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . 0.437 ' HB3' ' HB3' ' A' ' 45' ' ' HIS . 3.7 p30 -77.12 130.15 36.97 Favored 'General case' 0 CA--C 1.501 -0.928 0 CA-C-O 121.515 0.674 . . . . 0.0 109.956 -179.748 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 15.8 mmtm -129.72 141.35 41.52 Favored Pre-proline 0 C--N 1.287 -2.137 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.08 -179.558 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -61.53 137.58 70.31 Favored 'Trans proline' 0 CA--C 1.499 -1.246 0 C-N-CA 123.571 2.847 . . . . 0.0 112.7 -174.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 11.6 t90 -81.5 108.58 11.22 Favored Pre-proline 0 C--N 1.304 -1.409 0 N-CA-C 106.393 -1.706 . . . . 0.0 106.393 -177.479 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -76.22 87.69 1.41 Allowed 'Trans proline' 0 N--CA 1.447 -1.248 0 C-N-CA 121.231 1.287 . . . . 0.0 112.718 -172.045 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.532 HG22 ' CD2' ' A' ' 77' ' ' TYR . 57.6 t -137.83 146.53 27.18 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.203 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 177.544 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.62 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -151.38 134.73 16.09 Favored 'General case' 0 C--N 1.286 -2.174 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 177.446 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.469 HD21 HD11 ' A' ' 129' ' ' LEU . 16.7 mt -102.87 99.95 9.9 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 108.398 -0.964 . . . . 0.0 108.398 179.443 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.498 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 71.5 m-85 -78.36 81.36 4.71 Favored 'General case' 0 C--N 1.308 -1.22 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 177.513 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.656 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.1 mm? -107.1 118.6 37.13 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 176.366 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -120.99 148.41 48.72 Favored Pre-proline 0 N--CA 1.41 -2.448 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.253 -173.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -66.13 120.96 8.18 Favored 'Trans proline' 0 N--CA 1.44 -1.646 0 C-N-CA 122.892 2.395 . . . . 0.0 113.47 -175.055 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.532 ' O ' HG22 ' A' ' 30' ' ' VAL . 21.7 m -81.03 -157.29 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.393 -3.297 0 CA-C-N 114.49 -1.232 . . . . 0.0 108.814 170.75 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 30.9 m -82.96 -26.47 31.34 Favored 'General case' 0 C--N 1.252 -3.645 0 CA-C-O 121.699 0.761 . . . . 0.0 110.912 -170.127 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 19.6 t -83.36 13.64 4.21 Favored 'General case' 0 N--CA 1.431 -1.424 0 CA-C-N 115.197 -0.911 . . . . 0.0 110.189 -179.633 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -98.3 125.31 43.35 Favored 'General case' 0 N--CA 1.428 -1.557 0 CA-C-N 115.722 -0.672 . . . . 0.0 109.569 179.352 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -168.67 129.74 1.94 Allowed Glycine 0 N--CA 1.431 -1.642 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 178.687 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 67.71 -148.8 49.94 Favored Glycine 0 CA--C 1.493 -1.322 0 CA-C-O 119.232 -0.76 . . . . 0.0 111.883 -177.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.451 ' CG1' ' HE3' ' A' ' 121' ' ' LYS . 65.9 t -60.04 101.66 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.248 0.991 0 CA-C-O 122.078 0.942 . . . . 0.0 111.117 -176.435 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -101.57 -23.11 14.34 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 114.137 -1.392 . . . . 0.0 111.498 -177.709 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.459 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 61.8 mt -136.7 141.21 41.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 N-CA-C 108.088 -1.078 . . . . 0.0 108.088 179.68 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.548 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.6 mmpt? -116.2 141.31 48.31 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 120.843 0.354 . . . . 0.0 110.347 177.006 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.4 ' H ' ' HB3' ' A' ' 153' ' ' ASP . . . -69.06 148.07 50.58 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.725 179.667 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 71.78 14.37 75.49 Favored Glycine 0 C--O 1.218 -0.845 0 CA-C-N 115.828 -0.623 . . . . 0.0 111.555 178.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 20.0 m -119.08 143.4 47.16 Favored 'General case' 0 N--CA 1.421 -1.891 0 N-CA-C 110.0 -0.37 . . . . 0.0 110.0 -175.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -68.6 127.05 31.61 Favored 'General case' 0 C--O 1.242 0.659 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.167 -178.032 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.78 ' HB ' HG21 ' A' ' 67' ' ' VAL . 27.9 pt -115.9 -26.91 2.67 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . 0.411 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -159.92 168.13 26.42 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 109.8 -0.445 . . . . 0.0 109.8 -178.041 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 65.7 t -142.64 114.06 3.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 179.443 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.469 HD11 HD21 ' A' ' 107' ' ' LEU . 56.8 mt -115.43 155.76 26.85 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 107.939 -1.134 . . . . 0.0 107.939 178.3 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.523 ' O ' HD12 ' A' ' 58' ' ' LEU . 5.1 mp -135.68 131.13 50.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 CA-C-N 118.52 0.6 . . . . 0.0 109.751 177.733 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.433 HD13 HG23 ' A' ' 56' ' ' VAL . 1.8 pp -92.58 139.79 30.21 Favored 'General case' 0 CA--C 1.489 -1.399 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 172.624 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 27.1 tpt180 -97.31 108.0 20.64 Favored 'General case' 0 C--N 1.251 -3.714 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 179.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 19.4 tp60 -87.67 118.6 27.27 Favored 'General case' 0 N--CA 1.43 -1.439 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -177.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 22.2 m -137.03 140.52 42.14 Favored 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 173.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.634 ' CB ' HG23 ' A' ' 52' ' ' ILE . 10.8 p30 -146.82 175.54 10.56 Favored 'General case' 0 N--CA 1.444 -0.751 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.899 178.008 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.407 HD22 HG22 ' A' ' 53' ' ' THR . 7.3 p30 -89.21 -13.76 37.51 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.546 -1.206 . . . . 0.0 113.158 -169.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 48.5 t80 -105.42 -57.09 2.08 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-O 120.868 0.366 . . . . 0.0 111.829 -172.277 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . 0.418 ' HB3' ' OD1' ' A' ' 140' ' ' ASP . 18.5 m120 -84.24 145.78 28.14 Favored 'General case' 0 CA--C 1.483 -1.621 0 CA-C-O 121.221 0.534 . . . . 0.0 109.886 178.656 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 9.1 p -97.7 22.01 9.64 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 172.372 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . 0.418 ' OD1' ' HB3' ' A' ' 138' ' ' ASN . 1.8 m-20 -90.3 58.9 4.2 Favored 'General case' 0 N--CA 1.432 -1.336 0 CA-C-N 113.085 -1.871 . . . . 0.0 107.911 -178.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -77.64 73.7 4.2 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 122.269 1.033 . . . . 0.0 110.923 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -93.96 179.99 5.16 Favored 'General case' 0 N--CA 1.425 -1.723 0 N-CA-C 108.143 -1.058 . . . . 0.0 108.143 176.153 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -141.86 149.46 40.3 Favored 'General case' 0 C--N 1.282 -2.366 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 176.918 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 9.7 m-30 -109.26 125.25 52.07 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 -174.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.405 ' O ' ' HA ' ' A' ' 17' ' ' SER . 48.2 t -89.27 135.52 25.75 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.926 0 O-C-N 123.749 0.656 . . . . 0.0 110.074 -178.209 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . 0.483 ' CZ2' ' HB3' ' A' ' 3' ' ' CYS . 61.6 m95 -120.38 96.26 5.07 Favored 'General case' 0 C--N 1.284 -2.246 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 -179.317 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 37.3 m-80 -80.58 112.83 18.31 Favored 'General case' 0 C--N 1.291 -1.946 0 N-CA-C 106.587 -1.634 . . . . 0.0 106.587 179.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.433 HG22 HD11 ' A' ' 126' ' ' ILE . 28.1 mm -87.48 122.83 39.72 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.797 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -176.193 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 61.2 m-85 -117.12 151.9 35.85 Favored 'General case' 0 C--N 1.3 -1.544 0 C-N-CA 123.786 0.834 . . . . 0.0 109.442 178.464 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.68 130.21 34.98 Favored 'General case' 0 N--CA 1.413 -2.318 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 176.064 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . 0.416 ' HB3' ' HB3' ' A' ' 23' ' ' ASN . 39.6 t-20 -89.12 -17.52 29.05 Favored 'General case' 0 C--N 1.288 -2.068 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 -178.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -147.17 143.04 27.93 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-N 114.418 -1.265 . . . . 0.0 109.462 -174.477 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . 0.4 ' HB3' ' H ' ' A' ' 122' ' ' ALA . 12.8 p-10 -86.07 138.66 31.78 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 124.083 0.865 . . . . 0.0 111.477 -178.733 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.529 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.8 t -114.44 137.82 46.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 114.946 -1.025 . . . . 0.0 112.334 -171.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -117.79 138.28 48.99 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.351 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 177.494 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.471 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 53.2 t -101.89 103.66 30.52 Favored Pre-proline 0 C--N 1.29 -1.979 0 C-N-CA 123.618 0.767 . . . . 0.0 109.756 178.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.453 ' HD2' ' O ' ' A' ' 28' ' ' VAL . 30.8 Cg_endo -68.08 -26.11 37.17 Favored 'Trans proline' 0 CA--C 1.506 -0.908 0 C-N-CA 122.429 2.086 . . . . 0.0 111.878 177.295 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.4 t . . . . . 0 C--N 1.349 0.578 0 O-C-N 124.748 1.28 . . . . 0.0 112.33 179.233 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.676 ' CZ ' ' HB3' ' A' ' 133' ' ' GLN . 0.1 OUTLIER . . . . . 0 CA--C 1.495 -1.157 0 N-CA-C 113.802 1.038 . . . . 0.0 113.802 . . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.479 ' HB3' ' NE2' ' A' ' 45' ' ' HIS . . . -148.47 162.49 39.51 Favored 'General case' 0 C--N 1.29 -2.001 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 167.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.418 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 63.1 m -134.39 155.41 50.34 Favored 'General case' 0 C--N 1.288 -2.071 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.786 -174.105 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.5 155.52 43.15 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-O 121.223 0.535 . . . . 0.0 109.917 -176.333 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.602 HG22 HG22 ' A' ' 20' ' ' VAL . 72.9 p -92.25 175.01 7.01 Favored 'General case' 0 C--N 1.292 -1.922 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.77 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -85.61 -11.49 53.81 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.278 -1.328 . . . . 0.0 109.716 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -95.21 -27.35 15.57 Favored 'General case' 0 N--CA 1.43 -1.449 0 CA-C-N 115.138 -0.937 . . . . 0.0 111.751 -178.279 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 136.64 1.04 2.8 Favored Glycine 0 C--O 1.222 -0.621 0 C-N-CA 119.155 -1.498 . . . . 0.0 114.845 169.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 5.2 m -87.86 105.94 17.76 Favored 'General case' 0 C--N 1.295 -1.802 0 CA-C-O 121.455 0.645 . . . . 0.0 109.579 -179.495 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -98.99 119.55 37.97 Favored 'General case' 0 C--N 1.291 -1.953 0 CA-C-N 114.735 -1.12 . . . . 0.0 109.224 176.402 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.435 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 60.0 mt -100.36 114.66 65.79 Favored Pre-proline 0 C--N 1.303 -1.429 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.102 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 76.2 Cg_endo -76.59 171.87 17.26 Favored 'Trans proline' 0 C--O 1.249 1.037 0 C-N-CA 122.385 2.057 . . . . 0.0 111.354 177.262 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.419 HG12 ' O ' ' A' ' 1' ' ' PHE . 68.4 mt -58.06 134.03 22.85 Favored 'Isoleucine or valine' 0 C--O 1.238 0.495 0 CA-C-N 116.245 -0.434 . . . . 0.0 109.967 179.031 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 128.59 2.75 5.74 Favored Glycine 0 C--N 1.303 -1.257 0 C-N-CA 120.344 -0.931 . . . . 0.0 112.466 179.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 82.04 164.89 34.82 Favored Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.13 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 158.74 -166.51 34.44 Favored Glycine 0 C--N 1.295 -1.743 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.701 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 12.1 p -141.24 154.33 45.72 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -178.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -143.37 159.38 42.48 Favored 'General case' 0 N--CA 1.421 -1.88 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 179.36 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 5.8 p30 -103.22 122.87 45.65 Favored 'General case' 0 C--N 1.275 -2.67 0 N-CA-C 106.351 -1.722 . . . . 0.0 106.351 173.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.602 HG22 HG22 ' A' ' 5' ' ' THR . 40.3 t -106.81 129.71 59.95 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.76 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.737 177.826 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 22.6 m-85 -112.88 121.17 43.88 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 120.982 0.42 . . . . 0.0 111.23 -179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.589 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.3 p -133.92 130.24 55.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-N 115.318 -0.856 . . . . 0.0 111.164 -178.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -92.25 130.83 37.85 Favored 'General case' 0 C--N 1.296 -1.758 0 CA-C-O 121.37 0.605 . . . . 0.0 110.429 177.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.683 HD21 HG22 ' A' ' 36' ' ' VAL . 6.9 mp -109.18 161.85 14.83 Favored 'General case' 0 C--N 1.287 -2.118 0 CA-C-N 114.489 -1.232 . . . . 0.0 108.877 179.454 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -58.01 121.1 48.17 Favored Pre-proline 0 C--O 1.209 -1.06 0 O-C-N 124.777 1.298 . . . . 0.0 109.486 179.177 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.511 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 66.1 Cg_endo -75.7 -0.91 10.72 Favored 'Trans proline' 0 CA--C 1.531 0.332 0 C-N-CA 122.906 2.404 . . . . 0.0 113.539 -176.78 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 96.0 t -127.93 109.63 20.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 178.407 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.567 HG21 HD22 ' A' ' 34' ' ' LEU . 5.7 t -145.59 112.43 1.22 Allowed 'Isoleucine or valine' 0 C--O 1.189 -2.116 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 -177.558 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.488 ' H ' ' HG3' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -100.78 152.12 20.88 Favored 'General case' 0 C--N 1.266 -3.064 0 C-N-CA 123.138 0.575 . . . . 0.0 111.004 -179.843 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 41.5 t -43.81 116.51 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 123.727 0.811 . . . . 0.0 111.631 175.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 107.51 -5.52 35.39 Favored Glycine 0 C--O 1.227 -0.296 0 CA-C-N 115.421 -0.808 . . . . 0.0 112.99 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.488 ' HG3' ' H ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -69.34 -177.89 1.24 Allowed 'General case' 0 C--N 1.316 -0.861 0 C-N-CA 123.669 0.788 . . . . 0.0 111.786 177.817 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -126.62 86.19 2.48 Favored 'General case' 0 CA--C 1.482 -1.646 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 176.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.609 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 24.4 tp -95.73 134.98 38.02 Favored 'General case' 0 N--CA 1.41 -2.433 0 C-N-CA 119.202 -0.999 . . . . 0.0 109.453 -179.51 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.421 ' CG2' ' HB1' ' A' ' 106' ' ' ALA . 1.7 p -141.78 137.79 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.38 -3.941 0 CA-C-N 114.729 -1.123 . . . . 0.0 112.07 -177.633 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.683 HG22 HD21 ' A' ' 24' ' ' LEU . 58.4 t -90.48 89.89 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.335 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 176.26 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -76.01 106.57 7.68 Favored 'General case' 0 C--N 1.297 -1.717 0 C-N-CA 120.057 -0.657 . . . . 0.0 109.669 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.8 mt -95.03 -1.16 52.87 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.822 -179.188 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 15.2 m -77.41 0.58 21.98 Favored 'General case' 0 C--N 1.309 -1.163 0 CA-C-O 122.074 0.94 . . . . 0.0 109.478 -177.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 3.2 p -128.46 5.39 5.68 Favored 'General case' 0 N--CA 1.421 -1.901 0 CA-C-N 114.855 -1.066 . . . . 0.0 110.157 178.776 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.589 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 47.1 mm-40 -122.74 -24.21 4.91 Favored 'General case' 0 CA--C 1.503 -0.835 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.73 -174.385 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 19.7 mt -130.47 140.07 49.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 107.738 -1.208 . . . . 0.0 107.738 -176.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -138.13 149.74 46.18 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 -176.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.418 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 70.2 m -125.87 134.08 51.73 Favored 'General case' 0 C--N 1.289 -2.047 0 C-N-CA 122.794 0.437 . . . . 0.0 110.061 176.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.479 ' NE2' ' HB3' ' A' ' 2' ' ' ALA . 11.6 p-80 -119.35 150.79 39.57 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-O 121.998 0.904 . . . . 0.0 110.386 -177.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -99.35 101.99 13.44 Favored 'General case' 0 C--N 1.272 -2.789 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 -179.022 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 18.3 p-10 -86.62 -17.63 33.4 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 111.863 0.32 . . . . 0.0 111.863 -179.247 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 67.3 m-85 -138.47 62.79 31.66 Favored Pre-proline 0 N--CA 1.477 0.91 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 175.184 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -69.8 -3.31 11.79 Favored 'Trans proline' 0 N--CA 1.485 0.971 0 C-N-CA 123.208 2.605 . . . . 0.0 114.454 -171.074 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -115.54 -17.35 11.2 Favored 'General case' 0 C--N 1.299 -1.625 0 CA-C-O 121.286 0.565 . . . . 0.0 110.272 -178.137 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.464 ' HB ' HD12 ' A' ' 52' ' ' ILE . 1.9 m -102.23 -30.36 11.15 Favored 'General case' 0 N--CA 1.424 -1.766 0 CA-C-O 122.064 0.935 . . . . 0.0 108.826 -174.38 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.52 HG23 ' CB ' ' A' ' 135' ' ' ASN . 2.0 mp -123.58 137.07 58.02 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.493 0 CA-C-N 114.164 -1.38 . . . . 0.0 109.043 -178.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 3.9 t -83.97 122.35 28.63 Favored 'General case' 0 N--CA 1.419 -1.986 0 N-CA-C 102.68 -3.082 . . . . 0.0 102.68 168.431 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 22.8 m-20 -88.98 107.76 19.21 Favored 'General case' 0 C--N 1.261 -3.268 0 C-N-CA 118.313 -1.355 . . . . 0.0 109.013 -172.338 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.557 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 17.0 t80 -122.63 131.58 53.88 Favored 'General case' 0 C--N 1.285 -2.204 0 CA-C-N 114.382 -1.281 . . . . 0.0 109.638 -174.727 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.455 ' CG2' ' HG ' ' A' ' 131' ' ' LEU . 14.9 p -136.87 144.8 31.32 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.138 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.685 -175.705 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -150.02 118.49 6.49 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 178.04 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.535 HD12 ' O ' ' A' ' 130' ' ' ILE . 48.0 tp -53.91 111.03 0.67 Allowed 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 169.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.428 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 3.1 tp-100 -59.74 -51.06 71.37 Favored 'General case' 0 C--O 1.21 -0.976 0 C-N-CA 125.793 1.637 . . . . 0.0 110.574 179.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.428 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 11.0 ptp180 -170.01 158.68 7.25 Favored 'General case' 0 N--CA 1.428 -1.567 0 CA-C-N 115.172 -0.922 . . . . 0.0 108.804 -176.328 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -134.6 145.74 17.8 Favored Glycine 0 N--CA 1.405 -3.433 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 179.319 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 72.3 m -132.88 150.85 52.12 Favored 'General case' 0 C--N 1.283 -2.326 0 C-N-CA 124.062 0.945 . . . . 0.0 109.918 -177.322 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.517 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -115.3 157.77 23.32 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 108.68 -0.859 . . . . 0.0 108.68 -178.545 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.523 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 95.9 m-85 -155.09 -179.6 8.22 Favored 'General case' 0 C--O 1.236 0.36 0 C-N-CA 124.302 1.041 . . . . 0.0 109.008 -178.403 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 54.77 -140.05 38.7 Favored Glycine 0 N--CA 1.455 -0.093 0 O-C-N 123.812 0.695 . . . . 0.0 113.464 178.195 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -73.35 -15.46 78.94 Favored Glycine 0 C--O 1.2 -2.014 0 C-N-CA 120.822 -0.704 . . . . 0.0 112.004 178.344 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.755 HG21 ' HB ' ' A' ' 126' ' ' ILE . 84.4 t -67.12 -40.03 84.44 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 C-N-CA 123.637 0.775 . . . . 0.0 111.78 -176.823 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.517 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -87.99 -16.43 33.76 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 118.919 -1.112 . . . . 0.0 112.158 178.326 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 23.2 t -100.74 -59.13 1.75 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-O 121.328 0.585 . . . . 0.0 111.992 -174.976 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.491 ' O ' HG22 ' A' ' 112' ' ' VAL . 34.0 m-20 -90.69 -22.44 21.14 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.875 -171.893 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.636 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 90.4 m-85 -110.63 157.16 20.0 Favored 'General case' 0 N--CA 1.422 -1.854 0 C-N-CA 119.97 -0.692 . . . . 0.0 110.594 178.759 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 6.4 t -166.17 130.63 2.21 Favored 'General case' 0 N--CA 1.417 -2.075 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 176.269 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.478 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -160.98 -99.77 0.15 Allowed Glycine 0 C--N 1.286 -2.199 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 177.664 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.451 HG22 ' HA ' ' A' ' 83' ' ' PRO . 0.7 OUTLIER -168.89 -179.97 3.9 Favored 'General case' 0 N--CA 1.474 0.734 0 C-N-CA 124.893 1.277 . . . . 0.0 109.97 -177.643 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.0 147.03 32.36 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 C-N-CA 123.255 0.622 . . . . 0.0 109.536 178.324 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.576 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.9 tttt -124.68 147.92 48.29 Favored 'General case' 0 N--CA 1.43 -1.454 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.239 -179.43 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.441 ' CD2' HG22 ' A' ' 105' ' ' VAL . 61.3 t80 -148.4 108.8 4.13 Favored 'General case' 0 C--N 1.314 -0.965 0 N-CA-C 108.753 -0.832 . . . . 0.0 108.753 -179.429 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 11.2 t 51.78 43.04 30.33 Favored 'General case' 0 C--N 1.315 -0.926 0 C-N-CA 124.251 1.02 . . . . 0.0 111.546 177.841 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.78 8.26 70.07 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.188 -1.006 . . . . 0.0 113.435 179.038 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.576 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 23.0 t -80.68 -179.66 7.34 Favored 'General case' 0 C--N 1.314 -0.958 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 177.297 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 12.3 p -158.89 106.61 1.84 Allowed 'General case' 0 C--N 1.288 -2.1 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . . . . . . . . . 2.6 p90 -151.52 158.45 34.29 Favored Pre-proline 0 C--N 1.308 -1.205 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -174.449 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.451 ' HA ' HG22 ' A' ' 74' ' ' THR . 44.9 Cg_endo -67.16 148.9 81.64 Favored 'Trans proline' 0 C--N 1.36 1.16 0 C-N-CA 123.092 2.528 . . . . 0.0 112.703 -177.053 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.588 ' CD2' HD21 ' A' ' 109' ' ' LEU . 60.6 t80 -122.07 131.7 24.37 Favored Pre-proline 0 C--N 1.312 -1.035 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.694 -179.447 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.516 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 72.7 Cg_endo -70.89 150.27 92.73 Favored 'Cis proline' 0 CA--C 1.539 0.731 0 C-N-CA 122.956 -1.685 . . . . 0.0 109.915 -1.296 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 9.9 t -59.47 -177.99 0.06 Allowed 'General case' 0 CA--C 1.559 1.309 0 CA-C-O 121.928 0.87 . . . . 0.0 112.504 -174.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.1 p -115.0 -15.6 11.75 Favored 'General case' 0 N--CA 1.43 -1.433 0 CA-C-N 115.34 -0.846 . . . . 0.0 110.067 -173.596 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.6 t -158.15 -109.53 0.02 OUTLIER 'General case' 0 N--CA 1.415 -2.213 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 178.457 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . 0.412 ' HB2' ' O ' ' A' ' 58' ' ' LEU . 0.5 OUTLIER -132.93 -164.01 1.42 Allowed 'General case' 0 N--CA 1.436 -1.16 0 CA-C-N 118.349 0.522 . . . . 0.0 111.723 179.295 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.464 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 10.8 p -100.14 164.56 16.16 Favored Pre-proline 0 C--N 1.299 -1.606 0 C-N-CA 123.618 0.767 . . . . 0.0 112.405 -177.642 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -65.98 168.74 14.79 Favored 'Trans proline' 0 C--N 1.36 1.148 0 C-N-CA 123.411 2.741 . . . . 0.0 111.21 174.359 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.557 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 3.2 tmm_? -70.2 128.44 36.26 Favored 'General case' 0 N--CA 1.44 -0.964 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 -178.77 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 74.0 t -142.59 120.92 7.94 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.666 0 C-N-CA 124.439 1.095 . . . . 0.0 108.11 -178.381 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 3.0 p -119.81 140.32 44.22 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.209 0 CA-C-O 120.956 0.408 . . . . 0.0 110.775 -177.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.47 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 9.5 m-85 -94.26 112.46 24.26 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 177.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 13.9 m120 -97.49 8.64 44.25 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-O 121.657 0.741 . . . . 0.0 109.218 178.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 5.8 m -76.7 -175.95 3.61 Favored 'General case' 0 N--CA 1.427 -1.6 0 C-N-CA 124.729 1.212 . . . . 0.0 109.988 -177.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 15.0 ptp180 -143.64 30.57 1.34 Allowed 'General case' 0 C--N 1.309 -1.174 0 CA-C-O 121.001 0.429 . . . . 0.0 110.611 177.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 13.1 t -163.48 -178.01 5.61 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.02 -0.733 . . . . 0.0 109.02 -175.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.7 m-20 -67.31 99.37 0.71 Allowed 'General case' 0 C--O 1.242 0.691 0 O-C-N 123.894 0.746 . . . . 0.0 109.772 178.016 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 11.2 mptt -104.96 141.43 22.53 Favored Pre-proline 0 C--N 1.283 -2.306 0 N-CA-C 106.86 -1.533 . . . . 0.0 106.86 175.641 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -60.85 147.05 96.51 Favored 'Trans proline' 0 C--O 1.243 0.771 0 C-N-CA 122.409 2.073 . . . . 0.0 112.23 -177.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . 0.47 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 11.9 t90 -91.25 104.66 10.28 Favored Pre-proline 0 C--N 1.309 -1.167 0 N-CA-C 105.387 -2.079 . . . . 0.0 105.387 179.588 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 59.7 Cg_endo -75.51 88.12 1.31 Allowed 'Trans proline' 0 N--CA 1.445 -1.366 0 C-N-CA 121.449 1.433 . . . . 0.0 113.0 -171.052 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.441 HG22 ' CD2' ' A' ' 77' ' ' TYR . 72.4 t -136.15 150.78 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.333 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 177.456 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.595 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -156.87 134.45 10.77 Favored 'General case' 0 N--CA 1.421 -1.893 0 O-C-N 123.633 0.583 . . . . 0.0 109.758 176.773 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.464 HD21 HD11 ' A' ' 129' ' ' LEU . 19.7 mt -103.45 99.86 9.71 Favored 'General case' 0 C--N 1.294 -1.843 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 179.437 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.478 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 65.4 m-85 -78.55 81.56 4.87 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 110.236 -0.283 . . . . 0.0 110.236 178.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.636 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.0 mm? -107.03 117.03 32.98 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-O 121.122 0.487 . . . . 0.0 110.629 176.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -120.17 146.88 43.5 Favored Pre-proline 0 N--CA 1.413 -2.3 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.319 -174.54 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -61.0 119.96 7.41 Favored 'Trans proline' 0 C--O 1.249 1.067 0 C-N-CA 123.226 2.618 . . . . 0.0 112.309 -177.538 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.491 HG22 ' O ' ' A' ' 70' ' ' ASN . 3.0 m -68.35 -118.5 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.193 -1.891 0 CA-C-N 114.261 -1.336 . . . . 0.0 111.862 173.783 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.8 t -112.87 -33.11 6.18 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 175.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 36.3 m -80.03 34.5 0.3 Allowed 'General case' 0 N--CA 1.399 -2.982 0 C-N-CA 125.698 1.599 . . . . 0.0 112.742 -178.169 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -118.12 130.01 55.87 Favored 'General case' 0 C--N 1.281 -2.397 0 CA-C-N 116.495 -0.32 . . . . 0.0 110.365 179.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -170.08 128.18 1.6 Allowed Glycine 0 C--O 1.239 0.467 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.647 179.405 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 65.98 -150.48 51.84 Favored Glycine 0 CA--C 1.499 -0.964 0 CA-C-O 118.985 -0.897 . . . . 0.0 111.589 -176.097 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.406 HG11 ' HE3' ' A' ' 121' ' ' LYS . 95.1 t -56.93 105.2 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.527 0 CA-C-O 121.873 0.844 . . . . 0.0 111.435 -178.291 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -105.41 -21.58 13.2 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-N 114.327 -1.306 . . . . 0.0 110.919 -177.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.509 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 63.6 mt -135.84 140.54 44.03 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.517 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.3 mmpt? -115.87 139.56 50.09 Favored 'General case' 0 C--N 1.317 -0.817 0 C-N-CA 122.319 0.248 . . . . 0.0 111.232 178.071 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.409 ' H ' ' HB3' ' A' ' 153' ' ' ASP . . . -70.53 134.73 47.96 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.709 -0.678 . . . . 0.0 109.227 179.38 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 87.01 -7.91 78.55 Favored Glycine 0 C--N 1.307 -1.035 0 C-N-CA 121.353 -0.451 . . . . 0.0 112.115 -179.233 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 34.7 t -96.11 143.63 27.07 Favored 'General case' 0 N--CA 1.422 -1.843 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 179.711 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.463 HD11 HG23 ' A' ' 128' ' ' VAL . 3.0 tm? -69.86 128.21 35.58 Favored 'General case' 0 N--CA 1.436 -1.17 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.384 -178.463 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.755 ' HB ' HG21 ' A' ' 67' ' ' VAL . 32.6 pt -112.43 -27.05 2.86 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 N-CA-C 112.327 0.492 . . . . 0.0 112.327 -179.886 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . . . . . . . . . . . -161.84 168.03 23.76 Favored 'General case' 0 CA--C 1.505 -0.765 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -178.283 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.463 HG23 HD11 ' A' ' 125' ' ' LEU . 59.9 t -142.03 116.94 5.25 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 N-CA-C 107.426 -1.324 . . . . 0.0 107.426 179.112 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.464 HD11 HD21 ' A' ' 107' ' ' LEU . 68.3 mt -117.46 137.58 52.43 Favored 'General case' 0 C--N 1.28 -2.444 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 178.483 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.535 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.3 mp -118.57 122.71 70.15 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.857 0 C-N-CA 119.015 -1.074 . . . . 0.0 109.934 177.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.548 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.8 OUTLIER -88.53 141.35 28.6 Favored 'General case' 0 C--N 1.266 -3.064 0 C-N-CA 125.053 1.341 . . . . 0.0 108.166 177.554 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . . . . . . . . . 24.9 ttp180 -122.35 131.01 53.69 Favored 'General case' 0 N--CA 1.409 -2.497 0 C-N-CA 120.153 -0.619 . . . . 0.0 109.815 174.307 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.676 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 0.0 OUTLIER -98.28 143.66 28.53 Favored 'General case' 0 N--CA 1.42 -1.942 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 -179.487 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.465 ' O ' ' HB3' ' A' ' 55' ' ' TYR . 11.0 m -154.78 138.04 15.73 Favored 'General case' 0 C--N 1.281 -2.402 0 N-CA-C 106.488 -1.671 . . . . 0.0 106.488 173.649 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.52 ' CB ' HG23 ' A' ' 52' ' ' ILE . 11.0 p30 -135.6 -177.17 4.55 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 119.227 0.921 . . . . 0.0 112.515 176.108 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 9.4 p30 -88.54 -29.05 20.36 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-O 121.472 0.653 . . . . 0.0 112.023 -174.602 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 82.5 t80 -92.59 -68.01 0.82 Allowed 'General case' 0 C--N 1.291 -1.947 0 C-N-CA 123.975 0.91 . . . . 0.0 110.814 -169.181 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -89.36 170.71 10.32 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.31 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 26.7 t -101.97 58.37 0.83 Allowed 'General case' 0 N--CA 1.397 -3.092 0 N-CA-C 106.12 -1.807 . . . . 0.0 106.12 172.402 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 73.9 m-20 -81.64 45.73 0.91 Allowed 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.608 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . 0.579 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 2.9 m-20 -79.64 53.82 1.67 Allowed 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 124.4 1.08 . . . . 0.0 109.005 -179.056 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -101.73 156.44 17.5 Favored 'General case' 0 N--CA 1.426 -1.673 0 N-CA-C 107.606 -1.257 . . . . 0.0 107.606 179.548 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . 0.519 ' HB2' ' O ' ' A' ' 131' ' ' LEU . 13.9 pt20 -124.49 142.55 51.24 Favored 'General case' 0 N--CA 1.415 -2.215 0 C-N-CA 118.541 -1.264 . . . . 0.0 111.844 178.534 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 3.3 m-30 -106.69 129.37 54.6 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -175.344 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 48.5 t -94.53 129.18 45.12 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -178.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . 0.548 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 60.4 m95 -118.47 103.09 9.43 Favored 'General case' 0 C--N 1.278 -2.507 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 -179.141 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 36.8 m-80 -82.05 110.86 17.67 Favored 'General case' 0 C--N 1.286 -2.159 0 N-CA-C 106.699 -1.593 . . . . 0.0 106.699 178.155 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.416 HG22 HD11 ' A' ' 126' ' ' ILE . 23.4 mm -85.52 121.14 36.8 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.903 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 -178.046 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 93.8 m-85 -117.72 151.3 37.55 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 123.618 0.767 . . . . 0.0 109.676 178.463 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -79.97 130.84 35.59 Favored 'General case' 0 N--CA 1.413 -2.295 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 175.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 15.1 t-20 -92.32 -6.43 50.29 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 -179.317 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.1 t30 -155.39 142.45 19.2 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.205 -176.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . 0.409 ' HB3' ' H ' ' A' ' 122' ' ' ALA . 17.5 p-10 -86.83 136.15 33.08 Favored 'General case' 0 C--N 1.309 -1.173 0 O-C-N 123.998 0.811 . . . . 0.0 112.004 -177.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.511 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 78.7 t -110.32 140.79 27.81 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 CA-C-N 114.966 -1.016 . . . . 0.0 111.987 -171.79 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 13.9 t -122.93 137.45 56.34 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.045 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 -179.529 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.507 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 70.0 t -103.28 103.27 33.95 Favored Pre-proline 0 C--N 1.286 -2.165 0 C-N-CA 123.699 0.799 . . . . 0.0 110.106 179.534 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.434 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 38.0 Cg_endo -69.47 -21.88 34.18 Favored 'Trans proline' 0 N--CA 1.463 -0.312 0 C-N-CA 121.959 1.772 . . . . 0.0 111.346 177.322 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.403 ' HB ' HG12 ' A' ' 156' ' ' VAL . 3.6 t . . . . . 0 C--O 1.244 0.784 0 C-N-CA 124.698 1.199 . . . . 0.0 113.251 176.802 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 33.3 t80 . . . . . 0 CA--C 1.503 -0.839 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.408 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -145.73 170.1 17.18 Favored 'General case' 0 N--CA 1.439 -1.005 0 C-N-CA 119.943 -0.703 . . . . 0.0 111.04 -177.697 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.404 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 80.0 m -143.67 159.05 43.16 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -177.478 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.6 pptp? -141.8 164.51 29.99 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-O 121.384 0.612 . . . . 0.0 111.621 -176.35 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.565 HG22 HG22 ' A' ' 20' ' ' VAL . 76.7 p -103.25 167.27 9.93 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.168 179.257 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -74.34 -9.49 58.65 Favored 'General case' 0 C--N 1.296 -1.729 0 CA-C-N 113.729 -1.578 . . . . 0.0 112.474 179.563 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 1.8 p30 -94.37 -33.42 13.18 Favored 'General case' 0 C--O 1.239 0.516 0 C-N-CA 119.105 -1.038 . . . . 0.0 109.078 179.381 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 139.3 4.8 1.42 Allowed Glycine 0 N--CA 1.426 -1.972 0 C-N-CA 119.345 -1.407 . . . . 0.0 113.708 176.861 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.0 m -84.54 106.99 16.53 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 177.765 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -99.93 117.2 33.72 Favored 'General case' 0 C--N 1.286 -2.175 0 N-CA-C 108.372 -0.973 . . . . 0.0 108.372 175.996 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.408 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 62.0 mt -84.21 116.95 67.37 Favored Pre-proline 0 C--N 1.308 -1.212 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 -179.711 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -76.96 166.8 26.23 Favored 'Trans proline' 0 N--CA 1.443 -1.497 0 C-N-CA 122.271 1.981 . . . . 0.0 111.381 179.167 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 72.1 mt -62.19 133.24 28.04 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.97 -179.894 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 126.96 4.44 6.04 Favored Glycine 0 C--N 1.311 -0.838 0 C-N-CA 120.506 -0.854 . . . . 0.0 112.466 178.916 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 83.04 146.44 6.48 Favored Glycine 0 N--CA 1.442 -0.944 0 C-N-CA 120.494 -0.86 . . . . 0.0 111.174 -177.025 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 177.62 -173.94 46.5 Favored Glycine 0 C--N 1.296 -1.666 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -179.231 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 60.3 p -134.06 151.12 51.27 Favored 'General case' 0 C--N 1.295 -1.792 0 N-CA-C 109.243 -0.651 . . . . 0.0 109.243 -179.651 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.49 168.67 18.81 Favored 'General case' 0 N--CA 1.432 -1.364 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 178.56 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 16.0 m-80 -118.14 108.69 15.49 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 -179.489 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.565 HG22 HG22 ' A' ' 5' ' ' THR . 46.9 t -94.72 136.64 25.33 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.018 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 -179.705 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 86.4 m-85 -125.1 117.39 23.83 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 -177.333 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.479 HG11 HG13 ' A' ' 36' ' ' VAL . 2.7 p -124.3 129.52 73.96 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.833 0 CA-C-O 121.704 0.764 . . . . 0.0 111.479 -176.913 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -82.26 124.62 30.11 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-N 114.988 -1.005 . . . . 0.0 108.459 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 35.5 mt -113.44 156.16 24.01 Favored 'General case' 0 C--N 1.276 -2.593 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 179.951 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.53 121.67 50.16 Favored Pre-proline 0 C--O 1.201 -1.483 0 O-C-N 124.207 0.942 . . . . 0.0 109.899 -179.311 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.505 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 62.3 Cg_endo -71.37 -2.46 11.27 Favored 'Trans proline' 0 N--CA 1.487 1.094 0 C-N-CA 123.185 2.59 . . . . 0.0 113.294 -176.699 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.528 HG13 ' HG3' ' A' ' 157' ' ' PRO . 64.8 t -130.4 111.26 20.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 -179.94 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.458 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 5.8 t -145.76 110.3 0.98 Allowed 'Isoleucine or valine' 0 C--O 1.191 -2.024 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 -179.383 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.552 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -99.68 156.62 16.99 Favored 'General case' 0 C--N 1.264 -3.109 0 C-N-CA 122.94 0.496 . . . . 0.0 111.18 -179.539 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 25.4 t -47.93 116.5 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 123.887 0.875 . . . . 0.0 111.675 177.299 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.87 0.51 45.46 Favored Glycine 0 N--CA 1.444 -0.827 0 CA-C-N 115.36 -0.836 . . . . 0.0 112.983 -179.96 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.552 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -73.73 -177.05 2.6 Favored 'General case' 0 C--N 1.315 -0.893 0 C-N-CA 123.888 0.875 . . . . 0.0 111.099 176.221 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -128.39 87.88 2.66 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 178.484 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.643 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 18.7 tp -97.35 132.67 42.85 Favored 'General case' 0 N--CA 1.417 -2.091 0 C-N-CA 118.663 -1.215 . . . . 0.0 108.753 178.095 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 2.1 p -141.41 129.55 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.386 -3.65 0 CA-C-N 114.859 -1.064 . . . . 0.0 111.618 -177.747 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.609 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 46.8 t -90.54 89.22 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.393 -3.277 0 CA-C-N 113.374 -1.739 . . . . 0.0 107.825 -179.039 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 18.2 t70 -77.98 112.22 14.67 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-O 121.015 0.436 . . . . 0.0 109.952 179.08 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 92.1 mt -96.3 -0.54 49.47 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.619 -0.719 . . . . 0.0 111.337 -177.766 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 35.6 t -74.56 0.97 13.17 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.847 0.832 . . . . 0.0 110.366 -179.561 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.8 p -126.85 3.32 6.65 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.086 178.597 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.422 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 47.9 mm-40 -121.8 -26.79 4.78 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.686 -172.925 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 20.6 mt -130.43 139.63 50.85 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 -175.525 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 59.5 m-85 -139.48 158.74 43.63 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 -176.095 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.404 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 49.1 m -136.21 141.47 44.0 Favored 'General case' 0 C--N 1.294 -1.846 0 C-N-CA 123.472 0.709 . . . . 0.0 109.972 179.58 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 5.6 p80 -136.92 153.47 50.72 Favored 'General case' 0 N--CA 1.43 -1.47 0 CA-C-O 121.9 0.857 . . . . 0.0 110.681 -178.427 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.467 HD21 ' HA ' ' A' ' 98' ' ' ARG . 6.6 p30 -95.01 109.93 21.9 Favored 'General case' 0 C--N 1.277 -2.556 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.408 177.187 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -73.87 -28.98 61.84 Favored 'General case' 0 C--N 1.297 -1.674 0 CA-C-N 114.694 -1.139 . . . . 0.0 109.931 -179.429 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 32.1 m-85 -136.52 79.6 41.0 Favored Pre-proline 0 C--N 1.313 -0.996 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 175.569 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -71.54 5.01 2.6 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 C-N-CA 123.257 2.638 . . . . 0.0 113.023 -176.164 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -120.34 -13.31 8.88 Favored 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.594 179.144 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.452 ' HB ' HD12 ' A' ' 52' ' ' ILE . 2.6 m -117.14 -25.64 7.07 Favored 'General case' 0 N--CA 1.422 -1.859 0 CA-C-O 121.408 0.623 . . . . 0.0 110.789 -172.575 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.452 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.7 mp -128.95 130.48 68.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 CA-C-N 115.971 -0.558 . . . . 0.0 109.5 -175.581 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.402 HG22 HD22 ' A' ' 136' ' ' ASN . 12.4 t -75.63 146.48 40.26 Favored 'General case' 0 N--CA 1.441 -0.923 0 O-C-N 123.714 0.634 . . . . 0.0 109.707 -179.695 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.555 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 3.0 m-20 -89.96 109.97 20.97 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 115.426 -0.807 . . . . 0.0 109.341 -174.178 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 82.2 t80 -146.03 141.68 27.87 Favored 'General case' 0 C--N 1.296 -1.721 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -179.128 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.1 p -151.44 144.78 16.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 175.802 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -150.27 131.7 14.7 Favored 'General case' 0 C--O 1.212 -0.904 0 CA-C-O 119.759 -0.162 . . . . 0.0 110.575 175.654 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.555 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 56.8 tp -72.84 107.88 5.49 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.157 0.504 . . . . 0.0 109.984 176.827 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.467 ' HG3' ' HG2' ' A' ' 60' ' ' ARG . 3.0 tp-100 -51.55 -53.63 35.89 Favored 'General case' 0 C--O 1.207 -1.138 0 C-N-CA 125.554 1.541 . . . . 0.0 111.149 175.825 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.467 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 2.8 ptp180 -168.62 161.4 11.39 Favored 'General case' 0 CA--C 1.493 -1.235 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 -178.072 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.411 ' H ' HG22 ' A' ' 86' ' ' THR . . . -142.1 123.52 2.23 Favored Glycine 0 N--CA 1.404 -3.485 0 N-CA-C 108.898 -1.681 . . . . 0.0 108.898 -178.771 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.412 ' HA ' ' HB3' ' A' ' 85' ' ' PRO . 68.9 m -115.62 149.79 37.73 Favored 'General case' 0 C--N 1.284 -2.245 0 C-N-CA 124.297 1.039 . . . . 0.0 110.32 -173.804 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.522 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -112.7 157.75 20.9 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 -179.302 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.476 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 88.6 m-85 -156.7 -178.91 7.7 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 124.316 1.047 . . . . 0.0 109.037 -177.68 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 60.71 -143.08 48.26 Favored Glycine 0 C--N 1.33 0.231 0 O-C-N 123.465 0.478 . . . . 0.0 112.512 177.785 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . 0.408 ' HA3' ' O ' ' A' ' 119' ' ' ALA . . . -78.94 -7.77 88.21 Favored Glycine 0 C--O 1.21 -1.382 0 C-N-CA 120.978 -0.629 . . . . 0.0 111.876 176.773 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.848 HG21 ' HB ' ' A' ' 126' ' ' ILE . 89.5 t -69.4 -39.96 79.4 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 C-N-CA 123.72 0.808 . . . . 0.0 111.535 -178.4 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.522 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -86.01 -15.97 39.74 Favored 'General case' 0 C--N 1.299 -1.609 0 C-N-CA 119.171 -1.012 . . . . 0.0 112.053 178.836 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 16.9 t -99.67 -56.9 2.27 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.057 0.456 . . . . 0.0 111.324 -175.221 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.525 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 37.4 m-80 -85.67 -29.09 24.27 Favored 'General case' 0 CA--C 1.486 -1.513 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 -176.09 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.646 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 81.2 m-85 -106.79 157.39 17.78 Favored 'General case' 0 N--CA 1.416 -2.172 0 C-N-CA 119.365 -0.934 . . . . 0.0 110.38 -178.362 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.0 t -168.58 128.14 1.17 Allowed 'General case' 0 N--CA 1.42 -1.933 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 175.503 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.497 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -158.37 -109.92 0.28 Allowed Glycine 0 N--CA 1.404 -3.445 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 174.91 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.434 HG22 ' HA ' ' A' ' 83' ' ' PRO . 3.5 p -156.09 179.99 8.7 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 123.591 0.756 . . . . 0.0 109.859 -176.196 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -130.34 146.76 33.56 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.082 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 177.891 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.635 ' HG3' ' O ' ' A' ' 80' ' ' SER . 82.3 tttt -124.63 142.91 51.03 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.225 -179.564 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.496 ' CD2' HG22 ' A' ' 105' ' ' VAL . 51.5 t80 -142.51 107.87 5.02 Favored 'General case' 0 C--N 1.314 -0.935 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 -178.998 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 33.0 t 54.04 36.85 25.59 Favored 'General case' 0 CA--C 1.555 1.149 0 CA-C-O 121.541 0.686 . . . . 0.0 111.373 179.364 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.427 ' HA2' ' CE ' ' A' ' 76' ' ' LYS . . . 90.39 9.32 65.15 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.321 -0.942 . . . . 0.0 113.514 -178.645 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.635 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 22.9 t -79.96 172.53 13.66 Favored 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 177.425 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 6.2 p -152.84 100.58 2.53 Favored 'General case' 0 C--N 1.277 -2.58 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -177.757 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.445 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 1.6 p90 -144.93 159.52 49.81 Favored Pre-proline 0 C--N 1.301 -1.506 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -173.731 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.434 ' HA ' HG22 ' A' ' 74' ' ' THR . 47.3 Cg_endo -66.68 151.97 81.59 Favored 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 122.97 2.446 . . . . 0.0 112.734 -176.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.616 ' CD2' HD21 ' A' ' 109' ' ' LEU . 57.6 t80 -127.48 130.34 23.71 Favored Pre-proline 0 N--CA 1.438 -1.042 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.675 179.654 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.492 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 59.8 Cg_endo -69.37 149.46 87.67 Favored 'Cis proline' 0 C--O 1.244 0.803 0 C-N-CA 122.972 -1.678 . . . . 0.0 110.509 -0.393 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.411 HG22 ' H ' ' A' ' 61' ' ' GLY . 9.8 t -63.73 -176.56 0.18 Allowed 'General case' 0 CA--C 1.55 0.966 0 CA-C-O 121.298 0.57 . . . . 0.0 111.745 -175.233 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 17.1 p -113.15 -39.31 4.21 Favored 'General case' 0 N--CA 1.418 -2.041 0 CA-C-O 121.658 0.742 . . . . 0.0 109.303 -175.267 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 14.0 t -129.82 -107.59 0.28 Allowed 'General case' 0 N--CA 1.401 -2.878 0 CA-C-N 115.249 -0.887 . . . . 0.0 109.259 -179.784 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -134.92 -166.82 1.88 Allowed 'General case' 0 N--CA 1.438 -1.04 0 CA-C-N 117.854 0.297 . . . . 0.0 110.633 -177.821 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.555 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 36.4 p -99.49 170.86 6.27 Favored Pre-proline 0 C--N 1.309 -1.153 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 178.174 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . 0.444 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 23.2 Cg_endo -61.34 161.75 22.58 Favored 'Trans proline' 0 C--O 1.249 1.033 0 C-N-CA 122.913 2.409 . . . . 0.0 111.099 169.636 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.7 tmm_? -78.44 119.97 22.51 Favored 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 107.889 -1.152 . . . . 0.0 107.889 -178.433 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 92.4 t -126.97 126.51 68.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.23 0 O-C-N 123.599 0.562 . . . . 0.0 110.189 -178.612 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 75.3 t -107.9 131.16 58.95 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 176.701 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.555 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 3.0 m-85 -77.77 131.11 37.48 Favored 'General case' 0 C--N 1.309 -1.186 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 175.795 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -117.05 58.56 0.77 Allowed 'General case' 0 C--N 1.285 -2.233 0 N-CA-C 107.594 -1.262 . . . . 0.0 107.594 -179.826 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 21.0 m -143.11 157.35 44.6 Favored 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.598 -176.231 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.467 ' HA ' HD21 ' A' ' 46' ' ' ASN . 14.7 ptp180 -121.83 37.61 4.32 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.845 0.831 . . . . 0.0 109.694 178.128 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 7.7 t -157.26 172.23 18.99 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 -176.028 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -73.26 120.67 19.2 Favored 'General case' 0 C--O 1.244 0.808 0 CA-C-O 121.391 0.615 . . . . 0.0 109.471 -179.203 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -117.92 142.32 30.66 Favored Pre-proline 0 C--N 1.277 -2.545 0 CA-C-N 115.128 -0.942 . . . . 0.0 110.423 -177.212 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -65.81 147.39 85.36 Favored 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.771 2.314 . . . . 0.0 111.834 176.807 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 13.8 t90 -89.17 108.88 27.01 Favored Pre-proline 0 C--N 1.31 -1.143 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 -177.205 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_endo -77.5 88.18 1.44 Allowed 'Trans proline' 0 N--CA 1.45 -1.046 0 C-N-CA 121.641 1.561 . . . . 0.0 113.38 -172.989 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.496 HG22 ' CD2' ' A' ' 77' ' ' TYR . 64.0 t -135.9 148.87 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.183 0 N-CA-C 107.317 -1.364 . . . . 0.0 107.317 176.069 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.609 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -152.85 131.35 12.19 Favored 'General case' 0 C--N 1.288 -2.099 0 CA-C-O 120.92 0.391 . . . . 0.0 110.375 177.198 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.47 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 16.7 mt -100.9 99.98 10.55 Favored 'General case' 0 C--N 1.291 -1.952 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 179.585 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.497 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 51.3 m-85 -78.17 80.36 4.59 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.659 -0.497 . . . . 0.0 109.659 177.397 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.646 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 2.7 mm? -104.02 116.66 32.63 Favored 'General case' 0 CA--C 1.491 -1.325 0 CA-C-O 120.997 0.427 . . . . 0.0 110.523 176.681 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -123.69 146.75 51.26 Favored Pre-proline 0 N--CA 1.407 -2.593 0 CA-C-N 115.766 -0.652 . . . . 0.0 109.447 -175.535 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.525 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 18.8 Cg_endo -60.7 122.16 10.83 Favored 'Trans proline' 0 N--CA 1.447 -1.236 0 C-N-CA 122.987 2.458 . . . . 0.0 112.334 -178.248 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.516 HG22 ' O ' ' A' ' 70' ' ' ASN . 3.3 m -70.0 -120.52 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.195 -1.772 0 CA-C-N 113.831 -1.531 . . . . 0.0 111.78 174.874 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 33.4 t -111.69 -34.57 6.01 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 174.355 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 20.0 t -85.56 40.91 0.87 Allowed 'General case' 0 N--CA 1.431 -1.386 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.572 -177.347 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -114.06 135.88 53.53 Favored 'General case' 0 N--CA 1.418 -2.075 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 176.89 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -176.32 135.1 2.79 Favored Glycine 0 N--CA 1.439 -1.116 0 C-N-CA 120.053 -1.07 . . . . 0.0 111.927 178.96 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 63.41 -151.07 48.95 Favored Glycine 0 CA--C 1.498 -1.016 0 CA-C-O 119.269 -0.74 . . . . 0.0 112.757 -178.642 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 98.4 t -58.32 99.46 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 122.06 0.933 . . . . 0.0 110.981 -177.648 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . 0.408 ' O ' ' HA3' ' A' ' 66' ' ' GLY . . . -99.68 -25.43 14.4 Favored 'General case' 0 C--N 1.295 -1.795 0 CA-C-N 114.608 -1.178 . . . . 0.0 110.735 -177.371 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.565 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 55.2 mt -134.56 138.01 50.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 -179.188 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.511 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 5.0 mmpt? -112.36 138.02 49.69 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-O 121.084 0.469 . . . . 0.0 111.184 177.375 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -70.45 125.15 25.98 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 177.74 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 93.97 -2.47 69.22 Favored Glycine 0 C--N 1.31 -0.885 0 N-CA-C 111.644 -0.582 . . . . 0.0 111.644 -178.13 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 28.8 t -96.13 143.84 26.9 Favored 'General case' 0 N--CA 1.431 -1.409 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 -179.913 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.434 HD11 HG23 ' A' ' 128' ' ' VAL . 3.1 tm? -71.53 124.0 23.68 Favored 'General case' 0 N--CA 1.435 -1.183 0 N-CA-C 107.652 -1.24 . . . . 0.0 107.652 178.349 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.848 ' HB ' HG21 ' A' ' 67' ' ' VAL . 30.6 pt -111.63 -26.17 3.23 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 N-CA-C 112.432 0.53 . . . . 0.0 112.432 -178.54 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . 0.431 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -160.75 168.2 25.28 Favored 'General case' 0 N--CA 1.443 -0.796 0 N-CA-C 110.065 -0.346 . . . . 0.0 110.065 -178.196 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.434 HG23 HD11 ' A' ' 125' ' ' LEU . 70.5 t -143.0 114.06 2.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.634 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.903 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.44 HD11 HD21 ' A' ' 107' ' ' LEU . 55.8 mt -116.67 147.89 41.53 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.184 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.485 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.5 mp -133.01 127.69 55.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.849 -0.532 . . . . 0.0 110.002 179.714 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . . . . . . . . . 2.3 pp -96.4 147.04 24.23 Favored 'General case' 0 CA--C 1.496 -1.119 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 177.419 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.464 ' HD3' ' NE2' ' A' ' 59' ' ' GLN . 26.5 mmm-85 -96.49 118.39 32.89 Favored 'General case' 0 C--N 1.277 -2.576 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 172.858 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.704 ' O ' ' HA ' ' A' ' 141' ' ' ASP . 7.1 tp-100 -96.02 122.03 38.41 Favored 'General case' 0 N--CA 1.421 -1.911 0 N-CA-C 107.14 -1.43 . . . . 0.0 107.14 173.151 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 22.1 m -134.61 134.01 40.79 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 177.085 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.432 ' CB ' HG23 ' A' ' 52' ' ' ILE . 27.2 p30 -136.41 -174.27 3.65 Favored 'General case' 0 C--N 1.31 -1.11 0 C-N-CA 120.464 -0.494 . . . . 0.0 110.819 -179.736 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.402 HD22 HG22 ' A' ' 53' ' ' THR . 7.7 p30 -109.04 -0.78 19.32 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-N 115.416 -0.811 . . . . 0.0 111.226 -172.425 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 74.6 t80 -127.43 -72.02 0.65 Allowed 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 114.699 1.37 . . . . 0.0 114.699 -168.717 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . 0.615 ' HB3' ' OD1' ' A' ' 140' ' ' ASP . 0.1 OUTLIER -78.66 -7.63 57.86 Favored 'General case' 0 N--CA 1.43 -1.426 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -169.052 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 18.9 t 69.83 17.47 7.6 Favored 'General case' 0 C--O 1.24 0.605 0 C-N-CA 123.953 0.901 . . . . 0.0 110.691 174.484 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . 0.615 ' OD1' ' HB3' ' A' ' 138' ' ' ASN . 5.9 p-10 -79.04 56.41 1.98 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.943 0.878 . . . . 0.0 112.53 179.443 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . 0.704 ' HA ' ' O ' ' A' ' 133' ' ' GLN . 14.3 t70 -77.74 84.96 4.06 Favored 'General case' 0 CA--C 1.499 -1.016 0 CA-C-N 114.407 -1.27 . . . . 0.0 107.806 173.163 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -126.26 157.09 39.21 Favored 'General case' 0 C--N 1.282 -2.352 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 178.997 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 12.6 pt20 -115.08 132.12 56.71 Favored 'General case' 0 N--CA 1.407 -2.624 0 C-N-CA 119.037 -1.065 . . . . 0.0 110.248 -177.86 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 11.1 m-30 -100.77 129.35 46.64 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.206 -0.906 . . . . 0.0 108.785 -175.087 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 47.1 t -93.3 130.83 41.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 123.764 0.665 . . . . 0.0 109.973 -178.016 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 63.9 m95 -118.21 97.92 6.03 Favored 'General case' 0 C--N 1.275 -2.636 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 -178.853 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 47.2 m-80 -80.18 112.3 17.37 Favored 'General case' 0 C--N 1.285 -2.223 0 N-CA-C 106.732 -1.581 . . . . 0.0 106.732 178.249 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.431 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 24.0 mm -86.03 122.06 38.12 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.819 0 N-CA-C 108.126 -1.064 . . . . 0.0 108.126 -177.96 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -116.63 153.31 32.52 Favored 'General case' 0 C--N 1.286 -2.156 0 C-N-CA 124.052 0.941 . . . . 0.0 108.685 177.716 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -82.37 133.72 35.23 Favored 'General case' 0 N--CA 1.407 -2.585 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 176.066 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -92.94 -8.92 41.8 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -177.457 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -150.04 143.93 25.46 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 113.937 -1.483 . . . . 0.0 110.008 -176.653 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -84.65 136.16 33.87 Favored 'General case' 0 C--N 1.312 -1.033 0 O-C-N 123.966 0.791 . . . . 0.0 110.419 179.43 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.565 ' HB ' ' HB ' ' A' ' 120' ' ' ILE . 69.6 t -118.59 140.05 43.64 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.978 -173.642 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -119.78 138.34 50.71 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.136 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 178.476 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.458 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 71.6 t -99.93 101.13 13.02 Favored Pre-proline 0 C--N 1.293 -1.889 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 176.688 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.528 ' HG3' HG13 ' A' ' 27' ' ' VAL . 21.4 Cg_endo -67.47 -29.72 37.07 Favored 'Trans proline' 0 CA--C 1.504 -1.002 0 C-N-CA 122.215 1.943 . . . . 0.0 111.511 179.075 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 6.1 t . . . . . 0 C--O 1.267 1.974 0 O-C-N 125.002 1.439 . . . . 0.0 112.534 179.387 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.639 ' HB3' ' OD1' ' A' ' 54' ' ' ASP . 0.0 OUTLIER . . . . . 0 CA--C 1.496 -1.122 0 CA-C-O 120.84 0.352 . . . . 0.0 110.964 . . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.427 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -142.97 -178.87 6.04 Favored 'General case' 0 C--N 1.284 -2.275 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.052 178.487 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 12.4 t -148.76 156.76 42.8 Favored 'General case' 0 N--CA 1.426 -1.642 0 C-N-CA 119.395 -0.922 . . . . 0.0 109.711 -175.25 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.547 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -143.64 161.71 37.82 Favored 'General case' 0 C--N 1.297 -1.687 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.408 -175.102 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 54.9 p -97.64 -179.96 4.63 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-O 121.015 0.436 . . . . 0.0 110.71 179.679 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -81.44 -22.56 38.09 Favored 'General case' 0 C--N 1.298 -1.642 0 CA-C-O 121.551 0.691 . . . . 0.0 109.206 177.848 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -85.74 -28.89 24.31 Favored 'General case' 0 N--CA 1.433 -1.297 0 CA-C-N 114.821 -1.082 . . . . 0.0 112.518 -175.784 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 130.43 22.79 1.05 Allowed Glycine 0 CA--C 1.49 -1.488 0 C-N-CA 118.868 -1.634 . . . . 0.0 113.974 171.588 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -103.04 99.42 9.3 Favored 'General case' 0 C--N 1.291 -1.937 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.363 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -94.25 114.15 26.19 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 115.879 -0.601 . . . . 0.0 109.399 176.825 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.427 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 68.5 mt -84.55 126.91 67.7 Favored Pre-proline 0 C--N 1.3 -1.582 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -179.171 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_endo -80.2 164.53 21.94 Favored 'Trans proline' 0 C--O 1.246 0.921 0 C-N-CA 122.614 2.209 . . . . 0.0 111.369 178.405 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.5 mt -65.91 126.31 24.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 177.984 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 135.57 10.02 1.49 Allowed Glycine 0 C--N 1.307 -1.028 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.613 -179.577 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 88.03 161.31 36.82 Favored Glycine 0 C--N 1.319 -0.392 0 N-CA-C 110.964 -0.855 . . . . 0.0 110.964 -177.924 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 161.61 -172.97 37.92 Favored Glycine 0 CA--C 1.495 -1.169 0 C-N-CA 119.938 -1.125 . . . . 0.0 111.331 178.448 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.435 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 65.2 p -144.51 144.03 31.14 Favored 'General case' 0 N--CA 1.43 -1.465 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 -179.306 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -130.98 162.16 30.36 Favored 'General case' 0 N--CA 1.415 -2.192 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.286 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -111.96 116.11 30.06 Favored 'General case' 0 C--N 1.271 -2.838 0 N-CA-C 107.043 -1.465 . . . . 0.0 107.043 174.773 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.464 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.2 m -99.63 139.03 22.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.683 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 179.22 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 23.7 m-85 -117.72 115.98 26.12 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-O 120.879 0.371 . . . . 0.0 111.994 -179.715 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.516 HG22 ' HG3' ' A' ' 41' ' ' GLN . 19.3 t -115.68 129.34 72.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.805 -173.819 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 3.9 p30 -89.27 119.75 30.03 Favored 'General case' 0 C--N 1.293 -1.849 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 177.778 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 28.1 mt -110.74 152.24 26.81 Favored 'General case' 0 C--N 1.282 -2.333 0 CA-C-N 115.051 -0.977 . . . . 0.0 108.984 -176.939 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -52.73 119.32 15.48 Favored Pre-proline 0 C--O 1.204 -1.296 0 O-C-N 124.513 1.133 . . . . 0.0 110.326 179.319 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.576 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 60.9 Cg_endo -73.83 -0.53 9.56 Favored 'Trans proline' 0 CA--C 1.544 0.993 0 C-N-CA 122.502 2.135 . . . . 0.0 113.616 -175.584 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.445 HG13 ' HG3' ' A' ' 157' ' ' PRO . 98.4 t -131.06 109.61 16.75 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 N-CA-C 107.844 -1.169 . . . . 0.0 107.844 178.161 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.449 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 14.0 t -146.12 108.38 0.8 Allowed 'Isoleucine or valine' 0 C--O 1.193 -1.909 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 -177.248 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.537 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.6 OUTLIER -95.87 154.22 17.34 Favored 'General case' 0 C--N 1.273 -2.747 0 C-N-CA 123.864 0.865 . . . . 0.0 111.031 -179.84 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.526 HG22 ' O ' ' A' ' 112' ' ' VAL . 99.1 t -47.18 117.55 0.42 Allowed 'Isoleucine or valine' 0 C--O 1.235 0.328 0 C-N-CA 123.436 0.694 . . . . 0.0 111.197 176.482 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.92 0.38 45.27 Favored Glycine 0 C--N 1.312 -0.803 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.924 -179.634 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.537 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -74.9 -176.7 3.0 Favored 'General case' 0 C--N 1.316 -0.884 0 C-N-CA 123.751 0.821 . . . . 0.0 110.329 175.876 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.2 t-20 -127.09 89.75 3.03 Favored 'General case' 0 CA--C 1.491 -1.32 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 177.721 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.559 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 20.0 tp -98.34 133.68 42.4 Favored 'General case' 0 C--N 1.295 -1.8 0 C-N-CA 118.898 -1.121 . . . . 0.0 109.256 177.158 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.405 ' CG2' ' HB1' ' A' ' 106' ' ' ALA . 2.1 p -141.56 130.75 23.92 Favored 'Isoleucine or valine' 0 N--CA 1.382 -3.854 0 CA-C-N 114.797 -1.092 . . . . 0.0 112.075 -178.028 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.6 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 47.8 t -87.61 89.56 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.576 0 CA-C-N 113.832 -1.531 . . . . 0.0 107.266 178.801 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.47 ' O ' ' HG2' ' A' ' 41' ' ' GLN . 18.2 t70 -77.26 102.83 6.87 Favored 'General case' 0 C--N 1.309 -1.189 0 CA-C-O 120.708 0.289 . . . . 0.0 110.683 -179.173 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 91.3 mt -85.08 -3.65 58.87 Favored 'General case' 0 C--N 1.311 -1.094 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.306 -178.512 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 35.2 t -73.27 0.1 12.91 Favored 'General case' 0 CA--C 1.542 0.636 0 CA-C-O 121.478 0.656 . . . . 0.0 110.135 -179.624 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.3 p -130.2 5.23 4.85 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 115.793 -0.64 . . . . 0.0 110.206 176.468 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.516 ' HG3' HG22 ' A' ' 22' ' ' VAL . 48.6 mm-40 -120.45 -20.75 7.08 Favored 'General case' 0 C--O 1.239 0.511 0 CA-C-O 121.03 0.443 . . . . 0.0 110.299 -174.177 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.401 HD11 HG11 ' A' ' 20' ' ' VAL . 37.4 mt -138.75 138.7 41.92 Favored 'Isoleucine or valine' 0 C--O 1.243 0.714 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 -177.103 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.547 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 48.7 m-85 -142.47 127.44 18.37 Favored 'General case' 0 N--CA 1.476 0.862 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 -176.836 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 75.8 m -109.17 138.69 45.14 Favored 'General case' 0 C--N 1.295 -1.776 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -178.648 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.421 ' NE2' ' HB3' ' A' ' 2' ' ' ALA . 10.9 p-80 -121.07 154.34 36.24 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-O 122.335 1.064 . . . . 0.0 112.085 -176.47 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.486 HD22 ' CG ' ' A' ' 54' ' ' ASP . 3.0 m120 -96.9 114.81 26.46 Favored 'General case' 0 C--N 1.28 -2.434 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -179.423 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -77.09 -32.51 56.71 Favored 'General case' 0 CA--C 1.496 -1.118 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.301 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 38.4 m-85 -138.68 83.03 20.38 Favored Pre-proline 0 C--N 1.315 -0.934 0 CA-C-N 114.331 -1.304 . . . . 0.0 108.921 -176.955 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -75.95 3.68 5.88 Favored 'Trans proline' 0 CA--C 1.541 0.831 0 C-N-CA 122.59 2.194 . . . . 0.0 113.685 -176.06 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -117.64 -22.35 8.11 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 121.268 0.556 . . . . 0.0 110.434 178.275 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.516 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.7 OUTLIER -98.49 -28.72 13.48 Favored 'General case' 0 N--CA 1.424 -1.741 0 CA-C-O 122.074 0.94 . . . . 0.0 109.244 -172.035 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.516 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.1 mp -122.67 135.79 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.087 0 CA-C-N 114.306 -1.316 . . . . 0.0 109.648 -178.346 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.446 HG22 HD22 ' A' ' 136' ' ' ASN . 3.3 t -86.42 124.29 32.59 Favored 'General case' 0 N--CA 1.417 -2.114 0 N-CA-C 103.022 -2.955 . . . . 0.0 103.022 169.22 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.639 ' OD1' ' HB3' ' A' ' 1' ' ' PHE . 16.1 m-20 -91.47 107.88 19.51 Favored 'General case' 0 C--N 1.271 -2.811 0 C-N-CA 118.815 -1.154 . . . . 0.0 109.433 -169.005 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 22.0 t80 -117.89 139.56 50.95 Favored 'General case' 0 C--N 1.273 -2.746 0 CA-C-N 114.341 -1.3 . . . . 0.0 109.588 -175.74 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.507 HG23 ' HG ' ' A' ' 131' ' ' LEU . 12.9 p -145.59 145.39 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.794 0 O-C-N 123.626 0.579 . . . . 0.0 109.815 -179.577 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -149.4 125.11 10.44 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.085 174.584 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.505 HD12 ' O ' ' A' ' 130' ' ' ILE . 41.9 tp -61.82 110.35 1.51 Allowed 'General case' 0 C--N 1.312 -1.032 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 169.975 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.6 tp-100 -60.18 -56.95 15.34 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 126.63 1.972 . . . . 0.0 109.861 -179.074 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 10.8 ptp180 -164.14 160.16 21.11 Favored 'General case' 0 N--CA 1.426 -1.634 0 CA-C-N 114.505 -1.225 . . . . 0.0 108.874 -175.274 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -141.38 139.96 9.9 Favored Glycine 0 N--CA 1.411 -2.998 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -178.756 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 73.2 m -126.06 150.63 48.0 Favored 'General case' 0 C--N 1.289 -2.025 0 C-N-CA 124.139 0.976 . . . . 0.0 110.266 -176.807 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.48 ' HB2' ' CE2' ' A' ' 84' ' ' PHE . . . -114.2 157.69 22.34 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.202 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.461 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 87.0 m-85 -155.13 -178.88 7.56 Favored 'General case' 0 C--O 1.239 0.537 0 C-N-CA 124.12 0.968 . . . . 0.0 109.244 -178.609 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 60.25 -138.65 48.54 Favored Glycine 0 C--O 1.228 -0.279 0 O-C-N 123.537 0.523 . . . . 0.0 113.236 176.886 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.44 -8.79 85.76 Favored Glycine 0 N--CA 1.432 -1.631 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.355 177.037 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.815 HG21 ' HB ' ' A' ' 126' ' ' ILE . 84.0 t -69.13 -41.25 81.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 C-N-CA 123.52 0.728 . . . . 0.0 111.572 -176.709 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.471 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -83.21 -21.01 33.55 Favored 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.73 -0.788 . . . . 0.0 112.359 179.692 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 18.4 m -101.71 -50.69 3.63 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 115.25 1.574 . . . . 0.0 115.25 -174.802 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.493 ' O ' HG22 ' A' ' 112' ' ' VAL . 47.7 m-20 -93.73 -23.45 18.2 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -175.628 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.625 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 88.2 m-85 -108.1 159.24 16.73 Favored 'General case' 0 N--CA 1.423 -1.802 0 C-N-CA 120.02 -0.672 . . . . 0.0 109.324 176.979 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.6 t -167.5 125.11 1.21 Allowed 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 107.992 -1.114 . . . . 0.0 107.992 175.617 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.475 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -159.51 -110.28 0.27 Allowed Glycine 0 N--CA 1.407 -3.284 0 N-CA-C 109.914 -1.274 . . . . 0.0 109.914 176.648 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.3 p -156.96 179.97 8.78 Favored 'General case' 0 C--N 1.296 -1.744 0 C-N-CA 123.531 0.733 . . . . 0.0 110.965 -173.101 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.429 HG13 ' CE2' ' A' ' 82' ' ' TYR . 2.6 p -133.69 144.37 36.05 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 177.919 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.678 ' HG3' ' O ' ' A' ' 80' ' ' SER . 86.0 tttt -123.42 150.19 44.09 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.318 -178.699 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.441 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 60.8 t80 -148.94 109.42 4.19 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 -178.812 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.6 t 51.48 41.01 28.07 Favored 'General case' 0 CA--C 1.554 1.105 0 C-N-CA 124.32 1.048 . . . . 0.0 111.396 178.037 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.83 6.73 67.08 Favored Glycine 0 CA--C 1.526 0.756 0 CA-C-N 115.615 -0.721 . . . . 0.0 113.987 179.82 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.678 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 22.8 t -79.57 179.98 7.18 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 178.43 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 3.6 p -157.99 107.15 2.06 Favored 'General case' 0 C--N 1.292 -1.896 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 -179.489 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.441 ' OH ' ' HB2' ' A' ' 77' ' ' TYR . 2.5 p90 -151.49 158.44 34.32 Favored Pre-proline 0 C--N 1.308 -1.228 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 -174.418 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -69.25 148.54 68.58 Favored 'Trans proline' 0 C--N 1.358 1.033 0 C-N-CA 122.819 2.346 . . . . 0.0 112.977 -176.385 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.601 ' CD2' HD21 ' A' ' 109' ' ' LEU . 63.0 t80 -121.92 133.4 24.29 Favored Pre-proline 0 N--CA 1.438 -1.058 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.773 179.98 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.493 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 74.1 Cg_endo -71.15 146.63 85.49 Favored 'Cis proline' 0 CA--C 1.548 1.223 0 C-N-CA 123.079 -1.634 . . . . 0.0 110.56 -1.856 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.1 t -64.13 -176.74 0.22 Allowed 'General case' 0 CA--C 1.558 1.262 0 C-N-CA 123.547 0.739 . . . . 0.0 112.279 -174.015 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 19.9 p -129.54 -27.6 2.37 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 113.161 0.8 . . . . 0.0 113.161 -172.449 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 t -127.62 -73.46 0.6 Allowed 'General case' 0 N--CA 1.435 -1.21 0 C-N-CA 119.736 -0.786 . . . . 0.0 110.684 -178.45 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -177.78 -174.57 0.46 Allowed 'General case' 0 C--O 1.243 0.726 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 -176.684 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.456 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 12.4 p -102.07 163.28 18.05 Favored Pre-proline 0 C--N 1.299 -1.592 0 O-C-N 123.432 0.458 . . . . 0.0 112.196 178.083 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -64.55 157.48 54.98 Favored 'Trans proline' 0 C--N 1.36 1.176 0 C-N-CA 122.669 2.246 . . . . 0.0 111.576 174.996 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.4 tmm_? -68.79 110.81 4.51 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 114.898 -1.046 . . . . 0.0 110.209 -175.757 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 71.0 t -122.35 132.83 70.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.826 -178.093 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 95.6 t -117.24 136.25 55.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 115.3 -0.863 . . . . 0.0 109.494 178.97 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.485 ' OH ' ' HA ' ' A' ' 103' ' ' TRP . 4.1 m-85 -82.99 94.97 7.88 Favored 'General case' 0 CA--C 1.499 -0.985 0 CA-C-O 121.41 0.624 . . . . 0.0 110.348 177.516 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 17.6 m120 -89.26 61.13 5.59 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 178.754 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.6 m -143.67 -179.3 6.36 Favored 'General case' 0 N--CA 1.423 -1.798 0 N-CA-C 108.207 -1.035 . . . . 0.0 108.207 -176.959 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 4.5 ptm180 -146.08 50.7 1.16 Allowed 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 121.425 0.631 . . . . 0.0 109.979 179.998 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 14.0 t -169.87 177.41 4.4 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 -175.201 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -71.77 98.02 1.89 Allowed 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 106.608 -1.627 . . . . 0.0 106.608 173.07 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 11.5 tptt -103.14 139.33 20.01 Favored Pre-proline 0 N--CA 1.407 -2.602 0 N-CA-C 107.202 -1.407 . . . . 0.0 107.202 -177.678 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_endo -58.9 147.26 90.23 Favored 'Trans proline' 0 CA--C 1.511 -0.632 0 C-N-CA 122.605 2.203 . . . . 0.0 112.631 -176.993 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . 0.485 ' HA ' ' OH ' ' A' ' 95' ' ' TYR . 10.1 t90 -90.48 105.93 13.41 Favored Pre-proline 0 C--N 1.302 -1.472 0 N-CA-C 106.338 -1.727 . . . . 0.0 106.338 178.6 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -77.83 87.94 1.47 Allowed 'Trans proline' 0 N--CA 1.443 -1.456 0 C-N-CA 121.616 1.544 . . . . 0.0 112.21 -173.094 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.438 HG22 ' CD2' ' A' ' 77' ' ' TYR . 86.7 t -139.01 147.03 25.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 N-CA-C 106.879 -1.526 . . . . 0.0 106.879 177.851 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.6 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -153.14 134.26 14.1 Favored 'General case' 0 C--N 1.284 -2.265 0 CA-C-O 120.811 0.338 . . . . 0.0 110.381 178.522 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.47 HD21 HD11 ' A' ' 129' ' ' LEU . 18.7 mt -101.6 99.86 10.2 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 179.151 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.475 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 74.2 m-85 -79.59 77.43 6.19 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 177.746 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.625 ' HB3' ' HB3' ' A' ' 71' ' ' PHE . 3.2 mm? -102.54 118.72 37.47 Favored 'General case' 0 CA--C 1.488 -1.414 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 176.365 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -122.18 146.91 47.97 Favored Pre-proline 0 N--CA 1.402 -2.867 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -174.964 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -63.4 123.14 11.61 Favored 'Trans proline' 0 CA--C 1.491 -1.625 0 C-N-CA 123.245 2.63 . . . . 0.0 113.379 -175.469 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.526 ' O ' HG22 ' A' ' 30' ' ' VAL . 24.3 m -83.22 -159.25 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.385 -3.689 0 CA-C-N 114.181 -1.372 . . . . 0.0 108.871 171.15 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.8 m -79.21 -29.56 42.86 Favored 'General case' 0 C--N 1.252 -3.631 0 CA-C-O 121.464 0.65 . . . . 0.0 110.296 -170.352 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 11.3 t -82.52 25.5 0.63 Allowed 'General case' 0 N--CA 1.428 -1.53 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.188 -179.77 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -109.17 136.75 48.15 Favored 'General case' 0 N--CA 1.422 -1.842 0 O-C-N 121.828 -0.545 . . . . 0.0 109.818 178.847 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -174.91 134.49 2.77 Favored Glycine 0 N--CA 1.432 -1.6 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 178.332 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 60.49 -149.3 43.29 Favored Glycine 0 CA--C 1.494 -1.221 0 CA-C-O 119.32 -0.711 . . . . 0.0 112.151 -177.637 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 94.0 t -57.95 105.11 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.061 0 CA-C-O 121.923 0.868 . . . . 0.0 111.261 -177.884 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -104.37 -22.22 13.37 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 114.51 -1.223 . . . . 0.0 110.62 -178.772 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.483 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 67.9 mt -136.83 138.13 46.44 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 N-CA-C 107.987 -1.116 . . . . 0.0 107.987 179.474 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.509 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.6 mmpt? -116.6 143.01 46.14 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.066 0.46 . . . . 0.0 109.79 174.744 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -71.5 131.05 42.74 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.891 -179.17 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 96.63 -6.07 64.87 Favored Glycine 0 N--CA 1.44 -1.083 0 C-N-CA 121.231 -0.509 . . . . 0.0 112.157 -179.316 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 27.2 m -94.9 147.53 23.27 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-O 120.778 0.323 . . . . 0.0 110.747 -179.302 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -74.25 124.04 25.66 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.271 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.815 ' HB ' HG21 ' A' ' 67' ' ' VAL . 31.2 pt -111.27 -26.28 3.2 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 N-CA-C 112.847 0.684 . . . . 0.0 112.847 -178.555 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . 0.42 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -161.83 168.52 22.93 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 110.169 -0.308 . . . . 0.0 110.169 -177.679 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 73.7 t -143.4 114.44 2.54 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.487 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.47 HD11 HD21 ' A' ' 107' ' ' LEU . 62.9 mt -116.01 142.5 46.72 Favored 'General case' 0 C--N 1.291 -1.968 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 178.631 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.505 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.9 mp -121.08 126.54 75.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 C-N-CA 119.272 -0.971 . . . . 0.0 110.77 177.477 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.527 ' HB3' ' HE1' ' A' ' 146' ' ' TRP . 0.2 OUTLIER -98.05 131.41 44.49 Favored 'General case' 0 C--N 1.271 -2.813 0 C-N-CA 124.68 1.192 . . . . 0.0 109.182 179.422 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.636 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 12.6 tpt180 -104.9 124.53 49.64 Favored 'General case' 0 C--N 1.298 -1.661 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -179.86 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.579 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 12.6 mm100 -105.84 118.54 36.87 Favored 'General case' 0 C--N 1.319 -0.72 0 O-C-N 123.592 0.557 . . . . 0.0 110.345 179.242 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 5.1 m -136.6 149.7 48.18 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 106.377 -1.712 . . . . 0.0 106.377 177.462 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.49 ' CB ' HG23 ' A' ' 52' ' ' ILE . 12.6 p30 -144.86 178.82 7.74 Favored 'General case' 0 C--N 1.324 -0.529 0 C-N-CA 119.458 -0.897 . . . . 0.0 112.249 175.555 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.446 HD22 HG22 ' A' ' 53' ' ' THR . 8.9 p30 -80.15 -24.53 40.36 Favored 'General case' 0 N--CA 1.476 0.874 0 CA-C-O 121.253 0.549 . . . . 0.0 112.231 -175.135 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 85.3 t80 -97.09 -65.35 0.97 Allowed 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 123.589 0.756 . . . . 0.0 111.026 -170.357 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . 0.45 ' HB3' ' H ' ' A' ' 140' ' ' ASP . 17.5 m120 -74.52 150.18 39.92 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 123.202 0.601 . . . . 0.0 110.773 179.061 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 21.4 t -97.05 7.87 45.71 Favored 'General case' 0 C--N 1.309 -1.192 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 172.524 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . 0.45 ' H ' ' HB3' ' A' ' 138' ' ' ASN . 5.1 m-20 -72.06 63.26 0.49 Allowed 'General case' 0 N--CA 1.467 0.412 0 C-N-CA 125.872 1.669 . . . . 0.0 110.844 179.661 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -86.55 89.62 7.97 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 115.229 -0.896 . . . . 0.0 109.644 179.495 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -119.34 167.45 11.89 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.314 -178.354 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . 0.636 ' HB3' ' HD2' ' A' ' 132' ' ' ARG . 14.0 pt20 -129.34 145.92 51.3 Favored 'General case' 0 N--CA 1.417 -2.089 0 C-N-CA 119.812 -0.755 . . . . 0.0 111.336 177.851 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.447 ' HB2' HD22 ' A' ' 131' ' ' LEU . 11.0 m-30 -109.5 130.44 55.5 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 -178.007 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.435 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 61.9 t -90.36 131.77 36.69 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.053 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 179.86 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . 0.527 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 69.2 m95 -119.9 97.96 5.87 Favored 'General case' 0 C--N 1.275 -2.636 0 N-CA-C 108.882 -0.785 . . . . 0.0 108.882 -179.273 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 49.2 m-80 -80.01 114.7 19.11 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 178.634 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.464 ' HA ' HG22 ' A' ' 20' ' ' VAL . 23.6 mm -88.21 122.06 39.31 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 -177.718 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -118.19 156.1 29.33 Favored 'General case' 0 C--N 1.299 -1.591 0 C-N-CA 123.241 0.616 . . . . 0.0 109.697 178.506 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -84.1 131.61 34.77 Favored 'General case' 0 N--CA 1.414 -2.258 0 CA-C-N 115.238 -0.892 . . . . 0.0 108.682 177.33 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 27.4 t-20 -95.75 -12.12 25.9 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 107.813 -1.18 . . . . 0.0 107.813 -176.812 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -155.08 146.49 22.99 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 113.84 -1.527 . . . . 0.0 108.326 -178.089 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 17.8 p-10 -86.05 148.15 25.86 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 124.152 0.981 . . . . 0.0 111.564 -177.181 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.576 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 77.7 t -123.57 136.04 61.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-N 115.459 -0.792 . . . . 0.0 111.194 -174.542 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.5 t -118.29 135.1 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.058 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 178.767 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.449 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 69.1 t -99.37 103.77 22.73 Favored Pre-proline 0 C--N 1.291 -1.975 0 C-N-CA 123.867 0.867 . . . . 0.0 109.871 -179.972 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.486 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 50.1 Cg_endo -72.77 -17.11 26.11 Favored 'Trans proline' 0 C--N 1.333 -0.289 0 C-N-CA 122.034 1.822 . . . . 0.0 111.424 178.021 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . 0.273 4.0 t . . . . . 0 C--O 1.239 0.543 0 C-N-CA 125.414 1.486 . . . . 0.0 113.568 177.75 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.563 ' CZ ' ' HB3' ' A' ' 133' ' ' GLN . 0.3 OUTLIER . . . . . 0 CA--C 1.5 -0.976 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 . . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.484 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -147.51 -175.32 4.81 Favored 'General case' 0 C--N 1.291 -1.973 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 -175.289 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 14.7 t -148.78 157.01 43.13 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.394 -0.922 . . . . 0.0 109.958 -177.006 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.495 ' HE2' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.91 156.28 43.9 Favored 'General case' 0 C--N 1.308 -1.216 0 CA-C-O 121.868 0.842 . . . . 0.0 111.434 -174.789 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 36.3 p -94.97 171.47 8.74 Favored 'General case' 0 C--N 1.297 -1.697 0 CA-C-N 115.183 -0.917 . . . . 0.0 110.749 178.402 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -80.7 -10.93 59.7 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 114.661 -1.154 . . . . 0.0 110.332 -179.127 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -93.06 -33.22 14.18 Favored 'General case' 0 N--CA 1.431 -1.384 0 CA-C-N 114.96 -1.018 . . . . 0.0 111.796 -177.556 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 142.88 -1.59 1.53 Allowed Glycine 0 CA--C 1.507 -0.448 0 C-N-CA 119.158 -1.496 . . . . 0.0 114.462 171.461 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 7.4 m -86.35 104.99 16.38 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 122.202 -0.587 . . . . 0.0 110.93 -178.441 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -96.31 118.66 33.31 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 173.773 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.484 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 66.2 mt -89.84 122.58 67.8 Favored Pre-proline 0 C--N 1.297 -1.694 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 -179.649 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -77.24 171.91 16.95 Favored 'Trans proline' 0 C--O 1.239 0.563 0 C-N-CA 122.939 2.426 . . . . 0.0 111.582 179.6 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 62.7 mt -72.85 120.1 20.88 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.807 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 179.155 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 140.98 23.36 0.25 Allowed Glycine 0 C--N 1.301 -1.415 0 CA-C-N 115.393 -0.822 . . . . 0.0 112.027 -179.668 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 73.79 167.41 14.75 Favored Glycine 0 C--N 1.335 0.494 0 C-N-CA 121.156 -0.545 . . . . 0.0 112.309 -177.28 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 153.97 -172.01 32.64 Favored Glycine 0 CA--C 1.483 -1.966 0 C-N-CA 120.087 -1.054 . . . . 0.0 110.925 176.229 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.43 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 78.3 p -141.43 156.27 45.8 Favored 'General case' 0 N--CA 1.42 -1.953 0 N-CA-C 109.652 -0.499 . . . . 0.0 109.652 178.918 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -137.23 160.22 39.66 Favored 'General case' 0 N--CA 1.422 -1.864 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 177.536 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 18.9 m-80 -114.15 109.89 19.12 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 105.143 -2.169 . . . . 0.0 105.143 175.713 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.495 HG22 ' HA ' ' A' ' 148' ' ' ILE . 0.8 OUTLIER -91.84 143.2 11.8 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.328 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 -178.132 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 63.2 m-85 -119.52 116.07 25.32 Favored 'General case' 0 C--N 1.297 -1.711 0 C-N-CA 120.803 -0.359 . . . . 0.0 111.557 -179.249 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.436 HG22 ' HG3' ' A' ' 41' ' ' GLN . 22.0 t -119.58 132.75 68.49 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 115.923 -0.58 . . . . 0.0 111.041 -174.888 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 45.4 m-80 -88.6 123.09 32.75 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 176.881 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.467 HD11 HG22 ' A' ' 36' ' ' VAL . 2.9 mm? -104.14 160.44 14.86 Favored 'General case' 0 C--N 1.287 -2.143 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.502 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -59.33 123.71 71.48 Favored Pre-proline 0 C--N 1.316 -0.886 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.382 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 88.0 Cg_endo -78.53 1.58 8.91 Favored 'Trans proline' 0 C--N 1.33 -0.427 0 C-N-CA 122.78 2.32 . . . . 0.0 113.159 -175.264 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 98.7 t -129.53 109.77 18.83 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 177.311 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 2.0 t -143.03 103.53 0.92 Allowed 'Isoleucine or valine' 0 C--O 1.18 -2.585 0 N-CA-C 108.27 -1.011 . . . . 0.0 108.27 -176.347 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.728 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -95.16 155.27 16.8 Favored 'General case' 0 C--N 1.272 -2.783 0 C-N-CA 122.364 0.266 . . . . 0.0 111.01 -179.838 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.606 HG22 ' O ' ' A' ' 112' ' ' VAL . 87.5 t -46.94 118.71 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 C-N-CA 123.06 0.544 . . . . 0.0 111.064 175.387 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.98 9.61 57.05 Favored Glycine 0 C--N 1.31 -0.887 0 CA-C-N 115.212 -0.904 . . . . 0.0 112.939 179.467 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.728 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -80.77 -177.72 6.46 Favored 'General case' 0 C--N 1.313 -1.01 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 175.413 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -130.88 87.65 2.51 Favored 'General case' 0 C--N 1.31 -1.146 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 178.859 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.66 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 27.1 tp -88.1 144.56 26.42 Favored 'General case' 0 C--N 1.292 -1.906 0 C-N-CA 119.589 -0.844 . . . . 0.0 109.685 -178.803 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.7 t -137.7 130.33 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.882 0 N-CA-C 109.021 -0.733 . . . . 0.0 109.021 -177.597 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.565 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 40.3 t -97.54 88.75 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.413 -2.304 0 N-CA-C 105.685 -1.968 . . . . 0.0 105.685 172.734 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.411 ' O ' ' HG2' ' A' ' 41' ' ' GLN . 12.9 t70 -82.03 109.74 16.64 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 -177.781 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 85.9 mt -92.47 -1.32 57.06 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-O 121.072 0.463 . . . . 0.0 111.284 -178.012 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.579 ' O ' ' HB3' ' A' ' 102' ' ' PRO . 34.1 t -76.25 0.27 19.81 Favored 'General case' 0 C--N 1.31 -1.121 0 CA-C-O 121.652 0.739 . . . . 0.0 109.459 -178.713 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.6 p -129.81 5.51 5.04 Favored 'General case' 0 N--CA 1.412 -2.33 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.599 178.83 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.436 ' HG3' HG22 ' A' ' 22' ' ' VAL . 48.9 mm-40 -124.69 -21.13 4.88 Favored 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.854 -173.89 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 39.0 mt -134.8 138.73 48.81 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.974 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 -177.333 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.495 ' HB2' ' HE2' ' A' ' 4' ' ' LYS . 49.5 m-85 -142.32 128.63 19.95 Favored 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -176.065 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 85.0 m -107.57 145.9 32.61 Favored 'General case' 0 C--N 1.284 -2.251 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 -179.032 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 12.1 p80 -131.62 128.35 38.95 Favored 'General case' 0 C--N 1.296 -1.728 0 CA-C-O 122.16 0.981 . . . . 0.0 111.744 -176.516 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . . . . . . . . . 20.8 p-10 -97.11 89.66 4.87 Favored 'General case' 0 C--N 1.282 -2.335 0 CA-C-O 122.257 1.027 . . . . 0.0 108.693 178.572 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . 0.586 ' HB2' ' CD2' ' A' ' 48' ' ' TYR . 1.4 m-20 -51.74 -43.62 62.99 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.25 -175.676 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . 0.586 ' CD2' ' HB2' ' A' ' 47' ' ' ASP . 29.2 m-85 -121.84 83.27 43.01 Favored Pre-proline 0 C--N 1.315 -0.913 0 N-CA-C 107.837 -1.172 . . . . 0.0 107.837 -175.278 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . . . . . . . . . 87.8 Cg_endo -83.01 -5.51 11.32 Favored 'Trans proline' 0 C--O 1.234 0.29 0 C-N-CA 122.99 2.46 . . . . 0.0 112.786 -173.606 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -103.78 -23.35 13.42 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.023 -178.09 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.711 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.3 OUTLIER -100.33 -30.76 11.69 Favored 'General case' 0 N--CA 1.415 -2.222 0 CA-C-O 122.02 0.914 . . . . 0.0 108.867 -176.0 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.711 HD12 ' HB ' ' A' ' 51' ' ' THR . 2.9 mp -128.96 134.9 63.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 CA-C-N 114.636 -1.166 . . . . 0.0 109.927 -176.584 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.459 HG22 HD22 ' A' ' 136' ' ' ASN . 5.9 t -86.51 139.05 31.24 Favored 'General case' 0 N--CA 1.438 -1.052 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 171.5 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.464 ' HB3' ' HB2' ' A' ' 95' ' ' TYR . 14.6 t70 -96.07 108.78 21.25 Favored 'General case' 0 C--N 1.275 -2.664 0 C-N-CA 119.673 -0.811 . . . . 0.0 109.147 -175.832 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . . . . . . . . . 23.6 t80 -122.64 122.15 38.12 Favored 'General case' 0 C--N 1.288 -2.065 0 CA-C-O 121.799 0.809 . . . . 0.0 110.065 -177.702 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.443 HG22 ' NE2' ' A' ' 133' ' ' GLN . 85.3 t -125.95 138.52 54.29 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 CA-C-N 114.169 -1.378 . . . . 0.0 110.067 -176.084 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 1.2 p -144.46 135.3 24.97 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 108.508 -0.923 . . . . 0.0 108.508 172.602 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.547 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 38.9 tp -74.58 104.91 5.45 Favored 'General case' 0 N--CA 1.436 -1.132 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 175.429 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -52.96 -54.2 38.49 Favored 'General case' 0 C--O 1.201 -1.457 0 C-N-CA 126.278 1.831 . . . . 0.0 111.048 -179.55 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.405 ' HG3' HD13 ' A' ' 130' ' ' ILE . 0.4 OUTLIER -165.52 156.35 13.74 Favored 'General case' 0 C--N 1.298 -1.66 0 N-CA-C 107.127 -1.435 . . . . 0.0 107.127 -177.766 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -144.87 118.34 1.11 Allowed Glycine 0 N--CA 1.398 -3.846 0 N-CA-C 108.941 -1.663 . . . . 0.0 108.941 -178.099 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.403 ' HA ' ' HB3' ' A' ' 85' ' ' PRO . 52.8 m -114.52 146.56 40.58 Favored 'General case' 0 C--N 1.279 -2.472 0 C-N-CA 124.584 1.153 . . . . 0.0 110.029 -170.859 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.527 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -106.26 156.66 18.25 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 123.496 0.718 . . . . 0.0 109.112 -178.715 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.484 ' O ' ' HB ' ' A' ' 67' ' ' VAL . 99.5 m-85 -154.48 -179.35 7.88 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 124.08 0.952 . . . . 0.0 109.742 -176.978 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.06 -136.44 51.18 Favored Glycine 0 N--CA 1.458 0.121 0 O-C-N 123.653 0.595 . . . . 0.0 112.669 178.012 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -83.79 -9.07 83.49 Favored Glycine 0 C--O 1.206 -1.635 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 177.477 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.826 HG21 ' HB ' ' A' ' 126' ' ' ILE . 77.7 t -69.67 -36.42 70.36 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 C-N-CA 123.745 0.818 . . . . 0.0 111.852 -176.107 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.527 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.2 OUTLIER -87.16 -20.25 27.28 Favored 'General case' 0 C--N 1.297 -1.684 0 C-N-CA 119.216 -0.993 . . . . 0.0 112.296 178.306 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 9.6 t -101.03 -52.79 3.2 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.472 0.653 . . . . 0.0 112.195 -173.757 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.485 ' O ' HG22 ' A' ' 112' ' ' VAL . 31.6 m-20 -91.78 -25.81 18.85 Favored 'General case' 0 CA--C 1.49 -1.353 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -173.69 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.639 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 86.1 m-85 -106.61 155.85 19.21 Favored 'General case' 0 N--CA 1.416 -2.152 0 C-N-CA 120.008 -0.677 . . . . 0.0 109.291 177.254 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 9.3 t -165.48 117.83 1.14 Allowed 'General case' 0 N--CA 1.43 -1.452 0 N-CA-C 108.011 -1.107 . . . . 0.0 108.011 176.992 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.506 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -153.56 -111.88 0.46 Allowed Glycine 0 N--CA 1.412 -2.924 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 176.714 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.9 p -154.51 -179.72 8.23 Favored 'General case' 0 C--N 1.297 -1.687 0 C-N-CA 123.561 0.744 . . . . 0.0 110.93 -173.66 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -133.95 144.02 36.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 C-N-CA 123.319 0.648 . . . . 0.0 109.874 177.762 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.61 ' HG3' ' O ' ' A' ' 80' ' ' SER . 85.0 tttt -121.68 142.82 49.78 Favored 'General case' 0 N--CA 1.432 -1.374 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.648 178.767 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.46 ' CD2' HG22 ' A' ' 105' ' ' VAL . 62.6 t80 -142.42 110.35 5.89 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.517 -179.055 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 8.9 t 49.77 38.9 16.66 Favored 'General case' 0 CA--C 1.557 1.231 0 C-N-CA 124.43 1.092 . . . . 0.0 111.735 176.017 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.28 18.3 50.05 Favored Glycine 0 CA--C 1.524 0.596 0 C-N-CA 120.922 -0.656 . . . . 0.0 113.624 -179.404 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.61 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 12.2 t -92.73 -179.84 5.27 Favored 'General case' 0 C--N 1.308 -1.212 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 174.597 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 56.3 p -157.87 105.53 1.99 Allowed 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 179.652 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.443 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 2.7 p90 -150.73 160.83 31.79 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 109.986 -0.376 . . . . 0.0 109.986 -173.791 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.443 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 45.0 Cg_endo -68.51 148.19 72.35 Favored 'Trans proline' 0 C--N 1.357 0.984 0 C-N-CA 122.935 2.423 . . . . 0.0 113.357 -177.788 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.602 ' CD2' HD21 ' A' ' 109' ' ' LEU . 60.5 t80 -123.61 134.15 25.08 Favored Pre-proline 0 N--CA 1.433 -1.289 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.484 -179.431 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.46 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 60.2 Cg_endo -70.54 148.76 89.19 Favored 'Cis proline' 0 CA--C 1.541 0.862 0 C-N-CA 122.77 -1.763 . . . . 0.0 110.469 -0.838 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 11.2 t -67.24 -177.22 0.65 Allowed 'General case' 0 CA--C 1.549 0.919 0 CA-C-O 121.266 0.555 . . . . 0.0 110.997 -176.86 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 18.5 p -130.39 -19.88 3.04 Favored 'General case' 0 N--CA 1.436 -1.174 0 N-CA-C 112.597 0.592 . . . . 0.0 112.597 -173.459 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 21.6 t -130.71 -89.36 0.47 Allowed 'General case' 0 C--O 1.204 -1.335 0 C-N-CA 120.429 -0.508 . . . . 0.0 110.309 -179.988 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -166.58 -173.01 2.33 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 177.888 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.547 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 61.8 p -100.32 163.48 18.17 Favored Pre-proline 0 C--N 1.304 -1.387 0 N-CA-C 112.795 0.665 . . . . 0.0 112.795 179.798 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_endo -56.65 165.27 4.83 Favored 'Trans proline' 0 C--O 1.248 0.99 0 C-N-CA 123.518 2.812 . . . . 0.0 111.43 172.711 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -74.47 122.17 22.62 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.479 -175.959 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 73.2 t -134.9 133.46 53.81 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 -178.348 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 54' ' ' ASP . 1.5 p -132.97 134.6 57.94 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.292 0 CA-C-N 115.971 -0.558 . . . . 0.0 109.596 -178.55 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.464 ' HB2' ' HB3' ' A' ' 54' ' ' ASP . 2.6 m-85 -83.07 117.91 23.18 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 179.182 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 9.9 m120 -102.07 27.56 6.52 Favored 'General case' 0 C--N 1.299 -1.591 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.756 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.9 m -99.23 -171.56 2.1 Favored 'General case' 0 N--CA 1.426 -1.628 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.291 -178.328 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 14.1 ptm180 -151.15 43.58 0.79 Allowed 'General case' 0 C--N 1.314 -0.952 0 CA-C-O 121.465 0.65 . . . . 0.0 110.39 175.769 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 15.3 t -168.18 -178.63 3.73 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -176.735 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -67.18 106.78 2.11 Favored 'General case' 0 CA--C 1.511 -0.542 0 C-N-CA 123.344 0.658 . . . . 0.0 109.39 179.607 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -112.6 135.1 21.52 Favored Pre-proline 0 C--N 1.293 -1.866 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 176.342 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.579 ' HB3' ' O ' ' A' ' 39' ' ' SER . 51.4 Cg_exo -53.69 139.61 67.41 Favored 'Trans proline' 0 CA--C 1.503 -1.067 0 C-N-CA 123.865 3.043 . . . . 0.0 112.295 177.357 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 15.5 t90 -85.0 106.85 9.74 Favored Pre-proline 0 C--N 1.298 -1.655 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 179.161 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . 0.403 ' HD3' ' O ' ' A' ' 102' ' ' PRO . 60.2 Cg_endo -77.0 88.22 1.42 Allowed 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 121.368 1.379 . . . . 0.0 113.096 -172.952 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.46 HG22 ' CD2' ' A' ' 77' ' ' TYR . 92.6 t -140.62 146.88 23.6 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.103 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 178.127 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.565 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -150.38 135.05 17.43 Favored 'General case' 0 C--N 1.294 -1.817 0 CA-C-O 120.757 0.313 . . . . 0.0 110.431 177.34 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.496 HD21 HD11 ' A' ' 129' ' ' LEU . 20.1 mt -100.97 105.18 16.38 Favored 'General case' 0 C--N 1.29 -1.984 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 178.083 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.506 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 43.9 m-85 -83.63 72.58 10.31 Favored 'General case' 0 C--N 1.289 -2.028 0 CA-C-O 120.67 0.272 . . . . 0.0 110.716 178.095 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.66 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -98.66 129.17 45.14 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 176.342 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.42 146.89 63.43 Favored Pre-proline 0 N--CA 1.41 -2.426 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 -175.9 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.458 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 40.4 Cg_endo -65.37 126.07 15.61 Favored 'Trans proline' 0 CA--C 1.496 -1.416 0 C-N-CA 123.133 2.555 . . . . 0.0 113.002 -175.181 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.606 ' O ' HG22 ' A' ' 30' ' ' VAL . 16.7 m -84.3 -154.78 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.401 -2.889 0 CA-C-N 114.518 -1.219 . . . . 0.0 108.044 171.667 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 18.5 m -82.76 -30.32 29.05 Favored 'General case' 0 C--N 1.255 -3.508 0 CA-C-O 121.497 0.665 . . . . 0.0 110.025 -170.609 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 18.1 t -84.73 30.81 0.55 Allowed 'General case' 0 N--CA 1.435 -1.201 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.156 -179.821 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -112.23 138.12 49.37 Favored 'General case' 0 N--CA 1.422 -1.831 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.874 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -179.22 128.01 1.2 Allowed Glycine 0 N--CA 1.437 -1.239 0 C-N-CA 120.367 -0.92 . . . . 0.0 112.425 -179.967 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 68.32 -149.05 49.54 Favored Glycine 0 CA--C 1.486 -1.728 0 CA-C-O 119.125 -0.819 . . . . 0.0 111.928 -177.436 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 57.4 t -59.85 103.4 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 CA-C-N 117.308 0.554 . . . . 0.0 110.088 -177.126 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -103.78 -29.16 11.2 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.04 -0.982 . . . . 0.0 110.953 -178.223 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.527 ' HB ' HG22 ' A' ' 154' ' ' VAL . 73.6 mt -126.69 137.48 57.7 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.849 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 176.947 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.46 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.9 mmpt? -114.06 141.87 46.9 Favored 'General case' 0 C--N 1.31 -1.131 0 C-N-CA 122.959 0.504 . . . . 0.0 110.121 177.048 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -73.03 135.71 44.94 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.286 179.677 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 84.49 11.31 77.98 Favored Glycine 0 N--CA 1.449 -0.476 0 N-CA-C 111.59 -0.604 . . . . 0.0 111.59 -179.016 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 27.3 t -113.98 147.76 38.06 Favored 'General case' 0 N--CA 1.433 -1.324 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 -179.332 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 23.1 tp -73.52 134.99 43.96 Favored 'General case' 0 CA--C 1.506 -0.747 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.795 -179.801 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.826 ' HB ' HG21 ' A' ' 67' ' ' VAL . 35.8 pt -120.12 -25.0 2.75 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.717 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 179.215 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . 0.408 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -163.35 166.0 23.43 Favored 'General case' 0 C--O 1.21 -1.017 0 N-CA-C 110.312 -0.255 . . . . 0.0 110.312 -178.022 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 67.1 t -139.48 113.18 6.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 179.3 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.496 HD11 HD21 ' A' ' 107' ' ' LEU . 48.1 mt -118.48 143.29 46.81 Favored 'General case' 0 C--N 1.29 -1.995 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 179.751 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.573 HG21 ' NE2' ' A' ' 143' ' ' GLN . 5.3 mp -124.23 128.52 73.92 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.982 0 C-N-CA 119.7 -0.8 . . . . 0.0 110.67 178.419 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.566 HD23 ' O ' ' A' ' 131' ' ' LEU . 0.0 OUTLIER -96.11 135.15 38.28 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 175.433 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.539 ' HD2' ' HB3' ' A' ' 143' ' ' GLN . 8.8 tpt180 -97.92 122.26 40.83 Favored 'General case' 0 C--N 1.285 -2.223 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.573 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . 0.563 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 0.0 OUTLIER -105.82 104.7 14.47 Favored 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 123.406 0.682 . . . . 0.0 109.268 -177.587 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 6.9 m -127.34 142.14 51.52 Favored 'General case' 0 C--N 1.284 -2.255 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 179.197 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.587 ' CB ' HG23 ' A' ' 52' ' ' ILE . 9.1 p30 -132.01 170.87 14.33 Favored 'General case' 0 C--N 1.309 -1.166 0 C-N-CA 119.988 -0.685 . . . . 0.0 110.446 176.498 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.459 HD22 HG22 ' A' ' 53' ' ' THR . 4.7 p30 -85.98 -10.86 54.39 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 114.676 -1.147 . . . . 0.0 112.474 -170.668 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 60.1 t80 -109.39 -62.16 1.53 Allowed 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 112.316 0.488 . . . . 0.0 112.316 -171.957 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 16.9 m120 -80.22 148.5 30.8 Favored 'General case' 0 CA--C 1.49 -1.328 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.774 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 20.2 p -88.24 10.14 20.62 Favored 'General case' 0 C--N 1.298 -1.63 0 CA-C-O 121.79 0.805 . . . . 0.0 109.88 176.964 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -78.68 94.5 5.08 Favored 'General case' 0 CA--C 1.505 -0.764 0 CA-C-N 114.466 -1.243 . . . . 0.0 109.147 177.8 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 20.2 t0 -112.83 106.7 15.08 Favored 'General case' 0 C--N 1.292 -1.895 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.958 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -128.14 173.51 10.03 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 120.992 0.425 . . . . 0.0 109.935 -176.741 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . 0.573 ' NE2' HG21 ' A' ' 130' ' ' ILE . 17.3 pt20 -134.79 143.93 47.36 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 109.786 -0.45 . . . . 0.0 109.786 175.514 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.496 ' HB2' HD22 ' A' ' 131' ' ' LEU . 9.4 m-30 -109.65 130.38 55.52 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 -179.175 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.43 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 52.2 t -90.81 132.27 35.82 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 O-C-N 123.592 0.557 . . . . 0.0 109.799 -178.617 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . 0.474 ' HE1' ' HB3' ' A' ' 131' ' ' LEU . 61.9 m95 -117.47 96.18 5.29 Favored 'General case' 0 C--N 1.279 -2.48 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 -179.304 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 43.9 m-80 -79.45 112.63 16.89 Favored 'General case' 0 C--N 1.285 -2.211 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 177.989 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.495 ' HA ' HG22 ' A' ' 20' ' ' VAL . 26.6 mm -86.37 122.14 38.33 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.816 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 -175.799 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 40.6 m-85 -117.25 156.2 28.16 Favored 'General case' 0 CA--C 1.487 -1.474 0 CA-C-O 121.633 0.73 . . . . 0.0 110.605 179.222 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -84.28 129.37 34.89 Favored 'General case' 0 N--CA 1.405 -2.685 0 CA-C-N 114.544 -1.207 . . . . 0.0 108.684 175.808 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 15.8 t-20 -91.43 -13.77 31.74 Favored 'General case' 0 C--N 1.29 -2.008 0 N-CA-C 107.383 -1.339 . . . . 0.0 107.383 -178.793 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.3 t30 -150.14 143.62 25.17 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 113.633 -1.621 . . . . 0.0 109.008 -175.201 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -86.37 144.79 27.17 Favored 'General case' 0 C--N 1.307 -1.249 0 O-C-N 124.241 0.963 . . . . 0.0 110.169 -179.777 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.527 HG22 ' HB ' ' A' ' 120' ' ' ILE . 1.5 m -123.96 150.52 28.46 Favored 'Isoleucine or valine' 0 C--O 1.253 1.249 0 C-N-CA 120.701 -0.4 . . . . 0.0 111.24 -177.284 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 3.2 t -124.32 138.27 54.4 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.124 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -179.613 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.462 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 79.0 t -100.21 100.83 12.64 Favored Pre-proline 0 C--N 1.296 -1.759 0 C-N-CA 123.983 0.913 . . . . 0.0 109.453 178.06 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.502 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 27.5 Cg_endo -66.37 -26.19 48.47 Favored 'Trans proline' 0 CA--C 1.515 -0.428 0 C-N-CA 122.208 1.939 . . . . 0.0 111.773 178.908 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 3.3 t . . . . . 0 C--O 1.254 1.312 0 O-C-N 124.516 1.135 . . . . 0.0 113.223 176.882 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . . . . . . . . . 30.6 t80 . . . . . 0 CA--C 1.479 -1.753 0 N-CA-C 105.331 -2.1 . . . . 0.0 105.331 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.458 ' HB1' ' O ' ' A' ' 11' ' ' ILE . . . -140.3 176.41 8.79 Favored 'General case' 0 C--N 1.289 -2.058 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -178.191 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 44' ' ' CYS . 13.6 t -147.4 159.37 43.77 Favored 'General case' 0 N--CA 1.428 -1.555 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.647 -174.784 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.587 ' HE3' ' HB2' ' A' ' 43' ' ' PHE . 0.0 OUTLIER -144.81 168.72 19.54 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-O 121.36 0.6 . . . . 0.0 110.747 -173.717 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . . . . . . . . . 76.2 p -105.5 175.82 5.37 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-O 121.08 0.467 . . . . 0.0 110.798 179.771 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -73.66 -22.05 60.08 Favored 'General case' 0 C--N 1.298 -1.637 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.627 178.651 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -84.28 -33.33 24.01 Favored 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 120.256 -0.578 . . . . 0.0 110.641 -177.784 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 135.13 9.47 1.66 Allowed Glycine 0 N--CA 1.445 -0.741 0 C-N-CA 119.564 -1.303 . . . . 0.0 113.699 176.808 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 4.1 m -85.16 100.02 11.46 Favored 'General case' 0 N--CA 1.433 -1.317 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 179.884 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -95.1 117.33 30.0 Favored 'General case' 0 C--N 1.297 -1.71 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.591 178.638 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.458 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 67.3 mt -86.63 127.26 61.16 Favored Pre-proline 0 C--N 1.299 -1.627 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 178.692 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -81.06 169.34 16.28 Favored 'Trans proline' 0 C--O 1.248 0.984 0 C-N-CA 122.78 2.32 . . . . 0.0 111.305 177.985 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 61.3 mt -69.16 132.11 33.35 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.731 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 177.855 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 129.89 -5.22 6.12 Favored Glycine 0 C--N 1.3 -1.462 0 C-N-CA 120.172 -1.013 . . . . 0.0 111.507 -179.528 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 101.42 163.6 27.33 Favored Glycine 0 N--CA 1.432 -1.595 0 N-CA-C 110.689 -0.964 . . . . 0.0 110.689 -177.694 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 160.41 -177.45 36.84 Favored Glycine 0 C--N 1.297 -1.614 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 178.612 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.415 ' CB ' ' HB ' ' A' ' 145' ' ' VAL . 59.7 p -138.99 147.74 42.55 Favored 'General case' 0 C--N 1.296 -1.749 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 -179.763 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -132.0 161.05 34.1 Favored 'General case' 0 N--CA 1.426 -1.63 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 177.999 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 19.7 m-80 -116.2 109.06 16.93 Favored 'General case' 0 C--N 1.289 -2.055 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 177.784 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.455 HG22 ' HA ' ' A' ' 148' ' ' ILE . 1.3 m -91.1 147.68 5.08 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.416 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 -177.893 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 42.7 m-85 -131.04 118.87 21.2 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 -177.354 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.538 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.8 p -125.43 135.63 63.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.108 -176.389 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 30.7 m-80 -91.08 122.7 33.95 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 179.988 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . 0.411 HD11 HG22 ' A' ' 36' ' ' VAL . 2.8 mm? -101.94 160.61 14.34 Favored 'General case' 0 C--N 1.285 -2.223 0 N-CA-C 108.323 -0.991 . . . . 0.0 108.323 178.103 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.2 122.21 52.48 Favored Pre-proline 0 C--N 1.314 -0.955 0 O-C-N 124.116 0.885 . . . . 0.0 108.728 174.76 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.531 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 72.8 Cg_endo -74.71 -1.84 11.67 Favored 'Trans proline' 0 CA--C 1.533 0.441 0 C-N-CA 122.895 2.397 . . . . 0.0 112.968 -176.148 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.408 HG13 ' HG3' ' A' ' 157' ' ' PRO . 95.6 t -129.11 111.27 22.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 -179.995 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.475 ' O ' ' HA ' ' A' ' 156' ' ' VAL . 10.3 t -148.19 111.1 0.68 Allowed 'Isoleucine or valine' 0 C--O 1.188 -2.17 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 -177.341 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.592 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.5 OUTLIER -96.83 154.65 17.17 Favored 'General case' 0 C--N 1.272 -2.775 0 C-N-CA 123.646 0.778 . . . . 0.0 110.962 179.834 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.581 HG22 ' O ' ' A' ' 112' ' ' VAL . 71.5 t -46.67 122.66 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 C-N-CA 123.051 0.541 . . . . 0.0 110.734 176.24 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 98.25 1.24 58.16 Favored Glycine 0 C--N 1.315 -0.592 0 CA-C-N 115.536 -0.756 . . . . 0.0 112.919 179.663 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.592 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -73.38 -176.98 2.42 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 123.396 0.678 . . . . 0.0 110.678 175.93 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -131.42 92.13 3.12 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 178.131 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.654 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 28.5 tp -94.09 141.05 28.99 Favored 'General case' 0 C--N 1.291 -1.942 0 C-N-CA 119.444 -0.902 . . . . 0.0 109.906 -179.66 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 56.9 t -131.87 120.93 45.98 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.019 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.022 -176.443 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.573 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 48.3 t -90.86 88.21 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.89 0 N-CA-C 105.249 -2.13 . . . . 0.0 105.249 173.655 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -83.26 109.75 17.5 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.318 -177.473 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.415 ' HA ' ' HG2' ' A' ' 41' ' ' GLN . 84.2 mt -95.0 -3.64 48.04 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 115.351 -0.84 . . . . 0.0 110.111 -178.164 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 1.1 m -71.15 0.15 8.38 Favored 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 114.831 -1.077 . . . . 0.0 110.125 -179.945 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 6.5 p -133.21 6.86 3.9 Favored 'General case' 0 N--CA 1.425 -1.677 0 C-N-CA 124.24 1.016 . . . . 0.0 109.911 178.639 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.538 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 46.2 mm-40 -122.23 -19.28 6.57 Favored 'General case' 0 CA--C 1.507 -0.699 0 CA-C-O 121.067 0.461 . . . . 0.0 110.717 -174.557 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 45.2 mt -134.36 138.24 50.2 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 -176.219 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.587 ' HB2' ' HE3' ' A' ' 4' ' ' LYS . 72.8 m-85 -143.02 143.44 31.9 Favored 'General case' 0 CA--C 1.492 -1.27 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 -174.467 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 3' ' ' CYS . 64.8 m -126.87 140.64 52.19 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 -176.327 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -121.89 151.17 40.98 Favored 'General case' 0 C--N 1.31 -1.137 0 CA-C-O 121.313 0.578 . . . . 0.0 110.256 -176.203 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.653 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 24.0 p-10 -107.18 104.06 13.6 Favored 'General case' 0 N--CA 1.411 -2.387 0 CA-C-O 122.886 1.327 . . . . 0.0 110.068 179.988 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.2 p30 -74.84 -34.64 62.35 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-N 112.942 -1.935 . . . . 0.0 111.319 -174.847 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 49.5 m-85 -134.23 72.79 70.76 Favored Pre-proline 0 C--N 1.3 -1.566 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.539 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.653 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 58.7 Cg_endo -72.34 -3.05 12.64 Favored 'Trans proline' 0 C--N 1.334 -0.224 0 C-N-CA 122.775 2.317 . . . . 0.0 113.386 -174.378 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -118.83 -4.19 10.7 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 121.138 0.494 . . . . 0.0 109.799 -178.278 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.52 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -117.99 -29.1 5.72 Favored 'General case' 0 N--CA 1.418 -2.033 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.883 -174.016 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.52 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.0 mp -130.6 134.84 61.54 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.487 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 13.5 t -69.57 139.74 53.75 Favored 'General case' 0 N--CA 1.43 -1.466 0 N-CA-C 108.957 -0.756 . . . . 0.0 108.957 177.463 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -86.76 107.96 18.49 Favored 'General case' 0 C--N 1.285 -2.207 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -173.347 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.504 ' CD2' ' HB ' ' A' ' 134' ' ' THR . 73.1 t80 -150.16 145.35 26.24 Favored 'General case' 0 C--N 1.295 -1.794 0 C-N-CA 120.973 -0.291 . . . . 0.0 110.427 -171.357 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.495 HG13 ' HB2' ' A' ' 131' ' ' LEU . 59.9 t -150.66 139.67 15.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 C-N-CA 124.559 1.144 . . . . 0.0 108.666 177.655 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -147.27 122.61 10.29 Favored 'General case' 0 C--O 1.21 -0.992 0 O-C-N 123.311 0.382 . . . . 0.0 110.607 174.617 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.527 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 63.5 tp -64.77 114.92 4.79 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-O 121.315 0.579 . . . . 0.0 110.004 177.195 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.472 ' HB2' ' HG2' ' A' ' 132' ' ' ARG . 4.2 tp-100 -59.12 -60.02 4.53 Favored 'General case' 0 C--N 1.315 -0.933 0 C-N-CA 126.287 1.835 . . . . 0.0 110.555 176.566 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . 0.454 ' HG2' ' HG3' ' A' ' 59' ' ' GLN . 4.5 ptp180 -163.06 161.91 25.56 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 115.052 -0.976 . . . . 0.0 108.424 -177.011 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.403 ' H ' HG22 ' A' ' 86' ' ' THR . . . -142.44 131.25 4.59 Favored Glycine 0 N--CA 1.401 -3.641 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 -179.384 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.412 ' HA ' ' HB3' ' A' ' 85' ' ' PRO . 49.1 m -120.07 149.52 42.05 Favored 'General case' 0 C--N 1.288 -2.089 0 C-N-CA 124.072 0.949 . . . . 0.0 110.395 -174.575 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.544 ' O ' HD23 ' A' ' 68' ' ' LEU . . . -111.5 153.4 26.26 Favored 'General case' 0 N--CA 1.486 1.356 0 CA-C-O 117.792 -1.099 . . . . 0.0 108.398 -179.457 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.8 ' O ' HG22 ' A' ' 67' ' ' VAL . 95.2 m-85 -158.35 -179.75 8.39 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 123.646 0.779 . . . . 0.0 111.277 -176.951 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 59.91 -134.02 51.03 Favored Glycine 0 C--N 1.317 -0.485 0 C-N-CA 121.409 -0.424 . . . . 0.0 112.265 179.769 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -82.62 -10.22 83.6 Favored Glycine 0 N--CA 1.422 -2.25 0 C-N-CA 120.327 -0.939 . . . . 0.0 112.839 177.306 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.8 HG22 ' O ' ' A' ' 64' ' ' TYR . 12.5 m -73.84 -28.6 24.47 Favored 'Isoleucine or valine' 0 C--O 1.205 -1.252 0 CA-C-N 118.295 1.048 . . . . 0.0 112.262 -174.143 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.544 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -91.14 -19.94 22.54 Favored 'General case' 0 C--N 1.297 -1.675 0 C-N-CA 119.876 -0.73 . . . . 0.0 111.895 177.664 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . . . . . . . . . 7.4 t -100.45 -49.35 4.26 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.481 0.658 . . . . 0.0 111.239 -173.627 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.509 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 49.6 m-20 -96.99 -17.82 19.81 Favored 'General case' 0 C--N 1.304 -1.408 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 -174.332 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.566 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 87.2 m-85 -119.31 163.55 16.98 Favored 'General case' 0 C--N 1.294 -1.812 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.957 -179.329 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 8.2 t -173.06 132.6 0.51 Allowed 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 178.729 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.498 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -167.15 -112.5 0.26 Allowed Glycine 0 N--CA 1.406 -3.334 0 N-CA-C 110.624 -0.99 . . . . 0.0 110.624 174.178 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.411 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.2 p -154.93 -179.96 8.55 Favored 'General case' 0 C--N 1.292 -1.921 0 C-N-CA 123.628 0.771 . . . . 0.0 110.403 -172.933 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.402 ' HB ' ' CD1' ' A' ' 84' ' ' PHE . 2.5 p -134.27 145.5 32.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 179.319 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.731 ' HG3' ' O ' ' A' ' 80' ' ' SER . 71.0 tttt -123.22 142.99 50.34 Favored 'General case' 0 N--CA 1.416 -2.139 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.397 -179.395 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.479 ' CD1' HG22 ' A' ' 105' ' ' VAL . 71.7 t80 -143.81 112.0 6.3 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.521 -178.429 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 14.7 t 52.78 37.94 25.21 Favored 'General case' 0 CA--C 1.561 1.4 0 CA-C-O 122.025 0.917 . . . . 0.0 110.875 175.951 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.08 10.37 64.49 Favored Glycine 0 CA--C 1.528 0.903 0 CA-C-N 115.684 -0.689 . . . . 0.0 113.731 179.934 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.731 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 21.6 t -84.94 -179.72 7.13 Favored 'General case' 0 C--O 1.206 -1.211 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 177.836 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 48.5 m -159.06 108.83 1.95 Allowed 'General case' 0 C--N 1.279 -2.483 0 N-CA-C 107.258 -1.386 . . . . 0.0 107.258 177.297 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.475 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 4.0 p90 -149.38 163.1 26.5 Favored Pre-proline 0 C--N 1.306 -1.308 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 -174.517 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.475 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 58.6 Cg_endo -68.99 148.79 70.85 Favored 'Trans proline' 0 C--N 1.358 1.057 0 C-N-CA 122.612 2.208 . . . . 0.0 113.425 -175.862 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.509 ' CD2' HD21 ' A' ' 109' ' ' LEU . 51.6 t80 -123.72 132.76 24.3 Favored Pre-proline 0 N--CA 1.435 -1.18 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 179.383 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.47 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 66.8 Cg_endo -72.22 147.58 89.11 Favored 'Cis proline' 0 CA--C 1.542 0.914 0 C-N-CA 122.734 -1.777 . . . . 0.0 110.497 -1.369 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . 0.403 HG22 ' H ' ' A' ' 61' ' ' GLY . 11.5 t -68.28 -175.84 0.67 Allowed 'General case' 0 CA--C 1.55 0.955 0 CA-C-O 121.229 0.537 . . . . 0.0 111.04 -176.181 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 7.9 p -130.37 -42.88 1.17 Allowed 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 116.07 -0.514 . . . . 0.0 112.289 -175.554 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.2 t -101.3 -86.63 0.4 Allowed 'General case' 0 N--CA 1.431 -1.414 0 C-N-CA 120.7 -0.4 . . . . 0.0 110.592 -175.467 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -170.19 -169.68 0.88 Allowed 'General case' 0 N--CA 1.438 -1.043 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 177.825 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.527 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 21.4 p -101.37 162.77 19.45 Favored Pre-proline 0 C--N 1.302 -1.477 0 N-CA-C 112.468 0.544 . . . . 0.0 112.468 177.325 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -63.79 159.4 41.78 Favored 'Trans proline' 0 C--N 1.358 1.059 0 C-N-CA 122.748 2.299 . . . . 0.0 111.64 174.526 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 1.7 tmm_? -65.35 118.29 9.14 Favored 'General case' 0 C--N 1.315 -0.918 0 C-N-CA 124.695 1.198 . . . . 0.0 109.554 -177.523 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 68.5 t -127.81 128.82 69.68 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.329 -177.07 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 74.2 t -114.29 140.73 33.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.402 179.416 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 4.1 m-85 -87.36 95.65 10.07 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 121.24 0.543 . . . . 0.0 110.093 177.931 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -86.97 64.57 8.55 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-O 121.183 0.516 . . . . 0.0 110.392 -179.046 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 49.5 m -155.21 -179.59 8.23 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 -179.527 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . 0.556 ' HA ' HD21 ' A' ' 46' ' ' ASN . 16.7 ptm180 -141.28 50.32 1.61 Allowed 'General case' 0 N--CA 1.44 -0.971 0 CA-C-O 121.899 0.857 . . . . 0.0 110.128 178.996 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 6.9 t -163.39 170.75 17.02 Favored 'General case' 0 N--CA 1.424 -1.733 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 -178.868 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 20.3 t70 -69.92 101.59 1.79 Allowed 'General case' 0 C--O 1.251 1.169 0 CA-C-O 122.581 1.182 . . . . 0.0 108.755 178.242 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . . . . . . . . . 1.8 tptm -101.1 137.02 19.6 Favored Pre-proline 0 C--N 1.268 -2.945 0 CA-C-N 113.002 -1.908 . . . . 0.0 109.368 -175.878 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -64.74 146.09 87.81 Favored 'Trans proline' 0 C--O 1.246 0.904 0 C-N-CA 122.673 2.248 . . . . 0.0 111.892 177.073 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . 0.404 ' NE1' HG11 ' A' ' 56' ' ' VAL . 15.7 t90 -86.95 108.61 19.33 Favored Pre-proline 0 N--CA 1.44 -0.932 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 -178.563 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -76.63 89.01 1.32 Allowed 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 121.864 1.709 . . . . 0.0 113.154 -173.273 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.479 HG22 ' CD1' ' A' ' 77' ' ' TYR . 81.2 t -139.89 145.86 25.9 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.038 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 177.824 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.573 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -149.92 136.31 19.01 Favored 'General case' 0 C--N 1.287 -2.121 0 CA-C-O 120.95 0.405 . . . . 0.0 110.223 177.586 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.454 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 15.9 mt -103.69 106.08 16.49 Favored 'General case' 0 C--N 1.287 -2.135 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 178.335 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.498 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 14.6 m-85 -83.01 75.0 9.92 Favored 'General case' 0 C--N 1.284 -2.249 0 N-CA-C 110.159 -0.312 . . . . 0.0 110.159 177.849 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.654 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -95.83 124.96 40.08 Favored 'General case' 0 CA--C 1.489 -1.373 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 174.776 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -128.97 146.25 59.87 Favored Pre-proline 0 N--CA 1.409 -2.492 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 -176.86 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.509 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 36.2 Cg_endo -63.78 126.01 16.56 Favored 'Trans proline' 0 N--CA 1.444 -1.424 0 C-N-CA 122.712 2.274 . . . . 0.0 113.685 -175.813 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.581 ' O ' HG22 ' A' ' 30' ' ' VAL . 13.9 m -85.62 -155.96 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.392 -3.346 0 CA-C-N 114.007 -1.451 . . . . 0.0 108.465 171.648 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 14.4 m -79.86 -33.39 40.15 Favored 'General case' 0 C--N 1.262 -3.225 0 CA-C-O 121.446 0.641 . . . . 0.0 110.12 -170.36 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.2 t -83.19 26.89 0.6 Allowed 'General case' 0 N--CA 1.425 -1.684 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.558 -178.137 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.424 ' HB2' ' O ' ' A' ' 70' ' ' ASN . . . -107.8 134.35 50.87 Favored 'General case' 0 N--CA 1.424 -1.766 0 N-CA-C 109.58 -0.526 . . . . 0.0 109.58 178.478 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -176.78 129.21 1.44 Allowed Glycine 0 N--CA 1.437 -1.235 0 C-N-CA 120.571 -0.824 . . . . 0.0 111.469 178.814 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 66.4 -150.71 52.01 Favored Glycine 0 CA--C 1.495 -1.204 0 N-CA-C 111.118 -0.793 . . . . 0.0 111.118 -176.305 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 7.6 p -55.9 105.99 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 CA-C-O 122.522 1.153 . . . . 0.0 111.932 -178.211 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -106.61 -28.33 10.3 Favored 'General case' 0 C--N 1.294 -1.812 0 CA-C-N 114.51 -1.223 . . . . 0.0 111.375 -177.922 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.443 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 54.8 mt -130.07 135.01 61.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 179.118 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.507 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 4.1 mmpt? -109.84 141.48 42.47 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-O 121.164 0.507 . . . . 0.0 111.123 176.767 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . 0.4 ' H ' ' HB3' ' A' ' 153' ' ' ASP . . . -72.09 123.28 22.52 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.464 -0.789 . . . . 0.0 109.429 178.965 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 97.94 -0.0 58.95 Favored Glycine 0 C--N 1.306 -1.097 0 N-CA-C 111.316 -0.714 . . . . 0.0 111.316 -176.613 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 31.0 t -97.16 145.42 26.04 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.329 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.416 HD23 ' CZ ' ' A' ' 149' ' ' TYR . 3.2 tm? -76.84 123.43 26.23 Favored 'General case' 0 N--CA 1.431 -1.38 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.82 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.556 ' HB ' HG11 ' A' ' 67' ' ' VAL . 28.4 pt -108.63 -29.75 2.53 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.745 -179.746 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . 0.464 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -158.88 168.5 26.64 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 119.46 -0.896 . . . . 0.0 110.639 -177.238 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.405 HG23 HD11 ' A' ' 125' ' ' LEU . 72.3 t -142.12 113.48 3.29 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 N-CA-C 107.802 -1.184 . . . . 0.0 107.802 179.021 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.412 HD11 HD21 ' A' ' 107' ' ' LEU . 57.0 mt -117.24 151.53 36.73 Favored 'General case' 0 C--N 1.29 -1.991 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 178.533 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . 0.522 ' O ' HD12 ' A' ' 58' ' ' LEU . 4.5 mp -135.71 129.69 48.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 178.027 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.495 ' HB2' HG13 ' A' ' 56' ' ' VAL . 1.2 pp -97.34 142.0 29.75 Favored 'General case' 0 CA--C 1.499 -0.991 0 C-N-CA 119.864 -0.734 . . . . 0.0 109.022 177.352 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.472 ' HG2' ' HB2' ' A' ' 59' ' ' GLN . 15.4 mmm180 -96.64 116.11 28.55 Favored 'General case' 0 C--N 1.279 -2.477 0 C-N-CA 124.264 1.026 . . . . 0.0 108.551 175.848 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 26.2 tp60 -85.12 135.48 33.96 Favored 'General case' 0 N--CA 1.413 -2.302 0 N-CA-C 105.55 -2.019 . . . . 0.0 105.55 174.966 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.504 ' HB ' ' CD2' ' A' ' 55' ' ' TYR . 25.2 m -139.0 135.33 34.17 Favored 'General case' 0 C--N 1.262 -3.199 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 174.807 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.52 ' HB2' HG23 ' A' ' 52' ' ' ILE . 24.1 p-10 -142.85 145.91 33.62 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-O 121.695 0.759 . . . . 0.0 110.909 -176.742 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -86.18 -31.21 21.89 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 114.512 -1.222 . . . . 0.0 112.806 -170.115 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 72.4 t80 -80.95 -65.09 1.06 Allowed 'General case' 0 C--N 1.315 -0.905 0 C-N-CA 123.314 0.646 . . . . 0.0 110.434 -174.408 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 96.0 m-20 -93.92 169.35 10.35 Favored 'General case' 0 CA--C 1.479 -1.786 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 173.532 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 14.9 p -107.46 58.35 0.62 Allowed 'General case' 0 C--N 1.276 -2.611 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 175.454 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 72.0 m-20 -97.43 39.44 1.2 Allowed 'General case' 0 CA--C 1.499 -1.014 0 CA-C-N 114.038 -1.437 . . . . 0.0 108.627 179.964 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -80.77 72.73 7.75 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-O 122.639 1.209 . . . . 0.0 110.165 -179.009 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 74.7 m-85 -101.01 -179.53 4.07 Favored 'General case' 0 N--CA 1.43 -1.474 0 N-CA-C 107.243 -1.392 . . . . 0.0 107.243 177.713 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . . . . . . . . . 13.5 pt20 -132.48 144.89 50.76 Favored 'General case' 0 C--N 1.292 -1.911 0 C-N-CA 118.937 -1.105 . . . . 0.0 111.341 179.992 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 10.2 m-30 -109.24 127.52 54.32 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 -177.078 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . 0.415 ' HB ' ' CB ' ' A' ' 17' ' ' SER . 48.5 t -91.17 137.04 22.63 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 123.538 0.524 . . . . 0.0 110.18 -178.027 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . . . . . . . . . 60.6 m95 -125.35 96.56 4.87 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 -178.084 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 46.5 m-80 -81.56 114.44 20.27 Favored 'General case' 0 C--N 1.285 -2.212 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 178.146 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.464 ' HB ' ' HB3' ' A' ' 127' ' ' ALA . 20.9 mm -88.0 122.85 40.12 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -176.268 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . 0.416 ' CZ ' HD23 ' A' ' 125' ' ' LEU . 83.4 m-85 -119.01 152.92 35.53 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-N 115.97 -0.559 . . . . 0.0 109.822 178.584 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -83.12 129.6 35.04 Favored 'General case' 0 N--CA 1.407 -2.591 0 N-CA-C 108.019 -1.104 . . . . 0.0 108.019 177.211 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 10.9 t-20 -90.47 -12.89 35.98 Favored 'General case' 0 C--N 1.294 -1.809 0 CA-C-O 122.452 1.12 . . . . 0.0 108.082 -177.088 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -149.03 144.47 26.74 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 113.964 -1.471 . . . . 0.0 108.911 -175.133 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . 0.4 ' HB3' ' H ' ' A' ' 122' ' ' ALA . 17.3 p-10 -86.63 141.92 28.62 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 123.982 0.801 . . . . 0.0 111.762 -179.11 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.531 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 70.5 t -117.46 139.04 46.14 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 CA-C-N 115.228 -0.897 . . . . 0.0 111.632 -173.597 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.4 t -120.1 132.3 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 N-CA-C 107.599 -1.26 . . . . 0.0 107.599 179.21 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.475 ' HA ' ' O ' ' A' ' 28' ' ' VAL . 71.7 t -97.71 103.59 17.4 Favored Pre-proline 0 C--N 1.292 -1.904 0 C-N-CA 123.933 0.893 . . . . 0.0 109.927 179.909 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . 0.411 ' HG2' ' HB3' ' A' ' 29' ' ' ASN . 23.2 Cg_endo -68.15 -27.41 35.43 Favored 'Trans proline' 0 CA--C 1.509 -0.754 0 C-N-CA 121.978 1.786 . . . . 0.0 111.816 179.719 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . . . . . . . . . 5.0 t . . . . . 0 CA--C 1.549 0.94 0 C-N-CA 124.706 1.202 . . . . 0.0 113.628 177.911 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' PHE . . . . . 0.587 ' CZ ' ' HB3' ' A' ' 44' ' ' CYS . 59.4 t80 . . . . . 0 CA--C 1.49 -1.356 0 CA-C-O 120.5 0.191 . . . . 0.0 111.001 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.478 ' HB3' ' CE1' ' A' ' 45' ' ' HIS . . . -147.88 173.67 12.61 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 172.344 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.455 ' HB2' ' CZ2' ' A' ' 146' ' ' TRP . 64.4 m -144.99 168.47 20.2 Favored 'General case' 0 C--N 1.3 -1.569 0 C-N-CA 120.193 -0.603 . . . . 0.0 110.726 -176.616 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.455 ' HA ' ' O ' ' A' ' 9' ' ' THR . 0.3 OUTLIER -148.82 162.2 40.28 Favored 'General case' 0 C--N 1.31 -1.122 0 C-N-CA 123.632 0.773 . . . . 0.0 109.477 178.868 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' THR . . . . . 0.501 HG22 HG22 ' A' ' 20' ' ' VAL . 71.9 p -100.24 175.86 5.58 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 121.394 0.616 . . . . 0.0 110.414 -179.744 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -77.29 -13.54 59.92 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-N 114.371 -1.286 . . . . 0.0 110.654 179.157 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 5.3 p30 -87.82 -34.31 18.3 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 118.895 -1.122 . . . . 0.0 108.63 175.265 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 134.19 7.2 2.29 Favored Glycine 0 N--CA 1.436 -1.304 0 C-N-CA 120.0 -1.095 . . . . 0.0 113.301 177.049 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.455 ' O ' ' HA ' ' A' ' 4' ' ' LYS . 5.1 m -76.55 99.28 4.91 Favored 'General case' 0 N--CA 1.442 -0.873 0 CA-C-N 117.601 0.7 . . . . 0.0 109.121 179.869 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -92.55 118.43 30.99 Favored 'General case' 0 C--N 1.294 -1.819 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.271 178.314 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.422 ' O ' ' HB1' ' A' ' 2' ' ' ALA . 62.4 mt -96.53 118.79 64.98 Favored Pre-proline 0 C--N 1.302 -1.459 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 177.233 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -79.12 174.85 11.55 Favored 'Trans proline' 0 C--O 1.252 1.193 0 C-N-CA 122.637 2.224 . . . . 0.0 110.655 177.935 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 53.8 mt -71.99 119.85 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.247 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 177.217 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 151.76 -12.11 0.73 Allowed Glycine 0 C--N 1.291 -1.96 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 -172.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . 94.24 161.2 34.88 Favored Glycine 0 N--CA 1.433 -1.547 0 N-CA-C 110.82 -0.912 . . . . 0.0 110.82 177.651 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 162.05 -167.92 36.9 Favored Glycine 0 CA--C 1.473 -2.564 0 C-N-CA 118.888 -1.625 . . . . 0.0 111.904 179.109 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 14.5 m -144.6 147.64 33.39 Favored 'General case' 0 C--N 1.286 -2.19 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 -179.386 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -135.22 156.44 48.98 Favored 'General case' 0 N--CA 1.426 -1.637 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 -179.134 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -104.78 111.02 23.6 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 179.91 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.501 HG22 HG22 ' A' ' 5' ' ' THR . 41.3 t -98.68 139.59 20.26 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.901 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.347 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . . . . . . . . . 56.2 m-85 -128.66 119.09 24.04 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -177.288 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . 0.53 ' HB ' ' HG3' ' A' ' 41' ' ' GLN . 2.9 p -122.74 129.75 74.96 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-O 121.884 0.85 . . . . 0.0 111.089 -175.899 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -88.73 119.17 28.97 Favored 'General case' 0 C--N 1.291 -1.974 0 CA-C-N 114.847 -1.07 . . . . 0.0 109.439 179.546 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' LEU . . . . . . . . . . . . . 27.8 mt -107.06 160.79 15.29 Favored 'General case' 0 C--N 1.28 -2.453 0 CA-C-N 114.625 -1.17 . . . . 0.0 109.185 -177.58 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' ALA . . . . . . . . . . . . . . . -57.5 121.56 49.22 Favored Pre-proline 0 C--O 1.206 -1.2 0 O-C-N 124.01 0.819 . . . . 0.0 108.871 177.826 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' PRO . . . . . 0.557 ' HA ' ' HA ' ' A' ' 154' ' ' VAL . 60.1 Cg_endo -73.99 -2.47 12.32 Favored 'Trans proline' 0 CA--C 1.53 0.282 0 C-N-CA 122.786 2.324 . . . . 0.0 113.302 -175.627 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 96.0 t -127.83 109.96 21.04 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -179.308 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.421 HG21 HD22 ' A' ' 34' ' ' LEU . 5.8 t -146.57 106.74 0.66 Allowed 'Isoleucine or valine' 0 C--O 1.189 -2.114 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 -178.035 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' ASN . . . . . 0.568 ' O ' ' HB2' ' A' ' 32' ' ' GLN . 0.4 OUTLIER -94.27 153.98 17.76 Favored 'General case' 0 C--N 1.277 -2.581 0 C-N-CA 123.246 0.618 . . . . 0.0 111.506 179.983 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.52 HG22 ' O ' ' A' ' 112' ' ' VAL . 85.5 t -50.66 118.98 0.84 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.738 0 C-N-CA 123.274 0.629 . . . . 0.0 111.051 179.405 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 100.37 7.88 50.92 Favored Glycine 0 C--N 1.309 -0.917 0 CA-C-N 114.98 -1.009 . . . . 0.0 112.138 -178.527 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . 0.568 ' HB2' ' O ' ' A' ' 29' ' ' ASN . 0.0 OUTLIER -78.66 -177.24 5.28 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 123.493 0.717 . . . . 0.0 109.633 173.09 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -132.93 92.4 3.03 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 177.984 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.68 ' HB3' ' O ' ' A' ' 109' ' ' LEU . 23.9 tp -92.67 145.51 24.37 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 119.705 -0.798 . . . . 0.0 109.247 179.407 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.9 t -136.09 121.74 29.2 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.584 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -177.536 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.622 ' O ' ' HA ' ' A' ' 106' ' ' ALA . 62.0 t -91.74 88.62 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.406 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 175.298 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -84.2 115.53 22.48 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 120.008 -0.677 . . . . 0.0 110.641 -178.681 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.4 mt -94.7 -1.23 53.43 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.718 -179.313 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 31.6 t -75.04 2.17 11.24 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-O 121.925 0.869 . . . . 0.0 109.477 178.797 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 1.5 p -129.25 4.26 5.21 Favored 'General case' 0 C--N 1.288 -2.074 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.46 176.348 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.53 ' HG3' ' HB ' ' A' ' 22' ' ' VAL . 42.7 mm-40 -124.58 -20.8 5.01 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-O 121.091 0.472 . . . . 0.0 110.726 -174.651 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 26.8 mt -133.82 136.47 53.93 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.978 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -176.32 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.448 ' HA ' ' HA ' ' A' ' 102' ' ' PRO . 62.5 m-85 -133.49 139.75 46.84 Favored 'General case' 0 CA--C 1.496 -1.12 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 -176.938 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 44' ' ' CYS . . . . . 0.587 ' HB3' ' CZ ' ' A' ' 1' ' ' PHE . 60.5 m -125.03 134.22 52.65 Favored 'General case' 0 C--N 1.272 -2.784 0 CA-C-O 121.273 0.559 . . . . 0.0 111.743 -177.783 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.478 ' CE1' ' HB3' ' A' ' 2' ' ' ALA . 10.5 p80 -119.9 129.89 54.58 Favored 'General case' 0 C--N 1.295 -1.772 0 CA-C-O 121.816 0.817 . . . . 0.0 110.775 -178.118 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 46' ' ' ASN . . . . . 0.599 ' ND2' ' HB3' ' A' ' 49' ' ' PRO . 4.8 p-10 -97.84 95.0 7.23 Favored 'General case' 0 C--N 1.275 -2.658 0 CA-C-O 123.053 1.406 . . . . 0.0 107.567 178.317 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -78.54 -19.93 51.8 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-N 113.64 -1.618 . . . . 0.0 113.715 -172.304 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -135.24 65.05 62.77 Favored Pre-proline 0 C--N 1.313 -0.98 0 C-N-CA 120.147 -0.621 . . . . 0.0 110.947 178.758 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 49' ' ' PRO . . . . . 0.599 ' HB3' ' ND2' ' A' ' 46' ' ' ASN . 35.7 Cg_endo -64.98 -18.48 62.3 Favored 'Trans proline' 0 C--N 1.355 0.895 0 C-N-CA 123.182 2.588 . . . . 0.0 115.302 -171.213 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -108.14 -15.98 14.37 Favored 'General case' 0 C--N 1.289 -2.045 0 C-N-CA 119.66 -0.816 . . . . 0.0 110.641 -176.249 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 51' ' ' THR . . . . . 0.575 ' HB ' HD12 ' A' ' 52' ' ' ILE . 0.2 OUTLIER -101.14 -31.22 11.14 Favored 'General case' 0 N--CA 1.415 -2.211 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 -174.11 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.575 HD12 ' HB ' ' A' ' 51' ' ' THR . 3.2 mp -126.47 141.87 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.348 0 N-CA-C 106.5 -1.667 . . . . 0.0 106.5 178.969 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.44 HG22 HD22 ' A' ' 136' ' ' ASN . 7.5 t -86.78 122.13 30.23 Favored 'General case' 0 N--CA 1.405 -2.698 0 N-CA-C 103.462 -2.792 . . . . 0.0 103.462 172.205 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 54' ' ' ASP . . . . . 0.532 ' OD1' ' HB2' ' A' ' 1' ' ' PHE . 17.1 m-20 -93.39 106.02 18.03 Favored 'General case' 0 C--N 1.256 -3.484 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 -175.125 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 55' ' ' TYR . . . . . 0.552 ' CE1' ' HG2' ' A' ' 92' ' ' ARG . 10.7 t80 -123.13 133.43 54.27 Favored 'General case' 0 C--N 1.285 -2.22 0 CA-C-N 113.852 -1.522 . . . . 0.0 109.974 -172.613 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 8.2 t -128.46 142.99 42.42 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 115.285 -0.87 . . . . 0.0 109.27 -174.966 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 57' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -150.12 128.93 12.46 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 123.715 0.634 . . . . 0.0 109.332 172.619 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.525 ' HB3' ' CG2' ' A' ' 90' ' ' THR . 34.3 tp -71.2 102.86 2.63 Favored 'General case' 0 N--CA 1.429 -1.49 0 N-CA-C 108.054 -1.091 . . . . 0.0 108.054 173.353 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . . . . . . . . . 2.5 tp-100 -56.22 -56.66 18.28 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 112.9 -1.954 . . . . 0.0 110.019 -176.928 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 60' ' ' ARG . . . . . . . . . . . . . 6.1 ptp180 -158.76 151.14 21.61 Favored 'General case' 0 N--CA 1.41 -2.47 0 CA-C-N 114.251 -1.34 . . . . 0.0 108.197 -177.956 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -142.79 123.99 2.26 Favored Glycine 0 N--CA 1.405 -3.412 0 N-CA-C 108.611 -1.795 . . . . 0.0 108.611 -178.656 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.421 ' HA ' ' HB3' ' A' ' 85' ' ' PRO . 66.0 m -116.47 148.18 41.0 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 124.519 1.127 . . . . 0.0 110.83 -171.529 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 63' ' ' ALA . . . . . 0.511 ' HB1' HG23 ' A' ' 67' ' ' VAL . . . -107.72 154.99 20.68 Favored 'General case' 0 N--CA 1.477 0.882 0 C-N-CA 124.266 1.026 . . . . 0.0 108.62 -179.852 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 64' ' ' TYR . . . . . 0.767 ' O ' HG22 ' A' ' 67' ' ' VAL . 87.4 m-85 -156.06 -179.35 8.05 Favored 'General case' 0 N--CA 1.483 1.193 0 CA-C-N 118.351 0.523 . . . . 0.0 111.852 -176.956 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 56.33 -122.0 26.22 Favored Glycine 0 C--N 1.319 -0.393 0 CA-C-N 116.281 -0.418 . . . . 0.0 113.068 178.384 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -91.06 -10.38 62.64 Favored Glycine 0 N--CA 1.417 -2.57 0 C-N-CA 120.888 -0.672 . . . . 0.0 112.843 177.076 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.767 HG22 ' O ' ' A' ' 64' ' ' TYR . 12.5 m -76.77 -25.59 15.95 Favored 'Isoleucine or valine' 0 C--O 1.206 -1.23 0 CA-C-N 118.174 0.987 . . . . 0.0 112.289 -172.1 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.505 HD23 ' O ' ' A' ' 63' ' ' ALA . 0.3 OUTLIER -90.66 -23.75 20.68 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 121.495 0.664 . . . . 0.0 111.74 177.701 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 69' ' ' SER . . . . . 0.402 ' N ' HD12 ' A' ' 68' ' ' LEU . 21.7 m -102.03 -52.91 3.05 Favored 'General case' 0 C--N 1.305 -1.366 0 N-CA-C 113.943 1.09 . . . . 0.0 113.943 -175.226 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 70' ' ' ASN . . . . . 0.496 ' O ' ' HA ' ' A' ' 111' ' ' PRO . 53.7 m-20 -88.09 -22.63 24.03 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 -177.41 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 71' ' ' PHE . . . . . 0.556 ' HB3' ' HB3' ' A' ' 109' ' ' LEU . 87.6 m-85 -115.48 164.12 14.75 Favored 'General case' 0 C--N 1.294 -1.842 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.944 179.832 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.3 t -172.63 134.22 0.63 Allowed 'General case' 0 N--CA 1.416 -2.13 0 N-CA-C 107.314 -1.365 . . . . 0.0 107.314 177.266 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.613 ' HA3' ' O ' ' A' ' 108' ' ' TYR . . . -165.58 -114.75 0.3 Allowed Glycine 0 N--CA 1.398 -3.847 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 173.401 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.411 HG22 ' HA ' ' A' ' 83' ' ' PRO . 1.0 OUTLIER -153.52 -179.85 8.15 Favored 'General case' 0 C--N 1.273 -2.728 0 C-N-CA 124.176 0.991 . . . . 0.0 110.113 -173.917 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 2.7 p -132.7 152.04 35.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 C-N-CA 122.714 0.406 . . . . 0.0 109.958 178.586 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 76' ' ' LYS . . . . . 0.636 ' HG3' ' O ' ' A' ' 80' ' ' SER . 81.4 tttt -129.04 145.67 51.2 Favored 'General case' 0 N--CA 1.431 -1.386 0 C-N-CA 123.79 0.836 . . . . 0.0 110.128 -179.475 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 77' ' ' TYR . . . . . 0.424 ' HB2' ' OH ' ' A' ' 82' ' ' TYR . 58.1 t80 -147.28 112.49 5.52 Favored 'General case' 0 C--N 1.314 -0.96 0 O-C-N 123.777 0.673 . . . . 0.0 109.301 -178.655 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 78' ' ' SER . . . . . . . . . . . . . 23.0 t 54.97 36.28 26.48 Favored 'General case' 0 CA--C 1.551 1.003 0 C-N-CA 123.627 0.771 . . . . 0.0 110.448 177.188 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.58 8.18 66.05 Favored Glycine 0 CA--C 1.529 0.941 0 CA-C-N 115.459 -0.791 . . . . 0.0 114.095 -179.421 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . 0.636 ' O ' ' HG3' ' A' ' 76' ' ' LYS . 17.3 t -79.68 -179.52 6.94 Favored 'General case' 0 CA--C 1.543 0.682 0 CA-C-N 117.275 0.537 . . . . 0.0 109.994 -179.678 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 81' ' ' SER . . . . . . . . . . . . . 22.6 t -157.08 111.88 2.76 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 107.705 -1.22 . . . . 0.0 107.705 178.713 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 82' ' ' TYR . . . . . 0.433 ' HB2' ' HD2' ' A' ' 83' ' ' PRO . 2.6 p90 -154.6 161.42 29.4 Favored Pre-proline 0 CA--C 1.552 1.056 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -175.5 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.433 ' HD2' ' HB2' ' A' ' 82' ' ' TYR . 54.0 Cg_endo -67.97 150.53 78.01 Favored 'Trans proline' 0 C--N 1.361 1.218 0 C-N-CA 122.884 2.389 . . . . 0.0 113.503 -176.761 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.474 ' CD1' ' HA ' ' A' ' 85' ' ' PRO . 57.8 t80 -126.39 132.65 24.4 Favored Pre-proline 0 N--CA 1.44 -0.967 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.067 179.785 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 85' ' ' PRO . . . . . 0.474 ' HA ' ' CD1' ' A' ' 84' ' ' PHE . 62.4 Cg_endo -69.95 147.07 84.29 Favored 'Cis proline' 0 CA--C 1.549 1.254 0 C-N-CA 123.125 -1.615 . . . . 0.0 111.16 -1.21 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 86' ' ' THR . . . . . . . . . . . . . 12.1 t -69.35 -176.98 1.04 Allowed 'General case' 0 CA--C 1.549 0.941 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.014 -175.294 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 14.1 p -127.41 -42.6 1.65 Allowed 'General case' 0 N--CA 1.432 -1.346 0 N-CA-C 112.799 0.666 . . . . 0.0 112.799 -172.418 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.6 t -108.12 -72.17 0.73 Allowed 'General case' 0 N--CA 1.432 -1.334 0 C-N-CA 119.74 -0.784 . . . . 0.0 111.527 -175.533 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.6 pt-20 176.6 -177.42 0.14 Allowed 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 -174.991 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.525 ' CG2' ' HB3' ' A' ' 58' ' ' LEU . 43.5 p -101.32 168.44 9.15 Favored Pre-proline 0 C--N 1.295 -1.781 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 178.555 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 91' ' ' PRO . . . . . 0.443 ' HD2' ' HB ' ' A' ' 90' ' ' THR . 12.1 Cg_endo -54.43 164.73 2.72 Favored 'Trans proline' 0 C--O 1.252 1.175 0 C-N-CA 123.162 2.574 . . . . 0.0 112.188 171.305 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.552 ' HG2' ' CE1' ' A' ' 55' ' ' TYR . 1.7 tmm_? -84.82 101.44 12.27 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.131 -172.625 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 87.6 t -114.14 121.22 65.84 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 CA-C-N 114.893 -1.049 . . . . 0.0 111.402 -176.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 93.5 t -108.28 142.29 21.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 CA-C-N 115.106 -0.952 . . . . 0.0 108.739 177.72 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.8 m-85 -98.52 110.6 23.17 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 176.085 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 46.2 m-80 -108.46 32.16 5.05 Favored 'General case' 0 C--N 1.309 -1.19 0 CA-C-O 121.708 0.766 . . . . 0.0 110.075 178.891 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 20.3 m -85.16 -172.53 4.22 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.375 -177.674 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 98' ' ' ARG . . . . . . . . . . . . . 16.4 ptp180 -145.99 36.46 1.03 Allowed 'General case' 0 C--N 1.307 -1.242 0 CA-C-O 121.85 0.833 . . . . 0.0 109.688 178.079 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 99' ' ' THR . . . . . . . . . . . . . 12.4 t -168.89 177.69 4.88 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 105.435 -2.061 . . . . 0.0 105.435 -178.995 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . 0.413 ' CB ' ' HB3' ' A' ' 45' ' ' HIS . 1.5 p-10 -84.75 127.71 34.25 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 178.509 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 101' ' ' LYS . . . . . 0.549 ' HE2' ' HA ' ' A' ' 101' ' ' LYS . 6.5 mmpt? -117.66 147.34 40.72 Favored Pre-proline 0 C--N 1.28 -2.447 0 N-CA-C 108.298 -1.001 . . . . 0.0 108.298 -179.666 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . 0.448 ' HA ' ' HA ' ' A' ' 43' ' ' PHE . 31.0 Cg_endo -67.62 143.5 62.61 Favored 'Trans proline' 0 N--CA 1.44 -1.626 0 C-N-CA 122.375 2.05 . . . . 0.0 111.013 -178.718 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 103' ' ' TRP . . . . . . . . . . . . . 14.7 t90 -80.81 107.95 8.76 Favored Pre-proline 0 C--N 1.305 -1.361 0 N-CA-C 106.595 -1.632 . . . . 0.0 106.595 -176.742 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 104' ' ' PRO . . . . . . . . . . . . . 70.6 Cg_endo -77.25 88.98 1.36 Allowed 'Trans proline' 0 N--CA 1.443 -1.459 0 C-N-CA 121.276 1.317 . . . . 0.0 112.683 -172.273 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 96.3 t -139.9 144.34 28.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 177.291 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 106' ' ' ALA . . . . . 0.622 ' HA ' ' O ' ' A' ' 36' ' ' VAL . . . -147.84 134.47 19.87 Favored 'General case' 0 N--CA 1.419 -1.98 0 CA-C-O 120.785 0.326 . . . . 0.0 110.155 178.096 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 107' ' ' LEU . . . . . 0.469 HD21 HD11 ' A' ' 129' ' ' LEU . 17.7 mt -101.73 104.3 15.1 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.242 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 108' ' ' TYR . . . . . 0.613 ' O ' ' HA3' ' A' ' 73' ' ' GLY . 16.5 m-85 -79.56 68.42 5.6 Favored 'General case' 0 C--N 1.287 -2.123 0 CA-C-O 120.514 0.197 . . . . 0.0 111.167 177.814 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.68 ' O ' ' HB3' ' A' ' 34' ' ' LEU . 3.1 mm? -90.59 128.53 36.62 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 175.358 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.15 145.29 56.73 Favored Pre-proline 0 N--CA 1.416 -2.154 0 N-CA-C 108.702 -0.851 . . . . 0.0 108.702 -178.182 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . 0.496 ' HA ' ' O ' ' A' ' 70' ' ' ASN . 30.7 Cg_endo -63.17 124.5 14.01 Favored 'Trans proline' 0 CA--C 1.498 -1.3 0 C-N-CA 122.927 2.418 . . . . 0.0 113.936 -176.24 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 112' ' ' VAL . . . . . 0.52 ' O ' HG22 ' A' ' 30' ' ' VAL . 19.5 m -86.36 -158.67 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.391 -3.419 0 CA-C-N 114.242 -1.345 . . . . 0.0 108.19 171.187 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 44.9 m -81.2 -22.35 38.91 Favored 'General case' 0 C--N 1.254 -3.575 0 O-C-N 121.636 -0.665 . . . . 0.0 111.069 -171.792 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . . . . . . . . . 10.3 t -81.8 12.19 4.21 Favored 'General case' 0 CA--C 1.549 0.931 0 CA-C-O 121.771 0.796 . . . . 0.0 109.977 179.491 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.477 ' HB2' ' O ' ' A' ' 70' ' ' ASN . . . -98.98 135.42 40.41 Favored 'General case' 0 N--CA 1.419 -2.017 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.455 -179.708 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 116' ' ' GLY . . . . . . . . . . . . . . . -179.82 122.96 0.81 Allowed Glycine 0 C--O 1.245 0.842 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 179.266 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 70.0 -155.01 53.09 Favored Glycine 0 C--N 1.307 -1.075 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 -174.922 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 6.1 p -53.88 106.86 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.314 -0.964 0 CA-C-O 122.541 1.162 . . . . 0.0 112.123 -178.174 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -108.56 -22.04 12.45 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 114.302 -1.317 . . . . 0.0 111.159 -176.848 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 120' ' ' ILE . . . . . 0.549 ' HB ' ' HB ' ' A' ' 154' ' ' VAL . 62.2 mt -136.34 133.47 49.67 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.053 0 N-CA-C 107.516 -1.291 . . . . 0.0 107.516 178.341 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.435 ' HE2' ' HA ' ' A' ' 121' ' ' LYS . 3.0 mmpt? -111.53 139.09 47.25 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 110.006 -0.368 . . . . 0.0 110.006 177.384 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 122' ' ' ALA . . . . . . . . . . . . . . . -67.32 125.96 27.75 Favored 'General case' 0 C--N 1.306 -1.293 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 177.922 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . . . . . . . . . . . 101.36 -10.77 58.14 Favored Glycine 0 N--CA 1.428 -1.885 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.298 -178.089 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 124' ' ' SER . . . . . . . . . . . . . 97.8 p -94.05 148.64 21.97 Favored 'General case' 0 C--O 1.252 1.22 0 C-N-CA 119.861 -0.736 . . . . 0.0 110.241 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . 0.445 HD11 HG23 ' A' ' 128' ' ' VAL . 3.0 tm? -76.35 124.15 27.06 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-N 115.011 -0.995 . . . . 0.0 108.878 -179.202 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 126' ' ' ILE . . . . . 0.582 ' HB ' HG11 ' A' ' 67' ' ' VAL . 27.6 pt -108.38 -29.92 2.53 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.389 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.878 179.901 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 127' ' ' ALA . . . . . 0.446 ' HB3' ' HB ' ' A' ' 148' ' ' ILE . . . -157.97 165.5 34.99 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.605 -0.838 . . . . 0.0 110.376 -176.595 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.445 HG23 HD11 ' A' ' 125' ' ' LEU . 64.4 t -139.6 114.18 7.37 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.796 0 N-CA-C 107.818 -1.179 . . . . 0.0 107.818 177.929 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . 0.469 HD11 HD21 ' A' ' 107' ' ' LEU . 40.0 mt -119.58 145.49 46.35 Favored 'General case' 0 C--N 1.291 -1.966 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 179.971 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 130' ' ' ILE . . . . . . . . . . . . . 5.4 mp -129.64 128.85 66.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 C-N-CA 120.324 -0.551 . . . . 0.0 110.078 177.155 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 131' ' ' LEU . . . . . 0.432 ' C ' HD12 ' A' ' 131' ' ' LEU . 1.5 pp -92.62 138.31 31.61 Favored 'General case' 0 N--CA 1.424 -1.733 0 N-CA-C 106.911 -1.515 . . . . 0.0 106.911 172.856 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 132' ' ' ARG . . . . . 0.449 ' HE ' ' HB3' ' A' ' 143' ' ' GLN . 3.9 tpm_? -97.24 112.95 24.52 Favored 'General case' 0 C--N 1.249 -3.803 0 N-CA-C 106.538 -1.653 . . . . 0.0 106.538 176.256 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 133' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.1 130.46 40.26 Favored 'General case' 0 N--CA 1.422 -1.849 0 N-CA-C 104.991 -2.226 . . . . 0.0 104.991 177.686 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.511 ' HA ' ' HB2' ' A' ' 141' ' ' ASP . 63.6 m -137.92 138.65 39.22 Favored 'General case' 0 C--N 1.273 -2.731 0 C-N-CA 120.396 -0.522 . . . . 0.0 110.179 174.277 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.489 ' CB ' HG23 ' A' ' 52' ' ' ILE . 20.0 p30 -126.93 170.38 12.32 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 121.524 0.678 . . . . 0.0 112.051 -175.717 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 136' ' ' ASN . . . . . 0.44 HD22 HG22 ' A' ' 53' ' ' THR . 9.5 p30 -106.67 -20.83 13.23 Favored 'General case' 0 N--CA 1.473 0.7 0 CA-C-N 114.825 -1.08 . . . . 0.0 110.903 -174.782 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 73.8 t80 -89.2 -72.91 0.53 Allowed 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 115.395 -0.821 . . . . 0.0 110.078 -170.813 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 138' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -86.29 -178.56 6.5 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 175.507 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 69.9 m -117.96 27.0 9.27 Favored 'General case' 0 C--N 1.286 -2.161 0 CA-C-O 121.799 0.809 . . . . 0.0 108.974 176.683 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 140' ' ' ASP . . . . . . . . . . . . . 7.1 p30 -91.93 48.89 1.48 Allowed 'General case' 0 C--N 1.315 -0.906 0 CA-C-O 122.192 0.996 . . . . 0.0 110.619 179.203 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 141' ' ' ASP . . . . . 0.511 ' HB2' ' HA ' ' A' ' 134' ' ' THR . 7.8 p-10 -84.52 86.25 7.31 Favored 'General case' 0 N--CA 1.434 -1.245 0 CA-C-O 122.867 1.318 . . . . 0.0 110.066 179.15 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -99.16 175.51 5.87 Favored 'General case' 0 C--N 1.289 -2.029 0 CA-C-N 114.594 -1.185 . . . . 0.0 109.42 179.451 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 143' ' ' GLN . . . . . 0.449 ' HB3' ' HE ' ' A' ' 132' ' ' ARG . 13.7 pt20 -130.22 141.32 50.65 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.647 179.884 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 7.0 m-30 -104.6 127.99 52.48 Favored 'General case' 0 C--N 1.298 -1.67 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 -175.575 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 145' ' ' VAL . . . . . . . . . . . . . 57.6 t -93.24 136.24 25.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -178.923 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 146' ' ' TRP . . . . . 0.455 ' CZ2' ' HB2' ' A' ' 3' ' ' CYS . 66.9 m95 -123.87 95.79 4.7 Favored 'General case' 0 C--N 1.281 -2.381 0 N-CA-C 108.272 -1.011 . . . . 0.0 108.272 -177.19 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 147' ' ' ASN . . . . . . . . . . . . . 51.3 m-80 -80.94 114.17 19.64 Favored 'General case' 0 C--N 1.291 -1.954 0 N-CA-C 107.275 -1.38 . . . . 0.0 107.275 177.961 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 148' ' ' ILE . . . . . 0.449 HG22 HD11 ' A' ' 126' ' ' ILE . 22.6 mm -89.92 122.03 40.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.709 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 -175.785 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 149' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -118.14 157.99 25.89 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 178.241 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -81.6 131.89 35.29 Favored 'General case' 0 N--CA 1.407 -2.599 0 CA-C-N 115.002 -0.999 . . . . 0.0 108.523 176.216 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 34.2 t-20 -95.52 -8.96 33.76 Favored 'General case' 0 C--N 1.29 -2.007 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 -178.401 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 152' ' ' ASN . . . . . . . . . . . . . 3.4 t30 -153.79 145.43 23.31 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 113.869 -1.514 . . . . 0.0 108.713 -175.959 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 153' ' ' ASP . . . . . . . . . . . . . 7.0 p-10 -84.8 140.41 31.23 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 124.138 0.899 . . . . 0.0 111.198 -178.539 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.557 ' HA ' ' HA ' ' A' ' 26' ' ' PRO . 70.3 t -118.17 134.66 61.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 115.343 -0.844 . . . . 0.0 111.015 -176.653 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 155' ' ' VAL . . . . . . . . . . . . . 2.1 t -119.24 133.08 67.21 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.545 0 N-CA-C 107.178 -1.415 . . . . 0.0 107.178 -179.966 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 156' ' ' VAL . . . . . 0.453 HG12 ' HB ' ' A' ' 158' ' ' THR . 75.2 t -97.65 102.64 13.66 Favored Pre-proline 0 C--N 1.289 -2.033 0 C-N-CA 123.375 0.67 . . . . 0.0 109.962 179.389 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 157' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -70.58 -24.55 25.8 Favored 'Trans proline' 0 CA--C 1.516 -0.403 0 C-N-CA 121.87 1.714 . . . . 0.0 111.584 -179.261 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 158' ' ' THR . . . . . 0.453 ' HB ' HG12 ' A' ' 156' ' ' VAL . 7.3 t . . . . . 0 CA--C 1.545 0.779 0 C-N-CA 125.303 1.441 . . . . 0.0 112.723 176.95 . . . . . . . . 1 1 . 1 stop_ save_